IL-2	B-DNA
gene	I-DNA
expression	O
and	O
NF-kappa	B-protein
B	I-protein
activation	O
through	O
CD28	B-protein
requires	O
reactive	O
oxygen	O
production	O
by	O
5-lipoxygenase	B-protein
.	O

Activation	O
of	O
the	O
CD28	B-protein
surface	I-protein
receptor	I-protein
provides	O
a	O
major	O
costimulatory	O
signal	O
for	O
T	O
cell	O
activation	O
resulting	O
in	O
enhanced	O
production	O
of	O
interleukin-2	B-protein
(	O
IL-2	B-protein
)	O
and	O
cell	O
proliferation	O
.	O

In	O
primary	B-cell_type
T	I-cell_type
lymphocytes	I-cell_type
we	O
show	O
that	O
CD28	B-protein
ligation	O
leads	O
to	O
the	O
rapid	O
intracellular	O
formation	O
of	O
reactive	O
oxygen	O
intermediates	O
(	O
ROIs	O
)	O
which	O
are	O
required	O
for	O
CD28	B-protein
-mediated	O
activation	O
of	O
the	O
NF-kappa	B-protein
B	I-protein
/	O
CD28-responsive	B-protein
complex	I-protein
and	O
IL-2	B-protein
expression	O
.	O

Delineation	O
of	O
the	O
CD28	B-protein
signaling	O
cascade	O
was	O
found	O
to	O
involve	O
protein	B-protein
tyrosine	I-protein
kinase	I-protein
activity	O
,	O
followed	O
by	O
the	O
activation	O
of	O
phospholipase	B-protein
A2	I-protein
and	O
5-lipoxygenase	B-protein
.	O

Our	O
data	O
suggest	O
that	O
lipoxygenase	B-protein
metabolites	I-protein
activate	O
ROI	O
formation	O
which	O
then	O
induce	O
IL-2	B-protein
expression	O
via	O
NF-kappa	B-protein
B	I-protein
activation	O
.	O

These	O
findings	O
should	O
be	O
useful	O
for	O
therapeutic	O
strategies	O
and	O
the	O
development	O
of	O
immunosuppressants	O
targeting	O
the	O
CD28	B-protein
costimulatory	O
pathway	O
.	O

The	O
peri-kappa	B-DNA
B	I-DNA
site	I-DNA
mediates	O
human	B-DNA
immunodeficiency	I-DNA
virus	I-DNA
type	I-DNA
2	I-DNA
enhancer	I-DNA
activation	O
in	O
monocytes	B-cell_type
but	O
not	O
in	O
T	B-cell_type
cells	I-cell_type
.	O

Human	O
immunodeficiency	O
virus	O
type	O
2	O
(	O
HIV-2	O
)	O
,	O
like	O
HIV-1	O
,	O
causes	O
AIDS	O
and	O
is	O
associated	O
with	O
AIDS	O
cases	O
primarily	O
in	O
West	O
Africa	O
.	O

HIV-1	O
and	O
HIV-2	O
display	O
significant	O
differences	O
in	O
nucleic	O
acid	O
sequence	O
and	O
in	O
the	O
natural	O
history	O
of	O
clinical	O
disease	O
.	O

Consistent	O
with	O
these	O
differences	O
,	O
we	O
have	O
previously	O
demonstrated	O
that	O
the	O
enhancer/promoter	B-DNA
region	I-DNA
of	O
HIV-2	O
functions	O
quite	O
differently	O
from	O
that	O
of	O
HIV-1	O
.	O

Whereas	O
activation	O
of	O
the	O
HIV-1	B-DNA
enhancer	I-DNA
following	O
T-cell	O
stimulation	O
is	O
mediated	O
largely	O
through	O
binding	O
of	O
the	O
transcription	B-protein
factor	I-protein
NF-kappa	B-protein
B	I-protein
to	O
two	O
adjacent	O
kappa	B-DNA
B	I-DNA
sites	I-DNA
in	O
the	O
HIV-1	B-DNA
long	I-DNA
terminal	I-DNA
repeat	I-DNA
,	O
activation	O
of	O
the	O
HIV-2	B-DNA
enhancer	I-DNA
in	O
monocytes	B-cell_type
and	O
T	B-cell_type
cells	I-cell_type
is	O
dependent	O
on	O
four	O
cis-acting	B-DNA
elements	I-DNA
:	O
a	O
single	O
kappa	B-DNA
B	I-DNA
site	I-DNA
,	O
two	O
purine-rich	B-DNA
binding	I-DNA
sites	I-DNA
,	O
PuB1	B-DNA
and	O
PuB2	B-DNA
,	O
and	O
a	O
pets	B-DNA
site	I-DNA
.	O

We	O
have	O
now	O
identified	O
a	O
novel	O
cis-acting	B-DNA
element	I-DNA
within	O
the	O
HIV-2	B-DNA
enhancer	I-DNA
,	O
immediately	O
upstream	O
of	O
the	O
kappa	B-DNA
B	I-DNA
site	I-DNA
,	O
designated	O
peri-kappa	B-DNA
B	I-DNA
.	O

This	O
site	O
is	O
conserved	O
among	O
isolates	O
of	O
HIV-2	O
and	O
the	O
closely	O
related	O
simian	O
immunodeficiency	O
virus	O
,	O
and	O
transfection	O
assays	O
show	O
this	O
site	O
to	O
mediate	O
HIV-2	B-DNA
enhancer	I-DNA
activation	O
following	O
stimulation	O
of	O
monocytic	B-cell_line
but	O
not	O
T-cell	B-cell_line
lines	I-cell_line
.	O

This	O
is	O
the	O
first	O
description	O
of	O
an	O
HIV-2	B-DNA
enhancer	I-DNA
element	I-DNA
which	O
displays	O
such	O
monocyte	O
specificity	O
,	O
and	O
no	O
comparable	O
enhancer	B-DNA
element	I-DNA
has	O
been	O
clearly	O
defined	O
for	O
HIV-1	O
.	O

While	O
a	O
nuclear	B-protein
factor	I-protein
(	O
s	O
)	O
from	O
both	O
peripheral	B-cell_type
blood	I-cell_type
monocytes	I-cell_type
and	O
T	B-cell_type
cells	I-cell_type
binds	O
the	O
peri-kappa	B-DNA
B	I-DNA
site	I-DNA
,	O
electrophoretic	O
mobility	O
shift	O
assays	O
suggest	O
that	O
either	O
a	O
different	O
protein	O
binds	O
to	O
this	O
site	O
in	O
monocytes	B-cell_type
versus	O
T	B-cell_type
cells	I-cell_type
or	O
that	O
the	O
protein	O
recognizing	O
this	O
enhancer	B-DNA
element	I-DNA
undergoes	O
differential	O
modification	O
in	O
monocytes	B-cell_type
and	O
T	B-cell_type
cells	I-cell_type
,	O
thus	O
supporting	O
the	O
transfection	O
data	O
.	O

Further	O
,	O
while	O
specific	O
constitutive	O
binding	O
to	O
the	O
peri-kappa	B-DNA
B	I-DNA
site	I-DNA
is	O
seen	O
in	O
monocytes	B-cell_type
,	O
stimulation	O
with	O
phorbol	O
esters	O
induces	O
additional	O
,	O
specific	O
binding	O
.	O

Understanding	O
the	O
monocyte-specific	O
function	O
of	O
the	O
peri-kappa	B-protein
B	I-protein
factor	I-protein
may	O
ultimately	O
provide	O
insight	O
into	O
the	O
different	O
role	O
monocytes	B-cell_type
and	O
T	B-cell_type
cells	I-cell_type
play	O
in	O
HIV	O
pathogenesis	O
.	O

E1A	B-DNA
gene	I-DNA
expression	O
induces	O
susceptibility	O
to	O
killing	O
by	O
NK	B-cell_type
cells	I-cell_type
following	O
immortalization	O
but	O
not	O
adenovirus	O
infection	O
of	O
human	B-cell_type
cells	I-cell_type
.	O

Adenovirus	O
(	O
Ad	O
)	O
infection	O
and	O
E1A	B-protein
transfection	O
were	O
used	O
to	O
model	O
changes	O
in	O
susceptibility	O
to	O
NK	O
cell	O
killing	O
caused	O
by	O
transient	O
vs	O
stable	O
E1A	B-protein
expression	O
in	O
human	B-cell_type
cells	I-cell_type
.	O

Only	O
stably	O
transfected	B-cell_line
target	I-cell_line
cells	I-cell_line
exhibited	O
cytolytic	O
susceptibility	O
,	O
despite	O
expression	O
of	O
equivalent	O
levels	O
of	O
E1A	B-protein
proteins	I-protein
in	O
Ad-infected	B-cell_line
targets	I-cell_line
.	O

The	O
inability	O
of	O
E1A	B-DNA
gene	I-DNA
products	O
to	O
induce	O
cytolytic	O
susceptibility	O
during	O
infection	O
was	O
not	O
explained	O
by	O
an	O
inhibitory	O
effect	O
of	O
viral	O
infection	O
on	O
otherwise	O
susceptible	O
target	B-cell_type
cells	I-cell_type
or	O
by	O
viral	B-DNA
gene	I-DNA
effects	O
on	O
class	B-protein
I	I-protein
MHC	I-protein
antigen	I-protein
expression	O
on	O
target	B-cell_type
cells	I-cell_type
.	O

This	O
differential	O
effect	O
of	O
E1A	B-protein
expression	O
on	O
the	O
cytolytic	O
phenotypes	O
of	O
infected	O
and	O
stably	O
transfected	O
human	B-cell_type
cells	I-cell_type
suggests	O
that	O
human	B-cell_type
NK	I-cell_type
cells	I-cell_type
provide	O
an	O
effective	O
immunologic	O
barrier	O
against	O
the	O
in	O
vivo	O
survival	O
and	O
neoplastic	O
progression	O
of	O
E1A-immortalized	B-cell_line
cells	I-cell_line
that	O
may	O
emerge	O
from	O
the	O
reservoir	O
of	O
persistently	B-cell_type
infected	I-cell_type
cells	I-cell_type
in	O
the	O
human	O
host	O
.	O

Distinct	O
signaling	O
properties	O
identify	O
functionally	O
different	O
CD4	B-protein
epitopes	I-protein
.	O

The	O
CD4	B-protein
coreceptor	I-protein
interacts	O
with	O
non-polymorphic	B-protein
regions	I-protein
of	O
major	B-protein
histocompatibility	I-protein
complex	I-protein
class	I-protein
II	I-protein
molecules	I-protein
on	O
antigen-presenting	B-cell_type
cells	I-cell_type
and	O
contributes	O
to	O
T	O
cell	O
activation	O
.	O

We	O
have	O
investigated	O
the	O
effect	O
of	O
CD4	B-protein
triggering	O
on	O
T	O
cell	O
activating	O
signals	O
in	O
a	O
lymphoma	O
model	O
using	O
monoclonal	B-protein
antibodies	I-protein
(	O
mAb	B-protein
)	O
which	O
recognize	O
different	O
CD4	B-protein
epitopes	I-protein
.	O

We	O
demonstrate	O
that	O
CD4	B-protein
triggering	O
delivers	O
signals	O
capable	O
of	O
activating	O
the	O
NF-AT	B-protein
transcription	I-protein
factor	I-protein
which	O
is	O
required	O
for	O
interleukin-2	B-protein
gene	O
expression	O
.	O

Whereas	O
different	O
anti-CD4	B-protein
mAb	I-protein
or	O
HIV-1	B-protein
gp120	I-protein
could	O
all	O
trigger	O
activation	O
of	O
the	O
protein	B-protein
tyrosine	I-protein
kinases	I-protein
p56lck	B-protein
and	O
p59fyn	B-protein
and	O
phosphorylation	O
of	O
the	O
Shc	B-protein
adaptor	I-protein
protein	I-protein
,	O
which	O
mediates	O
signals	O
to	O
Ras	B-protein
,	O
they	O
differed	O
significantly	O
in	O
their	O
ability	O
to	O
activate	O
NF-AT	B-protein
.	O

Lack	O
of	O
full	O
activation	O
of	O
NF-AT	B-protein
could	O
be	O
correlated	O
to	O
a	O
dramatically	O
reduced	O
capacity	O
to	O
induce	O
calcium	O
flux	O
and	O
could	O
be	O
complemented	O
with	O
a	O
calcium	O
ionophore	O
.	O

The	O
results	O
identify	O
functionally	O
distinct	O
epitopes	B-protein
on	O
the	O
CD4	B-protein
coreceptor	I-protein
involved	O
in	O
activation	O
of	O
the	O
Ras/protein	B-protein
kinase	I-protein
C	I-protein
and	O
calcium	O
pathways	O
.	O

Ligand-dependent	O
repression	O
of	O
the	O
erythroid	B-protein
transcription	I-protein
factor	I-protein
GATA-1	B-protein
by	O
the	O
estrogen	B-protein
receptor	I-protein
.	O

High-dose	O
estrogen	O
administration	O
induces	O
anemia	O
in	O
mammals	O
.	O

In	O
chickens	O
,	O
estrogens	O
stimulate	O
outgrowth	O
of	O
bone	B-cell_type
marrow-derived	I-cell_type
erythroid	I-cell_type
progenitor	I-cell_type
cells	I-cell_type
and	O
delay	O
their	O
maturation	O
.	O

This	O
delay	O
is	O
associated	O
with	O
down-regulation	O
of	O
many	O
erythroid	B-DNA
cell-specific	I-DNA
genes	I-DNA
,	O
including	O
alpha-	B-DNA
and	I-DNA
beta-globin	I-DNA
,	O
band	O
3	O
,	O
band	O
4.1	O
,	O
and	O
the	O
erythroid	B-protein
cell-specific	I-protein
histone	I-protein
H5	B-protein
.	O

We	O
show	O
here	O
that	O
estrogens	O
also	O
reduce	O
the	O
number	O
of	O
erythroid	B-cell_type
progenitor	I-cell_type
cells	I-cell_type
in	O
primary	B-cell_line
human	I-cell_line
bone	I-cell_line
marrow	I-cell_line
cultures	I-cell_line
.	O

To	O
address	O
potential	O
mechanisms	O
by	O
which	O
estrogens	O
suppress	O
erythropoiesis	O
,	O
we	O
have	O
examined	O
their	O
effects	O
on	O
GATA-1	B-protein
,	O
an	O
erythroid	B-protein
transcription	I-protein
factor	I-protein
that	O
participates	O
in	O
the	O
regulation	O
of	O
the	O
majority	O
of	O
erythroid	B-DNA
cell-specific	I-DNA
genes	I-DNA
and	O
is	O
necessary	O
for	O
full	O
maturation	O
of	O
erythrocytes	B-cell_type
.	O

We	O
demonstrate	O
that	O
the	O
transcriptional	O
activity	O
of	O
GATA-1	B-protein
is	O
strongly	O
repressed	O
by	O
the	O
estrogen	B-protein
receptor	I-protein
(	O
ER	B-protein
)	O
in	O
a	O
ligand-dependent	O
manner	O
and	O
that	O
this	O
repression	O
is	O
reversible	O
in	O
the	O
presence	O
of	O
4-hydroxytamoxifen	O
.	O

ER	B-protein
-mediated	O
repression	O
of	O
GATA-1	B-protein
activity	O
occurs	O
on	O
an	O
artificial	B-DNA
promoter	I-DNA
containing	O
a	O
single	O
GATA-binding	B-DNA
site	I-DNA
,	O
as	O
well	O
as	O
in	O
the	O
context	O
of	O
an	O
intact	B-DNA
promoter	I-DNA
which	O
is	O
normally	O
regulated	O
by	O
GATA-1	B-protein
.	O

GATA-1	B-protein
and	O
ER	B-protein
bind	O
to	O
each	O
other	O
in	O
vitro	O
in	O
the	O
absence	O
of	O
DNA	O
.	O

In	O
coimmunoprecipitation	O
experiments	O
using	O
transfected	O
COS	B-cell_line
cells	I-cell_line
,	O
GATA-1	B-protein
and	O
ER	B-protein
associate	O
in	O
a	O
ligand-dependent	O
manner	O
.	O

Mapping	O
experiments	O
indicate	O
that	O
GATA-1	B-protein
and	O
the	O
ER	B-protein
form	O
at	O
least	O
two	O
contacts	O
,	O
which	O
involve	O
the	O
finger	O
region	O
and	O
the	O
N-terminal	B-protein
activation	I-protein
domain	I-protein
of	O
GATA-1	B-protein
.	O

We	O
speculate	O
that	O
estrogens	O
exert	O
effects	O
on	O
erythropoiesis	O
by	O
modulating	O
GATA-1	B-protein
activity	O
through	O
protein-protein	O
interaction	O
with	O
the	O
ER	B-protein
.	O

(	O
ABSTRACT	O
TRUNCATED	O
AT	O
250	O
WORDS	O
)	O

Mouse	B-DNA
interleukin-2	I-DNA
receptor	I-DNA
alpha	I-DNA
gene	I-DNA
expression	O
.	O

Interleukin-1	B-protein
and	O
interleukin-2	B-protein
control	O
transcription	O
via	O
distinct	O
cis-acting	B-DNA
elements	I-DNA
.	O

We	O
have	O
shown	O
that	O
interleukin-1	B-protein
(	O
IL-1	B-protein
)	O
and	O
IL-2	B-protein
control	O
IL-2	B-DNA
receptor	I-DNA
alpha	I-DNA
(	I-DNA
IL-2R	I-DNA
alpha	I-DNA
)	I-DNA
gene	I-DNA
transcription	O
in	O
CD4-CD8-	B-cell_line
murine	I-cell_line
T	I-cell_line
lymphocyte	I-cell_line
precursors	I-cell_line
.	O

Here	O
we	O
map	O
the	O
cis-acting	B-DNA
elements	I-DNA
that	O
mediate	O
interleukin	O
responsiveness	O
of	O
the	O
mouse	B-DNA
IL-2R	I-DNA
alpha	I-DNA
gene	I-DNA
using	O
a	O
thymic	B-cell_line
lymphoma-derived	I-cell_line
hybridoma	I-cell_line
(	O
PC60	B-cell_line
)	O
.	O

The	O
transcriptional	O
response	O
of	O
the	O
IL-2R	B-DNA
alpha	I-DNA
gene	I-DNA
to	O
stimulation	O
by	O
IL-1	B-protein
+	O
IL-2	B-protein
is	O
biphasic	O
.	O

IL-1	B-protein
induces	O
a	O
rapid	O
,	O
protein	O
synthesis-independent	O
appearance	O
of	O
IL-2R	B-RNA
alpha	I-RNA
mRNA	I-RNA
that	O
is	O
blocked	O
by	O
inhibitors	O
of	O
NF-kappa	B-protein
B	I-protein
activation	O
.	O

It	O
also	O
primes	O
cells	O
to	O
become	O
IL-2	B-protein
responsive	O
and	O
thereby	O
prepares	O
the	O
second	O
phase	O
,	O
in	O
which	O
IL-2	B-protein
induces	O
a	O
100-fold	O
further	O
increase	O
in	O
IL-2R	B-RNA
alpha	I-RNA
transcripts	I-RNA
.	O

Transient	O
transfection	O
experiments	O
show	O
that	O
several	O
elements	O
in	O
the	O
promoter-proximal	B-DNA
region	I-DNA
of	O
the	O
IL-2R	B-DNA
alpha	I-DNA
gene	I-DNA
contribute	O
to	O
IL-1	B-protein
responsiveness	O
,	O
most	O
importantly	O
an	O
NF-kappa	B-DNA
B	I-DNA
site	I-DNA
conserved	O
in	O
the	O
human	B-DNA
and	I-DNA
mouse	I-DNA
gene	I-DNA
.	O

IL-2	B-protein
responsiveness	O
,	O
on	O
the	O
other	O
hand	O
,	O
depends	O
on	O
a	O
78-nucleotide	B-DNA
segment	I-DNA
1.3	O
kilobases	O
upstream	O
of	O
the	O
major	B-DNA
transcription	I-DNA
start	I-DNA
site	I-DNA
.	O

This	O
segment	O
functions	O
as	O
an	O
IL-2-inducible	B-DNA
enhancer	I-DNA
and	O
lies	O
within	O
a	O
region	O
that	O
becomes	O
DNase	B-protein
I	I-protein
hypersensitive	O
in	O
normal	O
T	B-cell_type
cells	I-cell_type
in	O
which	O
IL-2R	B-protein
alpha	I-protein
expression	O
has	O
been	O
induced	O
.	O

IL-2	B-protein
responsiveness	O
requires	O
three	O
distinct	O
elements	B-DNA
within	O
the	O
enhancer	B-DNA
.	O

Two	O
of	O
these	O
are	O
potential	O
binding	O
sites	O
for	O
STAT	B-protein
proteins	I-protein
.	O

Hematopoietic	B-cell_type
lineage	I-cell_type
commitment	O
:	O
role	O
of	O
transcription	B-protein
factors	I-protein
.	O

This	O
review	O
focuses	O
on	O
the	O
roles	O
of	O
transcription	B-protein
factors	I-protein
in	O
hematopoietic	O
lineage	O
commitment	O
.	O

A	O
brief	O
introduction	O
to	O
lineage	O
commitment	O
and	O
asymmetric	O
cell	O
division	O
is	O
followed	O
by	O
a	O
discussion	O
of	O
several	O
methods	O
used	O
to	O
identify	O
transcription	B-protein
factors	I-protein
important	O
in	O
specifying	O
hematopoietic	B-cell_type
cell	I-cell_type
types	I-cell_type
.	O

Next	O
is	O
presented	O
a	O
discussion	O
of	O
the	O
use	O
of	O
embryonic	B-cell_type
stem	I-cell_type
cells	I-cell_type
in	O
the	O
analysis	O
of	O
hematopoietic	B-DNA
gene	I-DNA
expression	O
and	O
the	O
use	O
of	O
targeted	O
gene	O
disruption	O
to	O
analyze	O
the	O
role	O
of	O
transcription	B-protein
factors	I-protein
in	O
hematopoiesis	O
.	O

Finally	O
,	O
the	O
status	O
of	O
our	O
current	O
knowledge	O
concerning	O
the	O
roles	O
of	O
transcription	B-protein
factors	I-protein
in	O
the	O
commitment	O
to	O
erythroid	B-cell_type
,	I-cell_type
myeloid	I-cell_type
and	I-cell_type
lymphoid	I-cell_type
cell	I-cell_type
types	I-cell_type
is	O
summarized	O
.	O

Epstein-Barr	O
virus	O
replicative	O
gene	O
transcription	O
during	O
de	O
novo	O
infection	O
of	O
human	B-cell_type
thymocytes	I-cell_type
:	O
simultaneous	O
early	O
expression	O
of	O
BZLF-1	B-protein
and	O
its	O
repressor	O
RAZ	B-protein
.	O

Epstein-Barr	O
virus	O
(	O
EBV	O
)	O
is	O
known	O
to	O
infect	O
B	B-cell_type
cells	I-cell_type
and	O
epithelial	B-cell_type
cells	I-cell_type
.	O

We	O
and	O
others	O
have	O
shown	O
that	O
EBV	O
can	O
also	O
infect	O
a	O
subset	O
of	O
thymocytes	B-cell_type
.	O

Infection	O
of	O
thymocytes	B-cell_type
was	O
accompanied	O
by	O
the	O
appearance	O
of	O
linear	B-DNA
EBV	I-DNA
genome	I-DNA
within	O
8	O
hr	O
of	O
infection	O
.	O

Circularization	O
of	O
the	O
EBV	B-DNA
genome	I-DNA
was	O
not	O
detected	O
.	O

This	O
is	O
in	O
contrast	O
to	O
the	O
infection	O
in	O
B	B-cell_type
cells	I-cell_type
where	O
the	O
genome	O
can	O
circularize	O
within	O
24	O
hr	O
of	O
infection	O
.	O

The	O
appearance	O
of	O
the	O
BamHI	B-protein
ZLF-1	I-protein
gene	I-protein
product	I-protein
,	O
ZEBRA	B-protein
,	O
by	O
RT-PCR	O
,	O
was	O
observed	O
within	O
8	O
hr	O
of	O
infection	O
.	O

The	O
appearance	O
of	O
a	O
novel	O
fusion	B-protein
transcript	I-protein
(	O
RAZ	B-protein
)	O
,	O
which	O
comprised	O
regions	O
of	O
the	O
BZLF-1	B-DNA
locus	I-DNA
and	O
the	O
adjacent	O
BRLF-1	B-DNA
locus	I-DNA
,	O
was	O
detected	O
by	O
RT-PCR	O
.	O

ZEBRA	B-protein
protein	I-protein
was	O
also	O
identified	O
in	O
infected	O
thymocytes	B-cell_type
by	O
immunoprecipitation	O
.	O

In	O
addition	O
,	O
we	O
demonstrated	O
that	O
the	O
EBNA-1	B-DNA
gene	I-DNA
in	O
infected	O
thymocytes	B-cell_type
was	O
transcribed	O
from	O
the	O
Fp	B-DNA
promoter	I-DNA
,	O
rather	O
than	O
from	O
the	O
Cp/Wp	B-DNA
promoter	I-DNA
which	O
is	O
used	O
in	O
latently	B-cell_type
infected	I-cell_type
B	I-cell_type
cells	I-cell_type
.	O

Transcripts	O
encoding	O
gp350/220	B-protein
,	O
the	O
major	B-protein
coat	I-protein
protein	I-protein
of	O
EBV	O
,	O
were	O
identified	O
,	O
but	O
we	O
did	O
not	O
find	O
any	O
evidence	O
of	O
transcription	O
from	O
the	O
LMP-2A	B-DNA
or	O
EBER-1	B-DNA
loci	I-DNA
in	O
infected	O
thymocytes	B-cell_type
.	O

These	O
observations	O
suggest	O
that	O
de	O
novo	O
EBV	O
infection	O
of	O
thymocytes	B-cell_type
differs	O
from	O
infection	O
of	O
B	B-cell_type
cells	I-cell_type
.	O

The	O
main	O
difference	O
is	O
that	O
with	O
thymocytes	B-cell_type
,	O
no	O
evidence	O
could	O
be	O
found	O
that	O
the	O
virus	O
ever	O
circularizes	O
.	O

Rather	O
,	O
EBV	O
remains	O
in	O
a	O
linear	O
configuration	O
from	O
which	O
replicative	B-DNA
genes	I-DNA
are	O
transcribed	O
.	O

Identification	O
and	O
purification	O
of	O
human	B-protein
Stat	I-protein
proteins	I-protein
activated	O
in	O
response	O
to	O
interleukin-2	B-protein
.	O

A	O
key	O
cytokine	B-protein
induced	O
during	O
the	O
immune	O
response	O
is	O
IL-2	B-protein
.	O

Following	O
T	O
cell	O
activation	O
,	O
the	O
genes	O
encoding	O
IL-2	B-protein
and	O
the	O
various	O
chains	O
of	O
its	O
receptor	O
are	O
transcriptionally	O
induced	O
.	O

In	O
turn	O
,	O
secreted	O
IL-2	B-protein
serves	O
to	O
stimulate	O
the	O
proliferation	O
and	O
differentiation	O
of	O
T	B-cell_type
lymphocytes	I-cell_type
.	O

Several	O
recent	O
studies	O
have	O
implicated	O
Jak	O
kinases	O
in	O
the	O
signaling	O
pathway	O
induced	O
by	O
IL-2	B-protein
.	O

Following	O
this	O
lead	O
,	O
we	O
set	O
out	O
to	O
identify	O
transcription	B-protein
factors	I-protein
induced	O
in	O
response	O
to	O
IL-2	B-protein
.	O

Human	B-cell_type
peripheral	I-cell_type
blood	I-cell_type
lymphocytes	I-cell_type
were	O
observed	O
to	O
contain	O
several	O
IL-2	B-protein
-inducible	O
DNA	O
binding	O
activities	O
.	O

Similar	O
activities	O
were	O
also	O
observed	O
in	O
a	O
transformed	B-cell_line
human	I-cell_line
lymphocyte	I-cell_line
line	I-cell_line
,	O
termed	O
YT	B-cell_line
.	O

We	O
have	O
purified	O
these	O
activities	O
and	O
found	O
that	O
the	O
principal	O
IL-2-inducible	B-protein
component	I-protein
bears	O
significant	O
relatedness	O
to	O
a	O
prolactin-induced	B-protein
transcription	I-protein
factor	I-protein
first	O
identified	O
in	O
sheep	B-cell_type
mammary	I-cell_type
gland	I-cell_type
tissue	I-cell_type
.	O

We	O
hypothesize	O
that	O
activation	O
of	O
this	O
protein	O
,	O
designated	O
hStat5	B-protein
,	O
helps	O
govern	O
the	O
biological	O
effects	O
of	O
IL-2	B-protein
during	O
the	O
immune	O
response	O
.	O

E2F-1	B-protein
and	O
a	O
cyclin-like	B-protein
DNA	I-protein
repair	I-protein
enzyme	I-protein
,	O
uracil-DNA	B-protein
glycosylase	I-protein
,	O
provide	O
evidence	O
for	O
an	O
autoregulatory	O
mechanism	O
for	O
transcription	O
.	O

The	O
cell	B-protein
cycle-dependent	I-protein
transcription	I-protein
factor	I-protein
,	O
E2F-1	B-protein
,	O
regulates	O
the	O
cyclin	B-protein
-like	O
species	O
of	O
the	O
DNA	B-protein
repair	I-protein
enzyme	I-protein
uracil-DNA	B-DNA
glycosylase	I-DNA
(	I-DNA
UDG	I-DNA
)	I-DNA
gene	I-DNA
in	O
human	B-cell_line
osteosarcoma	I-cell_line
(	I-cell_line
Saos-2	I-cell_line
)	I-cell_line
cells	I-cell_line
.	O

We	O
demonstrate	O
,	O
through	O
the	O
deletion	O
of	O
the	O
human	B-DNA
UDG	I-DNA
promoter	I-DNA
sequences	I-DNA
,	O
that	O
expression	O
of	O
E2F-1	B-protein
activates	O
the	O
UDG	B-DNA
promoter	I-DNA
through	O
several	O
E2F	B-DNA
sites	I-DNA
.	O

The	O
major	B-DNA
putative	I-DNA
downstream	I-DNA
site	I-DNA
for	O
E2F	B-protein
,	O
located	O
in	O
the	O
first	B-DNA
exon	I-DNA
,	O
serves	O
as	O
a	O
target	O
for	O
E2F-1/DP1	B-protein
complex	I-protein
binding	O
in	O
vitro	O
.	O

We	O
also	O
provide	O
evidence	O
for	O
the	O
functional	O
relationship	O
between	O
the	O
cyclin-like	B-protein
UDG	I-protein
gene	I-protein
product	I-protein
and	O
E2F	B-protein
.	O

High	O
levels	O
of	O
UDG	B-protein
expression	O
in	O
a	O
transient	O
transfection	O
assay	O
result	O
in	O
the	O
down-regulation	O
of	O
transcriptional	O
activity	O
through	O
elements	B-DNA
specific	O
for	O
E2F	B-protein
-mediated	O
transcription	O
.	O

Overexpression	O
of	O
UDG	B-protein
in	O
Saos	B-cell_line
2	I-cell_line
cells	I-cell_line
was	O
observed	O
to	O
delay	O
growth	O
late	O
in	O
G1	O
phase	O
and	O
transiently	O
arrest	O
these	O
cells	O
from	O
progressing	O
into	O
the	O
S	O
phase	O
.	O

This	O
hypothetical	O
model	O
integrates	O
one	O
mechanism	O
of	O
DNA	O
repair	O
with	O
the	O
cell	O
cycle	O
control	O
of	O
gene	O
transcription	O
,	O
likely	O
through	O
E2F	B-protein
.	O

This	O
implicates	O
E2F	B-protein
as	O
a	O
multifunctional	O
target	O
for	O
proteins	O
and	O
enzymes	O
,	O
possibly	O
,	O
responsive	O
to	O
DNA	O
damage	O
through	O
the	O
negative	O
effect	O
of	O
UDG	B-protein
on	O
E2F	B-protein
-mediated	O
transcriptional	O
activity	O
.	O

Cellular	O
and	O
molecular	O
mechanisms	O
of	O
IFN-gamma	B-protein
production	O
induced	O
by	O
IL-2	B-protein
and	O
IL-12	B-protein
in	O
a	O
human	B-cell_line
NK	I-cell_line
cell	I-cell_line
line	I-cell_line
.	O

Interferon-gamma	B-protein
(	O
IFN-gamma	B-protein
)	O
is	O
an	O
important	O
immunoregulatory	B-protein
protein	I-protein
produced	O
predominantly	O
by	O
T	B-cell_type
cells	I-cell_type
and	O
large	B-cell_type
granular	I-cell_type
lymphocytes	I-cell_type
(	O
LGL	B-cell_type
)	O
in	O
response	O
to	O
different	O
extracellular	O
signals	O
.	O

In	O
particular	O
,	O
two	O
interleukins	B-protein
(	O
ILs	B-protein
)	O
,	O
IL-2	B-protein
and	O
IL-12	B-protein
,	O
have	O
been	O
shown	O
to	O
be	O
potent	O
inducers	O
of	O
IFN-gamma	B-protein
gene	O
expression	O
in	O
both	O
T	B-cell_type
cells	I-cell_type
and	O
LGL	B-cell_type
.	O

Although	O
it	O
has	O
been	O
reported	O
that	O
there	O
are	O
some	O
T	B-cell_line
cell	I-cell_line
lines	I-cell_line
that	O
produce	O
IFN-gamma	B-protein
in	O
response	O
to	O
IL-2	O
and	O
IL-12	O
stimulation	O
,	O
there	O
has	O
as	O
yet	O
been	O
no	O
report	O
of	O
a	O
natural	B-cell_line
killer	I-cell_line
(	I-cell_line
NK	I-cell_line
)	I-cell_line
cell	I-cell_line
line	I-cell_line
that	O
responds	O
in	O
a	O
similar	O
manner	O
.	O

In	O
this	O
report	O
we	O
present	O
evidence	O
that	O
the	O
cell	B-cell_line
line	I-cell_line
NK3.3	I-cell_line
derived	O
from	O
human	B-cell_type
NK	I-cell_type
cells	I-cell_type
,	O
responds	O
to	O
both	O
IL-2	B-protein
and	O
IL-12	B-protein
,	O
as	O
measured	O
by	O
increases	O
in	O
IFN-gamma	B-protein
and	O
granulocyte-macrophage	B-protein
colony-stimulating	I-protein
factor	I-protein
(	O
GM-CSF	B-protein
)	O
cytoplasmic	O
mRNA	O
and	O
protein	O
expression	O
.	O

In	O
addition	O
,	O
when	O
used	O
together	O
IL-2	B-protein
and	O
IL-12	B-protein
synergized	O
in	O
the	O
induction	O
of	O
IFN-gamma	B-protein
and	O
GM-CSF	B-protein
and	O
this	O
synergy	O
was	O
attributed	O
to	O
an	O
increased	O
accumulation	O
and	O
stability	O
of	O
the	O
IFN-gamma	B-RNA
and	I-RNA
GM-CSF	I-RNA
mRNAs	I-RNA
.	O

To	O
investigate	O
the	O
signaling	O
pathways	O
involved	O
in	O
the	O
gene	O
induction	O
,	O
five	O
inhibitors	O
,	O
cyclosporin	O
A	O
(	O
CsA	O
)	O
,	O
transforming	B-protein
growth	I-protein
factor-beta	I-protein
,	O
cycloheximide	O
,	O
genistein	O
,	O
and	O
staurosporine	O
A	O
,	O
were	O
used	O
in	O
analyzing	O
the	O
effects	O
of	O
IL-2	B-protein
and	O
IL-12	B-protein
on	O
NK3.3	B-cell_line
cells	I-cell_line
.	O

The	O
results	O
suggest	O
that	O
activation	O
of	O
protein	B-protein
kinase	I-protein
C	I-protein
,	O
but	O
not	O
new	O
protein	O
synthesis	O
,	O
is	O
required	O
for	O
IL-2	B-protein
induction	O
of	O
IFN-gamma	B-RNA
and	I-RNA
GM-CSF	I-RNA
cytoplasmic	I-RNA
mRNA	I-RNA
.	O

In	O
contrast	O
,	O
IL-12	B-protein
induction	O
of	O
IFN-gamma	B-RNA
cytoplasmic	I-RNA
mRNA	I-RNA
appears	O
to	O
only	O
partially	O
depend	O
on	O
activation	O
of	O
protein	B-protein
kinase	I-protein
C	I-protein
.	O

Furthermore	O
,	O
both	O
transforming	B-protein
growth	I-protein
factor-beta	I-protein
and	O
genistein	O
,	O
a	O
tyrosine	O
kinase	O
inhibitor	O
,	O
could	O
suppress	O
IL-2	B-protein
and	O
IL-12	B-protein
signaling	O
but	O
CsA	O
was	O
generally	O
inactive	O
.	O

It	O
also	O
was	O
observed	O
that	O
suppression	O
of	O
cytokine	B-DNA
gene	I-DNA
expression	O
by	O
these	O
agents	O
was	O
independent	O
of	O
the	O
inhibition	O
of	O
proliferation	O
.	O

In	O
addition	O
,	O
IL-2	B-protein
but	O
not	O
IL-12	B-protein
induced	O
nuclear	B-protein
factors	I-protein
NF-kappa	B-protein
B	I-protein
and	O
AP1	B-protein
,	O
and	O
regulation	O
of	O
the	O
nuclear	O
levels	O
of	O
these	O
two	O
DNA	B-protein
binding	I-protein
protein	I-protein
complexes	I-protein
is	O
correlated	O
with	O
IFN-gamma	O
and	O
GM-CSF	O
gene	O
expression	O
.	O

These	O
data	O
indicate	O
that	O
IL-2	B-protein
and	O
IL-12	B-protein
may	O
have	O
distinct	O
signaling	O
pathways	O
leading	O
to	O
the	O
induction	O
of	O
IFN-gamma	B-protein
and	O
GM-CSF	B-protein
gene	O
expression	O
,	O
and	O
that	O
the	O
NK3.3	B-cell_line
cell	I-cell_line
line	I-cell_line
may	O
serve	O
as	O
a	O
novel	O
model	O
for	O
dissecting	O
the	O
biochemical	O
and	O
molecular	O
events	O
involved	O
in	O
these	O
pathways	O
.	O

A	O
functional	O
T-cell	B-protein
receptor	I-protein
signaling	O
pathway	O
is	O
required	O
for	O
p95vav	B-protein
activity	O
.	O

Stimulation	O
of	O
the	O
T-cell	B-protein
antigen	I-protein
receptor	I-protein
(	O
TCR	B-protein
)	O
induces	O
activation	O
of	O
multiple	O
tyrosine	B-protein
kinases	I-protein
,	O
resulting	O
in	O
phosphorylation	O
of	O
numerous	O
intracellular	O
substrates	O
.	O

One	O
substrate	O
is	O
p95vav	B-protein
,	O
which	O
is	O
expressed	O
exclusively	O
in	O
hematopoietic	B-cell_type
and	I-cell_type
trophoblast	I-cell_type
cells	I-cell_type
.	O

It	O
contains	O
a	O
number	O
of	O
structural	B-protein
motifs	I-protein
,	O
including	O
Src	B-protein
homology	I-protein
2	I-protein
,	I-protein
Src	I-protein
homology	I-protein
3	I-protein
,	I-protein
and	I-protein
pleckstrin	I-protein
homology	I-protein
domains	I-protein
and	O
a	O
putative	B-protein
guanine	I-protein
nucleotide	I-protein
exchange	I-protein
domain	I-protein
.	O

The	O
role	O
of	O
p95vav	B-protein
in	O
TCR	B-protein
-mediated	O
signaling	O
processes	O
is	O
unclear	O
.	O

Here	O
,	O
we	O
show	O
that	O
overexpression	O
of	O
p95vav	B-protein
alone	O
in	O
Jurkat	O
T	B-cell_type
cells	I-cell_type
leads	O
to	O
activation	O
of	O
the	O
nuclear	B-protein
factors	I-protein
,	O
including	O
NFAT	B-protein
,	O
involved	O
in	O
interleukin-2	B-protein
expression	O
.	O

Furthermore	O
,	O
p95vav	B-protein
synergizes	O
with	O
TCR	B-protein
stimulation	O
in	O
inducing	O
NFAT-	O
and	O
interleukin-2-dependent	O
transcription	O
.	O

In	O
contrast	O
,	O
NFAT	B-protein
activation	O
by	O
a	O
G-protein-coupled	B-protein
receptor	I-protein
is	O
not	O
modulated	O
by	O
p95vav	B-protein
overexpression	O
,	O
suggesting	O
that	O
the	O
effect	O
is	O
specific	O
to	O
the	O
TCR	B-protein
signaling	O
pathways	O
.	O

Although	O
removal	O
of	O
the	O
first	B-protein
67	I-protein
amino	I-protein
acids	I-protein
of	O
p95vav	B-protein
activates	O
its	O
transforming	O
potential	O
in	O
NIH	B-cell_line
3T3	I-cell_line
cells	I-cell_line
,	O
this	O
region	O
appears	O
to	O
be	O
required	O
for	O
its	O
function	O
in	O
T	B-cell_type
cells	I-cell_type
.	O

We	O
further	O
demonstrate	O
that	O
the	O
p95vav	B-protein
-induced	O
NFAT	B-protein
activation	O
is	O
not	O
mimicked	O
by	O
Ras	B-protein
activation	O
,	O
though	O
its	O
function	O
is	O
dependent	O
upon	O
Ras	B-protein
and	O
Raf	B-protein
.	O

Furthermore	O
,	O
the	O
activating	O
function	O
of	O
p95vav	B-protein
is	O
blocked	O
by	O
FK506	O
,	O
suggesting	O
that	O
its	O
activity	O
also	O
depends	O
on	O
calcineurin	B-protein
.	O

To	O
further	O
dissect	O
p95vav	B-protein
involvement	O
in	O
TCR	B-protein
signaling	O
,	O
we	O
analyzed	O
various	O
Jurkat	B-cell_line
mutants	I-cell_line
deficient	O
in	O
TCR	B-protein
signaling	O
function	O
or	O
TCR	B-protein
expression	O
and	O
showed	O
that	O
an	O
intact	O
TCR	B-protein
signaling	O
pathway	O
is	O
required	O
for	O
p95vav	B-protein
to	O
function	O
.	O

However	O
,	O
overexpression	O
of	O
p95vav	B-protein
does	O
not	O
appear	O
to	O
influence	O
TCR	B-protein
-induced	O
protein	O
tyrosine	O
phosphorylation	O
or	O
increases	O
in	O
cytoplasmic	O
free	O
calcium	O
.	O

Taken	O
together	O
,	O
our	O
data	O
suggest	O
that	O
p95vav	B-protein
plays	O
an	O
important	O
role	O
at	O
an	O
yet	O
unidentified	O
proximal	O
position	O
in	O
the	O
TCR	B-protein
signaling	O
cascade	O
.	O

Positive	O
and	O
negative	O
regulation	O
of	O
granulocyte-macrophage	B-protein
colony-stimulating	I-protein
factor	I-protein
promoter	O
activity	O
by	O
AML1-related	B-protein
transcription	I-protein
factor	I-protein
,	O
PEBP2	B-protein
.	O

The	O
granulocyte-macrophage	B-DNA
colony-stimulating	I-DNA
factor	I-DNA
(	I-DNA
GM-CSF	I-DNA
)	I-DNA
gene	I-DNA
promoter	I-DNA
contains	O
a	O
consensus	O
sequence	O
for	O
the	O
polyomavirus	B-protein
enhancer	I-protein
binding-protein	I-protein
2	I-protein
(	I-protein
PEBP2	I-protein
)	I-protein
transcription	I-protein
factor	I-protein
,	O
which	O
consists	O
of	O
alpha	B-protein
and	I-protein
beta	I-protein
subunits	I-protein
.	O

There	O
are	O
at	O
least	O
two	O
genes	O
,	O
alpha	B-DNA
A	I-DNA
and	O
alpha	B-DNA
B	I-DNA
,	O
encoding	O
the	O
alpha	B-protein
subunit	I-protein
.	O

alpha	B-DNA
B	I-DNA
is	O
the	O
mouse	B-DNA
homologue	I-DNA
of	O
human	B-DNA
AML1	I-DNA
gene	I-DNA
detected	O
at	O
the	O
breakpoints	O
of	O
t	O
(	O
8	O
;	O
21	O
)	O
and	O
t	O
(	O
3	O
;	O
21	O
)	O
myeloid	O
leukemias	O
.	O

We	O
examined	O
alpha	B-protein
A1	I-protein
(	O
an	O
alpha	B-protein
A-gene	I-protein
product	I-protein
)	O
and	O
alpha	B-protein
B1	I-protein
and	O
alpha	B-protein
B2	I-protein
(	O
two	O
alpha	B-protein
B-encoded	I-protein
isomers	I-protein
)	O
for	O
their	O
effects	O
on	O
the	O
GM-CSF	B-DNA
promoter	I-DNA
.	O

PEBP2	B-protein
alpha	I-protein
A1	I-protein
,	O
alpha	B-protein
B1	I-protein
,	O
and	O
alpha	B-protein
B2	I-protein
proteins	I-protein
bound	O
the	O
PEBP2	B-DNA
site	I-DNA
within	O
the	O
mouse	B-DNA
GM-CSF	I-DNA
promoter	I-DNA
.	O

PEBP2	B-protein
alpha	I-protein
A1	I-protein
and	O
alpha	B-protein
B1	I-protein
enhanced	O
the	O
expression	O
of	O
the	O
GM-CSF	B-DNA
promoter-driven	I-DNA
reporter	I-DNA
plasmid	I-DNA
in	O
unstimulated	B-cell_line
and	I-cell_line
12-O-tetradecanoylphorbol	I-cell_line
13-acetate/phytohemagglutinin-stimulated	I-cell_line
human	I-cell_line
Jurkat	I-cell_line
T	I-cell_line
cells	I-cell_line
.	O

In	O
contrast	O
,	O
the	O
promoter	O
activity	O
was	O
suppressed	O
by	O
alpha	B-protein
B2	I-protein
.	O

Coexpression	O
of	O
alpha	B-protein
B1	I-protein
and	O
alpha	B-protein
B2	I-protein
showed	O
that	O
the	O
promoter	O
activity	O
could	O
be	O
determined	O
by	O
the	O
alpha	B-protein
B1	I-protein
/alpha	B-protein
B2	I-protein
ratio	O
.	O

Jurkat	O
cell	O
extract	O
contained	O
PEBP2	B-protein
site-binding	I-protein
protein	I-protein
(	O
s	O
)	O
that	O
cross-reacted	O
with	O
antimouse	B-protein
alpha	I-protein
A1	I-protein
antibodies	I-protein
.	O

Northern	O
blot	O
analysis	O
indicated	O
the	O
expression	O
of	O
human	O
PEBP2	B-protein
alpha	I-protein
A	I-protein
,	O
alpha	B-DNA
B	I-DNA
(	O
AML1	B-DNA
)	O
,	O
and	O
beta	B-DNA
genes	I-DNA
in	O
Jurkat	B-cell_line
cells	I-cell_line
.	O

Although	O
further	O
studies	O
are	O
required	O
to	O
determine	O
the	O
precise	O
role	O
of	O
PEBP2	B-protein
in	O
the	O
GM-CSF	B-protein
promoter	O
activity	O
,	O
the	O
present	O
findings	O
suggested	O
the	O
importance	O
of	O
the	O
relative	O
ratio	O
of	O
different	O
PEBP2	B-protein
isoforms	I-protein
in	O
regulating	O
the	O
levels	O
of	O
the	O
promoter	O
activity	O
.	O

IFN-gamma	B-protein
priming	O
of	O
monocytes	B-cell_type
enhances	O
LPS-induced	O
TNF	B-protein
production	O
by	O
augmenting	O
both	O
transcription	O
and	O
MRNA	O
stability	O
.	O

The	O
induction	O
of	O
cytokine	B-protein
expression	O
in	O
monocytes	B-cell_type
/	O
macrophages	B-cell_type
by	O
bacterial	B-protein
endotoxin	I-protein
or	O
lipopolysaccharide	O
is	O
a	O
critical	O
,	O
highly	O
regulated	O
host	O
defence	O
response	O
.	O

The	O
augmentation	O
of	O
LPS	O
responses	O
by	O
interferon	B-protein
gamma	I-protein
(	O
IFN-gamma	B-protein
)	O
,	O
referred	O
to	O
as	O
priming	O
,	O
is	O
well	O
established	O
.	O

However	O
,	O
the	O
mechanism	O
(	O
s	O
)	O
by	O
which	O
priming	O
occurs	O
is	O
poorly	O
defined	O
.	O

Using	O
tumour	B-protein
necrosis	I-protein
factor	I-protein
(	O
TNF	B-protein
)	O
induction	O
as	O
a	O
model	O
,	O
experiments	O
were	O
designed	O
to	O
analyse	O
in	O
detail	O
the	O
priming	O
effect	O
on	O
the	O
LPS	O
response	O
in	O
human	B-cell_type
monocytes	I-cell_type
.	O

Priming	O
by	O
IFN-gamma	B-protein
was	O
primarily	O
manifested	O
at	O
the	O
level	O
of	O
TNF	B-RNA
mRNA	I-RNA
accumulation	O
.	O

IFN-gamma	B-protein
pre-treatment	O
affected	O
the	O
magnitude	O
rather	O
than	O
the	O
sensitivity	O
of	O
the	O
LPS	O
response	O
.	O

Priming	O
occurred	O
after	O
several	O
hours	O
of	O
treatment	O
,	O
and	O
the	O
primed	O
state	O
was	O
induced	O
by	O
either	O
IFN-gamma	B-protein
or	O
GM-CSF	B-protein
,	O
but	O
not	O
M-CSF	B-protein
.	O

Primed	O
monocytes	B-cell_type
transcribed	O
TNF	B-RNA
mRNA	I-RNA
at	O
a	O
higher	O
rate	O
than	O
freshly	O
isolated	O
monocytes	B-cell_type
upon	O
activation	O
with	O
LPS	O
.	O

The	O
increased	O
transcriptional	O
rate	O
correlated	O
with	O
a	O
marked	O
increase	O
in	O
nuclear	B-protein
factor-kappa	I-protein
B	I-protein
activity	O
in	O
these	O
cells	O
as	O
determined	O
by	O
electrophoretic	O
mobility	O
shift	O
assay	O
using	O
a	O
consensus	B-DNA
NF-kappa	I-DNA
B	I-DNA
oligonucleotide	I-DNA
.	O

An	O
additional	O
significant	O
finding	O
was	O
than	O
TNF	B-RNA
mRNA	I-RNA
induced	O
in	O
primed	B-cell_line
cells	I-cell_line
was	O
much	O
more	O
stable	O
than	O
in	O
unprimed	B-cell_line
cells	I-cell_line
(	O
T1/2	O
increased	O
6-8-fold	O
)	O
.	O

Consistent	O
with	O
the	O
increased	O
mRNA	B-RNA
stability	O
,	O
the	O
duration	O
of	O
mRNA	B-RNA
accumulation	O
was	O
longer	O
following	O
LPS	O
stimulation	O
in	O
primed	O
monocytes	B-cell_type
,	O
in	O
addition	O
to	O
being	O
of	O
greater	O
magnitude	O
.	O

Finally	O
,	O
primed	O
and	O
unprimed	O
cells	O
possessed	O
a	O
differential	O
sensitivity	O
to	O
the	O
kinase	O
inhibitor	O
H-89	O
.	O

H-89	O
substantially	O
suppressed	O
LPS-induced	O
TNF	B-RNA
mRNA	I-RNA
accumulation	O
in	O
unprimed	B-cell_line
cells	I-cell_line
,	O
but	O
had	O
no	O
effect	O
on	O
primed	B-cell_line
monocytes	I-cell_line
following	O
LPS	O
stimulation	O
.	O

(	O
ABSTRACT	O
TRUNCATED	O
AT	O
250	O
WORDS	O
)	O

A	O
Myc-associated	B-DNA
zinc	I-DNA
finger	I-DNA
protein	I-DNA
binding	I-DNA
site	I-DNA
is	O
one	O
of	O
four	O
important	O
functional	B-DNA
regions	I-DNA
in	O
the	O
CD4	B-DNA
promoter	I-DNA
.	O

The	O
CD4	B-DNA
promoter	I-DNA
plays	O
an	O
important	O
role	O
in	O
the	O
developmental	O
control	O
of	O
CD4	B-protein
transcription	O
.	O

In	O
this	O
report	O
,	O
we	O
show	O
that	O
the	O
minimal	O
CD4	B-DNA
promoter	I-DNA
has	O
four	O
factor	B-DNA
binding	I-DNA
sites	I-DNA
,	O
each	O
of	O
which	O
is	O
required	O
for	O
full	O
function	O
.	O

Using	O
biochemical	O
and	O
mutagenesis	O
analyses	O
,	O
we	O
determined	O
that	O
multiple	O
nuclear	B-protein
factors	I-protein
bind	O
to	O
these	O
independent	O
sites	O
.	O

We	O
determined	O
that	O
an	O
initiator-like	B-DNA
sequence	I-DNA
present	O
at	O
the	O
cap	B-DNA
site	I-DNA
and	O
an	O
Ets	B-DNA
consensus	I-DNA
sequence	I-DNA
are	O
required	O
for	O
full	O
promoter	B-DNA
function	O
.	O

We	O
also	O
demonstrate	O
that	O
the	O
Myc-associated	B-protein
zinc	I-protein
finger	I-protein
protein	I-protein
(	O
MAZ	B-protein
)	O
appears	O
to	O
be	O
the	O
predominant	B-protein
factor	I-protein
binding	O
to	O
one	O
of	O
these	O
sites	O
.	O

This	O
last	O
site	O
closely	O
resembles	O
the	O
ME1a1	B-DNA
G3AG4AG3	I-DNA
motif	I-DNA
previously	O
shown	O
to	O
be	O
a	O
critical	O
element	O
in	O
the	O
P2	B-DNA
promoter	I-DNA
of	O
the	O
c-myc	B-DNA
gene	I-DNA
.	O

We	O
therefore	O
believe	O
that	O
the	O
MAZ	B-protein
transcription	I-protein
factor	I-protein
is	O
also	O
likely	O
to	O
play	O
an	O
important	O
role	O
in	O
the	O
control	O
of	O
developmental	O
expression	O
of	O
the	O
CD4	B-DNA
gene	I-DNA
.	O

Erythropoietin	B-protein
stimulates	O
transcription	O
of	O
the	O
TAL1/SCL	B-DNA
gene	I-DNA
and	O
phosphorylation	O
of	O
its	O
protein	B-protein
products	I-protein
.	O

Activation	O
of	O
the	O
TAL1	B-DNA
(	I-DNA
or	I-DNA
SCL	I-DNA
)	I-DNA
gene	I-DNA
,	O
originally	O
identified	O
through	O
its	O
involvement	O
by	O
a	O
recurrent	O
chromosomal	O
translocation	O
,	O
is	O
the	O
most	O
frequent	O
molecular	O
lesion	O
recognized	O
in	O
T-cell	O
acute	O
lymphoblastic	O
leukemia	O
.	O

The	O
protein	B-protein
products	I-protein
of	O
this	O
gene	O
contain	O
the	O
basic-helix-loop-helix	B-protein
motif	I-protein
characteristic	O
of	O
a	O
large	O
family	O
of	O
transcription	B-protein
factors	I-protein
that	O
bind	O
to	O
the	O
canonical	B-DNA
DNA	I-DNA
sequence	I-DNA
CANNTG	I-DNA
as	O
protein	B-protein
heterodimers	I-protein
.	O

TAL1	B-protein
expression	O
by	O
erythroid	B-cell_type
cells	I-cell_type
in	O
vivo	O
and	O
in	O
chemical-induced	B-cell_line
erythroleukemia	I-cell_line
cell	I-cell_line
lines	I-cell_line
in	O
vivo	O
suggested	O
the	O
gene	O
might	O
regulate	O
aspects	O
of	O
erythroid	O
differentiation	O
.	O

Since	O
the	O
terminal	O
events	O
of	O
erythropoiesis	O
are	O
controlled	O
by	O
the	O
glycoprotein	B-protein
hormone	I-protein
erythropoietin	I-protein
(	O
Epo	B-protein
)	O
,	O
we	O
investigated	O
whether	O
the	O
expression	O
or	O
activity	O
of	O
the	O
TAL1	B-DNA
gene	I-DNA
and	O
its	O
protein	B-protein
products	I-protein
were	O
affected	O
by	O
Epo	B-protein
in	O
splenic	B-cell_type
erythroblasts	I-cell_type
from	O
mice	O
infected	O
with	O
an	O
anemia-inducing	O
strain	O
of	O
Friend	O
virus	O
(	O
FVA	O
cells	O
)	O
.	O

Epo	B-protein
elicited	O
a	O
rapid	O
,	O
dose-related	O
increase	O
in	O
TAL1	B-RNA
mRNA	I-RNA
by	O
increasing	O
transcription	O
of	O
the	O
gene	O
and	O
stabilizing	O
one	O
of	O
its	O
mRNAs	B-RNA
.	O

An	O
Epo	B-protein
-inducible	O
TAL1	B-protein
DNA	O
binding	O
activity	O
was	O
identified	O
in	O
FVA	O
cell	O
nuclear	O
extracts	O
that	O
subsequently	O
decayed	O
despite	O
accumulating	O
mRNA	B-RNA
and	O
protein	O
.	O

Induction	O
of	O
DNA	O
binding	O
activity	O
was	O
associated	O
temporally	O
with	O
Epo	B-protein
-induced	O
phosphorylation	O
of	O
nuclear	B-protein
TAL1	I-protein
protein	I-protein
.	O

These	O
results	O
indicate	O
that	O
Epo	B-protein
acts	O
at	O
both	O
transcriptional	O
and	O
posttranscriptional	O
levels	O
on	O
the	O
TAL1	B-protein
locus	O
in	O
Friend	B-cell_line
virus-induced	I-cell_line
erythroblasts	I-cell_line
and	O
establish	O
a	O
link	O
between	O
Epo	B-protein
signaling	O
mechanisms	O
and	O
a	O
member	O
of	O
a	O
family	O
of	O
transcription	B-protein
factors	I-protein
involved	O
in	O
the	O
differentiation	O
of	O
diverse	B-cell_type
cell	I-cell_type
lineages	I-cell_type
.	O

Nonradioactive	O
quantification	O
of	O
glucocorticoid	B-protein
receptor	I-protein
expression	O
during	O
differentiation	O
of	O
human	O
monocytic	B-cell_type
cells	I-cell_type
(	O
U937	B-cell_line
)	O
.	O

We	O
describe	O
a	O
method	O
for	O
relative	O
quantification	O
of	O
specific	O
mRNA	B-RNA
using	O
a	O
nonradioactive	O
assay	O
based	O
on	O
DNA	O
strand	O
competition	O
between	O
identical	O
sequences	O
of	O
biotin-	O
and	O
fluorescein-labeled	O
amplicon	O
(	O
probe	O
)	O
and	O
unlabeled	O
amplicon	O
(	O
target	O
)	O
during	O
hybridization	O
.	O

As	O
the	O
target	O
quantity	O
increased	O
,	O
that	O
of	O
the	O
double-labeled	O
probe	O
decreased	O
in	O
accordance	O
with	O
the	O
mass	O
action	O
law	O
.	O

This	O
technique	O
was	O
successfully	O
applied	O
to	O
evaluate	O
differences	O
in	O
glucocorticoid	B-protein
receptor	I-protein
expression	O
in	O
U937	B-cell_line
cells	I-cell_line
before	O
and	O
after	O
the	O
addition	O
of	O
potent	O
differentiation	O
inducers	O
:	O
12-O-tetradecanoylphorbol	O
13-acetate	O
(	O
TPA	O
)	O
and	O
a	O
combination	O
of	O
all-trans	O
retinoic	O
acid	O
(	O
RA	O
)	O
and	O
1	O
,	O
25-dihydroxyvitamin	O
D2	O
(	O
VD	O
)	O
.	O

We	O
observed	O
that	O
TPA	O
treatment	O
was	O
associated	O
with	O
an	O
increase	O
in	O
specific	O
binding	O
of	O
[	O
3H	O
]	O
dexamethasone	O
and	O
up-regulation	O
of	O
GR	B-RNA
mRNA	I-RNA
while	O
no	O
enhanced	O
GR	B-protein
expression	O
was	O
perceived	O
with	O
RA/VD	O
treatment	O
.	O

Induction	O
of	O
Sp1	B-protein
phosphorylation	O
and	O
NF-kappa	B-DNA
B-independent	I-DNA
HIV	I-DNA
promoter	I-DNA
domain	O
activity	O
in	O
T	B-cell_type
lymphocytes	I-cell_type
stimulated	O
by	O
okadaic	O
acid	O
.	O

In	O
contrast	O
to	O
the	O
purely	O
enhancer-dependent	O
effect	O
of	O
cytokines	B-protein
such	O
as	O
TNF	B-protein
on	O
the	O
activity	O
of	O
the	O
HIV	B-DNA
regulatory	I-DNA
region	I-DNA
(	O
LTR	B-DNA
)	O
,	O
we	O
observed	O
that	O
okadaic	O
acid	O
(	O
OKA	O
)	O
activates	O
HIV	O
transcription	O
through	O
both	O
the	O
enhancer	O
,	O
responding	O
to	O
the	O
factor	O
NF-kappa	B-protein
B	I-protein
,	O
and	O
the	O
promoter	B-DNA
domain	I-DNA
of	O
the	O
LTR	B-DNA
.	O

The	O
inducibility	O
of	O
HIV	B-DNA
LTR-driven	I-DNA
luciferase	I-DNA
expression	I-DNA
constructs	I-DNA
in	O
lymphoblastoid	B-cell_type
cells	I-cell_type
stimulated	O
by	O
OKA	O
depended	O
on	O
both	O
functional	B-DNA
Sp1	I-DNA
binding	I-DNA
elements	I-DNA
and	O
the	O
ability	O
of	O
the	O
TATA	B-DNA
box	I-DNA
to	O
bind	O
the	O
protein	O
TBP	B-protein
.	O

In	O
both	O
transformed	B-cell_type
and	I-cell_type
normal	I-cell_type
lymphocytes	I-cell_type
,	O
OKA	O
stimulation	O
induced	O
intense	O
phosphorylation	O
of	O
the	O
constitutively	O
expressed	O
Sp1	B-protein
protein	I-protein
in	O
the	O
nucleus	O
,	O
a	O
property	O
of	O
OKA	O
not	O
shared	O
by	O
TNF	B-protein
,	O
phorbol	O
ester	O
,	O
or	O
PHA	B-protein
and	O
interleukin	B-protein
2	I-protein
.	O

Responsiveness	O
of	O
LTR	B-DNA
constructs	I-DNA
deleted	O
of	O
kappa	B-DNA
B	I-DNA
elements	I-DNA
to	O
HIV	B-protein
Tat	I-protein
expression	O
was	O
increased	O
upon	O
OKA	O
but	O
not	O
TNF	B-protein
stimulation	O
.	O

Our	O
results	O
suggest	O
that	O
SP1	B-protein
phosphorylation	O
induced	O
by	O
OKA	O
,	O
a	O
selective	O
inhibitor	O
of	O
the	O
serine-threonine	B-protein
phosphatase	I-protein
PP2A	B-protein
,	O
facilitates	O
the	O
formation	O
of	O
a	O
transcription	B-protein
complex	I-protein
involving	O
general	O
transcription	B-protein
factors	I-protein
,	O
HIV	B-protein
Tat	I-protein
,	O
and	O
Sp1	B-protein
proteins	I-protein
.	O

The	O
formation	O
of	O
this	O
complex	O
would	O
increase	O
,	O
independently	O
of	O
an	O
in	O
synergy	O
with	O
NF-kappa	B-protein
B	I-protein
,	O
the	O
low	O
basal	O
activity	O
of	O
the	O
HIV	B-DNA
LTR	I-DNA
observed	O
in	O
normal	B-cell_type
T	I-cell_type
lymphocytes	I-cell_type
.	O

The	O
role	O
of	O
shared	B-protein
receptor	I-protein
motifs	I-protein
and	O
common	B-protein
Stat	I-protein
proteins	I-protein
in	O
the	O
generation	O
of	O
cytokine	B-protein
pleiotropy	O
and	O
redundancy	O
by	O
IL-2	B-protein
,	O
IL-4	B-protein
,	O
IL-7	B-protein
,	O
IL-13	B-protein
,	O
and	O
IL-15	B-protein
.	O

To	O
understand	O
the	O
molecular	O
bases	O
for	O
cytokine	O
redundancy	O
and	O
pleiotropy	O
,	O
we	O
have	O
compared	O
the	O
Stat	B-protein
proteins	I-protein
activated	O
in	O
peripheral	B-cell_type
blood	I-cell_type
lymphocytes	I-cell_type
(	O
PBLs	B-cell_type
)	O
by	O
cytokines	B-protein
with	O
shared	O
and	O
distinct	O
actions	O
.	O

Interleukin-2	B-protein
(	O
IL-2	B-protein
)	O
rapidly	O
activated	O
Stat5	B-protein
in	O
fresh	O
PBL	B-cell_type
,	O
and	O
Stat3	B-protein
and	O
Stat5	B-protein
in	O
preactivated	B-cell_type
PBL	I-cell_type
.	O

IL-7	B-protein
and	O
IL-15	B-protein
induced	O
the	O
same	O
complexes	O
as	O
IL-2	B-protein
,	O
a	O
feature	O
explained	O
by	O
the	O
existence	O
of	O
similar	O
tyrosine-phosphorylated	B-protein
motifs	I-protein
in	O
the	O
cytoplasmic	B-protein
domains	I-protein
of	O
IL-2R	B-protein
beta	I-protein
and	O
IL-7R	B-protein
that	O
can	O
serve	O
as	O
docking	O
sites	O
for	O
Stat	B-protein
proteins	I-protein
.	O

IL-13	B-protein
Induced	O
the	O
same	O
complexes	O
as	O
IL-4	B-protein
,	O
a	O
finding	O
explained	O
by	O
our	O
studies	O
implicating	O
IL-4R	B-protein
as	O
a	O
shared	O
component	O
of	O
the	O
receptors	B-protein
.	O

These	O
studies	O
demonstrate	O
that	O
a	O
single	O
cytokine	B-protein
can	O
activate	O
different	O
combinations	O
of	O
Stat	B-protein
proteins	I-protein
under	O
different	O
physiological	O
conditions	O
,	O
and	O
also	O
indicate	O
two	O
mechanisms	O
by	O
which	O
distinct	O
cytokines	B-protein
can	O
activate	O
the	O
same	O
Stat	B-protein
protein	I-protein
.	O

Control	O
of	O
I	B-protein
kappa	I-protein
B-alpha	I-protein
proteolysis	O
by	O
site-specific	O
,	O
signal-induced	O
phosphorylation	O
.	O

I	B-protein
kappa	I-protein
B-alpha	I-protein
inhibits	O
transcription	B-protein
factor	I-protein
NF-kappa	B-protein
B	I-protein
by	O
retaining	O
it	O
in	O
the	O
cytoplasm	O
.	O

Various	O
stimuli	O
,	O
typically	O
those	O
associated	O
with	O
stress	O
or	O
pathogens	O
,	O
rapidly	O
inactivate	O
I	B-protein
kappa	I-protein
B-alpha	I-protein
.	O

This	O
liberates	O
NF-kappa	B-protein
B	I-protein
to	O
translocate	O
to	O
the	O
nucleus	O
and	O
initiate	O
transcription	O
of	O
genes	B-DNA
important	O
for	O
the	O
defense	O
of	O
the	O
organism	O
.	O

Activation	O
of	O
NF-kappa	B-protein
B	I-protein
correlates	O
with	O
phosphorylation	O
of	O
I	B-protein
kappa	I-protein
B-alpha	I-protein
and	O
requires	O
the	O
proteolysis	O
of	O
this	O
inhibitor	O
.	O

When	O
either	O
serine-32	O
or	O
serine-36	O
of	O
I	B-protein
kappa	I-protein
B-alpha	I-protein
was	O
mutated	O
,	O
the	O
protein	O
did	O
not	O
undergo	O
signal-induced	O
phosphorylation	O
or	O
degradation	O
,	O
and	O
NF-kappa	B-protein
B	I-protein
could	O
not	O
be	O
activated	O
.	O

These	O
results	O
suggest	O
that	O
phosphorylation	O
at	O
one	O
or	O
both	O
of	O
these	O
residues	O
is	O
critical	O
for	O
activation	O
of	O
NF-kappa	B-protein
B	I-protein
.	O

Regulation	O
of	O
transcription	O
of	O
the	O
human	B-DNA
erythropoietin	I-DNA
receptor	I-DNA
gene	I-DNA
by	O
proteins	O
binding	O
to	O
GATA-1	B-DNA
and	I-DNA
Sp1	I-DNA
motifs	I-DNA
.	O

Erythropoietin	B-protein
(	O
Epo	B-protein
)	O
,	O
the	O
primary	O
regulator	O
of	O
the	O
production	O
of	O
erythroid	B-cell_type
cells	I-cell_type
,	O
acts	O
by	O
binding	O
to	O
a	O
cell	B-protein
surface	I-protein
receptor	I-protein
(	O
EpoR	B-protein
)	O
on	O
erythroid	B-cell_type
progenitors	I-cell_type
.	O

We	O
used	O
deletion	O
analysis	O
and	O
transfection	O
assays	O
with	O
reporter	B-DNA
gene	I-DNA
constructs	I-DNA
to	O
examine	O
the	O
transcription	B-DNA
control	I-DNA
elements	I-DNA
in	O
the	O
5	B-DNA
'	I-DNA
flanking	I-DNA
region	I-DNA
of	O
the	O
human	B-DNA
EpoR	I-DNA
gene	I-DNA
.	O

In	O
erythroid	B-cell_type
cells	I-cell_type
most	O
of	O
the	O
transcription	O
activity	O
was	O
contained	O
in	O
a	O
150	B-DNA
bp	I-DNA
promoter	I-DNA
fragment	O
with	O
binding	B-DNA
sites	I-DNA
for	O
transcription	B-protein
factors	I-protein
AP2	B-protein
,	O
Sp1	B-protein
and	O
the	O
erythroid-specific	B-protein
GATA-1	I-protein
.	O

The	O
150	B-DNA
bp	I-DNA
hEpoR	I-DNA
promoter	I-DNA
exhibited	O
high	O
and	O
low	O
activity	O
in	O
erythroid	O
OCIM1	B-cell_line
and	O
K562	B-cell_line
cells	I-cell_line
,	O
respectively	O
,	O
reflecting	O
the	O
high	O
and	O
low	O
levels	O
of	O
constitutive	O
hEpoR	B-protein
expression	O
.	O

The	O
GATA-1	B-DNA
and	I-DNA
Sp1	I-DNA
binding	I-DNA
sites	I-DNA
in	O
this	O
promoter	O
lacking	O
a	O
TATA	B-DNA
sequence	I-DNA
were	O
necessary	O
for	O
a	O
high	O
level	O
of	O
transcription	O
activation	O
.	O

Protein-DNA	O
binding	O
studies	O
suggested	O
that	O
Sp1	B-protein
and	O
two	O
other	O
CCGCCC	B-protein
binding	I-protein
proteins	I-protein
from	O
erythroid	B-cell_type
and	I-cell_type
non-erythroid	I-cell_type
cells	I-cell_type
could	O
bind	O
to	O
the	O
Sp1	B-DNA
binding	I-DNA
motif	I-DNA
.	O

By	O
increasing	O
GATA-1	B-protein
levels	O
via	O
co-transfection	O
,	O
we	O
were	O
able	O
to	O
transactivate	O
the	O
hEpoR	B-DNA
promoter	I-DNA
in	O
K562	B-cell_line
cells	I-cell_line
and	O
non-erythroid	B-cell_type
cells	I-cell_type
,	O
but	O
not	O
in	O
the	O
highly	O
active	O
OCIM1	B-cell_type
cells	I-cell_type
,	O
although	O
GATA-1	B-RNA
mRNA	I-RNA
levels	O
were	O
comparable	O
in	O
OCIM1	B-cell_line
and	O
K562	B-cell_line
.	O

Interestingly	O
,	O
when	O
we	O
mutated	O
the	O
Sp1	B-DNA
site	I-DNA
,	O
resulting	O
in	O
a	O
marked	O
decrease	O
in	O
hEpoR	B-DNA
promoter	I-DNA
activity	O
,	O
we	O
could	O
restore	O
transactivation	O
by	O
increasing	O
GATA-1	B-protein
levels	O
in	O
OCIM1	B-cell_type
cells	I-cell_type
.	O

These	O
data	O
suggest	O
that	O
while	O
GATA-1	B-protein
can	O
transactivate	O
the	O
EpoR	B-DNA
promoter	I-DNA
,	O
the	O
level	O
of	O
hEpoR	B-DNA
gene	I-DNA
expression	O
does	O
not	O
depend	O
on	O
GATA-1	B-protein
alone	O
.	O

Rather	O
,	O
hEpoR	B-protein
transcription	O
activity	O
depends	O
on	O
coordination	O
between	O
Sp1	B-protein
and	O
GATA-1	B-protein
with	O
other	O
cell-specific	B-protein
factors	I-protein
,	O
including	O
possibly	O
other	O
Sp1-like	B-protein
binding	I-protein
proteins	I-protein
,	O
to	O
provide	O
high	O
level	O
,	O
tissue-specific	O
expression	O
.	O

Overexpression	O
of	O
DR-nm23	B-protein
,	O
a	O
protein	O
encoded	O
by	O
a	O
member	O
of	O
the	O
nm23	B-DNA
gene	I-DNA
family	I-DNA
,	O
inhibits	O
granulocyte	B-cell_type
differentiation	O
and	O
induces	O
apoptosis	O
in	O
32Dc13	B-cell_line
myeloid	I-cell_line
cells	I-cell_line
.	O

Chronic	O
myelogenous	O
leukemia	O
evolves	O
in	O
two	O
clinically	O
distinct	O
stages	O
:	O
a	O
chronic	O
and	O
a	O
blast	O
crisis	O
phase	O
.	O

The	O
molecular	O
changes	O
associated	O
with	O
chronic	O
phase	O
to	O
blast	O
crisis	O
transition	O
are	O
largely	O
unknown	O
.	O

We	O
have	O
identified	O
a	O
cDNA	B-DNA
clone	I-DNA
,	O
DR-nm23	B-protein
,	O
differentially	O
expressed	O
in	O
a	O
blast-crisis	B-DNA
cDNA	I-DNA
library	I-DNA
,	I-DNA
which	O
has	O
approximately	O
70	O
%	O
sequence	O
similarity	O
to	O
the	O
putative	B-DNA
metastatic	I-DNA
suppressor	I-DNA
genes	I-DNA
,	O
nm23-H1	B-DNA
and	O
nm23-H2	B-DNA
.	O

The	O
deduced	O
amino	O
acid	O
sequence	O
similarity	O
to	O
the	O
proteins	O
encoded	O
by	O
these	O
two	O
latter	O
genes	O
is	O
approximately	O
65	O
%	O
and	O
includes	O
domains	O
and	O
amino	O
acid	O
residues	O
(	O
the	O
leucine	B-protein
zipper-like	I-protein
and	O
the	O
RGD	B-protein
domain	I-protein
,	O
a	O
serine	O
and	O
a	O
histidine	O
residue	O
in	O
the	O
NH2-	B-protein
and	O
in	O
the	O
COOH-terminal	B-protein
portion	I-protein
of	O
the	O
protein	O
,	O
respectively	O
)	O
postulated	O
to	O
be	O
important	O
for	O
nm23	B-protein
function	O
.	O

DR-nm23	B-RNA
mRNA	I-RNA
is	O
preferentially	O
expressed	O
at	O
early	O
stages	O
of	O
myeloid	O
differentiation	O
of	O
highly	B-cell_line
purified	I-cell_line
CD34+	I-cell_line
cells	I-cell_line
.	O

Its	O
constitutive	O
expression	O
in	O
the	O
myeloid	B-cell_line
precursor	I-cell_line
32Dc13	I-cell_line
cell	I-cell_line
line	I-cell_line
,	O
which	O
is	O
growth-factor	O
dependent	O
for	O
both	O
proliferation	O
and	O
differentiation	O
,	O
results	O
in	O
inhibition	O
of	O
granulocytic	O
differentiation	O
induced	O
by	O
granulocyte	B-protein
colony-stimulating	I-protein
factor	I-protein
and	O
causes	O
apoptotic	O
cell	O
death	O
.	O

These	O
results	O
are	O
consistent	O
with	O
a	O
role	O
for	O
DR-nm23	B-protein
in	O
normal	O
hematopoiesis	O
and	O
raise	O
the	O
possibility	O
that	O
its	O
overexpression	O
contributes	O
to	O
differentiation	O
arrest	O
,	O
a	O
feature	O
of	O
blastic	O
transformation	O
in	O
chronic	O
myelogenous	O
leukemia	O
.	O

An	O
interferon-gamma	B-DNA
activation	I-DNA
sequence	I-DNA
mediates	O
the	O
transcriptional	O
regulation	O
of	O
the	O
IgG	B-DNA
Fc	I-DNA
receptor	I-DNA
type	I-DNA
IC	I-DNA
gene	I-DNA
by	O
interferon-gamma	B-protein
.	O

Expression	O
of	O
the	O
IgG	B-protein
Fc	I-protein
receptor	I-protein
type	I-protein
I	I-protein
(	O
Fc	B-protein
gamma	I-protein
RI	I-protein
)	O
on	O
myeloid	B-cell_type
cells	I-cell_type
is	O
dramatically	O
increased	O
by	O
treatment	O
with	O
interferon-gamma	B-protein
(	O
IFN-gamma	B-protein
)	O
.	O

We	O
observed	O
that	O
Fc	B-protein
gamma	I-protein
RI	I-protein
transcript	O
levels	O
in	O
monoblast-like	B-cell_line
U937	I-cell_line
cells	I-cell_line
were	O
elevated	O
within	O
3	O
hr	O
and	O
peaked	O
12	O
hr	O
after	O
exposure	O
to	O
IFN-gamma	B-protein
.	O

Treatment	O
of	O
U937	B-cell_line
with	O
IFN-gamma	B-protein
for	O
9	O
hr	O
in	O
the	O
presence	O
of	O
cycloheximide	O
led	O
to	O
super-induction	O
of	O
Fc	B-protein
gamma	I-protein
RI	I-protein
expression	O
.	O

Nuclear	O
run-on	O
analysis	O
revealed	O
that	O
the	O
rate	O
of	O
Fc	B-protein
gamma	I-protein
RI	I-protein
transcription	O
was	O
increased	O
by	O
IFN-gamma	B-protein
.	O

Genomic	O
sequence	O
upstream	O
of	O
the	O
Fc	B-DNA
gamma	I-DNA
RIC	I-DNA
gene	I-DNA
was	O
cloned	O
and	O
subjected	O
to	O
primer	O
extension	O
analysis	O
,	O
which	O
demonstrated	O
a	O
single	O
transcription	B-DNA
initiation	I-DNA
site	I-DNA
without	O
a	O
TATA	B-DNA
box	I-DNA
.	O

Transient	O
transfections	O
of	O
CAT	B-DNA
reporter	I-DNA
gene	I-DNA
constructs	I-DNA
containing	O
various	O
Fc	B-DNA
gamma	I-DNA
RIC	I-DNA
promoter	I-DNA
sequences	I-DNA
into	O
U937	B-cell_line
cells	I-cell_line
revealed	O
that	O
a	O
20-bp	B-DNA
region	I-DNA
surrounding	O
the	O
transcription	B-DNA
start	I-DNA
site	I-DNA
(	O
-7	O
to	O
+13	O
)	O
was	O
capable	O
of	O
mediating	O
transcription	O
initiation	O
and	O
that	O
an	O
IFN-gamma	B-DNA
responsive	I-DNA
element	I-DNA
(	O
GIRE	B-DNA
)	O
was	O
present	O
within	O
74	B-DNA
bp	I-DNA
upstream	I-DNA
of	O
the	O
transcription	B-DNA
initiation	I-DNA
site	I-DNA
.	O

A	O
17-bp	B-DNA
sequence	I-DNA
between	O
positions	O
-51	O
and	O
-35	O
conferred	O
IFN-gamma	B-protein
responsiveness	O
on	O
a	O
heterologous	B-DNA
promoter	I-DNA
.	O

Double-stranded	B-DNA
GIRE	I-DNA
sequence	I-DNA
,	O
but	O
not	O
a	O
scrambled	B-DNA
sequence	I-DNA
,	O
was	O
specifically	O
bound	O
by	O
nuclear	B-protein
proteins	I-protein
from	O
IFN-gamma	B-cell_line
treated	I-cell_line
U937	I-cell_line
cells	I-cell_line
.	O

Gel	O
shift	O
experiments	O
further	O
showed	O
that	O
the	O
STAT1	B-protein
alpha	I-protein
protein	I-protein
bound	O
to	O
the	O
Fc	B-DNA
gamma	I-DNA
RIC	I-DNA
GIRE	I-DNA
in	O
response	O
to	O
IFN-gamma	B-protein
treatment	O
of	O
U937	B-cell_line
cells	I-cell_line
.	O

The	O
Fc	B-DNA
gamma	I-DNA
RIC	I-DNA
GIRE	I-DNA
is	O
homologous	O
to	O
the	O
IFN-gamma	B-DNA
activation	I-DNA
sequence	I-DNA
(	O
GAS	B-DNA
)	O
of	O
the	O
guanylate	B-protein
binding	I-protein
protein	I-protein
and	O
to	O
X	B-DNA
box	I-DNA
elements	I-DNA
of	O
class	B-DNA
II	I-DNA
MHC	I-DNA
genes	I-DNA
.	O

Our	O
results	O
demonstrate	O
that	O
transcriptional	O
regulation	O
of	O
the	O
Fc	B-DNA
gamma	I-DNA
RIC	I-DNA
gene	I-DNA
by	O
IFN-gamma	B-protein
involves	O
the	O
binding	O
of	O
STAT1	B-protein
alpha	I-protein
to	O
a	O
17-bp	B-DNA
GAS	I-DNA
homology	I-DNA
in	O
the	O
proximal	B-DNA
promoter	I-DNA
.	O

Constitutively	O
activated	O
Jak	B-protein
-STAT	B-protein
pathway	O
in	O
T	B-cell_type
cells	I-cell_type
transformed	O
with	O
HTLV-I	O
.	O

Human	O
T	O
cell	O
lymphotropic	O
virus	O
I	O
(	O
HTLV-I	O
)	O
is	O
the	O
etiological	O
agent	O
for	O
adult	O
T	O
cell	O
leukemia	O
and	O
tropical	O
spastic	O
paraparesis	O
(	O
also	O
termed	O
HTLV-I-associated	O
myelopathy	O
)	O
.	O

HTLV-I-infected	B-cell_type
peripheral	I-cell_type
blood	I-cell_type
T	I-cell_type
cells	I-cell_type
exhibit	O
an	O
initial	O
phase	O
of	O
interleukin-2	B-protein
(	O
IL-2	B-protein
)	O
-dependent	O
growth	O
;	O
over	O
time	O
,	O
by	O
an	O
unknown	O
mechanism	O
,	O
the	O
cells	O
become	O
IL-2	B-protein
-independent	O
.	O

Whereas	O
the	O
Jak	B-protein
kinases	I-protein
Jak1	B-protein
and	O
Jak3	B-protein
and	O
the	O
signal	O
transducer	O
and	O
activator	O
of	O
transcription	B-protein
proteins	I-protein
Stat3	B-protein
and	O
Stat5	B-protein
are	O
activated	O
in	O
normal	B-cell_type
T	I-cell_type
cells	I-cell_type
in	O
response	O
to	O
IL-2	B-protein
,	O
this	O
signaling	O
pathway	O
was	O
constitutively	O
activated	O
in	O
HTLV-I-transformed	B-cell_line
cells	I-cell_line
.	O

In	O
HTLV-I-infected	B-cell_line
cord	I-cell_line
blood	I-cell_line
lymphocytes	I-cell_line
,	O
the	O
transition	O
from	O
IL-2	B-protein
-dependent	O
to	O
IL-2	B-protein
-independent	O
growth	O
correlated	O
with	O
the	O
acquisition	O
of	O
a	O
constitutively	O
activated	O
Jak	B-protein
-STAT	B-protein
pathway	O
,	O
which	O
suggests	O
that	O
this	O
pathway	O
participates	O
in	O
HTLV-I-mediated	O
T	O
cell	O
transformation	O
.	O

Nitric	O
oxide	O
decreases	O
cytokine	B-protein
-induced	O
endothelial	O
activation	O
.	O

Nitric	O
oxide	O
selectively	O
reduces	O
endothelial	O
expression	O
of	O
adhesion	B-protein
molecules	I-protein
and	O
proinflammatory	B-protein
cytokines	I-protein
.	O

To	O
test	O
the	O
hypothesis	O
that	O
nitric	O
oxide	O
(	O
NO	O
)	O
limits	O
endothelial	O
activation	O
,	O
we	O
treated	O
cytokine-stimulated	B-cell_line
human	I-cell_line
saphenous	I-cell_line
vein	I-cell_line
endothelial	I-cell_line
cells	I-cell_line
with	O
several	O
NO	O
donors	O
and	O
assessed	O
their	O
effects	O
on	O
the	O
inducible	O
expression	O
of	O
vascular	B-protein
cell	I-protein
adhesion	I-protein
molecule-1	I-protein
(	O
VCAM-1	B-protein
)	O
.	O

In	O
a	O
concentration-dependent	O
manner	O
,	O
NO	O
inhibited	O
interleukin	B-protein
(	I-protein
IL	I-protein
)	I-protein
-1	I-protein
alpha-stimulated	O
VCAM-1	B-protein
expression	O
by	O
35-55	O
%	O
as	O
determined	O
by	O
cell	O
surface	O
enzyme	O
immunoassays	O
and	O
flow	O
cytometry	O
.	O

This	O
inhibition	O
was	O
paralleled	O
by	O
reduced	O
monocyte	O
adhesion	O
to	O
endothelial	O
monolayers	O
in	O
nonstatic	O
assays	O
,	O
was	O
unaffected	O
by	O
cGMP	O
analogues	O
,	O
and	O
was	O
quantitatively	O
similar	O
after	O
stimulation	O
by	O
either	O
IL-1	B-protein
alpha	I-protein
,	O
IL-1	B-protein
beta	I-protein
,	O
IL-4	B-protein
,	O
tumor	B-protein
necrosis	I-protein
factor	I-protein
(	O
TNF	B-protein
alpha	I-protein
)	O
,	O
or	O
bacterial	O
lipopolysaccharide	O
.	O

NO	O
also	O
decreased	O
the	O
endothelial	O
expression	O
of	O
other	O
leukocyte	B-protein
adhesion	I-protein
molecules	I-protein
(	O
E-selectin	B-protein
and	O
to	O
a	O
lesser	O
extent	O
,	O
intercellular	B-protein
adhesion	I-protein
molecule-1	I-protein
)	O
and	O
secretable	O
cytokines	B-protein
(	O
IL-6	B-protein
and	O
IL-8	B-protein
)	O
.	O

Inhibition	O
of	O
endogenous	O
NO	O
production	O
by	O
L-N-monomethyl-arginine	O
also	O
induced	O
the	O
expression	O
of	O
VCAM-1	B-protein
,	O
but	O
did	O
not	O
augment	O
cytokine-induced	O
VCAM-1	B-protein
expression	O
.	O

Nuclear	O
run-on	O
assays	O
,	O
transfection	O
studies	O
using	O
various	O
VCAM-1	B-DNA
promoter	I-DNA
reporter	I-DNA
gene	I-DNA
constructs	I-DNA
,	O
and	O
electrophoretic	O
mobility	O
shift	O
assays	O
indicated	O
that	O
NO	O
represses	O
VCAM-1	B-protein
gene	O
transcription	O
,	O
in	O
part	O
,	O
by	O
inhibiting	O
NF-kappa	B-protein
B	I-protein
.	O

We	O
propose	O
that	O
NO	O
's	O
ability	O
to	O
limit	O
endothelial	O
activation	O
and	O
inhibit	O
monocyte	O
adhesion	O
may	O
contribute	O
to	O
some	O
of	O
its	O
antiatherogenic	O
and	O
antiinflammatory	O
properties	O
within	O
the	O
vessel	O
wall	O
.	O

MIP1	B-protein
alpha	I-protein
nuclear	I-protein
protein	I-protein
(	O
MNP	B-protein
)	O
,	O
a	O
novel	O
transcription	B-protein
factor	I-protein
expressed	O
in	O
hematopoietic	O
cells	O
that	O
is	O
crucial	O
for	O
transcription	O
of	O
the	O
human	B-DNA
MIP-1	I-DNA
alpha	I-DNA
gene	I-DNA
.	O

Murine	B-protein
macrophage	I-protein
inflammatory	I-protein
protein	I-protein
1	I-protein
alpha	I-protein
(	O
MIP-1	B-protein
alpha	I-protein
)	O
and	O
its	O
human	B-protein
equivalent	I-protein
(	O
GOS19	B-protein
,	O
LD78	B-protein
,	O
or	O
AT464	B-protein
)	O
are	O
members	O
of	O
the	O
-C-C	B-protein
family	I-protein
of	O
low-molecular-weight	B-protein
chemokines	I-protein
.	O

Secreted	O
from	O
activated	B-cell_type
T	I-cell_type
cells	I-cell_type
and	O
macrophages	B-cell_type
,	O
bone	O
marrow-derived	B-protein
MIP-1	I-protein
alpha/GOS19	I-protein
inhibits	O
primitive	B-cell_type
hematopoietic	I-cell_type
stem	I-cell_type
cells	I-cell_type
and	O
appears	O
to	O
be	O
involved	O
in	O
the	O
homeostatic	O
control	O
of	O
stem	B-cell_type
cell	I-cell_type
proliferation	O
.	O

It	O
also	O
induces	O
chemotaxis	O
and	O
inflammatory	O
responses	O
in	O
mature	B-cell_type
cell	I-cell_type
types	I-cell_type
.	O

Therefore	O
,	O
it	O
is	O
important	O
to	O
understand	O
the	O
mechanisms	O
which	O
control	O
the	O
expression	O
of	O
MIP-1	B-protein
alpha	I-protein
/GOS19	B-protein
.	O

Previous	O
work	O
has	O
shown	O
that	O
in	O
Jurkat	B-cell_line
T	I-cell_line
cells	I-cell_line
,	O
a	O
set	O
of	O
widely	O
expressed	O
transcription	B-protein
factors	I-protein
(	O
the	O
ICK-1	B-protein
family	I-protein
)	O
affect	O
the	O
GOS19	B-DNA
promoter	I-DNA
.	O

One	O
member	O
,	O
ICK-1A	B-protein
,	O
behaves	O
as	O
a	O
strong	B-protein
negative	I-protein
regulator	I-protein
.	O

In	O
this	O
communication	O
,	O
we	O
provide	O
evidence	O
that	O
the	O
pathway	O
of	O
induction	O
in	O
the	O
macrophage	B-cell_line
cell	I-cell_line
line	I-cell_line
U937	B-cell_line
is	O
different	O
from	O
that	O
in	O
Jurkat	B-cell_line
cells	I-cell_line
.	O

Furthermore	O
,	O
we	O
show	O
that	O
the	O
ICK-1	B-DNA
binding	I-DNA
site	I-DNA
does	O
not	O
confer	O
negative	O
regulation	O
in	O
U937	B-cell_line
cells	I-cell_line
.	O

We	O
provide	O
evidence	O
for	O
an	O
additional	O
binding	B-DNA
site	I-DNA
,	O
the	O
MIP-1	B-DNA
alpha	I-DNA
nuclear	I-DNA
protein	I-DNA
(	I-DNA
MNP	I-DNA
)	I-DNA
site	I-DNA
,	O
which	O
overlaps	O
the	O
ICK-1	B-DNA
site	I-DNA
.	O

Interaction	O
of	O
nuclear	O
extracts	O
from	O
various	B-cell_line
cell	I-cell_line
lines	I-cell_line
and	O
tissue	O
with	O
the	O
MNP	B-DNA
site	I-DNA
leads	O
to	O
the	O
formation	O
of	O
fast-migrating	B-protein
protein-DNA	I-protein
complexes	I-protein
with	O
similar	O
but	O
distinct	O
electrophoretic	O
mobilities	O
.	O

A	O
mutation	O
of	O
the	O
MNP	B-DNA
site	I-DNA
which	O
does	O
not	O
abrogate	O
ICK-1	O
binding	O
inactivates	O
the	O
GOS19.1	B-DNA
promoter	I-DNA
in	O
U937	B-cell_line
cells	I-cell_line
and	O
reduces	O
its	O
activity	O
by	O
fourfold	O
in	O
Jurkat	B-cell_line
cells	I-cell_line
.	O

We	O
propose	O
that	O
the	O
MNP	B-protein
protein	I-protein
(	O
s	O
)	O
binding	O
at	O
the	O
MNP	B-DNA
site	I-DNA
constitutes	O
a	O
novel	O
transcription	B-protein
factor	I-protein
(	O
s	O
)	O
expressed	O
in	O
hematopoietic	B-cell_type
cells	I-cell_type
.	O

The	O
effect	O
of	O
Toremifene	O
on	O
the	O
expression	O
of	O
some	O
genes	O
in	O
human	B-cell_type
mononuclear	I-cell_type
cells	I-cell_type
.	O

Toremifene	O
exerts	O
multiple	O
and	O
varied	O
effects	O
on	O
the	O
gene	O
expression	O
of	O
human	B-cell_type
peripheral	I-cell_type
mononuclear	I-cell_type
cells	I-cell_type
.	O

After	O
short-term	O
,	O
in	O
vitro	O
exposure	O
to	O
therapeutical	O
levels	O
,	O
distinct	O
changes	O
in	O
P-glycoprotein	O
,	O
steroid	O
receptors	O
,	O
p53	O
and	O
Bcl-2	O
expression	O
take	O
place	O
.	O

In	O
view	O
of	O
the	O
increasing	O
use	O
of	O
antiestrogens	O
in	O
cancer	O
therapy	O
and	O
prevention	O
,	O
there	O
is	O
obvious	O
merit	O
in	O
long-term	O
in	O
vivo	O
studies	O
to	O
be	O
conducted	O
.	O

The	O
interleukin-5	B-protein
/receptor	O
interaction	O
activates	O
Lyn	B-protein
and	I-protein
Jak2	I-protein
tyrosine	I-protein
kinases	I-protein
and	O
propagates	O
signals	O
via	O
the	O
Ras-Raf-1-MAP	B-protein
kinase	I-protein
and	O
the	O
Jak	B-protein
-STAT	B-protein
pathways	O
in	O
eosinophils	B-cell_type
.	O

We	O
have	O
shown	O
that	O
the	O
interaction	O
of	O
interleukin	B-protein
(	I-protein
IL	I-protein
)	I-protein
-5	I-protein
with	O
the	O
receptor	O
activates	O
Lyn	B-protein
tyrosine	I-protein
kinase	I-protein
within	O
1	O
min	O
and	O
Jak2	B-protein
tyrosine	I-protein
kinase	I-protein
within	O
1-3	O
min	O
.	O

IL-5	B-protein
also	O
stimulates	O
GTP	O
binding	O
to	O
p21ras	B-protein
.	O

The	O
signal	O
is	O
subsequently	O
propagated	O
through	O
the	O
activation	O
of	O
Raf-1	B-protein
,	O
MEK	B-protein
,	O
and	O
MAP	B-protein
kinases	I-protein
as	O
shown	O
by	O
their	O
increased	O
autophosphorylation	O
in	O
vitro	O
and	O
phosphorylation	O
in	O
situ	O
.	O

Jak2	B-protein
kinase	I-protein
has	O
been	O
shown	O
to	O
phosphorylate	O
STAT	B-protein
nuclear	I-protein
proteins	I-protein
.	O

The	O
activation	O
of	O
STAT	B-protein
nuclear	I-protein
factors	I-protein
was	O
studied	O
by	O
electrophoretic	O
mobility	O
shift	O
assay	O
using	O
a	O
gamma	B-DNA
activation	I-DNA
site	I-DNA
(	O
GAS	B-DNA
)	O
probe	O
.	O

We	O
found	O
that	O
IL-5	B-protein
induces	O
two	O
GAS-binding	B-protein
proteins	I-protein
in	O
eosinophils	B-cell_type
,	O
one	O
of	O
which	O
is	O
STAT1	B-protein
.	O

We	O
conclude	O
that	O
IL-5	B-protein
induced	O
signals	O
are	O
propagated	O
through	O
two	O
distinct	O
pathways	O
:	O
(	O
1	O
)	O
Lyn	B-protein
--	O
>	O
Ras	B-protein
--	O
>	O
Raf-1	B-protein
--	O
>	O
MEK	B-protein
--	O
>	O
MAP	B-protein
kinase	I-protein
and	O
(	O
2	O
)	O
Jak2	B-protein
--	O
>	O
STAT1	B-protein
.	O

The	O
retinoblastoma	B-protein
gene	I-protein
product	I-protein
negatively	O
regulates	O
transcriptional	O
activation	O
mediated	O
by	O
the	O
human	B-protein
cytomegalovirus	I-protein
IE2	I-protein
protein	I-protein
.	O

The	O
IE2	B-protein
gene	I-protein
product	I-protein
of	O
human	O
cytomegalovirus	O
(	O
HCMV	O
)	O
is	O
one	O
of	O
a	O
few	O
viral	B-protein
regulatory	I-protein
proteins	I-protein
expressed	O
immediately	O
upon	O
infection	O
of	O
the	O
host	B-cell_type
cell	I-cell_type
.	O

It	O
is	O
a	O
potent	O
transcriptional	B-protein
activator	I-protein
of	O
many	O
viral	B-DNA
and	I-DNA
cellular	I-DNA
promoters	I-DNA
.	O

We	O
found	O
that	O
the	O
retinoblastoma	B-protein
susceptibility	I-protein
gene	I-protein
product	I-protein
(	O
Rb	B-protein
)	O
dramatically	O
suppressed	O
this	O
IE2	B-protein
transactivation	O
of	O
various	B-DNA
promoters	I-DNA
.	O

However	O
,	O
unlike	O
another	O
tumor	B-protein
suppressor	I-protein
protein	I-protein
,	O
p53	B-protein
,	O
Rb	B-protein
did	O
not	O
have	O
any	O
significant	O
effect	O
on	O
basal	O
levels	O
of	O
transcription	O
,	O
suggesting	O
that	O
Rb	B-protein
specifically	O
interacts	O
with	O
IE2	B-protein
rather	O
than	O
other	O
cellular	B-protein
factors	I-protein
involved	O
in	O
the	O
general	O
transcription	O
machinery	O
.	O

We	O
found	O
by	O
protein-affinity	O
chromatography	O
that	O
Rb	B-protein
in	O
nuclear	O
extracts	O
or	O
produced	O
by	O
in	O
vitro	O
translation	O
directly	O
bound	O
to	O
IE2	B-protein
.	O

Our	O
results	O
suggest	O
that	O
Rb	B-protein
may	O
regulate	O
the	O
life	O
cycle	O
of	O
HCMV	O
,	O
which	O
is	O
endemic	O
in	O
the	O
human	O
population	O
.	O

Furthermore	O
,	O
these	O
data	O
may	O
provide	O
new	O
insights	O
into	O
the	O
slow	O
rate	O
of	O
HCMV	O
DNA	O
replication	O
in	O
cells	O
and	O
the	O
possible	O
involvement	O
of	O
HCMV	O
in	O
tumorigenesis	O
.	O

Expression	O
of	O
the	O
nucleoside	B-protein
diphosphate	I-protein
kinase	I-protein
in	O
human	O
skin	O
cancers	O
:	O
an	O
immunohistochemical	O
study	O
.	O

Expression	O
of	O
nucleoside	B-protein
diphosphate	I-protein
(	I-protein
NDP	I-protein
)	I-protein
kinase	I-protein
,	O
which	O
is	O
homologous	O
to	O
the	O
nm23	B-protein
gene	I-protein
product	I-protein
in	O
a	O
variety	O
of	O
species	O
,	O
has	O
been	O
found	O
to	O
be	O
inversely	O
associated	O
with	O
metastatic	O
potential	O
.	O

However	O
,	O
the	O
relationship	O
remains	O
controversial	O
according	O
to	O
the	O
tumor	B-cell_type
cell	I-cell_type
types	I-cell_type
and	O
experimental	O
system	O
,	O
with	O
conflicting	O
results	O
from	O
different	O
research	O
groups	O
.	O

In	O
order	O
to	O
determine	O
whether	O
NDP	B-protein
kinase	I-protein
expression	O
serves	O
as	O
a	O
marker	O
for	O
metastatic	O
potential	O
in	O
human	O
skin	O
cancer	O
,	O
we	O
assessed	O
the	O
levels	O
of	O
NDP	B-protein
kinase	I-protein
expression	O
in	O
9	O
keratoacanthomas	O
(	O
KAs	O
)	O
,	O
26	O
squamous	O
cell	O
carcinomas	O
(	O
SCCs	O
)	O
,	O
and	O
25	O
basal	O
cell	O
carcinomas	O
(	O
BCCs	O
)	O
using	O
immunohistochemistry	O
.	O

The	O
expression	O
of	O
NDP	B-protein
kinase	I-protein
was	O
intense	O
in	O
KA	O
and	O
SCC	O
compared	O
with	O
BCC	O
.	O

However	O
,	O
the	O
difference	O
of	O
NDP	B-protein
kinase	I-protein
expression	O
between	O
KA	O
and	O
SCC	O
was	O
not	O
statistically	O
significant	O
.	O

And	O
there	O
was	O
no	O
statistically	O
significant	O
difference	O
in	O
NDP	B-protein
kinase	I-protein
expression	O
between	O
SCC	O
with	O
metastasis	O
and	O
SCC	O
without	O
metastasis	O
.	O

Our	O
results	O
contradict	O
the	O
hypothesis	O
concerning	O
the	O
possible	O
role	O
of	O
nm23	B-DNA
gene	I-DNA
as	O
a	O
metastatic	O
suppressor	O
gene	O
in	O
human	O
skin	O
cancer	O
.	O

The	O
mechanism	O
of	O
overexpression	O
in	O
various	O
tumor	B-cell_type
cell	I-cell_type
types	I-cell_type
and	O
its	O
biological	O
significance	O
in	O
cutaneous	O
carcinogenesis	O
remain	O
to	O
be	O
determined	O
.	O

RB	B-protein
and	O
a	O
novel	O
E2F-1	B-protein
binding	I-protein
protein	I-protein
in	O
MHC	B-cell_line
class	I-cell_line
II	I-cell_line
deficient	I-cell_line
B-cell	I-cell_line
lines	I-cell_line
and	O
normal	O
IFN-gamma	B-protein
induction	O
of	O
the	O
class	B-DNA
IL	I-DNA
transactivator	I-DNA
CIITA	B-DNA
in	O
class	B-cell_line
II	I-cell_line
non-inducible	I-cell_line
RB-defective	I-cell_line
tumor	I-cell_line
lines	I-cell_line
.	O

The	O
major	B-DNA
histocompatibility	I-DNA
(	I-DNA
MHC	I-DNA
)	I-DNA
class	I-DNA
II	I-DNA
genes	I-DNA
encode	O
cell	B-protein
surface	I-protein
proteins	I-protein
that	O
bind	O
antigenic	O
peptide	O
for	O
presentation	O
to	O
T-cells	B-cell_type
.	O

The	O
class	B-protein
II	I-protein
proteins	I-protein
are	O
expressed	O
constitutively	O
on	O
B-cells	B-cell_type
and	O
EBV-transformed	B-cell_line
B-cells	I-cell_line
,	I-cell_line
and	O
are	O
inducible	O
by	O
IFN-gamma	B-protein
on	O
a	O
wide	O
variety	O
of	O
cell	B-cell_type
types	I-cell_type
.	O

Retinoblastoma	B-protein
protein	I-protein
(	O
RB	B-protein
)	O
is	O
a	O
tumor	O
suppressor	O
and	O
functions	O
as	O
a	O
transcriptional	B-protein
repressor	I-protein
by	O
binding	O
and	O
inactivating	O
the	O
transactivator	B-DNA
E2F-I	I-DNA
.	O

RB-defective	B-cell_line
tumor	I-cell_line
lines	I-cell_line
are	O
non-inducible	O
for	O
MHC	B-protein
class	I-protein
II	I-protein
by	O
IFN-gamma	B-protein
,	O
or	O
very	O
weakly	O
inducible	O
,	O
but	O
transfection	O
of	O
2	O
different	O
lines	O
with	O
RB	B-DNA
expression	I-DNA
vectors	I-DNA
re-establishes	O
or	O
substantially	O
enhances	O
class	O
II	O
inducibility	O
.	O

Therefore	O
,	O
we	O
examined	O
the	O
RB	B-protein
status	O
of	O
a	O
series	O
of	O
B-cell	O
mutants	O
that	O
are	O
defective	O
in	O
class	O
II	O
expression	O
,	O
generated	O
either	O
in	O
vitro	O
or	O
derived	O
from	O
Bare	O
Lymphocyte	O
Syndrome	O
(	O
BLS	O
)	O
patients	O
.	O

Nuclear	O
matrix-bound	O
RB	B-protein
was	O
detectable	O
in	O
all	O
cases	O
,	O
indicating	O
that	O
loss	O
of	O
RB	B-protein
is	O
not	O
responsible	O
for	O
decreased	O
class	O
II	O
expression	O
in	O
these	O
lines	O
.	O

A	O
second	O
E2F-I	O
binding	O
protein	O
,	O
most	O
likely	O
DP-I	O
,	O
was	O
also	O
apparently	O
normal	O
in	O
both	O
class	O
II-positive	O
and	O
-negative	O
B-cell	O
lines	O
.	O

We	O
also	O
examined	O
the	O
IFN-gamma	B-protein
induction	O
of	O
CIITA	B-DNA
in	O
RB	B-protein
-defective	O
lines	O
.	O

CIITA	B-DNA
is	O
a	O
class	B-DNA
II	I-DNA
gene	I-DNA
transactivator	I-DNA
known	O
to	O
be	O
defective	O
in	O
one	O
form	O
of	O
BLS	O
and	O
to	O
be	O
required	O
for	O
the	O
induction	O
of	O
MHC	B-protein
class	I-protein
II	I-protein
by	O
IFN-gamma	B-protein
.	O

CIITA	B-RNA
mRNA	I-RNA
is	O
normally	O
inducible	O
by	O
IFN-gamma	B-protein
in	O
class	B-cell_line
II	I-cell_line
non-inducible	I-cell_line
,	I-cell_line
RB-defective	I-cell_line
lines	I-cell_line
,	O
and	O
in	O
one	O
line	O
,	O
re-expression	O
of	O
RB	B-protein
has	O
no	O
effect	O
on	O
CIITA	B-RNA
mRNA	I-RNA
induction	O
levels	O
.	O

Thus	O
,	O
the	O
block	O
in	O
MHC	O
class	O
II	O
inducibility	O
in	O
RB-defective	B-cell_line
cells	I-cell_line
is	O
not	O
due	O
to	O
a	O
block	O
in	O
CIITA	B-DNA
inducibility	O
.	O

Interleukin	B-protein
12	I-protein
induces	O
tyrosine	O
phosphorylation	O
and	O
activation	O
of	O
STAT4	B-protein
in	O
human	B-cell_type
lymphocytes	I-cell_type
.	O

Interleukin	B-protein
12	I-protein
(	O
IL-12	B-protein
)	O
is	O
an	O
important	O
immunoregulatory	B-protein
cytokine	I-protein
whose	O
receptor	O
is	O
a	O
member	O
of	O
the	O
hematopoietin	B-protein
receptor	I-protein
superfamily	I-protein
.	O

We	O
have	O
recently	O
demonstrated	O
that	O
stimulation	O
of	O
human	B-cell_type
T	I-cell_type
and	I-cell_type
natural	I-cell_type
killer	I-cell_type
cells	I-cell_type
with	O
IL-12	B-protein
induces	O
tyrosine	O
phosphorylation	O
of	O
the	O
Janus	B-protein
family	I-protein
tyrosine	I-protein
kinase	I-protein
JAK2	B-protein
and	O
Tyk2	B-protein
,	O
implicating	O
these	O
kinases	B-protein
in	O
the	O
immediate	O
biochemical	O
response	O
to	O
IL-12	B-protein
.	O

Recently	O
,	O
transcription	B-protein
factors	I-protein
known	O
as	O
STATs	B-protein
(	O
signal	B-protein
transducers	I-protein
and	I-protein
activators	I-protein
of	I-protein
transcription	I-protein
)	O
have	O
been	O
shown	O
to	O
be	O
tyrosine	O
phosphorylated	O
and	O
activated	O
in	O
response	O
to	O
a	O
number	O
of	O
cytokines	B-protein
that	O
bind	O
hematopoietin	B-protein
receptors	I-protein
and	O
activate	O
JAK	B-protein
kinases	I-protein
.	O

In	O
this	O
report	O
we	O
demonstrate	O
that	O
IL-12	B-protein
induces	O
tyrosine	O
phosphorylation	O
of	O
a	O
recently	O
identified	O
STAT	B-protein
family	I-protein
member	I-protein
,	O
STAT4	B-protein
,	O
and	O
show	O
that	O
STAT4	B-protein
expression	O
is	O
regulated	O
by	O
T-cell	O
activation	O
.	O

Furthermore	O
,	O
we	O
show	O
that	O
IL-12	B-protein
stimulates	O
formation	O
of	O
a	O
DNA-binding	B-protein
complex	I-protein
that	O
recognizes	O
a	O
DNA	O
sequence	O
previously	O
shown	O
to	O
bind	O
STAT	B-protein
proteins	I-protein
and	O
that	O
this	O
complex	O
contains	O
STAT4	B-protein
.	O

These	O
data	O
,	O
and	O
the	O
recent	O
demonstration	O
of	O
JAK	B-protein
phosphorylation	O
by	O
IL-12	B-protein
,	O
identify	O
a	O
rapid	O
signal-transduction	O
pathway	O
likely	O
to	O
mediate	O
IL-12	B-protein
-induced	O
gene	O
expression	O
.	O

Temperature-induced	O
down-regulation	O
of	O
the	O
glucocorticoid	B-protein
receptor	I-protein
in	O
peripheral	B-cell_type
blood	I-cell_type
mononuclear	I-cell_type
leucocyte	I-cell_type
in	O
patients	O
with	O
sepsis	O
or	O
septic	O
shock	O
.	O

OBJECTIVE	O
:	O
Activation	O
of	O
the	O
hypothalamic-pituitary-adrenal	O
axis	O
is	O
of	O
vital	O
importance	O
during	O
critical	O
illness	O
.	O

We	O
have	O
studied	O
the	O
adaptive	O
mechanisms	O
which	O
occur	O
at	O
the	O
level	O
of	O
the	O
glucocorticoid	B-protein
receptor	I-protein
in	O
glucocorticoid	O
target	O
tissues	O
in	O
patients	O
with	O
sepsis	O
or	O
septic	O
shock	O
.	O

DESIGN	O
:	O
The	O
effects	O
of	O
hypercortisolaemia	O
,	O
hyperthermia	O
and	O
cellular	O
composition	O
on	O
number	O
of	O
glucocorticoid	B-protein
receptors	I-protein
per	O
cell	O
and	O
their	O
affinity	O
were	O
evaluated	O
,	O
both	O
in	O
vitro	O
and	O
in	O
vivo	O
,	O
in	O
peripheral	B-cell_type
blood	I-cell_type
mononuclear	I-cell_type
leucocytes	I-cell_type
of	O
control	O
subjects	O
and	O
in	O
patients	O
with	O
sepsis	O
or	O
septic	O
shock	O
.	O

SUBJECTS	O
:	O
Fifteen	O
patients	O
(	O
age	O
25-79	O
)	O
with	O
sepsis	O
or	O
septic	O
shock	O
who	O
were	O
admitted	O
to	O
an	O
intensive	O
care	O
unit	O
were	O
studied	O
.	O

The	O
control	O
group	O
consisted	O
of	O
24	O
healthy	O
laboratory	O
employees	O
.	O

MEASUREMENTS	O
:	O
The	O
binding	O
capacity	O
and	O
affinity	O
of	O
the	O
glucocorticoid	B-protein
receptors	I-protein
were	O
measured	O
and	O
compared	O
to	O
clinical	O
data	O
and	O
the	O
plasma	O
cortisol	O
concentrations	O
.	O

RESULTS	O
:	O
Hypercortisolaemia	O
,	O
in	O
vitro	O
,	O
resulted	O
in	O
a	O
decreased	O
affinity	O
and	O
a	O
decreased	O
binding	O
capacity	O
of	O
the	O
glucocorticoid	B-protein
receptor	I-protein
.	O

In	O
vitro	O
,	O
hyperthermia	O
as	O
well	O
as	O
variations	O
in	O
the	O
cellular	O
composition	O
did	O
not	O
influence	O
the	O
glucocorticoid	O
receptor	O
.	O

In	O
vivo	O
,	O
there	O
was	O
no	O
change	O
in	O
the	O
number	O
of	O
receptors	O
per	O
cell	O
in	O
patients	O
with	O
sepsis	O
or	O
septic	O
shock	O
as	O
compared	O
to	O
healthy	O
controls	O
.	O

However	O
,	O
a	O
decreased	O
affinity	O
of	O
the	O
glucocorticoid	B-protein
receptor	I-protein
was	O
observed	O
.	O

There	O
was	O
a	O
weak	O
but	O
significant	O
negative	O
correlation	O
between	O
body	O
temperature	O
and	O
the	O
number	O
of	O
glucocorticoid	B-protein
receptors	I-protein
in	O
the	O
patient	O
group	O
.	O

There	O
was	O
no	O
relation	O
between	O
circulating	O
cortisol	O
concentrations	O
and	O
glucocorticoid	B-protein
receptor	I-protein
affinity	O
and	O
number	O
.	O

CONCLUSIONS	O
:	O
There	O
is	O
no	O
obvious	O
regulation	O
of	O
the	O
number	O
of	O
glucocorticoid	B-protein
receptors	I-protein
by	O
plasma	O
cortisol	O
concentrations	O
in	O
vivo	O
.	O

The	O
decreased	O
affinity	O
of	O
the	O
glucocorticoid	B-protein
receptor	I-protein
together	O
with	O
the	O
negative	O
correlation	O
between	O
hyperthermia	O
and	O
the	O
number	O
of	O
glucocorticoid	B-protein
receptors	I-protein
in	O
patients	O
with	O
sepsis	O
or	O
septic	O
shock	O
suggest	O
that	O
hypothalamic-pituitary-adrenal	O
axis	O
activation	O
during	O
critical	O
illness	O
is	O
accompanied	O
by	O
peripheral	O
adaptation	O
in	O
glucocorticoid	B-protein
receptor	I-protein
number	O
and	O
affinity	O
.	O

Integrin-mediated	O
tyrosine	O
phosphorylation	O
and	O
cytokine	B-protein
message	O
induction	O
in	O
monocytic	B-cell_type
cells	I-cell_type
.	O

A	O
possible	O
signaling	O
role	O
for	O
the	O
Syk	B-protein
tyrosine	I-protein
kinase	I-protein
.	O

Activation	O
of	O
cytoplasmic	B-protein
tyrosine	I-protein
kinases	I-protein
is	O
an	O
important	O
aspect	O
of	O
signal	O
transduction	O
mediated	O
by	O
integrins	B-protein
.	O

In	O
the	O
human	B-cell_line
monocytic	I-cell_line
cell	I-cell_line
line	I-cell_line
THP-1	I-cell_line
,	O
either	O
integrin	B-protein
-dependent	O
cell	O
adhesion	O
to	O
fibronectin	B-protein
or	O
ligation	O
of	O
beta	O
1	O
integrins	O
with	O
antibodies	B-protein
causes	O
a	O
rapid	O
and	O
intense	O
tyrosine	O
phosphorylation	O
of	O
two	O
sets	O
of	O
proteins	O
of	O
about	O
65-75	B-protein
and	I-protein
120-125	I-protein
kDa	I-protein
.	O

In	O
addition	O
,	O
integrin	B-protein
ligation	O
leads	O
to	O
nuclear	O
translocation	O
of	O
the	O
p50	B-protein
and	O
p65	B-protein
subunits	I-protein
of	O
the	O
NF-kappa	B-protein
B	I-protein
transcription	I-protein
factor	I-protein
,	O
to	O
activation	O
of	O
a	O
reporter	B-DNA
gene	I-DNA
driven	O
by	O
a	O
promoter	B-DNA
containing	O
NF-kappa	B-DNA
B	I-DNA
sites	I-DNA
,	O
and	O
to	O
increased	O
levels	O
of	O
mRNAs	B-RNA
for	O
immediate-early	B-DNA
genes	I-DNA
,	O
including	O
the	O
cytokine	B-protein
interleukin	I-protein
(	I-protein
IL	I-protein
)	I-protein
-1	I-protein
beta	I-protein
.	O

The	O
tyrosine	O
kinase	O
inhibitors	O
genistein	O
and	O
herbimycin	O
A	O
block	O
both	O
integrin	B-protein
-mediated	O
tyrosine	O
phosphorylation	O
and	O
increases	O
in	O
IL-1	B-protein
beta	I-protein
message	O
levels	O
,	O
indicating	O
a	O
causal	O
relationship	O
between	O
the	O
two	O
events	O
.	O

The	O
components	O
tyrosine	O
phosphorylated	O
subsequent	O
to	O
cell	O
adhesion	O
include	O
paxillin	B-protein
,	O
pp125FAK	B-protein
,	O
and	O
the	O
SH2	B-protein
domain	I-protein
containing	I-protein
tyrosine	I-protein
kinase	I-protein
Syk	I-protein
.	O

In	O
contrast	O
,	O
integrin	B-protein
ligation	O
with	O
antibodies	B-protein
induces	O
tyrosine	O
phosphorylation	O
of	O
Syk	B-protein
but	O
not	O
of	O
FAK	B-protein
or	O
paxillin	B-protein
.	O

In	O
adhering	B-cell_type
cells	I-cell_type
,	O
pre-treatment	O
with	O
cytochalasin	O
D	O
suppresses	O
tyrosine	O
phosphorylation	O
of	O
FAK	B-protein
and	O
paxillin	B-protein
but	O
not	O
of	O
Syk	B-protein
,	O
while	O
IL-1	B-protein
beta	I-protein
message	O
induction	O
is	O
unaffected	O
.	O

These	O
observations	O
indicate	O
that	O
the	O
Syk	B-protein
tyrosine	O
kinase	O
may	O
be	O
an	O
important	O
component	O
of	O
an	O
integrin	B-protein
signaling	O
pathway	O
in	O
monocytic	B-cell_type
cells	I-cell_type
,	O
leading	O
to	O
activation	O
of	O
NF-kappa	B-protein
B	I-protein
and	O
to	O
increased	O
levels	O
of	O
cytokine	B-protein
messages	O
.	O

Inhibition	O
of	O
dexamethasone	O
binding	O
to	O
human	B-protein
glucocorticoid	I-protein
receptor	I-protein
by	O
New	O
World	O
primate	O
cell	O
extracts	O
.	O

To	O
determine	O
if	O
New	O
World	O
primates	O
express	O
an	O
inhibitor	O
that	O
influences	O
glucocorticoid	B-protein
receptor	I-protein
(	O
GR	B-protein
)	O
binding	O
characteristics	O
,	O
we	O
examined	O
[	O
3H	O
]	O
dexamethasone	O
binding	O
in	O
cytosol	O
prepared	O
from	O
B95-8	B-cell_line
lymphoid	I-cell_line
cells	I-cell_line
,	O
derived	O
from	O
the	O
cotton	O
top	O
tamarin	O
(	O
Saguinus	O
oedipus	O
)	O
,	O
in	O
combination	O
with	O
cytosol	O
prepared	O
from	O
human	O
or	O
rat	O
tissues	O
.	O

B95-8	O
cytosol	O
inhibited	O
specific	O
binding	O
of	O
[	O
3H	O
]	O
dexamethasone	O
(	O
P	O
<	O
0.01	O
)	O
when	O
mixed	O
with	O
cytosol	O
prepared	O
from	O
either	O
a	O
human	B-cell_line
lymphoid	I-cell_line
cell	I-cell_line
line	I-cell_line
(	O
HL	B-cell_line
)	O
or	O
rat	O
thymus	O
.	O

The	O
inhibitory	O
activity	O
was	O
heat	O
labile	O
and	O
trypsin	B-protein
sensitive	O
.	O

Peak	O
inhibitory	O
activity	O
was	O
found	O
in	O
the	O
150-200	O
kd	O
fractions	O
after	O
Sephacryl	O
G-200	O
ultrafiltration	O
.	O

Scatchard	O
analysis	O
of	O
[	O
3H	O
]	O
dexamethasone	O
binding	O
using	O
mixed	O
cytosol	O
showed	O
a	O
diminished	O
GR	B-protein
apparent	O
binding	O
affinity	O
when	O
compared	O
to	O
HL	O
cytosol	O
.	O

Kinetic	O
studies	O
using	O
mixed	O
cytosol	O
indicated	O
that	O
B95-8	O
cytosol	O
did	O
not	O
affect	O
the	O
apparent	O
dissociation	O
rate	O
of	O
[	O
3H	O
]	O
dexamethasone	O
.	O

These	O
data	O
demonstrate	O
that	O
B95-8	B-cell_type
cells	I-cell_type
contain	O
a	O
competitive	O
inhibitor	O
that	O
prevents	O
binding	O
of	O
dexamethasone	O
to	O
its	O
cognate	B-protein
receptor	I-protein
.	O

Disruption	O
of	O
a	O
GATA	B-DNA
motif	I-DNA
in	O
the	O
Duffy	B-DNA
gene	I-DNA
promoter	I-DNA
abolishes	O
erythroid	B-DNA
gene	I-DNA
expression	O
in	O
Duffy-negative	O
individuals	O
.	O

The	O
mRNA	B-RNA
for	O
the	O
Duffy	B-protein
blood	I-protein
group	I-protein
antigen	I-protein
,	O
the	O
erythrocyte	B-protein
receptor	I-protein
for	O
the	O
Plasmodium	O
vivax	O
malaria	O
parasite	O
,	O
has	O
recently	O
been	O
cloned	O
and	O
shown	O
to	O
encode	O
a	O
widely	O
expressed	O
chemokine	B-protein
receptor	I-protein
.	O

Here	O
,	O
we	O
show	O
that	O
the	O
Duffy	B-DNA
antigen/chemokine	I-DNA
receptor	I-DNA
gene	I-DNA
(	O
DARC	B-DNA
)	O
is	O
composed	O
of	O
a	O
single	O
exon	B-DNA
and	O
that	O
most	O
Duffy-negative	O
blacks	O
carry	O
a	O
silent	B-DNA
FY*B	I-DNA
allele	I-DNA
with	O
a	O
single	O
T	O
to	O
C	O
substitution	O
at	O
nucleotide	O
-46	O
.	O

This	O
mutation	O
impairs	O
the	O
promoter	O
activity	O
in	O
erythroid	B-cell_type
cells	I-cell_type
by	O
disrupting	O
a	O
binding	B-DNA
site	I-DNA
for	O
the	O
GATA1	B-protein
erythroid	I-protein
transcription	I-protein
factor	I-protein
.	O

With	O
the	O
recent	O
characterization	O
of	O
the	O
FY*A	B-DNA
and	I-DNA
FY*B	I-DNA
alleles	I-DNA
,	O
these	O
findings	O
provide	O
the	O
molecular	O
basis	O
of	O
the	O
Duffy	O
blood	O
group	O
system	O
and	O
an	O
explanation	O
for	O
the	O
erythroid-specific	O
repression	O
of	O
the	O
DARC	B-DNA
gene	I-DNA
in	O
Duffy-negative	O
individuals	O
.	O

Activation	O
of	O
pp90rsk	B-protein
and	O
early	B-DNA
growth	I-DNA
response-1	I-DNA
gene	I-DNA
expression	O
by	O
pokeweed	B-protein
mitogen	I-protein
in	O
human	B-cell_type
B	I-cell_type
cells	I-cell_type
.	O

The	O
present	O
studies	O
have	O
examined	O
the	O
effects	O
of	O
pokeweed	B-protein
mitogen	I-protein
(	O
PWM	B-protein
)	O
on	O
the	O
induction	O
of	O
early	B-DNA
growth	I-DNA
response-1	I-DNA
gene	I-DNA
(	O
EGR-1	B-DNA
)	O
in	O
normal	B-cell_type
human	I-cell_type
B	I-cell_type
cells	I-cell_type
.	O

PWM	B-protein
regulates	O
EGR-1	B-DNA
gene	O
expression	O
by	O
both	O
transcriptional	O
and	O
post-transcriptional	O
mechanisms	O
.	O

Transient	O
transfection	O
assays	O
with	O
EGR-1	B-DNA
promoter	I-DNA
fragments	I-DNA
linked	O
to	O
the	O
chloramphenicol	B-DNA
acetyltransferase	I-DNA
(	I-DNA
CAT	I-DNA
)	I-DNA
gene	I-DNA
demonstrated	O
that	O
PWM	B-protein
induced	O
EGR-1	B-DNA
transcription	O
is	O
conferred	O
by	O
the	O
CArG	B-DNA
motif	I-DNA
(	O
C	B-DNA
C	I-DNA
[	I-DNA
AT	I-DNA
]	I-DNA
6GG	I-DNA
)	O
in	O
the	O
EGR-1	B-DNA
promoter	I-DNA
.	O

The	O
results	O
further	O
demonstrated	O
the	O
activation	O
of	O
S6	B-protein
kinase	I-protein
(	O
pp90rsk	B-protein
)	O
,	O
evidenced	O
by	O
phosphorylation	O
of	O
S6	B-protein
and	O
serum	O
response	O
factor	O
(	O
SRF	O
)	O
peptides	O
,	O
in	O
PWM	B-cell_line
treated	I-cell_line
B	I-cell_line
cells	I-cell_line
.	O

Taken	O
together	O
,	O
these	O
findings	O
suggest	O
that	O
PWM	B-protein
is	O
able	O
to	O
initiate	O
an	O
intracytoplasmic	O
signalling	O
cascade	O
and	O
EGR-1	B-DNA
induction	O
in	O
normal	B-cell_type
human	I-cell_type
B	I-cell_type
cells	I-cell_type
.	O

A	O
conserved	B-DNA
motif	I-DNA
in	O
the	O
promoters	B-DNA
of	O
several	O
cytokines	B-protein
expressed	O
by	O
human	B-cell_line
Th2-type	I-cell_line
lymphocytes	I-cell_line
.	O

We	O
have	O
recently	O
found	O
a	O
novel	O
conserved	B-DNA
motif	I-DNA
in	O
the	O
promoters	B-DNA
of	O
several	O
T-cell-expressed	B-protein
cytokines	I-protein
[	O
human	B-protein
interleukin-2	I-protein
,	I-protein
-4	I-protein
,	I-protein
-5	I-protein
and	I-protein
-13	I-protein
and	O
human	B-protein
and	I-protein
mouse	I-protein
granulocyte/macrophage-colony	I-protein
stimulating	I-protein
factor	I-protein
(	O
GM-CSF	B-protein
)	O
]	O
.	O

It	O
contains	O
a	O
core	B-DNA
sequence	I-DNA
CTTGG	O
...	O
CCAAG	O
which	O
is	O
present	O
as	O
part	O
of	O
larger	O
palindromic	B-DNA
sequences	I-DNA
in	O
each	O
gene	O
.	O

This	O
suggest	O
that	O
they	O
may	O
interact	O
with	O
a	O
new	O
family	O
of	O
trans-acting	B-protein
factors	I-protein
.	O

In	O
transfection	O
assays	O
,	O
the	O
human	B-DNA
GM-CSF	I-DNA
element	I-DNA
has	O
a	O
strong	O
positive	O
effect	O
on	O
the	O
expression	O
of	O
a	O
reporter	B-DNA
gene	I-DNA
by	O
the	O
human	B-cell_line
T	I-cell_line
cell	I-cell_line
line	I-cell_line
Jurkat	B-cell_line
J6	I-cell_line
upon	O
stimulation	O
.	O

In	O
DNA	O
mobility	O
shift	O
assays	O
,	O
this	O
sequence	O
can	O
give	O
either	O
six	O
different	O
specific	O
bands	O
which	O
are	O
competed	O
out	O
by	O
different	O
parts	O
of	O
the	O
sequence	O
or	O
one	O
specific	O
band	O
which	O
is	O
competed	O
out	O
by	O
each	O
of	O
the	O
inverted	O
repeats	O
,	O
depending	O
on	O
the	O
reconstitution	O
conditions	O
.	O

In	O
different	O
genes	B-DNA
,	O
the	O
core	B-DNA
sequences	I-DNA
are	O
separated	O
by	O
integer	O
numbers	O
of	O
helical	O
turns	O
.	O

Considering	O
the	O
strong	O
positive	O
regulatory	O
effect	O
of	O
this	O
element	B-DNA
and	O
its	O
presence	O
in	O
several	O
T-cell-expressed	B-DNA
cytokine	I-DNA
genes	I-DNA
,	O
it	O
may	O
be	O
crucial	O
to	O
the	O
coordinated	O
expression	O
of	O
these	O
cytokines	B-protein
in	O
T	B-cell_type
helper	I-cell_type
cells	I-cell_type
.	O

cDNA	B-DNA
cloning	O
of	O
a	O
NGFI-B/nur77-related	B-protein
transcription	I-protein
factor	I-protein
from	O
an	O
apoptotic	B-cell_line
human	I-cell_line
T	I-cell_line
cell	I-cell_line
line	I-cell_line
.	O

A	O
human	B-cell_line
T	I-cell_line
lymphoid	I-cell_line
cell	I-cell_line
line	I-cell_line
,	O
PEER	B-cell_line
,	O
dies	O
by	O
apoptosis	O
in	O
the	O
presence	O
of	O
PMA	O
and	O
calcium	O
ionophore	O
.	O

A	O
new	O
gene	B-DNA
,	O
TINUR	B-DNA
,	O
was	O
cloned	O
from	O
apoptotic	B-cell_line
PEER	I-cell_line
cells	I-cell_line
.	O

The	O
expression	O
of	O
the	O
TINUR	B-DNA
gene	I-DNA
is	O
induced	O
within	O
1	O
h	O
after	O
the	O
cross-linking	O
of	O
the	O
T	B-protein
cell	I-protein
Ag	I-protein
receptor	I-protein
complex	I-protein
.	O

TINUR	B-DNA
belongs	O
to	O
the	O
NGFI-B/nur77	B-protein
family	I-protein
of	O
the	O
steroid	B-protein
receptor	I-protein
superfamily	I-protein
and	O
is	O
an	O
orphan	B-protein
receptor	I-protein
.	O

TINUR	B-DNA
binds	O
to	O
the	O
same	O
DNA	B-DNA
sequence	I-DNA
as	O
NGFI-B/nur77	B-protein
.	O

We	O
also	O
propose	O
that	O
the	O
NGFI-B/nur77	B-protein
family	I-protein
can	O
be	O
classified	O
into	O
two	O
subtypes	O
.	O

Aspirin	O
inhibits	O
nuclear	B-protein
factor-kappa	I-protein
B	I-protein
mobilization	O
and	O
monocyte	O
adhesion	O
in	O
stimulated	B-cell_line
human	I-cell_line
endothelial	I-cell_line
cells	I-cell_line
.	O

BACKGROUND	O
:	O
The	O
induction	O
of	O
vascular	B-protein
cell	I-protein
adhesion	I-protein
molecule-1	I-protein
(	O
VCAM-1	B-protein
)	O
and	O
E-selectin	B-protein
by	O
tumor	B-protein
necrosis	I-protein
factor-alpha	I-protein
(	O
TNF	B-protein
)	O
is	O
mediated	O
by	O
mobilization	O
of	O
the	O
transcription	B-protein
factor	I-protein
nuclear	B-protein
factor-kappa	I-protein
B	I-protein
(	O
NF-kappa	B-protein
B	I-protein
)	O
.	O

Since	O
salicylates	O
have	O
been	O
reported	O
to	O
inhibit	O
NF-kappa	B-protein
B	I-protein
activation	O
by	O
preventing	O
the	O
degradation	O
of	O
its	O
inhibitor	O
I	B-protein
kappa	I-protein
B	I-protein
,	O
we	O
studied	O
a	O
potential	O
inhibition	O
of	O
this	O
pathway	O
by	O
acetylsalicylate	O
(	O
aspirin	O
)	O
in	O
human	B-cell_line
umbilical	I-cell_line
vein	I-cell_line
endothelial	I-cell_line
cells	I-cell_line
(	O
HUVECs	B-cell_line
)	O
.	O

METHODS	O
AND	O
RESULTS	O
:	O
Gel-shift	O
analyses	O
demonstrated	O
dose-dependent	O
inhibition	O
of	O
TNF	B-protein
-induced	O
NF-kappa	B-protein
B	I-protein
mobilization	O
by	O
aspirin	O
at	O
concentrations	O
ranging	O
from	O
1	O
to	O
10	O
mmol/L	O
.	O

Induction	O
of	O
VCAM-1	B-protein
and	O
E-selectin	B-protein
surface	O
expression	O
by	O
TNF	B-protein
was	O
dose-dependently	O
reduced	O
by	O
aspirin	O
over	O
the	O
same	O
range	O
,	O
while	O
induction	O
of	O
intercellular	B-protein
adhesion	I-protein
molecule-1	I-protein
(	O
ICAM-1	B-protein
)	O
was	O
hardly	O
affected	O
.	O

Aspirin	O
appeared	O
to	O
prevent	O
VCAM-1	B-protein
transcription	O
,	O
since	O
it	O
dose-dependently	O
inhibited	O
induction	O
of	O
VCAM-1	B-RNA
mRNA	I-RNA
by	O
TNF	B-protein
.	O

As	O
a	O
functional	O
consequence	O
,	O
adhesion	O
of	O
U937	B-cell_line
monocytes	I-cell_line
to	O
TNF-stimulated	B-cell_line
HUVECs	I-cell_line
was	O
markedly	O
reduced	O
by	O
aspirin	O
due	O
to	O
suppression	O
of	O
VCAM-1	B-protein
and	O
E-selectin	B-protein
upregulation	O
.	O

These	O
effects	O
of	O
aspirin	O
were	O
not	O
related	O
to	O
the	O
inhibition	O
of	O
cyclooxygenase	B-protein
activity	O
,	O
since	O
indomethacin	O
was	O
ineffective	O
.	O

CONCLUSIONS	O
:	O
Our	O
data	O
suggest	O
that	O
aspirin	O
inhibits	O
NF-kappa	B-protein
B	I-protein
mobilization	O
,	O
induction	O
of	O
VCAM-1	B-protein
and	O
E-selectin	B-protein
,	O
and	O
subsequent	O
monocyte	O
adhesion	O
in	O
endothelial	B-cell_type
cells	I-cell_type
stimulated	O
by	O
TNF	B-protein
,	O
thereby	O
providing	O
an	O
additional	O
mechanism	O
for	O
therapeutic	O
effects	O
of	O
aspirin	O
.	O

Activation	O
of	O
NF-kappa	B-protein
B	I-protein
by	O
phosphatase	B-protein
inhibitors	O
involves	O
the	O
phosphorylation	O
of	O
I	B-protein
kappa	I-protein
B	I-protein
alpha	I-protein
at	O
phosphatase	B-protein
2A-sensitive	I-protein
sites	I-protein
.	O

Activation	O
of	O
NF-kappa	B-protein
B	I-protein
by	O
various	O
cellular	O
stimuli	O
involves	O
the	O
phosphorylation	O
and	O
subsequent	O
degradation	O
of	O
its	O
inhibitor	O
,	O
I	B-protein
kappa	I-protein
B	I-protein
alpha	I-protein
,	O
although	O
the	O
underlying	O
mechanism	O
remains	O
unclear	O
.	O

In	O
the	O
present	O
study	O
,	O
the	O
role	O
of	O
serine/threonine	B-protein
phosphatases	I-protein
in	O
the	O
regulation	O
of	O
I	B-protein
kappa	I-protein
B	I-protein
alpha	I-protein
phosphorylation	O
was	O
investigated	O
.	O

Our	O
studies	O
demonstrate	O
that	O
incubation	O
of	O
human	B-cell_type
T	I-cell_type
cells	I-cell_type
with	O
low	O
concentrations	O
(	O
approximately	O
1-5	O
nM	O
)	O
of	O
calyculin	O
A	O
or	O
okadaic	O
acid	O
,	O
potent	O
inhibitors	O
of	O
protein	B-protein
phosphatase	I-protein
type	I-protein
1	I-protein
(	I-protein
PP-1	I-protein
)	I-protein
and	I-protein
type	I-protein
2A	I-protein
(	O
PP-2A	B-protein
)	O
,	O
induces	O
the	O
phosphorylation	O
of	O
I	B-protein
kappa	I-protein
B	I-protein
alpha	I-protein
even	O
in	O
the	O
absence	O
of	O
any	O
cellular	O
stimulus	O
.	O

This	O
action	O
of	O
the	O
phosphatase	O
inhibitors	O
,	O
which	O
is	O
associated	O
with	O
the	O
activation	O
of	O
the	O
RelA.p50	B-protein
NF-kappa	I-protein
B	I-protein
heterodimer	I-protein
,	O
is	O
not	O
affected	O
by	O
agents	O
that	O
block	O
the	O
induction	O
of	O
I	B-protein
kappa	I-protein
B	I-protein
alpha	I-protein
phosphorylation	O
by	O
tumor	B-protein
necrosis	I-protein
factor	I-protein
alpha	I-protein
(	O
TNF-alpha	B-protein
)	O
.	O

Furthermore	O
,	O
the	O
phosphorylated	B-protein
I	I-protein
kappa	I-protein
B	I-protein
alpha	I-protein
from	O
calyculin	B-cell_line
A-treated	I-cell_line
cells	I-cell_line
,	O
but	O
not	O
that	O
from	O
TNF-alpha-stimulated	B-cell_line
cells	I-cell_line
,	O
is	O
sensitive	O
to	O
PP-2A	B-protein
in	O
vitro	O
,	O
suggesting	O
the	O
existence	O
of	O
fundamental	O
differences	O
in	O
the	O
phosphorylation	O
of	O
I	B-protein
kappa	I-protein
B	I-protein
alpha	I-protein
induced	O
by	O
the	O
two	O
different	O
NF-kappa	B-protein
B	I-protein
inducers	O
.	O

However	O
,	O
induction	O
of	O
I	B-protein
kappa	I-protein
B	I-protein
alpha	I-protein
phosphorylation	O
by	O
both	O
TNF-alpha	B-protein
and	O
the	O
phosphatase	O
inhibitors	O
is	O
associated	O
with	O
the	O
subsequent	O
degradation	O
of	O
I	B-protein
kappa	I-protein
B	I-protein
alpha	I-protein
.	O

We	O
further	O
demonstrate	O
that	O
TNF-alpha-	O
and	O
calyculin	O
A-induced	O
I	O
kappa	O
B	O
alpha	O
degradation	O
exhibits	O
similar	O
but	O
not	O
identical	O
sensitivities	O
to	O
a	O
proteasome	O
inhibitor	O
.	O

Together	O
,	O
these	O
results	O
suggest	O
that	O
phosphorylation	O
of	O
I	B-protein
kappa	I-protein
B	I-protein
alpha	I-protein
,	O
mediated	O
through	O
both	O
the	O
TNF-alpha	B-protein
-inducible	O
and	O
the	O
PP-2A-opposing	B-protein
kinases	I-protein
,	O
may	O
serve	O
to	O
target	O
I	B-protein
kappa	I-protein
B	I-protein
alpha	I-protein
for	O
proteasome	B-protein
-mediated	O
degradation	O
.	O

Sp1	B-protein
functions	O
in	O
a	O
chromatin	B-DNA
-dependent	O
manner	O
to	O
augment	O
human	B-DNA
alpha-globin	I-DNA
promoter	I-DNA
activity	O
.	O

The	O
5	B-DNA
'	I-DNA
flanking	I-DNA
region	I-DNA
of	O
the	O
human	B-DNA
alpha-globin	I-DNA
gene	I-DNA
is	O
highly	O
G	O
+	O
C	O
rich	O
and	O
contains	O
multiple	O
copies	O
of	O
the	O
consensus	B-DNA
sequence	I-DNA
for	O
the	O
Sp1	B-DNA
binding	I-DNA
site	I-DNA
.	O

We	O
investigated	O
the	O
role	O
of	O
this	O
G	B-DNA
+	I-DNA
C-rich	I-DNA
region	I-DNA
in	O
augmenting	O
alpha-globin	B-DNA
promoter	I-DNA
activity	O
in	O
the	O
presence	O
of	O
the	O
far-upstream	B-DNA
alpha-globin	I-DNA
enhancer	I-DNA
,	O
HS-40	B-DNA
.	O

We	O
show	O
that	O
in	O
transiently	B-cell_line
transfected	I-cell_line
erythroid	I-cell_line
cells	I-cell_line
,	O
deletion	O
of	O
the	O
alpha-globin	B-DNA
G	I-DNA
+	I-DNA
C-rich	I-DNA
5	I-DNA
'	I-DNA
flanking	I-DNA
region	I-DNA
has	O
no	O
effect	O
on	O
alpha-globin	B-DNA
promoter	I-DNA
activity	O
.	O

However	O
,	O
upon	O
stable	O
integration	O
into	O
chromatin	B-DNA
,	O
deletion	O
of	O
this	O
region	O
causes	O
a	O
nearly	O
90	O
%	O
decrease	O
in	O
promoter	O
activity	O
compared	O
with	O
expression	O
from	O
an	O
alpha-globin	B-DNA
promoter	I-DNA
retaining	O
this	O
region	O
.	O

These	O
results	O
suggest	O
that	O
the	O
alpha-globin	B-DNA
G	I-DNA
+	I-DNA
C-rich	I-DNA
5	I-DNA
'	I-DNA
flanking	I-DNA
region	I-DNA
augments	O
alpha-globin	B-DNA
promoter	I-DNA
activity	O
in	O
a	O
chromatin	B-DNA
-dependent	O
manner	O
.	O

We	O
further	O
show	O
that	O
this	O
G	B-DNA
+	I-DNA
C-rich	I-DNA
region	I-DNA
is	O
required	O
for	O
the	O
activation	O
of	O
alpha-globin	B-DNA
gene	I-DNA
expression	O
during	O
erythroid	O
differentiation	O
.	O

Finally	O
,	O
we	O
show	O
by	O
both	O
footprint	O
analysis	O
and	O
functional	O
assays	O
that	O
the	O
ability	O
of	O
the	O
G	B-DNA
+	I-DNA
C-rich	I-DNA
region	I-DNA
to	O
increase	O
alpha-globin	B-DNA
promoter	I-DNA
activity	O
from	O
a	O
stably	O
integrated	O
alpha-globin	B-DNA
gene	I-DNA
is	O
mediated	O
by	O
its	O
multiple	B-DNA
binding	I-DNA
sites	I-DNA
for	O
the	O
transcription	B-protein
factor	I-protein
Sp1	B-protein
.	O

Costimulation	O
of	O
human	B-cell_line
CD4+	I-cell_line
T	I-cell_line
cells	I-cell_line
with	O
LFA-3	B-protein
and	O
B7	B-protein
induce	O
distinct	O
effects	O
on	O
AP-1	O
and	O
NF-kappa	B-protein
B	I-protein
transcription	B-protein
factors	I-protein
.	O

We	O
have	O
earlier	O
shown	O
that	O
stimulation	O
of	O
human	B-cell_line
CD4+	I-cell_line
T	I-cell_line
cells	I-cell_line
with	O
SEA	O
presented	O
on	O
Chinese	B-cell_line
hamster	I-cell_line
ovary	I-cell_line
(	I-cell_line
CHO	I-cell_line
)	I-cell_line
-DR	I-cell_line
transfectants	I-cell_line
coexpressing	O
either	O
B7	B-protein
or	O
LFA-3	B-protein
resulted	O
in	O
distinct	O
cytokine	B-protein
profiles	O
.	O

We	O
now	O
demonstrate	O
that	O
B7	B-protein
,	O
but	O
not	O
LFA-3	B-protein
,	O
strongly	O
costimulated	O
IL-2	B-protein
transcription	O
and	O
mRNA	O
expression	O
in	O
CD4+	B-cell_line
T	I-cell_line
cells	I-cell_line
.	O

Maximal	O
increase	O
in	O
IL-2	B-protein
transcription	O
was	O
recorded	O
with	O
CHO-DR/B7/LFA-3	B-protein
,	O
suggesting	O
a	O
cooperative	O
effect	O
of	O
B7	B-protein
and	O
LFA-3	B-protein
at	O
the	O
transcriptional	O
level	O
.	O

Gel-shift	O
analysis	O
demonstrated	O
that	O
stimulation	O
of	O
CD4+	B-cell_line
T	I-cell_line
cells	I-cell_line
with	O
CHO-DR	B-protein
and	O
staphylococcal	O
enterotoxin	O
A	O
was	O
sufficient	O
to	O
induce	O
significant	O
amounts	O
of	O
NF-kappa	B-protein
B	I-protein
binding	O
proteins	O
,	O
whereas	O
induction	O
of	O
AP-1	B-protein
binding	I-protein
proteins	I-protein
required	O
costimulation	O
.	O

LFA-3	B-protein
induced	O
moderate	O
levels	O
of	O
AP-1	B-protein
,	O
but	O
did	O
not	O
influence	O
the	O
levels	O
of	O
NF-kappa	B-protein
B	I-protein
,	O
while	O
B7	B-protein
costimulation	O
strongly	O
induced	O
both	O
AP-1	B-protein
and	O
substantially	O
enhanced	O
NF-kappa	B-protein
B	I-protein
binding	I-protein
proteins	I-protein
.	O

The	O
CHO-DR/B7/LFA-3	B-cell_line
triple	I-cell_line
transfectant	I-cell_line
induced	O
a	O
further	O
increase	O
in	O
AP-1	B-protein
and	O
NF-kappa	B-protein
B	I-protein
binding	B-protein
proteins	I-protein
compared	O
with	O
the	O
double	B-cell_line
transfectants	I-cell_line
.	O

The	O
level	O
of	O
Oct-1	B-protein
binding	I-protein
proteins	I-protein
remained	O
similar	O
in	O
all	O
samples	O
.	O

Super-shift	O
analysis	O
revealed	O
that	O
the	O
NF-kappa	B-protein
B	I-protein
complex	I-protein
of	O
costimulated	B-cell_line
CD4+	I-cell_line
T	I-cell_line
cells	I-cell_line
contained	O
large	O
amounts	O
of	O
p50	B-protein
,	O
substantial	O
amounts	O
of	O
p65	B-protein
,	O
and	O
marginal	O
levels	O
of	O
c-Rel	B-protein
proteins	I-protein
.	O

The	O
AP-1	B-protein
binding	I-protein
proteins	I-protein
contained	O
c-Jun	B-protein
,	O
Jun-D	B-protein
,	O
and	O
Fra-1	B-protein
,	O
but	O
marginal	O
amounts	O
of	O
Jun-B	B-protein
and	O
c-Fos	B-protein
.	O

Our	O
results	O
indicate	O
distinct	O
effects	O
of	O
B7	B-protein
and	O
LFA-3	B-protein
costimulation	O
on	O
the	O
activity	O
of	O
AP-1	B-protein
and	O
NF-kappa	B-protein
B	I-protein
.	O

These	O
may	O
partly	O
account	O
for	O
the	O
differential	O
effects	O
of	O
B7	B-protein
and	O
LFA-3	B-protein
costimulation	O
on	O
IL-2	B-protein
expression	O
.	O

The	O
Ah	B-protein
receptor	I-protein
recognizes	O
DNA	B-DNA
binding	I-DNA
sites	I-DNA
for	O
the	O
B	B-protein
cell	I-protein
transcription	I-protein
factor	I-protein
,	O
BSAP	B-protein
:	O
a	O
possible	O
mechanism	O
for	O
dioxin-mediated	O
alteration	O
of	O
CD19	B-DNA
gene	I-DNA
expression	O
in	O
human	B-cell_type
B	I-cell_type
lymphocytes	I-cell_type
.	O

2	O
,	O
3	O
,	O
7	O
,	O
8-tetrachlorodibenzo-p-dioxin	O
(	O
TCDD	O
)	O
inhibits	O
murine	O
and	O
human	O
B	O
lymphocyte	O
immunoglobulin	O
production	O
through	O
an	O
unknown	O
mechanism	O
.	O

This	O
study	O
investigated	O
the	O
effect	O
of	O
TCDD	O
on	O
expression	O
of	O
the	O
CD19	B-DNA
gene	I-DNA
in	O
a	O
human	B-cell_line
B	I-cell_line
lymphocyte	I-cell_line
cell	I-cell_line
line	I-cell_line
.	O

Northern	O
blot	O
analysis	O
showed	O
that	O
TCDD	O
treatment	O
decreased	O
steady	O
state	O
levels	O
of	O
CD19	B-RNA
mRNA	I-RNA
by	O
67	O
%	O
in	O
the	O
IM-9	B-cell_line
cell	I-cell_line
line	I-cell_line
.	O

Using	O
a	O
gel	O
mobility	O
shift	O
assay	O
,	O
we	O
identified	O
a	O
DNA-binding	B-protein
complex	I-protein
in	O
IM-9	O
nuclear	O
extracts	O
that	O
by	O
several	O
criteria	O
appears	O
to	O
be	O
the	O
Ah	B-protein
receptor	I-protein
.	O

In	O
addition	O
,	O
the	O
Ah	B-protein
receptor	I-protein
complex	I-protein
recognized	O
a	O
DNA	B-DNA
binding	I-DNA
site	I-DNA
for	O
B	B-protein
cell	I-protein
lineage-specific	I-protein
activator	I-protein
protein	I-protein
(	O
BSAP	B-protein
)	O
in	O
the	O
promoter	B-DNA
region	I-DNA
of	O
the	O
human	O
CD19	B-DNA
gene	I-DNA
which	O
is	O
similar	O
to	O
the	O
consensus	B-DNA
Ah	I-DNA
receptor	I-DNA
DNA	I-DNA
binding	I-DNA
site	I-DNA
.	O

These	O
results	O
suggest	O
that	O
the	O
AhR	B-protein
could	O
interfere	O
with	O
BSAP	B-protein
-stimulated	O
CD19	B-DNA
gene	I-DNA
transcription	O
by	O
competition	O
for	O
a	O
common	O
DNA	B-DNA
binding	I-DNA
site	I-DNA
.	O

Inhibitory	O
action	O
of	O
nm23	B-protein
proteins	I-protein
on	O
induction	O
of	O
erythroid	O
differentiation	O
of	O
human	B-cell_type
leukemia	I-cell_type
cells	I-cell_type
.	O

We	O
recently	O
identified	O
a	O
differentiation	B-protein
inhibitory	I-protein
factor	I-protein
(	O
I-factor	B-protein
)	O
in	O
mouse	B-cell_line
myeloid	I-cell_line
leukemia	I-cell_line
M1	I-cell_line
cells	I-cell_line
as	O
a	O
murine	B-protein
homolog	I-protein
of	O
the	O
human	B-protein
nm23-H2	I-protein
gene	I-protein
product	I-protein
.	O

nm23	B-DNA
genes	I-DNA
encode	O
proteins	O
that	O
participate	O
in	O
tumor	O
metastasis	O
regulation	O
and	O
in	O
various	O
fundamental	O
cellular	O
processes	O
,	O
although	O
their	O
mechanisms	O
of	O
action	O
are	O
still	O
unknown	O
.	O

Although	O
all	O
nm23	B-protein
proteins	I-protein
contain	O
nucleoside	B-protein
diphosphate	I-protein
(	I-protein
NDP	I-protein
)	I-protein
kinase	I-protein
activity	O
,	O
it	O
has	O
not	O
been	O
established	O
that	O
the	O
enzyme	O
activity	O
mediated	O
the	O
various	O
functions	O
of	O
nm23	B-protein
proteins	I-protein
.	O

In	O
the	O
present	O
experiment	O
,	O
we	O
examined	O
the	O
effect	O
of	O
nm23	B-protein
proteins	I-protein
on	O
various	O
differentiation	O
induction	O
systems	O
of	O
human	B-cell_type
leukemic	I-cell_type
cells	I-cell_type
including	O
HL-60	B-cell_line
,	I-cell_line
U937	I-cell_line
,	I-cell_line
HEL/S	I-cell_line
,	I-cell_line
KU812F	I-cell_line
,	I-cell_line
K562	I-cell_line
,	I-cell_line
and	I-cell_line
HEL	I-cell_line
cells	I-cell_line
.	O

Native	B-protein
human	I-protein
erythrocyte	I-protein
NDP	I-protein
kinase	I-protein
protein	I-protein
inhibited	O
the	O
induction	O
of	O
erythroid	O
differentiation	O
of	O
HEL	B-cell_line
,	I-cell_line
KU812	I-cell_line
and	I-cell_line
K562	I-cell_line
cells	I-cell_line
,	O
but	O
not	O
the	O
induction	O
of	O
monocytic	O
or	O
granulocytic	O
differentiation	O
of	O
HL-60	B-cell_line
,	I-cell_line
U937	I-cell_line
and	I-cell_line
HEL/S	I-cell_line
cells	I-cell_line
.	O

The	O
erythroid	O
differentiation	O
of	O
HEL	B-cell_line
cells	I-cell_line
was	O
inhibited	O
by	O
recombinant	B-protein
human	I-protein
nm23-H1	I-protein
,	I-protein
-H2	I-protein
,	I-protein
mouse	I-protein
nm23-M1	I-protein
,	I-protein
and	I-protein
-M2	I-protein
proteins	I-protein
.	O

Moreover	O
,	O
both	O
the	O
mutant	B-protein
nm23-H2His	I-protein
protein	I-protein
and	O
truncated	B-protein
nm23-H2	I-protein
protein	I-protein
containing	O
N-terminal	B-protein
(	I-protein
1-60	I-protein
)	I-protein
peptide	I-protein
,	O
which	O
do	O
not	O
have	O
NDP	B-protein
kinase	I-protein
activity	O
,	O
also	O
inhibited	O
erythroid	O
differentiation	O
of	O
HEL	B-cell_line
cells	I-cell_line
.	O

These	O
results	O
suggest	O
that	O
(	O
1	O
)	O
the	O
differentiation	O
inhibitory	O
activity	O
of	O
I-factor/nm23	B-protein
protein	I-protein
is	O
not	O
restricted	O
to	O
monocytic	O
differentiation	O
of	O
M1	B-cell_line
cells	I-cell_line
,	O
(	O
2	O
)	O
the	O
inhibitory	O
activity	O
is	O
exhibited	O
without	O
species	O
specificity	O
,	O
and	O
(	O
3	O
)	O
the	O
differentiation	O
inhibitory	O
activity	O
of	O
the	O
nm23/NDP	B-protein
kinase	I-protein
protein	I-protein
is	O
independent	O
of	O
its	O
enzyme	O
activity	O
and	O
requires	O
the	O
presence	O
of	O
N-terminal	O
peptides	O
.	O

Lipopolysaccharide-induced	O
E-selectin	B-protein
expression	O
requires	O
continuous	O
presence	O
of	O
LPS	O
and	O
is	O
inhibited	O
by	O
bactericidal/permeability-increasing	B-protein
protein	I-protein
.	O

Endothelial	B-cell_type
cells	I-cell_type
stimulated	O
by	O
LPS	O
express	O
E-selectin	B-protein
,	O
which	O
plays	O
an	O
important	O
role	O
in	O
mediating	O
neutrophil	B-cell_type
adhesion	O
during	O
inflammation	O
.	O

E-selectin	B-protein
is	O
induced	O
within	O
1-2	O
h	O
,	O
peaks	O
at	O
4-6	O
h	O
,	O
and	O
gradually	O
returns	O
to	O
basal	O
level	O
by	O
24	O
h	O
.	O

rBPI21	B-protein
,	O
a	O
recombinant	B-protein
N-terminal	I-protein
fragment	I-protein
of	O
human	B-protein
bactericidal/permeability-increasing	I-protein
protein	I-protein
(	O
BPI	B-protein
)	O
,	O
inhibited	O
LPS-induced	O
E-selectin	B-protein
expression	O
when	O
added	O
at	O
the	O
same	O
time	O
as	O
,	O
and	O
up	O
to	O
6	O
h	O
after	O
,	O
LPS	O
.	O

Delayed	O
administration	O
of	O
rBPI21	B-protein
also	O
affected	O
LPS-mediated	O
activation	O
of	O
the	O
nuclear	B-protein
factor	I-protein
,	O
NF-kappa	B-protein
B	I-protein
.	O

Two	O
to	O
4	O
h	O
following	O
LPS	O
addition	O
to	O
endothelial	B-cell_type
cells	I-cell_type
,	O
when	O
NF-kappa	B-protein
B	I-protein
was	O
already	O
activated	O
,	O
addition	O
of	O
rBPI21	B-protein
resulted	O
in	O
marked	O
reduction	O
of	O
NF-kappa	B-protein
B	I-protein
detectable	O
at	O
4	O
or	O
6	O
h	O
.	O

These	O
results	O
indicate	O
that	O
endothelial	O
activation	O
requires	O
continuous	O
presence	O
of	O
LPS	O
,	O
and	O
rBPI21	B-protein
acts	O
to	O
reverse	O
LPS-mediated	O
endothelial	O
activation	O
by	O
interrupting	O
the	O
on-going	O
LPS	O
signal	O
.	O

GM-CSF	B-protein
and	O
IL-2	B-protein
share	O
common	O
control	O
mechanisms	O
in	O
response	O
to	O
costimulatory	O
signals	O
in	O
T	B-cell_type
cells	I-cell_type
.	O

Antigen	O
complexed	O
with	O
major	B-protein
histocompatibility	I-protein
complex	I-protein
class	I-protein
I	I-protein
or	I-protein
II	I-protein
molecules	I-protein
on	O
the	O
surface	O
of	O
antigen	B-cell_type
presenting	I-cell_type
cells	I-cell_type
interacts	O
with	O
the	O
T	B-protein
cell	I-protein
receptor	I-protein
(	O
TCR	B-protein
)	O
on	O
the	O
surface	O
of	O
T	B-cell_type
cells	I-cell_type
and	O
initiates	O
an	O
activation	O
cascade	O
.	O

So	O
called	O
costimulatory	O
signals	O
,	O
mediated	O
by	O
other	O
cell	O
surface	O
interactions	O
or	O
soluble	B-protein
cytokines	I-protein
produced	O
by	O
antigen	B-cell_type
presenting	I-cell_type
cells	I-cell_type
,	O
are	O
also	O
required	O
for	O
complete	O
T	O
cell	O
activation	O
.	O

High	O
levels	O
of	O
cytokine	B-protein
gene	O
expression	O
in	O
T	B-cell_type
cells	I-cell_type
also	O
required	O
both	O
TCR	B-protein
and	O
costimulatory	O
signals	O
.	O

The	O
granulocyte-macrophage	B-protein
colony-stimulating	I-protein
factor	I-protein
requires	O
sequences	O
in	O
the	O
promoter	B-DNA
as	O
well	O
as	O
a	O
powerful	O
enhancer	B-DNA
located	O
3kb	O
upstream	O
to	O
respond	O
to	O
TCR	B-protein
-like	O
signals	O
.	O

These	O
promoter	B-DNA
and	I-DNA
enhancer	I-DNA
regions	I-DNA
are	O
mainly	O
activated	O
by	O
the	O
transcription	B-protein
factor	I-protein
nuclear	I-protein
factor	I-protein
of	I-protein
activated	I-protein
T	I-protein
cells	I-protein
(	O
NFAT	B-protein
)	O
.	O

The	O
activation	O
of	O
NFAT	B-protein
by	O
TCR	B-protein
signals	O
has	O
been	O
well	O
described	O
for	O
interleukin-2	O
(	O
IL-2	B-protein
)	O
and	O
IL-4	O
gene	O
transcription	O
in	O
T	B-cell_type
cells	I-cell_type
.	O

Costimulatory	O
signals	O
,	O
such	O
as	O
activation	O
of	O
the	O
CD28	B-protein
cell	I-protein
surface	I-protein
molecule	I-protein
on	O
T	B-cell_type
cells	I-cell_type
,	O
lead	O
to	O
activation	O
through	O
a	O
distinct	O
region	O
of	O
the	O
granulocyte-macrophage	B-DNA
colony-stimulating	I-DNA
factor	I-DNA
(	I-DNA
GM-CSF	I-DNA
)	I-DNA
promoter	I-DNA
.	O

This	O
region	O
is	O
termed	O
the	O
CK-1	B-DNA
or	O
CD28RE	B-DNA
and	O
appears	O
to	O
bind	O
specific	O
members	O
of	O
the	O
NF-kappa	B-protein
B	I-protein
family	I-protein
of	O
transcription	B-protein
factors	I-protein
.	O

Human	O
T	O
leukemia	O
virus	O
type	O
1	O
(	O
HTLV-1	O
)	O
infects	O
T	B-cell_type
cells	I-cell_type
and	O
can	O
lead	O
to	O
increase	O
GM-CSF	B-protein
expression	O
.	O

We	O
have	O
found	O
that	O
the	O
HTLV-1	B-protein
transactivator	I-protein
protein	I-protein
,	O
tax	B-protein
,	O
acts	O
as	O
a	O
costimulatory	O
signal	O
for	O
GM-CSF	O
and	O
IL-2	O
gene	O
transcription	O
,	O
in	O
that	O
it	O
can	O
cooperate	O
with	O
TCR	B-protein
signals	O
to	O
mediate	O
high	O
level	O
gene	O
expression	O
.	O

Tax	O
activates	O
the	O
GM-CSF	B-DNA
promoter	I-DNA
through	O
the	O
CK-1	B-DNA
/CD28RE	B-DNA
region	O
and	O
also	O
activates	O
nuclear	B-protein
factor-kappa	I-protein
B	I-protein
binding	O
to	O
this	O
region	O
.	O

However	O
,	O
other	O
transcription	B-protein
factors	I-protein
or	O
coactivators	O
of	O
NF-kappa	B-protein
B	I-protein
are	O
required	O
for	O
tax	B-protein
activation	O
but	O
these	O
remain	O
to	O
be	O
identified	O
.	O

The	O
CK-1	B-DNA
/CD28RE	B-DNA
of	O
GM-CSF	B-protein
shows	O
a	O
high	O
degree	O
of	O
similarity	O
to	O
the	O
IL-2	B-protein
CD28RE	B-DNA
and	O
the	O
IL-3	B-DNA
gene	I-DNA
also	O
contains	O
a	O
related	O
region	O
.	O

This	O
observation	O
,	O
together	O
with	O
the	O
fact	O
that	O
both	O
GM-CSF	B-protein
and	O
IL-2	B-protein
respond	O
to	O
TCR	B-protein
signals	O
via	O
NFAT	B-protein
,	O
implies	O
a	O
high	O
degree	O
of	O
conservation	O
in	O
the	O
regulation	O
of	O
cytokine	B-protein
gene	O
expression	O
in	O
T	B-cell_type
cells	I-cell_type
.	O

Danazol	O
decreases	O
transcription	O
of	O
estrogen	B-DNA
receptor	I-DNA
gene	I-DNA
in	O
human	B-cell_type
monocytes	I-cell_type
.	O

1.	O
Administration	O
of	O
danazol	O
for	O
over	O
one	O
month	O
reduced	O
the	O
levels	O
of	O
estrogen	B-protein
receptor	I-protein
(	O
ER	B-protein
)	O
and	O
its	O
mRNA	B-RNA
to	O
approximately	O
50	O
and	O
20	O
%	O
,	O
respectively	O
in	O
monocytes	B-cell_type
.	O

2.	O
Danazol	O
did	O
not	O
alter	O
the	O
degradation	O
rate	O
of	O
ER	B-RNA
mRNA	I-RNA
in	O
monocytes	B-cell_type
.	O

3.	O
Danazol	O
decreased	O
the	O
transcription	O
rate	O
of	O
ER	B-DNA
gene	I-DNA
to	O
approximately	O
50	O
%	O
in	O
monocytes	B-cell_type
in	O
a	O
run-on	O
assay	O
.	O

4.	O
Danazol	O
may	O
release	O
estrogen	O
predominance	O
via	O
the	O
reduction	O
of	O
transcription	O
for	O
ER	B-DNA
gene	I-DNA
,	O
which	O
leads	O
to	O
the	O
reduction	O
of	O
ER	B-RNA
mRNA	I-RNA
and	O
ER	B-protein
expressions	O
in	O
monocytes	B-cell_type
.	O

Functional	O
characterization	O
of	O
novel	O
IL-2	B-protein
transcriptional	O
inhibitors	O
.	O

IL-2	B-protein
-mediated	O
T	B-cell_type
cell	I-cell_type
proliferation	O
is	O
a	O
critical	O
early	O
event	O
in	O
the	O
inflammatory	O
process	O
.	O

Formation	O
of	O
the	O
NFAT-1	B-protein
transcriptional	I-protein
complex	I-protein
on	O
the	O
IL-2	B-DNA
promoter	I-DNA
is	O
essential	O
for	O
IL-2	B-protein
transcription	O
.	O

Using	O
a	O
cell	O
line	O
that	O
is	O
stably	O
transfected	O
with	O
a	O
trimer	O
of	O
the	O
NFAT-1	B-DNA
regulatory	I-DNA
element	I-DNA
linked	O
to	O
a	O
lac-Z	B-DNA
reporter	I-DNA
gene	I-DNA
,	O
we	O
screened	O
for	O
inhibitors	O
of	O
NFAT	B-protein
-1-mediated	O
beta-galactosidase	B-protein
activity	O
.	O

WIN	O
61058	O
and	O
WIN	O
53071	O
were	O
identified	O
as	O
microM	O
inhibitors	O
.	O

These	O
compounds	O
also	O
inhibited	O
beta-galactosidase	B-RNA
mRNA	I-RNA
levels	O
.	O

Similar	O
inhibition	O
of	O
NFAT	B-protein
-1-mediated	O
gene	O
expression	O
was	O
observed	O
in	O
a	O
second	O
cell	B-cell_line
line	I-cell_line
,	O
which	O
is	O
stably	O
transfected	O
with	O
NFAT-1	B-DNA
regulatory	I-DNA
elements	I-DNA
linked	O
to	O
the	O
reporter	B-DNA
gene	I-DNA
for	I-DNA
sCD8	I-DNA
.	O

At	O
10	O
microM	O
,	O
both	O
compounds	O
inhibited	O
IL-2	O
mRNA	O
and	O
protein	O
levels	O
in	O
the	O
NFAT-1-linked	B-cell_line
lac-Z	I-cell_line
transfectants	I-cell_line
,	O
and	O
in	O
human	B-cell_type
lymphocytes	I-cell_type
.	O

Both	O
compounds	O
inhibited	O
the	O
mixed	O
lymphocyte	O
reaction	O
,	O
and	O
this	O
inhibition	O
was	O
reversed	O
by	O
exogenous	O
IL-2	B-protein
.	O

WIN	O
53071	O
inhibited	O
IL-2	B-protein
production	O
induced	O
in	O
the	O
calcium-dependent	O
PMA	O
and	O
ionomycin	O
pathway	O
.	O

Conversely	O
,	O
calcium-independent	B-protein
anti-CD28	I-protein
Ab	I-protein
and	O
PMA-induced	O
IL-2	B-protein
production	O
was	O
resistant	O
.	O

Both	O
compounds	O
altered	O
the	O
NFAT-1	B-protein
transcriptional	I-protein
complex	I-protein
,	O
causing	O
its	O
retarded	O
mobility	O
on	O
gels	O
.	O

By	O
these	O
functional	O
criteria	O
,	O
we	O
believe	O
we	O
have	O
identified	O
two	O
structurally	O
distinct	O
,	O
novel	O
inhibitors	O
of	O
NFAT	B-protein
-1-mediated	O
transcription	O
.	O

Transcriptional	O
regulation	O
of	O
the	O
vacuolar	B-DNA
H	I-DNA
(	I-DNA
+	I-DNA
)	I-DNA
-ATPase	I-DNA
B2	I-DNA
subunit	I-DNA
gene	I-DNA
in	O
differentiating	B-cell_line
THP-1	I-cell_line
cells	I-cell_line
.	O

Monocyte-macrophage	O
differentiation	O
was	O
used	O
as	O
a	O
model	O
system	O
for	O
studying	O
gene	O
regulation	O
of	O
the	O
human	B-protein
vacuolar	I-protein
H	I-protein
(	I-protein
+	I-protein
)	I-protein
-ATPase	I-protein
(	O
V-ATPase	B-protein
)	O
.	O

We	O
examined	O
mRNA	B-RNA
levels	O
of	O
various	O
V-ATPase	B-protein
subunits	O
during	O
differentiation	O
of	O
both	O
native	B-cell_type
monocytes	I-cell_type
and	O
the	O
cell	B-cell_line
line	I-cell_line
THP-1	B-cell_line
,	O
and	O
found	O
that	O
transcriptional	O
and	O
post-transcriptional	O
mechanisms	O
could	O
account	O
for	O
increases	O
in	O
cell	O
V-ATPase	B-protein
content	O
.	O

From	O
nuclear	O
runoff	O
experiments	O
,	O
we	O
found	O
that	O
one	O
subunit	O
in	O
particular	O
,	O
the	O
B2	B-protein
isoform	I-protein
(	O
Mr	O
=	O
56	O
,	O
000	O
)	O
,	O
was	O
amplified	O
primarily	O
by	O
transcriptional	O
means	O
.	O

We	O
have	O
begun	O
to	O
examine	O
the	O
structure	O
of	O
the	O
B2	B-DNA
subunit	I-DNA
promoter	I-DNA
region	I-DNA
.	O

Isolation	O
and	O
sequencing	O
of	O
the	O
first	B-DNA
exon	I-DNA
and	O
5'-flanking	B-DNA
region	I-DNA
of	O
this	O
gene	O
reveal	O
a	O
TATA-less	B-DNA
promoter	I-DNA
with	O
a	O
high	O
G	O
+	O
C	O
content	O
.	O

Primer	O
extension	O
and	O
ribonuclease	B-protein
protection	O
analyses	O
indicate	O
a	O
single	O
major	B-DNA
transcriptional	I-DNA
start	I-DNA
site	I-DNA
.	O

We	O
transfected	O
promoter-luciferase	B-DNA
reporter	I-DNA
plasmids	I-DNA
into	O
THP-1	B-cell_line
cells	I-cell_line
to	O
define	O
sequences	O
that	O
mediate	O
transcriptional	O
control	O
during	O
monocyte	O
differentiation	O
.	O

We	O
found	O
that	O
sequences	O
downstream	O
from	O
the	O
transcriptional	O
start	O
site	O
were	O
sufficient	O
to	O
confer	O
increased	O
expression	O
during	O
THP-1	B-cell_line
differentiation	O
.	O

DNase	B-protein
I	I-protein
footprinting	O
and	O
sequence	O
analysis	O
revealed	O
the	O
existence	O
of	O
multiple	O
AP2	B-DNA
and	I-DNA
Sp1	I-DNA
binding	I-DNA
sites	I-DNA
in	O
the	O
5'-untranslated	B-DNA
and	I-DNA
proximal	I-DNA
coding	I-DNA
regions	I-DNA
.	O

Synergy	O
between	O
signal	O
transduction	O
pathways	O
is	O
obligatory	O
for	O
expression	O
of	O
c-fos	B-DNA
in	O
B	B-cell_line
and	I-cell_line
T	I-cell_line
cell	I-cell_line
lines	I-cell_line
:	O
implication	O
for	O
c-fos	B-DNA
control	O
via	O
surface	B-protein
immunoglobulin	I-protein
and	O
T	B-protein
cell	I-protein
antigen	I-protein
receptors	I-protein
.	O

Expression	O
of	O
the	O
protooncogene	B-DNA
c-fos	I-DNA
is	O
controlled	O
by	O
three	O
main	O
regulatory	O
pathways	O
involving	O
kinase	B-protein
C	I-protein
,	O
cAMP	O
,	O
and	O
calcium	O
.	O

Kinase	B-protein
C	I-protein
mediates	O
its	O
effects	O
via	O
phosphorylation	O
of	O
serum	B-protein
response	I-protein
factor	I-protein
(	O
SRF	B-protein
)	O
which	O
interacts	O
with	O
the	O
serum	B-DNA
response	I-DNA
element	I-DNA
(	O
SRE	B-DNA
)	O
;	O
cAMP	O
and	O
calcium	O
mediate	O
their	O
effects	O
via	O
phosphorylation	O
of	O
CREB	B-protein
(	O
cAMP	B-protein
regulatory	I-protein
element	I-protein
binding	I-protein
protein	I-protein
)	O
presumably	O
by	O
activation	O
of	O
a	O
protein	B-protein
kinase	I-protein
A	I-protein
or	O
calmodulin-regulated	B-protein
kinase	I-protein
.	O

We	O
have	O
examined	O
the	O
function	O
of	O
these	O
elements	O
in	O
Burkitt	B-cell_line
's	I-cell_line
lymphoma	I-cell_line
cells	I-cell_line
(	O
Ramos	B-cell_line
and	O
Daudi	B-cell_line
)	O
as	O
well	O
as	O
a	O
T	B-cell_line
lymphocytic	I-cell_line
cell	I-cell_line
line	I-cell_line
(	O
Jurkat	B-cell_line
)	O
.	O

We	O
have	O
found	O
that	O
stimulation	O
of	O
any	O
one	O
of	O
these	O
pathways	O
alone	O
has	O
little	O
or	O
no	O
effect	O
on	O
c-fos	B-DNA
induction	O
.	O

However	O
,	O
kinase	B-protein
C	I-protein
activation	O
(	O
PMA	O
stimulation	O
)	O
combined	O
with	O
either	O
cAMP	O
(	O
forskolin	O
plus	O
MIX	O
)	O
or	O
calcium	O
stimulation	O
(	O
ionophore	O
)	O
leads	O
to	O
greatly	O
enhanced	O
c-fos	B-DNA
induction	O
.	O

By	O
contrast	O
,	O
cAMP	O
in	O
the	O
presence	O
of	O
calcium	O
shows	O
no	O
synergy	O
in	O
c-fos	B-DNA
induction	O
.	O

Okadaic	O
acid	O
augments	O
PMA-	O
as	O
well	O
as	O
calcium-mediated	O
activation	O
of	O
c-fos	B-DNA
,	O
and	O
has	O
little	O
or	O
no	O
effect	O
when	O
combined	O
with	O
cAMP	O
.	O

The	O
main	O
difference	O
between	O
Ramos	B-cell_line
(	O
B	B-cell_type
cells	I-cell_type
)	O
and	O
Jurkat	B-cell_line
(	O
T	B-cell_type
cells	I-cell_type
)	O
in	O
the	O
regulation	O
of	O
c-fos	B-DNA
is	O
that	O
cAMP	O
plus	O
calcium	O
is	O
strongly	O
synergistic	O
in	O
Jurkat	B-cell_line
and	O
is	O
without	O
effect	O
in	O
Ramos	B-cell_line
.	O

Analysis	O
of	O
AP-1	B-protein
activity	O
using	O
gel	O
mobility	O
shift	O
assays	O
confirms	O
that	O
the	O
requirements	O
for	O
synergy	O
in	O
c-fos	B-RNA
mRNA	I-RNA
induction	O
are	O
paralleled	O
by	O
requirements	O
for	O
synergy	O
in	O
induction	O
of	O
AP-1	B-protein
activity	O
.	O

Signaling	O
in	O
B	B-cell_type
cells	I-cell_type
due	O
to	O
anti-Ig	B-protein
stimulation	O
involves	O
both	O
kinase	B-protein
C	I-protein
activation	O
and	O
release	O
of	O
intracellular	O
calcium	O
,	O
and	O
results	O
in	O
c-fos	B-RNA
mRNA	I-RNA
induction	O
.	O

Our	O
results	O
indicate	O
that	O
synergy	O
between	O
the	O
kinase	B-protein
C	I-protein
activation	O
and	O
calcium	O
is	O
needed	O
for	O
efficient	O
c-fos	B-DNA
induction	O
since	O
neither	O
of	O
these	O
two	O
alone	O
induces	O
c-fos	B-DNA
well	O
.	O

That	O
synergy	O
of	O
signaling	O
pathways	O
is	O
relevant	O
for	O
the	O
anti-Ig	B-protein
induction	O
of	O
c-fos	B-DNA
is	O
supported	O
by	O
the	O
fact	O
that	O
cAMP-inducing	O
agents	O
and	O
okadaic	O
acid	O
further	O
enhance	O
anti-Ig	B-protein
induction	O
of	O
c-fos	B-DNA
.	O

These	O
results	O
suggest	O
that	O
cell-specific	O
patterns	O
of	O
synergy	O
are	O
an	O
essential	O
feature	O
for	O
c-fos	B-DNA
induction	O
and	O
may	O
be	O
relevant	O
for	O
c-fos	B-DNA
control	O
through	O
B	B-protein
and	I-protein
T	I-protein
cell	I-protein
antigen	I-protein
receptors	I-protein
.	O

Multiple	O
signals	O
are	O
required	O
for	O
function	O
of	O
the	O
human	B-DNA
granulocyte-macrophage	I-DNA
colony-stimulating	I-DNA
factor	I-DNA
gene	I-DNA
promoter	I-DNA
in	O
T	B-cell_type
cells	I-cell_type
.	O

The	O
human	B-DNA
granulocyte-macrophage	I-DNA
CSF	I-DNA
(	I-DNA
GM-CSF	I-DNA
)	I-DNA
gene	I-DNA
is	O
expressed	O
in	O
T	B-cell_type
cells	I-cell_type
in	O
response	O
to	O
TCR	B-protein
activation	O
that	O
can	O
be	O
mimicked	O
by	O
treatment	O
of	O
the	O
cells	O
with	O
PMA	O
and	O
Ca2+	O
ionophore	O
.	O

The	O
gene	O
contains	O
a	O
proximal	B-DNA
functional	I-DNA
promoter	I-DNA
region	I-DNA
(	O
-620	B-DNA
to	I-DNA
+34	I-DNA
)	O
,	O
as	O
well	O
as	O
a	O
powerful	O
enhancer	B-DNA
located	O
3	O
kb	O
upstream	O
,	O
both	O
of	O
which	O
are	O
involved	O
in	O
the	O
response	O
of	O
the	O
gene	O
to	O
TCR	B-protein
activation	O
.	O

The	O
proximal	B-DNA
promoter	I-DNA
contains	O
a	O
region	O
termed	O
CLEO	B-DNA
(	O
-54	B-DNA
to	I-DNA
-31	I-DNA
)	O
that	O
consists	O
of	O
a	O
purine-rich	B-DNA
element	I-DNA
abutting	O
an	O
activator	B-DNA
protein-1	I-DNA
(	I-DNA
AP-1	I-DNA
)	I-DNA
-like	I-DNA
site	I-DNA
,	O
as	O
well	O
as	O
an	O
upstream	B-DNA
nuclear	I-DNA
factor-kappa	I-DNA
B	I-DNA
(	I-DNA
NF-kappa	I-DNA
B	I-DNA
)	I-DNA
site	I-DNA
(	O
-85	B-DNA
to	I-DNA
-76	I-DNA
)	O
and	O
a	O
CK-1	B-DNA
element	I-DNA
(	O
-101	B-DNA
to	I-DNA
-92	I-DNA
)	O
.	O

We	O
show	O
in	O
this	O
work	O
that	O
mutations	O
in	O
either	O
the	O
purine-rich	B-DNA
region	I-DNA
of	O
the	O
CLEO	B-DNA
element	I-DNA
or	O
the	O
NF-kappa	B-DNA
B	I-DNA
site	I-DNA
result	O
in	O
reduced	O
PMA/Ca2+	O
activation	O
of	O
a	O
620-bp	B-DNA
human	I-DNA
GM-CSF	I-DNA
promoter-luciferase	I-DNA
reporter	I-DNA
construct	I-DNA
in	O
Jurkat	B-cell_line
T	I-cell_line
cells	I-cell_line
by	O
65	O
%	O
and	O
50	O
%	O
,	O
respectively	O
.	O

The	O
major	O
inducible	B-protein
protein	I-protein
complex	I-protein
that	O
binds	O
to	O
the	O
human	B-DNA
CLEO	I-DNA
(	I-DNA
hCLEO	I-DNA
)	I-DNA
element	I-DNA
is	O
an	O
AP-1-like	B-protein
complex	I-protein
that	O
is	O
inducible	O
by	O
PMA	O
alone	O
,	O
but	O
shows	O
increased	O
binding	O
in	O
response	O
to	O
PMA	O
together	O
with	O
Ca2+	O
ionophore	O
.	O

Although	O
the	O
binding	O
of	O
this	O
complex	O
is	O
not	O
cyclosporin-sensitive	O
,	O
promoter	O
induction	O
is	O
inhibited	O
by	O
cyclosporin	O
treatment	O
.	O

A	O
second	O
weak	O
inducible	O
complex	O
resembling	O
nuclear	B-protein
factor	I-protein
of	I-protein
activated	I-protein
T	I-protein
cells	I-protein
(	O
NF-AT	B-protein
)	O
was	O
also	O
observed	O
binding	O
to	O
the	O
hCLEO	B-DNA
region	I-DNA
.	O

By	O
using	O
recombinant	B-protein
proteins	I-protein
,	O
we	O
confirmed	O
that	O
AP-1	B-protein
,	O
NF-ATp	B-protein
,	O
and	O
a	O
higher	O
order	O
NF-ATp/AP-1	B-protein
complex	I-protein
could	O
all	O
form	O
with	O
the	O
hCLEO	B-DNA
element	I-DNA
,	O
and	O
we	O
have	O
also	O
defined	O
the	O
sequence	O
requirements	O
for	O
binding	O
of	O
each	O
of	O
these	O
complexes	O
.	O

We	O
found	O
that	O
expression	O
of	O
a	O
constitutively	O
active	O
form	O
of	O
calcineurin	B-protein
could	O
substitute	O
for	O
Ca2+	O
ionophore	O
and	O
synergize	O
with	O
PMA	O
to	O
activate	O
the	O
GM-CSF	B-DNA
promoter	I-DNA
,	O
and	O
conversely	O
that	O
mutant-activated	B-protein
Ras	I-protein
could	O
substitute	O
for	O
PMA	O
and	O
cooperate	O
with	O
Ca2+	O
ionophore	O
.	O

Co-expression	O
of	O
Ras	B-protein
and	O
calcineurin	B-protein
,	O
however	O
,	O
did	O
not	O
activate	O
the	O
GM-CSF	B-DNA
promoter	I-DNA
,	O
but	O
required	O
the	O
additional	O
expression	O
of	O
NF-kappa	B-protein
B	I-protein
p65	I-protein
.	O

These	O
results	O
imply	O
that	O
at	O
least	O
three	O
signals	O
are	O
required	O
to	O
activate	O
the	O
GM-CSF	B-DNA
proximal	I-DNA
promoter	I-DNA
,	O
and	O
that	O
the	O
signals	O
impinge	O
on	O
distinct	O
transcription	B-protein
factors	I-protein
that	O
bind	O
to	O
the	O
hCLEO	B-DNA
and	I-DNA
NF-kappa	I-DNA
B	I-DNA
regions	I-DNA
of	O
the	O
promoter	B-DNA
.	O

IL-10	O
induces	O
the	O
tyrosine	O
phosphorylation	O
of	O
tyk2	B-protein
and	O
Jak1	B-protein
and	O
the	O
differential	O
assembly	O
of	O
STAT1	B-protein
alpha	I-protein
and	O
STAT3	B-protein
complexes	I-protein
in	O
human	B-cell_type
T	I-cell_type
cells	I-cell_type
and	O
monocytes	B-cell_type
.	O

IL-10	B-protein
affects	O
monocytes	B-cell_type
and	O
T	B-cell_type
cells	I-cell_type
by	O
driving	O
the	O
progression	O
of	O
immune	O
responsiveness	O
such	O
that	O
Th2	O
lymphocyte-mediated	O
effects	O
predominate	O
.	O

In	O
this	O
report	O
,	O
we	O
show	O
that	O
in	O
monocytes	B-cell_type
and	O
T	B-cell_type
cells	I-cell_type
IL-10	B-protein
stimulates	O
tyrosine	O
phosphorylation	O
of	O
the	O
signal	B-protein
transducers	I-protein
and	O
activators	B-protein
of	I-protein
transcription	I-protein
,	O
STAT1	B-protein
alpha	I-protein
and	O
STAT3	B-protein
,	O
in	O
a	O
differential	O
manner	O
such	O
that	O
the	O
relative	O
formation	O
of	O
homo-	B-protein
and	I-protein
heterodimers	I-protein
varies	O
between	O
the	O
two	O
cell	O
types	O
.	O

Moreover	O
,	O
monocytes	B-cell_type
express	O
a	O
novel	O
IL-10-stimulated	B-protein
STAT	I-protein
protein	I-protein
with	O
an	O
M	O
(	O
r	O
)	O
of	O
70	B-protein
kDa	I-protein
that	O
is	O
recognized	O
by	O
the	O
anti-STAT3	B-protein
Ab	I-protein
but	O
is	O
not	O
observed	O
in	O
T	B-cell_type
cells	I-cell_type
.	O

IL-10	B-protein
treatment	O
of	O
both	O
T	B-cell_type
cells	I-cell_type
and	O
monocytes	B-cell_type
results	O
in	O
the	O
ligand-induced	O
tyrosine	O
phosphorylation	O
of	O
tyk2	B-protein
and	O
Jak1	B-protein
,	O
but	O
not	O
Jak2	B-protein
or	O
Jak3	B-protein
.	O

Selective	O
modulation	O
of	O
immune	O
responsiveness	O
by	O
IL-10	B-protein
in	O
cells	O
such	O
as	O
monocytes	B-cell_type
and	O
T	B-cell_type
cells	I-cell_type
may	O
result	O
in	O
part	O
from	O
the	O
differential	O
activation	O
of	O
STAT	B-protein
protein	I-protein
pairs	I-protein
.	O

Use	O
of	O
new	O
biologic	O
markers	O
in	O
the	O
ovulation	O
induction	O
.	O

Biological	O
markers	O
of	O
ovulation	O
,	O
after	O
a	O
great	O
in	O
the	O
past	O
,	O
have	O
been	O
fallen	O
into	O
disuse	O
for	O
the	O
large	O
diffusion	O
of	O
biochemical	O
and	O
biophysical	O
ones	O
.	O

However	O
,	O
the	O
real	O
effect	O
of	O
hormones	O
involved	O
in	O
ovulation	O
is	O
expressed	O
by	O
biological	O
modifications	O
on	O
target	B-cell_type
tissues	I-cell_type
.	O

To	O
explore	O
the	O
modifications	O
of	O
not	O
reproductive	O
target	O
tissues	O
as	O
ovulation	O
markers	O
we	O
studied	O
the	O
behaviour	O
of	O
Albuminemia	O
,	O
Platelet	B-protein
Factor	I-protein
IV	I-protein
(	O
as	O
indicator	O
of	O
Platelet	O
Aggregation	O
)	O
,	O
Type	B-protein
II	I-protein
estrogenic	I-protein
receptors	I-protein
in	O
42	O
ovulation	O
induced	O
women	O
,	O
undergoing	O
our	O
observation	O
.	O

33	O
of	O
them	O
had	O
ovulation	O
and	O
9	O
developed	O
a	O
LUF	O
syndrome	O
,	O
constituting	O
two	O
biological	O
models	O
of	O
an	O
opposite	O
situation	O
for	O
the	O
three	O
markers	O
observed	O
.	O

All	O
the	O
markers	O
considered	O
were	O
sufficiently	O
sensitive	O
,	O
but	O
among	O
them	O
,	O
Platelet	B-protein
Factor	I-protein
IV	I-protein
was	O
the	O
most	O
reliable	O
to	O
the	O
hormonal	O
ovulatory	O
situation	O
.	O

Abnormal	O
regulation	O
of	O
the	O
IL-2	B-DNA
promoter	I-DNA
in	O
lpr	O
CD4-CD8-	B-cell_line
T	I-cell_line
lymphocytes	I-cell_line
results	O
in	O
constitutive	O
expression	O
of	O
a	O
novel	B-protein
nuclear	I-protein
factor	I-protein
of	I-protein
activated	I-protein
T	I-protein
cells-binding	I-protein
factor	I-protein
.	O

The	O
inert	O
quality	O
of	O
MRL-Ipr/Ipr	B-cell_line
(	I-cell_line
Ipr	I-cell_line
)	I-cell_line
peripheral	I-cell_line
CD4-CD8-	I-cell_line
(	I-cell_line
CD4-8-	I-cell_line
)	I-cell_line
T	I-cell_line
cells	I-cell_line
manifests	O
primarily	O
as	O
an	O
inability	O
to	O
proliferate	O
or	O
produce	O
IL-2	B-protein
in	O
response	O
to	O
TCR	B-protein
or	O
mitogenic	O
stimulation	O
.	O

Yet	O
these	O
same	O
cells	O
do	O
initiate	O
early	O
TCR	B-protein
-mediated	O
signaling	O
events	O
,	O
such	O
as	O
generation	O
of	O
inositol	O
phosphates	O
and	O
increased	O
intracellular	O
calcium	O
.	O

They	O
also	O
display	O
constitutively	O
high	O
levels	O
of	O
p59fyn	B-protein
and	O
CD3	B-protein
zeta	I-protein
tyrosine	O
phosphorylation	O
.	O

The	O
generation	O
of	O
second	O
messengers	O
in	O
T	B-cell_type
cells	I-cell_type
normally	O
leads	O
to	O
downstream	O
signaling	O
that	O
results	O
in	O
transcriptional	O
activation	O
of	O
the	O
IL-2	B-DNA
gene	I-DNA
.	O

We	O
,	O
therefore	O
,	O
compared	O
the	O
activation	O
state	O
of	O
the	O
IL-2	B-DNA
gene	I-DNA
promoter	I-DNA
region	I-DNA
in	O
freshly	O
isolated	O
and	O
stimulated	O
Ipr	B-cell_line
CD4-8-	I-cell_line
T	I-cell_line
cells	I-cell_line
with	O
that	O
of	O
normal	B-cell_type
T	I-cell_type
lymphocytes	I-cell_type
.	O

Levels	O
of	O
the	O
octamer	O
,	O
NF-kappa	B-protein
B	I-protein
(	O
p50-p65	B-protein
heterodimer	I-protein
)	O
,	O
and	O
AP-1	B-protein
transcriptional	I-protein
factors	I-protein
are	O
constitutively	O
elevated	O
in	O
freshly	O
isolated	O
Ipr	B-cell_line
CD4-8-	I-cell_line
T	I-cell_line
cells	I-cell_line
,	O
consistent	O
with	O
the	O
activated	O
phenotype	O
of	O
these	O
cells	O
.	O

Upon	O
stimulation	O
with	O
mitogens	O
,	O
formation	O
of	O
the	O
transactivating	O
complex	O
,	O
nuclear	B-protein
factor	I-protein
of	I-protein
activated	I-protein
T	I-protein
cells	I-protein
(	O
NF-AT	B-protein
)	O
,	O
occurs	O
with	O
normal	O
kinetics	O
in	O
Ipr	B-cell_line
CD4-8-	I-cell_line
T	I-cell_line
cells	I-cell_line
.	O

Yet	O
,	O
the	O
levels	O
of	O
the	O
activating	O
NF-AT	B-protein
complex	I-protein
never	O
reach	O
those	O
observed	O
in	O
similarly	O
stimulated	O
normal	O
T	B-cell_type
cells	I-cell_type
.	O

Furthermore	O
,	O
nuclear	O
extracts	O
from	O
Ipr	B-cell_line
CD4-8-	I-cell_line
T	I-cell_line
cells	I-cell_line
display	O
high	O
levels	O
of	O
a	O
novel	O
specific	O
binding	O
activity	O
at	O
the	O
NF-AT	B-DNA
site	I-DNA
,	O
which	O
is	O
present	O
at	O
much	O
lower	O
levels	O
in	O
freshly	O
isolated	O
normal	B-cell_type
T	I-cell_type
lymphocytes	I-cell_type
.	O

Upon	O
mitogenic	O
stimulation	O
,	O
the	O
binding	O
activity	O
of	O
the	O
novel	O
NF-AT-binding	B-protein
factor	I-protein
is	O
rapidly	O
down-regulated	O
in	O
normal	O
T	B-cell_type
cells	I-cell_type
,	O
but	O
persists	O
at	O
high	O
levels	O
in	O
Ipr	B-cell_line
CD4-8-	I-cell_line
T	I-cell_line
cells	I-cell_line
.	O

These	O
two	O
abnormalities	O
at	O
the	O
NF-AT	B-DNA
site	I-DNA
provide	O
a	O
potential	O
mechanism	O
to	O
account	O
for	O
the	O
defect	O
in	O
IL-2	B-protein
production	O
from	O
Ipr	B-cell_line
CD4-8-	I-cell_line
T	I-cell_line
cells	I-cell_line
.	O

Cross-linking	O
of	O
CD30	B-protein
induces	O
HIV	O
expression	O
in	O
chronically	O
infected	O
T	B-cell_type
cells	I-cell_type
.	O

CD30	B-protein
,	O
a	O
member	O
of	O
the	O
tumor	O
necrosis	O
factor	O
(	O
TNF	O
)	O
receptor	O
family	O
,	O
is	O
expressed	O
constitutively	O
on	O
the	O
surface	O
of	O
the	O
human	O
T	O
cell	O
line	O
ACH-2	O
,	O
which	O
is	O
chronically	O
infected	O
with	O
human	O
immunodeficiency	O
virus	O
type-1	O
(	O
HIV	O
)	O
-1	O
.	O

We	O
demonstrate	O
that	O
cross-linking	O
CD30	B-protein
with	O
an	O
anti-	O
CD30	B-protein
-specific	O
monoclonal	O
antibody	O
,	O
which	O
mimics	O
the	O
described	O
biological	O
activities	O
of	O
the	O
CD30	B-protein
ligand	I-protein
(	O
CD30L	B-protein
)	O
,	O
results	O
in	O
HIV	O
expression	O
.	O

CD30	B-protein
cross-linking	O
does	O
not	O
alter	O
proliferation	O
of	O
ACH-2	B-cell_line
cells	I-cell_line
and	O
the	O
induction	O
of	O
HIV	O
expression	O
is	O
not	O
mediated	O
by	O
endogenous	O
TNF	B-protein
alpha/beta	I-protein
.	O

Furthermore	O
,	O
cross-linking	O
of	O
CD30	B-protein
leads	O
to	O
NF-kappa	B-protein
B	I-protein
activation	O
and	O
enhanced	O
HIV	O
transcription	O
.	O

Thus	O
,	O
CD30	B-protein
-CD30L	B-protein
interactions	O
mediate	O
the	O
induction	O
of	O
HIV	O
expression	O
by	O
a	O
kappa	O
B-dependent	O
pathway	O
that	O
is	O
independent	O
of	O
TNF	B-protein
.	O

This	O
mechanism	O
may	O
be	O
important	O
in	O
the	O
activation	O
of	O
HIV	O
expression	O
from	O
latently	O
infected	O
CD4+	B-cell_line
T	I-cell_line
cells	I-cell_line
,	O
especially	O
in	O
lymphoid	O
organs	O
where	O
cell	O
to	O
cell	O
contact	O
is	O
conducive	O
to	O
receptor-ligand	O
interactions	O
.	O

Human	O
MHC	B-DNA
class	I-DNA
II	I-DNA
gene	I-DNA
transcription	O
directed	O
by	O
the	O
carboxyl	B-protein
terminus	I-protein
of	O
CIITA	B-DNA
,	O
one	O
of	O
the	O
defective	B-DNA
genes	I-DNA
in	O
type	O
II	O
MHC	B-protein
combined	O
immune	O
deficiency	O
.	O

Type	B-protein
II	I-protein
major	I-protein
histocompatibility	I-protein
complex	I-protein
combined	O
immune	O
deficiency	O
(	O
type	O
II	O
MHC	B-protein
CID	O
or	O
bare	O
lymphocyte	O
syndrome	O
)	O
is	O
a	O
congenital	O
immunodeficiency	O
disease	O
characterized	O
by	O
absent	O
MHC	B-protein
class	I-protein
II	I-protein
expression	O
.	O

Four	O
distinct	O
complementation	O
groups	O
have	O
been	O
identified	O
.	O

Recently	O
,	O
the	O
defective	B-DNA
gene	I-DNA
in	O
group	O
II	O
type	O
II	O
MHC	B-protein
CID	O
has	O
been	O
isolated	O
and	O
termed	O
CIITA	B-DNA
.	O

Here	O
,	O
we	O
demonstrate	O
that	O
CIITA	B-DNA
is	O
an	O
MHC	B-DNA
class	I-DNA
II	I-DNA
gene-specific	I-DNA
transcription	I-DNA
activator	I-DNA
.	O

The	O
transcription	O
activation	O
function	O
is	O
provided	O
by	O
the	O
N-terminal	B-protein
acidic	I-protein
domain	I-protein
(	O
amino	B-protein
acids	I-protein
26-137	I-protein
)	O
,	O
which	O
is	O
experimentally	O
exchangeable	O
with	O
a	O
heterologous	B-protein
viral	I-protein
transcription-activating	I-protein
domain	I-protein
.	O

The	O
specificity	O
of	O
CIITA	B-protein
for	O
three	O
major	O
MHC	B-DNA
class	I-DNA
II	I-DNA
genes	I-DNA
,	O
DR	B-DNA
,	O
DQ	B-DNA
and	O
DP	B-DNA
,	O
is	O
mediated	O
by	O
its	O
remaining	O
C-terminal	B-protein
residues	I-protein
(	O
amino	B-protein
acids	I-protein
317-1130	I-protein
)	O
.	O

The	O
transactivation	O
of	O
multiple	B-DNA
cis	I-DNA
elements	I-DNA
,	O
especially	O
S	B-DNA
and	O
X2	B-DNA
,	O
of	O
the	O
DR	B-DNA
alpha	I-DNA
proximal	I-DNA
promoter	I-DNA
in	O
group	B-cell_line
II	I-cell_line
CID	I-cell_line
cells	I-cell_line
is	O
CIITA	B-protein
dependent	O
.	O

Since	O
CIITA	B-protein
overexpression	O
in	O
normal	B-cell_type
cells	I-cell_type
did	O
not	O
increase	O
class	O
II	O
expression	O
,	O
we	O
propose	O
that	O
initiation	O
of	O
CIITA	B-protein
expression	O
serves	O
as	O
the	O
on-off	O
switch	O
,	O
while	O
availability	O
of	O
downstream	O
interactor	O
(	O
s	O
)	O
limits	O
transcription	O
.	O

Monocyte	O
tethering	O
by	O
P-selectin	B-protein
regulates	O
monocyte	B-protein
chemotactic	I-protein
protein-1	I-protein
and	O
tumor	B-protein
necrosis	I-protein
factor-alpha	I-protein
secretion	O
.	O

Signal	O
integration	O
and	O
NF-kappa	B-protein
B	I-protein
translocation	O
[	O
see	O
comments	O
]	O

Adhesion	B-protein
molecules	I-protein
that	O
tether	O
circulating	B-cell_type
leukocytes	I-cell_type
to	O
endothelial	B-cell_type
cells	I-cell_type
may	O
also	O
transduce	O
or	O
modulate	O
outside-in	O
signals	O
for	O
cellular	O
activation	O
,	O
providing	O
an	O
initial	O
regulatory	O
point	O
in	O
the	O
inflammatory	O
response	O
.	O

Adhesion	O
of	O
human	B-cell_type
monocytes	I-cell_type
to	O
P-selectin	B-protein
,	O
the	O
most	O
rapidly	O
expressed	O
endothelial	B-protein
tethering	I-protein
factor	I-protein
,	O
increased	O
the	O
secretion	O
of	O
monocyte	B-protein
chemotactic	I-protein
protein-1	I-protein
(	O
MCP-1	B-protein
)	O
and	O
tumor	B-protein
necrosis	I-protein
factor-alpha	I-protein
(	O
TNF-alpha	B-protein
)	O
by	O
the	O
leukocytes	B-cell_type
when	O
they	O
were	O
stimulated	O
with	O
platelet-activating	B-protein
factor	I-protein
.	O

Increased	O
cytokine	O
secretion	O
was	O
specifically	O
inhibited	O
by	O
G1	B-protein
,	O
an	O
anti-P-selectin	B-protein
mAb	I-protein
that	O
prevents	O
P-selectin	B-protein
from	O
binding	O
to	O
its	O
ligand	O
(	O
P-selectin	B-protein
glycoprotein	I-protein
ligand-1	I-protein
)	O
on	O
myeloid	B-cell_type
cells	I-cell_type
.	O

Moreover	O
,	O
tethering	O
by	O
P-selectin	B-protein
specifically	O
enhanced	O
nuclear	O
translocation	O
of	O
nuclear	B-protein
factor-kappa	I-protein
B	I-protein
(	O
NF-kappa	B-protein
B	I-protein
)	O
,	O
a	O
transcription	B-protein
factor	I-protein
required	O
for	O
expression	O
of	O
MCP-1	B-protein
,	O
TNF-alpha	B-protein
,	O
and	O
other	O
immediate-early	B-DNA
genes	I-DNA
.	O

These	O
results	O
demonstrate	O
that	O
P-selectin	B-protein
,	O
through	O
its	O
ligands	O
on	O
monocytes	B-cell_type
,	O
may	O
locally	O
regulate	O
cytokine	B-protein
secretion	O
in	O
inflamed	O
tissues	O
.	O

Functional	O
roles	O
of	O
in	B-DNA
vivo	I-DNA
footprinted	I-DNA
DNA	I-DNA
motifs	I-DNA
within	O
an	O
alpha-globin	B-DNA
enhancer	I-DNA
.	O

Erythroid	O
lineage	O
and	O
developmental	O
stage	O
specificities	O
.	O

Transcriptional	O
regulation	O
of	O
the	O
human	B-DNA
alpha-like	I-DNA
globin	I-DNA
genes	I-DNA
,	O
embryonic	B-DNA
zeta	I-DNA
2	I-DNA
and	O
adult	B-DNA
alpha	I-DNA
,	O
during	O
erythroid	O
development	O
is	O
mediated	O
by	O
a	O
distal	B-DNA
enhancer	I-DNA
,	O
HS-40	B-DNA
.	O

Previous	O
protein-DNA	O
binding	O
studies	O
have	O
shown	O
that	O
HS-40	B-DNA
consists	O
of	O
multiple	O
nuclear	B-DNA
factor	I-DNA
binding	I-DNA
motifs	I-DNA
that	O
are	O
occupied	O
in	O
vivo	O
in	O
an	O
erythroid	O
lineage-	O
and	O
developmental	O
stage-specific	O
manner	O
.	O

We	O
have	O
systematically	O
analyzed	O
the	O
functional	O
roles	O
of	O
these	O
factor	B-DNA
binding	I-DNA
motifs	I-DNA
of	O
HS-40	B-DNA
by	O
site-directed	O
mutagenesis	O
and	O
transient	O
expression	O
assay	O
in	O
erythroid	B-cell_line
cell	I-cell_line
cultures	I-cell_line
.	O

Three	O
of	O
these	O
HS-40	B-DNA
enhancer	I-DNA
motifs	I-DNA
,	O
5'NF-E2/AP1	B-DNA
,	O
GT	B-DNA
II	I-DNA
,	O
and	O
GATA-1	B-DNA
(	I-DNA
c	I-DNA
)	I-DNA
,	O
positively	O
regulate	O
the	O
zeta	B-DNA
2-globin	I-DNA
promoter	I-DNA
activity	O
in	O
embryonic/fetal	B-cell_line
erythroid	I-cell_line
K562	I-cell_line
cells	I-cell_line
and	O
the	O
adult	B-DNA
alpha-globin	I-DNA
promoter	I-DNA
activity	O
in	O
adult	B-cell_line
erythroid	I-cell_line
MEL	I-cell_line
cells	I-cell_line
.	O

On	O
the	O
other	O
hand	O
,	O
the	O
3'NF-E2/AP1	B-DNA
motif	I-DNA
is	O
able	O
to	O
exert	O
both	O
positive	O
and	O
negative	O
regulatory	O
effects	O
on	O
the	O
zeta	B-DNA
2-globin	I-DNA
promoter	I-DNA
activity	O
in	O
K562	B-cell_line
cells	I-cell_line
,	O
and	O
this	O
dual	O
function	O
appears	O
to	O
be	O
modulated	O
through	O
differential	O
binding	O
of	O
the	O
ubiquitous	B-protein
AP1	I-protein
factors	I-protein
and	O
the	O
erythroid-enriched	B-protein
NF-E2	I-protein
factor	I-protein
.	O

Mutation	O
in	O
the	O
GATA-1	B-DNA
(	I-DNA
d	I-DNA
)	I-DNA
motif	I-DNA
,	O
which	O
exhibits	O
an	O
adult	B-DNA
erythroid-specific	I-DNA
genomic	I-DNA
footprint	I-DNA
,	O
decreases	O
the	O
HS-40	B-DNA
enhancer	I-DNA
function	O
in	O
dimethyl	B-cell_line
sulfoxide-induced	I-cell_line
MEL	I-cell_line
cells	I-cell_line
but	O
not	O
in	O
K562	B-cell_line
cells	I-cell_line
.	O

These	O
studies	O
have	O
defined	O
the	O
regulatory	O
roles	O
of	O
the	O
different	O
HS-40	B-DNA
motifs	I-DNA
.	O

The	O
remarkable	O
correlation	O
between	O
genomic	O
footprinting	O
data	O
and	O
the	O
mutagenesis	O
results	O
also	O
suggests	O
that	O
the	O
erythroid	O
lineage-	O
and	O
developmental	O
stage-specific	O
regulation	O
of	O
human	B-DNA
alpha-like	I-DNA
globin	I-DNA
promoters	I-DNA
is	O
indeed	O
modulated	O
by	O
stable	O
binding	O
of	O
specific	B-protein
nuclear	I-protein
factors	I-protein
in	O
vivo	O
.	O

Nitric	O
oxide-stimulated	O
guanine	O
nucleotide	O
exchange	O
on	O
p21ras	B-protein
.	O

The	O
protooncogene	B-DNA
p21ras	I-DNA
,	O
a	O
monomeric	B-protein
G	I-protein
protein	I-protein
family	I-protein
member	I-protein
,	O
plays	O
a	O
critical	O
role	O
in	O
converting	O
extracellular	O
signals	O
into	O
intracellular	O
biochemical	O
events	O
.	O

Here	O
,	O
we	O
report	O
that	O
nitric	O
oxide	O
(	O
NO	O
)	O
activates	O
p21ras	B-DNA
in	O
human	B-cell_type
T	I-cell_type
cells	I-cell_type
as	O
evidenced	O
by	O
an	O
increase	O
in	O
GTP-bound	B-protein
p21ras	I-protein
.	O

In	O
vitro	O
studies	O
using	O
pure	B-protein
recombinant	I-protein
p21ras	I-protein
demonstrate	O
that	O
the	O
activation	O
is	O
direct	O
and	O
reversible	O
.	O

Circular	O
dichroism	O
analysis	O
reveals	O
that	O
NO	O
induces	O
a	O
profound	O
conformational	O
change	O
in	O
p21ras	B-DNA
in	O
association	O
with	O
GDP/GTP	O
exchange	O
.	O

The	O
mechanism	O
of	O
activation	O
is	O
due	O
to	O
S-nitrosylation	O
of	O
a	O
critical	O
cysteine	O
residue	O
which	O
stimulates	O
guanine	O
nucleotide	O
exchange	O
.	O

Furthermore	O
,	O
we	O
demonstrate	O
that	O
p21ras	B-protein
is	O
essential	O
for	O
NO-induced	O
downstream	O
signaling	O
,	O
such	O
as	O
NF-kappa	B-protein
B	I-protein
activation	O
,	O
and	O
that	O
endogenous	O
NO	O
can	O
activate	O
p21ras	B-protein
in	O
the	O
same	O
cell	O
.	O

These	O
studies	O
identify	O
p21ras	B-DNA
as	O
a	O
target	O
of	O
the	O
same	O
cell	O
.	O

These	O
studies	O
identify	O
p21ras	B-DNA
as	O
a	O
target	O
of	O
NO	O
in	O
T	B-cell_type
cells	I-cell_type
and	O
suggest	O
that	O
NO	O
activates	O
p21ras	B-DNA
by	O
an	O
action	O
which	O
mimics	O
that	O
of	O
guanine	B-protein
nucleotide	I-protein
exchange	I-protein
factors	I-protein
.	O

Interleukin-2	B-DNA
promoter	I-DNA
activity	O
in	O
Epstein-Barr	B-cell_line
virus-transformed	I-cell_line
B	I-cell_line
lymphocytes	I-cell_line
is	O
controlled	O
by	O
nuclear	B-protein
factor-chi	I-protein
B	I-protein
.	O

The	O
regulation	O
of	O
interleukin	B-DNA
(	I-DNA
IL	I-DNA
)	I-DNA
-2	I-DNA
gene	I-DNA
expression	O
has	O
been	O
investigated	O
mainly	O
in	O
T	B-cell_type
lymphocytes	I-cell_type
,	O
the	O
predominant	O
producers	O
of	O
IL-2	B-protein
.	O

However	O
,	O
B	B-cell_type
cells	I-cell_type
can	O
also	O
synthesize	O
IL-2	B-protein
.	O

In	O
the	O
present	O
study	O
we	O
analyzed	O
the	O
control	O
of	O
IL-2	B-DNA
promoter	I-DNA
activity	O
in	O
Epstein-Barr	B-cell_line
virus	I-cell_line
(	I-cell_line
EBV	I-cell_line
)	I-cell_line
-transformed	I-cell_line
B	I-cell_line
cell	I-cell_line
clones	I-cell_line
which	O
are	O
capable	O
of	O
secreting	O
IL-2	B-protein
at	O
a	O
low	O
level	O
after	O
stimulation	O
with	O
phorbol	O
12-myristate	O
13-acetate	O
and	O
the	O
Ca2+	O
ionophore	O
ionomycin	O
.	O

Transient	O
transfections	O
using	O
reporter	B-DNA
constructs	I-DNA
with	O
multiples	O
of	O
transcription	B-DNA
factor	I-DNA
binding	I-DNA
sites	I-DNA
from	O
the	O
IL-2	B-DNA
promoter	I-DNA
[	O
distal	B-protein
nuclear	I-protein
factor	I-protein
(	I-protein
NF	I-protein
)	I-protein
-AT	I-protein
,	O
proximal	B-protein
NF-AT	I-protein
,	O
AP-1/Octamer	B-protein
(	O
UPS	B-protein
)	O
or	O
NF-chi	B-protein
B	I-protein
(	O
TCEd	B-protein
)	O
sites	O
]	O
were	O
performed	O
.	O

In	O
EBV-transformed	B-cell_line
B	I-cell_line
clones	I-cell_line
,	O
the	O
chi	B-DNA
B	I-DNA
site	I-DNA
exerted	O
the	O
strongest	O
inducible	O
activity	O
;	O
the	O
NF-AT	B-DNA
binding	I-DNA
sites	I-DNA
showed	O
either	O
no	O
or	O
only	O
weak	O
activity	O
compared	O
to	O
Jurkat	B-cell_line
T	I-cell_line
cells	I-cell_line
.	O

An	O
IL-2	B-DNA
promoter	I-DNA
bearing	O
a	O
defective	O
NF-chi	B-DNA
B	I-DNA
site	I-DNA
was	O
completely	O
inactive	O
in	O
EBV-transformed	B-cell_line
B	I-cell_line
cells	I-cell_line
,	O
while	O
it	O
still	O
had	O
activity	O
in	O
Jurkat	B-cell_line
T	I-cell_line
cells	I-cell_line
.	O

In	O
seven	O
EBV-B	B-cell_line
cell	I-cell_line
clones	I-cell_line
or	O
lines	O
differing	O
in	O
their	O
capacity	O
to	O
secrete	O
IL-2	B-protein
,	O
the	O
activity	O
of	O
the	O
IL-2	B-DNA
promoter	I-DNA
correlated	O
well	O
with	O
the	O
status	O
of	O
IL-2	B-protein
secretion	O
.	O

Similarly	O
,	O
a	O
human	B-DNA
immunodeficiency	I-DNA
virus	I-DNA
promoter	I-DNA
,	O
whose	O
activity	O
is	O
controlled	O
through	O
chi	B-protein
B	I-protein
factors	I-protein
,	O
was	O
found	O
to	O
be	O
active	O
in	O
the	O
IL-2	B-cell_line
producing	I-cell_line
EBV-B	I-cell_line
cells	I-cell_line
,	O
but	O
inactive	O
in	O
the	O
non-IL-2-producing	B-cell_line
cells	I-cell_line
.	O

Electrophoretic	O
mobility	O
shift	O
assays	O
using	O
protein	O
extracts	O
from	O
EBV-B	B-cell_line
cells	I-cell_line
and	O
the	O
IL-2	B-protein
NF-chi	B-protein
B	I-protein
probe	O
revealed	O
the	O
constitutive	O
generation	O
of	O
chi	B-protein
B	I-protein
complexes	I-protein
in	O
IL-2-secreting	B-cell_line
cells	I-cell_line
consisting	O
mainly	O
of	O
heterodimeric	B-protein
p50/p65	I-protein
complexes	I-protein
.	O

A	O
weaker	O
chi	B-DNA
B	I-DNA
complex	O
formation	O
and	O
faster-migrating	O
complexes	O
were	O
detected	O
in	O
non-IL-2-secreting	B-cell_line
cells	I-cell_line
.	O

These	O
results	O
demonstrate	O
that	O
the	O
IL-2	B-DNA
NF-chi	I-DNA
B	I-DNA
site	I-DNA
is	O
indispensable	O
for	O
the	O
activity	O
of	O
the	O
IL-2	B-DNA
promoter	I-DNA
in	O
EBV-transformed	B-cell_line
B	I-cell_line
cells	I-cell_line
,	O
whereas	O
other	O
transcription	B-protein
factors	I-protein
appear	O
to	O
be	O
less	O
important	O
for	O
IL-2	B-protein
expression	O
in	O
these	O
cells	O
.	O

Latent	B-protein
membrane	I-protein
protein-1	I-protein
induces	O
cyclin	B-protein
D2	I-protein
expression	O
,	O
pRb	B-protein
hyperphosphorylation	O
,	O
and	O
loss	O
of	O
TGF-beta	B-protein
1	I-protein
-mediated	O
growth	O
inhibition	O
in	O
EBV-positive	B-cell_type
B	I-cell_type
cells	I-cell_type
.	O

The	O
normal	O
cell	O
cycle	O
is	O
regulated	O
by	O
several	O
molecules	O
,	O
such	O
as	O
the	O
tumor-suppressor	B-protein
protein	I-protein
pRb	I-protein
,	O
the	O
G1	B-protein
cyclins	I-protein
,	O
the	O
cyclin-dependent	B-protein
kinases	I-protein
,	O
and	O
their	O
inhibitors	O
.	O

These	O
regulators	O
are	O
targeted	O
by	O
negative	O
growth	O
regulatory	O
signals	O
,	O
such	O
as	O
that	O
provided	O
by	O
TGF-beta	B-protein
.	O

Here	O
,	O
we	O
show	O
that	O
the	O
presence	O
of	O
either	O
wild-type	O
EBV	O
or	O
its	O
transforming	B-protein
latent	I-protein
membrane	I-protein
protein-1	I-protein
(	O
LMP-1	B-protein
)	O
results	O
in	O
the	O
loss	O
of	O
TGF-beta	B-protein
1	I-protein
-mediated	O
growth	O
inhibition	O
in	O
human	B-cell_type
B	I-cell_type
cells	I-cell_type
.	O

Chemical	O
cross-linking	O
with	O
125I-labeled	B-protein
TGF-beta	I-protein
1	I-protein
showed	O
an	O
essentially	O
normal	O
TGF-beta	B-protein
receptor	I-protein
profile	O
in	O
EBV-positive	B-cell_line
and	I-cell_line
EBV-negative	I-cell_line
Burkitt	I-cell_line
's	I-cell_line
lymphoma	I-cell_line
cell	I-cell_line
lines	I-cell_line
,	O
and	O
these	O
receptors	O
were	O
shown	O
to	O
be	O
functional	O
in	O
transducing	O
signals	O
,	O
as	O
evidenced	O
by	O
the	O
TGF-beta	B-protein
1	I-protein
-mediated	O
modulation	O
of	O
junB	B-DNA
gene	I-DNA
expression	O
.	O

However	O
,	O
TGF-beta	B-protein
1	I-protein
did	O
not	O
induce	O
dephosphorylation	O
of	O
pRb	B-protein
in	O
EBV	B-cell_line
(	I-cell_line
or	I-cell_line
LMP-1	I-cell_line
)	I-cell_line
-positive	I-cell_line
cells	I-cell_line
as	O
opposed	O
to	O
EBV-negative	B-cell_line
cells	I-cell_line
,	O
suggesting	O
a	O
dichotomy	O
in	O
the	O
TGF-beta	B-protein
1	I-protein
signaling	O
pathway	O
leading	O
to	O
separable	O
gene	O
regulatory	O
and	O
growth	O
inhibitory	O
responses	O
.	O

Furthermore	O
,	O
LMP-1	B-protein
was	O
found	O
to	O
induce	O
the	O
expression	O
of	O
cyclin	B-protein
D2	I-protein
;	O
normal	O
B	B-cell_type
cells	I-cell_type
or	O
EBV-negative	B-cell_line
Burkitt	I-cell_line
's	I-cell_line
lymphoma	I-cell_line
cells	I-cell_line
do	O
not	O
express	O
D-type	B-protein
cyclins	I-protein
.	O

Taken	O
together	O
,	O
these	O
data	O
point	O
to	O
a	O
potential	O
mechanism	O
underlying	O
EBV-mediated	O
B	O
cell	O
transformation	O
whereby	O
constitutive	O
induction	O
of	O
key	B-protein
cell	I-protein
cycle	I-protein
regulators	I-protein
by	O
LMP-1	B-protein
can	O
lead	O
to	O
pRb	B-protein
hyperphosphorylation	O
and	O
uncontrolled	O
cell	O
proliferation	O
.	O

Does	O
thyroidectomy	O
,	O
radioactive	O
iodine	O
therapy	O
,	O
or	O
antithyroid	O
drug	O
treatment	O
alter	O
reactivity	O
of	O
patients	O
'	O
T	B-cell_type
cells	I-cell_type
to	O
epitopes	O
of	O
thyrotropin	B-protein
receptor	I-protein
in	O
autoimmune	O
thyroid	O
diseases	O
?	O

The	O
effect	O
of	O
treatment	O
on	O
thyroid	O
antibody	O
production	O
and	O
T	O
cell	O
reactivity	O
to	O
thyroid	O
antigens	O
was	O
studied	O
in	O
15	O
patients	O
with	O
Graves	O
'	O
disease	O
(	O
GD	O
)	O
before	O
and	O
after	O
thyroidectomy	O
,	O
19	O
patients	O
with	O
GD	O
before	O
and	O
after	O
radioactive	O
iodine	O
(	O
RAI	O
)	O
therapy	O
,	O
and	O
9	O
patients	O
maintained	O
euthyroid	O
on	O
antithyroid	O
drugs	O
(	O
ATD	O
)	O
.	O

Twenty	O
subjects	O
matched	O
for	O
age	O
and	O
sex	O
without	O
known	O
thyroid	O
disease	O
served	O
as	O
controls	O
.	O

In	O
GD	O
patients	O
,	O
the	O
responses	O
of	O
peripheral	B-cell_type
blood	I-cell_type
mononuclear	I-cell_type
cells	I-cell_type
(	O
PBMC	B-cell_type
)	O
and	O
TSH	B-cell_line
receptor	I-cell_line
(	I-cell_line
TSHR	I-cell_line
)	I-cell_line
-specific	I-cell_line
T	I-cell_line
cell	I-cell_line
lines	I-cell_line
to	O
recombinant	B-protein
human	I-protein
TSHR	I-protein
extracellular	I-protein
domain	I-protein
,	O
thyroglobulin	B-protein
,	O
and	O
TSHR	B-protein
peptides	O
were	O
examined	O
on	O
the	O
day	O
of	O
surgery	O
or	O
RAI	O
therapy	O
(	O
day	O
0	O
)	O
and	O
also	O
6-8	O
weeks	O
and	O
3-6	O
months	O
thereafter	O
.	O

Reactivity	O
to	O
TSHR	B-protein
peptides	O
before	O
surgery	O
was	O
heterogeneous	O
and	O
spanned	O
the	O
entire	O
extracellular	B-protein
domain	I-protein
.	O

Six	O
to	O
8	O
weeks	O
after	O
subtotal	O
thyroidectomy	O
,	O
the	O
number	O
of	O
patients	O
'	O
PBMC	B-cell_type
responding	O
to	O
any	O
peptide	O
and	O
the	O
average	O
number	O
of	O
recognized	O
peptides	O
decreased	O
.	O

A	O
further	O
decrease	O
in	O
the	O
T	O
cell	O
reactivity	O
to	O
TSHR	B-protein
peptides	O
was	O
observed	O
3-6	O
months	O
after	O
surgery	O
.	O

The	O
responses	O
of	O
PBMC	B-cell_type
from	O
Graves	O
'	O
patients	O
before	O
RAI	O
therapy	O
were	O
less	O
than	O
those	O
in	O
the	O
presurgical	O
group	O
.	O

Six	O
to	O
8	O
weeks	O
after	O
RAI	O
therapy	O
,	O
the	O
number	O
of	O
patients	O
responding	O
to	O
any	O
peptide	O
and	O
the	O
average	O
number	O
of	O
recognized	O
peptides	O
increased	O
.	O

Three	O
to	O
6	O
months	O
after	O
RAI	O
,	O
T	O
cell	O
responses	O
to	O
TSHR	B-protein
peptides	O
were	O
less	O
than	O
those	O
6-8	O
weeks	O
after	O
RAI	O
therapy	O
,	O
but	O
still	O
higher	O
than	O
the	O
values	O
on	O
day	O
0	O
.	O

Responses	O
of	O
PBMC	B-cell_type
from	O
patients	O
with	O
GD	O
,	O
maintained	O
euthyroid	O
on	O
ATD	O
,	O
were	O
lower	O
than	O
those	O
before	O
surgery	O
or	O
RAI	O
therapy	O
.	O

The	O
reactivity	O
of	O
T	B-cell_line
cell	I-cell_line
lines	I-cell_line
in	O
different	O
groups	O
reflected	O
a	O
pattern	O
similar	O
to	O
PBMC	B-cell_type
after	O
treatment	O
.	O

TSHR	B-protein
antibody	I-protein
and	O
microsomal	B-protein
antibody	I-protein
levels	O
decreased	O
after	O
surgery	O
,	O
but	O
increased	O
after	O
RAI	O
therapy	O
.	O

The	O
difference	O
in	O
the	O
number	O
of	O
recognized	O
peptides	O
by	O
patients	O
'	O
PBMC	B-cell_type
before	O
RAI	O
and	O
surgery	O
may	O
reflect	O
the	O
effect	O
of	O
long	O
term	O
therapy	O
with	O
ATD	O
in	O
the	O
patients	O
before	O
RAI	O
vs.	O
the	O
shorter	O
period	O
in	O
patients	O
before	O
surgery	O
.	O

The	O
decreased	O
T	O
cell	O
reactivity	O
to	O
thyroid	B-protein
antigens	I-protein
after	O
thyroidectomy	O
could	O
be	O
the	O
result	O
of	O
removal	O
of	O
a	O
major	O
part	O
of	O
the	O
thyroid	O
gland	O
or	O
redistribution	O
of	O
suppressor-inducer	O
T	B-cell_type
cells	I-cell_type
.	O

The	O
increased	O
T	O
cell	O
response	O
after	O
RAI	O
therapy	O
is	O
probably	O
epitope	O
specific	O
,	O
rather	O
than	O
a	O
response	O
to	O
the	O
whole	O
TSHR	B-protein
molecule	O
.	O

Synchronous	O
recognition	O
of	O
peptides	O
158-176	O
and	O
248-263	O
is	O
important	O
for	O
the	O
development	O
of	O
GD	O
,	O
and	O
the	O
loss	O
of	O
recognition	O
of	O
one	O
of	O
these	O
epitopes	B-protein
may	O
be	O
an	O
early	O
sign	O
of	O
immune	O
remission	O
and	O
a	O
predictor	O
of	O
euthyroidism	O
.	O

Circumvention	O
of	O
tolerance	O
for	O
the	O
nuclear	B-protein
T	I-protein
cell	I-protein
protein	I-protein
TCF-1	B-protein
by	O
immunization	O
of	O
TCF-1	B-protein
knock-out	O
mice	O
.	O

Molecular	O
events	O
that	O
underlie	O
the	O
well-defined	O
phenotypic	O
changes	O
of	O
the	O
differentiating	B-cell_type
thymocyte	I-cell_type
are	O
poorly	O
understood	O
.	O

A	O
candidate	O
gene	O
to	O
control	O
thymocyte	B-cell_type
differentiation	O
,	O
T	B-protein
cell	I-protein
factor-1	I-protein
(	O
TCF-1	B-protein
)	O
*	O
encodes	O
a	O
DNA-binding	B-protein
protein	I-protein
.	O

Its	O
mRNA	O
expression	O
pattern	O
is	O
complex	O
during	O
embryogenesis	O
,	O
yet	O
restricted	O
to	O
lymphocytes	B-cell_type
postnatally	O
.	O

Expression	O
studies	O
on	O
TCF-1	B-protein
protein	I-protein
have	O
been	O
hampered	O
by	O
the	O
difficulty	O
to	O
raise	O
antibodies	B-protein
due	O
to	O
extreme	O
evolutionary	O
conservation	O
.	O

TCF-1	B-protein
knock-out	O
mice	O
,	O
generated	O
recently	O
in	O
our	O
laboratory	O
,	O
have	O
strongly	O
decreased	O
numbers	O
of	O
thymocytes	B-cell_type
,	O
but	O
are	O
otherwise	O
normal	O
.	O

We	O
have	O
used	O
these	O
mice	O
to	O
generate	O
anti-TCF-1	B-protein
antibodies	I-protein
.	O

By	O
immunization	O
with	O
a	O
recombinant	B-protein
fusion	I-protein
protein	I-protein
,	O
we	O
show	O
that	O
TCF-1	B-protein
knock-out	O
mice	O
readily	O
yield	O
antiserum	O
titers	O
against	O
human	O
and	O
mouse	O
TCF-1	O
protein	O
.	O

Wild-type	O
littermates	O
remain	O
unresponsive	O
to	O
TCF-1	B-protein
while	O
they	O
mount	O
a	O
high-titer	O
antibody	O
response	O
to	O
the	O
fusion	B-protein
protein	I-protein
,	O
Maltose	B-protein
Binding	I-protein
Protein	I-protein
(	O
MBP	B-protein
)	O
.	O

Subsequently	O
,	O
TCF-1-specific	B-cell_line
hybridomas	I-cell_line
could	O
be	O
prepared	O
from	O
the	O
spleens	O
of	O
immunized	O
knock-out	O
mice	O
.	O

This	O
study	O
illustrates	O
the	O
almost	O
complete	O
tolerance	O
of	O
mice	O
for	O
human	B-protein
TCF-1	I-protein
and	O
demonstrates	O
that	O
this	O
tolerance	O
is	O
readily	O
broken	O
by	O
gene	O
knock-out	O
.	O

Furthermore	O
,	O
the	O
usefulness	O
of	O
knock-out	O
mice	O
for	O
the	O
generation	O
of	O
monoclonal	B-protein
antibodies	I-protein
against	O
the	O
gene	O
product	O
of	O
interest	O
is	O
underscored	O
.	O

The	O
transcription	B-protein
factor	I-protein
,	O
Nm23H2	B-protein
,	O
binds	O
to	O
and	O
activates	O
the	O
translocated	O
c-myc	B-DNA
allele	I-DNA
in	O
Burkitt	O
's	O
lymphoma	O
.	O

We	O
have	O
identified	O
an	O
in	O
vivo	O
footprint	O
over	O
the	O
PuF	B-DNA
site	I-DNA
on	O
the	O
translocated	O
c-myc	B-DNA
allele	I-DNA
in	O
Burkitt	O
's	O
lymphoma	O
cells	O
.	O

The	O
PuF	B-DNA
site	I-DNA
on	O
the	O
silent	B-DNA
normal	I-DNA
c-myc	I-DNA
allele	I-DNA
was	O
unoccupied	O
.	O

We	O
demonstrated	O
by	O
electrophoretic	O
mobility	O
shift	O
assay	O
,	O
electrophoretic	O
mobility	O
shift	O
assay	O
with	O
antibody	O
,	O
UV	O
cross-linking	O
followed	O
by	O
SDS-gel	O
electrophoresis	O
,	O
and	O
Western	O
analysis	O
that	O
Nm23H2	B-protein
in	O
B	O
cell	O
nuclear	O
extracts	O
bound	O
to	O
the	O
c-myc	O
PuF	B-DNA
site	I-DNA
.	O

Transfection	O
experiments	O
with	O
c-myc	B-DNA
promoter	I-DNA
constructs	I-DNA
in	O
both	O
DHL-9	B-cell_line
and	O
Raji	B-cell_line
cells	I-cell_line
revealed	O
that	O
the	O
PuF	B-DNA
site	I-DNA
functioned	O
as	O
a	O
positive	B-DNA
regulatory	I-DNA
element	I-DNA
in	O
B	B-cell_type
cells	I-cell_type
with	O
a	O
drop	O
in	O
activity	O
with	O
mutation	O
of	O
this	O
site	O
.	O

Access	O
to	O
this	O
site	O
is	O
blocked	O
in	O
the	O
normal	B-DNA
silent	I-DNA
c-myc	I-DNA
allele	I-DNA
;	O
these	O
data	O
suggest	O
that	O
the	O
Nm23H2	B-protein
protein	O
is	O
involved	O
in	O
deregulation	O
of	O
the	O
translocated	O
c-myc	B-DNA
allele	I-DNA
in	O
Burkitt	B-cell_line
's	I-cell_line
lymphoma	I-cell_line
cells	I-cell_line
.	O

Identification	O
of	O
two	O
novel	O
regulatory	B-DNA
elements	I-DNA
within	O
the	O
5'-untranslated	B-DNA
region	I-DNA
of	O
the	O
human	B-DNA
A	I-DNA
gamma-globin	I-DNA
gene	I-DNA
.	O

Interaction	O
between	O
the	O
stage	B-DNA
selector	I-DNA
element	I-DNA
(	O
SSE	O
)	O
in	O
the	O
proximal	B-DNA
gamma-globin	I-DNA
promoter	I-DNA
and	O
hypersensitivity	B-DNA
site	I-DNA
2	I-DNA
in	O
the	O
locus	B-DNA
control	I-DNA
region	I-DNA
partly	O
mediates	O
the	O
competitive	O
silencing	O
of	O
the	O
beta-globin	B-DNA
promoter	I-DNA
in	O
the	O
fetal	O
developmental	O
stage	O
.	O

We	O
have	O
now	O
demonstrated	O
that	O
a	O
second	O
SSE-like	B-DNA
element	I-DNA
in	O
the	O
5'-untranslated	B-DNA
region	I-DNA
of	O
the	O
gamma-gene	B-DNA
also	O
contributes	O
to	O
this	O
competitive	O
silencing	O
of	O
the	O
beta-gene	B-DNA
.	O

Utilizing	O
transient	O
transfection	O
assays	O
in	O
the	O
fetal	B-cell_line
erythroid	I-cell_line
cell	I-cell_line
line	I-cell_line
,	O
K562	B-cell_line
,	O
we	O
have	O
shown	O
that	O
the	O
core	B-DNA
enhancer	I-DNA
of	O
hypersensitivity	B-DNA
site	I-DNA
2	I-DNA
can	O
preferentially	O
interact	O
with	O
the	O
proximal	B-DNA
gamma-promoter	I-DNA
in	O
the	O
absence	O
of	O
the	O
SSE	B-DNA
,	O
completely	O
silencing	O
a	O
linked	B-DNA
beta-promoter	I-DNA
.	O

Mutation	O
of	O
a	O
20-base	O
pair	O
sequence	O
of	O
the	O
gamma-gene	B-DNA
5'-untranslated	I-DNA
region	I-DNA
(	O
UTR	B-DNA
)	O
led	O
to	O
derepression	O
of	O
beta-promoter	B-DNA
activity	O
.	O

A	O
marked	O
activation	O
of	O
gamma-promoter	B-DNA
activity	O
was	O
also	O
observed	O
with	O
this	O
mutation	O
,	O
suggesting	O
the	O
presence	O
of	O
a	O
repressor	O
.	O

Fine	O
mutagenesis	O
dissected	O
these	O
activities	O
to	O
different	O
regions	O
of	O
the	O
5'-UTR	B-DNA
.	O

The	O
stage	O
selector	O
activity	O
was	O
localized	O
to	O
a	O
region	O
centered	O
on	O
nucleotides	B-DNA
+13	I-DNA
to	I-DNA
+15	I-DNA
.	O

Electromobility	O
shift	O
assays	O
utilizing	O
this	O
sequence	O
demonstrated	O
binding	O
of	O
a	O
fetal	B-protein
and	I-protein
erythroid-specific	I-protein
protein	I-protein
.	O

The	O
repressor	O
activity	O
of	O
the	O
5'-UTR	B-DNA
was	O
localized	O
to	O
tandem	O
GATA-like	B-DNA
sites	I-DNA
,	O
which	O
appear	O
to	O
bind	O
a	O
complex	O
of	O
two	O
proteins	O
,	O
one	O
of	O
which	O
is	O
the	O
erythroid	B-protein
transcription	I-protein
factor	I-protein
GATA-1	B-protein
.	O

These	O
results	O
indicate	O
that	O
the	O
5'-UTR	B-DNA
of	O
the	O
gamma-gene	B-DNA
contains	O
sequences	O
that	O
may	O
be	O
important	O
for	O
its	O
transcriptional	O
and	O
developmental	O
regulation	O
.	O

Coupling	O
of	O
a	O
signal	B-protein
response	I-protein
domain	I-protein
in	O
I	B-protein
kappa	I-protein
B	I-protein
alpha	I-protein
to	O
multiple	O
pathways	O
for	O
NF-kappa	B-protein
B	I-protein
activation	O
.	O

The	O
eukaryotic	B-protein
transcription	I-protein
factor	I-protein
NF-kappa	B-protein
B	I-protein
plays	O
a	O
central	O
role	O
in	O
the	O
induced	O
expression	O
of	O
human	O
immunodeficiency	O
virus	O
type	O
1	O
and	O
in	O
many	O
aspects	O
of	O
the	O
genetic	O
program	O
mediating	O
normal	O
T-cell	O
activation	O
and	O
growth	O
.	O

The	O
nuclear	O
activity	O
of	O
NF-kappa	B-protein
B	I-protein
is	O
tightly	O
regulated	O
from	O
the	O
cytoplasmic	O
compartment	O
by	O
an	O
inhibitory	B-protein
subunit	I-protein
called	O
I	B-protein
kappa	I-protein
B	I-protein
alpha	I-protein
.	O

This	O
cytoplasmic	O
inhibitor	O
is	O
rapidly	O
phosphorylated	O
and	O
degraded	O
in	O
response	O
to	O
a	O
diverse	O
set	O
of	O
NF-kappa	B-protein
B-inducing	I-protein
agents	I-protein
,	O
including	O
T-cell	B-protein
mitogens	I-protein
,	I-protein
proinflammatory	B-protein
cytokines	I-protein
,	O
and	O
viral	B-protein
transactivators	I-protein
such	O
as	O
the	O
Tax	B-protein
protein	I-protein
of	O
human	O
T-cell	O
leukemia	O
virus	O
type	O
1	O
.	O

To	O
explore	O
these	O
I	B-protein
kappa	I-protein
B	I-protein
alpha	I-protein
-dependent	O
mechanisms	O
for	O
NF-kappa	B-protein
B	I-protein
induction	O
,	O
we	O
identified	O
novel	O
mutants	O
of	O
I	B-protein
kappa	I-protein
B	I-protein
alpha	I-protein
that	O
uncouple	O
its	O
inhibitory	O
and	O
signal-transducing	O
functions	O
in	O
human	B-cell_type
T	I-cell_type
lymphocytes	I-cell_type
.	O

Specifically	O
,	O
removal	O
of	O
the	O
N-terminal	B-protein
36	I-protein
amino	I-protein
acids	I-protein
of	O
I	B-protein
kappa	I-protein
B	I-protein
alpha	I-protein
failed	O
to	O
disrupt	O
its	O
ability	O
to	O
form	O
latent	O
complexes	O
with	O
NF-kappa	B-protein
B	I-protein
in	O
the	O
cytoplasm	O
.	O

However	O
,	O
this	O
deletion	O
mutation	O
prevented	O
the	O
induced	O
phosphorylation	O
,	O
degradative	O
loss	O
,	O
and	O
functional	O
release	O
of	O
I	B-protein
kappa	I-protein
B	I-protein
alpha	I-protein
from	O
NF-kappa	B-protein
B	I-protein
in	O
Tax-expressing	B-cell_line
cells	I-cell_line
.	O

Alanine	O
substitutions	O
introduced	O
at	O
two	O
serine	O
residues	O
positioned	O
within	O
this	O
N-terminal	B-protein
regulatory	I-protein
region	I-protein
of	O
I	B-protein
kappa	I-protein
B	I-protein
alpha	I-protein
also	O
yielded	O
constitutive	O
repressors	O
that	O
escaped	O
from	O
Tax	B-protein
-induced	O
turnover	O
and	O
that	O
potently	O
inhibited	O
immune	O
activation	O
pathways	O
for	O
NF-kappa	B-protein
B	I-protein
induction	O
,	O
including	O
those	O
initiated	O
from	O
antigen	B-protein
and	I-protein
cytokine	I-protein
receptors	I-protein
.	O

In	O
contrast	O
,	O
introduction	O
of	O
a	O
phosphoserine	O
mimetic	O
at	O
these	O
sites	O
rectified	O
this	O
functional	O
defect	O
,	O
a	O
finding	O
consistent	O
with	O
a	O
causal	O
linkage	O
between	O
the	O
phosphorylation	O
status	O
and	O
proteolytic	O
stability	O
of	O
this	O
cytoplasmic	B-protein
inhibitor	I-protein
.	O

Together	O
,	O
these	O
in	O
vivo	O
studies	O
define	O
a	O
critical	O
signal	O
response	O
domain	O
in	O
I	B-protein
kappa	I-protein
B	I-protein
alpha	I-protein
that	O
coordinately	O
controls	O
the	O
biologic	O
activities	O
of	O
I	B-protein
kappa	I-protein
B	I-protein
alpha	I-protein
and	O
NF-kappa	B-protein
B	I-protein
in	O
response	O
to	O
viral	O
and	O
immune	O
stimuli	O
.	O

Growth	O
regulation	O
and	O
cellular	O
changes	O
during	O
differentiation	O
of	O
human	B-cell_line
prostatic	I-cell_line
cancer	I-cell_line
LNCaP	I-cell_line
cells	I-cell_line
as	O
induced	O
by	O
T	O
lymphocyte-conditioned	O
medium	O
.	O

Human	B-cell_line
prostatic	I-cell_line
epithelial	I-cell_line
cells	I-cell_line
from	O
an	O
androgen-dependent	B-cell_line
LNCaP	I-cell_line
cell	I-cell_line
line	I-cell_line
were	O
examined	O
in	O
response	O
to	O
conditioned	O
medium	O
(	O
CM	O
)	O
derived	O
from	O
phytohemagglutinin	B-cell_line
(	I-cell_line
PHA	I-cell_line
)	I-cell_line
-stimulated	I-cell_line
lymphocytes	I-cell_line
.	O

Addition	O
of	O
CM	O
caused	O
a	O
greater	O
than	O
70	O
%	O
reduction	O
of	O
cell	O
proliferation	O
by	O
cell	O
counting	O
and	O
cell	O
cycle	O
.	O

These	O
cells	O
showed	O
G1	O
phase	O
arrest	O
and	O
the	O
clonogenicity	O
was	O
reduced	O
.	O

The	O
growth-modulating	O
effect	O
was	O
dose-dependent	O
and	O
not	O
due	O
to	O
cell	O
lysis	O
or	O
apoptosis	O
.	O

The	O
binding	O
of	O
androgen	O
to	O
androgen	B-protein
receptor	I-protein
on	O
these	O
cells	O
showed	O
approximately	O
50	O
%	O
reduction	O
,	O
underlining	O
a	O
proliferation	O
reduction	O
mechanism	O
.	O

The	O
prostate-specific	B-protein
antigen	I-protein
(	O
PSA	B-protein
)	O
was	O
downregulated	O
to	O
approximately	O
75	O
%	O
during	O
the	O
process	O
.	O

Cell	O
morphology	O
showed	O
dendritic	O
processes	O
extending	O
from	O
cytoplasm	O
and	O
other	O
neuroendocrine	B-cell_type
cell	I-cell_type
characteristics	O
.	O

The	O
expression	O
of	O
several	O
cytoskeleton	B-protein
and	I-protein
intracellular	I-protein
proteins	I-protein
increased	O
as	O
determined	O
by	O
immunostaining	O
on	O
slides	O
and	O
by	O
ELISA	O
procedures	O
.	O

These	O
included	O
vimentin	B-protein
,	O
correlating	O
to	O
cell	O
shape	O
changes	O
,	O
cytokeratins	B-protein
8	I-protein
and	I-protein
18	I-protein
,	O
associated	O
with	O
differentiated	B-cell_type
cell	I-cell_type
types	I-cell_type
of	O
prostate	O
epithelia	O
,	O
and	O
neuron-specific	B-protein
enolase	I-protein
and	O
serotonin	O
,	O
associated	O
with	O
neuroendocrine	B-cell_type
cells	I-cell_type
.	O

From	O
these	O
cellular	O
changes	O
,	O
we	O
can	O
infer	O
that	O
the	O
cell	O
growth	O
was	O
modulated	O
along	O
with	O
induction	O
of	O
terminal	O
differentiation	O
.	O

Activated	O
T	B-cell_type
cells	I-cell_type
were	O
demonstrated	O
to	O
be	O
important	O
in	O
providing	O
the	O
modulating	O
activity	O
.	O

This	O
growth	B-protein
modulator	I-protein
was	O
semipurified	O
and	O
had	O
an	O
estimated	O
molecular	O
weight	O
13	O
,	O
000	O
to	O
24	O
,	O
000	O
Da	O
.	O

The	O
activity	O
was	O
determined	O
to	O
be	O
distinct	O
from	O
TGF	B-protein
,	O
TNF	B-protein
,	O
and	O
some	O
commonly	O
known	O
lymphokines	B-protein
.	O

The	O
interaction	O
between	O
lymphoid	B-cell_type
and	I-cell_type
prostatic	I-cell_type
cells	I-cell_type
in	O
growth	O
and	O
development	O
is	O
described	O
.	O

Platelet-activating	B-protein
factor	I-protein
stimulates	O
transcription	O
of	O
the	O
heparin-binding	B-protein
epidermal	I-protein
growth	I-protein
factor-like	I-protein
growth	I-protein
factor	I-protein
in	O
monocytes	B-cell_type
.	O

Correlation	O
with	O
an	O
increased	O
kappa	O
B	O
binding	O
activity	O
.	O

Human	O
peripheral	O
blood	O
monocytes	B-cell_type
responded	O
to	O
stimulation	O
of	O
platelet-activating	B-protein
factor	I-protein
(	O
PAF	B-protein
)	O
with	O
up-regulation	O
of	O
the	O
transcript	O
for	O
heparin-binding	B-protein
epidermal	I-protein
growth	I-protein
factor-like	I-protein
growth	I-protein
factor	I-protein
(	O
HB-EGF	B-protein
)	O
,	O
a	O
potent	B-protein
mitogen	I-protein
for	O
vascular	B-cell_type
smooth	I-cell_type
muscle	I-cell_type
cells	I-cell_type
.	O

This	O
function	O
of	O
PAF	B-protein
was	O
observed	O
at	O
nanomolar	O
concentrations	O
of	O
the	O
ligand	O
,	O
starting	O
at	O
30	O
min	O
after	O
stimulation	O
.	O

The	O
PAF	B-protein
-induced	O
up-regulation	O
of	O
HB-EGF	B-RNA
mRNA	I-RNA
was	O
accompanied	O
by	O
an	O
increase	O
in	O
kappa	O
B	O
binding	O
activity	O
.	O

These	O
functions	O
of	O
PAF	B-protein
appeared	O
to	O
be	O
mediated	O
through	O
the	O
cell	B-protein
surface	I-protein
PAF	I-protein
receptors	I-protein
,	O
as	O
two	O
PAF	B-protein
receptor	O
antagonists	O
,	O
WEB	O
2086	O
and	O
L-659	O
,	O
989	O
,	O
blocked	O
both	O
the	O
up-regulation	O
of	O
HB-EGF	B-RNA
mRNA	I-RNA
and	O
kappa	O
B	O
binding	O
activity	O
induced	O
by	O
PAF	B-protein
.	O

The	O
antagonists	O
,	O
however	O
,	O
had	O
no	O
effect	O
on	O
phorbol	O
ester-induced	O
up-regulation	O
of	O
HB-EGF	B-RNA
mRNA	I-RNA
and	O
kappa	O
B	O
binding	O
activity	O
.	O

Pretreatment	O
of	O
monocytes	B-cell_type
with	O
pertussis	O
toxin	O
inhibited	O
these	O
functions	O
of	O
PAF	B-protein
,	O
whereas	O
cholera	O
toxin	O
had	O
no	O
inhibitory	O
effect	O
.	O

Pyrrolidine	O
dithiocarbamate	O
,	O
an	O
inhibitor	O
for	O
NF-kappa	B-protein
B	I-protein
activation	O
,	O
markedly	O
reduced	O
PAF	B-protein
-stimulated	O
kappa	O
B	O
binding	O
activity	O
as	O
well	O
as	O
up-regulation	O
of	O
HB-EGF	B-RNA
mRNA	I-RNA
.	O

These	O
results	O
suggest	O
a	O
potential	O
role	O
of	O
PAF	B-protein
in	O
HB-EGF	B-protein
expression	O
and	O
provide	O
evidence	O
that	O
this	O
stimulation	O
may	O
occur	O
through	O
increased	O
kappa	O
B	O
binding	O
activity	O
.	O

Mapping	O
of	O
the	O
interaction	B-protein
site	I-protein
of	O
the	O
defective	B-protein
transcription	I-protein
factor	I-protein
in	O
the	O
class	B-cell_line
II	I-cell_line
major	I-cell_line
histocompatibility	I-cell_line
complex	I-cell_line
mutant	I-cell_line
cell	I-cell_line
line	I-cell_line
clone-13	I-cell_line
to	O
the	O
divergent	B-DNA
X2-box	I-DNA
.	O

We	O
have	O
previously	O
described	O
a	O
mutant	B-cell_line
B	I-cell_line
lymphoblastoid	I-cell_line
cell	I-cell_line
line	I-cell_line
,	O
Clone-13	B-cell_line
,	I-cell_line
that	O
expresses	O
HLA-DQ	B-protein
in	O
the	O
absence	O
of	O
HLA-DR	B-protein
and	I-protein
-DP	I-protein
.	O

Several	O
criteria	O
indicated	O
that	O
the	O
defect	O
in	O
this	O
cell	O
line	O
influences	O
the	O
activity	O
of	O
an	O
isotype-specific	B-protein
transcription	I-protein
factor	I-protein
.	O

Indeed	O
,	O
transient	O
transfection	O
of	O
HLA-DRA	B-DNA
and	I-DNA
DQB	I-DNA
reporter	I-DNA
constructs	I-DNA
indicated	O
that	O
the	O
affected	O
factor	O
operates	O
via	O
cis-elements	B-DNA
located	O
between	O
-141	B-DNA
base	I-DNA
pairs	I-DNA
and	O
the	O
transcription	B-DNA
initiation	I-DNA
site	I-DNA
.	O

A	O
series	O
of	O
hybrid	B-DNA
DRA/DQB	I-DNA
reporter	I-DNA
constructs	I-DNA
was	O
generated	O
to	O
further	O
map	O
the	O
relevant	O
cis-elements	B-DNA
in	O
this	O
system	O
.	O

Insertion	O
of	O
oligonucleotides	O
spanning	O
the	O
DQB	B-DNA
X-box	I-DNA
(	O
but	O
not	O
the	O
DQB-W	B-DNA
region	I-DNA
or	O
the	O
DQB	B-DNA
Y-box	I-DNA
)	O
upstream	B-DNA
of	I-DNA
-141	I-DNA
in	O
a	O
DRA	B-DNA
reporter	I-DNA
plasmid	I-DNA
rescued	O
expression	O
to	O
nearly	O
wild-type	O
levels	O
.	O

Substitution	O
promoters	O
were	O
then	O
generated	O
where	O
the	O
entire	O
X-box	B-DNA
,	O
or	O
only	O
the	O
X1-	B-DNA
or	I-DNA
X2-boxes	I-DNA
of	O
HLA-DRA	B-DNA
were	O
replaced	O
with	O
the	O
analogous	O
regions	O
of	O
HLA-DQB	B-DNA
.	O

The	O
DQB	B-DNA
X2-box	I-DNA
was	O
able	O
to	O
restore	O
expression	O
to	O
the	O
silent	B-DNA
DRA	I-DNA
reporter	I-DNA
construct	I-DNA
.	O

Moreover	O
,	O
replacement	O
of	O
the	O
DQB	B-DNA
X2-box	I-DNA
with	O
the	O
DRA	B-DNA
X2-box	I-DNA
markedly	O
diminished	O
the	O
activity	O
of	O
the	O
DQB	B-DNA
promoter	I-DNA
in	O
the	O
mutant	B-cell_line
cell	I-cell_line
.	O

None	O
of	O
the	O
hybrid	B-DNA
reporter	I-DNA
constructs	I-DNA
were	O
defective	O
when	O
transfected	O
into	O
the	O
wild-type	B-protein
,	O
HLA-DR/-DQ	B-cell_line
positive	I-cell_line
parental	I-cell_line
cell	I-cell_line
line	I-cell_line
,	O
Jijoye	B-cell_line
.	O

These	O
studies	O
suggest	O
that	O
the	O
divergent	B-DNA
X2-box	I-DNA
of	O
the	O
class	B-DNA
II	I-DNA
major	I-DNA
histocompatibility	I-DNA
complex	I-DNA
promoters	I-DNA
plays	O
an	O
important	O
role	O
in	O
influencing	O
differential	O
expression	O
of	O
the	O
human	B-DNA
class	I-DNA
II	I-DNA
isotypes	I-DNA
.	O

Restoration	O
of	O
the	O
Epstein-Barr	B-protein
virus	I-protein
ZEBRA	I-protein
protein	I-protein
's	O
capacity	O
to	O
disrupt	O
latency	O
by	O
the	O
addition	O
of	O
heterologous	B-protein
activation	I-protein
regions	I-protein
.	O

The	O
ZEBRA	B-protein
protein	I-protein
has	O
a	O
unique	O
biological	O
function	O
among	O
herpesviral	B-protein
proteins	I-protein
.	O

It	O
is	O
responsible	O
for	O
the	O
disruption	O
of	O
Epstein-Barr	O
virus	O
(	O
EBV	O
)	O
latency	O
and	O
the	O
induction	O
of	O
the	O
lytic	O
cycle	O
.	O

ZEBRA	B-protein
is	O
a	O
bZIP	B-protein
transcriptional	I-protein
activator	I-protein
which	O
binds	O
as	O
a	O
dimer	O
to	O
7-bp	B-DNA
response	I-DNA
elements	I-DNA
within	O
EBV	B-DNA
promoters	I-DNA
and	O
is	O
directly	O
involved	O
in	O
the	O
stimulation	O
of	O
virus	O
replication	O
at	O
the	O
EBV	B-DNA
lytic	I-DNA
origin	I-DNA
.	O

We	O
have	O
employed	O
the	O
ZEBRA	B-protein
/EBV	O
biological	O
system	O
to	O
test	O
whether	O
a	O
heterologous	B-protein
activation	I-protein
domain	I-protein
can	O
substitute	O
for	O
another	O
activation	O
domain	O
(	O
the	O
ZEBRA	B-protein
domain	I-protein
)	O
.	O

The	O
ZEBRA	B-protein
activation	I-protein
region	I-protein
was	O
replaced	O
with	O
the	O
potent	O
acid	B-protein
activation	I-protein
region	I-protein
from	O
the	O
herpes	B-protein
simplex	I-protein
virus	I-protein
VP16	I-protein
protein	I-protein
or	O
with	O
the	O
activation	B-protein
region	I-protein
of	O
the	O
EBV	B-protein
R	I-protein
protein	I-protein
.	O

Both	O
chimeras	O
were	O
found	O
to	O
transactivate	O
model	O
and	O
native	O
promoters	O
at	O
equivalent	O
or	O
better	O
levels	O
than	O
ZEBRA	B-protein
itself	O
.	O

Activation	O
was	O
not	O
target-	O
or	O
cell-type	O
dependent	O
,	O
nor	O
was	O
it	O
dependent	O
on	O
the	O
presence	O
of	O
virus	O
.	O

These	O
activation	O
domains	O
restored	O
ZEBRA	B-protein
's	O
ability	O
to	O
induce	O
early	B-protein
antigen	I-protein
and	O
to	O
stimulate	O
origin	O
replication	O
to	O
levels	O
that	O
were	O
equal	O
to	O
or	O
greater	O
than	O
those	O
of	O
wild	O
type	O
.	O

These	O
studies	O
suggest	O
that	O
the	O
specificities	O
of	O
some	O
of	O
the	O
known	O
biological	O
functions	O
of	O
ZEBRA	B-protein
are	O
not	O
dependent	O
upon	O
the	O
nature	O
of	O
the	O
activation	B-protein
domain	I-protein
present	I-protein
within	O
ZEBRA	B-protein
.	O

Interleukin	B-protein
4	I-protein
activates	O
a	O
signal	O
transducer	O
and	O
activator	O
of	O
transcription	B-protein
(	I-protein
Stat	I-protein
)	I-protein
protein	I-protein
which	O
interacts	O
with	O
an	O
interferon-gamma	B-DNA
activation	I-DNA
site-like	I-DNA
sequence	I-DNA
upstream	O
of	O
the	O
I	B-DNA
epsilon	I-DNA
exon	I-DNA
in	O
a	O
human	B-cell_line
B	I-cell_line
cell	I-cell_line
line	I-cell_line
.	O

Evidence	O
for	O
the	O
involvement	O
of	O
Janus	B-protein
kinase	I-protein
3	I-protein
and	O
interleukin-4	B-protein
Stat	I-protein
.	O

Germ	B-RNA
line	I-RNA
C	I-RNA
transcripts	I-RNA
can	O
be	O
induced	O
by	O
IL-4	B-protein
in	O
the	O
human	B-cell_line
B	I-cell_line
cell	I-cell_line
line	I-cell_line
,	O
BL-2	B-cell_line
.	O

Utilizing	O
a	O
IFN-gamma	B-DNA
activation	I-DNA
site-like	I-DNA
DNA	I-DNA
sequence	I-DNA
element	I-DNA
located	O
upstream	O
of	O
the	O
I	B-DNA
epsilon	I-DNA
exon	I-DNA
,	O
we	O
demonstrated	O
by	O
gel	O
mobility	O
shift	O
assays	O
that	O
IL-4	B-protein
induced	O
a	O
binding	O
activity	O
in	O
the	O
cytosol	O
and	O
nucleus	O
of	O
BL-2	B-cell_line
cells	I-cell_line
.	O

This	O
factor	O
was	O
designated	O
IL-4	B-protein
NAF	I-protein
(	O
IL-4-induced	B-protein
nuclear-activating	I-protein
factors	I-protein
)	O
and	O
was	O
identified	O
as	O
a	O
tyrosine	B-protein
phosphoprotein	I-protein
,	O
which	O
translocates	O
from	O
the	O
cytosol	O
to	O
the	O
nucleus	O
upon	O
IL-4	B-protein
treatment	O
.	O

Because	O
these	O
are	O
the	O
characteristics	O
of	O
a	O
signal	B-protein
transducer	I-protein
and	I-protein
activator	I-protein
of	I-protein
transcription	I-protein
(	I-protein
Stat	I-protein
)	I-protein
protein	I-protein
,	O
we	O
determined	O
whether	O
antibodies	B-protein
to	I-protein
Stat	I-protein
proteins	I-protein
will	O
interfere	O
with	O
gel	O
mobility	O
shift	O
and	O
found	O
that	O
antibodies	B-protein
to	I-protein
IL-4	I-protein
Stat	I-protein
,	O
also	O
known	O
as	O
Stat6	B-protein
,	O
but	O
not	O
antibodies	B-protein
to	O
other	O
Stat	B-protein
proteins	I-protein
,	O
interfere	O
with	O
the	O
formation	O
of	O
the	O
IL-4	B-protein
NAF	I-protein
complex	I-protein
.	O

Congruous	O
with	O
the	O
involvement	O
of	O
a	O
Stat	B-protein
protein	I-protein
,	O
IL-4	B-protein
induced	O
robust	O
Janus	B-protein
kinase	I-protein
3	I-protein
(	O
JAK3	B-protein
)	O
activity	O
in	O
BL-2	B-cell_line
cells	I-cell_line
.	O

Cotransfection	O
of	O
JAK3	B-protein
with	O
IL-4	B-protein
Stat	I-protein
into	O
COS-7	B-cell_line
cells	I-cell_line
produced	O
an	O
intracellular	O
activity	O
which	O
bound	O
the	O
same	O
IFN-gamma	B-DNA
activation	I-DNA
site-like	I-DNA
sequence	I-DNA
and	O
comigrated	O
with	O
IL-4	B-protein
NAF	I-protein
in	O
electrophoretic	O
mobility	O
shift	O
assay	O
.	O

These	O
results	O
show	O
that	O
IL-4	B-protein
NAF	I-protein
is	O
IL-4	B-protein
Stat	I-protein
,	O
which	O
is	O
activated	O
by	O
JAK3	B-protein
in	O
response	O
to	O
IL-4	B-protein
receptor	O
engagement	O
.	O

Does	O
activation	O
of	O
the	O
TAL1	B-DNA
gene	I-DNA
occur	O
in	O
a	O
majority	O
of	O
patients	O
with	O
T-cell	O
acute	O
lymphoblastic	O
leukemia	O
?	O
A	O
pediatric	O
oncology	O
group	O
study	O
.	O

Almost	O
25	O
%	O
of	O
patients	O
with	O
T-cell	O
acute	O
lymphoblastic	O
leukemia	O
(	O
T-ALL	O
)	O
have	O
tumor-specific	O
rearrangements	O
of	O
the	O
TAL1	B-DNA
gene	I-DNA
.	O

Although	O
TAL1	B-protein
expression	O
has	O
not	O
been	O
observed	O
in	O
normal	B-cell_type
lymphocytes	I-cell_type
,	O
TAL1	B-protein
gene	I-protein
products	I-protein
are	O
readily	O
detected	O
in	O
leukemic	B-cell_type
cells	I-cell_type
that	O
harbor	O
a	O
rearranged	B-DNA
TAL1	I-DNA
allele	I-DNA
.	O

Hence	O
,	O
it	O
has	O
been	O
proposed	O
that	O
ectopic	O
expression	O
of	O
TAL1	B-protein
promotes	O
the	O
development	O
of	O
T-ALL	O
.	O

In	O
this	O
report	O
,	O
we	O
show	O
that	O
TAL1	B-protein
is	O
expressed	O
in	O
the	O
leukemic	B-cell_type
cells	I-cell_type
of	O
most	O
patients	O
with	O
T-ALL	O
,	O
including	O
many	O
that	O
do	O
not	O
display	O
an	O
apparent	O
TAL1	B-DNA
gene	I-DNA
alteration	O
.	O

A	O
polymorphic	O
dinucleotide	O
repeat	O
in	O
the	O
transcribed	O
sequences	O
of	O
TAL1	B-protein
was	O
used	O
to	O
determine	O
the	O
allele	O
specificity	O
of	O
TAL1	B-protein
transcription	O
in	O
primary	B-cell_type
T-ALL	I-cell_type
cells	I-cell_type
.	O

Monoallelic	O
expression	O
of	O
TAL1	B-protein
was	O
observed	O
in	O
the	O
leukemic	B-cell_type
cells	I-cell_type
of	O
all	O
patients	O
(	O
8	O
of	O
8	O
)	O
bearing	O
a	O
TAL1	B-DNA
gene	I-DNA
rearrangement	O
.	O

In	O
the	O
leukemic	B-cell_type
cells	I-cell_type
of	O
patients	O
without	O
detectable	O
TAL1	B-protein
rearrangements	O
,	O
TAL1	B-protein
transcription	O
occurred	O
in	O
either	O
a	O
monoallelic	O
(	O
3	O
of	O
7	O
patients	O
)	O
or	O
a	O
biallelic	O
(	O
4	O
of	O
7	O
patients	O
)	O
fashion	O
.	O

Thus	O
,	O
TAL1	B-protein
activation	O
in	O
these	O
patients	O
may	O
result	O
from	O
subtle	O
alterations	O
in	O
cis-acting	B-DNA
regulatory	I-DNA
sequences	I-DNA
(	O
affecting	O
expression	O
of	O
a	O
single	B-DNA
TAL1	I-DNA
allele	I-DNA
)	O
or	O
changes	O
in	O
trans-acting	O
factors	O
that	O
control	O
TAL1	B-protein
transcription	O
(	O
affecting	O
expression	O
of	O
both	O
TAL1	B-DNA
alleles	I-DNA
)	O
.	O

Expression	O
of	O
erythroid-specific	B-DNA
genes	I-DNA
in	O
acute	O
megakaryoblastic	O
leukaemia	O
and	O
transient	O
myeloproliferative	O
disorder	O
in	O
Down	O
's	O
syndrome	O
.	O

Acute	O
megakaryoblastic	O
leukaemia	O
(	O
M7	O
)	O
and	O
transient	O
myeloproliferative	O
disorder	O
in	O
Down	O
's	O
syndrome	O
(	O
TMD	O
)	O
are	O
characterized	O
by	O
rapid	O
growth	O
of	O
abnormal	B-cell_type
blast	I-cell_type
cells	I-cell_type
which	O
express	O
megakaryocytic	B-protein
markers	I-protein
.	O

To	O
clarify	O
properties	O
of	O
the	O
blast	B-cell_type
cells	I-cell_type
in	O
M7	O
and	O
TMD	O
cases	O
,	O
we	O
examined	O
erythroid	O
markers	O
expression	O
in	O
blasts	B-cell_type
from	O
six	O
cases	O
with	O
M7	O
and	O
seven	O
cases	O
with	O
TMD	O
in	O
this	O
study	O
.	O

Erythroid-specific	B-RNA
mRNAs	I-RNA
encoding	O
gamma-globin	B-protein
and	O
erythroid	B-protein
delta-aminolevulinate	I-protein
synthase	I-protein
were	O
found	O
to	O
be	O
expressed	O
in	O
blasts	B-cell_type
from	O
most	O
of	O
these	O
cases	O
,	O
indicating	O
that	O
majorities	O
of	O
the	O
blasts	B-cell_type
in	O
M7	O
and	O
TMD	O
cases	O
have	O
erythroid	O
and	O
megakaryocytic	O
phenotypes	O
.	O

We	O
also	O
found	O
that	O
mRNAs	B-RNA
encoding	O
GATA-1	B-protein
and	O
GATA-2	B-protein
are	O
expressed	O
in	O
all	O
these	O
cases	O
.	O

These	O
results	O
suggest	O
that	O
M7	B-cell_type
blasts	I-cell_type
and	O
TMD	B-cell_type
blasts	I-cell_type
correspond	O
to	O
the	O
erythroid/megakaryocytic	B-cell_type
bipotential	I-cell_type
progenitor	I-cell_type
cells	I-cell_type
.	O

Expression	O
of	O
Ah	B-protein
receptor	I-protein
(	O
TCDD	B-protein
receptor	I-protein
)	O
during	O
human	O
monocytic	O
differentiation	O
.	O

We	O
have	O
previously	O
found	O
a	O
high	O
expression	O
of	O
human	B-RNA
Ah	I-RNA
receptor	I-RNA
(	I-RNA
TCDD	I-RNA
receptor	I-RNA
)	I-RNA
mRNA	I-RNA
in	O
peripheral	B-cell_type
blood	I-cell_type
cells	I-cell_type
of	O
individuals	O
.	O

In	O
this	O
paper	O
,	O
the	O
expression	O
of	O
this	O
gene	O
in	O
blood	B-cell_type
cells	I-cell_type
was	O
first	O
investigated	O
in	O
fractions	O
of	O
nucleated	B-cell_type
cells	I-cell_type
,	O
revealing	O
predominant	O
expression	O
of	O
the	O
Ah	B-DNA
receptor	I-DNA
gene	I-DNA
in	O
the	O
monocyte	B-cell_type
fraction	I-cell_type
.	O

Then	O
the	O
expression	O
levels	O
of	O
AhR	B-RNA
mRNA	I-RNA
in	O
various	O
hematopoietic	B-cell_line
cell	I-cell_line
lines	I-cell_line
were	O
examined	O
together	O
with	O
those	O
of	O
Arnt	B-protein
and	O
P450IA1	B-protein
.	O

AhR	B-protein
was	O
expressed	O
at	O
high	O
levels	O
in	O
monocytoid	B-cell_line
U937	I-cell_line
,	O
THP1	B-cell_line
,	O
and	O
HEL/S	B-cell_line
cells	I-cell_line
,	O
and	O
at	O
moderate	O
levels	O
in	O
promyelocytic	B-cell_line
HL60	I-cell_line
cells	I-cell_line
and	O
erythroblastic	B-cell_line
HEL	I-cell_line
cells	I-cell_line
.	O

However	O
,	O
it	O
was	O
not	O
detected	O
in	O
lymphoid	B-cell_type
cells	I-cell_type
MOLT4	B-cell_line
(	O
T	B-cell_type
cell	I-cell_type
)	O
and	O
BALL1	B-cell_line
(	O
B	B-cell_type
cell	I-cell_type
)	O
,	O
nor	O
in	O
K562	B-cell_line
erythroblasts	I-cell_line
.	O

Furthermore	O
,	O
a	O
specific	O
induction	O
of	O
AhR	B-protein
during	O
monocytic	O
differentiation	O
was	O
investigated	O
in	O
HL60	B-cell_line
and	O
HEL	B-cell_line
cells	I-cell_line
.	O

HL60	B-cell_line
cells	I-cell_line
were	O
induced	O
to	O
differentiate	O
toward	O
monocytes-macrophages	B-cell_type
by	O
incubation	O
with	O
phorbol	O
ester	O
,	O
showing	O
a	O
5-	O
to	O
2-fold	O
increase	O
of	O
AhR	B-RNA
mRNA	I-RNA
.	O

The	O
incubation	O
with	O
transforming	B-protein
growth	I-protein
factor	I-protein
beta	I-protein
1	I-protein
and	O
1	O
alpha	O
,	O
25-dihydroxyvitamin	O
D3	O
resulted	O
in	O
a	O
5-	O
to	O
7-fold	O
increase	O
of	O
AhR	B-RNA
mRNA	I-RNA
.	O

The	O
HEL	B-cell_line
cells	I-cell_line
also	O
exhibited	O
a	O
similar	O
elevation	O
of	O
AhR	B-RNA
mRNA	I-RNA
level	O
,	O
when	O
they	O
had	O
differentiated	O
toward	O
monocyte-macrophage	B-cell_type
cells	I-cell_type
by	O
these	O
combined	O
inducers	O
,	O
but	O
little	O
change	O
in	O
the	O
mRNA	O
level	O
was	O
observed	O
when	O
the	O
cells	O
were	O
induced	O
to	O
differentiate	O
into	O
other	O
cell	O
types	O
.	O

Treatment	O
of	O
the	O
differentiated	B-cell_line
HL60	I-cell_line
cells	I-cell_line
with	O
3-methylcholanthrene	O
,	O
a	O
ligand	O
of	O
AhR	B-protein
,	O
induced	O
the	O
expression	O
of	O
the	O
P450IA1	B-protein
gene	O
.	O

These	O
results	O
indicated	O
that	O
expression	O
of	O
AhR	B-RNA
mRNA	I-RNA
was	O
significantly	O
induced	O
during	O
monocytic	O
differentiation	O
and	O
that	O
the	O
differentiated	B-cell_type
cells	I-cell_type
were	O
responsive	O
to	O
xenobiotics	O
.	O

Our	O
results	O
suggest	O
that	O
AhR	B-protein
may	O
play	O
an	O
important	O
role	O
in	O
the	O
function	O
of	O
monocytes	B-cell_type
and	O
also	O
in	O
the	O
eventual	O
activation	O
of	O
environmental	O
carcinogens	O
.	O

Neutrophils	B-cell_type
and	O
monocytes	B-cell_type
express	O
high	O
levels	O
of	O
PU.1	B-protein
(	O
Spi-1	B-protein
)	O
but	O
not	O
Spi-B	B-protein
.	O

PU.1	B-protein
(	O
the	O
Spi-1	B-DNA
oncogene	I-DNA
)	O
and	O
Spi-B	B-protein
are	O
closely	O
related	O
members	O
of	O
the	O
ets	B-protein
transcription	I-protein
factor	I-protein
family	I-protein
,	O
sharing	O
similar	O
DNA	O
binding	O
specificities	O
mediated	O
by	O
similar	O
DNA	B-protein
binding	I-protein
domains	I-protein
.	O

PU.1	B-protein
and	O
Spi-B	B-protein
have	O
been	O
previously	O
described	O
as	O
being	O
predominantly	O
expressed	O
coordinately	O
in	O
macrophages	B-cell_type
and	O
B	B-cell_type
cells	I-cell_type
,	O
but	O
their	O
expression	O
in	O
early	O
hematopoietic	O
stages	O
and	O
during	O
the	O
course	O
of	O
myeloid	O
differentiation	O
to	O
monocytes	B-cell_type
and	O
macrophages	B-cell_type
or	O
to	O
neutrophils	B-cell_type
has	O
not	O
been	O
extensively	O
investigated	O
.	O

Here	O
,	O
we	O
report	O
that	O
PU.1	B-RNA
mRNA	I-RNA
is	O
upregulated	O
during	O
myeloid	O
differentiation	O
of	O
human	B-cell_line
purified	I-cell_line
CD34+	I-cell_line
cells	I-cell_line
and	O
murine	B-cell_line
multipotential	I-cell_line
FDCP-mix	I-cell_line
A4	I-cell_line
cells	I-cell_line
,	O
suggesting	O
that	O
PU.1	B-protein
is	O
upregulated	O
as	O
an	O
early	O
event	O
during	O
differentiation	O
of	O
multipotential	B-cell_type
progenitor	I-cell_type
cells	I-cell_type
.	O

PU.1	B-protein
expression	O
is	O
maintained	O
at	O
stable	O
levels	O
during	O
differentiation	O
of	O
myeloid	B-cell_line
cell	I-cell_line
lines	I-cell_line
U937	B-cell_line
and	O
HL-60	B-cell_line
to	O
monocytic	B-cell_type
and	I-cell_type
neutrophilic	I-cell_type
cells	I-cell_type
.	O

PU.1	B-protein
is	O
expressed	O
at	O
highest	O
levels	O
in	O
mature	B-cell_type
human	I-cell_type
monocytes	I-cell_type
and	O
human	B-cell_type
peripheral	I-cell_type
blood	I-cell_type
neutrophils	I-cell_type
.	O

In	O
contrast	O
to	O
PU.1	B-protein
,	O
significant	O
levels	O
of	O
Spi-B	B-RNA
mRNA	I-RNA
and	O
protein	O
are	O
found	O
only	O
in	O
some	O
B-cell	B-cell_line
lines	I-cell_line
and	O
spleen	O
but	O
are	O
not	O
found	O
in	O
myeloid	B-cell_line
cell	I-cell_line
lines	I-cell_line
,	O
neutrophils	B-cell_type
,	O
or	O
macrophages	B-cell_type
.	O

In	O
vitro	O
translated	O
Spi-B	B-protein
protein	I-protein
can	O
bind	O
to	O
PU.1	B-DNA
binding	I-DNA
sites	I-DNA
in	O
myeloid	B-DNA
promoters	I-DNA
and	O
transactivate	O
these	O
promoters	B-DNA
in	O
nonmyeloid	B-cell_type
cells	I-cell_type
.	O

Therefore	O
,	O
although	O
PU.1	B-protein
and	O
Spi-B	B-protein
may	O
bind	O
to	O
similar	O
DNA	O
control	O
elements	O
and	O
have	O
redundancy	O
of	O
transactivation	O
function	O
in	O
vitro	O
,	O
the	O
lack	O
of	O
significant	O
levels	O
of	O
Spi-B	B-protein
in	O
myeloid	B-cell_type
cells	I-cell_type
makes	O
it	O
unlikely	O
that	O
Spi-B	B-protein
plays	O
a	O
significant	O
role	O
in	O
myeloid	O
lineage	O
development	O
and	O
gene	O
expression	O
.	O

In	O
contrast	O
,	O
PU.1	B-protein
is	O
expressed	O
at	O
high	O
levels	O
not	O
only	O
in	O
monocytes	B-cell_type
and	O
macrophages	B-cell_type
but	O
also	O
in	O
neutrophils	B-cell_type
,	O
indicating	O
that	O
PU.1	B-protein
can	O
activate	O
gene	O
expression	O
in	O
both	O
major	B-cell_type
myeloid	I-cell_type
lineages	I-cell_type
.	O

Identification	O
of	O
a	O
major	O
positive	B-DNA
regulatory	I-DNA
element	I-DNA
located	O
5	O
'	O
to	O
the	O
human	B-DNA
zeta-globin	I-DNA
gene	I-DNA
.	O

The	O
function	O
of	O
the	O
zeta-globin	B-DNA
promoter	I-DNA
was	O
studied	O
using	O
a	O
series	O
of	O
zeta-globin	B-DNA
promoter	I-DNA
deletion	I-DNA
constructs	I-DNA
to	O
drive	O
luciferase	B-protein
expression	O
in	O
transiently	B-cell_line
transfected	I-cell_line
human	I-cell_line
erythroleukemia	I-cell_line
cells	I-cell_line
.	O

The	O
promoters	B-DNA
were	O
used	O
without	O
enhancers	B-DNA
,	O
or	O
with	O
enhancers	B-DNA
derived	O
from	O
the	O
beta-globin	B-DNA
locus	I-DNA
control	I-DNA
region	I-DNA
and	O
the	O
alpha-globin	B-DNA
HS-40	I-DNA
enhancer	I-DNA
.	O

When	O
transfected	O
into	O
K562	B-cell_line
cells	I-cell_line
,	O
which	O
express	O
zeta-globin	B-protein
,	O
comparable	O
amounts	O
of	O
activity	O
were	O
obtained	O
from	O
the	O
-557	B-DNA
and	I-DNA
-417	I-DNA
zeta-luciferase	I-DNA
constructs	I-DNA
and	O
the	O
alpha-luciferase	B-DNA
constructs	I-DNA
when	O
no	O
enhancers	B-DNA
or	O
the	O
alpha-globin	B-DNA
locus	I-DNA
enhancers	I-DNA
were	O
used	O
.	O

When	O
the	O
constructs	O
were	O
transfected	O
into	O
OCIM1	B-cell_line
cells	I-cell_line
,	O
which	O
do	O
not	O
express	O
zeta-globin	B-protein
,	O
the	O
zeta-globin	B-DNA
promoters	I-DNA
were	O
at	O
best	O
20	O
%	O
as	O
active	O
as	O
the	O
alpha-globin	B-DNA
promoters	I-DNA
.	O

When	O
sequences	B-DNA
from	I-DNA
-417	I-DNA
to	I-DNA
-207	I-DNA
5	I-DNA
'	I-DNA
to	O
the	O
zeta-globin	B-RNA
mRNA	I-RNA
cap	I-RNA
site	I-RNA
were	O
deleted	O
,	O
up	O
to	O
95	O
%	O
of	O
the	O
zeta-globin	B-DNA
promoter	I-DNA
activity	O
was	O
lost	O
in	O
K562	B-cell_line
cells	I-cell_line
.	O

Reinsertion	O
of	O
these	O
sequences	O
into	O
zeta-luciferase	B-DNA
constructs	I-DNA
missing	O
the	O
-417	O
to	O
-207	O
region	O
showed	O
that	O
the	O
sequences	O
lack	O
classical	O
enhancer	O
activity	O
.	O

Point	O
mutation	O
of	O
a	O
GATA-1	B-DNA
site	I-DNA
at	O
-230	O
reduced	O
promoter	O
activity	O
by	O
37	O
%	O
.	O

Point	O
mutation	O
of	O
a	O
CCACC	B-DNA
site	I-DNA
at	O
-240	O
had	O
no	O
effect	O
.	O

Electrophoretic	O
mobility	O
shift	O
assays	O
indicated	O
that	O
the	O
-230	B-DNA
GATA-1	I-DNA
site	I-DNA
has	O
a	O
relatively	O
low	O
affinity	O
for	O
GATA-1	B-protein
.	O

These	O
experiments	O
show	O
the	O
presence	O
of	O
a	O
strong	O
positive-acting	B-DNA
element	I-DNA
,	O
located	O
between	O
-417	B-DNA
and	I-DNA
-207	I-DNA
bp	I-DNA
5	I-DNA
'	I-DNA
to	O
the	O
zeta-globin	B-DNA
mRNA	I-DNA
cap	I-DNA
site	I-DNA
,	O
is	O
necessary	O
for	O
high-level	O
promoter	O
activity	O
in	O
K562	B-cell_line
cells	I-cell_line
.	O

This	O
element	O
requires	O
GATA-1	B-protein
and	O
additional	B-protein
unknown	I-protein
factors	I-protein
for	O
maximal	O
activity	O
.	O

Analysis	O
of	O
the	O
role	O
of	O
protein	B-protein
kinase	I-protein
C-alpha	I-protein
,	I-protein
-epsilon	I-protein
,	I-protein
and	I-protein
-zeta	I-protein
in	O
T	O
cell	O
activation	O
.	O

T	B-cell_type
cells	I-cell_type
express	O
multiple	O
isotypes	O
of	O
protein	B-protein
kinase	I-protein
C	I-protein
(	O
PKC	B-protein
)	O
and	O
although	O
it	O
is	O
well	O
accepted	O
that	O
PKCs	B-protein
have	O
an	O
important	O
role	O
in	O
T	O
cell	O
activation	O
,	O
little	O
is	O
known	O
about	O
the	O
function	O
of	O
individual	O
PKC	B-protein
isotypes	I-protein
.	O

To	O
address	O
this	O
issue	O
,	O
mutationally	O
active	O
PKC-alpha	B-protein
,	I-protein
-epsilon	I-protein
,	I-protein
or	I-protein
-zeta	I-protein
have	O
been	O
transfected	O
into	O
T	B-cell_type
cells	I-cell_type
and	O
the	O
consequences	O
for	O
T	O
cell	O
activation	O
determined	O
.	O

p21ras	B-protein
plays	O
an	O
essential	O
role	O
in	O
T	O
cell	O
activation	O
.	O

Accordingly	O
,	O
the	O
effects	O
of	O
the	O
constitutively	B-protein
active	I-protein
PKCs	I-protein
were	O
compared	O
to	O
the	O
effects	O
of	O
mutationally	O
activated	O
p21ras	B-protein
.	O

The	O
data	O
indicate	O
that	O
PKC-epsilon	B-protein
and	O
,	O
to	O
a	O
lesser	O
extent	O
PKC-alpha	B-protein
but	O
not	O
-zeta	B-protein
,	O
can	O
regulate	O
the	O
transcription	B-protein
factors	I-protein
AP-1	B-protein
and	O
nuclear	O
factor	B-protein
of	I-protein
activated	I-protein
T	I-protein
cells	I-protein
(	O
NF-AT-1	B-protein
)	O
.	O

The	O
ability	O
of	O
PKC-epsilon	B-protein
to	O
induce	O
transactivation	O
of	O
NF-AT-1	B-protein
and	O
AP-1	B-protein
was	O
similar	O
to	O
the	O
stimulatory	O
effect	O
of	O
a	O
constitutively	B-protein
activated	I-protein
p21ras	I-protein
.	O

PKC-epsilon	B-protein
,	O
but	O
not	O
PKC-alpha	B-protein
nor	O
activated	O
p21ras	B-protein
,	O
was	O
able	O
to	O
induce	O
NF-KB	B-protein
activity	O
.	O

Phorbol	O
esters	O
induce	O
expression	O
of	O
CD69	B-protein
whereas	O
none	O
of	O
the	O
activated	B-protein
PKC	I-protein
isotypes	I-protein
tested	O
were	O
able	O
to	O
have	O
this	O
effect	O
.	O

Activated	O
Src	B-protein
and	O
p21ras	B-protein
were	O
able	O
to	O
induce	O
CD69	B-protein
expression	O
.	O

These	O
results	O
indicate	O
selective	O
functions	O
for	O
different	O
PKC	B-protein
isotypes	I-protein
in	O
T	B-cell_type
cells	I-cell_type
.	O

Moreover	O
,	O
the	O
data	O
comparing	O
the	O
effects	O
of	O
activated	B-protein
Ras	I-protein
and	O
PKC	B-protein
mutants	I-protein
suggest	O
that	O
PKC-alpha	B-protein
,	O
p21ras	B-protein
,	O
and	O
PKC-epsilon	B-protein
are	O
not	O
positioned	O
linearly	O
on	O
a	O
single	O
signal	O
transduction	O
pathway	O
.	O

Differences	O
in	O
binding	O
of	O
glucocorticoid	B-protein
receptor	I-protein
to	O
DNA	O
in	O
steroid-resistant	O
asthma	O
.	O

Although	O
glucocorticosteroids	O
are	O
a	O
very	O
effective	O
treatment	O
for	O
asthma	O
and	O
other	O
chronic	O
inflammatory	O
diseases	O
,	O
a	O
small	O
proportion	O
of	O
patients	O
are	O
resistant	O
to	O
their	O
therapeutic	O
effects	O
.	O

The	O
molecular	O
mechanism	O
for	O
this	O
steroid	O
resistance	O
is	O
unclear	O
.	O

Steroid	O
resistance	O
can	O
not	O
be	O
explained	O
by	O
pharmacokinetic	O
mechanisms	O
,	O
by	O
a	O
defect	O
in	O
the	O
binding	O
of	O
steroids	O
to	O
glucocorticoid	B-protein
receptors	I-protein
,	O
nor	O
by	O
defective	O
nuclear	O
translocation	O
of	O
this	O
receptor	O
,	O
thereby	O
suggesting	O
that	O
the	O
molecular	O
abnormality	O
lies	O
distal	O
to	O
nuclear	O
translocation	O
.	O

We	O
examined	O
the	O
ability	O
of	O
nuclear	O
translocated	O
glucocorticoid	B-protein
receptors	I-protein
to	O
bind	O
to	O
their	O
DNA	B-DNA
binding	I-DNA
sites	I-DNA
(	O
GRE	B-DNA
)	O
using	O
electrophoretic	O
mobility	O
shift	O
assays	O
in	O
PBMC	B-cell_type
from	O
patients	O
with	O
steroid-sensitive	O
and	O
steroid-resistant	O
asthma	O
.	O

The	O
binding	O
of	O
the	O
glucocorticoid	B-protein
receptor	I-protein
to	O
DNA	O
in	O
these	O
patients	O
was	O
also	O
studied	O
using	O
Scatchard	O
analysis	O
.	O

Dexamethasone	O
induced	O
a	O
significant	O
rapid	O
and	O
sustained	O
twofold	O
increase	O
in	O
GRE	B-DNA
binding	O
in	O
PBMCs	B-cell_type
from	O
steroid-sensitive	O
asthmatic	O
patients	O
and	O
nonasthmatic	O
individuals	O
,	O
but	O
this	O
was	O
markedly	O
reduced	O
in	O
steroid-resistant	O
asthmatic	O
patients	O
.	O

Scatchard	O
analysis	O
of	O
glucocorticoid	B-protein
receptor	I-protein
-	O
GRE	B-DNA
binding	O
showed	O
no	O
change	O
in	O
binding	O
affinity	O
but	O
did	O
show	O
a	O
reduced	O
number	O
of	O
receptors	B-protein
available	O
for	O
DNA	O
binding	O
in	O
the	O
steroid-resistant	O
patients	O
.	O

These	O
results	O
suggest	O
that	O
the	O
ability	O
of	O
the	O
glucocorticoid	B-protein
receptor	I-protein
to	O
bind	O
to	O
GRE	B-DNA
is	O
impaired	O
in	O
steroid-resistant	O
patients	O
because	O
of	O
a	O
reduced	O
number	O
of	O
receptors	B-protein
available	O
for	O
binding	O
to	O
DNA	O
.	O

Interleukin-5	B-protein
signaling	O
in	O
human	B-cell_type
eosinophils	I-cell_type
involves	O
JAK2	B-protein
tyrosine	I-protein
kinase	I-protein
and	O
Stat1	B-protein
alpha	I-protein
.	O

Signaling	O
by	O
a	O
wide	O
variety	O
of	O
cytokines	B-protein
,	O
including	O
interferons	B-protein
,	O
interleukins	B-protein
,	O
and	O
growth	B-protein
factors	I-protein
,	O
involves	O
activation	O
of	O
JAK	B-protein
kinases	I-protein
and	O
Stat	B-protein
(	I-protein
Signal	I-protein
transducers	I-protein
and	I-protein
activators	I-protein
of	I-protein
transcription	I-protein
)	I-protein
proteins	I-protein
.	O

At	O
present	O
,	O
not	O
much	O
is	O
known	O
about	O
the	O
molecular	O
mechanisms	O
by	O
which	O
interleukin-5	B-protein
(	O
IL-5	B-protein
)	O
exerts	O
its	O
diverse	O
biologic	O
effects	O
.	O

Human	B-cell_type
eosinophils	I-cell_type
are	O
one	O
of	O
the	O
most	O
important	O
target	B-cell_type
cells	I-cell_type
for	O
IL-5	B-protein
and	O
were	O
used	O
here	O
to	O
study	O
IL-5	B-protein
signaling	O
in	O
a	O
primary	B-cell_type
human	I-cell_type
cell	I-cell_type
.	O

IL-5	B-protein
induced	O
rapid	O
and	O
transient	O
tyrosine	O
phosphorylation	O
of	O
JAK2	B-protein
.	O

Moreover	O
,	O
IL-5	B-protein
induced	O
at	O
least	O
two	O
DNA-binding	B-protein
complexes	I-protein
,	O
using	O
nuclear	O
extracts	O
from	O
normal	O
human	B-cell_type
eosinophils	I-cell_type
and	O
the	O
IL-6/interferon-gamma	B-DNA
response	I-DNA
element	I-DNA
of	O
the	O
ICAM-1	B-DNA
promoter	I-DNA
(	O
ICAM-1	B-DNA
pIRE	I-DNA
)	O
in	O
an	O
electromobility	O
shift	O
assay	O
.	O

From	O
supershift	O
experiments	O
it	O
was	O
concluded	O
that	O
one	O
DNA-binding	B-protein
complex	I-protein
contained	O
Stat1	B-protein
alpha	I-protein
,	O
probably	O
as	O
a	O
homodimer	O
.	O

Both	O
DNA-binding	B-protein
complexes	I-protein
were	O
inhibited	O
by	O
a	O
phosphotyrosine	B-protein
antibody	I-protein
(	O
4G10	B-protein
)	O
,	O
suggesting	O
that	O
tyrosine	O
phosphorylation	O
is	O
required	O
for	O
complex	O
formation	O
.	O

IL-3	B-protein
and	O
granulocyte-macrophage	B-protein
colony-stimulating	I-protein
factor	I-protein
induced	O
,	O
similar	O
to	O
IL-5	B-protein
,	O
two	O
DNA-binding	B-protein
complexes	I-protein
in	O
human	B-cell_type
eosinophils	I-cell_type
,	O
including	O
Stat1	B-protein
alpha	I-protein
.	O

These	O
data	O
show	O
for	O
the	O
first	O
time	O
that	O
molecular	O
mechanisms	O
of	O
IL-5	B-protein
signaling	O
in	O
human	B-cell_type
eosinophils	I-cell_type
involve	O
members	O
of	O
the	O
JAK	B-protein
kinase	I-protein
family	I-protein
as	O
well	O
as	O
members	O
of	O
the	O
Stat	B-protein
family	I-protein
.	O

Infection	O
and	O
replication	O
of	O
Tat-	O
human	O
immunodeficiency	O
viruses	O
:	O
genetic	O
analyses	O
of	O
LTR	B-DNA
and	O
tat	B-protein
mutations	I-protein
in	O
primary	B-cell_type
and	I-cell_type
long-term	I-cell_type
human	I-cell_type
lymphoid	I-cell_type
cells	I-cell_type
.	O

Tat	B-protein
is	O
an	O
essential	O
regulatory	B-protein
protein	I-protein
for	O
the	O
replication	O
of	O
human	O
immunodeficiency	O
virus	O
(	O
HIV	O
)	O
.	O

Mutations	O
in	O
the	O
tat	B-DNA
gene	I-DNA
have	O
been	O
shown	O
to	O
block	O
HIV	O
replication	O
in	O
human	B-cell_type
T	I-cell_type
cells	I-cell_type
.	O

Several	O
studies	O
have	O
established	O
that	O
Tat	B-protein
releases	O
an	O
elongation	B-protein
block	I-protein
to	O
the	O
transcription	O
of	O
HIV	B-DNA
long	I-DNA
terminal	I-DNA
repeat	I-DNA
(	O
LTR	B-DNA
)	O
;	O
however	O
,	O
it	O
is	O
not	O
known	O
whether	O
this	O
mechanism	O
alone	O
is	O
sufficient	O
to	O
explain	O
the	O
block	O
to	O
HIV	O
replication	O
in	O
human	B-cell_type
T	I-cell_type
cells	I-cell_type
when	O
Tat	B-protein
is	O
absent	O
.	O

It	O
is	O
possible	O
that	O
Tat	B-protein
is	O
also	O
needed	O
for	O
other	O
functions	O
during	O
HIV	O
replication	O
.	O

To	O
test	O
these	O
hypotheses	O
,	O
we	O
studied	O
several	O
tat	B-protein
mutants	I-protein
,	O
including	O
two	O
stop	B-protein
codon	I-protein
mutants	I-protein
and	O
one	O
deletion	B-protein
mutant	I-protein
using	O
replication-competent	B-DNA
HIV-1	I-DNA
constructs	I-DNA
carrying	O
wild-type	B-DNA
or	I-DNA
mutant	I-DNA
LTRs	I-DNA
with	O
modifications	O
in	O
the	O
NF-kappa	B-DNA
B	I-DNA
and/or	I-DNA
Sp1	I-DNA
binding	I-DNA
sites	I-DNA
.	O

In	O
this	O
study	O
,	O
we	O
show	O
that	O
Tat-	O
HIV-1	O
with	O
wild-type	B-DNA
LTRs	I-DNA
can	O
replicate	O
in	O
HeLa	B-cell_line
cells	I-cell_line
,	O
and	O
the	O
virus	O
produced	O
from	O
HeLa	B-cell_line
cells	I-cell_line
can	O
infect	O
primary	O
peripheral	B-cell_type
blood	I-cell_type
lymphocytes	I-cell_type
and	O
macrophages	B-cell_type
.	O

It	O
was	O
found	O
that	O
the	O
propagation	O
of	O
the	O
Tat	B-protein
mutants	I-protein
containing	O
wild-type	B-DNA
LTRs	I-DNA
was	O
less	O
efficient	O
than	O
that	O
of	O
the	O
LTR-modified	B-protein
Tat	I-protein
mutants	I-protein
.	O

Large	O
amounts	O
of	O
viral	B-RNA
RNA	I-RNA
and	O
particles	O
were	O
synthesized	O
in	O
infections	O
established	O
using	O
the	O
tat	B-protein
mutants	I-protein
that	O
contain	O
modified	B-DNA
LTRs	I-DNA
.	O

However	O
,	O
this	O
efficient	O
propagation	O
of	O
the	O
LTR-modified	B-protein
tat	I-protein
mutants	I-protein
was	O
restricted	O
to	O
some	O
lymphoid	B-cell_line
cell	I-cell_line
lines	I-cell_line
that	O
have	O
been	O
transformed	O
with	O
other	O
viruses	O
.	O

Thus	O
,	O
despite	O
its	O
essential	O
role	O
for	O
releasing	O
an	O
elongation	B-protein
block	I-protein
,	O
Tat	B-protein
is	O
not	O
otherwise	O
absolutely	O
required	O
for	O
synthesis	O
of	O
full-length	B-RNA
HIV	I-RNA
transcripts	I-RNA
and	O
assembly	O
of	O
virus	O
particles	O
.	O

Direct	O
sequencing	O
of	O
the	O
viral	B-DNA
genomes	I-DNA
and	O
reinfection	O
kinetics	O
showed	O
no	O
evidence	O
of	O
wild-type	O
reversion	O
even	O
after	O
prolonged	O
infection	O
with	O
the	O
Tat	B-protein
-virus	O
.	O

The	O
implications	O
for	O
in	O
vivo	O
HIV-1	O
replication	O
and	O
potential	O
application	O
of	O
this	O
system	O
to	O
the	O
study	O
of	O
alternative	O
Tat	B-protein
function	O
are	O
discussed	O
.	O

Functional	O
roles	O
of	O
the	O
transcription	B-protein
factor	I-protein
Oct-2A	I-protein
and	O
the	O
high	B-protein
mobility	I-protein
group	I-protein
protein	I-protein
I/Y	B-protein
in	O
HLA-DRA	B-DNA
gene	I-DNA
expression	O
.	O

The	O
class	B-DNA
II	I-DNA
major	I-DNA
histocompatibility	I-DNA
complex	I-DNA
gene	I-DNA
HLA-DRA	B-DNA
is	O
expressed	O
in	O
B	B-cell_type
cells	I-cell_type
,	O
activated	O
T	B-cell_type
lymphocytes	I-cell_type
,	O
and	O
in	O
antigen-presenting	B-cell_type
cells	I-cell_type
.	O

In	O
addition	O
,	O
HLA-DRA	B-DNA
gene	I-DNA
expression	O
is	O
inducible	O
in	O
a	O
variety	O
of	O
cell	O
types	O
by	O
interferon-gamma	B-protein
(	O
IFN-gamma	B-protein
)	O
.	O

Here	O
we	O
show	O
that	O
the	O
lymphoid-specific	B-protein
transcription	I-protein
factor	I-protein
Oct-2A	I-protein
plays	O
a	O
critical	O
role	O
in	O
HLA-DRA	B-DNA
gene	I-DNA
expression	O
in	O
class	B-cell_line
II-positive	I-cell_line
B	I-cell_line
cell	I-cell_line
lines	I-cell_line
,	O
and	O
that	O
the	O
high	B-protein
mobility	I-protein
group	I-protein
protein	I-protein
(	O
HMG	B-protein
)	O
I/Y	B-protein
binds	O
to	O
multiple	O
sites	O
within	O
the	O
DRA	B-DNA
promoter	I-DNA
,	O
including	O
the	O
Oct-2A	B-DNA
binding	I-DNA
site	I-DNA
.	O

Coexpression	O
of	O
HMG	B-protein
I/Y	I-protein
and	O
Oct-2	B-protein
in	O
cell	B-cell_line
lines	I-cell_line
lacking	O
Oct-2	B-protein
results	O
in	O
high	O
levels	O
of	O
HLA-DRA	B-DNA
gene	I-DNA
expression	O
,	O
and	O
in	O
vitro	O
DNA-binding	O
studies	O
reveal	O
that	O
HMG	O
I/Y	B-protein
stimulates	O
Oct-2A	B-protein
binding	O
to	O
the	O
HLA-DRA	B-DNA
promoter	I-DNA
.	O

Thus	O
,	O
Oct-2A	B-protein
and	O
HMG	B-protein
I/Y	I-protein
may	O
synergize	O
to	O
activate	O
HLA-DRA	B-DNA
expression	O
in	O
B	B-cell_type
cells	I-cell_type
.	O

By	O
contrast	O
,	O
Oct-2A	B-protein
is	O
not	O
involved	O
in	O
the	O
IFN-gamma	B-protein
induction	O
of	O
the	O
HLA-DRA	B-DNA
gene	I-DNA
in	O
HeLa	B-cell_line
cells	I-cell_line
,	O
but	O
antisense	B-DNA
HMG	I-DNA
I/Y	I-DNA
dramatically	O
decreases	O
the	O
level	O
of	O
induction	O
.	O

We	O
conclude	O
that	O
distinct	O
sets	O
of	O
transcription	B-protein
factors	I-protein
are	O
involved	O
in	O
the	O
two	O
modes	O
of	O
HLA-DRA	B-DNA
expression	O
,	O
and	O
that	O
HMG	B-protein
I/Y	I-protein
may	O
be	O
important	O
for	O
B	O
cell-specific	O
expression	O
,	O
and	O
is	O
essential	O
for	O
IFN-gamma	B-protein
induction	O
.	O

Heterogeneous	O
expression	O
of	O
Epstein-Barr	B-protein
virus	I-protein
latent	I-protein
proteins	I-protein
in	O
endemic	O
Burkitt	O
's	O
lymphoma	O
.	O

Epstein-Barr	B-cell_type
virus	I-cell_type
(	I-cell_type
EBV	I-cell_type
)	I-cell_type
-infected	I-cell_type
cells	I-cell_type
may	O
sustain	O
three	O
distinct	O
forms	O
of	O
virus	O
latency	O
.	O

In	O
lymphoblastoid	B-cell_line
cell	I-cell_line
lines	I-cell_line
,	O
six	O
EBV-encoded	B-protein
nuclear	I-protein
antigens	I-protein
(	O
EBNA1	B-protein
,	I-protein
2	I-protein
,	I-protein
3A	I-protein
,	I-protein
3B	I-protein
,	I-protein
3C	I-protein
,	I-protein
-LP	I-protein
)	O
,	O
three	O
latent	B-protein
membrane	I-protein
proteins	I-protein
(	O
LMP1	B-protein
,	O
2A	B-protein
,	O
2B	B-protein
)	O
,	O
and	O
two	O
nuclear	B-RNA
RNAs	I-RNA
(	O
EBERs	B-RNA
)	O
are	O
expressed	O
.	O

This	O
form	O
of	O
latency	O
,	O
termed	O
latency	O
III	O
,	O
is	O
also	O
encountered	O
in	O
some	O
posttransplant	O
lymphoproliferative	O
disorders	O
.	O

In	O
EBV-positive	O
cases	O
of	O
Hodgkin	O
's	O
disease	O
,	O
the	O
EBERs	B-RNA
,	O
EBNA1	B-protein
,	O
and	O
the	O
LMPs	B-protein
are	O
expressed	O
(	O
latency	O
II	O
)	O
,	O
whereas	O
in	O
Burkitt	O
's	O
lymphoma	O
(	O
BL	O
)	O
only	O
the	O
EBERs	B-RNA
and	O
EBNA1	B-protein
have	O
been	O
detected	O
(	O
latency	O
I	O
)	O
.	O

We	O
have	O
studied	O
the	O
expression	O
of	O
EBV	B-protein
proteins	I-protein
in	O
17	O
cases	O
of	O
EBV-positive	O
endemic	O
BL	O
by	O
immunohistology	O
.	O

Expression	O
of	O
LMP1	B-protein
was	O
seen	O
in	O
variable	O
proportions	O
of	O
tumor	B-cell_type
cells	I-cell_type
in	O
two	O
cases	O
and	O
EBNA2	B-protein
was	O
detected	O
in	O
some	O
tumor	B-cell_type
cells	I-cell_type
in	O
three	O
other	O
cases	O
.	O

Also	O
,	O
the	O
BZLF1	B-protein
trans-activator	I-protein
protein	I-protein
was	O
expressed	O
in	O
a	O
few	O
tumor	B-cell_type
cells	I-cell_type
in	O
6	O
cases	O
,	O
indicating	O
entry	O
into	O
the	O
lytic	O
cycle	O
.	O

A	O
phenotypic	O
drift	O
from	O
latency	O
I	O
to	O
latency	O
III	O
has	O
been	O
observed	O
previously	O
in	O
some	O
BL	B-cell_line
cell	I-cell_line
lines	I-cell_line
.	O

Our	O
results	O
suggest	O
that	O
a	O
similar	O
phenomenon	O
may	O
occur	O
in	O
BL	O
in	O
vivo	O
and	O
indicate	O
that	O
the	O
operational	O
definition	O
of	O
EBV	O
latencies	O
is	O
not	O
easily	O
applied	O
to	O
human	O
tumors	O
.	O

The	O
activation	O
of	O
the	O
Jak	B-protein
-STAT	B-protein
1	I-protein
signaling	O
pathway	O
by	O
IL-5	B-protein
in	O
eosinophils	B-cell_type
.	O

The	O
intracellular	O
signal	O
transduction	O
of	O
IL-5	B-protein
in	O
eosinophils	B-cell_type
is	O
unknown	O
.	O

The	O
objective	O
of	O
this	O
study	O
was	O
to	O
investigate	O
the	O
involvement	O
of	O
the	O
newly	O
discovered	O
Jak	B-protein
-STAT	B-protein
pathway	O
in	O
the	O
IL-5	B-protein
signal	O
transduction	O
mechanism	O
.	O

Eosinophils	B-cell_type
were	O
purified	O
from	O
peripheral	O
blood	O
by	O
discontinuous	O
Percoll	O
gradients	O
and	O
stimulated	O
with	O
IL-5	B-protein
.	O

The	O
involvement	O
of	O
Jak	B-protein
2	I-protein
was	O
investigated	O
by	O
immunoprecipitation	O
followed	O
by	O
immunoblotting	O
for	O
tyrosine	O
phosphorylation	O
.	O

The	O
activation	O
of	O
Jak	B-protein
2	I-protein
was	O
studied	O
by	O
autophosphorylation	O
of	O
the	O
immunoprecipitated	B-protein
kinase	I-protein
.	O

Jak	B-protein
2	I-protein
was	O
tyrosine	O
phosphorylated	O
within	O
1	O
to	O
3	O
min	O
after	O
stimulation	O
of	O
eosinophils	B-cell_type
with	O
IL-5	B-protein
.	O

Further	O
,	O
the	O
immunoprecipitated	B-protein
Jak	I-protein
2	I-protein
obtained	O
from	O
IL-5-stimulated	B-cell_line
cells	I-cell_line
underwent	O
autophosphorylation	O
.	O

Jak	B-protein
2	I-protein
coprecipitated	O
with	O
the	O
beta-subunit	O
of	O
the	O
IL-5	B-protein
receptor	I-protein
,	O
suggesting	O
a	O
physical	O
association	O
of	O
the	O
kinase	B-protein
with	O
the	O
receptor	O
.	O

The	O
nuclear	B-protein
factor	I-protein
STAT-1	I-protein
(	O
p91	B-protein
)	O
was	O
investigated	O
by	O
immunoprecipitation	O
followed	O
by	O
immunoblotting	O
for	O
tyrosine	O
phosphorylation	O
.	O

STAT-1	B-protein
was	O
tyrosine	O
phosphorylated	O
within	O
15	O
min	O
of	O
IL-5	B-protein
stimulation	O
.	O

The	O
presence	O
of	O
STAT-1	B-protein
in	O
the	O
nuclear	O
extract	O
was	O
studied	O
by	O
electrophoretic	O
mobility	O
shift	O
assay	O
.	O

IL-5	B-protein
induced	O
two	O
proteins	O
that	O
bound	O
to	O
the	O
gamma-activating	B-DNA
sequence	I-DNA
.	O

In	O
the	O
presence	O
of	O
an	O
anti-STAT-1	B-protein
Ab	I-protein
,	O
the	O
band	O
was	O
supershifted	O
.	O

Thus	O
,	O
we	O
demonstrated	O
that	O
IL-5	B-protein
activated	O
the	O
Jak	B-protein
2	I-protein
-STAT	B-protein
1	I-protein
signaling	O
pathway	O
in	O
eosinophils	B-cell_type
.	O

We	O
speculate	O
that	O
the	O
Jak	B-protein
2	I-protein
-STAT	B-protein
1	I-protein
pathway	O
may	O
be	O
involved	O
in	O
the	O
activation	O
of	O
IL-5-inducible	B-DNA
genes	I-DNA
in	O
eosinophils	B-cell_type
.	O

Reduced	O
mitogenic	O
stimulation	O
of	O
peripheral	B-cell_type
blood	I-cell_type
mononuclear	I-cell_type
cells	I-cell_type
as	O
a	O
prognostic	O
parameter	O
for	O
the	O
course	O
of	O
breast	O
cancer	O
:	O
a	O
prospective	O
longitudinal	O
study	O
.	O

Immunosuppression	O
has	O
been	O
often	O
associated	O
with	O
the	O
course	O
of	O
malignant	O
diseases	O
.	O

In	O
the	O
present	O
study	O
,	O
the	O
proliferation	O
of	O
peripheral	B-cell_type
blood	I-cell_type
mononuclear	I-cell_type
cells	I-cell_type
(	O
PBMCs	B-cell_type
)	O
in	O
response	O
to	O
mitogenic	O
stimulation	O
with	O
phytohaemagglutinin	B-protein
(	O
PHA	B-protein
)	O
was	O
assessed	O
prospectively	O
in	O
90	O
patients	O
with	O
stage	O
I-III	O
breast	O
cancer	O
.	O

Whereas	O
PHA	B-protein
-induced	O
proliferation	O
of	O
PBMCs	B-cell_type
derived	O
from	O
patients	O
with	O
breast	O
cancer	O
preoperatively	O
was	O
significantly	O
decreased	O
when	O
compared	O
with	O
data	O
obtained	O
in	O
healthy	O
control	O
individuals	O
(	O
P	O
<	O
0.001	O
)	O
,	O
the	O
degree	O
of	O
the	O
defect	O
in	O
PHA	B-protein
-induced	O
proliferation	O
of	O
PBMCs	B-cell_type
depended	O
upon	O
the	O
tumour	O
burden	O
as	O
manifested	O
by	O
tumour	O
size	O
and	O
axillary	O
lymph	O
node	O
involvement	O
(	O
P	O
<	O
0.003	O
in	O
each	O
case	O
)	O
.	O

PHA	B-protein
-induced	O
proliferation	O
of	O
PBMCs	B-cell_type
dropped	O
significantly	O
in	O
patients	O
who	O
received	O
adjuvant	O
chemotherapy	O
consisting	O
of	O
cyclophosphamide	O
,	O
methotrexate	O
and	O
fluorouracil	O
(	O
CMF	O
)	O
after	O
an	O
observation	O
period	O
of	O
6	O
months	O
(	O
P	O
<	O
0.01	O
)	O
,	O
but	O
not	O
in	O
patients	O
under	O
adjuvant	O
treatment	O
with	O
tamoxifen	O
only	O
.	O

After	O
an	O
additional	O
6	O
months	O
(	O
i.e.	O
12	O
months	O
after	O
surgery	O
)	O
,	O
PHA	B-protein
-induced	O
proliferation	O
of	O
PBMCs	B-cell_type
was	O
similar	O
in	O
patients	O
after	O
adjuvant	O
chemotherapy	O
with	O
CMF	O
and	O
in	O
those	O
receiving	O
continued	O
adjuvant	O
tamoxifen	O
treatment	O
(	O
P	O
>	O
0.1	O
)	O
,	O
but	O
in	O
all	O
patients	O
still	O
significantly	O
decreased	O
as	O
compared	O
with	O
healthy	O
controls	O
(	O
P	O
<	O
0.001	O
)	O
.	O

When	O
data	O
obtained	O
preoperatively	O
and	O
after	O
12	O
months	O
were	O
compared	O
,	O
it	O
was	O
found	O
that	O
out	O
of	O
23	O
patients	O
whose	O
PBMCs	B-cell_type
had	O
experienced	O
a	O
drop	O
in	O
their	O
PHA	B-protein
-induced	O
proliferation	O
,	O
14	O
(	O
61	O
%	O
)	O
had	O
developed	O
metastatic	O
disease	O
within	O
the	O
subsequent	O
24	O
months	O
(	O
i.e.	O
36	O
months	O
after	O
surgery	O
)	O
.	O

In	O
contrast	O
,	O
out	O
of	O
59	O
patients	O
whose	O
PBMCs	B-cell_type
showed	O
an	O
increase	O
in	O
their	O
PHA	B-protein
-induced	O
proliferation	O
within	O
the	O
first	O
12	O
months	O
after	O
surgery	O
,	O
only	O
one	O
(	O
2	O
%	O
)	O
presented	O
with	O
disease	O
progression	O
.	O

We	O
thus	O
conclude	O
that	O
PHA	B-protein
-induced	O
proliferation	O
of	O
PBMCs	B-cell_type
derived	O
from	O
patients	O
with	O
breast	O
cancer	O
depends	O
upon	O
the	O
tumour	O
load	O
and	O
is	O
a	O
good	O
clinical	O
predictor	O
for	O
the	O
further	O
course	O
of	O
the	O
disease	O
.	O

Activation	O
of	O
transcription	O
by	O
binding	O
of	O
NF-E1	B-protein
(	O
YY1	B-protein
)	O
to	O
a	O
newly	O
identified	O
element	O
in	O
the	O
first	O
exon	O
of	O
the	O
human	B-DNA
DR	I-DNA
alpha	I-DNA
gene	I-DNA
.	O

A	O
previously	O
unrecognized	O
element	O
,	O
located	O
downstream	O
of	O
the	O
start	B-DNA
site	I-DNA
of	I-DNA
transcription	I-DNA
in	O
the	O
first	O
exon	B-DNA
of	O
the	O
DR	B-DNA
alpha	I-DNA
gene	I-DNA
,	O
has	O
been	O
defined	O
that	O
enhances	O
promoter	O
activity	O
up	O
to	O
eightfold	O
in	O
a	O
position-dependent	O
manner	O
.	O

Mutations	O
in	O
this	O
DNA-binding	B-DNA
site	I-DNA
abolished	O
binding	O
of	O
a	O
nuclear	B-protein
factor	I-protein
in	O
human	O
B	O
cell	O
nuclear	O
extract	O
and	O
decreased	O
the	O
activity	O
of	O
the	O
DR	B-DNA
alpha	I-DNA
promoter	I-DNA
to	O
a	O
basal	O
level	O
.	O

Significant	O
sequence	O
homology	O
of	O
this	O
element	B-DNA
was	O
found	O
in	O
the	O
DNA	O
of	O
the	O
DR	B-DNA
beta	I-DNA
,	I-DNA
DP	I-DNA
alpha	I-DNA
and	I-DNA
-beta	I-DNA
,	I-DNA
and	I-DNA
DQ	I-DNA
alpha	I-DNA
genes	I-DNA
,	O
always	O
located	O
downstream	O
of	O
the	O
transcriptional	B-DNA
start	I-DNA
site	I-DNA
.	O

The	O
nuclear	O
factor	O
binds	O
to	O
the	O
DR	B-DNA
alpha	I-DNA
and	I-DNA
DP	I-DNA
alpha	I-DNA
element	I-DNA
but	O
not	O
to	O
the	O
element	O
in	O
the	O
DQ	B-DNA
alpha	I-DNA
gene	I-DNA
.	O

It	O
was	O
identified	O
as	O
NF-E1	B-protein
(	O
YY1	B-protein
)	O
.	O

This	O
protein	O
,	O
previously	O
identified	O
by	O
its	O
binding	O
to	O
the	O
Ig	B-DNA
kappa	I-DNA
3	I-DNA
'	I-DNA
enhancer	I-DNA
and	O
the	O
Ig	B-DNA
heavy	I-DNA
chain	I-DNA
mu	I-DNA
E1	I-DNA
site	I-DNA
,	O
thus	O
also	O
appears	O
to	O
be	O
quite	O
important	O
in	O
the	O
regulation	O
of	O
MHC	B-DNA
class	I-DNA
II	I-DNA
gene	I-DNA
expression	O
.	O

Transcriptional	O
activity	O
of	O
core	B-protein
binding	I-protein
factor-alpha	I-protein
(	I-protein
AML1	I-protein
)	I-protein
and	I-protein
beta	I-protein
subunits	O
on	O
murine	B-DNA
leukemia	I-DNA
virus	I-DNA
enhancer	I-DNA
cores	I-DNA
.	O

Core	B-protein
binding	I-protein
factor	I-protein
(	O
CBF	B-protein
)	O
,	O
also	O
known	O
as	O
polyomavirus	B-protein
enhancer-binding	I-protein
protein	I-protein
2	I-protein
and	O
SL3	B-protein
enhancer	I-protein
factor	I-protein
1	I-protein
,	O
is	O
a	O
mammalian	B-protein
transcription	I-protein
factor	I-protein
that	O
binds	O
to	O
an	O
element	O
termed	O
the	O
core	O
within	O
the	O
enhancers	B-DNA
of	O
the	O
murine	O
leukemia	O
virus	O
family	O
of	O
retroviruses	O
.	O

The	O
core	B-DNA
elements	I-DNA
of	O
the	O
SL3	O
virus	O
are	O
important	O
genetic	O
determinants	O
of	O
the	O
ability	O
of	O
this	O
virus	O
to	O
induce	O
T-cell	O
lymphomas	O
and	O
the	O
transcriptional	O
activity	O
of	O
the	O
viral	B-DNA
long	I-DNA
terminal	I-DNA
repeat	I-DNA
in	O
T	B-cell_type
lymphocytes	I-cell_type
.	O

CBF	B-protein
consists	O
of	O
two	O
subunits	O
,	O
a	O
DNA	B-protein
binding	I-protein
subunit	I-protein
,	O
CBF	B-protein
alpha	I-protein
,	O
and	O
a	O
second	O
subunit	O
,	O
CBF	B-protein
beta	I-protein
,	O
that	O
stimulates	O
the	O
DNA	O
binding	O
activity	O
of	O
CBF	B-protein
alpha	I-protein
.	O

One	O
of	O
the	O
genes	O
that	O
encodes	O
a	O
CBF	B-protein
alpha	I-protein
subunit	I-protein
is	O
AML1	B-protein
,	O
also	O
called	O
Cbf	B-protein
alpha	I-protein
2	I-protein
.	O

This	O
locus	O
is	O
rearranged	O
by	O
chromosomal	O
translocations	O
in	O
human	O
myeloproliferative	O
disorders	O
and	O
leukemias	O
.	O

An	O
exogenously	O
expressed	O
Cbf	B-protein
alpha	I-protein
2-encoded	I-protein
subunit	I-protein
(	O
CBF	B-protein
alpha	I-protein
2-451	I-protein
)	O
stimulated	O
transcription	O
from	O
the	O
SL3	B-DNA
enhancer	I-DNA
in	O
P19	B-protein
and	O
HeLa	B-cell_line
cells	I-cell_line
.	O

Activity	O
was	O
mediated	O
through	O
the	O
core	B-DNA
elements	I-DNA
.	O

Three	O
different	O
isoforms	O
of	O
CBF	B-protein
beta	I-protein
were	O
also	O
tested	O
for	O
transcriptional	O
activity	O
on	O
the	O
SL3	B-DNA
enhancer	I-DNA
.	O

The	O
longest	O
form	O
,	O
CBF	B-protein
beta-187	I-protein
,	O
increased	O
the	O
transcriptional	O
stimulation	O
by	O
CBF	B-protein
alpha	I-protein
2-451	I-protein
twofold	O
in	O
HeLa	B-cell_line
cells	I-cell_line
,	O
although	O
it	O
had	O
no	O
effect	O
in	O
P19	B-cell_line
cells	I-cell_line
.	O

Transcriptional	O
activation	O
by	O
CBF	B-protein
beta	I-protein
required	O
binding	O
to	O
the	O
CBF	B-protein
alpha	I-protein
subunit	I-protein
,	O
as	O
a	O
form	O
of	O
CBF	B-protein
beta	I-protein
that	O
lacked	O
binding	O
ability	O
,	O
CBF	B-protein
beta-148	I-protein
,	O
failed	O
to	O
increase	O
activity	O
.	O

These	O
results	O
indicated	O
that	O
at	O
least	O
in	O
certain	O
cell	O
types	O
,	O
the	O
maximum	O
activity	O
of	O
CBF	B-protein
required	O
both	O
subunits	O
.	O

They	O
also	O
provided	O
support	O
for	O
the	O
hypothesis	O
that	O
CBF	B-protein
is	O
a	O
factor	O
in	O
T	B-cell_type
lymphocytes	I-cell_type
that	O
is	O
responsible	O
for	O
recognition	O
of	O
the	O
SL3	B-DNA
cores	I-DNA
.	O

We	O
also	O
examined	O
whether	O
CBF	B-protein
could	O
distinguish	O
a	O
1-bp	O
difference	O
between	O
the	O
enhancer	O
core	O
of	O
SL3	O
and	O
the	O
core	O
of	O
the	O
nonleukemogenic	O
virus	O
,	O
Akv	O
.	O

This	O
difference	O
strongly	O
affects	O
transcription	O
in	O
T	O
cells	O
and	O
leukemogenicity	O
of	O
SL3	B-DNA
.	O

However	O
,	O
no	O
combination	O
of	O
CBF	B-protein
alpha	I-protein
and	O
CBF	B-protein
beta	I-protein
subunits	O
that	O
we	O
tested	O
was	O
able	O
to	O
distinguish	O
the	O
1-bp	O
difference	O
in	O
transcription	O
assays	O
.	O

Thus	O
,	O
a	O
complete	O
understanding	O
of	O
how	O
T	B-cell_type
cells	I-cell_type
recognize	O
the	O
SL3	B-DNA
core	I-DNA
remains	O
to	O
be	O
elucidated	O
.	O

Interleukin	B-protein
(	I-protein
IL	I-protein
)	I-protein
-10	I-protein
inhibits	O
nuclear	B-protein
factor	I-protein
kappa	I-protein
B	I-protein
(	O
NF	B-protein
kappa	I-protein
B	I-protein
)	O
activation	O
in	O
human	B-cell_type
monocytes	I-cell_type
.	O

IL-10	B-protein
and	O
IL-4	B-protein
suppress	O
cytokine	B-protein
synthesis	O
by	O
different	O
mechanisms	O
.	O

Our	O
previous	O
studies	O
in	O
human	B-cell_type
monocytes	I-cell_type
have	O
demonstrated	O
that	O
interleukin	B-protein
(	I-protein
IL	I-protein
)	I-protein
-10	I-protein
inhibits	O
lipopolysaccharide	O
(	O
LPS	O
)	O
-stimulated	O
production	O
of	O
inflammatory	B-protein
cytokines	I-protein
,	O
IL-1	B-protein
beta	I-protein
,	O
IL-6	B-protein
,	O
IL-8	B-protein
,	O
and	O
tumor	B-protein
necrosis	I-protein
factor	I-protein
(	I-protein
TNF	I-protein
)	I-protein
-alpha	I-protein
by	O
blocking	O
gene	O
transcription	O
.	O

Using	O
electrophoretic	O
mobility	O
shift	O
assays	O
(	O
EMSA	O
)	O
,	O
we	O
now	O
show	O
that	O
,	O
in	O
monocytes	O
stimulated	O
with	O
LPS	O
or	O
TNF	B-protein
alpha	I-protein
,	O
IL-10	B-protein
inhibits	O
nuclear	O
stimulation	O
of	O
nuclear	B-protein
factor	I-protein
kappa	I-protein
B	I-protein
(	O
NF	B-protein
kappa	I-protein
B	I-protein
)	O
,	O
a	O
transcription	B-protein
factor	I-protein
involved	O
in	O
the	O
expression	O
of	O
inflammatory	B-DNA
cytokine	I-DNA
genes	I-DNA
.	O
Several	O
other	O
transcription	B-protein
factors	I-protein
including	O
NF-	O
IL-6	B-protein
,	O
AP-1	B-protein
,	O
AP-2	B-protein
,	O
GR	B-protein
,	O
CREB	B-protein
,	O
Oct-1	B-protein
,	O
and	O
Sp-1	B-protein
are	O
not	O
affected	O
by	O
IL-10	B-protein
.	O

This	O
selective	O
inhibition	O
by	O
IL-10	B-protein
of	O
NF	B-protein
kappa	I-protein
B	I-protein
activation	O
occurs	O
rapidly	O
and	O
in	O
a	O
dose-dependent	O
manner	O
and	O
correlates	O
well	O
with	O
IL-10	B-protein
's	O
cytokine	B-protein
synthesis	O
inhibitory	O
activity	O
in	O
terms	O
of	O
both	O
kinetics	O
and	O
dose	O
responsiveness	O
.	O

Furthermore	O
,	O
compounds	O
such	O
as	O
tosylphenylalanyl	O
chloromethyl	O
ketone	O
and	O
pyrrolidinedithiocarbamate	O
that	O
are	O
known	O
to	O
selectively	O
inhibit	O
NF	B-protein
kappa	I-protein
B	I-protein
activation	O
block	O
cytokine	O
gene	O
transcription	O
in	O
LPS-stimulated	B-cell_line
monocytes	I-cell_line
.	O

Taken	O
together	O
,	O
these	O
results	O
suggest	O
that	O
inhibition	O
of	O
NF	B-protein
kappa	I-protein
B	I-protein
activation	O
may	O
be	O
an	O
important	O
mechanism	O
for	O
IL-10	B-protein
suppression	O
of	O
cytokine	O
gene	O
transcription	O
in	O
human	B-cell_type
monocytes	I-cell_type
.	O

IL-4	B-protein
,	O
another	O
cytokine	B-protein
that	O
inhibits	O
cytokine	B-RNA
mRNA	I-RNA
accumulation	O
in	O
monocytes	B-cell_type
,	O
shows	O
little	O
inhibitory	O
effect	O
on	O
LPS-induced	O
NF	B-protein
kappa	I-protein
B	I-protein
activation	O
.	O

Further	O
examination	O
reveals	O
that	O
,	O
unlike	O
IL-10	B-protein
,	O
IL-4	B-protein
enhances	O
mRNA	B-RNA
degradation	O
and	O
does	O
not	O
suppress	O
cytokine	O
gene	O
transcription	O
.	O

These	O
data	O
indicate	O
that	O
IL-10	B-protein
and	O
IL-4	B-protein
inhibit	O
cytokine	B-protein
production	O
by	O
different	O
mechanisms	O
.	O

LMP-1	B-protein
activates	O
NF-kappa	B-protein
B	I-protein
by	O
targeting	O
the	O
inhibitory	B-protein
molecule	I-protein
I	I-protein
kappa	I-protein
B	I-protein
alpha	I-protein
.	O

LMP-1	B-protein
,	O
an	O
Epstein-Barr	B-protein
virus	I-protein
membrane	I-protein
protein	I-protein
expressed	O
during	O
latent	O
infection	O
,	O
has	O
oncogenic	O
properties	O
,	O
as	O
judged	O
from	O
its	O
ability	O
to	O
transform	O
B	O
lymphocytes	B-cell_type
and	O
rodent	B-cell_type
fibroblasts	I-cell_type
.	O

LMP-1	B-protein
induces	O
the	O
expression	O
of	O
bcl2	B-DNA
,	O
an	O
oncogene	B-DNA
which	O
protects	O
cells	O
from	O
apoptosis	O
,	O
as	O
well	O
as	O
of	O
genes	O
encoding	O
other	O
proteins	O
involved	O
in	O
cell	O
regulation	O
and	O
growth	O
control	O
.	O

The	O
mechanisms	O
by	O
which	O
LMP-1	B-protein
upregulates	O
these	O
proteins	O
is	O
unknown	O
,	O
but	O
it	O
is	O
plausible	O
that	O
LMP-1	B-protein
modifies	O
signal	O
transduction	O
pathways	O
that	O
result	O
in	O
the	O
activation	O
of	O
one	O
or	O
more	O
transcription	B-protein
factors	I-protein
that	O
ultimately	O
regulate	O
transcription	O
of	O
oncogenic	B-DNA
genes	I-DNA
.	O

NF-kappa	B-protein
B	I-protein
,	O
a	O
transcription	B-protein
factor	I-protein
controlling	O
the	O
expression	O
of	O
genes	B-DNA
involved	O
in	O
cell	O
activation	O
and	O
growth	O
control	O
,	O
has	O
been	O
shown	O
to	O
be	O
activated	O
by	O
LMP-1	B-protein
.	O

The	O
mechanism	O
(	O
s	O
)	O
regulating	O
this	O
activation	O
remains	O
unknown	O
.	O

Our	O
data	O
indicate	O
that	O
increased	O
NF-kappa	B-protein
B	I-protein
DNA	O
binding	O
and	O
functional	O
activity	O
are	O
present	O
in	O
B-lymphoid	B-cell_type
cells	I-cell_type
stably	O
or	O
transiently	O
expressing	O
LMP-1	B-protein
.	O

I	B-protein
kappa	I-protein
B	I-protein
alpha	I-protein
is	O
selectively	O
modified	O
in	O
LMP-1-expressing	B-cell_line
B	I-cell_line
cells	I-cell_line
.	O

A	O
phosphorylated	O
form	O
of	O
I	B-protein
kappa	I-protein
B	I-protein
alpha	I-protein
and	O
increased	O
protein	O
turnover-degradation	O
correlate	O
with	O
increased	O
NF-kappa	B-protein
B	I-protein
nuclear	O
translocation	O
.	O

This	O
results	O
in	O
increased	O
transcription	O
of	O
NF-kappa	B-DNA
B-dependent-genes	I-DNA
,	O
including	O
those	O
encoding	O
p105	B-protein
and	O
I	B-protein
kappa	I-protein
B	I-protein
alpha	I-protein
(	O
MAD3	B-DNA
)	O
.	O

These	O
results	O
indicate	O
that	O
LMP-1	B-protein
activates	O
NF-kappa	B-protein
B	I-protein
in	O
B-cell	B-cell_line
lines	I-cell_line
by	O
targeting	O
I	B-protein
kappa	I-protein
B	I-protein
alpha	I-protein
.	O

Identification	O
of	O
the	O
pathways	O
activated	O
by	O
LMP-1	B-protein
to	O
result	O
in	O
posttranslational	O
modifications	O
of	O
I	B-protein
kappa	I-protein
B	I-protein
alpha	I-protein
will	O
aid	O
in	O
determining	O
the	O
role	O
of	O
this	O
virus-host	O
cell	O
protein	O
interaction	O
in	O
Epstein-Barr	O
virus-mediated	O
oncogenesis	O
.	O

Identification	O
of	O
human	B-DNA
TR2	I-DNA
orphan	I-DNA
receptor	I-DNA
response	I-DNA
element	I-DNA
in	O
the	O
transcriptional	B-DNA
initiation	I-DNA
site	I-DNA
of	O
the	O
simian	B-DNA
virus	I-DNA
40	I-DNA
major	I-DNA
late	I-DNA
promoter	I-DNA
[	O
published	O
erratum	O
appears	O
in	O
J	O
Biol	O
Chem	O
1995	O
Nov	O
3	O
;	O
270	O
(	O
44	O
)	O
:	O
26721	O
]	O

A	O
DNA	B-DNA
response	I-DNA
element	I-DNA
(	O
TR2RE-SV40	B-DNA
)	O
for	O
the	O
TR2	B-protein
orphan	I-protein
receptor	I-protein
,	O
a	O
member	O
of	O
the	O
steroid-thyroid	B-protein
hormone	I-protein
receptor	I-protein
superfamily	I-protein
,	O
has	O
been	O
identified	O
in	O
the	O
simian	B-DNA
virus	I-DNA
40	I-DNA
(	I-DNA
SV40	I-DNA
)	I-DNA
+55	I-DNA
region	I-DNA
(	O
nucleotide	B-DNA
numbers	I-DNA
368-389	I-DNA
,	O
5'-GTTAAGGTTCGTAGGTCATGGA-3	O
'	O
)	O
.	O

Electrophoretic	O
mobility	O
shift	O
assay	O
,	O
using	O
in	O
vitro	O
translated	O
TR2	B-protein
orphan	I-protein
receptor	I-protein
with	O
a	O
molecular	O
mass	O
of	O
67	B-protein
kilodaltons	I-protein
,	O
showed	O
a	O
specific	O
binding	O
with	O
high	O
affinity	O
(	O
dissociation	O
constant	O
=	O
9	O
nM	O
)	O
for	O
this	O
DNA	O
sequence	O
.	O

DNA-swap	O
experiments	O
using	O
chloramphenicol	B-protein
acetyl-transferase	I-protein
assay	O
demonstrated	O
that	O
androgen	O
can	O
suppress	O
the	O
transcriptional	O
activities	O
of	O
SV40	B-DNA
early	I-DNA
promoter	I-DNA
via	O
the	O
interaction	O
between	O
this	O
TR2RE-SV40	B-DNA
and	O
the	O
chimeric	B-protein
receptor	I-protein
AR/TR2/AR	I-protein
with	O
the	O
DNA-binding	B-protein
domain	I-protein
of	O
the	O
TR2	B-protein
orphan	I-protein
receptor	I-protein
flanked	O
by	O
the	O
N-terminal	B-protein
and	I-protein
androgen-binding	I-protein
domains	I-protein
of	O
the	O
androgen	B-protein
receptor	I-protein
.	O

In	O
addition	O
,	O
this	O
TR2RE-SV40	B-DNA
can	O
function	O
as	O
a	O
repressor	O
to	O
suppress	O
the	O
transcriptional	O
activities	O
of	O
both	O
SV40	B-DNA
early	I-DNA
and	I-DNA
late	I-DNA
promoters	I-DNA
.	O

Together	O
,	O
these	O
data	O
suggest	O
the	O
TR2RE-SV40	B-DNA
may	O
represent	O
the	O
first	O
identified	O
natural	O
DNA	B-DNA
response	I-DNA
element	I-DNA
for	O
the	O
TR2	B-protein
orphan	I-protein
receptor	I-protein
that	O
may	O
function	O
as	O
a	O
repressor	O
for	O
the	O
SV40	O
gene	O
expression	O
.	O

Detection	O
of	O
the	O
chromosome	B-RNA
16	I-RNA
CBF	I-RNA
beta-MYH11	I-RNA
fusion	I-RNA
transcript	I-RNA
in	O
myelomonocytic	O
leukemias	O
.	O

Karyotypic	O
detection	O
of	O
chromosomal	O
16	O
abnormalities	O
classically	O
associated	O
with	O
AML	O
M4Eo	O
can	O
be	O
difficult	O
.	O

Characterization	O
of	O
the	O
two	O
genes	O
involved	O
in	O
the	O
inv	O
(	O
16	O
)	O
(	O
p13q22	O
)	O
,	O
CBF	B-DNA
beta	I-DNA
and	O
MYH11	B-DNA
,	O
has	O
allowed	O
the	O
detection	O
of	O
fusion	B-RNA
transcripts	I-RNA
by	O
reverse-transcriptase	O
polymerase	O
chain	O
reaction	O
(	O
RT-PCR	O
)	O
.	O

We	O
have	O
analyzed	O
CBF	B-RNA
beta-MYH11	I-RNA
fusion	I-RNA
transcripts	I-RNA
by	O
RT-PCR	O
in	O
myelomonocytic	O
leukemias	O
,	O
with	O
or	O
without	O
eosinophilia	O
,	O
to	O
determine	O
whether	O
their	O
presence	O
correlates	O
with	O
morphology	O
.	O

Fifty-three	O
cases	O
(	O
11	O
AML	O
M4Eo	O
;	O
1	O
AML	O
M4	O
with	O
atypical	B-cell_type
abnormal	I-cell_type
eosinophils	I-cell_type
(	O
AML	O
M4	O
``	O
Eo	O
''	O
)	O
;	O
29	O
AML	O
M4	O
;	O
8	O
AML	O
M5	O
;	O
3	O
CMML	O
;	O
and	O
1	O
AML	O
M2	O
with	O
eosinophilia	O
)	O
were	O
analyzed	O
.	O

All	O
11	O
typical	O
AML	O
M4Eo	O
were	O
CBF	B-DNA
beta	I-DNA
-MYH11	B-DNA
positive	O
.	O

The	O
single	O
case	O
of	O
AML	O
M4	O
with	O
distinctive	O
eosinophil	O
abnormalities	O
was	O
negative	O
by	O
karyotype	O
,	O
RT-PCR	O
and	O
fluorescent	O
in	O
situ	O
hybridization	O
(	O
FISH	O
)	O
.	O

Three	O
of	O
29	O
(	O
10	O
%	O
)	O
AML	O
M4	O
without	O
abnormal	B-cell_type
eosinophils	I-cell_type
were	O
CBF	B-DNA
beta	I-DNA
-MYH11	B-DNA
positive	O
,	O
1	O
of	O
which	O
did	O
not	O
show	O
any	O
apparent	O
chromosome	B-DNA
16	I-DNA
abnormalities	O
by	O
classical	O
metaphase	O
analysis	O
(	O
2	O
not	O
tested	O
)	O
.	O

Both	O
cases	O
tested	O
also	O
showed	O
MYH11	B-DNA
genomic	O
rearrangement	O
.	O

None	O
of	O
the	O
other	O
leukemias	O
were	O
RT-PCR	O
positive	O
.	O

Follow-up	O
of	O
three	O
patient	O
showed	O
residual	O
positivity	O
in	O
apparent	O
complete	O
remission	O
.	O

These	O
data	O
show	O
that	O
CBF	B-RNA
beta-MYH11	I-RNA
fusion	I-RNA
transcripts	I-RNA
occur	O
not	O
only	O
in	O
the	O
vast	O
majority	O
of	O
typical	O
AML	O
M4Eo	O
,	O
but	O
also	O
in	O
approximately	O
10	O
%	O
of	O
AML	O
M4	O
without	O
eosinophilic	O
abnormalities	O
,	O
a	O
much	O
higher	O
incidence	O
than	O
the	O
sporadic	O
reports	O
of	O
chromosome	B-DNA
16	I-DNA
abnormalities	O
in	O
AML	O
M4	O
would	O
suggest	O
.	O

Taken	O
together	O
with	O
the	O
detection	O
of	O
CBF	B-DNA
beta	I-DNA
-	O
MYH11	B-RNA
transcripts	I-RNA
in	O
the	O
absence	O
of	O
apparent	O
chromosome	B-DNA
16	I-DNA
abnormalities	O
by	O
classical	O
banding	O
techniques	O
,	O
these	O
data	O
show	O
that	O
additional	O
screening	O
by	O
either	O
RT-PCR	O
or	O
FISH	O
should	O
be	O
performed	O
in	O
all	O
AML	O
M4	O
,	O
regardless	O
of	O
morphologic	O
features	O
,	O
to	O
allow	O
accurate	O
evaluation	O
of	O
the	O
prognostic	O
importance	O
of	O
this	O
fusion	B-RNA
transcript	I-RNA
.	O

HIV-1	B-protein
Tat	I-protein
potentiates	O
TNF	B-protein
-induced	O
NF-kappa	B-protein
B	I-protein
activation	O
and	O
cytotoxicity	O
by	O
altering	O
the	O
cellular	O
redox	O
state	O
.	O

This	O
study	O
demonstrates	O
that	O
human	B-protein
immunodeficiency	I-protein
virus	I-protein
type	I-protein
1	I-protein
(	I-protein
HIV-1	I-protein
)	I-protein
Tat	I-protein
protein	I-protein
amplifies	O
the	O
activity	O
of	O
tumor	B-protein
necrosis	I-protein
factor	I-protein
(	O
TNF	B-protein
)	O
,	O
a	O
cytokine	O
that	O
stimulates	O
HIV-1	O
replication	O
through	O
activation	O
of	O
NF-kappa	B-protein
B	I-protein
.	O

In	O
HeLa	B-cell_line
cells	I-cell_line
stably	O
transfected	O
with	O
the	O
HIV-1	B-DNA
tat	I-DNA
gene	I-DNA
(	O
HeLa-tat	B-cell_line
cells	I-cell_line
)	O
,	O
expression	O
of	O
the	O
Tat	B-protein
protein	I-protein
enhanced	O
both	O
TNF	B-protein
-induced	O
activation	O
of	O
NF-kappa	B-protein
B	I-protein
and	O
TNF	B-protein
-mediated	O
cytotoxicity	O
.	O

A	O
similar	O
potentiation	O
of	O
TNF	B-protein
effects	O
was	O
observed	O
in	O
Jurkat	O
T	O
cells	O
and	O
HeLa	B-cell_line
cells	I-cell_line
treated	O
with	O
soluble	O
Tat	B-protein
protein	I-protein
.	O

TNF	B-protein
-mediated	O
activation	O
of	O
NF-kappa	B-protein
B	I-protein
and	O
cytotoxicity	O
involves	O
the	O
intracellular	O
formation	O
of	O
reactive	O
oxygen	O
intermediates	O
.	O

Therefore	O
,	O
Tat	B-protein
-mediated	O
effects	O
on	O
the	O
cellular	O
redox	O
state	O
were	O
analyzed	O
.	O

In	O
both	O
T	B-cell_type
cells	I-cell_type
and	O
HeLa	B-cell_line
cells	I-cell_line
HIV-1	B-protein
Tat	I-protein
suppressed	O
the	O
expression	O
of	O
Mn-dependent	B-protein
superoxide	I-protein
dismutase	I-protein
(	O
Mn-SOD	B-protein
)	O
,	O
a	O
mitochondrial	B-protein
enzyme	I-protein
that	O
is	O
part	O
of	O
the	O
cellular	O
defense	O
system	O
against	O
oxidative	O
stress	O
.	O

Thus	O
,	O
Mn-SOD	B-protein
RNA	O
protein	O
levels	O
and	O
activity	O
were	O
markedly	O
reduced	O
in	O
the	O
presence	O
of	O
Tat	B-protein
.	O

Decreased	O
Mn-SOD	B-protein
expression	O
was	O
associated	O
with	O
decreased	O
levels	O
of	O
glutathione	O
and	O
a	O
lower	O
ratio	O
of	O
reduced	O
:	O
oxidized	O
glutathione	O
.	O

A	O
truncated	O
Tat	B-protein
protein	I-protein
(	O
Tat1-72	B-protein
)	O
,	O
known	O
to	O
transactivate	O
the	O
HIV-1	B-DNA
long	I-DNA
terminal	I-DNA
repeat	I-DNA
(	O
LTR	B-DNA
)	O
,	O
no	O
longer	O
affected	O
Mn-SOD	B-protein
expression	O
,	O
the	O
cellular	O
redox	O
state	O
or	O
TNF	B-protein
-mediated	O
cytotoxicity	O
.	O

Thus	O
,	O
our	O
experiments	O
demonstrate	O
that	O
the	O
C-terminal	B-protein
region	I-protein
of	O
HIV-1	B-protein
Tat	I-protein
is	O
required	O
to	O
suppress	O
Mn-SOD	B-protein
expression	O
and	O
to	O
induce	O
pro-oxidative	O
conditions	O
reflected	O
by	O
a	O
drop	O
in	O
reduced	O
glutathione	O
(	O
GSH	B-protein
)	O
and	O
the	O
GSH	O
:	O
oxidized	O
GSH	O
(	O
GSSG	O
)	O
ratio	O
.	O

(	O
ABSTRACT	O
TRUNCATED	O
AT	O
250	O
WORDS	O
)	O

The	O
use	O
of	O
glucocorticoids	O
in	O
acute	O
lymphoblastic	O
leukemia	O
of	O
childhood	O
.	O

Molecular	O
,	O
cellular	O
,	O
and	O
clinical	O
considerations	O
.	O

Glucocorticoids	O
have	O
been	O
included	O
in	O
almost	O
all	O
treatment	O
regimens	O
for	O
childhood	O
acute	O
lymphoblastic	O
leukemia	O
for	O
decades	O
.	O

However	O
,	O
optimal	O
agents	O
,	O
doses	O
,	O
and/or	O
schedules	O
have	O
yet	O
to	O
be	O
defined	O
despite	O
extensive	O
clinical	O
application	O
.	O

New	O
data	O
on	O
the	O
pharmacokinetics	O
,	O
pharmacodynamics	O
,	O
and	O
molecular	O
mechanisms	O
of	O
action	O
of	O
glucocorticoids	O
have	O
suggested	O
alternative	O
approaches	O
in	O
ALL	O
.	O

These	O
suggest	O
that	O
prolonged	O
,	O
i.e.	O
28	O
day	O
,	O
glucocorticoid	O
therapy	O
may	O
be	O
unnecessary	O
as	O
exposure	O
to	O
glucocorticoid	O
induces	O
down-regulation	O
of	O
glucocorticoid	B-protein
receptors	I-protein
.	O

Dexamethasone	O
may	O
be	O
superior	O
to	O
prednisone	O
in	O
conventional	O
equi-effective	O
doses	O
.	O

Blast	O
sensitivity	O
to	O
glucocorticoids	O
correlates	O
closely	O
with	O
sensitivity	O
to	O
other	O
,	O
putatively	O
non-cross-resisting	O
agents	O
and	O
with	O
outcome	O
after	O
multi-agent	O
therapy	O
,	O
suggesting	O
overlapping	O
mechanisms	O
of	O
action	O
,	O
and	O
focusing	O
attention	O
on	O
the	O
determinants	O
of	O
the	O
threshold	O
for	O
apoptosis	O
.	O

Increasing	O
success	O
in	O
the	O
treatment	O
of	O
childhood	O
acute	O
lymphoblastic	O
leukemia	O
has	O
led	O
to	O
increasing	O
awareness	O
of	O
avascular	O
necrosis	O
of	O
bone	O
as	O
a	O
potentially	O
disabling	O
sequela	O
of	O
glucocorticoid	O
therapy	O
,	O
especially	O
in	O
adolescent	O
and	O
young	O
adult	O
patients	O
.	O

Epstein-Barr	B-protein
virus	I-protein
nuclear	I-protein
protein	I-protein
2	I-protein
transactivation	O
of	O
the	O
latent	B-DNA
membrane	I-DNA
protein	I-DNA
1	I-DNA
promoter	I-DNA
is	O
mediated	O
by	O
J	B-protein
kappa	I-protein
and	O
PU.1	B-protein
.	O

Expression	O
of	O
the	O
Epstein-Barr	B-DNA
virus	I-DNA
(	I-DNA
EBV	I-DNA
)	I-DNA
latent	I-DNA
membrane	I-DNA
protein	I-DNA
1	I-DNA
(	I-DNA
LMP-1	I-DNA
)	I-DNA
oncogene	I-DNA
is	O
regulated	O
by	O
the	O
EBV	B-protein
nuclear	I-protein
protein	I-protein
2	I-protein
(	I-protein
EBNA-2	I-protein
)	I-protein
transactivator	I-protein
.	O

EBNA-2	B-protein
is	O
known	O
to	O
interact	O
with	O
the	O
cellular	B-protein
DNA-binding	I-protein
protein	I-protein
J	B-protein
kappa	I-protein
and	O
is	O
recruited	O
to	O
promoters	B-DNA
containing	O
the	O
GTGGGAA	O
J	B-DNA
kappa	I-DNA
recognition	I-DNA
sequence	I-DNA
.	O

The	O
minimal	B-DNA
EBNA-2-responsive	I-DNA
LMP-1	I-DNA
promoter	I-DNA
includes	O
one	O
J	B-DNA
kappa-binding	I-DNA
site	I-DNA
,	O
and	O
we	O
now	O
show	O
that	O
mutation	O
of	O
that	O
site	O
,	O
such	O
that	O
J	B-protein
kappa	I-protein
can	O
not	O
bind	O
,	O
reduces	O
EBNA-2	B-protein
responsiveness	O
by	O
60	O
%	O
.	O

To	O
identify	O
other	O
factors	O
which	O
interact	O
with	O
the	O
LMP-1	B-DNA
EBNA-2	I-DNA
response	I-DNA
element	I-DNA
(	O
E2RE	B-DNA
)	O
,	O
a	O
-236/-145	B-DNA
minimal	I-DNA
E2RE	I-DNA
was	O
used	O
as	O
a	O
probe	O
in	O
an	O
electrophoretic	O
mobility	O
shift	O
assay	O
.	O

The	O
previously	O
characterized	O
factors	O
J	B-protein
kappa	I-protein
,	O
PU.1	B-protein
,	O
and	O
AML1	B-protein
bind	O
to	O
the	O
LMP-1	B-DNA
E2RE	I-DNA
,	O
along	O
with	O
six	O
other	O
unidentified	O
factors	O
(	O
LBF2	B-protein
to	O
LBF7	B-protein
)	O
.	O

Binding	O
sites	O
were	O
mapped	O
for	O
each	O
factor	O
.	O

LBF4	B-protein
is	O
B-	O
and	O
T-cell	O
specific	O
and	O
recognizes	O
the	O
PU.1	B-DNA
GGAA	I-DNA
core	I-DNA
sequence	I-DNA
as	O
shown	O
by	O
methylation	O
interference	O
.	O

LBF4	B-protein
has	O
a	O
molecular	O
mass	O
of	O
105	O
kDa	O
and	O
is	O
probably	O
unrelated	O
to	O
PU.1	B-protein
.	O

LBF2	B-protein
was	O
found	O
only	O
in	O
epithelial	B-cell_line
cell	I-cell_line
lines	I-cell_line
,	O
whereas	O
LBF3	B-protein
,	O
LBF5	B-protein
,	O
LBF6	B-protein
,	O
and	O
LBF7	B-protein
were	O
not	O
cell	O
type	O
specific	O
.	O

Mutations	O
of	O
the	O
AML1-	B-DNA
or	I-DNA
LBF4-binding	I-DNA
sites	I-DNA
had	O
no	O
effect	O
on	O
EBNA-2	B-protein
transactivation	O
,	O
whereas	O
mutation	O
of	O
the	O
PU.1-binding	B-DNA
site	I-DNA
completely	O
eliminated	O
EBNA-2	B-protein
responses	O
.	O

A	O
gst-EBNA-2	B-protein
fusion	I-protein
protein	I-protein
specifically	O
depleted	O
PU.1	B-protein
from	O
nuclear	O
extracts	O
and	O
bound	O
in	O
vitro	O
translated	O
PU.1	B-protein
,	O
providing	O
biochemical	O
evidence	O
for	O
a	O
direct	O
EBNA-2	B-protein
-PU.1	B-protein
interaction	O
.	O

Thus	O
,	O
EBNA-2	B-protein
transactivation	O
of	O
the	O
LMP-1	B-DNA
promoter	I-DNA
is	O
dependent	O
on	O
interaction	O
with	O
at	O
least	O
two	O
distinct	O
sequence-specific	O
DNA-binding	B-protein
proteins	I-protein
,	O
J	B-protein
kappa	I-protein
and	O
PU.1	B-protein
.	O

LBF3	B-protein
,	O
LBF5	B-protein
,	O
LBF6	B-protein
,	O
or	O
LBF7	B-protein
may	O
also	O
be	O
involved	O
,	O
since	O
their	O
binding	O
sites	O
also	O
contribute	O
to	O
EBNA-2	B-protein
responsiveness	O
.	O

Lymphocyte	B-protein
glucocorticoid	I-protein
receptor	I-protein
:	O
predictor	O
of	O
sertraline	O
response	O
in	O
adolescent	O
major	O
depressive	O
disorder	O
(	O
MDD	O
)	O
.	O

Major	O
depressive	O
disorder	O
(	O
MDD	O
)	O
in	O
adolescents	O
demonstrates	O
resistance	O
to	O
tricyclic	O
antidepressants	O
and	O
absence	O
of	O
hypercortisolemia	O
.	O

The	O
efficacy	O
of	O
serotonin	O
reuptake	O
inhibitors	O
(	O
SRIs	O
)	O
is	O
uncertain	O
,	O
and	O
response	O
predictors	O
are	O
unavailable	O
.	O

Abnormal	O
fast	O
feedback	O
and	O
negative	O
feedback	O
of	O
the	O
hypothalamic-pituitary-adrenal	O
axis	O
implicates	O
a	O
dampened	O
limbic-hippocampal	B-protein
glucocorticoid	I-protein
type	I-protein
II	I-protein
receptor	I-protein
(	O
GCII	B-protein
)	O
.	O

We	O
hypothesized	O
that	O
lymphocyte	B-protein
GCII	I-protein
is	O
altered	O
in	O
adolescent	O
MDD	O
and	O
could	O
serve	O
as	O
a	O
marker	O
for	O
response	O
to	O
SRIs	O
.	O

In	O
an	O
open-label	O
study	O
,	O
adolescents	O
(	O
n	O
=	O
20	O
)	O
meeting	O
DSM-III-R	O
criteria	O
for	O
MDD	O
showed	O
baseline	O
lymphocyte	B-protein
GCII	I-protein
sites	I-protein
per	O
cell	O
(	O
sites/cell	O
)	O
values	O
of	O
793	O
+/-	O
106	O
versus	O
2	O
,	O
563	O
+/-	O
499	O
(	O
+/-	O
SEM	O
)	O
for	O
matched	O
controls	O
(	O
n	O
=	O
18	O
)	O
(	O
t	O
=	O
3.5	O
;	O
df	O
=	O
36	O
;	O
p	O
<	O
.001	O
)	O
.	O

GCII	B-protein
was	O
bimodally	O
distributed	O
,	O
with	O
SRI	O
responders	O
differing	O
from	O
nonresponders	O
(	O
t	O
=	O
3.9	O
;	O
df	O
=	O
14	O
;	O
p	O
<	O
.001	O
)	O
.	O

GCII	B-protein
accurately	O
classified	O
90	O
percent	O
of	O
sertraline	O
responders	O
and	O
80	O
percent	O
of	O
nonresponders	O
.	O

Only	O
SRI	O
responders	O
showed	O
GCII	B-protein
sites/cell	O
upregulated	O
after	O
6	O
weeks	O
of	O
treatment	O
(	O
t	O
=	O
2.1	O
,	O
df	O
=	O
10	O
;	O
p	O
<	O
.05	O
)	O
.	O

The	O
role	O
of	O
NFATp	B-protein
in	O
cyclosporin	B-DNA
A-sensitive	I-DNA
tumor	I-DNA
necrosis	I-DNA
factor-alpha	I-DNA
gene	I-DNA
transcription	O
.	O

The	O
tumor	B-DNA
necrosis	I-DNA
factor-alpha	I-DNA
(	I-DNA
TNF	I-DNA
alpha	I-DNA
)	I-DNA
gene	I-DNA
is	O
an	O
immediate	O
early	O
gene	O
in	O
activated	O
T	B-cell_type
cells	I-cell_type
,	O
in	O
that	O
it	O
is	O
rapidly	O
induced	O
without	O
a	O
requirement	O
for	O
protein	O
synthesis	O
.	O

Maximal	O
induction	O
of	O
TNF	B-RNA
alpha	I-RNA
mRNA	I-RNA
can	O
be	O
induced	O
by	O
treatment	O
of	O
T	B-cell_type
cells	I-cell_type
with	O
calcium	O
ionophores	O
alone	O
,	O
via	O
a	O
calcineurin	B-protein
-dependent	O
process	O
that	O
is	O
blocked	O
by	O
cyclosporin	O
A	O
.	O

We	O
have	O
previously	O
identified	O
a	O
promoter	B-DNA
element	I-DNA
,	O
kappa	B-DNA
3	I-DNA
,	O
that	O
is	O
required	O
for	O
calcium-stimulated	O
,	O
cyclosporin	O
A-sensitive	O
induction	O
of	O
the	O
TNF	B-DNA
alpha	I-DNA
gene	I-DNA
in	O
activated	O
T	B-cell_type
cells	I-cell_type
.	O

Here	O
,	O
we	O
demonstrate	O
that	O
the	O
kappa	B-protein
3	I-protein
binding	I-protein
factor	I-protein
contains	O
NFATp	B-protein
,	O
a	O
cyclosporin-sensitive	B-protein
DNA-binding	I-protein
protein	I-protein
required	O
for	O
interleukin-2	B-DNA
gene	I-DNA
transcription	O
.	O

NFATp	B-protein
binds	O
to	O
two	O
sites	O
within	O
the	O
kappa	B-DNA
3	I-DNA
element	I-DNA
,	O
and	O
occupancy	O
of	O
both	O
sites	O
is	O
required	O
for	O
TNF	B-protein
alpha	O
gene	O
induction	O
.	O

Thus	O
,	O
although	O
the	O
kappa	B-DNA
3	I-DNA
element	I-DNA
has	O
little	O
sequence	O
similarity	O
to	O
other	O
NFATp-binding	B-DNA
sites	I-DNA
,	O
it	O
appears	O
to	O
function	O
as	O
a	O
cyclosporin-sensitive	B-DNA
promoter	I-DNA
element	I-DNA
in	O
T	B-cell_type
cells	I-cell_type
by	O
virtue	O
of	O
its	O
ability	O
to	O
bind	O
NFATp	B-protein
.	O

The	O
involvement	O
of	O
NFATp	B-protein
in	O
transcriptional	O
activation	O
of	O
both	O
the	O
interleukin-2	B-protein
and	O
TNF	B-DNA
alpha	I-DNA
genes	I-DNA
suggests	O
that	O
this	O
factor	O
plays	O
an	O
important	O
role	O
in	O
the	O
coordinate	O
induction	O
of	O
multiple	O
cytokine	B-DNA
genes	I-DNA
,	O
starting	O
at	O
the	O
earliest	O
stages	O
of	O
T	O
cell	O
activation	O
.	O

Regulation	O
and	O
specificity	O
of	O
MNDA	B-protein
expression	O
in	O
monocytes	B-cell_type
,	O
macrophages	B-cell_type
,	O
and	O
leukemia/B	B-cell_line
lymphoma	I-cell_line
cell	I-cell_line
lines	I-cell_line
.	O

The	O
expression	O
of	O
the	O
human	B-protein
myeloid	I-protein
cell	I-protein
nuclear	I-protein
differentiation	I-protein
antigen	I-protein
(	O
MNDA	B-protein
)	O
was	O
observed	O
specifically	O
in	O
cells	O
of	O
the	O
granulocyte-macrophage	O
lineage	O
in	O
our	O
earlier	O
reports	O
.	O

The	O
specificity	O
of	O
MNDA	B-protein
expression	O
for	O
cells	O
in	O
the	O
granulocyte-macrophage	O
lineage	O
was	O
reexamined	O
in	O
cell	B-cell_line
lines	I-cell_line
established	O
from	O
patients	O
with	O
Philadelphia	O
chromosome-positive	O
chronic	O
myeloid	O
leukemia	O
.	O

Cell	O
lines	O
that	O
expressed	O
MNDA	B-protein
exhibited	O
myeloid	O
cell	O
features	O
and	O
granulocyte	O
or	O
monocyte	O
differentiation	O
could	O
be	O
induced	O
in	O
vitro	O
,	O
while	O
cell	O
lines	O
exhibiting	O
properties	O
of	O
very	O
early	O
stage	O
cells	O
or	O
multipotential	B-cell_type
cells	I-cell_type
did	O
not	O
express	O
MNDA	B-protein
.	O

Cells	O
originating	O
from	O
cases	O
of	O
Burkitt	O
's	O
lymphoma	O
were	O
negative	O
.	O

By	O
contrast	O
,	O
three	O
lymphoblastoid	B-cell_line
cell	I-cell_line
lines	I-cell_line
(	O
immortalized	O
in	O
vitro	O
with	O
Epstein-Barr	O
virus	O
)	O
were	O
weakly	O
positive	O
and	O
MNDA	B-protein
was	O
up-regulated	O
by	O
interferon-alpha	B-protein
(	O
IFN-alpha	B-protein
)	O
treatment	O
.	O

As	O
we	O
reported	O
previously	O
,	O
MNDA	B-RNA
mRNA	I-RNA
level	O
in	O
adherent	O
monocytes	B-cell_type
is	O
elevated	O
by	O
IFN-alpha	B-protein
;	O
in	O
this	O
study	O
,	O
we	O
further	O
assessed	O
MNDA	B-protein
expression	O
in	O
in	O
vitro	O
monocyte-derived	O
macrophages	B-cell_type
.	O

Three	O
additional	O
agents	O
(	O
endotoxin	O
,	O
phytohemagglutinin	B-protein
,	O
and	O
phorbol	O
ester	O
)	O
and	O
other	O
conditions	O
that	O
affect	O
function	O
,	O
cytokine	B-protein
production	O
,	O
differentiation	O
,	O
and/or	O
growth	O
of	O
monocytes	B-cell_type
were	O
examined	O
for	O
their	O
ability	O
to	O
alter	O
MNDA	B-protein
expression	O
.	O

The	O
results	O
varied	O
with	O
the	O
agent	O
,	O
cell	O
type	O
,	O
and	O
stage	O
of	O
differentiation	O
.	O

Changes	O
in	O
MNDA	B-protein
expression	O
occurred	O
slowly	O
(	O
hours	O
to	O
days	O
)	O
,	O
suggesting	O
that	O
MNDA	B-protein
could	O
mediate	O
changes	O
realized	O
over	O
a	O
long	O
period	O
.	O

The	O
results	O
also	O
reveal	O
a	O
discordance	O
in	O
certain	O
MNDA	B-cell_line
positive	I-cell_line
cells	I-cell_line
between	O
steady-state	O
levels	O
or	O
changes	O
in	O
levels	O
of	O
protein	O
and	O
mRNA	B-RNA
indicating	O
that	O
the	O
regulation	O
of	O
MNDA	B-protein
expression	O
occurs	O
at	O
more	O
than	O
one	O
point	O
.	O

Changes	O
in	O
MNDA	B-protein
expression	O
are	O
consistent	O
with	O
a	O
role	O
in	O
opposing	O
macrophage	O
differentiation	O
and	O
activation	O
of	O
monocytes	B-cell_type
/macrophages	B-cell_type
.	O

DNA-binding	O
studies	O
of	O
the	O
Epstein-Barr	B-protein
virus	I-protein
nuclear	I-protein
antigen	I-protein
2	I-protein
(	O
EBNA-2	B-protein
)	O
:	O
evidence	O
for	O
complex	O
formation	O
by	O
latent	B-protein
membrane	I-protein
protein	I-protein
gene	I-protein
promoter-binding	I-protein
proteins	I-protein
in	O
EBNA-2-positive	B-cell_line
cell	I-cell_line
lines	I-cell_line
.	O

The	O
Epstein-Barr	B-protein
virus	I-protein
(	I-protein
EBV	I-protein
)	I-protein
nuclear	I-protein
antigen	I-protein
2	I-protein
(	O
EBNA-2	B-protein
)	O
protein	O
is	O
essential	O
for	O
the	O
immortalization	O
of	O
human	B-cell_type
primary	I-cell_type
B	I-cell_type
cells	I-cell_type
by	O
EBV	O
.	O

EBNA-2	B-protein
trans-activates	O
cellular	B-DNA
and	I-DNA
viral	I-DNA
genes	I-DNA
like	O
CD23	B-DNA
,	O
c-fgr	B-DNA
,	O
latent	B-protein
membrane	I-protein
protein	I-protein
1	I-protein
(	O
LMP1	B-protein
)	O
and	O
terminal	B-protein
protein	I-protein
1	I-protein
(	O
TP1	B-protein
)	O
.	O

Trans-activation	O
of	O
the	O
TP1	B-DNA
promoter	I-DNA
and	O
of	O
the	O
BamHI	B-DNA
C	I-DNA
promoter	I-DNA
has	O
already	O
been	O
investigated	O
in	O
detail	O
and	O
appears	O
to	O
be	O
mediated	O
via	O
protein-protein	O
interactions	O
and	O
not	O
by	O
direct	O
binding	O
of	O
EBNA-2	B-protein
type	I-protein
A	I-protein
(	O
of	O
EBV	O
type	O
1	O
)	O
to	O
the	O
DNA	O
.	O

EBNA-2	B-protein
is	O
able	O
to	O
trans-activate	O
the	O
expression	O
of	O
the	O
LMP	B-DNA
gene	I-DNA
in	O
several	O
cell	O
lines	O
.	O

Various	O
reports	O
have	O
delineated	O
the	O
cis-acting	B-DNA
elements	I-DNA
of	O
the	O
LMP	B-DNA
promoter	I-DNA
through	O
which	O
EBNA-2	B-protein
mediates	O
trans-activation	O
.	O

To	O
determine	O
whether	O
EBNA-2	B-protein
also	O
trans-activates	O
the	O
LMP	B-DNA
promoter	I-DNA
by	O
protein-protein	O
interactions	O
,	O
we	O
performed	O
a	O
series	O
of	O
gel	O
retardation	O
assays	O
and	O
competition	O
experiments	O
with	O
LMP	B-DNA
promoter	I-DNA
fragments	I-DNA
of	O
different	O
sizes	O
.	O

We	O
determined	O
that	O
the	O
protein-binding	B-DNA
region	I-DNA
on	O
the	O
LMP	B-DNA
promoter	I-DNA
was	O
within	O
a	O
42	B-DNA
bp	I-DNA
fragment	I-DNA
encompassing	O
nucleotides	O
-135	O
to	O
-176	O
relative	O
to	O
the	O
LMP	B-DNA
transcriptional	I-DNA
start	I-DNA
site	I-DNA
.	O

None	O
of	O
the	O
DNA	O
fragments	O
investigated	O
indicated	O
interaction	O
of	O
EBNA-2	B-protein
with	O
the	O
DNA	O
via	O
protein-protein	O
interactions	O
.	O

No	O
significant	O
differences	O
between	O
EBNA-2	B-protein
-positive	O
and	O
EBNA-2	B-protein
-negative	O
nuclear	O
extracts	O
could	O
be	O
seen	O
in	O
the	O
gel	O
retardation	O
assay	O
under	O
conditions	O
that	O
clearly	O
showed	O
binding	O
of	O
EBNA-2A	B-protein
to	O
the	O
TP1	B-DNA
promoter	I-DNA
.	O

However	O
,	O
analysis	O
of	O
sucrose	O
gradient	O
fractions	O
in	O
the	O
gel	O
retardation	O
assay	O
provided	O
evidence	O
that	O
the	O
LMP	B-protein
promoter-binding	I-protein
proteins	I-protein
form	O
a	O
complex	O
of	O
higher	O
M	O
(	O
r	O
)	O
in	O
EBNA-2-positive	B-cell_type
cell	I-cell_type
extracts	O
.	O

These	O
complexes	O
were	O
destroyed	O
by	O
detergent	O
.	O

We	O
deduce	O
from	O
these	O
results	O
that	O
EBNA-2-positive	B-cell_line
cells	I-cell_line
might	O
indeed	O
contain	O
specific	B-protein
complexes	I-protein
bound	O
to	O
the	O
LMP	B-DNA
promoter	I-DNA
which	O
are	O
,	O
however	O
,	O
too	O
labile	O
to	O
be	O
detected	O
in	O
a	O
standard	O
gel	O
retardation	O
assay	O
.	O

Simultaneous	O
activation	O
of	O
Ig	B-protein
and	O
Oct-2	B-protein
synthesis	O
and	O
reduction	O
of	O
surface	O
MHC	B-protein
class	I-protein
II	I-protein
expression	O
by	O
IL-6	B-protein
.	O

Terminal	O
differentiation	O
of	O
B	B-cell_type
cells	I-cell_type
to	O
plasma	B-cell_type
cells	I-cell_type
in	O
vivo	O
is	O
characterized	O
by	O
secretion	O
of	O
Ig	B-protein
and	O
extinction	O
of	O
MHC	B-protein
class	I-protein
II	I-protein
expression	O
on	O
the	O
cell	O
surface	O
.	O

We	O
show	O
that	O
IL-6	B-protein
signaling	O
leads	O
to	O
marked	O
increases	O
in	O
the	O
synthesis	O
and	O
secretion	O
of	O
Ig	B-protein
in	O
clonal	B-cell_line
human	I-cell_line
B	I-cell_line
cell	I-cell_line
lines	I-cell_line
and	O
newly	O
isolated	B-cell_type
polyclonal	I-cell_type
B	I-cell_type
lymphocytes	I-cell_type
in	O
vitro	O
.	O

The	O
IL-6-induced	B-cell_line
cells	I-cell_line
resemble	O
plasma	B-cell_type
cells	I-cell_type
in	O
ultrastructure	O
and	O
in	O
reduced	O
expression	O
of	O
surface	B-protein
MHC	I-protein
class	I-protein
II	I-protein
.	O

Enhanced	O
Ig	B-protein
synthesis	O
is	O
a	O
result	O
of	O
coordinated	O
transcriptional	O
activation	O
of	O
Ig	B-DNA
genes	I-DNA
without	O
promoter	O
or	O
isotype	O
specificity	O
,	O
and	O
differential	O
accumulation	O
of	O
the	O
mRNA	B-RNA
encoding	O
the	O
secreted	O
form	O
of	O
Ig	B-protein
heavy	I-protein
chain	I-protein
.	O

It	O
is	O
saturable	O
and	O
subject	O
to	O
negative	O
control	O
when	O
IL-6	B-protein
stimulation	O
is	O
prolonged	O
.	O

Coordinate	O
with	O
temporal	O
changes	O
in	O
Ig	B-protein
synthesis	O
,	O
the	O
DNA-binding	O
activity	O
and	O
the	O
synthesis	O
of	O
the	O
B	B-protein
cell-enriched	I-protein
transcription	I-protein
factor	I-protein
Oct-2	B-protein
are	O
regulated	O
.	O

Thus	O
,	O
differentiation	O
of	O
B	B-cell_type
cells	I-cell_type
with	O
IL-6	B-protein
in	O
vitro	O
recapitulates	O
the	O
hallmarks	O
of	O
terminal	O
B	O
differentiation	O
in	O
vivo	O
;	O
Oct-2	B-protein
may	O
have	O
a	O
role	O
in	O
this	O
process	O
.	O

T-cell	B-DNA
functional	I-DNA
regions	I-DNA
of	O
the	O
human	B-DNA
IL-3	I-DNA
proximal	I-DNA
promoter	I-DNA
.	O

The	O
human	B-DNA
interleukin-3	I-DNA
(	I-DNA
IL-3	I-DNA
)	I-DNA
gene	I-DNA
is	O
expressed	O
almost	O
exclusively	O
in	O
activated	O
T	B-cell_type
cells	I-cell_type
.	O

Its	O
expression	O
is	O
regulated	O
at	O
both	O
the	O
transcriptional	O
and	O
post-transcriptional	O
level	O
.	O

We	O
have	O
previously	O
shown	O
that	O
treatment	O
of	O
Jurkat	B-cell_line
T	I-cell_line
cells	I-cell_line
with	O
phytohemaglutinin	B-protein
(	O
PHA	B-protein
)	O
and	O
the	O
phorbol	O
ester	O
,	O
PMA	O
,	O
activated	O
transcription	O
initiation	O
from	O
the	O
IL-3	B-DNA
gene	I-DNA
.	O

To	O
define	O
the	O
regions	O
of	O
the	O
gene	O
required	O
for	O
transcription	O
activation	O
,	O
we	O
generated	O
a	O
series	O
of	O
reporter	O
constructs	O
containing	O
different	O
regions	O
of	O
the	O
IL-3	B-DNA
gene	I-DNA
5	I-DNA
'	I-DNA
and	I-DNA
3	I-DNA
'	I-DNA
flanking	I-DNA
sequences	I-DNA
.	O

Both	O
positive	B-DNA
and	I-DNA
negative	I-DNA
regulatory	I-DNA
elements	I-DNA
were	O
identified	O
in	O
the	O
proximal	B-DNA
5	I-DNA
'	I-DNA
flanking	I-DNA
region	I-DNA
of	O
the	O
IL-3	B-DNA
gene	I-DNA
.	O

The	O
promoter	B-DNA
region	I-DNA
between	O
-173	B-DNA
and	I-DNA
-60	I-DNA
contained	O
the	O
strongest	O
activating	B-DNA
elements	I-DNA
.	O

The	O
transcription	B-protein
factor	I-protein
AP-1	B-protein
could	O
bind	O
to	O
this	O
positive	O
activator	O
region	O
of	O
the	O
promoter	O
.	O

We	O
also	O
examined	O
the	O
function	O
of	O
the	O
IL-3	B-DNA
CK-1/CK-2	I-DNA
elements	I-DNA
that	O
are	O
present	O
in	O
many	O
cytokine	B-DNA
genes	I-DNA
and	O
found	O
that	O
they	O
acted	O
as	O
a	O
repressor	O
of	O
basal	O
level	O
expression	O
when	O
cloned	O
upstream	O
of	O
a	O
heterologous	B-DNA
promoter	I-DNA
but	O
were	O
also	O
inducible	O
by	O
PMA	O
/PHA	B-protein
.	O

Expression	O
of	O
the	O
Runt	B-DNA
domain-encoding	I-DNA
PEBP2	I-DNA
alpha	I-DNA
genes	I-DNA
in	O
T	B-cell_type
cells	I-cell_type
during	O
thymic	O
development	O
.	O

The	O
PEBP2	B-DNA
alpha	I-DNA
A	I-DNA
and	I-DNA
PEBP2	I-DNA
alpha	I-DNA
B	I-DNA
genes	I-DNA
encode	O
the	O
DNA-binding	B-protein
subunit	I-protein
of	O
a	O
murine	B-protein
transcription	I-protein
factor	I-protein
,	O
PEBP2	B-protein
,	O
which	O
is	O
implicated	O
as	O
a	O
T-cell-specific	B-protein
transcriptional	I-protein
regulator	I-protein
.	O

These	O
two	O
related	O
genes	O
share	O
the	O
evolutionarily	O
conserved	O
region	O
encoding	O
the	O
Runt	B-protein
domain	I-protein
.	O

PEBP2	B-protein
alpha	I-protein
B	I-protein
is	O
the	O
murine	B-protein
counterpart	I-protein
of	O
human	B-protein
AML1	I-protein
,	O
which	O
is	O
located	O
at	O
the	O
breakpoints	O
of	O
the	O
8	B-DNA
;	I-DNA
21	I-DNA
and	I-DNA
3	I-DNA
;	I-DNA
21	I-DNA
chromosome	I-DNA
translocations	I-DNA
associated	O
with	O
acute	O
myeloid	O
leukemia	O
.	O

Northern	O
(	O
RNA	O
)	O
blots	O
of	O
various	O
adult	O
mouse	O
tissues	O
revealed	O
that	O
the	O
levels	O
of	O
expression	O
of	O
both	O
genes	O
were	O
most	O
prominent	O
in	O
the	O
thymus	O
.	O

Furthermore	O
,	O
transcripts	O
of	O
PEBP2	B-protein
alpha	I-protein
A	I-protein
and	O
mouse	B-protein
AML1/PEBP2	I-protein
alpha	I-protein
B	I-protein
were	O
detected	O
in	O
T	B-cell_type
lymphocytes	I-cell_type
in	O
the	O
thymuses	O
from	O
day	O
16	O
embryos	O
and	O
newborns	O
,	O
as	O
well	O
as	O
4-week-old	O
adult	O
mice	O
,	O
by	O
in	O
situ	O
hybridization	O
.	O

The	O
expression	O
of	O
the	O
genes	O
persisted	O
in	O
peripheral	O
lymph	O
nodes	O
of	O
adult	O
mice	O
.	O

The	O
transcripts	O
were	O
detected	O
in	O
all	O
the	O
CD4-	B-cell_type
CD8-	I-cell_type
,	I-cell_type
CD4+	I-cell_type
CD8+	I-cell_type
,	I-cell_type
CD4+	I-cell_type
CD8-	I-cell_type
,	I-cell_type
and	I-cell_type
CD4-	I-cell_type
CD8+	I-cell_type
cell	I-cell_type
populations	I-cell_type
.	O

The	O
results	O
indicated	O
that	O
both	O
genes	O
are	O
expressed	O
in	O
T	B-cell_type
cells	I-cell_type
throughout	O
their	O
development	O
,	O
supporting	O
the	O
notion	O
that	O
PEBP2	B-protein
is	O
a	O
T-cell-specific	B-protein
transcription	I-protein
factor	I-protein
.	O

Transcripts	O
of	O
mouse	B-protein
AML1/PEBP2	I-protein
alpha	I-protein
B	I-protein
were	O
also	O
detected	O
in	O
day	O
12	O
fetal	O
hematopoietic	O
liver	O
and	O
in	O
the	O
bone	B-cell_type
marrow	I-cell_type
cells	I-cell_type
of	O
newborn	O
mice	O
.	O

The	O
implication	O
of	O
mouse	O
AML1/PEBP2	B-protein
alpha	I-protein
B	I-protein
expression	O
in	O
hematopoietic	B-cell_type
cells	I-cell_type
other	O
than	O
those	O
of	O
T-cell	B-cell_type
lineage	I-cell_type
is	O
discussed	O
in	O
relation	O
to	O
myeloid	O
leukemogenesis	O
.	O

Effects	O
of	O
glucocorticoids	O
on	O
transcription	O
factor	O
activation	O
in	O
human	B-cell_type
peripheral	I-cell_type
blood	I-cell_type
mononuclear	I-cell_type
cells	I-cell_type
.	O

Glucocorticoids	O
have	O
an	O
inhibitory	O
effect	O
on	O
inflammatory	O
and	O
immune	O
responses	O
,	O
and	O
this	O
may	O
be	O
through	O
the	O
modulation	O
of	O
transcription	B-protein
factor	I-protein
binding	O
to	O
DNA	O
.	O

The	O
interaction	O
of	O
the	O
transcription	B-protein
factors	I-protein
,	O
activator	B-protein
protein-1	I-protein
(	O
AP-1	B-protein
)	O
,	O
nuclear	B-protein
factor	I-protein
kappa	I-protein
B	I-protein
(	O
NF	B-protein
kappa	I-protein
B	I-protein
)	O
,	O
and	O
cAMP-responsive	B-protein
element	I-protein
binding	I-protein
protein	I-protein
(	O
CREB	B-protein
)	O
with	O
DNA	O
and	O
glucocorticoid	B-protein
receptors	I-protein
(	O
GR	B-protein
)	O
was	O
analyzed	O
in	O
human	B-cell_type
peripheral	I-cell_type
blood	I-cell_type
mononuclear	I-cell_type
cells	I-cell_type
by	O
gel	O
mobility	O
shift	O
assays	O
.	O

TNF-alpha	O
,	O
IL-1	O
beta	O
and	O
phorbol	O
myristate	O
acetate	O
(	O
PMA	O
)	O
treatment	O
increased	O
AP-1	B-protein
and	O
NF	O
kappa	O
B	O
DNA	O
binding	O
by	O
up	O
to	O
200	O
%	O
but	O
decreased	O
CREB	B-protein
binding	O
(	O
38	O
%	O
)	O
over	O
a	O
60-min	O
time	O
course	O
.	O

Dexamethasone	O
produced	O
a	O
rapid	O
and	O
sustained	O
increase	O
in	O
glucocorticoid	B-DNA
response	I-DNA
element	I-DNA
binding	O
and	O
a	O
concomitant	O
40-50	O
%	O
decrease	O
in	O
AP-1	O
,	O
NF	O
kappa	O
B	O
,	O
and	O
CREB	O
DNA	O
binding	O
that	O
was	O
blocked	O
by	O
combined	O
dexamethasone	O
and	O
cytokine	B-protein
or	O
PMA	O
treatment	O
.	O

These	O
latter	O
effects	O
were	O
due	O
to	O
increases	O
in	O
the	O
nuclear	O
localization	O
of	O
GR	B-protein
,	O
not	O
to	O
reduced	O
amounts	O
of	O
the	O
other	O
transcription	B-protein
factors	I-protein
.	O

This	O
suggests	O
that	O
in	O
these	O
cells	O
GR	B-protein
within	O
the	O
nucleus	O
interacts	O
with	O
cytokine-stimulated	B-protein
transcription	I-protein
factors	I-protein
by	O
the	O
process	O
of	O
cross	O
coupling	O
.	O

This	O
may	O
be	O
an	O
important	O
molecular	O
site	O
of	O
steroid	O
action	O
.	O

Differential	O
induction	O
of	O
the	O
NF-AT	B-protein
complex	I-protein
during	O
restimulation	O
and	O
the	O
induction	O
of	O
T-cell	O
anergy	O
.	O

Stimulation	O
of	O
human	B-cell_line
CD4+	I-cell_line
T-cell	I-cell_line
clones	I-cell_line
through	O
the	O
T-cell	B-protein
receptor	I-protein
(	O
TcR	B-protein
)	O
by	O
high	O
doses	O
of	O
specific	O
peptide	O
results	O
in	O
the	O
induction	O
of	O
a	O
long-lived	O
state	O
of	O
nonresponsiveness	O
that	O
has	O
been	O
called	O
anergy	O
.	O

During	O
the	O
induction	O
of	O
anergy	O
,	O
T	B-cell_type
cells	I-cell_type
are	O
phenotypically	O
similar	O
to	O
cells	O
responding	O
to	O
an	O
immunogenic	O
stimulus	O
.	O

The	O
amount	O
of	O
TcR	B-protein
at	O
the	O
cell	O
surface	O
is	O
downmodulated	O
,	O
whereas	O
the	O
CD2	B-protein
and	I-protein
CD25	I-protein
receptors	I-protein
are	O
increased	O
.	O

When	O
restimulated	O
,	O
however	O
,	O
anergic	B-cell_type
T	I-cell_type
cells	I-cell_type
fail	O
to	O
up-regulate	O
transcription	O
of	O
the	O
IL-2	B-DNA
gene	I-DNA
and	O
in	O
consequence	O
do	O
not	O
produce	O
IL-2	B-protein
.	O

In	O
this	O
study	O
,	O
we	O
have	O
compared	O
the	O
ability	O
of	O
various	O
transcription	B-protein
factors	I-protein
to	O
bind	O
to	O
their	O
appropriate	O
site	O
on	O
DNA	O
.	O

Factors	O
were	O
isolated	O
from	O
the	O
nuclei	O
of	O
T	B-cell_type
cells	I-cell_type
that	O
were	O
in	O
the	O
induction	O
phase	O
of	O
anergy	O
or	O
were	O
undergoing	O
activation	O
.	O

The	O
pattern	O
of	O
binding	O
activity	O
in	O
restimulated	O
T	B-cell_type
cells	I-cell_type
is	O
consistent	O
with	O
the	O
pattern	O
that	O
has	O
previously	O
been	O
shown	O
to	O
regulate	O
T-cell-specific	O
expression	O
of	O
the	O
IL-2	B-protein
and	O
the	O
beta	O
chain	O
of	O
the	O
TcR	B-DNA
genes	I-DNA
.	O

The	O
measured	O
binding	O
to	O
a	O
TCF-1	B-DNA
site	I-DNA
is	O
the	O
same	O
in	O
the	O
nuclei	O
of	O
resting	B-cell_type
,	I-cell_type
activated	I-cell_type
,	I-cell_type
and	I-cell_type
anergized	I-cell_type
cells	I-cell_type
.	O

The	O
inducible	B-protein
factors	I-protein
NK-kappa	B-protein
B	I-protein
,	O
beta	B-protein
E2	I-protein
,	O
CD28RC	B-protein
,	O
and	O
AP-1	B-protein
are	O
not	O
expressed	O
in	O
resting	B-cell_type
cells	I-cell_type
and	O
are	O
twofold	O
lower	O
in	O
anergized	O
as	O
compared	O
with	O
activated	O
cells	O
.	O

In	O
contrast	O
,	O
anergic	B-cell_type
T	I-cell_type
cells	I-cell_type
express	O
approximately	O
eightfold	O
lower	O
amounts	O
of	O
NF-AT	B-protein
,	O
a	O
member	O
of	O
the	O
class	O
of	O
inducible	B-protein
factors	I-protein
that	O
regulates	O
IL-2	B-DNA
gene	I-DNA
transcription	O
.	O

(	O
ABSTRACT	O
TRUNCATED	O
AT	O
250	O
WORDS	O
)	O

The	O
number	O
of	O
glucocorticoid	B-protein
receptors	I-protein
in	O
peripheral	B-cell_type
human	I-cell_type
lymphocytes	I-cell_type
is	O
elevated	O
by	O
a	O
zinc	O
containing	O
trace	O
element	O
preparation	O
.	O

A	O
trace	O
element	O
preparation	O
(	O
Beres	O
Drops	O
Plus	O
,	O
BDP	O
)	O
elevates	O
the	O
number	O
of	O
glucocorticoid	B-protein
receptors	I-protein
(	O
gcR	B-protein
)	O
in	O
peripheral	B-cell_type
lymphocytes	I-cell_type
isolated	O
both	O
from	O
healthy	O
blood	O
donors	O
and	O
rheumatoid	O
arthritis	O
patients	O
.	O

This	O
enhancement	O
by	O
BDP	O
was	O
found	O
either	O
for	O
constitutive	O
expression	O
of	O
gcRs	B-protein
or	O
in	O
experiments	O
when	O
the	O
lymphocytes	B-cell_type
were	O
stimulated	O
by	O
interleukin	B-protein
(	I-protein
IL	I-protein
)	I-protein
-6	I-protein
.	O

There	O
was	O
no	O
significant	O
effect	O
of	O
BDP	O
on	O
IL-1	B-protein
and	O
tumour	B-protein
necrosis	I-protein
factor	I-protein
alpha	I-protein
(	O
TNF	B-protein
alpha	I-protein
)	O
-induced	O
changes	O
of	O
gcRs	B-protein
.	O

The	O
effect	O
of	O
BDP	O
was	O
greatly	O
dependent	O
on	O
the	O
presence	O
of	O
Zn++	O
ions	O
in	O
the	O
preparation	O
,	O
since	O
the	O
augmenting	O
effect	O
was	O
abolished	O
if	O
BDP	O
did	O
not	O
contain	O
zinc	O
.	O

The	O
DNA	O
and	O
steroid	B-protein
binding	I-protein
domains	I-protein
of	O
the	O
glucocorticoid	B-protein
receptor	I-protein
are	O
not	O
altered	O
in	O
mononuclear	B-cell_type
cells	I-cell_type
of	O
treated	O
CLL	O
patients	O
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
investigate	O
whether	O
mutations	O
in	O
the	O
glucocorticoid	B-protein
receptor	I-protein
could	O
account	O
for	O
the	O
increasing	O
unresponsiveness	O
of	O
patients	O
with	O
chronic	O
lymphatic	O
leukemia	O
(	O
CLL	O
)	O
to	O
combination	O
chemotherapy	O
.	O

The	O
receptor	O
was	O
tested	O
immunocytochemically	O
,	O
in	O
steroid	O
binding	O
assays	O
,	O
and	O
by	O
a	O
mutation	O
screening	O
(	O
denaturing	O
gradient	O
gel	O
electrophoresis	O
)	O
of	O
the	O
receptor-cDNA	B-protein
.	O

The	O
receptor	O
concentration	O
,	O
as	O
measured	O
by	O
staining	O
and	O
steroid	O
binding	O
test	O
,	O
varied	O
considerably	O
but	O
showed	O
no	O
clear	O
correlation	O
to	O
clinical	O
response	O
.	O

Using	O
a	O
highly	O
sensitive	O
mutation	O
screening	O
assay	O
of	O
the	O
DNA-	B-protein
and	I-protein
the	I-protein
steroid-binding	I-protein
region	I-protein
,	O
none	O
of	O
the	O
treated	O
patients	O
revealed	O
any	O
mutation	O
,	O
suggesting	O
that	O
the	O
glucocorticoid	B-protein
receptor	I-protein
in	O
the	O
CLL	O
patients	O
tested	O
is	O
not	O
altered	O
in	O
these	O
domains	O
.	O

In	O
one	O
individual	O
who	O
had	O
not	O
been	O
treated	O
before	O
analysis	O
a	O
silent	O
mutation	O
was	O
found	O
in	O
one	O
receptor	O
allele	O
.	O

The	O
results	O
suggest	O
that	O
mechanisms	O
other	O
than	O
altered	O
ligand	O
or	O
DNA	O
binding	O
of	O
the	O
receptor	O
may	O
be	O
responsible	O
for	O
the	O
lack	O
of	O
response	O
to	O
chemotherapy	O
.	O

This	O
conclusion	O
is	O
discussed	O
in	O
relation	O
to	O
the	O
mechanism	O
of	O
corticoid	O
resistance	O
in	O
mouse	B-cell_line
and	I-cell_line
human	I-cell_line
lymphoma	I-cell_line
cells	I-cell_line
in	O
culture	O
.	O

An	O
AP1	B-DNA
binding	I-DNA
site	I-DNA
upstream	O
of	O
the	O
kappa	B-DNA
immunoglobulin	I-DNA
intron	I-DNA
enhancer	I-DNA
binds	O
inducible	B-protein
factors	I-protein
and	O
contributes	O
to	O
expression	O
.	O

Expression	O
of	O
the	O
kappa	O
immunoglobulin	O
light	O
chain	O
gene	O
requires	O
developmental-	O
and	O
tissue-specific	O
regulation	O
by	O
trans-acting	B-protein
factors	I-protein
which	O
interact	O
with	O
two	O
distinct	O
enhancer	B-DNA
elements	I-DNA
.	O

A	O
new	O
protein-DNA	O
interaction	O
has	O
been	O
identified	O
upstream	O
of	O
the	O
intron	B-DNA
enhancer	I-DNA
,	O
within	O
the	O
matrix-associated	B-DNA
region	I-DNA
of	O
the	O
J-C	B-DNA
intron	I-DNA
.	O

The	O
binding	O
activity	O
is	O
greatly	O
inducible	O
in	O
pre-B	B-cell_type
cells	I-cell_type
by	O
bacterial	O
lipopolysaccharide	O
and	O
interleukin-1	B-protein
but	O
specific	O
complexes	O
are	O
found	O
at	O
all	O
stages	O
of	O
B	O
cell	O
development	O
tested	O
.	O

The	O
footprinted	B-DNA
binding	I-DNA
site	I-DNA
is	O
homologous	O
to	O
the	O
consensus	B-DNA
AP1	I-DNA
motif	I-DNA
.	O

The	O
protein	O
components	O
of	O
this	O
complex	O
are	O
specifically	O
competed	O
by	O
an	O
AP1	B-DNA
consensus	I-DNA
motif	I-DNA
and	O
were	O
shown	O
by	O
supershift	O
to	O
include	O
c-Jun	B-protein
and	O
c-Fos	B-protein
,	O
suggesting	O
that	O
this	O
binding	B-DNA
site	I-DNA
is	O
an	O
AP1	B-DNA
motif	I-DNA
and	O
that	O
the	O
Jun	B-protein
and	I-protein
Fos	I-protein
families	I-protein
of	O
transcription	B-protein
factors	I-protein
play	O
a	O
role	O
in	O
the	O
regulation	O
of	O
the	O
kappa	B-DNA
light	I-DNA
chain	I-DNA
gene	I-DNA
.	O

Mutation	O
of	O
the	O
AP1	B-DNA
motif	I-DNA
in	O
the	O
context	O
of	O
the	O
intron	B-DNA
enhancer	I-DNA
was	O
shown	O
to	O
decrease	O
enhancer-mediated	O
activation	O
of	O
the	O
promoter	O
in	O
both	O
pre-B	B-cell_type
cells	I-cell_type
induced	O
with	O
LPS	O
and	O
constitutive	O
expression	O
in	O
mature	B-cell_type
B	I-cell_type
cells	I-cell_type
.	O

Distinct	O
DNase-I	B-DNA
hypersensitive	I-DNA
sites	I-DNA
are	O
associated	O
with	O
TAL-1	B-protein
transcription	O
in	O
erythroid	B-cell_line
and	I-cell_line
T-cell	I-cell_line
lines	I-cell_line
.	O

The	O
tal-1	B-DNA
gene	I-DNA
,	O
frequently	O
activated	O
in	O
human	O
T-cell	O
acute	O
lymphoblastic	O
leukemia	O
(	O
T-ALL	O
)	O
,	O
is	O
expressed	O
in	O
the	O
erythroid	B-cell_type
,	I-cell_type
megakaryocytic	I-cell_type
,	I-cell_type
and	I-cell_type
mast	I-cell_type
cell	I-cell_type
lineages	I-cell_type
during	O
normal	O
hematopoiesis	O
.	O

To	O
gain	O
further	O
insight	O
into	O
the	O
molecular	O
mechanisms	O
that	O
control	O
tal-1	B-DNA
expression	O
,	O
we	O
investigated	O
tal-1	B-DNA
chromatin	O
structure	O
in	O
erythroid/megakaryocytic	B-cell_line
cell	I-cell_line
lines	I-cell_line
and	O
in	O
T-cell	B-cell_line
lines	I-cell_line
either	O
with	O
or	O
without	O
tal-1	B-DNA
rearrangements	I-DNA
.	O

Tal-1	O
transcription	O
was	O
shown	O
to	O
be	O
monoallelic	O
in	O
Jurkat	B-cell_line
,	O
a	O
T-cell	O
line	O
that	O
expresses	O
tal-1	B-DNA
in	O
the	O
absence	O
of	O
apparent	O
genomic	O
alteration	O
of	O
the	O
locus	O
.	O

Methylation	O
studies	O
indicated	O
that	O
the	O
tal-15	B-DNA
'	I-DNA
GC-rich	I-DNA
region	I-DNA
behaves	O
like	O
a	O
CpG	B-DNA
island	I-DNA
,	O
hypomethylated	O
in	O
normal	B-cell_type
cells	I-cell_type
,	O
and	O
methylated	O
de	O
novo	O
on	O
transcriptionally	B-DNA
inactive	I-DNA
alleles	I-DNA
in	O
established	B-cell_line
cell	I-cell_line
lines	I-cell_line
.	O

Five	O
major	O
DNase-I	B-DNA
hypersensitive	I-DNA
sites	I-DNA
(	O
HS	B-DNA
)	O
were	O
mapped	O
in	O
the	O
tal-1	B-DNA
locus	O
.	O

HS	B-DNA
I	I-DNA
,	I-DNA
IV	I-DNA
,	I-DNA
and	I-DNA
V	I-DNA
were	O
exclusively	O
observed	O
in	O
the	O
erythroid/megakaryocytic	B-cell_line
cell	I-cell_line
lines	I-cell_line
that	O
express	O
tal-1	B-DNA
from	O
the	O
promoters	B-DNA
1a	I-DNA
and	I-DNA
1b	I-DNA
.	O

HS	B-DNA
II	I-DNA
was	O
weak	O
in	O
hematopoietic	B-cell_line
cell	I-cell_line
lines	I-cell_line
,	O
absent	O
in	O
Hela	B-cell_line
,	O
and	O
greatly	O
enhanced	O
in	O
Jurkat	B-cell_line
,	O
suggesting	O
that	O
this	O
region	O
might	O
be	O
implicated	O
in	O
the	O
cis-activation	O
of	O
tal-1	B-DNA
promoter	I-DNA
1b	I-DNA
in	O
this	O
cell	O
line	O
.	O

HS	B-DNA
III	I-DNA
was	O
weak	O
in	O
HEL	B-cell_line
and	O
Jurkat	B-cell_line
,	O
and	O
greatly	O
enhanced	O
in	O
DU528	B-cell_line
,	O
a	O
T-cell	B-cell_line
line	I-cell_line
that	O
bears	O
a	B-DNA
t	I-DNA
(	I-DNA
1	I-DNA
;	I-DNA
14	I-DNA
)	I-DNA
and	O
initiates	O
tal-1	B-DNA
transcription	O
within	O
exon	B-DNA
4	I-DNA
.	O

These	O
results	O
suggest	O
that	O
distinct	O
regulatory	B-DNA
elements	I-DNA
are	O
associated	O
with	O
the	O
use	O
of	O
the	O
different	O
tal-1	B-DNA
promoters	I-DNA
.	O

Erythropoietin	B-protein
-dependent	O
induction	O
of	O
hemoglobin	B-protein
synthesis	O
in	O
a	O
cytokine-dependent	B-cell_line
cell	I-cell_line
line	I-cell_line
M-TAT	B-cell_line
.	O

M-TAT	B-cell_line
is	O
a	O
cytokine-dependent	B-cell_line
cell	I-cell_line
line	I-cell_line
with	O
the	O
potential	O
to	O
differentiate	O
along	O
the	O
erythroid	B-cell_type
and	I-cell_type
megakaryocytic	I-cell_type
lineages	I-cell_type
.	O

We	O
cultured	O
M-TAT	B-cell_line
cells	I-cell_line
long	O
term	O
(	O
>	O
1	O
year	O
)	O
in	O
the	O
continuous	O
presence	O
of	O
erythropoietin	B-protein
(	O
EPO	B-protein
)	O
,	O
granulocyte-macrophage	B-protein
colony-stimulating	I-protein
factor	I-protein
(	O
GM-CSF	B-protein
)	O
,	O
or	O
stem	B-protein
cell	I-protein
factor	I-protein
(	O
SCF	B-protein
)	O
.	O

These	O
long	O
term	O
cultures	O
are	O
referred	O
to	O
as	O
M-TAT/EPO	B-cell_line
,	I-cell_line
M-TAT/GM-CSF	I-cell_line
,	I-cell_line
and	I-cell_line
M-TAT/SCF	I-cell_line
cells	I-cell_line
,	O
respectively	O
.	O

Hemoglobin	B-protein
concentration	O
and	O
gamma-globin	B-protein
and	O
erythroid	B-RNA
delta-aminolevulinate	I-RNA
synthase	I-RNA
mRNA	I-RNA
levels	O
were	O
significantly	O
higher	O
in	O
M-TAT/EPO	B-cell_line
cells	I-cell_line
than	O
in	O
M-TAT/GM-CSF	B-cell_line
cells	I-cell_line
.	O

When	O
the	O
supplemented	O
cytokine	B-protein
was	O
switched	O
from	O
GM-CSF	B-protein
to	O
EPO	B-protein
,	O
hemoglobin	B-protein
synthesis	O
in	O
M-TAT/GM-CSF	B-cell_line
cells	I-cell_line
increased	O
rapidly	O
(	O
within	O
5	O
h	O
)	O
,	O
and	O
the	O
level	O
of	O
GATA-1	B-RNA
mRNA	I-RNA
increased	O
.	O

In	O
contrast	O
,	O
the	O
addition	O
of	O
GM-CSF	B-protein
to	O
the	O
M-TAT/EPO	B-cell_line
cell	I-cell_line
culture	I-cell_line
decreased	O
the	O
amount	O
of	O
hemoglobin	O
,	O
even	O
in	O
the	O
presence	O
of	O
EPO	B-protein
,	O
indicating	O
that	O
the	O
EPO	B-protein
signal	O
for	O
erythroid	O
differentiation	O
is	O
suppressed	O
by	O
GM-CSF	B-protein
.	O

Thus	O
,	O
erythroid	O
development	O
of	O
M-TAT	B-cell_line
cells	I-cell_line
is	O
promoted	O
by	O
EPO	B-protein
and	O
suppressed	O
by	O
GM-CSF	B-protein
.	O

These	O
results	O
support	O
the	O
hypothesis	O
that	O
EPO	B-protein
actively	O
influences	O
the	O
programming	O
of	O
gene	O
expression	O
required	O
for	O
erythroid	B-cell_type
progenitor	I-cell_type
cell	I-cell_type
differentiation	O
.	O

The	O
role	O
of	O
cellular	B-protein
transcription	I-protein
factor	I-protein
E2F	I-protein
in	O
the	O
regulation	O
of	O
cdc2	B-RNA
mRNA	I-RNA
expression	O
and	O
cell	O
cycle	O
control	O
of	O
human	O
hematopoietic	B-cell_type
cells	I-cell_type
.	O

cdc2	B-RNA
mRNA	I-RNA
transcripts	I-RNA
were	O
detected	O
in	O
immature	B-cell_type
bone	I-cell_type
marrow	I-cell_type
cells	I-cell_type
and	O
became	O
undetectable	O
along	O
with	O
differentiation	O
.	O

Peripheral	B-cell_type
blood	I-cell_type
resting	I-cell_type
cells	I-cell_type
did	O
not	O
express	O
cdc2	B-RNA
mRNA	I-RNA
,	O
but	O
it	O
was	O
induced	O
in	O
T-lymphocytes	B-cell_type
when	O
the	O
cells	O
reentered	O
the	O
cell	O
cycle	O
in	O
response	O
to	O
specific	O
mitogens	O
.	O

In	O
contrast	O
,	O
cdc2	B-RNA
mRNA	I-RNA
could	O
not	O
be	O
induced	O
in	O
granulocytes	B-cell_type
and	O
monocytes	B-cell_type
even	O
after	O
the	O
culture	O
with	O
the	O
appropriate	O
stimulants	O
.	O

In	O
order	O
to	O
investigate	O
the	O
mechanism	O
of	O
the	O
regulation	O
of	O
cdc2	B-RNA
mRNA	I-RNA
expression	O
in	O
hematopoietic	B-cell_type
cells	I-cell_type
,	O
we	O
isolated	O
the	O
5'-flanking	B-DNA
sequence	I-DNA
of	O
the	O
cdc2	B-DNA
gene	I-DNA
and	O
found	O
the	O
putative	O
E2F	O
binding	B-DNA
site	I-DNA
at	O
the	O
position	O
of	O
nucleotides	B-DNA
-124	I-DNA
to	I-DNA
-117	I-DNA
.	O

The	O
binding	O
of	O
E2F	B-protein
at	O
this	O
region	O
was	O
detected	O
by	O
a	O
gel-retardation	O
assay	O
and	O
DNaseI	B-protein
footprinting	O
in	O
phytohemagglutinin-stimulated	B-cell_line
T-lymphocytes	I-cell_line
,	O
which	O
was	O
coincident	O
with	O
the	O
expression	O
of	O
cdc2	B-RNA
mRNA	I-RNA
.	O

E2F	B-protein
binding	O
was	O
not	O
observed	O
in	O
both	O
granulocytes	B-cell_type
and	O
monocytes	B-cell_type
.	O

Transient	O
chloramphenicol	B-protein
acetyltransferase	I-protein
assay	O
revealed	O
that	O
the	O
region	O
containing	O
E2F	B-DNA
binding	I-DNA
site	I-DNA
had	O
a	O
strong	O
promoter	O
activity	O
,	O
and	O
introduction	O
of	O
the	O
mutation	O
at	O
the	O
E2F	B-DNA
binding	I-DNA
site	I-DNA
resulted	O
in	O
a	O
significant	O
loss	O
of	O
the	O
activity	O
.	O

E2F-1	B-RNA
and	I-RNA
DP-1	I-RNA
mRNAs	I-RNA
were	O
not	O
detectable	O
in	O
granulocytes	B-cell_type
,	O
monocytes	B-cell_type
and	O
resting	B-cell_type
T-lymphocytes	I-cell_type
but	O
were	O
induced	O
after	O
the	O
mitogenic	O
stimulation	O
of	O
T-lymphocytes	B-cell_type
.	O

The	O
induction	O
of	O
E2F	B-protein
activity	O
preceded	O
the	O
appearance	O
of	O
cdc2	B-RNA
mRNA	I-RNA
,	O
which	O
is	O
consistent	O
with	O
the	O
role	O
of	O
E2F	B-protein
in	O
the	O
regulation	O
of	O
cdc2	B-cell_type
mRNA	I-cell_type
expression	I-cell_type
.	O

These	O
results	O
suggest	O
that	O
cdc2	B-RNA
mRNA	I-RNA
expression	O
is	O
related	O
to	O
the	O
cell	O
cycling	O
of	O
normal	B-cell_type
human	I-cell_type
hematopoietic	I-cell_type
cells	I-cell_type
and	O
that	O
E2F	B-protein
plays	O
some	O
roles	O
in	O
the	O
regulation	O
of	O
its	O
expression	O
.	O

Association	O
of	O
alterations	O
in	O
NF-kappa	B-protein
B	I-protein
moieties	I-protein
with	O
HIV	O
type	O
1	O
proviral	O
latency	O
in	O
certain	O
monocytic	B-cell_type
cells	I-cell_type
.	O

Human	O
immunodeficiency	O
virus	O
type	O
1	O
(	O
HIV-1	O
)	O
replication	O
is	O
controlled	O
by	O
a	O
complex	O
array	O
of	O
virally	B-protein
encoded	I-protein
and	I-protein
cellular	I-protein
proteins	I-protein
.	O

A	O
wide	O
spectrum	O
of	O
levels	O
of	O
HIV-1	O
expression	O
have	O
been	O
demonstrated	O
in	O
various	O
cells	O
,	O
both	O
in	O
cell	O
culture	O
and	O
in	O
vivo	O
.	O

Molecular	O
mechanisms	O
leading	O
to	O
restricted	O
HIV-1	O
replication	O
may	O
differ	O
between	O
certain	O
cell	O
types	O
.	O

It	O
is	O
now	O
demonstrated	O
that	O
HIV-1	O
proviral	O
latency	O
in	O
the	O
monocytic	B-cell_line
cell	I-cell_line
line	I-cell_line
U1	I-cell_line
,	O
in	O
which	O
only	O
extremely	O
low	O
levels	O
of	O
HIV-1	O
expression	O
are	O
detected	O
in	O
the	O
baseline	O
unstimulated	O
state	O
,	O
is	O
associated	O
with	O
alterations	O
in	O
nuclear	O
factor-kappa	B-protein
B	I-protein
(	I-protein
NF-kappa	I-protein
B	I-protein
)	I-protein
moieties	I-protein
demonstrated	O
in	O
these	O
cells	O
by	O
electrophoretic	O
mobility	O
shift	O
assays	O
(	O
EMSAs	O
)	O
and	O
in	O
situ	O
UV	O
cross-linking	O
studies	O
.	O

A	O
predominance	O
of	O
p50	B-protein
NF-kappa	I-protein
B	I-protein
moieties	I-protein
and	O
possibly	O
p50	B-protein
homodimers	I-protein
or	O
closely	O
related	O
species	O
,	O
rather	O
than	O
the	O
p50-p56	B-protein
heterodimer	I-protein
of	O
NF-kappa	B-protein
B	I-protein
that	O
is	O
the	O
predominant	O
NF-kappa	B-protein
B	I-protein
species	O
in	O
most	O
T	B-cell_type
lymphocytic	I-cell_type
and	I-cell_type
monocytic	I-cell_type
cells	I-cell_type
,	O
is	O
demonstrated	O
in	O
the	O
nuclei	O
of	O
U1	B-cell_line
cells	I-cell_line
.	O

This	O
pattern	O
of	O
NF-kappa	B-protein
B-related	I-protein
moieties	I-protein
differs	O
from	O
the	O
latently	B-cell_line
infected	I-cell_line
T	I-cell_line
lymphocytic	I-cell_line
cell	I-cell_line
line	I-cell_line
ACH-2	I-cell_line
,	O
and	O
from	O
the	O
U937	B-cell_line
monocytic	I-cell_line
line	I-cell_line
,	O
the	O
parental	B-cell_line
cell	I-cell_line
line	I-cell_line
of	O
the	O
U1	B-cell_line
cellular	I-cell_line
clone	I-cell_line
.	O

As	O
such	O
,	O
these	O
data	O
suggest	O
that	O
different	O
proximal	O
mechanisms	O
may	O
lead	O
to	O
restricted	O
HIV-1	O
replication	O
in	O
various	O
cell	O
types	O
.	O

[	O
Regulation	O
of	O
transcription	O
of	O
the	O
interleukin-2	B-DNA
gene	I-DNA
in	O
B-lymphocytes	B-cell_type
]	O

Since	O
most	O
B	B-cell_line
cell	I-cell_line
clones	I-cell_line
immortalized	O
with	O
EBV	O
virus	O
can	O
be	O
induced	O
to	O
produce	O
interleukin-2	B-protein
,	O
a	O
typical	O
T	B-protein
cell	I-protein
cytokine	I-protein
,	O
we	O
studied	O
the	O
role	O
of	O
different	O
elements	O
of	O
the	O
IL-2	B-DNA
promoter	I-DNA
in	O
such	O
clones	O
by	O
transfection	O
.	O

It	O
was	O
found	O
,	O
in	O
particular	O
,	O
that	O
the	O
element	O
TCEd	B-DNA
,	O
which	O
binds	O
the	O
transcription	B-protein
factor	I-protein
NF-kB	B-protein
,	O
is	O
very	O
active	O
in	O
all	O
three	O
B	B-cell_line
clones	I-cell_line
tested	O
.	O

This	O
element	O
has	O
no	O
activity	O
in	O
T	B-cell_type
cells	I-cell_type
of	O
the	O
Jurkat	B-cell_line
line	I-cell_line
.	O

The	O
NFATd	B-DNA
element	I-DNA
,	O
which	O
binds	O
the	O
transcription	B-protein
factor	I-protein
NFAT-1	B-protein
and	O
is	O
very	O
active	O
in	O
T	B-cell_type
cells	I-cell_type
,	O
is	O
only	O
weakly	O
active	O
in	O
one	O
B	B-cell_line
clone	I-cell_line
and	O
not	O
at	O
all	O
in	O
another	O
.	O

Different	O
elements	O
thus	O
contribute	O
to	O
IL-2	B-DNA
promoter	I-DNA
activity	O
in	O
different	O
cells	O
.	O

Regulation	O
of	O
I	B-protein
kappa	I-protein
B	I-protein
alpha	I-protein
and	O
p105	B-protein
in	O
monocytes	B-cell_type
and	O
macrophages	B-cell_type
persistently	O
infected	O
with	O
human	O
immunodeficiency	O
virus	O
.	O

The	O
mechanisms	O
regulating	O
human	O
immunodeficiency	O
virus	O
(	O
HIV	O
)	O
persistence	O
in	O
human	O
monocytes	B-cell_type
/macrophages	B-cell_type
are	O
partially	O
understood	O
.	O

Persistent	O
HIV	O
infection	O
of	O
U937	B-cell_line
monocytic	I-cell_line
cells	I-cell_line
results	O
in	O
NF-kappa	B-protein
B	I-protein
activation	O
.	O

Whether	O
virus-induced	O
NF-kappa	B-protein
B	I-protein
activation	O
is	O
a	O
mechanism	O
that	O
favors	O
continuous	O
viral	O
replication	O
in	O
macrophages	B-cell_type
remains	O
unknown	O
.	O

To	O
further	O
delineate	O
the	O
molecular	O
mechanisms	O
involved	O
in	O
the	O
activation	O
of	O
NF-kappa	B-protein
B	I-protein
in	O
HIV-infected	O
monocytes	B-cell_type
and	O
macrophages	B-cell_type
,	O
we	O
have	O
focused	O
on	O
the	O
regulation	O
of	O
the	O
I	O
kappa	O
B	O
molecules	O
.	O

First	O
,	O
we	O
show	O
that	O
persistent	O
HIV	O
infection	O
results	O
in	O
the	O
activation	O
of	O
NF-kappa	O
B	O
not	O
only	O
in	O
monocytic	O
cells	O
but	O
also	O
in	O
macrophages	B-cell_type
.	O

In	O
HIV-infected	O
cells	O
,	O
I	B-protein
kappa	I-protein
B	I-protein
alpha	I-protein
protein	O
levels	O
are	O
decreased	O
secondary	O
to	O
enhanced	O
protein	O
degradation	O
.	O

This	O
parallels	O
the	O
increased	O
I	B-protein
kappa	I-protein
B	I-protein
alpha	I-protein
synthesis	O
secondary	O
to	O
increased	O
I	B-protein
kappa	I-protein
B	I-protein
alpha	I-protein
gene	O
transcription	O
,	O
i.e.	O
,	O
increased	O
RNA	O
and	O
transcriptional	O
activity	O
of	O
its	O
promoter-enhancer	O
.	O

Another	O
protein	O
with	O
I	O
kappa	O
B	O
function	O
,	O
p105	B-protein
,	O
is	O
also	O
modified	O
in	O
HIV-infected	O
cells	O
:	O
p105	B-protein
and	O
p50	B-protein
steady-state	O
protein	O
levels	O
are	O
increased	O
as	O
a	O
result	O
of	O
increased	O
synthesis	O
and	O
proteolytic	O
processing	O
of	O
p105	B-protein
.	O

Transcriptional	O
activity	O
of	O
p105	B-protein
is	O
also	O
increased	O
in	O
infected	B-cell_type
cells	I-cell_type
and	O
is	O
also	O
mediated	O
by	O
NF-kappa	B-protein
B	I-protein
through	O
a	O
specific	O
kappa	B-DNA
B	I-DNA
motif	I-DNA
.	O

These	O
results	O
demonstrate	O
the	O
existence	O
of	O
a	O
triple	O
autoregulatory	O
loop	O
in	O
monocytes	B-cell_type
and	O
macrophages	B-cell_type
involving	O
HIV	O
,	O
p105	B-protein
and	O
p50	B-protein
,	O
and	O
MAD3	B-protein
,	O
with	O
the	O
end	O
result	O
of	O
persistent	O
NF-kappa	O
B	O
activation	O
and	O
viral	O
persistence	O
.	O

Furthermore	O
,	O
persistent	O
HIV	O
infection	O
of	O
monocytes	B-cell_type
and	O
macrophages	B-cell_type
provides	O
a	O
useful	O
model	O
with	O
which	O
to	O
study	O
concomitant	O
modifications	O
of	O
different	O
I	B-protein
kappa	I-protein
B	I-protein
molecules	I-protein
.	O

Glucocorticoid-induced	O
apoptosis	O
of	O
human	B-cell_type
leukemic	I-cell_type
cells	I-cell_type
is	O
caused	O
by	O
the	O
repressive	O
function	O
of	O
the	O
glucocorticoid	B-protein
receptor	I-protein
.	O

Induction	O
of	O
apoptosis	O
in	O
lymphocytes	B-cell_type
,	O
which	O
may	O
account	O
for	O
the	O
therapeutic	O
effects	O
of	O
glucocorticoids	O
in	O
various	O
diseases	O
including	O
leukemia	O
,	O
depends	O
on	O
the	O
glucocorticoid	B-protein
receptor	I-protein
.	O

However	O
,	O
the	O
events	O
leading	O
from	O
the	O
activated	O
receptor	O
to	O
cell	O
lysis	O
are	O
not	O
understood	O
.	O

A	O
prevailing	O
hypothesis	O
postulates	O
induction	O
of	O
so-called	O
'	O
lysis	B-DNA
genes	I-DNA
'	O
by	O
the	O
activated	B-protein
receptor	I-protein
.	O

In	O
this	O
study	O
,	O
we	O
show	O
that	O
an	O
activation-deficient	B-protein
glucocorticoid	I-protein
receptor	I-protein
mutant	I-protein
is	O
as	O
effective	O
as	O
the	O
wild-type	B-protein
receptor	I-protein
in	O
repression	O
of	O
AP-1	B-protein
activity	O
,	O
inhibition	O
of	O
interleukin-2	B-protein
production	O
,	O
inhibition	O
of	O
c-myc	B-DNA
expression	O
and	O
induction	O
of	O
apoptosis	O
.	O

Furthermore	O
,	O
we	O
show	O
that	O
retinoic	O
acid	O
can	O
also	O
induce	O
apoptosis	O
in	O
these	O
cells	O
through	O
the	O
retinoic	B-protein
acid	I-protein
receptor	I-protein
,	O
whose	O
repressive	O
functions	O
but	O
not	O
target	O
site	O
specificity	O
,	O
are	O
similar	O
to	O
those	O
of	O
the	O
glucocorticoid	B-protein
receptor	I-protein
.	O

Therefore	O
,	O
the	O
primary	O
effect	O
of	O
the	O
receptor	O
in	O
glucocorticoid-mediated	O
apoptosis	O
correlates	O
with	O
transcriptional	O
repression	O
rather	O
than	O
activation	O
and	O
could	O
be	O
mediated	O
by	O
interference	O
with	O
other	O
transcription	B-protein
factors	I-protein
required	O
for	O
cell	O
survival	O
.	O

HIV	O
type	O
1	O
protease	B-protein
activation	O
of	O
NF-kappa	B-protein
B	I-protein
within	O
T	B-cell_type
lymphoid	I-cell_type
cells	I-cell_type
.	O

NF-kappa	B-protein
B	I-protein
is	O
a	O
nuclear	B-protein
protein	I-protein
of	O
the	O
rel	B-protein
oncogene	I-protein
family	I-protein
capable	O
of	O
enhancing	O
transcription	O
of	O
several	B-DNA
cellular	I-DNA
genes	I-DNA
,	O
including	O
IL-2	B-protein
and	O
the	O
IL-2	B-protein
receptor	I-protein
,	O
and	O
viral	B-DNA
genes	I-DNA
transcribed	O
from	O
the	O
HIV-1	B-DNA
LTR	I-DNA
.	O

It	O
has	O
been	O
reported	O
that	O
HIV-1	B-protein
protease	I-protein
may	O
cleave	O
the	O
NF-kappa	B-protein
B	I-protein
precursor	O
to	O
its	O
active	O
form	O
in	O
vitro	O
.	O

In	O
this	O
study	O
the	O
effects	O
of	O
HIV	O
protease	O
on	O
NF-kappa	B-protein
B	I-protein
precursor	O
activation	O
were	O
examined	O
in	O
Jurkat	O
T	B-cell_type
cells	I-cell_type
by	O
introducing	O
a	O
protease	B-DNA
expression	I-DNA
vector	I-DNA
into	O
the	O
cells	O
.	O

Increased	O
NF-kappa	B-protein
B	I-protein
activity	O
was	O
observed	O
and	O
this	O
increased	O
activity	O
was	O
blocked	O
by	O
a	O
specific	O
inhibitor	O
of	O
the	O
viral	B-protein
protease	I-protein
.	O

Viral	O
transcription	O
,	O
as	O
measured	O
using	O
LTR	B-DNA
-CAT	B-protein
assays	O
,	O
was	O
only	O
slightly	O
enhanced	O
in	O
the	O
HIV-protease	B-cell_type
expressing	I-cell_type
cells	I-cell_type
,	O
while	O
secretion	O
of	O
IL-2	B-protein
and	O
expression	O
of	O
the	O
IL-2	B-protein
receptor	O
were	O
not	O
affected	O
.	O

The	O
limited	O
activation	O
of	O
NF-kappa	B-protein
B	I-protein
by	O
HIV	B-protein
protease	I-protein
appears	O
unlikely	O
to	O
have	O
a	O
significant	O
effect	O
on	O
virus	O
expression	O
or	O
T	O
cell	O
function	O
.	O

Inhibition	O
of	O
human	O
immunodeficiency	O
virus	O
type	O
1	O
replication	O
by	O
a	O
Tat-activated	B-DNA
,	I-DNA
transduced	I-DNA
interferon	I-DNA
gene	I-DNA
:	O
targeted	O
expression	O
to	O
human	B-cell_type
immunodeficiency	I-cell_type
virus	I-cell_type
type	I-cell_type
1-infected	I-cell_type
cells	I-cell_type
.	O

We	O
have	O
examined	O
the	O
feasibility	O
of	O
using	O
interferon	B-protein
(	O
IFN	B-protein
)	O
gene	O
transfer	O
as	O
a	O
novel	O
approach	O
to	O
anti-human	O
immunodeficiency	O
virus	O
type	O
1	O
(	O
HIV-1	O
)	O
therapy	O
in	O
this	O
study	O
.	O

To	O
limit	O
expression	O
of	O
a	O
transduced	O
HIV-1	B-DNA
long	I-DNA
terminal	I-DNA
repeat	I-DNA
(	I-DNA
LTR	I-DNA
)	I-DNA
-IFNA2	I-DNA
(	O
the	O
new	O
approved	O
nomenclature	O
for	O
IFN	B-DNA
genes	I-DNA
is	O
used	O
throughout	O
this	O
article	O
)	O
hybrid	B-DNA
gene	I-DNA
to	O
the	O
HIV-1-infected	B-cell_line
cells	I-cell_line
,	O
HIV-1	B-DNA
LTR	I-DNA
was	O
modified	O
.	O

Deletion	O
of	O
the	O
NF-kappa	B-DNA
B	I-DNA
elements	I-DNA
of	O
the	O
HIV-1	B-DNA
LTR	I-DNA
significantly	O
inhibited	O
Tat	B-protein
-mediated	O
transactivation	O
in	O
T-cell	B-cell_line
lines	I-cell_line
,	O
as	O
well	O
as	O
in	O
a	O
monocyte	B-cell_line
line	I-cell_line
,	O
U937	B-cell_line
.	O

Replacement	O
of	O
the	O
NF-kappa	B-DNA
B	I-DNA
elements	I-DNA
in	O
the	O
HIV-1	B-DNA
LTR	I-DNA
by	O
a	O
DNA	B-DNA
fragment	I-DNA
derived	O
from	O
the	O
5'-flanking	B-DNA
region	I-DNA
of	O
IFN-stimulated	B-DNA
gene	I-DNA
15	I-DNA
(	O
ISG15	B-DNA
)	O
,	O
containing	O
the	O
IFN-stimulated	B-DNA
response	I-DNA
element	I-DNA
,	O
partially	O
restored	O
Tat	B-protein
-mediated	O
activation	O
of	O
LTR	B-DNA
in	O
T	B-cell_type
cells	I-cell_type
as	O
well	O
as	O
in	O
monocytes	B-cell_type
.	O

Insertion	O
of	O
this	O
chimeric	B-DNA
promoter	I-DNA
(	O
ISG15	B-DNA
LTR	I-DNA
)	O
upstream	O
of	O
the	O
human	B-DNA
IFNA2	I-DNA
gene	I-DNA
directed	O
high	O
levels	O
of	O
IFN	B-protein
synthesis	O
in	O
Tat-expressing	B-cell_line
cells	I-cell_line
,	O
while	O
this	O
promoter	O
was	O
not	O
responsive	O
to	O
tumor	B-protein
necrosis	I-protein
factor	I-protein
alpha	I-protein
-mediated	O
activation	O
.	O

ISG15-LTR-IFN	B-DNA
hybrid	I-DNA
gene	I-DNA
inserted	O
into	O
the	O
retrovirus	B-DNA
vector	I-DNA
was	O
transduced	O
into	O
Jurkat	B-cell_line
and	O
U937	B-cell_line
cells	I-cell_line
.	O

Selected	O
transfected	B-cell_line
clones	I-cell_line
produced	O
low	O
levels	O
of	O
IFN	B-protein
A	I-protein
(	O
IFNA	B-protein
)	O
constitutively	O
,	O
and	O
their	O
abilities	O
to	O
express	O
interleukin-2	B-protein
and	O
interleukin-2	B-protein
receptor	I-protein
upon	O
stimulation	O
with	O
phytohemagglutinin	B-protein
and	O
phorbol	O
myristate	O
acetate	O
were	O
retained	O
.	O

Enhancement	O
of	O
IFNA	B-protein
synthesis	O
observed	O
upon	O
HIV-1	O
infection	O
resulted	O
in	O
significant	O
inhibition	O
of	O
HIV-1	O
replication	O
for	O
a	O
period	O
of	O
at	O
least	O
30	O
days	O
.	O

Virus	O
isolated	O
from	O
IFNA-producing	B-cell_line
cells	I-cell_line
was	O
able	O
to	O
replicate	O
in	O
the	O
U937	B-cell_line
cells	I-cell_line
but	O
did	O
not	O
replicate	O
efficiently	O
in	O
U937	B-cell_line
cells	I-cell_line
transduced	O
with	O
the	O
IFNA	B-DNA
gene	I-DNA
.	O

These	O
results	O
suggest	O
that	O
targeting	O
IFN	B-protein
synthesis	O
to	O
HIV-1-infected	B-cell_line
cells	I-cell_line
is	O
an	O
attainable	O
goal	O
and	O
that	O
autocrine	O
IFN	B-protein
synthesis	O
results	O
in	O
a	O
long-lasting	O
and	O
permanent	O
suppression	O
of	O
HIV-1	O
replication	O
.	O

Chromosomal	O
localization	O
of	O
two	O
KOX	B-DNA
zinc	I-DNA
finger	I-DNA
genes	I-DNA
on	O
chromosome	B-DNA
bands	I-DNA
7q21-q22	B-DNA
.	O

Human	B-DNA
cDNAs	I-DNA
encoding	O
Kruppel-type	B-protein
zinc	I-protein
finger	I-protein
domains	I-protein
,	O
designated	O
KOX	B-DNA
1-32	I-DNA
,	O
have	O
been	O
cloned	O
from	O
human	B-DNA
T	I-DNA
lymphocyte	I-DNA
cell	I-DNA
line	I-DNA
libraries	I-DNA
.	O

We	O
report	O
here	O
the	O
regional	O
localizations	O
by	O
in	O
situ	O
hybridization	O
of	O
KOX	B-DNA
18	I-DNA
and	O
KOX	B-DNA
25	I-DNA
on	O
chromosome	B-DNA
bands	I-DNA
7q21q22	I-DNA
.	O

Pulse-field	O
gel	O
electrophoresis	O
(	O
PFGE	O
)	O
analysis	O
showed	O
that	O
these	O
genes	O
are	O
physically	O
located	O
within	O
a	O
DNA	B-DNA
fragment	I-DNA
of	O
250	B-DNA
kb	I-DNA
.	O

The	O
genes	O
KOX	B-DNA
4	I-DNA
and	O
KOX	B-DNA
9	I-DNA
,	O
mapped	O
on	O
chromosome	B-DNA
8q24	I-DNA
,	O
were	O
found	O
to	O
be	O
located	O
within	O
a	O
DNA	B-DNA
fragment	I-DNA
of	O
450	O
kb	O
.	O

From	O
the	O
present	O
and	O
previous	O
data	O
,	O
eighteen	O
different	O
KOX	B-DNA
genes	I-DNA
have	O
been	O
located	O
at	O
least	O
two	O
by	O
two	O
within	O
nine	O
DNA	B-DNA
fragments	I-DNA
of	O
200	O
to	O
580	O
kb	O
.	O

Influence	O
of	O
age	O
on	O
the	O
production	O
of	O
Fos	B-protein
and	O
Jun	B-protein
by	O
influenza	B-cell_type
virus-exposed	I-cell_type
T	I-cell_type
cells	I-cell_type
.	O

This	O
study	O
investigated	O
age-related	O
T	O
cell	O
responses	O
after	O
in	O
vitro	O
exposure	O
to	O
influenza	O
A	O
virus	O
.	O

Mononuclear	B-cell_type
leukocytes	I-cell_type
from	O
young	O
or	O
elderly	O
persons	O
were	O
sham-exposed	O
or	O
exposed	O
to	O
influenza	O
virus	O
for	O
1	O
,	O
24	O
,	O
and	O
72	O
h	O
.	O

Immunofluorescent	O
staining	O
and	O
flow	O
cytometric	O
analysis	O
were	O
then	O
used	O
to	O
detect	O
T	B-cell_type
cells	I-cell_type
producing	O
the	O
transcriptional	B-protein
regulating	I-protein
proteins	I-protein
Fos	B-protein
and	O
Jun	B-protein
.	O

Fewer	O
virus-exposed	O
cells	O
from	O
elderly	O
donors	O
stained	O
for	O
Fos	B-protein
and	O
Jun	B-protein
at	O
each	O
data	O
point	O
compared	O
with	O
cells	O
from	O
young	O
donors	O
.	O

Flow	O
cytometric	O
analysis	O
also	O
showed	O
that	O
at	O
72	O
h	O
of	O
virus	O
exposure	O
fewer	O
T	B-cell_type
cells	I-cell_type
from	O
the	O
elderly	O
produced	O
interferon-gamma	B-protein
(	O
IFN-gamma	B-protein
)	O
,	O
suggesting	O
a	O
link	O
between	O
the	O
magnitude	O
of	O
the	O
Fos	B-protein
and	O
Jun	B-protein
and	O
IFN-gamma	B-protein
responses	O
.	O

Thus	O
,	O
failure	O
of	O
virus-exposed	B-cell_type
T	I-cell_type
cells	I-cell_type
to	O
produce	O
Fos	B-protein
and	O
Jun	B-protein
could	O
contribute	O
to	O
the	O
increase	O
in	O
illness	O
due	O
to	O
influenza	O
virus	O
in	O
the	O
elderly	O
.	O

The	O
regulation	O
of	O
HIV	O
by	O
retinoic	O
acid	O
correlates	O
with	O
cellular	O
expression	O
of	O
the	O
retinoic	B-protein
acid	I-protein
receptors	I-protein
.	O

OBJECTIVES	O
:	O
To	O
analyze	O
the	O
effect	O
of	O
retinoic	O
acids	O
(	O
RA	O
)	O
on	O
HIV-1	O
expression	O
and	O
correlate	O
this	O
effect	O
with	O
expression	O
levels	O
of	O
RA	B-protein
receptors	I-protein
(	O
RARs	B-protein
)	O
in	O
T-lymphoid	B-cell_line
and	I-cell_line
monocytoid	I-cell_line
cell	I-cell_line
lines	I-cell_line
.	O

DESIGN	O
AND	O
METHODS	O
:	O
The	O
effect	O
of	O
all-trans	O
and	O
9-cis	O
RA	O
on	O
HIV-1	O
production	O
in	O
T-lymphoid	B-cell_line
(	O
H9	B-cell_line
,	I-cell_line
CEM	I-cell_line
)	O
and	O
monocytoid	B-cell_line
(	I-cell_line
U937	I-cell_line
,	I-cell_line
THP-1	I-cell_line
)	I-cell_line
cell	I-cell_line
lines	I-cell_line
was	O
measured	O
during	O
acute	O
and	O
chronic	O
infection	O
.	O

The	O
expression	O
levels	O
of	O
human	B-protein
RAR	I-protein
alpha	I-protein
(	O
hRAR	B-protein
alpha	I-protein
,	I-protein
receptor	I-protein
for	O
all-trans	O
RA	O
)	O
and	O
the	O
human	B-protein
retinoid-X	I-protein
receptor	I-protein
alpha	I-protein
(	O
hRXR	B-protein
alpha	I-protein
receptor	I-protein
for	O
9-cis	O
RA	O
)	O
were	O
determined	O
by	O
Northern	O
blot	O
analysis	O
.	O

RESULTS	O
:	O
Both	O
all-trans	O
and	O
9-cis	O
RA	O
inhibited	O
virus	O
replication	O
in	O
HIV-1	B-cell_line
IIIB-infected	I-cell_line
monocytoid	I-cell_line
cells	I-cell_line
,	O
in	O
the	O
presence	O
and	O
absence	O
of	O
the	O
co-stimulatory	O
agent	O
phorbol	O
myristate	O
acetate	O
(	O
PMA	O
)	O
.	O

The	O
retinoids	O
had	O
weak	O
or	O
no	O
stimulatory	O
effects	O
on	O
HIV	O
production	O
by	O
T-cell	B-cell_line
lines	I-cell_line
.	O

HIV	O
production	O
by	O
PMA-stimulated	B-cell_line
T-cell	I-cell_line
lines	I-cell_line
was	O
inhibited	O
by	O
these	O
retinoids	O
.	O

The	O
9-cis	O
RA	O
was	O
generally	O
more	O
effective	O
than	O
all-trans	O
RA	O
in	O
inhibiting	O
HIV	O
production	O
and	O
in	O
combination	O
generally	O
more	O
effective	O
than	O
the	O
single	O
agents	O
alone	O
.	O

Human	B-protein
RAR	I-protein
alpha	I-protein
was	O
expressed	O
in	O
H9	B-cell_line
,	O
U937	B-cell_line
and	O
THP-1	B-cell_line
cells	I-cell_line
,	O
but	O
almost	O
undetectable	O
in	O
CEM	B-cell_line
cells	I-cell_line
.	O

Human	B-protein
RXR	I-protein
alpha	I-protein
was	O
significantly	O
expressed	O
in	O
U937	B-cell_line
and	I-cell_line
THP-1	I-cell_line
cells	I-cell_line
,	O
weakly	O
expressed	O
in	O
H9	B-cell_line
cells	I-cell_line
and	O
not	O
detectable	O
in	O
CEM	B-cell_line
cells	I-cell_line
.	O

After	O
stimulation	O
by	O
PMA	O
,	O
RXR	B-protein
alpha	I-protein
expression	O
increased	O
in	O
H9	B-cell_line
and	O
U937	B-cell_line
cells	I-cell_line
but	O
not	O
in	O
CEM	B-cell_line
cells	I-cell_line
.	O

Human	O
RAR	O
alpha	O
expression	O
was	O
unchanged	O
in	O
H9	B-cell_line
and	O
CEM	B-cell_line
cells	I-cell_line
,	O
and	O
elevated	O
in	O
U937	B-cell_line
cells	I-cell_line
,	O
after	O
PMA	O
stimulation	O
.	O

CONCLUSION	O
:	O
The	O
effect	O
of	O
RA	O
on	O
HIV-1	O
expression	O
was	O
cell-type-dependent	O
and	O
partially	O
correlated	O
with	O
cellular	O
expression	O
of	O
RARs	B-protein
.	O

Endogenous	O
or	O
exogenously	O
administered	O
RA	O
may	O
have	O
a	O
significant	O
role	O
in	O
HIV	O
regulation	O
.	O

Functions	O
of	O
glutathione	O
and	O
glutathione	O
disulfide	O
in	O
immunology	O
and	O
immunopathology	O
.	O

Even	O
a	O
moderate	O
increase	O
in	O
the	O
cellular	O
cysteine	O
supply	O
elevates	O
the	O
intracellular	O
glutathione	O
(	O
GSH	O
)	O
and	O
glutathione	O
disulfide	O
(	O
GSSG	O
)	O
levels	O
and	O
potentiates	O
immunological	O
functions	O
of	O
lymphocytes	B-cell_type
in	O
vitro	O
.	O

At	O
low	O
GSSG	O
levels	O
,	O
T	B-cell_type
cells	I-cell_type
can	O
not	O
optimally	O
activate	O
the	O
immunologically	O
important	O
transcription	B-protein
factor	I-protein
NF	B-protein
kappa	I-protein
B	I-protein
,	O
whereas	O
high	O
GSSG	O
levels	O
inhibit	O
the	O
DNA	O
binding	O
activity	O
of	O
NF	B-protein
kappa	I-protein
B	I-protein
.	O

The	O
effects	O
of	O
GSSG	O
are	O
antagonized	O
by	O
reduced	O
thioredoxin	B-protein
(	O
TRX	B-protein
)	O
.	O

As	O
the	O
protein	B-protein
tyrosine	I-protein
kinase	I-protein
activities	O
p56lck	B-protein
and	O
p59fyn	B-protein
are	O
activated	O
in	O
intact	O
cells	O
by	O
hydrogen	O
peroxide	O
,	O
they	O
are	O
likely	O
targets	O
for	O
GSSG	O
action	O
.	O

These	O
redox-regulated	B-protein
enzymes	I-protein
trigger	O
signal	O
cascades	O
for	O
NF	B-protein
kappa	I-protein
B	I-protein
activation	O
and	O
transduce	O
signals	O
from	O
the	O
T	B-protein
cell	I-protein
antigen	I-protein
receptor	I-protein
,	O
from	O
CD4	B-protein
and	O
CD8	B-protein
molecules	I-protein
,	O
and	O
from	O
the	O
IL-2	B-protein
receptor	I-protein
beta-chain	I-protein
.	O

The	O
effector	O
phase	O
of	O
cytotoxic	B-cell_type
T	I-cell_type
cell	I-cell_type
responses	O
and	O
IL-2	B-protein
-dependent	O
functions	O
are	O
inhibited	O
even	O
by	O
a	O
partial	O
depletion	O
of	O
the	O
intracellular	O
GSH	O
pool	O
.	O

As	O
signal	O
transduction	O
is	O
facilitated	O
by	O
prooxidant	O
conditions	O
,	O
we	O
propose	O
that	O
the	O
well-known	O
immunological	O
consequences	O
of	O
GSH	O
depletion	O
ultimately	O
may	O
be	O
results	O
of	O
the	O
accompanying	O
GSSG	O
deficiency	O
.	O

As	O
HIV-infected	O
patients	O
and	O
SIV-infected	O
rhesus	O
macaques	O
have	O
,	O
on	O
the	O
average	O
,	O
significantly	O
decreased	O
plasma	O
cyst	O
(	O
e	O
)	O
ine	O
and	O
intracellular	O
GSH	O
levels	O
,	O
we	O
also	O
hypothesize	O
that	O
AIDS	O
may	O
be	O
the	O
consequence	O
of	O
a	O
GSSG	O
deficiency	O
as	O
well	O
.	O

T	B-cell_type
cells	I-cell_type
from	O
renal	O
cell	O
carcinoma	O
patients	O
exhibit	O
an	O
abnormal	O
pattern	O
of	O
kappa	O
B-specific	O
DNA-binding	O
activity	O
:	O
a	O
preliminary	O
report	O
.	O

Recent	O
data	O
suggest	O
that	O
the	O
poor	O
induction	O
of	O
a	O
T-cell	O
response	O
to	O
human	O
renal	O
cell	O
carcinoma	O
(	O
RCC	O
)	O
may	O
be	O
related	O
to	O
alterations	O
in	O
signal	O
transduction	O
pathways	O
.	O

We	O
report	O
that	O
T	B-cell_type
cells	I-cell_type
from	O
RCC	O
patients	O
have	O
two	O
alterations	O
in	O
kappa	O
B	O
motif-specific	O
DNA-binding	O
activity	O
.	O

The	O
first	O
alteration	O
involves	O
the	O
constitutive	O
expression	O
of	O
substantial	O
kappa	O
B-binding	O
activity	O
in	O
nuclear	O
extracts	O
,	O
which	O
was	O
observed	O
in	O
the	O
electrophoretic	O
mobility	O
shift	O
assay	O
.	O

The	O
magnitude	O
of	O
kappa	O
B	O
activity	O
in	O
unstimulated	B-cell_type
patient	I-cell_type
T	I-cell_type
cells	I-cell_type
was	O
similar	O
to	O
that	O
observed	O
in	O
T	B-cell_type
cells	I-cell_type
from	O
normal	O
individuals	O
that	O
had	O
been	O
activated	O
in	O
vitro	O
.	O

On	O
the	O
basis	O
of	O
Western	O
blotting	O
experiments	O
using	O
antibodies	B-protein
to	O
kappa	B-protein
B/Rel	I-protein
family	I-protein
proteins	I-protein
,	O
the	O
kappa	O
B-binding	O
activity	O
constitutively	O
expressed	O
in	O
T	B-cell_type
cells	I-cell_type
from	O
RCC	O
patients	O
is	O
composed	O
mostly	O
of	O
the	O
NF-kappa	B-protein
B1	I-protein
(	I-protein
p50	I-protein
)	I-protein
subunit	I-protein
.	O

The	O
second	O
abnormality	O
in	O
kappa	O
B-binding	O
activity	O
in	O
T	B-cell_type
cells	I-cell_type
from	O
these	O
patients	O
is	O
that	O
RelA	B-protein
,	O
a	O
member	O
of	O
the	O
Rel	B-protein
homology	I-protein
family	I-protein
which	O
is	O
part	O
of	O
the	O
normal	O
NF-kappa	B-protein
B	I-protein
complex	I-protein
,	O
was	O
not	O
induced	O
in	O
the	O
nucleus	O
following	O
activation	O
.	O

Western	O
blotting	O
analysis	O
did	O
not	O
detect	O
any	O
RelA	B-protein
in	O
nuclear	O
extracts	O
either	O
before	O
or	O
after	O
stimulation	O
of	O
T	B-cell_type
cells	I-cell_type
.	O

The	O
altered	O
kappa	O
B-binding	O
activity	O
in	O
T	B-cell_type
cells	I-cell_type
from	O
RCC	O
patients	O
may	O
impair	O
their	O
capacity	O
to	O
respond	O
normally	O
to	O
various	O
stimuli	O
.	O

Hemoglobin	B-protein
switching	O
in	O
humans	O
is	O
accompanied	O
by	O
changes	O
in	O
the	O
ratio	O
of	O
the	O
transcription	B-protein
factors	I-protein
,	O
GATA-1	B-protein
and	O
SP1	B-protein
.	O

BACKGROUND	O
:	O
Understanding	O
the	O
mechanism	O
of	O
developmental	O
regulation	O
of	O
hemoglobin	B-protein
switching	O
has	O
scientific	O
as	O
well	O
as	O
clinical	O
relevance	O
because	O
of	O
the	O
influence	O
of	O
fetal	O
hemoglobin	B-protein
(	O
HbF	B-protein
)	O
production	O
in	O
adulthood	O
on	O
the	O
clinical	O
manifestation	O
of	O
thalassemia	O
and	O
sickle	O
cell	O
anemia	O
.	O

We	O
have	O
previously	O
found	O
that	O
the	O
normal	O
developmental	O
patterns	O
of	O
globin	B-DNA
gene	I-DNA
expression	O
are	O
recapitulated	O
in	O
an	O
experimental	O
system	O
of	O
primary	B-cell_line
cultures	I-cell_line
that	O
support	O
differentiation	O
of	O
erythroid	B-cell_type
progenitors	I-cell_type
.	O

We	O
further	O
found	O
that	O
high	O
activities	O
of	O
the	O
transcriptional	B-protein
activators	I-protein
,	O
GATA-1	B-protein
and	O
SP1	B-protein
,	O
are	O
associated	O
with	O
normal	O
adult	O
erythroid	O
differentiation	O
.	O

MATERIALS	O
AND	O
METHODS	O
:	O
In	O
the	O
present	O
work	O
,	O
we	O
have	O
studied	O
,	O
the	O
activities	O
of	O
GATA-1	B-protein
and	O
SP1	B-protein
during	O
differentiation	O
of	O
cultured	O
erythroid	B-cell_type
progenitors	I-cell_type
derived	O
from	O
cord	O
blood	O
and	O
from	O
fetal	O
livers	O
,	O
as	O
well	O
as	O
from	O
beta	O
zero-thalassemia	O
patients	O
.	O

RESULTS	O
:	O
The	O
results	O
showed	O
high	O
GATA-1	B-protein
binding	O
activity	O
and	O
very	O
low	O
SP1	B-protein
activity	O
in	O
the	O
fetal	B-cell_line
liver	I-cell_line
cultures	I-cell_line
.	O

This	O
pattern	O
was	O
in	O
contrast	O
to	O
cultures	O
derived	O
from	O
normal	O
adult	O
peripheral	O
blood	O
,	O
in	O
which	O
both	O
GATA-1	B-protein
and	O
SP1	B-protein
activities	O
were	O
high	O
.	O

Cord	O
blood	O
cultures	O
showed	O
an	O
additive	O
combination	O
of	O
``	O
adult	O
''	O
and	O
``	O
fetal	O
''	O
patterns	O
.	O

The	O
progenitors	O
derived	O
from	O
a	O
beta	O
zero-thalassemia	O
patient	O
with	O
high	O
HbF	B-protein
production	O
showed	O
``	O
fetal	O
''	O
pattern	O
.	O

On	O
the	O
other	O
hand	O
,	O
in	O
cultures	O
of	O
2	O
beta	O
zero-thalassemia	O
patients	O
without	O
high	O
HbF	B-protein
,	O
``	O
adult	O
''	O
pattern	O
was	O
observed	O
.	O

CONCLUSIONS	O
:	O
In	O
the	O
present	O
work	O
,	O
we	O
show	O
that	O
human	B-cell_type
fetal	I-cell_type
and	I-cell_type
adult	I-cell_type
erythroid	I-cell_type
progenitors	I-cell_type
are	O
distinct	O
in	O
their	O
transcription	B-protein
factors	I-protein
,	O
and	O
that	O
the	O
commitment	O
to	O
fetal	O
or	O
adult	O
program	O
occurs	O
at	O
a	O
very	O
early	O
differentiation	O
stage	O
.	O

Our	O
studies	O
also	O
demonstrate	O
that	O
under	O
anemic	O
stress	O
,	O
recruitment	O
of	O
fetal	B-cell_type
progenitors	I-cell_type
may	O
occur	O
in	O
adulthood	O
.	O

Transcription-independent	O
turnover	O
of	O
I	B-protein
kappa	I-protein
B	I-protein
alpha	I-protein
during	O
monocyte	O
adherence	O
:	O
implications	O
for	O
a	O
translational	O
component	O
regulating	O
I	B-RNA
kappa	I-RNA
B	I-RNA
alpha/MAD-3	I-RNA
mRNA	I-RNA
levels	O
.	O

We	O
identified	O
I	B-protein
kappa	I-protein
B	I-protein
alpha/MAD-3	I-protein
as	O
an	O
immediate-early	B-DNA
gene	I-DNA
in	O
human	B-cell_type
monocytes	I-cell_type
that	O
is	O
expressed	O
in	O
response	O
to	O
a	O
variety	O
of	O
signals	O
,	O
including	O
adhesion	O
,	O
lipopolysaccharide	O
,	O
and	O
phorbol	O
myristate	O
acetate	O
.	O

Within	O
5	O
min	O
of	O
monocyte	O
adhesion	O
,	O
the	O
level	O
of	O
the	O
I	B-protein
kappa	I-protein
B	I-protein
alpha	I-protein
protein	I-protein
is	O
markedly	O
diminished	O
but	O
is	O
rapidly	O
replaced	O
in	O
a	O
cycloheximide-sensitive	O
manner	O
within	O
20	O
min	O
.	O

Accompanying	O
the	O
rapid	O
turnover	O
of	O
the	O
I	B-protein
kappa	I-protein
B	I-protein
alpha	I-protein
protein	I-protein
is	O
simultaneous	O
translocation	O
of	O
NF-kappa	B-protein
B-related	I-protein
transcription	I-protein
factors	I-protein
to	O
nuclei	O
of	O
adhered	O
monocytes	O
.	O

The	O
demonstration	O
that	O
NF-kappa	B-protein
B	I-protein
can	O
regulate	O
I	B-DNA
kappa	I-DNA
B	I-DNA
alpha/MAD-3	I-DNA
gene	I-DNA
transcription	O
in	O
other	O
cell	O
types	O
suggested	O
that	O
the	O
rapid	O
increase	O
in	O
steady-state	O
I	B-RNA
kappa	I-RNA
B	I-RNA
alpha/MAD-3	I-RNA
mRNA	I-RNA
levels	O
we	O
observed	O
within	O
30	O
min	O
of	O
monocyte	O
adherence	O
would	O
result	O
from	O
NF-kappa	B-protein
B	I-protein
-dependent	O
transcriptional	O
stimulation	O
of	O
the	O
I	B-DNA
kappa	I-DNA
B	I-DNA
alpha/MAD-3	I-DNA
gene	I-DNA
.	O

Nuclear	O
run-on	O
analyses	O
indicated	O
that	O
,	O
instead	O
,	O
while	O
several	O
immediate-early	B-DNA
cytokine	I-DNA
genes	I-DNA
,	O
such	O
as	O
the	O
interleukin	B-DNA
1	I-DNA
beta	I-DNA
(	I-DNA
IL-1	I-DNA
beta	I-DNA
)	I-DNA
gene	I-DNA
,	O
were	O
transcriptionally	O
activated	O
during	O
monocyte	O
adhesion	O
,	O
the	O
rate	O
of	O
I	B-DNA
kappa	I-DNA
B	I-DNA
alpha/MAD-3	I-DNA
gene	I-DNA
transcription	O
remained	O
constant	O
.	O

The	O
adherence-dependent	O
increase	O
in	O
I	B-RNA
kappa	I-RNA
B	I-RNA
alpha/MAD-3	I-RNA
mRNA	I-RNA
levels	O
was	O
also	O
not	O
a	O
consequence	O
of	O
mRNA	B-RNA
stabilization	O
events	O
.	O

Interestingly	O
,	O
while	O
increases	O
in	O
both	O
IL-1	O
beta	O
and	O
I	O
kappa	O
B	O
alpha/MAD-3	O
mRNA	O
levels	O
were	O
detected	O
in	O
nuclei	O
of	O
adherent	B-cell_type
monocytes	I-cell_type
,	O
cytoplasmic	O
levels	O
of	O
IL-1	B-RNA
beta	I-RNA
mRNA	I-RNA
increased	O
during	O
adherence	O
whereas	O
those	O
of	O
I	B-RNA
kappa	I-RNA
B	I-RNA
alpha/MAD-3	I-RNA
mRNA	I-RNA
did	O
not	O
.	O

Taken	O
together	O
,	O
our	O
data	O
suggest	O
that	O
two	O
interactive	O
mechanisms	O
regulate	O
monocytic	B-RNA
I	I-RNA
kappa	I-RNA
B	I-RNA
alpha/MAD-3	I-RNA
mRNA	I-RNA
levels	O
.	O

We	O
propose	O
that	O
adherent	B-cell_type
monocytes	I-cell_type
regulate	O
nuclear	O
processing	O
(	O
or	O
decay	O
)	O
of	O
I	B-RNA
kappa	I-RNA
B	I-RNA
alpha/MAD-3	I-RNA
mRNA	I-RNA
,	O
thereby	O
increasing	O
mRNA	O
levels	O
without	O
stimulating	O
I	B-DNA
kappa	I-DNA
B	I-DNA
alpha/MAD-3	I-DNA
gene	I-DNA
transcription	O
.	O

Moreover	O
,	O
since	O
inhibition	O
of	O
protein	O
synthesis	O
leads	O
to	O
accumulation	O
of	O
I	B-RNA
kappa	I-RNA
B	I-RNA
alpha/MAD-3	I-RNA
mRNA	I-RNA
without	O
stimulating	O
I	B-DNA
kappa	I-DNA
B	I-DNA
alpha/MAD-3	I-DNA
gene	I-DNA
transcription	O
,	O
we	O
suggest	O
that	O
low	O
cytoplasmic	O
levels	O
of	O
I	B-RNA
kappa	I-RNA
B	I-RNA
alpha/MAD-3	I-RNA
mRNA	I-RNA
are	O
maintained	O
by	O
a	O
translation-dependent	O
degradation	O
mechanism	O
.	O

Distinct	O
roles	O
of	O
the	O
molecular	O
chaperone	B-protein
hsp90	I-protein
in	O
modulating	O
dioxin	O
receptor	O
function	O
via	O
the	O
basic	O
helix-loop-helix	B-protein
and	O
PAS	B-protein
domains	I-protein
.	O

The	O
intracellular	B-protein
dioxin	I-protein
receptor	I-protein
mediates	O
signal	O
transduction	O
by	O
dioxin	O
and	O
functions	O
as	O
a	O
ligand-activated	B-protein
transcription	I-protein
factor	I-protein
.	O

It	O
contains	O
a	O
basic	B-protein
helix-loop-helix	I-protein
(	I-protein
bHLH	I-protein
)	I-protein
motif	I-protein
contiguous	O
with	O
a	O
Per-Arnt-Sim	B-protein
(	I-protein
PAS	I-protein
)	I-protein
homology	I-protein
region	I-protein
.	O

In	O
extracts	O
from	O
nonstimulated	O
cells	O
the	O
receptor	O
is	O
recovered	O
in	O
an	O
inducible	O
cytoplasmic	O
form	O
associated	O
with	O
the	O
90-kDa	B-protein
heat	I-protein
shock	I-protein
protein	I-protein
(	O
hsp90	B-protein
)	O
,	O
a	O
molecular	B-protein
chaperone	I-protein
.	O

We	O
have	O
reconstituted	O
ligand-dependent	O
activation	O
of	O
the	O
receptor	O
to	O
a	O
DNA-binding	B-protein
form	I-protein
by	O
using	O
the	O
dioxin	B-protein
receptor	I-protein
and	O
its	O
bHLH-PAS	B-protein
partner	I-protein
factor	I-protein
Arnt	B-protein
expressed	O
by	O
in	O
vitro	O
translation	O
in	O
reticulocyte	O
lysate	O
.	O

Deletion	O
of	O
the	O
PAS	B-protein
domain	I-protein
of	O
the	O
receptor	O
resulted	O
in	O
constitutive	O
dimerization	O
with	O
Arnt	B-protein
.	O

In	O
contrast	O
,	O
this	O
receptor	O
mutant	O
showed	O
low	O
levels	O
of	O
xenobiotic	O
response	O
element-binding	O
activity	O
,	O
indicating	O
that	O
the	O
PAS	B-protein
domain	I-protein
may	O
be	O
important	O
for	O
DNA-binding	O
affinity	O
and/or	O
specificity	O
of	O
the	O
receptor	O
.	O

It	O
was	O
not	O
possible	O
to	O
reconstitute	O
dioxin	B-protein
receptor	I-protein
function	O
with	O
proteins	O
expressed	O
in	O
wheat	O
germ	O
lysate	O
.	O

In	O
line	O
with	O
these	O
observations	O
,	O
reticulocyte	O
lysate	O
but	O
not	O
wheat	O
germ	O
lysate	O
promoted	O
the	O
association	O
of	O
de	O
novo	O
synthesized	O
dioxin	B-protein
receptor	I-protein
with	O
hsp90	B-protein
.	O

At	O
least	O
two	O
distinct	O
domains	O
of	O
the	O
receptor	O
mediated	O
interaction	O
with	O
hsp90	B-protein
:	O
the	O
ligand-binding	B-protein
domain	I-protein
located	O
within	O
the	O
PAS	B-protein
region	I-protein
and	O
,	O
surprisingly	O
,	O
the	O
bHLH	B-protein
domain	I-protein
.	O

Whereas	O
ligand-binding	O
activity	O
correlated	O
with	O
association	O
with	O
hsp90	B-protein
,	O
bHLH-	O
hsp90	B-protein
interaction	O
appeared	O
to	O
be	O
important	O
for	O
DNA-binding	O
activity	O
but	O
not	O
for	O
dimerization	O
of	O
the	O
receptor	O
.	O

Several	O
distinct	O
roles	O
for	O
hsp90	B-protein
in	O
modulating	O
dioxin	B-protein
receptor	I-protein
function	O
are	O
therefore	O
likely	O
:	O
correct	O
folding	O
of	O
the	O
ligand-binding	O
domain	O
,	O
interference	O
with	O
Arnt	B-protein
heterodimerization	O
,	O
and	O
folding	O
of	O
a	O
DNA-binding	O
conformation	O
of	O
the	O
bHLH	B-protein
domain	I-protein
.	O

Thus	O
,	O
the	O
dioxin	B-protein
receptor	I-protein
system	O
provides	O
a	O
complex	O
and	O
interesting	O
model	O
of	O
the	O
regulation	O
of	O
transcription	B-protein
factors	I-protein
by	O
hsp90	B-protein
.	O

Induction	O
of	O
transcription	B-protein
factors	I-protein
in	O
human	B-cell_type
T	I-cell_type
lymphocytes	I-cell_type
by	O
aspirin-like	O
drugs	O
.	O

Aspirin-like	O
drugs	O
(	O
ALD	O
)	O
induce	O
calcium	O
mobilization	O
,	O
an	O
essential	O
component	O
of	O
T	O
cell	O
activation	O
,	O
but	O
do	O
not	O
induce	O
the	O
biosynthesis	O
of	O
IL-2	B-protein
.	O

To	O
understand	O
the	O
extent	O
to	O
which	O
ALD	O
may	O
mimic	O
mitogenic	O
stimulation	O
,	O
we	O
studied	O
cytoplasmic	O
and	O
nuclear	O
signaling	O
steps	O
in	O
ALD-treated	B-cell_line
T	I-cell_line
cells	I-cell_line
.	O

We	O
found	O
that	O
ALD	O
induce	O
a	O
transient	O
activation	O
of	O
protein	B-protein
kinase	I-protein
(	O
PKC	B-protein
)	O
but	O
have	O
no	O
effect	O
(	O
in	O
comparison	O
to	O
anti-CD3	B-protein
antibodies	I-protein
)	O
on	O
protein	O
tyrosine	O
phosphorylation	O
nor	O
on	O
PCL	O
gamma	O
1	O
tyrosine	O
phosphorylation	O
.	O

ALD-induced	O
calcium	O
mobilization	O
and	O
PKC	B-protein
activation	O
are	O
independent	O
of	O
tyrosine	B-protein
protein	I-protein
kinase	I-protein
activity	O
as	O
shown	O
by	O
the	O
lack	O
of	O
effect	O
of	O
herbimycin	O
,	O
a	O
tyrosine-protein	B-protein
kinase	I-protein
-specific	O
inhibitor	O
.	O

Although	O
we	O
detected	O
no	O
IL-2	B-RNA
mRNA	I-RNA
in	O
ALD-treated	B-cell_line
cells	I-cell_line
,	O
the	O
nuclei	O
of	O
these	O
cells	O
contain	O
proteins	O
capable	O
of	O
binding	O
to	O
three	O
regulatory	B-DNA
sequences	I-DNA
in	O
the	O
IL-2	B-DNA
promoter	I-DNA
region	I-DNA
:	O
NFAT	B-protein
,	O
NF	B-protein
kappa	I-protein
B	I-protein
,	O
and	O
AP-1	B-protein
.	O

These	O
binding	O
activities	O
are	O
expressed	O
only	O
in	O
activated	B-cell_type
T	I-cell_type
cells	I-cell_type
.	O

The	O
expression	O
of	O
AP-1	B-protein
depended	O
on	O
calcium	O
mobilization	O
and	O
PKC	B-protein
activation	O
.	O

These	O
data	O
suggest	O
that	O
ALD	O
cause	O
transient	O
but	O
significant	O
changes	O
in	O
T	O
cell	O
transmembrane	O
signaling	O
,	O
although	O
some	O
events	O
induced	O
by	O
stimulation	O
with	O
anti-CD3	B-protein
antibodies	I-protein
are	O
not	O
induced	O
by	O
ALD	O
.	O

The	O
signal	O
is	O
transmitted	O
to	O
the	O
nucleus	O
and	O
induces	O
DNA-binding	O
activity	O
by	O
several	O
transcription	B-protein
factors	I-protein
.	O

However	O
,	O
the	O
ALD	O
stimulus	O
is	O
not	O
capable	O
of	O
causing	O
complete	O
T	O
cell	O
activation	O
.	O

Protein	B-protein
kinase	I-protein
C	I-protein
is	O
not	O
a	O
downstream	O
effector	O
of	O
p21ras	B-DNA
in	O
activated	B-cell_type
T	I-cell_type
cells	I-cell_type
.	O

The	O
aim	O
of	O
this	O
present	O
study	O
was	O
to	O
investigate	O
the	O
role	O
of	O
protein	B-protein
kinase	I-protein
C	I-protein
(	O
PKC	B-protein
)	O
,	O
downstream	O
of	O
p21ras	B-DNA
,	O
in	O
activating	O
interleukin-2	B-DNA
(	I-DNA
IL-2	I-DNA
)	I-DNA
gene	I-DNA
expression	O
.	O

It	O
has	O
been	O
reported	O
that	O
PKC	B-protein
is	O
an	O
effector	B-protein
of	O
p21ras	B-DNA
in	O
T	B-cell_type
cells	I-cell_type
.	O

Data	O
is	O
presented	O
,	O
using	O
the	O
potent	O
and	O
selective	O
PKC	B-protein
inhibitor	O
Ro	O
31-8425	O
and	O
transient	O
expression	O
of	O
a	O
constitutively	O
active	O
ras	O
mutant	O
,	O
which	O
clearly	O
shows	O
that	O
PKC	B-protein
is	O
not	O
downstream	O
of	O
p21ras	B-DNA
in	O
the	O
induction	O
of	O
NF-AT	B-protein
and	O
AP-1	B-protein
transcriptional	O
activity	O
and	O
in	O
the	O
expression	O
of	O
IL-2	B-protein
in	O
human	B-cell_line
Jurkat	I-cell_line
T	I-cell_line
cells	I-cell_line
.	O

Reporter	O
gene	O
experiments	O
demonstrated	O
that	O
NF-kappa	B-protein
B	I-protein
transcriptional	O
activity	O
is	O
not	O
affected	O
by	O
expression	O
of	O
activated	O
p21ras	B-DNA
.	O

The	O
signaling	O
pathways	O
involving	O
PKC	B-protein
activation	O
,	O
calcium	O
mobilization	O
and	O
ras	B-protein
activation	O
combine	O
to	O
provide	O
the	O
necessary	O
components	O
for	O
production	O
of	O
IL-2	B-protein
during	O
T	O
cell	O
activation	O
.	O

The	O
C-terminus	B-protein
of	O
the	O
B	B-protein
cell	I-protein
activator	I-protein
Oct-2	B-protein
functions	O
as	O
an	O
activation	B-protein
domain	I-protein
in	O
yeast	O
.	O

Oct-1	B-protein
and	O
Oct-2	B-protein
are	O
human	O
transcriptional	B-protein
activators	I-protein
that	O
bind	O
to	O
the	O
same	O
DNA	O
element	O
but	O
activate	O
distinct	O
sets	O
of	O
genes	O
.	O

We	O
expressed	O
these	O
factors	O
in	O
S.	O
cerevisiae	O
and	O
observed	O
greater	O
than	O
5-fold	O
stimulation	O
of	O
a	O
lacZ	B-DNA
reporter	I-DNA
gene	I-DNA
only	O
with	O
Oct-2	B-protein
.	O

Transfer	O
of	O
the	O
Oct-2	B-protein
C-terminal	I-protein
domain	I-protein
onto	O
either	O
Oct-1	B-protein
(	O
Oct1.2	B-protein
)	O
or	O
a	O
nonactivating	B-protein
DNA-binding	I-protein
domain	I-protein
from	O
GAL4	B-protein
created	O
activators	O
capable	O
of	O
greater	O
than	O
15	O
and	O
10-fold	O
stimulation	O
of	O
activity	O
,	O
respectively	O
.	O

Thus	O
,	O
the	O
C-terminus	B-protein
of	O
Oct-2	B-protein
is	O
sufficient	O
to	O
confer	O
activation	O
potential	O
to	O
nonactive	O
DNA-binding	B-DNA
fragments	I-DNA
in	O
yeast	O
.	O

Glucocorticoid-induced	O
apoptosis	O
of	O
lymphoid	B-cell_type
cells	I-cell_type
.	O

The	O
induction	O
of	O
cell	O
death	O
in	O
lymphoid	B-cell_type
cells	I-cell_type
by	O
glucocorticoids	O
is	O
one	O
of	O
the	O
earliest	O
and	O
most	O
thoroughly	O
studied	O
models	O
of	O
apoptosis	O
.	O

Although	O
the	O
exact	O
mechanism	O
by	O
which	O
apoptosis	O
occurs	O
in	O
lymphocytes	B-cell_type
is	O
unknown	O
many	O
biochemical	O
and	O
molecular	O
changes	O
have	O
been	O
shown	O
to	O
occur	O
in	O
these	O
cells	O
in	O
response	O
to	O
glucocorticoids	O
.	O

The	O
role	O
of	O
chromatin	B-DNA
degradation	O
and	O
endonucleases	B-protein
in	O
the	O
apoptotic	O
process	O
has	O
been	O
closely	O
studied	O
,	O
as	O
well	O
as	O
the	O
involvement	O
of	O
several	O
oncogenes	B-DNA
in	O
glucocorticoid-induced	O
cell	O
lysis	O
.	O

In	O
addition	O
,	O
the	O
clinical	O
importance	O
of	O
glucocorticoid-induced	O
apoptosis	O
in	O
the	O
treatment	O
of	O
lymphoid	O
neoplasms	O
has	O
recently	O
received	O
increased	O
attention	O
.	O

Interleukin-2	B-protein
induces	O
tyrosine	O
phosphorylation	O
and	O
nuclear	O
translocation	O
of	O
stat3	B-protein
in	O
human	B-cell_type
T	I-cell_type
lymphocytes	I-cell_type
.	O

An	O
early	O
biochemical	O
event	O
associated	O
with	O
T	O
cell	O
activation	O
through	O
the	O
interleukin-2	B-protein
receptor	I-protein
(	O
IL-2R	B-protein
)	O
is	O
tyrosine	O
phosphorylation	O
of	O
several	O
intracellular	O
substrates	O
.	O

The	O
exact	O
mechanism	O
by	O
which	O
IL-2	B-protein
regulates	O
transcription	O
of	O
different	O
genes	O
is	O
presently	O
unknown	O
.	O

Here	O
,	O
we	O
report	O
that	O
stimulation	O
through	O
the	O
IL-2R	B-protein
induced	O
tyrosine	O
phosphorylation	O
and	O
subsequent	O
nuclear	O
translocation	O
of	O
stat3	B-protein
,	O
a	O
newly	O
identified	O
member	O
of	O
the	O
signal	B-protein
transducers	I-protein
and	I-protein
activators	I-protein
of	I-protein
transcription	I-protein
(	I-protein
STAT	I-protein
)	I-protein
family	I-protein
of	O
proteins	O
.	O

In	O
contrast	O
,	O
stat1	O
proteins	O
were	O
not	O
tyrosine	O
phosphorylated	O
after	O
IL-2	B-protein
ligation	O
,	O
whereas	O
tyrosine-phosphorylated	B-protein
stat1	I-protein
proteins	I-protein
(	O
91	B-protein
and	I-protein
84	I-protein
kDa	I-protein
proteins	I-protein
)	O
were	O
translocated	O
to	O
the	O
nucleus	O
following	O
interferon-gamma	B-protein
treatment	O
of	O
HeLa	B-cell_line
cells	I-cell_line
.	O

Apart	O
from	O
stat3	B-protein
,	O
another	O
cytoplasmic	B-protein
protein	I-protein
was	O
tyrosine	O
phosphorylated	O
and	O
subsequently	O
translocated	O
to	O
the	O
nucleus	O
in	O
response	O
to	O
IL-2	B-protein
.	O

This	O
protein	O
had	O
an	O
apparent	O
molecular	O
mass	O
of	O
84	O
kDa	O
and	O
was	O
not	O
recognized	O
by	O
stat3	B-protein
or	O
stat1	B-protein
mAb	I-protein
or	O
antisera	O
.	O

Since	O
IL-2	B-protein
induced	O
nuclear	O
translocation	O
of	O
the	O
84	B-protein
kDa	I-protein
protein	I-protein
and	O
stat3	B-protein
followed	O
identical	O
kinetics	O
,	O
p84	B-protein
is	O
a	O
candidate	O
for	O
a	O
new	O
,	O
yet	O
undefined	O
,	O
member	O
of	O
the	O
STAT	O
family	O
.	O

Taken	O
together	O
,	O
we	O
report	O
that	O
IL-2	B-protein
induces	O
tyrosine	O
phosphorylation	O
and	O
subsequent	O
nuclear	O
translocation	O
of	O
stat3	B-protein
and	O
an	O
as	O
yet	O
undefined	O
84-kDa	B-protein
protein	I-protein
in	O
antigen-specific	B-cell_line
human	I-cell_line
T	I-cell_line
cell	I-cell_line
lines	I-cell_line
.	O

Human	O
T-cell	O
leukemia	O
virus	O
type	O
I	O
Tax	B-protein
activation	O
of	O
NF-kappa	B-protein
B/Rel	I-protein
involves	O
phosphorylation	O
and	O
degradation	O
of	O
I	B-protein
kappa	I-protein
B	I-protein
alpha	I-protein
and	O
RelA	B-protein
(	O
p65	B-protein
)	O
-mediated	O
induction	O
of	O
the	O
c-rel	B-DNA
gene	I-DNA
.	O

The	O
tax	O
gene	O
product	O
of	O
human	O
T-cell	O
leukemia	O
virus	O
type	O
I	O
(	O
HTLV-I	O
)	O
is	O
a	O
potent	O
transcriptional	B-protein
activator	I-protein
that	O
both	O
stimulates	O
viral	O
gene	O
expression	O
and	O
activates	O
an	O
array	O
of	O
cellular	B-DNA
genes	I-DNA
involved	O
in	O
T-cell	B-cell_type
growth	O
.	O

Tax	O
acts	O
indirectly	O
by	O
inducing	O
or	O
modifying	O
the	O
action	O
of	O
various	O
host	O
transcription	B-protein
factors	I-protein
,	O
including	O
members	O
of	O
the	O
NF-kappa	B-protein
B/Rel	I-protein
family	I-protein
of	O
enhancer-binding	B-protein
proteins	I-protein
.	O

In	O
resting	B-cell_type
T	I-cell_type
cells	I-cell_type
,	O
many	O
of	O
these	O
NF-kappa	B-protein
B/Rel	I-protein
factors	I-protein
are	O
sequestered	O
in	O
the	O
cytoplasm	O
by	O
various	O
ankyrin-rich	B-protein
inhibitory	I-protein
proteins	I-protein
,	O
including	O
I	B-protein
kappa	I-protein
B	I-protein
alpha	I-protein
.	O

HTLV-I	B-protein
Tax	I-protein
expression	O
leads	O
to	O
the	O
constitutive	O
nuclear	O
expression	O
of	O
biologically	O
active	O
NF-kappa	B-protein
B	I-protein
and	O
c-Rel	B-protein
complexes	I-protein
;	O
however	O
,	O
the	O
biochemical	O
mechanism	O
(	O
s	O
)	O
underlying	O
this	O
response	O
remains	O
poorly	O
understood	O
.	O

In	O
this	O
study	O
,	O
we	O
demonstrate	O
that	O
Tax	B-protein
-stimulated	O
nuclear	O
expression	O
of	O
NF-kappa	B-protein
B	I-protein
in	O
both	O
HTLV-I-infected	B-cell_line
and	I-cell_line
Tax-transfected	I-cell_line
human	I-cell_line
T	I-cell_line
cells	I-cell_line
is	O
associated	O
with	O
the	O
phosphorylation	O
and	O
rapid	O
proteolytic	O
degradation	O
of	O
I	B-protein
kappa	I-protein
B	I-protein
alpha	I-protein
.	O

In	O
contrast	O
to	O
prior	O
in	O
vitro	O
studies	O
,	O
at	O
least	O
a	O
fraction	O
of	O
the	O
phosphorylated	O
form	O
of	O
I	B-protein
kappa	I-protein
B	I-protein
alpha	I-protein
remains	O
physically	O
associated	O
with	O
the	O
NF-kappa	B-protein
B	I-protein
complex	I-protein
in	O
vivo	O
but	O
is	O
subject	O
to	O
rapid	O
degradation	O
,	O
thereby	O
promoting	O
the	O
nuclear	O
translocation	O
of	O
the	O
active	O
NF-kappa	B-protein
B	I-protein
complex	I-protein
.	O

We	O
further	O
demonstrate	O
that	O
Tax	B-protein
induction	O
of	O
nuclear	O
c-Rel	B-protein
expression	O
is	O
activated	O
by	O
the	O
RelA	B-protein
(	O
p65	B-protein
)	O
subunit	O
of	O
NF-kappa	B-protein
B	I-protein
,	O
which	O
activates	O
transcription	O
of	O
the	O
c-rel	B-DNA
gene	I-DNA
through	O
an	O
intrinsic	O
kappa	B-DNA
B	I-DNA
enhancer	I-DNA
element	I-DNA
.	O

In	O
normal	O
cells	O
,	O
the	O
subsequent	O
accumulation	O
of	O
nuclear	B-protein
c-Rel	I-protein
acts	O
to	O
inhibit	O
its	O
own	O
continued	O
production	O
,	O
indicating	O
the	O
presence	O
of	O
an	O
autoregulatory	O
loop	O
.	O

(	O
ABSTRACT	O
TRUNCATED	O
AT	O
250	O
WORDS	O
)	O

Activation	O
of	O
NF-kappa	B-protein
B	I-protein
in	O
vivo	O
is	O
regulated	O
by	O
multiple	O
phosphorylations	O
.	O

The	O
activation	O
of	O
nuclear	B-protein
factor	I-protein
kappa	I-protein
B	I-protein
(	O
NF-kappa	B-protein
B	I-protein
)	O
in	O
intact	O
cells	O
is	O
mechanistically	O
not	O
well	O
understood	O
.	O

Therefore	O
we	O
investigated	O
the	O
modifications	O
imposed	O
on	O
NF-kappa	B-protein
B/I	I-protein
kappa	I-protein
B	I-protein
components	I-protein
following	O
stimulation	O
and	O
show	O
that	O
the	O
final	O
step	O
of	O
NF-kappa	B-protein
B	I-protein
induction	O
in	O
vivo	O
involves	O
phosphorylation	O
of	O
several	O
members	O
of	O
the	O
NF-kappa	B-protein
B/I	I-protein
kappa	I-protein
B	I-protein
protein	I-protein
families	I-protein
.	O

In	O
HeLa	B-cell_line
cells	I-cell_line
as	O
well	O
as	O
in	O
B	B-cell_type
cells	I-cell_type
,	O
TNF-alpha	O
rapidly	O
induced	O
nuclear	O
translocation	O
primarily	O
of	O
p50-p65	B-protein
,	O
but	O
not	O
of	O
c-rel	B-protein
.	O

Both	O
NF-kappa	B-protein
B	I-protein
precursors	O
and	O
I	B-protein
kappa	I-protein
B	I-protein
alpha	I-protein
became	O
strongly	O
phosphorylated	O
with	O
the	O
same	O
kinetics	O
.	O

In	O
addition	O
to	O
the	O
inducible	O
phosphorylation	O
after	O
stimulation	O
,	O
B	B-cell_type
lymphocytes	I-cell_type
containing	O
constitutive	O
nuclear	O
NF-kappa	B-protein
B	I-protein
revealed	O
constitutively	O
phosphorylated	O
p65	B-protein
and	O
I	B-protein
kappa	I-protein
B	I-protein
alpha	I-protein
.	O

Phosphorylation	O
was	O
accompanied	O
by	O
induced	O
processing	O
of	O
the	O
precursors	O
p100	B-protein
and	O
p105	B-protein
and	O
by	O
degradation	O
of	O
I	B-protein
kappa	I-protein
B	I-protein
alpha	I-protein
.	O

As	O
an	O
in	O
vitro	O
model	O
we	O
show	O
that	O
phosphorylation	O
of	O
p105	B-protein
impedes	O
its	O
ability	O
to	O
interact	O
with	O
NF-kappa	B-protein
B	I-protein
,	O
as	O
has	O
been	O
shown	O
before	O
for	O
I	B-protein
kappa	I-protein
B	I-protein
alpha	I-protein
.	O

Surprisingly	O
,	O
even	O
p65	B-protein
,	O
but	O
not	O
c-rel	B-protein
,	O
was	O
phosphorylated	O
after	O
induction	O
in	O
vivo	O
,	O
suggesting	O
that	O
TNF-alpha	B-protein
selectively	O
activates	O
only	O
specific	O
NF-kappa	B-protein
B	I-protein
heteromers	O
and	O
that	O
modifications	O
regulate	O
not	O
only	O
I	B-protein
kappa	I-protein
B	I-protein
molecules	I-protein
but	O
also	O
NF-kappa	B-protein
B	I-protein
molecules	O
.	O

In	O
fact	O
,	O
cellular	O
NF-kappa	B-protein
B	I-protein
activity	O
was	O
phosphorylation-dependent	O
and	O
the	O
DNA	O
binding	O
activity	O
of	O
p65-containing	B-protein
NF-kappa	I-protein
B	I-protein
was	O
enhanced	O
by	O
phosphorylation	O
in	O
vitro	O
.	O

Furthermore	O
,	O
we	O
found	O
that	O
the	O
induction	O
by	O
hydrogen	O
peroxide	O
of	O
NF-kappa	B-protein
B	I-protein
translocation	O
to	O
the	O
nucleus	O
,	O
which	O
is	O
assumed	O
to	O
be	O
triggered	O
by	O
reactive	O
oxygen	O
intermediates	O
,	O
also	O
coincided	O
with	O
incorporation	O
of	O
phosphate	O
into	O
the	O
same	O
subunits	O
that	O
were	O
modified	O
after	O
stimulation	O
by	O
TNF-alpha	B-protein
.	O

Thus	O
,	O
phosphorylation	O
appears	O
to	O
be	O
a	O
general	O
mechanism	O
for	O
activation	O
of	O
NF-kappa	B-protein
B	I-protein
in	O
vivo	O
.	O

Treatment	O
of	O
HL60	B-cell_line
cells	I-cell_line
with	O
various	O
combinations	O
of	O
retinoids	O
and	O
1	O
alpha	O
,	O
25	O
dihydroxyvitamin	O
D3	O
results	O
in	O
differentiation	O
towards	O
neutrophils	B-cell_type
or	O
monocytes	B-cell_type
or	O
a	O
failure	O
to	O
differentiate	O
and	O
apoptosis	O
.	O

It	O
is	O
well	O
documented	O
that	O
treatment	O
of	O
serum-grown	B-cell_line
HL60	I-cell_line
cells	I-cell_line
with	O
10	O
(	O
-7	O
)	O
M	O
all-trans	O
retinoic	O
acid	O
(	O
all-trans	O
RA	O
)	O
induces	O
neutrophil	B-cell_type
differentiation	O
,	O
whereas	O
treatment	O
with	O
10	O
(	O
-7	O
)	O
M	O
1	O
alpha	O
,	O
25	O
dihydroxyvitamin	O
D3	O
(	O
D3	O
)	O
induces	O
differentiation	O
towards	O
monocytes	B-cell_type
.	O

In	O
recent	O
investigations	O
,	O
using	O
serum-free	B-cell_line
grown	I-cell_line
HL60	I-cell_line
cells	I-cell_line
,	O
we	O
observed	O
that	O
all-trans	O
RA	O
,	O
at	O
10	O
(	O
-7	O
)	O
M	O
,	O
did	O
not	O
induce	O
neutrophil	O
differentiation	O
and	O
that	O
all-trans	O
RA	O
,	O
at	O
10	O
(	O
-8	O
)	O
M	O
,	O
reduced	O
the	O
D3	O
concentration	O
required	O
for	O
monocyte	B-cell_type
differentiation	O
to	O
5	O
x	O
10	O
(	O
-9	O
)	O
M	O
.	O

In	O
this	O
study	O
,	O
co-operative	O
interactions	O
between	O
all-trans	O
and	O
9-cis	O
RA	O
and	O
D3	O
which	O
promote	O
neutrophil	O
and	O
monocyte	O
differentiation	O
of	O
HL60	B-cell_line
cells	I-cell_line
have	O
been	O
analysed	O
in	O
detail	O
.	O

Treatment	O
of	O
serum-free	B-cell_line
grown	I-cell_line
HL60	I-cell_line
cells	I-cell_line
with	O
5	O
x	O
10	O
(	O
-7	O
)	O
M	O
all-trans	O
RA	O
or	O
9-cis	O
RA	O
resulted	O
in	O
sub-optimal	O
neutrophil	O
differentiation	O
(	O
up	O
to	O
25	O
%	O
mature	O
cells	O
)	O
.	O

As	O
shown	O
for	O
all-trans	O
RA	O
,	O
9-cis	O
RA	O
cooperated	O
with	O
D3	O
to	O
promote	O
monocyte	O
differentiation	O
.	O

Culture	O
of	O
HL60	B-cell_line
cells	I-cell_line
in	O
5	O
x	O
10	O
(	O
-7	O
)	O
M	O
9-cis	O
RA	O
together	O
with	O
a	O
wide	O
range	O
of	O
concentrations	O
of	O
D3	O
resulted	O
in	O
promotion	O
of	O
neutrophil	O
differentiation	O
at	O
10	O
(	O
-15	O
)	O
-10	O
(	O
-12	O
)	O
D3	O
,	O
a	O
failure	O
to	O
differentiate	O
and	O
apoptosis	O
at	O
10	O
(	O
-11	O
)	O
-10	O
(	O
-10	O
)	O
M	O
D3	O
,	O
followed	O
by	O
co-operativity	O
between	O
9-cis	O
RA	O
and	O
5	O
x	O
10	O
(	O
-9	O
)	O
M	O
D3	O
in	O
inducing	O
monocyte	O
differentiation	O
in	O
the	O
absence	O
of	O
neutrophil	O
differentiation	O
.	O

Similar	O
results	O
were	O
obtained	O
when	O
HL60	B-cell_line
cells	I-cell_line
were	O
treated	O
with	O
5	O
x	O
10	O
(	O
-7	O
)	O
all-trans	O
RA	O
together	O
with	O
a	O
wide	O
range	O
of	O
concentrations	O
of	O
D3	O
.	O

Cross	O
titration	O
analyses	O
of	O
the	O
effects	O
of	O
9-cis	O
RA	O
and	O
D3	O
on	O
HL60	B-cell_line
cell	I-cell_line
differentiation	O
were	O
undertaken	O
to	O
determine	O
the	O
boundaries	O
of	O
the	O
concentrations	O
of	O
each	O
agent	O
,	O
alone	O
and	O
in	O
combination	O
,	O
that	O
give	O
rise	O
to	O
optimal	O
neutrophil	O
and	O
monocyte	O
differentiation	O
of	O
HL60	B-cell_line
cells	I-cell_line
.	O

The	O
observed	O
cooperativities	O
between	O
either	O
9-cis	O
RA	O
or	O
all-trans	O
RA	O
and	O
D3	O
have	O
important	O
implications	O
for	O
the	O
use	O
of	O
combinations	O
of	O
these	O
agents	O
in	O
differentiation	O
therapy	O
.	O

Isolation	O
of	O
differentially	O
expressed	O
sequence	O
tags	O
from	O
steroid-responsive	B-cell_type
cells	I-cell_type
using	O
mRNA	B-RNA
differential	O
display	O
.	O

Transcriptional	O
control	O
of	O
steroid-regulated	B-DNA
gene	I-DNA
networks	I-DNA
by	O
nuclear	B-protein
receptor	I-protein
proteins	I-protein
results	O
in	O
the	O
coordinate	O
expression	O
of	O
a	O
limited	O
number	O
of	O
target	B-DNA
genes	I-DNA
.	O

Although	O
much	O
is	O
known	O
about	O
the	O
structure	O
and	O
function	O
of	O
steroid	O
receptors	O
,	O
relatively	O
few	O
cell-specific	O
steroid-regulated	O
genes	O
have	O
been	O
isolated	O
and	O
characterized	O
.	O

In	O
this	O
paper	O
we	O
describe	O
results	O
using	O
mRNA	B-RNA
differential	O
display	O
reverse	B-protein
transcriptase	I-protein
PCR	O
(	O
DDPCR	O
)	O
to	O
identify	O
and	O
isolate	O
short	O
cDNA	O
sequence	O
tags	O
from	O
thymocyte	B-cell_type
and	O
prostate	B-cell_type
cells	I-cell_type
under	O
various	O
hormone	O
conditions	O
.	O

Using	O
this	O
technique	O
we	O
have	O
isolated	O
several	O
differentially	B-DNA
expressed	I-DNA
sequence	I-DNA
tags	I-DNA
(	O
DESTs	B-DNA
)	O
from	O
the	O
mouse	B-cell_line
thymocyte	I-cell_line
cell	I-cell_line
line	I-cell_line
WEHI	B-cell_line
7.2	I-cell_line
.	O

Two	O
of	O
these	O
DESTs	B-DNA
,	O
GIG10	B-DNA
and	O
GIG18	B-DNA
,	O
are	O
rapidly	O
induced	O
by	O
dexamethasone	O
within	O
2	O
h	O
of	O
treatment	O
.	O

GIG10	B-DNA
is	O
a	O
novel	O
sequence	O
and	O
GIG18	B-DNA
is	O
the	O
mouse	O
homologue	O
of	O
a	O
human	B-DNA
expressed	I-DNA
sequence	I-DNA
tag	I-DNA
isolated	O
from	O
activated	B-cell_type
B	I-cell_type
lymphocytes	I-cell_type
.	O

We	O
also	O
used	O
DDPCR	O
to	O
isolate	O
DESTs	B-DNA
from	O
androgen-modulated	O
rat	O
ventral	O
prostate	O
tissue	O
,	O
one	O
of	O
which	O
we	O
characterized	O
and	O
found	O
to	O
correspond	O
to	O
the	O
3	B-RNA
'	I-RNA
end	I-RNA
of	O
prostatic	B-RNA
spermine	I-RNA
binding	I-RNA
protein	I-RNA
mRNA	I-RNA
,	O
a	O
known	O
androgen-regulated	B-DNA
gene	I-DNA
.	O

Modifications	O
of	O
the	O
original	O
DDPCR	O
protocol	O
,	O
which	O
we	O
found	O
can	O
potentially	O
decrease	O
the	O
frequency	O
of	O
isolating	O
false-positive	O
DESTs	B-DNA
,	O
are	O
described	O
and	O
the	O
merits	O
of	O
DDPCR	O
,	O
relative	O
to	O
other	O
differential	O
cDNA	O
cloning	O
strategies	O
,	O
are	O
discussed	O
.	O

Activation	O
of	O
human	B-cell_type
thymocytes	I-cell_type
after	O
infection	O
by	O
EBV	O
.	O

The	O
discovery	O
of	O
EBV	O
in	O
certain	O
T	O
cell	O
malignancies	O
and	O
the	O
expression	O
of	O
the	O
EBV	B-protein
receptor	I-protein
,	O
CR2/CD21	B-protein
,	O
on	O
a	O
population	O
of	O
immature	B-cell_type
thymocytes	I-cell_type
,	O
T	B-cell_line
lymphoblastoid	I-cell_line
cell	I-cell_line
lines	I-cell_line
,	O
and	O
childhood	B-cell_type
acute	I-cell_type
T	I-cell_type
lymphoblastic	I-cell_type
leukemia	I-cell_type
cells	I-cell_type
suggested	O
that	O
EBV-receptor	O
interactions	O
on	O
T	B-cell_type
cells	I-cell_type
may	O
be	O
of	O
importance	O
.	O

We	O
have	O
shown	O
that	O
,	O
within	O
the	O
thymus	O
,	O
a	O
population	O
of	O
large	B-cell_type
,	I-cell_type
immature	I-cell_type
cells	I-cell_type
expresses	O
CD21	B-protein
.	O

EBV	O
altered	O
the	O
activation	O
responses	O
of	O
immature	B-cell_type
thymocytes	I-cell_type
in	O
vitro	O
.	O

Triggering	O
through	O
CD2	B-protein
is	O
mitogenic	O
for	O
mature	O
,	O
but	O
not	O
immature	O
,	O
T	B-cell_type
cells	I-cell_type
.	O

However	O
,	O
during	O
infection	O
by	O
EBV	O
,	O
ligation	O
of	O
CD2	B-protein
caused	O
thymocytes	B-cell_type
to	O
proliferate	O
in	O
the	O
absence	O
of	O
exogenous	B-protein
cytokines	I-protein
.	O

This	O
function	O
was	O
a	O
result	O
of	O
the	O
interaction	O
of	O
EBV	O
with	O
its	O
receptor	O
,	O
CD21	B-protein
,	O
but	O
was	O
caused	O
by	O
infection	O
rather	O
than	O
surface	O
signaling	O
,	O
because	O
neither	O
specific	B-protein
mAb	I-protein
nor	O
the	O
P3HR-1	O
strain	O
of	O
virus	O
mimicked	O
the	O
effect	O
of	O
B95-8	O
.	O

Immature	O
thymocytes	B-cell_type
were	O
infected	O
by	O
EBV	O
,	O
as	O
determined	O
by	O
the	O
internalization	O
of	O
the	O
viral	B-DNA
genome	I-DNA
and	O
its	O
transcriptional	O
activity	O
.	O

Consistent	O
with	O
the	O
activity	O
of	O
B95-8	B-protein
,	O
EBNA-2	B-RNA
transcripts	I-RNA
were	O
identified	O
within	O
infected	B-cell_line
thymocyte	I-cell_line
populations	I-cell_line
.	O

In	O
addition	O
,	O
components	O
of	O
the	O
viral	O
replicative	O
pathway	O
were	O
expressed	O
during	O
infection	O
of	O
thymocytes	B-cell_type
.	O

These	O
components	O
included	O
transcription	O
of	O
BZLF-1	B-DNA
,	O
an	O
early	B-DNA
gene	I-DNA
that	O
characterizes	O
EBV-infected	B-cell_type
B	I-cell_type
cells	I-cell_type
after	O
disruption	O
of	O
latency	O
.	O

A	O
second	O
transcript	O
was	O
identified	O
as	O
encoding	O
the	O
recently	O
characterized	O
RAZ	B-protein
,	O
which	O
also	O
is	O
associated	O
with	O
replicative	O
infection	O
.	O

The	O
consequences	O
of	O
EBV	O
infection	O
of	O
T	B-cell_type
cells	I-cell_type
at	O
an	O
early	O
stage	O
of	O
differentiation	O
may	O
lead	O
to	O
failure	O
of	O
normal	O
T	O
cell	O
repertoire	O
development	O
,	O
autoimmunity	O
,	O
or	O
malignancy	O
.	O

Effects	O
of	O
intranasal	O
glucocorticoids	O
on	O
endogenous	O
glucocorticoid	O
peripheral	O
and	O
central	O
function	O
.	O

Glucocorticoids	O
are	O
among	O
the	O
most	O
potent	O
antiinflammatory	O
agents	O
that	O
can	O
be	O
used	O
in	O
the	O
treatment	O
of	O
rhinitis	O
.	O

Their	O
mechanisms	O
of	O
action	O
are	O
multiple	O
and	O
complex	O
and	O
a	O
number	O
of	O
reports	O
describe	O
significant	O
systemic	O
effects	O
of	O
locally	O
administered	O
glucocorticoids	O
.	O

In	O
order	O
to	O
evaluate	O
the	O
short-term	O
systemic	O
effects	O
of	O
intranasally	O
administered	O
glucocorticoids	O
,	O
14	O
normal	O
healthy	O
subjects	O
were	O
treated	O
with	O
two	O
doses	O
of	O
either	O
budesonide	O
(	O
BUD	O
)	O
or	O
fluticasone	O
propionate	O
(	O
FP	O
)	O
for	O
2	O
weeks	O
.	O

Before	O
treatment	O
,	O
at	O
regular	O
intervals	O
during	O
the	O
treatment	O
,	O
1	O
week	O
and	O
finally	O
6	O
weeks	O
after	O
termination	O
of	O
treatment	O
,	O
the	O
effects	O
on	O
glucocorticoid	O
receptor	O
(	O
GR	O
)	O
and	O
methallothionein	O
(	O
MTIIa	O
)	O
mRNA	O
expression	O
levels	O
were	O
examined	O
in	O
peripheral	B-cell_type
lymphocytes	I-cell_type
using	O
a	O
solution	O
hybridization	O
assay	O
.	O

Serum	O
cortisol	O
,	O
osteocalcin	O
and	O
urinary	O
cortisol	O
levels	O
were	O
also	O
determined	O
.	O

An	O
insulin	O
tolerance	O
test	O
(	O
ITT	O
)	O
was	O
performed	O
at	O
the	O
end	O
of	O
the	O
second	O
week	O
of	O
treatment	O
and	O
at	O
the	O
end	O
of	O
the	O
6-week	O
washout	O
period	O
with	O
no	O
statistically	O
significant	O
change	O
in	O
cortisol	O
response	O
.	O

In	O
peripheral	B-cell_type
lymphocytes	I-cell_type
,	O
GR	B-RNA
mRNA	I-RNA
levels	O
were	O
significantly	O
down-regulated	O
.	O

MTIIa	B-RNA
mRNA	I-RNA
levels	O
increased	O
significantly	O
.	O

Serum	O
osteocalcin	B-protein
decreased	O
significantly	O
during	O
treatment	O
with	O
both	O
BUD	O
and	O
FP	O
.	O

Serum	O
cortisol	O
decreased	O
after	O
1	O
week	O
of	O
treatment	O
whereas	O
urinary	O
cortisol	O
was	O
not	O
affected	O
until	O
the	O
second	O
week	O
of	O
treatment	O
.	O

In	O
conclusion	O
,	O
intranasal	O
glucocorticoids	O
at	O
clinically	O
recommended	O
doses	O
have	O
not	O
only	O
significant	O
systemic	O
effects	O
on	O
adrenal	O
function	O
,	O
but	O
also	O
have	O
an	O
effect	O
on	O
specific	O
gene	O
expression	O
in	O
peripheral	B-cell_type
lymphocytes	I-cell_type
.	O

These	O
effects	O
are	O
receptor-dependent	O
,	O
reversible	O
,	O
and	O
according	O
to	O
serum	O
and	O
urinary	O
cortisol	O
levels	O
and	O
ITT	O
,	O
leave	O
the	O
hypothalamic-pituitary-adrenal	O
function	O
intact	O
.	O

Finally	O
,	O
these	O
short-term	O
systemic	O
effects	O
were	O
not	O
associated	O
with	O
any	O
of	O
the	O
noticeable	O
side-effects	O
usually	O
observed	O
during	O
long-term	O
treatment	O
with	O
glucocorticoids	O
.	O

Biphasic	O
control	O
of	O
nuclear	B-protein
factor-kappa	I-protein
B	I-protein
activation	O
by	O
the	O
T	B-protein
cell	I-protein
receptor	I-protein
complex	I-protein
:	O
role	O
of	O
tumor	B-protein
necrosis	I-protein
factor	I-protein
alpha	I-protein
.	O

The	O
regulation	O
of	O
nuclear	B-protein
factor	I-protein
(	I-protein
NF	I-protein
)	I-protein
-kappa	I-protein
B	I-protein
activation	O
by	O
the	O
T	B-protein
cell	I-protein
receptor	I-protein
(	I-protein
TcR	I-protein
)	I-protein
/CD3	I-protein
complex	I-protein
in	O
primary	O
human	O
T	B-cell_type
cells	I-cell_type
has	O
been	O
studied	O
at	O
various	O
times	O
after	O
activation	O
.	O

Only	O
p50	B-protein
NF-kappa	I-protein
B	I-protein
protein	I-protein
bound	O
the	O
kappa	B-DNA
B	I-DNA
element	I-DNA
of	O
interleukin-2	B-DNA
receptor	I-DNA
(	I-DNA
IL-2R	I-DNA
)	I-DNA
alpha	I-DNA
chain	I-DNA
promoter	I-DNA
on	O
resting	O
T	B-cell_type
cells	I-cell_type
.	O

However	O
,	O
immediately	O
after	O
TcR/CD3	B-protein
cross-linking	O
(	O
after	O
approximately	O
1	O
h	O
;	O
immediate	O
)	O
binding	O
of	O
p50.p65	B-protein
heterodimers	I-protein
was	O
observed	O
.	O

p50.c-rel	B-protein
heterodimers	I-protein
were	O
also	O
detected	O
bound	O
to	O
this	O
sequence	O
at	O
early	O
time	O
points	O
(	O
7-16	O
h	O
;	O
early	O
)	O
,	O
and	O
both	O
remained	O
active	O
at	O
later	O
time	O
points	O
(	O
40	O
h	O
;	O
late	O
)	O
after	O
activation	O
.	O

This	O
regulation	O
takes	O
place	O
mainly	O
at	O
the	O
level	O
of	O
nuclear	O
translocation	O
of	O
p65	B-protein
and	O
c-rel	B-protein
,	O
at	O
immediate	O
and	O
early	O
time	O
points	O
.	O

Activation	O
also	O
induced	O
c-rel	O
and	O
p105/p50	O
mRNA	O
synthesis	O
,	O
but	O
not	O
p65	B-RNA
mRNA	I-RNA
whose	O
expression	O
was	O
constitutive	O
.	O

Interestingly	O
,	O
all	O
those	O
early	O
and	O
late	O
events	O
,	O
but	O
not	O
the	O
immediate	O
ones	O
,	O
were	O
inhibited	O
by	O
a	O
neutralizing	O
anti-tumor	B-protein
necrosis	I-protein
factor	I-protein
alpha	I-protein
(	I-protein
TNF-alpha	I-protein
)	I-protein
monoclonal	I-protein
antibody	I-protein
.	O

Similarly	O
,	O
cycloheximide	O
prevented	O
the	O
p65	B-protein
and	O
c-rel	B-protein
translocation	O
and	O
consequent	O
formation	O
of	O
active	O
binding	O
heterodimers	O
,	O
at	O
early	O
and	O
late	O
times	O
.	O

Cyclosporin	O
A	O
impaired	O
not	O
only	O
early	O
and	O
late	O
,	O
but	O
also	O
immediate	O
events	O
;	O
however	O
,	O
addition	O
of	O
TNF-alpha	B-protein
prevented	O
all	O
inhibition	O
.	O

These	O
results	O
indicate	O
that	O
the	O
regulation	O
of	O
NF-kappa	B-protein
B	I-protein
activation	O
during	O
T	O
cell	O
activation	O
by	O
TcR/CD3	B-protein
signals	O
is	O
biphasic	O
:	O
TcR/CD3	B-protein
triggers	O
its	O
immediate	O
translocation	O
,	O
which	O
is	O
transient	O
if	O
no	O
TNF-alpha	B-protein
is	O
present	O
.	O

TNF-alpha	B-protein
,	O
therefore	O
,	O
emerges	O
as	O
the	O
main	O
factor	O
responsible	O
for	O
a	O
second	O
phase	O
of	O
NF-kappa	B-protein
B	I-protein
regulation	O
,	O
controlling	O
both	O
translocation	O
of	O
p65	B-protein
and	O
c-rel	B-protein
,	O
and	O
new	O
mRNA	B-RNA
synthesis	O
for	O
c-rel	B-protein
and	O
p105/p50	B-protein
.	O

The	O
transcription	B-protein
factor	I-protein
Sp1	I-protein
is	O
required	O
for	O
induction	O
of	O
the	O
murine	B-DNA
GM-CSF	I-DNA
promoter	I-DNA
in	O
T	B-cell_type
cells	I-cell_type
.	O

The	O
cis-acting	B-DNA
region	I-DNA
,	O
GM-kappa	B-DNA
B/GC-box	I-DNA
(	O
positions	B-DNA
-95	I-DNA
and	O
-73	B-DNA
)	O
,	O
within	O
the	O
murine	B-DNA
GM-CSF	I-DNA
gene	I-DNA
promoter	I-DNA
is	O
required	O
for	O
maximal	O
induction	O
by	O
stimulation	O
with	O
phorbol-12-myristate	O
acetate	O
(	O
PMA	O
)	O
and	O
calcium	O
ionophore	O
(	O
A23187	O
)	O
in	O
T	B-cell_type
cells	I-cell_type
.	O

GM-kappa	B-protein
B	I-protein
defines	O
a	O
binding	O
site	O
for	O
NF-kappa	B-protein
B	I-protein
,	O
and	O
GC-box	B-DNA
defines	O
a	O
binding	O
site	O
for	O
three	O
(	O
A1	B-protein
,	O
A2	B-protein
,	O
B	B-protein
)	O
constitutive	B-protein
proteins	I-protein
.	O

We	O
report	O
here	O
that	O
three	O
copies	O
of	O
the	O
GC-box	B-DNA
can	O
functionally	O
compensate	O
for	O
the	O
GM-kappa	B-DNA
B/GC-box	I-DNA
region	I-DNA
,	O
suggesting	O
that	O
the	O
GC-motif	O
can	O
function	O
independently	O
of	O
the	O
GM-kappa	B-DNA
B	I-DNA
motif	I-DNA
.	O

The	O
major	O
GC-box	B-DNA
binding	O
activity	O
A1	B-protein
was	O
purified	O
and	O
identified	O
as	O
the	O
transcription	B-protein
factor	I-protein
Sp1	I-protein
.	O

We	O
show	O
that	O
depletion	O
of	O
Sp1	B-protein
(	O
A1	B-protein
)	O
from	O
nuclear	O
extracts	O
specifically	O
decreases	O
in	O
vitro	O
transcription	O
activity	O
on	O
GM-CSF	B-protein
templates	O
.	O

Since	O
the	O
human	B-DNA
GM-CSF	I-DNA
promoter	I-DNA
has	O
a	O
base	O
difference	O
within	O
the	O
GC-box	B-DNA
,	O
we	O
speculate	O
that	O
this	O
may	O
explain	O
why	O
the	O
human	O
promoter	O
is	O
weak	O
and	O
that	O
an	O
upstream	B-DNA
enhancer	I-DNA
is	O
required	O
for	O
the	O
induction	O
of	O
the	O
human	B-DNA
GM-CSF	I-DNA
gene	I-DNA
.	O

A	O
factor	O
that	O
regulates	O
the	O
class	B-DNA
II	I-DNA
major	I-DNA
histocompatibility	I-DNA
complex	I-DNA
gene	I-DNA
DPA	B-DNA
is	O
a	O
member	O
of	O
a	O
subfamily	O
of	O
zinc	B-protein
finger	I-protein
proteins	I-protein
that	O
includes	O
a	O
Drosophila	B-protein
developmental	I-protein
control	I-protein
protein	I-protein
.	O

A	O
novel	O
DNA	B-DNA
sequence	I-DNA
element	I-DNA
termed	O
the	O
J	B-DNA
element	I-DNA
involved	O
in	O
the	O
regulated	O
expression	O
of	O
class	B-DNA
II	I-DNA
major	I-DNA
histocompatibility	I-DNA
complex	I-DNA
genes	I-DNA
was	O
recently	O
described	O
.	O

To	O
study	O
this	O
element	O
and	O
its	O
role	O
in	O
class	B-DNA
II	I-DNA
gene	I-DNA
regulation	O
further	O
,	O
a	O
cDNA	B-DNA
library	I-DNA
was	O
screened	O
with	O
oligonucleotide	O
probes	O
containing	O
both	O
the	O
S	B-DNA
element	I-DNA
and	O
the	O
nearby	O
J	B-DNA
element	I-DNA
of	O
the	O
human	B-DNA
DPA	I-DNA
gene	I-DNA
.	O

Several	O
DNA	B-DNA
clones	I-DNA
were	O
obtained	O
by	O
this	O
procedure	O
,	O
one	O
of	O
which	O
,	O
clone	B-DNA
18	I-DNA
,	O
is	O
reported	O
and	O
characterized	O
here	O
.	O

It	O
encodes	O
a	O
protein	O
predicted	O
to	O
contain	O
688	O
amino	O
acid	O
residues	O
,	O
including	O
11	O
zinc	B-protein
finger	I-protein
motifs	I-protein
of	O
the	O
C2H2	B-protein
type	I-protein
in	O
the	O
C-terminal	B-protein
region	I-protein
,	O
that	O
are	O
Kruppel-like	O
in	O
the	O
conservation	O
of	O
the	O
H/C	B-protein
link	I-protein
sequence	I-protein
connecting	O
them	O
.	O

The	O
160	B-protein
N-terminal	I-protein
amino	I-protein
acids	I-protein
in	O
the	O
nonfinger	B-protein
region	I-protein
of	O
clone	B-protein
18	I-protein
are	O
highly	O
homologous	O
with	O
similar	O
regions	O
of	O
several	O
other	O
human	B-DNA
,	I-DNA
mouse	I-DNA
,	I-DNA
and	I-DNA
Drosophila	I-DNA
sequences	I-DNA
,	O
defining	O
a	O
subfamily	O
of	O
Kruppel-like	O
zinc	B-protein
finger	I-protein
proteins	I-protein
termed	O
TAB	B-protein
(	O
tramtrack	B-protein
[	I-protein
ttk	I-protein
]	I-protein
-associated	I-protein
box	I-protein
)	O
here	O
.	O

One	O
of	O
the	O
Drosophila	B-DNA
sequences	I-DNA
,	O
ttk	B-DNA
,	O
is	O
a	O
developmental	B-DNA
control	I-DNA
gene	I-DNA
,	O
while	O
a	O
second	O
does	O
not	O
contain	O
a	O
zinc	B-protein
finger	I-protein
region	I-protein
but	O
encodes	O
a	O
structure	O
important	O
in	O
oocyte	O
development	O
.	O

An	O
acidic	B-protein
activation	I-protein
domain	I-protein
is	O
located	O
between	O
the	O
N-terminal	B-protein
conserved	I-protein
region	I-protein
of	O
clone	B-protein
18	I-protein
and	O
its	O
zinc	B-protein
fingers	I-protein
.	O

This	O
protein	O
appears	O
to	O
require	O
both	O
the	O
S	B-DNA
and	I-DNA
J	I-DNA
elements	I-DNA
,	O
which	O
are	O
separated	O
by	O
10	O
bp	O
for	O
optimal	O
binding	O
.	O

Antisense	O
cDNA	O
to	O
clone	B-protein
18	I-protein
inhibited	O
the	O
expression	O
of	O
a	O
reporter	O
construct	O
containing	O
the	O
DPA	B-DNA
promoter	I-DNA
,	O
indicating	O
its	O
functional	O
importance	O
in	O
the	O
expression	O
of	O
this	O
class	B-DNA
II	I-DNA
gene	I-DNA
.	O

Separation	O
of	O
oxidant-initiated	O
and	O
redox-regulated	O
steps	O
in	O
the	O
NF-kappa	B-protein
B	I-protein
signal	O
transduction	O
pathway	O
.	O

Studies	O
presented	O
here	O
show	O
that	O
overall	O
NF-kappa	B-protein
B	I-protein
signal	O
transduction	O
begins	O
with	O
a	O
parallel	O
series	O
of	O
stimuli-specific	O
pathways	O
through	O
which	O
cytokines	B-protein
(	O
tumor	B-protein
necrosis	I-protein
factor	I-protein
alpha	I-protein
)	O
,	O
oxidants	O
(	O
hydrogen	O
peroxide	O
and	O
mitomycin	O
C	O
)	O
,	O
and	O
phorbol	O
ester	O
(	O
phorbol	O
12-myristate	O
13-acetate	O
)	O
individually	O
initiate	O
signaling	O
.	O

These	O
initial	O
pathways	O
culminate	O
in	O
a	O
common	O
pathway	O
through	O
which	O
all	O
of	O
the	O
stimulating	O
agents	O
ultimately	O
signal	O
NF-kappa	B-protein
B	I-protein
activation	O
.	O

We	O
distinguish	O
the	O
stimuli-specific	O
pathways	O
by	O
showing	O
that	O
the	O
oxidative	O
stimuli	O
trigger	O
NF-kappa	B-protein
B	I-protein
activation	O
in	O
only	O
one	O
of	O
two	O
human	B-cell_line
T-cell	I-cell_line
lines	I-cell_line
(	O
Wurzburg	B-cell_line
but	O
not	O
Jurkat	B-cell_line
)	O
,	O
whereas	O
tumor	B-protein
necrosis	I-protein
factor	I-protein
alpha	I-protein
and	O
phorbol	O
12-myristate	O
13-acetate	O
readily	O
stimulate	O
in	O
both	O
lines	O
.	O

We	O
propose	O
the	O
common	O
pathway	O
as	O
the	O
simplest	O
way	O
of	O
accounting	O
for	O
the	O
common	O
requirements	O
and	O
properties	O
of	O
the	O
signaling	O
pathway	O
.	O

We	O
include	O
a	O
redox-regulatory	O
mechanism	O
(	O
s	O
)	O
in	O
this	O
common	O
pathway	O
to	O
account	O
for	O
the	O
previously	O
demonstrated	O
redox	O
regulation	O
of	O
NF-kappa	B-protein
B	I-protein
activation	O
in	O
Jurkat	B-cell_line
cells	I-cell_line
(	O
in	O
which	O
oxidants	O
do	O
n't	O
activate	O
NF-kappa	B-protein
B	I-protein
)	O
;	O
we	O
put	O
tyrosine	O
phosphorylation	O
in	O
the	O
common	O
pathway	O
by	O
showing	O
that	O
kinase	O
activity	O
(	O
inhibitable	O
by	O
herbimycin	O
A	O
and	O
tyrphostin	O
47	O
)	O
is	O
required	O
for	O
NF-kappa	B-protein
B	I-protein
activation	O
by	O
all	O
stimuli	O
tested	O
in	O
both	O
cell	O
lines	O
.	O

Since	O
internal	O
sites	O
of	O
oxidant	O
production	O
have	O
been	O
shown	O
to	O
play	O
a	O
key	O
role	O
in	O
the	O
cytokine	B-protein
-stimulated	O
activation	O
of	O
NF-kappa	B-protein
B	I-protein
,	O
and	O
since	O
tyrosine	O
kinase	O
and	O
phosphatase	O
activities	O
are	O
known	O
to	O
be	O
altered	O
by	O
oxidants	O
,	O
these	O
findings	O
suggest	O
that	O
intracellular	O
redox	O
status	O
controls	O
NF-kappa	B-protein
B	I-protein
activation	O
by	O
regulating	O
tyrosine	O
phosphorylation	O
event	O
(	O
s	O
)	O
within	O
the	O
common	O
step	O
of	O
the	O
NF-kappa	B-protein
B	I-protein
signal	O
transduction	O
pathway	O
.	O

Deleted	O
chromosome	B-DNA
20	I-DNA
from	O
a	O
patient	O
with	O
Alagille	O
syndrome	O
isolated	O
in	O
a	O
cell	O
hybrid	O
through	O
leucine	O
transport	O
selection	O
:	O
study	O
of	O
three	O
candidate	O
genes	O
.	O

Alagille	O
syndrome	O
(	O
AGS	O
)	O
is	O
a	O
well-defined	O
genetic	O
entity	O
assigned	O
to	O
the	O
short	B-DNA
arm	I-DNA
of	O
Chromosome	B-DNA
(	I-DNA
Chr	I-DNA
)	I-DNA
20	I-DNA
by	O
a	O
series	O
of	O
observations	O
of	O
AGS	O
patients	O
associated	O
with	O
microdeletions	O
in	O
this	O
region	O
.	O

By	O
fusing	O
lymphoblastoid	B-cell_type
cells	I-cell_type
of	O
an	O
AGS	O
patient	O
that	O
exhibited	O
a	O
microdeletion	O
in	O
the	O
short	B-DNA
arm	I-DNA
of	I-DNA
Chr	I-DNA
20	I-DNA
encompassing	O
bands	O
p11.23	B-DNA
to	I-DNA
p12.3	I-DNA
with	O
rodent	B-cell_line
thermosensitive	I-cell_line
mutant	I-cell_line
cells	I-cell_line
(	O
CHOtsH1-1	B-cell_line
)	O
deficient	O
in-leucyl-tRNA	B-protein
synthetase	I-protein
,	O
we	O
isolated	O
a	O
somatic	B-cell_line
cell	I-cell_line
hybrid	I-cell_line
segregating	O
the	O
deleted	O
human	O
Chr	B-DNA
20	I-DNA
.	O

This	O
hybrid	O
clone	O
,	O
designated	O
NR2	B-cell_line
,	O
was	O
characterized	O
by	O
several	O
methods	O
,	O
including	O
PCR	O
,	O
with	O
eight	O
pairs	O
of	O
oligonucleotides	O
mapped	O
to	O
Chr	B-DNA
20	I-DNA
:	O
D20S5	B-DNA
,	O
D20S41	B-DNA
,	O
D20S42	B-DNA
,	O
D20S56	B-DNA
,	O
D20S57	B-DNA
,	O
D20S58	B-DNA
,	O
adenosine	B-DNA
deaminase	I-DNA
(	O
ADA	B-protein
)	O
,	O
and	O
Prion	B-DNA
protein	I-DNA
(	O
PRIP	B-protein
)	O
;	O
Restriction	O
Fragment	O
Length	O
Polymorphism	O
(	O
RFLP	B-DNA
)	O
analyses	O
with	O
four	O
genomic	B-DNA
anonymous	I-DNA
probes	I-DNA
(	O
D20S5	B-DNA
,	O
cD3H12	B-DNA
,	O
D20S17	B-DNA
,	O
D20S18	B-DNA
)	O
;	O
and	O
fluorescent	O
in	O
situ	O
hybridization	O
(	O
FISH	O
)	O
with	O
total	B-DNA
human	I-DNA
DNA	I-DNA
and	O
D20Z1	B-DNA
,	O
a	O
sequence	O
specific	O
to	O
the	O
human	B-DNA
Chr	I-DNA
20	I-DNA
centromere	I-DNA
,	O
as	O
probes	O
.	O

The	O
NR2	B-cell_line
hybrid	I-cell_line
allowed	O
us	O
to	O
exclude	O
three	O
candidate	B-DNA
genes	I-DNA
for	O
AGS	O
:	O
hepatic	B-DNA
nuclear	I-DNA
factor	I-DNA
3	I-DNA
beta	I-DNA
(	O
HNF3	B-DNA
beta	I-DNA
)	O
,	O
paired	B-DNA
box	I-DNA
1	I-DNA
(	O
PAX1	B-DNA
)	O
,	O
and	O
cystatin	B-DNA
C	I-DNA
(	O
CST3	B-DNA
)	O
as	O
shown	O
by	O
their	O
localization	O
outside	O
of	O
the	O
deletion	O
.	O

The	O
NR2	B-cell_line
hybrid	I-cell_line
is	O
a	O
powerful	O
tool	O
for	O
the	O
mapping	O
of	O
new	O
probes	O
of	O
this	O
region	O
,	O
as	O
well	O
as	O
for	O
obtaining	O
new	O
informative	O
probes	O
specific	O
for	O
the	O
deletion	O
by	O
subtractive	O
cloning	O
of	O
the	O
region	O
.	O

Such	O
markers	O
will	O
be	O
useful	O
for	O
linkage	O
analysis	O
and	O
screening	O
of	O
cDNA	B-DNA
libraries	I-DNA
.	O

Positive	O
and	O
negative	O
regulation	O
of	O
the	O
composite	B-DNA
octamer	I-DNA
motif	I-DNA
of	O
the	O
interleukin	B-DNA
2	I-DNA
enhancer	I-DNA
by	O
AP-1	B-protein
,	O
Oct-2	B-protein
,	O
and	O
retinoic	B-protein
acid	I-protein
receptor	I-protein
.	O

The	O
differentiating	O
agent	O
retinoic	O
acid	O
(	O
RA	O
)	O
has	O
been	O
previously	O
reported	O
to	O
interfere	O
with	O
12-O-tetradecanoyl-phorbol-13-acetate	O
(	O
TPA	O
)	O
/Ca	O
(	O
2+	O
)	O
-induced	O
signals	O
for	O
the	O
regulation	O
of	O
the	O
-96	B-DNA
to	I-DNA
-66-bp	I-DNA
octamer	I-DNA
motif	I-DNA
found	O
in	O
the	O
enhancer	O
for	O
the	O
interleukin	B-DNA
(	I-DNA
IL	I-DNA
)	I-DNA
-2	I-DNA
gene	I-DNA
,	O
which	O
encodes	O
a	O
major	O
T	B-protein
lymphocyte	I-protein
growth	I-protein
factor	I-protein
.	O

The	O
IL-2	B-DNA
octamer	I-DNA
motif	I-DNA
is	O
a	O
composite	O
cis-element	B-DNA
which	O
binds	O
Oct-1	B-protein
and	O
Oct-2	B-protein
as	O
well	O
as	O
a	O
TPA/Ca	B-protein
(	I-protein
2+	I-protein
)	I-protein
-inducible	I-protein
nuclear	I-protein
factor	I-protein
,	O
previously	O
termed	O
octamer-associated	B-protein
protein	I-protein
(	O
OAP40	B-protein
)	O
.	O

We	O
show	O
here	O
that	O
Oct-2	B-protein
,	O
despite	O
the	O
presence	O
of	O
an	O
active	O
transcriptional	O
activation	O
domain	O
,	O
requires	O
TPA/Ca	O
(	O
2+	O
)	O
-induced	O
signals	O
to	O
strongly	O
transactivate	O
the	O
IL-2	B-DNA
octamer	I-DNA
motif	I-DNA
in	O
Jurkat	O
T	O
cells	O
.	O

This	O
Oct-2	B-protein
-dependent	O
transactivation	O
is	O
inhibited	O
by	O
RA	O
.	O

The	O
presence	O
of	O
an	O
intact	B-protein
COOH-terminal	I-protein
domain	I-protein
of	O
Oct-2	B-protein
contributes	O
to	O
both	O
TPA/Ca	O
(	O
2+	O
)	O
-induced	O
transactivation	O
and	O
the	O
RA-mediated	O
repression	O
.	O

We	O
also	O
show	O
that	O
both	O
Fos	B-protein
and	O
Jun	B-protein
components	O
of	O
the	O
AP-1	B-protein
factors	O
participate	O
in	O
the	O
OAP40	B-protein
complex	I-protein
.	O

Furthermore	O
,	O
transfected	O
c-jun	B-DNA
,	I-DNA
jun-B	I-DNA
,	I-DNA
jun-D	I-DNA
,	I-DNA
c-fos	I-DNA
,	I-DNA
or	I-DNA
Fos-B	I-DNA
expression	I-DNA
vectors	I-DNA
partially	O
substitute	O
for	O
TPA	O
and	O
Ca2+	O
and	O
cooperate	O
with	O
Oct-2	B-protein
for	O
the	O
transactivation	O
of	O
the	O
combined	O
OAP/octamer	B-DNA
cis-element	I-DNA
.	O

Mutations	O
of	O
the	O
genuine	B-DNA
octamer-binding	I-DNA
site	I-DNA
abrogate	O
both	O
the	O
binding	O
of	O
Oct-1	B-protein
and	O
Oct-2	B-protein
and	O
the	O
TPA/Ca	O
(	O
2+	O
)	O
-induced	O
transactivation	O
of	O
the	O
OAP/octamer	B-DNA
motif	I-DNA
.	O

OAP	B-protein
confers	O
to	O
Oct-2	B-protein
responsivity	O
to	O
both	O
TPA/Ca2+	O
and	O
RA	O
,	O
since	O
specific	O
mutations	O
of	O
the	O
AP-1/OAP-binding	B-DNA
site	I-DNA
significantly	O
reduce	O
the	O
transactivation	O
by	O
Oct-2	B-protein
in	O
response	O
to	O
TPA	O
and	O
Ca2+	O
and	O
abolish	O
the	O
inhibition	O
by	O
RA	O
.	O

Furthermore	O
,	O
retinoic	B-protein
acid	I-protein
receptor	I-protein
(	O
RAR	B-protein
)	O
alpha	O
is	O
able	O
to	O
inhibit	O
in	O
vitro	O
the	O
formation	O
of	O
the	O
complex	O
between	O
the	O
nuclear	O
AP-1	B-protein
/OAP	B-protein
and	O
its	O
specific	O
binding	O
site	O
,	O
resulting	O
in	O
the	O
interference	O
with	O
Oct-2	B-protein
-dependent	O
cis-regulatory	O
function	O
of	O
this	O
AP-1	B-protein
element	O
.	O

Therefore	O
,	O
we	O
propose	O
that	O
the	O
TPA/calcium-activated	O
AP-1	B-protein
/OAP	B-protein
element	O
is	O
the	O
main	O
target	O
of	O
positive	O
or	O
negative	O
regulatory	O
signals	O
influencing	O
the	O
IL-2	B-DNA
octamer	I-DNA
motif	I-DNA
,	O
through	O
synergism	O
with	O
Oct-2	B-protein
and	O
antagonism	O
by	O
RAR	B-protein
.	O

Missense	O
mutation	O
in	O
exon	B-DNA
7	I-DNA
of	O
the	O
common	B-DNA
gamma	I-DNA
chain	I-DNA
gene	I-DNA
causes	O
a	O
moderate	O
form	O
of	O
X-linked	O
combined	O
immunodeficiency	O
.	O

Clinical	O
and	O
immunologic	O
features	O
of	O
a	O
recently	O
recognized	O
X-linked	O
combined	O
immunodeficiency	O
disease	O
(	O
XCID	O
)	O
suggested	O
that	O
XCID	O
and	O
X-linked	O
severe	O
combined	O
immunodeficiency	O
(	O
XSCID	O
)	O
might	O
arise	O
from	O
different	O
genetic	O
defects	O
.	O

The	O
recent	O
discovery	O
of	O
mutations	O
in	O
the	O
common	B-DNA
gamma	I-DNA
chain	I-DNA
(	I-DNA
gamma	I-DNA
c	I-DNA
)	I-DNA
gene	I-DNA
,	O
a	O
constituent	O
of	O
several	O
cytokine	B-protein
receptors	I-protein
,	O
in	O
XSCID	O
provided	O
an	O
opportunity	O
to	O
test	O
directly	O
whether	O
a	O
previously	O
unrecognized	O
mutation	O
in	O
this	O
same	O
gene	O
was	O
responsible	O
for	O
XCID	O
.	O

The	O
status	O
of	O
X	B-DNA
chromosome	I-DNA
inactivation	O
in	O
blood	O
leukocytes	O
from	O
obligate	O
carriers	O
of	O
XCID	O
was	O
determined	O
from	O
the	O
polymorphic	O
,	O
short	O
tandem	O
repeats	O
(	O
CAG	O
)	O
,	O
in	O
the	O
androgen	B-DNA
receptor	I-DNA
gene	I-DNA
,	O
which	O
also	O
contains	O
a	O
methylation-sensitive	B-DNA
HpaII	I-DNA
site	I-DNA
.	O

As	O
in	O
XSCID	O
,	O
X-chromosome	O
inactivation	O
in	O
obligate	O
carriers	O
of	O
XCID	O
was	O
nonrandom	O
in	O
T	B-cell_type
and	I-cell_type
B	I-cell_type
lymphocytes	I-cell_type
.	O

In	O
addition	O
,	O
X	B-DNA
chromosome	I-DNA
inactivation	O
in	O
PMNs	O
was	O
variable	O
.	O

Findings	O
from	O
this	O
analysis	O
prompted	O
sequencing	O
of	O
the	O
gamma	B-DNA
c	I-DNA
gene	I-DNA
in	O
this	O
pedigree	O
.	O

A	O
missense	O
mutation	O
in	O
the	O
region	O
coding	O
for	O
the	O
cytoplasmic	O
portion	O
of	O
the	O
gamma	B-DNA
c	I-DNA
gene	I-DNA
was	O
found	O
in	O
three	O
affected	O
males	O
but	O
not	O
in	O
a	O
normal	O
brother	O
.	O

Therefore	O
,	O
this	O
point	O
mutation	O
in	O
the	O
gamma	B-DNA
c	I-DNA
gene	I-DNA
leads	O
to	O
a	O
less	O
severe	O
degree	O
of	O
deficiency	O
in	O
cellular	O
and	O
humoral	O
immunity	O
than	O
that	O
seen	O
in	O
XSCID	O
.	O

Posttranscriptional	O
regulation	O
of	O
macrophage	O
tissue	B-protein
factor	I-protein
expression	O
by	O
antioxidants	O
.	O

Tissue	B-protein
factor	I-protein
(	O
TF	B-protein
)	O
expression	O
by	O
cells	O
of	O
monocyte/macrophage	B-cell_type
lineage	I-cell_type
represents	O
an	O
important	O
mechanism	O
underlying	O
the	O
initiation	O
of	O
fibrin	B-protein
deposition	O
at	O
sites	O
of	O
extravascular	O
inflammation	O
.	O

Recent	O
evidence	O
suggests	O
a	O
role	O
for	O
oxidant	O
stress	O
in	O
the	O
signalling	O
pathway	O
of	O
various	O
cell	O
types	O
by	O
virtue	O
of	O
its	O
ability	O
to	O
induce	O
DNA	O
binding	O
of	O
various	O
transcription	B-protein
factors	I-protein
,	O
including	O
nuclear	B-protein
factor	I-protein
kappa	I-protein
B	I-protein
and	O
AP-1	B-protein
.	O

The	O
effect	O
of	O
antioxidant	O
treatment	O
on	O
lipopolysaccharide	O
(	O
LPS	O
)	O
-induced	O
TF	B-protein
expression	O
was	O
examined	O
in	O
murine	B-cell_type
peritoneal	I-cell_type
macrophages	I-cell_type
and	O
human	B-cell_type
monocytes	I-cell_type
.	O

Both	O
pyrrolidine	O
dithiocarbamate	O
,	O
an	O
oxidant	O
scavenger	O
,	O
and	O
N-acetyl-cysteine	O
,	O
a	O
precursor	O
of	O
the	O
endogenous	O
antioxidant	O
glutathione	O
,	O
inhibited	O
stimulation	O
of	O
macrophage	O
procoagulant	O
activity	O
by	O
LPS	O
.	O

Northern	O
blot	O
analysis	O
showed	O
that	O
neither	O
of	O
these	O
agents	O
reduced	O
LPS-stimulated	O
TF	B-protein
mRNA	O
accumulation	O
,	O
thereby	O
suggesting	O
a	O
posttranscriptional	O
mechanism	O
for	O
the	O
effect	O
.	O

Immunofluorescence	O
studies	O
of	O
human	B-cell_type
monocytes	I-cell_type
using	O
polyclonal	O
anti-TF	B-protein
antibody	I-protein
showed	O
that	O
N-acetyl-cysteine	O
treatment	O
prevented	O
the	O
characteristic	O
plasmalemmal	O
localization	O
of	O
TF	B-protein
antigen	I-protein
that	O
occurs	O
in	O
response	O
to	O
LPS	O
.	O

Western	O
blot	O
analysis	O
showed	O
that	O
N-acetyl-cysteine	O
reduced	O
the	O
accumulation	O
of	O
the	O
47-kD	B-protein
mature	I-protein
glycoprotein	I-protein
in	O
LPS-treated	B-cell_line
cells	I-cell_line
,	O
a	O
finding	O
consistent	O
with	O
the	O
results	O
of	O
the	O
immunofluorescence	O
studies	O
.	O

Furthermore	O
,	O
these	O
conditions	O
did	O
not	O
result	O
in	O
an	O
accumulation	O
of	O
the	O
less	O
mature	O
forms	O
of	O
TF	B-protein
.	O

When	O
considered	O
together	O
,	O
these	O
data	O
suggest	O
that	O
antioxidants	O
exert	O
their	O
effects	O
by	O
impairing	O
translation	O
and/or	O
by	O
causing	O
degradation	O
of	O
newly	O
translated	B-protein
protein	I-protein
.	O

The	O
effect	O
of	O
antioxidants	O
on	O
tumor	B-protein
necrosis	I-protein
factor	I-protein
appeared	O
to	O
be	O
species	O
specific	O
,	O
with	O
no	O
effect	O
on	O
LPS-induced	O
tumor	O
necrosis	O
factor	O
in	O
murine	O
cells	O
,	O
but	O
with	O
inhibition	O
in	O
human	B-cell_type
monocytes	I-cell_type
.	O

The	O
posttranscriptional	O
effect	O
of	O
antioxidants	O
on	O
TF	B-protein
expression	O
data	O
suggests	O
a	O
novel	O
mechanism	O
whereby	O
these	O
agents	O
might	O
modulate	O
monocyte	B-cell_type
/macrophage	B-cell_type
activation	O
.	O

Characterization	O
of	O
the	O
CD48	B-DNA
gene	I-DNA
demonstrates	O
a	O
positive	O
element	O
that	O
is	O
specific	O
to	O
Epstein-Barr	B-cell_type
virus-immortalized	I-cell_type
B-cell	I-cell_type
lines	I-cell_type
and	O
contains	O
an	O
essential	O
NF-kappa	B-DNA
B	I-DNA
site	I-DNA
.	O

Epstein-Barr	O
virus	O
(	O
EBV	O
)	O
infection	O
of	O
mature	O
,	O
resting	B-cell_type
B	I-cell_type
cells	I-cell_type
drives	O
them	O
to	O
become	O
lymphoblasts	O
expressing	O
high	O
levels	O
of	O
cell	O
surface	O
molecules	O
,	O
such	O
as	O
CD48	B-protein
,	O
characteristically	O
expressed	O
on	O
normal	B-cell_type
activated	I-cell_type
B	I-cell_type
cells	I-cell_type
.	O

Here	O
,	O
we	O
report	O
on	O
the	O
identification	O
of	O
an	O
enhancer	B-DNA
element	I-DNA
in	O
the	O
CD48	B-DNA
gene	I-DNA
which	O
reproducibly	O
confers	O
strong	O
transcriptional	O
activity	O
only	O
in	O
EBV-positive	B-cell_line
B-lymphoblastoid	I-cell_line
cell	I-cell_line
lines	I-cell_line
.	O

The	O
element	O
is	O
not	O
activated	O
upon	O
infection	O
of	O
established	O
EBV-negative	B-cell_line
B-cell	I-cell_line
lines	I-cell_line
,	O
indicating	O
that	O
EBV	O
fails	O
to	O
drive	O
these	O
cells	O
to	O
a	O
fully	O
lymphoblastoid	B-cell_type
phenotype	I-cell_type
.	O

An	O
NF-kappa	B-protein
B	I-protein
binding	O
site	O
is	O
an	O
essential	O
component	O
of	O
the	O
element	O
but	O
alone	O
is	O
not	O
sufficient	O
to	O
account	O
for	O
the	O
activity	O
or	O
the	O
specificity	O
of	O
the	O
element	O
.	O

We	O
have	O
detected	O
a	O
specific	O
nuclear	B-protein
protein	I-protein
complex	I-protein
that	O
binds	O
to	O
the	O
element	O
and	O
show	O
that	O
NF-kappa	B-protein
B1	I-protein
(	O
p50	B-protein
)	O
is	O
a	O
part	O
of	O
this	O
complex	O
.	O

The	O
EBV-encoded	B-protein
latent	I-protein
membrane	I-protein
protein	I-protein
1	I-protein
is	O
capable	O
of	O
transactivating	O
the	O
isolated	O
CD48	B-protein
NF-kappa	B-DNA
B	I-DNA
site	I-DNA
but	O
not	O
the	O
intact	B-DNA
element	I-DNA
,	O
suggesting	O
that	O
the	O
latent	B-protein
membrane	I-protein
protein	I-protein
1	I-protein
-driven	O
activation	O
of	O
NF-kappa	B-protein
B/Rel	I-protein
must	O
interact	O
with	O
other	O
regulatory	O
pathways	O
to	O
control	O
expression	O
of	O
cellular	O
genes	O
as	O
EBV	O
drives	O
resting	B-cell_type
B	I-cell_type
cells	I-cell_type
into	O
the	O
cell	O
cycle	O
.	O

Thapsigargin	O
induces	O
IL-2	B-protein
receptor	I-protein
alpha-chain	I-protein
in	O
human	B-cell_type
peripheral	I-cell_type
and	O
Jurkat	B-cell_line
T	I-cell_line
cells	I-cell_line
via	O
a	O
protein	B-protein
kinase	I-protein
C	I-protein
-independent	O
mechanism	O
.	O

Thapsigargin	O
(	O
TG	O
)	O
,	O
an	O
inhibitor	O
of	O
Ca	B-protein
(	I-protein
2+	I-protein
)	I-protein
-ATPase	I-protein
,	O
depletes	O
intracellular	O
Ca2+	O
stores	O
and	O
induces	O
a	O
sustained	O
Ca2+	O
influx	O
without	O
altering	O
phosphatidyl	O
inositol	O
levels	O
.	O

TG	O
plus	O
phorbol	O
myristate	O
acetate	O
(	O
PMA	O
)	O
but	O
not	O
TG	O
alone	O
induced	O
IL-2	B-protein
in	O
Jurkat	B-cell_line
T	I-cell_line
cells	I-cell_line
,	O
suggesting	O
that	O
TG	O
had	O
no	O
effect	O
on	O
protein	B-protein
kinase	I-protein
C	I-protein
(	O
PKC	B-protein
)	O
.	O

However	O
,	O
TG	O
induced	O
increases	O
in	O
IL-2R	B-protein
alpha	I-protein
protein	I-protein
as	O
well	O
as	O
IL-2R	B-RNA
alpha	I-RNA
mRNA	I-RNA
in	O
Jurkat	B-cell_line
T	I-cell_line
cells	I-cell_line
in	O
a	O
dose-dependent	O
manner	O
.	O

A	O
similar	O
increase	O
in	O
IL-2R	B-protein
alpha	I-protein
by	O
TG	O
was	O
also	O
observed	O
in	O
human	B-cell_type
peripheral	I-cell_type
T	I-cell_type
cells	I-cell_type
.	O

Further	O
,	O
like	O
PMA	O
,	O
TG	O
markedly	O
induced	O
NF	B-protein
kappa	I-protein
B	I-protein
in	O
Jurkat	B-cell_line
T	I-cell_line
cells	I-cell_line
.	O

However	O
,	O
TG	O
and	O
PMA	O
exhibited	O
a	O
synergistic	O
action	O
on	O
IL-2R	B-protein
alpha	I-protein
expression	O
,	O
suggesting	O
that	O
TG	O
and	O
PMA	O
induce	O
IL-2R	B-protein
alpha	I-protein
through	O
distinct	O
pathways	O
.	O

PMA	B-protein
-but	I-protein
not	I-protein
TG-induced	I-protein
IL-2R	I-protein
alpha	I-protein
is	O
inhibited	O
by	O
the	O
PKC	B-protein
inhibitor	O
H7	O
,	O
whereas	O
TG	B-protein
-but	I-protein
not	I-protein
PMA-induced	I-protein
IL-2R	I-protein
alpha	I-protein
was	O
inhibited	O
by	O
cholera	O
toxin	O
,	O
forskolin	O
and	O
1	O
,	O
9-dideoxy	O
forskolin	O
.	O

In	O
toto	O
,	O
these	O
results	O
suggest	O
that	O
TG	O
induces	O
IL-2R	B-protein
alpha	I-protein
in	O
human	B-cell_type
T	I-cell_type
cells	I-cell_type
through	O
a	O
PKC	B-protein
-independent	O
pathway	O
.	O

Physiological	O
concentration	O
of	O
estradiol	O
inhibits	O
polymorphonuclear	B-cell_type
leukocyte	I-cell_type
chemotaxis	O
via	O
a	O
receptor	O
mediated	O
system	O
.	O

Estrogen	O
exhibits	O
a	O
variety	O
of	O
actions	O
,	O
including	O
immuno-modulatory	O
effects	O
,	O
in	O
vivo	O
and	O
in	O
vitro	O
.	O

The	O
mechanism	O
by	O
which	O
estrogen	O
exerts	O
its	O
anti-inflammatory	O
effect	O
is	O
not	O
yet	O
understood	O
.	O

We	O
investigated	O
the	O
possible	O
mechanisms	O
of	O
estradiol	O
acting	O
via	O
the	O
polymorphonuclear	B-cell_type
leukocytes	I-cell_type
(	O
PMNs	B-cell_type
)	O
,	O
which	O
are	O
important	O
in	O
the	O
immune	O
response	O
.	O

The	O
agent	O
,	O
17	O
beta-estradiol	O
,	O
but	O
not	O
17	O
alpha-estradiol	O
,	O
significantly	O
reduced	O
PMNs	B-cell_type
chemotaxis	O
to	O
FMLP	O
in	O
a	O
dose-dependent	O
manner	O
(	O
control	O
vs	O
estrogen	O
10	O
(	O
-10	O
)	O
-	O
(	O
-6	O
)	O
M	O
,	O
P	O
<	O
0.05	O
)	O
.	O

Physiological	O
concentrations	O
of	O
estradiol	O
significantly	O
reduced	O
the	O
chemotaxis	O
of	O
PMNs	B-cell_type
(	O
10	O
(	O
-10	O
)	O
mol	O
)	O
.	O

Pre-incubation	O
with	O
clomiphene	O
or	O
tamoxifen	O
which	O
are	O
estrogen	O
receptor	O
antagonists	O
,	O
eliminated	O
the	O
inhibitory	O
effect	O
of	O
17	O
beta-estradiol	O
on	O
the	O
chemotaxis	O
of	O
PMNs	B-cell_type
,	O
restoring	O
it	O
to	O
the	O
control	O
level	O
.	O

These	O
observations	O
suggest	O
that	O
17	O
beta-estradiol	O
suppressed	O
the	O
chemotaxis	O
of	O
PMNs	B-cell_type
by	O
a	O
receptor-dependent	O
mechanism	O
.	O

In	O
addition	O
,	O
the	O
level	O
of	O
estradiol	O
in	O
human	B-cell_type
plasma	I-cell_type
,	O
which	O
PMNs	B-cell_type
were	O
drawn	O
,	O
showed	O
a	O
close	O
,	O
inverse	O
correlation	O
with	O
the	O
PMNs	B-cell_type
chemotaxis	O
to	O
FMLP	O
(	O
r	O
=	O
-0.821	O
p	O
<	O
0.001	O
)	O
.	O

Estrogen	O
may	O
modify	O
the	O
activity	O
of	O
neutrophils	B-cell_type
during	O
the	O
normal	O
menstrual	O
cycle	O
,	O
not	O
only	O
during	O
pregnancy	O
,	O
and	O
influence	O
inflammation	O
.	O

Identification	O
of	O
the	O
TCL1	B-DNA
gene	I-DNA
involved	O
in	O
T-cell	B-cell_type
malignancies	O
.	O

The	O
TCL1	B-DNA
locus	I-DNA
on	O
chromosome	B-DNA
14q32.1	I-DNA
is	O
frequently	O
involved	O
in	O
chromosomal	O
translocations	O
and	O
inversions	O
with	O
one	O
of	O
the	O
T-cell	B-DNA
receptor	I-DNA
loci	I-DNA
in	O
human	O
T-cell	O
leukemias	O
and	O
lymphomas	O
.	O

The	O
chromosome	B-DNA
14	I-DNA
region	I-DNA
translocated	O
or	O
rearranged	O
involves	O
approximately	O
350	O
kb	O
of	O
DNA	O
at	O
chromosome	O
band	O
14q32.1	O
.	O

Within	O
this	O
region	O
we	O
have	O
identified	O
a	O
gene	O
coding	O
for	O
a	O
1.3-kb	B-RNA
transcript	I-RNA
,	O
expressed	O
only	O
in	O
restricted	O
subsets	O
of	O
cells	O
within	O
the	O
lymphoid	B-cell_type
lineage	I-cell_type
and	O
expressed	O
at	O
high	O
levels	O
in	O
leukemic	B-cell_type
cells	I-cell_type
carrying	O
a	O
t	O
(	O
14	O
;	O
14	O
)	O
(	O
q11	O
;	O
q32	O
)	O
chromosome	O
translocation	O
or	O
a	O
inv	O
(	O
14	O
)	O
(	O
q11	O
;	O
q32	O
)	O
chromosome	O
inversion	O
.	O

The	O
cognate	B-DNA
cDNA	I-DNA
sequence	I-DNA
reveals	O
an	O
open	B-DNA
reading	I-DNA
frame	I-DNA
of	O
342	O
nt	O
encoding	O
a	O
protein	B-protein
of	I-protein
14	I-protein
kDa	I-protein
.	O

The	O
TCL1	B-DNA
gene	I-DNA
sequence	O
,	O
which	O
,	O
to	O
our	O
knowledge	O
,	O
shows	O
no	O
sequence	O
homology	O
with	O
other	O
human	B-DNA
genes	I-DNA
,	O
is	O
preferentially	O
expressed	O
early	O
in	O
T-	B-cell_type
and	I-cell_type
B-lymphocyte	I-cell_type
differentiation	O
.	O

Identification	O
of	O
a	O
region	O
which	O
directs	O
the	O
monocytic	O
activity	O
of	O
the	O
colony-stimulating	B-DNA
factor	I-DNA
1	I-DNA
(	I-DNA
macrophage	I-DNA
colony-stimulating	I-DNA
factor	I-DNA
)	I-DNA
receptor	I-DNA
promoter	I-DNA
and	O
binds	O
PEBP2/CBF	B-protein
(	O
AML1	B-protein
)	O
.	O

The	O
receptor	O
for	O
the	O
macrophage	B-protein
colony-stimulating	I-protein
factor	I-protein
(	O
or	O
colony-stimulating	B-protein
factor	I-protein
1	I-protein
[	O
CSF-1	B-protein
]	O
)	O
is	O
expressed	O
from	O
different	O
promoters	O
in	O
monocytic	B-cell_type
cells	I-cell_type
and	O
placental	B-cell_type
trophoblasts	I-cell_type
.	O

We	O
have	O
demonstrated	O
that	O
the	O
monocyte-specific	O
expression	O
of	O
the	O
CSF-1	B-protein
receptor	I-protein
is	O
regulated	O
at	O
the	O
level	O
of	O
transcription	O
by	O
a	O
tissue-specific	B-DNA
promoter	I-DNA
whose	O
activity	O
is	O
stimulated	O
by	O
the	O
monocyte/B-cell-specific	B-protein
transcription	I-protein
factor	I-protein
PU.1	B-protein
(	O
D.-E.Zhang	O
,	O
C.J.Hetherington	O
,	O
H.-M.Chen	O
,	O
and	O
D.G.Tenen	O
,	O
Mol.Cell.	O
Biol.14	O
:	O
373-381	O
,	O
1994	O
)	O
.	O

Here	O
we	O
report	O
that	O
the	O
tissue	O
specificity	O
of	O
this	O
promoter	B-DNA
is	O
also	O
mediated	O
by	O
sequences	O
in	O
a	O
region	B-DNA
II	I-DNA
(	O
bp	O
-88	O
to	O
-	O
59	O
)	O
,	O
which	O
lies	O
10	B-DNA
bp	I-DNA
upstream	I-DNA
from	O
the	O
PU.1-binding	B-DNA
site	I-DNA
.	O

When	O
analyzed	O
by	O
DNase	B-protein
footprinting	O
,	O
region	B-DNA
II	I-DNA
was	O
protected	O
preferentially	O
in	O
monocytic	B-cell_type
cells	I-cell_type
.	O

Electrophoretic	O
mobility	O
shift	O
assays	O
confirmed	O
that	O
region	B-DNA
II	I-DNA
interacts	O
specifically	O
with	O
nuclear	B-protein
proteins	I-protein
from	O
monocytic	B-cell_type
cells	I-cell_type
.	O

Two	O
gel	B-protein
shift	I-protein
complexes	I-protein
(	O
Mono	B-protein
A	I-protein
and	O
Mono	B-protein
B	I-protein
)	O
were	O
formed	O
with	O
separate	O
sequence	O
elements	O
within	O
this	O
region	O
.	O

Competition	O
and	O
supershift	O
experiments	O
indicate	O
that	O
Mono	B-protein
B	I-protein
contains	O
a	O
member	O
of	O
the	O
polyomavirus	B-protein
enhancer-binding	I-protein
protein	I-protein
2/core-binding	I-protein
factor	I-protein
(	I-protein
PEBP2/CBF	I-protein
)	I-protein
family	I-protein
,	I-protein
which	O
includes	O
the	O
AML1	O
gene	O
product	O
,	O
while	O
Mono	B-protein
A	I-protein
is	O
a	O
distinct	O
complex	O
preferentially	O
expressed	O
in	O
monocytic	B-cell_type
cells	I-cell_type
.	O

Promoter	B-DNA
constructs	I-DNA
with	O
mutations	O
in	O
these	O
sequence	O
elements	O
were	O
no	O
longer	O
expressed	O
specifically	O
in	O
monocytes	B-cell_type
.	O

Furthermore	O
,	O
multimerized	B-DNA
region	I-DNA
II	I-DNA
sequence	I-DNA
elements	I-DNA
enhanced	O
the	O
activity	O
of	O
a	O
heterologous	O
thymidine	O
kinase	O
promoter	O
in	O
monocytic	B-cell_type
cells	I-cell_type
but	O
not	O
other	O
cell	O
types	O
tested	O
.	O

These	O
results	O
indicate	O
that	O
the	O
monocyte/B-cell-specific	B-protein
transcription	I-protein
factor	I-protein
PU.1	B-protein
and	O
the	O
Mono	B-protein
A	I-protein
and	I-protein
Mono	I-protein
B	I-protein
protein	I-protein
complexes	I-protein
act	O
in	O
concert	O
to	O
regulate	O
monocyte-specific	O
transcription	O
of	O
the	O
CSF-1	B-protein
receptor	I-protein
.	O

Pyrrolidine	O
dithiocarbamate	O
,	O
a	O
potent	O
inhibitor	O
of	O
nuclear	B-protein
factor	I-protein
kappa	I-protein
B	I-protein
(	O
NF-kappa	B-protein
B	I-protein
)	O
activation	O
,	O
prevents	O
apoptosis	O
in	O
human	O
promyelocytic	B-cell_line
leukemia	I-cell_line
HL-60	I-cell_line
cells	I-cell_line
and	O
thymocytes	B-cell_type
.	O

We	O
examined	O
the	O
effect	O
of	O
pyrrolidine	O
dithiocarbamate	O
(	O
PDTC	O
)	O
,	O
which	O
potently	O
blocks	O
the	O
activation	O
of	O
nuclear	B-protein
factor	I-protein
kappa	I-protein
B	I-protein
(	O
NF-kappa	B-protein
B	I-protein
)	O
,	O
on	O
the	O
induction	O
of	O
apoptosis	O
by	O
a	O
variety	O
of	O
agents	O
.	O

Treatment	O
of	O
a	O
human	B-cell_line
promyelocytic	I-cell_line
leukemia	I-cell_line
cell	I-cell_line
line	I-cell_line
,	O
HL-60	B-cell_line
,	O
with	O
10	O
micrograms/mL	O
etoposide	O
or	O
2	O
microM	O
1-beta-D-arabinofuranosylcytosine	O
induced	O
NF-kappa	B-protein
B	I-protein
activation	O
within	O
1	O
hr	O
and	O
subsequently	O
caused	O
apoptosis	O
within	O
3-4	O
hr	O
.	O

The	O
simultaneous	O
addition	O
of	O
50-500	O
microM	O
PDTC	O
with	O
these	O
agents	O
blocked	O
NF-kappa	B-protein
B	I-protein
activation	O
and	O
completely	O
abrogated	O
both	O
morphologically	O
apoptotic	O
changes	O
and	O
internucleosomal	O
DNA	O
fragmentation	O
for	O
up	O
to	O
6	O
hr	O
.	O

However	O
,	O
PDTC	O
failed	O
to	O
inhibit	O
the	O
endonuclease	B-protein
activity	O
contained	O
in	O
the	O
whole	O
cell	O
lysates	O
.	O

The	O
inhibitory	O
effect	O
of	O
PDTC	O
was	O
also	O
observed	O
in	O
etoposide	O
-and	O
dexamethasone-induced	O
apoptosis	O
in	O
human	B-cell_type
thymocytes	I-cell_type
at	O
a	O
concentration	O
of	O
1-10	O
microM	O
.	O

Since	O
PDTC	O
has	O
both	O
antioxidant	O
and	O
metal-ion	O
chelating	O
activities	O
,	O
we	O
tested	O
the	O
effects	O
of	O
N-acetyl-L-cysteine	O
(	O
NAC	O
)	O
(	O
antioxidant	O
)	O
or	O
o-phenanthroline	O
(	O
OP	O
)	O
(	O
metal-ion	O
chelator	O
)	O
on	O
the	O
induction	O
of	O
apoptosis	O
.	O

Pretreatment	O
of	O
HL-60	O
cells	O
or	O
thymocytes	B-cell_type
with	O
100-500	O
microM	O
OP	O
for	O
2	O
hr	O
,	O
but	O
not	O
10-60	O
mM	O
NAC	O
,	O
suppressed	O
subsequent	O
occurrence	O
of	O
apoptosis	O
induced	O
by	O
etoposide	O
.	O

These	O
results	O
suggest	O
that	O
the	O
activation	O
of	O
NF-kappa	B-protein
B	I-protein
plays	O
an	O
important	O
role	O
in	O
the	O
apoptotic	O
process	O
of	O
human	B-cell_type
hematopoietic	I-cell_type
cells	I-cell_type
.	O

Overexpression	O
of	O
protein	B-protein
kinase	I-protein
C-zeta	I-protein
stimulates	O
leukemic	B-cell_type
cell	I-cell_type
differentiation	O
.	O

A	O
function	O
for	O
protein	B-protein
kinase	I-protein
C-zeta	I-protein
(	O
PKC-zeta	B-protein
)	O
,	O
a	O
member	O
of	O
the	O
phorbol	O
ester	O
nonresponsive	O
atypical	O
protein	B-protein
kinase	I-protein
C	I-protein
subfamily	I-protein
,	O
in	O
modulating	O
differentiation	O
was	O
examined	O
in	O
the	O
leukemic	B-cell_line
U937	I-cell_line
cell	I-cell_line
.	O

Transfected	O
U937	B-cell_line
cells	I-cell_line
stably	O
overexpressing	O
PKC-zeta	B-protein
displayed	O
a	O
longer	O
doubling	O
time	O
,	O
lower	O
saturation	O
density	O
at	O
confluency	O
,	O
and	O
an	O
increase	O
in	O
adherence	O
to	O
plastic	O
as	O
compared	O
to	O
control	B-cell_line
cells	I-cell_line
.	O

PKC-zeta	B-cell_line
cells	I-cell_line
expressed	O
a	O
more	O
differentiated	O
phenotype	O
as	O
assessed	O
by	O
changes	O
in	O
morphology	O
,	O
surface	O
antigen	O
expression	O
,	O
and	O
lysosomal	B-protein
enzyme	I-protein
activities	O
and	O
were	O
distinct	O
from	O
parental	B-cell_line
U937	I-cell_line
cells	I-cell_line
stimulated	O
to	O
differentiate	O
by	O
exposure	O
to	O
phorbol	O
esters	O
.	O

In	O
contrast	O
to	O
parental	O
U937	B-cell_line
cells	I-cell_line
,	O
PKC-zeta	B-cell_line
cells	I-cell_line
constitutively	O
expressed	O
mRNA	B-RNA
transcripts	I-RNA
for	O
c-jun	B-DNA
and	O
a	O
low	O
mobility	O
AP-1	B-protein
binding	O
activity	O
.	O

Thus	O
,	O
PKC-zeta	B-protein
overexpression	O
stimulates	O
a	O
type	O
of	O
phenotypic	O
differentiation	O
that	O
differs	O
significantly	O
from	O
maturation	O
occurring	O
upon	O
activation	O
of	O
other	O
PKC	B-protein
subfamilies	I-protein
induced	O
by	O
phorbol	O
ester	O
treatment	O
.	O

Increased	O
expression	O
of	O
the	O
c-jun	B-DNA
protooncogene	O
and	O
an	O
increase	O
in	O
AP-1	B-protein
binding	O
activity	O
in	O
PKC-zeta	B-cell_line
cells	I-cell_line
provides	O
a	O
potential	O
mechanism	O
for	O
explaining	O
the	O
altered	O
differentiation	O
status	O
of	O
this	O
cell	O
.	O

A	O
family	O
of	O
serine	B-protein
proteases	I-protein
expressed	O
exclusively	O
in	O
myelo-	O
monocytic	B-cell_type
cells	I-cell_type
specifically	O
processes	O
the	O
nuclear	B-protein
factor-kappa	I-protein
B	I-protein
subunit	I-protein
p65	I-protein
in	O
vitro	O
and	O
may	O
impair	O
human	O
immunodeficiency	O
virus	O
replication	O
in	O
these	O
cells	O
.	O

Two	O
groups	O
of	O
U937	B-cell_line
promonocytic	I-cell_line
cells	I-cell_line
were	O
obtained	O
by	O
limiting	O
dilution	O
cloning	O
which	O
differed	O
strikingly	O
in	O
their	O
ability	O
to	O
support	O
human	O
immunodeficiency	O
virus	O
1	O
(	O
HIV-1	O
)	O
replication	O
.	O

``	B-cell_line
Plus	I-cell_line
''	I-cell_line
clones	I-cell_line
replicated	O
the	O
virus	O
efficiently	O
,	O
whereas	O
``	B-cell_line
minus	I-cell_line
''	I-cell_line
clones	I-cell_line
did	O
not	O
.	O

We	O
examined	O
these	O
clones	O
for	O
differences	O
in	O
nuclear	B-protein
factor	I-protein
(	I-protein
NF	I-protein
)	I-protein
-kappa	I-protein
B	I-protein
activity	O
which	O
might	O
account	O
for	O
the	O
observed	O
phenomenon	O
.	O

Stimulation	O
of	O
plus	B-cell_line
clones	I-cell_line
liberated	O
the	O
classical	O
p50-p65	B-protein
complex	I-protein
from	O
cytoplasmic	O
pools	O
,	O
whereas	O
minus	B-cell_line
clones	I-cell_line
produced	O
an	O
apparently	O
novel	O
,	O
faster-migrating	B-protein
complex	I-protein
,	O
as	O
judged	O
by	O
electrophoretic	O
mobility	O
shift	O
assays	O
.	O

It	O
is	O
surprising	O
that	O
the	O
faster-migrating	B-protein
complex	I-protein
was	O
composed	O
also	O
of	O
p50	B-protein
and	O
p65	B-protein
.	O

However	O
,	O
the	O
p65	B-protein
subunit	I-protein
was	O
COOH-terminally	O
truncated	O
,	O
as	O
shown	O
by	O
immunoprecipitation	O
.	O

The	O
truncation	O
resulted	O
from	O
limited	O
proteolysis	O
of	O
p65	B-protein
during	O
cellular	O
extraction	O
which	O
released	O
particular	O
lysosomal	B-protein
serine	I-protein
proteases	I-protein
,	O
such	O
as	O
elastase	B-protein
,	O
cathepsin	B-protein
G	I-protein
,	O
and	O
proteinase	B-protein
3	I-protein
.	O

These	O
specific	O
proteases	O
are	O
coordinately	O
expressed	O
and	O
were	O
present	O
exclusively	O
in	O
the	O
minus	B-cell_line
U937	I-cell_line
clones	I-cell_line
,	O
but	O
not	O
in	O
the	O
plus	B-cell_line
clones	I-cell_line
,	O
as	O
demonstrated	O
in	O
the	O
case	O
of	O
cathepsin	B-protein
G	I-protein
.	O

In	O
addition	O
,	O
these	O
proteases	O
were	O
detected	O
in	O
certain	O
subclones	O
of	O
THP-1	B-cell_line
and	O
HL-60	B-cell_line
cells	I-cell_line
and	O
in	O
primary	O
monocytes	B-cell_type
,	O
in	O
each	O
case	O
correlating	O
with	O
the	O
truncated	O
from	O
of	O
p65	B-protein
.	O

We	O
demonstrate	O
in	O
vitro	O
cleavage	O
of	O
p65	B-protein
by	O
purified	O
elastase	B-protein
and	O
cathepsin	B-protein
G	I-protein
.	O

It	O
is	O
possible	O
that	O
particular	O
serine	B-protein
proteases	I-protein
may	O
have	O
inhibiting	O
effects	O
on	O
the	O
replication	O
of	O
HIV-1	O
in	O
myelo-monocytic	B-cell_line
cells	I-cell_line
.	O

The	O
data	O
also	O
demonstrate	O
that	O
special	O
precautions	O
must	O
be	O
taken	O
when	O
making	O
extracts	O
from	O
myelo-monocytic	B-cell_line
cells	I-cell_line
.	O

A	O
germline	B-DNA
TaqI	I-DNA
restriction	I-DNA
fragment	I-DNA
length	I-DNA
polymorphism	I-DNA
in	O
the	O
progesterone	B-DNA
receptor	I-DNA
gene	I-DNA
in	O
ovarian	O
carcinoma	O
[	O
see	O
comments	O
]	O

Clinical	O
outcome	O
in	O
ovarian	O
carcinoma	O
is	O
predicted	O
by	O
progesterone	B-protein
receptor	I-protein
status	O
,	O
indicating	O
an	O
endocrine	O
aspect	O
to	O
this	O
disease	O
.	O

Peripheral	B-DNA
leucocyte	I-DNA
genomic	I-DNA
DNAs	I-DNA
were	O
obtained	O
from	O
41	O
patients	O
with	O
primary	O
ovarian	O
carcinoma	O
and	O
83	O
controls	O
from	O
Ireland	O
,	O
as	O
well	O
as	O
from	O
26	O
primary	O
ovarian	O
carcinoma	O
patients	O
and	O
101	O
controls	O
in	O
Germany	O
.	O

Southern	O
analysis	O
using	O
a	O
human	B-DNA
progesterone	I-DNA
receptor	I-DNA
(	I-DNA
hPR	I-DNA
)	I-DNA
cDNA	I-DNA
probe	I-DNA
identified	O
a	O
germline	B-DNA
TaqI	I-DNA
restriction	I-DNA
fragment	I-DNA
length	I-DNA
polymorphism	I-DNA
(	O
RFLP	B-DNA
)	O
defined	O
by	O
two	O
alleles	O
:	O
T1	B-DNA
,	O
represented	O
by	O
a	O
2.7	B-DNA
kb	I-DNA
fragment	I-DNA
;	O
and	O
T2	B-DNA
,	O
represented	O
by	O
a	O
1.9	B-DNA
kb	I-DNA
fragment	I-DNA
and	O
characterised	O
by	O
an	O
additional	O
TaqI	B-DNA
restriction	I-DNA
site	I-DNA
with	O
respect	O
to	O
T1	B-DNA
.	O

An	O
over-representation	O
of	O
T2	B-DNA
in	O
ovarian	O
cancer	O
patients	O
compared	O
with	O
controls	O
in	O
the	O
pooled	O
Irish/German	O
population	O
(	O
P	O
<	O
0.025	O
)	O
was	O
observed	O
.	O

A	O
difference	O
(	O
P	O
<	O
0.02	O
)	O
in	O
the	O
distribution	O
of	O
the	O
RFLP	B-DNA
genotypes	O
between	O
Irish	O
and	O
German	O
control	O
populations	O
was	O
also	O
observed	O
.	O

The	O
allele	O
distributions	O
could	O
not	O
be	O
shown	O
to	O
differ	O
significantly	O
from	O
Hardy-Weinberg	O
distribution	O
in	O
any	O
subgroup	O
.	O

Using	O
hPR	B-DNA
cDNA	I-DNA
region-specific	I-DNA
probes	I-DNA
,	O
the	O
extra	O
TaqI	O
restriction	O
site	O
was	O
mapped	O
to	O
intron	B-DNA
G	I-DNA
of	O
the	O
hPR	B-DNA
gene	I-DNA
.	O

OBF-1	B-protein
,	O
a	O
novel	B-protein
B	I-protein
cell-specific	I-protein
coactivator	I-protein
that	O
stimulates	O
immunoglobulin	B-DNA
promoter	I-DNA
activity	O
through	O
association	O
with	O
octamer-binding	B-protein
proteins	I-protein
.	O

Recent	O
biochemical	O
and	O
genetic	O
studies	O
indicate	O
that	O
in	O
addition	O
to	O
the	O
octamer-binding	B-protein
proteins	I-protein
Oct-1	B-protein
and	O
Oct-2	B-protein
,	O
other	O
B	B-protein
cell	I-protein
components	I-protein
are	O
required	O
for	O
lymphoid-restricted	O
,	O
octamer	O
site-mediated	O
immunoglobulin	B-DNA
gene	I-DNA
promoter	I-DNA
activity	O
.	O

Using	O
a	O
genetic	O
screen	O
in	O
yeast	O
,	O
we	O
have	O
isolated	O
B	B-DNA
cell-derived	I-DNA
cDNAs	I-DNA
encoding	O
Oct-binding	B-protein
factor	I-protein
1	I-protein
(	O
OBF-1	B-protein
)	O
,	O
a	O
novel	O
protein	O
that	O
specifically	O
associates	O
with	O
Oct-1	B-protein
and	O
Oct-2	B-protein
.	O

Biochemical	O
studies	O
demonstrate	O
that	O
OBF-1	B-protein
has	O
no	O
intrinsic	O
DNA-binding	O
activity	O
and	O
recognizes	O
the	O
POU	B-protein
domains	I-protein
of	O
Oct-1	B-protein
and	O
Oct-2	B-protein
,	O
but	O
not	O
those	O
of	O
Oct-4	B-protein
and	O
Oct-6	B-protein
.	O

The	O
OBF-1	B-RNA
mRNA	I-RNA
is	O
expressed	O
in	O
a	O
highly	O
cell-specific	O
manner	O
,	O
being	O
most	O
abundant	O
in	O
B	B-cell_type
cells	I-cell_type
and	O
essentially	O
absent	O
in	O
most	O
of	O
the	O
other	O
cells	O
or	O
tissues	O
tested	O
.	O

Furthermore	O
,	O
expression	O
of	O
OBF-1	B-protein
in	O
HeLa	B-cell_line
cells	I-cell_line
selectively	O
stimulates	O
the	O
activity	O
of	O
a	O
natural	O
immunoglobulin	B-DNA
promoter	I-DNA
in	O
an	O
octamer	B-DNA
site	I-DNA
-dependent	O
manner	O
.	O

Thus	O
,	O
OBF-1	B-protein
has	O
all	O
the	O
properties	O
expected	O
for	O
a	O
B	B-protein
cell-specific	I-protein
transcriptional	I-protein
coactivator	I-protein
protein	I-protein
.	O

Modulation	O
of	O
transcription	B-protein
factor	I-protein
NF	I-protein
kappa	I-protein
B	I-protein
activity	O
by	O
intracellular	O
glutathione	O
levels	O
and	O
by	O
variations	O
of	O
the	O
extracellular	O
cysteine	O
supply	O
.	O

HIV-infected	O
individuals	O
and	O
SIV-infected	O
rhesus	O
macaques	O
have	O
,	O
on	O
the	O
average	O
,	O
decreased	O
plasma	O
cysteine	O
and	O
cystine	O
concentrations	O
and	O
decreased	O
intracellular	O
glutathione	O
levels	O
.	O

We	O
now	O
show	O
that	O
a	O
depletion	O
of	O
intracellular	O
glutathione	O
in	O
a	O
human	B-cell_line
T	I-cell_line
cell	I-cell_line
line	I-cell_line
(	O
Molt-4	B-cell_line
)	O
inhibits	O
the	O
activation	O
and	O
nuclear	O
translocation	O
of	O
the	O
transcription	B-protein
factor	I-protein
NF	I-protein
kappa	I-protein
B	I-protein
,	O
whereas	O
incubation	O
with	O
increasing	O
extracellular	O
concentrations	O
of	O
cysteine	O
inhibits	O
the	O
DNA-binding	O
and	O
transactivating	O
activity	O
of	O
NF	B-protein
kappa	I-protein
B	I-protein
.	O

Because	O
inhibition	O
of	O
DNA-binding	O
activity	O
is	O
associated	O
with	O
increasing	O
intracellular	O
glutathione	O
disulfide	O
levels	O
and	O
GSSG	B-protein
can	O
be	O
shown	O
to	O
inhibit	O
the	O
DNA-binding	O
activity	O
directly	O
in	O
cell-free	O
systems	O
,	O
our	O
studies	O
suggest	O
that	O
GSSG	B-protein
is	O
a	O
physiologically	O
relevant	O
inhibitor	O
in	O
intact	B-cell_type
cells	I-cell_type
also	O
.	O

NF	B-protein
kappa	I-protein
B	I-protein
controls	O
many	O
immunologically	B-DNA
important	I-DNA
genes	I-DNA
,	O
so	O
our	O
studies	O
suggest	O
that	O
the	O
immune	O
system	O
may	O
be	O
sensitive	O
not	O
only	O
against	O
a	O
cysteine	O
and	O
glutathione	O
deficiency	O
but	O
also	O
against	O
an	O
excess	O
of	O
cysteine	O
.	O

Two	O
distinct	O
signalling	O
pathways	O
are	O
involved	O
in	O
the	O
control	O
of	O
the	O
biphasic	O
junB	B-DNA
transcription	O
induced	O
by	O
interleukin-6	B-protein
in	O
the	O
B	B-cell_line
cell	I-cell_line
hybridoma	I-cell_line
7TD1	I-cell_line
.	O

We	O
have	O
measured	O
the	O
level	O
of	O
junB	B-RNA
mRNA	I-RNA
in	O
the	O
B	B-cell_line
hybridoma	I-cell_line
cell	I-cell_line
line	I-cell_line
7TD1	I-cell_line
,	O
under	O
interleukin-6	B-protein
(	O
IL-6	B-protein
)	O
stimulation	O
.	O

IL-6	B-protein
increases	O
junB	B-RNA
mRNA	I-RNA
in	O
a	O
biphasic	O
fashion	O
.	O

The	O
first	O
early-induced	O
peak	O
was	O
transient	O
and	O
likely	O
corresponds	O
to	O
the	O
well	O
documented	O
typical	O
junB	B-RNA
mRNA	I-RNA
,	O
stimulated	O
in	O
response	O
to	O
numerous	O
growth	B-protein
factors	I-protein
,	O
including	O
IL-6	B-protein
.	O

At	O
variance	O
,	O
the	O
second	O
peak	O
which	O
has	O
never	O
been	O
reported	O
previously	O
,	O
lasted	O
several	O
hours	O
.	O

As	O
a	O
consequence	O
of	O
its	O
effect	O
on	O
junB	B-RNA
mRNA	I-RNA
,	O
IL-6	B-protein
stimulated	O
,	O
in	O
a	O
biphasic	O
fashion	O
,	O
the	O
nuclear	O
accumulation	O
of	O
the	O
JunB	B-protein
protein	I-protein
.	O

In	O
this	O
study	O
,	O
we	O
demonstrated	O
that	O
IL-6	B-protein
regulation	O
occurred	O
exclusively	O
at	O
the	O
transcriptional	O
level	O
and	O
that	O
the	O
bimodal	O
increase	O
of	O
junB	B-RNA
mRNA	I-RNA
and	O
JunB	B-protein
protein	I-protein
can	O
be	O
accounted	O
for	O
by	O
a	O
biphasic	O
stimulation	O
of	O
junB	B-DNA
transcription	O
.	O

Furthermore	O
,	O
our	O
data	O
point	O
to	O
two	O
major	O
differences	O
between	O
the	O
mechanism	O
of	O
control	O
of	O
the	O
early	O
and	O
the	O
late	O
IL-6	B-protein
-induced	O
junB	B-DNA
transcription	O
waves	O
.	O

First	O
,	O
cycloheximide	O
strongly	O
potentiated	O
the	O
transcription	O
of	O
the	O
second	O
wave	O
,	O
whereas	O
it	O
failed	O
to	O
affect	O
the	O
early-induced	O
burst	O
.	O

Second	O
,	O
tyrphostin	O
,	O
a	O
tyrosine	O
kinase	O
inhibitor	O
,	O
impaired	O
the	O
expression	O
of	O
the	O
first	O
but	O
not	O
the	O
second	O
junB	B-RNA
mRNA	I-RNA
peak	O
.	O

Conversely	O
,	O
genistein	O
,	O
another	O
tyrosine	O
kinase	O
inhibitor	O
,	O
totally	O
abolished	O
the	O
expression	O
of	O
the	O
second	O
peak	O
of	O
junB	B-RNA
mRNA	I-RNA
whereas	O
it	O
did	O
not	O
affect	O
the	O
expression	O
of	O
the	O
first	O
peak	O
.	O

Altogether	O
these	O
data	O
indicate	O
that	O
,	O
in	O
7TD1	B-cell_line
cells	I-cell_line
,	O
IL-6	B-protein
controls	O
junB	B-DNA
transcription	O
in	O
a	O
biphasic	O
fashion	O
by	O
means	O
of	O
two	O
separate	O
transduction	O
pathways	O
.	O

A	O
newly	O
established	O
megakaryoblastic/erythroid	B-cell_line
cell	I-cell_line
line	I-cell_line
that	O
differentiates	O
to	O
red	B-cell_type
cells	I-cell_type
in	O
the	O
presence	O
of	O
erythropoietin	B-protein
and	O
produces	O
platelet-like	B-cell_type
particles	I-cell_type
.	O

In	O
August	O
,	O
1992	O
,	O
we	O
established	O
a	O
leukemic	B-cell_line
cell	I-cell_line
line	I-cell_line
(	O
NS-Meg	B-cell_line
)	O
from	O
a	O
patient	O
in	O
megakaryoblastic	O
transformation	O
of	O
Philadelphia	O
chromosome-positive	O
chronic	O
myeloid	O
leukemia	O
.	O

The	O
NS-Meg	B-cell_line
cells	I-cell_line
were	O
positive	O
for	O
alpha-naphthyl	B-protein
acetate	I-protein
esterase	I-protein
and	O
periodic	O
acid-Schiff	O
(	O
PAS	O
)	O
staining	O
and	O
for	O
surface	O
CD4	B-protein
,	O
CD7	B-protein
,	O
CD13	B-protein
,	O
CD34	B-protein
,	O
CD41a	B-protein
,	O
and	O
glycophorin	B-protein
A	I-protein
antigens	I-protein
.	O

Ultrastructurally	O
,	O
the	O
cells	O
had	O
alpha-granules	O
,	O
demarcation	O
membranes	O
,	O
and	O
platelet	B-protein
peroxidase	I-protein
activity	O
.	O

The	O
NS-Meg	B-cell_line
cells	I-cell_line
spontaneously	O
produced	O
platelet-like	B-cell_type
particles	I-cell_type
which	O
contained	O
alpha-granules	O
,	O
mitochondria	O
and	O
dense	O
bodies	O
,	O
strongly	O
suggesting	O
platelet	O
production	O
.	O

Erythropoietin	B-protein
(	O
Epo	B-protein
)	O
,	O
granulocyte/macrophage	B-protein
colony	I-protein
stimulating	I-protein
factor	I-protein
(	O
GM-CSF	B-protein
)	O
,	O
and	O
interleukin	B-protein
3	I-protein
(	O
IL-3	B-protein
)	O
promoted	O
the	O
growth	O
of	O
NS-Meg	B-cell_line
cells	I-cell_line
.	O

Phorbol-12-myristate-13-acetate	O
increased	O
the	O
expression	O
of	O
both	O
CD41a	B-protein
and	O
CD61	O
antigens	O
.	O

Ten-day	O
exposure	O
to	O
Epo	B-protein
induced	O
mature	B-cell_type
erythroblasts	I-cell_type
and	O
red	B-cell_type
cells	I-cell_type
.	O

These	O
benzidine-positive	B-cell_line
cells	I-cell_line
were	O
positive	O
for	O
hemoglobin	B-protein
F	O
staining	O
.	O

Untreated	O
NS-Meg	B-cell_line
cells	I-cell_line
expressed	O
mRNA	B-RNA
for	O
the	O
Epo	B-protein
receptor	I-protein
(	O
EpoR	B-protein
)	O
,	O
for	O
GATA-1	B-protein
,	O
and	O
for	O
alpha	B-DNA
1	I-DNA
,	I-DNA
alpha	I-DNA
2	I-DNA
and	I-DNA
gamma	I-DNA
globin	I-DNA
genes	I-DNA
.	O

These	O
results	O
indicate	O
that	O
NS-Meg	B-cell_line
cells	I-cell_line
undergo	O
terminal	O
differentiation	O
of	O
both	O
megakaryocytic	B-cell_type
and	I-cell_type
erythroid	I-cell_type
lineages	I-cell_type
.	O

This	O
cell	B-cell_line
line	I-cell_line
should	O
be	O
a	O
very	O
useful	O
tool	O
for	O
the	O
investigation	O
of	O
both	O
megakaryocytic	O
and	O
erythroid	O
maturation	O
.	O

Differential	O
regulation	O
of	O
proto-oncogenes	B-DNA
c-jun	B-DNA
and	O
c-fos	B-DNA
in	O
T	B-cell_type
lymphocytes	I-cell_type
activated	O
through	O
CD28	B-protein
.	O

The	O
T	B-protein
cell	I-protein
surface	I-protein
molecule	I-protein
CD28	B-protein
binds	O
to	O
ligands	O
on	O
accessory	B-cell_type
cells	I-cell_type
and	O
APCs	B-cell_type
,	O
playing	O
an	O
important	O
costimulatory	O
role	O
in	O
the	O
response	O
of	O
T	B-cell_type
cells	I-cell_type
to	O
Ags	B-protein
.	O

Our	O
knowledge	O
of	O
the	O
intracellular	O
signaling	O
pathways	O
coupled	O
to	O
this	O
receptor	O
is	O
incomplete	O
.	O

In	O
addition	O
to	O
activation	O
of	O
phospholipase	B-protein
C	I-protein
gamma	I-protein
1	I-protein
,	O
ligation	O
of	O
this	O
receptor	O
also	O
seems	O
to	O
activate	O
a	O
calcium-independent	O
,	O
CD28	B-protein
-specific	O
pathway	O
.	O

In	O
this	O
paper	O
,	O
we	O
report	O
that	O
cross-linking	O
of	O
CD28	B-protein
(	O
but	O
not	O
CD2	B-protein
,	O
CD5	B-protein
,	O
LFA-1	B-protein
,	O
or	O
CD7	B-protein
)	O
leads	O
to	O
an	O
elevation	O
of	O
c-jun	B-RNA
mRNA	I-RNA
,	O
with	O
only	O
minimal	O
activation	O
of	O
c-fos	B-DNA
expression	O
.	O

CD28	B-protein
-dependent	O
induction	O
of	O
c-jun	B-DNA
expression	O
requires	O
protein	B-protein
tyrosine	I-protein
kinase	I-protein
activity	O
,	O
but	O
does	O
not	O
depend	O
on	O
activation	O
of	O
a	O
phorbol	B-protein
ester-responsive	I-protein
protein	I-protein
kinase	I-protein
C	I-protein
or	O
elevation	O
of	O
cytosolic	O
calcium	O
.	O

Furthermore	O
,	O
CD28	B-protein
-dependent	O
elevation	O
of	O
c-jun	B-RNA
mRNA	I-RNA
does	O
not	O
appear	O
to	O
be	O
mediated	O
at	O
the	O
level	O
of	O
mRNA	O
stability	O
.	O

A	O
mechanism	O
is	O
suggested	O
whereby	O
expression	O
of	O
c-jun	B-DNA
and	O
junB	B-DNA
,	O
in	O
the	O
absence	O
of	O
members	O
of	O
the	O
fos	B-DNA
family	I-DNA
,	O
can	O
prevent	O
inappropriate	O
activation	O
of	O
T	B-cell_type
cells	I-cell_type
caused	O
by	O
ligation	O
of	O
CD28	B-protein
in	O
the	O
absence	O
of	O
a	O
specific	O
antigenic	O
stimulus	O
.	O

Enhanced	O
responsiveness	O
to	O
nuclear	B-protein
factor	I-protein
kappa	I-protein
B	I-protein
contributes	O
to	O
the	O
unique	O
phenotype	O
of	O
simian	O
immunodeficiency	O
virus	O
variant	O
SIVsmmPBj14	O
.	O

Infection	O
with	O
a	O
variant	O
of	O
simian	O
immunodeficiency	O
virus	O
,	O
SIVsmmPBj14	O
,	O
leads	O
to	O
severe	O
acute	O
disease	O
in	O
macaques	O
.	O

This	O
study	O
was	O
designed	O
to	O
investigate	O
the	O
functional	O
significance	O
of	O
previously	O
described	O
mutations	O
in	O
the	O
viral	B-DNA
long	I-DNA
terminal	I-DNA
repeat	I-DNA
(	O
LTR	B-DNA
)	O
and	O
to	O
elucidate	O
their	O
contribution	O
to	O
the	O
unique	O
phenotype	O
of	O
SIVsmmPBj14	O
.	O

LTR	B-DNA
-directed	O
transcription	O
was	O
measured	O
by	O
using	O
luciferase	B-DNA
reporter	I-DNA
constructs	I-DNA
that	O
were	O
transiently	O
transfected	O
into	O
cultured	B-cell_line
cells	I-cell_line
.	O

In	O
a	O
wide	O
range	O
of	O
cell	O
types	O
,	O
the	O
basal	O
transcriptional	O
activity	O
of	O
the	O
LTR	B-DNA
from	O
SIVsmmPBj14	O
was	O
found	O
to	O
be	O
2-	O
to	O
4.5-fold	O
higher	O
than	O
that	O
of	O
an	O
LTR	B-DNA
from	O
a	O
non-acutely	O
pathogenic	O
strain	O
.	O

These	O
LTRs	B-DNA
differ	O
by	O
five	O
point	O
mutations	O
and	O
a	O
22-bp	B-DNA
duplication	I-DNA
in	O
SIVsmmPBj14	O
,	O
which	O
includes	O
a	O
nuclear	B-DNA
factor	I-DNA
kappa	I-DNA
B	I-DNA
(	I-DNA
NF	I-DNA
kappa	I-DNA
B	I-DNA
)	I-DNA
site	I-DNA
.	O

Transcriptional	O
differences	O
between	O
these	O
LTRs	B-DNA
were	O
further	O
enhanced	O
by	O
two-	O
to	O
threefold	O
upon	O
treatment	O
of	O
cells	O
with	O
phorbol	O
ester	O
or	O
tumor	B-protein
necrosis	I-protein
factor	I-protein
alpha	I-protein
or	O
by	O
cotransfection	O
with	O
plasmids	B-DNA
expressing	O
NF	B-protein
kappa	I-protein
B	I-protein
subunits	O
.	O

Mutagenesis	O
studies	O
,	O
and	O
the	O
use	O
of	O
a	O
reporter	O
construct	O
containing	O
an	O
enhancerless	O
promoter	O
,	O
indicate	O
that	O
these	O
transcriptional	O
effects	O
are	O
due	O
principally	O
to	O
the	O
22-bp	B-DNA
sequence	I-DNA
duplication	I-DNA
and	O
the	O
NF	B-DNA
kappa	I-DNA
B	I-DNA
site	I-DNA
contained	O
within	O
it	O
.	O

Finally	O
,	O
infectious	O
virus	O
stocks	O
that	O
were	O
isogenic	O
except	O
for	O
the	O
LTR	B-DNA
were	O
generated	O
.	O

The	O
LTR	B-DNA
from	O
SIVsmmPBj14	O
was	O
found	O
to	O
confer	O
an	O
increase	O
in	O
the	O
kinetics	O
of	O
virus	O
replication	O
in	O
cultured	B-cell_line
cells	I-cell_line
.	O

Inclusion	O
of	O
this	O
LTR	B-DNA
in	O
recombinant	O
SIVs	O
also	O
resulted	O
in	O
a	O
two-	O
to	O
threefold	O
rise	O
in	O
the	O
extent	O
of	O
cellular	O
proliferation	O
that	O
was	O
induced	O
in	O
quiescent	B-cell_line
simian	I-cell_line
peripheral	I-cell_line
blood	I-cell_line
mononuclear	I-cell_line
cells	I-cell_line
.	O

These	O
studies	O
are	O
consistent	O
with	O
the	O
hypothesis	O
that	O
LTR	B-DNA
mutations	O
assist	O
SIVsmmPBj14	O
in	O
responding	O
efficiently	O
to	O
cellular	O
stimulation	O
and	O
allow	O
it	O
to	O
replicate	O
to	O
high	O
titers	O
during	O
the	O
acute	O
phase	O
of	O
viral	O
infection	O
.	O

Constitutive	O
nuclear	B-protein
NF-kappa	I-protein
B	I-protein
in	O
cells	O
of	O
the	O
monocyte	O
lineage	O
.	O

In	O
monocytes	B-cell_type
,	O
the	O
nuclear	B-protein
factor	I-protein
NF-kappa	I-protein
B	I-protein
has	O
been	O
invoked	O
as	O
an	O
important	O
transcription	B-protein
factor	I-protein
in	O
the	O
expression	O
of	O
cytokine	B-DNA
genes	I-DNA
,	O
of	O
cell-surface	B-protein
receptors	I-protein
and	O
in	O
the	O
expression	O
of	O
human	O
immunodeficiency	O
virus	O
.	O

In	O
such	O
cells	O
,	O
DNA	O
binding	O
activity	O
of	O
NF-kappa	B-protein
B	I-protein
can	O
be	O
detected	O
without	O
intentional	O
stimulation	O
.	O

In	O
our	O
studies	O
,	O
cells	O
of	O
the	O
human	B-cell_line
monocytic	I-cell_line
line	I-cell_line
Mono	B-cell_line
Mac	I-cell_line
6	I-cell_line
,	O
cultured	O
in	O
medium	O
containing	O
fetal-calf	O
serum	O
and	O
low	O
levels	O
of	O
lipopolysaccharide	O
(	O
LPS	O
)	O
,	O
also	O
exhibit	O
such	O
'constitutive	O
'	O
NF-kappa	B-protein
B	I-protein
,	O
as	O
demonstrated	O
by	O
mobility-shift	O
analysis	O
of	O
nuclear	O
extracts	O
.	O

This	O
nuclear	B-protein
NF-kappa	I-protein
B	I-protein
was	O
still	O
present	O
when	O
contaminant	O
LPS	O
was	O
removed	O
by	O
ultrafiltration	O
and	O
when	O
serum	O
was	O
omitted	O
.	O

Protein-DNA	O
complexes	O
of	O
constitutive	O
NF-kappa	B-protein
B	I-protein
are	O
similar	O
in	O
mobility	O
to	O
the	O
LPS-induced	B-protein
NF-kappa	I-protein
B	I-protein
and	O
both	O
are	O
recognized	O
by	O
an	O
antibody	O
specific	O
to	O
the	O
p50	B-protein
subunit	I-protein
of	O
NF-kappa	B-protein
B	I-protein
.	O

By	O
contrast	O
,	O
treatment	O
of	O
cells	O
with	O
pyrrolidine	O
dithiocarbamate	O
(	O
PDTC	O
)	O
will	O
only	O
block	O
LPS-induced	B-protein
NF-kappa	I-protein
B	I-protein
,	O
but	O
not	O
the	O
constitutive	B-protein
binding	I-protein
protein	I-protein
.	O

Using	O
LPS-free	O
and	O
serum-free	O
conditions	O
,	O
constitutive	O
NF-kappa	B-protein
B	I-protein
can	O
be	O
detected	O
in	O
different	O
cell	B-cell_line
lines	I-cell_line
of	O
the	O
monocytic	B-cell_type
lineage	I-cell_type
(	O
HL60	B-cell_line
,	O
U937	B-cell_line
,	O
THP-1	B-cell_line
,	O
Mono	B-cell_line
Mac	I-cell_line
1	I-cell_line
and	O
Mono	B-cell_line
Mac	I-cell_line
6	I-cell_line
)	O
,	O
but	O
not	O
in	O
Molt	B-cell_line
4	I-cell_line
T	I-cell_line
cells	I-cell_line
or	O
K562	B-cell_line
stem	I-cell_line
cells	I-cell_line
.	O

When	O
ordered	O
according	O
to	O
stage	O
of	O
maturation	O
,	O
the	O
amount	O
of	O
constitutive	O
NF-kappa	B-protein
B	I-protein
was	O
not	O
increased	O
in	O
more	O
mature	B-cell_line
cell	I-cell_line
lines	I-cell_line
.	O

Furthermore	O
,	O
when	O
inducing	O
differentiation	O
in	O
Mono	B-cell_line
Mac	I-cell_line
6	I-cell_line
cells	I-cell_line
,	O
with	O
vitamin	O
D3	O
,	O
no	O
change	O
in	O
constitutive	O
or	O
inducible	O
NF-kappa	B-protein
B	I-protein
can	O
be	O
detected	O
.	O

Analysis	O
of	O
primary	O
cells	O
revealed	O
substantial	O
constitutive	O
NF-kappa	B-protein
B	I-protein
-binding	O
activity	O
in	O
blood	B-cell_type
monocytes	I-cell_type
,	O
pleural	B-cell_type
macrophages	I-cell_type
and	O
alveolar	B-cell_type
macrophages	I-cell_type
.	O

The	O
constitutive	O
NF-kappa	B-protein
B	I-protein
appears	O
to	O
be	O
functionally	O
active	O
,	O
since	O
a	O
low	O
level	O
of	O
tumour	B-RNA
necrosis	I-RNA
factor	I-RNA
(	I-RNA
TNF	I-RNA
)	I-RNA
transcript	I-RNA
is	O
detectable	O
in	O
monocytes	B-cell_type
,	O
and	O
this	O
level	O
can	O
be	O
increased	O
by	O
blocking	O
transcript	O
degradation	O
using	O
cycloheximide	O
.	O

The	O
level	O
of	O
constitutive	O
NF-kappa	B-protein
B	I-protein
in	O
these	O
cells	O
is	O
variable	O
and	O
is	O
frequently	O
found	O
to	O
be	O
lower	O
in	O
the	O
more	O
mature	B-cell_type
macrophages	I-cell_type
.	O

Constitutive	O
NF-kappa	B-protein
B	I-protein
was	O
not	O
maintained	O
by	O
autocrine	O
action	O
of	O
cytokines	B-protein
TNF	B-protein
,	O
interleukin	B-protein
6	I-protein
,	O
interleukin	B-protein
10	O
,	O
granulocyte-macrophage	B-protein
colony-stimulating	I-protein
factor	I-protein
or	O
macrophage	B-protein
colony-stimulating	I-protein
factor	I-protein
,	O
since	O
neutralizing	O
antibodies	O
did	O
not	O
reduce	O
constitutive	O
DNA-binding	O
activity	O
.	O

Furthermore	O
,	O
blockade	O
of	O
prostaglandin	O
or	O
leukotriene	O
biosynthesis	O
did	O
not	O
affect	O
constitutive	O
NF-kappa	B-protein
B	I-protein
.	O

(	O
ABSTRACT	O
TRUNCATED	O
AT	O
400	O
WORDS	O
)	O

Steel	B-protein
factor	I-protein
affects	O
SCL	B-protein
expression	O
during	O
normal	O
erythroid	O
differentiation	O
.	O

Steel	B-protein
factor	I-protein
is	O
one	O
of	O
the	O
growth	B-protein
factors	I-protein
that	O
controls	O
the	O
proliferation	O
and	O
differentiation	O
of	O
hematopoietic	B-cell_type
cells	I-cell_type
and	O
SCL	B-protein
,	O
also	O
known	O
as	O
Tcl-5	B-protein
or	O
Tal-1	B-protein
,	O
is	O
a	O
transcription	B-protein
factor	I-protein
involved	O
in	O
erythropoiesis	O
.	O

In	O
this	O
report	O
,	O
we	O
studied	O
the	O
role	O
of	O
SCL	O
in	O
the	O
proliferation	O
of	O
human	B-cell_type
peripheral	I-cell_type
blood	I-cell_type
burst-forming	I-cell_type
unit-erythroid	I-cell_type
(	O
BFU-E	B-cell_type
)	O
and	O
the	O
effects	O
of	O
Steel	B-protein
factor	I-protein
on	O
SCL	B-protein
expression	O
in	O
proliferating	B-cell_type
erythroid	I-cell_type
cells	I-cell_type
.	O

BFU-E-derived	B-cell_line
colonies	I-cell_line
increase	O
progressively	O
in	O
size	O
,	O
as	O
determined	O
by	O
cell	O
number	O
,	O
from	O
day	O
7	O
to	O
day	O
14	O
of	O
culture	O
,	O
with	O
the	O
greatest	O
increase	O
in	O
colony	O
size	O
(	O
10-fold	O
expansion	O
)	O
occurring	O
between	O
day	O
7	O
and	O
day	O
10	O
.	O

SCL	B-protein
protein	I-protein
levels	O
in	O
BFU-E-derived	B-cell_line
cells	I-cell_line
were	O
highest	O
in	O
day	O
7	O
cells	O
and	O
decreased	O
progressively	O
from	O
day	O
7	O
to	O
day	O
14	O
of	O
culture	O
,	O
suggesting	O
an	O
association	O
of	O
SCL	B-protein
with	O
erythroid	O
proliferation	O
.	O

In	O
contrast	O
,	O
SCL	B-RNA
mRNA	I-RNA
levels	O
did	O
not	O
decrease	O
significantly	O
between	O
day	O
7	O
and	O
day	O
14	O
cells	O
,	O
suggesting	O
that	O
posttranscriptional	O
mechanisms	O
are	O
largely	O
responsible	O
for	O
the	O
decrease	O
in	O
SCL	B-protein
protein	I-protein
observed	O
.	O

The	O
role	O
of	O
SCL	B-protein
in	O
Steel	B-protein
factor	I-protein
-induced	O
erythroid	O
proliferation	O
was	O
then	O
examined	O
.	O

In	O
BFU-E-derived	B-cell_line
colonies	I-cell_line
cultured	O
with	O
Steel	B-protein
factor	I-protein
,	O
colony	O
size	O
was	O
significantly	O
increased	O
compared	O
to	O
control	O
.	O

In	O
day	O
7	O
and	O
day	O
10	O
erythroid	B-cell_type
precursors	I-cell_type
cultured	O
with	O
Steel	B-protein
factor	I-protein
,	O
SCL	B-protein
protein	I-protein
was	O
increased	O
significantly	O
compared	O
to	O
control	O
.	O

The	O
increase	O
in	O
SCL	B-protein
protein	O
levels	O
in	O
early	O
erythroid	B-cell_type
precursors	I-cell_type
stimulated	O
with	O
Steel	B-protein
factor	I-protein
suggests	O
one	O
mechanism	O
through	O
which	O
Steel	B-protein
factor	I-protein
may	O
enhance	O
normal	O
erythroid	O
proliferation	O
.	O

SCL	B-RNA
mRNA	I-RNA
levels	O
assessed	O
by	O
Northern	O
blot	O
in	O
day	O
7	O
cells	O
did	O
not	O
increase	O
significantly	O
in	O
response	O
to	O
Steel	B-protein
factor	I-protein
stimulation	O
,	O
suggesting	O
that	O
posttranscriptional	O
mechanisms	O
may	O
also	O
be	O
important	O
in	O
the	O
increase	O
in	O
SCL	B-protein
protein	I-protein
observed	O
in	O
response	O
to	O
Steel	B-protein
.	O

C/EBP	B-protein
beta	I-protein
regulation	O
of	O
the	O
tumor	B-DNA
necrosis	I-DNA
factor	I-DNA
alpha	I-DNA
gene	I-DNA
.	O

Activated	B-cell_type
macrophages	I-cell_type
contribute	O
to	O
chronic	O
inflammation	O
by	O
the	O
secretion	O
of	O
cytokines	B-protein
and	O
proteinases	B-protein
.	O

Tumor	B-protein
necrosis	I-protein
factor	I-protein
alpha	I-protein
(	O
TNF	B-protein
alpha	I-protein
)	O
is	O
particularly	O
important	O
in	O
this	O
process	O
because	O
of	O
its	O
ability	O
to	O
regulate	O
other	O
inflammatory	O
mediators	O
in	O
an	O
autocrine	O
and	O
paracrine	O
fashion	O
.	O

The	O
mechanism	O
(	O
s	O
)	O
responsible	O
for	O
the	O
cell	O
type-specific	O
regulation	O
of	O
TNF	B-protein
alpha	I-protein
is	O
not	O
known	O
.	O

We	O
present	O
data	O
to	O
show	O
that	O
the	O
expression	O
of	O
TNF	B-protein
alpha	I-protein
is	O
regulated	O
by	O
the	O
transcription	B-protein
factor	I-protein
C/EBP	B-protein
beta	I-protein
(	O
NF-IL6	B-protein
)	O
.	O

C/EBP	B-protein
beta	I-protein
activated	O
the	O
TNF	B-DNA
alpha	I-DNA
gene	I-DNA
promoter	I-DNA
in	O
cotransfection	O
assays	O
and	O
bound	O
to	O
it	O
at	O
a	O
site	O
which	O
failed	O
to	O
bind	O
the	O
closely	O
related	O
protein	O
C/EBP	B-protein
alpha	I-protein
.	O

Finally	O
,	O
a	O
dominant-negative	O
version	O
of	O
C/EBP	B-protein
beta	I-protein
blocked	O
TNF	B-DNA
alpha	I-DNA
promoter	I-DNA
activation	O
in	O
myeloid	B-cell_type
cells	I-cell_type
.	O

Our	O
results	O
implicate	O
C/EBP	B-protein
beta	I-protein
as	O
an	O
important	O
regulator	O
of	O
TNF	B-protein
alpha	I-protein
by	O
myelomonocytic	B-cell_type
cells	I-cell_type
.	O

Calcium/calmodulin-dependent	B-protein
protein	I-protein
kinase	I-protein
II	I-protein
downregulates	O
both	O
calcineurin	O
and	O
protein	O
kinase	O
C-mediated	O
pathways	O
for	O
cytokine	B-DNA
gene	I-DNA
transcription	O
in	O
human	B-cell_type
T	I-cell_type
cells	I-cell_type
.	O

Engagement	O
of	O
the	O
T	B-protein
cell	I-protein
receptor	I-protein
for	O
antigen	O
activates	O
phospholipase	B-protein
C	I-protein
resulting	O
in	O
an	O
increase	O
in	O
intracellular	O
free	O
calcium	O
concentration	O
(	O
[	O
Ca2+	O
]	O
i	O
)	O
and	O
activation	O
of	O
protein	B-protein
kinase	I-protein
C	I-protein
(	O
PKC	B-protein
)	O
.	O

Increased	O
[	O
Ca2+	O
]	O
i	O
activates	O
Ca2+/calmodulin-dependent	B-protein
kinases	I-protein
including	O
the	O
multifunctional	O
Ca2+/calmodulin-dependent	B-protein
protein	I-protein
kinase	I-protein
II	I-protein
(	O
CaM-K	B-protein
II	I-protein
)	O
,	O
as	O
well	O
as	O
calcineurin	B-protein
,	O
a	O
type	B-protein
2B	I-protein
protein	I-protein
phosphatase	I-protein
.	O

Recent	O
studies	O
have	O
identified	O
calcineurin	B-protein
as	O
a	O
key	O
enzyme	O
for	O
interleukin	O
(	O
IL	O
)	O
-2	O
and	O
IL-4	O
promoter	O
activation	O
.	O

However	O
,	O
the	O
role	O
of	O
CaM-K	B-protein
II	I-protein
remains	O
unknown	O
.	O

We	O
have	O
used	O
mutants	O
of	O
these	O
kinases	B-protein
and	O
phosphatases	B-protein
(	O
gamma	B-protein
B*CaM-K	I-protein
and	O
delta	B-protein
CaM-AI	I-protein
,	O
respectively	O
)	O
to	O
explore	O
their	O
relative	O
role	O
in	O
cytokine	B-DNA
gene	I-DNA
transcription	O
and	O
their	O
interactions	O
with	O
PKC	B-protein
-dependent	O
signaling	O
systems	O
.	O

gamma	B-protein
B*CaM-K	I-protein
and	O
delta	B-protein
CaM-AI	I-protein
,	O
known	O
to	O
exhibit	O
constitutive	O
Ca	O
(	O
2+	O
)	O
-independent	O
activity	O
,	O
were	O
cotransfected	O
(	O
alone	O
or	O
in	O
combination	O
)	O
in	O
Jurkat	B-cell_line
T	I-cell_line
cells	I-cell_line
with	O
a	O
plasmid	O
containing	O
the	O
intact	O
IL-2	B-DNA
promoter	I-DNA
driving	O
the	O
expression	O
of	O
the	O
chloramphenicol	B-DNA
acetyltransferase	I-DNA
reporter	I-DNA
gene	I-DNA
.	O

Cotransfection	O
of	O
gamma	B-protein
B*CaM-K	I-protein
with	O
the	O
IL-2	B-DNA
promoter	I-DNA
construct	I-DNA
downregulated	O
its	O
transcription	O
in	O
response	O
to	O
stimulation	O
with	O
ionomycin	O
and	O
phorbol	O
myristate	O
acetate	O
(	O
PMA	O
)	O
.	O

The	O
inhibitory	O
effect	O
of	O
CaM-K	B-protein
II	I-protein
on	O
IL-2	B-DNA
promoter	I-DNA
was	O
associated	O
with	O
decreased	O
transcription	O
of	O
its	O
AP-1	O
and	O
NF-AT	O
transactivating	O
pathways	O
.	O

Under	O
the	O
same	O
conditions	O
,	O
delta	B-protein
CaM-AI	I-protein
superinduced	O
IL-2	B-DNA
promoter	I-DNA
activity	O
(	O
approximately	O
twofold	O
increase	O
)	O
.	O

When	O
both	O
mutants	O
were	O
used	O
in	O
combination	O
,	O
gamma	B-protein
B*CaM-K	I-protein
inhibited	O
the	O
induction	O
of	O
the	O
IL-2	B-DNA
promoter	I-DNA
by	O
delta	B-protein
CaM-AI	I-protein
.	O

Similar	O
results	O
were	O
obtained	O
when	O
a	O
construct	O
containing	O
the	O
IL-4	B-DNA
promoter	I-DNA
also	O
was	O
used	O
.	O

gamma	B-protein
B*CaM-K	I-protein
also	O
downregulated	O
the	O
activation	O
of	O
AP-1	B-protein
in	O
response	O
to	O
transfection	O
with	O
a	O
constitutively	O
active	O
mutant	O
of	O
PKC	B-protein
or	O
stimulation	O
with	O
PMA	O
.	O

These	O
results	O
suggest	O
that	O
CaM-K	B-protein
II	I-protein
may	O
exert	O
negative	O
influences	O
on	O
cytokine	B-DNA
gene	I-DNA
transcription	O
in	O
human	B-cell_type
T	I-cell_type
cells	I-cell_type
,	O
and	O
provide	O
preliminary	O
evidence	O
for	O
negative	O
cross-talk	O
with	O
the	O
calcineurin-	O
and	O
PKC-	O
dependent	O
signaling	O
systems	O
.	O

Induction	O
of	O
ICAM-1	B-protein
and	O
LFA-3	B-protein
by	O
Tax1	B-protein
of	O
human	O
T-cell	O
leukemia	O
virus	O
type	O
1	O
and	O
mechanism	O
of	O
down-regulation	O
of	O
ICAM-1	B-protein
or	O
LFA-1	B-protein
in	O
adult-T-cell-leukemia	B-cell_line
cell	I-cell_line
lines	I-cell_line
.	O

The	O
present	O
study	O
was	O
undertaken	O
to	O
determine	O
the	O
role	O
of	O
HTLV-I	B-protein
TaxI	I-protein
in	O
the	O
up-regulation	O
of	O
ICAM-I	B-protein
and	O
LFA-3	B-protein
in	O
human	B-cell_type
T	I-cell_type
cells	I-cell_type
transformed	O
with	O
HTLV-I	O
and	O
the	O
mechanism	O
of	O
down-regulation	O
of	O
ICAM-I	B-protein
and	O
LFA-I	B-protein
in	O
ATL-derived	B-cell_line
cell	I-cell_line
lines	I-cell_line
.	O

Induction	O
of	O
TaxI	B-protein
in	O
a	O
human	B-cell_line
T-cell	I-cell_line
line	I-cell_line
Jurkat	I-cell_line
carrying	O
the	O
TaxI	B-DNA
gene	I-DNA
under	O
the	O
metallothionein	B-DNA
promoter	I-DNA
led	O
to	O
increases	O
in	O
mRNA	B-RNA
and	O
surface	O
expression	O
of	O
ICAM-I	B-protein
.	O

The	O
response	O
of	O
LFA-3	B-protein
to	O
TaxI	B-protein
induction	O
was	O
,	O
on	O
the	O
other	O
hand	O
,	O
relatively	O
slow	O
and	O
weak	O
,	O
and	O
might	O
be	O
indirect	O
.	O

Transactivation	O
of	O
the	O
ICAM-I	B-DNA
promoter	I-DNA
by	O
TaxI	B-protein
was	O
further	O
shown	O
by	O
co-transfection	O
of	O
a	O
CAT	B-DNA
reporter	I-DNA
construct	I-DNA
with	O
the	O
ICAM-I	B-DNA
promoter	I-DNA
and	O
a	O
plasmid	B-DNA
expressing	O
TaxI	B-protein
.	O

The	O
mechanism	O
of	O
down-regulation	O
of	O
ICAM-I	B-protein
or	O
LFA-I	B-protein
in	O
4	B-cell_line
ATL	I-cell_line
cell	I-cell_line
lines	I-cell_line
was	O
next	O
examined	O
.	O

ICAM-I	B-RNA
mRNA	I-RNA
was	O
quite	O
low	O
in	O
MT-I	B-cell_line
,	O
but	O
no	O
genomic	O
changes	O
were	O
found	O
.	O

The	O
CAT	B-DNA
reporter	I-DNA
with	O
the	O
ICAM-I	B-DNA
promoter	I-DNA
was	O
inactive	O
in	O
MT-I	B-cell_line
.	O

Finally	O
,	O
combined	O
treatment	O
of	O
MT-I	B-cell_line
with	O
5-azacytidine	O
and	O
IFN-gamma	B-protein
induced	O
re-expression	O
of	O
ICAM-I	B-protein
.	O

Collectively	O
,	O
(	O
a	O
)	O
transcriptional	B-protein
factor	I-protein
(	O
s	O
)	O
necessary	O
for	O
expression	O
of	O
ICAM-I	B-DNA
gene	I-DNA
may	O
be	O
repressed	O
in	O
MT-I	B-cell_line
through	O
DNA	O
methylation	O
.	O

Three	O
other	O
ATL	B-cell_line
cell	I-cell_line
lines	I-cell_line
(	O
TL-OmI	B-cell_line
,	O
H582	B-cell_line
,	O
HuT102	B-cell_line
)	O
were	O
found	O
to	O
have	O
little	O
mRNA	B-RNA
for	O
the	O
LFA-I	B-protein
beta	I-protein
chain	I-protein
(	O
CD18	B-protein
)	O
.	O

H582	B-cell_line
and	O
HuT102	B-cell_line
were	O
also	O
negative	O
for	O
the	O
LFA-I	B-RNA
alpha	I-RNA
chain	I-RNA
(	I-RNA
CDIIa	I-RNA
)	I-RNA
mRNA	I-RNA
.	O

No	O
genomic	O
changes	O
were	O
found	O
,	O
and	O
a	O
CAT	B-DNA
reporter	I-DNA
gene	I-DNA
with	O
the	O
CD18	B-DNA
promoter	I-DNA
was	O
inactive	O
in	O
the	O
3	O
of	O
them	O
,	O
again	O
suggesting	O
lack	O
of	O
(	O
a	O
)	O
transcriptional	B-protein
factor	I-protein
(	O
s	O
)	O
necessary	O
for	O
CD18	B-protein
expression	O
.	O

Infection	O
with	O
Theileria	O
annulata	O
induces	O
expression	O
of	O
matrix	B-protein
metalloproteinase	I-protein
9	I-protein
and	O
transcription	B-protein
factor	I-protein
AP-1	B-protein
in	O
bovine	B-cell_type
leucocytes	I-cell_type
.	O

Theileria	O
annulata	O
infects	O
bovine	B-cell_type
leucocytes	I-cell_type
and	O
results	O
in	O
their	O
reversible	O
transformation	O
such	O
that	O
they	O
become	O
immortalised	O
and	O
metastatic	O
.	O

The	O
present	O
study	O
describes	O
parasite-induced	O
changes	O
in	O
host	B-DNA
cell	I-DNA
gene	I-DNA
expression	O
which	O
have	O
a	O
direct	O
bearing	O
on	O
this	O
transformation	O
process	O
.	O

T.	B-cell_type
annulata-infected	I-cell_type
leucocytes	I-cell_type
produce	O
a	O
number	O
of	O
novel	O
metalloproteinase	B-protein
activities	O
.	O

One	O
of	O
these	O
,	O
previously	O
called	O
B1	B-protein
,	O
is	O
a	O
97-kDa	B-protein
protein	I-protein
which	O
is	O
secreted	O
in	O
large	O
amounts	O
and	O
has	O
been	O
purified	O
from	O
protein-free	O
,	O
conditioned	O
medium	O
.	O

An	O
antiserum	O
to	O
this	O
enzyme	O
was	O
used	O
to	O
isolate	O
a	O
cDNA	B-DNA
clone	I-DNA
.	O

The	O
predicted	O
protein	O
sequence	O
of	O
B1	B-protein
is	O
81	O
%	O
identical	O
to	O
human	O
matrix	B-protein
metalloproteinase	I-protein
9	I-protein
(	O
MMP9	B-protein
)	O
,	O
demonstrating	O
that	O
it	O
is	O
the	O
bovine	O
homologue	O
of	O
this	O
enzyme	O
.	O

RNAase	B-protein
protection	O
assays	O
demonstrated	O
that	O
the	O
MMP9	B-protein
activity	O
,	O
unique	O
to	O
infected	B-cell_type
cells	I-cell_type
,	O
is	O
due	O
to	O
increased	O
MMP9	B-protein
mRNA	O
levels	O
.	O

We	O
also	O
assayed	O
the	O
levels	O
of	O
transcription	B-protein
factor	I-protein
AP-1	B-protein
and	O
demonstrated	O
that	O
it	O
was	O
constitutively	O
present	O
in	O
increased	O
amounts	O
in	O
Theileria-infected	B-cell_type
cells	I-cell_type
.	O

In	O
addition	O
we	O
assayed	O
the	O
level	O
of	O
mRNA	B-RNA
encoding	O
c-Fos	B-protein
,	O
a	O
common	O
component	O
of	O
AP-1	B-protein
and	O
observed	O
that	O
it	O
was	O
indeed	O
up-regulated	O
in	O
infected	B-cell_type
cells	I-cell_type
.	O

Since	O
AP-1	B-protein
is	O
implicated	O
in	O
the	O
control	O
of	O
the	O
cell	O
cycle	O
,	O
and	O
MMP9	B-protein
can	O
confer	O
metastatic	O
properties	O
,	O
these	O
results	O
are	O
of	O
considerable	O
significance	O
with	O
respect	O
to	O
the	O
transformed	O
phenotype	O
induced	O
by	O
Theileria	O
infection	O
.	O

B-cell	B-cell_type
proliferation	O
and	O
induction	O
of	O
early	O
G1-regulating	B-protein
proteins	I-protein
by	O
Epstein-Barr	O
virus	O
mutants	O
conditional	O
for	O
EBNA2	B-protein
.	O

Infection	O
of	O
primary	B-cell_type
B-lymphocytes	I-cell_type
by	O
Epstein-Barr	O
virus	O
(	O
EBV	O
)	O
leads	O
to	O
growth	O
transformation	O
of	O
these	O
B-cells	B-cell_type
in	O
vitro	O
.	O

EBV	O
nuclear	O
antigen	O
2	O
(	O
EBNA2	B-protein
)	O
,	O
one	O
of	O
the	O
first	O
genes	O
expressed	O
after	O
EBV	O
infection	O
of	O
B-cells	B-cell_type
,	O
is	O
a	O
transcriptional	O
activator	O
of	O
viral	B-DNA
and	I-DNA
cellular	I-DNA
genes	I-DNA
and	O
is	O
essential	O
for	O
the	O
transforming	O
potential	O
of	O
the	O
virus	O
.	O

We	O
generated	O
conditional	O
EBV	O
mutants	O
by	O
expressing	O
EBNA2	B-protein
as	O
chimeric	B-protein
fusion	I-protein
protein	I-protein
with	O
the	O
hormone	O
binding	O
domain	O
of	O
the	O
estrogen	B-protein
receptor	I-protein
on	O
the	O
genetic	O
background	O
of	O
the	O
virus	O
.	O

Growth	O
transformation	O
of	O
primary	B-cell_type
normal	I-cell_type
B-cells	I-cell_type
by	O
mutant	O
virus	O
resulted	O
in	O
estrogen-dependent	B-cell_line
lymphoblastoid	I-cell_line
cell	I-cell_line
lines	I-cell_line
expressing	O
the	O
chimeric	O
EBNA2	B-protein
protein	I-protein
.	O

In	O
the	O
absence	O
of	O
estrogen	O
about	O
half	O
of	O
the	O
cells	O
enter	O
a	O
quiescent	O
non-proliferative	O
state	O
whereas	O
the	O
others	O
die	O
by	O
apoptosis	O
.	O

EBNA2	B-protein
is	O
thus	O
required	O
not	O
only	O
for	O
initiation	O
but	O
also	O
for	O
maintenance	O
of	O
transformation	O
.	O

Growth	O
arrest	O
occurred	O
at	O
G1	O
and	O
G2	O
stages	O
of	O
the	O
cell	O
cycle	O
,	O
indicating	O
that	O
functional	O
EBNA2	B-protein
is	O
required	O
at	O
different	O
restriction	O
points	O
of	O
the	O
cell	O
cycle	O
.	O

Growth	O
arrest	O
is	O
reversible	O
for	O
G1/G0	B-cell_type
cells	I-cell_type
as	O
indicated	O
by	O
the	O
sequential	O
accumulation	O
and	O
modification	O
of	O
cell	B-protein
cycle	I-protein
regulating	I-protein
proteins	I-protein
.	O

EBV	O
induces	O
the	O
same	O
cell	O
cycle	O
regulating	O
proteins	O
as	O
polyclonal	O
stimuli	O
in	O
primary	O
B-cells	B-cell_type
.	O

These	O
data	O
suggest	O
that	O
EBV	O
is	O
using	O
a	O
common	O
pathway	O
for	O
B-cell	O
activation	O
bypassing	O
the	O
requirement	O
for	O
antigen	O
,	O
T-cell	O
signals	O
and	O
growth	B-protein
factors	I-protein
.	O

IL-1	B-protein
receptor	I-protein
and	O
TCR	B-protein
signals	O
synergize	O
to	O
activate	O
NF-kappa	B-protein
B	I-protein
-mediated	O
gene	O
transcription	O
.	O

Previous	O
studies	O
have	O
demonstrated	O
that	O
IL-1	B-protein
receptor	I-protein
(	O
IL-1R	B-protein
)	O
-	O
and	O
TCR	B-protein
-initiated	O
signals	O
can	O
interact	O
synergistically	O
to	O
increase	O
the	O
rate	O
of	O
transcription	O
of	O
several	O
lymphokine	B-DNA
and	I-DNA
lymphokine	I-DNA
receptor	I-DNA
genes	I-DNA
during	O
the	O
competence	O
phase	O
of	O
the	O
activation	O
program	O
in	O
T	B-cell_type
helper	I-cell_type
lymphocytes	I-cell_type
.	O

In	O
this	O
report	O
we	O
describe	O
how	O
signals	O
initiated	O
through	O
the	O
type	B-protein
I	I-protein
IL-1R	I-protein
interact	O
with	O
signals	O
from	O
the	O
antigen	O
receptor	O
to	O
synergistically	O
augment	O
the	O
transactivating	O
properties	O
of	O
NF-kappa	B-protein
B	I-protein
.	O

The	O
synergistic	O
antigen	B-protein
receptor	I-protein
initiated	O
signals	O
are	O
mediated	O
through	O
protein	B-protein
kinase	I-protein
C	I-protein
because	O
they	O
can	O
be	O
mimicked	O
by	O
the	O
phorbol	O
ester	O
,	O
12-O-tetradecanoylphorbol-13-acetate	O
,	O
but	O
not	O
with	O
calcium	O
ionophores	O
;	O
and	O
are	O
staurosporine	O
sensitive	O
but	O
cyclosporine	O
resistant	O
.	O

Gel	O
shift	O
analyses	O
demonstrate	O
that	O
NF-kappa	B-protein
B	I-protein
nuclear	O
translocation	O
is	O
stimulated	O
primarily	O
by	O
IL-1	B-protein
rather	O
than	O
by	O
antigen	B-protein
receptor	I-protein
signals	O
.	O

Western	O
blot	O
and	O
phosphorylation	O
analyses	O
demonstrate	O
that	O
the	O
synergistic	O
effect	O
on	O
NF-kappa	B-protein
B	I-protein
functional	O
activity	O
is	O
independent	O
of	O
I	B-protein
kappa	I-protein
B	I-protein
alpha	I-protein
(	O
MAD3	B-protein
)	O
-	O
NF-kappa	B-protein
B	I-protein
dissociation	O
in	O
the	O
cytosol	O
and	O
is	O
not	O
associated	O
with	O
I	B-protein
kappa	I-protein
B	I-protein
nuclear	O
translocation	O
.	O

The	O
IL-1	B-protein
-induced	O
NF-kappa	B-protein
B	I-protein
DNA	O
nuclear	O
localization	O
is	O
transient	O
and	O
can	O
be	O
prolonged	O
either	O
by	O
an	O
antigen	O
receptor-initiated	O
signal	O
or	O
by	O
inhibiting	O
protein	O
synthesis	O
.	O

These	O
results	O
suggest	O
that	O
IL-1	B-protein
induces	O
both	O
NF-kappa	B-protein
B	I-protein
nuclear	O
translocation	O
and	O
the	O
synthesis	O
of	O
a	O
protein	O
(	O
s	O
)	O
responsible	O
for	O
terminating	O
NF-kappa	B-protein
B	I-protein
-DNA	O
interaction	O
in	O
the	O
nucleus	O
.	O

Antigen	O
receptor	O
signals	O
prolong	O
NF-kappa	B-protein
B	I-protein
-DNA	O
interaction	O
,	O
probably	O
by	O
functionally	O
antagonizing	O
the	O
IL-1	B-protein
-induced	O
synthesis	O
of	O
a	O
protein	O
(	O
s	O
)	O
responsible	O
for	O
the	O
transient	O
NF-kappa	B-protein
B	I-protein
-DNA	O
interaction	O
and	O
consequently	O
synergistically	O
enhance	O
IL-1	B-protein
-induced	O
NF-kappa	B-protein
B	I-protein
-dependent	O
gene	O
transcription	O
.	O

Identification	O
of	O
the	O
promoter	B-DNA
region	I-DNA
of	O
chicken	O
anemia	O
virus	O
(	O
CAV	O
)	O
containing	O
a	O
novel	O
enhancer-like	B-DNA
element	I-DNA
.	O

The	O
single	O
promoter	B-DNA
region	I-DNA
in	O
the	O
cloned	O
genome	O
[	O
Noteborn	O
et	O
al.	O
,	O
J.	O
Virol.	O
65	O
(	O
1991	O
)	O
3131-3139	O
]	O
of	O
chicken	O
anemia	O
virus	O
(	O
CAV	O
)	O
in	O
chicken	B-cell_type
T-cells	I-cell_type
was	O
analysed	O
via	O
CAT	B-protein
assays	O
.	O

A	O
unique	O
region	O
containing	O
four	O
or	O
five	O
near-perfect	O
direct	O
repeats	O
(	O
DR	O
)	O
of	O
21	O
bp	O
with	O
one	O
12-bp	B-DNA
insert	I-DNA
was	O
proven	O
to	O
be	O
the	O
main	O
transcription-activation	B-DNA
element	I-DNA
,	O
with	O
enhancer-like	O
characteristics	O
.	O

PCR	O
studies	O
revealed	O
that	O
CAV	O
isolates	O
from	O
across	O
the	O
world	O
all	O
contained	O
this	O
promoter	B-DNA
sequence	I-DNA
.	O

Electrophoretic	O
mobility-shift	O
assays	O
(	O
EMSA	O
)	O
showed	O
that	O
individual	B-DNA
DR	I-DNA
units	I-DNA
,	O
as	O
well	O
as	O
the	O
12-bp	B-DNA
insert	I-DNA
,	O
can	O
bind	O
to	O
nuclear	B-protein
factors	I-protein
of	O
chicken	B-cell_type
T-cells	I-cell_type
.	O

Competition	O
assays	O
revealed	O
that	O
the	O
DR	B-DNA
units	I-DNA
bound	O
to	O
factors	O
other	O
than	O
the	O
12-bp	B-DNA
insert	I-DNA
.	O

A	O
synthetic	O
oligodeoxyribonucleotide	O
containing	O
an	O
SP1-box	B-DNA
(	O
5'-GGGCGG	O
)	O
could	O
compete	O
with	O
factors	O
binding	O
to	O
the	O
12-bp	B-DNA
insert	I-DNA
.	O

Purified	O
human	B-protein
SP1	I-protein
was	O
shown	O
to	O
have	O
very	O
strong	O
affinity	O
for	O
the	O
12-bp	B-DNA
insert	I-DNA
.	O

Functional	O
Myc-Max	B-protein
heterodimer	I-protein
is	O
required	O
for	O
activation-induced	O
apoptosis	O
in	O
T	B-cell_line
cell	I-cell_line
hybridomas	I-cell_line
.	O

T	B-cell_line
cell	I-cell_line
hybridomas	I-cell_line
respond	O
to	O
activation	O
signals	O
by	O
undergoing	O
apoptotic	O
cell	O
death	O
,	O
and	O
this	O
is	O
likely	O
to	O
represent	O
comparable	O
events	O
related	O
to	O
tolerance	O
induction	O
in	O
immature	B-cell_type
and	I-cell_type
mature	I-cell_type
T	I-cell_type
cells	I-cell_type
in	O
vivo	O
.	O

Previous	O
studies	O
using	O
antisense	O
oligonucleotides	O
implicated	O
the	O
c-Myc	B-protein
protein	I-protein
in	O
the	O
phenomenon	O
of	O
activation-induced	O
apoptosis	O
.	O

This	O
role	O
for	O
c-Myc	B-protein
in	O
apoptosis	O
is	O
now	O
confirmed	O
in	O
studies	O
using	O
a	O
dominant	O
negative	O
form	O
of	O
its	O
heterodimeric	O
binding	O
partner	O
,	O
Max	B-protein
,	O
which	O
we	O
show	O
here	O
inhibits	O
activation-induced	O
apoptosis	O
.	O

Further	O
,	O
coexpression	O
of	O
a	O
reciprocally	B-protein
mutant	I-protein
Myc	I-protein
protein	I-protein
capable	O
of	O
forming	O
functional	O
heterodimers	B-protein
with	O
the	O
mutant	O
Max	B-protein
can	O
compensate	O
for	O
the	O
dominant	O
negative	O
activity	O
and	O
restore	O
activation-induced	O
apoptosis	O
.	O

These	O
results	O
imply	O
that	O
Myc	B-protein
promotes	O
activation-induced	O
apoptosis	O
by	O
obligatory	O
heterodimerization	O
with	O
Max	B-protein
,	O
and	O
therefore	O
,	O
by	O
regulating	O
gene	O
transcription	O
.	O

Epstein-Barr	B-protein
virus	I-protein
SM	I-protein
protein	I-protein
.	O

The	O
protein	O
products	O
of	O
the	O
Epstein-Barr	O
virus	O
(	O
EBV	O
)	O
BMLF1	O
open	O
reading	O
frame	O
have	O
been	O
characterized	O
in	O
the	O
early	O
productive	O
cycle	O
in	O
B95-8	B-cell_line
and	O
Akata	B-cell_line
cells	I-cell_line
.	O

The	O
SM	B-protein
protein	I-protein
derived	O
from	O
the	O
spliced	O
RNA	O
joining	O
BSLF2	B-protein
to	O
BMLF1	B-protein
is	O
much	O
the	O
most	O
abundant	O
protein	O
.	O

SM	B-protein
is	O
a	O
phosphoprotein	B-protein
in	O
EBV	O
-infected	B-cell_type
cells	I-cell_type
and	O
can	O
be	O
phosphorylated	O
in	O
vitro	O
with	O
casein	B-protein
kinase	I-protein
II	I-protein
(	O
CKII	B-protein
)	O
.	O

Computer	O
analysis	O
of	O
the	O
SM	B-protein
protein	I-protein
sequence	O
showed	O
a	O
C	B-protein
terminal	I-protein
section	I-protein
of	O
SM	B-protein
to	O
be	O
related	O
to	O
genome	B-protein
positional	I-protein
homologues	I-protein
of	O
four	O
other	O
herpesviruses	O
and	O
revealed	O
consensus	B-protein
CKII	I-protein
sites	I-protein
near	O
the	O
N	B-protein
termini	I-protein
of	O
the	O
EBV	B-protein
SM	I-protein
protein	I-protein
,	O
the	O
herpes	B-protein
simplex	I-protein
virus	I-protein
(	I-protein
HSV	I-protein
)	I-protein
ICP27	I-protein
protein	I-protein
and	O
the	O
herpesvirus	B-protein
saimiri	I-protein
(	I-protein
HVS	I-protein
)	I-protein
open	I-protein
reading	I-protein
frame	I-protein
57	I-protein
protein	I-protein
.	O

Site-directed	O
mutagenesis	O
of	O
the	O
consensus	B-DNA
CKII	I-DNA
site	I-DNA
in	O
EBV	O
SM	O
greatly	O
reduced	O
the	O
in	O
vitro	O
phosphorylation	O
of	O
SM	B-protein
by	O
CKII	B-protein
.	O

The	O
mechanism	O
of	O
transactivation	O
by	O
BMLF1	B-protein
proteins	I-protein
has	O
been	O
controversial	O
but	O
SM	B-protein
was	O
shown	O
to	O
transactivate	O
gene	O
expression	O
from	O
a	O
CAT	B-DNA
reporter	I-DNA
construct	I-DNA
by	O
increasing	O
the	O
amount	O
of	O
cytoplasmic	B-RNA
CAT	I-RNA
mRNA	I-RNA
.	O

Mutagenesis	O
of	O
the	O
CKII	B-protein
site	O
in	O
SM	B-protein
made	O
no	O
difference	O
to	O
the	O
transactivation	O
in	O
this	O
transient	O
transfection	O
assay	O
.	O

Inducible	O
binding	O
to	O
the	O
c-fos	O
serum	O
response	O
element	O
during	O
T	O
cell	O
activation	O
is	O
regulated	O
by	O
a	O
phosphotyrosine-containing	B-protein
protein	I-protein
.	O

The	O
proto-oncogene	B-DNA
c-fos	I-DNA
is	O
an	O
immediate-early	B-DNA
gene	I-DNA
,	O
and	O
one	O
of	O
the	O
first	O
genes	O
transcribed	O
after	O
stimulation	O
of	O
most	O
cells	O
with	O
a	O
variety	O
of	O
ligands	O
.	O

Fos	O
expression	O
may	O
be	O
a	O
pivotal	O
event	O
in	O
converting	O
ligand-receptor	O
interactions	O
at	O
the	O
membrane	O
into	O
functional	O
modulation	O
of	O
cell	O
phenotype	O
.	O

The	O
serum	B-DNA
response	I-DNA
element	I-DNA
(	O
SRE	B-DNA
)	O
in	O
the	O
c-fos	B-DNA
regulatory	I-DNA
region	I-DNA
participates	O
in	O
induction	O
of	O
transcription	O
by	O
various	O
growth	B-protein
factors	I-protein
and	O
by	O
phorbol	O
esters	O
and	O
subsequent	O
squelching	O
of	O
transcription	O
.	O

We	O
show	O
that	O
an	O
inducible	O
protein	B-protein
complex	I-protein
(	O
Band	B-protein
A	I-protein
)	O
binds	O
to	O
SRE	B-DNA
DNA	I-DNA
within	O
10	O
min	O
after	O
mitogenic	O
stimulation	O
of	O
human	B-cell_line
PBL-T	I-cell_line
,	O
and	O
becomes	O
nondetectable	O
by	O
60	O
min	O
.	O

Band	B-protein
A	I-protein
contains	O
the	O
serum	B-protein
response	I-protein
factor	I-protein
plus	O
additional	O
factor	O
(	O
s	O
)	O
.	O

A	O
protein	O
that	O
is	O
phosphorylated	O
on	O
a	O
tyrosine	O
residue	O
in	O
resting	B-cell_line
PBL-T	I-cell_line
suppresses	O
binding	O
of	O
a	O
component	O
of	O
Band	B-protein
A	I-protein
to	O
the	O
SRE	B-DNA
motif	I-DNA
.	O

Upon	O
stimulation	O
of	O
the	O
cells	O
,	O
this	O
protein	O
no	O
longer	O
prevents	O
binding	O
of	O
DNA	O
by	O
Band	B-protein
A	I-protein
,	O
and	O
suppression	O
of	O
binding	O
is	O
restored	O
within	O
30	O
min	O
.	O

The	O
phosphorylated	O
tyrosine	O
residue	O
itself	O
is	O
important	O
for	O
the	O
protein-protein	O
interaction	O
.	O

In	O
vivo	O
modification	O
of	O
major	B-DNA
histocompatibility	I-DNA
complex	I-DNA
class	I-DNA
II	I-DNA
DRA	I-DNA
promoter	I-DNA
occupancy	O
mediated	O
by	O
the	O
AIR-1	B-protein
trans-activator	I-protein
.	O

RJ	B-cell_line
2.2.5	I-cell_line
is	O
a	O
human	B-cell_line
B	I-cell_line
cell	I-cell_line
mutant	I-cell_line
derived	O
from	O
the	O
Burkitt	B-cell_line
lymphoma	I-cell_line
Raji	I-cell_line
cell	I-cell_line
which	O
is	O
defective	O
in	O
the	O
AIR-1	O
locus	O
function	O
.	O

This	O
locus	O
encodes	O
a	O
transcriptional	O
trans-activator	O
required	O
for	O
the	O
constitutive	O
expression	O
of	O
major	B-DNA
histocompatibility	I-DNA
complex	I-DNA
(	I-DNA
MHC	I-DNA
)	I-DNA
class	I-DNA
II	I-DNA
genes	I-DNA
.	O

Here	O
we	O
show	O
,	O
by	O
in	O
vivo	O
DNase	B-protein
I	I-protein
footprinting	O
,	O
that	O
the	O
AIR-1	B-DNA
locus	I-DNA
defect	I-DNA
correlates	O
with	O
changes	O
in	O
the	O
DRA	B-DNA
promoter	I-DNA
occupancy	O
.	O

Interestingly	O
,	O
reexpression	O
of	O
human	B-DNA
MHC	I-DNA
class	I-DNA
II	I-DNA
genes	I-DNA
in	O
RJ	B-cell_line
2.2.5	I-cell_line
x	I-cell_line
mouse	I-cell_line
spleen	I-cell_line
cell	I-cell_line
hybrids	I-cell_line
is	O
associated	O
with	O
partial	O
reversion	O
of	O
DRA	B-DNA
promoter	I-DNA
occupancy	O
to	O
the	O
Raji	O
pattern	O
.	O

DRA	B-DNA
promoter	I-DNA
occupancy	O
in	O
other	O
class	B-cell_line
II-negative	I-cell_line
B	I-cell_line
cell	I-cell_line
lines	I-cell_line
,	O
derived	O
from	O
patients	O
with	O
bare	O
lymphocyte	O
syndrome	O
,	O
is	O
drastically	O
different	O
from	O
the	O
one	O
observed	O
in	O
RJ	B-cell_line
2.2.5	I-cell_line
and	O
Raji	B-cell_line
cells	I-cell_line
.	O

Moreover	O
,	O
the	O
use	O
of	O
the	O
DNase	B-protein
I	I-protein
as	O
an	O
in	O
vivo	O
footprinting	O
agent	O
reveals	O
that	O
the	O
patients	B-cell_line
'	I-cell_line
cell	I-cell_line
lines	I-cell_line
do	O
not	O
display	O
a	O
completely	O
``	O
bare	B-DNA
promoter	I-DNA
``	O
as	O
previously	O
reported	O
using	O
dimethyl	O
sulfate	O
as	O
the	O
footprinting	O
agent	O
.	O

Thus	O
,	O
the	O
use	O
of	O
DNase	B-protein
I	I-protein
allowed	O
us	O
,	O
for	O
the	O
first	O
time	O
,	O
to	O
correlate	O
the	O
AIR-1	B-DNA
locus	I-DNA
defect	I-DNA
with	O
class	B-DNA
II	I-DNA
promoter	I-DNA
occupancy	O
alterations	O
and	O
distinguish	O
these	O
alterations	O
from	O
the	O
ones	O
observed	O
in	O
phenotypically	O
similar	O
but	O
genetically	O
distinct	O
MHC	B-cell_line
class	I-cell_line
II-negative	I-cell_line
cells	I-cell_line
.	O

Regulation	O
of	O
cell-type-specific	O
interleukin-2	B-protein
receptor	I-protein
alpha-chain	I-protein
gene	O
expression	O
:	O
potential	O
role	O
of	O
physical	O
interactions	O
between	O
Elf-1	B-protein
,	O
HMG-I	B-protein
(	I-protein
Y	I-protein
)	I-protein
,	O
and	O
NF-kappa	B-protein
B	I-protein
family	I-protein
proteins	I-protein
.	O

The	O
interleukin	B-DNA
2	I-DNA
receptor	I-DNA
alpha-chain	I-DNA
(	I-DNA
IL-2R	I-DNA
alpha	I-DNA
)	I-DNA
gene	I-DNA
is	O
rapidly	O
and	O
potently	O
induced	O
in	O
T	B-cell_type
cells	I-cell_type
in	O
response	O
to	O
mitogenic	O
stimuli	O
.	O

Previously	O
,	O
an	O
inducible	B-DNA
enhancer	I-DNA
between	O
nucleotides	B-DNA
-299	I-DNA
and	I-DNA
-228	I-DNA
that	O
contains	O
NF-kappa	B-DNA
B	I-DNA
and	I-DNA
CArG	I-DNA
motifs	I-DNA
was	O
identified	O
.	O

We	O
now	O
report	O
the	O
characterization	O
of	O
a	O
second	O
essential	B-DNA
positive	I-DNA
regulatory	I-DNA
element	I-DNA
located	O
between	O
nucleotides	B-DNA
-137	I-DNA
and	I-DNA
-64	I-DNA
that	O
binds	O
Elf-1	B-protein
and	O
HMG-I	B-protein
(	I-protein
Y	I-protein
)	I-protein
.	O

This	O
element	O
had	O
maximal	O
activity	O
in	O
lymphoid	B-cell_type
cells	I-cell_type
,	O
paralleling	O
the	O
cell	O
type	O
specificity	O
of	O
Elf-1	B-protein
expression	O
.	O

Transcription	O
from	O
the	O
IL-2R	B-DNA
alpha	I-DNA
promoter	I-DNA
was	O
inhibited	O
when	O
either	O
the	O
Elf-1	B-DNA
or	I-DNA
the	I-DNA
HMG-I	I-DNA
(	I-DNA
Y	I-DNA
)	I-DNA
binding	I-DNA
site	I-DNA
was	O
mutated	O
.	O

Coexpression	O
of	O
both	O
proteins	O
activated	O
transcription	O
of	O
the	O
-137	B-DNA
to	I-DNA
-64	I-DNA
element	I-DNA
in	O
COS-7	B-cell_line
cells	I-cell_line
.	O

Elf-1	B-protein
physically	O
associated	O
with	O
HMG-I	B-protein
and	O
with	O
NF-kappa	B-protein
B	I-protein
p50	B-protein
and	O
c-Rel	B-protein
in	O
vitro	O
,	O
suggesting	O
that	O
protein-protein	O
interactions	O
might	O
functionally	O
coordinate	O
the	O
actions	O
of	O
the	O
upstream	B-DNA
and	I-DNA
downstream	I-DNA
positive	I-DNA
regulatory	I-DNA
elements	I-DNA
.	O

This	O
is	O
the	O
first	O
report	O
of	O
a	O
physical	O
interaction	O
between	O
an	O
Ets	O
family	O
member	O
and	O
NF-kappa	B-protein
B	I-protein
family	I-protein
proteins	I-protein
.	O

These	O
findings	O
provide	O
significant	O
new	O
insights	O
into	O
the	O
protein-protein	O
and	O
protein-DNA	O
interactions	O
that	O
regulate	O
cell-type-specific	O
and	O
inducible	O
IL-2R	B-protein
alpha	I-protein
gene	O
expression	O
and	O
also	O
have	O
implications	O
for	O
other	O
genes	O
regulated	O
by	O
Elf-1	B-protein
and	O
NF-kappa	B-protein
B	I-protein
family	I-protein
proteins	I-protein
.	O

Isolation	O
of	O
cDNA	B-DNA
clones	I-DNA
for	O
42	O
different	O
Kruppel-related	B-protein
zinc	I-protein
finger	I-protein
proteins	I-protein
expressed	O
in	O
the	O
human	B-cell_line
monoblast	I-cell_line
cell	I-cell_line
line	I-cell_line
U-937	I-cell_line
.	O

To	O
study	O
the	O
complexity	O
and	O
structural	O
characteristics	O
of	O
zinc	B-protein
finger	I-protein
proteins	I-protein
expressed	O
during	O
human	O
hematopoiesis	O
and	O
to	O
isolate	O
novel	O
regulators	O
of	O
blood	O
cell	O
development	O
,	O
a	O
degenerate	O
oligonucleotide	O
probe	O
specific	O
for	O
a	O
consensus	B-protein
zinc	I-protein
finger	I-protein
peptide	I-protein
domain	I-protein
was	O
used	O
to	O
isolate	O
63	O
cDNA	B-DNA
clones	I-DNA
for	O
Kruppel-related	B-DNA
zinc	I-DNA
finger	I-DNA
genes	I-DNA
from	O
the	O
human	B-cell_line
monoblast	I-cell_line
cell	I-cell_line
line	I-cell_line
U-937	I-cell_line
.	O

By	O
extensive	O
nucleotide	O
sequence	O
and	O
Northern	O
blot	O
analysis	O
,	O
these	O
cDNA	B-DNA
clones	I-DNA
were	O
found	O
to	O
originate	O
from	O
approximately	O
42	O
different	O
genes	O
(	O
HZF	B-DNA
1-42	I-DNA
)	O
of	O
which	O
only	O
8	O
have	O
previously	O
been	O
described	O
.	O

Northern	O
blot	O
analysis	O
showed	O
that	O
a	O
majority	O
of	O
these	O
genes	O
were	O
expressed	O
at	O
comparable	O
levels	O
in	O
U-937	B-cell_line
and	O
HeLa	B-cell_line
cells	I-cell_line
.	O

The	O
large	O
number	O
of	O
individual	O
genes	O
represented	O
among	O
the	O
63	O
clones	O
and	O
their	O
apparent	O
non-cell-type-specific	O
expression	O
suggest	O
that	O
the	O
majority	O
of	O
the	O
Kruppel-related	B-DNA
zinc	I-DNA
finger	I-DNA
genes	I-DNA
are	O
likely	O
to	O
be	O
expressed	O
in	O
most	O
human	O
tissues	O
.	O

In	O
contrast	O
,	O
some	O
of	O
the	O
genes	O
displayed	O
a	O
restricted	O
expression	O
pattern	O
,	O
indicating	O
that	O
they	O
represent	O
potential	O
regulators	O
of	O
monocyte	O
differentiation	O
or	O
proliferation	O
.	O

Detailed	O
structural	O
analysis	O
of	O
the	O
first	O
12	O
cDNAs	B-DNA
(	O
HZF	B-DNA
1-10	I-DNA
)	O
and	O
a	O
partial	O
characterization	O
of	O
HZF	B-DNA
11-42	I-DNA
revealed	O
that	O
a	O
common	O
feature	O
of	O
human	B-protein
Kruppel-related	I-protein
zinc	I-protein
finger	I-protein
proteins	I-protein
is	O
the	O
presence	O
of	O
tandem	O
arrays	O
of	O
zinc	B-protein
fingers	I-protein
ranging	O
in	O
number	O
from	O
3	O
to	O
over	O
20	O
that	O
are	O
preferentially	O
located	O
in	O
the	O
carboxy-terminal	B-protein
regions	I-protein
of	O
the	O
proteins	O
.	O

In	O
addition	O
,	O
several	O
novel	O
KRAB-containing	B-DNA
zinc	I-DNA
finger	I-DNA
genes	I-DNA
and	O
a	O
novel	O
conserved	B-DNA
sequence	I-DNA
element	I-DNA
were	O
identified	O
.	O

CAG	O
repeat	O
length	O
variation	O
in	O
sperm	B-cell_type
from	O
a	O
patient	O
with	O
Kennedy	O
's	O
disease	O
.	O

Using	O
a	O
modified	O
sperm	B-cell_type
typing	O
protocol	O
,	O
the	O
mutation	O
frequency	O
of	O
the	O
CAG	B-DNA
repeat	I-DNA
region	I-DNA
at	O
the	O
androgen	B-DNA
receptor	I-DNA
locus	I-DNA
has	O
been	O
measured	O
using	O
a	O
rare	O
semen	O
sample	O
from	O
an	O
individual	O
with	O
spinal	O
and	O
bulbar	O
muscular	O
atrophy	O
(	O
SBMA	O
)	O
.	O

Among	O
258	O
X	B-cell_type
chromosome-containing	I-cell_type
sperm	I-cell_type
,	O
19	O
%	O
had	O
a	O
repeat	O
number	O
equal	O
to	O
the	O
donor	B-DNA
's	I-DNA
somatic	I-DNA
DNA	I-DNA
(	O
47	O
repeats	O
)	O
,	O
66	O
%	O
were	O
expansions	O
and	O
15	O
%	O
were	O
contractions	O
.	O

The	O
average	O
expansion	O
was	O
2.7	O
repeats	O
.	O

More	O
than	O
half	O
of	O
the	O
expansions	O
involved	O
one	O
or	O
two	O
repeats	O
;	O
the	O
largest	O
was	O
11	O
repeats	O
.	O

68	O
%	O
of	O
the	O
contractions	O
were	O
also	O
one	O
or	O
two	O
repeats	O
but	O
six	O
(	O
16	O
%	O
)	O
were	O
very	O
large	O
(	O
12-25	O
repeats	O
)	O
.	O

One	O
contraction	O
generated	O
an	O
allele	O
in	O
an	O
intermediate	O
size	O
range	O
(	O
33-39	O
repeats	O
)	O
.	O

Such	O
alleles	O
have	O
not	O
been	O
observed	O
among	O
more	O
than	O
900	O
normal	O
and	O
SBMA	B-DNA
X-chromosomes	I-DNA
that	O
have	O
been	O
examined	O
.	O

Comparison	O
of	O
the	O
SBMA	O
sperm	B-cell_type
typing	O
results	O
with	O
mutation	O
frequency	O
data	O
on	O
normal	O
alleles	O
supports	O
the	O
hypothesis	O
that	O
trinucleotide	B-DNA
repeat	I-DNA
expansions	O
may	O
have	O
a	O
different	O
molecular	O
origin	O
than	O
contractions	O
.	O

Aspirin-like	O
drugs	O
can	O
protect	O
human	B-cell_type
T	I-cell_type
lymphocytes	I-cell_type
against	O
benzoquinone	O
cytotoxicity	O
:	O
evidence	O
for	O
a	O
NAD	B-protein
(	I-protein
P	I-protein
)	I-protein
H	I-protein
:	I-protein
quinone	I-protein
reductase	I-protein
-dependent	O
mechanism	O
.	O

Benzene	O
toxicity	O
towards	O
lymphocytes	B-cell_type
is	O
thought	O
to	O
be	O
mediated	O
by	O
metabolites	O
of	O
benzene	O
including	O
benzoquinone	O
(	O
BQ	O
)	O
.	O

NAD	B-protein
(	I-protein
P	I-protein
)	I-protein
H	I-protein
:	I-protein
quinone	I-protein
reductase	I-protein
(	O
QR	B-protein
)	O
is	O
known	O
to	O
protect	O
against	O
BQ	O
toxicity	O
.	O

The	O
expression	O
of	O
the	O
QR	B-DNA
gene	I-DNA
is	O
regulated	O
by	O
the	O
transcription	B-protein
factor	I-protein
AP-1	B-protein
.	O

We	O
had	O
previously	O
found	O
that	O
aspirin-like	O
drugs	O
(	O
ALD	O
)	O
induce	O
AP-1	B-protein
in	O
human	B-cell_type
T	I-cell_type
lymphocytes	I-cell_type
.	O

It	O
was	O
therefore	O
hypothesized	O
that	O
ALD	O
would	O
protect	O
lymphocytes	B-cell_type
against	O
BQ	O
toxicity	O
by	O
inducing	O
QR	B-protein
.	O

Molt-4	B-cell_line
cells	I-cell_line
(	O
M4	B-cell_line
)	O
,	O
a	O
human	B-cell_line
T	I-cell_line
lymphocyte	I-cell_line
cell	I-cell_line
line	I-cell_line
,	O
were	O
incubated	O
with	O
different	O
concentrations	O
of	O
two	O
ALD	O
,	O
flurbiprofen	O
and	O
sodium	O
diclofenac	O
,	O
and	O
then	O
exposed	O
to	O
BQ	O
.	O

Toxicity	O
was	O
measured	O
by	O
viability	O
(	O
trypan	O
blue	O
exclusion	O
)	O
.	O

Both	O
drugs	O
protected	O
the	O
cells	O
against	O
BQ	O
cytotoxicity	O
in	O
a	O
dose-dependent	O
manner	O
,	O
e.g.	O
,	O
sodium	O
diclofenac	O
at	O
15	O
microM	O
reduced	O
the	O
fraction	O
of	O
BQ-treated	O
dead	O
cells	O
by	O
70	O
%	O
.	O

ALDs	O
induced	O
QR	B-protein
activity	O
in	O
the	O
M4	O
cells	O
in	O
the	O
same	O
range	O
of	O
concentrations	O
that	O
protected	O
the	O
cells	O
against	O
BQ	O
toxicity	O
.	O

The	O
protective	O
effect	O
of	O
ALD	O
was	O
significantly	O
reduced	O
by	O
dicoumarol	O
,	O
a	O
QR	B-protein
-specific	O
inhibitor	O
.	O

Since	O
human	B-cell_type
T	I-cell_type
cells	I-cell_type
and	O
T	B-cell_type
cell	I-cell_type
lines	I-cell_type
do	O
not	O
metabolize	O
arachidonic	O
acid	O
,	O
our	O
data	O
suggest	O
that	O
ALD	O
can	O
protect	O
human	B-cell_type
T	I-cell_type
lymphocytes	I-cell_type
against	O
a	O
metabolite	O
of	O
benzene	O
by	O
induction	O
of	O
QR	B-protein
activity	O
.	O

Correlation	O
of	O
differentiation-inducing	O
activity	O
of	O
retinoids	O
on	O
human	B-cell_line
leukemia	I-cell_line
cell	I-cell_line
lines	I-cell_line
HL-60	B-cell_line
and	O
NB4	B-cell_line
.	O

Retinoids	O
,	O
including	O
all-trans-retinoic	O
acid	O
,	O
its	O
isomers	O
,	O
and	O
fifty	O
synthetic	O
retinoids	O
(	O
retinobenzoic	O
acids	O
)	O
,	O
were	O
tested	O
for	O
differentiation-inducing	O
activity	O
on	O
human	B-cell_line
leukemia	I-cell_line
cell	I-cell_line
lines	I-cell_line
HL-60	B-cell_line
and	O
NB4	B-cell_line
.	O

A	O
good	O
linear	O
correlation	O
,	O
with	O
an	O
r	O
value	O
of	O
0.91	O
,	O
between	O
the	O
ED50	O
values	O
for	O
the	O
differentiation-inducing	O
activity	O
towards	O
HL-60	B-cell_line
cells	I-cell_line
and	O
that	O
towards	O
NB4	B-cell_line
cells	I-cell_line
was	O
found	O
.	O

Platelet-activating	B-protein
factor	I-protein
(	O
PAF	B-protein
)	O
positively	O
auto-regulates	O
the	O
expression	O
of	O
human	B-protein
PAF	I-protein
receptor	I-protein
transcript	I-protein
1	I-protein
(	O
leukocyte-type	O
)	O
through	O
NF-kappa	B-protein
B	I-protein
.	O

The	O
human	B-DNA
platelet-activating	I-DNA
factor	I-DNA
receptor	I-DNA
(	I-DNA
PAFR	I-DNA
)	I-DNA
gene	I-DNA
is	O
transcribed	O
by	O
two	O
distinct	O
promoters	B-DNA
(	O
promoter	B-DNA
1	I-DNA
and	O
promoter	B-DNA
2	I-DNA
)	O
to	O
generate	O
two	O
transcripts	O
(	O
designated	O
as	O
PAFR	B-RNA
transcript	I-RNA
1	I-RNA
and	O
PAFR	B-RNA
transcript	I-RNA
2	I-RNA
)	O
,	O
though	O
their	O
open	O
reading	O
frames	O
are	O
identical	O
.	O

By	O
primer	O
extension	O
analysis	O
to	O
discriminate	O
two	O
transcripts	O
,	O
we	O
found	O
that	O
the	O
levels	O
of	O
PAFR	B-RNA
transcript	I-RNA
1	I-RNA
(	O
leukocyte-type	O
)	O
,	O
but	O
not	O
PAFR	B-RNA
transcript	I-RNA
2	I-RNA
(	O
tissue-type	O
)	O
,	O
are	O
upregulated	O
by	O
PAF	B-protein
as	O
well	O
as	O
by	O
12-O-tetradecanoylphorbol-13-acetate	O
(	O
TPA	O
)	O
in	O
the	O
human	B-cell_line
stomach	I-cell_line
cancer	I-cell_line
cell	I-cell_line
line	I-cell_line
(	O
JR-St	B-cell_line
cells	I-cell_line
)	O
which	O
expresses	O
both	O
functional	O
PAFR	B-RNA
transcript	I-RNA
1	I-RNA
and	O
PAFR	B-RNA
transcript	I-RNA
2	I-RNA
endogenously	O
.	O

Functional	O
analysis	O
of	O
the	O
promoter	B-DNA
1	I-DNA
with	O
a	O
transient	O
expression	O
assay	O
using	O
chloramphenicol	B-DNA
acetyltransferase	I-DNA
(	I-DNA
CAT	I-DNA
)	I-DNA
gene	I-DNA
as	O
a	O
reporter	O
showed	O
that	O
both	O
PAF	B-protein
and	O
TPA	O
activated	O
the	O
promoter	B-DNA
1	I-DNA
but	O
not	O
the	O
deleted	O
promoter	O
lacking	O
the	O
three	O
consensus	B-DNA
binding	I-DNA
sites	I-DNA
for	O
NF-kappa	B-protein
B	I-protein
located	O
from	O
-571	O
bp	O
to	O
-459	O
bp	O
.	O

These	O
findings	O
suggest	O
a	O
molecular	O
mechanism	O
of	O
positive	O
regulation	O
of	O
PAFR	B-protein
gene	O
expression	O
by	O
PAF	B-protein
through	O
NF-kappa	B-protein
B	I-protein
,	O
possibly	O
by	O
a	O
phosphorylation	O
reaction	O
involving	O
protein	B-protein
kinase	I-protein
C	I-protein
by	O
PAF	B-protein
.	O

One	O
gene	O
,	O
two	O
transcripts	B-RNA
:	O
isolation	O
of	O
an	O
alternative	O
transcript	O
encoding	O
for	O
the	O
autoantigen	B-protein
La/SS-B	I-protein
from	O
a	O
cDNA	B-DNA
library	I-DNA
of	O
a	O
patient	O
with	O
primary	O
Sjogrens	O
'	O
syndrome	O
.	O

A	O
cDNA	B-DNA
library	I-DNA
was	O
prepared	O
from	O
peripheral	O
blood	O
lymphocytes	B-cell_type
of	O
an	O
autoimmune	O
patient	O
with	O
primary	O
Sjogrens	O
'	O
syndrome	O
.	O

The	O
cDNA	B-DNA
library	I-DNA
was	O
screened	O
with	O
the	O
patients	O
own	O
autoimmune	O
serum	O
being	O
monospecific	O
for	O
the	O
nuclear	B-protein
autoantigen	I-protein
La/SS-B	I-protein
.	O

Thereby	O
an	O
alternative	O
type	O
of	O
La	B-RNA
mRNA	I-RNA
was	O
identified	O
that	O
differed	O
from	O
the	O
known	O
La	B-RNA
mRNA	I-RNA
due	O
to	O
an	O
exchange	O
of	O
the	O
exon	B-DNA
1	I-DNA
.	O

Sequencing	O
of	O
the	O
genomic	O
region	O
between	O
the	O
exons	B-DNA
1	I-DNA
and	I-DNA
2	I-DNA
showed	O
that	O
the	O
alternative	B-DNA
5'-end	I-DNA
is	O
a	O
part	O
of	O
the	O
intron	B-DNA
.	O

In	O
addition	O
,	O
the	O
presence	O
of	O
an	O
alternative	B-DNA
promoter	I-DNA
site	I-DNA
,	O
which	O
exists	O
within	O
the	O
intron	B-DNA
downstream	O
of	O
the	O
exon	B-DNA
1	I-DNA
,	O
became	O
evident	O
.	O

In	O
consequence	O
,	O
the	O
alternative	B-RNA
La	I-RNA
mRNA	I-RNA
is	O
the	O
result	O
of	O
a	O
promoter	O
switching	O
combined	O
with	O
an	O
alternative	O
splicing	O
mechanism	O
.	O

In	O
the	O
intron	O
,	O
further	O
transcription	B-protein
factor	I-protein
binding	O
sites	O
,	O
including	O
a	O
NF-kappa	B-DNA
B	I-DNA
element	I-DNA
,	O
were	O
identified	O
leading	O
to	O
the	O
suggestion	O
that	O
the	O
expression	O
of	O
the	O
gene	O
encoding	O
for	O
the	O
nuclear	B-protein
autoantigen	I-protein
La/SS-B	I-protein
alters	O
in	O
dependence	O
on	O
disease	O
conditions	O
.	O

Cross-linking	O
CD40	B-protein
on	O
B	B-cell_type
cells	I-cell_type
rapidly	O
activates	O
nuclear	B-protein
factor-kappa	I-protein
B	I-protein
.	O

The	O
B	B-protein
cell-associated	I-protein
surface	I-protein
molecule	I-protein
CD40	I-protein
functions	O
to	O
regulate	O
B	O
cell	O
responses	O
.	O

Cross-linking	O
CD40	B-protein
on	O
B	B-cell_type
cells	I-cell_type
can	O
lead	O
to	O
homotypic	O
cell	O
adhesion	O
,	O
IL-6	B-protein
production	O
,	O
and	O
,	O
in	O
combination	O
with	O
cytokines	B-protein
,	O
to	O
Ig	O
isotype	O
switching	O
.	O

Tyrosine	O
kinase	O
activity	O
is	O
increased	O
shortly	O
after	O
engagement	O
of	O
this	O
receptor	O
.	O

Little	O
is	O
known	O
about	O
how	O
the	O
very	O
early	O
events	O
induced	O
by	O
CD40	B-protein
cross-linking	O
link	O
to	O
cellular	O
responses	O
.	O

In	O
this	O
study	O
,	O
we	O
demonstrate	O
that	O
nuclear	B-protein
factor	I-protein
(	I-protein
NF	I-protein
)	I-protein
-kappa	I-protein
B	I-protein
and	O
NF-kappa	B-protein
B-like	I-protein
transcription	I-protein
factors	I-protein
are	O
activated	O
after	O
cross-linking	O
CD40	B-protein
on	O
resting	O
human	B-cell_type
tonsillar	I-cell_type
B	I-cell_type
cells	I-cell_type
and	O
on	O
B	B-cell_line
cell	I-cell_line
lines	I-cell_line
.	O

The	O
activation	O
is	O
rapid	O
and	O
is	O
mediated	O
through	O
a	O
tyrosine	O
kinase-dependent	O
pathway	O
.	O

The	O
complexes	O
detected	O
in	O
electrophoretic	O
mobility	O
shift	O
assays	O
contain	O
p50	B-protein
,	O
p65	B-protein
(	O
RelA	B-protein
)	O
,	O
c-Rel	B-protein
,	O
and	O
most	O
likely	O
other	O
components	O
.	O

By	O
using	O
transient	O
transfection	O
assays	O
,	O
we	O
found	O
that	O
cross-linking	O
CD40	B-protein
supports	O
NF-kappa	B-protein
B	I-protein
-dependent	O
gene	O
expression	O
.	O

Our	O
results	O
define	O
the	O
NF-kappa	B-protein
B	I-protein
system	O
as	O
an	O
intermediate	O
event	O
in	O
CD40	B-protein
signaling	O
and	O
suggest	O
that	O
the	O
CD40	B-protein
pathway	O
can	O
influence	O
the	O
expression	O
of	O
B	B-DNA
cell-associated	I-DNA
genes	I-DNA
with	O
NF-kappa	B-DNA
B	I-DNA
consensus	I-DNA
sites	I-DNA
.	O

Protease	O
inhibitors	O
block	O
lipopolysaccharide	O
induction	O
of	O
tissue	O
factor	O
gene	O
expression	O
in	O
human	B-cell_type
monocytic	I-cell_type
cells	I-cell_type
by	O
preventing	O
activation	O
of	O
c-Rel/p65	B-protein
heterodimers	I-protein
.	O

Tissue	B-protein
factor	I-protein
(	O
TF	B-protein
)	O
is	O
expressed	O
rapidly	O
by	O
human	B-cell_type
monocytes	I-cell_type
exposed	O
to	O
bacterial	B-protein
endotoxin	I-protein
(	O
lipopolysaccharide	O
,	O
or	O
LPS	O
)	O
.	O

Transcriptional	O
regulation	O
is	O
mediated	O
by	O
binding	O
of	O
c-Rel/p65	B-protein
heterodimers	I-protein
to	O
a	O
kappa	B-DNA
B-like	I-DNA
site	I-DNA
in	O
the	O
TF	B-DNA
promoter	I-DNA
.	O

Nuclear	O
translocation	O
of	O
cytosolic	B-protein
c-Rel/p65	I-protein
heterodimers	I-protein
and	O
other	O
members	O
of	O
the	O
NF-kappa	B-protein
B/Rel	I-protein
family	I-protein
requires	O
dissociation	O
and	O
proteolytic	O
degradation	O
of	O
the	O
inhibitor	B-protein
protein	I-protein
,	O
I	B-protein
kappa	I-protein
B	I-protein
alpha	I-protein
.	O

The	O
protease	O
inhibitors	O
N	O
alpha-tosylphenylalanyl	O
chloromethyl	O
ketone	O
(	O
TPCK	O
)	O
and	O
N	O
alpha-tosyl-L-lysine	O
chloromethyl	O
ketone	O
(	O
TLCK	O
)	O
block	O
activation	O
of	O
NF-kappa	B-protein
B/Rel	I-protein
proteins	I-protein
by	O
preventing	O
degradation	O
of	O
I	B-protein
kappa	I-protein
B	I-protein
alpha	I-protein
.	O

To	O
determine	O
if	O
TPCK	O
and	O
TLCK	O
inhibited	O
LPS	O
induction	O
of	O
TF	B-protein
expression	O
,	O
freshly	O
isolated	O
human	B-cell_type
monocytes	I-cell_type
and	O
monocytic	B-cell_line
THP-1	I-cell_line
cells	I-cell_line
were	O
pretreated	O
with	O
these	O
inhibitors	O
for	O
30	O
min	O
before	O
LPS	O
stimulation	O
.	O

Both	O
TPCK	O
and	O
TLCK	O
inhibited	O
LPS	O
induction	O
of	O
TF	B-protein
protein	I-protein
,	O
TF	B-RNA
mRNA	I-RNA
and	O
TF	B-protein
promoter	O
activity	O
in	O
a	O
dose-dependent	O
manner	O
.	O

These	O
inhibitors	O
specifically	O
prevented	O
degradation	O
of	O
I	B-protein
kappa	I-protein
B	I-protein
alpha	I-protein
and	O
nuclear	O
translocation	O
of	O
c-Rel/p65	B-protein
heterodimers	I-protein
.	O

In	O
contrast	O
,	O
TPCK	O
and	O
TLCK	O
did	O
not	O
block	O
induction	O
of	O
an	O
immediate-early	B-DNA
gene	I-DNA
encoding	O
the	O
transcription	B-protein
factor	I-protein
,	O
Egr-1	B-protein
.	O

Taken	O
together	O
,	O
these	O
data	O
indicated	O
that	O
inhibiting	O
nuclear	O
translocation	O
of	O
c-Rel/p65	B-protein
heterodimers	I-protein
prevented	O
LPS	O
induction	O
of	O
TF	B-protein
gene	O
transcription	O
in	O
monocytic	B-cell_type
cells	I-cell_type
.	O

1	B-protein
,	I-protein
25-Dihydroxyvitamin	I-protein
D3	I-protein
receptors	I-protein
in	O
peripheral	B-cell_type
blood	I-cell_type
mononuclear	I-cell_type
cells	I-cell_type
from	O
patients	O
with	O
primary	O
and	O
secondary	O
hyperparathyroidism	O
.	O

A	O
decreased	O
number	O
of	O
calcitriol	B-protein
(	I-protein
1	I-protein
,	I-protein
25	I-protein
(	I-protein
OH	I-protein
)	I-protein
2D3	I-protein
)	I-protein
receptors	I-protein
has	O
been	O
observed	O
in	O
parathyroid	O
glands	O
of	O
uremic	O
animals	O
.	O

In	O
humans	O
,	O
studies	O
carried	O
out	O
in	O
surgically	O
removed	O
parathyroid	O
glands	O
have	O
shown	O
that	O
calcitriol	O
binding	O
is	O
higher	O
in	O
primary	O
than	O
in	O
secondary	O
hyperparathyroidism	O
.	O

Since	O
specific	O
receptors	O
for	O
calcitriol	O
have	O
been	O
described	O
in	O
peripheral	B-cell_type
blood	I-cell_type
mononuclear	I-cell_type
cells	I-cell_type
(	O
PBMC	B-cell_type
)	O
,	O
we	O
have	O
investigated	O
the	O
specific	O
uptake	O
of	O
3H-labelled	O
1	O
,	O
25	O
(	O
OH	O
)	O
2D3	O
in	O
PBMC	B-cell_type
of	O
12	O
women	O
with	O
primary	O
hyperparathyroidism	O
(	O
PHP	O
)	O
,	O
8	O
women	O
with	O
hyperparathyroidism	O
secondary	O
to	O
chronic	O
renal	O
failure	O
(	O
SH	O
)	O
,	O
9	O
women	O
with	O
renal	O
transplant	O
(	O
RT	O
)	O
,	O
and	O
23	O
healthy	O
women	O
.	O

The	O
median	O
dissociation	O
constant	O
(	O
Kd	O
)	O
was	O
similar	O
in	O
all	O
three	O
groups	O
of	O
patients	O
and	O
in	O
healthy	O
women	O
(	O
mean	O
+/-	O
S.D.	O
(	O
range	O
)	O
:	O
PHP	O
,	O
1.2	O
+/-	O
1.0	O
(	O
0.2-4	O
)	O
x	O
10	O
(	O
-10	O
)	O
M	O
;	O
SH	O
,	O
0.6	O
+/-	O
0.4	O
(	O
0.2-1.2	O
)	O
x	O
10	O
(	O
-10	O
)	O
M	O
;	O
RT	O
,	O
1.1	O
+/-	O
0.5	O
(	O
0.4-1.9	O
)	O
x	O
10	O
(	O
-10	O
)	O
M	O
;	O
controls	O
,	O
1.0	O
+/-	O
0.6	O
(	O
0.3-2.6	O
)	O
x	O
10	O
(	O
-10	O
)	O
M	O
)	O
.	O
However	O
,	O
the	O
maximal	O
binding	O
capacity	O
(	O
Nmax	O
)	O
was	O
significantly	O
enhanced	O
in	O
PHP	O
(	O
3.9	O
+/-	O
1.9	O
(	O
1.3-7.6	O
)	O
fmol/10	O
(	O
7	O
)	O
cells	O
vs.	O
2.3	O
+/-	O
0.9	O
(	O
1.1-4.4	O
)	O
fmol/10	O
(	O
7	O
)	O
cells	O
in	O
controls	O
;	O
P	O
=	O
0.0006	O
)	O
and	O
decreased	O
in	O
SH	O
(	O
0.8	O
+/-	O
0.5	O
(	O
0.2-1.6	O
)	O
fmol/10	O
(	O
7	O
)	O
cells	O
vs.	O
2.3	O
+/-	O
0.9	O
(	O
1.1-4.4	O
)	O
fmol/10	O
(	O
7	O
)	O
cells	O
in	O
controls	O
;	O
P	O
=	O
0.0001	O
)	O
,	O
whereas	O
no	O
changes	O
were	O
seen	O
in	O
RT	O
(	O
2.3	O
+/-	O
0.7	O
(	O
1.2-3.3	O
)	O
fmol/10	O
(	O
7	O
)	O
cells	O
vs.	O
2.3	O
+/-	O
0.9	O
(	O
1.1-4.4	O
)	O
fmol/10	O
(	O
7	O
)	O
cells	O
in	O
controls	O
)	O
.	O

In	O
three	O
patients	O
with	O
PHP	O
who	O
were	O
subjected	O
to	O
parathyroidectomy	O
,	O
the	O
calcitriol	O
number	O
came	O
down	O
to	O
normal	O
.	O

Changes	O
of	O
calcitriol	B-protein
receptors	I-protein
in	O
primary	O
and	O
secondary	O
hyperparathyroidism	O
could	O
magnify	O
the	O
consequences	O
of	O
disturbances	O
in	O
serum	O
concentration	O
of	O
calcitriol	O
itself	O
and	O
might	O
play	O
an	O
important	O
role	O
in	O
the	O
development	O
of	O
secondary	O
hyperparathyroidism	O
in	O
uremia	O
.	O

The	O
severe	O
phenotype	O
of	O
females	O
with	O
tiny	B-DNA
ring	I-DNA
X	I-DNA
chromosomes	I-DNA
is	O
associated	O
with	O
inability	O
of	O
these	O
chromosomes	B-DNA
to	O
undergo	O
X	O
inactivation	O
.	O

Mental	O
retardation	O
and	O
a	O
constellation	O
of	O
congenital	O
malformations	O
not	O
usually	O
associated	O
with	O
Turner	O
syndrome	O
are	O
seen	O
in	O
some	O
females	O
with	O
a	O
mosaic	O
45	O
,	O
X/46	O
,	O
X	O
,	O
r	O
(	O
X	O
)	O
karyotype	O
.	O

Studies	O
of	O
these	O
females	O
show	O
that	O
the	O
XIST	B-DNA
locus	I-DNA
on	O
their	O
tiny	B-DNA
ring	I-DNA
X	I-DNA
chromosomes	I-DNA
is	O
either	O
not	O
present	O
or	O
not	O
expressed	O
.	O

As	O
XIST	B-DNA
transcription	O
is	O
well	O
correlated	O
with	O
inactivation	O
of	O
the	O
X	B-DNA
chromosome	I-DNA
in	O
female	B-cell_type
somatic	I-cell_type
cells	I-cell_type
and	O
spermatogonia	B-cell_type
,	O
nonexpression	O
of	O
the	O
locus	O
even	O
when	O
it	O
is	O
present	O
suggests	O
that	O
these	O
chromosomes	B-DNA
are	O
transcriptionally	O
active	O
.	O

We	O
examined	O
the	O
transcriptional	O
activity	O
of	O
ring	O
X	B-DNA
chromosomes	I-DNA
lacking	O
XIST	B-DNA
expression	O
(	O
XISTE-	O
)	O
,	O
from	O
three	O
females	O
with	O
severe	O
phenotypes	O
.	O

The	O
two	O
tiny	O
ring	O
X	B-DNA
chromosomes	I-DNA
studied	O
with	O
an	O
antibody	B-protein
specific	O
for	O
the	O
acetylated	O
isoforms	O
of	O
histone	B-protein
H4	I-protein
marking	O
transcribed	B-DNA
chromatin	I-DNA
domains	I-DNA
were	O
labeled	O
at	O
a	O
level	O
consistent	O
with	O
their	O
being	O
active	O
.	O

We	O
also	O
examined	O
tow	O
of	O
the	O
XISTE-	B-DNA
ring	I-DNA
chromosomes	I-DNA
to	O
determine	O
whether	O
genes	B-DNA
that	O
are	O
normally	O
silent	O
on	O
an	O
inactive	B-DNA
X	I-DNA
are	O
expressed	O
from	O
these	O
chromosomes	B-DNA
.	O

Analyses	O
of	O
hybrid	B-cell_line
cells	I-cell_line
show	O
that	O
TIMP	B-DNA
,	O
ZXDA	B-DNA
,	O
and	O
ZXDB	B-DNA
loci	I-DNA
on	O
the	O
proximal	B-DNA
short	I-DNA
arm	I-DNA
,	O
and	O
AR	B-DNA
and	O
PHKA1	B-DNA
loci	I-DNA
on	O
the	O
long	O
arm	O
,	O
are	O
well	O
expressed	O
from	O
the	O
tiny	B-DNA
ring	I-DNA
X	I-DNA
chromosome	I-DNA
lacking	O
XIST	B-DNA
DNA	I-DNA
.	O

Studies	O
of	O
the	O
ring	B-DNA
chromosome	I-DNA
that	O
has	O
XIST	B-DNA
DNA	I-DNA
but	O
does	O
not	O
transcribe	O
it	O
show	O
that	O
its	O
AR	O
allele	O
is	O
transcribed	O
along	O
with	O
the	O
one	O
on	O
the	O
normal	O
X	O
allele	O
.	O

(	O
ABSTRACT	O
TRUNCATED	O
AT	O
250	O
WORDS	O
)	O

Inhibition	O
of	O
activation	O
of	O
transcription	B-protein
factor	I-protein
AP-1	I-protein
by	O
CD28	B-protein
signalling	O
in	O
human	B-cell_type
T-cells	I-cell_type
.	O

Co-stimulation	O
of	O
T-lymphocytes	B-cell_type
by	O
T-cell	B-protein
receptor	I-protein
(	O
TcR	B-protein
)	O
occupancy	O
and	O
activation	O
of	O
the	O
CD28	B-protein
surface	I-protein
molecule	I-protein
results	O
in	O
enhanced	O
proliferation	O
and	O
interleukin	B-protein
2	I-protein
(	O
IL-2	B-protein
)	O
production	O
.	O

The	O
increase	O
in	O
IL-2	B-protein
gene	O
expression	O
triggered	O
by	O
CD28	B-protein
involves	O
a	O
kappa	B-DNA
B-like	I-DNA
sequence	I-DNA
in	O
the	O
5'-regulatory	B-DNA
region	I-DNA
of	O
the	O
IL-2	B-DNA
promoter	I-DNA
,	O
called	O
CD28-responsive	B-DNA
element	I-DNA
.	O

Stimulation	O
of	O
T-cells	B-cell_type
by	O
agonistic	O
anti-CD28	B-protein
antibodies	I-protein
in	O
conjunction	O
with	O
phorbol	O
12-myristate	O
13-acetate	O
(	O
PMA	O
)	O
-	O
or	O
TcR	B-protein
-derived	O
signals	O
induces	O
the	O
enhanced	O
activation	O
of	O
the	O
transcription	B-protein
factor	I-protein
NF-kappa	B-protein
B	I-protein
.	O

Here	O
we	O
report	O
that	O
CD28	B-protein
engagement	O
,	O
however	O
,	O
exerts	O
opposite	O
effects	O
on	O
the	O
transcription	B-protein
factor	I-protein
AP-1	I-protein
.	O

Whereas	O
anti-CD28	B-protein
together	O
with	O
PMA	O
increased	O
the	O
DNA	O
binding	O
and	O
trans-activation	O
activity	O
of	O
NF-kappa	B-protein
B	I-protein
,	O
PMA-induced	O
activation	O
of	O
AP-1	B-protein
was	O
significantly	O
suppressed	O
.	O

The	O
inhibitory	O
effect	O
exerted	O
by	O
anti-CD28	B-protein
was	O
observed	O
at	O
the	O
level	O
of	O
DNA	O
binding	O
as	O
well	O
as	O
in	O
functional	O
reporter-gene	O
assays	O
.	O

These	O
results	O
suggest	O
that	O
the	O
two	O
transcription	B-protein
factors	I-protein
are	O
independently	O
regulated	O
and	O
may	O
perform	O
different	O
functions	O
during	O
T-cell	O
activation	O
.	O

HIV-1	B-protein
Nef	I-protein
leads	O
to	O
inhibition	O
or	O
activation	O
of	O
T	B-cell_type
cells	I-cell_type
depending	O
on	O
its	O
intracellular	O
localization	O
.	O

Nef	B-protein
of	O
primate	O
lentiviruses	O
is	O
required	O
for	O
viremia	O
and	O
progression	O
to	O
AIDS	O
in	O
monkeys	O
.	O

Negative	O
,	O
positive	O
,	O
and	O
no	O
effects	O
of	O
Nef	B-protein
have	O
also	O
been	O
reported	O
on	O
viral	O
replication	O
in	O
cells	O
.	O

To	O
reconcile	O
these	O
observations	O
,	O
we	O
expressed	O
a	O
hybrid	B-protein
CD8-Nef	I-protein
protein	I-protein
in	O
Jurkat	B-cell_line
cells	I-cell_line
.	O

Two	O
opposite	O
phenotypes	O
were	O
found	O
,	O
which	O
depended	O
on	O
the	O
intracellular	O
localization	O
of	O
Nef	B-protein
.	O

Expressed	O
in	O
the	O
cytoplasm	O
or	O
on	O
the	O
cell	O
surface	O
,	O
the	O
chimera	B-protein
inhibited	O
or	O
activated	O
early	O
signaling	O
events	O
from	O
the	O
T	B-protein
cell	I-protein
antigen	I-protein
receptor	I-protein
.	O

Activated	O
Jurkat	B-cell_line
cells	I-cell_line
died	O
by	O
apoptosis	O
,	O
and	O
only	O
cells	O
with	O
mutated	O
nef	B-DNA
genes	I-DNA
expressing	O
truncated	O
Nefs	B-protein
survived	O
,	O
which	O
rendered	O
Nef	B-protein
nonfunctional	O
.	O

These	O
mutations	O
paralleled	O
those	O
in	O
other	O
viral	O
strains	O
passaged	O
in	O
vitro	O
.	O

Not	O
only	O
do	O
these	O
positional	O
effects	O
of	O
Nef	B-protein
reconcile	O
diverse	O
phenotypes	O
of	O
Nef	B-protein
and	O
suggest	O
a	O
role	O
for	O
its	O
N-terminal	O
myristylation	O
,	O
but	O
they	O
also	O
explain	O
effects	O
of	O
Nef	B-protein
in	O
HIV	O
infection	O
and	O
progression	O
to	O
AIDS	O
.	O

An	O
intricate	O
arrangement	O
of	O
binding	O
sites	O
for	O
the	O
Ets	B-protein
family	I-protein
of	O
transcription	B-protein
factors	I-protein
regulates	O
activity	O
of	O
the	O
alpha	B-DNA
4	I-DNA
integrin	I-DNA
gene	I-DNA
promoter	I-DNA
.	O

alpha	B-protein
4	I-protein
integrins	I-protein
mediate	O
cell-cell	O
and	O
cell-extracellular	O
matrix	O
interactions	O
that	O
are	O
critical	O
for	O
maturation	O
and	O
function	O
of	O
the	O
immune	O
system	O
as	O
well	O
as	O
differentiation	O
of	O
skeletal	O
muscle	O
.	O

Here	O
we	O
examine	O
molecular	O
mechanisms	O
controlling	O
the	O
pattern	O
of	O
alpha	B-protein
4	I-protein
expression	O
.	O

The	O
activity	O
of	O
constructs	O
containing	O
5	B-DNA
'	I-DNA
deletion	I-DNA
mutants	I-DNA
of	O
the	O
alpha	B-DNA
4	I-DNA
gene	I-DNA
promoter	I-DNA
was	O
compared	O
in	O
transfection	O
assays	O
into	O
cell	B-cell_line
lines	I-cell_line
that	O
express	O
alpha	B-protein
4	I-protein
and	O
cell	B-cell_line
lines	I-cell_line
that	O
do	O
not	O
.	O

The	O
sequence	O
between	O
position	O
-42	B-DNA
and	I-DNA
-76	I-DNA
base	I-DNA
pairs	I-DNA
(	O
bp	O
)	O
was	O
required	O
for	O
efficient	O
transcription	O
in	O
cells	O
that	O
express	O
alpha	B-protein
4	I-protein
,	O
but	O
it	O
showed	O
no	O
activity	O
in	O
HeLa	B-cell_line
cells	I-cell_line
,	O
which	O
do	O
not	O
express	O
alpha	B-protein
4	I-protein
.	O

Three	O
binding	B-DNA
sites	I-DNA
for	O
the	O
Ets	B-protein
family	I-protein
of	O
transcription	B-protein
factors	I-protein
are	O
found	O
in	O
this	O
region	O
:	O
two	O
adjacent	O
sites	O
at	O
positions	O
-50	B-DNA
and	I-DNA
-54	I-DNA
bp	I-DNA
and	O
a	O
more	O
5	B-DNA
'	I-DNA
site	I-DNA
at	O
position	O
-67	B-DNA
bp	I-DNA
.	O

Using	O
a	O
series	O
of	O
constructs	O
containing	O
deletions	O
and	O
mutations	O
in	O
this	O
region	O
,	O
we	O
found	O
that	O
the	O
3'-most	B-DNA
site	I-DNA
alone	O
was	O
sufficient	O
for	O
binding	O
GA-binding	B-protein
protein	I-protein
alpha	I-protein
(	O
GABP	B-protein
alpha	I-protein
)	I-protein
/GABP	I-protein
beta	I-protein
and	O
for	O
a	O
low	O
level	O
of	O
transcriptional	O
activation	O
.	O

When	O
all	O
three	O
sites	O
were	O
present	O
,	O
a	O
second	O
complex	O
``	O
a	O
''	O
was	O
detected	O
,	O
which	O
contains	O
an	O
unknown	O
member	O
of	O
the	O
Ets	B-protein
family	I-protein
.	O

Formation	O
of	O
complex	O
a	O
was	O
cell-type	O
specific	O
and	O
correlated	O
with	O
a	O
high	O
level	O
of	O
transcription	O
.	O

Deletion	O
of	O
the	O
5'-most	B-DNA
Ets	I-DNA
site	I-DNA
had	O
no	O
effect	O
on	O
binding	O
to	O
GABP	B-protein
alpha/GABP	I-protein
beta	I-protein
,	O
but	O
it	O
eliminated	O
a	O
.	O

Concomitant	O
with	O
this	O
loss	O
of	O
a	O
,	O
a	O
new	B-protein
Ets-1-containing	I-protein
complex	I-protein
``	O
c	B-protein
``	O
appeared	O
.	O

Complex	O
c	O
substituted	O
efficiently	O
for	O
complex	O
a	O
in	O
transcriptional	O
activation	O
.	O

We	O
conclude	O
that	O
although	O
neither	O
of	O
the	O
two	O
5'-most	B-DNA
Ets	I-DNA
sites	I-DNA
alone	O
binds	O
nuclear	B-protein
protein	I-protein
,	O
they	O
appear	O
to	O
act	O
as	O
modulators	O
which	O
control	O
the	O
pattern	O
of	O
Ets	B-protein
proteins	I-protein
that	O
bind	O
the	O
alpha	B-DNA
4	I-DNA
gene	I-DNA
promoter	I-DNA
.	O

This	O
arrangement	O
of	O
Ets	B-DNA
sites	I-DNA
,	O
coupled	O
with	O
the	O
tissue-	O
and	O
developmental-specific	O
expression	O
of	O
Ets	B-protein
members	I-protein
,	O
likely	O
play	O
a	O
key	O
role	O
in	O
defining	O
the	O
pattern	O
of	O
alpha	B-protein
4	I-protein
integrin	I-protein
.	O

Mechanism	O
of	O
antiandrogen	O
action	O
:	O
conformational	O
changes	O
of	O
the	O
receptor	O
.	O

Androgen	B-RNA
receptor	I-RNA
mRNA	I-RNA
was	O
translated	O
in	O
vitro	O
,	O
and	O
androgen-	B-protein
and	I-protein
antiandrogen-bound	I-protein
receptor	I-protein
complexes	I-protein
were	O
studied	O
using	O
limited	O
proteolytic	O
digestion	O
by	O
trypsin	B-protein
.	O

Partial	O
proteolysis	O
of	O
androgen-bound	B-protein
receptor	I-protein
protein	I-protein
resulted	O
in	O
a	O
29-kDa	B-protein
proteolysis-resisting	I-protein
fragment	I-protein
,	O
whereas	O
antiandrogen	O
binding	O
stabilised	O
a	O
35-kDa	B-protein
fragment	I-protein
.	O

Both	O
fragments	O
contain	O
the	O
entire	O
ligand	B-protein
binding	I-protein
domain	I-protein
,	O
and	O
the	O
35-kDa	B-protein
fragment	I-protein
extended	O
into	O
the	O
hinge	B-protein
region	I-protein
of	O
the	O
receptor	O
.	O

Several	O
antiandrogens	O
show	O
agonistic	O
properties	O
for	O
a	O
mutated	B-protein
androgen	I-protein
receptor	I-protein
(	O
LNCaP	B-cell_line
cell	I-cell_line
variant	I-cell_line
)	O
;	O
trypsin	B-protein
digestion	O
of	O
antiandrogen-bound	B-protein
mutated	I-protein
receptor	I-protein
also	O
resulted	O
in	O
a	O
29-kDa	B-protein
fragment	I-protein
.	O

Our	O
results	O
point	O
to	O
an	O
important	O
difference	O
between	O
antiandrogens	O
and	O
antagonists	O
of	O
other	O
steroid	B-protein
hormone	I-protein
receptors	I-protein
.	O

Antiandrogens	O
result	O
in	O
protection	O
of	O
both	O
the	O
hinge	B-protein
region	I-protein
and	O
C-terminus	B-protein
of	O
the	O
androgen	B-protein
receptor	I-protein
agonist	O
proteolytic	O
attack	O
,	O
whereas	O
other	O
studies	O
showed	O
that	O
antiestrogens	O
and	O
antiprogestagens	O
expose	O
the	O
C-terminal	B-protein
end	I-protein
of	O
the	O
ligand	B-protein
binding	I-protein
domain	I-protein
of	O
their	O
respective	O
receptors	O
to	O
protease	B-protein
.	O

Differences	O
in	O
conformation	O
of	O
the	O
hinge	B-protein
region	I-protein
distinguish	O
androgen-bound	B-protein
from	O
antiandrogen-bound	B-protein
receptor	I-protein
complexes	I-protein
,	O
which	O
represents	O
an	O
important	O
feature	O
of	O
antiandrogen	O
action	O
.	O

Activation	O
of	O
nuclear	B-protein
factor	I-protein
kappa	I-protein
B	I-protein
in	O
human	B-cell_line
neuroblastoma	I-cell_line
cell	I-cell_line
lines	I-cell_line
.	O

The	O
nuclear	B-protein
factor	I-protein
kappa	I-protein
B	I-protein
(	O
NF-kappa	B-protein
B	I-protein
)	O
is	O
a	O
eukaryotic	O
transcription	B-protein
factor	I-protein
.	O

In	O
B	B-cell_type
cells	I-cell_type
and	O
macrophages	B-cell_type
it	O
is	O
constitutively	O
present	O
in	O
cell	O
nuclei	O
,	O
whereas	O
in	O
many	O
other	O
cell	O
types	O
,	O
NF-kappa	B-protein
B	I-protein
translocates	O
from	O
cytosol	O
to	O
nucleus	O
as	O
a	O
result	O
of	O
transduction	O
by	O
tumor	B-protein
necrosis	I-protein
factor	I-protein
alpha	I-protein
(	O
TNF	B-protein
alpha	I-protein
)	O
,	O
phorbol	O
ester	O
,	O
and	O
other	O
polyclonal	O
signals	O
.	O

Using	O
neuroblastoma	B-cell_line
cell	I-cell_line
lines	I-cell_line
as	O
models	O
,	O
we	O
have	O
shown	O
that	O
in	O
neural	B-cell_type
cells	I-cell_type
NF-kappa	B-protein
B	I-protein
was	O
present	O
in	O
the	O
cytosol	O
and	O
translocated	O
into	O
nuclei	O
as	O
a	O
result	O
of	O
TNF	B-protein
alpha	I-protein
treatment	O
.	O

The	O
TNF	B-protein
alpha	I-protein
-activated	O
NF-kappa	B-protein
B	I-protein
was	O
transcriptionally	O
functional	O
.	O

NF-kappa	B-protein
B	I-protein
activation	O
by	O
TNF	B-protein
alpha	I-protein
was	O
not	O
correlated	O
with	O
cell	O
differentiation	O
or	O
proliferation	O
.	O

However	O
,	O
reagents	O
such	O
as	O
nerve	B-protein
growth	I-protein
factor	I-protein
(	O
NGF	B-protein
)	O
and	O
the	O
phorbol	O
ester	O
phorbol	O
12-myristate	O
13-acetate	O
(	O
PMA	O
)	O
,	O
which	O
induce	O
phenotypical	O
differentiation	O
of	O
the	O
SH-SY5Y	B-cell_line
neuroblastoma	I-cell_line
cell	I-cell_line
line	I-cell_line
,	O
activated	O
NF-kappa	B-protein
B	I-protein
,	O
but	O
only	O
in	O
that	O
particular	O
cell	B-cell_line
line	I-cell_line
.	O

In	O
a	O
NGF-responsive	B-cell_line
rat	I-cell_line
pheochromocytoma	I-cell_line
cell	I-cell_line
line	I-cell_line
,	O
PC12	B-cell_line
,	O
PMA	O
activated	O
NF-kappa	B-protein
B	I-protein
,	O
whereas	O
NGF	B-protein
did	O
not	O
.	O

In	O
other	O
neuroblastoma	B-cell_line
cell	I-cell_line
lines	I-cell_line
,	O
such	O
as	O
SK-N-Be	B-cell_line
(	I-cell_line
2	I-cell_line
)	I-cell_line
,	O
the	O
lack	O
of	O
PMA	O
induction	O
of	O
differentiation	O
was	O
correlated	O
with	O
the	O
lack	O
of	O
NF-kappa	B-protein
B	I-protein
activation	O
.	O

We	O
found	O
,	O
moreover	O
,	O
that	O
in	O
SK-N-Be	B-cell_line
(	I-cell_line
2	I-cell_line
)	I-cell_line
cells	I-cell_line
protein	B-protein
kinase	I-protein
C	I-protein
(	O
PKC	B-protein
)	O
enzymatic	O
activity	O
was	O
much	O
lower	O
compared	O
with	O
that	O
in	O
a	O
control	B-cell_line
cell	I-cell_line
line	I-cell_line
and	O
that	O
the	O
low	O
PKC	B-protein
enzymatic	O
activity	O
was	O
due	O
to	O
low	O
PKC	B-protein
protein	O
expression	O
.	O

NF-kappa	B-protein
B	I-protein
was	O
not	O
activated	O
by	O
retinoic	O
acid	O
,	O
which	O
induced	O
morphological	O
differentiation	O
of	O
all	O
the	O
neuroblastoma	B-cell_line
cell	I-cell_line
lines	I-cell_line
used	O
in	O
the	O
present	O
study	O
.	O

Thus	O
,	O
NF-kappa	B-protein
B	I-protein
activation	O
was	O
not	O
required	O
for	O
neuroblastoma	B-cell_type
cell	O
differentiation	O
.	O

Furthermore	O
,	O
the	O
results	O
obtained	O
with	O
TNF	B-protein
alpha	I-protein
proved	O
that	O
NF-kappa	B-protein
B	I-protein
activation	O
was	O
not	O
sufficient	O
for	O
induction	O
of	O
neuroblastoma	B-cell_type
differentiation	O
.	O

ERP	B-protein
,	O
a	O
new	O
member	O
of	O
the	O
ets	B-protein
transcription	I-protein
factor/oncoprotein	I-protein
family	I-protein
:	O
cloning	O
,	O
characterization	O
,	O
and	O
differential	O
expression	O
during	O
B-lymphocyte	O
development	O
.	O

The	O
ets	B-DNA
gene	I-DNA
family	I-DNA
encodes	O
a	O
group	O
of	O
proteins	O
which	O
function	O
as	O
transcription	B-protein
factors	I-protein
under	O
physiological	O
conditions	O
and	O
,	O
if	O
aberrantly	O
expressed	O
,	O
can	O
cause	O
cellular	O
transformation	O
.	O

We	O
have	O
recently	O
identified	O
two	O
regulatory	O
elements	O
in	O
the	O
murine	B-DNA
immunoglobulin	I-DNA
heavy-chain	I-DNA
(	I-DNA
IgH	I-DNA
)	I-DNA
enhancer	I-DNA
,	O
pi	B-DNA
and	O
microB	B-DNA
,	O
which	O
exhibit	O
striking	O
similarity	O
to	O
binding	B-DNA
sites	I-DNA
for	O
ets-related	B-DNA
proteins	I-DNA
.	O

To	O
identify	O
ets-related	B-protein
transcriptional	I-protein
regulators	I-protein
expressed	O
in	O
pre-B	B-cell_type
lymphocytes	I-cell_type
that	O
may	O
interact	O
with	O
either	O
the	O
pi	B-DNA
or	O
the	O
microB	B-DNA
site	I-DNA
,	O
we	O
have	O
used	O
a	O
PCR	O
approach	O
with	O
degenerate	O
oligonucleotides	O
encoding	O
conserved	O
sequences	O
in	O
all	O
members	O
of	O
the	O
ets	B-DNA
family	I-DNA
.	O

We	O
have	O
cloned	O
the	O
gene	O
for	O
a	O
new	O
ets-related	B-protein
transcription	I-protein
factor	I-protein
,	O
ERP	B-protein
(	O
ets-related	B-protein
protein	I-protein
)	O
,	O
from	O
the	O
murine	B-cell_line
pre-B	I-cell_line
cell	I-cell_line
line	I-cell_line
BASC	B-cell_line
6C2	I-cell_line
and	O
from	O
mouse	O
lung	O
tissue	O
.	O

The	O
ERP	B-protein
protein	O
contains	O
a	O
region	O
of	O
high	O
homology	O
with	O
the	O
ETS	O
DNA-binding	O
domain	O
common	O
to	O
all	O
members	O
of	O
the	O
ets	B-protein
transcription	I-protein
factor/oncoprotein	I-protein
family	I-protein
.	O

Three	O
additional	O
smaller	O
regions	O
show	O
homology	O
to	O
the	O
ELK-1	O
and	O
SAP-1	B-protein
genes	O
,	O
a	O
subgroup	O
of	O
the	O
ets	B-DNA
gene	I-DNA
family	I-DNA
that	O
interacts	O
with	O
the	O
serum	B-protein
response	I-protein
factor	I-protein
.	O

Full-length	O
ERP	B-protein
expresses	O
only	O
negligible	O
DNA-binding	O
activity	O
by	O
itself	O
.	O

Removal	O
of	O
the	O
carboxy	B-protein
terminus	I-protein
enables	O
ERP	B-protein
to	O
interact	O
with	O
a	O
variety	O
of	O
ets-binding	B-DNA
sites	I-DNA
including	O
the	O
E74	B-DNA
site	I-DNA
,	O
the	O
IgH	B-DNA
enhancer	I-DNA
pi	I-DNA
site	I-DNA
,	O
and	O
the	O
lck	B-DNA
promoter	I-DNA
ets	I-DNA
site	I-DNA
,	O
suggesting	O
a	O
carboxy-terminal	B-protein
negative	I-protein
regulatory	I-protein
domain	I-protein
.	O

At	O
least	O
three	O
ERP-related	B-protein
transcripts	I-protein
are	O
expressed	O
in	O
a	O
variety	O
of	O
tissues	O
.	O

However	O
,	O
within	O
the	O
B-cell	B-cell_type
lineage	I-cell_type
,	O
ERP	B-protein
is	O
highly	O
expressed	O
primarily	O
at	O
early	O
stages	O
of	O
B-lymphocyte	B-cell_type
development	O
,	O
and	O
expression	O
declines	O
drastically	O
upon	O
B-cell	O
maturation	O
,	O
correlating	O
with	O
the	O
enhancer	O
activity	O
of	O
the	O
IgH	B-DNA
pi	I-DNA
site	I-DNA
.	O

These	O
data	O
suggest	O
that	O
ERP	B-protein
might	O
play	O
a	O
role	O
in	O
B-cell	B-cell_type
development	O
and	O
in	O
IgH	B-DNA
gene	I-DNA
regulation	O
.	O

Gene	O
for	O
a	O
tissue-specific	B-protein
transcriptional	I-protein
activator	I-protein
(	O
EBF	B-protein
or	O
Olf-1	B-protein
)	O
,	O
expressed	O
in	O
early	B-cell_type
B	I-cell_type
lymphocytes	I-cell_type
,	O
adipocytes	B-cell_type
,	O
and	O
olfactory	B-cell_type
neurons	I-cell_type
,	O
is	O
located	O
on	O
human	B-DNA
chromosome	I-DNA
5	I-DNA
,	O
band	B-DNA
q34	I-DNA
,	O
and	O
proximal	B-DNA
mouse	I-DNA
chromosome	I-DNA
11	I-DNA
.	O

Murine	B-cell_type
B	I-cell_type
lymphocytes	I-cell_type
,	O
adipocytes	B-cell_type
,	O
and	O
olfactory	B-cell_type
neurons	I-cell_type
contain	O
a	O
DNA-binding	B-protein
protein	I-protein
that	O
participates	O
in	O
the	O
regulation	O
of	O
genes	B-DNA
encoding	O
tissue-specific	O
components	O
of	O
signal	O
transduction	O
.	O

Purification	O
and	O
cloning	O
of	O
this	O
protein	O
,	O
termed	O
early	O
B-cell	B-protein
factor	I-protein
(	O
EBF	B-protein
)	O
,	O
from	O
murine	B-cell_type
B	I-cell_type
lymphocytes	I-cell_type
and	O
independent	O
cloning	O
of	O
a	O
protein	O
,	O
termed	O
Olf-1	B-protein
,	O
from	O
olfactory	B-cell_type
neuronal	I-cell_type
cells	I-cell_type
revealed	O
virtual	O
complete	O
amino	O
acid	O
sequence	O
identity	O
between	O
these	O
proteins	O
.	O

As	O
a	O
first	O
step	O
towards	O
identifying	O
a	O
human	O
genetic	O
disorder	O
or	O
mouse	O
mutation	O
for	O
which	O
EBF	B-protein
could	O
be	O
a	O
candidate	O
gene	O
,	O
we	O
have	O
chromosomally	O
mapped	O
the	O
corresponding	O
locus	O
in	O
both	O
species	O
.	O

By	O
Southern	O
hybridization	O
analyses	O
of	O
somatic	O
cell	O
hybrid	O
panels	O
with	O
murine	B-DNA
cDNA	I-DNA
probe	I-DNA
,	O
fluorescence	O
chromosomal	O
in	O
situ	O
hybridization	O
(	O
FISH	O
)	O
of	O
human	B-DNA
genomic	I-DNA
clones	I-DNA
,	O
and	O
analysis	O
of	O
recombinant	B-cell_line
inbred	I-cell_line
mouse	I-cell_line
strains	I-cell_line
,	O
we	O
have	O
found	O
single	O
sites	O
for	O
EBF	B-DNA
homologous	I-DNA
sequences	I-DNA
on	O
human	O
Chromosome	O
(	O
Chr	O
)	O
5	O
,	O
band	B-DNA
q34	I-DNA
,	O
and	O
on	O
proximal	B-DNA
mouse	I-DNA
Chr	I-DNA
11	I-DNA
,	O
in	O
an	O
evolutionarily	B-DNA
conserved	I-DNA
region	I-DNA
.	O

Calcineurin	B-protein
activates	O
transcription	O
from	O
the	O
GM-CSF	B-DNA
promoter	I-DNA
in	O
synergy	O
with	O
either	O
protein	B-protein
kinase	I-protein
C	I-protein
or	O
NF-kappa	B-protein
B	I-protein
/AP-1	B-protein
in	O
T	B-cell_type
cells	I-cell_type
.	O

Two	O
cis-acting	B-DNA
elements	I-DNA
GM-kappa	B-DNA
B/GC-box	I-DNA
and	O
CLE0	B-DNA
,	O
of	O
the	O
granulocyte-macrophage	B-DNA
colony-stimulating	I-DNA
factor	I-DNA
(	I-DNA
GM-CSF	I-DNA
)	I-DNA
gene	I-DNA
are	O
required	O
for	O
maximal	O
induction	O
in	O
Jurkat	B-cell_line
T	I-cell_line
cells	I-cell_line
by	O
costimulation	O
with	O
phorbol-12-myristate	O
acetate	O
(	O
PMA	O
)	O
and	O
Ca2+	O
ionophore	O
(	O
A23187	O
)	O
.	O

The	O
GM-kappa	B-DNA
B	I-DNA
sequence	I-DNA
is	O
recognized	O
by	O
NF-kappa	B-protein
B	I-protein
,	O
which	O
is	O
mainly	O
induced	O
by	O
PMA	O
.	O

The	O
CLE0	B-DNA
sequence	I-DNA
interacts	O
with	O
factors	O
,	O
related	O
to	O
a	O
PMA-induced	B-protein
AP-1	I-protein
and	O
a	O
PMA/A23187-induced	B-protein
NF-AT	I-protein
.	O

We	O
examined	O
whether	O
signal	O
transducing	O
components	O
in	O
T	B-cell_type
cells	I-cell_type
can	O
activate	O
transcription	O
of	O
the	O
GM-CSF	B-DNA
gene	I-DNA
.	O

Cotransfection	O
of	O
NF-kappa	B-DNA
B	I-DNA
(	I-DNA
p50/p65	I-DNA
)	I-DNA
-	I-DNA
or	I-DNA
AP-1	I-DNA
(	I-DNA
c-Jun/c-Fos	I-DNA
)	I-DNA
-	I-DNA
expression	I-DNA
vectors	I-DNA
into	O
Jurkat	B-cell_line
cells	I-cell_line
with	O
a	O
luciferase	B-DNA
reporter	I-DNA
containing	O
the	O
GM-CSF	B-DNA
promoter	I-DNA
did	O
not	O
stimulate	O
transcription	O
from	O
the	O
GM-CSF	B-DNA
promoter	I-DNA
.	O

In	O
contrast	O
,	O
cotransfection	O
with	O
a	O
combination	O
of	O
NF-kappa	B-protein
B	I-protein
and	O
AP-1	B-protein
significantly	O
augmented	O
transcription	O
from	O
the	O
GM-CSF	B-DNA
promoter	I-DNA
containing	O
the	O
GM-kappa	B-DNA
B/GC-box	I-DNA
and	O
the	O
CLE0	B-DNA
(	O
AP-1/NF-AT	B-protein
)	O
.	O

Expression	O
of	O
a	O
constitutively	O
active	O
calcineurin	B-protein
(	O
CN	B-protein
)	O
,	O
a	O
Ca2+/calmodulin-dependent	B-protein
protein	I-protein
phosphatase	I-protein
,	O
potentiated	O
by	O
two	O
fold	O
the	O
transcriptional	O
activation	O
by	O
NF-kappa	B-protein
B	I-protein
/AP-1	B-protein
.	O

Both	O
constitutively	O
active	O
forms	O
of	O
CN	B-protein
and	O
protein	B-protein
kinase	I-protein
C	I-protein
(	O
PKC	B-protein
)	O
synergistically	O
activated	O
transcription	O
from	O
the	O
GM-CSF	B-DNA
promoter	I-DNA
.	O

These	O
results	O
suggest	O
that	O
cooperation	O
among	O
NF-kappa	B-DNA
B-	I-DNA
,	I-DNA
AP-1-	I-DNA
and	I-DNA
NF-AT-binding	I-DNA
sequences	I-DNA
is	O
required	O
for	O
induction	O
of	O
the	O
GM-CSF	B-DNA
gene	I-DNA
through	O
PKC-	O
and	O
Ca2+-	O
signaling	O
pathways	O
downstream	O
of	O
T	O
cell	O
activation	O
.	O

Nonpituitary	B-DNA
human	I-DNA
prolactin	I-DNA
gene	I-DNA
transcription	O
is	O
independent	O
of	O
Pit-1	B-protein
and	O
differentially	O
controlled	O
in	O
lymphocytes	B-cell_type
and	O
in	O
endometrial	O
stroma	O
.	O

Expression	O
of	O
the	O
human	B-DNA
PRL	I-DNA
(	I-DNA
hPRL	I-DNA
)	I-DNA
gene	I-DNA
in	O
extrapituitary	O
sites	O
such	O
as	O
the	O
uterus	O
(	O
decidualized	O
endometrial	O
stroma	O
and	O
myometrium	O
)	O
and	O
cells	O
of	O
the	O
hematopoietic	B-cell_type
lineage	I-cell_type
is	O
directed	O
by	O
an	O
alternative	B-DNA
promoter	I-DNA
which	O
is	O
located	O
approximately	O
6	B-DNA
kilobases	I-DNA
(	I-DNA
kb	I-DNA
)	I-DNA
upstream	I-DNA
of	O
the	O
pituitary-specific	B-DNA
start	I-DNA
site	I-DNA
.	O

In	O
order	O
to	O
delineate	O
the	O
tissue-specific	O
mechanisms	O
governing	O
the	O
control	O
of	O
nonpituitary	O
PRL	B-DNA
gene	I-DNA
expression	O
,	O
we	O
have	O
cloned	O
and	O
sequenced	O
3	B-DNA
kb	I-DNA
5'-flanking	I-DNA
DNA	I-DNA
of	O
the	O
upstream	O
decidual/lymphoid	B-DNA
(	I-DNA
dPRL	I-DNA
)	I-DNA
promoter	I-DNA
.	O

Based	O
on	O
sequence	O
homology	O
we	O
identified	O
two	O
binding	B-DNA
motifs	I-DNA
for	O
Pit-1	B-protein
and	O
seven	O
half-sites	B-DNA
for	O
glucocorticoid	B-protein
receptor/progesterone	I-protein
receptor	I-protein
(	O
PR	B-protein
)	O
binding	O
.	O

We	O
focused	O
our	O
studies	O
on	O
the	O
role	O
of	O
Pit-1	B-protein
and	O
of	O
PR	B-protein
as	O
potential	O
transcriptional	B-protein
regulators	I-protein
,	O
since	O
the	O
POU	B-protein
domain	I-protein
protein	I-protein
Pit-1	B-protein
is	O
essential	O
in	O
the	O
control	O
of	O
pituitary	O
PRL	B-protein
expression	O
,	O
and	O
progesterone	O
induces	O
decidual	O
transformation	O
of	O
the	O
endometrial	O
stroma	O
,	O
a	O
differentiation	O
process	O
during	O
which	O
the	O
decidual	O
PRL	B-DNA
gene	I-DNA
is	O
activated	O
.	O

We	O
demonstrate	O
in	O
a	O
variety	O
of	O
cell	O
types	O
,	O
including	O
lymphocytes	B-cell_type
and	O
endometrial	O
stroma	O
,	O
that	O
Pit-1	B-protein
is	O
not	O
involved	O
in	O
the	O
regulation	O
of	O
dPRL	B-DNA
promoter/reporter	I-DNA
gene	I-DNA
constructs	I-DNA
carrying	O
3	B-DNA
kb	I-DNA
5'-flanking	I-DNA
DNA	I-DNA
.	O

Our	O
experiments	O
also	O
show	O
that	O
activated	O
PR	B-protein
does	O
not	O
confer	O
direct	O
transcriptional	O
control	O
on	O
the	O
dPRL	B-DNA
promoter	I-DNA
.	O

When	O
we	O
compared	O
the	O
activity	O
of	O
the	O
transfected	O
dPRL	B-DNA
promoter	I-DNA
in	O
PRL-secreting	B-cell_type
and	I-cell_type
nonsecreting	I-cell_type
lymphoid	I-cell_type
cells	I-cell_type
,	O
we	O
found	O
that	O
the	O
3	B-DNA
kb	I-DNA
5'-flanking	I-DNA
region	I-DNA
of	O
the	O
dPRL	B-DNA
promoter	I-DNA
did	O
not	O
contain	O
elements	O
restricting	O
expression	O
to	O
only	O
those	O
lymphocytes	B-cell_type
that	O
produce	O
PRL	O
but	O
allowed	O
expression	O
of	O
fusion	O
reporter	O
genes	O
irrespective	O
of	O
the	O
status	O
of	O
the	O
endogenous	O
PRL	B-DNA
gene	I-DNA
.	O

This	O
was	O
in	O
sharp	O
contrast	O
to	O
endometrial	O
cells	O
where	O
3	O
kb	O
5'-flanking	O
DNA	O
conferred	O
strong	O
transcriptional	O
activation	O
on	O
the	O
dPRL	B-DNA
promoter	I-DNA
in	O
decidualized	O
endometrial	B-cell_type
stromal	I-cell_type
cells	I-cell_type
actively	O
secreting	O
PRL	B-protein
,	O
but	O
did	O
not	O
allow	O
transcription	O
in	O
undifferentiated	O
non-PRL-secreting	B-cell_type
endometrial	I-cell_type
stromal	I-cell_type
cells	I-cell_type
.	O

Activation	O
of	O
the	O
dPRL	B-DNA
promoter	I-DNA
construct	O
in	O
these	O
undifferentiated	O
cells	O
could	O
however	O
be	O
induced	O
by	O
the	O
addition	O
of	O
cAMP	O
,	O
in	O
the	O
absence	O
of	O
progesterone	O
,	O
suggesting	O
that	O
a	O
signal	O
transduced	O
through	O
the	O
cAMP	O
signaling	O
pathway	O
is	O
a	O
primary	O
inducer	O
of	O
decidual	O
PRL	B-DNA
gene	I-DNA
expression	O
.	O

Signals	O
and	O
nuclear	B-protein
factors	I-protein
that	O
regulate	O
the	O
expression	O
of	O
interleukin-4	B-DNA
and	I-DNA
interleukin-5	I-DNA
genes	I-DNA
in	O
helper	B-cell_type
T	I-cell_type
cells	I-cell_type
.	O

Mouse	B-cell_line
thymoma	I-cell_line
line	I-cell_line
EL-4	I-cell_line
cells	I-cell_line
produce	O
cytokines	B-protein
such	O
as	O
interleukin	B-protein
(	I-protein
IL	I-protein
)	I-protein
-2	I-protein
,	O
IL-3	B-protein
,	O
IL-4	B-protein
,	O
IL-10	B-protein
,	O
and	O
granulocyte-macrophage	B-protein
colony-stimulating	I-protein
factor	I-protein
in	O
response	O
to	O
phorbol	O
12-myristate	O
13-acetate	O
(	O
PMA	O
)	O
.	O

EL-4	B-cell_line
cells	I-cell_line
also	O
produce	O
low	O
levels	O
of	O
IL-5	B-protein
when	O
stimulated	O
by	O
PMA	O
alone	O
;	O
however	O
,	O
cAMP	O
greatly	O
augments	O
PMA-dependent	O
IL-5	B-protein
production	O
.	O

A	O
transient	O
transfection	O
assay	O
revealed	O
that	O
two	O
signals	O
,	O
PMA	O
and	O
cAMP	O
,	O
are	O
required	O
for	O
optimal	O
activation	O
of	O
the	O
IL-5	B-DNA
promoter	I-DNA
.	O

In	O
contrast	O
,	O
cAMP	O
almost	O
completely	O
inhibited	O
the	O
PMA-dependent	O
activation	O
of	O
the	O
endogenous	B-DNA
IL-2	I-DNA
gene	I-DNA
,	O
as	O
well	O
as	O
the	O
transfected	O
IL-2	B-DNA
promoter	I-DNA
.	O

These	O
results	O
indicate	O
that	O
the	O
IL-5	B-DNA
gene	I-DNA
is	O
positively	O
regulated	O
by	O
cAMP	O
in	O
a	O
manner	O
opposite	O
to	O
that	O
for	O
the	O
IL-2	B-DNA
gene	I-DNA
.	O

One	O
of	O
the	O
nuclear	B-protein
factors	I-protein
(	O
NFs	B-protein
)	O
that	O
regulates	O
the	O
response	O
of	O
the	O
IL-5	B-DNA
promoter	I-DNA
to	O
cAMP	O
and	O
PMA	O
has	O
properties	O
similar	O
to	O
NF	B-protein
for	O
activated	B-cell_type
t	I-cell_type
cell	I-cell_type
.	O

The	O
P	B-DNA
sequence	I-DNA
of	O
the	O
IL-4	B-DNA
gene	I-DNA
,	O
defined	O
as	O
a	O
responsive	B-DNA
element	I-DNA
for	O
PMA	O
and	O
calcium	O
ionophore	O
(	O
A23187	O
)	O
,	O
shares	O
sequence	O
similarity	O
with	O
the	O
NF	B-DNA
kappa	I-DNA
B	I-DNA
and	I-DNA
the	I-DNA
NF-activated	I-DNA
T	I-DNA
cell	I-DNA
binding	I-DNA
sites	I-DNA
.	O

We	O
attempted	O
to	O
determine	O
whether	O
NF	B-protein
(	I-protein
P	I-protein
)	I-protein
,	O
a	O
nuclear	O
factor	O
specific	O
for	O
the	O
P	B-DNA
sequence	I-DNA
,	O
is	O
related	O
to	O
NF-kappa	B-protein
B	I-protein
and	O
nuclear	B-protein
factor	I-protein
for	I-protein
activated	I-protein
T	I-protein
cell	I-protein
(	O
NF-AT	B-protein
)	O
.	O

In	O
electromobility	O
shift	O
assays	O
both	O
NF-kappa	B-protein
B	I-protein
(	O
P65	B-protein
or	O
P65/P50	B-protein
heterodimer	I-protein
)	O
and	O
NF-AT	B-protein
bound	O
to	O
the	O
P	B-DNA
sequence	I-DNA
.	O

However	O
,	O
sequence	O
specificity	O
of	O
NF-AT	B-protein
was	O
more	O
similar	O
to	O
that	O
of	O
NF	B-protein
(	I-protein
P	I-protein
)	I-protein
,	O
and	O
only	O
a	O
small	O
amount	O
of	O
P65	B-protein
was	O
detected	O
in	O
NF	B-protein
(	I-protein
P	I-protein
)	I-protein
.	O

These	O
results	O
indicate	O
that	O
a	O
component	O
or	O
components	O
of	O
NF-AT	B-protein
have	O
the	O
potential	O
to	O
reconstitute	O
NF	B-protein
(	I-protein
P	I-protein
)	I-protein
,	O
whereas	O
NF-kappa	B-protein
B	I-protein
alone	O
does	O
not	O
account	O
for	O
NF	B-protein
(	I-protein
P	I-protein
)	I-protein
in	O
Jurkat	O
crude	O
extract	O
.	O

Taken	O
together	O
,	O
these	O
results	O
suggest	O
that	O
NF-AT-like	B-protein
factors	I-protein
are	O
involved	O
in	O
the	O
regulation	O
of	O
IL-4	B-DNA
and	I-DNA
IL-5	I-DNA
genes	I-DNA
.	O

Solution	O
structure	O
of	O
a	O
POU-specific	B-protein
homeodomain	I-protein
:	O
3D-NMR	O
studies	O
of	O
human	O
B-cell	B-protein
transcription	I-protein
factor	I-protein
Oct-2	B-protein
.	O

The	O
POU	B-protein
DNA-binding	I-protein
motif	I-protein
defines	O
a	O
conserved	O
family	O
of	O
eukaryotic	B-protein
transcription	I-protein
factors	I-protein
involved	O
in	O
regulation	O
of	O
gene	O
expression	O
.	O

This	O
bipartite	B-protein
motif	I-protein
consists	O
of	O
an	O
N-terminal	B-protein
POU-specific	I-protein
domain	I-protein
(	O
POUs	B-protein
)	O
,	O
a	O
flexible	B-protein
linker	I-protein
,	O
and	O
a	O
C-terminal	B-protein
POU-specific	I-protein
homeodomain	I-protein
(	O
POUHD	B-protein
)	O
.	O

Here	O
we	O
describe	O
the	O
solution	O
structure	O
of	O
a	O
POU-specific	B-protein
homeodomain	I-protein
.	O

An	O
NMR	O
model	O
is	O
obtained	O
from	O
Oct-2	B-protein
,	O
a	O
human	B-protein
B-cell	I-protein
specific	I-protein
transcription	I-protein
factor	I-protein
which	O
participates	O
in	O
the	O
regulation	O
of	O
immunoglobulin	B-DNA
genes	I-DNA
.	O

A	O
fragment	O
of	O
Oct-2	B-protein
containing	O
POUHD	B-protein
and	O
an	O
adjoining	O
linker	O
was	O
expressed	O
in	O
Escherichia	O
coli	O
and	O
characterized	O
by	O
three-dimensional	O
nuclear	O
magnetic	O
resonance	O
(	O
3D-NMR	O
)	O
spectroscopy	O
.	O

Complete	O
1H	O
and	O
15N	O
resonance	O
assignment	O
of	O
the	O
POUHD	B-protein
moiety	I-protein
is	O
presented	O
.	O

The	O
POUHD	B-protein
solution	O
structure	O
,	O
as	O
calculated	O
by	O
distance	O
geometry	O
and	O
simulated	O
annealing	O
(	O
DG/SA	O
)	O
,	O
is	O
similar	O
to	O
that	O
of	O
canonical	B-protein
homeodomains	I-protein
.	O

A	O
salient	O
difference	O
between	O
solution	O
and	O
crystal	O
structures	O
is	O
observed	O
in	O
the	O
C-terminal	B-protein
segment	I-protein
of	O
alpha-helix	B-protein
3	I-protein
(	O
the	O
HTH	B-protein
recognition	I-protein
helix	I-protein
)	O
,	O
which	O
is	O
not	O
well	O
ordered	O
in	O
solution	O
.	O

Because	O
this	O
segment	O
presumably	O
folds	O
upon	O
specific	O
DNA	O
binding	O
,	O
its	O
flexibility	O
in	O
solution	O
may	O
reduce	O
the	O
intrinsic	O
DNA	O
affinity	O
of	O
POUHD	B-protein
in	O
the	O
absence	O
of	O
POUs	B-protein
.	O

NF-kappa	O
B-dependent	O
and	O
-independent	O
pathways	O
of	O
HIV	O
activation	O
in	O
a	O
chronically	B-cell_line
infected	I-cell_line
T	I-cell_line
cell	I-cell_line
line	I-cell_line
.	O

J	B-cell_line
delta	I-cell_line
K	I-cell_line
cells	I-cell_line
were	O
isolated	O
as	O
a	O
chronically	B-cell_line
infected	I-cell_line
survivor	I-cell_line
cell	I-cell_line
line	I-cell_line
,	O
following	O
infection	O
of	O
Jurkat	B-cell_line
CD4+	I-cell_line
T	I-cell_line
cells	I-cell_line
with	O
dl-NF	O
,	O
a	O
mutated	O
strain	O
of	O
human	O
immunodeficiency	O
virus	O
type	O
1	O
(	O
HIV-1	O
)	O
containing	O
a	O
deletion	O
of	O
the	O
long	B-DNA
terminal	I-DNA
repeat	I-DNA
(	O
LTR	B-DNA
)	O
NF-kappa	B-protein
B	I-protein
sites	O
.	O

J	B-cell_line
delta	I-cell_line
K	I-cell_line
cells	I-cell_line
exhibited	O
very	O
low	O
levels	O
of	O
constitutive	O
HIV	O
production	O
.	O

HIV-1	O
expression	O
was	O
activated	O
from	O
J	B-cell_line
delta	I-cell_line
K	I-cell_line
cells	I-cell_line
by	O
treatment	O
with	O
phorbol	O
myristate	O
acetate	O
(	O
PMA	O
)	O
,	O
sodium	O
butyrate	O
(	O
NaB	O
)	O
,	O
or	O
hexamethylene	O
bisacetamide	O
(	O
HMBA	O
)	O
,	O
but	O
not	O
tumor	B-protein
necrosis	I-protein
factor	I-protein
alpha	I-protein
(	O
TNF-alpha	B-protein
)	O
,	O
confirming	O
the	O
role	O
of	O
NF-kappa	B-protein
B	I-protein
in	O
mediating	O
TNF-alpha	B-protein
induction	O
of	O
HIV	O
transcription	O
.	O

The	O
strong	O
induction	O
of	O
HIV	O
expression	O
by	O
NaB	O
or	O
HMBA	O
in	O
J	B-cell_line
delta	I-cell_line
K	I-cell_line
cells	I-cell_line
clearly	O
demonstrates	O
the	O
existence	O
of	O
NF-kappa	B-protein
B	I-protein
-independent	O
mechanisms	O
of	O
HIV	O
activation	O
in	O
chronically	B-cell_type
infected	I-cell_type
cells	I-cell_type
.	O

J	B-cell_line
delta	I-cell_line
K	I-cell_line
cells	I-cell_line
may	O
provide	O
a	O
useful	O
model	O
for	O
characterizing	O
NF-kappa	B-protein
B	I-protein
-independent	O
transcriptional	O
activation	O
of	O
the	O
HIV	B-DNA
LTR	I-DNA
.	O

JNK	B-protein
is	O
involved	O
in	O
signal	O
integration	O
during	O
costimulation	O
of	O
T	B-cell_type
lymphocytes	I-cell_type
.	O

T	B-cell_type
lymphocyte	I-cell_type
activation	O
and	O
interleukin-2	B-protein
(	O
IL-2	B-protein
)	O
production	O
require	O
at	O
least	O
two	O
signals	O
,	O
generated	O
by	O
phorbol	O
ester	O
(	O
TPA	O
)	O
and	O
Ca2+	O
ionophore	O
or	O
costimulation	O
of	O
the	O
T	B-protein
cell	I-protein
receptor	I-protein
(	O
TCR	B-protein
)	O
and	O
the	O
CD28	B-protein
auxiliary	I-protein
receptor	I-protein
.	O

We	O
investigated	O
how	O
these	O
stimuli	O
affect	O
mitogen	B-protein
activated	I-protein
protein	I-protein
(	I-protein
MAP	I-protein
)	I-protein
kinases	I-protein
.	O

Full	O
activation	O
of	O
the	O
MAP	B-protein
kinases	I-protein
that	O
phosphorylate	O
the	O
Jun	B-protein
activation	I-protein
domain	I-protein
,	O
JNK1	B-protein
and	O
JNK2	B-protein
,	O
required	O
costimulation	O
of	O
T	B-cell_type
cells	I-cell_type
with	O
either	O
TPA	O
and	O
Ca2+	O
ionophore	O
or	O
antibodies	O
to	O
TCR	B-protein
and	O
CD28	B-protein
.	O

Alone	O
,	O
each	O
stimulus	O
resulted	O
in	O
little	O
or	O
no	O
activation	O
.	O

Similar	O
to	O
its	O
effect	O
on	O
IL-2	B-protein
induction	O
,	O
cyclosporin	O
A	O
(	O
CsA	O
)	O
inhibited	O
the	O
synergistic	O
activation	O
of	O
JNK	B-protein
,	O
and	O
a	O
competitive	O
inhibitor	O
of	O
Jun	B-protein
phosphorylation	O
by	O
JNK	B-protein
inhibited	O
IL-2	B-DNA
promoter	I-DNA
activation	O
.	O

By	O
contrast	O
,	O
the	O
MAP	B-protein
kinases	I-protein
ERK1	B-protein
and	O
ERK2	B-protein
were	O
fully	O
activated	O
by	O
TPA	O
or	O
TCR	B-protein
stimulation	O
and	O
were	O
not	O
affected	O
by	O
Ca2+	O
,	O
CD28	O
,	O
or	O
CsA	O
.	O

Hence	O
,	O
integration	O
of	O
signals	O
that	O
lead	O
to	O
T	O
cell	O
activation	O
occurs	O
at	O
the	O
level	O
of	O
JNK	B-protein
activation	O
.	O

Inhibition	O
of	O
rat	B-cell_type
splenocyte	I-cell_type
proliferation	O
with	O
methylprednisolone	O
:	O
in	O
vivo	O
effect	O
of	O
liposomal	O
formulation	O
.	O

The	O
effect	O
of	O
a	O
liposomal	O
formulation	O
of	O
methylprednisolone	O
(	O
MPL	O
)	O
on	O
the	O
inhibition	O
of	O
lymphocyte	O
proliferation	O
in	O
spleen	B-cell_type
cells	I-cell_type
was	O
investigated	O
following	O
IV	O
dosing	O
in	O
rats	O
.	O

Liposomes	O
do	O
not	O
alter	O
the	O
suppressive	O
action	O
of	O
MPL	O
when	O
placed	O
in	O
lymphocyte	B-cell_line
culture	I-cell_line
.	O

Rat	B-cell_type
splenocytes	I-cell_type
were	O
found	O
to	O
have	O
greater	O
sensitivity	O
to	O
MPL	O
(	O
EC50	O
=	O
7.9	O
nM	O
)	O
than	O
do	O
human	B-cell_type
peripheral	I-cell_type
blood	I-cell_type
lymphocytes	I-cell_type
(	O
EC50	O
=	O
28	O
nM	O
)	O
.	O

In	O
vivo	O
studies	O
in	O
rats	O
utilized	O
2	O
mg/kg	O
IV	O
bolus	O
doses	O
of	O
liposomal	O
MPL	O
compared	O
to	O
drug	O
in	O
solution	O
.	O

Animals	O
were	O
sacrificed	O
at	O
various	O
times	O
post-dosing	O
until	O
120	O
h	O
,	O
spleen	O
was	O
excised	O
and	O
,	O
after	O
incubation	O
of	O
lymphocytes	B-cell_type
with	O
PHA	B-protein
,	O
splenocyte	O
blastogenic	O
responses	O
were	O
assessed	O
by	O
measuring	O
cellular	O
incorporation	O
of	O
3H-thymidine	O
.	O

The	O
suppressive	O
effect	O
of	O
liposomal	O
MPL	O
in	O
comparison	O
with	O
free	O
drug	O
was	O
significantly	O
prolonged	O
(	O
>	O
120	O
h	O
vs	O
<	O
18	O
h	O
)	O
.	O

Inhibition	O
effects	O
versus	O
time	O
were	O
described	O
by	O
a	O
pharmacodynamic	O
model	O
using	O
MPL	O
concentrations	O
in	O
plasma	B-cell_type
as	O
an	O
input	O
function	O
.	O

A	O
nonlinear	O
relationship	O
was	O
found	O
between	O
suppression	O
of	O
splenocyte	B-cell_type
proliferation	O
and	O
the	O
concentration	O
of	O
bound	O
glucocorticoid	B-protein
receptors	I-protein
in	O
spleen	O
.	O

Only	O
partial	O
receptor	O
occupancy	O
accompanied	O
complete	O
lymphocyte	O
suppression	O
.	O

The	O
suppression	O
of	O
endogenous	O
corticosterone	O
in	O
plasma	B-cell_type
for	O
both	O
treatments	O
was	O
similar	O
with	O
values	O
from	O
L-MPL	O
rats	O
returning	O
to	O
baseline	O
after	O
24	O
h	O
.	O

These	O
results	O
demonstrate	O
enhanced	O
efficacy	O
of	O
local	O
immunosuppression	O
by	O
targeting	O
spleen	O
with	O
liposomal	O
MPL	O
.	O

Function	O
of	O
NF-kappa	B-DNA
B/Rel	I-DNA
binding	I-DNA
sites	I-DNA
in	O
the	O
major	B-DNA
histocompatibility	I-DNA
complex	I-DNA
class	I-DNA
II	I-DNA
invariant	I-DNA
chain	I-DNA
promoter	I-DNA
is	O
dependent	O
on	O
cell-specific	O
binding	O
of	O
different	O
NF-kappa	B-protein
B/Rel	I-protein
subunits	I-protein
.	O

The	O
promoter	B-DNA
of	O
the	O
human	O
major	O
histocompatibility	B-DNA
complex	I-DNA
class	I-DNA
II-associated	I-DNA
invariant-chain	I-DNA
gene	I-DNA
(	O
Ii	B-DNA
)	O
contains	O
two	O
NF-kappa	B-DNA
B/Rel	I-DNA
binding	I-DNA
sites	I-DNA
located	O
at	O
-109	B-DNA
to	I-DNA
-118	I-DNA
(	O
Ii	B-DNA
kappa	I-DNA
B-1	I-DNA
)	O
and	O
-163	B-DNA
to	I-DNA
-172	I-DNA
(	O
Ii	B-DNA
kappa	I-DNA
B-2	I-DNA
)	O
from	O
the	O
transcription	O
start	O
site	O
.	O

We	O
report	O
here	O
that	O
the	O
differential	O
function	O
of	O
each	O
of	O
these	O
NF-kappa	B-DNA
B/Rel	I-DNA
sites	I-DNA
in	O
several	O
distinct	O
cell	O
types	O
depends	O
on	O
cell-specific	O
binding	O
of	O
NF-kappa	B-protein
B/Rel	I-protein
transcription	I-protein
factors	I-protein
.	O

Ii	B-DNA
kappa	I-DNA
B-1	I-DNA
is	O
a	O
positive	B-DNA
regulatory	I-DNA
element	I-DNA
in	O
B-cell	B-cell_line
lines	I-cell_line
and	O
in	O
the	O
Ii-expressing	B-cell_line
T-cell	I-cell_line
line	I-cell_line
,	O
H9	B-cell_line
,	O
but	O
acts	O
as	O
a	O
negative	B-DNA
regulatory	I-DNA
element	I-DNA
in	O
myelomonocytic	B-cell_line
and	I-cell_line
glia	I-cell_line
cell	I-cell_line
lines	I-cell_line
.	O

In	O
vivo	O
protein-DNA	O
contacts	O
are	O
detectable	O
at	O
Ii	B-DNA
kappa	I-DNA
B-1	I-DNA
in	O
cell	B-cell_line
lines	I-cell_line
in	O
which	O
this	O
site	O
is	O
functional	O
as	O
either	O
a	O
positive	B-DNA
or	I-DNA
negative	I-DNA
regulator	I-DNA
.	O

Electrophoretic	O
mobility	O
supershift	O
assays	O
determine	O
that	O
members	O
of	O
the	O
NF-kappa	B-protein
B/Rel	I-protein
family	I-protein
of	O
transcription	B-protein
factors	I-protein
can	O
bind	O
to	O
this	O
site	O
in	O
vitro	O
and	O
that	O
DNA-binding	B-protein
complexes	I-protein
that	O
contain	O
p50	B-protein
,	O
p52	B-protein
,	O
p65	B-protein
,	O
and	O
cRel	B-protein
correlate	O
with	O
positive	O
regulation	O
whereas	O
the	O
presence	O
of	O
p50	B-protein
correlates	O
with	O
negative	O
regulation	O
.	O

Ii	B-DNA
kappa	I-DNA
B-2	I-DNA
is	O
a	O
site	O
of	O
positive	O
regulation	O
in	O
B-cell	B-cell_line
lines	I-cell_line
and	O
a	O
site	O
of	O
negative	O
regulation	O
in	O
H9	B-cell_line
T	I-cell_line
cells	I-cell_line
,	O
myelomonocytic	B-cell_line
,	I-cell_line
and	I-cell_line
glial	I-cell_line
cell	I-cell_line
lines	I-cell_line
.	O

In	O
vivo	O
occupancy	O
of	O
this	O
site	O
is	O
observed	O
only	O
in	O
the	O
H9	B-cell_line
T-cell	I-cell_line
line	I-cell_line
.	O

Again	O
,	O
in	O
vitro	O
supershift	O
studies	O
indicate	O
that	O
the	O
presence	O
of	O
p50	B-protein
,	O
p52	B-protein
,	O
p65	B-protein
,	O
and	O
cRel	B-protein
correlates	O
with	O
positive	O
function	O
whereas	O
the	O
presence	O
of	O
only	O
p50	B-protein
and	O
p52	B-protein
correlates	O
with	O
negative	O
function	O
.	O

This	O
differential	O
binding	O
of	O
specific	O
NF-kappa	B-protein
B/Rel	I-protein
subunits	I-protein
is	O
likely	O
to	O
mediate	O
the	O
disparate	O
functions	O
of	O
these	O
two	O
NF-kappa	B-DNA
B/Rel	I-DNA
binding	I-DNA
sites	I-DNA
.	O

Epstein-Barr	O
virus	O
(	O
EBV	O
)	O
replicative	O
gene	O
expression	O
in	O
tumour	B-cell_type
cells	I-cell_type
of	O
AIDS-related	O
non-Hodgkin	O
's	O
lymphoma	O
in	O
relation	O
to	O
CD4	B-protein
cell	O
number	O
and	O
antibody	O
titres	O
to	O
EBV	O
.	O

OBJECTIVE	O
:	O
To	O
determine	O
whether	O
activation	O
of	O
Epstein-Barr	O
virus	O
(	O
EBV	O
)	O
replication	O
in	O
tumour	B-cell_type
cells	I-cell_type
of	O
AIDS-related	O
non-Hodgkin	O
's	O
lymphoma	O
(	O
ARNHL	O
)	O
is	O
correlated	O
with	O
CD4+	B-protein
cell	O
counts	O
and	O
influences	O
antibody	O
response	O
to	O
EBV	O
[	O
anti-Z	B-protein
Epstein-Barr	I-protein
replicative	I-protein
activator	I-protein
(	O
ZEBRA	B-protein
)	O
,	O
anti-early	B-protein
antigen	I-protein
(	O
EA	B-protein
)	O
,	O
anti-viral	B-protein
capsid	I-protein
antigen	I-protein
(	O
VCA	B-protein
)	O
]	O
.	O

DESIGN	O
:	O
Retrospective	O
study	O
based	O
on	O
immunohistochemistry	O
and	O
in	O
situ	O
hybridization	O
to	O
detect	O
EBV	O
replicative	O
gene	O
products	O
in	O
tissue	O
samples	O
from	O
patients	O
affected	O
by	O
ARNHL	O
and	O
correlation	O
with	O
CD4+	B-protein
cell	O
counts	O
and	O
results	O
of	O
EBV	O
serology	O
(	O
including	O
anti-	O
ZEBRA	B-protein
activity	O
)	O
in	O
sera	O
from	O
the	O
same	O
patients	O
.	O

METHODS	O
:	O
Seventeen	O
out	O
of	O
22	O
cases	O
of	O
ARNHL	O
were	O
selected	O
for	O
the	O
presence	O
of	O
EBV	O
[	O
Epstein-Barr	O
early	O
region	O
(	O
EBER	O
)	O
RNA-positive	O
]	O
.	O

Immunohistochemistry	O
was	O
performed	O
with	O
anti-ZEBRA	B-protein
,	O
anti-EA-restricted	B-protein
,	I-protein
anti-VCA	I-protein
antibodies	I-protein
and	O
in	O
situ	O
hybridization	O
with	O
BHLF1/NotI	O
oligoprobes	O
on	O
tumour	O
samples	O
.	O

Results	O
were	O
statistically	O
correlated	O
with	O
those	O
of	O
CD4+	B-protein
cell	O
counts	O
(	O
17	O
out	O
of	O
17	O
)	O
and	O
with	O
anti-EBV	O
antibody	O
titres	O
(	O
13	O
out	O
of	O
17	O
)	O
assessed	O
using	O
standard	O
immunofluorescence	O
method	O
and	O
enzyme-linked	O
immunosorbent	O
assay	O
procedure	O
using	O
recombinant	B-protein
ZEBRA	I-protein
protein	I-protein
and	O
synthetic	O
peptides	O
as	O
antigens	B-protein
.	O

RESULTS	O
:	O
BZLF1	B-protein
(	O
ZEBRA	B-protein
)	O
or	O
early	B-protein
gene	I-protein
products	I-protein
(	O
EA-R	B-protein
and	O
EA-D/BHLF1/NotI	B-protein
)	O
were	O
detected	O
in	O
a	O
small	O
proportion	O
(	O
<	O
0.01-5	O
%	O
)	O
of	O
tumour	B-cell_type
cells	I-cell_type
in	O
eight	O
of	O
these	O
17	O
cases	O
by	O
immunohistochemistry	O
and	O
in	O
situ	O
hybridization	O
.	O

Demonstration	O
of	O
replicative	O
gene	O
expression	O
did	O
not	O
correlate	O
with	O
either	O
low	O
CD4+	B-protein
cell	O
counts	O
(	O
P	O
>	O
0.05	O
)	O
or	O
anti-EBV	O
antibody	O
titres	O
(	O
P	O
>	O
0.05	O
)	O
.	O

Anti-	O
ZEBRA	B-protein
activity	O
was	O
not	O
significantly	O
increased	O
in	O
patients	O
affected	O
with	O
ARNHL	O
,	O
the	O
cells	O
of	O
which	O
expressed	O
replicative	O
gene	O
products	O
(	O
P	O
>	O
0.05	O
)	O
.	O

CONCLUSION	O
:	O
The	O
degree	O
of	O
immunodeficiency	O
does	O
not	O
clearly	O
enhance	O
replicative	O
gene	O
expression	O
in	O
tumour	B-cell_type
cells	I-cell_type
of	O
ARNHL	O
.	O

EBV	O
serology	O
,	O
including	O
anti-	O
ZEBRA	B-protein
activity	O
,	O
is	O
not	O
a	O
reliable	O
tool	O
for	O
predicting	O
the	O
occurrence	O
of	O
such	O
proliferations	O
.	O

Effects	O
of	O
prostaglandin	B-protein
E2	I-protein
on	O
Th0-type	B-cell_line
human	I-cell_line
T	I-cell_line
cell	I-cell_line
clones	I-cell_line
:	O
modulation	O
of	O
functions	O
of	O
nuclear	B-protein
proteins	I-protein
involved	O
in	O
cytokine	B-protein
production	O
.	O

The	O
effects	O
of	O
prostaglandin	B-protein
E2	I-protein
(	O
PGE2	B-protein
)	O
on	O
cytokine	B-protein
production	O
and	O
proliferation	O
of	O
the	O
CD4+	B-cell_line
human	I-cell_line
helper	I-cell_line
T	I-cell_line
cell	I-cell_line
clone	I-cell_line
SP-B21	I-cell_line
were	O
investigated	O
.	O

In	O
cells	O
stimulated	O
with	O
anti-CD3	B-protein
mAb	I-protein
,	O
PGE2	B-protein
inhibited	O
cell	O
proliferation	O
and	O
the	O
production	O
of	O
all	O
the	O
cytokines	B-protein
examined	O
.	O

Addition	O
of	O
rIL-2	B-protein
fully	O
restored	O
the	O
proliferative	O
response	O
and	O
partially	O
restored	O
the	O
production	O
of	O
IL-4	B-protein
and	O
IL-5	B-protein
,	O
but	O
not	O
that	O
of	O
other	O
cytokines	B-protein
.	O

In	O
contrast	O
,	O
in	O
cells	O
stimulated	O
with	O
phorbol	O
myristate	O
acetate	O
(	O
PMA	O
)	O
/A23187	O
,	O
PGE2	B-protein
enhanced	O
the	O
production	O
of	O
IL-4	B-protein
and	O
IL-5	B-protein
,	O
and	O
only	O
partially	O
inhibited	O
the	O
production	O
of	O
other	O
cytokines	B-protein
.	O

Therefore	O
,	O
the	O
effects	O
of	O
PGE2	B-protein
vary	O
depending	O
on	O
the	O
mode	O
of	O
T	O
cell	O
activation	O
,	O
and	O
the	O
IL-4	B-protein
and	O
IL-5	B-protein
are	O
regulated	O
differently	O
from	O
other	O
cytokines	B-protein
.	O

In	O
a	O
mobility	O
shift	O
assay	O
,	O
only	O
the	O
NF-kappa	B-protein
B	I-protein
(	I-protein
p50/p50	I-protein
)	I-protein
homodimer	I-protein
was	O
observed	O
in	O
a	O
complex	O
formed	O
with	O
the	O
kappa	B-DNA
B	I-DNA
sequence	I-DNA
in	O
unstimulated	O
SP-B21	O
cells	O
.	O

When	O
cells	O
were	O
stimulated	O
with	O
anti-CD3	B-protein
mAb	I-protein
or	O
PMA/A23187	O
,	O
a	O
complex	O
formation	O
of	O
NF-kappa	B-protein
B	I-protein
(	O
p50	B-protein
/p65	B-protein
)	O
heterodimer	O
with	O
the	O
kappa	B-DNA
B	I-DNA
sequence	I-DNA
was	O
induced	O
.	O

Interestingly	O
,	O
PGE2	B-protein
or	O
di-butyryl	O
(	O
Bt2	O
)	O
cAMP	O
abolished	O
the	O
binding	O
of	O
NF-kappa	B-protein
B	I-protein
(	I-protein
p50/p65	I-protein
)	I-protein
heterodimer	I-protein
to	O
the	O
kappa	B-DNA
B	I-DNA
sequence	I-DNA
in	O
cells	O
stimulated	O
with	O
anti-CD3	B-protein
mAb	I-protein
but	O
not	O
with	O
PMA/A23187	O
.	O

Our	O
results	O
suggest	O
that	O
the	O
target	O
of	O
PGE2	B-protein
action	O
is	O
a	O
component	O
in	O
the	O
signal	O
transduction	O
pathway	O
leading	O
to	O
the	O
activation	O
of	O
protein	B-protein
kinase	I-protein
C	I-protein
.	O

However	O
,	O
the	O
inhibition	O
of	O
the	O
T	O
cell	O
activation	O
signals	O
by	O
PGE2	B-protein
is	O
selective	O
.	O

PGE2	B-protein
enhanced	O
the	O
complex	O
formation	O
with	O
NF-AT	B-DNA
,	I-DNA
AP-1	I-DNA
and	I-DNA
CLE0	I-DNA
sequences	I-DNA
when	O
the	O
cells	O
were	O
activated	O
by	O
either	O
anti-CD3	B-protein
mAb	I-protein
or	O
PMA/A23187	O
stimulation	O
.	O

It	O
seems	O
therefore	O
that	O
PGE2	B-protein
,	O
by	O
elevating	O
cAMP	O
levels	O
,	O
interferes	O
with	O
the	O
activation	O
pathway	O
for	O
NF-kappa	B-protein
B	I-protein
but	O
not	O
for	O
NF-AT	B-protein
,	O
AP-1	B-protein
or	O
CLE0	B-protein
binding	I-protein
protein	I-protein
.	O

Characterization	O
of	O
NF	B-protein
(	I-protein
P	I-protein
)	I-protein
,	O
the	O
nuclear	B-protein
factor	I-protein
that	O
interacts	O
with	O
the	O
regulatory	O
P	B-DNA
sequence	I-DNA
(	O
5'-CGAAAATTTCC-3	O
'	O
)	O
of	O
the	O
human	B-DNA
interleukin-4	I-DNA
gene	I-DNA
:	O
relationship	O
to	O
NF-kappa	B-protein
B	I-protein
and	O
NF-AT	B-protein
.	O

The	O
P	B-DNA
sequence	I-DNA
of	O
the	O
human	B-DNA
interleukin-4	I-DNA
(	I-DNA
IL-4	I-DNA
)	I-DNA
gene	I-DNA
,	O
which	O
was	O
defined	O
as	O
a	O
responsive	B-DNA
element	I-DNA
for	O
phorbol	O
12-myristate	O
13-acetate	O
and	O
calcium	O
ionophore	O
(	O
A23187	O
)	O
in	O
Jurkat	B-cell_line
T	I-cell_line
cells	I-cell_line
,	O
shares	O
sequence	O
similarity	O
with	O
the	O
NF-kappa	B-DNA
B	I-DNA
and	I-DNA
the	I-DNA
NF-AT	I-DNA
binding	I-DNA
sites	I-DNA
.	O

We	O
examined	O
whether	O
NF	B-protein
(	I-protein
P	I-protein
)	I-protein
,	O
a	O
nuclear	B-protein
factor	I-protein
specific	O
for	O
the	O
P	B-DNA
sequence	I-DNA
,	O
is	O
related	O
to	O
NF-kappa	B-protein
B	I-protein
and	O
NF-AT	B-protein
.	O

NF-kappa	B-protein
B	I-protein
(	O
P65	B-protein
or	O
P65/P50	B-protein
heterodimer	I-protein
)	O
bound	O
to	O
the	O
P	B-DNA
sequence	I-DNA
in	O
electrophoretic	O
mobility	O
shift	O
assays	O
(	O
EMSA	O
)	O
and	O
activated	O
transcription	O
through	O
the	O
P	B-DNA
sequence	I-DNA
when	O
expression	B-DNA
plasmids	I-DNA
were	O
cotransfected	O
with	O
P	B-DNA
sequence-driven	I-DNA
reporter	I-DNA
plasmids	I-DNA
in	O
Jurkat	B-cell_line
T	I-cell_line
cells	I-cell_line
.	O

In	O
EMSAs	O
,	O
NF	B-protein
(	I-protein
P	I-protein
)	I-protein
binding	O
was	O
inhibited	O
by	O
the	O
unlabeled	B-DNA
NF-AT	I-DNA
binding	I-DNA
site	I-DNA
but	O
not	O
by	O
the	O
unlabeled	B-DNA
AP1	I-DNA
binding	I-DNA
site	I-DNA
and	O
purified	B-protein
NF-AT	I-protein
contained	O
an	O
activity	O
that	O
bound	O
to	O
the	O
P	B-DNA
sequence	I-DNA
.	O

Both	O
mobility	O
shift	O
and	O
sequence	O
specificity	O
of	O
NF-AT	B-protein
were	O
similar	O
to	O
those	O
of	O
NF	B-protein
(	I-protein
P	I-protein
)	I-protein
and	O
only	O
a	O
small	O
amount	O
of	O
P65	B-protein
was	O
detected	O
in	O
NF	B-protein
(	I-protein
P	I-protein
)	I-protein
in	O
crude	O
nuclear	O
extracts	O
.	O

These	O
results	O
indicate	O
that	O
the	O
component	O
(	O
s	O
)	O
of	O
NF-AT	B-protein
has	O
the	O
potential	O
to	O
reconstitute	O
NF	B-protein
(	I-protein
P	I-protein
)	I-protein
whereas	O
NF-kappa	B-protein
B	I-protein
alone	O
can	O
not	O
account	O
for	O
NF	B-protein
(	I-protein
P	I-protein
)	I-protein
in	O
crude	O
extracts	O
.	O

Unlike	O
NF-AT	B-protein
,	O
NF	B-protein
(	I-protein
P	I-protein
)	I-protein
does	O
not	O
contain	O
AP1	B-protein
as	O
its	O
DNA	B-protein
binding	I-protein
component	I-protein
.	O

Activation	O
of	O
early	B-DNA
growth	I-DNA
response	I-DNA
1	I-DNA
gene	I-DNA
transcription	O
and	O
pp90rsk	B-protein
during	O
induction	O
of	O
monocytic	O
differentiation	O
.	O

The	O
present	O
work	O
has	O
studied	O
mechanisms	O
responsible	O
for	O
induction	O
of	O
early	B-DNA
growth	I-DNA
response	I-DNA
1	I-DNA
(	I-DNA
EGR-1	I-DNA
)	I-DNA
gene	I-DNA
expression	O
during	O
monocytic	O
differentiation	O
of	O
U-937	B-cell_line
myeloid	I-cell_line
leukemia	I-cell_line
cells	I-cell_line
.	O

Differentiation	O
of	O
U-937	B-cell_line
cells	I-cell_line
with	O
12-O-tetradecanoylphorbol-13-acetate	O
(	O
TPA	O
)	O
,	O
an	O
activator	O
of	O
the	O
serine/threonine	B-protein
protein	I-protein
kinase	I-protein
C	I-protein
,	O
was	O
associated	O
with	O
transcriptional	O
activation	O
of	O
EGR-1	B-DNA
promoter-reporter	I-DNA
constructs	I-DNA
.	O

The	O
EGR-1	B-DNA
promoter	I-DNA
contains	O
six	O
CC	O
(	O
A/T	O
)	O
6GG	O
(	O
CArG	O
)	O
motifs	O
.	O

The	O
two	O
5'-most	B-DNA
distal	I-DNA
CArG	I-DNA
sequences	I-DNA
conferred	O
TPA	O
inducibility	O
.	O

In	O
contrast	O
,	O
there	O
was	O
little	O
effect	O
of	O
TPA	O
on	O
EGR-1	B-DNA
transcription	O
in	O
a	O
TPA-resistant	B-cell_line
U-937	I-cell_line
cell	I-cell_line
variant	I-cell_line
,	O
designated	O
TUR	B-cell_line
.	O

Treatment	O
of	O
both	O
U-937	B-cell_line
and	O
TUR	B-cell_line
cells	I-cell_line
with	O
okadaic	O
acid	O
,	O
an	O
inhibitor	O
of	O
serine/threonine	B-protein
protein	I-protein
phosphatases	I-protein
1	I-protein
and	I-protein
2A	I-protein
,	O
was	O
associated	O
with	O
induction	O
of	O
monocytic	O
differentiation	O
and	O
EGR-1	B-DNA
transcription	O
through	O
the	O
5'-most	B-DNA
CArG	I-DNA
element	I-DNA
.	O

Since	O
these	O
findings	O
supported	O
the	O
involvement	O
of	O
serine/threonine	O
protein	O
phosphorylation	O
in	O
the	O
regulation	O
of	O
EGR-1	B-DNA
expression	O
,	O
we	O
studied	O
activation	O
of	O
the	O
40S	B-protein
ribosomal	I-protein
protein	I-protein
S6	I-protein
serine/threonine	I-protein
kinases	I-protein
,	O
pp70S6K	B-protein
and	O
pp90rsk	B-protein
.	O

Although	O
both	O
kinases	O
participate	O
in	O
regulating	O
cell	O
growth	O
,	O
there	O
was	O
no	O
detectable	O
activation	O
of	O
pp70S6K	B-protein
during	O
TPA-	O
or	O
okadaic	O
acid-induced	O
monocytic	O
differentiation	O
.	O

Moreover	O
,	O
rapamycin	O
,	O
an	O
inhibitor	O
of	O
pp70S6K	B-protein
activation	O
,	O
had	O
no	O
effect	O
on	O
induction	O
of	O
EGR-1	B-DNA
expression	O
.	O

In	O
contrast	O
,	O
analysis	O
of	O
pp90rsk	B-protein
activity	O
by	O
phosphorylation	O
of	O
a	O
peptide	O
derived	O
from	O
S6	B-protein
protein	I-protein
demonstrated	O
stimulation	O
of	O
this	O
kinase	B-protein
in	O
TPA-treated	B-cell_line
U-937	I-cell_line
,	I-cell_line
and	I-cell_line
not	I-cell_line
TUR	I-cell_line
,	I-cell_line
cells	I-cell_line
.	O

Okadaic	O
acid	O
treatment	O
of	O
both	O
cell	O
types	O
was	O
associated	O
with	O
activation	O
of	O
pp90rsk	B-protein
.	O

Antioxidants	O
inhibit	O
monocyte	B-cell_type
adhesion	O
by	O
suppressing	O
nuclear	B-protein
factor-kappa	I-protein
B	I-protein
mobilization	O
and	O
induction	O
of	O
vascular	B-protein
cell	I-protein
adhesion	I-protein
molecule-1	I-protein
in	O
endothelial	B-cell_type
cells	I-cell_type
stimulated	O
to	O
generate	O
radicals	O
.	O

Cell	O
adhesion	O
to	O
endothelial	B-cell_type
cells	I-cell_type
stimulated	B-protein
by	I-protein
tumor	I-protein
necrosis	I-protein
factor-alpha	I-protein
(	O
TNF	B-protein
)	O
is	O
due	O
to	O
induction	O
of	O
surface	B-protein
receptors	I-protein
,	O
such	O
as	O
vascular	B-protein
cell	I-protein
adhesion	I-protein
molecule-1	I-protein
(	O
VCAM-1	B-protein
)	O
.	O

The	O
antioxidant	O
pyrrolidine	O
dithiocarbamate	O
(	O
PDTC	O
)	O
specifically	O
inhibits	O
activation	O
of	O
nuclear	B-protein
factor-kappa	I-protein
B	I-protein
(	O
NF-kappa	B-protein
B	I-protein
)	O
.	O

Since	O
kappa	B-DNA
B	I-DNA
motifs	I-DNA
are	O
present	O
in	O
VCAM-1	B-DNA
and	I-DNA
intercellular	I-DNA
adhesion	I-DNA
molecule-1	I-DNA
(	I-DNA
ICAM-1	I-DNA
)	I-DNA
promoters	I-DNA
,	O
we	O
used	O
PDTC	O
to	O
study	O
the	O
regulatory	O
mechanisms	O
of	O
VCAM-1	B-protein
and	O
ICAM-1	B-protein
induction	O
and	O
subsequent	O
monocyte	B-cell_type
adhesion	O
in	O
TNF-treated	B-cell_line
human	I-cell_line
umbilical	I-cell_line
vein	I-cell_line
endothelial	I-cell_line
cells	I-cell_line
(	O
HUVECs	B-cell_line
)	O
.	O

PDTC	O
or	O
N-acetylcysteine	O
dose	O
dependently	O
reduced	O
TNF-induced	B-protein
VCAM-1	I-protein
but	O
not	O
ICAM-1	B-protein
surface	I-protein
protein	I-protein
(	O
also	O
in	O
human	B-cell_type
umbilical	I-cell_type
arterial	I-cell_type
endothelial	I-cell_type
cells	I-cell_type
)	O
and	O
mRNA	O
expression	O
(	O
by	O
70	O
%	O
at	O
100	O
mumol/L	O
PDTC	O
)	O
in	O
HUVECs	B-cell_line
as	O
assessed	O
by	O
flow	O
cytometry	O
and	O
polymerase	O
chain	O
reaction	O
.	O

Gel-shift	O
analysis	O
in	O
HUVECs	B-cell_line
demonstrated	O
that	O
PDTC	O
prevented	O
NF-kappa	B-protein
B	I-protein
mobilization	O
by	O
TNF	B-protein
,	O
suggesting	O
that	O
only	O
VCAM-1	B-protein
induction	O
was	O
controlled	O
by	O
NF-kappa	B-protein
B	I-protein
.	O

Since	O
HUVECs	B-cell_line
released	O
superoxide	O
anions	O
in	O
response	O
to	O
TNF	O
,	O
and	O
H2O2	O
induces	O
VCAM-1	B-protein
,	O
PDTC	O
may	O
act	O
as	O
a	O
radical	O
scavenger	O
.	O

Although	O
ICAM-1	B-protein
induction	O
was	O
unaffected	O
,	O
inhibitors	O
of	O
NADPH	B-protein
oxidase	I-protein
(	O
apocynin	O
)	O
or	O
cytochrome	B-protein
P-450	I-protein
(	O
SKF525a	O
)	O
suppressed	O
VCAM-1	B-protein
induction	O
by	O
TNF	O
,	O
revealing	O
that	O
several	O
radical-generating	O
systems	O
are	O
involved	O
in	O
its	O
regulation	O
.	O

PDTC	O
,	O
apocynin	O
,	O
or	O
SKF525a	O
decreased	O
adhesion	O
of	O
monocytic	B-cell_line
U937	I-cell_line
cells	I-cell_line
to	O
TNF-treated	B-cell_line
HUVECs	I-cell_line
(	O
by	O
75	O
%	O
at	O
100	O
mumol/L	O
PDTC	O
)	O
.	O

Inhibition	O
by	O
anti-VCAM-1	B-protein
monoclonal	I-protein
antibody	I-protein
1G11	B-protein
indicated	O
that	O
U937	B-cell_line
adhesion	O
was	O
VCAM-1	B-protein
dependent	O
and	O
suppression	O
by	O
antioxidants	O
was	O
due	O
to	O
reduced	O
VCAM-1	B-protein
induction	O
.	O

(	O
ABSTRACT	O
TRUNCATED	O
AT	O
250	O
WORDS	O
)	O

Displacement	O
of	O
an	O
E-box-binding	B-protein
repressor	I-protein
by	O
basic	B-protein
helix-loop-helix	I-protein
proteins	I-protein
:	O
implications	O
for	O
B-cell	O
specificity	O
of	O
the	O
immunoglobulin	B-DNA
heavy-chain	I-DNA
enhancer	I-DNA
.	O

The	O
activity	O
of	O
the	O
immunoglobulin	B-DNA
heavy-chain	I-DNA
(	I-DNA
IgH	I-DNA
)	I-DNA
enhancer	I-DNA
is	O
restricted	O
to	O
B	B-cell_type
cells	I-cell_type
,	O
although	O
it	O
binds	O
both	O
B-cell-restricted	B-protein
and	I-protein
ubiquitous	I-protein
transcription	I-protein
factors	I-protein
.	O

Activation	O
of	O
the	O
enhancer	B-DNA
in	O
non-B	B-cell_type
cells	I-cell_type
upon	O
overexpression	O
of	O
the	O
basic	B-protein
helix-loop-helix	I-protein
(	I-protein
bHLH	I-protein
)	I-protein
protein	I-protein
E2A	B-protein
appears	O
to	O
be	O
mediated	O
not	O
only	O
by	O
the	O
binding	O
of	O
E2A	B-protein
to	O
its	O
cognate	O
E	B-DNA
box	I-DNA
but	O
also	O
by	O
the	O
resulting	O
displacement	O
of	O
a	O
repressor	B-protein
from	O
that	O
same	O
site	O
.	O

We	O
have	O
identified	O
a	O
``	B-protein
two-handed	I-protein
''	I-protein
zinc	I-protein
finger	I-protein
protein	I-protein
,	O
denoted	O
ZEB	B-protein
,	O
the	O
DNA-binding	O
specificity	O
of	O
which	O
mimics	O
that	O
of	O
the	O
cellular	B-protein
repressor	I-protein
.	O

By	O
employing	O
a	O
derivative	O
E	B-DNA
box	I-DNA
that	O
binds	O
ZEB	B-protein
but	O
not	O
E2A	B-protein
,	O
we	O
have	O
shown	O
that	O
the	O
repressor	B-protein
is	O
active	O
in	O
B	B-cell_type
cells	I-cell_type
and	O
the	O
IgH	B-DNA
enhancer	I-DNA
is	O
silenced	O
in	O
the	O
absence	O
of	O
binding	O
competition	O
by	O
bHLH	B-protein
proteins	I-protein
.	O

Hence	O
,	O
we	O
propose	O
that	O
a	O
necessary	O
prerequisite	O
of	O
enhancer	B-DNA
activity	O
is	O
the	O
B-cell-specific	O
displacement	O
of	O
a	O
ZEB-like	B-protein
repressor	I-protein
by	O
bHLH	B-protein
proteins	I-protein
.	O

Inhibition	O
of	O
NF-kappa	B-protein
B	I-protein
by	O
sodium	O
salicylate	O
and	O
aspirin	O
[	O
see	O
comments	O
]	O

The	O
transcription	B-protein
factor	I-protein
nuclear	B-protein
factor-kappa	I-protein
B	I-protein
(	O
NF-kappa	B-protein
B	I-protein
)	O
is	O
critical	O
for	O
the	O
inducible	O
expression	O
of	O
multiple	O
cellular	B-DNA
and	I-DNA
viral	I-DNA
genes	I-DNA
involved	O
in	O
inflammation	O
and	O
infection	O
including	O
interleukin-1	B-protein
(	O
IL-1	B-protein
)	O
,	O
IL-6	B-protein
,	O
and	O
adhesion	B-protein
molecules	I-protein
.	O

The	O
anti-inflammatory	O
drugs	O
sodium	O
salicylate	O
and	O
aspirin	O
inhibited	O
the	O
activation	O
of	O
NF-kappa	B-protein
B	I-protein
,	O
which	O
further	O
explains	O
the	O
mechanism	O
of	O
action	O
of	O
these	O
drugs	O
.	O

This	O
inhibition	O
prevented	O
the	O
degradation	O
of	O
the	O
NF-kappa	B-protein
B	I-protein
inhibitor	I-protein
,	O
I	B-protein
kappa	I-protein
B	I-protein
,	O
and	O
therefore	O
NF-kappa	B-protein
B	I-protein
was	O
retained	O
in	O
the	O
cytosol	O
.	O

Sodium	O
salicylate	O
and	O
aspirin	O
also	O
inhibited	O
NF-kappa	B-protein
B	I-protein
-dependent	O
transcription	O
from	O
the	O
Ig	B-DNA
kappa	I-DNA
enhancer	I-DNA
and	O
the	O
human	B-DNA
immunodeficiency	I-DNA
virus	I-DNA
(	I-DNA
HIV	I-DNA
)	I-DNA
long	I-DNA
terminal	I-DNA
repeat	I-DNA
(	O
LTR	B-DNA
)	O
in	O
transfected	B-cell_line
T	I-cell_line
cells	I-cell_line
.	O

Effects	O
of	O
the	O
antisense	O
myb	O
expression	O
on	O
hemin-	O
and	O
erythropoietin-	O
induced	O
erythroid	O
differentiation	O
of	O
K562	B-cell_line
cells	I-cell_line
.	O

In	O
order	O
to	O
elucidate	O
the	O
role	O
of	O
c-myb	B-DNA
gene	I-DNA
in	O
erythroid	O
differentiation	O
of	O
K562	B-cell_line
cell	I-cell_line
induced	O
by	O
hemin	B-protein
(	O
Hm	B-protein
)	O
and	O
erythropoietin	B-protein
(	O
Epo	B-protein
)	O
,	O
we	O
constructed	O
recombinant	B-DNA
plasmid	I-DNA
that	O
could	O
produce	O
antisense	B-RNA
myb	I-RNA
RNA	I-RNA
after	O
induction	O
with	O
dexamethasone	O
.	O

During	O
treatment	O
with	O
Hm	B-protein
,	O
K562	B-cell_line
cells	I-cell_line
constitutively	O
expressed	O
c-myb	B-RNA
mRNA	I-RNA
,	O
and	O
50	O
%	O
of	O
them	O
began	O
to	O
synthesize	O
hemoglobin	B-protein
(	O
Hb	B-protein
)	O
.	O

Expression	O
of	O
antisense	B-RNA
myb	I-RNA
RNA	I-RNA
reduced	O
the	O
amount	O
of	O
c-myb	B-RNA
mRNA	I-RNA
,	O
and	O
the	O
percentage	O
of	O
Hb-synthesizing	B-cell_line
cells	I-cell_line
was	O
decreased	O
to	O
20	O
%	O
.	O

In	O
the	O
presence	O
of	O
Epo	B-protein
,	O
c-myb	B-RNA
mRNA	I-RNA
declined	O
and	O
20	O
%	O
of	O
K562	B-cell_line
cells	I-cell_line
synthesized	O
Hb	B-protein
regardless	O
of	O
antisense	B-RNA
myb	I-RNA
RNA	I-RNA
expression	O
.	O

It	O
is	O
suggested	O
that	O
constitutive	O
expression	O
of	O
c-myb	B-RNA
mRNA	I-RNA
is	O
necessary	O
for	O
Hm	B-protein
-induced	O
differentiation	O
,	O
and	O
that	O
a	O
decrease	O
in	O
the	O
amount	O
of	O
c-myb	B-RNA
mRNA	I-RNA
induced	O
by	O
antisense	B-RNA
myb	I-RNA
RNA	I-RNA
expression	O
suppresses	O
Hm	B-protein
-induced	O
differentiation	O
.	O

The	O
amount	O
of	O
c-myb	B-RNA
mRNA	I-RNA
in	O
K562	B-cell_line
cells	I-cell_line
was	O
reduced	O
during	O
the	O
differentiation	O
induced	O
by	O
Epo	B-protein
.	O

Expression	O
of	O
GATA-1	B-RNA
mRNA	I-RNA
was	O
almost	O
constant	O
during	O
Hm	B-protein
-induced	O
differentiation	O
,	O
but	O
increased	O
during	O
Epo	B-protein
treatment	O
.	O

It	O
is	O
supposed	O
that	O
the	O
mechanism	O
of	O
Hm	B-protein
-induced	O
differentiation	O
is	O
distinguished	O
from	O
that	O
of	O
Epo	B-protein
-induced	O
differentiation	O
in	O
K562	B-cell_line
cells	I-cell_line
.	O

Prenatal	O
immune	O
challenge	O
alters	O
the	O
hypothalamic-pituitary-adrenocortical	O
axis	O
in	O
adult	O
rats	O
.	O

We	O
investigated	O
whether	O
non-abortive	O
maternal	O
infections	O
would	O
compromise	O
fetal	O
brain	O
development	O
and	O
alter	O
hypothalamic-pituitary-adrenocortical	O
(	O
HPA	O
)	O
axis	O
functioning	O
when	O
adult	O
.	O

To	O
study	O
putative	O
teratogenic	O
effects	O
of	O
a	O
T	O
cell-mediated	O
immune	O
response	O
versus	O
an	O
endotoxic	O
challenge	O
,	O
10-d-pregnant	O
rats	O
received	O
a	O
single	O
intraperitoneal	O
injection	O
of	O
5	O
x	O
10	O
(	O
8	O
)	O
human	B-cell_type
red	I-cell_type
blood	I-cell_type
cells	I-cell_type
(	O
HRBC	B-cell_type
)	O
or	O
gram-negative	O
bacterial	O
endotoxin	O
(	O
Escherichia	O
coli	O
LPS	O
:	O
30	O
micrograms/kg	O
)	O
.	O

The	O
adult	O
male	O
progeny	O
(	O
3	O
mo	O
old	O
)	O
of	O
both	O
experimental	O
groups	O
showed	O
increased	O
basal	O
plasma	O
corticosterone	O
levels	O
.	O

In	O
addition	O
,	O
after	O
novelty	O
stress	O
the	O
HRBC	B-cell_type
group	O
,	O
but	O
not	O
the	O
LPS	B-cell_line
group	I-cell_line
,	O
showed	O
increased	O
ACTH	O
and	O
corticosterone	O
levels	O
.	O

Both	O
groups	O
showed	O
substantial	O
decreases	O
in	O
mineralocorticoid	O
(	O
MR	O
)	O
and	O
glucocorticoid	O
receptor	O
(	O
GR	O
)	O
levels	O
in	O
the	O
hippocampus	O
,	O
a	O
limbic	O
brain	O
structure	O
critical	O
for	O
HPA	O
axis	O
regulation	O
,	O
whereas	O
GR	B-protein
concentrations	O
in	O
the	O
hypothalamus	O
were	O
unchanged	O
and	O
in	O
anterior	O
pituitary	O
were	O
slightly	O
increased	O
.	O

HRBC	B-cell_type
and	O
LPS	O
indeed	O
stimulated	O
the	O
maternal	O
immune	O
system	O
as	O
revealed	O
by	O
specific	O
anti-HRBC	B-protein
antibody	I-protein
production	O
and	O
enhanced	O
IL-1	O
beta	O
mRNA	O
expression	O
in	O
splenocytes	B-cell_type
,	O
respectively	O
.	O

This	O
study	O
demonstrates	O
that	O
a	O
T	O
cell-mediated	O
immune	O
response	O
as	O
well	O
as	O
an	O
endotoxic	O
challenge	O
during	O
pregnancy	O
can	O
induce	O
anomalies	O
in	O
HPA	O
axis	O
function	O
in	O
adulthood	O
.	O

Clinically	O
,	O
it	O
may	O
be	O
postulated	O
that	O
disturbed	O
fetal	O
brain	O
development	O
due	O
to	O
prenatal	O
immune	O
challenge	O
increases	O
the	O
vulnerability	O
to	O
develop	O
mental	O
illness	O
involving	O
inadequate	O
responses	O
to	O
stress	O
.	O

A	O
low	O
NM23.H1	B-DNA
gene	I-DNA
expression	O
identifying	O
high	O
malignancy	O
human	O
melanomas	O
.	O

The	O
NM23	B-DNA
gene	I-DNA
has	O
been	O
proposed	O
as	O
a	O
metastasis-suppressor	B-DNA
gene	I-DNA
,	O
and	O
its	O
use	O
has	O
been	O
suggested	O
as	O
prognostic	O
factor	O
.	O

NM23	B-protein
was	O
identified	O
in	O
a	O
system	O
of	O
murine	B-cell_line
melanoma	I-cell_line
cell	I-cell_line
lines	I-cell_line
,	O
in	O
which	O
an	O
inverse	O
relationship	O
was	O
found	O
between	O
NM23	B-protein
expression	O
and	O
metastatic	O
ability	O
.	O

In	O
a	O
human	O
malignant	O
melanoma	O
study	O
NM23	B-protein
expression	O
was	O
found	O
to	O
be	O
significantly	O
lower	O
in	O
metastases	O
that	O
developed	O
less	O
than	O
24	O
months	O
after	O
diagnosis	O
of	O
the	O
primary	O
tumours	O
.	O

The	O
present	O
paper	O
studies	O
the	O
expression	O
of	O
the	O
NM23.H1	B-DNA
gene	I-DNA
in	O
cell	B-cell_line
lines	I-cell_line
which	O
derive	O
from	O
primary	O
or	O
metastatic	O
human	O
malignant	O
melanomas	O
in	O
relation	O
to	O
staging	O
,	O
infiltration	O
degree	O
,	O
lymphocytic	O
infiltration	O
,	O
cell	O
morphology	O
,	O
cell	O
pigmentation	O
,	O
karyotype	O
,	O
and	O
disease-free	O
survival	O
.	O

The	O
level	O
of	O
mRNA	O
expression	O
of	O
the	O
NM23	B-DNA
gene	I-DNA
is	O
significantly	O
lower	O
in	O
cell	B-cell_line
lines	I-cell_line
that	O
derive	O
from	O
more	O
infiltrating	O
primary	O
melanomas	O
than	O
in	O
cell	B-cell_line
lines	I-cell_line
obtained	O
from	O
less	O
infiltrating	O
tumours	O
.	O

Moreover	O
,	O
cell	B-cell_line
lines	I-cell_line
derived	O
from	O
tumours	O
of	O
patients	O
with	O
a	O
disease-free	O
survival	O
of	O
more	O
than	O
24	O
months	O
(	O
24-58	O
months	O
)	O
express	O
the	O
NM23	B-DNA
gene	I-DNA
at	O
higher	O
levels	O
than	O
cell	B-cell_line
lines	I-cell_line
obtained	O
from	O
melanomas	O
of	O
patients	O
with	O
a	O
disease-free	O
survival	O
of	O
less	O
than	O
24	O
months	O
(	O
6-15	O
months	O
)	O
.	O

Activation	O
of	O
a	O
novel	O
serine/threonine	B-protein
kinase	I-protein
that	O
phosphorylates	O
c-Fos	B-protein
upon	O
stimulation	O
of	O
T	B-cell_type
and	I-cell_type
B	I-cell_type
lymphocytes	I-cell_type
via	O
antigen	O
and	O
cytokine	B-protein
receptors	I-protein
.	O

Ligation	O
of	O
Ag	B-protein
receptors	I-protein
in	O
T	B-cell_type
and	I-cell_type
B	I-cell_type
lymphocytes	I-cell_type
initiates	O
signal	O
transduction	O
cascades	O
which	O
alter	O
the	O
expression	O
of	O
genes	O
that	O
regulate	O
cellular	O
proliferation	O
and	O
differentiation	O
.	O

The	O
transmission	O
of	O
signals	O
from	O
the	O
membrane	O
to	O
the	O
nucleus	O
is	O
mediated	O
principally	O
through	O
the	O
action	O
of	O
protein	B-protein
tyrosine	I-protein
and	I-protein
serine/threonine	I-protein
kinases	I-protein
.	O

We	O
have	O
identified	O
and	O
characterized	O
a	O
novel	O
serine/threonine	B-protein
kinase	I-protein
that	O
phosphorylated	O
the	O
proto-oncogene	B-protein
product	I-protein
,	O
c-Fos	B-protein
,	O
and	O
is	O
termed	O
Fos	B-protein
kinase	I-protein
.	O

Fos	B-protein
kinase	I-protein
was	O
rapidly	O
activated	O
after	O
ligation	O
of	O
the	O
CD3	B-protein
and	I-protein
CD2	I-protein
receptors	I-protein
in	O
Jurkat	B-cell_line
and	O
normal	B-cell_type
human	I-cell_type
T	I-cell_type
lymphocytes	I-cell_type
and	O
in	O
response	O
to	O
IL-6	B-protein
and	O
anti-IgM	B-protein
in	O
the	O
human	B-cell_line
B	I-cell_line
cell	I-cell_line
lines	I-cell_line
AF10	B-cell_line
and	O
Ramos	B-cell_line
,	O
respectively	O
.	O

The	O
phorbol	O
ester	O
,	O
PMA	O
,	O
was	O
also	O
a	O
potent	O
inducer	O
of	O
Fos	B-protein
kinase	I-protein
activity	O
in	O
all	O
of	O
the	O
above	O
populations	O
,	O
suggesting	O
that	O
PKC	B-protein
plays	O
a	O
role	O
in	O
the	O
regulation	O
of	O
this	O
enzyme	B-protein
.	O

Fos	B-protein
kinase	I-protein
phosphorylates	O
c-Fos	B-protein
at	O
a	O
site	O
near	O
the	O
C-terminus	B-protein
,	O
as	O
well	O
as	O
a	O
peptide	O
derived	O
from	O
this	O
region	O
(	O
residues	B-protein
359-370	I-protein
,	O
RKGSSSNEPSSD	B-protein
)	O
,	O
and	O
Fos	O
peptide	O
competitively	O
inhibited	O
c-Fos	B-protein
phosphorylation	O
.	O

Fos	B-protein
kinase	I-protein
was	O
shown	O
to	O
be	O
distinct	O
from	O
other	O
identified	O
serine/threonine	B-protein
kinases	I-protein
,	O
including	O
protein	B-protein
kinase	I-protein
A	I-protein
,	O
protein	B-protein
kinase	I-protein
C	I-protein
,	O
casein	B-protein
kinase	I-protein
II	I-protein
,	O
MAP	B-protein
kinases	I-protein
,	O
p70S6K	B-protein
and	O
p90RSK	B-protein
.	O

Fos	B-protein
kinase	I-protein
was	O
purified	O
by	O
anion	O
exchange	O
chromatography	O
and	O
exhibited	O
an	O
apparent	O
M	O
(	O
r	O
)	O
=	O
65	O
,	O
000	O
and	O
isoelectric	O
point	O
=	O
6.1	O
.	O

Fos	B-protein
kinase	I-protein
may	O
play	O
a	O
role	O
in	O
transcriptional	O
regulation	O
through	O
its	O
capacity	O
to	O
phosphorylate	O
c-Fos	B-protein
at	O
a	O
site	O
required	O
for	O
expression	O
of	O
the	O
transcriptional	O
transrepressive	O
activity	O
of	O
this	O
molecule	O
.	O

Moreover	O
,	O
its	O
rapid	O
activation	O
suggests	O
it	O
may	O
have	O
a	O
wider	O
role	O
within	O
signal	O
transduction	O
cascades	O
in	O
lymphocytes	B-cell_type
.	O

Antigenic	O
specificities	O
of	O
human	B-cell_line
CD4+	I-cell_line
T-cell	I-cell_line
clones	I-cell_line
recovered	O
from	O
recurrent	O
genital	O
herpes	O
simplex	O
virus	O
type	O
2	O
lesions	O
.	O

Lesions	O
resulting	O
from	O
recurrent	O
genital	O
herpes	O
simplex	O
virus	O
(	O
HSV	O
)	O
infection	O
are	O
characterized	O
by	O
infiltration	O
of	O
CD4+	B-cell_type
lymphocytes	I-cell_type
.	O

We	O
have	O
investigated	O
the	O
antigenic	O
specificity	O
of	O
47	O
HSV-specific	B-cell_line
CD4+	I-cell_line
T-cell	I-cell_line
clones	I-cell_line
recovered	O
from	O
the	O
HSV-2	O
buttock	O
and	O
thigh	O
lesions	O
of	O
five	O
patients	O
.	O

Clones	O
with	O
proliferative	O
responses	O
to	O
recombinant	B-protein
truncated	I-protein
glycoprotein	I-protein
B	I-protein
(	O
gB	B-protein
)	O
or	O
gD	B-protein
of	O
HSV-2	O
or	O
purified	O
natural	O
gC	O
of	O
HSV-2	O
comprised	O
a	O
minority	O
of	O
the	O
total	O
number	O
of	O
HSV-specific	B-cell_line
clones	I-cell_line
isolated	O
from	O
lesions	O
.	O

The	O
gC2-	B-cell_line
and	I-cell_line
gD2-specific	I-cell_line
CD4+	I-cell_line
clones	I-cell_line
had	O
cytotoxic	O
activity	O
.	O

The	O
approximate	O
locations	O
of	O
the	O
HSV-2	O
genes	O
encoding	O
HSV-2	O
type-specific	O
CD4+	B-protein
antigens	I-protein
have	O
been	O
determined	O
by	O
using	O
HSV-1	O
x	O
HSV-2	O
intertypic	O
recombinant	O
virus	O
and	O
include	O
the	O
approximate	O
map	O
regions	O
0.30	O
to	O
0.46	O
,	O
0.59	O
to	O
0.67	O
,	O
0.67	O
to	O
0.73	O
,	O
and	O
0.82	O
to	O
1.0	O
units	O
.	O

The	O
antigenic	O
specificity	O
of	O
an	O
HLA	B-cell_line
DQ2-restricted	I-cell_line
,	I-cell_line
HSV-2	I-cell_line
type-specific	I-cell_line
T-cell	I-cell_line
clone	I-cell_line
was	O
mapped	O
to	O
amino	B-protein
acids	I-protein
425	I-protein
to	I-protein
444	I-protein
of	O
VP16	B-protein
of	O
HSV-2	O
by	O
sequential	O
use	O
of	O
an	O
intertypic	O
recombinant	O
virus	O
containing	O
VP16	B-protein
of	O
HSV-2	O
in	O
an	O
HSV-1	O
background	O
,	O
recombinant	B-protein
VP16	I-protein
fusion	I-protein
proteins	I-protein
,	O
and	O
synthetic	O
peptides	O
.	O

Each	O
of	O
the	O
remaining	O
four	O
patients	O
also	O
yielded	O
at	O
least	O
one	O
type-specific	B-cell_line
T-cell	I-cell_line
clone	I-cell_line
reactive	O
with	O
an	O
HSV-2	O
epitope	O
mapping	O
to	O
approximately	O
0.67	O
to	O
0.73	O
map	O
units	O
.	O

The	O
antigenic	O
specificities	O
of	O
lesion-derived	B-cell_line
CD4+	I-cell_line
T-cell	I-cell_line
clones	I-cell_line
are	O
quite	O
diverse	O
and	O
include	O
at	O
least	O
10	O
epitopes	O
.	O

Human	B-cell_line
T-cell	I-cell_line
clones	I-cell_line
reactive	O
with	O
gC	B-protein
and	O
VP16	B-protein
are	O
reported	O
here	O
for	O
the	O
first	O
time	O
.	O

Marked	O
basophilia	O
in	O
acute	O
promyelocytic	O
leukaemia	O
treated	O
with	O
all-trans	O
retinoic	O
acid	O
:	O
molecular	O
analysis	O
of	O
the	O
cell	O
origin	O
of	O
the	O
basophils	B-cell_type
.	O

We	O
report	O
a	O
patient	O
with	O
acute	O
promyelocytic	O
leukaemia	O
who	O
developed	O
marked	O
basophilia	O
during	O
all-trans	O
retinoic	O
acid	O
treatment	O
.	O

We	O
studied	O
genomic	B-DNA
DNA	I-DNA
and	O
RNA	O
extracted	O
from	O
the	O
patient	O
's	O
peripheral	B-cell_type
leucocytes	I-cell_type
in	O
order	O
to	O
determine	O
the	O
origin	O
of	O
the	O
basophils	B-cell_type
.	O

The	O
RAR	B-protein
alpha	I-protein
rearranged	O
band	O
in	O
the	O
Southern	O
blot	O
analysis	O
and	O
a	O
chimaeric	B-protein
product	I-protein
of	O
PML-RAR	B-protein
alpha	I-protein
by	O
polymerase	O
chain	O
reaction	O
were	O
strongly	O
visible	O
before	O
ATRA	O
treatment	O
,	O
but	O
at	O
the	O
time	O
of	O
maximal	O
basophilia	O
both	O
of	O
them	O
were	O
markedly	O
diminished	O
.	O

These	O
findings	O
suggest	O
that	O
the	O
basophils	B-cell_type
which	O
appeared	O
during	O
the	O
ATRA	O
treatment	O
are	O
reactive	O
in	O
nature	O
rather	O
than	O
a	O
leukaemic	B-cell_line
clone	I-cell_line
.	O

Activation	O
of	O
the	O
interleukin	B-DNA
6	I-DNA
gene	I-DNA
by	O
Mycobacterium	O
tuberculosis	O
or	O
lipopolysaccharide	O
is	O
mediated	O
by	O
nuclear	B-protein
factors	I-protein
NF-IL6	I-protein
and	O
NF-kappa	B-protein
B	I-protein
[	O
published	O
erratum	O
appears	O
in	O
Proc	O
Natl	O
Acad	O
Sci	O
U	O
S	O
A	O
1995	O
Apr	O
11	O
;	O
92	O
(	O
8	O
)	O
:	O
3632	O
]	O

The	O
host	O
response	O
to	O
Mycobacterium	O
tuberculosis	O
includes	O
granuloma	O
formation	O
at	O
sites	O
of	O
infection	O
and	O
systemic	O
symptoms	O
.	O

Cytokines	B-protein
have	O
been	O
identified	O
by	O
immunohistochemistry	O
in	O
granulomas	O
in	O
animal	O
models	O
of	O
bacillus	O
Calmette-Guerin	O
(	O
BCG	O
)	O
infection	O
and	O
are	O
released	O
by	O
mononuclear	B-cell_type
phagocytes	I-cell_type
upon	O
stimulation	O
by	O
mycobacterial	O
proteins	O
.	O

In	O
this	O
regard	O
,	O
the	O
cytokine	B-protein
interleukin	B-protein
6	I-protein
(	O
IL-6	B-protein
)	O
may	O
play	O
a	O
role	O
in	O
the	O
clinical	O
manifestations	O
and	O
pathological	O
events	O
of	O
tuberculosis	O
infection	O
.	O

We	O
have	O
demonstrated	O
that	O
lipoarabinomannan	B-protein
(	O
LAM	B-protein
)	O
from	O
the	O
mycobacterial	O
cell	O
wall	O
,	O
which	O
was	O
virtually	O
devoid	O
of	O
lipopolysaccharide	O
(	O
LPS	O
)	O
,	O
stimulated	O
mononuclear	B-cell_type
phagocytes	I-cell_type
to	O
release	O
IL-6	B-protein
in	O
a	O
dose-response	O
manner	O
.	O

LAM	B-protein
and	O
LPS	O
were	O
potent	O
inducers	O
of	O
IL-6	B-DNA
gene	I-DNA
expression	O
in	O
peripheral	B-cell_type
blood	I-cell_type
monocytes	I-cell_type
.	O

Both	O
LAM	B-protein
-and	O
LPS-inducible	B-DNA
IL-6	I-DNA
promoter	I-DNA
activity	O
was	O
localized	O
to	O
a	O
DNA	B-DNA
fragment	I-DNA
,	O
positions	O
-158	B-DNA
to	I-DNA
-49	I-DNA
,	O
by	O
deletion	O
analysis	O
and	O
chloramphenicol	B-protein
acetyltransferase	I-protein
assay	O
.	O

Two	O
nuclear	B-protein
factor	I-protein
NF-IL6	I-protein
(	O
positions	O
-153	B-DNA
to	I-DNA
-145	I-DNA
and	O
-83	O
to	O
-75	O
)	O
and	O
one	O
nuclear	B-DNA
factor	I-DNA
NF-kappa	I-DNA
B	I-DNA
(	I-DNA
positions	I-DNA
-72	I-DNA
to	I-DNA
-63	I-DNA
)	I-DNA
motifs	I-DNA
are	O
present	O
within	O
this	O
fragment	O
.	O

Site-directed	O
mutagenesis	O
of	O
one	O
or	O
more	O
of	O
these	O
motifs	O
within	O
the	O
IL-6	B-protein
promoter	O
demonstrated	O
that	O
each	O
has	O
positive	O
regulatory	O
activity	O
and	O
that	O
they	O
could	O
act	O
in	O
a	O
function-	O
and	O
orientation-independent	O
manner	O
.	O

Deletion	O
of	O
all	O
three	O
elements	O
abolished	O
inducibility	O
of	O
IL-6	B-DNA
promoter	I-DNA
activity	O
by	O
both	O
LAM	B-protein
and	O
LPS	O
.	O

We	O
conclude	O
that	O
the	O
NF-IL6	B-DNA
and	I-DNA
NF-kappa	I-DNA
B	I-DNA
sites	I-DNA
mediate	O
IL-6	B-protein
induction	O
in	O
response	O
to	O
both	O
LPS	O
and	O
LAM	B-protein
,	O
acting	O
as	O
bacterial	B-DNA
or	I-DNA
mycobacterial	I-DNA
response	I-DNA
elements	I-DNA
.	O

Regulation	O
of	O
CD14	B-protein
expression	O
during	O
monocytic	O
differentiation	O
induced	O
with	O
1	O
alpha	O
,	O
25-dihydroxyvitamin	O
D3	O
.	O

CD14	B-protein
,	O
a	O
monocyte/macrophage	B-protein
receptor	I-protein
for	O
the	O
complex	O
of	O
LPS	O
and	O
LPS	B-protein
binding	I-protein
protein	I-protein
,	O
is	O
a	O
differentiation	O
marker	O
for	O
the	O
monocyte/macrophage	B-cell_type
lineage	I-cell_type
.	O

We	O
have	O
analyzed	O
the	O
regulation	O
of	O
CD14	B-protein
expression	O
during	O
1	O
alpha	O
,	O
25-dihydroxyvitamin	O
D3	O
(	O
VitD3	O
)	O
-induced	O
monocytic	O
differentiation	O
.	O

Using	O
FACS	O
,	O
Northern	O
blotting	O
,	O
and	O
nuclear	O
run-on	O
analyses	O
,	O
we	O
demonstrate	O
that	O
the	O
up-regulation	O
of	O
CD14	B-protein
expression	O
during	O
monocytic	O
cell	O
maturation	O
is	O
regulated	O
mainly	O
at	O
the	O
level	O
of	O
gene	O
transcription	O
,	O
and	O
that	O
new	O
protein	O
synthesis	O
is	O
required	O
for	O
CD14	B-protein
induction	O
.	O

We	O
have	O
recently	O
cloned	O
the	O
CD14	B-DNA
5	I-DNA
'	I-DNA
upstream	I-DNA
sequence	I-DNA
and	O
demonstrated	O
its	O
tissue-specific	B-DNA
promoter	I-DNA
activity	O
.	O

Using	O
stable	O
transfection	O
of	O
the	O
monocytoid	B-cell_line
U937	I-cell_line
cell	I-cell_line
line	I-cell_line
with	O
a	O
series	O
of	O
deletion	O
mutants	O
of	O
the	O
CD14	B-DNA
5	I-DNA
'	I-DNA
upstream	I-DNA
sequence	I-DNA
coupled	O
to	O
a	O
reporter	O
gene	O
construct	O
,	O
we	O
show	O
that	O
bp	B-DNA
-128	I-DNA
to	I-DNA
-70	I-DNA
is	O
the	O
critical	O
region	O
for	O
the	O
induction	O
of	O
CD14	B-protein
expression	O
.	O

This	O
region	O
contains	O
two	O
binding	B-DNA
sites	I-DNA
for	O
the	O
Sp1	B-protein
transcription	I-protein
factor	I-protein
.	O

A	O
3-bp	O
mutation	O
at	O
the	O
distal	O
Sp1-binding	B-DNA
site	I-DNA
not	O
only	O
eliminates	O
Sp1	B-protein
interaction	O
,	O
but	O
also	O
abolishes	O
most	O
of	O
the	O
VitD3	O
induction	O
of	O
CD14	B-protein
expression	O
.	O

Electrophoretic	O
mobility	O
shift	O
analysis	O
does	O
not	O
detect	O
a	O
direct	O
interaction	O
of	O
the	O
CD14	B-protein
distal	O
Sp1-binding	B-DNA
site	I-DNA
with	O
the	O
vitamin	B-protein
D3	I-protein
receptor	I-protein
and	O
its	O
partner	O
,	O
the	O
retinoid	B-protein
X	I-protein
receptor	I-protein
.	O

These	O
data	O
demonstrate	O
that	O
VitD3	O
induces	O
CD14	B-protein
indirectly	O
through	O
some	O
intermediary	B-protein
factor	I-protein
,	O
and	O
suggest	O
a	O
critical	O
role	O
for	O
Sp1	B-protein
in	O
this	O
process	O
.	O

DNA-binding	O
and	O
transcriptional	O
regulatory	O
properties	O
of	O
hepatic	B-protein
leukemia	I-protein
factor	I-protein
(	O
HLF	B-protein
)	O
and	O
the	O
t	O
(	O
17	O
;	O
19	O
)	O
acute	B-protein
lymphoblastic	I-protein
leukemia	I-protein
chimera	I-protein
E2A-HLF	I-protein
.	O

The	O
t	B-DNA
(	I-DNA
17	I-DNA
;	I-DNA
19	I-DNA
)	I-DNA
translocation	O
in	O
acute	O
lymphoblastic	O
leukemias	O
results	O
in	O
creation	O
of	O
E2A-hepatic	B-protein
leukemia	I-protein
factor	I-protein
(	O
HLF	B-protein
)	O
chimeric	B-protein
proteins	I-protein
that	O
contain	O
the	O
DNA-binding	B-protein
and	I-protein
protein	I-protein
dimerization	I-protein
domains	I-protein
of	O
the	O
basic	B-protein
leucine	I-protein
zipper	I-protein
(	I-protein
bZIP	I-protein
)	I-protein
protein	I-protein
HLF	B-protein
fused	O
to	O
a	O
portion	O
of	O
E2A	B-protein
proteins	I-protein
with	O
transcriptional	O
activation	O
properties	O
.	O

An	O
in	O
vitro	O
binding	O
site	O
selection	O
procedure	O
was	O
used	O
to	O
determine	O
DNA	O
sequences	O
preferentially	O
bound	O
by	O
wild-type	B-protein
HLF	I-protein
and	O
chimeric	B-protein
E2A-HLF	I-protein
proteins	O
isolated	O
from	O
various	O
t	B-cell_line
(	I-cell_line
17	I-cell_line
;	I-cell_line
19	I-cell_line
)	I-cell_line
-bearing	I-cell_line
leukemias	I-cell_line
.	O

All	O
were	O
found	O
to	O
selectively	O
bind	O
the	O
consensus	B-DNA
sequence	I-DNA
5'-GTTACGTAAT-3	O
'	O
with	O
high	O
affinity	O
.	O

Wild-type	O
and	O
chimeric	B-protein
HLF	I-protein
proteins	I-protein
also	O
bound	O
closely	O
related	O
sites	O
identified	O
previously	O
for	O
bZIP	B-protein
proteins	I-protein
of	O
both	O
the	O
proline	B-protein
-and	O
acidic	O
amino	O
acid-rich	O
(	O
PAR	B-protein
)	O
and	O
C/EBP	B-protein
subfamilies	I-protein
;	O
however	O
,	O
E2A-HLF	B-protein
proteins	O
were	O
significantly	O
less	O
tolerant	O
of	O
certain	O
deviations	O
from	O
the	O
HLF	B-DNA
consensus	I-DNA
binding	I-DNA
site	I-DNA
.	O

These	O
differences	O
were	O
directly	O
attributable	O
to	O
loss	O
of	O
an	O
HLF	B-DNA
ancillary	I-DNA
DNA-binding	I-DNA
domain	I-DNA
in	O
all	O
E2A-HLF	B-protein
chimeras	I-protein
and	O
were	O
further	O
exacerbated	O
by	O
a	O
zipper	O
mutation	O
in	O
one	O
isolate	O
.	O

Both	O
wild-type	B-protein
and	O
chimeric	B-protein
HLF	I-protein
proteins	I-protein
displayed	O
transcriptional	B-protein
activator	I-protein
properties	O
in	O
lymphoid	B-cell_type
and	I-cell_type
nonlymphoid	I-cell_type
cells	I-cell_type
on	O
reporter	B-DNA
genes	I-DNA
containing	O
HLF	B-DNA
or	I-DNA
C/EBP	I-DNA
consensus	I-DNA
binding	I-DNA
sites	I-DNA
.	O

But	O
on	O
reporter	B-DNA
genes	I-DNA
with	O
nonoptimal	B-DNA
binding	I-DNA
sites	I-DNA
,	O
their	O
transcriptional	O
properties	O
diverged	O
and	O
E2A-HLF	B-protein
competitively	O
inhibited	O
activation	O
by	O
wild-type	B-protein
PAR	I-protein
proteins	I-protein
.	O

These	O
findings	O
establish	O
a	O
spectrum	O
of	O
binding	O
site-specific	O
transcriptional	O
properties	O
for	O
E2A-HLF	B-protein
which	O
may	O
preferentially	O
activate	O
expression	O
of	O
select	O
subordinate	O
genes	O
as	O
a	O
homodimer	O
and	O
potentially	O
antagonize	O
expression	O
of	O
others	O
through	O
heteromeric	O
interactions	O
.	O

ZAP-70	B-protein
tyrosine	I-protein
kinase	I-protein
,	O
CD45	B-protein
,	O
and	O
T	B-protein
cell	I-protein
receptor	I-protein
involvement	O
in	O
UV-	O
and	O
H2O2-induced	O
T	O
cell	O
signal	O
transduction	O
.	O

Several	O
mammalian	O
responses	O
to	O
UV	O
irradiation	O
,	O
including	O
the	O
activation	O
of	O
NF-kappa	B-protein
B	I-protein
,	O
are	O
believed	O
to	O
involve	O
tyrosine	O
phosphorylation	O
.	O

UV	O
irradiation	O
and	O
H2O2	O
treatment	O
of	O
T	B-cell_type
lymphocytes	I-cell_type
induce	O
protein	O
tyrosine	O
phosphorylation	O
and	O
Ca2+	O
signals	O
similar	O
to	O
those	O
observed	O
following	O
biological	O
stimulation	O
.	O

We	O
have	O
examined	O
the	O
role	O
of	O
cell	O
surface	O
molecules	O
in	O
these	O
responses	O
.	O

Normal	O
T	B-cell_type
lymphocytes	I-cell_type
whose	O
surface	O
expression	O
of	O
CD3	B-protein
was	O
depleted	O
showed	O
impaired	O
UV-induced	O
tyrosine	O
phosphorylation	O
and	O
Ca2+	O
signals	O
.	O

Similarly	O
,	O
Jurkat	B-cell_line
T	I-cell_line
cell	I-cell_line
lines	I-cell_line
deficient	O
in	O
CD3	O
or	O
CD45	O
expression	O
also	O
gave	O
impaired	O
UV	O
responses	O
.	O

However	O
,	O
all	O
these	O
cell	O
types	O
still	O
gave	O
strong	O
Ca2+	O
and	O
tyrosine	O
phosphorylation	O
responses	O
to	O
H2O2	O
.	O

The	O
T	O
cell	O
tyrosine	O
kinase	B-protein
ZAP-70	I-protein
was	O
found	O
to	O
be	O
highly	O
responsive	O
to	O
UV	O
and	O
H2O2	O
treatment	O
.	O

ZAP-70	B-protein
responsiveness	O
to	O
UV	O
required	O
expression	O
of	O
both	O
CD3	B-protein
and	O
CD45	B-protein
,	O
whereas	O
only	O
CD3	B-protein
was	O
required	O
for	O
the	O
response	O
to	O
H2O2	O
.	O

UV-induced	O
activation	O
of	O
NF-kappa	B-protein
B	I-protein
was	O
blocked	O
by	O
CD3	B-protein
depletion	O
,	O
indicating	O
the	O
importance	O
of	O
such	O
cell	B-protein
surface	I-protein
molecules	I-protein
in	O
biological	O
responses	O
to	O
UV	O
.	O

In	O
nonlymphoid	B-cell_type
cells	I-cell_type
,	O
the	O
epidermal	B-protein
growth	I-protein
factor	I-protein
receptor	I-protein
displayed	O
increased	O
tyrosine	O
phosphorylation	O
within	O
seconds	O
of	O
UV	O
irradiation	O
.	O

These	O
results	O
suggest	O
that	O
UV-induced	O
signal	O
transduction	O
is	O
mediated	O
via	O
cell	B-protein
surface	I-protein
receptors	I-protein
that	O
normally	O
respond	O
to	O
biological	O
stimulation	O
,	O
whereas	O
H2O2	O
is	O
able	O
to	O
partially	O
bypass	O
this	O
requirement	O
.	O

Inhibition	O
of	O
the	O
differentiation	O
of	O
human	B-cell_line
myeloid	I-cell_line
cell	I-cell_line
lines	I-cell_line
by	O
redox	O
changes	O
induced	O
through	O
glutathione	O
depletion	O
.	O

We	O
have	O
investigated	O
the	O
effect	O
of	O
redox	O
changes	O
in	O
vivo	O
on	O
the	O
differentiation	O
of	O
two	O
human	B-cell_line
myeloid	I-cell_line
cell	I-cell_line
lines	I-cell_line
,	O
HL-60	B-cell_line
and	O
KG-1	B-cell_line
.	O

The	O
glutathione-depleting	O
agent	O
diethyl	O
maleate	O
(	O
DEM	O
)	O
prevented	O
the	O
development	O
of	O
differentiated	O
features	O
in	O
response	O
to	O
phorbol	O
esters	O
,	O
including	O
adherence	O
of	O
the	O
cells	O
to	O
plastic	O
surfaces	O
and	O
repression	O
of	O
the	O
myeloperoxidase	B-DNA
and	I-DNA
CD34	I-DNA
genes	I-DNA
.	O

Moreover	O
,	O
DEM	O
abolished	O
phorbol	O
12-myristate	O
13-acetate-induced	O
activation	O
of	O
the	O
transcription	B-protein
factors	I-protein
AP-1	B-protein
and	O
Egr-1	B-protein
,	O
suggesting	O
that	O
inhibition	O
of	O
differentiation	O
may	O
be	O
due	O
,	O
at	O
least	O
in	O
part	O
,	O
to	O
redox	O
modifications	O
of	O
these	O
proteins	B-protein
.	O

Lipopolysaccharide	O
induction	O
of	O
tissue	B-DNA
factor	I-DNA
gene	I-DNA
expression	O
in	O
monocytic	B-cell_type
cells	I-cell_type
is	O
mediated	O
by	O
binding	O
of	O
c-Rel/p65	B-protein
heterodimers	I-protein
to	O
a	O
kappa	B-DNA
B-like	I-DNA
site	I-DNA
.	O

Exposure	O
of	O
monocytic	B-cell_type
cells	I-cell_type
to	O
bacterial	O
lipopolysaccharide	O
(	O
LPS	O
)	O
activates	O
the	O
NF-kappa	B-protein
B/Rel	I-protein
family	I-protein
of	O
proteins	O
and	O
leads	O
to	O
the	O
rapid	O
induction	O
of	O
inflammatory	B-protein
gene	I-protein
products	I-protein
,	O
including	O
tissue	B-protein
factor	I-protein
(	O
TF	B-protein
)	O
.	O

TF	B-protein
is	O
the	O
primary	O
cellular	O
initiator	O
of	O
the	O
coagulation	B-protein
protease	I-protein
cascades	O
.	O

Here	O
we	O
report	O
the	O
characterization	O
of	O
a	O
nuclear	B-protein
complex	I-protein
from	O
human	O
monocytic	B-cell_type
cells	I-cell_type
that	O
bound	O
to	O
a	O
kappa	B-DNA
B-like	I-DNA
site	I-DNA
,	O
5'-CGGAGTTTCC-3	B-DNA
'	I-DNA
,	O
in	O
the	O
5'-flanking	B-DNA
region	I-DNA
of	O
the	O
human	B-DNA
TF	I-DNA
gene	I-DNA
.	O

This	O
nuclear	B-protein
complex	I-protein
was	O
activated	O
by	O
LPS	O
with	O
kinetics	O
that	O
preceded	O
induction	O
of	O
the	O
TF	B-DNA
gene	I-DNA
.	O

In	O
vitro	O
binding	O
studies	O
demonstrated	O
that	O
the	O
TF	B-DNA
site	I-DNA
bound	O
translated	O
c-Rel	B-protein
and	I-protein
p65	I-protein
homodimers	I-protein
but	O
not	O
p50/p65	B-protein
heterodimers	I-protein
or	O
p50	B-protein
homodimers	I-protein
.	O

Base-pair	O
substitutions	O
in	O
the	O
TF	B-DNA
site	I-DNA
indicated	O
that	O
the	O
presence	O
of	O
a	O
cytosine	O
at	O
position	B-protein
1	I-protein
precluded	O
binding	O
of	O
NF-kappa	B-protein
B	I-protein
.	O

In	O
fact	O
,	O
under	O
low-ionic-strength	O
conditions	O
,	O
the	O
TF	B-protein
complex	I-protein
did	O
not	O
migrate	O
with	O
translated	O
p50/p65	B-protein
dimers	I-protein
but	O
instead	O
comigrated	O
with	O
c-Rel/p65	B-protein
dimers	I-protein
.	O

Antibodies	O
against	O
the	O
NF-kappa	B-protein
B	I-protein
and	O
Rel	O
proteins	O
and	O
UV	O
cross-linking	O
studies	O
revealed	O
the	O
presence	O
of	O
c-Rel	B-protein
and	O
p65	O
and	O
the	O
absence	O
of	O
p50	B-protein
in	O
the	O
TF	B-protein
complex	I-protein
and	O
further	O
showed	O
that	O
c-Rel/p65	B-protein
heterodimers	I-protein
selectively	O
bound	O
to	O
the	O
TF	B-DNA
kappa	I-DNA
B-like	I-DNA
site	I-DNA
.	O

Functional	O
studies	O
indicated	O
that	O
the	O
TF	B-DNA
site	I-DNA
conferred	O
LPS	O
inducibility	O
on	O
a	O
heterologous	B-DNA
promoter	I-DNA
and	O
was	O
transactivated	O
by	O
c-Rel	B-protein
or	O
p65	O
.	O

Taken	O
together	O
,	O
our	O
results	O
demonstrated	O
that	O
binding	O
of	O
c-Rel/p65	B-protein
heterodimers	I-protein
to	O
a	O
novel	O
kappa	B-DNA
B-like	I-DNA
site	I-DNA
mediated	O
LPS	O
induction	O
of	O
TF	B-protein
gene	O
expression	O
in	O
monocytic	B-cell_type
cells	I-cell_type
.	O

Inhibition	O
of	O
T	O
cell	O
activation	O
by	O
the	O
extracellular	B-protein
matrix	I-protein
protein	I-protein
tenascin	B-protein
.	O

Tenascin	B-protein
(	O
TN	B-protein
)	O
is	O
an	O
extracellular	B-protein
matrix	I-protein
protein	I-protein
that	O
is	O
expressed	O
widely	O
in	O
the	O
fetus	O
and	O
sparingly	O
in	O
the	O
adult	O
,	O
but	O
reappears	O
at	O
high	O
levels	O
in	O
certain	O
areas	O
of	O
tissue	O
insult	O
such	O
as	O
tumor	O
matrices	O
and	O
sites	O
of	O
wound	O
healing	O
.	O

We	O
show	O
here	O
that	O
soluble	O
TN	B-protein
inhibits	O
proliferation	O
of	O
human	B-cell_type
T	I-cell_type
cells	I-cell_type
in	O
response	O
to	O
alpha	B-protein
CD3	I-protein
Ab	I-protein
co-immobilized	O
with	O
the	O
extracellular	B-protein
matrix	I-protein
protein	I-protein
fibronectin	B-protein
(	O
FN	B-protein
)	O
.	O

TN	B-protein
also	O
inhibits	O
proliferation	O
driven	O
by	O
alpha	B-protein
CD3/IL-2	I-protein
or	O
by	O
phorbol	B-protein
ester/IL-2	I-protein
,	I-protein
and	O
it	O
prevents	O
high	O
level	O
induction	O
of	O
IL-2R	B-protein
.	O

The	O
presence	O
of	O
TN	B-protein
in	O
culture	O
medium	O
does	O
not	O
detectably	O
alter	O
the	O
pattern	O
of	O
tyrosine	O
phosphorylation	O
resulting	O
from	O
T	O
cell	O
triggering	O
with	O
alpha	B-protein
CD3	I-protein
,	O
but	O
at	O
later	O
time	O
points	O
prevents	O
the	O
appearance	O
of	O
functional	O
NF-AT1	B-protein
transcription	I-protein
factor	I-protein
complexes	I-protein
in	O
T	O
cell	O
nuclear	O
extracts	O
.	O

These	O
findings	O
are	O
consistent	O
with	O
the	O
postulated	O
role	O
for	O
TN	B-protein
as	O
a	O
natural	O
antagonist	O
to	O
FN	B-protein
action	O
,	O
and	O
suggest	O
that	O
T	O
cell	O
responses	O
occurring	O
at	O
tissue	O
sites	O
in	O
which	O
TN	B-protein
is	O
expressed	O
could	O
be	O
influenced	O
by	O
its	O
presence	O
.	O

Human	O
immunodeficiency	O
virus	O
type	O
1	O
Nef	O
protein	O
down-regulates	O
transcription	B-protein
factors	I-protein
NF-kappa	B-protein
B	I-protein
and	O
AP-1	B-protein
in	O
human	B-cell_type
T	I-cell_type
cells	I-cell_type
in	O
vitro	O
after	O
T-cell	O
receptor	O
stimulation	O
.	O

Human	O
immunodeficiency	O
virus	O
type	O
1	O
(	O
HIV-1	O
)	O
negative	B-protein
factor	I-protein
(	O
Nef	B-protein
)	O
has	O
been	O
shown	O
to	O
down-regulate	O
the	O
transcription	B-protein
factors	I-protein
NF-kappa	B-protein
B	I-protein
and	O
AP-1	B-protein
in	O
vitro	O
.	O

To	O
define	O
the	O
mechanism	O
of	O
action	O
of	O
the	O
Nef	B-protein
protein	O
,	O
the	O
signal	O
transduction	O
pathways	O
which	O
may	O
be	O
affected	O
in	O
T	B-cell_type
cells	I-cell_type
by	O
constitutive	O
expression	O
of	O
the	O
nef	O
gene	O
were	O
examined	O
.	O

Stimulation	O
of	O
T	B-cell_type
cells	I-cell_type
with	O
tumor	O
necrosis	O
factor	O
,	O
interleukin-1	O
,	O
or	O
lipopolysaccharide	O
resulted	O
in	O
the	O
recruitment	O
of	O
transcriptional	O
factors	O
to	O
a	O
similar	O
level	O
whether	O
or	O
not	O
the	O
cells	O
expressed	O
the	O
nef	O
gene	O
.	O

On	O
the	O
other	O
hand	O
,	O
stimulation	O
of	O
T	B-cell_type
cells	I-cell_type
by	O
mitogens	O
or	O
antibodies	O
to	O
the	O
T-cell	O
receptor	O
(	O
TCR	O
)	O
-	O
CD3	B-protein
complex	O
resulted	O
in	O
the	O
down-regulation	O
of	O
transcriptional	O
factors	O
NF-kappa	B-protein
B	I-protein
and	O
AP-1	B-protein
in	O
cells	O
expressing	O
the	O
nef	O
gene	O
compared	O
with	O
cells	O
not	O
expressing	O
the	O
nef	O
gene	O
.	O

Because	O
the	O
Nef	B-protein
protein	O
does	O
not	O
affect	O
the	O
surface	O
expression	O
of	O
the	O
CD3	B-protein
-TCR	O
complex	O
,	O
we	O
conclude	O
that	O
the	O
Nef	B-protein
protein	O
down-regulates	O
the	O
transcriptional	O
factors	O
NF-kappa	B-protein
B	I-protein
and	O
AP-1	B-protein
in	O
T	B-cell_type
cells	I-cell_type
in	O
vitro	O
through	O
an	O
effect	O
on	O
the	O
TCR-dependent	O
signal	O
transduction	O
pathway	O
.	O

Effects	O
of	O
alpha-lipoic	O
acid	O
and	O
dihydrolipoic	O
acid	O
on	O
expression	O
of	O
proto-oncogene	B-DNA
c-fos	I-DNA
.	O

The	O
transcription	B-protein
factor	I-protein
AP-1	B-protein
is	O
an	O
important	O
human	O
mediator	O
of	O
the	O
cellular	O
response	O
to	O
serum	O
,	O
growth	B-protein
factors	I-protein
,	O
and	O
phorbol	O
esters	O
such	O
as	O
12-O-tetradecanoyl-phorbol-13	O
acetate	O
(	O
TPA	O
)	O
.	O

The	O
AP-1	B-protein
complex	O
consists	O
of	O
distinct	O
protein	B-protein
heterodimers	I-protein
encoded	O
by	O
the	O
proto-oncogene	B-DNA
c-fos	I-DNA
and	O
c-jun	B-RNA
mRNA	I-RNA
whose	O
gene	O
expression	O
can	O
be	O
induced	O
by	O
TPA	O
,	O
cyclic	O
AMP	O
and	O
growth	B-protein
factors	I-protein
.	O

Recent	O
findings	O
suggest	O
an	O
involvement	O
of	O
reactive	O
oxygen	O
species	O
in	O
the	O
pathway	O
of	O
TPA	O
and	O
protein	B-protein
kinase	I-protein
C	I-protein
leading	O
to	O
expression	O
of	O
c-fos	B-RNA
and	I-RNA
c-jun	I-RNA
mRNA	I-RNA
.	O

To	O
investigate	O
the	O
role	O
of	O
reactive	O
oxygen	O
species	O
we	O
studied	O
the	O
effects	O
of	O
alpha-lipoic	O
acid	O
and	O
dihydrolipoic	O
acid	O
(	O
natural	O
thiol	O
antioxidants	O
)	O
on	O
the	O
expression	O
of	O
c-fos	B-RNA
mRNA	I-RNA
in	O
human	B-cell_line
Jurkat	I-cell_line
T	I-cell_line
cells	I-cell_line
.	O

When	O
cells	O
were	O
preincubated	O
with	O
dihydrolipoic	O
acid	O
(	O
0.2	O
mM	O
)	O
the	O
expression	O
of	O
c-fos	B-RNA
mRNA	I-RNA
was	O
suppressed	O
at	O
30	O
min	O
after	O
stimulation	O
of	O
TPA	O
(	O
0.5	O
microM	O
)	O
whereas	O
in	O
the	O
case	O
of	O
preincubation	O
of	O
alpha-lipoic	O
acid	O
(	O
0.2	O
microM	O
)	O
,	O
the	O
expression	O
was	O
enhanced	O
at	O
30	O
min	O
.	O

These	O
studies	O
support	O
the	O
idea	O
that	O
superoxide	O
anion	O
radical	O
plays	O
a	O
role	O
in	O
the	O
expression	O
of	O
c-fos	B-RNA
mRNA	I-RNA
.	O

Appraisal	O
of	O
potential	O
therapeutic	O
index	O
of	O
antioxidants	O
on	O
the	O
basis	O
of	O
their	O
in	O
vitro	O
effects	O
on	O
HIV	O
replication	O
in	O
monocytes	B-cell_type
and	O
interleukin	B-protein
2	I-protein
-induced	O
lymphocyte	O
proliferation	O
.	O

Antioxidant	O
molecules	O
have	O
been	O
suggested	O
to	O
be	O
of	O
therapeutic	O
value	O
in	O
the	O
treatment	O
of	O
HIV-infected	O
patients	O
.	O

To	O
evaluate	O
this	O
possibility	O
,	O
we	O
examined	O
in	O
vitro	O
the	O
effects	O
of	O
two	O
types	O
of	O
antioxidant	O
molecules	O
in	O
terms	O
of	O
inhibition	O
of	O
HIV	O
replication	O
in	O
monocytes	B-cell_type
,	O
one	O
of	O
the	O
main	O
reservoirs	O
of	O
HIV	O
,	O
and	O
also	O
in	O
terms	O
of	O
modulation	O
of	O
the	O
immune	O
competence	O
as	O
measured	O
by	O
PBMC	B-cell_type
proliferation	O
.	O

We	O
tested	O
the	O
effects	O
of	O
BHA	O
,	O
a	O
phenolic	O
,	O
lipid-soluble	O
,	O
chain-breaking	O
antioxidant	O
,	O
and	O
NAC	O
,	O
a	O
known	O
glutathione	O
precursor	O
with	O
some	O
direct	O
free-radical	O
scavenging	O
properties	O
as	O
well	O
,	O
on	O
the	O
regulation	O
of	O
HIV-1	O
expression	O
in	O
latently	O
infected	O
U1	B-cell_line
cells	I-cell_line
and	O
in	O
productively	O
and	O
chronically	O
infected	O
U937	B-cell_line
cells	I-cell_line
.	O

Both	O
antioxidants	O
inhibited	O
TNF	B-protein
-or	O
PMA-induced	O
NF-kappa	B-protein
B	I-protein
activity	O
in	O
U1	B-cell_line
cells	I-cell_line
,	O
as	O
well	O
as	O
the	O
sustained	O
NF-kappa	B-protein
B	I-protein
activity	O
permanently	O
induced	O
by	O
the	O
virus	O
itself	O
in	O
chronically	O
HIV-infected	O
U937	B-cell_line
cells	I-cell_line
.	O

This	O
resulted	O
in	O
only	O
a	O
partial	O
inhibition	O
of	O
TNF	B-protein
-or	O
PMA-	O
induced	O
HIV	O
replication	O
in	O
U1	B-cell_line
cells	I-cell_line
,	O
and	O
no	O
detectable	O
effect	O
on	O
HIV	O
replication	O
in	O
chronically	B-cell_line
infected	I-cell_line
U937	I-cell_line
cells	I-cell_line
.	O

This	O
may	O
be	O
the	O
first	O
limitation	O
to	O
potential	O
antiviral	O
effects	O
of	O
antioxidant	O
therapies	O
.	O

Another	O
limitation	O
is	O
that	O
antioxidant	O
concentrations	O
high	O
enough	O
to	O
block	O
NK-kappa	B-protein
B	I-protein
activation	O
were	O
shown	O
to	O
have	O
a	O
suppressive	O
effect	O
on	O
immune	O
functions	O
in	O
vitro	O
,	O
because	O
NAC	O
and	O
BHA	O
blocked	O
IL-2-induced	B-cell_type
PBMC	I-cell_type
proliferation	O
.	O

These	O
data	O
warrant	O
prudence	O
in	O
the	O
design	O
of	O
antioxidant-based	O
therapies	O
aimed	O
at	O
suppressing	O
HIV	O
replication	O
.	O

Isolation	O
and	O
characterization	O
of	O
gelatinase	O
granules	O
from	O
human	B-cell_type
neutrophils	I-cell_type
.	O

We	O
recently	O
confirmed	O
the	O
existence	O
of	O
gelatinase	O
granules	O
as	O
a	O
subpopulation	O
of	O
peroxidase-negative	O
granules	O
by	O
double-labeling	O
immunogold	O
electron	O
microscopy	O
on	O
intact	O
cells	O
and	O
by	O
subcellular	O
fractionation	O
.	O

Further	O
characterization	O
of	O
gelatinase	O
granules	O
has	O
been	O
hampered	O
by	O
poor	O
separation	O
of	O
specific	O
and	O
gelatinase	O
granules	O
on	O
both	O
two-layer	O
Percoll	O
gradients	O
and	O
sucrose	O
gradients	O
.	O

We	O
have	O
developed	O
a	O
three-layer	O
Percoll	O
density	O
gradient	O
that	O
allows	O
separation	O
of	O
the	O
different	O
granules	O
and	O
vesicles	O
from	O
human	B-cell_type
neutrophils	I-cell_type
;	O
in	O
particular	O
,	O
it	O
allows	O
separation	O
of	O
specific	O
and	O
gelatinase	O
granules	O
.	O

This	O
allows	O
us	O
to	O
characterize	O
these	O
two	O
granule	O
populations	O
with	O
regard	O
to	O
their	O
content	O
of	O
membrane	B-protein
proteins	I-protein
,	O
which	O
become	O
incorporated	O
into	O
the	O
plasma	O
membrane	O
during	O
exocytosis	O
.	O

We	O
found	O
that	O
gelatinase	O
granules	O
,	O
defined	O
as	O
peroxidase-negative	O
granules	O
containing	O
gelatinase	B-protein
but	O
lacking	O
lactoferrin	B-protein
,	O
contain	O
50	O
%	O
of	O
total	O
cell	O
gelatinase	B-protein
,	O
with	O
the	O
remaining	O
residing	O
in	O
specific	O
granules	O
.	O

Furthermore	O
,	O
we	O
found	O
that	O
20	O
%	O
to	O
25	O
%	O
of	O
both	O
the	O
adhesion	B-protein
protein	I-protein
Mac-1	I-protein
and	O
the	O
NADPH-oxidase	B-protein
component	I-protein
cytochrome	I-protein
b558	B-protein
is	O
localized	O
in	O
gelatinase	B-protein
granules	O
.	O

Although	O
no	O
qualitative	O
difference	O
was	O
observed	O
between	O
specific	O
granules	O
and	O
gelatinase	B-protein
granules	O
with	O
respect	O
to	O
cytochrome	B-protein
b558	I-protein
and	O
Mac-1	B-protein
,	O
stimulation	O
of	O
the	O
neutrophil	B-cell_type
with	O
FMLP	B-protein
resulted	O
in	O
a	O
selective	O
mobilization	O
of	O
the	O
least	O
dense	O
peroxidase-negative	O
granules	O
,	O
ie	O
,	O
gelatinase	B-protein
granules	O
,	O
which	O
,	O
in	O
concert	O
with	O
secretory	O
vesicles	O
,	O
furnish	O
the	O
plasma	O
membrane	O
with	O
Mac-1	B-protein
and	O
cytochrome	B-protein
b558	I-protein
.	O

This	O
shows	O
that	O
gelatinase	B-protein
granules	O
are	O
functionally	O
important	O
relative	O
to	O
specific	O
granules	O
in	O
mediating	O
early	O
inflammatory	O
responses	O
.	O

Regulation	O
of	O
interleukin-2	B-protein
receptor	I-protein
alpha	I-protein
chain	I-protein
expression	O
and	O
nuclear	B-protein
factor.kappa	I-protein
B	I-protein
activation	O
by	O
protein	B-protein
kinase	I-protein
C	I-protein
in	O
T	B-cell_type
lymphocytes	I-cell_type
.	O

Autocrine	O
role	O
of	O
tumor	B-protein
necrosis	I-protein
factor	I-protein
alpha	I-protein
.	O

The	O
regulation	O
of	O
interleukin-2	B-protein
receptor	I-protein
alpha	I-protein
chain	I-protein
(	O
IL-2R	B-protein
alpha	I-protein
)	O
expression	O
and	O
nuclear	B-protein
factor	I-protein
(	O
NF	O
)	O
activation	O
by	O
protein	B-protein
kinase	I-protein
C	I-protein
(	O
PKC	B-protein
)	O
in	O
resting	B-cell_type
T	I-cell_type
cells	I-cell_type
,	O
has	O
been	O
studied	O
.	O

Treatment	O
of	O
human	O
resting	B-cell_type
T	I-cell_type
cells	I-cell_type
with	O
phorbol	O
esters	O
strongly	O
induced	O
the	O
expression	O
of	O
IL-2R	B-protein
alpha	I-protein
and	O
the	O
activation	O
of	O
NF.kappa	B-protein
B	I-protein
.	O

This	O
activation	O
was	O
due	O
to	O
the	O
translocation	O
of	O
p65	B-protein
and	O
c-Rel	B-protein
NF.kappa	B-protein
B	I-protein
proteins	O
from	O
cytoplasmic	O
stores	O
to	O
the	O
nucleus	O
,	O
where	O
they	O
bound	O
the	O
kappa	B-DNA
B	I-DNA
sequence	I-DNA
of	O
the	O
IL-2R	B-DNA
alpha	I-DNA
promoter	I-DNA
either	O
as	O
p50.p65	B-protein
or	O
as	O
p50.c-Rel	B-protein
heterodimers	O
.	O

Interestingly	O
,	O
all	O
of	O
those	O
events	O
were	O
largely	O
indirect	O
and	O
mediated	O
by	O
endogenously	O
secreted	O
tumor	B-protein
necrosis	I-protein
factor	I-protein
alpha	I-protein
(	O
TNF	B-protein
alpha	I-protein
)	O
,	O
as	O
they	O
were	O
strongly	O
inhibited	O
by	O
a	O
neutralizing	B-protein
anti-TNF	I-protein
alpha	I-protein
monoclonal	I-protein
antibody	I-protein
.	O

Furthermore	O
,	O
cyclosporin	O
A	O
,	O
which	O
blocked	O
TNF	B-protein
alpha	I-protein
production	O
induced	O
by	O
PKC	B-protein
,	O
strongly	O
inhibited	O
IL-2R	B-protein
alpha	I-protein
and	O
NF.kappa	B-protein
B	I-protein
activation	O
.	O

The	O
addition	O
of	O
either	O
TNF	B-protein
alpha	I-protein
or	O
IL-2	B-protein
partially	O
recovered	O
cyclosporin	O
A-induced	O
IL-2R	B-protein
alpha	I-protein
inhibition	O
,	O
but	O
only	O
TNF	B-protein
alpha	I-protein
completely	O
recovered	O
NF.kappa	B-protein
B	I-protein
activation	O
.	O

Those	O
results	O
indicate	O
that	O
,	O
in	O
resting	B-cell_type
T	I-cell_type
cells	I-cell_type
,	O
PKC	B-protein
activation	O
has	O
only	O
a	O
triggering	O
role	O
,	O
whereas	O
the	O
endogenously	O
secreted	O
TNF	B-protein
alpha	I-protein
plays	O
an	O
essential	O
role	O
in	O
the	O
quantitative	O
control	O
of	O
the	O
expression	O
of	O
IL-2R	B-protein
alpha	I-protein
chain	O
or	O
NF.kappa	B-protein
B	I-protein
activation	O
.	O

Superantigens	B-protein
activate	O
HIV-1	O
gene	O
expression	O
in	O
monocytic	B-cell_type
cells	I-cell_type
.	O

Binding	O
of	O
superantigens	O
to	O
MHC	B-protein
class	I-protein
II	I-protein
molecules	I-protein
results	O
in	O
transduction	O
of	O
biochemical	O
signals	O
leading	O
to	O
cellular	O
activation	O
and	O
gene	O
expression	O
.	O

We	O
demonstrate	O
that	O
the	O
staphylococcal	B-protein
superantigens	I-protein
toxic	B-protein
shock	I-protein
syndrome	I-protein
toxin-1	I-protein
(	O
TSST-1	B-protein
)	O
and	O
staphylococcal	B-protein
enterotoxin	I-protein
A	I-protein
(	O
SEA	B-protein
)	O
activate	O
HIV-1-LTR	B-DNA
-driven	O
transcription	O
of	O
chloramphenicol	B-protein
acetyl	I-protein
transferase	I-protein
in	O
the	O
human	B-cell_line
monocytic	I-cell_line
cell	I-cell_line
line	I-cell_line
THP-1	B-cell_line
.	O

Induction	O
of	O
HIV-1-	O
LTR	B-DNA
-driven	O
transcription	O
in	O
THP-1	B-cell_line
cells	I-cell_line
by	O
superantigens	B-protein
was	O
associated	O
with	O
the	O
induction	O
of	O
nuclear	B-protein
factor-kappa	I-protein
B	I-protein
DNA-binding	O
activity	O
.	O

Superantigens	B-protein
also	O
increased	O
viral	O
protein	O
secretion	O
from	O
the	O
granulocyte-macrophage	B-cell_line
colony-stimulating	I-cell_line
factor-pretreated	I-cell_line
chronically	I-cell_line
infected	I-cell_line
human	I-cell_line
monocytic	I-cell_line
cell	I-cell_line
line	I-cell_line
U1	I-cell_line
.	O

Induction	O
of	O
HIV-1	O
gene	O
expression	O
in	O
monocytic	B-cell_type
cells	I-cell_type
by	O
superantigens	B-protein
occurred	O
via	O
tumor	O
necrosis	O
factor-alpha-dependent	O
and	O
-independent	O
mechanisms	O
.	O

Our	O
results	O
suggest	O
that	O
superantigens	B-protein
and	O
other	O
MHC	B-protein
class	I-protein
II	I-protein
ligands	I-protein
may	O
activate	O
HIV-1	O
gene	O
expression	O
in	O
monocytes/macrophages	B-cell_type
.	O

Mitogen	O
activation	O
of	O
human	B-cell_type
peripheral	I-cell_type
T	I-cell_type
lymphocytes	I-cell_type
induces	O
the	O
formation	O
of	O
new	O
cyclic	B-protein
AMP	I-protein
response	I-protein
element-binding	I-protein
protein	I-protein
nuclear	I-protein
complexes	I-protein
.	O

A	O
large	O
body	O
of	O
evidence	O
indicates	O
that	O
experimental	O
agents	O
which	O
raise	O
cellular	O
cAMP	O
levels	O
inhibit	O
T	O
cell	O
growth	O
and	O
division	O
.	O

By	O
contrast	O
,	O
many	O
studies	O
have	O
reported	O
that	O
mitogen	B-protein
activation	O
of	O
T	B-cell_type
cells	I-cell_type
increases	O
cAMP	O
levels	O
,	O
implying	O
a	O
positive	O
physiological	O
role	O
for	O
cAMP	O
in	O
the	O
activation	O
process	O
.	O

In	O
the	O
present	O
study	O
we	O
demonstrate	O
that	O
mitogen	B-protein
activation	O
of	O
human	B-cell_type
peripheral	I-cell_type
T	I-cell_type
lymphocytes	I-cell_type
induces	O
nuclear	O
factors	O
that	O
form	O
complexes	O
with	O
cyclic	B-protein
AMP	I-protein
response	I-protein
element-binding	I-protein
protein	I-protein
(	O
CREB	B-protein
)	O
.	O

Four	O
complexes	O
are	O
identified	O
by	O
the	O
electrophoretic	O
mobility	O
shift	O
assay	O
,	O
two	O
of	O
which	O
are	O
induced	O
by	O
mitogen	B-protein
activation	O
.	O

All	O
four	O
complexes	O
contain	O
CREB	B-protein
and	O
are	O
bound	O
to	O
the	O
cAMP	B-DNA
response	I-DNA
element	I-DNA
(	I-DNA
CRE	I-DNA
)	I-DNA
core	I-DNA
sequence	I-DNA
(	O
TGACGTCA	O
)	O
,	O
as	O
indicated	O
by	O
antibody	O
and	O
oligonucleotide	O
competition	O
experiments	O
.	O

Binding	O
of	O
the	O
four	O
complexes	O
to	O
CRE	B-DNA
is	O
prevented	O
by	O
dephosphorylation	O
of	O
nuclear	O
extracts	O
and	O
is	O
restored	O
by	O
rephosphorylation	O
with	O
cAMP-dependent	B-protein
protein	I-protein
kinase	I-protein
or	O
endogenous	B-protein
kinases	I-protein
.	O

Similar	O
complexes	O
are	O
detected	O
in	O
nuclear	O
extracts	O
of	O
Jurkat	B-cell_line
cells	I-cell_line
.	O

Mitogen	O
induction	O
of	O
the	O
electrophoretic	B-protein
mobility	I-protein
shift	I-protein
assay	I-protein
complexes	I-protein
is	O
not	O
accounted	O
for	O
by	O
protein	O
phosphorylation	O
or	O
by	O
induction	O
of	O
CREB	B-protein
.	O

Rather	O
,	O
the	O
data	O
indicate	O
that	O
mitogen	O
increases	O
the	O
levels	O
of	O
a	O
nuclear	O
factor	O
(	O
s	O
)	O
that	O
dimerizes	O
with	O
CREB	B-protein
.	O

Induction	O
of	O
new	O
CREB	B-protein
complexes	I-protein
implies	O
a	O
physiological	O
role	O
for	O
cAMP	O
in	O
mitogen	B-protein
activation	O
of	O
T	B-cell_type
lymphocytes	I-cell_type
.	O

Alpha-tocopherol	O
inhibits	O
agonist-induced	O
monocytic	O
cell	O
adhesion	O
to	O
cultured	B-cell_line
human	I-cell_line
endothelial	I-cell_line
cells	I-cell_line
.	O

Antioxidants	O
have	O
been	O
proposed	O
to	O
be	O
anti-atherosclerotic	O
agents	O
;	O
however	O
,	O
the	O
mechanisms	O
underlying	O
their	O
beneficial	O
effects	O
are	O
poorly	O
understood	O
.	O

We	O
have	O
examined	O
the	O
effect	O
of	O
alpha-tocopherol	O
(	O
alpha-tcp	O
)	O
on	O
one	O
cellular	O
event	O
in	O
atherosclerotic	O
plaque	O
development	O
,	O
monocyte	O
adhesion	O
to	O
stimulated	B-cell_type
endothelial	I-cell_type
cells	I-cell_type
(	O
ECs	B-cell_type
)	O
.	O

Human	O
umbilical	O
vein	O
ECs	B-cell_type
were	O
pretreated	O
with	O
alpha-tcp	O
before	O
stimulation	O
with	O
known	O
agonists	O
of	O
monocyte	O
adhesion	O
:	O
IL-1	B-protein
(	O
10	O
ng/ml	O
)	O
,	O
LPS	O
(	O
10	O
ng/ml	O
)	O
,	O
thrombin	B-protein
(	O
30	O
U/ml	O
)	O
,	O
or	O
PMA	O
(	O
10	O
nM	O
)	O
.	O

Agonist-induced	O
monocytic	O
cell	O
adhesion	O
,	O
but	O
not	O
basal	O
adhesion	O
,	O
was	O
inhibited	O
in	O
a	O
time-	O
and	O
concentration-dependent	O
manner	O
by	O
alpha-tcp	O
.	O

The	O
IC50	O
of	O
alpha-tcp	O
on	O
an	O
IL-1	B-protein
-induced	O
response	O
was	O
45	O
microM	O
.	O

The	O
inhibition	O
correlated	O
with	O
a	O
decrease	O
in	O
steady	O
state	O
levels	O
of	O
E-selectin	B-RNA
mRNA	I-RNA
and	O
cell	O
surface	O
expression	O
of	O
E-selectin	B-protein
which	O
is	O
consistent	O
with	O
the	O
ability	O
of	O
a	O
monoclonal	B-protein
antibody	I-protein
to	O
E-selectin	B-protein
to	O
inhibit	O
monocytic	O
cell	O
adhesion	O
in	O
this	O
system	O
.	O

Probucol	O
(	O
50	O
microM	O
)	O
and	O
N-acetylcysteine	O
(	O
20	O
mM	O
)	O
also	O
inhibited	O
agonist-induced	O
monocytic	O
cell	O
adhesion	O
;	O
whereas	O
,	O
several	O
other	O
antioxidants	O
had	O
no	O
significant	O
effect	O
.	O

Protein	B-protein
kinase	I-protein
C	I-protein
(	O
PKC	B-protein
)	O
does	O
not	O
appear	O
to	O
play	O
a	O
role	O
in	O
the	O
alpha-tcp	O
effect	O
since	O
no	O
suppression	O
of	O
phosphorylation	O
of	O
PKC	B-protein
substrates	O
was	O
observed	O
.	O

Activation	O
of	O
the	O
transcription	B-protein
factor	I-protein
NF-kappa	B-protein
B	I-protein
is	O
reported	O
to	O
be	O
necessary	O
but	O
not	O
sufficient	O
for	O
E-selectin	B-protein
expression	O
in	O
EC	B-cell_line
.	O

Electrophoretic	O
mobility	O
shift	O
assays	O
failed	O
to	O
show	O
an	O
alpha-tcp-induced	O
decrease	O
in	O
activation	O
of	O
this	O
transcription	B-protein
factor	I-protein
after	O
cytokine	B-protein
stimulation	O
.	O

It	O
has	O
been	O
hypothesized	O
that	O
alpha-tcp	O
acts	O
as	O
an	O
anti-atherosclerotic	O
molecule	O
by	O
inhibiting	O
generation	O
of	O
oxidized	O
LDL	O
--	O
a	O
putative	O
triggering	O
molecule	O
in	O
the	O
atherosclerotic	O
process	O
.	O

Our	O
results	O
point	O
to	O
a	O
novel	O
alternative	O
mechanism	O
of	O
action	O
of	O
alpha-tcp	O
.	O

Central	B-cell_type
nervous	I-cell_type
system-derived	I-cell_type
cells	I-cell_type
express	O
a	O
kappa	O
B-binding	O
activity	O
that	O
enhances	O
human	O
immunodeficiency	O
virus	O
type	O
1	O
transcription	O
in	O
vitro	O
and	O
facilitates	O
TAR	B-DNA
-independent	O
transactivation	O
by	O
Tat	B-protein
.	O

The	O
Tat	B-protein
protein	I-protein
of	O
human	O
immunodeficiency	O
virus	O
type	O
1	O
(	O
HIV-1	O
)	O
is	O
a	O
potent	O
activator	O
of	O
long	B-DNA
terminal	I-DNA
repeat	I-DNA
-directed	O
transcription	O
.	O

While	O
in	O
most	O
cell	O
types	O
,	O
activation	O
requires	O
interaction	O
of	O
Tat	O
with	O
the	O
unusual	O
transcription	B-DNA
element	I-DNA
TAR	B-DNA
,	O
astrocytic	B-cell_type
glial	I-cell_type
cells	I-cell_type
support	O
TAR	B-DNA
-independent	O
transactivation	O
of	O
HIV-1	O
transcription	O
by	O
Tat	O
.	O

This	O
alternative	O
pathway	O
of	O
Tat	B-protein
activation	O
is	O
mediated	O
by	O
the	O
viral	B-DNA
enhancer	I-DNA
,	O
a	O
kappa	O
B	O
domain	O
capable	O
of	O
binding	O
the	O
prototypical	O
form	O
of	O
the	O
transcription	B-protein
factor	I-protein
nuclear	O
factor	O
kappa	O
B	O
(	O
NF-kappa	B-protein
B	I-protein
)	O
present	O
in	O
many	O
cell	O
types	O
,	O
including	O
T	B-cell_type
lymphocytes	I-cell_type
.	O

Tat	B-protein
transactivation	O
mediated	O
by	O
the	O
kappa	B-DNA
B	I-DNA
domain	I-DNA
is	O
sufficient	O
to	O
allow	O
replication	O
of	O
TAR	B-DNA
-deleted	O
mutant	O
HIV-1	O
in	O
astrocytes	B-cell_type
.	O

The	O
present	O
study	O
demonstrates	O
the	O
existence	O
of	O
kappa	B-protein
B-specific	I-protein
binding	I-protein
factors	I-protein
present	O
in	O
human	B-cell_type
glial	I-cell_type
astrocytes	I-cell_type
that	O
differ	O
from	O
prototypical	O
NF-kappa	B-protein
B	I-protein
.	O

The	O
novel	O
astrocyte-derived	O
kappa	O
B-binding	O
activity	O
is	O
retained	O
on	O
an	O
HIV-1	O
Tat	B-protein
affinity	O
column	O
,	O
while	O
prototypical	O
NF-kappa	B-protein
B	I-protein
from	O
Jurkat	B-cell_line
T	I-cell_line
cells	I-cell_line
is	O
not	O
.	O

In	O
vitro	O
transcription	O
studies	O
demonstrate	O
that	O
astrocyte-derived	B-protein
kappa	I-protein
B-binding	I-protein
factors	I-protein
activate	O
transcription	O
of	O
the	O
HIV-1	B-DNA
long	I-DNA
terminal	I-DNA
repeat	I-DNA
and	O
that	O
this	O
activation	O
is	O
dependent	O
on	O
the	O
kappa	B-DNA
B	I-DNA
domain	I-DNA
.	O

Moreover	O
,	O
TAR	B-DNA
-independent	O
transactivation	O
of	O
HIV-1	O
transcription	O
is	O
reproduced	O
in	O
vitro	O
in	O
an	O
astrocyte	O
factor-dependent	O
manner	O
which	O
correlates	O
with	O
kappa	O
B-binding	O
activity	O
.	O

The	O
importance	O
of	O
the	O
central	B-protein
nervous	I-protein
system-enriched	I-protein
kappa	I-protein
B	I-protein
transcription	B-protein
factor	I-protein
in	O
the	O
regulation	O
of	O
HIV-1	O
expression	O
is	O
discussed	O
.	O

Human	B-protein
interleukin-13	I-protein
activates	O
the	O
interleukin-4-dependent	B-protein
transcription	I-protein
factor	I-protein
NF-IL4	B-protein
sharing	O
a	O
DNA	B-protein
binding	I-protein
motif	I-protein
with	O
an	O
interferon-gamma-induced	B-protein
nuclear	I-protein
binding	I-protein
factor	I-protein
.	O

The	O
effects	O
of	O
interleukin-13	B-protein
(	O
IL-13	B-protein
)	O
and	O
interleukin-4	B-protein
(	O
IL-4	B-protein
)	O
on	O
cellular	O
functions	O
were	O
shown	O
to	O
be	O
quite	O
similar	O
.	O

We	O
provide	O
evidence	O
that	O
in	O
monocytes	O
as	O
well	O
as	O
in	O
T	B-cell_type
lymphocytes	I-cell_type
both	O
IL-4	B-protein
and	O
IL-13	B-protein
activate	O
the	O
same	O
recently	O
identified	O
transcription	B-protein
factor	I-protein
NF-IL4	B-protein
which	O
binds	O
to	O
the	O
specific	B-DNA
responsive	I-DNA
element	I-DNA
IL-4RE	I-DNA
.	O

In	O
addition	O
,	O
we	O
show	O
that	O
a	O
nuclear	B-protein
factor	I-protein
activated	O
by	O
interferon-gamma	O
also	O
interacts	O
with	O
the	O
IL-4RE	B-DNA
.	O

It	O
differs	O
from	O
NF-IL4	B-protein
in	O
the	O
electrophoretic	O
mobility	O
of	O
the	O
complex	O
with	O
DNA	O
,	O
in	O
its	O
DNA-binding	O
specificity	O
and	O
in	O
the	O
proteins	O
interacting	O
with	O
the	O
DNA	B-DNA
sequence	I-DNA
.	O

Sensitivity	O
against	O
various	O
enzyme	O
inhibitors	O
suggests	O
that	O
components	O
of	O
the	O
signal	O
transduction	O
pathway	O
are	O
shared	O
by	O
all	O
three	O
cytokines	B-protein
.	O

Encephalomyocarditis	O
virus	O
internal	O
ribosomal	O
entry	O
site	O
RNA-protein	O
interactions	O
.	O

Translational	O
initiation	O
of	O
encephalomyocarditis	B-RNA
virus	I-RNA
(	I-RNA
EMCV	I-RNA
)	I-RNA
mRNA	I-RNA
occurs	O
by	O
ribosomal	O
entry	O
into	O
the	O
5	B-DNA
'	I-DNA
nontranslated	I-DNA
region	I-DNA
of	O
the	O
EMCV	B-RNA
mRNA	I-RNA
,	O
rather	O
than	O
by	O
ribosomal	O
scanning	O
.	O

Internal	O
ribosomal	O
binding	O
requires	O
a	O
cis-acting	B-DNA
element	I-DNA
termed	O
the	O
internal	B-DNA
ribosomal	I-DNA
entry	I-DNA
site	I-DNA
(	O
IRES	B-DNA
)	O
.	O

IRES	B-DNA
elements	I-DNA
have	O
been	O
proposed	O
to	O
be	O
involved	O
in	O
the	O
translation	O
of	O
picornavirus	B-RNA
mRNAs	I-RNA
and	O
some	O
cellular	B-RNA
mRNAs	I-RNA
.	O

Internal	O
ribosome	O
binding	O
likely	O
requires	O
the	O
interaction	O
of	O
trans-acting	B-protein
factors	I-protein
that	O
recognize	O
both	O
the	O
mRNA	B-RNA
and	O
the	O
ribosomal	B-protein
complex	I-protein
.	O

Five	O
cellular	B-protein
proteins	I-protein
(	O
p52	B-protein
,	O
p57	B-protein
,	O
p70	B-protein
,	O
p72	B-protein
,	O
and	O
p100	B-protein
)	O
cross-link	O
the	O
EMCV	O
IRES	B-DNA
or	O
fragments	O
of	O
the	O
IRES	B-DNA
.	O

For	O
one	O
of	O
these	O
proteins	O
,	O
p57	B-protein
,	O
binding	O
to	O
the	O
IRES	B-DNA
correlates	O
with	O
translation	O
.	O

Recently	O
,	O
p57	B-protein
was	O
identified	O
to	O
be	O
very	O
similar	O
,	O
if	O
not	O
identical	O
,	O
to	O
polypyrimidine	B-protein
tract-binding	I-protein
protein	I-protein
.	O

On	O
the	O
basis	O
of	O
cross-linking	O
results	O
with	O
21	O
different	O
EMCV	B-DNA
IRES	I-DNA
fragments	I-DNA
and	O
cytoplasmic	O
HeLa	O
extract	O
or	O
rabbit	O
reticulocyte	O
lysate	O
as	O
the	O
source	O
of	O
polypeptides	O
,	O
consensus	B-DNA
binding	I-DNA
sites	I-DNA
for	O
p52	B-protein
,	O
p57	B-protein
,	O
p70	B-protein
,	O
and	O
p100	B-protein
are	O
proposed	O
.	O

It	O
is	O
suggested	O
that	O
each	O
of	O
these	O
proteins	O
recognizes	O
primarily	O
a	O
structural	O
feature	O
of	O
the	O
RNA	O
rather	O
than	O
a	O
specific	O
sequence	O
.	O

A	O
novel	O
heterodimerization	B-protein
partner	I-protein
for	O
thyroid	B-protein
hormone	I-protein
receptor	I-protein
.	O

Peroxisome	B-protein
proliferator-activated	I-protein
receptor	I-protein
.	O

Retinoid-like	B-protein
receptors	I-protein
play	O
a	O
central	O
role	O
in	O
hormonal	O
responses	O
by	O
forming	O
heterodimers	B-protein
with	O
other	O
nuclear	B-protein
hormone	I-protein
receptors	I-protein
.	O

In	O
this	O
study	O
we	O
have	O
identified	O
the	O
peroxisome	B-protein
proliferator-activated	I-protein
receptor	I-protein
(	O
PPAR	B-protein
)	O
as	O
a	O
new	O
thyroid	B-protein
hormone	I-protein
receptor	I-protein
(	I-protein
THR	I-protein
)	I-protein
auxiliary	I-protein
nuclear	I-protein
protein	I-protein
,	O
heterodimerizing	O
with	O
THR	B-protein
in	O
solution	O
.	O

Although	O
these	O
heterodimers	B-protein
do	O
not	O
recognize	O
a	O
classical	O
thyroid	B-DNA
hormone	I-DNA
response	I-DNA
element	I-DNA
(	O
TRE	B-DNA
)	O
characterized	O
by	O
direct	O
repeat	O
separated	O
by	O
four	O
nucleotides	O
(	O
DR+4	B-DNA
)	O
,	O
PPAR	B-protein
behaves	O
as	O
a	O
dominant	O
negative	O
regulator	O
of	O
thyroid	O
hormone	O
(	O
TH	O
)	O
action	O
.	O

However	O
,	O
a	O
TH-dependent	O
positive	O
effect	O
is	O
elicited	O
by	O
selective	O
interaction	O
of	O
the	O
THR	B-protein
beta-PPAR	I-protein
but	O
not	O
the	O
THR	B-protein
alpha-PPAR	I-protein
heterodimer	I-protein
with	O
a	O
novel	O
TRE	B-DNA
(	O
DR+2	B-DNA
)	O
.	O

The	O
critical	O
region	O
of	O
THR	B-protein
beta	O
was	O
mapped	O
to	O
3	O
amino	O
acids	O
in	O
the	O
distal	B-protein
box	I-protein
of	O
the	O
DNA	B-protein
binding	I-protein
domain	I-protein
.	O

Hence	O
,	O
PPAR	B-protein
can	O
positively	O
or	O
negatively	O
influence	O
TH	O
action	O
depending	O
on	O
TRE	B-DNA
structure	O
and	O
THR	B-protein
isotype	I-protein
.	O

Comparison	O
of	O
retinoic	O
acid	O
and	O
phorbol	O
myristate	O
acetate	O
as	O
inducers	O
of	O
monocytic	O
differentiation	O
.	O

Several	O
human	B-cell_line
myeloid	I-cell_line
leukemia	I-cell_line
cell	I-cell_line
lines	I-cell_line
growing	O
in	O
vitro	O
can	O
be	O
induced	O
to	O
differentiate	O
to	O
more	O
mature	O
monocyte/macrophage-like	B-cell_type
cells	I-cell_type
by	O
treatment	O
with	O
protein	B-protein
kinase	I-protein
C	I-protein
-activating	O
phorbol	O
esters	O
,	O
such	O
as	O
PMA	O
.	O

In	O
addition	O
to	O
PMA	O
,	O
cells	O
of	O
the	O
THP-1	B-cell_line
myeloid	I-cell_line
leukemia	I-cell_line
cell	I-cell_line
line	I-cell_line
acquire	O
macrophage-like	O
characteristics	O
after	O
treatment	O
with	O
all-trans	O
retinoic	O
acid	O
(	O
RA	O
)	O
.	O

To	O
analyze	O
the	O
signal	O
transduction	O
mechanisms	O
induced	O
by	O
RA	O
,	O
we	O
first	O
compared	O
the	O
effects	O
of	O
PMA	O
and	O
RA	O
on	O
the	O
expression	O
of	O
genes	O
which	O
are	O
known	O
to	O
be	O
regulated	O
during	O
monocytic	O
differentiation	O
.	O

Both	O
RA	O
and	O
PMA	O
effectively	O
down-regulated	O
c-myc	B-DNA
expression	O
,	O
while	O
c-myb	B-DNA
expression	O
decreased	O
only	O
after	O
PMA	O
treatment	O
.	O

Expression	O
of	O
the	O
beta	B-DNA
2-integrin	I-DNA
genes	I-DNA
,	O
CD11a	B-DNA
and	O
CD11b	B-DNA
,	O
was	O
clearly	O
increased	O
after	O
both	O
of	O
these	O
treatments	O
.	O

Their	O
effects	O
on	O
the	O
src-family	B-DNA
tyrosine	I-DNA
kinase	I-DNA
genes	I-DNA
were	O
different	O
:	O
hck	B-DNA
expression	O
was	O
similarly	O
induced	O
by	O
these	O
agents	O
but	O
lyn	O
expression	O
was	O
stronger	O
and	O
more	O
rapid	O
after	O
RA	O
treatment	O
.	O

RA	O
also	O
enhanced	O
lyn	B-RNA
mRNA	I-RNA
production	O
rapidly	O
in	O
HL-60	B-cell_line
,	O
indicating	O
that	O
the	O
activation	O
of	O
lyn	B-DNA
gene	I-DNA
expression	O
is	O
common	O
in	O
monocytic	O
and	O
granulocytic	O
maturation	O
of	O
myeloid	B-cell_type
leukemia	I-cell_type
cells	I-cell_type
.	O

To	O
examine	O
whether	O
the	O
AP-1	B-DNA
enhancer	I-DNA
activity	O
is	O
involved	O
in	O
RA-induced	O
monocytic	O
differentiation	O
,	O
THP-1	B-cell_line
cells	I-cell_line
were	O
transiently	O
transfected	O
with	O
a	O
chloramphenicol	B-DNA
acetyl	I-DNA
transferase	I-DNA
(	I-DNA
CAT	I-DNA
)	I-DNA
-reporter	I-DNA
gene	I-DNA
containing	O
5	O
copies	O
of	O
the	O
AP-1	B-DNA
binding	I-DNA
sites	I-DNA
.	O

In	O
contrast	O
to	O
PMA	O
,	O
RA	O
did	O
not	O
induce	O
any	O
CAT	B-protein
activity	O
in	O
these	O
cells	O
,	O
thus	O
suggesting	O
that	O
the	O
RA-induced	O
changes	O
in	O
the	O
expression	O
of	O
those	O
genes	O
described	O
above	O
were	O
not	O
dependent	O
on	O
the	O
AP-1	B-DNA
enhancer	I-DNA
activity	O
.	O

An	O
active	O
v-abl	B-protein
protein	I-protein
tyrosine	I-protein
kinase	I-protein
blocks	O
immunoglobulin	B-DNA
light-chain	I-DNA
gene	I-DNA
rearrangement	O
.	O

Lymphoid	B-cell_type
cells	I-cell_type
transformed	O
by	O
Abelson	O
murine	O
leukemia	O
virus	O
have	O
provided	O
one	O
of	O
the	O
classic	O
models	O
for	O
study	O
of	O
early	O
B-cell	O
development	O
and	O
immunoglobulin	B-protein
rearrangement	O
.	O

Most	O
of	O
these	O
cells	O
have	O
rearranged	O
their	O
heavy-chain	B-DNA
locus	I-DNA
but	O
not	O
their	O
light	B-DNA
chain	I-DNA
genes	I-DNA
,	O
suggesting	O
that	O
an	O
active	O
v-abl	B-protein
protein	I-protein
interferes	O
with	O
this	O
differentiation	O
step	O
.	O

To	O
test	O
this	O
hypothesis	O
,	O
light-chain	B-DNA
gene	I-DNA
structure	I-DNA
was	O
examined	O
in	O
pre-B	B-cell_line
cells	I-cell_line
transformed	O
by	O
temperature-sensitive	O
mutants	O
of	O
the	O
Abelson	O
virus	O
and	O
in	O
derivatives	O
that	O
survive	O
at	O
the	O
nonpermissive	O
temperature	O
because	O
they	O
express	O
a	O
human	B-DNA
BCL-2	I-DNA
gene	I-DNA
.	O

Our	O
studies	O
reveal	O
that	O
inactivation	O
of	O
the	O
v-abl	B-protein
protein	I-protein
tyrosine	I-protein
kinase	I-protein
triggers	O
high-frequency	O
rearrangement	O
of	O
kappa	B-DNA
and	I-DNA
lambda	I-DNA
light-chain	I-DNA
genes	I-DNA
.	O

These	O
events	O
are	O
accompanied	O
by	O
marked	O
increases	O
in	O
the	O
expression	O
of	O
RAG-1	B-RNA
and	I-RNA
RAG-2	I-RNA
RNAs	I-RNA
.	O

These	O
increases	O
occur	O
in	O
the	O
absence	O
of	O
protein	O
synthesis	O
but	O
are	O
dependent	O
on	O
inactivation	O
of	O
the	O
v-abl	B-protein
protein	I-protein
tyrosine	I-protein
kinase	I-protein
.	O

As	O
documented	O
in	O
the	O
accompanying	O
paper	O
(	O
Klug	O
et	O
al.	O
,	O
this	O
issue	O
)	O
,	O
an	O
active	O
v-abl	B-protein
protein	I-protein
also	O
suppresses	O
the	O
activity	O
of	O
NF-kappa	B-protein
B/rel	I-protein
and	O
expression	O
controlled	O
by	O
the	O
kappa	B-DNA
intron	I-DNA
enhancer	I-DNA
.	O

Together	O
these	O
data	O
demonstrate	O
that	O
the	O
v-abl	B-protein
protein	I-protein
specifically	O
interferes	O
with	O
light-chain	B-DNA
gene	I-DNA
rearrangement	O
by	O
suppressing	O
at	O
least	O
two	O
pathways	O
essential	O
for	O
this	O
stage	O
of	O
B-cell	B-cell_type
differentiation	O
and	O
suggest	O
that	O
tyrosine	O
phosphorylation	O
is	O
important	O
in	O
regulating	O
RAG	B-DNA
gene	I-DNA
expression	O
.	O

Calcium	O
signalling	O
in	O
T	B-cell_type
cells	I-cell_type
stimulated	O
by	O
a	O
cyclophilin	B-protein
B-binding	I-protein
protein	I-protein
.	O

The	O
immunosuppressant	O
drug	O
cyclosporin	O
A	O
blocks	O
a	O
calcium-dependent	O
signal	O
from	O
the	O
T-cell	B-protein
receptor	I-protein
(	O
TCR	B-protein
)	O
that	O
normally	O
leads	O
to	O
T-cell	O
activation	O
.	O

When	O
bound	O
to	O
cyclophilin	B-protein
,	O
cyclosporin	O
A	O
binds	O
and	O
inactivates	O
the	O
key	O
signalling	O
intermediate	O
calcineurin	B-protein
.	O

To	O
identify	O
potential	O
cellular	O
homologues	O
of	O
cyclosporin	O
A	O
that	O
might	O
regulate	O
calcium	O
signalling	O
,	O
we	O
have	O
cloned	O
human	O
genes	O
encoding	O
cyclophilin	B-protein
B-binding-proteins	I-protein
using	O
the	O
yeast	O
two-hybrid	O
system	O
.	O

One	O
gene	O
product	O
,	O
when	O
overexpressed	O
in	O
Jurkat	B-cell_line
T	I-cell_line
cells	I-cell_line
,	O
specifically	O
induced	O
transcription	O
from	O
the	O
interleukin-2	B-DNA
enhancer	I-DNA
,	O
by	O
activating	O
the	O
T-cell-specific	B-protein
transcription	I-protein
factors	I-protein
NF-AT	B-protein
and	O
NF-IL2A	B-protein
.	O

This	O
protein	O
,	O
termed	O
calcium-signal	B-protein
modulating	I-protein
cyclophilin	I-protein
ligand	I-protein
(	O
CAML	B-protein
)	O
,	O
acts	O
downstream	O
of	O
the	O
TCR	B-protein
and	O
upstream	O
of	O
calcineurin	B-protein
by	O
causing	O
an	O
influx	O
of	O
calcium	O
.	O

CAML	B-protein
appears	O
to	O
be	O
a	O
new	O
participant	O
in	O
the	O
calcium-signal	O
transduction	O
pathway	O
,	O
implicating	O
cyclophilin	B-protein
B	I-protein
in	O
calcium	O
signalling	O
,	O
even	O
in	O
the	O
absence	O
of	O
cyclosporin	O
.	O

Expression	O
and	O
genomic	O
configuration	O
of	O
GM-CSF	B-protein
,	O
IL-3	B-protein
,	O
M-CSF	B-protein
receptor	I-protein
(	O
C-FMS	B-protein
)	O
,	O
early	B-DNA
growth	I-DNA
response	I-DNA
gene-1	I-DNA
(	O
EGR-1	B-DNA
)	O
and	O
M-CSF	B-DNA
genes	I-DNA
in	O
primary	O
myelodysplastic	O
syndromes	O
.	O

Peripheral	O
blood	O
mononuclear	O
cells	O
from	O
seventeen	O
patients	O
with	O
primary	O
myelodysplastic	O
syndromes	O
(	O
MDS	O
)	O
in	O
advanced	O
stage	O
were	O
enriched	O
for	O
blasts	B-cell_type
and	O
tested	O
for	O
(	O
1	O
)	O
karyotype	O
,	O
(	O
2	O
)	O
genomic	O
configuration	O
and	O
(	O
3	O
)	O
expression	O
of	O
IL-3	B-DNA
,	I-DNA
GM-CSF	I-DNA
,	I-DNA
FMS	I-DNA
and	I-DNA
EGR-1	I-DNA
genes	I-DNA
which	O
are	O
all	O
located	O
on	O
the	O
long	B-DNA
arm	I-DNA
of	I-DNA
chromosome	I-DNA
5	I-DNA
.	O

The	O
expression	O
of	O
the	O
M-CSF	B-DNA
gene	I-DNA
,	O
that	O
has	O
been	O
recently	O
reassigned	O
to	O
the	O
short	B-DNA
arm	I-DNA
of	I-DNA
chromosome	I-DNA
1	I-DNA
(	O
lp	B-DNA
)	O
,	O
was	O
also	O
investigated	O
.	O

Aims	O
of	O
the	O
study	O
were	O
to	O
(	O
1	O
)	O
assess	O
the	O
potential	O
role	O
of	O
the	O
expression	O
of	O
these	O
genes	O
in	O
the	O
maintenance	O
and	O
expansion	O
of	O
the	O
neoplastic	B-cell_line
clones	I-cell_line
and	O
(	O
2	O
)	O
search	O
for	O
constitutional	O
losses	O
or	O
rearrangements	O
of	O
one	O
allele	B-DNA
followed	O
by	O
a	O
deletion	O
of	O
the	O
second	O
allele	B-DNA
of	O
the	O
same	O
genes	O
in	O
the	O
leukemic	B-cell_type
cells	I-cell_type
.	O

The	O
latter	O
issue	O
was	O
investigated	O
by	O
comparing	O
,	O
in	O
8	O
cases	O
,	O
constitutive	B-DNA
DNA	I-DNA
from	O
skin	B-cell_type
fibroblasts	I-cell_type
with	O
leukemic	B-DNA
DNA	I-DNA
.	O

Eleven	O
of	O
the	O
17	O
patients	O
had	O
abnormal	O
karyotypes	O
.	O

The	O
M-CSF	B-DNA
gene	I-DNA
was	O
expressed	O
in	O
6	O
cases	O
and	O
the	O
FMS	B-DNA
and	O
the	O
EGR-1	B-DNA
genes	I-DNA
were	O
expressed	O
in	O
2	O
of	O
the	O
latter	O
cases	O
.	O

An	O
autocrine	O
mechanism	O
of	O
growth	O
could	O
be	O
hypothesized	O
only	O
for	O
the	O
2	O
patients	O
whose	O
cells	O
expressed	O
both	O
the	O
M-CSF	B-DNA
and	I-DNA
FMS	I-DNA
genes	I-DNA
.	O

No	O
germline	O
changes	O
or	O
rearrangements	O
were	O
observed	O
in	O
any	O
of	O
the	O
genes	O
studied	O
.	O

Thus	O
,	O
deregulation	O
of	O
genes	O
encoding	O
for	O
certain	O
hemopoietic	B-protein
growth	I-protein
factors	I-protein
or	O
receptors	O
does	O
not	O
seem	O
to	O
represent	O
a	O
major	O
mechanism	O
of	O
MDS	O
progression	O
.	O

A	O
novel	O
human	B-DNA
homeobox	I-DNA
gene	I-DNA
distantly	O
related	O
to	O
proboscipedia	B-DNA
is	O
expressed	O
in	O
lymphoid	O
and	O
pancreatic	O
tissues	O
.	O

A	O
novel	O
human	B-DNA
homeobox	I-DNA
gene	I-DNA
,	O
HB9	B-DNA
,	O
was	O
isolated	O
from	O
a	O
cDNA	B-DNA
library	I-DNA
prepared	O
from	O
in	O
vitro	B-cell_type
stimulated	I-cell_type
human	I-cell_type
tonsil	I-cell_type
B	I-cell_type
lymphocytes	I-cell_type
and	O
from	O
a	O
human	B-DNA
genomic	I-DNA
library	I-DNA
.	O

The	O
HB9	B-DNA
gene	I-DNA
is	O
composed	O
of	O
3	O
exons	B-DNA
spread	O
over	O
6	O
kilobases	O
of	O
DNA	O
.	O

An	O
open	B-DNA
reading	I-DNA
frame	I-DNA
of	O
1206	O
nucleotides	O
is	O
in	O
frame	O
with	O
a	O
diverged	B-DNA
homeodomain	I-DNA
.	O

The	O
predicted	O
HB9	B-protein
protein	I-protein
has	O
a	O
molecular	O
mass	O
of	O
41	O
kilodaltons	O
and	O
is	O
enriched	O
for	O
alanine	O
,	O
glycine	O
,	O
and	O
leucine	O
.	O

The	O
HB9	B-DNA
homeodomain	I-DNA
is	O
most	O
similar	O
to	O
that	O
of	O
the	O
Drosophila	B-DNA
melanogaster	I-DNA
homeobox	I-DNA
gene	I-DNA
proboscipedia	B-DNA
.	O

Northern	O
blot	O
analysis	O
of	O
poly	B-RNA
(	I-RNA
A	I-RNA
)	I-RNA
RNA	I-RNA
purified	O
from	O
the	O
human	B-cell_line
B	I-cell_line
cell	I-cell_line
line	I-cell_line
RPMI	I-cell_line
8226	I-cell_line
and	O
from	O
activated	B-cell_type
T	I-cell_type
cells	I-cell_type
revealed	O
a	O
major	B-RNA
mRNA	I-RNA
transcript	I-RNA
of	O
2.2	O
kilobases	O
.	O

Similar	O
analysis	O
of	O
poly	B-RNA
(	I-RNA
A	I-RNA
)	I-RNA
RNA	I-RNA
from	O
a	O
variety	O
of	O
adult	O
tissues	O
demonstrated	O
HB9	B-DNA
transcripts	O
in	O
pancreas	O
,	O
small	O
intestine	O
,	O
and	O
colon	O
.	O

Reverse	O
transcriptase-polymerase	O
chain	O
reaction	O
was	O
used	O
to	O
examine	O
HB9	B-RNA
RNA	I-RNA
transcripts	I-RNA
in	O
hematopoietic	B-cell_line
cell	I-cell_line
lines	I-cell_line
.	O

HB9	B-RNA
RNA	I-RNA
transcripts	I-RNA
were	O
most	O
prevalent	O
in	O
several	O
human	B-cell_line
B	I-cell_line
cell	I-cell_line
lines	I-cell_line
and	O
K562	B-cell_line
cells	I-cell_line
.	O

In	O
addition	O
,	O
transcripts	O
were	O
detected	O
in	O
RNA	O
prepared	O
from	O
tonsil	B-cell_type
B	I-cell_type
cells	I-cell_type
and	O
in	O
situ	O
hybridization	O
studies	O
localized	O
them	O
in	O
the	O
germinal	O
center	O
region	O
of	O
adult	O
tonsil	O
.	O

These	O
findings	O
suggest	O
the	O
involvement	O
of	O
HB9	B-DNA
in	O
regulating	O
gene	O
transcription	O
in	O
lymphoid	O
and	O
pancreatic	O
tissues	O
.	O

Human	B-protein
immunodeficiency	I-protein
virus	I-protein
type	I-protein
1	I-protein
Tat	I-protein
upregulates	O
interleukin-2	B-protein
secretion	O
in	O
activated	B-cell_type
T	I-cell_type
cells	I-cell_type
.	O

Dysregulation	O
of	O
cytokines	B-protein
secreted	O
by	O
T	B-cell_type
cells	I-cell_type
may	O
play	O
an	O
important	O
role	O
in	O
the	O
pathogenesis	O
of	O
AIDS	O
.	O

To	O
investigate	O
the	O
effects	O
of	O
human	B-protein
immunodeficiency	I-protein
virus	I-protein
type	I-protein
1	I-protein
(	I-protein
HIV-1	I-protein
)	I-protein
Tat	I-protein
on	O
interleukin-2	B-protein
(	O
IL-2	B-protein
)	O
expression	O
,	O
we	O
used	O
IL-2	B-DNA
promoter-chloramphenicol	I-DNA
acetyltransferase	I-DNA
constructs	I-DNA
and	O
IL-2-secreting	B-cell_line
Jurkat	I-cell_line
T	I-cell_line
cells	I-cell_line
as	O
a	O
model	O
system	O
.	O

Transient	O
expression	O
of	O
HIV-1	B-protein
Tat	I-protein
induced	O
a	O
five-	O
to	O
eightfold	O
increase	O
in	O
IL-2	B-DNA
promoter	I-DNA
activity	O
in	O
Jurkat	B-cell_line
T	I-cell_line
cells	I-cell_line
stimulated	O
with	O
phytohemagglutinin	B-protein
and	O
phorbol	O
myristate	O
acetate	O
.	O

IL-2	B-protein
secretion	O
was	O
increased	O
more	O
than	O
twofold	O
in	O
both	O
Jurkat	B-cell_line
T	I-cell_line
cells	I-cell_line
and	O
primary	B-cell_line
T	I-cell_line
cells	I-cell_line
stimulated	O
by	O
extracellular	B-protein
HIV-1	I-protein
Tat	I-protein
protein	I-protein
.	O

Analysis	O
of	O
mRNA	B-RNA
suggested	O
that	O
Tat	O
exerts	O
its	O
effect	O
on	O
IL-2	B-protein
primarily	O
at	O
the	O
transcriptional	O
level	O
.	O

The	O
NF-kappa	B-DNA
B	I-DNA
site	I-DNA
at	O
positions	O
-206	B-DNA
to	I-DNA
-195	I-DNA
of	O
the	O
IL-2	B-DNA
promoter	I-DNA
was	O
required	O
but	O
not	O
sufficient	O
for	O
the	O
Tat	B-protein
effect	O
.	O

The	O
Tat	B-protein
-mediated	O
increase	O
in	O
IL-2	B-DNA
promoter	I-DNA
activity	O
could	O
selectively	O
be	O
blocked	O
by	O
antisense	O
tat	O
or-unlike	O
the	O
analogous	O
effect	O
of	O
human	B-protein
T-cell	I-protein
lymphotropic	I-protein
virus	I-protein
type	I-protein
1	I-protein
Tax	I-protein
-by	O
cyclosporin	O
A	O
.	O

The	O
observed	O
increase	O
in	O
IL-2	B-protein
levels	O
might	O
facilitate	O
virus	O
spread	O
from	O
or	O
to	O
T	B-cell_type
cells	I-cell_type
.	O

Furthermore	O
,	O
it	O
might	O
contribute	O
to	O
the	O
hypergammaglobulinemia	O
or	O
,	O
together	O
with	O
other	O
cytokines	B-protein
found	O
to	O
be	O
dysregulated	O
,	O
the	O
T-helper	O
cell	O
dysfunctions	O
observed	O
in	O
AIDS	O
patients	O
.	O

Activation	O
of	O
nuclear	B-protein
factor	I-protein
kappa	I-protein
B	I-protein
in	O
human	B-cell_type
lymphoblastoid	I-cell_type
cells	I-cell_type
by	O
low-dose	O
ionizing	O
radiation	O
.	O

Nuclear	B-protein
factor	I-protein
kappa	I-protein
B	I-protein
(	O
NF-kappa	B-protein
B	I-protein
)	O
is	O
a	O
pleiotropic	B-protein
transcription	I-protein
factor	I-protein
which	O
is	O
involved	O
in	O
the	O
transcriptional	O
regulation	O
of	O
several	O
specific	O
genes	O
.	O

Recent	O
reports	O
demonstrated	O
that	O
ionizing	O
radiation	O
in	O
the	O
dose	O
range	O
of	O
2-50	O
Gy	O
results	O
in	O
expression	O
of	O
NF-kappa	B-protein
B	I-protein
in	O
human	B-cell_line
KG-1	I-cell_line
myeloid	I-cell_line
leukemia	I-cell_line
cells	I-cell_line
and	O
human	B-cell_type
B-lymphocyte	I-cell_type
precursor	I-cell_type
cells	I-cell_type
;	O
the	O
precise	O
mechanism	O
involved	O
and	O
the	O
significance	O
are	O
not	O
yet	O
known	O
.	O

The	O
present	O
report	O
demonstrates	O
that	O
even	O
lower	O
doses	O
of	O
ionizing	O
radiation	O
,	O
0.25-2.0	O
Gy	O
,	O
are	O
capable	O
of	O
inducing	O
expression	O
of	O
NF-kappa	B-protein
B	I-protein
in	O
EBV-transformed	B-cell_line
244B	I-cell_line
human	I-cell_line
lymphoblastoid	I-cell_line
cells	I-cell_line
.	O

These	O
results	O
are	O
in	O
a	O
dose	O
range	O
where	O
the	O
viability	O
of	O
the	O
cells	O
remains	O
very	O
high	O
.	O

After	O
exposure	O
to	O
137Cs	O
gamma	O
rays	O
at	O
a	O
dose	O
rate	O
of	O
1.17	O
Gy/min	O
,	O
a	O
maximum	O
in	O
expression	O
of	O
NF-kappa	B-protein
B	I-protein
was	O
seen	O
at	O
8	O
h	O
after	O
a	O
0.5-Gy	O
exposure	O
.	O

Time-course	O
studies	O
revealed	O
a	O
biphasic	O
time-dependent	O
expression	O
after	O
0.5-	O
,	O
1-	O
and	O
2-Gy	O
exposures	O
.	O

However	O
,	O
for	O
each	O
time	O
examined	O
,	O
the	O
expression	O
of	O
NF-kappa	B-protein
B	I-protein
was	O
maximum	O
after	O
the	O
0.5-Gy	O
exposure	O
.	O

The	O
expression	O
of	O
the	O
p50	B-protein
and	I-protein
p65	I-protein
NF-kappa	I-protein
B	I-protein
subunits	I-protein
was	O
also	O
shown	O
to	O
be	O
regulated	O
differentially	O
after	O
exposures	O
to	O
1.0	O
and	O
2.0	O
Gy	O
.	O

Alternative	O
splicing	O
of	O
RNA	B-RNA
transcripts	I-RNA
encoded	O
by	O
the	O
murine	B-DNA
p105	I-DNA
NF-kappa	I-DNA
B	I-DNA
gene	I-DNA
generates	O
I	B-protein
kappa	I-protein
B	I-protein
gamma	I-protein
isoforms	I-protein
with	O
different	O
inhibitory	O
activities	O
.	O

The	O
gene	O
encoding	O
the	O
105-kDa	B-protein
protein	I-protein
(	I-protein
p105	I-protein
)	I-protein
precursor	I-protein
of	O
the	O
p50	B-protein
subunit	O
of	O
transcription	O
factor	O
NF-kappa	B-protein
B	I-protein
also	O
encodes	O
a	O
p70	B-protein
I	I-protein
kappa	I-protein
B	I-protein
protein	I-protein
,	O
I	B-protein
kappa	I-protein
B	I-protein
gamma	I-protein
,	O
which	O
is	O
identical	O
to	O
the	O
C-terminal	B-protein
607	I-protein
amino	I-protein
acids	I-protein
of	O
p105	B-protein
.	O

Here	O
we	O
show	O
that	O
alternative	O
RNA	O
splicing	O
generates	O
I	B-protein
kappa	I-protein
B	I-protein
gamma	I-protein
isoforms	I-protein
with	O
properties	O
different	O
from	O
those	O
of	O
p70	B-protein
.	O

One	O
63-kDa	B-protein
isoform	I-protein
,	O
termed	O
I	B-protein
kappa	I-protein
B	I-protein
gamma-1	I-protein
,	O
which	O
lacks	O
59	O
amino	O
acids	O
C-terminal	O
to	O
ankyrin	B-protein
repeat	I-protein
7	I-protein
,	O
has	O
a	O
novel	O
35-amino	B-protein
acid	I-protein
C	I-protein
terminus	I-protein
encoded	O
by	O
an	O
alternative	B-DNA
reading	I-DNA
frame	I-DNA
of	O
the	O
p105	B-DNA
gene	I-DNA
.	O

A	O
55-kDa	B-protein
isoform	I-protein
,	O
I	B-protein
kappa	I-protein
B	I-protein
gamma-2	I-protein
,	O
lacks	O
the	O
190	B-protein
C-terminal	I-protein
amino	I-protein
acids	I-protein
of	O
p70	B-protein
I	B-protein
kappa	I-protein
B	I-protein
gamma	I-protein
.	O

In	O
contrast	O
to	O
p70	B-protein
I	B-protein
kappa	I-protein
B	I-protein
gamma	I-protein
,	O
which	O
is	O
a	O
cytoplasmic	B-protein
protein	I-protein
,	O
I	B-protein
kappa	I-protein
B	I-protein
gamma-1	I-protein
is	O
found	O
in	O
both	O
the	O
cytoplasm	O
and	O
nucleus	O
,	O
whereas	O
I	B-protein
kappa	I-protein
B	I-protein
gamma-2	I-protein
is	O
predominantly	O
nuclear	O
.	O

The	O
I	B-protein
kappa	I-protein
B	I-protein
gamma	I-protein
isoforms	I-protein
also	O
display	O
differences	O
in	O
specificity	O
and	O
affinity	O
for	O
Rel/NF-kappa	B-protein
B	I-protein
proteins	I-protein
.	O

While	O
p70	B-protein
I	B-protein
kappa	I-protein
B	I-protein
gamma	I-protein
inhibits	O
p50-	O
,	O
p65-	O
,	O
and	O
c-Rel-mediated	O
transactivation	O
and/or	O
DNA	O
binding	O
,	O
both	O
I	B-protein
kappa	I-protein
B	I-protein
gamma-1	I-protein
and	O
I	B-protein
kappa	I-protein
B	I-protein
gamma-2	I-protein
are	O
specific	O
for	O
p50	B-protein
and	O
have	O
different	O
affinities	O
for	O
this	O
subunit	O
.	O

The	O
absence	O
in	O
I	B-protein
kappa	I-protein
B	I-protein
gamma-1	I-protein
and	O
I	B-protein
kappa	I-protein
B	I-protein
gamma-2	I-protein
of	O
a	O
protein	B-DNA
kinase	I-DNA
A	I-DNA
site	I-DNA
whose	O
phosphorylation	O
modulates	O
p70	B-protein
I	B-protein
kappa	I-protein
B	I-protein
gamma	I-protein
inhibitory	O
activity	O
suggests	O
that	O
alternative	O
RNA	O
splicing	O
may	O
be	O
used	O
to	O
generate	O
I	B-protein
kappa	I-protein
B	I-protein
gamma	I-protein
isoforms	I-protein
that	O
respond	O
differently	O
to	O
intracellular	O
signals	O
.	O

Structure	O
and	O
expression	O
of	O
the	O
human	B-DNA
GATA3	I-DNA
gene	I-DNA
.	O

GATA3	B-protein
,	O
a	O
member	O
of	O
the	O
GATA	B-protein
family	I-protein
that	O
is	O
abundantly	O
expressed	O
in	O
the	O
T-lymphocyte	B-cell_type
lineage	I-cell_type
,	O
is	O
thought	O
to	O
participate	O
in	O
T-cell	B-protein
receptor	I-protein
gene	O
activation	O
through	O
binding	O
to	O
enhancers	B-DNA
.	O

To	O
understand	O
GATA3	B-DNA
gene	I-DNA
regulation	O
,	O
we	O
cloned	O
the	O
human	B-DNA
gene	I-DNA
and	O
the	O
5	B-DNA
'	I-DNA
end	I-DNA
of	O
the	O
mouse	B-DNA
GATA3	I-DNA
gene	I-DNA
.	O

We	O
show	O
that	O
the	O
human	B-DNA
GATA3	I-DNA
gene	I-DNA
contains	O
six	O
exons	B-DNA
distributed	O
over	O
17	O
kb	O
of	O
DNA	O
.	O

The	O
two	O
human	B-protein
GATA3	I-protein
zinc	I-protein
fingers	I-protein
are	O
encoded	O
by	O
two	O
separate	O
exons	B-DNA
highly	O
conserved	O
with	O
those	O
of	O
GATA1	B-protein
,	O
but	O
no	O
other	O
structural	O
homologies	O
between	O
these	O
two	O
genes	O
can	O
be	O
found	O
.	O

The	O
human	B-DNA
and	I-DNA
mouse	I-DNA
GATA3	I-DNA
transcription	I-DNA
units	I-DNA
start	O
at	O
a	O
major	B-DNA
initiation	I-DNA
site	I-DNA
.	O

The	O
promoter	O
sequence	O
analysis	O
of	O
these	O
two	O
genes	O
revealed	O
that	O
they	O
are	O
embedded	O
within	O
a	O
CpG	B-DNA
island	I-DNA
and	O
share	O
structural	O
features	O
often	O
found	O
in	O
the	O
promoters	B-DNA
of	O
housekeeping	B-DNA
genes	I-DNA
.	O

Finally	O
,	O
we	O
show	O
that	O
a	O
DNA	B-DNA
fragment	I-DNA
containing	O
the	O
human	B-DNA
GATA3	I-DNA
transcription	I-DNA
unit	I-DNA
,	O
3	B-DNA
kb	I-DNA
upstream	I-DNA
from	O
the	O
initiation	B-DNA
site	I-DNA
and	O
4	B-DNA
kb	I-DNA
downstream	I-DNA
from	O
the	O
polyadenylation	B-DNA
site	I-DNA
,	O
displays	O
T-cell	O
specificity	O
.	O

Characterization	O
of	O
the	O
human	B-DNA
gene	I-DNA
encoding	O
LBR	B-protein
,	O
an	O
integral	B-protein
protein	I-protein
of	O
the	O
nuclear	O
envelope	O
inner	O
membrane	O
.	O

We	O
have	O
characterized	O
the	O
human	B-DNA
gene	I-DNA
encoding	O
LBR	B-protein
,	O
an	O
integral	B-protein
protein	I-protein
of	O
the	O
nuclear	O
envelope	O
inner	O
membrane	O
.	O

Restriction	O
mapping	O
shows	O
that	O
the	O
transcription	B-DNA
unit	I-DNA
spans	O
approximately	O
35	O
kilobases	O
.	O

A	O
transcription	O
start	O
site	O
is	O
located	O
approximately	O
4	O
kilobases	O
5	O
'	O
to	O
the	O
translation	B-DNA
initiation	I-DNA
codon	I-DNA
,	O
and	O
an	O
RNA	O
splice	O
of	O
3863	O
bases	O
occurs	O
in	O
the	O
5'-untranslated	B-DNA
region	I-DNA
to	O
generate	O
mature	B-RNA
HeLa	I-RNA
cell	I-RNA
mRNA	I-RNA
.	O

5	O
'	O
to	O
the	O
identified	O
transcription	B-DNA
start	I-DNA
site	I-DNA
are	O
two	O
CCAAT	B-DNA
sequences	I-DNA
and	O
potential	B-DNA
recognition	I-DNA
sites	I-DNA
for	O
several	O
transcription	B-protein
factors	I-protein
including	O
Sp1	B-protein
,	O
AP-1	B-protein
,	O
AP-2	B-protein
,	O
and	O
NF-kB	B-protein
.	O

There	O
are	O
13	O
protein	O
coding	O
exons	B-DNA
in	O
the	O
LBR	B-DNA
gene	I-DNA
.	O

LBR	B-protein
's	O
nucleoplasmic	B-protein
domain	I-protein
is	O
encoded	O
by	O
exons	B-DNA
1-4	I-DNA
,	O
and	O
its	O
hydrophobic	B-protein
domain	I-protein
,	O
with	O
eight	O
putative	O
transmembrane	B-protein
segments	I-protein
,	O
is	O
encoded	O
by	O
exons	B-DNA
5-13	I-DNA
.	O

The	O
hydrophobic	B-protein
domain	I-protein
is	O
homologous	O
to	O
three	O
yeast	O
polypeptides	O
,	O
suggesting	O
that	O
this	O
higher	B-DNA
eukaryotic	I-DNA
gene	I-DNA
could	O
have	O
evolved	O
from	O
recombination	O
between	O
a	O
gene	O
that	O
encoded	O
a	O
soluble	B-protein
nuclear	I-protein
protein	I-protein
and	O
a	O
membrane	B-DNA
protein	I-DNA
gene	I-DNA
similar	O
to	O
those	O
in	O
yeast	O
.	O

These	O
results	O
are	O
the	O
first	O
to	O
demonstrate	O
the	O
structural	O
organization	O
of	O
a	O
vertebrate	B-DNA
gene	I-DNA
encoding	O
an	O
integral	B-protein
membrane	I-protein
protein	I-protein
of	O
the	O
nuclear	O
envelope	O
that	O
may	O
be	O
a	O
member	O
of	O
a	O
family	O
of	O
polypeptides	O
conserved	O
in	O
evolution	O
.	O

Retinoic	O
acid-induced	O
expression	O
of	O
CD38	B-protein
antigen	I-protein
in	O
myeloid	B-cell_type
cells	I-cell_type
is	O
mediated	O
through	O
retinoic	B-protein
acid	I-protein
receptor-alpha	I-protein
.	O

CD38	B-protein
is	O
a	O
leukocyte	B-protein
differentiation	I-protein
antigen	I-protein
that	O
has	O
been	O
thought	O
to	O
be	O
a	O
phenotypic	O
marker	O
of	O
different	O
subpopulations	O
of	O
T-	B-cell_type
and	I-cell_type
B-	I-cell_type
lymphocytes	I-cell_type
.	O

In	O
myeloid	B-cell_type
cells	I-cell_type
,	O
CD38	B-protein
is	O
expressed	O
during	O
early	O
stages	O
of	O
differentiation	O
.	O

Virtually	O
no	O
information	O
is	O
available	O
on	O
regulation	O
and	O
functions	O
of	O
CD38	B-protein
.	O

Recently	O
we	O
reported	O
that	O
all-trans-retinoic	O
acid	O
(	O
ATRA	O
)	O
is	O
a	O
potent	O
and	O
highly	O
specific	O
inducer	O
of	O
CD38	B-protein
expression	O
in	O
human	B-cell_type
promyelocytic	I-cell_type
leukemia	I-cell_type
cells	I-cell_type
.	O

Here	O
we	O
report	O
that	O
ATRA-induced	O
expression	O
of	O
CD38	B-protein
antigen	I-protein
in	O
myeloid	B-cell_type
cells	I-cell_type
is	O
mediated	O
through	O
retinoic	B-protein
acid-alpha	I-protein
receptor	I-protein
(	O
RAR	B-protein
alpha	I-protein
)	O
.	O

ATRA	O
failed	O
to	O
induce	O
CD38	B-protein
expression	O
in	O
a	O
mutant	B-cell_line
subclone	I-cell_line
of	O
the	O
HL-60	B-cell_line
myeloid	I-cell_line
leukemia	I-cell_line
cell	I-cell_line
line	I-cell_line
(	O
designated	O
HL-60R	B-cell_line
)	O
that	O
is	O
relatively	O
resistant	O
to	O
ATRA-induced	O
granulocytic	O
differentiation	O
.	O

Retroviral	O
vector-mediated	O
transduction	O
of	O
RA	B-protein
receptor	I-protein
(	O
RAR	B-protein
alpha	I-protein
)	O
into	O
this	O
HL-60R	B-cell_line
subclone	I-cell_line
completely	O
restored	O
the	O
sensitivity	O
of	O
these	O
cells	O
to	O
ATRA	O
in	O
terms	O
of	O
their	O
ability	O
to	O
express	O
CD38	B-protein
.	O

In	O
contrast	O
,	O
CD38	B-protein
expression	O
was	O
not	O
inducible	O
by	O
ATRA	O
in	O
HL-60R	B-cell_line
cells	I-cell_line
,	O
transfected	O
with	O
a	O
functional	O
RAR	B-protein
beta	I-protein
,	O
RAR	B-protein
gamma	I-protein
,	O
or	O
RXR	B-protein
alpha	I-protein
receptor	I-protein
.	O

Induction	O
of	O
CD38	B-protein
in	O
acute	B-cell_type
promyelocytic	I-cell_type
and	I-cell_type
acute	I-cell_type
myeloblastic	I-cell_type
leukemia	I-cell_type
cells	I-cell_type
was	O
independent	O
of	O
ATRA-induced	O
cytodifferentiation	O
.	O

Following	O
culture	O
with	O
ATRA	O
,	O
increased	O
CD38	B-protein
protein	O
levels	O
were	O
also	O
observed	O
in	O
normal	B-cell_type
CD34+	I-cell_type
bone	I-cell_type
marrow	I-cell_type
cells	I-cell_type
,	O
but	O
not	O
on	O
normal	B-cell_type
circulating	I-cell_type
granulocytes	I-cell_type
.	O

From	O
these	O
results	O
,	O
we	O
conclude	O
that	O
CD38	B-protein
is	O
ATRA	O
inducible	O
in	O
myeloid	B-cell_type
leukemia	I-cell_type
cells	I-cell_type
and	O
normal	B-cell_type
CD34+	I-cell_type
bone	I-cell_type
marrow	I-cell_type
cells	I-cell_type
.	O

This	O
effect	O
is	O
independent	O
of	O
differentiation	O
and	O
is	O
mediated	O
by	O
RAR	B-protein
alpha	I-protein
in	O
HL-60	B-cell_type
cells	I-cell_type
,	O
suggesting	O
a	O
similar	O
role	O
for	O
RAR	B-protein
alpha	I-protein
in	O
CD38	B-protein
expression	O
in	O
other	O
hematopoietic	B-cell_type
cells	I-cell_type
.	O

Some	O
antioxidants	O
inhibit	O
,	O
in	O
a	O
co-ordinate	O
fashion	O
,	O
the	O
production	O
of	O
tumor	B-protein
necrosis	I-protein
factor-alpha	I-protein
,	O
IL-beta	B-protein
,	O
and	O
IL-6	B-protein
by	O
human	B-cell_type
peripheral	I-cell_type
blood	I-cell_type
mononuclear	I-cell_type
cells	I-cell_type
.	O

Some	O
antioxidants	O
,	O
including	O
butylated	O
hydroxyanisole	O
(	O
BHA	O
)	O
,	O
tetrahydropapaveroline	O
(	O
THP	O
)	O
,	O
nordihydroguiauretic	O
acid	O
,	O
and	O
10	O
,	O
11-dihydroxyaporphine	O
(	O
DHA	O
)	O
,	O
were	O
found	O
to	O
be	O
potent	O
inhibitors	O
of	O
the	O
production	O
of	O
tumor	B-protein
necrosis	I-protein
factor	I-protein
(	I-protein
TNF	I-protein
)	I-protein
-alpha	I-protein
,	O
IL-1	B-protein
beta	I-protein
,	O
and	O
IL-6	B-protein
by	O
human	B-cell_type
peripheral	I-cell_type
blood	I-cell_type
mononuclear	I-cell_type
cells	I-cell_type
(	O
PBMC	B-cell_type
)	O
stimulated	O
by	O
lipopolysaccharide	O
(	O
LPS	O
)	O
(	O
IC50s	O
in	O
the	O
low	O
micromolar	O
range	O
)	O
.	O

Inhibition	O
of	O
cytokine	B-protein
production	O
was	O
gene	O
selective	O
and	O
not	O
due	O
to	O
general	O
effects	O
on	O
protein	O
synthesis	O
.	O

Inhibition	O
of	O
cytokine	B-protein
production	O
by	O
PBMC	B-cell_type
was	O
observed	O
also	O
when	O
other	O
inducers	O
were	O
used	O
(	O
staphylococci	O
,	O
silica	O
,	O
zymosan	O
)	O
.	O

Much	O
higher	O
concentrations	O
of	O
other	O
antioxidants	O
--	O
including	O
ascorbic	O
acid	O
,	O
trolox	O
,	O
alpha-tocopherol	O
,	O
butylated	O
hydroxytoluene	O
,	O
and	O
the	O
5-lipoxygenase	O
inhibitor	O
zileuton	O
--	O
did	O
not	O
affect	O
the	O
production	O
of	O
these	O
cytokines	B-protein
.	O

The	O
active	O
compounds	O
did	O
not	O
inhibit	O
IL-1	B-protein
-induced	O
production	O
of	O
IL-6	B-protein
in	O
fibroblasts	B-cell_type
,	O
showing	O
the	O
cell	O
selectivity	O
of	O
the	O
effect	O
.	O

Antioxidant-mediated	O
inhibition	O
of	O
cytokine	B-protein
production	O
was	O
correlated	O
with	O
low	O
levels	O
of	O
the	O
corresponding	O
messenger	B-RNA
RNAs	I-RNA
.	O

Nuclear	O
run-on	O
experiments	O
showed	O
that	O
THP	O
inhibited	O
transcription	O
of	O
the	O
IL-1	B-DNA
beta	I-DNA
gene	I-DNA
.	O

THP	O
decreased	O
the	O
concentration	O
of	O
the	O
transcription	B-protein
factors	I-protein
NF-kappa	B-protein
B	I-protein
and	O
AP-1	B-protein
detected	O
in	O
nuclear	O
extracts	O
of	O
PBMC	B-cell_type
cultured	O
in	O
the	O
presence	O
or	O
absence	O
of	O
LPS	O
.	O

THP	O
and	O
DHA	O
markedly	O
decreased	O
the	O
levels	O
of	O
TNF-alpha	B-protein
and	O
IL-1	B-protein
beta	I-protein
in	O
the	O
circulation	O
of	O
mice	O
following	O
LPS	O
injection	O
.	O

Thus	O
antioxidants	O
vary	O
widely	O
in	O
potency	O
as	O
inhibitors	O
of	O
the	O
activation	O
of	O
transcription	B-protein
factors	I-protein
and	O
of	O
the	O
transcription	O
of	O
genes	B-DNA
for	O
pro-inflammatory	B-protein
cytokines	I-protein
.	O

Coordinate	O
inhibition	O
of	O
the	O
transcription	O
of	O
genes	O
for	O
inflammatory	O
cytokines	B-protein
could	O
provide	O
a	O
strategy	O
for	O
therapy	O
of	O
diseases	O
with	O
inflammatory	O
pathogenesis	O
and	O
for	O
septic	O
shock	O
.	O

An	O
interleukin-4-induced	B-protein
transcription	I-protein
factor	I-protein
:	O
IL-4	B-protein
Stat	I-protein
.	O

Interleukin-4	B-protein
(	O
IL-4	B-protein
)	O
is	O
an	O
immunomodulatory	O
cytokine	O
secreted	O
by	O
activated	O
T	B-cell_type
lymphocytes	I-cell_type
,	O
basophils	B-cell_type
,	O
and	O
mast	B-cell_type
cells	I-cell_type
.	O

It	O
plays	O
an	O
important	O
role	O
in	O
modulating	O
the	O
balance	O
of	O
T	B-cell_type
helper	I-cell_type
(	I-cell_type
Th	I-cell_type
)	I-cell_type
cell	I-cell_type
subsets	I-cell_type
,	O
favoring	O
expansion	O
of	O
the	O
Th2	B-cell_type
lineage	I-cell_type
relative	O
to	O
Th1	B-cell_type
.	O

Imbalance	O
of	O
these	O
T	B-cell_type
lymphocyte	I-cell_type
subsets	I-cell_type
has	O
been	O
implicated	O
in	O
immunological	O
diseases	O
including	O
allergy	O
,	O
inflammation	O
,	O
and	O
autoimmune	O
disease	O
.	O

IL-4	B-protein
may	O
mediate	O
its	O
biological	O
effects	O
,	O
at	O
least	O
in	O
part	O
,	O
by	O
activating	O
a	O
tyrosine-phosphorylated	B-protein
DNA	I-protein
binding	I-protein
protein	I-protein
.	O

This	O
protein	O
has	O
now	O
been	O
purified	O
and	O
its	O
encoding	O
gene	O
cloned	O
.	O

Examination	O
of	O
the	O
primary	O
amino	O
acid	O
sequence	O
of	O
this	O
protein	O
indicates	O
that	O
it	O
is	O
a	O
member	O
of	O
the	O
signal	B-protein
transducers	I-protein
and	I-protein
activators	I-protein
of	I-protein
transcription	I-protein
(	I-protein
Stat	I-protein
)	I-protein
family	I-protein
of	O
DNA	B-protein
binding	I-protein
proteins	I-protein
,	O
hereby	O
designated	O
IL-4	B-protein
Stat	I-protein
.	O

Study	O
of	O
the	O
inhibitory	O
activities	O
of	O
phosphotyrosine-containing	O
peptides	O
derived	O
from	O
the	O
intracellular	B-protein
domain	I-protein
of	I-protein
the	I-protein
IL-4	I-protein
receptor	I-protein
provided	O
evidence	O
for	O
direct	O
coupling	O
of	O
receptor	B-protein
and	O
transcription	B-protein
factor	I-protein
during	O
the	O
IL-4	B-protein
Stat	I-protein
activation	O
cycle	O
.	O

Such	O
observations	O
indicate	O
that	O
IL-4	B-protein
Stat	I-protein
has	O
the	O
same	O
functional	B-protein
domain	I-protein
for	O
both	O
receptor	O
coupling	O
and	O
dimerization	O
.	O

Evaluation	O
of	O
the	O
respiratory	O
epithelium	O
of	O
normals	O
and	O
individuals	O
with	O
cystic	O
fibrosis	O
for	O
the	O
presence	O
of	O
adenovirus	B-DNA
E1a	I-DNA
sequences	I-DNA
relevant	O
to	O
the	O
use	O
of	O
E1a-	O
adenovirus	O
vectors	O
for	O
gene	O
therapy	O
for	O
the	O
respiratory	O
manifestations	O
of	O
cystic	O
fibrosis	O
.	O

Lung	O
disease	O
associated	O
with	O
disorders	O
such	O
as	O
cystic	O
fibrosis	O
(	O
CF	O
)	O
may	O
be	O
amenable	O
to	O
somatic	O
gene	O
therapy	O
in	O
which	O
there	O
is	O
delivery	O
of	O
the	O
normal	B-DNA
gene	I-DNA
directly	O
to	O
the	O
respiratory	O
epithelium	O
using	O
E1a-	O
adenovirus	O
(	O
Ad	O
)	O
type	O
2-	O
or	O
5-based	O
vectors	O
.	O

For	O
safety	O
reasons	O
,	O
the	O
Ad	O
vectors	O
are	O
rendered	O
replication	O
deficient	O
by	O
deletion	O
of	O
the	O
E1a	B-DNA
region	I-DNA
.	O

Because	O
there	O
is	O
the	O
theoretical	O
possibility	O
of	O
an	O
E1a-	O
replication-deficient	O
vector	O
replicating	O
as	O
a	O
result	O
of	O
recombination	O
or	O
complementation	O
with	O
Ad	B-DNA
2/5	I-DNA
E1a	I-DNA
sequences	I-DNA
present	O
in	O
the	O
target	O
cell	O
,	O
this	O
study	O
is	O
directed	O
toward	O
evaluating	O
respiratory	O
epithelium	O
of	O
normals	O
and	O
individuals	O
with	O
CF	O
for	O
the	O
presence	O
of	O
E1a	O
sequences	O
.	O

Using	O
Ad	B-DNA
2/5	I-DNA
E1a-specific	I-DNA
primers	I-DNA
and	O
the	O
polymerase	O
chain	O
reaction	O
to	O
evaluate	O
DNA	O
recovered	O
from	O
freshly	O
isolated	O
nasal	O
and	O
bronchial	O
epithelium	O
recovered	O
by	O
brushing	O
,	O
E1a	B-DNA
sequences	I-DNA
were	O
detected	O
in	O
respiratory	O
epithelium	O
of	O
19	O
of	O
91	O
normals	O
(	O
21	O
%	O
)	O
.	O

In	O
the	O
E1a-positive	O
samples	O
,	O
the	O
average	O
of	O
E1a	O
copy	O
number	O
was	O
55	O
+/-	O
18/10	O
(	O
3	O
)	O
recovered	O
cells	O
.	O

In	O
CF	O
individuals	O
,	O
7	O
of	O
52	O
(	O
13	O
%	O
)	O
had	O
detectable	O
E1a	B-DNA
sequences	I-DNA
in	O
the	O
respiratory	O
epithelium	O
,	O
with	O
E1a	O
copy	O
number	O
in	O
the	O
positive	O
samples	O
of	O
80	O
+/-	O
21/10	O
(	O
3	O
)	O
recovered	O
cells	O
.	O

These	O
results	O
demonstrate	O
that	O
there	O
are	O
detectable	O
Ad	B-DNA
2/5	I-DNA
E1a	I-DNA
sequences	I-DNA
in	O
the	O
respiratory	O
epithelium	O
of	O
a	O
small	O
percentage	O
of	O
normals	O
and	O
individuals	O
with	O
CF	O
.	O

Because	O
of	O
the	O
theoretical	O
potential	O
of	O
such	O
sequences	O
supporting	O
replication	O
of	O
E1a-	O
Ad	O
vectors	O
,	O
human	O
gene	O
therapy	O
protocols	O
for	O
CF	O
utilizing	O
such	O
vectors	O
should	O
consider	O
evaluating	O
study	O
individuals	O
for	O
the	O
presence	O
of	O
Ad	B-DNA
2/5	I-DNA
E1a	I-DNA
sequences	I-DNA
in	O
the	O
respiratory	O
epithelium	O
.	O

Leiomyosarcoma	O
of	O
the	O
vulva	O
:	O
report	O
of	O
a	O
case	O
.	O

A	O
52-year-old	O
female	O
presented	O
with	O
a	O
progressively	O
enlarging	O
vulvar	O
mass	O
.	O

Pathological	O
evaluation	O
revealed	O
a	O
high-grade	O
vulvar	O
leiomyosarcoma	O
.	O

Immunohistochemical	O
and	O
ultrastructural	O
studies	O
were	O
performed	O
to	O
support	O
the	O
diagnosis	O
.	O

In	O
an	O
effort	O
to	O
better	O
understand	O
the	O
biology	O
of	O
this	O
tumor	O
additional	O
immunohistochemical	O
studies	O
for	O
the	O
protein	B-protein
product	I-protein
of	O
p53	B-DNA
tumor	I-DNA
suppressor	I-DNA
gene	I-DNA
and	O
estrogen	B-protein
receptor	I-protein
expression	O
by	O
tumor	B-cell_type
cells	I-cell_type
,	O
as	O
well	O
as	O
the	O
type	O
of	O
immune	B-cell_type
cells	I-cell_type
infiltrating	O
the	O
tumor	O
were	O
performed	O
.	O

Tumor	B-cell_type
cells	I-cell_type
showed	O
an	O
overexpression	O
of	O
p53	B-protein
protein	I-protein
and	O
were	O
estrogen	B-protein
receptor	I-protein
-positive	O
.	O

Macrophages	B-cell_type
and	O
T	B-cell_type
and	I-cell_type
B	I-cell_type
lymphocytes	I-cell_type
infiltrated	O
the	O
tumor	O
in	O
moderate	O
numbers	O
with	O
occasional	O
lymphoid	O
aggregate	O
formation	O
.	O

This	O
study	O
is	O
the	O
first	O
attempt	O
to	O
better	O
understand	O
the	O
biology	O
of	O
these	O
tumors	O
.	O

Stimulation	O
of	O
HIV	O
replication	O
in	O
mononuclear	B-cell_type
phagocytes	I-cell_type
by	O
leukemia	B-protein
inhibitory	I-protein
factor	I-protein
.	O

This	O
study	O
examined	O
the	O
effects	O
of	O
leukemia	B-protein
inhibitory	I-protein
factor	I-protein
(	O
LIF	B-protein
)	O
on	O
human	O
immunodeficiency	O
virus	O
(	O
HIV	O
)	O
replication	O
in	O
mononuclear	B-cell_type
phagocytes	I-cell_type
(	O
MNP	B-cell_type
)	O
.	O

LIF	B-protein
induced	O
a	O
dose-dependent	O
increase	O
in	O
p24	B-protein
antigen	I-protein
production	O
in	O
the	O
chronically	B-cell_line
infected	I-cell_line
promonocytic	I-cell_line
cell	I-cell_line
line	I-cell_line
U1	I-cell_line
.	O

The	O
magnitude	O
and	O
time	O
kinetics	O
of	O
the	O
LIF	B-protein
effects	O
were	O
similar	O
to	O
interleukin	B-protein
1	I-protein
(	O
IL-1	B-protein
)	O
,	O
IL-6	B-protein
,	O
and	O
tumor	B-protein
necrosis	I-protein
factor	I-protein
(	O
TNF	B-protein
)	O
,	O
other	O
cytokines	O
known	O
to	O
induce	O
HIV	O
replication	O
in	O
this	O
cell	O
line	O
.	O

To	O
characterize	O
mechanisms	O
responsible	O
for	O
these	O
LIF	B-protein
effects	O
,	O
levels	O
of	O
HIV	B-RNA
mRNA	I-RNA
,	O
activation	O
of	O
the	O
DNA	B-protein
binding	I-protein
protein	I-protein
nuclear	I-protein
factor	I-protein
(	B-protein
NF	I-protein
)	I-protein
-kB	I-protein
,	O
signal	O
transduction	O
pathways	O
,	O
and	O
potential	O
interactions	O
with	O
other	O
cytokines	B-protein
were	O
analyzed	O
.	O

LIF	B-protein
increased	O
steady-state	O
levels	O
of	O
HIV	B-RNA
mRNA	I-RNA
at	O
2.0	O
,	O
4.3	O
,	O
and	O
9.2	O
kB	O
.	O

This	O
was	O
detectable	O
by	O
24	O
h	O
and	O
persisted	O
until	O
72	O
h	O
.	O

The	O
DNA	B-protein
binding	I-protein
protein	I-protein
NF-kB	I-protein
is	O
a	O
central	O
mediator	O
in	O
cytokine	B-protein
activation	O
of	O
HIV	O
transcription	O
.	O

NF-kB	B-protein
levels	O
were	O
higher	O
in	O
unstimulated	B-cell_line
U1	I-cell_line
cells	I-cell_line
as	O
compared	O
to	O
the	O
parent	B-cell_line
cell	I-cell_line
line	I-cell_line
U937	B-cell_line
.	O

In	O
both	O
cell	O
lines	O
LIF	B-protein
increased	O
NF-kB	B-protein
activity	O
.	O

Induction	O
of	O
NF-kB	B-protein
and	O
HIV	O
replication	O
by	O
cytokines	B-protein
are	O
at	O
least	O
in	O
part	O
dependent	O
on	O
reactive	O
oxygen	O
intermediates	O
.	O

The	O
oxygen	O
radical	O
scavenger	O
N-acetyl-L-cysteine	O
,	O
but	O
not	O
an	O
inhibitor	O
of	O
nitric	B-protein
oxide	I-protein
synthase	I-protein
,	O
inhibited	O
LIF	B-protein
-induced	O
HIV	O
replication	O
.	O

LIF	B-protein
induces	O
the	O
production	O
of	O
other	O
cytokines	B-protein
in	O
monocytes	O
but	O
its	O
effects	O
on	O
HIV	O
replication	O
were	O
not	O
inhibited	O
by	O
antibodies	B-protein
to	O
IL-1	B-protein
,	O
TNF	B-protein
,	O
or	O
IL-6	B-protein
.	O

These	O
results	O
identify	O
LIF	B-protein
as	O
a	O
stimulus	O
of	O
HIV	O
replication	O
.	O

(	O
ABSTRACT	O
TRUNCATED	O
AT	O
250	O
WORDS	O
)	O

Mechanisms	O
involved	O
in	O
the	O
inhibition	O
of	O
growth	O
of	O
a	O
human	B-cell_line
B	I-cell_line
lymphoma	I-cell_line
cell	I-cell_line
line	I-cell_line
,	O
B104	B-cell_line
,	O
by	O
anti-MHC	B-protein
class	I-protein
II	I-protein
antibodies	I-protein
.	O

The	O
mechanisms	O
involved	O
in	O
the	O
inhibition	O
of	O
growth	O
of	O
a	O
human	B-cell_line
B	I-cell_line
lymphoma	I-cell_line
cell	I-cell_line
line	I-cell_line
,	O
B104	B-cell_line
,	O
by	O
anti-MHC	B-protein
class	I-protein
II	I-protein
antibodies	I-protein
(	O
Ab	B-protein
)	O
were	O
compared	O
with	O
those	O
in	O
anti-IgM	B-protein
Ab	I-protein
-induced	O
B104	O
growth	O
inhibition	O
.	O

Two	O
anti-MHC	B-protein
class	I-protein
II	I-protein
Ab	I-protein
,	O
L227	B-protein
and	O
2.06	B-protein
,	O
inhibited	O
the	O
growth	O
of	O
B104	B-cell_line
cells	I-cell_line
,	O
although	O
2.06	B-protein
,	O
but	O
not	O
L227	B-protein
,	O
needed	O
to	O
be	O
further	O
cross-linked	O
with	O
a	O
goat	B-protein
anti-mouse	I-protein
IgG	I-protein
Ab	I-protein
(	O
GAM	B-protein
)	O
to	O
show	O
the	O
effect	O
.	O

L227	B-protein
induced	O
an	O
increase	O
in	O
intracellular	O
free	O
Ca2+	O
concentration	O
(	O
[	O
Ca2+	O
]	O
i	O
)	O
from	O
the	O
intracellular	O
pool	O
and	O
little	O
or	O
no	O
protein	O
tyrosine	O
phosphorylation	O
,	O
phosphatidyl	O
inositol	O
turnover	O
,	O
or	O
expression	O
of	O
Egr-1	B-RNA
mRNA	I-RNA
,	O
whereas	O
2.06	B-protein
plus	O
GAM	B-protein
induced	O
an	O
increase	O
in	O
[	O
Ca2+	O
]	O
i	O
from	O
both	O
the	O
intracellular	O
and	O
,	O
in	O
particular	O
,	O
the	O
extracellular	O
pools	O
.	O

The	O
inhibition	O
of	O
B104	B-cell_line
cell	I-cell_line
growth	O
induced	O
by	O
anti-MHC	B-protein
class	I-protein
II	I-protein
Ab	I-protein
was	O
Ca	O
(	O
2+	O
)	O
-independent	O
and	O
not	O
inhibited	O
by	O
actinomycin	O
D	O
or	O
cyclosporin	O
A	O
,	O
and	O
cell	O
cycle	O
arrest	O
at	O
the	O
G2/M	O
interphase	O
was	O
not	O
observed	O
.	O

These	O
features	O
are	O
very	O
different	O
from	O
those	O
observed	O
in	O
B104	B-cell_line
cell	I-cell_line
death	O
induced	O
by	O
anti-IgM	B-protein
Ab	I-protein
.	O

Neither	O
DNA	O
fragmentation	O
nor	O
the	O
morphology	O
of	O
apoptosis	O
was	O
observed	O
.	O

These	O
findings	O
demonstrate	O
that	O
cross-linking	O
of	O
MHC	B-protein
class	I-protein
II	I-protein
molecules	I-protein
transduced	O
the	O
negative	O
signals	O
through	O
intracellular	O
mechanisms	O
different	O
from	O
those	O
present	O
in	O
the	O
cross-linking	O
of	O
surface	O
IgM	B-protein
.	O

Functional	O
block	O
for	O
1	O
alpha	O
,	O
25-dihydroxyvitamin	O
D3-mediated	O
gene	O
regulation	O
in	O
human	B-cell_type
B	I-cell_type
lymphocytes	I-cell_type
.	O

Elements	O
necessary	O
for	O
the	O
steroid	O
hormone	O
1	O
alpha	O
,	O
25-dihydroxyvitamin	O
D3	O
(	O
1	O
alpha	O
,	O
25-	O
(	O
OH	O
)	O
2D3	O
)	O
to	O
induce	O
a	O
biological	O
response	O
include	O
the	O
presence	O
of	O
specific	O
intracellular	B-protein
receptors	I-protein
(	O
vitamin	B-protein
D3	I-protein
receptors	I-protein
(	O
VDR	B-protein
)	O
)	O
and	O
modulation	O
of	O
gene	O
expression	O
via	O
hormone-activated	O
receptor	O
binding	O
to	O
regulatory	B-protein
regions	I-protein
of	O
target	B-DNA
genes	I-DNA
.	O

These	O
parameters	O
were	O
examined	O
in	O
normal	O
and	O
Epstein-Barr	B-cell_line
virus-immortalized	I-cell_line
human	I-cell_line
B	I-cell_line
cells	I-cell_line
and	O
compared	O
with	O
1	B-cell_line
alpha	I-cell_line
,	I-cell_line
25-	I-cell_line
(	I-cell_line
OH	I-cell_line
)	I-cell_line
2D3-responsive	I-cell_line
cells	I-cell_line
of	O
the	O
T	B-cell_type
and	I-cell_type
monocytic	I-cell_type
lineages	I-cell_type
.	O

Although	O
resting	O
tonsillar	O
B	O
cells	O
did	O
not	O
express	O
VDR	B-RNA
mRNA	I-RNA
,	O
activation	O
of	O
these	O
cells	O
with	O
interleukin-4	B-protein
induced	O
VDR	B-protein
in	O
the	O
absence	O
of	O
exogenously	O
supplemented	O
1	O
alpha	O
,	O
25-	O
(	O
OH	O
)	O
2D3	O
.	O

As	O
indicators	O
of	O
hormone-mediated	O
gene	O
regulation	O
we	O
analyzed	O
modulation	O
of	O
CD23	B-protein
,	O
a	O
common	B-protein
B	I-protein
cell/monocyte	I-protein
surface	I-protein
antigen	I-protein
,	O
and	O
24-hydroxylase	B-protein
.	O

1	O
alpha	O
,	O
25-	O
(	O
OH	O
)	O
2D3	O
inhibited	O
CD23	B-protein
expression	O
in	O
U937	B-cell_line
cells	I-cell_line
,	O
yet	O
failed	O
to	O
modulate	O
CD23	B-protein
expression	O
in	O
B	B-cell_type
cells	I-cell_type
.	O

Furthermore	O
,	O
1	O
alpha	O
,	O
25-	O
(	O
OH	O
)	O
2D3	O
induced	O
24-hydroxylase	B-protein
mRNA	O
expression	O
and	O
metabolic	O
activity	O
in	O
both	O
U937	B-cell_line
cells	I-cell_line
and	O
lectin-activated	B-cell_type
T	I-cell_type
cells	I-cell_type
,	O
yet	O
failed	O
to	O
induce	O
24-hydroxylase	B-RNA
mRNA	I-RNA
or	O
its	O
metabolic	O
activity	O
in	O
B	B-cell_type
cells	I-cell_type
.	O

These	O
findings	O
suggest	O
that	O
although	O
human	B-cell_type
B	I-cell_type
lymphocytes	I-cell_type
can	O
express	O
VDR	B-RNA
mRNA	I-RNA
and	O
protein	B-protein
,	O
they	O
exhibit	O
a	O
functional	O
block	O
for	O
vitamin	O
D-dependent	O
gene	O
regulation	O
.	O

Positive	O
and	O
negative	O
regulation	O
of	O
IL-2	B-protein
gene	O
expression	O
:	O
role	O
of	O
multiple	O
regulatory	O
sites	O
.	O

Interleukin	O
2	O
(	O
IL-2	B-protein
)	O
is	O
an	O
important	O
lymphokine	B-protein
required	O
in	O
the	O
process	O
of	O
T	O
cell	O
activation	O
,	O
proliferation	O
,	O
clonal	O
expansion	O
and	O
differentiation	O
.	O

The	O
IL-2	B-DNA
gene	I-DNA
displays	O
both	O
T	O
cell	O
specific	O
and	O
inducible	O
expression	O
:	O
it	O
is	O
only	O
expressed	O
in	O
CD4+	B-cell_type
T	I-cell_type
cells	I-cell_type
after	O
antigenic	O
or	O
mitogenic	O
stimulation	O
.	O

Several	O
cis-acting	B-DNA
regulatory	I-DNA
sites	I-DNA
are	O
required	O
for	O
induction	O
of	O
the	O
IL-2	B-DNA
gene	I-DNA
after	O
stimulation	O
.	O

In	O
this	O
study	O
,	O
we	O
have	O
analysed	O
the	O
function	O
of	O
these	O
cis-acting	B-DNA
regulatory	I-DNA
sites	I-DNA
in	O
the	O
context	O
of	O
the	O
native	O
IL-2	B-DNA
enhancer	I-DNA
and	O
promoter	B-DNA
sequence	I-DNA
.	O

The	O
results	O
of	O
this	O
study	O
suggest	O
that	O
the	O
NFAT	B-protein
(	O
-276	B-DNA
to	I-DNA
-261	I-DNA
)	O
,	O
the	O
distal	B-DNA
octamer	I-DNA
(	O
-256	B-DNA
to	I-DNA
-248	I-DNA
)	O
and	O
the	O
proximal	B-DNA
octamer	I-DNA
(	O
-75	B-DNA
to	I-DNA
-66	I-DNA
)	O
sites	O
not	O
only	O
act	O
as	O
enhancers	O
of	O
IL-2	B-DNA
gene	I-DNA
transcription	O
in	O
the	O
presence	O
of	O
cellular	O
stimulation	O
,	O
but	O
also	O
have	O
a	O
silencing	O
effect	O
on	O
IL-2	B-DNA
gene	I-DNA
expression	O
in	O
resting	O
cells	O
.	O

Two	O
other	O
sites	O
display	O
disparate	O
effects	O
on	O
IL-2	B-DNA
gene	I-DNA
expression	O
in	O
different	O
T	B-cell_line
leukemia	I-cell_line
cell	I-cell_line
lines	I-cell_line
:	O
the	O
distal	B-DNA
purine	I-DNA
box	I-DNA
(	O
-291	B-DNA
to	I-DNA
-277	I-DNA
)	O
and	O
the	O
proximal	B-DNA
purine	I-DNA
box	I-DNA
sites	I-DNA
(	O
-145	B-DNA
to	I-DNA
-128	I-DNA
)	O
.	O

Finally	O
,	O
the	O
AP-1	B-DNA
(	I-DNA
-186	I-DNA
to	I-DNA
-176	I-DNA
)	I-DNA
and	I-DNA
the	I-DNA
kappa	I-DNA
B	I-DNA
sites	I-DNA
(	O
-206	B-DNA
to	I-DNA
-195	I-DNA
)	O
respond	O
to	O
different	O
cellular	O
activation	O
in	O
EL4	B-cell_line
cells	I-cell_line
.	O

The	O
AP-1	B-DNA
site	I-DNA
mediated	O
the	O
response	O
to	O
PMA	O
stimulation	O
while	O
the	O
kappa	B-DNA
B	I-DNA
site	I-DNA
responded	O
to	O
IL-1	B-protein
stimulation	O
.	O

These	O
data	O
suggest	O
that	O
the	O
regulation	O
of	O
IL-2	B-DNA
gene	I-DNA
expression	O
is	O
a	O
complex	O
process	O
and	O
multiple	O
cis-acting	B-DNA
regulatory	I-DNA
sites	I-DNA
interact	O
to	O
exert	O
different	O
effects	O
in	O
T	B-cell_type
cells	I-cell_type
representative	O
of	O
alternative	O
stages	O
of	O
differentiation	O
.	O

Sp1	B-protein
is	O
a	O
critical	O
factor	O
for	O
the	O
monocytic	O
specific	O
expression	O
of	O
human	B-protein
CD14	I-protein
.	O

CD14	B-protein
is	O
a	O
membrane	B-protein
glycoprotein	I-protein
expressed	O
specifically	O
on	O
monocytes	B-cell_type
and	O
macrophages	B-cell_type
,	O
and	O
its	O
expression	O
is	O
markedly	O
increased	O
during	O
the	O
process	O
of	O
monocyte	B-cell_type
differentiation	O
.	O

In	O
order	O
to	O
study	O
CD14	B-DNA
gene	I-DNA
regulation	O
,	O
the	O
human	B-DNA
CD14	I-DNA
gene	I-DNA
was	O
cloned	O
from	O
a	O
partial	O
EcoRI	B-DNA
digested	I-DNA
chromosome	I-DNA
5	I-DNA
library	I-DNA
.	O

A	O
5.5-kilobase	B-DNA
genomic	I-DNA
clone	I-DNA
contained	O
the	O
full-length	O
CD14	B-DNA
coding	I-DNA
sequence	I-DNA
and	O
4.2	B-DNA
kilobases	I-DNA
of	I-DNA
5'-upstream	I-DNA
sequence	I-DNA
.	O

One	O
major	B-DNA
and	I-DNA
one	I-DNA
minor	I-DNA
transcription	I-DNA
start	I-DNA
site	I-DNA
were	O
identified	O
101	B-DNA
and	I-DNA
130	I-DNA
base	I-DNA
pairs	I-DNA
(	I-DNA
bp	I-DNA
)	I-DNA
upstream	I-DNA
,	O
respectively	O
,	O
from	O
the	O
protein	B-DNA
translation	I-DNA
start	I-DNA
ATG	I-DNA
.	O

A	O
DNA	B-DNA
fragment	I-DNA
containing	O
128	B-DNA
bp	I-DNA
of	I-DNA
upstream	I-DNA
sequence	I-DNA
had	O
strong	O
,	O
monocyte-specific	O
promoter	O
activity	O
in	O
the	O
CD14	B-cell_line
positive	I-cell_line
monocytic	I-cell_line
cell	I-cell_line
line	I-cell_line
Mono	B-cell_line
Mac	I-cell_line
6	I-cell_line
as	O
compared	O
to	O
the	O
nonmonocytic	B-cell_line
cell	I-cell_line
lines	I-cell_line
HeLa	B-cell_line
and	O
REX	B-cell_line
.	O

Four	O
regions	O
in	O
this	O
DNA	B-DNA
fragment	I-DNA
interact	O
with	O
nuclear	B-protein
proteins	I-protein
isolated	O
from	O
monocytic	B-cell_type
cells	I-cell_type
.	O

The	O
Sp1	B-protein
transcription	B-protein
factor	I-protein
bound	O
to	O
three	O
different	O
regions	O
in	O
the	O
CD14	B-DNA
promoter	I-DNA
.	O

Mutation	O
of	O
the	O
major	B-DNA
Sp1	I-DNA
binding	I-DNA
site	I-DNA
(	O
-110	B-DNA
bp	I-DNA
)	O
decreased	O
tissue-specific	O
promoter	O
activity	O
,	O
and	O
these	O
results	O
,	O
together	O
with	O
transactivation	O
experiments	O
,	O
demonstrate	O
that	O
Sp1	B-protein
plays	O
a	O
critical	O
role	O
in	O
the	O
tissue-specific	O
expression	O
of	O
CD14	B-protein
in	O
monocytic	B-cell_type
cells	I-cell_type
.	O

CD14	B-protein
Sp1	B-protein
site	O
oligonucleotides	O
bound	O
preferentially	O
to	O
a	O
105-kDa	B-protein
Sp1	I-protein
species	I-protein
,	O
which	O
is	O
present	O
in	O
higher	O
relative	O
levels	O
in	O
monocytic	B-cell_type
than	O
non-monocytic	B-cell_type
cells	I-cell_type
,	O
suggesting	O
that	O
modification	O
of	O
Sp1	B-protein
,	O
such	O
as	O
phosphorylation	O
,	O
may	O
explain	O
how	O
the	O
Sp1	B-protein
site	O
mediates	O
monocytic	O
specific	O
promoter	O
activity	O
.	O

The	O
interleukin-8	B-DNA
AP-1	I-DNA
and	I-DNA
kappa	I-DNA
B-like	I-DNA
sites	I-DNA
are	O
genetic	O
end	O
targets	O
of	O
FK506-sensitive	O
pathway	O
accompanied	O
by	O
calcium	O
mobilization	O
.	O

FK506	O
,	O
an	O
immunosuppressant	O
,	O
inhibits	O
the	O
production	O
of	O
several	O
cytokines	B-protein
in	O
T	B-cell_type
lymphocytes	I-cell_type
.	O

We	O
observed	O
that	O
FK506	O
suppressed	O
the	O
transcription	O
of	O
a	O
chemotactic	B-protein
cytokine	I-protein
,	O
interleukin-8	B-protein
(	O
IL-8	B-protein
)	O
in	O
a	O
human	B-cell_line
T	I-cell_line
cell	I-cell_line
line	I-cell_line
,	O
Jurkat	B-cell_line
cells	I-cell_line
,	O
activated	O
by	O
phorbol	O
12-myristate	O
13-acetate	O
(	O
PMA	O
)	O
and	O
calcium	O
(	O
Ca2+	O
)	O
ionophore	O
(	O
ionomycin	O
)	O
.	O

By	O
deleted	O
and	O
mutated	O
analysis	O
of	O
the	O
IL-8	B-DNA
promoters	I-DNA
,	O
the	O
AP-1	B-DNA
and	I-DNA
kappa	I-DNA
B-like	I-DNA
sites	I-DNA
were	O
identified	O
as	O
the	O
responsive	O
elements	O
for	O
PMA	O
and	O
ionomycin	O
.	O

FK506	O
suppressed	O
the	O
transcriptions	O
through	O
the	O
AP-1	B-DNA
or	O
kappa	B-DNA
B-like	I-DNA
sites	I-DNA
induced	O
by	O
PMA	O
plus	O
Ca	O
(	O
2+	O
)	O
-mobilizing	O
agents	O
,	O
but	O
not	O
those	O
induced	O
by	O
Ca	O
(	O
2+	O
)	O
-independent	O
stimuli	O
.	O

In	O
gel	O
retardation	O
analysis	O
,	O
FK506	O
had	O
little	O
effect	O
on	O
the	O
binding	O
to	O
the	O
AP-1	B-DNA
site	I-DNA
of	O
PMA/ionomycin-induced	O
nuclear	O
factors	O
,	O
which	O
were	O
recognized	O
with	O
anti-JunD	B-protein
or	O
c-Fos	B-protein
antibody	I-protein
.	O

In	O
contrast	O
,	O
FK506	O
or	O
EGTA	O
(	O
Ca2+	O
chelator	O
)	O
similarly	O
affected	O
the	O
formation	O
of	O
kappa	B-protein
B-like	I-protein
site	I-protein
binding	I-protein
complexes	I-protein
,	O
which	O
were	O
not	O
recognized	O
by	O
any	O
antibodies	B-protein
against	O
the	O
human	B-protein
Rel	I-protein
family	I-protein
proteins	I-protein
(	O
c-Rel	B-protein
,	O
p65	B-protein
,	O
p50	B-protein
,	O
and	O
p49	B-protein
)	O
.	O

Furthermore	O
,	O
we	O
confirmed	O
the	O
previous	O
report	O
that	O
FK506	O
suppressed	O
the	O
PMA/ionomycin-induced	O
activation	O
through	O
authentic	O
kappa	B-DNA
B	I-DNA
site	I-DNA
of	O
immunoglobulin	B-DNA
(	I-DNA
Ig	I-DNA
)	I-DNA
gene	I-DNA
,	O
to	O
which	O
NF-kappa	B-protein
B	I-protein
binding	O
was	O
also	O
decreased	O
by	O
FK506	O
,	O
indicating	O
that	O
both	O
IL-8	B-DNA
kappa	I-DNA
B-like	I-DNA
site	I-DNA
and	O
Ig	O
kappa	B-DNA
B	I-DNA
site	I-DNA
are	O
FK506-sensitive	O
in	O
spite	O
of	O
the	O
difference	O
of	O
binding	B-protein
factors	I-protein
.	O

Our	O
results	O
indicate	O
that	O
not	O
only	O
the	O
reported	O
IL-2	B-DNA
NF-AT	I-DNA
and	I-DNA
NFIL-2A	I-DNA
sites	I-DNA
and	O
Ig	O
kappa	B-DNA
B	I-DNA
site	I-DNA
,	O
but	O
also	O
the	O
IL-8	B-protein
AP-1	B-DNA
and	O
kappa	B-DNA
B-like	I-DNA
sites	I-DNA
are	O
terminals	O
of	O
FK506-sensitive	O
pathway	O
involving	O
Ca2+	O
mobilization	O
.	O

Androgen	B-protein
binding	I-protein
sites	I-protein
in	O
peripheral	B-cell_type
human	I-cell_type
mononuclear	I-cell_type
leukocytes	I-cell_type
of	O
healthy	O
males	O
and	O
females	O
.	O

Androgen	B-protein
binding	I-protein
sites	I-protein
have	O
been	O
identified	O
in	O
circulating	B-cell_type
human	I-cell_type
mononuclear	I-cell_type
leukocytes	I-cell_type
of	O
healthy	O
donors	O
of	O
both	O
sexes	O
.	O

Cells	O
were	O
separated	O
from	O
blood	O
samples	O
on	O
a	O
Ficoll	O
gradient	O
and	O
incubated	O
with	O
different	O
concentrations	O
of	O
[	O
3H	O
]	O
testosterone	O
in	O
the	O
presence	O
or	O
absence	O
of	O
a	O
400-fold	O
excess	O
of	O
unlabelled	O
testosterone	O
.	O

Binding	O
data	O
were	O
derived	O
from	O
Scatchard	O
analysis	O
.	O

The	O
binding	B-protein
sites	I-protein
fulfil	O
the	O
required	O
criteria	O
for	O
specific	O
steroid	B-protein
binding	I-protein
sites	I-protein
however	O
differ	O
somewhat	O
from	O
the	O
classic	O
androgen	B-protein
receptors	I-protein
from	O
genital	B-cell_type
skin	I-cell_type
fibroblast	I-cell_type
:	O
in	O
fertile	O
adult	O
males	O
(	O
n	O
=	O
20	O
)	O
the	O
binding	B-protein
sites	I-protein
showed	O
(	O
1	O
)	O
a	O
high	O
affinity	O
for	O
testosterone	O
(	O
1.32	O
+/-	O
0.49	O
nM	O
;	O
mean	O
+/-	O
SD	O
)	O
,	O
(	O
2	O
)	O
a	O
saturable	O
capacity	O
(	O
184	O
+/-	O
52	O
binding	B-protein
sites	I-protein
per	O
cell	O
;	O
mean	O
+/-	O
SD	O
)	O
,	O
and	O
(	O
3	O
)	O
a	O
characteristic	O
competitive	O
binding	O
profile	O
for	O
other	O
steroid	O
hormones	O
(	O
relative	O
binding	O
affinities	O
:	O
testosterone	O
=	O
dihydrotestosterone	O
>	O
17	O
beta-estradiol	O
>	O
progesterone	O
,	O
whereas	O
aldosterone	O
,	O
17-hydroxy-progesterone	O
and	O
cortisol	O
did	O
not	O
compete	O
appreciably	O
)	O
.	O

Furthermore	O
the	O
number	O
of	O
binding	B-protein
sites	I-protein
determined	O
using	O
[	O
3H	O
]	O
dihydrotestosterone	O
,	O
[	O
3H	O
]	O
RU-1881	O
,	O
or	O
[	O
3H	O
]	O
testosterone	O
were	O
comparable	O
.	O

This	O
raises	O
the	O
possibility	O
that	O
androgen	B-protein
receptors	I-protein
in	O
peripheral	B-cell_type
mononuclear	I-cell_type
leukocytes	I-cell_type
differ	O
from	O
those	O
in	O
genital	B-cell_type
skin	I-cell_type
fibroblasts	I-cell_type
.	O

There	O
was	O
no	O
apparent	O
correlation	O
between	O
serum	O
testosterone	O
concentrations	O
and	O
androgen	B-protein
binding	I-protein
sites	I-protein
.	O

In	O
fertile	O
women	O
remarkable	O
changes	O
in	O
androgen	B-protein
binding	I-protein
sites	I-protein
were	O
seen	O
in	O
the	O
course	O
of	O
the	O
menstrual	O
cycle	O
,	O
with	O
a	O
significant	O
increase	O
in	O
the	O
immediate	O
preovulatory	O
period	O
.	O

The	O
presence	O
of	O
androgen	B-protein
receptors	I-protein
in	O
peripheral	B-cell_type
mononuclear	I-cell_type
leukocytes	I-cell_type
provides	O
for	O
the	O
first	O
time	O
the	O
experimental	O
basis	O
for	O
an	O
hypothesis	O
of	O
direct	O
,	O
receptor-mediated	O
effects	O
of	O
androgens	O
on	O
mature	B-cell_type
immunocompetent	I-cell_type
cells	I-cell_type
.	O

The	O
immunological	O
implications	O
of	O
these	O
results	O
are	O
discussed	O
.	O

Induction	O
of	O
IL-8	B-protein
expression	O
in	O
T	B-cell_type
cells	I-cell_type
uses	O
the	O
CD28	B-protein
costimulatory	O
pathway	O
.	O

IL-8	B-protein
,	O
a	O
potent	O
chemotactic	B-protein
factor	I-protein
for	O
neutrophil	B-cell_type
granulocytes	I-cell_type
and	O
lymphocytes	B-cell_type
,	O
is	O
a	O
proinflammatory	O
cytokine	O
secreted	O
by	O
a	O
variety	O
of	O
cell	O
types	O
,	O
including	O
T	B-cell_type
cells	I-cell_type
.	O

Stimulation	O
of	O
the	O
CD28	B-protein
cell	I-protein
surface	I-protein
molecule	I-protein
delivers	O
costimulatory	O
signals	O
essential	O
for	O
lymphokine	B-protein
production	O
in	O
activated	B-cell_type
T	I-cell_type
cells	I-cell_type
via	O
a	O
conserved	B-DNA
sequence	I-DNA
element	I-DNA
found	O
in	O
the	O
promoter	B-DNA
of	O
several	O
lymphokine	B-DNA
genes	I-DNA
.	O

Anti-CD28-stimulated	B-cell_line
T	I-cell_line
cells	I-cell_line
produced	O
significant	O
amounts	O
of	O
IL-8	B-protein
;	O
additionally	O
,	O
costimulation	O
with	O
anti-CD3	B-protein
and	O
anti-CD28	B-protein
Abs	I-protein
resulted	O
in	O
a	O
synergistic	O
induction	O
of	O
IL-8	B-protein
secretion	O
.	O

Sequence	O
homology	O
,	O
single	O
nucleotide	O
mutations	O
,	O
and	O
anti-CD28	B-protein
Ab	I-protein
stimulation	O
studies	O
established	O
that	O
the	O
NF-kappa	B-DNA
B-like	I-DNA
sequence	I-DNA
in	O
the	O
promoter	B-DNA
of	O
the	O
IL-8	B-DNA
gene	I-DNA
functioned	O
as	O
a	O
CD28	B-DNA
response	I-DNA
element	I-DNA
.	O

Furthermore	O
,	O
cyclosporin	O
A	O
,	O
but	O
not	O
rapamycin	O
,	O
blocked	O
the	O
synergistic	O
induction	O
of	O
IL-8	B-protein
expression	O
achieved	O
with	O
anti-CD3	B-protein
and	O
anti-	O
CD28	B-protein
costimulation	O
.	O

The	O
involvement	O
of	O
a	O
CD28	B-DNA
response	I-DNA
element	I-DNA
in	O
the	O
induction	O
of	O
IL-8	B-protein
expression	O
in	O
activated	B-cell_type
T	I-cell_type
cells	I-cell_type
may	O
provide	O
new	O
insights	O
into	O
the	O
pathogenesis	O
and	O
persistence	O
of	O
immune	O
disorders	O
characterized	O
by	O
increased	O
levels	O
of	O
IL-8	B-protein
,	O
such	O
as	O
psoriasis	O
and	O
rheumatoid	O
arthritis	O
.	O

MHC	B-protein
class	I-protein
II	I-protein
signaling	O
in	O
B-cell	B-cell_type
activation	O
[	O
see	O
comments	O
]	O

The	O
cognate	O
interaction	O
between	O
T	B-cell_type
cells	I-cell_type
and	O
antigen-presenting	B-cell_type
cells	I-cell_type
(	O
APCs	B-cell_type
)	O
,	O
mediated	O
by	O
major	B-protein
histocompatibility	I-protein
complex	I-protein
(	I-protein
MHC	I-protein
)	I-protein
class	I-protein
II	I-protein
molecules	I-protein
,	O
results	O
in	O
the	O
delivery	O
of	O
activation	O
signals	O
to	O
the	O
APC	B-cell_type
.	O

These	O
signals	O
contribute	O
to	O
the	O
expression	O
of	O
co-stimulatory	O
activity	O
by	O
APCs	B-cell_type
and	O
have	O
important	O
consequences	O
for	O
cell	O
effector	O
function	O
.	O

MHC	B-protein
class	I-protein
II	I-protein
molecules	O
also	O
serve	O
as	O
receptors	O
for	O
B-cell	B-cell_type
stimulation	O
by	O
microbial	B-protein
superantigens	I-protein
.	O

In	O
this	O
review	O
,	O
Paul	O
Scholl	O
and	O
Raif	O
Geha	O
discuss	O
recent	O
advances	O
in	O
our	O
understanding	O
of	O
mechanisms	O
of	O
MHC	B-protein
class	I-protein
II	I-protein
signaling	O
and	O
analyse	O
their	O
role	O
in	O
human	O
B-cell	B-cell_type
activation	O
.	O

Effects	O
of	O
glucocorticoids	O
in	O
rheumatoid	O
arthritis	O
.	O

Diminished	O
glucocorticoid	B-protein
receptors	I-protein
do	O
not	O
result	O
in	O
glucocorticoid	O
resistance	O
.	O

OBJECTIVE	O
.	O

Lymphocytes	O
of	O
patients	O
with	O
rheumatoid	O
arthritis	O
(	O
RA	O
)	O
have	O
diminished	O
receptor	O
density	O
;	O
thus	O
,	O
patients	O
with	O
RA	O
should	O
show	O
partial	O
resistance	O
to	O
glucocorticoids	O
.	O

We	O
investigated	O
the	O
glucocorticoid	O
sensitivity	O
of	O
lymphocytes	B-cell_type
in	O
RA	O
patients	O
compared	O
with	O
healthy	O
subjects	O
.	O

METHODS	O
.	O

We	O
determined	O
the	O
effects	O
of	O
glucocorticoids	O
on	O
lymphocyte	B-cell_type
proliferation	O
and	O
cytokine	B-protein
release	O
.	O

RESULTS	O
.	O

Proliferation	O
and	O
cytokine	B-protein
release	O
were	O
inhibited	O
in	O
RA	O
patients	O
to	O
the	O
same	O
extent	O
as	O
in	O
healthy	O
controls	O
.	O

CONCLUSION	O
.	O

Diminished	O
receptor	O
density	O
in	O
RA	O
patients	O
does	O
not	O
result	O
in	O
glucocorticoid	O
resistance	O
.	O

Arrested	O
development	O
:	O
understanding	O
v-abl	B-DNA
.	O

The	O
protein	B-protein
tyrosine	I-protein
kinase	I-protein
activity	O
of	O
the	O
v-abl	B-DNA
oncogene	I-DNA
has	O
been	O
demonstrated	O
to	O
subvert	O
the	O
normal	O
second	O
messenger	O
systems	O
used	O
by	O
lymphoid	B-cell_type
cells	I-cell_type
for	O
growth	O
and	O
differentiation	O
.	O

Transformation	O
of	O
bone	O
marrow	O
with	O
the	O
Abelson	O
murine	O
leukemia	O
virus	O
results	O
in	O
the	O
appearance	O
of	O
B	B-cell_type
cell	I-cell_type
lineage	I-cell_type
cells	I-cell_type
arrested	O
at	O
the	O
pre-B	O
cell	O
stage	O
.	O

Recent	O
reports	O
have	O
characterized	O
these	O
cells	O
expressing	O
high	O
v-abl	B-DNA
kinase	O
activity	O
as	O
deficient	O
in	O
detectable	O
NF-kappaB	B-protein
DNA	O
binding	O
activity	O
and	O
low	O
level	O
RAG	B-DNA
gene	I-DNA
expression	O
.	O

These	O
observations	O
suggest	O
that	O
v-abl	B-DNA
may	O
be	O
inhibiting	O
the	O
differentiation	O
of	O
B	B-cell_type
cells	I-cell_type
by	O
blocking	O
these	O
two	O
crucial	O
elements	O
in	O
the	O
maturation	O
pathway	O
.	O

Corticosteroid	B-protein
receptors	I-protein
in	O
lymphocytes	B-cell_type
:	O
a	O
possible	O
marker	O
of	O
brain	O
involution	O
?	O

A	O
similarity	O
has	O
recently	O
been	O
found	O
between	O
the	O
regulation	O
of	O
corticosteroid	B-protein
receptors	I-protein
in	O
brain	O
and	O
in	O
lymphoid	O
tissue	O
.	O

We	O
have	O
studied	O
the	O
regulation	O
of	O
corticosteroid	B-protein
receptors	I-protein
in	O
human	B-cell_type
mononuclear	I-cell_type
leukocytes	I-cell_type
as	O
a	O
possible	O
marker	O
of	O
brain	O
involution	O
.	O

Type	B-protein
I	I-protein
corticosteroid	I-protein
receptors	I-protein
are	O
down	O
regulated	O
by	O
excess	O
of	O
mineralocorticoids	O
(	O
primary	O
and	O
secondary	O
hyperaldosteronism	O
,	O
pseudohyperaldosteronism	O
)	O
and	O
of	O
glucocorticoids	O
(	O
Cushing	O
's	O
syndrome	O
)	O
.	O
Type	B-protein
II	I-protein
corticosteroid	I-protein
receptors	I-protein
are	O
not	O
reduced	O
by	O
excess	O
of	O
endogenous	O
corticosteroids	O
(	O
Cushing	O
's	O
syndrome	O
)	O
.	O

In	O
normal	O
adults	O
there	O
is	O
a	O
direct	O
significant	O
correlation	O
between	O
plasma	O
cortisol	O
and	O
Type	B-protein
I	I-protein
and	O
between	O
plasma	O
cortisol	O
and	O
Type	B-protein
II	I-protein
receptors	I-protein
in	O
mononuclear	B-cell_type
leukocytes	I-cell_type
,	O
while	O
in	O
Cushing	O
's	O
syndrome	O
the	O
correlation	O
is	O
inverse	O
between	O
plasma	O
cortisol	O
at	O
8	O
a.m.	O
and	O
Type	B-protein
II	I-protein
receptors	I-protein
.	O

In	O
an	O
aged	O
population	O
the	O
mean	O
numbers	O
of	O
Type	B-protein
I	I-protein
and	O
of	O
Type	B-protein
II	I-protein
receptors	I-protein
are	O
lower	O
and	O
plasma	O
cortisol	O
is	O
higher	O
than	O
in	O
adult	O
controls	O
,	O
but	O
the	O
increase	O
of	O
plasma	O
cortisol	O
is	O
not	O
followed	O
by	O
a	O
clinical	O
picture	O
of	O
hypercorticism	O
.	O

Corticosteroid	B-protein
Type	I-protein
I	I-protein
and	I-protein
Type	I-protein
II	I-protein
receptors	I-protein
are	O
inversely	O
correlated	O
with	O
age	O
.	O

After	O
dexamethasone	O
suppression	O
(	O
1	O
mg	O
at	O
11	O
p.m.	O
)	O
Type	B-protein
I	I-protein
receptors	I-protein
always	O
decrease	O
in	O
controls	O
while	O
the	O
response	O
of	O
Type	B-protein
II	I-protein
is	O
not	O
homogeneous	O
.	O

In	O
an	O
aged	O
group	O
of	O
patients	O
,	O
both	O
receptors	O
are	O
reduced	O
by	O
dexamethasone	O
.	O

We	O
conclude	O
that	O
the	O
decrease	O
with	O
age	O
of	O
corticosteroid	B-protein
receptors	I-protein
is	O
possibly	O
related	O
to	O
a	O
physiological	O
involution	O
of	O
corticosteroid	B-protein
receptors	I-protein
and	O
that	O
this	O
reduction	O
does	O
increase	O
plasma	O
cortisol	O
concentration	O
,	O
without	O
affecting	O
the	O
glucocorticoid	O
effector	O
mechanism	O
.	O

All-trans	O
retinoic	O
acid	O
and	O
1	O
alpha	O
,	O
25-dihydroxyvitamin	O
D3	O
co-operate	O
to	O
promote	O
differentiation	O
of	O
the	O
human	B-cell_line
promyeloid	I-cell_line
leukemia	I-cell_line
cell	I-cell_line
line	I-cell_line
HL60	B-cell_line
to	O
monocytes	B-cell_type
.	O

A	O
basis	O
for	O
differentiation	O
therapy	O
of	O
leukemias	O
is	O
provided	O
by	O
knowledge	O
of	O
agents	O
which	O
induce	O
specific	O
lineage	O
maturation	O
.	O

All-trans	O
retinoic	O
acid	O
(	O
RA	O
)	O
induces	O
differentiation	O
of	O
HL60	B-cell_line
cells	I-cell_line
to	O
neutrophils	B-cell_type
and	O
is	O
used	O
to	O
treat	O
acute	O
promyelocytic	O
leukemia	O
.	O

We	O
observed	O
that	O
RA	O
did	O
not	O
induced	O
neutrophil	O
differentiation	O
in	O
serum-free	B-cell_line
grown	I-cell_line
HL60	I-cell_line
cells	I-cell_line
whereas	O
50	O
nM	O
1	O
alpha	O
,	O
25-dihydroxyvitamin	O
D3	O
(	O
D3	O
)	O
induced	O
maximal	O
monocyte	O
differentiation	O
.	O

Increasing	O
RA	O
concentrations	O
reduced	O
the	O
D3	O
concentration	O
required	O
for	O
monocyte	O
differentiation	O
.	O

Cells	O
treated	O
with	O
5	O
nM	O
D3	O
showed	O
little	O
response	O
,	O
but	O
differentiated	O
maximally	O
with	O
5	O
nM	O
D3	O
and	O
10	O
nM	O
RA	O
.	O

The	O
D3	O
analogs	O
MC903	O
,	O
EB1089	O
and	O
KH1060	O
were	O
more	O
potent	O
inducers	O
of	O
monocyte	O
differentiation	O
.	O

The	O
extent	O
to	O
which	O
analog	O
activity	O
was	O
increased	O
after	O
cotreatment	O
with	O
RA	O
was	O
inversely	O
related	O
to	O
potency	O
.	O

Twenty-four	O
hour	O
treatment	O
with	O
10	O
nM	O
RA	B-cell_line
primed	I-cell_line
cells	I-cell_line
for	O
response	O
to	O
5	O
nM	O
D3	O
;	O
the	O
reverse	O
sequence	O
being	O
ineffective	O
.	O

Priming	O
with	O
10	O
nM	O
RA	O
,	O
or	O
subsequent	O
treatment	O
with	O
D3	O
(	O
5	O
nM	O
)	O
,	O
did	O
not	O
alter	O
expression	O
of	O
mRNAs	B-RNA
encoding	O
receptors	B-protein
for	O
D3	O
(	O
VDR	B-protein
)	O
,	O
RA	O
(	O
RAR	B-protein
alpha	I-protein
)	O
or	O
9-CIS	O
RA	O
(	O
RXR	B-protein
alpha	I-protein
,	I-protein
beta	I-protein
,	I-protein
gamma	I-protein
)	O
.	O

That	O
RA	O
promotes	O
both	O
neutrophil	O
and	O
monocyte	O
differentiation	O
has	O
implications	O
for	O
the	O
use	O
of	O
RA	O
and	O
D3	O
in	O
treatment	O
of	O
leukemias	O
and	O
provides	O
insight	O
into	O
mechanisms	O
whereby	O
RAR	O
,	O
VDR	B-protein
and	O
RXR	B-protein
facilitate	O
monocyte	O
differentiation	O
.	O

[	O
An	O
overexpression	O
of	O
retinoic	B-protein
acid	I-protein
receptor	I-protein
alpha	I-protein
blocks	O
myeloid	B-cell_type
cell	I-cell_type
differentiation	O
at	O
the	O
promyelocyte	O
stage	O
]	O

Retinoic	O
acid	O
(	O
RA	O
)	O
,	O
a	O
vitamin	O
A	O
derivative	O
,	O
exerts	O
a	O
wide	O
range	O
of	O
biological	O
effects	O
related	O
to	O
cell	O
proliferation	O
and	O
differentiation	O
.	O

The	O
pleiotropic	O
effects	O
of	O
RA	O
are	O
thought	O
to	O
be	O
mediated	O
through	O
specific	O
nuclear	O
RA	B-protein
receptors	I-protein
(	O
RARs	B-protein
)	O
.	O

RARs	B-protein
are	O
members	O
of	O
the	O
steroid/thyroid	B-protein
hormone	I-protein
receptor	I-protein
superfamily	I-protein
and	O
exhibit	O
a	O
molecular	O
structure	O
that	O
possess	O
discrete	O
DNA-binding	O
and	O
RA	B-protein
(	I-protein
ligand	I-protein
)	I-protein
-binding	I-protein
domains	I-protein
.	O

In	O
hematopoietic	O
system	O
,	O
RA	O
and	O
RARs	B-protein
,	O
predominantly	O
RAR	B-protein
alpha	I-protein
may	O
play	O
key	O
roles	O
for	O
the	O
proliferation	O
and	O
differentiation	O
of	O
hematopoietic	B-cell_type
progenitors	I-cell_type
.	O

However	O
,	O
it	O
is	O
currently	O
unknown	O
how	O
RA	O
and	O
RARs	B-protein
are	O
involved	O
in	O
regulating	O
normal	O
hematopoietic	O
differentiation	O
.	O

To	O
make	O
clear	O
the	O
roles	O
of	O
RA	O
and	O
RAR	B-protein
alpha	I-protein
in	O
the	O
normal	O
hematopoiesis	O
,	O
I	O
have	O
introduced	O
the	O
construct	O
of	O
human	B-protein
RAR	I-protein
alpha	I-protein
(	O
hRAR	B-protein
alpha	I-protein
)	O
into	O
murine	B-cell_type
bone	I-cell_type
marrow	I-cell_type
cells	I-cell_type
with	O
retroviral	O
vector	O
,	O
and	O
selected	O
infected	O
cells	O
with	O
drug	B-DNA
resistant	I-DNA
marker	I-DNA
(	O
Neo	B-DNA
(	I-DNA
r	I-DNA
)	I-DNA
)	O
cultured	O
on	O
the	O
stroma	B-cell_line
cell	I-cell_line
line	I-cell_line
(	O
PA6-neo	B-cell_line
)	O
,	O
and	O
analyzed	O
the	O
behavior	O
of	O
infected	B-cell_type
cells	I-cell_type
.	O

All	O
of	O
procedure	O
were	O
done	O
in	O
vitro	O
.	O

Most	O
cells	O
infected	O
with	O
hRAR	B-protein
alpha	I-protein
exhibited	O
promyelocytic	B-cell_type
morphology	I-cell_type
and	O
were	O
thought	O
to	O
be	O
blocked	O
at	O
the	O
promyelocytic	O
stage	O
in	O
their	O
myeloid	O
differentiation	O
.	O

Furthermore	O
,	O
these	O
immature	B-cell_type
cells	I-cell_type
differentiated	O
terminally	O
into	O
mature	O
granulocytes	O
by	O
adding	O
with	O
RA	O
(	O
10	O
(	O
-6	O
)	O
M	O
)	O
.	O

RAR	B-protein
alpha	I-protein
infected	B-cell_type
cells	I-cell_type
were	O
also	O
able	O
to	O
differentiate	O
into	O
mature	B-cell_type
macrophages	I-cell_type
in	O
the	O
both	O
of	O
long	O
term	O
culture	O
and	O
IL3	B-cell_line
colony	I-cell_line
.	O

These	O
observations	O
suggest	O
that	O
an	O
overexpression	O
of	O
RAR	B-protein
alpha	I-protein
alone	O
is	O
effective	O
to	O
suppress	O
myeloid	B-cell_type
cell	I-cell_type
differentiation	O
and	O
RAR	B-protein
alpha	I-protein
plays	O
a	O
crucial	O
role	O
in	O
the	O
terminal	O
differentiation	O
of	O
myeloid	O
precursors	O
.	O

The	O
system	O
described	O
here	O
may	O
serve	O
as	O
a	O
model	O
for	O
studying	O
the	O
the	O
essential	B-DNA
genes	I-DNA
for	O
differentiation	O
of	O
normal	B-cell_type
bone	I-cell_type
marrow	I-cell_type
cells	I-cell_type
.	O

Hypoxic	O
induction	O
of	O
interleukin-8	B-DNA
gene	I-DNA
expression	O
in	O
human	B-cell_type
endothelial	I-cell_type
cells	I-cell_type
.	O

Because	O
leukocyte-mediated	O
tissue	O
damage	O
is	O
an	O
important	O
component	O
of	O
the	O
pathologic	O
picture	O
in	O
ischemia/reperfusion	O
,	O
we	O
have	O
sought	O
mechanisms	O
by	O
which	O
PMNs	B-cell_type
are	O
directed	O
into	O
hypoxic	O
tissue	O
.	O

Incubation	O
of	O
human	B-cell_type
endothelial	I-cell_type
cells	I-cell_type
(	O
ECs	B-cell_type
)	O
in	O
hypoxia	O
,	O
PO2	O
approximately	O
14-18	O
Torr	O
,	O
led	O
to	O
time-dependent	O
release	O
of	O
IL-8	B-protein
antigen	O
into	O
the	O
conditioned	O
medium	O
;	O
this	O
was	O
accompanied	O
by	O
increased	O
chemotactic	O
activity	O
for	O
PMNs	B-cell_type
,	O
blocked	O
by	O
antibody	O
to	O
IL-8	B-protein
.	O

Production	O
of	O
IL-8	B-protein
by	O
hypoxic	O
ECs	B-cell_type
occurred	O
concomitantly	O
with	O
both	O
increased	O
levels	O
of	O
IL-8	B-RNA
mRNA	I-RNA
,	O
based	O
on	O
polymerase	O
chain	O
reaction	O
analysis	O
,	O
and	O
increased	O
IL-8	B-protein
transcription	O
,	O
based	O
on	O
nuclear	O
run-on	O
assays	O
.	O

Northern	O
analysis	O
of	O
mRNA	O
from	O
hypoxic	O
ECs	B-cell_type
also	O
demonstrated	O
increased	O
levels	O
of	O
mRNA	B-RNA
for	O
macrophage	B-protein
chemotactic	I-protein
protein-1	I-protein
,	O
another	O
member	O
of	O
the	O
chemokine	B-protein
superfamily	I-protein
of	O
proinflammatory	B-protein
cytokines	I-protein
.	O

IL-8	B-DNA
gene	I-DNA
induction	O
was	O
associated	O
with	O
the	O
presence	O
of	O
increased	O
binding	O
activity	O
in	O
nuclear	O
extracts	O
from	O
hypoxic	B-cell_type
ECs	I-cell_type
for	O
the	O
NF-kB	O
site	O
.	O

Studies	O
with	O
human	O
umbilical	O
vein	O
segments	O
exposed	O
to	O
hypoxia	O
also	O
demonstrated	O
increased	O
elaboration	O
of	O
IL-8	B-protein
antigen	I-protein
compared	O
with	O
normoxic	O
controls	O
.	O

In	O
mice	O
exposed	O
to	O
hypoxia	O
(	O
PO2	O
approximately	O
30-40	O
Torr	O
)	O
,	O
there	O
was	O
increased	O
pulmonary	O
leukostasis	O
,	O
as	O
evidenced	O
by	O
increased	O
myeloperoxidase	B-protein
activity	O
in	O
tissue	O
homogenates	O
.	O

In	O
parallel	O
,	O
increased	O
levels	O
of	O
transcripts	O
for	O
IP-10	B-protein
,	O
a	O
murine	O
homologue	O
in	O
the	O
chemokine	B-protein
family	I-protein
related	O
to	O
IL-8	B-protein
,	O
were	O
observed	O
in	O
hypoxic	O
lung	O
tissue	O
.	O

Taken	O
together	O
,	O
these	O
data	O
suggest	O
that	O
hypoxia	O
constitutes	O
a	O
stimulus	O
for	O
leukocyte	O
chemotaxis	O
and	O
tissue	O
leukostasis	O
.	O

Thrombin	B-protein
and	O
thrombin	B-protein
receptor	I-protein
agonist	O
peptide	O
induce	O
early	O
events	O
of	O
T	O
cell	O
activation	O
and	O
synergize	O
with	O
TCR	B-protein
cross-linking	O
for	O
CD69	B-protein
expression	O
and	O
interleukin	O
2	O
production	O
.	O

Thrombin	B-protein
stimulation	O
of	O
the	O
T	B-cell_line
leukemic	I-cell_line
cell	I-cell_line
line	I-cell_line
Jurkat	I-cell_line
induced	O
a	O
transient	O
increase	O
in	O
[	O
Ca2+	O
]	O
i	O
.	O

Proteolytic	O
activity	O
of	O
the	O
enzyme	B-protein
was	O
required	O
for	O
this	O
effect	O
since	O
diisopropyl	B-protein
fluorophosphate-thrombin	I-protein
failed	O
to	O
increase	O
[	O
Ca2+	O
]	O
i	O
.	O

Furthermore	O
,	O
hirudin	O
and	O
anti-thrombin	B-protein
III	I-protein
inhibited	O
the	O
thrombin-induced	O
[	O
Ca2+	O
]	O
i	O
rise	O
in	O
Jurkat	B-cell_line
T	I-cell_line
cells	I-cell_line
.	O

A	O
synthetic	O
thrombin	B-protein
receptor	I-protein
agonist	O
peptide	O
(	O
TRP	O
)	O
of	O
7	O
residues	O
(	O
SFLLRNP	O
)	O
was	O
found	O
to	O
be	O
as	O
effective	O
as	O
thrombin	B-protein
for	O
[	O
Ca2+	O
]	O
i	O
mobilization	O
,	O
and	O
both	O
agonists	O
induced	O
Ca2+	O
release	O
exclusively	O
from	O
internal	O
stores	O
.	O

Thrombin	B-protein
stimulated	O
tyrosine	O
phosphorylation	O
of	O
several	O
proteins	O
of	O
molecular	B-protein
mass	I-protein
40	I-protein
,	I-protein
42	I-protein
,	I-protein
70	I-protein
,	I-protein
120	I-protein
,	I-protein
and	I-protein
130	I-protein
kDa	I-protein
.	O

There	O
was	O
a	O
good	O
correlation	O
between	O
thrombin	B-protein
-induced	O
tyrosine	O
phosphorylation	O
of	O
the	O
latter	O
three	O
proteins	O
and	O
Ca2+	O
mobilization	O
.	O

Thrombin	B-protein
and	O
TRP	O
also	O
caused	O
translocation	O
of	O
protein	B-protein
kinase	I-protein
C	I-protein
from	O
the	O
cytosol	O
to	O
the	O
plasma	O
membrane	O
.	O

As	O
a	O
likely	O
consequence	O
of	O
these	O
events	O
,	O
thrombin	B-protein
activated	O
the	O
nuclear	B-protein
factor	I-protein
NF-kB	I-protein
.	O

Several	O
cell	O
lines	O
of	O
hematopoietic	O
origin	O
including	O
the	O
leukemic	B-cell_line
T	I-cell_line
cell	I-cell_line
line	I-cell_line
HPB.ALL	I-cell_line
and	O
the	O
erythroleukemic	B-cell_line
cell	I-cell_line
line	I-cell_line
K562	I-cell_line
were	O
responsive	O
to	O
thrombin	B-protein
,	O
whereas	O
others	O
such	O
as	O
THP1	B-cell_line
,	O
a	O
myelomonocytic	B-cell_line
cell	I-cell_line
line	I-cell_line
,	O
and	O
BL2	B-cell_line
,	I-cell_line
a	O
Burkitt	B-cell_line
lymphoma	I-cell_line
were	O
refractory	O
to	O
thrombin	B-protein
or	O
TRP	O
stimulation	O
.	O

The	O
magnitude	O
of	O
the	O
thrombin	B-protein
response	O
in	O
the	O
different	O
cell	O
types	O
paralleled	O
the	O
expression	O
of	O
the	O
thrombin	B-RNA
receptor	I-RNA
mRNA	I-RNA
.	O

We	O
found	O
that	O
activation	O
of	O
Jurkat	B-cell_line
T	I-cell_line
cells	I-cell_line
by	O
a	O
combination	O
of	O
phytohemagglutinin	B-protein
and	O
phorbol	O
12-myristate	O
13-acetate	O
led	O
to	O
a	O
dramatic	O
inhibition	O
of	O
thrombin	B-RNA
receptor	I-RNA
mRNA	I-RNA
expression	O
and	O
to	O
a	O
concomitant	O
loss	O
of	O
the	O
thrombin	B-protein
response	O
.	O

Finally	O
,	O
we	O
demonstrate	O
that	O
thrombin	B-protein
and	O
TRP	O
enhanced	O
CD69	B-protein
expression	O
and	O
interleukin	B-protein
2	I-protein
production	O
induced	O
by	O
T	B-protein
cell	I-protein
receptor	I-protein
cross-linking	O
in	O
both	O
Jurkat	B-cell_line
T	I-cell_line
cells	I-cell_line
and	O
peripheral	O
blood	O
lymphocytes	B-cell_type
.	O

These	O
findings	O
highlight	O
the	O
role	O
of	O
thrombin	B-protein
as	O
a	O
potential	O
regulator	O
of	O
T	B-cell_type
lymphocyte	I-cell_type
activation	O
.	O

Stress	O
response	O
of	O
senescent	B-cell_type
T	I-cell_type
lymphocytes	I-cell_type
:	O
reduced	O
hsp70	B-protein
is	O
independent	O
of	O
the	O
proliferative	O
block	O
.	O

Senescent	B-cell_line
human	I-cell_line
T	I-cell_line
lymphocyte	I-cell_line
cultures	I-cell_line
are	O
unable	O
to	O
undergo	O
proliferation	O
,	O
but	O
show	O
no	O
difference	O
from	O
early	B-cell_line
passage	I-cell_line
cells	I-cell_line
in	O
cytotoxic	O
function	O
or	O
surface	O
antigenic	O
profile	O
.	O

A	O
second	O
feature	O
of	O
senescent	B-cell_line
T	I-cell_line
cells	I-cell_line
is	O
the	O
dramatic	O
reduction	O
in	O
hsp70	B-protein
production	O
in	O
response	O
to	O
heat	O
shock	O
.	O

This	O
decline	O
is	O
associated	O
with	O
a	O
decrease	O
in	O
binding	O
of	O
nuclear	O
extracts	O
to	O
the	O
consensus	B-DNA
heat	I-DNA
shock	I-DNA
element	I-DNA
.	O

Interestingly	O
,	O
the	O
progressive	O
decline	O
in	O
the	O
heat	O
shock	O
response	O
of	O
cultured	B-cell_line
T	I-cell_line
cells	I-cell_line
correlates	O
with	O
the	O
percent	O
proliferative	O
life	O
span	O
completed	O
rather	O
than	O
with	O
the	O
actual	O
proliferative	O
activity	O
at	O
the	O
time	O
of	O
heat	O
shock	O
.	O

This	O
suggests	O
that	O
for	O
senescent	B-cell_type
T	I-cell_type
cells	I-cell_type
the	O
reduced	O
ability	O
to	O
respond	O
to	O
heat	O
shock	O
by	O
producing	O
hsp70	B-protein
,	O
although	O
possibly	O
lying	O
at	O
the	O
level	O
of	O
transcriptional	O
control	O
,	O
may	O
nevertheless	O
be	O
unrelated	O
to	O
the	O
reduced	O
DNA	O
synthesis	O
or	O
the	O
diminished	O
proliferative	O
activity	O
also	O
manifested	O
by	O
these	O
cells	O
.	O

Involvement	O
of	O
phospholipase	B-protein
D	I-protein
in	O
the	O
activation	O
of	O
transcription	B-protein
factor	I-protein
AP-1	I-protein
in	O
human	B-cell_line
T	I-cell_line
lymphoid	I-cell_line
Jurkat	I-cell_line
cells	I-cell_line
.	O

The	O
induction	O
of	O
the	O
AP-1	B-protein
transcription	B-protein
factor	I-protein
has	O
been	O
ascribed	O
to	O
the	O
early	O
events	O
leading	O
to	O
T	O
lymphocyte	O
activation	O
.	O

We	O
have	O
examined	O
the	O
possibility	O
that	O
stimulation	O
of	O
phospholipase	B-protein
D	I-protein
(	O
PLD	B-protein
)	O
may	O
regulate	O
activation	O
of	O
transcription	B-protein
factor	I-protein
AP-1	I-protein
in	O
human	O
T	O
cells	O
by	O
transfecting	O
human	O
T	B-cell_line
lymphocyte	I-cell_line
Jurkat	I-cell_line
cells	I-cell_line
with	O
a	O
plasmid	O
containing	O
an	O
AP-1	B-DNA
enhancer	I-DNA
element	I-DNA
and	O
a	O
chloramphenicol	B-DNA
acetyltransferase	I-DNA
reporter	I-DNA
gene	I-DNA
.	O

We	O
have	O
detected	O
activatable	O
PLD	B-protein
in	O
Jurkat	B-cell_line
cells	I-cell_line
,	O
and	O
we	O
have	O
found	O
that	O
addition	O
of	O
phosphatidic	O
acid	O
(	O
PA	O
)	O
,	O
the	O
physiologic	O
product	O
of	O
PLD	B-protein
action	O
on	O
phospholipids	O
,	O
is	O
rapidly	O
incorporated	O
into	O
Jurkat	B-cell_line
cells	I-cell_line
and	O
leads	O
to	O
activation	O
of	O
transcription	B-protein
factor	I-protein
AP-1	I-protein
.	O

Treatment	O
of	O
Jurkat	B-cell_line
cells	I-cell_line
with	O
anti-CD3	B-protein
mAb	I-protein
activated	O
both	O
PLD	B-protein
and	O
transcription	B-protein
factor	I-protein
AP-1	I-protein
.	O

Wortmannin	O
,	O
an	O
inhibitor	O
of	O
receptor-coupled	O
PLD	B-protein
activation	O
,	O
blocked	O
the	O
anti-CD3	B-protein
-induced	O
increases	O
in	O
both	O
PLD	B-protein
activity	O
and	O
AP-1	B-DNA
enhancer	I-DNA
activity	O
.	O

We	O
found	O
a	O
good	O
correlation	O
in	O
the	O
transfected	B-cell_line
cells	I-cell_line
between	O
PLD	B-protein
activation	O
and	O
induction	O
of	O
AP-1	B-DNA
enhancer	I-DNA
activity	O
under	O
different	O
experimental	O
conditions	O
.	O

Furthermore	O
,	O
ethanol	O
,	O
an	O
inhibitor	O
of	O
the	O
PLD	B-protein
pathway	O
,	O
blocked	O
the	O
anti-CD3-stimulated	O
AP-1	B-DNA
enhancer	I-DNA
activity	O
.	O

However	O
,	O
this	O
anti-CD3	B-protein
-mediated	O
response	O
was	O
not	O
inhibited	O
by	O
neomycin	O
,	O
an	O
inhibitor	O
of	O
phosphoinositide	O
hydrolysis	O
.	O

The	O
increases	O
in	O
AP-1	B-DNA
enhancer	I-DNA
activity	O
induced	O
by	O
PA	O
or	O
anti-CD3	B-protein
mAb	I-protein
were	O
efficiently	O
abrogated	O
by	O
the	O
presence	O
of	O
propranolol	O
,	O
an	O
inhibitor	O
of	O
PA	O
phosphohydrolase	B-protein
and	O
protein	B-protein
kinase	I-protein
C	I-protein
(	O
PKC	B-protein
)	O
.	O

Furthermore	O
,	O
the	O
PA	O
-and	O
the	O
anti-CD3	B-protein
-induced	O
increases	O
in	O
AP-1	B-DNA
enhancer	I-DNA
activity	O
were	O
blocked	O
by	O
the	O
presence	O
of	O
PKC	B-protein
inhibitors	O
or	O
by	O
PKC	B-protein
down-regulation	O
.	O

These	O
data	O
indicate	O
that	O
PLD	B-protein
stimulation	O
can	O
activate	O
the	O
transcription	B-protein
factor	I-protein
AP-1	I-protein
in	O
T	B-cell_type
lymphocytes	I-cell_type
,	O
and	O
suggest	O
that	O
the	O
induction	O
of	O
AP-1	B-DNA
enhancer	I-DNA
factor	O
activity	O
by	O
PA	O
is	O
mediated	O
via	O
PKC	B-protein
stimulation	O
,	O
either	O
through	O
a	O
direct	O
activating	O
effect	O
of	O
PA	O
or	O
through	O
PA-derived	O
diacylglycerol	O
formation	O
.	O

These	O
data	O
also	O
provide	O
evidence	O
for	O
a	O
role	O
of	O
PLD	B-protein
-derived	O
lipids	O
in	O
the	O
induction	O
of	O
AP-1	B-DNA
enhancer	I-DNA
activity	O
resulting	O
from	O
stimulation	O
of	O
the	O
TCR/CD3	B-protein
complex	I-protein
,	O
suggesting	O
that	O
increased	O
PLD	B-protein
activity	O
can	O
play	O
an	O
important	O
role	O
in	O
T	B-cell_type
lymphocyte	I-cell_type
activation	O
.	O

Upregulation	O
of	O
bcl-2	B-DNA
by	O
the	O
Epstein-Barr	B-protein
virus	I-protein
latent	I-protein
membrane	I-protein
protein	I-protein
LMP1	B-protein
:	O
a	O
B-cell-specific	O
response	O
that	O
is	O
delayed	O
relative	O
to	O
NF-kappa	B-protein
B	I-protein
activation	O
and	O
to	O
induction	O
of	O
cell	B-protein
surface	I-protein
markers	I-protein
.	O

An	O
ability	O
of	O
the	O
Epstein-Barr	B-protein
virus	I-protein
latent	I-protein
membrane	I-protein
protein	I-protein
LMP1	B-protein
to	O
enhance	O
the	O
survival	O
of	O
infected	B-cell_type
B	I-cell_type
cells	I-cell_type
through	O
upregulation	O
of	O
the	O
bcl-2	B-DNA
oncogene	I-DNA
was	O
first	O
suggested	O
by	O
experiments	O
involving	O
gene	O
transfection	O
and	O
the	O
selection	O
of	O
stable	O
LMP1+	B-cell_line
clones	I-cell_line
(	O
S.Henderson	O
,	O
M.	O
Rowe	O
,	O
C.Gregory	O
,	O
F.Wang	O
,	O
E.Kieff	O
,	O
and	O
A.Rickinson	O
,	O
Cell	O
65	O
:	O
1107-1115	O
,	O
1991	O
)	O
.	O

However	O
,	O
it	O
was	O
not	O
possible	O
to	O
ascertain	O
whether	O
Bcl-2	B-protein
upregulation	O
was	O
a	O
specific	O
consequence	O
of	O
LMP1	B-protein
expression	O
or	O
an	O
artifact	O
of	O
the	O
selection	O
procedure	O
whereby	O
rare	O
Bcl-2+	B-cell_line
cells	I-cell_line
already	O
present	O
in	O
the	O
starting	O
population	O
might	O
best	O
be	O
able	O
to	O
tolerate	O
the	O
potentially	O
toxic	O
effects	O
of	O
LMP1	B-protein
.	O

We	O
therefore	O
reexamined	O
this	O
issue	O
by	O
using	O
two	O
different	O
experimental	O
approaches	O
that	O
allowed	O
LMP1	B-protein
-induced	O
effects	O
to	O
be	O
monitored	O
immediately	O
following	O
expression	O
of	O
the	O
viral	O
protein	O
and	O
in	O
the	O
absence	O
of	O
selective	O
pressures	O
;	O
activation	O
of	O
the	O
NF-kappa	B-protein
B	I-protein
transcription	B-protein
factor	I-protein
and	O
upregulation	O
of	O
the	O
cell	B-protein
adhesion	I-protein
molecule	I-protein
ICAM-1	B-protein
were	O
used	O
as	O
early	O
indices	O
of	O
LMP1	B-protein
function	O
.	O

In	O
the	O
first	O
approach	O
,	O
stable	O
clones	O
of	O
two	O
B-cell	B-cell_line
lines	I-cell_line
carrying	O
an	O
LMP1	B-protein
gene	O
under	O
the	O
control	O
of	O
an	O
inducible	O
metallothionein	B-DNA
promoter	I-DNA
were	O
induced	O
to	O
express	O
LMP1	B-protein
in	O
all	O
cells	O
.	O

Activation	O
of	O
NK-kappa	B-protein
B	I-protein
and	O
upregulation	O
of	O
ICAM-1	B-protein
occurred	O
within	O
24	O
h	O
and	O
were	O
followed	O
at	O
48	O
to	O
72	O
h	O
by	O
upregulation	O
of	O
Bcl-2	B-protein
.	O

In	O
the	O
second	O
approach	O
,	O
we	O
tested	O
the	O
generality	O
of	O
this	O
phenomenon	O
by	O
transiently	O
expressing	O
LMP1	B-protein
from	O
a	O
strong	O
constitutively	O
active	O
promoter	O
in	O
a	O
range	O
of	O
different	O
cell	O
types	O
.	O

All	O
six	O
B-cell	B-cell_line
lines	I-cell_line
tested	O
showed	O
NF-kappa	B-protein
B	I-protein
activation	O
in	O
response	O
to	O
LMP1	B-protein
expression	O
,	O
and	O
this	O
was	O
followed	O
in	O
five	O
of	O
six	O
lines	O
by	O
expression	O
of	O
ICAM-1	B-protein
and	O
Bcl-2	B-protein
.	O

In	O
the	O
same	O
experiments	O
,	O
all	O
three	O
non-	O
B-cell	B-cell_line
lines	I-cell_line
showed	O
NF-kappa	B-protein
B	I-protein
activation	O
and	O
ICAM-1	B-protein
upregulation	O
but	O
never	O
any	O
effect	O
upon	O
Bcl-2	B-protein
.	O

We	O
therefore	O
conclude	O
that	O
Bcl-2	B-protein
upregulation	O
is	O
part	O
of	O
the	O
panoply	O
of	O
cellular	O
changes	O
induced	O
by	O
LMP1	B-protein
but	O
that	O
the	O
effect	O
is	O
cell	O
type	O
specific	O
.	O

Our	O
data	O
also	O
suggest	O
that	O
whilst	O
NF-kappa	B-protein
B	I-protein
may	O
be	O
an	O
essential	O
component	O
of	O
LMP1	B-protein
signal	O
transduction	O
,	O
other	O
cell-specific	B-protein
factors	I-protein
may	O
be	O
required	O
to	O
effect	O
some	O
functions	O
of	O
the	O
viral	B-protein
protein	I-protein
.	O

Long-term	O
inositol	O
phosphate	O
release	O
,	O
but	O
not	O
tyrosine	B-protein
kinase	I-protein
activity	O
,	O
correlates	O
with	O
IL-2	B-protein
secretion	O
and	O
NF-AT	B-protein
induction	O
in	O
anti-CD3-activated	B-cell_line
peripheral	I-cell_line
human	I-cell_line
T	I-cell_line
lymphocytes	I-cell_line
.	O

The	O
cascade	O
of	O
events	O
within	O
the	O
first	O
few	O
minutes	O
of	O
T	B-cell_type
cell	I-cell_type
stimulation	O
has	O
been	O
well	O
characterized	O
.	O

Although	O
many	O
second	O
messengers	O
have	O
been	O
shown	O
to	O
be	O
necessary	O
and	O
sufficient	O
for	O
T	B-cell_type
cell	I-cell_type
activation	O
in	O
a	O
number	O
of	O
model	O
systems	O
,	O
the	O
rate-limiting	O
step	O
in	O
peripheral	B-cell_type
T	I-cell_type
cells	I-cell_type
has	O
not	O
been	O
demonstrated	O
.	O

To	O
model	O
effective	O
versus	O
ineffective	O
CD3	B-protein
-mediated	O
stimulation	O
in	O
peripheral	B-cell_type
T	I-cell_type
cells	I-cell_type
,	O
we	O
used	O
two	O
anti-CD3	B-protein
mAbs	I-protein
that	O
differ	O
in	O
their	O
ability	O
to	O
stimulate	O
purified	B-cell_type
T	I-cell_type
cells	I-cell_type
:	O
OKT3	B-protein
,	O
which	O
causes	O
early	O
second	O
messenger	O
generation	O
but	O
is	O
unable	O
to	O
activate	O
T	B-cell_type
cells	I-cell_type
without	O
a	O
second	O
signal	O
,	O
and	O
64.1	B-protein
,	O
which	O
stimulates	O
T	B-cell_type
cell	I-cell_type
proliferation	O
on	O
its	O
own	O
.	O

We	O
found	O
that	O
tyrosine	B-protein
kinase	I-protein
activity	O
was	O
similar	O
for	O
both	O
mAbs	B-protein
over	O
a	O
period	O
of	O
hours	O
.	O

However	O
,	O
the	O
inositol	O
phosphate	O
response	O
was	O
stronger	O
for	O
64.1	B-protein
than	O
for	O
OKT3	B-protein
.	O

To	O
tie	O
these	O
events	O
to	O
gene	O
activation	O
,	O
we	O
measured	O
NF-kappa	B-protein
B	I-protein
and	O
NF-AT	B-protein
activity	O
in	O
the	O
nucleus	O
after	O
anti-CD3	B-protein
stimulation	O
.	O

Both	O
stimuli	O
induced	O
the	O
appearance	O
of	O
the	O
NF-kappa	B-protein
B	I-protein
components	I-protein
(	O
c-Rel	B-protein
,	O
p65	B-protein
(	O
RelA	B-protein
)	O
,	O
and	O
p50	B-protein
(	O
NF-kappa	B-protein
B1	I-protein
)	O
)	O
and	O
NF-kappa	B-protein
B	I-protein
DNA	O
binding	O
activity	O
in	O
the	O
nucleus	O
.	O

However	O
,	O
only	O
64.1	B-protein
induced	O
NF-AT	B-protein
in	O
the	O
nucleus	O
,	O
correlating	O
with	O
its	O
ability	O
to	O
activate	O
T	B-cell_type
cells	I-cell_type
.	O

Thus	O
,	O
NF-AT	B-protein
induction	O
and	O
IL-2	B-protein
secretion	O
were	O
correlated	O
with	O
the	O
levels	O
of	O
inositol	O
phosphate	O
release	O
but	O
not	O
with	O
gross	O
levels	O
of	O
tyrosine	B-protein
kinase	I-protein
activity	O
induced	O
late	O
following	O
the	O
response	O
.	O

On	O
the	O
other	O
hand	O
,	O
NF-kappa	B-protein
B	I-protein
induction	O
and	O
IL-2	B-protein
receptor	O
expression	O
occurred	O
even	O
with	O
the	O
smaller	O
second	O
messenger	O
response	O
generated	O
by	O
OKT3	B-protein
.	O

HLA-DR-	O
,	O
CD33+	O
,	O
CD56+	O
,	O
CD16-	O
myeloid/natural	O
killer	O
cell	O
acute	O
leukemia	O
:	O
a	O
previously	O
unrecognized	O
form	O
of	O
acute	O
leukemia	O
potentially	O
misdiagnosed	O
as	O
French-American-British	O
acute	O
myeloid	O
leukemia-M3	O
[	O
see	O
comments	O
]	O

We	O
have	O
identified	O
and	O
characterized	O
a	O
previously	O
unrecognized	O
form	O
of	O
acute	O
leukemia	O
that	O
shares	O
features	O
of	O
both	O
myeloid	B-cell_type
and	I-cell_type
natural	I-cell_type
killer	I-cell_type
(	I-cell_type
NK	I-cell_type
)	I-cell_type
cells	I-cell_type
.	O

From	O
a	O
consecutive	O
series	O
of	O
350	O
cases	O
of	O
adult	O
de	O
novo	O
acute	O
myeloid	O
leukemia	O
(	O
AML	O
)	O
,	O
we	O
identified	O
20	O
cases	O
(	O
6	O
%	O
)	O
with	O
a	O
unique	O
immunophenotype	O
:	O
CD33+	O
,	O
CD56+	O
,	O
CD11a+	O
,	O
CD13lo	O
,	O
CD15lo	O
,	O
CD34+/-	O
,	O
HLA-DR	B-protein
-	O
,	O
CD16	B-protein
-	O
.	O

Multicolor	O
flow	O
cytometric	O
assays	O
confirmed	O
the	O
coexpression	O
of	O
myeloid	B-protein
(	I-protein
CD33	I-protein
,	I-protein
CD13	I-protein
,	I-protein
CD15	I-protein
)	I-protein
and	I-protein
NK	I-protein
cell-associated	I-protein
(	I-protein
CD56	I-protein
)	I-protein
antigens	I-protein
in	O
each	O
case	O
,	O
whereas	O
reverse	O
transcription	O
polymerase	O
chain	O
reaction	O
(	O
RT-PCR	O
)	O
assays	O
confirmed	O
the	O
identity	O
of	O
CD56	B-protein
(	O
neural	B-protein
cell	I-protein
adhesion	I-protein
molecule	I-protein
)	O
in	O
leukemic	B-cell_type
blasts	I-cell_type
.	O

Although	O
two	O
cases	O
expressed	O
CD4	B-protein
,	O
no	O
case	O
expressed	O
CD2	B-protein
,	O
CD3	B-protein
,	O
or	O
CD8	B-protein
and	O
no	O
case	O
showed	O
clonal	O
rearrangement	O
of	O
genes	O
encoding	O
the	O
T-cell	B-protein
receptor	I-protein
(	O
TCR	B-protein
beta	I-protein
,	I-protein
gamma	I-protein
,	I-protein
delta	I-protein
)	O
.	O

Leukemic	O
blasts	O
in	O
the	O
majority	O
of	O
cases	O
shared	O
unique	O
morphologic	O
features	O
(	O
deeply	O
invaginated	O
nuclear	O
membranes	O
,	O
scant	O
cytoplasm	O
with	O
fine	O
azurophilic	O
granularity	O
,	O
and	O
finely	O
granular	O
Sudan	O
black	O
B	O
and	O
myeloperoxidase	B-protein
cytochemical	O
reactivity	O
)	O
that	O
were	O
remarkably	O
similar	O
to	O
those	O
of	O
acute	O
promyelocytic	O
leukemia	O
(	O
APL	O
)	O
;	O
particularly	O
the	O
microgranular	B-protein
variant	I-protein
(	O
FAB	B-protein
AML-M3v	I-protein
)	O
.	O

However	O
,	O
all	O
20	O
cases	O
lacked	O
the	O
t	O
(	O
15	O
;	O
17	O
)	O
and	O
17	O
cases	O
tested	O
lacked	O
the	O
promyelocytic/retinoic	B-RNA
acid	I-RNA
receptor	I-RNA
alpha	I-RNA
(	I-RNA
RAR	I-RNA
alpha	I-RNA
)	I-RNA
fusion	I-RNA
transcript	I-RNA
in	O
RT-PCR	O
assays	O
;	O
12	O
cases	O
had	O
46	O
,	O
XX	O
or	O
46	O
,	O
XY	O
karyotypes	O
,	O
whereas	O
2	O
cases	O
had	O
abnormalities	O
of	O
chromosome	B-DNA
17q	I-DNA
:	O
1	O
with	O
del	B-DNA
(	I-DNA
17	I-DNA
)	I-DNA
(	I-DNA
q25	I-DNA
)	I-DNA
and	O
the	O
other	O
with	O
t	B-DNA
(	I-DNA
11	I-DNA
;	I-DNA
17	I-DNA
)	I-DNA
(	I-DNA
q23	I-DNA
;	I-DNA
q21	I-DNA
)	I-DNA
and	O
the	O
promyelocytic	B-RNA
leukemia	I-RNA
zinc	I-RNA
finger/RAR	I-RNA
alpha	I-RNA
fusion	I-RNA
transcript	I-RNA
.	O

All	O
cases	O
tested	O
(	O
6/20	O
)	O
,	O
including	O
the	O
case	O
with	O
t	B-DNA
(	I-DNA
11	I-DNA
;	I-DNA
17	I-DNA
)	I-DNA
,	O
failed	O
to	O
differentiate	O
in	O
vitro	O
in	O
response	O
to	O
all-trans	O
retinoic	O
acid	O
(	O
ATRA	O
)	O
,	O
suggesting	O
that	O
these	O
cases	O
may	O
account	O
for	O
some	O
APLs	O
that	O
have	O
not	O
shown	O
a	O
clinical	O
response	O
to	O
ATRA	O
.	O

Four	O
of	O
6	O
cases	O
tested	O
showed	O
functional	O
NK	O
cell-mediated	O
cytotoxicity	O
,	O
suggesting	O
a	O
relationship	O
between	O
these	O
unique	O
CD33+	O
,	O
CD56+	O
,	O
CD16	B-protein
-acute	O
leukemias	O
and	O
normal	B-cell_type
CD56+	I-cell_type
,	I-cell_type
CD16-	I-cell_type
NK	I-cell_type
precursor	I-cell_type
cells	I-cell_type
.	O

Using	O
a	O
combination	O
of	O
panning	O
and	O
multiparameter	O
flow	O
cytometric	O
sorting	O
,	O
we	O
identified	O
a	O
normal	B-cell_type
CD56+	I-cell_type
,	I-cell_type
CD33+	I-cell_type
,	I-cell_type
CD16-	I-cell_type
counterpart	I-cell_type
cell	I-cell_type
at	O
a	O
frequency	O
of	O
1	O
%	O
to	O
2	O
%	O
in	O
the	O
peripheral	O
blood	O
of	O
healthy	O
individuals	O
.	O

Our	O
studies	O
suggest	O
that	O
this	O
form	O
of	O
acute	O
leukemia	O
may	O
arise	O
from	O
transformation	O
of	O
a	O
precursor	O
cell	O
common	O
to	O
both	O
the	O
myeloid	B-cell_type
and	I-cell_type
NK	I-cell_type
cell	I-cell_type
lineages	I-cell_type
;	O
thus	O
we	O
propose	O
the	O
designation	O
myeloid/NK	O
acute	O
leukemia	O
.	O

Recognition	O
of	O
this	O
new	O
leukemic	O
entity	O
will	O
be	O
important	O
in	O
distinguishing	O
these	O
ATRA-nonresponsive	O
cases	O
from	O
ATRA-responsive	O
true	O
APL	O
.	O

IL-4	B-protein
down-regulates	O
IL-2	B-protein
-	O
,	O
IL-3	B-protein
-	O
,	O
and	O
GM-CSF	B-protein
-induced	O
cytokine	O
gene	O
expression	O
in	O
peripheral	O
blood	O
monocytes	O
.	O

IL-4	B-protein
,	O
a	O
product	O
of	O
the	O
T-helper	B-cell_type
0	I-cell_type
(	I-cell_type
Th0	I-cell_type
)	I-cell_type
and	I-cell_type
2	I-cell_type
(	I-cell_type
Th2	I-cell_type
)	I-cell_type
subset	I-cell_type
,	O
was	O
originally	O
described	O
as	O
a	O
B-cell	B-protein
stimulatory	I-protein
factor	I-protein
and	O
has	O
subsequently	O
been	O
found	O
to	O
suppress	O
IL-1	O
alpha	O
,	O
IL-1	O
beta	O
,	O
IL-6	O
,	O
IL-8	O
,	O
and	O
TNF-alpha	O
gene	O
expression	O
in	O
monocytes	B-cell_type
stimulated	O
with	O
LPS	O
,	O
and	O
to	O
upregulate	O
IL-1	B-DNA
receptor	I-DNA
antagonist	I-DNA
(	I-DNA
IL1-RA	I-DNA
)	I-DNA
gene	I-DNA
expression	O
.	O

In	O
this	O
study	O
we	O
investigated	O
the	O
effect	O
of	O
IL-4	B-protein
on	O
the	O
expression	O
of	O
cytokine	B-DNA
genes	I-DNA
in	O
monocytes	B-cell_type
evoked	O
by	O
other	O
T-helper	B-protein
cell	I-protein
cytokines	I-protein
:	O
IL-2	B-protein
,	O
IL-3	B-protein
,	O
and	O
GM-CSF	B-protein
.	O

IL-4	B-protein
down-regulated	O
mRNA	O
accumulation	O
of	O
the	O
proinflammatory	B-protein
cytokines	I-protein
IL-1	B-protein
beta	I-protein
,	O
IL-8	B-protein
,	O
and	O
TNF-alpha	B-protein
in	O
monocytes	B-cell_type
stimulated	O
with	O
IL-2	B-protein
,	O
IL-3	B-protein
,	O
and	O
GM-CSF	B-protein
.	O

IL-4	B-protein
also	O
suppressed	O
the	O
IL-2	B-protein
-induced	O
IL-6	B-protein
mRNA	O
expression	O
.	O

Temporal	O
analysis	O
of	O
the	O
IL-4	B-protein
down-regulatory	O
effect	O
on	O
the	O
IL-2-	O
,	O
IL-3-	O
,	O
or	O
GM-CSF-induced	O
proinflammatory	O
cytokine	O
gene	O
expression	O
in	O
monocytes	B-cell_type
provided	O
evidence	O
that	O
IL-4	B-protein
acts	O
predominantly	O
on	O
the	O
post-transcriptional	O
level	O
.	O

This	O
was	O
supported	O
by	O
the	O
observation	O
that	O
the	O
down-regulatory	O
capacity	O
of	O
IL-4	B-protein
appeared	O
to	O
be	O
dependent	O
on	O
de	O
novo	O
protein	O
synthesis	O
.	O

IL-4	B-protein
did	O
not	O
exert	O
significant	O
influence	O
on	O
the	O
induction	O
of	O
expression	O
of	O
IL-1-RA	B-protein
or	O
various	O
CSFs	B-protein
by	O
IL-2	B-protein
,	O
IL-3	B-protein
,	O
and	O
GM-CSF	B-protein
.	O

(	O
ABSTRACT	O
TRUNCATED	O
AT	O
250	O
WORDS	O
)	O

Induction	O
of	O
proto-oncogene	B-DNA
and	O
cytokine	B-protein
expression	O
in	O
human	O
peripheral	O
blood	O
monocytes	B-cell_type
and	O
the	O
monocytic	B-cell_line
cell	I-cell_line
line	I-cell_line
THP-1	B-cell_line
after	O
stimulation	O
with	O
mycoplasma-derived	O
material	O
MDHM	O
.	O

Mycoplasma	O
fermentans-derived	O
high-molecular-weight	O
material	O
(	O
MDHM	O
)	O
was	O
originally	O
described	O
to	O
induce	O
differentiation	O
of	O
murine	B-cell_type
thymocytes	I-cell_type
to	O
cytolytic	B-cell_type
effector	I-cell_type
T-cells	I-cell_type
by	O
stimulating	O
IL-6	B-protein
release	O
from	O
adherent	B-cell_type
cells	I-cell_type
.	O

This	O
study	O
shows	O
that	O
human	O
peripheral	O
blood	O
monocytes	B-cell_type
(	O
PBMo	B-cell_type
)	O
also	O
respond	O
to	O
MDHM	O
with	O
increases	O
in	O
IL-1	B-protein
beta	I-protein
,	O
IL-6	B-protein
and	O
TNF	B-protein
alpha	I-protein
expression	O
,	O
both	O
at	O
the	O
mRNA	O
and	O
protein	O
level	O
.	O

The	O
induced	O
expression	O
of	O
IL-1	B-RNA
beta	I-RNA
and	I-RNA
TNF	I-RNA
alpha	I-RNA
mRNA	I-RNA
in	O
the	O
monocytic	O
THP-1	B-cell_line
cell	I-cell_line
line	I-cell_line
increased	O
as	O
quickly	O
as	O
in	O
primary	B-cell_type
cells	I-cell_type
.	O

In	O
contrast	O
to	O
PBMo	B-cell_type
,	O
THP-1	B-cell_line
and	O
14	O
other	O
monocytic/myeloid	B-cell_line
leukemia-derived	I-cell_line
cell	I-cell_line
lines	I-cell_line
did	O
not	O
secrete	O
measurable	O
amounts	O
of	O
the	O
cytokines	B-protein
upon	O
treatment	O
with	O
MDHM	O
.	O

IL-1	B-DNA
beta	I-DNA
and	I-DNA
IL-6	I-DNA
genes	I-DNA
contain	O
AP-1	B-DNA
binding	I-DNA
sites	I-DNA
as	O
regulatory	B-DNA
elements	I-DNA
,	O
the	O
AP-1	B-protein
protein	O
being	O
composed	O
of	O
c-jun	B-protein
and	I-protein
c-fos	I-protein
gene	I-protein
products	I-protein
.	O

In	O
THP-1	B-cell_line
cells	I-cell_line
c-jun	B-RNA
mRNA	I-RNA
expression	O
increased	O
after	O
incubation	O
with	O
MDHM	O
while	O
positive	O
c-fos	B-DNA
expression	O
remained	O
unaffected	O
.	O

Although	O
these	O
data	O
suggest	O
AP-1	B-protein
regulated	O
cytokine	B-protein
mRNA	O
expression	O
,	O
results	O
from	O
PBMo	B-cell_type
are	O
not	O
in	O
accordance	O
with	O
this	O
notion	O
.	O

In	O
the	O
primary	B-cell_type
cells	I-cell_type
MDHM-induced	O
elevation	O
of	O
cytokine	B-RNA
mRNA	I-RNA
levels	O
was	O
preceded	O
by	O
a	O
downregulation	O
of	O
c-fos	B-DNA
expression	O
while	O
positive	O
c-jun	B-DNA
expression	O
was	O
not	O
modulated	O
.	O

c-myc	B-RNA
mRNA	I-RNA
expression	O
,	O
constitutively	O
high	O
in	O
THP-1	B-cell_line
cells	I-cell_line
,	O
was	O
induced	O
in	O
MDHM-stimulated	O
PBMo	B-cell_type
.	O

In	O
conclusion	O
,	O
MDHM-stimulated	O
induction	O
of	O
cytokine	B-RNA
mRNA	I-RNA
expression	O
was	O
accompanied	O
by	O
different	O
proto-oncogene	B-DNA
responses	O
in	O
PBMo	B-cell_type
and	O
THP-1	B-cell_line
cells	I-cell_line
.	O

These	O
differences	O
may	O
represent	O
different	O
regulatory	O
pathways	O
of	O
the	O
two	O
cell	O
systems	O
.	O

Alternatively	O
,	O
these	O
data	O
support	O
the	O
notion	O
that	O
neither	O
AP-1	B-protein
nor	O
the	O
c-myc	B-protein
protein	I-protein
are	O
involved	O
in	O
the	O
MDHM-induced	O
increase	O
in	O
IL-1	O
beta	O
,	O
IL-6	O
or	O
TNF	O
alpha	O
mRNA	O
levels	O
.	O

Furthermore	O
,	O
the	O
present	O
results	O
demonstrate	O
clearly	O
that	O
mycoplasma	B-protein
products	I-protein
can	O
have	O
a	O
profound	O
impact	O
on	O
the	O
activation	O
status	O
of	O
eukaryotic	B-cell_type
cells	I-cell_type
.	O

Novel	B-protein
membrane	I-protein
receptors	I-protein
for	O
aldosterone	O
in	O
human	B-cell_type
lymphocytes	I-cell_type
:	O
a	O
50	B-protein
kDa	I-protein
protein	I-protein
on	O
SDS-PAGE	O
.	O

Fast	O
in	O
vitro	O
effects	O
of	O
aldosterone	O
on	O
the	O
Na+/H	B-protein
(	I-protein
+	I-protein
)	I-protein
-exchanger	I-protein
,	O
inositoltrisphosphate	O
generation	O
and	O
corresponding	O
specific	O
binding	O
to	O
plasma	O
membranes	O
at	O
Kd-values	O
of	O
approximately	O
0.1	O
nM	O
have	O
been	O
found	O
in	O
human	B-cell_type
mononuclear	I-cell_type
leukocytes	I-cell_type
and	O
vascular	B-cell_type
smooth	I-cell_type
muscle	I-cell_type
cells	I-cell_type
.	O

The	O
novel	O
aldosterone	O
membrane	O
receptor	O
was	O
analyzed	O
on	O
SDS-PAGE	O
after	O
labeling	O
of	O
microsomal	O
membranes	O
from	O
human	B-cell_type
mononuclear	I-cell_type
leukocytes	I-cell_type
with	O
a	O
[	O
125I	O
]	O
-aldosterone-derivative	O
by	O
use	O
of	O
BASED	O
as	O
a	O
photoactivatable	O
crosslinker	O
.	O

Binding	O
of	O
1	O
nM	O
[	O
125I	O
]	O
-aldosterone	O
was	O
found	O
at	O
a	O
molecular	O
weight	O
of	O
approximately	O
50	O
kDa	O
which	O
was	O
absent	O
with	O
1	O
microM	O
cold	O
aldosterone	O
,	O
but	O
not	O
cortisol	O
in	O
the	O
binding	O
media	O
.	O

This	O
aldosterone-selectivity	O
is	O
typical	O
and	O
discriminatory	O
for	O
the	O
new	O
aldosterone	B-protein
membrane	I-protein
receptor	I-protein
.	O

Solubilization	O
of	O
the	O
receptor	B-protein
protein	I-protein
from	O
membranes	O
by	O
high	O
salt	O
concentrations	O
(	O
1	O
M	O
NaCl	O
,	O
1	O
mM	O
EDTA	O
)	O
was	O
not	O
achieved	O
.	O

It	O
,	O
thus	O
,	O
appears	O
as	O
an	O
integral	B-protein
membrane	I-protein
protein	I-protein
.	O

Dithiothreitol	O
,	O
a	O
sulfhydryl	O
agent	O
,	O
does	O
not	O
reduce	O
specific	O
aldosterone	O
binding	O
indicating	O
the	O
absence	O
of	O
SH-groups	B-protein
in	O
the	O
binding	B-protein
domain	I-protein
or	O
sensitive	O
structures	O
of	O
the	O
receptors	O
.	O

The	O
results	O
are	O
the	O
first	O
to	O
characterize	O
the	O
novel	B-protein
membrane	I-protein
receptor	I-protein
for	O
aldosterone	O
with	O
regard	O
to	O
molecular	O
weight	O
and	O
basic	O
properties	O
.	O

These	O
findings	O
and	O
other	O
related	O
results	O
are	O
reviewed	O
here	O
.	O

A	O
transcriptional	B-DNA
regulatory	I-DNA
element	I-DNA
is	O
associated	O
with	O
a	O
nuclease-hypersensitive	B-DNA
site	I-DNA
in	O
the	O
pol	B-DNA
gene	I-DNA
of	O
human	O
immunodeficiency	O
virus	O
type	O
1	O
.	O

Analysis	O
of	O
the	O
chromatin	O
organization	O
of	O
the	O
integrated	O
human	B-DNA
immunodeficiency	I-DNA
virus	I-DNA
type	I-DNA
1	I-DNA
(	I-DNA
HIV-1	I-DNA
)	I-DNA
genome	I-DNA
has	O
previously	O
revealed	O
a	O
major	B-DNA
constitutive	I-DNA
DNase	I-DNA
I-hypersensitive	I-DNA
site	I-DNA
associated	O
with	O
the	O
pol	B-DNA
gene	I-DNA
(	O
E.	O
Verdin	O
,	O
J.	O
Virol.	O
65	O
:	O
6790-6799	O
,	O
1991	O
)	O
.	O

In	O
the	O
present	O
report	O
,	O
high-resolution	O
mapping	O
of	O
this	O
site	O
with	O
DNase	B-protein
I	I-protein
and	O
micrococcal	B-protein
nuclease	I-protein
identified	O
a	O
nucleosome-free	B-DNA
region	I-DNA
centered	O
around	O
nucleotides	B-DNA
(	I-DNA
nt	I-DNA
)	I-DNA
4490	I-DNA
to	I-DNA
4766	I-DNA
.	O

A	O
500-bp	B-DNA
fragment	I-DNA
encompassing	O
this	O
hypersensitive	B-DNA
site	I-DNA
(	O
nt	B-DNA
4481	I-DNA
to	I-DNA
4982	I-DNA
)	O
exhibited	O
transcription-enhancing	O
activity	O
(	O
two-	O
to	O
threefold	O
)	O
when	O
it	O
was	O
cloned	O
in	O
its	O
natural	O
position	O
with	O
respect	O
to	O
the	O
HIV-1	B-DNA
promoter	I-DNA
after	O
transient	O
transfection	O
in	O
U937	B-cell_line
and	O
CEM	B-cell_line
cells	I-cell_line
.	O

Using	O
in	O
vitro	O
footprinting	O
and	O
gel	O
shift	O
assays	O
,	O
we	O
have	O
identified	O
four	O
distinct	O
binding	B-DNA
sites	I-DNA
for	O
nuclear	B-protein
proteins	I-protein
within	O
this	O
positive	B-DNA
regulatory	I-DNA
element	I-DNA
.	O

Site	B-DNA
B	I-DNA
(	O
nt	B-DNA
4519	I-DNA
to	I-DNA
4545	I-DNA
)	O
specifically	O
bound	O
four	O
distinct	O
nuclear	B-protein
protein	I-protein
complexes	I-protein
:	O
a	O
ubiquitous	B-protein
factor	I-protein
,	O
a	O
T-cell-specific	B-protein
factor	I-protein
,	O
a	O
B-cell-specific	B-protein
factor	I-protein
,	O
and	O
the	O
monocyte/macrophage-	B-protein
and	I-protein
B-cell-specific	I-protein
transcription	I-protein
factor	I-protein
PU.1/Spi-1	B-protein
.	O

In	O
most	O
HIV-1	O
isolates	O
in	O
which	O
this	O
PU	B-DNA
box	I-DNA
was	O
not	O
conserved	O
,	O
it	O
was	O
replaced	O
by	O
a	O
binding	B-DNA
site	I-DNA
for	O
the	O
related	O
factor	O
Ets1	B-protein
.	O

Factors	O
binding	O
to	O
site	B-DNA
C	I-DNA
(	O
nt	B-DNA
4681	I-DNA
to	I-DNA
4701	I-DNA
)	O
had	O
a	O
DNA-binding	O
specificity	O
similar	O
to	O
that	O
of	O
factors	O
binding	O
to	O
site	B-DNA
B	I-DNA
,	O
except	O
for	O
PU.1/Spi-1	B-protein
.	O

A	O
GC	B-DNA
box	I-DNA
containing	O
a	O
binding	B-DNA
site	I-DNA
for	O
Sp1	B-protein
was	O
identified	O
(	O
nt	B-DNA
4623	I-DNA
to	I-DNA
4631	I-DNA
)	O
.	O

Site	B-DNA
D	I-DNA
(	O
nt	B-DNA
4816	I-DNA
to	I-DNA
4851	I-DNA
)	O
specifically	O
bound	O
a	O
ubiquitously	B-protein
expressed	I-protein
factor	I-protein
.	O

These	O
results	O
identify	O
a	O
transcriptional	B-DNA
regulatory	I-DNA
element	I-DNA
associated	O
with	O
a	O
nuclease-hypersensitive	B-DNA
site	I-DNA
in	O
the	O
pol	B-DNA
gene	I-DNA
of	O
HIV-1	O
and	O
suggest	O
that	O
its	O
activity	O
may	O
be	O
controlled	O
by	O
a	O
complex	O
interplay	O
of	O
cis-	O
regulatory	B-DNA
elements	I-DNA
.	O

Expression	O
of	O
v-src	B-DNA
in	O
T	B-cell_type
cells	I-cell_type
correlates	O
with	O
nuclear	O
expression	O
of	O
NF-kappa	B-protein
B	I-protein
.	O

NF-kappa	B-protein
B	I-protein
is	O
a	O
rapidly	O
inducible	O
transcriptional	B-DNA
activator	I-DNA
that	O
responds	O
to	O
a	O
variety	O
of	O
signals	O
and	O
influences	O
the	O
expression	O
of	O
many	O
genes	O
involved	O
in	O
the	O
immune	O
response	O
.	O

Protein	O
tyrosine	B-protein
kinases	I-protein
transmit	O
signals	O
from	O
cytokine	B-protein
and	I-protein
immune	I-protein
receptors	I-protein
.	O

Very	O
little	O
information	O
exists	O
linking	O
these	O
two	O
important	O
classes	O
of	O
signaling	B-protein
molecules	I-protein
.	O

We	O
now	O
demonstrate	O
that	O
v-src	B-DNA
expression	O
correlates	O
with	O
nuclear	O
expression	O
of	O
a	O
kappa	B-protein
B	I-protein
binding	I-protein
complex	I-protein
similar	O
to	O
that	O
induced	O
by	O
phorbol	O
ester	O
and	O
ionomycin	O
,	O
as	O
detected	O
by	O
electrophoretic	O
mobility	O
shift	O
assay	O
using	O
a	O
variety	O
of	O
kappa	B-DNA
B	I-DNA
sites	I-DNA
.	O

This	O
complex	O
was	O
blocked	O
by	O
the	O
tyrosine	B-protein
kinase	I-protein
inhibitor	O
,	O
herbimycin	O
A	O
.	O

The	O
v-src-induced	B-protein
complex	I-protein
comprised	O
the	O
p50	B-protein
and	O
p65	B-protein
components	O
of	O
NF-kappa	B-protein
B	I-protein
,	O
as	O
determined	O
by	O
supershift	O
and	O
immunoblot	O
analysis	O
.	O

As	O
a	O
functional	O
correlate	O
of	O
this	O
finding	O
,	O
transient	O
co-transfection	O
of	O
HIV-1	B-DNA
LTR	I-DNA
reporter	I-DNA
constructs	I-DNA
in	O
a	O
different	O
T	B-cell_line
cell	I-cell_line
line	I-cell_line
demonstrated	O
that	O
v-src	B-DNA
activated	O
this	O
promoter	B-protein
in	O
a	O
kappa	O
B-dependent	O
manner	O
.	O

We	O
found	O
that	O
transactivation	O
of	O
the	O
HIV-1	B-DNA
LTR	I-DNA
by	O
v-src	B-DNA
was	O
more	O
sensitive	O
to	O
mutations	O
of	O
the	O
proximal	O
,	O
rather	O
than	O
the	O
distal	O
,	O
kappa	B-DNA
B	I-DNA
element	I-DNA
.	O

The	O
implications	O
for	O
T	B-protein
cell	I-protein
receptor	I-protein
signaling	O
and	O
HIV-1	B-DNA
gene	I-DNA
expression	O
are	O
considered	O
.	O

trans-activation	O
of	O
the	O
HIV	B-DNA
promoter	I-DNA
by	O
a	O
cDNA	O
and	O
its	O
genomic	O
clones	O
of	O
human	O
herpesvirus-6	O
.	O

Human	O
herpesvirus	O
6	O
(	O
HHV-6	O
)	O
is	O
a	O
lymphotropic	O
herpesvirus	O
,	O
and	O
in	O
vitro	O
,	O
it	O
can	O
productively	O
infect	O
human	O
CD4+	B-cell_line
T	I-cell_line
cells	I-cell_line
as	O
HIV-1	O
.	O

Co-infection	O
of	O
T	B-cell_type
cells	I-cell_type
by	O
HIV-1	O
and	O
HHV-6	O
can	O
lead	O
to	O
both	O
activation	O
of	O
the	O
HIV-1	B-DNA
promoter	I-DNA
and	O
acceleration	O
of	O
the	O
cytopathic	O
effects	O
.	O

An	O
HHV-6	B-DNA
(	I-DNA
GS	I-DNA
)	I-DNA
cDNA	I-DNA
clone	I-DNA
,	O
pCD41	B-DNA
,	O
encoding	O
for	O
a	O
41-kDa	B-protein
nuclear	I-protein
protein	I-protein
was	O
identified	O
and	O
characterized	O
previously	O
(	O
Chang	O
and	O
Balachandran	O
,	O
J.	O
Virol.	O
65	O
,	O
2884-2894	O
and	O
7085	O
,	O
1991	O
)	O
.	O

Sequence	O
analyses	O
show	O
that	O
this	O
protein	O
has	O
significant	O
homology	O
with	O
the	O
human	B-DNA
cytomegalovirus	I-DNA
UL44	I-DNA
gene	I-DNA
coding	O
for	O
the	O
ICP36	B-protein
family	I-protein
of	O
early-late-class	B-protein
phosphoprotein	I-protein
.	O

Using	O
this	O
cDNA	B-DNA
as	O
the	O
probe	O
,	O
a	O
3.8-kb	B-DNA
EcoRI	I-DNA
genomic	I-DNA
fragment	I-DNA
encoding	O
the	O
HHV-6	B-protein
(	I-protein
GS	I-protein
)	I-protein
P41	I-protein
was	O
cloned	O
and	O
designated	O
as	O
pGD41	B-DNA
.	O

When	O
cotransfected	O
with	O
the	O
HIV	B-DNA
LTR	I-DNA
CAT	I-DNA
into	O
CV-1	B-cell_line
cells	I-cell_line
,	O
both	O
the	O
pCD41	B-DNA
and	O
pGD41	B-DNA
clones	O
trans-activated	O
the	O
HIV	B-DNA
LTR	I-DNA
.	O

Sequence	O
analyses	O
of	O
pCD41	B-DNA
indicate	O
that	O
there	O
are	O
two	O
potential	O
open	B-DNA
reading	I-DNA
frames	I-DNA
(	O
ORFs	B-DNA
)	O
,	O
A	B-DNA
and	O
B	B-DNA
,	O
which	O
are	O
homologous	O
to	O
the	O
ORFs	B-DNA
found	O
in	O
the	O
genomic	O
clone	O
pGD41	B-DNA
.	O

Deletion	O
constructs	O
of	O
the	O
pCD41	B-DNA
clone	I-DNA
demonstrated	O
that	O
ORF-A	B-protein
was	O
critical	O
for	O
the	O
HIV	B-DNA
LTR	I-DNA
activation	O
.	O

Deletion	O
analyses	O
of	O
the	O
pCD41	B-DNA
ORF-A	B-protein
and	O
the	O
use	O
of	O
promoter	B-DNA
constructs	I-DNA
further	O
mapped	O
an	O
internal	O
functional	O
promoter	O
within	O
the	O
pCD41	B-DNA
sequence	O
that	O
can	O
direct	O
the	O
synthesis	O
of	O
the	O
trans-activating	B-protein
protein	I-protein
.	O

By	O
using	O
HIV	B-DNA
LTR	I-DNA
deletion	I-DNA
mutants	I-DNA
,	O
the	O
NF-kappa	B-protein
B	I-protein
binding	B-DNA
sites	I-DNA
were	O
found	O
to	O
be	O
critical	O
for	O
response	O
to	O
the	O
pCD41	B-DNA
trans-activation	O
.	O

CD14	B-protein
-mediated	O
translocation	O
of	O
nuclear	B-protein
factor-kappa	I-protein
B	I-protein
induced	O
by	O
lipopolysaccharide	O
does	O
not	O
require	O
tyrosine	B-protein
kinase	I-protein
activity	O
.	O

During	O
the	O
course	O
of	O
serious	O
bacterial	O
infections	O
,	O
lipopolysaccharide	O
(	O
LPS	O
)	O
is	O
believed	O
to	O
interact	O
with	O
macrophage	B-protein
receptors	I-protein
,	O
resulting	O
in	O
the	O
generation	O
of	O
inflammatory	O
mediators	O
and	O
systemic	O
symptoms	O
including	O
hemodynamic	O
instability	O
and	O
shock	O
.	O

CD14	B-protein
,	O
a	O
glycosylphosphatidylinositol-linked	B-protein
antigen	I-protein
,	O
functions	O
as	O
an	O
LPS	B-protein
signaling	I-protein
receptor	I-protein
.	O

A	O
critical	O
issue	O
concerns	O
the	O
mechanism	O
by	O
which	O
CD14	B-protein
,	O
which	O
has	O
no	O
transmembrane	B-protein
domain	I-protein
,	O
transduces	O
its	O
signal	O
following	O
LPS	O
binding	O
.	O

Recently	O
,	O
investigators	O
have	O
hypothesized	O
that	O
CD14	B-protein
-mediated	O
signaling	O
is	O
effected	O
through	O
a	O
receptor-associated	O
tyrosine	B-protein
kinase	I-protein
(	O
TK	O
)	O
,	O
suggesting	O
a	O
multicomponent	O
receptor	O
model	O
of	O
LPS	O
signaling	O
.	O

Wild-type	O
Chinese	B-cell_line
hamster	I-cell_line
ovary	I-cell_line
(	I-cell_line
CHO	I-cell_line
)	I-cell_line
-K1	I-cell_line
cells	I-cell_line
can	O
be	O
activated	O
by	O
endotoxin	O
to	O
release	O
arachidonate	O
following	O
transfection	O
with	O
human	O
CD14	B-protein
(	O
CHO/CD14	B-protein
)	O
.	O

Nuclear	O
translocation	O
of	O
cytosolic	O
NF-kappa	O
B	O
is	O
correlated	O
with	O
a	O
number	O
of	O
LPS-inducible	O
responses	O
.	O

We	O
sought	O
to	O
determine	O
if	O
this	O
pathway	O
were	O
present	O
in	O
CHO/CD14	B-cell_line
cells	I-cell_line
and	O
to	O
elucidate	O
the	O
relationship	O
of	O
NF-kappa	B-protein
B	I-protein
activation	O
to	O
the	O
CD14	B-protein
receptor	O
system	O
.	O

LPS-stimulated	O
translocation	O
of	O
NF-kappa	B-protein
B	I-protein
in	O
CHO/CD14	B-cell_line
cells	I-cell_line
resembled	O
the	O
same	O
response	O
in	O
the	O
murine	B-cell_line
macrophage-like	I-cell_line
cell	I-cell_line
line	I-cell_line
RAW	B-cell_line
264.7	I-cell_line
.	O

Protein	O
synthesis	O
inhibitors	O
and	O
corticosteroids	O
,	O
which	O
suppress	O
arachidonate	O
release	O
and	O
the	O
synthesis	O
of	O
proinflammatory	B-protein
cytokines	I-protein
,	O
had	O
no	O
effect	O
on	O
translocation	O
of	O
NF-kappa	B-protein
B	I-protein
in	O
CHO/	O
CD14	B-protein
or	O
RAW	B-cell_line
264.7	I-cell_line
cells	I-cell_line
,	O
demonstrating	O
that	O
NF-kappa	B-protein
B	I-protein
translocation	O
is	O
an	O
early	O
event	O
.	O

Although	O
TK	O
activity	O
was	O
consistently	O
observed	O
by	O
immunoblotting	O
extracts	O
from	O
activated	O
RAW	B-cell_line
264.7	I-cell_line
cells	I-cell_line
,	O
LPS-induced	O
phosphotyrosine	O
residues	O
were	O
not	O
observed	O
from	O
similarly	O
treated	O
CHO/CD14	B-cell_line
cells	I-cell_line
.	O

Furthermore	O
,	O
the	O
TK	O
inhibitors	O
herbimycin	O
A	O
and	O
genistein	O
failed	O
to	O
inhibit	O
translocation	O
of	O
NF-kappa	B-protein
B	I-protein
in	O
CHO/CD14	B-cell_line
or	O
RAW	B-cell_line
264.7	I-cell_line
cells	I-cell_line
,	O
although	O
both	O
of	O
these	O
agents	O
inhibited	O
LPS-induced	O
TK	O
activity	O
in	O
RAW	B-cell_line
264.7	I-cell_line
cells	I-cell_line
.	O

These	O
results	O
imply	O
that	O
TK	O
activity	O
is	O
not	O
obligatory	O
for	O
CD14	B-protein
-mediated	O
signal	O
transduction	O
to	O
occur	O
in	O
response	O
to	O
LPS	O
.	O

Signals	O
transduced	O
through	O
the	O
CD4	B-protein
molecule	I-protein
on	O
T	B-cell_type
lymphocytes	I-cell_type
activate	O
NF-kappa	B-protein
B	I-protein
.	O

We	O
have	O
demonstrated	O
that	O
native	B-protein
envelope	I-protein
glycoproteins	I-protein
of	O
HIV-1	O
,	O
gp160	O
can	O
induce	O
activation	O
of	O
the	O
transcription	B-protein
factor	I-protein
,	O
NF-kappa	B-protein
B	I-protein
.	O

The	O
stimulatory	O
effects	O
of	O
gp160	O
are	O
mediated	O
through	O
the	O
CD4	B-protein
molecule	I-protein
,	O
since	O
pretreatment	O
with	O
soluble	O
CD4	B-protein
abrogates	O
its	O
activity	O
.	O

The	O
gp160-induced	B-protein
NF-kappa	I-protein
B	I-protein
complex	I-protein
consists	O
of	O
p65	B-protein
,	O
p50	B-protein
and	O
c-rel	B-protein
proteins	I-protein
.	O

The	O
stimulatory	O
effect	O
of	O
gp160	O
on	O
NF-kappa	B-protein
B	I-protein
activation	O
is	O
protein	O
synthesis	O
independent	O
,	O
is	O
dependent	O
upon	O
protein	O
tyrosine	O
phosphorylation	O
,	O
and	O
abrogated	O
by	O
inhibitors	O
of	O
protein	B-protein
kinase	I-protein
C	I-protein
.	O

The	O
gp160-mediated	O
activation	O
of	O
NF-kappa	B-protein
B	I-protein
in	O
CD4	B-cell_type
positive	I-cell_type
T	I-cell_type
cells	I-cell_type
may	O
be	O
involved	O
in	O
biological	O
effects	O
,	O
e.g.	O
,	O
enhanced	O
HIV	O
replication	O
,	O
hypergammaglobulinemia	O
,	O
increased	O
cytokine	B-protein
secretion	O
,	O
hypercellularity	O
in	O
bone	O
marrow	O
and	O
apoptosis	O
.	O

No	O
evidence	O
for	O
the	O
expression	O
of	O
the	O
progesterone	B-protein
receptor	I-protein
on	O
peripheral	B-cell_type
blood	I-cell_type
lymphocytes	I-cell_type
during	O
pregnancy	O
[	O
see	O
comments	O
]	O

The	O
expression	O
of	O
the	O
progesterone	B-protein
receptor	I-protein
in	O
human	B-cell_type
peripheral	I-cell_type
blood	I-cell_type
lymphocytes	I-cell_type
was	O
analysed	O
,	O
using	O
an	O
enzyme	O
linked	O
immunosorbent	O
assay	O
(	O
Abbott	O
PgR-EIA	O
monoclonal	O
)	O
,	O
in	O
order	O
to	O
evaluate	O
its	O
prognostic	O
character	O
in	O
the	O
context	O
of	O
spontaneous	O
abortion	O
.	O

Cytosols	O
were	O
prepared	O
from	O
lymphocytes	O
of	O
24	O
healthy	O
pregnant	O
women	O
(	O
11	O
first	O
,	O
10	O
second	O
and	O
three	O
third	O
trimester	O
)	O
,	O
seven	O
healthy	O
non-pregnant	O
women	O
,	O
nine	O
women	O
with	O
recurrent	O
spontaneous	O
abortion	O
,	O
and	O
six	O
healthy	O
men	O
.	O

In	O
addition	O
,	O
a	O
human	B-cell_line
breast	I-cell_line
carcinoma	I-cell_line
cell	I-cell_line
line	I-cell_line
(	O
ZR-75-1	B-cell_line
)	O
,	O
which	O
expresses	O
the	O
progesterone	B-protein
receptor	I-protein
,	O
was	O
analysed	O
throughout	O
.	O

The	O
ZR-75-1	B-cell_line
cell	I-cell_line
line	I-cell_line
showed	O
an	O
expression	O
of	O
642	O
fmol/mg	O
whereas	O
lymphocytes	O
of	O
pregnant	O
women	O
showed	O
an	O
expression	O
<	O
or	O
=	O
4	O
fmol/mg	O
.	O

Lymphocytes	B-cell_type
of	O
non-pregnant	O
women	O
,	O
women	O
with	O
threatened	O
pre-term	O
delivery	O
,	O
and	O
men	O
showed	O
equivalent	O
levels	O
:	O
3	O
+/-	O
1	O
,	O
3	O
+/-	O
2	O
and	O
5	O
+/-	O
4	O
fmol/mg	O
respectively	O
.	O

These	O
results	O
show	O
that	O
there	O
is	O
no	O
evidence	O
of	O
specific	O
expression	O
of	O
the	O
progesterone	B-protein
receptor	I-protein
in	O
pregnancy	O
and	O
exclude	O
any	O
prognostic	O
character	O
in	O
spontaneous	O
abortion	O
.	O

A	O
role	O
for	O
the	O
progesterone	B-protein
receptor	I-protein
in	O
the	O
mechanism	O
of	O
the	O
known	O
effect	O
of	O
progesterone	O
on	O
peripheral	B-cell_type
blood	I-cell_type
lymphocytes	I-cell_type
is	O
also	O
excluded	O
.	O

Tolerance	O
to	O
lipopolysaccharide	O
involves	O
mobilization	O
of	O
nuclear	B-protein
factor	I-protein
kappa	I-protein
B	I-protein
with	O
predominance	O
of	O
p50	B-protein
homodimers	O
.	O

Stimulation	O
of	O
the	O
human	B-cell_line
monocytic	I-cell_line
cell	I-cell_line
line	I-cell_line
Mono	B-cell_line
Mac	I-cell_line
6	I-cell_line
with	O
lipopolysaccharide	O
(	O
LPS	O
)	O
leads	O
to	O
rapid	O
and	O
transient	O
expression	O
of	O
cytokines	B-protein
like	O
tumor	B-protein
necrosis	I-protein
factor	I-protein
(	O
TNF	B-protein
)	O
.	O

When	O
such	O
cells	O
are	O
precultured	O
for	O
2	O
days	O
with	O
a	O
low	O
dose	O
of	O
LPS	O
(	O
20	O
ng/ml	O
)	O
followed	O
by	O
stimulation	O
with	O
a	O
high	O
dose	O
of	O
LPS	O
(	O
1	O
microgram/ml	O
)	O
,	O
expression	O
of	O
the	O
TNF	B-DNA
gene	I-DNA
is	O
minimal	O
,	O
i.e.	O
the	O
cells	O
are	O
tolerant	O
.	O

In	O
nuclear	O
run-on	O
analysis	O
,	O
such	O
tolerant	B-cell_type
cells	I-cell_type
show	O
only	O
a	O
low	O
degree	O
of	O
transcription	O
,	O
indicating	O
that	O
tolerance	O
operates	O
at	O
or	O
upstream	O
of	O
the	O
transcription	O
level	O
.	O

The	O
CD14	B-protein
LPS	O
receptor	O
is	O
,	O
however	O
,	O
up-regulated	O
(	O
not	O
down-regulated	O
)	O
in	O
tolerant	B-cell_line
cells	I-cell_line
,	O
and	O
LPS	O
can	O
,	O
in	O
fact	O
,	O
still	O
lead	O
to	O
activation	O
of	O
tolerant	B-cell_line
cells	I-cell_line
as	O
evidenced	O
by	O
mobilization	O
of	O
the	O
transcription	B-protein
factor	I-protein
nuclear	B-protein
factor	I-protein
kappa	I-protein
B	I-protein
(	O
NF-kappa	B-protein
B	I-protein
)	O
.	O

Resolution	O
of	O
the	O
NF-kappa	B-protein
B	I-protein
complex	I-protein
in	O
gel	O
shift	O
analysis	O
shows	O
that	O
the	O
binding	B-protein
protein	I-protein
,	O
mobilized	O
in	O
naive	B-cell_line
Mono	I-cell_line
Mac	I-cell_line
6	I-cell_line
cells	I-cell_line
,	O
consists	O
mainly	O
of	O
p50-p65	B-protein
heterodimers	I-protein
,	O
while	O
in	O
tolerant	B-cell_line
cells	I-cell_line
,	O
the	O
p50	B-protein
homodimer	I-protein
is	O
predominant	O
.	O

This	O
increase	O
in	O
p50	B-protein
homodimers	I-protein
coincides	O
with	O
an	O
increase	O
in	O
p105	B-RNA
mRNA	I-RNA
,	O
suggestive	O
of	O
a	O
transcriptional	O
up-regulation	O
of	O
p50	B-protein
.	O

Reporter	O
gene	O
analysis	O
reveals	O
that	O
the	O
NF-kappa	B-protein
B	I-protein
complex	I-protein
mobilized	O
in	O
tolerant	B-cell_line
cells	I-cell_line
is	O
functionally	O
inactive	O
in	O
that	O
NF-kappa	B-DNA
B-dependent	I-DNA
luciferase	I-DNA
constructs	I-DNA
containing	O
the	O
human	B-DNA
immunodeficiency	I-DNA
virus	I-DNA
long	I-DNA
terminal	I-DNA
repeat	I-DNA
or	O
the	O
TNF	B-DNA
5'-region	I-DNA
show	O
only	O
minimal	O
transactivation	O
after	O
LPS	O
stimulation	O
.	O

Similar	O
to	O
Mono	B-cell_line
Mac	I-cell_line
6	I-cell_line
cells	I-cell_line
,	O
primary	B-cell_type
blood	I-cell_type
monocytes	I-cell_type
,	O
when	O
precultured	O
with	O
a	O
low	O
dose	O
of	O
LPS	O
,	O
also	O
become	O
tolerant	O
and	O
produce	O
little	O
TNF	B-protein
after	O
LPS	O
stimulation	O
.	O

The	O
tolerant	B-cell_type
blood	I-cell_type
monocytes	I-cell_type
also	O
up-regulate	O
CD14	B-protein
,	O
and	O
they	O
mobilize	O
NF-kappa	B-protein
B	I-protein
with	O
a	O
predominance	O
of	O
p50	B-protein
homodimers	I-protein
.	O

Taken	O
together	O
,	O
these	O
results	O
demonstrate	O
that	O
tolerance	O
to	O
LPS	O
is	O
determined	O
by	O
post-receptor	O
mechanisms	O
that	O
involve	O
an	O
altered	O
composition	O
of	O
the	O
NF-kappa	B-protein
B	I-protein
complex	I-protein
.	O

Analysis	O
of	O
Oct2-isoform	B-protein
expression	O
in	O
lipopolysaccharide-stimulated	B-cell_line
B	I-cell_line
lymphocytes	I-cell_line
.	O

Oct2-isoform	B-protein
expression	O
in	O
splenic	B-cell_type
B	I-cell_type
cells	I-cell_type
stimulated	O
with	O
lipopolysaccharide	O
or	O
lipopolysaccharide	O
plus	O
phorbol-di-butyrate	O
was	O
analysed	O
by	O
cDNA	O
cloning	O
.	O

The	O
frequency	O
of	O
Oct2-positive	B-cell_line
clones	I-cell_line
was	O
1/15	O
,	O
000	O
in	O
both	O
libraries	O
.	O

Two	O
new	O
isoforms	O
were	O
found	O
that	O
generate	O
novel	O
amino-	B-protein
or	I-protein
carboxy-terminal	I-protein
sequences	I-protein
.	O

An	O
isoform	O
lacking	O
exon	B-DNA
11	I-DNA
destroyed	O
the	O
carboxy-terminal	B-protein
leucin-zipper	I-protein
region	I-protein
and	O
introduced	O
a	O
frame	O
shift	O
creating	O
a	O
novel	O
,	O
proline-rich	B-protein
carboxy	I-protein
terminus	I-protein
.	O

A	O
new	O
exon	B-DNA
containing	O
a	O
highly	O
basic	O
region	O
(	O
4c	O
)	O
was	O
characterized	O
,	O
between	B-DNA
exons	I-DNA
4	I-DNA
and	I-DNA
5	I-DNA
.	O

This	O
exon	O
was	O
inserted	O
between	B-DNA
glutamine-rich	I-DNA
regions	I-DNA
2	I-DNA
and	I-DNA
3	I-DNA
,	O
carboxy	B-protein
terminal	I-protein
of	O
a	O
tentative	O
leucine-zipper	B-protein
structure	I-protein
.	O

In	O
addition	O
,	O
a	O
new	O
combination	O
isoform	O
containing	O
Oct2a	B-protein
's	I-protein
amino	I-protein
terminal	I-protein
insert	I-protein
(	O
exon	B-DNA
7a	I-DNA
)	O
and	O
Oct2b	B-protein
's	I-protein
carboxy	I-protein
terminal	I-protein
insert	I-protein
(	O
exon	B-DNA
13	I-DNA
)	O
was	O
found	O
that	O
created	O
a	O
novel	O
large	O
isoform	O
,	O
Oct2ab	B-protein
.	O

More	O
frequent	O
use	O
of	O
the	O
classical	O
Oct2a	B-protein
and	O
Oct2b	B-protein
isoforms	O
was	O
observed	O
in	O
the	O
lipopolysaccharide-stimulated	B-cell_line
B	I-cell_line
cells	I-cell_line
,	O
while	O
a	O
preference	O
for	O
the	O
Oct2ab	B-protein
and	O
Oct2ba	B-protein
isoforms	O
was	O
observed	O
in	O
lipopolysaccharide	B-cell_line
plus	I-cell_line
phorbol-di-butyrate-treated	I-cell_line
cells	I-cell_line
.	O

Positive	O
regulators	O
of	O
the	O
lineage-specific	O
transcription	B-protein
factor	I-protein
GATA-1	B-protein
in	O
differentiating	B-cell_type
erythroid	I-cell_type
cells	I-cell_type
.	O

The	O
zinc	B-protein
finger	I-protein
transcription	I-protein
factor	I-protein
GATA-1	B-protein
is	O
a	O
major	O
regulator	O
of	O
gene	O
expression	O
in	O
erythroid	B-cell_type
,	I-cell_type
megakaryocyte	I-cell_type
,	I-cell_type
and	I-cell_type
mast	I-cell_type
cell	I-cell_type
lineages	I-cell_type
.	O

GATA-1	B-protein
binds	O
to	O
WGATAR	B-DNA
consensus	I-DNA
motifs	I-DNA
in	O
the	O
regulatory	B-DNA
regions	I-DNA
of	O
virtually	O
all	O
erythroid	B-DNA
cell-specific	I-DNA
genes	I-DNA
.	O

Analyses	O
with	O
cultured	B-cell_line
cells	I-cell_line
and	O
cell-free	O
systems	O
have	O
provided	O
strong	O
evidence	O
that	O
GATA-1	B-protein
is	O
involved	O
in	O
control	O
of	O
globin	B-DNA
gene	I-DNA
expression	O
during	O
erythroid	O
differentiation	O
.	O

Targeted	O
mutagenesis	O
of	O
the	O
GATA-1	B-DNA
gene	I-DNA
in	O
embryonic	B-cell_type
stem	I-cell_type
cells	I-cell_type
has	O
demonstrated	O
its	O
requirement	O
in	O
normal	O
erythroid	O
development	O
.	O

Efficient	O
rescue	O
of	O
the	O
defect	O
requires	O
an	O
intact	O
GATA	B-DNA
element	I-DNA
in	O
the	O
distal	B-DNA
promoter	I-DNA
,	O
suggesting	O
autoregulatory	O
control	O
of	O
GATA-1	B-protein
transcription	O
.	O

To	O
examine	O
whether	O
GATA-1	B-protein
expression	O
involves	O
additional	O
regulatory	B-protein
factors	I-protein
or	O
is	O
maintained	O
entirely	O
by	O
an	O
autoregulatory	O
loop	O
,	O
we	O
have	O
used	O
a	O
transient	O
heterokaryon	O
system	O
to	O
test	O
the	O
ability	O
of	O
erythroid	B-protein
factors	I-protein
to	O
activate	O
the	O
GATA-1	B-DNA
gene	I-DNA
in	O
nonerythroid	O
nuclei	O
.	O

We	O
show	O
here	O
that	O
proerythroblasts	B-cell_type
and	O
mature	B-cell_type
erythroid	I-cell_type
cells	I-cell_type
contain	O
a	O
diffusible	O
activity	O
(	O
TAG	O
)	O
capable	O
of	O
transcriptional	O
activation	O
of	O
GATA-1	B-protein
and	O
that	O
this	O
activity	O
decreases	O
during	O
the	O
terminal	O
differentiation	O
of	O
erythroid	B-cell_type
cells	I-cell_type
.	O

Nuclei	O
from	O
GATA-1	B-cell_line
-mutant	I-cell_line
embryonic	I-cell_line
stem	I-cell_line
cells	I-cell_line
can	O
still	O
be	O
reprogrammed	O
to	O
express	O
their	O
globin	B-DNA
genes	I-DNA
in	O
erythroid	B-cell_type
heterokaryons	I-cell_type
,	O
indicating	O
that	O
de	O
novo	O
induction	O
of	O
GATA-1	B-protein
is	O
not	O
required	O
for	O
globin	B-DNA
gene	I-DNA
activation	O
following	O
cell	O
fusion	O
.	O

Role	O
of	O
HIV-1	B-protein
Nef	I-protein
expression	O
in	O
activation	O
pathways	O
in	O
CD4	B-protein
+	O
T	O
cells	O
.	O

The	O
role	O
of	O
the	O
human	B-protein
immunodeficiency	I-protein
virus	I-protein
(	I-protein
HIV-1	I-protein
)	I-protein
Nef	I-protein
protein	I-protein
in	O
T	O
cell	O
activation	O
pathways	O
was	O
investigated	O
using	O
a	O
Jurkat	B-cell_line
CD4+	I-cell_line
cell	I-cell_line
line	I-cell_line
stably	O
transfected	O
with	O
a	O
Nef	O
expression	O
vector	O
.	O

Secretion	O
of	O
IL-2	B-protein
and	O
TNF-alpha	B-protein
,	O
surface	O
expression	O
of	O
IL-2R	B-protein
,	O
and	O
DNA-binding	O
activity	O
of	O
NF-kappa	B-protein
B	I-protein
and	O
AP-1	B-protein
(	I-protein
Fos/Jun	I-protein
)	I-protein
complex	I-protein
in	O
response	O
to	O
phorbol	O
myristate	O
acetate	O
,	O
TNF-alpha	B-protein
,	O
or	O
immobilized	O
antibodies	O
to	O
CD3	B-protein
were	O
monitored	O
.	O

These	O
parameters	O
were	O
not	O
modified	O
by	O
Nef	B-protein
expression	O
in	O
Jurkat	B-cell_line
cells	I-cell_line
,	O
whereas	O
stimulation	O
with	O
the	O
same	O
stimuli	O
resulted	O
in	O
partial	O
inhibition	O
of	O
LTR	B-DNA
activation	O
in	O
Nef+	B-cell_line
Jurkat	I-cell_line
cells	I-cell_line
.	O

This	O
inhibition	O
was	O
not	O
mediated	O
through	O
Nef	B-protein
phosphorylation	O
on	O
Thr-15	O
or	O
GTP-binding	O
activity	O
because	O
mutations	O
in	O
critical	O
sites	O
did	O
not	O
alter	O
this	O
inhibition	O
.	O

Analysis	O
of	O
truncated	O
LTRs	B-DNA
confirmed	O
that	O
inhibition	O
of	O
LTR	B-DNA
activation	O
was	O
not	O
mediated	O
through	O
NF-kappa	B-protein
B	I-protein
-binding	O
activity	O
but	O
through	O
the	O
region	O
containing	O
the	O
negative	B-DNA
responding	I-DNA
elements	I-DNA
(	O
NREs	B-DNA
)	O
.	O

These	O
results	O
suggest	O
that	O
Nef	B-protein
downmodulates	O
LTR	B-DNA
activation	O
without	O
significantly	O
inhibiting	O
the	O
capacity	O
of	O
T	B-cell_type
cells	I-cell_type
to	O
respond	O
to	O
immunological	O
activations	O
.	O

Tat-binding	B-protein
protein	I-protein
7	I-protein
is	O
a	O
subunit	O
of	O
the	O
26S	B-protein
protease	I-protein
.	O

Subunit	B-protein
6	I-protein
(	O
S6	B-protein
)	O
,	O
an	O
integral	O
component	O
of	O
the	O
26S	B-protein
protease	I-protein
from	O
human	B-cell_type
erythrocytes	I-cell_type
,	O
has	O
been	O
studied	O
by	O
SDS-PAGE	O
,	O
peptide	O
mapping	O
and	O
sequence	O
analysis	O
.	O

S6	B-protein
was	O
cleaved	O
with	O
CNBr	B-protein
and	O
three	O
internal	O
peptides	O
were	O
sequenced	O
.	O

A	O
comparison	O
with	O
known	O
proteins	O
in	O
Genbank	O
revealed	O
that	O
all	O
three	O
S6	B-protein
peptides	O
match	O
the	O
predicted	O
sequence	O
of	O
TBP7	B-protein
,	O
Tat-binding	B-protein
protein	I-protein
7	I-protein
.	O

Based	O
on	O
peptide	O
matches	O
covering	O
more	O
than	O
10	O
%	O
of	O
the	O
TBP7	B-protein
sequence	O
,	O
and	O
the	O
fact	O
that	O
the	O
migration	O
of	O
S6	B-protein
on	O
SDS-PAGE	O
is	O
consistent	O
with	O
the	O
estimated	O
molecular	O
mass	O
for	O
TBP7	B-protein
,	O
we	O
conclude	O
that	O
subunit	B-protein
6	I-protein
of	O
the	O
26S	B-protein
protease	I-protein
is	O
TBP7	B-protein
.	O

Hypoxia	O
causes	O
the	O
activation	O
of	O
nuclear	B-protein
factor	I-protein
kappa	I-protein
B	I-protein
through	O
the	O
phosphorylation	O
of	O
I	B-protein
kappa	I-protein
B	I-protein
alpha	I-protein
on	O
tyrosine	O
residues	O
.	O

The	O
response	O
of	O
mammalian	B-cell_type
cells	I-cell_type
to	O
stress	O
is	O
controlled	O
by	O
transcriptional	B-protein
regulatory	I-protein
proteins	I-protein
such	O
as	O
nuclear	B-protein
factor	I-protein
kappa	I-protein
B	I-protein
(	O
NF-kappa	B-protein
B	I-protein
)	O
to	O
induce	O
a	O
wide	O
variety	O
of	O
early	B-DNA
response	I-DNA
genes	I-DNA
.	O

In	O
this	O
report	O
,	O
we	O
show	O
that	O
exposure	O
of	O
cells	O
to	O
hypoxia	O
(	O
0.02	O
%	O
O2	O
)	O
results	O
in	O
I	B-protein
kappa	I-protein
B	I-protein
alpha	I-protein
degradation	O
,	O
increased	O
NF-kappa	B-protein
B	I-protein
DNA	O
binding	O
activity	O
,	O
and	O
transactivation	O
of	O
a	O
reporter	B-DNA
gene	I-DNA
construct	I-DNA
containing	O
two	O
NF-kappa	B-DNA
B	I-DNA
DNA	I-DNA
binding	I-DNA
sites	I-DNA
.	O

Pretreatment	O
of	O
cells	O
with	O
protein	O
tyrosine	B-protein
kinase	I-protein
inhibitors	O
and	O
the	O
dominant	B-DNA
negative	I-DNA
allele	I-DNA
of	O
c-Raf-1	B-DNA
(	O
Raf	B-protein
301	I-protein
)	O
inhibited	O
I	B-protein
kappa	I-protein
B	I-protein
alpha	I-protein
degradation	O
,	O
NF-kappa	B-protein
B	I-protein
binding	O
,	O
and	O
transactivation	O
of	O
kappa	B-DNA
B	I-DNA
reporter	I-DNA
constructs	I-DNA
by	O
hypoxia	O
.	O

To	O
demonstrate	O
a	O
direct	O
link	O
between	O
changes	O
in	O
the	O
phosphorylation	O
pattern	O
of	O
I	B-protein
kappa	I-protein
B	I-protein
alpha	I-protein
with	O
NF-kappa	B-protein
B	I-protein
activation	O
,	O
we	O
immunoprecipitated	O
I	B-protein
kappa	I-protein
B	I-protein
alpha	I-protein
after	O
varying	O
times	O
of	O
hypoxic	O
exposure	O
and	O
found	O
that	O
its	O
tyrosine	O
phosphorylation	O
status	O
increased	O
during	O
hypoxic	O
exposure	O
.	O

Inhibition	O
of	O
the	O
transfer	O
of	O
tyrosine	O
phosphoryl	O
groups	O
onto	O
I	B-protein
kappa	I-protein
B	I-protein
alpha	I-protein
prevented	O
I	B-protein
kappa	I-protein
B	I-protein
alpha	I-protein
degradation	O
and	O
NF-kappa	B-protein
B	I-protein
binding	O
.	O

In	O
comparison	O
to	O
other	O
activators	O
of	O
NF-kappa	B-protein
B	I-protein
such	O
as	O
phorbol	O
myristate	O
acetate	O
or	O
tumor	B-protein
necrosis	I-protein
factor	I-protein
,	O
we	O
did	O
not	O
detect	O
changes	O
in	O
the	O
tyrosine	O
phosphorylation	O
status	O
of	O
I	B-protein
kappa	I-protein
B	I-protein
alpha	I-protein
following	O
treatment	O
with	O
either	O
of	O
these	O
agents	O
.	O

These	O
results	O
suggest	O
that	O
tyrosine	O
phosphorylation	O
of	O
I	B-protein
kappa	I-protein
B	I-protein
alpha	I-protein
during	O
hypoxia	O
is	O
an	O
important	O
proximal	O
step	O
which	O
precedes	O
its	O
dissociation	O
and	O
degradation	O
from	O
NF-kappa	B-protein
B	I-protein
.	O

Overproduction	O
of	O
NFKB2	B-protein
(	O
lyt-10	B-protein
)	O
and	O
c-Rel	B-protein
:	O
a	O
mechanism	O
for	O
HTLV-I	B-protein
Tax	I-protein
-mediated	O
trans-activation	O
via	O
the	O
NF-kappa	B-protein
B	I-protein
signalling	O
pathway	O
.	O

Molecular	O
,	O
biochemical	O
and	O
epidemiological	O
evidence	O
implicate	O
HTLV-I	O
as	O
an	O
etiologic	O
agent	O
of	O
adult	O
T	O
cell	O
leukemia	O
(	O
ATL	O
)	O
.	O

The	O
Tax	B-protein
protein	I-protein
of	O
HTLV-I	O
,	O
a	O
positive	B-protein
transcriptional	I-protein
activator	I-protein
of	O
HTLV-I	O
gene	O
expression	O
,	O
is	O
a	O
viral	O
oncogene	O
that	O
also	O
increases	O
transcription	O
of	O
cellular	B-DNA
genes	I-DNA
including	O
GM-CSF	B-protein
,	O
IL-2R	B-protein
alpha	I-protein
and	O
IL-2	B-protein
.	O

One	O
of	O
the	O
cellular	O
targets	O
of	O
the	O
trans-activating	O
effects	O
of	O
Tax	O
is	O
the	O
NF-kappa	B-protein
B/Rel	I-protein
family	I-protein
of	O
transcription	B-protein
factors	I-protein
,	O
pleiotropic	B-protein
regulators	I-protein
of	O
immunoregulatory	O
,	O
cytokine	O
and	O
viral	O
gene	O
expression	O
.	O

In	O
this	O
report	O
,	O
we	O
demonstrate	O
that	O
NFKB2	B-protein
(	O
lyt-10	B-protein
)	O
and	O
c-Rel	B-protein
are	O
overexpressed	O
in	O
HTLV-I	O
infected	O
and	O
Tax-expressing	B-cell_type
cells	I-cell_type
and	O
,	O
together	O
,	O
account	O
for	O
the	O
majority	O
of	O
the	O
constitutive	O
NF-kappa	B-protein
B	I-protein
binding	O
activity	O
in	O
these	O
cells	O
before	O
and	O
after	O
PMA	O
stimulation	O
.	O

Most	O
importantly	O
,	O
we	O
show	O
a	O
Tax	B-protein
-dependent	O
correlation	O
between	O
expression	O
of	O
NFKB2	B-protein
(	O
p100	B-protein
)	O
and	O
processing	O
to	O
the	O
DNA	O
binding	O
NFKB2	B-protein
(	O
p52	B-protein
)	O
form	O
,	O
induction	O
of	O
c-Rel	B-protein
,	O
and	O
trans-activation	O
of	O
NF-kappa	B-protein
B	I-protein
-mediated	O
gene	O
expression	O
.	O

Furthermore	O
,	O
the	O
NFKB2	B-protein
precursor	O
is	O
physically	O
associated	O
with	O
c-Rel	B-protein
and	O
with	O
Tax	B-protein
in	O
HTLV-I	B-cell_type
infected	I-cell_type
cells	I-cell_type
.	O

We	O
propose	O
that	O
NFKB2	B-protein
synthesis	O
and	O
processing	O
allows	O
continuous	O
nuclear	O
expression	O
of	O
an	O
otherwise	O
cytoplasmic	B-protein
protein	I-protein
and	O
,	O
in	O
conjunction	O
with	O
overexpression	O
of	O
c-Rel	B-protein
,	O
NFKB2	B-protein
alters	O
the	O
NF-kappa	B-protein
B	I-protein
signalling	O
pathway	O
and	O
contributes	O
to	O
leukemic	O
transformation	O
of	O
T	B-cell_type
cells	I-cell_type
by	O
HTLV-I	O
.	O

Retinoic	O
acid	O
downmodulates	O
erythroid	O
differentiation	O
and	O
GATA1	B-protein
expression	O
in	O
purified	B-cell_line
adult-progenitor	I-cell_line
culture	I-cell_line
.	O

All-trans	O
retinoic	O
acid	O
(	O
RA	O
)	O
is	O
an	O
important	O
morphogen	O
in	O
vertebrate	O
development	O
,	O
a	O
normal	O
constituent	O
in	O
human	O
adult	O
blood	O
and	O
is	O
also	O
involved	O
in	O
the	O
control	O
of	O
cell	O
growth	O
and	O
differentiation	O
in	O
acute	O
promyelocytic	O
leukemia	O
.	O

We	O
have	O
examined	O
the	O
effects	O
of	O
RA	O
on	O
normal	O
hematopoiesis	O
by	O
using	O
early	O
hematopoietic	B-cell_type
progenitor	I-cell_type
cells	I-cell_type
(	O
HPC	B-cell_type
)	O
stringently	O
purified	O
from	O
adult	O
peripheral	O
blood	O
.	O

In	O
clonogenetic	B-cell_line
fetal	I-cell_line
calf	I-cell_line
serum-supplemented	I-cell_line
(	I-cell_line
FCS+	I-cell_line
)	I-cell_line
or	I-cell_line
-nonsupplemented	I-cell_line
(	I-cell_line
FCS-	I-cell_line
)	I-cell_line
culture	I-cell_line
treated	O
with	O
saturating	O
levels	O
of	O
interleukin-3	B-protein
(	O
IL-3	B-protein
)	O
granulocyte-macrophage	B-protein
colony-stimulating	I-protein
factor	I-protein
(	O
GM-CSF	B-protein
)	O
and	O
erythropoietin	B-protein
(	O
Ep	B-protein
)	O
(	O
combined	O
with	O
c-kit	B-protein
ligand	O
in	O
FCS	O
(	O
-	O
)	O
-culture	O
conditions	O
)	O
,	O
RA	O
induces	O
a	O
dramatic	O
dose-dependent	O
shift	O
from	O
erythroid	O
to	O
granulomonocytic	O
colony	O
formation	O
,	O
the	O
latter	O
colonies	O
being	O
essentially	O
represented	O
by	O
granulocytic	B-cell_line
clones	I-cell_line
.	O

This	O
shift	O
is	O
apparently	O
not	O
caused	O
by	O
a	O
recruitment	O
phenomenon	O
,	O
because	O
in	O
FCS+	B-cell_line
culture	I-cell_line
,	O
the	O
total	O
number	O
of	O
colonies	O
is	O
not	O
significantly	O
modified	O
by	O
RA	O
addition	O
.	O

In	O
FCS-	B-cell_line
liquid-suspension	I-cell_line
culture	I-cell_line
supplemented	O
with	O
saturating	O
Ep	B-protein
level	O
and	O
low-dose	B-protein
IL-3/GM-CSF	I-protein
,	O
adult	O
HPC	B-cell_type
undergo	O
unilineage	O
erythropoietic	O
differentiation	O
:	O
Here	O
again	O
,	O
treatment	O
with	O
high-dose	O
RA	O
induces	O
a	O
shift	O
from	O
the	O
erythroid	O
to	O
granulocytic	O
differentiation	O
pathway	O
.	O

Studies	O
on	O
RA	O
time-response	O
or	O
pulse	O
treatment	O
in	O
semisolid	O
or	O
liquid	O
culture	O
show	O
that	O
early	O
RA	O
addition	O
is	O
most	O
effective	O
,	O
thus	O
indicating	O
that	O
early	O
but	O
not	O
late	O
HPC	B-cell_type
are	O
sensitive	O
to	O
its	O
action	O
.	O

We	O
then	O
analyzed	O
the	O
expression	O
of	O
the	O
master	B-DNA
GATA1	I-DNA
gene	I-DNA
,	O
which	O
encodes	O
a	O
finger	B-protein
transcription	I-protein
factor	I-protein
required	O
for	O
normal	O
erythroid	O
development	O
;	O
addition	O
of	O
RA	O
to	O
HPC	B-cell_type
stimulated	O
into	O
unilineage	O
erythropoietic	O
differentiation	O
in	O
liquid	O
culture	O
caused	O
a	O
virtually	O
complete	O
inhibition	O
of	O
GATA1	B-RNA
mRNA	I-RNA
induction	O
.	O

These	O
results	O
indicate	O
that	O
RA	O
directly	O
inhibits	O
the	O
erythroid	O
differentiation	O
program	O
at	O
the	O
level	O
of	O
early	O
adult	O
HPC	B-cell_type
,	O
and	O
may	O
lead	O
to	O
a	O
shift	O
from	O
the	O
erythroid	O
to	O
granulocytic	O
differentiation	O
pathway	O
.	O

This	O
phenomenon	O
is	O
correlated	O
with	O
inhibition	O
of	O
GATA1	B-protein
induction	O
in	O
the	O
early	O
stages	O
of	O
erythropoietic	O
differentiation	O
.	O

Induction	O
of	O
phosphatidylinositol	O
turnover	O
and	O
EGR-1	B-RNA
mRNA	I-RNA
expression	O
by	O
crosslinking	O
of	O
surface	O
IgM	B-protein
and	O
IgD	B-protein
in	O
the	O
human	B-cell_line
B	I-cell_line
cell	I-cell_line
line	I-cell_line
B104	I-cell_line
.	O

We	O
have	O
previously	O
shown	O
that	O
a	O
human	B-cell_line
B	I-cell_line
lymphoma	I-cell_line
cell	I-cell_line
line	I-cell_line
,	I-cell_line
B104	I-cell_line
,	O
expressed	O
surface	B-protein
IgM	I-protein
(	O
sIgM	B-protein
)	O
and	O
surface	B-protein
IgD	I-protein
(	O
sIgD	B-protein
)	O
,	O
and	O
that	O
crosslinking	O
of	O
sIgM	B-protein
and	O
sIgD	B-protein
by	O
anti-IgM	B-protein
antibody	I-protein
(	I-protein
Ab	I-protein
)	I-protein
and	O
anti-IgD	B-protein
Ab	I-protein
,	O
respectively	O
,	O
induced	O
Ca2+	O
influx	O
to	O
almost	O
the	O
same	O
degree	O
,	O
whereas	O
only	O
sIgM	B-protein
-crosslinking	O
caused	O
B104	B-cell_line
cell	I-cell_line
death	O
.	O

Here	O
,	O
we	O
investigated	O
the	O
accumulation	O
of	O
cyclic	O
AMP	O
(	O
cAMP	O
)	O
,	O
the	O
hydrolysis	O
of	O
inositol	O
phosphates	O
,	O
protein	B-protein
kinase	I-protein
C	I-protein
(	O
PKC	B-protein
)	O
activity	O
and	O
the	O
induction	O
of	O
Egr-1	O
and	O
c-fos	O
mRNA	O
expression	O
by	O
sIgM-	O
and	O
sIgD-crosslinking	O
to	O
examine	O
differences	O
in	O
the	O
signals	O
mediated	O
through	O
sIgM	B-protein
and	O
sIgD	B-protein
in	O
B104	B-cell_line
cells	I-cell_line
.	O

Both	O
sIgM-	O
and	O
sIgD-crosslinking	O
with	O
antibodies	O
induced	O
elevation	O
of	O
cAMP	O
levels	O
,	O
phosphatidylinositol	O
turnover	O
,	O
PKC	B-protein
activation	O
and	O
expression	O
of	O
Egr-1	B-RNA
and	I-RNA
c-fos	I-RNA
mRNA	I-RNA
,	O
although	O
sIgM	B-protein
-crosslinking	O
was	O
more	O
effective	O
than	O
sIgD	B-protein
-crosslinking	O
,	O
presumably	O
due	O
to	O
the	O
higher	O
expression	O
of	O
sIgM	B-protein
than	O
of	O
sIgD	B-protein
.	O

Egr-1	B-RNA
mRNA	I-RNA
expression	O
induced	O
by	O
sIgM-	O
and	O
sIgD-crosslinking	O
was	O
inhibited	O
by	O
H7	B-protein
,	O
erbstatin	O
and	O
genistein	O
,	O
but	O
not	O
by	O
HA1004	O
.	O

Erbstatin	O
and	O
genistein	O
inhibited	O
the	O
sIg-crosslinking-induced	O
Egr-1	B-RNA
mRNA	I-RNA
expression	O
in	O
a	O
dose-dependent	O
manner	O
parallel	O
to	O
that	O
observed	O
in	O
the	O
inhibition	O
of	O
sIg-crosslinking-induced	O
protein	O
tyrosine	O
phosphorylation	O
.	O

Phorbol	O
myristate	O
acetate	O
induced	O
Egr-1	B-RNA
mRNA	I-RNA
expression	O
but	O
forskolin	O
and	O
dibutyryl	O
cyclic	O
AMP	O
did	O
not	O
.	O

These	O
findings	O
suggest	O
that	O
the	O
Egr-1	B-RNA
mRNA	I-RNA
activating	O
signals	O
through	O
sIgM	B-protein
and	O
sIgD	B-protein
are	O
protein	O
tyrosine	O
kinase-	O
and	O
PKC-dependent	O
,	O
but	O
protein	B-protein
kinase	I-protein
A	I-protein
-independent	O
.	O

Cyclosporin	O
A	O
(	O
CsA	O
)	O
and	O
FK506	O
rescued	O
B104	B-cell_line
cells	I-cell_line
from	O
death	O
induced	O
by	O
anti-IgM	B-protein
Ab	I-protein
,	O
but	O
did	O
not	O
affect	O
the	O
expression	O
of	O
Egr-1	B-protein
and	O
c-fos	B-RNA
mRNA	I-RNA
,	O
showing	O
that	O
CsA	O
and	O
FK506	O
affect	O
signal	O
transducers	O
differently	O
from	O
or	O
downstream	O
to	O
these	O
molecules	O
.	O

The	O
difference	O
in	O
signals	O
transduced	O
through	O
sIgM	B-protein
and	O
sIgD	B-protein
in	O
B104	B-cell_line
cells	I-cell_line
is	O
discussed	O
.	O

Direct	O
exposure	O
to	O
2	O
,	O
3	O
,	O
7	O
,	O
8-tetrachlorodibenzo-p-dioxin	O
(	O
TCDD	O
)	O
increases	O
infectivity	O
of	O
human	B-cell_type
erythrocytes	I-cell_type
to	O
a	O
malarial	O
parasite	O
.	O

Direct	O
exposure	O
to	O
10	O
nM	O
2	O
,	O
3	O
,	O
7	O
,	O
8-TCDD	O
caused	O
a	O
75	O
%	O
increase	O
and	O
a	O
2-fold	O
increase	O
in	O
the	O
infectivity	O
of	O
isolated	O
human	B-cell_type
erythrocytes	I-cell_type
to	O
P.	O
falciparum	O
after	O
48	O
hours	O
when	O
the	O
parasites	O
were	O
in	O
an	O
unsynchronized	O
or	O
synchronized	O
state	O
of	O
growth	O
,	O
respectively	O
.	O

Treatment	O
of	O
human	B-cell_type
erythrocytes	I-cell_type
with	O
10	O
microM	O
sodium	O
orthovanadate	O
(	O
NaOV	O
)	O
,	O
an	O
inhibitor	O
of	O
plasma	B-protein
membrane	I-protein
Ca-ATPase	I-protein
and	O
phosphotyrosine	B-protein
phosphatase	I-protein
,	O
decreased	O
parasitemia	O
by	O
30	O
%	O
.	O

Co-treatment	O
of	O
RBCs	B-cell_type
with	O
TCDD	O
and	O
NaOV	O
completely	O
blocked	O
the	O
TCDD-induced	O
increase	O
in	O
parasitemia	O
.	O

Because	O
erythrocytes	B-cell_type
are	O
anucleated	O
,	O
these	O
results	O
are	O
discussed	O
as	O
evidence	O
for	O
biochemical	O
changes	O
by	O
TCDD	O
without	O
requiring	O
the	O
activation	O
of	O
gene	B-protein
products	I-protein
.	O

Evidence	O
for	O
a	O
trans-acting	B-protein
activator	I-protein
function	O
regulating	O
the	O
expression	O
of	O
the	O
human	B-protein
CD5	I-protein
antigen	I-protein
.	O

Interspecies	O
somatic	B-cell_line
cell	I-cell_line
hybrids	I-cell_line
were	O
generated	O
by	O
fusing	O
the	O
mouse	B-cell_line
T-lymphoma	I-cell_line
cell	I-cell_line
line	I-cell_line
,	O
BW5147	B-cell_line
,	O
with	O
normal	B-cell_type
human	I-cell_type
T	I-cell_type
lymphocytes	I-cell_type
at	O
different	O
stages	O
of	O
differentiation	O
.	O

Thymocytes	B-cell_type
,	O
activated	B-cell_type
peripheral	I-cell_type
T	I-cell_type
lymphocytes	I-cell_type
,	O
or	O
an	O
activated	B-cell_line
T-cell	I-cell_line
clone	I-cell_line
were	O
used	O
as	O
human	O
partners	O
,	O
respectively	O
,	O
in	O
three	O
independent	O
fusions	O
.	O

Irrespective	O
of	O
the	O
human	O
cell	O
partner	O
used	O
for	O
fusion	O
,	O
a	O
certain	O
number	O
of	O
hybrids	B-cell_line
lost	O
CD5	B-protein
surface	O
expression	O
over	O
a	O
period	O
of	O
time	O
in	O
culture	O
.	O

Analysis	O
at	O
the	O
phenotype	O
and	O
genetic	O
level	O
showed	O
that	O
lack	O
of	O
CD5	B-protein
expression	O
was	O
due	O
neither	O
to	O
segregation	O
of	O
human	B-DNA
autosome	I-DNA
11	I-DNA
,	O
on	O
which	O
the	O
CD5	B-DNA
gene	I-DNA
has	O
been	O
mapped	O
,	O
nor	O
to	O
deletion	O
of	O
the	O
CD5	B-DNA
structural	I-DNA
gene	I-DNA
.	O

Furthermore	O
,	O
loss	O
of	O
CD5	B-protein
surface	O
expression	O
correlated	O
with	O
the	O
absence	O
of	O
specific	O
mRNA	B-RNA
.	O

Since	O
these	O
hybrids	O
preferentially	O
segregate	O
human	O
chromosomes	O
,	O
these	O
results	O
indicate	O
the	O
existence	O
of	O
a	O
non-syntenic	B-DNA
trans-active	I-DNA
locus	I-DNA
,	O
or	O
loci	O
,	O
positively	O
controlling	O
the	O
expression	O
of	O
the	O
human	B-DNA
CD5	I-DNA
gene	I-DNA
.	O

Induction	O
of	O
the	O
CD11b	B-DNA
gene	I-DNA
during	O
activation	O
of	O
the	O
monocytic	B-cell_line
cell	I-cell_line
line	I-cell_line
U937	I-cell_line
requires	O
a	O
novel	O
nuclear	B-protein
factor	I-protein
MS-2	B-protein
[	O
published	O
erratum	O
appears	O
in	O
J	O
Immunol	O
1999	O
Jul	O
15	O
;	O
163	O
(	O
2	O
)	O
:	O
1091	O
]	O

The	O
differentiation	O
of	O
myeloid	B-cell_type
precursors	I-cell_type
into	O
mature	O
myelomonocytic	B-cell_type
cells	I-cell_type
is	O
characterized	O
by	O
the	O
induction	O
of	O
the	O
gene	O
encoding	O
the	O
beta2	B-protein
integrin	I-protein
CD11b	B-protein
.	O

The	O
transcription	B-protein
factors	I-protein
Sp1	B-protein
and	O
PU.1	B-protein
prime	I-protein
the	O
CD11b	B-DNA
promoter	I-DNA
,	O
but	O
the	O
nature	O
of	O
the	O
factors	O
responsible	O
for	O
its	O
inducible	O
expression	O
are	O
unknown	O
.	O

In	O
addition	O
to	O
the	O
CD11b	B-DNA
gene	I-DNA
,	O
the	O
homologous	O
genes	O
encoding	O
CD11a	B-protein
and	O
CD11c	B-protein
also	O
exhibit	O
inducible	O
expression	O
during	O
myeloid	O
differentiation	O
.	O

Therefore	O
,	O
we	O
compared	O
the	O
nucleotide	B-DNA
sequences	I-DNA
of	O
the	O
CD11a	B-DNA
,	I-DNA
CD11b	I-DNA
,	I-DNA
and	I-DNA
CD11c	I-DNA
gene	I-DNA
promoters	I-DNA
to	O
identify	O
common	O
elements	O
that	O
might	O
contribute	O
to	O
inducible	O
expression	O
.	O

This	O
analysis	O
identified	O
one	O
such	O
element	O
repeated	O
four	O
times	O
within	O
the	O
CD11b	B-DNA
promoter	I-DNA
.	O

Mutation	O
of	O
these	O
elements	O
indicated	O
that	O
two	O
,	O
MS-2beta	B-protein
and	O
MS-2gamma	B-protein
,	O
are	O
critical	O
to	O
the	O
induction	O
of	O
the	O
CD11b	B-DNA
gene	I-DNA
during	O
differentiation	O
of	O
the	O
pro-monocytic	B-cell_line
cell	I-cell_line
line	I-cell_line
U937	I-cell_line
.	O

Electrophoretic	O
mobility	O
shift	O
assays	O
indicate	O
that	O
MS-2beta	B-protein
and	O
MS-2gamma	B-protein
interact	O
with	O
nuclear	B-protein
factors	I-protein
that	O
are	O
induced	O
during	O
U937	B-cell_line
differentiation	O
.	O

These	O
factors	O
are	O
detected	O
at	O
the	O
time	O
the	O
CD11b	B-DNA
promoter	I-DNA
is	O
activated	O
.	O

The	O
molecular	O
mass	O
of	O
these	O
factors	O
is	O
approximately	O
28	O
kDa	O
,	O
and	O
their	O
DNA	O
binding	O
characteristics	O
are	O
indistinguishable	O
from	O
those	O
of	O
the	O
novel	O
nuclear	B-protein
factor	I-protein
MS-2	B-protein
.	O

Taken	O
together	O
,	O
our	O
data	O
indicate	O
that	O
MS-2	B-protein
mediates	O
induction	O
of	O
the	O
CD11b	B-DNA
gene	I-DNA
as	O
cells	O
of	O
the	O
monocytic	O
lineage	O
mature	O
.	O

The	O
presence	O
of	O
multiple	O
potential	O
binding	O
sites	O
for	O
MS-2	B-protein
in	O
the	O
promoter	O
regions	O
of	O
a	O
wide	O
range	O
of	O
genes	O
expressed	O
in	O
mature	B-cell_type
myeloid	I-cell_type
cells	I-cell_type
suggests	O
this	O
factor	O
plays	O
a	O
general	O
role	O
in	O
myeloid	O
differentiation	O
.	O

Acetylsalicylic	O
acid	O
and	O
sodium	O
salicylate	O
inhibit	O
LPS-induced	O
NF-kappa	B-protein
B/c-Rel	I-protein
nuclear	O
translocation	O
,	O
and	O
synthesis	O
of	O
tissue	B-protein
factor	I-protein
(	O
TF	B-protein
)	O
and	O
tumor	B-protein
necrosis	I-protein
factor	I-protein
alfa	I-protein
(	O
TNF-alpha	B-protein
)	O
in	O
human	B-cell_type
monocytes	I-cell_type
.	O

We	O
have	O
investigated	O
the	O
effects	O
of	O
acetylsalicylic	O
acid	O
and	O
sodium	O
salicylate	O
on	O
the	O
LPS-induced	O
synthesis	O
of	O
the	O
pro-coagulant	O
protein	O
tissue	O
factor	O
(	O
TF	O
)	O
and	O
the	O
pro-inflammatory	O
protein	O
tumor	O
necrosis	O
factor-alpha	O
(	O
TNF-alpha	B-protein
)	O
,	O
as	O
well	O
as	O
the	O
prostaglandin	B-protein
PGE2	I-protein
in	O
human	B-cell_type
monocytes	I-cell_type
.	O

Both	O
drugs	O
dose-dependently	O
inhibited	O
LPS-induced	B-protein
TF	I-protein
and	O
TNF-alpha	B-protein
synthesis	O
at	O
the	O
mRNA	B-RNA
and	O
the	O
protein	O
level	O
,	O
and	O
reduced	O
PGE2	B-protein
production	O
.	O

As	O
evidenced	O
by	O
electro	O
mobility	O
shift	O
assay	O
(	O
EMSA	O
)	O
and	O
the	O
use	O
of	O
a	O
NF-kappa	B-DNA
B	I-DNA
prototypic	I-DNA
probe	I-DNA
,	O
these	O
drugs	O
probably	O
exert	O
their	O
inhibitory	O
effects	O
by	O
interference	O
with	O
the	O
nuclear	O
translocation	O
of	O
NF-kappa	B-protein
B/c-Rel	I-protein
proteins	I-protein
.	O

These	O
data	O
may	O
expand	O
the	O
understanding	O
of	O
the	O
anti-thrombotic	O
and	O
anti-inflammatory	O
effects	O
of	O
these	O
drugs	O
when	O
activation	O
of	O
monocytes	B-cell_type
occurs	O
.	O

Interferon	O
augments	O
PML	B-protein
and	O
PML/RAR	B-protein
alpha	I-protein
expression	O
in	O
normal	O
myeloid	B-cell_type
and	O
acute	B-cell_type
promyelocytic	I-cell_type
cells	I-cell_type
and	O
cooperates	O
with	O
all-trans	O
retinoic	O
acid	O
to	O
induce	O
maturation	O
of	O
a	O
retinoid-resistant	B-cell_line
promyelocytic	I-cell_line
cell	I-cell_line
line	I-cell_line
.	O

The	O
PML	B-DNA
gene	I-DNA
is	O
fused	O
to	O
the	O
retinoic	B-DNA
acid	I-DNA
receptor	I-DNA
alpha	I-DNA
gene	I-DNA
(	O
RAR	B-DNA
alpha	I-DNA
)	O
in	O
the	O
acute	O
promyelocytic	O
leukemia	O
(	O
APL	O
)	O
15	O
;	O
17	O
translocation	O
.	O

PML	B-protein
is	O
expressed	O
in	O
diverse	O
tissues	O
and	O
cell	O
lines	O
and	O
localized	O
in	O
the	O
nucleus	O
with	O
a	O
typical	O
speckled	O
pattern	O
.	O

In	O
the	O
bone	O
marrow	O
,	O
it	O
is	O
preferentially	O
expressed	O
in	O
myeloid	B-cell_type
cells	I-cell_type
.	O

PML	B-protein
appears	O
to	O
be	O
transcriptionally	O
regulated	O
by	O
class	B-protein
I	I-protein
and	I-protein
II	I-protein
interferons	I-protein
,	O
which	O
raises	O
the	O
possibility	O
that	O
interferons	O
modulate	O
the	O
function	O
and	O
growth	O
and	O
differentiation	O
potential	O
of	O
normal	O
myeloid	B-cell_type
cells	I-cell_type
and	O
precursors	O
by	O
activating	O
PML	B-protein
-dependent	O
pathways	O
.	O

Similarly	O
,	O
interferons	O
could	O
act	O
on	O
APL	B-cell_type
cells	I-cell_type
,	O
alone	O
or	O
in	O
combination	O
with	O
all-trans	O
retinoic	O
acid	O
(	O
RA	O
)	O
,	O
especially	O
if	O
the	O
PML/RAR	B-RNA
alpha	I-RNA
fusion	I-RNA
transcript	I-RNA
that	O
results	O
from	O
the	O
t	B-DNA
(	I-DNA
15	I-DNA
;	I-DNA
17	I-DNA
)	I-DNA
is	O
induced	O
by	O
interferon	B-protein
.	O

We	O
report	O
here	O
that	O
PML	B-protein
is	O
expressed	O
at	O
low	O
levels	O
or	O
not	O
expressed	O
in	O
normal	O
circulating	O
human	B-cell_type
monocytes	I-cell_type
,	O
lymphocytes	B-cell_type
,	O
and	O
polymorphonucleate	B-cell_type
cells	I-cell_type
,	O
but	O
is	O
markedly	O
induced	O
by	O
interferon	B-protein
;	O
that	O
PML	B-protein
and	O
PML/RAR	B-protein
alpha	I-protein
expression	O
is	O
augmented	O
by	O
interferon	B-protein
in	O
the	O
NB4	B-cell_line
APL	I-cell_line
cell	I-cell_line
line	I-cell_line
,	O
which	O
carries	O
the	O
t	B-DNA
(	I-DNA
15	I-DNA
;	I-DNA
17	I-DNA
)	I-DNA
,	O
and	O
in	O
APL	B-cell_type
blasts	I-cell_type
from	O
patients	O
;	O
that	O
interferon	B-protein
inhibits	O
growth	O
and	O
survival	O
of	O
NB4	O
APL	B-cell_type
cells	I-cell_type
in	O
cooperation	O
with	O
RA	O
;	O
that	O
interferons	O
alone	O
have	O
minimal	O
maturation	O
effect	O
on	O
NB4	B-cell_line
cells	I-cell_line
;	O
and	O
,	O
finally	O
,	O
that	O
interferon	B-protein
gamma	I-protein
,	I-protein
but	I-protein
not	I-protein
alpha	I-protein
or	I-protein
beta	I-protein
,	O
induces	O
maturation	O
and	O
growth	O
suppression	O
of	O
NB4	B-cell_line
cells	I-cell_line
with	O
de	O
novo	O
retinoid	O
resistance	O
,	O
and	O
partially	O
restores	O
RA	O
response	O
.	O

Effects	O
of	O
Ara-C	O
on	O
neutral	B-protein
sphingomyelinase	I-protein
and	O
mitogen-	B-protein
and	I-protein
stress-	I-protein
activated	I-protein
protein	I-protein
kinases	I-protein
in	O
T-lymphocyte	B-cell_line
cell	I-cell_line
lines	I-cell_line
.	O

Neutral	B-protein
sphingomyelinase	I-protein
(	O
SMase	B-protein
)	O
can	O
be	O
activated	O
by	O
extracellular	O
signals	O
to	O
produce	O
ceramide	O
,	O
which	O
may	O
affect	O
mitogen-activated	B-protein
protein	I-protein
kinase	I-protein
(	O
MAPK	B-protein
)	O
activities	O
.	O

Neutral	O
SMase	B-protein
activity	O
was	O
assessed	O
in	O
membranes	O
from	O
Jurkat	B-cell_line
,	O
a	O
human	B-cell_line
T-cell	I-cell_line
line	I-cell_line
,	O
and	O
EL4	B-cell_line
,	O
a	O
murine	B-cell_line
T-cell	I-cell_line
line	I-cell_line
.	O

Ara-C	O
activated	O
SMase	B-protein
with	O
10	O
minutes	O
in	O
both	O
Jurkat	O
and	O
EL4	B-cell_line
cells	I-cell_line
,	O
while	O
phorbol	O
ester	O
(	O
PMA	O
)	O
had	O
no	O
effect	O
.	O

PMA	O
,	O
but	O
not	O
Ara-C	O
or	O
ceramides	O
,	O
activated	O
ERK	B-protein
MAPKS	I-protein
,	O
in	O
Jurkat	B-cell_line
and	O
EL4	B-cell_line
.	O

PMA	O
acted	O
synergistically	O
with	O
ionomycin	O
to	O
activate	O
JNK	B-protein
MAPKs	I-protein
in	O
Jurkat	B-cell_line
and	O
EL4	B-cell_line
within	O
10	O
minutes	O
.	O

Ara-C	O
activated	O
JNKs	B-protein
only	O
after	O
prolonged	O
incubation	O
(	O
90-120	O
minutes	O
)	O
.	O

Thus	O
,	O
ceramide	O
is	O
not	O
a	O
positive	O
signal	O
for	O
ERK	B-protein
activation	O
in	O
T-cell	B-cell_line
lines	I-cell_line
.	O

The	O
effects	O
of	O
Ara-C	O
on	O
JNK	B-protein
activity	O
may	O
be	O
mediated	O
through	O
secondary	O
response	O
pathways	O
.	O

Comparative	O
analysis	O
identifies	O
conserved	O
tumor	B-DNA
necrosis	I-DNA
factor	I-DNA
receptor-associated	I-DNA
factor	I-DNA
3	I-DNA
binding	I-DNA
sites	I-DNA
in	O
the	O
human	B-DNA
and	I-DNA
simian	I-DNA
Epstein-Barr	I-DNA
virus	I-DNA
oncogene	I-DNA
LMP1	I-DNA
.	O

Nonhuman	O
primates	O
are	O
naturally	O
infected	O
with	O
a	O
B-lymphotropic	O
herpesvirus	O
closely	O
related	O
to	O
Epstein-Barr	O
virus	O
(	O
EBV	O
)	O
.	O

These	O
simian	O
EBV	O
share	O
considerable	O
genetic	O
,	O
biologic	O
,	O
and	O
epidemiologic	O
features	O
with	O
human	O
EBV	O
,	O
including	O
virus-induced	O
tumorigenesis	O
.	O

However	O
,	O
latent	O
,	O
transformation-associated	O
viral	O
genes	O
demonstrate	O
marked	O
sequence	O
divergence	O
among	O
species	O
despite	O
the	O
conserved	O
functions	O
.	O

We	O
have	O
cloned	O
the	O
latent	B-protein
membrane	I-protein
protein	I-protein
1	I-protein
(	I-protein
LMP1	I-protein
)	I-protein
homologs	I-protein
from	O
the	O
simian	O
EBV	O
naturally	O
infecting	O
baboons	O
(	O
cercopithicine	O
herpesvirus	O
12	O
,	O
herpesvirus	O
papio	O
)	O
and	O
rhesus	O
monkeys	O
(	O
cercopithicine	O
herpesvirus	O
15	O
)	O
for	O
a	O
comparative	O
study	O
with	O
the	O
human	O
EBV	O
oncogene	O
.	O

The	O
transmembrane	O
domains	O
are	O
well	O
conserved	O
,	O
but	O
there	O
is	O
striking	O
sequence	O
divergence	O
of	O
the	O
carboxy-terminal	B-protein
cytoplasmic	I-protein
domain	I-protein
essential	O
for	O
B-cell	B-cell_type
immortalization	O
and	O
interaction	O
with	O
the	O
tumor	B-protein
necrosis	I-protein
factor	I-protein
receptor	I-protein
signaling	O
pathway	O
.	O

Nevertheless	O
,	O
the	O
simian	B-protein
EBV	I-protein
LMP1s	I-protein
retain	O
most	O
functions	O
in	O
common	O
with	O
EBV	O
LMP1	B-protein
,	O
including	O
the	O
ability	O
to	O
induce	O
NF-	B-protein
(	I-protein
kappa	I-protein
)	I-protein
B	I-protein
activity	O
in	O
human	B-cell_type
cells	I-cell_type
,	O
to	O
bind	O
the	O
tumor	B-protein
necrosis	I-protein
factor-associated	I-protein
factor	I-protein
3	I-protein
(	O
TRAF3	B-protein
)	O
in	O
vitro	O
,	O
and	O
to	O
induce	O
expression	O
of	O
tumor	B-DNA
necrosis	I-DNA
factor-responsive	I-DNA
genes	I-DNA
,	O
such	O
as	O
ICAM1	B-DNA
,	O
in	O
human	B-cell_type
B	I-cell_type
lymphocytes	I-cell_type
.	O

Multiple	O
TRAF3	B-DNA
binding	I-DNA
sites	I-DNA
containing	O
a	O
PXQXT/S	B-DNA
core	I-DNA
sequence	I-DNA
can	O
be	O
identified	O
in	O
the	O
simian	B-protein
EBV	I-protein
LMP1s	I-protein
by	O
an	O
in	O
vitro	O
binding	O
assay	O
.	O

A	O
PXQXT/S-containing	B-DNA
sequence	I-DNA
is	O
also	O
present	O
in	O
the	O
cytoplasmic	B-protein
domain	I-protein
of	O
the	O
Hodgkin	O
's	O
disease	O
marker	O
,	O
CD30	B-protein
,	O
and	O
binds	O
TRAF3	B-protein
in	O
vitro	O
.	O

The	O
last	B-protein
13	I-protein
amino	I-protein
acids	I-protein
containing	O
a	O
PXQXT/S	B-DNA
sequence	I-DNA
are	O
highly	O
conserved	O
in	O
human	O
and	O
simian	O
EBV	O
LMP1	B-protein
but	O
do	O
not	O
bind	O
TRAF3	B-protein
,	O
suggesting	O
a	O
distinct	O
role	O
for	O
this	O
conserved	O
region	O
of	O
LMP1	B-protein
.	O

The	O
conserved	O
TRAF3	B-DNA
binding	I-DNA
sites	I-DNA
in	O
LMP1	B-protein
and	O
the	O
CD30	B-protein
Hodgkin	I-protein
's	I-protein
disease	I-protein
marker	I-protein
provides	O
further	O
evidence	O
that	O
a	O
TRAF3	B-protein
-mediated	O
signal	O
transduction	O
pathway	O
may	O
be	O
important	O
in	O
malignant	O
transformation	O
.	O

Chromosome	B-DNA
1	I-DNA
aneusomy	O
with	O
1p36	B-DNA
under-representation	O
is	O
related	O
to	O
histologic	O
grade	O
,	O
DNA	O
aneuploidy	O
,	O
high	O
c-erb	B-protein
B-2	I-protein
and	O
loss	O
of	O
bcl-2	B-DNA
expression	O
in	O
ductal	O
breast	O
carcinoma	O
.	O

Chromosome	B-DNA
1	I-DNA
abnormalities	O
with	O
loss	O
of	O
1p36	B-DNA
have	O
been	O
investigated	O
in	O
95	O
breast-cancer	O
samples	O
by	O
means	O
of	O
a	O
dual-target	O
fluorescence	O
in-situ	O
hybridization	O
(	O
FISH	O
)	O
technique	O
using	O
the	O
pUC	B-DNA
1.77	I-DNA
and	O
p1-79	B-DNA
probes	I-DNA
,	O
specific	O
for	O
the	O
1q12	B-DNA
and	I-DNA
1p36	I-DNA
regions	I-DNA
,	O
respectively	O
.	O

Abnormalities	O
for	O
one	O
or	O
both	O
probes	O
were	O
detected	O
in	O
83/95	O
samples	O
.	O

Relative	O
1p36	B-DNA
under-representation	O
was	O
found	O
in	O
79/95	O
.	O

The	O
clinical	O
relevance	O
of	O
these	O
alterations	O
was	O
studied	O
by	O
comparing	O
the	O
FISH	O
results	O
with	O
several	O
parameters	O
currently	O
used	O
in	O
breast-cancer	O
pathology	O
.	O

Distinct	O
patterns	O
of	O
chromosome	B-DNA
1	I-DNA
abnormalities	O
were	O
found	O
among	O
the	O
histologic	O
types	O
of	O
breast	O
carcinoma	O
.	O

Lobular	O
or	O
mucinous	O
samples	O
showed	O
few	O
or	O
no	O
alterations	O
,	O
whereas	O
most	O
ductal	O
samples	O
had	O
high	O
chromosome	B-DNA
1	I-DNA
polysomy	O
with	O
under-representation	O
of	O
1p36	B-DNA
.	O

In	O
ductal	O
carcinomas	O
,	O
chromosome	B-DNA
1	I-DNA
alterations	O
increased	O
with	O
histologic	O
grade	O
,	O
DNA	O
aneuploidy	O
,	O
loss	O
of	O
bcl-2	O
and	O
high	O
c-erb	B-protein
B-2	I-protein
expression	O
.	O

These	O
associations	O
were	O
found	O
to	O
be	O
statistically	O
significant	O
.	O

No	O
correlation	O
between	O
chromosome	B-DNA
1	I-DNA
alterations	O
and	O
nuclear	O
grade	O
,	O
age	O
,	O
size	O
,	O
lymph-node	O
involvement	O
,	O
hormonal	O
receptor	O
presence	O
,	O
proliferation	O
activity	O
or	O
p53	B-protein
protein	O
expression	O
was	O
detected	O
.	O

These	O
results	O
indicate	O
the	O
utility	O
of	O
this	O
FISH	O
technique	O
for	O
a	O
better	O
definition	O
of	O
the	O
biological	O
characteristics	O
of	O
ductal	O
carcinomas	O
.	O

G	O
(	O
Anh	O
)	O
MTetra	O
,	O
a	O
natural	O
bacterial	O
cell	O
wall	O
breakdown	O
product	O
,	O
induces	O
interleukin-1	B-protein
beta	I-protein
and	O
interleukin-6	B-protein
expression	O
in	O
human	B-cell_type
monocytes	I-cell_type
.	O

A	O
study	O
of	O
the	O
molecular	O
mechanisms	O
involved	O
in	O
inflammatory	B-protein
cytokine	I-protein
expression	O
[	O
published	O
erratum	O
appears	O
in	O
J	O
Biol	O
Chem	O
1994	O
Jun	O
17	O
;	O
269	O
(	O
24	O
)	O
:	O
16983	O
]	O

It	O
is	O
believed	O
that	O
induction	O
of	O
cytokine	B-protein
expression	O
by	O
bacterial	O
cell	O
wall	O
components	O
plays	O
a	O
role	O
in	O
the	O
development	O
and	O
course	O
of	O
sepsis	O
.	O

However	O
,	O
most	O
attention	O
has	O
been	O
focused	O
on	O
lipopolysaccharide	O
(	O
LPS	O
)	O
.	O

We	O
studied	O
the	O
ability	O
of	O
N-acetylglucosaminyl-1	O
,	O
6-anhydro-N-acetylmuramyl-L-alanyl-D-	O
isoglutamyl-m-diaminopimelyl-D-alanine	O
(	O
G	O
(	O
Anh	O
)	O
MTetra	O
)	O
,	O
a	O
naturally	O
occurring	O
breakdown	O
product	O
of	O
peptidoglycan	O
that	O
is	O
produced	O
by	O
soluble	O
lytic	B-protein
transglycosylase	I-protein
of	O
Escherichia	O
coli	O
,	O
to	O
induce	O
cytokine	B-protein
expression	O
in	O
human	B-cell_type
monocytes	I-cell_type
.	O

G	O
(	O
Anh	O
)	O
MTetra	O
was	O
found	O
to	O
strongly	O
induce	O
interleukin	B-protein
(	I-protein
IL	I-protein
)	I-protein
-1	I-protein
beta	I-protein
and	O
IL-6	B-RNA
mRNA	I-RNA
expression	O
after	O
2	O
h	O
and	O
IL-1	B-protein
beta	I-protein
and	O
IL-6	B-protein
protein	I-protein
secretion	O
after	O
48	O
h	O
of	O
activation	O
.	O

The	O
increase	O
in	O
mRNA	O
accumulation	O
was	O
at	O
least	O
partly	O
due	O
to	O
an	O
increase	O
in	O
the	O
transcription	O
rates	O
of	O
the	O
respective	O
genes	B-DNA
and	O
was	O
accompanied	O
by	O
a	O
strong	O
induction	O
of	O
nuclear	O
factor-kappa	O
B	O
and	O
activator	O
protein-1	O
transcription	O
factor	O
expression	O
.	O

Experiments	O
using	O
inhibitors	O
of	O
protein	B-protein
kinase	I-protein
C	I-protein
,	O
protein	B-protein
kinase	I-protein
A	I-protein
,	O
and	O
tyrosine	O
kinase-dependent	O
pathways	O
revealed	O
that	O
G	O
(	O
Anh	O
)	O
MTetra-induced	O
IL-1	B-protein
beta	I-protein
and	O
IL-6	B-RNA
mRNA	I-RNA
expression	O
involves	O
activation	O
of	O
an	O
H7-inhibitable	O
pathway	O
.	O

By	O
using	O
the	O
protein	O
synthesis	O
inhibitor	O
cycloheximide	O
,	O
it	O
was	O
shown	O
that	O
G	O
(	O
Anh	O
)	O
MTetra-induced	O
IL-6	B-RNA
mRNA	I-RNA
expression	O
depends	O
on	O
the	O
synthesis	O
of	O
new	O
protein	O
,	O
whereas	O
G	O
(	O
Anh	O
)	O
MTetra-induced	O
IL-1	B-protein
beta	I-protein
mRNA	O
accumulation	O
does	O
not	O
.	O

When	O
responses	O
to	O
G	O
(	O
Anh	O
)	O
MTetra	O
were	O
compared	O
with	O
those	O
to	O
LPS	O
and	O
muramyldipeptide	O
(	O
MDP	O
)	O
,	O
it	O
was	O
found	O
that	O
the	O
optimal	O
response	O
to	O
G	O
(	O
Anh	O
)	O
MTetra	O
induction	O
was	O
similar	O
to	O
that	O
of	O
LPS	O
but	O
significantly	O
higher	O
than	O
the	O
response	O
to	O
MDP	O
.	O

Furthermore	O
,	O
maximal	O
G	O
(	O
Anh	O
)	O
MTetra-induced	O
IL-1	B-protein
beta	I-protein
and	O
IL-6	B-RNA
mRNA	I-RNA
expression	O
could	O
be	O
enhanced	O
by	O
co-stimulation	O
with	O
LPS	O
or	O
MDP	O
,	O
suggesting	O
that	O
different	O
receptors	O
and/or	O
transduction	O
pathways	O
were	O
involved	O
.	O

These	O
results	O
indicate	O
that	O
G	O
(	O
Anh	O
)	O
MTetra	O
induces	O
IL-1	B-protein
beta	I-protein
and	O
IL-6	B-protein
expression	O
in	O
human	B-cell_type
monocytes	I-cell_type
suggesting	O
a	O
possible	O
role	O
for	O
G	O
(	O
Anh	O
)	O
MTetra	O
in	O
the	O
release	O
of	O
cytokines	B-protein
during	O
sepsis	O
.	O

Increased	O
proliferation	O
,	O
cytotoxicity	O
,	O
and	O
gene	O
expression	O
after	O
stimulation	O
of	O
human	B-cell_type
peripheral	I-cell_type
blood	I-cell_type
T	I-cell_type
lymphocytes	I-cell_type
through	O
a	O
surface	O
ganglioside	O
(	O
GD3	O
)	O
[	O
published	O
erratum	O
appears	O
in	O
J	O
Immunol	O
1994	O
Jul	O
15	O
;	O
153	O
(	O
2	O
)	O
:	O
910	O
]	O

Previous	O
studies	O
have	O
suggested	O
that	O
gangliosides	O
have	O
an	O
important	O
role	O
in	O
cell	O
signaling	O
and	O
recognition	O
.	O

However	O
,	O
their	O
specific	O
function	O
in	O
these	O
processes	O
has	O
not	O
been	O
clearly	O
defined	O
.	O

A	O
mAb	B-protein
,	O
R24	B-protein
,	O
that	O
reacts	O
specifically	O
with	O
a	O
cell	O
surface	O
ganglioside	O
(	O
GD3	O
)	O
has	O
been	O
demonstrated	O
to	O
stimulate	O
proliferation	O
of	O
T	B-cell_type
cells	I-cell_type
derived	O
from	O
human	O
peripheral	O
blood	O
.	O

In	O
this	O
study	O
,	O
we	O
have	O
investigated	O
the	O
mechanisms	O
by	O
which	O
the	O
R24	B-protein
mAb	I-protein
affects	O
T	O
cell	O
functions	O
.	O

We	O
have	O
observed	O
that	O
the	O
R24	B-protein
mAb	I-protein
stimulates	O
GD3+	O
T	O
cell	O
proliferation	O
,	O
cytotoxicity	O
,	O
and	O
surface	O
marker	O
expression	O
of	O
IL-2R	B-protein
alpha-chain	I-protein
,	O
IL-2R	B-protein
beta-chain	I-protein
,	O
HLA-DR	B-protein
,	O
CD11a	B-protein
,	O
and	O
CD11c	B-protein
.	O

Additionally	O
,	O
IFN-gamma	B-protein
activity	O
but	O
not	O
IL-1	O
,	O
IL-2	O
,	O
or	O
IL-4	O
activity	O
was	O
present	O
in	O
culture	O
supernatants	O
72	O
h	O
after	O
R24	B-protein
stimulation	O
.	O

In	O
some	O
donors	O
,	O
increased	O
IL-6	B-protein
and	O
TNF-alpha	B-protein
activity	O
also	O
was	O
detected	O
after	O
R24	B-protein
treatment	O
.	O

Furthermore	O
,	O
R24	B-protein
treatment	O
resulted	O
in	O
translocation	O
of	O
c-rel	B-protein
,	O
but	O
little	O
or	O
no	O
NF	B-protein
kappa	I-protein
B	I-protein
p50	I-protein
or	O
p65	B-protein
,	O
from	O
the	O
cytoplasm	O
to	O
the	O
nucleus	O
and	O
an	O
increase	O
of	O
NF	B-protein
kappa	I-protein
B	I-protein
binding	I-protein
complexes	I-protein
containing	O
c-rel	B-protein
and	O
p50	B-protein
.	O

This	O
treatment	O
also	O
caused	O
increased	O
tyrosine	O
phosphorylation	O
of	O
specific	O
protein	O
substrates	O
.	O

R24	B-protein
-stimulated	O
increases	O
in	O
proliferation	O
,	O
cytotoxicity	O
,	O
and	O
cell	O
surface	O
protein	O
expression	O
could	O
be	O
blocked	O
by	O
cyclosporin	O
and	O
staurosporin	O
,	O
indicating	O
that	O
cyclophilin/calcineurin	B-protein
and	O
protein	B-protein
kinase	I-protein
C	I-protein
may	O
be	O
involved	O
in	O
the	O
R24	B-protein
signaling	O
pathway	O
.	O

Additionally	O
,	O
herbimycin	O
A	O
,	O
a	O
tyrosine	B-protein
kinase	I-protein
inhibitor	O
,	O
blocked	O
the	O
R24	B-protein
-stimulated	O
increase	O
in	O
proliferation	O
but	O
not	O
cytotoxicity	O
at	O
concentrations	O
consistent	O
with	O
specificity	O
for	O
tyrosine	B-protein
kinases	I-protein
.	O

These	O
results	O
suggest	O
that	O
multiple	O
biochemical	O
pathways	O
are	O
involved	O
in	O
the	O
activation	O
of	O
human	B-cell_type
T	I-cell_type
cells	I-cell_type
by	O
R24	B-protein
.	O

Genes	O
encoding	O
general	B-protein
initiation	I-protein
factors	I-protein
for	O
RNA	B-protein
polymerase	I-protein
II	I-protein
transcription	O
are	O
dispersed	O
in	O
the	O
human	B-DNA
genome	I-DNA
.	O

General	B-protein
transcription	I-protein
factors	I-protein
are	O
required	O
for	O
accurate	O
initiation	O
of	O
transcription	O
by	O
RNA	B-protein
polymerase	I-protein
II	I-protein
.	O

Human	B-DNA
cDNAs	I-DNA
encoding	O
subunits	O
of	O
these	O
factors	O
have	O
been	O
cloned	O
and	O
sequenced	O
.	O

Using	O
fluorescence	O
in	O
situ	O
hybridization	O
(	O
FISH	O
)	O
,	O
we	O
show	O
here	O
that	O
the	O
genes	B-DNA
encoding	O
the	O
TATA-box	B-protein
binding	I-protein
protein	I-protein
(	O
TBP	B-protein
)	O
,	O
TFIIB	B-protein
,	O
TFIIE	B-protein
alpha	I-protein
,	O
TFIIE	B-protein
beta	I-protein
,	O
RAP30	B-protein
,	O
RAP74	B-protein
and	O
the	O
62	B-protein
kDa	I-protein
subunit	I-protein
,	O
of	O
TFIIH	B-protein
are	O
located	O
at	O
the	O
human	B-DNA
chromosomal	I-DNA
bands	I-DNA
6q26-27	I-DNA
,	I-DNA
1p21-22	I-DNA
,	I-DNA
3q21-24	I-DNA
,	I-DNA
8p12	I-DNA
,	I-DNA
13q14	I-DNA
,	I-DNA
19p13.3	I-DNA
and	I-DNA
11p14-15.1	I-DNA
,	O
respectively	O
.	O

This	O
dispersed	O
localization	O
of	O
a	O
group	O
of	O
functionally	O
related	O
gene	O
provides	O
insights	O
into	O
the	O
molecular	O
mechanism	O
of	O
human	B-DNA
genome	I-DNA
evolution	O
and	O
their	O
possible	O
involvement	O
in	O
human	O
diseases	O
.	O

BCL-6	B-protein
and	O
the	O
molecular	O
pathogenesis	O
of	O
B-cell	O
lymphoma	O
.	O

The	O
results	O
presented	O
identify	O
the	O
first	O
genetic	O
lesion	O
associated	O
with	O
DLCL	O
,	O
the	O
most	O
clinically	O
relevant	O
form	O
of	O
NHL	O
.	O

Although	O
no	O
proof	O
yet	O
exists	O
of	O
a	O
role	O
for	O
these	O
lesions	O
in	O
DLCL	O
pathogenesis	O
,	O
the	O
feature	O
of	O
the	O
BCL-6	B-protein
gene	I-protein
product	I-protein
,	O
its	O
specific	O
pattern	O
of	O
expression	O
in	O
B	B-cell_type
cells	I-cell_type
,	O
and	O
the	O
clustering	O
of	O
lesions	O
disrupting	O
its	O
regulatory	O
domain	O
strongly	O
suggest	O
that	O
deregulation	O
of	O
BCL-6	B-protein
expression	O
may	O
contribute	O
to	O
DLCL	O
development	O
.	O

A	O
more	O
precise	O
definition	O
of	O
the	O
role	O
of	O
BCL-6	B-protein
in	O
normal	O
and	O
neoplastic	O
B-cell	O
development	O
is	O
the	O
goal	O
of	O
ongoing	O
study	O
of	O
transgenic	O
mice	O
engineered	O
either	O
to	O
express	O
BCL-6	B-protein
under	O
heterologous	B-DNA
promoters	I-DNA
or	O
lacking	O
BCL-6	B-protein
function	O
due	O
to	O
targeted	O
deletions	O
.	O

In	O
addition	O
to	O
contributing	O
to	O
the	O
understanding	O
of	O
DLCL	O
pathogenesis	O
,	O
the	O
identification	O
of	O
BCL-6	B-protein
lesions	O
may	O
have	O
relevant	O
clinical	O
implications	O
.	O

DLCL	O
represent	O
a	O
heterogeneous	O
group	O
of	O
neoplasms	O
which	O
are	O
treated	O
homogeneously	O
despite	O
the	O
fact	O
that	O
only	O
50	O
%	O
of	O
patients	O
experience	O
long-term	O
disease-free	O
survival	O
(	O
Schneider	O
et	O
al.	O
1990	O
)	O
.	O

The	O
fact	O
that	O
BCL-6	B-protein
rearrangements	O
identify	O
biologically	O
and	O
clinically	O
distinct	O
subsets	O
of	O
DLCL	O
suggests	O
that	O
these	O
lesions	O
may	O
be	O
useful	O
as	O
markers	O
in	O
selection	O
of	O
differential	O
therapeutic	O
strategies	O
based	O
on	O
different	O
risk	O
groups	O
.	O

Furthermore	O
,	O
the	O
BCL-6	B-protein
rearrangements	O
can	O
be	O
used	O
to	O
identify	O
and	O
monitor	O
the	O
malignant	B-cell_type
clone	I-cell_type
with	O
sensitive	O
PCR-based	O
techniques	O
.	O

Since	O
clinical	O
remission	O
has	O
been	O
observed	O
in	O
a	O
significant	O
fraction	O
of	O
DLCL	O
cases	O
,	O
these	O
markers	O
may	O
serve	O
as	O
critical	O
tools	O
for	O
sensitive	O
monitoring	O
of	O
minimal	O
residual	O
disease	O
and	O
early	O
diagnosis	O
of	O
relapse	O
(	O
Gribben	O
et	O
al.	O
1993	O
)	O
.	O

Pancreatic	O
development	O
and	O
maturation	O
of	O
the	O
islet	B-cell_type
B	I-cell_type
cell	I-cell_type
.	O

Studies	O
of	O
pluripotent	B-cell_line
islet	I-cell_line
cultures	I-cell_line
.	O

Pancreas	O
organogenesis	O
is	O
a	O
highly	O
regulated	O
process	O
,	O
in	O
which	O
two	O
anlage	O
evaginate	O
from	O
the	O
primitive	O
gut	O
.	O

They	O
later	O
fuse	O
,	O
and	O
,	O
under	O
the	O
influence	O
of	O
the	O
surrounding	O
mesenchyme	O
,	O
the	O
mature	O
organ	O
develops	O
,	O
being	O
mainly	O
composed	O
of	O
ductal	O
,	O
exocrine	O
and	O
endocrine	O
compartments	O
.	O

Early	O
buds	O
are	O
characterized	O
by	O
a	O
branching	O
morphogenesis	O
of	O
the	O
ductal	O
epithelium	O
from	O
which	O
endocrine	B-cell_type
and	I-cell_type
exocrine	I-cell_type
precursor	I-cell_type
cells	I-cell_type
bud	O
to	O
eventually	O
form	O
the	O
two	O
other	O
compartments	O
.	O

The	O
three	O
compartments	O
are	O
thought	O
to	O
be	O
of	O
common	O
endodermal	O
origin	O
;	O
in	O
contrast	O
to	O
earlier	O
hypotheses	O
,	O
which	O
suggested	O
that	O
the	O
endocrine	O
compartment	O
was	O
of	O
neuroectodermal	O
origin	O
.	O

It	O
is	O
thus	O
generally	O
believed	O
that	O
the	O
pancreatic	O
endocrine-lineage	O
possesses	O
the	O
ability	O
to	O
mature	O
along	O
a	O
differentiation	O
pathway	O
that	O
shares	O
many	O
characteristics	O
with	O
those	O
of	O
neuronal	O
differentiation	O
.	O

During	O
recent	O
years	O
,	O
studies	O
of	O
insulin-gene	B-DNA
regulation	O
and	O
,	O
in	O
particular	O
,	O
the	O
tissue-specific	O
transcriptional	O
control	O
of	O
insulin-gene	B-DNA
activity	O
have	O
provided	O
information	O
on	O
pancreas	O
development	O
in	O
general	O
.	O

The	O
present	O
review	O
summarizes	O
these	O
findings	O
,	O
with	O
a	O
special	O
focus	O
on	O
our	O
own	O
studies	O
on	O
pluripotent	B-cell_line
endocrine	I-cell_line
cultures	I-cell_line
of	O
rat	O
pancreas	O
.	O

Octamer	O
independent	O
activation	O
of	O
transcription	O
from	O
the	O
kappa	B-DNA
immunoglobulin	I-DNA
germline	I-DNA
promoter	I-DNA
.	O

Previous	O
analyses	O
of	O
immunoglobulin	B-DNA
V	I-DNA
region	I-DNA
promoters	I-DNA
has	O
led	O
to	O
the	O
discovery	O
of	O
a	O
common	O
octamer	B-DNA
motif	I-DNA
which	O
is	O
functionally	O
important	O
in	O
the	O
tissue-specific	O
and	O
developmentally	O
regulated	O
transcriptional	O
activation	O
of	O
immunoglobulin	B-DNA
genes	I-DNA
.	O

The	O
germline	B-DNA
promoters	I-DNA
(	O
Ko	B-DNA
)	O
located	O
upstream	O
of	O
the	O
J	B-DNA
region	I-DNA
gene	I-DNA
segments	I-DNA
of	O
the	O
kappa	B-DNA
locus	I-DNA
also	O
contain	O
an	O
octamer	B-DNA
motif	I-DNA
(	O
containing	O
a	O
single	O
base	B-DNA
pair	I-DNA
mutation	I-DNA
and	O
referred	O
to	O
as	O
the	O
variant	O
octamer	O
)	O
which	O
has	O
been	O
shown	O
previously	O
to	O
bind	O
Oct-1	B-protein
and	O
Oct-2	B-protein
transcription	B-protein
factors	I-protein
in	O
vitro	O
.	O

To	O
further	O
elucidate	O
the	O
role	O
of	O
this	O
variant	O
octamer	B-DNA
motif	I-DNA
in	O
the	O
regulation	O
of	O
germline	B-DNA
transcription	O
from	O
the	O
unrearranged	O
kappa	B-DNA
locus	I-DNA
,	O
we	O
have	O
quantitated	O
the	O
relative	O
binding	O
affinity	O
of	O
Oct-1	B-protein
and	O
Oct-2	B-protein
for	O
the	O
variant	O
octamer	B-DNA
motif	I-DNA
and	O
determined	O
the	O
functional	O
role	O
of	O
this	O
octamer	B-DNA
motif	I-DNA
in	O
transcriptional	O
activation	O
.	O

We	O
find	O
that	O
,	O
although	O
the	O
variant	O
octamer	B-DNA
motif	I-DNA
binds	O
Oct-1	B-protein
and	O
Oct-2	B-protein
in	O
vitro	O
with	O
5-fold	O
lower	O
affinity	O
than	O
the	O
consensus	B-DNA
octamer	I-DNA
motif	I-DNA
,	O
mutation	O
of	O
the	O
variant	O
octamer	B-DNA
motif	I-DNA
to	O
either	O
a	O
consensus	B-DNA
octamer	I-DNA
or	O
non-octamer	B-DNA
motif	I-DNA
has	O
no	O
effect	O
on	O
transcriptional	O
activation	O
from	O
the	O
germline	B-DNA
promoter	I-DNA
.	O

We	O
also	O
find	O
significant	O
differences	O
in	O
activation	O
of	O
germline	B-DNA
and	O
V	B-DNA
region	I-DNA
promoters	I-DNA
by	O
kappa	B-DNA
enhancers	I-DNA
.	O

Our	O
results	O
suggest	O
that	O
the	O
germline	B-DNA
promoters	I-DNA
and	O
V	B-DNA
region	I-DNA
promoters	I-DNA
differ	O
in	O
their	O
dependence	O
on	O
octamer	B-DNA
for	O
activation	O
and	O
respond	O
differently	O
to	O
enhancer	O
activation	O
.	O

These	O
findings	O
have	O
important	O
implications	O
in	O
regulation	O
of	O
germline	B-DNA
transcription	O
as	O
well	O
as	O
concomitant	O
activation	O
of	O
the	O
V-J	O
recombination	O
of	O
the	O
kappa	B-DNA
light	I-DNA
chain	I-DNA
locus	I-DNA
.	O

Generation	O
of	O
CD1+RelB+	B-cell_type
dendritic	I-cell_type
cells	I-cell_type
and	O
tartrate-resistant	B-cell_type
acid	I-cell_type
phosphatase-positive	I-cell_type
osteoclast-like	I-cell_type
multinucleated	I-cell_type
giant	I-cell_type
cells	I-cell_type
from	O
human	B-cell_type
monocytes	I-cell_type
.	O

We	O
previously	O
showed	O
that	O
granulocyte-macrophage	B-protein
colony-stimulating	I-protein
factor	I-protein
(	O
GM-CSF	B-protein
)	O
and	O
macrophage	B-protein
colony-stimulating	I-protein
factor	I-protein
(	O
M-CSF	B-protein
)	O
stimulate	O
the	O
differentiation	O
of	O
human	B-cell_type
monocytes	I-cell_type
into	O
two	O
phenotypically	O
distinct	O
types	O
of	O
macrophages	B-cell_type
.	O

However	O
,	O
in	O
vivo	O
,	O
not	O
only	O
CSF	B-protein
but	O
also	O
many	O
other	O
cytokines	B-protein
are	O
produced	O
under	O
various	O
conditions	O
.	O

Those	O
cytokines	B-protein
may	O
modulate	O
the	O
differentiation	O
of	O
monocytes	B-cell_type
by	O
CSFs	B-protein
.	O

In	O
the	O
present	O
study	O
,	O
we	O
showed	O
that	O
CD14+	B-cell_type
adherent	I-cell_type
human	I-cell_type
monocytes	I-cell_type
can	O
differentiate	O
into	O
CD1+relB+	B-cell_type
dendritic	I-cell_type
cells	I-cell_type
(	O
DC	B-cell_type
)	O
by	O
the	O
combination	O
of	O
GM-CSF	B-protein
plus	O
interleukin-4	B-protein
(	O
IL-4	B-protein
)	O
and	O
that	O
they	O
differentiate	O
into	O
tartrate-resistant	B-cell_type
acid	I-cell_type
phosphatase	I-cell_type
(	I-cell_type
TRAP	I-cell_type
)	I-cell_type
-positive	I-cell_type
osteoclast-like	I-cell_type
multinucleated	I-cell_type
giant	I-cell_type
cells	I-cell_type
(	O
MGC	B-cell_type
)	O
by	O
the	O
combination	O
of	O
M-CSF	B-protein
plus	O
IL-4	B-protein
.	O

However	O
,	O
the	O
monocyte-derived	B-cell_line
DC	I-cell_line
were	O
not	O
terminally	B-cell_line
differentiated	I-cell_line
cells	I-cell_line
;	O
they	O
could	O
still	O
convert	O
to	O
macrophages	B-cell_type
in	O
response	O
to	O
M-CSF	B-protein
.	O

Tumor	B-protein
necrosis	I-protein
factor-alpha	I-protein
(	O
TNF-alpha	B-protein
)	O
stimulated	O
the	O
terminal	O
differentiation	O
of	O
the	O
DC	B-cell_type
by	O
downregulating	O
the	O
expression	O
of	O
the	O
M-CSF	B-protein
receptor	I-protein
,	O
cfms	B-RNA
mRNA	I-RNA
,	O
and	O
aborting	O
the	O
potential	O
to	O
convert	O
to	O
macrophages	B-cell_type
.	O

In	O
contrast	O
to	O
IL-4	B-protein
,	O
interferon-gamma	B-protein
(	O
IFN-gamma	B-protein
)	O
had	O
no	O
demonstrable	O
effect	O
on	O
the	O
differentiation	O
of	O
monocytes	B-cell_type
.	O

Rather	O
,	O
IFN-gamma	B-protein
antagonized	O
the	O
effect	O
of	O
IL-4	B-protein
and	O
suppressed	O
the	O
DC	B-cell_type
and	O
MGC	B-cell_type
formation	O
induced	O
by	O
GM-CSF	B-protein
+	O
IL-4	B-protein
and	O
M-CSF	B-protein
+	O
IL-4	B-protein
,	O
respectively	O
.	O

Taken	O
together	O
,	O
these	O
results	O
provide	O
a	O
new	O
aspect	O
to	O
our	O
knowledge	O
of	O
monocyte	O
differentiation	O
and	O
provide	O
evidence	O
that	O
human	B-cell_type
monocytes	I-cell_type
are	O
flexible	O
in	O
their	O
differentiation	O
potential	O
and	O
are	O
precursors	O
not	O
only	O
of	O
macrophages	B-cell_type
but	O
also	O
of	O
CD1+relB+DC	B-cell_type
and	O
TRAP-positive	B-cell_type
MGC	I-cell_type
.	O

Such	O
a	O
diverse	O
pathway	O
of	O
monocyte	O
differentiation	O
may	O
constitute	O
one	O
of	O
the	O
basic	O
mechanisms	O
of	O
immune	O
regulation	O
.	O

The	O
NF-kappa	B-protein
B	I-protein
inhibitor	O
,	O
tepoxalin	O
,	O
suppresses	O
surface	O
expression	O
of	O
the	O
cell	B-protein
adhesion	I-protein
molecules	I-protein
CD62E	B-protein
,	O
CD11b/CD18	B-protein
and	O
CD106	B-protein
.	O

Tepoxalin	O
,	O
a	O
dual	O
enzyme	O
inhibitor	O
of	O
cyclooxygenase	B-protein
and	O
5-lipoxygenase	B-protein
has	O
been	O
shown	O
to	O
inhibit	O
T-cell	O
activation	O
.	O

Its	O
immunosuppressive	O
property	O
is	O
distinct	O
from	O
cyclosporin	O
because	O
only	O
tepoxalin	O
,	O
but	O
not	O
cyclosporin	O
,	O
suppresses	O
NF-kappa	B-protein
B	I-protein
activation	O
.	O

Here	O
we	O
report	O
that	O
tepoxalin	O
selectively	O
inhibits	O
intercellular	B-protein
adhesion	I-protein
molecule-1	I-protein
(	B-protein
ICAM-1	I-protein
,	I-protein
CD54	I-protein
)	I-protein
/MAC-1	I-protein
(	O
CD11b/CD18	B-protein
)	O
dependent	O
adhesion	O
of	O
polymorphonuclear	B-cell_type
cells	I-cell_type
to	O
IL-1	B-protein
activated	O
human	B-cell_type
umbilical	I-cell_type
vein	I-cell_type
endothelial	I-cell_type
cells	I-cell_type
.	O

The	O
mechanism	O
of	O
inhibition	O
is	O
related	O
to	O
the	O
surface	O
expression	O
of	O
several	O
cell	O
adhesion	B-protein
molecules	I-protein
.	O

Flow	O
cytometry	O
analyses	O
on	O
cultured	O
cells	O
that	O
were	O
treated	O
with	O
tepoxalin	O
or	O
antisense	O
oligonucleotides	O
to	O
the	O
P65/p50	B-protein
subunit	I-protein
of	O
NF-kappa	B-protein
B	I-protein
,	O
and	O
then	O
stimulated	O
with	O
PMA	O
,	O
revealed	O
a	O
reduced	O
expression	O
of	O
CD11b/CD18	B-protein
on	O
monocytic	B-cell_line
HL60	I-cell_line
cells	I-cell_line
,	O
and	O
endothelial	B-protein
adhesion	I-protein
molecule-1	I-protein
(	O
CD62E	B-protein
)	O
and	O
vascular	B-protein
adhesion	I-protein
molecule-1	I-protein
(	O
CD106	B-protein
)	O
on	O
human	B-cell_type
umbilical	I-cell_type
vein	I-cell_type
endothelial	I-cell_type
cells	I-cell_type
.	O

Expression	O
of	O
other	O
adhesion	B-protein
molecules	I-protein
such	O
as	O
lymphocyte	B-protein
function	I-protein
associated-antigen-1	I-protein
(	O
CD11a/CD18	B-protein
)	O
and	O
CD54	B-protein
were	O
unaffected	O
.	O

Tepoxalin	O
also	O
inhibited	O
the	O
secretion	O
of	O
a	O
NF-kappa	B-protein
B	I-protein
regulated	I-protein
chemokine	I-protein
,	O
IL-8	B-protein
,	O
a	O
known	O
inducer	O
of	O
CD11b/CD18	B-protein
expression	O
.	O

Thus	O
the	O
suppression	O
of	O
CD11b/CD18	B-protein
expression	O
by	O
tepoxalin	O
may	O
involve	O
IL-8	B-protein
.	O

Our	O
results	O
suggest	O
that	O
by	O
inhibiting	O
NF-kappa	B-protein
B	I-protein
activation	O
,	O
surface	O
expression	O
of	O
several	O
adhesion	B-protein
molecules	I-protein
can	O
be	O
modulated	O
and	O
that	O
tepoxalin	O
may	O
be	O
useful	O
in	O
treating	O
selected	O
adhesion	O
mediated	O
events	O
such	O
as	O
leukocyte	O
migration	O
or	O
atherosclerotic	O
plaque	O
formation	O
.	O

Characterization	O
of	O
a	O
CD43/leukosialin	B-protein
-mediated	O
pathway	O
for	O
inducing	O
apoptosis	O
in	O
human	B-cell_type
T-lymphoblastoid	I-cell_type
cells	I-cell_type
.	O

The	O
monoclonal	B-protein
antibody	I-protein
(	O
mAb	B-protein
)	O
J393	B-protein
induces	O
apoptosis	O
in	O
Jurkat	B-cell_line
T-cells	I-cell_line
.	O

NH2	B-protein
-terminal	O
amino	O
acid	O
sequence	O
analysis	O
identified	O
the	O
140-kDa	B-protein
surface	I-protein
antigen	I-protein
for	O
mAb	B-protein
J393	I-protein
as	O
CD43/leukosialin	B-protein
,	O
the	O
major	O
sialoglycoprotein	B-protein
of	O
leukocytes	B-cell_type
.	O

While	O
Jurkat	B-cell_line
cells	I-cell_line
co-expressed	O
two	O
discrete	O
cell-surface	B-protein
isoforms	I-protein
of	O
CD43	B-protein
,	O
recognized	O
by	O
mAb	B-protein
J393	I-protein
and	O
mAb	B-protein
G10-2	I-protein
,	O
respectively	O
,	O
only	O
J393/CD43	B-protein
signaled	O
apoptosis	O
.	O

J393/CD43	B-protein
was	O
found	O
to	O
be	O
hyposialylated	O
,	O
bearing	O
predominantly	O
O-linked	O
monosaccharide	O
glycans	O
,	O
whereas	O
G10-2/CD43	B-protein
bore	O
complex	O
sialylated	O
tetra-	O
and	O
hexasaccharide	O
chains	O
.	O

Treatment	O
with	O
soluble	O
,	O
bivalent	O
mAb	B-protein
J393	I-protein
killed	O
25-50	O
%	O
of	O
the	O
cell	B-cell_line
population	I-cell_line
,	O
while	O
concomitant	O
engagement	O
of	O
either	O
the	O
CD3.TcR	B-protein
complex	I-protein
or	O
the	O
integrins	B-protein
CD18	B-protein
and	O
CD29	B-protein
significantly	O
potentiated	O
this	O
effect	O
.	O

Treatment	O
of	O
Jurkat	B-cell_line
cells	I-cell_line
with	O
mAb	B-protein
J393	I-protein
induced	O
tyrosine	O
phosphorylation	O
of	O
specific	O
protein	B-protein
substrates	I-protein
that	O
underwent	O
hyperphosphorylation	O
upon	O
antigen	B-protein
receptor	I-protein
costimulation	O
.	O

Tyrosine	B-protein
kinase	I-protein
inhibition	O
by	O
herbimycin	O
A	O
diminished	O
J393/CD43	B-protein
-mediated	O
apoptosis	O
,	O
whereas	O
inhibition	O
of	O
phosphotyrosine	B-protein
phosphatase	I-protein
activity	O
by	O
bis	O
(	O
maltolato	O
)	O
oxovanadium-IV	O
enhanced	O
cell	O
death	O
.	O

Signal	O
transduction	O
through	O
tyrosine	O
kinase	O
activation	O
may	O
lead	O
to	O
altered	O
gene	O
expression	O
,	O
as	O
J393/	O
CD43	B-protein
ligation	O
prompted	O
decreases	O
in	O
the	O
nuclear	O
localization	O
of	O
the	O
transcriptional	B-protein
regulatory	I-protein
protein	I-protein
NF-kappaB	B-protein
and	O
proteins	O
binding	O
the	O
interferon-inducible	B-DNA
regulatory	I-DNA
element	I-DNA
.	O

Since	O
peripheral	B-cell_type
blood	I-cell_type
T-lymphocytes	I-cell_type
express	O
cryptic	B-protein
epitopes	I-protein
for	O
mAb	B-protein
J393	I-protein
,	O
these	O
findings	O
demonstrate	O
the	O
existence	O
of	O
a	O
tightly	O
regulated	O
CD43	B-protein
-mediated	O
pathway	O
for	O
inducing	O
apoptosis	O
in	O
human	B-cell_type
T-cell	I-cell_type
lineages	I-cell_type
.	O

Sterol	O
dependent	O
LDL-receptor	B-DNA
gene	I-DNA
transcription	O
in	O
lymphocytes	B-cell_type
from	O
normal	O
and	O
CML	O
patients	O
.	O

Sterol	B-DNA
regulatory	I-DNA
element	I-DNA
(	O
SRE	B-DNA
)	O
has	O
been	O
recognized	O
to	O
regulate	O
various	O
key	O
genes	B-DNA
coding	O
for	O
especially	O
low	B-protein
density	I-protein
lipoprotein	I-protein
(	I-protein
LDL	I-protein
)	I-protein
-receptor	I-protein
,	O
3-hydroxy-3-methylglutaryl	B-protein
coenzyme	I-protein
A	I-protein
(	I-protein
HMG-CoA	I-protein
)	I-protein
reductase	I-protein
and	O
HMG-CoA	B-protein
synthase	I-protein
known	O
to	O
play	O
a	O
crucial	O
role	O
in	O
the	O
cholesterol	O
feedback	O
mechanism	O
.	O

The	O
deranged	O
cholesterol	O
feedback	O
mechanism	O
has	O
been	O
widely	O
recognised	O
in	O
initiation	O
as	O
well	O
as	O
progression	O
of	O
various	O
types	O
of	O
cancers	O
including	O
chronic	O
myeloid	O
leukaemia	O
(	O
CML	O
)	O
.	O

Consequently	O
,	O
the	O
present	O
study	O
was	O
addressed	O
to	O
understand	O
this	O
phenomenon	O
and	O
revealed	O
the	O
existence	O
of	O
a	O
unique	B-protein
47	I-protein
kDa	I-protein
protein	I-protein
factor	I-protein
having	O
affinity	O
for	O
this	O
SRE	B-DNA
sequence	I-DNA
in	O
lymphocytes	B-cell_type
from	O
normal	O
subjects	O
as	O
well	O
as	O
its	O
absence	O
in	O
lymphocytes	B-cell_type
from	O
untreated	O
CML	O
patients	O
.	O

However	O
,	O
this	O
factor	O
appeared	O
when	O
the	O
CML	O
patients	O
achieved	O
complete	O
haematological	O
remission	O
(	O
CHR	O
)	O
through	O
alpha-interferon	B-protein
therapy	O
.	O

Further	O
,	O
an	O
inverse	O
relationship	O
was	O
also	O
observed	O
between	O
sterol	O
modulated	O
LDL-receptor	B-DNA
gene	I-DNA
transcription	O
and	O
the	O
binding	O
affinity	O
of	O
this	O
47	B-protein
kDa	I-protein
factor	I-protein
to	O
the	O
SRE	B-DNA
sequence	I-DNA
.	O

Based	O
upon	O
these	O
results	O
we	O
propose	O
that	O
alpha-interferon	B-protein
through	O
its	O
receptor	O
initiates	O
phosphatidic	O
acid	O
dependent	O
signalling	O
which	O
in	O
turn	O
regulates	O
the	O
affinity	O
of	O
47	B-protein
kDa	I-protein
sterol	I-protein
regulatory	I-protein
element	I-protein
binding	I-protein
factor	I-protein
as	O
well	O
as	O
LDL-receptor	B-DNA
gene	I-DNA
transcription	O
in	O
lymphocytes	B-cell_type
from	O
CML	O
patients	O
.	O

Multiple	O
prolactin-responsive	B-DNA
elements	I-DNA
mediate	O
G1	O
and	O
S	O
phase	O
expression	O
of	O
the	O
interferon	B-DNA
regulatory	I-DNA
factor-1	I-DNA
gene	I-DNA
.	O

The	O
interferon	B-DNA
regulatory	I-DNA
factor-1	I-DNA
(	I-DNA
IRF-1	I-DNA
)	I-DNA
gene	I-DNA
is	O
both	O
an	O
immediate-early	B-DNA
G1	I-DNA
phase	I-DNA
gene	I-DNA
and	O
an	O
S	B-DNA
phase	I-DNA
gene	I-DNA
inducible	O
by	O
PRL	B-protein
in	O
rat	B-cell_line
Nb2	I-cell_line
T	I-cell_line
lymphocytes	I-cell_line
.	O

To	O
understand	O
the	O
mechanism	O
by	O
which	O
PRL	B-protein
regulates	O
the	O
biphasic	O
expression	O
of	O
IRF-1	B-protein
,	O
we	O
cloned	O
the	O
rat	B-DNA
IRF-1	I-DNA
gene	I-DNA
and	O
functionally	O
characterized	O
the	O
IRF-1	B-DNA
promoter	I-DNA
.	O

Upon	O
transfection	O
into	O
Nb2	B-cell_line
T	I-cell_line
cells	I-cell_line
,	O
1.7	O
kilobases	O
(	O
kb	O
)	O
of	O
IRF-1	B-DNA
5'-flanking	I-DNA
DNA	I-DNA
linked	O
to	O
a	O
chloramphenicol	B-DNA
acetyl	I-DNA
transferase	I-DNA
(	I-DNA
CAT	I-DNA
)	I-DNA
reporter	I-DNA
gene	I-DNA
mediated	O
a	O
30-fold	O
induction	O
of	O
CAT	B-protein
enzyme	I-protein
activity	O
in	O
response	O
to	O
24	O
h	O
of	O
PRL	B-protein
stimulation	O
.	O

Deletion	O
mutants	O
containing	O
1.3	B-DNA
,	I-DNA
0.6	I-DNA
,	I-DNA
and	I-DNA
0.2	I-DNA
kb	I-DNA
5'-flanking	I-DNA
DNA	I-DNA
were	O
incrementally	O
less	O
transcriptionally	O
active	O
,	O
although	O
0.2	O
kb	O
still	O
mediated	O
a	O
12-fold	O
induction	O
by	O
PRL	B-protein
.	O

The	O
sequence	O
between	O
-1.7	O
and	O
-0.2	O
kb	O
linked	O
to	O
a	O
heterologous	B-DNA
thymidine	I-DNA
kinase	I-DNA
promoter	I-DNA
failed	O
to	O
respond	O
to	O
PRL	B-protein
stimulation	O
,	O
suggesting	O
that	O
the	O
activity	O
of	O
upstream	B-DNA
PRL	I-DNA
response	I-DNA
elements	I-DNA
may	O
require	O
an	O
interaction	O
with	O
promoter-proximal	B-DNA
elements	I-DNA
.	O

By	O
assaying	O
CAT	B-protein
enzyme	I-protein
activity	O
across	O
a	O
24-h	O
PRL	B-protein
induction	O
time	O
course	O
,	O
we	O
were	O
able	O
to	O
assign	O
G1	O
vs.	O
S	O
phase	O
PRL	B-protein
responses	O
of	O
the	O
IRF-1	B-DNA
gene	I-DNA
to	O
different	O
regions	O
of	O
the	O
IRF-1	B-protein
5'-flanking	B-DNA
and	O
promoter	B-DNA
DNA	I-DNA
.	O

The	O
0.2-kb	O
IRF-CAT	B-DNA
construct	I-DNA
was	O
induced	O
by	O
PRL	B-protein
stimulation	O
during	O
the	O
G1	O
phase	O
of	O
the	O
cell	O
cycle	O
.	O

In	O
contrast	O
,	O
the	O
1.7-kb	O
IRF-	O
CAT	B-protein
construct	O
was	O
inducible	O
by	O
PRL	B-protein
during	O
both	O
G1	O
and	O
S	O
phase	O
of	O
the	O
cell	O
cycle	O
.	O

Hence	O
,	O
the	O
PRL	B-protein
-induced	O
biphasic	O
expression	O
of	O
the	O
IRF-1	B-DNA
gene	I-DNA
appears	O
to	O
be	O
controlled	O
by	O
separate	O
PRL-responsive	B-DNA
elements	I-DNA
:	O
elements	O
in	O
the	O
first	O
0.2	O
kb	O
of	O
the	O
IRF-1	B-DNA
promoter	I-DNA
region	I-DNA
act	O
during	O
early	O
activation	O
,	O
and	O
elements	O
between	O
0.2	O
and	O
1.7	O
kb	O
act	O
in	O
concert	O
with	O
the	O
proximal	O
0.2-kb	O
region	O
during	O
S	O
phase	O
progression	O
.	O

Regulation	O
of	O
the	O
BZLF1	B-DNA
promoter	I-DNA
of	O
Epstein-Barr	O
virus	O
by	O
second	O
messengers	O
in	O
anti-immunoglobulin-treated	B-cell_line
B	I-cell_line
cells	I-cell_line
.	O

Initiation	O
of	O
the	O
Epstein-Barr	O
virus	O
(	O
EBV	O
)	O
lytic	O
cycle	O
is	O
dependent	O
on	O
the	O
transcription	O
of	O
the	O
BZLF1	B-DNA
gene	I-DNA
.	O

The	O
BZLF1	B-DNA
gene	I-DNA
promoter	I-DNA
(	O
Zp	B-DNA
)	O
was	O
activated	O
by	O
crosslinking	O
of	O
cell	B-protein
surface	I-protein
immunoglobulin	I-protein
(	O
Ig	B-protein
)	O
with	O
anti-Ig	B-protein
antibody	I-protein
in	O
B	B-cell_type
cells	I-cell_type
,	O
even	O
in	O
the	O
absence	O
of	O
other	O
viral	O
genes	O
.	O

We	O
identified	O
several	O
anti-Ig	O
response	O
elements	O
within	O
Zp	B-DNA
,	O
which	O
were	O
originally	O
defined	O
as	O
12-O-tetradecanoylphorbol-13-acetate	B-DNA
(	I-DNA
TPA	I-DNA
)	I-DNA
response	I-DNA
elements	I-DNA
(	O
ZI	O
repeats	O
and	O
ZII	B-DNA
,	O
an	O
AP-1-like	B-DNA
domain	I-DNA
)	O
.	O

Since	O
anti-Ig	O
crosslinking	O
leads	O
to	O
activation	O
of	O
protein	B-protein
kinase	I-protein
C	I-protein
(	O
PKC	B-protein
)	O
and	O
an	O
increase	O
in	O
intracellular	O
calcium	O
level	O
,	O
Zp	B-DNA
was	O
tested	O
for	O
the	O
response	O
to	O
these	O
cellular	B-protein
factors	I-protein
.	O

Treatment	O
with	O
calcium	O
ionophore	O
A23187	O
increased	O
Zp	B-DNA
activity	O
.	O

When	O
the	O
calcium	O
ionophore	O
was	O
used	O
in	O
conjunction	O
with	O
TPA	O
,	O
a	O
PKC	B-protein
activator	O
,	O
the	O
Zp	B-DNA
induction	O
was	O
synergistically	O
enhanced	O
.	O

1-	O
(	O
5-Isoquinolinyl	O
sulfonyl	O
)	O
-2-methylpiperazine	O
,	O
an	O
inhibitor	O
of	O
PKC	B-protein
,	O
inhibited	O
the	O
anti-Ig	B-protein
inducibility	O
of	O
Zp	B-DNA
.	O

Calmodulin	O
antagonists	O
,	O
compound	O
R24571	O
and	O
trifluoperazine	O
,	O
blocked	O
the	O
Zp	B-DNA
activation	O
with	O
anti-Ig	B-protein
.	O

These	O
findings	O
suggest	O
that	O
Zp	B-DNA
responds	O
directly	O
to	O
changes	O
in	O
the	O
activity	O
of	O
both	O
PKC	B-protein
and	O
calcium/calmodulin-dependent	B-protein
protein	I-protein
kinase	I-protein
.	O

Requirement	O
of	O
tyrosine	B-protein
kinase	I-protein
activation	O
for	O
the	O
anti-Ig	B-protein
-mediated	O
Zp	B-DNA
activation	O
was	O
also	O
demonstrated	O
through	O
the	O
use	O
of	O
the	O
tyrosine	O
kinase	O
inhibitor	O
herbimycin	O
.	O

These	O
cellular	B-protein
gene	I-protein
regulatory	I-protein
molecules	I-protein
induced	O
with	O
anti-Ig	O
may	O
cooperatively	O
play	O
an	O
important	O
part	O
in	O
achieving	O
efficient	O
EBV	O
activation	O
as	O
seen	O
with	O
anti-Ig	B-protein
treatment	O
in	O
B	B-cell_type
cells	I-cell_type
.	O

The	O
SCL	B-protein
protein	I-protein
displays	O
cell-specific	O
heterogeneity	O
in	O
size	O
.	O

SCL	B-protein
protein	I-protein
production	O
was	O
examined	O
in	O
a	O
variety	O
of	O
hemopoietic	B-cell_line
cell	I-cell_line
lines	I-cell_line
by	O
immunoblotting	O
using	O
specific	O
polyclonal	O
antisera	O
.	O

SCL	B-protein
protein	I-protein
was	O
detected	O
in	O
erythroid	B-cell_line
,	I-cell_line
megakaryocyte	I-cell_line
,	I-cell_line
mast	I-cell_line
and	I-cell_line
early	I-cell_line
myeloid	I-cell_line
cell	I-cell_line
lines	I-cell_line
,	O
as	O
well	O
as	O
in	O
several	O
lymphoid	B-cell_line
leukemia	I-cell_line
cell	I-cell_line
lines	I-cell_line
which	O
are	O
known	O
to	O
harbor	O
SCL	B-DNA
gene	I-DNA
rearrangements	I-DNA
.	O

In	O
most	O
cell	O
lines	O
,	O
proteins	O
of	O
molecular	O
weight	O
49	O
and	O
44	O
kDa	O
were	O
found	O
,	O
however	O
two	O
myeloid	O
cell	O
lines	O
expressed	O
only	O
lower	O
molecular	B-protein
weight	I-protein
species	I-protein
of	I-protein
24	I-protein
and	I-protein
22	I-protein
kDa	I-protein
.	O

This	O
size	O
discrepancy	O
appeared	O
to	O
be	O
due	O
to	O
cell-specific	O
translational	O
regulation	O
,	O
since	O
overexpression	O
of	O
a	O
retrovirally	O
transfected	O
SCL	B-DNA
gene	I-DNA
yielded	O
the	O
higher	O
molecular	O
weight	O
forms	O
in	O
most	O
cell	B-cell_line
lines	I-cell_line
(	O
GP+E-86	B-cell_line
,	O
AT2.5	B-cell_line
,	O
M1	B-cell_line
)	O
but	O
only	O
the	O
22	B-protein
kDa	I-protein
form	I-protein
in	O
the	O
myeloid	B-cell_line
cell	I-cell_line
line	I-cell_line
,	O
WEHI-3B/D+	B-cell_line
.	O

Overexpression	O
of	O
full-length	O
SCL	B-protein
protein	I-protein
in	O
the	O
lymphoid	B-cell_line
cell	I-cell_line
lines	I-cell_line
,	O
SupT1	O
and	O
Raji	O
,	O
did	O
not	O
alter	O
cell	O
phenotype	O
and	O
there	O
was	O
no	O
evidence	O
for	O
autoregulation	O
of	O
SCL	B-protein
transcription	O
.	O

The	O
restricted	O
pattern	O
of	O
SCL	B-protein
protein	I-protein
synthesis	O
is	O
consistent	O
with	O
the	O
restricted	O
expression	O
of	O
SCL	B-RNA
mRNA	I-RNA
documented	O
previously	O
.	O

In	O
addition	O
,	O
the	O
present	O
results	O
indicate	O
that	O
SCL	B-protein
protein	I-protein
size	O
was	O
determined	O
by	O
regulation	O
of	O
translation	O
in	O
a	O
cell-specific	O
manner	O
.	O

Description	O
and	O
functional	O
implications	O
of	O
a	O
novel	O
mutation	O
in	O
the	O
sex-determining	B-DNA
gene	I-DNA
SRY	B-DNA
.	O

The	O
sex-determining	O
gene	O
SRY	B-DNA
was	O
screened	O
for	O
molecular	O
alteration	O
in	O
an	O
XY	O
sex-reversed	O
female	O
by	O
single-strand	O
conformation	O
polymorphism	O
(	O
SSCP	O
)	O
technique	O
.	O

An	O
A-to-G	O
transition	O
was	O
detected	O
which	O
leads	O
to	O
an	O
exchange	O
of	O
a	O
tyrosine	O
by	O
a	O
cysteine	O
in	O
the	O
SRY	B-protein
protein	I-protein
.	O

The	O
affected	O
tyrosine	O
residue	O
located	O
at	O
the	O
C	B-protein
terminus	I-protein
of	O
the	O
DNA	B-protein
binding	I-protein
protein	I-protein
is	O
evolutionarily	O
strongly	O
conserved	O
among	O
the	O
members	O
of	O
the	O
HMG	B-protein
box	I-protein
containing	I-protein
proteins	I-protein
.	O

Using	O
gel	O
shift	O
assay	O
and	O
peptide	O
synthesis	O
such	O
a	O
mutation	O
is	O
shown	O
to	O
abolish	O
the	O
SRY	B-DNA
protein	O
DNA	O
binding	O
ability	O
.	O

The	O
involvement	O
of	O
this	O
particular	O
amino	O
acid	O
in	O
the	O
binding	O
specificity	O
is	O
also	O
discussed	O
.	O

Induction	O
of	O
tyrosine	O
phosphorylation	O
and	O
T-cell	B-cell_type
activation	O
by	O
vanadate	O
peroxide	O
,	O
an	O
inhibitor	O
of	O
protein	B-protein
tyrosine	I-protein
phosphatases	I-protein
.	O

Rapid	O
tyrosine	O
phosphorylation	O
of	O
key	O
cellular	O
proteins	O
is	O
a	O
crucial	O
event	O
in	O
the	O
transduction	O
of	O
activation	O
signals	O
to	O
T-lymphocytes	B-cell_type
.	O

The	O
regulatory	O
role	O
of	O
protein	B-protein
tyrosine	I-protein
phosphatases	I-protein
(	O
PTPases	B-protein
)	O
in	O
this	O
process	O
was	O
explored	O
by	O
studying	O
the	O
effects	O
of	O
a	O
powerful	O
PTPase	B-protein
inhibitor	O
,	O
vanadate	O
peroxide	O
(	O
pervanadate	O
)	O
,	O
on	O
the	O
activation	O
cascade	O
of	O
Jurkat	B-cell_line
human	I-cell_line
leukaemic	I-cell_line
T-cells	I-cell_line
.	O

Pervanadate	O
induced	O
activation	O
of	O
the	O
tyrosine	B-protein
kinases	I-protein
lck	B-protein
and	O
fyn	B-protein
(	O
4-	O
and	O
3-fold	O
respectively	O
)	O
and	O
a	O
dramatic	O
increase	O
in	O
tyrosine	O
phosphorylation	O
of	O
cellular	B-protein
proteins	I-protein
,	O
notably	O
phospholipase	B-protein
C	I-protein
gamma	I-protein
1	I-protein
.	O

After	O
this	O
event	O
,	O
we	O
observed	O
a	O
rise	O
in	O
intracellular	O
Ca2+	O
concentration	O
,	O
corresponding	O
to	O
an	O
influx	O
.	O

This	O
effect	O
required	O
surface	O
expression	O
of	O
the	O
CD45	B-protein
PTPase	I-protein
and	O
was	O
not	O
observed	O
in	O
CD45-deficient	B-cell_line
variants	I-cell_line
of	O
Jurkat	B-cell_line
cells	I-cell_line
.	O

In	O
the	O
CD45-negative	B-cell_line
variant	I-cell_line
,	O
the	O
effect	O
of	O
pervanadate	O
on	O
tyrosine	O
phosphorylation	O
was	O
globally	O
decreased	O
and	O
some	O
phosphorylated	O
substrates	O
were	O
specifically	O
missing	O
.	O

Pervanadate	O
also	O
stimulated	O
transcription	O
of	O
the	O
c-fos	B-DNA
gene	I-DNA
and	O
accumulation	O
of	O
its	O
mRNA	B-RNA
as	O
well	O
as	O
several	O
other	O
hallmarks	O
of	O
T-lymphocyte	B-cell_type
activation	O
such	O
as	O
surface	O
expression	O
of	O
the	O
CD69	O
antigen	O
and	O
the	O
interleukin	O
2	O
receptor	O
alpha-chain	O
(	O
CD25	O
)	O
.	O

Pervanadate	O
synergized	O
with	O
signals	O
delivered	O
by	O
T-cell	B-cell_type
antigen	B-protein
receptor	I-protein
engagement	O
or	O
by	O
a	O
phorbol	O
ester	O
to	O
induce	O
interleukin	O
2	O
production	O
.	O

Pervanadate	B-protein
activated	I-protein
NF-kappa	I-protein
B	I-protein
,	O
as	O
shown	O
by	O
an	O
increase	O
in	O
DNA-binding	O
activity	O
of	O
this	O
transcription	B-protein
factor	I-protein
.	O

We	O
thus	O
conclude	O
that	O
PTPases	B-protein
play	O
a	O
crucial	O
role	O
in	O
the	O
negative	O
regulation	O
of	O
signal	O
transduction	O
culminating	O
in	O
T-lymphocyte	B-cell_type
activation	O
.	O

Moreover	O
,	O
induction	O
of	O
tyrosine	O
phosphorylation	O
appears	O
sufficient	O
per	O
se	O
to	O
initiate	O
a	O
complete	O
activation	O
programme	O
.	O

Activation	O
of	O
nuclear	B-protein
factor-kappaB	I-protein
via	O
T	B-protein
cell	I-protein
receptor	I-protein
requires	O
a	O
Raf	B-protein
kinase	I-protein
and	O
Ca2+	O
influx	O
.	O

Functional	O
synergy	O
between	O
Raf	B-protein
and	O
calcineurin	B-protein
.	O

Signals	O
transduced	O
via	O
the	O
TCR	B-protein
activate	O
the	O
transcription	B-protein
factor	I-protein
nuclear	B-protein
factor-kappaB	I-protein
(	O
NF-kappaB	B-protein
)	O
,	O
which	O
,	O
in	O
turn	O
,	O
is	O
critical	O
to	O
the	O
transcriptional	O
induction	O
of	O
many	O
genes	O
important	O
for	O
the	O
proliferation	O
and	O
expression	O
of	O
a	O
differentiated	O
phenotype	O
.	O

Treatment	O
of	O
T	B-cell_type
cells	I-cell_type
with	O
the	O
protein	B-protein
kinase	I-protein
C	I-protein
activator	O
PMA	O
in	O
combination	O
with	O
Ca2+	O
ionophores	O
mimics	O
this	O
process	O
,	O
and	O
the	O
two	O
agents	O
are	O
often	O
substituted	O
for	O
TCR	B-protein
stimulation	O
,	O
bypassing	O
the	O
TCR	B-protein
.	O

Here	O
we	O
identify	O
intracellular	O
signaling	O
components	O
involved	O
in	O
activation	O
of	O
NF-kappaB	B-protein
following	O
TCR	B-protein
stimulation	O
.	O

TCR	B-protein
signaling	O
was	O
triggered	O
by	O
treating	O
Jurkat	B-cell_line
T	I-cell_line
cells	I-cell_line
with	O
PHA	B-protein
or	O
anti-CD3	B-protein
Abs	I-protein
,	O
and	O
NF-kappaB	B-protein
activation	O
was	O
monitored	O
by	O
electrophoretic	O
mobility	O
shift	O
assays	O
and/or	O
by	O
kappaB	B-protein
-dependent	O
reporter	O
assays	O
.	O

Contrary	O
to	O
the	O
idea	O
that	O
protein	B-protein
kinase	I-protein
C	I-protein
is	O
involved	O
in	O
TCR	B-protein
-mediated	O
activation	O
of	O
NF-kappaB	B-protein
,	O
high	O
doses	O
of	O
staurosporine	O
did	O
not	O
interfere	O
with	O
activation	O
of	O
NF-kappaB	B-protein
by	O
PHA	B-protein
,	O
while	O
the	O
same	O
dose	O
of	O
staurosporine	O
completely	O
blocked	O
activation	O
by	O
PMA	O
.	O

PHA	B-protein
-induced	O
kappaB-dependent	O
reporter	O
activity	O
was	O
,	O
however	O
,	O
effectively	O
blocked	O
by	O
a	O
dominant	O
negative	O
form	O
of	O
Raf-1	B-protein
,	O
suggesting	O
a	O
critical	O
role	O
for	O
a	O
Raf	B-protein
kinase	I-protein
.	O

The	O
TCR	B-protein
-mediated	O
activation	O
of	O
NF-kappaB	B-protein
was	O
also	O
dependent	O
on	O
a	O
Ca2+	O
influx	O
,	O
because	O
the	O
Ca2+	O
channel	O
blocker	O
,	O
SK	O
&	O
F	O
96365	O
,	O
as	O
well	O
as	O
other	O
agents	O
that	O
prevented	O
the	O
Ca2+	O
influx	O
,	O
inhibited	O
NF-kappaB	B-protein
activation	O
.	O

Cotransfection	O
of	O
a	O
constitutively	O
active	O
form	O
of	O
calcineurin	B-protein
largely	O
substituted	O
for	O
the	O
Ca2+	O
requirement	O
and	O
reversed	O
the	O
blockade	O
by	O
SK	O
&	O
F	O
96365	O
.	O

Consistent	O
with	O
these	O
observations	O
,	O
coexpression	O
of	O
constitutively	O
active	O
forms	O
of	O
Raf-1	B-protein
and	O
calcineurin	B-protein
synergistically	O
induced	O
kappaB	B-protein
-dependent	O
reporter	O
activity	O
,	O
suggesting	O
a	O
physiologically	O
relevant	O
functional	O
interaction	O
between	O
the	O
kinase	B-protein
and	O
the	O
phosphatase	B-protein
.	O

Synergistic	O
interactions	O
between	O
overlapping	B-DNA
binding	I-DNA
sites	I-DNA
for	O
the	O
serum	B-protein
response	I-protein
factor	I-protein
and	O
ELK-1	B-protein
proteins	I-protein
mediate	O
both	O
basal	O
enhancement	O
and	O
phorbol	O
ester	O
responsiveness	O
of	O
primate	B-DNA
cytomegalovirus	I-DNA
major	I-DNA
immediate-early	I-DNA
promoters	I-DNA
in	O
monocyte	O
and	O
T-lymphocyte	B-cell_type
cell	O
types	O
.	O

Cytomegalovirus	O
(	O
CMV	O
)	O
infection	O
is	O
nonpermissive	O
or	O
persistent	O
in	O
many	O
lymphoid	B-cell_type
and	I-cell_type
myeloid	I-cell_type
cell	I-cell_type
types	I-cell_type
but	O
can	O
be	O
activated	O
in	O
differentiated	B-cell_type
macrophages	I-cell_type
.	O

We	O
have	O
shown	O
elsewhere	O
that	O
both	O
the	O
major	B-DNA
immediate-early	I-DNA
gene	I-DNA
(	O
MIE	B-DNA
)	O
and	O
lytic	O
cycle	O
infectious	O
progeny	O
virus	O
expression	O
can	O
be	O
induced	O
in	O
otherwise	O
nonpermissive	O
monocyte-like	B-cell_line
U-937	I-cell_line
cell	I-cell_line
cultures	I-cell_line
infected	O
with	O
either	O
human	O
CMV	O
(	O
HCMV	O
)	O
or	O
simian	O
CMV	O
(	O
SCMV	O
)	O
by	O
treatment	O
with	O
the	O
phorbol	O
ester	O
12-O-tetradecanoylphorbol-13-acetate	O
(	O
TPA	O
)	O
.	O

Two	O
multicopy	B-DNA
basal	I-DNA
enhancer	I-DNA
motifs	I-DNA
within	O
the	O
SCMV	O
MIE	B-DNA
enhancer	I-DNA
,	O
namely	O
,	O
11	O
copies	O
of	O
the	O
16-bp	O
cyclic	B-DNA
AMP	I-DNA
response	I-DNA
element	I-DNA
(	O
CRE	B-DNA
)	O
and	O
3	O
copies	O
of	O
novel	O
17-bp	O
serum	B-DNA
response	I-DNA
factor	I-DNA
(	I-DNA
SRF	I-DNA
)	I-DNA
binding	I-DNA
sites	I-DNA
referred	O
to	O
as	O
the	O
SNE	B-DNA
(	O
SRF/NFkappaB-like	B-DNA
element	I-DNA
)	O
,	O
as	O
well	O
as	O
four	O
classical	O
NFkappaB	B-DNA
sites	I-DNA
within	O
the	O
HCMV	O
version	O
,	O
contribute	O
to	O
TPA	O
responsiveness	O
in	O
transient	O
assays	O
in	O
monocyte	B-cell_type
and	I-cell_type
T-cell	I-cell_type
types	I-cell_type
.	O

The	O
SCMV	B-DNA
SNE	I-DNA
sites	I-DNA
contain	O
potential	O
overlapping	O
core	O
recognition	O
binding	O
motifs	O
for	O
SRF	B-protein
,	O
Rel/NFkappaB	B-protein
,	O
ETS	B-protein
,	O
and	O
YY1	B-protein
class	I-protein
transcription	I-protein
factors	I-protein
but	O
fail	O
to	O
respond	O
to	O
either	O
serum	B-protein
or	I-protein
tumor	I-protein
necrosis	I-protein
factor	I-protein
alpha	I-protein
.	O

Therefore	O
,	O
to	O
evaluate	O
the	O
mechanism	O
of	O
TPA	O
responsiveness	O
of	O
the	O
SNE	B-DNA
motifs	I-DNA
and	O
of	O
a	O
related	O
16-bp	O
SEE	B-DNA
(	O
SRF/ETS	B-DNA
element	I-DNA
)	O
motif	O
found	O
in	O
the	O
HCMV	B-DNA
and	I-DNA
chimpanzee	I-DNA
CMV	I-DNA
MIE	I-DNA
enhancers	I-DNA
,	O
we	O
have	O
examined	O
the	O
functional	O
responses	O
and	O
protein	O
binding	O
properties	O
of	O
multimerized	B-DNA
wild-type	I-DNA
and	I-DNA
mutant	I-DNA
elements	I-DNA
added	O
upstream	O
to	O
the	O
SCMV	B-DNA
MIE	I-DNA
or	O
simian	B-DNA
virus	I-DNA
40	I-DNA
minimal	I-DNA
promoter	I-DNA
regions	I-DNA
in	O
the	O
U-937	B-cell_line
,	O
K-562	B-cell_line
,	O
HL-60	B-cell_line
,	O
THP-1	B-cell_line
,	O
and	O
Jurkat	B-cell_line
cell	I-cell_line
lines	I-cell_line
.	O

Unlike	O
classical	O
NFkappaB	B-DNA
sites	I-DNA
,	O
neither	O
the	O
SNE	B-DNA
nor	O
the	O
SEE	B-DNA
motif	I-DNA
responded	O
to	O
phosphatase	O
inhibition	O
by	O
okadaic	O
acid	O
.	O

However	O
,	O
the	O
TPA	O
responsiveness	O
of	O
both	O
CMV	B-DNA
elements	I-DNA
proved	O
to	O
involve	O
synergistic	O
interactions	O
between	O
the	O
core	O
SRF	B-DNA
binding	I-DNA
site	I-DNA
(	O
CCATATATGG	O
)	O
and	O
the	O
adjacent	O
inverted	O
ETS	B-DNA
binding	I-DNA
motifs	I-DNA
(	O
TTCC	O
)	O
,	O
which	O
correlated	O
directly	O
with	O
formation	O
of	O
a	O
bound	O
tripartite	B-protein
complex	I-protein
containing	O
both	O
the	O
cellular	O
SRF	B-protein
and	O
ELK-1	B-protein
proteins	I-protein
.	O

This	O
protein	B-protein
complex	I-protein
was	O
more	O
abundant	O
in	O
U-937	O
,	O
K-562	O
,	O
and	O
HeLa	O
cell	O
extracts	O
than	O
in	O
Raji	B-cell_line
,	O
HF	B-cell_line
,	O
BALB/c	B-cell_line
3T3	I-cell_line
,	O
or	O
HL-60	B-cell_line
cells	I-cell_line
,	O
but	O
the	O
binding	O
activity	O
was	O
altered	O
only	O
twofold	O
after	O
TPA	O
treatment	O
.	O

A	O
40-fold	O
stimulation	O
of	O
chloramphenicol	B-protein
acetyltransferase	I-protein
activity	O
mediated	O
by	O
four	O
tandem	B-DNA
repeats	I-DNA
of	O
the	O
SNE	B-DNA
could	O
be	O
induced	O
within	O
2	O
h	O
(	O
and	O
up	O
to	O
250-fold	O
within	O
6	O
h	O
)	O
after	O
addition	O
of	O
TPA	O
in	O
DNA-transfected	B-cell_line
U-937	I-cell_line
cells	I-cell_line
,	O
indicating	O
that	O
the	O
stimulation	O
appeared	O
likely	O
to	O
be	O
a	O
true	O
protein	B-protein
kinase	I-protein
C	I-protein
-mediated	O
signal	O
transduction	O
event	O
rather	O
than	O
a	O
differentiation	O
response	O
.	O

Slight	O
differences	O
in	O
the	O
sequence	O
of	O
the	O
core	B-DNA
SRF	I-DNA
binding	I-DNA
site	I-DNA
compared	O
with	O
that	O
of	O
the	O
classical	O
c-Fos	B-DNA
promoter	I-DNA
serum	I-DNA
response	I-DNA
element	I-DNA
,	O
together	O
with	O
differences	O
in	O
the	O
spacing	O
between	O
the	O
SRF	B-DNA
and	I-DNA
ETS	I-DNA
motifs	I-DNA
,	O
appear	O
to	O
account	O
for	O
the	O
inability	O
of	O
the	O
SCMV	B-DNA
SNEs	I-DNA
to	O
respond	O
to	O
serum	O
induction	O
.	O

T-cell	B-cell_type
-directed	O
TAL-1	B-protein
expression	O
induces	O
T-cell	O
malignancies	O
in	O
transgenic	O
mice	O
.	O

The	O
TAL-1	B-DNA
gene	I-DNA
specifies	O
for	O
a	O
basic	O
domain-helix-loop-helix	B-protein
protein	I-protein
,	O
which	O
is	O
involved	O
in	O
the	O
control	O
of	O
normal	O
hematopoiesis	O
.	O

In	O
human	O
pathology	O
,	O
the	O
TAL-1	B-protein
gene	I-protein
product	I-protein
is	O
expressed	O
in	O
a	O
high	O
percentage	O
of	O
T-cell	B-cell_type
acute	O
lymphoblastic	O
leukemias	O
in	O
the	O
pediatric	O
age	O
range	O
;	O
however	O
,	O
it	O
has	O
not	O
been	O
established	O
whether	O
the	O
expression	O
has	O
a	O
causal	O
role	O
in	O
oncogenesis	O
.	O

In	O
this	O
report	O
,	O
we	O
describe	O
the	O
phenotype	O
of	O
mouse	B-cell_line
transgenic	I-cell_line
lines	I-cell_line
obtained	O
by	O
inducing	O
tal-1	B-protein
protein	I-protein
expression	O
in	O
lymphoid	O
tissues	O
using	O
the	O
LCK	B-DNA
promoter	I-DNA
.	O

The	O
survival	O
rate	O
of	O
tal-1	B-DNA
transgenic	O
animals	O
was	O
much	O
lower	O
as	O
compared	O
with	O
control	O
mice	O
.	O

Histopathological	O
analysis	O
revealed	O
lymphomas	O
of	O
T-cell	O
type	O
,	O
often	O
comprising	O
a	O
minor	O
B-cell	O
component	O
.	O

Some	O
mice	O
showed	O
marked	O
splenic	O
lymphocyte	O
depletion	O
.	O

Primary	B-cell_line
lymphocyte	I-cell_line
cultures	I-cell_line
showed	O
partial	O
independence	O
from	O
exogenous	O
growth	O
stimuli	O
and	O
increased	O
resistance	O
to	O
low-serum	O
apoptosis	O
.	O

To	O
further	O
unravel	O
the	O
tal-1	B-DNA
oncogenic	O
potential	O
,	O
a	O
strain	O
of	O
tal-1	B-DNA
transgenic	O
mice	O
was	O
crossbred	O
with	O
p53-/-	O
mice	O
;	O
the	O
survival	O
rate	O
in	O
these	O
animals	O
was	O
reduced	O
by	O
more	O
than	O
one-half	O
when	O
compared	O
with	O
that	O
of	O
tal-1	B-DNA
mice	O
,	O
and	O
histopathological	O
analysis	O
revealed	O
exclusively	O
T-cell	B-cell_type
lymphomas	O
.	O

These	O
data	O
indicate	O
that	O
TAL-1	B-protein
,	O
expressed	O
in	O
T	B-cell_type
cells	I-cell_type
,	O
is	O
per	O
se	O
a	O
potent	O
oncogene	O
,	O
which	O
may	O
exert	O
a	O
key	O
leukemogenetic	O
role	O
in	O
the	O
majority	O
of	O
T-cell	B-cell_type
acute	O
lymphoblastic	O
leukemias	O
.	O

Tissue	O
and	O
cell-type	O
specific	O
expression	O
of	O
the	O
tuberous	B-DNA
sclerosis	I-DNA
gene	I-DNA
,	O
TSC2	B-DNA
,	O
in	O
human	O
tissues	O
.	O

TSC2	B-DNA
is	O
a	O
gene	O
on	O
chromosome	B-DNA
16p13.3	I-DNA
associated	O
with	O
the	O
autosomal	O
dominant	O
neurocutaneous	O
disorder	O
,	O
tuberous	O
sclerosis	O
complex	O
(	O
TSC	O
)	O
.	O

By	O
using	O
a	O
partial	O
nucleotide	O
sequence	O
from	O
the	O
cloned	O
TSC2	B-DNA
and	O
polymerase	O
chain	O
reaction	O
methodology	O
,	O
we	O
constructed	O
a	O
digoxigenin-labeled	B-DNA
complementary	I-DNA
DNA	I-DNA
probe	I-DNA
to	O
examine	O
TSC2	B-DNA
gene	O
expression	O
in	O
autopsy-	O
or	O
biopsy-derived	O
human	O
tissues	O
by	O
in	O
situ	O
hybridization	O
.	O

TSC2	B-RNA
messenger	I-RNA
RNA	I-RNA
was	O
widely	O
expressed	O
in	O
various	O
cell	O
types	O
throughout	O
the	O
body	O
,	O
including	O
epithelia	O
,	O
lymphocytes	B-cell_type
,	O
and	O
cells	O
with	O
endocrine	O
functions	O
,	O
e.g.	O
,	O
adrenal	O
cortex	O
and	O
anterior	O
pituitary	O
.	O

It	O
was	O
prominently	O
and	O
selectively	O
(	O
within	O
the	O
central	O
nervous	O
system	O
)	O
expressed	O
in	O
pyramidal	B-cell_type
cells	I-cell_type
of	O
the	O
cerebral	O
cortex	O
and	O
other	O
motor	B-cell_type
neurons	I-cell_type
,	O
e.g.	O
,	O
in	O
spinal	O
cord	O
and	O
brainstem	O
nuclei	O
.	O

Visceral	O
TSC2	B-DNA
expression	O
was	O
comparable	O
in	O
autopsy	O
tissues	O
from	O
patients	O
with	O
and	O
without	O
TSC	O
;	O
TSC2	B-DNA
messenger	O
RNA	O
expression	O
was	O
most	O
prominent	O
in	O
cells	O
with	O
a	O
rapid	O
mitotic	O
rate	O
and	O
turnover	O
,	O
e.g.	O
,	O
epithelia	O
and	O
lymphocytes	B-cell_type
,	O
with	O
central	O
nervous	O
system	O
pyramidal	B-cell_type
cells	I-cell_type
and	O
other	O
neurons	O
being	O
an	O
obvious	O
exception	O
,	O
and/or	O
in	O
cells	O
with	O
important	O
secretory/transport	O
functions	O
.	O

This	O
widespread	O
expression	O
of	O
the	O
TSC2	B-DNA
gene	I-DNA
supports	O
the	O
view	O
that	O
it	O
encodes	O
a	O
protein	O
vital	O
to	O
cell	O
growth	O
and	O
metabolism	O
or	O
one	O
that	O
functions	O
as	O
a	O
tumor/growth	O
suppressor	O
.	O

Apoptosis	O
signaling	O
pathways	O
in	O
normal	O
T	B-cell_type
cells	I-cell_type
:	O
differential	O
activity	O
of	O
Bcl-2	B-protein
and	O
IL-1beta-converting	B-protein
enzyme	I-protein
family	I-protein
protease	O
inhibitors	O
on	O
glucocorticoid-	O
and	O
Fas-mediated	O
cytotoxicity	O
.	O

Fas	B-protein
-mediated	O
apoptosis	O
plays	O
an	O
important	O
role	O
in	O
regulating	O
the	O
immune	O
response	O
in	O
peripheral	B-cell_type
T	I-cell_type
cells	I-cell_type
.	O

Restimulation	O
of	O
T	B-cell_type
cell	I-cell_type
blasts	I-cell_type
up-regulates	O
Fas	B-protein
and	O
Fas	B-protein
ligand	O
expression	O
,	O
with	O
subsequent	O
interaction	O
leading	O
to	O
cell	O
death	O
.	O

Overexpression	O
of	O
Bcl-2	B-protein
in	O
tumor	B-cell_type
cells	I-cell_type
blocks	O
apoptosis	O
induced	O
by	O
many	O
stimuli	O
,	O
but	O
inhibition	O
of	O
Fas	B-protein
-mediated	O
killing	O
has	O
not	O
been	O
consistently	O
observed	O
.	O

To	O
examine	O
the	O
behavior	O
of	O
Bcl-2	B-protein
in	O
normal	B-cell_type
cells	I-cell_type
,	O
T	B-cell_type
cell	I-cell_type
blasts	I-cell_type
were	O
transiently	O
transfected	O
with	O
Bcl-2	B-protein
and	O
related	O
gene	B-protein
products	I-protein
to	O
determine	O
the	O
effect	O
on	O
apoptotic	O
signaling	O
.	O

Transient	O
overexpression	O
of	O
Bcl-2	B-protein
in	O
mouse	O
and	O
human	O
T	B-cell_type
cell	I-cell_type
blasts	I-cell_type
did	O
not	O
block	O
Fas	B-protein
-mediated	O
apoptosis	O
,	O
whereas	O
etoposide-	O
and	O
glucocorticoid-induced	O
cytotoxicity	O
was	O
potently	O
inhibited	O
.	O

Expression	O
of	O
Bcl-xL	B-protein
and	O
adenovirus	B-protein
E1B	I-protein
19K	I-protein
did	O
not	O
interfere	O
with	O
anti-	O
Fas	B-protein
killing	O
.	O

In	O
contrast	O
,	O
interleukin-1beta-converting	O
enzyme	O
family	O
protease	O
inhibitors	O
Ac-DEVD-CHO	O
and	O
CrmA	O
blocked	O
Fas	B-protein
-mediated	O
apoptosis	O
.	O

These	O
results	O
suggest	O
that	O
peripheral	B-cell_type
T	I-cell_type
cells	I-cell_type
use	O
distinct	O
apoptosis	O
signaling	O
pathways	O
with	O
differential	O
sensitivity	O
to	O
Bcl-2	B-protein
and	O
interleukin-1beta-converting	O
enzyme	O
family	O
protease	O
inhibitors	O
.	O

Since	O
T	B-cell_type
cells	I-cell_type
normally	O
express	O
Bcl-2	B-protein
and	O
Bcl-xL	B-protein
following	O
activation	O
,	O
their	O
inability	O
to	O
block	O
Fas	B-protein
-mediated	O
apoptosis	O
may	O
allow	O
for	O
the	O
elimination	O
of	O
self-reactive	B-cell_type
cells	I-cell_type
and	O
the	O
appropriate	O
regulation	O
of	O
immune	O
responses	O
.	O

Increased	O
interleukin	B-protein
2	I-protein
transcription	O
in	O
murine	B-cell_type
lymphocytes	I-cell_type
by	O
ciprofloxacin	O
.	O

The	O
fluoroquinolone	O
antibiotic	O
,	O
ciprofloxacin	O
(	O
cipro	O
)	O
,	O
induces	O
hyperproduction	O
of	O
interleukin	B-protein
2	I-protein
(	O
IL-2	B-protein
)	O
and	O
interferon-gamma	B-protein
(	O
IFN-gamma	B-protein
)	O
in	O
stimulated	O
human	B-cell_type
peripheral	I-cell_type
blood	I-cell_type
lymphocytes	I-cell_type
.	O

In	O
this	O
investigation	O
an	O
enhanced	O
and	O
prolonged	O
IL-2	B-protein
and	O
IL-2	B-RNA
mRNA	I-RNA
response	O
was	O
also	O
detected	O
in	O
both	O
stimulated	O
(	O
T	B-protein
cell	I-protein
mitogens	I-protein
or	O
alloantigens	B-protein
)	O
murine	B-cell_type
splenocytes	I-cell_type
and	O
in	O
the	O
stimulated	O
murine	B-cell_line
T	I-cell_line
cell	I-cell_line
line	I-cell_line
EL-4	I-cell_line
in	O
the	O
presence	O
of	O
ciprofloxacin	O
(	O
5-80	O
micrograms/ml	O
)	O
as	O
compared	O
to	O
control	O
cells	O
without	O
antibiotics	O
.	O

However	O
,	O
in	O
contrast	O
to	O
human	B-cell_type
lymphocytes	I-cell_type
,	O
IFN-gamma	B-protein
production	O
was	O
inhibited	O
and	O
IFN-gamma	B-RNA
mRNA	I-RNA
levels	O
were	O
unaffected	O
at	O
24	O
h	O
and	O
only	O
slightly	O
upregulated	O
at	O
48	O
and	O
72	O
h	O
of	O
culture	O
in	O
murine	B-cell_type
splenocytes	I-cell_type
incubated	O
with	O
cipro	O
(	O
20	O
micrograms/ml	O
)	O
.	O

EL-4	B-cell_type
cells	I-cell_type
were	O
transfected	O
with	O
a	O
plasmid	O
containing	O
the	O
IL-2	B-DNA
promoter	I-DNA
and	O
enhancer	B-DNA
region	I-DNA
linked	O
to	O
the	O
chloramphenicol	B-DNA
acetyltransferase	I-DNA
(	I-DNA
CAT	I-DNA
)	I-DNA
reporter	I-DNA
gene	I-DNA
.	O

Analysis	O
of	O
CAT	B-protein
activity	O
revealed	O
that	O
cipro	O
enhanced	O
IL-2	O
gene	O
induction	O
.	O

In	O
addition	O
,	O
EL-4	B-cell_type
cells	I-cell_type
incubated	O
with	O
ciprofloxacin	O
showed	O
an	O
early	O
peak	O
and	O
more	O
activated	O
nuclear	O
factor	O
of	O
activated	B-cell_type
T	I-cell_type
cells	I-cell_type
(	O
NFAT-1	B-protein
)	O
as	O
compared	O
to	O
control	O
cells	O
without	O
antibiotics	O
.	O

Cipro	O
did	O
not	O
affect	O
the	O
nuclear	B-protein
transcription	I-protein
factors	I-protein
AP-1	B-protein
or	O
NFIL-2A	B-protein
.	O

Taken	O
together	O
,	O
cipro	O
inhibited	O
IFN-gamma	B-protein
synthesis	O
,	O
but	O
enhanced	O
IL-2	B-protein
production	O
in	O
murine	B-cell_type
lymphocytes	I-cell_type
by	O
means	O
of	O
influencing	O
NFAT-1	B-protein
and	O
causing	O
an	O
increased	O
IL-2	B-protein
transcription	O
.	O

Human	O
T-cell	O
leukemia	O
virus	O
type	O
I	O
Tax	B-protein
associates	O
with	O
and	O
is	O
negatively	O
regulated	O
by	O
the	O
NF-kappa	B-protein
B2	I-protein
p100	I-protein
gene	I-protein
product	I-protein
:	O
implications	O
for	O
viral	O
latency	O
.	O

Human	O
T-cell	O
leukemia	O
virus	O
type	O
I	O
(	O
HTLV-I	O
)	O
is	O
the	O
etiologic	O
agent	O
of	O
the	O
adult	O
T-cell	O
leukemia	O
,	O
an	O
aggressive	O
and	O
often	O
fatal	O
malignancy	O
of	O
activated	B-cell_line
human	I-cell_line
CD4	I-cell_line
T	I-cell_line
cells	I-cell_line
.	O

HTLV-I	O
encodes	O
an	O
essential	O
40-kDa	B-protein
protein	I-protein
termed	O
Tax	B-protein
that	O
not	O
only	O
transactivates	O
the	O
long	O
terminal	O
repeat	O
of	O
this	O
retrovirus	O
but	O
also	O
induces	O
an	O
array	O
of	O
cellular	B-DNA
genes	I-DNA
.	O

Tax	B-protein
-mediated	O
transformation	O
of	O
T	B-cell_type
cells	I-cell_type
likely	O
involves	O
the	O
deregulated	O
expression	O
of	O
various	O
cellular	B-DNA
genes	I-DNA
that	O
normally	O
regulate	O
lymphocyte	B-cell_type
growth	O
produced	O
by	O
altered	O
activity	O
of	O
various	O
endogenous	O
host	O
transcription	B-protein
factors	I-protein
.	O

In	O
particular	O
,	O
Tax	B-protein
is	O
capable	O
of	O
modulating	O
the	O
expression	O
or	O
activity	O
of	O
various	O
host	O
transcription	B-protein
factors	I-protein
,	O
including	O
members	O
of	O
the	O
NF-kappa	B-protein
B/Rel	I-protein
and	O
CREB/ATF	B-protein
families	I-protein
,	O
as	O
well	O
as	O
the	O
cellular	B-protein
factors	I-protein
HEB-1	B-protein
and	O
p67SRF	B-protein
.	O

An	O
additional	O
distinguishing	O
characteristic	O
of	O
HTLV-I	O
infection	O
is	O
the	O
profound	O
state	O
of	O
viral	O
latency	O
that	O
is	O
present	O
in	O
circulating	O
primary	B-cell_type
leukemic	I-cell_type
T	I-cell_type
cells	I-cell_type
.	O

In	O
this	O
study	O
,	O
we	O
demonstrate	O
that	O
HTLV-I	O
Tax	B-protein
can	O
physically	O
associate	O
with	O
p100	B-protein
,	O
the	O
product	O
of	O
the	O
Rel-related	B-DNA
NF-kappa	I-DNA
B2	I-DNA
gene	I-DNA
,	O
both	O
in	O
transfected	B-cell_line
cells	I-cell_line
and	O
in	O
HTLV-I-infected	B-cell_line
leukemic	I-cell_line
T-cell	I-cell_line
lines	I-cell_line
.	O

Furthermore	O
,	O
the	O
physical	O
interaction	O
of	O
Tax	B-protein
with	O
p100	B-protein
leads	O
to	O
the	O
inhibition	O
of	O
Tax	B-protein
-induced	O
activation	O
of	O
the	O
HTLV-I	O
and	O
human	B-DNA
immunodeficiency	I-DNA
virus	I-DNA
type	I-DNA
1	I-DNA
long	I-DNA
terminal	I-DNA
repeats	I-DNA
,	O
reflecting	O
p100	B-protein
-mediated	O
cytoplasmic	O
sequestration	O
of	O
the	O
normally	O
nuclearly	O
expressed	O
Tax	B-protein
protein	I-protein
.	O

In	O
contrast	O
,	O
a	O
mutant	O
of	O
Tax	B-protein
that	O
selectively	O
fails	O
to	O
activate	O
nuclear	O
NF-kappa	B-protein
B	I-protein
expression	O
does	O
not	O
associate	O
with	O
p100	B-protein
.	O

(	O
ABSTRACT	O
TRUNCATED	O
AT	O
250	O
WORDS	O
)	O

Rhabdomyosarcomas	O
do	O
not	O
contain	O
mutations	O
in	O
the	O
DNA	O
binding	O
domains	O
of	O
myogenic	O
transcription	B-protein
factors	I-protein
.	O

Skeletal	O
myogenesis	O
is	O
regulated	O
by	O
a	O
group	O
of	O
transcription	B-protein
factors	I-protein
(	O
MyoD	B-protein
,	O
myogenin	B-protein
,	O
myf5	B-protein
,	O
and	O
myf6	B-protein
)	O
that	O
are	O
``	B-protein
basic	I-protein
helix-loop-helix	I-protein
''	I-protein
proteins	I-protein
that	O
bind	O
to	O
the	O
promoters	B-DNA
of	O
muscle-specific	B-DNA
genes	I-DNA
and	O
promote	O
their	O
expression	O
.	O

We	O
have	O
previously	O
shown	O
that	O
after	O
a	O
mutation	O
of	O
Leu122	O
to	O
Arg	O
the	O
DNA	B-protein
binding	I-protein
basic	I-protein
domain	I-protein
of	O
MyoD	B-protein
confers	O
c-myc	B-DNA
-like	O
functional	O
characteristics	O
to	O
the	O
protein	O
.	O

In	O
this	O
study	O
we	O
used	O
single-strand	O
conformation	O
polymorphism	O
analysis	O
to	O
determine	O
whether	O
such	O
mutations	O
occur	O
naturally	O
in	O
rhabdomyosarcomas	O
.	O

We	O
have	O
found	O
that	O
the	O
basic	B-protein
domains	I-protein
of	O
all	O
the	O
myogenic	B-protein
factors	I-protein
remain	O
unaltered	O
in	O
rhabdomyosarcomas	O
.	O

Selection	O
against	O
such	O
mutations	O
may	O
be	O
the	O
result	O
of	O
functional	O
redundancy	O
of	O
these	O
myogenic	B-protein
transcription	I-protein
factors	I-protein
.	O

Function	O
and	O
activation	O
of	O
NF-kappa	B-protein
B	I-protein
in	O
the	O
immune	O
system	O
.	O

NF-kappa	B-protein
B	I-protein
is	O
a	O
ubiquitous	B-protein
transcription	I-protein
factor	I-protein
.	O

Nevertheless	O
,	O
its	O
properties	O
seem	O
to	O
be	O
most	O
extensively	O
exploited	O
in	O
cells	O
of	O
the	O
immune	O
system	O
.	O

Among	O
these	O
properties	O
are	O
NF-kappa	B-protein
B	I-protein
's	O
rapid	O
posttranslational	O
activation	O
in	O
response	O
to	O
many	O
pathogenic	O
signals	O
,	O
its	O
direct	O
participation	O
in	O
cytoplasmic/nuclear	O
signaling	O
,	O
and	O
its	O
potency	O
to	O
activate	O
transcription	O
of	O
a	O
great	O
variety	O
of	O
genes	O
encoding	O
immunologically	B-protein
relevant	I-protein
proteins	I-protein
.	O

In	O
vertebrates	O
,	O
five	O
distinct	O
DNA	B-protein
binding	I-protein
subunits	I-protein
are	O
currently	O
known	O
which	O
might	O
extensively	O
heterodimerize	O
,	O
thereby	O
forming	O
complexes	O
with	O
distinct	O
transcriptional	O
activity	O
,	O
DNA	O
sequence	O
specificity	O
,	O
and	O
cell	O
type-	O
and	O
cell	O
stage-specific	O
distribution	O
.	O

The	O
activity	O
of	O
DNA	B-protein
binding	I-protein
NF-kappa	I-protein
B	I-protein
dimers	I-protein
is	O
tightly	O
controlled	O
by	O
accessory	B-protein
proteins	I-protein
called	O
I	B-protein
kappa	I-protein
B	I-protein
subunits	I-protein
of	O
which	O
there	O
are	O
also	O
five	O
different	O
species	O
currently	O
known	O
in	O
vertebrates	O
.	O

I	B-protein
kappa	I-protein
B	I-protein
proteins	I-protein
inhibit	O
DNA	O
binding	O
and	O
prevent	O
nuclear	O
uptake	O
of	O
NF-kappa	B-protein
B	I-protein
complexes	I-protein
.	O

An	O
exception	O
is	O
the	O
Bcl-3	B-protein
protein	I-protein
which	O
in	O
addition	O
can	O
function	O
as	O
a	O
transcription	B-protein
activating	I-protein
subunit	I-protein
in	O
th	O
nucleus	O
.	O

Other	O
I	B-protein
kappa	I-protein
B	I-protein
proteins	I-protein
are	O
rather	O
involved	O
in	O
terminating	O
NF-kappa	B-protein
B	I-protein
's	O
activity	O
in	O
the	O
nucleus	O
.	O

The	O
intracellular	O
events	O
that	O
lead	O
to	O
the	O
inactivation	O
of	O
I	B-protein
kappa	I-protein
B	I-protein
,	O
i.e.	O
the	O
activation	O
of	O
NF-kappa	B-protein
B	I-protein
,	O
are	O
complex	O
.	O

They	O
involve	O
phosphorylation	O
and	O
proteolytic	O
reactions	O
and	O
seem	O
to	O
be	O
controlled	O
by	O
the	O
cells	O
'	O
redox	O
status	O
.	O

Interference	O
with	O
the	O
activation	O
or	O
activity	O
of	O
NF-kappa	B-protein
B	I-protein
may	O
be	O
beneficial	O
in	O
suppressing	O
toxic/septic	O
shock	O
,	O
graft-vs-host	O
reactions	O
,	O
acute	O
inflammatory	O
reactions	O
,	O
acute	O
phase	O
response	O
,	O
and	O
radiation	O
damage	O
.	O

The	O
inhibition	O
of	O
NF-kappa	B-protein
B	I-protein
activation	O
by	O
antioxidants	O
and	O
specific	O
protease	O
inhibitors	O
may	O
provide	O
a	O
pharmacological	O
basis	O
for	O
interfering	O
with	O
these	O
acute	O
processes	O
.	O

Lack	O
of	O
T-cell-mediated	O
recognition	O
of	O
the	O
fusion	O
region	O
of	O
the	O
pml/RAR-alpha	B-protein
hybrid	I-protein
protein	I-protein
by	O
lymphocytes	B-cell_type
of	O
acute	O
promyelocytic	O
leukemia	O
patients	O
.	O

In	O
previous	O
studies	O
,	O
it	O
was	O
shown	O
that	O
the	O
fusion	O
region	O
of	O
the	O
pml/RAR-alpha	B-protein
protein	I-protein
,	O
expressed	O
by	O
acute	B-cell_line
promyelocytic	I-cell_line
leukemia	I-cell_line
(	I-cell_line
APL	I-cell_line
)	I-cell_line
cells	I-cell_line
,	O
can	O
be	O
specifically	O
recognized	O
in	O
vitro	O
by	O
donor	O
(	O
D.	O
E.	O
)	O
CD4	B-cell_line
T	I-cell_line
cells	I-cell_line
in	O
a	O
HLA	B-protein
class	I-protein
II	I-protein
DR11-restricted	O
fashion	O
.	O

We	O
present	O
here	O
the	O
results	O
on	O
the	O
recognition	O
of	O
several	O
pml/RAR-alpha	O
peptides	O
by	O
APL	O
patients	O
expressing	O
HLA	B-protein
DR11	I-protein
.	O

The	O
in	O
vitro	O
immunization	O
of	O
peripheral	B-cell_type
blood	I-cell_type
lymphocytes	I-cell_type
from	O
four	O
patients	O
in	O
remission	O
(	O
S.R.	O
,	O
F.R.	O
,	O
M.M.	O
,	O
P.	O
G.	O
)	O
with	O
BCR1/25	O
,	O
a	O
25-mer	O
pml/	O
RAR-alpha	B-protein
,	O
did	O
not	O
elicit	O
either	O
a	O
polyclonal	O
or	O
a	O
clonal	O
immune	O
response	O
specific	O
to	O
the	O
peptide	O
.	O

We	O
then	O
generated	O
new	O
donor	O
anti-pml/RAR-alpha	B-cell_line
CD4	I-cell_line
(	I-cell_line
+	I-cell_line
)	I-cell_line
T-cell	I-cell_line
clones	I-cell_line
.	O

These	O
clones	O
were	O
tested	O
for	O
their	O
recognition	O
of	O
BCR1/25	O
.	O

One	O
clone	O
(	O
C3/5	B-cell_line
,	I-cell_line
CD3	I-cell_line
(	I-cell_line
+	I-cell_line
)	I-cell_line
,	I-cell_line
CD4	I-cell_line
(	I-cell_line
+	I-cell_line
)	I-cell_line
,	I-cell_line
CD8	I-cell_line
(	I-cell_line
-	I-cell_line
)	I-cell_line
)	O
was	O
selected	O
for	O
further	O
analysis	O
.	O

Clone	B-cell_line
C3/5	I-cell_line
showed	O
specific	O
proliferation	O
,	O
cytotoxicity	O
,	O
and	O
cytokine	O
(	O
tumor	B-protein
necrosis	I-protein
factor	I-protein
alpha	I-protein
,	O
granulocyte-macrophage	B-protein
colony-stimulating	I-protein
factor	I-protein
)	O
production	O
when	O
challenged	O
with	O
autologous	B-cell_line
lymphoblastic	I-cell_line
cell	I-cell_line
lines	I-cell_line
pulsed	O
with	O
peptide	O
BCR1/25	O
.	O

C3/5	B-cell_line
cells	I-cell_line
developed	O
specific	O
proliferation	O
and	O
cytotoxicity	O
when	O
challenged	O
with	O
peptide-pulsed	B-cell_line
lymphoblastic	I-cell_line
cell	I-cell_line
lines	I-cell_line
and	O
peripheral	B-cell_type
blood	I-cell_type
lymphocytes	I-cell_type
from	O
the	O
four	O
DR11	O
(	O
+	O
)	O
APL	O
patients	O
.	O

APL	B-cell_type
blasts	I-cell_type
,	O
available	O
only	O
from	O
patients	O
F.R.	O
and	O
P.G.	O
,	O
were	O
not	O
lysed	O
by	O
C3/5	B-cell_line
and	O
were	O
unable	O
to	O
present	O
peptide	O
BCR1/25	O
.	O

Incubation	O
of	O
APL	B-cell_line
cells	I-cell_line
with	O
IFN-gamma	B-protein
failed	O
to	O
induce	O
HLA	B-protein
class	I-protein
II	I-protein
molecules	I-protein
and	O
recognition	O
by	O
the	O
C3/5	B-cell_line
clone	I-cell_line
.	O

Since	O
APL	B-cell_line
cells	I-cell_line
do	O
not	O
express	O
HLA	B-protein
class	I-protein
II	I-protein
molecules	I-protein
,	O
we	O
tested	O
in	O
two	O
donors	O
(	O
D.E.	O
and	O
C.H.R.	O
)	O
and	O
in	O
patients	O
S.R.and	O
P.G.whether	O
the	O
use	O
of	O
9-mer	O
peptides	O
(	O
BCR1/9	O
)	O
would	O
generate	O
a	O
CD8	B-protein
/HLA	B-protein
class	I-protein
I	I-protein
-restricted	O
response	O
.	O

No	O
peptide-specific	B-cell_line
T-cell	I-cell_line
line	I-cell_line
or	O
clone	O
could	O
be	O
generated	O
from	O
both	O
donors	O
and	O
patients	O
.	O

These	O
findings	O
are	O
discussed	O
in	O
relation	O
to	O
possible	O
therapeutic	O
approaches	O
to	O
the	O
immunotherapy	O
of	O
APL	O
.	O

The	O
proximal	O
regulatory	O
element	O
of	O
the	O
interferon-gamma	B-DNA
promoter	I-DNA
mediates	O
selective	O
expression	O
in	O
T	B-cell_type
cells	I-cell_type
.	O

Interferon-gamma	B-protein
(	O
IFN-gamma	B-protein
)	O
is	O
produced	O
by	O
natural	B-cell_type
killer	I-cell_type
cells	I-cell_type
and	O
certain	O
subsets	O
of	O
T	B-cell_type
cells	I-cell_type
,	O
but	O
the	O
basis	O
for	O
its	O
selective	O
expression	O
is	O
unknown	O
.	O

Within	O
the	O
region	O
between	O
-108	O
and	O
-40	O
base	O
pairs	O
of	O
the	O
IFN-gamma	B-protein
promoter	O
are	O
two	O
conserved	O
and	O
essential	O
regulatory	B-DNA
elements	I-DNA
,	O
which	O
confer	O
activation-specific	O
expression	O
in	O
T	B-cell_type
cells	I-cell_type
.	O

This	O
report	O
describes	O
studies	O
indicating	O
that	O
the	O
most	O
proximal	O
of	O
these	O
two	O
regulatory	B-DNA
elements	I-DNA
is	O
an	O
important	O
determinant	O
of	O
its	O
restricted	O
expression	O
.	O

The	O
proximal	O
element	O
is	O
a	O
composite	O
site	O
that	O
binds	O
members	O
of	O
the	O
CREB/ATF	B-protein
,	O
AP-1	B-protein
,	O
and	O
octamer	B-protein
families	I-protein
of	O
transcription	B-protein
factors	I-protein
.	O

Jun	B-protein
is	O
essential	O
for	O
activation-induced	O
transcription	O
and	O
binds	O
preferably	O
as	O
a	O
heterodimer	O
with	O
ATF-2	B-protein
.	O

In	O
contrast	O
,	O
CREB	B-protein
appears	O
to	O
dampen	O
transcription	O
from	O
this	O
element	O
.	O

The	O
CpG	O
dinucleotide	O
in	O
this	O
element	B-DNA
is	O
selectively	O
methylated	O
in	O
Th2	B-cell_type
T	I-cell_type
cells	I-cell_type
and	O
other	O
cells	O
that	O
do	O
not	O
express	O
IFN-gamma	B-protein
,	O
and	O
methylation	O
markedly	O
reduces	O
transcription	B-protein
factor	I-protein
binding	O
.	O

As	O
a	O
target	O
for	O
DNA	O
methylation	O
and	O
for	O
binding	O
of	O
transcription	B-protein
factors	I-protein
that	O
mediate	O
or	O
impede	O
transcription	O
,	O
this	O
element	O
appears	O
to	O
play	O
a	O
central	O
role	O
in	O
controlling	O
IFN-gamma	B-protein
expression	O
.	O

CD40	B-protein
,	O
but	O
not	O
lipopolysaccharide	O
and	O
anti-IgM	B-protein
stimulation	O
of	O
primary	B-cell_type
B	I-cell_type
lymphocytes	I-cell_type
,	O
leads	O
to	O
a	O
persistent	O
nuclear	O
accumulation	O
of	O
RelB	B-protein
.	O

In	O
this	O
study	O
we	O
analyzed	O
the	O
effect	O
of	O
CD40	B-protein
stimulation	O
on	O
the	O
activity	O
and	O
nuclear	O
appearance	O
of	O
Rel/nuclear	B-protein
factor	I-protein
kappaB	I-protein
(	I-protein
NF-kappaB	I-protein
)	I-protein
factors	I-protein
in	O
primary	B-cell_type
murine	I-cell_type
B	I-cell_type
lymphocytes	I-cell_type
.	O

We	O
show	O
that	O
triggering	O
of	O
CD40	B-protein
signaling	O
pathway	O
(	O
s	O
)	O
by	O
CD40	B-protein
ligands	I-protein
expressed	O
on	O
L	B-cell_type
cells	I-cell_type
led	O
to	O
strong	O
activation	O
of	O
an	O
NF-kappaB-controlled	B-DNA
beta-globin	I-DNA
reporter	I-DNA
gene	I-DNA
in	O
primary	B-cell_type
B	I-cell_type
lymphocytes	I-cell_type
from	O
transgenic	O
mice	O
.	O

Analyses	O
of	O
nuclear	O
translocation	O
of	O
individual	O
members	O
of	O
Rel	B-protein
proteins	I-protein
after	O
CD40	B-protein
induction	O
of	O
primary	B-cell_type
B	I-cell_type
cells	I-cell_type
showed	O
a	O
strong	O
and	O
long-lasting	O
accumulation	O
of	O
RelB	B-protein
and	O
,	O
less	O
pronounced	O
,	O
of	O
c-Rel	B-protein
.	O

LPS	O
stimulation	O
did	O
not	O
give	O
rise	O
to	O
a	O
persistent	O
nuclear	O
accumulation	O
of	O
RelB	B-protein
and	O
c-Rel	B-protein
,	O
whereas	O
nuclear	O
c-Rel	B-protein
,	O
but	O
not	O
RelB	B-protein
,	O
accumulated	O
after	O
B	O
cell	O
receptor	O
stimulation	O
.	O

CD40	B-protein
induced	O
not	O
only	O
nuclear	O
translocation	O
but	O
also	O
de	O
novo	O
synthesis	O
of	O
RelB	B-RNA
RNA	I-RNA
and	O
protein	O
.	O

S107	B-cell_line
plasmacytoma	I-cell_line
cells	I-cell_line
,	O
which	O
express	O
CD40	B-protein
but	O
are	O
defective	O
for	O
the	O
nuclear	O
appearance	O
of	O
p50/p65-NF-kappaB	B-protein
,	O
do	O
not	O
express	O
RelB	B-protein
after	O
CD40	B-protein
stimulation	O
.	O

In	O
S107	B-cell_line
cells	I-cell_line
stably	O
transfected	O
with	O
relB	B-DNA
genes	I-DNA
,	O
stimulation	O
of	O
nuclear	O
RelB	B-protein
translocation	O
by	O
CD40	B-protein
was	O
observed	O
.	O

These	O
results	O
indicate	O
that	O
stimulation	O
of	O
CD40	B-protein
signaling	O
pathways	O
exerts	O
a	O
long-lasting	O
stimulatory	O
effect	O
on	O
both	O
the	O
transcription	O
and	O
nuclear	O
translocation	O
of	O
RelB	B-protein
.	O

Since	O
LPS	O
and	O
anti-IgM	B-protein
were	O
unable	O
to	O
activate	O
RelB	B-protein
,	O
CD40	B-protein
appears	O
to	O
trigger	O
a	O
special	O
program	O
of	O
gene	O
expression	O
involved	O
in	O
the	O
proliferation	O
and/or	O
differentiation	O
of	O
B	B-cell_type
lymphocytes	I-cell_type
.	O

Identification	O
and	O
characterization	O
of	O
a	O
leukocyte-specific	O
component	O
of	O
the	O
nuclear	O
body	O
.	O

The	O
nuclear	O
body	O
(	O
NB	O
)	O
is	O
a	O
cellular	O
organelle	O
that	O
is	O
involved	O
in	O
the	O
pathogenesis	O
of	O
acute	O
promyelocytic	O
leukemia	O
and	O
viral	O
infection	O
.	O

The	O
NB	O
is	O
also	O
a	O
target	O
of	O
antibodies	B-protein
in	O
the	O
serum	O
of	O
patients	O
with	O
the	O
autoimmune	O
disease	O
primary	O
biliary	O
cirrhosis	O
.	O

In	O
this	O
study	O
,	O
serum	O
from	O
a	O
patient	O
with	O
primary	O
biliary	O
cirrhosis	O
was	O
used	O
to	O
identify	O
a	O
cDNA	O
encoding	O
a	O
novel	O
component	O
of	O
the	O
NB	O
,	O
a	O
140-kDa	B-protein
protein	I-protein
designated	O
Sp140	B-protein
.	O

The	O
predicted	O
amino	O
acid	O
sequence	O
of	O
the	O
amino-terminal	B-protein
portion	I-protein
of	O
Sp140	B-protein
was	O
similar	O
to	O
Sp100	B-protein
,	O
a	O
previously	O
identified	O
NB	B-protein
protein	I-protein
.	O

The	O
carboxyl	B-protein
portion	I-protein
of	O
Sp140	B-protein
contained	O
a	O
zinc-finger	B-protein
domain	I-protein
and	O
a	O
bromodomain	B-protein
,	O
motifs	O
that	O
are	O
present	O
in	O
proteins	O
regulating	O
gene	O
transcription	O
.	O

High	O
levels	O
of	O
Sp140	B-RNA
mRNA	I-RNA
were	O
detected	O
in	O
human	O
spleen	O
and	O
peripheral	B-cell_type
blood	I-cell_type
leukocytes	I-cell_type
,	O
but	O
not	O
other	O
human	O
tissues	O
.	O

The	O
level	O
of	O
SP140	B-RNA
mRNA	I-RNA
in	O
myeloid	B-cell_line
precursor	I-cell_line
cell	I-cell_line
lines	I-cell_line
HL60	B-cell_line
and	O
NB4	B-cell_line
markedly	O
increased	O
in	O
response	O
to	O
chemically	O
induced	O
cellular	O
differentiation	O
.	O

Immunohistochemical	O
techniques	O
were	O
used	O
to	O
demonstrate	O
that	O
SP140	B-protein
localized	O
to	O
the	O
NB	O
in	O
differentiated	O
HL60	B-cell_line
and	O
NB4	B-cell_line
cells	I-cell_line
.	O

The	O
location	O
of	O
Sp140	B-protein
in	O
the	O
NB	O
,	O
and	O
expression	O
of	O
this	O
gene	O
in	O
cells	O
involved	O
in	O
host	O
defense	O
,	O
suggest	O
that	O
Sp140	B-protein
may	O
be	O
involved	O
in	O
the	O
pathogenesis	O
of	O
acute	O
promyelocytic	O
leukemia	O
and	O
viral	O
infection	O
.	O

Regulation	O
of	O
cytokine	B-protein
and	O
cytokine	B-protein
receptor	I-protein
expression	O
by	O
glucocorticoids	O
.	O

Glucocorticoids	O
(	O
GCS	O
)	O
profoundly	O
inhibit	O
several	O
aspects	O
of	O
T	O
cell	O
immunity	O
largely	O
through	O
inhibition	O
of	O
cytokine	B-protein
expression	O
at	O
the	O
transcriptional	O
and	O
posttranscriptional	O
levels	O
.	O

GCS	O
were	O
also	O
reported	O
to	O
act	O
indirectly	O
by	O
inducing	O
transforming	O
growth	B-protein
factor-beta	I-protein
expression	O
,	O
which	O
in	O
turn	O
blocks	O
T	O
cell	O
immunity	O
.	O

In	O
exerting	O
their	O
antiproliferative	O
effects	O
,	O
GCS	O
diffuse	O
into	O
target	B-cell_type
cells	I-cell_type
where	O
they	O
bind	O
their	O
cytoplasmic	B-protein
receptor	I-protein
,	O
which	O
in	O
turn	O
translocates	O
to	O
the	O
nucleus	O
where	O
it	O
inhibits	O
transcription	O
of	O
cytokine	B-DNA
genes	I-DNA
through	O
direct	O
binding	O
to	O
the	O
glucocorticoid	B-DNA
response	I-DNA
elements	I-DNA
(	O
GRE	B-DNA
)	O
,	O
which	O
are	O
located	O
in	O
the	O
promoter	O
region	O
of	O
cytokine	B-DNA
genes	I-DNA
or	O
,	O
alternatively	O
,	O
through	O
antagonism	O
of	O
the	O
action	O
of	O
transcription	B-protein
factors	I-protein
required	O
for	O
optimal	O
transcriptional	O
activation	O
.	O

In	O
contrast	O
to	O
their	O
inhibitory	O
effects	O
on	O
cytokine	B-protein
expression	O
,	O
GCS	O
up-regulate	O
cytokine	B-protein
receptor	I-protein
expression	O
that	O
correlates	O
with	O
enhanced	O
cytokine	B-protein
effects	O
on	O
target	B-cell_type
cells	I-cell_type
.	O

In	O
this	O
review	O
,	O
we	O
summarize	O
the	O
current	O
state	O
of	O
knowledge	O
of	O
the	O
mechanism	O
of	O
action	O
of	O
GCS	O
,	O
including	O
the	O
phenomenon	O
of	O
steroid-induced	O
rebound	O
,	O
which	O
ensues	O
upon	O
GCS	O
withdrawal	O
.	O

Isolation	O
and	O
characterization	O
of	O
murine	B-DNA
fra-1	I-DNA
:	O
induction	O
mediated	O
by	O
CD40	B-protein
and	O
surface	B-protein
Ig	I-protein
is	O
protein	B-protein
kinase	I-protein
C	I-protein
dependent	O
.	O

The	O
murine	B-DNA
fra-1	I-DNA
gene	I-DNA
,	O
encoding	O
Fos-related	B-protein
Ag	I-protein
1	I-protein
,	O
was	O
isolated	O
from	O
a	O
splenic	B-DNA
cDNA	I-DNA
library	I-DNA
and	O
sequenced	O
.	O

Murine	B-DNA
fra-1	I-DNA
was	O
highly	O
homologous	O
to	O
rat	B-DNA
and	I-DNA
human	I-DNA
fra-1	I-DNA
.	O

Oligonucleotide	O
primers	O
based	O
on	O
the	O
murine	B-DNA
sequence	I-DNA
were	O
used	O
to	O
construct	O
a	O
quantitative	O
reverse	O
transcription-PCR	O
assay	O
for	O
gene	O
expression	O
.	O

B	B-cell_type
lymphocyte	I-cell_type
stimulation	O
via	O
both	O
CD40	B-protein
and	O
surface	B-protein
Ig	I-protein
(	I-protein
sIg	I-protein
)	I-protein
receptors	I-protein
substantially	O
induced	O
fra-1	B-DNA
expression	O
,	O
and	O
for	O
both	O
receptors	O
,	O
induction	O
was	O
protein	B-protein
kinase	I-protein
C	I-protein
(	O
PKC	B-protein
)	O
dependent	O
.	O

This	O
contrasts	O
with	O
induction	O
of	O
c-fos	B-DNA
by	O
both	O
CD40	B-protein
and	O
sIg	B-protein
,	O
which	O
is	O
PKC	B-protein
independent	O
and	O
indicates	O
that	O
CD40	B-protein
is	O
capable	O
of	O
signaling	O
through	O
PKC	B-protein
or	O
a	O
closely	O
related	O
kinase	B-protein
.	O

Induction	O
of	O
fra-1	B-DNA
following	O
engagement	O
of	O
CD40	B-protein
did	O
not	O
require	O
protein	O
synthesis	O
,	O
suggesting	O
that	O
the	O
PKC	B-protein
-dependent	O
linkage	O
between	O
CD40	B-protein
and	O
fra-1	B-DNA
is	O
direct	O
.	O

CD40	B-protein
-mediated	O
fra-1	B-DNA
induction	O
did	O
require	O
tyrosine	B-protein
kinase	I-protein
activity	O
.	O

These	O
results	O
demonstrate	O
that	O
CD40	B-protein
,	O
like	O
sIg	B-protein
,	O
may	O
employ	O
PKC	B-protein
in	O
producing	O
select	O
outcomes	O
,	O
that	O
individual	O
B	B-protein
cell	I-protein
receptors	I-protein
may	O
signal	O
downstream	O
events	O
via	O
both	O
PKC-dependent	O
and	O
PKC-independent	O
pathways	O
,	O
and	O
that	O
multiple	O
signal	O
transduction	O
pathways	O
may	O
be	O
used	O
to	O
activate	O
the	O
expression	O
of	O
closely	O
related	O
genes	B-DNA
.	O

Pentoxifylline	O
for	O
the	O
treatment	O
of	O
infection	O
with	O
human	O
immunodeficiency	O
virus	O
.	O

Cytokine	O
dysregulation	O
in	O
human	O
immunodeficiency	O
virus	O
type	O
1	O
(	O
HIV-1	O
)	O
infection	O
has	O
been	O
documented	O
in	O
numerous	O
studies	O
and	O
has	O
been	O
cited	O
as	O
an	O
important	O
component	O
in	O
the	O
pathogenesis	O
of	O
this	O
retroviral	O
infection	O
.	O

Pharmacological	O
modification	O
of	O
cytokine	B-protein
dysregulation	O
,	O
therefore	O
,	O
has	O
been	O
suggested	O
as	O
a	O
therapeutic	O
modality	O
for	O
HIV-1	O
infection	O
.	O

Dr.	O
Dezube	O
of	O
Beth	O
Israel	O
Hospital	O
(	O
Boston	O
)	O
concisely	O
reviews	O
the	O
state	O
of	O
our	O
knowledge	O
regarding	O
the	O
effects	O
of	O
pentoxifylline	O
on	O
expression	O
of	O
tumor	B-protein
necrosis	I-protein
factor-alpha	I-protein
,	O
a	O
cytokine	B-protein
known	O
to	O
influence	O
HIV-1	O
replication	O
and	O
to	O
play	O
a	O
possible	O
role	O
in	O
the	O
clinical	O
manifestations	O
of	O
advanced	O
infection	O
with	O
this	O
virus	O
.	O

Pentoxifylline	O
,	O
a	O
trisubstituted	O
xanthine	O
derivative	O
,	O
has	O
been	O
used	O
to	O
decrease	O
blood	O
viscosity	O
and	O
is	O
reasonably	O
well	O
tolerated	O
by	O
most	O
recipients	O
of	O
the	O
drug	O
.	O

Results	O
of	O
preliminary	O
studies	O
,	O
many	O
of	O
which	O
were	O
conducted	O
by	O
Dr.	O
Dezube	O
,	O
suggest	O
that	O
use	O
of	O
this	O
agent	O
in	O
combination	O
with	O
antiretroviral	O
compounds	O
may	O
prove	O
useful	O
in	O
the	O
treatment	O
of	O
patients	O
with	O
HIV-1	O
infection	O
.	O

Activation	O
of	O
the	O
granulocyte-macrophage	B-DNA
colony-stimulating	I-DNA
factor	I-DNA
promoter	I-DNA
in	O
T	B-cell_type
cells	I-cell_type
requires	O
cooperative	O
binding	O
of	O
Elf-1	B-protein
and	O
AP-1	B-protein
transcription	B-protein
factors	I-protein
.	O

The	O
granulocyte-macrophage	B-DNA
colony-stimulating	I-DNA
factor	I-DNA
(	I-DNA
GM-CSF	I-DNA
)	I-DNA
gene	I-DNA
has	O
been	O
studied	O
extensively	O
as	O
a	O
model	O
system	O
of	O
transcriptional	O
induction	O
during	O
T-lymphocyte	O
activation	O
.	O

The	O
GM-CSF	B-DNA
gene	I-DNA
is	O
not	O
expressed	O
in	O
resting	B-cell_type
peripheral	I-cell_type
blood	I-cell_type
T	I-cell_type
cells	I-cell_type
but	O
is	O
rapidly	O
induced	O
at	O
the	O
transcriptional	O
level	O
following	O
activation	O
through	O
the	O
cell	B-protein
surface	I-protein
T-cell	I-protein
receptor	I-protein
.	O

A	O
highly	O
conserved	O
19-bp	O
element	O
located	O
immediately	O
5	O
'	O
of	O
the	O
human	B-DNA
GM-CSF	I-DNA
TATA	I-DNA
box	I-DNA
(	O
bp	B-DNA
-34	I-DNA
to	I-DNA
-52	I-DNA
)	O
,	O
herein	O
called	O
purine	B-DNA
box	I-DNA
1	I-DNA
(	O
PB1	B-DNA
)	O
,	O
has	O
been	O
shown	O
to	O
bind	O
a	O
T-cell	B-protein
nuclear	I-protein
protein	I-protein
complex	I-protein
and	O
to	O
be	O
required	O
for	O
transcriptional	O
induction	O
of	O
the	O
GM-CSF	B-DNA
gene	I-DNA
following	O
T-cell	O
activation	O
.	O

The	O
PB1	B-DNA
sequence	O
motif	O
is	O
highly	O
conserved	O
in	O
both	O
human	B-DNA
and	I-DNA
murine	I-DNA
GM-CSF	I-DNA
genes	I-DNA
.	O

In	O
this	O
report	O
,	O
we	O
demonstrate	O
that	O
the	O
PB1	B-DNA
element	I-DNA
alone	O
confers	O
inducibility	O
on	O
a	O
heterologous	O
promoter	O
following	O
transfection	O
into	O
human	B-cell_line
Jurkat	I-cell_line
T	I-cell_line
cells	I-cell_line
.	O

In	O
addition	O
,	O
we	O
identify	O
a	O
major	O
PB1	B-protein
nuclear	I-protein
protein-binding	I-protein
complex	I-protein
that	O
is	O
not	O
present	O
in	O
resting	B-cell_type
peripheral	I-cell_type
blood	I-cell_type
T	I-cell_type
cells	I-cell_type
but	O
is	O
rapidly	O
induced	O
following	O
T-cell	O
activation	O
.	O

Sequence	O
analysis	O
revealed	O
that	O
PB1	B-DNA
is	O
composed	O
of	O
adjacent	B-DNA
binding	I-DNA
sites	I-DNA
for	O
Ets	B-protein
and	O
AP-1	B-protein
transcription	B-protein
factors	I-protein
.	O

In	O
vitro	O
mutagenesis	O
experiments	O
demonstrated	O
that	O
both	O
the	O
Ets	B-DNA
and	I-DNA
AP-1	I-DNA
sites	I-DNA
are	O
required	O
for	O
binding	O
of	O
the	O
inducible	O
PB1	B-protein
nuclear	I-protein
protein	I-protein
complex	I-protein
and	O
for	O
the	O
transcriptional	O
activity	O
of	O
this	O
element	O
and	O
the	O
GM-CSF	B-DNA
promoter	I-DNA
in	O
activated	B-cell_type
T	I-cell_type
cells	I-cell_type
.	O

(	O
ABSTRACT	O
TRUNCATED	O
AT	O
250	O
WORDS	O
)	O

Steroid-resistant	O
asthma	O
.	O

Cellular	O
mechanisms	O
contributing	O
to	O
inadequate	O
response	O
to	O
glucocorticoid	O
therapy	O
.	O

The	O
current	O
study	O
examined	O
whether	O
alterations	O
in	O
glucocorticoid	B-protein
receptor	I-protein
(	O
GR	B-protein
)	O
binding	O
contribute	O
to	O
poor	O
response	O
to	O
glucocorticoid	O
therapy	O
in	O
asthma	O
.	O

29	O
asthma	O
patients	O
with	O
forced	O
expiratory	O
volume	O
in	O
1	O
s	O
(	O
FEV1	O
)	O
<	O
70	O
%	O
predicted	O
were	O
studied	O
.	O

Patients	O
were	O
classified	O
as	O
steroid	O
sensitive	O
(	O
SS	O
)	O
if	O
their	O
morning	O
FEV1	O
increased	O
>	O
30	O
%	O
after	O
a	O
1-wk	O
course	O
of	O
oral	O
prednisone	O
20	O
mg	O
twice	O
daily	O
and	O
steroid	O
resistant	O
(	O
SR	O
)	O
if	O
they	O
failed	O
to	O
increase	O
>	O
15	O
%	O
.	O

PBMC	O
obtained	O
from	O
these	O
two	O
groups	O
,	O
17	O
SR	O
and	O
12	O
SS	O
,	O
as	O
well	O
as	O
12	O
normal	O
controls	O
were	O
analyzed.	O
SR	O
patients	O
had	O
two	O
distinguishable	O
GR	B-protein
binding	O
abnormalities	O
:	O
15	O
of	O
the	O
17	O
SR	O
patients	O
demonstrated	O
a	O
significantly	O
reduced	O
GR	B-protein
binding	O
affinity	O
,	O
as	O
compared	O
with	O
SS	O
patients	O
(	O
P	O
=	O
0.0001	O
)	O
and	O
normal	O
controls	O
(	O
P	O
=	O
0.0001	O
)	O
.	O

This	O
defect	O
was	O
localized	O
to	O
T	B-cell_type
cells	I-cell_type
and	O
reverted	O
to	O
normal	O
after	O
48	O
h	O
in	O
culture	O
media	O
.	O

However	O
,	O
incubation	O
with	O
a	O
combination	O
of	O
IL-2	B-protein
and	O
IL-4	B-protein
sustained	O
this	O
abnormality	O
.	O

The	O
other	O
two	O
SR	O
patients	O
had	O
an	O
abnormally	O
low	O
GR	B-protein
number	O
with	O
normal	O
binding	O
affinity	O
that	O
was	O
not	O
limited	O
to	O
T	B-cell_type
cells	I-cell_type
.	O

Furthermore	O
,	O
GR	B-protein
number	O
failed	O
to	O
normalize	O
after	O
incubation	O
in	O
media	O
alone	O
or	O
IL-2	B-protein
and	O
IL-4	B-protein
.	O

Therefore	O
,	O
SR	O
asthma	O
may	O
be	O
due	O
to	O
more	O
than	O
one	O
abnormality	O
,	O
the	O
majority	O
related	O
to	O
a	O
reversible	O
cytokine	B-protein
-induced	O
reduction	O
in	O
GR	B-protein
binding	O
affinity	O
and	O
the	O
second	O
related	O
to	O
an	O
irreversible	O
reduction	O
in	O
GR	B-protein
number	O
.	O

These	O
findings	O
may	O
have	O
important	O
implications	O
for	O
the	O
design	O
of	O
alternative	O
treatment	O
approaches	O
for	O
recalcitrant	O
asthma	O
.	O

Prevalence	O
of	O
aneuploidy	O
,	O
overexpressed	O
ER	B-protein
,	O
and	O
overexpressed	O
EGFR	B-protein
in	O
random	O
breast	O
aspirates	O
of	O
women	O
at	O
high	O
and	O
low	O
risk	O
for	O
breast	O
cancer	O
.	O

Breast	O
tissue	O
biomarkers	O
which	O
accurately	O
predict	O
breast	O
cancer	O
development	O
within	O
a	O
10	O
year	O
period	O
in	O
high	O
risk	O
women	O
are	O
needed	O
but	O
currently	O
not	O
available	O
.	O

We	O
initiated	O
this	O
study	O
to	O
determine	O
1	O
)	O
the	O
prevalence	O
of	O
one	O
or	O
more	O
breast	O
tissue	O
abnormalities	O
in	O
a	O
group	O
of	O
women	O
at	O
high	O
risk	O
for	O
breast	O
cancer	O
,	O
and	O
2	O
)	O
if	O
the	O
prevalence	O
of	O
biomarker	O
abnormalities	O
is	O
greater	O
in	O
high	O
risk	O
than	O
in	O
low	O
risk	O
women	O
.	O

Eligible	O
high	O
risk	O
women	O
were	O
those	O
with	O
a	O
first	O
degree	O
relative	O
with	O
breast	O
cancer	O
,	O
prior	O
breast	O
cancer	O
,	O
or	O
precancerous	O
mastopathy	O
.	O

Low	O
risk	O
women	O
were	O
those	O
without	O
these	O
or	O
other	O
major	O
identifiable	O
risk	O
factors	O
.	O

Ductal	B-cell_type
cells	I-cell_type
were	O
obtained	O
via	O
random	O
fine	O
needle	O
aspirations	O
and	O
cytologically	O
classified	O
.	O

Biomarkers	O
included	O
DNA	O
ploidy	O
,	O
estrogen	B-protein
receptor	I-protein
(	O
ER	B-protein
)	O
,	O
and	O
epidermal	B-protein
growth	I-protein
factor	I-protein
receptor	I-protein
(	O
EGFR	B-protein
)	O
.	O

The	O
prevalence	O
of	O
DNA	O
aneuploidy	O
was	O
30	O
%	O
,	O
overexpression	O
of	O
ER	B-protein
10	O
%	O
,	O
and	O
overexpression	O
of	O
EGFR	B-protein
35	O
%	O
,	O
in	O
the	O
206	O
high	O
risk	O
women	O
whose	O
median	O
10	O
year	O
Gail	O
risk	O
(	O
projected	O
probability	O
)	O
of	O
developing	O
breast	O
cancer	O
was	O
4.5	O
%	O
.	O

The	O
prevalence	O
of	O
aneuploidy	O
and	O
overexpressed	O
EGFR	B-protein
was	O
significantly	O
higher	O
in	O
the	O
high	O
risk	O
women	O
than	O
in	O
the	O
25	O
low	O
risk	O
controls	O
(	O
p	O
<	O
0.002	O
)	O
,	O
whose	O
median	O
10	O
year	O
Gail	O
risk	O
was	O
0.7	O
%	O
.	O

The	O
difference	O
in	O
the	O
prevalence	O
of	O
ER	B-protein
overexpression	O
between	O
high	O
and	O
low	O
risk	O
groups	O
was	O
not	O
statistically	O
significant	O
(	O
p	O
=	O
0.095	O
)	O
.	O

This	O
may	O
be	O
due	O
to	O
the	O
low	O
prevalence	O
of	O
overexpressed	O
ER	B-protein
and	O
the	O
small	O
number	O
of	O
controls	O
.	O

A	O
significant	O
difference	O
was	O
noted	O
in	O
the	O
prevalence	O
of	O
one	O
or	O
more	O
abnormal	O
biomarkers	O
between	O
the	O
high	O
risk	O
and	O
low	O
risk	O
women	O
(	O
p	O
<	O
0.001	O
)	O
.	O

A	O
large	O
prospective	O
trial	O
is	O
needed	O
to	O
determine	O
if	O
one	O
or	O
more	O
of	O
these	O
biomarkers	O
,	O
is	O
predictive	O
of	O
breast	O
cancer	O
development	O
.	O

Inhibition	O
of	O
nuclear	B-RNA
factor	I-RNA
kappa	I-RNA
B	I-RNA
subunit	I-RNA
p65	I-RNA
mRNA	I-RNA
accumulation	O
in	O
lipopolysaccharide-stimulated	B-cell_line
human	I-cell_line
monocytic	I-cell_line
cells	I-cell_line
treated	O
with	O
sodium	O
salicylate	O
.	O

Lipopolysaccharide	O
is	O
one	O
of	O
the	O
most	O
potent	O
trigger	O
substances	O
for	O
monocytes	O
and	O
macrophages	O
causing	O
secretion	O
of	O
inflammatory	B-protein
mediators	I-protein
such	O
as	O
tumor	B-protein
necrosis	I-protein
factor	I-protein
and	O
interleukin-1	B-protein
.	O

The	O
nature	O
of	O
the	O
nuclear	O
factors	O
involved	O
in	O
regulation	O
of	O
these	O
cytokine	B-DNA
genes	I-DNA
is	O
still	O
unknown	O
.	O

Nuclear	B-protein
factor	I-protein
kappa	I-protein
B	I-protein
(	I-protein
NF-kappa	I-protein
B	I-protein
;	I-protein
heterodimer	I-protein
of	I-protein
p50	I-protein
and	I-protein
p65	I-protein
)	I-protein
proteins	I-protein
have	O
been	O
suggested	O
to	O
play	O
an	O
important	O
role	O
in	O
gene	O
transcription	O
of	O
inflammatory	B-protein
mediators	I-protein
when	O
monocytes	B-cell_type
are	O
stimulated	O
with	O
lipopolysaccharide	O
.	O

Nonsteroidal	O
anti-inflammatory	O
drugs	O
such	O
as	O
salicylates	O
have	O
been	O
used	O
to	O
treat	O
symptoms	O
of	O
inflammation	O
,	O
and	O
a	O
new	O
mechanism	O
of	O
drug	O
action	O
was	O
suggested	O
recently	O
.	O

Salicylates	O
have	O
been	O
shown	O
to	O
inhibit	O
lipopolysaccharide-induced	O
gene	O
transcription	O
via	O
inhibition	O
of	O
NF-kappa	B-protein
B	I-protein
activation	O
by	O
preventing	O
the	O
degradation	O
of	O
NF-kappa	B-protein
B	I-protein
inhibitor	I-protein
``	O
I	B-protein
kappa	I-protein
B	I-protein
``	O
,	O
blocking	O
the	O
translocation	O
of	O
NF-kappa	B-protein
B	I-protein
into	O
the	O
nuclear	O
compartment	O
.	O

However	O
,	O
the	O
nature	O
of	O
the	O
subunit	O
involved	O
in	O
this	O
mechanism	O
has	O
not	O
been	O
defined	O
.	O

To	O
examine	O
the	O
mechanisms	O
by	O
which	O
salicylates	O
affect	O
cytokine	B-protein
gene	O
transcription	O
,	O
the	O
amount	O
of	O
active	O
and	O
inactive	O
NF-kappa	B-protein
B	I-protein
and	O
NF-kappa	B-RNA
B	I-RNA
mRNA	I-RNA
,	O
in	O
Porphyromonas	O
gingivalis	O
lipopolysaccharide-stimulated	B-cell_line
human	I-cell_line
monocytic	I-cell_line
cells	I-cell_line
was	O
assessed	O
.	O

High	O
doses	O
of	O
sodium	O
salicylate	O
suppressed	O
NF-kappa	B-protein
B	I-protein
p65	B-RNA
mRNA	I-RNA
accumulation	O
,	O
resulting	O
in	O
suppression	O
of	O
total	O
NF-kappa	B-protein
B	I-protein
,	O
p50	B-protein
on	O
tissue	O
oligonucleotide	O
had	O
no	O
effects	O
on	O
lipopolysaccharide-induced	O
NF-kappa	B-protein
B	I-protein
activation	O
.	O

The	O
data	O
demonstrate	O
that	O
the	O
p65	B-protein
subunit	O
of	O
NF-kappa	B-protein
B	I-protein
is	O
inhibited	O
by	O
salicylate	O
treatment	O
and	O
highlight	O
the	O
role	O
of	O
salicylate	O
in	O
the	O
control	O
of	O
gene	O
expression	O
of	O
inflammatory	B-protein
mediators	I-protein
.	O

Glucocorticoid-mediated	O
inhibition	O
of	O
RANTES	B-protein
expression	O
in	O
human	B-cell_type
T	I-cell_type
lymphocytes	I-cell_type
.	O

The	O
chemokine	B-protein
RANTES	B-protein
has	O
been	O
implicated	O
in	O
the	O
pathogenesis	O
of	O
allergic	O
inflammatory	O
diseases	O
including	O
asthma	O
and	O
rhinitis	O
which	O
are	O
frequently	O
treated	O
with	O
glucocorticoids	O
.	O

We	O
observed	O
that	O
dexamethasone	O
dramatically	O
inhibited	O
RANTES	B-RNA
mRNA	I-RNA
expression	O
dose	O
dependently	O
in	O
anti-CD3	B-cell_line
activated	I-cell_line
Hut-78	I-cell_line
T	I-cell_line
cells	I-cell_line
and	O
human	B-cell_type
PBMCs	I-cell_type
.	O

Inhibition	O
of	O
RANTES	B-protein
expression	O
did	O
not	O
appear	O
to	O
be	O
secondary	O
to	O
IL-2	B-protein
inhibition	O
and	O
required	O
binding	O
to	O
the	O
intracellular	O
glucocorticoid	B-protein
receptor	I-protein
.	O

The	O
down-regulation	O
of	O
RANTES	B-protein
expression	O
by	O
glucocorticoids	O
in	O
T	B-cell_type
cells	I-cell_type
may	O
directly	O
contribute	O
to	O
the	O
efficacy	O
of	O
these	O
agents	O
in	O
suppressing	O
cellular	O
infiltration	O
and	O
to	O
their	O
anti-inflammatory	O
properties	O
.	O

Association	O
of	O
TRAF1	B-protein
,	O
TRAF2	B-protein
,	O
and	O
TRAF3	B-protein
with	O
an	O
Epstein-Barr	B-DNA
virus	I-DNA
LMP1	I-DNA
domain	I-DNA
important	O
for	O
B-lymphocyte	B-cell_type
transformation	O
:	O
role	O
in	O
NF-kappaB	B-protein
activation	O
.	O

The	O
Epstein-Barr	B-protein
virus	I-protein
(	I-protein
EBV	I-protein
)	I-protein
transforming	I-protein
protein	I-protein
LMP1	I-protein
appears	O
to	O
be	O
a	O
constitutively	B-protein
activated	I-protein
tumor	I-protein
necrosis	I-protein
factor	I-protein
receptor	I-protein
(	O
TNFR	B-protein
)	O
on	O
the	O
basis	O
of	O
an	O
intrinsic	O
ability	O
to	O
aggregate	O
in	O
the	O
plasma	O
membrane	O
and	O
an	O
association	O
of	O
its	O
cytoplasmic	B-protein
carboxyl	I-protein
terminus	I-protein
(	O
CT	B-protein
)	O
with	O
TNFR-associated	B-protein
factors	I-protein
(	O
TRAFs	B-protein
)	O
.	O

We	O
now	O
show	O
that	O
in	O
EBV-transformed	B-cell_line
B	I-cell_line
lymphocytes	I-cell_line
most	O
of	O
TRAF1	B-protein
or	O
TRAF3	B-protein
and	O
5	O
%	O
of	O
TRAF2	B-protein
are	O
associated	O
with	O
LMP1	B-protein
and	O
that	O
most	O
of	O
LMP1	B-protein
is	O
associated	O
with	O
TRAF1	B-protein
or	O
TRAF3	B-protein
.	O

TRAF1	B-protein
,	O
TRAF2	B-protein
,	O
and	O
TRAF3	B-protein
bind	O
to	O
a	O
single	O
site	O
in	O
the	O
LMP1	B-protein
CT	I-protein
corresponding	O
to	O
amino	O
acids	O
(	O
aa	O
)	O
199	O
to	O
214	O
,	O
within	O
a	O
domain	O
which	O
is	O
important	O
for	O
B-lymphocyte	O
growth	O
transformation	O
(	O
aa	O
187	O
to	O
231	O
)	O
.	O

Further	O
deletional	O
and	O
alanine	O
mutagenesis	O
analyses	O
and	O
comparison	O
with	O
TRAF	B-DNA
binding	I-DNA
sequences	I-DNA
in	O
CD40	O
,	O
in	O
CD30	O
,	O
and	O
in	O
the	O
LMP1	B-protein
of	O
other	O
lymphycryptoviruses	O
provide	O
the	O
first	O
evidence	O
that	O
PXQXT/S	B-DNA
is	O
a	O
core	O
TRAF	B-DNA
binding	I-DNA
motif	I-DNA
.	O

The	O
negative	O
effects	O
of	O
point	O
mutations	O
in	O
the	O
LMP1	B-DNA
(	I-DNA
1-231	I-DNA
)	I-DNA
core	I-DNA
TRAF	I-DNA
binding	I-DNA
motif	I-DNA
on	O
TRAF	O
binding	O
and	O
NF-kappaB	B-protein
activation	O
genetically	O
link	O
the	O
TRAFs	B-protein
to	O
LMP1	B-protein
(	O
1-231	O
)	O
-mediated	O
NF-kappaB	B-protein
activation	O
.	O

NF-kappaB	B-protein
activation	O
by	O
LMP1	B-protein
(	O
1-231	O
)	O
is	O
likely	O
to	O
be	O
mediated	O
by	O
TRAF1	B-protein
/TRAF2	B-protein
heteroaggregates	O
since	O
TRAF1	B-protein
is	O
unique	O
among	O
the	O
TRAFs	B-protein
in	O
coactivating	O
NF-kappaB	B-protein
with	O
LMP1	B-protein
(	O
1-231	O
)	O
,	O
a	O
TRAF2	B-protein
dominant-negative	O
mutant	O
can	O
block	O
LMP1	B-protein
(	O
1-231	O
)	O
-mediated	O
NF-kappaB	B-protein
activation	O
as	O
well	O
as	O
TRAF1	B-protein
coactivation	O
,	O
and	O
30	O
%	O
of	O
TRAF2	B-protein
is	O
associated	O
with	O
TRAF1	B-protein
in	O
EBV-transformed	O
B	O
cells	O
.	O

TRAF3	B-protein
is	O
a	O
negative	O
modulator	O
of	O
LMP1	B-protein
(	O
1-231	O
)	O
-mediated	O
NF-kappaB	B-protein
activation	O
.	O

Surprisingly	O
,	O
TRAF1	B-protein
,	I-protein
-2	I-protein
,	I-protein
or	I-protein
-3	I-protein
does	O
not	O
interact	O
with	O
the	O
terminal	B-protein
LMP1	I-protein
CT	I-protein
aa	O
333	O
to	O
386	O
which	O
can	O
independently	O
mediate	O
NF-kappaB	B-protein
activation	O
.	O

The	O
constitutive	O
association	O
of	O
TRAFs	B-protein
with	O
LMP1	B-protein
through	O
the	O
aa	B-protein
187	I-protein
to	I-protein
231	I-protein
domain	I-protein
which	O
is	O
important	O
in	O
NF-kappaB	B-protein
activation	O
and	O
primary	O
B-lymphocyte	B-cell_type
growth	O
transformation	O
implicates	O
TRAF	B-protein
aggregation	O
in	O
LMP1	B-protein
signaling	O
.	O

Lack	O
of	O
IL-12	B-protein
signaling	O
in	O
human	B-cell_line
allergen-specific	I-cell_line
Th2	I-cell_line
cells	I-cell_line
.	O

IL-12	B-protein
is	O
a	O
powerful	O
skewer	O
of	O
CD4+	B-cell_type
T	I-cell_type
cell	I-cell_type
responses	O
toward	O
the	O
Th1	O
phenotype	O
by	O
inducing	O
IFN-gamma	B-protein
production	O
in	O
naive	B-cell_line
Th	I-cell_line
cells	I-cell_line
.	O

In	O
the	O
present	O
study	O
we	O
addressed	O
the	O
question	O
of	O
whether	O
IL-12	B-protein
can	O
reverse	O
established	O
Th2	O
responses	O
into	O
Th1/Th0	O
responses	O
by	O
inducing	O
IFN-gamma	B-protein
production	O
in	O
memory	B-cell_line
Th2	I-cell_line
cells	I-cell_line
.	O

To	O
this	O
aim	O
,	O
allergen-specific	B-cell_line
CD4+	I-cell_line
T	I-cell_line
cell	I-cell_line
clones	I-cell_line
(	O
TCC	B-cell_line
)	O
were	O
generated	O
from	O
the	O
peripheral	O
blood	O
of	O
three	O
atopic	O
patients	O
,	O
and	O
their	O
cytokine	B-protein
profiles	O
were	O
analyzed	O
.	O

The	O
majority	O
of	O
these	O
TCC	B-cell_line
exhibited	O
a	O
strongly	O
polarized	O
Th2	O
cytokine	B-protein
profile	O
,	O
and	O
the	O
production	O
of	O
IFN-gamma	B-protein
could	O
not	O
be	O
induced	O
by	O
exogenous	O
IL-12	B-protein
.	O

Only	O
those	O
TCC	B-cell_line
with	O
low	O
IFN-gamma	B-protein
levels	O
in	O
the	O
absence	O
of	O
IL-12	B-protein
responded	O
to	O
IL-12	B-protein
by	O
additional	O
enhancement	O
of	O
IFN-gamma	B-protein
production	O
.	O

The	O
IL-12	B-protein
nonresponsiveness	O
of	O
the	O
Th2	B-cell_line
clones	I-cell_line
was	O
further	O
evident	O
by	O
the	O
total	O
lack	O
of	O
IL-12	B-protein
-induced	O
phosphorylation	O
of	O
STAT4	B-protein
(	O
signal	B-protein
transducer	I-protein
and	I-protein
activator	I-protein
of	I-protein
transcription-4	I-protein
)	O
,	O
a	O
transcription	B-protein
factor	I-protein
that	O
is	O
typically	O
involved	O
in	O
IL-12	B-protein
signaling	O
.	O

Consequently	O
,	O
IL-12	B-protein
also	O
failed	O
to	O
induce	O
the	O
DNA-binding	O
activity	O
of	O
STAT4-containing	B-protein
complexes	I-protein
in	O
the	O
nuclei	O
of	O
these	O
Th2	B-cell_line
clones	I-cell_line
.	O

All	O
TCC	B-cell_line
expressed	O
equal	O
levels	O
of	O
the	O
low-affinity	B-protein
IL-12R	I-protein
beta1	I-protein
subunit	I-protein
.	O

Our	O
results	O
indicate	O
that	O
human	O
allergen-specific	O
Th	O
cells	O
with	O
strongly	O
polarized	O
Th2	O
cytokine	B-protein
profiles	O
do	O
not	O
respond	O
to	O
IL-12	B-protein
and	O
,	O
therefore	O
,	O
can	O
not	O
be	O
induced	O
to	O
produce	O
IFN-gamma	B-protein
.	O

The	O
apparent	O
high	O
frequency	O
of	O
IL-12-nonresponsive	B-cell_line
Th	I-cell_line
cells	I-cell_line
within	O
the	O
allergen-specific	O
populations	O
in	O
atopic	O
patients	O
predicts	O
a	O
limited	O
skewing	O
potential	O
of	O
IL-12	B-protein
in	O
the	O
case	O
of	O
established	O
Th2	O
responses	O
,	O
but	O
only	O
affecting	O
newly	O
recruited	O
naive	O
Th	B-cell_line
cells	I-cell_line
.	O

Cloning	O
and	O
expression	O
of	O
the	O
Epstein-Barr	B-protein
virus-encoded	I-protein
dUTPase	I-protein
:	O
patients	O
with	O
acute	O
,	O
reactivated	O
or	O
chronic	O
virus	O
infection	O
develop	O
antibodies	B-protein
against	O
the	O
enzyme	B-protein
.	O

The	O
gene	O
encoding	O
the	O
Epstein-Barr	B-protein
virus	I-protein
(	I-protein
EBV	I-protein
)	I-protein
-specific	I-protein
dUTPase	I-protein
was	O
amplified	O
from	O
virus	B-DNA
DNA	I-DNA
by	O
PCR	O
.	O

The	O
active	O
enzyme	O
was	O
expressed	O
in	O
Escherichia	O
coli	O
and	O
in	O
insect	B-cell_type
cells	I-cell_type
as	O
a	O
non-fusion	B-protein
protein	I-protein
.	O

The	O
protein	O
from	O
E.	O
coli	O
specifically	O
converted	O
dUTP	O
to	O
dUMP	O
and	O
did	O
not	O
react	O
with	O
other	O
dNTPs	O
or	O
NTPs	O
.	O

Preliminary	O
experiments	O
yielded	O
a	O
Km	O
value	O
of	O
about	O
0.8	O
microM	O
for	O
dUTP	O
.	O

MAbs	O
against	O
the	O
dUTPase	B-protein
reacted	O
with	O
a	O
protein	O
of	O
approximately	O
31	O
kDa	O
in	O
12-O-tetradecanoyl-phorbol-13-acetate	B-cell_line
(	I-cell_line
TPA	I-cell_line
)	I-cell_line
-stimulated	I-cell_line
B	I-cell_line
cells	I-cell_line
harbouring	O
either	O
type	O
1	O
or	O
type	O
2	O
EBV	O
.	O

The	O
protein	O
was	O
found	O
in	O
untreated	B-cell_type
cells	I-cell_type
at	O
low	O
levels	O
,	O
whereas	O
induction	O
of	O
the	O
lytic	O
replication	O
cycle	O
by	O
TPA	O
treatment	O
or	O
by	O
providing	O
the	O
immediate	B-protein
early	I-protein
transactivator	I-protein
BZLF1	B-protein
in	O
trans	O
resulted	O
in	O
increased	O
expression	O
.	O

We	O
demonstrated	O
that	O
the	O
virus	B-protein
dUTPase	I-protein
isolated	O
from	O
EBV-infected	B-cell_type
cells	I-cell_type
is	O
a	O
phosphoprotein	B-protein
.	O

The	O
protein	O
expressed	O
in	O
insect	B-cell_type
cells	I-cell_type
was	O
used	O
to	O
test	O
for	O
the	O
presence	O
of	O
specific	B-protein
antibodies	I-protein
in	O
sera	O
from	O
normal	O
,	O
healthy	O
carriers	O
and	O
from	O
patients	O
with	O
various	O
diseases	O
.	O

While	O
the	O
sera	O
of	O
EBV-negative	O
individuals	O
(	O
0/3	O
)	O
or	O
healthy	O
carriers	O
(	O
0/33	O
)	O
did	O
not	O
contain	O
detectable	O
levels	O
of	O
antibodies	O
,	O
patients	O
with	O
mononucleosis	O
(	O
5/18	O
)	O
,	O
chronic	O
EBV	O
infection	O
(	O
2/7	O
)	O
,	O
EBV	O
reactivation	O
(	O
7/20	O
)	O
and	O
human	O
immunodeficiency	O
virus	O
infection	O
(	O
5/24	O
)	O
showed	O
elevated	O
antibody	O
titres	O
against	O
the	O
enzyme	O
.	O

This	O
indicated	O
that	O
the	O
dUTPase	O
is	O
expressed	O
during	O
EBV	O
replication	O
and	O
reactivation	O
.	O

The	O
enzyme	O
might	O
therefore	O
be	O
a	O
potential	O
target	O
for	O
drug	O
therapy	O
under	O
conditions	O
of	O
active	O
DNA	O
replication	O
.	O

The	O
catalytic	B-protein
domain	I-protein
of	O
pp56	B-protein
(	I-protein
lck	I-protein
)	I-protein
,	O
but	O
not	O
its	O
regulatory	B-protein
domain	I-protein
,	O
is	O
sufficient	O
for	O
inducing	O
IL-2	B-protein
production	O
.	O

The	O
lymphoid	B-protein
src	I-protein
kinase	I-protein
pp56	B-protein
(	I-protein
lck	I-protein
)	I-protein
has	O
been	O
shown	O
to	O
be	O
essential	O
for	O
the	O
induction	O
of	O
different	O
T	B-cell_type
lymphocyte	I-cell_type
responses	O
,	O
including	O
CD4	B-protein
-mediated	O
enhancement	O
of	O
Ag-induced	O
T	O
cell	O
activation	O
,	O
early	O
T	O
cell	O
differentiation	O
,	O
induction	O
of	O
IL-2	B-protein
production	O
,	O
and	O
cytotoxicity	O
.	O

It	O
is	O
assumed	O
that	O
pp56	B-protein
(	I-protein
lck	I-protein
)	I-protein
acts	O
on	O
these	O
processes	O
by	O
phosphorylating	O
substrates	O
.	O

However	O
,	O
it	O
has	O
been	O
recently	O
reported	O
that	O
the	O
NH2	B-protein
regulatory	B-protein
domain	I-protein
is	O
sufficient	O
to	O
mediate	O
CD4	B-protein
accessory	O
function	O
.	O

In	O
this	O
report	O
we	O
address	O
the	O
contribution	O
of	O
the	O
regulatory	B-protein
and	I-protein
catalytic	I-protein
domains	I-protein
of	O
pp56	B-protein
(	I-protein
lck	I-protein
)	I-protein
to	O
another	O
function	O
of	O
this	O
enzyme	O
independent	O
of	O
CD4	B-protein
:	O
TCR-induced	O
IL-2	B-protein
production	O
.	O

Two	O
pp56	B-protein
(	I-protein
lck	I-protein
)	I-protein
mutants	I-protein
lacking	O
either	O
the	O
entire	O
catalytic	B-protein
domain	I-protein
or	O
the	O
entire	O
NH2	B-protein
regulatory	B-protein
domain	I-protein
were	O
generated	O
,	O
and	O
their	O
abilities	O
to	O
trigger	O
transactivation	O
of	O
the	O
TCR-regulated	B-DNA
nuclear	I-DNA
factor	I-DNA
of	I-DNA
activated	I-DNA
T	I-DNA
cells	I-DNA
(	I-DNA
NF-AT	I-DNA
)	I-DNA
region	I-DNA
of	O
the	O
IL-2	B-DNA
promoter	I-DNA
were	O
compared	O
.	O

Only	O
the	O
catalytic	O
,	O
but	O
not	O
the	O
NH2	B-protein
regulatory	O
,	O
domain	O
of	O
pp56	B-protein
(	I-protein
lck	I-protein
)	I-protein
was	O
able	O
to	O
induce	O
NF-AT	B-protein
region	O
transactivation	O
on	O
its	O
own	O
and	O
to	O
cooperate	O
with	O
other	O
intracellular	O
signals	O
to	O
trigger	O
this	O
response	O
.	O

Moreover	O
,	O
the	O
catalytic	B-protein
domain	I-protein
of	O
pp56	B-protein
(	I-protein
lck	I-protein
)	I-protein
was	O
able	O
to	O
induce	O
IL-2	B-protein
cytokine	B-protein
production	O
to	O
an	O
extent	O
similar	O
to	O
that	O
of	O
wild-type	O
pp56	B-protein
(	I-protein
lck	I-protein
)	I-protein
.	O

We	O
conclude	O
that	O
different	O
domains	O
of	O
the	O
pp56	B-protein
(	I-protein
lck	I-protein
)	I-protein
molecule	O
contribute	O
to	O
regulate	O
distinct	O
biologic	O
functions	O
.	O

In	O
fact	O
,	O
while	O
the	O
NH2	B-protein
regulatory	B-protein
domain	I-protein
is	O
sufficient	O
to	O
mediate	O
CD4	B-protein
accessory	O
function	O
,	O
we	O
show	O
here	O
that	O
the	O
catalytic	B-protein
domain	I-protein
of	O
pp56	B-protein
(	I-protein
lck	I-protein
)	I-protein
is	O
sufficient	O
for	O
induction	O
of	O
IL-2	B-protein
production	O
,	O
mimicking	O
TCR	B-protein
ligation	O
.	O

[	O
The	O
changes	O
in	O
glucocorticoid	O
receptors	O
in	O
peripheral	B-cell_type
leukocytes	I-cell_type
in	O
asthmatic	O
subjects	O
]	O

The	O
number	O
of	O
glucocorticoid	B-protein
receptors	I-protein
(	O
GCR	B-protein
)	O
in	O
peripheral	B-cell_type
leukocytes	I-cell_type
was	O
determined	O
by	O
radioligand-binding	O
assay	O
in	O
extrinsic	O
and	O
intrinsic	O
asthmatics	O
.	O

Their	O
corresponding	O
plasma	O
cortisol	O
levels	O
were	O
assessed	O
.	O

The	O
results	O
showed	O
that	O
the	O
average	O
number	O
of	O
GCR	B-protein
in	O
asthmatics	O
was	O
significantly	O
lower	O
than	O
that	O
in	O
healthy	O
subjects	O
(	O
P	O
<	O
0.01	O
)	O
,	O
and	O
there	O
was	O
a	O
linear	O
correlation	O
between	O
the	O
number	O
of	O
GCR	B-protein
and	O
the	O
course	O
of	O
asthma	O
.	O

Besides	O
,	O
there	O
was	O
also	O
a	O
linear	O
correlation	O
between	O
the	O
number	O
of	O
GCR	B-protein
and	O
the	O
age	O
of	O
the	O
initial	O
attack	O
of	O
asthma	O
.	O

No	O
difference	O
in	O
plasma	O
cortisol	O
level	O
was	O
found	O
between	O
asthmatics	O
and	O
healthy	O
subjects	O
.	O

These	O
findings	O
suggest	O
that	O
there	O
is	O
no	O
primary	O
and	O
general	O
impairment	O
of	O
glucocorticoid	O
metabolism	O
in	O
the	O
asthmatics	O
,	O
but	O
the	O
number	O
of	O
GCR	B-protein
in	O
the	O
asthmatics	O
is	O
lower	O
than	O
that	O
in	O
healthy	O
controls	O
.	O

The	O
decrease	O
of	O
the	O
number	O
of	O
GCR	B-protein
in	O
asthmatics	O
,	O
we	O
think	O
,	O
is	O
related	O
to	O
heredity	O
and	O
repeated	O
attacks	O
of	O
asthma	O
.	O

Novel	O
aldosterone	B-protein
receptors	I-protein
:	O
specificity-conferring	O
mechanism	O
at	O
the	O
level	O
of	O
the	O
cell	O
membrane	O
.	O

Functional	O
studies	O
in	O
extra-renal	B-cell_type
,	I-cell_type
nonepithelial	I-cell_type
cells	I-cell_type
such	O
as	O
smooth	B-cell_type
muscle	I-cell_type
cells	I-cell_type
and	O
more	O
recently	O
circulating	O
human	B-cell_type
lymphocytes	I-cell_type
have	O
provided	O
increasing	O
evidence	O
that	O
aldosterone	O
produces	O
not	O
only	O
classical	O
genomic	O
effects	O
,	O
but	O
also	O
rapid	O
non-genomic	O
effects	O
on	O
transmembrane	O
electrolyte	O
movements	O
.	O

These	O
involve	O
activation	O
of	O
the	O
sodium/proton-exchanger	B-protein
of	O
the	O
cell	O
membrane	O
at	O
very	O
low	O
,	O
physiological	O
concentrations	O
of	O
aldosterone	O
with	O
an	O
acute	O
onset	O
within	O
1-2	O
minutes	O
.	O

A	O
second	O
messenger	O
cascade	O
involved	O
is	O
the	O
inositol-1	O
,	O
4	O
,	O
5-trisphosphate/calcium	O
pathway	O
which	O
responds	O
over	O
the	O
same	O
rapid	O
time	O
course	O
.	O

Such	O
changes	O
clearly	O
can	O
not	O
be	O
explained	O
by	O
genomic	O
mechanisms	O
,	O
which	O
are	O
responsible	O
for	O
later	O
effects	O
than	O
the	O
membrane-related	O
rapid	O
responses	O
.	O

In	O
addition	O
to	O
its	O
rapid	O
time	O
course	O
the	O
unique	O
characteristics	O
of	O
this	O
new	O
pathway	O
for	O
steroid	O
action	O
include	O
a	O
10000-fold	O
selectivity	O
for	O
aldosterone	O
over	O
cortisol	O
and	O
the	O
ineffectiveness	O
of	O
spironolactones	O
,	O
classical	O
mineralocorticoid	O
antagonists	O
,	O
as	O
antagonists	O
of	O
the	O
response	O
.	O

Subsequently	O
binding	O
sites	O
have	O
been	O
demonstrated	O
in	O
the	O
plasma	O
membrane	O
of	O
human	B-cell_type
lymphocytes	I-cell_type
which	O
show	O
pharmacological	O
(	O
aldosterone	O
specificity	O
)	O
and	O
kinetic	O
(	O
high	O
turnover	O
)	O
properties	O
identical	O
with	O
those	O
of	O
the	O
rapid	O
aldosterone	O
effects	O
in	O
the	O
same	O
cells	O
.	O

SDS-PAGE	O
analysis	O
of	O
the	O
receptor	B-protein
protein	I-protein
has	O
shown	O
a	O
molecular	O
weight	O
of	O
approximately	O
50	O
kD	O
.	O

The	O
present	O
paper	O
reviews	O
the	O
data	O
supporting	O
a	O
new	O
,	O
two-step	O
model	O
for	O
non-genomic	O
and	O
genomic	O
aldosterone	O
effects	O
.	O

It	O
also	O
suggests	O
a	O
novel	O
specificity-conferring	O
mechanism	O
for	O
mineralocorticoid	O
action	O
at	O
the	O
membrane	O
level	O
.	O

The	O
macrophage	B-protein
transcription	I-protein
factor	I-protein
PU.1	B-protein
directs	O
tissue-specific	O
expression	O
of	O
the	O
macrophage	B-protein
colony-stimulating	I-protein
factor	I-protein
receptor	I-protein
.	O

The	O
macrophage	B-protein
colony-stimulating	I-protein
factor	I-protein
(	I-protein
M-CSF	I-protein
)	I-protein
receptor	I-protein
is	O
expressed	O
in	O
a	O
tissue-specific	O
fashion	O
from	O
two	O
distinct	O
promoters	B-DNA
in	O
monocytes/macrophages	B-cell_type
and	O
the	O
placenta	O
.	O

In	O
order	O
to	O
further	O
understand	O
the	O
transcription	O
factors	O
which	O
play	O
a	O
role	O
in	O
the	O
commitment	O
of	O
multipotential	B-cell_type
progenitors	I-cell_type
to	O
the	O
monocyte/macrophage	O
lineage	O
,	O
we	O
have	O
initiated	O
an	O
investigation	O
of	O
the	O
factors	O
which	O
activate	O
the	O
M-CSF	B-protein
receptor	I-protein
very	O
early	O
during	O
the	O
monocyte	O
differentiation	O
process	O
.	O

Here	O
we	O
demonstrate	O
that	O
the	O
human	B-DNA
monocytic	I-DNA
M-CSF	I-DNA
receptor	I-DNA
promoter	I-DNA
directs	O
reporter	O
gene	O
activity	O
in	O
a	O
tissue-specific	O
fashion	O
.	O

Since	O
one	O
of	O
the	O
few	O
transcription	B-protein
factors	I-protein
which	O
have	O
been	O
implicated	O
in	O
the	O
regulation	O
of	O
monocyte	B-DNA
genes	I-DNA
is	O
the	O
macrophage-	B-protein
and	I-protein
B-cell-specific	I-protein
PU.1	I-protein
transcription	B-protein
factor	I-protein
,	O
we	O
investigated	O
whether	O
PU.1	B-protein
binds	O
and	O
activates	O
the	O
M-CSF	B-DNA
receptor	I-DNA
promoter	I-DNA
.	O

Here	O
we	O
demonstrate	O
that	O
both	O
in	O
vitro-translated	B-protein
PU.1	I-protein
and	O
PU.1	B-protein
from	O
nuclear	O
extracts	O
bind	O
to	O
a	O
specific	O
site	O
in	O
the	O
M-CSF	B-DNA
receptor	I-DNA
promoter	I-DNA
just	O
upstream	O
from	O
the	O
major	B-DNA
transcription	I-DNA
initiation	I-DNA
site	I-DNA
.	O

Mutations	O
in	O
this	O
site	O
which	O
eliminate	O
PU.1	B-protein
binding	O
decrease	O
M-CSF	B-protein
receptor	I-protein
promoter	O
activity	O
significantly	O
in	O
macrophage	B-cell_line
cell	I-cell_line
lines	I-cell_line
only	O
.	O

Furthermore	O
,	O
PU.1	B-protein
transactivates	O
the	O
M-CSF	B-DNA
receptor	I-DNA
promoter	I-DNA
in	O
nonmacrophage	B-cell_type
cells	I-cell_type
.	O

These	O
results	O
suggest	O
that	O
PU.1	B-protein
plays	O
a	O
major	O
role	O
in	O
macrophage	O
gene	O
regulation	O
and	O
development	O
by	O
directing	O
the	O
expression	O
of	O
a	O
receptor	O
for	O
a	O
key	B-protein
macrophage	I-protein
growth	I-protein
factor	I-protein
.	O

Increased	O
natural	O
killer	O
cell	O
activity	O
correlates	O
with	O
low	O
or	O
negative	O
expression	O
of	O
the	O
HER-2/neu	B-DNA
oncogene	I-DNA
in	O
patients	O
with	O
breast	O
cancer	O
.	O

BACKGROUND	O
.	O

Increased	O
expression	O
of	O
the	O
HER-2/neu	B-DNA
oncogene	I-DNA
in	O
breast	O
cancer	O
correlates	O
with	O
decreased	O
estrogen	B-protein
receptor	I-protein
concentration	O
and	O
seems	O
to	O
be	O
an	O
important	O
prognostic	O
factor	O
.	O

The	O
authors	O
investigated	O
whether	O
there	O
is	O
a	O
correlation	O
between	O
HER-2/neu	B-protein
expression	O
and	O
immunologic	O
parameters	O
representing	O
tumor	O
defense	O
in	O
patients	O
with	O
breast	O
cancer	O
.	O

METHOD	O
.	O

A	O
Western	O
blot	O
analysis	O
was	O
used	O
to	O
investigate	O
HER-2/neu	B-protein
expression	O
,	O
whereas	O
a	O
chromium-release	O
assay	O
using	O
the	O
K562	B-cell_line
cell	I-cell_line
line	I-cell_line
as	O
target	O
was	O
used	O
to	O
measure	O
natural	B-cell_type
killer	I-cell_type
(	I-cell_type
NK	I-cell_type
)	I-cell_type
cell	I-cell_type
activity	O
.	O

RESULTS	O
.	O

In	O
patients	O
with	O
breast	O
cancer	O
,	O
NK	B-cell_type
cell	I-cell_type
activity	O
was	O
significantly	O
higher	O
compared	O
with	O
patients	O
with	O
benign	B-cell_type
tumors	I-cell_type
(	O
P	O
=	O
0.006	O
)	O
or	O
healthy	O
control	O
subjects	O
(	O
P	O
=	O
0.002	O
)	O
.	O

Moreover	O
,	O
23.3	O
%	O
of	O
patients	O
with	O
breast	O
cancer	O
showed	O
an	O
overexpression	O
of	O
HER-2/neu	B-protein
protein	I-protein
.	O

Within	O
this	O
group	O
of	O
patients	O
,	O
NK	B-cell_type
cell	I-cell_type
activity	O
was	O
significantly	O
lower	O
(	O
45.6	O
+/-	O
16.1	O
%	O
)	O
compared	O
with	O
the	O
group	O
with	O
no	O
HER-2/neu	B-protein
overexpression	O
(	O
57.3	O
+/-	O
11.0	O
%	O
)	O
.	O

NK	B-cell_type
cell	I-cell_type
activity	O
did	O
not	O
increase	O
in	O
patients	O
with	O
HER-2/neu	B-protein
overexpression	O
.	O

Thus	O
,	O
there	O
was	O
a	O
statistically	O
significant	O
correlation	O
of	O
cytolytic	O
effector	O
cell	O
function	O
with	O
HER-2/neu	B-protein
expression	O
of	O
the	O
tumor	O
(	O
P	O
=	O
0.003	O
)	O
,	O
and	O
HER-2/neu	B-protein
overexpression	O
correlated	O
with	O
a	O
negative	O
estrogen	B-protein
receptor	I-protein
status	O
(	O
P	O
=	O
0.005	O
)	O
.	O

CONCLUSION	O
.	O

These	O
data	O
add	O
further	O
evidence	O
to	O
previous	O
observations	O
from	O
the	O
authors	O
'	O
laboratory	O
that	O
certain	O
tumor	O
characteristics	O
may	O
be	O
associated	O
with	O
reactions	O
of	O
the	O
host	O
with	O
breast	O
cancer	O
.	O

[	O
The	O
value	O
of	O
the	O
clinical	O
test	O
of	O
glucocorticoid	B-protein
receptors	I-protein
of	O
peripheral	B-cell_type
blood	I-cell_type
leukocytes	I-cell_type
in	O
patients	O
with	O
chronic	O
pulmonary	O
heart	O
disease	O
]	O

In	O
order	O
to	O
inquire	O
into	O
the	O
functional	O
state	O
of	O
adrenal	O
cortex	O
in	O
patients	O
with	O
pulmonary	O
heart	O
disease	O
,	O
the	O
number	O
of	O
glucocorticoid	B-protein
receptors	I-protein
(	O
GCR	B-protein
)	O
of	O
peripheral	B-cell_type
blood	I-cell_type
leukocytes	I-cell_type
in	O
patients	O
with	O
chronic	O
pulmonary	O
heart	O
disease	O
was	O
determined	O
with	O
radioligand-binding	O
assay	O
and	O
the	O
corresponding	O
plasma	O
cortisol	O
levels	O
were	O
assessed	O
with	O
radioimmune	O
assays	O
.	O

The	O
results	O
showed	O
that	O
the	O
number	O
of	O
GCR	B-protein
in	O
the	O
patients	O
was	O
significantly	O
reduced	O
(	O
P	O
<	O
0.01	O
)	O
and	O
it	O
was	O
increased	O
when	O
their	O
health	O
state	O
was	O
improved	O
.	O

However	O
,	O
it	O
was	O
still	O
lower	O
than	O
that	O
in	O
healthy	O
subjects	O
(	O
P	O
<	O
0.01	O
)	O
.	O

The	O
number	O
of	O
GCR	B-protein
in	O
the	O
patients	O
was	O
greatly	O
increased	O
when	O
these	O
patients	O
were	O
treated	O
with	O
oxygen	O
(	O
P	O
<	O
0.01	O
)	O
.	O

No	O
difference	O
in	O
plasma	O
cortisol	O
was	O
found	O
between	O
the	O
patients	O
and	O
the	O
healthy	O
subjects	O
(	O
P	O
>	O
0.05	O
)	O
.	O

These	O
results	O
indicate	O
that	O
the	O
function	O
of	O
adrenal	O
cortex	O
may	O
be	O
improved	O
by	O
the	O
compensation	O
mechanism	O
of	O
the	O
patients	O
,	O
but	O
the	O
lower	O
GCR	B-protein
number	O
was	O
the	O
result	O
of	O
lacking	O
of	O
oxygen	O
in	O
the	O
patients	O
.	O

The	O
number	O
of	O
GCR	B-protein
may	O
be	O
improved	O
by	O
inhalation	O
of	O
oxygen	O
.	O

Therefore	O
oxygen	O
therapy	O
is	O
helpful	O
in	O
raising	O
the	O
activity	O
of	O
glucocorticoid	B-protein
receptors	I-protein
and	O
controlling	O
the	O
development	O
of	O
the	O
disease	O
.	O

Signaling	O
via	O
IL-2	B-protein
and	O
IL-4	B-protein
in	O
JAK3-deficient	B-cell_line
severe	I-cell_line
combined	I-cell_line
immunodeficiency	I-cell_line
lymphocytes	I-cell_line
:	O
JAK3	B-protein
-dependent	O
and	O
independent	O
pathways	O
.	O

Both	O
IL-2	B-protein
and	O
IL-4	B-protein
bind	O
to	O
receptors	O
containing	O
the	O
common	B-protein
gamma	I-protein
chain	I-protein
and	O
JAK3	B-protein
.	O

Although	O
JAK3	B-protein
is	O
required	O
for	O
proper	O
lymphoid	O
development	O
,	O
the	O
precise	O
roles	O
of	O
this	O
kinase	O
in	O
IL-2	B-protein
and	O
IL-4	B-protein
signaling	O
in	O
lymphocytes	B-cell_type
have	O
not	O
been	O
defined	O
.	O

Here	O
,	O
we	O
have	O
studied	O
IL-2	B-protein
and	O
IL-4	B-protein
signaling	O
in	O
B	B-cell_line
cell	I-cell_line
lines	I-cell_line
lacking	O
JAK3	B-protein
.	O

Although	O
IL-2	B-protein
-induced	O
phosphorylation	O
of	O
IL-2R	B-protein
beta	I-protein
,	O
JAK1	B-protein
,	O
and	O
STAT5	B-protein
all	O
required	O
the	O
presence	O
of	O
JAK3	B-protein
,	O
IL-4	B-protein
-mediated	O
phosphorylation	O
of	O
JAK1	B-protein
,	O
STAT6	B-protein
,	O
and	O
insulin	B-protein
receptor	I-protein
substrates	O
1	O
and	O
2	O
did	O
not	O
.	O

However	O
,	O
IL-4	B-protein
-induced	O
effects	O
were	O
clearly	O
improved	O
following	O
JAK3	B-protein
expression	O
.	O

These	O
data	O
indicate	O
that	O
IL-4	B-protein
signaling	O
occurs	O
in	O
the	O
absence	O
of	O
of	O
JAK3	B-protein
,	O
but	O
is	O
comparatively	O
inefficient	O
.	O

These	O
findings	O
may	O
help	O
in	O
understanding	O
the	O
pathogenesis	O
of	O
the	O
immunodeficiency	O
that	O
occurs	O
with	O
mutations	O
of	O
JAK3	B-protein
and	O
may	O
suggest	O
a	O
mechanism	O
for	O
the	O
pleiotropic	O
effects	O
of	O
IL-4	B-protein
.	O

Elf-1	B-protein
and	O
Stat5	B-protein
bind	O
to	O
a	O
critical	O
element	O
in	O
a	O
new	O
enhancer	O
of	O
the	O
human	B-DNA
interleukin-2	I-DNA
receptor	I-DNA
alpha	I-DNA
gene	I-DNA
[	O
published	O
erratum	O
appears	O
in	O
Mol	O
Cell	O
Biol	O
1997	O
Apr	O
;	O
17	O
(	O
4	O
)	O
:	O
2351	O
]	O

The	O
interleukin	B-DNA
2	I-DNA
receptor	I-DNA
alpha-chain	I-DNA
(	I-DNA
IL-2R	I-DNA
alpha	I-DNA
)	I-DNA
gene	I-DNA
is	O
a	O
key	O
regulator	O
of	O
lymphocyte	O
proliferation	O
.	O

IL-2R	B-protein
alpha	I-protein
is	O
rapidly	O
and	O
potently	O
induced	O
in	O
T	B-cell_type
cells	I-cell_type
in	O
response	O
to	O
mitogenic	O
stimuli	O
.	O

Interleukin	B-protein
2	I-protein
(	O
IL-2	B-protein
)	O
stimulates	O
IL-2R	B-protein
alpha	I-protein
.	O

transcription	O
,	O
thereby	O
amplifying	O
expression	O
of	O
its	O
own	O
high-affinity	B-protein
receptor	I-protein
.	O

IL-2R	B-protein
alpha	I-protein
transcription	O
is	O
at	O
least	O
in	O
part	O
controlled	O
by	O
two	O
positive	B-protein
regulatory	I-protein
regions	I-protein
,	O
PRRI	B-DNA
and	O
PRRII	B-DNA
.	O

PRRI	B-DNA
is	O
an	O
inducible	B-DNA
proximal	I-DNA
enhancer	I-DNA
,	O
located	O
between	B-DNA
nucleotides	I-DNA
-276	I-DNA
and	I-DNA
-244	I-DNA
,	O
which	O
contains	O
NF-kappaB	B-DNA
and	I-DNA
SRE/CArG	I-DNA
motifs	I-DNA
.	O

PRRII	B-DNA
is	O
a	O
T-cell-specific	B-DNA
enhancer	I-DNA
,	O
located	O
between	O
nucleotides	O
-137	O
and	O
-64	O
,	O
which	O
binds	O
the	O
T-cell-specific	B-protein
Ets	I-protein
protein	I-protein
Elf-1	B-protein
and	O
HMG-I	B-protein
(	I-protein
Y	I-protein
)	I-protein
proteins	I-protein
.	O

However	O
,	O
none	O
of	O
these	O
proximal	O
regions	O
account	O
for	O
the	O
induction	O
of	O
IL-2R	O
alpha	O
transcription	O
by	O
IL-2	B-protein
.	O

To	O
find	O
new	O
regulatory	B-DNA
regions	I-DNA
of	O
the	O
IL-2R	B-DNA
alpha	I-DNA
gene	I-DNA
,	O
8.5	O
kb	O
of	O
the	O
5	O
'	O
end	O
noncoding	O
sequence	O
of	O
the	O
IL-2R	B-DNA
alpha	I-DNA
gene	I-DNA
have	O
been	O
sequenced	O
.	O

We	O
identified	O
an	O
86-nucleotide	O
fragment	O
that	O
is	O
90	O
%	O
identical	O
to	O
the	O
recently	O
characterized	O
murine	B-DNA
IL-2-responsive	I-DNA
element	I-DNA
(	O
mIL-2rE	B-DNA
)	O
.	O

This	O
putative	O
human	B-DNA
IL-2rE	I-DNA
,	O
designated	O
PRRIII	B-DNA
,	O
confers	O
IL-2	B-protein
responsiveness	O
on	O
a	O
heterologous	B-DNA
promoter	I-DNA
.	O

PRRIII	B-DNA
contains	O
a	O
Stat	B-DNA
protein	I-DNA
binding	I-DNA
site	I-DNA
that	O
overlaps	O
with	O
an	O
EBS	B-DNA
motif	I-DNA
(	O
GASd/EBSd	B-DNA
)	O
.	O

These	O
are	O
essential	O
for	O
IL-2	B-protein
inducibility	O
of	O
PRRIII/CAT	B-DNA
reporter	I-DNA
constructs	I-DNA
.	O

IL-2	B-protein
induced	O
the	O
binding	O
of	O
Stat5a	B-protein
and	I-protein
b	I-protein
proteins	I-protein
to	O
the	O
human	B-DNA
GASd	I-DNA
element	I-DNA
.	O

To	O
confirm	O
the	O
physiological	O
relevance	O
of	O
these	O
findings	O
,	O
we	O
carried	O
out	O
in	O
vivo	O
footprinting	O
experiments	O
which	O
showed	O
that	O
stimulation	O
of	O
IL-2R	B-protein
alpha	I-protein
expression	O
correlated	O
with	O
occupancy	O
of	O
the	O
GASd	B-DNA
element	I-DNA
.	O

Our	O
data	O
demonstrate	O
a	O
major	O
role	O
of	O
the	O
GASd/EBSd	B-DNA
element	I-DNA
in	O
IL-2R	B-protein
alpha	I-protein
regulation	O
and	O
suggest	O
that	O
the	O
T-cell-specific	B-protein
Elf-1	I-protein
factor	I-protein
can	O
serve	O
as	O
a	O
transcriptional	B-protein
repressor	I-protein
.	O

Signal	O
transduction	O
by	O
DR3	B-protein
,	O
a	O
death	B-protein
domain-containing	I-protein
receptor	I-protein
related	O
to	O
TNFR-1	B-protein
and	O
CD95	B-protein
.	O

Tumor	B-protein
necrosis	I-protein
factor	I-protein
receptor-1	I-protein
(	O
TNFR-1	B-protein
)	O
and	O
CD95	B-protein
(	O
also	O
called	O
Fas	B-protein
or	O
APO-1	B-protein
)	O
are	O
cytokine	B-protein
receptors	I-protein
that	O
engage	O
the	O
apoptosis	O
pathway	O
through	O
a	O
region	O
of	O
intracellular	O
homology	O
,	O
designated	O
the	O
``	O
death	B-protein
domain	I-protein
.	O
''	O
Another	O
death	B-protein
domain-containing	I-protein
member	I-protein
of	O
the	O
TNFR	B-protein
family	I-protein
,	O
death	B-protein
receptor	I-protein
3	I-protein
(	O
DR3	B-protein
)	O
,	O
was	O
identified	O
and	O
was	O
shown	O
to	O
induce	O
both	O
apoptosis	O
and	O
activation	O
of	O
nuclear	B-protein
factor	I-protein
kappaB	I-protein
.	O

Expression	O
of	O
DR3	B-protein
appears	O
to	O
be	O
restricted	O
to	O
tissues	O
enriched	O
in	O
lymphocytes	B-cell_type
.	O

DR3	B-protein
signal	O
transduction	O
is	O
mediated	O
by	O
a	O
complex	O
of	O
intracellular	B-protein
signaling	I-protein
molecules	I-protein
including	O
TRADD	B-protein
,	O
TRAF2	B-protein
,	O
FADD	B-protein
,	O
and	O
FLICE	B-protein
.	O

Thus	O
,	O
DR3	B-protein
likely	O
plays	O
a	O
role	O
in	O
regulating	O
lymphocyte	O
homeostasis	O
.	O

Differential	O
nuclear	O
localization	O
of	O
p50	B-protein
,	O
p52	B-protein
,	O
and	O
RelB	B-protein
proteins	O
in	O
human	B-cell_type
accessory	I-cell_type
cells	I-cell_type
of	O
the	O
immune	O
response	O
in	O
situ	O
.	O

The	O
Rel/NF-kappa	B-protein
B	I-protein
proteins	I-protein
,	O
p50	B-protein
,	O
p52	B-protein
,	O
p65	B-protein
,	O
c-Rel	B-protein
,	O
and	O
RelB	B-protein
,	O
constitute	O
a	O
family	O
of	O
transcription	B-protein
factors	I-protein
involved	O
in	O
the	O
positive	O
regulation	O
of	O
a	O
variety	O
of	O
genes	O
during	O
the	O
immune	O
response	O
.	O

Recently	O
,	O
it	O
has	O
been	O
shown	O
that	O
RelB	B-protein
knockout	O
mice	O
have	O
no	O
dendritic	B-cell_type
cells	I-cell_type
(	O
DC	B-cell_type
)	O
.	O

An	O
overexpression	O
of	O
p50	B-protein
has	O
been	O
described	O
in	O
follicular	B-cell_type
dendritic	I-cell_type
cells	I-cell_type
(	O
FDC	B-cell_type
)	O
.	O

A	O
constitutive	O
NF-kappa	B-protein
B	I-protein
activity	O
has	O
been	O
reported	O
in	O
mature	B-cell_type
macrophages	I-cell_type
.	O

This	O
led	O
to	O
the	O
hypothesis	O
that	O
some	O
of	O
the	O
Rel/NF-kappa	B-protein
B	I-protein
proteins	I-protein
were	O
key	O
nuclear	B-protein
factors	I-protein
in	O
functions	O
of	O
accessory	B-cell_type
cells	I-cell_type
of	O
the	O
immune	O
response	O
.	O

Therefore	O
,	O
we	O
investigated	O
in	O
situ	O
the	O
nuclear	O
localization	O
of	O
Rel/NF-kappa	B-protein
B	I-protein
proteins	I-protein
in	O
accessory	B-cell_type
cells	I-cell_type
of	O
the	O
immune	O
system	O
by	O
immunohistochemistry	O
and	O
double	O
labeling	O
by	O
immunofluorescence	O
from	O
five	O
normal	O
human	O
tonsils	O
and	O
five	O
lymph	O
nodes	O
with	O
follicular	O
hyperplasia	O
.	O

Nuclear	O
p65	B-protein
and	O
c-Rel	B-protein
proteins	O
were	O
found	O
in	O
all	O
cell	O
types	O
including	O
lymphocytes	B-cell_type
.	O

In	O
germinal	O
centers	O
GC	O
,	O
p50	B-protein
,	O
p52	B-protein
,	O
and	O
RelB	B-protein
were	O
found	O
in	O
the	O
nuclei	O
of	O
FDC	B-cell_type
only	O
and	O
were	O
not	O
detected	O
in	O
the	O
nuclei	O
of	O
CD68+	B-cell_line
cells	I-cell_line
.	O

In	O
T	O
cell	O
areas	O
,	O
p50	B-protein
,	O
p52	B-protein
,	O
and	O
RelB	B-protein
were	O
found	O
in	O
the	O
nuclei	O
of	O
HLA-DR+	B-cell_line
cells	I-cell_line
with	O
an	O
antigen-presenting	O
cell	O
(	O
APC	O
)	O
morphology	O
.	O

p52	B-protein
and	O
RelB	B-protein
were	O
detected	O
in	O
the	O
nuclei	O
in	O
both	O
CD1a+	B-cell_line
and	O
CD68+	B-cell_line
cells	I-cell_line
from	O
the	O
T	O
cell	O
area	O
,	O
whereas	O
p50	B-protein
was	O
found	O
only	O
in	O
CD68-	B-cell_line
and	I-cell_line
CD1a-	I-cell_line
cells	I-cell_line
.	O

Cells	O
with	O
nuclear	O
p50	B-protein
were	O
negative	O
for	O
the	O
CD38	B-protein
,	O
CD20	B-protein
and	O
CD2	B-protein
markers	I-protein
.	O

These	O
results	O
show	O
that	O
,	O
physiologically	O
,	O
high	O
levels	O
of	O
nuclear	O
of	O
p50	B-protein
,	O
p52	B-protein
and	O
RelB	B-protein
are	O
restricted	O
to	O
accessory	B-cell_type
cells	I-cell_type
of	O
the	O
immune	O
system	O
,	O
which	O
include	O
FDC	B-cell_type
in	O
GC	O
,	O
and	O
DC	B-cell_type
and	O
macrophages	O
in	O
the	O
T	O
cell	O
zone	O
,	O
that	O
specialized	O
scavenger	B-cell_type
macrophages	I-cell_type
from	O
GC	B-cell_type
do	O
not	O
have	O
detectable	O
levels	O
of	O
p52	B-protein
and	O
RelB	B-protein
,	O
whereas	O
macrophages	B-cell_type
from	O
the	O
T	O
cell	O
area	O
,	O
known	O
to	O
present	O
the	O
antigen	O
to	O
T	B-cell_type
cells	I-cell_type
,	O
do	O
have	O
both	O
nuclear	O
p52	B-protein
and	O
RelB	B-protein
,	O
and	O
that	O
in	O
the	O
T	O
cell	O
zone	O
,	O
p52	B-protein
and	O
RelB	B-protein
are	O
located	O
in	O
nuclei	O
of	O
both	O
CD1a+	B-cell_line
,	O
CD68+	B-cell_line
or	O
both	O
,	O
cells	O
APC	B-cell_type
,	O
whereas	O
p50	B-protein
is	O
restricted	O
to	O
CD1a-	B-cell_type
and	O
CD68-	B-cell_type
APC	I-cell_type
.	O

The	O
different	O
patterns	O
of	O
p50	B-protein
,	O
p52	B-protein
and	O
RelB	B-protein
protein	O
nuclear	O
localization	O
may	O
provide	O
insight	O
into	O
their	O
different	O
roles	O
during	O
the	O
immune	O
response	O
in	O
vivo	O
.	O

Tyrosines	O
113	O
,	O
128	O
,	O
and	O
145	O
of	O
SLP-76	B-protein
are	O
required	O
for	O
optimal	O
augmentation	O
of	O
NFAT	B-DNA
promoter	I-DNA
activity	O
.	O

SLP-76	B-protein
(	O
SH2	B-protein
domain	I-protein
leukocyte	I-protein
protein	I-protein
of	O
76	O
kDa	O
)	O
is	O
a	O
recently	O
identified	O
substrate	O
of	O
the	O
TCR-stimulated	B-protein
protein	I-protein
tyrosine	B-protein
kinases	I-protein
that	O
functions	O
in	O
the	O
signal	O
transduction	O
cascade	O
linking	O
the	O
TCR	B-protein
with	O
IL-2	B-protein
gene	O
expression	O
.	O

In	O
this	O
report	O
,	O
we	O
demonstrate	O
that	O
engagement	O
of	O
the	O
TCR	B-protein
results	O
in	O
tyrosine	O
phosphorylation	O
of	O
SLP-76	B-protein
in	O
its	O
amino-terminal	B-protein
acidic	I-protein
region	I-protein
.	O

Two	O
tyrosines	O
(	O
Y113	O
and	O
Y128	O
)	O
fall	O
within	O
an	O
identical	O
five	O
amino-acid	O
motif	O
and	O
are	O
shown	O
to	O
be	O
phosphorylated	O
upon	O
TCR	B-protein
ligation	O
.	O

Although	O
mutation	O
of	O
either	O
Y113	O
and	O
Y128	O
has	O
a	O
minimal	O
effect	O
on	O
SLP-76	B-protein
function	O
,	O
mutation	O
of	O
both	O
residues	O
decreases	O
significantly	O
the	O
ability	O
of	O
SLP-76	B-protein
to	O
promote	O
T	O
cell	O
activation	O
.	O

A	O
third	O
tyrosine	O
within	O
the	O
amino-terminal	B-protein
region	I-protein
(	O
Y145	O
)	O
appears	O
to	O
be	O
the	O
most	O
important	O
for	O
optimal	O
SLP-76	B-protein
function	O
,	O
as	O
altering	O
it	O
alone	O
to	O
phenylalanine	O
has	O
a	O
potent	O
impact	O
on	O
SLP-76	B-protein
augmentation	O
of	O
NFAT	B-DNA
promoter	I-DNA
activity	O
.	O

Human	B-DNA
interferon	I-DNA
regulatory	I-DNA
factor	I-DNA
2	I-DNA
gene	I-DNA
.	O

Intron-exon	O
organization	O
and	O
functional	O
analysis	O
of	O
5'-flanking	B-DNA
region	I-DNA
.	O

Interferon	B-protein
regulatory	I-protein
factor	I-protein
2	I-protein
(	O
IRF-2	B-protein
)	O
is	O
a	O
transcriptional	B-protein
regulatory	I-protein
protein	I-protein
that	O
terminates	O
interferon	B-protein
beta	I-protein
expression	O
initiated	O
by	O
interferon	B-protein
regulatory	I-protein
factor	I-protein
1	I-protein
.	O

In	O
this	O
study	O
,	O
we	O
isolated	O
the	O
genomic	B-DNA
DNA	I-DNA
for	O
human	B-DNA
IRF-2	I-DNA
gene	I-DNA
,	O
determined	O
the	O
intron-exon	O
structure	O
of	O
the	O
human	B-DNA
IRF-2	I-DNA
gene	I-DNA
,	O
mapped	O
the	O
major	B-DNA
transcription	I-DNA
initiation	I-DNA
site	I-DNA
,	O
identified	O
a	O
number	O
of	O
potential	O
regulatory	O
elements	O
in	O
the	O
5'-flanking	B-DNA
region	I-DNA
,	O
and	O
localized	O
the	O
IRF-2	B-DNA
gene	I-DNA
on	O
human	B-DNA
chromosome	I-DNA
4	I-DNA
.	O

The	O
IRF-2	B-protein
promoter	B-DNA
region	I-DNA
contains	O
a	O
CpG	O
island	O
,	O
with	O
several	O
GC	B-DNA
boxes	I-DNA
,	O
a	O
putative	O
NF-kappa	B-DNA
B-binding	I-DNA
site	I-DNA
,	O
and	O
a	O
CAAT	B-DNA
box	I-DNA
,	O
but	O
no	O
TATA	B-DNA
box	I-DNA
.	O

When	O
the	O
promoter	B-DNA
region	I-DNA
was	O
linked	O
with	O
a	O
heterologous	B-DNA
reporter	I-DNA
gene	I-DNA
,	O
we	O
found	O
that	O
the	O
promoter	B-DNA
region	I-DNA
is	O
inducible	O
by	O
both	O
interferons	B-protein
(	O
interferon-alpha	B-protein
and	I-protein
-gamma	I-protein
)	O
and	O
interferon	B-protein
regulatory	I-protein
factor	I-protein
1	I-protein
.	O

The	O
region	O
which	O
induced	O
these	O
inductions	O
was	O
identified	O
as	O
being	O
confined	O
to	O
40	B-DNA
nucleotides	I-DNA
5	I-DNA
'	I-DNA
to	O
the	O
major	B-DNA
transcriptional	I-DNA
initiation	I-DNA
site	I-DNA
by	O
testing	O
a	O
series	O
of	O
clones	O
with	O
truncated	B-DNA
promoter	I-DNA
of	O
IRF-2	B-protein
.	O

This	O
region	O
contains	O
elements	O
which	O
are	O
shared	O
with	O
the	O
transcriptional	B-DNA
enhancers	I-DNA
of	O
other	O
genes	O
including	O
interferon	B-protein
regulatory	I-protein
factor	I-protein
1	I-protein
,	O
interferon	B-protein
beta	I-protein
,	O
and	O
interferon-inducible	B-DNA
genes	I-DNA
.	O

These	O
data	O
suggest	O
that	O
interferon	B-protein
regulatory	I-protein
factor	I-protein
1	I-protein
not	O
only	O
triggers	O
the	O
activation	O
of	O
the	O
interferon	B-protein
signal	O
transduction	O
pathway	O
,	O
but	O
also	O
may	O
play	O
a	O
role	O
in	O
limiting	O
the	O
duration	O
of	O
this	O
response	O
by	O
activating	O
the	O
transcription	O
of	O
IRF-2	B-protein
.	O

Interferon	B-protein
alpha	I-protein
selectively	O
affects	O
expression	O
of	O
the	O
human	B-protein
myeloid	I-protein
cell	I-protein
nuclear	I-protein
differentiation	I-protein
antigen	I-protein
in	O
late	B-cell_type
stage	I-cell_type
cells	I-cell_type
in	O
the	O
monocytic	B-cell_type
but	O
not	O
the	O
granulocytic	B-cell_type
lineage	I-cell_type
.	O

The	O
human	B-protein
myeloid	I-protein
cell	I-protein
nuclear	I-protein
differentiation	I-protein
antigen	I-protein
(	O
MNDA	B-protein
)	O
is	O
expressed	O
constitutively	O
in	O
cells	O
of	O
the	O
myeloid	B-cell_type
lineage	I-cell_type
,	O
appearing	O
in	O
myeloblast	B-cell_type
cells	I-cell_type
in	O
some	O
cases	O
of	O
acute	O
myeloid	O
leukemia	O
and	O
consistently	O
being	O
detected	O
in	O
promyelocyte	B-cell_type
stage	I-cell_type
cells	I-cell_type
as	O
well	O
as	O
in	O
all	O
later	B-cell_type
stage	I-cell_type
cells	I-cell_type
including	O
peripheral	B-cell_type
blood	I-cell_type
monocytes	I-cell_type
and	O
granulocytes	B-cell_type
.	O

The	O
human	B-cell_line
myeloid	I-cell_line
leukemia	I-cell_line
cell	I-cell_line
lines	I-cell_line
,	O
HL-60	B-cell_line
,	O
U937	B-cell_line
,	O
and	O
THP-1	B-cell_line
,	O
express	O
similar	O
levels	O
of	O
immunochemically	O
detectable	O
MNDA	B-protein
.	O

Although	O
,	O
the	O
level	O
of	O
MNDA	B-RNA
mRNA	I-RNA
in	O
primary	B-cell_type
monocytes	I-cell_type
is	O
very	O
low	O
it	O
was	O
up-regulated	O
at	O
6	O
h	O
following	O
the	O
addition	O
of	O
interferon	B-protein
alpha	I-protein
.	O

The	O
effect	O
of	O
interferon	B-protein
alpha	I-protein
on	O
the	O
MNDA	B-RNA
mRNA	I-RNA
is	O
also	O
observed	O
in	O
the	O
cell	B-cell_line
lines	I-cell_line
HL-60	B-cell_line
,	O
U937	B-cell_line
,	O
and	O
THP-1	B-cell_line
.	O

The	O
MNDA	B-RNA
mRNA	I-RNA
level	O
in	O
primary	B-cell_type
granulocytes	I-cell_type
was	O
unaffected	O
by	O
addition	O
of	O
interferon	B-protein
alpha	I-protein
and	O
other	O
agents	O
including	O
interferon	B-protein
gamma	I-protein
,	O
endotoxin	B-protein
,	O
poly	B-protein
(	I-protein
I	I-protein
)	I-protein
.poly	I-protein
(	I-protein
C	I-protein
)	I-protein
,	O
and	O
FMLP	B-protein
.	O

The	O
MNDA	B-RNA
mRNA	I-RNA
level	O
in	O
the	O
myeloid	B-cell_line
cell	I-cell_line
lines	I-cell_line
was	O
also	O
unaffected	O
by	O
the	O
latter	O
four	O
agents	O
.	O

Induction	O
of	O
differentiation	O
in	O
the	O
myeloid	B-cell_line
cell	I-cell_line
lines	I-cell_line
with	O
phorbol	O
ester	O
induces	O
monocyte	O
differentiation	O
which	O
was	O
accompanied	O
by	O
a	O
decrease	O
in	O
MNDA	B-RNA
mRNA	I-RNA
level	O
.	O

This	O
reduced	O
level	O
of	O
mRNA	B-RNA
could	O
then	O
be	O
elevated	O
with	O
subsequent	O
interferon	B-protein
alpha	I-protein
treatment	O
.	O

The	O
effects	O
of	O
phorbol	O
ester	O
on	O
MNDA	B-RNA
mRNA	I-RNA
appeared	O
to	O
be	O
associated	O
with	O
induced	O
differentiation	O
since	O
inhibiting	O
cell	O
proliferation	O
did	O
not	O
alter	O
the	O
level	O
of	O
MNDA	B-RNA
mRNA	I-RNA
and	O
cell	O
cycle	O
variation	O
in	O
MNDA	B-RNA
mRNA	I-RNA
levels	O
were	O
not	O
observed	O
.	O

The	O
ability	O
of	O
interferon	B-protein
alpha	I-protein
to	O
up-regulate	O
MNDA	B-RNA
mRNA	I-RNA
in	O
phorbol	O
ester	O
treated	O
myeloid	B-cell_line
cell	I-cell_line
lines	I-cell_line
is	O
consistent	O
with	O
the	O
observations	O
made	O
in	O
primary	B-cell_type
monocytes	I-cell_type
.	O

(	O
ABSTRACT	O
TRUNCATED	O
AT	O
250	O
WORDS	O
)	O

Involvement	O
of	O
transcription	B-protein
factor	I-protein
YB-1	B-protein
in	O
human	O
T-cell	O
lymphotropic	O
virus	O
type	O
I	O
basal	O
gene	O
expression	O
.	O

Sequences	O
which	O
control	O
basal	O
human	O
T-cell	O
lymphotropic	O
virus	O
type	O
I	O
(	O
HTLV-I	O
)	O
transcription	O
likely	O
play	O
an	O
important	O
role	O
in	O
initiation	O
and	O
maintenance	O
of	O
virus	O
replication	O
.	O

We	O
previously	O
identified	O
and	O
analyzed	O
a	O
45-nucleotide	B-DNA
sequence	I-DNA
(	O
downstream	B-DNA
regulatory	I-DNA
element	I-DNA
1	I-DNA
[	O
DRE	B-DNA
1	I-DNA
]	O
)	O
,	O
+195	B-DNA
to	I-DNA
+240	I-DNA
,	O
at	O
the	O
boundary	O
of	O
the	O
R/U5	B-DNA
region	I-DNA
of	O
the	O
long	B-DNA
terminal	I-DNA
repeat	I-DNA
which	O
is	O
required	O
for	O
HTLV-I	O
basal	O
transcription	O
.	O

We	O
identified	O
a	O
protein	O
,	O
p37	O
,	O
which	O
specifically	O
bound	O
to	O
DRE	B-DNA
1	I-DNA
.	O

An	O
affinity	O
column	O
fraction	O
,	O
containing	O
p37	B-protein
,	O
stimulated	O
HTLV-I	O
transcription	O
approximately	O
12-fold	O
in	O
vitro	O
.	O

We	O
now	O
report	O
the	O
identification	O
of	O
a	O
cDNA	B-DNA
clone	I-DNA
(	O
15B-7	B-DNA
)	O
,	O
from	O
a	O
Jurkat	B-DNA
expression	I-DNA
library	I-DNA
,	O
that	O
binds	O
specifically	O
to	O
the	O
DRE	B-DNA
1	I-DNA
regulatory	I-DNA
sequence	I-DNA
.	O

Binding	O
of	O
the	O
cDNA	B-protein
fusion	I-protein
protein	I-protein
,	O
similarly	O
to	O
the	O
results	O
obtained	O
with	O
purified	O
Jurkat	O
protein	O
,	O
was	O
decreased	O
by	O
introduction	O
of	O
site-specific	O
mutations	O
in	O
the	O
DRE	B-DNA
1	I-DNA
regulatory	I-DNA
sequence	I-DNA
.	O

In	O
vitro	O
transcription	O
and	O
translation	O
of	O
15B-7	B-DNA
cDNA	I-DNA
produced	O
a	O
fusion	B-protein
protein	I-protein
which	O
bound	O
specifically	O
to	O
the	O
HTLV-I	O
+195	O
to	O
+240	O
oligonucleotide	O
.	O

The	O
partial	B-DNA
cDNA	I-DNA
encodes	O
a	O
protein	O
which	O
is	O
homologous	O
to	O
the	O
C-terminal	B-protein
196	I-protein
amino	I-protein
acids	I-protein
of	O
the	O
36-kDa	B-protein
transcription	I-protein
factor	I-protein
,	O
YB-1	B-protein
.	O

Cotransfection	O
of	O
a	O
YB-1	B-DNA
expression	I-DNA
plasmid	I-DNA
increases	O
HTLV-I	O
basal	O
transcription	O
approximately	O
14-fold	O
in	O
Jurkat	B-cell_line
T	I-cell_line
lymphocytes	I-cell_line
.	O

On	O
the	O
basis	O
of	O
the	O
molecular	O
weight	O
,	O
DNA-binding	O
characteristics	O
,	O
and	O
in	O
vivo	O
transactivation	O
activity	O
,	O
we	O
suggest	O
that	O
the	O
previously	O
identified	O
DRE	B-DNA
1	I-DNA
-binding	O
protein	O
,	O
p37	B-protein
,	O
is	O
YB-1	B-protein
.	O

Changes	O
in	O
triiodothyronine	O
(	O
T3	O
)	O
mononuclear	O
leukocyte	O
receptor	O
kinetics	O
after	O
T3	O
administration	O
and	O
multiple	O
cold-air	O
exposures	O
.	O

Repeated	O
cold-air	O
exposures	O
increase	O
human	O
triiodothyronine	O
(	O
T3	O
)	O
plasma	O
clearance	O
rates	O
.	O

To	O
study	O
the	O
response	O
of	O
the	O
nuclear	B-protein
T3	I-protein
receptor	I-protein
(	O
NT3R	B-protein
)	O
in	O
this	O
condition	O
,	O
binding	O
characteristics	O
were	O
analyzed	O
in	O
human	B-cell_type
mononuclear	I-cell_type
leukocytes	I-cell_type
(	O
MNL	B-cell_type
)	O
.	O

In	O
addition	O
,	O
we	O
supplemented	O
one	O
group	O
of	O
individuals	O
with	O
a	O
daily	O
oral	O
replacement	O
dose	O
of	O
T3	O
to	O
isolate	O
the	O
influence	O
of	O
serum	O
thyroxine	O
(	O
T4	O
)	O
and	O
thyrotropin	O
(	O
TSH	O
)	O
levels	O
on	O
receptor	O
kinetics	O
.	O

The	O
subjects	O
were	O
exposed	O
to	O
cold	O
air	O
(	O
4	O
degrees	O
C	O
)	O
twice/d	O
,	O
30	O
min/exposure	O
,	O
for	O
a	O
total	O
of	O
80	O
exposures	O
.	O

The	O
T3-subjects	O
received	O
placebo	O
[	O
n	O
=	O
8	O
]	O
and	O
the	O
T3	O
+	O
subjects	O
received	O
T3	O
(	O
30	O
micrograms/d	O
)	O
[	O
n	O
=	O
8	O
]	O
in	O
a	O
double-blind	O
fashion	O
.	O

Mononuclear	B-cell_type
leukocytes	I-cell_type
were	O
isolated	O
from	O
peripheral	O
blood	O
before	O
the	O
cold	O
exposure	O
and	O
drug	O
regimen	O
began	O
,	O
and	O
then	O
after	O
every	O
20	O
exposures	O
.	O

The	O
dissociation	O
constant	O
(	O
Kd	O
)	O
and	O
maximum	O
binding	O
capacity	O
(	O
MBC	O
)	O
of	O
the	O
NT3R	B-protein
values	O
were	O
log	O
transformed	O
to	O
minimize	O
between-subject	O
variability	O
.	O

In	O
the	O
T3+	O
group	O
,	O
serum	O
total	O
thyroxine	O
(	O
TT4	O
)	O
,	O
free	O
T4	O
(	O
FT4	O
)	O
,	O
and	O
TSH	O
were	O
approx	O
50	O
%	O
lower	O
than	O
both	O
basal	O
and	O
T3-values	O
.	O

The	O
log10Kd	O
increased	O
0.304	O
+/-	O
0.139	O
(	O
p	O
<	O
0.04	O
)	O
and	O
the	O
log10MBC	O
increased	O
0.49	O
+/-	O
0.10	O
(	O
p	O
<	O
0.001	O
)	O
in	O
the	O
T3+	O
subjects	O
compared	O
to	O
baseline	O
.	O

This	O
change	O
in	O
MBC	O
represents	O
a	O
311	O
%	O
increase	O
in	O
the	O
MBC	O
over	O
baseline	O
and	O
a	O
fivefold	O
increase	O
over	O
placebo-treated	O
subjects	O
.	O

The	O
T3	O
-group	O
showed	O
no	O
change	O
in	O
MBC	O
over	O
the	O
study	O
.	O

These	O
results	O
describe	O
for	O
the	O
first	O
time	O
the	O
rapid	O
modulation	O
of	O
the	O
NT3R	B-protein
in	O
response	O
to	O
the	O
combined	O
influence	O
of	O
cold	O
exposure	O
and	O
reduced	O
circulating	O
T4	O
and	O
TSH	O
.	O

HIV-1	B-DNA
LTR	I-DNA
activity	O
in	O
human	B-cell_line
CD40-activated	I-cell_line
B	I-cell_line
lymphocytes	I-cell_line
is	O
dependent	O
on	O
NF-kappaB	B-protein
.	O

CD40-stimulated	B-cell_line
human	I-cell_line
B	I-cell_line
lymphocytes	I-cell_line
are	O
highly	O
permissive	O
to	O
a	O
productive	O
infection	O
by	O
the	O
human	O
immunodeficiency	O
virus	O
type	O
1	O
.	O

In	O
these	O
cells	O
,	O
nuclear	B-protein
factors	I-protein
involved	O
in	O
activation	O
of	O
the	O
HIV-1	B-DNA
LTR	I-DNA
,	O
which	O
contains	O
the	O
transcriptional	B-DNA
control	I-DNA
elements	I-DNA
of	O
the	O
virus	O
,	O
are	O
unknown	O
.	O

Transient	O
expression	O
assays	O
with	O
plasmids	O
containing	O
deleted	O
parts	O
of	O
the	O
LTR	B-DNA
region	I-DNA
linked	O
to	O
a	O
reporter	O
gene	O
showed	O
that	O
the	O
NF-kappaB	B-DNA
binding	I-DNA
site	I-DNA
was	O
essential	O
for	O
HIV-1	B-DNA
LTR	I-DNA
activity	O
in	O
CD40-stimulated	B-cell_line
B	I-cell_line
lymphocytes	I-cell_line
.	O

In	O
addition	O
,	O
electrophoretic	O
mobility	O
shift	O
and	O
supershift	O
assays	O
revealed	O
that	O
important	O
NF-kappaB	B-protein
binding	O
activity	O
composed	O
of	O
at	O
least	O
p50	B-protein
,	O
p65	B-protein
,	O
and	O
c-Rel	B-protein
NF-kappaB	B-protein
subunits	I-protein
was	O
present	O
in	O
nuclei	O
of	O
CD40-stimulated	B-cell_line
B	I-cell_line
cells	I-cell_line
.	O

These	O
results	O
confirm	O
at	O
a	O
molecular	O
level	O
the	O
ability	O
of	O
HIV-1	O
to	O
replicate	O
in	O
B	B-cell_type
cells	I-cell_type
and	O
that	O
this	O
activity	O
is	O
strongly	O
associated	O
with	O
NF-kappaB	B-protein
.	O

Sequence	O
analysis	O
and	O
expression	O
in	O
cultured	B-cell_type
lymphocytes	I-cell_type
of	O
the	O
human	O
FOSB	B-DNA
gene	I-DNA
(	O
G0S3	B-DNA
)	O
.	O

G0S3	B-DNA
is	O
a	O
member	O
of	O
a	O
set	O
of	O
putative	B-DNA
G0/G1	I-DNA
switch	I-DNA
regulatory	I-DNA
genes	I-DNA
(	O
G0S	B-DNA
genes	I-DNA
)	O
selected	O
by	O
screening	O
cDNA	B-DNA
libraries	I-DNA
prepared	O
from	O
human	B-cell_type
blood	I-cell_type
mononuclear	I-cell_type
cells	I-cell_type
cultured	O
for	O
2	O
hr	O
with	O
lectin	B-protein
and	O
cycloheximide	O
.	O

The	O
sequence	O
shows	O
high	O
homology	O
with	O
the	O
murine	B-DNA
FOSB	I-DNA
gene	I-DNA
,	O
which	O
encodes	O
a	O
component	O
of	O
the	O
AP1	B-protein
transcriptional	I-protein
regulator	I-protein
.	O

Comparison	O
of	O
cDNA	B-DNA
and	O
genomic	O
sequences	O
reveals	O
a	O
4-exon	B-DNA
structure	I-DNA
characteristic	O
of	O
the	O
FOS	B-DNA
family	I-DNA
of	I-DNA
genes	I-DNA
.	O

Freshly	O
isolated	O
cells	O
show	O
high	O
levels	O
of	O
FOSB/G0S3	B-RNA
and	I-RNA
FOS/G0S7	I-RNA
mRNAs	I-RNA
,	O
which	O
decline	O
rapidly	O
during	O
incubation	O
in	O
culture	O
medium	O
.	O

The	O
kinetics	O
of	O
expression	O
suggest	O
that	O
the	O
high	O
initial	O
levels	O
are	O
caused	O
by	O
the	O
isolation	O
procedure	O
,	O
and	O
do	O
not	O
reflect	O
constitutive	O
expression	O
.	O

In	O
cells	O
preincubated	O
for	O
a	O
day	O
,	O
levels	O
of	O
FOS	B-RNA
mRNA	I-RNA
reach	O
a	O
maximum	O
20	O
min	O
after	O
the	O
addition	O
of	O
lectin	B-protein
and	O
decline	O
to	O
control	O
levels	O
over	O
the	O
next	O
3	O
hr	O
.	O

Levels	O
of	O
FOSB	B-RNA
mRNA	I-RNA
reach	O
a	O
maximum	O
40	O
min	O
after	O
the	O
addition	O
of	O
lectin	B-protein
and	O
decline	O
to	O
control	O
levels	O
over	O
the	O
next	O
6	O
hr	O
.	O

In	O
freshly	O
isolated	O
cells	O
,	O
both	O
FOS	B-RNA
and	I-RNA
FOSB	I-RNA
mRNAs	I-RNA
increase	O
dramatically	O
in	O
response	O
to	O
the	O
protein	O
synthesis	O
inhibitor	O
cycloheximide	O
.	O

In	O
preincubated	O
cells	O
,	O
the	O
cycloheximide	O
response	O
is	O
decreased	O
,	O
especially	O
in	O
the	O
case	O
of	O
FOSB	B-DNA
.	O

These	O
differences	O
in	O
expression	O
of	O
FOS	B-DNA
and	O
FOSB	B-DNA
suggest	O
different	O
roles	O
and	O
regulation	O
.	O

Regions	O
of	O
low	O
base	O
order-dependent	O
stem-loop	O
potential	O
in	O
the	O
region	O
of	O
the	O
gene	O
are	O
defined	O
.	O

These	O
indicate	O
where	O
base	O
order	O
has	O
been	O
adapted	O
for	O
purposes	O
other	O
than	O
stem-loop	O
stability	O
(	O
e.g.	O
,	O
encoding	O
proteins	O
or	O
gene	O
regulation	O
)	O
.	O

Regions	O
of	O
low	O
potential	O
in	O
a	O
68.5-kb	O
genomic	O
segment	O
containing	O
the	O
FOSB	B-DNA
gene	I-DNA
suggest	O
that	O
the	O
potential	O
may	O
help	O
locate	O
genes	O
in	O
uncharted	B-DNA
DNA	I-DNA
sequences	I-DNA
.	O

Susceptibility	O
to	O
natural	B-cell_type
killer	I-cell_type
cells	I-cell_type
and	O
down	O
regulation	O
of	O
MHC	B-protein
class	O
I	O
expression	O
in	O
adenovirus	B-cell_line
12	I-cell_line
transformed	I-cell_line
cells	I-cell_line
are	O
regulated	O
by	O
different	O
E1A	B-DNA
domains	I-DNA
.	O

All	O
human	O
adenoviruses	O
transform	O
rodent	B-cell_type
cells	I-cell_type
in	O
vitro	O
,	O
but	O
only	O
cells	O
transformed	O
by	O
serotypes	O
belonging	O
to	O
subgroups	O
A	O
(	O
Ad12	O
)	O
and	O
B	O
(	O
Ad3	O
)	O
are	O
tumorigenic	O
for	O
immunocompetent	O
animals	O
.	O

In	O
these	O
cells	O
,	O
the	O
expression	O
of	O
MHC-class	B-protein
I	I-protein
antigens	I-protein
is	O
repressed	O
and	O
might	O
allow	O
them	O
to	O
escape	O
from	O
recognition	O
by	O
cytotoxic	B-cell_type
T	I-cell_type
lymphocytes	I-cell_type
(	O
CTL	B-cell_type
)	O
and	O
to	O
develop	O
in	O
tumor	O
.	O

Furthermore	O
,	O
these	O
cell	B-cell_line
lines	I-cell_line
appear	O
resistant	O
to	O
lysis	O
by	O
natural	B-cell_type
killer	I-cell_type
(	I-cell_type
NK	I-cell_type
)	I-cell_type
cells	I-cell_type
.	O

To	O
determine	O
the	O
E1A	B-DNA
domain	I-DNA
(	O
s	O
)	O
responsible	O
for	O
these	O
properties	O
several	O
cell	B-cell_line
lines	I-cell_line
were	O
created	O
by	O
transforming	O
baby	B-cell_line
rat	I-cell_line
kidney	I-cell_line
(	I-cell_line
BRK	I-cell_line
)	I-cell_line
cells	I-cell_line
with	O
a	O
set	O
of	O
plasmids	B-DNA
expressing	O
different	O
Ad2/Ad12	B-protein
hybrid	I-protein
E1A	I-protein
gene	I-protein
products	I-protein
.	O

The	O
MHC	B-DNA
class	I-DNA
1	I-DNA
gene	I-DNA
expression	O
was	O
inhibited	O
in	O
cells	O
expressing	O
the	O
Ad12	B-protein
13S	I-protein
mRNA	I-protein
product	I-protein
and	O
in	O
cells	O
transformed	O
with	O
Ad2/Ad12	B-protein
hybrid	I-protein
E1A	I-protein
gene	I-protein
product	I-protein
harboring	O
the	O
C-terminal	B-protein
part	I-protein
of	O
the	O
conserved	B-DNA
region	I-DNA
(	I-DNA
CR	I-DNA
)	I-DNA
3	I-DNA
of	O
Ad12	O
.	O

Susceptibility	O
of	O
these	O
transformed	O
cell	B-cell_line
lines	I-cell_line
to	O
NK	B-cell_type
cells	I-cell_type
was	O
determined	O
by	O
cytolytic	O
assays	O
.	O

The	O
results	O
obtained	O
suggest	O
that	O
two	O
Ad12	B-DNA
E1A	I-DNA
domains	I-DNA
are	O
required	O
to	O
induce	O
resistance	O
of	O
the	O
cell	B-cell_line
lines	I-cell_line
to	O
NK	B-cell_type
cells	I-cell_type
.	O

Cell	O
specific	O
expression	O
of	O
human	B-DNA
Bruton	I-DNA
's	I-DNA
agammaglobulinemia	I-DNA
tyrosine	I-DNA
kinase	I-DNA
gene	I-DNA
(	O
Btk	B-protein
)	O
is	O
regulated	O
by	O
Sp1-	B-protein
and	O
Spi-1/PU.1-family	B-protein
members	I-protein
.	O

Bruton	B-protein
's	I-protein
agammaglobulinemia	I-protein
tyrosine	I-protein
kinase	I-protein
(	O
Btk	B-protein
)	O
is	O
a	O
cytoplasmic	B-protein
tyrosine	I-protein
kinase	I-protein
involved	O
in	O
the	O
human	O
disease	O
X-linked	O
agammaglobulinemia	O
(	O
XLA	O
)	O
.	O

The	O
gene	O
is	O
expressed	O
in	O
all	O
hematopoietic	B-cell_type
cells	I-cell_type
with	O
the	O
exception	O
of	O
T-cells	B-cell_type
and	O
plasma	B-cell_type
cells	I-cell_type
.	O

For	O
this	O
expression	O
pattern	O
the	O
first	O
280	B-DNA
bp	I-DNA
upstream	I-DNA
of	O
the	O
major	B-DNA
transcriptional	I-DNA
start	I-DNA
site	I-DNA
seems	O
to	O
be	O
sufficient	O
.	O

In	O
vitro	O
footprinting	O
analysis	O
within	O
this	O
part	O
of	O
the	O
promoter	B-DNA
revealed	O
two	O
Sp1	B-DNA
binding	I-DNA
sites	I-DNA
as	O
well	O
as	O
a	O
PU-box	B-DNA
.	O

The	O
transcription	B-protein
factor	I-protein
Spi-1/PU.1	B-protein
as	O
well	O
as	O
the	O
closely	O
related	O
factor	O
Spi-B	B-protein
bound	O
to	O
the	O
PU-box	B-DNA
in	O
B-cells	O
.	O

In	O
the	O
erythroleukemia	B-cell_line
cell	I-cell_line
line	I-cell_line
K562	I-cell_line
,	O
due	O
to	O
the	O
absence	O
of	O
Spi-B	B-protein
,	O
only	O
PU.1	B-protein
bound	O
to	O
the	O
Btk	B-DNA
promoter	I-DNA
.	O

Mutation	O
of	O
either	O
site	O
reduced	O
the	O
expression	O
in	O
transient	O
transfection	O
experiments	O
.	O

However	O
,	O
mutation	O
of	O
the	O
PU	B-DNA
box	I-DNA
had	O
no	O
effect	O
in	O
the	O
T-cell	B-cell_line
line	I-cell_line
Jurkat	I-cell_line
,	O
where	O
none	O
of	O
the	O
Spi-1	B-protein
family	I-protein
members	I-protein
is	O
expressed	O
.	O

In	O
addition	O
Spi-B	B-protein
as	O
well	O
as	O
PU.1	B-protein
were	O
able	O
to	O
transactivate	O
Btk	B-protein
expression	O
.	O

In	O
fetal	O
liver	O
of	O
PU.1-/-	O
mice	O
,	O
which	O
lack	O
lymphoid	B-cell_type
and	I-cell_type
myeloid	I-cell_type
cells	I-cell_type
,	O
expression	O
of	O
Btk	B-protein
was	O
reduced	O
two-	O
to	O
threefold	O
but	O
not	O
abolished	O
.	O

Collectively	O
this	O
study	O
shows	O
that	O
expression	O
of	O
the	O
Btk	B-DNA
gene	I-DNA
is	O
regulated	O
by	O
the	O
combined	O
action	O
of	O
Sp1-	B-protein
and	I-protein
PU.1-family	I-protein
members	I-protein
.	O

T	O
cell	O
response	O
to	O
Epstein-Barr	B-protein
virus	I-protein
transactivators	I-protein
in	O
chronic	O
rheumatoid	O
arthritis	O
.	O

Rheumatoid	O
arthritis	O
is	O
a	O
multistep	O
disorder	O
associated	O
with	O
autoimmune	O
features	O
of	O
yet	O
unknown	O
etiology	O
.	O

Implication	O
of	O
viruses	O
such	O
as	O
Epstein-Barr	O
virus	O
(	O
EBV	O
)	O
in	O
rheumatoid	O
arthritis	O
pathogenesis	O
has	O
been	O
suspected	O
on	O
the	O
basis	O
of	O
several	O
indirect	O
observations	O
,	O
but	O
thus	O
far	O
,	O
a	O
direct	O
link	O
between	O
EBV	O
and	O
rheumatoid	O
arthritis	O
has	O
not	O
been	O
provided	O
.	O

Here	O
we	O
show	O
that	O
a	O
large	O
fraction	O
of	O
T	B-cell_type
cells	I-cell_type
infiltrating	O
affected	O
joints	O
from	O
a	O
patient	O
with	O
chronic	O
rheumatoid	O
arthritis	O
recognizes	O
two	O
EBV	B-protein
transactivators	I-protein
(	O
BZLF1	B-protein
and	O
BMLF1	B-protein
)	O
in	O
a	O
major	B-protein
histocompatibility	I-protein
complex	I-protein
-restricted	O
fashion	O
.	O

Responses	O
to	O
these	O
EBV	B-protein
antigens	I-protein
by	O
synovial	O
lymphocytes	O
from	O
several	O
other	O
chronic	O
rheumatoid	O
arthritis	O
patients	O
were	O
readily	O
detectable	O
.	O

Thus	O
these	O
results	O
suggest	O
a	O
direct	O
contribution	O
of	O
EBV	O
to	O
chronic	O
rheumatoid	O
arthritis	O
pathogenesis	O
.	O

They	O
also	O
demonstrate	O
for	O
the	O
first	O
time	O
the	O
occurrence	O
of	O
T	O
cell	O
responses	O
against	O
EBV	B-protein
transactivating	I-protein
factors	I-protein
,	O
which	O
might	O
be	O
central	O
in	O
the	O
control	O
of	O
virus	O
reactivation	O
.	O

CD14	B-protein
-mediated	O
signal	O
pathway	O
of	O
Porphyromonas	O
gingivalis	O
lipopolysaccharide	O
in	O
human	B-cell_type
gingival	I-cell_type
fibroblasts	I-cell_type
.	O

Lipopolysaccharide	O
(	O
LPS	O
)	O
induces	O
expression	O
of	O
inflammatory	B-protein
cytokines	I-protein
in	O
monocytes/macrophages	B-cell_type
via	O
CD14	B-protein
,	O
one	O
of	O
the	O
LPS	B-protein
receptors	I-protein
,	O
which	O
is	O
expressed	O
predominantly	O
in	O
these	O
cells	O
.	O

It	O
has	O
been	O
demonstrated	O
that	O
Porphyromonas	O
gingivalis	O
LPS	O
(	O
P-LPS	O
)	O
also	O
is	O
able	O
to	O
induce	O
inflammatory	B-protein
cytokines	I-protein
in	O
human	B-cell_type
gingival	I-cell_type
fibroblasts	I-cell_type
.	O

Therefore	O
,	O
it	O
is	O
important	O
to	O
determine	O
whether	O
CD14	B-protein
is	O
expressed	O
in	O
gingival	B-cell_type
fibroblasts	I-cell_type
and	O
to	O
define	O
the	O
P-LPS-mediated	O
signal-transducing	B-protein
mechanism	O
in	O
the	O
cells	O
.	O

In	O
this	O
study	O
,	O
we	O
observed	O
unexpectedly	O
by	O
immunohistochemical	O
,	O
Western	O
blotting	O
(	O
immunoblotting	O
)	O
,	O
and	O
Northern	O
(	O
RNA	O
)	O
blotting	O
assays	O
that	O
CD14	B-protein
is	O
expressed	O
at	O
high	O
density	O
in	O
human	B-cell_type
gingival	I-cell_type
fibroblasts	I-cell_type
.	O

P-LPS-induced	O
expression	O
of	O
the	O
monocyte	B-DNA
chemoattractant	I-DNA
protein	I-DNA
1	I-DNA
(	I-DNA
MCP-1	I-DNA
)	I-DNA
gene	I-DNA
in	O
the	O
cells	O
was	O
inhibited	O
markedly	O
by	O
treatment	O
with	O
anti-human	O
CD14	B-protein
antibody	O
and	O
was	O
completely	O
inhibited	O
by	O
herbimycin	O
A	O
,	O
a	O
potent	O
inhibitor	O
of	O
tyrosine	B-protein
kinase	I-protein
.	O

The	O
inhibitor	O
also	O
dramatically	O
inhibited	O
monocyte	O
chemotactic	O
activity	O
of	O
and	O
MCP-1	B-protein
production	O
by	O
the	O
cells	O
.	O

Furthermore	O
,	O
P-LPS-induced	O
expression	O
of	O
the	O
MCP-1	B-DNA
gene	I-DNA
in	O
the	O
cells	O
also	O
was	O
blocked	O
by	O
inhibitors	O
of	O
two	O
transcription	B-protein
factors	I-protein
,	O
i.e.	O
,	O
curcumin	O
,	O
an	O
inhibitor	O
of	O
AP-1	B-protein
,	O
and	O
pyrolidine	O
dithiocarbamate	O
,	O
an	O
inhibitor	O
of	O
NF-kappaB	B-protein
.	O

Both	O
inhibitors	O
inhibited	O
monocyte	O
chemotactic	O
activity	O
in	O
the	O
culture	O
supernatant	O
of	O
P-LPS-treated	O
cells	O
.	O

Gel	O
shift	O
mobility	O
assay	O
showed	O
stimulation	O
of	O
the	O
AP-1	B-protein
and	O
NF-kappaB	B-protein
contents	O
in	O
P-LPS-treated	O
cells	O
.	O

This	O
study	O
is	O
the	O
first	O
to	O
demonstrate	O
the	O
expression	O
of	O
CD14	B-protein
in	O
human	B-cell_type
gingival	I-cell_type
fibroblasts	I-cell_type
and	O
to	O
show	O
that	O
the	O
signal-transducing	O
pathway	O
of	O
P-LPS	O
in	O
the	O
cells	O
is	O
mediated	O
by	O
CD14	B-protein
.	O

rel	B-protein
Is	O
rapidly	O
tyrosine-phosphorylated	O
following	O
granulocyte-colony	B-protein
stimulating	I-protein
factor	I-protein
treatment	O
of	O
human	O
neutrophils	O
.	O

Stimulation	O
of	O
neutrophils	B-cell_type
with	O
granulocyte-colony	B-protein
stimulating	I-protein
factor	I-protein
(	O
G-CSF	B-protein
)	O
results	O
in	O
an	O
enhanced	O
respiratory	O
burst	O
,	O
prolonged	O
survival	O
,	O
and	O
increased	O
tumor	O
cell	O
killing	O
.	O

The	O
effects	O
of	O
G-CSF	B-protein
are	O
mediated	O
by	O
binding	O
to	O
specific	O
,	O
high	O
affinity	B-protein
receptors	I-protein
.	O

G-CSF	B-protein
receptors	I-protein
lack	O
intrinsic	O
tyrosine	B-protein
kinase	I-protein
activity	O
,	O
but	O
activation	O
of	O
the	O
receptor	O
results	O
in	O
the	O
rapid	O
induction	O
of	O
tyrosine	O
kinase	O
activity	O
.	O

Antiphosphotyrosine	O
immunoblots	O
of	O
whole	O
cell	O
lysates	O
prepared	O
from	O
neutrophils	B-cell_type
show	O
that	O
the	O
G-CSF	B-protein
rapidly	O
induces	O
prominent	O
tyrosine	O
phosphorylation	O
of	O
a	O
protein	O
of	O
a	O
relative	O
molecular	O
mass	O
of	O
80	O
kDa	O
.	O

Using	O
monospecific	B-protein
antibodies	I-protein
,	O
the	O
80-kDa	O
tyrosine-phosphorylated	B-protein
protein	I-protein
has	O
been	O
shown	O
to	O
be	O
p80c-rel	B-protein
,	O
a	O
proto-oncogene	B-DNA
belonging	O
to	O
a	O
family	O
of	O
transcriptional	B-protein
regulators	I-protein
which	O
include	O
NF-kB	B-protein
.	O

The	O
induction	O
of	O
tyrosine	O
phosphorylation	O
of	O
p80c-rel	B-protein
was	O
unique	O
to	O
G-CSF	B-protein
in	O
that	O
granulocyte-macrophage	B-protein
colony	I-protein
stimulating	I-protein
factor	I-protein
which	O
also	O
stimulates	O
neutrophils	B-cell_type
and	O
induces	O
tyrosine	O
phosphorylation	O
does	O
not	O
result	O
in	O
tyrosine	O
phosphorylation	O
of	O
p80c-rel	B-protein
.	O

The	O
consequences	O
of	O
p80c-rel	B-protein
tyrosine	O
phosphorylation	O
are	O
not	O
yet	O
known	O
;	O
however	O
,	O
tyrosine-phosphorylated	O
p80c-rel	B-protein
is	O
capable	O
of	O
binding	O
to	O
DNA	O
,	O
and	O
G-CSF	B-protein
stimulation	O
results	O
in	O
an	O
increase	O
in	O
the	O
amount	O
of	O
p80c-rel	B-protein
which	O
binds	O
to	O
DNA	O
.	O

These	O
results	O
demonstrate	O
that	O
one	O
of	O
the	O
first	O
biochemical	O
events	O
which	O
occurs	O
in	O
neutrophils	B-cell_type
following	O
G-CSF	B-protein
stimulation	O
,	O
activation	O
of	O
a	O
tyrosine	B-protein
kinase	I-protein
,	O
leads	O
directly	O
to	O
the	O
tyrosine	O
phosphorylation	O
of	O
p80c-rel	B-protein
.	O

Thus	O
,	O
the	O
tyrosine	B-protein
kinase	I-protein
activated	O
by	O
G-CSF	B-protein
appears	O
to	O
directly	O
transduce	O
a	O
signal	O
to	O
a	O
protein	O
which	O
functions	O
as	O
a	O
transcriptional	B-protein
regulator	I-protein
.	O

Patterns	O
of	O
Pan	B-protein
expression	O
and	O
role	O
of	O
Pan	B-protein
proteins	I-protein
in	O
endocrine	O
cell	O
type-specific	O
complex	O
formation	O
.	O

The	O
Pan	B-DNA
gene	I-DNA
encodes	O
at	O
least	O
two	O
distinct	O
transcripts	O
,	O
Pan-1	B-protein
and	O
Pan-2	B-protein
(	O
also	O
known	O
as	O
E47	B-protein
and	O
E12	B-protein
,	O
respectively	O
)	O
,	O
by	O
the	O
mechanism	O
of	O
alternative	O
RNA	O
splicing	O
.	O

Northern	O
blot	O
analyses	O
performed	O
on	O
rat	O
and	O
mouse	O
tissues	O
have	O
detected	O
ubiquitously	O
expressed	O
Pan	O
transcripts	O
,	O
but	O
the	O
abundance	O
,	O
distribution	O
,	O
and	O
form	O
of	O
Pan	B-protein
proteins	I-protein
have	O
not	O
been	O
clearly	O
defined	O
.	O

Studies	O
of	O
cell	B-cell_line
lines	I-cell_line
representing	O
endocrine	B-cell_type
,	I-cell_type
fibroblast	I-cell_type
,	I-cell_type
and	I-cell_type
lymphoid	I-cell_type
lineages	I-cell_type
using	O
polyclonal	O
antisera	O
to	O
detect	O
E2A	B-protein
proteins	I-protein
have	O
suggested	O
that	O
significant	O
E2A	B-protein
protein	I-protein
expression	O
is	O
restricted	O
to	O
B-lymphocytes	B-cell_type
.	O

We	O
have	O
developed	O
a	O
monoclonal	B-protein
antibody	I-protein
,	O
Yae	B-protein
,	O
which	O
is	O
specific	O
for	O
Pan/E2A	B-protein
proteins	I-protein
,	O
and	O
have	O
used	O
the	O
Yae	B-protein
antibody	I-protein
to	O
examine	O
a	O
variety	O
of	O
endocrine	B-cell_type
and	I-cell_type
nonendocrine	I-cell_type
cell	I-cell_type
lineages	I-cell_type
for	O
differences	O
in	O
Pan/	O
E2A	B-protein
protein	I-protein
expression	O
,	O
subcellular	O
localization	O
,	O
and	O
heteromeric	O
complex	O
formation	O
.	O

In	O
contrast	O
to	O
previous	O
results	O
obtained	O
using	O
polyclonal	O
antiseras	O
to	O
detect	O
Pan/	O
E2A	B-protein
proteins	I-protein
,	O
we	O
report	O
comparable	O
levels	O
of	O
Pan	B-protein
proteins	I-protein
in	O
GH/PRL-	B-cell_line
and	I-cell_line
insulin-producing	I-cell_line
,	I-cell_line
B-	I-cell_line
and	I-cell_line
T-lymphocyte	I-cell_line
cells	I-cell_line
.	O

IEF-1	B-protein
,	O
a	O
pancreatic	O
beta-cell	O
type-specific	O
complex	O
believed	O
to	O
regulate	O
insulin	O
expression	O
,	O
is	O
demonstrated	O
to	O
consist	O
of	O
at	O
least	O
two	O
distinct	O
species	O
,	O
one	O
of	O
which	O
does	O
not	O
contain	O
Pan	B-protein
molecules	I-protein
.	O

Although	O
it	O
has	O
been	O
postulated	O
that	O
pituitary	B-cell_type
endocrine	I-cell_type
cells	I-cell_type
and	O
pancreatic	B-cell_type
endocrine	I-cell_type
beta-cells	I-cell_type
share	O
identical	O
Pan/E2A	B-protein
complexes	I-protein
,	O
native-Western	O
analyses	O
of	O
pituitary	O
and	O
endocrine	B-cell_type
beta-cells	I-cell_type
detect	O
Pan	B-protein
proteins	I-protein
in	O
distinct	O
cell	B-protein
type-specific	I-protein
complexes	I-protein
.	O

Visualization	O
of	O
the	O
endogenous	B-protein
NF-kappa	I-protein
B	I-protein
p50	I-protein
subunit	I-protein
in	O
the	O
nucleus	O
of	O
follicular	B-cell_type
dendritic	I-cell_type
cells	I-cell_type
in	O
germinal	O
centers	O
.	O

NF-kappa	B-protein
B	I-protein
,	O
a	O
50	B-protein
kDa/65	I-protein
kDa	I-protein
(	I-protein
p50/p65	I-protein
)	I-protein
heterodimer	I-protein
,	O
is	O
a	O
ubiquitous	B-protein
transcription	I-protein
factor	I-protein
involved	O
in	O
the	O
positive	O
regulation	O
of	O
various	O
immune	B-DNA
genes	I-DNA
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
determine	O
whether	O
NF-kappa	B-protein
B	I-protein
is	O
related	O
to	O
a	O
particular	O
cell	O
type	O
and/or	O
differentiation	O
step	O
during	O
immunopoiesis	O
.	O

Using	O
in	O
situ	O
hybridization	O
on	O
sections	O
from	O
non	O
HIV	O
hyperplastic	O
lymph	O
nodes	O
,	O
we	O
found	O
that	O
the	O
gene	O
of	O
the	O
105	B-protein
kDa	I-protein
precursor	I-protein
of	O
p50	B-protein
was	O
overexpressed	O
in	O
the	O
light	O
zone	O
of	O
germinal	O
centers	O
,	O
with	O
a	O
network	O
aspect	O
,	O
which	O
suggested	O
the	O
involvement	O
of	O
follicular	B-cell_type
dendritic	I-cell_type
cells	I-cell_type
(	O
FDC	B-cell_type
)	O
.	O

By	O
immunohistochemistry	O
,	O
p50	B-protein
protein	O
was	O
detected	O
in	O
the	O
cytoplasm	O
and	O
nucleus	O
of	O
FDC	B-cell_type
,	O
confirming	O
the	O
involvement	O
of	O
FDC	B-cell_type
.	O

Furthermore	O
,	O
p50	B-protein
protein	O
was	O
detected	O
in	O
the	O
cytoplasm	O
of	O
all	O
lymphocytes	B-cell_type
.	O

Thus	O
,	O
we	O
focused	O
our	O
study	O
on	O
isolated	O
FDC	B-cell_type
clusters	O
from	O
normal	O
tonsils	O
.	O

As	O
showed	O
on	O
tissue	O
sections	O
,	O
we	O
detected	O
the	O
p50	B-protein
in	O
both	O
cytoplasm	O
and	O
nucleus	O
of	O
FDC	B-cell_type
.	O

Nuclei	O
of	O
lymphocytes	B-cell_type
from	O
FDC	B-cell_type
clusters	O
were	O
negative	O
.	O

We	O
next	O
studied	O
p65	O
and	O
c-Rel	O
protein	O
expression	O
in	O
FDC	B-cell_type
clusters	O
.	O

p65	B-protein
was	O
detected	O
in	O
the	O
cytoplasm	O
of	O
FDC	B-cell_type
,	O
whereas	O
nuclei	O
were	O
negative	O
.	O

Furthermore	O
,	O
p65	B-protein
was	O
detected	O
in	O
the	O
nuclei	O
of	O
some	O
lymphocytes	B-cell_type
.	O

c-Rel	B-protein
protein	I-protein
was	O
detected	O
only	O
in	O
the	O
cytoplasm	O
of	O
lymphocytes	B-cell_type
and	O
not	O
in	O
the	O
nucleus	O
and	O
cytoplasm	O
of	O
FDC	B-cell_type
.	O

Our	O
results	O
indicated	O
that	O
,	O
in	O
the	O
context	O
of	O
T	O
cell-dependent	O
B	O
cell	O
immunopoiesis	O
occurring	O
in	O
FDC	B-cell_type
clusters	O
,	O
p50	B-protein
is	O
mainly	O
related	O
to	O
FDC	B-cell_type
with	O
a	O
massive	O
overexpression	O
in	O
the	O
nuclei	O
,	O
whereas	O
p65	B-protein
is	O
expressed	O
in	O
a	O
scattered	O
manner	O
in	O
the	O
nuclei	O
of	O
lymphocytes	B-cell_type
and	O
c-Rel	O
protein	O
exclusively	O
in	O
the	O
cytoplasm	O
of	O
lymphocytes	B-cell_type
from	O
FDC	B-cell_type
clusters	O
.	O

These	O
results	O
suggested	O
that	O
the	O
two	O
subunits	O
of	O
NF-kappa	B-protein
B	I-protein
and	O
the	O
c-Rel	B-protein
protein	I-protein
have	O
different	O
roles	O
in	O
different	O
cell	O
types	O
during	O
B	O
cell	O
immunopoiesis	O
.	O

Cloning	O
and	O
characterization	O
of	O
NF-ATc	B-protein
and	O
NF-ATp	B-protein
:	O
the	O
cytoplasmic	O
components	O
of	O
NF-AT	B-protein
.	O

Present	O
evidence	O
indicates	O
a	O
pathway	O
of	O
signal	O
transmission	O
in	O
T	B-cell_type
cells	I-cell_type
that	O
is	O
outlined	O
in	O
figure	O
1	O
.	O

The	O
elevation	O
in	O
intracellular	O
calcium	O
that	O
is	O
induced	O
by	O
interactions	O
at	O
the	O
antigen	B-protein
receptor	I-protein
leads	O
to	O
the	O
activation	O
of	O
the	O
calcium-dependent	B-protein
phosphatase	I-protein
calcineurin	B-protein
.	O

This	O
in	O
turn	O
leads	O
to	O
the	O
nuclear	O
association	O
of	O
the	O
cytosolic	B-protein
component	I-protein
of	O
NF-ATc	B-protein
.	O

The	O
activation	O
of	O
calcineurin	B-protein
and	O
the	O
nuclear	O
import	O
of	O
NF-ATc	B-protein
can	O
both	O
be	O
blocked	O
by	O
cyclosporin	O
A	O
or	O
FK506	O
in	O
complex	O
with	O
their	O
respective	O
immunophilins	B-protein
.	O

Once	O
in	O
the	O
nucleus	O
,	O
NF-ATc	B-protein
interacts	O
with	O
NF-ATn	B-protein
to	O
form	O
an	O
active	B-protein
transcriptional	I-protein
complex	I-protein
.	O

NF-ATn	B-protein
is	O
a	O
ubiquitous	O
protein	O
,	O
can	O
be	O
synthesized	O
in	O
response	O
to	O
PMA	O
,	O
and	O
has	O
many	O
similarities	O
to	O
AP-1	B-protein
.	O

The	O
mechanism	O
by	O
which	O
NF-ATc	B-protein
enters	O
the	O
nucleus	O
is	O
unknown	O
,	O
and	O
although	O
it	O
appears	O
to	O
require	O
calcineurin	B-protein
,	O
NF-ATc	B-protein
has	O
not	O
yet	O
been	O
shown	O
to	O
be	O
an	O
in	O
vivo	O
substrate	O
of	O
calcineurin	B-protein
.	O

Alternative	O
mechanisms	O
include	O
the	O
possibility	O
that	O
NF-ATc	B-protein
operates	O
on	O
some	O
cytoplasmic	B-protein
anchor	I-protein
or	O
that	O
other	O
proteins	O
that	O
are	O
controlled	O
by	O
calcineurin	B-protein
carry	O
out	O
the	O
nuclear	O
import	O
of	O
NF-ATc	B-protein
.	O

Although	O
NF-ATp	B-protein
copurifies	O
with	O
NF-ATc	B-protein
,	O
there	O
is	O
as	O
yet	O
no	O
understanding	O
of	O
how	O
NF-ATp	B-protein
is	O
functioning	O
in	O
vivo	O
.	O

Now	O
that	O
these	O
proteins	O
are	O
purified	O
and	O
cloned	O
,	O
the	O
major	O
goals	O
will	O
be	O
to	O
understand	O
their	O
role	O
and	O
the	O
roles	O
of	O
other	O
family	O
members	O
in	O
thymic	O
development	O
.	O

Induction	O
of	O
vascular	B-protein
cell	I-protein
adhesion	I-protein
molecule-1	I-protein
by	O
low-density	B-protein
lipoprotein	I-protein
.	O

Low-density	B-protein
lipoprotein	I-protein
(	O
LDL	B-protein
)	O
is	O
a	O
well-established	O
risk	O
factor	O
for	O
atherosclerosis	O
.	O

When	O
endothelial	O
cells	O
are	O
incubated	O
with	O
this	O
lipoprotein	O
in	O
pathophysiologic	O
amounts	O
,	O
the	O
cells	O
are	O
activated	O
.	O

Among	O
the	O
documented	O
cellular	O
responses	O
to	O
LDL	B-protein
is	O
increased	O
recruitment	O
of	O
monocytes	B-cell_type
,	O
which	O
are	O
believed	O
to	O
play	O
a	O
major	O
role	O
in	O
promoting	O
intimal	O
plaque	O
formation	O
.	O

The	O
findings	O
presented	O
here	O
link	O
an	O
atheogenic	B-protein
lipoprotein	I-protein
,	O
LDL	B-protein
,	O
with	O
the	O
induction	O
of	O
an	O
adhesion	O
molecule	O
important	O
in	O
atherogenesis	O
Human	O
LDL	B-protein
induces	O
the	O
vascular	B-protein
cell	I-protein
adhesion	I-protein
molecule-1	I-protein
(	O
VCAM-1	B-protein
)	O
transcriptionally	O
with	O
an	O
increase	O
in	O
mRNA	O
levels	O
through	O
activation	O
of	O
the	O
VCAM	B-DNA
promoter	I-DNA
.	O

This	O
effect	O
is	O
blocked	O
by	O
anti-VCAM	B-protein
antibodies	I-protein
.	O

After	O
a	O
2-day	O
incubation	O
in	O
LDL	B-protein
,	O
the	O
binding	O
of	O
NF-kappa	B-protein
B	I-protein
,	O
which	O
is	O
believed	O
to	O
be	O
a	O
key	O
oxidative-stress	O
sensor	O
for	O
VCAM	B-protein
regulation	O
,	O
remains	O
at	O
basal	O
level	O
.	O

In	O
contrast	O
,	O
the	O
binding	O
activities	O
of	O
AP-1	B-protein
and	O
GATA	B-protein
,	O
on	O
the	O
other	O
hand	O
,	O
are	O
increased	O
by	O
LDL	B-protein
.	O

Thus	O
,	O
a	O
component	O
of	O
LDL	B-protein
-enhanced	O
endothelial	O
recruitment	O
of	O
monocytes	B-cell_type
is	O
attributed	O
to	O
VCAM-1	B-protein
expression	O
,	O
which	O
appears	O
to	O
be	O
mediated	O
through	O
AP-1	B-protein
and	O
GATA	B-protein
.	O

These	O
data	O
identify	O
LDL	B-protein
as	O
a	O
VCAM	B-protein
-inducer	O
possibly	O
distinct	O
from	O
cytokines	B-protein
and	O
endotoxin	B-protein
.	O

Involvement	O
of	O
nuclear	B-protein
factor-kappa	I-protein
B	I-protein
activation	O
in	O
IgE	B-protein
synthesis	O
in	O
human	B-cell_type
B	I-cell_type
cells	I-cell_type
.	O

Nuclear	B-protein
factor-kappa	I-protein
B	I-protein
(	O
NF-kappa	B-protein
B	I-protein
)	O
is	O
a	O
transcription	O
factor	O
that	O
binds	O
to	O
the	O
consensus	B-DNA
DNA	I-DNA
sequence	I-DNA
in	O
the	O
cis-acting	B-DNA
elements	I-DNA
of	O
various	B-DNA
genes	I-DNA
.	O

Although	O
NF-kappa	B-protein
B	I-protein
activates	O
the	O
expression	O
of	O
many	O
genes	O
involved	O
in	O
immune	O
and	O
inflammatory	O
responses	O
,	O
little	O
is	O
known	O
about	O
the	O
role	O
of	O
NF-kappa	B-protein
B	I-protein
activation	O
in	O
the	O
induction	O
of	O
IgE	O
synthesis	O
in	O
human	B-cell_type
B	I-cell_type
cells	I-cell_type
.	O

Therefore	O
we	O
first	O
examined	O
the	O
participation	O
of	O
NF-kappa	B-protein
B	I-protein
in	O
germline	B-cell_line
C	I-cell_line
epsilon	I-cell_line
transcription	O
in	O
a	O
human	B-cell_line
Burkitt	I-cell_line
lymphoma	I-cell_line
B	I-cell_line
cell	I-cell_line
line	I-cell_line
,	O
DND39	B-cell_line
.	O

Stimulation	O
of	O
DND39	B-cell_line
cells	I-cell_line
with	O
IL-4	B-protein
or	O
anti-CD40	B-protein
monoclonal	I-protein
antibody	I-protein
(	O
mAb	B-protein
)	O
activated	O
phosphatidylinositol	B-protein
3-kinase	I-protein
and	O
subsequently	O
induced	O
nuclear	O
expression	O
of	O
NF-kappa	B-protein
B	I-protein
,	O
which	O
was	O
identified	O
by	O
electrophoretic	O
mobility	O
shift	O
assays	O
.	O

n-Acetyl-L-cysteine	O
(	O
NAC	O
)	O
,	O
a	O
potent	O
antioxidant	O
,	O
blocked	O
NF-kappa	B-protein
B	I-protein
activation	O
caused	O
by	O
IL-4	B-protein
and	O
by	O
anti-CD40	B-protein
mAb	I-protein
.	O

Although	O
inhibition	O
of	O
IL-4-driven	B-cell_line
germline	I-cell_line
C	I-cell_line
epsilon	I-cell_line
transcription	O
by	O
NAC	O
was	O
not	O
sufficient	O
,	O
the	O
agent	O
remarkably	O
diminished	O
anti-CD40	B-protein
mAb	I-protein
-mediated	O
up-regulation	O
of	O
germline	B-DNA
C	O
epsilon	O
transcription	O
.	O

Second	O
,	O
we	O
studied	O
the	O
effect	O
of	O
NAC	O
on	O
IgE	B-protein
synthesis	O
in	O
human	O
normal	O
B	O
cells	O
costimulated	O
with	O
IL-4	B-protein
and	O
anti-CD40	B-protein
mAb	I-protein
.	O

NAC	O
was	O
effective	O
in	O
inhibiting	O
mature	O
C	O
epsilon	O
transcription	O
and	O
IgE	B-protein
synthesis	O
in	O
the	O
T	O
cell-independent	O
culture	O
system	O
.	O

However	O
,	O
NAC	O
did	O
not	O
significantly	O
affect	O
the	O
spontaneous	O
production	O
of	O
IgE	B-protein
by	O
atopic	B-cell_type
B	I-cell_type
cells	I-cell_type
.	O

These	O
results	O
indicate	O
that	O
NF-kappa	B-protein
B	I-protein
activity	O
is	O
commonly	O
inducible	O
in	O
DND39	B-cell_line
cells	I-cell_line
by	O
IL-4	B-protein
and	O
anti-CD40	B-protein
mAb	I-protein
and	O
suggest	O
that	O
NF-kappa	B-protein
B	I-protein
sensitive	O
to	O
NAC	O
may	O
play	O
a	O
role	O
in	O
regulating	O
IgE	B-protein
synthesis	O
in	O
B	B-cell_type
cells	I-cell_type
.	O

Prostaglandin	O
E2	O
induction	O
of	O
binding	O
activity	O
to	O
CRE	B-DNA
and	O
AP-2	B-DNA
elements	I-DNA
in	O
human	B-cell_type
T	I-cell_type
lymphocytes	I-cell_type
.	O

Prostaglandins	O
of	O
the	O
E	O
series	O
are	O
immunomodulatory	O
agents	O
which	O
exert	O
inhibitory	O
as	O
well	O
as	O
stimulatory	O
effects	O
on	O
a	O
variety	O
of	O
immune	O
responses	O
.	O

Since	O
it	O
is	O
known	O
that	O
PGE2	O
is	O
able	O
to	O
increase	O
cAMP	O
levels	O
,	O
we	O
investigated	O
whether	O
it	O
can	O
affect	O
gene	O
expression	O
through	O
the	O
activation	O
of	O
the	O
transcription	B-protein
factors	I-protein
which	O
bind	O
enhancer	O
elements	O
in	O
the	O
promoter	O
regions	O
of	O
cAMP-regulated	B-DNA
genes	I-DNA
.	O

Using	O
electrophoretic	O
mobility	O
shift	O
assay	O
,	O
we	O
demonstrated	O
that	O
a	O
short	O
treatment	O
of	O
human	B-cell_type
T	I-cell_type
lymphocytes	I-cell_type
with	O
PGE2	O
induces	O
specific	O
binding	O
activity	O
to	O
CRE	B-DNA
and	O
AP-2	B-DNA
,	O
but	O
not	O
AP-1	B-DNA
,	I-DNA
DNA	I-DNA
elements	I-DNA
.	O

Since	O
the	O
okadaic	O
acid	O
,	O
a	O
potent	O
protein	O
phosphatase	O
inhibitor	O
,	O
prolongs	O
the	O
induction	O
of	O
the	O
binding	O
activity	O
,	O
phosphorylation	O
events	O
are	O
likely	O
to	O
occur	O
.	O

This	O
activity	O
seems	O
to	O
be	O
due	O
to	O
increased	O
cAMP	O
levels	O
because	O
forskolin	O
and	O
IBMX	O
mimic	O
the	O
effects	O
of	O
PGE2	O
.	O

More	O
interestingly	O
,	O
transfection	O
experiments	O
with	O
CRE-CAT	B-DNA
plasmide	I-DNA
show	O
that	O
PGE2	O
activates	O
the	O
transcription	O
of	O
a	O
CRE-containing	B-DNA
promoter	I-DNA
.	O

These	O
data	O
support	O
the	O
positive	O
role	O
for	O
PGE2	O
on	O
some	O
immune	O
functions	O
.	O

Nasal	B-cell_type
NK-	I-cell_type
and	I-cell_type
T-cell	I-cell_type
lymphomas	I-cell_type
share	O
the	O
same	O
type	O
of	O
Epstein-Barr	O
virus	O
latency	O
as	O
nasopharyngeal	O
carcinoma	O
and	O
Hodgkin	O
's	O
disease	O
.	O

Nasal	B-cell_type
T/NK-cell	I-cell_type
lymphomas	I-cell_type
can	O
be	O
further	O
separated	O
into	O
those	O
of	O
natural	B-cell_type
killer	I-cell_type
(	I-cell_type
NK	I-cell_type
)	I-cell_type
cell	I-cell_type
lineage	I-cell_type
or	O
of	O
T-cell	B-cell_type
lineage	I-cell_type
,	O
with	O
differences	O
in	O
cellular	O
phenotype	O
,	O
T-cell	B-DNA
receptor	I-DNA
(	I-DNA
TcR	I-DNA
)	I-DNA
gene	I-DNA
rearrangement	O
and	O
TcR	O
transcript	O
expression	O
.	O

Both	O
NK-	B-cell_type
and	I-cell_type
T-cell	I-cell_type
subtypes	I-cell_type
are	O
closely	O
associated	O
with	O
Epstein-Barr	O
virus	O
(	O
EBV	O
)	O
.	O

In	O
this	O
study	O
,	O
EBV	B-DNA
gene	I-DNA
expression	O
was	O
determined	O
in	O
23	O
cases	O
of	O
nasal	O
lymphoma	O
(	O
NL	O
)	O
by	O
in	O
situ	O
hybridisation	O
(	O
ISH	O
)	O
,	O
reverse	B-protein
transcriptase	I-protein
-polymerase	O
chain	O
reaction	O
(	O
RT-PCR	O
)	O
and	O
immunohistochemistry	O
(	O
IH	O
)	O
.	O

Of	O
the	O
23	O
cases	O
,	O
19	O
were	O
classified	O
as	O
NK-cell	O
and	O
4	O
as	O
T-cell	O
tumours	O
.	O

ISH	O
for	O
EBV-encoded	B-RNA
small	I-RNA
non-polyadenylated	I-RNA
RNAs	I-RNA
showed	O
that	O
all	O
cases	O
,	O
whether	O
NK	O
or	O
T	O
,	O
harboured	O
EBV	O
in	O
virtually	O
all	O
tumour	B-cell_type
cells	I-cell_type
.	O

RT-PCR	O
demonstrated	O
that	O
NL	B-cell_type
of	O
both	O
subtypes	O
expressed	O
EBNAI	B-protein
of	O
the	O
QUK	O
splice	O
pattern	O
,	O
the	O
latent	B-protein
membrane	I-protein
proteins	I-protein
,	O
LMP1	B-protein
and	I-protein
2	I-protein
and	O
the	O
BamHI	B-RNA
A	I-RNA
rightward	I-RNA
transcripts	I-RNA
in	O
the	O
absence	O
of	O
EBNA2	B-RNA
mRNAs	I-RNA
,	O
compatible	O
with	O
the	O
latency	O
type	O
II	O
pattern	O
.	O

In	O
addition	O
,	O
analysis	O
of	O
EBV	O
protein	O
expression	O
by	O
IH	O
revealed	O
a	O
heterogeneous	O
pattern	O
of	O
EBV	B-DNA
gene	I-DNA
expression	O
at	O
the	O
single-cell	O
level	O
consisting	O
of	O
both	O
LMP1+	B-cell_type
and	I-cell_type
LMP1-	I-cell_type
tumour	I-cell_type
cells	I-cell_type
,	O
suggesting	O
a	O
mixture	O
of	O
latency	O
I	O
and	O
II	O
.	O

Although	O
2	O
early	B-protein
lytic	I-protein
transcripts	I-protein
,	O
BZLF1	B-protein
and	O
BHRF1	B-protein
,	O
were	O
also	O
detected	O
in	O
13	O
and	O
10	O
cases	O
,	O
respectively	O
,	O
the	O
lack	O
of	O
ZEBRA	B-protein
staining	O
in	O
any	O
case	O
indicates	O
that	O
these	O
lytic	O
transcripts	O
are	O
most	O
likely	O
expressed	O
by	O
rare	O
cells	O
in	O
the	O
biopsies	O
entering	O
lytic	O
cycle	O
.	O

The	O
viral	O
transcriptional	O
pattern	O
similar	O
to	O
that	O
of	O
nasopharyngeal	O
carcinoma	O
and	O
Hodgkin	O
's	O
disease	O
suggests	O
that	O
EBV	O
can	O
exploit	O
common	O
regulatory	O
mechanisms	O
for	O
gene	O
transcription	O
in	O
diverse	O
host	O
cell	O
types	O
.	O

Down-regulation	O
of	O
immunogenic	B-protein
proteins	I-protein
(	O
EBNA2-EBNA6	B-protein
)	O
in	O
nasal	O
lymphoma	O
may	O
enable	O
tumour	B-cell_type
cells	I-cell_type
to	O
evade	O
host	O
cytotoxic	O
T-cell	O
surveillance	O
.	O

Potent	O
gene	O
regulatory	O
and	O
antiproliferative	O
activities	O
of	O
20-methyl	O
analogues	O
of	O
1	O
,	O
25	O
dihydroxyvitamin	O
D3	O
.	O

The	O
biological	O
active	O
form	O
of	O
vitamin	O
D3	O
,	O
1	O
,	O
25-dihydroxyvitamin	O
D3	O
(	O
VD	O
)	O
,	O
regulates	O
cellular	O
growth	O
and	O
differentiation	O
.	O

This	O
provides	O
the	O
hormone	O
with	O
an	O
interesting	O
therapeutic	O
potential	O
.	O

However	O
,	O
hypercalcemia	O
is	O
a	O
side	O
effect	O
,	O
which	O
is	O
caused	O
by	O
VD	O
's	O
classical	O
action	O
,	O
the	O
regulation	O
of	O
calcium	O
homeostasis	O
.	O

This	O
made	O
the	O
need	O
for	O
VD	O
analogues	O
with	O
selectively	O
increased	O
cell	O
regulatory	O
properties	O
.	O

Studies	O
with	O
20-epi	O
analogues	O
pointed	O
out	O
the	O
importance	O
of	O
the	O
carbon-20	O
position	O
and	O
led	O
to	O
the	O
development	O
of	O
20-methyl	O
derivatives	O
of	O
VD	O
.	O

In	O
this	O
report	O
the	O
biological	O
properties	O
of	O
the	O
compounds	O
ZK161422	O
and	O
ZK157202	O
,	O
which	O
are	O
20-methyl-	O
and	O
20-methyl-23-eneanalogues	O
,	O
respectively	O
,	O
have	O
been	O
analyzed	O
in	O
comparison	O
with	O
VD	O
.	O

Both	O
compounds	O
show	O
about	O
2-fold	O
lower	O
affinity	O
to	O
the	O
VD	O
receptor	O
(	O
VDR	O
)	O
than	O
VD	O
.	O

However	O
,	O
compared	O
to	O
VD	O
,	O
their	O
antiproliferative	O
effect	O
is	O
up	O
to	O
30-fold	O
higher	O
on	O
human	B-cell_type
peripheral	I-cell_type
blood	I-cell_type
mononuclear	I-cell_type
cells	I-cell_type
and	O
even	O
up	O
to	O
300-fold	O
higher	O
on	O
human	B-cell_line
breast	I-cell_line
cancer	I-cell_line
MCF-7	I-cell_line
cells	I-cell_line
.	O

Whereas	O
the	O
hypercalcemic	O
effect	O
for	O
ZK157202	O
is	O
also	O
increased	O
10-fold	O
,	O
ZK161422	O
has	O
the	O
same	O
calcium-mobilizing	O
potency	O
as	O
VD	O
.	O

Moreover	O
,	O
ZK161422	O
,	O
but	O
not	O
ZK157202	O
,	O
showed	O
preference	O
for	O
gene	O
activation	O
from	O
a	O
promoter	B-DNA
carrying	O
a	O
VD	B-DNA
response	I-DNA
element	I-DNA
with	O
a	O
palindromic	O
arrangement	O
of	O
two	O
hexameric	B-DNA
receptor	I-DNA
binding	I-DNA
sites	I-DNA
spaced	O
by	O
9	O
nucleotides	O
(	O
IP9	O
)	O
rather	O
than	O
for	O
activation	O
from	O
a	O
response	B-DNA
element	I-DNA
formed	O
by	O
a	O
direct	O
repeat	O
spaced	O
by	O
3	O
nucleotides	O
(	O
DR3	O
)	O
.	O

This	O
observation	O
supports	O
a	O
model	O
,	O
in	O
which	O
promoter	O
selectivity	O
reflects	O
the	O
selectively	O
increased	O
antiproliferative	O
effect	O
of	O
VD	O
analogues	O
.	O

Calcium-dependent	O
immediate-early	B-DNA
gene	I-DNA
induction	O
in	O
lymphocytes	B-cell_type
is	O
negatively	O
regulated	O
by	O
p21Ha-ras	B-protein
.	O

The	O
induction	O
of	O
immediate-early	B-DNA
(	I-DNA
IE	I-DNA
)	I-DNA
response	I-DNA
genes	I-DNA
,	O
such	O
as	O
egr-1	B-DNA
,	O
c-fos	B-DNA
,	O
and	O
c-jun	B-DNA
,	O
occurs	O
rapidly	O
after	O
the	O
activation	O
of	O
T	B-cell_type
lymphocytes	I-cell_type
.	O

The	O
process	O
of	O
activation	O
involves	O
calcium	O
mobilization	O
,	O
activation	O
of	O
protein	B-protein
kinase	I-protein
C	I-protein
(	O
PKC	B-protein
)	O
,	O
and	O
phosphorylation	O
of	O
tyrosine	B-protein
kinases	I-protein
.	O

p21	B-protein
(	I-protein
ras	I-protein
)	I-protein
,	O
a	O
guanine	B-protein
nucleotide	I-protein
binding	I-protein
factor	I-protein
,	O
mediates	O
T-cell	O
signal	O
transduction	O
through	O
PKC	B-protein
-dependent	O
and	O
PKC	B-protein
-independent	O
pathways	O
.	O

The	O
involvement	O
of	O
p21	B-protein
(	I-protein
ras	I-protein
)	I-protein
in	O
the	O
regulation	O
of	O
calcium-dependent	O
signals	O
has	O
been	O
suggested	O
through	O
analysis	O
of	O
its	O
role	O
in	O
the	O
activation	O
of	O
NF-AT	B-protein
.	O

We	O
have	O
investigated	O
the	O
inductions	O
of	O
the	O
IE	B-DNA
genes	I-DNA
in	O
response	O
to	O
calcium	O
signals	O
in	O
Jurkat	B-cell_line
cells	I-cell_line
(	O
in	O
the	O
presence	O
of	O
activated	O
p21	B-protein
(	I-protein
ras	I-protein
)	I-protein
)	O
and	O
their	O
correlated	O
consequences	O
.	O

The	O
expression	O
of	O
activated	O
p21	B-protein
(	I-protein
ras	I-protein
)	I-protein
negatively	O
regulated	O
the	O
induction	O
of	O
IE	B-DNA
genes	I-DNA
by	O
calcium	O
ionophore	O
.	O

This	O
inhibition	O
of	O
calcium-activated	O
IE	B-DNA
gene	I-DNA
induction	O
was	O
reversed	O
by	O
treatment	O
with	O
cyclosporin	O
A	O
,	O
suggesting	O
the	O
involvement	O
of	O
calcineurin	B-protein
in	O
this	O
regulation	O
.	O

A	O
later	O
result	O
of	O
inhibition	O
of	O
this	O
activation	O
pathway	O
by	O
p21	B-protein
(	I-protein
ras	I-protein
)	I-protein
was	O
down-regulation	O
of	O
the	O
activity	O
of	O
the	O
transcription	B-protein
factor	I-protein
AP-1	B-protein
and	O
subsequent	O
coordinate	O
reductions	O
in	O
IL-2	B-DNA
gene	I-DNA
expression	O
and	O
protein	O
production	O
.	O

These	O
results	O
suggest	O
that	O
p2l	B-protein
(	I-protein
ras	I-protein
)	I-protein
is	O
an	O
essential	O
mediator	O
in	O
generating	O
not	O
only	O
positive	O
but	O
also	O
negative	O
modulatory	O
mechanisms	O
controlling	O
the	O
competence	O
of	O
T	B-cell_type
cells	I-cell_type
in	O
response	O
to	O
inductive	O
stimulations	O
.	O

Calcineurin	B-protein
acts	O
in	O
synergy	O
with	O
PMA	O
to	O
inactivate	O
I	B-protein
kappa	I-protein
B/MAD3	I-protein
,	O
an	O
inhibitor	O
of	O
NF-kappa	B-protein
B	I-protein
.	O

The	O
interleukin-2	B-DNA
(	I-DNA
IL-2	I-DNA
)	I-DNA
promoter	I-DNA
consists	O
of	O
several	O
independent	O
T	B-DNA
cell	I-DNA
receptor	I-DNA
(	I-DNA
TcR	I-DNA
)	I-DNA
responsive	I-DNA
elements	I-DNA
.	O

The	O
induction	O
of	O
promoters	B-DNA
dependent	O
on	O
these	O
elements	O
is	O
inhibitable	O
by	O
the	O
immunosuppressants	O
cyclosporin	O
A	O
(	O
CsA	O
)	O
and	O
tacrolimus	O
(	O
FK-506	O
)	O
.	O

Calcineurin	B-protein
,	O
a	O
Ca2+/calmodulin-dependent	B-protein
protein	I-protein
phosphatase	I-protein
,	O
is	O
the	O
FK-506	O
-and	O
CsA-sensitive	O
enzyme	O
required	O
for	O
TcR	O
mediated	O
activation	O
of	O
the	O
IL-2	B-DNA
promoter	I-DNA
.	O

We	O
report	O
that	O
a	O
constitutively	O
active	O
form	O
of	O
calcineurin	B-protein
partially	O
substitutes	O
for	O
the	O
Ca2+	O
co-stimulus	O
required	O
to	O
activate	O
the	O
IL-2	B-DNA
promoter	I-DNA
elements	I-DNA
IL-2A	B-DNA
(	O
which	O
binds	O
the	O
factors	O
OAP	B-protein
and	O
Oct-1	B-protein
)	O
and	O
IL-2E	B-DNA
(	O
which	O
binds	O
NF-AT	B-protein
)	O
,	O
and	O
completely	O
substitutes	O
for	O
the	O
Ca2+	O
co-stimulus	O
required	O
to	O
stimulate	O
an	O
NF-kappa	B-protein
B	I-protein
-dependent	O
element	O
.	O

Calcineurin	B-protein
stimulates	O
the	O
NF-kappa	B-DNA
B	I-DNA
element	I-DNA
by	O
enhancing	O
inactivation	O
of	O
I	B-protein
kappa	I-protein
B/MAD3	I-protein
,	O
an	O
inhibitor	O
of	O
NF-kappa	B-protein
B	I-protein
,	O
thereby	O
increasing	O
the	O
amount	O
of	O
nuclear	O
NF-kappa	B-protein
B	I-protein
DNA	O
binding	O
activity	O
.	O

These	O
data	O
provide	O
the	O
first	O
demonstration	O
in	O
vivo	O
that	O
activation	O
of	O
a	O
protein	B-protein
phosphatase	I-protein
can	O
inactivate	O
I	B-protein
kappa	I-protein
B	I-protein
,	O
and	O
suggest	O
one	O
possible	O
explanation	O
for	O
mechanism-based	O
toxicities	O
associated	O
with	O
FK-506	O
and	O
CsA	O
by	O
demonstrating	O
that	O
these	O
drugs	O
can	O
inhibit	O
the	O
calcineurin	B-protein
-dependent	O
activation	O
of	O
a	O
virtually	O
ubiquitous	B-protein
transcription	I-protein
factor	I-protein
.	O

Detection	O
of	O
minimal	O
residual	O
disease	O
in	O
a	O
patient	O
with	O
acute	O
promyelocytic	O
leukemia	O
by	O
RT-PCR	O
:	O
necessity	O
of	O
chemotherapy	O
following	O
ATRA	O
therapy	O
.	O

The	O
PML/RAR	B-DNA
alpha	I-DNA
fusion	I-DNA
gene	I-DNA
resulting	O
from	O
the	O
t	B-DNA
(	I-DNA
15	I-DNA
;	I-DNA
17	I-DNA
)	I-DNA
translocation	I-DNA
is	O
a	O
specific	O
marker	O
for	O
acute	O
promyelocytic	O
leukemia	O
(	O
APL	O
)	O
.	O

We	O
examined	O
bone	O
marrow	O
cells	O
by	O
reverse	O
transcriptase-polymerase	O
chain	O
reaction	O
(	O
RT-PCR	O
)	O
to	O
detect	O
residual	O
PML/RAR	B-cell_type
alpha	I-cell_type
mRNA-containing	I-cell_type
cells	I-cell_type
following	O
treatment	O
with	O
all-trans	O
retinoic	O
acid	O
(	O
ATRA	O
)	O
and	O
cytotoxic	O
chemotherapy	O
in	O
a	O
patient	O
with	O
APL	O
.	O

This	O
RT-PCR	O
assay	O
can	O
detect	O
one	O
leukemic	B-cell_type
cell	I-cell_type
in	O
10	O
(	O
2	O
)	O
normal	B-cell_type
cells	I-cell_type
in	O
vitro	O
.	O

We	O
show	O
that	O
PML/RAR	B-RNA
alpha	I-RNA
mRNA	I-RNA
was	O
still	O
detectable	O
despite	O
clinical	O
remission	O
following	O
ATRA	O
treatment	O
,	O
but	O
undetectable	O
following	O
consolidation	O
with	O
chemotherapy	O
.	O

These	O
data	O
show	O
that	O
this	O
technique	O
is	O
useful	O
for	O
the	O
identification	O
of	O
minimal	O
residual	O
disease	O
in	O
patients	O
with	O
APL	O
and	O
that	O
cytotoxic	O
chemotherapy	O
following	O
ATRA	O
therapy	O
is	O
required	O
for	O
the	O
elimination	O
of	O
APL	B-cell_type
cells	I-cell_type
.	O

Glucocorticoid-mediated	O
inhibition	O
of	O
interleukin-2	O
receptor	O
alpha	O
and	O
-beta	O
subunit	O
expression	O
by	O
human	O
T	O
cells	O
.	O

To	O
determine	O
the	O
mechanism	O
of	O
glucocorticoid	O
(	O
GC	O
)	O
-mediated	O
inhibition	O
of	O
T	O
cell	O
functions	O
,	O
the	O
effect	O
of	O
dexamethasone	O
(	O
DM	O
)	O
on	O
T	B-cell_type
cell	I-cell_type
proliferation	O
and	O
interleukin-2	B-protein
receptor	I-protein
(	O
IL-2R	B-protein
)	O
generation	O
were	O
studied	O
.	O

Dexamethasone	O
inhibited	O
IL-2	B-protein
-induced	O
T	B-cell_type
cell	I-cell_type
proliferation	O
by	O
30	O
%	O
-88	O
%	O
,	O
relative	O
to	O
its	O
concentration	O
within	O
the	O
cultures	O
.	O

The	O
effect	O
of	O
DM	O
on	O
expression	O
of	O
IL-2R	B-protein
alpha	I-protein
(	O
Tac	B-protein
,	O
p55	B-protein
,	O
CD25	B-protein
)	O
and	O
beta	B-DNA
(	I-DNA
p75	I-DNA
)	I-DNA
genes	I-DNA
in	O
activated	B-cell_type
T	I-cell_type
cells	I-cell_type
was	O
examined	O
next	O
.	O

In	O
T	B-cell_type
cells	I-cell_type
stimulated	O
with	O
purified	O
phytohemagglutinin	B-protein
(	O
PHA-p	B-protein
)	O
and	O
4	O
beta-phorbol	O
12-myristate	O
13-acetate	O
(	O
PMA	O
)	O
addition	O
of	O
DM	O
to	O
the	O
cultures	O
resulted	O
in	O
a	O
60	O
%	O
reduction	O
in	O
IL-2R	B-protein
alpha	I-protein
and	O
a	O
30	O
%	O
reduction	O
in	O
IL-2R	B-protein
beta	I-protein
membrane	O
expression	O
compared	O
to	O
T	B-cell_type
cells	I-cell_type
cultured	O
in	O
the	O
absence	O
of	O
DM	O
(	O
p	O
<	O
0.01	O
)	O
.	O

Inhibition	O
of	O
membrane	O
IL-2R	B-protein
alpha	I-protein
and	O
IL-2R	B-protein
beta	I-protein
expression	O
by	O
10	O
(	O
-6	O
)	O
M	O
DM	O
was	O
partially	O
reversible	O
by	O
recombinant	B-protein
human	I-protein
IL-2	I-protein
(	O
rhIL-2	B-protein
)	O
.	O

By	O
Northern	O
blot	O
analysis	O
,	O
DM	O
caused	O
a	O
comparable	O
decrease	O
in	O
IL-2R	B-protein
alpha	I-protein
and	O
in	O
IL-2R	B-protein
beta	I-protein
mRNA	O
levels	O
to	O
membrane	O
receptor	O
expression	O
in	O
mitogen-stimulated	B-cell_type
T	I-cell_type
cells	I-cell_type
.	O

By	O
in	O
vitro	O
transcription	O
assays	O
,	O
DM	O
regulated	O
IL-2R	B-protein
alpha	I-protein
gene	O
expression	O
at	O
a	O
transcriptional	O
level	O
while	O
transcription	O
of	O
IL-2R	B-DNA
beta	I-DNA
gene	I-DNA
was	O
unaffected	O
by	O
DM	O
.	O

The	O
mechanism	O
of	O
action	O
of	O
DM	O
on	O
IL-2R	B-protein
alpha	I-protein
transcription	O
was	O
examined	O
by	O
determining	O
the	O
mRNA	O
levels	O
of	O
the	O
p50	O
subunit	O
of	O
nuclear	O
factor	O
kappa	O
B	O
(	O
NF-kappa	B-protein
B	I-protein
)	O
,	O
a	O
transcription	B-protein
factor	I-protein
that	O
stimulates	O
IL-2R	B-protein
alpha	I-protein
gene	O
expression	O
.	O

The	O
data	O
indicate	O
that	O
10	O
(	O
-6	O
)	O
M	O
DM	O
increased	O
T	B-cell_type
cell	I-cell_type
p50	O
NF-kappa	B-RNA
B	I-RNA
mRNA	I-RNA
levels	O
by	O
four-fold	O
compared	O
to	O
the	O
levels	O
obtained	O
in	O
the	O
absence	O
of	O
DM	O
.	O

Further	O
,	O
the	O
level	O
of	O
nuclear	B-protein
proteins	I-protein
capable	O
of	O
binding	O
to	O
the	O
NF-kappa	B-DNA
B	I-DNA
sites	I-DNA
in	O
activated	B-cell_type
T	I-cell_type
cells	I-cell_type
increased	O
in	O
response	O
to	O
DM	O
.	O

In	O
sum	O
,	O
DM	O
regulates	O
T	B-cell_type
cell	I-cell_type
membrane	O
expression	O
of	O
IL-2R	B-protein
by	O
more	O
than	O
one	O
molecular	O
mechanism	O
.	O

Alteration	O
of	O
structural	O
order	O
of	O
human	O
erythrocyte	O
ghost	O
membrane	O
by	O
glucocorticoids	O
and	O
the	O
influence	O
of	O
the	O
glucocorticoid	O
receptor	O
antagonist	O
RU	O
486	O
.	O

High-dose	O
pulse	O
glucocorticoid	O
therapy	O
has	O
been	O
used	O
successfully	O
in	O
the	O
clinic	O
in	O
severe	O
pathological	O
conditions	O
for	O
about	O
20	O
years	O
.	O

The	O
mode	O
of	O
glucocorticoid	O
action	O
after	O
administration	O
of	O
such	O
megadoses	O
is	O
inexplicable	O
up	O
to	O
now	O
.	O

It	O
is	O
supposed	O
that	O
some	O
effects	O
may	O
be	O
due	O
to	O
membrane	O
alterations	O
.	O

In	O
the	O
present	O
in-vitro	O
experiments	O
the	O
effect	O
of	O
dexamethasone	O
,	O
of	O
further	O
glucocorticoids	O
,	O
and	O
of	O
the	O
glucocorticoid	O
receptor	O
antagonist	O
RU	O
486	O
,	O
on	O
structural	O
order	O
of	O
human	O
erythrocyte	O
ghost	O
membranes	O
was	O
investigated	O
by	O
determining	O
the	O
steady-state	O
fluorescence	O
anisotropy	O
of	O
diphenylhexatriene	O
(	O
DPH	O
)	O
.	O

Dexamethasone	O
was	O
found	O
to	O
induce	O
a	O
significant	O
decrease	O
in	O
membrane	O
structural	O
order	O
at	O
concentrations	O
of	O
about	O
10	O
(	O
-6	O
)	O
M	O
in	O
a	O
concentration-dependent	O
manner	O
.	O

We	O
found	O
a	O
correlation	O
between	O
the	O
uptake	O
of	O
dexamethasone	O
by	O
the	O
ghost	O
membranes	O
and	O
the	O
decrease	O
in	O
the	O
structural	O
order	O
.	O

The	O
other	O
glucocorticoids	O
tested	O
,	O
methylprednisolone	O
and	O
corticosterone	O
,	O
were	O
also	O
effective	O
at	O
concentrations	O
of	O
10	O
(	O
-5	O
)	O
M	O
or	O
greater	O
.	O

We	O
observed	O
no	O
change	O
in	O
membrane	O
structural	O
order	O
with	O
RU	O
486	O
up	O
to	O
a	O
concentration	O
of	O
10	O
(	O
-4	O
)	O
M	O
.	O

However	O
,	O
simultaneous	O
incubation	O
of	O
RU	O
486	O
with	O
dexamethasone	O
caused	O
a	O
distinct	O
interference	O
of	O
RU	O
486	O
with	O
dexamethasone	O
.	O

Thus	O
,	O
the	O
glucocorticoid-induced	O
membrane	O
perturbation	O
,	O
the	O
possibility	O
to	O
inhibit	O
it	O
by	O
RU	O
486	O
,	O
and	O
the	O
inactivity	O
of	O
the	O
structurally	O
related	O
progesterone	O
,	O
refer	O
to	O
relatively	O
specific	O
binding	B-DNA
sites	I-DNA
for	O
the	O
glucocorticoids	O
in	O
the	O
membrane	O
of	O
erythrocyte	B-cell_type
ghosts	I-cell_type
.	O

Mutation	O
of	O
tyrosines	O
492/493	O
in	O
the	O
kinase	B-protein
domain	I-protein
of	O
ZAP-70	B-protein
affects	O
multiple	O
T-cell	B-protein
receptor	I-protein
signaling	O
pathways	O
.	O

The	O
protein-tyrosine	B-protein
kinase	I-protein
ZAP-70	B-protein
is	O
implicated	O
,	O
together	O
with	O
the	O
Src	B-protein
kinase	I-protein
p56	B-protein
(	I-protein
lck	I-protein
)	I-protein
,	O
in	O
controlling	O
the	O
early	O
steps	O
of	O
the	O
T-cell	O
antigen	O
receptor	O
(	O
TCR	B-protein
)	O
signaling	O
cascade	O
.	O

To	O
help	O
elucidate	O
further	O
the	O
mechanism	O
by	O
which	O
ZAP-70	B-protein
regulates	O
these	O
initial	O
events	O
,	O
we	O
used	O
a	O
dominant-negative	O
mutant	O
approach	O
.	O

We	O
overexpressed	O
in	O
the	O
Jurkat	B-cell_line
T-cell	I-cell_line
line	I-cell_line
ZAP-70	B-protein
mutated	O
on	O
Tyr-492	O
and	O
Tyr-493	O
in	O
the	O
putative	O
regulatory	O
loop	O
of	O
its	O
kinase	B-protein
domain	I-protein
.	O

This	O
mutant	O
inhibited	O
TCR	B-protein
-induced	O
activation	O
of	O
nuclear	B-protein
factor	I-protein
of	I-protein
activated	I-protein
T	I-protein
cells	I-protein
by	O
interfering	O
with	O
both	O
intracellular	O
calcium	O
increase	O
and	O
Ras	B-protein
-regulated	O
activation	O
of	O
extracellular	B-protein
signal-regulated	I-protein
kinases	I-protein
.	O

Moreover	O
,	O
TCR	B-protein
-induced	O
phosphorylation	O
of	O
pp36-38	B-protein
,	O
thought	O
to	O
play	O
a	O
role	O
upstream	O
of	O
these	O
pathways	O
,	O
was	O
found	O
to	O
be	O
reduced	O
.	O

In	O
contrast	O
,	O
overexpression	O
of	O
wild-type	B-protein
ZAP-70	I-protein
induced	O
constitutive	O
activation	O
of	O
nuclear	B-protein
factor	I-protein
of	I-protein
activated	I-protein
T	I-protein
cells	I-protein
.	O

The	O
ZAP-70	B-protein
mutant	O
studied	O
here	O
could	O
be	O
phosphorylated	O
on	O
tyrosine	O
when	O
associated	O
to	O
the	O
TCR	B-protein
zeta	I-protein
chain	I-protein
and	O
was	O
able	O
to	O
bind	O
p56	B-protein
(	I-protein
lck	I-protein
)	I-protein
.	O

This	O
result	O
demonstrates	O
that	O
Tyr-492	O
and	O
Tyr-493	O
are	O
not	O
responsible	O
for	O
the	O
Src	O
homology	O
domain	O
2-mediated	O
association	O
of	O
p56	B-protein
(	I-protein
lck	I-protein
)	I-protein
with	O
ZAP-70	B-protein
.	O

Our	O
data	O
are	O
most	O
consistent	O
with	O
a	O
model	O
in	O
which	O
recruitment	O
to	O
the	O
TCR	B-protein
allows	O
ZAP-70	B-protein
autophosphorylation	O
and	O
binding	O
to	O
p56	B-protein
(	I-protein
lck	I-protein
)	I-protein
,	O
which	O
in	O
turn	O
phosphorylates	O
Tyr-492	O
and/or	O
Tyr-493	O
with	O
consequent	O
up-regulation	O
of	O
the	O
ZAP-70	B-protein
kinase	O
activity	O
.	O

ZAP-70	B-protein
will	O
then	O
be	O
able	O
to	O
effectively	O
control	O
phosphorylation	O
of	O
its	O
substrates	O
and	O
lead	O
to	O
gene	O
activation	O
.	O

Effects	O
of	O
glucocorticoids	O
on	O
lymphocyte	O
activation	O
in	O
patients	O
with	O
steroid-sensitive	O
and	O
steroid-resistant	O
asthma	O
.	O

BACKGROUND	O
:	O
Glucocorticoids	O
are	O
important	O
medications	O
used	O
to	O
control	O
the	O
airway	O
inflammation	O
associated	O
with	O
asthma	O
.	O

Synthetic	O
glucocorticoids	O
vary	O
in	O
their	O
binding	O
affinity	O
for	O
the	O
glucocorticoid	O
receptor	O
(	O
GCR	O
)	O
.	O

METHODS	O
:	O
We	O
compared	O
hydrocortisone	O
,	O
beclomethasone	O
dipropionate	O
,	O
triamcinolone	O
acetonide	O
,	O
flunisolide	O
,	O
and	O
budesonide	O
with	O
regard	O
to	O
their	O
capacity	O
to	O
inhibit	O
phytohemagglutinin	B-protein
-induced	O
peripheral	B-cell_type
blood	I-cell_type
mononuclear	I-cell_type
cell	I-cell_type
proliferation	O
from	O
six	O
patients	O
with	O
steroid-sensitive	O
asthma	O
and	O
seven	O
patients	O
with	O
steroid-resistant	O
asthma	O
.	O

Peripheral	O
blood	O
mononuclear	O
cell	O
GCR	B-protein
binding	O
affinities	O
for	O
dexamethasone	O
and	O
budesonide	O
were	O
also	O
determined	O
for	O
both	O
patient	O
groups	O
by	O
using	O
a	O
radioligand	O
binding	O
assay	O
and	O
Scatchard	O
analysis	O
.	O

RESULTS	O
:	O
Dose-dependent	O
inhibition	O
was	O
demonstrated	O
for	O
all	O
glucocorticoids	O
in	O
both	O
patient	O
groups	O
,	O
with	O
the	O
steroid-resistant	O
group	O
requiring	O
approximately	O
2	O
log-fold	O
more	O
glucocorticoids	O
for	O
an	O
equivalent	O
degree	O
of	O
inhibition	O
.	O

The	O
mean	O
concentrations	O
necessary	O
to	O
cause	O
50	O
%	O
inhibition	O
of	O
lymphocyte	O
proliferation	O
(	O
IC50s	O
)	O
for	O
the	O
steroid-sensitive	O
group	O
ranged	O
from	O
2	O
x	O
10	O
(	O
-10	O
)	O
mol/L	O
for	O
budesonide	O
to	O
7	O
x	O
10	O
(	O
-8	O
)	O
mol/L	O
for	O
hydrocortisone	O
,	O
whereas	O
the	O
mean	O
IC50s	O
for	O
the	O
steroid-resistant	O
group	O
ranged	O
from	O
approximately	O
2	O
x	O
10	O
(	O
-8	O
)	O
mol/L	O
for	O
budesonide	O
to	O
greater	O
than	O
10	O
(	O
-6	O
)	O
mol/L	O
for	O
hydrocortisone	O
.	O

In	O
addition	O
,	O
a	O
significant	O
correlation	O
was	O
noted	O
between	O
the	O
degree	O
of	O
inhibition	O
of	O
lymphocyte	O
proliferation	O
(	O
IC50	O
)	O
and	O
the	O
binding	O
affinity	O
of	O
dexamethasone	O
to	O
the	O
GCR	B-protein
.	O

Patients	O
with	O
steroid-resistant	O
asthma	O
have	O
been	O
shown	O
to	O
have	O
a	O
reduced	O
GCR	B-protein
binding	O
affinity	O
.	O

The	O
GCR	B-protein
binding	O
affinity	O
for	O
budesonide	O
was	O
significantly	O
higher	O
in	O
both	O
groups	O
(	O
i.e.	O
,	O
lower	O
dissociation	O
constant	O
)	O
than	O
that	O
obtained	O
for	O
dexamethasone	O
.	O

CONCLUSION	O
:	O
These	O
data	O
suggest	O
that	O
glucocorticoids	O
such	O
as	O
budesonide	O
,	O
by	O
virtue	O
of	O
their	O
high	O
GCR	B-protein
binding	O
affinities	O
and	O
greater	O
ability	O
to	O
suppress	O
lymphocyte	O
proliferation	O
,	O
may	O
therefore	O
be	O
beneficial	O
in	O
the	O
management	O
of	O
difficult-to-control	O
asthma	O
.	O

Characterization	O
of	O
the	O
murine	B-DNA
cyclin-dependent	I-DNA
kinase	I-DNA
inhibitor	I-DNA
gene	I-DNA
p27Kip1	B-DNA
.	O

The	O
cyclin-dependent	B-DNA
kinase	I-DNA
inhibitor	I-DNA
p27Kip1	B-DNA
plays	O
an	O
important	O
role	O
in	O
regulating	O
cell-cycle	O
progression	O
.	O

p27Kip1	B-DNA
directly	O
inhibits	O
the	O
catalytic	O
activity	O
of	O
cyclin/cdks	B-protein
(	I-protein
cyclin-dependent	I-protein
kinase	I-protein
)	I-protein
complexes	I-protein
and/or	O
interferes	O
physically	O
with	O
cyclin/cdks	B-protein
activation	O
by	O
CAK	B-protein
.	O

Interestingly	O
,	O
the	O
expression	O
level	O
of	O
p27Kip1	B-RNA
mRNA	I-RNA
was	O
maximal	O
in	O
resting	B-cell_type
Go	I-cell_type
T-cells	I-cell_type
and	O
rapidly	O
declined	O
following	O
anti-CD3	B-protein
activation	O
.	O

We	O
report	O
here	O
the	O
cloning	O
of	O
p27Kip1	B-DNA
gene	I-DNA
from	O
murine	B-DNA
genomic	I-DNA
DNA	I-DNA
and	O
the	O
functional	O
analysis	O
of	O
the	O
promoter	O
of	O
the	O
p27Kip1	B-DNA
gene	O
.	O

The	O
gene	O
consists	O
of	O
at	O
least	O
three	O
exons	O
and	O
spans	O
more	O
than	O
5.6	B-DNA
kb	I-DNA
of	I-DNA
DNA	I-DNA
.	O

Primer	O
extension	O
and	O
nuclease	O
S1	O
protection	O
analysis	O
revealed	O
two	O
major	O
transcription	B-DNA
initiation	I-DNA
sites	I-DNA
.	O

The	O
promoter	B-DNA
region	I-DNA
lacked	O
a	O
TATA	B-DNA
box	I-DNA
but	O
contained	O
potential	O
binding	O
sites	O
for	O
the	O
transcriptional	B-protein
factors	I-protein
including	O
two	O
Sp1	B-protein
,	O
CRE	B-protein
,	O
Myb	B-protein
and	O
NFkB	B-protein
located	O
at	O
positions	B-DNA
-153	I-DNA
,	I-DNA
-178	I-DNA
,	I-DNA
-286	I-DNA
,	I-DNA
-875	I-DNA
,	I-DNA
and	I-DNA
-1011	I-DNA
,	O
respectively	O
.	O

To	O
analyze	O
the	O
regulatory	O
mechanisms	O
controlling	O
p27Kip1	B-DNA
gene	O
expression	O
,	O
we	O
characterized	O
the	O
5'-flanking	B-DNA
region	I-DNA
from	O
nt	B-DNA
-1609	I-DNA
to	I-DNA
+178	I-DNA
.	O

The	O
-326	B-DNA
to	I-DNA
-615	I-DNA
region	I-DNA
contained	O
positive	B-DNA
regulatory	I-DNA
elements	I-DNA
.	O

Nuclear	B-protein
NF-ATp	I-protein
is	O
a	O
hallmark	O
of	O
unstimulated	B-cell_type
B	I-cell_type
cells	I-cell_type
from	O
B-CLL	O
patients	O
.	O

B	B-cell_type
lymphocytes	I-cell_type
from	O
the	O
peripheral	O
blood	O
of	O
patients	O
with	O
chronic	O
lymphocytic	O
leukaemia	O
(	O
CLL	O
)	O
were	O
analysed	O
for	O
the	O
nuclear	O
presence	O
and	O
DNA	O
binding	O
of	O
a	O
panel	O
of	O
transcription	B-protein
factors	I-protein
which	O
are	O
involved	O
in	O
the	O
gene	O
control	O
of	O
lymphoid	B-cell_type
cells	I-cell_type
.	O

The	O
following	O
transcription	B-protein
factors	I-protein
were	O
studied	O
:	O
the	O
Octamer	B-protein
factors	I-protein
Oct-1	B-protein
and	O
Oct-2	B-protein
,	O
members	O
of	O
the	O
AP-1	B-protein
factor	I-protein
family	I-protein
,	O
NF-AT	B-protein
factors	I-protein
,	O
in	O
particular	O
NF-ATp	B-protein
,	O
and	O
members	O
of	O
the	O
Rel/NF-kB	B-protein
family	I-protein
.	O

We	O
show	O
that	O
the	O
constitutive	O
nuclear	O
translocation	O
of	O
NF-ATp	B-protein
,	O
a	O
member	O
of	O
the	O
growing	O
family	O
of	O
NF-AT	B-protein
factors	I-protein
,	O
is	O
a	O
hallmark	O
of	O
nonstimulated	B-cell_type
B	I-cell_type
cells	I-cell_type
from	O
CLL	O
patients	O
that	O
distinguishes	O
B-CLL	B-cell_type
cells	I-cell_type
from	O
'normal	B-cell_type
'	I-cell_type
B	I-cell_type
lymphocytes	I-cell_type
.	O

Constitutive	O
nuclear	O
appearance	O
was	O
also	O
observed	O
for	O
NF-kB2/p52	O
.	O

Constitutive	O
binding	O
of	O
further	O
factor	B-protein
proteins	I-protein
to	O
DNA	O
,	O
such	O
as	O
JunD	B-protein
,	O
c-Fos	B-protein
and	O
FosB	B-protein
,	O
was	O
detected	O
in	O
several	O
patients	O
whereas	O
the	O
localisation	O
and	O
DNA	O
binding	O
of	O
other	O
factors	O
such	O
as	O
c-Jun	B-protein
,	O
RelA/p65	B-protein
and	O
c-Rel	B-protein
was	O
unaltered	O
.	O

It	O
is	O
remarkable	O
that	O
in	O
B-CLL	B-cell_type
cells	I-cell_type
the	O
nuclear	O
appearance	O
and	O
DNA	O
binding	O
of	O
specific	O
transcription	B-protein
factors	I-protein
is	O
dramatically	O
affected	O
whereas	O
other	O
members	O
of	O
the	O
same	O
factor	B-protein
family	I-protein
remained	O
unaltered	O
in	O
these	O
leukemic	O
cells	O
.	O

It	O
remains	O
to	O
be	O
shown	O
which	O
molecular	O
events	O
lead	O
to	O
the	O
specific	O
'pre-activation	O
'	O
,	O
i.e	O
.	O

constitutive	O
nuclear	O
translocation	O
and	O
DNA	O
binding	O
,	O
of	O
these	O
members	O
of	O
NF-AT	B-protein
,	O
NF-kB	B-protein
and	O
AP-1	B-protein
factor	I-protein
families	I-protein
.	O

Naive	B-cell_type
(	I-cell_type
CD45RA+	I-cell_type
)	I-cell_type
T	I-cell_type
lymphocytes	I-cell_type
are	O
more	O
sensitive	O
to	O
oxidative	O
stress-induced	O
signals	O
than	O
memory	B-cell_type
(	I-cell_type
CD45RO+	I-cell_type
)	I-cell_type
cells	I-cell_type
.	O

Formation	O
of	O
reactive	O
oxygen	O
intermediates	O
(	O
ROI	O
)	O
after	O
oxidative	O
stress	O
has	O
been	O
shown	O
to	O
be	O
an	O
activation	O
signal	O
for	O
T	B-cell_type
lymphocytes	I-cell_type
,	O
e.g.	O
,	O
expression	O
of	O
IL-2	B-protein
and	O
its	O
receptor	B-protein
are	O
induced	O
.	O

These	O
ROI-induced	O
effects	O
can	O
,	O
to	O
a	O
large	O
extent	O
,	O
be	O
attributed	O
to	O
the	O
activation	O
of	O
the	O
transcription	B-protein
factor	I-protein
NF-kappaB	B-protein
.	O

Now	O
we	O
have	O
examined	O
whether	O
naive	B-cell_type
and	I-cell_type
memory	I-cell_type
T	I-cell_type
lymphocytes	I-cell_type
differ	O
in	O
their	O
sensitivity	O
to	O
ROI-mediated	O
signals	O
.	O

When	O
CD45RA+	B-cell_type
(	I-cell_type
naive	I-cell_type
)	I-cell_type
and	O
CD45RO+	B-cell_type
(	I-cell_type
memory	I-cell_type
)	I-cell_type
T	I-cell_type
lymphocytes	I-cell_type
were	O
directly	O
stimulated	O
with	O
H2O2	O
,	O
NF-kappaB	B-protein
nuclear	O
translocation	O
was	O
stronger	O
in	O
naive	B-cell_type
cells	I-cell_type
than	O
in	O
memory	B-cell_type
cells	I-cell_type
and	O
it	O
could	O
be	O
induced	O
with	O
lower	O
doses	O
.	O

The	O
composition	O
of	O
the	O
induced	O
nuclear	B-protein
NF-kappaB	I-protein
(	O
levels	O
of	O
p50	B-protein
and	O
RelA	B-protein
proteins	I-protein
)	O
was	O
similar	O
in	O
these	O
cell	O
types	O
.	O

The	O
magnitude	O
and	O
kinetics	O
of	O
intracellular	O
ROI	O
were	O
similar	O
,	O
suggesting	O
that	O
there	O
were	O
no	O
differences	O
in	O
ROI-forming	O
mechanisms	O
or	O
antioxidative	O
capacities	O
.	O

The	O
probable	O
regulatory	O
point	O
was	O
the	O
cytoplasmic	O
IkappaB	B-protein
inhibitor	O
:	O
in	O
CD45RA+	O
cells	O
,	O
H2O2	O
caused	O
a	O
more	O
profound	O
depression	O
in	O
the	O
levels	O
of	O
IkappaB	B-protein
alpha	I-protein
.	O

These	O
findings	O
indicate	O
that	O
T	B-cell_type
cells	I-cell_type
representing	O
different	O
activation	O
and/or	O
differentiation	O
stages	O
can	O
be	O
differentially	O
responsive	O
to	O
ROI-mediated	O
signals	O
.	O

Rapid	O
shuttling	O
of	O
NF-AT	B-protein
in	O
discrimination	O
of	O
Ca2+	O
signals	O
and	O
immunosuppression	O
.	O

Cells	O
need	O
to	O
distinguish	O
between	O
transient	O
Ca2+	O
signals	O
that	O
induce	O
events	O
such	O
as	O
muscle	O
contraction	O
,	O
secretion	O
,	O
adhesion	O
and	O
synaptic	O
transmission	O
,	O
and	O
sustained	O
Ca2+	O
signals	O
that	O
are	O
involved	O
in	O
cell	O
proliferation	O
and	O
differentiation	O
.	O

The	O
latter	O
class	O
of	O
events	O
is	O
blocked	O
in	O
lymphocytes	B-cell_type
by	O
the	O
immunosuppressive	O
drugs	O
cyclosporin	O
A	O
and	O
FK506	O
,	O
which	O
inhibit	O
calcineurin	B-protein
,	O
a	O
Ca2+-activated	B-protein
serine/threonine	I-protein
phosphatase	I-protein
necessary	O
for	O
the	O
nuclear	O
import	O
of	O
NF-AT	B-protein
transcription	B-protein
factors	I-protein
.	O

Here	O
we	O
report	O
that	O
sustained	O
high	O
concentrations	O
of	O
Ca2+	O
,	O
but	O
not	O
transient	O
pulses	O
,	O
are	O
required	O
to	O
maintain	O
NF-AT	B-protein
transcription	B-protein
factors	I-protein
in	O
the	O
nucleus	O
,	O
where	O
they	O
participate	O
in	O
Ca2+-dependent	O
induction	O
of	O
genes	B-DNA
required	O
for	O
lymphocyte	B-cell_type
activation	O
and	O
proliferation	O
.	O

Furthermore	O
,	O
overexpression	O
and	O
constitutive	O
nuclear	O
localization	O
of	O
NF-AT	B-protein
,	O
but	O
not	O
Jun	B-protein
,	I-protein
Fos	I-protein
,	I-protein
NF-kappaB	I-protein
,	I-protein
Oct	I-protein
or	I-protein
Ets	I-protein
family	I-protein
members	I-protein
,	O
renders	O
the	O
interleukin-2	B-DNA
enhancer	I-DNA
in	O
Jurkat	B-cell_line
T	I-cell_line
lymphocytes	I-cell_line
resistant	O
to	O
FK506	O
and	O
cyclosporin	O
A	O
.	O

Thus	O
a	O
primary	O
effect	O
of	O
these	O
immunosuppressive	O
reagents	O
is	O
to	O
control	O
the	O
subcellular	O
localization	O
of	O
the	O
NF-AT	B-protein
family	O
of	O
transcription	B-protein
factors	I-protein
.	O

Autoregulation	O
of	O
the	O
NF-kappa	B-protein
B	I-protein
transactivator	I-protein
RelA	B-protein
(	O
p65	B-protein
)	O
by	O
multiple	O
cytoplasmic	B-protein
inhibitors	I-protein
containing	O
ankyrin	B-protein
motifs	I-protein
.	O

RelA	B-protein
(	O
p65	B-protein
)	O
functions	O
as	O
the	O
critical	O
transactivating	O
component	O
of	O
the	O
heterodimeric	B-protein
p50-p65	I-protein
NF-kappa	I-protein
B	I-protein
complex	I-protein
and	O
contains	O
a	O
high-affinity	B-protein
binding	I-protein
site	I-protein
for	O
its	O
cytoplasmic	B-protein
inhibitor	I-protein
,	O
I	B-protein
kappa	I-protein
B	I-protein
alpha	I-protein
.	O

After	O
cellular	O
activation	O
,	O
I	B-protein
kappa	I-protein
B	I-protein
alpha	I-protein
is	O
rapidly	O
degraded	O
in	O
concert	O
with	O
the	O
induced	O
nuclear	O
translocation	O
of	O
NF-kappa	B-protein
B	I-protein
.	O

The	O
present	O
study	O
demonstrates	O
that	O
tumor	B-protein
necrosis	I-protein
factor	I-protein
alpha	I-protein
-induced	O
degradation	O
of	O
I	B-protein
kappa	I-protein
B	I-protein
alpha	I-protein
in	O
human	B-cell_type
T	I-cell_type
cells	I-cell_type
is	O
preceded	O
by	O
its	O
rapid	O
phosphorylation	O
in	O
vivo	O
.	O

However	O
,	O
these	O
effects	O
on	O
I	B-protein
kappa	I-protein
B	I-protein
alpha	I-protein
result	O
in	O
nuclear	O
mobilization	O
of	O
only	O
a	O
fraction	O
of	O
the	O
entire	O
cytoplasmic	O
pool	O
of	O
RelA	B-protein
.	O

Subsequent	O
studies	O
have	O
revealed	O
that	O
(	O
i	O
)	O
cytoplasmic	B-protein
RelA	I-protein
is	O
stably	O
associated	O
not	O
only	O
with	O
I	B-protein
kappa	I-protein
B	I-protein
alpha	I-protein
but	O
also	O
with	O
other	O
ankyrin	B-protein
motif-rich	I-protein
proteins	I-protein
including	O
the	O
products	O
of	O
the	O
NF-kappa	B-DNA
B2	I-DNA
(	I-DNA
p100	I-DNA
)	I-DNA
and	I-DNA
NF-kappa	I-DNA
B1	I-DNA
(	I-DNA
p105	I-DNA
)	I-DNA
genes	I-DNA
;	O
(	O
ii	O
)	O
in	O
contrast	O
to	O
RelA	B-protein
-I	B-protein
kappa	I-protein
B	I-protein
alpha	I-protein
,	O
RelA-p100	B-protein
cytoplasmic	I-protein
complexes	I-protein
are	O
not	O
dissociated	O
following	O
tumor	B-protein
necrosis	I-protein
factor	I-protein
alpha	I-protein
activation	O
;	O
(	O
iii	O
)	O
p100	B-protein
functions	O
as	O
a	O
potent	O
inhibitor	O
of	O
RelA	B-protein
-mediated	O
transcription	O
in	O
vivo	O
;	O
(	O
iv	O
)	O
the	O
interaction	O
of	O
RelA	B-protein
and	O
p100	B-protein
involves	O
the	O
conserved	B-protein
Rel	I-protein
homology	I-protein
domain	I-protein
of	O
both	O
proteins	O
but	O
not	O
the	O
nuclear	B-protein
localization	I-protein
signal	I-protein
of	O
RelA	B-protein
,	O
which	O
is	O
required	O
for	O
I	B-protein
kappa	I-protein
B	I-protein
alpha	I-protein
binding	O
;	O
(	O
v	O
)	O
p100	B-protein
inhibition	O
of	O
RelA	B-protein
function	O
requires	O
the	O
C-terminal	B-protein
ankyrin	I-protein
motif	I-protein
domain	I-protein
,	O
which	O
mediates	O
cytoplasmic	O
retention	O
of	O
RelA	B-protein
;	O
and	O
(	O
vi	O
)	O
as	O
observed	O
with	O
I	B-protein
kappa	I-protein
B	I-protein
alpha	I-protein
,	O
nuclear	O
RelA	B-protein
stimulates	O
p100	B-RNA
mRNA	I-RNA
and	O
protein	O
expression	O
.	O

These	O
findings	O
thus	O
reveal	O
the	O
presence	O
of	O
a	O
second	O
inducible	O
autoregulated	O
inhibitory	O
pathway	O
that	O
helps	O
ensure	O
the	O
rapid	O
but	O
transient	O
action	O
of	O
nuclear	B-protein
NF-kappa	I-protein
B	I-protein
.	O

Effects	O
of	O
CD45	B-protein
on	O
NF-kappa	B-protein
B	I-protein
.	O

Implications	O
for	O
replication	O
of	O
HIV-1	O
.	O

Increased	O
levels	O
of	O
replication	O
of	O
the	O
HIV	O
type	O
1	O
are	O
observed	O
after	O
the	O
activation	O
of	O
infected	B-cell_type
T	I-cell_type
cells	I-cell_type
through	O
the	O
TCR	B-protein
.	O

However	O
,	O
anti-	O
CD45	B-protein
antibodies	O
inhibit	O
these	O
effects	O
in	O
cells	O
from	O
infected	O
individuals	O
.	O

In	O
this	O
study	O
,	O
we	O
examined	O
interrelationships	O
between	O
CD45	B-protein
and	O
HIV-1	O
further	O
.	O

We	O
measured	O
effects	O
on	O
the	O
HIV-1	B-DNA
LTR	I-DNA
in	O
T	B-cell_line
cell	I-cell_line
lines	I-cell_line
that	O
were	O
stimulated	O
with	O
antibodies	O
against	O
CD45	B-protein
and	O
in	O
those	O
that	O
lacked	O
the	O
expression	O
of	O
CD45	B-protein
on	O
their	O
surfaces	O
.	O

First	O
,	O
anti-CD45	B-protein
antibodies	I-protein
did	O
not	O
affect	O
basal	O
but	O
decreased	O
activated	O
levels	O
of	O
expression	O
from	O
the	O
HIV-1	B-DNA
LTR	I-DNA
.	O

Second	O
,	O
T	B-cell_type
cells	I-cell_type
,	O
which	O
lack	O
CD45	B-protein
and	O
can	O
not	O
signal	O
via	O
the	O
TCR	B-protein
,	O
supported	O
higher	O
levels	O
of	O
viral	O
replication	O
and	O
gene	O
expression	O
.	O

This	O
was	O
due	O
to	O
the	O
presence	O
of	O
active	O
NF-kappa	B-protein
B	I-protein
complexes	I-protein
in	O
the	O
nucleus	O
of	O
CD45	B-protein
-T	O
cells	O
.	O

Additionally	O
,	O
infected	B-cell_type
T	I-cell_type
cells	I-cell_type
displayed	O
lower	O
levels	O
of	O
CD45	B-protein
on	O
their	O
surfaces	O
.	O

Thus	O
,	O
CD45	B-protein
plays	O
an	O
active	O
role	O
in	O
the	O
physiology	O
of	O
T	B-cell_type
cells	I-cell_type
and	O
in	O
the	O
replication	O
of	O
HIV-1	O
.	O

Calcineurin	B-protein
potentiates	O
activation	O
of	O
the	O
granulocyte-macrophage	B-DNA
colony-stimulating	I-DNA
factor	I-DNA
gene	I-DNA
in	O
T	B-cell_type
cells	I-cell_type
:	O
involvement	O
of	O
the	O
conserved	B-DNA
lymphokine	I-DNA
element	I-DNA
0	I-DNA
.	O

Granulocyte-macrophage	B-protein
colony-stimulating	I-protein
factor	I-protein
(	O
GM-CSF	B-protein
)	O
and	O
interleukin-2	B-protein
(	O
IL-2	B-protein
)	O
are	O
produced	O
by	O
stimulation	O
with	O
phorbol-12-myristate	O
acetate	O
(	O
PMA	O
)	O
and	O
calcium	O
ionophore	O
(	O
A23187	O
)	O
in	O
human	B-cell_line
T	I-cell_line
cell	I-cell_line
leukemia	I-cell_line
Jurkat	I-cell_line
cells	I-cell_line
.	O

The	O
expression	O
of	O
GM-CSF	B-protein
and	O
IL-2	B-protein
is	O
inhibited	O
by	O
immunosuppressive	O
drugs	O
such	O
as	O
cyclosporin	O
A	O
(	O
CsA	O
)	O
and	O
FK506	O
.	O

Earlier	O
studies	O
on	O
the	O
IL-2	B-protein
gene	O
expression	O
showed	O
that	O
overexpression	O
of	O
calcineurin	B-protein
(	O
CN	B-protein
)	O
,	O
a	O
Ca2+/calmodulin-dependent	B-protein
protein	I-protein
phosphatase	I-protein
,	O
can	O
stimulate	O
transcription	O
from	O
the	O
IL-2	B-DNA
promoter	I-DNA
through	O
the	O
NF-AT-binding	B-DNA
site	I-DNA
.	O

In	O
this	O
study	O
,	O
we	O
obtained	O
evidence	O
that	O
transfection	O
of	O
the	O
cDNAs	B-DNA
for	O
CN	B-protein
A	I-protein
(	I-protein
catalytic	I-protein
)	I-protein
and	I-protein
CN	I-protein
B	I-protein
(	I-protein
regulatory	I-protein
)	I-protein
subunits	I-protein
also	O
augments	O
transcription	O
from	O
the	O
GM-CSF	B-DNA
promoter	I-DNA
and	O
recovers	O
the	O
transcription	O
inhibited	O
by	O
CsA	O
.	O

The	O
constitutively	O
active	O
type	O
of	O
the	O
CN	B-protein
A	I-protein
subunit	I-protein
,	O
which	O
lacks	O
the	O
auto-inhibitory	B-protein
and	O
calmodulin-binding	B-protein
domains	I-protein
,	O
acts	O
in	O
synergy	O
with	O
PMA	O
to	O
activate	O
transcription	O
from	O
the	O
GM-CSF	B-DNA
promoter	I-DNA
.	O

We	O
also	O
found	O
that	O
the	O
active	O
CN	B-protein
partially	O
replaces	O
calcium	O
ionophore	O
in	O
synergy	O
with	O
PMA	O
to	O
induce	O
expression	O
of	O
endogenous	O
GM-CSF	B-protein
and	O
IL-2	B-protein
.	O

By	O
multimerizing	O
the	O
regulatory	B-DNA
elements	I-DNA
of	O
the	O
GM-CSF	B-DNA
promoter	I-DNA
,	O
we	O
found	O
that	O
one	O
of	O
the	O
target	B-DNA
sites	I-DNA
for	O
the	O
CN	B-protein
action	O
is	O
the	O
conserved	B-DNA
lymphokine	I-DNA
element	I-DNA
0	I-DNA
(	O
CLE0	B-DNA
)	O
,	O
located	O
at	O
positions	O
between	O
-54	O
and	O
-40	O
.	O

Mobility	O
shift	O
assays	O
showed	O
that	O
the	O
CLE0	B-DNA
sequence	O
has	O
an	O
AP1-binding	B-DNA
site	I-DNA
and	O
is	O
associated	O
with	O
an	O
NF-AT-like	B-protein
factor	I-protein
,	O
termed	O
NF-CLE0	B-protein
gamma	I-protein
.	O

NF-	O
CLE0	B-DNA
gamma	O
binding	O
is	O
induced	O
by	O
PMA/A23187	O
and	O
is	O
inhibited	O
by	O
treatment	O
with	O
CsA	O
.	O

These	O
results	O
suggest	O
that	O
CN	B-protein
is	O
involved	O
in	O
the	O
coordinated	O
induction	O
of	O
the	O
GM-CSF	B-DNA
and	I-DNA
IL-2	I-DNA
genes	I-DNA
and	O
that	O
the	O
CLE0	B-DNA
sequence	I-DNA
of	O
the	O
GM-CSF	B-DNA
gene	I-DNA
is	O
a	O
functional	O
analogue	O
of	O
the	O
NF-AT-binding	B-DNA
site	I-DNA
in	O
the	O
IL-2	B-DNA
promoter	I-DNA
,	O
which	O
mediates	O
signals	O
downstream	O
of	O
T	O
cell	O
activation	O
.	O

Alternate	O
immune	O
system	O
targets	O
for	O
TCDD	O
:	O
lymphocyte	B-cell_type
stem	I-cell_type
cells	I-cell_type
and	O
extrathymic	B-cell_type
T-cell	I-cell_type
development	O
.	O

We	O
here	O
summarize	O
evidence	O
that	O
thymic	O
atrophy	O
induced	O
by	O
2	O
,	O
3	O
,	O
7	O
,	O
8-tetrachlorodibenzo-p-dioxin	O
(	O
TCDD	O
)	O
can	O
be	O
mediated	O
,	O
at	O
least	O
in	O
part	O
,	O
by	O
damage	O
to	O
extrathymic	B-cell_type
T-cell	I-cell_type
precursors	I-cell_type
in	O
bone	O
marrow	O
and	O
fetal	O
liver	O
.	O

This	O
atrophy	O
induction	O
does	O
not	O
involve	O
apoptotic	O
mechanisms	O
in	O
thymocytes	B-cell_type
affected	O
by	O
the	O
bcl-2	B-DNA
proto-oncogene	I-DNA
.	O

TCDD	O
mediates	O
atrophy	O
induction	O
through	O
its	O
specific	O
receptor	O
(	O
the	O
AhR	B-protein
)	O
and	O
not	O
through	O
effects	O
on	O
the	O
estrogen	O
receptor	O
.	O

Both	O
TCDD	O
and	O
estradiol	O
induce	O
extrathymic	O
T-cell	O
differentiation	O
in	O
the	O
liver	O
.	O

These	O
extrathymic	B-cell_type
T-cell	I-cell_type
populations	I-cell_type
include	O
cells	O
expressing	O
elevated	O
levels	O
of	O
V	B-protein
beta	I-protein
T-cell	I-protein
receptors	I-protein
that	O
are	O
normally	O
deleted	O
in	O
thymic	O
development	O
.	O

Identification	O
of	O
Bcd	B-DNA
,	O
a	O
novel	O
proto-oncogene	B-DNA
expressed	O
in	O
B-cells	B-cell_type
.	O

A	O
novel	B-cell_type
B-cell	I-cell_type
derived	O
(	O
Bcd	B-DNA
)	O
oncogene	B-DNA
has	O
been	O
isolated	O
from	O
the	O
peripheral	O
blood	O
lymphocytes	O
of	O
one	O
B-cell	O
chronic	O
lymphocytic	O
leukemia	O
(	O
B-CLL	O
)	O
patient	O
using	O
DNA	O
transfer	O
and	O
a	O
mouse	O
tumorigenicity	O
assay	O
.	O

The	O
Bcd	B-DNA
proto-oncogene	B-DNA
was	O
activated	O
by	O
a	O
truncation	O
in	O
the	O
5	B-DNA
'	I-DNA
UTR	I-DNA
.	O

It	O
predicts	O
for	O
two	O
open	B-DNA
reading	I-DNA
frames	I-DNA
(	O
ORFs	B-DNA
)	O
.	O

ORF1	B-DNA
consists	O
of	O
240	O
bp	O
that	O
would	O
encode	O
80	O
amino	O
acids	O
,	O
while	O
the	O
major	B-DNA
ORF2	I-DNA
consists	O
of	O
648	O
bp	O
capable	O
of	O
coding	O
for	O
216	O
amino	O
acids	O
.	O

Predicted	B-protein
peptide	I-protein
sequence	I-protein
of	O
ORF2	B-DNA
contained	O
a	O
zinc	B-protein
finger	I-protein
domain	I-protein
which	O
showed	O
significant	O
homology	O
to	O
GC	B-protein
box	I-protein
binding	I-protein
proteins	I-protein
BTEB2	B-protein
and	O
SP1	B-protein
.	O

Transfection	O
of	O
an	O
expression	B-DNA
vector	I-DNA
containing	O
ORF2	B-DNA
but	O
not	O
full	B-DNA
length	I-DNA
cDNA	I-DNA
was	O
able	O
to	O
transform	O
NIH3T3	B-cell_line
cells	I-cell_line
and	O
induce	O
tumors	O
in	O
nude	O
mice	O
.	O

Bcd	B-RNA
mRNA	I-RNA
transcripts	I-RNA
of	O
<	O
or	O
=	O
2.6	O
kb	O
were	O
selectively	O
expressed	O
in	O
PBL	B-cell_line
and	O
testis	O
of	O
healthy	O
individuals	O
.	O

Within	O
the	O
PBL	B-cell_type
,	O
Bcd	B-DNA
gene	O
expression	O
was	O
restricted	O
to	O
CD19+	B-cell_type
B-cells	I-cell_type
and	O
absent	O
from	O
CD14+	B-cell_type
monocytes	I-cell_type
and	O
T-cells	B-cell_type
.	O

Bcd	B-DNA
transcripts	O
were	O
detected	O
in	O
all	O
normal	O
PBL	B-cell_type
samples	O
tested	O
but	O
not	O
in	O
several	O
malignant	B-cell_line
human	I-cell_line
B-cell	I-cell_line
lines	I-cell_line
and	O
not	O
in	O
50	O
%	O
of	O
B-cells	B-cell_type
from	O
B-CLL	O
patients	O
.	O

However	O
,	O
stimulation	O
of	O
B-cells	B-cell_type
from	O
B-CLL	O
patients	O
under	O
conditions	O
which	O
induced	O
differentiation	O
into	O
plasma	B-cell_type
cells	I-cell_type
was	O
associated	O
with	O
induction	O
of	O
Bcd	B-DNA
gene	O
expression	O
.	O

The	O
Bcd	B-DNA
gene	I-DNA
may	O
therefore	O
play	O
an	O
important	O
role	O
in	O
B-cell	O
growth	O
and	O
development	O
.	O

A	O
novel	B-DNA
SP-1	I-DNA
site	I-DNA
in	O
the	O
human	B-DNA
interleukin-1	I-DNA
beta	I-DNA
promoter	I-DNA
confers	O
preferential	O
transcriptional	O
activity	O
in	O
keratinocytes	B-cell_type
.	O

To	O
investigate	O
the	O
mechanisms	O
of	O
transcriptional	O
activation	O
of	O
interleukin-1beta	B-protein
(	O
IL-1beta	B-protein
)	O
in	O
non-monocytic	O
cells	O
,	O
we	O
constructed	O
a	O
series	O
of	O
reporter	O
plasmids	O
with	O
the	O
bacterial	O
chloramphenicol	O
acetyltransferase	O
gene	O
linked	O
to	O
various	O
parts	O
of	O
the	O
human	B-DNA
IL-1beta	I-DNA
promoter	I-DNA
and	O
performed	O
transient	O
transfection	O
experiments	O
.	O

We	O
identified	O
a	O
promoter	O
segment	O
that	O
activates	O
transcription	O
most	O
efficiently	O
in	O
keratinocytes	B-cell_type
.	O

Electrophoretic	O
mobility	O
shift	O
assays	O
(	O
EMSA	O
)	O
with	O
a	O
43-mer	B-DNA
oligonucleotide	I-DNA
derived	O
from	O
the	O
functionally	O
identified	O
cis-acting	B-DNA
element	I-DNA
revealed	O
specific	O
complexes	O
.	O

By	O
competition	O
analysis	O
with	O
transcription	B-DNA
factor	I-DNA
consensus	I-DNA
sequence	I-DNA
oligonucleotides	I-DNA
and	O
by	O
immunosupershift	O
,	O
transcription	B-protein
factor	I-protein
SP-1	I-protein
or	O
a	O
closely	O
related	O
protein	O
was	O
shown	O
to	O
bind	O
to	O
this	O
regulatory	B-DNA
element	I-DNA
.	O

The	O
closest	O
match	O
to	O
the	O
known	O
SP-1	B-DNA
consensus	I-DNA
sequence	I-DNA
within	O
the	O
respective	O
region	O
is	O
a	O
TCCCCTCCCCT	B-DNA
motif	I-DNA
.	O

Mutation	O
of	O
this	O
motif	O
almost	O
completely	O
,	O
and	O
specifically	O
,	O
abolished	O
the	O
binding	O
of	O
two	O
low-mobility	B-protein
complexes	I-protein
and	O
led	O
to	O
a	O
95	O
%	O
decrease	O
of	O
constitutive	O
transcriptional	O
activation	O
of	O
a	O
reporter	O
construct	O
IL-1beta	B-protein
(	O
-170/+108	O
)	O
.	O

Likewise	O
,	O
activation	O
of	O
this	O
reporter	O
construct	O
by	O
tumor	B-protein
necrosis	I-protein
factor-alpha	I-protein
depended	O
on	O
the	O
SP-1	B-DNA
site	I-DNA
.	O

These	O
observations	O
suggest	O
that	O
a	O
so-far-unrecognized	O
SP-1	B-DNA
site	I-DNA
in	O
the	O
human	B-DNA
IL-1beta	I-DNA
promoter	I-DNA
may	O
participate	O
in	O
the	O
transcriptional	O
regulation	O
of	O
this	O
gene	O
in	O
keratinocytes	B-cell_type
.	O

Expression	O
of	O
Egr-1	B-protein
correlates	O
with	O
the	O
transformed	O
phenotype	O
and	O
the	O
type	O
of	O
viral	O
latency	O
in	O
EBV	B-cell_line
genome	I-cell_line
positive	I-cell_line
lymphoid	I-cell_line
cell	I-cell_line
lines	I-cell_line
.	O

In	O
this	O
paper	O
we	O
have	O
investigated	O
the	O
role	O
of	O
Egr-1	B-protein
in	O
B	O
cell	O
growth	O
regulation	O
by	O
examining	O
the	O
gene	O
expression	O
in	O
a	O
panel	O
of	O
B	B-cell_line
cell	I-cell_line
lines	I-cell_line
,	O
including	O
both	O
EBV	B-DNA
genome	I-DNA
negative	O
and	O
EBV	B-cell_line
carrying	I-cell_line
cell	I-cell_line
lines	I-cell_line
.	O

Egr-1	B-protein
expression	O
correlates	O
with	O
the	O
cellular	O
phenotype	O
and	O
the	O
specific	O
pattern	O
of	O
viral	O
latency	O
established	O
within	O
the	O
individual	B-cell_line
cell	I-cell_line
lines	I-cell_line
.	O

Thus	O
,	O
constitutive	O
activation	O
of	O
Egr-1	B-protein
gene	O
is	O
invariably	O
associated	O
with	O
unrestricted	O
expression	O
of	O
viral	O
latent	O
genes	O
in	O
all	O
group	B-cell_line
III	I-cell_line
EBV	I-cell_line
genome	I-cell_line
carrying	I-cell_line
cell	I-cell_line
lines	I-cell_line
.	O

In	O
contrast	O
,	O
Egr-1	B-protein
expression	O
is	O
abrogated	O
in	O
group	B-cell_line
I	I-cell_line
Burkitt	I-cell_line
tumor	I-cell_line
cells	I-cell_line
,	O
irrespective	O
of	O
the	O
EBV	B-DNA
genome	I-DNA
carrying	O
status	O
.	O

Activated	O
viral	O
gene	O
expression	O
associated	O
with	O
phenotypic	O
conversion	O
of	O
group	B-cell_line
I	I-cell_line
cell	I-cell_line
lines	I-cell_line
in	O
to	O
group	B-cell_line
II	I-cell_line
or	O
III	B-cell_line
restores	O
the	O
Egr-1	B-DNA
gene	I-DNA
expression	O
.	O

Several	O
forms	O
of	O
EGR-1	B-protein
protein	I-protein
are	O
found	O
within	O
the	O
different	O
groups	O
of	O
cell	O
lines	O
,	O
and	O
the	O
binding	O
activity	O
to	O
DNA	B-DNA
consensus	I-DNA
sequences	I-DNA
was	O
investigated	O
.	O

Finally	O
,	O
time	O
course	O
analysis	O
of	O
Egr-1	B-protein
expression	O
during	O
the	O
early	O
steps	O
of	O
EBV	O
infection	O
in	O
vitro	O
demonstrated	O
that	O
Egr-1	B-protein
is	O
upregulated	O
within	O
minutes	O
from	O
the	O
initial	O
interaction	O
with	O
the	O
B	B-cell_type
lymphocyte	I-cell_type
.	O

Expression	O
of	O
erythroid-specific	B-DNA
genes	I-DNA
in	O
megakaryoblastic	O
disorders	O
.	O

Currently	O
available	O
data	O
indicate	O
that	O
erythroid	O
and	O
megakaryocytic	O
differentiation	O
pathways	O
are	O
closely	O
related	O
to	O
each	O
other	O
,	O
and	O
there	O
may	O
exist	O
progenitor	B-cell_type
cells	I-cell_type
common	O
to	O
those	O
two	O
lineages	O
may	O
exist	O
.	O

Acute	O
megakaryoblastic	O
leukemia	O
(	O
AML-M7	O
)	O
and	O
transient	O
myeloproliferative	O
disorder	O
in	O
Down	O
's	O
syndrome	O
(	O
TMD	O
)	O
are	O
characterized	O
by	O
rapid	O
growth	O
of	O
abnormal	B-cell_type
blast	I-cell_type
cells	I-cell_type
which	O
express	O
megakaryocytic	B-protein
markers	I-protein
.	O

These	O
blast	B-cell_type
cells	I-cell_type
express	O
lineage-specific	B-protein
transcription	I-protein
factors	I-protein
such	O
as	O
GATA-1	B-protein
common	O
to	O
these	O
lineages	O
and	O
frequently	O
express	O
erythroid-specific	B-RNA
mRNAs	I-RNA
such	O
as	O
gamma-globin	B-protein
and	O
erythroid	B-protein
delta-aminolevulinate	I-protein
synthase	I-protein
(	O
ALAS-E	B-protein
)	O
,	O
indicating	O
that	O
most	O
of	O
the	O
blasts	O
in	O
M7	O
and	O
TMD	O
cases	O
have	O
erythroid	O
and	O
megakaryocytic	O
phenotypes	O
.	O

These	O
results	O
suggest	O
that	O
blasts	B-cell_type
in	O
M7	O
and	O
TMD	O
may	O
correspond	O
to	O
progenitors	B-cell_type
of	O
both	O
erythroid	B-cell_type
and	I-cell_type
megakaryocytic	I-cell_type
lineages	I-cell_type
.	O

Stat3	B-protein
recruitment	O
by	O
two	O
distinct	O
ligand-induced	B-protein
,	I-protein
tyrosine-phosphorylated	I-protein
docking	I-protein
sites	I-protein
in	O
the	O
interleukin-10	B-protein
receptor	I-protein
intracellular	I-protein
domain	I-protein
.	O

Recent	O
work	O
has	O
shown	O
that	O
IL-10	B-protein
induces	O
activation	O
of	O
the	O
JAK	B-protein
-STAT	B-protein
signaling	O
pathway	O
.	O

To	O
define	O
the	O
mechanism	O
underlying	O
signal	B-protein
transducer	I-protein
and	I-protein
activator	I-protein
of	I-protein
transcription	I-protein
(	I-protein
STAT	I-protein
)	I-protein
protein	I-protein
recruitment	O
to	O
the	O
interleukin	B-protein
10	I-protein
(	I-protein
IL-10	I-protein
)	I-protein
receptor	I-protein
,	O
the	O
STAT	B-protein
proteins	I-protein
activated	O
by	O
IL-10	B-protein
in	O
different	O
cell	O
populations	O
were	O
first	O
defined	O
using	O
electrophoretic	O
mobility	O
shift	O
assays	O
.	O

In	O
all	O
cells	O
tested	O
,	O
IL-10	B-protein
activated	O
Stat1	B-protein
and	O
Stat3	B-protein
and	O
induced	O
the	O
formation	O
of	O
three	O
distinct	O
DNA	B-protein
binding	I-protein
complexes	I-protein
that	O
contained	O
different	O
combinations	O
of	O
these	O
two	O
transcription	B-protein
factors	I-protein
.	O

IL-10	B-protein
also	O
activated	O
Stat5	B-protein
in	O
Ba/F3	B-cell_line
cells	I-cell_line
that	O
stably	O
expressed	O
the	O
murine	O
IL-10	B-protein
receptor	I-protein
.	O

Using	O
a	O
structure-function	O
mutagenesis	O
approach	O
,	O
two	O
tyrosine	O
residues	O
(	O
Tyr427	O
and	O
Tyr477	O
)	O
in	O
the	O
intracellular	B-protein
domain	I-protein
of	O
the	O
murine	O
IL-10	B-protein
receptor	O
were	O
found	O
to	O
be	O
redundantly	O
required	O
for	O
receptor	O
function	O
and	O
for	O
activation	O
of	O
Stat3	B-protein
but	O
not	O
for	O
Stat1	B-protein
or	O
Stat5	B-protein
.	O

Twelve	O
amino	O
acid	O
peptides	O
encompassing	O
either	O
of	O
these	O
two	O
tyrosine	O
residues	O
in	O
phosphorylated	B-protein
form	I-protein
coprecipitated	O
Stat3	B-protein
but	O
not	O
Stat1	B-protein
and	O
blocked	O
IL-10	B-protein
-induced	O
Stat3	B-protein
phosphorylation	O
in	O
a	O
cell-free	O
system	O
.	O

In	O
contrast	O
,	O
tyrosine-phosphorylated	O
peptides	O
containing	O
Tyr374	O
or	O
Tyr396	O
did	O
not	O
interact	O
with	O
Stat3	B-protein
or	O
block	O
Stat3	B-protein
activation	O
.	O

These	O
data	O
demonstrate	O
that	O
Stat3	B-protein
but	O
not	O
Stat1	B-protein
or	O
Stat5	B-protein
is	O
directly	O
recruited	O
to	O
the	O
ligand-activated	B-protein
IL-10	I-protein
receptor	I-protein
by	O
binding	O
to	O
specific	O
but	O
redundant	O
receptor	B-protein
intracellular	I-protein
domain	I-protein
sequences	I-protein
containing	O
phosphotyrosine	O
.	O

This	O
study	O
thus	O
supports	O
the	O
concept	O
that	O
utilization	O
of	O
distinct	O
STAT	B-protein
proteins	I-protein
by	O
different	O
cytokine	B-protein
receptors	I-protein
is	O
dependent	O
on	O
the	O
expression	O
of	O
particular	O
ligand-activatable	O
,	O
tyrosine-containing	B-protein
STAT	I-protein
docking	I-protein
sites	I-protein
in	O
receptor	B-protein
intracellular	I-protein
domains	I-protein
.	O

Silencing	O
of	O
human	O
fetal	O
globin	B-protein
expression	O
is	O
impaired	O
in	O
the	O
absence	O
of	O
the	O
adult	B-protein
beta-globin	I-protein
gene	I-protein
activator	I-protein
protein	I-protein
EKLF	B-protein
.	O

Globin	B-DNA
genes	I-DNA
are	O
subject	O
to	O
tissue-specific	O
and	O
developmental	O
stage-specific	O
regulation	O
.	O

A	O
switch	O
from	O
human	B-protein
fetal	I-protein
(	I-protein
gamma	I-protein
)	I-protein
-to	O
adult	B-protein
(	I-protein
beta	I-protein
)	I-protein
-globin	I-protein
expression	O
occurs	O
within	O
erythroid	B-cell_type
precursor	I-cell_type
cells	I-cell_type
of	O
the	O
adult	B-cell_type
lineage	I-cell_type
.	O

Previously	O
we	O
and	O
others	O
showed	O
by	O
targeted	O
gene	O
disruption	O
that	O
the	O
zinc	B-DNA
finger	I-DNA
gene	I-DNA
,	O
erythroid	B-protein
Kruppel-like	I-protein
factor	I-protein
(	O
EKLF	B-protein
)	O
,	O
is	O
required	O
for	O
expression	O
of	O
the	O
beta-globin	B-DNA
gene	I-DNA
in	O
mice	O
,	O
presumably	O
through	O
interaction	O
with	O
a	O
high-affinity	B-DNA
binding	I-DNA
site	I-DNA
in	O
the	O
proximal	B-DNA
promoter	I-DNA
.	O

To	O
examine	O
the	O
role	O
of	O
EKLF	B-protein
in	O
the	O
developmental	O
regulation	O
of	O
the	O
human	B-DNA
gamma-globin	I-DNA
gene	I-DNA
we	O
interbred	O
EKLF	B-protein
heterozygotes	I-protein
(	O
+/-	O
)	O
with	O
mice	O
harboring	O
a	O
human	B-DNA
beta-globin	I-DNA
yeast	I-DNA
artificial	I-DNA
chromosome	I-DNA
transgene	I-DNA
.	O

We	O
find	O
that	O
in	O
the	O
absence	O
of	O
EKLF	B-protein
,	O
while	O
human	B-protein
beta-globin	I-protein
expression	O
is	O
dramatically	O
reduced	O
,	O
gamma-globin	B-RNA
transcripts	I-RNA
are	O
elevated	O
approximately	O
5-fold	O
.	O

Impaired	O
silencing	O
of	O
gamma-globin	B-protein
expression	O
identifies	O
EKLF	B-protein
as	O
the	O
first	O
transcription	B-protein
factor	I-protein
participating	O
quantitatively	O
in	O
the	O
gamma-globin	B-protein
to	O
beta-globin	B-protein
switch	O
.	O

Our	O
findings	O
are	O
compatible	O
with	O
a	O
competitive	O
model	O
of	O
switching	O
in	O
which	O
EKLF	B-protein
mediates	O
an	O
adult	O
stage-specific	O
interaction	O
between	O
the	O
beta-globin	B-DNA
gene	I-DNA
promoter	I-DNA
and	O
the	O
locus	B-DNA
control	I-DNA
region	I-DNA
that	O
excludes	O
the	O
gamma-globin	B-DNA
gene	I-DNA
.	O

Stimulation	O
of	O
human	B-cell_type
peripheral	I-cell_type
blood	I-cell_type
mononuclear	I-cell_type
cells	I-cell_type
by	O
zinc	O
and	O
related	O
cations	O
.	O

Zinc	O
is	O
an	O
important	O
trace	O
element	O
for	O
immune	O
function	O
.	O

Here	O
,	O
we	O
show	O
that	O
zinc	O
addition	O
in	O
a	O
serum-	O
and	O
lipopolysaccharide-free	O
cell	O
culture	O
system	O
leads	O
to	O
significantly	O
enhanced	O
levels	O
of	O
interleukin	B-protein
1	I-protein
beta	I-protein
(	O
IL-1	B-protein
beta	I-protein
)	O
and	O
tumour	B-protein
necrosis	I-protein
factor	I-protein
alpha	I-protein
(	O
TNF-alpha	B-protein
)	O
and	O
to	O
expression	O
of	O
the	O
corresponding	O
mRNA	B-RNA
in	O
human	B-cell_type
peripheral	I-cell_type
blood	I-cell_type
mononuclear	I-cell_type
cells	I-cell_type
(	O
PBMC	B-cell_type
)	O
.	O

Structurally	O
related	O
divalent	O
cations	O
like	O
cobalt	O
,	O
nickel	O
,	O
and	O
mercury	O
also	O
partially	O
increase	O
monokine	O
secretion	O
but	O
to	O
a	O
much	O
lower	O
and	O
thus	O
insignificant	O
extent	O
.	O

They	O
fail	O
to	O
induce	O
mRNA	B-RNA
of	O
TNF-alpha	B-protein
after	O
3	O
h	O
of	O
culture	O
.	O

Therefore	O
,	O
monokine	O
induction	O
is	O
a	O
zinc-specific	O
effect	O
influenced	O
by	O
the	O
physicochemical	O
properties	O
of	O
the	O
ion	O
.	O

Confirmation	O
of	O
the	O
unique	O
significance	O
of	O
zinc	O
for	O
immune	O
function	O
provides	O
a	O
better	O
understanding	O
of	O
the	O
mechanisms	O
of	O
specific	O
zinc-mediated	O
immune	O
modulation	O
.	O

E3	B-protein
,	O
a	O
hematopoietic-specific	B-protein
transcript	I-protein
directly	O
regulated	O
by	O
the	O
retinoic	B-protein
acid	I-protein
receptor	I-protein
alpha	I-protein
.	O

Retinoic	O
acid	O
(	O
RA	O
)	O
-induced	O
maturation	O
mediated	O
by	O
the	O
retinoic	B-protein
acid	I-protein
receptor	I-protein
alpha	I-protein
(	O
RAR	B-protein
alpha	I-protein
)	O
has	O
been	O
implicated	O
in	O
myeloid	O
development	O
.	O

We	O
have	O
used	O
differential	O
hybridization	O
analysis	O
of	O
a	O
cDNA	B-DNA
library	I-DNA
constructed	O
from	O
the	O
murine	O
RA-inducible	B-cell_line
MPRO	I-cell_line
promyelocyte	I-cell_line
cell	I-cell_line
line	I-cell_line
to	O
identify	O
immediate-early	B-DNA
genes	I-DNA
induced	O
by	O
RA	O
during	O
granulocytic	O
differentiation	O
.	O

E3	B-protein
,	O
one	O
of	O
nine	O
sequences	O
identified	O
,	O
was	O
upregulated	O
in	O
an	O
immediate-early	O
manner	O
,	O
with	O
transcript	O
levels	O
peaking	O
after	O
60	O
minutes	O
exposure	O
to	O
RA	O
.	O

E3	B-protein
transcripts	I-protein
were	O
RA-inducible	O
in	O
HL60	B-cell_line
cells	I-cell_line
,	O
but	O
not	O
in	O
an	O
RA-resistant	B-cell_line
subclone	I-cell_line
,	O
HL60R	B-cell_line
,	O
that	O
harbors	O
a	O
mutated	O
RAR	B-DNA
alpha	I-DNA
gene	I-DNA
.	O

However	O
,	O
when	O
HL60R	B-cell_line
cells	I-cell_line
were	O
transduced	O
with	O
a	O
functional	O
copy	O
of	O
the	O
RAR	B-DNA
alpha	I-DNA
gene	I-DNA
,	O
RA	O
induced	O
a	O
10-fold	O
increase	O
in	O
E3	B-protein
mRNA	O
levels	O
.	O

E3	B-protein
transcripts	I-protein
are	O
present	O
in	O
the	O
myeloid	B-cell_type
,	I-cell_type
B-lymphoid	I-cell_type
,	I-cell_type
and	I-cell_type
erythroid	I-cell_type
lineages	I-cell_type
,	O
absent	O
in	O
nonhematopoietic	B-cell_type
cells	I-cell_type
,	O
and	O
encode	O
a	O
highly	O
hydrophobic	O
,	O
potentially	O
phosphorylated	O
polypeptide	O
of	O
unknown	O
function	O
with	O
significant	O
homology	O
to	O
a	O
putative	O
protein	O
expressed	O
in	O
myeloid	B-cell_type
cells	I-cell_type
.	O

The	O
murine	O
E3	B-DNA
promoter	I-DNA
harbors	O
a	O
single	O
bipartite	B-DNA
retinoic	I-DNA
acid	I-DNA
response	I-DNA
element	I-DNA
which	O
in	O
transient	O
transfection	O
assays	O
conferred	O
RA	O
sensitivity	O
.	O

These	O
results	O
indicate	O
that	O
E3	B-protein
is	O
a	O
hematopoietic-specific	B-DNA
gene	I-DNA
that	O
is	O
an	O
immediate	O
target	O
for	O
the	O
activated	O
RAR	B-protein
alpha	I-protein
during	O
myelopoiesis	O
.	O

Multifactor	O
cis-dominant	O
negative	O
regulation	O
of	O
IL-2	B-DNA
gene	I-DNA
expression	O
in	O
anergized	B-cell_type
T	I-cell_type
cells	I-cell_type
.	O

The	O
molecular	O
mechanism	O
underlying	O
IL-2	B-protein
transcriptional	O
blockade	O
in	O
anergic	B-cell_line
T	I-cell_line
cell	I-cell_line
clones	I-cell_line
is	O
not	O
fully	O
understood	O
.	O

To	O
examine	O
whether	O
an	O
active	O
negative	O
regulatory	O
process	O
occurs	O
,	O
we	O
created	O
a	O
reporter	B-DNA
construct	I-DNA
containing	O
as	O
an	O
enhancer	B-DNA
four	O
copies	O
of	O
the	O
NF-AT	B-DNA
site	I-DNA
and	O
one	O
copy	O
of	O
the	O
octamer	B-DNA
site	I-DNA
(	O
4X	B-DNA
NF-AT-Oct	I-DNA
)	O
.	O

This	O
construct	O
was	O
only	O
slightly	O
reduced	O
(	O
1.3-fold	O
)	O
in	O
its	O
expression	O
when	O
stimulated	O
under	O
anergic	O
conditions	O
,	O
while	O
a	O
whole	O
mouse	O
IL-2	B-DNA
enhancer	I-DNA
construct	I-DNA
showed	O
a	O
reduction	O
of	O
4.3-fold	O
.	O

Addition	O
of	O
the	O
-176	B-DNA
to	I-DNA
-96	I-DNA
sequence	I-DNA
to	O
the	O
4X	B-DNA
NF-AT-Oct	I-DNA
construct	I-DNA
did	O
not	O
impart	O
the	O
ability	O
to	O
be	O
affected	O
by	O
anergy	O
,	O
but	O
addition	O
of	O
the	O
-236	B-DNA
to	I-DNA
-96	I-DNA
sequence	I-DNA
did	O
,	O
demonstrating	O
that	O
anergy	O
is	O
an	O
active	O
inhibitory	O
process	O
and	O
that	O
more	O
than	O
the	O
presence	O
of	O
the	O
-150	B-DNA
AP-1	I-DNA
binding	I-DNA
site	I-DNA
(	O
-152	B-DNA
to	I-DNA
-147	I-DNA
)	O
is	O
required	O
to	O
mediate	O
the	O
effect	O
.	O

Mutational	O
studies	O
of	O
the	O
-236	B-DNA
to	I-DNA
-96	I-DNA
sequence	I-DNA
indicated	O
that	O
the	O
presence	O
of	O
both	O
the	O
-130	B-DNA
AP-1-like	I-DNA
site	I-DNA
(	O
-187	B-DNA
to	I-DNA
-181	I-DNA
)	O
and	O
the	O
-150	B-DNA
proximal	I-DNA
AP-1	I-DNA
site	I-DNA
were	O
necessary	O
to	O
observe	O
anergy	O
.	O

Because	O
the	O
-180	B-DNA
site	I-DNA
is	O
not	O
required	O
for	O
trans-activation	O
,	O
it	O
was	O
possible	O
to	O
confirm	O
by	O
mutation	O
in	O
the	O
normal	O
mouse	B-DNA
IL-2	I-DNA
enhancer	I-DNA
that	O
this	O
site	O
is	O
absolutely	O
essential	O
for	O
anergy	O
induction	O
.	O

The	O
simplest	O
model	O
to	O
explain	O
these	O
results	O
is	O
that	O
anergy	O
is	O
mediated	O
by	O
a	O
complex	O
of	O
multiple	O
transcription	B-protein
factors	I-protein
that	O
exert	O
a	O
cis-acting	O
dominant	O
negative	O
regulatory	O
effect	O
on	O
the	O
trans-activation	O
of	O
the	O
IL-2	B-DNA
gene	I-DNA
.	O

Severe	O
combined	O
immunodeficiency	O
due	O
to	O
defective	O
binding	O
of	O
the	O
nuclear	B-protein
factor	I-protein
of	I-protein
activated	I-protein
T	I-protein
cells	I-protein
in	O
T	B-cell_type
lymphocytes	I-cell_type
of	O
two	O
male	O
siblings	O
.	O

Peripheral	B-cell_type
blood	I-cell_type
lymphocytes	I-cell_type
(	O
PBL	B-cell_type
)	O
and	O
alloreactive	B-cell_line
T	I-cell_line
cell	I-cell_line
lines	I-cell_line
of	O
two	O
male	O
infants	O
born	O
to	O
consanguinous	O
parents	O
and	O
presenting	O
with	O
severe	O
combined	O
immunodeficiency	O
(	O
SCID	O
)	O
showed	O
a	O
pronounced	O
deficiency	O
in	O
T	O
cell	O
activation	O
.	O

Although	O
phenotypically	O
normal	O
,	O
the	O
proliferative	O
response	O
of	O
the	O
childrens	O
'	O
T	B-cell_type
cells	I-cell_type
was	O
strongly	O
reduced	O
but	O
could	O
be	O
improved	O
by	O
the	O
addition	O
of	O
interleukin-2	B-protein
(	O
IL-2	B-protein
)	O
.	O

Furthermore	O
both	O
childrens	O
'	O
T	B-cell_type
cells	I-cell_type
were	O
unable	O
to	O
produce	O
the	O
cytokines	B-protein
IL-2	B-protein
,	O
interferon-gamma	B-protein
(	O
IFN-gamma	B-protein
)	O
,	O
IL-4	B-protein
and	O
tumor	B-protein
necrosis	I-protein
factor-alpha	I-protein
(	O
TNF-alpha	B-protein
)	O
.	O

This	O
multiple	O
cytokine	B-protein
production	O
deficiency	O
could	O
not	O
be	O
restored	O
by	O
IL-2	B-protein
or	O
co-stimulatory	O
signals	O
provided	O
by	O
antigen-presenting	B-cell_type
cells	I-cell_type
(	O
APC	B-cell_type
)	O
.	O

Moreover	O
,	O
mRNA	B-RNA
for	O
IL-2	B-protein
and	O
IFN-gamma	B-protein
could	O
not	O
be	O
detected	O
.	O

In	O
contrast	O
,	O
expression	O
of	O
the	O
activation-dependent	B-protein
cell	I-protein
surface	I-protein
markers	I-protein
CD25	B-protein
and	O
CD69	B-protein
was	O
within	O
normal	O
limits	O
.	O

To	O
determine	O
whether	O
the	O
functional	O
defect	O
of	O
the	O
patients	O
'	O
T	B-cell_type
cells	I-cell_type
was	O
due	O
to	O
the	O
absence	O
or	O
abnormal	O
binding	O
of	O
transcription	B-protein
factors	I-protein
involved	O
in	O
cytokine	B-DNA
gene	I-DNA
expression	O
,	O
electrophoretic	O
mobility	O
shift	O
assays	O
were	O
used	O
to	O
examine	O
the	O
DNA	O
binding	O
of	O
AP-1	B-protein
,	O
Oct	B-protein
,	O
CREB	B-protein
,	O
SP1	B-protein
,	O
NF-kappa	B-protein
B	I-protein
and	O
the	O
nuclear	B-protein
factor	I-protein
of	I-protein
activated	I-protein
T	I-protein
cells	I-protein
(	O
NF-AT	B-protein
)	O
to	O
their	O
respective	O
response	B-DNA
elements	I-DNA
in	O
the	O
promoter	B-DNA
of	O
the	O
IL-2	B-DNA
gene	I-DNA
.	O

Whereas	O
AP-1	B-protein
,	O
NF-kappa	O
B	O
,	O
Oct	B-protein
,	O
CREB	B-protein
and	O
SP1	B-protein
displayed	O
normal	O
binding	O
activities	O
in	O
nuclear	O
extracts	O
,	O
the	O
binding	O
of	O
NF-AT	B-protein
to	O
its	O
IL-2	B-protein
promoter	O
response	O
element	O
was	O
barely	O
detectable	O
both	O
before	O
and	O
after	O
T	O
cell	O
stimulation	O
.	O

Our	O
results	O
strongly	O
suggest	O
that	O
this	O
NF-AT	B-protein
/DNA	O
binding	O
defect	O
is	O
responsible	O
for	O
the	O
multiple	O
cytokine	B-protein
deficiency	O
and	O
the	O
SCID	O
phenotype	O
observed	O
in	O
the	O
two	O
infant	O
brothers	O
.	O

oriP	B-DNA
is	O
essential	O
for	O
EBNA	B-DNA
gene	I-DNA
promoter	O
activity	O
in	O
Epstein-Barr	B-cell_line
virus-immortalized	I-cell_line
lymphoblastoid	I-cell_line
cell	I-cell_line
lines	I-cell_line
.	O

During	O
Epstein-Barr	O
virus	O
latent	O
infection	O
of	O
B	B-cell_type
lymphocytes	I-cell_type
in	O
vitro	O
,	O
six	O
viral	B-protein
nuclear	I-protein
antigens	I-protein
(	O
EBNAs	B-protein
)	O
are	O
expressed	O
from	O
one	O
of	O
two	O
promoters	B-DNA
,	O
Cp	B-DNA
or	O
Wp	B-DNA
,	O
whose	O
activities	O
are	O
mutually	O
exclusive	O
.	O

Upon	O
infection	O
,	O
Wp	B-DNA
is	O
initially	O
active	O
,	O
followed	O
by	O
a	O
switch	O
to	O
Cp	B-DNA
for	O
the	O
duration	O
of	O
latency	O
.	O

In	O
this	O
study	O
,	O
the	O
region	O
upstream	O
of	O
Cp	B-DNA
was	O
analyzed	O
for	O
the	O
presence	O
of	O
cis	O
elements	O
involved	O
in	O
regulating	O
the	O
activities	O
of	O
the	O
EBNA	B-DNA
gene	I-DNA
promoters	I-DNA
in	O
established	O
in	B-cell_line
vitro	I-cell_line
immortalized	I-cell_line
lymphoblastoid	I-cell_line
cell	I-cell_line
lines	I-cell_line
(	O
LCLs	B-cell_line
)	O
.	O

It	O
was	O
determined	O
that	O
oriP	B-DNA
,	O
the	O
origin	O
for	O
episomal	O
maintenance	O
during	O
latency	O
,	O
is	O
essential	O
for	O
efficient	O
transcription	O
initiation	O
from	O
either	O
Cp	B-DNA
or	O
Wp	B-DNA
in	O
LCLs	B-cell_line
,	O
as	O
well	O
as	O
in	O
some	O
Burkitt	B-cell_line
's	I-cell_line
lymphoma	I-cell_line
cell	I-cell_line
lines	I-cell_line
.	O

Deletion	O
of	O
the	O
EBNA2-dependent	B-DNA
enhancer	I-DNA
located	O
upstream	O
of	O
Cp	B-DNA
resulted	O
in	O
a	O
ca.	O
two-	O
to	O
fivefold	O
reduction	O
in	O
Cp	B-DNA
activity	O
in	O
the	O
LCLs	B-cell_line
assayed	O
.	O

More	O
extensive	O
deletion	O
of	O
sequences	O
upstream	O
of	O
Cp	B-DNA
,	O
including	O
the	O
EBNA2-dependent	B-DNA
enhancer	I-DNA
,	O
resulted	O
in	O
nearly	O
complete	O
loss	O
of	O
Cp	B-DNA
activity	O
.	O

This	O
loss	O
of	O
activity	O
was	O
shown	O
to	O
correlate	O
with	O
deletion	O
of	O
two	O
CCAAT	B-DNA
boxes	I-DNA
,	O
a	O
proximal	B-DNA
CCAAT	I-DNA
box	I-DNA
located	O
at	O
bp	B-DNA
-61	I-DNA
to	I-DNA
-65	I-DNA
and	O
a	O
distal	O
CCAAT	B-DNA
box	I-DNA
located	O
at	O
bp	O
-253	B-DNA
to	I-DNA
-257	I-DNA
,	O
upstream	O
of	O
Cp	B-DNA
.	O

Site-directed	O
mutagenesis	O
of	O
these	O
cis	B-DNA
elements	I-DNA
demonstrated	O
that	O
Cp	B-DNA
activity	O
is	O
highly	O
dependent	O
on	O
the	O
presence	O
of	O
a	O
properly	O
positioned	O
CCAAT	B-DNA
box	I-DNA
,	O
with	O
the	O
dependence	O
on	O
the	O
distal	B-DNA
CCAAT	I-DNA
box	I-DNA
apparent	O
only	O
when	O
the	O
proximal	B-DNA
CCAAT	I-DNA
box	I-DNA
was	O
deleted	O
or	O
mutated	O
.	O

Deletion	O
of	O
the	O
glucocorticoid	O
response	O
elements	O
located	O
at	O
ca.	B-DNA
bp	I-DNA
-850	I-DNA
upstream	O
of	O
Cp	B-DNA
did	O
not	O
result	O
in	O
a	O
significant	O
loss	O
in	O
activity	O
.	O

In	O
general	O
,	O
deletions	O
which	O
diminished	O
Cp	B-DNA
activity	O
resulted	O
in	O
induction	O
of	O
Wp	B-DNA
activity	O
,	O
consistent	O
with	O
suppression	O
of	O
Wp	B-DNA
activity	O
by	O
transcriptional	O
interference	O
from	O
Cp	B-DNA
.	O

The	O
identification	O
of	O
oriP	B-DNA
and	O
the	O
EBNA2-dependent	B-DNA
enhancer	I-DNA
as	O
the	O
major	O
positive	O
cis	B-DNA
elements	I-DNA
involved	O
in	O
regulating	O
Cp	B-DNA
activity	O
in	O
LCL	B-cell_line
suggests	O
that	O
EBNA	B-DNA
gene	I-DNA
transcription	O
is	O
largely	O
autoregulated	O
by	O
EBNA	B-protein
1	I-protein
and	O
EBNA	B-protein
2	I-protein
.	O

Protein-tyrosine	O
kinase	O
activation	O
is	O
required	O
for	O
lipopolysaccharide	O
induction	O
of	O
interleukin	B-protein
1beta	I-protein
and	O
NFkappaB	B-protein
activation	O
,	O
but	O
not	O
NFkappaB	B-protein
nuclear	O
translocation	O
.	O

In	O
human	B-cell_type
monocytes	I-cell_type
,	O
interleukin	B-protein
1beta	I-protein
protein	O
production	O
and	O
steady	O
state	O
mRNA	O
levels	O
are	O
increased	O
in	O
response	O
to	O
lipopolysaccharide	O
,	O
predominantly	O
as	O
a	O
result	O
of	O
increased	O
transcription	O
of	O
the	O
interleukin	B-protein
1beta	I-protein
gene	O
.	O

Expression	O
of	O
interleukin	B-protein
1beta	I-protein
and	O
other	O
cytokines	B-protein
,	O
such	O
as	O
interleukin	B-protein
6	I-protein
and	O
tumor	B-protein
necrosis	I-protein
factor	I-protein
alpha	I-protein
,	O
has	O
been	O
shown	O
to	O
be	O
dependent	O
on	O
the	O
activation	O
of	O
the	O
transcription	B-protein
factor	I-protein
,	O
NFkappaB	B-protein
.	O

Since	O
recent	O
studies	O
have	O
shown	O
that	O
lipopolysaccharide-induced	O
tyrosine	B-protein
kinase	I-protein
activation	O
is	O
not	O
required	O
for	O
NFkappaB	B-protein
nuclear	O
translocation	O
,	O
we	O
sought	O
to	O
determine	O
whether	O
NFkappaB	B-protein
translocated	O
in	O
the	O
absence	O
of	O
tyrosine	B-protein
kinase	I-protein
activity	O
was	O
active	O
in	O
stimulating	O
transcription	O
.	O

We	O
have	O
found	O
that	O
,	O
in	O
the	O
human	O
pro-monocytic	B-cell_line
cell	I-cell_line
line	I-cell_line
,	O
THP-1	B-cell_line
,	O
the	O
lipopolysaccharide-induced	O
expression	O
of	O
interleukin	B-protein
1beta	I-protein
is	O
dependent	O
on	O
tyrosine	B-protein
kinase	I-protein
activation	O
.	O

Tyrosine	O
kinases	O
are	O
not	O
required	O
for	O
lipopolysaccharide-mediated	O
nuclear	O
translocation	O
of	O
NFkappaB	B-protein
.	O

However	O
,	O
in	O
the	O
absence	O
of	O
tyrosine	B-protein
kinase	I-protein
activity	O
,	O
the	O
ability	O
of	O
NFkappaB	B-protein
to	O
stimulate	O
transcription	O
is	O
impaired	O
.	O

This	O
inhibition	O
of	O
transcription	O
is	O
specific	O
for	O
NFkappaB	B-protein
;	O
in	O
the	O
absence	O
of	O
tyrosine	B-protein
kinase	I-protein
activity	O
,	O
AP-1	B-protein
-dependent	O
transcription	O
is	O
enhanced	O
.	O

These	O
results	O
suggest	O
that	O
,	O
while	O
lipopolysaccharide-induced	O
expression	O
of	O
inflammatory	B-protein
mediators	I-protein
requires	O
tyrosine	B-protein
kinase	I-protein
activity	O
,	O
tyrosine	B-protein
kinase	I-protein
activity	O
is	O
not	O
obligatory	O
for	O
lipopolysaccharide	O
signal	O
transduction	O
.	O

Chronic	O
human	O
immunodeficiency	O
virus	O
type	O
1	O
infection	O
of	O
myeloid	B-cell_type
cells	I-cell_type
disrupts	O
the	O
autoregulatory	O
control	O
of	O
the	O
NF-kappaB/Rel	B-protein
pathway	O
via	O
enhanced	O
IkappaBalpha	B-protein
degradation	O
.	O

Productive	O
human	O
immunodeficiency	O
virus	O
type	O
1	O
(	O
HIV-1	O
)	O
infection	O
causes	O
sustained	O
NF-kappaB	B-protein
DNA-binding	O
activity	O
in	O
chronically	O
infected	O
monocytic	O
cells	O
.	O

A	O
direct	O
temporal	O
correlation	O
exists	O
between	O
HIV	O
infection	O
and	O
the	O
appearance	O
of	O
NF-kappaB	B-protein
DNA-binding	O
activity	O
in	O
myelomonoblastic	B-cell_line
PLB-985	I-cell_line
cells	I-cell_line
.	O

To	O
examine	O
the	O
molecular	O
basis	O
of	O
constitutive	O
NF-kappaB	B-protein
DNA-binding	O
activity	O
in	O
HIV1	B-cell_type
-infected	I-cell_type
cells	I-cell_type
,	O
we	O
analyzed	O
the	O
phosphorylation	O
and	O
turnover	O
of	O
IkappaBalpha	B-protein
protein	O
,	O
the	O
activity	O
of	O
the	O
double-stranded	B-protein
RNA-dependent	I-protein
protein	I-protein
kinase	I-protein
(	O
PKR	B-protein
)	O
and	O
the	O
intracellular	O
levels	O
of	O
NF-kappaB	B-protein
subunits	I-protein
in	O
the	O
PLB-985	B-cell_line
and	O
U937	B-cell_line
myeloid	I-cell_line
cell	I-cell_line
models	I-cell_line
.	O

HIV-1	O
infection	O
resulted	O
in	O
constitutive	O
,	O
low-level	O
expression	O
of	O
type	B-protein
1	I-protein
interferon	I-protein
(	O
IFN	B-protein
)	O
at	O
the	O
mRNA	O
level	O
.	O

Constitutive	O
PKR	B-protein
activity	O
was	O
also	O
detected	O
in	O
HIV-1-infected	B-cell_line
cells	I-cell_line
as	O
a	O
result	O
of	O
low-level	O
IFN	B-protein
production	O
,	O
since	O
the	O
addition	O
of	O
anti-IFN-alpha/beta	B-protein
antibody	I-protein
to	O
the	O
cells	O
decreased	O
PKR	B-protein
expression	O
.	O

Furthermore	O
,	O
the	O
analysis	O
of	O
IkappaBalpha	B-protein
turnover	O
demonstrated	O
an	O
increased	O
degradation	O
of	O
IkappaBalpha	B-protein
in	O
HIV-1-infected	B-cell_line
cells	I-cell_line
that	O
may	O
account	O
for	O
the	O
constitutive	B-DNA
DNA	I-DNA
binding	O
activity	O
.	O

A	O
dramatic	O
increase	O
in	O
the	O
intracellular	O
levels	O
of	O
NF-kappaB	B-protein
subunits	O
c-Rel	B-protein
and	O
NF-kappaB2	B-protein
p100	I-protein
and	O
a	O
moderate	O
increase	O
in	O
NF-kappaB2	B-protein
p52	I-protein
and	O
RelA	B-protein
(	I-protein
p65	I-protein
)	I-protein
were	O
detected	O
in	O
HIV-1-infected	B-cell_line
cells	I-cell_line
,	O
whereas	O
NF-kappaB1	B-protein
p105/p50	I-protein
levels	O
were	O
not	O
altered	O
relative	O
to	O
the	O
levels	O
in	O
uninfected	B-cell_type
cells	I-cell_type
.	O

We	O
suggest	O
that	O
HIV-1	O
infection	O
of	O
myeloid	B-cell_type
cells	I-cell_type
induces	O
IFN	B-protein
production	O
and	O
PKR	B-protein
activity	O
,	O
which	O
in	O
turn	O
contribute	O
to	O
enhanced	O
IkappaBalpha	B-protein
phosphorylation	O
and	O
subsequent	O
degradation	O
.	O

Nuclear	O
translocation	O
of	O
NF-kappaB	B-protein
subunits	I-protein
may	O
ultimately	O
increase	O
the	O
intracellular	O
pool	O
of	O
NF-kappaB/IkappaBalpha	B-protein
by	O
an	O
autoregulatory	O
mechanism	O
.	O

Enhanced	O
turnover	O
of	O
IkappaBalpha	B-protein
and	O
the	O
accumulation	O
of	O
NF-kappaB/Rel	B-protein
proteins	I-protein
may	O
contribute	O
to	O
the	O
chronically	O
activated	O
state	O
of	O
HIV-1-infected	B-cell_line
cells	I-cell_line
.	O

The	O
c-Jun	B-protein
delta-domain	I-protein
inhibits	O
neuroendocrine	B-DNA
promoter	I-DNA
activity	O
in	O
a	O
DNA	O
sequence-	O
and	O
pituitary-specific	O
manner	O
.	O

The	O
transcription	O
and	O
transformation	O
activity	O
of	O
c-Jun	B-protein
is	O
governed	O
by	O
a	O
27-amino	B-protein
acid	I-protein
regulatory	I-protein
motif	I-protein
,	O
labeled	O
the	O
delta-domain	B-protein
,	O
which	O
is	O
deleted	O
in	O
v-Jun	B-protein
.	O

We	O
have	O
previously	O
shown	O
that	O
c-Jun	B-protein
is	O
a	O
potent	O
inhibitor	O
of	O
the	O
rat	B-DNA
prolactin	I-DNA
(	I-DNA
rPRL	I-DNA
)	I-DNA
promoter	I-DNA
activity	O
induced	O
by	O
either	O
oncogenic	B-protein
Ras	I-protein
or	O
phorbol	O
esters	O
.	O

Here	O
,	O
we	O
have	O
characterized	O
the	O
structural	O
and	O
cell-specific	O
requirements	O
for	O
this	O
c-Jun	B-protein
inhibitory	O
response	O
,	O
and	O
we	O
show	O
that	O
this	O
c-Jun	B-protein
inhibitory	O
response	O
mapped	O
to	O
the	O
rPRL	B-DNA
footprint	I-DNA
II	I-DNA
repressor	I-DNA
site	I-DNA
,	O
was	O
pituitary-specific	O
and	O
required	O
the	O
c-Jun	B-protein
delta-domain	I-protein
.	O

Moreover	O
,	O
alteration	O
of	O
any	O
one	O
of	O
these	O
features	O
(	O
e.g.	O
,	O
cis-element	B-DNA
,	O
trans-factor	B-DNA
,	O
or	O
cell-specific	O
background	O
)	O
switched	O
c-Jun	B-protein
to	O
a	O
transcriptional	B-protein
activator	I-protein
of	O
the	O
rPRL	B-DNA
promoter	I-DNA
.	O

In	O
HeLa	B-cell_line
nonpituitary	I-cell_line
cells	I-cell_line
,	O
c-Jun	B-protein
alone	O
activated	O
the	O
rPRL	B-DNA
promoter	I-DNA
via	O
the	O
most	O
proximal	O
GHF-1/Pit-1	B-DNA
binding	I-DNA
site	I-DNA
,	O
footprint	B-DNA
I	I-DNA
,	O
and	O
synergized	O
with	O
GHF-1	B-protein
.	O

Finally	O
,	O
recombinant	O
GHF-1	B-protein
interacted	O
directly	O
with	O
c-Jun	B-protein
but	O
not	O
c-Fos	B-protein
proteins	I-protein
.	O

These	O
data	O
provide	O
important	O
fundamental	O
insights	O
into	O
the	O
molecular	O
mechanisms	O
by	O
which	O
the	O
c-Jun	B-protein
delta-domain	I-protein
functions	O
as	O
a	O
modulatory	O
switch	O
and	O
further	O
imply	O
that	O
the	O
functional	O
role	O
of	O
c-Jun	B-protein
is	O
dictated	O
by	O
cell-specific	O
influences	O
and	O
the	O
delta-domain	B-protein
motif	I-protein
.	O

Retinoic	O
acid	O
activates	O
interferon	B-protein
regulatory	I-protein
factor-1	I-protein
gene	O
expression	O
in	O
myeloid	B-cell_type
cells	I-cell_type
.	O

All-trans-retinoic	O
acid	O
(	O
ATRA	O
)	O
is	O
the	O
drug	O
of	O
choice	O
in	O
the	O
treatment	O
of	O
acute	O
promyelocytic	O
leukemia	O
(	O
APL	O
)	O
.	O

ATRA	O
induces	O
both	O
in	O
vitro	O
and	O
in	O
vivo	O
differentiation	O
of	O
APL	B-cell_line
cells	I-cell_line
into	O
mature	B-cell_type
granulocytes	I-cell_type
.	O

However	O
,	O
the	O
molecular	O
mechanisms	O
involved	O
in	O
ATRA-dependent	O
growth	O
inhibition	O
and	O
cellular	O
differentiation	O
are	O
not	O
presently	O
understood	O
.	O

The	O
NB4	B-cell_line
cell	I-cell_line
line	I-cell_line
,	O
which	O
is	O
derived	O
from	O
the	O
bone	O
marrow	O
of	O
a	O
patient	O
with	O
APL	O
during	O
relapse	O
,	O
can	O
be	O
used	O
as	O
a	O
model	O
system	O
to	O
study	O
the	O
growth	O
and	O
differentiation	O
of	O
APL	B-cell_line
cells	I-cell_line
.	O

Because	O
interferon	B-protein
(	I-protein
IFN	I-protein
)	I-protein
regulatory	I-protein
factors	I-protein
(	O
IRF-1	B-protein
and	O
IRF-2	B-protein
)	O
and	O
other	O
IFN-inducible	B-protein
gene	I-protein
products	I-protein
regulate	O
cell	O
growth	O
,	O
we	O
analyzed	O
the	O
effects	O
of	O
ATRA	O
on	O
the	O
expression	O
of	O
these	O
genes	O
.	O

We	O
show	O
that	O
ATRA	O
directly	O
activates	O
IRF-1	B-DNA
gene	I-DNA
expression	O
,	O
followed	O
by	O
activation	O
of	O
IRF-2	B-protein
and	O
2'-5	B-protein
'	I-protein
oligoadenylate	I-protein
synthetase	I-protein
(	O
OAS	O
)	O
gene	O
expression	O
with	O
slower	O
kinetics	O
.	O

In	O
addition	O
to	O
NB4	O
cells	O
,	O
ATRA	O
also	O
activated	O
IRF-1	B-DNA
gene	I-DNA
expression	O
in	O
HL-60	B-cell_line
,	O
U937	B-cell_line
,	O
and	O
THP-1	B-cell_line
cells	I-cell_line
,	O
which	O
all	O
respond	O
to	O
ATRA	O
by	O
growth	O
inhibition	O
.	O

A	O
more	O
than	O
additive	O
increase	O
in	O
IRF-1	B-DNA
gene	I-DNA
expression	O
was	O
seen	O
with	O
ATRA	O
and	O
IFN-gamma	B-protein
in	O
NB4	B-cell_line
cells	I-cell_line
.	O

ATRA	O
did	O
not	O
activate	O
nuclear	O
factor	O
kappa	O
B	O
or	O
signal	O
transducer	O
and	O
activator	O
of	O
transcription	O
(	O
STAT	O
)	O
activation	O
pathways	O
,	O
suggesting	O
that	O
an	O
alternate	O
mechanism	O
is	O
involved	O
in	O
IRF-1	B-DNA
gene	I-DNA
activation	O
.	O

The	O
ATRA-induced	O
expression	O
of	O
IRF-1	B-protein
,	O
an	O
activator	O
of	O
transcription	O
and	O
repressor	O
of	O
transformation	O
,	O
may	O
be	O
one	O
of	O
the	O
molecular	O
mechanisms	O
of	O
ATRA-induced	O
growth	O
inhibition	O
,	O
and	O
the	O
basis	O
for	O
the	O
synergistic	O
actions	O
of	O
ATRA	O
and	O
IFNs	B-protein
in	O
myeloid	B-cell_line
leukemia	I-cell_line
cells	I-cell_line
.	O

Recombinant	O
NFAT1	B-protein
(	O
NFATp	O
)	O
is	O
regulated	O
by	O
calcineurin	O
in	O
T	B-cell_type
cells	I-cell_type
and	O
mediates	O
transcription	O
of	O
several	O
cytokine	B-DNA
genes	I-DNA
.	O

Transcription	B-protein
factors	I-protein
of	O
the	O
NFAT	B-protein
family	I-protein
play	O
a	O
key	O
role	O
in	O
the	O
transcription	O
of	O
cytokine	B-DNA
genes	I-DNA
and	O
other	O
genes	O
during	O
the	O
immune	O
response	O
.	O

We	O
have	O
identified	O
two	O
new	O
isoforms	O
of	O
the	O
transcription	B-protein
factor	I-protein
NFAT1	B-protein
(	O
previously	O
termed	O
NFATp	B-protein
)	O
that	O
are	O
the	O
predominant	O
isoforms	O
expressed	O
in	O
murine	B-cell_type
and	I-cell_type
human	I-cell_type
T	I-cell_type
cells	I-cell_type
.	O

When	O
expressed	O
in	O
Jurkat	B-cell_line
T	I-cell_line
cells	I-cell_line
,	O
recombinant	O
NFAT1	B-protein
is	O
regulated	O
,	O
as	O
expected	O
,	O
by	O
the	O
calmodulin-dependent	B-protein
phosphatase	I-protein
calcineurin	B-protein
,	O
and	O
its	O
function	O
is	O
inhibited	O
by	O
the	O
immunosuppressive	O
agent	O
cyclosporin	O
A	O
(	O
CsA	O
)	O
.	O

Transactivation	O
by	O
recombinant	O
NFAT1	B-protein
in	O
Jurkat	B-cell_line
T	I-cell_line
cells	I-cell_line
requires	O
dual	O
stimulation	O
with	O
ionomycin	O
and	O
phorbol	O
12-myristate	O
13-acetate	O
;	O
this	O
activity	O
is	O
potentiated	O
by	O
coexpression	O
of	O
constitutively	O
active	O
calcineurin	B-protein
and	O
is	O
inhibited	O
by	O
CsA	O
.	O

Immunocytochemical	O
analysis	O
indicates	O
that	O
recombinant	O
NFAT1	B-protein
localizes	O
in	O
the	O
cytoplasm	O
of	O
transiently	B-cell_type
transfected	I-cell_type
T	I-cell_type
cells	I-cell_type
and	O
translocates	O
into	O
the	O
nucleus	O
in	O
a	O
CsA-sensitive	O
manner	O
following	O
ionomycin	O
stimulation	O
.	O

When	O
expressed	O
in	O
COS	B-cell_line
cells	I-cell_line
,	O
however	O
,	O
NFAT1	B-protein
is	O
capable	O
of	O
transactivation	O
,	O
but	O
it	O
is	O
not	O
regulated	O
correctly	O
:	O
its	O
subcellular	O
localization	O
and	O
transcriptional	O
function	O
are	O
not	O
affected	O
by	O
stimulation	O
of	O
the	O
COS	B-cell_line
cells	I-cell_line
with	O
ionomycin	O
and	O
phorbol	O
12-myristate	O
13-acetate	O
.	O

Recombinant	O
NFAT1	B-protein
can	O
mediate	O
transcription	O
of	O
the	O
interleukin-2	B-protein
,	O
interleukin-4	O
,	O
tumor	B-protein
necrosis	I-protein
factor	I-protein
alpha	I-protein
,	O
and	O
granulocyte-macrophage	B-DNA
colony-stimulating	I-DNA
factor	I-DNA
promoters	I-DNA
in	O
T	B-cell_type
cells	I-cell_type
,	O
suggesting	O
that	O
NFAT1	B-protein
contributes	O
to	O
the	O
CsA-sensitive	O
transcription	O
of	O
these	O
genes	B-DNA
during	O
the	O
immune	O
response	O
.	O

Human	B-protein
TAFII	I-protein
105	I-protein
is	O
a	O
cell	B-protein
type-specific	I-protein
TFIID	I-protein
subunit	I-protein
related	O
to	O
hTAFII130	B-protein
.	O

We	O
previously	O
characterized	O
Drosophila	B-protein
and	I-protein
human	I-protein
TAF	I-protein
subunits	I-protein
that	O
make	O
up	O
the	O
core	O
TFIID	B-protein
complex	I-protein
found	O
in	O
all	O
cells	O
.	O

Here	O
,	O
we	O
report	O
that	O
differentiated	B-cell_type
B	I-cell_type
cells	I-cell_type
contain	O
a	O
novel	O
substoichiometric	O
TAF	B-protein
of	O
105	O
kDa	O
not	O
found	O
associated	O
with	O
TFIID	B-protein
isolated	O
from	O
other	O
cell	O
types	O
.	O

The	O
cDNA	B-DNA
encoding	O
hTAFII105	B-protein
reveals	O
a	O
highly	O
conserved	O
C-terminal	B-protein
domain	I-protein
shared	O
by	O
hTAFII130	B-protein
and	O
oTAFII110	B-protein
,	O
while	O
the	O
N-terminal	B-protein
coactivator	I-protein
domain	I-protein
has	O
diverged	O
significantly	O
.	O

All	O
cells	O
tested	O
express	O
TAFII105	B-RNA
mRNA	I-RNA
,	O
but	O
only	O
B	B-cell_type
cells	I-cell_type
contain	O
significant	O
levels	O
of	O
protein	O
associated	O
with	O
TFIID	B-protein
.	O

Transient	O
overexpression	O
of	O
hTAFII105	B-protein
selectively	O
squelches	O
the	O
transcription	O
of	O
some	O
genes	O
in	O
B	B-cell_type
cells	I-cell_type
.	O

These	O
properties	O
suggest	O
that	O
TAFII105	B-protein
is	O
a	O
cell	O
type-specific	O
subunit	O
of	O
TFIID	B-protein
that	O
may	O
be	O
responsible	O
for	O
mediating	O
transcription	O
by	O
a	O
subset	O
of	O
activators	O
in	O
B	B-cell_type
cells	I-cell_type
.	O

Interstitial	O
deletion	O
constitutes	O
the	O
major	O
mechanism	O
for	O
loss	O
of	O
heterozygosity	O
on	O
chromosome	B-DNA
20q	I-DNA
in	O
polycythemia	O
vera	O
.	O

An	O
acquired	O
deletion	O
of	O
the	O
long	O
arm	O
of	O
chromosome	B-DNA
20	I-DNA
is	O
a	O
recurrent	O
abnormality	O
in	O
myeloproliferative	O
disorders	O
,	O
particularly	O
polycythemia	O
vera	O
and	O
myelodysplastic	O
syndromes	O
.	O

The	O
association	O
of	O
20q	B-DNA
deletions	I-DNA
with	O
myeloid	O
``	O
stem	O
cell	O
''	O
disorders	O
suggests	O
that	O
the	O
deletions	O
mark	O
the	O
site	O
of	O
one	O
or	O
more	O
genes	O
,	O
loss	O
or	O
inactivation	O
of	O
which	O
plays	O
a	O
role	O
in	O
the	O
regulation	O
of	O
normal	B-cell_type
hematopoietic	I-cell_type
progenitors	I-cell_type
.	O

We	O
have	O
recently	O
performed	O
a	O
detailed	O
molecular	O
analysis	O
of	O
20q	B-DNA
deletions	I-DNA
in	O
peripheral	B-cell_type
blood	I-cell_type
(	I-cell_type
PB	I-cell_type
)	I-cell_type
granulocytes	I-cell_type
and	O
defined	O
a	O
commonly	B-DNA
deleted	I-DNA
region	I-DNA
of	O
16	O
to	O
21	O
centimorgan	O
(	O
cM	O
)	O
.	O

To	O
further	O
reduce	O
the	O
size	O
of	O
the	O
common	O
deleted	O
region	O
we	O
have	O
searched	O
for	O
small	O
deletions	O
or	O
mitotic	O
recombination	O
events	O
,	O
neither	O
of	O
which	O
would	O
be	O
detected	O
by	O
conventional	O
cytogenetics	O
.	O

We	O
have	O
studied	O
48	O
patients	O
with	O
polycythemia	O
vera	O
and	O
four	O
patients	O
with	O
idiopathic	O
myelofibrosis	O
.	O

In	O
each	O
case	O
,	O
cytogenetic	O
analysis	O
had	O
either	O
failed	O
or	O
had	O
shown	O
no	O
abnormalities	O
of	O
chromosome	B-DNA
20	I-DNA
.	O

Seventeen	O
microsatellite	B-DNA
markers	I-DNA
that	O
span	O
the	O
common	O
deleted	O
region	O
were	O
used	O
to	O
search	O
for	O
loss	O
of	O
heterozygosity	O
in	O
granulocyte	B-DNA
DNA	I-DNA
.	O

No	O
instance	O
of	O
microsatellite	O
instability	O
was	O
observed	O
in	O
a	O
total	O
of	O
880	O
comparisons	O
of	O
granulocyte	B-DNA
and	I-DNA
T-cell	I-DNA
DNA	I-DNA
.	O

Granulocyte	O
DNA	O
from	O
four	O
patients	O
exhibited	O
allele	O
loss	O
on	O
20q	B-DNA
.	O

In	O
each	O
case	O
the	O
allele	O
loss	O
was	O
caused	O
by	O
an	O
interstitial	O
deletion	O
because	O
heterozygosity	O
at	O
distal	B-DNA
markers	I-DNA
was	O
retained	O
and	O
because	O
quantitative	O
Southern	O
blotting	O
demonstrated	O
hemizygosity	O
.	O

Loss	O
of	O
heterozygosity	O
in	O
PB	B-cell_type
granulocytes	I-cell_type
would	O
be	O
masked	O
by	O
the	O
presence	O
of	O
significant	O
numbers	O
of	O
normal	B-cell_type
granulocytes	I-cell_type
not	O
derived	O
from	O
the	O
malignant	B-cell_line
clone	I-cell_line
.	O

Therefore	O
,	O
the	O
human	B-protein
androgen	I-protein
receptor	I-protein
assay	O
(	O
HUMARA	O
)	O
was	O
used	O
to	O
determine	O
granulocyte	O
clonality	O
.	O

In	O
21	O
of	O
27	O
informative	O
female	O
patients	O
the	O
majority	O
of	O
the	O
granulocytes	B-cell_type
were	O
clonally	O
derived	O
.	O

In	O
5	O
patients	O
the	O
granulocytes	B-cell_type
appeared	O
polyclonal	O
and	O
in	O
1	O
patient	O
unilateral	O
X	O
inactivation	O
was	O
observed	O
in	O
both	O
granulocytes	B-cell_type
and	O
T	B-cell_type
cells	I-cell_type
.	O

These	O
results	O
show	O
that	O
,	O
in	O
the	O
vast	O
majority	O
of	O
patients	O
presented	O
here	O
,	O
the	O
failure	O
to	O
detect	O
loss	O
of	O
heterozygosity	O
can	O
not	O
be	O
attributed	O
to	O
the	O
presence	O
of	O
normal	B-cell_line
polyclonal	I-cell_line
granulocytes	I-cell_line
.	O

Our	O
results	O
therefore	O
show	O
that	O
allele	O
loss	O
on	O
chromosome	B-DNA
20q	I-DNA
in	O
polycythemia	O
vera	O
does	O
not	O
commonly	O
involve	O
mitotic	O
recombination	O
or	O
chromosome	B-DNA
loss	O
and	O
that	O
microsatellite	O
instability	O
is	O
a	O
rare	O
event	O
in	O
this	O
disorder	O
.	O

Interleukin-6	B-protein
promotes	O
multiple	O
myeloma	O
cell	O
growth	O
via	O
phosphorylation	O
of	O
retinoblastoma	B-protein
protein	I-protein
.	O

Interleukin-6	B-protein
(	O
IL-6	B-protein
)	O
mediates	O
autocrine	O
and	O
paracrine	O
growth	O
of	O
multiple	B-cell_line
myeloma	I-cell_line
(	I-cell_line
MM	I-cell_line
)	I-cell_line
cells	I-cell_line
and	O
inhibits	O
tumor	O
cell	O
apoptosis	O
.	O

Abnormalities	O
of	O
retinoblastoma	B-protein
protein	I-protein
(	O
pRB	B-protein
)	O
and	O
mutations	O
of	O
RB	O
gene	O
have	O
been	O
reported	O
in	O
up	O
to	O
70	O
%	O
of	O
MM	O
patients	O
and	O
80	O
%	O
of	O
MM-derived	B-cell_line
cell	I-cell_line
lines	I-cell_line
.	O

Because	O
dephosphorylated	B-protein
(	I-protein
activated	I-protein
)	I-protein
pRB	I-protein
blocks	O
transition	O
from	O
G1	O
to	O
S	O
phase	O
of	O
the	O
cell	O
cycle	O
whereas	O
phosphorylated	B-protein
(	I-protein
inactivated	I-protein
)	I-protein
pRB	I-protein
releases	O
this	O
growth	O
arrest	O
,	O
we	O
characterized	O
the	O
role	O
of	O
pRB	B-protein
in	O
IL-6	B-protein
-mediated	O
MM	O
cell	O
growth	O
.	O

Both	O
phosphorylated	O
and	O
dephosphorylated	O
pRB	B-protein
were	O
expressed	O
in	O
all	O
serum-starved	O
MM	O
patient	O
cells	O
and	O
MM-derived	B-cell_line
cell	I-cell_line
lines	I-cell_line
,	O
but	O
pRB	B-protein
was	O
predominantly	O
in	O
its	O
phosphorylated	O
form	O
.	O

In	O
MM	B-cell_line
cells	I-cell_line
that	O
proliferated	O
in	O
response	O
to	O
IL-6	B-protein
,	O
exogenous	O
IL-6	B-protein
downregulated	O
dephosphorylated	B-protein
pRB	I-protein
and	O
decreased	O
dephosphorylated	O
pRB-E2F	B-protein
complexes	I-protein
.	O

Importantly	O
,	O
culture	O
of	O
MM	B-cell_line
cells	I-cell_line
with	O
RB	O
antisense	O
,	O
but	O
not	O
RB	O
sense	O
,	O
oligonucleotide	O
(	O
ODN	O
)	O
triggered	O
IL-6	B-protein
secretion	O
and	O
proliferation	O
in	O
MM	B-cell_line
cells	I-cell_line
;	O
however	O
,	O
proliferation	O
was	O
only	O
partially	O
inhibited	O
by	O
neutralizing	O
anti-IL-6	B-protein
monoclonal	I-protein
antibody	I-protein
(	O
MoAb	B-protein
)	O
.	O

In	O
contrast	O
to	O
MM	B-cell_line
cells	I-cell_line
,	O
normal	O
splenic	B-cell_type
B	I-cell_type
cells	I-cell_type
express	O
dephosphorylated	B-protein
pRB	I-protein
.	O

Although	O
CD40	B-protein
ligand	I-protein
(	O
CD40L	B-protein
)	O
triggers	O
a	O
shift	O
from	O
dephosphorylated	O
to	O
phosphorylated	O
pRB	B-protein
and	O
proliferation	O
of	O
B	B-cell_type
cells	I-cell_type
,	O
the	O
addition	O
of	O
exogenous	O
IL-6	B-protein
to	O
CD40L	B-protein
-treated	O
B	B-cell_type
cells	I-cell_type
does	O
not	O
alter	O
either	O
pRB	B-protein
or	O
proliferation	O
,	O
as	O
observed	O
in	O
MM	B-cell_line
cells	I-cell_line
.	O

These	O
results	O
suggest	O
that	O
phosphorylated	B-protein
pRB	I-protein
is	O
constitutively	O
expressed	O
in	O
MM	B-cell_line
cells	I-cell_line
and	O
that	O
IL-6	B-protein
further	O
shifts	O
pRB	B-protein
from	O
its	O
dephosphorylated	O
to	O
its	O
phosphorylated	O
form	O
,	O
thereby	O
promoting	O
MM	O
cell	O
growth	O
via	O
two	O
mechanisms	O
;	O
by	O
decreasing	O
the	O
amount	O
of	O
E2F	O
bound	O
by	O
dephosphorylated	B-protein
pRB	I-protein
due	O
to	O
reduced	O
dephosphorylated	B-protein
pRB	I-protein
,	O
thereby	O
releasing	O
growth	O
arrest	O
;	O
and	O
by	O
upregulating	O
IL-6	B-protein
secretion	O
by	O
MM	B-cell_line
cells	I-cell_line
and	O
related	O
IL-6	B-protein
-mediated	O
autocrine	O
tumor	O
cell	O
growth	O
.	O

Soluble	B-protein
factors	I-protein
secreted	O
by	O
activated	B-cell_type
T-lymphocytes	I-cell_type
modulate	O
the	O
transcription	O
of	O
the	O
immunosuppressive	B-protein
cytokine	I-protein
TGF-beta	B-protein
2	I-protein
in	O
glial	B-cell_type
cells	I-cell_type
.	O

Coordination	O
of	O
the	O
immune	O
response	O
to	O
injury	O
or	O
disease	O
in	O
the	O
brain	O
is	O
postulated	O
to	O
involve	O
bi-directional	O
discourse	O
between	O
the	O
immune	O
system	O
and	O
the	O
central	O
nervous	O
system	O
.	O

This	O
cross	O
communication	O
involves	O
soluble	O
mediators	O
,	O
including	O
various	O
growth	B-protein
factors	I-protein
,	O
cytokines	B-protein
,	O
and	O
neuropeptides	O
.	O

In	O
this	O
report	O
,	O
we	O
demonstrate	O
that	O
the	O
supernatant	O
from	O
activated	B-cell_type
T-lymphocytes	I-cell_type
is	O
able	O
to	O
induce	O
the	O
transcription	O
of	O
a	O
potent	O
cytokine	B-protein
,	O
TGF-beta	B-protein
2	I-protein
in	O
glial	B-cell_type
cells	I-cell_type
.	O

The	O
activating	O
stimulus	O
invokes	O
signaling	O
mechanisms	O
distinct	O
from	O
known	O
kinase	O
or	O
protease	O
pathways	O
.	O

Activation	O
of	O
TGF-beta	B-protein
2	I-protein
transcription	O
correlates	O
with	O
the	O
loss	O
of	O
binding	O
activity	O
for	O
an	O
80	B-protein
kDA	I-protein
glial	I-protein
labile	I-protein
repressor	I-protein
protein	I-protein
,	O
GLRP	B-protein
,	O
to	O
a	O
responsive	O
region	O
within	O
the	O
TFG-beta	B-DNA
2	I-DNA
promoter	I-DNA
.	O

Although	O
GLRP	B-protein
shares	O
some	O
characteristics	O
with	O
the	O
inducible	O
transcription	B-protein
factor	I-protein
AP-1	B-protein
,	O
it	O
appears	O
to	O
be	O
distinct	O
from	O
known	O
AP-1	B-protein
family	I-protein
members	I-protein
.	O

These	O
data	O
along	O
with	O
previous	O
observations	O
demonstrating	O
the	O
potent	O
immunosuppressive	O
activity	O
of	O
TGF-beta	B-protein
2	I-protein
,	O
support	O
a	O
model	O
for	O
a	O
feedback	O
mechanism	O
between	O
the	O
activated	O
T-lymphocytes	B-cell_type
and	O
astrocytes	B-cell_type
via	O
TGF-beta	B-protein
2	I-protein
to	O
regulate	O
the	O
immune	O
response	O
.	O

Various	O
modes	O
of	O
basic	B-protein
helix-loop-helix	I-protein
protein	I-protein
-mediated	O
regulation	O
of	O
murine	O
leukemia	O
virus	O
transcription	O
in	O
lymphoid	B-cell_line
cell	I-cell_line
lines	I-cell_line
.	O

The	O
transcriptionally	B-DNA
regulatory	I-DNA
regions	I-DNA
of	O
the	O
lymphomagenic	O
Akv	O
and	O
SL3-3	O
murine	O
leukemia	O
retroviruses	O
(	O
MLVs	O
)	O
contain	O
two	O
types	O
of	O
E-box	B-DNA
consensus	I-DNA
motifs	I-DNA
,	O
CAGATG	O
.	O

One	O
type	O
,	O
EA/S	B-DNA
,	O
is	O
located	O
in	O
the	O
upstream	B-DNA
promoter	I-DNA
region	I-DNA
,	O
and	O
the	O
other	O
,	O
E	B-DNA
(	I-DNA
gre	I-DNA
)	I-DNA
,	O
is	O
located	O
in	O
a	O
tandem	B-DNA
repeat	I-DNA
with	O
enhancer	O
properties	O
.	O

We	O
have	O
examined	O
the	O
requirements	O
of	O
the	O
individual	O
E-boxes	B-DNA
in	O
MLV	O
transcriptional	O
regulation	O
.	O

In	O
lymphoid	B-cell_line
cell	I-cell_line
lines	I-cell_line
only	O
,	O
the	O
E	B-protein
(	I-protein
gre	I-protein
)	I-protein
-binding	I-protein
protein	I-protein
complexes	I-protein
included	O
ALF1	B-protein
or	O
HEB	B-protein
and	O
E2A	B-protein
basic	I-protein
helix-loop-helix	I-protein
proteins	I-protein
.	O

Ectopic	O
ALF1	B-protein
and	O
E2A	B-protein
proteins	I-protein
required	O
intact	O
E	B-DNA
(	I-DNA
gre	I-DNA
)	I-DNA
motifs	I-DNA
for	O
mediating	O
transcriptional	O
activation	O
.	O

ALF1	B-protein
transactivated	O
transcription	O
of	O
Akv	O
MLV	O
through	O
the	O
two	O
E	B-DNA
(	I-DNA
gre	I-DNA
)	I-DNA
motifs	I-DNA
equally	O
,	O
whereas	O
E2A	B-protein
protein	I-protein
required	O
the	O
promoter-proximal	O
E	B-DNA
(	I-DNA
gre	I-DNA
)	I-DNA
motif	O
.	O

In	O
T-	B-cell_line
and	I-cell_line
B-cell	I-cell_line
lines	I-cell_line
,	O
the	O
E	B-DNA
(	I-DNA
gre	I-DNA
)	I-DNA
motifs	I-DNA
were	O
of	O
major	O
importance	O
for	O
Akv	O
MLV	O
transcriptional	O
activity	O
,	O
while	O
the	O
EA/S	B-DNA
motif	I-DNA
had	O
some	O
effect	O
.	O

In	O
contrast	O
,	O
neither	O
E	B-DNA
(	I-DNA
gre	I-DNA
)	I-DNA
nor	O
EA/S	B-DNA
motifs	I-DNA
contributed	O
pronouncedly	O
to	O
Akv	O
MLV	O
transcription	O
in	O
NIH	B-cell_line
3T3	I-cell_line
cells	I-cell_line
lacking	O
DNA-binding	O
ALF1	B-protein
or	O
HEB	B-protein
and	O
E2A	B-protein
proteins	I-protein
.	O

The	O
Id1	O
protein	O
was	O
found	O
to	O
repress	O
ALF1	B-protein
activity	O
in	O
vitro	O
and	O
in	O
vivo	O
.	O

Moreover	O
,	O
ectopic	B-protein
Id1	I-protein
repressed	O
E	B-DNA
(	I-DNA
gre	I-DNA
)	I-DNA
-directed	O
but	O
not	O
EA/S	B-DNA
-directed	O
MLV	O
transcription	O
in	O
lymphoid	B-cell_line
cell	I-cell_line
lines	I-cell_line
.	O

In	O
conclusion	O
,	O
E	B-DNA
(	I-DNA
gre	I-DNA
)	I-DNA
motifs	O
and	O
interacting	O
basic	B-protein
helix-loop-helix	I-protein
proteins	I-protein
are	O
important	O
determinants	O
for	O
MLV	O
transcriptional	O
activity	O
in	O
lymphocytic	B-cell_line
cell	I-cell_line
lines	I-cell_line
.	O

Reversal	O
of	O
apoptosis	O
by	O
the	O
leukaemia-associated	O
E2A-HLF	B-protein
chimaeric	I-protein
transcription	I-protein
factor	I-protein
.	O

The	O
E2A-HLF	B-DNA
(	I-DNA
for	I-DNA
hepatic	I-DNA
leukaemia	I-DNA
factor	I-DNA
)	I-DNA
fusion	I-DNA
gene	I-DNA
,	O
formed	O
by	O
action	O
of	O
the	O
t	B-DNA
(	I-DNA
17	I-DNA
;	I-DNA
19	I-DNA
)	I-DNA
(	I-DNA
q22	I-DNA
;	I-DNA
p13	I-DNA
)	I-DNA
chromosomal	O
translocation	O
,	O
drives	O
the	O
leukaemic	O
transformation	O
of	O
early	O
B-cell	B-cell_type
precursors	I-cell_type
,	O
but	O
the	O
mechanism	O
of	O
this	O
activity	O
remains	O
unknown	O
.	O

Here	O
we	O
report	O
that	O
human	B-cell_type
leukaemia	I-cell_type
cells	I-cell_type
carrying	O
the	O
translocation	O
t	B-DNA
(	I-DNA
17	I-DNA
;	I-DNA
19	I-DNA
)	I-DNA
rapidly	O
died	O
by	O
apoptosis	O
when	O
programmed	O
to	O
express	O
a	O
dominant-negative	O
suppressor	O
of	O
the	O
fusion	O
protein	O
E2A-HLF	B-protein
,	O
indicating	O
that	O
the	O
chimaeric	B-protein
oncoprotein	I-protein
probably	O
affects	O
cell	O
survival	O
rather	O
than	O
cell	O
growth	O
.	O

Moreover	O
,	O
when	O
introduced	O
into	O
murine	B-cell_line
pro-B	I-cell_line
lymphocytes	I-cell_line
,	O
the	O
oncogenic	B-protein
E2A-HLF	I-protein
fusion	I-protein
protein	I-protein
reversed	O
both	O
interleukin-3-dependent	O
and	O
p53-mediated	O
apoptosis	O
.	O

The	O
close	O
homology	O
of	O
the	O
basic	B-protein
region/leucine	I-protein
zipper	I-protein
(	O
bZIP	B-protein
)	O
DNA-binding	O
and	O
dimerization	B-protein
domain	I-protein
of	O
HLF	B-protein
to	O
that	O
of	O
the	O
CES-2	B-protein
cell-death	I-protein
specification	I-protein
protein	I-protein
of	O
Caenorhabditis	O
elegans	O
suggests	O
a	O
model	O
of	O
leukaemogenesis	O
in	O
which	O
E2A-HLF	B-protein
blocks	O
an	O
early	O
step	O
within	O
an	O
evolutionarily	O
conserved	O
cell-death	O
pathway	O
.	O

The	O
role	O
of	O
early	B-DNA
growth	I-DNA
response	I-DNA
gene	I-DNA
1	I-DNA
(	O
egr-1	B-DNA
)	O
in	O
regulation	O
of	O
the	O
immune	O
response	O
.	O

The	O
induction	O
of	O
immediate	B-DNA
early	I-DNA
genes	I-DNA
in	O
cells	O
of	O
the	O
immune	O
system	O
is	O
critical	O
to	O
determining	O
the	O
ultimate	O
outcome	O
of	O
exposure	O
to	O
antigen	O
.	O

The	O
importance	O
of	O
many	O
of	O
these	O
genes	O
relates	O
to	O
the	O
role	O
their	O
transcription	B-protein
factor	I-protein
products	I-protein
play	O
in	O
dictating	O
patterns	O
of	O
expression	O
of	O
downstream	O
,	O
function-related	B-DNA
genes	I-DNA
.	O

Evidence	O
from	O
several	O
systems	O
indicates	O
that	O
the	O
immediate	B-DNA
early	I-DNA
gene	I-DNA
,	O
egr-1	B-DNA
may	O
be	O
of	O
particular	O
importance	O
in	O
the	O
immune	O
system	O
.	O

Recently	O
,	O
the	O
egr-1	B-DNA
promoter	I-DNA
has	O
been	O
shown	O
to	O
be	O
highly	O
responsive	O
to	O
the	O
diverse	O
biochemical	O
signals	O
generated	O
by	O
antigen	O
and	O
cytokines	B-protein
in	O
cells	O
of	O
the	O
immune	O
system	O
.	O

Furthermore	O
,	O
an	O
important	O
role	O
for	O
egr-1	B-DNA
in	O
determining	O
the	O
differentiation	O
pathway	O
of	O
myeloid	B-cell_type
cell	I-cell_type
precursors	I-cell_type
has	O
been	O
recently	O
elaborated	O
.	O

Finally	O
,	O
potential	O
targets	O
of	O
regulation	O
by	O
the	O
zinc-finger	B-protein
transcription	I-protein
factor	I-protein
encoded	O
by	O
egr-1	B-DNA
include	O
the	O
interleukin-2	B-DNA
,	I-DNA
CD44	I-DNA
,	I-DNA
ICAM-1	I-DNA
,	I-DNA
and	I-DNA
tumor	I-DNA
necrosis	I-DNA
factor	I-DNA
genes	I-DNA
.	O

The	O
role	O
of	O
egr-1	B-DNA
in	O
regulation	O
of	O
the	O
immune	O
response	O
will	O
be	O
discussed	O
in	O
the	O
context	O
of	O
these	O
recent	O
studies	O
.	O

Peptide	O
vaccination	O
can	O
lead	O
to	O
enhanced	O
tumor	O
growth	O
through	O
specific	O
T-cell	O
tolerance	O
induction	O
.	O

Vaccination	O
with	O
synthetic	O
peptides	O
representing	O
cytotoxic	O
T	O
lymphocyte	O
(	O
CTL	O
)	O
epitopes	O
can	O
lead	O
to	O
a	O
protective	O
CTL-mediated	O
immunity	O
against	O
tumors	O
or	O
viruses	O
.	O

We	O
now	O
report	O
that	O
vaccination	O
with	O
a	O
CTL	O
epitope	O
derived	O
from	O
the	O
human	B-DNA
adenovirus	I-DNA
type	I-DNA
5	I-DNA
E1A-region	I-DNA
(	O
Ad5E1A234-243	B-DNA
)	O
,	O
which	O
can	O
serve	O
as	O
a	O
target	O
for	O
tumor-eradicating	B-cell_type
CTL	I-cell_type
,	O
enhances	O
rather	O
than	O
inhibits	O
the	O
growth	O
of	O
Ad5E1A-expressing	O
tumors	O
.	O

This	O
adverse	O
effect	O
of	O
peptide	O
vaccination	O
was	O
rapidly	O
evoked	O
,	O
required	O
low	O
doses	O
of	O
peptide	O
(	O
10	O
micrograms	O
)	O
,	O
and	O
was	O
achieved	O
by	O
a	O
mode	O
of	O
peptide	O
delivery	O
that	O
induces	O
protective	O
T-cell-mediated	O
immunity	O
in	O
other	O
models	O
.	O

Ad5E1A	B-protein
-specific	O
CTL	O
activity	O
could	O
no	O
longer	O
be	O
isolated	O
from	O
mice	O
after	O
injection	O
of	O
Ad5E1A-peptide	O
,	O
indicating	O
that	O
tolerization	O
of	O
Ad5E1A	B-protein
-specific	O
CTL	O
activity	O
causes	O
the	O
enhanced	O
tumor	O
outgrowth	O
.	O

In	O
contrast	O
to	O
peptide	O
vaccination	O
,	O
immunization	O
with	O
adenovirus	O
,	O
expressing	O
Ad5E1A	B-protein
,	O
induced	O
Ad5E1A	B-protein
-specific	O
immunity	O
and	O
prevented	O
the	O
outgrowth	O
of	O
Ad5E1A	B-protein
-expressing	O
tumors	O
.	O

These	O
results	O
show	O
that	O
immunization	O
with	O
synthetic	O
peptides	O
can	O
lead	O
to	O
the	O
elimination	O
of	O
anti-tumor	O
CTL	O
responses	O
.	O

These	O
findings	O
are	O
important	O
for	O
the	O
design	O
of	O
safe	O
peptide-based	O
vaccines	O
against	O
tumors	O
,	O
allogeneic	O
organ	O
transplants	O
,	O
and	O
T-cell-mediated	O
autoimmune	O
diseases	O
.	O

[	O
NGFI-B/nur77	B-protein
family	I-protein
involved	O
in	O
T-cell	O
apoptosis	O
]	O

NGFI-B/nur77	B-protein
is	O
a	O
member	O
of	O
the	O
steroid	B-protein
receptor	I-protein
superfamily	I-protein
.	O

NGFI-B/nur77	B-protein
and	O
its	O
related	O
genes	O
constitute	O
a	O
family	O
and	O
the	O
NGFI-B/nur77	B-protein
family	I-protein
consists	O
of	O
three	O
subtypes	O
,	O
named	O
nur77	B-protein
alpha	I-protein
,	O
nur77	B-protein
beta	I-protein
,	O
nur77	B-protein
gamma	I-protein
.	O

We	O
cloned	O
human	O
nur77	B-DNA
beta	I-DNA
cDNA	I-DNA
,	O
called	O
TINUR	B-DNA
.	O

Although	O
NGFI-B/nur77	B-protein
is	O
essential	O
for	O
TCR-mediated	O
apoptosis	O
in	O
T-cell	B-protein
hybridomas	I-protein
,	O
the	O
reports	O
on	O
nur77	O
knock-out	O
mice	O
and	O
nur77	O
dominant	O
negative	O
transgenic	O
mice	O
suggest	O
that	O
there	O
is	O
a	O
functional	O
redundancy	O
among	O
NGFI-B/nur77	B-protein
family	I-protein
.	O

NGFI-B/nur77	B-protein
binds	O
to	O
the	O
response	B-DNA
element	I-DNA
by	O
monomer	O
or	O
heterodimer	O
with	O
retinoid	B-protein
X	I-protein
receptor	I-protein
(	O
RXR	B-protein
)	O
.	O

Assuming	O
that	O
9-cis-retinoic	O
acid	O
(	O
9-cis-RA	O
)	O
inhibits	O
TCR-mediated	O
apoptosis	O
,	O
nur77	B-protein
may	O
cause	O
apoptosis	O
by	O
monomer	O
in	O
the	O
absence	O
of	O
9-cis-RA	O
and	O
may	O
inhibit	O
apoptosis	O
by	O
heterodimer	O
with	O
RXR	B-protein
in	O
the	O
presence	O
of	O
9-cis-RA	O
.	O

Glucocorticoids	O
and	O
interferon-alpha	B-protein
in	O
the	O
acquired	O
immunodeficiency	O
syndrome	O
.	O

Some	O
patients	O
with	O
acquired	O
immunodeficiency	O
syndrome	O
(	O
AIDS	O
)	O
develop	O
glucocorticoid	O
resistance	O
characterized	O
by	O
low	O
receptor	O
affinity	O
(	O
Kd	O
)	O
for	O
glucocorticoids	O
in	O
mononuclear	B-cell_type
,	O
cells	O
and	O
high	O
values	O
of	O
ACTH	O
and	O
cortisol	O
.	O

As	O
glucocorticoids	O
regulate	O
interferon-alpha	B-protein
(	O
IFN	B-protein
alpha	I-protein
)	O
production	O
,	O
we	O
hypothesized	O
that	O
IFN	B-protein
alpha	I-protein
,	O
a	O
cytokine	B-protein
produced	O
predominantly	O
by	O
monocytes	B-cell_type
in	O
AIDS	O
,	O
should	O
be	O
increased	O
in	O
cortisol-resistant	O
AIDS	O
,	O
attributing	O
the	O
lack	O
of	O
cortisol	O
inhibition	O
to	O
IFN	B-protein
alpha	I-protein
production	O
.	O

Therefore	O
,	O
we	O
examined	O
glucocorticoid	B-protein
receptor	I-protein
characteristics	O
on	O
monocytes	B-cell_type
by	O
[	O
3H	O
]	O
dexamethasone	O
binding	O
and	O
measured	O
IFN	B-protein
alpha	I-protein
,	O
cortisol	O
,	O
and	O
ACTH	O
in	O
AIDS	O
patients	O
with	O
(	O
AIDS-GR	O
)	O
or	O
without	O
glucocorticoid	O
resistance	O
(	O
AIDS-C	O
)	O
and	O
controls	O
(	O
C	O
)	O
.	O

Monocytes	O
of	O
AIDS-GR	O
patients	O
had	O
a	O
receptor	O
Kd	O
of	O
10.5	O
+/-	O
4.2	O
nmol/L	O
that	O
was	O
higher	O
than	O
that	O
in	O
the	O
AIDS-C	O
group	O
(	O
2.9	O
+/-	O
0.8	O
nmol/L	O
)	O
and	O
normal	O
subjects	O
(	O
2.0	O
+/-	O
0.8	O
nmol/L	O
;	O
P	O
<	O
0.01	O
)	O
.	O

IFN	B-protein
alpha	I-protein
levels	O
were	O
increased	O
in	O
the	O
AIDS-GR	O
group	O
(	O
17	O
+/-	O
6	O
vs	O
.	O

4	O
+/-	O
1	O
U/mL	O
in	O
the	O
AIDS-C	O
group	O
and	O
2	O
+/-	O
0.5	O
U/mL	O
in	O
the	O
C	O
group	O
;	O
P	O
<	O
0.01	O
)	O
.	O

Correlations	O
were	O
found	O
between	O
plasma	B-protein
IFN	I-protein
alpha	I-protein
and	O
receptor	O
Kd	O
on	O
monocytes	B-cell_type
of	O
AIDS-GR	O
(	O
r	O
=	O
0.77	O
)	O
and	O
between	O
IFN	B-protein
alpha	I-protein
and	O
plasma	O
cortisol	O
in	O
the	O
same	O
group	O
(	O
r	O
=	O
0.74	O
)	O
.	O

The	O
poly	B-protein
(	I-protein
I	I-protein
)	I-protein
-poly	I-protein
(	I-protein
C	I-protein
)	I-protein
-induced	I-protein
IFN	I-protein
alpha	I-protein
production	O
by	O
monocytes	B-cell_type
was	O
inhibited	O
by	O
glucocorticoids	O
in	O
the	O
C	O
and	O
AIDS-C	O
groups	O
(	O
approximately	O
80	O
%	O
inhibition	O
in	O
both	O
groups	O
)	O
;	O
the	O
effect	O
was	O
reversed	O
by	O
the	O
receptor	O
antagonist	O
RU-38486	O
.	O

By	O
contrast	O
,	O
glucocorticoids	O
failed	O
to	O
inhibit	O
IFNalpha	B-protein
production	O
from	O
AIDS-GR	B-cell_type
monocytes	I-cell_type
(	O
approximately	O
20	O
%	O
inhibition	O
)	O
.	O

In	O
conclusion	O
,	O
elevated	O
IFN	B-protein
alpha	I-protein
levels	O
in	O
AIDS-GR	O
may	O
be	O
due	O
to	O
the	O
lack	O
of	O
inhibitory	O
effect	O
of	O
cortisol	O
on	O
IFN	B-protein
alpha	I-protein
production	O
due	O
to	O
cortisol	O
resistance	O
in	O
monocytes	B-cell_type

JNK	B-protein
(	O
c-Jun	B-protein
NH2-terminal	I-protein
kinase	I-protein
)	O
is	O
a	O
target	O
for	O
antioxidants	O
in	O
T	B-cell_type
lymphocytes	I-cell_type
.	O

AP-1	B-protein
has	O
been	O
shown	O
to	O
behave	O
as	O
a	O
redox-sensitive	B-protein
transcription	I-protein
factor	I-protein
that	O
can	O
be	O
activated	O
by	O
both	O
oxidant	O
and	O
antioxidant	O
stimuli	O
.	O

However	O
,	O
the	O
mechanisms	O
involved	O
in	O
the	O
activation	O
of	O
AP-1	B-protein
by	O
antioxidants	O
are	O
largely	O
unknown	O
.	O

In	O
this	O
study	O
we	O
show	O
that	O
the	O
structurally	O
unrelated	O
antioxidant	O
agents	O
pyrrolidine	O
dithiocarbamate	O
(	O
PDTC	O
)	O
,	O
butylated	O
hydroxyanisole	O
,	O
and	O
Nacetylcysteine	O
activated	O
JNK	B-protein
(	O
c-Jun	B-protein
NH2-terminal	I-protein
kinase	I-protein
)	O
in	O
Jurkat	B-cell_line
T	I-cell_line
cells	I-cell_line
.	O

This	O
activation	O
differed	O
substantially	O
from	O
that	O
mediated	O
by	O
phorbol	O
12-myristate	O
13-acetate	O
(	O
PMA	O
)	O
and	O
Ca2+	O
ionophore	O
or	O
produced	O
by	O
costimulation	O
with	O
antibodies	B-protein
against	O
the	O
T	B-protein
cell	I-protein
receptor-CD3	I-protein
complex	I-protein
and	O
to	O
CD28	B-protein
.	O

The	O
activation	O
of	O
JNK	B-protein
by	O
classical	O
T	O
cell	O
stimuli	O
was	O
transient	O
,	O
whereas	O
that	O
mediated	O
by	O
PDTC	O
and	O
butylated	O
hydroxyanisole	O
(	O
but	O
not	O
N-acetylcysteine	O
)	O
was	O
sustained	O
.	O

The	O
kinetics	O
of	O
JNK	B-protein
activation	O
correlated	O
with	O
the	O
expression	O
of	O
c-jun	B-DNA
which	O
was	O
transient	O
after	O
stimulation	O
with	O
PMA	O
plus	O
ionophore	O
and	O
prolonged	O
in	O
response	O
to	O
PDTC	O
,	O
which	O
also	O
transiently	O
induced	O
c-fos	B-DNA
.	O

In	O
addition	O
,	O
JNK	B-protein
activation	O
by	O
PMA	O
plus	O
ionophore	O
was	O
sensitive	O
to	O
inhibitors	O
of	O
signaling	O
pathways	O
involving	O
Ca2+	O
,	O
protein	B-protein
kinase	I-protein
C	I-protein
,	O
and	O
tyrosine	O
phosphorylation	O
,	O
which	O
failed	O
to	O
inhibit	O
the	O
activation	O
mediated	O
by	O
PDTC	O
.	O

Transfection	O
of	O
trans-dominant	B-DNA
negative	I-DNA
expression	I-DNA
vectors	I-DNA
of	O
ras	B-DNA
and	O
raf	B-DNA
,	O
together	O
with	O
AP-1-dependent	B-DNA
reporter	I-DNA
constructs	I-DNA
,	O
as	O
well	O
as	O
Western	O
blot	O
analysis	O
using	O
anti-ERK	B-protein
(	I-protein
extracellular	I-protein
signal-regulated	I-protein
kinase	I-protein
)	I-protein
antibodies	I-protein
,	O
indicated	O
that	O
the	O
Ras/Raf/ERK	O
pathway	O
did	O
not	O
appear	O
to	O
mediate	O
the	O
effect	O
of	O
the	O
antioxidant	O
.	O

However	O
,	O
the	O
combined	O
treatment	O
with	O
PDTC	O
and	O
PMA	O
,	O
two	O
agents	O
that	O
synergize	O
on	O
AP-1	B-protein
activation	O
,	O
resulted	O
in	O
the	O
persistent	O
phosphorylation	O
of	O
ERK-2	B-protein
.	O

In	O
conclusion	O
,	O
our	O
results	O
identify	O
JNK	B-protein
as	O
a	O
target	O
of	O
antioxidant	O
agents	O
which	O
can	O
be	O
regulated	O
differentially	O
under	O
oxidant	O
and	O
antioxidant	O
conditions	O
.	O

[	O
Molecular	O
mechanisms	O
of	O
age-related	O
lymphocyte	O
dysfunction	O
]	O

Aging	O
is	O
classically	O
accompanied	O
by	O
a	O
dysregulation	O
of	O
the	O
immunologic	O
machinery	O
.	O

As	O
a	O
consequence	O
,	O
the	O
immune	O
response	O
developed	O
in	O
senescent	O
organisms	O
is	O
usually	O
inappropriate	O
,	O
often	O
inefficient	O
,	O
sometimes	O
aberrant	O
,	O
and	O
potentially	O
detrimental	O
.	O

The	O
age-associated	O
immune	O
dysfunction	O
may	O
be	O
implicated	O
to	O
some	O
degree	O
in	O
the	O
extreme	O
susceptibility	O
of	O
the	O
elderly	O
to	O
infection	O
and	O
neoplasia	O
and	O
may	O
even	O
participate	O
in	O
various	O
aspects	O
of	O
senescence	O
.	O

The	O
current	O
understanding	O
of	O
the	O
molecular	O
mechanisms	O
underlying	O
immunosenescence	O
is	O
still	O
fragmentary	O
.	O

The	O
most	O
extensively	O
studied	O
phenomenon	O
is	O
the	O
progressive	O
decline	O
in	O
the	O
proliferative	O
capacities	O
of	O
T	B-cell_type
lymphocytes	I-cell_type
with	O
aging	O
.	O

The	O
loss	O
of	O
proliferative	O
potential	O
in	O
response	O
to	O
antigenic	O
challenge	O
is	O
a	O
characteristic	O
feature	O
of	O
immune	O
senescence	O
.	O

It	O
is	O
directly	O
implicated	O
in	O
the	O
emergence	O
of	O
the	O
age-related	O
immune	O
deficiency	O
.	O

The	O
purpose	O
of	O
this	O
review	O
is	O
to	O
show	O
how	O
the	O
accumulation	O
of	O
various	O
biochemical	O
lesions	O
with	O
advancing	O
age	O
leads	O
to	O
the	O
failure	O
of	O
a	O
critical	O
cell	O
function	O
,	O
namely	O
the	O
activation-induced	O
lymphocyte	O
proliferation	O
.	O

The	O
biochemical	O
modifications	O
responsible	O
for	O
the	O
defect	O
in	O
transduction	O
and	O
execution	O
of	O
the	O
proliferative	O
signal	O
are	O
analyzed	O
as	O
a	O
function	O
of	O
age	O
.	O

The	O
multiple	O
alterations	O
observed	O
on	O
the	O
various	O
biochemical	O
pathways	O
may	O
appear	O
as	O
a	O
consequence	O
of	O
a	O
unique	O
deleterious	O
mechanism	O
more	O
fundamentally	O
related	O
to	O
the	O
process	O
of	O
senescence	O
such	O
as	O
the	O
inability	O
to	O
cope	O
with	O
oxidative	O
stress	O
.	O

Induction	O
of	O
bcl-2	B-protein
expression	O
by	O
phosphorylated	O
CREB	O
proteins	O
during	O
B-cell	O
activation	O
and	O
rescue	O
from	O
apoptosis	O
.	O

Engagement	O
of	O
surface	O
immunoglobulin	O
on	O
mature	O
B	O
cells	O
leads	O
to	O
rescue	O
from	O
apoptosis	O
and	O
to	O
proliferation	O
.	O

Levels	O
of	O
bcl-2	B-RNA
mRNA	I-RNA
and	O
protein	O
increase	O
with	O
cross-linking	O
of	O
surface	B-protein
immunoglobulin	I-protein
.	O

We	O
have	O
located	O
the	O
major	O
positive	O
regulatory	O
region	O
for	O
control	O
of	O
bcl-2	B-protein
expression	O
in	O
B	B-cell_type
cells	I-cell_type
in	O
the	O
5'-flanking	B-DNA
region	I-DNA
.	O

The	O
positive	O
region	O
can	O
be	O
divided	O
into	O
an	O
upstream	B-DNA
and	I-DNA
a	I-DNA
downstream	I-DNA
regulatory	I-DNA
region	I-DNA
.	O

The	O
downstream	O
regulatory	O
region	O
contains	O
a	O
cyclic	B-DNA
AMP-responsive	I-DNA
element	I-DNA
(	O
CRE	B-DNA
)	O
.	O

We	O
show	O
by	O
antibody	O
supershift	O
experiments	O
and	O
UV	O
cross-linking	O
followed	O
by	O
denaturing	O
polyacrylamide	O
gel	O
electrophoresis	O
that	O
both	O
CREB	O
and	O
ATF	O
family	O
members	O
bind	O
to	O
this	O
region	O
in	O
vitro	O
.	O

Mutations	O
of	O
the	O
CRE	B-DNA
site	I-DNA
that	O
result	O
in	O
loss	O
of	O
CREB	B-protein
binding	O
also	O
lead	O
to	O
loss	O
of	O
functional	O
activity	O
of	O
the	O
bcl-2	O
promoter	O
in	O
transient-transfection	O
assays	O
.	O

The	O
presence	O
of	O
an	O
active	O
CRE	B-DNA
site	I-DNA
in	O
the	O
bcl-2	B-DNA
promoter	I-DNA
implies	O
that	O
the	O
regulation	O
of	O
bcl-2	B-protein
expression	O
is	O
linked	O
to	O
a	O
signal	O
transduction	O
pathway	O
in	O
B	B-cell_type
cells	I-cell_type
.	O

Treatment	O
of	O
the	O
mature	B-cell_line
B-cell	I-cell_line
line	I-cell_line
BAL-17	I-cell_line
with	O
either	O
anti-immunoglobulin	O
M	O
or	O
phorbol	O
12-myristate	O
13-acetate	O
leads	O
to	O
an	O
increase	O
in	O
bcl-2	B-protein
expression	O
that	O
is	O
mediated	O
by	O
the	O
CRE	B-DNA
site	I-DNA
.	O

Treatment	O
of	O
the	O
more	O
immature	B-cell_line
B-cell	I-cell_line
line	I-cell_line
,	O
Ramos	B-cell_line
,	O
with	O
phorbol	O
esters	O
rescues	O
the	O
cells	O
from	O
calcium-dependent	O
apoptosis	O
.	O

bcl-2	B-protein
expression	O
is	O
increased	O
following	O
phorbol	O
ester	O
treatment	O
,	O
and	O
the	O
increased	O
expression	O
is	O
dependent	O
on	O
the	O
CRE	B-DNA
site	I-DNA
.	O

These	O
stimuli	O
result	O
in	O
phosphorylation	O
of	O
CREB	B-protein
at	O
serine	O
133	O
.	O

The	O
phosphorylation	O
of	O
CREB	B-protein
that	O
results	O
in	O
activation	O
is	O
mediated	O
by	O
protein	B-protein
kinase	I-protein
C	I-protein
rather	O
than	O
by	O
protein	B-protein
kinase	I-protein
A	I-protein
.	O

Although	O
the	O
CRE	B-DNA
site	I-DNA
is	O
necessary	O
,	O
optimal	O
induction	O
of	O
bcl-2	B-protein
expression	O
requires	O
participation	O
of	O
the	O
upstream	B-DNA
regulatory	I-DNA
element	I-DNA
,	O
suggesting	O
that	O
phosphorylation	O
of	O
CREB	B-protein
alters	O
its	O
interaction	O
with	O
the	O
upstream	B-DNA
regulatory	I-DNA
element	I-DNA
.	O

The	O
CRE	B-DNA
site	I-DNA
in	O
the	O
bcl-2	B-DNA
promoter	I-DNA
appears	O
to	O
play	O
a	O
major	O
role	O
in	O
the	O
induction	O
of	O
bcl-2	B-protein
expression	O
during	O
the	O
activation	O
of	O
mature	B-cell_type
B	I-cell_type
cells	I-cell_type
and	O
during	O
the	O
rescue	O
of	O
immature	B-cell_type
B	I-cell_type
cells	I-cell_type
from	O
apoptosis	O
.	O

It	O
is	O
possible	O
that	O
the	O
CRE	B-DNA
site	I-DNA
is	O
responsible	O
for	O
induction	O
of	O
bcl-2	B-protein
expression	O
in	O
other	O
cell	O
types	O
,	O
particularly	O
those	O
in	O
which	O
protein	B-protein
kinase	I-protein
C	I-protein
is	O
involved	O
.	O

Characterization	O
of	O
the	O
human	B-DNA
myeloid	I-DNA
cell	I-DNA
nuclear	I-DNA
differentiation	I-DNA
antigen	I-DNA
gene	I-DNA
promoter	I-DNA
.	O

MNDA	B-protein
(	O
myeloid	B-protein
cell	I-protein
nuclear	I-protein
differentiation	I-protein
antigen	I-protein
)	O
is	O
an	O
interferon	B-protein
alpha	I-protein
regulated	I-protein
nuclear	I-protein
protein	I-protein
expressed	O
only	O
in	O
cells	O
of	O
the	O
human	B-cell_type
myelomonocytic	I-cell_type
lineage	I-cell_type
.	O

To	O
identify	O
mechanisms	O
responsible	O
for	O
this	O
lineage-specific	O
and	O
interferon-regulated	O
expression	O
,	O
the	O
5	B-DNA
'	I-DNA
flanking	I-DNA
sequence	I-DNA
of	O
the	O
gene	O
has	O
been	O
characterized	O
.	O

Two	O
interferon-stimulated	B-DNA
response	I-DNA
elements	I-DNA
(	O
ISRE	B-DNA
)	O
flank	O
a	O
multiple	O
transcription	O
start	O
site	O
region	O
identifying	O
MNDA	B-protein
as	O
a	O
TATA-less	B-DNA
interferon-regulated	I-DNA
gene	I-DNA
.	O

Other	O
DNA	B-DNA
elements	I-DNA
present	O
include	O
a	O
cluster	O
of	O
Myb	B-DNA
sites	I-DNA
,	O
several	O
Ets	B-DNA
,	O
an	O
Ets	B-DNA
related	I-DNA
PU.1	I-DNA
site	I-DNA
and	O
an	O
Sp1	B-DNA
site	I-DNA
located	O
within	O
600	O
bp	O
of	O
the	O
transcription	B-DNA
start	I-DNA
sites	I-DNA
.	O

In	O
addition	O
,	O
DNA	O
methylation	O
was	O
revealed	O
as	O
one	O
of	O
the	O
possible	O
factors	O
in	O
establishing	O
MNDA	B-protein
expression	O
.	O

The	O
5	B-DNA
'	I-DNA
flanking	I-DNA
sequence	I-DNA
has	O
promoter	O
activity	O
which	O
is	O
elevated	O
by	O
interferon	B-protein
alpha	I-protein
.	O

The	O
findings	O
indicate	O
that	O
MNDA	B-protein
expression	O
is	O
regulated	O
by	O
mechanisms	O
similar	O
to	O
other	O
myelomonocytic	B-DNA
cell	I-DNA
specific	I-DNA
genes	I-DNA
and	O
genes	O
up-regulated	O
by	O
interferon	B-protein
alpha	I-protein
.	O

Abnormality	O
of	O
Oct-1	B-protein
DNA	O
binding	O
in	O
T	B-cell_type
cells	I-cell_type
from	O
Sjogren	O
's	O
syndrome	O
patients	O
.	O

Primary	O
Sjogren	O
's	O
syndrome	O
(	O
SS	O
)	O
is	O
an	O
autoimmune	O
rheumatic	O
disease	O
characterized	O
by	O
T	O
cell	O
hypoactivity	O
.	O

To	O
understand	O
the	O
diminished	O
T	O
cell	O
response	O
to	O
activation	O
signals	O
,	O
we	O
measured	O
nucleoprotein	O
DNA-binding	O
activities	O
regulating	O
gene	O
expression	O
during	O
T	O
cell	O
activation	O
using	O
the	O
electrophoretic	O
mobility	O
shift	O
assay	O
.	O

Peripheral	B-cell_type
blood	I-cell_type
lymphocytes	I-cell_type
from	O
9/19	O
SS	O
patients	O
were	O
found	O
to	O
be	O
defective	O
in	O
their	O
ability	O
to	O
bind	O
an	O
october	B-protein
sequence	I-protein
(	O
Oct-1	B-protein
)	O
.	O

This	O
Oct-1	B-protein
-binding	O
phenotype	O
remained	O
stable	O
in	O
culture	O
for	O
up	O
to	O
3	O
days	O
prior	O
to	O
activation	O
.	O

This	O
abnormality	O
was	O
not	O
seen	O
in	O
resting	B-cell_type
T	I-cell_type
cells	I-cell_type
nor	O
T	B-cell_type
cells	I-cell_type
from	O
patients	O
with	O
systemic	O
lupus	O
erythematosus	O
,	O
rheumatoid	O
arthritis	O
(	O
RA	O
)	O
,	O
or	O
SS	O
accompanied	O
by	O
RA	O
.	O

The	O
SS	O
Oct-1	B-protein
DNA-binding	O
abnormality	O
correlated	O
significantly	O
with	O
an	O
inability	O
of	O
cells	O
to	O
exit	O
the	O
Gzero/G1	O
cell	O
cycle	O
phase	O
when	O
stimulated	O
in	O
vitro	O
.	O

Importantly	O
,	O
nucleoprotein	O
extracts	O
showing	O
decreased	O
DNA-binding	O
activity	O
had	O
normal	O
amounts	O
of	O
Oct-1	B-protein
proteins	O
as	O
determined	O
by	O
immunoprecipitation	O
,	O
implying	O
a	O
functional	O
defect	O
in	O
the	O
Oct-1	B-protein
protein	I-protein
.	O

Moreover	O
,	O
defective	O
DNA	O
binding	O
was	O
corrected	O
by	O
treatment	O
with	O
acid	O
phosphatase	O
.	O

Characterization	O
of	O
a	O
new	O
isoform	O
of	O
the	O
NFAT	B-protein
(	O
nuclear	B-protein
factor	I-protein
of	I-protein
activated	I-protein
T	I-protein
cells	I-protein
)	O
gene	O
family	O
member	O
NFATc	B-protein
[	O
published	O
erratum	O
appears	O
in	O
J	O
Biol	O
Chem	O
1996	O
Dec	O
27	O
;	O
271	O
(	O
52	O
)	O
:	O
33705	O
]	O

The	O
cyclosporin	B-protein
A	I-protein
(	I-protein
CsA	I-protein
)	I-protein
/FK506-sensitive	I-protein
nuclear	I-protein
factor	I-protein
of	I-protein
activated	I-protein
T	I-protein
cells	I-protein
(	O
NFAT	B-protein
)	O
plays	O
a	O
key	O
role	O
in	O
the	O
inducible	O
expression	O
of	O
cytokine	B-DNA
genes	I-DNA
in	O
T	B-cell_type
cells	I-cell_type
.	O

Although	O
NFAT	B-protein
has	O
been	O
recently	O
shown	O
to	O
be	O
inducible	O
in	O
several	O
non-T	B-cell_type
immune	I-cell_type
cells	I-cell_type
,	O
the	O
NFAT	B-DNA
gene	I-DNA
family	I-DNA
members	I-DNA
characterized	O
to	O
date	O
have	O
been	O
isolated	O
only	O
from	O
T	B-cell_type
cells	I-cell_type
.	O

To	O
further	O
characterize	O
NFAT	B-protein
function	O
in	O
human	B-cell_type
B	I-cell_type
cells	I-cell_type
and	O
to	O
demonstrate	O
cytokine	O
gene	O
specificity	O
of	O
NFAT	B-protein
proteins	I-protein
,	O
we	O
report	O
here	O
the	O
isolation	O
and	O
characterization	O
of	O
a	O
cDNA	B-DNA
clone	I-DNA
from	O
the	O
Raji	B-cell_line
B	I-cell_line
cell	I-cell_line
line	I-cell_line
.	O

The	O
cDNA	B-DNA
clone	I-DNA
encodes	O
a	O
new	O
isoform	O
,	O
NFATc.beta	B-protein
,	O
of	O
the	O
NFAT	B-protein
gene	I-protein
family	I-protein
member	I-protein
NFATc	B-protein
(	O
designated	O
here	O
NFATc.alpha	B-protein
)	O
.	O

The	O
amino	B-protein
acid	I-protein
sequence	I-protein
of	O
NFATc.beta	B-protein
differs	O
from	O
that	O
of	O
NFATc	B-protein
.	O

alpha	O
in	O
the	O
first	O
NH2-terminal	B-protein
29	I-protein
residues	I-protein
and	O
contains	O
an	O
additional	O
region	O
of	O
142	B-protein
residues	I-protein
at	O
the	O
COOH	B-protein
terminus	I-protein
.	O

Northern	O
analysis	O
using	O
a	O
probe	O
encompassing	O
a	O
common	O
region	O
of	O
both	O
isoforms	O
showed	O
two	O
mRNA	B-RNA
species	I-RNA
of	O
2.7	B-RNA
and	I-RNA
4.5	I-RNA
kilobase	I-RNA
pairs	I-RNA
,	O
while	O
an	O
NFATc.beta-specific	B-DNA
probe	I-DNA
detected	O
only	O
the	O
4.5-kilobase	B-RNA
pair	I-RNA
mRNA	I-RNA
which	O
was	O
preferentially	O
expressed	O
in	O
the	O
spleen	O
.	O

Transient	O
expression	O
of	O
NFATc.beta	B-protein
was	O
capable	O
of	O
activating	O
an	O
interleukin-2	B-DNA
NFAT-driven	I-DNA
reporter	I-DNA
gene	I-DNA
in	O
stimulated	B-cell_line
Jurkat	I-cell_line
cells	I-cell_line
in	O
a	O
CsA-sensitive	O
manner	O
.	O

However	O
,	O
NFATc.beta	B-protein
neither	O
bound	O
to	O
the	O
kappa3	B-DNA
element	I-DNA
(	O
an	O
NFAT-binding	B-DNA
site	I-DNA
)	O
in	O
the	O
tumor	B-DNA
necrosis	I-DNA
factor-alpha	I-DNA
promoter	I-DNA
nor	O
activated	O
the	O
tumor	B-DNA
necrosis	I-DNA
factor-alpha	I-DNA
promoter	I-DNA
in	O
cotransfection	O
assays	O
.	O

These	O
data	O
suggest	O
that	O
different	O
members	O
or	O
isoforms	O
of	O
NFAT	B-DNA
gene	I-DNA
family	O
may	O
regulate	O
inducible	O
expression	O
of	O
different	O
cytokine	B-DNA
genes	I-DNA
.	O

Regulation	O
of	O
interferon-gamma	B-protein
gene	O
expression	O
.	O

Interferon-gamma	O
(	O
IFN-gamma	B-protein
)	O
,	O
also	O
known	O
as	O
type	B-protein
II	I-protein
interferon	I-protein
,	O
is	O
an	O
important	O
immunoregulatory	O
gene	O
that	O
has	O
multiple	O
effects	O
on	O
the	O
development	O
,	O
maturation	O
,	O
and	O
function	O
of	O
the	O
immune	O
system	O
.	O

IFN-gamma	B-RNA
mRNA	I-RNA
and	O
protein	O
are	O
expressed	O
predominantly	O
by	O
T	B-cell_type
cells	I-cell_type
and	O
large	B-cell_type
granular	I-cell_type
lymphocytes	I-cell_type
.	O

The	O
IFN-gamma	B-RNA
mRNA	I-RNA
is	O
induced/inhibited	O
in	O
these	O
cell	O
types	O
by	O
a	O
wide	O
variety	O
of	O
extracellular	O
signals	O
,	O
thus	O
implicating	O
a	O
number	O
of	O
diverse	O
,	O
yet	O
convergent	O
signal	O
transduction	O
pathways	O
in	O
its	O
transcriptional	O
control	O
.	O

In	O
this	O
review	O
,	O
I	O
describe	O
how	O
DNA	O
methylation	O
and	O
specific	O
DNA	B-protein
binding	I-protein
proteins	I-protein
may	O
regulate	O
transcription	O
of	O
the	O
IFN-gamma	B-DNA
gene	I-DNA
in	O
response	O
to	O
extracellular	O
signals	O
.	O

Transcriptional	O
analysis	O
of	O
Epstein-Barr	O
virus	O
gene	O
expression	O
in	O
EBV-positive	O
gastric	O
carcinoma	O
:	O
unique	O
viral	O
latency	O
in	O
the	O
tumour	B-cell_type
cells	I-cell_type
.	O

Although	O
case-oriented	O
evidence	O
for	O
an	O
association	O
of	O
Epstein-Barr	O
virus	O
(	O
EBV	O
)	O
with	O
gastric	O
carcinoma	O
has	O
been	O
accumulating	O
recently	O
,	O
the	O
interaction	O
(	O
s	O
)	O
between	O
EBV	O
and	O
gastric	B-cell_type
epithelial	I-cell_type
cells	I-cell_type
is/are	O
largely	O
unknown	O
.	O

In	O
this	O
study	O
,	O
we	O
examined	O
seven	O
EBV-positive	O
gastric	O
carcinoma	O
tissues	O
for	O
viral	O
gene	O
expression	O
at	O
the	O
mRNA	O
level	O
,	O
from	O
which	O
studies	O
on	O
the	O
EBV	O
oncogenicity	O
in	O
human	B-cell_type
epithelial	I-cell_type
cells	I-cell_type
will	O
benefit	O
.	O

Reverse	O
transcription-PCR	O
analysis	O
showed	O
that	O
all	O
seven	O
EBV-positive	O
tumour	O
tissues	O
constitutively	O
expressed	O
EBV	B-RNA
nuclear	I-RNA
antigen	I-RNA
(	I-RNA
EBNA	I-RNA
)	I-RNA
1	I-RNA
mRNA	I-RNA
,	O
but	O
not	O
EBNA2	B-RNA
mRNA	I-RNA
.	O

The	O
EBNA	B-protein
transcription	O
was	O
initiated	O
from	O
one	O
of	O
three	O
EBNA	B-DNA
promoters	I-DNA
,	O
Qp	B-DNA
:	O
by	O
contrast	O
,	O
both	O
Cp	B-DNA
and	O
Wp	B-DNA
were	O
silent	O
,	O
thus	O
resulting	O
in	O
the	O
lack	O
of	O
EBNA2	B-RNA
mRNA	I-RNA
.	O

Latent	B-RNA
membrane	I-RNA
protein	I-RNA
(	I-RNA
LMP	I-RNA
)	I-RNA
2A	I-RNA
mRNA	I-RNA
was	O
detected	O
in	O
three	O
of	O
seven	O
cases	O
;	O
however	O
,	O
neither	B-RNA
LMP1	I-RNA
nor	I-RNA
LMP2B	I-RNA
mRNA	I-RNA
was	O
detected	O
in	O
any	O
of	O
the	O
tumours	O
tested	O
.	O

Transcripts	O
from	O
the	O
BamHI-A	B-DNA
region	I-DNA
of	O
the	O
viral	B-DNA
genome	I-DNA
were	O
detectable	O
in	O
all	O
cases	O
.	O

BZLF1	B-RNA
mRNA	I-RNA
and	O
the	O
product	O
,	O
an	O
immediate-early	B-DNA
gene	I-DNA
for	O
EBV	O
replication	O
,	O
was	O
not	O
expressed	O
in	O
any	O
of	O
them	O
,	O
thereby	O
suggesting	O
that	O
the	O
tumour	B-cell_type
cells	I-cell_type
carried	O
EBV	B-DNA
genomes	I-DNA
in	O
a	O
tightly	O
latent	O
form	O
.	O

These	O
findings	O
further	O
extended	O
our	O
previous	O
data	O
regarding	O
EBV	O
latency	O
in	O
gastric	B-cell_type
carcinoma	I-cell_type
cells	I-cell_type
at	O
the	O
protein	O
level	O
,	O
and	O
have	O
affirmed	O
that	O
the	O
programme	O
of	O
viral	O
gene	O
expression	O
in	O
the	O
tumour	O
more	O
closely	O
resembles	O
'latency	O
I	O
'	O
represented	O
by	O
Burkitt	O
's	O
lymphoma	O
than	O
'latency	O
II	O
'	O
represented	O
by	O
the	O
majority	O
of	O
nasopharyngeal	O
carcinomas	O
.	O

Characterization	O
of	O
Grb2-binding	B-protein
proteins	I-protein
in	O
human	B-cell_type
platelets	I-cell_type
activated	O
by	O
Fc	B-protein
gamma	I-protein
RIIA	I-protein
cross-linking	O
.	O

Glutathione-S-transferase	B-protein
(	I-protein
GST	I-protein
)	I-protein
-Grb2	I-protein
fusion	I-protein
proteins	I-protein
have	O
been	O
used	O
to	O
identify	O
the	O
potential	O
role	O
of	O
Grb2-binding	B-protein
proteins	I-protein
in	O
platelet	B-cell_type
activation	O
by	O
the	O
platelet	B-protein
low-affinity	I-protein
IgG	I-protein
receptor	I-protein
,	O
Fc	B-protein
gamma	I-protein
RIIA	I-protein
.	O

Two	O
tyrosine	B-protein
phosphoproteins	I-protein
of	O
38	O
and	O
63	O
kD	O
bind	O
to	O
the	O
SH2	B-protein
domain	I-protein
of	O
Grb2	B-protein
following	O
Fc	B-protein
gamma	I-protein
RIIA	I-protein
stimulation	O
of	O
platelets	B-cell_type
.	O

Both	O
are	O
located	O
in	O
the	O
particulate	O
fraction	O
following	O
platelet	B-cell_type
activation	O
and	O
are	O
also	O
able	O
to	O
bind	O
to	O
a	O
GST-construct	B-protein
containing	O
the	O
SH2	B-protein
and	I-protein
SH3	I-protein
domains	I-protein
of	O
phospholipase	B-protein
C	I-protein
gamma	I-protein
1	I-protein
.	O

p38	O
also	O
forms	O
a	O
complex	O
with	O
the	O
tyrosine	B-protein
kinase	I-protein
csk	I-protein
in	O
stimulated	B-cell_type
cells	I-cell_type
and	O
is	O
a	O
substrate	O
for	O
the	O
kinase	B-protein
.	O

The	O
SH3	B-protein
domains	I-protein
of	O
Grb2	B-protein
form	O
a	O
stable	O
complex	O
with	O
SOS1	B-protein
and	O
two	O
proteins	O
of	O
75	B-protein
kD	I-protein
and	O
120	B-protein
kD	I-protein
,	O
which	O
undergo	O
tyrosine	O
phosphorylation	O
in	O
Fc	B-cell_line
gamma	I-cell_line
RIIA	I-cell_line
stimulated	I-cell_line
cells	I-cell_line
.	O

The	O
75-kD	B-protein
protein	I-protein
is	O
recognized	O
by	O
antibodies	O
to	O
SLP-76	B-protein
,	O
which	O
has	O
recently	O
been	O
isolated	O
from	O
T	B-cell_type
cells	I-cell_type
and	O
sequenced	O
.	O

Tyrosine	O
phosphorylation	O
of	O
p38	B-protein
and	O
p63	B-protein
is	O
also	O
observed	O
in	O
platelets	B-cell_type
stimulated	O
by	O
the	O
tyrosine	B-protein
kinase	I-protein
-linked	O
receptor	O
agonist	O
collagen	B-protein
and	O
by	O
the	O
G	B-protein
protein	I-protein
-coupled	O
receptor	O
agonist	O
thrombin	B-protein
,	O
although	O
phosphorylation	O
of	O
SLP-76	B-protein
is	O
only	O
observed	O
in	O
collagen	B-protein
-stimulated	O
platelets	B-cell_type
.	O

p38	B-protein
and	O
p63	B-protein
may	O
provide	O
a	O
docking	O
site	O
for	O
Grb2	B-protein
,	O
thereby	O
linking	O
Grb2	B-protein
SH3-binding	I-protein
proteins	I-protein
SOS1	B-protein
,	O
SLP-76	B-protein
,	O
and	O
p120	B-protein
to	O
downstream	O
signalling	O
events	O
.	O

Constitutive	O
expression	O
of	O
specific	O
interferon	B-protein
isotypes	I-protein
in	O
peripheral	B-cell_type
blood	I-cell_type
leukocytes	I-cell_type
from	O
normal	O
individuals	O
and	O
in	O
promonocytic	B-cell_line
U937	I-cell_line
cells	I-cell_line
.	O

Constitutive	O
expression	O
of	O
IFN-alpha5	B-protein
and	O
IFN-beta	B-protein
was	O
detected	O
in	O
different	O
lymphoid	B-cell_type
cells	I-cell_type
including	O
peripheral	B-cell_type
blood	I-cell_type
mononuclear	I-cell_type
cells	I-cell_type
from	O
normal	O
individuals	O
following	O
amplification	O
of	O
IFN	B-RNA
mRNA	I-RNA
by	O
reverse	B-protein
transcriptase	I-protein
-polymerase	O
chain	O
reaction	O
and	O
direct	O
sequencing	O
of	O
the	O
amplified	B-DNA
product	I-DNA
.	O

The	O
activated	O
form	O
of	O
the	O
interferon-induced	B-protein
transcription	I-protein
factor	I-protein
complex	I-protein
ISGF3	B-protein
was	O
also	O
detected	O
in	O
nuclear	O
extracts	O
from	O
uninduced	B-cell_line
cells	I-cell_line
.	O

Culture	O
supernatants	O
from	O
uninduced	B-cell_line
U937	I-cell_line
cells	I-cell_line
were	O
also	O
found	O
to	O
activate	O
an	O
ISRE	B-DNA
cloned	O
upstream	O
of	O
the	O
luciferase	B-DNA
reporter	I-DNA
gene	I-DNA
,	O
indicating	O
the	O
presence	O
of	O
endogenous	B-protein
IFN	I-protein
activity	O
equivalent	O
to	O
approximately	O
0.3	O
to	O
0.5	O
IU/mL	O
.	O

This	O
endogenous	B-protein
IFN	I-protein
was	O
also	O
shown	O
to	O
play	O
a	O
role	O
in	O
maintaining	O
the	O
basal	O
level	O
of	O
expression	O
of	O
the	O
major	B-DNA
histocompatibility	I-DNA
class	I-DNA
I	I-DNA
genes	I-DNA
in	O
lymphoid	B-cell_type
cells	I-cell_type
.	O

These	O
results	O
suggest	O
that	O
IFN-alpha5	B-protein
and	O
IFN-beta	B-protein
are	O
produced	O
at	O
low	O
levels	O
in	O
normal	O
tissues	O
and	O
play	O
an	O
important	O
role	O
in	O
the	O
regulation	O
of	O
cell	O
function	O
and	O
in	O
the	O
maintenance	O
of	O
homeostasis	O
.	O

An	O
IL-2	B-DNA
response	I-DNA
element	I-DNA
in	O
the	O
human	B-DNA
IL-2	I-DNA
receptor	I-DNA
alpha	I-DNA
chain	I-DNA
promoter	I-DNA
is	O
a	O
composite	B-DNA
element	I-DNA
that	O
binds	O
Stat5	B-protein
,	O
Elf-1	B-protein
,	O
HMG-I	B-protein
(	I-protein
Y	I-protein
)	I-protein
and	O
a	O
GATA	B-protein
family	I-protein
protein	I-protein
.	O

Expression	O
of	O
the	O
human	B-DNA
interleukin-2	I-DNA
(	I-DNA
IL-2	I-DNA
)	I-DNA
receptor	I-DNA
alpha	I-DNA
chain	I-DNA
gene	I-DNA
is	O
potently	O
upregulated	O
by	O
its	O
own	O
ligand	O
,	O
IL-2	B-protein
.	O

In	O
this	O
study	O
,	O
we	O
characterize	O
an	O
essential	O
upstream	O
IL-2	B-DNA
response	I-DNA
element	I-DNA
that	O
contains	O
both	O
consensus	B-DNA
and	I-DNA
non-consensus	I-DNA
GAS	I-DNA
motifs	I-DNA
,	O
two	O
putative	O
Ets	B-DNA
binding	I-DNA
sites	I-DNA
(	O
EBS	B-DNA
)	O
,	O
one	O
of	O
which	O
overlaps	O
the	O
consensus	B-DNA
GAS	I-DNA
motif	I-DNA
,	O
and	O
a	O
GATA	B-DNA
motif	I-DNA
,	O
which	O
overlaps	O
the	O
non-consensus	B-DNA
GAS	I-DNA
motif	I-DNA
.	O

We	O
demonstrate	O
that	O
although	O
the	O
individual	O
components	O
of	O
this	O
element	O
do	O
not	O
respond	O
to	O
IL-2	B-protein
,	O
together	O
they	O
form	O
a	O
composite	O
element	O
capable	O
of	O
conferring	O
IL-2	B-protein
responsiveness	O
to	O
a	O
heterologous	B-DNA
promoter	I-DNA
.	O

Multiple	O
factors	O
including	O
Stat5	B-protein
,	O
Elf-1	B-protein
,	O
HMG-I	B-protein
(	I-protein
Y	I-protein
)	I-protein
and	O
GATA	B-protein
family	I-protein
proteins	I-protein
bind	O
to	O
the	O
IL-2	B-DNA
response	I-DNA
element	I-DNA
and	O
mutation	O
of	O
any	O
one	O
of	O
these	O
binding	O
sites	O
diminishes	O
the	O
activity	O
of	O
this	O
element	O
.	O

An	O
unidentified	O
Ets	B-protein
family	I-protein
protein	I-protein
binds	O
to	O
the	O
EBS	B-DNA
overlapping	O
the	O
consensus	B-DNA
GAS	I-DNA
motif	I-DNA
and	O
appears	O
to	O
negatively	O
regulate	O
the	O
human	B-DNA
IL-2R	I-DNA
alpha	I-DNA
promoter	I-DNA
.	O

Thus	O
,	O
IL-2	B-protein
-induced	O
IL-2R	B-DNA
alpha	I-DNA
promoter	I-DNA
activity	O
requires	O
a	O
complex	B-DNA
upstream	I-DNA
element	I-DNA
,	O
which	O
appears	O
to	O
contain	O
binding	B-DNA
sites	I-DNA
for	O
both	O
positive	B-protein
and	I-protein
negative	I-protein
regulatory	I-protein
factors	I-protein
.	O

Lymphocytes	B-cell_type
from	O
CML	O
patients	O
lack	O
a	O
47	B-protein
kDa	I-protein
factor	I-protein
having	O
affinity	O
for	O
a	O
genomic	B-DNA
sterol	I-DNA
regulatory	I-DNA
sequence	I-DNA
.	O

Deranged	O
cellular	O
cholesterol	O
homeostasis	O
has	O
been	O
widely	O
recognized	O
in	O
the	O
initiation	O
as	O
well	O
as	O
progression	O
of	O
various	O
types	O
of	O
cancers	O
including	O
chronic	O
myeloid	O
leukaemia	O
(	O
CML	O
)	O
.	O

Since	O
the	O
human	B-DNA
genomic	I-DNA
sterol	I-DNA
regulatory	I-DNA
element	I-DNA
(	O
SRE	B-DNA
)	O
has	O
been	O
shown	O
to	O
regulate	O
various	O
key	O
genes	O
involved	O
in	O
this	O
phenomenon	O
,	O
the	O
present	O
study	O
revealed	O
the	O
existence	O
of	O
a	O
unique	O
47	B-protein
kDa	I-protein
protein	I-protein
factor	I-protein
having	O
affinity	O
for	O
this	O
SRE	B-DNA
sequence	I-DNA
in	O
lymphocytes	B-cell_type
from	O
normal	O
subjects	O
,	O
as	O
well	O
as	O
its	O
absence	O
in	O
lymphocytes	B-cell_type
from	O
untreated	O
CML	O
patients	O
.	O

However	O
,	O
this	O
factor	O
appeared	O
when	O
these	O
CML	O
patients	O
achieved	O
complete	O
haematological	O
remission	O
(	O
CHR	O
)	O
through	O
alpha-interferon	B-protein
therapy	O
.	O

Furthermore	O
,	O
an	O
inverse	O
relationship	O
was	O
also	O
observed	O
between	O
the	O
LDL	B-DNA
receptor	I-DNA
gene	I-DNA
expression	O
at	O
the	O
transcriptional	O
level	O
and	O
the	O
binding	O
affinity	O
of	O
this	O
47	B-protein
kDa	I-protein
protein	I-protein
factor	I-protein
to	O
the	O
SRE	B-DNA
sequence	I-DNA
.	O

Based	O
upon	O
these	O
results	O
we	O
propose	O
that	O
this	O
factor	O
may	O
have	O
a	O
role	O
in	O
pathophysiology	O
of	O
chronic	O
myeloid	O
leukaemia	O
.	O

Cloning	O
and	O
characterization	O
of	O
the	O
beta	B-protein
subunit	I-protein
of	O
human	B-protein
proximal	I-protein
sequence	I-protein
element-binding	I-protein
transcription	I-protein
factor	I-protein
and	O
its	O
involvement	O
in	O
transcription	O
of	O
small	B-DNA
nuclear	I-DNA
RNA	I-DNA
genes	I-DNA
by	O
RNA	B-protein
polymerases	I-protein
II	I-protein
and	I-protein
III	I-protein
.	O

The	O
proximal	B-protein
sequence	I-protein
element	I-protein
(	I-protein
PSE	I-protein
)	I-protein
-binding	I-protein
transcription	I-protein
factor	I-protein
(	O
PTF	B-protein
)	O
,	O
which	O
binds	O
the	O
PSE	B-DNA
of	O
both	O
RNA	B-DNA
polymerase	I-DNA
II	I-DNA
-and	I-DNA
RNA	I-DNA
polymerase	I-DNA
III-transcribed	I-DNA
mammalian	I-DNA
small	I-DNA
nuclear	I-DNA
RNA	I-DNA
(	I-DNA
snRNA	I-DNA
)	I-DNA
genes	I-DNA
,	O
is	O
essential	O
for	O
their	O
transcription	O
.	O

We	O
previously	O
reported	O
the	O
purification	O
of	O
human	B-protein
PTF	I-protein
,	O
a	O
complex	O
of	O
four	B-protein
subunits	I-protein
,	O
and	O
the	O
molecular	O
cloning	O
and	O
characterization	O
of	O
PTF	B-protein
gamma	I-protein
and	I-protein
delta	I-protein
subunits	I-protein
.	O

Here	O
we	O
describe	O
the	O
isolation	O
and	O
expression	O
of	O
a	O
cDNA	B-DNA
encoding	O
PTF	B-protein
beta	I-protein
,	O
as	O
well	O
as	O
functional	O
studies	O
using	O
anti-PTF	B-protein
beta	I-protein
antibodies	I-protein
.	O

Native	O
PTF	B-protein
beta	I-protein
,	O
in	O
either	O
protein	O
fractions	O
or	O
a	O
PTF-Oct-1-DNA	B-protein
complex	I-protein
,	O
can	O
be	O
recognized	O
by	O
polyclonal	B-protein
antibodies	I-protein
raised	O
against	O
recombinant	B-protein
PTF	I-protein
beta	I-protein
.	O

Immunodepletion	O
studies	O
show	O
that	O
PTF	B-protein
beta	I-protein
is	O
required	O
for	O
transcription	O
of	O
both	O
classes	O
of	O
snRNA	B-DNA
genes	I-DNA
in	O
vitro	O
.	O

In	O
addition	O
,	O
immunoprecipitation	O
analyses	O
demonstrate	O
that	O
substantial	O
and	O
similar	O
molar	O
amounts	O
of	O
TATA-binding	B-protein
protein	I-protein
(	O
TBP	B-protein
)	O
and	O
TFIIIB90	B-protein
can	O
weakly	O
associate	O
with	O
PTF	B-protein
at	O
low	O
salt	O
conditions	O
,	O
but	O
this	O
association	O
is	O
dramatically	O
reduced	O
at	O
high	O
salt	O
concentrations	O
.	O

Along	O
with	O
our	O
previous	O
demonstration	O
of	O
both	O
physical	O
interactions	O
between	O
PTF	B-protein
gamma/PTF	I-protein
delta	I-protein
and	O
TBP	B-protein
and	O
the	O
involvement	O
of	O
TFIIIB90	B-protein
in	O
the	O
transcription	O
of	O
class	B-DNA
III	I-DNA
snRNA	I-DNA
genes	I-DNA
,	O
these	O
results	O
are	O
consistent	O
with	O
the	O
notion	O
that	O
a	O
TBP-containing	B-protein
complex	I-protein
related	O
to	O
TFIIIB	B-protein
is	O
required	O
for	O
the	O
transcription	O
of	O
class	B-DNA
III	I-DNA
snRNA	I-DNA
genes	I-DNA
,	O
and	O
acts	O
through	O
weak	O
interaction	O
with	O
the	O
four-subunit	B-protein
PTF	I-protein
.	O

Attenuated	O
function	O
of	O
a	O
variant	O
form	O
of	O
the	O
helix-loop-helix	B-protein
protein	I-protein
,	O
Id-3	B-protein
,	O
generated	O
by	O
an	O
alternative	O
splicing	O
mechanism	O
.	O

The	O
Id	O
family	O
of	O
helix-loop-helix	B-protein
proteins	I-protein
function	O
as	O
negative	O
regulators	O
of	O
DNA	O
binding	O
,	O
basic	O
helix-loop-helix	B-protein
proteins	I-protein
in	O
the	O
regulation	O
of	O
cell	O
growth	O
and	O
differentiation	O
.	O

We	O
report	O
here	O
on	O
the	O
identification	O
of	O
a	O
17	B-protein
kDa	I-protein
variant	I-protein
of	O
the	O
14	B-protein
kDa	I-protein
Id-3	I-protein
protein	O
termed	O
Id-3L	B-protein
(	O
long	O
version	O
)	O
which	O
possesses	O
a	O
unique	O
60	B-protein
amino	I-protein
acid	I-protein
carboxy-terminus	I-protein
generated	O
by	O
read	O
through	O
of	O
a	O
'	O
coding	B-DNA
intron	I-DNA
'	O
and	O
alternative	O
splicing	O
.	O

Northern	O
analysis	O
revealed	O
expression	O
of	O
a	O
minor	O
1.1	B-RNA
kb	I-RNA
Id-3L	I-RNA
transcript	I-RNA
together	O
with	O
the	O
predominant	O
0.95	B-RNA
kb	I-RNA
Id-3	I-RNA
transcript	I-RNA
in	O
the	O
majority	O
of	O
adult	O
human	O
tissues	O
analysed	O
.	O

The	O
variant	O
Id-3L	B-protein
protein	I-protein
is	O
functionally	O
distinguishable	O
from	O
conventional	O
Id-3	B-protein
since	O
in	O
in	O
vitro	O
DNA	O
mobility	O
shift	O
assays	O
,	O
it	O
was	O
greatly	O
impaired	O
in	O
its	O
ability	O
to	O
abrogate	O
binding	O
of	O
the	O
basic	O
helix-loop-helix	B-protein
protein	I-protein
,	O
E47	B-protein
,	O
to	O
an	O
E	B-DNA
box	I-DNA
recognition	I-DNA
sequence	I-DNA
.	O

Tyloxapol	O
inhibits	O
NF-kappa	B-protein
B	I-protein
and	O
cytokine	B-protein
release	O
,	O
scavenges	O
HOCI	B-protein
,	O
and	O
reduces	O
viscosity	O
of	O
cystic	O
fibrosis	O
sputum	O
.	O

Cystic	O
fibrosis	O
(	O
CF	O
)	O
patients	O
develop	O
progressive	O
cytokine	B-protein
-mediated	O
inflammatory	O
lung	O
disease	O
,	O
with	O
abundant	O
production	O
of	O
thick	O
,	O
tenacious	O
,	O
protease	B-protein
-and	O
oxidant-rich	O
purulent	O
airway	O
secretions	O
that	O
are	O
difficult	O
to	O
clear	O
even	O
with	O
physiotherapy	O
.	O

In	O
the	O
search	O
for	O
a	O
potential	O
treatment	O
,	O
we	O
have	O
tested	O
tyloxapol	O
,	O
an	O
alkylaryl	O
polyether	O
alcohol	O
polymer	O
detergent	O
previously	O
used	O
as	O
a	O
mucolytic	O
agent	O
in	O
adult	O
chronic	O
bronchitis	O
.	O

Tyloxapol	O
inhibits	O
activation	O
of	O
the	O
transcription	B-protein
factor	I-protein
nuclear	I-protein
factor-kappa	I-protein
B	I-protein
(	O
NK-kappa	B-protein
B	I-protein
)	O
,	O
reduces	O
resting	O
secretion	O
of	O
the	O
cytokine	B-protein
interleukin-8	B-protein
(	O
IL-8	B-protein
)	O
in	O
cultured	B-cell_line
human	I-cell_line
monocytes	I-cell_line
,	O
and	O
inhibits	O
lipopolysaccharide	O
(	O
LPS	O
)	O
-stimulated	O
release	O
of	O
tumor	B-protein
necrosis	I-protein
factor-alpha	I-protein
(	O
TNF-alpha	B-protein
)	O
,	O
IL-1	B-protein
beta	I-protein
,	O
IL-6	B-protein
,	O
IL-8	B-protein
,	O
granulocyte-macrophage	B-protein
colony-stimulating	I-protein
factor	I-protein
(	O
GM-CSF	B-protein
)	O
,	O
and	O
the	O
eiconsanoids	O
thromboxane	O
A2	O
and	O
leukotriene	O
B4	O
(	O
LTB4	O
)	O
.	O

We	O
have	O
previously	O
shown	O
that	O
tyloxapol	O
is	O
a	O
potent	O
antioxidant	O
for	O
hydroxyl	O
radicals	O
(	O
OH	O
)	O
.	O

Tyloxapol	O
(	O
0.05	O
to	O
0.1	O
%	O
wt/vol	O
)	O
effectively	O
scavenges	O
the	O
oxidant	O
hypochlorous	O
acid	O
(	O
HOCl	O
;	O
1	O
to	O
7.5	O
mM	O
)	O
in	O
vitro	O
,	O
and	O
protects	O
from	O
HOCl-mediated	O
lung	O
injury	O
in	O
rats	O
.	O

Tyloxapol	O
also	O
reduces	O
the	O
viscosity	O
of	O
CF	O
sputum	O
(	O
from	O
463	O
+/-	O
133	O
to	O
128	O
+/-	O
52	O
centipoise	O
)	O
.	O

We	O
conclude	O
that	O
tyloxapol	O
is	O
potentially	O
useful	O
as	O
a	O
new	O
antiinflammatory	O
therapy	O
for	O
CF	O
lung	O
disease	O
,	O
and	O
could	O
possibly	O
promote	O
clearance	O
of	O
secretions	O
in	O
the	O
CF	O
airway	O
.	O

Elevated	O
cyclic	O
AMP	O
inhibits	O
NF-kappaB	B-protein
-mediated	O
transcription	O
in	O
human	O
monocytic	O
cells	O
and	O
endothelial	O
cells	O
.	O

The	O
NF-kappaB/Rel	B-protein
family	I-protein
of	O
transcription	B-protein
factors	I-protein
regulates	O
the	O
inducible	O
expression	O
of	O
many	O
genes	O
in	O
activated	B-cell_type
human	I-cell_type
monocytes	I-cell_type
and	O
endothelial	B-cell_type
cells	I-cell_type
.	O

In	O
this	O
study	O
,	O
we	O
examined	O
the	O
molecular	O
mechanism	O
by	O
which	O
agents	O
that	O
elevate	O
intracellular	O
cAMP	O
inhibit	O
the	O
expression	O
of	O
the	O
tumor	B-protein
necrosis	I-protein
factor	I-protein
alpha	I-protein
(	O
TNFalpha	B-protein
)	O
,	O
tissue	B-protein
factor	I-protein
,	O
endothelial	B-protein
leukocyte	I-protein
adhesion	I-protein
molecule-1	I-protein
,	O
and	O
vascular	B-DNA
cell	I-DNA
adhesion	I-DNA
molecule-1	I-DNA
genes	I-DNA
.	O

Both	O
forskolin	O
and	O
dibutyryl	O
cAMP	O
,	O
which	O
elevate	O
intracellular	O
cAMP	O
by	O
independent	O
mechanisms	O
,	O
inhibited	O
TNFalpha	B-protein
and	O
tissue	B-protein
factor	I-protein
expression	O
at	O
the	O
level	O
of	O
transcription	O
.	O

Induction	O
of	O
NF-kappaB	B-protein
-dependent	O
gene	O
expression	O
in	O
transiently	O
transfected	O
human	B-cell_line
monocytic	I-cell_line
THP-1	I-cell_line
cells	I-cell_line
and	O
human	B-cell_type
umbilical	I-cell_type
vein	I-cell_type
endothelial	I-cell_type
cells	I-cell_type
was	O
inhibited	O
by	O
elevated	O
cAMP	O
and	O
by	O
overexpression	O
of	O
the	O
catalytic	B-protein
subunit	I-protein
of	O
protein	B-protein
kinase	I-protein
A	I-protein
(	O
PKA	B-protein
)	O
.	O

Elevated	O
cAMP	O
did	O
not	O
prevent	O
nuclear	O
translocation	O
of	O
p50/p65	B-protein
and	O
c-Rel/p65	B-protein
heterodimers	I-protein
,	O
decrease	O
nuclear	O
translocation	O
of	O
p65	B-protein
,	O
or	O
significantly	O
modify	O
TNFalpha	B-protein
-induced	O
phosphorylation	O
of	O
p65	B-protein
.	O

Functional	O
studies	O
demonstrated	O
that	O
transcriptional	O
activation	O
of	O
a	O
plasmid	B-DNA
containing	O
multimerized	B-DNA
kappaB	I-DNA
sites	I-DNA
by	O
p65	B-protein
was	O
inhibited	O
by	O
agents	O
that	O
elevate	O
cAMP	O
and	O
by	O
overexpression	O
of	O
the	O
catalytic	B-protein
subunit	I-protein
of	O
PKA	B-protein
.	O

This	O
study	O
indicates	O
that	O
activation	O
of	O
PKA	B-protein
reduces	O
the	O
induction	O
of	O
a	O
distinct	O
set	O
of	O
genes	B-DNA
in	O
monocytes	B-cell_type
and	O
endothelial	B-cell_type
cells	I-cell_type
by	O
inhibiting	O
NF-kappaB	B-protein
-mediated	O
transcription	O
.	O

Molecular	O
mechanisms	O
of	O
steroid	O
action	O
:	O
a	O
novel	O
type	O
of	O
cross-talk	O
between	O
glucocorticoids	O
and	O
NF-kappa	B-protein
B	I-protein
transcription	B-protein
factors	I-protein
.	O

Despite	O
the	O
widespread	O
use	O
of	O
glucocorticoids	O
in	O
the	O
treatment	O
of	O
diseases	O
characterized	O
by	O
inflammation	O
,	O
the	O
molecular	O
mechanism	O
(	O
s	O
)	O
by	O
which	O
these	O
hormones	O
exert	O
this	O
beneficial	O
effect	O
in	O
patients	O
with	O
asthma	O
remains	O
to	O
be	O
elucidated	O
.	O

Therefore	O
,	O
we	O
have	O
studied	O
the	O
transcriptional	O
regulation	O
of	O
intercellular	B-protein
adhesion	I-protein
molecule-1	I-protein
(	O
ICAM-1	B-protein
)	O
as	O
adhesion	B-protein
molecules	I-protein
are	O
likely	O
to	O
play	O
a	O
causal	O
role	O
in	O
inflammation	O
in	O
promoting	O
cell-cell	O
and	O
cell-matrix	O
interactions	O
.	O

We	O
observed	O
that	O
in	O
a	O
monocytic	B-cell_line
(	I-cell_line
U937	I-cell_line
)	I-cell_line
and	O
a	O
bronchial	B-cell_line
epithelial	I-cell_line
(	I-cell_line
H292	I-cell_line
)	I-cell_line
cell-line	I-cell_line
dexamethasone	O
strongly	O
suppressed	O
basal	O
and	O
induced	O
ICAM-1	B-protein
expression	O
.	O

Subsequent	O
analysis	O
of	O
the	O
human	B-DNA
ICAM-1	I-DNA
promoter	I-DNA
has	O
revealed	O
that	O
both	O
12-O-tetradecanoylphorbol	O
13-acetate	O
(	O
TPA	O
)	O
and	O
tumour	B-protein
necrosis	I-protein
factor-alpha	I-protein
(	O
TNF-alpha	B-protein
)	O
upregulate	O
ICAM-1	B-protein
expression	O
through	O
the	O
presence	O
of	O
a	O
nuclear	B-DNA
factor	I-DNA
(	I-DNA
NF-kappa	I-DNA
B	I-DNA
)	I-DNA
target	I-DNA
sequence	I-DNA
(	O
TGGAAATTCC	O
)	O
.	O

No	O
glucocorticoid	B-DNA
recognition	I-DNA
sequences	I-DNA
are	O
present	O
in	O
this	O
promoter	B-DNA
region	I-DNA
and	O
dexamethasone	O
is	O
still	O
able	O
to	O
repress	O
transcription	O
when	O
the	O
multimerized	B-DNA
NF-kappa	I-DNA
B	I-DNA
sequence	I-DNA
is	O
transactivated	O
by	O
TNF-alpha	B-protein
upon	O
transfection	O
in	O
293	B-cell_line
cells	I-cell_line
.	O

We	O
propose	O
that	O
direct	O
interaction	O
between	O
the	O
glucocorticoid	B-protein
receptor	I-protein
and	O
nuclear	B-protein
factor-kappa	I-protein
B	I-protein
factors	I-protein
is	O
at	O
least	O
a	O
partial	O
explanation	O
for	O
the	O
effects	O
of	O
this	O
hormone	O
in	O
inflammatory	O
diseases	O
.	O

Abnormalities	O
of	O
p16	B-DNA
,	I-DNA
p15	I-DNA
and	I-DNA
CDK4	I-DNA
genes	I-DNA
in	O
recurrent	O
malignant	O
astrocytomas	O
.	O

Abnormalities	O
in	O
the	O
p16	B-DNA
,	I-DNA
p15	I-DNA
and	I-DNA
CDK4	I-DNA
genes	I-DNA
that	O
regulate	O
transition	O
through	O
the	O
G1	O
phase	O
of	O
the	O
cell	O
cycle	O
have	O
been	O
implicated	O
in	O
the	O
malignant	O
progression	O
of	O
astrocytomas	O
.	O

The	O
results	O
of	O
the	O
present	O
study	O
demonstrate	O
that	O
dysfunction	O
of	O
these	O
genes	B-DNA
also	O
occurs	O
during	O
recurrence	O
of	O
glial	O
tumors	O
that	O
were	O
highly	O
malignant	O
at	O
first	O
presentation	O
.	O

Analysis	O
of	O
10	O
matched	O
pairs	O
of	O
high	O
grade	O
malignant	O
astrocytomas	O
and	O
their	O
subsequent	O
recurrences	O
identified	O
three	O
distinct	O
groups	O
.	O

The	O
primary	O
and	O
recurrent	O
tumors	O
in	O
Group	O
A	O
did	O
not	O
show	O
structural	O
alterations	O
in	O
the	O
p16	B-DNA
,	I-DNA
p15	I-DNA
or	I-DNA
CDK4	I-DNA
genes	I-DNA
,	O
whereas	O
homozygous	O
codeletion	O
of	O
p16	B-DNA
and	O
p15	B-DNA
was	O
observed	O
in	O
both	O
primary	O
and	O
recurrent	O
tumors	O
in	O
Group	O
B	O
.	O

The	O
primary	O
tumors	O
in	O
Group	O
C	O
had	O
a	O
normal	O
profile	O
of	O
p16	B-protein
,	O
p15	B-protein
and	O
CDK4	B-protein
at	O
presentation	O
.	O

Upon	O
recurrence	O
,	O
however	O
,	O
the	O
tumors	O
sustained	O
either	O
deletion	O
of	O
p16	B-protein
alone	O
or	O
codeletion	O
of	O
both	O
p16	B-protein
and	O
p15	B-protein
or	O
amplification	O
of	O
CDK4	B-protein
.	O

Analysis	O
of	O
the	O
molecular	O
differences	O
between	O
primary	O
anaplastic	O
astrocytomas/glioblastomas	O
and	O
their	O
subsequent	O
recurrences	O
,	O
which	O
are	O
clinically	O
indistinguishable	O
,	O
may	O
provide	O
better	O
therapeutic	O
options	O
for	O
treatment	O
.	O

BCL-6	B-protein
,	O
a	O
POZ/zinc-finger	B-protein
protein	I-protein
,	O
is	O
a	O
sequence-specific	B-protein
transcriptional	I-protein
repressor	I-protein
.	O

Approximately	O
40	O
%	O
of	O
diffuse	O
large	O
cell	O
lymphoma	O
are	O
associated	O
with	O
chromosomal	O
translocations	O
that	O
deregulate	O
the	O
expression	O
of	O
the	O
BCL6	B-DNA
gene	I-DNA
by	O
juxtaposing	O
heterologous	B-DNA
promoters	I-DNA
to	O
the	O
BCL-6	B-DNA
coding	I-DNA
domain	I-DNA
.	O

The	O
BCL6	B-DNA
gene	I-DNA
encodes	O
a	O
95-kDa	B-protein
protein	I-protein
containing	O
six	O
C-terminal	B-protein
zinc-finger	I-protein
motifs	I-protein
and	O
an	O
N-terminal	B-protein
POZ	I-protein
domain	I-protein
,	O
suggesting	O
that	O
it	O
may	O
function	O
as	O
a	O
transcription	B-protein
factor	I-protein
.	O

By	O
using	O
a	O
DNA	B-DNA
sequence	I-DNA
selected	O
for	O
its	O
ability	O
to	O
bind	O
recombinant	B-protein
BCL-6	I-protein
in	O
vitro	O
,	O
we	O
show	O
here	O
that	O
BCL-6	B-protein
is	O
present	O
in	O
DNA-binding	B-protein
complexes	I-protein
in	O
nuclear	O
extracts	O
from	O
various	O
B-cell	B-cell_line
lines	I-cell_line
.	O

In	O
transient	O
transfectin	O
experiments	O
,	O
BCL6	B-protein
can	O
repress	O
transcription	O
from	O
promoters	B-DNA
linked	O
to	O
its	O
DNA	B-DNA
target	I-DNA
sequence	I-DNA
and	O
this	O
activity	O
is	O
dependent	O
upon	O
specific	O
DNA-binding	O
and	O
the	O
presence	O
of	O
an	O
intact	O
N-terminal	B-protein
half	I-protein
of	O
the	O
protein	O
.	O

We	O
demonstrate	O
that	O
this	O
part	O
of	O
the	O
BCL6	B-protein
molecule	I-protein
contains	O
an	O
autonomous	B-protein
transrepressor	I-protein
domain	I-protein
and	O
that	O
two	O
noncontiguous	B-protein
regions	I-protein
,	O
including	O
the	O
POZ	B-protein
motif	I-protein
,	O
mediate	O
maximum	O
transrepressive	O
activity	O
.	O

These	O
results	O
indicate	O
that	O
the	O
BCL-6	B-protein
protein	I-protein
can	O
function	O
as	O
a	O
sequence-specific	B-protein
transcriptional	I-protein
repressor	I-protein
and	O
have	O
implications	O
for	O
the	O
role	O
of	O
BCL6	B-protein
in	O
normal	O
lymphoid	O
development	O
and	O
lymphomagenesis	O
.	O

Signals	O
leading	O
to	O
the	O
activation	O
of	O
NF-kappa	B-protein
B	I-protein
transcription	I-protein
factor	I-protein
are	O
stronger	O
in	O
neonatal	B-cell_type
than	I-cell_type
adult	I-cell_type
T	I-cell_type
lymphocytes	I-cell_type
.	O

The	O
molecular	O
background	O
of	O
the	O
defects	O
in	O
the	O
immune	O
reactivity	O
of	O
human	O
neonates	O
has	O
not	O
been	O
fully	O
elucidated	O
.	O

As	O
the	O
NF-kappa	B-protein
B	I-protein
transcription	I-protein
factor	I-protein
has	O
a	O
central	O
role	O
in	O
the	O
control	O
of	O
transcription	O
of	O
several	O
genes	B-DNA
involved	O
in	O
immune	O
and	O
inflammatory	O
responses	O
,	O
the	O
authors	O
have	O
analysed	O
the	O
activation	O
of	O
NF-kappa	B-protein
B	I-protein
in	O
human	B-cell_type
umbilical	I-cell_type
cord	I-cell_type
T	I-cell_type
lymphocytes	I-cell_type
.	O

The	O
activity	O
was	O
tested	O
by	O
quantitating	O
the	O
nuclear	B-protein
proteins	I-protein
binding	O
to	O
an	O
oligonucleotide	O
containing	O
the	O
consensus	B-DNA
kappa	I-DNA
B	I-DNA
binding	I-DNA
sequence	I-DNA
(	O
electrophoretic	O
mobility	O
shift	O
assay	O
)	O
.	O

The	O
data	O
obtained	O
demonstrate	O
that	O
phorbol	O
dibutyrate/calcium	O
ionophore	O
A23187	O
(	O
PDBu/iono	O
)	O
combination	O
induced	O
a	O
clearly	O
higher	O
nuclear	O
translocation	O
of	O
NF-kappa	B-protein
B	I-protein
in	O
neonatal	B-cell_type
than	I-cell_type
adult	I-cell_type
T	I-cell_type
cells	I-cell_type
.	O

This	O
higher	O
NF-kappa	B-protein
B	I-protein
activity	O
was	O
restricted	O
to	O
the	O
CD4+	B-cell_type
T-cell	I-cell_type
subset	I-cell_type
.	O

Analysis	O
of	O
the	O
nuclear	O
extracts	O
with	O
antibodies	B-protein
directed	O
against	O
the	O
major	O
components	O
of	O
NF-kappa	B-protein
B	I-protein
the	O
p50	B-protein
and	I-protein
RelA	I-protein
(	I-protein
p65	I-protein
)	I-protein
proteins	I-protein
,	O
indicated	O
that	O
the	O
composition	O
of	O
NF-kappa	B-protein
B	I-protein
was	O
similar	O
in	O
neonatal	B-cell_type
and	I-cell_type
adult	I-cell_type
cells	I-cell_type
.	O

These	O
results	O
suggest	O
that	O
neonatal	B-cell_type
T	I-cell_type
cells	I-cell_type
are	O
exposed	O
to	O
oxidative	O
stress-inducing	O
signals	O
during	O
delivery	O
and/or	O
are	O
inherently	O
more	O
sensitive	O
to	O
NF-kappa	B-protein
B	I-protein
activating	O
signals	O
than	O
adult	B-cell_type
T	I-cell_type
cells	I-cell_type
.	O

Dual	O
action	O
of	O
retinoic	O
acid	O
on	O
human	O
embryonic/fetal	O
hematopoiesis	O
:	O
blockade	O
of	O
primitive	O
progenitor	O
proliferation	O
and	O
shift	O
from	O
multipotent/erythroid/monocytic	O
to	O
granulocytic	O
differentiation	O
program	O
.	O

In	O
preliminary	O
studies	O
,	O
we	O
have	O
analyzed	O
the	O
hematopoietic	B-protein
growth	I-protein
factor	I-protein
(	O
HGF	B-protein
)	O
requirement	O
of	O
hematopoietic	B-cell_type
progenitor	I-cell_type
cells	I-cell_type
(	O
HPCs	B-cell_type
)	O
purified	O
from	O
embryonic-fetal	O
liver	O
(	O
FL	O
)	O
and	O
grown	O
in	O
fetal	O
calf	O
serum-supplemented	O
(	O
FCS+	O
)	O
clonogenic	O
culture	O
.	O

The	O
key	O
role	O
of	O
erythropoietin	B-protein
(	O
Epo	B-protein
)	O
for	O
colony	O
formation	O
by	O
early	B-cell_type
erythroid	I-cell_type
progenitors	I-cell_type
(	O
burst-forming	B-cell_type
units-erythroid	I-cell_type
[	O
BFU-E	B-cell_type
]	O
)	O
has	O
been	O
confirmed	O
.	O

Furthermore	O
,	O
in	O
the	O
absence	O
of	O
exogenous	O
HGFs	B-protein
,	O
FL	B-cell_type
monocytic	I-cell_type
progenitors	I-cell_type
(	O
colony-forming	B-cell_type
unit	I-cell_type
monocyte	I-cell_type
[	O
CFU-M	B-cell_type
]	O
)	O
generate	O
large	O
colonies	O
exclusively	O
composed	O
of	O
monocytes-macrophages	O
;	O
these	O
colonies	O
are	O
absent	O
in	O
FCS-	O
clonogenic	O
culture	O
.	O

On	O
this	O
basis	O
,	O
we	O
have	O
investigated	O
the	O
role	O
of	O
all-trans	O
retinoic	O
acid	O
(	O
ATRA	O
)	O
and	O
its	O
isomer	O
9-cis	O
RA	O
in	O
FL	O
hematopoiesis	O
.	O

Both	O
compounds	O
modulate	O
the	O
growth	O
of	O
purified	B-cell_line
FL	I-cell_line
HPCs	I-cell_line
,	O
which	O
show	O
a	O
dose-dependent	O
shift	O
from	O
mixed/erythroid/monocytic	O
to	O
granulocytic	O
colony	O
formation	O
.	O

Studies	O
on	O
unicellular	B-cell_line
and	I-cell_line
paired	I-cell_line
daughter	I-cell_line
cell	I-cell_line
culture	I-cell_line
unequivocally	O
indicate	O
that	O
the	O
shift	O
is	O
mediated	O
by	O
modulation	O
of	O
the	O
HPC	O
differentiation	O
program	O
to	O
the	O
granulopoietic	O
pathway	O
(	O
rather	O
than	O
RA-induced	O
down-modulation	O
of	O
multipotent	O
/erythroid/monocytic	O
HPC	O
growth	O
coupled	O
with	O
recruitment	O
of	O
granulocytic	B-cell_type
HPCs	I-cell_type
)	O
.	O

ATRA	O
and	O
9-cis	O
RA	O
also	O
exert	O
their	O
effect	O
on	O
the	O
proliferation	O
of	O
primitive	B-cell_type
HPCs	I-cell_type
(	O
high-proliferative	B-cell_line
potential	I-cell_line
colony-forming	I-cell_line
cells	I-cell_line
[	O
HPP-CFCs	B-cell_line
]	O
)	O
and	O
putative	B-cell_type
hematopoietic	I-cell_type
stem	I-cell_type
cells	I-cell_type
(	O
HSCs	B-cell_type
;	O
assayed	O
in	O
Dexter-type	O
long-term	O
culture	O
)	O
.	O

High	O
concentrations	O
of	O
either	O
compound	O
(	O
1	O
)	O
drastically	O
reduced	O
the	O
number	O
of	O
primary	O
HPP-CFC	B-cell_line
colonies	I-cell_line
and	O
totally	O
abolished	O
their	O
recloning	O
capacity	O
and	O
(	O
2	O
)	O
inhibited	O
HSC	B-cell_type
proliferation	O
.	O

It	O
is	O
crucial	O
that	O
these	O
results	O
mirror	O
recent	O
observations	O
indicating	O
that	O
murine	O
adult	O
HPCs	B-cell_type
transduced	O
with	O
dominant	O
negative	O
ATRA	B-DNA
receptor	I-DNA
(	I-DNA
RAR	I-DNA
)	I-DNA
gene	I-DNA
are	O
immortalized	O
and	O
show	O
a	O
selective	O
blockade	O
of	O
granulocytic	O
differentiation	O
.	O

Altogether	O
,	O
these	O
results	O
suggest	O
that	O
ATRA/9-cis	O
RA	O
may	O
play	O
a	O
key	O
role	O
in	O
FL	O
hematopoiesis	O
via	O
a	O
dual	O
effect	O
hypothetically	O
mediated	O
by	O
interaction	O
with	O
the	O
RAR/RXR	B-protein
heterodimer	I-protein
,	O
ie	O
,	O
inhibition	O
of	O
HSC/	B-cell_line
primitive	I-cell_line
HPC	I-cell_line
proliferation	O
and	O
induction	O
of	O
CFU-GEMM/	O
BFU-E/CFU-M	O
shift	O
from	O
the	O
multipotent/erythroid/monocytic	O
to	O
the	O
granulocytic-neutrophilic	O
differentiation	O
program	O
.	O

Dexamethasone	O
suppression	O
test	O
:	O
corticosteroid	B-protein
receptors	I-protein
regulation	O
in	O
mononuclear	B-cell_type
leukocytes	I-cell_type
of	O
young	O
and	O
aged	O
subjects	O
.	O

The	O
dexamethasone	O
suppression	O
test	O
(	O
DST	O
)	O
is	O
considered	O
an	O
indicator	O
of	O
the	O
function	O
of	O
the	O
adrenal	O
pituitary	O
axis	O
.	O

The	O
effect	O
of	O
the	O
steroid	O
is	O
mediated	O
by	O
its	O
binding	O
to	O
corticosteroid	B-protein
receptors	I-protein
.	O

We	O
previously	O
suggested	O
that	O
the	O
measurement	O
of	O
corticosteroid	B-protein
receptors	I-protein
in	O
lymphocytes	B-cell_type
is	O
an	O
index	O
of	O
an	O
analogous	O
pattern	O
in	O
brain	O
.	O

In	O
the	O
present	O
study	O
,	O
corticosteroid	B-protein
Type	I-protein
I	I-protein
and	I-protein
Type	I-protein
II	I-protein
receptors	I-protein
in	O
mononuclear	B-cell_type
leukocytes	I-cell_type
were	O
measured	O
in	O
10	O
elderly	O
subjects	O
and	O
in	O
9	O
young	O
adults	O
,	O
before	O
and	O
after	O
overnight	O
DST	O
(	O
1	O
mg	O
)	O
.	O

Receptors	O
were	O
measured	O
by	O
radioreceptor	O
assay	O
.	O

In	O
all	O
the	O
subjects	O
,	O
dexamethasone	O
was	O
able	O
to	O
suppress	O
plasma	O
cortisol	O
.	O

The	O
number	O
of	O
Type	B-protein
I	I-protein
and	I-protein
Type	I-protein
II	I-protein
receptors	I-protein
before	O
the	O
test	O
was	O
lower	O
in	O
elderly	O
subjects	O
than	O
in	O
adults	O
.	O

In	O
the	O
control	O
group	O
,	O
dexamethasone	O
produced	O
a	O
significant	O
depression	O
of	O
Type	B-protein
I	I-protein
receptors	I-protein
(	O
from	O
267	O
+/-	O
72	O
to	O
169	O
+/-	O
71	O
receptors	O
per	O
cell	O
)	O
,	O
which	O
can	O
be	O
interpreted	O
as	O
a	O
primary	O
involvement	O
of	O
Type	B-protein
I	I-protein
receptors	I-protein
in	O
the	O
response	O
to	O
dexamethasone	O
;	O
Type	B-protein
II	I-protein
receptors	I-protein
decreased	O
in	O
half	O
the	O
subjects	O
(	O
from	O
2849	O
+/-	O
703	O
to	O
2345	O
+/-	O
569	O
receptors	O
per	O
cell	O
)	O
.	O

In	O
elderly	O
healthy	O
subjects	O
,	O
Type	B-protein
II	I-protein
receptors	I-protein
were	O
also	O
significantly	O
decreased	O
(	O
from	O
1796	O
+/-	O
671	O
to	O
720	O
+/-	O
345	O
)	O
.	O

We	O
suggest	O
that	O
in	O
young	O
subjects	O
Type	B-protein
II	I-protein
receptors	I-protein
are	O
initially	O
up-regulated	O
by	O
dexamethasone	O
,	O
and	O
then	O
down-regulated	O
,	O
while	O
in	O
aged	O
subjects	O
an	O
up-regulation	O
can	O
not	O
be	O
achieved	O
,	O
as	O
suggested	O
by	O
the	O
higher	O
values	O
of	O
plasma	O
cortisol	O
usually	O
found	O
in	O
aging	O
subjects	O
.	O

Analysis	O
of	O
the	O
ligand-binding	B-protein
domain	I-protein
of	O
human	B-protein
retinoic	I-protein
acid	I-protein
receptor	I-protein
alpha	I-protein
by	O
site-directed	O
mutagenesis	O
.	O

Three	O
subtypes	O
of	O
retinoic	B-protein
acid	I-protein
receptors	I-protein
(	O
RAR	B-protein
)	O
,	O
termed	O
RAR	B-protein
alpha	I-protein
,	O
RAR	B-protein
beta	I-protein
,	O
and	O
RAR	B-protein
gamma	I-protein
,	O
have	O
been	O
described	O
.	O

They	O
are	O
composed	O
of	O
different	O
structural	B-protein
domains	I-protein
,	O
including	O
distinct	O
domains	O
for	O
DNA	O
and	O
ligand	O
binding	O
.	O

RARs	B-protein
specifically	O
bind	O
all-trans-retinoic	O
acid	O
(	O
RA	O
)	O
,	O
9-cis-RA	O
,	O
and	O
retinoid	O
analogs	O
.	O

In	O
this	O
study	O
,	O
we	O
examined	O
the	O
functional	O
role	O
of	O
cysteine	O
and	O
arginine	O
residues	O
in	O
the	O
ligand-binding	B-protein
domain	I-protein
of	O
hRAR	B-protein
alpha	I-protein
(	O
hRAR	B-protein
alpha-LBD	I-protein
,	O
amino	B-protein
acids	I-protein
154	I-protein
to	I-protein
462	I-protein
)	O
.	O

All	O
conserved	O
cysteine	O
and	O
arginine	O
residues	O
in	O
this	O
domain	O
were	O
mutated	O
by	O
site-directed	O
mutagenesis	O
,	O
and	O
the	O
mutant	B-protein
proteins	I-protein
were	O
characterized	O
by	O
blocking	O
reactions	O
,	O
ligand-binding	O
experiments	O
,	O
transactivation	O
assays	O
,	O
and	O
protease	B-protein
mapping	O
.	O

Changes	O
of	O
any	O
cysteine	O
residue	O
of	O
the	O
hRAR	B-protein
alpha-LBD	I-protein
had	O
no	O
significant	O
influence	O
on	O
the	O
binding	O
of	O
all-trans	O
RA	O
or	O
9-cis	O
RA	O
.	O

Interestingly	O
,	O
residue	O
C-235	O
is	O
specifically	O
important	O
in	O
antagonist	O
binding	O
.	O

With	O
respect	O
to	O
arginine	O
residues	O
,	O
only	O
the	O
two	O
single	O
mutations	O
of	O
R-276	O
and	O
R-394	O
to	O
alanine	O
showed	O
a	O
dramatic	O
decrease	O
of	O
agonist	O
and	O
antagonist	O
binding	O
whereas	O
the	O
R272A	O
mutation	O
showed	O
only	O
a	O
slight	O
effect	O
.	O

For	O
all	O
other	O
arginine	O
mutations	O
,	O
no	O
differences	O
in	O
affinity	O
were	O
detectable	O
.	O

The	O
two	O
mutations	O
R217A	O
and	O
R294A	O
caused	O
an	O
increased	O
binding	O
efficiency	O
for	O
antagonists	O
but	O
no	O
change	O
in	O
agonist	O
binding	O
.	O

From	O
these	O
results	O
,	O
we	O
can	O
conclude	O
that	O
electrostatic	O
interactions	O
of	O
retinoids	O
with	O
the	O
RAR	B-protein
alpha-LBD	I-protein
play	O
a	O
significant	O
role	O
in	O
ligand	O
binding	O
.	O

In	O
addition	O
,	O
antagonists	O
show	O
distinctly	O
different	O
requirements	O
for	O
efficient	O
binding	O
,	O
which	O
may	O
contribute	O
to	O
their	O
interference	O
in	O
the	O
ligand-inducible	O
transactivation	O
function	O
of	O
RAR	B-protein
alpha	I-protein
.	O

IL4	B-protein
and	I-protein
IL13	I-protein
receptors	I-protein
share	O
the	O
gamma	B-protein
c	I-protein
chain	I-protein
and	O
activate	O
STAT6	B-protein
,	I-protein
STAT3	I-protein
and	I-protein
STAT5	I-protein
proteins	I-protein
in	O
normal	B-cell_type
human	I-cell_type
B	I-cell_type
cells	I-cell_type
.	O

IL13	B-protein
induces	O
the	O
same	O
biological	O
effects	O
as	O
IL4	B-protein
in	O
normal	B-cell_type
human	I-cell_type
B	I-cell_type
cells	I-cell_type
.	O

We	O
show	O
that	O
as	O
in	O
the	O
IL4R	B-protein
complex	I-protein
,	O
both	O
IL4R	B-protein
alpha	I-protein
and	O
IL2R	B-protein
gamma	I-protein
c	I-protein
are	O
components	O
of	O
the	O
IL13R	B-protein
and	O
that	O
both	O
cytokines	B-protein
induced	O
STAT6	B-protein
,	O
STAT3	B-protein
and	O
STAT5	B-protein
activation	O
in	O
B	B-cell_type
cells	I-cell_type
.	O

In	O
spite	O
of	O
this	O
similar	O
downstream	O
signalling	O
,	O
IL4	B-protein
and	O
IL13	B-protein
used	O
a	O
different	O
set	O
of	O
Janus	B-protein
kinases	I-protein
:	O
IL13	B-protein
is	O
unable	O
to	O
activate	O
JAK1	B-protein
and	O
JAK3	B-protein
.	O

Calcineurin	B-protein
mutants	I-protein
render	O
T	B-cell_type
lymphocytes	I-cell_type
resistant	O
to	O
cyclosporin	O
A	O
.	O

The	O
immunosuppressants	O
cyclosporin	O
A	O
(	O
CsA	O
)	O
and	O
FK506	O
have	O
been	O
widely	O
used	O
to	O
prevent	O
and	O
treat	O
graft	O
rejection	O
after	O
human	O
organ	O
and	O
tissue	O
transplantations	O
.	O

CsA	O
and	O
FK506	O
associate	O
with	O
intracellular	B-protein
binding	I-protein
proteins	I-protein
(	O
i.e.	O
,	O
CsA	O
with	O
cyclophilin	B-protein
A	I-protein
and	O
FK506	O
with	O
FKBP12	B-protein
)	O
to	O
form	O
protein/drug	O
complexes	O
that	O
suppress	O
the	O
immune	O
system	O
by	O
preventing	O
activation	O
of	O
T	B-cell_type
cells	I-cell_type
in	O
response	O
to	O
antigen	O
presentation	O
.	O

The	O
common	O
target	O
of	O
CsA	O
and	O
FK506	O
is	O
calcineurin	B-protein
,	O
a	O
Ca2+/calmodulin-regulated	B-protein
,	I-protein
serine/threonine-specific	I-protein
protein	I-protein
phosphatase	I-protein
that	O
regulates	O
the	O
nuclear	O
import	O
of	O
a	O
transcription	B-protein
factor	I-protein
,	O
NF-AT	B-protein
,	O
required	O
for	O
expression	O
of	O
T	B-DNA
cell	I-DNA
activation	I-DNA
genes	I-DNA
.	O

In	O
previous	O
studies	O
,	O
we	O
identified	O
calcineurin	B-protein
mutations	O
that	O
block	O
binding	O
by	O
the	O
cyclophilin	B-protein
A/CsA	I-protein
or	I-protein
FKBP12/FK506	I-protein
complexes	I-protein
and	O
thereby	O
render	O
yeast	O
cells	O
resistant	O
to	O
the	O
antifungal	O
effects	O
of	O
CsA	O
or	O
FK506	O
.	O

In	O
this	O
report	O
,	O
we	O
demonstrate	O
that	O
the	O
corresponding	O
mutations	O
in	O
murine	O
calcineurin	B-protein
render	O
the	O
T	B-protein
cell	I-protein
receptor	I-protein
signal	O
transduction	O
cascade	O
CsA	O
resistant	O
in	O
human	B-cell_line
Jurkat	I-cell_line
T	I-cell_line
cells	I-cell_line
.	O

Our	O
findings	O
support	O
the	O
recently	O
determined	O
calcineurin	B-protein
X-ray	O
crystal	O
structure	O
,	O
provide	O
evidence	O
that	O
calcineurin	B-protein
is	O
the	O
only	O
CsA-sensitive	B-protein
component	I-protein
limiting	O
signaling	O
from	O
the	O
T	B-protein
cell	I-protein
receptor	I-protein
to	O
the	O
nucleus	O
,	O
and	O
suggest	O
a	O
means	O
to	O
render	O
cells	O
and	O
tissues	O
resistant	O
to	O
the	O
toxic	O
side	O
effects	O
of	O
CsA	O
and	O
FK506	O
.	O

Epstein-Barr	O
viral	O
latency	O
is	O
disrupted	O
by	O
the	O
immediate-early	B-protein
BRLF1	I-protein
protein	I-protein
through	O
a	O
cell-specific	O
mechanism	O
.	O

Epstein-Barr	O
virus	O
(	O
EBV	O
)	O
,	O
the	O
causative	O
agent	O
of	O
infectious	O
mononucleosis	O
,	O
is	O
a	O
human	O
herpesvirus	O
associated	O
with	O
epithelial	O
cell	O
malignancies	O
(	O
nasopharyngeal	O
carcinoma	O
)	O
as	O
well	O
as	O
B-cell	O
malignancies	O
.	O

Understanding	O
how	O
viral	O
latency	O
is	O
disrupted	O
is	O
a	O
central	O
issue	O
in	O
herpesvirus	O
biology	O
.	O

Epithelial	O
cells	O
are	O
the	O
major	O
site	O
of	O
lytic	O
EBV	O
replication	O
within	O
the	O
human	O
host	O
,	O
and	O
viral	O
reactivation	O
occurs	O
in	O
EBV-associated	O
nasopharyngeal	O
carcinomas	O
.	O

It	O
is	O
known	O
that	O
expression	O
of	O
a	O
single	O
viral	B-protein
immediate-early	I-protein
protein	I-protein
,	O
BZLF1	B-protein
,	O
is	O
sufficient	O
to	O
initiate	O
the	O
switch	O
from	O
latent	O
to	O
lytic	O
infection	O
in	O
B	B-cell_type
cells	I-cell_type
.	O

Cellular	O
regulation	O
of	O
BZLF1	B-protein
transcription	O
is	O
therefore	O
thought	O
to	O
play	O
a	O
key	O
role	O
in	O
regulating	O
the	O
stringency	O
of	O
viral	O
latency	O
.	O

Here	O
we	O
show	O
that	O
,	O
unexpectedly	O
,	O
expression	O
of	O
another	O
viral	B-protein
immediate-early	I-protein
protein	I-protein
,	O
BRLF1	B-protein
,	O
can	O
disrupt	O
viral	O
latency	O
in	O
an	O
epithelial	O
cell-specific	O
fashion	O
.	O

Therefore	O
,	O
the	O
mechanisms	O
leading	O
to	O
disruption	O
of	O
EBV	O
latency	O
appear	O
to	O
be	O
cell-type	O
specific	O
.	O

Eosinophil	B-cell_type
priming	O
by	O
cytokines	B-protein
:	O
from	O
cellular	O
signal	O
to	O
in	O
vivo	O
modulation	O
.	O

Eosinophils	B-cell_type
play	O
an	O
important	O
role	O
in	O
the	O
effector	O
phase	O
of	O
allergic	O
inflammation	O
.	O

This	O
review	O
will	O
focus	O
on	O
the	O
conversion	O
of	O
the	O
unprimed	O
eosinophil	O
phenotype	O
in	O
the	O
peripheral	O
blood	O
of	O
normal	O
individuals	O
to	O
the	O
primed	O
phenotype	O
found	O
in	O
the	O
peripheral	O
blood	O
and	O
tissues	O
of	O
allergic	O
patients	O
,	O
a	O
phenomenon	O
called	O
priming	O
.	O

Recent	O
data	O
on	O
the	O
signals	O
initiated	O
after	O
cytokine	B-protein
receptor	I-protein
activation	O
on	O
eosinophils	B-cell_type
will	O
be	O
reviewed	O
.	O

CTL	O
recognition	O
of	O
an	O
altered	O
peptide	O
associated	O
with	O
asparagine	O
bond	O
rearrangement	O
.	O

Implications	O
for	O
immunity	O
and	O
vaccine	O
design	O
.	O

The	O
extent	O
to	O
which	O
peptides	O
containing	O
chemically	O
and	O
post-translationally	O
modified	O
amino	B-protein
acid	I-protein
side	I-protein
chains	I-protein
are	O
recognized	O
by	O
primed	B-cell_line
CTL	I-cell_line
has	O
not	O
been	O
clearly	O
defined	O
.	O

We	O
report	O
on	O
the	O
CTL	O
recognition	O
of	O
a	O
MHC	O
class	O
I-restricted	O
peptide	O
containing	O
a	O
cyclized	O
asparagine	O
(	O
succinimide	O
)	O
residue	O
.	O

This	O
modification	O
of	O
the	O
asparagine	O
side	O
chain	O
is	O
a	O
common	O
intermediate	O
structure	O
during	O
deamidation	O
,	O
isomerization	O
,	O
and	O
bond	O
rearrangements	O
of	O
amide-containing	O
amino	O
acids	O
and	O
also	O
occurs	O
as	O
a	O
side	O
reaction	O
in	O
peptide	O
synthesis	O
.	O

The	O
CTL	B-cell_type
specifically	O
recognized	O
the	O
succinimide-containing	O
peptide	O
showing	O
only	O
weak	O
cross-reactivity	O
at	O
high	O
concentrations	O
of	O
the	O
parent	O
peptide	O
containing	O
unmodified	O
asparagine	O
.	O

Similarly	O
,	O
CTL	B-cell_type
raised	O
against	O
the	O
parent	O
peptide	O
did	O
not	O
recognize	O
the	O
succinimide	O
derivative	O
of	O
this	O
peptide	O
.	O

Naturally	O
processed	O
forms	O
of	O
these	O
structures	O
are	O
likely	O
to	O
occur	O
given	O
the	O
importance	O
and	O
frequency	O
of	O
deamidation	O
both	O
in	O
vitro	O
and	O
in	O
vivo	O
.	O

Moreover	O
,	O
since	O
succinimide	O
intermediates	O
of	O
deamidated	O
peptides	O
can	O
occasionally	O
be	O
very	O
stable	O
,	O
these	O
peptides	O
have	O
the	O
potential	O
to	O
act	O
as	O
altered	O
self-Ags	O
with	O
significant	O
implications	O
for	O
autoimmunity	O
.	O

In	O
addition	O
,	O
unwanted	O
and	O
potentially	O
hazardous	O
specificities	O
may	O
be	O
elicited	O
when	O
using	O
synthetic	O
peptides	O
in	O
subunit	O
vaccines	O
in	O
which	O
succinimide	O
residues	O
may	O
form	O
spontaneously	O
during	O
storage	O
or	O
chemical	O
synthesis	O
.	O

A	O
3	O
'	O
--	O
>	O
5	O
'	O
XPB	B-protein
helicase	I-protein
defect	O
in	O
repair/transcription	B-protein
factor	I-protein
TFIIH	B-protein
of	O
xeroderma	O
pigmentosum	O
group	O
B	O
affects	O
both	O
DNA	O
repair	O
and	O
transcription	O
.	O

XPB	B-protein
is	O
a	O
subunit	O
of	O
the	O
basal	O
transcription	B-protein
factor	I-protein
TFIIH	B-protein
,	O
which	O
is	O
also	O
involved	O
in	O
nucleotide	O
excision	O
repair	O
(	O
NER	O
)	O
and	O
potentially	O
in	O
cell	O
cycle	O
regulation	O
.	O

A	O
frameshift	O
mutation	O
in	O
the	O
3'-end	O
of	O
the	O
XPB	B-DNA
gene	I-DNA
is	O
responsible	O
for	O
a	O
concurrence	O
of	O
two	O
disorders	O
:	O
xeroderma	O
pigmentosum	O
(	O
XP	O
)	O
and	O
Cockayne	O
's	O
syndrome	O
(	O
CS	O
)	O
.	O

We	O
have	O
isolated	O
TFIIH	B-protein
from	O
cells	O
derived	O
from	O
a	O
patient	O
(	O
XP11BE	O
)	O
who	O
carries	O
this	O
frameshift	O
mutation	O
(	O
TFIIHmut	B-protein
)	O
and	O
from	O
the	O
mother	O
of	O
this	O
patient	O
(	O
TFIIHwt	B-protein
)	O
to	O
determine	O
the	O
biochemical	O
consequences	O
of	O
the	O
mutation	O
.	O

Although	O
identical	O
in	O
composition	O
and	O
stoichiometry	O
to	O
TFIIHwt	B-protein
,	O
TFIIHmut	B-protein
shows	O
a	O
reduced	O
3	O
'	O
--	O
>	O
5	O
'	O
XPB	B-protein
helicase	O
activity	O
.	O

A	O
decrease	O
in	O
helicase	O
and	O
DNA-dependent	B-protein
ATPase	I-protein
activities	O
was	O
also	O
observed	O
with	O
the	O
mutated	O
recombinant	O
XPB	B-protein
protein	I-protein
.	O

The	O
XPB	B-protein
mutation	O
causes	O
a	O
severe	O
NER	O
defect	O
.	O

In	O
addition	O
,	O
we	O
provide	O
evidence	O
for	O
a	O
decrease	O
in	O
basal	O
transcription	O
activity	O
in	O
vitro	O
.	O

The	O
latter	O
defect	O
may	O
provide	O
an	O
explanation	O
for	O
many	O
of	O
the	O
XP	O
and	O
CS	O
symptoms	O
that	O
are	O
difficult	O
to	O
rationalize	O
based	O
solely	O
on	O
an	O
NER	O
defect	O
.	O

Thus	O
,	O
this	O
work	O
presents	O
the	O
first	O
detailed	O
analysis	O
of	O
a	O
naturally	O
occurring	O
mutation	O
in	O
a	O
basal	B-protein
transcription	I-protein
factor	I-protein
and	O
supports	O
the	O
concept	O
that	O
the	O
combined	O
XP/CS	O
clinical	O
entity	O
is	O
actually	O
the	O
result	O
of	O
a	O
combined	O
transcription/repair	O
deficiency	O
.	O

The	O
Ets	O
protein	O
Spi-B	B-protein
is	O
expressed	O
exclusively	O
in	O
B	B-cell_type
cells	I-cell_type
and	O
T	B-cell_type
cells	I-cell_type
during	O
development	O
.	O

Spi-B	B-protein
and	O
PU.1	B-protein
are	O
hematopoietic-specific	B-protein
transcription	I-protein
factors	I-protein
that	O
constitute	O
a	O
subfamily	O
of	O
the	O
Ets	B-protein
family	I-protein
of	O
DNA-binding	B-protein
proteins	I-protein
.	O

Here	O
we	O
show	O
that	O
contrary	O
to	O
previous	O
reports	O
,	O
PU.1	B-protein
and	O
Spi-B	B-protein
have	O
very	O
different	O
expression	O
patterns	O
.	O

PU.1	B-protein
is	O
expressed	O
at	O
high	O
levels	O
in	O
B	B-cell_type
cells	I-cell_type
,	O
mast	B-cell_type
cells	I-cell_type
,	O
megakaryocytes	B-cell_type
,	O
macrophages	B-cell_type
,	O
neutrophils	B-cell_type
,	O
and	O
immature	B-cell_type
erythroid	I-cell_type
cells	I-cell_type
and	O
at	O
lower	O
levels	O
in	O
mature	B-cell_type
erythrocytes	I-cell_type
.	O

PU.1	B-protein
is	O
completely	O
absent	O
from	O
peripheral	B-cell_type
T	I-cell_type
cells	I-cell_type
and	O
most	O
T	B-cell_line
cell	I-cell_line
lines	I-cell_line
based	O
on	O
sensitive	O
RT-PCR	O
assays	O
.	O

In	O
contrast	O
,	O
Spi-B	B-protein
is	O
expressed	O
exclusively	O
in	O
lymphoid	B-cell_type
cells	I-cell_type
and	O
can	O
be	O
detected	O
in	O
early	O
fetal	O
thymus	O
and	O
spleen	O
.	O

In	O
situ	O
hybridizations	O
of	O
adult	O
murine	O
tissues	O
demonstrate	O
Spi-B	B-RNA
mRNA	I-RNA
in	O
the	O
medulla	O
of	O
the	O
thymus	O
,	O
the	O
white	O
pulp	O
of	O
the	O
spleen	O
,	O
and	O
the	O
germinal	O
centers	O
of	O
lymph	O
nodes	O
.	O

Spi-B	B-protein
expression	O
is	O
very	O
abundant	O
in	O
B	B-cell_type
cells	I-cell_type
and	O
both	O
Spi-B	B-RNA
mRNA	I-RNA
and	O
protein	O
are	O
detected	O
in	O
some	O
T	B-cell_type
cells	I-cell_type
.	O

In	O
situ	O
hybridization	O
and	O
Northern	O
blot	O
analysis	O
suggest	O
that	O
Spi-B	B-protein
gene	O
expression	O
increases	O
during	O
B	O
cell	O
maturation	O
and	O
decreases	O
during	O
T	O
cell	O
maturation	O
.	O

Gel-retardation	O
experiments	O
show	O
that	O
Spi-B	B-protein
can	O
bind	O
to	O
all	O
putative	B-DNA
PU.1	I-DNA
binding	I-DNA
sites	I-DNA
,	O
but	O
do	O
not	O
reveal	O
any	O
preferred	O
Spi-B	B-DNA
binding	I-DNA
site	I-DNA
.	O

Finally	O
,	O
both	O
PU.1	B-protein
and	O
Spi-B	B-protein
function	O
as	O
transcriptional	O
activators	O
of	O
the	O
immunoglobulin	B-DNA
light-chain	I-DNA
enhancer	I-DNA
E	I-DNA
lambda	I-DNA
2.4	I-DNA
when	O
coexpressed	O
with	O
Pip	B-protein
(	O
PU.1-interaction	B-protein
partner	I-protein
)	O
in	O
NIH-3T3	B-cell_line
cells	I-cell_line
.	O

Taken	O
together	O
,	O
these	O
data	O
suggest	O
that	O
differences	O
in	O
patterns	O
of	O
expression	O
between	O
Spi-B	B-protein
and	O
PU.1	B-protein
distinguish	O
the	O
function	O
of	O
each	O
protein	O
during	O
development	O
of	O
the	O
immune	O
system	O
.	O

A	O
critical	O
role	O
of	O
Sp1-	B-protein
and	I-protein
Ets-related	I-protein
transcription	I-protein
factors	I-protein
in	O
maintaining	O
CTL-specific	O
expression	O
of	O
the	O
mouse	B-DNA
perforin	I-DNA
gene	I-DNA
.	O

This	O
study	O
was	O
designed	O
to	O
determine	O
the	O
potential	O
cis-elements	B-DNA
involved	O
in	O
transcriptional	O
regulation	O
of	O
the	O
mouse	B-DNA
perforin	I-DNA
gene	I-DNA
.	O

DNase	B-DNA
I	I-DNA
hypersensitive	I-DNA
site	I-DNA
(	O
DHS	B-DNA
)	O
mapping	O
revealed	O
that	O
the	O
perforin	B-DNA
locus	I-DNA
contained	O
six	O
DHS	B-DNA
within	O
7.0	O
kb	O
of	O
the	O
5	B-DNA
'	I-DNA
upstream	I-DNA
sequence	I-DNA
(	O
-7.0	O
kb	O
)	O
and	O
two	O
DHS	B-DNA
in	O
intron	B-DNA
2	I-DNA
.	O

The	O
six	O
5	B-DNA
'	I-DNA
upstream	I-DNA
and	O
one	O
intronic	B-DNA
DHS	I-DNA
were	O
detected	O
in	O
only	O
perforin-expressing	B-cell_type
lymphocytes	I-cell_type
.	O

Chloramphenicol	B-protein
acetyltransferase	I-protein
(	O
CAT	B-protein
)	O
activities	O
directed	O
by	O
5	B-DNA
'	I-DNA
upstream	I-DNA
promoter	I-DNA
were	O
detected	O
preferentially	O
in	O
perforin-expressing	B-cell_line
cell	I-cell_line
lines	I-cell_line
.	O

A	O
construct	O
termed	O
PFP5a	B-DNA
containing	O
-795	B-DNA
bp	I-DNA
exhibited	O
the	O
highest	O
CAT	B-protein
activity	O
,	O
and	O
PFP9a20	B-DNA
containing	O
only	O
-73	B-DNA
bp	I-DNA
also	O
produced	O
significantly	O
high	O
CAT	B-protein
activity	O
in	O
CTLL-R8	B-cell_line
cells	I-cell_line
.	O

The	O
proximal	B-DNA
region	I-DNA
in	O
PFP9a20	B-DNA
contained	O
two	O
potential	O
Sp1	B-DNA
binding	I-DNA
sites	I-DNA
(	O
GC	B-DNA
box	I-DNA
and	O
GT	B-DNA
box	I-DNA
)	O
and	O
one	O
Ets	B-DNA
binding	I-DNA
site	I-DNA
(	O
EBS	B-DNA
)	O
.	O

Electrophoretic	O
mobility	O
shift	O
assay	O
showed	O
that	O
each	O
of	O
the	O
cis-elements	B-DNA
bound	O
specific	O
protein	B-protein
factors	I-protein
.	O

When	O
single-point	O
mutation	O
was	O
introduced	O
to	O
each	O
GC	B-DNA
box	I-DNA
,	O
EBS	B-DNA
,	O
and	O
GT	B-DNA
box	I-DNA
in	O
PFP9a20	B-DNA
,	O
at	O
least	O
3-fold	O
less	O
CAT	B-protein
activity	O
was	O
observed	O
in	O
CTLL-R8	B-cell_line
cells	I-cell_line
.	O

To	O
confirm	O
the	O
importance	O
of	O
the	O
three	O
cis-acting	B-DNA
elements	I-DNA
in	O
the	O
perforin	B-DNA
gene	I-DNA
expression	O
,	O
point	O
mutation	O
was	O
introduced	O
again	O
to	O
each	O
proximal	B-DNA
GC	I-DNA
box	I-DNA
,	O
EBS	B-DNA
,	O
and	O
GT	B-DNA
box	I-DNA
of	O
PFP5a	B-DNA
.	O

The	O
point	O
mutations	O
resulted	O
in	O
a	O
2.5-	O
to	O
3-fold	O
reduction	O
of	O
CAT	B-protein
activity	O
.	O

The	O
results	O
suggest	O
that	O
a	O
combination	O
of	O
the	O
three	O
proximal	O
cis-acting	B-DNA
elements	I-DNA
may	O
constitute	O
a	O
minimal	O
region	O
responsible	O
for	O
CTL-specific	O
expression	O
of	O
perforin	B-protein
.	O

The	O
Oct-2	B-protein
transcription	I-protein
factor	I-protein
.	O

The	O
Oct-2	B-protein
transcription	I-protein
factor	I-protein
is	O
a	O
member	O
of	O
the	O
POU	B-protein
(	I-protein
Pit-Oct-Unc	I-protein
)	I-protein
family	I-protein
of	O
transcription	B-protein
factors	I-protein
and	O
is	O
expressed	O
only	O
in	O
B	B-cell_type
lymphocytes	I-cell_type
and	O
in	O
neuronal	B-cell_type
cells	I-cell_type
but	O
not	O
in	O
other	O
cell	O
types	O
.	O

The	O
primary	B-RNA
RNA	I-RNA
transcript	I-RNA
of	O
the	O
gene	O
is	O
subject	O
to	O
alternative	O
splicing	O
to	O
yield	O
different	O
variants	O
which	O
can	O
either	O
activate	O
or	O
repress	O
gene	O
expression	O
.	O

The	O
forms	O
produced	O
in	O
B	B-cell_type
lymphocytes	I-cell_type
have	O
a	O
predominantly	O
activating	O
effect	O
on	O
gene	O
expression	O
whereas	O
those	O
produced	O
in	O
neuronal	B-cell_type
cells	I-cell_type
have	O
a	O
predominantly	O
inhibitory	O
effect	O
and	O
can	O
repress	O
the	O
expression	O
of	O
both	O
the	O
herpes	B-DNA
simplex	I-DNA
virus	I-DNA
immediate-early	I-DNA
genes	I-DNA
and	O
the	O
cellular	B-DNA
tyrosine	I-DNA
hydroxylase	I-DNA
gene	I-DNA
.	O

Thus	O
Oct-2	B-protein
plays	O
an	O
important	O
role	O
in	O
the	O
regulation	O
of	O
cellular	O
gene	O
expression	O
in	O
both	O
B	B-cell_type
cells	I-cell_type
and	O
neuronal	B-cell_type
cells	I-cell_type
as	O
well	O
as	O
in	O
the	O
control	O
of	O
viral	O
latency	O
.	O

Cell-type-specific	O
regulation	O
of	O
the	O
human	B-DNA
tumor	I-DNA
necrosis	I-DNA
factor	I-DNA
alpha	I-DNA
gene	I-DNA
in	O
B	B-cell_type
cells	I-cell_type
and	O
T	B-cell_type
cells	I-cell_type
by	O
NFATp	B-protein
and	O
ATF-2/JUN	B-protein
.	O

The	O
human	B-DNA
tumor	I-DNA
necrosis	I-DNA
factor	I-DNA
alpha	I-DNA
(	I-DNA
TNF-alpha	I-DNA
)	I-DNA
gene	I-DNA
is	O
one	O
of	O
the	O
earliest	O
genes	O
transcribed	O
after	O
the	O
stimulation	O
of	O
a	O
B	B-cell_type
cell	I-cell_type
through	O
its	O
antigen	B-protein
receptor	I-protein
or	O
via	O
the	O
CD-40	O
pathway	O
.	O

In	O
both	O
cases	O
,	O
induction	O
of	O
TNF-alpha	B-DNA
gene	I-DNA
transcription	O
can	O
be	O
blocked	O
by	O
the	O
immunosuppressants	O
cyclosporin	O
A	O
and	O
FK506	O
,	O
which	O
suggested	O
a	O
role	O
for	O
the	O
NFAT	B-protein
family	I-protein
of	O
proteins	O
in	O
the	O
regulation	O
of	O
the	O
gene	O
in	O
B	B-cell_type
cells	I-cell_type
.	O

Furthermore	O
,	O
in	O
T	B-cell_type
cells	I-cell_type
,	O
two	O
molecules	O
of	O
NFATp	B-protein
bind	O
to	O
the	O
TNF-alpha	B-DNA
promoter	I-DNA
element	I-DNA
kappa	I-DNA
3	I-DNA
in	O
association	O
with	O
ATF-2	B-protein
and	O
Jun	B-protein
proteins	I-protein
bound	O
to	O
an	O
immediately	O
adjacent	O
cyclic	B-DNA
AMP	I-DNA
response	I-DNA
element	I-DNA
(	I-DNA
CRE	I-DNA
)	I-DNA
site	I-DNA
.	O

Here	O
,	O
using	O
the	O
murine	B-cell_line
B-cell	I-cell_line
lymphoma	I-cell_line
cell	I-cell_line
line	I-cell_line
A20	B-cell_line
,	O
we	O
show	O
that	O
the	O
TNF-alpha	B-DNA
gene	I-DNA
is	O
regulated	O
in	O
a	O
cell-type-specific	O
manner	O
.	O

In	O
A20	B-cell_line
B	I-cell_line
cells	I-cell_line
,	O
the	O
TNF-alpha	B-DNA
gene	I-DNA
is	O
not	O
regulated	O
by	O
NFATp	B-protein
bound	O
to	O
the	O
kappa	B-DNA
3	I-DNA
element	I-DNA
.	O

Instead	O
,	O
ATF-2	B-protein
and	O
Jun	B-protein
proteins	I-protein
bind	O
to	O
the	O
composite	B-DNA
kappa	I-DNA
3/CRE	I-DNA
site	I-DNA
and	O
NFATp	B-protein
binds	O
to	O
a	O
newly	O
identified	O
second	O
NFAT	B-DNA
site	I-DNA
centered	O
at	O
-76	B-DNA
nucleotides	I-DNA
relative	O
to	O
the	O
TNF-alpha	B-DNA
transcription	I-DNA
start	I-DNA
site	I-DNA
.	O

This	O
new	O
site	O
plays	O
a	O
critical	O
role	O
in	O
the	O
calcium-mediated	O
,	O
cyclosporin	O
A-sensitive	O
induction	O
of	O
TNF-alpha	B-protein
in	O
both	O
A20	B-cell_line
B	I-cell_line
cells	I-cell_line
and	O
Ar-5	B-cell_line
cells	I-cell_line
.	O

Consistent	O
with	O
these	O
results	O
,	O
quantitative	O
DNase	B-protein
footprinting	O
of	O
the	O
TNF-alpha	B-DNA
promoter	I-DNA
using	O
increasing	O
amounts	O
of	O
recombinant	O
NFATp	B-protein
demonstrated	O
that	O
the	O
-76	B-DNA
site	I-DNA
binds	O
to	O
NFATp	B-protein
with	O
a	O
higher	O
affinity	O
than	O
the	O
kappa	B-DNA
3	I-DNA
site	I-DNA
.	O

Two	O
other	O
previously	O
unrecognized	O
NFATp-binding	B-DNA
sites	I-DNA
in	O
the	O
proximal	O
TNF-alpha	B-DNA
promoter	I-DNA
were	O
also	O
identified	O
by	O
this	O
analysis	O
.	O

Thus	O
,	O
through	O
the	O
differential	O
use	O
of	O
the	O
same	O
promoter	B-DNA
element	I-DNA
,	O
the	O
composite	B-DNA
kappa	I-DNA
3/CRE	I-DNA
site	I-DNA
,	O
the	O
TNF-alpha	B-DNA
gene	I-DNA
is	O
regulated	O
in	O
a	O
cell-type-specific	O
manner	O
in	O
response	O
to	O
the	O
same	O
extracellular	O
signal	O
.	O

Activation	O
of	O
Stat	B-protein
5b	I-protein
in	O
erythroid	B-cell_type
progenitors	I-cell_type
correlates	O
with	O
the	O
ability	O
of	O
ErbB	B-protein
to	O
induce	O
sustained	O
cell	O
proliferation	O
.	O

Self	O
renewal	O
of	O
normal	O
erythroid	B-cell_type
progenitors	I-cell_type
is	O
induced	O
by	O
the	O
receptor	B-protein
tyrosine	I-protein
kinase	I-protein
c-ErbB	B-protein
,	O
whereas	O
other	O
receptors	B-protein
(	O
c-Kit/Epo-R	B-protein
)	O
regulate	O
erythroid	O
differentiation	O
.	O

To	O
address	O
possible	O
mechanisms	O
that	O
could	O
explain	O
this	O
selective	O
activity	O
of	O
c-ErbB	B-protein
,	O
we	O
analyzed	O
the	O
ability	O
of	O
these	O
receptors	O
to	O
activate	O
the	O
different	O
members	O
of	O
the	O
Stat	B-protein
transcription	I-protein
factor	I-protein
family	I-protein
.	O

Ligand	O
activation	O
of	O
c-ErbB	B-protein
induced	O
the	O
tyrosine	O
phosphorylation	O
,	O
DNA-binding	O
,	O
and	O
reporter	B-DNA
gene	I-DNA
transcription	O
of	O
Stat	B-protein
5b	I-protein
in	O
erythroblasts	B-cell_type
.	O

In	O
contrast	O
,	O
ligand	O
activation	O
of	O
c-Kit	B-protein
was	O
unable	O
to	O
induce	O
any	O
of	O
these	O
effects	O
in	O
the	O
same	O
cells	O
.	O

Activation	O
of	O
the	O
erythropoietin	B-protein
receptor	I-protein
caused	O
specific	O
DNA-binding	O
of	O
Stat	B-protein
5b	I-protein
,	O
but	O
failed	O
to	O
induce	O
reporter	B-DNA
gene	I-DNA
transcription	O
.	O

These	O
biochemical	O
findings	O
correlate	O
perfectly	O
with	O
the	O
selective	O
ability	O
of	O
c-ErbB	B-protein
to	O
cause	O
sustained	O
self	O
renewal	O
in	O
erythroid	B-cell_type
progenitors	I-cell_type
.	O

Defective	O
transcription	O
of	O
the	O
IL-2	B-DNA
gene	I-DNA
is	O
associated	O
with	O
impaired	O
expression	O
of	O
c-Fos	B-protein
,	O
FosB	B-protein
,	O
and	O
JunB	B-protein
in	O
anergic	B-cell_line
T	I-cell_line
helper	I-cell_line
1	I-cell_line
cells	I-cell_line
.	O

Anergic	B-cell_line
CD4+	I-cell_line
Th	I-cell_line
cells	I-cell_line
do	O
not	O
produce	O
IL-2	B-protein
when	O
challenged	O
with	O
Ag-pulsed	B-cell_line
accessory	I-cell_line
cells	I-cell_line
because	O
of	O
a	O
transcriptional	O
defect	O
.	O

In	O
this	O
work	O
,	O
we	O
report	O
that	O
these	O
anergic	B-cell_line
T	I-cell_line
cells	I-cell_line
are	O
defective	O
in	O
their	O
ability	O
to	O
up-regulate	O
protein	O
binding	O
and	O
transactivation	O
at	O
two	O
critical	O
IL-2	B-DNA
DNA	I-DNA
enhancer	I-DNA
elements	I-DNA
:	O
NF-AT	B-protein
(	O
nuclear	B-protein
factor	I-protein
of	I-protein
activated	I-protein
T	I-protein
cells	I-protein
;	O
a	O
sequence	O
that	O
binds	O
a	O
heterotrimeric	B-protein
NFATp	I-protein
,	I-protein
Fos	I-protein
,	I-protein
and	I-protein
Jun	I-protein
protein	I-protein
complex	I-protein
)	O
and	O
Activator	B-protein
Protein-1	I-protein
(	O
AP-1	B-protein
)	O
(	O
that	O
binds	O
Fos	B-protein
and	I-protein
Jun	I-protein
heterodimers	I-protein
)	O
.	O

Western	O
blot	O
analysis	O
of	O
nuclear	O
extracts	O
showed	O
that	O
the	O
impaired	O
DNA-protein	O
interactions	O
in	O
anergic	B-cell_line
T	I-cell_line
cells	I-cell_line
were	O
associated	O
with	O
poor	O
expression	O
of	O
the	O
inducible	O
AP-1	B-protein
family	O
members	O
c-Fos	B-protein
,	O
FosB	B-protein
,	O
and	O
JunB	B-protein
.	O

However	O
,	O
the	O
reduced	O
expression	O
of	O
these	O
proteins	O
was	O
not	O
the	O
result	O
of	O
a	O
global	O
TCR/CD3	B-protein
-signaling	O
defect	O
because	O
CD3	B-protein
cross-linking	O
induced	O
an	O
equivalent	O
increase	O
in	O
intracellular-free	O
calcium	O
ions	O
,	O
as	O
well	O
as	O
NFATp	B-protein
dephosphorylation	O
,	O
translocation	O
to	O
the	O
nucleus	O
,	O
and	O
DNA	O
binding	O
in	O
both	O
normal	B-cell_type
and	O
anergic	B-cell_line
T	I-cell_line
cells	I-cell_line
.	O

Thus	O
,	O
defective	O
IL-2	B-DNA
gene	I-DNA
transcription	O
appears	O
to	O
be	O
due	O
,	O
at	O
least	O
in	O
part	O
,	O
to	O
a	O
selective	O
block	O
in	O
the	O
expression	O
of	O
the	O
AP-1	B-protein
Fos	I-protein
and	I-protein
Jun	I-protein
family	I-protein
members	I-protein
in	O
anergic	B-cell_line
T	I-cell_line
cells	I-cell_line
.	O

Sequence-specific	O
DNA	O
binding	O
of	O
the	O
B-cell-specific	B-protein
coactivator	I-protein
OCA-B	B-protein
.	O

B-cell-specific	O
transcription	O
of	O
immunoglobulin	B-DNA
genes	I-DNA
is	O
mediated	O
by	O
the	O
interaction	O
of	O
a	O
POU	B-DNA
domain	I-DNA
containing	O
transcription	B-protein
factor	I-protein
Oct-1	B-protein
or	O
Oct-2	B-protein
,	O
with	O
the	O
B-cell-specific	B-protein
coactivator	I-protein
OCA-B	B-protein
(	O
Bob-1	B-protein
,	O
OBF-1	B-protein
)	O
and	O
a	O
prototype	B-DNA
octamer	I-DNA
element	I-DNA
.	O

We	O
find	O
that	O
OCA-B	B-protein
binds	O
DNA	O
directly	O
in	O
the	O
major	O
groove	O
between	O
the	O
two	O
subdomains	O
of	O
the	O
POU	B-DNA
domain	I-DNA
,	O
requiring	O
both	O
an	O
A	O
at	O
the	O
fifth	B-DNA
position	I-DNA
of	O
the	O
octamer	B-DNA
element	I-DNA
and	O
contact	O
with	O
the	O
POU	B-DNA
domain	I-DNA
.	O

An	O
amino-terminal	B-protein
fragment	I-protein
of	O
OCA-B	B-protein
binds	O
the	O
octamer	B-DNA
site	I-DNA
in	O
the	O
absence	O
of	O
a	O
POU	B-DNA
domain	I-DNA
with	O
the	O
same	O
sequence	O
specificity	O
.	O

Coactivator	O
OCA-B	B-protein
may	O
undergo	O
a	O
POU-dependent	O
conformational	O
change	O
that	O
exposes	O
its	O
amino	O
terminus	O
,	O
allowing	O
it	O
to	O
recognize	O
specific	O
DNA	B-DNA
sequences	I-DNA
in	O
the	O
major	O
groove	O
within	O
the	O
binding	O
site	O
for	O
Oct-1	B-protein
or	O
Oct-2	B-protein
.	O

The	O
recognition	O
of	O
both	O
the	O
POU	B-DNA
domain	I-DNA
and	O
the	O
octamer	B-DNA
sequence	I-DNA
by	O
OCA-B	B-protein
provides	O
a	O
mechanism	O
for	O
differential	O
regulation	O
of	O
octamer	B-DNA
sites	I-DNA
containing	O
genes	O
by	O
the	O
ubiquitous	B-protein
factor	I-protein
Oct-1	B-protein
.	O

Uneven	O
X	B-DNA
inactivation	O
in	O
a	O
female	O
monozygotic	O
twin	O
pair	O
with	O
Fabry	O
disease	O
and	O
discordant	O
expression	O
of	O
a	O
novel	O
mutation	O
in	O
the	O
alpha-galactosidase	B-DNA
A	I-DNA
gene	I-DNA
.	O

We	O
describe	O
two	O
female	O
monozygotic	O
(	O
MZ	O
)	O
twins	O
heterozygous	O
for	O
Fabry	O
disease	O
,	O
an	O
X	O
linked	O
disorder	O
resulting	O
from	O
the	O
deficient	O
activity	O
of	O
alpha-galactosidase	B-protein
A	I-protein
.	O

While	O
one	O
of	O
the	O
twins	O
was	O
clinically	O
affected	O
,	O
the	O
other	O
was	O
asymptomatic	O
.	O

Enzymatic	O
assay	O
of	O
alpha-galactosidase	B-protein
in	O
blood	B-cell_type
leucocytes	I-cell_type
,	O
skin	B-cell_type
fibroblasts	I-cell_type
,	O
Epstein-Barr	B-cell_line
virus	I-cell_line
transformed	I-cell_line
lymphoid	I-cell_line
cell	I-cell_line
lines	I-cell_line
,	O
and	O
hair	O
follicles	O
of	O
the	O
twins	O
and	O
their	O
parents	O
confirmed	O
the	O
heterozygous	O
status	O
of	O
the	O
twins	O
and	O
indicated	O
that	O
Fabry	O
disease	O
had	O
occurred	O
as	O
a	O
result	O
of	O
a	O
de	O
novo	O
mutation	O
.	O

The	O
son	O
of	O
the	O
unaffected	O
twin	O
sister	O
was	O
shown	O
to	O
be	O
hemizygous	O
.	O

Molecular	O
analysis	O
of	O
the	O
alpha-galactosidase	B-DNA
A	I-DNA
gene	I-DNA
permitted	O
the	O
identification	O
of	O
an	O
as	O
yet	O
undescribed	O
point	O
mutation	O
at	O
position	B-DNA
10182	I-DNA
of	I-DNA
exon	I-DNA
5	I-DNA
which	O
causes	O
an	O
Asp	O
to	O
Asn	O
substitution	O
at	O
codon	B-DNA
231	I-DNA
.	O

Single	O
strand	O
conformation	O
polymorphism	O
(	O
SSCP	O
)	O
analysis	O
again	O
showed	O
the	O
heterozygous	O
status	O
of	O
the	O
twins	O
and	O
a	O
normal	O
pattern	O
in	O
their	O
parents	O
.	O

The	O
basis	O
for	O
the	O
discordant	O
expression	O
of	O
this	O
d	O
novo	O
mutation	O
in	O
the	O
twins	O
was	O
investigated	O
by	O
studying	O
their	O
X	O
inactivation	O
status	O
.	O

Analysis	O
of	O
the	O
inactive	B-DNA
X	I-DNA
specific	O
methylation	O
at	O
the	O
androgen	B-DNA
receptor	I-DNA
gene	I-DNA
showed	O
unbalanced	O
inactivation	O
in	O
the	O
twins	O
'	O
fibroblasts	O
and	O
in	O
opposite	O
directions	O
.	O

While	O
the	O
maternally	B-DNA
derived	I-DNA
X	I-DNA
chromosome	I-DNA
was	O
preferentially	O
active	O
in	O
the	O
asymptomatic	O
twin	O
,	O
the	O
paternal	B-DNA
X	I-DNA
chromosome	I-DNA
was	O
active	O
in	O
the	O
other	O
,	O
affected	O
twin	O
and	O
was	O
found	O
in	O
her	O
hemizygotic	O
nephew	O
.	O

These	O
data	O
suggest	O
that	O
the	O
paternal	B-DNA
X	I-DNA
chromosome	I-DNA
carries	O
the	O
de	O
novo	O
alpha-galactosidase	B-protein
A	I-protein
mutation	O
and	O
that	O
uneven	O
X	O
inactivation	O
is	O
the	O
underlying	O
mechanism	O
for	O
disease	O
expression	O
in	O
this	O
novel	O
female	O
MZ	O
twin	O
pair	O
.	O

This	O
is	O
the	O
first	O
documented	O
case	O
of	O
female	O
twins	O
discordant	O
for	O
Fabry	O
disease	O
.	O

Precise	O
alignment	B-DNA
of	I-DNA
sites	I-DNA
required	O
for	O
mu	B-DNA
enhancer	I-DNA
activation	O
in	O
B	B-cell_type
cells	I-cell_type
.	O

The	O
lymphocyte-specific	B-DNA
immunoglobulin	I-DNA
mu	I-DNA
heavy-chain	I-DNA
gene	I-DNA
intronic	I-DNA
enhancer	I-DNA
is	O
regulated	O
by	O
multiple	O
nuclear	B-protein
factors	I-protein
.	O

The	O
previously	O
defined	O
minimal	B-DNA
enhancer	I-DNA
containing	O
the	O
muA	B-DNA
,	I-DNA
muE3	I-DNA
,	I-DNA
and	I-DNA
muB	I-DNA
sites	I-DNA
is	O
transactivated	O
by	O
a	O
combination	O
of	O
the	O
ETS-domain	B-protein
proteins	I-protein
PU.1	B-protein
and	O
Ets-1	B-protein
in	O
nonlymphoid	B-cell_type
cells	I-cell_type
.	O

The	O
core	O
GGAAs	O
of	O
the	O
muA	B-DNA
and	I-DNA
muB	I-DNA
sites	I-DNA
are	O
separated	O
by	O
30	O
nucleotides	O
,	O
suggesting	O
that	O
ETS	B-protein
proteins	I-protein
bind	O
to	O
these	O
sites	O
from	O
these	O
same	O
side	O
of	O
the	O
DNA	O
helix	O
.	O

We	O
tested	O
the	O
necessity	O
for	O
appropriate	O
spatial	O
alignment	O
of	O
these	O
elements	B-DNA
by	O
using	O
mutated	B-DNA
enhancers	I-DNA
with	O
altered	O
spacings	O
.	O

A	O
4-	O
or	O
10-bp	O
insertion	O
between	O
muE3	B-DNA
and	O
muB	B-DNA
inactivated	O
the	O
mu	B-DNA
enhancer	I-DNA
in	O
S194	B-cell_line
plasma	I-cell_line
cells	I-cell_line
but	O
did	O
not	O
affect	O
in	O
vitro	O
binding	O
of	O
Ets-1	O
,	O
PU.1	B-protein
,	O
or	O
the	O
muE3-binding	B-protein
protein	I-protein
TFE3	B-protein
,	O
alone	O
or	O
in	O
pairwise	O
combinations	O
.	O

Circular	O
permutation	O
and	O
phasing	O
analyses	O
demonstrated	O
that	O
PU.1	B-protein
binding	O
but	O
not	O
TFE3	B-protein
or	O
Ets-1	B-protein
bends	O
mu	B-DNA
enhancer	I-DNA
DNA	I-DNA
toward	O
the	O
major	O
groove	O
.	O

We	O
propose	O
that	O
the	O
requirement	O
for	O
precise	O
spacing	O
of	O
the	O
muA	B-DNA
and	I-DNA
muB	I-DNA
elements	I-DNA
is	O
due	O
in	O
part	O
to	O
a	O
directed	O
DNA	O
bend	O
induced	O
by	O
PU.1	B-protein
.	O

[	O
Cortisone-resistant	O
bronchial	O
asthma	O
]	O

There	O
is	O
general	O
agreement	O
on	O
the	O
inflammatory	O
pathogenesis	O
of	O
bronchial	O
asthma	O
:	O
an	O
accumulation	O
of	O
activated	B-cell_type
eosinophils	I-cell_type
,	O
degranulated	B-cell_type
mast	I-cell_type
cells	I-cell_type
,	O
T	B-cell_type
lymphocytes	I-cell_type
and	O
in	O
very	O
severe	O
forms	O
,	O
granulocytes	B-cell_type
has	O
constantly	O
been	O
found	O
in	O
the	O
bronchial	O
mucosa	O
.	O

In	O
allergic	O
bronchial	O
asthma	O
,	O
inflammation	O
seems	O
to	O
be	O
orchestrated	O
predominantly	O
by	O
a	O
subset	O
of	O
T	B-cell_type
lymphocytes	I-cell_type
,	O
with	O
a	O
phenotype	O
similar	O
to	O
the	O
Th2	B-cell_type
subset	I-cell_type
able	O
to	O
produce	O
IL-4	B-protein
and	O
IL-5	B-protein
.	O

Although	O
corticosteroids	O
are	O
the	O
most	O
potent	O
therapeutic	O
agents	O
used	O
for	O
this	O
disease	O
,	O
their	O
anti-inflammatory	O
effect	O
differs	O
from	O
patient	O
to	O
patient	O
.	O

Some	O
criteria	O
which	O
can	O
be	O
used	O
to	O
define	O
steroid-resistant	O
bronchial	O
asthma	O
are	O
listed	O
here	O
.	O

This	O
review	O
analyzes	O
various	O
molecular	O
alterations	O
responsible	O
for	O
the	O
deficient	O
response	O
to	O
corticosteroid	O
treatment	O
observed	O
in	O
steroid-resistant	O
bronchial	O
asthmatic	O
subjects	O
.	O

New	O
knowledge	O
on	O
the	O
mechanism	O
of	O
steroid	O
resistance	O
may	O
have	O
important	O
implications	O
for	O
the	O
treatment	O
of	O
chronic	O
asthma	O
and	O
other	O
diseases	O
.	O

Mechanisms	O
of	O
transactivation	O
by	O
nuclear	B-protein
factor	I-protein
of	I-protein
activated	I-protein
T	I-protein
cells-1	I-protein
.	O

Nuclear	B-protein
factor	I-protein
of	I-protein
activated	I-protein
T	I-protein
cells-family	I-protein
proteins	I-protein
(	O
NFAT1/NFATp	B-protein
,	O
NFATc	B-protein
,	O
NFAT3	B-protein
,	O
and	O
NFAT4/NFATx/NFATc3	B-protein
)	O
play	O
a	O
key	O
role	O
in	O
the	O
transcription	O
of	O
cytokine	B-DNA
genes	I-DNA
and	O
other	O
genes	O
during	O
the	O
immune	O
response	O
.	O

We	O
have	O
defined	O
the	O
mechanisms	O
of	O
transactivation	O
by	O
NFAT1	B-protein
.	O

NFAT1	B-protein
possesses	O
two	O
transactivation	B-DNA
domains	I-DNA
whose	O
sequences	O
are	O
not	O
conserved	O
in	O
the	O
other	O
NFAT-family	B-protein
proteins	I-protein
,	O
and	O
a	O
conserved	O
DNA-binding	B-DNA
domain	I-DNA
that	O
mediates	O
the	O
recruitment	O
of	O
cooperating	O
nuclear	B-protein
transcription	I-protein
factors	I-protein
even	O
when	O
it	O
is	O
expressed	O
in	O
the	O
absence	O
of	O
other	O
regions	O
of	O
the	O
protein	O
.	O

The	O
activity	O
of	O
the	O
NH2-terminal	B-protein
transactivation	I-protein
domain	I-protein
is	O
modulated	O
by	O
an	O
adjacent	O
regulatory	B-protein
region	I-protein
that	O
contains	O
several	O
conserved	B-DNA
sequence	I-DNA
motifs	I-DNA
represented	O
only	O
in	O
the	O
NFAT	B-protein
family	I-protein
.	O

Our	O
results	O
emphasize	O
the	O
multiple	O
levels	O
at	O
which	O
NFAT-dependent	O
transactivation	O
is	O
regulated	O
,	O
and	O
predict	O
significant	O
differences	O
in	O
the	O
architecture	O
of	O
cooperative	O
transcription	B-protein
complexes	I-protein
containing	O
different	O
NFAT-family	B-protein
proteins	I-protein
.	O

Induction	O
of	O
activator	B-protein
protein	I-protein
(	I-protein
AP	I-protein
)	I-protein
-1	I-protein
and	O
nuclear	B-protein
factor-kappaB	I-protein
by	O
CD28	B-protein
stimulation	O
involves	O
both	O
phosphatidylinositol	B-protein
3-kinase	I-protein
and	O
acidic	B-protein
sphingomyelinase	I-protein
signals	O
.	O

A	O
major	O
obstacle	O
in	O
understanding	O
the	O
signaling	O
events	O
that	O
follow	O
CD28	B-protein
receptor	O
ligation	O
arises	O
from	O
the	O
fact	O
that	O
CD28	B-protein
acts	O
as	O
a	O
costimulus	O
to	O
TCR	B-protein
engagement	O
,	O
making	O
it	O
difficult	O
to	O
assess	O
the	O
relative	O
contribution	O
of	O
CD28	B-protein
signals	O
as	O
distinct	O
from	O
those	O
of	O
the	O
TCR	B-protein
.	O

To	O
overcome	O
this	O
problem	O
,	O
we	O
have	O
exploited	O
the	O
observation	O
that	O
activated	O
human	B-cell_type
T	I-cell_type
cell	I-cell_type
blasts	I-cell_type
can	O
be	O
stimulated	O
via	O
the	O
CD28	B-protein
surface	I-protein
molecule	I-protein
in	O
the	O
absence	O
of	O
antigenic	O
challenge	O
;	O
thus	O
,	O
we	O
have	O
been	O
able	O
to	O
observe	O
the	O
response	O
of	O
normal	B-cell_type
T	I-cell_type
cells	I-cell_type
to	O
CD28	B-protein
activation	O
in	O
isolation	O
.	O

Using	O
this	O
system	O
,	O
we	O
observed	O
that	O
CD28	B-protein
stimulation	O
by	O
B7-transfected	B-cell_line
CHO	I-cell_line
cells	I-cell_line
induced	O
a	O
proliferative	O
response	O
in	O
T	B-cell_type
cells	I-cell_type
that	O
was	O
not	O
accompanied	O
by	O
measurable	O
IL-2	B-protein
production	O
.	O

However	O
,	O
subsequent	O
analysis	O
of	O
transcription	B-protein
factor	I-protein
generation	O
revealed	O
that	O
B7	O
stimulation	O
induced	O
both	O
activator	B-protein
protein-1	I-protein
(	O
AP-1	B-protein
)	O
and	O
nuclear	B-protein
factor-kappaB	I-protein
(	I-protein
NF-kappaB	I-protein
)	I-protein
complexes	I-protein
,	O
but	O
not	O
NF-AT	B-protein
.	O

In	O
contrast	O
,	O
engagement	O
of	O
the	O
TCR	B-protein
by	O
class	B-protein
II	I-protein
MHC/superantigen	I-protein
,	O
either	O
with	O
or	O
without	O
CD28	B-protein
ligation	O
,	O
resulted	O
in	O
the	O
induction	O
of	O
NF-AT	B-protein
,	O
AP-1	B-protein
,	O
and	O
NF-kappaB	B-protein
as	O
well	O
as	O
IL-2	B-protein
production	O
.	O

Using	O
selective	O
inhibitors	O
,	O
we	O
investigated	O
the	O
signaling	O
pathways	O
involved	O
in	O
the	O
CD28	B-protein
-mediated	O
induction	O
of	O
AP-1	B-protein
and	O
NF-kappaB	B-protein
.	O

This	O
revealed	O
that	O
NF-kappaB	B-protein
generation	O
was	O
sensitive	O
to	O
chloroquine	O
,	O
an	O
inhibitor	O
of	O
acidic	B-protein
sphingomyelinase	I-protein
,	O
but	O
not	O
to	O
the	O
phosphatidylinositol	B-protein
3-kinase	I-protein
inhibitor	O
,	O
wortmannin	O
.	O

In	O
contrast	O
,	O
AP-1	B-protein
generation	O
was	O
inhibited	O
by	O
wortmannin	O
and	O
was	O
also	O
variably	O
sensitive	O
to	O
chloroquine	O
.	O

These	O
data	O
suggest	O
that	O
in	O
activated	O
normal	B-cell_type
T	I-cell_type
cells	I-cell_type
,	O
CD28	B-protein
-derived	O
signals	O
can	O
stimulate	O
proliferation	O
at	O
least	O
in	O
part	O
via	O
NF-kappaB	O
and	O
AP-1	O
generation	O
,	O
and	O
that	O
this	O
response	O
uses	O
both	O
acidic	B-protein
sphingomyelinase	I-protein
and	O
phosphatidylinositol	B-protein
3-kinase	I-protein
-linked	O
pathways	O
.	O

Presence	O
of	O
a	O
variant	O
form	O
of	O
the	O
estrogen	B-protein
receptor	I-protein
in	O
peripheral	B-cell_type
blood	I-cell_type
mononuclear	I-cell_type
cells	I-cell_type
from	O
normal	O
individuals	O
and	O
lupus	O
patients	O
.	O

Estrogen	O
may	O
participate	O
in	O
the	O
pathogenesis	O
of	O
systemic	O
lupus	O
erythematosus	O
(	O
SLE	O
)	O
via	O
its	O
intracellular	B-protein
receptor	I-protein
.	O

To	O
investigate	O
the	O
presence	O
of	O
various	O
isoforms	O
of	O
the	O
estrogen	B-protein
receptor	I-protein
(	O
ER	B-protein
)	O
in	O
SLE	O
we	O
isolated	O
RNA	O
from	O
mononuclear	B-cell_type
cells	I-cell_type
of	O
lupus	O
patients	O
and	O
normal	O
controls	O
.	O

Using	O
RT-PCR	O
we	O
were	O
able	O
to	O
identify	O
both	O
the	O
full	B-protein
length	I-protein
wild-type	I-protein
form	I-protein
and	O
an	O
isoform	O
of	O
the	O
ER	B-protein
which	O
precisely	O
lacks	O
exon	B-DNA
V	I-DNA
in	O
both	O
patient	O
and	O
normal	O
individuals	O
.	O

Our	O
results	O
,	O
although	O
limited	O
,	O
suggest	O
that	O
normal	O
individuals	O
can	O
express	O
both	O
the	O
wild-type	O
and	O
truncated	O
version	O
at	O
the	O
same	O
time	O
,	O
whereas	O
lupus	O
patients	O
only	O
express	O
either	O
the	O
wild-type	B-protein
or	I-protein
the	I-protein
truncated	I-protein
ER	I-protein
.	O

This	O
finding	O
may	O
lead	O
to	O
a	O
better	O
understanding	O
of	O
the	O
reasons	O
for	O
the	O
prevalence	O
of	O
lupus	O
in	O
females	O
and	O
of	O
the	O
estrogenic	O
effects	O
on	O
SLE	O
disease	O
activity	O
.	O

Regulation	O
of	O
sialoadhesin	B-protein
expression	O
on	O
rat	B-cell_type
macrophages	I-cell_type
.	O

Induction	O
by	O
glucocorticoids	O
and	O
enhancement	O
by	O
IFN-beta	B-protein
,	O
IFN-gamma	B-protein
,	O
IL-4	B-protein
,	O
and	O
lipopolysaccharide	O
.	O

Sialoadhesin	B-protein
is	O
a	O
macrophage-restricted	B-protein
member	I-protein
of	O
the	O
Ig	B-protein
superfamily	I-protein
that	O
mediates	O
adhesion	O
with	O
lymphoid	B-cell_type
and	I-cell_type
myeloid	I-cell_type
cells	I-cell_type
.	O

It	O
is	O
expressed	O
on	O
a	O
subpopulation	O
of	O
macrophages	B-cell_type
in	O
lymphoid	O
tissues	O
and	O
in	O
chronic	O
inflammation	O
(	O
e.g.	O
,	O
during	O
autoimmune	O
diseases	O
)	O
.	O

We	O
have	O
studied	O
the	O
regulation	O
of	O
sialoadhesin	B-protein
expression	O
in	O
vitro	O
and	O
show	O
that	O
glucocorticoids	O
(	O
GC	O
)	O
induce	O
sialoadhesin	B-protein
expression	O
on	O
freshly	O
isolated	O
rat	B-cell_type
macrophages	I-cell_type
and	O
the	O
rat	B-cell_line
macrophage	I-cell_line
cell	I-cell_line
line	I-cell_line
R2	I-cell_line
.	O

The	O
cytokines	B-protein
IFN-beta	B-protein
,	O
IFN-gamma	B-protein
,	O
IL-4	B-protein
,	O
and	O
LPS	O
,	O
although	O
unable	O
to	O
induce	O
sialoadhesin	B-protein
expression	O
by	O
themselves	O
,	O
were	O
able	O
to	O
enhance	O
GC-mediated	O
induction	O
of	O
sialoadhesin	B-protein
.	O

Sialoadhesin	B-protein
expression	O
was	O
functional	O
as	O
shown	O
by	O
cell	O
adhesion	O
assays	O
with	O
human	B-cell_type
RBCs	I-cell_type
.	O

Northern	O
blotting	O
experiments	O
indicated	O
that	O
regulation	O
predominantly	O
occurred	O
at	O
the	O
mRNA	O
level	O
.	O

Comparison	O
of	O
the	O
different	O
combinations	O
of	O
GC	O
and	O
cytokines	B-protein
/LPS	O
revealed	O
differences	O
in	O
the	O
level	O
of	O
GC-dependent	O
enhancement	O
of	O
sialoadhesin	B-protein
expression	O
,	O
with	O
IFN-beta	B-protein
and	O
IL-4	B-protein
being	O
more	O
potent	O
than	O
IFN-gamma	B-protein
and	O
LPS	O
.	O

Moreover	O
,	O
the	O
effects	O
of	O
IFN-gamma	B-protein
and	O
LPS	O
could	O
be	O
reproduced	O
by	O
priming	O
,	O
whereas	O
IFN-beta	B-protein
and	O
IL-4	B-protein
were	O
required	O
simultaneously	O
with	O
GC	O
.	O

The	O
regulation	O
of	O
sialoadhesin	B-protein
expression	O
was	O
mediated	O
by	O
the	O
GC	B-protein
receptor	I-protein
,	O
and	O
not	O
by	O
mineralocorticoid	B-protein
receptor	I-protein
,	O
as	O
shown	O
by	O
inhibition	O
experiments	O
with	O
specific	O
antagonists	O
.	O

Finally	O
,	O
it	O
is	O
demonstrated	O
that	O
macrophages	B-cell_type
in	O
the	O
adrenal	O
gland	O
,	O
the	O
major	O
site	O
of	O
endogenous	O
GC	O
production	O
,	O
express	O
sialoadhesin	B-protein
.	O

This	O
study	O
demonstrates	O
that	O
GC	O
act	O
as	O
a	O
primary	O
inducer	O
of	O
sialoadhesin	B-protein
expression	O
on	O
rat	B-cell_type
macrophages	I-cell_type
,	O
and	O
that	O
the	O
response	O
can	O
be	O
enhanced	O
by	O
IFN-beta	B-protein
,	O
T	B-protein
cell-derived	I-protein
cytokines	I-protein
,	O
or	O
LPS	O
.	O

Apoptosis	O
mediated	O
by	O
HIV	B-protein
protease	I-protein
is	O
preceded	O
by	O
cleavage	O
of	O
Bcl-2	B-protein
.	O

Expression	O
of	O
the	O
human	B-protein
immunodeficiency	I-protein
virus	I-protein
type	I-protein
1	I-protein
(	I-protein
HIV	I-protein
)	I-protein
protease	I-protein
in	O
cultured	B-cell_line
cells	I-cell_line
leads	O
to	O
apoptosis	O
,	O
preceded	O
by	O
cleavage	O
of	O
bcl-2	B-protein
,	O
a	O
key	O
negative	O
regulator	O
of	O
cell	O
death	O
.	O

In	O
contrast	O
,	O
a	O
high	O
level	O
of	O
bcl-2	B-protein
protects	O
cells	O
in	O
vitro	O
and	O
in	O
vivo	O
from	O
the	O
viral	B-protein
protease	I-protein
and	O
prevents	O
cell	O
death	O
following	O
HIV	O
infection	O
of	O
human	B-cell_type
lymphocytes	I-cell_type
,	O
while	O
reducing	O
the	O
yields	O
of	O
viral	B-protein
structural	I-protein
proteins	I-protein
,	O
infectivity	O
,	O
and	O
tumor	B-protein
necrosis	I-protein
factor	I-protein
alpha	I-protein
.	O

We	O
present	O
a	O
model	O
for	O
HIV	O
replication	O
in	O
which	O
the	O
viral	B-protein
protease	I-protein
depletes	O
the	O
infected	O
cells	O
of	O
bcl-2	B-protein
,	O
leading	O
to	O
oxidative	O
stress-dependent	O
activation	O
of	O
NF	B-protein
kappa	I-protein
B	I-protein
,	O
a	O
cellular	B-protein
factor	I-protein
required	O
for	O
HIV	O
transcription	O
,	O
and	O
ultimately	O
to	O
cell	O
death	O
.	O

Purified	O
bcl-2	B-protein
is	O
cleaved	O
by	O
HIV	B-protein
protease	I-protein
between	O
phenylalanine	O
112	O
and	O
alanine	O
113	O
.	O

The	O
results	O
suggest	O
a	O
new	O
option	O
for	O
HIV	O
gene	O
therapy	O
;	O
bcl-2	B-protein
muteins	I-protein
that	O
have	O
noncleavable	B-protein
alterations	I-protein
surrounding	O
the	O
HIV	B-protein
protease	I-protein
cleavage	I-protein
site	I-protein
.	O

Alpha	B-protein
4	I-protein
beta	I-protein
1	I-protein
(	I-protein
CD49d/CD29	I-protein
)	I-protein
integrin	I-protein
costimulation	O
of	O
human	B-cell_type
T	I-cell_type
cells	I-cell_type
enhances	O
transcription	B-protein
factor	I-protein
and	O
cytokine	O
induction	O
in	O
the	O
absence	O
of	O
altered	O
sensitivity	O
to	O
anti-CD3	B-protein
stimulation	O
.	O

The	O
integrin	B-protein
alpha	I-protein
4	I-protein
beta	I-protein
1	I-protein
can	O
provide	O
a	O
costimulus	O
to	O
induce	O
IL-2	B-protein
secretion	O
and	O
IL-2R	B-protein
expression	O
leading	O
to	O
enhanced	O
proliferation	O
of	O
purified	O
,	O
peripheral	B-cell_type
blood	I-cell_type
T	I-cell_type
cells	I-cell_type
.	O

Similar	O
to	O
expression	O
of	O
IL-2	B-protein
,	O
we	O
demonstrated	O
that	O
recombinant	B-protein
vascular-cell	I-protein
adhesion	I-protein
molecule-1	I-protein
,	O
when	O
co-immobilized	O
with	O
anti-CD3	B-protein
mAb	I-protein
,	O
significantly	O
enhanced	O
the	O
induction	O
of	O
transcription	B-protein
factors	I-protein
NF-AT	B-protein
,	O
AP-1	B-protein
,	O
and	O
NF-kappa	B-protein
B	I-protein
as	O
determined	O
by	O
electromobility	O
shift	O
assays	O
.	O

alpha	B-protein
4	I-protein
beta	I-protein
1	I-protein
ligation	O
alone	O
had	O
no	O
effect	O
on	O
transcription	B-protein
factor	I-protein
binding	O
.	O

The	O
requirements	O
for	O
induction	O
of	O
transcription	B-protein
factors	I-protein
reflected	O
the	O
requirements	O
for	O
the	O
secretion	O
of	O
multiple	O
cytokines	B-protein
,	O
including	O
IL-2	B-protein
,	O
TNF-alpha	B-protein
,	O
IFN-gamma	B-protein
,	O
and	O
granulocyte	B-protein
macrophage-CSF	I-protein
.	O

In	O
contrast	O
to	O
freshly	B-cell_type
isolated	I-cell_type
T	I-cell_type
cells	I-cell_type
,	O
in	O
vitro-cultured	B-cell_line
T	I-cell_line
cells	I-cell_line
did	O
not	O
require	O
costimulation	O
for	O
cytokine	B-protein
secretion	O
in	O
response	O
to	O
anti-CD3	B-protein
alone	O
.	O

Comparison	O
of	O
the	O
dose	O
response	O
to	O
anti-CD3	B-protein
stimulation	O
demonstrated	O
that	O
half-maximal	O
induction	O
of	O
IL-2	B-protein
was	O
achieved	O
using	O
the	O
same	O
dose	O
of	O
anti-CD3	B-protein
for	O
both	O
freshly	B-cell_type
isolated	I-cell_type
and	O
cultured	B-cell_line
T	I-cell_line
cells	I-cell_line
.	O

Furthermore	O
,	O
the	O
dose	O
of	O
OKT3	B-protein
required	O
to	O
achieve	O
half-maximal	O
activation	O
was	O
the	O
same	O
using	O
PMA	O
or	O
different	O
concentrations	O
of	O
alpha	B-protein
4	I-protein
beta	I-protein
1	I-protein
ligands	O
.	O

Therefore	O
,	O
costimulation	O
by	O
alpha	B-protein
4	I-protein
beta	I-protein
1	I-protein
ligands	O
was	O
not	O
due	O
to	O
stabilization	O
of	O
the	O
interaction	O
of	O
the	O
cells	O
with	O
its	O
substrate	O
.	O

We	O
conclude	O
,	O
rather	O
,	O
that	O
alpha	B-protein
4	I-protein
beta	I-protein
1	I-protein
in	O
freshly	B-cell_type
isolated	I-cell_type
T	I-cell_type
cells	I-cell_type
delivers	O
a	O
distinct	O
signal	O
that	O
synergizes	O
early	O
with	O
signals	O
initiated	O
by	O
TCR/CD3	B-protein
ligation	O
to	O
induce	O
DNA	O
binding	O
of	O
multiple	O
transcription	B-protein
factors	I-protein
required	O
for	O
cytokine	B-DNA
gene	I-DNA
induction	O
.	O

Inhibition	O
of	O
T	B-cell_type
lymphocyte	I-cell_type
activation	O
by	O
cAMP	O
is	O
associated	O
with	O
down-regulation	O
of	O
two	O
parallel	O
mitogen-activated	O
protein	B-protein
kinase	I-protein
pathways	O
,	O
the	O
extracellular	B-protein
signal-related	I-protein
kinase	I-protein
and	O
c-Jun	B-protein
N-terminal	I-protein
kinase	I-protein
.	O

The	O
induction	O
of	O
T	O
cell	O
proliferation	O
requires	O
signals	O
from	O
the	O
TCR	B-protein
and	O
a	O
co-receptor	B-protein
molecule	I-protein
,	O
such	O
as	O
CD28	B-protein
,	O
that	O
activate	O
parallel	O
and	O
partially	O
cross-reactive	O
signaling	O
pathways	O
.	O

These	O
pathways	O
are	O
disrupted	O
by	O
agonists	O
that	O
utilize	O
adenylate	B-protein
cyclase	I-protein
and	O
cAMP-dependent	B-protein
protein	I-protein
kinase	I-protein
A	I-protein
(	O
PKA	B-protein
)	O
.	O

We	O
found	O
that	O
the	O
adenylate	B-protein
cyclase	I-protein
activator	O
,	O
forskolin	O
,	O
inhibits	O
anti-CD3	B-protein
-induced	O
shift	O
in	O
Lck	B-protein
electrophoretic	O
mobility	O
,	O
suggesting	O
an	O
intervention	O
at	O
the	O
TCR	B-protein
-coupled	O
phosphoinositide	O
turnover	O
that	O
precedes	O
the	O
activation	O
of	O
PKC	B-protein
.	O

The	O
shift	O
of	O
Lck	B-protein
following	O
direct	O
PKC	B-protein
activation	O
by	O
12-O-tetradecanoyl	O
phorbol	O
13-acetate	O
,	O
which	O
bypasses	O
early	O
receptor-triggered	O
biochemical	O
events	O
,	O
is	O
insensitive	O
to	O
forskolin	O
.	O

Nevertheless	O
,	O
forskolin	O
also	O
inhibits	O
PKC	B-protein
downstream	O
events	O
,	O
such	O
as	O
c-jun	B-DNA
expression	O
,	O
which	O
is	O
critical	O
for	O
the	O
activation	O
process	O
of	O
T	B-cell_type
cells	I-cell_type
.	O

To	O
further	O
analyze	O
potential	O
cross	O
points	O
between	O
positively	O
and	O
negatively	O
regulating	O
signaling	O
pathways	O
in	O
T	B-cell_type
cells	I-cell_type
,	O
we	O
tested	O
the	O
effects	O
of	O
activators	O
of	O
the	O
adenylate	B-protein
cyclase	I-protein
or	O
PKA	B-protein
on	O
two	O
parallel	O
mitogen-activated	O
protein	O
kinase	O
signaling	O
pathways	O
mediated	O
by	O
extracellular	B-protein
signal-regulated	I-protein
kinase	I-protein
(	O
ERK	B-protein
)	O
and	O
c-Jun	B-protein
N-terminal	I-protein
kinase	I-protein
.	O

Using	O
a	O
PKC	B-protein
-specific	O
inhibitor	O
,	O
GF109203X	O
,	O
or	O
PKC-depleted	B-cell_line
T	I-cell_line
cells	I-cell_line
,	O
we	O
found	O
that	O
a	O
large	O
part	O
of	O
the	O
anti-CD3	B-protein
-induced	O
ERK	B-protein
activation	O
is	O
PKC	B-protein
dependent	O
.	O

Both	O
PKC-	O
dependent	O
and	O
-independent	O
activation	O
of	O
ERK	B-protein
were	O
sensitive	O
to	O
inhibition	O
by	O
forskolin	O
or	O
a	O
cell-permeable	O
cAMP	O
analogue	O
,	O
dbcAMP	O
.	O

Furthermore	O
,	O
the	O
effect	O
of	O
12-O-tetradecanoyl	O
phorbol	O
13-acetate	O
and	O
ionomycin	O
,	O
which	O
synergized	O
to	O
fully	O
activate	O
c-Jun	B-protein
N-terminal	I-protein
kinase	I-protein
,	O
was	O
also	O
sensitive	O
to	O
inhibition	O
by	O
forskolin	O
.	O

Our	O
results	O
suggest	O
that	O
PKA	B-protein
inhibits	O
T	O
cell	O
activation	O
by	O
interfering	O
with	O
multiple	O
events	O
along	O
the	O
two	O
signaling	O
pathways	O
operating	O
downstream	O
of	O
the	O
TCR	B-protein
and	O
the	O
CD28	B-protein
co-receptor	I-protein
molecules	I-protein
.	O

Transcriptional	O
and	O
posttranscriptional	O
regulation	O
of	O
erythroid	B-DNA
gene	I-DNA
expression	O
in	O
anthracycline-induced	O
differentiation	O
of	O
human	B-cell_type
erythroleukemic	I-cell_type
cells	I-cell_type
.	O

Aclacinomycin	O
(	O
ACLA	O
)	O
and	O
doxorubicin	O
(	O
DOX	O
)	O
were	O
used	O
at	O
subtoxic	O
concentrations	O
to	O
induce	O
erythroid	O
differentiation	O
in	O
the	O
human	B-cell_line
leukemic	I-cell_line
cell	I-cell_line
line	I-cell_line
K562	I-cell_line
.	O

Cell	O
hemoglobinization	O
was	O
accompanied	O
by	O
the	O
increased	O
expression	O
of	O
genes	B-DNA
encoding	O
gamma-globin	B-protein
and	I-protein
porphobilinogen	I-protein
deaminase	I-protein
(	O
PBGD	B-protein
)	O
,	O
an	O
enzyme	O
of	O
heme	O
synthesis	O
.	O

By	O
using	O
run-on	O
assays	O
,	O
ACLA	O
was	O
shown	O
to	O
induce	O
an	O
enhancement	O
of	O
the	O
transcription	O
of	O
erythroid	B-DNA
genes	I-DNA
,	O
including	O
gamma-globin	B-protein
,	O
PBGD	B-protein
,	O
erythropoietin	B-protein
receptor	I-protein
,	O
and	O
GATA-1	B-protein
transcription	B-protein
factor	I-protein
.	O

In	O
contrast	O
,	O
in	O
DOX-treated	B-cell_line
cells	I-cell_line
,	O
the	O
transcription	O
rate	O
of	O
these	O
genes	B-DNA
was	O
unchanged	O
in	O
comparison	O
with	O
control	B-cell_type
cells	I-cell_type
.	O

In	O
addition	O
,	O
inhibition	O
of	O
mRNA	B-RNA
synthesis	O
with	O
actinomycin	O
D	O
indicated	O
that	O
DOX	O
induced	O
an	O
increased	O
stability	O
of	O
PBGD	B-RNA
and	I-RNA
GATA-1	I-RNA
mRNAs	I-RNA
,	O
whereas	O
ACLA	O
did	O
not	O
affect	O
the	O
half-lives	O
of	O
these	O
mRNAs	B-RNA
.	O

Because	O
the	O
increase	O
in	O
erythroid	B-RNA
mRNA	I-RNA
steady-state	O
level	O
in	O
anthracycline-treated	B-cell_type
cells	I-cell_type
was	O
inhibited	O
by	O
cycloheximide	O
,	O
this	O
suggests	O
that	O
transcriptional	O
activation	O
in	O
ACLA-treated	B-cell_line
cells	I-cell_line
and	O
mRNA	O
stabilization	O
in	O
DOX-treated	B-cell_type
cells	I-cell_type
were	O
dependent	O
on	O
de	O
novo	O
protein	O
synthesis	O
.	O

Finally	O
,	O
GATA-1	B-protein
protein	O
level	O
was	O
shown	O
to	O
be	O
increased	O
in	O
ACLA-treated	B-cell_line
but	I-cell_line
not	I-cell_line
in	I-cell_line
DOX-treated	I-cell_line
cells	I-cell_line
.	O

These	O
two	O
anthracyclines	O
,	O
although	O
closely	O
related	O
in	O
their	O
structures	O
,	O
appeared	O
to	O
act	O
as	O
differentiation	O
inducers	O
by	O
distinct	O
mechanisms	O
.	O

Indeed	O
,	O
erythroid	B-DNA
gene	I-DNA
expression	O
was	O
demonstrated	O
to	O
be	O
regulated	O
transcriptionally	O
by	O
ACLA	O
and	O
mainly	O
posttranscriptionally	O
by	O
DOX	O
.	O

Interleukin-7	B-protein
signaling	O
in	O
human	B-cell_line
B	I-cell_line
cell	I-cell_line
precursor	I-cell_line
acute	I-cell_line
lymphoblastic	I-cell_line
leukemia	I-cell_line
cells	I-cell_line
and	O
murine	B-cell_line
BAF3	I-cell_line
cells	I-cell_line
involves	O
activation	O
of	O
STAT1	B-protein
and	O
STAT5	B-protein
mediated	O
via	O
the	O
interleukin-7	B-protein
receptor	I-protein
alpha	I-protein
chain	I-protein
.	O

Interleukin-7	B-protein
(	O
IL-7	B-protein
)	O
stimulates	O
the	O
proliferation	O
of	O
normal	B-cell_type
and	I-cell_type
leukemic	I-cell_type
B	I-cell_type
and	I-cell_type
T	I-cell_type
cell	I-cell_type
precursors	I-cell_type
and	I-cell_type
T	I-cell_type
lymphocytes	I-cell_type
.	O

Activation	O
of	O
the	O
JAK	B-protein
/STAT	B-protein
pathway	O
has	O
been	O
implicated	O
in	O
IL-7R	B-protein
signaling	O
.	O

We	O
investigated	O
which	O
STAT	B-protein
complexes	I-protein
are	O
formed	O
upon	O
stimulation	O
of	O
B	B-cell_line
cell	I-cell_line
precursor	I-cell_line
acute	I-cell_line
lymphoblastic	I-cell_line
leukemia	I-cell_line
(	I-cell_line
BCP-ALL	I-cell_line
)	I-cell_line
cells	I-cell_line
with	O
IL-7	B-protein
.	O

Gel	O
retardation	O
assays	O
with	O
STAT-binding	O
oligonucleotides	O
showed	O
that	O
IL-7	B-protein
induces	O
the	O
formation	O
of	O
two	O
major	O
STAT	B-protein
complexes	I-protein
in	O
BCP-ALL	B-cell_line
cells	I-cell_line
.	O

Supershifts	O
with	O
anti-STAT	O
antibodies	O
identified	O
these	O
as	O
STAT1	B-protein
and	O
STAT5	B-protein
complexes	I-protein
.	O

This	O
pattern	O
of	O
STAT	B-protein
activation	O
was	O
seen	O
in	O
all	O
BCP-ALL	O
cases	O
that	O
respond	O
to	O
IL-7	B-protein
in	O
proliferation	O
assays	O
.	O

IL-7	B-protein
also	O
induced	O
STAT	B-protein
/DNA	O
binding	O
in	O
BCP-ALL	O
cases	O
that	O
failed	O
to	O
proliferate	O
in	O
response	O
to	O
IL-7	B-protein
,	O
suggesting	O
that	O
the	O
ability	O
of	O
IL-7R	B-protein
to	O
activate	O
the	O
JAK	B-protein
/STAT	B-protein
pathway	O
per	O
se	O
is	O
not	O
sufficient	O
for	O
proliferation	O
induction	O
.	O

To	O
determine	O
the	O
contribution	O
of	O
the	O
cytoplasmic	B-protein
domain	I-protein
of	O
the	O
IL-7	B-protein
receptor	I-protein
alpha	I-protein
chain	I-protein
(	O
IL-7R	B-protein
alpha	I-protein
)	O
to	O
activation	O
of	O
STAT	B-protein
proteins	I-protein
,	O
transfectants	O
of	O
the	O
murine	B-cell_line
pro-B	I-cell_line
cell	I-cell_line
line	I-cell_line
BAF3	I-cell_line
were	O
made	O
that	O
express	O
chimeric	B-protein
receptors	I-protein
consisting	O
of	O
the	O
extracellular	B-protein
domain	I-protein
of	O
human	B-protein
granulocyte	I-protein
colony-stimulating	I-protein
factor	I-protein
receptor	I-protein
(	O
G-CSF-R	B-protein
)	O
and	O
the	O
transmembrane	B-protein
and	I-protein
intracellular	I-protein
domains	I-protein
of	O
human	B-protein
IL-7R	I-protein
alpha	I-protein
.	O

Activation	O
of	O
the	O
chimeric	B-protein
G-CSF-R/IL-7R	I-protein
alpha	I-protein
with	O
G-CSF	B-protein
resulted	O
in	O
a	O
full	O
proliferative	O
response	O
and	O
induced	O
the	O
phosphorylation	O
of	O
JAK1	B-protein
but	O
not	O
JAK2	B-protein
.	O

Major	O
STAT	B-protein
complexes	I-protein
activated	O
by	O
G-CSF-R/IL-7R	B-protein
alpha	I-protein
contained	O
STAT1	B-protein
or	O
STAT5	B-protein
,	O
while	O
some	O
formation	O
of	O
STAT3-containing	B-protein
complexes	I-protein
was	O
also	O
seen	O
.	O

These	O
findings	O
establish	O
that	O
STAT1	B-protein
and	O
STAT5	B-protein
,	O
and	O
possibly	O
STAT3	B-protein
,	O
are	O
activated	O
upon	O
stimulation	O
of	O
precursor	B-cell_type
B	I-cell_type
cells	I-cell_type
with	O
IL-7	B-protein
.	O

The	O
data	O
further	O
indicate	O
that	O
the	O
IL-7R	B-protein
alpha	I-protein
chains	I-protein
are	O
directly	O
involved	O
in	O
the	O
activation	O
of	O
JAKs	B-protein
and	O
STATs	B-protein
and	O
have	O
a	O
major	O
role	O
in	O
proliferative	O
signaling	O
in	O
precursor	B-cell_type
B	I-cell_type
cells	I-cell_type
.	O

Stimulation	O
of	O
human	O
lymphocyte	O
proliferation	O
and	O
CD40	B-protein
antigen	O
expression	O
by	O
phosphorothioate	O
oligonucleotides	O
complementary	O
to	O
hepatitis	B-DNA
B	I-DNA
virus	I-DNA
genome	I-DNA
.	O

We	O
have	O
studied	O
the	O
proliferation	O
and	O
CD40	B-protein
antigen	O
expression	O
of	O
lymphocytes	B-cell_type
,	O
and	O
the	O
cytotoxicity	O
to	O
monocytes	B-cell_type
,	O
of	O
antisense	O
phosphorothioate	O
oligodeoxynucleotides	O
complementary	O
to	O
the	O
SP	B-DNA
II	I-DNA
promoter	I-DNA
of	O
HBV	B-RNA
mRNA	I-RNA
(	O
sequence	O
I	O
)	O
and	O
the	O
X	B-DNA
gene	I-DNA
(	O
sequence	O
II	O
)	O
in	O
patients	O
with	O
chronic	O
hepatitis	O
B	O
.	O

The	O
oligo	O
sequence	O
I	O
stimulated	O
proliferation	O
of	O
both	O
T	B-cell_type
and	I-cell_type
,	I-cell_type
to	I-cell_type
a	I-cell_type
lesser	I-cell_type
extent	I-cell_type
,	I-cell_type
B	I-cell_type
cells	I-cell_type
.	O

The	O
percentage	O
of	O
cells	O
expressing	O
CD40	B-protein
in	O
T	B-cell_line
and	I-cell_line
B	I-cell_line
cell	I-cell_line
co-cultures	I-cell_line
increased	O
from	O
4.2	O
%	O
to	O
13.8	O
%	O
after	O
oligo	O
stimulation	O
in	O
patients	O
,	O
while	O
it	O
increased	O
form	O
4.7	O
%	O
to	O
48.6	O
%	O
in	O
healthy	O
controls	O
.	O

The	O
sense	O
sequence	O
(	O
sequence	O
III	O
)	O
of	O
the	O
X	B-DNA
gene	I-DNA
also	O
enhanced	O
the	O
expression	O
of	O
CD40	B-protein
antigen	I-protein
in	O
patients	O
with	O
hepatitis	O
B	O
.	O

The	O
proportion	O
of	O
CD40	B-cell_line
cells	I-cell_line
(	O
26	O
%	O
)	O
in	O
a	O
resting	B-cell_line
B-cell	I-cell_line
preparation	I-cell_line
from	O
hepatitis	O
B	O
patients	O
decreased	O
to	O
zero	O
after	O
a	O
5-day	O
culture	O
with	O
sequence	O
I	O
,	O
but	O
IgG	O
levels	O
in	O
the	O
culture	O
supernatant	O
increased	O
.	O

The	O
cytotoxic	O
properties	O
of	O
monocytes	B-cell_type
were	O
not	O
influenced	O
by	O
the	O
oligos	O
.	O

These	O
findings	O
indicate	O
that	O
antisense	O
oligos	O
against	O
hepatitis	O
B	O
virus	O
(	O
HBV	O
)	O
have	O
mitogenic	O
effects	O
on	O
the	O
proliferation	O
of	O
human	B-cell_type
lymphocytes	I-cell_type
in	O
a	O
non-specific	O
manner	O
and	O
may	O
activate	O
T	B-cell_type
cells	I-cell_type
to	O
express	O
CD40	B-protein
antigen	I-protein
.	O

Activation	B-protein
protein	I-protein
1	I-protein
-dependent	O
transcriptional	O
activation	O
of	O
interleukin	B-DNA
2	I-DNA
gene	I-DNA
by	O
Ca2+/calmodulin	B-protein
kinase	I-protein
type	I-protein
IV/Gr	I-protein
.	O

The	O
Ca2+/calmodulin-dependent	B-protein
protein	I-protein
kinase	I-protein
(	I-protein
CaMK	I-protein
)	I-protein
type	I-protein
IV/Gr	I-protein
is	O
selectively	O
expressed	O
in	O
T	B-cell_type
lymphocytes	I-cell_type
and	O
is	O
activated	O
after	O
signaling	O
via	O
the	O
T	B-protein
cell	I-protein
antigen	I-protein
receptor	I-protein
(	O
TCR	B-protein
)	O
,	O
indicating	O
that	O
it	O
mediates	O
some	O
of	O
the	O
Ca	O
(	O
2+	O
)	O
-dependent	O
transcriptional	O
events	O
that	O
follow	O
TCR	B-protein
engagement	O
.	O

Here	O
we	O
show	O
that	O
CaMKIV/Gr	B-protein
induces	O
the	O
transcription	B-protein
factor	I-protein
activation	I-protein
protein	I-protein
1	I-protein
(	O
AP-1	B-protein
)	O
alone	O
or	O
in	O
synergy	O
with	O
T	B-protein
cell	I-protein
mitogens	I-protein
and	O
with	O
the	O
p21ras	B-protein
oncoprotein	I-protein
.	O

CaMKIV/	B-protein
Gr	I-protein
signaling	O
is	O
associated	O
with	O
transcriptional	O
activation	O
of	O
c-fos	B-DNA
but	O
is	O
independent	O
of	O
p21ras	B-DNA
or	O
calcineurin	B-protein
.	O

AP-1	B-protein
is	O
an	O
integral	O
component	O
of	O
the	O
nuclear	B-protein
factor	I-protein
of	I-protein
activated	I-protein
T	I-protein
cells	I-protein
(	I-protein
NFAT	I-protein
)	I-protein
transcriptional	I-protein
complex	I-protein
,	O
which	O
is	O
required	O
for	O
interleukin	B-DNA
2	I-DNA
gene	I-DNA
expression	O
in	O
T	B-cell_type
cells	I-cell_type
.	O

We	O
demonstrate	O
that	O
CaMKIV/Gr	B-protein
reconstitutes	O
the	O
capacity	O
of	O
the	O
cytosolic	O
component	O
of	O
NFAT	B-protein
to	O
direct	O
transcription	O
from	O
NFAT	B-DNA
sites	I-DNA
in	O
non-	O
T	B-cell_type
cells	I-cell_type
.	O

These	O
results	O
reveal	O
a	O
central	O
role	O
for	O
CaMKIV/Gr	B-protein
as	O
a	O
Ca	O
(	O
2+	O
)	O
-regulated	O
activator	O
of	O
gene	O
transcription	O
in	O
T	B-cell_type
lymphocytes	I-cell_type
.	O

IL-12	B-protein
-induced	O
activation	O
of	O
NK	B-cell_type
and	I-cell_type
T	I-cell_type
cells	I-cell_type
occurs	O
in	O
the	O
absence	O
of	O
immediate-early	B-DNA
activation	I-DNA
gene	I-DNA
expression	O
.	O

The	O
responses	O
of	O
lymphocytes	B-cell_type
to	O
IL-2	B-protein
and	O
IL-12	B-protein
,	O
involving	O
proliferation	O
,	O
differentiation	O
,	O
and	O
cytokine	B-protein
production	O
,	O
are	O
only	O
partially	O
overlapping	O
,	O
and	O
may	O
depend	O
on	O
induced	O
differential	O
expression	O
of	O
specific	O
sets	O
of	O
genes	B-protein
.	O

Using	O
reverse-transcription	O
PCR	O
differential	O
display	O
,	O
we	O
isolated	O
an	O
mRNA	B-RNA
species	I-RNA
expressed	O
in	O
IL-2	B-cell_type
-but	I-cell_type
not	I-cell_type
IL-12-stimulated	I-cell_type
NK	I-cell_type
cells	I-cell_type
.	O

This	O
was	O
identified	O
as	O
the	O
mRNA	B-RNA
encoding	O
the	O
transcription	B-protein
factor	I-protein
egr-1	B-protein
,	O
which	O
is	O
expressed	O
with	O
fast	O
kinetics	O
in	O
T	B-cell_type
and	I-cell_type
NK	I-cell_type
cells	I-cell_type
upon	O
IL-2	B-protein
,	O
but	O
not	O
IL-12	B-protein
,	O
stimulation	O
.	O

Analysis	O
of	O
the	O
accumulation	O
of	O
mRNA-encoding	B-protein
members	I-protein
of	O
the	O
AP-1	B-protein
transcription	I-protein
factor	I-protein
family	I-protein
demonstrated	O
that	O
c-fos	B-DNA
and	O
junB	B-DNA
are	O
also	O
expressed	O
upon	O
stimulation	O
of	O
NK	B-cell_type
and	I-cell_type
T	I-cell_type
cells	I-cell_type
with	O
IL-2	B-protein
,	O
but	O
not	O
IL-12	B-protein
,	O
whereas	O
expression	O
of	O
c-jun	B-DNA
and	O
junD	B-DNA
is	O
not	O
modified	O
by	O
either	O
cytokine	B-protein
.	O

Accordingly	O
,	O
increased	O
AP-1	B-protein
DNA-binding	O
activity	O
and	O
AP-1	B-protein
-dependent	O
transcriptional	O
activity	O
were	O
detected	O
exclusively	O
in	O
IL-2-stimulated	B-cell_line
cells	I-cell_line
.	O

Analysis	O
of	O
the	O
expression	O
of	O
genes	B-protein
reported	O
to	O
regulate	O
cytokine	B-protein
-induced	O
proliferation	O
demonstrated	O
that	O
both	O
IL-2	B-protein
and	O
IL-12	B-protein
induce	O
c-myc	B-RNA
mRNA	I-RNA
accumulation	O
in	O
NK	B-cell_type
and	I-cell_type
T	I-cell_type
cells	I-cell_type
,	O
whereas	O
only	O
IL-2	B-protein
induces	O
bcl-2	B-DNA
expression	O
.	O

Our	O
data	O
provide	O
the	O
first	O
demonstration	O
that	O
IL-12	B-protein
-mediated	O
activation	O
of	O
T	B-cell_type
and	I-cell_type
NK	I-cell_type
cells	I-cell_type
does	O
not	O
involve	O
expression	O
of	O
members	O
of	O
the	O
immediate-early	B-DNA
activation	I-DNA
genes	I-DNA
family	I-DNA
(	O
egr-1	B-DNA
,	O
c-fos	B-DNA
,	O
and	O
junB	B-DNA
)	O
,	O
AP-1	B-protein
transcriptional	O
activity	O
,	O
or	O
bcl-2	B-DNA
expression	O
.	O

This	O
indicates	O
that	O
functional	O
differences	O
observed	O
in	O
IL-2-	B-cell_line
and	I-cell_line
IL-12-stimulated	I-cell_line
cells	I-cell_line
may	O
depend	O
,	O
at	O
least	O
in	O
part	O
,	O
on	O
differential	O
gene	O
regulation	O
.	O

Active	O
suppression	O
of	O
the	O
class	B-DNA
II	I-DNA
transactivator-encoding	I-DNA
AIR-1	I-DNA
locus	I-DNA
is	O
responsible	O
for	O
the	O
lack	O
of	O
major	B-DNA
histocompatibility	I-DNA
complex	I-DNA
class	I-DNA
II	I-DNA
gene	I-DNA
expression	O
observed	O
during	O
differentiation	O
from	O
B	B-cell_type
cells	I-cell_type
to	O
plasma	B-cell_type
cells	I-cell_type
.	O

In	O
this	O
study	O
the	O
genetic	O
control	O
of	O
major	B-DNA
histocompatibility	I-DNA
complex	I-DNA
(	I-DNA
MHC	I-DNA
)	I-DNA
class	I-DNA
II	I-DNA
gene	I-DNA
expression	O
during	O
the	O
transition	O
from	O
B	B-cell_type
cell	I-cell_type
to	O
plasma	B-cell_type
cell	I-cell_type
has	O
been	O
analyzed	O
.	O

Class	B-protein
II	I-protein
molecules	I-protein
are	O
not	O
expressed	O
in	O
plasma	B-cell_type
cells	I-cell_type
because	O
of	O
an	O
active	O
suppression	O
resulting	O
in	O
the	O
abrogation	O
of	O
class	B-DNA
II	I-DNA
gene	I-DNA
transcription	O
.	O

We	O
show	O
here	O
that	O
the	O
plasma	O
cell-specific	O
repressor	O
function	O
,	O
designated	O
SIR	B-DNA
(	O
suppressor	B-DNA
of	I-DNA
immune	I-DNA
response	I-DNA
genes	I-DNA
)	O
,	O
does	O
not	O
act	O
directly	O
on	O
the	O
transcription	O
of	O
class	B-DNA
II	I-DNA
genes	I-DNA
,	O
but	O
instead	O
on	O
the	O
transcription	O
of	O
the	O
AIR-1	B-DNA
gene	I-DNA
,	O
whose	O
product	O
,	O
the	O
class	B-protein
II	I-protein
transactivator	I-protein
(	O
CIITA	B-protein
)	O
,	O
is	O
fundamental	O
for	O
the	O
regulation	O
of	O
the	O
constitutive	O
and	O
inducible	O
expression	O
of	O
MHC	B-DNA
class	I-DNA
II	I-DNA
genes	I-DNA
.	O

This	O
was	O
unambiguously	O
demonstrated	O
by	O
the	O
fact	O
that	O
plasmacytoma	B-cell_line
x	I-cell_line
B	I-cell_line
cell	I-cell_line
hybrids	I-cell_line
carrying	O
an	O
AIR-1	B-DNA
locus	I-DNA
derived	O
from	O
CIITA-expressing	B-cell_line
cells	I-cell_line
do	O
not	O
express	O
CIITA-specific	B-RNA
transcripts	I-RNA
.	O

Transfection	O
of	O
a	O
cDNA	O
containing	O
the	O
human	B-DNA
CIITA	I-DNA
coding	I-DNA
sequence	I-DNA
under	O
the	O
control	O
of	O
an	O
heterologous	B-DNA
promoter	I-DNA
restores	O
expression	O
of	O
human	B-DNA
MHC	I-DNA
class	I-DNA
II	I-DNA
genes	I-DNA
in	O
the	O
hybrids	O
and	O
is	O
responsible	O
for	O
de	O
novo	O
expression	O
of	O
mouse	B-DNA
MHC	I-DNA
class	I-DNA
II	I-DNA
genes	I-DNA
in	O
both	O
the	O
mouse	B-cell_line
plasmacytoma	I-cell_line
cell	I-cell_line
line	I-cell_line
and	O
the	O
hybrids	B-cell_line
.	O

These	O
results	O
confirm	O
and	O
extend	O
the	O
notion	O
of	O
the	O
functional	O
conservation	O
of	O
the	O
AIR-1	B-protein
gene	I-protein
product	I-protein
across	O
species	O
barriers	O
.	O

Interestingly	O
,	O
in	O
CIITA-transfected	B-cell_line
cell	I-cell_line
hybrids	I-cell_line
,	O
cell	O
surface	O
expression	O
of	O
the	O
human	B-protein
HLA-DQ	I-protein
heterodimer	I-protein
was	O
not	O
observed	O
.	O

This	O
result	O
was	O
not	O
attributable	O
to	O
lack	O
of	O
HLA-DQ	O
alpha	O
or	O
-DQ	O
beta	O
transcription	O
,	O
because	O
both	O
transcripts	O
were	O
present	O
in	O
the	O
CIITA-transfected	B-cell_line
hybrids	I-cell_line
,	O
although	O
at	O
reduced	O
levels	O
.	O

These	O
findings	O
further	O
support	O
our	O
previous	O
observations	O
on	O
the	O
distinct	O
regulation	O
of	O
expression	O
of	O
the	O
human	B-DNA
HLA-DQ	I-DNA
class	I-DNA
II	I-DNA
subset	I-DNA
,	O
which	O
may	O
be	O
thus	O
controlled	O
at	O
the	O
posttranscriptional	O
level	O
by	O
a	O
CIITA	B-protein
-independent	O
mechanism	O
.	O

Requirements	O
for	O
induction	O
of	O
vitamin	O
D-mediated	O
gene	O
regulation	O
in	O
normal	B-cell_type
human	I-cell_type
B	I-cell_type
lymphocytes	I-cell_type
.	O

Mature	O
human	B-cell_type
lymphocytes	I-cell_type
are	O
unique	O
targets	O
of	O
1	O
alpha	O
,	O
25-dihydroxyvitamin	O
D3	O
(	O
1	O
alpha	O
,	O
25	O
(	O
OH	O
)	O
2D3	O
)	O
in	O
that	O
vitamin	B-protein
D	I-protein
receptors	I-protein
(	O
VDR	B-protein
)	O
are	O
not	O
constitutively	O
expressed	O
,	O
and	O
specific	O
cellular	O
activation	O
signals	O
are	O
required	O
for	O
both	O
the	O
up-regulation	O
of	O
VDR	B-protein
and	O
establishment	O
of	O
reactivity	O
to	O
the	O
lipophilic	O
ligand	O
.	O

Treatment	O
of	O
B	B-cell_type
lymphocytes	I-cell_type
with	O
the	O
cytokine	B-protein
IL-4	B-protein
(	O
IL-4	B-protein
)	O
,	O
in	O
the	O
absence	O
of	O
prior	O
activation	O
,	O
induces	O
a	O
weak	O
up-regulation	O
of	O
VDR	B-protein
expression	O
but	O
fails	O
to	O
generate	O
vitamin	B-protein
D-responsive	I-protein
element	I-protein
(	I-protein
VDRE	I-protein
)	I-protein
-reactive	I-protein
nuclear	I-protein
protein	I-protein
complexes	I-protein
or	O
to	O
initiate	O
the	O
genomic	O
transcription	O
of	O
25-hydroxyvitamin	B-protein
D3	I-protein
24-hydroxylase	I-protein
.	O

Stimulation	O
of	O
B	B-cell_type
lymphocytes	I-cell_type
by	O
either	O
ligation	O
of	O
CD40	B-protein
Ag	I-protein
or	O
cross-linking	O
the	O
Ig	B-protein
receptor	I-protein
is	O
also	O
insufficient	O
to	O
render	O
B	B-cell_type
lymphocytes	I-cell_type
responsive	O
to	O
1	O
alpha	O
,	O
25	O
(	O
OH	O
)	O
2D3	O
.	O

However	O
,	O
this	O
apparent	O
lack	O
of	O
response	O
to	O
the	O
secosterol	O
can	O
be	O
overcome	O
by	O
stimulation	O
of	O
B	B-cell_type
lymphocytes	I-cell_type
with	O
a	O
combination	O
of	O
these	O
cellular	O
activation	O
signals	O
,	O
which	O
are	O
sufficient	O
to	O
lead	O
to	O
G1	O
cell	O
cycle	O
progression	O
.	O

In	O
the	O
presence	O
of	O
1	O
alpha	O
,	O
25	O
(	O
OH	O
)	O
2D3	O
,	O
cellular	O
activation	O
associated	O
with	O
stimulation	O
of	O
such	O
a	O
progression	O
appears	O
to	O
be	O
sufficient	O
for	O
the	O
up-regulation	O
of	O
VDR	B-protein
message	O
and	O
protein	O
and	O
necessary	O
for	O
the	O
establishment	O
of	O
VDRE	B-protein
binding	I-protein
complexes	I-protein
and	O
the	O
induction	O
of	O
24-hydroxylase	B-protein
message	O
.	O

Furthermore	O
,	O
biologic	O
functions	O
are	O
modulated	O
,	O
in	O
that	O
the	O
hormone	O
inhibits	O
proliferation	O
in	O
a	O
subset	O
of	O
the	O
activated	O
B	B-cell_type
cells	I-cell_type
.	O

These	O
observations	O
suggest	O
that	O
reactivity	O
to	O
1	O
alpha	O
,	O
25	O
(	O
OH	O
)	O
2D3	O
is	O
tightly	O
regulated	O
in	O
B	B-cell_type
lymphocytes	I-cell_type
,	O
requiring	O
specific	O
signals	O
for	O
its	O
initiation	O
.	O

Cross	O
talk	O
between	O
cell	O
death	O
and	O
cell	O
cycle	O
progression	O
:	O
BCL-2	B-protein
regulates	O
NFAT	B-protein
-mediated	O
activation	O
.	O

BCL-2-deficient	B-cell_line
T	I-cell_line
cells	I-cell_line
demonstrate	O
accelerated	O
cell	O
cycle	O
progression	O
and	O
increased	O
apoptosis	O
following	O
activation	O
.	O

Increasing	O
the	O
levels	O
of	O
BCL-2	B-protein
retarded	O
the	O
G0	O
--	O
>	O
S	O
transition	O
,	O
sustained	O
the	O
levels	O
of	O
cyclin-dependent	B-protein
kinase	I-protein
inhibitor	O
p27Kip1	O
,	O
and	O
repressed	O
postactivation	O
death	O
.	O

Proximal	O
signal	O
transduction	O
events	O
and	O
immediate	B-DNA
early	I-DNA
gene	I-DNA
transcription	O
were	O
unaffected	O
.	O

However	O
,	O
the	O
transcription	O
and	O
synthesis	O
of	O
interleukin	B-protein
2	I-protein
and	O
other	O
delayed	O
early	O
cytokines	B-protein
were	O
markedly	O
attenuated	O
by	O
BCL-2	B-protein
.	O

In	O
contrast	O
,	O
a	O
cysteine	O
protease	O
inhibitor	O
that	O
also	O
blocks	O
apoptosis	O
had	O
no	O
substantial	O
affect	O
upon	O
cytokine	B-protein
production	O
.	O

InterleUkin	B-protein
2	I-protein
expression	O
requires	O
several	O
transcription	B-protein
factors	I-protein
of	O
which	O
nuclear	O
translocation	O
of	O
NFAT	B-protein
(	O
nuclear	B-protein
factor	I-protein
of	I-protein
activated	I-protein
T	I-protein
cells	I-protein
)	O
and	O
NFAT	B-protein
-mediated	O
transactivation	O
were	O
impaired	O
by	O
BCL-2	B-protein
.	O

Thus	O
,	O
select	O
genetic	O
aberrations	O
in	O
the	O
apoptotic	O
pathway	O
reveal	O
a	O
cell	O
autonomous	O
coregulation	O
of	O
activation	O
.	O

Interaction	O
of	O
the	O
human	B-protein
T-cell	I-protein
lymphotropic	I-protein
virus	I-protein
type	I-protein
1	I-protein
tax	I-protein
transactivator	I-protein
with	O
transcription	B-protein
factor	I-protein
IIA	I-protein
.	O

The	O
Tax	B-protein
protein	I-protein
of	O
human	O
T-cell	O
lymphotropic	O
virus	O
type	O
1	O
(	O
HTLV-1	O
)	O
is	O
a	O
40-kDa	B-protein
transcriptional	I-protein
activator	I-protein
which	O
is	O
critical	O
for	O
HTLV-1	O
gene	O
regulation	O
and	O
virus-induced	O
cellular	O
transformation	O
.	O

Tax	B-protein
is	O
localized	O
to	O
the	O
DNA	O
through	O
its	O
interaction	O
with	O
the	O
site-specific	B-protein
activators	I-protein
cyclic	B-protein
AMP-responsive	I-protein
element-binding	I-protein
protein	I-protein
,	O
NF-kappaB	B-protein
,	O
and	O
serum	B-protein
response	I-protein
factor	I-protein
.	O

It	O
has	O
been	O
suggested	O
that	O
the	O
recruitment	O
of	O
Tax	B-protein
to	O
the	O
DNA	O
positions	O
Tax	B-protein
for	O
interaction	O
with	O
the	O
basal	O
transcriptional	O
machinery	O
.	O

On	O
the	O
basis	O
of	O
several	O
independent	O
assays	O
,	O
we	O
now	O
report	O
a	O
physical	O
and	O
functional	O
interaction	O
between	O
Tax	B-protein
and	O
the	O
transcription	B-protein
factor	I-protein
,	O
TFIIA	B-protein
.	O

First	O
,	O
Tax	B-protein
was	O
found	O
to	O
interact	O
with	O
the	O
35-kDa	B-protein
(	I-protein
alpha	I-protein
)	I-protein
subunit	I-protein
of	O
TFIIA	B-protein
in	O
the	O
yeast	O
two-hybrid	O
interaction	O
system	O
.	O

Importantly	O
,	O
two	O
previously	O
characterized	O
mutants	B-protein
with	O
point	O
mutations	O
in	O
Tax	B-protein
,	O
M32	B-protein
(	O
Y196A	O
,	O
K197S	O
)	O
and	O
M41	B-protein
(	O
H287A	O
,	O
P288S	O
)	O
,	O
which	O
were	O
shown	O
to	O
be	O
defective	O
in	O
Tax	B-protein
-activated	O
transcription	O
were	O
unable	O
to	O
interact	O
with	O
TFIIA	B-protein
in	O
this	O
assay	O
.	O

Second	O
,	O
a	O
glutathione-S-transferase	O
(	O
GST	B-protein
)	O
affinity-binding	O
assay	O
showed	O
that	O
the	O
interaction	O
of	O
holo-	O
TFIIA	B-protein
with	O
GST-Tax	B-protein
was	O
20-fold	O
higher	O
than	O
that	O
observed	O
with	O
either	O
the	O
GST-Tax	B-protein
M32	I-protein
activation	I-protein
mutant	I-protein
or	O
the	O
GST	O
control	O
.	O

Third	O
,	O
a	O
coimmunoprecipitation	O
assay	O
showed	O
that	O
in	O
HTLV-1-infected	B-cell_line
human	I-cell_line
T	I-cell_line
lymphocytes	I-cell_line
,	O
Tax	B-protein
and	O
TFIIA	B-protein
were	O
associated	O
.	O

Finally	O
,	O
TFIIA	B-protein
facilitates	O
Tax	B-protein
transactivation	O
in	O
vitro	O
and	O
in	O
vivo	O
.	O

In	O
vitro	O
transcription	O
studies	O
showed	O
reduced	O
levels	O
of	O
Tax	B-protein
-activated	O
transcription	O
in	O
cell	O
extracts	O
depleted	O
of	O
TFIIA	B-protein
.	O

In	O
addition	O
,	O
transfection	O
of	O
human	B-cell_type
T	I-cell_type
lymphocytes	I-cell_type
with	O
TFIIA	B-DNA
expression	I-DNA
vectors	I-DNA
enhanced	O
Tax	B-protein
-activated	O
transcription	O
of	O
an	O
HTLV-1	B-DNA
long	I-DNA
terminal	I-DNA
repeat-chloramphenicol	I-DNA
acetyltransferase	I-DNA
reporter	I-DNA
construct	I-DNA
.	O

Our	O
study	O
suggests	O
that	O
the	O
interaction	O
of	O
Tax	B-protein
with	O
the	O
transcription	B-protein
factor	I-protein
TFIIA	B-protein
may	O
play	O
a	O
role	O
in	O
Tax	B-protein
-mediated	O
transcriptional	O
activation	O
.	O

Inhibition	O
of	O
transcription	B-protein
factor	I-protein
Stat1	B-protein
activity	O
in	O
mononuclear	B-cell_line
cell	I-cell_line
cultures	I-cell_line
and	O
T	B-cell_type
cells	I-cell_type
by	O
the	O
cyclic	O
AMP	O
signaling	O
pathway	O
.	O

Activation	O
of	O
T	B-cell_type
cells	I-cell_type
results	O
in	O
a	O
cascade	O
of	O
gene	O
activation	O
and	O
subsequent	O
proliferation	O
and	O
differentiation	O
into	O
effector	O
phenotypes	O
.	O

The	O
regulation	O
of	O
transcription	B-protein
factors	I-protein
belonging	O
to	O
the	O
signal	B-protein
transducer	I-protein
and	I-protein
activator	I-protein
of	I-protein
transcription	I-protein
(	I-protein
STAT	I-protein
)	I-protein
family	I-protein
was	O
analyzed	O
in	O
PHA-activated	B-cell_line
mononuclear	I-cell_line
cells	I-cell_line
and	O
in	O
purified	B-cell_line
T	I-cell_line
cells	I-cell_line
activated	O
by	O
cross-linking	O
cell	B-protein
surface	I-protein
CD3	I-protein
.	O

Cell	O
activation	O
resulted	O
in	O
a	O
delayed	O
induction	O
of	O
STAT	B-protein
DNA-binding	O
activity	O
,	O
which	O
was	O
sustained	O
for	O
several	O
days	O
,	O
was	O
composed	O
predominantly	O
of	O
Stat1	B-protein
and	O
Stat3	B-protein
,	O
and	O
was	O
blocked	O
by	O
cycloheximide	O
and	O
actinomycin	O
D	O
.	O

Increased	O
Stat1	O
and	O
Stat3	O
mRNA	O
and	O
protein	O
levels	O
were	O
detected	O
,	O
respectively	O
4	O
and	O
24	O
h	O
after	O
activation	O
.	O

Stimulation	O
of	O
the	O
cAMP	O
signal	O
transduction	O
pathway	O
,	O
which	O
skews	O
cytokine	B-protein
production	O
toward	O
a	O
Th2	O
pattern	O
,	O
resulted	O
in	O
the	O
preferential	O
suppression	O
of	O
Stat1	B-protein
activity	O
.	O

cAMP	O
inhibited	O
the	O
induction	O
of	O
expression	O
of	O
IL-2	B-protein
receptor	I-protein
components	I-protein
,	O
but	O
did	O
not	O
inhibit	O
IL-4	B-protein
receptor	I-protein
alpha-chain	I-protein
and	O
CD69	B-protein
expression	O
or	O
the	O
induction	O
of	O
activator	B-protein
protein	I-protein
1	I-protein
transcription	I-protein
factors	I-protein
.	O

cAMP	O
signaling	O
inhibited	O
Stat1	B-protein
at	O
several	O
different	O
levels	O
,	O
including	O
suppression	O
of	O
DNA	O
binding	O
and	O
down-regulation	O
of	O
Stat1	O
protein	O
and	O
mRNA	O
levels	O
.	O

Our	O
results	O
demonstrate	O
the	O
regulation	O
of	O
STAT	B-protein
activity	O
by	O
a	O
signaling	O
pathway	O
that	O
regulates	O
the	O
T	O
cell	O
functional	O
phenotype	O
and	O
is	O
distinct	O
from	O
the	O
cytokine	B-protein
-activated	O
Janus	B-protein
kinase	I-protein
-STAT	B-protein
signaling	O
pathway	O
.	O

Suppression	O
of	O
c-jun	B-DNA
by	O
antisense	O
oligonucleotides	O
inhibits	O
cell	O
adhesion	O
but	O
not	O
respiratory	O
burst	O
during	O
phorbol	O
ester-induced	O
differentiation	O
of	O
U937	B-cell_line
human	I-cell_line
monoblastic	I-cell_line
cells	I-cell_line
.	O

We	O
studied	O
the	O
role	O
of	O
the	O
immediate	B-DNA
early	I-DNA
gene	I-DNA
c-jun	B-DNA
in	O
cell	O
proliferation	O
and	O
phorbol	O
12-myristate	O
13-acetate	O
(	O
PMA	O
)	O
-induced	O
differentiation	O
in	O
U937	B-cell_line
human	I-cell_line
monoblastic	I-cell_line
cells	I-cell_line
,	O
using	O
c-jun	B-DNA
-specific	O
antisense	O
(	O
AS	O
)	O
phosphorothioate	O
oligonucleotides	O
.	O

In	O
selecting	O
the	O
most	O
specific	O
and	O
potent	O
oligonucleotide	O
sequence	O
,	O
we	O
performed	O
extensive	O
analyses	O
for	O
the	O
binding	O
specificity	O
between	O
all	O
candidates	O
of	O
c-jun	B-DNA
AS	O
oligonucleotides	O
and	O
the	O
whole	O
sequences	O
in	O
GenBank	O
database	O
,	O
using	O
a	O
computer	O
program	O
.	O

Among	O
the	O
20	O
selected	O
oligonucleotides	O
,	O
two	O
potent	O
15-mer	O
AS	O
oligonucleotides	O
(	O
C-JUN	O
AS	O
oligonucleotides	O
)	O
exhibited	O
significant	O
inhibition	O
of	O
cell	O
growth	O
in	O
a	O
dose-dependent	O
manner	O
between	O
2	O
and	O
10	O
microM	O
.	O

Reverse	O
transcription-PCR	O
and	O
Western	O
blot	O
analysis	O
demonstrated	O
that	O
10	O
microM	O
of	O
C-JUN	O
AS	O
oligonucleotides	O
reduced	O
c-jun	B-DNA
expression	O
at	O
both	O
the	O
mRNA	B-RNA
and	O
protein	O
levels	O
.	O

More	O
importantly	O
,	O
C-JUN	O
AS	O
oligonucleotides	O
showed	O
distinct	O
effects	O
on	O
two	O
markers	O
of	O
PMA-induced	O
differentiation	O
;	O
the	O
C-JUN	O
AS	O
oligonucleotides	O
inhibited	O
cell	O
adhesion	O
,	O
whereas	O
they	O
did	O
not	O
affect	O
another	O
marker	O
of	O
differentiation	O
,	O
respiratory	O
burst	O
(	O
measured	O
by	O
nitro	O
blue	O
tetrazolium	O
reduction	O
assay	O
)	O
.	O

These	O
results	O
suggest	O
a	O
critical	O
role	O
of	O
c-jun	B-DNA
in	O
both	O
cell	O
proliferation	O
and	O
PMA-induced	O
cell	O
adhesion	O
but	O
not	O
in	O
PMA-induced	O
respiratory	O
burst	O
in	O
U937	B-cell_line
cells	I-cell_line
.	O

Effects	O
of	O
IL-10	B-protein
and	O
IL-4	B-protein
on	O
LPS-induced	O
transcription	B-protein
factors	I-protein
(	O
AP-1	B-protein
,	O
NF-IL6	B-protein
and	O
NF-kappa	B-protein
B	I-protein
)	O
which	O
are	O
involved	O
in	O
IL-6	B-protein
regulation	O
.	O

Interleukin-10	B-protein
(	O
IL-10	B-protein
)	O
,	O
like	O
IL-4	B-protein
,	O
is	O
known	O
to	O
inhibit	O
cytokine	B-protein
expression	O
in	O
activated	B-cell_type
human	I-cell_type
monocytes	I-cell_type
.	O

We	O
showed	O
that	O
both	O
IL-10	B-protein
and	O
IL-4	B-protein
inhibit	O
LPS-induced	B-RNA
IL-6	I-RNA
mRNA	I-RNA
and	O
protein	O
expression	O
by	O
inhibiting	O
the	O
transcription	O
rate	O
of	O
the	O
IL-6	B-DNA
gene	I-DNA
.	O

The	O
strong	O
inhibition	O
of	O
the	O
IL-6	B-protein
transcription	O
rate	O
prompted	O
us	O
to	O
study	O
the	O
effect	O
of	O
IL-10	B-protein
and	O
IL-4	B-protein
on	O
the	O
expression	O
of	O
transcription	B-protein
factors	I-protein
.	O

We	O
questioned	O
whether	O
or	O
not	O
IL-10	B-protein
and	O
IL-4	B-protein
affected	O
the	O
expression	O
of	O
transcription	B-protein
factors	I-protein
that	O
are	O
known	O
to	O
be	O
involved	O
in	O
the	O
control	O
of	O
the	O
IL-6	B-protein
transcription	O
rate	O
,	O
namely	O
activator	O
protein-1	O
(	O
AP-1	B-protein
)	O
,	O
nuclear	B-protein
factor	I-protein
IL-6	B-protein
(	O
NF-IL6	B-protein
)	O
,	O
and	O
nuclear	B-protein
factor	I-protein
kappa	I-protein
B	I-protein
(	O
NF-kappaB	B-protein
)	O
.	O

In	O
electrophoretic	O
mobility	O
shift	O
assays	O
(	O
EMSAs	O
)	O
we	O
showed	O
that	O
IL-10	B-protein
and	O
IL-4	B-protein
inhibited	O
LPS-induced	O
AP-1	B-protein
binding	O
activity	O
.	O

The	O
inhibiting	O
effect	O
of	O
IL-4	B-protein
was	O
slightly	O
more	O
pronounced	O
than	O
that	O
of	O
IL-10	B-protein
.	O

Downregulation	O
of	O
LPS-induced	B-protein
AP-1	I-protein
was	O
accompanied	O
,	O
and	O
thus	O
possibly	O
explained	O
,	O
by	O
a	O
reduced	O
expression	O
at	O
mRNA	B-RNA
level	O
of	O
the	O
two	O
major	O
components	O
of	O
the	O
AP-1	B-protein
complex	I-protein
,	O
namely	O
c-fos	B-DNA
and	O
c-jun	B-DNA
as	O
determined	O
by	O
Northern	O
experiments	O
.	O

Binding	O
activity	O
of	O
NF-IL6	B-protein
was	O
also	O
strongly	O
inhibited	O
by	O
IL-4	B-protein
whereas	O
IL-10	B-protein
showed	O
no	O
effect	O
.	O

NF-IL6	B-RNA
mRNA	I-RNA
levels	O
were	O
not	O
affected	O
by	O
IL-10	B-protein
or	O
IL-4	B-protein
,	O
suggesting	O
that	O
IL-4	B-protein
affects	O
binding	O
activity	O
of	O
preexisting	O
NF-IL6	B-protein
.	O

Neither	O
IL-10	B-protein
nor	O
IL-4	B-protein
inhibited	O
LPS-induced	O
NF-kappa	B-protein
B	I-protein
binding	O
activity	O
.	O

In	O
agreement	O
with	O
this	O
finding	O
,	O
Northern	O
experiments	O
where	O
p65	O
and	O
p105	O
mRNA	O
levels	O
were	O
determined	O
,	O
demonstrated	O
that	O
expression	O
of	O
these	O
components	O
of	O
the	O
NF-kappa	B-protein
B	I-protein
transcription	O
factor	O
were	O
not	O
affected	O
by	O
IL-10	B-protein
or	O
IL-4	B-protein
.	O

Furthermore	O
,	O
neither	O
IL-10	B-protein
nor	O
IL-4	B-protein
showed	O
any	O
effect	O
on	O
I-kappa	B-RNA
B	I-RNA
mRNA	I-RNA
expression	O
as	O
determined	O
by	O
Northern	O
experiments	O
.	O

Thus	O
,	O
IL-10	B-protein
and	O
IL-4	B-protein
similarly	O
affect	O
IL-6	B-protein
expression	O
.	O

However	O
,	O
for	O
IL-4	B-protein
this	O
was	O
accompanied	O
with	O
a	O
reduction	O
of	O
AP-1	O
and	O
NF-IL6	O
binding	O
activity	O
whereas	O
IL-10	B-protein
only	O
inhibited	O
AP-1	B-protein
binding	O
activity	O
.	O

Regulation	O
of	O
GM-CSF	B-DNA
gene	I-DNA
transcription	O
by	O
core-binding	B-protein
factor	I-protein
.	O

GM-CSF	B-DNA
gene	I-DNA
activation	O
in	O
T	B-cell_type
cells	I-cell_type
is	O
known	O
to	O
involve	O
the	O
transcription	B-protein
factors	I-protein
nuclear	B-protein
factor-kappa	I-protein
B	I-protein
,	O
AP-1	B-protein
,	O
NFAT	B-protein
,	O
and	O
Sp1	O
.	O

Here	O
we	O
demonstrate	O
that	O
the	O
human	B-DNA
GM-CSF	I-DNA
promoter	I-DNA
and	I-DNA
enhancer	I-DNA
also	O
encompass	O
binding	O
sites	O
for	O
core-binding	B-protein
factor	I-protein
(	O
CBF	B-protein
)	O
.	O

Significantly	O
,	O
the	O
CBF	B-DNA
sites	I-DNA
are	O
in	O
each	O
case	O
contained	O
within	O
the	O
minimum	O
essential	B-DNA
core	I-DNA
regions	I-DNA
required	O
for	O
inducible	O
activation	O
of	O
transcription	O
.	O

Furthermore	O
,	O
these	O
core	O
regions	O
of	O
the	O
enhancer	O
and	O
promoter	O
each	O
encompass	O
closely	B-DNA
linked	I-DNA
binding	I-DNA
sites	I-DNA
for	O
CBF	B-protein
,	O
AP-1	B-protein
,	O
and	O
NFATp	B-protein
.	O

The	O
GM-CSF	B-DNA
promoter	I-DNA
CBF	I-DNA
site	I-DNA
TGTGGTCA	O
is	O
located	O
51	B-DNA
bp	I-DNA
upstream	I-DNA
of	O
the	O
transcription	B-DNA
start	I-DNA
site	I-DNA
and	O
also	O
overlaps	O
a	O
YY-1	B-DNA
binding	I-DNA
site	I-DNA
.	O

A	O
2-bp	B-DNA
mutation	I-DNA
within	O
the	O
CBF	B-protein
site	O
resulted	O
in	O
a	O
2-3-fold	O
decrease	O
in	O
the	O
activities	O
of	O
both	O
a	O
69-bp	B-DNA
proximal	I-DNA
promoter	I-DNA
fragment	I-DNA
and	O
a	O
627-bp	B-DNA
full-length	I-DNA
promoter	I-DNA
fragment	I-DNA
.	O

Stepwise	O
deletions	O
into	O
the	O
proximal	B-DNA
promoter	I-DNA
also	O
revealed	O
that	O
the	O
CBF	B-protein
site	O
,	O
but	O
not	O
the	O
YY-1	B-DNA
site	I-DNA
,	O
was	O
required	O
for	O
efficient	O
induction	O
of	O
transcriptional	O
activation	O
.	O

The	O
AML1	B-DNA
and	I-DNA
CBF	I-DNA
beta	I-DNA
genes	I-DNA
that	O
encode	O
CBF	B-protein
each	O
have	O
the	O
ability	O
to	O
influence	O
cell	O
growth	O
and	O
differentiation	O
and	O
have	O
been	O
implicated	O
as	O
proto-oncogenes	B-DNA
in	O
acute	O
myeloid	O
leukemia	O
.	O

This	O
study	O
adds	O
GM-CSF	B-protein
to	O
a	O
growing	O
list	O
of	O
cytokines	B-protein
and	O
receptors	O
that	O
are	O
regulated	O
by	O
CBF	B-protein
and	O
which	O
control	O
the	O
growth	O
,	O
differentiation	O
,	O
and	O
activation	O
of	O
hemopoietic	B-cell_type
cells	I-cell_type
.	O

The	O
GM-CSF	B-DNA
locus	I-DNA
may	O
represent	O
one	O
of	O
several	O
target	O
genes	B-protein
that	O
are	O
dysregulated	O
in	O
acute	O
myeloid	O
leukemia	O
.	O

Sublethal	O
levels	O
of	O
oxidative	O
stress	O
stimulate	O
transcriptional	O
activation	O
of	O
c-jun	B-DNA
and	O
suppress	O
IL-2	B-DNA
promoter	I-DNA
activation	O
in	O
Jurkat	B-cell_line
T	I-cell_line
cells	I-cell_line
.	O

Sublethal	O
levels	O
of	O
oxidative	O
stress	O
are	O
well	O
known	O
to	O
alter	O
T	O
cell	O
functional	O
responses	O
,	O
but	O
the	O
underlying	O
mechanisms	O
are	O
unknown	O
.	O

The	O
current	O
study	O
examined	O
the	O
effects	O
of	O
oxidative	O
stress	O
on	O
transcriptional	O
activities	O
mediated	O
by	O
c-Fos/c-Jun	B-protein
AP-1	B-protein
and	O
the	O
nuclear	B-protein
factor	I-protein
of	I-protein
activated	I-protein
T	I-protein
cells	I-protein
(	O
NF-AT	B-protein
)	O
.	O

The	O
present	O
results	O
show	O
that	O
Jurkat	B-cell_line
T	I-cell_line
cells	I-cell_line
acutely	O
exposed	O
to	O
micromolar	O
concentrations	O
of	O
H2O2	O
exhibit	O
substantial	O
increases	O
in	O
AP-1	B-protein
binding	O
activity	O
and	O
the	O
expression	O
of	O
c-jun	B-DNA
but	O
not	O
c-fos	B-RNA
mRNA	I-RNA
.	O

The	O
preferential	O
induction	O
of	O
c-jun	B-DNA
by	O
H2O2	O
did	O
not	O
represent	O
redox	O
stabilization	O
of	O
mRNA	B-RNA
transcripts	I-RNA
,	O
and	O
oxidative	O
signals	O
closely	O
resembled	O
PHA/PMA	O
stimulation	O
by	O
effectively	O
transactivating	O
the	O
full	O
length	O
c-jun	B-DNA
promoter	O
via	O
the	O
proximal	B-DNA
jun1	I-DNA
tumor	I-DNA
promoter-responsive	I-DNA
element	I-DNA
(	I-DNA
TRE	I-DNA
)	I-DNA
-like	I-DNA
promoter	I-DNA
element	I-DNA
.	O

Similarly	O
,	O
the	O
complexes	O
binding	O
the	O
consensus	B-DNA
AP-1	I-DNA
TRE	I-DNA
and	O
jun	B-DNA
TRE-like	I-DNA
motifs	I-DNA
in	O
cells	O
exposed	O
to	O
oxidative	O
signals	O
or	O
PHA/PMA	O
were	O
indistinguishable	O
,	O
being	O
composed	O
of	O
c-Fos	B-protein
,	O
c-Jun	B-protein
,	O
and	O
JunD	B-protein
.	O

However	O
,	O
PHA/PMA	O
but	O
not	O
oxidative	O
signals	O
induced	O
the	O
coordinate	O
activation	O
of	O
reporter	B-DNA
constructs	I-DNA
containing	O
the	O
AP-1-TRE	B-DNA
,	I-DNA
NF-AT	I-DNA
,	I-DNA
and	I-DNA
IL-2	I-DNA
promoter	I-DNA
regions	I-DNA
along	O
with	O
IL-2	B-RNA
mRNA	I-RNA
expression	O
.	O

Furthermore	O
,	O
sublethal	O
levels	O
of	O
H2O2	O
actively	O
suppressed	O
the	O
transcriptional	O
activation	O
of	O
NF-AT	B-protein
and	O
IL-2	B-DNA
reporters	I-DNA
as	O
well	O
as	O
the	O
expression	O
of	O
IL-2	B-RNA
mRNA	I-RNA
in	O
cells	O
stimulated	O
with	O
PHA/PMA	O
.	O

Gel	O
shift	O
analysis	O
revealed	O
that	O
oxidative	O
suppression	O
of	O
NF-AT	B-protein
represented	O
inhibition	O
in	O
the	O
early	O
generation	O
of	O
NFAT	B-protein
complexes	I-protein
rather	O
than	O
the	O
binding	O
of	O
preformed	O
NF-AT	B-protein
complexes	I-protein
.	O

These	O
results	O
suggest	O
that	O
oxidative	O
signals	O
can	O
positively	O
and	O
negatively	O
regulate	O
T	B-cell_type
cell	I-cell_type
transcriptional	O
events	O
and	O
that	O
changes	O
in	O
cellular	O
redox	O
can	O
uncouple	O
AP-1	B-protein
regulation	O
of	O
c-jun	B-DNA
from	O
transcriptional	O
up-regulation	O
of	O
IL-2	B-protein
via	O
NF-AT	B-protein
.	O

Inorganic	O
lead	O
activates	O
NF-kappa	B-protein
B	I-protein
in	O
primary	B-cell_type
human	I-cell_type
CD4+	I-cell_type
T	I-cell_type
lymphocytes	I-cell_type
.	O

Inorganic	O
lead	O
(	O
Pb	O
)	O
is	O
a	O
ubiquitous	O
environmental	O
contaminant	O
that	O
produces	O
a	O
variety	O
of	O
effects	O
on	O
humoral	O
and	O
cell	O
mediated	O
immune	O
responses	O
.	O

The	O
underlying	O
molecular	O
mechanism	O
for	O
Pb	O
's	O
complex	O
effects	O
on	O
the	O
immune	O
system	O
remain	O
obscure	O
.	O

Many	O
of	O
Pb	O
's	O
effects	O
on	O
the	O
immune	O
system	O
could	O
be	O
explained	O
through	O
activation	O
of	O
the	O
transcription	B-protein
factor	I-protein
,	O
NF-kappa	B-protein
B	I-protein
.	O

NF-kappa	B-protein
B	I-protein
is	O
critical	O
for	O
T	O
lymphocyte	O
function	O
and	O
is	O
a	O
strong	O
inducer	O
of	O
HIV-LTR	B-DNA
activation	O
.	O

We	O
demonstrate	O
that	O
Pb	O
at	O
physiologically	O
relevant	O
concentrations	O
activates	O
NF-kappa	B-protein
B	I-protein
in	O
primary	B-cell_type
human	I-cell_type
CD4+	I-cell_type
T	I-cell_type
lymphocytes	I-cell_type
.	O

Pb-induced	O
activation	O
of	O
NF-kappa	B-protein
B	I-protein
is	O
blocked	O
by	O
antibodies	B-protein
for	O
p65	B-protein
and	O
p50	B-protein
subunits	O
but	O
not	O
cRel	B-protein
,	O
indicating	O
that	O
the	O
p65	B-protein
:	I-protein
p50	I-protein
heterodimer	I-protein
(	O
NF-kappa	B-protein
B	I-protein
)	O
is	O
involved	O
.	O

Functional	O
activation	O
of	O
gene	O
expression	O
by	O
Pb	O
was	O
confirmed	O
using	O
primary	B-cell_line
CD4+	I-cell_line
T	I-cell_line
cells	I-cell_line
transfected	O
with	O
an	O
NF-kappa	B-DNA
B	I-DNA
dependent	I-DNA
reporter	I-DNA
gene	I-DNA
construct	I-DNA
.	O

Pb	O
did	O
not	O
activate	O
NF-kappa	B-protein
B	I-protein
in	O
4	O
different	O
T	B-cell_line
cell	I-cell_line
lines	I-cell_line
,	O
suggesting	O
that	O
lymphoid	O
cell	O
lines	O
may	O
not	O
be	O
reliable	O
surrogates	O
for	O
the	O
study	O
of	O
transcriptional	O
activation	O
in	O
human	B-cell_type
T	I-cell_type
cells	I-cell_type
.	O

These	O
data	O
suggest	O
that	O
NF-kappa	B-protein
B	I-protein
may	O
be	O
an	O
important	O
molecular	O
mediator	O
of	O
Pb-induced	O
immunotoxicity	O
.	O

Tyrosine	B-protein
kinase	I-protein
and	O
cAMP-dependent	B-protein
protein	I-protein
kinase	I-protein
activities	O
in	O
CD40-activated	B-cell_line
human	I-cell_line
B	I-cell_line
lymphocytes	I-cell_line
.	O

In	O
vitro	O
,	O
human	B-cell_type
B	I-cell_type
lymphocytes	I-cell_type
undergo	O
long-term	O
proliferation	O
when	O
activated	O
through	O
CD40	B-protein
,	O
a	O
protein	O
expressed	O
on	O
their	O
cell	O
surface	O
.	O

The	O
nature	O
of	O
CD40	B-protein
-dependent	O
signals	O
in	O
proliferating	O
fresh	O
human	B-cell_line
Epstein-Barr	I-cell_line
virus-negative	I-cell_line
B	I-cell_line
lymphocytes	I-cell_line
is	O
currently	O
unknown	O
.	O

In	O
this	O
study	O
,	O
a	O
CD40	B-protein
-dependent	O
B	O
cell	O
culture	O
system	O
was	O
used	O
to	O
examine	O
the	O
role	O
of	O
different	O
signal	B-DNA
transduction	I-DNA
elements	I-DNA
.	O

Protein	O
kinase	O
C	O
(	O
PKC	B-protein
)	O
depletion	O
generated	O
by	O
a	O
long-term	O
phorbol	O
12	O
myristate	O
13-acetate	O
treatment	O
had	O
weak	O
effects	O
on	O
proliferation	O
.	O

Rather	O
,	O
tyrosine	O
phosphorylation	O
was	O
shown	O
to	O
be	O
directly	O
involved	O
in	O
mediating	O
CD40	B-protein
-dependent	O
signals	O
.	O

The	O
use	O
of	O
the	O
protein	B-protein
tyrosine	I-protein
kinase	I-protein
(	O
PTK	B-protein
)	O
-specific	O
inhibitor	O
herbimycin	O
A	O
dramatically	O
decreased	O
cellular	O
proliferation	O
without	O
altering	O
the	O
activity	O
of	O
the	O
human	B-DNA
immunodeficiency	I-DNA
virus-1	I-DNA
long	I-DNA
terminal	I-DNA
repeat	I-DNA
(	O
HIV-1	B-DNA
LTR	I-DNA
)	O
,	O
a	O
promoter	B-DNA
largely	O
dependent	O
on	O
the	O
binding	O
of	O
nuclear	B-protein
factor	I-protein
kappa	I-protein
B	I-protein
(	O
NF-	B-protein
kappa	I-protein
B	I-protein
)	O
.	O

In	O
contrast	O
,	O
the	O
cAMP-dependent	B-protein
protein	I-protein
kinase	I-protein
specific	O
inhibitor	O
H-89	O
totally	O
inhibited	O
HIV-1	B-DNA
LTR	I-DNA
activity	O
at	O
a	O
concentration	O
as	O
low	O
as	O
100	O
nM	O
without	O
affecting	O
cellular	O
proliferation	O
.	O

Electrophoretic	O
mobility	O
shift	O
assay	O
(	O
EMSA	O
)	O
and	O
supershift	O
assay	O
using	O
an	O
NF-kappa	B-DNA
B	I-DNA
binding	I-DNA
sequence	I-DNA
from	O
the	O
kappa	B-protein
light	I-protein
chain	I-protein
as	O
a	O
probe	O
,	O
revealed	O
that	O
both	O
p65	B-protein
(	O
RelA	B-protein
)	O
and	O
c-Rel	B-protein
were	O
present	O
in	O
CD40-stimulated	B-cell_type
B	I-cell_type
cells	I-cell_type
.	O

While	O
PKC	B-protein
depletion	O
did	O
not	O
alter	O
the	O
NF-kappa	B-protein
B	I-protein
level	O
,	O
treatment	O
of	O
B	B-cell_type
lymphocytes	I-cell_type
with	O
H-89	O
or	O
herbimycin	O
A	O
provoked	O
a	O
decrease	O
in	O
the	O
NF-kappa	B-protein
B	I-protein
level	O
.	O

These	O
observations	O
establish	O
the	O
importance	O
of	O
different	O
signal	O
transducing	O
pathways	O
leading	O
to	O
CD40	B-protein
activation	O
of	O
B	B-cell_type
lymphocytes	I-cell_type
.	O

Interferons	B-protein
induce	O
normal	O
and	O
aberrant	O
retinoic-acid	B-protein
receptors	I-protein
type	I-protein
alpha	I-protein
in	O
acute	B-cell_type
promyelocytic	I-cell_type
leukemia	I-cell_type
cells	I-cell_type
:	O
potentiation	O
of	O
the	O
induction	O
of	O
retinoid-dependent	O
differentiation	B-protein
markers	I-protein
.	O

Treatment	O
of	O
the	O
acute	B-cell_line
promyelocytic	I-cell_line
(	I-cell_line
APL	I-cell_line
)	I-cell_line
cell	I-cell_line
line	I-cell_line
NB4	B-cell_line
with	O
interferon	B-protein
alpha	I-protein
(	O
IFN	B-protein
(	I-protein
alpha	I-protein
)	I-protein
)	O
,	O
as	O
well	O
as	O
IFN	B-protein
(	I-protein
beta	I-protein
)	I-protein
and	I-protein
gamma	I-protein
,	O
results	O
in	O
an	O
increased	O
expression	O
of	O
the	O
transcripts	O
coding	O
for	O
retinoic-acid	B-protein
receptor	I-protein
type	I-protein
alpha	I-protein
(	O
RAR	B-protein
(	I-protein
alpha	I-protein
)	I-protein
)	O
and	O
the	O
leukemia-specific	B-protein
retinoic	I-protein
acid	I-protein
receptor	I-protein
PML-RAR	B-protein
.	O

Transcriptional	O
induction	O
of	O
the	O
RAR	B-RNA
(	I-RNA
alpha	I-RNA
)	I-RNA
and	I-RNA
PML-RAR	I-RNA
mRNAs	I-RNA
is	O
rapid	O
and	O
it	O
is	O
parallelled	O
by	O
an	O
increase	O
in	O
the	O
corresponding	O
proteins	O
.	O

Up-regulation	O
of	O
RAR	B-protein
(	I-protein
alpha	I-protein
)	I-protein
and	O
PML-RAR	B-protein
gene	O
expression	O
by	O
IFN	B-protein
(	I-protein
alpha	I-protein
)	I-protein
is	O
accompanied	O
by	O
a	O
strong	O
potentiation	O
in	O
the	O
induction	O
of	O
2	O
retinoid-dependent	B-protein
granulocytic	I-protein
markers	I-protein
,	O
i.e.	O
,	O
granulocyte-colony-stimulating	B-RNA
factor	I-RNA
receptor	I-RNA
mRNA	I-RNA
and	O
leukocyte	B-protein
alkaline	I-protein
phosphatase	I-protein
.	O

However	O
,	O
IFN	B-protein
(	I-protein
alpha	I-protein
)	I-protein
does	O
not	O
have	O
any	O
effects	O
on	O
the	O
retinoid-dependent	O
regulation	O
of	O
the	O
myeloid	B-protein
surface	I-protein
markers	I-protein
CD11b	B-protein
and	O
CD33	B-protein
.	O

The	O
IFN	B-protein
-dependent	O
increase	O
in	O
RAR	B-protein
(	I-protein
alpha	I-protein
)	I-protein
levels	O
and	O
the	O
enhancing	O
effect	O
of	O
the	O
cytokine	B-protein
on	O
retinoid-dependent	B-protein
granulocytic	I-protein
markers	I-protein
expression	O
may	O
be	O
a	O
characteristic	O
of	O
PML-RAR	B-cell_line
positive	I-cell_line
cells	I-cell_line
,	O
since	O
the	O
phenomena	O
are	O
not	O
observed	O
in	O
HL-60	B-cell_line
promyelocytes	I-cell_line
.	O

Interferons	B-protein
as	O
well	O
as	O
retinoids	O
inhibit	O
the	O
growth	O
of	O
NB4	B-cell_line
cells	I-cell_line
,	O
although	O
the	O
2	O
classes	O
of	O
compounds	O
do	O
not	O
significantly	O
interact	O
in	O
terms	O
of	O
anti-proliferative	O
activity	O
.	O

These	O
results	O
suggest	O
the	O
possible	O
use	O
of	O
combinations	O
between	O
IFNs	B-protein
and	O
retinoic	O
acid	O
in	O
the	O
cyto-differentiating	O
treatment	O
of	O
APL	O
patients	O
.	O

Modulatory	O
effects	O
of	O
glucocorticoids	O
and	O
catecholamines	O
on	O
human	O
interleukin	B-protein
-12	O
and	O
interleukin	B-protein
-10	O
production	O
:	O
clinical	O
implications	O
.	O

Interleukin-12	B-protein
(	O
IL-12	B-protein
)	O
is	O
a	O
key	O
inducer	O
of	O
differentiation	O
of	O
uncommitted	B-cell_type
T	I-cell_type
helper	I-cell_type
(	I-cell_type
TH	I-cell_type
)	I-cell_type
cells	I-cell_type
toward	O
the	O
TH1	O
phenotype	O
,	O
which	O
regulates	O
cellular	O
immunity	O
,	O
whereas	O
IL-10	B-protein
inhibits	O
TH1	O
functions	O
and	O
potentiates	O
TH2-regulated	O
responses	O
(	O
i.e.	O
,	O
humoral	O
immunity	O
)	O
.	O

To	O
examine	O
the	O
potential	O
effects	O
of	O
stress	O
on	O
TH1/TH2	O
balance	O
,	O
we	O
studied	O
the	O
ability	O
of	O
three	O
prototype	O
stress	O
hormones-dexamethasone	O
(	O
a	O
synthetic	O
glucocorticoid	O
)	O
and	O
the	O
catecholamines	O
norepinephrine	O
and	O
epinephrine-to	O
alter	O
the	O
production	O
of	O
IL-12	B-protein
(	O
p70	B-protein
)	O
and	O
IL-10	B-protein
induced	O
by	O
bacterial	O
lipopolysaccharide	O
(	O
LPS	O
)	O
in	O
human	O
whole	O
blood	O
.	O

Dexamethasone	O
inhibited	O
LPS-induced	O
bioactive	O
IL-12	B-protein
production	O
in	O
a	O
dose-dependent	O
fashion	O
and	O
at	O
physiologically	O
relevant	O
concentrations	O
;	O
it	O
had	O
no	O
effect	O
on	O
IL-10	B-protein
secretion	O
.	O

The	O
glucocorticoid-induced	O
reduction	O
of	O
IL-12	B-protein
production	O
was	O
antagonized	O
by	O
RU	O
486	O
,	O
a	O
glucocorticoid-receptor	O
antagonist	O
,	O
suggesting	O
that	O
it	O
was	O
mediated	O
by	O
the	O
glucocorticoid	O
receptor	O
.	O

Norepinephrine	O
and	O
epinephrine	O
also	O
suppressed	O
IL-12	B-protein
production	O
in	O
a	O
dose-dependent	O
fashion	O
and	O
at	O
physiological	O
concentrations	O
;	O
both	O
catecholamines	O
,	O
however	O
,	O
dose-dependently	O
increased	O
the	O
production	O
of	O
IL-10	B-protein
.	O

The	O
effects	O
of	O
either	O
catecholamine	O
on	O
IL-12	B-protein
or	O
IL-10	B-protein
secretion	O
were	O
blocked	O
completely	O
by	O
propranolol	O
,	O
a	O
beta-adrenoreceptor	O
antagonist	O
,	O
indicating	O
that	O
they	O
were	O
mediated	O
by	O
the	O
beta-adrenergic	B-protein
receptor	I-protein
.	O

These	O
findings	O
suggest	O
that	O
the	O
central	O
nervous	O
system	O
may	O
regulate	O
IL-12	O
and	O
IL-10	O
secretion	O
and	O
,	O
hence	O
,	O
TH1/TH2	O
balance	O
via	O
the	O
peripheral	O
end-effectors	O
of	O
the	O
stress	O
system	O
.	O

Thus	O
,	O
stress	O
may	O
cause	O
a	O
selective	O
suppression	O
of	O
TH1	O
functions	O
and	O
a	O
shift	O
toward	O
a	O
TH2	B-protein
cytokine	I-protein
pattern	O
rather	O
than	O
generalized	O
TH	O
suppression	O
.	O

The	O
TH1-to-TH2	O
shift	O
may	O
be	O
responsible	O
for	O
the	O
stress-induced	O
susceptibility	O
of	O
the	O
organism	O
to	O
certain	O
infections	O
.	O

Through	O
the	O
same	O
or	O
a	O
reciprocal	O
mechanism	O
,	O
states	O
associated	O
with	O
chronic	O
hyperactivity	O
or	O
hypoactivity	O
of	O
the	O
stress	O
system	O
might	O
influence	O
the	O
susceptibility	O
of	O
an	O
individual	O
to	O
certain	O
autoimmune	O
,	O
allergic	O
,	O
infectious	O
,	O
or	O
neoplastic	O
diseases	O
.	O

Activation	O
of	O
human	B-cell_type
monocytic	I-cell_type
cells	I-cell_type
by	O
Treponema	B-protein
pallidum	I-protein
and	I-protein
Borrelia	I-protein
burgdorferi	I-protein
lipoproteins	I-protein
and	O
synthetic	O
lipopeptides	O
proceeds	O
via	O
a	O
pathway	O
distinct	O
from	O
that	O
of	O
lipopolysaccharide	O
but	O
involves	O
the	O
transcriptional	O
activator	O
NF-kappa	B-protein
B	I-protein
.	O

There	O
is	O
increasing	O
evidence	O
that	O
lipoproteins	B-protein
of	O
Treponema	O
pallidum	O
and	O
Borrelia	O
burgdorferi	O
are	O
key	O
inflammatory	O
mediators	O
during	O
syphilis	O
and	O
Lyme	O
disease	O
.	O

A	O
principal	O
objective	O
of	O
the	O
present	O
study	O
was	O
to	O
identify	O
more	O
precisely	O
similarities	O
and	O
divergences	O
among	O
lipopolysaccharide	O
(	O
LPS	O
)	O
-	O
and	O
lipoprotein-lipopeptide-induced	O
immune	O
cell	O
signaling	O
events	O
.	O

Like	O
LPS	O
,	O
purified	B-protein
native	I-protein
B.	I-protein
burgdorferi	I-protein
OspA	I-protein
and	O
synthetic	O
analogs	O
of	O
OspA	B-protein
,	O
OspB	B-protein
,	O
and	O
two	O
T.	B-protein
pallidum	I-protein
lipoproteins	I-protein
(	O
Tpp47	B-protein
and	O
Tpp17	B-protein
)	O
all	O
induced	O
NF-kappa	B-protein
B	I-protein
translocation	O
in	O
THP-1	B-cell_type
human	I-cell_type
monocytoid	I-cell_type
cells	I-cell_type
.	O

Acylation	O
of	O
OspA	B-protein
and	O
the	O
synthetic	O
peptides	O
was	O
requisite	O
for	O
cell	O
activation	O
.	O

Polymyxin	O
B	O
abrogated	O
only	O
the	O
response	O
to	O
LPS	O
.	O

By	O
using	O
70Z/3-derived	B-cell_line
pre-B-cell	I-cell_line
lines	I-cell_line
either	O
lacking	O
or	O
expressing	O
human	B-protein
CD14	I-protein
(	O
the	O
LPS	B-protein
receptor	I-protein
)	O
,	O
it	O
was	O
observed	O
that	O
expression	O
of	O
human	B-protein
CD14	I-protein
imparted	O
responsiveness	O
to	O
LPS	O
but	O
not	O
to	O
OspA	B-protein
or	O
spirochetal	B-protein
lipopeptides	I-protein
(	O
assessed	O
by	O
induction	O
of	O
NF-kappa	B-protein
B	I-protein
and	O
expression	O
of	O
surface	B-protein
immunoglobulin	I-protein
M	I-protein
)	O
.	O

Finally	O
,	O
the	O
biological	O
relevance	O
of	O
the	O
observation	O
that	O
T.	B-protein
pallidum	I-protein
lipoproteins	I-protein
-lipopeptides	O
induce	O
both	O
NF-kappa	B-protein
B	I-protein
and	O
cytokine	B-protein
production	O
in	O
monocytes	B-cell_type
was	O
supported	O
by	O
the	O
ability	O
of	O
the	O
synthetic	O
analogs	O
to	O
promote	O
human	O
immunodeficiency	O
virus	O
replication	O
in	O
chronically	O
infected	O
U1	O
monocytoid	O
cells	O
;	O
these	O
observations	O
also	O
suggest	O
a	O
potential	O
mechanism	O
whereby	O
a	O
syphilitic	O
chancre	O
can	O
serve	O
as	O
a	O
cofactor	O
for	O
human	O
immunodeficiency	O
virus	O
transmission	O
.	O

The	O
combined	O
data	O
lend	O
additional	O
support	O
to	O
the	O
proposal	O
that	O
spirochetal	B-protein
lipoproteins	I-protein
and	O
LPS	O
initiate	O
monocyte	O
activation	O
via	O
different	O
cell	O
surface	O
events	O
but	O
that	O
the	O
signaling	O
pathways	O
ultimately	O
converge	O
to	O
produce	O
qualitatively	O
similar	O
cellular	O
responses	O
.	O

LYSP100	B-protein
-associated	O
nuclear	O
domains	O
(	O
LANDs	O
)	O
:	O
description	O
of	O
a	O
new	O
class	O
of	O
subnuclear	O
structures	O
and	O
their	O
relationship	O
to	O
PML	O
nuclear	O
bodies	O
.	O

The	O
PML	B-DNA
gene	I-DNA
is	O
fused	O
to	O
the	O
retinoic	B-DNA
acid	I-DNA
receptor	I-DNA
alpha	I-DNA
(	I-DNA
RAR	I-DNA
alpha	I-DNA
)	I-DNA
gene	I-DNA
in	O
t	O
(	O
15	O
;	O
17	O
)	O
acute	O
promyelocytic	O
leukemia	O
(	O
APL	O
)	O
,	O
creating	O
a	O
PML-RAR	B-protein
alpha	I-protein
fusion	I-protein
oncoprotein	I-protein
.	O

The	O
PML	B-protein
gene	I-protein
product	I-protein
has	O
been	O
localized	O
to	O
subnuclear	B-cell_line
dot-like	I-cell_line
structures	I-cell_line
variously	O
termed	O
PODs	O
,	O
ND10s	O
,	O
Kr	O
bodies	O
,	O
or	O
PML	O
nuclear	O
bodies	O
(	O
PML	O
NBs	O
)	O
.	O

The	O
present	O
study	O
describes	O
the	O
cloning	O
of	O
a	O
lymphoid-restricted	B-DNA
gene	I-DNA
,	O
LYSP100	B-DNA
,	O
that	O
is	O
homologous	O
to	O
another	O
protein	O
that	O
localizes	O
to	O
PML	O
NBs	O
,	O
SP100	B-protein
.	O

In	O
addition	O
to	O
SP100	B-DNA
homology	I-DNA
regions	I-DNA
,	O
one	O
LYSP100	B-DNA
cDNA	I-DNA
isoform	I-DNA
contains	O
a	O
bromodomain	B-protein
and	O
a	O
PHD/TTC	B-protein
domain	I-protein
,	O
which	O
are	O
present	O
in	O
a	O
variety	O
of	O
transcriptional	B-protein
regulatory	I-protein
proteins	I-protein
.	O

By	O
immunofluorescence	O
,	O
LYSP100	B-DNA
was	O
localized	O
to	O
nuclear	O
dots	O
that	O
were	O
surprisingly	O
largely	O
nonoverlapping	O
with	O
PML	O
NBs	O
.	O

However	O
,	O
a	O
minority	O
of	O
LYSP100	B-DNA
nuclear	O
dots	O
exactly	O
colocalized	O
with	O
PML	B-cell_type
and	O
SP100	B-protein
.	O

We	O
term	O
the	O
LYSP100	B-DNA
structures	O
``	O
LANDs	O
,	O
''	O
for	O
LYSP100	B-DNA
-associated	O
nuclear	O
domains	O
.	O

Although	O
LYSP100	B-DNA
is	O
expressed	O
only	O
in	O
lymphoid	B-cell_type
cells	I-cell_type
,	O
LANDs	O
could	O
be	O
visualized	O
in	O
HeLa	B-cell_line
cells	I-cell_line
by	O
transfection	O
of	O
a	O
LYSP100	B-DNA
cDNA	I-DNA
.	O

Immunoelectron	O
microscopy	O
revealed	O
LANDs	O
to	O
be	O
globular	O
,	O
electron-dense	O
structures	O
morphologically	O
distinct	O
from	O
the	O
annular	O
structures	O
characteristic	O
of	O
PML	O
NBs	O
.	O

LANDs	O
were	O
most	O
often	O
found	O
in	O
the	O
nucleoplasm	O
,	O
but	O
were	O
also	O
found	O
at	O
the	O
nuclear	O
membrane	O
and	O
in	O
the	O
cytoplasm	O
,	O
suggesting	O
that	O
these	O
structures	O
may	O
traffic	O
between	O
the	O
cytoplasm	O
and	O
the	O
nucleus	O
.	O

By	O
double-immunogold	O
labeling	O
of	O
PML	B-cell_type
and	O
LYSP100	B-DNA
,	O
some	O
LANDs	O
were	O
shown	O
to	O
contain	O
both	O
PML	B-cell_type
and	O
LYSP100	B-DNA
.	O

Thus	O
,	O
PML	B-cell_type
is	O
localized	O
to	O
a	O
second	O
subnuclear	O
domain	O
that	O
is	O
morphologically	O
and	O
biochemically	O
distinct	O
from	O
PML	B-cell_type
NBs	O
.	O

Transcriptional	O
control	O
of	O
steroid-regulated	O
apoptosis	O
in	O
murine	B-cell_type
thymoma	I-cell_type
cells	I-cell_type
.	O

Early	O
studies	O
in	O
murine	O
T	B-cell_line
cell	I-cell_line
lines	I-cell_line
indicated	O
that	O
transcriptional	O
transactivation	O
functions	O
encoded	O
in	O
the	O
glucocorticoid	B-protein
receptor	I-protein
(	I-protein
GR	I-protein
)	I-protein
N-terminal	I-protein
domain	I-protein
are	O
required	O
for	O
glucocorticoid-mediated	O
apoptosis	O
.	O

However	O
,	O
more	O
recent	O
studies	O
in	O
human	B-cell_line
T	I-cell_line
cell	I-cell_line
lines	I-cell_line
have	O
suggested	O
that	O
the	O
N-terminal	B-protein
domain	I-protein
is	O
not	O
necessary	O
for	O
steroid-regulated	O
apoptosis	O
and	O
that	O
GR	B-protein
-mediated	O
transrepression	O
may	O
be	O
the	O
more	O
critical	O
mechanism	O
.	O

To	O
better	O
understand	O
the	O
contribution	O
of	O
the	O
GR	B-protein
N-terminal	I-protein
transactivation	I-protein
domain	I-protein
in	O
mediating	O
murine	O
thymocyte	O
apoptosis	O
,	O
we	O
stably	O
transfected	O
GR	B-protein
,	O
GR	B-protein
variants	I-protein
,	O
and	O
the	O
androgen	B-protein
receptor	I-protein
(	O
AR	B-protein
)	O
into	O
receptor-negative	B-cell_line
S49	I-cell_line
murine	I-cell_line
thymoma	I-cell_line
cells	I-cell_line
.	O

GR	B-protein
expression	O
levels	O
were	O
shown	O
to	O
be	O
rate-limiting	O
for	O
initiating	O
the	O
apoptotic	O
pathway	O
,	O
and	O
a	O
positive	O
correlation	O
between	O
steroid	O
sensitivity	O
and	O
GR	B-protein
-mediated	O
induction	O
of	O
an	O
integrated	O
mouse	B-DNA
mammary	I-DNA
tumor	I-DNA
virus	I-DNA
(	I-DNA
MMTV	I-DNA
)	I-DNA
LTR	I-DNA
reporter	I-DNA
gene	I-DNA
was	O
observed	O
.	O

Analysis	O
of	O
GR	B-protein
chimeric	I-protein
receptors	I-protein
containing	O
the	O
potent	O
VP16	B-DNA
and	I-DNA
E1A	I-DNA
viral	I-DNA
transactivation	I-DNA
domains	I-DNA
in	O
place	O
of	O
the	O
GR	B-protein
N	I-protein
terminus	I-protein
revealed	O
that	O
even	O
low	O
level	O
expression	O
of	O
these	O
receptors	O
resulted	O
in	O
both	O
enhanced	O
steroid	O
sensitivity	O
and	O
MMTV	O
induction	O
,	O
thus	O
supporting	O
a	O
role	O
for	O
transactivation	O
in	O
apoptosis	O
.	O

In	O
contrast	O
,	O
we	O
found	O
that	O
AR	B-protein
can	O
initiate	O
apoptosis	O
in	O
S49	B-cell_line
cells	I-cell_line
after	O
treatment	O
with	O
5	O
alpha-dihydrotestosterone	O
,	O
despite	O
its	O
relative	O
inability	O
to	O
induce	O
high	O
level	O
expression	O
of	O
MMTV	O
.	O

To	O
investigate	O
this	O
further	O
,	O
we	O
examined	O
the	O
steroid-regulated	O
expression	O
of	O
an	O
endogenous	O
thymocyte-specific	B-DNA
gene	I-DNA
called	O
GIG18	B-DNA
.	O

We	O
found	O
that	O
GIG18	B-DNA
was	O
rapidly	O
induced	O
to	O
comparable	O
levels	O
by	O
both	O
AR	B-protein
and	O
GR	B-protein
,	O
demonstrating	O
that	O
AR	B-protein
can	O
indeed	O
function	O
as	O
a	O
transcriptional	O
activator	O
in	O
S49	B-cell_line
cells	I-cell_line
and	O
,	O
moreover	O
,	O
that	O
GIG18	B-DNA
induction	O
may	O
be	O
a	O
marker	O
of	O
early	O
apoptotic	O
events	O
in	O
steroid-treated	O
cells	O
.	O

Taken	O
together	O
,	O
these	O
results	O
support	O
our	O
conclusion	O
that	O
transcriptional	O
transactivation	O
is	O
a	O
necessary	O
signaling	O
component	O
of	O
S49	O
cell	O
apoptosis	O
,	O
although	O
an	O
additional	O
role	O
for	O
GR	B-protein
-mediated	O
transrepression	O
can	O
not	O
be	O
excluded	O
.	O

Multiple	O
p21ras	B-protein
effector	O
pathways	O
regulate	O
nuclear	O
factor	O
of	O
activated	B-cell_type
T	I-cell_type
cells	I-cell_type
.	O

The	O
transcription	B-protein
factor	I-protein
,	O
Nuclear	B-protein
Factor	I-protein
of	I-protein
Activated	I-protein
T	I-protein
cells	I-protein
(	O
NFAT	B-protein
)	O
is	O
a	O
major	O
target	O
for	O
p21ras	B-protein
and	O
calcium	O
signalling	O
pathways	O
in	O
the	O
IL-2	B-DNA
gene	I-DNA
and	O
is	O
induced	O
by	O
p21ras	B-protein
signals	O
acting	O
in	O
synergy	O
with	O
calcium	O
/calcineurin	B-protein
signals	O
.	O

One	O
p21ras	B-protein
effector	O
pathway	O
involves	O
the	O
MAP	B-protein
kinase	I-protein
ERK-2	B-protein
,	O
and	O
we	O
have	O
examined	O
its	O
role	O
in	O
NFAT	B-protein
regulation	O
.	O

Expression	O
of	O
dominant	B-protein
negative	I-protein
MAPKK-1	I-protein
prevents	O
NFAT	B-protein
induction	O
.	O

Constitutively	O
active	O
MAPKK-1	B-protein
fully	O
activates	O
ERK-2	B-protein
and	O
the	O
transcription	B-protein
factor	I-protein
Elk-1	B-protein
,	O
but	O
does	O
not	O
substitute	O
for	O
activated	O
p21ras	B-protein
and	O
synergize	O
with	O
calcium	O
/calcineurin	B-protein
signals	O
to	O
induce	O
NFAT	B-protein
.	O

Expression	O
of	O
dominant	B-protein
negative	I-protein
N17Rac	I-protein
also	O
prevents	O
TCR	B-protein
and	O
p21ras	B-protein
activation	O
of	O
NFAT	B-protein
,	O
but	O
without	O
interfering	O
with	O
the	O
ERK-2	B-protein
pathway	O
.	O

The	O
transcriptional	O
activity	O
of	O
the	O
NFAT	B-DNA
binding	I-DNA
site	I-DNA
is	O
mediated	O
by	O
a	O
complex	O
comprising	O
a	O
member	O
of	O
the	O
NFAT	B-protein
group	O
and	O
AP-1	B-protein
family	I-protein
proteins	I-protein
.	O

The	O
induction	O
of	O
AP-1	B-protein
by	O
p21ras	B-protein
also	O
requires	O
Rac-1	B-protein
function	O
.	O

Activated	B-protein
Rac-1	I-protein
could	O
mimic	O
activated	B-protein
p21ras	I-protein
to	O
induce	O
AP-1	B-protein
but	O
not	O
to	O
induce	O
NFAT	B-protein
.	O

Moreover	O
,	O
the	O
combination	O
of	O
activated	O
MAPKK-1	B-protein
and	O
Rac-1	B-protein
could	O
not	O
substitute	O
for	O
activated	O
p21ras	B-protein
and	O
synergize	O
with	O
calcium	O
signals	O
to	O
induce	O
NFAT	B-protein
.	O

Thus	O
,	O
p21ras	B-protein
regulation	O
of	O
NFAT	B-protein
in	O
T	B-cell_type
cells	I-cell_type
requires	O
the	O
activity	O
of	O
multiple	O
effector	O
pathways	O
including	O
those	O
regulated	O
by	O
MAPKK-1	B-protein
/ERK-2	B-protein
and	O
Rac-1	B-protein
.	O

Retinoid	O
differentiation	O
therapy	O
in	O
promyelocytic	O
leukemia	O
.	O

Acute	O
promyelocytic	O
leukemia	O
(	O
APL	O
)	O
is	O
a	O
specific	O
type	O
of	O
acute	O
myeloid	O
leukemia	O
characterized	O
by	O
the	O
morphology	O
of	O
the	O
blast	B-cell_type
cells	I-cell_type
,	O
a	O
specific	O
t	O
(	O
15	O
;	O
17	O
)	O
translocation	O
,	O
and	O
risks	O
of	O
definite	O
coagulopathy	O
.	O

Recently	O
this	O
leukemia	O
was	O
further	O
characterized	O
by	O
an	O
exquisite	O
sensitivity	O
to	O
all-trans	O
retinoic	O
acid	O
's	O
differentiation	O
effect	O
and	O
the	O
production	O
of	O
a	O
fusion	B-DNA
gene	I-DNA
altering	O
the	O
gene	O
of	O
RARalpha	B-protein
and	O
a	O
novel	B-DNA
gene	I-DNA
PML	I-DNA
.	O

In	O
vivo	O
differentiation	O
therapy	O
with	O
retinoids	O
in	O
APL	O
patients	O
follows	O
strict	O
guidelines	O
related	O
both	O
to	O
the	O
APL	O
cell	O
and	O
the	O
biodisposal	O
of	O
all-trans	O
retinoic	O
acid	O
.	O

Differential	O
utilization	O
of	O
Janus	B-protein
kinase	I-protein
-signal	O
transducer	O
activator	O
of	O
transcription	O
signaling	O
pathways	O
in	O
the	O
stimulation	O
of	O
human	B-cell_type
natural	I-cell_type
killer	I-cell_type
cells	I-cell_type
by	O
IL-2	B-protein
,	O
IL-12	B-protein
,	O
and	O
IFN-alpha	B-protein
.	O

IL-2-	O
,	O
IL-12-	O
,	O
and	O
IFN-alpha-mediated	O
signaling	O
pathways	O
were	O
analyzed	O
in	O
primary	B-cell_type
NK	I-cell_type
cells	I-cell_type
and	O
in	O
the	O
NK3.3	B-cell_line
cell	I-cell_line
line	I-cell_line
.	O

Gel	O
mobility	O
shift	O
and	O
immunoprecipitation	O
analyses	O
revealed	O
that	O
in	O
addition	O
to	O
activating	O
STAT3	B-protein
(	O
signal	B-protein
transducer	I-protein
and	I-protein
activator	I-protein
of	I-protein
transcription-3	I-protein
)	O
and	O
STAT5	B-protein
,	O
IL-2	B-protein
induced	O
tyrosine	O
and	O
serine	O
phosphorylation	O
of	O
STAT1	B-protein
alpha	I-protein
,	O
which	O
formed	O
IFN-gamma-activated	B-protein
sequence-binding	I-protein
complexes	I-protein
by	O
itself	O
and	O
with	O
STAT3	B-protein
.	O

Although	O
IL-2	B-protein
and	O
IFN-alpha	B-protein
activated	O
STAT1	B-protein
alpha	I-protein
and	O
STAT5	B-protein
,	O
IL-2	B-protein
predominantly	O
activated	O
STAT5	B-protein
,	O
while	O
IFN-alpha	B-protein
predominantly	O
activated	O
STAT1	B-protein
alpha	I-protein
.	O

IL-2	B-protein
induced	O
less	O
STAT1	B-protein
alpha	I-protein
activation	O
and	O
IFN-alpha	B-protein
induced	O
greater	O
STAT5	B-protein
activation	O
in	O
NK3.3	B-cell_line
cells	I-cell_line
compared	O
with	O
preactivated	B-cell_line
primary	I-cell_line
NK	I-cell_line
cells	I-cell_line
.	O

In	O
NK3.3	B-cell_line
cells	I-cell_line
,	O
IL-2	B-protein
induced	O
comparable	O
formation	O
of	O
c-fos	B-protein
promoter	I-protein
sis-inducible	I-protein
element	I-protein
IFN-gamma-activated	I-protein
sequence-binding	I-protein
complexes	I-protein
containing	O
STAT3	B-protein
alone	O
with	O
complexes	O
containing	O
STAT3	B-protein
and	O
STAT1	B-protein
alpha	I-protein
,	O
while	O
in	O
preactivated	B-cell_line
primary	I-cell_line
NK	I-cell_line
cells	I-cell_line
,	O
it	O
preferentially	O
induced	O
complexes	O
containing	O
STAT3	B-protein
and	O
STAT1	B-protein
alpha	I-protein
.	O

Thus	O
,	O
signaling	O
in	O
NK3.3	B-cell_line
cells	I-cell_line
is	O
not	O
always	O
identical	O
with	O
that	O
in	O
primary	B-cell_type
NK	I-cell_type
cells	I-cell_type
.	O

In	O
contrast	O
to	O
IL-2	B-protein
and	O
IFN-alpha	B-protein
,	O
IL-12	B-protein
induced	O
strong	O
tyrosine	O
phosphorylation	O
of	O
STAT4	B-protein
and	O
variable	O
weak	O
phosphorylation	O
of	O
STAT3	B-protein
.	O

However	O
,	O
supershift	O
analyses	O
using	O
the	O
c-fos	B-DNA
promoter	I-DNA
sis-inducible	I-DNA
element	I-DNA
probe	I-DNA
showed	O
that	O
IL-12	B-protein
activated	O
STAT4	B-protein
,	O
STAT1	B-protein
alpha	I-protein
,	O
and	O
STAT3	B-protein
,	O
and	O
induced	O
complexes	O
containing	O
STAT4	B-protein
only	O
,	O
STAT4	B-protein
with	O
STAT1	B-protein
alpha	I-protein
,	O
STAT3	B-protein
with	O
STAT1	B-protein
alpha	I-protein
,	O
or	O
STAT1	B-protein
alpha	I-protein
only	O
in	O
preactivated	B-cell_line
primary	I-cell_line
NK	I-cell_line
cells	I-cell_line
.	O

STAT1	B-protein
alpha	I-protein
activation	O
by	O
IL-12	B-protein
correlated	O
with	O
increased	O
phosphorylation	O
of	O
serine	O
,	O
but	O
not	O
tyrosine	O
.	O

Finally	O
,	O
IL-2	B-protein
induced	O
tyrosine	O
phosphorylation	O
of	O
JAK1	B-protein
and	O
JAK3	B-protein
,	O
while	O
IL-12	B-protein
induced	O
phosphorylation	O
of	O
JAK2	B-protein
and	O
TYK2	B-protein
in	O
both	O
preactivated	B-cell_line
primary	I-cell_line
NK	I-cell_line
and	I-cell_line
NK3.3	I-cell_line
cells	I-cell_line
.	O

Differential	O
phosphorylation	O
and	O
consequent	O
differential	O
activation	O
of	O
both	O
separate	O
and	O
overlapping	O
STAT	B-protein
proteins	I-protein
by	O
IL-2	B-protein
,	O
IL-12	B-protein
,	O
and	O
IFN-alpha	B-protein
may	O
provide	O
a	O
molecular	O
basis	O
for	O
the	O
similarities	O
and	O
differences	O
in	O
the	O
actions	O
of	O
these	O
cytokines	B-protein
on	O
NK	B-cell_type
cells	I-cell_type
.	O

The	O
suppression	O
of	O
T	B-cell_type
cell	I-cell_type
function	O
and	O
NF	B-protein
(	I-protein
kappa	I-protein
)	I-protein
B	I-protein
expression	O
by	O
serine	O
protease	O
inhibitors	O
is	O
blocked	O
by	O
N-acetylcysteine	O
.	O

Direct	O
evidence	O
that	O
N-acetylcysteine	O
(	O
NAC	O
)	O
enhances	O
the	O
immune	O
response	O
of	O
peripheral	B-cell_type
blood	I-cell_type
T	I-cell_type
cells	I-cell_type
at	O
the	O
level	O
of	O
NF	B-protein
(	I-protein
kappa	I-protein
)	I-protein
B	I-protein
is	O
presented	O
.	O

In	O
addition	O
,	O
NAC	O
blocks	O
the	O
suppression	O
of	O
T	O
cell	O
mitogenesis	O
and	O
cytokine	B-protein
production	O
by	O
protease	O
inhibitors	O
such	O
as	O
N-tosylphenylalanine	O
chloromethyl	O
ketone	O
(	O
TPCK	O
)	O
.	O

The	O
proliferative	O
responses	O
of	O
purified	B-cell_type
CD4+	I-cell_type
or	I-cell_type
CD8+	I-cell_type
T	I-cell_type
cells	I-cell_type
are	O
suppressed	O
more	O
strongly	O
by	O
TPCK	O
when	O
anti-CD28	B-protein
rather	O
than	O
the	O
phorbol	O
ester	O
PMA	O
is	O
used	O
as	O
the	O
mitogenic	O
coactivator	B-protein
.	O

Cytokine	B-protein
(	O
IL-2	B-protein
,	O
IL-6	B-protein
,	O
INF-gamma	B-protein
)	O
production	O
is	O
inhibited	O
95-100	O
%	O
by	O
concentrations	O
of	O
TPCK	O
that	O
totally	O
suppress	O
the	O
mitogenesis	O
of	O
CD4+	B-cell_type
or	I-cell_type
CD8+	I-cell_type
cells	I-cell_type
.	O

Using	O
electrophoretic	O
mobility	O
shift	O
assays	O
,	O
we	O
find	O
that	O
TPCK	O
virtually	O
abolishes	O
(	O
to	O
less	O
than	O
1	O
%	O
)	O
the	O
levels	O
of	O
NF	B-protein
(	I-protein
kappa	I-protein
)	I-protein
B	I-protein
(	O
but	O
not	O
Oct-1	B-protein
)	O
found	O
in	O
nuclear	O
and	O
whole	O
cell	O
extracts	O
of	O
activated	B-cell_type
T	I-cell_type
cells	I-cell_type
.	O

Strikingly	O
,	O
the	O
immunosuppressive	O
effects	O
of	O
TPCK	O
are	O
blocked	O
when	O
T	B-cell_type
cells	I-cell_type
are	O
pretreated	O
for	O
15	O
min	O
with	O
5	O
mM	O
NAC	O
.	O

NAC	O
not	O
only	O
blocks	O
the	O
effect	O
of	O
TPCK	O
but	O
enhances	O
mitogenesis	O
and	O
cytokine	B-protein
production	O
(	O
>	O
2.5-fold	O
in	O
some	O
cases	O
)	O
upon	O
activation	O
of	O
unsuppressed	B-cell_type
T	I-cell_type
cells	I-cell_type
.	O

Our	O
data	O
support	O
the	O
notion	O
that	O
NF	B-protein
(	I-protein
kappa	I-protein
)	I-protein
B	I-protein
and	O
I	B-protein
(	I-protein
kappa	I-protein
)	I-protein
B	I-protein
proteases	I-protein
play	O
obligate	O
roles	O
in	O
T	O
cell	O
activation	O
and	O
mitogenesis	O
,	O
roles	O
that	O
are	O
enhanced	O
significantly	O
by	O
NAC	O
.	O

Signaling	O
by	O
IL-2	B-protein
and	O
related	O
cytokines	B-protein
:	O
JAKs	B-protein
,	O
STATs	B-protein
,	O
and	O
relationship	O
to	O
immunodeficiency	O
.	O

Cytokines	B-protein
that	O
bind	O
to	O
the	O
interleukin-2	B-protein
(	I-protein
IL-2	I-protein
)	I-protein
receptor	I-protein
common	I-protein
gamma	I-protein
chain	I-protein
(	O
gamma	B-protein
c	I-protein
)	O
,	O
including	O
IL-2	B-protein
,	O
IL-4	B-protein
,	O
IL-7	B-protein
,	O
IL-9	B-protein
,	O
and	O
IL-15	B-protein
,	O
are	O
important	O
for	O
the	O
growth	O
and	O
differentiation	O
of	O
T	B-cell_type
and	I-cell_type
B	I-cell_type
lymphocytes	I-cell_type
,	O
natural	B-cell_type
killer	I-cell_type
cells	I-cell_type
,	O
macrophages	B-cell_type
,	O
and	O
monoctyes	B-cell_type
.	O

These	O
cytokines	B-protein
have	O
overlapping	O
biological	O
effects	O
that	O
in	O
part	O
result	O
from	O
the	O
use	O
of	O
the	O
shared	B-protein
receptor	I-protein
subunit	I-protein
gamma	I-protein
c	I-protein
.	O

Recently	O
it	O
has	O
become	O
clear	O
that	O
these	O
cytokines	B-protein
activate	O
a	O
number	O
of	O
important	O
intracellular	B-protein
signaling	I-protein
molecules	I-protein
,	O
including	O
the	O
Janus	B-protein
kinases	I-protein
JAK1	B-protein
and	O
JAK3	B-protein
and	O
members	O
of	O
the	O
transcription	B-protein
factor	I-protein
family	I-protein
of	O
signal	B-protein
transducers	I-protein
and	O
activators	B-protein
of	I-protein
transcription	I-protein
(	O
STATs	B-protein
)	O
.	O

The	O
discovery	O
of	O
these	O
signaling	O
pathways	O
has	O
led	O
to	O
important	O
new	O
insights	O
into	O
their	O
role	O
in	O
lymphocyte	O
maturation	O
,	O
as	O
it	O
has	O
emerged	O
that	O
mutations	O
in	O
the	O
genes	O
encoding	O
both	O
gamma	B-protein
c	I-protein
and	O
JAK3	B-protein
result	O
in	O
similar	O
forms	O
of	O
severe	O
combined	O
immunodeficiency	O
(	O
SCID	O
)	O
.	O

In	O
this	O
review	O
we	O
examine	O
the	O
structure	O
and	O
function	O
of	O
cytokine	B-protein
receptors	I-protein
and	O
the	O
signaling	O
pathways	O
involved	O
in	O
their	O
regulation	O
of	O
gene	O
expression	O
.	O

Furthermore	O
,	O
we	O
discuss	O
recent	O
advances	O
that	O
have	O
led	O
to	O
a	O
better	O
understanding	O
of	O
how	O
cytokines	B-protein
elicit	O
intracellular	O
responses	O
,	O
as	O
well	O
as	O
their	O
role	O
in	O
normal	O
lymphoid	O
development	O
.	O

Cytomegalovirus	O
modulates	O
interleukin-6	B-DNA
gene	I-DNA
expression	O
.	O

Complications	O
after	O
lung	O
transplantation	O
include	O
the	O
development	O
of	O
rejection	O
and	O
an	O
increased	O
incidence	O
of	O
infection	O
,	O
particularly	O
with	O
cytomegalovirus	O
(	O
CMV	O
)	O
.	O

Several	O
recent	O
studies	O
have	O
suggested	O
that	O
interleukin	O
(	O
IL	O
)	O
-6	O
may	O
be	O
used	O
to	O
detect	O
both	O
infection	O
and	O
rejection	O
after	O
lung	O
transplantation	O
.	O

In	O
addition	O
,	O
IL-6	B-protein
may	O
play	O
a	O
role	O
in	O
the	O
development	O
of	O
bronchiolitis	O
obliterans	O
after	O
transplantation	O
.	O

Because	O
CMV	O
is	O
also	O
associated	O
with	O
the	O
development	O
of	O
bronchiolitis	O
obliterans	O
after	O
transplantation	O
,	O
we	O
determined	O
whether	O
CMV	O
induces	O
IL-6	B-protein
gene	O
expression	O
.	O

We	O
demonstrated	O
that	O
CMV	O
infection	O
increased	O
both	O
IL-6	B-protein
protein	I-protein
and	O
mRNA	B-RNA
in	O
peripheral	B-cell_type
blood	I-cell_type
mononuclear	I-cell_type
cells	I-cell_type
.	O

We	O
also	O
demonstrated	O
that	O
the	O
CMV	B-protein
immediate	I-protein
early	I-protein
1	I-protein
gene	I-protein
product	I-protein
increased	O
expression	O
of	O
the	O
IL-6	B-DNA
promoter	I-DNA
.	O

This	O
effect	O
of	O
the	O
CMV	B-protein
immediate	I-protein
early	I-protein
1	I-protein
gene	I-protein
product	I-protein
was	O
dependent	O
upon	O
the	O
presence	O
of	O
specific	O
transcription	B-DNA
factor	I-DNA
binding	I-DNA
sites	I-DNA
in	O
the	O
IL-6	B-DNA
promoter	I-DNA
.	O

These	O
studies	O
demonstrate	O
that	O
CMV	O
may	O
be	O
an	O
important	O
cofactor	O
in	O
the	O
development	O
of	O
rejection	O
and	O
infection	O
after	O
transplantation	O
through	O
its	O
effects	O
on	O
IL-6	B-protein
.	O

Vitamin	O
D3-	O
and	O
retinoic	O
acid-induced	O
monocytic	O
differentiation	O
:	O
interactions	O
between	O
the	O
endogenous	B-protein
vitamin	I-protein
D3	I-protein
receptor	I-protein
,	O
retinoic	B-protein
acid	I-protein
receptors	I-protein
,	O
and	O
retinoid	B-protein
X	I-protein
receptors	I-protein
in	O
U-937	B-cell_line
cells	I-cell_line
.	O

Retinoic	O
acid	O
(	O
RA	O
)	O
and	O
1	O
,	O
25	O
alpha-dihydroxycholecalciferol	O
(	O
VitD3	O
)	O
are	O
potent	O
regulators	O
of	O
hematopoletic	O
differentiation	O
.	O

Yet	O
,	O
little	O
is	O
known	O
as	O
to	O
how	O
the	O
RA	B-protein
and	I-protein
VitD3	I-protein
receptor	I-protein
network	I-protein
operates	O
in	O
hematopoietic	B-cell_type
cells	I-cell_type
,	O
and	O
whether	O
receptor	O
interactions	O
can	O
explain	O
the	O
interplay	O
between	O
the	O
RA	O
-and	O
VitD3-signaling	O
pathways	O
during	O
differentiation	O
.	O

Therefore	O
,	O
we	O
analyzed	O
the	O
expression	O
,	O
DNA	O
binding	O
,	O
and	O
transcriptional	O
activity	O
of	O
the	O
endogenous	B-protein
RA	I-protein
and	I-protein
VitD3	I-protein
receptors	I-protein
[	O
retinoic	B-protein
acid	I-protein
receptors	I-protein
(	O
RARs	B-protein
)	O
,	O
retinoid	B-protein
X	I-protein
receptors	I-protein
(	O
RXRs	B-protein
)	O
,	O
and	O
VitD3	B-protein
receptor	I-protein
(	O
VDR	B-protein
)	O
]	O
in	O
the	O
U-937	B-cell_line
cell	I-cell_line
line	I-cell_line
,	O
in	O
which	O
RA	O
and	O
VitD3	O
induce	O
distinct	O
monocytic	O
differentiation	O
pathways	O
.	O

VitD3	O
induction	O
resulted	O
in	O
the	O
formation	O
of	O
VDR/RXR	B-protein
DNA-binding	I-protein
complexes	I-protein
on	O
both	O
VitD3	B-DNA
response	I-DNA
elements	I-DNA
and	O
RA	B-DNA
response	I-DNA
elements	I-DNA
(	O
RAREs	B-DNA
)	O
.	O

However	O
,	O
transcriptional	O
activation	O
was	O
only	O
observed	O
from	O
a	O
VitD3	B-DNA
response	I-DNA
element-driven	I-DNA
reporter	I-DNA
construct	I-DNA
.	O

Several	O
DNA-binding	B-protein
complexes	I-protein
were	O
detected	O
on	O
RAREs	B-DNA
in	O
undifferentiated	B-cell_type
cells	I-cell_type
.	O

Stimulation	O
by	O
RA	O
resulted	O
in	O
increased	O
RAR	B-protein
beta	I-protein
/RXR	B-protein
DNA	O
binding	O
,	O
activated	O
RARE	B-DNA
-dependent	O
transcription	O
,	O
and	O
increased	O
expression	O
of	O
RAR-beta	B-protein
.	O

Concomitant	O
stimulation	O
by	O
VitD3	O
inhibited	O
the	O
RA-stimulated	O
formation	O
of	O
RAR	B-protein
beta/RXR	I-protein
heterodimers	I-protein
,	O
favoring	O
VDR	B-protein
/RXR	B-protein
binding	O
to	O
the	O
RARE	B-DNA
.	O

Also	O
,	O
VitD3	O
inhibited	O
the	O
expression	O
of	O
CD23	B-protein
and	O
CD49f	B-protein
,	O
characteristic	O
markers	O
of	O
retinoid-induced	O
U-937	B-cell_line
cell	I-cell_line
differentiation	O
.	O

In	O
contrast	O
,	O
neither	O
the	O
RA-stimulated	O
,	O
RARE	B-DNA
-mediated	O
transcription	O
nor	O
the	O
induced	O
RAR-beta	B-protein
expression	O
was	O
suppressed	O
by	O
VitD3	O
,	O
suggesting	O
that	O
VitD3	O
selectively	O
inhibited	O
the	O
retinoid-induced	O
differentiation	O
program	O
but	O
not	O
the	O
RARE	B-DNA
-mediated	O
signal	O
.	O

These	O
results	O
demonstrate	O
a	O
complex	O
role	O
for	O
VitD3	O
in	O
modifying	O
the	O
retinoid	O
differentiation	O
pathway	O
and	O
may	O
have	O
implications	O
for	O
differentiation-inducing	O
therapy	O
of	O
hematopoietic	O
tumors	O
.	O

The	O
human	B-protein
T-cell	I-protein
leukemia	I-protein
virus	I-protein
type	I-protein
1	I-protein
posttranscriptional	I-protein
trans-activator	I-protein
Rex	B-protein
contains	O
a	O
nuclear	B-protein
export	I-protein
signal	I-protein
.	O

The	O
Rex	B-protein
protein	I-protein
of	O
human	O
T-cell	O
leukemia	O
virus	O
type	O
1	O
is	O
required	O
for	O
the	O
nuclear	O
export	O
of	O
unspliced	B-RNA
viral	I-RNA
mRNA	I-RNA
and	O
,	O
therefore	O
,	O
for	O
virus	O
replication	O
.	O

In	O
this	O
manuscript	O
,	O
we	O
demonstrate	O
that	O
Rex	B-protein
shuttles	O
between	O
the	O
nucleus	O
and	O
the	O
cytoplasm	O
and	O
that	O
its	O
activation	B-protein
domain	I-protein
constitutes	O
a	O
nuclear	B-protein
export	I-protein
signal	I-protein
that	O
specifies	O
efficient	O
transport	O
to	O
the	O
cytoplasm	O
.	O

These	O
findings	O
are	O
consistent	O
with	O
a	O
model	O
for	O
Rex	B-protein
-mediated	O
trans-activation	O
in	O
which	O
Rex-viral	B-protein
mRNA	I-protein
complexes	I-protein
are	O
targeted	O
for	O
nuclear	O
export	O
by	O
the	O
direct	O
action	O
of	O
the	O
activation	B-protein
domain	I-protein
.	O

Granulocyte-macrophage	B-protein
colony-stimulating	I-protein
factor	I-protein
preferentially	O
activates	O
the	O
94-kD	B-protein
STAT5A	I-protein
and	O
an	O
80-kD	B-protein
STAT5A	I-protein
isoform	I-protein
in	O
human	O
peripheral	O
blood	O
monocytes	O
.	O

Granulocyte-macrophage	B-protein
colony-stimulating	I-protein
factor	I-protein
(	O
GM-CSF	B-protein
)	O
induces	O
immediate	O
effects	O
in	O
monocytes	O
by	O
activation	O
of	O
the	O
Janus	B-protein
kinase	I-protein
(	O
JAK2	B-protein
)	O
and	O
STAT	B-protein
transcription	I-protein
factor	I-protein
(	O
STAT5	B-protein
)	O
pathway	O
.	O

Recent	O
studies	O
have	O
identified	O
homologues	O
of	O
STAT5	B-protein
,	O
STAT5A	B-protein
,	O
and	O
STAT5B	B-protein
,	O
as	O
well	O
as	O
lower	O
molecular	O
weight	O
variants	O
of	O
STAT5	B-protein
.	O

To	O
define	O
the	O
activation	O
of	O
the	O
STAT5	B-protein
homologues	I-protein
and	O
lower	O
molecular	O
weight	O
variant	O
in	O
human	B-cell_type
monocytes	I-cell_type
and	O
monocytes	B-cell_type
differentiated	O
into	O
macrophages	B-cell_type
by	O
culture	O
in	O
macrophage-CSF	B-protein
(	O
M-CSF	B-protein
)	O
,	O
we	O
measured	O
the	O
GM-CSF	B-protein
induced	O
tyrosine	O
phosphorylation	O
of	O
STAT5A	B-protein
,	O
STAT5B	B-protein
,	O
and	O
any	O
lower	O
molecular	O
weight	O
STAT5	B-protein
isoforms	I-protein
.	O

Freshly	O
isolated	O
monocytes	O
expressed	O
94-kD	B-protein
STAT5A	I-protein
,	O
92-kD	O
STAT5B	B-protein
,	O
and	O
an	O
80-kD	B-protein
STAT5A	I-protein
molecule	I-protein
.	O

Whereas	O
94-kD	B-protein
STAT5A	I-protein
was	O
clearly	O
tyrosine	O
phosphorylated	O
and	O
bound	O
to	O
the	O
enhancer	B-DNA
element	I-DNA
,	O
the	O
gamma	B-DNA
response	I-DNA
region	I-DNA
(	O
GRR	B-DNA
)	O
,	O
of	O
the	O
Fc	B-DNA
gamma	I-DNA
RI	I-DNA
gene	I-DNA
,	O
substantially	O
less	O
tyrosine	O
phosphorylated	O
STAT5B	B-protein
bound	O
to	O
the	O
immobilized	O
GRR	B-DNA
element	I-DNA
.	O

Macrophages	O
lost	O
their	O
ability	O
to	O
express	O
the	O
80-kD	B-protein
STAT5A	I-protein
protein	I-protein
,	O
but	O
retained	O
their	O
ability	O
to	O
activate	O
STAT5A	B-protein
.	O

STAT5A-STAT5A	B-protein
homodimers	I-protein
and	O
STAT5A-STAT5B	B-protein
heterodimers	I-protein
formed	O
in	O
response	O
to	O
GM-CSF	B-protein
.	O

Therefore	O
,	O
activation	O
of	O
STAT5A	B-protein
predominates	O
compared	O
to	O
STAT5B	B-protein
when	O
assayed	O
by	O
direct	O
immunoprecipitation	O
and	O
by	O
evaluation	O
of	O
bound	O
STATs	B-protein
to	O
immobilized	O
GRR	B-DNA
.	O

Selective	O
activation	O
of	O
STAT5	B-protein
homologues	I-protein
in	O
addition	O
to	O
generation	O
of	O
lower	O
molecular	O
isoforms	O
may	O
provide	O
specificity	O
and	O
control	O
to	O
genes	O
expressed	O
in	O
response	O
to	O
cytokines	B-protein
such	O
as	O
GM-CSF	B-protein
.	O

Translocation	B-DNA
(	I-DNA
3	I-DNA
;	I-DNA
14	I-DNA
)	I-DNA
(	I-DNA
q27	I-DNA
;	I-DNA
q11	I-DNA
)	I-DNA
:	O
a	O
new	O
variant	O
translocation	O
in	O
a	O
patient	O
with	O
non-Hodgkin	O
's	O
lymphoma	O
of	O
B-cell	O
type	O
with	O
BCL6	B-DNA
rearrangement	O
.	O

We	O
report	O
a	O
65-year-old	O
woman	O
with	O
non-Hodgkin	O
's	O
lymphoma	O
(	O
NHL	O
)	O
carrying	O
a	O
t	B-DNA
(	I-DNA
3	I-DNA
;	I-DNA
14	I-DNA
)	I-DNA
(	I-DNA
q27	I-DNA
;	I-DNA
q11	I-DNA
)	I-DNA
and	O
BCL6	B-DNA
rearrangement	O
in	O
the	O
affected	B-cell_type
cells	I-cell_type
.	O

She	O
had	O
generalized	O
lymphadenopathy	O
and	O
the	O
bone	O
marrow	O
was	O
infiltrated	O
by	O
lymphoma	B-cell_type
cells	I-cell_type
at	O
presentation	O
.	O

Histological	O
diagnosis	O
was	O
``	O
malignant	O
lymphoma	O
,	O
diffuse	O
,	O
large	O
cell	O
''	O
type	O
according	O
to	O
an	O
International	O
Working	O
Formulation	O
.	O

Chromosome	O
analysis	O
revealed	O
a	O
t	B-DNA
(	I-DNA
3	I-DNA
;	I-DNA
14	I-DNA
)	I-DNA
(	I-DNA
q27	I-DNA
;	I-DNA
q11	I-DNA
)	I-DNA
,	O
which	O
is	O
a	O
new	O
variant	O
translocation	O
of	O
t	B-DNA
(	I-DNA
3	I-DNA
;	I-DNA
14	I-DNA
)	I-DNA
(	I-DNA
q27	I-DNA
;	I-DNA
q32	I-DNA
)	I-DNA
.	O

Southern	O
blot	O
analysis	O
showed	O
rearrangement	O
of	O
BCL6	B-DNA
,	O
JH	B-DNA
,	O
and	O
TCR	B-DNA
beta	I-DNA
but	O
not	O
of	O
TCR	B-DNA
delta	I-DNA
.	O

Cosmid	B-DNA
probe	I-DNA
of	O
BCL6	B-DNA
hybridized	O
to	O
14q11	B-DNA
and	O
3q27	B-DNA
by	O
fluorescence	O
in	O
situ	O
hybridization	O
(	O
FISH	O
)	O
.	O

Although	O
the	O
band	B-DNA
14q11	I-DNA
is	O
a	O
locus	O
of	O
T-cell	B-protein
receptor	I-protein
alpha-	I-protein
and	I-protein
delta-chains	I-protein
(	O
TCR	B-protein
alpha/delta	I-protein
)	O
,	O
lymphoma	B-cell_type
cells	I-cell_type
expressed	O
B-cell	B-cell_type
,	I-cell_type
IgGk	I-cell_type
phenotype	I-cell_type
.	O

The	O
findings	O
suggest	O
that	O
a	O
novel	B-DNA
proto-oncogene	I-DNA
in	O
the	O
vicinity	O
of	O
TCR	B-DNA
alpha/delta	I-DNA
is	O
involved	O
in	O
this	O
translocation	O
.	O

Transgenic	O
expression	O
of	O
PML/RARalpha	B-protein
impairs	O
myelopoiesis	O
.	O

The	O
translocation	O
found	O
in	O
acute	O
promyelocytic	O
leukemia	O
rearranges	O
the	O
promyelocytic	B-DNA
leukemia	I-DNA
gene	I-DNA
(	O
PML	B-DNA
)	O
on	O
chromosome	B-DNA
15	I-DNA
with	O
the	O
retinoic	B-DNA
acid	I-DNA
receptor	I-DNA
alpha	I-DNA
(	O
RARalpha	B-protein
)	O
on	O
chromosome	B-DNA
17	I-DNA
.	O

This	O
yields	O
a	O
fusion	O
transcript	O
,	O
PML/RARalpha	B-protein
,	O
a	O
transcription	B-protein
factor	I-protein
with	O
reported	O
dominant	O
negative	O
functions	O
in	O
the	O
absence	O
of	O
hormone	O
.	O

Clinical	O
remissions	O
induced	O
with	O
all-trans	O
retinoic	O
acid	O
(	O
RA	O
)	O
treatment	O
in	O
acute	O
promyelocytic	O
leukemia	O
are	O
linked	O
to	O
PML/RARalpha	B-protein
expression	O
in	O
leukemic	B-cell_type
cells	I-cell_type
.	O

To	O
evaluate	O
the	O
PML/RARalpha	B-protein
role	O
in	O
myelopoiesis	O
,	O
transgenic	O
mice	O
expressing	O
PML/RARalpha	B-protein
were	O
engineered	O
.	O

A	O
full-length	O
PML/RARalpha	B-DNA
cDNA	I-DNA
driven	O
by	O
the	O
CD11b	B-DNA
promoter	I-DNA
was	O
expressed	O
in	O
transgenic	O
mice	O
.	O

Expression	O
was	O
confirmed	O
in	O
the	O
bone	O
marrow	O
with	O
a	O
reverse	O
transcription	O
PCR	O
assay	O
.	O

Basal	O
total	O
white	O
blood	O
cell	O
and	O
granulocyte	O
counts	O
did	O
not	O
appreciably	O
differ	O
between	O
PML/RARalpha	B-protein
transgenic	O
and	O
control	O
mice	O
.	O

Cell	O
sorter	O
analysis	O
of	O
CD11b+	B-cell_type
bone	I-cell_type
marrow	I-cell_type
cells	I-cell_type
revealed	O
similar	O
CD11b+	B-cell_type
populations	I-cell_type
in	O
transgenic	O
and	O
control	O
mice	O
.	O

However	O
,	O
in	O
vitro	O
clonal	O
growth	O
assays	O
performed	O
on	O
peripheral	O
blood	O
from	O
transgenic	O
versus	O
control	O
mice	O
revealed	O
a	O
marked	O
reduction	O
of	O
myeloid	B-cell_type
progenitors	I-cell_type
,	O
especially	O
in	O
those	O
responding	O
to	O
granulocyte/	B-protein
macrophage	I-protein
colony-stimulating	I-protein
factor	I-protein
.	O

Granulocyte/macrophage	B-protein
colony-stimulating	I-protein
factor	I-protein
and	O
kit	O
ligand	O
cotreatment	O
did	O
not	O
overcome	O
this	O
inhibition	O
.	O

Impaired	O
myelopoiesis	O
in	O
vivo	O
was	O
shown	O
by	O
stressing	O
these	O
mice	O
with	O
sublethal	O
irradiation	O
.	O

Following	O
irradiation	O
,	O
PML/RARalpha	B-protein
transgenic	O
mice	O
,	O
as	O
compared	O
with	O
controls	O
,	O
more	O
rapidly	O
depressed	O
peripheral	O
white	O
blood	O
cell	O
and	O
granulocyte	O
counts	O
.	O

As	O
expected	O
,	O
nearly	O
all	O
control	O
mice	O
(	O
94.4	O
%	O
)	O
survived	O
irradiation	O
,	O
yet	O
this	O
irradiation	O
was	O
lethal	O
to	O
45.8	O
%	O
of	O
PML/RARalpha	B-protein
transgenic	O
mice	O
.	O

Lethality	O
was	O
associated	O
with	O
more	O
severe	O
leukopenia	O
in	O
transgenic	O
versus	O
control	O
mice	O
.	O

Retinoic	O
acid	O
treatment	O
of	O
irradiated	O
PML/RARalpha	B-protein
mice	O
enhanced	O
granulocyte	B-cell_type
recovery	O
.	O

These	O
data	O
suggest	O
that	O
abnormal	O
myelopoiesis	O
due	O
to	O
PML/RARalpha	B-protein
expression	O
is	O
an	O
early	O
event	O
in	O
oncogenic	O
transformation	O
.	O

C/EBP	B-protein
activators	I-protein
are	O
required	O
for	O
HIV-1	O
replication	O
and	O
proviral	O
induction	O
in	O
monocytic	B-cell_line
cell	I-cell_line
lines	I-cell_line
.	O

Previous	O
work	O
has	O
shown	O
that	O
C/EBP	B-DNA
sites	I-DNA
and	O
C/EBP	B-protein
transcriptional	I-protein
activators	I-protein
are	O
necessary	O
for	O
HIV-1	B-DNA
LTR	I-DNA
activity	O
in	O
monocytes/macrophages	B-cell_type
.	O

We	O
have	O
investigated	O
the	O
role	O
that	O
C/EBP	B-protein
proteins	I-protein
play	O
in	O
induction	O
and	O
replication	O
of	O
HIV-1	O
.	O

Ectopic	O
expression	O
of	O
the	O
dominant	O
negative	O
C/EBP	B-protein
protein	I-protein
LIP	I-protein
inhibited	O
HIV-1	O
mRNA	O
and	O
virus	O
production	O
in	O
activated	B-cell_line
U1	I-cell_line
cells	I-cell_line
,	O
demonstrating	O
that	O
C/EBP	B-protein
proteins	I-protein
are	O
required	O
for	O
provirus	O
induction	O
.	O

U1	B-cell_line
lines	I-cell_line
overexpressing	O
C/EBP	B-protein
activator	I-protein
NF-IL-6	B-protein
produced	O
more	O
viral	B-RNA
mRNA	I-RNA
and	O
virus	O
particles	O
following	O
cellular	O
activation	O
than	O
control	B-cell_line
lines	I-cell_line
,	O
demonstrating	O
that	O
C/EBP	B-protein
proteins	I-protein
are	O
limiting	O
for	O
virus	O
transcription	O
.	O

HIV-1	O
harboring	O
mutations	O
within	O
two	O
C/EBP	B-DNA
sites	I-DNA
were	O
crippled	O
in	O
their	O
ability	O
to	O
replicate	O
in	O
U937	B-cell_line
promonocytic	I-cell_line
cells	I-cell_line
,	O
indicating	O
that	O
these	O
sites	O
are	O
required	O
for	O
replication	O
.	O

These	O
data	O
identify	O
C/EBP	B-protein
proteins	I-protein
as	O
regulators	O
of	O
HIV-1	O
expression	O
in	O
monocytes/macrophages	B-cell_type
.	O

Epstein-Barr	B-protein
virus	I-protein
nuclear	I-protein
antigen	I-protein
2	I-protein
and	O
latent	B-protein
membrane	I-protein
protein	I-protein
independently	O
transactivate	O
p53	B-protein
through	O
induction	O
of	O
NF-kappaB	B-protein
activity	O
.	O

B-cell	B-cell_type
immortalization	O
by	O
Epstein-Barr	O
virus	O
(	O
EBV	O
)	O
is	O
dependent	O
on	O
permanent	O
control	O
of	O
the	O
cellular	O
processes	O
which	O
normally	O
regulate	O
cell	O
division	O
and	O
apoptosis	O
,	O
functions	O
possessed	O
by	O
p53	B-protein
in	O
a	O
number	O
of	O
normal	O
cell	O
types	O
.	O

In	O
studies	O
initiated	O
to	O
evaluate	O
relationships	O
between	O
EBV	B-DNA
latent	I-DNA
genes	I-DNA
and	O
p53	B-protein
,	O
p53	B-protein
levels	O
were	O
found	O
to	O
increase	O
approximately	O
10-fold	O
4	O
to	O
5	O
days	O
after	O
EBV	O
infection	O
of	O
purified	O
resting	B-cell_type
human	I-cell_type
B	I-cell_type
cells	I-cell_type
;	O
the	O
induced	O
p53	B-protein
was	O
transcriptionally	O
active	O
.	O

Latent	B-protein
membrane	I-protein
protein	I-protein
1	I-protein
and	O
,	O
to	O
a	O
lesser	O
extent	O
,	O
EBV	B-protein
nuclear	I-protein
antigen	I-protein
2	I-protein
mediated	O
the	O
increase	O
in	O
p53	B-protein
levels	O
via	O
activation	O
of	O
the	O
NF-kappaB	B-protein
transcription	B-protein
factor	I-protein
.	O

Cooperation	O
between	O
core	B-protein
binding	I-protein
factor	I-protein
and	O
adjacent	B-DNA
promoter	I-DNA
elements	I-DNA
contributes	O
to	O
the	O
tissue-specific	O
expression	O
of	O
interleukin-3	B-protein
.	O

Tissue-specific	O
expression	O
of	O
interleukin-3	B-protein
(	O
IL-3	B-protein
)	O
is	O
mediated	O
via	O
cis-acting	B-DNA
elements	I-DNA
located	O
within	O
315	O
base	O
pairs	O
of	O
the	O
transcription	B-DNA
start	I-DNA
.	O

This	O
is	O
achieved	O
in	O
part	O
through	O
the	O
positive	O
activities	O
of	O
the	O
AP-1	B-DNA
and	I-DNA
Elf-1	I-DNA
sites	I-DNA
in	O
the	O
IL-3	B-DNA
promoter	I-DNA
.	O

The	O
contribution	O
to	O
T	O
cell-specific	O
expression	O
by	O
other	O
promoter	B-DNA
sites	I-DNA
was	O
assessed	O
in	O
a	O
transient	O
expression	O
assay	O
with	O
IL-3	B-DNA
promoter	I-DNA
constructs	I-DNA
linked	O
to	O
a	O
luciferase	B-DNA
gene	I-DNA
,	O
focusing	O
initially	O
on	O
the	O
core	B-DNA
binding	I-DNA
factor	I-DNA
(	I-DNA
CBF	I-DNA
)	I-DNA
site	I-DNA
,	O
which	O
is	O
footprinted	O
in	O
vivo	O
upon	O
T	O
cell	O
activation	O
.	O

Activity	O
of	O
the	O
CBF	B-DNA
site	I-DNA
is	O
shown	O
to	O
be	O
critically	O
dependent	O
on	O
the	O
adjacent	B-DNA
activator	I-DNA
site	I-DNA
Act-1	I-DNA
.	O

Together	O
the	O
Act-1	B-DNA
and	O
CBF	B-DNA
sites	I-DNA
form	O
a	O
functional	B-DNA
unit	I-DNA
(	O
AC	B-DNA
unit	I-DNA
)	O
with	O
dual	O
activity	O
.	O

The	O
AC	B-DNA
unit	I-DNA
is	O
demonstrated	O
to	O
enhance	O
basal	O
activity	O
of	O
promoters	O
both	O
in	O
fibroblasts	B-cell_type
and	O
T	B-cell_type
cells	I-cell_type
.	O

This	O
activity	O
is	O
further	O
inducible	O
in	O
activated	O
T	B-cell_type
cells	I-cell_type
,	O
but	O
not	O
in	O
fibroblasts	B-cell_type
.	O

In	O
addition	O
to	O
the	O
already	O
identified	O
NIP	B-DNA
repressor	I-DNA
site	I-DNA
,	O
evidence	O
is	O
presented	O
for	O
a	O
second	B-DNA
repressor	I-DNA
region	I-DNA
that	O
restricts	O
promoter	O
activity	O
in	O
fibroblasts	B-cell_type
.	O

Finally	O
,	O
a	O
novel	O
positive	B-DNA
regulatory	I-DNA
element	I-DNA
has	O
been	O
mapped	O
in	O
the	O
IL-3	B-DNA
promoter	I-DNA
between	O
nucleotide	O
-180	O
and	O
-210	O
that	O
leads	O
to	O
increased	O
expression	O
in	O
T	B-cell_type
cells	I-cell_type
.	O

Together	O
these	O
results	O
demonstrate	O
that	O
T	O
cell	O
expression	O
of	O
IL-3	B-protein
is	O
not	O
specified	O
by	O
the	O
activity	O
of	O
a	O
single	O
tissue-specific	B-DNA
element	I-DNA
,	O
but	O
instead	O
involves	O
multiple	O
interacting	B-DNA
elements	I-DNA
that	O
provide	O
both	O
specific	O
positive	O
regulation	O
in	O
T	B-cell_type
cells	I-cell_type
and	O
specific	O
negative	O
regulation	O
in	O
fibroblasts	B-cell_type
.	O

Modulation	O
of	O
the	O
expression	O
of	O
the	O
IFN-gamma	B-protein
receptor	I-protein
beta-chain	I-protein
controls	O
responsiveness	O
to	O
IFN-gamma	B-protein
in	O
human	B-cell_type
peripheral	I-cell_type
blood	I-cell_type
T	I-cell_type
cells	I-cell_type
.	O

IFN-gamma	B-protein
has	O
potent	O
antiproliferative	O
and	O
apoptotic	O
effects	O
in	O
T	B-cell_type
cells	I-cell_type
that	O
are	O
important	O
in	O
determining	O
T	O
cell	O
development	O
and	O
polarized	O
differentiation	O
.	O

Therefore	O
,	O
any	O
event	O
that	O
enables	O
T	B-cell_type
cells	I-cell_type
to	O
become	O
less	O
responsive	O
to	O
IFN-	B-protein
gamma	I-protein
may	O
potentially	O
alter	O
immune	O
responsiveness	O
to	O
Ag	B-protein
.	O

In	O
this	O
work	O
,	O
we	O
show	O
that	O
human	B-cell_type
peripheral	I-cell_type
blood	I-cell_type
T	I-cell_type
cells	I-cell_type
that	O
are	O
stimulated	O
through	O
the	O
TCR	B-protein
and	O
expanded	O
with	O
IL-2	B-protein
are	O
unresponsive	O
to	O
IFN-gamma	B-protein
,	O
as	O
determined	O
by	O
a	O
lack	O
of	O
activation	O
of	O
jak	B-protein
kinases	I-protein
and	O
the	O
transcription	B-protein
factor	I-protein
,	O
STAT1	B-protein
(	I-protein
alpha	I-protein
)	I-protein
,	O
a	O
signal	O
transducer	O
and	O
activator	O
of	O
transcription	O
.	O

This	O
nonresponsiveness	O
occurs	O
because	O
of	O
a	O
lack	O
of	O
expression	O
of	O
the	O
beta-	B-protein
chain	I-protein
(	O
accessory	O
factor	O
)	O
of	O
the	O
IFN-gamma	B-protein
receptor	I-protein
,	O
while	O
at	O
the	O
same	O
time	O
maintaining	O
IFN-gamma	B-protein
receptor	I-protein
alpha-chain	I-protein
expression	O
.	O

Expression	O
of	O
the	O
beta-chain	B-protein
can	O
be	O
restored	O
by	O
secondary	O
TCR	B-protein
ligation	O
or	O
PMA	O
treatment	O
.	O

T	B-cell_type
cell	I-cell_type
blasts	I-cell_type
treated	O
with	O
PMA	O
are	O
now	O
responsive	O
to	O
IFN-gamma	B-protein
.	O

When	O
freshly	O
isolated	O
,	O
highly	O
enriched	O
(	O
>	O
98	O
%	O
)	O
T	B-cell_type
cells	I-cell_type
are	O
examined	O
for	O
IFN-gamma	B-protein
responsiveness	O
;	O
these	O
cells	O
can	O
respond	O
to	O
IFN-gamma	B-protein
and	O
express	O
beta-chain	B-protein
.	O

Therefore	O
,	O
as	O
T	B-cell_type
cells	I-cell_type
progress	O
from	O
primary	O
TCR	B-protein
activation	O
through	O
IL-2	B-protein
-dependent	O
proliferation	O
,	O
followed	O
by	O
secondary	O
TCR	B-protein
stimulation	O
,	O
their	O
responsiveness	O
to	O
IFN-gamma	B-protein
varies	O
,	O
and	O
this	O
may	O
affect	O
their	O
ability	O
to	O
participate	O
in	O
an	O
ongoing	O
immune	O
response	O
.	O

Age-related	O
decreases	O
in	O
IL-2	B-protein
production	O
by	O
human	B-cell_type
T	I-cell_type
cells	I-cell_type
are	O
associated	O
with	O
impaired	O
activation	O
of	O
nuclear	B-protein
transcriptional	I-protein
factors	I-protein
AP-1	B-protein
and	O
NF-AT	B-protein
.	O

Although	O
transcriptional	B-protein
factors	I-protein
AP-1	B-protein
and	O
nuclear	O
factor	O
of	O
activated	O
T	O
cells	O
(	O
NF-AT	B-protein
)	O
are	O
important	O
for	O
the	O
normal	O
induction	O
of	O
IL-2	B-protein
,	O
it	O
is	O
unknown	O
if	O
the	O
age-related	O
decline	O
in	O
IL-2	B-protein
production	O
by	O
activated	O
human	B-cell_type
T	I-cell_type
cells	I-cell_type
may	O
be	O
associated	O
with	O
aberrancies	O
in	O
transcriptional	B-protein
regulatory	I-protein
proteins	I-protein
.	O

In	O
the	O
current	O
studies	O
,	O
IL-2	B-protein
production	O
by	O
T	B-cell_type
cells	I-cell_type
from	O
elderly	O
(	O
mean	O
78	O
years	O
)	O
and	O
young	O
(	O
mean	O
37	O
years	O
)	O
humans	O
was	O
measured	O
in	O
cultures	O
stimulated	O
with	O
PHA	B-protein
,	O
PHA	B-protein
plus	O
PMA	O
,	O
crosslinked	O
anti-CD3	O
mAB	O
OKT3	O
plus	O
PMA	O
,	O
or	O
PMA	O
plus	O
ionomycin	O
.	O

Substantial	O
decreases	O
of	O
IL-2	B-protein
production	O
were	O
observed	O
for	O
cell	O
cultures	O
from	O
7	O
of	O
12	O
elderly	O
individuals	O
in	O
response	O
to	O
the	O
different	O
stimuli	O
,	O
whereas	O
the	O
levels	O
of	O
IL-2	B-protein
produced	O
by	O
stimulated	O
T	B-cell_type
cells	I-cell_type
from	O
other	O
elderly	O
individuals	O
were	O
equivalent	O
to	O
those	O
observed	O
for	O
stimulated	O
T	O
cells	O
of	O
young	O
subjects	O
.	O

Analyses	O
of	O
nuclear	O
extracts	O
by	O
electrophoretic	O
DNA	O
mobility	O
shift	O
assays	O
showed	O
that	O
decreased	O
IL-2	B-protein
production	O
by	O
stimulated	B-cell_type
T	I-cell_type
cells	I-cell_type
of	O
elderly	O
individuals	O
was	O
closely	O
associated	O
with	O
impairments	O
in	O
the	O
activation	O
of	O
both	O
AP-1	B-protein
and	O
NF-AT	B-protein
.	O

By	O
contrast	O
,	O
T	B-cell_type
cells	I-cell_type
from	O
elderly	O
subjects	O
with	O
normal	O
levels	O
of	O
IL-2	B-protein
production	O
exhibited	O
normal	O
activation	O
of	O
AP-1	B-protein
and	O
NF-AT	B-protein
.	O

In	O
addition	O
,	O
the	O
results	O
of	O
competition	O
experiments	O
analyzing	O
the	O
normal	O
components	O
of	O
NF-AT	B-protein
showed	O
that	O
the	O
age-related	O
reductions	O
in	O
stimulus-dependent	O
NF-AT	B-protein
complexes	I-protein
corresponded	O
to	O
the	O
slow	O
migrating	O
complexes	O
that	O
were	O
composed	O
of	O
c-Fos/c-Jun	B-protein
AP-1	B-protein
.	O

The	O
resting	O
and	O
stimulated	O
levels	O
of	O
NF	B-protein
kappa	I-protein
B	I-protein
were	O
reduced	O
in	O
T	B-cell_type
cells	I-cell_type
from	O
certain	O
elderly	O
individuals	O
;	O
however	O
,	O
alterations	O
of	O
NF	B-protein
kappa	I-protein
B	I-protein
did	O
not	O
correlate	O
with	O
changes	O
in	O
IL-2	B-protein
expression	O
.	O

Thus	O
,	O
these	O
results	O
show	O
that	O
age-related	O
impairments	O
in	O
the	O
activation	O
of	O
AP-1	B-protein
and	O
NF-AT	B-protein
are	O
closely	O
associated	O
with	O
decreased	O
expression	O
of	O
IL-2	B-protein
and	O
further	O
suggest	O
that	O
aberrancies	O
in	O
the	O
signaling	O
pathways	O
important	O
for	O
the	O
induction	O
of	O
transcriptionally	O
active	O
c-Fos/c-Jun	B-protein
AP-1	B-protein
may	O
contribute	O
to	O
the	O
impaired	O
activation	O
of	O
NF-AT	B-protein
.	O

IL-13	B-protein
induces	O
phosphorylation	O
and	O
activation	O
of	O
JAK2	B-protein
Janus	I-protein
kinase	I-protein
in	O
human	B-cell_line
colon	I-cell_line
carcinoma	I-cell_line
cell	I-cell_line
lines	I-cell_line
:	O
similarities	O
between	O
IL-4	B-protein
and	O
IL-13	B-protein
signaling	O
.	O

We	O
have	O
recently	O
reported	O
that	O
IL-13R	B-protein
may	O
share	O
a	O
component	O
with	O
IL-4R	B-protein
.	O
Here	O
we	O
report	O
that	O
both	O
IL-4	B-protein
and	O
IL-13	B-protein
share	O
signaling	O
events	O
in	O
human	B-cell_line
colon	I-cell_line
carcinoma	I-cell_line
cell	I-cell_line
lines	I-cell_line
(	O
HT-29	B-cell_line
and	O
WiDr	B-cell_line
)	O
.	O

IL-13	B-protein
caused	O
rapid	O
phosphorylation	O
of	O
the	O
three	O
out	O
of	O
four	O
members	O
of	O
the	O
known	O
Janus	B-protein
family	I-protein
of	I-protein
kinases	I-protein
(	O
JAKs	B-protein
)	O
.	O

We	O
show	O
that	O
JAK2	B-protein
kinase	I-protein
is	O
rapidly	O
phosphorylated	O
and	O
activated	O
in	O
response	O
to	O
IL-13	B-protein
.	O

Within	O
1	O
min	O
of	O
activation	O
,	O
JAK2	B-protein
was	O
phosphorylated	O
,	O
and	O
peaked	O
in	O
10	O
min	O
.	O

In	O
addition	O
,	O
IL-13	B-protein
phosphorylated	O
insulin	B-protein
response	I-protein
substrate-1	I-protein
,	O
IL-4R	B-protein
p140	I-protein
,	O
JAK1	B-protein
,	O
and	O
Tyk2	B-protein
,	O
but	O
not	O
JAK3	B-protein
kinase	I-protein
.	O

IL-4	B-protein
also	O
stimulated	O
all	O
three	O
kinases	B-protein
and	O
substrates	O
,	O
but	O
unlike	O
in	O
immune	B-cell_type
cells	I-cell_type
,	O
IL-4	B-protein
did	O
not	O
involve	O
JAK3	B-protein
activation	O
for	O
its	O
signaling	O
in	O
colon	B-cell_line
cancer	I-cell_line
cell	I-cell_line
lines	I-cell_line
.	O

Furthermore	O
,	O
JAK2	B-protein
associated	O
with	O
the	O
IL-4R	B-protein
p140	I-protein
before	O
and	O
after	O
stimulation	O
with	O
IL-13	B-protein
.	O

Both	O
IL-13	B-protein
and	O
IL-4	B-protein
induced	O
phosphorylation	O
of	O
IL-4	B-protein
STAT	I-protein
(	O
STAT6	B-protein
)	O
but	O
not	O
STAT1	B-protein
,	O
STAT3	B-protein
,	O
or	O
STAT5	B-protein
.	O

125I-IL-13	B-protein
did	O
not	O
bind	O
to	O
colon	B-cell_line
cancer	I-cell_line
cell	I-cell_line
lines	I-cell_line
,	O
but	O
unlabeled	O
IL-13	B-protein
competed	O
for	O
the	O
binding	O
of	O
125I-IL-4	B-protein
.	O

Our	O
data	O
suggest	O
that	O
IL-13	B-protein
utilizes	O
IL-4R	B-protein
and	O
its	O
signaling	O
pathway	O
,	O
and	O
JAK2	B-protein
may	O
play	O
an	O
important	O
role	O
in	O
the	O
function	O
of	O
IL-4R	B-protein
and	O
IL-13R	B-protein
in	O
colon	B-cell_type
cancer	I-cell_type
cells	I-cell_type
.	O

Differential	O
regulation	O
of	O
IL-6	B-DNA
gene	I-DNA
transcription	O
and	O
expression	O
by	O
IL-4	B-protein
and	O
IL-10	B-protein
in	O
human	B-cell_line
monocytic	I-cell_line
cell	I-cell_line
lines	I-cell_line
.	O

IL-4	B-protein
and	O
IL-10	B-protein
inhibit	O
the	O
cytokine	B-protein
production	O
and	O
mRNA	O
expression	O
by	O
monocytes/macrophages	B-cell_type
.	O

To	O
investigate	O
the	O
molecular	O
mechanism	O
of	O
the	O
inhibitory	O
effect	O
on	O
transcriptional	O
or	O
post-transcriptional	O
regulation	O
of	O
IL-6	B-DNA
gene	I-DNA
expression	O
by	O
IL-4	B-protein
and	O
IL-10	B-protein
,	O
we	O
studied	O
IL-6	B-protein
production	O
,	O
expression	O
level	O
of	O
IL-6	B-RNA
mRNA	I-RNA
,	O
IL-6	B-protein
promoter	O
activity	O
,	O
transcriptional	O
activity	O
of	O
NF-kappaB	B-protein
and	O
NF-IL-6	B-protein
,	O
and	O
IL-6	B-RNA
mRNA	I-RNA
stability	O
in	O
human	B-cell_line
monocytic	I-cell_line
cell	I-cell_line
lines	I-cell_line
,	O
THP-1	B-cell_line
and	O
U937	B-cell_line
,	O
stimulated	O
by	O
PMA	O
and	O
LPS	O
in	O
the	O
absence	O
or	O
the	O
presence	O
of	O
IL-4	B-protein
or	O
IL-10	B-protein
.	O

Both	O
IL-4	B-protein
and	O
IL-10	B-protein
were	O
seen	O
to	O
inhibit	O
IL-6	B-protein
production	O
and	O
the	O
expression	O
of	O
IL-6	B-RNA
mRNA	I-RNA
in	O
both	O
monocytic	B-cell_line
cell	I-cell_line
lines	I-cell_line
studied	O
.	O

In	O
chloramphenicol	B-protein
acetyltransferase	I-protein
assays	O
,	O
utilizing	O
the	O
transient	O
transfection	O
of	O
a	O
chloramphenicol	B-DNA
acetyltransferase	I-DNA
reporter	I-DNA
plasmid	I-DNA
containing	O
the	O
IL-6	B-DNA
gene	I-DNA
promoter	I-DNA
,	O
IL-4	B-protein
,	O
but	O
not	O
IL-10	B-protein
,	O
suppressed	O
the	O
transcriptional	O
activity	O
of	O
the	O
IL-6	O
gene	O
promoter	O
stimulated	O
by	O
PMA	O
and	O
LPS	O
.	O

Electrophoretic	O
mobility	O
shift	O
assays	O
showed	O
that	O
IL-4	B-protein
,	O
but	O
not	O
IL-10	B-protein
,	O
inhibited	O
nuclear	O
NF-kappaB	B-protein
activity	O
,	O
and	O
that	O
IL-4	B-protein
and	O
IL-10	B-protein
did	O
not	O
affect	O
NF-	O
IL-6	B-protein
activity	O
.	O

On	O
the	O
other	O
hand	O
,	O
IL-10	B-protein
enhanced	O
the	O
degradation	O
of	O
IL-6	B-RNA
mRNA	I-RNA
in	O
a	O
mRNA	O
stability	O
assay	O
.	O

These	O
results	O
suggest	O
that	O
IL-4	B-protein
may	O
inhibit	O
the	O
transcription	O
of	O
the	O
IL-6	B-DNA
gene	I-DNA
by	O
affecting	O
NF-kappaB	B-protein
binding	O
activity	O
,	O
while	O
IL-10	B-protein
may	O
inhibit	O
the	O
IL-6	B-RNA
mRNA	I-RNA
levels	O
post-transcriptionally	O
,	O
without	O
suppressing	O
promoter	O
activity	O
.	O

Therefore	O
,	O
we	O
conclude	O
that	O
IL-4	B-protein
and	O
IL-10	B-protein
inhibit	O
IL-6	B-protein
production	O
by	O
different	O
mechanisms	O
in	O
human	B-cell_line
monocytic	I-cell_line
cell	I-cell_line
lines	I-cell_line
.	O

Activation	O
of	O
nuclear	B-protein
factor	I-protein
of	I-protein
activated	I-protein
T	I-protein
cells	I-protein
in	O
a	O
cyclosporin	O
A-resistant	O
pathway	O
.	O

The	O
mechanism	O
of	O
action	O
of	O
the	O
immunosuppressive	O
drug	O
cyclosporin	O
A	O
(	O
CsA	O
)	O
is	O
the	O
inactivation	O
of	O
the	O
Ca2+/calmodulin-dependent	B-protein
serine-threonine	I-protein
phosphatase	I-protein
calcineurin	B-protein
by	O
the	O
drug-immunophilin	B-protein
complex	I-protein
.	O

Inactive	O
calcineurin	B-protein
is	O
unable	O
to	O
activate	O
the	O
nuclear	B-protein
factor	I-protein
of	I-protein
activated	I-protein
T	I-protein
cells	I-protein
(	O
NFAT	B-protein
)	O
,	O
a	O
transcription	B-protein
factor	I-protein
required	O
for	O
expression	O
of	O
the	O
interleukin	B-DNA
2	I-DNA
(	I-DNA
IL-2	I-DNA
)	I-DNA
gene	I-DNA
.	O

IL-2	B-protein
production	O
by	O
CsA-treated	B-cell_line
cells	I-cell_line
is	O
therefore	O
dramatically	O
reduced	O
.	O

We	O
demonstrate	O
here	O
,	O
however	O
,	O
that	O
NFAT	B-protein
can	O
be	O
activated	O
,	O
and	O
significant	O
levels	O
of	O
IL-2	B-protein
can	O
be	O
produced	O
by	O
the	O
CsA-resistant	O
CD28	B-protein
-signaling	O
pathway	O
.	O

In	O
transient	O
transfection	O
assays	O
,	O
both	O
multicopy	O
NFAT	B-protein
-and	O
IL-2	B-DNA
promoter-beta-galactosidase	I-DNA
reporter	I-DNA
gene	I-DNA
constructs	I-DNA
could	O
be	O
activated	O
by	O
phorbol	O
12-myristate	O
13-acetate	O
(	O
PMA	O
)	O
/alpha-	O
CD28	B-protein
stimulation	O
,	O
and	O
this	O
activation	O
was	O
resistant	O
to	O
CsA	O
.	O

Electrophoretic	O
mobility	O
shift	O
assay	O
showed	O
the	O
induction	O
of	O
a	O
CsA-resistant	B-protein
NFAT	I-protein
complex	I-protein
in	O
the	O
nuclear	O
extracts	O
of	O
peripheral	B-cell_type
blood	I-cell_type
T	I-cell_type
cells	I-cell_type
stimulated	O
with	O
PMA	O
plus	O
alphaCD28	B-protein
.	O

Peripheral	B-cell_type
blood	I-cell_type
T	I-cell_type
cells	I-cell_type
stimulated	O
with	O
PMA	O
/alphaCD28	B-protein
produced	O
IL-2	B-protein
in	O
the	O
presence	O
of	O
CsA	O
.	O

Collectively	O
,	O
these	O
data	O
suggest	O
that	O
NFAT	B-protein
can	O
be	O
activated	O
and	O
IL-2	B-protein
can	O
be	O
produced	O
in	O
a	O
calcineurin	B-protein
independent	O
manner	O
.	O

Effects	O
of	O
interleukin-10	B-protein
on	O
human	B-cell_type
peripheral	I-cell_type
blood	I-cell_type
mononuclear	I-cell_type
cell	I-cell_type
responses	O
to	O
Cryptococcus	O
neoformans	O
,	O
Candida	O
albicans	O
,	O
and	O
lipopolysaccharide	O
.	O

Deactivation	O
of	O
mononuclear	B-cell_type
phagocytes	I-cell_type
is	O
critical	O
to	O
limit	O
the	O
inflammatory	O
response	O
but	O
can	O
be	O
detrimental	O
in	O
the	O
face	O
of	O
progressive	O
infection	O
.	O

We	O
compared	O
the	O
effects	O
of	O
the	O
deactivating	B-protein
cytokine	I-protein
interleukin	B-protein
10	I-protein
(	O
IL-10	B-protein
)	O
on	O
human	B-cell_type
peripheral	I-cell_type
blood	I-cell_type
mononuclear	I-cell_type
cell	I-cell_type
(	O
PBMC	B-cell_type
)	O
responses	O
to	O
lipopolysaccharide	O
(	O
LPS	O
)	O
,	O
Cryptococcus	O
neoformans	O
,	O
and	O
Candida	O
albicans	O
.	O

IL-10	B-protein
effected	O
dose-dependent	O
inhibition	O
of	O
tumor	B-protein
necrosis	I-protein
factor	I-protein
alpha	I-protein
(	O
TNF-alpha	B-protein
)	O
release	O
in	O
PBMC	B-cell_type
stimulated	O
by	O
LPS	O
and	O
C.	O
neoformans	O
,	O
with	O
significant	O
inhibition	O
seen	O
with	O
0.1	O
U/ml	O
and	O
greater	O
than	O
90	O
%	O
inhibition	O
noted	O
with	O
10	O
U/ml	O
.	O

In	O
contrast	O
,	O
even	O
at	O
doses	O
as	O
high	O
as	O
100	O
U/ml	O
,	O
IL-10	B-protein
inhibited	O
TNF-alpha	B-protein
release	O
in	O
response	O
to	O
C.	O
albicans	O
by	O
only	O
50	O
%	O
.	O

IL-10	B-protein
profoundly	O
inhibited	O
release	O
of	O
IL-1beta	B-protein
from	O
PBMC	B-cell_type
stimulated	O
by	O
all	O
three	O
stimuli	O
.	O

TNF-alpha	B-RNA
mRNA	I-RNA
and	O
release	O
was	O
inhibited	O
even	O
if	O
IL-10	B-protein
was	O
added	O
up	O
to	O
8	O
h	O
after	O
cryptococcal	O
stimulation	O
.	O

In	O
contrast	O
,	O
inhibition	O
of	O
IL-1	B-RNA
beta	I-RNA
mRNA	I-RNA
was	O
of	O
lesser	O
magnitude	O
and	O
occurred	O
only	O
when	O
IL-10	B-protein
was	O
added	O
within	O
2	O
h	O
of	O
cryptococcal	O
stimulation	O
.	O

IL-10	B-protein
inhibited	O
translocation	O
of	O
NF-kappaB	B-protein
in	O
response	O
to	O
LPS	O
but	O
not	O
the	O
fungal	O
stimuli	O
.	O

All	O
three	O
stimuli	O
induced	O
IL-10	B-protein
production	O
in	O
PBMC	B-cell_type
,	O
although	O
over	O
10-fold	O
less	O
IL-10	B-protein
was	O
released	O
in	O
response	O
to	O
C.	O
neoformans	O
compared	O
with	O
LPS	O
and	O
C.	O
albicans	O
.	O

Thus	O
,	O
while	O
IL-10	B-protein
has	O
deactivating	O
effects	O
on	O
PBMC	B-cell_type
responses	O
to	O
all	O
three	O
stimuli	O
,	O
disparate	O
stimulus-	O
and	O
response-specific	O
patterns	O
of	O
deactivation	O
are	O
seen	O
.	O

Inhibition	O
by	O
IL-10	B-protein
of	O
proinflammatory	B-protein
cytokine	I-protein
release	O
appears	O
to	O
occur	O
at	O
the	O
level	O
of	O
gene	O
transcription	O
for	O
TNF-alpha	B-protein
and	O
both	O
transcriptionally	O
and	O
posttranscriptionally	O
for	O
IL-1beta	B-protein
.	O

Characterization	O
and	O
purification	O
of	O
a	O
protein	B-protein
kinase	I-protein
C	I-protein
substrate	I-protein
in	O
human	B-cell_type
B	I-cell_type
cells	I-cell_type
.	O

Identification	O
as	O
lymphocyte-specific	B-protein
protein	I-protein
1	I-protein
(	O
LSP1	B-protein
)	O
.	O

Incubation	O
of	O
B-chronic	B-cell_line
lymphocytic	I-cell_line
leukemia	I-cell_line
(	I-cell_line
B-CLL	I-cell_line
)	I-cell_line
cells	I-cell_line
with	O
phorbol	O
esters	O
resulted	O
in	O
the	O
phosphorylation	O
of	O
two	O
major	O
PKC	B-protein
substrates	I-protein
,	O
MARCKS	B-protein
(	O
myristoylated	B-protein
,	I-protein
alanine-rich	I-protein
C	I-protein
kinase	I-protein
substrate	I-protein
)	O
and	O
MRP	B-protein
(	O
MARCKS-related	B-protein
protein	I-protein
)	O
,	O
and	O
of	O
a	O
third	O
protein	O
,	O
with	O
an	O
apparent	O
m.w.	O
of	O
60	O
,	O
000	O
that	O
was	O
the	O
most	O
prominent	O
protein	B-protein
kinase	I-protein
C	I-protein
substrate	I-protein
in	O
these	O
cells	O
.	O

p60	B-protein
phosphorylation	O
was	O
time	O
and	O
PMA	O
dose	O
dependent	O
,	O
and	O
was	O
induced	O
by	O
cell-permeable	O
diacylglycerol	O
,	O
but	O
not	O
by	O
inactive	O
phorbol	O
esters	O
.	O

Two-dimensional	O
electrophoretic	O
analysis	O
of	O
the	O
protein	O
phosphorylation	O
pattern	O
from	O
the	O
B	B-cell_line
cell	I-cell_line
line	I-cell_line
CESS	I-cell_line
demonstrated	O
the	O
identity	O
between	O
the	O
p60	B-protein
protein	I-protein
expressed	O
in	O
this	O
cell	O
line	O
and	O
that	O
expressed	O
in	O
B-CLL	B-cell_line
cells	I-cell_line
.	O

p60	B-protein
was	O
purified	O
from	O
CESS	B-cell_line
cells	I-cell_line
and	O
peptide	O
microsequencing	O
of	O
this	O
protein	O
revealed	O
that	O
it	O
was	O
lymphocyte-specific	B-protein
protein	I-protein
1	I-protein
(	O
LSP1	B-protein
)	O
,	O
that	O
is	O
here	O
characterized	O
as	O
the	O
most	O
prominent	O
protein	B-protein
kinase	I-protein
C	I-protein
substrate	I-protein
in	O
B	B-cell_type
cells	I-cell_type
.	O

Transcription	B-protein
factors	I-protein
of	O
T	B-cell_type
and	I-cell_type
B	I-cell_type
lymphocytes	I-cell_type
--	O
basic	O
research	O
and	O
clinical	O
perspectives	O
for	O
gastroenterology	O
.	O

Tissue	O
specific	O
regulation	O
of	O
gene	O
expression	O
by	O
transcription	B-protein
factors	I-protein
is	O
a	O
fascinating	O
new	O
field	O
in	O
molecular	O
immunology	O
.	O

This	O
review	O
summarizes	O
data	O
on	O
specific	O
regulation	O
of	O
promoters	B-DNA
and	O
enhancers	B-DNA
by	O
nuclear	B-protein
trans-acting	I-protein
factors	I-protein
in	O
lymphocytes	B-cell_type
.	O

The	O
structural	O
classes	O
of	O
transcription	B-protein
factors	I-protein
are	O
described	O
and	O
basic	O
methods	O
for	O
detection	O
and	O
analysis	O
of	O
transcription	B-protein
factors	I-protein
are	O
detailed	O
.	O

Furthermore	O
,	O
the	O
most	O
important	O
trans-acting	B-protein
factors	I-protein
of	O
T	B-cell_type
and	I-cell_type
B	I-cell_type
lymphocytes	I-cell_type
(	O
e.g	O
.	O
NF-kB	B-protein
,	O
NF-AT	B-protein
and	O
STAT	B-protein
families	I-protein
)	O
and	O
their	O
functional	O
importance	O
are	O
described	O
.	O

Several	O
methods	O
for	O
specific	O
down-regulation	O
of	O
transcription	B-protein
factors	I-protein
are	O
shown	O
that	O
may	O
be	O
relevant	O
to	O
treatment	O
of	O
human	O
disease	O
.	O

The	O
data	O
are	O
discussed	O
with	O
regard	O
to	O
their	O
potential	O
clinical	O
relevance	O
for	O
gastroenterology	O
.	O

Selective	O
effects	O
of	O
DNA	O
damaging	O
agents	O
on	O
HIV	B-DNA
long	I-DNA
terminal	I-DNA
repeat	I-DNA
activation	O
and	O
virus	O
replication	O
in	O
vitro	O
.	O

Much	O
attention	O
has	O
recently	O
focused	O
on	O
the	O
observation	O
that	O
UV	O
light	O
can	O
activate	O
the	O
long	B-DNA
terminal	I-DNA
repeat	I-DNA
(	O
LTR	B-DNA
)	O
of	O
the	O
human	O
immunodeficiency	O
virus	O
(	O
HIV	O
)	O
.	O

Although	O
the	O
mechanism	O
of	O
LTR	B-DNA
activation	O
remains	O
obscure	O
,	O
several	O
lines	O
of	O
investigation	O
have	O
suggested	O
that	O
it	O
is	O
a	O
result	O
of	O
activation	O
of	O
the	O
NF-kappa	B-protein
B	I-protein
transcription	B-protein
factor	I-protein
(	O
s	O
)	O
following	O
signaling	O
events	O
related	O
to	O
generalized	O
DNA	O
damage	O
.	O

In	O
this	O
report	O
,	O
we	O
present	O
data	O
demonstrating	O
that	O
HIV	O
LTR	B-DNA
activation	O
is	O
not	O
a	O
general	O
consequence	O
of	O
cellular	B-DNA
DNA	I-DNA
damage	O
,	O
but	O
rather	O
a	O
process	O
unique	O
to	O
specific	O
genotoxic	O
stimuli	O
,	O
and	O
that	O
it	O
does	O
not	O
necessarily	O
depend	O
on	O
activation	O
of	O
NF-kappa	B-protein
B	I-protein
.	O

Furthermore	O
,	O
we	O
demonstrate	O
that	O
several	O
of	O
these	O
agents	O
can	O
significantly	O
increase	O
HIV	O
replication	O
and	O
accelerate	O
CD4	B-protein
-positive	O
lymphocyte	O
cytotoxicity	O
in	O
vitro	O
.	O

These	O
findings	O
,	O
therefore	O
,	O
could	O
have	O
clinical	O
significance	O
to	O
AIDS	O
patients	O
with	O
malignancies	O
who	O
are	O
undergoing	O
radiotherapy	O
and	O
chemotherapy	O
.	O

Receptors	O
for	O
interleukin	B-protein
(	I-protein
IL	I-protein
)	I-protein
-10	I-protein
and	I-protein
IL-6-type	I-protein
cytokines	I-protein
use	O
similar	O
signaling	O
mechanisms	O
for	O
inducing	O
transcription	O
through	O
IL-6	B-DNA
response	I-DNA
elements	I-DNA
.	O

The	O
cytoplasmic	B-protein
domain	I-protein
of	O
the	O
receptor	O
for	O
interleukin	B-protein
10	I-protein
(	O
IL-10R	B-protein
)	O
contains	O
two	O
box	B-protein
3	I-protein
sequence	I-protein
motifs	I-protein
that	O
have	O
been	O
identified	O
in	O
the	O
signal-transducing	B-protein
receptor	I-protein
subunits	I-protein
for	O
IL-6-type	B-protein
cytokines	I-protein
and	O
noted	O
to	O
be	O
required	O
for	O
activating	O
STAT3	B-protein
and	O
inducing	O
transcription	O
through	O
IL-6-responsive	B-DNA
elements	I-DNA
.	O

To	O
determine	O
whether	O
the	O
IL-10R	B-protein
has	O
signaling	O
functions	O
similar	O
to	O
IL-6R	B-protein
in	O
cells	O
normally	O
expressing	O
these	O
receptors	O
,	O
leukocytes	B-cell_type
of	O
the	O
B-	B-cell_type
,	I-cell_type
T-	I-cell_type
,	I-cell_type
and	I-cell_type
NK-cell	I-cell_type
lineages	I-cell_type
were	O
treated	O
with	O
either	O
cytokine	O
.	O

Both	O
cytokines	B-protein
activated	O
factors	O
that	O
bound	O
to	O
the	O
sis-inducible	B-DNA
element	I-DNA
and	O
included	O
STAT1	B-protein
and	O
STAT3	B-protein
.	O

The	O
cell	O
response	O
to	O
IL-10	B-protein
characteristically	O
differed	O
from	O
that	O
to	O
IL-2/IL-15	B-protein
,	O
IL-4	B-protein
,	O
and	O
interferon	B-protein
gamma	I-protein
.	O

The	O
signaling	O
capabilities	O
of	O
the	O
IL-10R	B-protein
for	O
activating	O
specific	O
STAT	B-protein
proteins	I-protein
and	O
inducing	O
gene	O
transcription	O
were	O
defined	O
by	O
reconstitution	O
of	O
receptor	O
functions	O
in	O
transfected	B-cell_line
tissue	I-cell_line
culture	I-cell_line
cells	I-cell_line
.	O

COS-1	B-cell_line
cells	I-cell_line
,	O
co-expressing	O
the	O
human	O
IL-10R	B-protein
and	O
individual	O
STAT	B-protein
proteins	I-protein
,	O
confirmed	O
a	O
preference	O
of	O
the	O
IL-10R	B-protein
for	O
STAT3	B-protein
and	O
STAT1	B-protein
.	O

Unlike	O
many	O
hematopoietin	B-protein
receptors	I-protein
,	O
the	O
IL-10R	B-protein
did	O
not	O
detectably	O
activate	O
STAT5	B-protein
.	O

The	O
IL-10R	B-protein
,	O
together	O
with	O
reporter	O
gene	O
constructs	O
containing	O
different	O
IL-6-responsive	B-DNA
gene	I-DNA
elements	I-DNA
,	O
reconstituted	O
in	O
hepatoma	B-cell_type
cells	I-cell_type
an	O
induction	O
of	O
transcription	O
by	O
IL-10	B-protein
that	O
was	O
comparable	O
to	O
that	O
by	O
IL-6	B-protein
.	O

This	O
regulation	O
could	O
not	O
be	O
appreciably	O
modified	O
by	O
enhanced	O
expression	O
of	O
STAT	B-protein
proteins	I-protein
.	O

The	O
similar	O
actions	O
of	O
IL-10R	B-protein
and	O
IL-6R	B-protein
on	O
the	O
induction	O
of	O
endogenous	O
IL-6-responsive	B-DNA
genes	I-DNA
were	O
demonstrated	O
in	O
hepatoma	B-cell_type
cells	I-cell_type
stably	O
expressing	O
the	O
IL-10R	B-protein
.	O

These	O
receptor	O
functions	O
required	O
the	O
presence	O
of	O
the	O
box	B-protein
3	I-protein
motifs	I-protein
,	O
as	O
shown	O
by	O
the	O
analysis	O
of	O
the	O
mouse	O
IL-10R	B-protein
constructs	O
containing	O
progressively	B-protein
truncated	I-protein
cytoplasmic	I-protein
domains	I-protein
.	O

The	O
data	O
demonstrate	O
that	O
the	O
IL-10R	B-protein
,	O
unlike	O
other	O
members	O
of	O
the	O
interferon	O
receptor	O
family	O
,	O
is	O
highly	O
effective	O
in	O
recruiting	O
the	O
signaling	O
pathways	O
of	O
IL-6-type	B-protein
cytokine	I-protein
receptors	I-protein
.	O

Induction	O
of	O
CIITA	B-protein
and	O
modification	O
of	O
in	O
vivo	O
HLA-DR	B-DNA
promoter	I-DNA
occupancy	O
in	O
normal	B-cell_type
thymic	I-cell_type
epithelial	I-cell_type
cells	I-cell_type
treated	O
with	O
IFN-gamma	B-protein
:	O
similarities	O
and	O
distinctions	O
with	O
respect	O
to	O
HLA-DR-constitutive	B-cell_type
B	I-cell_type
cells	I-cell_type
.	O

In	O
this	O
study	O
,	O
the	O
IFN-gamma	B-protein
induction	O
of	O
MHC	B-DNA
class	I-DNA
II	I-DNA
gene	I-DNA
expression	O
in	O
primary	O
cultures	O
of	O
thymic	B-cell_line
epithelial	I-cell_line
cells	I-cell_line
(	O
TEC	B-cell_line
)	O
was	O
analyzed	O
.	O

This	O
cellular	O
system	O
offers	O
the	O
advantage	O
that	O
MHC	B-protein
class	I-protein
II	I-protein
induction	O
is	O
studied	O
in	O
a	O
``	B-cell_type
physiologic	I-cell_type
''	I-cell_type
cell	I-cell_type
lineage	I-cell_type
that	O
,	O
as	O
a	O
result	O
of	O
this	O
expression	O
within	O
the	O
thymus	O
,	O
is	O
thought	O
to	O
participate	O
to	O
the	O
selection	O
and	O
maturation	O
of	O
the	O
T	B-cell_type
cells	I-cell_type
.	O

It	O
was	O
found	O
that	O
the	O
MHC	B-DNA
class	I-DNA
II	I-DNA
gene	I-DNA
expression	O
was	O
associated	O
with	O
the	O
de	O
novo	O
transcription	O
of	O
the	O
gene	O
encoding	O
the	O
CIITA	B-protein
trans-activator	I-protein
,	O
a	O
crucial	O
MHC	B-protein
class	I-protein
II	I-protein
gene	I-protein
regulatory	I-protein
factor	I-protein
.	O

Furthermore	O
,	O
the	O
anatomy	O
of	O
interaction	O
between	O
the	O
MHC	B-DNA
class	I-DNA
II	I-DNA
DRA	I-DNA
promoter	I-DNA
and	O
corresponding	O
binding	B-protein
factors	I-protein
was	O
analyzed	O
by	O
in	O
vivo	O
DNAse	B-protein
I	I-protein
footprint	O
.	O

It	O
was	O
found	O
that	O
treatment	O
with	O
IFN-gamma	B-protein
induces	O
changes	O
in	O
the	O
occupancy	O
of	O
the	O
DRA	B-DNA
gene	I-DNA
regulatory	I-DNA
sequences	I-DNA
by	O
nuclear	B-protein
factors	I-protein
.	O

The	O
resulting	O
occupancy	O
displays	O
strong	O
similarities	O
with	O
the	O
one	O
observed	O
in	O
the	O
MHC	B-cell_type
class	I-cell_type
II-constitutive	I-cell_type
B	I-cell_type
cells	I-cell_type
,	O
represented	O
by	O
both	O
the	O
Burkitt	B-cell_line
lymphoma	I-cell_line
line	I-cell_line
Raji	I-cell_line
and	O
normal	B-cell_type
tonsil-	I-cell_type
derived	I-cell_type
B	I-cell_type
cells	I-cell_type
.	O

However	O
,	O
some	O
peculiar	O
differences	O
were	O
observed	O
between	O
the	O
TEC	B-cell_line
,	O
either	O
IFN-gamma	B-protein
-induced	O
or	O
not	O
,	O
and	O
the	O
constitutive	O
B	B-cell_line
cells	I-cell_line
.	O

These	O
results	O
suggest	O
that	O
both	O
common	O
mechanisms	O
,	O
such	O
as	O
the	O
one	O
mediated	O
by	O
the	O
CIITA	B-protein
trans-activator	I-protein
,	O
and	O
distinct	O
tissue-specific	O
constraints	O
contribute	O
to	O
the	O
transcriptional	O
control	O
of	O
constitutive	O
and	O
IFN-gamma	B-protein
-induced	O
MHC	B-DNA
class	I-DNA
II	I-DNA
gene	I-DNA
expression	O
.	O

Inhibitory	O
effect	O
of	O
E3330	O
,	O
a	O
novel	O
quinone	O
derivative	O
able	O
to	O
suppress	O
tumor	B-protein
necrosis	I-protein
factor-alpha	I-protein
generation	O
,	O
on	O
activation	O
of	O
nuclear	B-protein
factor-kappa	I-protein
B	I-protein
.	O

(	O
2E	O
)	O
-3-	O
[	O
5-	O
(	O
2	O
,	O
3-Dimethoxy-6-methyl-1	O
,	O
4-benzoquinoyl	O
)	O
]	O
-2-nonyl-2-	O
propenoic	O
acid	O
(	O
E3330	O
)	O
,	O
is	O
a	O
novel	O
agent	O
with	O
hepatoprotective	O
activity	O
.	O

We	O
report	O
the	O
effect	O
of	O
E3330	O
on	O
transcriptional	O
activation	O
of	O
tumor	B-DNA
necrosis	I-DNA
factor	I-DNA
(	I-DNA
TNF	I-DNA
)	I-DNA
-alpha	I-DNA
gene	I-DNA
and	O
on	O
nuclear	B-protein
factor	I-protein
(	I-protein
NF	I-protein
)	I-protein
-kappa	I-protein
B	I-protein
activation	O
.	O

Nuclear	O
run-on	O
experiments	O
showed	O
that	O
E3330	O
decreases	O
transcriptional	O
activation	O
of	O
TNF-alpha	B-DNA
gene	I-DNA
induced	O
by	O
lipopolysaccharide	O
(	O
LPS	O
)	O
stimulation	O
in	O
human	B-cell_type
peripheral	I-cell_type
monocytes	I-cell_type
.	O

To	O
investigate	O
the	O
inhibitory	O
mechanisms	O
,	O
we	O
constructed	O
a	O
secreted-type	B-DNA
placental	I-DNA
alkaline	I-DNA
phosphatase	I-DNA
(	I-DNA
PLAP	I-DNA
)	I-DNA
reporter	I-DNA
gene	I-DNA
whose	O
transcription	O
is	O
controlled	O
by	O
a	O
1.4-kb	B-DNA
human	I-DNA
TNF-alpha	I-DNA
promoter	I-DNA
.	O

A	O
stable	O
transformant	O
of	O
the	O
PLAP	B-DNA
reporter	I-DNA
gene	I-DNA
derived	O
from	O
human	B-cell_line
monocytic	I-cell_line
cell	I-cell_line
line	I-cell_line
showed	O
very	O
little	O
activity	O
on	O
the	O
promoter	O
before	O
stimulation	O
,	O
whereas	O
LPS	O
stimulation	O
led	O
to	O
a	O
dramatic	O
increase	O
in	O
PLAP	B-protein
activity	O
.	O

E3330	O
inhibited	O
this	O
induced	O
promoter	O
activity	O
in	O
a	O
dose-dependent	O
manner	O
.	O

There	O
are	O
four	O
putative	O
NF-kappa	B-DNA
B	I-DNA
binding	I-DNA
sites	I-DNA
(	O
kappa	B-DNA
B-1	I-DNA
,	O
kappa	B-DNA
B-2	I-DNA
,	O
kappa	B-DNA
B-3	I-DNA
,	O
kappa	B-DNA
B-4	I-DNA
)	O
in	O
human	B-DNA
TNF-alpha	I-DNA
promoter	I-DNA
.	O

By	O
using	O
mutated	B-DNA
promoter-PLAP	I-DNA
plasmids	I-DNA
,	O
we	O
established	O
that	O
these	O
NF-kappa	B-DNA
B	I-DNA
sites	I-DNA
were	O
necessary	O
for	O
induction	O
of	O
TNF-alpha	B-protein
transcription	O
on	O
stimulation	O
with	O
LPS	O
.	O

A	O
gel	O
retardation	O
experiment	O
with	O
synthetic	O
double-stranded	O
oligonucleotides	O
showed	O
that	O
activated	O
NF-kappa	B-protein
B	I-protein
consisting	O
of	O
p50/p65	B-protein
heterodimer	I-protein
bound	O
to	O
all	O
four	O
putative	O
NF-kappa	B-DNA
B	I-DNA
DNA	I-DNA
probes	I-DNA
,	O
suggesting	O
that	O
all	O
four	O
putative	O
NF-kappa	B-DNA
B	I-DNA
recognition	I-DNA
sites	I-DNA
play	O
an	O
important	O
role	O
in	O
inducible	O
TNF-alpha	B-protein
expression	O
.	O

E3330	O
decreased	O
activated	O
NF-kappa	B-protein
B	I-protein
in	O
nuclei	O
,	O
suggesting	O
that	O
E3330	O
inhibits	O
NF-kappa	B-protein
B	I-protein
activation	O
and/or	O
translocation	O
of	O
the	O
nuclei	O
.	O

Western	O
blotting	O
analysis	O
with	O
anti-I	B-protein
kappa	I-protein
B-alpha	I-protein
antibody	I-protein
indicated	O
that	O
E3330	O
inhibited	O
degradation	O
of	O
I	B-protein
kappa	I-protein
B-alpha	I-protein
,	O
which	O
is	O
an	O
inhibitory	B-protein
protein	I-protein
of	O
NF-kappa	B-protein
B	I-protein
,	O
in	O
LPS-stimulated	B-cell_line
monocytes	I-cell_line
.	O

E3330	O
may	O
suppress	O
the	O
production	O
of	O
active	O
oxygen	O
species	O
serving	O
as	O
common	O
messengers	O
to	O
activate	O
NF-kappa	B-protein
B	I-protein
.	O

C-terminal	B-protein
activating	I-protein
and	I-protein
inhibitory	I-protein
domains	I-protein
determine	O
the	O
transactivation	O
potential	O
of	O
BSAP	B-protein
(	O
Pax-5	B-DNA
)	O
,	O
Pax-2	B-DNA
and	O
Pax-8	B-DNA
.	O

Pax-5	B-DNA
encodes	O
the	O
transcription	B-protein
factor	I-protein
BSAP	B-protein
which	O
plays	O
an	O
essential	O
role	O
in	O
early	O
B	O
cell	O
development	O
and	O
midbrain	O
patterning	O
.	O

In	O
this	O
study	O
we	O
have	O
analysed	O
the	O
structural	O
requirements	O
for	O
transcriptional	O
activation	O
by	O
BSAP	B-protein
.	O

In	O
vitro	O
mutagenesis	O
and	O
transient	O
transfection	O
experiments	O
indicate	O
that	O
the	O
C-terminal	B-protein
serine/threonine/proline-rich	I-protein
region	I-protein
of	O
BSAP	B-protein
contains	O
a	O
potent	O
transactivation	B-protein
domain	I-protein
of	O
55	O
amino	O
acids	O
which	O
is	O
active	O
from	O
promoter	B-DNA
and	I-DNA
enhancer	I-DNA
positions	I-DNA
.	O

This	O
transactivation	B-protein
domain	I-protein
was	O
found	O
to	O
be	O
inactivated	O
by	O
a	O
naturally	O
occurring	O
frameshift	O
mutation	O
in	O
one	O
PAX-5	B-DNA
allele	I-DNA
of	O
the	O
acute	B-cell_line
lymphoblastic	I-cell_line
leukemia	I-cell_line
cell	I-cell_line
line	I-cell_line
REH	I-cell_line
.	O

The	O
function	O
of	O
the	O
transactivation	B-protein
domain	I-protein
is	O
negatively	O
regulated	O
by	O
adjacent	O
sequences	O
from	O
the	O
extreme	B-protein
C-terminus	I-protein
.	O

The	O
activating	O
and	O
inhibitory	O
domains	O
function	O
together	O
as	O
an	O
independent	O
regulatory	O
module	O
in	O
different	O
cell	O
types	O
as	O
shown	O
by	O
fusion	O
to	O
the	O
GAL4	B-protein
DNA	I-protein
binding	I-protein
domain	I-protein
.	O

The	O
same	O
arrangement	O
of	O
positively	B-DNA
and	I-DNA
negatively	I-DNA
acting	I-DNA
sequences	I-DNA
has	O
been	O
conserved	O
in	O
the	O
mammalian	B-DNA
Pax-2	I-DNA
and	O
Pax-8	B-DNA
,	O
the	O
zebrafish	B-DNA
Pax-b	I-DNA
as	O
well	O
as	O
the	O
sea	B-protein
urchin	I-protein
Pax-258	I-protein
proteins	I-protein
.	O

These	O
data	O
demonstrate	O
that	O
the	O
transcriptional	O
competence	O
of	O
a	O
subfamily	O
of	O
Pax	B-protein
proteins	I-protein
is	O
determined	O
by	O
a	O
C-terminal	B-protein
regulatory	I-protein
module	I-protein
composed	O
of	O
activating	B-DNA
and	I-DNA
inhibitory	I-DNA
sequences	I-DNA
.	O

Second	O
messenger	O
up-regulation	O
of	O
androgen	B-DNA
receptor	I-DNA
gene	I-DNA
transcription	O
is	O
absent	O
in	O
androgen	B-cell_line
insensitive	I-cell_line
human	I-cell_line
prostatic	I-cell_line
carcinoma	I-cell_line
cell	I-cell_line
lines	I-cell_line
,	O
PC-3	B-cell_line
and	O
DU-145	B-cell_line
.	O

A	O
theoretical	O
pathway	O
of	O
transcriptional	O
regulation	O
of	O
the	O
androgen	B-DNA
receptor	I-DNA
(	I-DNA
AR	I-DNA
)	I-DNA
gene	I-DNA
is	O
via	O
a	O
cAMP	B-DNA
response	I-DNA
element	I-DNA
(	O
CRE	B-DNA
)	O
present	O
in	O
its	O
promoter	B-DNA
region	I-DNA
(	O
-508	O
to	O
-501	O
)	O
.	O

After	O
20	O
h	O
of	O
stimulation	O
with	O
8-bromo-cAMP	O
,	O
AR	B-RNA
mRNA	I-RNA
was	O
upregulated	O
in	O
LNCaP	B-cell_line
but	O
not	O
in	O
either	O
PC-3	B-cell_line
or	O
DU-145	B-cell_line
cell	I-cell_line
lines	I-cell_line
.	O

We	O
have	O
demonstrated	O
that	O
the	O
level	O
of	O
CRE	B-protein
binding	I-protein
protein	I-protein
(	O
CREB	B-protein
)	O
was	O
the	O
same	O
in	O
all	O
cell	O
lines	O
and	O
that	O
the	O
putative	O
AR-CRE	B-protein
forms	O
specific	O
and	O
compatible	O
protein	O
interactions	O
with	O
CREB	B-protein
.	O

The	O
ability	O
to	O
regulate	O
AR	B-DNA
gene	I-DNA
transcription	O
via	O
the	O
second	O
messenger	O
pathway	O
is	O
lost	O
in	O
the	O
PC-3	B-cell_line
and	I-cell_line
DU-145	I-cell_line
cell	I-cell_line
lines	I-cell_line
.	O

This	O
may	O
be	O
an	O
important	O
primary	O
mechanism	O
of	O
androgen	O
insensitivity	O
in	O
prostate	O
cancer	O
.	O

Structural	O
and	O
functional	O
characterization	O
of	O
the	O
human	B-DNA
CD36	I-DNA
gene	I-DNA
promoter	I-DNA
:	O
identification	O
of	O
a	O
proximal	O
PEBP2/CBF	B-DNA
site	I-DNA
.	O

CD36	B-protein
is	O
a	O
cell	O
surface	O
glycoprotein	B-protein
composed	O
of	O
a	O
single	O
polypeptide	O
chain	O
,	O
which	O
interacts	O
with	O
thrombospondin	B-protein
,	O
collagens	B-protein
type	I-protein
I	I-protein
and	I-protein
IV	I-protein
,	O
oxidized	O
low	B-protein
density	I-protein
lipoprotein	I-protein
,	O
fatty	O
acids	O
,	O
anionic	O
phospholipids	O
,	O
and	O
erythrocytes	B-cell_type
parasitized	O
with	O
Plasmodium	O
falciparum	O
.	O

Its	O
expression	O
is	O
restricted	O
to	O
a	O
few	O
cell	O
types	O
,	O
including	O
monocyte/macrophages	B-cell_type
.	O

In	O
these	O
cells	O
,	O
CD36	B-protein
is	O
involved	O
in	O
phagocytosis	O
of	O
apoptotic	B-cell_type
cells	I-cell_type
,	O
and	O
foam	O
cell	O
formation	O
by	O
uptake	O
of	O
oxidized	B-protein
low	I-protein
density	I-protein
lipoprotein	I-protein
.	O

To	O
study	O
the	O
molecular	O
mechanisms	O
that	O
control	O
the	O
transcription	O
of	O
the	O
CD36	B-protein
gene	O
in	O
monocytic	O
cells	O
we	O
have	O
isolated	O
and	O
analyzed	O
the	O
CD36	B-DNA
promoter	I-DNA
.	O

Transient	O
expression	O
experiments	O
of	O
5'-deletion	B-DNA
fragments	I-DNA
of	O
the	O
CD36	B-DNA
promoter	I-DNA
coupled	O
to	O
luciferase	B-protein
demonstrated	O
that	O
as	O
few	O
as	O
158	B-DNA
base	I-DNA
pairs	I-DNA
upstream	I-DNA
from	O
the	O
transcription	B-DNA
initiation	I-DNA
site	I-DNA
were	O
sufficient	O
to	O
direct	O
the	O
monocyte-specific	O
transcription	O
of	O
the	O
reporter	B-DNA
gene	I-DNA
.	O

Within	O
the	O
above	O
region	O
,	O
the	O
fragment	O
spanning	O
nucleotides	B-DNA
-158	I-DNA
to	I-DNA
-90	I-DNA
was	O
required	O
for	O
optimal	O
transcription	O
in	O
monocytic	B-cell_type
cells	I-cell_type
.	O

Biochemical	O
analysis	O
of	O
the	O
region	O
-158/-90	B-DNA
revealed	O
a	O
binding	O
site	O
for	O
transcription	B-protein
factors	I-protein
of	O
the	O
polyomavirus	B-protein
enhancer-binding	I-protein
protein	I-protein
2/core-binding	I-protein
factor	I-protein
(	I-protein
PEBP2/CBF	I-protein
)	I-protein
family	I-protein
at	O
position	B-DNA
-103	I-DNA
.	O

Disruption	O
of	O
the	O
PEBP2/CBF	B-DNA
site	I-DNA
markedly	O
diminished	O
the	O
role	O
of	O
the	O
PEBP2/CBF	B-protein
factors	I-protein
in	O
the	O
constitutive	O
transcription	O
of	O
the	O
CD36	B-DNA
gene	I-DNA
.	O

The	O
involvement	O
of	O
members	O
of	O
the	O
PEBP2/CBF	B-protein
family	I-protein
in	O
chromosome	O
translocations	O
associated	O
with	O
acute	O
myeloid	O
leukemia	O
,	O
and	O
in	O
the	O
transcriptional	O
regulation	O
of	O
the	O
myeloid-specific	B-DNA
genes	I-DNA
encoding	O
for	O
myeloperoxidase	B-protein
,	O
elastase	B-protein
,	O
and	O
the	O
colony-stimulating	B-protein
factor	I-protein
receptor	I-protein
,	O
highlights	O
the	O
relevance	O
of	O
the	O
regulation	O
of	O
the	O
CD36	B-DNA
gene	I-DNA
promoter	I-DNA
in	O
monocytic	B-cell_type
cells	I-cell_type
by	O
members	O
of	O
the	O
PEBP2/CBF	B-protein
family	I-protein
.	O

HLA-DQB1	B-DNA
codon	I-DNA
57	I-DNA
is	O
critical	O
for	O
peptide	O
binding	O
and	O
recognition	O
.	O

The	O
association	O
of	O
specific	O
HLA-DQ	B-DNA
alleles	I-DNA
with	O
autoimmunity	O
is	O
correlated	O
with	O
discrete	O
polymorphisms	O
in	O
the	O
HLA-DQ	B-DNA
sequence	I-DNA
that	O
are	O
localized	O
within	O
sites	O
suitable	O
for	O
peptide	O
recognition	O
.	O

The	O
polymorphism	O
at	O
residue	O
57	O
of	O
the	O
DQB1	O
polypeptide	O
is	O
of	O
particular	O
interest	O
since	O
it	O
may	O
play	O
a	O
major	O
structural	O
role	O
in	O
the	O
formation	O
of	O
a	O
salt	B-protein
bridge	I-protein
structure	I-protein
at	O
one	O
end	O
of	O
the	O
peptide-binding	B-protein
cleft	I-protein
of	O
the	O
DQ	O
molecules	O
.	O

This	O
polymorphism	O
at	O
residue	O
57	O
is	O
a	O
recurrent	O
feature	O
of	O
HLA-DQ	O
evolution	O
,	O
occurring	O
in	O
multiple	O
distinct	O
allelic	O
families	O
,	O
which	O
implies	O
a	O
functional	O
selection	O
for	O
maintaining	O
variation	O
at	O
this	O
position	O
in	O
the	O
class	B-protein
II	I-protein
molecule	I-protein
.	O

We	O
directly	O
tested	O
the	O
amino	O
acid	O
polymorphism	O
at	O
this	O
site	O
as	O
a	O
determinant	O
for	O
peptide	O
binding	O
and	O
for	O
antigen-specific	O
T	O
cell	O
stimulation	O
.	O

We	O
found	O
that	O
a	O
single	O
Ala	O
--	O
>	O
Asp	O
amino	O
acid	O
57	O
substitution	O
in	O
an	O
HLA-DQ3.2	O
molecule	O
regulated	O
binding	O
of	O
an	O
HSV-2	O
VP-16-derived	O
peptide	O
.	O

A	O
complementary	O
single-residue	O
substitution	O
in	O
the	O
peptide	O
abolished	O
its	O
binding	O
to	O
DQ3.2	O
and	O
converted	O
it	O
to	O
a	O
peptide	O
that	O
can	O
bind	O
to	O
DQ3.1	O
and	O
DQ3.3	B-protein
Asp-57-positive	I-protein
MHC	I-protein
molecules	I-protein
.	O

These	O
binding	O
studies	O
were	O
paralleled	O
by	O
specific	O
T	O
cell	O
recognition	O
of	O
the	O
class	B-protein
II-peptide	I-protein
complex	I-protein
,	O
in	O
which	O
the	O
substituted	O
peptide	O
abolished	O
T	O
cell	O
reactivity	O
,	O
which	O
was	O
directed	O
to	O
the	O
DQ3.2-peptide	B-protein
complex	I-protein
,	O
whereas	O
the	O
same	O
T	B-cell_line
cell	I-cell_line
clone	I-cell_line
recognized	O
the	O
substituted	O
peptide	O
presented	O
by	O
DQ3.3	O
,	O
a	O
class	O
II	O
restriction	O
element	O
differing	O
from	O
DQ3.2	O
only	O
at	O
residue	O
57	O
.	O

This	O
structural	O
and	O
functional	O
complementarity	O
for	O
residue	O
57	O
and	O
a	O
specific	O
peptide	O
residue	O
identifies	O
this	O
interaction	O
as	O
a	O
key	O
controlling	O
determinant	O
of	O
restricted	O
recognition	O
in	O
HLA-DQ-specific	O
immune	O
response	O
.	O

Autocrine	O
activation	O
by	O
interferon-gamma	B-protein
of	O
STAT	B-protein
factors	I-protein
following	O
T	O
cell	O
activation	O
.	O

The	O
activation	O
of	O
T	B-cell_type
cells	I-cell_type
requires	O
engagement	O
of	O
the	O
T	B-protein
cell	I-protein
receptor/CD3	I-protein
complex	I-protein
and	O
co-stimulatory	B-protein
molecules	I-protein
,	O
and	O
results	O
in	O
the	O
triggering	O
of	O
several	O
signaling	O
pathways	O
which	O
lead	O
rapidly	O
to	O
the	O
nuclear	O
translocation	O
of	O
several	O
transcription	B-protein
factors	I-protein
,	O
such	O
as	O
nuclear	B-protein
factor	I-protein
(	I-protein
NF	I-protein
)	I-protein
-kappa	I-protein
B	I-protein
and	O
NF-AT	B-protein
.	O

A	O
result	O
of	O
this	O
activation	O
process	O
is	O
the	O
induction	O
of	O
a	O
number	O
of	O
genes	O
,	O
including	O
those	O
encoding	O
cytokines	B-protein
such	O
as	O
interleukin-2	B-protein
,	O
tumor	B-protein
necrosis	I-protein
factor-alpha	I-protein
,	O
and	O
interferon	B-protein
(	I-protein
IFN	I-protein
)	I-protein
-gamma	I-protein
which	O
have	O
important	O
immunoregulatory	B-protein
effects	O
.	O

We	O
report	O
here	O
that	O
a	O
DNA-binding	B-protein
factor	I-protein
containing	O
STAT1	B-protein
also	O
becomes	O
activated	O
in	O
human	B-cell_type
peripheral	I-cell_type
blood	I-cell_type
T	I-cell_type
lymphocytes	I-cell_type
or	O
Jurkat	B-cell_line
cells	I-cell_line
,	O
although	O
not	O
until	O
1-2	O
h	O
after	O
stimulation	O
.	O

Activation	O
is	O
delayed	O
a	O
further	O
1-2	O
hr	O
when	O
mononuclear	B-cell_line
cell	I-cell_line
cultures	I-cell_line
are	O
stimulated	O
by	O
an	O
antigen	O
which	O
requires	O
processing	O
.	O

Appearance	O
of	O
the	O
STAT1	B-protein
factor	O
is	O
significantly	O
reduced	O
in	O
the	O
presence	O
of	O
cyclosporin	O
A	O
,	O
and	O
blocked	O
by	O
cycloheximide	O
,	O
indicating	O
that	O
its	O
activation	O
is	O
dependent	O
upon	O
a	O
protein	O
(	O
s	O
)	O
synthesized	O
in	O
response	O
to	O
initial	O
signaling	O
events	O
.	O

Neutralizing	O
antiserum	O
against	O
IFN-gamma	B-protein
,	O
but	O
not	O
other	O
cytokines	B-protein
tested	O
,	O
blocked	O
activation	O
of	O
the	O
factor	O
almost	O
completely	O
,	O
and	O
IFN-gamma	B-protein
was	O
found	O
in	O
the	O
culture	O
supernatants	O
of	O
stimulated	B-cell_line
cells	I-cell_line
at	O
levels	O
at	O
which	O
recombinant	O
IFN-gamma	B-protein
could	O
activate	O
the	O
factor	O
in	O
naive	B-cell_type
cells	I-cell_type
.	O

Therefore	O
,	O
a	O
STAT1	B-protein
transcription	B-protein
factor	I-protein
is	O
activated	O
by	O
IFN-gamma	B-protein
synthesized	O
and	O
released	O
upon	O
stimulation	O
of	O
T	B-cell_type
lymphocyte	I-cell_type
populations	I-cell_type
.	O

While	O
Jurkat	B-cell_line
cells	I-cell_line
both	O
secrete	O
and	O
respond	O
to	O
IFN-gamma	B-protein
in	O
an	O
autocrine	O
loop	O
,	O
it	O
seems	O
likely	O
that	O
the	O
responding	O
cells	O
may	O
differ	O
from	O
those	O
synthesizing	O
this	O
cytokine	B-protein
in	O
the	O
mononuclear	B-cell_line
cell	I-cell_line
cultures	I-cell_line
in	O
the	O
light	O
of	O
the	O
recent	O
report	O
that	O
Th1	B-cell_line
cells	I-cell_line
lack	O
the	O
IFN-gamma	B-protein
receptor	O
chain	O
necessary	O
for	O
activation	O
of	O
STAT1	B-protein
(	O
Pernis	O
,	O
A.	O
,	O
Gupta	O
,	O
S.	O
,	O
Gollob	O
,	O
K.J.	O
,	O
Garfein	O
,	O
E.	O
,	O
Coffman	O
,	O
R.L.	O
,	O
Schindler	O
,	O
C.	O
,	O
and	O
Rothman	O
,	O
P.	O
,	O
Science	O
1995.	O
269	O
:	O
245	O
)	O
.	O

Absence	O
of	O
T-cell-	B-protein
and	I-protein
B-cell-specific	I-protein
transcription	I-protein
factors	I-protein
TCF-1	B-protein
,	O
GATA-3	B-protein
,	O
and	O
BSAP	B-protein
in	O
Hodgkin	B-cell_line
's	I-cell_line
Reed-Sternberg	I-cell_line
cells	I-cell_line
.	O

Based	O
on	O
the	O
presence	O
of	O
T	B-DNA
cell	I-DNA
receptor-beta	I-DNA
(	I-DNA
TcR-beta	I-DNA
)	I-DNA
gene	I-DNA
rearrangements	I-DNA
in	O
L428	B-cell_line
and	I-cell_line
HDLM-1	I-cell_line
cells	I-cell_line
,	O
the	O
expression	O
of	O
CD2	B-protein
in	O
HDLM-1	B-cell_line
cells	I-cell_line
,	O
and	O
the	O
presence	O
of	O
immunoglobulin	B-DNA
heavy-chain	I-DNA
(	I-DNA
IgH	I-DNA
)	I-DNA
gene	I-DNA
rearrangement	I-DNA
in	O
KM-H2	B-cell_line
cells	I-cell_line
,	O
some	O
researchers	O
have	O
concluded	O
that	O
these	O
long-term	B-cell_line
cell	I-cell_line
lines	I-cell_line
derived	O
from	O
patients	O
with	O
Hodgkin	O
's	O
disease	O
are	O
lymphoid	O
in	O
nature	O
.	O

The	O
information	O
obtained	O
from	O
these	O
cell	B-cell_line
lines	I-cell_line
has	O
also	O
been	O
used	O
in	O
arguments	O
for	O
a	O
lymphoid	O
origin	O
of	O
H-RS	B-cell_line
cells	I-cell_line
in	O
tissue	O
despite	O
the	O
frequent	O
absence	O
of	O
lymphoid	B-protein
markers	I-protein
and	O
Ig/TcR	B-DNA
gene	I-DNA
rearrangements	I-DNA
in	O
these	O
cells	O
.	O

We	O
questioned	O
whether	O
one	O
can	O
use	O
the	O
limited	O
expression	O
of	O
lymphoid	B-protein
markers	I-protein
or	O
the	O
limited	O
gene	O
rearrangement	O
to	O
conclude	O
that	O
H-RS	B-cell_line
cells	I-cell_line
have	O
a	O
lymphoid	O
origin	O
,	O
because	O
these	O
markers	O
may	O
be	O
aberrant	O
in	O
tumor	B-cell_type
cells	I-cell_type
.	O

In	O
this	O
study	O
,	O
we	O
examined	O
the	O
expression	O
of	O
two	O
T-cell-specific	B-protein
transcription	I-protein
factors	I-protein
(	O
TCF-1	B-protein
and	O
GATA-3	B-protein
)	O
and	O
one	O
B-cell-specific	B-protein
transcription	I-protein
factor	I-protein
(	O
BSAP	B-protein
)	O
in	O
cultured	B-cell_line
H-RS	I-cell_line
cells	I-cell_line
by	O
using	O
a	O
gel	O
mobility	O
shift	O
assay	O
.	O

The	O
sensitivity	O
and	O
specificity	O
of	O
this	O
assay	O
for	O
determination	O
of	O
cell	B-cell_line
lineage	I-cell_line
have	O
been	O
established	O
in	O
a	O
large	O
number	O
of	O
cultured	B-cell_line
human	I-cell_line
and	I-cell_line
murine	I-cell_line
cell	I-cell_line
lines	I-cell_line
.	O

All	O
three	O
types	O
of	O
H-RS	B-cell_line
cell	I-cell_line
lines	I-cell_line
were	O
consistently	O
negative	O
for	O
BSAP	B-protein
,	O
TCF-1	B-protein
,	O
and	O
GATA-3	B-protein
.	O

The	O
absence	O
of	O
GATA-3	B-protein
was	O
confirmed	O
in	O
H-RS	B-cell_line
cells	I-cell_line
in	O
tissues	O
by	O
an	O
in	O
situ	O
hybridization	O
technique	O
.	O

Virtually	O
all	O
B-cell	B-cell_line
lines	I-cell_line
,	O
with	O
the	O
exception	O
of	O
some	O
myeloma	B-cell_line
cell	I-cell_line
lines	I-cell_line
,	O
are	O
positive	O
for	O
BSAP	B-protein
,	O
which	O
is	O
the	O
transcription	B-protein
factor	I-protein
for	O
promoters	B-DNA
for	O
several	O
B-cell	B-protein
markers	I-protein
,	O
including	O
VpreB1	B-protein
,	O
lambda	B-protein
5	I-protein
,	O
CD19	B-protein
,	O
and	O
CD20	B-protein
.	O

All	O
T-cell	B-cell_line
lines	I-cell_line
tested	O
were	O
positive	O
for	O
TCF-1	B-protein
and	O
GATA-3	B-protein
,	O
which	O
are	O
the	O
transcription	B-protein
factors	I-protein
for	O
promoters	O
for	O
several	O
T-cell-restricted	B-protein
markers	I-protein
,	O
including	O
CD2	B-protein
,	O
CD3	B-protein
,	O
TcR	B-protein
,	O
and	O
lck	B-protein
.	O

The	O
absence	O
of	O
BSAP	B-protein
,	O
TCF-1	B-protein
,	O
and	O
GATA-3	B-protein
clearly	O
indicates	O
an	O
underlying	O
difference	O
between	O
H-RS	B-cell_line
cells	I-cell_line
and	O
lymphoid	B-cell_type
cells	I-cell_type
.	O

MEK1	B-protein
and	O
the	O
extracellular	B-protein
signal-regulated	I-protein
kinases	I-protein
are	O
required	O
for	O
the	O
stimulation	O
of	O
IL-2	B-DNA
gene	I-DNA
transcription	O
in	O
T	B-cell_type
cells	I-cell_type
.	O

TCR	B-protein
engagement	O
stimulates	O
the	O
activation	O
of	O
the	O
protein	B-protein
kinase	I-protein
Raf-1	B-protein
.	O

Active	O
Raf-1	B-protein
phosphorylates	O
and	O
activates	O
the	O
mitogen-activated	B-protein
protein	I-protein
(	I-protein
MAP	I-protein
)	I-protein
kinase/extracellular	I-protein
signal-regulated	I-protein
kinase	I-protein
kinase	I-protein
1	I-protein
(	O
MEK1	B-protein
)	O
,	O
which	O
in	O
turn	O
phosphorylates	O
and	O
activates	O
the	O
MAP	B-protein
kinases/extracellular	I-protein
signal	I-protein
regulated	I-protein
kinases	I-protein
,	O
ERK1	B-protein
and	O
ERK2	B-protein
.	O

Raf-1	B-protein
activity	O
promotes	O
IL-2	O
production	O
in	O
activated	O
T	B-cell_type
lymphocytes	I-cell_type
.	O

Therefore	O
,	O
we	O
sought	O
to	O
determine	O
whether	O
MEK1	B-protein
and	O
ERK	B-protein
activities	O
also	O
stimulate	O
IL-2	B-DNA
gene	I-DNA
transcription	O
.	O

Expression	O
of	O
constitutively	O
active	O
Raf-1	B-protein
or	O
MEK1	B-protein
in	O
Jurkat	B-cell_line
T	I-cell_line
cells	I-cell_line
enhanced	O
the	O
stimulation	O
of	O
IL-2	B-DNA
promoter	I-DNA
-driven	O
transcription	O
stimulated	O
by	O
a	O
calcium	O
ionophore	O
and	O
PMA	O
,	O
and	O
together	O
with	O
a	O
calcium	O
ionophore	O
the	O
expression	O
of	O
each	O
protein	O
was	O
sufficient	O
to	O
stimulate	O
NF-AT	B-protein
activity	O
.	O

Expression	O
of	O
MEK1-interfering	B-protein
mutants	I-protein
inhibited	O
the	O
stimulation	O
of	O
IL-2	B-DNA
promoter	I-DNA
-driven	O
transcription	O
and	O
blocked	O
the	O
ability	O
of	O
constitutively	O
active	O
Ras	B-protein
and	O
Raf-1	B-protein
to	O
costimulate	O
NF-AT	B-protein
activity	O
with	O
a	O
calcium	O
ionophore	O
.	O

Expression	O
of	O
the	O
MAP	B-protein
kinase-specific	I-protein
phosphatase	I-protein
,	O
MKP-1	B-protein
,	O
which	O
blocks	O
ERK	B-protein
activation	O
,	O
inhibited	O
IL-2	B-DNA
promoter	I-DNA
and	O
NF-AT	B-protein
-driven	O
transcription	O
stimulated	O
by	O
a	O
calcium	O
ionophore	O
and	O
PMA	O
,	O
and	O
in	O
addition	O
,	O
MKP-1	B-protein
neutralized	O
the	O
transcriptional	O
enhancement	O
caused	O
by	O
active	O
Raf-1	O
and	O
MEK1	O
expression	O
.	O

We	O
conclude	O
that	O
the	O
MAP	B-protein
kinase	I-protein
signal	O
transduction	O
pathway	O
consisting	O
of	O
Raf-1	B-protein
,	O
MEK1	B-protein
,	O
and	O
ERK1	B-protein
and	O
ERK2	B-protein
functions	O
in	O
the	O
stimulation	O
IL-2	B-DNA
gene	I-DNA
transcription	O
in	O
activated	O
T	B-cell_type
lymphocytes	I-cell_type
.	O

Multiple	O
transcription	B-protein
factors	I-protein
are	O
required	O
for	O
activation	O
of	O
human	B-DNA
interleukin	I-DNA
9	I-DNA
gene	I-DNA
in	O
T	B-cell_type
cells	I-cell_type
.	O

The	O
genetic	O
elements	O
and	O
regulatory	O
mechanisms	O
responsible	O
for	O
human	B-DNA
interleukin	I-DNA
9	I-DNA
(	I-DNA
IL-9	I-DNA
)	I-DNA
gene	I-DNA
expression	O
in	O
a	O
human	B-cell_line
T	I-cell_line
cell	I-cell_line
leukemia	I-cell_line
virus	I-cell_line
type	I-cell_line
I-transformed	I-cell_line
human	I-cell_line
T	I-cell_line
cell	I-cell_line
line	I-cell_line
,	O
C5MJ2	B-cell_line
,	O
were	O
investigated	O
.	O

We	O
demonstrated	O
that	O
IL-9	B-DNA
gene	I-DNA
expression	O
is	O
controlled	O
,	O
at	O
least	O
in	O
part	O
,	O
by	O
transcriptional	O
activation	O
.	O

Transient	O
expression	O
of	O
the	O
luciferase	B-DNA
reporter	I-DNA
gene	I-DNA
linked	O
to	O
serially	O
deleted	O
sequences	O
of	O
the	O
5'-flanking	B-DNA
region	I-DNA
of	O
the	O
IL-9	B-DNA
gene	I-DNA
has	O
revealed	O
several	O
positive	O
and	O
negative	B-DNA
regulatory	I-DNA
elements	I-DNA
involved	O
in	O
the	O
basal	O
and	O
inducible	O
expression	O
of	O
the	O
IL-9	B-DNA
gene	I-DNA
in	O
C5MJ2	B-cell_line
cells	I-cell_line
.	O

An	O
AP-1	O
site	O
at	O
-146	O
to	O
-140	O
was	O
shown	O
to	O
be	O
involved	O
in	O
the	O
expression	O
of	O
the	O
IL-9	B-DNA
gene	I-DNA
.	O

A	O
proximal	B-DNA
region	I-DNA
between	O
-46	B-DNA
and	I-DNA
-80	I-DNA
was	O
identified	O
as	O
the	O
minimum	O
sequence	O
for	O
the	O
basal	O
and	O
inducible	O
expression	O
of	O
the	O
IL-9	B-DNA
gene	I-DNA
in	O
C5MJ2	B-cell_line
cells	I-cell_line
.	O

Within	O
this	O
region	O
,	O
an	O
NF-kappaB	B-DNA
site	I-DNA
at	O
-59	B-DNA
to	I-DNA
-50	I-DNA
and	O
its	O
adjacent	O
20-base	B-DNA
pair	I-DNA
upstream	I-DNA
sequence	I-DNA
were	O
demonstrated	O
to	O
play	O
a	O
critical	O
role	O
for	O
the	O
IL-9	B-DNA
promoter	I-DNA
activity	O
.	O

DNA-protein	O
binding	O
studies	O
indicated	O
that	O
NF-kappaB	B-protein
,	O
c-Jun	B-protein
,	O
and	O
potentially	O
novel	B-protein
proteins	I-protein
(	O
around	O
35	B-protein
kDa	I-protein
)	O
can	O
bind	O
to	O
this	O
important	O
sequence	O
.	O

Mutations	O
at	O
different	O
sites	O
within	O
this	O
proximal	B-DNA
promoter	I-DNA
region	I-DNA
abolished	O
the	O
promoter	O
activity	O
as	O
well	O
as	O
the	O
DNA	O
binding	O
.	O

Taken	O
together	O
,	O
these	O
results	O
suggest	O
that	O
the	O
cooperation	O
of	O
different	O
transcription	B-protein
factors	I-protein
is	O
essential	O
for	O
IL-9	B-DNA
gene	I-DNA
expression	O
in	O
T	B-cell_type
cells	I-cell_type
.	O

DNA	O
triplex	O
formation	O
selectively	O
inhibits	O
granulocyte-macrophage	B-DNA
colony-stimulating	I-DNA
factor	I-DNA
gene	I-DNA
expression	O
in	O
human	O
T	O
cells	O
.	O

Granulocyte-macrophage	B-protein
colony-stimulating	I-protein
factor	I-protein
(	O
GM-CSF	B-protein
)	O
is	O
a	O
hemopoietic	O
growth	O
factor	O
that	O
is	O
expressed	O
in	O
activated	O
T	O
cells	O
,	O
fibroblasts	O
,	O
macrophages	O
,	O
and	O
endothelial	O
cells	O
.	O

Although	O
GM-CSF	B-protein
does	O
not	O
appear	O
to	O
be	O
essential	O
for	O
normal	O
hemopoiesis	O
,	O
overexpression	O
of	O
GM-CSF	O
has	O
been	O
implicated	O
in	O
the	O
pathogenesis	O
of	O
some	O
diseases	O
such	O
as	O
myeloid	O
leukemia	O
and	O
chronic	O
inflammation	O
.	O

An	O
NF-kappaB	B-protein
/Rel	O
binding	O
site	O
within	O
the	O
GM-CSF	B-DNA
promoter	I-DNA
,	O
termed	O
the	O
kappaB	O
element	O
appears	O
to	O
be	O
important	O
for	O
controlling	O
expression	O
in	O
reporter	B-DNA
gene	I-DNA
assays	O
in	O
response	O
to	O
a	O
number	O
of	O
stimuli	O
in	O
T	B-cell_type
cells	I-cell_type
.	O

We	O
investigated	O
oligonucleotide-directed	O
triple	O
helix	O
formation	O
across	O
this	O
regulatory	B-DNA
sequence	I-DNA
as	O
a	O
potential	O
tool	O
to	O
inhibit	O
GM-CSF	B-protein
gene	O
transcription	O
.	O

A	O
15-base	O
oligonucleotide	O
,	O
GM3	O
,	O
was	O
targeted	O
to	O
a	O
purine-rich	B-DNA
region	I-DNA
in	O
the	O
GM-CSF	B-DNA
proximal	I-DNA
promoter	I-DNA
,	O
which	O
overlaps	O
the	O
kappaB	B-DNA
element	I-DNA
.	O

Gel	O
mobility	O
shift	O
assays	O
and	O
DNase	B-protein
I	I-protein
footprinting	O
demonstrated	O
that	O
GM3	O
formed	O
a	O
sequence-specific	O
collinear	O
triplex	O
with	O
its	O
double-stranded	B-DNA
DNA	I-DNA
target	I-DNA
.	O

Triplex	O
formation	O
by	O
GM3	O
blocked	O
recombinant	B-protein
and	I-protein
nuclear	I-protein
NF-kappaB	I-protein
proteins	I-protein
binding	O
to	O
the	O
GM-CSF	B-DNA
element	I-DNA
.	O

GM3	O
also	O
caused	O
selective	O
inhibition	O
of	O
the	O
human	B-protein
T-cell	I-protein
lymphotrophic	I-protein
virus-1	I-protein
Tax	I-protein
transactivator-induced	O
luciferase	B-protein
activity	O
from	O
a	O
reporter	O
construct	O
driven	O
by	O
the	O
GM-CSF	B-DNA
promoter	I-DNA
in	O
Jurkat	B-cell_line
T	I-cell_line
cells	I-cell_line
.	O

Finally	O
,	O
GM3	O
greatly	O
reduced	O
the	O
concentration	O
of	O
endogenous	O
GM-CSF	B-RNA
mRNA	I-RNA
induced	O
by	O
different	O
stimuli	O
in	O
Jurkat	B-cell_line
T	I-cell_line
cells	I-cell_line
but	O
did	O
not	O
affect	O
interleukin	B-RNA
3	I-RNA
mRNA	I-RNA
levels	O
in	O
the	O
same	O
cells	O
.	O

We	O
conclude	O
that	O
the	O
kappaB	B-DNA
element	I-DNA
in	O
the	O
GM-CSF	B-DNA
promoter	I-DNA
plays	O
a	O
central	O
role	O
in	O
the	O
transcriptional	O
activation	O
of	O
the	O
endogenous	O
GM-CSF	B-DNA
gene	I-DNA
.	O

Colinear	O
triplex	O
formation	O
acts	O
as	O
a	O
selective	O
transcriptional	O
repressor	O
of	O
the	O
GM-CSF	B-DNA
gene	I-DNA
and	O
may	O
have	O
potential	O
therapeutic	O
application	O
in	O
cases	O
of	O
undesirable	O
overexpression	O
of	O
this	O
protein	O
.	O

Reversible	O
differentiation	O
of	O
human	B-cell_line
monoblastic	I-cell_line
leukemia	I-cell_line
U937	I-cell_line
cells	I-cell_line
by	O
ML-9	O
,	O
an	O
inhibitor	O
of	O
myosin	B-protein
light	I-protein
chain	I-protein
kinase	I-protein
.	O

Human	B-cell_line
monoblastic	I-cell_line
leukemia	I-cell_line
U937	I-cell_line
cells	I-cell_line
are	O
induced	O
to	O
differentiate	O
into	O
monocytes	B-cell_type
and	O
macrophages	B-cell_type
by	O
various	O
agents	O
.	O

We	O
have	O
shown	O
that	O
1-	O
(	O
5-chloronaphthalene-1-sulfonyl	O
)	O
-1H-hexahydro-1	O
,	O
4-diazepine	O
hydrochloride	O
(	O
ML-9	O
)	O
,	O
an	O
inhibitor	O
of	O
myosin	B-protein
light	I-protein
chain	I-protein
kinase	I-protein
,	O
induces	O
differentiation	O
of	O
monocytoid	B-cell_line
leukemia	I-cell_line
cell	I-cell_line
lines	I-cell_line
U937	B-cell_line
and	O
THP-1	B-cell_line
but	O
not	O
of	O
myeloblastic	B-cell_line
leukemic	I-cell_line
ML-1	I-cell_line
cell	I-cell_line
or	O
erythroleukemia	B-cell_line
K562	I-cell_line
cells	I-cell_line
.	O

In	O
the	O
present	O
study	O
,	O
we	O
further	O
analyzed	O
the	O
effect	O
of	O
ML-9	O
in	O
comparison	O
with	O
that	O
of	O
1	O
alpha	O
,	O
25-dihydroxyvitamin	O
D3	O
(	O
VD3	O
)	O
a	O
typical	O
inducer	O
of	O
monocytic	O
differentiation	O
.	O

ML-9	O
induced	O
nitroblue	O
tetrazolium	O
(	O
NBT	O
)	O
-reducing	O
activity	O
of	O
U937	B-cell_line
cell	I-cell_line
more	O
rapidly	O
than	O
VD3	O
:	O
This	O
differentiation	O
marker	O
was	O
induced	O
significantly	O
after	O
incubation	O
with	O
ML-9	O
and	O
VD3	O
for	O
4	O
hours	O
and	O
1	O
day	O
,	O
respectively	O
.	O

ML-9	O
also	O
induced	O
alpha-naphthyl	B-protein
acetate	I-protein
esterase	I-protein
(	O
ANAE	B-protein
)	O
activity	O
,	O
another	O
monocytic	O
differentiation	O
marker	O
,	O
more	O
rapidly	O
than	O
VD3	O
.	O

The	O
maximum	O
levels	O
of	O
these	O
markers	O
induced	O
by	O
ML-9	O
were	O
comparable	O
to	O
those	O
induced	O
by	O
VD3	O
,	O
but	O
after	O
removal	O
of	O
ML-9	O
from	O
the	O
medium	O
by	O
washing	O
the	O
cells	O
,	O
the	O
expressions	O
of	O
theses	O
markers	O
decreased	O
within	O
4	O
hours	O
and	O
reached	O
basal	O
levels	O
in	O
1	O
day	O
,	O
indicating	O
that	O
ML-9	O
's	O
induction	O
of	O
expression	O
of	O
differentiation-associated	O
phenotypes	O
was	O
reversible	O
.	O

The	O
growth	O
inhibition	O
of	O
U937	B-cell_line
cells	I-cell_line
by	O
ML-9	O
was	O
also	O
reversible	O
.	O

Similar	O
effects	O
were	O
observed	O
in	O
another	O
line	O
of	O
human	B-cell_line
monoblastic	I-cell_line
cells	I-cell_line
,	O
THP-1	B-cell_line
.	O

ML-9	O
had	O
little	O
or	O
no	O
effect	O
on	O
the	O
morphology	O
of	O
U937	B-cell_line
cells	I-cell_line
but	O
increased	O
the	O
expression	O
of	O
monocyte-macrophage	B-protein
lineage-associated	I-protein
surface	I-protein
antigen	I-protein
,	O
CD14	B-protein
,	O
to	O
some	O
extent	O
.	O

Irreversible	O
terminal	O
differentiation	O
induced	O
by	O
VD3	O
is	O
associated	O
with	O
down	O
regulation	O
of	O
the	O
expression	O
of	O
c-myc	O
and	O
upregulation	O
of	O
the	O
expression	O
of	O
c-fos	O
and	O
c-jun	O
,	O
but	O
ML-9	O
did	O
not	O
affect	O
the	O
expression	O
of	O
these	O
oncogenes	O
appreciably	O
.	O

ML-9-induced	O
differentiation	O
was	O
also	O
reversible	O
when	O
the	O
cells	O
were	O
cultured	O
with	O
cultured	O
with	O
ML-9	O
plus	O
an	O
anti-cancer	O
drug	O
such	O
as	O
1-beta-D-arabino-furanosylcytosine	O
or	O
daunomycin	O
.	O

it	O
became	O
irreversible	O
,	O
however	O
,	O
upon	O
simultaneous	O
treatment	O
with	O
dexamethasone	O
and	O
transforming	B-protein
growth	I-protein
factor-beta	I-protein
1	I-protein
(	O
TGF-beta	B-protein
1	I-protein
)	O
,	O
which	O
did	O
not	O
induce	O
differentiation	O
of	O
U937	B-cell_line
cells	I-cell_line
but	O
caused	O
growth	O
arrest	O
of	O
the	O
cells	O
in	O
the	O
G0/G1	O
phase	O
of	O
the	O
cell	O
cycle	O
.	O

These	O
results	O
suggest	O
that	O
ML-9	O
should	O
be	O
useful	O
for	O
studying	O
the	O
mechanisms	O
of	O
monocytic	O
differentiation	O
.	O

Modulation	O
of	O
endogenous	O
IL-1	B-protein
beta	I-protein
and	O
IL-1	B-protein
receptor	I-protein
antagonist	O
results	O
in	O
opposing	O
effects	O
on	O
HIV	O
expression	O
in	O
chronically	B-cell_line
infected	I-cell_line
monocytic	I-cell_line
cells	I-cell_line
.	O

A	O
proportion	O
of	O
HIV-infected	O
individuals	O
experience	O
episodes	O
of	O
localized	O
or	O
systemic	O
bacterial	O
infections	O
caused	O
by	O
Gram-negative	O
bacteria	O
.	O

Many	O
of	O
the	O
clinical	O
side	O
effects	O
of	O
these	O
infections	O
are	O
associated	O
with	O
the	O
production	O
of	O
proinflammatory	B-protein
cytokines	I-protein
,	O
which	O
are	O
induced	O
primarily	O
by	O
LPS	O
,	O
a	O
constituent	O
of	O
the	O
bacterial	O
cell	O
wall	O
of	O
Gram-negative	O
bacteria	O
.	O

The	O
present	O
study	O
examines	O
the	O
mechanisms	O
involved	O
in	O
LPS-mediated	O
induction	O
of	O
HIV	O
expression	O
in	O
U1	B-cell_line
cells	I-cell_line
,	O
a	O
promonocytic	B-cell_line
cell	I-cell_line
line	I-cell_line
chronically	O
infected	O
with	O
HIV	O
.	O

Stimulation	O
of	O
U1	B-cell_line
cells	I-cell_line
by	O
LPS	O
alone	O
induced	O
minimal	O
levels	O
of	O
HIV	O
expression	O
,	O
which	O
was	O
significantly	O
enhanced	O
by	O
granulocyte-macrophage	B-protein
colony-stimulating	I-protein
factor	I-protein
(	O
GM-CSF	B-protein
)	O
.	O

Costimulation	O
of	O
U1	B-cell_line
cells	I-cell_line
with	O
LPS	O
plus	O
GM-CSF	B-protein
resulted	O
in	O
the	O
accumulation	O
of	O
steady-state	O
levels	O
of	O
HIV	B-RNA
RNA	I-RNA
;	O
however	O
,	O
only	O
a	O
weak	O
induction	O
of	O
HIV	B-DNA
long	I-DNA
terminal	I-DNA
repeat	I-DNA
-driven	O
transcription	O
,	O
which	O
was	O
not	O
associated	O
with	O
the	O
activation	O
of	O
the	O
cellular	B-protein
transcription	I-protein
factor	I-protein
nuclear	B-protein
factor-kappa	I-protein
B	I-protein
,	O
was	O
noted	O
.	O

Costimulation	O
of	O
cells	O
with	O
LPS	O
plus	O
GM-CSF	B-protein
induced	O
the	O
production	O
of	O
proinflammatory	B-protein
cytokines	I-protein
,	O
IL-8	B-protein
,	O
IL-1	B-protein
beta	I-protein
and	O
IL-6	B-protein
,	O
but	O
not	O
TNF-alpha	B-protein
.	O

IL-1	B-protein
receptor	I-protein
antagonist	O
(	O
ra	O
)	O
inhibited	O
LPS	O
enhancement	O
of	O
HIV	O
expression	O
in	O
GM-CSF-stimulated	B-cell_line
cells	I-cell_line
,	O
suggesting	O
that	O
endogenous	B-protein
IL-1	I-protein
was	O
involved	O
in	O
LPS-mediated	O
viral	O
production	O
.	O

In	O
this	O
regard	O
,	O
anti-inflammatory	B-protein
cytokines	I-protein
inhibited	O
LPS	O
plus	O
GM-CSF	B-protein
-stimulated	O
HIV	O
expression	O
,	O
and	O
this	O
effect	O
closely	O
correlated	O
with	O
inhibition	O
of	O
IL-1	B-protein
beta	I-protein
release	O
and	O
,	O
in	O
particular	O
,	O
with	O
up-regulation	O
of	O
endogenous	O
IL-1ra	O
production	O
.	O

Thus	O
,	O
the	O
balance	O
between	O
an	O
endogenously	B-protein
produced	I-protein
viral	I-protein
inducer	I-protein
(	O
IL-1	B-protein
beta	I-protein
)	O
and	O
an	O
inhibitor	O
(	O
IL-1ra	B-protein
)	O
may	O
represent	O
an	O
important	O
pathway	O
leading	O
to	O
modulation	O
of	O
HIV	O
expression	O
from	O
monocytic	B-cell_type
cells	I-cell_type
.	O

Herpesvirus	B-cell_line
saimiri	I-cell_line
immortalized	I-cell_line
gamma	I-cell_line
delta	I-cell_line
T	I-cell_line
cell	I-cell_line
line	I-cell_line
activated	O
by	O
IL-12	B-protein
.	O

IL-12	B-protein
is	O
a	O
novel	O
heterodimeric	B-protein
cytokine	I-protein
important	O
for	O
the	O
regulation	O
and	O
differentiation	O
of	O
lymphocytes	O
and	O
NK	O
cells	O
.	O

Like	O
other	O
cytokines	O
,	O
IL-12	B-protein
mediates	O
its	O
biologic	O
activity	O
through	O
high-affinity	O
receptors	O
expressed	O
on	O
responsive	B-cell_type
cells	I-cell_type
.	O

To	O
date	O
,	O
a	O
large	O
number	O
of	O
receptors	O
for	O
IL-12	B-protein
have	O
been	O
found	O
only	O
on	O
PBMC	B-cell_type
following	O
activation	O
with	O
PHA	B-protein
or	O
IL-2	B-protein
.	O

To	O
gain	O
further	O
knowledge	O
of	O
the	O
IL-12R	B-protein
complex	I-protein
and	O
the	O
IL-12	B-protein
signal	O
transduction	O
pathway	O
in	O
cytotoxic	B-cell_type
T	I-cell_type
cells	I-cell_type
,	O
we	O
studied	O
a	O
number	O
of	O
human	B-cell_line
T	I-cell_line
cell	I-cell_line
lines	I-cell_line
that	O
had	O
been	O
transformed	O
to	O
permanent	O
growth	O
with	O
Herpesvirus	O
saimiri	O
,	O
an	O
oncogenic	O
virus	O
of	O
nonhuman	O
primates	O
.	O

This	O
paper	O
reports	O
the	O
expression	O
of	O
IL-12R	B-protein
on	O
a	O
human	B-cell_line
gamma	I-cell_line
delta	I-cell_line
T	I-cell_line
cell	I-cell_line
line	I-cell_line
that	O
responds	O
to	O
IL-12	B-protein
with	O
enhanced	O
cytolytic	O
activity	O
and	O
increased	O
expression	O
of	O
cytolytic	B-protein
effector	I-protein
molecules	I-protein
granzyme	B-protein
B	I-protein
and	O
perforin	B-protein
.	O

Using	O
these	O
T	B-cell_type
cells	I-cell_type
as	O
a	O
model	O
of	O
IL-12	B-protein
signal	O
transduction	O
,	O
we	O
confirmed	O
that	O
these	O
events	O
involve	O
members	O
of	O
the	O
Janus	B-protein
kinase	I-protein
family	I-protein
of	O
nonreceptor	B-protein
tyrosine	I-protein
kinases	I-protein
JAK2	B-protein
,	O
TYK2	B-protein
,	O
and	O
signal	B-protein
transducer	I-protein
and	I-protein
activator	I-protein
of	I-protein
transcription	I-protein
4	I-protein
.	O

Regulation	O
of	O
gene	O
expression	O
at	O
early	O
stages	O
of	O
B-cell	O
and	O
T-cell	O
differentiation	O
.	O

The	O
expression	O
of	O
distinct	O
sets	O
of	O
genes	O
at	O
different	O
stages	O
of	O
B-lymphocyte	O
and	O
T-lymphocyte	O
differentiation	O
is	O
controlled	O
at	O
the	O
level	O
of	O
transcription	O
.	O

A	O
number	O
of	O
recent	O
studies	O
have	O
described	O
interactions	O
between	O
transcription	B-protein
factors	I-protein
in	O
lymphocytes	O
that	O
provide	O
new	O
insights	O
into	O
mechanisms	O
regulating	O
gene	O
expression	O
.	O

These	O
mechanisms	O
include	O
the	O
assembly	O
of	O
higher	B-protein
order	I-protein
nucleoprotein	I-protein
complexes	I-protein
and	O
other	O
protein-protein	O
interactions	O
that	O
enhance	O
the	O
functional	O
specificity	O
of	O
transcriptional	B-protein
regulators	I-protein
in	O
lymphocytes	O
.	O

Identification	O
of	O
a	O
human	B-DNA
LIM-Hox	I-DNA
gene	I-DNA
,	O
hLH-2	B-DNA
,	O
aberrantly	O
expressed	O
in	O
chronic	O
myelogenous	O
leukaemia	O
and	O
located	O
on	O
9q33-34.1	B-DNA
.	O

We	O
describe	O
the	O
isolation	O
of	O
human	B-protein
LH-2	I-protein
,	O
a	O
putative	B-protein
transcription	I-protein
factor	I-protein
containing	O
two	O
cysteine-rich	B-protein
regions	I-protein
(	O
LIM	B-protein
domains	I-protein
)	O
and	O
a	O
homeobox	B-protein
(	I-protein
Hox	I-protein
)	I-protein
DNA-binding	I-protein
domain	I-protein
.	O

High	O
levels	O
of	O
hLH-2	B-DNA
expression	O
were	O
observed	O
in	O
all	O
cases	O
of	O
chronic	O
myelogenous	O
leukaemia	O
(	O
CML	O
)	O
tested	O
,	O
regardless	O
of	O
disease	O
status	O
.	O

hLH-2	B-DNA
was	O
mapped	O
to	O
chromosome	B-DNA
9Q33-34.1	I-DNA
,	O
in	O
the	O
same	O
region	O
as	O
the	O
reciprocal	O
translocation	O
that	O
creates	O
the	O
BCR-ABL	B-protein
chimera	I-protein
of	O
the	O
Philadelphia	O
chromosome	O
(	O
Ph	O
'	O
)	O
,	O
the	O
hallmark	O
of	O
CML	O
;	O
hLH-2	B-DNA
was	O
retained	O
on	O
the	O
derivative	B-DNA
9	I-DNA
chromosome	I-DNA
and	O
is	O
therefore	O
centromeric	O
of	O
c-ABL	B-DNA
.	O

The	O
proximity	O
of	O
hLH-2	B-DNA
to	O
the	O
breakpoint	O
on	O
chromosome	B-DNA
9	I-DNA
raises	O
the	O
possibility	O
of	O
cis-activation	O
by	O
the	O
t	B-DNA
(	I-DNA
9	I-DNA
;	I-DNA
22	I-DNA
)	I-DNA
(	I-DNA
q34	I-DNA
;	I-DNA
q11	I-DNA
)	I-DNA
translocation	I-DNA
.	O

In	O
addition	O
to	O
finding	O
hLH-2	B-DNA
expression	O
in	O
all	O
cases	O
of	O
CML	O
,	O
expression	O
was	O
observed	O
in	O
lymphoid	O
malignancies	O
and	O
myeloid	B-cell_line
cell	I-cell_line
lines	I-cell_line
,	O
but	O
not	O
in	O
primary	O
cases	O
of	O
acute	O
myelogenous	O
leukaemia	O
.	O

The	O
role	O
of	O
hLH-2	B-DNA
in	O
the	O
development	O
or	O
progression	O
of	O
leukaemia	O
is	O
not	O
known	O
.	O

However	O
,	O
hLH-2	B-DNA
may	O
prove	O
useful	O
as	O
a	O
marker	O
of	O
CML	O
for	O
monitoring	O
residual	O
disease	O
.	O

Lymphoid	O
cell	O
resistance	O
to	O
glucocorticoids	O
in	O
HIV	O
infection	O
.	O

In	O
humans	O
infected	O
with	O
the	O
HIV-1	O
virus	O
there	O
may	O
be	O
a	O
disproportionate	O
severity	O
of	O
signs	O
and	O
symptoms	O
of	O
illness	O
compared	O
to	O
the	O
fraction	O
of	O
CD4+	B-cell_line
infected	I-cell_line
T-lymphoid	I-cell_line
cells	I-cell_line
.	O

In	O
part	O
,	O
this	O
may	O
be	O
due	O
to	O
altered	O
intercellular	O
signalling	O
systems	O
and	O
intracellular	O
signal	O
transduction	O
.	O

Glucocorticoids	O
are	O
well	O
known	O
for	O
their	O
effects	O
on	O
the	O
vitality	O
and	O
function	O
of	O
lymphoid	B-cell_type
cells	I-cell_type
.	O

Patients	O
with	O
HIV	O
infections	O
often	O
show	O
elevated	O
circulating	O
levels	O
of	O
cortisol	O
,	O
suggesting	O
some	O
misfunction	O
in	O
the	O
regulatory	O
systems	O
that	O
maintain	O
the	O
levels	O
of	O
this	O
critical	O
hormone	O
.	O

At	O
the	O
cellular	O
level	O
,	O
it	O
is	O
known	O
that	O
both	O
acute	O
HIV	O
infection	O
and	O
glucocorticoids	O
can	O
cause	O
apoptotic	O
cell	O
death	O
in	O
thymic	B-cell_type
lymphocytes	I-cell_type
.	O

However	O
,	O
chronically	B-cell_type
HIV-infected	I-cell_type
cells	I-cell_type
appear	O
to	O
be	O
resistant	O
to	O
glucocorticoid-evoked	O
cell	O
death	O
.	O

Glucocorticoid	B-protein
receptor	I-protein
-ligand	O
binding	O
studies	O
on	O
patients	O
'	O
cells	O
have	O
shown	O
reduced	O
affinity	O
between	O
the	O
receptor	B-protein
binding	I-protein
sites	I-protein
and	O
test	O
steroids	O
.	O

In	O
vitro	O
,	O
chronically	B-cell_line
HIV-infected	I-cell_line
cells	I-cell_line
of	O
the	O
lymphoid	B-cell_line
CEM	I-cell_line
line	I-cell_line
displayed	O
resistance	O
to	O
glucocorticoid-induced	O
apoptosis	O
.	O

These	O
cells	O
showed	O
reduced	O
numbers	O
of	O
binding	B-protein
sites	I-protein
with	O
little	O
alteration	O
in	O
apparent	O
affinity	O
between	O
ligand	O
and	O
receptor	O
.	O

Thus	O
it	O
appears	O
that	O
there	O
may	O
often	O
be	O
malfunction	O
of	O
the	O
normal	O
glucocorticoid	O
response	O
in	O
HIV-infected	B-cell_type
cells	I-cell_type
probably	O
due	O
to	O
altered	O
interactions	O
between	O
the	O
glucocorticoid	B-protein
receptor	I-protein
and	O
its	O
hormone	O
.	O

Such	O
alterations	O
may	O
have	O
clinical	O
consequences	O
,	O
including	O
the	O
possibility	O
of	O
a	O
relatively	O
longer	O
life	O
span	O
of	O
infected	B-cell_type
CD4+	I-cell_type
T-lymphocytes	I-cell_type
,	O
as	O
well	O
as	O
systemic	O
effects	O
of	O
chronically	O
elevated	O
cortisol	O
level	O
.	O

Abundant	O
expression	O
of	O
erythroid	B-RNA
transcription	I-RNA
factor	I-RNA
P45	I-RNA
NF-E2	I-RNA
mRNA	I-RNA
in	O
human	B-cell_type
peripheral	I-cell_type
granurocytes	I-cell_type
.	O

Transcription	B-protein
factor	I-protein
NF-E2	I-protein
is	O
crucial	O
for	O
regulation	O
of	O
erythroid-specific	O
gene	O
expression	O
.	O

p45	B-protein
subunit	I-protein
of	O
NF-E2	B-protein
contains	O
a	O
basic-leucine	B-protein
zipper	I-protein
domain	I-protein
and	O
dimerizes	O
with	O
the	O
small	B-protein
Maf	I-protein
family	I-protein
protein	I-protein
to	O
form	O
functional	O
NF-E2	B-protein
complex	I-protein
.	O

While	O
p45	B-protein
expression	O
was	O
shown	O
to	O
be	O
restricted	O
to	O
erythroid	B-cell_type
cells	I-cell_type
,	O
megakaryocytes	B-cell_type
and	O
mast	B-cell_type
cells	I-cell_type
in	O
hematopoietic	O
lineage	O
,	O
we	O
found	O
in	O
this	O
study	O
that	O
p45	B-RNA
mRNA	I-RNA
is	O
abundantly	O
transcribed	O
in	O
the	O
granulocyte	B-cell_type
fraction	I-cell_type
of	O
human	B-cell_type
peripheral	I-cell_type
blood	I-cell_type
cells	I-cell_type
.	O

As	O
neutrophils	B-cell_type
occupy	O
approximately	O
92	O
%	O
of	O
the	O
cells	O
in	O
granulocyte	B-cell_type
fraction	I-cell_type
of	O
human	B-cell_type
peripheral	I-cell_type
blood	I-cell_type
cells	I-cell_type
.	O

As	O
neutrophils	B-cell_type
occupy	O
approximately	O
92	O
%	O
of	O
the	O
cells	O
in	O
this	O
fraction	O
,	O
the	O
cells	O
expressing	O
p45	B-protein
is	O
most	O
likely	O
to	O
be	O
neutrophils	B-cell_type
.	O

p45	B-RNA
mRNA	I-RNA
is	O
also	O
expressed	O
in	O
HL-60	B-cell_line
promyelocytes	I-cell_line
,	O
albeit	O
the	O
expression	O
level	O
is	O
much	O
lower	O
than	O
that	O
of	O
the	O
granulocyte	B-cell_type
fraction	I-cell_type
.	O

HL-60	B-cell_line
cells	I-cell_line
were	O
found	O
to	O
express	O
mafK	B-RNA
mRNA	I-RNA
,	O
indicating	O
the	O
presence	O
of	O
genuine	O
NF-E2	B-protein
complex	I-protein
in	O
the	O
cells	O
.	O

Although	O
p45	B-RNA
mRNA	I-RNA
is	O
transcribed	O
from	O
two	O
different	O
promoters	O
,	O
aNF-E2	B-DNA
promoter	I-DNA
and	O
fNF-E2	B-DNA
promoter	I-DNA
,	O
in	O
erythroid	B-cell_type
and	I-cell_type
megakaryocytic	I-cell_type
lineage	I-cell_type
cells	I-cell_type
,	O
p45	B-RNA
mRNA	I-RNA
is	O
transcribed	O
only	O
from	O
aNF-E2	B-DNA
promoter	I-DNA
.	O

The	O
expression	O
of	O
p45	B-protein
megakaryocytic	B-cell_type
lineage	I-cell_type
cells	I-cell_type
,	O
p45	B-RNA
mRNA	I-RNA
is	O
transcribed	O
only	O
from	O
aNF-E2	B-DNA
promoter	I-DNA
.	O

The	O
expression	O
of	O
p45	B-RNA
mRNA	I-RNA
in	O
the	O
neutrophils	B-cell_type
declined	O
rapidly	O
after	O
transfer	O
of	O
the	O
cells	O
to	O
in	O
vitro	O
culture	O
and	O
G-CSF	B-protein
could	O
not	O
sustain	O
the	O
expression	O
from	O
the	O
down-regulation	O
,	O
suggesting	O
the	O
E2	B-protein
may	O
also	O
participate	O
in	O
the	O
regulation	O
of	O
neutrophil-specific	O
gene	O
expression	O
.	O

Expression	O
of	O
c-fos	B-protein
and	I-protein
c-jun	I-protein
proteins	I-protein
and	O
AP-1	B-protein
binding	O
activity	O
during	O
cell	O
cycle	O
progression	O
of	O
HL60	B-cell_line
cells	I-cell_line
and	O
phytohemagglutinin-stimulated	B-cell_line
lymphocytes	I-cell_line
.	O

The	O
protein	O
products	O
of	O
the	O
c-fos	B-DNA
(	O
p62c-fos	B-protein
)	O
and	O
c-jun	B-DNA
(	O
p39c-jun	B-protein
)	O
genes	O
are	O
members	O
of	O
the	O
AP-1	B-protein
transcription	I-protein
factor	I-protein
family	I-protein
and	O
are	O
thought	O
to	O
play	O
important	O
roles	O
in	O
the	O
regulation	O
of	O
gene	O
expression	O
during	O
the	O
cell	O
cycle	O
.	O

Most	O
studies	O
on	O
the	O
expression	O
of	O
these	O
proteins	O
in	O
relation	O
to	O
the	O
cell	O
cycle	O
have	O
been	O
performed	O
at	O
the	O
mRNA	O
level	O
,	O
and	O
therefore	O
do	O
not	O
give	O
direct	O
information	O
about	O
the	O
presence	O
of	O
the	O
proteins	O
during	O
the	O
cell	O
cycle	O
.	O

We	O
have	O
used	O
Western	O
blotting	O
to	O
investigate	O
the	O
presence	O
of	O
these	O
proteins	O
during	O
the	O
cell	O
cycles	O
of	O
two	O
different	O
cellular	B-cell_line
systems	I-cell_line
:	O
a	O
continuously	B-cell_line
growing	I-cell_line
myeloid	I-cell_line
leukemic	I-cell_line
cell	I-cell_line
line	I-cell_line
,	O
HL60	B-cell_line
,	O
and	O
normal	B-cell_type
cells	I-cell_type
stimulated	O
into	O
cycle	O
,	O
phyto-	B-cell_line
hemagglutinin	I-cell_line
(	I-cell_line
PHA	I-cell_line
)	I-cell_line
-stimulated	I-cell_line
normal	I-cell_line
human	I-cell_line
peripheral	I-cell_line
blood	I-cell_line
lymphocytes	I-cell_line
(	O
PBL	B-cell_type
)	O
.	O

The	O
binding	O
activity	O
of	O
transcription	O
factor	O
AP-1	B-protein
,	O
which	O
consists	O
of	O
dimers	O
of	O
Fos	B-protein
and	I-protein
Jun	I-protein
family	I-protein
proteins	I-protein
,	O
was	O
also	O
studied	O
using	O
a	O
gel	O
shift	O
assay	O
.	O

We	O
found	O
nuclear	O
p62c-fos	B-protein
,	O
p39c-jun	B-protein
,	O
and	O
AP-1	B-protein
binding	O
activity	O
throughout	O
the	O
cell	O
cycle	O
both	O
in	O
HL60	B-cell_line
cells	I-cell_line
and	O
in	O
PHA-stimulated	B-cell_line
PBL	I-cell_line
,	O
and	O
we	O
postulate	O
that	O
these	O
proteins	O
are	O
required	O
throughout	O
the	O
cell	O
cycle	O
and	O
not	O
transiently	O
in	O
the	O
G0	O
to	O
G1	O
transition	O
as	O
previous	O
mRNA	O
studies	O
have	O
indicated	O
.	O

We	O
demonstrated	O
an	O
uncoupling	O
of	O
AP-1	B-protein
binding	O
activity	O
from	O
p62c-fos	B-protein
,	O
and	O
p39c-jun	B-protein
AP-1	B-protein
activity	O
was	O
expressed	O
more	O
strongly	O
in	O
the	O
G1-	O
and	O
G2/M-phase	O
enriched	O
samples	O
than	O
in	O
the	O
S-phase	O
enriched	O
samples	O
of	O
HL60	B-cell_line
cells	I-cell_line
,	O
while	O
levels	O
of	O
nuclear	B-protein
p62c-fos	I-protein
and	I-protein
p39c-jun	I-protein
were	O
constant	O
.	O

Nuclei	O
of	O
unstimulated	B-cell_type
PBL	I-cell_type
from	O
different	O
donors	O
expressed	O
p62c-fos	B-protein
and	O
p39c-jun	B-protein
,	O
but	O
AP-1	B-protein
was	O
not	O
detected	O
in	O
the	O
majority	O
of	O
samples	O
.	O

Following	O
PHA	B-protein
stimulation	O
of	O
PBL	B-cell_type
,	O
the	O
increase	O
in	O
AP-1	B-protein
activity	O
was	O
delayed	O
with	O
respect	O
to	O
the	O
augmentation	O
of	O
p39c-jun	B-protein
expression	O
.	O

We	O
also	O
observed	O
that	O
cytoplasmic	B-protein
p62c-fos	I-protein
and	I-protein
p39c-jun	I-protein
were	O
present	O
in	O
HL60	B-cell_line
cells	I-cell_line
and	O
PHA-stimulated	B-cell_line
PBL	I-cell_line
.	O

However	O
,	O
no	O
cytoplasmic	B-protein
p62c-fos	I-protein
was	O
detected	O
in	O
unstimulated	B-cell_type
PBL	I-cell_type
,	O
although	O
in	O
some	O
cases	O
cytoplasmic	B-protein
p39c-jun	I-protein
was	O
detected	O
,	O
suggesting	O
that	O
subcellular	O
compartmentalization	O
of	O
these	O
proteins	B-protein
may	O
occur	O
under	O
certain	O
circumstances	O
.	O

Octamer	B-protein
binding	I-protein
factors	I-protein
and	O
their	O
coactivator	B-protein
can	O
activate	O
the	O
murine	B-DNA
PU.1	I-DNA
(	I-DNA
spi-1	I-DNA
)	I-DNA
promoter	I-DNA
.	O

PU.1	B-protein
(	O
spi-1	B-protein
)	O
,	O
a	O
member	O
of	O
the	O
Ets	B-protein
transcription	I-protein
factor	I-protein
family	I-protein
,	O
is	O
predominantly	O
expressed	O
in	O
myeloid	B-cell_type
and	I-cell_type
B	I-cell_type
cells	I-cell_type
,	O
activates	O
many	O
B	B-DNA
cell	I-DNA
and	I-DNA
myeloid	I-DNA
genes	I-DNA
,	O
and	O
is	O
critical	O
for	O
development	O
of	O
both	O
of	O
these	O
lineages	O
.	O

Our	O
previous	O
studies	O
(	O
Chen	O
,	O
H.M.	O
,	O
Ray-Gallet	O
,	O
D.	O
,	O
Zhang	O
,	O
P.	O
,	O
Hetherington	O
,	O
C.J.	O
,	O
Gonzalez	O
,	O
D.A.	O
,	O
Zhang	O
,	O
D.-E.	O
,	O
Moreau-Gachelin	O
,	O
F.	O
,	O
and	O
Tenen	O
,	O
D.G.	O
(	O
1995	O
)	O
Oncogene	O
11	O
,	O
1549-1560	O
)	O
demonstrate	O
that	O
the	O
PU.1	B-DNA
promoter	I-DNA
directs	O
cell	B-DNA
type-specific	I-DNA
reporter	I-DNA
gene	I-DNA
expression	O
in	O
myeloid	O
cell	O
lines	O
,	O
and	O
that	O
PU.1	B-protein
activates	O
its	O
own	O
promoter	O
in	O
an	O
autoregulatory	O
loop	O
.	O

Here	O
we	O
show	O
that	O
the	O
murine	B-DNA
PU.1	I-DNA
promoter	I-DNA
is	O
also	O
specifically	O
and	O
highly	O
functional	O
in	O
B	B-cell_line
cell	I-cell_line
lines	I-cell_line
as	O
well	O
.	O

Oct-1	B-protein
and	O
Oct-2	B-protein
can	O
bind	O
specifically	O
to	O
a	O
site	O
at	O
base	O
pair	O
-55	O
in	O
vitro	O
,	O
and	O
this	O
site	O
is	O
specifically	O
protected	O
in	O
B	B-cell_type
cells	I-cell_type
in	O
vivo	O
.	O

We	O
also	O
demonstrate	O
that	O
two	O
other	O
sites	O
contribute	O
to	O
promoter	O
activity	O
in	O
B	B-cell_type
cells	I-cell_type
;	O
an	O
Sp1	B-DNA
binding	I-DNA
site	I-DNA
adjacent	O
to	O
the	O
octamer	B-DNA
site	I-DNA
,	O
and	O
the	O
PU.1	B-DNA
autoregulatory	I-DNA
site	I-DNA
.	O

Finally	O
,	O
we	O
show	O
that	O
the	O
B	O
cell	O
coactivator	B-protein
OBF-1/Bob1/OCA-B	B-protein
is	O
only	O
expressed	O
in	O
B	B-cell_type
cells	I-cell_type
and	O
not	O
in	O
myeloid	B-cell_type
cells	I-cell_type
,	O
and	O
that	O
OBF-1/Bob1/OCA-B	B-protein
can	O
transactivate	O
the	O
PU.1	B-DNA
promoter	I-DNA
in	O
HeLa	B-cell_line
and	O
myeloid	B-cell_type
cells	I-cell_type
.	O

This	O
B	B-protein
cell	I-protein
restricted	I-protein
coactivator	I-protein
may	O
be	O
responsible	O
for	O
the	O
B	O
cell	O
specific	O
expression	O
of	O
PU.1	B-protein
mediated	O
by	O
the	O
octamer	B-DNA
site	I-DNA
.	O

Inhibition	O
of	O
p105	B-protein
processing	O
by	O
NF-kappaB	B-protein
proteins	I-protein
in	O
transiently	B-cell_line
transfected	I-cell_line
cells	I-cell_line
.	O

Regulation	O
of	O
the	O
transcription	O
factor	O
NF-kappaB	B-protein
involves	O
proteasome-mediated	O
processing	O
of	O
the	O
NF-kappaB1	B-protein
p105	I-protein
precursor	I-protein
protein	I-protein
,	O
which	O
generates	O
the	O
p50	B-protein
subunit	I-protein
of	O
NF-kappaB	B-protein
.	O

The	O
processing	O
of	O
p105	B-protein
occurs	O
constitutively	O
in	O
vivo	O
but	O
can	O
be	O
markedly	O
enhanced	O
by	O
various	O
cellular	O
activation	O
agents	O
,	O
although	O
the	O
underlying	O
regulatory	O
mechanism	O
is	O
not	O
yet	O
clear	O
.	O

In	O
the	O
present	O
study	O
,	O
we	O
demonstrate	O
that	O
signal-mediated	O
induction	O
of	O
p105	B-protein
processing	O
in	O
human	B-cell_type
T	I-cell_type
cells	I-cell_type
is	O
associated	O
with	O
de	O
novo	O
synthesis	O
of	O
this	O
precursor	B-protein
protein	I-protein
.	O

Transient	O
transfection	O
studies	O
performed	O
in	O
COS7	B-cell_line
cells	I-cell_line
revealed	O
that	O
the	O
newly	O
synthesized	O
p105	B-protein
protein	O
appears	O
to	O
be	O
more	O
rapidly	O
processed	O
compared	O
to	O
its	O
accumulated	O
form	O
that	O
is	O
already	O
associated	O
with	O
the	O
processed	O
product	O
p50	B-protein
.	O

Interestingly	O
,	O
the	O
processing	O
rate	O
of	O
p105	B-protein
is	O
markedly	O
inhibited	O
in	O
cells	O
co-transfected	O
with	O
p50	B-protein
or	O
other	O
NF-kappaB	B-protein
subunits	I-protein
,	O
including	O
RelA	B-protein
and	O
c-Rel	B-protein
,	O
that	O
physically	O
interact	O
with	O
p105	B-protein
.	O

These	O
findings	O
suggest	O
that	O
the	O
processing	O
of	O
p105	B-protein
is	O
subject	O
to	O
negative	O
regulation	O
by	O
the	O
various	O
NF-kappaB	B-protein
subunits	I-protein
.	O

We	O
further	O
demonstrate	O
that	O
p105	B-protein
undergoes	O
degradation	O
in	O
lipopolysaccharide-stimulated	B-cell_line
human	I-cell_line
monocytic	I-cell_line
cells	I-cell_line
.	O

However	O
,	O
the	O
inducible	O
degradation	O
of	O
p105	B-protein
is	O
not	O
coupled	O
with	O
the	O
generation	O
of	O
p50	B-protein
.	O

Together	O
,	O
these	O
studies	O
demonstrate	O
that	O
the	O
processing	O
and	O
inducible	O
degradation	O
of	O
p105	B-protein
are	O
differentially	O
regulated	O
.	O

Identification	O
of	O
an	O
inducible	B-protein
regulator	I-protein
of	O
c-myb	B-DNA
expression	O
during	O
T-cell	B-cell_type
activation	O
.	O

Resting	B-cell_type
T	I-cell_type
cells	I-cell_type
express	O
very	O
low	O
levels	O
of	O
c-Myb	B-protein
protein	I-protein
.	O

During	O
T-cell	O
activation	O
,	O
c-myb	B-DNA
expression	O
is	O
induced	O
and	O
much	O
of	O
the	O
increase	O
in	O
expression	O
occurs	O
at	O
the	O
transcriptional	O
level	O
.	O

We	O
identified	O
a	O
region	O
of	O
the	O
c-myb	B-DNA
5	I-DNA
'	I-DNA
flanking	I-DNA
sequence	I-DNA
that	O
increased	O
c-myb	B-DNA
expression	O
during	O
T-cell	O
activation	O
.	O

In	O
vivo	O
footprinting	O
by	O
ligation-mediated	O
PCR	O
was	O
performed	O
to	O
correlate	O
in	O
vivo	O
protein	O
binding	O
with	O
functional	O
activity	O
.	O

A	O
protein	O
footprint	O
was	O
visible	O
over	O
this	O
region	O
of	O
the	O
c-myb	B-DNA
5	I-DNA
'	I-DNA
flanking	I-DNA
sequence	I-DNA
in	O
activated	B-cell_type
T	I-cell_type
cells	I-cell_type
but	O
not	O
in	O
unactivated	B-cell_type
T	I-cell_type
cells	I-cell_type
.	O

An	O
electrophoretic	O
mobility	O
shift	O
assay	O
(	O
EMSA	O
)	O
with	O
nuclear	O
extract	O
from	O
activated	B-cell_type
T	I-cell_type
cells	I-cell_type
and	O
an	O
oligonucleotide	O
of	O
this	O
binding	O
site	O
demonstrated	O
a	O
new	O
protein-DNA	B-protein
complex	I-protein
,	O
referred	O
to	O
as	O
CMAT	B-protein
for	O
c-myb	B-protein
in	I-protein
activated	I-protein
T	I-protein
cells	I-protein
;	O
this	O
complex	O
was	O
not	O
present	O
in	O
unactivated	B-cell_type
T	I-cell_type
cells	I-cell_type
.	O

Because	O
the	O
binding	B-DNA
site	I-DNA
showed	O
some	O
sequence	O
similarity	O
with	O
the	O
nuclear	B-DNA
factor	I-DNA
of	I-DNA
activated	I-DNA
T	I-DNA
cells	I-DNA
(	I-DNA
NFAT	I-DNA
)	I-DNA
binding	I-DNA
site	I-DNA
,	O
we	O
compared	O
the	O
kinetics	O
of	O
induction	O
of	O
the	O
two	O
binding	O
complexes	O
and	O
the	O
molecular	O
masses	O
of	O
the	O
two	O
proteins	O
.	O

Studies	O
of	O
the	O
kinetics	O
of	O
induction	O
showed	O
that	O
the	O
NFAT	B-protein
EMSA	I-protein
binding	I-protein
complex	I-protein
appeared	O
earlier	O
than	O
the	O
CMAT	B-protein
complex	I-protein
.	O

The	O
NFAT	B-protein
protein	O
migrated	O
more	O
slowly	O
in	O
a	O
sodium	O
dodecyl	O
sulfate-polyacrylamide	O
gel	O
than	O
the	O
CMAT	B-protein
protein	I-protein
did	O
.	O

In	O
addition	O
,	O
an	O
antibody	O
against	O
NFAT	B-protein
did	O
not	O
cross-react	O
with	O
the	O
CMAT	B-protein
protein	I-protein
.	O

The	O
appearance	O
of	O
the	O
CMAT	B-protein
binding	I-protein
complex	I-protein
was	O
inhibited	O
by	O
both	O
cyclosporin	O
A	O
and	O
rapamycin	O
.	O

The	O
CMAT	B-protein
protein	O
appears	O
to	O
be	O
a	O
novel	O
inducible	O
protein	O
involved	O
in	O
the	O
regulation	O
of	O
c-myb	B-DNA
expression	O
during	O
T-cell	O
activation	O
.	O

CNI-1493	O
inhibits	O
monocyte/macrophage	B-protein
tumor	I-protein
necrosis	I-protein
factor	I-protein
by	O
suppression	O
of	O
translation	O
efficiency	O
.	O

Tumor	B-protein
necrosis	I-protein
factor	I-protein
(	O
TNF	B-protein
)	O
mediates	O
a	O
wide	O
variety	O
of	O
disease	O
states	O
including	O
septic	O
shock	O
,	O
acute	O
and	O
chronic	O
inflammation	O
,	O
and	O
cachexia	O
.	O

Recently	O
,	O
a	O
multivalent	O
guanylhydrazone	O
(	O
CNI-1493	O
)	O
developed	O
as	O
an	O
inhibitor	O
of	O
macrophage	O
activation	O
was	O
shown	O
to	O
suppress	O
TNF	B-protein
production	O
and	O
protect	O
against	O
tissue	O
inflammation	O
and	O
endotoxin	O
lethality	O
[	O
Bianchi	O
,	O
M.	O
,	O
Ulrich	O
,	O
P.	O
,	O
Bloom	O
,	O
O.	O
,	O
Meistrell	O
,	O
M.	O
,	O
Zimmerman	O
,	O
G.A.	O
,	O
Schmidtmayerova	O
,	O
H.	O
,	O
Bukrinsky	O
,	O
M.	O
,	O
Donnelley	O
,	O
T.	O
,	O
Bucala	O
,	O
R.	O
,	O
Sherry	O
,	O
B.	O
,	O
Manogue	O
,	O
K.R.	O
,	O
Tortolani	O
,	O
A.J.	O
,	O
Cerami	O
,	O
A.	O
&	O
Tracey	O
,	O
K.J.	O
(	O
1995	O
)	O
Mol.Med.1	O
,	O
254-266	O
,	O
and	O
Bianchi	O
,	O
M.	O
,	O
Bloom	O
,	O
O.	O
,	O
Raabe	O
,	O
T.	O
,	O
Cohen	O
,	O
P.	O
S.	O
,	O
Chesney	O
,	O
J.	O
,	O
Sherry	O
,	O
B.	O
,	O
Schmidtmayerova	O
,	O
H.	O
,	O
Zhang	O
,	O
X.	O
,	O
Bukrinsky	O
,	O
M.	O
,	O
Ulrich	O
,	O
P.	O
,	O
Cerami	O
,	O
A.	O
&	O
Tracey	O
,	O
J.	O
(	O
1996	O
)	O
J.Exp.Med.	O
,	O
in	O
press	O
]	O
.	O

We	O
have	O
now	O
elucidated	O
the	O
mechanism	O
by	O
which	O
CNI-1493	O
inhibits	O
macrophage	O
TNF	B-protein
synthesis	O
and	O
show	O
here	O
that	O
it	O
acts	O
through	O
suppression	O
of	O
TNF	B-protein
translation	O
efficiency	O
.	O

CNI-1493	O
blocked	O
neither	O
the	O
lipopolysaccharide	O
(	O
LPS	O
)	O
-induced	O
increases	O
in	O
the	O
expression	O
of	O
TNF	B-RNA
mRNA	I-RNA
nor	O
the	O
translocation	O
of	O
nuclear	B-protein
factor	I-protein
NF-kappa	I-protein
B	I-protein
to	O
the	O
nucleus	O
in	O
macrophages	B-cell_type
activated	O
by	O
15	O
min	O
of	O
LPS	O
stimulation	O
,	O
indicating	O
that	O
CNI-1493	O
does	O
not	O
interfere	O
with	O
early	O
NF-kappa	B-protein
B	I-protein
-mediated	O
transcriptional	O
regulation	O
of	O
TNF	B-protein
.	O

However	O
,	O
synthesis	O
of	O
the	O
26-kDa	B-protein
membrane	I-protein
form	I-protein
of	O
TNF	B-protein
was	O
effectively	O
blocked	O
by	O
CNI-1493	O
.	O

Further	O
evidence	O
for	O
the	O
translational	O
suppression	O
of	O
TNF	B-protein
is	O
given	O
by	O
experiments	O
using	O
chloram-phenicol	B-DNA
acetyltransferase	I-DNA
(	I-DNA
CAT	I-DNA
)	I-DNA
constructs	I-DNA
containing	O
elements	O
of	O
the	O
TNF	B-DNA
gene	I-DNA
that	O
are	O
involved	O
in	O
TNF	B-protein
translational	O
regulation	O
.	O

Both	O
the	O
5	B-DNA
'	I-DNA
and	I-DNA
3	I-DNA
'	I-DNA
untranslated	I-DNA
regions	I-DNA
of	O
the	O
TNF	B-DNA
gene	I-DNA
were	O
required	O
to	O
elicit	O
maximal	O
translational	O
suppression	O
by	O
CNI-1493	O
.	O

Identification	O
of	O
the	O
molecular	O
target	O
through	O
which	O
CNI-	O
1493	O
inhibits	O
TNF	B-protein
translation	O
should	O
provide	O
insight	O
into	O
the	O
regulation	O
of	O
macrophage	O
activation	O
and	O
mechanisms	O
of	O
inflammation	O
.	O

Soluble	B-protein
tumor	I-protein
necrosis	I-protein
factor	I-protein
receptors	I-protein
inhibit	O
phorbol	O
myristate	O
acetate	O
and	O
cytokine-induced	O
HIV-1	O
expression	O
chronically	O
infected	B-cell_type
U1	I-cell_type
cells	I-cell_type
.	O

Recombinant	B-protein
human	I-protein
tumor	I-protein
necrosis	I-protein
factor	I-protein
(	I-protein
TNF	I-protein
)	I-protein
binding	I-protein
protein-1	I-protein
(	O
r-h	B-protein
TBP-1	I-protein
)	O
and	O
recombinant	B-protein
human	I-protein
soluble	I-protein
dimeric	I-protein
TNF	I-protein
receptor	I-protein
(	O
rhu	B-protein
TNFR	I-protein
:	I-protein
Fc	I-protein
)	O
were	O
used	O
to	O
determine	O
the	O
relative	O
contributions	O
of	O
TNF	B-protein
to	O
phorbol	O
myristate	O
acetate	O
(	O
PMA	O
)	O
and	O
cytokine-induced	O
human	O
immunodeficiency	O
virus	O
type	O
1	O
(	O
HIV-1	O
)	O
replication	O
in	O
chronically	O
infected	O
cell	O
lines	O
.	O

Treatment	O
of	O
HIV-1-infected	B-cell_type
promonocytic	I-cell_type
U1	I-cell_type
cells	I-cell_type
with	O
r-h-TBP-1	B-protein
or	O
rhu	B-protein
TNFR	I-protein
:	I-protein
Fc	I-protein
reduced	O
PMA-induced	O
HIV-1	B-protein
p24	I-protein
antigen	I-protein
production	O
in	O
a	O
concentration-dependent	O
manner	O
,	O
with	O
a	O
maximal	O
inhibition	O
of	O
approximately	O
90	O
%	O
.	O

Maximal	O
inhibition	O
of	O
p24	B-protein
antigen	I-protein
production	O
in	O
T-lymphocytic	B-cell_line
ACH-2	I-cell_line
cells	I-cell_line
was	O
47	O
%	O
with	O
r-hTBP-1	B-protein
and	O
42	O
%	O
with	O
rhu	B-protein
TNFR	I-protein
:	I-protein
Fc	I-protein
.	O

r-hTBP-1	B-protein
and	O
rhu	B-protein
TNFR	I-protein
:	I-protein
Fc	I-protein
also	O
decreased	O
p24	B-protein
antigen	I-protein
synthesized	O
by	O
U1	B-cell_line
cells	I-cell_line
in	O
response	O
to	O
other	O
stimuli	O
,	O
including	O
phytohemagglutinin	B-protein
(	I-protein
PHA	I-protein
)	I-protein
-induced	I-protein
supernatant	I-protein
,	O
granulocyte-macrophage	B-protein
colony-stimulating	I-protein
factor	I-protein
,	O
interleukin-6	B-protein
,	O
and	O
TNF	B-protein
.	O

Addition	O
of	O
r-hTBP-1	B-protein
to	O
U1	B-cell_line
cells	I-cell_line
during	O
the	O
last	O
4	O
h	O
of	O
a	O
24	O
h	O
incubation	O
with	O
PMA	O
still	O
inhibited	O
p24	B-protein
antigen	I-protein
production	O
by	O
15	O
%	O
.	O

U1	B-cell_line
cells	I-cell_line
stimulated	O
with	O
10	O
(	O
-7	O
)	O
M	O
PMA	O
released	O
approximately	O
1	O
ng/ml	O
endogenous	B-protein
TBP-1	I-protein
with	O
an	O
initial	O
peak	O
observed	O
at	O
1	O
h	O
and	O
a	O
second	O
peak	O
at	O
24	O
h	O
after	O
PMA	O
stimulation	O
.	O

r-hTBP-1	B-protein
also	O
partially	O
reversed	O
inhibition	O
of	O
U1	O
cellular	O
proliferation	O
caused	O
by	O
PMA	O
.	O

Both	O
r-hTBP-1	B-protein
and	O
rhu	B-protein
TNFR	I-protein
:	I-protein
Fc	I-protein
blocked	O
PMA	O
induction	O
of	O
nuclear	B-protein
factor	I-protein
(	I-protein
NK	I-protein
)	I-protein
-	I-protein
kappa	I-protein
B	I-protein
DNA-binding	O
activity	O
in	O
U1	B-cell_line
cells	I-cell_line
in	O
association	O
with	O
decreases	O
in	O
HIV-1	O
replication	O
.	O

We	O
conclude	O
that	O
soluble	O
TNF	O
receptors	O
can	O
inhibit	O
stimuli-induced	O
HIV-1	O
expression	O
and	O
NK-	B-protein
kappa	I-protein
B	I-protein
DNA-binding	O
activity	O
in	O
chronically	O
infected	B-cell_type
U1	I-cell_type
cells	I-cell_type
.	O

Transcriptional	O
activation	O
of	O
RNA	B-DNA
polymerase	I-DNA
III-dependent	I-DNA
genes	I-DNA
by	O
the	O
human	B-protein
T-cell	I-protein
leukemia	I-protein
virus	I-protein
type	I-protein
1	I-protein
tax	I-protein
protein	I-protein
.	O

The	O
human	B-protein
T-cell	I-protein
leukemia	I-protein
virus-encoded	I-protein
tax	I-protein
protein	I-protein
is	O
a	O
potent	O
activator	O
of	O
many	O
viral	B-DNA
and	I-DNA
cellular	I-DNA
genes	I-DNA
transcribed	O
by	O
RNA	B-protein
polymerase	I-protein
II	I-protein
.	O

We	O
find	O
that	O
both	O
chromatin	B-DNA
and	O
cell	O
extracts	O
derived	O
from	O
human	B-cell_line
T-cell	I-cell_line
leukemia	I-cell_line
virus	I-cell_line
type	I-cell_line
1-infected	I-cell_line
human	I-cell_line
T	I-cell_line
lymphocytes	I-cell_line
support	O
higher	O
levels	O
of	O
5S	O
rRNA	O
and	O
tRNA	O
gene	O
transcription	O
than	O
chromatin	B-DNA
or	O
extracts	O
from	O
uninfected	B-cell_type
T	I-cell_type
lymphocytes	I-cell_type
.	O

The	O
viral	B-protein
protein	I-protein
Tax	I-protein
was	O
likely	O
responsible	O
for	O
this	O
higher	O
level	O
of	O
class	B-DNA
II	I-DNA
gene	I-DNA
transcription	O
,	O
as	O
purified	B-protein
Tax	I-protein
was	O
found	O
to	O
stimulate	O
both	O
genes	O
when	O
added	O
to	O
the	O
uninfected	O
cell	O
extract	O
or	O
in	O
reconstituted	O
systems	O
.	O

Both	O
limiting-component	O
transcription	O
assays	O
and	O
DNA	O
binding	O
assays	O
identified	O
the	O
class	B-protein
III	I-protein
gene	I-protein
transcription	I-protein
factor	I-protein
TFIIIB	B-protein
as	O
the	O
principle	O
target	O
of	O
Tax	B-protein
activity	O
.	O

Surprisingly	O
,	O
we	O
find	O
that	O
Tax	B-protein
increases	O
the	O
effective	O
concentration	O
of	O
active	B-protein
TFIIIB	I-protein
molecules	I-protein
.	O

These	O
data	O
suggest	O
that	O
Tax	B-protein
stimulates	O
RNA	B-DNA
polymerase	I-DNA
III-dependent	I-DNA
gene	I-DNA
expression	O
by	O
accelerating	O
the	O
rate	O
and/or	O
extent	O
of	O
transcription	B-protein
initiation	I-protein
complex	I-protein
assembly	O
.	O

Expression	O
of	O
Retinoid	B-protein
X	I-protein
Receptor	I-protein
alpha	I-protein
is	O
increased	O
upon	O
monocytic	O
cell	O
differentiation	O
.	O

1	O
alpha	O
,	O
25-Dihydroxyvitamin	O
D3	O
(	O
VD	O
)	O
is	O
a	O
potent	O
inducer	O
of	O
monocytic	O
differentiation	O
of	O
both	O
normal	B-cell_type
and	I-cell_type
leukemic	I-cell_type
cells	I-cell_type
.	O

Its	O
effects	O
are	O
mediated	O
by	O
its	O
nuclear	B-protein
receptor	I-protein
(	O
VDR	B-protein
)	O
.	O

Efficient	O
gene	O
activation	O
requires	O
the	O
heterodimerization	O
of	O
VDR	B-protein
with	O
Retinoid	B-protein
X	I-protein
Receptors	I-protein
(	O
RXR	B-protein
)	O
.	O

In	O
the	O
present	O
study	O
using	O
specific	B-protein
antibodies	I-protein
,	O
we	O
analyzed	O
the	O
expression	O
of	O
the	O
RXR	B-protein
alpha	I-protein
protein	I-protein
in	O
blood	B-cell_type
mononuclear	I-cell_type
cells	I-cell_type
from	O
acute	O
myeloid	O
patients	O
(	O
AML	O
)	O
(	O
10	O
cases	O
)	O
and	O
from	O
myelomonocytic	B-cell_line
cell	I-cell_line
lines	I-cell_line
arrested	O
at	O
different	O
stages	O
of	O
differentiation	O
.	O

We	O
observed	O
that	O
the	O
RXR	B-protein
alpha	I-protein
expression	O
increased	O
during	O
myelomonocytic	O
differentiation	O
,	O
since	O
the	O
highest	O
levels	O
were	O
found	O
in	O
AML	O
samples	O
and	O
in	O
myelomonocytic	B-cell_line
cell	I-cell_line
lines	I-cell_line
having	O
the	O
highest	O
amounts	O
of	O
monocytic	B-cell_type
precursors	I-cell_type
.	O

We	O
also	O
demonstrated	O
that	O
fresh	O
leukemic	B-cell_type
cells	I-cell_type
,	O
whatever	O
their	O
stage	O
of	O
differentiation	O
,	O
as	O
well	O
as	O
myelomonocytic	B-cell_line
cell	I-cell_line
lines	I-cell_line
,	O
respond	O
to	O
VD	O
by	O
an	O
increase	O
in	O
RXR	B-protein
alpha	I-protein
levels	O
.	O

Combinations	O
of	O
all-trans	O
retinoic	O
acid	O
(	O
RA	O
)	O
and	O
VD	O
,	O
in	O
some	O
cases	O
,	O
increased	O
this	O
effect	O
.	O

This	O
response	O
suggests	O
the	O
involvement	O
of	O
RXR	B-protein
alpha	I-protein
in	O
monocytic	O
differentiation	O
upon	O
VD	O
treatment	O
.	O

Expression	O
of	O
p13MTCP1	B-protein
is	O
restricted	O
to	O
mature	O
T-cell	O
proliferations	O
with	O
t	O
(	O
X	O
;	O
14	O
)	O
translocations	O
.	O

T-cell	O
prolymphocytic	O
leukemia	O
(	O
T-PLL	O
)	O
,	O
a	O
rare	O
form	O
of	O
mature	O
T-cell	O
leukemias	O
,	O
and	O
ataxia	O
telangiectasia	O
clonal	O
proliferation	O
,	O
a	O
related	O
condition	O
occurring	O
in	O
patients	O
suffering	O
from	O
ataxia	O
telangiectasia	O
,	O
have	O
been	O
associated	O
to	O
translocations	O
involving	O
the	O
14q32.1	B-DNA
or	O
Xq28	B-DNA
regions	I-DNA
,	O
where	O
are	O
located	O
the	O
TCL1	B-DNA
and	I-DNA
MTCP1	I-DNA
putative	I-DNA
oncogenes	I-DNA
,	O
respectively	O
.	O

The	O
MTCP1	B-DNA
gene	I-DNA
is	O
involved	O
in	O
the	O
t	B-DNA
(	I-DNA
X	I-DNA
;	I-DNA
14	I-DNA
)	I-DNA
(	I-DNA
q28	I-DNA
;	I-DNA
q11	I-DNA
)	I-DNA
translocation	I-DNA
associated	O
with	O
these	O
T-cell	O
proliferations	O
.	O

Alternative	O
splicing	O
generates	O
type	B-RNA
A	I-RNA
and	I-RNA
B	I-RNA
transcripts	I-RNA
that	O
potentially	O
encode	O
two	O
entirely	O
distinct	O
proteins	O
;	O
type	O
A	B-RNA
transcripts	I-RNA
code	O
for	O
a	O
small	O
mitochondrial	B-protein
protein	I-protein
,	O
p8MTCP1	B-protein
,	O
and	O
type	B-RNA
B	I-RNA
transcripts	I-RNA
,	O
containing	O
an	O
additional	O
open	B-DNA
reading	I-DNA
frame	I-DNA
,	O
may	O
code	O
for	O
107	B-protein
amino-acid	I-protein
protein	I-protein
,	O
p13MTCP1	B-protein
.	O

The	O
recently	O
cloned	O
TCL1	B-DNA
gene	I-DNA
,	O
also	O
involved	O
in	O
translocations	O
and	O
inversions	O
associated	O
with	O
T-cell	O
proliferations	O
,	O
codes	O
for	O
a	O
14-kD	B-protein
protein	I-protein
that	O
displays	O
significant	O
homology	O
with	O
p13MTCP1	B-protein
.	O

We	O
have	O
generated	O
rabbit	O
antisera	O
against	O
this	O
putative	O
p13MTCP1	B-protein
protein	I-protein
and	O
screened	O
for	O
expression	O
of	O
p13MTCP1	B-protein
normal	O
lymphoid	O
tissues	O
and	O
33	O
cases	O
of	O
immature	B-cell_type
and	I-cell_type
mature	I-cell_type
lymphoid	I-cell_type
T-cell	I-cell_type
proliferations	I-cell_type
using	O
a	O
sensitive	O
Western	O
blot	O
assay	O
.	O

We	O
also	O
investigated	O
the	O
MTCP1	B-DNA
locus	I-DNA
configuration	O
by	O
Southern	O
blot	O
analysis	O
.	O

The	O
p13MTCP1	B-protein
protein	I-protein
was	O
detected	O
in	O
the	O
three	O
T-cell	O
proliferations	O
with	O
MTCP1	B-DNA
rearrangements	I-DNA
because	O
of	O
t	O
(	O
X	O
;	O
14	O
)	O
translocations	O
,	O
but	O
neither	O
in	O
normal	O
resting	O
and	O
activated	B-cell_type
lymphocytes	I-cell_type
nor	O
in	O
the	O
other	O
T-cell	B-cell_type
leukemias	O
.	O

Our	O
data	O
support	O
the	O
hypothesis	O
that	O
p13MTCP1	B-protein
and	O
p14TCL1	B-protein
form	O
a	O
new	O
protein	B-protein
family	I-protein
that	O
plays	O
a	O
key	O
role	O
in	O
the	O
pathogenesis	O
of	O
T-PLL	O
and	O
related	O
conditions	O
.	O

Preassociation	O
of	O
STAT1	B-protein
with	O
STAT2	B-protein
and	O
STAT3	B-protein
in	O
separate	O
signalling	B-protein
complexes	I-protein
prior	O
to	O
cytokine	B-protein
stimulation	O
.	O

A	O
variety	O
of	O
cytokines	B-protein
and	O
growth	B-protein
factors	I-protein
act	O
through	O
an	O
induction	O
of	O
gene	O
expression	O
mediated	O
by	O
a	O
family	O
of	O
latent	B-protein
transcription	I-protein
factors	I-protein
called	O
STAT	B-protein
(	I-protein
signal	I-protein
transducers	I-protein
and	I-protein
activators	I-protein
of	I-protein
transcription	I-protein
)	I-protein
proteins	I-protein
.	O

Ligand-induced	O
tyrosine	O
phosphorylation	O
of	O
the	O
STATs	B-protein
promotes	O
their	O
homodimer	O
and	O
heterodimer	O
formation	O
and	O
subsequent	O
nuclear	O
translocation	O
.	O

We	O
demonstrate	O
here	O
that	O
STAT	B-protein
protein	I-protein
heterocomplexes	I-protein
exist	O
prior	O
to	O
cytokine	B-protein
treatment	O
.	O

When	O
unstimulated	B-cell_line
HeLa	I-cell_line
cells	I-cell_line
are	O
ruptured	O
in	O
hypotonic	O
buffer	O
without	O
salt	O
or	O
detergent	O
,	O
immunoadsorption	O
of	O
either	O
STAT1	B-protein
or	O
STAT2	B-protein
from	O
the	O
resulting	O
cytosol	O
yields	O
coimmunoadsorption	O
of	O
the	O
other	O
STAT	B-protein
protein	I-protein
.	O

Similarly	O
,	O
STAT1	B-protein
-STAT3	B-protein
heterocomplexes	O
are	O
coimmunoadsorbed	O
from	O
hypotonic	O
cytosol	O
.	O

STAT1	B-protein
and	O
STAT2	B-protein
or	O
STAT1	B-protein
and	O
STAT3	B-protein
translated	O
in	O
reticulocyte	O
lysate	O
spontaneously	O
form	O
heterocomplexes	O
when	O
the	O
translation	O
lysates	O
are	O
mixed	O
at	O
0	O
degrees	O
C	O
.	O

Our	O
data	O
suggest	O
that	O
interferon-alpha	B-protein
/beta-induced	O
tyrosine	O
phosphorylation	O
increases	O
the	O
stability	O
of	O
a	O
preexisting	O
,	O
latent	O
,	O
STAT1	B-protein
-	O
STAT2	B-protein
signaling	I-protein
complex	I-protein
.	O

Newly	O
translated	O
STAT1	B-protein
binds	O
in	O
equilibrium	O
fashion	O
to	O
STAT2	B-protein
and	O
STAT3	B-protein
,	O
but	O
we	O
show	O
that	O
STAT2	B-protein
and	O
STAT3	B-protein
exist	O
in	O
separate	O
heterocomplexes	B-protein
with	O
STAT1	B-protein
,	O
consistent	O
with	O
a	O
model	O
in	O
which	O
STAT1	B-protein
contains	O
a	O
common	O
binding	O
site	O
for	O
other	O
STAT	B-protein
proteins	I-protein
.	O

Interferon-gamma	B-protein
modulates	O
the	O
lipopolysaccharide-induced	O
expression	O
of	O
AP-1	B-protein
and	O
NF-kappa	B-protein
B	I-protein
at	O
the	O
mRNA	O
and	O
protein	O
level	O
in	O
human	B-cell_type
monocytes	I-cell_type
.	O

Interferon-gamma	B-protein
(	O
IFN-gamma	B-protein
)	O
modulates	O
the	O
expression	O
of	O
several	O
cytokines	B-protein
by	O
human	B-cell_type
monocytes	I-cell_type
at	O
the	O
transcriptional	O
level	O
.	O

In	O
view	O
of	O
these	O
findings	O
,	O
we	O
analyzed	O
the	O
effects	O
of	O
IFN-gamma	B-protein
on	O
the	O
expression	O
of	O
different	O
transcription	B-protein
factors	I-protein
in	O
activated	O
human	B-cell_type
monocytes	I-cell_type
.	O

Priming	O
of	O
human	B-cell_type
monocytes	I-cell_type
with	O
IFN-gamma	B-protein
resulted	O
in	O
the	O
down	O
regulation	O
of	O
c-fos	B-RNA
and	I-RNA
c-jun	I-RNA
mRNA	I-RNA
in	O
response	O
to	O
stimulation	O
with	O
lipopolysaccharide	O
(	O
LPS	O
)	O
compared	O
to	O
the	O
effects	O
of	O
LPS	O
alone	O
.	O

Not	O
only	O
was	O
this	O
effect	O
observed	O
at	O
the	O
mRNA	O
level	O
,	O
but	O
activator	B-protein
protein-1	I-protein
(	O
AP-1	B-protein
)	O
DNA	O
binding	O
capacity	O
was	O
affected	O
as	O
well	O
,	O
A	O
strong	O
reduction	O
was	O
observed	O
in	O
the	O
LPS-induced	O
DNA-binding	O
activity	O
of	O
AP-1	B-protein
in	O
the	O
presence	O
of	O
IFN-gamma	B-protein
.	O

LPS-stimulated	B-cell_type
monocytes	I-cell_type
showed	O
an	O
increased	O
expression	O
of	O
p105	B-RNA
mRNA	I-RNA
,	O
the	O
precursor	O
of	O
the	O
p50	B-protein
subunit	I-protein
of	O
the	O
transcription	B-protein
factor	I-protein
nuclear	I-protein
factor-kappa	I-protein
B	I-protein
(	O
NF-kappa	B-protein
B	I-protein
)	O
,	O
while	O
no	O
effect	O
was	O
noticed	O
on	O
the	O
expression	O
of	O
p65	B-RNA
mRNA	I-RNA
.	O

In	O
contrast	O
,	O
IFN-gamma	B-protein
priming	O
did	O
not	O
affect	O
the	O
expression	O
of	O
p105	B-RNA
transcripts	I-RNA
but	O
enhanced	O
the	O
expression	O
of	O
p65	B-RNA
mRNA	I-RNA
(	O
two-fold	O
)	O
.	O

Priming	O
with	O
IFN-gamma	B-protein
followed	O
by	O
LPS	O
stimulation	O
resulted	O
in	O
a	O
further	O
increase	O
in	O
the	O
expression	O
of	O
p65	B-RNA
mRNA	I-RNA
.	O

This	O
was	O
due	O
to	O
an	O
increase	O
in	O
the	O
half-life	O
of	O
p65	B-RNA
mRNA	I-RNA
(	O
75	O
vs	O
150	O
minutes	O
)	O
.	O

Electrophoretic	O
mobility	O
shift	O
assays	O
(	O
EMSAs	O
)	O
demonstrated	O
that	O
unstimulated	O
monocytes	O
predominantly	O
expressed	O
p50	B-protein
NF-kappa	B-protein
B	I-protein
.	O

Stimulation	O
with	O
LPS	O
or	O
IFN-gamma	B-protein
resulted	O
in	O
the	O
expression	O
of	O
p50	B-protein
and	O
p65	B-protein
subunits	I-protein
,	O
while	O
the	O
combination	O
of	O
IFN-gamma	B-protein
plus	O
LPS	O
caused	O
a	O
further	O
increase	O
in	O
the	O
expression	O
of	O
NF-kappa	B-protein
B	I-protein
.	O

With	O
Western	O
blotting	O
,	O
it	O
was	O
shown	O
that	O
nuclear	O
extracts	O
from	O
monocytes	B-cell_type
contained	O
p50	B-protein
and	O
p65	B-protein
protein	I-protein
in	O
response	O
to	O
LPS	O
and	O
IFN-gamma	B-protein
stimulation	O
.	O

However	O
,	O
the	O
combined	O
stimulation	O
did	O
not	O
result	O
in	O
enhanced	O
p50	B-protein
and	O
p65	B-protein
protein	I-protein
expression	O
.	O

The	O
effects	O
of	O
IFN-gamma	B-protein
on	O
the	O
transcription	B-protein
factors	I-protein
were	O
specific	O
,	O
since	O
no	O
change	O
was	O
observed	O
in	O
the	O
expression	O
of	O
NF-IL-6	B-protein
or	O
I	B-protein
kappa	I-protein
B	I-protein
alpha	I-protein
,	O
the	O
inhibitor	O
of	O
NF-kappa	B-protein
B	I-protein
.	O

We	O
conclude	O
that	O
the	O
effects	O
of	O
IFN-gamma	B-protein
on	O
the	O
expression	O
of	O
the	O
transcription	B-protein
factors	I-protein
AP-1	B-protein
and	O
NF-kappa	B-protein
B	I-protein
may	O
be	O
important	O
for	O
the	O
modulatory	O
effects	O
of	O
IFN-gamma	B-protein
on	O
the	O
cytokine	B-protein
expression	O
in	O
activated	O
human	B-cell_type
monocytes	I-cell_type
.	O

HIV-1	B-protein
tat	I-protein
induces	O
the	O
expression	O
of	O
a	O
new	O
hematopoietic	B-protein
cell-specific	I-protein
transcription	I-protein
factor	I-protein
and	O
downregulates	O
MIP-1	B-DNA
alpha	I-DNA
gene	I-DNA
expression	O
in	O
activated	B-cell_type
T-cells	I-cell_type
.	O

MIP-1	B-protein
alpha	I-protein
is	O
a	O
secreted	O
chemokine	B-protein
which	O
can	O
inhibit	O
hematopoietic	B-cell_type
stem	I-cell_type
cells	I-cell_type
and	O
modulate	O
inflammatory	O
responses	O
.	O

It	O
is	O
also	O
an	O
inhibitor	O
of	O
HIV	O
replication	O
in	O
CD8+	B-cell_type
T-cells	I-cell_type
.	O

The	O
expression	O
of	O
MIP-1	B-protein
alpha	I-protein
is	O
induced	O
during	O
cellular	O
activation	O
of	O
CD4+	B-cell_type
T-cells	I-cell_type
and	O
monocytes	B-cell_type
.	O

It	O
is	O
also	O
expressed	O
in	O
transformed	B-cell_line
B-cells	I-cell_line
.	O

We	O
have	O
previously	O
identified	O
a	O
new	O
transcription	B-protein
factor	I-protein
family	I-protein
(	O
the	O
MNP	B-protein
family	I-protein
)	O
whose	O
expression	O
is	O
crucial	O
for	O
the	O
induction	O
of	O
MIP-1	B-protein
alpha	I-protein
transcription	O
during	O
cellular	O
activation	O
and	O
in	O
transformed	B-cell_line
B	I-cell_line
cells	I-cell_line
.	O

Monocytes	O
and	O
transformed	B-cell_line
B-cells	I-cell_line
normally	O
express	O
MNP-1	B-protein
strongly	O
and	O
MNP-2	B-protein
weakly	O
,	O
while	O
T-cells	O
strongly	O
express	O
only	O
MNP-2	B-protein
.	O

Recently	O
,	O
we	O
reported	O
that	O
HIV-1	B-protein
tat	I-protein
downregulates	O
MIP-1	B-protein
alpha	I-protein
expression	O
in	O
Jurkat	B-cell_line
T-cells	I-cell_line
.	O

In	O
this	O
report	O
we	O
show	O
induction	O
of	O
MNP-1	B-protein
in	O
Jurkat	B-cell_line
T-cells	I-cell_line
expressing	O
HIV-1	B-protein
tat	I-protein
.	O

Expression	O
of	O
neither	O
HTLV-1	B-protein
tax	I-protein
in	O
Jurkat	B-cell_line
T-cells	I-cell_line
nor	O
EBV	O
in	O
B-cells	B-cell_type
had	O
any	O
effect	O
on	O
MNP-1	B-protein
or	O
MNP-2	B-protein
expression	O
,	O
showing	O
that	O
the	O
effect	O
is	O
specific	O
for	O
HIV-1	B-protein
tat	I-protein
.	O

We	O
propose	O
that	O
HIV-1	B-protein
tat	I-protein
may	O
inhibit	O
MIP-1	B-protein
alpha	I-protein
expression	O
by	O
inducing	O
MNP-1	B-protein
expression	O
in	O
T-cells	B-cell_type
,	O
probably	O
by	O
either	O
competing	O
with	O
MNP-2	B-protein
for	O
binding	O
to	O
the	O
MIP-1	B-DNA
alpha	I-DNA
promoter	I-DNA
or	O
by	O
sequestering	O
it	O
into	O
inactive	O
forms	O
.	O

Differentiation	O
of	O
T-helper	B-cell_type
lymphocytes	I-cell_type
:	O
selective	O
regulation	O
by	O
members	O
of	O
the	O
STAT	B-protein
family	I-protein
of	O
transcription	B-protein
factors	I-protein
.	O

Interleukin-4	B-protein
(	O
IL-4	B-protein
)	O
and	O
interleukin-12	B-protein
(	O
IL-12	B-protein
)	O
control	O
the	O
differentiation	O
of	O
T-helper	B-cell_type
cells	I-cell_type
.	O

Here	O
we	O
summarize	O
studies	O
which	O
investigate	O
the	O
mechanism	O
by	O
which	O
these	O
cytokines	B-protein
selectively	O
reprogramme	O
gene	O
expression	O
in	O
T-lymphocytes	B-cell_type
.	O

Cytokine	B-protein
stimulation	O
leads	O
to	O
the	O
phosphorylation	O
of	O
specific	O
tyrosine	O
residues	O
within	O
the	O
intracellular	B-protein
domain	I-protein
of	O
the	O
corresponding	O
cytokine	B-protein
receptor	I-protein
.	O

These	O
phosphotyrosines	O
serve	O
as	O
docking	B-protein
sites	I-protein
for	O
latent	O
,	O
cytoplasmic	B-protein
transcription	I-protein
factors	I-protein
known	O
as	O
signal	B-protein
transducers	I-protein
and	I-protein
activators	I-protein
of	I-protein
transcription	I-protein
(	I-protein
Stat	I-protein
)	I-protein
proteins	I-protein
.	O

Receptor/Stat	O
interaction	O
is	O
mediated	O
by	O
the	O
src	B-protein
homology	I-protein
2	I-protein
(	I-protein
SH2	I-protein
)	I-protein
domain	I-protein
of	O
the	O
corresponding	O
Stat	B-protein
protein	I-protein
.	O

Although	O
Stat	O
binding	O
to	O
the	O
intracellular	B-protein
domain	I-protein
of	O
the	O
cytokine	B-protein
receptor	I-protein
strongly	O
depends	O
on	O
the	O
phosphotyrosine	O
residue	O
,	O
the	O
recruitment	O
of	O
a	O
specific	O
Stat	B-protein
protein	I-protein
is	O
dictated	O
by	O
amino	O
acid	O
residues	O
C-terminal	O
to	O
the	O
phosphotyrosine	O
.	O

Specific	O
docking	B-protein
sites	I-protein
within	O
individual	O
cytokine	B-protein
receptors	I-protein
have	O
been	O
identified	O
for	O
almost	O
all	O
Stat	B-protein
proteins	I-protein
.	O

The	O
direct	O
coupling	O
between	O
cytokine	B-protein
receptor	I-protein
and	O
transcription	B-protein
factor	I-protein
helps	O
to	O
explain	O
how	O
different	O
cytokines	B-protein
elicit	O
distinct	O
patterns	O
of	O
gene	O
expression	O
.	O

Role	O
of	O
EGR1	B-protein
in	O
regulation	O
of	O
stimulus-dependent	O
CD44	B-protein
transcription	O
in	O
B	O
lymphocytes	O
.	O

The	O
immediate-early	B-DNA
gene	I-DNA
egr-1	B-DNA
encodes	O
a	O
transcription	B-protein
factor	I-protein
(	O
EGR1	B-protein
)	O
that	O
links	O
B-cell	B-protein
antigen	I-protein
receptor	I-protein
(	O
BCR	B-protein
)	O
signals	O
to	O
downstream	O
activation	O
events	O
through	O
the	O
regulation	O
of	O
previously	O
unidentified	O
target	B-DNA
genes	I-DNA
.	O

Here	O
we	O
identify	O
the	O
gene	O
encoding	O
the	O
lymphocyte	B-protein
homing	I-protein
and	I-protein
migration	I-protein
protein	I-protein
CD44	B-protein
as	O
a	O
target	O
of	O
EGR1	B-protein
regulation	O
in	O
B	B-cell_type
cells	I-cell_type
.	O

BCR	B-protein
-induced	O
increases	O
in	O
CD44	B-RNA
mRNA	I-RNA
expression	O
and	O
transcription	O
levels	O
are	O
shown	O
to	O
occur	O
in	O
EGR1-expressing	B-cell_line
but	I-cell_line
not	I-cell_line
in	I-cell_line
nonexpressing	I-cell_line
subclones	I-cell_line
of	O
the	O
B-cell	B-cell_line
line	I-cell_line
WEHI-231	B-cell_line
.	O

Kinetics	O
of	O
egr-1	B-DNA
transcription	O
and	O
the	O
appearance	O
of	O
nuclear	O
EGR1	B-protein
protein	I-protein
precede	O
CD44	B-protein
induction	O
and	O
occur	O
within	O
30	O
min	O
after	O
stimulation	O
in	O
the	O
EGR1-expressing	B-cell_line
subclone	I-cell_line
.	O

A	O
single	O
EGR1	B-protein
binding	O
motif	O
is	O
demonstrated	O
at	O
bp	O
-301	O
of	O
the	O
human	B-DNA
CD44	I-DNA
promoter	I-DNA
.	O

Cotransfection	O
of	O
a	O
CD44	B-DNA
promoter-chloramphenicol	I-DNA
acetyltransferase	I-DNA
reporter	I-DNA
construct	I-DNA
with	O
an	O
egr-1	B-DNA
expression	I-DNA
vector	I-DNA
resulted	O
in	O
a	O
6.5-	O
to	O
8.5-fold	O
induction	O
of	O
transcriptional	O
activity	O
relative	O
to	O
an	O
empty	B-DNA
expression	I-DNA
vector	I-DNA
.	O

The	O
EGR1	B-DNA
binding	I-DNA
motif	I-DNA
was	O
shown	O
to	O
be	O
necessary	O
for	O
stimulus-induced	O
expression	O
of	O
a	O
CD44	B-protein
promoter-chloramphenicol	B-DNA
acetyltransferase	I-DNA
reporter	I-DNA
construct	I-DNA
in	O
nontransformed	B-cell_type
B	I-cell_type
lymphocytes	I-cell_type
and	O
was	O
required	O
for	O
transactivation	O
by	O
an	O
EGR1	B-DNA
expression	I-DNA
vector	I-DNA
in	O
a	O
B-cell	B-cell_line
line	I-cell_line
.	O

These	O
studies	O
identify	O
EGR1	B-protein
as	O
an	O
intermediary	O
linking	O
BCR	B-protein
-derived	O
signals	O
to	O
the	O
induction	O
of	O
CD44	B-protein
.	O

The	O
relevance	O
of	O
these	O
molecular	O
events	O
to	O
BCR	B-protein
signal	O
transduction	O
and	O
antigen-stimulated	O
B-cell-mediated	O
immune	O
responses	O
is	O
discussed	O
.	O

Involvement	O
of	O
intracellular	O
Ca2+	O
in	O
oxidant-induced	O
NF-kappa	B-protein
B	I-protein
activation	O
.	O

In	O
human	B-cell_line
Jurkat	I-cell_line
T	I-cell_line
cells	I-cell_line
and	O
its	O
subclone	O
Wurzburg	B-cell_line
cells	I-cell_line
oxidant	O
challenge	O
elevated	O
[	O
Ca2+	O
]	O
i	O
by	O
mobilizing	O
Ca2+	O
from	O
intracellular	O
stores	O
.	O

In	O
Jurkat	B-cell_line
cells	I-cell_line
this	O
effect	O
was	O
rapid	O
and	O
transient	O
,	O
but	O
in	O
Wurzburg	B-cell_line
cells	I-cell_line
the	O
response	O
was	O
slow	O
and	O
sustained	O
.	O

H2O2-induced	O
NF-kappaB	B-protein
activation	O
in	O
Wurzburg	B-cell_line
cells	I-cell_line
was	O
not	O
influenced	O
by	O
the	O
presence	O
of	O
extracellular	O
EGTA	O
but	O
was	O
totally	O
inhibited	O
in	O
cells	O
that	O
were	O
loaded	O
with	O
esterified	O
EGTA	O
.	O

In	O
Jurkat	B-cell_line
cells	I-cell_line
that	O
are	O
not	O
sensitive	O
to	O
H2O2-induced	O
NF-kappaB	B-protein
activation	O
,	O
H2O2	O
potentiated	O
NF-kappaB	B-protein
activation	O
in	O
the	O
presence	O
of	O
sustained	O
high	O
[	O
Ca2+	O
]	O
i	O
following	O
thapsigargin	O
treatment	O
.	O

NF-kappaB	B-protein
regulatory	O
effect	O
of	O
alpha-lipoate	O
and	O
N-acetylcysteine	O
appeared	O
to	O
be	O
,	O
at	O
least	O
in	O
part	O
,	O
due	O
to	O
their	O
ability	O
to	O
stabilize	O
elevation	O
of	O
[	O
Ca2+	O
]	O
i	O
following	O
oxidant	O
challenge	O
.	O

Results	O
of	O
this	O
study	O
indicate	O
that	O
a	O
sustained	O
elevated	O
[	O
Ca2+	O
]	O
i	O
is	O
a	O
significant	O
factor	O
in	O
oxidant-induced	O
NF-kappaB	B-protein
activation	O
.	O

Transactivation	O
of	O
the	O
interleukin-1alpha	B-DNA
promoter	I-DNA
by	O
human	B-protein
T-cell	I-protein
leukemia	I-protein
virus	I-protein
type	I-protein
I	I-protein
and	I-protein
type	I-protein
II	I-protein
Tax	I-protein
proteins	I-protein
.	O

Human	B-cell_line
T-cell	I-cell_line
leukemia	I-cell_line
virus	I-cell_line
type	I-cell_line
I	I-cell_line
(	I-cell_line
HTLV-I	I-cell_line
)	I-cell_line
-infected	I-cell_line
T-cell	I-cell_line
lines	I-cell_line
constitutively	O
produce	O
high	O
levels	O
of	O
interleukin-1alpha	B-protein
(	O
IL-1alpha	B-protein
)	O
.	O

To	O
analyze	O
the	O
mechanisms	O
that	O
lead	O
to	O
the	O
expression	O
of	O
IL-1alpha	B-protein
in	O
HTLV-I-infected	B-cell_line
cell	I-cell_line
lines	I-cell_line
,	O
we	O
studied	O
regulatory	O
regions	O
of	O
the	O
human	O
IL-1alpha	B-DNA
promoter	I-DNA
involved	O
in	O
activation	O
of	O
the	O
IL-1alpha	B-DNA
gene	I-DNA
.	O

IL-1alpha	B-DNA
promoter	I-DNA
constructs	I-DNA
drive	O
transcription	O
of	O
the	O
chloramphenicol	B-DNA
acetyltransferase	I-DNA
(	I-DNA
CAT	I-DNA
)	I-DNA
reporter	I-DNA
gene	I-DNA
in	O
HTLV-I-positive	B-cell_line
MT-2	I-cell_line
cells	I-cell_line
,	O
which	O
constitutively	O
produce	O
IL-1alpha	B-protein
.	O

In	O
a	O
cotransfection	O
assay	O
,	O
the	O
Tax	B-protein
protein	I-protein
of	O
both	O
HTLV-I	O
and	O
HTLV-II	O
specifically	O
activated	O
transcription	O
from	O
the	O
IL-1alpha	B-DNA
promoter	I-DNA
in	O
an	O
uninfected	B-cell_line
Jurkat	I-cell_line
cell	I-cell_line
line	I-cell_line
.	O

A	O
mutant	O
Tax	B-protein
protein	I-protein
deficient	O
in	O
transactivation	O
of	O
genes	O
by	O
the	O
nuclear	B-protein
factor	I-protein
(	I-protein
NF	I-protein
)	I-protein
-kappaB	I-protein
pathway	O
was	O
unable	O
to	O
induce	O
transcriptional	O
activity	O
of	O
IL-1alpha	B-DNA
promoter-CAT	I-DNA
constructs	I-DNA
,	O
but	O
was	O
rescued	O
by	O
exogenous	O
provision	O
of	O
p65/p50	B-protein
NF-kappaB	B-protein
.	O

We	O
found	O
that	O
two	O
IL-1alpha	B-DNA
kappaB-like	I-DNA
sites	I-DNA
(	O
positions	O
-1	B-DNA
,	I-DNA
065	I-DNA
to	I-DNA
-1	I-DNA
,	I-DNA
056	I-DNA
and	O
+646	B-DNA
to	I-DNA
+655	I-DNA
)	O
specifically	O
formed	O
a	O
complex	O
with	O
NF-kappaB	B-protein
-containing	O
nuclear	O
extract	O
from	O
MT-2	B-cell_line
cells	I-cell_line
and	O
that	O
NF-kappaB	B-protein
bound	O
with	O
higher	O
affinity	O
to	O
the	O
3	B-DNA
'	I-DNA
NF-kappaB	I-DNA
binding	I-DNA
site	I-DNA
than	O
to	O
the	O
5	B-DNA
'	I-DNA
NF-kappaB	I-DNA
site	I-DNA
.	O

Moreover	O
,	O
deletion	O
of	O
either	O
5	B-DNA
'	I-DNA
or	I-DNA
3	I-DNA
'	I-DNA
NF-kappaB	I-DNA
sites	I-DNA
reduced	O
IL-1alpha	B-DNA
promoter	I-DNA
activity	O
in	O
MT-2	B-cell_line
cells	I-cell_line
and	O
transactivation	O
of	O
the	O
IL-1alpha	B-DNA
promoter	I-DNA
by	O
exogenous	O
NF-kappaB	B-protein
and	O
Tax	B-protein
in	O
Jurkat	B-cell_line
cells	I-cell_line
.	O

These	O
data	O
suggest	O
a	O
general	O
role	O
for	O
Tax	B-protein
induction	O
of	O
IL-1alpha	B-DNA
gene	I-DNA
transcription	O
by	O
the	O
NF-kappaB	B-protein
pathway	O
.	O

Expression	O
of	O
IL-1alpha	B-protein
by	O
HTLV-I	O
productively	O
infected	B-cell_type
cells	I-cell_type
may	O
be	O
important	O
in	O
the	O
hypercalcemia	O
,	O
osteolytic	O
bone	O
lesions	O
,	O
neutrophilia	O
,	O
elevation	O
of	O
C-reactive	B-protein
protein	I-protein
,	O
and	O
fever	O
frequently	O
seen	O
in	O
patients	O
with	O
HTLV-I-induced	O
adult	O
T-cell	O
leukemia/lymphoma	O
.	O

The	O
myeloid-cell-specific	B-DNA
c-fes	I-DNA
promoter	I-DNA
is	O
regulated	O
by	O
Sp1	B-protein
,	O
PU.1	B-protein
,	O
and	O
a	O
novel	O
transcription	B-protein
factor	I-protein
.	O

The	O
protein	O
product	O
of	O
the	O
c-fps/fes	B-DNA
(	I-DNA
c-fes	I-DNA
)	I-DNA
proto-oncogene	I-DNA
has	O
been	O
implicated	O
in	O
the	O
normal	O
development	O
of	O
myeloid	B-cell_type
cells	I-cell_type
(	O
macrophages	B-cell_type
and	O
neutrophils	B-cell_type
)	O
.	O

mRNA	O
for	O
c-fes	O
has	O
been	O
detected	O
exclusively	O
in	O
myeloid	B-cell_type
cells	I-cell_type
and	O
vascular	B-cell_type
endothelial	I-cell_type
cells	I-cell_type
in	O
adult	O
mammals	O
.	O

Although	O
a	O
13-kilobase-pair	B-DNA
(	I-DNA
kb	I-DNA
)	I-DNA
human	I-DNA
c-fes	I-DNA
transgene	I-DNA
exhibits	O
high	O
levels	O
of	O
expression	O
in	O
mice	O
,	O
the	O
sequences	O
that	O
confer	O
myeloid-cell-specific	O
expression	O
of	O
the	O
human	B-DNA
c-fes	I-DNA
gene	I-DNA
have	O
not	O
been	O
defined	O
.	O

Transient-transfection	O
experiments	O
demonstrated	O
that	O
plasmids	B-DNA
containing	O
446	O
bp	O
of	O
c-fes	B-DNA
5'-flanking	I-DNA
sequences	I-DNA
linked	O
to	O
a	O
luciferase	O
reporter	O
gene	O
were	O
active	O
exclusively	O
in	O
myeloid	B-cell_type
cells	I-cell_type
.	O

No	O
other	O
DNA	O
element	O
within	O
the	O
13-kb	B-DNA
human	I-DNA
c-fes	I-DNA
locus	I-DNA
contained	O
positive	B-DNA
cis-acting	I-DNA
elements	I-DNA
,	O
with	O
the	O
exception	O
of	O
a	O
weakly	O
active	O
region	O
within	O
the	O
3'-flanking	B-DNA
sequences	I-DNA
.	O

DNase	O
I	O
footprinting	O
assays	O
revealed	O
four	O
distinct	O
sites	O
that	O
bind	O
myeloid	B-protein
nuclear	I-protein
proteins	I-protein
(	O
-408	B-DNA
to	I-DNA
-386	I-DNA
,	O
-293	B-DNA
to	I-DNA
-254	I-DNA
,	O
-76	B-DNA
to	I-DNA
-65	I-DNA
,	O
and	O
-34	B-DNA
to	I-DNA
+3	I-DNA
)	O
.	O

However	O
,	O
the	O
first	O
two	O
footprints	O
resided	O
in	O
sequences	O
that	O
were	O
largely	O
dispensable	O
for	O
transient	O
activity	O
.	O

Plasmids	O
containing	O
151	B-DNA
bp	I-DNA
of	O
5'-flanking	B-DNA
sequences	I-DNA
confer	O
myeloid-cell-specific	O
gene	O
expression	O
.	O

Electrophoretic	O
mobility	O
shift	O
analyses	O
demonstrated	O
that	O
the	O
151-bp	B-DNA
region	I-DNA
contains	O
nuclear	B-DNA
protein	I-DNA
binding	I-DNA
sites	I-DNA
for	O
Sp1	B-protein
,	O
PU.1	B-protein
,	O
and/or	O
Elf-1	B-protein
,	O
and	O
a	O
novel	B-protein
factor	I-protein
.	O

This	O
unidentified	O
factor	O
binds	O
immediately	O
3	O
'	O
of	O
the	O
PU.1/Elf-1	B-DNA
sites	I-DNA
and	O
appears	O
to	O
be	O
myeloid	O
cell	O
specific	O
.	O

Mutation	O
of	O
the	O
PU.1	B-protein
/Elf-1	B-protein
site	O
or	O
the	O
3	B-DNA
'	I-DNA
site	I-DNA
(	O
FP4-3	B-DNA
'	I-DNA
)	O
within	O
the	O
context	O
of	O
the	O
c-fes	B-DNA
promoter	I-DNA
resulted	O
in	O
substantially	O
reduced	O
activity	O
in	O
transient	O
transfections	O
.	O

Furthermore	O
,	O
transient-cotransfection	O
assay	O
demonstrated	O
that	O
PU.1	B-protein
(	O
and	O
not	O
Elf-1	B-protein
)	O
can	O
transactivate	O
the	O
c-fes	B-DNA
promoter	I-DNA
in	O
nonmyeloid	B-cell_line
cell	I-cell_line
lines	I-cell_line
.	O

We	O
conclude	O
that	O
the	O
human	B-DNA
c-fes	I-DNA
gene	I-DNA
contains	O
a	O
strong	O
myeloid-cell-specific	B-DNA
promoter	I-DNA
that	O
is	O
regulated	O
by	O
Sp1	B-protein
,	O
PU.1	B-protein
,	O
and	O
a	O
novel	O
transcription	B-protein
factor	I-protein
.	O

IL-10	B-protein
inhibits	O
nuclear	B-protein
factor-kappa	I-protein
B/Rel	I-protein
nuclear	O
activity	O
in	O
CD3-stimulated	B-cell_line
human	I-cell_line
peripheral	I-cell_line
T	I-cell_line
lymphocytes	I-cell_line
.	O

IL-10	B-protein
markedly	O
reduces	O
nuclear	O
factor	O
(	B-protein
NF	I-protein
)	I-protein
-kappa	I-protein
B/Rel	I-protein
nuclear	O
activity	O
induced	O
in	O
PBMC	B-cell_type
by	O
stimulation	O
with	O
the	O
anti-CD3	B-protein
mAb	I-protein
OKT3	B-protein
.	O

The	O
inhibition	O
is	O
exerted	O
specifically	O
on	O
the	O
NF-kappa	B-protein
B/Rel	I-protein
activation	O
induced	O
by	O
mAb	B-protein
OKT3	I-protein
,	O
and	O
not	O
that	O
produced	O
by	O
PMA	O
.	O

As	O
judged	O
by	O
supershifting	O
the	O
DNA-protein	B-protein
complexes	I-protein
with	O
Abs	B-protein
recognizing	O
specific	O
components	O
of	O
the	O
NF-kappa	B-protein
B/Rel	I-protein
protein	I-protein
family	I-protein
,	O
the	O
p50/p65	B-protein
(	O
Rel	B-protein
A	I-protein
)	O
heterodimeric	O
form	O
of	O
NF-kappa	B-protein
B	I-protein
is	O
primarily	O
affected	O
.	O

The	O
maximal	O
effect	O
is	O
observed	O
at	O
the	O
IL-10	B-protein
concentration	O
of	O
20	O
U/ml	O
.	O

IL-10	B-protein
inhibitory	O
activity	O
is	O
exerted	O
on	O
T	B-cell_type
lymphocytes	I-cell_type
and	O
is	O
mediated	O
by	O
monocytes	B-cell_type
.	O

Indeed	O
,	O
monocytes	B-cell_type
pretreated	O
with	O
IL-10	B-protein
are	O
able	O
so	O
inhibit	O
NF-kappa	B-protein
B	I-protein
nuclear	O
activity	O
in	O
purified	O
T	B-cell_type
lymphocytes	I-cell_type
stimulated	O
with	O
OKT3	B-protein
.	O

Soluble	O
factors	O
do	O
not	O
appear	O
to	O
be	O
involved	O
in	O
the	O
mechanism	O
of	O
inhibition	O
.	O

On	O
the	O
other	O
hand	O
,	O
the	O
up-regulation	O
of	O
CD80	B-protein
Ag	I-protein
,	O
found	O
on	O
monocytes	B-cell_type
obtained	O
from	O
PBMC	B-cell_type
incubated	O
with	O
OKT3	B-protein
,	O
is	O
not	O
detected	O
after	O
addition	O
of	O
IL-10	B-protein
,	O
and	O
the	O
anti-CD28	B-protein
mAb	I-protein
CLB-CD28/1	B-protein
restores	O
the	O
NF-kappa	B-protein
B/Rel	I-protein
nuclear	O
activity	O
in	O
IL-10-inhibited	B-cell_line
lymphocytes	I-cell_line
.	O

Therefore	O
,	O
the	O
NF-kappa	B-protein
B/Rel	I-protein
inhibition	O
might	O
be	O
ascribed	O
to	O
a	O
lack	O
of	O
cooperation	O
between	O
accessory	O
cells	O
and	O
T	B-cell_type
lymphocytes	I-cell_type
,	O
resulting	O
from	O
down-regulation	O
of	O
a	O
costimulatory	O
molecule	O
,	O
such	O
as	O
CD80	B-protein
,	O
produced	O
by	O
IL-10	B-protein
on	O
activated	O
monocytes	B-cell_type
.	O

Our	O
results	O
demonstrate	O
that	O
IL-10	B-protein
can	O
inhibit	O
the	O
induction	O
of	O
NF-kappa	B-protein
B/Rel	I-protein
nuclear	O
activity	O
in	O
CD3-stimulated	B-cell_line
T	I-cell_line
lymphocytes	I-cell_line
.	O

Since	O
inappropriate	O
activation	O
of	O
kappa	B-DNA
B-driven	I-DNA
genes	I-DNA
has	O
a	O
physiopathologic	O
role	O
in	O
a	O
number	O
of	O
diseases	O
,	O
such	O
as	O
HIV	O
infection	O
,	O
our	O
findings	O
support	O
the	O
possibility	O
of	O
using	O
this	O
cytokine	O
to	O
suppress	O
an	O
undesirable	O
activation	O
of	O
these	O
transcription	B-protein
factors	I-protein
.	O

Expression	O
of	O
A-myb	B-DNA
,	O
but	O
not	O
c-myb	B-DNA
and	O
B-myb	B-DNA
,	O
is	O
restricted	O
to	O
Burkitt	O
's	O
lymphoma	O
,	O
sIg+	O
B-acute	O
lymphoblastic	O
leukemia	O
,	O
and	O
a	O
subset	O
of	O
chronic	O
lymphocytic	O
leukemias	O
.	O

The	O
A-myb	B-DNA
gene	I-DNA
encodes	O
a	O
transcription	B-protein
factor	I-protein
that	O
is	O
related	O
both	O
functionally	O
and	O
structurally	O
to	O
the	O
v-myb	B-DNA
oncogene	I-DNA
.	O

Following	O
our	O
observations	O
that	O
A-myb	B-DNA
is	O
expressed	O
in	O
a	O
restricted	O
subset	O
of	O
normal	O
mature	B-cell_type
human	I-cell_type
B	I-cell_type
lymphocytes	I-cell_type
,	O
with	O
the	O
phenotype	O
CD38+	O
,	O
CD39-	O
,	O
slgM-	O
,	O
we	O
have	O
now	O
investigated	O
the	O
pattern	O
of	O
A-myb	B-DNA
expression	O
in	O
neoplastic	O
B	B-cell_type
cells	I-cell_type
representating	O
the	O
whole	O
spectrum	O
of	O
B-cell	O
differentiation	O
and	O
compared	O
it	O
to	O
that	O
of	O
c-myb	B-DNA
and	O
B-myb	B-DNA
.	O

In	O
a	O
panel	O
of	O
32	O
B-cell	B-cell_line
lines	I-cell_line
,	O
A-myb	B-DNA
was	O
very	O
strongly	O
expressed	O
in	O
most	O
Burkitt	O
's	O
lymphoma	O
(	O
BL	O
)	O
cell	O
lines	O
,	O
but	O
weak	O
or	O
negative	O
in	O
2	O
pre-B	O
acute	O
lymphoblastic	O
leukemia	O
(	O
ALL	O
)	O
,	O
4	O
non-Hodgkin	O
's	O
lymphoma	O
(	O
NHL	O
)	O
,	O
6	O
Epstein-Barr	B-cell_line
virus-immortalized	I-cell_line
lymphoblastoid	I-cell_line
cell	I-cell_line
lines	I-cell_line
,	O
and	O
6	O
myeloma	B-cell_line
lines	I-cell_line
.	O

Protein	O
expression	O
paralleled	O
that	O
of	O
the	O
RNA	O
.	O

We	O
have	O
also	O
investigated	O
A-myb	B-DNA
expression	O
in	O
49	O
fresh	O
cases	O
of	O
B	O
leukemias	O
.	O

Among	O
24	O
ALL	O
,	O
6	O
were	O
of	O
the	O
null	O
and	O
11	O
of	O
the	O
common	O
type	O
and	O
all	O
these	O
were	O
negative	O
for	O
A-myb	B-protein
expression	O
;	O
on	O
the	O
other	O
hand	O
,	O
all	O
7	O
B-ALL	O
cases	O
(	O
slg+	O
)	O
,	O
as	O
well	O
as	O
one	O
fresh	O
BL	O
case	O
with	O
bone	O
marrow	O
infiltration	O
,	O
expressed	O
A-myb	B-DNA
.	O

A-myb	B-DNA
was	O
undetectable	O
in	O
4	O
prolymphocytic	O
leukemias	O
(	O
PLL	O
)	O
but	O
was	O
strongly	O
expressed	O
in	O
5/20	O
(	O
25	O
%	O
)	O
of	O
chronic	O
lymphocytic	O
leukemia	O
(	O
CLL	O
)	O
samples	O
.	O

In	O
the	O
latter	O
A-myb	B-DNA
did	O
not	O
correlate	O
with	O
phenotype	O
or	O
clinical	O
stage	O
.	O

Finally	O
,	O
we	O
have	O
studied	O
the	O
progression	O
of	O
one	O
case	O
of	O
CLL	O
into	O
Richter	O
's	O
syndrome	O
and	O
have	O
found	O
that	O
the	O
Richter	B-cell_line
's	I-cell_line
cells	I-cell_line
expressed	O
about	O
25-fold	O
less	O
A-myb	B-RNA
RNA	I-RNA
than	O
the	O
CLL	B-cell_line
cells	I-cell_line
from	O
the	O
same	O
patient.	O
The	O
pattern	O
of	O
c-myb	B-DNA
and	O
B-myb	B-DNA
was	O
clearly	O
distinct	O
from	O
that	O
of	O
A-myb	B-DNA
.	O

C-myb	O
and	O
B-myb	B-DNA
were	O
expressed	O
in	O
all	O
neoplastic	O
groups	O
,	O
except	O
in	O
CLL	B-cell_line
cells	I-cell_line
.	O

Thus	O
,	O
A-myb	B-DNA
expression	O
,	O
unlike	O
that	O
of	O
c-myb	B-DNA
and	O
B-myb	B-DNA
,	O
is	O
restricted	O
to	O
a	O
subset	O
of	O
B-cell	O
neoplasias	O
(	O
in	O
particular	O
BL	O
and	O
slg+B-ALL	O
)	O
representative	O
of	O
a	O
specific	O
stage	O
of	O
B-cell	O
differentiation	O
.	O

This	O
expression	O
may	O
in	O
part	O
reflect	O
expression	O
of	O
A-myb	B-DNA
by	O
the	O
normal	O
germinal	O
center	O
B	B-cell_type
cells	I-cell_type
that	O
are	O
the	O
normal	O
counterpart	O
of	O
these	O
transformed	B-cell_line
B	I-cell_line
cells	I-cell_line
.	O

The	O
data	O
presented	O
strongly	O
support	O
a	O
role	O
for	O
this	O
transcription	B-protein
factor	I-protein
in	O
B-cell	O
differentiation	O
and	O
perhaps	O
in	O
B-cell	O
transformation	O
in	O
some	O
neoplasias	O
.	O

Granulocyte-macrophage	B-protein
colony-stimulating	I-protein
factor	I-protein
stimulates	O
JAK2	B-protein
signaling	O
pathway	O
and	O
rapidly	O
activates	O
p93fes	B-protein
,	O
STAT1	B-protein
p91	I-protein
,	O
and	O
STAT3	B-protein
p92	I-protein
in	O
polymorphonuclear	B-cell_type
leukocytes	I-cell_type
.	O

Granulocyte-macrophage	B-protein
colony-stimulating	I-protein
factor	I-protein
(	O
GM-CSF	B-protein
)	O
,	O
supports	O
proliferation	O
,	O
differentiation	O
,	O
and	O
functional	O
activation	O
of	O
hemopoietic	O
cells	O
by	O
its	O
interaction	O
with	O
a	O
heterodimeric	O
receptor	O
.	O

Although	O
GM-CSF	B-protein
receptor	O
is	O
devoid	O
of	O
tyrosine	B-protein
kinase	I-protein
enzymatic	O
activity	O
,	O
GM-CSF-induced	B-cell_line
peripheral	I-cell_line
blood	I-cell_line
polymorphonuclear	I-cell_line
leukocytes	I-cell_line
(	O
PMN	B-cell_type
)	O
functional	O
activation	O
is	O
mediated	O
by	O
the	O
phosphorylation	O
of	O
a	O
large	O
number	O
of	O
intracellular	B-protein
signaling	I-protein
molecules	I-protein
.	O

We	O
have	O
previously	O
shown	O
that	O
JAK2	B-protein
becomes	O
tyrosine-phosphorylated	O
in	O
response	O
to	O
GM-CSF	B-protein
in	O
PMN	B-cell_type
.	O

In	O
the	O
present	O
study	O
we	O
demonstrate	O
that	O
also	O
the	O
signal	B-protein
transducers	I-protein
and	I-protein
activators	I-protein
of	I-protein
transcription	I-protein
(	I-protein
STAT	I-protein
)	I-protein
family	I-protein
members	I-protein
STAT1	B-protein
p91	I-protein
and	O
STAT3	B-protein
p92	I-protein
and	O
the	O
product	O
of	O
the	O
c-fps/fes	B-DNA
protooncogene	I-DNA
become	O
tyrosine-phosphorylated	O
upon	O
GM-CSF	B-protein
stimulation	O
and	O
physically	O
associated	O
with	O
both	O
GM-CSF	B-protein
receptor	O
beta	O
common	O
subunit	O
and	O
JAK2	B-protein
.	O

Moreover	O
GM-CSF	B-protein
was	O
able	O
to	O
induce	O
JAK2	B-protein
and	O
p93fes	B-protein
catalytic	O
activity	O
.	O

We	O
also	O
demonstrate	O
that	O
the	O
association	O
of	O
the	O
GM-CSF	B-protein
receptor	I-protein
beta	I-protein
common	I-protein
subunit	I-protein
with	O
JAK2	B-protein
is	O
ligand-dependent	O
.	O

Finally	O
we	O
demonstrate	O
that	O
GM-CSF	B-protein
induces	O
a	O
DNA-binding	B-protein
complex	I-protein
that	O
contains	O
both	O
p91	B-protein
and	O
p92	B-protein
.	O

These	O
results	O
identify	O
a	O
new	O
signal	O
transduction	O
pathway	O
activated	O
by	O
GM-CSF	B-protein
and	O
provide	O
a	O
mechanism	O
for	O
rapid	O
activation	O
of	O
gene	O
expression	O
in	O
GM-CSF-stimulated	B-cell_type
PMN	I-cell_type
.	O

Epstein-Barr	B-protein
virus	I-protein
nuclear	I-protein
antigen	I-protein
2	I-protein
(	I-protein
EBNA2	I-protein
)	I-protein
-oestrogen	I-protein
receptor	I-protein
fusion	I-protein
proteins	I-protein
complement	O
the	O
EBNA2-deficient	O
Epstein-Barr	O
virus	O
strain	O
P3HR1	O
in	O
transformation	O
of	O
primary	B-cell_type
B	I-cell_type
cells	I-cell_type
but	O
suppress	O
growth	O
of	O
human	B-cell_line
B	I-cell_line
cell	I-cell_line
lymphoma	I-cell_line
lines	I-cell_line
.	O

To	O
develop	O
a	O
transformation	O
system	O
with	O
a	O
conditional	O
Epstein-Barr	B-DNA
virus	I-DNA
nuclear	I-DNA
antigen	I-DNA
2	I-DNA
(	I-DNA
EBNA2	I-DNA
)	I-DNA
gene	I-DNA
,	O
we	O
fused	O
the	O
hormone	B-protein
binding	I-protein
domain	I-protein
of	O
the	O
oestrogen	O
receptor	O
to	O
the	O
N	B-protein
or	I-protein
C	I-protein
terminus	I-protein
of	O
EBNA2	B-protein
.	O

In	O
promoter	O
transactivation	O
as	O
well	O
as	O
primary	O
B	O
cell	O
transformation	O
assays	O
these	O
chimeric	O
EBNA2	B-protein
proteins	O
are	O
able	O
to	O
substitute	O
for	O
wild-type	B-protein
EBNA2	I-protein
in	O
the	O
presence	O
of	O
oestrogen	O
.	O

Here	O
we	O
provide	O
evidence	O
that	O
this	O
transformation	O
is	O
the	O
result	O
of	O
double	O
infection	O
of	O
a	O
cell	O
with	O
two	O
virions	O
,	O
the	O
P3HR1	B-DNA
virus	I-DNA
genome	I-DNA
and	O
a	O
mini-EBV	B-DNA
plasmid	I-DNA
carrying	O
the	O
chimeric	O
EBNA2	B-DNA
gene	I-DNA
.	O

Unexpectedly	O
,	O
expression	O
of	O
the	O
same	O
EBNA2	B-protein
-oestrogen	O
receptor	O
fusion	O
protein	O
in	O
established	B-cell_line
human	I-cell_line
B	I-cell_line
cell	I-cell_line
lymphoma	I-cell_line
lines	I-cell_line
resulted	O
in	O
growth	O
retardation	O
or	O
growth	O
arrest	O
upon	O
the	O
addition	O
of	O
oestrogen	O
.	O

By	O
titrating	O
the	O
oestrogen	O
concentration	O
in	O
these	O
stably	B-cell_line
transfected	I-cell_line
cells	I-cell_line
,	O
the	O
growth	O
retarding	O
and	O
the	O
transactivating	O
function	O
of	O
the	O
chimeric	B-protein
proteins	I-protein
could	O
not	O
be	O
dissociated	O
.	O

We	O
propose	O
that	O
growth	O
inhibition	O
of	O
established	O
B	B-cell_line
cell	I-cell_line
lymphoma	I-cell_line
lines	I-cell_line
is	O
a	O
novel	O
function	O
of	O
EBNA2	B-protein
which	O
has	O
not	O
been	O
detected	O
in	O
the	O
absence	O
of	O
an	O
inducible	O
system	O
.	O

It	O
remains	O
open	O
whether	O
the	O
growth	O
retarding	O
property	O
of	O
the	O
EBNA2-oestrogen	B-protein
receptor	I-protein
fusion	I-protein
protein	I-protein
in	O
B	B-cell_line
cell	I-cell_line
lymphoma	I-cell_line
lines	I-cell_line
is	O
due	O
to	O
unphysiologically	O
high	O
expression	O
of	O
the	O
chimeric	B-protein
protein	I-protein
or	O
to	O
interference	O
with	O
a	O
cellular	O
programme	O
driving	O
proliferation	O
in	O
these	O
cell	B-cell_line
lines	I-cell_line
.	O

Tissue-specific	O
activity	O
of	O
the	O
gammac	B-DNA
chain	I-DNA
gene	I-DNA
promoter	I-DNA
depends	O
upon	O
an	O
Ets	B-DNA
binding	I-DNA
site	I-DNA
and	O
is	O
regulated	O
by	O
GA-binding	B-protein
protein	I-protein
.	O

The	O
gammac	B-protein
chain	I-protein
is	O
a	O
subunit	O
of	O
multiple	O
cytokine	B-protein
receptors	I-protein
(	O
interleukin	B-protein
(	I-protein
IL	I-protein
)	I-protein
-2	I-protein
,	O
IL-4	B-protein
,	O
IL-7	B-protein
,	O
IL-9	B-protein
,	O
and	O
IL-15	B-protein
)	O
,	O
the	O
expression	O
of	O
which	O
is	O
restricted	O
to	O
hematopoietic	B-cell_type
lineages	I-cell_type
.	O

A	O
defect	O
in	O
gammac	O
leads	O
to	O
the	O
X-linked	O
severe	O
combined	O
immunodeficiency	O
characterized	O
by	O
a	O
block	O
in	O
T	O
cell	O
differentiation	O
.	O

In	O
order	O
to	O
better	O
characterize	O
the	O
human	B-DNA
gammac	I-DNA
promoter	I-DNA
and	O
define	O
the	O
minimal	B-DNA
tissue-specific	I-DNA
promoter	I-DNA
region	I-DNA
,	O
progressive	O
5'-deletion	B-DNA
constructs	I-DNA
of	O
a	O
segment	O
extending	O
1053	B-DNA
base	I-DNA
pairs	I-DNA
upstream	I-DNA
of	O
the	O
major	B-DNA
transcription	I-DNA
start	I-DNA
site	I-DNA
were	O
generated	O
and	O
tested	O
for	O
promoter	O
activity	O
in	O
various	O
hematopoietic	B-cell_type
and	I-cell_type
nonhematopoietic	I-cell_type
cell	I-cell_type
types	I-cell_type
.	O

The	O
-1053/+34	B-DNA
construct	I-DNA
allowed	O
promoter	O
activity	O
only	O
in	O
cells	O
of	O
hematopoietic	B-cell_type
origin	I-cell_type
,	O
and	O
tissue	O
specificity	O
was	O
conserved	O
in	O
all	O
other	O
constructs	O
tested	O
.	O

The	O
region	O
downstream	O
of	O
-90	O
appeared	O
critical	O
for	O
basal	O
promoter	O
activity	O
.	O

It	O
contains	O
two	O
potential	O
Ets	B-DNA
binding	I-DNA
sites	I-DNA
conserved	O
in	O
the	O
murine	B-DNA
gammac	I-DNA
promoter	I-DNA
gene	I-DNA
,	O
one	O
of	O
which	O
was	O
found	O
essential	O
for	O
functional	O
promoter	O
activity	O
as	O
determined	O
by	O
mutational	O
analysis	O
.	O

The	O
functional	O
Ets	B-DNA
binding	I-DNA
site	I-DNA
was	O
found	O
to	O
bind	O
Ets	B-protein
family	I-protein
proteins	I-protein
,	O
principally	O
GA-binding	B-protein
protein	I-protein
and	O
Elf-1	B-protein
and	O
could	O
be	O
transactivated	O
by	O
GABPalpha	B-protein
and	O
-beta	B-protein
synergistically	O
.	O

These	O
results	O
indicate	O
that	O
,	O
as	O
already	O
reported	O
for	O
the	O
IL2Rbeta	B-DNA
promoter	I-DNA
,	O
GA-binding	B-protein
protein	I-protein
is	O
an	O
essential	O
component	O
of	O
gammac	O
basal	O
promoter	O
activity	O
.	O

Although	O
GABP	B-protein
expression	O
is	O
not	O
restricted	O
to	O
the	O
hematopoietic	B-cell_type
lineage	I-cell_type
,	O
its	O
interaction	O
with	O
other	O
specific	B-protein
factors	I-protein
may	O
contribute	O
to	O
the	O
tissue-specific	O
expression	O
of	O
the	O
gammac	B-DNA
gene	I-DNA
.	O

Detection	O
of	O
intracellular	B-protein
signal	I-protein
transduction	I-protein
molecules	I-protein
in	O
PBMC	B-cell_type
from	O
rhesus	O
macaques	O
and	O
sooty	O
mangabeys	O
.	O

One	O
of	O
the	O
manifestations	O
of	O
human	O
HIV-1	O
and	O
nonhuman	O
primate	O
SIV	O
infection	O
that	O
lead	O
to	O
disease	O
is	O
reasoned	O
to	O
be	O
secondary	O
to	O
generalized	O
T-cell	O
dysfunction	O
.	O

The	O
molecular	O
mechanisms	O
associated	O
with	O
the	O
T-cell	O
dysfunction	O
remain	O
to	O
be	O
elucidated	O
.	O

To	O
address	O
this	O
issue	O
,	O
we	O
sought	O
to	O
utilize	O
the	O
nonhuman	O
primate	O
model	O
to	O
study	O
intracellular	O
signaling	O
events	O
in	O
cells	O
from	O
disease-susceptible	O
rhesus	O
macaques	O
and	O
disease-resistant	O
sooty	O
mangabeys	O
.	O

Because	O
relatively	O
little	O
is	O
known	O
about	O
these	O
events	O
in	O
nonhuman	O
primates	O
,	O
our	O
laboratory	O
defined	O
optimal	O
conditions	O
,	O
reagents	O
,	O
and	O
assays	O
for	O
the	O
study	O
of	O
signal	O
transduction	O
events	O
in	O
cells	O
from	O
nonhuman	O
primates	O
.	O

The	O
protein	O
phosphorylation	O
patterns	O
in	O
the	O
two	O
monkeys	O
exhibited	O
quantitative	O
,	O
qualitative	O
,	O
and	O
kinetic	O
differences	O
.	O

Antibodies	O
to	O
Stat6	B-protein
detected	O
a	O
unique	O
band	O
in	O
macaque	O
cell	O
lysates	O
.	O

This	O
band	O
is	O
markedly	O
decreased	O
human	O
cell	O
lysates	O
and	O
never	O
seen	O
in	O
mangabey	O
cell	O
lysates	O
.	O

Detection	O
of	O
various	O
other	O
intracellular	B-protein
signaling	I-protein
proteins	I-protein
is	O
also	O
described	O
.	O

Genetic	O
characterization	O
of	O
transactivation	O
of	O
the	O
human	B-DNA
T-cell	I-DNA
leukemia	I-DNA
virus	I-DNA
type	I-DNA
1	I-DNA
promoter	I-DNA
:	O
Binding	O
of	O
Tax	B-protein
to	O
Tax-responsive	B-DNA
element	I-DNA
1	I-DNA
is	O
mediated	O
by	O
the	O
cyclic	B-protein
AMP-responsive	I-protein
members	I-protein
of	O
the	O
CREB/ATF	B-protein
family	I-protein
of	O
transcription	O
factors	O
.	O

To	O
achieve	O
a	O
better	O
understanding	O
of	O
the	O
mechanism	O
of	O
transactivation	O
by	O
Tax	B-protein
of	O
human	O
T-cell	O
leukemia	O
virus	O
type	O
1	O
Tax-responsive	B-DNA
element	I-DNA
1	I-DNA
(	O
TRE-1	B-DNA
)	O
,	O
we	O
developed	O
a	O
genetic	O
approach	O
with	O
Saccharomyces	O
cerevisiae	O
.	O

We	O
constructed	O
a	O
yeast	O
reporter	O
strain	O
containing	O
the	O
lacZ	B-DNA
gene	I-DNA
under	O
the	O
control	O
of	O
the	O
CYC1	B-DNA
promoter	I-DNA
associated	O
with	O
three	O
copies	O
of	O
TRE-1	B-DNA
.	O

Expression	O
of	O
either	O
the	O
cyclic	B-protein
AMP	I-protein
response	I-protein
element-binding	I-protein
protein	I-protein
(	O
CREB	B-protein
)	O
or	O
CREB	B-protein
fused	O
to	O
the	O
GAL4	B-protein
activation	I-protein
domain	I-protein
(	O
GAD	B-protein
)	O
in	O
this	O
strain	O
did	O
not	O
modify	O
the	O
expression	O
of	O
the	O
reporter	B-DNA
gene	I-DNA
.	O

Tax	B-protein
alone	O
was	O
also	O
inactive	O
.	O

However	O
,	O
expression	O
of	O
the	O
reporter	B-DNA
gene	I-DNA
was	O
induced	O
by	O
coexpression	O
of	O
Tax	B-protein
and	O
CREB	B-protein
.	O

This	O
effect	O
was	O
stronger	O
with	O
the	O
GAD-CREB	B-protein
fusion	I-protein
protein	I-protein
.	O

Analysis	O
of	O
different	O
CREB	B-protein
mutants	I-protein
with	O
this	O
genetic	O
system	O
indicated	O
that	O
the	O
C-terminal	B-protein
92	I-protein
amino	I-protein
acid	I-protein
residues	I-protein
,	O
which	O
include	O
the	O
basic	B-protein
domain	I-protein
and	O
the	O
leucine	B-protein
zipper	I-protein
,	O
are	O
necessary	O
and	O
sufficient	O
to	O
mediate	O
transactivation	O
by	O
Tax	B-protein
.	O

To	O
identify	O
cellular	B-protein
proteins	I-protein
binding	O
to	O
TRE-1	B-DNA
in	O
a	O
Tax	B-protein
-dependent	O
manner	O
,	O
this	O
strain	O
was	O
also	O
used	O
to	O
screen	O
a	O
library	O
of	O
human	B-DNA
cDNAs	I-DNA
fused	O
to	O
GAD	B-protein
.	O

Of	O
five	O
positive	O
clones	O
isolated	O
from	O
0.75	O
x	O
10	O
(	O
6	O
)	O
yeast	O
colonies	O
,	O
four	O
were	O
members	O
of	O
the	O
CREB/activating	B-protein
transcription	I-protein
factor	I-protein
(	I-protein
ATF	I-protein
)	I-protein
family	I-protein
:	O
CREB	B-protein
,	O
two	B-protein
isoforms	I-protein
of	I-protein
the	I-protein
cyclic	I-protein
AMP-responsive	I-protein
element	I-protein
modulator	I-protein
(	O
CREM	B-protein
)	O
,	O
and	O
ATF-1	B-protein
.	O

Interestingly	O
,	O
these	O
three	O
proteins	O
can	O
be	O
phosphorylated	O
by	O
protein	B-protein
kinase	I-protein
A	I-protein
and	O
thus	O
form	O
a	O
particular	O
subgroup	O
within	O
the	O
CREB/ATF	B-protein
family	I-protein
.	O

Expression	O
of	O
ATF-2	B-protein
in	O
S.	O
cerevisiae	O
did	O
not	O
activate	O
TRE-1	B-DNA
in	O
the	O
presence	O
of	O
Tax	B-protein
.	O

This	O
shows	O
that	O
in	O
a	O
eukaryotic	O
nucleus	O
,	O
Tax	B-protein
specifically	O
interacts	O
with	O
the	O
basic	B-protein
domain-leucine	I-protein
zipper	I-protein
region	I-protein
of	O
ATF-1	B-protein
,	O
CREB	B-protein
,	O
and	O
CREM	B-protein
.	O

The	O
fifth	O
clone	O
identified	O
in	O
this	O
screening	O
corresponded	O
to	O
the	O
Ku	B-protein
autoantigen	I-protein
p70	I-protein
subunit	I-protein
.	O

When	O
fused	O
to	O
GAD	B-protein
,	O
the	O
C-terminal	B-protein
region	I-protein
of	O
Ku	B-protein
was	O
able	O
to	O
activate	O
transcription	O
via	O
TRE-1	B-DNA
but	O
this	O
activation	O
was	O
not	O
dependent	O
on	O
Tax	B-protein
.	O

A	O
mammalian	B-protein
histone	I-protein
deacetylase	I-protein
related	O
to	O
the	O
yeast	B-protein
transcriptional	I-protein
regulator	I-protein
Rpd3p	B-protein
[	O
see	O
comments	O
]	O

Trapoxin	O
is	O
a	O
microbially	O
derived	O
cyclotetrapeptide	O
that	O
inhibits	O
histone	B-protein
deacetylation	O
in	O
vivo	O
and	O
causes	O
mammalian	O
cells	O
to	O
arrest	O
in	O
the	O
cell	O
cycle	O
.	O

A	O
trapoxin	O
affinity	O
matrix	O
was	O
used	O
to	O
isolate	O
two	O
nuclear	O
proteins	O
that	O
copurified	O
with	O
histone	B-protein
deacetylase	I-protein
activity	O
.	O

Both	O
proteins	O
were	O
identified	O
by	O
peptide	O
microsequencing	O
,	O
and	O
a	O
complementary	B-DNA
DNA	I-DNA
encoding	O
the	O
histone	B-protein
deacetylase	I-protein
catalytic	I-protein
subunit	I-protein
(	O
HD1	B-protein
)	O
was	O
cloned	O
from	O
a	O
human	O
Jurkat	O
T	O
cell	O
library	O
.	O

As	O
the	O
predicted	O
protein	O
is	O
very	O
similar	O
to	O
the	O
yeast	B-protein
transcriptional	I-protein
regulator	I-protein
Rpd3p	B-protein
,	O
these	O
results	O
support	O
a	O
role	O
for	O
histone	B-protein
deacetylase	I-protein
as	O
a	O
key	O
regulator	O
of	O
eukaryotic	O
transcription	O
.	O

Coexpression	O
of	O
the	O
interleukin-13	B-DNA
and	I-DNA
interleukin-4	I-DNA
genes	I-DNA
correlates	O
with	O
their	O
physical	O
linkage	O
in	O
the	O
cytokine	B-DNA
gene	I-DNA
cluster	I-DNA
on	O
human	B-DNA
chromosome	I-DNA
5q23-31	I-DNA
.	O

Interleukin-13	B-protein
(	O
IL-13	B-protein
)	O
and	O
IL-4	B-protein
are	O
cytokines	O
produced	O
by	O
T	O
cells	O
that	O
are	O
encoded	O
by	O
the	O
q23-31	O
region	O
of	O
human	O
chromosome	O
5	O
.	O

To	O
investigate	O
the	O
regulation	O
of	O
IL-13	B-DNA
gene	I-DNA
expression	O
by	O
T	B-cell_type
cells	I-cell_type
,	O
we	O
isolated	O
and	O
sequenced	O
the	O
human	O
IL-13	B-DNA
gene	I-DNA
,	O
analyzed	O
its	O
5'-flanking	B-DNA
region	I-DNA
for	O
potential	O
transcriptional	B-DNA
activation	I-DNA
elements	I-DNA
,	O
and	O
examined	O
its	O
expression	O
in	O
nontransformed	B-cell_line
T-lineage	I-cell_line
cell	I-cell_line
populations	I-cell_line
.	O

The	O
human	B-DNA
IL-13	I-DNA
gene	I-DNA
was	O
located	O
12.5-kb	B-DNA
upstream	I-DNA
of	O
the	O
IL-4	B-DNA
gene	I-DNA
and	O
2-kb	B-DNA
downstream	I-DNA
of	O
a	O
CpG	B-DNA
island	I-DNA
.	O

The	O
IL-13	B-DNA
gene	I-DNA
5	I-DNA
'	I-DNA
flank	I-DNA
region	I-DNA
included	O
a	O
segment	O
with	O
sequence	O
homology	O
to	O
P	B-DNA
elements	I-DNA
of	O
the	O
IL-4	B-DNA
promoter	I-DNA
involved	O
in	O
transcriptional	O
activation	O
in	O
T	B-cell_type
cells	I-cell_type
.	O

Mutation	O
of	O
the	O
IL-13	B-DNA
P	I-DNA
element	I-DNA
site	I-DNA
significantly	O
reduced	O
IL-13	B-protein
promoter	O
activity	O
in	O
response	O
to	O
T-cell	O
activation	O
.	O

Oligonucleotides	O
containing	O
the	O
IL-13	B-protein
or	O
IL-4	B-DNA
P	I-DNA
element	I-DNA
sites	I-DNA
specifically	O
bound	O
the	O
transcriptional	B-protein
activator	I-protein
protein	I-protein
,	O
nuclear	B-protein
factor-activated	I-protein
T	I-protein
cells	I-protein
,	O
preformed	O
(	O
NF-ATp	B-protein
)	O
,	O
when	O
incubated	O
with	O
nuclear	O
protein	O
extracts	O
from	O
activated	B-cell_type
T	I-cell_type
cells	I-cell_type
.	O

Similar	O
to	O
IL-4	B-protein
,	O
IL-13	B-RNA
mRNA	I-RNA
expression	O
was	O
highest	O
in	O
T-cell	B-cell_line
populations	I-cell_line
enriched	O
for	O
cells	O
that	O
had	O
previously	O
been	O
primed	O
in	O
vivo	O
or	O
in	O
vitro	O
,	O
indicating	O
that	O
priming	O
increases	O
the	O
expression	O
of	O
the	O
IL-13	B-DNA
and	I-DNA
IL-4	I-DNA
genes	I-DNA
in	O
a	O
coordinate	O
manner	O
.	O

Because	O
the	O
primed	B-cell_line
T	I-cell_line
cells	I-cell_line
contain	O
higher	O
levels	O
of	O
nuclear	B-protein
NF-ATp	I-protein
,	O
capable	O
of	O
binding	O
to	O
P	B-DNA
elements	I-DNA
of	O
the	O
IL-4	B-DNA
and	I-DNA
IL-13	I-DNA
promoters	I-DNA
,	O
than	O
do	O
freshly-isolated	B-cell_type
T	I-cell_type
cells	I-cell_type
,	O
the	O
NF-AT-binding	B-DNA
P	I-DNA
elements	I-DNA
are	O
attractive	O
candidates	O
to	O
mediate	O
the	O
coordinate	O
expression	O
of	O
these	O
two	O
cytokine	B-DNA
genes	I-DNA
.	O

Inhibition	O
of	O
alpha	B-protein
interferon	I-protein
but	O
not	O
gamma	B-protein
interferon	I-protein
signal	O
transduction	O
by	O
phorbol	O
esters	O
is	O
mediated	O
by	O
a	O
tyrosine	B-protein
phosphatase	I-protein
.	O

Previous	O
studies	O
have	O
indicated	O
that	O
the	O
expression	O
of	O
viral	O
oncoproteins	O
,	O
cell	O
transformation	O
,	O
or	O
phorbol	O
ester	O
treatment	O
of	O
cells	O
can	O
inhibit	O
alpha/beta	O
interferon	O
(	O
IFN-alpha/beta	O
)	O
-induced	O
gene	O
expression	O
.	O

The	O
mechanisms	O
by	O
which	O
these	O
promoters	O
of	O
cell	O
growth	O
exert	O
their	O
inhibitory	O
effects	O
vary	O
,	O
but	O
in	O
most	O
instances	O
they	O
involve	O
a	O
disruption	O
of	O
the	O
IFN-alpha/beta-induced	O
transcription	O
complex	O
ISGF3	O
such	O
that	O
the	O
DNA-binding	O
component	O
of	O
this	O
complex	O
(	O
the	O
48-kDa	O
ISGF3gamma	O
protein	O
)	O
does	O
not	O
bind	O
to	O
the	O
interferon-stimulated	O
response	O
element	O
(	O
ISRE	O
)	O
.	O

In	O
this	O
report	O
,	O
we	O
demonstrated	O
that	O
phorbol	O
ester	O
treatment	O
of	O
human	O
peripheral	O
blood	O
monocytes	O
dramatically	O
inhibits	O
activation	O
of	O
IFN-alpha/B-stimulated	O
early	O
response	O
genes	O
but	O
by	O
a	O
mechanism	O
which	O
does	O
not	O
involve	O
abrogation	O
of	O
the	O
ISRE	O
binding	O
of	O
ISGF3gamma	O
.	O

Phorbol	O
ester	O
treatment	O
of	O
monocytes	O
inhibited	O
IFN	O
alpha-stimulated	O
tyrosine	O
phosphorylation	O
of	O
the	O
transcription	B-protein
factors	I-protein
Stat1alpha	B-protein
,	O
Stat2	B-protein
,	O
and	O
Stat3	B-protein
and	O
of	O
the	O
tyrosine	B-protein
kinase	I-protein
Tyk2	B-protein
but	O
had	O
no	O
effect	O
on	O
IFN-gamma	B-protein
activation	O
of	O
Stat1alpha	B-protein
.	O

IFNalpha-stimulated	O
tyrosine	O
phosphorylation	O
of	O
Jak1	B-protein
and	O
the	O
alpha	B-protein
subunit	I-protein
of	O
the	O
IFN-alpha	B-protein
receptor	I-protein
were	O
unaffected	O
by	O
phorbol	O
12-myristate	O
13-acetate	O
(	O
PMA	O
)	O
.	O

Moreover	O
,	O
PMA	O
caused	O
the	O
dephosphorylation	O
of	O
Tyk2	B-protein
but	O
not	O
of	O
Jak1	B-protein
,	O
which	O
was	O
activated	O
by	O
IFN	B-protein
.	O

Pretreatment	O
of	O
cells	O
with	O
vanadate	O
prevented	O
the	O
effects	O
of	O
PMA	O
with	O
regard	O
to	O
PMA-induced	O
Tyk2	B-protein
dephosphorylation	O
.	O

These	O
observations	O
suggest	O
that	O
PMA	O
exerts	O
its	O
inhibitory	O
effects	O
by	O
activation	O
of	O
a	O
tyrosine	B-protein
phosphatase	I-protein
which	O
selectively	O
regulates	O
Tyk2	B-protein
but	O
not	O
Jak1	B-protein
activity	O
.	O

Transcriptional	O
regulation	O
of	O
the	O
interleukin-2	B-DNA
gene	I-DNA
in	O
normal	O
human	B-cell_type
peripheral	I-cell_type
blood	I-cell_type
T	I-cell_type
cells	I-cell_type
.	O

Convergence	O
of	O
costimulatory	O
signals	O
and	O
differences	O
from	O
transformed	B-cell_type
T	I-cell_type
cells	I-cell_type
.	O

To	O
study	O
transcriptional	O
regulation	O
in	O
normal	B-cell_type
human	I-cell_type
T	I-cell_type
cells	I-cell_type
,	O
we	O
have	O
optimized	O
conditions	O
for	O
transient	O
transfection	O
.	O

Interleukin-2	B-DNA
(	I-DNA
IL-2	I-DNA
)	I-DNA
promoter	I-DNA
-reporter	B-DNA
gene	I-DNA
behavior	O
closely	O
parallels	O
the	O
endogenous	B-DNA
gene	I-DNA
in	O
response	O
to	O
T	B-protein
cell	I-protein
receptor	I-protein
and	O
costimulatory	O
signals	O
.	O

As	O
assessed	O
with	O
mutagenized	B-DNA
promoters	I-DNA
,	O
the	O
most	O
important	O
IL-2	B-DNA
cis-regulatory	I-DNA
elements	I-DNA
in	O
normal	B-cell_type
T	I-cell_type
cells	I-cell_type
are	O
the	O
proximal	B-DNA
AP-1	I-DNA
site	I-DNA
and	O
the	O
NF-	B-DNA
kappaB	I-DNA
site	I-DNA
.	O

Both	O
primary	O
activation	O
,	O
with	O
phytohemagglutinin	B-protein
or	O
antibodies	B-protein
to	I-protein
CD3	I-protein
,	O
and	O
costimulation	O
,	O
provided	O
by	O
pairs	O
of	O
CD2	B-protein
antibodies	I-protein
or	O
B7-positive	B-cell_type
(	I-cell_type
B	I-cell_type
cells	I-cell_type
)	I-cell_type
or	O
B7-negative	B-cell_type
(	I-cell_type
endothelial	I-cell_type
)	I-cell_type
accessory	I-cell_type
cells	I-cell_type
,	I-cell_type
are	O
mediated	O
through	O
the	O
same	O
cis-elements	B-DNA
.	O

Interestingly	O
,	O
the	O
nuclear	B-DNA
factor	I-DNA
of	I-DNA
activated	I-DNA
T	I-DNA
cell	I-DNA
sites	I-DNA
are	O
much	O
less	O
important	O
in	O
normal	B-cell_type
T	I-cell_type
cells	I-cell_type
than	O
in	O
Jurkat	B-cell_line
T	I-cell_line
cells	I-cell_line
.	O

We	O
conclude	O
that	O
IL-2	B-protein
transcriptional	O
regulation	O
differs	O
in	O
tumor	B-cell_line
cell	I-cell_line
lines	I-cell_line
compared	O
with	O
normal	B-cell_type
T	I-cell_type
cells	I-cell_type
and	O
that	O
different	O
costimulatory	O
signals	O
converge	O
on	O
the	O
same	O
cis-elements	B-DNA
in	O
the	O
IL-2	B-DNA
promoter	I-DNA
.	O

The	O
RAR-RXR	B-protein
as	O
well	O
as	O
the	O
RXR-RXR	B-protein
pathway	O
is	O
involved	O
in	O
signaling	O
growth	O
inhibition	O
of	O
human	B-cell_line
CD34+	I-cell_line
erythroid	I-cell_line
progenitor	I-cell_line
cells	I-cell_line
.	O

Previous	O
studies	O
have	O
shown	O
that	O
retinoic	O
acid	O
(	O
RA	O
)	O
,	O
similar	O
to	O
tumor	B-protein
necrosis	I-protein
factor-alpha	I-protein
(	O
TNF-alpha	B-protein
)	O
,	O
can	O
act	O
as	O
a	O
bifunctional	O
regulator	O
of	O
the	O
growth	O
of	O
bone	B-cell_type
marrow	I-cell_type
progenitors	I-cell_type
,	O
in	O
that	O
it	O
can	O
stimulate	O
granulocyte-macrophage	O
colony-stimulating	O
factor	O
(	O
GM-CSF	O
)	O
-	O
or	O
interleukin-3	O
(	O
IL-3	O
)	O
-induced	O
GM	O
colony	O
formation	O
,	O
but	O
potently	O
inhibit	O
G-CSF	B-protein
-induced	O
growth	O
.	O

The	O
present	O
study	O
,	O
using	O
highly	O
enriched	O
human	B-protein
CD34+	I-protein
as	O
well	O
as	O
Lin-	B-cell_line
murine	I-cell_line
bone	I-cell_line
marrow	I-cell_line
progenitor	I-cell_line
cells	I-cell_line
,	O
demonstrates	O
a	O
potent	O
inhibitory	O
effect	O
of	O
9-cis-RA	O
on	O
burst-forming	O
unit-erythroid	O
(	O
BFU-E	O
)	O
colony	O
formation	O
regardless	O
of	O
the	O
cytokine	B-protein
stimulating	O
growth	O
.	O

Specifically	O
,	O
9-cis-RA	O
potently	O
inhibited	O
the	O
growth	O
of	O
BFU-E	O
response	O
to	O
erythropoietin	B-protein
(	O
Epo	B-protein
)	O
(	O
100	O
%	O
)	O
,	O
stem	B-protein
cell	I-protein
factor	I-protein
(	O
SCF	B-protein
)	O
+	O
Epo	B-protein
(	O
92	O
%	O
)	O
,	O
IL-3	B-protein
+	O
Epo	B-protein
(	O
97	O
%	O
)	O
,	O
IL-4	B-protein
+	O
Epo	B-protein
(	O
88	O
%	O
)	O
,	O
and	O
IL-9	B-protein
+	O
Epo	B-protein
(	O
100	O
%	O
)	O
.	O

Erythroid	O
colony	O
growth	O
was	O
also	O
inhibited	O
when	O
CD34+	B-cell_type
progenitors	I-cell_type
were	O
seeded	O
at	O
one	O
cell	O
per	O
well	O
,	O
suggesting	O
a	O
direct	O
action	O
of	O
RA	O
.	O

Using	O
synthetic	O
ligands	O
to	O
retinoic	B-protein
acid	I-protein
receptors	I-protein
(	O
RARs	B-protein
)	O
and	O
retinoid	B-protein
X	I-protein
receptors	I-protein
(	O
RXRs	B-protein
)	O
that	O
selectively	O
bind	O
and	O
activate	O
RAR-RXR	B-protein
or	O
RXR-RXR	B-protein
dimers	O
,	O
respectively	O
,	O
we	O
dissected	O
the	O
involvement	O
of	O
the	O
two	O
retinoid	O
response	O
pathways	O
in	O
the	O
regulation	O
of	O
normal	O
myeloid	O
and	O
erythroid	O
progenitor	O
cell	O
growth	O
.	O

Transactivation	O
studies	O
showed	O
that	O
both	O
the	O
RAR	B-protein
(	O
Ro	O
13-7410	O
)	O
and	O
RXR	B-protein
(	O
Ro	O
25-6603	O
and	O
Ro	O
25-7386	O
)	O
ligands	O
were	O
highly	O
selective	O
at	O
100	O
nmol/L	O
.	O

At	O
this	O
concentration	O
,	O
Ro	O
13-7410	O
potently	O
inhibited	O
G-CSF	B-protein
-stimulated	O
myeloid	O
as	O
well	O
as	O
SCF	B-protein
+	O
Epo	B-protein
-induced	O
erythroid	O
colony	O
growth	O
.	O

At	O
the	O
same	O
concentration	O
,	O
Ro	O
25-6603	O
and	O
Ro	O
25-7386	O
had	O
little	O
or	O
no	O
effect	O
on	O
G-CSF	B-protein
-induced	O
colony	O
formation	O
,	O
whereas	O
they	O
inhibited	O
75	O
%	O
and	O
53	O
%	O
,	O
respectively	O
,	O
of	O
SCF	B-protein
+	O
Epo	B-protein
-stimulated	O
BFU-E	O
colony	O
growth	O
.	O

Thus	O
,	O
the	O
RAR-RXR	B-protein
response	O
pathway	O
can	O
signal	O
growth	O
inhibition	O
of	O
normal	B-cell_type
bone	I-cell_type
marrow	I-cell_type
myeloid	I-cell_type
and	I-cell_type
erythroid	I-cell_type
progenitor	I-cell_type
cells	I-cell_type
.	O

In	O
addition	O
,	O
we	O
demonstrate	O
a	O
unique	O
involvement	O
of	O
the	O
RXR-RXR	B-protein
pathway	O
in	O
mediating	O
growth	O
inhibition	O
of	O
erythroid	B-cell_type
but	O
not	O
myeloid	B-cell_type
progenitor	I-cell_type
cells	I-cell_type
.	O

AM580	O
,	O
a	O
stable	O
benzoic	O
derivative	O
of	O
retinoic	O
acid	O
,	O
has	O
powerful	O
and	O
selective	O
cyto-differentiating	O
effects	O
on	O
acute	B-cell_line
promyelocytic	I-cell_line
leukemia	I-cell_line
cells	I-cell_line
.	O

All-trans	O
retinoic	O
acid	O
(	O
ATRA	O
)	O
is	O
successfully	O
used	O
in	O
the	O
cyto-differentiating	O
treatment	O
of	O
acute	O
promyelocytic	O
leukemia	O
(	O
APL	O
)	O
.	O

Paradoxically	O
,	O
APL	B-cell_line
cells	I-cell_line
express	O
PML-RAR	B-protein
,	O
an	O
aberrant	O
form	O
of	O
the	O
retinoic	B-protein
acid	I-protein
receptor	I-protein
type	I-protein
alpha	I-protein
(	O
RAR	B-protein
alpha	I-protein
)	O
derived	O
from	O
the	O
leukemia-specific	B-DNA
t	I-DNA
(	I-DNA
15	I-DNA
;	I-DNA
17	I-DNA
)	I-DNA
chromosomal	I-DNA
translocation	I-DNA
.	O

We	O
show	O
here	O
that	O
AM580	O
,	O
a	O
stable	O
retinobenzoic	O
derivative	O
originally	O
synthesized	O
as	O
a	O
RAR	B-protein
alpha	I-protein
agonist	O
,	O
is	O
a	O
powerful	O
inducer	O
of	O
granulocytic	O
maturation	O
in	O
NB4	B-cell_line
,	O
an	O
APL-derived	B-cell_line
cell	I-cell_line
line	I-cell_line
,	O
and	O
in	O
freshly	B-cell_type
isolated	I-cell_type
APL	I-cell_type
blasts	I-cell_type
.	O

After	O
treatment	O
of	O
APL	B-cell_line
cells	I-cell_line
with	O
AM580	O
either	O
alone	O
or	O
in	O
combination	O
with	O
granulocyte	B-protein
colony-stimulating	I-protein
factor	I-protein
(	O
G-CSF	B-protein
)	O
,	O
the	O
compound	O
induces	O
granulocytic	O
maturation	O
,	O
as	O
assessed	O
by	O
determination	O
of	O
the	O
levels	O
of	O
leukocyte	B-RNA
alkaline	I-RNA
phosphatase	I-RNA
,	I-RNA
CD11b	I-RNA
,	I-RNA
CD33	I-RNA
,	I-RNA
and	I-RNA
G-CSF	I-RNA
receptor	I-RNA
mRNA	I-RNA
,	O
at	O
concentrations	O
that	O
are	O
10-	O
to	O
100-fold	O
lower	O
than	O
those	O
of	O
ATRA	O
necessary	O
to	O
produce	O
similar	O
effects	O
.	O

By	O
contrast	O
,	O
AM580	O
is	O
not	O
effective	O
as	O
ATRA	O
in	O
modulating	O
the	O
expression	O
of	O
these	O
differentiation	B-protein
markers	I-protein
in	O
the	O
HL-60	B-cell_line
cell	I-cell_line
line	I-cell_line
and	O
in	O
freshly	B-cell_type
isolated	I-cell_type
granulocytes	I-cell_type
obtained	O
from	O
the	O
peripheral	O
blood	O
of	O
chronic	O
myelogenous	O
leukemia	O
patients	O
during	O
the	O
stable	O
phase	O
of	O
the	O
disease	O
.	O

In	O
NB4	B-cell_line
cells	I-cell_line
,	O
two	O
other	O
synthetic	O
nonselective	O
RAR	O
ligands	O
are	O
capable	O
of	O
inducing	O
LAP	B-protein
as	O
much	O
as	O
AM580	O
,	O
whereas	O
RAR	O
beta-	O
or	O
RAR	O
gamma-specific	O
ligands	O
are	O
totally	O
ineffective	O
.	O

These	O
results	O
show	O
that	O
AM580	O
is	O
more	O
powerful	O
than	O
ATRA	O
in	O
modulating	O
the	O
expression	O
of	O
differentiation	O
antigens	O
only	O
in	O
cells	O
in	O
which	O
PML-RAR	B-protein
is	O
present	O
.	O

Binding	O
experiments	O
,	O
using	O
COS-7	B-cell_line
cells	I-cell_line
transiently	O
transfected	O
with	O
PML-RAR	B-protein
and	O
the	O
normal	O
RAR	B-protein
alpha	I-protein
,	O
show	O
that	O
AM580	O
has	O
a	O
lower	O
affinity	O
than	O
ATRA	O
for	O
both	O
receptors	O
.	O

However	O
,	O
in	O
the	O
presence	O
of	O
PML-RAR	B-protein
,	O
the	O
synthetic	O
retinoid	O
is	O
a	O
much	O
better	O
transactivator	O
of	O
retinoic	B-DNA
acid-responsive	I-DNA
element-containing	I-DNA
promoters	I-DNA
than	O
the	O
natural	O
retinoid	O
,	O
whereas	O
,	O
in	O
the	O
presence	O
of	O
RAR	B-protein
alpha	I-protein
,	O
AM580	O
and	O
ATRA	O
have	O
similar	O
activity	O
.	O

This	O
may	O
explain	O
the	O
strong	O
cyto-differentiating	O
potential	O
of	O
AM580	O
in	O
PML-RAR-containing	B-cell_type
leukemic	I-cell_type
cells	I-cell_type
.	O

Inhibition	O
of	O
vitamin	B-protein
D	I-protein
receptor-retinoid	I-protein
X	I-protein
receptor-vitamin	I-protein
D	I-protein
response	I-protein
element	I-protein
complex	I-protein
formation	O
by	O
nuclear	O
extracts	O
of	O
vitamin	B-cell_type
D-resistant	I-cell_type
New	I-cell_type
World	I-cell_type
primate	I-cell_type
cells	I-cell_type
.	O

Most	O
New	O
World	O
primate	O
(	O
NWP	O
)	O
genera	O
evolved	O
to	O
require	O
high	O
circulating	O
levels	O
of	O
steroid	O
hormones	O
and	O
vitamin	O
D	O
.	O

We	O
hypothesized	O
that	O
an	O
intracellular	B-protein
vitamin	I-protein
D	I-protein
binding	I-protein
protein	I-protein
(	O
IDBP	B-protein
)	O
,	O
present	O
in	O
both	O
nuclear	O
and	O
cytoplasmic	O
fractions	O
of	O
NWP	B-cell_line
cells	I-cell_line
,	O
or	O
another	O
protein	O
(	O
s	O
)	O
may	O
cause	O
or	O
contribute	O
to	O
the	O
steroid	O
hormone-resistant	O
state	O
in	O
NWP	B-cell_line
by	O
disruption	O
of	O
the	O
receptor	O
dimerization	O
process	O
and/or	O
by	O
interference	O
of	O
receptor	B-protein
complex	I-protein
binding	O
to	O
the	O
consensus	B-DNA
response	I-DNA
elements	I-DNA
present	O
in	O
the	O
enhancer	B-DNA
regions	I-DNA
of	O
steroid-responsive	B-DNA
genes	I-DNA
.	O

We	O
employed	O
electromobility	O
shift	O
assay	O
(	O
EMSA	O
)	O
to	O
screen	O
for	O
the	O
presence	O
of	O
proteins	O
capable	O
of	O
binding	O
to	O
the	O
vitamin	B-DNA
D	I-DNA
response	I-DNA
element	I-DNA
(	O
VDRE	B-DNA
)	O
.	O

Nuclear	O
and	O
post-nuclear	O
extracts	O
were	O
prepared	O
from	O
two	O
B-lymphoblastoid	B-cell_line
cell	I-cell_line
lines	I-cell_line
known	O
to	O
be	O
representative	O
of	O
the	O
vitamin	B-cell_line
D-resistant	I-cell_line
and	O
wild	B-cell_line
type	I-cell_line
phenotypes	I-cell_line
,	O
respectively	O
.	O

The	O
extracts	O
were	O
compared	O
for	O
their	O
ability	O
to	O
retard	O
the	O
migration	O
of	O
radiolabeled	O
double	O
stranded	O
oligomers	O
representative	O
of	O
the	O
VDREs	B-DNA
of	O
the	O
human	B-DNA
osteocalcin	I-DNA
and	I-DNA
the	I-DNA
mouse	I-DNA
osteopontin	I-DNA
gene	I-DNA
promoters	I-DNA
.	O

A	O
specific	O
,	O
retarded	O
band	O
containing	O
VDR-RXR	B-protein
was	O
identified	O
when	O
wild	O
type	O
cell	O
but	O
not	O
when	O
vitamin	O
D-resistant	O
cell	O
nuclear	O
extract	O
was	O
used	O
in	O
the	O
binding	O
reaction	O
with	O
either	O
probe	O
.	O

In	O
addition	O
,	O
vitamin	O
D-resistant	O
cell	O
nuclear	O
extract	O
contained	O
a	O
protein	O
(	O
s	O
)	O
which	O
was	O
bound	O
specifically	O
to	O
the	O
VDRE	B-DNA
and	O
was	O
capable	O
of	O
completely	O
inhibiting	O
VDR-RXR-VDRE	B-protein
complex	I-protein
formation	O
;	O
these	O
effects	O
were	O
not	O
demonstrated	O
with	O
nuclear	O
extract	O
from	O
the	O
wild	B-cell_line
type	I-cell_line
cell	I-cell_line
line	I-cell_line
or	O
with	O
the	O
post-nuclear	O
extract	O
of	O
the	O
vitamin	B-cell_line
D-resistant	I-cell_line
cell	I-cell_line
line	I-cell_line
.	O

We	O
conclude	O
that	O
a	O
VDRE-binding	B-protein
protein	I-protein
(	O
s	O
)	O
,	O
distinct	O
from	O
IDBP	B-protein
and	O
present	O
in	O
nuclear	O
extract	O
of	O
cells	O
from	O
a	O
prototypical	B-cell_line
vitamin	I-cell_line
D-resistant	I-cell_line
NWP	I-cell_line
,	O
is	O
capable	O
of	O
inhibiting	O
normal	O
VDR-RXR	B-protein
heterodimer	O
binding	O
to	O
the	O
VDRE	B-DNA
.	O

BCL-6	B-protein
expression	O
during	O
B-cell	O
activation	O
.	O

Translocations	O
involving	O
the	O
BCL-6	B-DNA
gene	I-DNA
are	O
common	O
in	O
the	O
diffuse	O
large	O
cell	O
subtype	O
of	O
non-Hodgkin	O
's	O
lymphoma	O
.	O

Invariably	O
,	O
the	O
BCL-6	B-protein
coding	O
region	O
is	O
intact	O
,	O
but	O
its	O
5	B-DNA
'	I-DNA
untranslated	I-DNA
region	I-DNA
is	O
replaced	O
with	O
sequences	O
from	O
the	O
translocation	B-DNA
partner	I-DNA
.	O

The	O
present	O
study	O
shows	O
that	O
BCL-6	B-protein
expression	O
is	O
regulated	O
in	O
lymphocytes	B-cell_type
during	O
mitogenic	O
stimulation	O
.	O

Resting	B-cell_type
B	I-cell_type
and	I-cell_type
T	I-cell_type
lymphocytes	I-cell_type
contain	O
high	O
levels	O
of	O
BCL-6	B-RNA
mRNA	I-RNA
.	O

Stimulation	O
of	O
mouse	B-cell_type
B	I-cell_type
cells	I-cell_type
with	O
anti-IgM	B-protein
or	I-protein
IgD	I-protein
antibodies	I-protein
,	O
bacterial	O
lipopolysaccharide	O
,	O
phorbol	O
12-myristate	O
13-acetate	O
plus	O
ionomycin	O
,	O
or	O
CD40	B-protein
ligand	I-protein
led	O
to	O
a	O
five-fold	O
to	O
35-fold	O
decrease	O
in	O
BCL-6	B-RNA
mRNA	I-RNA
levels	O
.	O

Similar	O
downregulation	O
of	O
BCL-6	B-RNA
mRNA	I-RNA
was	O
seen	O
in	O
human	B-cell_type
B	I-cell_type
cells	I-cell_type
stimulated	O
with	O
Staphylococcus	O
aureus	O
plus	O
interleukin-2	B-protein
or	O
anti-IgM	B-protein
antibodies	I-protein
and	O
in	O
human	B-cell_type
T	I-cell_type
lymphocytes	I-cell_type
stimulated	O
with	O
phytohemagglutinin	B-protein
.	O

BCL-6	B-RNA
mRNA	I-RNA
levels	O
began	O
to	O
decrease	O
8	O
to	O
16	O
hours	O
after	O
stimulation	O
,	O
before	O
cells	O
entered	O
S	O
phase	O
.	O

Although	O
polyclonal	O
activation	O
of	O
B	B-cell_type
cells	I-cell_type
in	O
vitro	O
invariably	O
decreased	O
BCL-6	B-protein
MRNA	O
expression	O
,	O
activated	B-cell_type
B	I-cell_type
cells	I-cell_type
from	O
human	O
germinal	O
centers	O
expressed	O
BCL-6	O
mRNA	O
at	O
levels	O
comparable	O
to	O
the	O
levels	O
in	O
resting	O
B	O
cells	O
.	O

Despite	O
these	O
similar	O
mRNA	O
levels	O
,	O
BCL-6	B-protein
protein	O
expression	O
was	O
threefold	O
to	O
34-fold	O
higher	O
in	O
germinal	B-cell_type
center	I-cell_type
B	I-cell_type
cells	I-cell_type
than	O
in	O
resting	B-cell_type
B	I-cell_type
cells	I-cell_type
,	O
suggesting	O
that	O
BCL-6	B-protein
protein	O
levels	O
are	O
controlled	O
by	O
translational	O
or	O
posttranslational	O
mechanisms	O
.	O

These	O
observations	O
suggest	O
that	O
the	O
germinal	O
center	O
reaction	O
provides	O
unique	O
activation	O
signals	O
to	O
B	B-cell_type
cells	I-cell_type
that	O
allow	O
for	O
continued	O
,	O
high-level	O
BCL-6	B-protein
expression	O
.	O

DNA-binding	B-protein
phosphoproteins	I-protein
induced	O
after	O
T	O
cell	O
activation	O
:	O
effects	O
of	O
cyclosporin	O
A	O
.	O

To	O
define	O
novel	B-protein
proteins	I-protein
involved	O
in	O
the	O
early	O
transcriptional	O
response	O
during	O
the	O
activation	O
of	O
human	B-cell_type
T	I-cell_type
lymphocytes	I-cell_type
,	O
we	O
used	O
a	O
high-resolution	O
,	O
two-dimensional	O
gel	O
electrophoresis	O
system	O
to	O
identify	O
nuclear	B-protein
,	I-protein
deoxyribonucleic	I-protein
acid	I-protein
(	I-protein
DNA	I-protein
)	I-protein
binding	I-protein
proteins	I-protein
exhibiting	O
rapid	O
changes	O
in	O
phosphorylation	O
following	O
cell	O
stimulation	O
.	O

We	O
identified	O
18	O
nuclear	B-protein
proteins	I-protein
whose	O
phosphorylation	O
level	O
changed	O
more	O
than	O
5-fold	O
upon	O
activation	O
.	O

Of	O
these	O
,	O
11	O
were	O
found	O
to	O
possess	O
DNA-binding	O
properties	O
.	O

The	O
11	O
phosphoproteins	B-protein
with	O
DNA-binding	O
activity	O
,	O
along	O
with	O
4	O
others	O
,	O
were	O
analyzed	O
further	O
.	O

Phosphoamino	O
acid	O
analysis	O
revealed	O
several	O
sets	O
of	O
proteins	O
with	O
different	O
phosphorylated	O
residues	O
Kinetic	O
analysis	O
of	O
the	O
phosphorylation	O
of	O
the	O
selected	O
proteins	O
was	O
performed	O
and	O
revealed	O
a	O
complex	O
group	O
of	O
transient	O
and	O
sustained	O
responses	O
to	O
cell	O
activation	O
.	O

Finally	O
,	O
the	O
activation-induced	O
changes	O
in	O
one	O
set	O
of	O
phosphoproteins	B-protein
were	O
dramatically	O
inhibited	O
by	O
cyclosporin	O
A	O
.	O

We	O
suggest	O
that	O
these	O
phosphoproteins	B-protein
may	O
be	O
directly	O
involved	O
in	O
regulating	O
the	O
transcriptional	O
response	O
to	O
cellular	O
activation	O
by	O
external	O
stimuli	O
.	O

Inactivation	O
of	O
IkappaBbeta	B-protein
by	O
the	O
tax	B-protein
protein	I-protein
of	O
human	O
T-cell	O
leukemia	O
virus	O
type	O
1	O
:	O
a	O
potential	O
mechanism	O
for	O
constitutive	O
induction	O
of	O
NF-kappaB	B-protein
.	O

In	O
resting	B-cell_type
T	I-cell_type
lymphocytes	I-cell_type
,	O
the	O
transcription	B-protein
factor	I-protein
NF-kappaB	B-protein
is	O
sequestered	O
in	O
the	O
cytoplasm	O
via	O
interactions	O
with	O
members	O
of	O
the	O
I	B-protein
kappa	I-protein
B	I-protein
family	I-protein
of	O
inhibitors	O
,	O
including	O
IkappaBalpha	B-protein
and	O
IkappaBbeta	B-protein
.	O

During	O
normal	O
T-cell	O
activation	O
,	O
IkappaBalpha	B-protein
is	O
rapidly	O
phosphorylated	O
,	O
ubiquitinated	O
,	O
and	O
degraded	O
by	O
the	O
26S	B-protein
proteasome	I-protein
,	O
thus	O
permitting	O
the	O
release	O
of	O
functional	O
NF-kappaB	B-protein
.	O

In	O
contrast	O
to	O
its	O
transient	O
pattern	O
of	O
nuclear	O
induction	O
during	O
an	O
immune	O
response	O
,	O
NF-kappaB	B-protein
is	O
constitutively	O
activated	O
in	O
cells	O
expressing	O
the	O
Tax	B-protein
transforming	I-protein
protein	I-protein
of	O
human	O
T-cell	O
leukemia	O
virus	O
type	O
I	O
(	O
HTLV-1	O
)	O
.	O

Recent	O
studies	O
indicate	O
that	O
HTLV-1	O
Tax	B-protein
targets	O
IkappaBalpha	B-protein
to	O
the	O
ubiquitin-proteasome	O
pathway	O
.	O

However	O
,	O
it	O
remains	O
unclear	O
how	O
this	O
viral	B-protein
protein	I-protein
induces	O
a	O
persistent	O
rather	O
than	O
transient	O
NF-kappaB	B-protein
response	O
.	O

In	O
this	O
report	O
,	O
we	O
provide	O
evidence	O
that	O
in	O
addition	O
to	O
acting	O
on	O
IkappaBalpha	B-protein
,	O
Tax	B-protein
stimulates	O
the	O
turnover	O
Of	O
IkappaBbeta	B-protein
via	O
a	O
related	O
targeting	O
mechanism	O
.	O

Like	O
IkappaBalpha	B-protein
,	O
Tax	B-protein
-mediated	O
breakdown	O
of	O
IkappaBbeta	B-protein
in	O
transfected	B-cell_line
T	I-cell_line
lymphocytes	I-cell_line
is	O
blocked	O
either	O
by	O
cell-permeable	O
proteasome	O
inhibitors	O
or	O
by	O
mutation	O
Of	O
IkappaBbeta	B-protein
at	O
two	O
serine	O
residues	O
present	O
within	O
its	O
N-terminal	B-protein
region	I-protein
.	O

Despite	O
the	O
dual	O
specificity	O
of	O
HTLV-1	O
Tax	B-protein
for	O
IkappaBalpha	B-protein
and	O
IkappaBbeta	B-protein
at	O
the	O
protein	O
level	O
,	O
Tax	B-protein
selectively	O
stimulates	O
NF-kappaB	B-protein
-directed	O
transcription	O
of	O
the	O
IkappaBalpha	B-DNA
gene	I-DNA
.	O

Consequently	O
,	O
IkappaBbeta	B-protein
protein	O
expression	O
is	O
chronically	O
downregulated	O
in	O
HTLV-1-infected	B-cell_type
T	I-cell_type
lymphocytes	I-cell_type
.	O

These	O
findings	O
with	O
IkappaBbeta	B-protein
provide	O
a	O
potential	O
mechanism	O
for	O
the	O
constitutive	O
activation	O
of	O
NF-kappaB	B-protein
in	O
Tax-expressing	B-cell_line
cells	I-cell_line
.	O

The	O
role	O
of	O
p16	B-protein
in	O
the	O
E2F-dependent	B-protein
thymidine	I-protein
kinase	I-protein
regulation	O
.	O

The	O
role	O
of	O
alterations	O
of	O
the	O
MTS1	B-DNA
tumor	I-DNA
suppressor	I-DNA
gene	I-DNA
on	O
chromosome	B-DNA
9p21	I-DNA
,	O
which	O
encodes	O
p16	B-protein
,	O
the	O
inhibitor	O
of	O
cyclin-dependent-kinase-4	B-protein
and	I-protein
6	I-protein
,	O
in	O
tumorigenesis	O
is	O
not	O
yet	O
clear	O
.	O

Phosphorylation	O
of	O
the	O
retinoblastoma	B-protein
protein	I-protein
by	O
cyclin-dependent	B-protein
kinases	I-protein
4	I-protein
and	I-protein
6	I-protein
prevents	O
its	O
interaction	O
with	O
the	O
transcription	B-protein
factor	I-protein
E2F	B-protein
,	O
which	O
subsequently	O
promotes	O
the	O
expression	O
of	O
S	B-DNA
phase	I-DNA
regulated	I-DNA
genes	I-DNA
,	O
such	O
as	O
thymidine	B-protein
kinase	I-protein
.	O

Although	O
a	O
role	O
of	O
p16	B-protein
in	O
this	O
regulation	O
has	O
been	O
presumed	O
,	O
there	O
is	O
no	O
proof	O
so	O
far	O
that	O
loss	O
of	O
this	O
tumor	B-DNA
suppressor	I-DNA
gene	I-DNA
really	O
affects	O
E2F	B-protein
-mediated	O
regulations	O
.	O

We	O
investigated	O
the	O
regulation	O
of	O
thymidine	B-protein
kinase	I-protein
in	O
phytohemagglutinin-stimulated	B-cell_line
normal	I-cell_line
human	I-cell_line
lymphocytes	I-cell_line
and	O
in	O
the	O
p16-negative	B-cell_line
human	I-cell_line
acute	I-cell_line
lymphoblastic	I-cell_line
leukemia	I-cell_line
cell	I-cell_line
lines	I-cell_line
,	O
MOLT-4	B-cell_line
and	O
CEM	B-cell_line
.	O

Compared	O
to	O
normal	B-cell_type
lymphocytes	I-cell_type
,	O
MOLT-4	B-cell_line
and	I-cell_line
CEM	I-cell_line
cells	I-cell_line
exhibited	O
an	O
altered	O
cell	O
cycle	O
regulation	O
of	O
thymidine	B-protein
kinase	I-protein
,	O
a	O
much	O
higher	O
intracellular	O
activity	O
of	O
this	O
enzyme	B-protein
,	O
and	O
higher	O
thymidine	B-RNA
kinase	I-RNA
mRNA	I-RNA
expression	O
.	O

Transient	O
expression	O
of	O
p16	B-protein
in	O
normal	O
human	O
lymphocytes	O
caused	O
arrest	O
in	O
G1	O
,	O
but	O
was	O
without	O
effect	O
on	O
the	O
cell	O
growth	O
of	O
MOLT-4	B-cell_line
and	I-cell_line
CEM	I-cell_line
cells	I-cell_line
,	O
although	O
all	O
of	O
them	O
express	O
functional	O
retinoblastoma	B-protein
protein	I-protein
.	O

Nevertheless	O
,	O
in	O
the	O
two	O
leukemia	B-cell_line
cell	I-cell_line
lines	I-cell_line
transient	O
overexpression	O
of	O
p16	B-protein
reestablished	O
the	O
normal	O
regulation	O
of	O
thymidine	B-protein
kinase	I-protein
,	O
paralleled	O
by	O
an	O
increase	O
of	O
the	O
underphosphorylated	O
form	O
of	O
retinoblastoma	B-protein
protein	I-protein
and	O
decrease	O
of	O
free	O
E2F	B-protein
bound	O
to	O
its	O
motif	O
in	O
the	O
thymidine	B-DNA
kinase	I-DNA
promoter	I-DNA
.	O

We	O
demonstrate	O
that	O
loss	O
of	O
p16	B-protein
causes	O
upregulation	O
of	O
this	O
DNA	O
precursor	O
pathway	O
enzyme	B-protein
via	O
activation	O
of	O
E2F	B-protein
by	O
a	O
mechanism	O
involving	O
retinoblastoma	B-protein
protein	I-protein
.	O

Interactions	O
of	O
a	O
transcriptional	B-DNA
activator	I-DNA
in	O
the	O
env	B-DNA
gene	I-DNA
of	O
the	O
mouse	O
mammary	O
tumor	O
virus	O
with	O
activation-dependent	B-protein
,	I-protein
T	I-protein
cell-specific	I-protein
transacting	I-protein
factors	I-protein
.	O

The	O
mouse	O
mammary	O
tumor	O
virus	O
env	B-DNA
gene	I-DNA
contains	O
a	O
transcriptional	B-DNA
activator	I-DNA
(	O
META	B-DNA
)	O
that	O
can	O
control	O
transcription	O
of	O
the	O
adjacent	O
long	B-DNA
terminal	I-DNA
repeat	I-DNA
region	I-DNA
.	O

Transcriptional	O
control	O
by	O
META	B-DNA
parallels	O
that	O
of	O
several	O
lymphokine	B-DNA
genes	I-DNA
,	O
being	O
specific	O
to	O
T	B-cell_type
cells	I-cell_type
,	O
dependent	O
on	O
their	O
activation	O
,	O
and	O
inhibited	O
by	O
the	O
immunosuppressive	O
drug	O
cyclosporine	O
(	O
CsA	O
)	O
.	O

DNase	B-protein
I	I-protein
footprinting	O
indicated	O
that	O
nuclear	B-protein
factors	I-protein
from	O
activated	B-cell_type
T	I-cell_type
lymphocytes	I-cell_type
bound	O
a	O
promoter-proximal	B-DNA
site	I-DNA
,	O
META	B-DNA
(	I-DNA
P	I-DNA
)	I-DNA
,	O
and	O
a	O
promoter-distal	B-DNA
site	I-DNA
,	O
META	B-DNA
(	I-DNA
D+	I-DNA
)	I-DNA
,	O
within	O
the	O
400-base	B-DNA
pair	I-DNA
META	I-DNA
region	I-DNA
.	O

Nuclear	B-protein
factors	I-protein
from	O
unstimulated	O
,	O
but	O
not	O
from	O
activated	O
cells	O
,	O
bound	O
a	O
site	O
,	O
META	B-DNA
(	I-DNA
D-	I-DNA
)	I-DNA
,	O
adjacent	O
to	O
META	B-DNA
(	I-DNA
D+	I-DNA
)	I-DNA
.	O

META	B-DNA
(	I-DNA
D+	I-DNA
)	I-DNA
directed	O
transcription	O
of	O
a	O
linked	O
luciferase	B-DNA
gene	I-DNA
,	O
and	O
gel	O
shift	O
analysis	O
revealed	O
binding	O
of	O
inducible	O
,	O
CsA-sensitive	B-protein
T	I-protein
cell	I-protein
factors	I-protein
,	O
in	O
parallel	O
with	O
transfection	O
results	O
.	O

Authentic	O
NFAT	B-DNA
and	I-DNA
NF-kappaB	I-DNA
targets	I-DNA
did	O
not	O
compete	O
for	O
the	O
META	B-protein
(	I-protein
D+	I-protein
)	I-protein
binding	I-protein
factor	I-protein
(	O
s	O
)	O
.	O

The	O
SV40	B-DNA
core	I-DNA
sequence	I-DNA
competed	O
for	O
META	B-protein
(	I-protein
D+	I-protein
)	I-protein
binding	I-protein
factors	I-protein
,	O
but	O
META	B-DNA
(	I-DNA
D+	I-DNA
)	I-DNA
failed	O
to	O
compete	O
for	O
the	O
complexes	O
obtained	O
with	O
the	O
SV40	O
probe	O
.	O

Our	O
results	O
,	O
taken	O
together	O
,	O
indicate	O
that	O
META	B-DNA
(	I-DNA
D+	I-DNA
)	I-DNA
is	O
a	O
novel	O
transcriptional	B-DNA
enhancer	I-DNA
element	I-DNA
that	O
is	O
similar	O
in	O
its	O
cell-type	O
specificity	O
,	O
activation	O
dependence	O
,	O
and	O
CsA	O
sensitivity	O
to	O
the	O
NFAT	B-DNA
element	I-DNA
.	O

It	O
may	O
be	O
relevant	O
to	O
the	O
role	O
of	O
MMTV	O
in	O
expression	O
of	O
Mls	B-protein
antigens	I-protein
or	O
the	O
induction	O
of	O
T	O
cell	O
lymphomas	O
.	O

A	O
novel	O
interferon	B-protein
regulatory	I-protein
factor	I-protein
family	I-protein
transcription	I-protein
factor	I-protein
,	O
ICSAT/Pip/LSIRF	B-protein
,	O
that	O
negatively	O
regulates	O
the	O
activity	O
of	O
interferon-regulated	B-DNA
genes	I-DNA
.	O

We	O
have	O
isolated	O
a	O
novel	B-DNA
cDNA	I-DNA
clone	I-DNA
encoding	O
interferon	B-protein
(	I-protein
IFN	I-protein
)	I-protein
consensus	I-protein
sequence-binding	I-protein
protein	I-protein
in	O
adult	B-cell_line
T-cell	I-cell_line
leukemia	I-cell_line
cell	I-cell_line
line	I-cell_line
or	O
activated	O
T	B-cell_type
cells	I-cell_type
(	O
ICSAT	B-protein
)	O
;	O
this	O
protein	O
is	O
the	O
human	O
homolog	O
of	O
the	O
recently	O
cloned	O
Pip/LSIRF	B-protein
.	O

ICSAT	B-protein
is	O
structurally	O
most	O
closely	O
related	O
to	O
the	O
previously	O
cloned	O
ICSBP	B-protein
,	O
a	O
member	O
of	O
the	O
IFN	B-protein
regulatory	I-protein
factor	I-protein
(	I-protein
IRF	I-protein
)	I-protein
family	I-protein
of	O
proteins	O
that	O
binds	O
to	O
interferon	B-DNA
consensus	I-DNA
sequences	I-DNA
(	O
ICSs	B-DNA
)	O
found	O
in	O
many	O
promoters	O
of	O
the	O
IFN-regulated	B-DNA
genes	I-DNA
.	O

Among	O
T-cell	B-cell_line
lines	I-cell_line
investigated	O
,	O
ICSAT	B-protein
was	O
abundantly	O
expressed	O
in	O
human	B-cell_line
T-cell	I-cell_line
leukemia	I-cell_line
virus	I-cell_line
type	I-cell_line
1	I-cell_line
(	I-cell_line
HTLV-1	I-cell_line
)	I-cell_line
-infected	I-cell_line
T	I-cell_line
cells	I-cell_line
.	O

When	O
the	O
HTLV-1	B-DNA
tax	I-DNA
gene	I-DNA
was	O
expressed	O
or	O
phorbol	O
myristake	O
acetate-A23187	O
stimulation	O
was	O
used	O
,	O
ICSAT	B-protein
expression	O
was	O
induced	O
in	O
Jurkat	B-cell_line
cells	I-cell_line
which	O
otherwise	O
do	O
not	O
express	O
ICSAT	B-protein
.	O

When	O
the	O
binding	O
of	O
ICSAT	B-protein
to	O
four	O
different	O
ICSs	B-DNA
was	O
tested	O
,	O
the	O
relative	O
differences	O
in	O
binding	O
affinities	O
for	O
those	O
ICSs	B-DNA
were	O
determined	O
.	O

To	O
study	O
the	O
functional	O
role	O
of	O
ICSAT	B-protein
,	O
we	O
performed	O
cotransfection	O
experiments	O
with	O
the	O
human	B-cell_line
embryonal	I-cell_line
carcinoma	I-cell_line
cell	I-cell_line
line	I-cell_line
N-Tera2	I-cell_line
.	O

ICSAT	B-protein
was	O
demonstrated	O
to	O
possess	O
repressive	O
function	O
over	O
the	O
gene	O
activation	O
induced	O
by	O
IFN	B-protein
stimulation	O
or	O
by	O
IRF-1	B-protein
cotransfection	O
.	O

Such	O
repressive	O
function	O
is	O
similar	O
to	O
that	O
seen	O
in	O
IRF-2	B-protein
or	O
ICSBP	B-protein
.	O

However	O
,	O
we	O
have	O
found	O
that	O
ICSAT	B-protein
has	O
a	O
different	O
repressive	O
effect	O
from	O
that	O
of	O
IRF-2	B-protein
or	O
ICSBP	B-protein
in	O
some	O
IFN-responsive	B-DNA
reporter	I-DNA
constructs	I-DNA
.	O

These	O
results	O
suggest	O
that	O
a	O
novel	O
mechanism	O
of	O
gene	O
regulation	O
by	O
``	O
differential	O
repression	O
''	O
is	O
used	O
by	O
multiple	O
members	O
of	O
repressor	B-protein
proteins	I-protein
with	O
different	O
repressive	O
effects	O
on	O
the	O
IFN-responsive	B-DNA
genes	I-DNA
.	O

Regulation	O
of	O
[	O
Ca2+	O
]	O
i	O
rise	O
activated	O
by	O
doxepin-sensitive	B-protein
H1-histamine	I-protein
receptors	I-protein
in	O
Jurkat	B-cell_line
cells	I-cell_line
,	O
cloned	B-cell_line
human	I-cell_line
T	I-cell_line
lymphocytes	I-cell_line
.	O

To	O
clarify	O
the	O
presence	O
of	O
histamine	B-protein
receptor	I-protein
and	O
its	O
transmembrane	O
mechanism	O
in	O
human	B-cell_type
T	I-cell_type
lymphocytes	I-cell_type
,	O
we	O
investigated	O
the	O
effects	O
of	O
agonists	O
or	O
antagonists	O
of	O
histamine	B-protein
receptor	I-protein
subtypes	O
and	O
bacterial	O
toxins	O
on	O
intracellular	O
concentration	O
of	O
Ca2+	O
[	O
Ca2+	O
]	O
i	O
)	O
,	O
[	O
3H	O
]	O
pyrilamine	O
binding	O
and	O
c-fos	B-RNA
mRNA	I-RNA
expression	O
in	O
Jurkat	B-cell_line
cells	I-cell_line
,	O
cloned	O
human	B-cell_type
T	I-cell_type
lymphocytes	I-cell_type
.	O

H1-agonists	O
(	O
histamine	O
and	O
2-methylhistamine	O
)	O
caused	O
a	O
transient	O
rise	O
of	O
[	O
Ca2+	O
]	O
,	O
and	O
H1-antagonists	O
(	O
pyrilamine	O
and	O
doxepin	O
)	O
inhibited	O
the	O
histamine-induced	O
[	O
Ca2+	O
]	O
i	O
rise	O
more	O
potently	O
than	O
the	O
H2-antagonist	O
(	O
cimetidine	O
)	O
on	O
the	O
H3-antagonist	O
(	O
impromidine	O
)	O
.	O

Binding	O
parameters	O
of	O
[	O
3H	O
]	O
pyrilamine	O
binding	O
were	O
Kd	O
=	O
5.53	O
nM	O
and	O
Bmax	O
=	O
2	O
,	O
647	O
sites/cell	O
.	O

Pretreatment	O
with	O
B.pertussis	O
,	O
V.cholera.	O
or	O
C.botulinum	O
toxin	O
did	O
not	O
influence	O
histamine-induced	O
[	O
Ca2+	O
]	O
i	O
rise	O
.	O

Western	O
Blot	O
analysis	O
using	O
antibodies	O
against	O
subunits	O
of	O
GTP-binding	B-protein
proteins	I-protein
indicated	O
that	O
Gq/G11	B-protein
richly	O
existed	O
in	O
Jurkat	B-cell_line
cells	I-cell_line
.	O

Histamine	O
induced	O
mRNA	B-RNA
expression	O
of	O
an	O
immediate	B-DNA
early	I-DNA
gene	I-DNA
c-fos	B-DNA
.	O

Pretreatment	O
with	O
a	O
protein	B-protein
kinase	I-protein
C	I-protein
activator	O
,	O
phorbol	O
12-myristate	O
13-acetate	O
,	O
caused	O
almost	O
complete	O
inhibition	O
of	O
histamine-induced	O
[	O
Ca2+	O
]	O
i	O
rise	O
,	O
but	O
did	O
not	O
do	O
so	O
by	O
activators	O
of	O
cAMP-	B-protein
and	I-protein
cGMP-dependent	I-protein
protein	I-protein
kinases	I-protein
.	O

STAT-related	O
transcription	B-protein
factors	I-protein
are	O
constitutively	O
activated	O
in	O
peripheral	B-cell_type
blood	I-cell_type
cells	I-cell_type
from	O
acute	O
leukemia	O
patients	O
.	O

A	O
signal	O
transduction	O
pathway	O
activated	O
by	O
many	O
cytokines	B-protein
has	O
recently	O
been	O
elaborated	O
.	O

The	O
JAK	B-protein
kinases	I-protein
and	O
the	O
signal	B-protein
transducers	I-protein
and	I-protein
activators	I-protein
of	I-protein
transcription	I-protein
(	I-protein
STAT	I-protein
)	I-protein
factors	I-protein
have	O
been	O
found	O
to	O
be	O
essential	O
components	O
.	O

In	O
this	O
report	O
,	O
we	O
describe	O
the	O
presence	O
of	O
constitutively	O
activated	O
STAT	B-protein
factors	I-protein
in	O
peripheral	B-cell_type
blood	I-cell_type
cells	I-cell_type
from	O
patients	O
with	O
acute	O
leukemia	O
.	O

We	O
used	O
oligonucleotide	O
probes	O
from	O
the	O
beta-casein	B-DNA
and	I-DNA
IRF-1	I-DNA
gene	I-DNA
promoters	I-DNA
and	O
the	O
ISRE	O
probe	O
to	O
detect	O
STAT	B-protein
proteins	I-protein
in	O
nuclear	O
extracts	O
from	O
acute	B-cell_type
leukemia	I-cell_type
cells	I-cell_type
in	O
bandshift	O
assays	O
.	O

Specific	O
DNA	O
protein	B-protein
complex	I-protein
formation	O
was	O
observed	O
with	O
the	O
probes	O
from	O
the	O
beta-casein	O
and	O
IRF-1	B-DNA
gene	I-DNA
promoters	I-DNA
,	O
but	O
not	O
with	O
the	O
ISRE	O
oligonucleotide	O
probe	O
,	O
when	O
cell	O
extracts	O
from	O
acute	O
lymphoblastic	O
leukemia	O
(	O
ALL	O
)	O
and	O
acute	O
myeloid	O
leukemia	O
(	O
AML	O
)	O
were	O
investigated	O
.	O

We	O
used	O
nonradioactive	O
oligonucleotides	O
as	O
competitors	O
to	O
show	O
the	O
specificity	O
of	O
the	O
complex	O
formation	O
.	O

Specific	O
antibodies	B-protein
directed	O
against	O
the	O
individual	O
STAT	B-protein
proteins	I-protein
were	O
used	O
in	O
supershift	O
experiments	O
.	O

STAT5-	B-protein
and	I-protein
STAT1-related	I-protein
factors	I-protein
were	O
detected	O
in	O
ALL	O
and	O
STAT1-	B-protein
,	I-protein
STAT3-	I-protein
,	I-protein
and	I-protein
STAT5-related	I-protein
proteins	I-protein
were	O
present	O
in	O
nuclear	O
cell	O
extracts	O
from	O
AML	O
.	O

Since	O
the	O
cells	O
were	O
not	O
treated	O
with	O
cytokines	B-protein
before	O
the	O
nuclear	B-protein
proteins	I-protein
were	O
extracted	O
,	O
we	O
conclude	O
that	O
these	O
factors	O
are	O
constitutively	O
activated	O
in	O
vivo	O
.	O

It	O
is	O
likely	O
that	O
the	O
constitutive	O
activation	O
of	O
STAT	B-protein
proteins	I-protein
is	O
a	O
part	O
of	O
the	O
events	O
of	O
leukemogenesis	O
.	O

An	O
element	B-DNA
upstream	O
from	O
the	O
human	B-DNA
delta-globin-encoding	I-DNA
gene	I-DNA
specifically	O
enhances	O
beta-globin	B-DNA
reporter	I-DNA
gene	I-DNA
expression	O
in	O
murine	B-cell_type
erythroleukemia	I-cell_type
cells	I-cell_type
.	O

We	O
have	O
previously	O
shown	O
that	O
a	O
DNA-binding	B-protein
factor	I-protein
specific	O
to	O
adult	B-cell_type
hematopoietic	I-cell_type
cells	I-cell_type
(	O
polypryrimidine-binding	B-protein
factor	I-protein
,	O
PYBF	B-protein
)	O
binds	O
to	O
a	O
pyrimidine-rich	B-DNA
region	I-DNA
1	B-DNA
kb	I-DNA
upstream	I-DNA
from	O
the	O
human	B-DNA
delta-globin-encoding	I-DNA
gene	I-DNA
(	O
HBD	B-DNA
)	O
.	O

The	O
developmental	O
stage-specificity	O
of	O
PYBF	B-protein
and	O
the	O
location	O
of	O
its	O
binding	O
site	O
between	O
the	O
fetal	B-DNA
and	I-DNA
adult	I-DNA
beta-globin	I-DNA
(	I-DNA
HBB	I-DNA
)	I-DNA
-like	I-DNA
genes	I-DNA
suggest	O
that	O
PBYF	B-protein
and	O
its	O
binding	O
site	O
may	O
function	O
in	O
fetal-to-adult	O
globin	B-DNA
gene	I-DNA
switching	O
.	O

Here	O
,	O
we	O
describe	O
the	O
effect	O
of	O
383-bp	B-DNA
(	I-DNA
delta383	I-DNA
)	I-DNA
and	I-DNA
99-bp	I-DNA
(	I-DNA
delta99	I-DNA
)	I-DNA
sequences	I-DNA
containing	O
the	O
PYBF-binding	B-DNA
site	I-DNA
on	O
transcription	O
from	O
various	O
globin	O
and	O
non-globin	O
promoters	O
,	O
using	O
a	O
transient	O
assay	O
with	O
the	O
cat	B-DNA
reporter	I-DNA
gene	I-DNA
in	O
murine	B-cell_line
erythroleukemia	I-cell_line
(	I-cell_line
MEL	I-cell_line
)	I-cell_line
cells	I-cell_line
,	O
a	O
cell	O
line	O
with	O
abundant	O
PYBF	B-protein
activity	O
.	O

We	O
show	O
that	O
both	O
delta383	B-DNA
and	O
delta99	B-DNA
specifically	O
enhance	O
expression	O
of	O
cat	B-protein
for	O
plasmids	B-DNA
containing	O
a	O
human	B-DNA
adult	I-DNA
globin	I-DNA
(	I-DNA
HBB	I-DNA
)	I-DNA
promoter	I-DNA
,	O
whereas	O
expression	O
of	O
similar	O
constructs	O
using	O
human	B-DNA
fetal	I-DNA
(	I-DNA
A	I-DNA
gamma-	I-DNA
)	I-DNA
globin	I-DNA
(	I-DNA
HBG1	I-DNA
)	I-DNA
or	I-DNA
simian	I-DNA
virus	I-DNA
40	I-DNA
(	I-DNA
SV40	I-DNA
)	I-DNA
promoters	I-DNA
is	O
not	O
enhanced	O
.	O

The	O
results	O
suggest	O
that	O
PYBF	B-protein
and	O
the	O
pyrimidine-rich	B-DNA
region	I-DNA
upstream	O
from	O
HBD	B-DNA
can	O
specifically	O
enhance	O
HBB	B-DNA
transcription	O
in	O
adult	B-cell_type
erythroid	I-cell_type
cells	I-cell_type
.	O

Translocation	B-DNA
breakpoints	I-DNA
in	O
three	O
patients	O
with	O
campomelic	O
dysplasia	O
and	O
autosomal	O
sex	O
reversal	O
map	O
more	O
than	O
130	O
kb	O
from	O
SOX9	B-DNA
.	O

Campomelic	O
dysplasia	O
(	O
CMPD1	O
)	O
and	O
autosomal	O
XY	O
sex	O
reversal	O
(	O
SRA1	O
)	O
are	O
caused	O
by	O
mutations	O
in	O
the	O
SRY-related	B-DNA
gene	I-DNA
SOX9	B-DNA
on	O
17q	B-DNA
.	O

Unexpectedly	O
,	O
the	O
17q	B-DNA
breakpoints	I-DNA
in	O
four	O
CMPD1	O
translocation	O
cases	O
previously	O
analyzed	O
by	O
us	O
and	O
others	O
map	O
50	O
kb	O
or	O
more	O
from	O
SOX9	B-DNA
.	O

Here	O
,	O
we	O
present	O
clinical	O
,	O
cytogenetic	O
,	O
and	O
molecular	O
data	O
from	O
a	O
new	O
CMPD1/SRA1	O
patient	O
with	O
t	B-DNA
(	I-DNA
6	I-DNA
;	I-DNA
17	I-DNA
)	I-DNA
(	I-DNA
q14	I-DNA
;	I-DNA
q24	I-DNA
)	I-DNA
.	O

Fluorescence	O
in	O
situ	O
hybridization	O
has	O
shown	O
that	O
the	O
17q	B-DNA
breakpoint	I-DNA
in	O
this	O
case	O
maps	O
to	O
the	O
same	O
region	O
as	O
the	O
breakpoints	O
in	O
the	O
other	O
translocation	O
cases	O
,	O
at	O
least	O
130	O
kb	O
from	O
SOX9	B-DNA
.	O

Likewise	O
,	O
the	O
breakpoints	O
in	O
two	O
of	O
the	O
previously	O
described	O
cases	O
also	O
map	O
more	O
than	O
130	O
kb	O
and	O
,	O
as	O
shown	O
by	O
pulsed	O
field	O
gel	O
electrophoresis	O
analysis	O
,	O
at	O
most	O
400	O
kb	O
or	O
690	O
kb	O
from	O
SOX9	B-DNA
.	O

By	O
using	O
a	O
SOX9	B-DNA
coding	I-DNA
sequence	I-DNA
polymorphism	I-DNA
,	O
expression	O
of	O
both	O
SOX9	B-DNA
alleles	O
has	O
been	O
demonstrated	O
by	O
the	O
reverse	B-protein
transcriptase	I-protein
polymerase	O
chain	O
reaction	O
in	O
lymphoblastoid	B-cell_type
cells	I-cell_type
from	O
one	O
of	O
the	O
translocation	O
cases	O
.	O

An	O
alternatively	O
spliced	O
isoform	O
of	O
the	O
Spi-B	B-protein
transcription	B-protein
factor	I-protein
.	O

Spi-B	B-protein
is	O
an	O
Ets	B-protein
transcription	I-protein
factor	I-protein
related	O
to	O
the	O
oncoprotein	B-protein
Spi-1/PU.1	B-protein
and	O
highly	O
expressed	O
in	O
B	B-cell_type
lymphoid	I-cell_type
cells	I-cell_type
.	O

The	O
Ets	B-protein
proteins	I-protein
share	O
a	O
conserved	O
Ets	B-protein
domain	I-protein
that	O
mediates	O
specific	O
DNA	O
binding	O
.	O

Spi-B	B-protein
binds	O
DNA	B-DNA
sequences	I-DNA
containing	O
a	O
core	O
5'-GGAA-3	O
'	O
and	O
activates	O
transcription	O
through	O
this	O
motif	O
.	O

Up	O
to	O
date	O
,	O
the	O
biological	O
function	O
of	O
Spi-B	B-protein
remains	O
unknown	O
.	O

Here	O
,	O
we	O
describe	O
the	O
characterization	O
of	O
an	O
alternatively	O
spliced	O
variant	O
of	O
Spi-B	B-protein
,	O
named	O
deltaSpi-B	B-protein
,	O
which	O
has	O
lost	O
the	O
Ets	B-protein
domain	I-protein
.	O

In	O
B	B-cell_type
lymphoid	I-cell_type
cells	I-cell_type
,	O
deltaspi-B	B-RNA
and	I-RNA
spi-B	I-RNA
mRNAs	I-RNA
were	O
present	O
simultaneously	O
in	O
a	O
ratio	O
of	O
around	O
10	O
%	O
.	O

DeltaSpi-B	B-protein
product	O
was	O
not	O
able	O
to	O
bind	O
DNA	O
and	O
was	O
recovered	O
in	O
cytoplasmic	O
cellular	O
extracts	O
.	O

We	O
raise	O
the	O
hypothesis	O
that	O
delta	B-protein
Spi-B	I-protein
might	O
affect	O
Spi-B	B-protein
function	O
by	O
recruiting	O
factors	O
involved	O
in	O
Spi-B	B-protein
activity	O
.	O

Binding	O
and	O
cooperative	O
interactions	O
between	O
two	O
B	B-protein
cell-specific	I-protein
transcriptional	I-protein
coactivators	I-protein
.	O

The	O
class	B-protein
II	I-protein
transactivator	I-protein
(	O
CIITA	B-protein
)	O
and	O
B	B-protein
cell	I-protein
octamer-binding	I-protein
protein	I-protein
1/octamer-binding	I-protein
factor	I-protein
1/Oct	I-protein
coactivator	I-protein
from	O
B	B-cell_type
cells	I-cell_type
(	O
Bob1/OBF-1/OCA-B	B-protein
)	O
represent	O
two	O
B	B-protein
cell-specific	I-protein
transcriptional	I-protein
coactivators	I-protein
.	O

CIITA	B-protein
and	O
Bob1	B-protein
interact	O
with	O
proteins	O
that	O
bind	O
to	O
conserved	B-DNA
upstream	I-DNA
sequences	I-DNA
in	O
promoters	B-DNA
of	O
class	B-DNA
II	I-DNA
major	I-DNA
histocompatibility	I-DNA
genes	I-DNA
and	O
octamer-binding	B-protein
transcription	I-protein
factors	I-protein
Oct-1	B-protein
and	O
Oct-2	B-protein
,	O
respectively	O
.	O

Both	O
CIITA	B-protein
and	O
Bob1	B-protein
increase	O
the	O
expression	O
from	O
the	O
DRA	B-DNA
promoter	I-DNA
,	O
which	O
is	O
a	O
prototypic	O
class	B-DNA
II	I-DNA
promoter	I-DNA
.	O

Moreover	O
,	O
in	O
the	O
presence	O
of	O
CIITA	B-protein
,	O
interactions	O
between	O
class	B-DNA
II	I-DNA
promoters	I-DNA
and	O
Bob1	B-protein
are	O
independent	O
of	O
the	O
octamer-binding	B-RNA
site	I-RNA
.	O

Using	O
in	O
vivo	O
and	O
in	O
vitro	O
binding	O
assays	O
,	O
we	O
confirm	O
that	O
Bob1	B-protein
binds	O
to	O
CIITA	B-protein
.	O

Thus	O
,	O
CIITA	B-protein
not	O
only	O
activates	O
the	O
expression	O
of	O
class	B-DNA
II	I-DNA
genes	I-DNA
but	O
recruits	O
another	O
B	O
cell-specific	O
coactivator	O
to	O
increase	O
transcriptional	O
activity	O
of	O
class	B-DNA
II	I-DNA
promoters	I-DNA
in	O
B	B-cell_type
cells	I-cell_type
.	O

Efficient	O
transcription	O
and	O
replication	O
of	O
simian	O
immunodeficiency	O
virus	O
in	O
the	O
absence	O
of	O
NF-kappaB	B-DNA
and	I-DNA
Sp1	I-DNA
binding	I-DNA
elements	I-DNA
.	O

Ten	O
mutants	O
of	O
the	O
simian	O
immunodeficiency	O
virus	O
(	O
SIV	O
)	O
SIVmac239	O
bearing	O
deletions	O
(	O
delta	O
)	O
or	O
substitutions	O
(	O
subst	O
)	O
in	O
the	O
NF-kappaB	B-DNA
and/or	O
Sp1	B-DNA
binding	I-DNA
elements	I-DNA
were	O
created	O
,	O
and	O
the	O
replicative	O
capacities	O
of	O
the	O
mutants	O
were	O
analyzed	O
.	O

All	O
mutants	O
,	O
including	O
one	O
extensively	O
mutagenized	O
strain	O
entirely	O
missing	O
the	O
NF-kappaB	B-DNA
and	I-DNA
four	I-DNA
Spl	I-DNA
binding	I-DNA
elements	I-DNA
,	O
replicated	O
with	O
wild-type	O
kinetics	O
and	O
to	O
a	O
wild-type	O
level	O
in	O
peripheral	B-cell_line
blood	I-cell_line
mononuclear	I-cell_line
cell	I-cell_line
cultures	I-cell_line
in	O
50	O
to	O
100	O
%	O
of	O
the	O
experiments	O
.	O

One	O
group	O
of	O
mutants	O
replicated	O
very	O
similarly	O
to	O
SIVmac239	O
in	O
kinetics	O
and	O
yield	O
in	O
CEMxl74	B-cell_line
cells	I-cell_line
(	O
2x	O
NFKappaB	B-protein
>	O
or	O
=	O
SlVmac239	B-protein
approximately	O
deltaNFkappaB	B-protein
approximately	O
deltaSpl234	B-protein
approximately	O
substNFkappaB	B-protein
approximately	O
substSpl2	B-protein
approximately	O
substSp23	B-protein
)	O
,	O
while	O
a	O
second	O
group	O
replicated	O
with	O
delayed	O
or	O
slightly	O
delayed	O
kinetics	O
in	O
CEMxl74	B-cell_line
cells	I-cell_line
(	O
SIVmac239	O
>	O
substSp34	B-protein
>	O
deltaNFkappaBdeltaSpl234	B-protein
approximately	O
deltaNFkappaBdeltaSp1	B-protein
>	O
substSpl234	B-protein
)	O
.	O

Reversions	O
or	O
additional	O
mutations	O
were	O
not	O
detected	O
in	O
the	O
U3	B-DNA
and	I-DNA
R	I-DNA
regions	I-DNA
of	O
proviral	B-DNA
DNA	I-DNA
from	O
CEMxl74	B-cell_line
cells	I-cell_line
infected	O
with	O
the	O
SIVmac239	O
mutants	O
.	O

Similar	O
results	O
were	O
obtained	O
when	O
mutants	O
of	O
SIVmacMER	O
(	O
a	O
macrophage-competent	O
derivative	O
of	O
SIVmac239	O
)	O
were	O
tested	O
in	O
peripheral	B-cell_type
blood	I-cell_type
mononuclear	I-cell_type
cell	I-cell_type
and	O
CEMx174	B-cell_line
cultures	I-cell_line
.	O

However	O
,	O
the	O
growth	O
of	O
most	O
mutated	O
viruses	O
was	O
suppressed	O
in	O
primary	B-cell_type
rhesus	I-cell_type
monkey	I-cell_type
alveolar	I-cell_type
macrophages	I-cell_type
(	O
SIVmacMER	O
approximately	O
2xNFkappaB	B-protein
approximately	O
substNFkappaB	B-protein
>	O
deltaNFkappaB	B-protein
>	O
deltaNFkappaB	B-protein
deltaSpl234	B-protein
approximately	O
deltaNFkappaBdeltaSpl	B-protein
>	O
deltaSpl234	B-protein
approximately	O
substSpl2	B-protein
>	O
substSp23	B-protein
approximately	O
substSp34	B-protein
approximately	O
substSpl234	B-protein
>	O
or	O
=	O
SIVmac239	O
)	O
.	O

Thus	O
,	O
changes	O
in	O
the	O
Sp1	B-DNA
binding	I-DNA
sites	I-DNA
had	O
the	O
most	O
dramatic	O
effects	O
on	O
SIVmac	O
replication	O
in	O
primary	B-cell_line
macrophage	I-cell_line
cultures	I-cell_line
.	O

Analysis	O
of	O
long	B-DNA
terminal	I-DNA
repeat	I-DNA
-driven	O
secreted	O
alkaline	B-protein
phosphatase	I-protein
activity	O
in	O
transient	O
assays	O
showed	O
that	O
,	O
unlike	O
human	O
immunodeficiency	O
virus	O
type	O
1	O
,	O
the	O
SIV	B-DNA
long	I-DNA
terminal	I-DNA
repeat	I-DNA
possesses	O
an	O
enhancer	B-DNA
region	I-DNA
just	O
upstream	O
of	O
the	O
NF-kappaB	B-DNA
element	I-DNA
which	O
maintains	O
significant	O
levels	O
of	O
basal	O
transcription	O
in	O
the	O
absence	O
of	O
NF-kappaB	B-DNA
and	I-DNA
Sp1	I-DNA
sites	I-DNA
.	O

This	O
region	O
is	O
responsive	O
to	O
transactivation	O
by	O
Tat	B-protein
.	O

In	O
addition	O
,	O
the	O
SIV	B-DNA
TATA	I-DNA
box	I-DNA
was	O
shown	O
to	O
be	O
stronger	O
than	O
that	O
of	O
human	O
immunodeficiency	O
virus	O
type	O
1	O
.	O

Therefore	O
,	O
the	O
surprisingly	O
high	O
replicative	O
capacity	O
of	O
NF-kappaB	O
and	O
Sp1	O
binding	O
site	O
mutants	O
of	O
SIVmac	O
is	O
due	O
to	O
unique	O
features	O
or	O
the	O
enhancer/promoter	B-DNA
region	I-DNA
.	O

cAMP	O
inducibility	O
of	O
transcriptional	B-protein
repressor	I-protein
ICER	B-protein
in	O
developing	O
and	O
mature	B-cell_type
human	I-cell_type
T	I-cell_type
lymphocytes	I-cell_type
[	O
published	O
erratum	O
appears	O
in	O
Proc	O
Natl	O
Acad	O
Sci	O
U	O
S	O
A	O
1996	O
Jul	O
23	O
;	O
93	O
(	O
15	O
)	O
:	O
8154	O
]	O

Stimulation	O
of	O
the	O
cAMP-dependent	O
signaling	O
pathway	O
exerts	O
an	O
inhibitory	O
effect	O
on	O
the	O
proliferation	O
and	O
effector	O
functions	O
of	O
T	B-cell_type
cells	I-cell_type
.	O

The	O
ability	O
of	O
T	B-cell_type
cells	I-cell_type
to	O
form	O
high	O
intracellular	O
levels	O
of	O
cAMP	O
is	O
acquired	O
during	O
development	O
in	O
the	O
human	O
thymus	O
and	O
is	O
retained	O
by	O
the	O
majority	O
of	O
mature	O
peripheral	B-cell_type
T	I-cell_type
lymphocytes	I-cell_type
.	O

Here	O
we	O
show	O
that	O
elevated	O
cAMP	O
levels	O
in	O
T	B-cell_type
cells	I-cell_type
correlate	O
with	O
the	O
expression	O
of	O
the	O
potent	B-protein
transcriptional	I-protein
repressor	I-protein
ICER	B-protein
(	O
inducible	B-protein
cAMP	I-protein
early	I-protein
repressor	I-protein
)	O
previously	O
described	O
in	O
the	O
hypothalamic-pituitary-gonadal	O
axis	O
.	O

Further	O
,	O
in	O
transcriptional	O
assays	O
in	O
vivo	O
,	O
ICER	B-protein
inhibits	O
calcineurin	B-protein
-mediated	O
expression	O
of	O
the	O
interleukin	B-DNA
2	I-DNA
promoter	I-DNA
as	O
well	O
as	O
Tax	B-protein
-mediated	O
transactivation	O
of	O
the	O
human	B-DNA
T-lymphotropic	I-DNA
virus	I-DNA
type	I-DNA
I	I-DNA
(	I-DNA
HTLV-I	I-DNA
)	I-DNA
promoter	I-DNA
.	O

Thus	O
,	O
the	O
induction	O
of	O
ICER	B-protein
in	O
T	B-cell_type
cells	I-cell_type
may	O
play	O
an	O
important	O
role	O
in	O
the	O
cAMP-induced	O
quiescence	O
and	O
the	O
persistent	O
latency	O
of	O
HTLV-I	O
.	O

A	O
hydrophobic	O
domain	O
of	O
Ca2+-modulating	B-protein
cyclophilin	I-protein
ligand	I-protein
modulates	O
calcium	O
influx	O
signaling	O
in	O
T	O
lymphocytes	O
.	O

Ca2+-modulating	B-protein
cyclophilin	I-protein
ligand	I-protein
(	O
CAML	B-protein
)	O
was	O
originally	O
described	O
as	O
a	O
cyclophilin	B-protein
B-binding	I-protein
protein	I-protein
whose	O
overexpression	O
in	O
T	B-cell_type
cells	I-cell_type
causes	O
a	O
rise	O
in	O
intracellular	O
calcium	O
,	O
thus	O
activating	O
transcription	B-protein
factors	I-protein
responsible	O
for	O
the	O
early	O
immune	O
response	O
.	O

As	O
reported	O
here	O
,	O
structure-function	O
analysis	O
of	O
the	O
CAML	B-DNA
gene	I-DNA
in	O
Jurkat	B-cell_line
T	I-cell_line
cells	I-cell_line
indicates	O
that	O
two	O
of	O
CAML	B-protein
's	O
putative	B-protein
membrane-spanning	I-protein
domains	I-protein
are	O
necessary	O
and	O
sufficient	O
for	O
the	O
modulation	O
of	O
intracellular	O
calcium	O
.	O

We	O
propose	O
that	O
the	O
hydrophobic	B-protein
C-terminal	I-protein
tail	I-protein
of	O
CAML	B-protein
forms	O
its	O
effector	O
domain	O
,	O
thus	O
implicating	O
the	O
N-terminal	B-protein
hydrophilic	I-protein
domain	I-protein
in	O
a	O
regulatory	O
role	O
.	O

These	O
findings	O
define	O
a	O
novel	B-protein
protein	I-protein
motif	I-protein
that	O
functions	O
in	O
intracellular	O
calcium	O
signaling	O
.	O

The	O
Epstein-Barr	B-protein
virus-encoded	I-protein
nuclear	I-protein
antigen	I-protein
EBNA-5	I-protein
accumulates	O
in	O
PML-containing	O
bodies	O
.	O

EBNA-5	B-protein
is	O
one	O
of	O
the	O
Epstein-Barr	B-protein
virus	I-protein
(	I-protein
EBV	I-protein
)	I-protein
-encoded	I-protein
nuclear	I-protein
proteins	I-protein
required	O
for	O
immortalization	O
of	O
human	B-cell_type
B	I-cell_type
lymphocytes	I-cell_type
.	O

In	O
the	O
nuclei	O
of	O
EBV-transformed	B-cell_line
lymphoblastoid	I-cell_line
cell	I-cell_line
lines	I-cell_line
EBNA-5	B-protein
is	O
preferentially	O
targetted	O
to	O
distinct	O
nuclear	O
foci	O
.	O

Previously	O
we	O
have	O
shown	O
(	O
W.Q.	O
Jiang	O
,	O
L.Szekely	O
,	O
V.Wendel-Hansen	O
,	O
N.Ringertz	O
,	O
G.Klein	O
,	O
and	O
A.	O
Rosen	O
,	O
Exp.Cell	O
Res	O
.	O

A	O
new	O
variant	O
translocation	O
in	O
acute	O
promyelocytic	O
leukaemia	O
:	O
molecular	O
characterization	O
and	O
clinical	O
correlation	O
.	O

Translocation	B-DNA
t	I-DNA
(	I-DNA
15	I-DNA
;	I-DNA
17	I-DNA
)	I-DNA
(	I-DNA
q22	I-DNA
;	I-DNA
q21	I-DNA
)	O
is	O
an	O
acquired	O
clonal	O
cytogenetic	O
change	O
present	O
in	O
almost	O
all	O
cases	O
of	O
acute	O
promelocytic	O
leukemia	O
(	O
APL	O
)	O
.	O

The	O
molecular	O
genetic	O
basis	O
of	O
the	O
translocation	O
supports	O
its	O
integral	O
role	O
in	O
pathogenesis	O
.	O

We	O
describe	O
a	O
patient	O
with	O
APL	O
in	O
whom	O
the	O
leukaemic	O
clone	O
was	O
characterized	O
by	O
a	O
true	O
variant	O
of	O
the	O
classical	B-DNA
t	I-DNA
(	I-DNA
15	I-DNA
;	I-DNA
17	I-DNA
)	I-DNA
.	O

The	O
patient	O
whose	O
disease	O
had	O
numerous	O
atypical	O
clinical	O
features	O
,	O
had	O
t	B-DNA
(	I-DNA
11	I-DNA
;	I-DNA
17	I-DNA
)	I-DNA
(	I-DNA
q13	I-DNA
;	I-DNA
121	I-DNA
)	I-DNA
.	O

The	O
chromosome	B-DNA
17	I-DNA
breakpoint	I-DNA
was	O
localized	O
to	O
intron	B-DNA
2	I-DNA
of	O
RARA	B-DNA
by	O
Southern	O
blotting	O
,	O
and	O
there	O
was	O
no	O
evidence	O
at	O
the	O
molecular	O
level	O
for	O
rearrangement	O
at	O
PML	B-DNA
locus	I-DNA
.	O

These	O
data	O
,	O
along	O
with	O
previous	O
reports	O
of	O
rare	O
variant	O
translocations	O
in	O
APL	O
,	O
indicate	O
that	O
while	O
dysregulation	O
of	O
RARA	B-DNA
by	O
gene	O
fusion	O
may	O
be	O
essential	O
for	O
the	O
APL	O
phenotype	O
,	O
the	O
particular	O
fusion	O
partner	O
may	O
determine	O
clinicopathological	O
aspects	O
,	O
including	O
presentation	O
,	O
response	O
to	O
treatment	O
with	O
all-trans	O
retinoic	O
acid	O
(	O
ATRA	O
)	O
,	O
and	O
prognosis	O
.	O

This	O
heterogeneity	O
suggests	O
that	O
the	O
variant	O
fusion	B-protein
partners	I-protein
of	O
RARA	B-DNA
in	O
APL	O
encode	O
factors	B-protein
with	O
properties	O
both	O
common	O
to	O
and	O
distinct	O
from	O
those	O
of	O
PML	B-cell_type
.	O

Investigation	O
of	O
these	O
factors	O
promises	O
to	O
shed	O
light	O
on	O
the	O
complex	O
development	O
pathways	O
involved	O
in	O
the	O
regulation	O
of	O
haematopoiesis	O
.	O

A	O
model	O
of	O
latent	O
adenovirus	O
5	O
infection	O
in	O
the	O
guinea	O
pig	O
(	O
Cavia	O
porcellus	O
)	O
.	O

A	O
model	O
of	O
adenovirus	O
5	O
(	O
Ad5	O
)	O
infection	O
was	O
developed	O
in	O
guinea	O
pigs	O
to	O
begin	O
to	O
study	O
its	O
role	O
in	O
the	O
pathogenesis	O
of	O
peripheral	O
lung	O
inflammation	O
.	O

Forty	O
animals	O
were	O
inoculated	O
intranasally	O
with	O
10	O
(	O
7.0	O
)	O
pfu	O
of	O
Ad5/animal	O
,	O
and	O
15	O
animals	O
inoculated	O
with	O
sterile	O
culture	O
media	O
served	O
as	O
controls	O
.	O

Viral	O
titres	O
were	O
10	O
(	O
4.4	O
)	O
,	O
10	O
(	O
6.1	O
)	O
,	O
10	O
(	O
5.2	O
)	O
,	O
and	O
10	O
(	O
2.9	O
)	O
pfu/animal	O
,	O
on	O
days	O
1	O
,	O
3	O
,	O
4	O
,	O
and	O
7	O
after	O
infection	O
,	O
respectively	O
.	O

In	O
situ	O
hybridization	O
to	O
viral	B-DNA
DNA	I-DNA
and	O
immunocytochemistry	O
for	O
Ad5	O
E1A	B-protein
protein	I-protein
localized	O
the	O
virus	O
to	O
airway	O
and	O
alveolar	B-cell_type
epithelial	I-cell_type
cells	I-cell_type
.	O

Histologic	O
examination	O
showed	O
an	O
extensive	O
inflammatory	O
cell	O
infiltration	O
around	O
the	O
airways	O
,	O
with	O
epithelial	O
necrosis	O
and	O
an	O
alveolar	O
exudate	O
that	O
caused	O
localized	O
alveolar	O
collapse	O
in	O
the	O
infected	O
areas	O
.	O

Immunocytochemistry	O
identified	O
the	O
cells	O
in	O
the	O
infiltrate	O
as	O
cytotoxic	B-cell_type
T	I-cell_type
cells	I-cell_type
.	O

Although	O
all	O
animals	O
20	O
and	O
47	O
days	O
after	O
infection	O
had	O
seroconverted	O
to	O
Ad5	O
,	O
virus	O
was	O
not	O
detected	O
in	O
these	O
groups	O
either	O
by	O
viral	O
plaque	O
assay	O
or	O
in	O
situ	O
hybridization	O
.	O

Ad5	B-DNA
E1A	I-DNA
DNA	I-DNA
was	O
detected	O
by	O
polymerase	O
chain	O
reaction	O
in	O
five	O
of	O
six	O
animals	O
20	O
days	O
after	O
infection	O
and	O
in	O
five	O
of	O
five	O
animals	O
47	O
days	O
after	O
infection	O
.	O

In	O
these	O
same	O
animals	O
,	O
E1A	B-protein
protein	I-protein
was	O
detected	O
20	O
days	O
after	O
infection	O
in	O
two	O
and	O
47	O
days	O
after	O
infection	O
in	O
one	O
while	O
persistent	O
bronchiolitis	O
was	O
observed	O
in	O
four	O
and	O
three	O
animals	O
20	O
and	O
47	O
days	O
after	O
infection	O
,	O
respectively	O
.	O

These	O
results	O
demonstrate	O
that	O
the	O
guinea	O
pig	O
provides	O
a	O
useful	O
model	O
to	O
study	O
the	O
role	O
of	O
Ad5	O
infection	O
in	O
chronic	O
airway	O
inflammation	O
.	O

Cyclic	O
AMP	O
-responsive	B-DNA
element	I-DNA
-dependent	O
activation	O
of	O
Epstein-Barr	O
virus	O
zebra	B-DNA
promoter	I-DNA
by	O
human	O
herpesvirus	O
6	O
.	O

We	O
have	O
recently	O
shown	O
that	O
infection	O
of	O
Epstein-Barr	B-cell_line
virus	I-cell_line
(	I-cell_line
EBV	I-cell_line
)	I-cell_line
genome-positive	I-cell_line
B	I-cell_line
cells	I-cell_line
by	O
human	O
herpesvirus	O
6	O
(	O
HHV-6	O
)	O
results	O
in	O
the	O
expression	O
of	O
the	O
immediate-early	B-DNA
EBV	I-DNA
Zebra	I-DNA
gene	I-DNA
,	O
followed	O
by	O
virus	O
replication	O
(	O
L.Flamand	O
,	O
I.Stefanescu	O
,	O
D.V.Ablashi	O
,	O
and	O
J.Menezes	O
,	O
J.Virol.67	O
:	O
6768-6777	O
,	O
1993	O
)	O
.	O

Here	O
we	O
show	O
that	O
HHV-6	O
upregulates	O
Zebra	B-DNA
gene	I-DNA
transcription	O
through	O
a	O
cyclic	B-DNA
AMP-responsive	I-DNA
element	I-DNA
(	O
CRE	B-DNA
)	O
located	O
within	O
the	O
Zebra	B-DNA
promoter	I-DNA
(	O
Zp	B-DNA
)	O
.	O

Using	O
human	B-cell_line
B-	I-cell_line
or	I-cell_line
T-cell	I-cell_line
lines	I-cell_line
transfected	O
with	O
ZpCat	B-DNA
reporter	I-DNA
gene	I-DNA
constructs	I-DNA
,	O
we	O
demonstrate	O
that	O
a	O
region	O
designated	O
the	O
ZII	B-DNA
domain	I-DNA
of	O
Zp	B-DNA
is	O
the	O
target	O
of	O
HHV-6	O
transactivation	O
.	O

Mutation	O
of	O
the	O
consensus	B-DNA
AP-1/CRE	I-DNA
site	I-DNA
within	O
ZII	B-DNA
abolished	O
the	O
inducibility	O
of	O
Zp	B-DNA
by	O
HHV-6	O
,	O
whereas	O
positioning	O
of	O
the	O
ZII	B-DNA
domain	I-DNA
upstream	O
of	O
the	O
beta-globin	B-DNA
minimal	I-DNA
promoter	I-DNA
conferred	O
responsiveness	O
following	O
HHV-6	O
infection	O
.	O

Binding	O
of	O
these	O
factors	O
to	O
ZII	B-DNA
was	O
prevented	O
by	O
oligonucleotides	O
containing	O
CRE	B-DNA
but	O
not	O
by	O
AP-1	B-DNA
consensus	I-DNA
sequences	I-DNA
.	O

Antibodies	O
against	O
CRE-binding	B-protein
(	I-protein
CREB	I-protein
)	I-protein
protein	I-protein
but	O
not	O
against	O
c-Fos	B-protein
or	O
c-Jun	B-protein
were	O
able	O
to	O
supershift	O
the	O
DNA-protein	B-protein
complex	I-protein
,	O
identifying	O
the	O
nature	O
of	O
the	O
transcription	B-protein
factor	I-protein
which	O
binds	O
to	O
ZII	B-DNA
as	O
a	O
member	O
of	O
the	O
CREB	B-protein
family	I-protein
of	I-protein
proteins	I-protein
.	O

Finally	O
,	O
transfection	O
of	O
CREB	B-protein
protein	I-protein
and	O
protein	B-DNA
kinase	I-DNA
A	I-DNA
expression	I-DNA
vectors	I-DNA
were	O
found	O
to	O
activate	O
Zp	B-DNA
in	O
Jurkat	B-cell_type
cells	I-cell_type
,	O
suggesting	O
that	O
phosphorylated	O
form	O
of	O
CREB	B-protein
protein	I-protein
can	O
play	O
a	O
determining	O
role	O
in	O
the	O
EBV	O
reactivation	O
process	O
.	O

Regulation	O
of	O
the	O
nuclear	B-protein
factor	I-protein
of	I-protein
activated	I-protein
T	I-protein
cells	I-protein
in	O
stably	O
transfected	O
Jurkat	B-cell_line
cell	I-cell_line
clones	I-cell_line
.	O

Two	O
Jurkat	B-cell_line
cell	I-cell_line
clones	I-cell_line
have	O
been	O
stably	O
transfected	O
with	O
a	O
reporter	B-DNA
vector	I-DNA
for	O
the	O
nuclear	B-protein
factor	I-protein
of	I-protein
activated	I-protein
T	I-protein
cells	I-protein
(	O
NFAT	B-protein
)	O
.	O

Upon	O
stimulation	O
,	O
they	O
express	O
high	O
levels	O
of	O
secreted	O
heat	O
stable	O
placental	B-protein
alkaline	I-protein
phosphatase	I-protein
.	O

With	O
these	O
clones	O
,	O
we	O
demonstrated	O
that	O
NFAT	B-protein
activation	O
induced	O
by	O
phorbol	O
12-myristate	O
13-acetate	O
and	O
ionomycin	O
was	O
inhibited	O
by	O
both	O
cyclosporin	O
A	O
(	O
CsA	O
)	O
(	O
IC50	O
=	O
8	O
nM	O
)	O
and	O
FK506	O
(	O
IC50	O
=	O
160	O
pM	O
)	O
,	O
presumably	O
by	O
inhibition	O
of	O
calcineurin	B-protein
activity	O
.	O

Selective	O
phosphatase	O
inhibitors	O
for	O
protein	B-protein
phosphatase	I-protein
1	I-protein
(	O
PP1	B-protein
)	O
and	O
2A	B-protein
(	O
PP2A	B-protein
)	O
that	O
do	O
not	O
inhibit	O
calcineurin	B-protein
,	O
such	O
as	O
okadaic	O
acid	O
and	O
calyculin	O
A	O
,	O
also	O
inhibited	O
NFAT	B-protein
activation	O
with	O
IC50s	O
of	O
87	O
nM	O
and	O
4	O
nM	O
,	O
respectively	O
,	O
suggesting	O
that	O
okadaic	O
acid	O
and	O
related	O
inhibitors	O
may	O
block	O
NFAT	B-protein
activation	O
through	O
the	O
inhibition	O
of	O
PP1	B-protein
,	O
instead	O
of	O
PP2A	B-protein
.	O

NFAT	B-protein
activation	O
was	O
also	O
inhibited	O
by	O
agents	O
that	O
increase	O
cAMP	O
concentrations	O
such	O
as	O
dibutyryl	O
cAMP	O
,	O
forskolin	O
and	O
prostaglandin	O
E2	O
.	O

These	O
stable	O
Jurkat	B-cell_line
cell	I-cell_line
clones	I-cell_line
provide	O
a	O
convenient	O
and	O
sensitive	O
tool	O
to	O
study	O
NFAT	B-protein
regulation	O
.	O

Glucocorticoids	O
induced	O
down-regulation	O
of	O
glucocorticoid	B-protein
receptor	I-protein
mRNA	O
expression	O
in	O
asthma	O
.	O

Although	O
their	O
precise	O
mechanism	O
of	O
action	O
remains	O
to	O
be	O
elucidated	O
,	O
glucocorticoids	O
represent	O
the	O
most	O
effective	O
therapy	O
in	O
the	O
treatment	O
of	O
asthma	O
.	O

Interactions	O
between	O
the	O
glucocorticoid	B-protein
receptor	I-protein
and	O
the	O
AP-1	B-protein
complex	I-protein
have	O
been	O
shown	O
to	O
regulate	O
the	O
transcription	O
of	O
some	O
genes	O
,	O
including	O
glucocorticoid	B-protein
receptor	I-protein
itself	O
.	O

The	O
aim	O
of	O
the	O
present	O
study	O
was	O
to	O
compare	O
the	O
expression	O
of	O
mRNA	B-RNA
for	O
glucocorticoid	B-protein
receptor	I-protein
in	O
human	B-cell_type
blood	I-cell_type
monocytes	I-cell_type
obtained	O
from	O
seven	O
unstable	O
untreated	O
asthmatic	O
patients	O
who	O
were	O
subsequently	O
treated	O
with	O
high	O
doses	O
of	O
parenteral	O
corticosteroid	O
(	O
methyl	O
prednisolone	O
120	O
mg/day	O
)	O
for	O
10	O
days	O
.	O

mRNA	B-RNA
expression	O
was	O
identified	O
after	O
RNA	O
extraction	O
using	O
RNAzol	O
and	O
analysed	O
after	O
reverse	B-protein
transcriptase	I-protein
,	O
by	O
polymerase	O
chain	O
reaction	O
using	O
a	O
semiquantitative	O
competitive	O
hybridization	O
assay	O
.	O

All	O
asthmatic	O
patients	O
showed	O
an	O
improvement	O
in	O
their	O
FEV1	O
values	O
after	O
corticosteroid	O
treatment	O
(	O
per	O
cent	O
of	O
predicted	O
value	O
68.28	O
+/-	O
4.93	O
versus	O
95.57	O
+/-	O
6.41	O
,	O
P	O
<	O
0.02	O
)	O
,	O
and	O
a	O
significant	O
decrease	O
for	O
glucocorticoid	B-protein
receptor	I-protein
mRNA	B-RNA
expression	O
(	O
P	O
<	O
0.02	O
)	O
was	O
observed	O
in	O
their	O
monocytes	O
.	O

This	O
is	O
the	O
first	O
report	O
of	O
an	O
ex	O
vivo	O
down-regulation	O
for	O
the	O
glucocorticoid	B-protein
receptor	I-protein
mRNA	B-RNA
expression	O
,	O
following	O
corticosteroid	O
treatment	O
.	O

Mapping	O
of	O
the	O
transcriptional	B-protein
repression	I-protein
domain	I-protein
of	O
the	O
lymphoid-specific	B-protein
transcription	I-protein
factor	I-protein
oct-2A	B-protein
.	O

The	O
lymphoid-specific	B-protein
transcription	I-protein
factor	I-protein
Oct-2a	B-protein
is	O
implicated	O
in	O
B	O
cell-specific	O
transcriptional	O
activity	O
via	O
the	O
octamer	O
motif	O
.	O

Structure/function	O
analysis	O
of	O
various	O
Oct-2a	B-protein
effector	I-protein
regions	I-protein
in	O
the	O
context	O
of	O
the	O
GAL4	B-protein
DNA-binding	I-protein
domain	I-protein
revealed	O
that	O
Oct-2a	B-protein
contains	O
two	O
functionally	O
different	O
activation	B-protein
domains	I-protein
at	O
the	O
N	B-protein
and	I-protein
the	I-protein
C	I-protein
termini	I-protein
.	O

The	O
transcriptional	O
activity	O
of	O
both	O
domains	O
is	O
strongly	O
potentiated	O
by	O
interactions	O
with	O
distinct	O
B	B-protein
cell-specific	I-protein
coactivators	I-protein
.	O

Recently	O
,	O
we	O
have	O
identified	O
a	O
repression	B-protein
domain	I-protein
located	O
within	O
the	O
N	B-protein
terminus	I-protein
of	O
Oct-2a	B-protein
(	O
amino	B-protein
acids	I-protein
2-99	I-protein
)	O
.	O

When	O
this	O
domain	O
was	O
transferred	O
to	O
a	O
potent	O
activator	O
,	O
transcription	O
was	O
strongly	O
inhibited	O
.	O

In	O
this	O
study	O
we	O
present	O
a	O
deletion	O
analysis	O
of	O
the	O
N-terminal	B-protein
region	I-protein
of	O
Oct-2a	B-protein
to	O
determine	O
the	O
minimal	B-protein
repression	I-protein
domain	I-protein
.	O

We	O
identified	O
a	O
stretch	O
of	O
23	O
amino	O
acids	O
,	O
rich	O
in	O
serine	O
and	O
threonine	O
residues	O
,	O
which	O
was	O
responsible	O
for	O
most	O
of	O
the	O
repression	O
activity	O
.	O

We	O
show	O
that	O
repression	O
is	O
strongly	O
dependent	O
on	O
the	O
type	O
of	O
enhancer	B-DNA
present	O
in	O
the	O
reporter	B-DNA
plasmid	I-DNA
as	O
well	O
as	O
on	O
the	O
cell	B-cell_line
line	I-cell_line
tested	O
.	O

The	O
possibility	O
that	O
Oct-2a	B-protein
can	O
act	O
as	O
an	O
activator	O
and/or	O
a	O
repressor	O
may	O
have	O
important	O
consequences	O
for	O
the	O
function	O
of	O
Oct-2a	B-protein
in	O
B	O
cell	O
differentiation	O
and	O
other	O
developmental	O
processes	O
.	O

Opposing	O
effects	O
of	O
glucocorticoids	O
on	O
the	O
rate	O
of	O
apoptosis	O
in	O
neutrophilic	B-cell_type
and	I-cell_type
eosinophilic	I-cell_type
granulocytes	I-cell_type
.	O

Eosinophils	B-cell_type
and	O
neutrophils	B-cell_type
are	O
closely	O
related	O
,	O
terminally	B-cell_type
differentiated	I-cell_type
cells	I-cell_type
that	O
in	O
vitro	O
undergo	O
constitutive	O
cell	O
death	O
by	O
apoptosis	O
.	O

The	O
onset	O
of	O
apoptosis	O
in	O
both	O
cell	O
types	O
can	O
be	O
delayed	O
by	O
hemopoietins	B-protein
and	O
inflammatory	B-protein
mediators	I-protein
.	O

Although	O
there	O
have	O
been	O
a	O
number	O
of	O
reports	O
demonstrating	O
that	O
glucocorticoids	O
(	O
in	O
particular	O
dexamethasone	O
)	O
antagonize	O
the	O
eosinophil	O
life-prolonging	O
effects	O
of	O
hemopoietins	B-protein
,	O
direct	O
effects	O
of	O
dexamethasone	O
on	O
eosinophil	O
apoptosis	O
have	O
not	O
been	O
documented	O
.	O

In	O
this	O
study	O
we	O
examined	O
the	O
direct	O
effects	O
of	O
glucocorticoids	O
on	O
eosinophil	B-cell_type
and	O
neutrophil	B-cell_type
apoptosis	O
in	O
light	O
of	O
their	O
common	O
therapeutic	O
use	O
as	O
anti-inflammatory	O
and	O
anti-allergic/hypereosinophilic	O
agents	O
.	O

We	O
found	O
that	O
treatment	O
with	O
dexamethasone	O
induced	O
eosinophil	B-cell_type
apoptosis	O
.	O

In	O
contrast	O
,	O
dexamethasone	O
was	O
a	O
potent	O
inhibitor	O
of	O
neutrophil	B-cell_type
apoptosis	O
.	O

The	O
effect	O
of	O
dexamethasone	O
on	O
both	O
cell	O
types	O
was	O
mediated	O
through	O
the	O
glucocorticoid	B-protein
receptor	I-protein
,	O
i.e.	O
,	O
it	O
was	O
abolished	O
by	O
the	O
glucocorticoid	B-protein
receptor	I-protein
antagonist	O
RU38486	O
.	O

This	O
is	O
the	O
first	O
description	O
of	O
an	O
agent	O
that	O
promotes	O
eosinophil	B-cell_type
apoptosis	O
while	O
inhibiting	O
neutrophil	B-cell_type
apoptosis	O
,	O
and	O
thus	O
presents	O
a	O
novel	O
approach	O
to	O
the	O
study	O
of	O
control	O
of	O
apoptosis	O
in	O
these	O
closely	O
related	O
cell	O
types	O
as	O
well	O
as	O
increases	O
our	O
understanding	O
of	O
the	O
clinical	O
action	O
of	O
glucocorticoids	O
in	O
inflammation	O
.	O

Permanent	O
occupancy	O
of	O
the	O
human	B-DNA
immunodeficiency	I-DNA
virus	I-DNA
type	I-DNA
1	I-DNA
enhancer	I-DNA
by	O
NF-kappa	B-protein
B	I-protein
is	O
needed	O
for	O
persistent	O
viral	O
replication	O
in	O
monocytes	B-cell_type
.	O

This	O
work	O
aimed	O
to	O
ascertain	O
the	O
role	O
of	O
kappaB-responsive	B-DNA
elements	I-DNA
of	O
the	O
human	B-DNA
immunodeficiency	I-DNA
virus	I-DNA
type	I-DNA
1	I-DNA
(	I-DNA
HIV-1	I-DNA
)	I-DNA
enhancer	I-DNA
not	O
only	O
in	O
early	O
initiation	O
but	O
also	O
in	O
long-term	O
maintenance	O
of	O
proviral	O
transcription	O
in	O
cells	O
of	O
the	O
monocytic	B-cell_type
lineage	I-cell_type
.	O

For	O
this	O
purpose	O
,	O
we	O
used	O
three	O
main	O
approaches	O
.	O

The	O
first	O
was	O
to	O
abruptly	O
terminate	O
tumor	O
necrosis	O
factor-induced	O
NF-kappaB	B-protein
binding	O
to	O
the	O
enhancer	O
sequences	O
in	O
U1	O
monocytic	O
cells	O
,	O
using	O
a	O
short	O
pulse	O
of	O
exogenous	B-protein
tumor	I-protein
necrosis	I-protein
factor	I-protein
.	O

This	O
resulted	O
in	O
concomitant	O
decrease	O
in	O
nuclear	O
NF-kappaB	B-protein
DNA-binding	O
activity	O
and	O
endogenous	B-DNA
long	I-DNA
terminal	I-DNA
repeat	I-DNA
transcriptional	O
activity	O
.	O

The	O
second	O
was	O
to	O
suppress	O
the	O
permanent	O
NF-kappaB	B-protein
translocation	O
induced	O
by	O
HIV-1	O
replication	O
itself	O
in	O
chronically	B-cell_line
infected	I-cell_line
U937	I-cell_line
cells	I-cell_line
,	O
using	O
a	O
specific	O
proteasome	O
inhibitor	O
(	O
Z-LLL-H	O
)	O
.	O

As	O
early	O
as	O
2	O
h	O
after	O
addition	O
of	O
the	O
inhibitor	O
to	O
the	O
culture	O
medium	O
,	O
there	O
was	O
an	O
inhibition	O
of	O
both	O
constitutive	O
activation	O
of	O
NF-kappaB	B-protein
and	O
HIV-1	O
genome	O
expression	O
.	O

The	O
third	O
approach	O
was	O
to	O
monitor	O
the	O
replication	O
competence	O
in	O
U937	B-cell_line
cells	I-cell_line
of	O
an	O
infectious	O
HIV-1	O
provirus	O
carrying	O
point	O
mutations	O
in	O
the	O
kappaB-responsive	B-DNA
elements	I-DNA
of	O
both	O
long	B-DNA
terminal	I-DNA
repeats	I-DNA
.	O

Compared	O
with	O
its	O
wild-type	O
counterpart	O
,	O
this	O
mutated	O
provirus	O
showed	O
a	O
profoundly	O
decreased	O
,	O
Z-LLL-H-insensitive	O
transcriptional	O
and	O
replicative	O
activity	O
in	O
U937	B-cell_line
monocytes	I-cell_line
.	O

Together	O
,	O
our	O
results	O
indicate	O
that	O
occupancy	O
of	O
the	O
viral	B-DNA
enhancer	I-DNA
by	O
NF-kappaB	B-protein
(	I-protein
p50/p65	I-protein
)	I-protein
heterodimers	I-protein
is	O
required	O
for	O
ongoing	O
transcription	O
of	O
integrated	O
HIV	O
provirus	O
in	O
monocytes	B-cell_type
,	O
even	O
in	O
cells	O
chronically	O
infected	O
and	O
permanently	O
producing	O
functional	O
HIV	B-protein
Tat	I-protein
protein	I-protein
.	O

Thus	O
,	O
the	O
ability	O
of	O
HIV-1	O
replication	O
to	O
activate	O
NF-kappaB	B-protein
is	O
crucial	O
to	O
the	O
intense	O
self-perpetuated	O
viral	O
transcription	O
observed	O
in	O
cells	O
of	O
the	O
monocytic	B-cell_type
lineage	I-cell_type
.	O

Rel-deficient	B-cell_type
T	I-cell_type
cells	I-cell_type
exhibit	O
defects	O
in	O
production	O
of	O
interleukin	B-protein
3	I-protein
and	O
granulocyte-macrophage	B-protein
colony-stimulating	I-protein
factor	I-protein
.	O

The	O
c-rel	B-DNA
protooncogene	I-DNA
encodes	O
a	O
subunit	O
of	O
the	O
NF-kappa	B-protein
B-like	I-protein
family	I-protein
of	I-protein
transcription	I-protein
factors	I-protein
.	O

Mice	O
lacking	O
Rel	B-protein
are	O
defective	O
in	O
mitogenic	O
activation	O
of	O
B	B-cell_type
and	I-cell_type
T	I-cell_type
lymphocytes	I-cell_type
and	O
display	O
impaired	O
humoral	O
immunity	O
.	O

In	O
an	O
attempt	O
to	O
identify	O
changes	O
in	O
gene	O
expression	O
that	O
accompany	O
the	O
T-cell	O
stimulation	O
defects	O
associated	O
with	O
the	O
loss	O
of	O
Rel	B-protein
,	O
we	O
have	O
examined	O
the	O
expression	O
of	O
cell	B-protein
surface	I-protein
activation	I-protein
markers	I-protein
and	O
cytokine	O
production	O
in	O
mitogen-stimulated	O
Rel-/-	B-cell_type
T	I-cell_type
cells	I-cell_type
.	O

The	O
expression	O
of	O
cell	O
surface	O
markers	O
including	O
the	O
interleukin	B-protein
2	I-protein
receptor	I-protein
alpha	I-protein
(	I-protein
IL-2R	I-protein
alpha	I-protein
)	I-protein
chain	I-protein
(	O
CD25	B-protein
)	O
,	O
CD69	B-protein
and	O
L-selectin	B-protein
(	O
CD62	B-protein
)	O
is	O
normal	O
in	O
mitogen-activated	B-cell_line
Rel-/-	I-cell_line
T	I-cell_line
cells	I-cell_line
,	O
but	O
cytokine	B-protein
production	O
is	O
impaired	O
.	O

In	O
Rel-/-	B-cell_line
splenic	I-cell_line
T	I-cell_line
cell	I-cell_line
cultures	I-cell_line
stimulated	O
with	O
phorbol	O
12-myristate	O
13-acetate	O
and	O
ionomycin	O
,	O
the	O
levels	O
of	O
IL-3	O
,	O
IL-5	O
,	O
granulocyte-	B-protein
macrophage	I-protein
colony-stimulating	I-protein
factor	I-protein
(	O
GM-CSF	B-protein
)	O
,	O
tumor	B-protein
necrosis	I-protein
factor	I-protein
alpha	I-protein
(	O
TNF-alpha	B-protein
)	O
,	O
and	O
gamma	B-protein
interferon	I-protein
(	O
IFN-gamma	B-protein
)	O
were	O
only	O
2-	O
to	O
3-fold	O
lower	O
compared	O
with	O
normal	O
T	O
cells	O
.	O

In	O
contrast	O
,	O
anti-CD3	B-protein
and	O
anti-CD28	B-protein
stimulated	O
Rel-/-	B-cell_line
T	I-cell_line
cells	I-cell_line
,	O
which	O
fail	O
to	O
proliferate	O
,	O
make	O
little	O
or	O
no	O
detectable	O
cytokines	B-protein
.	O

Exogenous	O
IL-2	B-protein
,	O
which	O
restitutes	O
the	O
proliferative	O
response	O
of	O
the	O
anti-CD3-	B-cell_line
and	I-cell_line
anti-CD28-treated	I-cell_line
Rel-/-	I-cell_line
T	I-cell_line
cells	I-cell_line
,	O
restores	O
production	O
of	O
IL-5	O
,	O
TNF-alpha	B-protein
,	O
and	O
IFN-gamma	B-protein
,	O
but	O
not	O
IL-3	B-protein
and	O
GM-CSF	B-protein
expression	O
to	O
approximately	O
normal	O
levels	O
.	O

In	O
contrast	O
to	O
mitogen-activated	B-cell_line
Rel-/-	I-cell_line
T	I-cell_line
cells	I-cell_line
,	O
lipopolysaccharide-stimulated	O
Rel-/-	B-cell_line
macrophages	I-cell_line
produce	O
higher	O
than	O
normal	O
levels	O
of	O
GM-CSF	B-protein
.	O

These	O
findings	O
establish	O
that	O
Rel	B-protein
can	O
function	O
as	O
an	O
activator	O
or	O
repressor	O
of	O
gene	O
expression	O
and	O
is	O
required	O
by	O
T	B-cell_type
lymphocytes	I-cell_type
for	O
production	O
of	O
IL-3	B-protein
and	O
GM-CSF	B-protein
.	O

Nuclear	O
appearance	O
of	O
a	O
factor	O
that	O
binds	O
the	O
CD28	B-DNA
response	I-DNA
element	I-DNA
within	O
the	O
interleukin-2	B-DNA
enhancer	I-DNA
correlates	O
with	O
interleukin-2	B-protein
production	O
.	O

Activation	O
of	O
T	B-cell_type
lymphocytes	I-cell_type
requires	O
the	O
combined	O
signaling	O
of	O
the	O
T	B-protein
cell	I-protein
receptor	I-protein
and	O
costimulatory	B-protein
molecules	I-protein
such	O
as	O
CD28	B-protein
.	O

The	O
ability	O
of	O
T	B-cell_type
cells	I-cell_type
to	O
produce	O
interleukin-2	B-protein
(	O
IL-2	B-protein
)	O
is	O
a	O
critical	O
control	O
point	O
in	O
T	O
lymphocyte	O
activation	O
.	O

The	O
IL-2	B-protein
enhancer	O
contains	O
a	O
functional	O
motif	O
named	O
CD28	B-DNA
response	I-DNA
element	I-DNA
(	O
CD28RE	B-DNA
)	O
that	O
serves	O
a	O
role	O
as	O
a	O
target	O
for	O
mitogenic	O
T	O
cell	O
activation	O
signals	O
.	O

The	O
CD28RE	B-DNA
sequence	O
reveals	O
similarity	O
to	O
the	O
consensus	B-DNA
kappaB	I-DNA
binding	I-DNA
motif	I-DNA
.	O

Here	O
we	O
demonstrate	O
that	O
CD28RE	B-DNA
binds	O
an	O
inducible	O
protein	O
with	O
a	O
molecular	O
mass	O
of	O
approximately	O
35	O
kDa	O
called	O
nuclear	B-protein
factor	I-protein
of	I-protein
mitogenic-activated	I-protein
T	I-protein
cells	I-protein
(	O
NF-MATp35	B-protein
)	O
that	O
is	O
clearly	O
different	O
from	O
the	O
known	O
NF-	B-protein
kappaB/Rel	I-protein
family	I-protein
members	I-protein
.	O

Induction	O
of	O
NF-MATp35	B-protein
was	O
shown	O
to	O
depend	O
on	O
de	O
novo	O
protein	O
synthesis	O
and	O
was	O
restricted	O
to	O
T	B-cell_type
cells	I-cell_type
that	O
received	O
a	O
mitogenic	O
combination	O
of	O
T	O
cell	O
stimuli	O
,	O
not	O
necessarily	O
including	O
CD28	B-protein
signaling	O
.	O

Nonmitogenic	O
T	O
cell	O
stimulation	O
did	O
not	O
result	O
in	O
appearance	O
of	O
NF-MATp35	B-protein
.	O

These	O
results	O
indicate	O
that	O
mitogenic	O
combinations	O
of	O
T	O
cell	O
activation	O
signals	O
are	O
integrated	O
at	O
the	O
level	O
of	O
NF-MATp35	B-protein
induction	O
.	O

Similar	O
to	O
its	O
effect	O
on	O
IL-2	B-protein
production	O
,	O
cyclosporin	O
A	O
inhibited	O
the	O
induction	O
of	O
NF-MATp35	B-protein
.	O

Taken	O
together	O
,	O
these	O
data	O
demonstrate	O
that	O
the	O
nuclear	O
appearance	O
of	O
NF-MATp35	B-protein
shows	O
excellent	O
correlation	O
with	O
IL-2	B-protein
production	O
,	O
which	O
is	O
a	O
unique	O
characteristic	O
among	O
nuclear	O
factors	O
implicated	O
in	O
the	O
control	O
of	O
IL-2	B-protein
gene	O
expression	O
.	O

Transcriptional	O
basis	O
for	O
hyporesponsiveness	O
of	O
the	O
human	B-DNA
inducible	I-DNA
nitric	I-DNA
oxide	I-DNA
synthase	I-DNA
gene	I-DNA
to	O
lipopolysaccharide/interferon-gamma	O
.	O

The	O
work	O
reported	O
here	O
resolves	O
,	O
at	O
the	O
level	O
of	O
gene	O
regulation	O
,	O
the	O
controversy	O
as	O
to	O
whether	O
or	O
not	O
human	B-cell_type
monocytes/macrophages	I-cell_type
can	O
produce	O
nitric	O
oxide	O
(	O
NO	O
)	O
when	O
stimulated	O
with	O
lipopolysaccharide	O
(	O
LPS	O
)	O
,	O
with	O
or	O
without	O
co-stimulation	O
by	O
interferon-gamma	O
(	O
IFN-gamma	B-protein
)	O
.	O

Studies	O
included	O
structural	O
comparison	O
of	O
the	O
promoters	O
for	O
human	O
and	O
mouse	O
inducible	B-DNA
NO	I-DNA
synthase	I-DNA
(	I-DNA
iNOS	I-DNA
)	I-DNA
genes	I-DNA
,	O
transfection	O
and	O
assay	O
of	O
human	O
and	O
mouse	O
iNOS	B-DNA
promoter	I-DNA
regions	I-DNA
in	O
response	O
to	O
LPS	O
+/-	O
IFN-gamma	B-protein
,	O
and	O
electrophoretic	O
mobility	O
shift	O
assays	O
of	O
kappa	B-DNA
B	I-DNA
response	I-DNA
elements	I-DNA
.	O

Two	O
explanations	O
for	O
hyporesponsiveness	O
of	O
the	O
human	B-DNA
iNOS	I-DNA
promoter	I-DNA
to	O
LPS	O
+/-	O
IFN-gamma	B-protein
were	O
found	O
:	O
(	O
1	O
)	O
multiple	O
inactivating	O
nucleotide	O
substitutions	O
in	O
the	O
human	O
counterpart	O
of	O
the	O
enhancer	B-DNA
element	I-DNA
that	O
has	O
been	O
shown	O
to	O
regulate	O
LPS/	O
IFN-gamma	B-protein
induced	O
expression	O
of	O
the	O
mouse	B-DNA
iNOS	I-DNA
gene	I-DNA
;	O
and	O
(	O
2	O
)	O
and	O
absence	O
of	O
one	O
or	O
more	O
nuclear	B-protein
factors	I-protein
in	O
human	B-cell_type
macrophages	I-cell_type
(	O
e.g.	O
,	O
an	O
LPS-inducible	B-protein
nuclear	I-protein
factor-kappa	I-protein
B/Rel	I-protein
complex	I-protein
)	O
,	O
that	O
is	O
(	O
are	O
)	O
required	O
for	O
maximal	O
expression	O
of	O
the	O
gene	O
.	O

The	O
importance	O
of	O
resolution	O
of	O
this	O
controversy	O
is	O
that	O
future	O
research	O
in	O
this	O
area	O
should	O
be	O
directed	O
toward	O
the	O
understanding	O
of	O
alternative	O
mechanisms	O
that	O
can	O
result	O
in	O
the	O
successful	O
production	O
of	O
NO	O
.	O

X	O
inactivation	O
analysis	O
in	O
a	O
female	O
with	O
hypomelanosis	O
of	O
Ito	O
associated	O
with	O
a	O
balanced	B-DNA
X	I-DNA
;	I-DNA
17	I-DNA
translocation	I-DNA
:	O
evidence	O
for	O
functional	O
disomy	O
of	O
Xp	O
.	O

X	O
inactivation	O
analysis	O
was	O
performed	O
on	O
normal	O
and	O
hypopigmented	O
skin	O
samples	O
obtained	O
from	O
a	O
female	O
with	O
hypomelanosis	O
of	O
Ito	O
associated	O
with	O
a	O
balanced	B-DNA
whole	I-DNA
arm	I-DNA
X	I-DNA
;	I-DNA
17	I-DNA
translocation	I-DNA
.	O

Severe	O
skewing	O
of	O
X	O
inactivation	O
resulting	O
in	O
inactivity	O
of	O
the	O
intact	O
X	B-DNA
was	O
found	O
in	O
blood	O
and	O
cultures	O
of	O
both	O
types	O
of	O
skin	O
,	O
but	O
analysis	O
of	O
DNA	O
prepared	O
directly	O
from	O
hypopigmented	O
skin	O
showed	O
significant	O
inactivation	O
of	O
the	O
translocated	O
X	B-DNA
,	O
inconsistent	O
with	O
the	O
usual	O
mechanism	O
of	O
phenotypic	O
expression	O
in	O
X	B-DNA
;	I-DNA
autosome	I-DNA
translocations	I-DNA
.	O

In	O
addition	O
,	O
dual	O
colour	O
FISH	O
analysis	O
using	O
centromere	O
specific	O
probes	O
for	O
chromosomes	O
X	B-DNA
and	O
17	B-DNA
showed	O
that	O
the	O
breakpoints	O
on	O
both	O
chromosomes	B-DNA
lie	O
within	O
the	O
alphoid	O
arrays	O
,	O
making	O
interruption	O
of	O
a	O
locus	O
on	O
either	O
chromosome	O
unlikely	O
.	O

While	O
partial	O
variable	O
monosomy	O
of	O
loci	O
on	O
chromosome	B-DNA
17p	I-DNA
can	O
not	O
be	O
excluded	O
as	O
contributing	O
to	O
the	O
phenotype	O
in	O
this	O
patient	O
,	O
it	O
is	O
argued	O
that	O
the	O
major	O
likely	O
factor	O
is	O
partial	O
functional	O
disomy	O
of	O
sequences	O
on	O
Xp	B-DNA
in	O
cell	O
lineages	O
that	O
have	O
failed	O
to	O
inactivate	O
the	O
intact	O
X	B-DNA
chromosome	I-DNA
.	O

Identification	O
of	O
a	O
herpesvirus	B-DNA
Saimiri	I-DNA
cis-acting	I-DNA
DNA	I-DNA
fragment	I-DNA
that	O
permits	O
stable	O
replication	O
of	O
episomes	O
in	O
transformed	O
T	B-cell_type
cells	I-cell_type
.	O

Herpesvirus	O
saimiri	O
is	O
a	O
lymphotropic	O
herpesvirus	O
capable	O
of	O
immortalizing	O
and	O
transforming	O
T	B-cell_type
cells	I-cell_type
both	O
in	O
vitro	O
and	O
in	O
vivo	O
.	O

Immortalized	O
and	O
transformed	O
T	B-cell_type
cells	I-cell_type
harbor	O
several	O
copies	O
of	O
the	O
viral	B-DNA
genome	I-DNA
as	O
a	O
persisting	B-DNA
genome	I-DNA
.	O

The	O
mapping	O
of	O
the	O
cis-acting	B-DNA
genetic	I-DNA
cis-acting	I-DNA
segment	I-DNA
(	O
oriP	B-DNA
)	O
required	O
for	O
viral	O
episomal	O
maintenance	O
is	O
reported	O
here	O
.	O

Viral	B-DNA
DNA	I-DNA
fragments	I-DNA
that	O
potentially	O
contain	O
oriP	B-DNA
were	O
cloned	O
into	O
a	O
plasmid	B-DNA
that	O
contains	O
the	O
hygromycin	B-DNA
resistance	I-DNA
gene	I-DNA
.	O

After	O
several	O
round	O
of	O
subcloning	O
followed	O
by	O
transfection	O
,	O
oriP	B-DNA
was	O
mapped	O
to	O
a	O
1.955-kb	B-DNA
viral	I-DNA
segment	I-DNA
.	O

This	O
viral	O
fragment	O
permits	O
stable	O
plasmid	B-DNA
replication	O
without	O
deletion	O
or	O
rearrangement	O
as	O
well	O
as	O
episomal	O
maintenance	O
without	O
integration	O
or	O
recombination	O
.	O

The	O
function	O
of	O
oriP	B-DNA
depends	O
on	O
a	O
trans-acting	B-protein
factor	I-protein
(	O
s	O
)	O
encoded	O
by	O
the	O
viral	B-DNA
genome	I-DNA
.	O

The	O
1.955-kb	B-DNA
viral	I-DNA
segment	I-DNA
includes	O
a	O
dyad	O
symmetry	O
region	O
located	O
between	O
two	O
small	B-DNA
nuclear	I-DNA
RNA	I-DNA
genes	I-DNA
and	O
is	O
located	O
upstream	O
of	O
the	O
dihydrofolate	B-DNA
reductase	I-DNA
gene	I-DNA
homolog	I-DNA
.	O

Therefore	O
,	O
this	O
oriP	B-DNA
contains	O
novel	O
elements	O
distinct	O
from	O
those	O
of	O
other	O
DNA	O
viruses	O
.	O

In	O
vivo	O
anergized	B-cell_line
CD4+	I-cell_line
T	I-cell_line
cells	I-cell_line
express	O
perturbed	O
AP-1	O
and	O
NF-kappa	B-protein
B	I-protein
transcription	B-protein
factors	I-protein
.	O

Anergy	O
is	O
a	O
major	O
mechanism	O
to	O
ensure	O
antigen-specific	O
tolerance	O
in	O
T	B-cell_type
lymphocytes	I-cell_type
in	O
the	O
adult	O
.	O

In	O
vivo	O
,	O
anergy	O
has	O
mainly	O
been	O
studied	O
at	O
the	O
cellular	O
level	O
.	O

In	O
this	O
study	O
,	O
we	O
used	O
the	O
T-cell-activating	B-protein
superantigen	I-protein
staphylococcal	B-protein
enterotoxin	I-protein
A	I-protein
(	O
SEA	B-protein
)	O
to	O
investigate	O
molecular	O
mechanisms	O
of	O
T-lymphocyte	O
anergy	O
in	O
vivo	O
.	O

Injection	O
of	O
SEA	B-protein
to	O
adult	O
mice	O
activates	O
CD4+	B-cell_type
T	I-cell_type
cells	I-cell_type
expressing	O
certain	O
T-cell	B-protein
receptor	I-protein
(	I-protein
TCR	I-protein
)	I-protein
variable	I-protein
region	I-protein
beta-chain	I-protein
families	I-protein
and	O
induces	O
strong	O
and	O
rapid	O
production	O
of	O
interleukin	O
2	O
(	O
IL-2	B-protein
)	O
.	O

In	O
contrast	O
,	O
repeated	O
injections	O
of	O
SEA	B-protein
cause	O
CD4+	B-cell_type
T-cell	I-cell_type
deletion	O
and	O
anergy	O
in	O
the	O
remaining	O
CD4+	O
T	B-cell_type
cells	I-cell_type
,	O
characterized	O
by	O
reduced	O
expression	O
of	O
IL-2	B-protein
at	O
mRNA	O
and	O
protein	O
levels	O
.	O

We	O
analyzed	O
expression	O
of	O
AP-1	B-protein
,	O
NF-kappa	B-protein
B	I-protein
,	O
NF-AT	B-protein
,	O
and	O
octamer	B-protein
binding	I-protein
transcription	I-protein
factors	I-protein
,	O
which	O
are	O
known	O
to	O
be	O
involved	O
in	O
the	O
regulation	O
of	O
IL-2	B-protein
gene	O
promoter	O
activity	O
.	O

Large	O
amounts	O
of	O
AP-1	B-protein
and	O
NF-kappa	B-protein
B	I-protein
and	O
significant	O
quantities	O
of	O
NF-AT	B-protein
were	O
induced	O
in	O
SEA-activated	B-cell_line
CD4+	I-cell_line
spleen	I-cell_line
T	I-cell_line
cells	I-cell_line
,	O
whereas	O
Oct-1	O
and	O
Oct-2	O
DNA	O
binding	O
activity	O
was	O
similar	O
in	O
both	O
resting	O
and	O
activated	B-cell_type
T	I-cell_type
cells	I-cell_type
.	O

In	O
contrast	O
,	O
anergic	B-cell_type
CD4+	I-cell_type
T	I-cell_type
cells	I-cell_type
contained	O
severely	O
reduced	O
levels	O
of	O
AP-1	B-protein
and	O
Fos/Jun-containing	B-protein
NF-AT	I-protein
complexes	I-protein
but	O
expressed	O
significant	O
amounts	O
of	O
NF-kappa	B-protein
B	I-protein
and	O
Oct	B-protein
binding	I-protein
proteins	I-protein
after	O
SEA	B-protein
stimulation	O
.	O

Resolution	O
of	O
the	O
NF-kappa	B-protein
B	I-protein
complex	I-protein
demonstrated	O
predominant	O
expression	O
of	O
p50-p65	B-protein
heterodimers	I-protein
in	O
activated	B-cell_type
CD4+	I-cell_type
T	I-cell_type
cells	I-cell_type
,	O
while	O
anergic	O
cells	O
mainly	O
expressed	O
the	O
transcriptionally	O
inactive	O
p50	B-protein
homodimer	I-protein
.	O

These	O
alterations	O
of	O
transcription	B-protein
factors	I-protein
are	O
likely	O
to	O
be	O
responsible	O
for	O
repression	O
of	O
IL-2	B-protein
in	O
anergic	B-cell_type
T	I-cell_type
cells	I-cell_type
.	O

Fas	B-protein
ligation	O
induces	O
apoptosis	O
and	O
Jun	B-protein
kinase	I-protein
activation	O
independently	O
of	O
CD45	B-protein
and	O
Lck	B-protein
in	O
human	B-cell_type
T	I-cell_type
cells	I-cell_type
.	O

Stimulation	O
through	O
the	O
Fas/APO-1	B-protein
receptor	I-protein
results	O
in	O
apoptosis	O
through	O
an	O
incompletely	O
characterized	O
signaling	O
pathway	O
.	O

More	O
is	O
known	O
regarding	O
signal	O
transduction	O
events	O
that	O
occur	O
after	O
ligation	O
of	O
the	O
T-cell	B-protein
antigen	I-protein
receptor	I-protein
(	O
TCR	B-protein
)	O
.	O

It	O
has	O
been	O
shown	O
that	O
TCR	B-protein
stimulation	O
requires	O
both	O
the	O
membrane	B-protein
tyrosine	I-protein
phosphatase	I-protein
,	O
CD45	B-protein
,	O
and	O
the	O
Src-family	B-protein
kinase	I-protein
,	O
Lck	B-protein
,	O
to	O
result	O
in	O
cellular	O
activation	O
.	O

Although	O
prior	O
studies	O
suggest	O
a	O
role	O
for	O
protein	B-protein
tyrosine	I-protein
kinases	I-protein
and	O
phosphatases	O
in	O
Fas	B-protein
signaling	O
,	O
we	O
report	O
here	O
that	O
Fas	O
ligation	O
induces	O
apoptosis	O
in	O
T	B-cell_type
cells	I-cell_type
deficient	O
in	O
either	O
CD45	B-protein
or	O
Lck	B-protein
.	O

Further	O
,	O
in	O
normal	O
and	O
CD45-	B-cell_line
or	I-cell_line
Lck-deficient	I-cell_line
cell	I-cell_line
lines	I-cell_line
,	O
Fas	O
stimulation	O
results	O
in	O
activation	O
of	O
Jun	B-protein
kinase	I-protein
(	O
JNK	B-protein
)	O
,	O
a	O
proposed	O
mediator	O
of	O
stress	O
activation	O
pathways	O
.	O

Previous	O
studies	O
have	O
also	O
demonstrated	O
a	O
role	O
for	O
endogenous	O
ceramide	O
release	O
in	O
Fas-mediated	O
apoptosis	O
.	O

We	O
show	O
that	O
stimulation	O
with	O
a	O
synthetic	O
ceramide	O
analog	O
results	O
in	O
JNK	B-protein
activation	O
as	O
well	O
as	O
apoptosis	O
,	O
suggesting	O
ceramide	O
release	O
occurs	O
proximal	O
to	O
JNK	B-protein
activation	O
in	O
Fas	B-protein
signaling	O
.	O

Our	O
data	O
suggest	O
that	O
although	O
CD45	B-protein
and	O
Lck	B-protein
are	O
not	O
required	O
for	O
Fas	B-protein
signaling	O
,	O
JNK	B-protein
activation	O
may	O
play	O
an	O
important	O
role	O
transducing	O
distal	O
signals	O
that	O
lead	O
to	O
apoptosis	O
after	O
Fas	B-protein
ligation	O
.	O

Globin	O
gene	O
switching	O
.	O

In	O
vivo	O
protein-DNA	O
interactions	O
of	O
the	O
human	B-DNA
beta-globin	I-DNA
locus	I-DNA
in	O
erythroid	B-cell_type
cells	I-cell_type
expressing	O
the	O
fetal	O
or	O
the	O
adult	O
globin	B-DNA
gene	I-DNA
program	O
.	O

To	O
characterize	O
the	O
protein-DNA	O
interactions	O
important	O
for	O
the	O
developmental	O
control	O
of	O
the	O
human	B-DNA
beta-globin	I-DNA
locus	I-DNA
,	O
we	O
analyzed	O
by	O
in	O
vivo	O
dimethyl	O
sulfate	O
footprinting	O
erythroid	B-cell_type
cells	I-cell_type
expressing	O
either	O
the	O
fetal	O
or	O
the	O
adult	O
globin	O
developmental	O
program	O
.	O

In	O
the	O
locus	B-DNA
control	I-DNA
region	I-DNA
(	O
LCR	B-DNA
)	O
of	O
the	O
beta-globin	B-DNA
locus	I-DNA
,	O
in	O
vivo	O
footprints	O
on	O
NF-E2	B-protein
(	O
or	O
AP-1	B-protein
)	O
and	O
GATA-1	B-DNA
motifs	I-DNA
remained	O
the	O
same	O
regardless	O
of	O
whether	O
the	O
fetal	O
or	O
the	O
adult	B-DNA
globin	I-DNA
genes	I-DNA
are	O
expressed	O
.	O

In	O
contrast	O
,	O
in	O
vivo	O
footprints	O
on	O
GT	B-DNA
(	I-DNA
CACCC	I-DNA
)	I-DNA
motifs	I-DNA
differed	O
between	O
the	O
cells	O
expressing	O
the	O
fetal	O
or	O
the	O
adult	O
globin	O
program	O
.	O

In	O
promoter	B-DNA
regions	I-DNA
,	O
the	O
actively	B-DNA
transcribed	I-DNA
genes	I-DNA
demonstrated	O
extensive	O
and	O
consistent	O
footprints	O
over	O
the	O
canonical	O
elements	O
,	O
such	O
as	O
CACCC	B-DNA
and	I-DNA
CCAAT	I-DNA
motifs	I-DNA
.	O

The	O
adult	B-cell_type
globin	I-cell_type
expressing	I-cell_type
cells	I-cell_type
displayed	O
more	O
extensive	O
footprints	O
than	O
the	O
fetal	B-cell_type
globin	I-cell_type
expressing	I-cell_type
cells	I-cell_type
in	O
the	O
3	B-DNA
'	I-DNA
regulatory	I-DNA
sequences	I-DNA
of	O
both	O
the	O
Agamma-	B-DNA
and	I-DNA
the	I-DNA
beta-globin	I-DNA
genes	I-DNA
,	O
suggesting	O
a	O
role	O
of	O
these	O
3	B-DNA
'	I-DNA
elements	I-DNA
in	O
beta-globin	B-DNA
gene	I-DNA
expression	O
.	O

Our	O
results	O
suggest	O
that	O
the	O
bulk	O
of	O
protein-DNA	O
interactions	O
that	O
underlies	O
the	O
developmental	O
control	O
of	O
globin	B-DNA
genes	I-DNA
takes	O
place	O
in	O
the	O
gamma-	B-DNA
and	I-DNA
beta-globin	I-DNA
gene	I-DNA
promoters	I-DNA
,	O
and	O
that	O
GT	B-DNA
motifs	I-DNA
of	O
the	O
beta-globin	B-DNA
locus	I-DNA
LCR	B-DNA
may	O
play	O
a	O
role	O
in	O
the	O
developmental	O
regulation	O
of	O
human	O
beta-globin	B-DNA
gene	I-DNA
expression	O
,	O
perhaps	O
by	O
increasing	O
the	O
probability	O
of	O
interaction	O
of	O
the	O
LCR	B-protein
holocomplex	I-protein
with	O
the	O
fetal	B-DNA
or	I-DNA
the	I-DNA
adult	I-DNA
globin	I-DNA
gene	I-DNA
.	O

Antisense	O
inhibition	O
of	O
vitamin	B-protein
D	I-protein
receptor	I-protein
expression	O
induces	O
apoptosis	O
in	O
monoblastoid	B-cell_line
U937	I-cell_line
cells	I-cell_line
.	O

The	O
active	O
vitamin	O
D3	O
metabolite	O
1	O
,	O
25-dihydroxycholecalciferol	O
(	O
1	O
,	O
25	O
(	O
OH	O
)	O
2D3	O
)	O
acts	O
as	O
an	O
antiproliferative	O
and	O
differentiating	O
agent	O
for	O
the	O
monoblastoid	B-cell_line
cell	I-cell_line
line	I-cell_line
U937	I-cell_line
and	O
as	O
an	O
important	O
immunologic	O
mediator	O
implicated	O
particularly	O
in	O
the	O
function	O
of	O
cells	O
belonging	O
to	O
the	O
monocyte/macrophage	B-cell_type
lineage	I-cell_type
.	O

These	O
effects	O
are	O
controlled	O
by	O
the	O
vitamin	B-protein
D	I-protein
receptor	I-protein
(	O
VDR	B-protein
)	O
,	O
a	O
member	O
of	O
the	O
steroid	B-protein
hormone	I-protein
receptor	I-protein
family	I-protein
.	O

The	O
objective	O
of	O
this	O
study	O
was	O
to	O
develop	O
U937	B-cell_line
transfectants	O
expressing	O
antisense	O
VDR	B-RNA
mRNA	I-RNA
,	O
and	O
to	O
use	O
these	O
to	O
examine	O
the	O
role	O
of	O
1	O
,	O
25	O
(	O
OH	O
)	O
2D3	O
-VDR	B-protein
interaction	O
in	O
this	O
lineage	O
.	O

A	O
2-kb	B-DNA
VDR	I-DNA
cDNA	I-DNA
insert	I-DNA
(	O
including	O
the	O
complete	O
VDR	B-DNA
coding	I-DNA
region	I-DNA
)	O
was	O
cloned	O
in	O
an	O
antisense	O
orientation	O
into	O
the	O
EBV	O
episomal	O
vector	O
pMEP4	O
under	O
the	O
control	O
of	O
an	O
inducible	B-DNA
promoter	I-DNA
and	O
transfected	O
into	O
U937	B-cell_line
.	O

The	O
resultant	B-cell_line
cell	I-cell_line
line	I-cell_line
,	O
DH42	B-cell_line
,	O
was	O
hygromycin	O
resistant	O
,	O
contained	O
VDR	B-DNA
cDNA	I-DNA
,	O
expressed	O
fewer	O
VDRs	B-protein
than	O
controls	O
,	O
and	O
showed	O
a	O
substantial	O
decrease	O
in	O
antiproliferative	O
response	O
to	O
1	O
,	O
25	O
(	O
OH	O
)	O
2D3	O
.	O

However	O
,	O
1	O
,	O
25	O
(	O
OH	O
)	O
2D3	O
increased	O
the	O
number	O
of	O
cells	O
expressing	O
macrophage	B-protein
cell	I-protein
surface	I-protein
Ags	I-protein
,	O
including	O
CD14	B-protein
and	O
CD11b	B-protein
.	O

A	O
subpopulation	O
of	O
smaller	O
cells	O
did	O
not	O
express	O
the	O
differentiation	O
markers	O
after	O
cadmium	O
stimulation	O
.	O

Cell	O
cycle	O
analysis	O
showed	O
shifts	O
in	O
the	O
distribution	O
of	O
cells	O
from	O
G1	O
to	O
S	O
phase	O
,	O
which	O
were	O
more	O
pronounced	O
after	O
cadmium	O
treatment	O
.	O

A	O
considerable	O
proportion	O
of	O
cells	O
were	O
outside	O
the	O
cycle	O
and	O
DNA	O
fragmentation	O
confirmed	O
apoptosis	O
.	O

Thus	O
,	O
the	O
functional	O
outcome	O
of	O
the	O
VDR	B-protein
antisense	O
transfection	O
suggests	O
that	O
in	O
the	O
myelomonocytic	B-cell_type
lineage	I-cell_type
,	O
VDR	B-protein
expression	O
may	O
act	O
as	O
a	O
protective	O
mechanism	O
against	O
programmed	O
cell	O
death	O
.	O

Human	O
T	O
lymphotropic	O
virus-I	O
infection	O
of	O
human	B-cell_type
T	I-cell_type
lymphocytes	I-cell_type
induces	O
expression	O
of	O
the	O
beta-galactoside-binding	B-protein
lectin	I-protein
,	O
galectin-3	B-protein
.	O

Animal	O
lectins	B-protein
play	O
important	O
roles	O
in	O
a	O
variety	O
of	O
biological	O
processes	O
via	O
their	O
recognition	O
of	O
glycoconjugates	O
.	O

Galectin-3	O
is	O
a	O
beta-galactoside-binding	B-protein
lectin	I-protein
previously	O
designated	O
as	O
epsilon	B-protein
BP	I-protein
(	O
IgE-binding	B-protein
protein	I-protein
)	O
,	O
CBP35	B-protein
,	O
Mac-2	B-protein
,	O
L-29	B-protein
,	O
and	O
L-34	B-protein
,	O
and	O
its	O
expression	O
has	O
been	O
associated	O
with	O
various	O
physiological	O
and	O
pathological	O
processes	O
,	O
including	O
cell	O
growth	O
,	O
tumor	O
transformation	O
,	O
and	O
metastasis	O
.	O

Galectin-3	B-protein
is	O
widely	O
distributed	O
in	O
various	O
tissues	O
and	O
cell	O
types	O
and	O
is	O
expressed	O
in	O
many	O
leukocytes	B-cell_type
,	O
with	O
the	O
notable	O
exception	O
of	O
B	B-cell_type
and	I-cell_type
T	I-cell_type
lymphocytes	I-cell_type
.	O

We	O
now	O
report	O
that	O
galectin-3	B-protein
is	O
abundantly	O
expressed	O
in	O
a	O
number	O
of	O
human	B-cell_line
T	I-cell_line
lymphotropic	I-cell_line
virus	I-cell_line
(	I-cell_line
HTLV	I-cell_line
)	I-cell_line
-I-infected	I-cell_line
human	I-cell_line
T	I-cell_line
cell	I-cell_line
lines	I-cell_line
,	O
including	O
F6T	B-cell_line
,	O
HUT	B-cell_line
102	I-cell_line
,	O
K3T	B-cell_line
,	O
MT-2	B-cell_line
,	O
and	O
SLB-I	B-cell_line
,	O
but	O
is	O
not	O
expressed	O
in	O
non-HTLV-I-infected	B-cell_line
T	I-cell_line
cell	I-cell_line
lines	I-cell_line
such	O
as	O
Jurkat	B-cell_line
,	O
CEM	B-cell_line
,	O
and	O
MOLT-4	B-cell_line
.	O

In	O
addition	O
,	O
the	O
galectin-3	B-protein
level	O
was	O
markedly	O
increased	O
in	O
human	B-cell_type
thymocytes	I-cell_type
after	O
infection	O
with	O
HTLV-I	O
as	O
compared	O
with	O
uninfected	B-cell_type
thymocytes	I-cell_type
.	O

The	O
up-regulation	O
of	O
galectin-3	B-protein
expression	O
appeared	O
to	O
correlate	O
well	O
with	O
HTLV-I	O
gene	O
expression	O
,	O
as	O
undetectable	O
or	O
very	O
low	O
levels	O
of	O
galectin-3	B-protein
were	O
found	O
in	O
the	O
S1T	B-cell_line
and	I-cell_line
ATL-1K	I-cell_line
cell	I-cell_line
lines	I-cell_line
,	O
which	O
are	O
nonproductively	O
infected	O
with	O
HTLV-I	O
.	O

In	O
co-transfection	O
experiments	O
,	O
the	O
galectin-3	B-DNA
promoter	I-DNA
was	O
significantly	O
up-regulated	O
by	O
expression	B-DNA
vectors	I-DNA
encoding	O
the	O
40-kd	B-protein
Tax	I-protein
protein	I-protein
,	O
a	O
potent	O
transactivator	O
in	O
HTLV-I	O
.	O

Analysis	O
of	O
various	O
Tax	B-protein
mutants	I-protein
suggested	O
that	O
galectin-3	B-DNA
promoter	I-DNA
induction	O
is	O
dependent	O
on	O
activation	O
of	O
the	O
cyclic-AMP-responsive	B-protein
element	I-protein
binding	I-protein
protein/activation	I-protein
transcription	I-protein
factor	I-protein
family	I-protein
of	O
transcription	B-protein
factors	I-protein
and	O
,	O
to	O
a	O
lesser	O
extent	O
,	O
nuclear	B-protein
factor-kappa	I-protein
B/Rel	I-protein
induction	O
.	O

Transfection	O
of	O
human	B-cell_line
promonocytic	I-cell_line
U-937	I-cell_line
cells	I-cell_line
with	O
an	O
HTLV-I	O
Tax	O
expression	O
vector	O
induced	O
galectin-3	B-protein
expression	O
in	O
this	O
cell	O
line	O
.	O

Functionally	O
,	O
galectin-3	B-protein
was	O
shown	O
to	O
activate	O
interleukin-2	B-protein
production	O
in	O
Jurkat	B-cell_type
T	I-cell_type
cells	I-cell_type
.	O

Together	O
,	O
these	O
findings	O
raise	O
the	O
possibility	O
that	O
HTLV-I	O
Tax	B-protein
production	O
induces	O
the	O
transcription	O
and	O
subsequent	O
synthesis	O
and	O
secretion	O
of	O
galectin-3	B-protein
,	O
which	O
in	O
turn	O
may	O
further	O
activate	O
these	O
T	B-cell_type
cells	I-cell_type
and	O
contribute	O
to	O
the	O
altered	O
properties	O
of	O
cell	O
growth	O
found	O
in	O
adult	O
T	O
cell	O
leukemia	O
induced	O
by	O
HTLV-I	O
.	O

Monocytic	O
cell	O
type-specific	O
transcriptional	O
induction	O
of	O
collagenase	B-protein
.	O

Interstitial	O
collagenase	B-protein
(	O
MMP-1	B-protein
)	O
,	O
a	O
metalloproteinase	B-protein
produced	O
by	O
resident	B-cell_type
and	I-cell_type
inflammatory	I-cell_type
cells	I-cell_type
during	O
connective	O
tissue	O
turnover	O
,	O
cleaves	O
type	B-protein
I	I-protein
collagen	I-protein
fibrils	I-protein
.	O

This	O
catalytic	O
event	O
is	O
rate	O
limiting	O
in	O
remodeling	O
of	O
tissues	O
rich	O
in	O
fibrillar	B-protein
collagen	I-protein
such	O
as	O
the	O
skin	O
and	O
lungs	O
.	O

The	O
regulation	O
of	O
collagenase	B-protein
expression	O
is	O
cell-type	O
specific	O
;	O
bacterial	O
LPS	O
and	O
zymosan	O
,	O
a	O
yeast	O
cell	O
wall	O
derivative	O
,	O
are	O
potent	O
inducers	O
of	O
collagenase	B-protein
expression	O
in	O
macrophages	B-cell_type
,	O
but	O
do	O
not	O
alter	O
fibroblast	B-cell_type
collagenase	B-protein
expression	O
.	O

Since	O
promoter	O
elements	O
controlling	O
collagenase	B-protein
transcription	O
in	O
monocytic	O
cells	O
have	O
not	O
been	O
previously	O
defined	O
,	O
we	O
sought	O
to	O
delineate	O
responsive	O
cis-acting	B-DNA
elements	I-DNA
of	O
the	O
collagenase	B-DNA
promoter	I-DNA
in	O
transiently	O
transfected	O
human	B-cell_line
(	I-cell_line
U937	I-cell_line
)	I-cell_line
and	I-cell_line
murine	I-cell_line
(	I-cell_line
J774	I-cell_line
)	I-cell_line
monocytic	I-cell_line
cell	I-cell_line
lines	I-cell_line
.	O

Deletion	O
constructs	O
containing	O
as	O
little	O
as	O
72	O
bp	O
of	O
5	B-DNA
'	I-DNA
-flanking	I-DNA
sequence	I-DNA
of	O
the	O
collagenase	B-DNA
promoter	I-DNA
were	O
sufficient	O
for	O
LPS-	O
or	O
zymosan-mediated	O
transcriptional	O
induction	O
,	O
whereas	O
phorbol	O
inducibility	O
exhibited	O
an	O
absolute	O
requirement	O
for	O
upstream	O
elements	O
including	O
the	O
polyoma	B-DNA
enhancer	I-DNA
A-binding	I-DNA
protein-3	I-DNA
site	I-DNA
(	O
-83	B-DNA
to	I-DNA
-91	I-DNA
)	O
and	O
TTCA	B-DNA
sequence	I-DNA
(	O
-102	B-DNA
to	I-DNA
-105	I-DNA
)	O
in	O
both	O
monocytic	B-cell_type
cells	I-cell_type
and	O
fibroblasts	B-cell_type
.	O

Mutagenesis	O
of	O
the	O
activator	B-DNA
protein-1	I-DNA
[	I-DNA
AP-1	I-DNA
]	I-DNA
site	I-DNA
at	O
-72	B-DNA
abolished	O
basal	B-DNA
promoter	I-DNA
activity	O
and	O
LPS/zymosan	O
inducibility	O
,	O
while	O
mutagenesis	O
of	O
an	O
NF-kappaB-like	B-DNA
site	I-DNA
at	O
-20	O
to	O
-10	O
had	O
no	O
effect	O
.	O

Nuclear	O
extracts	O
from	O
LPS	O
-and	O
zymosan-treated	B-cell_type
cells	I-cell_type
showed	O
strong	O
AP-1	B-protein
activity	O
by	O
gel-shift	O
analysis	O
,	O
and	O
supershift	O
analysis	O
showed	O
the	O
AP-1	B-protein
complexes	I-protein
contained	O
specific	O
members	O
of	O
both	O
the	O
jun	B-DNA
and	I-DNA
fos	I-DNA
gene	I-DNA
families	I-DNA
.	O

These	O
data	O
indicate	O
that	O
,	O
in	O
contrast	O
to	O
most	O
LPS	O
effects	O
,	O
AP-1	B-protein
,	O
but	O
not	O
nuclear	B-protein
factor-kappaB	I-protein
,	O
mediates	O
LPS	O
induction	O
of	O
collagenase	B-protein
transcription	O
in	O
macrophagelike	B-cell_type
cells	I-cell_type
.	O

Furthermore	O
,	O
as	O
compared	O
to	O
regulation	O
by	O
phorbol	O
ester	O
,	O
collagenase	B-protein
induction	O
in	O
monocytic	B-cell_type
cells	I-cell_type
by	O
cell	O
wall	O
derivatives	O
of	O
bacteria	O
or	O
yeast	O
is	O
largely	O
independent	O
of	O
upstream	B-DNA
promoter	I-DNA
sequences	I-DNA
.	O

Activation	O
of	O
c-Jun	B-protein
N-terminal	I-protein
kinase	I-protein
in	O
bacterial	B-cell_type
lipopolysaccharide-stimulated	I-cell_type
macrophages	I-cell_type
.	O

Activation	O
of	O
macrophages	B-cell_type
by	O
bacterial	O
lipopolysaccharide	O
(	O
LPS	O
)	O
induces	O
transcription	O
of	O
genes	O
that	O
encode	O
for	O
proinflammatory	B-protein
regulators	I-protein
of	O
the	O
immune	O
response	O
.	O

Previous	O
work	O
has	O
suggested	O
that	O
activation	O
of	O
the	O
transcription	B-protein
factor	I-protein
activator	I-protein
protein	I-protein
1	I-protein
(	O
AP-1	B-protein
)	O
is	O
one	O
LPS-induced	O
event	O
that	O
mediates	O
this	O
response	O
.	O

Consistent	O
with	O
this	O
notion	O
,	O
we	O
found	O
that	O
LPS	O
stimulated	O
AP-1	B-protein
-mediated	O
transcription	O
of	O
a	O
transfected	B-DNA
reporter	I-DNA
gene	I-DNA
in	O
the	O
murine	B-cell_line
macrophage	I-cell_line
cell	I-cell_line
line	I-cell_line
RAW	I-cell_line
264.7	I-cell_line
.	O

As	O
AP-1	B-protein
activity	O
is	O
regulated	O
in	O
part	O
by	O
activation	O
of	O
the	O
c-Jun	B-protein
N-terminal	I-protein
kinase	I-protein
(	O
JNK	B-protein
)	O
,	O
which	O
phosphorylates	O
and	O
subsequently	O
increases	O
the	O
transcriptional	O
activity	O
of	O
c-Jun	O
,	O
we	O
examined	O
whether	O
LPS	O
treatment	O
of	O
macrophages	B-cell_type
resulted	O
in	O
activation	O
of	O
this	O
kinase	B-protein
.	O

LPS	O
treatment	O
of	O
RAW	B-cell_line
264.7	I-cell_line
cells	I-cell_line
,	O
murine	B-cell_type
bone	I-cell_type
marrow-derived	I-cell_type
macrophages	I-cell_type
,	O
and	O
the	O
human	B-cell_line
monocyte	I-cell_line
cell	I-cell_line
line	I-cell_line
THP-1	I-cell_line
resulted	O
in	O
rapid	O
activation	O
of	O
the	O
p46	B-protein
and	I-protein
p54	I-protein
isoforms	I-protein
of	O
JNK	B-protein
.	O

Treatment	O
with	O
wild-type	O
and	O
rough	O
mutant	O
forms	O
of	O
LPS	O
and	O
synthetic	O
lipid	O
A	O
resulted	O
in	O
JNK	B-protein
activation	O
,	O
while	O
pretreatment	O
with	O
the	O
tyrosine	B-protein
kinase	I-protein
inhibitor	O
herbimycin	O
A	O
inhibited	O
this	O
response	O
.	O

Binding	O
of	O
LPS-	O
LPS	B-protein
binding	I-protein
protein	I-protein
(	I-protein
LBP	I-protein
)	I-protein
complexes	I-protein
to	O
CD14	B-protein
,	O
a	O
surface	B-protein
receptor	I-protein
that	O
mediates	O
many	O
LPS	O
responses	O
,	O
was	O
found	O
to	O
be	O
crucial	O
,	O
as	O
pretreatment	O
of	O
THP-1	B-cell_line
cells	I-cell_line
with	O
the	O
monoclonal	B-protein
antibody	I-protein
60b	I-protein
,	O
which	O
blocks	O
this	O
binding	O
,	O
inhibited	O
JNK	B-protein
activation	O
.	O

These	O
results	O
suggest	O
that	O
LPS	O
activation	O
of	O
JNK	B-protein
in	O
monocyte/macrophage	B-cell_type
cells	I-cell_type
is	O
a	O
CD14-	O
and	O
protein	O
tyrosine	O
phosphorylation-dependent	O
event	O
that	O
may	O
mediate	O
the	O
early	O
activation	O
of	O
AP-1	B-protein
in	O
regulating	O
LPS-triggered	O
gene	O
induction	O
.	O

Surfactant	O
suppresses	O
NF-kappa	B-protein
B	I-protein
activation	O
in	O
human	O
monocytic	B-cell_type
cells	I-cell_type
.	O

In	O
addition	O
to	O
biophysical	O
properties	O
,	O
pulmonary	O
surfactant	O
has	O
immunomodulatory	O
activity	O
.	O

We	O
previously	O
demonstrated	O
that	O
both	O
synthetic	O
(	O
Exosurf	O
)	O
and	O
modified	O
natural	O
surfactant	O
(	O
Survanta	O
)	O
downregulated	O
endotoxin-stimulated	O
inflammatory	B-RNA
c	I-RNA
ytokine	I-RNA
mRNA	I-RNA
levels	O
and	O
protein	B-protein
products	I-protein
(	O
tumor	B-protein
necrosis	I-protein
factor-alpha	I-protein
[	O
TNF	O
]	O
,	O
interleukin-1-beta	B-protein
[	O
IL-1	B-protein
]	O
,	O
interleukin-6	B-protein
[	O
IL-6	B-protein
]	O
)	O
in	O
human	B-cell_type
alveolar	I-cell_type
macrophages	I-cell_type
.	O

In	O
this	O
study	O
,	O
we	O
report	O
that	O
both	O
Exosurf	O
and	O
Survanta	O
suppress	O
TNF	B-RNA
mRNA	I-RNA
and	O
secretion	O
(	O
85	O
+/-	O
4	O
%	O
mean	O
percent	O
inhibition	O
+/-	O
SEM	O
by	O
Exosurf	O
;	O
71	O
+/-	O
6	O
%	O
by	O
Survanta	O
)	O
by	O
endotoxin-stimulated	B-cell_line
THP-1	I-cell_line
,	O
a	O
human	B-cell_line
monocytic	I-cell_line
cell	I-cell_line
line	I-cell_line
.	O

Because	O
surfactant	O
downregulated	O
inflammatory	B-protein
cytokine	I-protein
production	O
similarly	O
in	O
both	O
normal	B-cell_type
human	I-cell_type
alveolar	I-cell_type
macrophages	I-cell_type
and	O
the	O
THP-1	B-cell_line
cell	I-cell_line
line	I-cell_line
,	O
we	O
used	O
this	O
cell	B-cell_line
line	I-cell_line
to	O
investigate	O
whether	O
surfactant	O
affected	O
transcriptional	O
mechanisms	O
.	O

Specifically	O
,	O
we	O
examined	O
nuclear	B-protein
factor-kappa	I-protein
B	I-protein
(	O
NF-kappa	B-protein
B	I-protein
)	O
activation	O
because	O
it	O
is	O
crucial	O
in	O
transcriptional	O
regulation	O
of	O
many	O
inflammatory	B-DNA
cytokine	I-DNA
genes	I-DNA
including	O
TNF	B-DNA
,	O
IL-1	B-DNA
,	O
and	O
IL-6	B-DNA
.	O

Electrophoretic	O
mobility	O
shift	O
assays	O
showed	O
that	O
both	O
surfactants	O
decreased	O
activation	O
of	O
NF-kappa	B-protein
B	I-protein
.	O

The	O
presence	O
of	O
both	O
p65	B-protein
and	O
p50	B-protein
NF-kappa	B-protein
B	I-protein
components	I-protein
in	O
LPS-activated	O
THP-1	B-cell_line
cells	I-cell_line
was	O
confirmed	O
by	O
specific	O
antibody	O
induction	O
of	O
supershifts	O
in	O
mobility	O
assays	O
.	O

These	O
results	O
are	O
the	O
first	O
to	O
suggest	O
that	O
surfactant	O
's	O
suppressive	O
effects	O
on	O
inflammatory	B-protein
cytokine	I-protein
production	O
may	O
involve	O
transcriptional	O
regulation	O
through	O
inhibition	O
of	O
NF-kappa	B-protein
B	I-protein
activation	O
.	O

A	O
cell	B-DNA
type-specific	I-DNA
enhancer	I-DNA
in	O
the	O
human	B-DNA
B7.1	I-DNA
gene	I-DNA
regulated	O
by	O
NF-kappaB	B-protein
.	O

The	O
costimulatory	B-protein
molecule	I-protein
B7.1	I-protein
provides	O
a	O
second	O
signal	O
critical	O
for	O
T	O
cell	O
activation	O
.	O

The	O
distribution	O
of	O
this	O
integral	B-protein
membrane	I-protein
protein	I-protein
is	O
restricted	O
to	O
certain	O
tissues	O
where	O
its	O
level	O
of	O
expression	O
is	O
modulated	O
by	O
multiple	O
exogenous	O
stimuli	O
.	O

To	O
identify	O
the	O
molecular	O
basis	O
for	O
specificity	O
and	O
inducibility	O
,	O
the	O
chromatin	B-DNA
configuration	O
of	O
the	O
human	B-DNA
B7.1	I-DNA
gene	I-DNA
was	O
examined	O
in	O
intact	O
nuclei	O
from	O
various	O
cell	O
types	O
.	O

The	O
identification	O
of	O
a	O
tissue-specific	O
deoxyribonuclease	B-DNA
I	I-DNA
hypersensitive	I-DNA
site	I-DNA
approximately	O
3kb	B-DNA
upstream	I-DNA
of	O
the	O
transcription	B-DNA
start	I-DNA
site	I-DNA
led	O
to	O
the	O
characterization	O
of	O
a	O
cell	B-DNA
type-specific	I-DNA
enhancer	I-DNA
region	I-DNA
.	O

This	O
183-bp	B-DNA
region	I-DNA
was	O
both	O
cell	O
type	O
specific	O
and	O
responsive	O
to	O
two	O
distinct	O
stimuli	O
,	O
lipopolysaccharide	O
and	O
dibutyryl	O
cAMP	O
,	O
known	O
to	O
regulate	O
B7.1	B-protein
expression	O
.	O

Deletional	O
and	O
site-directed	O
mutagenesis	O
revealed	O
the	O
presence	O
of	O
multiple	O
functionally	O
critical	O
cis	B-DNA
elements	I-DNA
within	O
this	O
region	O
,	O
one	O
of	O
which	O
was	O
a	O
nuclear	B-DNA
factor	I-DNA
(	I-DNA
NF	I-DNA
)	I-DNA
-kappaB	I-DNA
consensus	I-DNA
sequence	I-DNA
.	O

In	O
B7.1-positive	B-cell_type
B	I-cell_type
cells	I-cell_type
,	O
this	O
element	O
bound	O
several	O
members	O
of	O
the	O
NF-kappaB	B-protein
family	I-protein
,	O
transcription	B-protein
factors	I-protein
already	O
implicated	O
in	O
signal	O
transduction	O
pathways	O
relevant	O
to	O
B7.1	B-protein
expression	O
.	O

This	O
is	O
the	O
first	O
description	O
,	O
to	O
our	O
knowledge	O
,	O
of	O
regulatory	B-DNA
elements	I-DNA
that	O
control	O
expression	O
of	O
a	O
gene	O
encoding	O
a	O
B7	B-protein
costimulatory	I-protein
molecule	I-protein
.	O

Ubiquitinylation	O
of	O
transcription	B-protein
factors	I-protein
c-Jun	B-protein
and	O
c-Fos	B-protein
using	O
reconstituted	B-protein
ubiquitinylating	I-protein
enzymes	I-protein
.	O

Recombinant	O
c-Jun	B-protein
and	O
c-Fos	B-protein
were	O
ubiquitinylated	O
by	O
the	O
ubiquitin	B-protein
carrier	I-protein
enzymes	I-protein
E214K	B-protein
,	O
E220K	B-protein
,	O
or	O
E232K	B-protein
in	O
the	O
presence	O
of	O
the	O
ubiquitin-activating	B-protein
enzyme	I-protein
,	O
E1	B-protein
.	O

Addition	O
of	O
ubiquitin	B-protein
protein	I-protein
ligase	I-protein
E3	I-protein
substantially	O
enhanced	O
the	O
E214K	B-protein
-mediated	O
ubiquitinylation	O
of	O
c-Jun	B-protein
and	O
c-Fos	B-protein
.	O

Truncated	B-protein
c-Jun	I-protein
and	I-protein
c-Fos	I-protein
mutant	I-protein
proteins	I-protein
including	O
wbJun	B-protein
and	O
wbFos	B-protein
were	O
also	O
ubiquitinylated	O
under	O
the	O
same	O
conditions	O
,	O
suggesting	O
the	O
sites	O
of	O
ubiquitinylation	O
are	O
located	O
within	O
the	O
dimerization	B-protein
and	I-protein
DNA	I-protein
binding	I-protein
domains	I-protein
of	O
c-Jun	B-protein
and	O
c-Fos	B-protein
.	O

The	O
E3-dependent	O
ubiquitinylation	O
of	O
c-Jun	B-protein
was	O
inhibited	O
upon	O
the	O
heterodimerization	O
of	O
c-Jun	B-protein
with	O
c-Fos	B-protein
.	O

Further	O
addition	O
of	O
E220K	B-protein
significantly	O
enhanced	O
ubiquitinylation	O
of	O
c-Jun	B-protein
in	O
the	O
heterodimer	O
suggesting	O
a	O
regulatory	O
role	O
of	O
E220K	B-protein
.	O

Polyubiquitinylated	O
c-Jun	B-protein
,	O
wbFos	B-protein
,	O
and	O
wbJun	B-protein
,	O
but	O
not	O
E220K-ubiquitinylated	B-protein
c-Jun	I-protein
,	O
were	O
readily	O
degraded	O
by	O
the	O
ATP-dependent	B-protein
26	I-protein
S	I-protein
multicatalytic	I-protein
proteases	I-protein
.	O

These	O
results	O
suggest	O
that	O
the	O
temporal	O
control	O
of	O
c-Jun	B-protein
and	O
c-Fos	B-protein
may	O
be	O
regulated	O
through	O
the	O
ubiquitinylation	O
pathways	O
,	O
and	O
the	O
ubiquitinylation	O
of	O
c-Jun	B-protein
and	O
c-Fos	B-protein
may	O
in	O
turn	O
be	O
regulated	O
in	O
response	O
to	O
the	O
heterodimerization	O
between	O
them	O
and	O
the	O
cooperation	O
between	O
E220K	B-protein
and	O
E3	O
mediated	O
polyubiquitinylation	O
.	O

Cloning	O
and	O
characterization	O
of	O
the	O
murine	B-protein
B-cell	I-protein
specific	I-protein
transcriptional	I-protein
coactivator	I-protein
Bob1	B-protein
.	O

From	O
a	O
murine	B-DNA
B-cell	I-DNA
cDNA-library	I-DNA
we	O
have	O
cloned	O
a	O
cDNA	B-DNA
encoding	O
the	O
murine	B-protein
B-cell	I-protein
specific	I-protein
coactivator	I-protein
mBob1	B-protein
.	O

The	O
protein	O
is	O
the	O
murine	O
homologue	O
to	O
the	O
recently	O
described	O
human	B-protein
coactivator	I-protein
Bob1	I-protein
(	O
hBob1	B-protein
)	O
,	O
also	O
referred	O
to	O
as	O
OBF-1	B-protein
or	O
OCA-B	B-protein
.	O

We	O
have	O
also	O
characterized	O
the	O
genomic	B-protein
mBob1	I-protein
clone	I-protein
.	O

Analysis	O
of	O
its	O
intron-exon	O
structure	O
has	O
allowed	O
identification	O
of	O
a	O
C-terminal	B-protein
splice	I-protein
variant	I-protein
.	O

mBob1	B-protein
is	O
B-cell	O
restricted	O
,	O
and	O
is	O
found	O
in	O
all	O
B-cell	B-cell_line
lines	I-cell_line
representing	O
different	O
stages	O
of	O
B-cell	O
differentiation	O
.	O

mBob1	B-protein
interacts	O
with	O
the	O
octamer	B-protein
transcription	I-protein
factors	I-protein
Oct-1	B-protein
and	O
Oct-2	B-protein
and	O
stimulates	O
transcription	O
mediated	O
by	O
these	O
factors	O
.	O

HIV	B-protein
glycoprotein	I-protein
120	I-protein
enhances	O
intercellular	B-protein
adhesion	I-protein
molecule-1	I-protein
gene	O
expression	O
in	O
glial	B-cell_type
cells	I-cell_type
.	O

Involvement	O
of	O
Janus	B-protein
kinase	I-protein
/signal	B-protein
transducer	I-protein
and	I-protein
activator	I-protein
of	I-protein
transcription	I-protein
and	O
protein	B-protein
kinase	I-protein
C	I-protein
signaling	O
pathways	O
.	O

It	O
is	O
well	O
established	O
that	O
the	O
two	O
major	O
glial	B-cell_type
cells	I-cell_type
in	O
the	O
central	O
nervous	O
system	O
(	O
CNS	O
)	O
,	O
astrocytes	B-cell_type
and	O
microglia	B-cell_type
,	O
are	O
key	O
participants	O
in	O
mediating	O
the	O
neurologic	O
dysfunction	O
associated	O
with	O
HIV	O
infection	O
of	O
the	O
CNS	O
.	O

In	O
this	O
study	O
,	O
we	O
investigated	O
the	O
ability	O
of	O
the	O
major	B-protein
envelope	I-protein
glycoprotein	I-protein
of	O
HIV	O
,	O
glycoprotein	B-protein
120	I-protein
(	O
gp120	B-protein
)	O
,	O
to	O
regulate	O
intercellular	B-protein
adhesion	I-protein
molecule-1	I-protein
(	O
ICAM-1	B-protein
)	O
expression	O
in	O
glial	B-cell_type
cells	I-cell_type
,	O
because	O
ICAM-1	B-protein
is	O
important	O
in	O
mediating	O
immune	O
responsiveness	O
in	O
the	O
CNS	O
,	O
facilitating	O
entry	O
of	O
HIV-infected	B-cell_type
cells	I-cell_type
into	O
the	O
CNS	O
,	O
and	O
promoting	O
syncytia	O
formation	O
.	O

Our	O
results	O
indicate	O
that	O
gp120	B-protein
enhances	O
ICAM-1	B-protein
gene	O
expression	O
in	O
primary	B-cell_type
rat	I-cell_type
astrocytes	I-cell_type
,	O
primary	B-cell_type
human	I-cell_type
astrocytes	I-cell_type
,	O
a	O
human	B-cell_line
astroglioma	I-cell_line
cell	I-cell_line
line	I-cell_line
CRT	I-cell_line
,	O
and	O
primary	B-cell_type
rat	I-cell_type
microglia	I-cell_type
.	O

The	O
signal	O
transduction	O
events	O
involved	O
in	O
gp120	B-protein
-mediated	O
enhancement	O
of	O
ICAM-1	B-protein
appear	O
to	O
involve	O
activation	O
of	O
both	O
protein	B-protein
kinase	I-protein
C	I-protein
and	O
tyrosine	B-protein
kinase	I-protein
,	O
because	O
inhibitors	O
of	O
protein	B-protein
kinase	I-protein
C	I-protein
and	O
tyrosine	B-protein
kinase	I-protein
abrogate	O
gp120	B-protein
-mediated	O
ICAM-1	B-protein
expression	O
in	O
both	O
astrocytes	B-cell_type
and	O
microglia	B-cell_type
.	O

Moreover	O
,	O
gp120	B-protein
induces	O
tyrosine	O
phosphorylation	O
of	O
signal	B-protein
transducer	I-protein
and	I-protein
activator	I-protein
of	I-protein
transcription	I-protein
(	O
STAT-1	B-protein
alpha	I-protein
)	O
as	O
well	O
as	O
the	O
Janus	B-protein
kinase	I-protein
(	O
JAK2	B-protein
)	O
in	O
glial	B-cell_type
cells	I-cell_type
.	O

We	O
also	O
demonstrate	O
that	O
gp120	B-protein
-mediated	O
ICAM-1	B-protein
expression	O
has	O
functional	O
significance	O
,	O
as	O
it	O
enhances	O
the	O
ability	O
of	O
monocytic	B-cell_type
cells	I-cell_type
to	O
bind	O
to	O
gp120-stimulated	B-cell_type
human	I-cell_type
astrocytes	I-cell_type
in	O
an	O
ICAM-1	B-protein
/beta	O
2	O
integrin	B-protein
-dependent	O
fashion	O
.	O

These	O
results	O
provide	O
new	O
insights	O
into	O
how	O
gp120	B-protein
can	O
influence	O
the	O
involvement	O
of	O
glial	B-cell_type
cells	I-cell_type
in	O
the	O
pathogenesis	O
of	O
AIDS	O
dementia	O
complex	O
.	O

IL-10	B-protein
cooperates	O
with	O
TNF-alpha	B-protein
to	O
activate	O
HIV-1	O
from	O
latently	B-cell_type
and	I-cell_type
acutely	I-cell_type
infected	I-cell_type
cells	I-cell_type
of	O
monocyte/macrophage	B-cell_type
lineage	I-cell_type
.	O

IL-10	B-protein
is	O
elevated	O
in	O
HIV-1-infected	O
individuals	O
and	O
has	O
been	O
implicated	O
in	O
disease	O
progression	O
.	O

In	O
this	O
study	O
,	O
we	O
investigated	O
the	O
effects	O
of	O
IL-10	B-protein
on	O
the	O
activation	O
of	O
HIV-1	O
from	O
infected	B-cell_type
monocytes	I-cell_type
and	O
macrophages	B-cell_type
.	O

Although	O
IL-10	B-protein
alone	O
did	O
not	O
induce	O
HIV-1	O
replication	O
,	O
in	O
the	O
presence	O
of	O
TNF-alpha	B-protein
,	O
IL-10	B-protein
markedly	O
enhanced	O
virion	O
production	O
from	O
a	O
chronically	O
infected	O
promonocytic	B-cell_line
cell	I-cell_line
line	I-cell_line
(	O
U1	B-cell_line
)	O
and	O
in	O
acutely	O
infected	O
monocyte-derived	B-cell_type
macrophages	I-cell_type
.	O

Neutralizing	O
mAbs	B-protein
to	O
IL-10	B-protein
and	O
TNF-alpha	B-protein
indicated	O
that	O
both	O
cytokines	B-protein
were	O
essential	O
for	O
the	O
induction	O
and	O
were	O
required	O
to	O
generate	O
a	O
synergistic	O
increase	O
in	O
virus	O
expression	O
.	O

The	O
effects	O
of	O
the	O
two	O
cytokines	B-protein
were	O
distinguishable	O
functionally	O
since	O
pretreatment	O
with	O
TNF-alpha	B-protein
attenuated	O
the	O
cytokine	B-protein
cooperativity	O
,	O
while	O
pretreatment	O
with	O
IL-10	B-protein
potentiated	O
their	O
cooperativity	O
,	O
suggesting	O
that	O
IL-10	B-protein
and	O
TNF-alpha	B-protein
play	O
different	O
roles	O
in	O
the	O
activation	O
of	O
virus	O
.	O

Northern	O
blot	O
analysis	O
as	O
well	O
as	O
Ab	O
blocking	O
and	O
cytokine	B-protein
secretion	O
studies	O
indicated	O
that	O
the	O
induction	O
of	O
either	O
endogenous	B-protein
TNF-alpha	I-protein
or	O
IL-10	B-protein
was	O
not	O
involved	O
in	O
the	O
cooperativity	O
,	O
nor	O
was	O
an	O
up-regulation	O
of	O
TNF-alpha	B-protein
receptors	I-protein
.	O

In	O
combination	O
with	O
TNF-alpha	B-protein
,	O
IL-10	B-protein
stimulated	O
activating	B-protein
protein-1	I-protein
(	O
AP-1	B-protein
)	O
and	O
nuclear	B-protein
factor	I-protein
(	I-protein
NF	I-protein
)	I-protein
-kappa	I-protein
B	I-protein
binding	O
activities	O
and	O
cooperated	O
to	O
increase	O
HIV-1	O
steady-state	O
mRNA	O
levels	O
and	O
enhance	O
long	B-DNA
terminal	I-DNA
repeat	I-DNA
-directed	O
transcription	O
through	O
activation	O
of	O
the	O
NF-kappa	B-DNA
B	I-DNA
binding	I-DNA
sites	I-DNA
,	O
suggesting	O
the	O
IL-10	B-protein
effect	O
occurs	O
at	O
least	O
in	O
part	O
at	O
the	O
transcriptional	O
level	O
.	O

These	O
results	O
indicate	O
that	O
IL-10	B-protein
,	O
in	O
addition	O
to	O
down-regulating	O
the	O
cellular	O
immune	O
response	O
to	O
HIV-1	O
,	O
may	O
also	O
play	O
a	O
role	O
in	O
TNF-alpha	B-protein
-mediated	O
activation	O
of	O
HIV-1	O
replication	O
in	O
the	O
monocyte/macrophage	B-cell_type
lineage	I-cell_type
.	O

Interaction	O
of	O
HTLV-I	B-protein
Tax	I-protein
with	O
the	O
human	B-protein
proteasome	I-protein
:	O
implications	O
for	O
NF-kappa	B-protein
B	I-protein
induction	O
.	O

The	O
human	O
T-cell	O
leukemia	O
virus	O
type	O
I	O
(	O
HTLV-I	O
)	O
has	O
been	O
etiologically	O
associated	O
with	O
the	O
development	O
of	O
the	O
adult	O
T-cell	O
leukemia	O
(	O
ATL	O
)	O
as	O
well	O
as	O
degenerative	O
neurologic	O
syndrome	O
termed	O
tropical	O
spastic	O
paraparesis	O
(	O
TSP	O
)	O
.	O

HTLV-I	O
encodes	O
a	O
potent	O
transactivator	B-protein
protein	O
termed	O
Tax	B-protein
that	O
appears	O
to	O
play	O
an	O
important	O
role	O
in	O
the	O
process	O
of	O
T-cell	O
immortalization	O
.	O

Even	O
though	O
the	O
mechanisms	O
by	O
which	O
Tax	B-protein
induces	O
transformation	O
are	O
still	O
unknown	O
,	O
it	O
seems	O
likely	O
that	O
the	O
ability	O
of	O
Tax	B-protein
to	O
alter	O
the	O
expression	O
of	O
many	O
cellular	B-DNA
genes	I-DNA
plays	O
an	O
important	O
part	O
in	O
this	O
process	O
.	O

Tax	B-protein
does	O
not	O
bind	O
directly	O
to	O
DNA	O
but	O
rather	O
deregulates	O
the	O
activity	O
of	O
cellular	B-protein
transcription	I-protein
factors	I-protein
.	O

One	O
family	O
of	O
host	B-protein
transcription	I-protein
factors	I-protein
whose	O
activity	O
is	O
altered	O
by	O
Tax	B-protein
includes	O
NF-kappa	B-protein
B/Rel	I-protein
.	O

These	O
transcription	B-protein
factors	I-protein
are	O
post-transcriptionally	O
regulated	O
by	O
their	O
assembly	O
with	O
a	O
second	O
family	O
of	O
inhibitory	B-protein
proteins	I-protein
termed	O
I	B-protein
kappa	I-protein
B	I-protein
that	O
serve	O
to	O
sequester	O
the	O
NF-kappa	B-protein
B/Rel	I-protein
complexes	I-protein
in	O
the	O
cytoplasm	O
.	O

Upon	O
cellular	O
activation	O
,	O
I	B-protein
kappa	I-protein
B	I-protein
alpha	I-protein
is	O
phosphorylated	O
,	O
polyubiquitinated	O
,	O
and	O
degraded	O
in	O
the	O
proteasome	B-protein
.	O

This	O
proteolytic	O
event	O
liberates	O
NF-kappa	B-protein
B	I-protein
,	O
permitting	O
its	O
rapid	O
translocation	O
into	O
the	O
nucleus	O
where	O
it	O
binds	O
to	O
its	O
cognate	B-DNA
enhancer	I-DNA
elements	I-DNA
.	O

Similarly	O
,	O
the	O
p105	B-protein
precursor	I-protein
of	O
the	O
NF-kappa	B-protein
B	I-protein
p50	B-protein
subunit	I-protein
is	O
also	O
post-translationally	O
processed	O
in	O
the	O
proteasome	B-protein
.	O

The	O
mechanisms	O
by	O
which	O
Tax	B-protein
activates	O
NF-kappa	B-protein
B	I-protein
remain	O
unclear	O
,	O
and	O
findings	O
presented	O
in	O
the	O
literature	O
are	O
often	O
controversial	O
.	O

We	O
identified	O
a	O
physical	O
interaction	O
between	O
Tax	B-protein
and	O
the	O
HsN3	B-protein
subunit	I-protein
of	O
the	O
human	B-protein
proteasome	I-protein
.	O

This	O
raises	O
the	O
intriguing	O
possibility	O
that	O
physical	O
association	O
of	O
the	O
HsN3	B-protein
proteasome	I-protein
subunit	I-protein
with	O
HTLV-I	B-protein
Tax	I-protein
coupled	O
with	O
the	O
independent	O
interaction	O
of	O
Tax	B-protein
with	O
either	O
p100	O
or	O
p65-	O
I	B-protein
kappa	I-protein
B	I-protein
alpha	I-protein
targets	O
these	O
cytoplasmic	B-protein
NF-kappa	I-protein
B/Rel	I-protein
complexes	I-protein
to	O
the	O
proteasome	B-protein
for	O
processing	O
.	O

Immunophenotype	O
of	O
intraductal	O
carcinoma	O
.	O

OBJECTIVE	O
--	O
Mammography	O
and	O
breast-conserving	O
therapy	O
have	O
focused	O
attention	O
on	O
the	O
classification	O
of	O
intraductal	O
carcinoma	O
(	O
IDC	O
)	O
and	O
emphasized	O
the	O
prognostic	O
importance	O
of	O
comedo	O
versus	O
noncomedo	O
variants	O
.	O

We	O
used	O
histochemical	O
markers	O
to	O
define	O
the	O
immunophenotype	O
of	O
43	O
IDCs	O
with	O
respect	O
to	O
comedo	O
versus	O
noncomedo	O
status	O
and	O
patterns	O
of	O
angiogenesis	O
.	O

RESULTS	O
--	O
Reactions	O
in	O
comedo	O
carcinomas	O
were	O
significantly	O
negative	O
for	O
estrogen	B-protein
receptor	I-protein
and	O
progesterone	B-protein
receptor	I-protein
,	O
and	O
positive	O
for	O
p53	B-protein
and	O
HER-2/neu	B-protein
more	O
often	O
than	O
the	O
noncomedo	O
variant	O
.	O

All	O
seven	O
IDCs	O
associated	O
with	O
Paget	O
's	O
disease	O
showed	O
positive	O
reactions	O
for	O
HER-2/neu	B-protein
.	O

Basement	O
membrane	O
immunoreactivity	O
for	O
type	B-protein
IV	I-protein
collagen	I-protein
and	O
laminin	B-protein
was	O
discontinuous	O
in	O
most	O
examples	O
of	O
IDC	O
regardless	O
of	O
type	O
,	O
with	O
a	O
trend	O
toward	O
more	O
intense	O
staining	O
in	O
comedo	O
than	O
in	O
noncomedo	O
carcinomas	O
.	O

Periductal	O
angiogenesis	O
was	O
not	O
significantly	O
related	O
to	O
the	O
type	O
of	O
IDC	O
but	O
was	O
more	O
pronounced	O
with	O
comedo	O
carcinomas	O
.	O

CONCLUSIONS	O
--	O
These	O
observations	O
indicate	O
that	O
there	O
are	O
immunophenotypic	O
correlates	O
to	O
the	O
current	O
structural	O
classification	O
of	O
IDC	O
.	O

The	O
immunophenotype	O
of	O
IDC	O
is	O
helpful	O
in	O
subclassifying	O
an	O
IDC	O
and	O
could	O
prove	O
useful	O
as	O
a	O
prognostic	O
indicator	O
for	O
local	O
control	O
in	O
patients	O
treated	O
by	O
breast-conserving	O
therapy	O
.	O

Inhibition	O
of	O
protein	B-protein
phosphatase	I-protein
2A	I-protein
induces	O
serine/threonine	O
phosphorylation	O
,	O
subcellular	O
redistribution	O
,	O
and	O
functional	O
inhibition	O
of	O
STAT3	B-protein
.	O

Signal	B-protein
transducers	I-protein
and	I-protein
activators	I-protein
of	I-protein
transcription	I-protein
(	O
STATs	B-protein
)	O
are	O
rapidly	O
phosphorylated	O
on	O
tyrosine	O
residues	O
in	O
response	O
to	O
cytokine	B-protein
and	O
growth	B-protein
factor	I-protein
stimulation	O
of	O
cell	B-protein
surface	I-protein
receptors	I-protein
.	O

STATs	B-protein
hereafter	O
are	O
translocated	O
to	O
the	O
nucleus	O
where	O
they	O
act	O
as	O
transcription	B-protein
factors	I-protein
.	O

Recent	O
reports	O
suggest	O
that	O
serine	O
phosphorylation	O
of	O
STATs	B-protein
also	O
is	O
involved	O
in	O
the	O
regulation	O
of	O
STAT	B-protein
-mediated	O
gene	O
transcription	O
.	O

Here	O
,	O
we	O
studied	O
the	O
role	O
of	O
serine/threonine	B-protein
phosphatases	I-protein
in	O
STAT3	B-protein
signaling	O
in	O
human	B-cell_line
antigen-specific	I-cell_line
CD4	I-cell_line
(	I-cell_line
+	I-cell_line
)	I-cell_line
T	I-cell_line
cell	I-cell_line
lines	I-cell_line
and	O
cutaneous	B-cell_line
T	I-cell_line
cell	I-cell_line
lymphoma	I-cell_line
lines	I-cell_line
,	O
expressing	O
a	O
constitutively	O
activated	O
STAT3	B-protein
.	O

We	O
show	O
that	O
an	O
inhibitor	O
of	O
protein	B-protein
phosphatases	I-protein
(	O
PPs	B-protein
)	O
PP1/PP2A	B-protein
,	O
calyculin	B-protein
A	I-protein
,	O
induces	O
(	O
i	O
)	O
phosphorylation	O
of	O
STAT3	B-protein
on	O
serine	O
and	O
threonine	O
residues	O
,	O
(	O
ii	O
)	O
inhibition	O
of	O
STAT3	B-protein
tyrosine	O
phosphorylation	O
and	O
DNA	O
binding	O
activity	O
,	O
and	O
(	O
iii	O
)	O
relocation	O
of	O
STAT3	B-protein
from	O
the	O
nucleus	O
to	O
the	O
cytoplasm	O
.	O

Similar	O
results	O
were	O
obtained	O
with	O
other	O
PP2A	O
inhibitors	O
(	O
okadaic	O
acid	O
,	O
endothall	O
thioanhydride	O
)	O
but	O
not	O
with	O
inhibitors	O
of	O
PP1	B-protein
(	O
tautomycin	O
)	O
or	O
PP2B	B-protein
(	O
cyclosporine	O
A	O
)	O
.	O

Pretreatment	O
with	O
the	O
broad	O
serine/threonine	O
kinase	O
inhibitor	O
staurosporine	O
partly	O
blocked	O
the	O
calyculin	B-protein
A	I-protein
-induced	O
STAT3	B-protein
phosphorylation	O
,	O
whereas	O
inhibitors	O
of	O
serine/threonine	B-protein
kinases	I-protein
,	O
such	O
as	O
mitogen-activated	B-protein
protein	I-protein
kinase-1	I-protein
extracellular-regulated	I-protein
kinase-kinase	I-protein
,	O
mitogen-activated	B-protein
protein	I-protein
p38	I-protein
kinase	I-protein
,	O
and	O
phosphatidylinositol	B-protein
3-kinase	I-protein
,	O
did	O
not	O
.	O

In	O
conclusion	O
,	O
we	O
provide	O
evidence	O
that	O
PP2A	B-protein
plays	O
a	O
crucial	O
role	O
in	O
the	O
regulation	O
of	O
STAT3	B-protein
phosphorylation	O
and	O
subcellular	O
distribution	O
in	O
T	B-cell_type
cells	I-cell_type
.	O

Moreover	O
,	O
our	O
findings	O
suggest	O
that	O
the	O
level	O
of	O
STAT3	B-protein
phosphorylation	O
is	O
balanced	O
between	O
a	O
staurosporine-sensitive	B-protein
kinase	I-protein
(	O
s	O
)	O
and	O
PP2A	B-protein
.	O

Polyamines	O
in	O
human	O
breast	O
cancer	O
and	O
its	O
relations	O
to	O
classical	O
prognostic	O
features	O
:	O
clinical	O
implications	O
.	O

Experimental	O
evidence	O
suggest	O
an	O
important	O
role	O
of	O
polyamines	O
in	O
breast	O
cancer	O
development	O
.	O

Polyamines	O
have	O
been	O
determined	O
in	O
tissue	O
and	O
erythrocyte	O
samples	O
from	O
100	O
patients	O
with	O
primary	O
invasive	O
breast	O
cancer	O
and	O
30	O
patients	O
with	O
fibroadenomas	O
.	O

Statistical	O
analysis	O
was	O
performed	O
in	O
order	O
to	O
determine	O
the	O
prognostic	O
value	O
of	O
the	O
polyamine	O
patterns	O
of	O
tumor	O
tissues	O
and	O
erythrocytes	O
in	O
comparison	O
with	O
clinical	O
and	O
histological	O
prognostic	O
factors	O
.	O

In	O
malignant	O
tissues	O
,	O
polyamine	O
levels	O
were	O
significantly	O
higher	O
than	O
in	O
benign	O
tissues	O
.	O

They	O
correlated	O
with	O
markers	O
of	O
tumor	O
aggressivity	O
(	O
axillary	O
node	O
involvement	O
and	O
especially	O
with	O
markers	O
of	O
high	O
mitotic	O
rate	O
as	O
Ki-67	O
staining	O
,	O
histological	O
grade	O
)	O
.	O

No	O
correlation	O
was	O
found	O
between	O
estrogen	O
and	O
progesterone	O
status	O
,	O
tumor	O
size	O
and	O
polyamine	O
concentrations	O
.	O

Erythrocyte	O
polyamines	O
levels	O
were	O
identical	O
between	O
cancer	O
patients	O
and	O
controls	O
.	O

The	O
knowledge	O
of	O
the	O
polyamine	O
pattern	O
in	O
breast	O
cancer	O
could	O
become	O
useful	O
in	O
clinical	O
practice	O
particularly	O
if	O
polyamine	O
metabolism	O
is	O
targeted	O
as	O
a	O
therapeutic	O
approach	O
.	O

Signal	O
transduction	O
pathways	O
triggered	O
by	O
the	O
FcepsilonRIIb	B-protein
receptor	I-protein
(	O
CD23	B-protein
)	O
in	O
human	B-cell_type
monocytes	I-cell_type
lead	O
to	O
nuclear	B-protein
factor-kappaB	I-protein
activation	O
.	O

BACKGROUND	O
:	O
Alveolar	B-cell_type
macrophages	I-cell_type
play	O
a	O
key	O
role	O
in	O
the	O
initiation	O
of	O
the	O
inflammatory	O
reaction	O
of	O
allergic	O
asthma	O
.	O

Alveolar	B-cell_type
macrophages	I-cell_type
and	O
peripheral	B-cell_type
blood	I-cell_type
monocytes	I-cell_type
are	O
activated	O
when	O
IgE/allergen	B-protein
immune	I-protein
complexes	I-protein
bind	O
to	O
the	O
CD23	B-protein
receptor	I-protein
,	O
which	O
leads	O
to	O
the	O
production	O
of	O
inflammatory	B-protein
cytokines	I-protein
.	O

OBJECTIVE	O
:	O
We	O
sought	O
to	O
investigate	O
the	O
molecular	O
mechanisms	O
regulating	O
this	O
early	O
inflammatory	O
response	O
.	O

We	O
have	O
focused	O
on	O
the	O
study	O
of	O
the	O
signal	O
transduction	O
pathways	O
triggered	O
by	O
CD23	B-protein
in	O
human	B-cell_type
monocytes	I-cell_type
and	O
the	O
promonocytic	B-cell_line
cell	I-cell_line
line	I-cell_line
U937	I-cell_line
.	O

METHODS	O
:	O
CD23	B-protein
was	O
cross-linked	O
in	O
human	B-cell_type
monocytes	I-cell_type
and	O
U937	B-cell_line
cells	I-cell_line
with	O
IgE	B-protein
immune	I-protein
complexes	I-protein
.	O

Surface	O
expression	O
of	O
CD23	B-protein
was	O
determined	O
by	O
FACS	O
analysis	O
.	O

Transcription	B-protein
factor	I-protein
activation	O
and	O
gene	O
transcription	O
were	O
studied	O
by	O
gel-shift	O
assays	O
and	O
Northern	O
blot	O
analysis	O
,	O
respectively	O
.	O

IkappaBalpha	B-protein
phosphorylation	O
and	O
degradation	O
was	O
analyzed	O
by	O
Western	O
blot	O
.	O

RESULTS	O
:	O
Nuclear	B-protein
factor	I-protein
(	I-protein
NF	I-protein
)	I-protein
-kappaB	I-protein
is	O
the	O
main	O
transcription	O
factor	O
involved	O
in	O
the	O
gene	O
activation	O
that	O
follows	O
CD23	B-protein
cross-linking	O
in	O
monocytes	B-cell_type
.	O

CD23-induced	B-protein
NF-kappaB	I-protein
is	O
a	O
heterodimer	O
composed	O
of	O
p65/p50	B-protein
subunits	I-protein
.	O

NF-kappaB	O
nuclear	O
translocation	O
is	O
secondary	O
to	O
the	O
phosphorylation	O
and	O
subsequent	O
degradation	O
of	O
the	O
NF-kappaB	B-protein
inhibitory	I-protein
molecule	I-protein
IkappaBalpha	B-protein
.	O

Tyrosine	B-protein
kinase	I-protein
-dependent	O
,	O
and	O
not	O
protein	B-protein
kinase	I-protein
C	I-protein
-dependent	O
,	O
pathways	O
mediate	O
CD23	B-protein
-triggered	O
NF-kappaB	B-protein
activation	O
but	O
do	O
not	O
participate	O
in	O
the	O
direct	O
phosphorylation	O
of	O
IkappaBalpha	B-protein
.	O

IkappaBalpha	B-protein
degradation	O
and	O
NF-kappaB	B-protein
nuclear	O
translocation	O
correlate	O
with	O
transcriptional	O
activation	O
of	O
the	O
inflammatory	B-protein
cytokines	I-protein
TNF-alpha	B-protein
and	O
IL-1beta	O
.	O

CONCLUSIONS	O
:	O
NF-kappaB	B-protein
is	O
the	O
main	O
transcription	O
factor	O
involved	O
in	O
the	O
signal	O
transduction	O
pathway	O
of	O
CD23	B-protein
in	O
monocytes	B-cell_type
.	O

Suppression	O
of	O
TNFalpha	B-protein
-mediated	O
NFkappaB	B-protein
activity	O
by	O
myricetin	O
and	O
other	O
flavonoids	O
through	O
downregulating	O
the	O
activity	O
of	O
IKK	B-protein
in	O
ECV304	B-cell_line
cells	I-cell_line
.	O

Flavonoids	O
are	O
a	O
group	O
of	O
naturally-occurring	O
phenolic	O
compounds	O
in	O
the	O
plant	O
kingdom	O
,	O
and	O
many	O
flavonoids	O
are	O
found	O
with	O
vascular	O
protective	O
properties	O
.	O

Nevertheless	O
how	O
the	O
protective	O
response	O
is	O
exerted	O
by	O
flavonoids	O
is	O
not	O
well	O
characterized	O
.	O

In	O
view	O
of	O
the	O
nuclear	B-protein
factor-kappaB	I-protein
(	O
NFkappaB	B-protein
)	O
may	O
play	O
a	O
central	O
role	O
in	O
the	O
initiation	O
of	O
atherosclerosis	O
,	O
prevention	O
of	O
the	O
activation	O
of	O
NFkappaB	B-protein
represents	O
an	O
important	O
role	O
in	O
protecting	O
vascular	O
injury	O
.	O

In	O
this	O
study	O
,	O
the	O
effects	O
of	O
flavonoids	O
on	O
NFkappaB	B-protein
/inhibitor-kappaB	O
(	O
IkappaB	B-protein
)	O
system	O
in	O
ECV304	B-cell_line
cells	I-cell_line
activated	O
with	O
tumor	B-protein
necrosis	I-protein
factor-alpha	I-protein
(	O
TNFalpha	B-protein
)	O
were	O
examined	O
.	O

We	O
investigated	O
the	O
inhibitory	O
action	O
of	O
six	O
flavonoids	O
on	O
IkappaB	B-protein
kinase	I-protein
(	O
IKK	B-protein
)	O
activity	O
,	O
an	O
enzyme	O
recently	O
found	O
to	O
phosphorylate	O
critical	O
serine	O
residues	O
of	O
IkappaB	O
for	O
degradation	O
.	O

Of	O
six	O
flavonoids	O
tested	O
,	O
myricetin	O
was	O
found	O
to	O
strongly	O
inhibit	O
IKK	B-protein
kinase	O
activity	O
,	O
and	O
prevent	O
the	O
degradation	O
of	O
IkappaBalpha	B-protein
and	O
IkappaBbeta	B-protein
in	O
activated	O
endothelial	O
cells	O
.	O

Furthermore	O
,	O
myricetin	O
was	O
also	O
found	O
to	O
inhibit	O
NFkappaB	B-protein
activity	O
correlated	O
with	O
suppression	O
of	O
monocyte	O
adhesion	O
to	O
ECV304	B-cell_line
cells	I-cell_line
.	O

Therefore	O
we	O
conclude	O
that	O
flavonoids	O
may	O
be	O
of	O
therapeutic	O
value	O
for	O
vascular	O
disease	O
through	O
down	O
regulation	O
of	O
NFkappaB	B-protein
/IkappaB	B-protein
system	O
.	O

Copyright	O
1999	O
Wiley-Liss	O
,	O
Inc	O
.	O

Bcl-2	B-protein
-mediated	O
drug	O
resistance	O
:	O
inhibition	O
of	O
apoptosis	O
by	O
blocking	O
nuclear	B-protein
factor	I-protein
of	I-protein
activated	I-protein
T	I-protein
lymphocytes	I-protein
(	O
NFAT	B-protein
)	O
-induced	O
Fas	B-protein
ligand	O
transcription	O
.	O

Bcl-2	B-protein
inhibits	O
apoptosis	O
induced	O
by	O
a	O
variety	O
of	O
stimuli	O
,	O
including	O
chemotherapy	O
drugs	O
and	O
glucocorticoids	O
.	O

It	O
is	O
generally	O
accepted	O
that	O
Bcl-2	B-protein
exerts	O
its	O
antiapoptotic	O
effects	O
mainly	O
by	O
dimerizing	O
with	O
proapoptotic	O
members	O
of	O
the	O
Bcl-2	B-protein
family	I-protein
such	O
as	O
Bax	B-protein
and	O
Bad	B-protein
.	O

However	O
,	O
the	O
mechanism	O
of	O
the	O
antiapoptotic	O
effects	O
is	O
unclear	O
.	O

Paclitaxel	O
and	O
other	O
drugs	O
that	O
disturb	O
microtubule	B-protein
dynamics	O
kill	O
cells	O
in	O
a	O
Fas	B-protein
/Fas	B-protein
ligand	I-protein
(	O
FasL	B-protein
)	O
-dependent	O
manner	O
;	O
antibody	O
to	O
FasL	B-protein
inhibits	O
paclitaxel-induced	O
apoptosis	O
.	O

We	O
have	O
found	O
that	O
Bcl-2	B-protein
overexpression	O
leads	O
to	O
the	O
prevention	O
of	O
chemotherapy	O
(	O
paclitaxel	O
)	O
-induced	O
expression	O
of	O
FasL	B-protein
and	O
blocks	O
paclitaxel-induced	O
apoptosis	O
.	O

The	O
mechanism	O
of	O
this	O
effect	O
is	O
that	O
Bcl-2	B-protein
prevents	O
the	O
nuclear	O
translocation	O
of	O
NFAT	B-protein
(	O
nuclear	B-protein
factor	I-protein
of	I-protein
activated	I-protein
T	I-protein
lymphocytes	I-protein
,	O
a	O
transcription	B-protein
factor	I-protein
activated	O
by	O
microtubule	B-protein
damage	O
)	O
by	O
binding	O
and	O
sequestering	O
calcineurin	O
,	O
a	O
calcium-dependent	O
phosphatase	O
that	O
must	O
dephosphorylate	O
NFAT	B-protein
to	O
move	O
to	O
the	O
nucleus	O
.	O

Without	O
NFAT	B-protein
nuclear	O
translocation	O
,	O
the	O
FasL	B-protein
gene	O
is	O
not	O
transcribed	O
.	O

Thus	O
,	O
it	O
appears	O
that	O
paclitaxel	O
and	O
other	O
drugs	O
that	O
disturb	O
microtubule	B-protein
function	O
kill	O
cells	O
at	O
least	O
in	O
part	O
through	O
the	O
induction	O
of	O
FasL	B-protein
.	O

Furthermore	O
,	O
Bcl-2	B-protein
antagonizes	O
drug-induced	O
apoptosis	O
by	O
inhibiting	O
calcineurin	B-protein
activation	O
,	O
blocking	O
NFAT	B-protein
nuclear	O
translocation	O
,	O
and	O
preventing	O
FasL	B-protein
expression	O
.	O

The	O
effects	O
of	O
Bcl-2	B-protein
can	O
be	O
overcome	O
,	O
at	O
least	O
partially	O
,	O
through	O
phosphorylation	O
of	O
Bcl-2	B-protein
.	O

Phosphorylated	O
Bcl-2	B-protein
can	O
not	O
bind	O
calcineurin	B-protein
,	O
and	O
NFAT	B-protein
activation	O
,	O
FasL	B-protein
expression	O
,	O
and	O
apoptosis	O
can	O
occur	O
after	O
Bcl-2	B-protein
phosphorylation	O
.	O

MHC-peptide	O
ligand	O
interactions	O
establish	O
a	O
functional	O
threshold	O
for	O
antigen-specific	O
T	O
cell	O
recognition	O
.	O

Antigen-specific	O
T	O
cell	O
recognition	O
is	O
dependent	O
on	O
the	O
functional	O
density	O
of	O
the	O
TCR	B-protein
-ligand	O
,	O
which	O
consists	O
of	O
specific	O
MHC	B-protein
molecules	I-protein
and	O
a	O
specifically	O
bound	O
peptide	O
.	O

We	O
have	O
examined	O
the	O
influence	O
of	O
the	O
affinity	O
and	O
concentration	O
of	O
exogenous	O
peptide	O
and	O
the	O
density	O
of	O
specific	O
MHC	B-protein
molecules	I-protein
on	O
the	O
proliferation	O
of	O
a	O
CD4+	B-cell_line
,	I-cell_line
DQA1*0501/DQB1*0201	I-cell_line
(	I-cell_line
DQ2.1	I-cell_line
)	I-cell_line
-restricted	I-cell_line
,	I-cell_line
HSV-2-specific	I-cell_line
T	I-cell_line
cell	I-cell_line
clone	I-cell_line
.	O

Using	O
antigen	O
peptide	O
analogs	O
with	O
different	O
mutations	O
of	O
known	O
DQ2-anchor	O
residues	O
,	O
T	O
cell	O
response	O
was	O
reduced	O
in	O
an	O
peptide-affinity	O
and	O
-	O
concentration	O
specific	O
manner	O
.	O

The	O
decrease	O
using	O
weaker	O
binding	O
peptides	O
was	O
gradual	O
as	O
stimulation	O
with	O
a	O
peptide	O
with	O
intermediate	O
affinity	O
yielded	O
intermediate	O
T	B-cell_type
cell	I-cell_type
proliferation	O
and	O
the	O
poorest	O
binding	O
peptide	O
induced	O
an	O
even	O
weaker	O
T	B-cell_type
cell	I-cell_type
response	O
.	O

MHC	B-protein
class	I-protein
II	I-protein
density	O
on	O
the	O
APC	B-cell_type
was	O
modified	O
using	O
DQ2	B-cell_line
homo	I-cell_line
-and	I-cell_line
heterozygous	I-cell_line
B-LCLs	I-cell_line
as	O
APCs	B-cell_type
,	O
however	O
this	O
variation	O
of	O
MHC	O
concentration	O
had	O
no	O
effect	O
on	O
T	B-cell_type
cell	I-cell_type
proliferation	O
.	O

We	O
interpret	O
this	O
as	O
a	O
reflection	O
of	O
a	O
low	O
threshold	O
for	O
activation	O
of	O
the	O
T	B-cell_line
cell	I-cell_line
clone	I-cell_line
,	O
in	O
which	O
peptide-	O
MHC	B-protein
avidity	O
is	O
the	O
over-riding	O
determinant	O
of	O
the	O
strength	O
of	O
ligand	O
signal	O
.	O

Regulatory	O
effects	O
of	O
interleukin-11	B-protein
during	O
acute	O
lung	O
inflammatory	O
injury	O
.	O

The	O
role	O
of	O
interleukin-11	B-protein
(	O
IL-11	B-protein
)	O
was	O
evaluated	O
in	O
the	O
IgG	B-protein
immune	I-protein
complex	I-protein
model	O
of	O
acute	O
lung	O
injury	O
in	O
rats	O
.	O

IL-11	B-RNA
mRNA	I-RNA
and	O
protein	O
were	O
both	O
up-regulated	O
during	O
the	O
course	O
of	O
this	O
inflammatory	O
response	O
.	O

Exogenously	O
administered	O
IL-11	B-protein
substantially	O
reduced	O
,	O
in	O
a	O
dose-dependent	O
manner	O
,	O
the	O
intrapulmonary	O
accumulation	O
of	O
neutrophils	B-cell_type
and	O
the	O
lung	O
vascular	O
leak	O
of	O
albumin	B-protein
.	O

These	O
in	O
vivo	O
anti-inflammatory	O
effects	O
of	O
IL-11	B-protein
were	O
associated	O
with	O
reduced	O
NF-kappaB	B-protein
activation	O
in	O
lung	O
,	O
reduced	O
levels	O
of	O
tumor	B-protein
necrosis	I-protein
factor	I-protein
alpha	I-protein
(	O
TNF-alpha	B-protein
)	O
in	O
bronchoalveolar	O
lavage	O
(	O
BAL	O
)	O
fluids	O
,	O
and	O
diminished	O
up-regulation	O
of	O
lung	B-protein
vascular	I-protein
ICAM-1	I-protein
.	O

It	O
is	O
interesting	O
that	O
IL-11	B-protein
did	O
not	O
affect	O
BAL	O
fluid	O
content	O
of	O
the	O
CXC	B-protein
chemokines	I-protein
,	O
macrophage	B-protein
inflammatory	I-protein
protein-2	I-protein
(	O
MIP-2	B-protein
)	O
and	O
cytokine-inducible	B-protein
neutrophil	I-protein
chemoattractant	I-protein
(	O
CINC	B-protein
)	O
;	O
the	O
presence	O
of	O
IL-11	B-protein
did	O
not	O
affect	O
these	O
chemokines	B-protein
.	O

However	O
,	O
BAL	O
content	O
of	O
C5a	O
was	O
reduced	O
by	O
IL-11	B-protein
.	O

These	O
data	O
indicate	O
that	O
IL-11	B-protein
is	O
a	O
regulatory	B-protein
cytokine	I-protein
in	O
the	O
lung	O
and	O
that	O
,	O
like	O
other	O
members	O
of	O
this	O
family	O
,	O
its	O
anti-inflammatory	O
properties	O
appear	O
to	O
be	O
linked	O
to	O
its	O
suppression	O
of	O
NF-kappaB	B-protein
activation	O
,	O
diminished	O
production	O
of	O
TNF-alpha	B-protein
,	O
and	O
reduced	O
up-regulation	O
of	O
lung	B-protein
vascular	I-protein
ICAM-1	I-protein
.	O

Thrombopoietin	B-protein
induces	O
tyrosine	O
phosphorylation	O
of	O
Stat3	B-protein
and	O
Stat5	B-protein
in	O
human	B-cell_type
blood	I-cell_type
platelets	I-cell_type
.	O

Thrombopoietin	B-protein
is	O
known	O
to	O
be	O
essential	O
for	O
megakaryocytopoiesis	O
and	O
thrombopoiesis	O
.	O

Recently	O
,	O
we	O
and	O
others	O
have	O
shown	O
that	O
thrombopoietin	B-protein
induces	O
rapid	O
tyrosine	O
phosphorylation	O
of	O
Jak2	B-protein
and	O
other	O
proteins	O
in	O
human	B-cell_type
platelets	I-cell_type
and	O
BaF3	B-cell_line
cells	I-cell_line
,	O
genetically	O
engineered	O
to	O
express	O
c-Mpl	B-protein
,	O
a	O
receptor	O
for	O
thrombopoietin	B-protein
.	O

The	O
Jak	O
family	O
of	O
tyrosine	B-protein
kinases	I-protein
are	O
known	O
to	O
mediate	O
some	O
of	O
the	O
effects	O
of	O
cytokines	B-protein
or	O
hematopoietic	B-protein
growth	I-protein
factors	I-protein
by	O
recruitment	O
and	O
tyrosine	O
phosphorylation	O
of	O
a	O
variety	O
of	O
Stat	B-protein
(	O
signal	B-protein
transducers	I-protein
and	I-protein
activators	I-protein
of	I-protein
transcription	I-protein
)	O
proteins	O
.	O

Hence	O
,	O
we	O
have	O
investigated	O
whether	O
Stat	B-protein
proteins	I-protein
are	O
present	O
in	O
platelets	B-cell_type
and	O
,	O
if	O
so	O
,	O
whether	O
they	O
become	O
tyrosine	O
phosphorylated	O
in	O
response	O
to	O
thrombopoietin	B-protein
.	O

We	O
immunologically	O
identified	O
Stat1	B-protein
,	O
Stat2	B-protein
,	O
Stat3	B-protein
,	O
and	O
Stat5	B-protein
in	O
human	O
platelet	O
lysates	O
.	O

Thrombopoietin	B-protein
induced	O
tyrosine	O
phosphorylation	O
of	O
Stat3	B-protein
and	O
Stat5	B-protein
in	O
these	O
cells	O
.	O

Thrombopoietin	B-protein
also	O
induced	O
tyrosine	O
phosphorylation	O
of	O
Stat3	B-protein
and	O
Stat5	B-protein
in	O
FDCP-2	B-cell_line
cells	I-cell_line
genetically	O
engineered	O
to	O
constitutively	O
express	O
human	B-protein
c-Mpl	I-protein
.	O

Thus	O
,	O
our	O
data	O
indicate	O
that	O
Stat3	B-protein
and	O
Stat5	B-protein
may	O
be	O
involved	O
in	O
signal	O
transduction	O
after	O
ligand	O
binding	O
to	O
c-Mpl	B-protein
and	O
that	O
this	O
event	O
may	O
have	O
a	O
role	O
in	O
megakaryopoiesis/thrombopoiesis	O
or	O
possibly	O
a	O
mature	O
platelet	O
function	O
such	O
as	O
aggregation	O
.	O

Mechanisms	O
that	O
contribute	O
to	O
the	O
development	O
of	O
lymphoid	O
malignancies	O
:	O
roles	O
for	O
genetic	O
alterations	O
and	O
cytokine	B-protein
production	O
.	O

Recent	O
studies	O
have	O
defined	O
genetic	O
alterations	O
commonly	O
associated	O
with	O
transformed	B-cell_line
lymphocytes	I-cell_line
.	O

This	O
review	O
suggests	O
roles	O
for	O
these	O
alterations	O
in	O
the	O
development	O
of	O
lymphoid	O
neoplasms	O
.	O

Damage	O
to	O
the	O
genes	O
encoding	O
proteins	O
that	O
function	O
in	O
intracellular	O
signaling	O
,	O
transcription	O
,	O
or	O
regulation	O
of	O
the	O
cell	O
cycle	O
has	O
been	O
identified	O
and	O
linked	O
at	O
varying	O
degrees	O
to	O
the	O
progression	O
of	O
certain	O
lymphoid	O
malignancies	O
.	O

An	O
understanding	O
of	O
the	O
mechanistic	O
consequences	O
following	O
such	O
genetic	O
alterations	O
is	O
essential	O
to	O
an	O
understanding	O
of	O
the	O
development	O
of	O
these	O
lymphoid	O
neoplasms	O
.	O

In	O
contrast	O
,	O
it	O
is	O
also	O
becoming	O
clear	O
that	O
the	O
dysregulated	O
expression	O
of	O
proteins	O
that	O
are	O
not	O
genetically	O
altered	O
can	O
also	O
contribute	O
to	O
the	O
progression	O
of	O
lymphoid	O
malignancies	O
.	O

One	O
such	O
example	O
is	O
the	O
excessive	O
expression	O
of	O
``	B-protein
normal	I-protein
''	I-protein
lymphokines	I-protein
of	O
cytokines	B-protein
which	O
accompanies	O
many	O
lymphoproliferative	O
diseases	O
.	O

The	O
dysregulated	O
expression	O
of	O
cytokines	B-protein
during	O
malignancy	O
can	O
result	O
in	O
the	O
augmentation	O
of	O
growth	O
of	O
transformed	B-cell_line
lymphocytes	I-cell_line
,	O
as	O
well	O
as	O
an	O
alteration	O
of	O
the	O
anti-tumor	O
immune	O
response	O
.	O

The	O
latter	O
mechanism	O
is	O
especially	O
important	O
because	O
evasion	O
of	O
the	O
impending	O
immune	O
response	O
is	O
a	O
prerequisite	O
for	O
the	O
progression	O
of	O
lymphoproliferative	O
diseases	O
.	O

Taken	O
together	O
,	O
this	O
review	O
supports	O
the	O
notion	O
that	O
the	O
development	O
of	O
lymphoid	O
malignancies	O
is	O
multifactorial	O
,	O
involving	O
genetic	O
alterations	O
as	O
well	O
as	O
dysregulated	O
cytokine	B-protein
expression	O
.	O

Dehydroepiandrosterone	O
modulation	O
of	O
lipopolysaccharide-stimulated	O
monocyte	O
cytotoxicity	O
.	O

Dehydroepiandrosterone	O
(	O
DHEA	O
)	O
,	O
the	O
predominant	O
androgen	O
secreted	O
by	O
the	O
adrenal	O
cortex	O
,	O
can	O
be	O
converted	O
to	O
both	O
potent	O
androgens	O
and	O
estrogens	O
.	O

In	O
addition	O
to	O
its	O
role	O
as	O
a	O
precursor	O
for	O
other	O
steroid	O
hormones	O
,	O
DHEA	O
has	O
been	O
proposed	O
to	O
play	O
an	O
important	O
role	O
in	O
immunity	O
.	O

This	O
study	O
has	O
investigated	O
DHEA	O
modulation	O
of	O
LPS-induced	O
monocyte	O
cytotoxicity	O
.	O

Cytotoxicity	B-protein
markers	I-protein
assessed	O
include	O
tumor	O
cell	O
killing	O
,	O
IL-1	B-protein
secretion	O
,	O
reactive	O
oxygen	O
intermediate	O
release	O
,	O
nitric	B-protein
oxide	I-protein
synthetase	I-protein
activity	O
as	O
measured	O
by	O
the	O
release	O
of	O
reactive	O
nitrogen	O
intermediates	O
,	O
complement	B-protein
receptor-1	I-protein
cell	I-protein
surface	I-protein
protein	I-protein
,	O
and	O
TNF-alpha	B-protein
protein	I-protein
presence	O
.	O

Monocytes	B-cell_type
stimulated	O
with	O
LPS	O
concentrations	O
of	O
1.0	O
micrograms/ml	O
displayed	O
the	O
above	O
cytotoxic	O
markers	O
,	O
whereas	O
monocytes	B-cell_type
stimulated	O
with	O
DHEA	O
alone	O
or	O
with	O
LPS	O
at	O
a	O
lower	O
concentration	O
of	O
0.2	O
ng/ml	O
did	O
not	O
.	O

However	O
,	O
when	O
used	O
simultaneously	O
,	O
DHEA	O
and	O
LPS	O
0.2	O
ng/ml	O
displayed	O
a	O
synergistic	O
effect	O
on	O
monocyte	O
cytotoxicity	O
against	O
cancerous	B-cell_line
cell	I-cell_line
lines	I-cell_line
,	O
IL-1	B-protein
secretion	O
,	O
reactive	O
nitrogen	O
intermediate	O
release	O
,	O
complement	B-protein
receptor-1	I-protein
cell-surface	I-protein
protein	I-protein
,	O
and	O
TNF-alpha	B-protein
protein	I-protein
to	O
levels	O
comparable	O
with	O
levels	O
obtained	O
using	O
LPS	O
1.0	O
microgram/ml	O
.	O

Finally	O
,	O
Scatchard	O
plot	O
analysis	O
demonstrated	O
the	O
presence	O
of	O
a	O
DHEA	O
receptor	O
in	O
monocytes	B-cell_type
,	O
suggesting	O
that	O
DHEA	O
effects	O
on	O
LPS-stimulated	B-cell_line
monocytes	I-cell_line
are	O
mediated	O
through	O
a	O
receptor-dependent	O
process	O
.	O

Interferons	O
inhibit	O
activation	O
of	O
STAT6	B-protein
by	O
interleukin	B-protein
4	I-protein
in	O
human	B-cell_type
monocytes	I-cell_type
by	O
inducing	O
SOCS-1	B-DNA
gene	I-DNA
expression	O
.	O

Interferons	B-protein
(	O
IFNs	B-protein
)	O
inhibit	O
induction	O
by	O
IL-4	B-protein
of	O
multiple	O
genes	O
in	O
human	B-cell_type
monocytes	I-cell_type
.	O

However	O
,	O
the	O
mechanism	O
by	O
which	O
IFNs	B-protein
mediate	O
this	O
inhibition	O
has	O
not	O
been	O
defined	O
.	O

IL-4	B-protein
activates	O
gene	O
expression	O
by	O
inducing	O
tyrosine	O
phosphorylation	O
,	O
homodimerization	O
,	O
and	O
nuclear	O
translocation	O
of	O
the	O
latent	B-protein
transcription	I-protein
factor	I-protein
,	O
STAT6	B-protein
(	O
signal	B-protein
transducer	I-protein
and	I-protein
activator	I-protein
of	I-protein
transcription-6	I-protein
)	O
.	O

STAT6	B-protein
-responsive	O
elements	O
are	O
characteristically	O
present	O
in	O
the	O
promoters	B-DNA
of	O
IL-4-inducible	B-DNA
genes	I-DNA
.	O

Because	O
STAT6	B-protein
activation	O
is	O
essential	O
for	O
IL-4	B-protein
-induced	O
gene	O
expression	O
,	O
we	O
examined	O
the	O
ability	O
of	O
type	O
I	O
and	O
type	O
II	O
IFNs	B-protein
to	O
regulate	O
activation	O
of	O
STAT6	B-protein
by	O
IL-4	B-protein
in	O
primary	B-cell_type
human	I-cell_type
monocytes	I-cell_type
.	O

Pretreatment	O
of	O
monocytes	B-cell_type
with	O
IFN-beta	B-protein
or	O
IFN-gamma	B-protein
,	O
but	O
not	O
IL-1	B-protein
,	O
IL-2	B-protein
,	O
macrophage	B-protein
colony-stimulating	I-protein
factor	I-protein
,	O
granulocyte/macrophage	B-protein
colony-stimulating	I-protein
factor	I-protein
,	O
IL-6	B-protein
,	O
or	O
transforming	O
growth	O
factor	O
beta	O
suppressed	O
activation	O
of	O
STAT6	B-protein
by	O
IL-4	B-protein
.	O

This	O
inhibition	O
was	O
associated	O
with	O
decreased	O
tyrosine	O
phosphorylation	O
and	O
nuclear	O
translocation	O
of	O
STAT6	B-protein
and	O
was	O
not	O
evident	O
unless	O
the	O
cells	O
were	O
preincubated	O
with	O
IFN	B-protein
for	O
at	O
least	O
1	O
hr	O
before	O
IL-4	B-protein
stimulation	O
.	O

Furthermore	O
,	O
inhibition	O
by	O
IFN	B-protein
could	O
be	O
blocked	O
by	O
cotreatment	O
with	O
actinomycin	O
D	O
and	O
correlated	O
temporally	O
with	O
induction	O
of	O
the	O
JAK/STAT	B-DNA
inhibitory	I-DNA
gene	I-DNA
,	O
SOCS-1	B-DNA
.	O

Forced	O
expression	O
of	O
SOCS-1	B-DNA
in	O
a	O
macrophage	B-cell_line
cell	I-cell_line
line	I-cell_line
,	O
RAW264	B-cell_line
,	O
markedly	O
suppressed	O
trans-activation	O
of	O
an	O
IL-4-inducible	B-DNA
reporter	I-DNA
as	O
well	O
as	O
IL-6-	O
and	O
IFN-gamma-induced	O
reporter	O
gene	O
activity	O
.	O

These	O
findings	O
demonstrate	O
that	O
IFNs	B-protein
inhibit	O
IL-4	B-protein
-induced	O
activation	O
of	O
STAT6	B-protein
and	O
STAT6	B-protein
-dependent	O
gene	O
expression	O
,	O
at	O
least	O
in	O
part	O
,	O
by	O
inducing	O
expression	O
of	O
SOCS-1	B-DNA
.	O

An	O
activation-responsive	O
element	O
in	O
single	O
C	B-DNA
motif-1/lymphotactin	I-DNA
promoter	I-DNA
is	O
a	O
site	O
of	O
constitutive	O
and	O
inducible	O
DNA-protein	O
interactions	O
involving	O
nuclear	B-protein
factor	I-protein
of	I-protein
activated	I-protein
T	I-protein
cell	I-protein
.	O

Single	B-protein
C	I-protein
motif-1	I-protein
(	I-protein
SCM-1	I-protein
)	I-protein
/lymphotactin	I-protein
is	O
a	O
C-type	B-protein
chemokine	I-protein
whose	O
expression	O
is	O
activation	O
dependent	O
,	O
cyclosporin	O
A	O
sensitive	O
and	O
restricted	O
to	O
CD8+	B-cell_type
T	I-cell_type
cells	I-cell_type
,	O
double-negative	B-cell_type
thymocytes	I-cell_type
,	O
gammadelta-type	B-cell_type
T	I-cell_type
cells	I-cell_type
,	O
and	O
NK	B-cell_type
cells	I-cell_type
.	O

In	O
humans	O
,	O
there	O
are	O
two	O
highly	O
homologous	B-DNA
genes	I-DNA
encoding	O
SCM-1alpha	B-protein
and	O
SCM-1beta	B-protein
.	O

Here	O
we	O
examined	O
the	O
regulatory	O
mechanism	O
of	O
the	O
SCM-1	B-DNA
genes	I-DNA
.	O

The	O
luciferase	B-DNA
reporter	I-DNA
gene	I-DNA
under	O
the	O
control	O
of	O
the	O
5	B-DNA
'	I-DNA
flanking	I-DNA
region	I-DNA
of	O
0.7	O
kb	O
was	O
strongly	O
induced	O
upon	O
activation	O
with	O
anti-CD3	B-protein
or	O
PHA	B-protein
plus	O
PMA	O
only	O
in	O
SCM-1-producer	B-cell_line
T	I-cell_line
cell	I-cell_line
lines	I-cell_line
through	O
a	O
cyclosporin	O
A-sensitive	O
mechanism	O
.	O

An	O
element	O
termed	O
E1	B-DNA
located	O
at	O
-108	B-DNA
to	I-DNA
-95	I-DNA
nt	I-DNA
relative	O
to	O
the	O
major	O
transcription	O
start	O
site	O
was	O
found	O
to	O
be	O
critical	O
for	O
the	O
promoter	O
activity	O
.	O

In	O
electrophoretic	O
mobility	O
shift	O
assays	O
using	O
the	O
E1	B-DNA
oligonucleotide	O
as	O
probe	O
,	O
nuclear	O
extracts	O
from	O
unstimulated	O
T	O
and	O
B	B-cell_line
cell	I-cell_line
lines	I-cell_line
formed	O
a	O
constitutive	B-protein
complex	I-protein
termed	O
complex	B-protein
I	I-protein
,	O
while	O
nuclear	O
extracts	O
from	O
stimulated	O
SCM-1-producer	B-cell_line
T	I-cell_line
cell	I-cell_line
lines	I-cell_line
formed	O
a	O
higher	B-protein
mobility	I-protein
complex	I-protein
termed	O
complex	B-protein
II	I-protein
with	O
a	O
concomitant	O
decrease	O
in	O
complex	B-protein
I	I-protein
.	O

The	O
shift	O
from	O
complex	B-protein
I	I-protein
to	O
complex	B-protein
II	I-protein
seen	O
only	O
in	O
SCM-1-producer	B-cell_line
T	I-cell_line
cell	I-cell_line
lines	I-cell_line
upon	O
activation	O
was	O
completely	O
suppressed	O
by	O
cyclosporin	O
A	O
.	O

Both	O
complexes	O
were	O
critically	O
dependent	O
on	O
the	O
NF-AT	B-DNA
core	I-DNA
sequence	I-DNA
TTTCC	O
in	O
the	O
E1	B-DNA
element	I-DNA
and	O
were	O
partially	O
supershifted	O
by	O
anti-NF-ATp	B-protein
.	O

One-hybrid	O
assays	O
in	O
yeast	B-protein
isolated	I-protein
NF-ATp	I-protein
as	O
an	O
E1	B-protein
binding	I-protein
protein	I-protein
,	O
and	O
transfection	O
of	O
NF-ATp	B-protein
into	O
T	B-cell_line
and	I-cell_line
B	I-cell_line
cell	I-cell_line
lines	I-cell_line
strongly	O
enhanced	O
the	O
activation-dependent	B-protein
SCM-1	I-protein
promoter	O
activity	O
.	O

Collectively	O
,	O
a	O
unique	O
mechanism	O
involving	O
NF-ATp	B-protein
appears	O
to	O
regulate	O
the	O
cell	O
type-specific	O
and	O
activation-dependent	O
expression	O
of	O
the	O
SCM-1	B-DNA
genes	I-DNA
.	O

Dopamine	O
stimulates	O
expression	O
of	O
the	O
human	O
immunodeficiency	O
virus	O
type	O
1	O
via	O
NF-kappaB	B-protein
in	O
cells	O
of	O
the	O
immune	O
system	O
.	O

Recent	O
studies	O
have	O
reported	O
that	O
lymphocytes	B-cell_type
produce	O
,	O
transport	O
and	O
bind	O
dopamine	O
present	O
in	O
plasma	O
.	O

However	O
,	O
the	O
action	O
of	O
dopamine	O
on	O
HIV-1	O
gene	O
expression	O
in	O
cells	O
of	O
the	O
immune	O
system	O
has	O
not	O
yet	O
been	O
examined	O
.	O

Here	O
,	O
we	O
have	O
investigated	O
the	O
regulation	O
of	O
HIV-1	O
expression	O
by	O
dopamine	O
in	O
Jurkat	B-cell_line
T	I-cell_line
cells	I-cell_line
and	O
in	O
primary	B-cell_type
blood	I-cell_type
mononuclear	I-cell_type
cells	I-cell_type
(	O
PBMC	B-cell_type
)	O
.	O

HIV-1	O
replication	O
was	O
increased	O
by	O
dopamine	O
,	O
which	O
correlated	O
with	O
the	O
increased	O
levels	O
of	O
HIV-1	O
transactivation	O
.	O

Our	O
transient	O
expression	O
data	O
revealed	O
that	O
dopamine	O
stimulated	O
transcription	O
through	O
the	O
NF-kappaB	B-DNA
element	I-DNA
present	O
in	O
the	O
long	B-DNA
terminal	I-DNA
repeat	I-DNA
.	O

The	O
importance	O
of	O
NF-kappaB	B-DNA
sites	I-DNA
was	O
confirmed	O
by	O
using	O
vectors	O
containing	O
wild-type	B-DNA
or	I-DNA
mutant	I-DNA
kappaB	I-DNA
sites	I-DNA
in	O
a	O
heterologous	B-DNA
promoter	I-DNA
.	O

Consistent	O
with	O
the	O
role	O
of	O
NF-kappaB	B-protein
in	O
mediating	O
dopamine	O
responsiveness	O
,	O
the	O
proteasome	O
inhibitor	O
MG132	O
abolished	O
dopamine-induced	O
transcriptional	O
activation	O
.	O

We	O
further	O
explored	O
the	O
effect	O
of	O
dopamine	O
in	O
the	O
presence	O
of	O
phorbol	O
esters	O
or	O
tumor	B-protein
necrosis	I-protein
factor-alpha	I-protein
(	O
TNF-alpha	B-protein
)	O
known	O
to	O
activate	O
NF-kappaB	B-protein
.	O

The	O
combination	O
of	O
dopamine	O
and	O
TNF-alpha	B-protein
led	O
to	O
a	O
stimulation	O
of	O
HIV-1	O
transcription	O
and	O
replication	O
.	O

However	O
,	O
in	O
contrast	O
with	O
TNF-alpha	B-protein
,	O
dopamine	O
treatment	O
did	O
not	O
affect	O
NF-kappaB	B-protein
DNA	O
binding	O
activity	O
nor	O
the	O
concentrations	O
of	O
p50	B-protein
,	O
p65	B-protein
and	O
IkappaB-alpha	B-protein
proteins	I-protein
,	O
which	O
suggests	O
a	O
distinct	O
NF-kappaB	B-protein
activation	O
mechanism	O
.	O

These	O
results	O
reveal	O
a	O
new	O
link	O
between	O
the	O
dopamine	O
system	O
,	O
cytokine	B-protein
signaling	O
pathway	O
and	O
regulation	O
of	O
gene	O
expression	O
via	O
the	O
involvement	O
of	O
NF-kappaB	B-protein
in	O
T	B-cell_type
cells	I-cell_type
and	O
PBMC	B-cell_type
.	O

[	O
Hormonal	O
metabolic	O
status	O
in	O
breast	O
cancer	O
patients	O
after	O
conservative	O
surgery	O
:	O
comparison	O
with	O
known	O
prognostic	O
criteria	O
]	O

Body	O
weight	O
,	O
body	O
mass	O
index	O
,	O
body	O
fat	O
,	O
lean	O
body	O
mass	O
,	O
blood-glucose	O
,	O
cholesterol	O
,	O
HDL-cholesterol	B-protein
,	O
triglyceride	O
,	O
beta-lipoproteins	B-protein
,	O
insulin	O
,	O
gonadotropin	O
,	O
estradiol	O
,	O
testosterone	O
,	O
SHBG	B-protein
,	O
T3	B-protein
,	O
T4	B-protein
and	O
TSH	O
levels	O
as	O
well	O
as	O
estradiol	O
and	O
progesterone	O
receptor	O
levels	O
in	O
excised	O
tumor	O
were	O
studied	O
in	O
40	O
patients	O
with	O
breast	O
cancer	O
prior	O
to	O
conservative	O
treatment	O
.	O

Said	O
anthropometric	O
,	O
metabolic	O
and	O
hormonal	O
parameters	O
were	O
compared	O
with	O
the	O
index	O
of	O
lymphocytic	O
infiltration	O
of	O
tumor	O
selected	O
as	O
a	O
prognostic	O
factor	O
.	O

A	O
significant	O
correlation	O
between	O
high	O
lymphocytic	O
infiltration	O
(	O
2.5	O
points	O
)	O
,	O
low	O
body	O
mass	O
and	O
fat	O
was	O
identified	O
.	O

Also	O
,	O
smoking	O
contributed	O
to	O
loss	O
of	O
body	O
mass	O
and	O
fat	O
;	O
however	O
,	O
it	O
caused	O
lymphocytic	O
infiltration	O
to	O
rise	O
.	O

Moderate	O
body	O
mass	O
,	O
relatively	O
low	O
fat	O
level	O
and	O
positive	O
receptor	O
status	O
are	O
among	O
factors	O
of	O
good	O
prognosis	O
in	O
breast	O
cancer	O
of	O
early	O
stages	O
.	O

Selective	O
DNA-binding	O
activity	O
of	O
interleukin-10-stimulated	B-protein
STAT	I-protein
molecules	I-protein
in	O
human	B-cell_type
monocytes	I-cell_type
.	O

It	O
has	O
been	O
demonstrated	O
that	O
interferon-gamma	B-protein
(	O
IFN-gamma	B-protein
)	O
and	O
interleukin-10	B-protein
(	O
IL-10	B-protein
)	O
have	O
various	O
reverse	O
effects	O
on	O
macrophages	B-cell_type
;	O
however	O
,	O
the	O
molecular	O
mechanism	O
of	O
this	O
difference	O
has	O
not	O
been	O
fully	O
understood	O
.	O

In	O
this	O
study	O
,	O
we	O
analyzed	O
the	O
binding	O
activity	O
of	O
IL-10-	B-protein
and	I-protein
IFN-gamma-activated	I-protein
STAT	I-protein
molecules	I-protein
to	O
two	O
kinds	O
of	O
GAS	B-DNA
-motif	O
sequences	O
.	O

IL-10-activated	B-protein
STAT1	I-protein
could	O
bind	O
to	O
the	O
GAS-motif	B-DNA
sequence	I-DNA
in	O
the	O
promoter	O
region	O
of	O
the	O
Fcgamma	B-protein
receptor	I-protein
,	O
but	O
not	O
to	O
that	O
in	O
the	O
promoter	B-DNA
region	I-DNA
of	O
the	O
COX-2	B-DNA
gene	I-DNA
,	O
whereas	O
IFN-gamma-activated	B-protein
STAT1	I-protein
and	O
STAT5	B-protein
could	O
bind	O
to	O
both	O
sequences	O
.	O

IL-10	B-protein
inhibited	O
IFN-gamma	B-protein
-induced	O
STAT	B-protein
activation	O
without	O
newly	B-protein
synthesized	I-protein
protein	I-protein
.	O

We	O
further	O
demonstrated	O
that	O
aspirin	O
,	O
but	O
not	O
dexamethasone	O
,	O
suppressed	O
IFN-gamma	B-protein
-induced	O
STAT	B-protein
activation	O
.	O

Taken	O
together	O
,	O
these	O
results	O
suggest	O
that	O
IL-10-activated	B-protein
STAT1	I-protein
has	O
a	O
specificity	O
in	O
binding	O
to	O
the	O
GAS-motif	B-DNA
sequences	I-DNA
,	O
whereas	O
IFN-gamma-activated	B-protein
STAT1	I-protein
and	O
STAT5	B-protein
have	O
a	O
broader	O
spectrum	O
in	O
binding	O
to	O
the	O
GAS-motif	B-DNA
sequences	I-DNA
.	O

This	O
may	O
explain	O
the	O
difference	O
between	O
IL-10	B-protein
and	O
IFN-gamma	B-protein
in	O
biological	O
activity	O
,	O
and	O
the	O
inhibitory	O
effect	O
of	O
IL-10	B-protein
on	O
IFN-gamma	B-protein
activities	O
.	O

Peptide	O
binding	O
affinity	O
and	O
pH	O
variation	O
establish	O
functional	O
thresholds	O
for	O
activation	O
of	O
HLA-DQ	B-DNA
-restricted	O
T	O
cell	O
recognition	O
.	O

Peptides	O
derived	O
from	O
the	O
HSV-2	B-protein
VP16	I-protein
protein	I-protein
were	O
utilized	O
for	O
studies	O
of	O
peptide	O
binding	O
to	O
DQ0302	O
molecules	O
and	O
T	O
cell	O
activation	O
at	O
both	O
neutral	O
and	O
acidic	O
pH	O
.	O

The	O
native	O
peptide	O
VP16	O
430-444	O
contains	O
an	O
Asp	O
at	O
position	B-protein
442	I-protein
,	O
binds	O
to	O
DQ0302	O
strongly	O
,	O
with	O
a	O
Kd	O
value	O
of	O
50nM	O
at	O
acidic	O
pH	O
and	O
very	O
weakly	O
,	O
with	O
a	O
Kd	O
value	O
of	O
greater	O
than	O
10	O
microM	O
at	O
neutral	O
pH	O
.	O

A	O
truncated	O
version	O
of	O
430-444	O
,	O
i.e.	O
,	O
VP16	O
433-442	O
,	O
binds	O
with	O
an	O
affinity	O
10-fold	O
lower	O
compared	O
to	O
430-444	O
at	O
acidic	O
pH	O
,	O
and	O
binding	O
at	O
neutral	O
pH	O
was	O
barely	O
detectable	O
.	O

The	O
homologous	O
peptide	O
430-444	O
,	O
442A	O
has	O
an	O
Asp	O
to	O
Ala	O
substitution	O
at	O
position	O
442	O
and	O
binds	O
to	O
DQ0302	O
with	O
a	O
Kd	O
similar	O
to	O
433-442	O
.	O

The	O
short	O
truncated	O
analog	O
433-442A	O
binds	O
very	O
poorly	O
at	O
both	O
acidic	O
and	O
neutral	O
pH	O
.	O

Both	O
the	O
wild	O
type	O
430-444	O
and	O
433-442	O
peptides	O
stimulated	O
a	O
HSV-specific	O
T	O
cell	O
clone	O
after	O
a	O
brief	O
incubation	O
with	O
antigen	B-cell_type
presenting	I-cell_type
cells	I-cell_type
(	O
APC	B-cell_type
)	O
expressing	O
DQ0302	O
at	O
acidic	O
pH	O
.	O

Much	O
higher	O
concentrations	O
of	O
wild	O
type	O
peptides	O
were	O
needed	O
to	O
activate	O
T	B-cell_type
cells	I-cell_type
at	O
neutral	O
pH	O
.	O

In	O
contrast	O
,	O
APC	B-cell_type
pulsed	O
with	O
Ala-substituted	O
peptides	O
430-444	O
,	O
442A	O
or	O
433-442A	O
at	O
neutral	O
pH	O
failed	O
to	O
stimulate	O
the	O
T	B-cell_line
cell	I-cell_line
clone	I-cell_line
,	O
while	O
APC	B-cell_type
pulsed	O
at	O
acidic	O
pH	O
and	O
subsequently	O
washed	O
led	O
to	O
successful	O
T	O
cell	O
activation	O
.	O

The	O
Ala-substituted	O
peptide	O
was	O
recognized	O
by	O
the	O
T	B-cell_line
cell	I-cell_line
clone	I-cell_line
at	O
neutral	O
pH	O
only	O
when	O
it	O
was	O
present	O
in	O
the	O
APC	B-cell_line
culture	I-cell_line
throughout	O
the	O
stimulation	O
process	O
.	O

While	O
the	O
MHC-peptide	B-protein
complexes	I-protein
formed	O
with	O
the	O
native	O
peptide	O
are	O
stable	O
,	O
complexes	O
formed	O
with	O
the	O
Ala-substituted	O
peptide	O
had	O
a	O
functional	O
t1/2	O
of	O
less	O
than	O
4	O
hr	O
at	O
neutral	O
pH	O
.	O

ETS	B-protein
transcription	I-protein
factors	I-protein
regulate	O
an	O
enhancer	O
activity	O
in	O
the	O
third	B-DNA
intron	I-DNA
of	O
TNF-alpha	B-protein
.	O

We	O
describe	O
an	O
enhancer	O
site	O
in	O
the	O
third	B-DNA
intron	I-DNA
of	O
tumor	B-protein
necrosis	I-protein
factor	I-protein
alpha	I-protein
(	O
TNF-alpha	B-protein
)	O
.	O

A	O
reporter	B-DNA
construct	I-DNA
containing	O
the	O
5'-flanking	B-DNA
region	I-DNA
of	O
the	O
mouse	O
TNF-alpha	B-DNA
gene	I-DNA
displayed	O
weak	O
activity	O
when	O
transfected	O
into	O
RAW264.7	B-cell_line
macrophage-like	I-cell_line
cells	I-cell_line
.	O

The	O
addition	O
of	O
the	O
third	B-DNA
intron	I-DNA
of	O
TNF-alpha	B-protein
to	O
this	O
construct	O
resulted	O
in	O
an	O
enhancement	O
of	O
CAT	B-protein
protein	I-protein
.	O

This	O
enhancement	O
was	O
eliminated	O
if	O
a	O
conserved	B-DNA
20-bp	I-DNA
sequence	I-DNA
was	O
removed	O
from	O
the	O
intron	B-DNA
or	O
if	O
a	O
dominant-negative	B-protein
ets-binding	I-protein
factor	I-protein
was	O
co-transfected	O
with	O
the	O
reporter	B-DNA
gene	I-DNA
.	O

Mutations	O
of	O
this	O
site	O
that	O
destroyed	O
potential	O
ets	B-DNA
transcription	I-DNA
factor	I-DNA
binding	I-DNA
sites	I-DNA
had	O
reduced	O
transcriptional	O
activity	O
.	O

The	O
major	O
transcription	O
factor	O
that	O
bound	O
to	O
the	O
oligonucleotide	O
was	O
confirmed	O
to	O
be	O
GABP	B-protein
by	O
supershift	O
and	O
competition	O
analysis	O
.	O

In	O
RAW264.7	B-cell_line
cells	I-cell_line
,	O
the	O
binding	O
was	O
constitutive	O
,	O
however	O
,	O
in	O
bone	B-cell_line
marrow-derived	I-cell_line
macrophages	I-cell_line
binding	O
activity	O
was	O
shown	O
to	O
be	O
interferon-gamma	B-protein
inducible	O
.	O

This	O
may	O
imply	O
a	O
role	O
for	O
ets	B-protein
transcription	I-protein
factors	I-protein
in	O
the	O
production	O
of	O
TNF-alpha	B-protein
.	O

E2F-1	B-protein
blocks	O
terminal	O
differentiation	O
and	O
causes	O
proliferation	O
in	O
transgenic	B-cell_type
megakaryocytes	I-cell_type
.	O

The	O
transcription	B-protein
factor	I-protein
E2F-1	B-protein
plays	O
a	O
central	O
role	O
in	O
the	O
cell	O
cycle	O
through	O
its	O
ability	O
to	O
activate	B-DNA
genes	I-DNA
involved	O
in	O
cell	O
division	O
.	O

E2F-1	B-protein
activity	O
is	O
regulated	O
by	O
a	O
number	O
of	O
proteins	O
,	O
including	O
the	O
retinoblastoma	O
susceptibility	B-DNA
gene	I-DNA
product	O
,	O
cyclin-dependent	B-protein
kinases	I-protein
,	O
and	O
their	O
inhibitors	O
,	O
proteins	O
that	O
have	O
been	O
implicated	O
in	O
the	O
control	O
of	O
certain	O
developmental	O
processes	O
.	O

To	O
investigate	O
a	O
potential	O
role	O
of	O
E2F-1	B-protein
in	O
differentiation	O
,	O
we	O
assayed	O
the	O
ability	O
of	O
megakaryocytes	B-cell_type
to	O
form	O
platelets	B-cell_type
in	O
an	O
in	O
vivo	O
transgenic	O
model	O
.	O

E2F-1	B-protein
expression	O
in	O
megakaryocytes	B-cell_type
blocked	O
differentiation	O
during	O
maturation	O
,	O
resulting	O
in	O
severe	O
thrombocytopenia	O
.	O

Ultrastructural	O
analysis	O
of	O
megakaryocytes	B-cell_type
revealed	O
abnormal	O
development	O
characterized	O
by	O
hyperdemarcation	O
of	O
cytoplasmic	O
membranes	O
and	O
reduced	O
numbers	O
of	O
alpha	O
granules	O
.	O

Administration	O
of	O
megakaryocyte	B-protein
growth	I-protein
and	I-protein
development	I-protein
factor	I-protein
or	O
interleukin	B-protein
6	I-protein
could	O
not	O
overcome	O
the	O
differentiation	O
block	O
.	O

Additionally	O
,	O
E2F-1	B-protein
caused	O
massive	O
megakaryocyte	B-cell_type
accumulation	O
in	O
both	O
normal	O
and	O
ectopic	O
sites	O
,	O
first	O
evident	O
in	O
E15	O
embryonic	O
liver	O
.	O

Furthermore	O
,	O
significant	O
apoptosis	O
was	O
observed	O
in	O
transgenic	B-cell_type
megakaryocytes	I-cell_type
.	O

These	O
data	O
indicate	O
that	O
E2F-1	B-protein
can	O
prevent	O
terminal	O
differentiation	O
,	O
probably	O
through	O
its	O
cell	O
cycle-stimulatory	O
activity	O
.	O

Polymorphic	O
nucleotides	O
within	O
the	O
human	B-DNA
IL-4	I-DNA
promoter	I-DNA
that	O
mediate	O
overexpression	O
of	O
the	O
gene	O
.	O

Atopy	O
,	O
which	O
predisposes	O
individuals	O
to	O
develop	O
asthma	O
,	O
severe	O
systemic	O
anaphylaxis	O
,	O
and	O
atopic	O
dermatitis	O
,	O
is	O
usually	O
associated	O
with	O
dramatically	O
elevated	O
total	O
serum	O
IgE	B-protein
levels	O
and	O
is	O
thought	O
to	O
be	O
controlled	O
by	O
a	O
major	O
susceptibility	B-DNA
gene	I-DNA
and	O
multiple	O
minor	O
susceptibility	B-DNA
genes	I-DNA
.	O

A	O
recent	O
sib-pair	O
analysis	O
revealed	O
a	O
tight	O
linkage	O
between	O
markers	O
on	O
5q31.1	B-DNA
and	O
a	O
major	B-DNA
susceptibility	I-DNA
gene	I-DNA
controlling	O
total	O
serum	O
IgE	B-protein
levels	O
.	O

Due	O
to	O
its	O
location	O
within	O
this	O
cluster	O
and	O
its	O
biologic	O
role	O
in	O
Ig	O
class	O
switching	O
and	O
Th2	B-cell_line
cell	I-cell_line
differentiation	O
,	O
the	O
IL-4	B-DNA
gene	I-DNA
has	O
emerged	O
as	O
one	O
major	O
candidate	O
for	O
the	O
atopy	B-DNA
gene	I-DNA
.	O

In	O
one	O
model	O
,	O
polymorphisms	O
within	O
IL-4	B-DNA
regulatory	I-DNA
elements	I-DNA
might	O
result	O
in	O
overexpression	O
of	O
the	O
gene	O
,	O
amplifying	O
Th2	B-cell_line
cell	I-cell_line
differentiation	O
and	O
class	O
switching	O
to	O
IgE	B-protein
.	O

In	O
support	O
of	O
this	O
model	O
,	O
we	O
report	O
that	O
the	O
human	B-DNA
IL-4	I-DNA
promoter	I-DNA
exists	O
in	O
multiple	O
allelic	O
forms	O
that	O
exhibit	O
distinct	O
transcriptional	O
activities	O
in	O
IL-4-positive	B-cell_type
T	I-cell_type
cells	I-cell_type
.	O

A	O
particular	O
allele	O
has	O
an	O
unusually	O
high	O
transcriptional	O
activity	O
.	O

A	O
nucleotide	O
substitution	O
within	O
a	O
recently	O
described	O
OAP40	B-DNA
element	I-DNA
located	O
just	O
upstream	O
of	O
an	O
NF-AT	B-DNA
site	I-DNA
(	O
P	B-DNA
sequence	I-DNA
)	O
appears	O
to	O
be	O
largely	O
responsible	O
for	O
the	O
increased	O
promotor	O
strength	O
of	O
this	O
particular	O
allelic	O
form	O
of	O
the	O
IL-4	B-DNA
promoter	I-DNA
.	O

In	O
EMSAs	O
,	O
this	O
substitution	O
results	O
in	O
a	O
markedly	O
enhanced	O
affinity	O
for	O
sequence-specific	O
complexes	O
exhibiting	O
an	O
AP-1	B-protein
specificity	O
.	O

The	O
identification	O
of	O
allelic	O
nucleotides	O
,	O
which	O
results	O
in	O
overexpression	O
of	O
the	O
IL-4	B-DNA
gene	I-DNA
,	O
provides	O
specific	O
targets	O
for	O
a	O
comprehensive	O
screening	O
of	O
atopic	O
and	O
nonatopic	O
individuals	O
and	O
may	O
provide	O
a	O
clue	O
for	O
genetic	O
predisposition	O
for	O
atopy	O
.	O

Evidence	O
for	O
lowered	O
induction	O
of	O
nuclear	B-protein
factor	I-protein
kappa	I-protein
B	I-protein
in	O
activated	B-cell_type
human	I-cell_type
T	I-cell_type
lymphocytes	I-cell_type
during	O
aging	O
.	O

Transcription	O
factor	O
NF	B-protein
kappa	I-protein
B	I-protein
(	O
nuclear	B-protein
factor	I-protein
kappa	I-protein
B	I-protein
)	O
is	O
induced	O
in	O
T	B-cell_type
lymphocytes	I-cell_type
from	O
young	O
individuals	O
following	O
activation	O
with	O
a	O
variety	O
of	O
stimuli	O
including	O
anti-CD3	B-protein
,	O
phorbol	O
myristate	O
acetate	O
(	O
PMA	O
)	O
,	O
and	O
tumor	B-protein
necrosis	I-protein
factor-alpha	I-protein
(	O
TNF-alpha	B-protein
)	O
.	O

In	O
contrast	O
,	O
activated	O
T	B-cell_type
lymphocytes	I-cell_type
from	O
older	O
individuals	O
show	O
a	O
significant	O
reduction	O
in	O
the	O
induction	O
of	O
NF	B-protein
kappa	I-protein
B	I-protein
in	O
response	O
to	O
the	O
same	O
stimuli	O
.	O

The	O
age-related	O
decline	O
in	O
induction	O
of	O
NF	B-protein
kappa	I-protein
B	I-protein
could	O
not	O
be	O
attributed	O
to	O
alteration	O
in	O
the	O
composition	O
of	O
subunits	O
,	O
p50	B-protein
and	O
p65	B-protein
were	O
found	O
to	O
be	O
the	O
predominant	O
subunits	O
of	O
induced	O
NF	B-protein
kappa	I-protein
B	I-protein
in	O
T	B-cell_type
cells	I-cell_type
from	O
young	O
as	O
well	O
as	O
elderly	O
donors	O
.	O

Furthermore	O
,	O
similar	O
levels	O
of	O
NF	B-protein
kappa	I-protein
B	I-protein
were	O
found	O
in	O
the	O
cytosols	O
of	O
unactivated	O
T	B-cell_type
cells	I-cell_type
from	O
both	O
young	O
and	O
elderly	O
donors	O
suggesting	O
that	O
precursor	O
levels	O
of	O
NF	B-protein
kappa	I-protein
B	I-protein
remain	O
unaltered	O
during	O
aging	O
.	O

These	O
results	O
suggest	O
that	O
an	O
age-associated	O
decline	O
in	O
the	O
induction	O
of	O
NF	B-protein
kappa	I-protein
B	I-protein
in	O
activated	O
T	B-cell_type
cells	I-cell_type
from	O
elderly	O
individuals	O
may	O
be	O
attributable	O
to	O
altered	O
regulation	O
of	O
the	O
inhibitor	O
,	O
I	B-protein
kappa	I-protein
B	I-protein
,	O
and	O
may	O
play	O
an	O
important	O
role	O
in	O
immune	O
dysregulation	O
accompanying	O
aging	O
.	O

Inhibition	O
of	O
lipopolysaccharide-induced	O
monocyte	B-protein
interleukin-1	I-protein
receptor	I-protein
antagonist	O
synthesis	O
by	O
cortisol	O
:	O
involvement	O
of	O
the	O
mineralocorticoid	B-protein
receptor	I-protein
.	O

Glucocorticoids	O
,	O
as	O
a	O
part	O
of	O
their	O
physiological	O
role	O
in	O
the	O
control	O
of	O
inflammatory	O
and	O
immune	O
processes	O
,	O
suppress	O
the	O
expression	O
of	O
interleukin-1	B-protein
(	O
IL-1	B-protein
)	O
and	O
other	O
cytokines	B-protein
.	O

Human	B-RNA
monocyte	I-RNA
IL-1	I-RNA
receptor	I-RNA
antagonist	I-RNA
(	I-RNA
IL-1ra	I-RNA
)	I-RNA
messenger	I-RNA
ribonucleic	I-RNA
acid	I-RNA
(	O
mRNA	O
)	O
expression	O
and	O
protein	O
secretion	O
are	O
inhibited	O
by	O
dexamethasone	O
.	O

We	O
have	O
now	O
further	O
studied	O
the	O
regulation	O
of	O
IL-1ra	B-protein
by	O
the	O
major	O
physiological	O
human	O
glucocorticoid	O
,	O
cortisol	O
.	O

We	O
found	O
that	O
cortisol	O
incubation	O
induced	O
a	O
decrease	O
in	O
IL-1ra	B-RNA
mRNA	I-RNA
expression	O
and	O
a	O
significant	O
inhibition	O
of	O
IL-1ra	B-protein
protein	I-protein
secretion	O
in	O
cell	O
cultures	O
of	O
human	B-cell_type
peripheral	I-cell_type
monocytes	I-cell_type
stimulated	O
with	O
the	O
bacterial	O
endotoxin	O
lipopolysaccharide	O
(	O
LPS	O
)	O
.	O

Oral	O
administration	O
of	O
276	O
mumol	O
cortisol	O
to	O
normal	O
subjects	O
also	O
decreased	O
LPS-induced	O
IL-1ra	B-protein
synthesis	O
in	O
cultured	B-cell_line
monocytes	I-cell_line
.	O

By	O
coincubating	O
the	O
monocytes	B-cell_type
with	O
either	O
the	O
mineralocorticoid	O
antagonist	O
spironolactone	O
or	O
the	O
glucocorticoid	B-protein
receptor	I-protein
antagonist	O
RU	O
38486	O
,	O
the	O
in	O
vitro	O
cortisol-induced	O
inhibition	O
of	O
LPS-stimulated	O
IL-1ra	B-protein
secretion	O
was	O
partially	O
reversed	O
.	O

The	O
mineralocorticoid	O
aldosterone	O
exerted	O
a	O
significant	O
decrease	O
in	O
LPS-induced	O
monocyte	O
IL-1ra	B-protein
secretion	O
in	O
vitro	O
,	O
which	O
was	O
blocked	O
by	O
coincubation	O
with	O
spironolactone	O
.	O

In	O
addition	O
,	O
the	O
expression	O
of	O
mineralocorticoid	B-RNA
receptor	I-RNA
mRNA	I-RNA
in	O
human	O
monocytes	B-cell_type
was	O
observed	O
by	O
PCR	O
of	O
reversed	B-RNA
transcribed	I-RNA
RNA	I-RNA
.	O

Our	O
results	O
further	O
indicate	O
that	O
corticosteroids	O
physiologically	O
control	O
the	O
IL-1/	O
IL-1ra	B-protein
system	O
during	O
inflammatory	O
or	O
immune	O
processes	O
.	O

Moreover	O
,	O
we	O
provide	O
evidence	O
that	O
,	O
in	O
addition	O
to	O
a	O
glucocorticoid	B-protein
receptor	I-protein
-mediated	O
effect	O
,	O
the	O
mineralocorticoid	B-protein
receptor	I-protein
is	O
involved	O
in	O
the	O
inhibition	O
of	O
monocyte	O
IL-1ra	B-protein
secretion	O
by	O
cortisol	O
.	O

Target	O
structures	O
of	O
the	O
CD8	O
(	O
+	O
)	O
-T-cell	O
response	O
to	O
human	O
cytomegalovirus	O
:	O
the	O
72-kilodalton	B-protein
major	I-protein
immediate-early	I-protein
protein	I-protein
revisited	O
.	O

Cell-mediated	O
immunity	O
plays	O
an	O
essential	O
role	O
in	O
the	O
control	O
of	O
infection	O
with	O
the	O
human	O
cytomegalovirus	O
(	O
HCMV	O
)	O
.	O

However	O
,	O
only	O
a	O
few	O
CD8	B-protein
(	I-protein
+	I-protein
)	I-protein
-T-cell	I-protein
epitopes	I-protein
are	O
known	O
,	O
with	O
the	O
majority	O
being	O
contained	O
in	O
the	O
pp65	B-protein
phosphoprotein	I-protein
,	O
which	O
is	O
believed	O
to	O
dominate	O
the	O
CD8	O
(	O
+	O
)	O
-T-cell	O
response	O
to	O
HCMV	O
.	O

Here	O
,	O
we	O
have	O
readdressed	O
the	O
issue	O
of	O
CD8	B-cell_type
(	I-cell_type
+	I-cell_type
)	I-cell_type
T	I-cell_type
cells	I-cell_type
specific	O
for	O
the	O
72-kDa	B-protein
major	I-protein
immediate-early	I-protein
protein	I-protein
(	O
IE-1	B-protein
)	O
,	O
which	O
is	O
nonstructural	O
but	O
is	O
found	O
very	O
early	O
and	O
throughout	O
the	O
replicative	O
cycle	O
.	O

Using	O
a	O
novel	O
flow-cytometric	O
assay	O
,	O
we	O
were	O
able	O
to	O
identify	O
CD8	B-protein
(	I-protein
+	I-protein
)	I-protein
-T-cell	I-protein
epitopes	I-protein
(	O
by	O
IE-1	B-protein
peptide-specific	O
induction	O
of	O
cytokine	B-protein
synthesis	O
)	O
and	O
simultaneously	O
measure	O
the	O
frequency	O
of	O
cells	O
directed	O
against	O
them	O
.	O

For	O
this	O
purpose	O
,	O
81	O
pentadecamer	O
peptides	O
covering	O
the	O
complete	O
491-amino-acid	B-protein
sequence	I-protein
of	O
IE-1	B-protein
were	O
tested	O
on	O
peripheral	B-cell_type
blood	I-cell_type
mononuclear	I-cell_type
cells	I-cell_type
of	O
anti-HCMV	O
immunoglobulin	O
G-seropositive	O
donors	O
.	O

At	O
least	O
10	O
new	O
epitopes	B-protein
were	O
identified	O
,	O
and	O
the	O
fine	O
specificity	O
and	O
presenting	O
HLA	B-protein
molecule	I-protein
of	O
the	O
first	O
of	O
them	O
was	O
determined	O
.	O

The	O
frequencies	O
of	O
CD8	B-cell_type
(	I-cell_type
+	I-cell_type
)	I-cell_type
T	I-cell_type
cells	I-cell_type
directed	O
against	O
IE-1	B-protein
were	O
similar	O
to	O
those	O
directed	O
against	O
pp65	B-protein
in	O
donors	O
tested	O
with	O
known	O
pp65	B-protein
-derived	O
peptides	O
.	O

Importantly	O
,	O
additional	O
testing	O
of	O
a	O
corresponding	O
set	O
of	O
peptides	O
covering	O
the	O
complete	O
sequence	O
of	O
pp65	B-protein
on	O
10	O
of	O
these	O
donors	O
identified	O
individuals	O
whose	O
CD8	B-cell_type
(	I-cell_type
+	I-cell_type
)	I-cell_type
T	I-cell_type
cells	I-cell_type
recognized	O
IE-1	B-protein
but	O
not	O
pp65	B-protein
and	O
vice	O
versa	O
,	O
clearly	O
illustrating	O
that	O
either	O
protein	O
may	O
be	O
a	O
major	O
target	O
.	O

In	O
summary	O
,	O
our	O
results	O
suggest	O
that	O
IE-1	B-protein
is	O
far	O
more	O
important	O
as	O
a	O
CD8	O
(	O
+	O
)	O
-T-cell	O
target	O
than	O
current	O
opinion	O
suggests	O
.	O

E1A	B-DNA
oncogene	I-DNA
induction	O
of	O
cellular	O
susceptibility	O
to	O
killing	O
by	O
cytolytic	B-cell_type
lymphocytes	I-cell_type
through	O
target	O
cell	O
sensitization	O
to	O
apoptotic	O
injury	O
.	O

E1A	B-DNA
oncogene	I-DNA
expression	O
increases	O
mammalian	O
cell	O
susceptibility	O
to	O
lysis	O
by	O
cytolytic	B-cell_type
lymphocytes	I-cell_type
(	O
CLs	B-cell_type
)	O
at	O
a	O
stage	O
in	O
this	O
intercellular	O
interaction	O
that	O
is	O
independent	O
of	O
cell	O
surface	O
recognition	O
events	O
.	O

Since	O
CLs	B-cell_type
can	O
induce	O
either	O
apoptotic	O
or	O
necrotic	O
cell	O
death	O
,	O
we	O
asked	O
whether	O
E1A	B-protein
sensitization	O
to	O
injury-induced	O
apoptosis	O
is	O
sufficient	O
to	O
explain	O
E1A	B-protein
-induced	O
cytolytic	O
susceptibility	O
.	O

Mouse	B-cell_type
,	I-cell_type
rat	I-cell_type
,	I-cell_type
hamster	I-cell_type
,	I-cell_type
and	I-cell_type
human	I-cell_type
cells	I-cell_type
that	O
were	O
rendered	O
cytolytic	O
susceptible	O
by	O
E1A	B-protein
were	O
also	O
sensitized	O
to	O
CL-induced	O
and	O
chemically	O
induced	O
apoptosis	O
.	O

In	O
contrast	O
,	O
E1A-positive	B-cell_type
cells	I-cell_type
were	O
no	O
more	O
susceptible	O
to	O
injury-induced	O
necrosis	O
than	O
E1A-negative	B-cell_type
cells	I-cell_type
.	O

Similar	O
to	O
induction	O
of	O
cytolytic	O
susceptibility	O
and	O
in	O
contrast	O
to	O
other	O
E1A	B-protein
activities	O
,	O
cellular	O
sensitization	O
to	O
chemically	O
induced	O
apoptosis	O
depended	O
on	O
high-level	O
E1A	B-protein
oncoprotein	B-protein
expression	O
.	O

Loss	O
of	O
both	O
cytolytic	O
susceptibility	O
and	O
sensitization	O
to	O
chemically	O
induced	O
apoptosis	O
was	O
coselected	O
during	O
in	O
vivo	O
selection	O
of	O
E1A-positive	B-cell_type
sarcoma	I-cell_type
cells	I-cell_type
for	O
increased	O
tumorigenicity	O
.	O

Furthermore	O
,	O
E1A	B-protein
mutant	B-protein
proteins	I-protein
that	O
can	O
not	O
bind	O
the	O
cellular	B-protein
transcriptional	I-protein
coactivator	I-protein
,	O
p300	B-protein
,	O
and	O
that	O
fail	O
to	O
induce	O
cytolytic	O
susceptibility	O
also	O
failed	O
to	O
sensitize	O
cells	O
to	O
injury-induced	O
apoptosis	O
.	O

These	O
data	O
indicate	O
that	O
E1A	B-protein
induces	O
susceptibility	O
to	O
killer	O
cell-induced	O
lysis	O
through	O
sensitization	O
of	O
cells	O
to	O
injury-induced	O
apoptosis	O
.	O

Copyright	O
1999	O
Academic	O
Press	O
.	O

TCL1	B-DNA
oncogene	I-DNA
expression	O
in	O
AIDS-related	O
lymphomas	O
and	O
lymphoid	O
tissues	O
.	O

AIDS-related	O
non-Hodgkin	O
's	O
lymphoma	O
(	O
AIDS	O
NHL	O
)	O
comprises	O
a	O
diverse	O
and	O
heterogeneous	O
group	O
of	O
high-grade	O
B	O
cell	O
tumors	O
.	O

Certain	O
classes	O
of	O
AIDS	O
NHL	O
are	O
associated	O
with	O
alterations	O
in	O
oncogenes	B-DNA
or	O
tumor-suppressor	B-DNA
genes	I-DNA
or	O
infections	O
by	O
oncogenic	O
herpesviruses	O
.	O

However	O
,	O
the	O
clinically	O
significant	O
class	O
of	O
AIDS	O
NHL	O
designated	O
immunoblastic	O
lymphoma	O
plasmacytoid	O
(	O
AIDS	O
IBLP	O
)	O
lacks	O
any	O
consistent	O
genetic	O
alterations	O
.	O

We	O
identified	O
the	O
TCL1	B-DNA
oncogene	I-DNA
from	O
a	O
set	O
of	O
AIDS	B-DNA
IBLP-associated	I-DNA
cDNA	I-DNA
fragments	I-DNA
generated	O
by	O
subtractive	O
hybridization	O
with	O
non-AIDS	O
IBLP	O
.	O

Aberrant	O
TCL1	B-protein
expression	O
has	O
been	O
implicated	O
in	O
T	O
cell	O
leukemia/lymphoma	O
development	O
,	O
and	O
its	O
expression	O
also	O
has	O
been	O
seen	O
in	O
many	O
established	O
B	B-cell_line
cell	I-cell_line
tumor	I-cell_line
lines	I-cell_line
.	O

However	O
,	O
TCL1	B-protein
expression	O
has	O
not	O
been	O
reported	O
in	O
AIDS	O
NHL	O
.	O

We	O
find	O
that	O
TCL1	B-protein
is	O
expressed	O
in	O
the	O
majority	O
of	O
AIDS	O
IBLP	O
tumors	O
examined	O
.	O

TCL1	B-protein
protein	O
expression	O
is	O
restricted	O
to	O
tumor	O
cells	O
in	O
AIDS	O
IBLP	O
tissue	O
samples	O
analyzed	O
with	O
immunohistochemical	O
staining	O
.	O

Hyperplastic	O
lymph	O
node	O
and	O
tonsil	O
also	O
exhibit	O
strong	O
TCL1	B-protein
protein	O
expression	O
in	O
mantle	B-cell_type
zone	I-cell_type
B	I-cell_type
cells	I-cell_type
and	O
in	O
rare	O
interfollicular	B-cell_type
zone	I-cell_type
cells	I-cell_type
,	O
whereas	O
follicle-center	B-cell_type
B	I-cell_type
cells	I-cell_type
(	O
centroblasts	B-cell_type
and	O
centrocytes	B-cell_type
)	O
show	O
weaker	O
expression	O
.	O

These	O
results	O
establish	O
TCL1	B-protein
as	O
the	O
most	O
prevalent	O
of	O
all	O
of	O
the	O
surveyed	O
oncogenes	B-DNA
associated	O
with	O
AIDS	O
IBLP	O
.	O

They	O
also	O
indicate	O
that	O
abundant	O
TCL1	B-protein
expression	O
in	O
quiescent	B-cell_type
mantle	I-cell_type
zone	I-cell_type
B	I-cell_type
cells	I-cell_type
is	O
down-regulated	O
in	O
activated	O
germinal	B-cell_type
center	I-cell_type
follicular	I-cell_type
B	I-cell_type
cells	I-cell_type
in	O
parallel	O
to	O
the	O
known	O
expression	O
pattern	O
of	O
BCL-2	B-protein
.	O

High-level	O
expression	O
in	O
nonproliferating	B-cell_type
B	I-cell_type
cells	I-cell_type
suggests	O
that	O
TCL1	B-protein
may	O
function	O
in	O
protecting	O
naive	B-cell_type
preactivated	I-cell_type
B	I-cell_type
cells	I-cell_type
from	O
apoptosis	O
.	O

IL-2	B-protein
-independent	O
activation	O
and	O
proliferation	O
in	O
human	B-cell_type
T	I-cell_type
cells	I-cell_type
induced	O
by	O
CD28	B-protein
.	O

Although	O
the	O
role	O
of	O
CD28	B-protein
in	O
T	O
cell	O
costimulation	O
is	O
firmly	O
established	O
,	O
the	O
mechanisms	O
by	O
which	O
it	O
exerts	O
its	O
costimulatory	O
actions	O
are	O
less	O
clear	O
.	O

In	O
many	O
circumstances	O
it	O
is	O
difficult	O
to	O
distinguish	O
the	O
effects	O
of	O
CD28	B-protein
from	O
subsequent	O
actions	O
of	O
cytokines	B-protein
,	O
such	O
as	O
IL-2	B-protein
,	O
on	O
T	O
cell	O
proliferation	O
.	O

Here	O
,	O
we	O
report	O
a	O
model	O
of	O
CD28	B-protein
costimulation	O
using	O
PMA	O
plus	O
the	O
natural	B-protein
ligand	I-protein
CD80	I-protein
that	O
resulted	O
in	O
very	O
limited	O
stimulation	O
of	O
IL-2	B-protein
,	O
as	O
evidenced	O
by	O
both	O
cytokine	B-protein
production	O
and	O
IL-2	B-DNA
promoter	I-DNA
stimulation	O
.	O

Promoter	O
assays	O
revealed	O
CD28	B-protein
-dependent	O
effects	O
on	O
both	O
NF-kappaB	B-protein
and	O
AP-1	B-protein
,	O
but	O
not	O
on	O
NF-AT	B-protein
or	O
the	O
intact	O
IL-2	B-DNA
promoter	I-DNA
.	O

In	O
addition	O
,	O
T	O
cell	O
proliferation	O
was	O
completely	O
resistant	O
to	O
the	O
actions	O
of	O
the	O
immunosuppressant	O
cyclosporin	O
A	O
(	O
CsA	O
)	O
.	O

Moreover	O
T	O
cell	O
proliferation	O
was	O
unaffected	O
by	O
the	O
addition	O
of	O
blocking	O
Abs	B-protein
to	O
both	O
IL-2	B-protein
and	O
the	O
IL-2	B-protein
receptor	I-protein
,	O
demonstrating	O
that	O
this	O
form	O
of	O
costimulation	O
by	O
CD28	B-protein
was	O
independent	O
of	O
IL-2	B-protein
.	O

We	O
also	O
investigated	O
the	O
effects	O
of	O
stimulating	O
T	B-cell_type
cell	I-cell_type
blasts	I-cell_type
with	O
CD80	B-protein
alone	O
and	O
found	O
that	O
there	O
was	O
a	O
limited	O
requirement	O
for	O
IL-2	B-protein
in	O
this	O
system	O
.	O

We	O
conclude	O
that	O
CD28	B-protein
costimulation	O
can	O
cause	O
substantial	O
T	O
cell	O
proliferation	O
in	O
the	O
absence	O
of	O
IL-2	B-protein
,	O
which	O
is	O
driven	O
by	O
a	O
soluble	B-protein
factor	I-protein
independent	O
of	O
NF-AT	B-protein
transactivation	O
.	O

The	O
Epstein-Barr	B-DNA
virus	I-DNA
latency	I-DNA
BamHI-Q	I-DNA
promoter	I-DNA
is	O
positively	O
regulated	O
by	O
STATs	B-protein
and	O
Zta	B-protein
interference	O
with	O
JAK	B-protein
/STAT	B-protein
activation	O
leads	O
to	O
loss	O
of	O
BamHI-Q	B-DNA
promoter	I-DNA
activity	O
.	O

In	O
Epstein-Barr	O
virus	O
(	O
EBV	O
)	O
-associated	O
tumors	O
in	O
nonimmunocompromised	O
patients	O
,	O
EBV	O
gene	O
expression	O
is	O
highly	O
restricted	O
.	O

EBV-encoded	B-protein
nuclear	I-protein
antigen	I-protein
(	I-protein
EBNA	I-protein
)	I-protein
-1	I-protein
is	O
expressed	O
,	O
whereas	O
the	O
immunogenic	O
and	O
proliferative	O
EBNAs	B-protein
are	O
not	O
.	O

This	O
pattern	O
of	O
EBNA	B-protein
expression	O
is	O
generated	O
by	O
usage	O
of	O
the	O
BamHI-Q	B-DNA
promoter	I-DNA
(	O
Qp	B-DNA
)	O
.	O

We	O
have	O
determined	O
that	O
the	O
JAK	B-protein
/STAT	B-protein
pathway	O
positively	O
regulates	O
Qp	B-DNA
activity	O
.	O

In	O
transient-transfection	O
assays	O
,	O
a	O
Qp-CAT	B-DNA
reporter	I-DNA
was	O
activated	O
by	O
cotransfected	O
JAK-1	B-protein
and	O
by	O
treatment	O
of	O
cells	O
with	O
the	O
cytokine	B-protein
IL-6	B-protein
.	O

The	O
ability	O
of	O
Qp	B-DNA
to	O
bind	O
signal	B-protein
transducer	I-protein
and	I-protein
activator	I-protein
of	I-protein
transcription	I-protein
(	I-protein
STAT	I-protein
)	I-protein
proteins	I-protein
was	O
directly	O
demonstrated	O
by	O
electrophoretic	O
mobility-shift	O
assay	O
,	O
and	O
mutation	O
of	O
potential	O
STAT-binding	B-DNA
sites	I-DNA
reduced	O
Qp	B-DNA
responsiveness	O
to	O
Janus	B-protein
kinase	I-protein
(	I-protein
JAK	I-protein
)	I-protein
-1	I-protein
.	O

Consistent	O
with	O
a	O
role	O
for	O
STATs	B-protein
in	O
Qp	B-DNA
function	O
,	O
Qp	B-DNA
using	O
Burkitt	B-cell_line
's	I-cell_line
lymphoma	I-cell_line
Rael	I-cell_line
cells	I-cell_line
and	O
cultured	B-cell_type
nasopharyngeal	I-cell_type
carcinoma	I-cell_type
(	I-cell_type
NPC	I-cell_type
)	I-cell_type
cells	I-cell_type
contained	O
nuclear	O
STAT	B-protein
protein	I-protein
.	O

We	O
investigated	O
whether	O
the	O
inability	O
to	O
maintain	O
EBV-positive	B-cell_line
NPC	I-cell_line
cell	I-cell_line
lines	I-cell_line
in	O
culture	O
was	O
related	O
to	O
Qp	B-DNA
activity	O
.	O

Passaging	O
of	O
the	O
NPC	B-cell_line
cell	I-cell_line
line	I-cell_line
HK666	I-cell_line
led	O
to	O
activation	O
of	O
expression	O
of	O
BZLF1	B-DNA
,	O
which	O
encodes	O
Zta	B-protein
and	O
loss	O
of	O
Qp	B-DNA
function	O
.	O

Transient	O
expression	O
assays	O
linked	O
Zta	B-protein
expression	O
to	O
the	O
down-regulation	O
of	O
Qp	B-DNA
.	O

Cotransfection	O
of	O
Zta	B-protein
reduced	O
Qp	B-DNA
activity	O
in	O
reporter	O
assays	O
.	O

This	O
negative	O
regulation	O
required	O
Zta	B-protein
DNA-binding	O
activity	O
.	O

We	O
provide	O
evidence	O
that	O
Zta	B-protein
up-regulation	O
of	O
p53	B-protein
leads	O
to	O
p53	B-protein
-mediated	O
interference	O
with	O
JAK	B-protein
/STAT	B-protein
activation	O
of	O
Qp	B-DNA
.	O

The	O
data	O
imply	O
that	O
JAK	B-protein
/STAT	B-protein
signaling	O
has	O
a	O
role	O
in	O
EBV-associated	O
malignancies	O
.	O

Reactive	O
oxygen	O
intermediate-release	O
of	O
fibre-exposed	B-cell_line
monocytes	I-cell_line
increases	O
inflammatory	O
cytokine-mRNA	B-RNA
level	O
,	O
protein	B-protein
tyrosine	I-protein
kinase	I-protein
and	O
NF-kappaB	B-protein
activity	O
in	O
co-cultured	B-cell_line
bronchial	I-cell_line
epithelial	I-cell_line
cells	I-cell_line
(	O
BEAS-2B	B-cell_line
)	O
.	O

Some	O
pulmonary	O
diseases	O
like	O
bronchitis	O
or	O
asthma	O
bronchiale	O
are	O
mediated	O
by	O
inflammatory	O
mechanisms	O
in	O
bronchial	B-cell_type
epithelial	I-cell_type
cells	I-cell_type
.	O

Alveolar	B-cell_type
macrophages	I-cell_type
are	O
located	O
directly	O
in	O
the	O
surrounding	O
of	O
these	O
cells	O
,	O
so	O
that	O
we	O
suppose	O
an	O
interaction	O
between	O
epithelial	B-cell_type
cells	I-cell_type
and	O
macrophages	B-cell_type
regarding	O
to	O
the	O
release	O
of	O
inflammatory	B-protein
mediators	I-protein
.	O

For	O
measuring	O
the	O
contribution	O
of	O
macrophages	B-cell_type
to	O
the	O
release	O
of	O
inflammatory	B-protein
mediators	I-protein
by	O
bronchial	B-cell_type
epithelial	I-cell_type
cells	I-cell_type
,	O
we	O
established	O
an	O
in	O
vitro	O
model	O
of	O
co-cultured	B-cell_type
blood	I-cell_type
monocytes	I-cell_type
(	O
BM	B-cell_type
)	O
and	O
BEAS-2B	B-cell_line
cells	I-cell_line
in	O
a	O
transwell	O
system	O
(	O
Costar	O
)	O
.	O

BM	B-cell_type
were	O
exposed	O
to	O
Chrysotile	O
B	O
and	O
soot	O
particle	O
FR	O
101	O
in	O
a	O
concentration	O
of	O
100	O
microg/10	O
(	O
6	O
)	O
cells	O
.	O

After	O
up	O
to	O
90	O
min	O
exposure	O
time	O
ELISA	O
,	O
EMSA	O
(	O
electromobility	O
shift	O
assay	O
)	O
and	O
RT-PCR	O
were	O
used	O
to	O
measure	O
protein	B-protein
tyrosine	I-protein
kinase	I-protein
activity	O
,	O
protein	O
activity	O
of	O
NF-kappaB	B-protein
and	O
cytokine	B-protein
(	O
IL-1beta	B-protein
,	O
IL-6	B-protein
,	O
TNF-alpha	B-protein
)	O
specific	O
mRNA	B-RNA
levels	O
in	O
BEAS-2B	B-cell_type
cells	I-cell_type
.	O

We	O
observed	O
an	O
increase	O
in	O
protein	B-protein
tyrosine	I-protein
kinase	I-protein
activity	O
(	O
up	O
to	O
1.8	O
+/-	O
0.5-fold	O
)	O
and	O
NF-kappaB	B-protein
protein	O
activity	O
in	O
BEAS-2B	B-cell_type
cells	I-cell_type
after	O
particle	O
or	O
fibre	O
exposure	O
of	O
co-cultured	B-cell_line
BM	I-cell_line
.	O

Consecutive	O
IL-1beta-	B-RNA
,	I-RNA
IL-6-	I-RNA
and	I-RNA
TNF-alpha-mRNA	I-RNA
were	O
elevated	O
(	O
up	O
to	O
1.9	O
+/-	O
0.58-fold	O
)	O
.	O

Protein	B-protein
tyrosine	I-protein
kinase	I-protein
activity	O
,	O
NF-kappaB	B-protein
activity	O
,	O
and	O
the	O
synthesis	O
of	O
cytokine-specific	B-RNA
mRNA	I-RNA
were	O
inhibited	O
by	O
antioxidants	O
.	O

These	O
data	O
suggest	O
a	O
ROI-dependent	O
NF-kappaB	B-protein
mediated	O
transcription	O
of	O
inflammatory	B-protein
cytokines	I-protein
in	O
bronchial	B-cell_type
epithelial	I-cell_type
cells	I-cell_type
.	O

Suppression	O
of	O
the	O
human	B-DNA
immunodeficiency	I-DNA
virus	I-DNA
long	I-DNA
terminal	I-DNA
repeat	I-DNA
by	O
CD8+	B-cell_type
T	I-cell_type
cells	I-cell_type
is	O
dependent	O
on	O
the	O
NFAT-1	B-DNA
element	I-DNA
.	O

CD8+	B-cell_type
T	I-cell_type
lymphocytes	I-cell_type
of	O
HIV-1	O
infected	O
individuals	O
produce	O
a	O
soluble	B-protein
factor	I-protein
that	O
efficiently	O
suppresses	O
HIV-1	O
replication	O
at	O
the	O
transcriptional	O
level	O
.	O

We	O
show	O
here	O
that	O
the	O
response	O
of	O
the	O
HIV-1	O
long	O
terminal	O
repeat	O
(	O
LTR	B-DNA
)	O
to	O
mitogenic	O
or	O
Tat	B-protein
-mediated	O
activation	O
is	O
sensitive	O
to	O
the	O
suppressive	O
action	O
of	O
a	O
Herpesvirus	B-cell_line
saimiri	I-cell_line
(	I-cell_line
HVS	I-cell_line
)	I-cell_line
-transformed	I-cell_line
CD8+	I-cell_line
T	I-cell_line
cell	I-cell_line
clone	I-cell_line
from	O
an	O
HIV-infected	O
individual	O
and	O
supernatants	O
from	O
CD8+	B-cell_type
T	I-cell_type
cells	I-cell_type
of	O
HIV-1-infected	O
asymptomatic	O
subjects	O
(	O
CD4+	B-protein
>	O
350/microliters	O
)	O
.	O

Mutagenesis	O
of	O
NF	B-DNA
kappa	I-DNA
B	I-DNA
or	I-DNA
Sp-1	I-DNA
elements	I-DNA
within	O
the	O
LTR	B-DNA
resulted	O
in	O
no	O
change	O
in	O
the	O
ability	O
of	O
CD8+	B-cell_type
T	I-cell_type
cell	I-cell_type
supernatants	O
to	O
inhibit	O
Tat-	O
or	O
mitogen-mediated	O
LTR	O
transcription	O
.	O

However	O
,	O
the	O
response	O
to	O
HIV-1	B-protein
Tat	I-protein
by	O
a	O
LTR	B-DNA
in	O
which	O
the	O
interleukin	B-DNA
(	I-DNA
IL	I-DNA
)	I-DNA
-2	I-DNA
homology	I-DNA
NFAT-1	I-DNA
region	I-DNA
was	O
mutated	O
resulted	O
in	O
almost	O
complete	O
elimination	O
of	O
suppression	O
by	O
CD8+	B-cell_type
T	I-cell_type
cells	I-cell_type
.	O

This	O
was	O
not	O
observed	O
when	O
the	O
NFAT-1	B-DNA
mutant	I-DNA
LTR	I-DNA
was	O
activated	O
by	O
mitogen	B-protein
.	O

We	O
have	O
previously	O
shown	O
that	O
gene	O
expression	O
directed	O
by	O
the	O
HIV-1	O
NF	B-DNA
kappa	I-DNA
B	I-DNA
elements	I-DNA
is	O
inhibited	O
by	O
CD8	B-protein
+	O
cell-derived	O
supernatants	O
(	O
Copeland	O
et	O
al.	O
,	O
AIDS	O
Res	O
Hum	O
Retroviruses	O
,	O
1995	O
;	O
11	O
:	O
1321-1326	O
)	O
.	O

Taken	O
together	O
,	O
these	O
observations	O
suggest	O
that	O
mitogenic	O
activation	O
,	O
mediated	O
primarily	O
through	O
the	O
NF	B-DNA
kappa	I-DNA
B	I-DNA
enhancer	I-DNA
,	O
is	O
susceptible	O
to	O
CD8	B-protein
-mediated	O
inhibition	O
,	O
however	O
,	O
inhibition	O
of	O
Tat	B-protein
-mediated	O
activation	O
may	O
rely	O
upon	O
a	O
different	O
pathway	O
that	O
is	O
NFAT-1	B-protein
dependent	O
.	O

Inhibition	O
of	O
NF-kappa	B-protein
B	I-protein
activation	O
in	O
human	B-cell_line
T-cell	I-cell_line
lines	I-cell_line
by	O
anetholdithiolthione	O
.	O

Nuclear	B-protein
factor	I-protein
(	I-protein
NF	I-protein
)	I-protein
-kappa	I-protein
B	I-protein
is	O
a	O
redox	B-protein
sensitive	I-protein
cytosolic	I-protein
transcription	I-protein
factor	I-protein
.	O

Redox	O
regulation	O
of	O
NF-kappa	B-protein
B	I-protein
has	O
been	O
implicated	O
in	O
the	O
activation	O
of	O
the	O
human	O
immuno-deficiency	O
virus	O
(	O
HIV	O
)	O
.	O

Therefore	O
,	O
inhibition	O
of	O
NF-kappa	B-protein
B	I-protein
activation	O
may	O
be	O
an	O
effective	O
strategy	O
for	O
acquired	O
immunodeficiency	O
syndrome	O
therapy	O
.	O

Anetholdithiolthione	O
(	O
ADT	O
,	O
5-	O
[	O
p-methoxyphenyl	O
]	O
-3H-1	O
,	O
2-dithiol-3-thione	O
)	O
is	O
an	O
antioxidant	O
which	O
has	O
been	O
used	O
to	O
protect	O
against	O
acetaminophen-	O
and	O
CCl4-induced	O
hepatotoxicity	O
,	O
lipid	O
peroxidation	O
,	O
radiation	O
injury	O
,	O
and	O
also	O
has	O
been	O
used	O
clinically	O
as	O
an	O
anti-choleretic	O
agent	O
.	O

The	O
present	O
study	O
examined	O
the	O
effect	O
of	O
ADT	O
pretreatment	O
on	O
NF-kappa	B-protein
B	I-protein
activation	O
in	O
response	O
to	O
a	O
variety	O
of	O
stimuli	O
such	O
as	O
H2O2	O
,	O
phorbol	O
myristate	O
acetate	O
(	O
PMA	O
)	O
or	O
tumor	B-protein
necrosis	I-protein
factor	I-protein
alpha	I-protein
(	O
TNF	B-protein
alpha	I-protein
)	O
.	O

PMA	O
and	O
TNF	B-protein
alpha	I-protein
induced	O
activation	O
of	O
(	B-protein
NF	I-protein
)	I-protein
-kappa	I-protein
B	I-protein
in	O
human	O
Jurkat	B-cell_line
T-cells	I-cell_line
was	O
partially	O
inhibited	O
by	O
ADT	O
(	O
0.1	O
mM	O
)	O
pretreatment	O
.	O

ADT	O
(	O
0.1	O
mM	O
)	O
also	O
inhibited	O
H2O2	O
induced	O
activation	O
of	O
the	O
transcription	B-protein
factor	I-protein
in	O
the	O
peroxide	B-cell_line
sensitive	I-cell_line
human	I-cell_line
Wurzburg	I-cell_line
T-cells	I-cell_line
.	O

Furthermore	O
,	O
ADT	O
treated	O
Wurzburg	B-cell_line
cells	I-cell_line
had	O
significantly	O
higher	O
glutathione	O
levels	O
as	O
compared	O
with	O
untreated	B-cell_type
cells	I-cell_type
.	O

H2O2	O
induced	O
lipid	O
peroxidation	O
in	O
Wurzburg	B-cell_line
cells	I-cell_line
was	O
remarkably	O
inhibited	O
by	O
ADT	O
pretreatment	O
.	O

ADT	O
,	O
a	O
pro-glutathione	O
antioxidant	O
,	O
was	O
observed	O
to	O
be	O
capable	O
of	O
modulating	O
NF-kappa	B-protein
B	I-protein
activation	O
.	O

Involvement	O
of	O
tyrosine	O
phosphorylation	O
in	O
endothelial	B-protein
adhesion	I-protein
molecule	I-protein
induction	O
.	O

Induction	O
of	O
endothelial	B-protein
adhesion	I-protein
molecules	I-protein
by	O
the	O
cytokine	B-protein
tumor	B-protein
necrosis	I-protein
factor-alpha	I-protein
(	O
TNF	B-protein
)	O
can	O
occur	O
independently	O
of	O
protein	B-protein
kinase	I-protein
C	I-protein
and	O
activation	O
of	O
a	O
protein	B-protein
tyrosine	I-protein
kinase	I-protein
(	O
PTK	B-protein
)	O
has	O
recently	O
been	O
implicated	O
in	O
the	O
upregulation	O
of	O
vascular	B-protein
cell	I-protein
adhesion	I-protein
molecule	I-protein
1	I-protein
(	O
VCAM-1	B-protein
)	O
by	O
interleukin-4	B-protein
(	O
IL-4	B-protein
)	O
on	O
endothelial	B-cell_type
cells	I-cell_type
.	O

We	O
demonstrate	O
that	O
the	O
PTK	B-protein
inhibitors	O
herbimycin	O
A	O
or	O
genistein	O
suppress	O
induction	O
of	O
endothelial	O
VCAM-1	B-protein
and	O
E-selectin	B-protein
,	O
as	O
well	O
as	O
subsequent	O
monocytic	O
cell	O
adhesion	O
to	O
endothelial	B-cell_type
cells	I-cell_type
stimulated	O
by	O
TNF	B-protein
.	O

Inhibition	O
studies	O
indicate	O
that	O
specific	O
tyrosine	O
phosphorylation	O
following	O
PTK	B-protein
activation	O
is	O
involved	O
in	O
the	O
mobilization	O
of	O
the	O
transcription	B-protein
factor	I-protein
,	O
nuclear	B-protein
factor	I-protein
kappa	I-protein
B	I-protein
,	O
and	O
VCAM-1	B-RNA
mRNA	I-RNA
expression	O
.	O

This	O
may	O
have	O
implications	O
for	O
pathophysiological	O
conditions	O
that	O
involve	O
the	O
upregulation	O
of	O
these	O
molecules	O
(	O
e.g.	O
inflammation	O
and	O
atherosclerosis	O
)	O
.	O

Protein	B-protein
kinase	I-protein
C-zeta	I-protein
mediates	O
NF-kappa	B-protein
B	I-protein
activation	O
in	O
human	B-cell_type
immunodeficiency	I-cell_type
virus-infected	I-cell_type
monocytes	I-cell_type
.	O

The	O
molecular	O
mechanisms	O
regulating	O
human	O
immunodeficiency	O
virus	O
(	O
HIV	O
)	O
persistence	O
in	O
a	O
major	O
cell	O
reservoir	O
such	O
as	O
the	O
macrophage	B-cell_type
remain	O
unknown	O
.	O

NF-kappa	B-protein
B	I-protein
is	O
a	O
transcription	B-protein
factor	I-protein
involved	O
in	O
the	O
regulation	O
of	O
the	O
HIV	B-DNA
long	I-DNA
terminal	I-DNA
repeat	I-DNA
and	O
is	O
selectively	O
activated	O
following	O
HIV	O
infection	O
of	O
human	B-cell_type
macrophages	I-cell_type
.	O

Although	O
little	O
information	O
as	O
to	O
what	O
signal	O
transduction	O
pathways	O
mediate	O
NF-kappa	B-protein
B	I-protein
activation	O
in	O
monocytes-macrophages	B-cell_type
is	O
available	O
,	O
our	O
previous	O
work	O
indicated	O
that	O
classical	O
protein	B-protein
kinase	I-protein
C	I-protein
(	I-protein
PKC	I-protein
)	I-protein
isoenzymes	I-protein
were	O
not	O
involved	O
in	O
the	O
HIV-mediated	O
NF-kappa	B-protein
B	I-protein
activation	O
.	O

In	O
this	O
study	O
,	O
we	O
have	O
focused	O
on	O
atypical	O
PKC	B-protein
isoenzymes	I-protein
.	O

PKC-zeta	B-protein
belongs	O
to	O
this	O
family	O
and	O
is	O
known	O
to	O
be	O
an	O
important	O
step	O
in	O
NF-kappa	B-protein
B	I-protein
activation	O
in	O
other	O
cell	O
systems	O
.	O

Immunoblotting	O
experiments	O
with	O
U937	B-cell_line
cells	I-cell_line
demonstrate	O
that	O
PKC-zeta	B-protein
is	O
present	O
in	O
these	O
cells	O
,	O
and	O
its	O
expression	O
can	O
be	O
downmodulated	O
by	O
antisense	O
oligonucleotides	O
(	O
AO	O
)	O
.	O

The	O
HIV-mediated	O
NF-kappa	B-protein
B	I-protein
activation	O
is	O
selectively	O
reduced	O
by	O
AO	O
to	O
PKC-zeta	B-protein
.	O

In	O
addition	O
,	O
cotransfection	O
of	O
a	O
negative	O
dominant	O
molecule	O
of	O
PKC-zeta	B-protein
(	O
PKC-zeta	B-protein
mut	I-protein
)	O
with	O
NF-kappa	B-protein
B	I-protein
-dependent	O
reporter	O
genes	O
selectively	O
inhibits	O
the	O
HIV	O
-but	O
not	O
phorbol	O
myristate	O
acetate-	O
or	O
lipopolysaccharide-mediated	O
activation	O
of	O
NF-kappa	B-protein
B	I-protein
.	O

That	O
PKC-zeta	B-protein
is	O
specific	O
in	O
regulating	O
NF-kappa	B-protein
B	I-protein
is	O
concluded	O
from	O
the	O
inability	O
of	O
PKC-zeta	B-protein
(	I-protein
mut	I-protein
)	I-protein
to	O
interfere	O
with	O
the	O
basal	O
or	O
phorbol	O
myristate	O
acetate-inducible	O
CREB	B-protein
-or	O
AP1	B-protein
-dependent	O
transcriptional	O
activity	O
.	O

Lastly	O
,	O
we	O
demonstrate	O
a	O
selective	O
inhibition	O
of	O
p24	B-protein
production	O
by	O
HIV-infected	B-cell_type
human	I-cell_type
macrophages	I-cell_type
when	O
treated	O
with	O
AO	O
to	O
PKC-zeta	B-protein
.	O

Altogether	O
,	O
these	O
results	O
suggest	O
that	O
atypical	B-protein
PKC	I-protein
isoenzymes	I-protein
,	O
including	O
PKC-zeta	B-protein
,	O
participate	O
in	O
the	O
signal	O
transduction	O
pathways	O
by	O
which	O
HIV	O
infection	O
results	O
in	O
the	O
activation	O
of	O
NF-kappa	B-protein
B	I-protein
in	O
human	B-cell_type
monocytic	I-cell_type
cells	I-cell_type
and	O
macrophages	B-cell_type
.	O

Induction	O
of	O
Bcl-x	B-protein
(	I-protein
L	I-protein
)	I-protein
expression	O
by	O
human	B-protein
T-cell	I-protein
leukemia	I-protein
virus	I-protein
type	I-protein
1	I-protein
Tax	I-protein
through	O
NF-kappaB	B-protein
in	O
apoptosis-resistant	B-cell_line
T-cell	I-cell_line
transfectants	I-cell_line
with	O
Tax	B-protein
.	O

Human	O
T-cell	O
leukemia	O
virus	O
type	O
1	O
(	O
HTLV-1	O
)	O
Tax	B-protein
is	O
thought	O
to	O
play	O
a	O
pivotal	O
role	O
in	O
immortalization	O
of	O
T	B-cell_type
cells	I-cell_type
.	O

We	O
have	O
recently	O
shown	O
that	O
the	O
expression	O
of	O
Tax	B-protein
protected	O
the	O
mouse	B-cell_line
T-cell	I-cell_line
line	I-cell_line
CTLL-2	I-cell_line
against	O
apoptosis	O
induced	O
by	O
interleukin-2	B-protein
(	O
IL-2	B-protein
)	O
deprivation	O
and	O
converted	O
its	O
growth	O
from	O
being	O
IL-2	B-protein
dependent	O
to	O
being	O
IL-2	B-protein
independent	O
.	O

In	O
this	O
study	O
,	O
we	O
demonstrate	O
that	O
constitutive	O
expression	O
of	O
bcl-xl	B-protein
but	O
not	O
bcl-2	B-protein
,	O
bcl-xs	B-protein
,	O
bak	B-protein
,	O
bad	B-protein
,	O
or	O
bax	B-protein
was	O
associated	O
with	O
apoptosis	O
resistance	O
after	O
IL-2	B-protein
deprivation	O
in	O
CTLL-2	B-cell_line
cells	I-cell_line
that	O
expressed	O
Tax	B-protein
.	O

Transient-transfection	O
assays	O
showed	O
that	O
bcl-x	B-DNA
promoter	I-DNA
was	O
transactivated	O
by	O
wild-type	B-protein
Tax	I-protein
.	O

Similar	O
effects	O
were	O
observed	O
in	O
mutant	O
Tax	B-protein
retaining	O
transactivating	O
ability	O
through	O
NF-kappaB	B-protein
.	O

Deletion	O
or	O
substitution	O
of	O
a	O
putative	B-protein
NF-kappaB	I-protein
binding	I-protein
site	I-protein
identified	O
in	O
the	O
bcl-x	B-DNA
promoter	I-DNA
significantly	O
decreased	O
Tax	B-protein
-induced	O
transactivation	O
.	O

This	O
NF-kappaB-like	B-DNA
element	I-DNA
was	O
able	O
to	O
form	O
a	O
complex	O
with	O
NF-kappaB	B-protein
family	I-protein
proteins	I-protein
in	O
vitro	O
.	O

Furthermore	O
,	O
Tax	B-protein
-induced	O
transactivation	O
of	O
the	O
bcl-x	B-DNA
promoter	I-DNA
was	O
also	O
diminished	O
by	O
the	O
mutant	B-protein
IkappaBalpha	I-protein
,	O
which	O
specifically	O
inhibits	O
NF-kappaB	B-protein
activity	O
.	O

Our	O
findings	O
suggest	O
that	O
constitutive	O
expression	O
of	O
Bcl-x	B-protein
(	I-protein
L	I-protein
)	I-protein
induced	O
by	O
Tax	B-protein
through	O
the	O
NF-kappaB	B-protein
pathway	O
contributes	O
to	O
the	O
inhibition	O
of	O
apoptosis	O
in	O
CTLL-2	B-cell_line
cells	I-cell_line
after	O
IL-2	B-protein
deprivation	O
.	O

The	O
beta-globin	B-DNA
promoter	I-DNA
is	O
important	O
for	O
recruitment	O
of	O
erythroid	B-protein
Kruppel-like	I-protein
factor	I-protein
to	O
the	O
locus	B-DNA
control	I-DNA
region	I-DNA
in	O
erythroid	B-cell_type
cells	I-cell_type
.	O

Erythroid	B-protein
Kruppel-like	I-protein
factor	I-protein
(	O
EKLF	B-protein
)	O
,	O
which	O
binds	O
to	O
the	O
CACCC	O
box	O
in	O
the	O
beta-globin	B-DNA
promoter	I-DNA
,	O
is	O
required	O
for	O
the	O
expression	O
of	O
the	O
beta-globin	B-DNA
gene	I-DNA
in	O
adult	B-cell_type
erythroid	I-cell_type
cells	I-cell_type
.	O

It	O
was	O
recently	O
demonstrated	O
that	O
EKLF	B-protein
is	O
also	O
required	O
for	O
the	O
activity	O
of	O
the	O
beta-globin	B-DNA
locus	I-DNA
control	I-DNA
region	I-DNA
(	O
LCR	B-DNA
)	O
5'HS3	B-DNA
.	O

Some	O
evidence	O
suggests	O
that	O
the	O
LCR	B-DNA
and	O
the	O
beta-globin	B-DNA
promoter	I-DNA
interact	O
in	O
adult	B-cell_type
erythroid	I-cell_type
cells	I-cell_type
,	O
and	O
the	O
network	O
of	O
protein-protein	O
interactions	O
that	O
exists	O
between	O
these	O
two	O
elements	O
may	O
regulate	O
how	O
EKLF	B-protein
is	O
recruited	O
to	O
the	O
LCR	B-DNA
.	O

In	O
this	O
report	O
,	O
we	O
use	O
the	O
PIN*POINT	O
assay	O
to	O
study	O
the	O
role	O
of	O
the	O
promoter	O
on	O
the	O
recruitment	O
of	O
EKLF	B-protein
to	O
5'HS2	B-DNA
and	O
5'HS3	B-DNA
of	O
the	O
LCR	B-DNA
.	O

We	O
find	O
that	O
recruitment	O
of	O
EKLF	B-protein
to	O
5'HS2	B-DNA
requires	O
the	O
TATA	B-DNA
box	I-DNA
,	O
but	O
recruitment	O
to	O
5'HS3	B-DNA
depends	O
on	O
the	O
CACCC	O
and	O
TATA	B-DNA
boxes	I-DNA
of	O
the	O
beta-globin	B-DNA
promoter	I-DNA
.	O

Furthermore	O
,	O
recruitment	O
of	O
EKLF	B-protein
to	O
5'HS3	B-DNA
only	O
occurred	O
in	O
beta-globin-expressing	B-cell_type
murine	I-cell_type
erythroid	I-cell_type
leukemia	I-cell_type
cells	I-cell_type
,	O
whereas	O
recruitment	O
of	O
EKLF	B-protein
to	O
5'HS2	B-DNA
occurred	O
in	O
both	O
gamma-globin-expressing	B-cell_line
K562	I-cell_line
cells	I-cell_line
and	O
murine	B-cell_type
erythroid	I-cell_type
leukemia	I-cell_type
cells	I-cell_type
.	O

Unlike	O
EKLF	B-protein
,	O
Sp1	B-protein
,	O
which	O
also	O
binds	O
to	O
CACCC	O
boxes	O
,	O
is	O
not	O
recruited	O
to	O
5'HS3	B-DNA
.	O

We	O
have	O
also	O
examined	O
how	O
one	O
5'HS	B-DNA
affects	O
the	O
recruitment	O
of	O
EKLF	B-protein
to	O
another	O
5'HS	B-DNA
.	O

We	O
have	O
found	O
that	O
the	O
recruitment	O
of	O
EKLF	B-protein
to	O
5'HS3	B-DNA
depends	O
on	O
the	O
presence	O
of	O
5'HS2	B-DNA
in	O
cis	O
,	O
but	O
the	O
recruitment	O
to	O
5'HS2	B-DNA
does	O
not	O
depend	O
on	O
5'HS3	B-DNA
.	O

Based	O
on	O
these	O
results	O
,	O
we	O
present	O
a	O
model	O
that	O
illustrates	O
how	O
EKLF	B-protein
may	O
be	O
recruited	O
to	O
the	O
beta-globin	B-DNA
locus	I-DNA
.	O

Estrogen	O
decreases	O
TNF	B-protein
gene	O
expression	O
by	O
blocking	O
JNK	B-protein
activity	O
and	O
the	O
resulting	O
production	O
of	O
c-Jun	B-protein
and	O
JunD	B-protein
.	O

Central	O
to	O
the	O
bone-sparing	O
effect	O
of	O
estrogen	O
(	O
E	O
(	O
2	O
)	O
)	O
is	O
its	O
ability	O
to	O
block	O
the	O
monocytic	O
production	O
of	O
the	O
osteoclastogenic	B-protein
cytokine	I-protein
TNF-alpha	I-protein
(	O
TNF	B-protein
)	O
.	O

However	O
,	O
the	O
mechanism	O
by	O
which	O
E	O
(	O
2	O
)	O
downregulates	O
TNF	B-protein
production	O
is	O
presently	O
unknown	O
.	O

Transient	O
transfection	O
studies	O
in	O
HeLa	B-cell_line
cells	I-cell_line
,	O
an	O
E	O
(	O
2	O
)	O
receptor-negative	O
line	O
,	O
suggest	O
that	O
E	O
(	O
2	O
)	O
inhibits	O
TNF	B-protein
gene	O
expression	O
through	O
an	O
effect	O
mediated	O
by	O
estrogen	B-protein
receptor	I-protein
beta	I-protein
(	O
ERbeta	B-protein
)	O
.	O

We	O
also	O
report	O
that	O
in	O
RAW	B-cell_line
264.7	I-cell_line
cells	I-cell_line
,	O
an	O
E	O
(	O
2	O
)	O
receptor-positive	O
murine	O
monocytic	O
line	O
,	O
E	O
(	O
2	O
)	O
downregulates	O
cytokine-induced	O
TNF	B-protein
gene	O
expression	O
by	O
decreasing	O
the	O
activity	O
of	O
the	O
Jun	B-protein
NH	I-protein
(	I-protein
2	I-protein
)	I-protein
-terminal	I-protein
kinase	I-protein
(	O
JNK	B-protein
)	O
.	O

The	O
resulting	O
diminished	O
phosphorylation	O
of	O
c-Jun	B-protein
and	O
JunD	B-protein
at	O
their	O
NH	B-protein
(	I-protein
2	I-protein
)	I-protein
-termini	I-protein
decreases	O
the	O
ability	O
of	O
these	O
nuclear	O
proteins	O
to	O
autostimulate	O
the	O
expression	O
of	O
the	O
c-Jun	B-DNA
and	I-DNA
JunD	I-DNA
genes	I-DNA
,	O
thus	O
leading	O
to	O
lower	O
production	O
of	O
c-Jun	B-protein
and	O
JunD	B-protein
.	O

The	O
consequent	O
decrease	O
in	O
the	O
nuclear	O
levels	O
of	O
c-Jun	B-protein
and	O
JunD	B-protein
leads	O
to	O
diminished	O
binding	O
of	O
c-Jun/c-Fos	B-protein
and	O
JunD/c-Fos	B-protein
heterodimers	I-protein
to	O
the	O
AP-1	B-DNA
consensus	I-DNA
sequence	I-DNA
in	O
the	O
TNF	B-DNA
promoter	I-DNA
and	O
,	O
thus	O
,	O
to	O
decreased	O
transactivation	O
of	O
the	O
TNF	B-DNA
gene	I-DNA
.	O

Cutting	O
edge	O
:	O
TCR	B-protein
stimulation	O
by	O
antibody	O
and	O
bacterial	O
superantigen	O
induces	O
Stat3	B-protein
activation	O
in	O
human	B-cell_type
T	I-cell_type
cells	I-cell_type
.	O

Recent	O
data	O
show	O
that	O
TCR/CD3	B-protein
stimulation	O
induces	O
activation	O
of	O
Stat5	B-protein
in	O
murine	B-cell_type
T	I-cell_type
cells	I-cell_type
.	O

Here	O
,	O
we	O
show	O
that	O
CD3	O
ligation	O
by	O
mAb	O
and	O
Staphylococcal	O
enterotoxin	O
(	O
SE	O
)	O
induce	O
a	O
rapid	O
,	O
gradually	O
accumulating	O
,	O
long-lasting	O
tyrosine	O
,	O
and	O
serine	O
phosphorylation	O
of	O
Stat3	B-protein
(	O
but	O
not	O
Stat5	B-protein
)	O
in	O
allogen-specific	B-cell_line
human	I-cell_line
CD4+	I-cell_line
T	I-cell_line
cell	I-cell_line
lines	I-cell_line
.	O

In	O
contrast	O
,	O
IL-2	B-protein
induces	O
a	O
rapid	O
and	O
transient	O
tyrosine	O
and	O
serine	O
phosphorylation	O
of	O
Stat3	B-protein
.	O

Compared	O
with	O
IL-2	B-protein
,	O
CD3	B-protein
ligation	O
induces	O
a	O
delayed	O
Stat3	B-protein
binding	O
to	O
oligonucleotide	O
probes	O
from	O
the	O
ICAM-1	B-protein
and	O
IL-2R	B-DNA
alpha	I-DNA
promoter	I-DNA
.	O

CD3	B-protein
-mediated	O
activation	O
of	O
Stat3	B-protein
is	O
almost	O
completely	O
inhibited	O
by	O
a	O
Src	B-protein
kinase	I-protein
inhibitor	I-protein
(	O
PP1	B-protein
)	O
,	O
whereas	O
IL-2	B-protein
-induced	O
Stat3	B-protein
activation	O
is	O
unaffected	O
.	O

In	O
conclusion	O
,	O
we	O
show	O
that	O
CD3	B-protein
ligation	O
by	O
mAb	B-protein
and	O
SE	O
triggers	O
a	O
rapid	O
,	O
PP1	B-protein
-sensitive	O
tyrosine	O
and	O
serine	O
phosphorylation	O
of	O
Stat3	B-protein
in	O
human	B-cell_type
CD4+	I-cell_type
T	I-cell_type
cells	I-cell_type
.	O

Moreover	O
,	O
we	O
provide	O
evidence	O
that	O
TCR/CD3	B-protein
and	O
IL-2	B-protein
induce	O
Stat3	B-protein
activation	O
via	O
distinct	O
signaling	O
pathways	O
.	O

Distinctive	O
gene	O
expression	O
patterns	O
in	O
human	B-cell_type
mammary	I-cell_type
epithelial	I-cell_type
cells	I-cell_type
and	O
breast	O
cancers	O
.	O

cDNA	B-DNA
microarrays	I-DNA
and	O
a	O
clustering	O
algorithm	O
were	O
used	O
to	O
identify	O
patterns	O
of	O
gene	O
expression	O
in	O
human	B-cell_type
mammary	I-cell_type
epithelial	I-cell_type
cells	I-cell_type
growing	O
in	O
culture	O
and	O
in	O
primary	O
human	O
breast	O
tumors	O
.	O

Clusters	O
of	O
coexpressed	B-DNA
genes	I-DNA
identified	O
through	O
manipulations	O
of	O
mammary	B-cell_type
epithelial	I-cell_type
cells	I-cell_type
in	O
vitro	O
also	O
showed	O
consistent	O
patterns	O
of	O
variation	O
in	O
expression	O
among	O
breast	O
tumor	O
samples	O
.	O

By	O
using	O
immunohistochemistry	O
with	O
antibodies	O
against	O
proteins	O
encoded	O
by	O
a	O
particular	O
gene	O
in	O
a	O
cluster	O
,	O
the	O
identity	O
of	O
the	O
cell	O
type	O
within	O
the	O
tumor	O
specimen	O
that	O
contributed	O
the	O
observed	O
gene	O
expression	O
pattern	O
could	O
be	O
determined	O
.	O

Clusters	O
of	O
genes	B-DNA
with	O
coherent	O
expression	O
patterns	O
in	O
cultured	B-cell_type
cells	I-cell_type
and	O
in	O
the	O
breast	O
tumors	O
samples	O
could	O
be	O
related	O
to	O
specific	O
features	O
of	O
biological	O
variation	O
among	O
the	O
samples	O
.	O

Two	O
such	O
clusters	O
were	O
found	O
to	O
have	O
patterns	O
that	O
correlated	O
with	O
variation	O
in	O
cell	O
proliferation	O
rates	O
and	O
with	O
activation	O
of	O
the	O
IFN	B-protein
-regulated	O
signal	O
transduction	O
pathway	O
,	O
respectively	O
.	O

Clusters	O
of	O
genes	B-DNA
expressed	O
by	O
stromal	B-cell_type
cells	I-cell_type
and	O
lymphocytes	B-cell_type
in	O
the	O
breast	O
tumors	O
also	O
were	O
identified	O
in	O
this	O
analysis	O
.	O

These	O
results	O
support	O
the	O
feasibility	O
and	O
usefulness	O
of	O
this	O
systematic	O
approach	O
to	O
studying	O
variation	O
in	O
gene	O
expression	O
patterns	O
in	O
human	O
cancers	O
as	O
a	O
means	O
to	O
dissect	O
and	O
classify	O
solid	O
tumors	O
.	O

PPARgamma	B-protein
activation	O
induces	O
the	O
expression	O
of	O
the	O
adipocyte	B-DNA
fatty	I-DNA
acid	I-DNA
binding	I-DNA
protein	I-DNA
gene	I-DNA
in	O
human	B-cell_type
monocytes	I-cell_type
.	O

The	O
peroxisome-proliferator	B-protein
activated	I-protein
receptor	I-protein
gamma	I-protein
(	O
PPARgamma	B-protein
)	O
,	O
a	O
member	O
of	O
the	O
nuclear	B-protein
receptor	I-protein
superfamily	I-protein
of	O
ligand	B-protein
activated	I-protein
transcription	I-protein
factors	I-protein
,	O
plays	O
a	O
key	O
role	O
in	O
the	O
anti-diabetic	O
actions	O
of	O
the	O
thiazolidinediones	O
(	O
TZDs	O
)	O
.	O

PPARgamma	B-protein
induces	O
the	O
expression	O
of	O
many	O
genes	B-DNA
involved	O
in	O
lipid	O
anabolism	O
,	O
including	O
the	O
adipocyte	B-protein
fatty	I-protein
acid	I-protein
binding	I-protein
protein	I-protein
(	O
aP2	B-protein
)	O
,	O
and	O
is	O
a	O
key	O
regulator	O
of	O
adipocyte	B-cell_type
differentiation	O
.	O

PPARgamma	B-protein
is	O
also	O
expressed	O
in	O
hematopoietic	B-cell_type
cells	I-cell_type
and	O
is	O
up-regulated	O
in	O
activated	O
monocytes/macrophages	B-cell_type
.	O

Activation	O
of	O
PPARgamma	B-protein
may	O
play	O
a	O
role	O
in	O
the	O
induction	O
of	O
differentiation	O
of	O
macrophages	B-cell_type
to	O
foam	B-cell_type
cells	I-cell_type
that	O
are	O
associated	O
with	O
atherosclerotic	O
lesions	O
.	O

We	O
report	O
that	O
both	O
natural	O
and	O
synthetic	O
PPARgamma	O
agonists	O
induce	O
time-	O
and	O
dose-dependent	O
increases	O
in	O
aP2	B-RNA
mRNA	I-RNA
in	O
both	O
primary	B-cell_type
human	I-cell_type
monocytes	I-cell_type
and	O
the	O
monocytic	B-cell_line
cell	I-cell_line
line	I-cell_line
,	O
THP-1	B-cell_line
.	O

These	O
data	O
suggest	O
that	O
PPARgamma	B-protein
activation	O
may	O
play	O
a	O
role	O
in	O
monocyte	B-cell_type
differentiation	O
and	O
function	O
analogous	O
to	O
its	O
well-characterized	O
role	O
in	O
adipocytes	B-cell_type
.	I-cell_type

Identification	O
of	O
a	O
physical	O
interaction	O
between	O
calcineurin	B-protein
and	O
nuclear	B-protein
factor	I-protein
of	I-protein
activated	I-protein
T	I-protein
cells	I-protein
(	O
NFATp	B-protein
)	O
.	O

In	O
T	B-cell_type
lymphocytes	I-cell_type
,	O
the	O
calcium/calmodulin-dependent	B-protein
serine/threonine	I-protein
phosphatase	I-protein
,	O
calcineurin	B-protein
,	O
plays	O
a	O
pivotal	O
role	O
in	O
transducing	O
membrane-associated	O
signals	O
to	O
the	O
nucleus	O
.	O

One	O
of	O
the	O
putative	O
targets	O
of	O
calcineurin	B-protein
is	O
the	O
pre-existing	O
,	O
cytosolic	B-protein
component	I-protein
of	O
the	O
nuclear	B-protein
factor	I-protein
of	I-protein
activated	I-protein
T	I-protein
cells	I-protein
(	O
NFATp	B-protein
;	O
also	O
referred	O
to	O
as	O
NFAT1	B-protein
)	O
,	O
which	O
is	O
one	O
of	O
several	O
transcription	B-protein
factors	I-protein
required	O
for	O
the	O
expression	O
of	O
interleukin	B-protein
2	I-protein
.	O

Inhibition	O
of	O
calcineurin	B-protein
by	O
the	O
immunosuppressive	O
drugs	O
cyclosporin	O
A	O
and	O
FK506	O
prevents	O
dephosphorylation	O
of	O
NFATp	B-protein
and	O
its	O
translocation	O
to	O
the	O
nucleus	O
.	O

However	O
,	O
a	O
physical	O
interaction	O
between	O
calcineurin	B-protein
and	O
NFATp	B-protein
has	O
not	O
been	O
demonstrated	O
.	O

Here	O
we	O
demonstrate	O
the	O
binding	O
of	O
NFATp	B-protein
from	O
lysates	O
of	O
T	B-cell_type
cells	I-cell_type
to	O
immobilized	O
calcineurin	B-protein
.	O

Stimulation	O
of	O
T	B-cell_type
cells	I-cell_type
with	O
calcium	O
ionophore	O
induced	O
a	O
shift	O
in	O
the	O
molecular	O
weight	O
of	O
NFATp	B-protein
that	O
is	O
due	O
to	O
its	O
dephosphorylation	O
.	O

This	O
dephosphorylation	O
was	O
inhibited	O
by	O
treatment	O
of	O
T	B-cell_type
cells	I-cell_type
with	O
cyclosporin	O
A	O
or	O
FK506	O
prior	O
to	O
stimulation	O
.	O

Of	O
note	O
,	O
both	O
the	O
phosphorylated	O
and	O
the	O
dephosphorylated	O
form	O
of	O
NFATp	B-protein
bound	O
to	O
calcineurin	B-protein
.	O

Furthermore	O
,	O
the	O
binding	O
of	O
both	O
forms	O
of	O
NFATp	B-protein
to	O
calcineurin	B-protein
was	O
inhibited	O
by	O
pretreatment	O
of	O
calcineurin	B-protein
with	O
a	O
complex	O
of	O
FK506	O
and	O
its	O
ligand	O
FKBP12	O
.	O

Taken	O
together	O
these	O
data	O
strongly	O
suggest	O
a	O
direct	O
interaction	O
of	O
calcineurin	B-protein
with	O
NFATp	B-protein
and	O
that	O
this	O
interaction	O
does	O
not	O
depend	O
upon	O
the	O
phosphorylation	B-DNA
sites	I-DNA
of	O
NFATp	B-protein
affected	O
by	O
activation	O
.	O

Cross-linking	O
CD40	B-protein
on	O
B	B-cell_type
cells	I-cell_type
preferentially	O
induces	O
stress-activated	B-protein
protein	I-protein
kinases	I-protein
rather	O
than	O
mitogen-activated	B-protein
protein	I-protein
kinases	I-protein
.	O

The	O
B	B-protein
cell-associated	I-protein
surface	I-protein
molecule	I-protein
CD40	B-protein
plays	O
a	O
key	O
role	O
in	O
T	O
cell-dependent	O
B	O
cell	O
maturation	O
,	O
as	O
individuals	O
with	O
defects	O
in	O
either	O
CD40	B-protein
or	O
its	O
ligand	O
are	O
impaired	O
in	O
immunoglobulin	B-protein
isotype	O
class	O
switching	O
and	O
germinal	O
center	O
formation	O
.	O

CD40	B-protein
signaling	O
activates	O
downstream	B-protein
effectors	I-protein
,	O
including	O
the	O
tyrosine	B-protein
protein	I-protein
kinase	I-protein
,	O
Lyn	B-protein
,	O
the	O
phosphatidylinositol-3-kinase	B-protein
(	O
PI-3	B-protein
kinase	I-protein
)	O
,	O
and	O
the	O
transcription	O
factor	O
,	O
NF-kappa	B-protein
B	I-protein
.	O

In	O
this	O
study	O
,	O
we	O
demonstrate	O
that	O
stress-activated	B-protein
protein	I-protein
kinases	I-protein
(	O
SAPK	B-protein
)	O
are	O
activated	O
after	O
CD40	B-protein
cross-linking	O
on	O
various	O
B	B-cell_line
cell	I-cell_line
lines	I-cell_line
or	O
human	B-cell_type
tonsillar	I-cell_type
B	I-cell_type
cells	I-cell_type
.	O

The	O
activation	O
is	O
rapid	O
and	O
transient	O
and	O
is	O
mediated	O
through	O
a	O
cyclosporin	O
A-insensitive	O
pathway	O
.	O

Furthermore	O
,	O
this	O
signaling	O
pathway	O
appears	O
not	O
to	O
rely	O
on	O
protein	B-protein
kinase	I-protein
C	I-protein
.	O

While	O
CD40	B-protein
ligation	O
strongly	O
activates	O
the	O
SAPKs	B-protein
(	O
up	O
to	O
25-fold	O
)	O
,	O
it	O
does	O
not	O
affect	O
members	O
of	O
the	O
mitogen-activated	B-protein
protein	I-protein
kinase	I-protein
family	I-protein
(	O
MAPK	B-protein
;	O
ERK1	B-protein
and	O
ERK2	B-protein
)	O
.	O

Consistent	O
with	O
these	O
data	O
,	O
CD40	B-protein
signals	O
up-regulate	O
c-jun	B-RNA
but	I-RNA
not	I-RNA
c-fos	I-RNA
mRNA	I-RNA
and	O
alter	O
the	O
transcription	B-protein
factor	I-protein
ATF2	B-protein
but	O
not	O
the	O
Raf-1	B-protein
protein	I-protein
.	O

In	O
summary	O
,	O
CD40	B-protein
signaling	O
preferentially	O
induces	O
SAPK	B-protein
but	O
not	O
MAPK	B-protein
.	O

Stimulation	O
of	O
the	O
T-cell	B-protein
antigen	I-protein
receptor-CD3	I-protein
complex	I-protein
signaling	O
pathway	O
by	O
the	O
tyrosine	B-protein
phosphatase	I-protein
inhibitor	O
pervanadate	O
is	O
mediated	O
by	O
inhibition	O
of	O
CD45	B-protein
:	O
evidence	O
for	O
two	O
interconnected	O
Lck/Fyn-	O
or	O
zap-70-dependent	O
signaling	O
pathways	O
.	O

The	O
tyrosine	B-protein
phosphatase	I-protein
specific	O
inhibitor	O
pervanadate	O
is	O
a	O
potent	O
activator	O
of	O
T	B-cell_type
lymphocytes	I-cell_type
through	O
induction	O
of	O
tyrosine	B-protein
phosphorylation	I-protein
and	O
downstream	O
events	O
of	O
the	O
activation	O
cascade	O
.	O

Using	O
CD45-	B-cell_line
or	I-cell_line
CD3-negative	I-cell_line
variants	I-cell_line
of	O
the	O
Jurkat	B-cell_line
leukemic	I-cell_line
T-cell	I-cell_line
line	I-cell_line
we	O
show	O
that	O
the	O
different	O
biochemical	O
events	O
induced	O
by	O
pervanadate	O
appeared	O
to	O
be	O
dependent	O
on	O
the	O
presence	O
at	O
the	O
cell	O
surface	O
of	O
either	O
CD45	B-protein
or	O
CD3	B-protein
.	O

CD45	B-protein
-dependent	O
events	O
such	O
as	O
tyrosine	B-protein
phosphorylation	I-protein
of	O
Shc	B-protein
,	O
activation	O
of	O
nuclear	B-protein
factor-kappa	I-protein
B	I-protein
(	O
NF-kappa	B-protein
B	I-protein
)	O
,	O
activator	B-protein
protein-1	I-protein
(	O
AP-1	B-protein
)	O
,	O
transcription	B-protein
factors	I-protein
,	O
and	O
stimulation	O
of	O
interleukin-2	B-DNA
(	I-DNA
IL-2	I-DNA
)	I-DNA
promoter	I-DNA
and	O
of	O
CD69	B-protein
and	O
CD25	B-protein
surface	O
expression	O
paralleled	O
activation	O
of	O
the	O
tyrosine	B-protein
kinases	I-protein
lck	B-protein
and	O
fyn	B-protein
.	O

By	O
contrast	O
,	O
stimulation	O
of	O
calcium	O
influx	O
,	O
a	O
CD3	B-protein
-dependent	O
event	O
,	O
paralleled	O
zap-70	B-protein
activation	O
.	O

The	O
data	O
demonstrate	O
that	O
the	O
T-cell	O
antigen	O
receptor	O
-CD3	B-protein
(	I-protein
TcR-CD3	I-protein
)	I-protein
complex	I-protein
is	O
functionally	O
linked	O
to	O
two	O
different	O
protein	B-protein
tyrosine	I-protein
kinase	I-protein
(	O
PTK	B-protein
)	O
modules	O
with	O
separate	O
specific	O
functions	O
and	O
that	O
CD45	B-protein
may	O
be	O
an	O
important	O
regulator	O
of	O
this	O
coupling	O
.	O

Vitamin	O
D	O
analogs	O
,	O
20-Epi-22-oxa-24a	O
,	O
26a	O
,	O
27a	O
,	O
-trihomo-1alpha	O
,	O
25	O
(	O
OH	O
)	O
2-vitamin	O
D3	O
,	O
1	O
,	O
24	O
(	O
OH	O
)	O
2-22-ene-24-cyclopropyl-vitamin	O
D3	O
and	O
1alpha	O
,	O
25	O
(	O
OH	O
)	O
2-lumisterol3	O
prime	O
NB4	B-cell_line
leukemia	I-cell_line
cells	I-cell_line
for	O
monocytic	O
differentiation	O
via	O
nongenomic	O
signaling	O
pathways	O
,	O
involving	O
calcium	O
and	O
calpain	O
.	O

Side-chain	O
modified	O
vitamin	O
D	O
analogs	O
including	O
20-Epi-22-oxa-24a	O
,	O
26a	O
,	O
27a-trihomo-1alpha	O
,	O
2	O
5-dihydroxyvitamin	O
D3	O
(	O
KH1060	O
)	O
,	O
and	O
1	O
,	O
24-dihydroxy-22-ene-24-cyclopropyl-vitamin	O
D3	O
(	O
MC903	O
)	O
were	O
originally	O
designed	O
to	O
aid	O
in	O
the	O
treatment	O
of	O
hyperproliferative	O
disorders	O
including	O
psoriasis	O
and	O
cancer	O
.	O

Here	O
we	O
demonstrate	O
that	O
these	O
analogs	O
,	O
as	O
well	O
as	O
the	O
6-cis-locked	O
conformer	O
,	O
1alpha	B-cell_line
,	I-cell_line
25-dihydroxy-lumisterol3	I-cell_line
(	I-cell_line
JN	I-cell_line
)	I-cell_line
prime	I-cell_line
NB4	I-cell_line
cells	I-cell_line
for	O
monocytic	O
differentiation	O
.	O

Previously	O
,	O
the	O
action	O
of	O
MC903	O
and	O
KH1060	O
was	O
presumed	O
to	O
be	O
mediated	O
by	O
the	O
nuclear	B-protein
vitamin	I-protein
D	I-protein
receptor	I-protein
(	O
VDRnuc	B-protein
)	O
.	O

Differentiation	O
in	O
response	O
to	O
all	O
analogs	O
was	O
shown	O
to	O
be	O
inhibited	O
by	O
1beta	O
,	O
25-dihydroxyvitamin	O
D3	O
(	O
HL	O
)	O
,	O
the	O
antagonist	O
to	O
the	O
nongenomic	O
activities	O
of	O
1	O
,	O
25D3	O
.	O

These	O
data	O
suggest	O
that	O
although	O
MC903	O
and	O
KH1060	O
may	O
bind	O
the	O
VDRnuc	B-protein
,	O
that	O
the	O
differentiative	O
activities	O
of	O
these	O
agents	O
requires	O
nongenomic	O
signaling	O
pathways	O
.	O

Here	O
we	O
show	O
that	O
1alpha	O
,	O
25	O
(	O
OH	O
)	O
2-d5-previtamin	O
D3	O
(	O
HF	O
)	O
,	O
JN	O
,	O
KH1060	O
,	O
and	O
MC903	O
induce	O
expression	O
of	O
PKC	B-protein
alpha	I-protein
and	O
PKC	B-protein
delta	I-protein
and	O
translocation	O
of	O
both	O
isoforms	O
to	O
the	O
particulate	O
fraction	O
,	O
and	O
PKC	B-protein
alpha	I-protein
to	O
the	O
nuclear	O
fraction	O
.	O

The	O
full	O
differentiation	O
response	O
with	O
combinations	O
of	O
analogs	O
and	O
TPA	O
was	O
inhibited	O
50	O
%	O
by	O
the	O
membrane	O
permeable	O
Ca2+	O
chelator	O
,	O
1	O
,	O
2-bis	O
(	O
o-aminophenoxy	O
)	O
-ethane-N	O
,	O
N	O
,	O
N	O
'	O
,	O
N'-tetraacetic	O
acid	O
(	O
BAPTA-AM	O
)	O
or	O
calpain	B-protein
inhibitor	O
I	O
.	O

These	O
data	O
demonstrate	O
that	O
intracellular	O
free	O
calcium	O
and	O
the	O
calcium-dependent	B-protein
protease	I-protein
,	O
calpain	B-protein
play	O
critical	O
roles	O
in	O
monocytic	O
differentiation	O
.	O

Intracellular	O
calcium	O
appears	O
to	O
be	O
most	O
critical	O
in	O
the	O
1	O
,	O
25D3-priming	O
stage	O
of	O
differentiation	O
,	O
while	O
calpain	B-protein
is	O
essential	O
in	O
the	O
TPA	O
maturation	O
response	O
.	O

Neutrophil	B-cell_type
maturation	O
and	O
the	O
role	O
of	O
retinoic	O
acid	O
.	O

Neutrophil	B-cell_type
maturation	O
occurs	O
in	O
well	O
defined	O
morphological	O
stages	O
that	O
correlate	O
with	O
the	O
acquisition	O
of	O
molecular	B-protein
markers	I-protein
associated	O
with	O
neutrophil	O
function	O
.	O

A	O
variety	O
of	O
factors	O
are	O
known	O
to	O
play	O
a	O
role	O
in	O
terminal	O
neutrophil	B-cell_type
maturation	O
,	O
including	O
the	O
vitamin	O
A	O
derivative	O
,	O
retinoic	O
acid	O
.	O

Retinoic	O
acid	O
can	O
directly	O
modulate	O
gene	O
expression	O
via	O
binding	O
to	O
its	O
nuclear	B-protein
receptors	I-protein
,	O
which	O
can	O
,	O
in	O
turn	O
,	O
activate	O
transcription	O
of	O
target	B-DNA
genes	I-DNA
.	O

A	O
role	O
for	O
retinoic	O
acid	O
during	O
neutrophil	B-cell_type
maturation	O
has	O
been	O
suggested	O
from	O
a	O
variety	O
of	O
sources.	O
Here	O
we	O
present	O
a	O
review	O
of	O
the	O
mechanism	O
of	O
retinoic	B-protein
acid	I-protein
receptor	I-protein
action	O
and	O
the	O
major	O
evidence	O
showing	O
that	O
normal	O
retinoid	O
signaling	O
is	O
required	O
for	O
neutrophil	B-cell_type
maturation	O
.	O

Human	B-DNA
T-cell	I-DNA
lymphotrophic	I-DNA
virus	I-DNA
type-I	I-DNA
tax	I-DNA
gene	I-DNA
induces	O
secretion	O
of	O
human	B-protein
macrophage	I-protein
inflammatory	I-protein
protein-1alpha	I-protein
.	O

Human	O
T-cell	O
lymphotropic	O
virus	O
I	O
(	O
HTLV-I	O
)	O
encodes	O
for	O
a	O
40-kDa	B-protein
protein	I-protein
,	O
Tax	B-protein
,	O
which	O
is	O
important	O
for	O
the	O
immortalization	O
of	O
T	B-cell_type
cells	I-cell_type
.	O

Tax	B-protein
has	O
been	O
shown	O
to	O
transactivate	O
several	O
cellular	B-DNA
genes	I-DNA
.	O

In	O
this	O
study	O
,	O
we	O
show	O
that	O
MIP-1alpha	B-protein
is	O
selectively	O
expressed	O
and	O
secreted	O
in	O
the	O
tax	B-cell_line
transfected	I-cell_line
Jurkat	I-cell_line
cell	I-cell_line
line	I-cell_line
upon	O
mitogen	B-protein
stimulation	O
.	O

Expression	O
of	O
MIP-1alpha-R	B-RNA
mRNA	I-RNA
in	O
these	O
cells	O
suggests	O
an	O
autocrine	O
role	O
for	O
this	O
chemokine	B-protein
in	O
HTLV-I	B-cell_type
infected	I-cell_type
T-cells	I-cell_type
.	O

Induced	O
MIP-1alpha	B-protein
expression	O
and	O
secretion	O
in	O
PMA/PHA	B-cell_line
stimulated	I-cell_line
tax	I-cell_line
transfected	I-cell_line
cells	I-cell_line
correlate	O
with	O
the	O
noninduction	O
of	O
MNP-1	B-protein
transcription	B-protein
factor	I-protein
,	O
which	O
is	O
intimately	O
involved	O
in	O
downmodulating	O
the	O
MIP-1alpha	B-DNA
gene	I-DNA
.	O

Copyright	O
1999	O
Academic	O
Press	O
.	O

Dendritic	B-cell_type
cells	I-cell_type
and	O
the	O
pathogenesis	O
of	O
rheumatoid	O
arthritis	O
.	O

Rheumatoid	O
arthritis	O
(	O
RA	O
)	O
is	O
a	O
chronic	O
autoimmune	O
inflammatory	O
disease	O
in	O
which	O
unknown	O
arthrogenic	B-protein
autoantigen	I-protein
is	O
presented	O
to	O
CD4+	B-cell_type
T	I-cell_type
cells	I-cell_type
.	O

The	O
strong	O
association	O
of	O
the	O
disease	O
with	O
an	O
epitope	B-protein
within	O
the	O
HLA-DR	B-protein
chain	I-protein
shared	O
between	O
various	O
alleles	O
of	O
HLA-DR4	B-protein
and	O
DR1	B-protein
emphasizes	O
the	O
importance	O
of	O
antigen	O
presentation	O
.	O

This	O
immune	O
response	O
predominantly	O
occurs	O
in	O
the	O
synovial	O
tissue	O
and	O
fluid	O
of	O
the	O
joints	O
and	O
autoreactive	B-cell_type
T	I-cell_type
cells	I-cell_type
are	O
readily	O
demonstrable	O
in	O
both	O
the	O
synovial	O
compartment	O
and	O
blood	O
.	O

Circulating	B-cell_type
dendritic	I-cell_type
cells	I-cell_type
(	O
DC	B-cell_type
)	O
are	O
phenotypically	O
and	O
functionally	O
identical	O
with	O
normal	B-cell_type
peripheral	I-cell_type
blood	I-cell_type
(	I-cell_type
PB	I-cell_type
)	I-cell_type
DC	I-cell_type
.	O

In	O
the	O
synovial	O
tissue	O
,	O
fully	O
differentiated	O
perivascular	B-cell_type
DC	I-cell_type
are	O
found	O
in	O
close	O
association	O
with	O
T	B-cell_type
cells	I-cell_type
and	O
with	O
B	B-cell_type
cell	I-cell_type
follicles	I-cell_type
,	O
sometimes	O
containing	O
follicular	B-cell_type
DC	I-cell_type
.	O

These	O
perivascular	B-cell_type
DC	I-cell_type
migrate	O
across	O
the	O
activated	O
endothelium	O
from	O
blood	O
and	O
receive	O
differentiative	O
signals	O
within	O
the	O
joint	O
from	O
monocyte-derived	B-protein
cytokines	I-protein
and	O
CD40-ligand+	B-cell_type
T	I-cell_type
cells	I-cell_type
.	O

In	O
the	O
SF	O
,	O
DC	B-cell_type
manifest	O
an	O
intermediate	O
phenotype	O
,	O
similar	O
to	O
that	O
of	O
monocyte-derived	B-cell_type
DC	I-cell_type
in	O
vitro	O
.	O

Like	O
a	O
delayed-type	O
hypersensitivity	O
response	O
,	O
the	O
rheumatoid	O
synovium	O
represents	O
an	O
effector	O
site	O
.	O

DC	O
at	O
many	O
effector	O
sites	O
have	O
a	O
characteristic	O
pattern	O
of	O
infiltration	O
and	O
differentiation	O
.	O

It	O
is	O
important	O
to	O
note	O
that	O
the	O
effector	O
response	O
is	O
not	O
self-limiting	O
in	O
RA	O
autoimmune	O
inflammation	O
.	O

In	O
this	O
article	O
,	O
we	O
argue	O
that	O
the	O
presentation	O
of	O
self-antigen	B-protein
by	O
DC	B-cell_type
and	O
by	O
autoantibody-producing	B-cell_type
B	I-cell_type
cells	I-cell_type
is	O
critical	O
for	O
the	O
perpetuation	O
of	O
the	O
autoimmune	O
response	O
.	O

Permanently	O
arresting	O
this	O
ongoing	O
immune	O
response	O
with	O
either	O
pharmaceutical	O
agents	O
or	O
immunotherapy	O
is	O
a	O
major	O
challenge	O
for	O
immunology	O
.	O

Thymocyte-thymic	O
epithelial	B-cell_type
cell	I-cell_type
interaction	O
leads	O
to	O
high-level	O
replication	O
of	O
human	O
immunodeficiency	O
virus	O
exclusively	O
in	O
mature	B-cell_type
CD4	I-cell_type
(	I-cell_type
+	I-cell_type
)	I-cell_type
CD8	I-cell_type
(	I-cell_type
-	I-cell_type
)	I-cell_type
CD3	I-cell_type
(	I-cell_type
+	I-cell_type
)	I-cell_type
thymocytes	I-cell_type
:	O
a	O
critical	O
role	O
for	O
tumor	B-protein
necrosis	I-protein
factor	I-protein
and	O
interleukin-7	B-protein
.	O

This	O
work	O
aims	O
at	O
identifying	O
the	O
thymocyte	O
subpopulation	O
able	O
to	O
support	O
human	O
immunodeficiency	O
virus	O
(	O
HIV	O
)	O
replication	O
under	O
the	O
biological	O
stimuli	O
of	O
the	O
thymic	O
microenvironment	O
.	O

In	O
this	O
report	O
we	O
demonstrate	O
that	O
interaction	O
with	O
thymic	B-cell_type
epithelial	I-cell_type
cells	I-cell_type
(	O
TEC	B-cell_type
)	O
induces	O
a	O
high-level	O
replication	O
of	O
the	O
T-tropic	B-protein
primary	I-protein
isolate	I-protein
HIV-1	I-protein
(	O
B-LAIp	B-protein
)	O
exclusively	O
in	O
the	O
mature	O
CD4	B-cell_type
(	I-cell_type
+	I-cell_type
)	I-cell_type
CD8	I-cell_type
(	I-cell_type
-	I-cell_type
)	I-cell_type
CD3	I-cell_type
(	I-cell_type
+	I-cell_type
)	I-cell_type
thymocytes	I-cell_type
.	O

Tumor	B-protein
necrosis	I-protein
factor	I-protein
(	O
TNF	B-protein
)	O
and	O
interleukin-7	B-protein
(	O
IL-7	B-protein
)	O
,	O
secreted	O
during	O
this	O
interaction	O
,	O
are	O
critical	O
cytokines	O
for	O
HIV	B-DNA
long	I-DNA
terminal	I-DNA
repeat	I-DNA
transactivation	O
through	O
NF-kappaB	B-protein
-dependent	O
activation	O
.	O

TNF	B-protein
is	O
the	O
major	O
inducer	O
of	O
NF-kappaB	B-protein
and	O
particularly	O
of	O
the	O
p50-p65	B-protein
complex	I-protein
,	O
whereas	O
IL-7	B-protein
acts	O
as	O
a	O
cofactor	O
by	O
sustaining	O
the	O
expression	O
of	O
the	O
p75	B-protein
TNF	I-protein
receptor	I-protein
.	O

The	O
requirement	O
for	O
TNF	B-protein
is	O
further	O
confirmed	O
by	O
the	O
observation	O
that	O
the	O
inability	O
of	O
the	O
intermediate	B-cell_type
CD4	I-cell_type
(	I-cell_type
+	I-cell_type
)	I-cell_type
CD8	I-cell_type
(	I-cell_type
-	I-cell_type
)	I-cell_type
CD3	I-cell_type
(	I-cell_type
-	I-cell_type
)	I-cell_type
thymocytes	I-cell_type
to	O
replicate	O
the	O
virus	O
is	O
associated	O
with	O
a	O
defect	O
in	O
TNF	B-protein
production	O
during	O
their	O
interaction	O
with	O
TEC	B-cell_type
and	O
correlates	O
with	O
the	O
absence	O
of	O
nuclear	O
NF-kappaB	B-protein
activity	O
in	O
these	O
freshly	B-cell_type
isolated	I-cell_type
thymocytes	I-cell_type
.	O

Addition	O
of	O
exogenous	O
TNF	B-protein
to	O
the	O
intermediate	B-cell_line
thymocyte	I-cell_line
cultures	I-cell_line
induces	O
NF-kappaB	B-protein
activity	O
and	O
is	O
sufficient	O
to	O
promote	O
HIV	O
replication	O
in	O
the	O
cocultures	O
with	O
TEC	B-cell_type
.	O

The	O
other	O
major	O
subpopulation	O
expressing	O
the	O
CD4	B-protein
receptor	I-protein
,	O
namely	O
,	O
the	O
double-positive	B-cell_type
(	I-cell_type
DP	I-cell_type
)	I-cell_type
CD4	I-cell_type
(	I-cell_type
+	I-cell_type
)	I-cell_type
CD8	I-cell_type
(	I-cell_type
+	I-cell_type
)	I-cell_type
CD3	I-cell_type
(	I-cell_type
+/-	I-cell_type
)	I-cell_type
thymocytes	I-cell_type
,	O
despite	O
the	O
entry	O
of	O
the	O
virus	O
,	O
do	O
not	O
produce	O
a	O
significant	O
level	O
of	O
virus	O
,	O
presumably	O
because	O
they	O
are	O
unresponsive	O
to	O
TNF	B-protein
and	O
IL-7	B-protein
.	O

Together	O
,	O
these	O
data	O
suggest	O
that	O
in	O
vivo	O
,	O
despite	O
an	O
efficient	O
entry	O
of	O
the	O
virus	O
in	O
all	O
the	O
CD4	B-cell_type
(	I-cell_type
+	I-cell_type
)	I-cell_type
subpopulations	I-cell_type
,	O
a	O
high	O
viral	O
load	O
may	O
be	O
generated	O
exclusively	O
within	O
the	O
mature	B-cell_type
CD4	I-cell_type
(	I-cell_type
+	I-cell_type
)	I-cell_type
CD8	I-cell_type
(	I-cell_type
-	I-cell_type
)	I-cell_type
CD3	I-cell_type
(	I-cell_type
+	I-cell_type
)	I-cell_type
subset	I-cell_type
of	I-cell_type
thymocytes	I-cell_type
.	O

However	O
,	O
under	O
conditions	O
of	O
inflammatory	O
response	O
after	O
infection	O
,	O
TNF	B-protein
might	O
also	O
be	O
present	O
in	O
the	O
intermediate	B-cell_type
thymocyte	I-cell_type
compartment	I-cell_type
,	O
leading	O
to	O
efficient	O
HIV	O
replication	O
in	O
these	O
cells	O
.	O

NF-kappaB-mediated	B-cell_type
up-regulation	I-cell_type
of	O
Bcl-x	B-protein
and	O
Bfl-1/A1	B-protein
is	O
required	O
for	O
CD40	B-protein
survival	O
signaling	O
in	O
B	B-cell_type
lymphocytes	I-cell_type
.	O

Activation	O
of	O
CD40	B-protein
is	O
essential	O
for	O
thymus-dependent	O
humoral	O
immune	O
responses	O
and	O
rescuing	O
B	B-cell_type
cells	I-cell_type
from	O
apoptosis	O
.	O

Many	O
of	O
the	O
effects	O
of	O
CD40	B-protein
are	O
believed	O
to	O
be	O
achieved	O
through	O
altered	O
gene	O
expression	O
.	O

In	O
addition	O
to	O
Bcl-x	B-protein
,	O
a	O
known	O
CD40-regulated	B-protein
antiapoptotic	I-protein
molecule	I-protein
,	O
we	O
identified	O
a	O
related	O
antiapoptotic	B-protein
molecule	I-protein
,	O
A1/Bfl-1	B-protein
,	O
as	O
a	O
CD40-inducible	B-DNA
gene	I-DNA
.	O

Inhibition	O
of	O
the	O
NF-kappaB	B-protein
pathway	O
by	O
overexpression	O
of	O
a	O
dominant-active	O
inhibitor	O
of	O
NF-kappaB	B-protein
abolished	O
CD40	B-protein
-induced	O
up-regulation	O
of	O
both	O
the	O
Bfl-1	B-protein
and	O
Bcl-x	B-protein
genes	O
and	O
also	O
eliminated	O
the	O
ability	O
of	O
CD40	B-protein
to	O
rescue	O
Fas	B-protein
-induced	O
cell	O
death	O
.	O

Within	O
the	O
upstream	B-DNA
promoter	I-DNA
region	I-DNA
of	O
Bcl-x	B-protein
,	O
a	O
potential	O
NF-kappaB-binding	B-DNA
sequence	I-DNA
was	O
found	O
to	O
support	O
NF-kappaB	B-protein
-dependent	O
transcriptional	O
activation	O
.	O

Furthermore	O
,	O
expression	O
of	O
physiological	O
levels	O
of	O
Bcl-x	B-cell_type
protected	I-cell_type
B	I-cell_type
cells	I-cell_type
from	O
Fas-mediated	O
apoptosis	O
in	O
the	O
absence	O
of	O
NF-kappaB	B-protein
signaling	O
.	O

Thus	O
,	O
our	O
results	O
suggest	O
that	O
CD40	B-protein
-mediated	O
cell	O
survival	O
proceeds	O
through	O
NF-kappaB	B-protein
-dependent	O
up-regulation	O
of	O
Bcl-2	B-protein
family	I-protein
members	I-protein
.	O

Stimulation	O
of	O
neutrophil	B-cell_type
interleukin-8	B-protein
production	O
by	O
eosinophil	B-protein
granule	I-protein
major	I-protein
basic	I-protein
protein	I-protein
.	O

We	O
evaluated	O
the	O
ability	O
of	O
eosinophil	B-protein
granule	I-protein
major	I-protein
basic	I-protein
protein	I-protein
(	O
MBP	B-protein
)	O
to	O
stimulate	O
interleukin	B-protein
(	I-protein
IL	I-protein
)	I-protein
-8	I-protein
production	O
by	O
neutrophils	B-cell_type
.	O

MBP	B-protein
over	O
the	O
concentration	O
range	O
of	O
0.1	O
to	O
10	O
microM	O
stimulated	O
the	O
release	O
of	O
up	O
to	O
approximately	O
8	O
ng/ml	O
IL-8	B-protein
.	O

Incubation	O
with	O
2	O
microM	O
MBP	B-protein
showed	O
that	O
,	O
after	O
a	O
1	O
h	O
lag	O
,	O
the	O
level	O
of	O
IL-8	B-protein
release	O
increased	O
with	O
time	O
for	O
approximately	O
10	O
h	O
.	O

At	O
the	O
2	O
microM	O
concentration	O
,	O
eosinophil	B-protein
cationic	I-protein
protein	I-protein
,	O
eosinophil-derived	O
neurotoxin	O
,	O
and	O
eosinophil	B-protein
peroxidase	I-protein
did	O
not	O
stimulate	O
significant	O
levels	O
of	O
IL-8	B-protein
production	O
.	O

MBP	B-protein
stimulated	O
2-fold	O
increases	O
in	O
IL-8	B-RNA
messenger	I-RNA
RNA	I-RNA
(	O
mRNA	B-RNA
)	O
after	O
1	O
and	O
3	O
h	O
of	O
incubation	O
,	O
which	O
were	O
blocked	O
by	O
pretreatment	O
with	O
actinomycin	O
D	O
.	O

However	O
,	O
stimulation	O
with	O
MBP	B-protein
did	O
not	O
produce	O
an	O
increase	O
in	O
the	O
binding	O
activity	O
of	O
nuclear	B-protein
factor	I-protein
(	I-protein
NF	I-protein
)	I-protein
-kappaB	I-protein
or	O
activator	B-protein
protein-1	I-protein
.	O

No	O
NF-IL-6	B-protein
binding	O
activity	O
was	O
detected	O
in	O
the	O
same	O
nuclear	O
extracts	O
.	O

In	O
addition	O
,	O
stimulation	O
with	O
MBP	B-protein
prolonged	O
the	O
stability	O
of	O
IL-8	B-RNA
mRNA	I-RNA
.	O

MBP	B-protein
also	O
induced	O
transient	O
increases	O
in	O
mRNA	B-RNA
for	O
macrophage	B-protein
inflammatory	I-protein
protein	I-protein
(	I-protein
MIP	I-protein
)	I-protein
-1alpha	I-protein
and	O
MIP-1beta	B-protein
,	O
but	O
did	O
not	O
stimulate	O
the	O
release	O
of	O
either	O
chemokine	B-protein
.	O

These	O
findings	O
indicate	O
that	O
MBP	B-protein
is	O
selective	O
among	O
the	O
eosinophil	B-protein
granule	I-protein
proteins	I-protein
as	O
a	O
stimulus	O
for	O
neutrophil	B-cell_type
IL-8	B-protein
release	O
and	O
,	O
further	O
,	O
that	O
stimulation	O
of	O
neutrophil	B-cell_type
IL-8	B-protein
release	O
by	O
MBP	B-protein
involves	O
both	O
transcriptional	O
and	O
posttranscriptional	O
regulation	O
.	O

We	O
postulate	O
that	O
MBP	B-protein
-induced	O
release	O
of	O
IL-8	B-protein
by	O
neutrophils	B-cell_type
may	O
contribute	O
to	O
the	O
pathophysiology	O
of	O
acute	O
asthma	O
and	O
other	O
inflammatory	O
lung	O
diseases	O
.	O

Expression	O
of	O
either	O
the	O
TCL1	B-DNA
oncogene	I-DNA
,	O
or	O
transcripts	O
from	O
its	O
homologue	O
MTCP1/c6.1B	B-DNA
,	O
in	O
leukaemic	O
and	O
non-leukaemic	B-cell_type
T	I-cell_type
cells	I-cell_type
from	O
ataxia	O
telangiectasia	O
patients	O
.	O

Patients	O
with	O
the	O
recessively	O
inherited	O
disorder	O
ataxia	O
telangiectasia	O
(	O
A-T	O
)	O
have	O
a	O
high	O
level	O
of	O
specific	O
chromosome	B-DNA
translocations	I-DNA
which	O
can	O
be	O
easily	O
observed	O
in	O
peripheral	B-cell_type
T	I-cell_type
cells	I-cell_type
and	O
show	O
a	O
greatly	O
increased	O
predisposition	O
to	O
leukaemia/lymphoma	O
,	O
mainly	O
of	O
T	B-cell_type
cell	I-cell_type
origin	O
.	O

Some	O
translocation	B-cell_type
cells	I-cell_type
proliferate	O
into	O
a	O
large	O
clone	O
and	O
may	O
develop	O
into	O
T	O
cell	O
prolymphocytic	O
leukaemia	O
(	O
T-PLL	O
)	O
.	O

By	O
the	O
time	O
of	O
diagnosis	O
of	O
T-PLL	O
,	O
the	O
clone	O
contains	O
many	O
more	O
genetic	O
changes	O
in	O
the	O
form	O
of	O
additional	O
translocations	O
.	O

T-PLL	O
is	O
also	O
seen	O
in	O
non-A-T	O
individuals	O
where	O
expression	O
of	O
either	O
TCL1	B-protein
(	O
at	O
14q32	B-DNA
)	O
or	O
the	O
c6.1B/MTCP1	B-protein
A1	I-protein
transcript	I-protein
(	O
at-Xq28	B-DNA
)	O
has	O
been	O
demonstrated	O
in	O
just	O
a	O
few	O
instances	O
.	O

We	O
show	O
here	O
,	O
that	O
expression	O
of	O
TCL1	B-protein
occurs	O
in	O
leukaemic	B-cell_type
T	I-cell_type
cells	I-cell_type
from	O
A-T	O
patients	O
with	O
chromosome	B-DNA
14	I-DNA
rearrangements	O
.	O

Expression	O
of	O
TCL1	B-protein
also	O
occurs	O
in	O
the	O
preleukaemic	B-cell_type
clone	I-cell_type
cells	I-cell_type
of	O
A-T	O
patients	O
containing	O
the	O
primary	O
translocation	O
alone	O
.	O

Some	O
expression	O
of	O
TCL1	B-protein
could	O
also	O
be	O
detected	O
in	O
randomly	O
selected	O
A-T	O
patients	O
without	O
large	O
cytogenetic	O
clones	O
and	O
without	O
any	O
evidence	O
of	O
leukaemic	O
change	O
.	O

We	O
also	O
show	O
that	O
expression	O
of	O
the	O
B1	B-RNA
transcript	I-RNA
from	O
a	O
second	O
gene	O
,	O
MTCP1	B-DNA
,	O
occurred	O
at	O
a	O
relatively	O
high	O
level	O
only	O
in	O
two	O
T-PLL	O
tumours	O
from	O
A-T	O
patients	O
with	O
t	O
(	O
X	O
;	O
14	O
)	O
translocations	O
whereas	O
the	O
MTCP1/A1	B-RNA
transcript	I-RNA
is	O
much	O
more	O
widely	O
expressed	O
in	O
both	O
tumour	B-cell_type
and	I-cell_type
non	I-cell_type
tumour	I-cell_type
cells	I-cell_type
of	O
A-T	O
and	O
non-A-T	O
individuals	O
.	O

[	O
Correlation	O
of	O
lymphocytic	O
infiltration	O
of	O
tumor	O
tissue	O
with	O
the	O
hormonal	O
and	O
metabolic	O
state	O
in	O
patients	O
with	O
breast	O
cancer	O
]	O

Lymphocyte	O
infiltration	O
of	O
tumor	O
was	O
studied	O
vis-a-vis	O
hormone	O
metabolic	O
status	O
,	O
tumor	O
tissue	O
hormone	O
sensitivity	O
and	O
tobacco	O
smoking	O
,	O
in	O
113	O
breast	O
cancer	O
patients	O
,	O
aged	O
25-77	O
.	O

On	O
the	O
average	O
,	O
no	O
correlation	O
was	O
established	O
between	O
degree	O
of	O
lymphocyte	O
infiltration	O
in	O
breast	O
tumor	O
and	O
age	O
and	O
menopause	O
onset	O
.	O

In	O
smoking	O
menopausal	O
patients	O
,	O
lymphocyte	O
infiltration	O
was	O
found	O
to	O
be	O
higher	O
than	O
in	O
non-smokers	O
(	O
p	O
<	O
0.05	O
)	O
.	O

There	O
was	O
a	O
direct	O
correlation	O
between	O
the	O
rate	O
of	O
lymphocyte	O
infiltration	O
and	O
the	O
level	O
of	O
progesterone	B-protein
receptors	I-protein
in	O
tumor	O
.	O

Some	O
subgroups	O
displayed	O
a	O
direct	O
correlation	O
between	O
infiltration	O
and	O
sex-binding	B-protein
globulin	I-protein
,	O
cholesterol	O
,	O
luteinizing	O
hormone	O
in	O
blood	O
,	O
and	O
lean	O
body	O
mass	O
.	O

It	O
was	O
matched	O
by	O
an	O
inverse	O
correlation	O
between	O
lymphocyte	O
infiltration	O
and	O
blood-thyroid	O
hormone	O
concentration	O
,	O
urine	O
catecholamines	O
and	O
free	O
cortisol	O
excretion	O
and	O
fat/lean	O
body	O
mass	O
ratio	O
.	O

Considering	O
the	O
abovesaid	O
as	O
well	O
as	O
the	O
lymphocyte	O
ability	O
to	O
perform	O
the	O
dual	O
function	O
of	O
immunocytes	B-cell_type
and	O
hormonocytes	B-cell_type
,	O
it	O
is	O
suggested	O
that	O
the	O
results	O
may	O
be	O
used	O
in	O
both	O
the	O
study	O
of	O
lymphocyte	O
infiltration	O
and	O
research	O
in	O
means	O
of	O
its	O
control	O
.	O

Gene	O
transcription	O
through	O
activation	O
of	O
G-protein-coupled	B-protein
chemoattractant	I-protein
receptors	I-protein
.	O

Receptors	O
for	O
leukocyte	B-protein
chemoattractants	I-protein
,	O
including	O
chemokines	B-protein
,	O
are	O
traditionally	O
considered	O
to	O
be	O
responsible	O
for	O
the	O
activation	O
of	O
special	O
leukocyte	O
functions	O
such	O
as	O
chemotaxis	O
,	O
degranulation	O
,	O
and	O
the	O
release	O
of	O
superoxide	O
anions	O
.	O

Recently	O
,	O
these	O
G-protein-coupled	B-protein
serpentine	I-protein
receptors	I-protein
have	O
been	O
found	O
to	O
transduce	O
signals	O
leading	O
to	O
gene	O
transcription	O
and	O
translation	O
in	O
leukocytes	B-cell_type
.	O

Transcription	B-protein
factors	I-protein
,	O
such	O
as	O
NF	B-protein
kappa	I-protein
B	I-protein
and	O
AP-1	B-protein
,	O
are	O
activated	O
upon	O
stimulation	O
of	O
the	O
cells	O
with	O
several	O
chemoattractants	O
at	O
physiologically	O
relevant	O
concentrations	O
.	O

Activation	O
of	O
transcription	O
factors	O
through	O
these	O
receptors	O
involves	O
G-protein	B-protein
coupling	O
and	O
the	O
activation	O
of	O
protein	B-protein
kinases	I-protein
.	O

The	O
underlying	O
signaling	O
pathways	O
appear	O
to	O
be	O
different	O
from	O
those	O
utilized	O
by	O
TNF-alpha	B-protein
,	O
a	O
better	O
characterized	O
cytokine	O
that	O
induces	O
the	O
transcription	O
of	O
immediate-early	B-DNA
genes	I-DNA
.	O

Chemoattractants	O
stimulate	O
the	O
expression	O
of	O
several	O
inflammatory	B-protein
cytokines	I-protein
and	O
chemokines	B-protein
,	O
which	O
in	O
turn	O
may	O
activate	O
their	O
respective	O
receptors	O
and	O
initiate	O
an	O
autocrine	O
regulatory	O
mechanism	O
for	O
persistent	O
cytokine	B-protein
and	O
chemokine	B-protein
gene	O
expression	O
.	O

Affinity-driven	O
peptide	O
selection	O
of	O
an	O
NFAT	O
inhibitor	O
more	O
selective	O
than	O
cyclosporin	O
A	O
[	O
see	O
comments	O
]	O

The	O
flow	O
of	O
information	O
from	O
calcium-mobilizing	B-protein
receptors	I-protein
to	O
nuclear	B-DNA
factor	I-DNA
of	I-DNA
activated	I-DNA
T	I-DNA
cells	I-DNA
(	I-DNA
NFAT	I-DNA
)	I-DNA
-dependent	I-DNA
genes	I-DNA
is	O
critically	O
dependent	O
on	O
interaction	O
between	O
the	O
phosphatase	B-protein
calcineurin	B-protein
and	O
the	O
transcription	B-protein
factor	I-protein
NFAT	B-protein
.	O

A	O
high-affinity	O
calcineurin	B-protein
-binding	O
peptide	O
was	O
selected	O
from	O
combinatorial	O
peptide	O
libraries	O
based	O
on	O
the	O
calcineurin	B-protein
docking	I-protein
motif	I-protein
of	O
NFAT	B-protein
.	O

This	O
peptide	O
potently	O
inhibited	O
NFAT	B-protein
activation	O
and	O
NFAT	B-protein
-dependent	O
expression	O
of	O
endogenous	B-DNA
cytokine	I-DNA
genes	I-DNA
in	O
T	B-cell_type
cells	I-cell_type
,	O
without	O
affecting	O
the	O
expression	O
of	O
other	O
cytokines	B-protein
that	O
require	O
calcineurin	B-protein
but	O
not	O
NFAT	B-protein
.	O

Substitution	O
of	O
the	O
optimized	O
peptide	O
sequence	O
into	O
the	O
natural	O
calcineurin	B-protein
docking	I-protein
site	I-protein
increased	O
the	O
calcineurin	B-protein
responsiveness	O
of	O
NFAT	B-protein
.	O

Compounds	O
that	O
interfere	O
selectively	O
with	O
the	O
calcineurin	B-protein
-NFAT	B-protein
interaction	O
without	O
affecting	O
calcineurin	B-protein
phosphatase	B-protein
activity	O
may	O
be	O
useful	O
as	O
therapeutic	O
agents	O
that	O
are	O
less	O
toxic	O
than	O
current	O
drugs	O
.	O

9-cis	O
retinoic	O
acid	O
induces	O
monocyte	B-protein
chemoattractant	I-protein
protein-1	I-protein
secretion	O
in	O
human	B-cell_type
monocytic	I-cell_type
THP-1	I-cell_type
cells	I-cell_type
.	O

Monocyte	O
migration	O
and	O
activation	O
are	O
regulated	O
by	O
monocyte	B-protein
chemoattractant	I-protein
protein-1	I-protein
(	O
MCP-1	B-protein
)	O
.	O

Prior	O
studies	O
have	O
shown	O
MCP-1	B-protein
expression	O
is	O
modulated	O
by	O
a	O
variety	O
of	O
ligands	O
that	O
act	O
through	O
extracellular	B-protein
receptors	I-protein
.	O

In	O
the	O
current	O
study	O
,	O
we	O
show	O
9-cis	O
retinoic	O
acid	O
(	O
RA	O
)	O
,	O
a	O
ligand	O
for	O
the	O
nuclear	B-protein
hormone	I-protein
receptor	I-protein
retinoid	I-protein
X	I-protein
receptor	I-protein
(	O
RXR	B-protein
)	O
and	O
retinoic	B-protein
acid	I-protein
receptor	I-protein
(	O
RAR	B-protein
)	O
,	O
markedly	O
induces	O
the	O
expression	O
of	O
MCP-1	B-protein
.	O

In	O
human	B-cell_line
THP-1	I-cell_line
monocytic	I-cell_line
leukemia	I-cell_line
cells	I-cell_line
cultured	O
with	O
RA	O
(	O
0.05	O
to	O
500	O
nmol/L	O
)	O
,	O
MCP-1	B-protein
expression	O
was	O
induced	O
rapidly	O
,	O
significantly	O
,	O
and	O
dose-dependently	O
by	O
as	O
much	O
as	O
165-fold	O
.	O

MCP-1	B-RNA
RNA	I-RNA
level	O
was	O
also	O
increased	O
in	O
RA-treated	O
cells	O
.	O

Expression	O
of	O
PPARgamma	B-protein
,	O
a	O
heterodimer	O
partner	O
of	O
RXR	B-protein
,	O
is	O
also	O
markedly	O
induced	O
by	O
RA	O
in	O
THP-1	B-cell_type
cells	I-cell_type
.	O

However	O
,	O
BRL49653	O
,	O
a	O
PPARgamma	B-protein
ligand	O
,	O
failed	O
to	O
induce	O
MCP-1	B-protein
secretion	O
either	O
alone	O
or	O
to	O
modify	O
the	O
expression	O
level	O
induced	O
by	O
RA	O
.	O

In	O
contrast	O
,	O
BRL49653	O
significantly	O
increased	O
MCP-1	B-protein
(	O
biotinylated	B-protein
MCP-1	I-protein
)	O
binding	O
to	O
THP-1	B-cell_type
cells	I-cell_type
,	O
whereas	O
RA	O
had	O
no	O
effect	O
.	O

Other	O
peroxisome	B-protein
proliferator	I-protein
activated	I-protein
receptor	I-protein
(	O
PPAR	B-protein
)	O
ligands	O
,	O
15d-PGJ	O
(	O
2	O
)	O
and	O
troglitazone	O
(	O
PPARgamma	B-protein
)	O
,	O
Wy14	O
,	O
643	O
(	O
PPARalpha	B-protein
)	O
,	O
and	O
PD195599	O
(	O
PPARbeta	B-protein
)	O
inhibited	O
the	O
induction	O
of	O
MCP-1	B-protein
by	O
RA	O
.	O

RA	O
's	O
effect	O
on	O
MCP-1	B-protein
expression	O
in	O
human	O
elutriated	O
monocytes	O
were	O
similar	O
to	O
that	O
observed	O
in	O
the	O
THP-1	B-cell_line
cells	I-cell_line
.	O

These	O
studies	O
identify	O
RA	O
as	O
a	O
nuclear	O
signal	O
for	O
MCP-1	B-protein
induction	O
in	O
undifferentiated	B-cell_type
human	I-cell_type
monocytic	I-cell_type
cells	I-cell_type
.	O

These	O
studies	O
also	O
suggest	O
monocyte	O
MCP-1	B-protein
expression	O
induced	O
through	O
RA	O
may	O
modulate	O
cell	O
migration	O
.	O

Classification	O
of	O
IVS1-10T	O
--	O
>	O
C	O
as	O
a	O
polymorphism	O
of	O
BRCA1	B-DNA
.	O

Mutations	O
inactivating	O
the	O
tumor	B-DNA
suppressor	I-DNA
gene	I-DNA
BRCA1	B-DNA
may	O
be	O
responsible	O
for	O
disease	O
for	O
up	O
to	O
80	O
%	O
of	O
familial	O
ovarian	O
cancer	O
cases	O
.	O

In	O
this	O
syndrome	O
,	O
tumorigenesis	O
classically	O
initiates	O
from	O
an	O
inherited	O
mutation	O
in	O
one	O
allele	B-DNA
followed	O
by	O
somatic	O
deletion	O
of	O
the	O
normal	B-DNA
allele	I-DNA
.	O

Sequencing	O
of	O
BRCA1	B-DNA
amplified	O
from	O
genomic	B-DNA
DNA	I-DNA
of	O
lymphocytes	B-cell_type
and	O
microdissected	B-cell_type
ovarian	I-cell_type
tumor	I-cell_type
cells	I-cell_type
of	O
a	O
familial	O
ovarian	O
cancer	O
patient	O
revealed	O
three	O
,	O
rare	O
heterozygous	O
DNA	O
variations	O
(	O
2418delA	O
,	O
233G	O
--	O
>	O
A	O
,	O
and	O
IVS1-10T	O
--	O
>	O
C	O
)	O
in	O
both	O
tumor	B-DNA
and	I-DNA
constitutional	I-DNA
(	I-DNA
lymphocyte	I-DNA
)	I-DNA
DNA	I-DNA
.	O

Thus	O
,	O
both	O
copies	O
of	O
BRCA1	B-DNA
were	O
retained	O
in	O
tumor	O
.	O

Haplotype	O
analysis	O
of	O
the	O
patient	O
and	O
four	O
siblings	O
assigned	O
2418delA	O
to	O
one	O
copy	O
of	O
BRCA1	B-DNA
and	O
233G	O
--	O
>	O
A	O
and	O
IVS1-10T	O
--	O
>	O
C	O
to	O
the	O
other	O
.	O

The	O
DNA	O
change	O
,	O
2418delA	O
,	O
is	O
considered	O
a	O
mutation	O
that	O
inactivated	O
one	O
BRCA1	B-DNA
allele	O
because	O
it	O
caused	O
a	O
frameshift	O
and	O
generation	O
of	O
a	O
premature	B-DNA
stop	I-DNA
codon	I-DNA
,	O
resulting	O
in	O
synthesis	O
of	O
a	O
truncated	O
peptide	O
as	O
evidenced	O
by	O
an	O
in	O
vitro	O
protein	O
truncation	O
test	O
.	O

The	O
DNA	O
variation	O
,	O
233G	O
--	O
>	O
A	O
,	O
does	O
not	O
result	O
in	O
an	O
amino	O
acid	O
change	O
,	O
and	O
is	O
considered	O
a	O
benign	O
polymorphism	O
.	O

IVS1-10T	O
--	O
>	O
C	O
is	O
a	O
unique	O
BRCA1	B-DNA
change	O
that	O
occurs	O
in	O
the	O
last	O
nucleotide	O
of	O
a	O
consensus	B-DNA
sequence	I-DNA
for	O
a	O
branch	B-DNA
site	I-DNA
critical	O
for	O
RNA	O
splicing	O
.	O

Therefore	O
,	O
we	O
investigated	O
whether	O
IVS1-10T	O
--	O
>	O
C	O
deleteriously	O
affected	O
BRCA1	B-DNA
splicing	O
or	O
expression	O
,	O
and	O
thereby	O
inactivated	O
the	O
other	O
BRCA1	B-DNA
allele	I-DNA
.	O

Using	O
the	O
technique	O
of	O
reverse	O
transcription-polymerase	O
chain	O
reaction	O
(	O
PCR	O
)	O
with	O
RNA	O
isolated	O
from	O
lymphoid	B-cell_line
cell	I-cell_line
lines	I-cell_line
of	O
the	O
patient	O
and	O
of	O
controls	O
,	O
no	O
evidence	O
was	O
found	O
that	O
IVS1-10TC	O
abnormally	O
disrupted	O
mRNA	B-RNA
splicing	O
or	O
caused	O
the	O
absence	O
of	O
BRCA1	B-RNA
mRNA	I-RNA
.	O

Thus	O
,	O
IVS1-10T	O
--	O
>	O
C	O
is	O
not	O
harmful	O
to	O
BRCA1	B-DNA
function	O
,	O
and	O
is	O
classified	O
a	O
benign	O
polymorphism	O
.	O

Retention	O
of	O
the	O
normal	O
BRCA1	B-DNA
allele	I-DNA
in	O
the	O
tumor	O
with	O
the	O
heterozygous	O
germline	O
BRCA1	B-DNA
mutation	O
,	O
2418delA	O
,	O
indicated	O
that	O
mutational	O
inactivation	O
of	O
both	O
BRCA1	B-DNA
alleles	I-DNA
was	O
not	O
required	O
for	O
tumorigenesis	O
.	O

It	O
is	O
possible	O
that	O
the	O
normal	B-DNA
allele	I-DNA
may	O
be	O
functionally	O
inactivated	O
by	O
a	O
nonmutational	O
mechanism	O
.	O

Myb-transformed	B-cell_type
hematopoietic	I-cell_type
cells	I-cell_type
as	O
a	O
model	O
for	O
monocyte	O
differentiation	O
into	O
dendritic	B-cell_type
cells	I-cell_type
and	O
macrophages	B-cell_type
.	O

Immune	O
induction	O
is	O
effected	O
through	O
the	O
interaction	O
of	O
antigen-presenting	B-cell_type
cells	I-cell_type
with	O
specific	O
receptors	B-protein
on	O
the	O
surface	O
of	O
thymus-derived	B-cell_type
lymphocytes	I-cell_type
.	O

Cells	O
most	O
able	O
to	O
ingest	O
,	O
process	O
,	O
and	O
present	O
antigen	O
appear	O
to	O
be	O
related	O
to	O
the	O
mononuclear	B-cell_type
phagocyte/neutrophil	I-cell_type
series	I-cell_type
.	O

For	O
example	O
dendritic	B-cell_type
cells	I-cell_type
(	O
DC	B-cell_type
)	O
can	O
be	O
found	O
in	O
colonies	O
of	O
GM-CSF-responsive	B-cell_type
bone	I-cell_type
marrow	I-cell_type
cells	I-cell_type
,	O
and	O
under	O
experimental	O
conditions	O
are	O
routinely	O
expanded	O
as	O
a	O
population	O
in	O
vitro	O
from	O
GM-CSF-responsive	B-cell_type
progenitor	I-cell_type
cells	I-cell_type
.	O

To	O
address	O
the	O
question	O
of	O
DC	B-cell_type
lineage	I-cell_type
and	O
to	O
determine	O
what	O
genes	O
are	O
involved	O
in	O
lineage	O
commitment	O
,	O
we	O
have	O
generated	O
a	O
series	O
of	O
GM-CSF-responsive	B-cell_line
cell	I-cell_line
lines	I-cell_line
that	O
can	O
be	O
induced	O
to	O
differentiate	O
in	O
a	O
homogeneous	O
manner	O
in	O
vitro	O
.	O

The	O
cloned	B-cell_line
cell	I-cell_line
lines	I-cell_line
are	O
derived	O
from	O
12-day	O
fetal	O
liver	O
and	O
are	O
transformed	O
with	O
a	O
truncated	O
form	O
of	O
c-myb	B-DNA
,	O
which	O
lacks	O
the	O
normal	O
autoregulatory	B-DNA
sequences	I-DNA
.	O

As	O
far	O
as	O
we	O
know	O
,	O
these	O
myb-transformed	B-cell_line
hemopoi-etic	I-cell_line
cells	I-cell_line
(	O
MTHC	B-cell_line
)	O
differ	O
from	O
normal	O
only	O
in	O
the	O
unregulated	O
expression	O
of	O
myb	O
,	O
a	O
gene	O
whose	O
expression	O
is	O
obligatory	O
for	O
proliferation	O
of	O
hemopoietic	O
cells	O
.	O

MTHC	B-cell_line
in	O
the	O
presence	O
of	O
TNF-alpha	B-protein
and	O
IL-4	B-protein
will	O
differentiate	O
into	O
cells	O
that	O
have	O
many	O
of	O
the	O
properties	O
of	O
macrophages	B-cell_type
.	O

When	O
the	O
same	O
MTHC	B-cell_line
lines	I-cell_line
are	O
exposed	O
to	O
TNF-alpha	B-protein
in	O
combination	O
with	O
IFN-gamma	B-protein
,	O
the	O
cells	O
instead	O
become	O
DC	B-cell_type
.	O

The	O
differentiated	O
DC	B-cell_type
are	O
potent	O
presenters	O
of	O
antigen	O
in	O
mixed	O
lymphocyte	O
reactions	O
and	O
of	O
soluble	O
antigen	O
to	O
specific	O
T	B-cell_line
cell	I-cell_line
lines	I-cell_line
.	O

Thus	O
,	O
cells	O
with	O
the	O
properties	O
of	O
both	O
macrophages	B-cell_type
and	O
DC	B-cell_type
can	O
be	O
derived	O
from	O
a	O
single	O
type	O
of	O
GM-CSF-responsive	B-cell_type
progenitor	I-cell_type
cell	I-cell_type
.	O

We	O
have	O
used	O
this	O
MTHC	B-cell_line
system	I-cell_line
to	O
analyze	O
differences	O
in	O
gene	O
expression	O
as	O
the	O
cells	O
mature	O
along	O
the	O
DC	B-cell_type
and	O
macrophage	B-cell_type
pathways	I-cell_type
.	O

A	O
distinctive	O
pattern	O
of	O
differentially	O
expressed	O
cDNAs	B-DNA
is	O
evident	O
where	O
macrophage-specific	B-DNA
cDNAs	I-DNA
are	O
homologous	O
to	O
genes	O
encoding	O
cytoskeletal	B-protein
and	I-protein
cell-surface	I-protein
proteins	I-protein
,	O
whereas	O
the	O
DC	B-cell_type
-specific	O
cDNAs	B-DNA
are	O
homologous	O
to	O
signaling	B-DNA
,	I-DNA
chemokine	I-DNA
,	I-DNA
and	I-DNA
IFN-gamma-inducible	I-DNA
genes	I-DNA
.	O

We	O
discuss	O
the	O
utility	O
of	O
MTHC	B-cell_line
in	O
analyzing	O
the	O
relationships	O
between	O
DC	B-cell_type
and	O
macrophages	B-cell_type
,	O
and	O
suggest	O
that	O
DC	B-cell_type
and	O
macrophages	B-cell_type
represent	O
extreme	O
phenotypes	O
in	O
a	O
spectrum	O
of	O
antigen	B-cell_type
handling	I-cell_type
cells	I-cell_type
that	O
are	O
somewhat	O
interchangeable	O
,	O
depending	O
on	O
their	O
immediate	O
environment	O
.	O

The	O
Legionella	O
pneumophila	O
rpoS	B-DNA
gene	I-DNA
is	O
required	O
for	O
growth	O
within	O
Acanthamoeba	O
castellanii	O
.	O

To	O
investigate	O
regulatory	O
networks	O
in	O
Legionella	O
pneumophila	O
,	O
the	O
gene	O
encoding	O
the	O
homolog	O
of	O
the	O
Escherichia	B-protein
coli	I-protein
stress	I-protein
and	I-protein
stationary-phase	I-protein
sigma	I-protein
factor	I-protein
RpoS	B-protein
was	O
identified	O
by	O
complementation	O
of	O
an	O
E.	O
coli	O
rpoS	B-DNA
mutation	O
.	O

An	O
open	B-DNA
reading	I-DNA
frame	I-DNA
that	O
is	O
approximately	O
60	O
%	O
identical	O
to	O
the	O
E.	B-DNA
coli	I-DNA
rpoS	I-DNA
gene	I-DNA
was	O
identified	O
.	O

Western	O
blot	O
analysis	O
showed	O
that	O
the	O
level	O
of	O
L.	O
pneumophila	O
RpoS	B-protein
increased	O
in	O
stationary	O
phase	O
.	O

An	O
insertion	O
mutation	O
was	O
constructed	O
in	O
the	O
rpoS	B-DNA
gene	I-DNA
on	O
the	O
chromosome	O
of	O
L.	O
pneumophila	O
,	O
and	O
the	O
ability	O
of	O
this	O
mutant	O
strain	O
to	O
survive	O
various	O
stress	O
conditions	O
was	O
assayed	O
and	O
compared	O
with	O
results	O
for	O
the	O
wild-type	O
strain	O
.	O

Both	O
the	O
mutant	O
and	O
wild-type	O
strains	O
were	O
more	O
resistant	O
to	O
stress	O
when	O
in	O
stationary	O
phase	O
than	O
when	O
in	O
the	O
logarithmic	O
phase	O
of	O
growth	O
.	O

This	O
finding	O
indicates	O
that	O
L.	O
pneumophila	O
RpoS	B-protein
is	O
not	O
required	O
for	O
a	O
stationary-phase-dependent	O
resistance	O
to	O
stress	O
.	O

Although	O
the	O
mutant	O
strain	O
was	O
able	O
to	O
kill	O
HL-60-	B-cell_type
and	I-cell_type
THP-1-derived	I-cell_type
macrophages	I-cell_type
,	O
it	O
could	O
not	O
replicate	O
within	O
a	O
protozoan	O
host	O
,	O
Acanthamoeba	O
castellanii	O
.	O

These	O
data	O
suggest	O
that	O
L.	O
pneumophila	O
possesses	O
a	O
growth	O
phase-dependent	O
resistance	O
to	O
stress	O
that	O
is	O
independent	O
of	O
RpoS	B-protein
control	O
and	O
that	O
RpoS	B-protein
likely	O
regulates	O
genes	O
that	O
enable	O
it	O
to	O
survive	O
in	O
the	O
environment	O
within	O
protozoa	O
.	O

Our	O
data	O
indicate	O
that	O
the	O
role	O
of	O
rpoS	B-DNA
in	O
L.	O
pneumophila	O
is	O
very	O
different	O
from	O
what	O
has	O
previously	O
been	O
reported	O
for	O
E.	O
coli	O
rpoS	B-DNA
.	O

Monoallelic	O
expression	O
of	O
Pax5	B-protein
:	O
a	O
paradigm	O
for	O
the	O
haploinsufficiency	O
of	O
mammalian	B-DNA
Pax	I-DNA
genes	I-DNA
?	O

It	O
is	O
generally	O
assumed	O
that	O
most	O
mammalian	B-DNA
genes	I-DNA
are	O
transcribed	O
from	O
both	O
alleles	B-DNA
.	O

Hence	O
,	O
the	O
diploid	O
state	O
of	O
the	O
genome	O
offers	O
the	O
advantage	O
that	O
a	O
loss-of-function	O
mutation	O
in	O
one	O
allele	B-DNA
can	O
be	O
compensated	O
for	O
by	O
the	O
remaining	O
wild-type	B-DNA
allele	I-DNA
of	O
the	O
same	O
gene	O
.	O

Indeed	O
,	O
the	O
vast	O
majority	O
of	O
human	O
disease	O
syndromes	O
and	O
engineered	O
mutations	O
in	O
the	O
mouse	B-DNA
genome	I-DNA
are	O
recessive	O
,	O
indicating	O
that	O
recessiveness	O
is	O
the	O
'default	O
'	O
state	O
.	O

However	O
,	O
a	O
minority	O
of	O
genes	O
are	O
semi-dominant	O
,	O
as	O
heterozygous	O
loss-of-function	O
mutation	O
in	O
these	O
genes	O
leads	O
to	O
phenotypic	O
abnormalities	O
.	O

This	O
condition	O
,	O
known	O
as	O
haploinsufficiency	O
,	O
has	O
been	O
described	O
for	O
five	O
of	O
the	O
nine	O
mammalian	B-DNA
Pax	I-DNA
genes	I-DNA
,	O
which	O
are	O
associated	O
with	O
mouse	O
developmental	O
mutants	O
and	O
human	O
disease	O
syndromes	O
.	O

Recently	O
we	O
have	O
reported	O
that	O
the	O
Pax5	B-DNA
gene	I-DNA
is	O
subject	O
to	O
allele	B-DNA
-specific	O
regulation	O
during	O
B	O
cell	O
development	O
.	O

Pax5	B-protein
is	O
predominantly	O
transcribed	O
from	O
only	O
one	O
of	O
its	O
two	O
alleles	B-DNA
in	O
early	B-cell_type
B-lymphoid	I-cell_type
progenitors	I-cell_type
and	O
mature	B-cell_type
B	I-cell_type
cells	I-cell_type
,	O
while	O
it	O
transiently	O
switches	O
to	O
a	O
biallelic	O
mode	O
of	O
transcription	O
in	O
pre-B	B-cell_type
and	I-cell_type
immature	I-cell_type
B	I-cell_type
cells	I-cell_type
.	O

As	O
a	O
consequence	O
,	O
B-lymphoid	O
tissues	O
are	O
mosaic	O
with	O
regard	O
to	O
the	O
transcribed	O
allele	B-DNA
,	O
and	O
heterozygous	O
mutation	O
of	O
Pax5	B-protein
therefore	O
results	O
in	O
deletion	O
of	O
B	B-cell_type
lymphocytes	I-cell_type
expressing	O
only	O
the	O
mutant	B-DNA
allele	I-DNA
.	O

The	O
allele	B-DNA
-specific	O
regulation	O
of	O
Pax5	B-protein
raises	O
the	O
intriguing	O
possibility	O
that	O
monoallelic	O
expression	O
may	O
also	O
be	O
the	O
mechanism	O
causing	O
the	O
haploinsufficiency	O
of	O
other	O
Pax	B-DNA
genes	I-DNA
.	O

In	O
this	O
review	O
,	O
we	O
discuss	O
different	O
models	O
accounting	O
for	O
the	O
haploinsufficiency	O
of	O
mammalian	B-DNA
Pax	I-DNA
genes	I-DNA
,	O
provide	O
further	O
evidence	O
in	O
support	O
of	O
the	O
allele	B-DNA
-specific	O
regulation	O
of	O
Pax5	B-protein
and	O
discuss	O
the	O
implication	O
of	O
these	O
findings	O
in	O
the	O
context	O
of	O
the	O
recent	O
literature	O
describing	O
the	O
stochastic	O
and	O
monoallelic	O
activation	O
of	O
other	O
hematopoietic	B-DNA
genes	I-DNA
.	O

Activation	O
of	O
STAT5	B-protein
by	O
IL-4	B-protein
relies	O
on	O
Janus	B-protein
kinase	I-protein
function	O
but	O
not	O
on	O
receptor	O
tyrosine	O
phosphorylation	O
,	O
and	O
can	O
contribute	O
to	O
both	O
cell	O
proliferation	O
and	O
gene	O
regulation	O
.	O

We	O
have	O
investigated	O
mechanisms	O
and	O
consequences	O
of	O
STAT5	B-protein
activation	O
through	O
the	O
human	B-protein
IL-4	I-protein
receptor	I-protein
(	O
IL-4R	B-protein
)	O
.	O

By	O
functionally	O
expressing	O
receptor	B-protein
mutants	I-protein
in	O
the	O
murine	B-cell_line
pro-B	I-cell_line
cell	I-cell_line
line	I-cell_line
Ba/F3	B-cell_line
,	O
we	O
could	O
show	O
that	O
phosphorylated	O
tyrosine	O
residues	O
within	O
the	O
IL-4R	B-protein
alpha	I-protein
chain	I-protein
are	O
dispensable	O
for	O
IL-4	B-protein
-induced	O
STAT5	B-protein
activity	O
.	O

However	O
,	O
disruption	O
of	O
a	O
membrane-proximal	B-protein
proline-rich	I-protein
sequence	I-protein
motif	I-protein
(	O
'	O
box1	B-protein
'	O
)	O
in	O
either	O
subunit	O
of	O
the	O
bipartite	B-protein
IL-4R	I-protein
abolished	O
not	O
only	O
ligand-induced	O
tyrosine	O
phosphorylation	O
of	O
Janus	B-protein
kinases	I-protein
JAK1	B-protein
and	O
JAK3	B-protein
,	O
but	O
also	O
IL-4	B-protein
-triggered	O
activation	O
of	O
STAT5	B-protein
and	O
concomitant	O
cell	O
proliferation	O
.	O

A	O
dominant-negative	B-protein
version	I-protein
of	O
STAT5b	B-protein
,	O
but	O
not	O
of	O
STAT5a	B-protein
,	O
interfered	O
with	O
IL-4	B-protein
-induced	O
DNA	O
synthesis	O
in	O
Ba/F3	B-cell_line
cells	I-cell_line
,	O
suggesting	O
an	O
involvement	O
of	O
STAT5b	B-protein
in	O
the	O
control	O
of	O
cell	O
proliferation	O
through	O
IL-4R	B-protein
.	O

Reporter	O
gene	O
experiments	O
finally	O
showed	O
that	O
transcription	O
from	O
promoters	O
of	O
STAT5	B-protein
target	O
genes	O
can	O
be	O
specifically	O
induced	O
by	O
challenging	O
cells	O
with	O
IL-4	B-protein
,	O
and	O
that	O
both	O
STAT5a	B-protein
and	O
STAT5b	B-protein
can	O
contribute	O
to	O
IL-4	B-protein
-triggered	O
transcriptional	O
control	O
.	O

Inhibition	O
of	O
NF-AT	B-protein
signal	O
transduction	O
events	O
by	O
a	O
dominant-negative	O
form	O
of	O
calcineurin	B-protein
.	O

An	O
inhibitory	O
,	O
``	O
dominant-negative	O
,	O
''	O
form	O
of	O
the	O
calcineurin	B-protein
catalytic	I-protein
(	I-protein
A	I-protein
)	I-protein
subunit	I-protein
was	O
prepared	O
,	O
which	O
lacks	O
the	O
calmodulin-binding	B-protein
domain	I-protein
,	O
autoinhibitory	B-protein
domain	I-protein
and	O
most	O
of	O
its	O
catalytic	O
core	O
but	O
possesses	O
the	O
regulatory	B-protein
(	I-protein
B	I-protein
)	I-protein
subunit	I-protein
binding	O
domain	O
.	O

When	O
tested	O
for	O
its	O
ability	O
to	O
block	O
calcineurin	B-protein
-dependent	O
signaling	O
in	O
Jurkat	O
cells	O
,	O
expression	O
of	O
this	O
``	B-DNA
B-subunit	I-DNA
knock-out	I-DNA
''	I-DNA
(	I-DNA
BKO	I-DNA
)	I-DNA
construct	I-DNA
suppressed	O
reporter	B-DNA
gene	I-DNA
activity	O
driven	O
by	O
NF-AT	B-protein
,	O
the	O
pivotal	O
promoter	B-DNA
element	I-DNA
for	O
interleukin	B-DNA
(	I-DNA
IL	I-DNA
)	I-DNA
-2	I-DNA
gene	I-DNA
induction	O
.	O

Immunoprecipitation	O
of	O
epitope-labeled	B-protein
BKO	I-protein
demonstrated	O
for	O
the	O
formation	O
of	O
a	O
tight	O
complex	O
with	O
endogenous	B-protein
B	I-protein
subunit	I-protein
in	O
Jurkat	B-cell_line
cells	I-cell_line
,	O
consistent	O
with	O
an	O
inhibitory	O
mechanism	O
that	O
involves	O
the	O
sequestration	O
of	O
the	O
B	B-protein
subunit	I-protein
.	O

Furthermore	O
,	O
the	O
sharply	O
reduced	O
NF-AT	B-protein
activity	O
produced	O
by	O
co-transfecting	B-DNA
BKO	I-DNA
could	O
be	O
``	O
rescued	O
''	O
by	O
overexpression	O
of	O
transfected	O
B	B-protein
subunit	I-protein
,	O
suggesting	O
that	O
depletion	O
of	O
this	O
subunit	O
was	O
responsible	O
for	O
the	O
inhibition	O
.	O

These	O
data	O
suggest	O
the	O
potential	O
utility	O
of	O
agents	O
that	O
disrupt	O
calcineurin	B-protein
-mediated	O
signal	O
transduction	O
pathways	O
by	O
blocking	O
formation	O
of	O
the	O
catalytically	B-protein
active	I-protein
dimer	I-protein
of	O
calcineurin	B-protein
A	I-protein
and	I-protein
B	I-protein
subunits	I-protein
.	O

Evaluation	O
of	O
monoclonal	O
anti-D	O
reagents	O
using	O
D	B-cell_line
variant	I-cell_line
cells	I-cell_line
.	O

Monoclonal	B-protein
anti-D	I-protein
antibodies	I-protein
submitted	O
to	O
the	O
Third	O
Monoclonal	O
International	O
Workshop	O
were	O
evaluated	O
against	O
a	O
number	O
of	O
D	B-cell_line
variant	I-cell_line
cells	I-cell_line
using	O
standard	O
serological	O
techniques	O
.	O

The	O
monoclonal	B-protein
antibodies	I-protein
were	O
able	O
to	O
discriminate	O
between	O
the	O
cells	O
of	O
Categories	B-cell_line
Va	I-cell_line
,	I-cell_line
VI	I-cell_line
and	I-cell_line
DFR	I-cell_line
but	I-cell_line
not	I-cell_line
Category	I-cell_line
III	I-cell_line
cells	I-cell_line
.	O

Cells	O
within	O
each	O
category	O
did	O
not	O
give	O
any	O
aberrant	O
results	O
.	O

The	O
Rh	B-cell_line
:	I-cell_line
33	I-cell_line
cells	I-cell_line
behaved	O
as	O
normal	B-cell_type
Rh	I-cell_type
(	I-cell_type
D	I-cell_type
)	I-cell_type
positive	I-cell_type
cells	I-cell_type
.	O

Interleukin	B-protein
10	I-protein
induced	O
c-fos	B-DNA
expression	O
in	O
human	B-cell_type
B	I-cell_type
cells	I-cell_type
by	O
activation	O
of	O
divergent	B-protein
protein	I-protein
kinases	I-protein
.	O

IL-10	B-protein
is	O
a	O
potent	O
mediator	O
of	O
human	B-cell_type
B	I-cell_type
cell	I-cell_type
growth	O
and	O
plasma	O
cell	O
formation	O
.	O

However	O
,	O
signal	O
transduction	O
of	O
IL-10	B-protein
in	O
B	B-cell_type
cells	I-cell_type
is	O
poorly	O
understood	O
.	O

In	O
this	O
study	O
the	O
effect	O
of	O
IL-10	B-protein
on	O
the	O
expression	O
of	O
the	O
protooncogene	B-DNA
c-fos	I-DNA
was	O
investigated	O
,	O
because	O
Fos	O
plays	O
a	O
potential	O
role	O
in	O
the	O
regulation	O
of	O
B	O
cell	O
proliferation	O
and	O
differentiation	O
.	O

B	B-cell_type
cells	I-cell_type
were	O
purified	O
from	O
buffy	O
coat	O
preparations	O
of	O
healthy	O
blood	O
donors	O
by	O
positive	O
selection	O
using	O
an	O
anti	B-protein
CD20	I-protein
monoclonal	I-protein
antibody	I-protein
and	O
a	O
MiniMACS	O
separation	O
unit	O
.	O

B	B-cell_type
cells	I-cell_type
were	O
prestimulated	O
with	O
SAC	O
for	O
48	O
hrs	O
.	O

Then	O
,	O
cells	O
were	O
incubated	O
with	O
medium	O
or	O
IL-10	B-protein
(	O
100	O
ng/ml	O
)	O
for	O
10	O
to	O
120	O
min	O
.	O

RNA	B-RNA
was	O
extracted	O
by	O
phenol/chloroform	O
and	O
c-fos	B-DNA
expression	O
was	O
analyzed	O
by	O
PCR	O
assisted	O
mRNA	O
assay	O
.	O

A	O
significant	O
2-4	O
fold	O
increase	O
of	O
c-fos	B-DNA
expression	O
was	O
observed	O
within	O
30	O
min	O
of	O
stimulation	O
with	O
IL-10	B-protein
(	O
p	O
<	O
0.01	O
)	O
.	O

After	O
2	O
hrs	O
c-fos	B-DNA
expression	O
declined	O
to	O
basal	O
levels	O
.	O

The	O
effect	O
of	O
IL-10	B-protein
was	O
dose-dependent	O
with	O
a	O
maximum	O
stimulation	O
using	O
100	O
ng/ml	O
of	O
IL-10	B-protein
.	O

The	O
IL-10	B-protein
effect	O
on	O
c-fos	B-DNA
expression	O
was	O
not	O
blocked	O
by	O
polymyxin	O
B	O
.	O

Using	O
the	O
tyrosine	O
kinase	O
inhibitor	O
genistein	O
(	O
10	O
microM	O
)	O
a	O
complete	O
inhibition	O
of	O
IL-10	B-protein
induced	O
c-fos	B-DNA
expression	O
was	O
observed	O
.	O

In	O
addition	O
,	O
H-7	O
(	O
10	O
microM	O
)	O
,	O
a	O
specific	O
inhibitor	O
of	O
serine/threonine	B-protein
kinases	I-protein
,	O
significantly	O
blocked	O
IL-10	B-protein
mediated	O
c-fos	B-DNA
expression	O
(	O
p	O
<	O
0.05	O
)	O
.	O

In	O
conclusion	O
,	O
these	O
data	O
show	O
that	O
IL-10	B-protein
induces	O
c-fos	B-DNA
expression	O
in	O
human	B-cell_type
B-cells	I-cell_type
by	O
activation	O
of	O
tyrosine	O
and	O
serine/threonine	B-protein
kinases	I-protein
.	O

Since	O
this	O
is	O
the	O
first	O
report	O
on	O
IL-10	B-protein
induced	O
signal	O
transduction	O
,	O
these	O
data	O
may	O
help	O
to	O
identify	O
the	O
intracellular	O
mechanisms	O
by	O
which	O
IL-10	B-protein
stimulates	O
human	B-cell_type
B-cells	I-cell_type
.	O

Immunocytochemical	O
analysis	O
of	O
MNDA	B-protein
in	O
tissue	O
sections	O
and	O
sorted	O
normal	O
bone	O
marrow	O
cells	O
documents	O
expression	O
only	O
in	O
maturing	O
normal	O
and	O
neoplastic	O
myelomonocytic	O
cells	O
and	O
a	O
subset	O
of	O
normal	O
and	O
neoplastic	O
B	O
lymphocytes	O
.	O

The	O
human	O
myeloid	O
cell	O
nuclear	O
differentiation	O
antigen	O
(	O
MNDA	B-protein
)	O
is	O
a	O
nuclear	O
antigen	O
known	O
to	O
be	O
expressed	O
in	O
mature	O
myelomonocytic	O
cell	O
lines	O
.	O

An	O
extensive	O
immunocytochemical	O
evaluation	O
of	O
fixed	O
tissues	O
confirmed	O
MNDA	B-protein
expression	O
in	O
normal	B-cell_type
maturing	I-cell_type
granulocytes	I-cell_type
and	O
monocytes	B-cell_type
and	O
in	O
acute	O
nonlymphocytic	O
leukemias	O
and	O
chronic	O
myelogenous	O
leukemia	O
.	O

MNDA	B-protein
was	O
not	O
detected	O
in	O
normal	O
tissue	O
histiocytes	O
but	O
was	O
found	O
in	O
activated	B-cell_type
macrophages	I-cell_type
and	O
foreign	B-cell_type
body	I-cell_type
giant	I-cell_type
cells	I-cell_type
associated	O
with	O
inflammation	O
.	O

Flow	O
cytometric	O
cell	O
sorting	O
of	O
normal	O
bone	O
marrow	O
established	O
that	O
MNDA	B-protein
is	O
initially	O
expressed	O
in	O
myeloid	B-cell_type
blast	I-cell_type
cells	I-cell_type
.	O

Examination	O
of	O
lymphoid	O
tissues	O
showed	O
a	O
low	O
level	O
of	O
expression	O
in	O
a	O
population	O
of	O
normal	O
mande	B-cell_line
B	I-cell_line
lymphocytes	I-cell_line
but	O
not	O
in	O
germinal	B-cell_type
center	I-cell_type
cells	I-cell_type
or	O
plasma	B-cell_type
cells	I-cell_type
.	O

A	O
subset	O
of	O
B	B-cell_type
cell	I-cell_type
neoplasms	I-cell_type
expressing	O
MNDA	B-protein
included	O
hairy	O
cell	O
leukemia	O
,	O
parafollicular	O
(	O
monocytoid	O
)	O
B	O
cell	O
lymphoma	O
,	O
mantle	O
cell	O
lymphoma	O
,	O
and	O
small	O
lymphocytic	O
lymphoma	O
.	O

Cell	O
sorting	O
of	O
normal	O
bone	O
marrow	O
showed	O
MNDA	B-protein
expression	O
in	O
CD20	B-protein
+/CD10-/CD5-	O
B	B-cell_type
cells	I-cell_type
.	O

MNDA	B-protein
was	O
not	O
detected	O
in	O
other	O
normal	O
bone	O
marrow	O
or	O
all	O
other	O
nonhematopoietic	B-cell_type
cells	I-cell_type
.	O

The	O
hematopoietic	O
cell-specific	O
pattern	O
of	O
MNDA	B-protein
expression	O
was	O
elucidated	O
through	O
a	O
comprehensive	O
analysis	O
of	O
normal	O
and	O
neoplastic	O
tissues	O
,	O
and	O
the	O
results	O
provide	O
further	O
evidence	O
of	O
the	O
coexpression	O
of	O
B-	B-protein
and	I-protein
myeloid	I-protein
cell	I-protein
markers	I-protein
in	O
neoplastic	B-cell_type
B	I-cell_type
cells	I-cell_type
and	O
identify	O
a	O
normal	B-cell_type
B	I-cell_type
cell	I-cell_type
population	I-cell_type
that	O
might	O
be	O
related	O
to	O
the	O
cell	O
of	O
origin	O
of	O
a	O
subset	O
of	O
B	B-cell_type
cell	I-cell_type
neoplasms	I-cell_type
.	O

Peroxisome	B-protein
proliferator-activated	I-protein
receptor	I-protein
activators	I-protein
target	O
human	B-cell_type
endothelial	I-cell_type
cells	I-cell_type
to	O
inhibit	O
leukocyte	B-cell_type
-endothelial	B-cell_type
cell	I-cell_type
interaction	O
.	O

An	O
early	O
event	O
in	O
acute	O
and	O
chronic	O
inflammation	O
and	O
associated	O
diseases	O
such	O
as	O
atherosclerosis	O
and	O
rheumatoid	O
arthritis	O
is	O
the	O
induced	O
expression	O
of	O
specific	O
adhesion	B-protein
molecules	I-protein
on	O
the	O
surface	O
of	O
endothelial	B-cell_type
cells	I-cell_type
(	O
ECs	B-cell_type
)	O
,	O
which	O
subsequently	O
bind	O
leukocytes	B-cell_type
.	O

Peroxisome	B-protein
proliferator-activated	I-protein
receptors	I-protein
(	O
PPARs	B-protein
)	O
,	O
members	O
of	O
the	O
nuclear	B-protein
receptor	I-protein
superfamily	I-protein
of	O
transcription	B-protein
factors	I-protein
,	O
are	O
activated	O
by	O
fatty	O
acid	O
metabolites	O
,	O
peroxisome	O
proliferators	O
,	O
and	O
thiazolidinediones	O
and	O
are	O
now	O
recognized	O
as	O
important	O
mediators	O
in	O
the	O
inflammatory	O
response	O
.	O

Whether	O
PPAR	O
activators	O
influence	O
the	O
inflammatory	O
responses	O
of	O
ECs	B-cell_type
is	O
unknown	O
.	O

We	O
show	O
that	O
the	O
PPAR	O
activators	O
15-deoxy-Delta	O
(	O
12	O
,	O
14	O
)	O
-prostaglandin	O
J	O
(	O
2	O
)	O
(	O
15d-PGJ	O
(	O
2	O
)	O
)	O
,	O
Wyeth	O
14643	O
,	O
ciglitazone	O
,	O
and	O
troglitazone	O
,	O
but	O
not	O
BRL	O
49653	O
,	O
partially	O
inhibit	O
the	O
induced	O
expression	O
of	O
vascular	B-protein
cell	I-protein
adhesion	I-protein
molecule-1	I-protein
(	O
VCAM-1	B-protein
)	O
,	O
as	O
measured	O
by	O
ELISA	O
,	O
and	O
monocyte	O
binding	O
to	O
human	B-cell_type
aortic	I-cell_type
endothelial	I-cell_type
cells	I-cell_type
(	O
HAECs	B-cell_type
)	O
activated	O
by	O
phorbol	O
12-myristate	O
13-acetate	O
(	O
PMA	O
)	O
or	O
lipopolysaccharide	O
.	O

The	O
``	O
natural	O
''	O
PPAR	O
activator	O
15d-PGJ	O
(	O
2	O
)	O
had	O
the	O
greatest	O
potency	O
and	O
was	O
the	O
only	O
tested	O
molecule	O
capable	O
of	O
partially	O
inhibiting	O
the	O
induced	O
expression	O
of	O
E-selectin	B-protein
and	O
neutrophil-like	O
HL60	B-cell_line
cell	I-cell_line
binding	O
to	O
PMA-activated	O
HAECs	B-cell_type
.	O

Intracellular	O
adhesion	O
molecule-1	O
induction	O
by	O
PMA	O
was	O
unaffected	O
by	O
any	O
of	O
the	O
molecules	O
tested	O
.	O

Both	O
PPAR-alpha	B-RNA
and	I-RNA
PPAR-gamma	I-RNA
mRNAs	I-RNA
were	O
detected	O
in	O
HAECs	B-cell_type
by	O
using	O
reverse	O
transcription-polymerase	O
chain	O
reaction	O
and	O
a	O
ribonuclease	B-protein
protection	O
assay	O
;	O
however	O
,	O
we	O
have	O
yet	O
to	O
determine	O
which	O
,	O
if	O
any	O
,	O
of	O
the	O
PPARs	B-protein
are	O
mediating	O
this	O
process	O
.	O

These	O
results	O
suggest	O
that	O
certain	O
PPAR	O
activators	O
may	O
help	O
limit	O
chronic	O
inflammation	O
mediated	O
by	O
VCAM-1	B-protein
and	O
monocytes	B-cell_type
without	O
affecting	O
acute	O
inflammation	O
mediated	O
by	O
E-selectin	B-protein
and	O
neutrophil	B-cell_type
binding	O
.	O

Dephosphorylation	O
of	O
ZAP-70	B-protein
and	O
inhibition	O
of	O
T	O
cell	O
activation	O
by	O
activated	B-protein
SHP1	I-protein
.	O

Studies	O
with	O
motheaten	O
mice	O
,	O
which	O
lack	O
the	O
SHP1	B-protein
protein	I-protein
tyrosine	B-protein
phosphatase	I-protein
,	O
indicate	O
that	O
this	O
enzyme	O
plays	O
an	O
important	O
negative	O
role	O
in	O
T	B-protein
cell	I-protein
antigen	I-protein
receptor	I-protein
(	O
TCR	B-protein
)	O
signaling	O
.	O

The	O
physiological	O
substrates	O
for	O
SHP1	B-protein
in	O
T	B-cell_type
lymphocytes	I-cell_type
,	O
however	O
,	O
have	O
remained	O
unclear	O
or	O
controversial	O
.	O

To	O
define	O
these	O
targets	O
for	O
SHP1	B-protein
we	O
have	O
compared	O
the	O
effects	O
of	O
constitutively	O
active	O
and	O
inactive	O
mutants	O
of	O
SHP1	B-protein
on	O
TCR	B-protein
signaling	O
.	O

Expression	O
of	O
wild-type	B-protein
SHP1	I-protein
had	O
a	O
very	O
small	O
effect	O
on	O
the	O
TCR-induced	O
tyrosine	O
phosphorylation	O
of	O
ZAP-70	B-protein
and	O
Syk	B-protein
,	O
even	O
when	O
SHP1	B-protein
was	O
overexpressed	O
20	O
-	O
100-fold	O
over	O
endogenous	B-protein
SHP1	I-protein
.	O

Inactive	B-protein
SHP1-D421A	I-protein
and	O
wild-type	B-protein
SHP2	I-protein
were	O
without	O
effects	O
.	O

Constitutively	B-protein
active	I-protein
SHP1-DeltaSH2	I-protein
had	O
a	O
more	O
pronounced	O
effect	O
on	O
ZAP-70	B-protein
and	O
Syk	B-protein
,	O
even	O
when	O
expressed	O
at	O
near	O
physiological	O
levels	O
.	O

SHP1-DeltaSH2	B-protein
also	O
inhibited	O
events	O
downstream	O
of	O
ZAP-70	B-protein
and	O
Syk	B-protein
,	O
such	O
as	O
activation	O
of	O
the	O
mitogen-activated	B-protein
protein	I-protein
kinase	I-protein
Erk2	B-protein
and	O
the	O
transcriptional	O
activation	O
of	O
the	O
interleukin-2	B-DNA
gene	I-DNA
.	O

In	O
contrast	O
,	O
a	O
constitutively	O
active	O
SHP2-DeltaSH2	B-protein
had	O
no	O
statistically	O
significant	O
effect	O
(	O
although	O
it	O
caused	O
a	O
slight	O
augmentation	O
in	O
some	O
individual	O
experiments	O
)	O
.	O

None	O
of	O
the	O
constructs	O
influenced	O
the	O
anti-CD3-induced	O
tyrosine	O
phosphorylation	O
of	O
the	O
TCR	B-protein
zeta-chain	I-protein
or	O
phospholipase	B-protein
Cgamma1	I-protein
,	O
indicating	O
that	O
Src	B-protein
family	I-protein
kinase	I-protein
function	O
was	O
intact	O
.	O

Taken	O
together	O
,	O
our	O
findings	O
support	O
the	O
notion	O
that	O
ZAP-70	B-protein
and	O
Syk	B-protein
can	O
be	O
direct	O
substrates	O
for	O
SHP1	B-protein
in	O
intact	O
cells	O
.	O

However	O
,	O
the	O
two	O
SH2	B-protein
domains	I-protein
of	O
SHP1	B-protein
did	O
not	O
facilitate	O
its	O
recognition	O
of	O
ZAP-70	B-protein
and	O
Syk	B-protein
as	O
substrates	O
in	O
intact	O
cells	O
.	O

Therefore	O
,	O
we	O
suggest	O
that	O
SHP1	B-protein
is	O
not	O
actively	O
recruited	O
to	O
inhibit	O
TCR	B-protein
signaling	O
induced	O
by	O
ligation	O
of	O
this	O
receptor	O
alone	O
.	O

Instead	O
,	O
we	O
propose	O
that	O
ligation	O
of	O
a	O
distinct	O
inhibitory	B-protein
receptor	I-protein
leads	O
to	O
the	O
recruitment	O
of	O
SHP1	B-protein
via	O
its	O
SH2	B-protein
domains	I-protein
,	O
activation	O
of	O
SHP1	B-protein
and	O
subsequently	O
inhibition	O
of	O
TCR	B-protein
signals	O
if	O
the	O
inhibitory	B-protein
receptor	I-protein
is	O
juxtaposed	O
to	O
the	O
TCR	B-protein
.	O

Immune	O
responses	O
to	O
adenoviruses	O
:	O
viral	O
evasion	O
mechanisms	O
and	O
their	O
implications	O
for	O
the	O
clinic	O
.	O

Adenoviruses	O
encode	O
proteins	O
that	O
block	O
responses	O
to	O
interferons	B-protein
,	O
intrinsic	O
cellular	O
apoptosis	O
,	O
killing	O
by	O
CD8	B-cell_type
(	I-cell_type
+	I-cell_type
)	I-cell_type
cytotoxic	I-cell_type
T	I-cell_type
lymphocytes	I-cell_type
and	O
killing	O
by	O
the	O
death	B-protein
ligands	I-protein
TNF	B-protein
,	O
Fas	B-protein
ligand	I-protein
and	O
TRAIL	B-protein
.	O

The	O
viral	B-protein
proteins	I-protein
are	O
believed	O
to	O
prolong	O
acute	O
and	O
persistent	O
adenovirus	O
infections	O
.	O

The	O
proteins	O
may	O
prove	O
useful	O
in	O
protecting	O
adenovirus	B-DNA
gene	I-DNA
therapy	I-DNA
vectors	I-DNA
and	O
transplanted	B-cell_line
cells	I-cell_line
from	O
the	O
immune	O
system	O
.	O

C/EBPbeta	B-protein
and	O
GATA-1	B-protein
synergistically	O
regulate	O
activity	O
of	O
the	O
eosinophil	B-DNA
granule	I-DNA
major	I-DNA
basic	I-DNA
protein	I-DNA
promoter	I-DNA
:	O
implication	O
for	O
C/EBPbeta	B-protein
activity	O
in	O
eosinophil	O
gene	O
expression	O
.	O

Eosinophil	B-protein
granule	I-protein
major	I-protein
basic	I-protein
protein	I-protein
(	O
MBP	B-protein
)	O
is	O
expressed	O
exclusively	O
in	O
eosinophils	B-cell_type
and	O
basophils	B-cell_type
in	O
hematopoietic	B-cell_type
cells	I-cell_type
.	O

In	O
our	O
previous	O
study	O
,	O
we	O
demonstrated	O
a	O
major	O
positive	O
regulatory	O
role	O
for	O
GATA-1	B-protein
and	O
a	O
negative	O
regulatory	O
role	O
for	O
GATA-2	B-protein
in	O
MBP	B-protein
gene	O
transcription	O
.	O

Further	O
analysis	O
of	O
the	O
MBP	B-DNA
promoter	I-DNA
region	I-DNA
identified	O
a	O
C/EBP	B-DNA
(	I-DNA
CCAAT/enhancer-binding	I-DNA
protein	I-DNA
)	I-DNA
consensus	I-DNA
binding	I-DNA
site	I-DNA
6	O
bp	O
upstream	O
of	O
the	O
functional	O
GATA-binding	B-DNA
site	I-DNA
in	O
the	O
MBP	B-DNA
gene	I-DNA
.	O

In	O
the	O
cell	B-cell_line
line	I-cell_line
HT93A	I-cell_line
,	O
which	O
is	O
capable	O
of	O
differentiating	O
towards	O
both	O
the	O
eosinophil	B-cell_type
and	O
neutrophil	O
lineages	O
in	O
response	O
to	O
retinoic	O
acid	O
(	O
RA	O
)	O
,	O
C/EBPalpha	B-RNA
mRNA	I-RNA
expression	O
decreased	O
significantly	O
concomitant	O
with	O
eosinophilic	O
and	O
neutrophilic	O
differentiation	O
,	O
whereas	O
C/EBPbeta	B-protein
expression	O
was	O
markedly	O
increased	O
.	O

Electrophoretic	O
mobility	O
shift	O
assays	O
(	O
EMSAs	O
)	O
showed	O
that	O
recombinant	O
C/EBPbeta	B-protein
protein	O
could	O
bind	O
to	O
the	O
potential	O
C/EBP-binding	B-DNA
site	I-DNA
(	O
bp	B-DNA
-90	I-DNA
to	I-DNA
-82	I-DNA
)	O
in	O
the	O
MBP	B-protein
promoter	O
.	O

Furthermore	O
,	O
we	O
have	O
demonstrated	O
that	O
both	O
C/EBPbeta	B-protein
and	O
GATA-1	B-protein
can	O
bind	O
simultaneously	O
to	O
the	O
C/EBP-	O
and	O
GATA-binding	B-DNA
sites	I-DNA
in	O
the	O
MBP	B-DNA
promoter	I-DNA
.	O

To	O
determine	O
the	O
functionality	O
of	O
both	O
the	O
C/EBP-	B-DNA
and	I-DNA
GATA-	I-DNA
binding	I-DNA
sites	I-DNA
,	O
we	O
analyzed	O
whether	O
C/EBPbeta	B-protein
and	O
GATA-1	B-protein
can	O
stimulate	O
the	O
MBP	B-DNA
promoter	I-DNA
in	O
the	O
C/EBPbeta	B-cell_line
and	I-cell_line
GATA-1	I-cell_line
negative	I-cell_line
Jurkat	I-cell_line
T-cell	I-cell_line
line	I-cell_line
.	O

Cotransfection	O
with	O
C/EBPbeta	B-DNA
and	I-DNA
GATA-1	I-DNA
expression	I-DNA
vectors	I-DNA
produced	O
a	O
5-fold	O
increase	O
compared	O
with	O
cotransfection	O
with	O
the	O
C/EBPbeta	B-protein
or	O
GATA-1	B-DNA
expression	I-DNA
vectors	I-DNA
individually	O
.	O

In	O
addition	O
,	O
GST	B-protein
pull-down	O
experiments	O
demonstrated	O
a	O
physical	O
interaction	O
between	O
human	O
GATA-1	B-protein
and	O
C/EBPbeta	B-protein
.	O

Expression	O
of	O
FOG	B-protein
(	O
riend	B-protein
ATA	I-protein
)	O
,	O
which	O
binds	O
to	O
GATA-1	B-protein
and	O
acts	O
as	O
a	O
cofactor	O
for	O
GATA-binding	B-protein
proteins	I-protein
,	O
decreased	O
transactivation	O
activity	O
of	O
GATA-1	B-protein
for	O
the	O
MBP	B-DNA
promoter	I-DNA
in	O
a	O
dose-dependent	O
manner	O
.	O

Our	O
results	O
provide	O
the	O
first	O
evidence	O
that	O
both	O
GATA-1	B-protein
and	O
C/EBPbeta	B-protein
synergistically	O
transactivate	O
the	O
promoter	B-DNA
of	O
an	O
eosinophil-specific	B-DNA
granule	I-DNA
protein	I-DNA
gene	I-DNA
and	O
that	O
FOG	B-protein
may	O
act	O
as	O
a	O
negative	O
cofactor	O
for	O
the	O
eosinophil	B-cell_type
lineage	I-cell_type
,	O
unlike	O
its	O
positively	O
regulatory	O
function	O
for	O
the	O
erythroid	B-cell_type
and	I-cell_type
megakaryocyte	I-cell_type
lineages	I-cell_type
.	O

Tissue-specific	O
regulation	O
of	O
the	O
ecto-5'-nucleotidase	B-DNA
promoter	I-DNA
.	O

Role	O
of	O
the	O
camp	B-DNA
response	I-DNA
element	I-DNA
site	I-DNA
in	O
mediating	O
repression	O
by	O
the	O
upstream	B-DNA
regulatory	I-DNA
region	I-DNA
.	O

We	O
have	O
isolated	O
the	O
5	B-DNA
'	I-DNA
region	I-DNA
of	O
the	O
ecto-5'-nucleotidase	B-DNA
(	I-DNA
low	I-DNA
K	I-DNA
(	I-DNA
m	I-DNA
)	I-DNA
5'-NT	I-DNA
)	I-DNA
gene	I-DNA
and	O
established	O
that	O
a	O
969-base	B-DNA
pair	I-DNA
(	I-DNA
bp	I-DNA
)	I-DNA
fragment	I-DNA
confers	O
cell-specific	O
expression	O
of	O
a	O
CAT	B-DNA
reporter	I-DNA
gene	I-DNA
that	O
correlates	O
with	O
the	O
expression	O
of	O
endogenous	B-RNA
ecto-5'-NT	I-RNA
mRNA	I-RNA
and	O
enzymatic	O
activity	O
.	O

A	O
768-bp	B-DNA
upstream	I-DNA
negative	I-DNA
regulatory	I-DNA
region	I-DNA
has	O
been	O
identified	O
that	O
conferred	O
lymphocyte-specific	O
negative	O
regulation	O
in	O
a	O
heterologous	O
system	O
with	O
a	O
244-bp	B-DNA
deoxycytidine	I-DNA
kinase	I-DNA
core	I-DNA
promoter	I-DNA
.	O

DNase	B-protein
I	I-protein
footprinting	O
identified	O
several	O
protected	O
areas	O
including	O
Sp1	B-DNA
,	I-DNA
Sp1/AP-2	I-DNA
,	I-DNA
and	I-DNA
cAMP	I-DNA
response	I-DNA
element	I-DNA
(	I-DNA
CRE	I-DNA
)	I-DNA
binding	I-DNA
sites	I-DNA
within	O
the	O
201-bp	O
core	O
promoter	O
region	O
and	O
Sp1	B-DNA
,	I-DNA
NRE-2a	I-DNA
,	I-DNA
TCF-1/LEF-1	I-DNA
,	I-DNA
and	I-DNA
Sp1/NF-AT	I-DNA
binding	I-DNA
sites	I-DNA
in	O
the	O
upstream	B-DNA
regulatory	I-DNA
region	I-DNA
.	O

Whereas	O
the	O
CRE	B-DNA
site	I-DNA
was	O
essential	O
in	O
mediating	O
the	O
negative	O
activity	O
of	O
the	O
upstream	B-DNA
regulatory	I-DNA
region	I-DNA
in	O
Jurkat	B-cell_line
but	O
not	O
in	O
HeLa	B-cell_line
cells	I-cell_line
,	O
mutation	O
of	O
the	O
Sp1/AP-2	B-DNA
site	I-DNA
decreased	O
promoter	O
activity	O
in	O
both	O
cell	O
lines	O
.	O

Electrophoretic	O
mobility	O
shift	O
assay	O
analysis	O
of	O
proteins	O
binding	O
to	O
the	O
CRE	B-DNA
site	I-DNA
identified	O
both	O
ATF-1	B-protein
and	O
ATF-2	B-protein
in	O
Jurkat	B-cell_line
cells	I-cell_line
.	O

Finally	O
,	O
phorbol	O
12-myristate	O
13-acetate	O
increased	O
the	O
activity	O
of	O
both	O
the	O
core	O
and	O
the	O
969-bp	B-DNA
promoter	I-DNA
fragments	I-DNA
,	O
and	O
this	O
increase	O
was	O
abrogated	O
by	O
mutations	O
at	O
the	O
CRE	B-DNA
site	I-DNA
.	O

In	O
summary	O
,	O
we	O
have	O
identified	O
a	O
tissue-specific	B-DNA
regulatory	I-DNA
region	I-DNA
5	O
'	O
of	O
the	O
ecto-5'-NT	B-DNA
core	I-DNA
promoter	I-DNA
that	O
requires	O
the	O
presence	O
of	O
a	O
functional	O
CRE	B-DNA
site	I-DNA
within	O
the	O
basal	B-DNA
promoter	I-DNA
for	O
its	O
suppressive	O
activity	O
.	O

Extracellular	O
signal-regulated	O
protein	O
kinase	O
(	O
ERK	O
)	O
-dependent	O
and	O
ERK-independent	O
pathways	O
target	O
STAT3	B-protein
on	O
serine-727	O
in	O
human	O
neutrophils	O
stimulated	O
by	O
chemotactic	B-protein
factors	I-protein
and	O
cytokines	B-protein
.	O

STAT3	B-protein
(	O
signal	B-protein
transducer	I-protein
and	I-protein
activator	I-protein
of	I-protein
transcription	I-protein
3	I-protein
)	O
is	O
a	O
latent	O
transcription	O
factor	O
that	O
is	O
activated	O
by	O
tyrosine	O
phosphorylation	O
(	O
Tyr-705	O
)	O
in	O
cells	O
stimulated	O
with	O
cytokines	B-protein
or	O
growth	B-protein
factors	I-protein
.	O

Recent	O
studies	O
suggest	O
that	O
one	O
or	O
more	O
cytoplasmic	B-protein
serine	I-protein
kinases	I-protein
also	O
phosphorylate	O
STAT3	B-protein
and	O
are	O
necessary	O
for	O
maximal	O
gene	O
activation	O
.	O

Here	O
we	O
demonstrate	O
,	O
with	O
a	O
site-specific	O
antibody	O
,	O
that	O
STAT3	B-protein
is	O
phosphorylated	O
on	O
Ser-727	O
in	O
human	B-cell_type
neutrophils	I-cell_type
stimulated	O
with	O
chemotactic	B-protein
factors	I-protein
(	O
N-formyl-methionyl-leucyl-phenylalanine	O
and	O
complement	O
C5a	O
)	O
,	O
cytokines	B-protein
[	O
granulocyte/macrophage	B-protein
colony-stimulating	I-protein
factor	I-protein
(	O
GM-CSF	B-protein
)	O
and	O
granulocyte	B-protein
colony-stimulating	I-protein
factor	I-protein
(	O
G-CSF	B-protein
)	O
]	O
,	O
or	O
a	O
protein	B-protein
kinase	I-protein
C	I-protein
activator	O
(	O
PMA	O
)	O
.	O

(	O
2-Amino-3'-methoxyphenyl	O
)	O
oxanaphthalen-4-one	O
(	O
PD	O
98059	O
)	O
,	O
an	O
inhibitor	O
of	O
extracellular	O
signal-regulated	B-protein
protein	I-protein
kinase	I-protein
(	O
ERK	B-protein
)	O
activation	O
,	O
blocked	O
the	O
serine	O
phosphorylation	O
of	O
STAT3	B-protein
induced	O
by	O
chemotactic	B-protein
factors	I-protein
or	O
PMA	O
.	O

The	O
drug	O
was	O
less	O
effective	O
on	O
cytokines	B-protein
:	O
it	O
virtually	O
abolished	O
the	O
response	O
to	O
GM-CSF	B-protein
that	O
occurred	O
5	O
min	O
after	O
stimulation	O
but	O
only	O
partly	O
decreased	O
those	O
at	O
15-30	O
min	O
and	O
did	O
not	O
appreciably	O
alter	O
responses	O
to	O
G-CSF	B-protein
regardless	O
of	O
incubation	O
time	O
.	O

1-	O
(	O
5-Isoquinolinylsulphonyl	O
)	O
-2-methylpiperazine	O
dihydrochloride	O
(	O
H7	O
)	O
,	O
an	O
inhibitor	O
of	O
a	O
putative	O
STAT3	B-protein
serine	I-protein
kinase	I-protein
,	O
and	O
4-	O
(	O
4-fluorophenyl	O
)	O
-2-	O
(	O
4-methylsulphinylphenyl	O
)	O
-5-	O
(	O
4-pyridyl	O
)	O
1H-imidazole	O
(	O
SB	O
203580	O
)	O
,	O
an	O
inhibitor	O
of	O
p38	B-protein
mitogen-activated	I-protein
protein	I-protein
(	I-protein
MAP	I-protein
)	I-protein
kinase	I-protein
,	O
did	O
not	O
dampen	O
any	O
of	O
these	O
serine	O
phosphorylation	O
responses	O
.	O

We	O
propose	O
that	O
neutrophils	B-cell_type
use	O
both	O
ERK-dependent	O
and	O
ERK-independent	O
pathways	O
to	O
phosphorylate	O
Ser-727	O
on	O
STAT3	B-protein
.	O

The	O
former	O
pathway	O
is	O
recruited	O
by	O
all	O
ERK	B-protein
-activating	O
stimuli	O
,	O
whereas	O
the	O
latter	O
pathway	O
uses	O
an	O
undefined	O
serine	B-protein
kinase	I-protein
and	O
is	O
recruited	O
selectively	O
by	O
cytokines	B-protein
.	O

GATA	B-protein
transcription	I-protein
factors	I-protein
associate	O
with	O
a	O
novel	O
class	O
of	O
nuclear	O
bodies	O
in	O
erythroblasts	B-cell_type
and	O
megakaryocytes	B-cell_type
.	O

The	O
nuclear	O
distribution	O
of	O
GATA	B-protein
transcription	I-protein
factors	I-protein
in	O
murine	B-cell_type
haemopoietic	I-cell_type
cells	I-cell_type
was	O
examined	O
by	O
indirect	O
immunofluorescence	O
.	O

Specific	O
bright	O
foci	O
of	O
GATA-1	B-protein
fluorescence	O
were	O
observed	O
in	O
erythroleukaemia	B-cell_type
cells	I-cell_type
and	O
primary	B-cell_type
murine	I-cell_type
erythroblasts	I-cell_type
and	O
megakaryocytes	B-cell_type
,	O
in	O
addition	O
to	O
diffuse	O
nucleoplasmic	O
localization	O
.	O

These	O
foci	O
,	O
which	O
were	O
preferentially	O
found	O
adjacent	O
to	O
nucleoli	O
or	O
at	O
the	O
nuclear	O
periphery	O
,	O
did	O
not	O
represent	O
sites	O
of	O
active	O
transcription	O
or	O
binding	O
of	O
GATA-1	B-protein
to	O
consensus	B-DNA
sites	I-DNA
in	O
the	O
beta-globin	B-DNA
loci	I-DNA
.	O

Immunoelectron	O
microscopy	O
demonstrated	O
the	O
presence	O
of	O
intensely	O
labelled	O
structures	O
likely	O
to	O
represent	O
the	O
GATA-1	B-protein
foci	O
seen	O
by	O
immunofluorescence	O
.	O

The	O
GATA-1	B-protein
nuclear	O
bodies	O
differed	O
from	O
previously	O
described	O
nuclear	O
structures	O
and	O
there	O
was	O
no	O
co-localization	O
with	O
nuclear	B-protein
antigens	I-protein
involved	O
in	O
RNA	O
processing	O
or	O
other	O
ubiquitous	B-protein
(	I-protein
Spl	I-protein
,	I-protein
c-Jun	I-protein
and	I-protein
TBP	I-protein
)	I-protein
or	I-protein
haemopoietic	I-protein
(	I-protein
NF-E2	I-protein
)	I-protein
transcription	I-protein
factors	I-protein
.	O

Interestingly	O
,	O
GATA-2	B-protein
and	O
GATA-3	B-protein
proteins	I-protein
also	O
localized	O
to	O
the	O
same	O
nuclear	O
bodies	O
in	O
cell	O
lines	O
co-expressing	O
GATA-1	B-protein
and	I-protein
-2	I-protein
or	I-protein
GATA-1	I-protein
and	I-protein
-3	I-protein
gene	I-protein
products	I-protein
.	O

This	O
pattern	O
of	O
distribution	O
is	O
,	O
thus	O
far	O
,	O
unique	O
to	O
the	O
GATA	B-protein
transcription	I-protein
factors	I-protein
and	O
suggests	O
a	O
protein-protein	O
interaction	O
with	O
other	O
components	O
of	O
the	O
nuclear	O
bodies	O
via	O
the	O
GATA	B-protein
zinc	I-protein
finger	I-protein
domain	I-protein
.	O

Energy	O
substrates	O
,	O
hormone	O
responses	O
and	O
glucocorticoid	O
binding	O
in	O
lymphocytes	B-cell_type
during	O
intense	O
physical	O
exercise	O
in	O
humans	O
following	O
phosphocreatine	O
administration	O
.	O

Eight	O
healthy	O
untrained	O
male	O
volunteers	O
pedalled	O
a	O
cycle	O
ergometer	O
according	O
to	O
two	O
exercise	O
protocols	O
:	O
the	O
first	O
involved	O
step-wise	O
increasing	O
physical	O
exercise	O
to	O
maximal	O
(	O
MPE	O
)	O
;	O
the	O
second	O
involved	O
prolonged	O
(	O
35	O
min	O
)	O
submaximal	O
physical	O
exercise	O
(	O
PPE	O
)	O
at	O
70	O
%	O
of	O
the	O
individual	O
's	O
maximal	O
oxygen	O
uptake	O
.	O

Each	O
volunteer	O
performed	O
these	O
exercise	O
twice	O
,	O
following	O
either	O
an	O
intravenous	O
injection	O
of	O
phosphocreatine	O
(	O
PCr	O
)	O
or	O
a	O
placebo	O
of	O
an	O
isotonic	O
NaCl	O
solution	O
.	O

Anaerobic	O
threshold	O
(	O
AT	O
)	O
was	O
determined	O
from	O
the	O
point	O
of	O
departure	O
of	O
the	O
ventilatory	O
response	O
from	O
linearity	O
and	O
from	O
the	O
sudden	O
increase	O
in	O
venous	O
blood	O
lactate	O
concentrations	O
during	O
MPE	O
.	O

After	O
exercise	O
following	O
placebo	O
administration	O
we	O
observed	O
increases	O
in	O
concentrations	O
of	O
blood	O
substrates	O
,	O
plasma	B-protein
adrenocorticotropin	I-protein
(	O
ACTH	B-protein
)	O
,	O
growth	O
hormone	O
and	O
cortisol	O
and	O
in	O
the	O
number	O
of	O
glucocorticoid	B-protein
receptors	I-protein
in	O
lymphocytes	B-cell_type
without	O
changes	O
in	O
the	O
dissociation	O
constant	O
.	O

Intravenous	O
administration	O
of	O
PCr	O
(	O
starting	O
1	O
day	O
before	O
exercise	O
)	O
led	O
to	O
an	O
increase	O
in	O
the	O
total	O
workload	O
(	O
on	O
average	O
by	O
5.8	O
%	O
)	O
and	O
in	O
AT	O
(	O
on	O
average	O
by	O
6.8	O
%	O
)	O
during	O
MPE	O
and	O
to	O
a	O
better	O
tolerance	O
of	O
exercise	O
during	O
PPE	O
.	O

Following	O
PCr	O
administration	O
we	O
observed	O
lower	O
blood	O
lactate	O
concentrations	O
and	O
different	O
patterns	O
of	O
some	O
enzyme	O
activities	O
,	O
less	O
pronounced	O
changes	O
in	O
plasma	B-protein
ACTH	I-protein
and	O
cortisol	O
concentrations	O
and	O
in	O
glucocorticoid	O
binding	O
in	O
lymphocytes	B-cell_type
,	O
but	O
no	O
changes	O
in	O
plasma	O
growth	O
hormone	O
concentrations	O
compared	O
to	O
the	O
placebo	O
.	O

The	O
results	O
showed	O
that	O
intense	O
physical	O
exercise	O
led	O
not	O
only	O
to	O
increases	O
in	O
blood	O
hormone	O
concentrations	O
but	O
also	O
to	O
an	O
increase	O
in	O
the	O
density	O
of	O
glucocorticoid	B-protein
receptors	I-protein
in	O
lymphocytes	B-cell_type
.	O

Intravenous	O
PCr	O
injection	O
led	O
to	O
smaller	O
changes	O
in	O
ACTH	B-protein
and	O
cortisol	O
concentrations	O
as	O
well	O
as	O
to	O
a	O
lower	O
activation	O
of	O
glucocorticoid	O
binding	O
in	O
lymphocytes	B-cell_type
.	O

Putative	B-protein
steroid	I-protein
binding	I-protein
domain	I-protein
of	O
the	O
human	B-protein
mineralocorticoid	I-protein
receptor	I-protein
,	O
expressed	O
in	O
E.	O
coli	O
in	O
the	O
presence	O
of	O
heat	B-protein
shock	I-protein
proteins	I-protein
shows	O
typical	O
native	O
receptor	O
characteristics	O
.	O

Domain	B-protein
E	I-protein
,	O
considered	O
as	O
the	O
putative	B-protein
hormone	I-protein
binding	I-protein
domain	I-protein
(	O
HBD	B-protein
)	O
of	O
the	O
human	B-protein
mineralocorticoid	I-protein
receptor	I-protein
(	O
hMR	B-protein
)	O
was	O
expressed	O
in	O
Escherichia	O
coli	O
as	O
a	O
fusion	O
protein	O
with	O
either	O
maltose	B-protein
binding	I-protein
protein	I-protein
(	O
MBP	B-protein
)	O
or	O
glutathione	B-protein
S-transferase	I-protein
(	O
GST	B-protein
)	O
.	O

These	O
bacterially-produced	B-DNA
MR	I-DNA
constructs	I-DNA
had	O
no	O
steroid	O
binding	O
activity	O
per	O
se	O
.	O

In	O
fact	O
,	O
heat	B-protein
shock	I-protein
protein	I-protein
association	O
(	O
hsp	B-protein
)	O
is	O
required	O
for	O
high	O
affinity	O
ligand-binding	O
of	O
the	O
MR	B-protein
.	O

After	O
incubation	O
of	O
purified	O
MBP-	B-protein
or	I-protein
GST-HBD	I-protein
with	O
rabbit	O
reticulocyte	O
lysate	O
,	O
known	O
to	O
be	O
rich	O
in	O
heat	B-protein
shock	I-protein
proteins	I-protein
,	O
we	O
obtained	O
saturable	O
binding	O
of	O
[	O
3H	O
]	O
aldosterone	O
.	O

The	O
Kd	O
value	O
for	O
aldosterone	O
was	O
0.3	O
nM	O
and	O
the	O
Bmax	O
=	O
32	O
pmol/mg	O
.	O

Hormone	O
binding	O
specificity	O
was	O
assessed	O
by	O
competition	O
studies	O
with	O
various	O
steroid	O
ligands	O
.	O

Sucrose	O
gradient	O
assays	O
performed	O
with	O
[	B-protein
3H	I-protein
]	I-protein
aldosterone-MBP-HBD	I-protein
revealed	O
complex	O
sedimenting	O
at	O
8.3S	O
and	O
4.9S	O
with	O
[	B-protein
3H	I-protein
]	I-protein
progesterone-MBP-HBD	I-protein
.	O

Western-blot	O
analysis	O
of	O
the	O
sedimentation	O
peak	O
showed	O
the	O
concomitant	O
presence	O
of	O
MBP-HBD	B-protein
by	O
a	O
monoclonal	B-protein
anti-MBP	I-protein
antibody	I-protein
,	O
and	O
hsp90	B-protein
by	O
a	O
monoclonal	B-protein
anti-hsp	I-protein
antibody	I-protein
.	O

Moreover	O
,	O
following	O
incubation	O
with	O
the	O
anti-rabbit	B-protein
hsp90	I-protein
monoclonal	I-protein
antibody	I-protein
the	O
sedimenting	O
gradient	O
showed	O
a	O
10.4S	B-protein
sedimenting	I-protein
complex	I-protein
.	O

These	O
analyses	O
demonstrated	O
that	O
the	O
[	O
3H	O
]	O
aldosterone-	O
MBP-HBD	B-protein
complex	I-protein
is	O
at	O
least	O
associated	O
with	O
hsp90	B-protein
in	O
reticulocyte	O
lysate	O
and	O
that	O
the	O
HBD	B-protein
of	O
hMR	B-protein
is	O
sufficient	O
to	O
bind	O
hsp90	B-protein
.	O

Deletions	O
of	O
a	O
relatively	O
short	O
amino-	B-protein
(	I-protein
729-766	I-protein
)	I-protein
or	I-protein
carboxy-	I-protein
terminal	I-protein
(	I-protein
940-984	I-protein
)	I-protein
region	I-protein
of	O
the	O
HBD	B-protein
fragment	I-protein
eliminated	O
all	O
steroid-binding	O
properties	O
.	O

Overall	O
,	O
these	O
results	O
indicate	O
that	O
the	O
integrity	O
of	O
domain	B-protein
E	I-protein
is	O
necessary	O
and	O
sufficient	O
to	O
bind	O
steroid	O
ligands	O
,	O
agonists	O
or	O
antagonists	O
,	O
with	O
characteristics	O
similar	O
to	O
the	O
entire	O
native	O
MR	B-protein
.	O

Renal	O
cell	O
carcinoma-derived	O
gangliosides	O
suppress	O
nuclear	B-protein
factor-kappaB	I-protein
activation	O
in	O
T	B-cell_type
cells	I-cell_type
.	O

Activation	O
of	O
the	O
transcription	B-protein
factor	I-protein
nuclear	I-protein
factor-kappaB	I-protein
(	O
NFkappaB	B-protein
)	O
is	O
impaired	O
in	O
T	B-cell_type
cells	I-cell_type
from	O
patients	O
with	O
renal	O
cell	O
carcinomas	O
(	O
RCCs	O
)	O
.	O

In	O
circulating	O
T	B-cell_type
cells	I-cell_type
from	O
a	O
subset	O
of	O
patients	O
with	O
RCCs	O
,	O
the	O
suppression	O
of	O
NFkappaB	B-protein
binding	O
activity	O
is	O
downstream	O
from	O
the	O
stimulus-induced	O
degradation	O
of	O
the	O
cytoplasmic	B-protein
factor	I-protein
IkappaBalpha	B-protein
.	O

Tumor-derived	B-protein
soluble	I-protein
products	I-protein
from	O
cultured	O
RCC	O
explants	O
inhibit	O
NFkappaB	B-protein
activity	O
in	O
T	B-cell_type
cells	I-cell_type
from	O
healthy	O
volunteers	O
,	O
despite	O
a	O
normal	O
level	O
of	O
stimulus-induced	O
IkappaBalpha	B-protein
degradation	O
in	O
these	O
cells	O
.	O

The	O
inhibitory	O
agent	O
has	O
several	O
features	O
characteristic	O
of	O
a	O
ganglioside	O
,	O
including	O
sensitivity	O
to	O
neuraminidase	B-protein
but	O
not	O
protease	B-protein
treatment	O
;	O
hydrophobicity	O
;	O
and	O
molecular	O
weight	O
less	O
than	O
3	O
kDa	O
.	O

Indeed	O
,	O
we	O
detected	O
gangliosides	O
in	O
supernatants	O
from	O
RCC	B-cell_type
explants	I-cell_type
and	O
not	O
from	O
adjacent	O
normal	O
kidney	O
tissue	O
.	O

Gangliosides	O
prepared	O
from	O
RCC	O
supernatants	O
,	O
as	O
well	O
as	O
the	O
purified	O
bovine	O
gangliosides	O
G	O
(	O
m1	O
)	O
and	O
G	O
(	O
d1a	O
)	O
,	O
suppressed	O
NFkappaB	B-protein
binding	O
activity	O
in	O
T	B-cell_type
cells	I-cell_type
and	O
reduced	O
expression	O
of	O
the	O
cytokines	B-protein
IL-2	B-protein
and	O
IFN-gamma	B-protein
.	O

Taken	O
together	O
,	O
our	O
findings	O
suggest	O
that	O
tumor-derived	O
gangliosides	O
may	O
blunt	O
antitumor	O
immune	O
responses	O
in	O
patients	O
with	O
RCCs	O
.	O

Nuclear	B-protein
factor-kappaB	I-protein
-dependent	O
induction	O
of	O
interleukin-8	B-protein
gene	O
expression	O
by	O
tumor	B-protein
necrosis	I-protein
factor	I-protein
alpha	I-protein
:	O
evidence	O
for	O
an	O
antioxidant	O
sensitive	O
activating	O
pathway	O
distinct	O
from	O
nuclear	O
translocation	O
.	O

Tumor	B-protein
necrosis	I-protein
factor	I-protein
alpha	I-protein
(	O
TNFalpha	B-protein
)	O
is	O
a	O
pluripotent	O
activator	O
of	O
inflammation	O
by	O
inducing	O
a	O
proinflammatory	B-protein
cytokine	I-protein
cascade	O
.	O

This	O
phenomenon	O
is	O
mediated	O
,	O
in	O
part	O
,	O
through	O
inducible	O
expression	O
of	O
the	O
CXC	B-protein
chemokine	I-protein
,	O
interleukin-8	B-protein
(	O
IL-8	O
)	O
.	O

In	O
this	O
study	O
,	O
we	O
investigate	O
the	O
role	O
of	O
TNFalpha	B-protein
-inducible	O
reactive	O
oxygen	O
species	O
(	O
ROS	O
)	O
in	O
IL-8	B-protein
expression	O
by	O
``	O
monocyte-like	O
''	O
U937	B-cell_line
histiocytic	I-cell_line
lymphoma	I-cell_line
cells	I-cell_line
.	O

TNFalpha	B-protein
is	O
a	O
rapid	O
activator	O
of	O
IL-8	B-DNA
gene	I-DNA
expression	O
by	O
U937	B-cell_line
,	O
producing	O
a	O
50-fold	O
induction	O
of	O
mRNA	B-RNA
within	O
1	O
hour	O
of	O
treatment	O
.	O

In	O
gene	O
transfection	O
assays	O
,	O
the	O
effect	O
of	O
TNFalpha	B-protein
requires	O
the	O
presence	O
of	O
an	O
inducible	B-DNA
nuclear	I-DNA
factor-kappaB	I-DNA
(	I-DNA
NF-kappaB	I-DNA
)	I-DNA
(	I-DNA
Rel	I-DNA
A	I-DNA
)	I-DNA
binding	I-DNA
site	I-DNA
in	O
the	O
IL-8	B-DNA
promoter	I-DNA
.	O

TNFalpha	B-protein
treatment	O
induces	O
a	O
rapid	O
translocation	O
of	O
the	O
65	B-protein
kD	I-protein
transcriptional	I-protein
activator	I-protein
NF-kappaB	B-protein
subunit	I-protein
,	O
Rel	B-protein
A	I-protein
,	O
whose	O
binding	O
in	O
the	O
nucleus	O
occurs	O
before	O
changes	O
in	O
intracellular	O
ROS	O
.	O

Pretreatment	O
(	O
or	O
up	O
to	O
15	O
minutes	O
posttreatment	O
)	O
relative	O
to	O
TNFalpha	B-protein
with	O
the	O
antioxidant	O
dimethyl	O
sulfoxide	O
(	O
DMSO	O
)	O
(	O
2	O
%	O
[	O
vol/vol	O
]	O
)	O
blocks	O
80	O
%	O
of	O
NF-kappaB	B-protein
-dependent	O
transcription	O
.	O

Surprisingly	O
,	O
however	O
,	O
DMSO	O
has	O
no	O
effect	O
on	O
inducible	O
Rel	B-protein
A	I-protein
binding	O
.	O

Similar	O
selective	O
effects	O
on	O
NF-kappaB	B-protein
transcription	O
are	O
seen	O
with	O
the	O
unrelated	O
antioxidants	O
,	O
N-acetylcysteine	O
(	O
NAC	O
)	O
and	O
vitamin	O
C	O
.	O

These	O
data	O
indicate	O
that	O
TNFalpha	B-protein
induces	O
a	O
delayed	O
ROS-dependent	O
signalling	O
pathway	O
that	O
is	O
required	O
for	O
NF-kappaB	B-protein
transcriptional	O
activation	O
and	O
is	O
separable	O
from	O
that	O
required	O
for	O
its	O
nuclear	O
translocation	O
.	O

Further	O
definition	O
of	O
this	O
pathway	O
will	O
yield	O
new	O
insights	O
into	O
inflammation	O
initiated	O
by	O
TNFalpha	B-protein
signalling	O
.	O

Gender	O
and	O
vascular	O
reactivity	O
.	O

Estrogen	B-protein
receptors	I-protein
are	O
found	O
on	O
vascular	B-cell_type
endothelial	I-cell_type
and	I-cell_type
smooth	I-cell_type
muscle	I-cell_type
cells	I-cell_type
;	O
their	O
expression	O
is	O
influenced	O
by	O
exposure	O
to	O
the	O
hormone	O
.	O

Estrogen	B-protein
receptors	I-protein
influence	O
non-genomic	O
events	O
,	O
which	O
are	O
rapid	O
in	O
onset	O
and	O
genomic	O
events	O
,	O
which	O
are	O
longer	O
acting	O
responses	O
.	O

Estrogens	O
affect	O
vascular	O
tone	O
indirectly	O
by	O
modulating	O
release	O
of	O
endothelium-derived	B-protein
vasoactive	I-protein
factors	I-protein
and	O
directly	O
by	O
modulating	O
intracellular	O
calcium	O
in	O
vascular	B-cell_type
smooth	I-cell_type
muscle	I-cell_type
cells	I-cell_type
.	O

Estrogens	O
indirectly	O
affect	O
thrombotic	O
events	O
and	O
inflammation	O
by	O
altering	O
platelet	B-cell_type
aggregation	O
and	O
leukocyte	B-cell_type
adherence	O
and	O
migration	O
,	O
respectively	O
.	O

Estrogens	O
also	O
influence	O
production	O
of	O
mitogens	O
which	O
,	O
when	O
released	O
at	O
sites	O
of	O
vascular	O
injury	O
,	O
affect	O
vascular	O
remodeling	O
.	O

Although	O
estrogens	O
initiate	O
vascular	O
responses	O
,	O
genomic	O
sex	O
may	O
influence	O
and/or	O
limit	O
expression	O
of	O
estrogen	O
receptors	O
and	O
therefore	O
actions	O
of	O
sex	O
steroid	O
hormones	O
throughout	O
the	O
vasculature	O
.	O

Induction	O
of	O
a	O
functional	O
vitamin	B-protein
D	I-protein
receptor	I-protein
in	O
all-trans-retinoic	O
acid-induced	O
monocytic	O
differentiation	O
of	O
M2-type	B-cell_line
leukemic	I-cell_line
blast	I-cell_line
cells	I-cell_line
.	O

Different	O
types	O
of	O
acute	B-cell_type
myeloid	I-cell_type
leukemia	I-cell_type
blast	I-cell_type
cells	I-cell_type
were	O
induced	O
to	O
differentiate	O
in	O
vitro	O
with	O
all-trans-retinoic	O
acid	O
(	O
ATRA	O
)	O
and	O
vitamin	O
D3	O
(	O
VD	O
)	O
.	O

M0/M1	B-cell_line
leukemic	I-cell_line
cells	I-cell_line
are	O
not	O
sensitive	O
to	O
differentiating	O
agents	O
,	O
whereas	O
M3	B-cell_line
leukemic	I-cell_line
cells	I-cell_line
are	O
induced	O
to	O
undergo	O
granulocytic	O
differentiation	O
after	O
ATRA	O
treatment	O
but	O
are	O
not	O
sensitive	O
to	O
VD	O
.	O

M2	B-cell_line
leukemic	I-cell_line
blast	I-cell_line
cells	I-cell_line
behave	O
differently	O
because	O
they	O
undergo	O
monocytic	O
differentiation	O
with	O
both	O
the	O
differentiation	O
inducers	O
.	O

To	O
gain	O
some	O
insight	O
into	O
the	O
maturation	O
of	O
M2-type	B-cell_type
leukemic	I-cell_type
cells	I-cell_type
,	O
we	O
studied	O
the	O
molecular	O
mechanisms	O
underlying	O
monocytic	O
differentiation	O
induced	O
by	O
ATRA	O
and	O
VD	O
in	O
spontaneous	O
M2	B-cell_line
blast	I-cell_line
cells	I-cell_line
as	O
well	O
as	O
in	O
Kasumi-1	B-cell_line
cells	I-cell_line
(	O
an	O
acute	B-cell_line
myeloid	I-cell_line
leukemia	I-cell_line
M2-type	I-cell_line
cell	I-cell_line
line	I-cell_line
)	O
.	O

Our	O
results	O
indicate	O
that	O
ATRA	O
as	O
well	O
as	O
VD	O
efficiently	O
increases	O
the	O
nuclear	O
abundance	O
of	O
VD	B-protein
receptor	I-protein
(	O
VDR	B-protein
)	O
and	O
promotes	O
monocytic	O
differentiation	O
.	O

VDR	B-protein
is	O
functionally	O
active	O
in	O
ATRA-treated	O
Kasumi-1	B-cell_line
cells	I-cell_line
because	O
it	O
efficiently	O
heterodimerizes	O
with	O
retinoid	B-protein
X	I-protein
receptor	I-protein
,	O
binds	O
to	O
a	O
DR3-type	B-DNA
vitamin	I-DNA
D-responsive	I-DNA
element	I-DNA
,	O
and	O
activates	O
the	O
transcription	O
of	O
a	O
vitamin	B-DNA
D-responsive	I-DNA
element-regulated	I-DNA
reporter	I-DNA
gene	I-DNA
.	O

Consistent	O
with	O
these	O
findings	O
,	O
VD-responsive	B-DNA
genes	I-DNA
are	O
induced	O
by	O
ATRA	O
treatment	O
of	O
Kasumi-1	B-cell_line
cells	I-cell_line
,	O
suggesting	O
that	O
the	O
genetic	O
program	O
underlying	O
monocytic	O
differentiation	O
is	O
activated	O
.	O

The	O
molecular	O
mechanism	O
by	O
which	O
ATRA	O
increases	O
the	O
nuclear	O
abundance	O
of	O
a	O
functional	O
VDR	B-protein
is	O
still	O
unknown	O
,	O
but	O
our	O
data	O
clearly	O
indicate	O
that	O
the	O
M2	B-cell_line
leukemic	I-cell_line
cell	I-cell_line
context	O
is	O
only	O
permissive	O
of	O
monocytic	O
differentiation	O
.	O

Protein	B-protein
kinase	I-protein
C	I-protein
and	O
calcineurin	B-protein
synergize	O
to	O
activate	O
IkappaB	B-protein
kinase	I-protein
and	O
NF-kappaB	B-protein
in	O
T	B-cell_type
lymphocytes	I-cell_type
.	O

The	O
nuclear	O
factor	O
of	O
kappaB	O
(	O
NF-kappaB	B-protein
)	O
is	O
a	O
ubiquitous	B-protein
transcription	I-protein
factor	I-protein
that	O
is	O
key	O
in	O
the	O
regulation	O
of	O
the	O
immune	O
response	O
and	O
inflammation	O
.	O

T	B-protein
cell	I-protein
receptor	I-protein
(	O
TCR	B-protein
)	O
cross-linking	O
is	O
in	O
part	O
required	O
for	O
activation	O
of	O
NF-kappaB	B-protein
,	O
which	O
is	O
dependent	O
on	O
the	O
phosphorylation	O
and	O
degradation	O
of	O
IkappaBalpha	B-protein
.	O

By	O
using	O
Jurkat	B-cell_line
and	O
primary	B-cell_type
human	I-cell_type
T	I-cell_type
lymphocytes	I-cell_type
,	O
we	O
demonstrate	O
that	O
the	O
simultaneous	O
activation	O
of	O
two	O
second	O
messengers	O
of	O
the	O
TCR	B-protein
-initiated	O
signal	O
transduction	O
,	O
protein	B-protein
kinase	I-protein
C	I-protein
(	O
PKC	B-protein
)	O
and	O
calcineurin	B-protein
,	O
results	O
in	O
the	O
synergistic	O
activation	O
of	O
the	O
IkappaBalpha	B-protein
kinase	I-protein
(	I-protein
IKK	I-protein
)	I-protein
complex	I-protein
but	O
not	O
of	O
another	O
putative	B-protein
IkappaBalpha	I-protein
kinase	I-protein
,	O
p90	B-protein
(	I-protein
rsk	I-protein
)	I-protein
.	O

We	O
also	O
demonstrate	O
that	O
the	O
IKK	B-protein
complex	I-protein
,	O
but	O
not	O
p90	B-protein
(	I-protein
rsk	I-protein
)	I-protein
,	O
is	O
responsible	O
for	O
the	O
in	O
vivo	O
phosphorylation	O
of	O
IkappaBalpha	B-protein
mediated	O
by	O
the	O
co-activation	O
of	O
PKC	B-protein
and	O
calcineurin	B-protein
.	O

Each	O
second	O
messenger	O
is	O
necessary	O
,	O
as	O
inhibition	O
of	O
either	O
one	O
reverses	O
the	O
activation	O
of	O
the	O
IKK	B-protein
complex	I-protein
and	O
IkappaBalpha	B-protein
phosphorylation	O
in	O
vivo	O
.	O

Overexpression	O
of	O
dominant	O
negative	O
forms	O
of	O
IKKalpha	B-protein
and	I-protein
-beta	I-protein
demonstrates	O
that	O
only	O
IKKbeta	B-protein
is	O
the	O
target	O
for	O
PKC	B-protein
and	O
calcineurin	B-protein
.	O

These	O
results	O
indicate	O
that	O
within	O
the	O
TCR	B-protein
/CD3	B-protein
signal	O
transduction	O
pathway	O
both	O
PKC	B-protein
and	O
calcineurin	B-protein
are	O
required	O
for	O
the	O
effective	O
activation	O
of	O
the	O
IKK	B-protein
complex	I-protein
and	O
NF-kappaB	B-protein
in	O
T	B-cell_type
lymphocytes	I-cell_type
.	O

Diminished	O
responses	O
to	O
IL-13	B-protein
by	O
human	O
monocytes	O
differentiated	O
in	O
vitro	O
:	O
role	O
of	O
the	O
IL-13Ralpha1	B-protein
chain	I-protein
and	O
STAT6	B-protein
.	O

The	O
primary	O
IL-13	B-protein
receptor	I-protein
complex	I-protein
on	O
human	B-cell_type
monocytes	I-cell_type
is	O
believed	O
to	O
be	O
a	O
heterodimer	O
comprised	O
of	O
the	O
IL-4R	B-protein
alpha	I-protein
chain	I-protein
and	O
the	O
IL-2R	B-protein
gamma	I-protein
chain	I-protein
(	B-protein
gamma	I-protein
(	I-protein
c	I-protein
)	I-protein
)	I-protein
-like	I-protein
molecule	I-protein
,	O
IL-13R	B-protein
alpha1	I-protein
.	O

mRNA	B-RNA
levels	O
for	O
IL-13R	B-protein
alpha1	I-protein
,	O
but	O
not	O
IL-4R	B-protein
alpha	I-protein
,	O
were	O
markedly	O
decreased	O
in	O
in	B-cell_line
vitro	I-cell_line
monocyte-derived	I-cell_line
macrophages	I-cell_line
(	O
MDMac	B-cell_line
)	O
,	O
and	O
with	O
increasing	O
time	O
of	O
monocytes	B-cell_type
in	O
culture	O
correlated	O
with	O
the	O
loss	O
of	O
IL-13	B-protein
regulation	O
of	O
lipopolysaccharide-induced	O
TNF-alpha	B-protein
production	O
.	O

Analysis	O
of	O
cell	B-cell_line
lines	I-cell_line
Daudi	B-cell_line
and	O
THP-1	B-cell_line
that	O
differentially	O
express	O
gamma	B-protein
(	I-protein
c	I-protein
)	I-protein
and	O
IL-13R	B-protein
alpha1	I-protein
showed	O
that	O
IL-13	B-protein
can	O
activate	O
STAT6	B-protein
in	O
IL-13R	B-cell_line
alpha1-positive	I-cell_line
THP-1	I-cell_line
cells	I-cell_line
but	O
not	O
in	O
gamma	B-cell_line
(	I-cell_line
c	I-cell_line
)	I-cell_line
-positive	I-cell_line
,	I-cell_line
IL-13R	I-cell_line
alpha1-negative	I-cell_line
Daudi	I-cell_line
cells	I-cell_line
.	O

IL-13	B-protein
activation	O
of	O
STAT6	B-protein
was	O
reduced	O
in	O
MDMac	B-cell_line
which	O
was	O
associated	O
with	O
diminished	O
IL-13	B-protein
-induced	O
expression	O
of	O
CD23	B-protein
and	O
MHC	B-protein
class	I-protein
II	I-protein
.	O

However	O
,	O
with	O
reduced	O
IL-13R	B-protein
alpha1	I-protein
expression	O
and	O
low	O
nuclear	O
STAT6	B-protein
activity	O
,	O
some	O
IL-13	B-protein
-induced	O
responses	O
were	O
unaltered	O
in	O
magnitude	O
in	O
MDMac	B-cell_line
.	O

In	O
the	O
absence	O
of	O
functional	O
IL-13R	B-protein
alpha1	I-protein
and	O
gamma	B-protein
(	I-protein
c	I-protein
)	I-protein
,	O
IL-13	B-protein
must	O
signal	O
through	O
an	O
alternative	O
receptor	B-protein
complex	I-protein
on	O
MDMac	B-cell_line
.	O

Experiments	O
with	O
a	O
blocking	O
antibody	O
to	O
IL-4R	B-protein
alpha	I-protein
showed	O
that	O
this	O
chain	O
remains	O
an	O
essential	O
component	O
of	O
the	O
IL-13	B-protein
receptor	I-protein
complex	I-protein
on	O
MDMac	B-cell_line
.	O

The	O
p53	B-protein
paradox	O
in	O
the	O
pathogenesis	O
of	O
tumor	O
progression	O
.	O

Recent	O
evidence	O
suggests	O
that	O
the	O
p53	B-protein
molecule	I-protein
appears	O
in	O
two	O
different	O
forms	O
:	O
the	O
mutant	B-protein
p53	I-protein
that	O
stimulates	O
tumor	O
progression	O
,	O
and	O
wild	B-protein
type	I-protein
p53	I-protein
that	O
inhibits	O
tumor	O
progression	O
.	O

In	O
addition	O
,	O
it	O
has	O
been	O
established	O
that	O
tumor	B-protein
necrosis	I-protein
factor-alpha	I-protein
(	O
TNF-alpha	B-protein
)	O
can	O
activate	O
the	O
expression	O
of	O
wild	B-protein
type	I-protein
p53	I-protein
in	O
concert	O
with	O
the	O
nuclear	B-protein
transcription	I-protein
factor	I-protein
,	O
NF-kappa	B-protein
B	I-protein
.	O

Both	O
TNF-alpha	B-protein
and	O
NF-kappa	B-protein
B	I-protein
are	O
also	O
involved	O
in	O
the	O
stimulation	O
of	O
the	O
pathway	O
that	O
leads	O
to	O
the	O
expression	O
of	O
major	B-protein
histocompatibility	I-protein
complex	I-protein
(	I-protein
MHC	I-protein
)	I-protein
class	I-protein
I	I-protein
molecules	I-protein
and	O
,	O
hence	O
,	O
antigen	O
presentation	O
to	O
the	O
T	B-cell_type
cells	I-cell_type
.	O

In	O
this	O
paper	O
we	O
shall	O
advance	O
the	O
hypothesis	O
that	O
:	O
(	O
i	O
)	O
TNF-alpha	B-protein
indirectly	O
controls	O
immune	O
surveillance	O
;	O
and	O
(	O
ii	O
)	O
TNF-alpha	B-protein
controls	O
DNA	O
repair	O
and	O
tumor	O
suppression	O
through	O
the	O
regulation	O
of	O
wild	B-protein
type	I-protein
p53	I-protein
.	O

Thus	O
,	O
it	O
is	O
hypothesized	O
that	O
elevated	O
TNF-alpha	B-protein
is	O
primarily	O
responsible	O
for	O
promoting	O
tumor	O
progression	O
.	O

The	O
promoter	B-DNA
and	O
5	B-DNA
'	I-DNA
flanking	I-DNA
sequences	I-DNA
controlling	O
human	O
B29	B-DNA
gene	I-DNA
expression	O
.	O

The	O
product	O
of	O
the	O
B-cell-specific	B-DNA
B29	I-DNA
gene	I-DNA
(	O
B29	B-protein
,	O
Ig	B-protein
beta	I-protein
,	O
CD79b	B-protein
)	O
is	O
essential	O
for	O
Ig-mediated	O
B-cell	O
activation	O
via	O
the	O
B-cell	B-protein
antigen	I-protein
receptor	I-protein
complex	I-protein
(	O
BCR	B-protein
)	O
on	O
human	B-cell_type
and	I-cell_type
murine	I-cell_type
B	I-cell_type
lymphocytes	I-cell_type
.	O

To	O
better	O
understand	O
the	O
regulation	O
of	O
this	O
pivotal	O
gene	O
,	O
we	O
have	O
analyzed	O
the	O
human	B-DNA
genomic	I-DNA
DNA	I-DNA
sequence	I-DNA
upstream	O
of	O
the	O
B29	B-protein
ATG	B-DNA
start	I-DNA
codon	I-DNA
for	O
transcriptional	O
control	O
activity	O
.	O

The	O
human	O
B29	B-DNA
gene	I-DNA
lacks	O
either	O
a	O
TATA	B-DNA
or	I-DNA
a	I-DNA
CAAT	I-DNA
box	I-DNA
and	O
transcription	O
is	O
initiated	O
at	O
multiple	B-DNA
sites	I-DNA
.	O

The	O
minimal	O
promoter	O
of	O
the	O
human	B-DNA
B29	I-DNA
gene	I-DNA
is	O
contained	O
within	O
a	O
193-bp	B-DNA
region	I-DNA
5	O
'	O
of	O
these	O
multiple	B-DNA
start	I-DNA
sites	I-DNA
.	O

This	O
minimal	B-DNA
promoter	I-DNA
exhibits	O
B-cell-specific	O
activity	O
and	O
contains	O
SP1	B-DNA
,	I-DNA
ETS	I-DNA
,	I-DNA
OCT	I-DNA
,	I-DNA
and	I-DNA
IKAROS/LYF-1	I-DNA
transcription	I-DNA
factor	I-DNA
motifs	I-DNA
.	O

All	O
these	O
motifs	O
are	O
strikingly	O
conserved	O
in	O
sequence	O
and	O
placement	O
relative	O
to	O
the	O
previously	O
characterized	O
murine	B-DNA
B29	I-DNA
promoter	I-DNA
.	O

Additional	O
upstream	O
gene	O
segments	O
dramatically	O
affected	O
B29	B-protein
minimal	B-DNA
promoter	I-DNA
activity	O
.	O

A	O
newly	O
identified	O
motif	O
called	O
the	O
B29	B-DNA
conserved	I-DNA
sequence	I-DNA
(	O
BCS	B-DNA
)	O
,	O
found	O
upstream	O
of	O
both	O
human	B-DNA
and	I-DNA
murine	I-DNA
B29	I-DNA
promoters	I-DNA
,	O
appears	O
to	O
stimulate	O
B29	B-protein
transcription	O
through	O
a	O
novel	O
mechanism	O
.	O

A	O
single	O
BCS	B-DNA
had	O
little	O
effect	O
either	O
on	O
the	O
minimal	O
B29	B-DNA
promoter	I-DNA
or	O
on	O
a	O
heterologous	O
promoter	O
.	O

Instead	O
,	O
the	O
BCS	B-DNA
stimulated	O
transcription	O
by	O
counteracting	O
5	B-DNA
'	I-DNA
negative	I-DNA
regulatory	I-DNA
DNA	I-DNA
sequences	I-DNA
that	O
block	O
the	O
activity	O
of	O
the	O
B29	B-protein
minimal	B-DNA
promoter	I-DNA
in	O
its	O
absence	O
.	O

These	O
findings	O
indicate	O
that	O
B29	B-DNA
gene	I-DNA
expression	O
is	O
controlled	O
by	O
the	O
complex	O
interplay	O
of	O
positive	O
and	O
negative	B-DNA
regulatory	I-DNA
elements	I-DNA
.	O

A	O
novel	O
immunosuppressive	B-protein
factor	I-protein
in	O
bovine	O
colostrum	O
blocks	O
activation	O
of	O
the	O
interleukin	B-DNA
2	I-DNA
gene	I-DNA
enhancer	I-DNA
at	O
the	O
NFAT	B-DNA
site	I-DNA
.	O

A	O
factor	O
in	O
bovine	O
colostrum	O
(	O
colostrum	B-protein
inhibitory	I-protein
factor	I-protein
,	O
CIF	B-protein
)	O
inhibits	O
interleukin	B-protein
2	I-protein
(	O
IL2	B-protein
)	O
production	O
in	O
activated	O
T	B-cell_type
helper	I-cell_type
cells	I-cell_type
by	O
blocking	O
the	O
accumulation	O
of	O
IL2	B-RNA
mRNA	I-RNA
.	O

To	O
determine	O
whether	O
CIF	B-protein
blocks	O
at	O
the	O
level	O
of	O
IL2	B-protein
transcription	O
,	O
we	O
introduced	O
reporter	O
plasmids	O
into	O
the	O
human	B-cell_line
T	I-cell_line
leukemia	I-cell_line
cell	I-cell_line
line	I-cell_line
Jurkat	I-cell_line
by	O
transient	O
transfection	O
.	O

These	O
contained	O
the	O
luciferase	B-DNA
gene	I-DNA
under	O
the	O
control	O
of	O
either	O
the	O
human	B-DNA
IL2	I-DNA
upstream	I-DNA
enhancer	I-DNA
region	O
(	O
segments	O
-326	O
to	O
+45	O
)	O
or	O
three	O
repeats	O
of	O
the	O
NFAT	B-DNA
element	I-DNA
contained	O
within	O
it	O
(	O
segments	O
-255	O
to	O
-285	O
)	O
.	O

Expression	O
of	O
luciferase	B-protein
in	O
these	O
cells	O
was	O
induced	O
by	O
phorbol	O
myristate	O
acetate	O
plus	O
a	O
calcium	O
ionophore	O
.	O

CIF	B-protein
inhibited	O
induction	O
of	O
either	O
construct	O
as	O
did	O
cyclosporine	O
,	O
which	O
is	O
known	O
to	O
block	O
activation	O
of	O
the	O
NFAT	B-protein
element	I-protein
.	O

CIF	B-protein
failed	O
to	O
inhibit	O
several	O
other	O
enhancer	B-DNA
elements	I-DNA
.	O

The	O
NFAT-controlled	B-DNA
luciferase	I-DNA
gene	I-DNA
system	I-DNA
distinguishes	O
CIF	B-protein
from	O
other	O
T	O
cell	O
inhibitory	O
activities	O
present	O
in	O
colostrum	O
,	O
in	O
particular	O
,	O
TGF	B-protein
beta	I-protein
1	I-protein
and	O
TGF	B-protein
beta	I-protein
2	I-protein
and	O
the	O
glucocorticoids	O
.	O

Stably	O
transfected	O
Jurkat	O
cells	O
behaved	O
similarly	O
to	O
the	O
transiently	O
transfected	O
ones	O
with	O
respect	O
to	O
inhibition	O
by	O
CIF	B-protein
and	O
cyclosporine	O
.	O

The	O
NFAT	B-protein
-luc	O
assay	O
is	O
a	O
useful	O
technique	O
for	O
the	O
rapid	O
,	O
sensitive	O
measurement	O
of	O
CIF	B-protein
or	O
other	O
immunosuppressants	O
with	O
a	O
similar	O
mode	O
of	O
action	O
.	O

Heat	O
shock	O
induces	O
HIV-1	O
replication	O
in	O
chronically	O
infected	O
promyelocyte	B-cell_line
cell	I-cell_line
line	I-cell_line
OM10.1	I-cell_line
.	O

A	O
long	O
period	O
of	O
clinical	O
latency	O
before	O
development	O
of	O
symptoms	O
is	O
characteristic	O
of	O
human	O
immunodeficiency	O
virus	O
type	O
1	O
(	O
HIV-1	O
)	O
infection	O
.	O

OM10.1	B-cell_line
,	O
a	O
promyelocyte	B-cell_line
cell	I-cell_line
line	I-cell_line
latently	O
infected	O
with	O
HIV-1	O
,	O
has	O
been	O
developed	O
as	O
a	O
model	O
for	O
studying	O
the	O
mechanism	O
of	O
viral	O
latency	O
and	O
the	O
activation	O
of	O
virus	O
expression	O
.	O

We	O
found	O
that	O
this	O
latently	O
infected	O
cell	O
line	O
with	O
heat	O
shock	O
at	O
42	O
degrees	O
C	O
for	O
2	O
h	O
resulted	O
in	O
a	O
high	O
level	O
of	O
HIV-1	O
production	O
without	O
addition	O
of	O
any	O
cytokines	B-protein
.	O

The	O
mechanism	O
of	O
activation	O
was	O
analyzed	O
by	O
using	O
anti-TNF-alpha	B-protein
antibody	I-protein
and	O
various	O
inhibitors	O
.	O

Although	O
the	O
TNF-alpha	B-protein
level	O
in	O
culture	O
supernatants	O
was	O
below	O
the	O
sensitivity	O
of	O
an	O
ELISA	O
assay	O
system	O
,	O
addition	O
of	O
anti-	O
TNF-alpha	B-protein
antibody	O
in	O
culture	O
medium	O
could	O
partially	O
suppress	O
the	O
heat	O
shock	O
induced	O
HIV-1	O
production	O
.	O

Staurosporine	O
(	O
PKC	O
inhibitor	O
)	O
,	O
pentoxifylline	O
(	O
NF-kappa	O
B	O
inhibitor	O
)	O
,	O
and	O
Ro5-3335	O
(	O
HIV-1	O
Tat	B-protein
inhibitor	O
)	O
also	O
inhibited	O
significantly	O
the	O
heat	O
shock	O
induced	O
virus	O
activation	O
.	O

In	O
particular	O
,	O
staurosporine	O
achieved	O
approximately	O
90	O
%	O
inhibition	O
of	O
the	O
HIV-1	O
antigen	O
expression	O
in	O
heat	B-cell_line
shock-treated	I-cell_line
OM10.1	I-cell_line
at	O
a	O
non-toxic	O
concentration	O
.	O

Although	O
the	O
mechanism	O
of	O
HIV-1	O
activation	O
with	O
heat	O
shock	O
has	O
not	O
been	O
fully	O
elucidated	O
yet	O
,	O
it	O
is	O
presumed	O
PKC	B-protein
plays	O
an	O
important	O
role	O
in	O
HIV-1	O
activation	O
.	O

Thus	O
,	O
the	O
present	O
observations	O
will	O
provide	O
a	O
further	O
insight	O
into	O
the	O
pathogenesis	O
of	O
HIV-1	O
infections	O
.	O

Activation	O
of	O
the	O
CDC42	B-protein
effector	I-protein
N-WASP	B-protein
by	O
the	O
Shigella	B-protein
flexneri	I-protein
IcsA	I-protein
protein	I-protein
promotes	O
actin	B-protein
nucleation	O
by	O
Arp2/3	B-protein
complex	I-protein
and	O
bacterial	O
actin	B-protein
-based	O
motility	O
.	O

To	O
propel	O
itself	O
in	O
infected	B-cell_type
cells	I-cell_type
,	O
the	O
pathogen	O
Shigella	O
flexneri	O
subverts	O
the	O
Cdc42	B-protein
-controlled	O
machinery	O
responsible	O
for	O
actin	B-protein
assembly	O
during	O
filopodia	O
formation	O
.	O

Using	O
a	O
combination	O
of	O
bacterial	O
motility	O
assays	O
in	O
platelet	O
extracts	O
with	O
Escherichia	O
coli	O
expressing	O
the	O
Shigella	B-protein
IcsA	I-protein
protein	I-protein
and	O
in	O
vitro	O
analysis	O
of	O
reconstituted	O
systems	O
from	O
purified	B-protein
proteins	I-protein
,	O
we	O
show	O
here	O
that	O
the	O
bacterial	B-protein
protein	I-protein
IcsA	I-protein
binds	O
N-WASP	B-protein
and	O
activates	O
it	O
in	O
a	O
Cdc42	B-protein
-like	O
fashion	O
.	O

Dramatic	O
stimulation	O
of	O
actin	B-protein
assembly	O
is	O
linked	O
to	O
the	O
formation	O
of	O
a	O
ternary	O
IcsA-N-WASP-Arp2/3	B-protein
complex	I-protein
,	O
which	O
nucleates	O
actin	B-protein
polymerization	O
.	O

The	O
Arp2/3	B-protein
complex	I-protein
is	O
essential	O
in	O
initiation	O
of	O
actin	B-protein
assembly	O
and	O
Shigella	O
movement	O
,	O
as	O
previously	O
observed	O
for	O
Listeria	O
monocytogenes	O
.	O

Activation	O
of	O
N-WASP	B-protein
by	O
IcsA	B-protein
unmasks	O
two	O
domains	O
acting	O
together	O
in	O
insertional	O
actin	B-protein
polymerization	O
.	O

The	O
isolated	O
COOH-terminal	B-protein
domain	I-protein
of	O
N-WASP	B-protein
containing	O
a	O
verprolin-homology	B-protein
region	I-protein
,	O
a	O
cofilin-homology	O
sequence	O
,	O
and	O
an	O
acidic	B-protein
terminal	I-protein
segment	I-protein
(	O
VCA	B-protein
)	O
interacts	O
with	O
G-actin	B-protein
in	O
a	O
unique	O
profilin-like	O
functional	O
fashion	O
.	O

Hence	O
,	O
when	O
N-WASP	B-protein
is	O
activated	O
,	O
its	O
COOH-terminal	B-protein
domain	I-protein
feeds	O
barbed	O
end	O
growth	O
of	O
filaments	O
and	O
lowers	O
the	O
critical	O
concentration	O
at	O
the	O
bacterial	O
surface	O
.	O

On	O
the	O
other	O
hand	O
,	O
the	O
NH	B-protein
(	I-protein
2	I-protein
)	I-protein
-terminal	I-protein
domain	I-protein
of	O
N-WASP	B-protein
interacts	O
with	O
F-actin	B-protein
,	O
mediating	O
the	O
attachment	O
of	O
the	O
actin	B-protein
tail	I-protein
to	O
the	O
bacterium	O
surface	O
.	O

VASP	O
is	O
not	O
involved	O
in	O
Shigella	O
movement	O
,	O
and	O
the	O
function	O
of	O
profilin	B-protein
does	O
not	O
require	O
its	O
binding	O
to	O
proline-rich	B-protein
regions	I-protein
.	O

c-Maf	B-protein
induces	O
monocytic	O
differentiation	O
and	O
apoptosis	O
in	O
bipotent	B-cell_type
myeloid	I-cell_type
progenitors	I-cell_type
.	O

The	O
transcriptional	O
mechanisms	O
that	O
drive	O
colony-forming	B-cell_line
unit	I-cell_line
granulocyte-macrophage	I-cell_line
(	I-cell_line
CFU-GM	I-cell_line
)	I-cell_line
myeloid	I-cell_line
progenitors	I-cell_line
to	O
differentiate	O
into	O
cells	O
of	O
either	O
the	O
granulocytic	B-cell_type
or	I-cell_type
monocytic	I-cell_type
lineage	I-cell_type
are	O
not	O
fully	O
understood	O
.	O

We	O
have	O
shown	O
that	O
the	O
c-Maf	B-protein
and	O
c-Myb	B-protein
transcription	I-protein
factors	I-protein
physically	O
interact	O
in	O
myeloid	O
cells	O
to	O
form	O
inhibitory	O
complexes	O
that	O
hinder	O
transactivation	O
of	O
c-Myb	B-DNA
target	I-DNA
genes	I-DNA
through	O
direct	O
binding	O
to	O
Myb	B-DNA
consensus	I-DNA
sites	I-DNA
.	O

These	O
complexes	O
arise	O
in	O
a	O
developmentally	O
regulated	O
pattern	O
,	O
peaking	O
at	O
the	O
promyelocyte	B-cell_type
stage	I-cell_type
,	O
or	O
in	O
cell	B-cell_line
model	I-cell_line
systems	I-cell_line
,	O
appearing	O
soon	O
after	O
the	O
induction	O
of	O
monocytic	O
differentiation	O
.	O

We	O
wished	O
to	O
determine	O
if	O
this	O
developmentally	O
related	O
interaction	O
is	O
a	O
consequence	O
of	O
myeloid	O
differentiation	O
or	O
an	O
intrinsic	O
differentiating	O
stimulus	O
.	O

Because	O
the	O
elevated	O
Myb	B-protein
:	I-protein
Maf	I-protein
status	O
seen	O
in	O
differentiating	B-cell_type
cells	I-cell_type
can	O
be	O
recapitulated	O
by	O
overexpression	O
of	O
c-Maf	B-protein
in	O
myeloid	O
cell	O
lines	O
,	O
we	O
inducibly	O
expressed	O
the	O
c-Maf	B-DNA
cDNA	I-DNA
in	O
2	O
bipotent	O
human	B-cell_type
myeloid	I-cell_type
progenitor	I-cell_type
cells	I-cell_type
.	O

Elevated	O
levels	O
of	O
c-Maf	B-protein
protein	I-protein
led	O
to	O
marked	O
increases	O
in	O
Myb	B-protein
:	I-protein
Maf	I-protein
complexes	I-protein
and	O
the	O
accumulation	O
of	O
monocyte/macrophage	B-cell_type
cells	I-cell_type
,	O
followed	O
by	O
eventual	O
programmed	O
cell	O
death	O
.	O

Analysis	O
of	O
targets	O
that	O
could	O
mediate	O
these	O
phenotypic	O
changes	O
indicated	O
that	O
c-Maf	B-protein
likely	O
plays	O
a	O
key	O
role	O
in	O
myeloid	O
cell	O
development	O
through	O
dual	O
mechanisms	O
;	O
inhibition	O
of	O
a	O
select	O
set	O
of	O
c-Myb	B-protein
regulated	O
targets	O
,	O
such	O
as	O
Bcl-2	B-protein
and	O
CD13/APN	B-protein
,	O
coupled	O
with	O
the	O
activation	O
of	O
as	O
yet	O
undefined	O
differentiation-promoting	B-DNA
genes	I-DNA
.	O

AML1	B-protein
(	I-protein
CBFalpha2	I-protein
)	I-protein
cooperates	O
with	O
B	B-protein
cell-specific	I-protein
activating	I-protein
protein	I-protein
(	I-protein
BSAP/PAX5	I-protein
)	I-protein
in	O
activation	O
of	O
the	O
B	B-DNA
cell-specific	I-DNA
BLK	I-DNA
gene	I-DNA
promoter	I-DNA
.	O

AML1	B-protein
plays	O
a	O
critical	O
role	O
during	O
hematopoiesis	O
and	O
chromosomal	O
translocations	O
involving	O
AML1	B-protein
are	O
commonly	O
associated	O
with	O
different	O
forms	O
of	O
leukemia	O
,	O
including	O
pre-B	O
acute	O
lymphoblastic	O
leukemia	O
.	O

To	O
understand	O
the	O
function	O
of	O
AML1	B-protein
during	O
B	B-cell_type
cell	I-cell_type
differentiation	O
,	O
we	O
analyzed	O
regulatory	B-DNA
regions	I-DNA
of	O
B	B-DNA
cell-specific	I-DNA
genes	I-DNA
for	O
potential	O
AML1-binding	B-DNA
sites	I-DNA
and	O
have	O
identified	O
a	O
putative	O
AML1-binding	B-DNA
site	I-DNA
in	O
the	O
promoter	O
of	O
the	O
B	B-DNA
cell-specific	I-DNA
tyrosine	I-DNA
kinase	I-DNA
gene	I-DNA
,	I-DNA
blk	I-DNA
.	O

Gel	O
mobility	O
shift	O
assays	O
and	O
transient	O
transfection	O
assays	O
demonstrate	O
that	O
AML1	B-protein
binds	O
specifically	O
to	O
this	O
site	O
in	O
the	O
blk	B-DNA
promoter	I-DNA
and	O
this	O
binding	O
site	O
is	O
important	O
for	O
blk	B-DNA
promoter	O
activity	O
.	O

Furthermore	O
,	O
in	O
vitro	O
binding	O
analysis	O
revealed	O
that	O
the	O
AML1	B-DNA
runt	I-DNA
DNA-binding	I-DNA
domain	I-DNA
physically	O
interacts	O
with	O
the	O
paired	B-DNA
DNA-binding	I-DNA
domain	I-DNA
of	O
BSAP	B-protein
,	O
a	O
B	B-protein
cell-specific	I-protein
transcription	I-protein
factor	I-protein
.	O

BSAP	B-protein
has	O
been	O
shown	O
previously	O
to	O
be	O
important	O
for	O
B	O
cell-specific	O
regulation	O
of	O
the	O
blk	B-DNA
gene	O
.	O

Physical	O
interaction	O
of	O
AML1	B-protein
with	O
BSAP	B-protein
correlates	O
with	O
functional	O
cooperativity	O
in	O
transfection	O
studies	O
where	O
AML1	B-protein
and	O
BSAP	B-protein
synergistically	O
activate	O
blk	B-DNA
promoter	O
transcription	O
by	O
more	O
than	O
50-fold	O
.	O

These	O
results	O
demonstrate	O
physical	O
and	O
functional	O
interactions	O
between	O
AML1	B-protein
and	O
BSAP	B-protein
and	O
suggest	O
that	O
AML1	B-protein
is	O
an	O
important	O
factor	O
for	O
regulating	O
a	O
critical	O
B	B-DNA
cell-specific	I-DNA
gene	I-DNA
,	O
blk	B-DNA
.	O

Transcriptional	O
inhibition	O
by	O
interleukin-6	B-protein
of	O
the	O
class	B-protein
A	I-protein
macrophage	I-protein
scavenger	I-protein
receptor	I-protein
in	O
macrophages	B-cell_type
derived	O
from	O
human	B-cell_type
peripheral	I-cell_type
monocytes	I-cell_type
and	O
the	O
THP-1	B-cell_line
monocytic	I-cell_line
cell	I-cell_line
line	I-cell_line
.	O

Expression	O
of	O
the	O
class	B-protein
A	I-protein
macrophage	I-protein
scavenger	I-protein
receptor	I-protein
(	I-protein
MSR	I-protein
)	I-protein
contributes	O
to	O
the	O
uptake	O
of	O
modified	B-protein
low	I-protein
density	I-protein
lipoproteins	I-protein
(	I-protein
LDL	I-protein
)	I-protein
by	O
macrophages	B-cell_type
and	O
transformation	O
of	O
these	O
cells	O
into	O
lipid-laden	B-cell_type
foam	I-cell_type
cells	I-cell_type
,	O
which	O
characterize	O
atherosclerosis	O
.	O

Many	O
environmental	O
factors	O
,	O
in	O
particular	O
,	O
proinflammatory	B-protein
cytokines	I-protein
and	O
growth	B-protein
factors	I-protein
,	O
can	O
exert	O
regulatory	O
effects	O
on	O
MSR	B-protein
expression	O
,	O
whereas	O
intracellular	O
accumulation	O
of	O
cholesterol	O
itself	O
does	O
not	O
influence	O
MSR	B-protein
levels	O
to	O
any	O
considerable	O
extent	O
.	O

In	O
the	O
present	O
study	O
,	O
by	O
using	O
an	O
in	O
vitro	O
model	O
,	O
we	O
examined	O
whether	O
stimulation	O
with	O
interleukin-6	B-protein
(	I-protein
IL-6	I-protein
)	I-protein
,	O
an	O
immunoregulatory	B-protein
,	O
multipotential	B-protein
cytokine	I-protein
,	O
modulates	O
the	O
expression	O
and	O
activities	O
of	O
the	O
MSR	B-protein
in	O
macrophages	B-cell_type
.	O

When	O
treated	O
with	O
IL-6	B-protein
,	O
macrophages	B-cell_type
derived	O
from	O
peripheral	B-cell_type
monocytes	I-cell_type
and	O
phorbol	B-cell_line
12-myristate	I-cell_line
13-acetate	I-cell_line
(	I-cell_line
PMA	I-cell_line
)	I-cell_line
-differentiated	I-cell_line
THP-1	I-cell_line
monocytic	I-cell_line
cells	I-cell_line
showed	O
significantly	O
reduced	O
uptake	O
and/or	O
binding	O
of	O
the	O
MSR	B-protein
ligand	O
,	O
acetylated	B-protein
LDL	I-protein
.	O

This	O
effect	O
was	O
paralleled	O
by	O
a	O
reduction	O
in	O
the	O
expression	O
of	O
MSR	B-protein
protein	O
and	O
mRNA	B-RNA
.	O

Analysis	O
of	O
MSR	B-DNA
promoter	I-DNA
activity	O
in	O
THP-1	B-cell_line
cells	I-cell_line
transfected	O
with	O
an	O
MSR	B-DNA
promoter-reporter	I-DNA
gene	I-DNA
construct	I-DNA
demonstrated	O
decreased	O
activity	O
of	O
the	O
MSR	B-DNA
promoter	I-DNA
in	O
IL-6	B-protein
-treated	O
THP-1	B-cell_line
macrophages	B-cell_type
.	O

Electrophoretic	O
mobility	O
gel	O
shift	O
assay	O
also	O
showed	O
a	O
reduction	O
in	O
the	O
binding	O
of	O
a	O
transcription	B-protein
factor	I-protein
to	O
the	O
MSR	B-DNA
promoter	I-DNA
AP-1/ets	I-DNA
elements	I-DNA
in	O
IL-6	B-protein
-treated	O
cells	O
.	O

Thus	O
,	O
exposure	O
to	O
IL-6	B-protein
may	O
inhibit	O
expression	O
of	O
the	O
class	B-protein
A	I-protein
MSR	I-protein
in	O
differentiated	O
macrophages	B-cell_type
at	O
transcriptional	O
levels	O
.	O

This	O
result	O
suggests	O
that	O
this	O
cytokine	B-protein
may	O
modulate	O
foam	O
cell	O
formation	O
during	O
atherogenesis	O
.	O

Retinoblastoma	O
protein	O
expression	O
leads	O
to	O
reduced	O
Oct-1	B-protein
DNA	O
binding	O
activity	O
and	O
enhances	O
interleukin-8	B-protein
expression	O
.	O

Tumor	O
cell	O
lines	O
with	O
a	O
defective	O
retinoblastoma	B-DNA
gene	I-DNA
are	O
unable	O
to	O
transcribe	O
the	O
HLA	B-DNA
class	I-DNA
II	I-DNA
genes	I-DNA
in	O
response	O
to	O
IFN-gamma	B-protein
treatment	O
,	O
and	O
reconstitution	O
of	O
functional	O
Rb	B-protein
rescues	O
IFN-gamma-induced	O
class	B-DNA
II	I-DNA
gene	I-DNA
expression	O
.	O

However	O
,	O
the	O
molecular	O
mechanism	O
of	O
Rb	B-protein
rescue	O
of	O
the	O
class	B-DNA
II	I-DNA
genes	I-DNA
is	O
unknown	O
.	O

We	O
have	O
examined	O
the	O
effect	O
of	O
Rb	B-protein
expression	O
on	O
the	O
activation	O
of	O
the	O
promoter	O
for	O
HLA-DRA	B-DNA
,	O
the	O
prototype	B-DNA
class	I-DNA
II	I-DNA
gene	I-DNA
.	O

Oct-1	B-protein
,	O
a	O
POU	B-protein
domain	I-protein
transcription	I-protein
factor	I-protein
,	O
was	O
identified	O
as	O
a	O
repressor	O
of	O
HLA-DRA	B-DNA
promoter	O
activity	O
in	O
the	O
Rb-defective	B-cell_type
cells	I-cell_type
.	O

Rb	B-protein
expression	O
led	O
to	O
phosphorylation	O
of	O
Oct-1	B-protein
,	O
thus	O
relieving	O
its	O
repressive	O
effect	O
.	O

Oct-1	B-protein
has	O
also	O
been	O
shown	O
to	O
repress	O
interleukin	B-protein
8	I-protein
promoter	O
activity	O
.	O

Consistent	O
with	O
reduced	O
levels	O
of	O
Oct-1	B-protein
DNA	O
binding	O
activity	O
in	O
the	O
Rb-transformed	B-cell_line
cell	I-cell_line
lines	I-cell_line
,	O
interleukin	B-protein
8	I-protein
expression	O
is	O
higher	O
in	O
these	O
cell	O
lines	O
.	O

Cell	O
activation	O
and	O
apoptosis	O
by	O
bacterial	B-protein
lipoproteins	I-protein
through	O
toll-like	B-protein
receptor-2	I-protein
.	O

Apoptosis	O
is	O
implicated	O
in	O
the	O
generation	O
and	O
resolution	O
of	O
inflammation	O
in	O
response	O
to	O
bacterial	O
pathogens	O
.	O

All	O
bacterial	O
pathogens	O
produce	O
lipoproteins	B-protein
(	I-protein
BLPs	I-protein
)	I-protein
,	O
which	O
trigger	O
the	O
innate	O
immune	O
response	O
.	O

BLPs	B-protein
were	O
found	O
to	O
induce	O
apoptosis	O
in	O
THP-1	B-cell_line
monocytic	I-cell_line
cells	I-cell_line
through	O
human	B-protein
Toll-like	I-protein
receptor-2	I-protein
(	I-protein
hTLR2	I-protein
)	I-protein
.	O

BLPs	B-protein
also	O
initiated	O
apoptosis	O
in	O
an	O
epithelial	B-cell_line
cell	I-cell_line
line	I-cell_line
transfected	O
with	O
hTLR2	B-protein
.	O

In	O
addition	O
,	O
BLPs	B-protein
stimulated	O
nuclear	B-protein
factor-kappaB	I-protein
,	O
a	O
transcriptional	B-protein
activator	I-protein
of	O
multiple	B-DNA
host	I-DNA
defense	I-DNA
genes	I-DNA
,	O
and	O
activated	O
the	O
respiratory	O
burst	O
through	O
hTLR2	B-protein
.	O

Thus	O
,	O
hTLR2	B-protein
is	O
a	O
molecular	O
link	O
between	O
microbial	O
products	O
,	O
apoptosis	O
,	O
and	O
host	O
defense	O
mechanisms	O
.	O

Possible	O
differences	O
in	O
the	O
mechanism	O
(	O
s	O
)	O
of	O
action	O
of	O
different	O
glucocorticoid	O
hormone	O
compounds	O
.	O

Different	O
glucocorticoid	O
hormones	O
(	O
GCH	O
)	O
show	O
differences	O
in	O
the	O
intensity	O
and	O
in	O
the	O
kinetics	O
of	O
their	O
immunomodulating	O
activity	O
.	O

The	O
mechanism	O
(	O
s	O
)	O
of	O
action	O
of	O
GCH	O
is	O
under	O
investigation	O
,	O
but	O
is	O
has	O
been	O
noted	O
that	O
they	O
exert	O
immune	O
activity	O
via	O
the	O
genomic	O
pathway	O
.	O

We	O
have	O
studied	O
the	O
effects	O
of	O
prednisone	O
(	O
PDN	O
)	O
,	O
deflazacort	O
(	O
DFC	O
)	O
,	O
and	O
dexamethasone	O
(	O
DXM	O
)	O
on	O
the	O
production	O
of	O
cytokines	B-protein
(	O
IL-2	B-protein
,	O
IL-6	B-protein
,	O
TNF-alpha	B-protein
,	O
IL-10	B-protein
)	O
by	O
peripheral	B-cell_type
T	I-cell_type
lymphocytes	I-cell_type
,	O
and	O
the	O
effects	O
on	O
the	O
inhibition	O
of	O
NF-kB	B-protein
DNA	O
binding	O
activity	O
by	O
activated	B-cell_line
Jurkat	I-cell_line
cell	I-cell_line
line	I-cell_line
.	O

The	O
data	O
obtained	O
show	O
that	O
the	O
three	O
GCH	O
molecules	O
exert	O
an	O
immunosuppression	O
on	O
cytokine	B-protein
production	O
by	O
T	B-cell_type
lymphocytes	I-cell_type
and	O
a	O
strong	O
decrease	O
in	O
the	O
nuclear	O
translocation	O
of	O
NF-kB	B-protein
in	O
Jurkat	B-cell_line
cells	I-cell_line
;	O
moreover	O
,	O
(	O
a	O
)	O
not	O
all	O
the	O
cytokines	B-protein
investigated	O
were	O
affected	O
,	O
and	O
not	O
with	O
the	O
same	O
intensity	O
,	O
by	O
the	O
three	O
GCH	O
and	O
(	O
b	O
)	O
DXM	O
inhibited	O
the	O
binding	O
activity	O
of	O
NF-kB	B-protein
less	O
than	O
that	O
of	O
DFC	O
and	O
PDN	O
.	O

These	O
data	O
are	O
in	O
agreement	O
with	O
the	O
concept	O
that	O
different	O
GCH	O
compounds	O
might	O
differ	O
in	O
their	O
binding	O
and	O
affinity	O
properties	O
,	O
tissue-specific	O
metabolism	O
,	O
and	O
interaction	O
with	O
transcription	B-protein
factor	I-protein
.	O

Distinctive	O
expression	O
pattern	O
of	O
the	O
BCL-6	B-protein
protein	I-protein
in	O
nodular	O
lymphocyte	O
predominance	O
Hodgkin	O
's	O
disease	O
.	O

The	O
BCL-6	B-RNA
gene	I-RNA
encoding	O
a	O
nuclear-located	B-protein
Kruppel-type	I-protein
zinc	I-protein
finger	I-protein
protein	I-protein
is	O
rearranged	O
in	O
about	O
30	O
%	O
diffuse	O
large	O
B-cell	B-cell_type
lymphomas	I-cell_type
and	O
is	O
expressed	O
predominantly	O
in	O
normal	O
germinal	B-cell_type
center	I-cell_type
B	I-cell_type
cells	I-cell_type
and	O
related	O
lymphomas	O
.	O

These	O
findings	O
suggest	O
that	O
BCL-6	B-protein
may	O
play	O
a	O
role	O
in	O
regulating	O
differentiation	O
of	O
normal	O
germinal	B-cell_type
center	I-cell_type
B	I-cell_type
cells	I-cell_type
and	O
that	O
its	O
deregulated	O
expression	O
caused	O
by	O
rearrangements	O
may	O
contribute	O
to	O
lymphomagenesis	O
.	O

This	O
prompted	O
us	O
to	O
investigate	O
the	O
expression	O
of	O
the	O
BCL-6	B-protein
protein	I-protein
in	O
Hodgkin	O
's	O
disease	O
(	O
HD	O
)	O
,	O
focusing	O
on	O
the	O
nodular	O
lymphocyte	O
predominance	O
subtype	O
(	O
NLPHD	O
)	O
,	O
which	O
differs	O
from	O
classical	O
HD	O
by	O
virtue	O
of	O
the	O
B-cell	O
nature	O
of	O
the	O
malignant	B-cell_type
cell	I-cell_type
population	I-cell_type
(	O
so-called	O
L	B-cell_type
&	I-cell_type
H	I-cell_type
cells	I-cell_type
)	O
and	O
its	O
relationship	O
with	O
germinal	O
centers	O
.	O

Forty-one	O
HD	O
samples	O
(	O
19	O
NLPHD	O
,	O
12	O
nodular	O
sclerosis	O
,	O
and	O
10	O
mixed	O
cellularity	O
)	O
were	O
immunostained	O
with	O
the	O
monoclonal	B-protein
antibodies	I-protein
PG-B6	B-protein
and	O
PG-B6p	B-protein
that	O
react	O
with	O
a	O
fixative-sensitive	O
and	O
a	O
formalin-resistant	B-protein
epitope	I-protein
on	O
the	O
aminoterminal	B-protein
region	I-protein
of	O
the	O
BCL-6	B-protein
gene	I-protein
product	I-protein
,	O
respectively	O
.	O

Strong	O
nuclear	O
positivity	O
for	O
the	O
BCL-6	B-protein
protein	I-protein
was	O
detected	O
in	O
tumor	B-cell_type
(	I-cell_type
L	I-cell_type
&	I-cell_type
H	I-cell_type
)	I-cell_type
cells	I-cell_type
in	O
all	O
cases	O
of	O
NLPHD	O
.	O

In	O
contrast	O
,	O
BCL-6	B-protein
was	O
expressed	O
only	O
in	O
a	O
small	O
percentage	O
of	O
Hodgkin	B-cell_line
and	I-cell_line
Reed-Sternberg	I-cell_line
cells	I-cell_line
in	O
about	O
30	O
%	O
of	O
classical	O
HD	O
cases	O
.	O

Notably	O
,	O
the	O
nuclei	O
of	O
reactive	B-cell_type
CD3+/CD4+	I-cell_type
T	I-cell_type
cells	I-cell_type
nearby	O
to	O
and	O
rosetting	O
around	O
L	B-cell_type
&	I-cell_type
H	I-cell_type
cells	I-cell_type
in	O
NLPHD	O
were	O
also	O
strongly	O
BCL-6	B-protein
+	O
,	O
but	O
lacked	O
CD40	B-protein
ligand	I-protein
(	O
CD40L	B-protein
)	O
expression	O
.	O

This	O
staining	O
pattern	O
clearly	O
differed	O
from	O
that	O
of	O
classical	O
HD	O
,	O
whose	O
cellular	O
background	O
was	O
made	O
up	O
of	O
CD3+/CD4+	B-cell_type
T	I-cell_type
cells	I-cell_type
showing	O
the	O
BCL-6	B-protein
-/	O
CD40L	B-protein
+	O
phenotype	O
.	O

These	O
results	O
further	O
support	O
the	O
concept	O
that	O
NLPHD	O
is	O
an	O
histogenetically	O
distinct	O
,	O
B-cell-derived	O
subtype	O
of	O
HD	O
and	O
suggest	O
a	O
role	O
for	O
BCL-6	B-protein
in	O
its	O
development	O
.	O

Selenium-mediated	O
inhibition	O
of	O
transcription	B-protein
factor	I-protein
NF-kappa	I-protein
B	I-protein
and	O
HIV-1	B-DNA
LTR	I-DNA
promoter	I-DNA
activity	O
.	O

The	O
eukaryotic	B-protein
transcription	I-protein
factor	I-protein
NF-kappa	I-protein
B	I-protein
is	O
involved	O
in	O
the	O
inducible	O
expression	O
of	O
various	O
inflammatory	B-DNA
genes	I-DNA
as	O
well	O
as	O
in	O
HIV-1	O
replication	O
.	O

Activation	O
of	O
NF-kappa	B-protein
B	I-protein
is	O
induced	O
by	O
prooxidants	O
and	O
several	O
stimuli	O
eliciting	O
oxidative	O
stress	O
,	O
such	O
as	O
cytokines	B-protein
,	O
lipopolysaccharide	O
,	O
UV	O
irradiation	O
and	O
other	O
mediators	O
.	O

Various	O
antioxidants	O
inhibit	O
NF-kappa	B-protein
B	I-protein
activation	O
in	O
response	O
to	O
these	O
stimuli	O
.	O

In	O
this	O
study	O
,	O
we	O
have	O
investigated	O
the	O
effects	O
of	O
selenium	O
,	O
an	O
integral	O
component	O
of	O
glutathione	B-protein
peroxidase	I-protein
(	O
GPX	B-protein
)	O
,	O
on	O
NF-kappa	B-protein
B	I-protein
activation	O
.	O

In	O
selenium-deprived	B-cell_line
Jurkat	I-cell_line
and	O
ESb-L	B-cell_line
T	I-cell_line
lymphocytes	I-cell_line
,	O
supplementation	O
of	O
selenium	O
led	O
to	O
a	O
substantial	O
increase	O
of	O
GPX	B-protein
activity	O
.	O

Analysis	O
of	O
DNA	O
binding	O
revealed	O
that	O
NF-kappa	B-protein
B	I-protein
activation	O
in	O
response	O
to	O
TNF	B-protein
was	O
significantly	O
inhibited	O
under	O
these	O
conditions	O
.	O

Likewise	O
,	O
reporter	O
gene	O
assays	O
using	O
luciferase	O
constructs	O
driven	O
by	O
the	O
HIV-1	B-DNA
long	I-DNA
terminal	I-DNA
repeat	I-DNA
showed	O
a	O
dose-dependent	O
inhibition	O
of	O
NF-kappa	B-protein
B	I-protein
controlled	O
gene	O
expression	O
by	O
selenium	O
.	O

The	O
effects	O
of	O
selenium	O
were	O
specific	O
for	O
NF-kappa	B-protein
B	I-protein
,	O
since	O
the	O
activity	O
of	O
the	O
transcription	O
factor	O
AP-1	B-protein
was	O
not	O
suppressed	O
.	O

These	O
data	O
suggest	O
that	O
selenium	O
supplementation	O
may	O
be	O
used	O
to	O
modulate	O
the	O
expression	O
of	O
NF-kappa	B-DNA
B	I-DNA
target	I-DNA
genes	I-DNA
and	O
HIV-1	O
.	O

The	O
involvement	O
of	O
p23	B-protein
,	O
hsp90	B-protein
,	O
and	O
immunophilins	B-protein
in	O
the	O
assembly	O
of	O
progesterone	B-protein
receptor	I-protein
complexes	I-protein
.	O

To	O
better	O
understand	O
the	O
assembly	O
mechanism	O
for	O
the	O
progesterone	B-protein
receptor	I-protein
(	O
PR	B-protein
)	O
,	O
we	O
have	O
developed	O
cell-free	O
systems	O
for	O
studying	O
interactions	O
of	O
PR	B-protein
,	O
hsp90	B-protein
,	O
and	O
other	O
associated	B-protein
proteins	I-protein
.	O

When	O
PR	B-protein
is	O
incubated	O
in	O
rabbit	O
reticulocyte	O
lysate	O
,	O
its	O
association	O
with	O
hsp90	B-protein
,	O
hsp70	B-protein
,	O
the	O
three	O
immunophilins	B-protein
FKBP54	B-protein
,	O
FKBP52	B-protein
and	O
CyP-40	B-protein
,	O
and	O
with	O
p23	B-protein
is	O
observed	O
.	O

These	O
interactions	O
require	O
ATP/Mg2+	O
and	O
when	O
ATP	O
is	O
limiting	O
the	O
PR	B-protein
complex	O
is	O
altered	O
to	O
one	O
containing	O
the	O
proteins	O
p60	B-protein
and	O
p48	B-protein
,	O
but	O
lacking	O
immunophilins	B-protein
and	O
p23	B-protein
.	O

We	O
have	O
studied	O
two	O
pre-formed	B-protein
hsp90	I-protein
complexes	I-protein
that	O
may	O
participate	O
in	O
the	O
assembly	O
of	O
PR	B-protein
complexes	I-protein
.	O

One	O
contains	O
hsp90	B-protein
bound	O
to	O
hsp70	B-protein
and	O
p60	B-protein
and	O
this	O
complex	O
forms	O
spontaneously	O
in	O
the	O
absence	O
of	O
ATP	O
.	O

A	O
second	O
complex	O
contains	O
hsp90	B-protein
bound	O
to	O
p23	B-protein
plus	O
the	O
three	O
immunophilins	B-protein
and	O
some	O
hsp70	B-protein
.	O

The	O
formation	O
of	O
this	O
complex	O
requires	O
ATP	O
.	O

In	O
further	O
studies	O
we	O
have	O
shown	O
that	O
purified	O
hsp90	B-protein
can	O
bind	O
to	O
purified	O
p23	B-protein
and	O
this	O
interaction	O
requires	O
both	O
ATP	O
and	O
molybdate	O
.	O

This	O
explains	O
,	O
in	O
part	O
,	O
the	O
known	O
effects	O
of	O
ATP	O
and	O
molybdate	O
on	O
assembly	O
of	O
PR	B-protein
complexes	I-protein
.	O

Increased	O
IkappaB	B-protein
expression	O
and	O
diminished	O
nuclear	B-protein
NF-kappaB	I-protein
in	O
human	B-cell_type
mononuclear	I-cell_type
cells	I-cell_type
following	O
hydrocortisone	O
injection	O
.	O

We	O
have	O
recently	O
demonstrated	O
that	O
hydrocortisone	O
and	O
other	O
glucocorticoids	O
inhibit	O
reactive	O
oxygen	O
species	O
(	O
ROS	O
)	O
generation	O
by	O
mononuclear	B-cell_type
(	I-cell_type
MNC	I-cell_type
)	I-cell_type
and	I-cell_type
polymorphonuclear	I-cell_type
leucocytes	I-cell_type
(	O
PMNL	B-cell_type
)	O
.	O

Since	O
NF-kappaB/	O
IkappaB	B-protein
system	O
regulates	O
the	O
transcription	O
of	O
proinflammatory	B-protein
genes	I-protein
,	O
including	O
those	O
responsible	O
for	O
ROS	O
generation	O
,	O
we	O
tested	O
the	O
hypothesis	O
that	O
hydrocortisone	O
may	O
stimulate	O
IkappaB	B-protein
production	O
thus	O
inhibiting	O
NF-kappaB	B-protein
translocation	O
from	O
the	O
cytosol	O
into	O
the	O
nucleus	O
in	O
MNC	B-cell_type
,	O
in	O
vivo	O
.	O

One	O
hundred	O
milligram	O
of	O
hydrocortisone	O
was	O
injected	O
intravenously	O
into	O
4	O
normal	O
subjects	O
.	O

Blood	O
samples	O
were	O
obtained	O
prior	O
to	O
the	O
injection	O
and	O
at	O
1	O
,	O
2	O
,	O
4	O
,	O
8	O
and	O
24	O
hr	O
after	O
the	O
injection	O
.	O

Nuclear	O
extracts	O
and	O
total	O
cell	O
lysates	O
were	O
prepared	O
from	O
MNC	B-cell_type
by	O
standard	O
techniques	O
.	O

IkappaB	B-protein
levels	O
in	O
MNC	B-cell_type
homogenates	O
increased	O
at	O
1	O
hr	O
,	O
peaked	O
at	O
2-4	O
hr	O
,	O
started	O
to	O
decrease	O
at	O
8	O
hr	O
,	O
and	O
returned	O
to	O
baseline	O
levels	O
at	O
24	O
hr	O
.	O

NF-kappaB	B-protein
in	O
MNC	B-cell_type
nuclear	O
extracts	O
decreased	O
at	O
1	O
hr	O
,	O
reached	O
a	O
nadir	O
at	O
4	O
hr	O
,	O
gradually	O
increased	O
at	O
8	O
hr	O
and	O
returned	O
back	O
to	O
baseline	O
levels	O
at	O
24	O
hr	O
.	O

The	O
total	O
protein	O
content	O
of	O
NF-kappaB	B-protein
subunit	I-protein
(	O
P65	B-protein
)	O
in	O
MNC	B-cell_type
lysates	O
also	O
showed	O
a	O
decrease	O
following	O
hydrocortisone	O
injection	O
.	O

This	O
decrease	O
was	O
observed	O
at	O
2	O
hr	O
,	O
reached	O
a	O
nadir	O
at	O
4	O
hr	O
,	O
and	O
returned	O
to	O
baseline	O
levels	O
at	O
24	O
hr	O
.	O

ROS	O
generation	O
inhibition	O
paralleled	O
NF-kappaB	B-protein
levels	O
in	O
the	O
nucleus	O
.	O

It	O
was	O
inhibited	O
at	O
1	O
hr	O
,	O
reached	O
a	O
nadir	O
at	O
2-4	O
hr	O
,	O
started	O
to	O
increase	O
at	O
8	O
hr	O
,	O
and	O
returned	O
to	O
basal	O
levels	O
at	O
24	O
hr	O
.	O

Our	O
data	O
demonstrate	O
that	O
hydrocortisone	O
induces	O
IkappaB	B-protein
and	O
suppresses	O
NF-kappaB	B-protein
expression	O
in	O
MNC	B-cell_type
in	O
parallel	O
.	O

IkappaB	B-protein
further	O
reduces	O
the	O
translocation	O
of	O
NF-kappaB	B-protein
into	O
the	O
nucleus	O
thus	O
preventing	O
the	O
expression	O
of	O
proinflammatory	B-DNA
genes	I-DNA
.	O

Glucocorticoids	O
induce	O
apoptosis	O
in	O
human	B-cell_type
monocytes	I-cell_type
:	O
potential	O
role	O
of	O
IL-1	B-protein
beta	I-protein
.	O

Glucocorticoids	O
(	O
GC	O
)	O
are	O
potent	O
anti-inflammatory	O
and	O
immunosuppressive	O
agents	O
that	O
act	O
on	O
a	O
variety	O
of	O
immune	B-cell_type
cells	I-cell_type
,	O
including	O
monocytes	B-cell_type
and	O
macrophages	B-cell_type
.	O

However	O
,	O
the	O
exact	O
cellular	O
mechanisms	O
underlying	O
this	O
anti-inflammatory	O
capacity	O
are	O
still	O
unknown	O
.	O

In	O
our	O
study	O
,	O
we	O
determined	O
the	O
induction	O
of	O
apoptosis	O
by	O
GC	O
in	O
human	B-cell_type
monocytes	I-cell_type
.	O

Peripheral	B-cell_type
blood	I-cell_type
monocytes	I-cell_type
were	O
isolated	O
by	O
density	O
centrifugation	O
methods	O
with	O
a	O
purity	O
of	O
>	O
90	O
%	O
and	O
were	O
cultured	O
in	O
RPMI	O
1640	O
medium	O
.	O

Monocyte	O
apoptosis	O
was	O
determined	O
by	O
four	O
independent	O
methods	O
,	O
including	O
annexin-V	O
staining	O
,	O
TUNEL	O
,	O
DNA-laddering	O
,	O
and	O
typical	O
morphology	O
by	O
means	O
of	O
transmission	O
electron	O
microscopy	O
.	O

TNF-alpha	B-protein
and	O
IL-1beta	B-protein
were	O
measured	O
by	O
ELISA	O
.	O

GC	B-protein
receptor	I-protein
was	O
blocked	O
with	O
mifepristone	O
.	O

Caspase	O
3	O
was	O
inhibited	O
with	O
caspase-3	O
inhibitor	O
(	O
DEVD-CHO	O
)	O
.	O

Stimulation	O
with	O
different	O
GC	O
at	O
therapeutic	O
concentrations	O
resulted	O
in	O
monocyte	O
apoptosis	O
in	O
a	O
time-	O
and	O
dose-dependent	O
manner	O
.	O

Necrosis	O
was	O
excluded	O
by	O
propidium	O
iodide	O
staining	O
.	O

Proinflammatory	B-protein
cytokines	I-protein
such	O
as	O
IL-1beta	B-protein
and	O
TNF-alpha	B-protein
were	O
down-regulated	O
by	O
GC	O
treatment	O
.	O

Continuous	O
treatment	O
of	O
monocytes	B-cell_type
with	O
IL-1beta	B-protein
,	O
but	O
not	O
with	O
TNF-alpha	B-protein
,	O
could	O
almost	O
completely	O
prevent	O
GC-induced	O
cell	O
death	O
.	O

The	O
addition	O
of	O
mifepristone	O
or	O
caspase-3	O
inhibitor	O
could	O
partially	O
abrogate	O
GC-induced	O
apoptosis	O
as	O
well	O
as	O
GC-induced	O
inhibition	O
of	O
IL-1beta	B-protein
.	O

This	O
is	O
the	O
first	O
study	O
to	O
demonstrate	O
induction	O
of	O
apoptosis	O
by	O
GC	O
in	O
human	B-cell_type
monocytes	I-cell_type
.	O

GC-induced	O
monocyte	O
apoptosis	O
may	O
be	O
partially	O
mediated	O
through	O
effects	O
on	O
IL-1beta	B-protein
production	O
.	O

It	O
is	O
conceivable	O
that	O
GC	O
exert	O
their	O
anti-inflammatory	O
capacity	O
in	O
various	O
diseases	O
,	O
at	O
least	O
in	O
part	O
,	O
by	O
the	O
induction	O
of	O
apoptosis	O
in	O
monocytes	B-cell_type
.	O

Differential	O
effects	O
of	O
lipopolysaccharide	O
and	O
tumor	B-protein
necrosis	I-protein
factor	I-protein
on	O
monocytic	B-protein
IkappaB	I-protein
kinase	I-protein
signalsome	O
activation	O
and	O
IkappaB	B-protein
proteolysis	O
.	O

The	O
inflammatory	O
mediators	O
lipopolysaccharide	O
(	O
LPS	O
)	O
and	O
tumor	B-protein
necrosis	I-protein
factor	I-protein
(	O
TNF	B-protein
)	O
are	O
potent	O
activators	O
of	O
NF-kappaB	B-protein
.	O

This	O
study	O
compared	O
the	O
effect	O
of	O
these	O
stimuli	O
on	O
endogenous	O
IkappaB	B-protein
kinase	I-protein
(	O
IKK	B-protein
)	O
signalsome	O
activation	O
and	O
IkappaB	B-protein
phosphorylation/proteolysis	O
in	O
human	B-cell_type
monocytic	I-cell_type
cells	I-cell_type
and	O
investigated	O
the	O
role	O
of	O
the	O
signalsome	B-protein
proteins	I-protein
IKK-alpha	B-protein
,	O
IKK-beta	B-protein
,	O
NF-kappaB-inducing	B-protein
kinase	I-protein
(	O
NIK	B-protein
)	O
,	O
IKK-gamma	B-protein
(	O
NF-kappaB	B-protein
essential	O
modulator	O
)	O
,	O
and	O
IKK	B-protein
complex-associated	I-protein
protein	I-protein
.	O

Kinase	O
assays	O
showed	O
that	O
TNF	B-protein
elicited	O
a	O
rapid	O
but	O
short-lived	O
induction	O
of	O
IKK	B-protein
activity	O
with	O
a	O
3-fold	O
greater	O
effect	O
on	O
IKK-alpha	B-protein
than	O
on	O
IKK-beta	B-protein
,	O
peaking	O
at	O
5	O
min	O
.	O

In	O
contrast	O
,	O
LPS	O
predominantly	O
stimulated	O
IKK-beta	B-protein
activity	O
,	O
which	O
slowly	O
increased	O
,	O
peaking	O
at	O
30	O
min	O
.	O

A	O
second	O
peak	O
was	O
observed	O
at	O
a	O
later	O
time	O
point	O
following	O
LPS	O
stimulation	O
,	O
which	O
consisted	O
of	O
both	O
IKK-alpha	O
and	O
-beta	O
activity	O
.	O

The	O
endogenous	O
levels	O
of	O
the	O
signalsome	O
components	O
were	O
unaffected	O
by	O
stimulation	O
.	O

Furthermore	O
,	O
our	O
studies	O
showed	O
association	O
of	O
the	O
IKK-alpha/beta	B-protein
heterodimer	I-protein
with	O
NIK	B-protein
,	O
IkappaB-alpha	B-protein
and	O
-epsilon	B-protein
in	O
unstimulated	B-cell_type
cells	I-cell_type
.	O

Exposure	O
to	O
LPS	O
or	O
TNF	B-protein
led	O
to	O
differential	O
patterns	O
of	O
IkappaB-alpha	B-protein
and	O
IkappaB-epsilon	B-protein
disappearance	O
from	O
and	O
reassembly	O
with	O
the	O
signalsome	O
,	O
whereas	O
IKK-alpha	B-protein
,	O
IKK-beta	B-protein
,	O
and	O
NIK	B-protein
remained	O
complex-associated	O
.	O

NIK	B-protein
can	O
not	O
phosphorylate	O
IkappaB-alpha	B-protein
directly	O
,	O
but	O
it	O
appears	O
to	O
be	O
a	O
functionally	O
important	O
subunit	O
,	O
because	O
mutated	O
NIK	B-protein
inhibited	O
stimulus-induced	O
kappaB	B-protein
-dependent	O
transcription	O
more	O
effectively	O
than	O
mutated	O
IKK-alpha	B-protein
or	O
-beta	B-protein
.	O

Overexpression	O
of	O
IKK	B-protein
complex-associated	I-protein
protein	I-protein
inhibited	O
stimulus-mediated	O
transcription	O
,	O
whereas	O
NF-kappaB	B-protein
essential	O
modulator	O
enhanced	O
it	O
.	O

The	O
understanding	O
of	O
LPS-	O
and	O
TNF-induced	O
signaling	O
may	O
allow	O
the	O
development	O
of	O
specific	O
strategies	O
to	O
treat	O
sepsis-associated	O
disease	O
.	O

Tumor	B-protein
necrosis	I-protein
factor	I-protein
alpha	I-protein
decreases	O
,	O
and	O
interleukin-10	B-protein
increases	O
,	O
the	O
sensitivity	O
of	O
human	B-cell_type
monocytes	I-cell_type
to	O
dexamethasone	O
:	O
potential	O
regulation	O
of	O
the	O
glucocorticoid	B-protein
receptor	I-protein
.	O

Resistance	O
to	O
glucocorticoid	O
therapy	O
has	O
been	O
observed	O
in	O
patients	O
with	O
autoimmune/inflammatory	O
diseases	O
and	O
may	O
be	O
related	O
to	O
the	O
inflammatory	O
process	O
itself	O
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
examine	O
the	O
ability	O
of	O
tumor	B-protein
necrosis	I-protein
factor	I-protein
alpha	I-protein
(	O
TNFalpha	B-protein
,	O
a	O
proinflammatory	B-protein
cytokine	I-protein
)	O
and	O
interleukin	B-protein
(	I-protein
IL	I-protein
)	I-protein
-10	I-protein
(	O
an	O
anti-inflammatory	B-protein
cytokine	I-protein
)	O
to	O
differentially	O
regulate	O
the	O
sensitivity	O
of	O
human	B-cell_type
monocytes	I-cell_type
/macrophages	B-cell_type
to	O
glucocorticoids	O
.	O

To	O
accomplish	O
this	O
,	O
we	O
first	O
analyzed	O
the	O
pattern	O
of	O
TNFalpha	B-protein
and	O
IL-10	O
inhibition	O
by	O
dexamethasone	O
in	O
LPS-stimulated	B-cell_line
whole-blood	I-cell_line
cell	I-cell_line
cultures	I-cell_line
.	O

Second	O
,	O
we	O
studied	O
the	O
modulation	O
of	O
the	O
sensitivity	O
of	O
these	O
cells	O
to	O
dexamethasone	O
by	O
preincubation	O
with	O
TNFalpha	B-protein
or	O
IL-10	B-protein
and	O
measurement	O
of	O
LPS-stimulated	O
IL-6	B-protein
secretion	O
.	O

In	O
addition	O
,	O
we	O
evaluated	O
the	O
effect	O
of	O
dexamethasone	O
on	O
phorbolmyristate-acetate-stimulated	O
IL-1	B-protein
receptor	I-protein
antagonist	O
secretion	O
by	O
the	O
human	B-cell_line
monocytic	I-cell_line
cell	I-cell_line
line	I-cell_line
U937	I-cell_line
.	O

Finally	O
,	O
we	O
investigated	O
whether	O
the	O
modulation	O
of	O
corticosensitivity	O
in	O
TNFalpha-	B-cell_line
and	I-cell_line
IL-10-pretreated	I-cell_line
U937	I-cell_line
cells	I-cell_line
was	O
related	O
to	O
a	O
change	O
of	O
the	O
glucocorticoid	B-protein
receptor	I-protein
concentration	O
and	O
affinity	O
.	O

Dexamethasone	O
had	O
different	O
effects	O
on	O
LPS-induced	O
TNFalpha	B-protein
and	O
IL-10	B-protein
secretion	O
;	O
whereas	O
it	O
suppressed	O
TNFalpha	B-protein
in	O
a	O
dose-dependent	O
fashion	O
,	O
its	O
effect	O
on	O
IL-10	B-protein
secretion	O
was	O
biphasic	O
,	O
producing	O
stimulation	O
at	O
lower	O
,	O
and	O
inhibition	O
at	O
higher	O
doses	O
.	O

The	O
concentration	O
of	O
LPS	O
employed	O
influenced	O
the	O
effect	O
of	O
dexamethasone	O
on	O
IL-10	B-protein
secretion	O
(	O
P	O
<	O
0.001	O
)	O
.	O

Pretreatment	O
with	O
TNFalpha	B-protein
diminished	O
,	O
and	O
with	O
IL-10	B-protein
improved	O
,	O
the	O
ability	O
of	O
dexamethasone	O
to	O
suppress	O
IL-6	B-protein
secretion	O
in	O
whole-blood	B-cell_type
cell	I-cell_type
cultures	I-cell_type
(	O
P	O
<	O
0.01	O
for	O
both	O
)	O
and	O
to	O
enhance	O
IL-1	B-protein
receptor	O
antagonist	O
secretion	O
by	O
U937	O
cells	O
(	O
P	O
<	O
0.05	O
for	O
both	O
)	O
.	O

TNFalpha	B-protein
decreased	O
(	O
P	O
<	O
0.001	O
)	O
,	O
while	O
IL-10	B-protein
increased	O
(	O
P	O
<	O
0.001	O
)	O
,	O
the	O
concentration	O
of	O
dexamethasone	O
binding	O
sites	O
in	O
these	O
cells	O
,	O
with	O
no	O
discernible	O
effect	O
on	O
their	O
binding	O
affinity	O
.	O

We	O
conclude	O
that	O
glucocorticoids	O
differentially	O
modulate	O
TNFalpha	B-protein
and	O
IL-10	B-protein
secretion	O
by	O
human	B-cell_type
monocytes	I-cell_type
in	O
a	O
LPS	O
dose-dependent	O
fashion	O
and	O
that	O
the	O
sensitivity	O
of	O
these	O
cells	O
to	O
glucocorticoids	O
is	O
altered	O
by	O
TNFalpha	B-protein
or	O
IL-10	B-protein
pretreatment	O
;	O
TNFalpha	B-protein
blocks	O
their	O
effects	O
,	O
whereas	O
IL-10	B-protein
acts	O
synergistically	O
with	O
glucocorticoids	O
.	O

This	O
is	O
accompanied	O
by	O
opposite	O
glucocorticoid	B-protein
receptor	I-protein
changes	O
,	O
respectively	O
opposing	O
and	O
favoring	O
glucocorticoid	O
actions	O
.	O

This	O
study	O
suggests	O
that	O
the	O
pattern	O
of	O
pro-/antiinflammatory	O
cytokine	B-protein
secretion	O
may	O
alter	O
the	O
response	O
of	O
patients	O
to	O
glucocorticoid	O
therapy	O
.	O

Block	O
of	O
granulocytic	O
differentiation	O
of	O
32Dcl3	B-cell_line
cells	I-cell_line
by	O
AML1/ETO	B-DNA
(	I-DNA
MTG8	I-DNA
)	I-DNA
but	O
not	O
by	O
highly	O
expressed	O
Bcl-2	B-protein
.	O

The	O
chimeric	B-DNA
gene	I-DNA
,	I-DNA
AML1/ETO	B-DNA
(	I-DNA
MTG8	I-DNA
)	I-DNA
,	O
generated	O
in	O
t	B-DNA
(	I-DNA
8	I-DNA
;	I-DNA
21	I-DNA
)	I-DNA
acute	O
myeloid	O
leukemia	O
enhances	O
the	O
expression	O
of	O
Bcl-2	B-protein
.	O

To	O
evaluate	O
whether	O
this	O
enhancement	O
is	O
the	O
primary	O
role	O
of	O
AML1/ETO	B-DNA
in	O
leukemogenesis	O
,	O
effects	O
of	O
over-expression	O
of	O
Bcl-2	B-protein
in	O
the	O
murine	B-cell_line
myeloid	I-cell_line
precursor	I-cell_line
cell	I-cell_line
line	I-cell_line
,	O
32Dcl3	B-cell_line
,	O
were	O
examined	O
.	O

When	O
32Dcl3	B-cell_line
cells	I-cell_line
expressing	O
exogenous	O
Bcl-2	B-protein
were	O
induced	O
to	O
differentiate	O
,	O
the	O
onset	O
of	O
morphological	O
differentiation	O
was	O
delayed	O
.	O

However	O
,	O
even	O
the	O
cells	O
expressing	O
very	O
high	O
levels	O
of	O
exogenous	O
Bcl-2	B-protein
eventually	O
underwent	O
differentiation	O
without	O
a	O
significant	O
decrease	O
in	O
the	O
synthesis	O
of	O
Bcl-2	B-protein
.	O

On	O
the	O
contrary	O
,	O
32Dcl3	B-cell_line
cells	I-cell_line
stably	O
expressing	O
AML1/ETO	B-DNA
were	O
completely	O
resistant	O
to	O
differentiation	O
and	O
continued	O
to	O
grow	O
in	O
the	O
presence	O
of	O
G-CSF	B-protein
.	O

These	O
results	O
are	O
consistent	O
with	O
the	O
interpretation	O
that	O
stimulation	O
of	O
Bcl-2	B-protein
expression	O
is	O
not	O
the	O
primary	O
target	O
of	O
AML1/ETO	B-DNA
.	O

Host	O
defense	O
mechanisms	O
triggered	O
by	O
microbial	B-protein
lipoproteins	I-protein
through	O
toll-like	B-protein
receptors	I-protein
.	O

The	O
generation	O
of	O
cell-mediated	O
immunity	O
against	O
many	O
infectious	O
pathogens	O
involves	O
the	O
production	O
of	O
interleukin-12	B-protein
(	O
IL-12	B-protein
)	O
,	O
a	O
key	O
signal	O
of	O
the	O
innate	O
immune	O
system	O
.	O

Yet	O
,	O
for	O
many	O
pathogens	O
,	O
the	O
molecules	O
that	O
induce	O
IL-12	B-protein
production	O
by	O
macrophages	B-cell_type
and	O
the	O
mechanisms	O
by	O
which	O
they	O
do	O
so	O
remain	O
undefined	O
.	O

Here	O
it	O
is	O
shown	O
that	O
microbial	B-protein
lipoproteins	I-protein
are	O
potent	O
stimulators	O
of	O
IL-12	B-protein
production	O
by	O
human	O
macrophages	B-cell_type
,	O
and	O
that	O
induction	O
is	O
mediated	O
by	O
Toll-like	B-protein
receptors	I-protein
(	O
TLRs	B-protein
)	O
.	O

Several	O
lipoproteins	O
stimulated	O
TLR-dependent	O
transcription	O
of	O
inducible	O
nitric	B-protein
oxide	I-protein
synthase	I-protein
and	O
the	O
production	O
of	O
nitric	O
oxide	O
,	O
a	O
powerful	O
microbicidal	O
pathway	O
.	O

Activation	O
of	O
TLRs	B-protein
by	O
microbial	B-protein
lipoproteins	I-protein
may	O
initiate	O
innate	O
defense	O
mechanisms	O
against	O
infectious	O
pathogens	O
.	O

Abnormal	O
NF-kappa	B-protein
B	I-protein
activity	O
in	O
T	B-cell_type
lymphocytes	I-cell_type
from	O
patients	O
with	O
systemic	O
lupus	O
erythematosus	O
is	O
associated	O
with	O
decreased	O
p65-RelA	B-protein
protein	O
expression	O
.	O

Numerous	O
cellular	O
and	O
biochemical	O
abnormalities	O
in	O
immune	O
regulation	O
have	O
been	O
described	O
in	O
patients	O
with	O
systemic	O
lupus	O
erythematosus	O
(	O
SLE	O
)	O
,	O
including	O
surface	O
Ag	B-protein
receptor	I-protein
-initiated	O
signaling	O
events	O
and	O
lymphokine	B-protein
production	O
.	O

Because	O
NF-kappa	B-protein
B	I-protein
contributes	O
to	O
the	O
transcription	O
of	O
numerous	O
inflammatory	B-DNA
genes	I-DNA
and	O
has	O
been	O
shown	O
to	O
be	O
a	O
molecular	O
target	O
of	O
antiinflammatory	O
drugs	O
,	O
we	O
sought	O
to	O
characterize	O
the	O
functional	O
role	O
of	O
the	O
NF-kappa	B-protein
B	I-protein
protein	I-protein
complex	I-protein
in	O
lupus	B-cell_type
T	I-cell_type
cells	I-cell_type
.	O

Freshly	O
isolated	O
T	B-cell_type
cells	I-cell_type
from	O
lupus	O
patients	O
,	O
rheumatoid	O
arthritis	O
(	O
RA	O
)	O
patients	O
,	O
and	O
normal	O
individuals	O
were	O
activated	O
physiologically	O
via	O
the	O
TCR	B-protein
with	O
anti-CD3	B-protein
and	O
anti-CD28	B-protein
Abs	I-protein
to	O
assess	O
proximal	O
membrane	O
signaling	O
,	O
and	O
with	O
PMA	O
and	O
a	O
calcium	O
ionophore	O
(	O
A23187	O
)	O
to	O
bypass	O
membrane-mediated	O
signaling	O
events	O
.	O

We	O
measured	O
the	O
NF-kappa	B-protein
B	I-protein
binding	O
activity	O
in	O
nuclear	O
extracts	O
by	O
gel	O
shift	O
analysis	O
.	O

When	O
compared	O
with	O
normal	B-cell_type
cells	I-cell_type
,	O
the	O
activation	O
of	O
NF-kappa	B-protein
B	I-protein
activity	O
in	O
SLE	O
patients	O
was	O
significantly	O
decreased	O
in	O
SLE	O
,	O
but	O
not	O
in	O
RA	O
,	O
patients	O
.	O

NF-kappa	B-protein
B	I-protein
binding	O
activity	O
was	O
absent	O
in	O
several	O
SLE	O
patients	O
who	O
were	O
not	O
receiving	O
any	O
medication	O
,	O
including	O
corticosteroids	O
.	O

Also	O
,	O
NF-kappa	B-protein
B	I-protein
activity	O
remained	O
absent	O
in	O
follow-up	O
studies	O
.	O

In	O
supershift	O
experiments	O
using	O
specific	O
Abs	B-protein
,	O
we	O
showed	O
that	O
,	O
in	O
the	O
group	O
of	O
SLE	O
patients	O
who	O
displayed	O
undetectable	O
NF-kappa	B-protein
B	I-protein
activity	O
,	O
p65	B-protein
complexes	I-protein
were	O
not	O
formed	O
.	O

Finally	O
,	O
immunoblot	O
analysis	O
of	O
nuclear	O
extracts	O
showed	O
decreased	O
or	O
absent	O
p65	B-protein
protein	I-protein
levels	O
.	O

As	O
p65	B-protein
complexes	I-protein
are	O
transcriptionally	O
active	O
in	O
comparison	O
to	O
the	O
p50	O
homodimer	O
,	O
this	O
novel	O
finding	O
may	O
provide	O
insight	O
on	O
the	O
origin	O
of	O
abnormal	B-protein
cytokine	I-protein
or	O
other	O
gene	O
transcription	O
in	O
SLE	O
patients	O
.	O

Signaling	O
events	O
induced	O
by	O
lipopolysaccharide-activated	B-protein
toll-like	I-protein
receptor	I-protein
2	I-protein
.	O

Human	B-protein
Toll-like	I-protein
receptor	I-protein
2	I-protein
(	I-protein
TLR2	I-protein
)	I-protein
is	O
a	O
signaling	B-protein
receptor	I-protein
that	O
responds	O
to	O
LPS	O
and	O
activates	O
NF-kappaB	B-protein
.	O

Here	O
,	O
we	O
investigate	O
further	O
the	O
events	O
triggered	O
by	O
TLR2	B-protein
in	O
response	O
to	O
LPS	O
.	O

We	O
show	O
that	O
TLR2	B-protein
associates	O
with	O
the	O
high-affinity	B-protein
LPS	I-protein
binding	I-protein
protein	I-protein
membrane	O
CD14	B-protein
to	O
serve	O
as	O
an	O
LPS	B-protein
receptor	I-protein
complex	I-protein
,	O
and	O
that	O
LPS	O
treatment	O
enhances	O
the	O
oligomerization	O
of	O
TLR2	B-protein
.	O

Concomitant	O
with	O
receptor	O
oligomerization	O
,	O
the	O
IL-1R-associated	B-protein
kinase	I-protein
(	I-protein
IRAK	I-protein
)	I-protein
is	O
recruited	O
to	O
the	O
TLR2	B-protein
complex	O
.	O

Intracellular	O
deletion	O
variants	O
of	O
TLR2	B-protein
lacking	O
C-terminal	O
13	O
or	O
141	O
aa	O
fail	O
to	O
recruit	O
IRAK	B-protein
,	O
which	O
is	O
consistent	O
with	O
the	O
inability	O
of	O
these	O
mutants	O
to	O
transmit	O
LPS	O
cellular	O
signaling	O
.	O

Moreover	O
,	O
both	O
deletion	O
mutants	O
could	O
still	O
form	O
complexes	O
with	O
wild-type	B-protein
TLR2	I-protein
and	O
act	O
in	O
a	O
dominant-negative	O
(	O
DN	O
)	O
fashion	O
to	O
block	O
TLR2	B-protein
-mediated	O
signal	O
transduction	O
.	O

DN	O
constructs	O
of	O
myeloid	B-protein
differentiation	I-protein
protein	I-protein
,	O
IRAK	B-protein
,	O
TNF	B-protein
receptor-associated	I-protein
factor	I-protein
6	I-protein
,	O
and	O
NF-kappaB-inducing	B-protein
kinase	I-protein
,	O
when	O
coexpressed	O
with	O
TLR2	B-protein
,	O
abrogate	O
TLR2	B-protein
-mediated	O
NF-kappaB	B-protein
activation	O
.	O

These	O
results	O
reveal	O
a	O
conserved	O
signaling	O
pathway	O
for	O
TLR2	B-protein
and	O
IL-1Rs	B-protein
and	O
suggest	O
a	O
molecular	O
mechanism	O
for	O
the	O
inhibition	O
of	O
TLR2	B-protein
by	O
DN	O
variants	O
.	O

Tyrphostin	O
AG-490	O
inhibits	O
cytokine-mediated	O
JAK3	B-protein
/STAT5a/b	B-protein
signal	O
transduction	O
and	O
cellular	O
proliferation	O
of	O
antigen-activated	O
human	O
T	B-cell_type
cells	I-cell_type
.	O

Janus	B-protein
kinase	I-protein
3	I-protein
(	I-protein
JAK3	I-protein
)	I-protein
is	O
a	O
cytoplasmic	B-protein
tyrosine	I-protein
kinase	I-protein
required	O
for	O
T	B-cell_type
cell	I-cell_type
development	O
and	O
activated	O
by	O
cytokines	B-protein
that	O
utilize	O
the	O
interleukin-2	B-protein
(	I-protein
IL-2	I-protein
)	I-protein
receptor	I-protein
common	I-protein
gamma	I-protein
chain	I-protein
(	I-protein
gamma	I-protein
(	I-protein
c	I-protein
)	I-protein
)	I-protein
.	O

Genetic	O
inactivation	O
of	O
JAK3	B-protein
is	O
manifested	O
as	O
severe	O
combined	O
immunodeficiency	O
disease	O
(	O
SCID	O
)	O
in	O
humans	O
and	O
mice	O
.	O

These	O
findings	O
have	O
suggested	O
that	O
JAK3	B-protein
represents	O
a	O
pharmacological	O
target	O
to	O
control	O
certain	O
lymphoid-derived	O
diseases	O
.	O

Here	O
we	O
provide	O
novel	O
evidence	O
that	O
AG-490	O
potently	O
inhibits	O
the	O
autokinase	O
activity	O
of	O
JAK3	B-protein
and	O
tyrosine	O
phosphorylation	O
and	O
DNA	O
binding	O
of	O
signal	B-protein
transducer	I-protein
and	I-protein
activator	I-protein
of	I-protein
transcription	I-protein
5a	I-protein
and	I-protein
5b	I-protein
(	I-protein
STAT5a/b	I-protein
)	I-protein
.	O

Similar	O
inhibitory	O
effects	O
were	O
observed	O
with	O
other	O
cytokines	B-protein
that	O
use	O
gamma	B-protein
(	I-protein
c	I-protein
)	I-protein
.	O

AG-490	O
also	O
inhibited	O
IL-2	B-protein
-mediated	O
proliferative	O
growth	O
in	O
human	O
T	B-cell_type
cells	I-cell_type
with	O
an	O
IC50	O
)	O
=	O
25	O
microM	O
that	O
was	O
partially	O
recoverable	O
.	O

Moreover	O
,	O
we	O
demonstrate	O
that	O
this	O
inhibitor	O
prevented	O
tetanus	O
toxoid	O
antigen-specific	O
T	O
cell	O
proliferation	O
and	O
expansion	O
but	O
failed	O
to	O
block	O
activation	O
of	O
Zap70	B-protein
or	O
p56Lck	B-protein
after	O
anti-CD3	B-protein
stimulation	O
of	O
human	O
T	B-cell_type
cells	I-cell_type
.	O

Taken	O
together	O
,	O
these	O
findings	O
suggest	O
that	O
AG-490	O
inhibits	O
the	O
JAK3	B-protein
-mediated	O
Type	O
II	O
signaling	O
pathway	O
but	O
not	O
the	O
T	B-cell_type
cell	I-cell_type
receptor-derived	O
Type	O
I	O
pathway	O
and	O
possesses	O
therapeutic	O
potential	O
for	O
T	B-cell_type
cell	I-cell_type
-derived	O
pathologies	O
such	O
as	O
graft-versus-host	O
disease	O
,	O
allergy	O
,	O
and	O
autoimmune	O
disorders	O
.	O

C/EBP	B-protein
beta	I-protein
in	O
rheumatoid	O
arthritis	O
:	O
correlation	O
with	O
inflammation	O
,	O
not	O
disease	O
specificity	O
.	O

Rheumatoid	O
arthritis	O
synovial	O
tissue	O
was	O
examined	O
and	O
compared	O
with	O
osteoarthritis	O
tissue	O
for	O
the	O
presence	O
of	O
the	O
nuclear	B-protein
transcription	I-protein
factor	I-protein
C/EBP	I-protein
beta	I-protein
(	I-protein
NF-IL-6	I-protein
)	I-protein
.	O

The	O
region	O
(	O
lining	O
or	O
sublining	O
)	O
,	O
cell	O
type	O
,	O
and	O
subcellular	O
distribution	O
(	O
cytoplasmic	O
or	O
nuclear	O
)	O
of	O
the	O
expression	O
of	O
C/EBP	B-protein
beta	I-protein
was	O
characterized	O
.	O

Rheumatoid	O
arthritis	O
synovial	O
fluid	O
and	O
blood	O
and	O
normal	O
peripheral	O
blood	O
were	O
also	O
examined	O
.	O

C/EBP	B-protein
beta	I-protein
was	O
detected	O
in	O
the	O
synovial	O
lining	O
and	O
in	O
sublining	B-cell_type
cells	I-cell_type
of	I-cell_type
synovial	I-cell_type
tissue	I-cell_type
from	O
patients	O
with	O
both	O
rheumatoid	O
and	O
osteoarthritis	O
.	O

A	O
significant	O
(	O
P	O
<	O
0.001	O
and	O
<	O
0.05	O
,	O
respectively	O
)	O
increase	O
in	O
the	O
percentage	O
of	O
cells	O
with	O
nuclear	O
staining	O
was	O
seen	O
in	O
the	O
lining	O
layer	O
,	O
compared	O
to	O
cells	O
in	O
the	O
sublining	O
region	O
,	O
in	O
rheumatoid	O
and	O
osteoarthritis	O
.	O

In	O
both	O
diseases	O
a	O
strong	O
correlation	O
(	O
r	O
=	O
0.79	O
,	O
P	O
<	O
0.001	O
)	O
was	O
observed	O
between	O
the	O
percentage	O
of	O
cells	O
in	O
the	O
synovial	O
lining	O
that	O
were	O
positive	O
for	O
nuclear	B-protein
C/EBP	I-protein
beta	I-protein
and	O
lining	O
cell	O
depth	O
.	O

Two-color	O
immunohistochemistry	O
demonstrated	O
that	O
both	O
macrophages	B-cell_type
and	O
fibroblast-like	B-cell_type
synoviocytes	I-cell_type
were	O
positive	O
for	O
nuclear	O
C/EBP	B-protein
beta	I-protein
.	O

The	O
presence	O
of	O
C/EBP	B-protein
beta	I-protein
was	O
confirmed	O
by	O
immunohistochemistry	O
and	O
Western	O
blot	O
analysis	O
with	O
isolated	O
synovial	B-cell_type
fibroblasts	I-cell_type
.	O

Nuclear	O
C/EBP	B-protein
beta	I-protein
was	O
also	O
detected	O
in	O
rheumatoid	B-cell_type
synovial	I-cell_type
fluid	I-cell_type
monocytes/macrophages	I-cell_type
,	I-cell_type
but	I-cell_type
not	I-cell_type
in	I-cell_type
lymphocytes	I-cell_type
or	I-cell_type
neutrophils	I-cell_type
.	O

Western	O
blot	O
analysis	O
confirmed	O
the	O
presence	O
of	O
C/EBP	B-protein
beta	I-protein
in	O
these	O
cells	O
.	O

The	O
intensity	O
of	O
C/EBP	B-protein
beta	I-protein
staining	O
was	O
greater	O
(	O
P	O
<	O
0.001	O
)	O
in	O
synovial	B-cell_type
fluid	I-cell_type
monocytes	I-cell_type
than	O
in	O
those	O
from	O
normal	B-cell_type
or	I-cell_type
rheumatoid	I-cell_type
peripheral	I-cell_type
blood	I-cell_type
.	O

In	O
conclusion	O
,	O
the	O
enhanced	O
nuclear	O
staining	O
for	O
C/EBP	B-protein
beta	I-protein
in	O
the	O
synovial	O
lining	O
,	O
compared	O
to	O
the	O
sublining	O
,	O
suggesting	O
activation	O
in	O
the	O
lining	O
,	O
and	O
the	O
positive	O
correlation	O
of	O
lining	O
layer	O
depth	O
with	O
the	O
percentage	O
of	O
cells	O
in	O
the	O
lining	O
positive	O
for	O
nuclear	O
C/EBP	B-protein
beta	I-protein
,	O
suggest	O
a	O
potential	O
role	O
for	O
C/EBP	B-protein
beta	I-protein
in	O
chronic	O
inflammation	O
.	O

The	O
regulation	O
of	O
the	O
production	O
or	O
activity	O
of	O
C/EBP	B-protein
beta	I-protein
,	O
to	O
inhibit	O
inflammatory	O
mediator	O
expression	O
by	O
synovial	B-cell_type
macrophages	I-cell_type
and	O
fibroblasts	B-cell_type
,	O
offers	O
a	O
novel	O
approach	O
to	O
therapeutic	O
intervention	O
.	O

Direct	O
interaction	O
of	O
hematopoietic	B-protein
transcription	I-protein
factors	I-protein
PU.1	I-protein
and	I-protein
GATA-1	I-protein
:	O
functional	O
antagonism	O
in	O
erythroid	B-cell_type
cells	I-cell_type
.	O

Malignant	O
transformation	O
usually	O
inhibits	O
terminal	O
cell	O
differentiation	O
but	O
the	O
precise	O
mechanisms	O
involved	O
are	O
not	O
understood	O
.	O

PU.1	B-protein
is	O
a	O
hematopoietic-specific	B-protein
Ets	I-protein
family	I-protein
transcription	I-protein
factor	I-protein
that	O
is	O
required	O
for	O
development	O
of	O
some	O
lymphoid	B-cell_type
and	I-cell_type
myeloid	I-cell_type
lineages	I-cell_type
.	O

PU.1	B-protein
can	O
also	O
act	O
as	O
an	O
oncoprotein	B-protein
as	O
activation	O
of	O
its	O
expression	O
in	O
erythroid	O
precursors	O
by	O
proviral	O
insertion	O
or	O
transgenesis	O
causes	O
erythroleukemias	O
in	O
mice	O
.	O

Restoration	O
of	O
terminal	O
differentiation	O
in	O
the	O
mouse	B-cell_line
erythroleukemia	I-cell_line
(	I-cell_line
MEL	I-cell_line
)	I-cell_line
cells	I-cell_line
requires	O
a	O
decline	O
in	O
the	O
level	O
of	O
PU.1	B-protein
,	O
indicating	O
that	O
PU.1	B-protein
can	O
block	O
erythroid	O
differentiation	O
.	O

Here	O
we	O
investigate	O
the	O
mechanism	O
by	O
which	O
PU.1	B-protein
interferes	O
with	O
erythroid	O
differentiation	O
.	O

We	O
find	O
that	O
PU.1	B-protein
interacts	O
directly	O
with	O
GATA-1	B-protein
,	O
a	O
zinc	B-protein
finger	I-protein
transcription	I-protein
factor	I-protein
required	O
for	O
erythroid	O
differentiation	O
.	O

Interaction	O
between	O
PU.1	B-protein
and	O
GATA-1	B-protein
requires	O
intact	O
DNA-binding	B-protein
domains	I-protein
in	O
both	O
proteins	O
.	O

PU.1	B-protein
represses	O
GATA-1	B-protein
-mediated	O
transcriptional	O
activation	O
.	O

Both	O
the	O
DNA	B-protein
binding	I-protein
and	O
transactivation	B-protein
domains	I-protein
of	O
PU.1	B-protein
are	O
required	O
for	O
repression	O
and	O
both	O
domains	O
are	O
also	O
needed	O
to	O
block	O
terminal	O
differentiation	O
in	O
MEL	B-cell_line
cells	I-cell_line
.	O

We	O
also	O
show	O
that	O
ectopic	O
expression	O
of	O
PU.1	B-protein
in	O
Xenopus	O
embryos	O
is	O
sufficient	O
to	O
block	O
erythropoiesis	O
during	O
normal	O
development	O
.	O

Furthermore	O
,	O
introduction	O
of	O
exogenous	O
GATA-1	B-protein
in	O
both	O
MEL	B-cell_line
cells	I-cell_line
and	O
Xenopus	O
embryos	O
and	O
explants	O
relieves	O
the	O
block	O
to	O
erythroid	O
differentiation	O
imposed	O
by	O
PU.1	B-protein
.	O

Our	O
results	O
indicate	O
that	O
the	O
stoichiometry	O
of	O
directly	O
interacting	O
but	O
opposing	O
transcription	B-protein
factors	I-protein
may	O
be	O
a	O
crucial	O
determinant	O
governing	O
processes	O
of	O
normal	O
differentiation	O
and	O
malignant	O
transformation	O
.	O

IL-12	B-protein
induces	O
IFN	B-protein
regulating	I-protein
factor-1	I-protein
(	I-protein
IRF-1	I-protein
)	I-protein
gene	O
expression	O
in	O
human	O
NK	B-cell_type
and	O
T	B-cell_type
cells	I-cell_type
.	O

IL-12	B-protein
is	O
a	O
critical	B-protein
immunoregulatory	I-protein
cytokine	I-protein
that	O
promotes	O
cell-mediated	O
immune	O
responses	O
and	O
the	O
differentiation	O
of	O
naive	O
CD4+	B-cell_type
cells	I-cell_type
to	O
Th1	B-cell_type
cells	I-cell_type
;	O
however	O
,	O
relatively	O
few	O
IL-12	B-protein
target	O
genes	O
have	O
been	O
identified	O
.	O

To	O
better	O
clarify	O
the	O
molecular	O
basis	O
of	O
IL-12	B-protein
action	O
,	O
we	O
set	O
out	O
to	O
characterize	O
genes	O
up-regulated	O
by	O
IL-12	B-protein
,	O
first	O
by	O
contrasting	O
IL-12	B-DNA
-and	O
IFN-alpha-inducible	B-DNA
genes	I-DNA
.	O

We	O
identified	O
several	O
genes	O
up-regulated	O
by	O
IL-12	B-protein
,	O
namely	O
,	O
MIP-1alpha	B-protein
,	O
MIP-1beta	B-protein
,	O
IL-1RA	B-protein
,	O
and	O
IFN	B-protein
regulatory	I-protein
factor-1	I-protein
(	I-protein
IRF-1	I-protein
)	I-protein
.	O

IRF-1	B-protein
is	O
a	O
transcription	B-protein
factor	I-protein
regulated	O
by	O
IFNs	B-protein
that	O
is	O
also	O
essential	O
for	O
Th1	B-cell_type
responses	O
.	O

We	O
demonstrated	O
that	O
IL-12	B-protein
directly	O
up-regulates	O
IRF-1	B-protein
to	O
the	O
same	O
extent	O
as	O
IFN-alpha	B-protein
in	O
normal	O
human	O
T	B-cell_type
cells	I-cell_type
and	O
in	O
NK	B-cell_type
cells	I-cell_type
.	O

We	O
showed	O
that	O
IL-12	B-protein
had	O
a	O
direct	O
effect	O
on	O
IRF-1	B-protein
,	O
an	O
effect	O
not	O
mediated	O
indirectly	O
by	O
the	O
induction	O
of	O
IFN-gamma	B-protein
production	O
.	O

Furthermore	O
,	O
IL-2	B-protein
and	O
IL-12	B-protein
synergistically	O
induced	O
IRF-1	B-protein
,	O
whereas	O
IFN-alpha	B-protein
and	O
IL-12	B-protein
did	O
not	O
.	O

The	O
participation	O
of	O
STAT4	B-protein
in	O
the	O
regulation	O
of	O
IRF-1	B-protein
was	O
demonstrated	O
in	O
two	O
ways	O
.	O

First	O
,	O
STAT4	B-protein
was	O
required	O
for	O
the	O
IL-12	B-protein
-dependent	O
transactivation	O
of	O
an	O
IRF-1	B-DNA
reporter	I-DNA
construct	I-DNA
,	O
and	O
second	O
,	O
STAT4	B-protein
binding	O
to	O
the	O
IRF-1	B-DNA
promoter	I-DNA
was	O
shown	O
using	O
EMSA	O
.	O

In	O
contrast	O
to	O
IL-12	B-protein
,	O
no	O
up-regulation	O
of	O
IRF-1	B-protein
was	O
found	O
in	O
IL-4-stimulated	B-cell_line
cells	I-cell_line
,	O
and	O
IL-4	B-protein
did	O
not	O
block	O
IL-12	B-protein
-dependent	O
up-regulation	O
of	O
IRF-1	B-protein
.	O

Therefore	O
,	O
IRF-1	B-protein
may	O
be	O
an	O
important	O
contributor	O
to	O
IL-12	B-protein
signaling	O
,	O
and	O
we	O
speculate	O
that	O
the	O
defective	O
IL-12	B-protein
responses	O
seen	O
in	O
IRF	B-protein
-1-/-	O
mice	O
might	O
be	O
attributable	O
,	O
in	O
part	O
,	O
to	O
the	O
absence	O
of	O
this	O
transcription	B-protein
factor	I-protein
.	O

Targeted	O
remodeling	O
of	O
human	O
beta-globin	O
promoter	O
chromatin	O
structure	O
produces	O
increased	O
expression	O
and	O
decreased	O
silencing	O
.	O

The	O
chromatin	O
structure	O
of	O
the	O
human	B-DNA
beta-globin	I-DNA
gene	I-DNA
locus	I-DNA
assumes	O
a	O
transcriptionally-active	O
conformation	O
in	O
erythroid	B-cell_type
cells	I-cell_type
.	O

One	O
feature	O
of	O
this	O
chromatin	O
reorganization	O
is	O
the	O
formation	O
of	O
DNase	B-DNA
1	I-DNA
hypersensitive	I-DNA
sites	I-DNA
in	O
the	O
regions	O
of	O
active	B-DNA
globin	I-DNA
gene	I-DNA
promoters	I-DNA
.	O

This	O
reorganization	O
requires	O
the	O
globin	B-DNA
locus	I-DNA
control	I-DNA
region	I-DNA
and	O
is	O
associated	O
with	O
normal	O
expression	O
of	O
the	O
beta-like	B-DNA
globin	I-DNA
genes	I-DNA
.	O

To	O
determine	O
whether	O
it	O
is	O
possible	O
to	O
artificially	O
enhance	O
the	O
opening	O
of	O
the	O
chromatin	O
structure	O
of	O
a	O
minimal	B-DNA
beta-globin	I-DNA
promoter	I-DNA
,	O
we	O
placed	O
a	O
101bp	O
,	O
erythroid-specific	B-DNA
DNase	I-DNA
1	I-DNA
hypersensitive	I-DNA
site-forming	I-DNA
element	I-DNA
(	O
HSFE	B-DNA
)	O
immediately	O
upstream	O
of	O
the	O
beta-globin	B-DNA
promoter	I-DNA
and	I-DNA
gene	I-DNA
.	O

This	O
element	O
includes	O
binding	O
sites	O
for	O
NF-E2	B-protein
,	O
AP-1	B-protein
,	O
GATA-1	B-protein
and	O
Sp-1	B-protein
.	O

Constructs	O
were	O
stably	O
transfected	O
into	O
murine	B-cell_type
erythroleukemia	I-cell_type
cells	I-cell_type
and	O
promoter	O
chromatin	O
structure	O
and	O
gene	O
expression	O
were	O
analyzed	O
.	O

The	O
HSFE	B-DNA
induced	O
an	O
area	O
of	O
enhanced	O
DNase	B-protein
1	I-protein
hypersensitivity	O
extending	O
from	O
the	O
transcriptional	O
start	O
site	O
to	O
-300bp	O
of	O
the	O
artificial	B-DNA
promoter	I-DNA
and	O
significantly	O
increased	O
the	O
proportion	O
of	O
beta-globin	B-DNA
promoters	I-DNA
in	O
an	O
open	O
chromatin	O
configuration	O
.	O

This	O
remodeling	O
of	O
promoter	O
chromatin	O
structure	O
resulted	O
in	O
3-fold	O
increases	O
in	O
beta-globin	B-DNA
gene	I-DNA
transcription	O
and	O
induction	O
,	O
and	O
inhibited	O
long-term	O
beta-globin	B-DNA
gene	I-DNA
silencing	O
.	O

These	O
results	O
indicate	O
that	O
a	O
relatively	O
small	O
cis-acting	B-DNA
element	I-DNA
is	O
able	O
to	O
enhance	O
remodeling	O
of	O
promoter	O
chromatin	O
structure	O
resulting	O
in	O
increased	O
beta-globin	B-DNA
gene	I-DNA
expression	O
.	O

Regulation	O
of	O
low	O
shear	O
flow-induced	O
HAEC	B-cell_line
VCAM-1	B-protein
expression	O
and	O
monocyte	O
adhesion	O
.	O

We	O
recently	O
reported	O
that	O
prolonged	O
exposure	O
of	O
human	B-cell_type
aortic	I-cell_type
endothelial	I-cell_type
cells	I-cell_type
(	O
HAEC	B-cell_line
)	O
to	O
low	O
shear	O
stress	O
flow	O
patterns	O
is	O
associated	O
with	O
a	O
sustained	O
increase	O
in	O
the	O
activated	O
form	O
of	O
the	O
transcriptional	O
regulator	O
nuclear	B-protein
factor-kappaB	I-protein
(	O
NF-kappaB	B-protein
)	O
.	O

Here	O
we	O
investigate	O
the	O
hypothesis	O
that	O
low	O
shear-induced	O
activation	O
of	O
NF-kappaB	B-protein
is	O
responsible	O
for	O
enhanced	O
expression	O
of	O
vascular	B-protein
cell	I-protein
adhesion	I-protein
molecule	I-protein
(	O
VCAM-1	B-protein
)	O
resulting	O
in	O
augmented	O
endothelial	O
cell-monocyte	O
(	O
EC-Mn	O
)	O
adhesion	O
and	O
that	O
this	O
activation	O
is	O
dependent	O
on	O
intracellular	O
oxidant	O
activity	O
.	O

Before	O
exposure	O
to	O
low	O
shear	O
(	O
2	O
dyn/cm2	O
)	O
for	O
6	O
h	O
,	O
HAEC	B-cell_line
were	O
preincubated	O
with	O
or	O
without	O
the	O
antioxidants	O
pyrrolidine	O
dithiocarbamate	O
(	O
PDTC	O
)	O
or	O
N-acetyl-L-cysteine	O
(	O
NAC	O
)	O
.	O

PDTC	O
strongly	O
inhibited	O
low	O
shear-induced	O
activation	O
of	O
NF-kappaB	B-protein
,	O
expression	O
of	O
VCAM-1	B-protein
,	O
and	O
EC-Mn	O
adhesion	O
.	O

Paradoxically	O
,	O
NAC	O
exerted	O
a	O
positive	O
effect	O
on	O
low	O
shear-induced	O
VCAM-1	B-protein
expression	O
and	O
EC-Mn	O
adhesion	O
and	O
only	O
slightly	O
downregulated	O
NF-kappaB	B-protein
activation	O
.	O

However	O
,	O
cytokine-induced	O
NF-kappaB	B-protein
activation	O
and	O
VCAM-1	B-protein
expression	O
are	O
blocked	O
by	O
both	O
PDTC	O
and	O
NAC	O
.	O

These	O
data	O
suggest	O
that	O
NF-kappaB	B-protein
plays	O
a	O
key	O
role	O
in	O
low	O
shear-induced	O
VCAM-1	B-protein
expression	O
and	O
that	O
pathways	O
mediating	O
low	O
shear-	O
and	O
cytokine-induced	O
EC-Mn	O
adhesion	O
may	O
be	O
differentially	O
regulated	O
.	O

Nuclear	B-protein
factor-90	I-protein
of	O
activated	B-cell_type
T-cells	I-cell_type
:	O
A	O
double-stranded	B-RNA
RNA	I-RNA
-binding	O
protein	O
and	O
substrate	O
for	O
the	O
double-stranded	B-protein
RNA-dependent	I-protein
protein	I-protein
kinase	I-protein
,	O
PKR	B-protein
.	O

NFAT	O
transcription	O
factors	O
play	O
a	O
central	O
role	O
in	O
initiating	O
T-cell	O
activation	O
through	O
the	O
induction	O
of	O
immediate-early	O
T-cell	O
specific	O
genes	O
including	O
interleukin-2	O
(	O
IL-2	B-protein
)	O
.	O

NFAT	O
transcription	O
factors	O
bind	O
to	O
a	O
sequence	O
in	O
the	O
IL-2	B-DNA
enhancer	I-DNA
known	O
as	O
the	O
antigen	B-DNA
receptor	I-DNA
response	I-DNA
element	I-DNA
2	I-DNA
(	O
ARRE-2	B-DNA
)	O
.	O

Multiple	O
proteins	O
exhibiting	O
ARRE-2	B-DNA
binding	O
activity	O
have	O
been	O
isolated	O
,	O
including	O
a	O
heterodimer	B-protein
from	O
stimulated	O
T-cell	O
nuclear	O
extracts	O
consisting	O
of	O
Mr	O
=	O
90	O
000	O
(	O
NF90	B-protein
)	O
and	O
Mr	O
=	O
45	O
000	O
(	O
NF45	B-protein
)	O
subunits	O
.	O

The	O
subunits	O
of	O
this	O
heterodimer	B-protein
have	O
been	O
cloned	O
,	O
and	O
NF90	B-protein
was	O
found	O
to	O
encode	O
a	O
protein	O
containing	O
two	O
domains	O
that	O
are	O
predicted	O
to	O
form	O
motifs	O
capable	O
of	O
binding	O
to	O
double-stranded	B-RNA
RNA	I-RNA
.	O

Using	O
in	O
vitro	O
translated	O
polypeptides	O
,	O
we	O
have	O
demonstrated	O
that	O
NF90	B-protein
specifically	O
binds	O
to	O
double-stranded	B-RNA
RNA	I-RNA
.	O

Furthermore	O
,	O
NF90	B-protein
was	O
phosphorylated	O
in	O
a	O
double-stranded	B-RNA
RNA	I-RNA
-dependent	O
manner	O
likely	O
by	O
the	O
interferon-induced	O
,	O
double-stranded	B-protein
RNA-dependent	I-protein
protein	I-protein
kinase	I-protein
,	O
PKR	B-protein
.	O

The	O
NF90	B-protein
protein	O
was	O
found	O
to	O
be	O
expressed	O
not	O
only	O
in	O
T-cells	B-cell_type
,	O
but	O
also	O
in	O
nonimmune	B-cell_line
HeLa	I-cell_line
cells	I-cell_line
.	O

In	O
HeLa	B-cell_line
cells	I-cell_line
,	O
the	O
protein	O
was	O
almost	O
exclusively	O
localized	O
to	O
the	O
ribosome	O
salt	O
wash	O
fraction	O
of	O
cell	O
lysates	O
.	O

NF-kappaB	B-protein
activation	O
is	O
required	O
for	O
C5a-induced	B-DNA
interleukin-8	I-DNA
gene	I-DNA
expression	O
in	O
mononuclear	B-cell_type
cells	I-cell_type
.	O

C5a	O
,	O
a	O
potent	O
peptide	O
chemoattractant	O
,	O
stimulates	O
interleukin-8	B-protein
(	O
IL-8	B-protein
)	O
secretion	O
from	O
peripheral	B-cell_type
blood	I-cell_type
mononuclear	I-cell_type
cells	I-cell_type
(	O
PBMC	B-cell_type
)	O
.	O

Experiments	O
were	O
conducted	O
to	O
understand	O
the	O
mechanisms	O
for	O
C5a-induced	O
IL-8	B-protein
production	O
,	O
which	O
was	O
14-fold	O
greater	O
than	O
that	O
in	O
unstimulated	B-cell_type
cells	I-cell_type
by	O
2	O
hours	O
.	O

IL-8	B-protein
secretion	O
was	O
accompanied	O
by	O
accumulation	O
of	O
IL-8	B-RNA
mRNA	I-RNA
in	O
the	O
cytosol	O
and	O
by	O
nuclear	O
expression	O
of	O
a	O
kappaB	B-protein
DNA	O
binding	O
activity	O
within	O
30	O
minutes	O
.	O

AP-1	B-protein
but	O
not	O
NF-IL-6	B-protein
DNA	O
binding	O
activity	O
was	O
also	O
detected	O
in	O
C5a-stimulated	B-cell_line
PBMC	I-cell_line
;	O
however	O
,	O
its	O
delayed	O
expression	O
(	O
maximal	O
at	O
4	O
hours	O
)	O
suggested	O
a	O
less	O
important	O
role	O
in	O
the	O
rapid	O
production	O
of	O
IL-8	B-protein
.	O

The	O
correlation	O
between	O
C5a-induced	O
kappaB	B-protein
binding	O
activity	O
and	O
IL-8	B-protein
gene	O
expression	O
was	O
examined	O
in	O
the	O
RAW264.7	B-cell_line
macrophage	I-cell_line
cells	I-cell_line
using	O
reporter	O
genes	O
directed	O
by	O
the	O
kappaB	B-DNA
sequence	I-DNA
from	O
IkappaBalpha	B-protein
and	O
IL-8	B-DNA
promoter	I-DNA
regions	I-DNA
.	O

C5a-induced	O
reporter	B-DNA
gene	I-DNA
expression	O
was	O
abolished	O
by	O
introducing	O
mutations	O
into	O
the	O
kappaB	B-DNA
sites	I-DNA
and	O
by	O
coexpression	O
of	O
a	O
dominant	B-DNA
negative	I-DNA
IkappaBalpha	I-DNA
construct	I-DNA
resistant	O
to	O
agonist-induced	O
phosphorylation	O
.	O

Pertussis	O
toxin	O
,	O
which	O
ADP-ribosylates	O
the	O
Gi	B-protein
proteins	I-protein
known	O
to	O
couple	O
to	O
the	O
C5a	B-protein
receptor	I-protein
,	O
produced	O
minimal	O
inhibition	O
of	O
C5a-induced	O
IL-8	B-protein
expression	O
and	O
had	O
little	O
effect	O
on	O
C5a-induced	O
calcium	O
mobilization	O
in	O
RAW264.7	B-cell_line
cells	I-cell_line
.	O

These	O
results	O
suggest	O
that	O
NF-kappaB	B-protein
activation	O
is	O
required	O
for	O
C5a-induced	O
IL-8	B-protein
gene	O
expression	O
and	O
that	O
this	O
response	O
is	O
mediated	O
primarily	O
through	O
a	O
pertussis	O
toxin-insensitive	O
pathway	O
.	O

Increased	O
glucocorticoid	B-protein
receptor	I-protein
beta	I-protein
in	O
airway	B-cell_type
cells	I-cell_type
of	O
glucocorticoid-insensitive	O
asthma	O
.	O

Glucocorticoid	O
(	O
GC	O
)	O
-insensitive	O
asthma	O
is	O
a	O
challenging	O
clinical	O
problem	O
that	O
can	O
be	O
associated	O
with	O
life-threatening	O
disease	O
progression	O
.	O

The	O
molecular	O
basis	O
of	O
GC	O
insensitivity	O
is	O
unknown	O
.	O

Alternative	O
splicing	O
of	O
the	O
GC	B-RNA
receptor	I-RNA
(	I-RNA
GCR	I-RNA
)	I-RNA
pre-mRNA	I-RNA
generates	O
a	O
second	O
GCR	B-protein
,	O
termed	O
GCRbeta	B-protein
,	O
which	O
does	O
not	O
bind	O
GC	O
but	O
antagonizes	O
the	O
transactivating	O
activity	O
of	O
the	O
classic	O
GCR	B-protein
.	O

Thus	O
increased	O
expression	O
of	O
GCRbeta	B-protein
could	O
account	O
for	O
glucocorticoid	O
insensitivity	O
.	O

Bronchoalveolar	B-cell_type
lavage	I-cell_type
(	I-cell_type
BAL	I-cell_type
)	I-cell_type
cells	I-cell_type
and	O
peripheral	O
blood	O
mononuclear	B-cell_type
cells	I-cell_type
(	O
PBMC	B-cell_type
)	O
were	O
examined	O
for	O
GCRbeta	B-protein
immunoreactivity	O
using	O
a	O
GCRbeta-specific	B-protein
antibody	I-protein
by	O
immunohistochemical	O
staining	O
.	O

Cell	O
localization	O
of	O
GCRbeta	B-protein
expression	O
was	O
performed	O
using	O
a	O
double	O
immunostaining	O
technique	O
.	O

Patients	O
with	O
GC-insensitive	O
asthma	O
expressed	O
a	O
significantly	O
higher	O
number	O
of	O
GCRbeta-immunoreactive	B-cell_type
cells	I-cell_type
in	O
their	O
BAL	O
and	O
peripheral	O
blood	O
than	O
GC-sensitive	O
asthmatics	O
or	O
normal	O
control	O
subjects	O
.	O

Furthermore	O
,	O
GCRbeta	B-protein
expression	O
in	O
GC-insensitive	O
asthma	O
was	O
particularly	O
high	O
in	O
airway	O
T	B-cell_type
cells	I-cell_type
,	O
which	O
are	O
thought	O
to	O
play	O
a	O
major	O
role	O
in	O
the	O
pathogenesis	O
of	O
asthma	O
.	O

We	O
also	O
examined	O
the	O
expression	O
of	O
GCRbeta	B-protein
in	O
specimens	O
from	O
the	O
airways	O
of	O
patients	O
with	O
chronic	O
bronchitis	O
.	O

In	O
chronic	O
bronchitis	O
,	O
few	O
cells	O
were	O
GCRbeta-positive	B-cell_type
and	O
their	O
numbers	O
did	O
not	O
differ	O
significantly	O
from	O
normal	O
control	O
subjects	O
.	O

We	O
conclude	O
that	O
GC-insensitive	O
asthma	O
is	O
associated	O
with	O
increased	O
expression	O
of	O
GCRbeta	B-protein
in	O
airway	O
T	B-cell_type
cells	I-cell_type
.	O

Activation	O
of	O
the	O
Janus	B-protein
kinase	I-protein
3	I-protein
-STAT5a	B-protein
pathway	O
after	O
CD40	B-protein
triggering	O
of	O
human	B-cell_type
monocytes	I-cell_type
but	O
not	O
of	O
resting	B-cell_type
B	I-cell_type
cells	I-cell_type
.	O

CD40	B-protein
/CD40	B-protein
ligand	O
interactions	O
play	O
a	O
key	O
role	O
in	O
the	O
immune	O
responses	O
of	O
B	B-cell_type
lymphocytes	I-cell_type
,	O
monocytes	B-cell_type
,	O
and	O
dendritic	B-cell_type
cells	I-cell_type
.	O

The	O
signal	O
transduction	O
events	O
triggered	O
by	O
cross-linking	O
of	O
the	O
CD40	B-protein
receptor	I-protein
have	O
been	O
widely	O
studied	O
in	O
B	B-cell_line
cell	I-cell_line
lines	I-cell_line
,	O
but	O
little	O
is	O
known	O
about	O
signaling	O
following	O
CD40	B-protein
stimulation	O
of	O
monocytes	B-cell_type
and	O
resting	B-cell_line
tonsillar	I-cell_line
B	I-cell_line
cells	I-cell_line
.	O

Therefore	O
,	O
we	O
studied	O
the	O
CD40	B-protein
pathway	O
in	O
highly	O
purified	O
human	B-cell_type
monocytes	I-cell_type
and	O
resting	B-cell_type
B	I-cell_type
cells	I-cell_type
.	O

After	O
CD40	B-protein
triggering	O
,	O
a	O
similar	O
activation	O
of	O
the	O
NF-kappaB	B-protein
(	O
but	O
not	O
of	O
the	O
AP-1	B-protein
)	O
transcription	B-protein
factor	I-protein
complex	I-protein
occurred	O
in	O
both	O
cell	O
preparations	O
.	O

However	O
,	O
the	O
components	O
of	O
the	O
NF-kappaB	B-protein
complexes	I-protein
were	O
different	O
in	O
monocytes	B-cell_type
and	O
B	O
cells	O
,	O
because	O
p50	B-protein
is	O
part	O
of	O
the	O
NF-kappaB	B-protein
complex	I-protein
induced	O
by	O
CD40	B-protein
triggering	O
in	O
both	O
monocytes	B-cell_type
and	O
B	B-cell_type
cells	I-cell_type
,	O
whereas	O
p65	B-protein
was	O
only	O
induced	O
in	O
B	B-cell_type
cells	I-cell_type
.	O
In	O
contrast	O
,	O
although	O
the	O
Janus	B-protein
kinase	I-protein
3	I-protein
tyrosine	I-protein
kinase	I-protein
was	O
associated	O
with	O
CD40	B-protein
molecules	O
in	O
both	O
monocytes	B-cell_type
and	O
resting	B-cell_type
B	I-cell_type
cells	I-cell_type
,	O
Janus	B-protein
kinase	I-protein
3	I-protein
phosphorylation	O
induction	O
was	O
observed	O
only	O
in	O
CD40-activated	B-cell_line
monocytes	I-cell_line
,	O
with	O
subsequent	O
induction	O
of	O
STAT5a	B-protein
DNA	O
binding	O
activity	O
in	O
the	O
nucleus	O
.	O

These	O
results	O
suggest	O
that	O
the	O
activation	O
signals	O
in	O
human	B-cell_type
B	I-cell_type
cells	I-cell_type
and	O
monocytes	B-cell_type
differ	O
following	O
CD40	B-protein
stimulation	O
.	O

This	O
observation	O
is	O
consistent	O
with	O
the	O
detection	O
of	O
normal	O
CD40	B-protein
-induced	O
monocyte	O
activation	O
in	O
patients	O
with	O
CD40	B-protein
ligand+	O
hyper	O
IgM	B-protein
syndrome	O
in	O
whom	O
a	O
defect	O
in	O
CD40	B-protein
-induced	O
B	O
cell	O
activation	O
has	O
been	O
reported	O
.	O

Genetic	O
evidence	O
for	O
an	O
additional	O
factor	O
required	O
for	O
erythropoietin	B-protein
-induced	O
signal	O
transduction	O
.	O

Erythropoietin	B-protein
(	O
EPO	B-protein
)	O
and	O
its	O
receptor	O
(	O
EPOR	B-protein
)	O
are	O
required	O
for	O
the	O
development	O
of	O
mature	O
erythrocytes	O
.	O

After	O
binding	O
of	O
ligand	O
,	O
the	O
EPOR	B-protein
activates	O
a	O
variety	O
of	O
signaling	O
pathways	O
that	O
ultimately	O
control	O
cellular	O
proliferation	O
,	O
survival	O
,	O
and	O
specific	O
gene	O
expression	O
.	O

Although	O
erythroid	B-cell_type
progenitors	I-cell_type
appear	O
to	O
be	O
the	O
principal	O
EPO-responsive	B-cell_type
cell	I-cell_type
type	I-cell_type
in	O
vivo	O
due	O
to	O
the	O
restricted	O
expression	O
of	O
the	O
EPOR	B-protein
,	O
many	O
growth	B-cell_line
factor-dependent	I-cell_line
cell	I-cell_line
lines	I-cell_line
expressing	O
the	O
EPOR	B-protein
can	O
respond	O
to	O
EPO	B-protein
by	O
activating	O
many	O
or	O
all	O
of	O
these	O
pathways	O
.	O

In	O
the	O
present	O
study	O
,	O
we	O
have	O
identified	O
a	O
cellular	O
context	O
(	O
the	O
interleukin-2	B-cell_line
[	I-cell_line
IL-2	I-cell_line
]	I-cell_line
-dependent	I-cell_line
HT-2	I-cell_line
line	I-cell_line
)	O
in	O
which	O
the	O
EPO	B-protein
stimulation	O
of	O
the	O
EPOR	B-protein
fails	O
to	O
support	O
cellular	O
proliferation	O
,	O
STAT-5	B-protein
induction	O
,	O
or	O
MAPK	B-protein
activation	O
,	O
despite	O
efficient	O
phosphorylation	O
of	O
the	O
EPOR	B-protein
and	O
JAK2	B-protein
and	O
inhibition	O
of	O
apoptosis	O
after	O
withdrawal	O
of	O
IL-2	B-protein
.	O

Interestingly	O
,	O
when	O
we	O
fused	O
HT-2	B-cell_line
cells	I-cell_line
expressing	O
the	O
EPOR	B-protein
with	O
Ba/F3	B-cell_line
cells	I-cell_line
in	O
a	O
complementation	O
assay	O
,	O
the	O
resulting	O
hybridomas	B-cell_line
proliferated	O
and	O
potently	O
activated	O
STAT-5	B-protein
and	O
MAPK	B-protein
in	O
response	O
to	O
EPO	B-protein
.	O

These	O
data	O
indicate	O
that	O
an	O
unidentified	B-protein
cellular	I-protein
factor	I-protein
is	O
needed	O
to	O
mediate	O
signaling	O
by	O
the	O
EPOR	B-protein
.	O

Moreover	O
,	O
Ba/F3	B-cell_line
cells	I-cell_line
apparently	O
express	O
this	O
factor	O
(	O
s	O
)	O
and	O
somatic	O
fusions	O
can	O
,	O
therefore	O
,	O
confer	O
EPO	B-protein
-responsiveness	O
to	O
HT-2	B-cell_line
cells	I-cell_line
that	O
lack	O
this	O
factor	O
.	O

Novel	O
therapies	O
for	O
inflammatory	O
bowel	O
disease	O
.	O

Looking	O
back	O
at	O
successes	O
and	O
failures	O
in	O
newer	O
approaches	O
to	O
treating	O
IBD	O
,	O
it	O
is	O
tempting	O
--	O
although	O
still	O
difficult	O
--	O
to	O
draw	O
conclusions	O
about	O
pathogenesis	O
.	O

When	O
a	O
therapy	O
proves	O
effective	O
,	O
do	O
clinicians	O
truly	O
know	O
how	O
it	O
works	O
?	O
Even	O
with	O
a	O
therapy	O
as	O
specific	O
as	O
anti-TNF	B-protein
antibody	I-protein
,	O
it	O
is	O
not	O
clear	O
if	O
the	O
benefit	O
is	O
attributable	O
to	O
simple	O
binding	O
and	O
clearance	O
of	O
TNF-alpha	B-protein
or	O
to	O
binding	O
on	O
the	O
cell	O
surface	O
and	O
subsequent	O
deletion	O
of	O
the	O
activated	B-cell_type
macrophage	I-cell_type
.	O

When	O
a	O
drug	O
appears	O
to	O
be	O
less	O
effective	O
than	O
preclinical	O
models	O
suggest	O
,	O
can	O
failures	O
in	O
effectiveness	O
from	O
delivery	O
or	O
dosing	O
be	O
differentiated	O
?	O
The	O
disappointing	O
results	O
of	O
clinical	O
trials	O
with	O
IL-10	B-protein
--	O
so	O
at	O
odds	O
with	O
the	O
prediction	O
of	O
benefit	O
from	O
animal	O
models	O
--	O
bring	O
into	O
question	O
the	O
validity	O
of	O
those	O
models	O
as	O
well	O
as	O
the	O
soundness	O
of	O
design	O
of	O
the	O
clinical	O
trials	O
on	O
which	O
efficacy	O
of	O
IL-10	B-protein
is	O
judged	O
.	O

The	O
variability	O
of	O
response	O
even	O
to	O
the	O
most	O
narrowly	O
targeted	O
agents	O
suggests	O
that	O
these	O
diseases	O
are	O
far	O
more	O
heterogeneous	O
in	O
humans	O
than	O
in	O
their	O
murine	O
counterparts	O
.	O

Clinicians	O
are	O
only	O
just	O
beginning	O
to	O
recognize	O
subclinical	O
markers	O
of	O
response	O
,	O
and	O
it	O
may	O
soon	O
be	O
possible	O
to	O
predict	O
response	O
on	O
the	O
basis	O
of	O
genetic	O
composition	O
.	O

For	O
the	O
moment	O
,	O
however	O
,	O
the	O
field	O
of	O
pharmacogenetics	O
is	O
embryonic	O
.	O

Challenges	O
in	O
developing	O
new	O
therapeutic	O
strategies	O
include	O
not	O
only	O
identifying	O
novel	O
agents	O
,	O
but	O
also	O
improving	O
the	O
definitions	O
of	O
clinical	O
endpoints	O
and	O
defining	O
efficacy	O
at	O
the	O
biologic	O
level	O
.	O

Only	O
through	O
considered	O
evaluation	O
of	O
clinical	O
evidence	O
may	O
clinicians	O
determine	O
which	O
therapies	O
should	O
remain	O
novelties	O
and	O
which	O
should	O
become	O
an	O
accepted	O
part	O
of	O
the	O
armamentarium	O
.	O

Potent	O
and	O
stable	O
attenuation	O
of	O
live-HIV-1	O
by	O
gain	O
of	O
a	O
proteolysis-resistant	B-protein
inhibitor	I-protein
of	O
NF-kappaB	B-protein
(	O
IkappaB-alphaS32/36A	B-protein
)	O
and	O
the	O
implications	O
for	O
vaccine	O
development	O
.	O

Live-attenuated	O
human	O
immunodeficiency	O
viruses	O
(	O
HIVs	O
)	O
are	O
candidates	O
for	O
Acquired	O
Immunodeficiency	O
Syndrome	O
(	O
AIDS	O
)	O
vaccine	O
.	O

Based	O
on	O
the	O
simian	O
immunodeficiency	O
virus	O
(	O
SIV	O
)	O
model	O
for	O
AIDS	O
,	O
loss-of-function	O
(	O
e.g.	O
deletion	O
of	O
accessory	O
genes	O
such	O
as	O
nef	B-DNA
)	O
has	O
been	O
forwarded	O
as	O
a	O
primary	O
approach	O
for	O
creating	O
enfeebled	O
,	O
but	O
replication-competent	O
,	O
HIV-1/SIV	O
.	O

Regrettably	O
,	O
recent	O
evidence	O
suggests	O
that	O
loss-of-function	O
alone	O
is	O
not	O
always	O
sufficient	O
to	O
prevent	O
the	O
emergence	O
of	O
virulent	O
mutants	O
.	O

New	O
strategies	O
that	O
attenuate	O
via	O
mechanisms	O
distinct	O
from	O
loss-of-function	O
are	O
needed	O
for	O
enhancing	O
the	O
safety	O
phenotype	O
of	O
viral	B-DNA
genome	I-DNA
.	O

Here	O
,	O
we	O
propose	O
gain-of-function	O
to	O
be	O
used	O
simultaneously	O
with	O
loss-of-function	O
as	O
a	O
novel	O
approach	O
for	O
attenuating	O
HIV-1	O
.	O

We	O
have	O
constructed	O
an	O
HIV-1	B-DNA
genome	I-DNA
carrying	O
the	O
cDNA	B-DNA
of	O
a	O
proteolysis-resistant	B-protein
nuclear	I-protein
factor-kappaB	I-protein
inhibitor	I-protein
(	O
IkappaB-alphaS32/36A	B-protein
)	O
in	O
the	O
nef	B-DNA
region	I-DNA
.	O

HIV-1	O
expressing	O
IkappaB-alphaS32/36A	B-protein
down-regulates	O
viral	O
expression	O
and	O
is	O
highly	O
attenuated	O
in	O
both	O
Jurkat	B-cell_line
and	O
peripheral	B-cell_type
blood	I-cell_type
mononuclear	I-cell_type
cells	I-cell_type
.	O

We	O
provide	O
formal	O
proof	O
that	O
the	O
phenotypic	O
and	O
attenuating	O
characteristics	O
of	O
IkappaB-alphaS32/36A	B-protein
permit	O
its	O
stable	O
maintenance	O
in	O
a	O
live	O
,	O
replicating	O
HIV-1	O
despite	O
180	O
days	O
of	O
forced	O
ex	O
vivo	O
passaging	O
in	O
tissue	O
culture	O
.	O

As	O
compared	O
with	O
other	O
open-reading	B-DNA
frames	I-DNA
embedded	O
into	O
HIV/SIV	B-DNA
genome	I-DNA
,	O
this	O
degree	O
of	O
stability	O
is	O
unprecedented	O
.	O

Thus	O
,	O
IkappaB-alphaS32/36A	B-protein
offers	O
proof-of-principle	O
that	O
artifactually	O
gained	O
functions	O
,	O
when	O
used	O
to	O
attenuate	O
the	O
replication	O
of	O
live	O
HIV-1	O
,	O
can	O
be	O
stable	O
.	O

These	O
findings	O
illustrate	O
gain-of-function	O
as	O
a	O
feasible	O
strategy	O
for	O
developing	O
safer	O
live-attenuated	O
HIVs	O
to	O
be	O
tested	O
as	O
candidates	O
for	O
AIDS	O
vaccine	O
.	O

Multiple	O
NF-ATc	B-protein
isoforms	I-protein
with	O
individual	O
transcriptional	O
properties	O
are	O
synthesized	O
in	O
T	B-cell_type
lymphocytes	I-cell_type
.	O

The	O
transcription	B-protein
factor	I-protein
NF-ATc	B-protein
that	O
controls	O
gene	O
expression	O
in	O
T	B-cell_type
lymphocytes	I-cell_type
and	O
embryonic	B-cell_type
cardiac	I-cell_type
cells	I-cell_type
is	O
expressed	O
in	O
three	O
prominent	O
isoforms	O
.	O

This	O
is	O
due	O
to	O
alternative	O
splice/polyadenylation	O
events	O
that	O
lead	O
to	O
the	O
predominant	O
synthesis	O
of	O
two	O
long	O
isoforms	O
in	O
naive	B-cell_type
T	I-cell_type
cells	I-cell_type
and	O
a	O
shorter	O
NF-ATc	B-protein
isoform	I-protein
in	O
effector	B-cell_type
T	I-cell_type
cells	I-cell_type
.	O

Whereas	O
the	O
previously	O
described	O
isoform	B-protein
NF-ATc/A	I-protein
contains	O
a	O
relatively	O
short	O
C	B-protein
terminus	I-protein
,	O
the	O
longer	O
isoforms	O
,	O
B	B-protein
and	O
C	B-protein
,	O
span	O
extra	O
C-terminal	O
peptides	O
of	O
128	O
and	O
246	O
aa	O
,	O
respectively	O
.	O

We	O
show	O
here	O
that	O
in	O
addition	O
to	O
the	O
strong	B-protein
N-terminal	I-protein
trans-activation	I-protein
domain	I-protein
,	O
TAD-A	B-protein
,	O
which	O
is	O
common	O
to	O
all	O
three	O
NF-ATc	B-protein
isoforms	I-protein
,	O
NF-ATc/C	B-protein
contains	O
a	O
second	O
trans-activation	B-protein
domain	I-protein
,	O
TAD-B	B-protein
,	O
in	O
its	O
C-terminal	O
peptide	O
.	O

Various	O
stimuli	O
of	O
T	B-cell_type
cells	I-cell_type
that	O
induce	O
the	O
activity	O
of	O
TAD-A	B-protein
also	O
enhance	O
the	O
activity	O
of	O
TAD-B	B-protein
,	O
but	O
,	O
unlike	O
TAD-A	B-protein
,	O
TAD-B	B-protein
remains	O
unphosphorylated	O
by	O
protein	O
from	O
12-O-tetradecanoyl	B-cell_line
12-phorbol	I-cell_line
13-acetate-stimulated	I-cell_line
T	I-cell_line
cells	I-cell_line
.	O

The	O
shorter	O
C-terminal	O
peptide	O
of	O
isoform	O
NF-ATc/B	B-protein
exerts	O
a	O
suppressive	O
transcriptional	O
effect	O
.	O

These	O
properties	O
of	O
NF-ATc/B	B-protein
and	I-protein
-C	I-protein
might	O
be	O
of	O
importance	O
for	O
gene	O
regulation	O
in	O
naive	B-cell_type
T	I-cell_type
lymphocytes	I-cell_type
in	O
which	O
NF-ATc/B	B-protein
and	I-protein
-C	I-protein
are	O
predominantly	O
synthesized	O
.	O

Selection	O
and	O
long-term	O
persistence	O
of	O
reactive	O
CTL	B-cell_line
clones	I-cell_line
during	O
an	O
EBV	O
chronic	O
response	O
are	O
determined	O
by	O
avidity	O
,	O
CD8	B-protein
variable	O
contribution	O
compensating	O
for	O
differences	O
in	O
TCR	B-protein
affinities	O
.	O

Recent	O
studies	O
have	O
suggested	O
that	O
the	O
diversity	O
of	O
TCR	B-protein
repertoire	O
after	O
primary	O
immunization	O
is	O
conserved	O
in	O
memory	B-cell_type
T	I-cell_type
cells	I-cell_type
and	O
that	O
a	O
progressive	O
narrowing	O
of	O
this	O
repertoire	O
may	O
take	O
place	O
during	O
recall	O
infections	O
.	O

It	O
now	O
remains	O
to	O
be	O
investigated	O
which	O
parameters	O
determine	O
the	O
repertoire	O
of	O
the	O
memory	O
response	O
and	O
possibly	O
restrict	O
its	O
diversity	O
after	O
subsequent	O
antigenic	O
challenges	O
.	O

To	O
address	O
this	O
question	O
,	O
we	O
took	O
advantage	O
of	O
a	O
panel	O
of	O
CD8+	B-cell_line
T	I-cell_line
cell	I-cell_line
clones	I-cell_line
from	O
the	O
joint	O
of	O
a	O
rheumatoid	O
arthritis	O
patient	O
and	O
selected	O
for	O
their	O
reactivity	O
against	O
a	O
single	B-protein
MHC/peptide	I-protein
complex	I-protein
.	O

Characterization	O
of	O
both	O
TCR	B-protein
chains	I-protein
documented	O
a	O
great	O
diversity	O
among	O
those	O
clones	O
and	O
the	O
persistence	O
of	O
clonotypes	O
over	O
a	O
2-yr	O
period	O
.	O

Strikingly	O
,	O
despite	O
the	O
observed	O
repertoire	O
heterogeneity	O
,	O
all	O
clones	O
displayed	O
a	O
narrow	O
range	O
of	O
MHC	B-protein
/peptide	O
density	O
requirements	O
in	O
cytotoxicity	O
assays	O
(	O
ED50	O
between	O
9	O
and	O
36	O
nM	O
)	O
.	O

TCR	B-protein
affinities	O
were	O
then	O
indirectly	O
estimated	O
by	O
blocking	O
CD8	B-protein
interaction	O
with	O
an	O
anti-CD8	B-protein
mAb	I-protein
.	O

We	O
found	O
a	O
wide	O
range	O
of	O
TCR	B-protein
affinities	O
among	O
the	O
different	O
clonotypes	O
that	O
segregated	O
with	O
Vbeta	O
usage	O
.	O

We	O
thus	O
propose	O
that	O
during	O
an	O
in	O
vivo	O
chronic	O
response	O
,	O
a	O
narrow	O
range	O
of	O
avidity	O
of	O
the	O
TCR-CD8	B-protein
complex	I-protein
conditions	O
long-term	O
clonotype	O
persistence	O
,	O
and	O
that	O
the	O
level	O
of	O
CD8	B-protein
contribution	O
is	O
adjusted	O
to	O
keep	O
clonotypes	O
with	O
variable	O
TCR	B-protein
affinities	O
within	O
this	O
avidity	O
window	O
.	O

Nuclear	O
localization	O
and	O
formation	O
of	O
beta-catenin-lymphoid	B-protein
enhancer	I-protein
factor	I-protein
1	I-protein
complexes	I-protein
are	O
not	O
sufficient	O
for	O
activation	O
of	O
gene	O
expression	O
.	O

In	O
response	O
to	O
activation	O
of	O
the	O
Wnt	O
signaling	O
pathway	O
,	O
beta-catenin	B-protein
accumulates	O
in	O
the	O
nucleus	O
,	O
where	O
it	O
cooperates	O
with	O
LEF/TCF	B-protein
(	O
for	O
lymphoid	B-protein
enhancer	I-protein
factor	I-protein
and	I-protein
T-cell	I-protein
factor	I-protein
)	O
transcription	B-protein
factors	I-protein
to	O
activate	O
gene	O
expression	O
.	O

The	O
mechanisms	O
by	O
which	O
beta-catenin	B-protein
undergoes	O
this	O
shift	O
in	O
location	O
and	O
participates	O
in	O
activation	O
of	O
gene	O
transcription	O
are	O
unknown	O
.	O

We	O
demonstrate	O
here	O
that	O
beta-catenin	B-protein
can	O
be	O
imported	O
into	O
the	O
nucleus	O
independently	O
of	O
LEF/TCF	B-protein
binding	O
,	O
and	O
it	O
may	O
also	O
be	O
exported	O
from	O
nuclei	O
.	O

We	O
have	O
introduced	O
a	O
small	O
deletion	O
within	O
beta-catenin	B-protein
(	O
Delta19	B-DNA
)	O
that	O
disrupts	O
binding	O
to	O
LEF-1	B-protein
,	O
E-cadherin	B-protein
,	O
and	O
APC	B-protein
but	O
not	O
axin	B-protein
.	O

This	O
Delta19	B-protein
beta-catenin	I-protein
mutant	I-protein
localizes	O
to	O
the	O
nucleus	O
because	O
it	O
may	O
not	O
be	O
efficiently	O
sequestered	O
in	O
the	O
cytoplasm	O
.	O

The	O
nuclear	O
localization	O
of	O
Delta19	B-DNA
definitively	O
demonstrates	O
that	O
the	O
mechanisms	O
by	O
which	O
beta-catenin	B-protein
localizes	O
in	O
the	O
nucleus	O
are	O
completely	O
independent	O
of	O
LEF/TCF	B-protein
factors	I-protein
.	O

beta-Catenin	B-protein
and	O
LEF-1	B-protein
complexes	I-protein
can	O
activate	O
reporter	O
gene	O
expression	O
in	O
a	O
transformed	B-cell_line
T-lymphocyte	I-cell_line
cell	I-cell_line
line	I-cell_line
(	O
Jurkat	B-cell_line
)	O
but	O
not	O
in	O
normal	B-cell_type
T	I-cell_type
lymphocytes	I-cell_type
,	O
even	O
though	O
both	O
factors	O
are	O
nuclear	O
.	O

Thus	O
,	O
localization	O
of	O
both	O
factors	O
to	O
the	O
nucleus	O
is	O
not	O
sufficient	O
for	O
activation	O
of	O
gene	O
expression	O
.	O

Excess	O
beta-catenin	B-protein
can	O
squelch	O
reporter	O
gene	O
activation	O
by	O
LEF-1-beta-catenin	B-protein
complexes	I-protein
but	O
not	O
activation	O
by	O
the	O
transcription	B-protein
factor	I-protein
VP16	B-protein
.	O

Taken	O
together	O
,	O
these	O
data	O
suggest	O
that	O
a	O
third	O
component	O
is	O
necessary	O
for	O
gene	O
activation	O
and	O
that	O
this	O
third	O
component	O
may	O
vary	O
with	O
cell	O
type	O
.	O

Control	O
of	O
lymphocyte	O
development	O
by	O
the	O
Ikaros	B-DNA
gene	I-DNA
family	I-DNA
.	O

Lymphoid	O
cell	O
differentiation	O
relies	O
on	O
precisely	O
orchestrated	O
gene	O
activation	O
and	O
repression	O
events	O
.	O

Gene	O
targeting	O
studies	O
have	O
demonstrated	O
crucial	O
roles	O
for	O
the	O
transcription	B-protein
factors	I-protein
Ikaros	B-protein
and	O
Aiolos	B-protein
in	O
regulating	O
multiple	O
stages	O
of	O
B	O
and	O
T	O
cell	O
development	O
.	O

Recent	O
experiments	O
suggest	O
that	O
Ikaros	B-protein
and	O
Aiolos	B-protein
set	O
B	O
cell	O
antigen-receptor	O
(	O
BCR	O
)	O
-	O
and	O
TCR-mediated	O
signaling	O
thresholds	O
and	O
that	O
the	O
molecules	O
exist	O
within	O
T	B-cell_type
cells	I-cell_type
in	O
nuclear	B-protein
complexes	I-protein
that	O
contain	O
nucleosome	O
remodeling	O
and	O
histone	B-protein
deacetylase	I-protein
activities	O
.	O

Transcriptional	O
targeting	O
of	O
retroviral	O
vectors	O
to	O
the	O
erythroblastic	B-cell_type
progeny	I-cell_type
of	O
transduced	B-cell_line
hematopoietic	I-cell_line
stem	I-cell_line
cells	I-cell_line
.	O

Targeted	O
expression	O
to	O
specific	O
tissues	O
or	O
cell	O
lineages	O
is	O
a	O
necessary	O
feature	O
of	O
a	O
gene	O
therapy	O
vector	O
for	O
many	O
clinical	O
applications	O
,	O
such	O
as	O
correction	O
of	O
hemoglobinopathies	O
or	O
thalassemias	O
by	O
transplantation	O
of	O
genetically	B-cell_type
modified	I-cell_type
hematopoietic	I-cell_type
stem	I-cell_type
cells	I-cell_type
.	O

We	O
developed	O
retroviral	O
vectors	O
in	O
which	O
the	O
constitutive	B-DNA
viral	I-DNA
enhancer	I-DNA
in	O
the	O
U3	B-DNA
region	I-DNA
of	O
the	O
3	B-DNA
'	I-DNA
LTR	I-DNA
is	O
replaced	O
by	O
an	O
autoregulatory	B-DNA
enhancer	I-DNA
of	O
the	O
erythroid-specific	B-DNA
GATA-1	I-DNA
transcription	I-DNA
factor	I-DNA
gene	I-DNA
.	O

The	O
replaced	B-DNA
enhancer	I-DNA
is	O
propagated	O
to	O
the	O
5	B-DNA
'	I-DNA
LTR	I-DNA
upon	O
integration	O
into	O
the	O
target	B-DNA
cell	I-DNA
genome	I-DNA
.	O

The	O
modified	O
vectors	O
were	O
used	O
to	O
transduce	O
human	B-cell_line
hematopoietic	I-cell_line
cell	I-cell_line
lines	I-cell_line
,	O
cord	B-cell_type
blood-derived	I-cell_type
CD34	I-cell_type
(	I-cell_type
+	I-cell_type
)	I-cell_type
stem/progenitor	I-cell_type
cells	I-cell_type
,	O
and	O
murine	B-cell_line
bone	I-cell_line
marrow	I-cell_line
repopulating	I-cell_line
stem	I-cell_line
cells	I-cell_line
.	O

The	O
expression	O
of	O
appropriate	O
reporter	B-DNA
genes	I-DNA
(	O
triangle	B-DNA
upLNGFR	I-DNA
,	O
EGFP	B-DNA
)	O
was	O
analyzed	O
in	O
the	O
differentiated	O
progeny	O
of	O
transduced	B-cell_line
stem	I-cell_line
cells	I-cell_line
in	O
vitro	O
,	O
in	O
liquid	O
culture	O
as	O
well	O
as	O
in	O
clonogenic	O
assay	O
,	O
and	O
in	O
vivo	O
,	O
after	O
bone	O
marrow	O
transplantation	O
in	O
lethally	O
irradiated	O
mice	O
.	O

The	O
GATA-1	B-DNA
autoregulatory	I-DNA
enhancer	I-DNA
effectively	O
restricts	O
the	O
expression	O
of	O
the	O
LTR-driven	B-DNA
proviral	I-DNA
transcription	I-DNA
unit	I-DNA
to	O
the	O
erythroblastic	B-cell_type
progeny	I-cell_type
of	O
both	O
human	B-cell_type
progenitors	I-cell_type
and	O
mouse-repopulating	B-cell_line
stem	I-cell_line
cells	I-cell_line
.	O

Packaging	O
of	O
viral	O
particles	O
,	O
integration	O
into	O
the	O
target	O
genome	O
,	O
and	O
stability	O
of	O
the	O
integrated	O
provirus	O
are	O
not	O
affected	O
by	O
the	O
LTR	B-DNA
modification	O
.	O

Enhancer	O
replacement	O
is	O
therefore	O
an	O
effective	O
strategy	O
to	O
target	O
expression	O
of	O
a	O
retroviral	B-DNA
transgene	I-DNA
to	O
a	O
specific	O
progeny	O
of	O
transduced	B-cell_line
hematopoietic	I-cell_line
stem	I-cell_line
cells	I-cell_line
.	O

Regulation	O
of	O
Fas	B-protein
ligand	I-protein
expression	O
and	O
cell	O
death	O
by	O
apoptosis-linked	B-DNA
gene	I-DNA
4	I-DNA
.	O

Programmed	O
cell	O
death	O
is	O
a	O
process	O
required	O
for	O
the	O
normal	O
development	O
of	O
an	O
organism	O
.	O

One	O
of	O
the	O
best	O
understood	O
apoptotic	O
pathways	O
occurs	O
in	O
T	B-cell_type
lymphocytes	I-cell_type
and	O
is	O
mediated	O
by	O
Fas	B-protein
/Fas	B-protein
ligand	I-protein
(	O
FasL	B-protein
)	O
interaction	O
.	O

During	O
studies	O
of	O
apoptosis	O
induced	O
by	O
T	O
cell-receptor	O
engagement	O
,	O
we	O
identified	O
ALG-4F	B-protein
,	O
a	O
truncated	B-protein
transcript	I-protein
that	O
prevents	O
T	O
cell-receptor-induced	O
FasL	B-protein
upregulation	O
and	O
cell	O
death	O
.	O

Overexpression	O
of	O
full-length	B-protein
ALG-4	I-protein
induced	O
transcription	O
of	O
FasL	B-protein
and	O
,	O
consequently	O
,	O
apoptosis	O
.	O

These	O
results	O
indicate	O
that	O
ALG-4	B-protein
is	O
necessary	O
and	O
sufficient	O
for	O
FasL	B-protein
expression	O
.	O

Fas/	O
FasL	B-protein
interaction	O
initiates	O
cell	O
death	O
in	O
many	O
other	O
systems	O
,	O
and	O
its	O
dysregulation	O
is	O
a	O
mechanism	O
by	O
which	O
several	O
pathologic	O
conditions	O
arise	O
.	O

Understanding	O
the	O
molecular	O
mechanisms	O
of	O
FasL	B-protein
regulation	O
could	O
be	O
very	O
useful	O
in	O
elucidating	O
how	O
these	O
diseases	O
develop	O
and	O
in	O
identifying	O
potential	O
therapeutic	O
targets	O
.	O

The	O
Epstein-Barr	B-protein
virus	I-protein
oncoprotein	I-protein
latent	I-protein
membrane	I-protein
protein	I-protein
1	I-protein
engages	O
the	O
tumor	B-protein
necrosis	I-protein
factor	I-protein
receptor-associated	I-protein
proteins	I-protein
TRADD	B-protein
and	O
receptor-interacting	B-protein
protein	I-protein
(	O
RIP	B-protein
)	O
but	O
does	O
not	O
induce	O
apoptosis	O
or	O
require	O
RIP	B-protein
for	O
NF-kappaB	B-protein
activation	O
.	O

A	O
site	O
in	O
the	O
Epstein-Barr	B-protein
virus	I-protein
(	I-protein
EBV	I-protein
)	I-protein
transforming	I-protein
protein	I-protein
LMP1	B-protein
that	O
constitutively	O
associates	O
with	O
the	O
tumor	B-protein
necrosis	I-protein
factor	I-protein
receptor	I-protein
1	I-protein
(	I-protein
TNFR1	I-protein
)	I-protein
-associated	I-protein
death	I-protein
domain	I-protein
protein	I-protein
TRADD	B-protein
to	O
mediate	O
NF-kappaB	B-protein
and	O
c-Jun	B-protein
N-terminal	I-protein
kinase	I-protein
activation	O
is	O
critical	O
for	O
long-term	O
lymphoblastoid	O
cell	O
proliferation	O
.	O

We	O
now	O
find	O
that	O
LMP1	B-protein
signaling	O
through	O
TRADD	B-protein
differs	O
from	O
TNFR1	B-protein
signaling	O
through	O
TRADD	B-protein
.	O

LMP1	B-protein
needs	O
only	O
11	O
amino	O
acids	O
to	O
activate	O
NF-kappaB	B-protein
or	O
synergize	O
with	O
TRADD	B-protein
in	O
NF-kappaB	B-protein
activation	O
,	O
while	O
TNFR1	B-protein
requires	O
approximately	O
70	O
residues	O
.	O

Further	O
,	O
LMP1	B-protein
does	O
not	O
require	O
TRADD	B-protein
residues	O
294	O
to	O
312	O
for	O
NF-kappaB	B-protein
activation	O
,	O
while	O
TNFR1	B-protein
requires	O
TRADD	B-protein
residues	O
296	O
to	O
302	O
.	O

LMP1	B-protein
is	O
partially	O
blocked	O
for	O
NF-kappaB	B-protein
activation	O
by	O
a	O
TRADD	B-protein
mutant	O
consisting	O
of	O
residues	B-protein
122	I-protein
to	I-protein
293	I-protein
.	O

Unlike	O
TNFR1	B-protein
,	O
LMP1	B-protein
can	O
interact	O
directly	O
with	O
receptor-interacting	B-protein
protein	I-protein
(	O
RIP	B-protein
)	O
and	O
stably	O
associates	O
with	O
RIP	B-protein
in	O
EBV-transformed	B-cell_line
lymphoblastoid	I-cell_line
cell	I-cell_line
lines	I-cell_line
.	O

Surprisingly	O
,	O
LMP1	B-protein
does	O
not	O
require	O
RIP	B-protein
for	O
NF-kappaB	B-protein
activation	O
.	O

Despite	O
constitutive	O
association	O
with	O
TRADD	B-protein
or	O
RIP	B-protein
,	O
LMP1	B-protein
does	O
not	O
induce	O
apoptosis	O
in	O
EBV-negative	B-cell_line
Burkitt	I-cell_line
lymphoma	I-cell_line
or	I-cell_line
human	I-cell_line
embryonic	I-cell_line
kidney	I-cell_line
293	I-cell_line
cells	I-cell_line
.	O

These	O
results	O
add	O
a	O
different	O
perspective	O
to	O
the	O
molecular	O
interactions	O
through	O
which	O
LMP1	B-protein
,	O
TRADD	B-protein
,	O
and	O
RIP	B-protein
participate	O
in	O
B-lymphocyte	O
activation	O
and	O
growth	O
.	O

Inhibition	O
of	O
NF-kappa	B-protein
B	I-protein
activity	O
in	O
human	O
T	O
lymphocytes	O
induces	O
caspase-dependent	O
apoptosis	O
without	O
detectable	O
activation	O
of	O
caspase-1	B-protein
and	I-protein
-3	I-protein
.	O

NF-kappa	B-protein
B	I-protein
is	O
involved	O
in	O
the	O
transcriptional	O
control	O
of	O
various	B-DNA
genes	I-DNA
that	O
act	O
as	O
extrinsic	O
and	O
intrinsic	O
survival	O
factors	O
for	O
T	B-cell_type
cells	I-cell_type
.	O

Our	O
findings	O
show	O
that	O
suppression	O
of	O
NF-kappa	B-protein
B	I-protein
activity	O
with	O
cell-permeable	O
SN50	O
peptide	O
,	O
which	O
masks	O
the	O
nuclear	O
localization	O
sequence	O
of	O
NF-kappa	B-protein
B1	I-protein
dimers	I-protein
and	O
prevents	O
their	O
nuclear	O
localization	O
,	O
induces	O
apoptosis	O
in	O
resting	B-cell_type
normal	I-cell_type
human	I-cell_type
PBL	I-cell_type
.	O

Inhibition	O
of	O
NF-kappa	B-protein
B	I-protein
resulted	O
in	O
the	O
externalization	O
of	O
phosphatidylserine	O
,	O
induction	O
of	O
DNA	O
breaks	O
,	O
and	O
morphological	O
changes	O
consistent	O
with	O
apoptosis	O
.	O

DNA	O
fragmentation	O
was	O
efficiently	O
blocked	O
by	O
the	O
caspase	B-protein
inhibitor	I-protein
Z-VAD-fmk	B-protein
and	O
partially	O
blocked	O
by	O
Ac-DEVD-fmk	B-protein
,	O
suggesting	O
that	O
SN50-mediated	O
apoptosis	O
is	O
caspase	B-protein
-dependent	O
.	O

Interestingly	O
,	O
apoptosis	O
induced	O
by	O
NF-kappa	B-protein
B	I-protein
suppression	O
,	O
in	O
contrast	O
to	O
that	O
induced	O
by	O
TPEN	O
(	O
N	O
,	O
N	O
,	O
N	O
'	O
,	O
N'-tetrakis	O
[	O
2-pyridylmethyl	O
]	O
ethylenediamine	O
)	O
or	O
soluble	B-protein
Fas	I-protein
ligand	I-protein
(	O
CD95	B-protein
)	O
,	O
was	O
observed	O
in	O
the	O
absence	O
of	O
active	B-protein
death	I-protein
effector	I-protein
proteases	I-protein
caspase-1	B-protein
-like	O
(	O
IL-1	B-protein
converting	I-protein
enzyme	I-protein
)	O
,	O
caspase-3	B-protein
-like	O
(	O
CPP32/Yama/apopain	B-protein
)	O
,	O
and	O
caspase-6	B-protein
-like	O
and	O
without	O
cleavage	O
of	O
caspase-3	B-protein
substrates	I-protein
poly	B-protein
(	I-protein
ADP-ribose	I-protein
)	I-protein
polymerase	I-protein
and	O
DNA	B-protein
fragmentation	I-protein
factor-45	I-protein
.	O

These	O
findings	O
suggest	O
either	O
low	O
level	O
of	O
activation	O
is	O
required	O
or	O
that	O
different	O
caspases	B-protein
are	O
involved	O
.	O

Preactivation	O
of	O
T	B-cell_type
cells	I-cell_type
resulting	O
in	O
NF-kappa	B-protein
B	I-protein
nuclear	O
translocation	O
protected	O
cells	O
from	O
SN50-induced	O
apoptosis	O
.	O

Our	O
findings	O
demonstrate	O
an	O
essential	O
role	O
of	O
NF-kappa	B-protein
B	I-protein
in	O
survival	O
of	O
naive	B-cell_type
PBL	I-cell_type
.	O

Signal	O
transduction	O
pathways	O
in	O
normal	B-cell_type
human	I-cell_type
monocytes	I-cell_type
stimulated	O
by	O
cytokines	B-protein
and	O
mediators	O
:	O
comparative	O
study	O
with	O
normal	B-cell_type
human	I-cell_type
neutrophils	I-cell_type
or	O
transformed	B-cell_line
cells	I-cell_line
and	O
the	O
putative	O
roles	O
in	O
functionality	O
and	O
cell	O
biology	O
.	O

Granulocyte-macrophage	B-protein
colony-stimulating	I-protein
factor	I-protein
(	O
GM-CSF	B-protein
)	O
and	O
interleukin	B-protein
(	I-protein
IL	I-protein
)	I-protein
-3	I-protein
induced	O
tyrosine	O
phosphorylation	O
of	O
92-kDa	B-protein
protein	I-protein
in	O
normal	B-cell_type
human	I-cell_type
monocytes	I-cell_type
.	O

We	O
identified	O
this	O
92-kDa	B-protein
protein	I-protein
as	O
STAT5	B-protein
,	O
but	O
not	O
as	O
STATs1	B-protein
,	I-protein
3	I-protein
,	I-protein
and	I-protein
6	I-protein
nor	O
c-fes	B-protein
and	O
vav	B-protein
protooncogene	I-protein
products	I-protein
,	O
and	O
demonstrated	O
its	O
translocation	O
to	O
the	O
nucleus	O
,	O
enhancement	O
of	O
specific	O
DNA	O
binding	O
capacity	O
,	O
and	O
potentiation	O
of	O
trancriptional	O
activity	O
by	O
GM-CSF	B-protein
.	O

N-formyl-methionyl-leucyl-phenylalanine	O
(	O
FMLP	O
)	O
and	O
phorbol	O
myristate	O
acetate	O
(	O
PMA	O
)	O
induced	O
tyrosine	O
phosphorylation	O
of	O
42-	B-protein
and	I-protein
44-kDa	I-protein
proteins	I-protein
,	O
which	O
were	O
identified	O
as	O
extracellular	B-protein
signal-regulated	I-protein
kinase	I-protein
(	O
ERK	B-protein
)	O
,	O
in	O
human	B-cell_type
monocytes	I-cell_type
.	O

In	O
marked	O
contrast	O
to	O
neutrophils	B-cell_type
and	O
MO7e	B-cell_type
cells	I-cell_type
,	O
GM-CSF	B-protein
did	O
not	O
induce	O
tyrosine	O
phosphorylation	O
and	O
activation	O
of	O
ERK	B-protein
in	O
monocytes	B-cell_type
.	O

Among	O
upstream	B-protein
signaling	I-protein
molecules	I-protein
of	O
ERK	B-protein
,	O
Shc	B-protein
was	O
constitutively	O
associated	O
with	O
Grb2	O
and	O
was	O
not	O
tyrosine-phosphorylated	O
by	O
GM-CSF	B-protein
and	O
FMLP	O
,	O
and	O
Sos1	B-protein
and	O
c-Raf-1	B-protein
were	O
not	O
phosphorylated	O
by	O
GM-CSF	B-protein
,	O
IL-3	O
,	O
TNF	O
,	O
and	O
FMLP	O
in	O
monocytes	B-cell_type
,	O
whereas	O
all	O
these	O
signaling	O
molecules	O
were	O
affected	O
and/or	O
utilized	O
by	O
GM-CSF	B-protein
in	O
MO7e	B-cell_type
cells	I-cell_type
.	O

In	O
contrast	O
to	O
neutrophils	B-cell_type
,	O
p38	B-protein
was	O
constitutively	O
phosphorylated	O
and	O
agonist-dependent	O
phosphorylation	O
and	O
activation	O
was	O
not	O
detected	O
in	O
human	B-cell_type
monocytes	I-cell_type
.	O

Superoxide	O
release	O
stimulated	O
by	O
FMLP	O
was	O
inhibited	O
partially	O
by	O
PD98059	O
or	O
SB203580	O
,	O
a	O
specific	O
inhibitor	O
of	O
ERK	O
or	O
p38	O
pathway	O
,	O
and	O
was	O
almost	O
completely	O
inhibited	O
by	O
the	O
combination	O
of	O
both	O
inhibitors	O
,	O
whereas	O
PMA-induced	O
superoxide	O
release	O
was	O
resistant	O
to	O
these	O
two	O
inhibitors	O
in	O
monocytes	B-cell_type
.	O

PD98059	O
inhibited	O
GM-CSF	B-protein
-dependent	O
proliferation	O
of	O
MO7e	B-cell_type
cells	I-cell_type
.	O

Present	O
results	O
indicate	O
trancriptional	O
roles	O
of	O
STAT5	B-protein
and	O
functional	O
roles	O
of	O
ERK	B-protein
and/or	O
p38	B-protein
in	O
normal	B-cell_type
human	I-cell_type
monocytes	I-cell_type
stimulated	O
by	O
physiological	O
receptor-mediated	O
agonists	O
GM-CSF	B-protein
and	O
FMLP	O
.	O

Possible	O
roles	O
of	O
ERK	B-protein
in	O
proliferation	O
of	O
transformed	B-cell_line
cells	I-cell_line
were	O
also	O
suggested	O
.	O

Aiolos	B-protein
transcription	B-protein
factor	I-protein
controls	O
cell	O
death	O
in	O
T	B-cell_type
cells	I-cell_type
by	O
regulating	O
Bcl-2	B-protein
expression	O
and	O
its	O
cellular	O
localization	O
.	O

We	O
searched	O
for	O
proteins	O
that	O
interact	O
with	O
Ras	B-protein
in	O
interleukin	B-cell_line
(	I-cell_line
IL	I-cell_line
)	I-cell_line
-2-stimulated	I-cell_line
or	I-cell_line
IL-2-deprived	I-cell_line
cells	I-cell_line
,	O
and	O
found	O
that	O
the	O
transcription	B-protein
factor	I-protein
Aiolos	B-protein
interacts	O
with	O
Ras	B-protein
.	O

The	O
Ras	B-protein
-Aiolos	B-protein
interaction	O
was	O
confirmed	O
in	O
vitro	O
and	O
in	O
vivo	O
by	O
co-immunoprecipitation	O
.	O

Indirect	O
immunofluorescence	O
shows	O
that	O
IL-2	B-protein
controls	O
the	O
cellular	O
distribution	O
of	O
Aiolos	B-protein
and	O
induces	O
its	O
tyrosine	O
phosphorylation	O
,	O
required	O
for	O
dissociation	O
from	O
Ras	B-protein
.	O

We	O
also	O
identified	O
functional	O
Aiolos-binding	B-DNA
sites	I-DNA
in	O
the	O
Bcl-2	B-DNA
promoter	I-DNA
,	O
which	O
are	O
able	O
to	O
activate	O
the	O
luciferase	B-DNA
reporter	I-DNA
gene	I-DNA
.	O

Mutation	O
of	O
Aiolos-binding	B-DNA
sites	I-DNA
within	O
the	O
Bcl-2	B-DNA
promoter	I-DNA
inhibits	O
transactivation	O
of	O
the	O
reporter	B-DNA
gene	I-DNA
luciferase	I-DNA
,	O
suggesting	O
direct	O
control	O
of	O
Bcl-2	B-protein
expression	O
by	O
Aiolos	B-protein
.	O

Co-transfection	O
experiments	O
confirm	O
that	O
Aiolos	B-protein
induces	O
Bcl-2	B-protein
expression	O
and	O
prevents	O
apoptosis	O
in	O
IL-2-deprived	B-cell_line
cells	I-cell_line
.	O

We	O
propose	O
a	O
model	O
for	O
the	O
regulation	O
of	O
Bcl-2	B-protein
expression	O
via	O
Aiolos	B-protein
.	O

Binding	O
of	O
YY1	B-protein
and	O
Oct1	B-protein
to	O
a	O
novel	O
element	O
that	O
downregulates	O
expression	O
of	O
IL-5	B-protein
in	O
human	O
T	B-cell_type
cells	I-cell_type
.	O

BACKGROUND	O
:	O
IL-5	B-protein
controls	O
development	O
of	O
eosinophilia	O
and	O
has	O
been	O
shown	O
to	O
be	O
involved	O
in	O
the	O
pathogenesis	O
of	O
allergic	O
diseases	O
.	O

In	O
both	O
atopic	O
and	O
nonatopic	O
asthma	O
,	O
elevated	O
IL-5	B-protein
has	O
been	O
detected	O
in	O
peripheral	O
blood	O
and	O
the	O
airways	O
.	O

IL-5	B-protein
is	O
produced	O
mainly	O
by	O
activated	O
T	B-cell_type
cells	I-cell_type
,	O
and	O
its	O
expression	O
is	O
regulated	O
at	O
the	O
transcriptional	O
level	O
.	O

OBJECTIVE	O
:	O
This	O
study	O
focuses	O
on	O
the	O
functional	O
analysis	O
of	O
the	O
human	B-DNA
IL-5	I-DNA
(	I-DNA
hIL-5	I-DNA
)	I-DNA
promoter	I-DNA
and	O
characterization	O
of	O
cis	O
-regulatory	O
elements	O
and	O
transcription	O
factors	O
involved	O
in	O
the	O
suppression	O
of	O
IL-5	B-protein
transcription	O
in	O
T	B-cell_type
cells	I-cell_type
.	O

METHODS	O
:	O
Methods	O
used	O
in	O
this	O
study	O
include	O
DNase	B-protein
I	I-protein
footprint	O
assays	O
,	O
electrophoretic	O
mobility	O
shift	O
assays	O
,	O
and	O
functional	O
analysis	O
by	O
mammalian	O
cell	O
transfection	O
involving	O
deletion	O
analysis	O
and	O
site-directed	O
mutagenesis	O
.	O

RESULTS	O
:	O
We	O
identified	O
5	O
protein	B-DNA
binding	I-DNA
regions	I-DNA
(	O
BRs	B-DNA
)	O
located	O
within	O
the	O
proximal	B-DNA
hIL-5	I-DNA
promoter	I-DNA
.	O

Functional	O
analysis	O
indicates	O
that	O
the	O
BRs	B-DNA
are	O
involved	O
in	O
control	O
of	O
hIL-5	B-DNA
promoter	I-DNA
activity	O
.	O

Two	O
of	O
these	O
regions	O
,	O
BR3	B-DNA
and	O
BR4	B-DNA
located	O
at	O
positions	O
-102	O
to	O
-73	O
,	O
have	O
not	O
previously	O
been	O
described	O
as	O
regulators	O
of	O
IL-5	B-protein
expression	O
in	O
T	B-cell_type
cells	I-cell_type
.	O

We	O
show	O
that	O
the	O
BR3	B-DNA
sequence	O
contains	O
a	O
novel	O
negative	B-DNA
regulatory	I-DNA
element	I-DNA
located	O
at	O
positions	O
-90	O
to	O
-79	O
of	O
the	O
hIL-5	B-DNA
promoter	I-DNA
,	O
which	O
binds	O
Oct1	B-protein
,	O
octamer-like	B-protein
,	O
and	O
YY1	B-protein
nuclear	I-protein
factors	I-protein
.	O

Substitution	O
mutations	O
,	O
which	O
abolished	O
binding	O
of	O
these	O
proteins	O
to	O
the	O
BR3	B-DNA
sequence	I-DNA
,	O
significantly	O
increased	O
hIL-5	B-DNA
promoter	I-DNA
activity	O
in	O
activated	B-cell_type
T	I-cell_type
cells	I-cell_type
.	O

CONCLUSION	O
:	O
We	O
suggest	O
that	O
Oct1	B-protein
,	O
YY1	B-protein
,	O
and	O
octamer-like	B-protein
factors	I-protein
binding	O
to	O
the	O
-90/-79	B-DNA
sequence	I-DNA
within	O
the	O
proximal	B-DNA
IL-5	I-DNA
promoter	I-DNA
are	O
involved	O
in	O
suppression	O
of	O
IL-5	B-protein
transcription	O
in	O
T	B-cell_type
cells	I-cell_type
.	O

New	O
immunosuppressive	O
drug	O
PNU156804	O
blocks	O
IL-2	B-protein
-dependent	O
proliferation	O
and	O
NF-kappa	O
B	O
and	O
AP-1	O
activation	O
.	O

We	O
had	O
previously	O
shown	O
that	O
the	O
drug	O
undecylprodigiosin	O
(	O
UP	O
)	O
blocks	O
human	B-cell_type
lymphocyte	I-cell_type
proliferation	O
in	O
vitro	O
.	O

We	O
have	O
now	O
investigated	O
the	O
mechanism	O
of	O
action	O
of	O
a	O
new	O
analogue	O
of	O
UP	O
,	O
PNU156804	O
,	O
which	O
shows	O
a	O
more	O
favorable	O
activity	O
profile	O
than	O
UP	O
in	O
mice	O
.	O

We	O
demonstrate	O
here	O
that	O
the	O
biological	O
effect	O
of	O
PNU156804	O
in	O
vitro	O
is	O
indistinguishable	O
from	O
UP	O
:	O
PNU156804	O
blocks	O
human	B-cell_type
T	I-cell_type
cell	I-cell_type
proliferation	O
in	O
mid-late	O
G1	O
,	O
as	O
determined	O
by	O
cell	O
cycle	O
analysis	O
,	O
expression	O
of	O
cyclins	B-protein
,	O
and	O
cyclin-dependent	B-protein
kinases	I-protein
and	O
retinoblastoma	O
phosphorylation	O
.	O

In	O
addition	O
,	O
we	O
show	O
that	O
PNU156804	O
does	O
not	O
block	O
significantly	O
the	O
induction	O
of	O
either	O
IL-2	B-protein
or	O
IL-2R	B-protein
alpha-	I-protein
and	I-protein
gamma-chains	I-protein
but	O
inhibits	O
IL-2	B-protein
-dependent	O
T	O
cell	O
proliferation	O
.	O

We	O
have	O
investigated	O
several	O
molecular	O
pathways	O
that	O
are	O
known	O
to	O
be	O
activated	O
by	O
IL-2	B-protein
in	O
T	B-cell_type
cells	I-cell_type
.	O

We	O
show	O
that	O
PNU156804	O
does	O
not	O
inhibit	O
c-myc	O
and	O
bcl-2	O
mRNA	O
induction	O
.	O

On	O
the	O
other	O
hand	O
,	O
PNU156804	O
efficiently	O
inhibits	O
the	O
activation	O
of	O
the	O
NF-kappa	B-protein
B	I-protein
and	O
AP-1	B-protein
transcription	O
factors	O
.	O

PNU156804	O
inhibition	O
of	O
NF-kappa	B-protein
B	I-protein
activation	O
is	O
due	O
to	O
the	O
inhibition	O
of	O
the	O
degradation	O
of	O
I	B-protein
kappa	I-protein
B-alpha	I-protein
and	O
I	B-protein
kappa	I-protein
B-beta	I-protein
.	O

PNU156804	O
action	O
is	O
restricted	O
to	O
some	O
signaling	O
pathways	O
;	O
it	O
does	O
not	O
affect	O
NF-kappa	B-protein
B	I-protein
activation	O
by	O
PMA	O
in	O
T	B-cell_type
cells	I-cell_type
but	O
blocks	O
that	O
induced	O
by	O
CD40	B-protein
cross-linking	O
in	O
B	B-cell_type
lymphocytes	I-cell_type
.	O

We	O
conclude	O
that	O
the	O
prodigiosin	O
family	O
of	O
immunosuppressants	O
is	O
a	O
new	O
family	O
of	O
molecules	O
that	O
show	O
a	O
novel	O
target	O
specificity	O
clearly	O
distinct	O
from	O
that	O
of	O
other	O
immunosuppressive	O
drugs	O
such	O
as	O
cyclosporin	O
A	O
,	O
FK506	O
,	O
and	O
rapamycin	O
.	O

Human	B-protein
T-cell	I-protein
leukemia	I-protein
virus	I-protein
type	I-protein
1	I-protein
Tax	I-protein
protein	I-protein
induces	O
the	O
expression	O
of	O
STAT1	B-DNA
and	I-DNA
STAT5	I-DNA
genes	I-DNA
in	O
T-cells	B-cell_type
.	O

Human	B-protein
T-cell	I-protein
leukemia	I-protein
virus	I-protein
type	I-protein
1	I-protein
(	I-protein
HTLV-1	I-protein
)	I-protein
Tax	I-protein
transforms	O
normal	O
T-cells	B-cell_type
in	O
the	O
presence	O
of	O
interleukin	B-protein
(	I-protein
IL	I-protein
)	I-protein
-2	I-protein
in	O
vitro	O
.	O

STAT	B-protein
is	O
a	O
family	O
of	O
transcription	B-protein
factors	I-protein
that	O
play	O
a	O
pivotal	O
role	O
in	O
cytokine-induced	O
functions	O
of	O
a	O
various	O
type	O
of	O
cells	O
.	O

We	O
investigated	O
the	O
involvement	O
of	O
STATs	B-protein
in	O
the	O
transformation	O
of	O
T-cells	B-cell_type
by	O
HTLV-1	O
.	O

HTLV-1-transformed	B-cell_line
T-cell	I-cell_line
lines	I-cell_line
expressed	O
higher	O
amounts	O
of	O
STAT1	B-RNA
,	I-RNA
STAT3	I-RNA
and	I-RNA
STAT5	I-RNA
RNA	I-RNA
and	O
proteins	O
than	O
virus-negative	B-cell_type
T	I-cell_type
cells	I-cell_type
.	O

The	O
expression	O
of	O
STAT1	B-protein
and	O
STAT5	B-protein
in	O
a	O
human	B-cell_line
T-cell	I-cell_line
line	I-cell_line
was	O
induced	O
by	O
Tax	B-protein
.	O

IL-2	B-protein
induced	O
the	O
DNA	O
binding	O
activity	O
of	O
STAT3	B-protein
and	O
STAT5	B-protein
of	O
a	O
HTLV-1-transformed	O
cell	O
line	O
and	O
then	O
stimulated	O
its	O
proliferation	O
.	O

In	O
contrast	O
,	O
IL-2	B-protein
did	O
neither	O
in	O
a	O
cell	O
line	O
lacking	O
STAT3	B-protein
and	O
STAT5	B-protein
.	O

The	O
expression	O
of	O
STAT1	B-RNA
,	I-RNA
STAT3	I-RNA
and	I-RNA
STAT5	I-RNA
mRNAs	I-RNA
were	O
also	O
induced	O
by	O
a	O
T-cell	B-protein
mitogen	I-protein
in	O
normal	O
human	B-cell_type
peripheral	I-cell_type
blood	I-cell_type
mononuclear	I-cell_type
cells	I-cell_type
.	O

Our	O
results	O
suggest	O
that	O
the	O
induction	O
of	O
STAT1	B-protein
and	O
STAT5	B-protein
by	O
Tax	B-protein
enhances	O
cytokine	B-protein
-induced	O
functions	O
of	O
virus-infected	O
T-cells	B-cell_type
,	O
hence	O
the	O
induction	O
may	O
play	O
a	O
role	O
in	O
IL-2	B-protein
-dependent	O
transformation	O
steps	O
of	O
T-cells	B-cell_type
by	O
HTLV-1	O
.	O

Transcriptional	O
control	O
of	O
the	O
IL-5	B-protein
gene	O
by	O
human	B-cell_type
helper	I-cell_type
T	I-cell_type
cells	I-cell_type
:	O
IL-5	B-protein
synthesis	O
is	O
regulated	O
independently	O
from	O
IL-2	B-protein
or	O
IL-4	B-protein
synthesis	O
.	O

BACKGROUND	O
:	O
IL-5	B-protein
is	O
fundamentally	O
involved	O
in	O
eosinophilic	O
inflammation	O
.	O

Control	O
of	O
IL-5	B-protein
production	O
may	O
be	O
effective	O
for	O
the	O
management	O
of	O
allergic	O
diseases	O
.	O

OBJECTIVE	O
:	O
We	O
aimed	O
to	O
find	O
the	O
transcriptional	O
mechanisms	O
that	O
regulate	O
the	O
IL-5	B-protein
gene	O
to	O
selectively	O
control	O
IL-5	B-protein
synthesis	O
.	O

METHODS	O
:	O
Allergen-specific	B-cell_line
T-cell	I-cell_line
clones	I-cell_line
and	O
T-cell	B-cell_line
hybridomas	I-cell_line
were	O
established	O
from	O
the	O
peripheral	B-cell_type
blood	I-cell_type
lymphocytes	I-cell_type
of	O
patients	O
with	O
asthma	O
,	O
and	O
the	O
transcriptional	O
regulation	O
of	O
the	O
IL-5	B-DNA
gene	I-DNA
was	O
investigated	O
with	O
transient	O
transfection	O
and	O
electrophoretic	O
mobility	O
shift	O
analysis	O
.	O

RESULTS	O
:	O
A	O
human	O
IL-5	B-DNA
promoter/enhancer-luciferase	I-DNA
gene	I-DNA
construct	I-DNA
,	O
pIL-5	B-DNA
(	I-DNA
-511	I-DNA
)	I-DNA
Luc	I-DNA
,	O
was	O
transcribed	O
on	O
activation	O
of	O
IL-5-producing	B-cell_line
T-cell	I-cell_line
clones	I-cell_line
,	O
but	O
not	O
IL-5-nonproducing	B-cell_line
clones	I-cell_line
.	O

pIL-5	B-DNA
(	I-DNA
-511	I-DNA
)	I-DNA
Luc	I-DNA
was	O
transcribed	O
by	O
T-cell	B-cell_line
hybridomas	I-cell_line
derived	O
from	O
fusion	O
between	O
IL-5-producing	B-cell_line
T-cell	I-cell_line
clones	I-cell_line
and	O
an	O
IL-5	B-cell_line
gene-nonexpressing	I-cell_line
T-cell	I-cell_line
line	I-cell_line
,	O
but	O
not	O
by	O
hybridomas	B-cell_line
derived	O
from	O
IL-5-nonproducing	B-cell_line
T-cell	I-cell_line
clones	I-cell_line
.	O

IL-5	B-protein
synthesis	O
was	O
not	O
only	O
induced	O
by	O
T-cell	O
receptor	O
stimulation	O
but	O
also	O
by	O
IL-2	B-protein
receptor	O
stimulation	O
.	O

Binding	O
of	O
NF-AT	B-protein
,	O
NF-kappaB	B-protein
,	O
and	O
AP-1	B-protein
was	O
induced	O
by	O
T-cell	B-protein
receptor	I-protein
(	O
TcR	B-protein
)	O
stimulation	O
,	O
although	O
there	O
was	O
no	O
significant	O
upregulation	O
of	O
binding	O
by	O
IL-2	B-protein
stimulation	O
.	O

CONCLUSION	O
:	O
IL-5	B-protein
synthesis	O
by	O
human	B-cell_type
helper	I-cell_type
T	I-cell_type
cells	I-cell_type
is	O
regulated	O
at	O
the	O
transcriptional	O
level	O
.	O

A	O
unique	O
transcriptional	O
mechanism	O
distinct	O
from	O
those	O
regulating	O
the	O
IL-2	B-DNA
or	I-DNA
IL-4	I-DNA
genes	I-DNA
seems	O
to	O
control	O
the	O
IL-5	B-DNA
gene	I-DNA
.	O

Selective	O
regulation	O
of	O
IL-5	B-protein
gene	O
transcription	O
may	O
be	O
useful	O
for	O
treating	O
eosinophlic	O
inflammation	O
.	O

Defining	O
therapeutic	O
targets	O
by	O
using	O
adenovirus	O
:	O
blocking	O
NF-kappaB	B-protein
inhibits	O
both	O
inflammatory	O
and	O
destructive	O
mechanisms	O
in	O
rheumatoid	O
synovium	O
but	O
spares	O
anti-inflammatory	B-protein
mediators	I-protein
.	O

The	O
role	O
of	O
the	O
transcription	B-protein
factor	I-protein
NF-kappaB	B-protein
in	O
the	O
pathogenesis	O
of	O
rheumatoid	O
arthritis	O
has	O
long	O
been	O
a	O
subject	O
of	O
controversy	O
.	O

We	O
used	O
an	O
adenoviral	O
technique	O
of	O
blocking	O
NF-kappaB	B-protein
through	O
overexpression	O
of	O
the	O
inhibitory	B-protein
subunit	I-protein
IkappaBalpha	B-protein
,	O
which	O
has	O
the	O
advantage	O
that	O
it	O
can	O
be	O
used	O
in	O
the	O
diseased	O
tissue	O
itself	O
,	O
with	O
>	O
90	O
%	O
of	O
the	O
synovial	B-cell_type
macrophages	I-cell_type
,	O
fibroblasts	B-cell_type
,	O
and	O
T	B-cell_type
cells	I-cell_type
infected	O
.	O

We	O
found	O
that	O
the	O
spontaneous	O
production	O
of	O
tumor	B-protein
necrosis	I-protein
factor	I-protein
alpha	I-protein
and	O
other	O
pro-inflammatory	B-protein
cytokines	I-protein
is	O
NF-kappaB	B-protein
-dependent	O
in	O
rheumatoid	O
synovial	O
tissue	O
,	O
in	O
contrast	O
to	O
the	O
main	O
anti-inflammatory	B-protein
mediators	I-protein
,	O
like	O
IL-10	B-protein
and	I-protein
-11	I-protein
,	O
and	O
the	O
IL-1	B-protein
receptor	I-protein
antagonist	I-protein
.	O

Of	O
even	O
more	O
interest	O
,	O
IkappaBalpha	B-protein
overexpression	O
inhibited	O
the	O
production	O
of	O
matrix	B-protein
metalloproteinases	I-protein
1	I-protein
and	I-protein
3	I-protein
while	O
not	O
affecting	O
their	O
tissue	O
inhibitor	O
.	O

Blocking	O
NF-kappaB	B-protein
in	O
the	O
rheumatoid	O
joint	O
thus	O
has	O
a	O
very	O
beneficial	O
profile	O
,	O
reducing	O
both	O
the	O
inflammatory	O
response	O
and	O
the	O
tissue	O
destruction	O
.	O

The	O
adenoviral	O
technique	O
described	O
here	O
has	O
widespread	O
applicability	O
,	O
allowing	O
rapid	O
testing	O
of	O
the	O
effects	O
of	O
blocking	O
a	O
potential	O
therapeutic	O
target	O
in	O
either	O
cultures	O
of	O
normal	B-cell_type
cells	I-cell_type
or	O
in	O
the	O
diseased	O
tissue	O
itself	O
.	O

Resistance	O
to	O
tumor	B-protein
necrosis	I-protein
factor	I-protein
induced	O
apoptosis	O
in	O
vitro	O
correlates	O
with	O
high	O
metastatic	O
capacity	O
of	O
cells	O
in	O
vivo	O
.	O

TNF	B-protein
is	O
one	O
of	O
the	O
cytokines	B-protein
secreted	O
by	O
the	O
cells	O
of	O
the	O
immune	O
system	O
.	O

Our	O
data	O
demonstrate	O
that	O
those	O
cell	B-cell_line
lines	I-cell_line
lacking	O
capability	O
to	O
form	O
metastatic	O
tumors	O
in	O
vivo	O
are	O
susceptible	O
to	O
TNF	B-protein
induced	O
apoptosis	O
in	O
vitro	O
.	O

However	O
,	O
cell	B-cell_line
lines	I-cell_line
with	O
high	O
metastatic	O
potential	O
are	O
resistant	O
to	O
TNF	B-protein
in	O
vitro	O
.	O

Furthermore	O
,	O
the	O
same	O
cell	B-cell_line
lines	I-cell_line
were	O
resistant	O
to	O
cytolytic	O
action	O
of	O
other	O
cytotoxic	B-protein
proteins	I-protein
secreted	O
by	O
LAK	B-cell_line
cells	I-cell_line
.	O

Our	O
data	O
showed	O
that	O
TNF	B-protein
resistance	O
in	O
vitro	O
correlates	O
with	O
the	O
increased	O
level	O
of	O
transcription	B-protein
factor	I-protein
NF-kappaB	B-protein
.	O

This	O
finding	O
may	O
provide	O
a	O
tool	O
to	O
improve	O
current	O
protocols	O
of	O
immunotherapy	O
and	O
insights	O
to	O
how	O
tumor	B-cell_type
cells	I-cell_type
are	O
or	O
are	O
not	O
killed	O
by	O
LAK	B-cell_line
cells	I-cell_line
.	O

Clonality	O
analysis	O
of	O
granulocytes	B-cell_type
and	O
T	B-cell_type
lymphocytes	I-cell_type
in	O
healthy	O
females	O
by	O
the	O
PCR-based	O
HUMARA	B-DNA
method	O
.	O

Clonality	O
analysis	O
utilizing	O
X-chromosome	B-DNA
inactivation	O
has	O
been	O
used	O
in	O
the	O
study	O
of	O
various	O
diseases	O
,	O
including	O
hematological	O
malignancies	O
.	O

The	O
human	B-DNA
androgen	I-DNA
receptor	I-DNA
gene	I-DNA
(	O
HUMARA	B-DNA
)	O
assay	O
is	O
the	O
newest	O
of	O
such	O
methods	O
,	O
and	O
the	O
majority	O
of	O
the	O
female	O
population	O
can	O
be	O
assessed	O
by	O
this	O
relatively	O
simple	O
procedure	O
.	O

One	O
problem	O
in	O
using	O
these	O
clonality	O
analysis	O
methods	O
,	O
however	O
,	O
is	O
that	O
there	O
may	O
be	O
significant	O
variation	O
in	O
Lyonization	O
in	O
blood	B-cell_type
cells	I-cell_type
in	O
normal	O
individuals	O
.	O

To	O
determine	O
the	O
diversity	O
in	O
X-chromosome	B-DNA
methylation	O
patterns	O
,	O
which	O
reflect	O
Lyonization	O
,	O
assessed	O
by	O
the	O
HUMARA	B-DNA
assay	O
in	O
the	O
supposedly	O
normal	O
population	O
,	O
we	O
analyzed	O
granulocytes	B-cell_type
and	O
T	B-cell_line
cells	I-cell_line
from	O
97	O
relatively	O
young	O
(	O
18-	O
to	O
35-year-old	O
)	O
healthy	O
female	O
volunteers	O
.	O

We	O
found	O
that	O
the	O
methylation	O
patterns	O
in	O
the	O
two	O
HUMARA	B-DNA
alleles	I-DNA
were	O
distributed	O
even	O
more	O
widely	O
,	O
both	O
in	O
granuloctyes	B-cell_type
and	O
in	O
T	B-cell_line
cells	I-cell_line
,	O
than	O
previously	O
reported	O
with	O
other	O
methods	O
.	O

We	O
also	O
found	O
that	O
the	O
deviation	O
of	O
methylation	O
in	O
granulocytes	B-cell_type
and	O
T	B-cell_line
cells	I-cell_line
was	O
well	O
correlated	O
.	O

Thus	O
,	O
we	O
conclude	O
that	O
appropriate	O
controls	O
from	O
the	O
same	O
individuals	O
,	O
such	O
as	O
T	B-cell_line
cells	I-cell_line
in	O
the	O
case	O
of	O
stem	O
cell	O
disorders	O
,	O
should	O
always	O
be	O
employed	O
to	O
conclusively	O
determine	O
whether	O
certain	O
cells	O
of	O
hematopoietic	O
origin	O
are	O
clonal	O
.	O

Functional	O
B-cell	O
response	O
in	O
intrahepatic	O
lymphoid	O
follicles	O
in	O
chronic	O
hepatitis	O
C	O
.	O

Intrahepatic	O
lymphoid	O
follicle	O
(	O
ILF	O
)	O
formation	O
is	O
one	O
of	O
the	O
most	O
characteristic	O
and	O
commonly	O
observed	O
histological	O
features	O
in	O
patients	O
with	O
chronic	O
hepatitis	O
C	O
.	O

However	O
,	O
little	O
is	O
known	O
regarding	O
whether	O
follicles	O
in	O
the	O
liver	O
belong	O
to	O
functional	O
lymphoid	O
tissues	O
,	O
where	O
B	O
cells	O
are	O
activated	O
,	O
differentiated	O
,	O
and	O
proliferated	O
,	O
or	O
if	O
the	O
lymphocytes	O
are	O
merely	O
infiltrated	O
after	O
recruitment	O
from	O
the	O
secondary	O
lymphoid	O
organs	O
.	O

To	O
ascertain	O
this	O
possibility	O
,	O
we	O
examined	O
the	O
expression	O
of	O
markers	O
for	O
B-cell	O
activation	O
,	O
differentiation	O
,	O
and	O
proliferation	O
in	O
ILFs	O
in	O
patients	O
with	O
chronic	O
hepatitis	O
C	O
using	O
surgically	O
resected	O
specimens	O
,	O
and	O
compared	O
them	O
with	O
specimens	O
of	O
perihepatic	O
lymph	O
nodes	O
by	O
an	O
immunohistochemical	O
technique	O
.	O

Germinal	O
center	O
(	O
GC	O
)	O
formation	O
in	O
the	O
ILFs	O
was	O
frequently	O
found	O
in	O
HCV-positive	O
cases	O
.	O

The	O
distribution	O
of	O
immunoglobulin	O
M	O
(	O
IgM	O
)	O
-	O
,	O
IgD-	O
,	O
and	O
IgG-positive	O
cells	O
and	O
the	O
expression	O
patterns	O
of	O
Ki-67	O
,	O
CD23	O
,	O
or	O
bcl-2	O
and	O
bcl-6	O
gene	O
products	O
in	O
the	O
follicles	O
with	O
GC	O
formation	O
in	O
the	O
liver	O
of	O
patients	O
with	O
chronic	O
hepatitis	O
C	O
were	O
similar	O
to	O
those	O
of	O
lymph	O
nodes	O
,	O
indicating	O
that	O
B	B-cell_type
cells	I-cell_type
are	O
activated	O
,	O
proliferated	O
,	O
and	O
differentiated	O
in	O
the	O
ILFs	O
with	O
GC	O
formation	O
in	O
patients	O
with	O
chronic	O
hepatitis	O
C	O
.	O

Oligoclonal	O
expansion	O
of	O
B	B-cell_type
cells	I-cell_type
in	O
the	O
livers	O
with	O
ILFs	O
was	O
confirmed	O
by	O
an	O
analysis	O
of	O
immunoglobulin	B-DNA
heavy	I-DNA
chain	I-DNA
(	I-DNA
IgH	I-DNA
)	I-DNA
gene	I-DNA
rearrangement	O
determined	O
by	O
polymerase	O
chain	O
reaction	O
(	O
PCR	O
)	O
.	O

These	O
data	O
strongly	O
suggest	O
that	O
ILFs	O
with	O
GC	O
formation	O
,	O
which	O
are	O
frequently	O
found	O
in	O
patients	O
with	O
chronic	O
hepatitis	O
C	O
,	O
may	O
functionally	O
be	O
the	O
same	O
as	O
those	O
found	O
in	O
lymph	O
nodes	O
with	O
respect	O
to	O
B-cell	O
expansion	O
and	O
maturation	O
.	O

Downregulation	O
of	O
Wilms	B-DNA
'	I-DNA
tumor	I-DNA
gene	I-DNA
(	O
WT1	B-DNA
)	O
is	O
not	O
a	O
prerequisite	O
for	O
erythroid	O
or	O
megakaryocytic	O
differentiation	O
of	O
the	O
leukemic	B-cell_line
cell	I-cell_line
line	I-cell_line
K562	I-cell_line
.	O

The	O
Wilms	B-DNA
'	I-DNA
tumor	I-DNA
gene	I-DNA
(	O
WT1	B-DNA
)	O
encodes	O
a	O
transcription	B-protein
factor	I-protein
of	O
the	O
zinc	B-protein
finger	I-protein
type	I-protein
.	O

A	O
high	O
expression	O
of	O
WT1	B-DNA
has	O
been	O
detected	O
in	O
a	O
range	O
of	O
acute	O
leukemias	O
,	O
and	O
WT1	B-DNA
is	O
downregulated	O
during	O
induced	O
differentiation	O
of	O
some	O
leukemic	B-cell_line
cell	I-cell_line
lines	I-cell_line
.	O

Overexpression	O
of	O
WT1	B-DNA
in	O
some	O
myeloid	B-cell_line
cell	I-cell_line
lines	I-cell_line
confers	O
resistance	O
to	O
differentiation	O
induction	O
.	O

These	O
observations	O
suggest	O
that	O
a	O
high	O
WT1	B-DNA
expression	O
in	O
hematopoietic	B-cell_type
cells	I-cell_type
is	O
incompatible	O
with	O
differentiation	O
.	O

In	O
this	O
study	O
,	O
each	O
of	O
the	O
four	O
different	O
isoforms	O
of	O
WT1	B-DNA
was	O
constitutively	O
overexpressed	O
in	O
the	O
leukemic	B-cell_line
cell	I-cell_line
line	I-cell_line
K562	I-cell_line
.	O

K562	B-cell_line
cells	I-cell_line
express	O
endogenous	O
WT1	B-DNA
,	O
which	O
is	O
downregulated	O
as	O
a	O
response	O
to	O
induced	O
differentiation	O
along	O
the	O
erythroid	O
and	O
megakaryocytic	O
pathways	O
.	O

We	O
now	O
demonstrate	O
that	O
a	O
forced	O
exogenous	O
expression	O
of	O
the	O
four	O
different	O
isoforms	O
of	O
WT1	B-DNA
in	O
K562	B-cell_line
does	O
not	O
affect	O
the	O
differentiation	O
response	O
,	O
as	O
judged	O
by	O
accumulation	O
of	O
hemoglobin	B-protein
in	O
response	O
to	O
hemin	B-protein
or	O
the	O
expression	O
of	O
megakaryocytic	B-protein
cell	I-protein
surface	I-protein
markers	I-protein
in	O
response	O
to	O
12-O-tetradecanoylphorbol-13-acetate	O
(	O
TPA	O
)	O
.	O

We	O
conclude	O
that	O
downregulation	O
of	O
WT1	B-DNA
during	O
induced	O
differentiation	O
of	O
K562	B-cell_line
cells	I-cell_line
is	O
not	O
a	O
prerequisite	O
for	O
erythroid	O
or	O
megakaryocytic	O
differentiation	O
of	O
these	O
cells	O
.	O

Association	O
of	O
the	O
interleukin-4	B-protein
receptor	I-protein
alpha	I-protein
chain	I-protein
with	O
p47phox	O
,	O
an	O
activator	O
of	O
the	O
phagocyte	B-protein
NADPH	I-protein
oxidase	I-protein
in	O
B	B-cell_type
cells	I-cell_type
.	O

Interleukin	B-protein
(	I-protein
IL	I-protein
)	I-protein
-4	I-protein
plays	O
an	O
important	O
role	O
in	O
IgE	B-protein
synthesis	O
in	O
B	B-cell_type
cells	I-cell_type
and	O
in	O
Th2	O
differentiation	O
in	O
T	B-cell_line
cells	I-cell_line
.	O

IL-4	B-protein
conducts	O
its	O
biological	O
activities	O
through	O
binding	O
to	O
the	O
IL-4	B-protein
receptor	I-protein
(	O
IL-4R	B-protein
)	O
on	O
the	O
surface	O
of	O
target	B-cell_type
cells	I-cell_type
.	O

IL-4R	B-protein
are	O
thought	O
to	O
be	O
composed	O
of	O
the	O
IL-4R	B-protein
alpha	I-protein
chain	I-protein
(	O
IL-4R	B-protein
alpha	I-protein
)	O
and	O
either	O
the	O
IL-2R	B-protein
gamma	I-protein
chain	I-protein
or	O
the	O
IL-13R	B-protein
alpha	I-protein
chain	I-protein
.	O

We	O
have	O
previously	O
shown	O
that	O
the	O
membrane-proximal	B-protein
portion	I-protein
in	O
the	O
cytoplasmic	B-protein
domain	I-protein
of	O
the	O
human	B-protein
IL-4R	I-protein
alpha	I-protein
(	O
hIL-4R	B-protein
alpha	I-protein
)	O
is	O
critical	O
for	O
proliferation	O
,	O
generation	O
of	O
germline	O
epsilon	O
transcript	O
,	O
and	O
activation	O
of	O
STAT6	B-protein
,	O
based	O
on	O
analyses	O
of	O
truncated	B-protein
hIL-4R	I-protein
alphas	I-protein
.	O

In	O
this	O
study	O
,	O
we	O
found	O
that	O
p47phox	O
,	O
an	O
activator	O
of	O
the	O
phagocyte	B-protein
NADPH	I-protein
oxidase	I-protein
,	O
binds	O
to	O
this	O
portion	O
by	O
the	O
two-hybrid	O
system	O
.	O

Furthermore	O
,	O
we	O
observed	O
the	O
association	O
of	O
p47phox	O
with	O
the	O
hIL-4R	B-protein
alpha	I-protein
in	O
B	B-cell_type
cells	I-cell_type
derived	O
from	O
a	O
normal	O
donor	O
.	O

These	O
results	O
suggest	O
that	O
p47phox	O
is	O
involved	O
in	O
the	O
signal	O
transduction	O
of	O
IL-4	B-protein
in	O
B	B-cell_type
cells	I-cell_type
.	O

However	O
,	O
activation	O
of	O
STAT6	B-protein
,	O
CD23	B-protein
expression	O
,	O
and	O
IgE	B-protein
synthesis	O
induced	O
by	O
IL-4	B-protein
were	O
not	O
affected	O
in	O
p47phox-deficient	O
patients	O
,	O
which	O
raises	O
the	O
possibility	O
that	O
p47phox	O
may	O
be	O
important	O
in	O
other	O
signaling	O
activities	O
as	O
well	O
in	O
B	B-cell_type
cells	I-cell_type
.	O

Effects	O
of	O
diesel	O
organic	O
extracts	O
on	O
chemokine	B-protein
production	O
by	O
peripheral	B-cell_type
blood	I-cell_type
mononuclear	I-cell_type
cells	I-cell_type
.	O

BACKGROUND	O
:	O
Polyaromatic	O
hydrocarbons	O
(	O
PAHs	O
)	O
associated	O
with	O
diesel	O
exhaust	O
particles	O
(	O
DEPs	O
)	O
are	O
found	O
in	O
the	O
atmospheric	O
urban	O
pollution	O
.	O

Such	O
compounds	O
have	O
been	O
shown	O
to	O
favor	O
IgE	B-protein
production	O
,	O
bronchial	O
hyperresponsiveness	O
,	O
and	O
airway	O
inflammation	O
.	O

Chemokines	O
are	O
a	O
group	O
of	O
chemotactic	B-protein
cytokines	I-protein
involved	O
in	O
the	O
recruitment	O
of	O
inflammatory	B-cell_type
cells	I-cell_type
.	O

OBJECTIVE	O
:	O
We	O
investigated	O
the	O
effect	O
of	O
DEP-PAHs	O
on	O
the	O
release	O
and	O
mRNA	B-RNA
expression	O
of	O
IL-8	B-protein
,	O
MCP-1	B-protein
,	O
and	O
RANTES	B-protein
by	O
PBMCs	B-cell_type
obtained	O
from	O
healthy	O
subjects	O
.	O

METHODS	O
:	O
Protein	O
production	O
in	O
supernatants	O
was	O
assessed	O
by	O
ELISA	O
,	O
and	O
mRNA	B-RNA
expression	O
was	O
evaluated	O
by	O
semiquantitative	O
RT-PCR	O
.	O

RESULTS	O
:	O
Secretion	O
of	O
IL-8	B-protein
and	O
RANTES	B-protein
increased	O
in	O
a	O
dose-dependent	O
manner	O
with	O
increasing	O
concentrations	O
of	O
DEP-PAHs	O
(	O
range	O
,	O
0.5	O
ng	O
to	O
50	O
ng/mL	O
)	O
.	O

On	O
the	O
contrary	O
,	O
the	O
release	O
of	O
MCP-1	B-protein
was	O
significantly	O
inhibited	O
,	O
also	O
in	O
a	O
dose-dependent	O
manner	O
.	O

Messenger	B-RNA
RNA	I-RNA
production	O
coding	O
for	O
IL-8	B-protein
,	O
RANTES	B-protein
,	O
and	O
MCP-1	B-protein
showed	O
parallel	O
variations	O
to	O
the	O
production	O
of	O
the	O
correspondent	B-protein
proteins	I-protein
.	O

Effects	O
of	O
DEP-PAHs	O
became	O
significant	O
at	O
7	O
hours	O
and	O
up	O
to	O
48	O
hours	O
time	O
culture	O
for	O
MCP-1	B-protein
,	O
and	O
up	O
to	O
24	O
hours	O
time	O
culture	O
for	O
IL-8	B-protein
and	O
RANTES	B-protein
.	O

Moreover	O
,	O
supernatants	O
from	O
DEP-PAH-activated	B-cell_type
cells	I-cell_type
,	O
compared	O
with	O
those	O
of	O
controls	O
,	O
exhibited	O
a	O
significantly	O
enhanced	O
chemotactic	O
activity	O
for	O
neutrophils	B-cell_type
and	O
eosinophils	B-cell_type
,	O
which	O
was	O
significantly	O
inhibited	O
by	O
pretreatment	O
with	O
anti-IL-8	B-protein
and	O
anti-RANTES	B-protein
neutralizing	O
antibodies	O
,	O
respectively	O
.	O

CONCLUSION	O
:	O
These	O
findings	O
suggest	O
that	O
the	O
chemokine	B-protein
pathways	O
are	O
modulated	O
by	O
DEP-PAHs	O
at	O
the	O
transcriptional	O
level	O
,	O
reinforcing	O
the	O
idea	O
that	O
the	O
development	O
of	O
inflammatory	O
reactions	O
might	O
be	O
affected	O
by	O
diesel	O
exhaust	O
emission	O
.	O

20-Epi	O
analogues	O
of	O
1	O
,	O
25-dihydroxyvitamin	O
D3	O
are	O
highly	O
potent	O
inducers	O
of	O
DRIP	B-protein
coactivator	I-protein
complex	I-protein
binding	O
to	O
the	O
vitamin	B-protein
D3	I-protein
receptor	I-protein
.	O

1	O
,	O
25-Dihydroxyvitamin	O
D3	O
(	O
1	O
,	O
25	O
(	O
OH	O
)	O
2D3	O
)	O
plays	O
a	O
major	O
role	O
in	O
the	O
stimulation	O
of	O
bone	O
growth	O
,	O
mineralization	O
,	O
and	O
intestinal	O
calcium	O
and	O
phosphate	O
absorption	O
;	O
it	O
also	O
acts	O
as	O
a	O
general	O
inhibitor	O
of	O
cellular	O
proliferation	O
.	O

Several	O
new	O
,	O
clinically	O
relevant	O
compounds	O
dissociate	O
antiproliferative	O
and	O
calcemic	O
activities	O
of	O
1	O
,	O
25	O
(	O
OH	O
)	O
2D3	O
,	O
but	O
the	O
molecular	O
basis	O
for	O
this	O
has	O
not	O
been	O
clearly	O
elucidated	O
.	O

Here	O
,	O
we	O
tested	O
whether	O
the	O
potency	O
of	O
one	O
class	O
of	O
compounds	O
,	O
20-epi	O
analogues	O
,	O
to	O
induce	O
myeloid	O
cell	O
differentiation	O
,	O
is	O
because	O
of	O
direct	O
molecular	O
effects	O
on	O
vitamin	B-protein
D	I-protein
receptor	I-protein
(	O
VDR	B-protein
)	O
.	O

We	O
report	O
that	O
two	O
20-epi	O
analogues	O
,	O
MC1627	O
and	O
MC1288	O
,	O
induced	O
differentiation	O
and	O
transcription	O
of	O
p21	B-DNA
(	O
Waf1	B-DNA
,	O
Cip1	B-DNA
)	O
,	O
a	O
key	O
VDR	B-DNA
target	I-DNA
gene	I-DNA
involved	O
in	O
growth	O
inhibition	O
,	O
at	O
a	O
concentration	O
100-fold	O
lower	O
than	O
that	O
of	O
1	O
,	O
25	O
(	O
OH	O
)	O
2D3	O
.	O

We	O
compared	O
this	O
sensitivity	O
to	O
analogue	O
effects	O
on	O
VDR	B-protein
interacting	O
proteins	O
:	O
RXR	B-protein
,	O
GRIP-1	B-protein
,	O
and	O
DRIP205	B-protein
,	O
a	O
subunit	O
of	O
the	O
DRIP	B-protein
coactivator	I-protein
complex	I-protein
.	O

Compared	O
with	O
the	O
interaction	O
of	O
VDR	B-protein
with	O
RXR	B-protein
or	O
GRIP-1	B-protein
,	O
the	O
differentiation	O
dose-response	O
most	O
closely	O
correlated	O
to	O
the	O
ligand-dependent	O
recruitment	O
of	O
the	O
DRIP	B-protein
coactivator	I-protein
complex	I-protein
to	O
VDR	B-protein
and	O
to	O
the	O
ability	O
of	O
the	O
receptor	O
to	O
activate	O
transcription	O
in	O
a	O
cell-free	O
system	O
.	O

These	O
results	O
provide	O
compelling	O
links	O
between	O
the	O
efficiency	O
of	O
the	O
20-epi	O
analogue	O
in	O
inducing	O
VDR	B-protein
/DRIP	O
interactions	O
,	O
transactivation	O
in	O
vitro	O
,	O
and	O
its	O
enhanced	O
ability	O
to	O
induce	O
cellular	O
differentiation	O
.	O

SLP-76	B-protein
and	O
Vav	B-protein
function	O
in	O
separate	O
,	O
but	O
overlapping	O
pathways	O
to	O
augment	O
interleukin-2	B-DNA
promoter	I-DNA
activity	O
.	O

SLP-76	B-protein
and	O
Vav	B-protein
,	O
two	O
hematopoietic	B-protein
cell	I-protein
specific	I-protein
molecules	I-protein
,	O
are	O
critical	O
for	O
T	O
cell	O
development	O
and	O
activation	O
.	O

Following	O
T	B-protein
cell	I-protein
antigen	I-protein
receptor	I-protein
stimulation	O
,	O
SLP-76	B-protein
and	O
Vav	B-protein
both	O
undergo	O
tyrosine	O
phosphorylation	O
and	O
associate	O
with	O
each	O
other	O
via	O
the	O
SH2	O
domain	O
of	O
Vav	B-protein
and	O
phosphorylated	O
tyrosines	O
of	O
SLP-76	B-protein
.	O

Furthermore	O
,	O
SLP-76	B-protein
and	O
Vav	B-protein
have	O
a	O
synergistic	O
effect	O
on	O
interleukin	B-DNA
(	I-DNA
IL	I-DNA
)	I-DNA
-2	I-DNA
promoter	I-DNA
activity	O
in	O
T	B-cell_line
cells	I-cell_line
.	O

In	O
this	O
report	O
,	O
we	O
show	O
that	O
two	O
tyrosines	O
,	O
Tyr-113	O
and	O
Tyr-128	O
,	O
of	O
SLP-76	B-protein
are	O
required	O
for	O
its	O
binding	O
to	O
Vav	B-protein
,	O
both	O
in	O
vitro	O
and	O
in	O
intact	B-cell_type
cells	I-cell_type
.	O

Surprisingly	O
,	O
we	O
find	O
also	O
that	O
the	O
interaction	O
between	O
SLP-76	B-protein
and	O
Vav	B-protein
is	O
not	O
required	O
for	O
their	O
cooperation	O
in	O
augmenting	O
IL-2	B-DNA
promoter	I-DNA
activity	O
,	O
as	O
the	O
two	O
molecules	O
appear	O
to	O
function	O
in	O
different	O
signaling	O
pathways	O
upstream	O
of	O
IL-2	B-DNA
gene	I-DNA
expression	O
.	O

Overexpression	O
of	O
SLP-76	B-protein
in	O
the	O
Jurkat	B-cell_line
T	I-cell_line
cell	I-cell_line
line	I-cell_line
potentiates	O
the	O
activities	O
of	O
both	O
nuclear	B-protein
factor	I-protein
of	I-protein
activated	I-protein
T	I-protein
cells	I-protein
and	O
AP-1	B-protein
transcription	I-protein
factors	I-protein
.	O

In	O
contrast	O
,	O
overexpression	O
of	O
Vav	B-protein
leads	O
to	O
enhanced	O
nuclear	B-protein
factor	I-protein
of	I-protein
activated	I-protein
T	I-protein
cells	I-protein
activity	O
without	O
affecting	O
AP-1	B-protein
.	O

Additionally	O
,	O
overexpression	O
of	O
Vav	B-protein
,	O
but	O
not	O
SLP-76	B-protein
,	O
augments	O
CD28-induced	O
IL-2	B-DNA
promoter	I-DNA
activity	O
.	O

These	O
findings	O
suggest	O
that	O
the	O
synergy	O
between	O
SLP-76	B-protein
and	O
Vav	B-protein
in	O
regulating	O
IL-2	B-DNA
gene	I-DNA
expression	O
reflects	O
the	O
cooperation	O
between	O
different	O
signaling	O
pathways	O
.	O

Rel/NF-kappaB	B-protein
can	O
trigger	O
the	O
Notch	O
signaling	O
pathway	O
by	O
inducing	O
the	O
expression	O
of	O
Jagged1	B-protein
,	O
a	O
ligand	O
for	O
Notch	B-protein
receptors	I-protein
.	O

Jagged1	B-protein
belongs	O
to	O
the	O
DSL	B-protein
family	I-protein
of	I-protein
ligands	I-protein
for	O
Notch	B-protein
receptors	I-protein
that	O
control	O
the	O
proliferation	O
and	O
differentiation	O
of	O
various	O
cell	B-cell_type
lineages	I-cell_type
.	O

However	O
,	O
little	O
is	O
known	O
about	O
the	O
transcription	B-protein
factors	I-protein
that	O
regulate	O
its	O
expression	O
.	O

Here	O
,	O
we	O
show	O
that	O
Jagged1	B-protein
is	O
a	O
Rel/NF-kappaB-responsive	B-DNA
gene	I-DNA
.	O

Both	O
c-Rel	B-protein
and	O
RelA	B-protein
induced	O
jagged1	O
gene	O
expression	O
,	O
whereas	O
a	O
mutant	O
defective	O
for	O
transactivation	O
did	O
not	O
.	O

Importantly	O
,	O
jagged1	B-protein
transcripts	I-protein
were	O
also	O
upregulated	O
by	O
endogenous	O
NF-kappaB	B-protein
activation	O
and	O
this	O
effect	O
was	O
inhibited	O
by	O
a	O
dominant	O
mutant	O
of	O
IkappaBalpha	B-protein
,	O
a	O
physiological	O
inhibitor	O
of	O
NF-kappaB	B-protein
.	O

Cell	O
surface	O
expression	O
of	O
Jagged1	B-protein
in	O
c-Rel-expressing	B-cell_line
cell	I-cell_line
monolayers	I-cell_line
led	O
to	O
a	O
functional	O
interaction	O
with	O
lymphocytes	B-cell_type
expressing	O
the	O
Notch1/TAN-1	B-protein
receptor	I-protein
.	O

This	O
correlated	O
with	O
the	O
initiation	O
of	O
signaling	O
downstream	O
of	O
Notch	O
,	O
as	O
evidenced	O
by	O
increased	O
levels	O
of	O
HES-1	B-RNA
transcripts	I-RNA
in	O
co-cultivated	B-cell_line
T	I-cell_line
cells	I-cell_line
and	O
of	O
CD23	B-RNA
transcripts	I-RNA
in	O
co-cultivated	O
B	B-cell_type
cells	I-cell_type
.	O

Consistent	O
with	O
its	O
Rel/NF-kappaB	B-protein
-dependent	O
induction	O
,	O
Jagged1	B-protein
was	O
found	O
to	O
be	O
highly	O
expressed	O
in	O
splenic	B-cell_type
B	I-cell_type
cells	I-cell_type
where	O
c-Rel	B-protein
is	O
expressed	O
constitutively	O
.	O

These	O
results	O
demonstrate	O
that	O
c-Rel	B-protein
can	O
trigger	O
the	O
Notch	O
signaling	O
pathway	O
in	O
neighboring	O
cells	O
by	O
inducing	O
jagged1	O
gene	O
expression	O
,	O
and	O
suggest	O
a	O
role	O
for	O
Jagged1	B-protein
in	O
B-cell	O
activation	O
,	O
differentiation	O
or	O
function	O
.	O

These	O
findings	O
also	O
highlight	O
the	O
potential	O
for	O
an	O
interplay	O
between	O
the	O
Notch	O
and	O
NF-kappaB	O
signaling	O
pathways	O
in	O
the	O
immune	O
system	O
.	O

Bacterial	O
peptidoglycan	O
induces	O
CD14	B-protein
-dependent	O
activation	O
of	O
transcription	B-protein
factors	I-protein
CREB/ATF	B-protein
and	O
AP-1	B-protein
.	O

Peptidoglycan	O
(	O
PGN	O
)	O
,	O
the	O
major	O
cell	O
wall	O
component	O
of	O
Gram-positive	O
bacteria	O
,	O
induces	O
secretion	O
of	O
cytokines	B-protein
in	O
macrophages	B-cell_type
through	O
CD14	B-protein
,	O
the	O
pattern	O
recognition	O
receptor	O
that	O
binds	O
lipopolysaccharide	O
and	O
other	O
microbial	O
products	O
.	O

To	O
begin	O
to	O
elucidate	O
the	O
mechanisms	O
that	O
regulate	O
the	O
transcription	O
of	O
cytokine	B-DNA
genes	I-DNA
,	O
we	O
wanted	O
to	O
determine	O
which	O
transcription	B-protein
factors	I-protein
are	O
activated	O
by	O
PGN	O
in	O
mouse	B-cell_line
RAW264.7	I-cell_line
and	O
human	B-cell_line
THP-1	I-cell_line
macrophage	I-cell_line
cells	I-cell_line
.	O

Our	O
results	O
demonstrated	O
that	O
:	O
(	O
i	O
)	O
PGN	O
induced	O
phosphorylation	O
of	O
the	O
transcription	B-protein
factors	I-protein
ATF-1	B-protein
and	O
CREB	B-protein
;	O
(	O
ii	O
)	O
ATF-1	B-protein
and	O
CREB	B-protein
bound	O
DNA	O
as	O
a	O
dimer	O
and	O
induced	O
transcriptional	O
activation	O
of	O
a	O
CRE	B-DNA
reporter	I-DNA
plasmid	I-DNA
,	O
which	O
was	O
inhibited	O
by	O
dominant	O
negative	O
CREB	B-protein
and	O
ATF-1	B-protein
;	O
(	O
iii	O
)	O
PGN	O
induced	O
phosphorylation	O
of	O
c-Jun	B-protein
,	O
protein	O
synthesis	O
of	O
JunB	B-protein
and	O
c-Fos	B-protein
,	O
and	O
transcriptional	O
activation	O
of	O
the	O
AP-1	B-DNA
reporter	I-DNA
plasmid	I-DNA
,	O
which	O
was	O
inhibited	O
by	O
dominant	O
negative	O
c-Fos	B-protein
;	O
and	O
(	O
iv	O
)	O
PGN-induced	O
activation	O
of	O
CREB/ATF	B-protein
and	O
AP-1	B-protein
was	O
mediated	O
through	O
CD14	B-protein
.	O

This	O
is	O
the	O
first	O
study	O
to	O
demonstrate	O
activation	O
of	O
CREB/ATF	B-protein
and	O
AP-1	B-protein
transcription	I-protein
factors	I-protein
by	O
PGN	O
or	O
by	O
any	O
other	O
component	O
of	O
Gram-positive	O
bacteria	O
.	O

Glucocorticoid	B-protein
receptors	I-protein
are	O
down-regulated	O
in	O
inflamed	O
colonic	O
mucosa	O
but	O
not	O
in	O
peripheral	B-cell_type
blood	I-cell_type
mononuclear	I-cell_type
cells	I-cell_type
from	O
patients	O
with	O
inflammatory	O
bowel	O
disease	O
[	O
see	O
comments	O
]	O

BACKGROUND	O
:	O
Growing	O
evidence	O
indicates	O
that	O
the	O
immune	O
system	O
and	O
the	O
hypothalamic-pituitary-adrenal	O
system	O
are	O
linked	O
by	O
several	O
mechanisms	O
,	O
for	O
example	O
intracellular	O
glucocorticoid	B-protein
receptors	I-protein
(	O
hGR	B-protein
)	O
.	O

Glucocorticoids	O
are	O
the	O
standard	O
treatment	O
of	O
acute	O
attacks	O
of	O
inflammatory	O
bowel	O
disease	O
(	O
IBD	O
)	O
.	O

Binding	O
of	O
glucocorticoids	O
to	O
hGR	B-protein
down-regulates	O
the	O
transcription	O
of	O
inflammatory	B-DNA
genes	I-DNA
that	O
can	O
propagate	O
IBD	O
.	O

PATIENTS	O
AND	O
METHODS	O
:	O
IBD	O
patients	O
were	O
either	O
treated	O
with	O
5-60	O
mg	O
of	O
prednisolone	O
for	O
more	O
than	O
1	O
week	O
or	O
were	O
without	O
glucocorticoid	O
treatment	O
for	O
more	O
than	O
4	O
weeks	O
.	O

hGR	B-protein
levels	O
were	O
determined	O
from	O
isolated	O
cytosol	O
of	O
peripheral	B-cell_type
blood	I-cell_type
mononuclear	I-cell_type
cells	I-cell_type
(	O
PBMCs	B-cell_type
)	O
or	O
mucosal	O
biopsies	O
using	O
a	O
radioassay	O
with	O
[	O
3H	O
]	O
-dexamethasone	O
.	O

Interleukin	O
(	O
IL	O
)	O
6	O
levels	O
were	O
determined	O
by	O
enzyme-linked	O
immunosorbent	O
assay	O
(	O
ELISA	O
)	O
.	O

RESULTS	O
:	O
The	O
systemic	O
(	O
PBMC	O
)	O
hGR	B-protein
levels	O
of	O
corticosteroid-treated	O
IBD	O
patients	O
were	O
significantly	O
lower	O
than	O
those	O
of	O
control	O
subjects	O
(	O
59.6	O
+/-	O
57.1	O
dpm	O
mg-1	O
cytosol	B-protein
protein	I-protein
vs	O
.	O

227.0	O
+/-	O
90.8	O
dpm	O
mg-1	O
cytosol	B-protein
protein	I-protein
,	O
P	O
=	O
0.007	O
)	O
and	O
IBD	O
patients	O
not	O
receiving	O
glucocorticoid	O
treatment	O
(	O
179.7	O
+/-	O
171.3	O
dpm	O
mg-1	O
cytosol	B-protein
protein	I-protein
,	O
P	O
=	O
0.002	O
)	O
.	O

Systemic	O
hGR	B-protein
levels	O
in	O
untreated	O
IBD	O
patients	O
did	O
not	O
differ	O
significantly	O
from	O
those	O
in	O
control	O
subjects	O
.	O

In	O
patients	O
with	O
connective	O
tissue	O
diseases	O
,	O
systemic	O
hGR	B-protein
levels	O
were	O
also	O
found	O
to	O
be	O
decreased	O
in	O
the	O
absence	O
of	O
glucocorticoid	O
treatment	O
.	O

Systemic	O
hGR	B-protein
levels	O
in	O
patients	O
with	O
Crohn	O
's	O
disease	O
(	O
CD	O
)	O
treated	O
with	O
steroids	O
(	O
66.6	O
+/-	O
61.0	O
dpm	O
mg-1	O
cytosol	B-protein
protein	I-protein
)	O
were	O
not	O
different	O
from	O
those	O
in	O
patients	O
with	O
ulcerative	O
colitis	O
(	O
UC	O
)	O
(	O
56.1	O
+/-	O
51.6	O
dpm	O
mg-1	O
cytosol	B-protein
protein	I-protein
)	O
.	O

In	O
contrast	O
to	O
these	O
findings	O
,	O
mucosal	O
hGR	B-protein
levels	O
were	O
significantly	O
decreased	O
in	O
both	O
steroid-treated	O
(	O
18.0	O
+/-	O
15.5	O
)	O
and	O
not	O
steroid-treated	O
(	O
37.8	O
+/-	O
30.5	O
)	O
patients	O
compared	O
with	O
control	O
subjects	O
(	O
125.6	O
+/-	O
97.1	O
;	O
P	O
=	O
0.00009	O
and	O
P	O
=	O
0.0008	O
respectively	O
)	O
.	O

IL-6	O
levels	O
in	O
all	O
IBD	O
groups	O
with	O
and	O
without	O
steroids	O
were	O
significantly	O
different	O
from	O
those	O
in	O
control	O
subjects	O
.	O

CONCLUSION	O
:	O
In	O
IBD	O
there	O
is	O
no	O
difference	O
in	O
systemic	O
hGR	B-protein
levels	O
between	O
not	O
steroid-treated	O
patients	O
and	O
control	O
subjects	O
,	O
in	O
spite	O
of	O
inflammatory	O
activity	O
(	O
IL-6	B-protein
)	O
.	O

Mucosal	O
hGR	B-protein
levels	O
were	O
decreased	O
independently	O
of	O
treatment	O
,	O
probably	O
leading	O
to	O
a	O
decreased	O
protection	O
against	O
NF-kappaB	B-protein
action	O
in	O
the	O
intestinal	O
mucosa	O
.	O

ICSAT	B-protein
overexpression	O
is	O
not	O
sufficient	O
to	O
cause	O
adult	O
T-cell	O
leukemia	O
or	O
multiple	O
myeloma	O
.	O

ICSAT	B-protein
(	O
Interferon	B-protein
Consensus	I-protein
Sequence	I-protein
binding	I-protein
protein	I-protein
for	I-protein
Activated	I-protein
T	I-protein
cells	I-protein
)	O
is	O
a	O
lymphocyte-specific	O
member	O
of	O
the	O
interferon	B-protein
regulatory	I-protein
factor	I-protein
(	I-protein
IRF	I-protein
)	I-protein
family	I-protein
of	O
transcription	O
factors	O
,	O
originally	O
identified	O
through	O
Southwestern	O
screening	O
of	O
the	O
ATL	B-DNA
(	I-DNA
Adult	I-DNA
T-cell	I-DNA
leukemia	I-DNA
)	I-DNA
-16T	I-DNA
expression	I-DNA
library	I-DNA
.	O

In	O
this	O
study	O
,	O
we	O
created	O
transgenic	O
mice	O
overexpressing	O
ICSAT	B-protein
in	O
lymphocytes	B-cell_type
.	O

Although	O
spontaneous	O
tumorigenesis	O
was	O
not	O
observed	O
,	O
IL-2	B-protein
production	O
with	O
Concanavalin	O
A	O
stimulation	O
was	O
significantly	O
increased	O
in	O
transgenic	O
mice	O
overexpressing	O
ICSAT	B-protein
.	O

ICSAT	B-protein
overexpression	O
in	O
lymphocytes	B-cell_type
seems	O
insufficient	O
for	O
the	O
leukemogenesis	O
of	O
ATL	O
or	O
multiple	O
myeloma	O
(	O
MM	O
)	O
,	O
however	O
,	O
it	O
may	O
regulate	O
T	O
cell	O
activation	O
and	O
its	O
overexpression	O
may	O
lead	O
to	O
leukemogenesis	O
via	O
controlling	O
IL-2	B-protein
production	O
.	O

Copyright	O
1999	O
Academic	O
Press	O
.	O

Altered	O
memory	B-cell_type
T	I-cell_type
cell	I-cell_type
differentiation	O
in	O
patients	O
with	O
early	O
rheumatoid	O
arthritis	O
.	O

The	O
chronic	O
immune	O
response	O
in	O
rheumatoid	O
arthritis	O
(	O
RA	O
)	O
might	O
be	O
driven	O
by	O
activated	O
Th1	O
cells	O
without	O
sufficient	O
Th2	O
cell	O
differentiation	O
to	O
down-modulate	O
inflammation	O
.	O

To	O
test	O
whether	O
disordered	O
memory	B-cell_type
T	I-cell_type
cell	I-cell_type
differentiation	O
contributes	O
to	O
the	O
typical	O
Th1-dominated	O
chronic	O
inflammation	O
in	O
RA	O
we	O
investigated	O
differentiation	O
of	O
resting	B-cell_type
CD4+	I-cell_type
memory	I-cell_type
T	I-cell_type
cells	I-cell_type
in	O
patients	O
with	O
early	O
(	O
6	O
wk	O
to	O
12	O
mo	O
)	O
untreated	O
RA	O
and	O
in	O
age-	O
and	O
sex-matched	O
healthy	O
controls	O
in	O
vitro	O
.	O

No	O
difference	O
in	O
cytokine	B-protein
secretion	O
profiles	O
of	O
freshly	B-cell_type
isolated	I-cell_type
memory	I-cell_type
T	I-cell_type
cells	I-cell_type
was	O
detected	O
between	O
patients	O
and	O
controls	O
.	O

A	O
cell	B-cell_line
culture	I-cell_line
system	I-cell_line
was	O
then	O
employed	O
that	O
permitted	O
the	O
differentiation	O
of	O
Th	B-protein
effectors	I-protein
from	O
resting	B-cell_type
memory	I-cell_type
T	I-cell_type
cells	I-cell_type
by	O
short	O
term	O
priming	O
.	O

Marked	O
differences	O
were	O
found	O
in	O
response	O
to	O
priming	O
.	O

Th2	B-cell_line
cells	I-cell_line
could	O
be	O
induced	O
in	O
all	O
healthy	O
controls	O
by	O
priming	O
with	O
anti-CD28	B-protein
in	O
the	O
absence	O
of	O
TCR	B-protein
ligation	O
.	O

By	O
contrast	O
,	O
priming	O
under	O
those	O
conditions	O
resulted	O
in	O
Th2	O
differentiation	O
in	O
only	O
9	O
of	O
24	O
RA	O
patients	O
.	O

Exogenous	O
IL-4	B-protein
could	O
overcome	O
the	O
apparent	O
Th2	O
differentiation	O
defect	O
in	O
seven	O
patients	O
but	O
was	O
without	O
effect	O
in	O
the	O
remaining	O
eight	O
patients	O
.	O

In	O
all	O
patients	O
a	O
marked	O
decrease	O
in	O
IL-2-producing	B-cell_type
cells	I-cell_type
and	O
a	O
significant	O
increase	O
in	O
well-differentiated	O
Th1	B-cell_type
cells	I-cell_type
that	O
produced	O
IFN-gamma	B-protein
but	O
not	O
IL-2	B-protein
were	O
evident	O
after	O
priming	O
with	O
anti-CD3	B-protein
and	O
anti-CD28	B-protein
.	O

The	O
data	O
suggest	O
that	O
CD4+	B-cell_type
memory	I-cell_type
T	I-cell_type
cells	I-cell_type
from	O
patients	O
with	O
early	O
untreated	O
RA	O
manifest	O
an	O
intrinsic	O
abnormality	O
in	O
their	O
ability	O
to	O
differentiate	O
into	O
specific	O
cytokine-producing	B-cell_type
effector	I-cell_type
cells	I-cell_type
that	O
might	O
contribute	O
to	O
the	O
characteristic	O
Th1-dominated	O
chronic	O
(	O
auto	O
)	O
immune	O
inflammation	O
in	O
RA	O
.	O

The	O
intracellular	O
parasite	O
Theileria	O
parva	O
protects	O
infected	B-cell_type
T	I-cell_type
cells	I-cell_type
from	O
apoptosis	O
.	O

Parasites	O
have	O
evolved	O
a	O
plethora	O
of	O
strategies	O
to	O
ensure	O
their	O
survival	O
.	O

The	O
intracellular	O
parasite	O
Theileria	O
parva	O
secures	O
its	O
propagation	O
and	O
spreads	O
through	O
the	O
infected	O
animal	O
by	O
infecting	O
and	O
transforming	O
T	B-cell_type
cells	I-cell_type
,	O
inducing	O
their	O
continuous	O
proliferation	O
and	O
rendering	O
them	O
metastatic	O
.	O

In	O
previous	O
work	O
,	O
we	O
have	O
shown	O
that	O
the	O
parasite	O
induces	O
constitutive	O
activation	O
of	O
the	O
transcription	B-protein
factor	I-protein
NF-kappaB	B-protein
,	O
by	O
inducing	O
the	O
constitutive	O
degradation	O
of	O
its	O
cytoplasmic	B-protein
inhibitors	I-protein
.	O

The	O
biological	O
significance	O
of	O
NF-kappaB	B-protein
activation	O
in	O
T.	B-cell_type
parva-infected	I-cell_type
cells	I-cell_type
,	O
however	O
,	O
has	O
not	O
yet	O
been	O
defined	O
.	O

Cells	O
that	O
have	O
been	O
transformed	O
by	O
viruses	O
or	O
oncogenes	B-DNA
can	O
persist	O
only	O
if	O
they	O
manage	O
to	O
avoid	O
destruction	O
by	O
the	O
apoptotic	O
mechanisms	O
that	O
are	O
activated	O
on	O
transformation	O
and	O
that	O
contribute	O
to	O
maintain	O
cellular	O
homeostasis	O
.	O

We	O
now	O
demonstrate	O
that	O
parasite-induced	O
NF-kappaB	B-protein
activation	O
plays	O
a	O
crucial	O
role	O
in	O
the	O
survival	O
of	O
T.	B-cell_type
parva-transformed	I-cell_type
T	I-cell_type
cells	I-cell_type
by	O
conveying	O
protection	O
against	O
an	O
apoptotic	O
signal	O
that	O
accompanies	O
parasite-mediated	O
transformation	O
.	O

Consequently	O
,	O
inhibition	O
of	O
NF-kappaB	B-protein
nuclear	O
translocation	O
and	O
the	O
expression	O
of	O
dominant	B-protein
negative	I-protein
mutant	I-protein
forms	O
of	O
components	O
of	O
the	O
NF-kappaB	B-protein
activation	O
pathway	O
,	O
such	O
as	O
IkappaBalpha	B-protein
or	O
p65	B-protein
,	O
prompt	O
rapid	O
apoptosis	O
of	O
T.	B-cell_type
parva-transformed	I-cell_type
T	I-cell_type
cells	I-cell_type
.	O

Our	O
findings	O
offer	O
important	O
insights	O
into	O
parasite	O
survival	O
strategies	O
and	O
demonstrate	O
that	O
parasite-induced	O
constitutive	O
NF-kappaB	B-protein
activation	O
is	O
an	O
essential	O
step	O
in	O
maintaining	O
the	O
transformed	O
phenotype	O
of	O
the	O
infected	B-cell_type
cells	I-cell_type
.	O

A	O
polymorphism	O
that	O
affects	O
OCT-1	B-protein
binding	O
to	O
the	O
TNF	B-DNA
promoter	I-DNA
region	I-DNA
is	O
associated	O
with	O
severe	O
malaria	O
[	O
see	O
comments	O
]	O

Genetic	O
variation	O
in	O
cytokine	B-DNA
promoter	I-DNA
regions	I-DNA
is	O
postulated	O
to	O
influence	O
susceptibility	O
to	O
infection	O
,	O
but	O
the	O
molecular	O
mechanisms	O
by	O
which	O
such	O
polymorphisms	O
might	O
affect	O
gene	O
regulation	O
are	O
unknown	O
.	O

Through	O
systematic	O
DNA	O
footprinting	O
of	O
the	O
TNF	O
(	O
encoding	O
tumour	O
necrosis	O
factor	O
,	O
TNF	O
)	O
promoter	O
region	O
,	O
we	O
have	O
identified	O
a	O
single	O
nucleotide	O
polymorphism	O
(	O
SNP	O
)	O
that	O
causes	O
the	O
helix-turn-helix	O
transcription	B-protein
factor	I-protein
OCT-1	O
to	O
bind	O
to	O
a	O
novel	O
region	O
of	O
complex	O
protein-DNA	O
interactions	O
and	O
alters	O
gene	O
expression	O
in	O
human	B-cell_type
monocytes	I-cell_type
.	O

The	O
OCT-1-binding	O
genotype	O
,	O
found	O
in	O
approximately	O
5	O
%	O
of	O
Africans	O
,	O
is	O
associated	O
with	O
fourfold	O
increased	O
susceptibility	O
to	O
cerebral	O
malaria	O
in	O
large	O
case-control	O
studies	O
of	O
West	O
African	O
and	O
East	O
African	O
populations	O
,	O
after	O
correction	O
for	O
other	O
known	O
TNF	O
polymorphisms	O
and	O
linked	O
HLA	B-DNA
alleles	I-DNA
.	O

UV-induced	O
CYP1A1	B-protein
gene	O
expression	O
in	O
human	O
cells	O
is	O
mediated	O
by	O
tryptophan	O
.	O

Induction	O
of	O
cytochrome	B-protein
P-4501A1	I-protein
(	O
CYP1A1	B-protein
)	O
activity	O
by	O
UV	O
has	O
been	O
observed	O
earlier	O
in	O
animal	O
studies	O
via	O
a	O
mechanism	O
that	O
has	O
not	O
yet	O
been	O
resolved	O
.	O

Our	O
previous	O
data	O
have	O
indicated	O
that	O
formylated	O
indolocarbazoles	O
which	O
are	O
formed	O
by	O
UV	O
irradiation	O
of	O
tryptophan	O
solutions	O
are	O
very	O
potent	O
Ah-receptor	O
agonists	O
.	O

To	O
evaluate	O
the	O
effect	O
of	O
UV	O
light	O
on	O
cytochrome	B-protein
P4501A1	I-protein
gene	O
expression	O
,	O
we	O
studied	O
the	O
induction	O
of	O
CYP1A1	B-RNA
mRNA	I-RNA
by	O
UV	O
irradiation	O
of	O
cultured	B-cell_line
human	I-cell_line
keratinocytes	I-cell_line
(	O
HaCaT	B-cell_line
cell	I-cell_line
line	I-cell_line
)	O
,	O
primary	B-cell_type
human	I-cell_type
blood	I-cell_type
lymphocytes	I-cell_type
and	O
mouse	B-cell_line
Hepa-1	I-cell_line
cells	I-cell_line
.	O

The	O
cells	O
were	O
exposed	O
to	O
UV	O
light	O
delivered	O
by	O
a	O
bank	O
of	O
6	O
Philips	O
TL20/12RS	O
sun	O
lamps	O
emitting	O
primarily	O
in	O
the	O
UVB	O
range	O
in	O
the	O
absence	O
and	O
presence	O
of	O
tryptophan	O
.	O

A	O
semiquantitative	O
reverse	B-protein
transcriptase	I-protein
-linked	O
polymerase	O
chain	O
reaction	O
(	O
RT-PCR	O
)	O
was	O
used	O
for	O
analysis	O
of	O
gene	O
expression	O
in	O
the	O
treated	B-cell_type
cells	I-cell_type
.	O

The	O
results	O
show	O
that	O
the	O
CYP1A1	B-RNA
mRNA	I-RNA
level	O
induced	O
by	O
UV	O
in	O
the	O
presence	O
of	O
tryptophan	O
was	O
higher	O
than	O
that	O
induced	O
by	O
UV	O
alone	O
in	O
both	O
HaCaT	B-cell_line
cells	I-cell_line
and	O
lymphocytes	B-cell_type
after	O
3	O
h	O
of	O
incubation	O
post-UV	O
irradiation	O
.	O

To	O
find	O
out	O
if	O
the	O
induction	O
by	O
UV	O
light	O
is	O
caused	O
by	O
the	O
formation	O
of	O
an	O
Ah	O
receptor	O
ligand	O
,	O
Hepa-1	B-cell_line
wild-type	I-cell_line
and	I-cell_line
Ah	I-cell_line
receptor	I-cell_line
deficient	I-cell_line
c12	I-cell_line
cell	I-cell_line
lines	I-cell_line
were	O
applied	O
.	O

Wild-type	B-cell_line
(	I-cell_line
wt	I-cell_line
)	I-cell_line
cells	I-cell_line
were	O
inducible	O
either	O
by	O
the	O
tryptophan	O
photoproduct	O
6-formylindolo	O
[	O
3	O
,	O
2-b	O
]	O
carbazole	O
(	O
FICZ	O
)	O
or	O
by	O
UV-irradiation	O
but	O
very	O
low	O
or	O
undetectable	O
levels	O
were	O
observed	O
in	O
the	O
c12	B-cell_type
cells	I-cell_type
.	O

This	O
shows	O
that	O
the	O
induction	O
of	O
gene	O
expression	O
by	O
FICZ	O
and	O
UV	O
is	O
Ah	B-protein
receptor	I-protein
dependent	O
.	O

Together	O
,	O
these	O
results	O
indicate	O
that	O
UV-induced	O
CYP1A1	B-protein
gene	O
expression	O
in	O
mammalian	B-cell_type
cells	I-cell_type
is	O
mediated	O
by	O
an	O
Ah	B-protein
receptor	I-protein
ligand	O
formed	O
from	O
tryptophan	O
.	O

Thus	O
,	O
the	O
photoproducts	O
of	O
tryptophan	O
are	O
suggested	O
to	O
be	O
mediators	O
of	O
light	O
via	O
binding	O
to	O
the	O
Ah	B-protein
receptor	I-protein
and	O
as	O
such	O
also	O
could	O
have	O
a	O
role	O
in	O
light-regulated	O
biological	O
rhythms	O
.	O

Repression	O
by	O
Ikaros	B-protein
and	O
Aiolos	B-protein
is	O
mediated	O
through	O
histone	B-protein
deacetylase	I-protein
complexes	I-protein
.	O

Here	O
we	O
show	O
that	O
the	O
lymphoid	B-protein
lineage-determining	I-protein
factors	I-protein
Ikaros	B-protein
and	O
Aiolos	B-protein
can	O
function	O
as	O
strong	B-protein
transcriptional	I-protein
repressors	I-protein
.	O

This	O
function	O
is	O
mediated	O
through	O
two	O
repression	B-protein
domains	I-protein
and	O
is	O
dependent	O
upon	O
the	O
promoter	O
context	O
and	O
cell	O
type	O
.	O

Repression	O
by	O
Ikaros	B-protein
proteins	I-protein
correlates	O
with	O
hypo-acetylation	O
of	O
core	B-protein
histones	I-protein
at	O
promoter	B-DNA
sites	I-DNA
and	O
is	O
relieved	O
by	O
histone	B-protein
deacetylase	I-protein
inhibitors	O
.	O

Consistent	O
with	O
these	O
findings	O
,	O
Ikaros	B-protein
and	O
its	O
repression	B-protein
domains	I-protein
can	O
interact	O
in	O
vivo	O
and	O
in	O
vitro	O
with	O
the	O
mSin3	B-protein
family	I-protein
of	O
co-repressors	O
which	O
bind	O
to	O
histone	B-protein
deacetylases	I-protein
.	O

Based	O
on	O
these	O
and	O
our	O
recent	O
findings	O
of	O
associations	O
between	O
Ikaros	B-protein
and	O
Mi-2-HDAC	B-protein
,	O
we	O
propose	O
that	O
Ikaros	B-protein
family	I-protein
members	I-protein
modulate	O
gene	O
expression	O
during	O
lymphocyte	O
development	O
by	O
recruiting	O
distinct	O
histone	B-protein
deacetylase	I-protein
complexes	I-protein
to	O
specific	B-DNA
promoters	I-DNA
.	O

Protein	B-protein
kinase	I-protein
B	I-protein
(	O
c-Akt	B-protein
)	O
,	O
phosphatidylinositol	B-protein
3-kinase	I-protein
,	O
and	O
STAT5	B-protein
are	O
activated	O
by	O
erythropoietin	B-protein
(	O
EPO	B-protein
)	O
in	O
HCD57	B-cell_line
erythroid	I-cell_line
cells	I-cell_line
but	O
are	O
constitutively	O
active	O
in	O
an	O
EPO-independent	B-cell_line
,	I-cell_line
apoptosis-resistant	I-cell_line
subclone	I-cell_line
(	O
HCD57-SREI	B-cell_line
cells	I-cell_line
)	O
.	O

We	O
found	O
that	O
erythropoietin	B-protein
(	O
EPO	B-protein
)	O
and	O
stem	B-protein
cell	I-protein
factor	I-protein
(	O
SCF	B-protein
)	O
activated	B-protein
protein	I-protein
kinase	I-protein
B	I-protein
(	O
PKB/Akt	B-protein
)	O
in	O
EPO-dependent	B-cell_line
HCD57	I-cell_line
erythroid	I-cell_line
cells	I-cell_line
.	O

To	O
better	O
understand	O
signals	O
controlling	O
proliferation	O
and	O
viability	O
,	O
erythroid	O
cells	O
that	O
resist	O
apoptosis	O
in	O
the	O
absence	O
of	O
EPO	B-protein
were	O
subcloned	O
and	O
characterized	O
(	O
HCD57-SREI	B-cell_line
cells	I-cell_line
)	O
.	O

Constitutive	O
activations	O
of	O
PKB/Akt	B-protein
,	O
STAT5a	B-protein
,	O
and	O
STAT5b	B-protein
were	O
noted	O
in	O
these	O
EPO-independent	B-cell_line
cells	I-cell_line
.	O

PI3-kinase	B-protein
activity	O
was	O
an	O
upstream	O
activator	O
of	O
PKB/Akt	B-protein
because	O
the	O
PI3-kinase	B-protein
inhibitor	O
LY294002	O
blocked	O
both	O
constitutive	O
PKB/Akt	B-protein
and	O
factor-dependent	O
PKB/Akt	B-protein
activity	O
.	O

The	O
LY294002	O
study	O
showed	O
that	O
proliferation	O
and	O
viability	O
of	O
both	O
HCD57-SREI	B-cell_line
and	O
HCD57	B-cell_line
cells	I-cell_line
correlated	O
with	O
the	O
activity	O
of	O
PKB/Akt	B-protein
;	O
however	O
,	O
PKB/Akt	B-protein
activity	O
alone	O
did	O
not	O
protect	O
these	O
cells	O
from	O
apoptosis	O
.	O

Treatment	O
of	O
HCD57	B-cell_line
cells	I-cell_line
with	O
SCF	B-protein
also	O
activated	O
PKB/Akt	B-protein
,	O
but	O
did	O
not	O
protect	O
from	O
apoptosis	O
.	O

This	O
result	O
suggested	O
that	O
PKB/PI3-kinase	B-protein
activity	O
is	O
necessary	O
but	O
not	O
sufficient	O
to	O
promote	O
viability	O
and/or	O
proliferation	O
.	O

Constitutive	O
STAT5	B-protein
activity	O
,	O
activated	O
through	O
an	O
unknown	O
pathway	O
not	O
including	O
JAK2	B-protein
or	O
EPOR	B-protein
,	O
may	O
act	O
in	O
concert	O
with	O
the	O
constitutive	O
PI3-kinase	B-protein
/PKB/Akt	B-protein
pathway	O
to	O
protect	O
the	O
EPO-independent	B-cell_line
HCD57-SREI	I-cell_line
cells	I-cell_line
from	O
apoptosis	O
and	O
promote	O
limited	O
proliferation	O
.	O

Disruption	O
of	O
alpha	O
beta	O
but	O
not	O
of	O
gamma	O
delta	O
T	O
cell	O
development	O
by	O
overexpression	O
of	O
the	O
helix-loop-helix	B-protein
protein	I-protein
Id3	B-protein
in	O
committed	B-cell_type
T	I-cell_type
cell	I-cell_type
progenitors	I-cell_type
.	O

Enforced	O
expression	O
of	O
Id3	B-protein
,	O
which	O
has	O
the	O
capacity	O
to	O
inhibit	O
many	O
basic	B-protein
helix-loop-helix	I-protein
(	I-protein
bHLH	I-protein
)	I-protein
transcription	I-protein
factors	I-protein
,	O
in	O
human	B-cell_type
CD34	I-cell_type
(	I-cell_type
+	I-cell_type
)	I-cell_type
hematopoietic	I-cell_type
progenitor	I-cell_type
cells	I-cell_type
that	O
have	O
not	O
undergone	O
T	B-DNA
cell	I-DNA
receptor	I-DNA
(	I-DNA
TCR	I-DNA
)	I-DNA
gene	I-DNA
rearrangements	I-DNA
inhibits	O
development	O
of	O
the	O
transduced	B-cell_type
cells	I-cell_type
into	O
TCRalpha	B-cell_line
beta	I-cell_line
and	I-cell_line
gamma	I-cell_line
delta	I-cell_line
cells	I-cell_line
in	O
a	O
fetal	B-cell_line
thymic	I-cell_line
organ	I-cell_line
culture	I-cell_line
(	O
FTOC	B-cell_line
)	O
.	O

Here	O
we	O
document	O
that	O
overexpression	O
of	O
Id3	B-protein
,	O
in	O
progenitors	B-cell_type
that	O
have	O
initiated	O
TCR	B-DNA
gene	I-DNA
rearrangements	I-DNA
(	O
pre-T	B-cell_type
cells	I-cell_type
)	O
,	O
inhibits	O
development	O
into	O
TCRalpha	B-cell_line
beta	I-cell_line
but	O
not	O
into	O
TCRgamma	B-cell_line
delta	I-cell_line
T	I-cell_line
cells	I-cell_line
.	O

Furthermore	O
,	O
Id3	B-protein
impedes	O
expression	O
of	O
recombination	O
activating	O
genes	O
and	O
downregulates	O
pre-Talpha	B-RNA
mRNA	I-RNA
.	O

These	O
observations	O
suggest	O
possible	O
mechanisms	O
by	O
which	O
Id3	B-protein
overexpression	O
can	O
differentially	O
affect	O
development	O
of	O
pre-T	B-cell_type
cells	I-cell_type
into	O
TCRalpha	B-cell_line
beta	I-cell_line
and	I-cell_line
gamma	I-cell_line
delta	I-cell_line
cells	I-cell_line
.	O

We	O
also	O
observed	O
that	O
cell	B-cell_type
surface	I-cell_type
CD4	I-cell_type
(	I-cell_type
-	I-cell_type
)	I-cell_type
CD8	I-cell_type
(	I-cell_type
-	I-cell_type
)	I-cell_type
CD3	I-cell_type
(	I-cell_type
-	I-cell_type
)	I-cell_type
cells	I-cell_type
with	O
rearranged	B-DNA
TCR	I-DNA
genes	I-DNA
developed	O
from	O
Id3-transduced	B-cell_line
but	O
not	O
from	O
control-transduced	B-cell_line
pre-T	I-cell_line
cells	I-cell_line
in	O
an	O
FTOC	B-cell_line
.	O

These	O
cells	O
had	O
properties	O
of	O
both	O
natural	B-cell_type
killer	I-cell_type
(	O
NK	B-cell_type
)	O
and	O
pre-T	B-cell_type
cells	I-cell_type
.	O

These	O
findings	O
suggest	O
that	O
bHLH	B-protein
factors	I-protein
are	O
required	O
to	O
control	O
T	O
cell	O
development	O
after	O
the	O
T/NK	O
developmental	O
checkpoint	O
.	O

HIV-1	O
reactivation	O
in	O
resting	B-cell_type
peripheral	I-cell_type
blood	I-cell_type
mononuclear	I-cell_type
cells	I-cell_type
of	O
infected	O
adults	O
upon	O
in	O
vitro	O
CD4	B-protein
cross-linking	O
by	O
ligands	O
of	O
the	O
CDR2-loop	B-protein
in	O
extracellular	B-protein
domain	I-protein
1	I-protein
.	O

HIV-1	O
infects	O
resting	B-cell_type
peripheral	I-cell_type
blood	I-cell_type
mononuclear	I-cell_type
cells	I-cell_type
(	O
PBMCs	B-cell_type
)	O
but	O
remains	O
inactive	O
state	O
until	O
subsequent	O
cell	O
activation	O
.	O

We	O
have	O
demonstrated	O
that	O
the	O
cross-linking	O
of	O
cell	B-protein
surface	I-protein
CD4	I-protein
by	O
gp120-anti-gp120	B-protein
immune	I-protein
complexes	I-protein
or	O
heat-inactivated	O
HIV-1	O
(	O
iHIV-1	O
)	O
is	O
sufficient	O
to	O
trigger	O
activation	O
signals	O
leading	O
to	O
virus	O
reactivation	O
(	O
9	O
)	O
.	O

In	O
this	O
study	O
,	O
we	O
demonstrate	O
that	O
NF-kappaB	B-protein
nuclear	O
translocation	O
and	O
stimulation	O
of	O
virus	O
production	O
by	O
iHIV-1	O
were	O
strictly	O
linked	O
to	O
the	O
concentrations	O
of	O
viral	B-protein
proteins	I-protein
used	O
as	O
exogenous	O
stimuli	O
.	O

Moreover	O
,	O
we	O
further	O
investigated	O
the	O
physiologic	O
relevance	O
of	O
these	O
observations	O
.	O

When	O
submitted	O
to	O
an	O
in	O
vitro	O
CD4	B-protein
cross-linking	O
by	O
iHIV-1	O
,	O
PBMCs	B-cell_type
from	O
HIV-1-infected	O
patients	O
were	O
found	O
to	O
produce	O
virus	O
.	O

This	O
viral	O
reactivation	O
was	O
associated	O
with	O
increased	O
NF-kappaB	B-protein
nuclear	O
translocation	O
in	O
patients	O
'	O
PBMCs	B-cell_type
.	O

Additionally	O
,	O
virus	O
reactivation	O
in	O
resting	B-cell_type
PBMCs	I-cell_type
infected	O
in	O
vitro	O
with	O
HIV-1	O
was	O
found	O
to	O
be	O
specifically	O
induced	O
by	O
ligands	O
of	O
the	O
CDR2-loop	B-protein
in	O
domain	B-protein
1	I-protein
(	O
D1	B-protein
)	O
of	O
CD4	B-protein
(	O
virus	B-protein
envelope	I-protein
and	I-protein
anti-CD4	I-protein
monoclonal	I-protein
antibodies	I-protein
)	O
.	O

In	O
contrast	O
,	O
virus	O
reactivation	O
was	O
not	O
observed	O
following	O
CD4	B-protein
oligomerization	O
by	O
antibodies	B-protein
that	O
bind	O
other	O
epitopes	O
in	O
D1	B-protein
,	O
including	O
the	O
D1/CDR3-loop	B-protein
.	O

Finally	O
,	O
soluble	B-protein
CD4	I-protein
(	O
sCD4	B-protein
)	O
prevented	O
virus	O
reactivation	O
by	O
D1/CDR2-loop	B-protein
ligands	I-protein
.	O

Our	O
results	O
indicate	O
that	O
the	O
signaling	O
events	O
initiated	O
in	O
PBMCs	B-cell_type
by	O
oligomerization	O
of	O
CD4	B-protein
at	O
the	O
D1/CDR2-loop	B-protein
can	O
trigger	O
HIV-1	O
upregulation	O
in	O
infected	O
individuals	O
.	O

Signaling	O
through	O
the	O
lymphotoxin-beta	B-protein
receptor	I-protein
stimulates	O
HIV-1	O
replication	O
alone	O
and	O
in	O
cooperation	O
with	O
soluble	O
or	O
membrane-bound	B-protein
TNF-alpha	I-protein
.	O

The	O
level	O
of	O
ongoing	O
HIV-1	O
replication	O
within	O
an	O
individual	O
is	O
critical	O
to	O
HIV-1	O
pathogenesis	O
.	O

Among	O
host	O
immune	O
factors	O
,	O
the	O
cytokine	B-protein
TNF-alpha	B-protein
has	O
previously	O
been	O
shown	O
to	O
increase	O
HIV-1	O
replication	O
in	O
various	O
monocyte	O
and	O
T	O
cell	O
model	O
systems	O
.	O

Here	O
,	O
we	O
demonstrate	O
that	O
signaling	O
through	O
the	O
TNF	B-protein
receptor	O
family	O
member	O
,	O
the	O
lymphotoxin-beta	B-protein
(	I-protein
LT-beta	I-protein
)	I-protein
receptor	I-protein
(	O
LT-betaR	B-protein
)	O
,	O
also	O
regulates	O
HIV-1	O
replication	O
.	O

Furthermore	O
,	O
HIV-1	O
replication	O
is	O
cooperatively	O
stimulated	O
when	O
the	O
distinct	O
LT-betaR	B-protein
and	O
TNF	B-protein
receptor	I-protein
systems	I-protein
are	O
simultaneously	O
engaged	O
by	O
their	O
specific	O
ligands	O
.	O

Moreover	O
,	O
in	O
a	O
physiological	O
coculture	O
cellular	O
assay	O
system	O
,	O
we	O
show	O
that	O
membrane-bound	B-protein
TNF-alpha	I-protein
and	O
LT-alpha1beta2	B-protein
act	O
virtually	O
identically	O
to	O
their	O
soluble	O
forms	O
in	O
the	O
regulation	O
of	O
HIV-1	O
replication	O
.	O

Thus	O
,	O
cosignaling	O
via	O
the	O
LT-beta	B-protein
and	I-protein
TNF-alpha	I-protein
receptors	I-protein
is	O
probably	O
involved	O
in	O
the	O
modulation	O
of	O
HIV-1	O
replication	O
and	O
the	O
subsequent	O
determination	O
of	O
HIV-1	O
viral	O
burden	O
in	O
monocytes	B-cell_type
.	O

Intriguingly	O
,	O
surface	O
expression	O
of	O
LT-alpha1beta2	B-protein
is	O
up-regulated	O
on	O
a	O
T	B-cell_line
cell	I-cell_line
line	I-cell_line
acutely	O
infected	O
with	O
HIV-1	O
,	O
suggesting	O
a	O
positive	O
feedback	O
loop	O
between	O
HIV-1	O
infection	O
,	O
LT-alpha1beta2	B-protein
expression	O
,	O
and	O
HIV-1	O
replication	O
.	O

Given	O
the	O
critical	O
role	O
that	O
LT-alpha1beta2	B-protein
plays	O
in	O
lymphoid	O
architecture	O
,	O
we	O
speculate	O
that	O
LT-alpha1beta2	B-protein
may	O
be	O
involved	O
in	O
HIV-associated	O
abnormalities	O
of	O
the	O
lymphoid	O
organs	O
.	O

Monoclonal	B-protein
anti-endothelial	I-protein
cell	I-protein
antibodies	I-protein
from	O
a	O
patient	O
with	O
Takayasu	O
arteritis	O
activate	O
endothelial	O
cells	O
from	O
large	O
vessels	O
.	O

OBJECTIVE	O
:	O
To	O
create	O
monoclonal	B-protein
anti-endothelial	I-protein
cell	I-protein
antibodies	I-protein
(	O
mAECA	B-protein
)	O
from	O
a	O
patient	O
with	O
Takayasu	O
arteritis	O
to	O
evaluate	O
their	O
ability	O
to	O
activate	O
human	B-cell_line
umbilical	I-cell_line
vein	I-cell_line
endothelial	I-cell_line
cells	I-cell_line
(	O
HUVEC	B-cell_line
)	O
,	O
and	O
to	O
characterize	O
the	O
mechanism	O
of	O
EC	O
activation	O
.	O

METHODS	O
:	O
A	O
panel	O
of	O
mAECA	B-protein
was	O
generated	O
from	O
peripheral	B-cell_type
blood	I-cell_type
lymphocytes	I-cell_type
of	O
a	O
patient	O
with	O
Takayasu	O
arteritis	O
,	O
using	O
Epstein-Barr	O
virus	O
transformation	O
.	O

Activity	O
against	O
macrovascular	B-cell_line
EC	I-cell_line
(	O
HUVEC	B-cell_line
)	O
and	O
microvascular	B-cell_line
EC	I-cell_line
(	O
human	B-cell_line
bone	I-cell_line
marrow	I-cell_line
EC	I-cell_line
immortalized	I-cell_line
by	I-cell_line
SV40	I-cell_line
)	O
antigens	O
was	O
detected	O
by	O
enzyme-linked	O
immunosorbent	O
assay	O
.	O

Inhibition	O
studies	O
were	O
used	O
to	O
select	O
the	O
monoclonal	B-protein
antibodies	I-protein
(	O
mAECA	B-protein
)	O
which	O
share	O
the	O
same	O
EC	O
epitope	O
binding	O
specificity	O
as	O
the	O
total	B-protein
IgG-AECA	I-protein
from	O
the	O
Takayasu	O
arteritis	O
patient	O
.	O

The	O
binding	O
of	O
the	O
mAECA	B-protein
to	O
human	B-cell_type
aortic	I-cell_type
EC	I-cell_type
was	O
studied	O
by	O
immunohistochemistry	O
.	O

The	O
secretion	O
levels	O
of	O
interleukin-6	B-protein
(	O
IL-6	B-protein
)	O
and	O
von	O
Willebrand	O
factor	O
(	O
vWF	O
)	O
were	O
determined	O
,	O
to	O
serve	O
as	O
markers	O
for	O
EC	O
activation	O
.	O

The	O
activated	B-cell_line
EC	I-cell_line
were	O
examined	O
for	O
the	O
adherence	O
of	O
a	O
monocytic	B-cell_line
cell	I-cell_line
line	I-cell_line
(	O
U937	B-cell_line
)	O
,	O
as	O
well	O
as	O
for	O
expression	O
of	O
vascular	B-protein
cell	I-protein
adhesion	I-protein
molecule	I-protein
1	I-protein
,	O
intercellular	O
adhesion	O
molecule	O
1	O
,	O
and	O
E-selectin	B-protein
.	O

In	O
addition	O
,	O
nuclear	O
extracts	O
of	O
the	O
mAECA-treated	B-cell_line
EC	I-cell_line
were	O
analyzed	O
for	O
the	O
induction	O
of	O
translocation	O
of	O
nuclear	B-protein
factor	I-protein
kappaB	I-protein
(	O
NF-kappaB	B-protein
)	O
,	O
using	O
a	O
specific	O
NF-kappaB	B-protein
oligoprobe	O
in	O
an	O
electrophoretic	O
mobility	O
shift	O
assay	O
.	O

RESULTS	O
:	O
Six	O
mAECA	B-protein
were	O
selected	O
,	O
the	O
mixture	O
of	O
which	O
produced	O
100	O
%	O
inhibition	O
of	O
binding	O
of	O
the	O
original	O
IgG	B-protein
(	O
from	O
the	O
patient	O
with	O
Takayasu	O
arteritis	O
)	O
to	O
HUVEC	B-cell_line
.	O

All	O
mAECA	B-protein
possessed	O
high	O
activity	O
against	O
macrovascular	B-cell_line
EC	I-cell_line
,	O
but	O
none	O
had	O
significant	O
antimicrovascular	O
EC	O
activity	O
.	O

The	O
mAECA	B-protein
,	O
but	O
not	O
normal	B-protein
human	I-protein
IgG	I-protein
,	O
had	O
anti-human	O
aortic	O
EC	O
activity	O
.	O

Four	O
of	O
the	O
6	O
mAECA	B-protein
activated	B-cell_line
EC	I-cell_line
,	O
manifested	O
by	O
increased	O
IL-6	B-protein
and	O
vWF	O
secretion	O
.	O

The	O
4	O
mAECA	B-protein
induced	O
EC	O
expression	O
of	O
adhesion	B-protein
molecules	I-protein
and	O
increased	O
adhesion	O
of	O
U937	B-cell_type
monocytic	I-cell_type
cells	I-cell_type
to	O
EC	B-cell_type
.	O

In	O
addition	O
,	O
these	O
mAECA	B-protein
stimulated	O
the	O
nuclear	O
translocation	O
of	O
the	O
NF-kappaB	B-protein
transcription	I-protein
factor	I-protein
.	O

CONCLUSION	O
:	O
Our	O
findings	O
suggest	O
that	O
AECA	B-protein
may	O
directly	O
stimulate	O
EC	B-cell_type
in	O
Takayasu	O
arteritis	O
through	O
elevation	O
of	O
adhesion	B-protein
molecule	I-protein
expression	O
associated	O
with	O
NF-kappaB	B-protein
activation	O
and	O
adhesion	O
of	O
monocytes	B-cell_type
,	O
and	O
may	O
therefore	O
play	O
a	O
pathogenic	O
role	O
in	O
the	O
development	O
of	O
the	O
vasculopathy	O
in	O
Takayasu	O
arteritis	O
.	O

Cutting	O
edge	O
:	O
expression	O
of	O
the	O
NF	B-protein
of	I-protein
activated	I-protein
T	I-protein
cells	I-protein
in	O
eosinophils	B-cell_type
:	O
regulation	O
by	O
IL-4	B-protein
and	O
IL-5	B-protein
.	O

We	O
report	O
that	O
NF-AT1	B-protein
and	O
NF-AT4	B-protein
are	O
expressed	O
cytoplasmically	O
in	O
resting	B-cell_type
eosinophils	I-cell_type
,	O
whereas	O
NF-AT2	B-protein
and	O
NF-AT3	B-protein
have	O
not	O
been	O
seen	O
.	O

Likewise	O
,	O
NF-AT1	B-RNA
mRNA	I-RNA
and	O
NF-AT4	B-RNA
mRNA	I-RNA
have	O
been	O
detected	O
in	O
resting	B-cell_type
eosinophils	I-cell_type
,	O
and	O
their	O
levels	O
can	O
be	O
significantly	O
up-regulated	O
by	O
the	O
Th2-associated	B-protein
cytokines	I-protein
IL-4	B-protein
and	O
IL-5	B-protein
.	O

There	O
is	O
no	O
detectable	O
NF-AT	B-protein
protein	O
expression	O
in	O
the	O
nuclei	O
of	O
resting	B-cell_type
eosinophils	I-cell_type
.	O

However	O
NF-ATs	B-protein
appear	O
in	O
the	O
nuclei	O
of	O
IL-4-	B-cell_line
,	I-cell_line
IL-5-	I-cell_line
,	I-cell_line
or	I-cell_line
ionomycin-stimulated	I-cell_line
eosinophils	I-cell_line
.	O

Only	O
NF-AT1	B-protein
and	O
NF-AT4	B-protein
,	O
but	O
not	O
NF-AT2	B-protein
and	O
NF-AT3	B-protein
,	O
have	O
translocated	O
into	O
the	O
nuclei	O
in	O
IL-4-	B-cell_line
or	I-cell_line
IL-5-stimulated	I-cell_line
eosinophils	I-cell_line
.	O

These	O
findings	O
delineate	O
a	O
novel	O
pathway	O
in	O
the	O
cytokine	O
network	O
in	O
which	O
Th2	B-cell_line
lymphocytes	I-cell_line
``	O
control	O
''	O
eosinophils	B-cell_type
via	O
the	O
release	O
of	O
IL-4	B-protein
and	O
IL-5	B-protein
,	O
and	O
activation	O
of	O
NF-AT	B-protein
in	O
eosinophils	B-cell_type
.	O

The	O
findings	O
also	O
suggest	O
that	O
a	O
later	O
feedback	O
``	O
talking	O
''	O
may	O
exist	O
between	O
eosinophils	B-cell_type
and	O
Th2	B-cell_line
lymphocytes	I-cell_line
.	O

PPARalpha	O
activators	O
inhibit	O
cytokine-induced	O
vascular	B-protein
cell	I-protein
adhesion	I-protein
molecule-1	I-protein
expression	O
in	O
human	B-cell_type
endothelial	I-cell_type
cells	I-cell_type
.	O

BACKGROUND	O
:	O
Adhesion	O
molecule	O
expression	O
on	O
the	O
endothelial	O
cell	O
(	O
EC	O
)	O
surface	O
is	O
critical	O
for	O
leukocyte	O
recruitment	O
to	O
atherosclerotic	O
lesions	O
.	O

Better	O
understanding	O
of	O
transcriptional	O
regulation	O
of	O
adhesion	B-protein
molecules	I-protein
in	O
ECs	B-cell_type
may	O
provide	O
important	O
insight	O
into	O
plaque	O
formation	O
.	O

Peroxisome	B-protein
proliferator-activated	I-protein
receptor-alpha	I-protein
(	O
PPARalpha	B-protein
)	O
,	O
a	O
member	O
of	O
the	O
nuclear	B-protein
receptor	I-protein
family	I-protein
,	O
regulates	O
gene	O
expression	O
in	O
response	O
to	O
certain	O
fatty	O
acids	O
and	O
fibric	O
acid	O
derivatives	O
.	O

The	O
present	O
study	O
investigated	O
PPARalpha	B-protein
expression	O
in	O
human	B-cell_type
ECs	I-cell_type
and	O
their	O
regulation	O
of	O
vascular	B-protein
cell	I-protein
adhesion	I-protein
molecule-1	I-protein
(	O
VCAM-1	B-protein
)	O
.	O

METHODS	O
AND	O
RESULTS	O
:	O
Immunohistochemistry	O
revealed	O
that	O
human	B-cell_type
carotid	I-cell_type
artery	I-cell_type
ECs	I-cell_type
express	O
PPARalpha	B-protein
.	O

Pretreatment	O
of	O
cultured	B-cell_type
human	I-cell_type
ECs	I-cell_type
with	O
the	O
PPARalpha	B-protein
activators	O
fenofibrate	O
or	O
WY14643	O
inhibited	O
TNF-alpha-induced	B-protein
VCAM-1	I-protein
in	O
a	O
time-	O
and	O
concentration-dependent	O
manner	O
,	O
an	O
effect	O
not	O
seen	O
with	O
PPARgamma	B-protein
activators	O
.	O

Both	O
PPARalpha	B-protein
activators	O
decreased	O
cytokine-induced	O
VCAM-1	B-protein
mRNA	O
expression	O
without	O
altering	O
its	O
mRNA	O
half-life	O
.	O

Transient	O
transfection	O
of	O
deletional	O
VCAM-1	B-DNA
promoter	I-DNA
constructs	I-DNA
and	O
electrophoretic	O
mobility	O
shift	O
assays	O
suggest	O
that	O
fenofibrate	O
inhibits	O
VCAM-1	B-protein
transcription	O
in	O
part	O
by	O
inhibiting	O
NF-kappaB	B-protein
.	O

Finally	O
,	O
PPARalpha	B-protein
activators	O
significantly	O
reduced	O
adhesion	O
of	O
U937	B-cell_line
cells	I-cell_line
to	O
cultured	B-cell_type
human	I-cell_type
ECs	I-cell_type
.	O

CONCLUSIONS	O
:	O
Human	B-cell_type
ECs	I-cell_type
express	O
PPARalpha	B-protein
,	O
a	O
potentially	O
important	O
regulator	O
of	O
atherogenesis	O
through	O
its	O
transcriptional	O
control	O
of	O
VCAM-1	B-protein
gene	O
expression	O
.	O

Such	O
findings	O
also	O
have	O
implications	O
regarding	O
the	O
clinical	O
use	O
of	O
lipid-lowering	O
agents	O
,	O
like	O
fibric	O
acids	O
,	O
which	O
can	O
activate	O
PPARalpha	B-protein
.	O

CBP/p300	B-protein
integrates	O
Raf	B-protein
/	O
Rac	B-protein
-signaling	O
pathways	O
in	O
the	O
transcriptional	O
induction	O
of	O
NF-ATc	B-protein
during	O
T	O
cell	O
activation	O
.	O

NF-ATc	B-protein
,	O
an	O
inducibly	O
expressed	O
transcription	B-protein
factor	I-protein
,	O
controls	O
gene	O
expression	O
in	O
T	B-cell_type
lymphocytes	I-cell_type
and	O
cardiomyocytes	B-cell_type
.	O

We	O
show	O
here	O
that	O
the	O
transcriptional	B-protein
co-activators	I-protein
CBP/p300	B-protein
bind	O
to	O
and	O
control	O
the	O
activity	O
of	O
the	O
inducible	B-protein
N-terminal	I-protein
transactivation	I-protein
domain	I-protein
of	O
NF-ATc	B-protein
,	O
TAD-A	B-protein
.	O

Similar	O
to	O
the	O
N	B-protein
terminal	I-protein
transactivation	I-protein
domain	I-protein
of	O
c-Jun	B-protein
,	O
TAD-A	B-protein
is	O
inducibly	O
phosphorylated	O
,	O
but	O
this	O
phosphorylation	O
is	O
dispensable	O
for	O
the	O
interaction	O
with	O
CBP/p300	B-protein
.	O

Constitutive	O
active	O
versions	O
of	O
c-Raf	B-protein
and	O
Rac	B-protein
synergistically	O
enhance	O
the	O
CBP/p300	B-protein
-mediated	O
increase	O
of	O
TAD-A	B-protein
activity	O
,	O
indicating	O
the	O
important	O
role	O
CBP/p300	B-protein
plays	O
in	O
the	O
integration	O
of	O
T	O
cell	O
activation	O
signals	O
.	O

Since	O
a	O
mutation	O
of	O
CBP	B-protein
abolishing	O
HAT	O
activity	O
is	O
almost	O
as	O
active	O
as	O
wild-type	B-protein
CBP	I-protein
in	O
T	B-cell_type
cells	I-cell_type
,	O
functions	O
of	O
CBP/p300	B-protein
other	O
than	O
histone	O
acetylation	O
appear	O
to	O
control	O
the	O
NF-AT	B-protein
-dependent	O
transcription	O
in	O
T	B-cell_type
cells	I-cell_type
.	O

Immune	O
functions	O
,	O
clinical	O
parameters	O
and	O
hormone	O
receptor	O
status	O
in	O
breast	O
cancer	O
patients	O
.	O

We	O
have	O
carried	O
out	O
a	O
detailed	O
analysis	O
of	O
the	O
cellular	O
immune	O
functions	O
of	O
breast	O
cancer	O
patients	O
in	O
comparison	O
with	O
healthy	O
controls	O
.	O

A	O
possible	O
correlation	O
between	O
immune	O
and	O
clinical	O
parameters	O
was	O
analysed	O
in	O
50	O
breast	O
cancer	O
patients	O
.	O

Immune	O
parameters	O
,	O
natural	B-cell_type
killer	I-cell_type
cell	I-cell_type
and	O
T	O
lymphocyte	O
functions	O
and	O
the	O
numbers	O
of	O
circulating	B-cell_type
T	I-cell_type
lymphocytes	I-cell_type
were	O
analysed	O
against	O
the	O
clinical	O
parameters	O
comprising	O
the	O
tumour	O
burden	O
,	O
the	O
stage	O
of	O
the	O
disease	O
and	O
the	O
expression	O
of	O
hormone	B-protein
receptors	I-protein
on	O
the	O
tumour	O
.	O

In	O
order	O
to	O
analyse	O
the	O
immune	O
function	O
data	O
effectively	O
,	O
low	O
responders	O
were	O
identified	O
with	O
stringent	O
cut-off	O
values	O
.	O

Considerably	O
higher	O
proportions	O
of	O
low	O
responders	O
were	O
found	O
among	O
the	O
patient	O
population	O
.	O

Elevated	O
numbers	O
of	O
circulating	B-cell_type
T	I-cell_type
lymphocytes	I-cell_type
and	O
CD3	B-protein
-directed	O
cytolysis	O
correlated	O
with	O
the	O
expression	O
of	O
oestrogen	B-protein
receptors	I-protein
independently	O
of	O
the	O
clinical/histological	O
parameters	O
.	O

Latent	B-protein
membrane	I-protein
protein	I-protein
1	I-protein
of	O
Epstein-Barr	O
virus	O
interacts	O
with	O
JAK3	B-protein
and	O
activates	O
STAT	B-protein
proteins	I-protein
.	O

Latent	B-protein
membrane	I-protein
protein	I-protein
1	I-protein
(	O
LMP1	B-protein
)	O
acts	O
like	O
a	O
permanently	B-protein
activated	I-protein
receptor	I-protein
of	O
the	O
tumor	B-protein
necrosis	I-protein
factor	I-protein
(	I-protein
TNF	I-protein
)	I-protein
-receptor	I-protein
superfamily	I-protein
and	O
is	O
absolutely	O
required	O
for	O
B	O
cell	O
immortalization	O
by	O
Epstein-Barr	O
virus	O
.	O

Molecular	O
and	O
biochemical	O
approaches	O
demonstrated	O
that	O
LMP1	B-protein
usurps	O
cellular	O
signaling	O
pathways	O
resulting	O
in	O
the	O
induction	O
of	O
NF-kappaB	B-protein
and	O
AP-1	B-protein
via	O
two	O
C-terminal	B-protein
activating	I-protein
regions	I-protein
.	O

We	O
demonstrate	O
here	O
that	O
a	O
third	O
region	O
encompassing	O
a	O
proline	B-protein
rich	I-protein
sequence	I-protein
within	O
the	O
33	O
bp	O
repetitive	O
stretch	O
of	O
LMP1	B-protein
's	O
C-terminus	B-protein
is	O
required	O
for	O
the	O
activation	O
of	O
Janus	B-protein
kinase	I-protein
3	I-protein
(	O
JAK3	B-protein
)	O
.	O

The	O
interaction	O
of	O
LMP1	B-protein
and	O
JAK3	B-protein
leads	O
to	O
the	O
enhanced	O
tyrosine	O
auto/transphosphorylation	O
of	O
JAK3	B-protein
within	O
minutes	O
after	O
crosslinking	O
of	O
a	O
conditional	O
NGF-R	B-protein
:	I-protein
LMP1	I-protein
chimera	I-protein
and	O
is	O
a	O
prerequisite	O
for	O
the	O
activation	O
of	O
STAT	B-protein
transcription	I-protein
factors	I-protein
.	O

These	O
results	O
reveal	O
a	O
novel	O
activating	O
region	O
in	O
the	O
LMP1	B-protein
C-terminus	B-protein
and	O
identify	O
the	O
JAK	B-protein
/STAT	B-protein
pathway	O
as	O
a	O
target	O
of	O
this	O
viral	B-protein
integral	I-protein
membrane	I-protein
protein	I-protein
in	O
B	B-cell_type
cells	I-cell_type
.	O

Monocyte	O
arrest	O
and	O
transmigration	O
on	O
inflamed	O
endothelium	O
in	O
shear	O
flow	O
is	O
inhibited	O
by	O
adenovirus-mediated	O
gene	O
transfer	O
of	O
IkappaB-alpha	B-protein
.	O

Mobilization	O
of	O
nuclear	B-protein
factor-kappaB	I-protein
(	O
NF-kappaB	B-protein
)	O
activates	O
transcription	O
of	O
genes	O
encoding	O
endothelial	B-protein
adhesion	I-protein
molecules	I-protein
and	O
chemokines	O
that	O
contribute	O
to	O
monocyte	O
infiltration	O
critical	O
in	O
atherogenesis	O
.	O

Inhibition	O
of	O
NF-kappaB	B-protein
has	O
been	O
achieved	O
by	O
pharmacological	O
and	O
genetic	O
approaches	O
;	O
however	O
,	O
monocyte	O
interactions	O
with	O
activated	O
endothelium	O
in	O
shear	O
flow	O
following	O
gene	O
transfer	O
of	O
the	O
NF-kappaB	B-protein
inhibitor	O
IkappaB-alpha	B-protein
have	O
not	O
been	O
studied	O
.	O

We	O
found	O
that	O
overexpression	O
of	O
IkappaB-alpha	B-protein
in	O
endothelial	B-cell_type
cells	I-cell_type
using	O
a	O
recombinant	O
adenovirus	O
prevented	O
tumor	B-protein
necrosis	I-protein
factor-alpha	I-protein
(	O
TNF-alpha	B-protein
)	O
-induced	O
degradation	O
of	O
IkappaB-alpha	B-protein
and	O
suppressed	O
the	O
upregulation	O
of	O
vascular	B-protein
cell	I-protein
adhesion	I-protein
molecule-1	I-protein
(	O
VCAM-1	B-protein
)	O
,	O
intercellular	B-protein
adhesion	I-protein
molecule-1	I-protein
(	O
ICAM-1	B-protein
)	O
,	O
and	O
E-selectin	B-RNA
mRNA	I-RNA
and	O
surface	O
protein	O
expression	O
and	O
the	O
upregulation	O
of	O
transcripts	O
for	O
the	O
chemokines	B-protein
monocyte	B-protein
chemoattractant	I-protein
protein	I-protein
1	I-protein
(	O
MCP-1	B-protein
)	O
and	O
growth-related	B-protein
activity-alpha	I-protein
(	O
GRO-alpha	B-protein
)	O
by	O
TNF-alpha	B-protein
.	O

This	O
was	O
associated	O
with	O
a	O
reduction	O
in	O
endothelial	O
MCP-1	B-protein
secretion	O
and	O
GRO-alpha	B-protein
immobilization	O
.	O

Adhesion	O
assays	O
under	O
physiological	O
shear	O
flow	O
conditions	O
showed	O
that	O
firm	O
arrest	O
,	O
spreading	O
,	O
and	O
transmigration	O
of	O
monocytes	B-cell_type
on	O
TNF-alpha	B-protein
-activated	O
endothelium	O
was	O
markedly	O
inhibited	O
by	O
IkappaB-alpha	B-protein
overexpression	O
.	O

Inhibition	O
with	O
monoclonal	B-protein
antibodies	I-protein
and	O
peptide	O
antagonists	O
inferred	O
that	O
this	O
was	O
due	O
to	O
reduced	O
expression	O
of	O
Ig	O
integrin	O
ligand	O
as	O
well	O
as	O
of	O
chemokines	B-protein
specifically	O
involved	O
in	O
these	O
events	O
.	O

In	O
contrast	O
,	O
rolling	O
of	O
monocytes	B-cell_type
was	O
increased	O
by	O
IkappaB-alpha	B-protein
transfer	O
and	O
was	O
partly	O
mediated	O
by	O
P-selectin	B-protein
;	O
however	O
,	O
it	O
appeared	O
to	O
be	O
unaffected	O
by	O
the	O
inhibition	O
of	O
E-selectin	B-protein
induction	O
.	O

Thus	O
,	O
our	O
data	O
provide	O
novel	O
evidence	O
that	O
selective	O
modulation	O
of	O
NF-kappaB	B-protein
by	O
adenoviral	O
transfer	O
of	O
IkappaB-alpha	B-protein
impairs	O
the	O
expression	O
of	O
multiple	O
endothelial	B-protein
gene	I-protein
products	I-protein
required	O
for	O
subsequent	O
monocyte	O
arrest	O
and	O
emigration	O
in	O
shear	O
flow	O
and	O
thus	O
for	O
monocyte	O
infiltration	O
in	O
atherosclerotic	O
plaques	O
.	O

Recognition	O
of	O
NFATp/AP-1	B-DNA
composite	I-DNA
elements	I-DNA
within	O
genes	O
induced	O
upon	O
the	O
activation	O
of	O
immune	B-cell_type
cells	I-cell_type
.	O

Composite	B-DNA
elements	I-DNA
are	O
regulatory	B-DNA
modules	I-DNA
of	O
promoters	B-DNA
or	O
enhancers	B-DNA
that	O
consist	O
of	O
binding	O
sites	O
of	O
two	O
different	O
but	O
synergizing	O
transcription	B-protein
factors	I-protein
.	O

A	O
well-studied	O
example	O
is	O
nuclear	B-DNA
factors	I-DNA
of	I-DNA
activated	I-DNA
T-cell	I-DNA
(	I-DNA
NFAT	I-DNA
)	I-DNA
sites	I-DNA
which	O
are	O
composite	O
elements	O
of	O
a	O
NFATp/c	B-DNA
and	I-DNA
an	I-DNA
activating	I-DNA
protein	I-DNA
1	I-DNA
(	I-DNA
AP-1	I-DNA
)	I-DNA
binding	I-DNA
site	I-DNA
.	O

We	O
have	O
developed	O
a	O
computational	O
approach	O
to	O
identify	O
potential	O
NFAT	B-DNA
target	I-DNA
genes	I-DNA
which	O
(	O
a	O
)	O
comprises	O
an	O
improved	O
method	O
to	O
scan	O
for	O
individual	O
NFAT	B-DNA
composite	I-DNA
elements	I-DNA
;	O
(	O
b	O
)	O
considers	O
positional	O
effects	O
relative	O
to	O
transcription	B-DNA
start	I-DNA
sites	I-DNA
;	O
and	O
(	O
c	O
)	O
involves	O
cluster	O
analysis	O
of	O
potential	O
NFAT	B-DNA
composite	I-DNA
elements	I-DNA
.	O

All	O
three	O
steps	O
progressively	O
helpX	O
?	O
ed	O
to	O
discriminate	O
T-cell-specific	B-DNA
promoter	I-DNA
sequences	I-DNA
against	O
other	O
functional	B-DNA
regions	I-DNA
(	O
coding	B-DNA
and	I-DNA
intronic	I-DNA
sequences	I-DNA
)	O
of	O
the	O
same	O
genes	O
,	O
against	O
promoters	B-DNA
of	O
muscle-specific	B-DNA
genes	I-DNA
or	O
against	O
random	B-DNA
sequences	I-DNA
.	O

Using	O
this	O
approach	O
,	O
we	O
identified	O
potential	O
NFAT	B-DNA
composite	I-DNA
elements	I-DNA
in	O
promoters	B-DNA
of	O
cytokine	B-DNA
genes	I-DNA
and	O
their	O
receptors	O
as	O
well	O
as	O
in	O
promoters	B-DNA
of	O
genes	O
for	O
AP-1	B-protein
family	I-protein
members	I-protein
,	O
Ca2+-binding	B-protein
proteins	I-protein
and	O
some	O
other	O
components	O
of	O
the	O
regulatory	O
network	O
operating	O
in	O
activated	B-cell_type
T-cells	I-cell_type
and	O
other	O
immune	B-cell_type
cells	I-cell_type
.	O

The	O
method	O
developed	O
can	O
be	O
adapted	O
to	O
characterize	O
and	O
identify	O
other	O
composite	B-DNA
elements	I-DNA
as	O
well	O
.	O

The	O
program	O
for	O
recognition	O
NFAT	B-DNA
composite	I-DNA
elements	I-DNA
is	O
available	O
through	O
the	O
World	O
Wide	O
Web	O
(	O
http	O
:	O
//compel.bionet.nsc.ru/FunSite/CompelScan.html	O
and	O
http	O
:	O
//transfac.gbf.de/dbsearch/funsitep/s_comp.html	O
)	O
.	O

Copyright	O
1999	O
Academic	O
Press	O
.	O

The	O
oestrogen	B-protein
receptor	I-protein
codon	B-DNA
10	I-DNA
polymorphism	O
detected	O
in	O
breast	O
cancer	O
is	O
also	O
present	O
in	O
non-malignant	B-cell_type
cells	I-cell_type
.	O

The	O
effect	O
of	O
oestrogens	O
on	O
oestrogen-receptive	O
organs	O
and	O
cells	O
is	O
mediated	O
via	O
intracellular	B-protein
receptors	I-protein
(	O
ERalpha	B-protein
and	O
ERbeta	B-protein
)	O
.	O

Oestrogen	B-protein
receptor	I-protein
gene	O
polymorphisms	O
in	O
the	O
region	O
encoding	O
the	O
N-terminal	B-protein
portion	I-protein
of	O
the	O
protein	O
are	O
reportedly	O
associated	O
with	O
pathological	O
conditions	O
including	O
breast	O
cancer	O
,	O
hypertension	O
,	O
spontaneous	O
abortion	O
and	O
coronary	O
heart	O
disease	O
.	O

A	O
silent	O
mutation	O
in	O
codon	B-DNA
10	I-DNA
of	O
exon	B-DNA
1	I-DNA
,	O
detected	O
in	O
ER-negative	B-cell_line
and	I-cell_line
ER-positive	I-cell_line
human	I-cell_line
breast	I-cell_line
cancer	I-cell_line
cell	I-cell_line
lines	I-cell_line
,	O
in	O
breast	O
tumors	O
and	O
blood	B-DNA
DNA	I-DNA
from	O
breast	O
cancer	O
patients	O
,	O
has	O
been	O
recognized	O
as	O
a	O
polymorphic	B-DNA
site	I-DNA
.	O

In	O
this	O
study	O
we	O
examined	O
,	O
by	O
denaturing	O
gradient-gel	O
electrophoresis	O
and	O
DNA	B-DNA
sequence	I-DNA
analysis	O
,	O
the	O
possible	O
presence	O
of	O
a	O
codon	B-DNA
10	I-DNA
polymorphic	I-DNA
site	I-DNA
in	O
normal	O
oestrogen	O
target	O
organs	O
and	O
cells	O
such	O
as	O
the	O
uterus	O
(	O
myometrium	O
and	O
endometrium	O
)	O
,	O
in	O
the	O
placenta	O
and	O
peripheral	B-cell_type
blood	I-cell_type
mononuclear	I-cell_type
cells	I-cell_type
and	O
in	O
a	O
benign	O
uterus	O
tumour	O
(	O
leiomyoma	O
)	O
.	O

We	O
have	O
detected	O
ER	B-DNA
codon	I-DNA
10	I-DNA
polymorphism	O
in	O
these	O
samples	O
and	O
have	O
compared	O
them	O
to	O
those	O
observed	O
in	O
breast	O
cancer	O
samples	O
.	O

All	O
tissues	O
and	O
cells	O
studied	O
were	O
homozygous	O
for	O
the	O
wild-type	B-DNA
gene	I-DNA
,	O
and	O
were	O
heterozygous	O
as	O
well	O
as	O
homozygous	O
for	O
the	O
codon-10-variant	B-DNA
type	I-DNA
.	O

These	O
results	O
indicate	O
that	O
the	O
presence	O
of	O
the	O
codon-10-variant	B-DNA
type	I-DNA
is	O
not	O
a	O
characteristic	O
of	O
breast	O
cancer	O
.	O

Out	O
current	O
findings	O
suggest	O
that	O
further	O
investigations	O
are	O
warranted	O
to	O
elucidate	O
the	O
possible	O
linkage	O
of	O
ER	B-DNA
codon	I-DNA
10	I-DNA
polymorphism	O
to	O
physiological	O
and	O
pathological	O
conditions	O
.	O

USF/c-Myc	B-protein
enhances	O
,	O
while	O
Yin-Yang	B-protein
1	I-protein
suppresses	O
,	O
the	O
promoter	O
activity	O
of	O
CXCR4	B-protein
,	O
a	O
coreceptor	B-protein
for	O
HIV-1	O
entry	O
.	O

Transcription	B-protein
factors	I-protein
USF1	B-protein
and	O
USF2	B-protein
up-regulate	O
gene	O
expression	O
(	O
i.e.	O
,	O
HIV-1	B-DNA
long	I-DNA
terminal	I-DNA
repeats	I-DNA
)	O
via	O
interaction	O
with	O
an	O
E	B-DNA
box	I-DNA
on	O
their	O
target	O
promoters	O
,	O
which	O
is	O
also	O
a	O
binding	B-DNA
site	I-DNA
for	O
c-Myc	B-protein
.	O

The	O
c-Myc	B-protein
oncoprotein	I-protein
is	O
important	O
in	O
control	O
of	O
cellular	O
proliferation	O
and	O
differentiation	O
,	O
while	O
Yin-Yang	B-protein
1	I-protein
(	O
YY1	B-protein
)	O
has	O
been	O
shown	O
to	O
control	O
the	O
expression	O
of	O
a	O
number	O
of	O
cellular	B-DNA
and	I-DNA
viral	I-DNA
genes	I-DNA
.	O

These	O
two	O
proteins	O
physically	O
interact	O
with	O
each	O
other	O
and	O
mutually	O
inhibit	O
their	O
respective	O
biological	O
functions	O
.	O

In	O
this	O
study	O
,	O
we	O
show	O
that	O
USF/c-Myc	B-protein
up-regulates	O
,	O
while	O
YY1	B-protein
down-regulates	O
the	O
promoter	O
activity	O
of	O
CXCR4	B-protein
,	O
a	O
coreceptor	O
for	O
T	O
cell-tropic	O
HIV-1	O
entry	O
.	O

We	O
have	O
identified	O
an	O
E	B-DNA
box	I-DNA
around	O
-260	B-DNA
and	O
a	O
YY1	B-DNA
binding	I-DNA
site	I-DNA
around	O
-300	B-DNA
relative	O
to	O
the	O
transcription	B-DNA
start	I-DNA
site	I-DNA
.	O

Mutation	O
of	O
the	O
E	B-DNA
box	I-DNA
abolished	O
USF/c-Myc	B-protein
-mediated	O
up-regulation	O
of	O
CXCR4	B-protein
promoter	O
activity	O
,	O
and	O
mutation	O
of	O
the	O
YY1	B-DNA
binding	I-DNA
site	I-DNA
was	O
associated	O
with	O
unresponsiveness	O
to	O
YY1	B-protein
-mediated	O
inhibition	O
.	O

These	O
data	O
suggest	O
that	O
USF/c-Myc	B-protein
and	O
YY1	B-protein
may	O
play	O
an	O
important	O
role	O
in	O
the	O
HIV-1-replicative	O
cycle	O
,	O
by	O
modulating	O
both	O
the	O
viral	O
fusion/entry	O
process	O
and	O
viral	O
expression	O
.	O

Suppression	O
of	O
NF-kappaB	B-protein
activation	O
in	O
normal	B-cell_type
T	I-cell_type
cells	I-cell_type
by	O
supernatant	O
fluid	O
from	O
human	O
renal	O
cell	O
carcinomas	O
.	O

T	B-cell_type
lymphocytes	I-cell_type
from	O
patients	O
with	O
renal	O
cell	O
carcinoma	O
(	O
RCC	O
)	O
show	O
reduced	O
immune	O
function	O
and	O
impaired	O
activation	O
of	O
the	O
transcription	B-protein
factor	I-protein
,	O
NF-kappaB	B-protein
.	O

We	O
determined	O
the	O
mechanism	O
of	O
NF-kappaB	B-protein
suppression	O
in	O
T	B-cell_type
cells	I-cell_type
of	O
RCC	O
patient	O
and	O
determined	O
whether	O
supernatant	O
fluid	O
from	O
RCC	O
explants	O
(	O
RCC-S	O
)	O
induced	O
the	O
same	O
phenotype	O
of	O
NF-kappaB	B-protein
suppression	O
in	O
normal	B-cell_type
T	I-cell_type
cells	I-cell_type
that	O
is	O
observed	O
in	O
patient	O
T	B-cell_type
cells	I-cell_type
.	O

The	O
pattern	O
of	O
kappaB	B-protein
-binding	O
activity	O
in	O
T	B-cell_type
cells	I-cell_type
of	O
RCC	O
patient	O
was	O
altered	O
as	O
compared	O
to	O
that	O
seen	O
in	O
T	B-cell_type
cells	I-cell_type
obtained	O
from	O
normal	O
volunteers	O
.	O

In	O
some	O
patients	O
,	O
no	O
activation	O
of	O
RelA/NFkappaB1	B-protein
-binding	O
activity	O
was	O
detectable	O
,	O
while	O
in	O
others	O
kappaB	B-protein
-binding	O
activity	O
was	O
modestly	O
induced	O
but	O
the	O
duration	O
was	O
reduced	O
.	O

IkappaBalpha	B-protein
was	O
degraded	O
normally	O
following	O
stimulation	O
in	O
both	O
normal	O
controls	O
and	O
T	B-cell_type
cells	I-cell_type
from	O
RCC	O
patients	O
.	O

RCC-S	O
did	O
not	O
alter	O
the	O
cytoplasmic	O
levels	O
of	O
RelA	B-protein
and	O
NF-kappaB1	B-protein
but	O
did	O
suppress	O
their	O
nuclear	O
localization	O
and	O
inhibited	O
the	O
activation	O
of	O
RelA/NF-kappaB1	B-protein
binding	I-protein
complexes	I-protein
.	O

These	O
results	O
show	O
that	O
RCC-S	O
can	O
induce	O
in	O
normal	B-cell_type
T	I-cell_type
cells	I-cell_type
the	O
same	O
phenotype	O
of	O
impaired	O
NF-kappaB	B-protein
activation	O
that	O
is	O
detected	O
in	O
T	B-cell_type
cells	I-cell_type
of	O
RCC	O
patient	O
.	O

It	O
also	O
appears	O
that	O
NF-kappaB	B-protein
suppression	O
by	O
RCC-S	O
may	O
contribute	O
to	O
the	O
immunosuppression	O
of	O
host	O
immunity	O
.	O

STAT1	B-protein
activation	O
during	O
monocyte	O
to	O
macrophage	O
maturation	O
:	O
role	O
of	O
adhesion	B-protein
molecules	I-protein
.	O

Human	B-cell_type
monocytes	I-cell_type
isolated	O
from	O
peripheral	O
blood	O
of	O
healthy	O
donors	O
show	O
a	O
time-dependent	O
differentiation	O
into	O
macrophages	B-cell_type
upon	O
in	O
vitro	O
cultivation	O
,	O
closely	O
mimicking	O
their	O
in	O
vivo	O
migration	O
and	O
maturation	O
into	O
extravascular	O
tissues	O
.	O

The	O
mediator	O
(	O
s	O
)	O
of	O
this	O
maturation	O
process	O
has	O
not	O
been	O
yet	O
defined	O
.	O

We	O
investigated	O
the	O
involvement	O
of	O
signal	B-protein
transducers	I-protein
and	I-protein
activators	I-protein
of	I-protein
transcription	I-protein
(	I-protein
STAT	I-protein
)	I-protein
factors	I-protein
in	O
this	O
phenomenon	O
and	O
reported	O
the	O
specific	O
,	O
time-dependent	O
,	O
activation	O
of	O
STAT1	B-protein
protein	O
starting	O
at	O
day	O
0/1	O
of	O
cultivation	O
and	O
maximally	O
expressed	O
at	O
day	O
5	O
.	O

STAT1	B-protein
activity	O
was	O
evident	O
on	O
the	O
STAT	B-DNA
binding	I-DNA
sequences	I-DNA
(	O
SBE	B-DNA
)	O
present	O
in	O
the	O
promoters	B-DNA
of	O
genes	O
which	O
are	O
up-regulated	O
during	O
monocyte	O
to	O
macrophage	O
maturation	O
such	O
as	O
FcgammaRI	B-DNA
and	O
ICAM-1	B-DNA
,	O
and	O
in	O
the	O
promoter	O
of	O
the	O
transcription	B-DNA
factor	I-DNA
IFN	I-DNA
regulatory	I-DNA
factor-1	I-DNA
.	O

Moreover	O
,	O
the	O
effect	O
of	O
cell	O
adhesion	O
to	O
fibronectin	O
or	O
laminin	O
was	O
studied	O
to	O
investigate	O
mechanisms	O
involved	O
in	O
STAT1	B-protein
activation	O
.	O

Compared	O
with	O
monocytes	B-cell_type
adherent	O
on	O
plastic	O
surfaces	O
,	O
freshly	O
isolated	O
cells	O
allowed	O
to	O
adhere	O
either	O
to	O
fibronectin-	O
or	O
laminin-coated	O
flasks	O
exhibited	O
an	O
increased	O
STAT1	B-protein
binding	O
activity	O
both	O
in	O
control	O
and	O
in	O
IFN-gamma-treated	B-cell_line
cells	I-cell_line
.	O

The	O
molecular	O
events	O
leading	O
to	O
enhanced	O
STAT1	B-protein
activation	O
and	O
cytokine	B-protein
responsiveness	O
concerned	O
both	O
Y701	B-protein
and	O
S727	B-protein
STAT1	I-protein
phosphorylation	O
.	O

Exogenous	O
addition	O
of	O
transforming	B-protein
growth	I-protein
factor-beta	I-protein
,	O
which	O
exerts	O
an	O
inhibitory	O
effect	O
on	O
some	O
monocytic	B-protein
differentiation	I-protein
markers	I-protein
,	O
inhibited	O
macrophage	O
maturation	O
,	O
integrin	O
expression	O
and	O
STAT1	B-protein
binding	O
activity	O
.	O

Taken	O
together	O
these	O
results	O
indicate	O
that	O
STAT1	B-protein
plays	O
a	O
pivotal	O
role	O
in	O
the	O
differentiation/maturation	O
process	O
of	O
monocytes	B-cell_type
as	O
an	O
early	O
transcription	B-protein
factor	I-protein
initially	O
activated	O
by	O
adherence	O
and	O
then	O
able	O
to	O
modulate	O
the	O
expression	O
of	O
functional	B-DNA
genes	I-DNA
,	O
such	O
as	O
ICAM-1	B-protein
and	O
FcgammaRI	B-protein
.	O

Expression	O
and	O
role	O
of	O
PML	B-DNA
gene	I-DNA
in	O
normal	O
adult	O
hematopoiesis	O
:	O
functional	O
interaction	O
between	O
PML	B-protein
and	I-protein
Rb	I-protein
proteins	I-protein
in	O
erythropoiesis	O
.	O

The	O
expression	O
of	O
the	O
PML	B-DNA
gene	I-DNA
was	O
investigated	O
in	O
purified	O
early	O
hematopoietic	B-cell_type
progenitor	I-cell_type
cells	I-cell_type
(	O
HPCs	B-cell_type
)	O
induced	O
to	O
unilineage	O
erythroid	O
or	O
granulocytic	O
differentiation	O
.	O

PML	B-RNA
mRNA	I-RNA
and	O
protein	B-protein
,	O
while	O
barely	O
detectable	O
in	O
quiescent	O
HPCs	B-cell_type
,	O
are	O
consistently	O
induced	O
by	O
growth	B-protein
factor	I-protein
stimulation	O
through	O
the	O
erythroid	O
or	O
granulocytic	O
lineage	O
.	O

Thereafter	O
,	O
PML	B-protein
is	O
downmodulated	O
in	O
late	O
granulocytic	O
maturation	O
,	O
whereas	O
it	O
is	O
sustainably	O
expressed	O
through	O
the	O
erythroid	O
pathway	O
.	O

In	O
functional	O
studies	O
,	O
PML	B-protein
expression	O
was	O
inhibited	O
by	O
addition	O
of	O
antisense	O
oligomers	O
targeting	O
PML	B-RNA
mRNA	I-RNA
(	O
alpha-PML	B-protein
)	O
.	O

Interestingly	O
,	O
early	O
treatment	O
(	O
day	O
0	O
HPCs	B-cell_type
)	O
with	O
alpha-PML	B-protein
reduced	O
the	O
number	O
of	O
both	O
erythroid	B-cell_line
and	I-cell_line
granulocytic	I-cell_line
colonies	I-cell_line
,	O
whereas	O
late	O
treatment	O
(	O
day	O
5	O
culture	O
)	O
reduced	O
erythroid	O
,	O
but	O
not	O
granulocytic	O
,	O
clonogenesis	O
.	O

These	O
findings	O
suggest	O
that	O
PML	B-protein
is	O
required	O
for	O
early	O
hematopoiesis	O
and	O
erythroid	O
,	O
but	O
not	O
granulocytic	O
maturation	O
.	O

The	O
pattern	O
of	O
PML	B-protein
expression	O
in	O
normal	O
hematopoiesis	O
mimics	O
that	O
of	O
retinoblastoma	B-cell_type
pRb	B-protein
105	I-protein
.	O

Combined	O
treatment	O
of	O
HPCs	B-cell_type
with	O
alpha-PML	B-protein
and	O
alpha-Rb	O
oligomers	O
inhibited	O
both	O
PML	O
and	O
Rb	O
protein	O
expression	O
and	O
completely	O
blocked	O
erythroid	O
colony	O
development	O
.	O

Furthermore	O
,	O
PML	B-protein
and	O
pRb	B-protein
105	I-protein
were	O
co-immunoprecipitated	O
in	O
cellular	O
lysates	O
derived	O
from	O
erythroid	B-cell_type
precursors	I-cell_type
indicating	O
that	O
this	O
functional	O
interaction	O
may	O
have	O
a	O
biochemical	O
basis	O
.	O

These	O
results	O
suggest	O
a	O
key	O
functional	O
role	O
of	O
PML	B-protein
in	O
early	O
hematopoiesis	O
and	O
late	O
erythropoiesis	O
:	O
the	O
latter	O
phenomenon	O
may	O
be	O
related	O
to	O
the	O
molecular	O
and	O
functional	O
interaction	O
of	O
PML	B-protein
with	O
pRb	B-protein
105	I-protein
.	O

Binding	O
characteristics	O
of	O
the	O
glucocorticoid	B-protein
receptor	I-protein
in	O
peripheral	B-cell_type
blood	I-cell_type
lymphocytes	I-cell_type
in	O
multiple	O
sclerosis	O
.	O

Although	O
the	O
exact	O
etiology	O
of	O
multiple	O
sclerosis	O
(	O
MS	O
)	O
remains	O
unresolved	O
,	O
immune	O
reactions	O
are	O
believed	O
to	O
be	O
the	O
central	O
pathogenic	O
mechanisms	O
.	O

Endogenous	O
and	O
therapeutic	O
steroid	O
hormones	O
affect	O
the	O
immune	O
system	O
,	O
and	O
inflammatory	O
diseases	O
are	O
associated	O
with	O
activation	O
of	O
the	O
hypothalamic-pituitary-adrenal	O
axis	O
,	O
providing	O
evidence	O
of	O
an	O
immune-endocrine	O
interplay	O
.	O

Function	O
tests	O
in	O
MS	O
have	O
revealed	O
dysregulation	O
of	O
the	O
hypothalamic-pituitary-adrenal	O
system	O
in	O
a	O
substantial	O
proportion	O
of	O
patients	O
.	O

We	O
characterized	O
glucocorticoid	B-protein
receptor	I-protein
(	O
GR	B-protein
)	O
binding	O
in	O
peripheral	B-cell_type
blood	I-cell_type
lymphocytes	I-cell_type
from	O
39	O
MS	O
patients	O
and	O
14	O
age-	O
and	O
sex-matched	O
controls	O
with	O
respect	O
to	O
dissociation	O
constant	O
and	O
binding	O
capacity	O
,	O
using	O
a	O
whole-cell	O
binding	O
assay	O
with	O
[	O
3H	O
]	O
dexamethasone	O
as	O
the	O
ligand	O
.	O

GR	B-protein
binding	O
parameters	O
did	O
not	O
differ	O
significantly	O
between	O
patients	O
(	O
Kd	O
8.98	O
+/-	O
1.07	O
nM	O
,	O
Bmax	O
183	O
+/-	O
29.8	O
fmol/mg	O
)	O
and	O
controls	O
(	O
Kd	O
9.36	O
+/-	O
1.17	O
nM	O
,	O
Bmax	O
158	O
+/-	O
16	O
fmol/mg	O
)	O
.	O

No	O
effect	O
of	O
age	O
,	O
sex	O
,	O
course	O
,	O
duration	O
or	O
severity	O
of	O
disease	O
,	O
or	O
prior	O
steroid	O
treatments	O
was	O
detected	O
.	O

GR	B-protein
binding	O
parameters	O
were	O
analyzed	O
in	O
relation	O
to	O
the	O
results	O
of	O
the	O
combined	O
dexamethasone	O
-CRH	B-protein
test	O
,	O
which	O
reflects	O
corticosteroid	O
receptor	O
function	O
at	O
the	O
hypothalamus	O
,	O
in	O
30	O
patients	O
and	O
9	O
controls	O
.	O

While	O
controls	O
showed	O
a	O
moderate	O
correlation	O
between	O
binding	O
affinity	O
of	O
the	O
GR	B-protein
in	O
lymphocytes	O
and	O
regulatory	O
function	O
at	O
the	O
hypothalamic	O
level	O
,	O
the	O
patients	O
did	O
not	O
.	O

These	O
data	O
suggest	O
that	O
the	O
physiological	O
relationship	O
between	O
binding	O
and	O
function	O
of	O
the	O
glucocorticoid	B-protein
receptor	I-protein
is	O
disturbed	O
in	O
MS	O
.	O

Phorbol	O
ester-induced	O
mononuclear	O
cell	O
differentiation	O
is	O
blocked	O
by	O
the	O
mitogen-activated	B-protein
protein	I-protein
kinase	I-protein
kinase	I-protein
(	O
MEK	B-protein
)	O
inhibitor	O
PD98059	O
.	O

The	O
purpose	O
of	O
this	O
study	O
was	O
to	O
evaluate	O
whether	O
the	O
mitogen-activated	B-protein
protein	I-protein
kinase	I-protein
(	O
MAPK	B-protein
)	O
signaling	O
pathway	O
contributes	O
to	O
12-O-tetradecanoylphorbol-13-acetate	O
(	O
TPA	O
)	O
-induced	O
mononuclear	O
differentiation	O
in	O
the	O
human	B-cell_line
myeloblastic	I-cell_line
leukemia	I-cell_line
ML-1	I-cell_line
cells	I-cell_line
.	O

Upon	O
TPA	O
treatment	O
,	O
the	O
activity	O
of	O
ERK1	B-protein
and	O
ERK2	B-protein
rapidly	O
increased	O
,	O
with	O
maximal	O
induction	O
between	O
1	O
and	O
3	O
h	O
,	O
while	O
ERK2	B-protein
protein	O
levels	O
remained	O
constant	O
.	O

The	O
activity	O
of	O
JNK1	B-protein
was	O
also	O
significantly	O
induced	O
,	O
with	O
JNK1	B-protein
protein	O
levels	O
increasing	O
moderately	O
during	O
exposure	O
to	O
TPA	O
.	O

Treatment	O
of	O
cells	O
with	O
PD98059	O
,	O
a	O
specific	O
inhibitor	O
of	O
mitogen-activated	B-protein
protein	I-protein
kinase	I-protein
kinase	I-protein
(	O
MEK	B-protein
)	O
,	O
inhibited	O
TPA-induced	O
ERK2	B-protein
activity	O
.	O

Furthermore	O
,	O
PD98059	O
completely	O
blocked	O
the	O
TPA-induced	O
differentiation	O
of	O
ML-1	B-cell_line
cells	I-cell_line
,	O
as	O
assessed	O
by	O
a	O
number	O
of	O
features	O
associated	O
with	O
mononuclear	O
differentiation	O
including	O
changes	O
in	O
morphology	O
,	O
nonspecific	O
esterase	B-protein
activity	O
,	O
phagocytic	O
ability	O
,	O
NADPH	B-protein
oxidase	I-protein
activity	O
,	O
mitochondrial	O
respiration	O
,	O
and	O
c-jun	B-RNA
mRNA	I-RNA
inducibility	O
.	O

We	O
conclude	O
that	O
activation	O
of	O
the	O
MEK	B-protein
/ERK	O
signaling	O
pathway	O
is	O
necessary	O
for	O
TPA-induced	O
mononuclear	O
cell	O
differentiation	O
.	O

Glucocorticoid	B-protein
receptors	I-protein
in	O
anorexia	O
nervosa	O
and	O
Cushing	O
's	O
disease	O
.	O

BACKGROUND	O
:	O
Patients	O
with	O
anorexia	O
nervosa	O
do	O
not	O
display	O
cushingoid	O
features	O
in	O
spite	O
of	O
elevated	O
cortisol	O
plasma	O
levels	O
.	O

Whether	O
a	O
cortisol	O
resistance	O
or	O
a	O
reduced	O
availability	O
of	O
the	O
metabolic	O
substrates	O
necessary	O
to	O
develop	O
the	O
effect	O
of	O
glucocorticoids	O
is	O
responsible	O
for	O
this	O
has	O
not	O
been	O
established	O
.	O

METHODS	O
:	O
Twenty-two	O
patients	O
with	O
severe	O
restrictive	O
anorexia	O
nervosa	O
,	O
10	O
patients	O
with	O
active	O
Cushing	O
's	O
disease	O
,	O
and	O
24	O
healthy	O
volunteers	O
without	O
psychiatric	O
disorders	O
or	O
mood	O
alterations	O
were	O
investigated	O
.	O

Glucocorticoid	O
receptor	O
characteristics	O
were	O
examined	O
on	O
mononuclear	B-cell_type
leukocytes	I-cell_type
by	O
measuring	O
[	O
3H	O
]	O
dexamethasone	O
binding	O
and	O
the	O
effect	O
of	O
dexamethasone	O
on	O
[	O
3H	O
]	O
thymidine	O
incorporation	O
,	O
which	O
represents	O
an	O
index	O
of	O
DNA	O
synthesis	O
.	O

RESULTS	O
:	O
The	O
number	O
of	O
glucocorticoid	B-protein
receptors	I-protein
on	O
mononuclear	B-cell_type
leukocytes	I-cell_type
(	O
MNL	B-cell_type
)	O
was	O
comparable	O
in	O
patients	O
with	O
anorexia	O
nervosa	O
,	O
patients	O
with	O
active	O
Cushing	O
's	O
disease	O
,	O
and	O
normal	O
subjects	O
(	O
binding	O
capacity	O
3.3	O
+/-	O
0.23	O
vs.	O
3.7	O
+/-	O
0.30	O
and	O
3.5	O
+/-	O
0.20	O
fmol/10	O
(	O
6	O
)	O
cells	O
)	O
.	O

Conversely	O
,	O
glucocorticoid	B-protein
receptor	I-protein
affinity	O
was	O
significantly	O
decreased	O
in	O
anorexia	O
nervosa	O
as	O
well	O
as	O
in	O
Cushing	O
's	O
patients	O
compared	O
to	O
control	O
subjects	O
(	O
dissociation	O
constant	O
4.0	O
+/-	O
0.31	O
and	O
4.1	O
+/-	O
0.34	O
vs.	O
2.9	O
+/-	O
0.29	O
nmol/L	O
,	O
p	O
<	O
.001	O
)	O
and	O
inversely	O
correlated	O
with	O
the	O
levels	O
of	O
urinary	O
free	O
cortisol	O
in	O
both	O
groups	O
of	O
patients	O
.	O

Basal	O
[	O
3H	O
]	O
thymidine	O
incorporation	O
in	O
MNL	B-cell_type
was	O
significantly	O
reduced	O
in	O
anorexia	O
nervosa	O
as	O
well	O
as	O
in	O
Cushing	O
's	O
patients	O
compared	O
to	O
control	O
subjects	O
(	O
p	O
<	O
.001	O
)	O
and	O
was	O
diminished	O
by	O
dexamethasone	O
to	O
an	O
extent	O
similar	O
to	O
control	O
subjects	O
in	O
patients	O
with	O
anorexia	O
nervosa	O
,	O
but	O
significantly	O
(	O
p	O
<	O
.001	O
)	O
less	O
in	O
those	O
with	O
Cushing	O
's	O
disease	O
.	O

In	O
patients	O
with	O
anorexia	O
nervosa	O
,	O
the	O
incorporation	O
of	O
[	O
3H	O
]	O
thymidine	O
into	O
the	O
MNL	B-cell_type
was	O
inversely	O
correlated	O
with	O
urinary	O
free	O
cortisol	O
levels	O
.	O

CONCLUSIONS	O
:	O
These	O
data	O
indicate	O
that	O
the	O
lack	O
of	O
cushingoid	O
features	O
in	O
patients	O
with	O
anorexia	O
nervosa	O
is	O
not	O
ascribable	O
to	O
a	O
reduced	O
sensitivity	O
to	O
glucocorticoids	O
but	O
is	O
more	O
likely	O
due	O
to	O
the	O
paucity	O
of	O
metabolic	O
substrates	O
.	O

Different	O
sequence	O
requirements	O
for	O
expression	O
in	O
erythroid	B-cell_type
and	I-cell_type
megakaryocytic	I-cell_type
cells	I-cell_type
within	O
a	O
regulatory	B-DNA
element	I-DNA
upstream	O
of	O
the	O
GATA-1	B-DNA
gene	I-DNA
.	O

The	O
lineage-restricted	B-protein
transcription	I-protein
factor	I-protein
GATA-1	B-protein
is	O
required	O
for	O
differentiation	O
of	O
erythroid	B-cell_type
and	I-cell_type
megakaryocytic	I-cell_type
cells	I-cell_type
.	O

We	O
have	O
localized	O
a	O
317	O
base	O
pair	O
cis-acting	B-DNA
regulatory	I-DNA
element	I-DNA
,	O
HS	B-DNA
I	I-DNA
,	O
associated	O
with	O
a	O
hematopoietic-specific	B-DNA
DNase	I-DNA
I	I-DNA
hypersensitive	I-DNA
site	I-DNA
,	O
which	O
lies	O
approx	O
.	O

3.7	O
kilobases	O
upstream	O
of	O
the	O
murine	B-DNA
hematopoietic-specific	I-DNA
GATA-1	I-DNA
IE	I-DNA
promoter	I-DNA
.	O

HS	B-DNA
I	I-DNA
directs	O
high-level	O
expression	O
of	O
reporter	O
GATA-1/lacZ	B-DNA
genes	I-DNA
to	O
primitive	B-cell_type
and	I-cell_type
definitive	I-cell_type
erythroid	I-cell_type
cells	I-cell_type
and	O
megakaryocytes	B-cell_type
in	O
transgenic	O
mice	O
.	O

Comparative	O
sequence	O
analysis	O
of	O
HS	B-DNA
I	I-DNA
between	O
human	O
and	O
mouse	O
shows	O
approx	O
.	O

63	O
%	O
nucleotide	O
identity	O
with	O
a	O
more	O
conserved	O
core	O
of	O
169	B-DNA
base	I-DNA
pairs	I-DNA
(	O
86	O
%	O
identity	O
)	O
.	O

This	O
core	O
contains	O
a	O
GATA	B-DNA
site	I-DNA
separated	O
by	O
10	O
base	O
pairs	O
from	O
an	O
E-box	B-DNA
motif	I-DNA
.	O

The	O
composite	B-DNA
motif	I-DNA
binds	O
a	O
multi-protein	B-protein
hematopoietic-specific	I-protein
transcription	I-protein
factor	I-protein
complex	I-protein
which	O
includes	O
GATA-1	B-protein
,	O
SCL/tal-1	B-protein
,	I-protein
E2A	B-protein
,	O
Lmo2	B-protein
and	O
Ldb-1	B-protein
.	O

Point	O
mutations	O
of	O
the	O
GATA	B-DNA
site	I-DNA
abolishes	O
HS	B-DNA
I	I-DNA
function	O
,	O
whereas	O
mutation	O
of	O
the	O
E-box	B-DNA
motif	I-DNA
still	O
allows	O
reporter	O
gene	O
expression	O
in	O
both	O
lineages	O
.	O

Strict	O
dependence	O
of	O
HS	B-DNA
I	I-DNA
activity	O
on	O
a	O
GATA	B-DNA
site	I-DNA
implies	O
that	O
assembly	O
of	O
a	O
protein	O
complex	O
containing	O
a	O
GATA-factor	B-protein
,	O
presumably	O
GATA-1	B-protein
or	O
GATA-2	B-protein
,	O
is	O
critical	O
to	O
activating	O
or	O
maintaining	O
its	O
function	O
.	O

Further	O
dissection	O
of	O
the	O
317	B-DNA
base	I-DNA
pair	I-DNA
region	I-DNA
demonstrates	O
that	O
,	O
whereas	O
all	O
317	B-DNA
base	I-DNA
pairs	I-DNA
are	O
required	O
for	O
expression	O
in	O
megakaryocytes	B-cell_type
,	O
only	O
the	O
5	B-DNA
'	I-DNA
62	I-DNA
base	I-DNA
pairs	I-DNA
are	O
needed	O
for	O
erythroid-specific	O
reporter	O
expression	O
.	O

These	O
findings	O
demonstrate	O
differential	O
lineage	O
requirements	O
for	O
expression	O
within	O
the	O
HS	B-DNA
I	I-DNA
element	I-DNA
.	O

Non-steroidal	O
anti-inflammatory	O
drugs	O
inhibit	O
the	O
expression	O
of	O
cytokines	B-protein
and	O
induce	O
HSP70	B-protein
in	O
human	B-cell_type
monocytes	I-cell_type
.	O

Recent	O
studies	O
have	O
shown	O
that	O
the	O
non-steroidal	O
anti-inflammatory	O
drugs	O
(	O
NSAIDs	O
)	O
activate	O
heat	B-protein
shock	I-protein
transcription	I-protein
factor	I-protein
(	O
HSF1	B-protein
)	O
from	O
a	O
latent	B-protein
cytoplasmic	I-protein
form	I-protein
to	O
a	O
nuclear	B-protein
,	I-protein
DNA	I-protein
binding	I-protein
state	I-protein
.	O

As	O
HSF1	B-protein
can	O
function	O
as	O
both	O
an	O
activator	O
of	O
heat	B-DNA
shock	I-DNA
genes	I-DNA
and	O
a	O
repressor	O
of	O
non-heat	B-DNA
shock	I-DNA
genes	I-DNA
such	O
as	O
IL1B	O
and	O
c-	O
fos	O
,	O
we	O
have	O
examined	O
the	O
potential	O
role	O
of	O
HSF1	B-protein
in	O
the	O
effects	O
of	O
NSAIDs	O
on	O
gene	O
expression	O
in	O
a	O
human	O
monocytic	B-cell_line
cell	I-cell_line
line	I-cell_line
THP-1	I-cell_line
.	O

We	O
found	O
that	O
two	O
members	O
of	O
the	O
NSAIDs	O
,	O
sodium	O
salicylate	O
and	O
sulindac	O
repress	O
the	O
IL1B	B-DNA
promoter	I-DNA
to	O
similar	O
degree	O
to	O
heat	O
shock	O
or	O
HSF1	B-protein
overexpression	O
.	O

In	O
addition	O
,	O
sodium	O
salicylate	O
and	O
additional	O
NSAIDs	O
used	O
at	O
concentrations	O
that	O
activate	O
HSF1	B-protein
also	O
inhibited	O
the	O
expression	O
of	O
other	O
monocytic	B-DNA
genes	I-DNA
(	O
TNF-alpha	B-DNA
,	O
IL-1beta	B-DNA
,	O
IL-6	B-DNA
,	O
IL-8	B-DNA
,	O
IL-10	B-DNA
,	O
ICAM-1	B-DNA
)	O
activated	O
by	O
exposure	O
to	O
a	O
pro-inflammatory	O
stimulus	O
(	O
lipopolysaccharide	O
,	O
LPS	O
)	O
.	O

At	O
least	O
in	O
the	O
case	O
of	O
the	O
IL1B	B-DNA
promoter	I-DNA
,	O
repression	O
did	O
not	O
seem	O
to	O
involve	O
another	O
factor	O
whose	O
activity	O
is	O
affected	O
by	O
the	O
NSAIDs	O
,	O
NFkappaB	B-protein
as	O
the	O
IL1B	B-DNA
promoter	I-DNA
fragment	I-DNA
used	O
in	O
our	O
studies	O
is	O
not	O
NFkappaB	B-protein
responsive	O
and	O
binds	O
specifically	O
to	O
HSF1	B-protein
.	O

Exposure	O
to	O
NSAIDs	O
had	O
a	O
complex	O
effect	O
on	O
HSP	O
gene	O
expression	O
and	O
while	O
sulindac	O
activated	O
the	O
stress	O
responsive	O
HSP70B	B-DNA
promoter	I-DNA
,	O
sodium	O
salicylate	O
did	O
not	O
.	O

In	O
addition	O
,	O
only	O
a	O
subset	O
of	O
the	O
NSAIDs	O
induced	O
HSP70	B-RNA
mRNA	I-RNA
species	I-RNA
.	O

These	O
findings	O
reflect	O
the	O
properties	O
of	O
HSF1	B-protein
which	O
can	O
be	O
activated	O
to	O
at	O
least	O
two	O
DNA	B-protein
binding	I-protein
forms	I-protein
only	O
one	O
of	O
which	O
activates	O
heat	B-DNA
shock	I-DNA
promoters	I-DNA
and	O
suggest	O
that	O
individual	O
NSAID	O
family	O
members	O
may	O
differentially	O
induce	O
one	O
or	O
other	O
of	O
these	O
forms	O
.	O

Overall	O
therefore	O
,	O
exposure	O
to	O
NSAIDs	O
leads	O
to	O
a	O
profound	O
switch	O
in	O
gene	O
expression	O
in	O
monocytic	B-cell_type
cells	I-cell_type
,	O
with	O
suppression	O
of	O
genes	O
involved	O
in	O
macrophage	O
activation	O
and	O
induction	O
of	O
stress	B-DNA
genes	I-DNA
and	O
HSF1	B-protein
appears	O
to	O
play	O
a	O
regulatory	O
role	O
in	O
these	O
effects	O
.	O

Copyright	O
1999	O
Academic	O
Press	O
.	O

Immortalization	O
of	O
CD4	B-cell_type
(	I-cell_type
+	I-cell_type
)	I-cell_type
and	I-cell_type
CD8	I-cell_type
(	I-cell_type
+	I-cell_type
)	I-cell_type
T	I-cell_type
lymphocytes	I-cell_type
by	O
human	O
T-cell	O
leukemia	O
virus	O
type	O
1	O
Tax	B-protein
mutants	I-protein
expressed	O
in	O
a	O
functional	B-cell_line
molecular	I-cell_line
clone	I-cell_line
.	O

The	O
human	B-protein
T-cell	I-protein
leukemia	I-protein
virus	I-protein
type	I-protein
1	I-protein
(	I-protein
HTLV-1	I-protein
)	I-protein
transcriptional	I-protein
trans-activator	I-protein
Tax	B-protein
has	O
been	O
demonstrated	O
to	O
have	O
transforming	O
activity	O
in	O
multiple	B-cell_line
cell	I-cell_line
culture	I-cell_line
and	O
transgenic-mouse	O
models	O
.	O

In	O
addition	O
to	O
activating	O
transcription	O
from	O
the	O
viral	B-DNA
long	I-DNA
terminal	I-DNA
repeat	I-DNA
(	O
LTR	B-DNA
)	O
through	O
the	O
cyclic	B-protein
AMP	I-protein
response	I-protein
element	I-protein
binding	I-protein
protein/activating	I-protein
transcription	I-protein
factor	I-protein
(	I-protein
CREB/ATF	I-protein
)	I-protein
family	I-protein
of	O
transcription	B-protein
factors	I-protein
,	O
Tax	B-protein
activates	O
the	O
expression	O
of	O
multiple	B-DNA
cellular	I-DNA
promoters	I-DNA
through	O
the	O
NF-kappaB	B-protein
pathway	O
of	O
transcriptional	O
activation	O
.	O

The	O
Tax	B-protein
mutants	I-protein
M22	B-protein
and	O
M47	B-protein
have	O
previously	O
been	O
demonstrated	O
to	O
selectively	O
abrogate	O
the	O
ability	O
of	O
Tax	B-protein
to	O
activate	O
transcription	O
through	O
the	O
NF-kappaB	O
or	O
CREB/ATF	O
pathway	O
,	O
respectively	O
.	O

These	O
mutations	O
were	O
introduced	O
in	O
the	O
tax	B-DNA
gene	I-DNA
of	O
the	O
ACH	B-DNA
functional	I-DNA
molecular	I-DNA
clone	I-DNA
of	O
HTLV-1	O
,	O
and	O
virus	O
produced	O
from	O
the	O
mutant	B-DNA
ACH	I-DNA
clones	I-DNA
was	O
examined	O
for	O
the	O
ability	O
to	O
replicate	O
and	O
immortalize	O
primary	B-cell_type
human	I-cell_type
lymphocytes	I-cell_type
.	O

While	O
virus	O
derived	O
from	O
the	O
clone	O
containing	O
the	O
M47	B-protein
mutation	O
retained	O
the	O
ability	O
to	O
immortalize	O
T	B-cell_type
lymphocytes	I-cell_type
,	O
the	O
M22	B-protein
mutant	O
lost	O
the	O
ability	O
to	O
immortalize	O
infected	B-cell_type
cells	I-cell_type
.	O

These	O
results	O
indicate	O
that	O
activation	O
of	O
the	O
CREB/ATF	B-protein
pathway	O
by	O
Tax	B-protein
is	O
dispensable	O
for	O
the	O
immortalization	O
of	O
T	B-cell_type
cells	I-cell_type
by	O
HTLV-1	O
,	O
whereas	O
activation	O
of	O
the	O
NF-kappaB	B-protein
pathway	O
may	O
be	O
critical	O
.	O

Fibroblast	B-protein
growth	I-protein
factor-1	I-protein
(	O
FGF-1	B-protein
)	O
enhances	O
IL-2	B-protein
production	O
and	O
nuclear	O
translocation	O
of	O
NF-kappaB	B-protein
in	O
FGF	B-cell_line
receptor-bearing	I-cell_line
Jurkat	I-cell_line
T	I-cell_line
cells	I-cell_line
.	O

Fibroblast	B-protein
growth	I-protein
factors	I-protein
(	O
FGFs	B-protein
)	O
are	O
heparin-binding	B-protein
proteins	I-protein
crucial	O
to	O
embryogenesis	O
,	O
angiogenesis	O
,	O
and	O
wound	O
healing	O
.	O

FGF-1	B-protein
is	O
abundantly	O
expressed	O
in	O
the	O
synovium	O
in	O
rheumatoid	O
arthritis	O
and	O
in	O
rejecting	O
allografts	O
,	O
sites	O
of	O
chronic	O
immune-mediated	O
inflammation	O
.	O

The	O
frequency	O
of	O
FGF-1	B-protein
-responsive	O
T	B-cell_type
cells	I-cell_type
is	O
increased	O
in	O
the	O
peripheral	O
blood	O
of	O
these	O
disorders	O
,	O
and	O
a	O
high	O
percentage	O
of	O
infiltrating	B-cell_type
T	I-cell_type
cells	I-cell_type
in	O
rheumatoid	O
arthritis	O
synovium	O
express	O
receptors	O
for	O
FGF-1	B-protein
.	O

To	O
understand	O
the	O
action	O
of	O
FGF-1	B-protein
in	O
T	B-cell_type
cells	I-cell_type
,	O
studies	O
were	O
initiated	O
in	O
Jurkat	B-cell_line
T	I-cell_line
cells	I-cell_line
that	O
express	O
the	O
signaling	O
isoform	O
of	O
FGF	B-protein
receptor-1	I-protein
.	O

These	O
experiments	O
show	O
that	O
FGF-1	B-protein
stimulation	O
of	O
Jurkat	B-cell_line
T	I-cell_line
cells	I-cell_line
provides	O
a	O
second	O
signal	O
that	O
augments	O
TCR-mediated	O
IL-2	B-protein
production	O
.	O

Analogous	O
to	O
costimulation	O
via	O
CD28	B-protein
,	O
this	O
activity	O
is	O
mediated	O
through	O
activation	O
of	O
Rel/kappaB	B-protein
,	O
a	O
family	O
of	O
transcription	B-protein
factors	I-protein
known	O
to	O
regulate	O
IL-2	B-protein
and	O
other	O
activation-inducible	B-protein
proteins	I-protein
.	O

FGF-1	B-protein
alone	O
induces	O
modest	O
nuclear	O
translocation	O
of	O
kappaB-binding	B-protein
proteins	I-protein
,	O
and	O
this	O
translocation	O
is	O
enhanced	O
by	O
the	O
combination	O
of	O
anti-CD3	B-protein
and	O
FGF-1	B-protein
.	O

This	O
NF-kappaB	B-protein
binding	I-protein
complex	I-protein
is	O
composed	O
of	O
transcriptionally	B-protein
active	I-protein
p65	I-protein
(	I-protein
RelA	I-protein
)	I-protein
/p50	I-protein
heterodimers	I-protein
and	O
results	O
primarily	O
from	O
the	O
targeted	O
degradation	O
of	O
IkappaB-alpha	B-protein
,	O
an	O
inhibitor	O
that	O
sequesters	O
Rel/kappaB	B-protein
in	O
the	O
cytoplasm	O
.	O

These	O
data	O
are	O
the	O
first	O
to	O
show	O
a	O
connection	O
between	O
FGF-1	B-protein
signaling	O
and	O
NF-kappaB	B-protein
activation	O
outside	O
of	O
embryonic	O
development	O
.	O

The	O
signaling	O
events	O
that	O
link	O
FGF	B-protein
receptor-1	I-protein
engagement	O
and	O
NF-kappaB	B-protein
activation	O
in	O
Jurkat	B-cell_line
are	O
probably	O
distinct	O
from	O
the	O
CD28	B-protein
costimulation	O
pathway	O
,	O
since	O
FGF-1	B-protein
-induced	O
Rel/kappaB	B-protein
binding	I-protein
proteins	I-protein
do	O
not	O
contain	O
significant	O
levels	O
of	O
c-Rel	B-protein
and	O
are	O
not	O
identical	O
with	O
the	O
CD28	B-protein
response	I-protein
complex	I-protein
.	O

Escape	O
of	O
human	O
cytomegalovirus	O
from	O
HLA-DR	B-protein
-restricted	O
CD4	O
(	O
+	O
)	O
T-cell	O
response	O
is	O
mediated	O
by	O
repression	O
of	O
gamma	B-protein
interferon	I-protein
-induced	O
class	B-protein
II	I-protein
transactivator	I-protein
expression	O
.	O

Human	O
cytomegalovirus	O
(	O
HCMV	O
)	O
,	O
a	O
betaherpesvirus	O
,	O
is	O
a	O
pathogen	O
which	O
escapes	O
immune	O
recognition	O
through	O
various	O
mechanisms	O
.	O

In	O
this	O
paper	O
,	O
we	O
show	O
that	O
HCMV	O
down	O
regulates	O
gamma	O
interferon	O
(	O
IFN-gamma	B-protein
)	O
-induced	O
HLA-DR	B-protein
expression	O
in	O
U373	B-cell_line
MG	I-cell_line
astrocytoma	I-cell_line
cells	I-cell_line
due	O
to	O
a	O
defect	O
downstream	O
of	O
STAT1	B-protein
phosphorylation	O
and	O
nuclear	O
translocation	O
.	O

Repression	O
of	O
class	O
II	O
transactivator	O
(	O
CIITA	B-DNA
)	O
mRNA	O
expression	O
is	O
detected	O
within	O
the	O
first	O
hours	O
of	O
IFN-gamma	B-protein
-HCMV	O
coincubation	O
and	O
results	O
in	O
the	O
absence	O
of	O
HLA-DR	B-protein
synthesis	O
.	O

This	O
defect	O
leads	O
to	O
the	O
absence	O
of	O
presentation	O
of	O
the	O
major	B-protein
immediate-early	I-protein
protein	I-protein
IE1	B-protein
to	O
specific	O
CD4	B-cell_line
(	I-cell_line
+	I-cell_line
)	I-cell_line
T-cell	I-cell_line
clones	I-cell_line
when	O
U373	B-cell_line
MG	I-cell_line
cells	I-cell_line
,	O
used	O
as	O
antigen-presenting	B-cell_type
cells	I-cell_type
,	O
are	O
treated	O
with	O
IFN-gamma	B-protein
plus	O
HCMV	O
.	O

However	O
,	O
presentation	O
of	O
endogenously	O
synthesized	O
IE1	B-protein
can	O
be	O
restored	O
when	O
U373	B-cell_line
MG	I-cell_line
cells	I-cell_line
are	O
transfected	O
with	O
CIITA	B-DNA
prior	O
to	O
infection	O
with	O
HCMV	O
.	O

Altogether	O
,	O
the	O
data	O
indicate	O
that	O
the	O
defect	O
induced	O
by	O
HCMV	O
resides	O
in	O
the	O
activation	O
of	O
the	O
IFN-gamma-responsive	B-DNA
promoter	I-DNA
of	O
CIITA	B-DNA
.	O

This	O
is	O
the	O
first	O
demonstration	O
of	O
a	O
viral	O
inhibition	O
of	O
CIITA	B-DNA
expression	O
.	O

3-deazaadenosine	O
,	O
a	O
S-adenosylhomocysteine	B-protein
hydrolase	I-protein
inhibitor	O
,	O
has	O
dual	O
effects	O
on	O
NF-kappaB	B-protein
regulation	O
.	O

Inhibition	O
of	O
NF-kappaB	B-protein
transcriptional	O
activity	O
and	O
promotion	O
of	O
IkappaBalpha	B-protein
degradation	O
.	O

Previously	O
we	O
reported	O
that	O
3-deazaadenosine	O
(	O
DZA	O
)	O
,	O
a	O
potent	O
inhibitor	O
and	O
substrate	O
for	O
S-adenosylhomocysteine	B-protein
hydrolase	I-protein
inhibits	O
bacterial	O
lipopolysaccharide-induced	O
transcription	O
of	O
tumor	B-protein
necrosis	I-protein
factor-alpha	I-protein
and	O
interleukin-1beta	B-protein
in	O
mouse	B-cell_line
macrophage	I-cell_line
RAW	I-cell_line
264.7	I-cell_line
cells	I-cell_line
.	O

In	O
this	O
study	O
,	O
we	O
demonstrate	O
the	O
effects	O
of	O
DZA	O
on	O
nuclear	B-protein
factor-kappaB	I-protein
(	O
NF-kappaB	B-protein
)	O
regulation	O
.	O

DZA	O
inhibits	O
the	O
transcriptional	O
activity	O
of	O
NF-kappaB	B-protein
through	O
the	O
hindrance	O
of	O
p65	B-protein
(	O
Rel-A	B-protein
)	O
phosphorylation	O
without	O
reduction	O
of	O
its	O
nuclear	O
translocation	O
and	O
DNA	O
binding	O
activity	O
.	O

The	O
inhibitory	O
effect	O
of	O
DZA	O
on	O
NF-kappaB	B-protein
transcriptional	O
activity	O
is	O
potentiated	O
by	O
the	O
addition	O
of	O
homocysteine	O
.	O

Taken	O
together	O
,	O
DZA	O
promotes	O
the	O
proteolytic	O
degradation	O
of	O
IkappaBalpha	B-protein
,	O
but	O
not	O
IkappaBbeta	B-protein
,	O
resulting	O
in	O
an	O
increase	O
of	O
DNA	O
binding	O
activity	O
of	O
NF-kappaB	B-protein
in	O
the	O
nucleus	O
in	O
the	O
absence	O
of	O
its	O
transcriptional	O
activity	O
in	O
RAW	B-cell_line
264.7	I-cell_line
cells	I-cell_line
.	O

The	O
reduction	O
of	O
IkappaBalpha	B-protein
by	O
DZA	O
is	O
neither	O
involved	O
in	O
IkappaB	B-protein
kinase	I-protein
complex	I-protein
activation	O
nor	O
modulated	O
by	O
the	O
addition	O
of	O
homocysteine	O
.	O

This	O
study	O
strongly	O
suggests	O
that	O
DZA	O
may	O
be	O
a	O
potent	O
drug	O
for	O
the	O
treatment	O
of	O
diseases	O
in	O
which	O
NF-kappaB	B-protein
plays	O
a	O
central	O
pathogenic	O
role	O
,	O
as	O
well	O
as	O
a	O
useful	O
tool	O
for	O
studying	O
the	O
regulation	O
and	O
physiological	O
functions	O
of	O
NF-kappaB	B-protein
.	O

The	O
role	O
of	O
gamma/delta	B-cell_type
T	I-cell_type
cell	I-cell_type
receptor	I-cell_type
positive	I-cell_type
cells	I-cell_type
in	O
pregnancy	O
.	O

PROBLEM	O
:	O
Due	O
to	O
the	O
lack	O
of	O
classical	B-protein
HLA	I-protein
antigens	I-protein
on	O
the	O
trophoblast	O
,	O
fetal	B-protein
antigens	I-protein
are	O
possibly	O
presented	O
in	O
a	O
non	O
major	B-protein
histocompatibility	I-protein
complex	I-protein
(	O
MHC	B-protein
)	O
restricted	O
way	O
.	O

Decidual	B-cell_type
gammadelta	I-cell_type
T	I-cell_type
cells	I-cell_type
,	O
which	O
significantly	O
increase	O
in	O
number	O
during	O
pregnancy	O
,	O
might	O
play	O
a	O
role	O
in	O
recognition	O
of	O
fetal	B-protein
antigens	I-protein
and	O
also	O
in	O
determining	O
the	O
quality	O
of	O
the	O
response	O
to	O
these	O
antigens	B-protein
.	O

Our	O
study	O
was	O
aimed	O
at	O
investigating	O
the	O
role	O
of	O
this	O
cell	O
population	O
in	O
progesterone-dependent	O
immunomodulation	O
.	O

METHOD	O
OF	O
STUDY	O
:	O
Peripheral	B-cell_type
lymphocytes	I-cell_type
from	O
healthy	O
pregnant	O
women	O
and	O
from	O
habitual	O
aborters	O
were	O
tested	O
by	O
immunocytochemistry	O
for	O
the	O
presence	O
of	O
gamma/delta	O
T	O
cell	O
receptor	O
(	O
TCR	O
)	O
and	O
progesterone	O
receptor	O
.	O

To	O
investigate	O
the	O
effect	O
of	O
treatment	O
with	O
a	O
pan	O
anti	B-protein
gamma/delta	I-protein
antibody	I-protein
,	O
lymphocytes	B-cell_type
were	O
incubated	O
for	O
3	O
hr	O
with	O
the	O
antibody	O
,	O
and	O
then	O
interleukin	B-protein
(	I-protein
IL	I-protein
)	I-protein
-10	I-protein
,	O
IL-12	B-protein
and	O
progesterone-induced	B-protein
blocking	I-protein
factor	I-protein
(	O
PIBF	B-protein
)	O
expression	O
(	O
by	O
immuno-cytochemistry	O
)	O
as	O
well	O
as	O
natural	B-cell_type
killer	I-cell_type
(	I-cell_type
NK	I-cell_type
)	I-cell_type
cell	I-cell_type
activity	O
were	O
determined	O
.	O

RESULTS	O
:	O
In	O
peripheral	O
blood	O
of	O
healthy	O
pregnant	O
women	O
the	O
percentage	O
of	O
gamma/delta	B-cell_type
TCR+	I-cell_type
cells	I-cell_type
was	O
significantly	O
higher	O
(	O
P	O
<	O
0.001	O
)	O
than	O
in	O
that	O
of	O
recurrent	O
aborters	O
or	O
of	O
non-pregnant	O
individuals	O
.	O

Ninety-seven	O
percent	O
of	O
gamma/delta	B-cell_type
TCR+	I-cell_type
pregnancy	I-cell_type
lymphocytes	I-cell_type
expressed	O
progesterone	B-protein
receptor	I-protein
.	O

Binding	O
of	O
a	O
specific	O
antibody	O
to	O
the	O
gamma/delta	O
TCR	O
inhibited	O
PIBF	O
-as	O
well	O
as	O
IL-10	O
production	O
,	O
whereas	O
it	O
increased	O
NK	O
activity	O
and	O
IL-12	B-protein
expression	O
.	O

CONCLUSIONS	O
:	O
These	O
data	O
suggest	O
the	O
role	O
of	O
gamma/delta	B-cell_type
TCR-bearing	I-cell_type
lymphocytes	I-cell_type
in	O
progesterone-dependent	O
immunomodulation	O
.	O

Monocyte	O
adhesion	O
and	O
spreading	O
on	O
human	B-cell_type
endothelial	I-cell_type
cells	I-cell_type
is	O
dependent	O
on	O
Rho	B-protein
-regulated	O
receptor	O
clustering	O
.	O

The	O
GTPase	B-protein
Rho	B-protein
is	O
known	O
to	O
mediate	O
the	O
assembly	O
of	O
integrin-containing	O
focal	O
adhesions	O
and	O
actin	O
stress	O
fibers	O
.	O

Here	O
,	O
we	O
investigate	O
the	O
role	O
of	O
Rho	B-protein
in	O
regulating	O
the	O
distribution	O
of	O
the	O
monocyte-binding	B-protein
receptors	I-protein
E-selectin	B-protein
,	O
ICAM-1	B-protein
,	O
and	O
VCAM-1	B-protein
in	O
human	B-cell_type
endothelial	I-cell_type
cells	I-cell_type
.	O

Inhibition	O
of	O
Rho	B-protein
activity	O
with	O
C3	B-protein
transferase	I-protein
or	O
N19RhoA	B-protein
,	O
a	O
dominant	O
negative	O
RhoA	B-protein
mutant	I-protein
,	O
reduced	O
the	O
adhesion	O
of	O
monocytes	B-cell_type
to	O
activated	O
endothelial	B-cell_type
cells	I-cell_type
and	O
inhibited	O
their	O
spreading	O
.	O

Similar	O
effects	O
were	O
observed	O
after	O
pretreatment	O
of	O
endothelial	B-cell_type
cells	I-cell_type
with	O
cytochalasin	O
D	O
.	O

In	O
contrast	O
,	O
dominant	B-protein
negative	I-protein
Rac	I-protein
and	I-protein
Cdc42	I-protein
proteins	I-protein
did	O
not	O
affect	O
monocyte	O
adhesion	O
or	O
spreading	O
.	O

C3	O
transferase	O
and	O
cytochalasin	O
D	O
did	O
not	O
alter	O
the	O
expression	O
levels	O
of	O
monocyte-binding	B-protein
receptors	I-protein
on	O
endothelial	B-cell_type
cells	I-cell_type
,	O
but	O
did	O
inhibit	O
clustering	O
of	O
E-selectin	B-protein
,	O
ICAM-1	B-protein
,	O
and	O
VCAM-1	B-protein
on	O
the	O
cell	O
surface	O
induced	O
by	O
monocyte	O
adhesion	O
or	O
cross-linking	B-protein
antibodies	I-protein
.	O

Similarly	O
,	O
N19RhoA	B-protein
inhibited	O
receptor	O
clustering	O
.	O

Monocyte	O
adhesion	O
and	O
receptor	O
cross-linking	O
induced	O
stress	O
fiber	O
assembly	O
,	O
and	O
inhibitors	O
of	O
myosin	B-protein
light	I-protein
chain	I-protein
kinase	I-protein
prevented	O
this	O
response	O
but	O
did	O
not	O
affect	O
receptor	O
clustering	O
.	O

Finally	O
,	O
receptor	O
clusters	O
colocalized	O
with	O
ezrin/moesin/radixin	B-protein
proteins	I-protein
.	O

These	O
results	O
suggest	O
that	O
Rho	B-protein
is	O
required	O
in	O
endothelial	B-cell_type
cells	I-cell_type
for	O
the	O
assembly	O
of	O
stable	O
adhesions	O
with	O
monocytes	B-cell_type
via	O
the	O
clustering	O
of	O
monocyte-binding	B-protein
receptors	I-protein
and	O
their	O
association	O
with	O
the	O
actin	O
cytoskeleton	O
,	O
independent	O
of	O
stress	O
fiber	O
formation	O
.	O

Selection	O
of	O
the	O
T	O
cell	O
repertoire	O
.	O

Advances	O
in	O
gene	O
technology	O
have	O
allowed	O
the	O
manipulation	O
of	O
molecular	O
interactions	O
that	O
shape	O
the	O
T	O
cell	O
repertoire	O
.	O

Although	O
recognized	O
as	O
fundamental	O
aspects	O
of	O
T	B-cell_type
lymphocyte	I-cell_type
development	O
,	O
only	O
recently	O
have	O
the	O
mechanisms	O
governing	O
positive	O
and	O
negative	O
selection	O
been	O
examined	O
at	O
a	O
molecular	O
level	O
.	O

Positive	O
selection	O
refers	O
to	O
the	O
active	O
process	O
of	O
rescuing	O
MHC-restricted	B-cell_type
thymocytes	I-cell_type
from	O
programmed	O
cell	O
death	O
.	O

Negative	O
selection	O
refers	O
to	O
the	O
deletion	O
or	O
inactivation	O
of	O
potentially	O
autoreactive	B-cell_type
thymocytes	I-cell_type
.	O

This	O
review	O
focuses	O
on	O
interactions	O
during	O
thymocyte	B-cell_type
maturation	O
that	O
define	O
the	O
T	O
cell	O
repertoire	O
,	O
with	O
an	O
emphasis	O
placed	O
on	O
current	O
literature	O
within	O
this	O
field	O
.	O

CD28	B-protein
costimulation	O
augments	O
IL-2	B-protein
secretion	O
of	O
activated	O
lamina	O
propria	O
T	O
cells	O
by	O
increasing	O
mRNA	O
stability	O
without	O
enhancing	O
IL-2	B-protein
gene	O
transactivation	O
.	O

The	O
pathways	O
leading	O
to	O
activation	O
in	O
lamina	B-cell_type
propria	I-cell_type
(	I-cell_type
LP	I-cell_type
)	I-cell_type
T	I-cell_type
cells	I-cell_type
are	O
different	O
from	O
peripheral	B-cell_type
T	I-cell_type
cells	I-cell_type
.	O

LP	B-cell_type
T	I-cell_type
cells	I-cell_type
exhibit	O
enhanced	O
IL-2	B-protein
secretion	O
when	O
activated	O
through	O
the	O
CD2	B-protein
pathway	O
.	O

Coligation	O
of	O
CD28	B-protein
leads	O
to	O
synergistic	O
enhancement	O
of	O
IL-2	B-protein
secretion	O
.	O

Previous	O
studies	O
have	O
characterized	O
the	O
CD28	B-protein
augmentation	O
of	O
TCR	B-protein
-mediated	O
signaling	O
in	O
peripheral	B-cell_type
blood	I-cell_type
T	I-cell_type
cells	I-cell_type
through	O
transcriptional	O
activation	O
of	O
an	O
IL-2	B-protein
promoter	O
CD28	B-DNA
response	I-DNA
element	I-DNA
(	O
CD28RE	B-DNA
)	O
,	O
along	O
with	O
enhanced	O
mRNA	O
stability	O
.	O

This	O
study	O
characterized	O
molecular	O
events	O
involved	O
in	O
CD28	B-protein
costimulation	O
of	O
IL-2	B-protein
production	O
in	O
LP	B-cell_type
mononuclear	I-cell_type
cells	I-cell_type
(	I-cell_type
LPMC	I-cell_type
)	I-cell_type
.	O

LPMC	B-cell_type
exhibited	O
increased	O
IL-2	B-protein
production	O
in	O
response	O
to	O
CD28	B-protein
costimulation	O
,	O
compared	O
with	O
cells	O
activated	O
through	O
CD2	B-protein
alone	O
.	O

IL-2	B-protein
secretion	O
was	O
paralleled	O
by	O
increased	O
expression	O
of	O
IL-2	B-RNA
mRNA	I-RNA
,	O
resulting	O
from	O
enhanced	O
IL-2	B-RNA
mRNA	I-RNA
stability	O
.	O

In	O
contrast	O
to	O
transcriptional	O
activation	O
in	O
PBMC	B-cell_type
,	O
EMSA	O
revealed	O
that	O
CD28	B-protein
coligation	O
of	O
CD2-activated	B-cell_type
LPMC	I-cell_type
does	O
not	O
result	O
in	O
increased	O
binding	O
of	O
trans-factors	O
to	O
the	O
CD28RE	B-DNA
,	O
nor	O
did	O
Western	O
blots	O
detect	O
changes	O
in	O
I-kappaBalpha	B-protein
or	O
I-kappaBbeta	B-protein
levels	O
following	O
CD28	B-protein
coligation	O
.	O

Furthermore	O
,	O
CD28	B-protein
coligation	O
fails	O
to	O
enhance	O
IL-2	B-DNA
promoter-reporter	I-DNA
or	O
RE/AP	B-protein
construct	O
expression	O
in	O
CD2-activated	B-cell_type
LPMC	I-cell_type
.	O

The	O
results	O
reported	O
herein	O
indicate	O
that	O
the	O
molecular	O
mechanisms	O
involved	O
in	O
CD28	B-protein
cosignaling	O
and	O
regulation	O
of	O
IL-2	B-protein
secretion	O
in	O
LP	B-cell_type
T	I-cell_type
cells	I-cell_type
are	O
unique	O
to	O
that	O
compartment	O
and	O
differ	O
from	O
those	O
seen	O
in	O
peripheral	B-cell_type
blood	I-cell_type
T	I-cell_type
cells	I-cell_type
.	O

These	O
observations	O
suggest	O
a	O
biological	O
significance	O
for	O
different	O
mechanisms	O
of	O
IL-2	B-protein
activation	O
in	O
initiation	O
and	O
maintenance	O
of	O
the	O
cytokine	B-protein
repertoire	I-protein
found	O
in	O
the	O
mucosa	O
.	O

Expression	O
of	O
Th1	B-protein
and	I-protein
Th2	I-protein
type	I-protein
cytokines	I-protein
responding	O
to	O
HBsAg	B-protein
and	O
HBxAg	B-protein
in	O
chronic	O
hepatitis	O
B	O
patients	O
.	O

The	O
cytokine	B-protein
pattern	I-protein
on	O
viral	O
antigen	O
recognition	O
is	O
believed	O
to	O
exert	O
a	O
profound	O
influence	O
on	O
the	O
resolution	O
of	O
viral	O
infections	O
and	O
viral	O
clearance	O
.	O

This	O
study	O
was	O
initiated	O
to	O
investigate	O
whether	O
a	O
cytokine	B-protein
imbalance	O
oriented	O
toward	O
Th2	O
type	O
response	O
plays	O
a	O
role	O
in	O
chronic	O
hepatitis	O
B	O
.	O

Cytokine	B-protein
profiles	I-protein
of	O
peripheral	B-cell_type
blood	I-cell_type
mononuclear	I-cell_type
cells	I-cell_type
associated	O
with	O
chronic	O
hepatitis	O
B	O
were	O
analysed	O
by	O
RT-PCR	O
.	O

Upon	O
HBsAg	B-protein
stimulation	O
,	O
expression	O
of	O
IFN-gamma	B-protein
,	O
IL-2	B-protein
,	O
IL-4	B-protein
,	O
and	O
IL-10	B-protein
was	O
detected	O
in	O
41	O
%	O
,	O
8	O
%	O
,	O
41	O
%	O
,	O
and	O
50	O
%	O
of	O
the	O
patients	O
,	O
respectively	O
.	O

Among	O
these	O
cytokines	B-protein
,	O
the	O
expression	O
of	O
IFN-gamma	B-protein
was	O
associated	O
with	O
high	O
levels	O
of	O
serum	B-protein
AST/ALT	I-protein
.	O

However	O
,	O
we	O
could	O
not	O
prove	O
that	O
Th2	B-protein
type	I-protein
cytokines	I-protein
had	O
a	O
protective	O
effect	O
on	O
hepatocytes	B-cell_type
.	O

Upon	O
HBxAg	B-protein
stimulation	O
,	O
there	O
was	O
no	O
recognizable	O
association	O
of	O
cytokine	B-protein
patterns	I-protein
with	O
AST/ALT	O
levels	O
.	O

In	O
conclusion	O
,	O
production	O
of	O
a	O
Th1	B-protein
cytokine	I-protein
,	O
IFN-gamma	B-protein
,	O
by	O
HBsAg	B-protein
-reactive	O
cells	O
was	O
associated	O
with	O
hepatocyte	O
damage	O
in	O
chronic	O
hepatitis	O
B	O
,	O
while	O
no	O
counteracting	O
effect	O
of	O
Th2	B-protein
cytokines	I-protein
produced	O
by	O
those	O
cells	O
was	O
observed	O
.	O

Apoptosis	O
and	O
growth	O
inhibition	O
in	O
malignant	B-cell_type
lymphocytes	I-cell_type
after	O
treatment	O
with	O
arsenic	O
trioxide	O
at	O
clinically	O
achievable	O
concentrations	O
[	O
see	O
comments	O
]	O

BACKGROUND	O
:	O
Arsenic	O
trioxide	O
(	O
As2O3	O
)	O
can	O
induce	O
clinical	O
remission	O
in	O
patients	O
with	O
acute	O
promyelocytic	O
leukemia	O
via	O
induction	O
of	O
differentiation	O
and	O
programmed	O
cell	O
death	O
(	O
apoptosis	O
)	O
.	O

We	O
investigated	O
the	O
effects	O
of	O
As2O3	O
on	O
a	O
panel	O
of	O
malignant	B-cell_type
lymphocytes	I-cell_type
to	O
determine	O
whether	O
growth-inhibitory	O
and	O
apoptotic	O
effects	O
of	O
As2O3	O
can	O
be	O
observed	O
in	O
these	O
cells	O
at	O
clinically	O
achievable	O
concentrations	O
.	O

METHODS	O
:	O
Eight	O
malignant	B-cell_line
lymphocytic	I-cell_line
cell	I-cell_line
lines	I-cell_line
and	O
primary	B-cell_line
cultures	I-cell_line
of	O
lymphocytic	B-cell_type
leukemia	I-cell_type
and	I-cell_type
lymphoma	I-cell_type
cells	I-cell_type
were	O
treated	O
with	O
As2O3	O
,	O
with	O
or	O
without	O
dithiothreitol	O
(	O
DTT	O
)	O
or	O
buthionine	O
sulfoximine	O
(	O
BSO	O
)	O
(	O
an	O
inhibitor	O
of	O
glutathione	O
synthesis	O
)	O
.	O

Apoptosis	O
was	O
assessed	O
by	O
cell	O
morphology	O
,	O
flow	O
cytometry	O
,	O
annexin	O
V	O
protein	O
level	O
,	O
and	O
terminal	B-protein
deoxynucleotidyl	I-protein
transferase	I-protein
labeling	O
of	O
DNA	B-DNA
fragments	I-DNA
.	O

Cellular	O
proliferation	O
was	O
determined	O
by	O
5-bromo-2'-deoxyuridine	O
incorporation	O
into	O
DNA	O
and	O
flow	O
cytometry	O
and	O
by	O
use	O
of	O
a	O
mitotic	O
arrest	O
assay	O
.	O

Mitochondrial	O
transmembrane	O
potential	O
(	O
delta	O
psi	O
(	O
m	O
)	O
)	O
was	O
measured	O
by	O
means	O
of	O
rhodamine	O
123	O
staining	O
and	O
flow	O
cytometry	O
.	O

Protein	O
expression	O
was	O
assessed	O
by	O
western	O
blot	O
analysis	O
or	O
immunofluorescence	O
.	O

RESULTS	O
:	O
Therapeutic	O
concentrations	O
of	O
As2O3	O
(	O
1-2	O
microM	O
)	O
had	O
dual	O
effects	O
on	O
malignant	B-cell_type
lymphocytes	I-cell_type
:	O
1	O
)	O
inhibition	O
of	O
growth	O
through	O
adenosine	O
triphosphate	O
(	O
ATP	O
)	O
depletion	O
and	O
prolongation	O
of	O
cell	O
cycle	O
time	O
and	O
2	O
)	O
induction	O
of	O
apoptosis	O
.	O

As2O3-induced	O
apoptosis	O
was	O
preceded	O
by	O
delta	O
psi	O
(	O
m	O
)	O
collapse	O
.	O

DTT	O
antagonized	O
and	O
BSO	O
enhanced	O
As2O3-induced	O
ATP	O
depletion	O
,	O
delta	O
psi	O
(	O
m	O
)	O
collapse	O
,	O
and	O
apoptosis	O
.	O

Caspase-3	B-protein
activation	O
,	O
usually	O
resulting	O
from	O
delta	O
psi	O
(	O
m	O
)	O
collapse	O
,	O
was	O
not	O
always	O
associated	O
with	O
As2O3-induced	O
apoptosis	O
.	O

As2O3	O
induced	O
PML	O
(	O
promyelocytic	O
leukemia	O
)	O
protein	O
degradation	O
but	O
did	O
not	O
modulate	O
expression	O
of	O
cell	B-protein
cycle-related	I-protein
proteins	I-protein
,	O
including	O
c-myc	B-protein
,	O
retinoblastoma	B-protein
protein	I-protein
,	O
cyclin-dependent	B-protein
kinase	I-protein
4	I-protein
,	O
cyclin	B-protein
D1	I-protein
,	O
and	O
p53	B-protein
,	O
or	O
expression	O
of	O
differentiation-related	B-protein
antigens	I-protein
.	O

CONCLUSIONS	O
:	O
Substantial	O
growth	O
inhibition	O
and	O
apoptosis	O
without	O
evidence	O
of	O
differentiation	O
were	O
induced	O
in	O
most	O
malignant	B-cell_type
lymphocytic	I-cell_type
cells	I-cell_type
treated	O
with	O
1-2	O
microM	O
As2O3	O
.	O

As2O3	O
may	O
prove	O
useful	O
in	O
the	O
treatment	O
of	O
malignant	O
lymphoproliferative	O
disorders	O
.	O

Control	O
of	O
cell	O
cycle	O
entry	O
and	O
apoptosis	O
in	O
B	B-cell_type
lymphocytes	I-cell_type
infected	O
by	O
Epstein-Barr	O
virus	O
.	O

Infection	O
of	O
human	B-cell_type
B	I-cell_type
cells	I-cell_type
with	O
Epstein-Barr	O
virus	O
(	O
EBV	O
)	O
results	O
in	O
activation	O
of	O
the	O
cell	O
cycle	O
and	O
cell	O
growth	O
.	O

To	O
interpret	O
the	O
mechanisms	O
by	O
which	O
EBV	O
activates	O
the	O
cell	O
,	O
we	O
have	O
assayed	O
many	O
proteins	O
involved	O
in	O
control	O
of	O
the	O
G0	O
and	O
G1	O
phases	O
of	O
the	O
cell	O
cycle	O
and	O
regulation	O
of	O
apoptosis	O
.	O

In	O
EBV	O
infection	O
most	O
of	O
the	O
changes	O
,	O
including	O
the	O
early	O
induction	O
of	O
cyclin	B-protein
D2	I-protein
,	O
are	O
dependent	O
on	O
expression	O
of	O
EBV	B-DNA
genes	I-DNA
,	O
but	O
an	O
alteration	O
in	O
the	O
E2F-4	B-protein
profile	O
was	O
partly	O
independent	O
of	O
viral	O
gene	O
expression	O
,	O
presumably	O
occurring	O
in	O
response	O
to	O
signal	O
transduction	O
activated	O
when	O
the	O
virus	O
binds	O
to	O
its	O
receptor	O
,	O
CD21	B-protein
.	O

By	O
comparing	O
the	O
expression	O
of	O
genes	O
controlling	O
apoptosis	O
,	O
including	O
those	O
encoding	O
several	O
members	O
of	O
the	O
BCL-2	B-protein
family	I-protein
of	O
proteins	O
,	O
the	O
known	O
relative	O
resistance	O
of	O
EBV-immortalized	B-cell_line
B-cell	I-cell_line
lines	I-cell_line
to	O
apoptosis	O
induced	O
by	O
low	O
serum	O
was	O
found	O
to	O
correlate	O
with	O
expression	O
of	O
both	O
BCL-2	B-protein
and	O
A20	B-protein
.	O

A20	O
can	O
be	O
regulated	O
by	O
the	O
NF-kappaB	B-protein
transcription	B-protein
factor	I-protein
,	O
which	O
is	O
known	O
to	O
be	O
activated	O
by	O
the	O
EBV	B-protein
LMP-1	I-protein
protein	I-protein
.	O

Quantitative	O
assays	O
demonstrated	O
a	O
direct	O
temporal	O
relationship	O
between	O
LMP-1	B-protein
protein	I-protein
levels	O
and	O
active	O
NF-kappaB	B-protein
during	O
the	O
time	O
course	O
of	O
infection	O
.	O

CTLA-4	B-protein
-Mediated	O
inhibition	O
of	O
early	O
events	O
of	O
T	O
cell	O
proliferation	O
.	O

CTLA-4	B-protein
engagement	O
by	O
mAbs	B-protein
inhibits	O
,	O
while	O
CD28	B-protein
enhances	O
,	O
IL-2	B-protein
production	O
and	O
proliferation	O
upon	O
T	O
cell	O
activation	O
.	O

Here	O
,	O
we	O
have	O
analyzed	O
the	O
mechanisms	O
involved	O
in	O
CTLA-4	B-protein
-mediated	O
inhibition	O
of	O
T	O
cell	O
activation	O
of	O
naive	O
CD4+	B-cell_type
T	I-cell_type
cells	I-cell_type
using	O
Ab	O
cross-linking	O
.	O

CTLA-4	B-protein
ligation	O
inhibited	O
CD3/	O
CD28	B-protein
-induced	O
IL-2	B-RNA
mRNA	I-RNA
accumulation	O
by	O
inhibiting	O
IL-2	B-protein
transcription	O
,	O
which	O
appears	O
to	O
be	O
mediated	O
in	O
part	O
through	O
decreasing	O
NF-AT	B-protein
accumulation	O
in	O
the	O
nuclei	O
.	O

However	O
,	O
CTLA-4	B-protein
ligation	O
did	O
not	O
appear	O
to	O
affect	O
the	O
CD28	B-protein
-mediated	O
stabilization	O
of	O
IL-2	B-RNA
mRNA	I-RNA
.	O

Further	O
,	O
CTLA-4	B-protein
engagement	O
inhibited	O
progression	O
through	O
the	O
cell	O
cycle	O
by	O
inhibiting	O
the	O
production	O
of	O
cyclin	B-protein
D3	I-protein
,	O
cyclin-dependent	B-protein
kinase	I-protein
(	B-protein
cdk	I-protein
)	I-protein
4	I-protein
,	O
and	O
cdk6	B-protein
when	O
the	O
T	B-cell_type
cells	I-cell_type
were	O
stimulated	O
with	O
anti-CD3/CD28	B-protein
and	O
with	O
anti-CD3	B-protein
alone	O
.	O

These	O
results	O
indicate	O
that	O
CTLA-4	B-protein
signaling	O
inhibits	O
events	O
early	O
in	O
T	O
cell	O
activation	O
both	O
at	O
IL-2	B-protein
transcription	O
and	O
at	O
the	O
level	O
of	O
IL-2	B-protein
-independent	O
events	O
of	O
the	O
cell	O
cycle	O
,	O
and	O
does	O
not	O
simply	O
oppose	O
CD28	B-protein
-mediated	O
costimulation	O
.	O

The	O
glucocorticoid	B-protein
receptor	I-protein
cooperates	O
with	O
the	O
erythropoietin	B-protein
receptor	I-protein
and	O
c-Kit	B-protein
to	O
enhance	O
and	O
sustain	O
proliferation	O
of	O
erythroid	B-cell_type
progenitors	I-cell_type
in	O
vitro	O
.	O

Although	O
erythropoietin	B-protein
(	O
Epo	B-protein
)	O
is	O
essential	O
for	O
the	O
production	O
of	O
mature	B-cell_type
red	I-cell_type
blood	I-cell_type
cells	I-cell_type
,	O
the	O
cooperation	O
with	O
other	O
factors	O
is	O
required	O
for	O
a	O
proper	O
balance	O
between	O
progenitor	O
proliferation	O
and	O
differentiation	O
.	O

In	O
avian	O
erythroid	B-cell_type
progenitors	I-cell_type
,	O
steroid	O
hormones	O
cooperate	O
with	O
tyrosine	B-protein
kinase	I-protein
receptors	I-protein
to	O
induce	O
renewal	O
of	O
erythroid	B-cell_type
progenitors	I-cell_type
.	O

We	O
examined	O
the	O
role	O
of	O
corticosteroids	O
in	O
the	O
in	O
vitro	O
expansion	O
of	O
primary	B-cell_type
human	I-cell_type
erythroid	I-cell_type
cells	I-cell_type
in	O
liquid	O
cultures	O
and	O
colony	O
assays	O
.	O

Dexamethasone	O
(	O
Dex	O
)	O
,	O
a	O
synthetic	O
glucocorticoid	O
hormone	O
,	O
cooperated	O
with	O
Epo	B-protein
and	O
stem	B-protein
cell	I-protein
factor	I-protein
to	O
induce	O
erythroid	B-cell_type
progenitors	I-cell_type
to	O
undergo	O
15	O
to	O
22	O
cell	O
divisions	O
,	O
corresponding	O
to	O
a	O
10	O
(	O
5	O
)	O
-	O
to	O
10	O
(	O
6	O
)	O
-fold	O
amplification	O
of	O
erythroid	B-cell_type
cells	I-cell_type
.	O

Dex	O
acted	O
directly	O
on	O
erythroid	B-cell_type
progenitors	I-cell_type
and	O
maintained	O
the	O
colony-forming	O
capacity	O
of	O
the	O
progenitor	B-cell_type
cells	I-cell_type
expanded	O
in	O
liquid	B-cell_line
cultures	I-cell_line
.	O

The	O
hormone	O
delayed	O
terminal	O
differentiation	O
into	O
erythrocytes	B-cell_type
,	O
which	O
was	O
assayed	O
by	O
morphology	O
,	O
hemoglobin	B-protein
accumulation	O
,	O
and	O
the	O
expression	O
of	O
genes	O
characteristic	O
for	O
immature	B-cell_type
cells	I-cell_type
.	O

Sustained	O
proliferation	O
of	O
erythroid	B-cell_type
progenitors	I-cell_type
could	O
be	O
induced	O
equally	O
well	O
from	O
purified	B-cell_line
erythroid	I-cell_line
burst-forming	I-cell_line
units	I-cell_line
(	O
BFU-E	B-cell_line
)	O
,	O
from	O
CD34	B-cell_type
(	I-cell_type
+	I-cell_type
)	I-cell_type
blast	I-cell_type
cells	I-cell_type
,	O
and	O
from	O
bone	O
marrow	O
depleted	O
from	O
CD34	B-cell_type
(	I-cell_type
+	I-cell_type
)	I-cell_type
cells	I-cell_type
.	O

NF-kappaB	B-protein
functions	O
as	O
both	O
a	O
proapoptotic	B-protein
and	I-protein
antiapoptotic	I-protein
regulatory	I-protein
factor	I-protein
within	O
a	O
single	O
cell	O
type	O
.	O

Recently	O
NF-kappaB	B-protein
has	O
been	O
shown	O
to	O
have	O
both	O
proapoptotic	O
and	O
antiapoptotic	O
functions	O
.	O

In	O
T	B-cell_line
cell	I-cell_line
hybridomas	I-cell_line
,	O
both	O
T	O
cell	O
activators	O
and	O
glucocorticoids	O
induce	O
apoptosis	O
.	O

Here	O
we	O
show	O
that	O
blockade	O
of	O
NF-kappaB	B-protein
activity	O
,	O
using	O
a	O
dominant	B-protein
negative	I-protein
IkappaBalpha	I-protein
,	O
has	O
opposite	O
effects	O
on	O
these	O
two	O
apoptotic	O
signals	O
.	O

Treatment	O
with	O
PMA	O
plus	O
ionomycin	O
(	O
P/I	O
)	O
results	O
in	O
the	O
upregulation	O
of	O
Fas	B-protein
Ligand	I-protein
(	O
FasL	B-protein
)	O
and	O
induction	O
of	O
apoptosis	O
.	O

Inhibition	O
of	O
NF-kappaB	B-protein
activity	O
inhibits	O
the	O
P/I	O
mediated	O
induction	O
of	O
FasL	B-RNA
mRNA	I-RNA
and	O
decreases	O
the	O
level	O
of	O
apoptosis	O
in	O
these	O
cultures	O
,	O
thus	O
establishing	O
NF-kappaB	B-protein
as	O
a	O
proapoptotic	B-protein
factor	I-protein
in	O
this	O
context	O
.	O

Conversely	O
,	O
inhibition	O
of	O
NF-kappaB	B-protein
confers	O
a	O
tenfold	O
increase	O
in	O
glucocorticoid	O
mediated	O
apoptosis	O
,	O
establishing	O
that	O
NF-kappaB	B-protein
also	O
functions	O
as	O
an	O
antiapoptotic	O
factor	O
.	O

We	O
conclude	O
that	O
NF-kappaB	B-protein
is	O
a	O
context-dependent	O
apoptosis	O
regulator	O
.	O

Our	O
data	O
suggests	O
that	O
NF-kappaB	B-protein
may	O
function	O
as	O
an	O
antiapoptotic	O
factor	O
in	O
thymocytes	B-cell_type
while	O
functioning	O
as	O
a	O
proapoptotic	O
factor	O
in	O
mature	B-cell_type
peripheral	I-cell_type
T	I-cell_type
cells	I-cell_type
.	O

SOCS-3	B-protein
is	O
tyrosine	O
phosphorylated	O
in	O
response	O
to	O
interleukin-2	B-protein
and	O
suppresses	O
STAT5	B-protein
phosphorylation	O
and	O
lymphocyte	O
proliferation	O
.	O

Members	O
of	O
the	O
recently	O
discovered	O
SOCS/CIS/SSI	B-protein
family	I-protein
have	O
been	O
proposed	O
as	O
regulators	O
of	O
cytokine	B-protein
signaling	O
,	O
and	O
while	O
targets	O
and	O
mechanisms	O
have	O
been	O
suggested	O
for	O
some	O
family	O
members	O
,	O
the	O
precise	O
role	O
of	O
these	O
proteins	O
remains	O
to	O
be	O
defined	O
.	O

To	O
date	O
no	O
SOCS	B-protein
proteins	I-protein
have	O
been	O
specifically	O
implicated	O
in	O
interleukin-2	B-protein
(	O
IL-2	B-protein
)	O
signaling	O
in	O
T	B-cell_type
cells	I-cell_type
.	O

Here	O
we	O
report	O
SOCS-3	B-protein
expression	O
in	O
response	O
to	O
IL-2	B-protein
in	O
both	O
T-cell	B-cell_line
lines	I-cell_line
and	O
human	B-cell_type
peripheral	I-cell_type
blood	I-cell_type
lymphocytes	I-cell_type
.	O

SOCS-3	B-protein
protein	O
was	O
detectable	O
as	O
early	O
as	O
30	O
min	O
following	O
IL-2	B-protein
stimulation	O
,	O
while	O
CIS	B-protein
was	O
seen	O
only	O
at	O
low	O
levels	O
after	O
2	O
h	O
.	O

Unlike	O
CIS	B-protein
,	O
SOCS-3	B-protein
was	O
rapidly	O
tyrosine	O
phosphorylated	O
in	O
response	O
to	O
IL-2	B-protein
.	O

Tyrosine	O
phosphorylation	O
of	O
SOCS-3	B-protein
was	O
observed	O
upon	O
coexpression	O
with	O
Jak1	B-protein
and	O
Jak2	B-protein
but	O
only	O
weakly	O
with	O
Jak3	B-protein
.	O

In	O
these	O
experiments	O
,	O
SOCS-3	B-protein
associated	O
with	O
Jak1	B-protein
and	O
inhibited	O
Jak1	B-protein
phosphorylation	O
,	O
and	O
this	O
inhibition	O
was	O
markedly	O
enhanced	O
by	O
the	O
presence	O
of	O
IL-2	B-protein
receptor	I-protein
beta	I-protein
chain	I-protein
(	O
IL-2Rbeta	B-protein
)	O
.	O

Moreover	O
,	O
following	O
IL-2	B-protein
stimulation	O
of	O
T	B-cell_type
cells	I-cell_type
,	O
SOCS-3	B-protein
was	O
able	O
to	O
interact	O
with	O
the	O
IL-2	B-protein
receptor	I-protein
complex	I-protein
,	O
and	O
in	O
particular	O
tyrosine	B-protein
phosphorylated	I-protein
Jak1	I-protein
and	O
IL-2Rbeta	B-protein
.	O

Additionally	O
,	O
in	O
lymphocytes	B-cell_type
expressing	O
SOCS-3	B-protein
but	O
not	O
CIS	B-protein
,	O
IL-2	B-protein
-induced	O
tyrosine	O
phosphorylation	O
of	O
STAT5b	B-protein
was	O
markedly	O
reduced	O
,	O
while	O
there	O
was	O
only	O
a	O
weak	O
effect	O
on	O
IL-3-mediated	B-protein
STAT5b	I-protein
tyrosine	O
phosphorylation	O
.	O

Finally	O
,	O
proliferation	O
induced	O
by	O
both	O
IL-2	B-protein
-and	O
IL-3	B-protein
was	O
significantly	O
inhibited	O
in	O
the	O
presence	O
of	O
SOCS-3	B-protein
.	O

The	O
findings	O
suggest	O
that	O
when	O
SOCS-3	B-protein
is	O
rapidly	O
induced	O
by	O
IL-2	B-protein
in	O
T	B-cell_type
cells	I-cell_type
,	O
it	O
acts	O
to	O
inhibit	O
IL-2	B-protein
responses	O
in	O
a	O
classical	O
negative	O
feedback	O
loop	O
.	O

Human	B-cell_type
alveolar	I-cell_type
macrophages	I-cell_type
are	O
markedly	O
deficient	O
in	O
REF-1	B-protein
and	O
AP-1	B-protein
DNA	O
binding	O
activity	O
.	O

Although	O
many	O
functions	O
of	O
human	B-cell_type
alveolar	I-cell_type
macrophages	I-cell_type
are	O
altered	O
compared	O
with	O
their	O
precursor	B-cell_type
cell	I-cell_type
,	O
the	O
blood	B-cell_type
monocyte	I-cell_type
(	O
monocyte	B-cell_type
)	O
,	O
the	O
reason	O
(	O
s	O
)	O
for	O
these	O
functional	O
changes	O
have	O
not	O
been	O
determined	O
.	O

We	O
recently	O
reported	O
that	O
human	B-cell_type
alveolar	I-cell_type
macrophages	I-cell_type
do	O
not	O
express	O
AP-1	B-protein
DNA	O
binding	O
activity	O
(	O
Monick	O
,	O
M.	O
M.	O
,	O
Carter	O
,	O
A.	O
B.	O
,	O
Gudmundsson	O
,	O
G.	O
,	O
Geist	O
,	O
L.	O
J.	O
,	O
and	O
Hunninghake	O
,	O
G.	O
W.	O
(	O
1998	O
)	O
Am.	O
J.	O
Physiol.	O
275	O
,	O
L389-L397	O
)	O
.	O

To	O
determine	O
why	O
alveolar	B-cell_type
macrophages	I-cell_type
do	O
not	O
express	O
AP-1	B-protein
DNA	O
binding	O
activity	O
,	O
we	O
first	O
showed	O
that	O
there	O
was	O
not	O
a	O
decrease	O
in	O
expression	O
of	O
the	O
FOS	B-protein
and	I-protein
JUN	I-protein
proteins	I-protein
that	O
make	O
up	O
the	O
AP-1	B-protein
complex	O
.	O

There	O
was	O
,	O
however	O
,	O
a	O
significant	O
difference	O
in	O
the	O
amounts	O
of	O
the	O
nuclear	B-protein
protein	I-protein
,	O
REF-1	B-protein
(	O
which	O
regulates	O
AP-1	B-protein
DNA	O
binding	O
by	O
altering	O
the	O
redox	O
status	O
of	O
FOS	B-protein
and	O
JUN	B-protein
proteins	I-protein
)	O
,	O
in	O
alveolar	B-cell_type
macrophages	I-cell_type
compared	O
with	O
monocytes	B-cell_type
.	O

In	O
addition	O
,	O
in	O
vitro	O
differentiation	O
of	O
monocytes	B-cell_type
to	O
a	O
macrophage-like	B-cell_type
cell	I-cell_type
resulted	O
in	O
decreased	O
amounts	O
of	O
REF-1	B-protein
.	O

Finally	O
,	O
addition	O
of	O
REF-1	B-protein
from	O
activated	B-cell_type
monocytes	I-cell_type
to	O
alveolar	O
macrophage	O
nuclear	O
proteins	O
resulted	O
in	O
a	O
marked	O
increase	O
in	O
AP-1	B-protein
DNA	O
binding	O
.	O

These	O
studies	O
strongly	O
suggest	O
that	O
the	O
process	O
of	O
differentiation	O
of	O
monocytes	B-cell_type
into	O
alveolar	B-cell_type
macrophages	I-cell_type
is	O
associated	O
with	O
a	O
loss	O
of	O
REF-1	B-protein
and	O
AP-1	B-protein
activity	O
.	O

This	O
observation	O
may	O
explain	O
,	O
in	O
part	O
,	O
some	O
of	O
the	O
functional	O
differences	O
observed	O
for	O
alveolar	B-cell_type
macrophages	I-cell_type
compared	O
with	O
monocytes	B-cell_type
.	O

Development	O
and	O
maturation	O
of	O
secondary	O
lymphoid	O
tissues	O
.	O

The	O
secondary	O
lymphoid	O
tissues	O
are	O
located	O
at	O
strategic	O
sites	O
where	O
foreign	B-protein
antigens	I-protein
can	O
be	O
efficiently	O
brought	O
together	O
with	O
immune	B-cell_type
system	I-cell_type
regulatory	I-cell_type
and	I-cell_type
effector	I-cell_type
cells	I-cell_type
.	O

The	O
organized	O
structure	O
of	O
the	O
secondary	O
lymphoid	O
tissues	O
is	O
thought	O
to	O
enhance	O
the	O
sensitivity	O
of	O
antigen	O
recognition	O
and	O
to	O
support	O
proper	O
regulation	O
of	O
the	O
activation	O
and	O
maturation	O
of	O
the	O
antigen-responsive	B-cell_type
lymphoid	I-cell_type
cells	I-cell_type
.	O

Although	O
a	O
substantial	O
amount	O
is	O
known	O
about	O
the	O
cellular	B-DNA
elements	I-DNA
that	O
compose	O
the	O
lymphoid	O
and	O
nonlymphoid	O
components	O
of	O
the	O
secondary	O
lymphoid	O
tissues	O
,	O
information	O
concerning	O
the	O
signals	O
that	O
control	O
the	O
development	O
of	O
the	O
tissues	O
and	O
that	O
maintain	O
the	O
organized	O
tissue	O
microenvironment	O
remain	O
undefined	O
.	O

Studies	O
over	O
the	O
past	O
few	O
years	O
have	O
identified	O
lymphotoxin	O
as	O
a	O
critical	O
signaling	O
molecule	O
not	O
only	O
for	O
the	O
organogenesis	O
of	O
secondary	O
lymphoid	O
tissues	O
but	O
for	O
the	O
maintenance	O
of	O
aspects	O
of	O
their	O
microarchitecture	O
as	O
well	O
.	O

Additional	O
signaling	O
molecules	O
that	O
contribute	O
to	O
the	O
formation	O
of	O
normal	O
lymphoid	O
tissue	O
structure	O
are	O
being	O
identified	O
at	O
an	O
accelerating	O
pace	O
.	O

Analyses	O
of	O
mouse	O
strains	O
with	O
congenital	O
defects	O
in	O
different	O
aspects	O
of	O
secondary	O
lymphoid	O
tissue	O
development	O
are	O
beginning	O
to	O
clarify	O
the	O
role	O
of	O
these	O
tissues	O
in	O
immune	O
responses	O
and	O
host	O
defense	O
.	O

This	O
review	O
focuses	O
on	O
studies	O
defining	O
recently	O
identified	O
crucial	O
signals	O
for	O
the	O
biogenesis	O
of	O
secondary	O
lymphoid	O
organs	O
and	O
for	O
the	O
maintenance	O
of	O
their	O
proper	O
microarchitecture	O
.	O

It	O
also	O
discusses	O
new	O
insights	O
into	O
how	O
the	O
structure	O
of	O
these	O
tissues	O
supports	O
effective	O
immune	O
responses	O
.	O

Modulation	O
of	O
CD28	B-protein
expression	O
:	O
distinct	O
regulatory	O
pathways	O
during	O
activation	O
and	O
replicative	O
senescence	O
.	O

The	O
costimulatory	B-protein
molecule	I-protein
CD28	B-protein
has	O
a	O
restricted	O
tissue	O
distribution	O
and	O
is	O
expressed	O
on	O
T	B-cell_type
cells	I-cell_type
and	O
some	O
plasmacytoma	B-cell_type
cells	I-cell_type
.	O

Although	O
CD28	B-protein
is	O
constitutively	O
expressed	O
,	O
its	O
expression	O
is	O
transiently	O
down-regulated	O
following	O
T	O
cell	O
activation	O
and	O
declines	O
progressively	O
with	O
in	O
vitro	O
senescence	O
.	O

In	O
vivo	O
,	O
CD8+	B-cell_type
T	I-cell_type
cells	I-cell_type
and	O
,	O
less	O
frequently	O
,	O
CD4+	B-cell_type
T	I-cell_type
cells	I-cell_type
may	O
completely	O
lose	O
CD28	B-protein
surface	O
expression	O
during	O
chronic	O
infections	O
and	O
with	O
aging	O
.	O

This	O
correlates	O
with	O
changes	O
of	O
nuclear	O
protein-binding	O
activities	O
to	O
two	O
motifs	O
,	O
site	B-protein
alpha	I-protein
and	I-protein
beta	I-protein
,	O
within	O
the	O
CD28	B-DNA
minimal	I-DNA
promoter	I-DNA
.	O

Both	O
alpha-	O
and	O
beta-bound	O
complexes	O
are	O
found	O
only	O
in	O
lymphoid	O
tissues	O
,	O
in	O
CD28+	B-cell_type
T	I-cell_type
cells	I-cell_type
,	O
and	O
in	O
some	O
transformed	B-cell_line
B	I-cell_line
cells	I-cell_line
.	O

These	O
complexes	O
are	O
coordinately	O
expressed	O
except	O
during	O
replicative	O
senescence	O
,	O
which	O
is	O
characterized	O
by	O
the	O
down-modulation	O
of	O
site	B-protein
beta	I-protein
-but	O
not	O
site	B-protein
alpha	I-protein
-binding	O
activities	O
.	O

In	O
contrast	O
,	O
T	O
cell	O
activation	O
induces	O
a	O
parallel	O
decline	O
in	O
both	O
site	O
alpha-	O
and	O
beta-binding	O
activities	O
.	O

CD4+	O
and	O
CD8+	B-cell_type
T	I-cell_type
cells	I-cell_type
differ	O
in	O
their	O
beta-binding	O
profiles	O
,	O
which	O
may	O
explain	O
the	O
more	O
pronounced	O
down-regulation	O
of	O
CD28	B-protein
in	O
senescent	O
CD8+	B-cell_type
T	I-cell_type
cells	I-cell_type
.	O

In	O
vivo	O
expanded	O
CD4+CD28null	B-cell_line
and	I-cell_line
CD8+CD28null	I-cell_line
T	I-cell_line
cells	I-cell_line
uniformly	O
lack	O
alpha-	B-protein
and	I-protein
beta-	I-protein
bound	I-protein
complexes	I-protein
,	O
resembling	O
the	O
pattern	O
seen	O
in	O
chronically	B-cell_type
activated	I-cell_type
cells	I-cell_type
and	O
not	O
of	O
senescent	B-cell_type
cells	I-cell_type
.	O

A	O
role	O
for	O
RanBP1	B-protein
in	O
the	O
release	O
of	O
CRM1	B-protein
from	O
the	O
nuclear	B-protein
pore	I-protein
complex	I-protein
in	O
a	O
terminal	O
step	O
of	O
nuclear	O
export	O
.	O

We	O
recently	O
developed	O
an	O
assay	O
in	O
which	O
nuclear	O
export	O
of	O
the	O
shuttling	O
transcription	B-protein
factor	I-protein
NFAT	I-protein
(	O
nuclear	B-protein
factor	I-protein
of	I-protein
activated	I-protein
T	I-protein
cells	I-protein
)	O
can	O
be	O
reconstituted	O
in	O
permeabilized	O
cells	O
with	O
the	O
GTPase	B-protein
Ran	B-protein
and	O
the	O
nuclear	O
export	O
receptor	O
CRM1	B-protein
.	O

We	O
have	O
now	O
used	O
this	O
assay	O
to	O
identify	O
another	O
export	O
factor	O
.	O

After	O
preincubation	O
of	O
permeabilized	B-cell_line
cells	I-cell_line
with	O
a	O
Ran	B-protein
mutant	I-protein
that	O
can	O
not	O
hydrolyze	O
GTP	O
(	O
RanQ69L	B-protein
)	O
,	O
cytosol	O
supports	O
NFAT	B-protein
export	O
,	O
but	O
CRM1	B-protein
and	O
Ran	B-protein
alone	O
do	O
not	O
.	O

The	O
RanQ69L	B-protein
preincubation	O
leads	O
to	O
accumulation	O
of	O
CRM1	B-protein
at	O
the	O
cytoplasmic	O
periphery	O
of	O
the	O
nuclear	B-protein
pore	I-protein
complex	I-protein
(	O
NPC	B-protein
)	O
in	O
association	O
with	O
the	O
p62	B-protein
complex	I-protein
and	O
Can/Nup214	O
.	O

Ran	B-protein
GTP-dependent	O
association	O
of	O
CRM1	B-protein
with	O
these	O
nucleoporins	B-protein
was	O
reconstituted	O
in	O
vitro	O
.	O

By	O
biochemical	O
fractionation	O
and	O
reconstitution	O
,	O
we	O
showed	O
that	O
RanBP1	B-protein
restores	O
nuclear	O
export	O
after	O
the	O
RanQ69L	B-protein
preincubation	O
.	O

It	O
also	O
stimulates	O
nuclear	O
export	O
in	O
cells	O
that	O
have	O
not	O
been	O
preincubated	O
with	O
RanQ69L	B-protein
.	O

RanBP1	B-protein
as	O
well	O
as	O
Ran-binding	B-protein
domains	I-protein
of	O
the	O
cytoplasmic	B-protein
nucleoporin	I-protein
RanBP2	B-protein
promote	O
the	O
release	O
of	O
CRM1	B-protein
from	O
the	O
NPC	B-protein
.	O

Taken	O
together	O
,	O
our	O
results	O
indicate	O
that	O
Ran	B-protein
GTP	O
is	O
important	O
for	O
the	O
targeting	O
of	O
export	O
complexes	O
to	O
the	O
cytoplasmic	O
side	O
of	O
the	O
NPC	B-protein
and	O
that	O
RanBP1	B-protein
and	O
probably	O
RanBP2	B-protein
are	O
involved	O
in	O
the	O
dissociation	O
of	O
nuclear	B-protein
export	I-protein
complexes	I-protein
from	O
the	O
NPC	B-protein
in	O
a	O
terminal	O
step	O
of	O
transport	O
.	O

c-Myc	B-protein
and	O
E1A	B-protein
induced	O
cellular	O
sensitivity	O
to	O
activated	B-cell_type
NK	I-cell_type
cells	I-cell_type
involves	O
cytotoxic	O
granules	O
as	O
death	O
effectors	O
.	O

The	O
contact	O
of	O
natural	B-cell_type
killer	I-cell_type
(	I-cell_type
NK	I-cell_type
)	I-cell_type
cells	I-cell_type
with	O
foreign	B-cell_type
cells	I-cell_type
and	O
with	O
certain	O
virus-infected	B-cell_type
or	I-cell_type
tumor	I-cell_type
cells	I-cell_type
triggers	O
the	O
cytolytic	O
machinery	O
of	O
NK	B-cell_type
cells	I-cell_type
.	O

This	O
triggering	O
leads	O
to	O
exocytosis	O
of	O
the	O
cytotoxic	B-cell_type
NK	I-cell_type
cell	I-cell_type
granules	I-cell_type
.	O

The	O
oncoproteins	B-protein
c-Myc	B-protein
and	O
E1A	B-protein
render	O
cells	O
vulnerable	O
to	O
NK	O
cell	O
mediated	O
cytolysis	O
yet	O
the	O
mechanisms	O
of	O
sensitization	O
are	O
not	O
well	O
understood	O
.	O

In	O
a	O
model	O
where	O
foreign	B-cell_type
cells	I-cell_type
(	O
rat	B-cell_type
fibroblasts	I-cell_type
)	O
were	O
cocultured	O
with	O
human	B-cell_type
IL-2	I-cell_type
activated	I-cell_type
NK	I-cell_type
cells	I-cell_type
,	O
we	O
observed	O
that	O
NK	B-cell_type
cells	I-cell_type
were	O
capable	O
of	O
efficiently	O
killing	O
their	O
targets	O
only	O
if	O
the	O
cells	O
overexpressed	O
the	O
oncogene	O
c-Myc	B-protein
or	O
E1A	B-protein
.	O

Both	O
the	O
parental	O
and	O
the	O
oncogene	B-cell_type
expressing	I-cell_type
fibroblasts	I-cell_type
similarly	O
triggered	O
phosphoinositide	O
hydrolysis	O
in	O
the	O
bound	O
NK	B-cell_type
cells	I-cell_type
,	O
demonstrating	O
that	O
NK	B-cell_type
cells	I-cell_type
were	O
cytolytically	O
activated	O
in	O
contact	O
with	O
both	O
resistant	O
parental	O
and	O
oncogene	B-cell_type
expressing	I-cell_type
sensitive	I-cell_type
target	I-cell_type
fibroblasts	I-cell_type
.	O

The	O
cell	O
death	O
was	O
independent	O
of	O
wild-type	B-protein
p53	I-protein
and	O
was	O
not	O
inhibited	O
by	O
an	O
anti-apoptotic	B-protein
protein	I-protein
EIB19K	I-protein
.	O

These	O
results	O
provided	O
evidence	O
that	O
c-Myc	B-protein
and	O
E1A	B-protein
activated	O
the	O
NK	O
cell	O
induced	O
cytolysis	O
at	O
a	O
post-triggering	O
stage	O
of	O
NK	O
cell-target	O
cell	O
interaction	O
.	O

In	O
consistence	O
,	O
the	O
c-Myc	B-protein
and	O
E1A	B-protein
overexpressing	O
fibroblasts	B-cell_type
were	O
more	O
sensitive	O
to	O
the	O
cytolytic	O
effects	O
of	O
isolated	O
NK	O
cell-derived	O
granules	O
than	O
parental	B-cell_type
cells	I-cell_type
.	O

The	O
data	O
indicate	O
that	O
oncogenes	B-DNA
activate	O
the	O
cytotoxicity	O
of	O
NK	O
cell	O
granules	O
.	O

This	O
mechanism	O
can	O
have	O
a	O
role	O
in	O
directing	O
the	O
cytolytic	O
action	O
of	O
NK	B-cell_type
cells	I-cell_type
towards	O
the	O
virus-infected	B-cell_type
and	I-cell_type
cancer	I-cell_type
cells	I-cell_type
.	O

Unicellular-unilineage	B-cell_line
erythropoietic	I-cell_line
cultures	I-cell_line
:	O
molecular	O
analysis	O
of	O
regulatory	O
gene	O
expression	O
at	O
sibling	O
cell	O
level	O
.	O

In	O
vitro	O
studies	O
on	O
hematopoietic	O
control	O
mechanisms	O
have	O
been	O
hampered	O
by	O
the	O
heterogeneity	O
of	O
the	O
analyzed	O
cell	O
populations	O
,	O
ie	O
,	O
lack	O
of	O
lineage	O
specificity	O
and	O
developmental	O
stage	O
homogeneity	O
of	O
progenitor/precursor	B-cell_type
cells	I-cell_type
growing	O
in	O
culture	O
.	O

We	O
developed	O
unicellular	O
culture	O
systems	O
for	O
unilineage	O
differentiation	O
of	O
purified	B-cell_type
hematopoietic	I-cell_type
progenitor	I-cell_type
cells	I-cell_type
followed	O
by	O
daughter	O
cell	O
analysis	O
at	O
cellular	O
and	O
molecular	O
level	O
.	O

In	O
the	O
culture	O
system	O
reported	O
here	O
,	O
(	O
1	O
)	O
the	O
growth	B-protein
factor	I-protein
(	O
GF	B-protein
)	O
stimulus	O
induces	O
cord	B-cell_type
blood	I-cell_type
(	I-cell_type
CB	I-cell_type
)	I-cell_type
progenitor	I-cell_type
cells	I-cell_type
to	O
proliferate	O
and	O
differentiate/mature	O
exclusively	O
along	O
the	O
erythroid	B-cell_type
lineage	I-cell_type
;	O
(	O
2	O
)	O
this	O
erythropoietic	O
wave	O
is	O
characterized	O
by	O
less	O
than	O
4	O
%	O
apoptotic	O
cells	O
;	O
(	O
3	O
)	O
asymmetric	O
divisions	O
are	O
virtually	O
absent	O
,	O
ie	O
,	O
nonresponsive	O
hematopoietic	B-cell_type
progenitors	I-cell_type
with	O
no	O
erythropoietic	O
potential	O
are	O
forced	O
into	O
apoptosis	O
;	O
(	O
4	O
)	O
the	O
system	O
is	O
cell	O
division	O
controlled	O
(	O
cdc	O
)	O
,	O
ie	O
,	O
the	O
number	O
of	O
divisions	O
performed	O
by	O
each	O
cell	O
is	O
monitored	O
.	O

Single-cell	O
reverse	B-protein
transcriptase	I-protein
-polymerase	O
chain	O
reaction	O
(	O
RT-PCR	O
)	O
analysis	O
was	O
applied	O
to	O
this	O
culture	O
system	O
to	O
investigate	O
gene	O
expression	O
of	O
diverse	O
receptors	B-protein
,	O
markers	B-protein
of	I-protein
differentiation	I-protein
,	O
and	O
transcription	B-protein
factors	I-protein
(	O
EKLF	B-protein
,	O
GATA-1	B-protein
,	O
GATA-2	B-protein
,	O
p45	B-protein
NF-E2	I-protein
,	O
PU.1	B-protein
,	O
and	O
SCL/Tal1	B-protein
)	O
at	O
discrete	O
stages	O
of	O
erythropoietic	O
development	O
.	O

Freshly	O
isolated	O
CD34	B-cell_type
(	I-cell_type
+	I-cell_type
)	I-cell_type
cells	I-cell_type
expressed	O
CD34	B-protein
,	O
c-kit	B-protein
,	O
PU.1	B-protein
,	O
and	O
GATA-2	B-protein
but	O
did	O
not	O
express	O
CD36	B-protein
,	O
erythropoietin	B-protein
receptor	I-protein
(	O
EpoR	B-protein
)	O
,	O
SCL/Tal1	B-protein
,	O
EKLF	B-protein
,	O
NF-E2	O
,	O
GATA-1	B-protein
,	O
or	O
glyocophorin	B-protein
A	I-protein
(	O
GPA	B-protein
)	O
.	O

In	O
early	O
to	O
intermediate	O
stages	O
of	O
erythroid	O
differentiation	O
we	O
monitored	O
the	O
induction	O
of	O
CD36	B-protein
,	O
Tal1	B-protein
,	O
EKLF	B-protein
,	O
NF-E2	B-protein
,	O
and	O
GATA-1	B-protein
that	O
preceeded	O
expression	O
of	O
EpoR	B-protein
.	O

In	O
late	O
stages	O
of	O
erythroid	O
maturation	O
,	O
GPA	B-protein
was	O
upregulated	O
,	O
whereas	O
CD34	B-protein
,	O
c-kit	B-protein
,	O
PU.1	B-protein
,	O
and	O
GATA-2	B-protein
were	O
barely	O
or	O
not	O
detected	O
.	O

In	O
addition	O
,	O
competitive	O
single-cell	O
RT-PCR	O
was	O
used	O
to	O
assay	O
CD34	B-RNA
mRNA	I-RNA
transcripts	I-RNA
in	O
sibling	B-cell_line
CD34	I-cell_line
(	I-cell_line
+	I-cell_line
)	I-cell_line
CD38	I-cell_line
(	I-cell_line
-	I-cell_line
)	I-cell_line
cells	I-cell_line
differentiating	O
in	O
unilineage	B-cell_line
erythroid	I-cell_line
cultures	I-cell_line
:	O
this	O
analysis	O
allowed	O
us	O
to	O
semiquantitate	O
the	O
gradual	O
downmodulation	O
of	O
CD34	B-RNA
mRNA	I-RNA
from	O
progenitor	B-cell_type
cells	I-cell_type
through	O
their	O
differentiating	B-cell_line
erythroid	I-cell_line
progeny	I-cell_line
.	O

It	O
is	O
concluded	O
that	O
this	O
novel	O
culture	O
system	O
,	O
coupled	O
with	O
single-cell	O
RT-PCR	O
analysis	O
,	O
may	O
eliminate	O
the	O
ambiguities	O
intrinsic	O
to	O
molecular	O
studies	O
on	O
heterogeneous	O
populations	O
of	O
hematopoietic	B-cell_type
progenitors/precursors	I-cell_type
growing	O
in	O
culture	O
,	O
particularly	O
in	O
the	O
initial	O
stages	O
of	O
development	O
.	O

Differences	O
in	O
phosphorylation	O
of	O
the	O
IL-2R	B-protein
associated	I-protein
JAK/STAT	I-protein
proteins	I-protein
between	O
HTLV-I	B-cell_line
(	I-cell_line
+	I-cell_line
)	I-cell_line
,	I-cell_line
IL-2-independent	I-cell_line
and	I-cell_line
IL-2-dependent	I-cell_line
cell	I-cell_line
lines	I-cell_line
and	O
uncultured	B-cell_type
leukemic	I-cell_type
cells	I-cell_type
from	O
patients	O
with	O
adult	O
T-cell	O
lymphoma/leukemia	O
.	O

To	O
determine	O
activation	O
status	O
of	O
the	O
IL-2R	B-protein
-associated	O
(	O
Jak/STAT	B-protein
)	O
pathway	O
in	O
the	O
HTLV-I	B-cell_line
infected	I-cell_line
cells	I-cell_line
,	O
we	O
examined	O
tyrosine	O
phosphorylation	O
of	O
Jak3	B-protein
,	O
STAT3	B-protein
,	O
and	O
STAT5	B-protein
in	O
several	O
HTLV-I	B-cell_line
(	I-cell_line
+	I-cell_line
)	I-cell_line
T-cell	I-cell_line
lines	I-cell_line
and	O
in	O
uncultured	B-cell_type
leukemic	I-cell_type
T	I-cell_type
cells	I-cell_type
isolated	O
from	O
patients	O
with	O
adult	O
T-cell	O
lymphoma/leukemia	O
(	O
ATLL	O
)	O
.	O

Constitutive	O
basal	O
phosphorylation	O
of	O
Jak3	B-protein
and	O
,	O
usually	O
,	O
STAT3	B-protein
and	O
STAT5	B-protein
was	O
detected	O
in	O
all	O
four	O
IL-2-independent	B-cell_line
cell	I-cell_line
lines	I-cell_line
tested	O
,	O
but	O
in	O
none	O
of	O
the	O
three	O
IL-2-dependent	B-cell_line
cell	I-cell_line
lines	I-cell_line
.	O

Similarly	O
,	O
there	O
was	O
no	O
detectable	O
basal	O
phosphorylation	O
of	O
Jak3	B-protein
and	O
STAT5	B-protein
in	O
the	O
leukemic	B-cell_type
cells	I-cell_type
from	O
ATLL	O
patients	O
(	O
0/8	O
and	O
0/3	O
,	O
respectively	O
)	O
.	O

However	O
,	O
stimulation	O
with	O
IL-2	B-protein
resulted	O
in	O
Jak3	B-protein
and	O
STAT5	B-protein
phosphorylation	O
in	O
both	O
leukemic	B-cell_type
ATLL	I-cell_type
cells	I-cell_type
and	O
IL-2-dependent	B-cell_line
lines	I-cell_line
.	O

Furthermore	O
,	O
expression	O
of	O
SHP-1	B-protein
phosphatase	I-protein
which	O
is	O
a	O
negative	O
regulator	O
of	O
cytokine	B-protein
receptor	I-protein
signaling	O
,	O
was	O
lost	O
in	O
most	O
IL-2	B-cell_line
independent	I-cell_line
cell	I-cell_line
lines	I-cell_line
(	O
3/4	O
)	O
but	O
not	O
in	O
the	O
leukemic	O
ATLL	B-cell_type
cells	I-cell_type
(	O
0/3	O
)	O
.	O

Finally	O
,	O
the	O
HTLV-I	B-cell_line
(	I-cell_line
+	I-cell_line
)	I-cell_line
T-cell	I-cell_line
lines	I-cell_line
(	O
313	O
)	O
but	O
not	O
the	O
control	O
,	O
HTLV-I	B-cell_line
(	I-cell_line
-	I-cell_line
)	I-cell_line
T-cell	I-cell_line
lines	I-cell_line
were	O
resistant	O
to	O
rapamycin	O
and	O
its	O
novel	O
analog	O
RAD	O
.	O

We	O
conclude	O
that	O
(	O
1	O
)	O
HTLV-I	O
infection	O
per	O
se	O
does	O
not	O
result	O
in	O
a	O
constitutive	O
phosphorylation	O
of	O
the	O
Jak3	B-protein
,	O
STAT3	B-protein
,	O
and	O
STAT5	B-protein
proteins	O
;	O
(	O
2	O
)	O
malignant	O
transformation	O
in	O
at	O
least	O
some	O
cases	O
of	O
ATLL	O
does	O
not	O
require	O
the	O
constitutive	O
,	O
but	O
may	O
require	O
IL-2	B-protein
-induced	O
,	O
activation	O
of	O
the	O
IL-2R	B-protein
Jak/STAT	B-protein
pathway	O
;	O
and	O
(	O
3	O
)	O
there	O
are	O
major	O
differences	O
in	O
T-cell	O
immortalization	O
mechanism	O
(	O
s	O
)	O
which	O
appear	O
to	O
involve	O
SHP-1	B-protein
and	O
target	O
molecules	O
for	O
rapamycin	O
and	O
RAD	O
.	O

Clonality	O
analysis	O
using	O
X-chromosome	B-DNA
inactivation	O
at	O
the	O
human	B-DNA
androgen	I-DNA
receptor	I-DNA
gene	I-DNA
(	O
Humara	B-DNA
)	O
.	O

Evaluation	O
of	O
large	O
cohorts	O
of	O
patients	O
with	O
chronic	O
myeloproliferative	O
diseases	O
,	O
secondary	O
neutrophilia	O
,	O
and	O
reactive	O
thrombocytosis	O
.	O

Chronic	O
myeloproliferative	O
diseases	O
(	O
MPDs	O
)	O
are	O
not	O
associated	O
with	O
consistent	O
cytogenetic	O
or	O
molecular	O
abnormalities	O
.	O

Demonstration	O
of	O
clonal	O
cell	O
growth	O
by	O
analysis	O
of	O
X-chromosome	B-DNA
inactivation	O
(	O
XCI	O
)	O
patterns	O
in	O
females	O
provides	O
a	O
promising	O
tool	O
for	O
diagnosis	O
.	O

However	O
,	O
this	O
technique	O
can	O
be	O
complicated	O
by	O
excessive	O
lyonization	O
of	O
normal	O
cells	O
mimicking	O
clonal	O
cell	O
growth	O
:	O
We	O
analyzed	O
XCI	O
patterns	O
at	O
the	O
human	B-DNA
androgen	I-DNA
receptor	I-DNA
(	I-DNA
HUMARA	I-DNA
)	I-DNA
locus	I-DNA
in	O
146	O
healthy	O
females	O
,	O
65	O
women	O
with	O
secondary	O
neutrophilia	O
,	O
31	O
women	O
with	O
reactive	O
thrombocytosis	O
,	O
and	O
86	O
women	O
with	O
chronic	O
MPDs	O
.	O

A	O
skewed	O
XCI	O
pattern	O
with	O
greater	O
than	O
75	O
%	O
amplification	O
of	O
1	O
allele	B-DNA
(	O
allele	B-DNA
ratio	O
>	O
3	O
:	O
1	O
)	O
was	O
found	O
in	O
22	O
(	O
9.1	O
%	O
)	O
of	O
242	O
control	O
subjects	O
.	O

The	O
incidence	O
of	O
skewing	O
was	O
statistically	O
significantly	O
lower	O
in	O
women	O
younger	O
than	O
30	O
years	O
(	O
2/73	O
)	O
compared	O
with	O
women	O
older	O
than	O
60	O
years	O
(	O
10/53	O
)	O
.	O

Of	O
86	O
patients	O
with	O
a	O
chronic	O
MPD	O
,	O
71	O
(	O
82	O
%	O
)	O
exhibited	O
an	O
allele	B-DNA
ratio	O
greater	O
than	O
3	O
:	O
1	O
,	O
whereas	O
only	O
10	O
(	O
12	O
%	O
)	O
of	O
86	O
age-matched	O
control	O
subjects	O
showed	O
a	O
skewed	O
XCI	O
pattern	O
.	O

Although	O
statistical	O
evaluation	O
of	O
the	O
data	O
showed	O
a	O
significant	O
difference	O
between	O
patients	O
with	O
a	O
chronic	O
MPD	O
and	O
control	O
subjects	O
,	O
proof	O
of	O
clonality	O
in	O
individual	O
,	O
especially	O
elderly	O
,	O
patients	O
is	O
difficult	O
.	O

GATA-1	B-protein
and	O
erythropoietin	B-protein
cooperate	O
to	O
promote	O
erythroid	O
cell	O
survival	O
by	O
regulating	O
bcl-xL	B-protein
expression	O
.	O

The	O
transcription	B-protein
factor	I-protein
GATA-1	B-protein
is	O
essential	O
for	O
normal	O
erythropoiesis	O
.	O

By	O
examining	O
in	O
vitro-differentiated	B-cell_line
embryonic	I-cell_line
stem	I-cell_line
cells	I-cell_line
,	O
we	O
showed	O
previously	O
that	O
in	O
the	O
absence	O
of	O
GATA-1	B-protein
,	O
committed	B-cell_line
erythroid	I-cell_line
precursors	I-cell_line
fail	O
to	O
complete	O
maturation	O
and	O
instead	O
undergo	O
apoptosis	O
.	O

The	O
mechanisms	O
by	O
which	O
GATA-1	B-protein
controls	O
cell	O
survival	O
are	O
unknown	O
.	O

Here	O
we	O
report	O
that	O
in	O
erythroid	B-cell_type
cells	I-cell_type
,	O
GATA-1	B-protein
strongly	O
induces	O
the	O
expression	O
of	O
the	O
anti-apoptotic	B-protein
protein	I-protein
bcl-xL	B-protein
,	O
but	O
not	O
the	O
related	O
proteins	O
bcl-2	B-protein
and	O
mcl-1	B-protein
.	O

Consistent	O
with	O
a	O
role	O
for	O
bcl-xL	B-protein
in	O
mediating	O
GATA-1	B-protein
-induced	O
erythroid	O
cell	O
survival	O
,	O
in	O
vitro-differentiated	B-cell_line
bcl-xL-/-	I-cell_line
embryonic	I-cell_line
stem	I-cell_line
cells	I-cell_line
fail	O
to	O
generate	O
viable	O
mature	O
definitive	O
erythroid	B-cell_type
cells	I-cell_type
,	O
a	O
phenotype	O
resembling	O
that	O
of	O
GATA-1	B-DNA
gene	I-DNA
disruption	O
.	O

In	O
addition	O
,	O
we	O
show	O
that	O
erythropoietin	B-protein
,	O
which	O
is	O
also	O
required	O
for	O
erythroid	O
cell	O
survival	O
,	O
cooperates	O
with	O
GATA-1	B-protein
to	O
stimulate	O
bcl-xL	B-protein
gene	O
expression	O
and	O
to	O
maintain	O
erythroid	O
cell	O
viability	O
during	O
terminal	O
maturation	O
.	O

Together	O
,	O
our	O
data	O
show	O
that	O
bcl-xL	B-protein
is	O
essential	O
for	O
normal	O
erythroid	O
development	O
and	O
suggest	O
a	O
regulatory	O
hierarchy	O
in	O
which	O
bcl-xL	B-protein
is	O
a	O
critical	O
downstream	O
effector	O
of	O
GATA-1	B-protein
and	O
erythropoietin	B-protein
-mediated	O
signals	O
.	O

p70	B-protein
(	I-protein
s6k	I-protein
)	I-protein
integrates	O
phosphatidylinositol	B-protein
3-kinase	I-protein
and	O
rapamycin-regulated	O
signals	O
for	O
E2F	B-protein
regulation	O
in	O
T	B-cell_type
lymphocytes	I-cell_type
.	O

In	O
T	B-cell_type
lymphocytes	I-cell_type
,	O
the	O
hematopoietic	B-protein
cytokine	I-protein
interleukin-2	B-protein
(	O
IL-2	B-protein
)	O
uses	O
phosphatidylinositol	B-protein
3-kinase	I-protein
(	O
PI	B-protein
3-kinase	I-protein
)	O
-induced	O
signaling	O
pathways	O
to	O
regulate	O
E2F	B-protein
transcriptional	O
activity	O
,	O
a	O
critical	O
cell	O
cycle	O
checkpoint	O
.	O

PI	B-protein
3-kinase	I-protein
also	O
regulates	O
the	O
activity	O
of	O
p70	B-protein
(	I-protein
s6k	I-protein
)	I-protein
,	O
the	O
40S	B-protein
ribosomal	I-protein
protein	I-protein
S6	I-protein
kinase	I-protein
,	O
a	O
response	O
that	O
is	O
abrogated	O
by	O
the	O
macrolide	O
rapamycin	O
.	O

This	O
immunosuppressive	O
drug	O
is	O
known	O
to	O
prevent	O
T-cell	O
proliferation	O
,	O
but	O
the	O
precise	O
point	O
at	O
which	O
rapamycin	O
regulates	O
T-cell	O
cycle	O
progression	O
has	O
yet	O
to	O
be	O
elucidated	O
.	O

Moreover	O
,	O
the	O
effects	O
of	O
rapamycin	O
on	O
,	O
and	O
the	O
role	O
of	O
p70	B-protein
(	I-protein
s6k	I-protein
)	I-protein
in	O
,	O
IL-2	B-protein
and	O
PI	B-protein
3-kinase	I-protein
activation	O
of	O
E2Fs	B-protein
have	O
not	O
been	O
characterized	O
.	O

Our	O
present	O
results	O
show	O
that	O
IL-2	B-protein
-and	O
PI	B-protein
3-kinase	I-protein
-induced	O
pathways	O
for	O
the	O
regulation	O
of	O
E2F	B-protein
transcriptional	O
activity	O
include	O
both	O
rapamycin-resistant	O
and	O
rapamycin-sensitive	O
components	O
.	O

Expression	O
of	O
a	O
rapamycin-resistant	B-protein
mutant	I-protein
of	O
p70	B-protein
(	I-protein
s6k	I-protein
)	I-protein
in	O
T	B-cell_type
cells	I-cell_type
could	O
restore	O
rapamycin-suppressed	O
E2F	B-protein
responses	O
.	O

Thus	O
,	O
the	O
rapamycin-controlled	O
processes	O
involved	O
in	O
E2F	B-protein
regulation	O
appear	O
to	O
be	O
mediated	O
by	O
p70	B-protein
(	I-protein
s6k	I-protein
)	I-protein
.	O

However	O
,	O
the	O
rapamycin-resistant	B-protein
p70	I-protein
(	I-protein
s6k	I-protein
)	I-protein
could	O
not	O
rescue	O
rapamycin	O
inhibition	O
of	O
T-cell	O
cycle	O
entry	O
,	O
consistent	O
with	O
the	O
involvement	O
of	O
additional	O
,	O
rapamycin-sensitive	O
pathways	O
in	O
the	O
control	O
of	O
T-cell	O
cycle	O
progression	O
.	O

The	O
present	O
results	O
thus	O
show	O
that	O
p70	B-protein
(	I-protein
s6k	I-protein
)	I-protein
is	O
able	O
to	O
regulate	O
E2F	B-protein
transcriptional	O
activity	O
and	O
provide	O
direct	O
evidence	O
for	O
the	O
first	O
time	O
for	O
a	O
link	O
between	O
IL-2	B-protein
receptors	O
,	O
PI	B-protein
3-kinase	I-protein
,	O
and	O
p70	B-protein
(	I-protein
s6k	I-protein
)	I-protein
that	O
regulates	O
a	O
crucial	O
G1	O
checkpoint	O
in	O
T	B-cell_type
lymphocytes	I-cell_type
.	O

Oxidative	O
stress	O
triggers	O
STAT3	B-protein
tyrosine	O
phosphorylation	O
and	O
nuclear	O
translocation	O
in	O
human	B-cell_type
lymphocytes	I-cell_type
.	O

Oxidizing	O
agents	O
are	O
powerful	O
activators	O
of	O
factors	O
responsible	O
for	O
the	O
transcriptional	O
activation	O
of	O
cytokine-encoding	B-DNA
genes	I-DNA
involved	O
in	O
tissue	O
injury	O
.	O

In	O
this	O
study	O
we	O
show	O
evidence	O
that	O
STAT3	B-protein
is	O
a	O
transcription	B-protein
factor	I-protein
whose	O
activity	O
is	O
modulated	O
by	O
H2O2	O
in	O
human	B-cell_type
lymphocytes	I-cell_type
,	O
in	O
which	O
endogenous	O
catalase	B-protein
had	O
previously	O
been	O
inhibited	O
.	O

H2O2-induced	O
nuclear	O
translocation	O
of	O
STAT3	B-protein
to	O
form	O
sequence-specific	B-protein
DNA-bound	I-protein
complexes	I-protein
was	O
evidenced	O
by	O
immunoblotting	O
of	O
nuclear	O
fractions	O
and	O
electrophoretic	O
mobility	O
shift	O
assays	O
,	O
and	O
vanadate	O
was	O
found	O
to	O
strongly	O
synergize	O
with	O
H2O2	O
.	O

Moreover	O
,	O
anti-	O
STAT3	B-protein
antibodies	I-protein
specifically	O
precipitated	O
a	O
protein	O
of	O
92	B-protein
kDa	I-protein
that	O
becomes	O
phosphorylated	O
on	O
tyrosine	O
upon	O
lymphocyte	O
treatment	O
with	O
H2O2	O
.	O

Phenylarsine	O
oxide	O
,	O
a	O
tyrosine	O
phosphatase	O
inhibitor	O
,	O
and	O
genistein	O
,	O
a	O
tyrosine	O
kinase	O
inhibitor	O
,	O
cooperated	O
and	O
cancelled	O
,	O
respectively	O
,	O
the	O
H2O2-promoted	O
STAT3	B-protein
nuclear	O
translocation	O
.	O

Evidence	O
is	O
also	O
presented	O
,	O
using	O
Fe2+/Cu2+	O
ions	O
,	O
that.OH	O
generated	O
from	O
H2O2	O
through	O
Fenton	O
reactions	O
could	O
be	O
a	O
candidate	O
oxygen	O
reactive	O
species	O
to	O
directly	O
activate	O
STAT3	B-protein
.	O

Present	O
data	O
suggest	O
that	O
H2O2	O
and	O
vanadate	O
are	O
likely	O
to	O
inhibit	O
the	O
activity	O
of	O
intracellular	B-protein
tyrosine	I-protein
phosphatase	I-protein
(	O
s	O
)	O
,	O
leading	O
to	O
enhanced	O
STAT3	B-protein
tyrosine	O
phosphorylation	O
and	O
hence	O
its	O
translocation	O
to	O
the	O
nucleus	O
.	O

These	O
results	O
demonstrate	O
that	O
the	O
DNA	O
binding	O
activity	O
of	O
STAT3	B-protein
can	O
be	O
modulated	O
by	O
oxidizing	O
agents	O
and	O
provide	O
a	O
framework	O
to	O
understand	O
the	O
effects	O
of	O
oxidative	O
stress	O
on	O
the	O
JAK	B-protein
-STAT	B-protein
signaling	O
pathway	O
.	O

Transcriptional	O
regulation	O
of	O
T	O
lymphocyte	O
development	O
and	O
function	O
.	O

The	O
development	O
and	O
function	O
of	O
T	B-cell_type
lymphocytes	I-cell_type
are	O
regulated	O
tightly	O
by	O
signal	O
transduction	O
pathways	O
that	O
include	O
specific	O
cell-surface	B-protein
receptors	I-protein
,	O
intracellular	B-protein
signaling	I-protein
molecules	I-protein
,	O
and	O
nuclear	B-protein
transcription	I-protein
factors	I-protein
.	O

Since	O
1988	O
,	O
several	O
families	O
of	O
functionally	O
important	O
T	B-protein
cell	I-protein
transcription	I-protein
factors	I-protein
have	O
been	O
identified	O
.	O

These	O
include	O
the	O
Ikaros	B-protein
,	O
LKLF	B-protein
,	O
and	O
GATA3	B-protein
zinc-finger	I-protein
proteins	I-protein
;	O
the	O
Ets	B-protein
,	O
CREB/ATF	B-protein
,	O
and	O
NF-kappa	B-protein
B/Rel/NFAT	I-protein
transcription	I-protein
factors	I-protein
;	O
the	O
Stat	B-protein
proteins	I-protein
;	O
and	O
HMG	B-protein
box	I-protein
transcription	I-protein
factors	I-protein
such	O
as	O
LEF1	B-protein
,	O
TCF1	B-protein
,	O
and	O
Sox4	B-protein
.	O

In	O
this	O
review	O
,	O
we	O
summarize	O
our	O
current	O
understanding	O
of	O
the	O
transcriptional	O
regulation	O
of	O
T	O
cell	O
development	O
and	O
function	O
with	O
particular	O
emphasis	O
on	O
the	O
results	O
of	O
recent	O
gene	O
targeting	O
and	O
transgenic	O
experiments	O
.	O

In	O
addition	O
to	O
increasing	O
our	O
understanding	O
of	O
the	O
molecular	O
pathways	O
that	O
regulate	O
T	O
cell	O
development	O
and	O
function	O
,	O
these	O
results	O
have	O
suggested	O
novel	O
targets	O
for	O
genetic	O
and	O
pharmacological	O
manipulation	O
of	O
T	O
cell	O
immunity	O
.	O

In	O
vivo	O
inhibition	O
of	O
NF-kappa	B-protein
B	I-protein
in	O
T-lineage	B-cell_type
cells	I-cell_type
leads	O
to	O
a	O
dramatic	O
decrease	O
in	O
cell	O
proliferation	O
and	O
cytokine	B-protein
production	O
and	O
to	O
increased	O
cell	O
apoptosis	O
in	O
response	O
to	O
mitogenic	O
stimuli	O
,	O
but	O
not	O
to	O
abnormal	O
thymopoiesis	O
.	O

To	O
understand	O
the	O
role	O
of	O
NF-kappa	B-protein
B	I-protein
complexes	O
in	O
T	O
cell	O
development	O
and	O
activation	O
,	O
we	O
have	O
generated	O
transgenic	O
mice	O
in	O
which	O
RelA	B-protein
and	O
c-Rel	B-protein
complexes	I-protein
were	O
selectively	O
inhibited	O
in	O
the	O
T-lineage	B-cell_type
cells	I-cell_type
by	O
specific	O
expression	O
of	O
a	O
trans-dominant	O
form	O
of	O
I	B-protein
kappa	I-protein
B	I-protein
alpha	I-protein
.	O

Transgene	O
expression	O
did	O
not	O
affect	O
the	O
thymic	O
development	O
,	O
but	O
led	O
to	O
lowered	O
numbers	O
of	O
splenic	O
T	B-cell_type
cells	I-cell_type
and	O
to	O
a	O
dramatic	O
decrease	O
in	O
the	O
ex	O
vivo	O
proliferative	O
response	O
of	O
splenic	B-cell_type
T	I-cell_type
lymphocytes	I-cell_type
.	O

Analysis	O
of	O
IL-2	B-protein
and	O
IL-2R	B-protein
alpha	I-protein
expression	O
demonstrated	O
that	O
the	O
perturbation	O
of	O
the	O
proliferation	O
response	O
was	O
not	O
attributable	O
to	O
an	O
abnormal	O
expression	O
of	O
these	O
genes	O
.	O

In	O
contrast	O
,	O
expression	O
of	O
IL-4	B-protein
,	O
IL-10	B-protein
,	O
and	O
IFN-gamma	B-protein
was	O
strongly	O
inhibited	O
in	O
the	O
transgenic	B-cell_type
T	I-cell_type
cells	I-cell_type
.	O

The	O
proliferative	O
deficiency	O
of	O
the	O
transgenic	B-cell_type
T	I-cell_type
cells	I-cell_type
was	O
associated	O
with	O
an	O
increased	O
apoptosis	O
.	O

These	O
results	O
point	O
out	O
the	O
involvement	O
of	O
NF-kappa	B-protein
B/Rel	I-protein
family	I-protein
proteins	I-protein
in	O
growth	O
signaling	O
pathways	O
by	O
either	O
regulating	B-protein
proteins	I-protein
involved	O
in	O
the	O
IL-2	B-protein
signaling	O
or	O
by	O
functionally	O
interfering	O
with	O
the	O
cell	O
cycle	O
progression	O
.	O

Paradoxical	O
priming	O
effects	O
of	O
IL-10	B-protein
on	O
cytokine	B-protein
production	O
.	O

IL-10	B-protein
is	O
a	O
well-known	O
immunosuppressive	B-protein
and/or	I-protein
anti-inflammatory	I-protein
cytokine	I-protein
.	O

However	O
,	O
we	O
report	O
in	O
vitro	O
experimental	O
studies	O
in	O
which	O
IL-10	B-cell_line
primed	I-cell_line
leukocytes	I-cell_line
and	O
led	O
to	O
an	O
enhanced	O
production	O
of	O
tumor	B-protein
necrosis	I-protein
factor	I-protein
(	O
TNF	B-protein
)	O
upon	O
further	O
stimulation	O
by	O
lipopolysaccharide	O
(	O
LPS	O
)	O
.	O

Monocytes	B-cell_type
and	O
peripheral	B-cell_type
blood	I-cell_type
mononuclear	I-cell_type
cells	I-cell_type
(	O
PBMC	B-cell_type
)	O
prepared	O
from	O
whole	O
blood	O
maintained	O
for	O
20	O
h	O
at	O
37	O
degrees	O
C	O
in	O
the	O
presence	O
of	O
recombinant	B-protein
human	I-protein
IL-10	I-protein
had	O
an	O
enhanced	O
capacity	O
to	O
produce	O
TNF	B-protein
in	O
response	O
to	O
LPS	O
.	O

In	O
addition	O
to	O
TNF	B-protein
,	O
LPS-induced	O
IL-6	O
and	O
spontaneous	O
IL-1ra	O
production	O
were	O
also	O
enhanced	O
.	O

When	O
isolated	O
PBMC	B-cell_type
were	O
first	O
cultured	O
for	O
20	O
h	O
in	O
the	O
presence	O
of	O
IL-10	B-protein
on	O
Teflon	O
to	O
prevent	O
adherence	O
,	O
washed	O
to	O
remove	O
IL-10	B-protein
and	O
then	O
further	O
cultured	O
in	O
plastic	O
dishes	O
for	O
an	O
additional	O
20	O
h	O
in	O
the	O
presence	O
of	O
LPS	O
or	O
IL-1beta	B-protein
,	O
an	O
enhanced	O
release	O
of	O
TNF	B-protein
was	O
observed	O
.	O

This	O
was	O
not	O
the	O
case	O
when	O
PBMC	B-cell_type
were	O
pre-cultured	O
in	O
plastic	O
multidishes	O
in	O
the	O
presence	O
of	O
IL-10	B-protein
.	O

TNF	B-RNA
mRNA	I-RNA
expression	O
induced	O
by	O
LPS	O
was	O
decreased	O
when	O
the	O
pre-treatment	O
of	O
PBMC	B-cell_type
with	O
IL-10	B-protein
was	O
performed	O
on	O
plastic	O
,	O
whereas	O
this	O
was	O
not	O
the	O
case	O
when	O
cells	O
were	O
pre-cultured	O
with	O
IL-10	B-protein
on	O
Teflon	O
.	O

Furthermore	O
,	O
NFkappaB	O
translocation	O
following	O
LPS	O
activation	O
was	O
higher	O
after	O
IL-10	B-protein
pre-treatment	O
on	O
Teflon	O
than	O
on	O
plastic	O
.	O

Interestingly	O
,	O
an	O
enhanced	O
frequency	O
of	O
CD16	B-protein
and	O
CD68	O
(	O
+	O
)	O
cells	O
among	O
the	O
CD14	O
(	O
+	O
)	O
cells	O
was	O
observed	O
in	O
the	O
presence	O
of	O
IL-10	B-protein
,	O
independently	O
of	O
the	O
pre-culture	O
conditions	O
of	O
the	O
PBMC	B-cell_type
.	O

Altogether	O
,	O
these	O
results	O
indicate	O
that	O
the	O
IL-10	B-protein
-induced	O
up-regulation	O
of	O
cytokine	B-protein
production	O
depends	O
on	O
the	O
prevention	O
of	O
monocyte	O
adherence	O
by	O
red	B-cell_type
cells	I-cell_type
in	O
the	O
whole	O
blood	O
assays	O
or	O
by	O
cultures	O
of	O
PBMC	B-cell_type
on	O
Teflon	O
.	O

In	O
contrast	O
,	O
the	O
adherence	O
parameter	O
has	O
no	O
effect	O
on	O
the	O
IL-10	B-protein
-induced	O
modulation	O
of	O
some	O
monocyte	B-protein
surface	I-protein
markers	I-protein
.	O

Cell	O
growth-regulated	O
expression	O
of	O
mammalian	B-DNA
MCM5	I-DNA
and	I-DNA
MCM6	I-DNA
genes	I-DNA
mediated	O
by	O
the	O
transcription	B-protein
factor	I-protein
E2F	B-protein
.	O

Initiation	O
of	O
DNA	O
replication	O
requires	O
the	O
function	O
of	O
MCM	B-protein
gene	I-protein
products	I-protein
,	O
which	O
participate	O
in	O
ensuring	O
that	O
DNA	O
replication	O
occurs	O
only	O
once	O
in	O
the	O
cell	O
cycle	O
.	O

Expression	O
of	O
all	O
mammalian	B-DNA
genes	I-DNA
of	O
the	O
MCM	B-DNA
family	I-DNA
is	O
induced	O
by	O
growth	O
stimulation	O
,	O
unlike	O
yeast	O
,	O
and	O
the	O
mRNA	O
levels	O
peak	O
at	O
G1/S	O
boundary	O
.	O

In	O
this	O
study	O
,	O
we	O
examined	O
the	O
transcriptional	O
activities	O
of	O
isolated	B-DNA
human	I-DNA
MCM	I-DNA
gene	I-DNA
promoters	I-DNA
.	O

Human	B-DNA
MCM5	I-DNA
and	I-DNA
MCM6	I-DNA
promoters	I-DNA
with	O
mutation	O
in	O
the	O
E2F	B-DNA
sites	I-DNA
failed	O
in	O
promoter	O
regulation	O
following	O
serum	O
stimulation	O
and	O
exogenous	O
E2F	B-protein
expression	O
.	O

In	O
addition	O
,	O
we	O
identified	O
a	O
novel	O
E2F-like	B-DNA
sequence	I-DNA
in	O
human	B-DNA
MCM6	I-DNA
promoter	I-DNA
which	O
cooperates	O
with	O
the	O
authentic	O
E2F	B-DNA
sites	I-DNA
in	O
E2F	B-protein
-dependent	O
regulation	O
.	O

Forced	O
expression	O
of	O
E2F1	B-protein
could	O
induce	O
expression	O
of	O
all	O
members	O
of	O
the	O
endogenous	B-DNA
MCM	I-DNA
genes	I-DNA
in	O
rat	B-cell_line
embryonal	I-cell_line
fibroblast	I-cell_line
REF52	I-cell_line
cells	I-cell_line
.	O

Our	O
results	O
demonstrated	O
that	O
the	O
growth-regulated	O
expression	O
of	O
mammalian	B-DNA
MCM5	I-DNA
and	I-DNA
MCM6	I-DNA
genes	I-DNA
,	O
and	O
presumably	O
other	O
MCM	O
members	O
,	O
is	O
primarily	O
regulated	O
by	O
E2F	B-protein
through	O
binding	O
to	O
multiple	B-DNA
E2F	I-DNA
sites	I-DNA
in	O
the	O
promoters	B-DNA
.	O

An	O
essential	O
role	O
for	O
NF-kappaB	B-protein
in	O
human	B-cell_type
CD34	I-cell_type
(	I-cell_type
+	I-cell_type
)	I-cell_type
bone	I-cell_type
marrow	I-cell_type
cell	I-cell_type
survival	O
.	O

The	O
transcription	B-protein
factor	I-protein
,	O
NF-kappaB	B-protein
,	O
is	O
important	O
for	O
T-cell	O
activation	O
,	O
B-cell	O
maturation	O
,	O
and	O
human	O
immunodeficiency	O
virus	O
transcription	O
and	O
plays	O
a	O
role	O
in	O
alternatively	O
mediating	O
and	O
protecting	O
against	O
apoptosis	O
in	O
a	O
variety	O
of	O
cell	O
types	O
.	O

However	O
,	O
a	O
role	O
for	O
NF-kappaB	B-protein
in	O
human	B-cell_type
CD34	I-cell_type
(	I-cell_type
+	I-cell_type
)	I-cell_type
bone	I-cell_type
marrow	I-cell_type
cells	I-cell_type
has	O
not	O
been	O
described	O
.	O

We	O
provide	O
evidence	O
here	O
that	O
virtually	O
all	O
human	B-cell_type
CD34	I-cell_type
(	I-cell_type
+	I-cell_type
)	I-cell_type
bone	I-cell_type
marrow	I-cell_type
cells	I-cell_type
express	O
NF-kappaB	B-protein
that	O
can	O
be	O
activated	O
by	O
exposure	O
to	O
phorbol	O
12-myristate	O
13-acetate	O
and	O
a	O
variety	O
of	O
cytokines	B-protein
,	O
eg	O
,	O
tumor	B-protein
necrosis	I-protein
factor	I-protein
alpha	I-protein
,	O
interleukin-3	B-protein
,	O
and	O
granulocyte-macrophage	B-protein
colony-stimulating	I-protein
factor	I-protein
.	O

In	O
addition	O
,	O
we	O
demonstrate	O
that	O
NF-kappaB	B-protein
may	O
be	O
required	O
for	O
human	O
CD34	B-cell_type
(	I-cell_type
+	I-cell_type
)	I-cell_type
bone	I-cell_type
marrow	I-cell_type
cell	I-cell_type
clonogenic	O
function	O
and	O
survival	O
.	O

These	O
results	O
offer	O
insight	O
into	O
a	O
new	O
role	O
for	O
NF-kappaB	B-protein
in	O
maintaining	O
survival	O
and	O
function	O
in	O
hematopoietic	B-cell_type
stem	I-cell_type
and	I-cell_type
progenitor	I-cell_type
cells	I-cell_type
and	O
suggest	O
that	O
proposed	O
strategies	O
involving	O
inhibition	O
of	O
NF-kappaB	B-protein
activation	O
as	O
an	O
adjunct	O
to	O
cancer	O
chemotherapy	O
should	O
be	O
approached	O
with	O
caution	O
.	O

High	O
molecular	O
weight	O
dextran	O
sulfate	O
increases	O
the	O
activity	O
of	O
NF-kappaB-regulated	B-DNA
promoter	I-DNA
in	O
monocyte-derived	B-cell_type
macrophages	I-cell_type
.	O

It	O
is	O
known	O
that	O
sulfated	O
polysaccharides	O
can	O
mimic	O
the	O
action	O
of	O
common	B-protein
T-cell	I-protein
mitogens	I-protein
.	O

To	O
investigate	O
the	O
molecular	O
basis	O
of	O
the	O
mitogenic	O
effect	O
of	O
high	O
molecular	O
weight	O
dextran	O
sulfate	O
(	O
HMDS	O
)	O
,	O
monocyte-derived	B-cell_type
macrophages	I-cell_type
were	O
transfected	O
with	O
recombinant	B-DNA
plasmid	I-DNA
containing	O
chloramphenicol	B-DNA
acetyl	I-DNA
transferase	I-DNA
(	I-DNA
CAT	I-DNA
)	I-DNA
reporter	I-DNA
gene	I-DNA
under	O
the	O
control	O
of	O
the	O
HIV-1	B-DNA
long	I-DNA
terminal	I-DNA
repeat	I-DNA
(	I-DNA
LTR	I-DNA
)	I-DNA
promoter	I-DNA
,	O
which	O
is	O
regulated	O
by	O
transcription	B-protein
factor	I-protein
NF-kappaB	B-protein
.	O

We	O
observed	O
that	O
HMDS	O
,	O
similar	O
to	O
bacterial	O
lipopolysaccharide	O
(	O
LPS	O
)	O
,	O
increases	O
the	O
expression	O
of	O
CAT	B-DNA
reporter	I-DNA
gene	I-DNA
suggesting	O
increased	O
activity	O
of	O
NF-kappaB	B-protein
.	O

The	O
activation	O
of	O
NF-kappaB	B-protein
correlated	O
with	O
the	O
increased	O
expression	O
of	O
B7.1	B-protein
molecules	I-protein
.	O

It	O
was	O
postulated	O
that	O
this	O
NF-kappaB-regulated	B-DNA
promoter	I-DNA
might	O
play	O
a	O
role	O
in	O
the	O
activation	O
of	O
the	O
accessory	O
cells	O
as	O
well	O
as	O
the	O
rate	O
of	O
replication	O
of	O
HIV-1	O
in	O
monocyte-derived	B-cell_type
macrophages	I-cell_type
.	O

Transcription	B-protein
factors	I-protein
Sp1	B-protein
and	O
AP-2	B-protein
mediate	O
induction	O
of	O
acid	B-protein
sphingomyelinase	I-protein
during	O
monocytic	O
differentiation	O
.	O

Cells	O
from	O
the	O
human	B-cell_line
monocytic	I-cell_line
leukemia	I-cell_line
cell	I-cell_line
line	I-cell_line
THP-1	B-cell_line
differentiate	O
towards	O
a	O
macrophage-like	O
phenotype	O
when	O
stimulated	O
with	O
phorbol	O
12-myristate	O
-13-	O
acetate	O
(	O
PMA	O
)	O
,	O
1	O
,	O
25-dihydroxy-vitamin	O
D3	O
,	O
and	O
various	O
other	O
agents	O
.	O

We	O
demonstrate	O
here	O
that	O
the	O
expression	O
of	O
the	O
lysosomal	B-protein
enzyme	I-protein
acid	B-protein
sphingomyelinase	I-protein
(	O
ASM	O
;	O
E.C.3.1.4.12	O
)	O
is	O
induced	O
during	O
this	O
process	O
and	O
is	O
strongly	O
elevated	O
in	O
differentiated	O
THP-1	B-cell_line
cells	I-cell_line
,	O
as	O
well	O
as	O
in	O
differentiated	O
human	B-cell_type
mononuclear	I-cell_type
phagocytes	I-cell_type
.	O

Using	O
Northern	O
blotting	O
,	O
RNase	B-protein
protection	O
assay	O
,	O
and	O
nuclear	O
run-on	O
analyses	O
,	O
we	O
show	O
that	O
the	O
up-regulation	O
of	O
ASM	O
expression	O
is	O
regulated	O
mainly	O
at	O
the	O
level	O
of	O
transcription	O
and	O
that	O
new	O
protein	O
synthesis	O
is	O
required	O
for	O
enhanced	O
ASM	O
activity	O
.	O

This	O
cell-type	O
specific	O
induction	O
by	O
PMA	O
treatment	O
was	O
further	O
investigated	O
with	O
respect	O
to	O
transcriptional	O
control	O
.	O

A	O
series	O
of	O
5	B-DNA
'	I-DNA
deletion	I-DNA
derivatives	I-DNA
of	O
the	O
upstream	B-DNA
regulatory	I-DNA
region	I-DNA
were	O
used	O
in	O
transient	O
transfection	O
assays	O
to	O
identify	O
promoter	B-DNA
elements	I-DNA
required	O
for	O
basal	O
and	O
inducible	O
gene	O
expression	O
.	O

A	O
PMA	B-DNA
responsive	I-DNA
element	I-DNA
was	O
localized	O
to	O
a	O
region	O
between	O
-319	B-DNA
and	I-DNA
-219	I-DNA
bp	I-DNA
upstream	I-DNA
of	O
the	O
initiation	O
codon	O
and	O
co-transfections	O
with	O
transcription	B-DNA
factor	I-DNA
expression	I-DNA
plasmids	I-DNA
for	O
AP-2	B-protein
and	O
Sp1	B-protein
resulted	O
in	O
augmented	O
ASM	O
promoter	O
activity	O
,	O
which	O
was	O
abolished	O
when	O
the	O
binding	B-DNA
sites	I-DNA
for	O
these	O
two	O
factors	O
were	O
deleted	O
.	O

Using	O
electrophoretic	O
mobility	O
shift	O
assays	O
and	O
supershift	O
assays	O
we	O
demonstrate	O
that	O
this	O
region	O
is	O
specifically	O
bound	O
by	O
Sp1	B-protein
and	O
AP-2	B-protein
.	O

These	O
factors	O
are	O
present	O
in	O
nuclear	O
extracts	O
prepared	O
from	O
both	O
induced	O
and	O
uninduced	O
THP-1	B-cell_line
cells	I-cell_line
.	O

However	O
,	O
the	O
intensity	O
of	O
the	O
complex	O
formed	O
appeared	O
to	O
increase	O
when	O
nuclear	O
extracts	O
from	O
PMA-treated	B-cell_line
cells	I-cell_line
were	O
used	O
.	O

From	O
these	O
studies	O
,	O
we	O
conclude	O
that	O
a	O
concerted	O
action	O
of	O
the	O
transcription	B-protein
factors	I-protein
AP-2	B-protein
and	O
Sp1	B-protein
is	O
essential	O
for	O
the	O
up	O
-regulation	O
of	O
ASM	O
expression	O
during	O
the	O
process	O
of	O
macrophage	O
differentiation	O
.	O

LPS-Induced	O
NF-kappaB	B-protein
activation	O
and	O
TNF-alpha	B-protein
release	O
in	O
human	B-cell_type
monocytes	I-cell_type
are	O
protein	B-protein
tyrosine	I-protein
kinase	I-protein
dependent	O
and	O
protein	B-protein
kinase	I-protein
C	I-protein
independent	O
.	O

BACKGROUND	O
:	O
Tumor	B-protein
necrosis	I-protein
factor	I-protein
alpha	I-protein
(	O
TNF-alpha	B-protein
)	O
is	O
an	O
important	O
mediator	O
of	O
septic	O
shock	O
.	O

Endotoxin	O
(	O
LPS	O
)	O
signal	O
transduction	O
in	O
human	B-cell_type
monocytes	I-cell_type
leads	O
to	O
activation	O
of	O
nuclear	B-protein
factor-kappa	I-protein
B	I-protein
(	O
NF-kappaB	B-protein
)	O
and	O
TNF-alpha	B-protein
release	O
.	O

Previous	O
studies	O
have	O
implicated	O
activation	O
of	O
both	O
protein	B-protein
kinase	I-protein
C	I-protein
(	O
PKC	B-protein
)	O
and	O
protein	B-protein
tyrosine	I-protein
kinases	I-protein
(	O
PTK	B-protein
)	O
in	O
LPS-induced	O
NF-kappaB	B-protein
activation	O
and	O
TNF-alpha	B-protein
production	O
.	O

We	O
hypothesized	O
that	O
inhibition	O
of	O
either	O
PKC	B-protein
or	O
PTK	B-protein
would	O
decrease	O
LPS-induced	O
NF-kappaB	B-protein
DNA	O
binding	O
and	O
TNF-alpha	B-protein
release	O
in	O
human	B-cell_type
monocytes	I-cell_type
.	O

MATERIALS	O
AND	O
METHODS	O
:	O
Human	B-cell_type
monocytes	I-cell_type
were	O
stimulated	O
with	O
PMA	O
(	O
50	O
ng/ml	O
)	O
alone	O
or	O
LPS	O
(	O
100	O
ng/ml	O
)	O
with	O
and	O
without	O
a	O
nonspecific	O
serine/threonine	B-protein
protein	I-protein
kinase	I-protein
inhibitor	O
staurosporine	O
(	O
Stauro	O
)	O
,	O
a	O
specific	O
pan-	O
PKC	B-protein
inhibitor	O
bisindolylmaleimide	O
(	O
Bis	O
)	O
,	O
or	O
an	O
inhibitor	O
of	O
PTK	B-protein
genistein	O
(	O
Gen	O
)	O
.	O

TNF-alpha	B-protein
release	O
in	O
culture	O
supernatants	O
was	O
measured	O
by	O
an	O
ELISA	O
.	O

NF-kappaB	B-protein
DNA	O
binding	O
was	O
evaluated	O
by	O
electrophoretic	O
mobility	O
shift	O
assay	O
.	O

RESULTS	O
:	O
LPS	O
increased	O
NF-kappaB	B-protein
DNA	O
binding	O
and	O
TNF-alpha	B-protein
release	O
in	O
human	B-cell_type
monocytes	I-cell_type
.	O

Nonspecific	O
protein	B-protein
kinase	I-protein
inhibition	O
inhibited	O
NF-kappaB	B-protein
activation	O
and	O
TNF-alpha	B-protein
release	O
,	O
while	O
specific	O
PKC	B-protein
inhibition	O
with	O
Bis	O
had	O
no	O
effect	O
on	O
LPS-induced	O
NF-kappaB	B-protein
DNA	O
binding	O
or	O
TNF-alpha	B-protein
release	O
.	O

PTK	B-protein
inhibition	O
with	O
Gen	O
attenuated	O
both	O
LPS-induced	O
NF-kappaB	B-protein
DNA	O
binding	O
and	O
TNF-alpha	B-protein
production	O
in	O
human	B-cell_type
monocytes	I-cell_type
.	O

Direct	O
activation	O
of	O
PKC	B-protein
with	O
PMA	O
induced	O
both	O
NF-kappaB	B-protein
activation	O
and	O
TNF-alpha	B-protein
production	O
by	O
human	B-cell_type
monocytes	I-cell_type
.	O

CONCLUSIONS	O
:	O
These	O
results	O
suggest	O
that	O
LPS-induced	O
NF-kappaB	B-protein
activation	O
and	O
TNF-alpha	B-protein
release	O
in	O
human	B-cell_type
monocytes	I-cell_type
are	O
independent	O
of	O
PKC	B-protein
activity	O
.	O

Furthermore	O
,	O
our	O
results	O
provide	O
evidence	O
that	O
PTK	B-protein
plays	O
a	O
role	O
in	O
LPS-induced	O
NF-kappaB	B-protein
activation	O
and	O
TNF-alpha	B-protein
release	O
in	O
human	B-cell_type
monocytes	I-cell_type
and	O
thus	O
could	O
be	O
a	O
potential	O
therapeutic	O
target	O
in	O
inflammatory	O
states	O
.	O

Copyright	O
1999	O
Academic	O
Press	O
.	O

Amelioration	O
of	O
rat	O
cerulein	O
pancreatitis	O
by	O
guamerin-derived	O
peptide	O
,	O
a	O
novel	O
elastase	B-protein
inhibitor	O
.	O

Increased	O
activity	O
of	O
various	O
proteases	B-protein
is	O
observed	O
in	O
both	O
human	O
and	O
experimental	O
pancreatitis	O
;	O
however	O
,	O
the	O
information	O
on	O
the	O
effects	O
of	O
specific	O
protease	O
inhibitors	O
on	O
the	O
disease	O
is	O
limited	O
.	O

In	O
this	O
study	O
we	O
show	O
that	O
a	O
novel	O
elastase	O
inhibitor	O
,	O
guamerin-derived	O
synthetic	O
peptide	O
(	O
GDSP	O
)	O
,	O
improves	O
the	O
parameters	O
of	O
cerulein-induced	O
acute	O
pancreatitis	O
in	O
the	O
rat	O
.	O

The	O
effects	O
of	O
GDSP	O
on	O
pancreatic	O
weight	O
,	O
serum	B-protein
amylase	I-protein
and	I-protein
lipase	I-protein
,	O
morphologic	O
changes	O
in	O
the	O
pancreas	O
,	O
neutrophil	O
infiltration	O
,	O
and	O
nuclear	B-protein
factor	I-protein
KB	I-protein
(	O
NF-KB	B-protein
)	O
activation	O
were	O
measured	O
in	O
rats	O
infused	O
with	O
supramaximal	O
dose	O
of	O
cerulein	O
(	O
5	O
(	O
g/kg/h	O
)	O
for	O
6	O
h	O
.	O

The	O
effects	O
of	O
GDSP	O
were	O
also	O
measured	O
on	O
superoxide	O
formation	O
by	O
activated	B-cell_type
human	I-cell_type
neutrophils	I-cell_type
.	O

The	O
effects	O
of	O
GDSP	O
were	O
compared	O
with	O
those	O
of	O
another	O
elastase	O
inhibitor	O
,	O
elastatinal	O
.	O

GDSP	O
significantly	O
inhibited	O
edema	O
formation	O
,	O
neutrophil	O
infiltration	O
,	O
acinar	O
cell	O
damage	O
,	O
and	O
plasma	B-protein
lipase	I-protein
and	O
amylase	B-protein
increases	O
caused	O
by	O
cerulein	O
.	O

GDSP	O
also	O
completely	O
inhibited	O
superoxide	O
formation	O
in	O
the	O
human	B-cell_type
neutrophils	I-cell_type
stimulated	O
by	O
N-formyl-methionine-leucine-phenyl-alanine	O
(	O
fMLP	O
)	O
or	O
12-O-tetradecanoylphorbol-13-acetate	O
(	O
TPA	O
)	O
.	O

Elastatinal	O
had	O
some	O
of	O
the	O
same	O
effects	O
as	O
GDSP	O
but	O
was	O
less	O
potent	O
and	O
effective	O
.	O

These	O
results	O
demonstrate	O
a	O
beneficial	O
effect	O
of	O
GDSP	O
,	O
a	O
novel	O
specific	O
elastase	O
inhibitor	O
,	O
on	O
the	O
development	O
of	O
rat	O
cerulein	O
pancreatitis	O
.	O

A	O
novel	O
lipopolysaccharide-induced	B-protein
transcription	I-protein
factor	I-protein
regulating	O
tumor	B-protein
necrosis	I-protein
factor	I-protein
alpha	I-protein
gene	O
expression	O
:	O
molecular	O
cloning	O
,	O
sequencing	O
,	O
characterization	O
,	O
and	O
chromosomal	O
assignment	O
.	O

Lipopolysaccharide	O
(	O
LPS	O
)	O
is	O
a	O
potent	O
stimulator	O
of	O
monocytes	B-cell_type
and	O
macrophages	B-cell_type
,	O
causing	O
secretion	O
of	O
tumor	B-protein
necrosis	I-protein
factor	I-protein
alpha	I-protein
(	O
TNF-alpha	B-protein
)	O
and	O
other	O
inflammatory	O
mediators	O
.	O

Given	O
the	O
deleterious	O
effects	O
to	O
the	O
host	O
of	O
TNF-alpha	B-protein
,	O
it	O
has	O
been	O
postulated	O
that	O
TNF-alpha	B-protein
gene	O
expression	O
must	O
be	O
tightly	O
regulated	O
.	O

The	O
nature	O
of	O
the	O
nuclear	B-protein
factor	I-protein
(	O
s	O
)	O
that	O
control	O
TNF-alpha	B-protein
gene	O
transcription	O
in	O
humans	O
remains	O
obscure	O
,	O
although	O
NF-kappaB	B-protein
has	O
been	O
suggested	O
.	O

Our	O
previous	O
studies	O
pertaining	O
to	O
macrophage	O
response	O
to	O
LPS	O
identified	O
a	O
novel	O
DNA-binding	B-protein
domain	I-protein
located	O
from	O
-550	O
to	O
-487	O
in	O
the	O
human	B-DNA
TNF-alpha	I-DNA
promoter	I-DNA
that	O
contains	O
transcriptional	O
activity	O
,	O
but	O
lacks	O
any	O
known	O
NF-kappaB	B-protein
-binding	B-DNA
sites	I-DNA
.	O

We	O
have	O
used	O
this	O
DNA	O
fragment	O
to	O
isolate	O
and	O
purify	O
a	O
60-kDa	B-protein
protein	I-protein
binding	O
to	O
this	O
fragment	O
and	O
obtained	O
its	O
amino-terminal	B-protein
sequence	I-protein
,	O
which	O
was	O
used	O
to	O
design	O
degenerate	B-DNA
probes	I-DNA
to	O
screen	O
a	O
cDNA	O
library	O
from	O
THP-1	B-cell_line
cells	I-cell_line
.	O

A	O
novel	O
cDNA	B-DNA
clone	I-DNA
(	O
1.8	O
kb	O
)	O
was	O
isolated	O
and	O
fully	O
sequenced	O
.	O

Characterization	O
of	O
this	O
cDNA	B-DNA
clone	I-DNA
revealed	O
that	O
its	O
induction	O
was	O
dependent	O
on	O
LPS	O
activation	O
of	O
THP-1	B-cell_line
cells	I-cell_line
;	O
hence	O
,	O
the	O
name	O
LPS-induced	B-protein
TNF-alpha	I-protein
factor	I-protein
(	O
LITAF	B-protein
)	O
.	O

Inhibition	O
of	O
LITAF	B-RNA
mRNA	I-RNA
expression	O
in	O
THP-1	B-cell_line
cells	I-cell_line
resulted	O
in	O
a	O
reduction	O
of	O
TNF-alpha	B-protein
transcripts	O
.	O

In	O
addition	O
,	O
high	O
level	O
of	O
expression	O
of	O
LITAF	B-RNA
mRNA	I-RNA
was	O
observed	O
predominantly	O
in	O
the	O
placenta	O
,	O
peripheral	B-cell_type
blood	I-cell_type
leukocytes	I-cell_type
,	O
lymph	O
nodes	O
,	O
and	O
the	O
spleen	O
.	O

Finally	O
,	O
chromosomal	O
localization	O
using	O
fluorescence	O
in	O
situ	O
hybridization	O
revealed	O
that	O
LITAF	B-protein
mapped	O
to	O
chromosome	B-DNA
16p12-16p13.3	I-DNA
.	O

Together	O
,	O
these	O
findings	O
suggest	O
that	O
LITAF	B-protein
plays	O
an	O
important	O
role	O
in	O
the	O
activation	O
of	O
the	O
human	B-DNA
TNF-alpha	I-DNA
gene	I-DNA
and	O
proposes	O
a	O
new	O
mechanism	O
to	O
control	O
TNF-alpha	B-protein
gene	O
expression	O
.	O

A	O
human	B-DNA
IFNGR1	I-DNA
small	I-DNA
deletion	I-DNA
hotspot	I-DNA
associated	O
with	O
dominant	O
susceptibility	O
to	O
mycobacterial	O
infection	O
[	O
see	O
comments	O
]	O

The	O
immunogenetic	O
basis	O
of	O
severe	O
infections	O
caused	O
by	O
bacille	O
Calmette-Guerin	O
vaccine	O
and	O
environmental	O
mycobacteria	O
in	O
humans	O
remains	O
largely	O
unknown	O
.	O

We	O
describe	O
18	O
patients	O
from	O
several	O
generations	O
of	O
12	O
unrelated	O
families	O
who	O
were	O
heterozygous	O
for	O
1	O
to	O
5	O
overlapping	B-DNA
IFNGR1	I-DNA
frameshift	I-DNA
small	I-DNA
deletions	I-DNA
and	O
a	O
wild-type	B-DNA
IFNGR1	I-DNA
allele	I-DNA
.	O

There	O
were	O
12	O
independent	O
mutation	O
events	O
at	O
a	O
single	B-DNA
mutation	I-DNA
site	I-DNA
,	O
defining	O
a	O
small	B-DNA
deletion	I-DNA
hotspot	I-DNA
.	O

Neighbouring	O
sequence	O
analysis	O
favours	O
a	O
small	O
deletion	O
model	O
of	O
slipped	O
mispairing	O
events	O
during	O
replication	O
.	O

The	O
mutant	O
alleles	O
encode	O
cell-surface	B-protein
IFNgamma	I-protein
receptors	I-protein
that	O
lack	O
the	O
intra-cytoplasmic	B-protein
domain	I-protein
,	O
which	O
,	O
through	O
a	O
combination	O
of	O
impaired	O
recycling	O
,	O
abrogated	O
signalling	O
and	O
normal	O
binding	O
to	O
IFNgamma	B-protein
exert	O
a	O
dominant-negative	O
effect	O
.	O

We	O
thus	O
report	O
a	O
hotspot	O
for	O
human	B-DNA
IFNGR1	I-DNA
small	I-DNA
deletions	I-DNA
that	O
confer	O
dominant	O
susceptibility	O
to	O
infections	O
caused	O
by	O
poorly	O
virulent	O
mycobacteria	O
.	O

Characterization	O
of	O
expression	O
of	O
the	O
gene	O
for	O
human	B-protein
pterin	I-protein
carbinolamine	I-protein
dehydratase/dimerization	I-protein
cofactor	I-protein
of	O
HNF1	B-protein
.	O

Pterin	B-protein
carbinolamine	I-protein
dehydratase/dimerization	I-protein
cofactor	I-protein
of	O
HNF1	B-protein
(	O
PCD/DCoH	B-protein
)	O
is	O
a	O
dual-function	B-protein
protein	I-protein
.	O

In	O
the	O
cytoplasm	O
it	O
acts	O
as	O
a	O
dehydratase	B-protein
in	O
the	O
regeneration	O
of	O
tetrahydrobiopterin	B-protein
,	O
the	O
cofactor	O
for	O
aromatic	B-protein
amino	I-protein
acid	I-protein
hydroxylases	I-protein
.	O

In	O
the	O
nucleus	O
,	O
it	O
functions	O
as	O
a	O
dimerization	B-protein
cofactor	I-protein
of	O
HNF1	B-protein
and	O
increases	O
the	O
transcriptional	O
activity	O
of	O
HNF1	B-protein
.	O

To	O
deepen	O
our	O
understanding	O
of	O
this	O
protein	O
,	O
we	O
characterized	O
its	O
expression	O
in	O
human	O
tissues	O
and	O
cells	O
.	O

Human	O
PCD/DCoH	B-protein
was	O
present	O
predominantly	O
in	O
liver	O
and	O
kidney	O
,	O
with	O
significant	O
amounts	O
in	O
testis	O
and	O
ovary	O
,	O
trace	O
amounts	O
in	O
lung	O
,	O
and	O
undetectable	O
levels	O
in	O
whole	O
brain	O
,	O
heart	O
,	O
and	O
spleen	O
.	O

It	O
was	O
expressed	O
in	O
all	O
of	O
the	O
cells	O
that	O
were	O
examined	O
.	O

Importantly	O
,	O
it	O
was	O
also	O
present	O
in	O
the	O
nucleus	O
of	O
HeLa	B-cell_line
cells	I-cell_line
,	O
which	O
lack	O
HNF1	B-protein
,	O
and	O
in	O
the	O
cytoplasm	O
of	O
fibroblasts	B-cell_type
that	O
have	O
little	O
or	O
no	O
tetrahydrobiopterin	B-protein
.	O

The	O
expression	O
of	O
human	B-protein
PCD/DCoH	I-protein
in	O
the	O
liver	O
and	O
nonhepatic	B-cell_type
cells	I-cell_type
was	O
compared	O
at	O
both	O
the	O
mRNA	O
and	O
protein	O
levels	O
.	O

Although	O
the	O
mRNA	O
level	O
in	O
liver	O
was	O
only	O
fourfold	O
higher	O
than	O
that	O
in	O
keratinocytes	B-cell_type
and	O
fibroblasts	B-cell_type
,	O
the	O
hepatic	B-protein
PCD/DCoH	I-protein
protein	I-protein
level	O
was	O
20-fold	O
higher	O
than	O
that	O
in	O
normal	B-cell_type
human	I-cell_type
epidermal	I-cell_type
keratinocytes	I-cell_type
and	O
dermal	B-cell_type
fibroblasts	I-cell_type
.	O

Cloning	O
of	O
the	O
5	B-DNA
'	I-DNA
and	I-DNA
3	I-DNA
'	I-DNA
untranslated	I-DNA
region	I-DNA
(	O
UTR	B-DNA
)	O
of	O
human	B-protein
keratinocyte	I-protein
PCD/DCoH	I-protein
revealed	O
that	O
it	O
has	O
53	O
bp	O
more	O
of	O
GC-rich	B-DNA
5	I-DNA
'	I-DNA
untranslated	I-DNA
sequence	I-DNA
than	O
the	O
published	O
liver	B-protein
PCD/DCoH	I-protein
.	O

In	O
vitro	O
transcription	O
and	O
translation	O
analysis	O
showed	O
that	O
the	O
longer	O
5	B-DNA
'	I-DNA
UTR	I-DNA
resulted	O
in	O
about	O
a	O
35	O
%	O
decrease	O
in	O
translation	O
efficiency	O
.	O

These	O
data	O
show	O
that	O
human	B-protein
PCD/DCoH	I-protein
is	O
not	O
only	O
present	O
in	O
cells	O
where	O
tetrahydrobiopterin	B-protein
is	O
synthesized	O
or	O
HNF1	B-protein
is	O
present	O
but	O
is	O
a	O
widely	O
distributed	O
protein	O
.	O

Its	O
differential	O
expression	O
in	O
different	O
tissues	O
and	O
cells	O
is	O
regulated	O
not	O
only	O
at	O
the	O
transcriptional	O
level	O
but	O
also	O
at	O
the	O
translational	O
level	O
.	O

NF-kappaB	B-protein
regulates	O
Fas/APO-1/CD95-	O
and	O
TCR-	O
mediated	O
apoptosis	O
of	O
T	B-cell_type
lymphocytes	I-cell_type
.	O

The	O
maintenance	O
of	O
lymphocyte	O
homeostasis	O
by	O
apoptosis	O
is	O
a	O
critical	O
regulatory	O
mechanism	O
in	O
the	O
normal	O
immune	O
system	O
.	O

The	O
transcription	B-protein
factor	I-protein
NF-kappaB	B-protein
has	O
been	O
shown	O
to	O
play	O
a	O
role	O
in	O
protecting	O
cells	O
against	O
death	O
mediated	O
by	O
TNF	B-protein
We	O
show	O
here	O
that	O
NF-kappaB	B-protein
also	O
has	O
a	O
role	O
in	O
regulating	O
Fas	B-protein
/	O
APO-1	B-protein
/	O
CD95	B-protein
-mediated	O
death	O
,	O
a	O
major	O
pathway	O
of	O
peripheral	B-cell_type
T	I-cell_type
cell	I-cell_type
death	O
.	O

Transfection	O
of	O
Jurkat	B-cell_line
cells	I-cell_line
with	O
the	O
NF-kappaB	B-protein
subunits	I-protein
p50	B-protein
and	O
p65	B-protein
confers	O
resistance	O
against	O
Fas-mediated	O
apoptosis	O
.	O

Reciprocally	O
,	O
inhibition	O
of	O
NF-kappaB	B-protein
activation	O
by	O
a	O
soluble	O
peptide	O
inhibitor	O
or	O
a	O
dominant	O
form	O
of	O
the	O
NF-kappaB	B-protein
inhibitor	O
,	O
IkappaB	B-protein
,	O
makes	O
the	O
cells	O
more	O
susceptible	O
to	O
Fas-mediated	O
apoptosis	O
.	O

Furthermore	O
,	O
inhibition	O
of	O
NF-kappaB	B-protein
activation	O
by	O
a	O
soluble	O
peptide	O
inhibitor	O
rendered	O
a	O
T	B-cell_line
cell	I-cell_line
hybridoma	I-cell_line
more	O
susceptible	O
to	O
TCR-mediated	O
apoptosis	O
.	O

Correspondingly	O
,	O
transfection	O
of	O
p50	B-protein
and	O
p65	B-protein
provided	O
considerable	O
protection	O
from	O
TCR-mediated	O
apoptosis	O
.	O

These	O
observations	O
were	O
corroborated	O
by	O
studies	O
on	O
Fas	B-protein
-mediated	O
death	O
in	O
primary	B-cell_type
T	I-cell_type
cells	I-cell_type
.	O

Concanavalin	O
A-activated	O
cycling	B-cell_line
T	I-cell_line
cell	I-cell_line
blasts	I-cell_line
from	O
mice	O
that	O
are	O
transgenic	O
for	O
the	O
dominant	B-protein
IkappaB	I-protein
molecule	I-protein
have	O
increased	O
sensitivity	O
to	O
Fas-mediated	O
apoptosis	O
,	O
associated	O
with	O
a	O
down-regulation	O
of	O
NF-kappaB	B-protein
complexes	I-protein
in	O
the	O
nucleus	O
.	O

In	O
addition	O
,	O
blocking	O
TNF	B-protein
,	O
itself	O
a	O
positive	O
regulator	O
of	O
NF-kappaB	B-protein
,	O
with	O
neutralizing	B-protein
antibodies	I-protein
renders	O
the	O
cells	O
more	O
susceptible	O
to	O
anti-Fas-mediated	O
apoptosis	O
.	O

In	O
summary	O
,	O
our	O
results	O
provide	O
compelling	O
evidence	O
that	O
NF-kappaB	B-protein
protects	O
against	O
Fas	B-protein
-mediated	O
death	O
and	O
is	O
likely	O
to	O
be	O
an	O
important	O
regulator	O
of	O
T	O
cell	O
homeostasis	O
and	O
tolerance	O
.	O

T	O
helper	O
differentiation	O
proceeds	O
through	O
Stat1-dependent	O
,	O
Stat4-dependent	O
and	O
Stat4-independent	O
phases	O
.	O

Much	O
of	O
our	O
focus	O
in	O
understanding	O
Th1/Th2	O
development	O
has	O
been	O
on	O
the	O
signals	O
delivered	O
by	O
IL-12	B-protein
and	O
IL-4	B-protein
as	O
final	O
determinants	O
of	O
terminal	O
T	O
cell	O
differentiation	O
.	O

Because	O
extinction	O
of	O
IL-12	B-protein
signaling	O
in	O
early	O
Th2	O
development	O
could	O
potentially	O
be	O
important	O
in	O
imprinting	O
a	O
more	O
permanent	O
Th2	O
phenotype	O
on	O
a	O
population	O
of	O
T	B-cell_type
cells	I-cell_type
,	O
we	O
have	O
also	O
examined	O
various	O
parameters	O
regulating	O
the	O
IL-12	B-protein
signaling	O
pathway	O
.	O

Whereas	O
IL-4	B-protein
appears	O
to	O
repress	O
functional	O
IL-12	B-protein
signaling	O
through	O
inhibition	O
of	O
IL-12R	B-protein
beta	I-protein
2	I-protein
expression	O
,	O
IFN-gamma	B-protein
in	O
the	O
mouse	O
,	O
and	O
IFN-alpha	B-protein
in	O
the	O
human	O
appear	O
to	O
induce	O
IL-12R	B-protein
beta	I-protein
2	I-protein
expression	O
and	O
promote	O
IL-12	B-protein
responsiveness	O
.	O

We	O
propose	O
that	O
Th1	O
development	O
can	O
be	O
considered	O
in	O
two	O
stages	O
,	O
capacitance	O
and	O
development	O
.	O

Capacitance	O
would	O
simply	O
involve	O
expression	O
of	O
IL-12R	B-protein
beta	I-protein
1	I-protein
and	I-protein
beta	I-protein
2	I-protein
subunits	I-protein
,	O
regulated	O
by	O
TCR	O
,	O
IL-4	B-protein
and	O
IFNs	B-protein
.	O

The	O
second	O
stage	O
,	O
development	O
,	O
we	O
propose	O
is	O
the	O
true	O
IL-12	B-protein
induced	O
developmental	O
stage	O
,	O
involving	O
expression	O
of	O
Stat4	B-protein
inducible	I-protein
proteins	I-protein
.	O

In	O
the	O
human	O
,	O
this	O
may	O
also	O
occur	O
via	O
IFN-alpha	B-protein
,	O
which	O
is	O
able	O
to	O
activate	O
Stat4	B-protein
.	O

It	O
is	O
perhaps	O
possible	O
that	O
all	O
of	O
Stat4	B-protein
actions	O
on	O
Th1	O
development	O
may	O
be	O
exert	O
directly	O
by	O
Stat4	B-protein
at	O
the	O
IFN-gamma	B-DNA
gene	I-DNA
,	O
however	O
we	O
suggest	O
that	O
,	O
more	O
likely	O
,	O
Stat4	B-protein
may	O
act	O
to	O
induce	O
Th1	O
development	O
through	O
the	O
induction	O
of	O
other	O
non-cytokine	B-DNA
genes	I-DNA
,	O
whose	O
stable	O
expression	O
maintains	O
the	O
transcriptional	O
state	O
of	O
a	O
Th1	B-cell_type
cell	I-cell_type
.	O

Lineage-specific	O
activation	O
of	O
STAT3	B-protein
by	O
interferon-gamma	B-protein
in	O
human	B-cell_type
neutrophils	I-cell_type
.	O

Binding	O
of	O
interferon-gamma	B-protein
(	O
IFN-gamma	B-protein
)	O
to	O
its	O
heterodimeric	O
receptor	O
induces	O
activation	O
of	O
the	O
tyrosine	B-protein
kinases	I-protein
JAK1	B-protein
and	O
JAK2	B-protein
followed	O
by	O
tyrosine	O
phosphorylation	O
of	O
STAT1alpha	B-protein
.	O

Selective	O
activation	O
of	O
STAT1alpha	B-protein
at	O
the	O
IFN-gamma	B-protein
receptor	I-protein
is	O
achieved	O
by	O
specific	O
interaction	O
between	O
a	O
cytosolic	B-protein
tyrosine	I-protein
motif	I-protein
including	O
Y440	B-protein
in	O
the	O
IFN-gamma	B-protein
receptor	I-protein
alpha-chain	I-protein
and	O
the	O
SH2	B-protein
domain	I-protein
of	O
STAT1alpha	B-protein
.	O

We	O
demonstrate	O
that	O
,	O
in	O
addition	O
to	O
STAT1alpha	B-protein
,	O
STAT3	B-protein
is	O
also	O
activated	O
by	O
IFN-gamma	B-protein
in	O
human	B-cell_type
neutrophils	I-cell_type
.	O

The	O
activation	O
of	O
STAT3	B-protein
was	O
not	O
found	O
in	O
human	B-cell_type
eosinophils	I-cell_type
,	O
monocytes	B-cell_type
,	O
and	O
HL-60	B-cell_line
cells	I-cell_line
,	O
although	O
the	O
STAT3	B-protein
protein	I-protein
was	O
expressed	O
in	O
these	O
cells	O
.	O

The	O
cell	O
type-specific	O
activation	O
of	O
STAT3	B-protein
by	O
IFN-gamma	B-protein
was	O
also	O
observed	O
in	O
neutrophils	B-cell_type
that	O
are	O
differentiated	O
in	O
vitro	O
from	O
human	B-cell_type
CD34+	I-cell_type
hematopoietic	I-cell_type
stem	I-cell_type
cells	I-cell_type
.	O

These	O
results	O
indicate	O
that	O
a	O
single	O
cytokine	B-protein
receptor	I-protein
can	O
activate	O
different	O
STAT	B-protein
family	I-protein
members	I-protein
in	O
a	O
cell-specific	O
manner	O
,	O
which	O
might	O
result	O
in	O
cell-specific	O
gene	O
transcription	O
.	O

Alternative	O
polyadenylation	O
events	O
contribute	O
to	O
the	O
induction	O
of	O
NF-ATc	B-protein
in	O
effector	B-cell_type
T	I-cell_type
cells	I-cell_type
.	O

The	O
transcription	B-protein
factor	I-protein
NF-ATc	B-protein
is	O
synthesized	O
in	O
three	O
prominent	O
isoforms	B-protein
.	O

These	O
differ	O
in	O
the	O
length	O
of	O
their	O
C	O
terminal	O
peptides	O
and	O
mode	O
of	O
synthesis	O
.	O

Due	O
to	O
a	O
switch	O
from	O
the	O
use	O
of	O
a	O
3	B-DNA
'	I-DNA
polyA	I-DNA
site	I-DNA
to	O
a	O
more	O
proximal	B-DNA
polyA	I-DNA
site	I-DNA
,	O
NF-ATc	B-protein
expression	O
switches	O
from	O
the	O
synthesis	O
of	O
the	O
two	O
longer	O
isoforms	O
in	O
naive	B-cell_type
T	I-cell_type
cells	I-cell_type
to	O
that	O
of	O
short	O
isoform	B-protein
A	I-protein
in	O
T	B-cell_type
effector	I-cell_type
cells	I-cell_type
.	O

The	O
relative	O
low	O
binding	O
affinity	O
of	O
cleavage	B-protein
stimulation	I-protein
factor	I-protein
CstF-64	B-protein
to	O
the	O
proximal	B-DNA
polyA	I-DNA
site	I-DNA
seems	O
to	O
contribute	O
to	O
its	O
neglect	O
in	O
naive	B-cell_type
T	I-cell_type
cells	I-cell_type
.	O

These	O
alternative	O
polyadenylation	O
events	O
ensure	O
the	O
rapid	O
accumulation	O
of	O
high	O
concentrations	O
of	O
NF-ATc	B-protein
necessary	O
to	O
exceed	O
critical	O
threshold	O
levels	O
of	O
NF-ATc	B-protein
for	O
gene	O
induction	O
in	O
effector	B-cell_type
T	I-cell_type
cells	I-cell_type
.	O

Estrogen	O
and	O
progesterone	O
induction	O
of	O
survival	O
of	O
monoblastoid	B-cell_type
cells	I-cell_type
undergoing	O
TNF-alpha	B-protein
-induced	O
apoptosis	O
.	O

Induction	O
of	O
apoptosis	O
of	O
mononucleated	B-cell_type
cells	I-cell_type
is	O
a	O
physiological	O
process	O
for	O
regulating	O
the	O
intensity	O
of	O
the	O
immune	O
response	O
.	O

The	O
female	O
steroid	O
hormones	O
estrogen	O
(	O
E2	O
)	O
and	O
progesterone	O
(	O
Prog	O
)	O
are	O
known	O
to	O
modulate	O
the	O
reactivity	O
of	O
the	O
immune	O
system	O
;	O
recently	O
it	O
has	O
been	O
demonstrated	O
that	O
they	O
can	O
regulate	O
induction	O
of	O
apoptosis	O
of	O
endothelial	B-cell_type
cells	I-cell_type
and	O
osteoblasts	B-cell_type
.	O

TNF-alpha	B-protein
-mediated	O
induction	O
of	O
apoptosis	O
has	O
been	O
well	O
characterized	O
in	O
myeloid	B-cell_type
cells	I-cell_type
.	O

We	O
investigated	O
whether	O
E2	O
and	O
Prog	O
could	O
interfere	O
with	O
TNF-alpha	B-protein
-induced	O
apoptosis	O
of	O
the	O
monoblastoid	B-cell_line
U937	I-cell_line
cell	I-cell_line
line	I-cell_line
.	O

Treatment	O
with	O
E2	O
or	O
Prog	O
increased	O
survival	O
and	O
prevented	O
apoptosis	O
induced	O
by	O
TNF-alpha	B-protein
in	O
both	O
undifferentiated	O
and	O
macrophage-like	O
PMA-differentiated	B-cell_line
U937	I-cell_line
cells	I-cell_line
,	O
as	O
assessed	O
by	O
trypan	O
blue	O
exclusion	O
cell	O
counting	O
,	O
thymidine	O
incorporation	O
,	O
AnnexinV	O
labeling	O
,	O
followed	O
by	O
flow	O
cytometry	O
and	O
DNA	O
fragmentation	O
studies	O
.	O

This	O
effect	O
can	O
be	O
associated	O
with	O
the	O
activation	O
of	O
specific	O
hormone	O
receptors	O
,	O
since	O
we	O
observed	O
the	O
expression	O
of	O
the	O
estrogen	B-RNA
receptor	I-RNA
alpha	I-RNA
(	I-RNA
ER-alpha	I-RNA
)	I-RNA
,	I-RNA
ER-beta	I-RNA
,	I-RNA
and	I-RNA
progesterone	I-RNA
receptor	I-RNA
(	I-RNA
PR	I-RNA
)	I-RNA
mRNAs	I-RNA
;	O
the	O
ER-alpha	B-protein
protein	O
expression	O
was	O
confirmed	O
by	O
immunocytochemical	O
analysis	O
.	O

In	O
addition	O
,	O
hormone-mediated	O
survival	O
against	O
apoptosis	O
was	O
concentration	O
dependent	O
,	O
reaching	O
the	O
half-maximal	O
effect	O
at	O
10	O
nM	O
and	O
blocked	O
by	O
the	O
ER	O
antagonist	O
ICI	O
182	O
,	O
780	O
in	O
undifferentiated	B-cell_type
cells	I-cell_type
,	O
further	O
supporting	O
a	O
receptor-mediated	O
mechanism	O
of	O
cell	O
survival	O
.	O

Other	O
steroid	O
receptor	O
drugs	O
such	O
as	O
Raloxifene	O
,	O
RU486	O
,	O
or	O
the	O
ICI	O
182	O
,	O
780	O
in	O
PMA-differentiated	B-cell_line
cells	I-cell_line
displayed	O
agonist	O
activity	O
by	O
preventing	O
TNF-alpha	B-protein
-induced	O
apoptosis	O
as	O
efficiently	O
as	O
the	O
hormones	O
alone	O
,	O
providing	O
further	O
evidence	O
to	O
the	O
notion	O
that	O
steroid	O
receptor	O
drugs	O
may	O
manifest	O
agonist	O
or	O
antagonist	O
activities	O
depending	O
on	O
the	O
cellular	O
context	O
in	O
which	O
they	O
are	O
studied	O
.	O

Treatment	O
with	O
E2	O
was	O
also	O
associated	O
with	O
a	O
time-dependent	O
decrease	O
in	O
the	O
mRNA	O
level	O
of	O
the	O
proapoptotic	B-protein
Nip-2	I-protein
protein	I-protein
,	O
supporting	O
the	O
hypothesis	O
that	O
hormone	O
responsiveness	O
of	O
U937	B-cell_line
cells	I-cell_line
is	O
mediated	O
by	O
target	O
gene	O
transcription	O
.	O

Together	O
,	O
these	O
results	O
demonstrate	O
that	O
ER	B-protein
and	O
PR	B-protein
can	O
be	O
activated	O
by	O
endogenous	O
or	O
exogenous	O
ligands	O
to	O
induce	O
a	O
genetic	O
response	O
that	O
impairs	O
TNF-alpha	B-protein
-induced	O
apoptosis	O
in	O
U937	B-cell_line
cells	I-cell_line
.	O

The	O
data	O
presented	O
here	O
suggest	O
that	O
the	O
female	B-protein
steroid	I-protein
receptors	I-protein
play	O
a	O
role	O
in	O
regulation	O
of	O
the	O
immune	O
response	O
by	O
preventing	O
apoptosis	O
of	O
monoblastoid	B-cell_type
cells	I-cell_type
;	O
this	O
effect	O
might	O
have	O
important	O
consequences	O
in	O
the	O
clinical	O
use	O
of	O
steroid	O
receptor	O
drugs	O
.	O

--	O
Vegeto	O
,	O
E.	O
,	O
Pollio	O
,	O
G.	O
,	O
Pellicciari	O
,	O
C.	O
,	O
Maggi	O
,	O
A	O
.	O

Estrogen	O
and	O
progesterone	O
induction	O
of	O
survival	O
of	O
monoblastoid	B-cell_type
cells	I-cell_type
undergoing	O
TNF-alpha	B-protein
-inuced	O
apoptosis	O
.	O

Dicarba-closo-dodecaboranes	O
as	O
a	O
pharmacophore	O
.	O

Retinoidal	O
antagonists	O
and	O
potential	O
agonists	O
.	O

Synthesis	O
and	O
biological	O
evaluation	O
of	O
the	O
first	O
dicarba-closo-dodecaborane	O
(	O
carborane	O
)	O
derivatives	O
of	O
retinoids	O
are	O
described	O
.	O

Their	O
retinoidal	O
activity	O
were	O
examined	O
in	O
terms	O
of	O
the	O
differentiation-inducing	O
ability	O
toward	O
human	B-cell_line
promyelocytic	I-cell_line
leukemia	I-cell_line
HL-60	I-cell_line
cells	I-cell_line
.	O

High	O
retinoidal	O
activity	O
(	O
agonist	O
or	O
antagonist	O
for	O
retinoic	B-protein
acid	I-protein
receptor	I-protein
(	O
RAR	B-protein
)	O
requires	O
a	O
carboxylic	O
acid	O
moiety	O
and	O
an	O
appropriate	O
hydrophobic	O
group	O
located	O
at	O
a	O
suitable	O
position	O
on	O
the	O
molecule	O
.	O

The	O
4-carboranyl-substituted	O
compounds	O
(	O
7	O
,	O
11	O
)	O
showed	O
antagonistic	O
activity	O
but	O
no	O
agonistic	O
activity	O
even	O
in	O
the	O
presence	O
of	O
the	O
potent	O
synergist	O
HX630	O
.	O

On	O
the	O
other	O
hand	O
,	O
the	O
3-carboranyl-substituted	O
compounds	O
(	O
8	O
,	O
12	O
)	O
showed	O
potential	O
agonistic	O
activity	O
,	O
but	O
no	O
antagonistic	O
activity	O
.	O

The	O
results	O
indicates	O
that	O
carboranes	O
are	O
applicable	O
as	O
the	O
hydrophobic	O
moiety	O
of	O
biologically	O
active	O
molecules	O
.	O

Inhibition	O
of	O
T	O
cell	O
signaling	O
by	O
mitogen-activated	B-protein
protein	I-protein
kinase-targeted	I-protein
hematopoietic	I-protein
tyrosine	I-protein
phosphatase	I-protein
(	O
HePTP	B-protein
)	O
.	O

Activation	O
of	O
T	B-cell_type
lymphocytes	I-cell_type
to	O
produce	O
cytokines	B-protein
is	O
regulated	O
by	O
the	O
counterbalance	O
of	O
protein-tyrosine	B-protein
kinases	I-protein
and	O
protein-tyrosine	O
phosphatases	O
,	O
many	O
of	O
which	O
have	O
a	O
high	O
degree	O
of	O
substrate	O
specificity	O
because	O
of	O
physical	O
association	O
with	O
their	O
targets	O
.	O

Overexpression	O
of	O
hematopoietic	B-protein
protein-tyrosine	I-protein
phosphatase	I-protein
(	O
HePTP	B-protein
)	O
results	O
in	O
suppression	O
of	O
T	O
lymphocyte	O
activation	O
as	O
measured	O
by	O
T	B-protein
cell	I-protein
antigen	I-protein
receptor	I-protein
-induced	O
activation	O
of	O
transcription	B-protein
factors	I-protein
binding	O
to	O
the	O
5	B-DNA
'	I-DNA
promoter	I-DNA
of	O
the	O
interleukin-2	B-DNA
gene	I-DNA
.	O

Efforts	O
to	O
pinpoint	O
the	O
exact	O
site	O
of	O
action	O
and	O
specificity	O
of	O
HePTP	B-protein
in	O
the	O
signaling	O
cascade	O
revealed	O
that	O
HePTP	B-protein
acts	O
directly	O
on	O
the	O
mitogen-activated	B-protein
protein	I-protein
(	I-protein
MAP	I-protein
)	I-protein
kinases	I-protein
Erk1	B-protein
and	I-protein
2	I-protein
and	O
consequently	O
reduces	O
the	O
magnitude	O
and	O
duration	O
of	O
their	O
catalytic	O
activation	O
in	O
intact	B-cell_type
T	I-cell_type
cells	I-cell_type
.	O

In	O
contrast	O
,	O
HePTP	B-protein
had	O
no	O
effects	O
on	O
N-terminal	B-protein
c-Jun	I-protein
kinase	I-protein
or	O
on	O
events	O
upstream	O
of	O
the	O
MAP	O
kinases	O
.	O

The	O
specificity	O
of	O
HePTP	B-protein
correlated	O
with	O
its	O
physical	O
association	O
through	O
its	O
noncatalytic	O
N	B-protein
terminus	I-protein
with	O
Erk	B-protein
and	O
another	O
MAP	B-protein
kinase	I-protein
,	O
p38	B-protein
,	O
but	O
not	O
Jnk	B-protein
or	O
other	O
proteins	O
.	O

We	O
propose	O
that	O
HePTP	B-protein
plays	O
a	O
negative	O
role	O
in	O
antigen	O
receptor	O
signaling	O
by	O
specifically	O
regulating	O
MAP	B-protein
kinases	I-protein
in	O
the	O
cytosol	O
and	O
at	O
early	O
time	O
points	O
of	O
T	O
cell	O
activation	O
before	O
the	O
activation-induced	O
expression	O
of	O
nuclear	B-protein
dual-specific	I-protein
MAP	I-protein
kinase	I-protein
phosphatases	I-protein
.	O

p38	B-protein
mitogen-activated	I-protein
protein	I-protein
kinase	I-protein
mediates	O
signal	O
integration	O
of	O
TCR	B-protein
/CD28	B-protein
costimulation	O
in	O
primary	B-cell_type
murine	I-cell_type
T	I-cell_type
cells	I-cell_type
.	O

Optimal	O
T	O
cell	O
activation	O
requires	O
two	O
signals	O
,	O
one	O
generated	O
by	O
TCR	B-protein
and	O
another	O
by	O
the	O
CD28	B-protein
costimulatory	I-protein
receptor	I-protein
.	O

In	O
this	O
study	O
,	O
we	O
investigated	O
the	O
regulation	O
of	O
costimulation-induced	O
mitogen-activated	B-protein
protein	I-protein
kinase	I-protein
(	O
MAPK	B-protein
)	O
activation	O
in	O
primary	B-cell_type
mouse	I-cell_type
T	I-cell_type
cells	I-cell_type
.	O

In	O
contrast	O
to	O
that	O
reported	O
for	O
human	B-cell_type
Jurkat	I-cell_type
T	I-cell_type
cells	I-cell_type
,	O
we	O
found	O
that	O
p38	B-protein
MAPK	I-protein
,	O
but	O
not	O
Jun	B-protein
NH2-terminal	I-protein
kinase	I-protein
(	O
JNK	B-protein
)	O
,	O
is	O
weakly	O
activated	O
upon	O
stimulation	O
with	O
either	O
anti-CD3	B-protein
or	O
anti-CD28	B-protein
in	O
murine	B-cell_type
thymocytes	I-cell_type
and	O
splenic	B-cell_type
T	I-cell_type
cells	I-cell_type
.	O

However	O
,	O
p38	B-protein
MAPK	I-protein
is	O
activated	O
strongly	O
and	O
synergistically	O
by	O
either	O
CD3/CD28	B-protein
coligation	O
or	O
PMA/Ca2+	O
ionophore	O
stimulation	O
,	O
which	O
mimics	O
TCR	B-protein
-	O
CD3/CD28	B-protein
-mediated	O
signaling	O
.	O

Activation	O
of	O
p38	B-protein
MAPK	I-protein
correlates	O
closely	O
with	O
the	O
stimulation	O
of	O
T	O
cell	O
proliferation	O
.	O

In	O
contrast	O
,	O
PMA-induced	O
JNK	B-protein
activation	O
is	O
inhibited	O
by	O
Ca2+	O
ionophore	O
.	O

T	O
cell	O
proliferation	O
and	O
production	O
of	O
IL-2	B-protein
,	O
IL-4	B-protein
,	O
and	O
IFN-gamma	B-protein
induced	O
by	O
both	O
CD3	B-protein
and	O
CD3	B-protein
/CD28	B-protein
ligation	O
and	O
the	O
nuclear	O
expression	O
of	O
the	O
c-Jun	B-protein
and	I-protein
ATF-2	I-protein
proteins	I-protein
are	O
each	O
blocked	O
by	O
the	O
p38	B-protein
MAPK	I-protein
inhibitor	O
SB203580	O
.	O

Our	O
findings	O
demonstrate	O
that	O
p38	B-protein
MAPK	I-protein
1	O
)	O
plays	O
an	O
important	O
role	O
in	O
signal	O
integration	O
during	O
costimulation	O
of	O
primary	B-cell_type
mouse	I-cell_type
T	I-cell_type
cells	I-cell_type
,	O
2	O
)	O
may	O
be	O
involved	O
in	O
the	O
induction	O
of	O
c-Jun	B-protein
activation	O
and	O
augmentation	O
of	O
AP-1	B-protein
transcriptional	O
activity	O
,	O
and	O
3	O
)	O
regulates	O
whether	O
T	B-cell_type
cells	I-cell_type
enter	O
a	O
state	O
of	O
functional	O
unresponsiveness	O
.	O

Erythroid	O
gene	O
expression	O
is	O
differentially	O
regulated	O
by	O
erythropoietin	B-protein
,	O
haemin	O
and	O
delta-aminolaevulinic	O
acid	O
in	O
UT-7	B-cell_line
cells	I-cell_line
.	O

Erythropoietin	O
(	O
Epo	O
)	O
is	O
essential	O
for	O
the	O
later	O
stages	O
of	O
erythropoiesis	O
,	O
acting	O
to	O
promote	O
cell	O
survival	O
and	O
proliferation	O
,	O
but	O
its	O
role	O
in	O
differentiation	O
remains	O
to	O
be	O
defined	O
.	O

The	O
UT-7	B-cell_line
cell	I-cell_line
line	I-cell_line
exhibits	O
both	O
erythroid	O
and	O
megakaryocytic	O
characteristics	O
and	O
can	O
be	O
induced	O
to	O
differentiate	O
along	O
the	O
erythroid	O
pathway	O
by	O
Epo	B-protein
or	O
the	O
megakaryocytic	O
pathway	O
by	O
phorbol	O
myristic	O
acetate	O
.	O

We	O
have	O
compared	O
the	O
effects	O
of	O
Epo	B-protein
and	O
the	O
chemical	O
inducers	O
,	O
delta-aminolaevulinic	O
acid	O
(	O
delta-ALA	O
)	O
and	O
haemin	O
on	O
the	O
differentiation	O
capacity	O
of	O
UT-7	B-cell_line
cells	I-cell_line
.	O

Epo	B-protein
alone	O
promoted	O
relatively	O
early	O
events	O
in	O
erythroid	O
maturation	O
,	O
without	O
significant	O
changes	O
in	O
haemoglobin	O
production	O
or	O
morphology	O
.	O

GATA-2	B-protein
and	O
c-myb	B-protein
were	O
down-regulated	O
by	O
Epo	B-protein
,	O
and	O
GATA-2	B-protein
was	O
further	O
down-modulated	O
by	O
the	O
inducers	O
.	O

Conversely	O
,	O
SCL	B-protein
expression	O
was	O
up-regulated	O
by	O
Epo	B-protein
and	O
further	O
increased	O
by	O
haemin	O
and	O
delta-ALA	O
.	O

Epo	B-protein
caused	O
an	O
increase	O
in	O
the	O
proportion	O
of	O
cells	O
expressing	O
cell	O
surface	O
glycophorin	B-protein
A	I-protein
(	O
GPA	B-protein
)	O
and	O
up-regulated	O
beta-	B-protein
and	I-protein
gamma-globin	I-protein
by	O
several	O
fold	O
.	O

Both	O
haemin	O
and	O
delta-ALA	O
caused	O
a	O
de	O
novo	O
increase	O
in	O
alpha-globin	B-protein
expression	O
as	O
well	O
as	O
enhancing	O
Epo	B-protein
-induced	O
beta-globin	B-protein
expression	O
,	O
leading	O
to	O
a	O
marked	O
increase	O
in	O
haemoglobin	O
production	O
.	O

These	O
results	O
suggest	O
that	O
haemoglobin	O
production	O
in	O
UT-7	B-cell_line
cells	I-cell_line
is	O
limited	O
by	O
a	O
deficiency	O
of	O
erythroid-specific	B-protein
aminolaevulinic	I-protein
acid	I-protein
synthase	I-protein
(	O
ALAS-E	B-protein
)	O
activity	O
or	O
globin	O
synthesis	O
as	O
a	O
consequence	O
of	O
their	O
immaturity	O
as	O
a	O
multipotential	B-cell_line
cell	I-cell_line
line	I-cell_line
.	O

Essential	O
role	O
of	O
alveolar	B-cell_type
macrophages	I-cell_type
in	O
intrapulmonary	O
activation	O
of	O
NF-kappaB	B-protein
.	O

Acute	O
inflammatory	O
injury	O
in	O
rat	O
lung	O
induced	O
by	O
deposition	O
of	O
immunoglobulin	B-protein
G	I-protein
immune	I-protein
complexes	I-protein
requires	O
expression	O
of	O
cytokines	B-protein
and	O
chemokines	B-protein
as	O
well	O
as	O
activation	O
of	O
the	O
transcription	B-protein
factor	I-protein
nuclear	B-protein
factor	I-protein
(	I-protein
NF	I-protein
)	I-protein
-kappaB	I-protein
.	O

There	O
is	O
little	O
direct	O
evidence	O
regarding	O
the	O
role	O
of	O
alveolar	B-cell_type
macrophages	I-cell_type
in	O
these	O
activation	O
events	O
.	O

In	O
the	O
present	O
studies	O
,	O
rat	O
lungs	O
were	O
depleted	O
of	O
alveolar	B-cell_type
macrophages	I-cell_type
by	O
airway	O
instillation	O
of	O
liposome-encapsulated	O
dichloromethylene	O
diphosphonate	O
.	O

These	O
procedures	O
,	O
which	O
greatly	O
reduced	O
the	O
number	O
of	O
retrievable	O
alveolar	B-cell_type
macrophages	I-cell_type
,	O
suppressed	O
activation	O
of	O
lung	B-protein
NF-kappaB	I-protein
in	O
the	O
inflammatory	O
model	O
.	O

In	O
addition	O
,	O
bronchoalveolar	O
lavage	O
levels	O
of	O
tumor	B-protein
necrosis	I-protein
factor-alpha	I-protein
(	O
TNF-alpha	B-protein
)	O
and	O
the	O
CXC	B-protein
chemokine	I-protein
,	O
macrophage	B-protein
inflammatory	I-protein
protein-2	I-protein
,	O
were	O
substantially	O
reduced	O
.	O

In	O
parallel	O
,	O
upregulation	O
of	O
the	O
lung	B-protein
vascular	I-protein
adhesion	I-protein
molecule	I-protein
,	O
intercellular	B-protein
adhesion	I-protein
molecule-1	I-protein
,	O
was	O
greatly	O
reduced	O
by	O
intrapulmonary	O
instillation	O
of	O
phosphonate-containing	O
liposomes	O
.	O

Neutrophil	O
accumulation	O
and	O
development	O
of	O
lung	O
injury	O
were	O
also	O
substantially	O
diminished	O
.	O

Lung	O
instillation	O
of	O
TNF-alpha	B-protein
in	O
alveolar	O
macrophage-depleted	O
rats	O
restored	O
the	O
NF-kappaB	B-protein
activation	O
response	O
in	O
whole	O
lung	O
.	O

These	O
data	O
suggest	O
that	O
,	O
in	O
this	O
inflammatory	O
model	O
,	O
initial	O
activation	O
of	O
NF-kappaB	B-protein
occurs	O
in	O
alveolar	B-cell_type
macrophages	I-cell_type
and	O
the	O
ensuing	O
production	O
of	O
TNF-alpha	B-protein
may	O
propagate	O
NF-kappaB	B-protein
activation	O
to	O
other	O
cell	O
types	O
in	O
the	O
lung	O
.	O

Interferon-beta	B-protein
mediates	O
stromal	O
cell	O
rescue	O
of	O
T	B-cell_type
cells	I-cell_type
from	O
apoptosis	O
.	O

The	O
resolution	O
of	O
immune	O
responses	O
is	O
characterized	O
by	O
extensive	O
apoptosis	O
of	O
activated	O
T	B-cell_type
cells	I-cell_type
.	O

However	O
,	O
to	O
generate	O
and	O
maintain	O
immunological	O
memory	O
,	O
some	O
antigen-specific	B-cell_type
T	I-cell_type
cells	I-cell_type
must	O
survive	O
and	O
revert	O
to	O
a	O
resting	O
G0/G1	O
state	O
.	O

Cytokines	B-protein
that	O
bind	O
to	O
the	O
common	O
gamma	B-protein
chain	I-protein
of	O
the	O
IL-2	B-protein
receptor	O
promote	O
the	O
survival	O
of	O
T	B-cell_type
cell	I-cell_type
blasts	I-cell_type
,	O
but	O
also	O
induce	O
proliferation	O
.	O

In	O
contrast	O
,	O
soluble	B-protein
factors	I-protein
secreted	O
by	O
stromal	B-cell_type
cells	I-cell_type
induce	O
Tcell	O
survival	O
in	O
a	O
resting	O
G0/G1	O
state	O
.	O

We	O
now	O
report	O
that	O
interferon-beta	O
is	O
the	O
principal	O
mediator	O
of	O
stromal	O
cell-mediated	O
Tcell	O
rescue	O
from	O
apoptosis	O
.	O

Interferon-alpha	B-protein
and	I-protein
-beta	I-protein
promote	O
the	O
reversion	O
of	O
blast	B-cell_type
Tcells	I-cell_type
to	O
a	O
resting	O
G0/G1	O
configuration	O
with	O
all	O
the	O
characteristic	O
features	O
of	O
stromal	O
cell	O
rescue	O
;	O
such	O
as	O
high	O
Bcl-XL	B-protein
expression	O
and	O
low	O
Bcl-2	B-protein
.	O

Type	B-protein
I	I-protein
interferons	I-protein
and	O
stromal	B-cell_type
cells	I-cell_type
stimulate	O
apparently	O
identical	O
signaling	O
pathways	O
,	O
leading	O
to	O
STAT-1	B-protein
activation	O
.	O

We	O
also	O
show	O
that	O
this	O
mechanism	O
may	O
play	O
a	O
fundamental	O
role	O
in	O
the	O
persistence	O
of	O
T	B-cell_type
cells	I-cell_type
at	O
sites	O
of	O
chronic	O
inflammation	O
;	O
suggesting	O
that	O
chronic	O
inflammation	O
is	O
an	O
aberrant	O
consequence	O
of	O
immunological	O
memory	O
.	O

Reduction	O
of	O
tumour	B-protein
necrosis	I-protein
factor	I-protein
alpha	I-protein
expression	O
and	O
signalling	O
in	O
peripheral	B-cell_type
blood	I-cell_type
mononuclear	I-cell_type
cells	I-cell_type
from	O
patients	O
with	O
thalassaemia	O
or	O
sickle	O
cell	O
anaemia	O
upon	O
treatment	O
with	O
desferrioxamine	O
.	O

Recent	O
evidence	O
indicates	O
that	O
the	O
rate	O
of	O
progression	O
of	O
the	O
HIV-1	O
disease	O
is	O
significantly	O
reduced	O
in	O
thalassaemia	O
major	O
patients	O
upon	O
treatment	O
with	O
high	O
doses	O
of	O
desferrioxamine	O
(	O
DFX	O
)	O
.	O

The	O
authors	O
have	O
previously	O
demonstrated	O
that	O
in	O
vitro	O
exposure	O
of	O
mononuclear	B-cell_type
cells	I-cell_type
to	O
DFX	O
decreases	O
the	O
bioavailability	O
of	O
tumour	B-protein
necrosis	I-protein
factor	I-protein
alpha	I-protein
(	O
TNF-alpha	B-protein
)	O
which	O
has	O
a	O
stimulatory	O
effect	O
on	O
HIV-1	O
replication	O
.	O

In	O
this	O
study	O
,	O
therefore	O
,	O
TNF-alpha	B-protein
bioavailability	O
from	O
mononuclear	B-cell_type
cells	I-cell_type
isolated	O
from	O
10	O
patients	O
with	O
thalassaemia	O
or	O
sickle	O
cell	O
anaemia	O
given	O
DFX	O
as	O
compared	O
to	O
10	O
untreated	O
subjects	O
has	O
been	O
evaluated	O
.	O

Evidence	O
is	O
presented	O
showing	O
that	O
DFX	O
treatment	O
reduces	O
TNF-alpha	B-protein
bioavailability	O
(	O
P	O
<	O
0.05	O
)	O
by	O
inhibiting	O
its	O
steady	O
state	O
(	O
P	O
<	O
0.05	O
)	O
and	O
by	O
enhancing	O
its	O
inactivation	O
through	O
binding	O
to	O
soluble	O
TNF-alpha	B-protein
receptor	O
type	O
II	O
(	O
P	O
<	O
0.05	O
)	O
.	O

We	O
also	O
show	O
that	O
DFX	O
treatment	O
limits	O
the	O
in	O
vivo	O
activation	O
of	O
NF-kappaB	B-protein
,	O
a	O
transcription	B-protein
factor	I-protein
involved	O
in	O
both	O
TNF-alpha	B-protein
gene	O
transcription	O
and	O
TNF-alpha	B-protein
signalling	O
(	O
P	O
<	O
0.005	O
)	O
.	O

We	O
conclude	O
that	O
TNF-alpha	B-protein
bioavailability	O
and	O
signalling	O
are	O
impaired	O
in	O
patients	O
upon	O
DFX	O
treatment	O
.	O

This	O
mechanism	O
may	O
contribute	O
to	O
delayed	O
progression	O
of	O
the	O
HIV-1	O
infection	O
in	O
vivo	O
.	O

Copyright	O
1999	O
Academic	O
Press	O
.	O

Involvement	O
of	O
NF-kappaB	B-protein
p50/p65	I-protein
heterodimer	I-protein
in	O
activation	O
of	O
the	O
human	B-DNA
pro-interleukin-1beta	I-DNA
gene	I-DNA
at	O
two	O
subregions	O
of	O
the	O
upstream	B-DNA
enhancer	I-DNA
element	I-DNA
.	O

A	O
region	O
between-3134	O
and	O
-2729	O
bp	O
upstream	O
from	O
the	O
transcription	B-DNA
site	I-DNA
of	O
the	O
human	B-DNA
pro-interleukin	I-DNA
1beta	I-DNA
(	I-DNA
proIL-1beta	I-DNA
)	I-DNA
gene	I-DNA
was	O
identified	O
as	O
an	O
LPS-responsive	B-DNA
enhancer	I-DNA
element	I-DNA
.	O

In	O
this	O
study	O
,	O
the	O
influence	O
of	O
the	O
sequences	O
located	O
between	B-DNA
-3134	I-DNA
and	I-DNA
-2987	I-DNA
on	O
the	O
transcriptional	O
activity	O
of	O
the	O
proIL-1beta	B-DNA
gene	I-DNA
in	O
LPS-stimulated	B-cell_line
Raw	I-cell_line
264.7	I-cell_line
cells	I-cell_line
was	O
examined	O
in	O
detail	O
.	O

The	O
results	O
obtained	O
by	O
transient	O
transfection	O
of	O
fos	O
-CAT	B-DNA
constructs	I-DNA
that	O
contained	O
serial	B-DNA
5'-deletion	I-DNA
mutations	I-DNA
showed	O
that	O
the	O
region	O
between	O
-3134	O
and	O
-3059	O
appears	O
to	O
be	O
required	O
for	O
the	O
induction	O
of	O
transcription	O
by	O
LPS	O
.	O

Gel	O
shift	O
assay	O
studies	O
with	O
synthetic	B-DNA
oligonucleotides	I-DNA
corresponding	O
to	O
partial	O
sequences	O
of	O
the	O
latter	O
region	O
and	O
nuclear	O
extracts	O
from	O
stimulated	O
cells	O
revealed	O
specific	O
protein	B-DNA
binding	I-DNA
sites	I-DNA
between	O
-3110	O
and	O
-3090	O
and	O
between	O
-3079	O
and	O
-3059	O
.	O

These	O
specific	O
bindings	O
were	O
time	O
and	O
LPS	O
dose	O
dependent	O
.	O

The	O
results	O
of	O
supershift	O
analysis	O
using	O
specific	O
antibodies	O
against	O
transcription	B-protein
factors	I-protein
suggested	O
that	O
both	O
binding	O
complexes	O
contained	O
the	O
NF-kappaB	B-protein
components	I-protein
p50	B-protein
and	O
p65	B-protein
,	O
and	O
did	O
not	O
contain	O
other	O
NF-kappaB	B-protein
proteins	I-protein
(	O
p52	B-protein
,	O
c-Rel	B-protein
,	O
Rel	B-protein
B	I-protein
)	O
,	O
AP-1	B-protein
proteins	I-protein
(	O
c-Fos	B-protein
,	O
C-Jun	B-protein
)	O
,	O
CREB	B-protein
or	O
C/EBPbeta	B-protein
(	O
NF-IL6	B-protein
)	O
.	O

Mutation	O
of	O
either	O
of	O
the	O
putative	O
NF-kappaB-binding	B-DNA
sites	I-DNA
in	O
the	O
enhancer	O
element	O
decreased	O
the	O
LPS-stimulated	O
transcriptional	O
activity	O
.	O

These	O
data	O
indicated	O
that	O
two	O
NF-kappaB-binding	B-DNA
sites	I-DNA
,	O
which	O
are	O
located	O
between	O
-3134	B-DNA
and	I-DNA
-3059	I-DNA
,	O
are	O
critical	O
for	O
the	O
activation	O
of	O
proIL-1beta	B-DNA
gene	I-DNA
transcription	O
.	O

Copyright	O
1999	O
Academic	O
Press	O
.	O

N-acetyl-L-cysteine	O
inhibits	O
primary	O
human	O
T	O
cell	O
responses	O
at	O
the	O
dendritic	O
cell	O
level	O
:	O
association	O
with	O
NF-kappaB	B-protein
inhibition	O
.	O

N-acetyl-L-cysteine	O
(	O
NAC	O
)	O
is	O
an	O
antioxidant	O
molecule	O
endowed	O
with	O
immunomodulatory	O
properties	O
.	O

To	O
investigate	O
the	O
effect	O
of	O
NAC	O
on	O
the	O
induction	O
phase	O
of	O
T	O
cell	O
responses	O
,	O
we	O
analyzed	O
its	O
action	O
on	O
human	O
dendritic	O
cells	O
(	O
DC	O
)	O
derived	O
from	O
adherent	O
PBMC	O
cultured	O
with	O
IL-4	B-protein
and	O
granulocyte-macrophage	B-protein
CSF	I-protein
.	O

We	O
first	O
found	O
that	O
NAC	O
inhibited	O
the	O
constitutive	O
as	O
well	O
as	O
the	O
LPS-induced	O
activity	O
of	O
the	O
transcription	B-protein
factor	I-protein
NF-kappaB	B-protein
.	O

In	O
parallel	O
,	O
NAC	O
was	O
shown	O
to	O
down-regulate	O
the	O
production	O
of	O
cytokines	B-protein
by	O
DC	B-cell_type
as	O
well	O
as	O
their	O
surface	O
expression	O
of	O
HLA-DR	B-protein
,	O
CD86	B-protein
(	O
B7-2	B-protein
)	O
,	O
and	O
CD40	B-protein
molecules	I-protein
both	O
at	O
the	O
basal	O
state	O
and	O
upon	O
LPS	O
activation	O
.	O

NAC	O
also	O
inhibited	O
DC	O
responses	O
induced	O
by	O
CD40	B-protein
engagement	O
.	O

The	O
inhibitory	O
effects	O
of	O
NAC	O
were	O
not	O
due	O
to	O
nonspecific	O
toxicity	O
as	O
neither	O
the	O
viability	O
of	O
DC	B-cell_type
nor	O
their	O
mannose	O
receptor-mediated	O
endocytosis	O
were	O
modified	O
by	O
NAC	O
.	O

Finally	O
,	O
we	O
found	O
that	O
the	O
addition	O
of	O
NAC	O
to	O
MLR	O
between	O
naive	B-cell_type
T	I-cell_type
cells	I-cell_type
and	O
allogeneic	O
DC	B-cell_type
resulted	O
in	O
a	O
profound	O
inhibition	O
of	O
alloreactive	O
responses	O
,	O
which	O
could	O
be	O
attributed	O
to	O
a	O
defect	O
of	O
DC	B-cell_type
as	O
APC-independent	O
T	O
cell	O
responses	O
were	O
not	O
inhibited	O
by	O
NAC	O
.	O

Altogether	O
,	O
our	O
results	O
suggest	O
that	O
NAC	O
might	O
impair	O
the	O
generation	O
of	O
primary	O
immune	O
responses	O
in	O
humans	O
through	O
its	O
inhibitory	O
action	O
on	O
DC	B-cell_type
.	O

Thrombin-induced	B-protein
p65	I-protein
homodimer	I-protein
binding	O
to	O
downstream	O
NF-kappa	B-DNA
B	I-DNA
site	I-DNA
of	O
the	O
promoter	O
mediates	O
endothelial	O
ICAM-1	B-protein
expression	O
and	O
neutrophil	B-cell_type
adhesion	O
.	O

We	O
investigated	O
the	O
mechanisms	O
by	O
which	O
proinflammatory	B-protein
mediator	I-protein
,	O
thrombin	B-protein
,	O
released	O
during	O
intravascular	O
coagulation	O
and	O
tissue	O
injury	O
,	O
induces	O
ICAM-1	B-protein
(	O
CD54	B-protein
)	O
expression	O
in	O
endothelial	B-cell_type
cells	I-cell_type
.	O

Stimulation	O
of	O
HUVEC	B-cell_line
with	O
thrombin	B-protein
resulted	O
in	O
dose-	O
and	O
time-dependent	O
increases	O
in	O
ICAM-1	B-RNA
mRNA	I-RNA
and	O
cell	O
surface	O
expression	O
and	O
in	O
ICAM-1	B-protein
-dependent	O
endothelial	O
adhesivity	O
toward	O
polymorphonuclear	B-cell_type
leukocytes	I-cell_type
.	O

Transient	O
transfection	O
of	O
endothelial	B-cell_type
cells	I-cell_type
with	O
ICAM-1	B-DNA
promoter	I-DNA
luciferase	I-DNA
reporter	I-DNA
gene	I-DNA
(	I-DNA
ICAM-1LUC	I-DNA
)	I-DNA
constructs	I-DNA
indicated	O
that	O
deletion	O
of	O
upstream	O
NF-kappa	B-DNA
B	I-DNA
site	I-DNA
(	O
-533	B-DNA
bases	I-DNA
from	O
translation	B-DNA
start	I-DNA
site	I-DNA
)	O
had	O
no	O
effect	O
on	O
thrombin	B-protein
responsiveness	O
,	O
whereas	O
mutation/deletion	O
of	O
downstream	O
NF-kappa	B-DNA
B	I-DNA
site	I-DNA
(	O
-223	B-DNA
bases	I-DNA
from	O
the	O
translation	B-DNA
start	I-DNA
site	I-DNA
)	O
prevented	O
the	O
activation	O
of	O
ICAM-1	B-DNA
promoter	I-DNA
,	O
indicating	O
that	O
the	O
downstream	O
NF-kappa	B-DNA
B	I-DNA
site	I-DNA
is	O
critical	O
for	O
thrombin	B-protein
inducibility	O
.	O

NF-kappa	B-protein
B	I-protein
-directed	O
luciferase	B-protein
activity	O
increased	O
approximately	O
3-fold	O
when	O
cells	O
transfected	O
with	O
the	O
plasmid	B-DNA
pNF-kappa	I-DNA
BLUC	I-DNA
containing	O
five	O
copies	O
of	O
consensus	B-DNA
NF-kappa	I-DNA
B	I-DNA
site	I-DNA
linked	O
to	O
a	O
minimal	O
adenovirus	B-DNA
E1B	I-DNA
promoter-luciferase	I-DNA
gene	I-DNA
were	O
exposed	O
to	O
thrombin	B-protein
,	O
indicating	O
that	O
activation	O
of	O
NF-kappa	B-protein
B	I-protein
was	O
essential	O
for	O
thrombin	B-protein
response	O
.	O

Gel	O
supershift	O
assays	O
demonstrated	O
that	O
thrombin	B-protein
induced	O
binding	O
of	O
NF-kappa	B-protein
Bp65	I-protein
(	O
Rel	B-protein
A	I-protein
)	O
to	O
downstream	O
NF-kappa	B-DNA
B	I-DNA
site	I-DNA
of	O
the	O
ICAM-1	B-DNA
promoter	I-DNA
.	O

Thrombin	B-protein
receptor	O
activation	O
peptide	O
,	O
a	O
14-amino-acid	O
peptide	O
representing	O
the	O
new	O
NH2	B-protein
terminus	I-protein
of	O
proteolytically	O
activated	O
receptor-1	B-protein
,	O
mimicked	O
thrombin	B-protein
's	O
action	O
in	O
inducing	O
ICAM-1	B-protein
expression	O
.	O

These	O
data	O
indicate	O
that	O
thrombin	B-protein
activates	O
endothelial	O
ICAM-1	B-protein
expression	O
and	O
polymorphonuclear	B-cell_type
leukocyte	I-cell_type
adhesion	O
by	O
NF-kappa	B-protein
Bp65	I-protein
binding	O
to	O
the	O
downstream	O
NF-kappa	B-DNA
B	I-DNA
site	I-DNA
of	O
ICAM-1	B-DNA
promoter	I-DNA
after	O
proteolytically	O
activated	O
receptor-1	O
activation	O
.	O

Differential	O
inhibition	O
of	O
Smad6	B-protein
and	O
Smad7	B-protein
on	O
bone	O
morphogenetic	O
protein-	O
and	O
activin-mediated	O
growth	O
arrest	O
and	O
apoptosis	O
in	O
B	B-cell_type
cells	I-cell_type
.	O

Smad6	B-protein
and	O
Smad7	B-protein
prevent	O
ligand-induced	O
activation	O
of	O
signal-transducing	B-protein
Smad	I-protein
proteins	I-protein
in	O
the	O
transforming	B-protein
growth	I-protein
factor-beta	I-protein
family	I-protein
.	O

Here	O
we	O
demonstrate	O
that	O
both	O
Smad6	B-protein
and	O
Smad7	B-protein
are	O
human	B-protein
bone	I-protein
morphogenetic	I-protein
protein-2	I-protein
(	O
hBMP-2	B-protein
)	O
-inducible	O
antagonists	O
of	O
hBMP-2	B-protein
-induced	O
growth	O
arrest	O
and	O
apoptosis	O
in	O
mouse	B-cell_line
B	I-cell_line
cell	I-cell_line
hybridoma	I-cell_line
HS-72	B-cell_line
cells	I-cell_line
.	O

Moreover	O
,	O
we	O
confirmed	O
that	O
the	O
ectopic	O
expressions	O
of	O
Smad6	B-protein
and	O
Smad7	B-protein
inhibited	O
the	O
hBMP-2	B-protein
-induced	O
Smad1/Smad5	B-protein
phosphorylation	O
.	O

We	O
previously	O
reported	O
that	O
Smad7	B-protein
is	O
an	O
activin	O
A-inducible	O
antagonist	O
of	O
activin	O
A-induced	O
growth	O
arrest	O
and	O
apoptosis	O
in	O
HS-72	B-cell_line
cells	I-cell_line
.	O

Interestingly	O
,	O
although	O
mRNA	O
expression	O
of	O
Smad6	B-protein
was	O
induced	O
by	O
activin	O
A	O
in	O
HS-72	B-cell_line
cells	I-cell_line
,	O
Smad6	B-protein
showed	O
no	O
antagonistic	O
effect	O
on	O
activin	O
A-induced	O
growth	O
arrest	O
and	O
apoptosis	O
.	O

Moreover	O
,	O
we	O
found	O
that	O
the	O
ectopic	O
expression	O
of	O
Smad7	B-protein
,	O
but	O
not	O
Smad6	B-protein
,	O
inhibited	O
the	O
activin	O
A-induced	O
Smad2	O
phosphorylation	O
in	O
HS-72	B-cell_line
cells	I-cell_line
.	O

Thus	O
,	O
Smad6	B-protein
and	O
Smad7	B-protein
exhibit	O
differential	O
inhibitory	O
effects	O
in	O
bone	O
morphogenetic	O
protein-2-	O
and	O
activin	O
A-mediated	O
signaling	O
in	O
B	B-cell_type
lineage	I-cell_type
cells	I-cell_type
.	O

Retinoic	O
acid	O
induces	O
apoptosis	O
of	O
human	B-cell_type
CD34+	I-cell_type
hematopoietic	I-cell_type
progenitor	I-cell_type
cells	I-cell_type
:	O
involvement	O
of	O
retinoic	B-protein
acid	I-protein
receptors	I-protein
and	O
retinoid	B-protein
X	I-protein
receptors	I-protein
depends	O
on	O
lineage	O
commitment	O
of	O
the	O
hematopoietic	B-cell_type
progenitor	I-cell_type
cells	I-cell_type
.	O

Retinoids	O
are	O
bifunctional	O
regulators	O
of	O
growth	O
and	O
differentiation	O
of	O
hematopoietic	B-cell_type
cells	I-cell_type
.	O

In	O
this	O
study	O
we	O
explored	O
the	O
effects	O
of	O
retinoic	O
acid	O
(	O
RA	O
)	O
on	O
apoptosis	O
of	O
human	B-cell_type
CD34+	I-cell_type
hematopoietic	I-cell_type
progenitor	I-cell_type
cells	I-cell_type
isolated	O
from	O
normal	O
bone	O
marrow	O
.	O

RA	O
(	O
100	O
nM	O
)	O
induced	O
an	O
increase	O
in	O
the	O
percentage	O
of	O
dead	B-cell_type
cells	I-cell_type
from	O
24	O
%	O
to	O
44	O
%	O
at	O
day	O
6	O
(	O
p	O
<	O
0.05	O
,	O
n	O
=	O
6	O
)	O
as	O
compared	O
to	O
control	B-cell_type
cells	I-cell_type
cultured	O
in	O
medium	O
alone	O
.	O

The	O
effect	O
was	O
dose	O
dependent	O
and	O
appeared	O
relatively	O
late	O
.	O

Significant	O
differences	O
were	O
observed	O
from	O
day	O
4	O
onward	O
.	O

Apoptosis	O
,	O
or	O
programmed	O
cell	O
death	O
,	O
was	O
demonstrated	O
as	O
the	O
mode	O
of	O
cell	O
death	O
by	O
using	O
the	O
TUNEL	O
assay	O
,	O
which	O
detects	O
single	O
strand	O
nicks	O
in	O
DNA	O
,	O
or	O
by	O
the	O
Nicoletti	O
technique	O
demonstrating	O
a	O
subdiploid	O
population	O
by	O
DNA	O
staining	O
.	O

RA	O
previously	O
was	O
found	O
to	O
inhibit	O
granulocyte	B-protein
colony-stimulating	I-protein
factor	I-protein
--	O
and	O
not	O
granulocyte-macrophage	B-protein
colony-stimulating	I-protein
factor	I-protein
--	O
stimulated	O
proliferation	O
of	O
CD34+	B-cell_type
cells	I-cell_type
.	O

However	O
,	O
we	O
found	O
that	O
RA	O
opposed	O
anti-apoptotic	O
effects	O
of	O
G-CSF	B-protein
and	O
GM-CSF	B-protein
on	O
CD34+	B-cell_type
cells	I-cell_type
(	O
G-CSF	B-protein
:	O
8	O
%	O
dead	B-cell_type
cells	I-cell_type
at	O
day	O
6	O
;	O
G-CSF	B-protein
+	O
RA	O
:	O
20	O
%	O
;	O
GM-CSF	B-protein
:	O
12	O
%	O
;	O
GM-CSF	B-protein
+	O
RA	O
:	O
27	O
%	O
)	O
.	O

Moreover	O
,	O
RA	O
induced	O
apoptosis	O
of	O
CD34+	B-cell_type
cells	I-cell_type
and	O
CD34+CD71+	B-cell_type
cells	I-cell_type
stimulated	O
with	O
erythropoietin	B-protein
.	O

To	O
explore	O
the	O
receptor	O
signaling	O
pathways	O
involved	O
in	O
RA-induced	O
apoptosis	O
,	O
we	O
used	O
selective	O
ligands	O
for	O
retinoic	B-protein
acid	I-protein
receptors	I-protein
(	O
RARs	O
;	O
RO13-7410	O
)	O
and	O
retinoid	B-protein
X	I-protein
receptors	I-protein
(	O
RXRs	B-protein
;	O
RO	O
25-6603	O
)	O
.	O

We	O
found	O
that	O
RARs	B-protein
were	O
involved	O
in	O
RA-mediated	O
apoptosis	O
of	O
myeloid	O
progenitor	O
cells	O
,	O
whereas	O
RARs	B-protein
as	O
well	O
as	O
RXRs	B-protein
were	O
involved	O
in	O
RA-mediated	O
apoptosis	O
of	O
erythroid	B-cell_type
progenitor	I-cell_type
cells	I-cell_type
.	O

Suppressive	O
effects	O
of	O
anti-inflammatory	O
agents	O
on	O
human	B-cell_type
endothelial	I-cell_type
cell	I-cell_type
activation	O
and	O
induction	O
of	O
heat	B-protein
shock	I-protein
proteins	I-protein
.	O

BACKGROUND	O
:	O
Studies	O
from	O
our	O
laboratory	O
have	O
shown	O
that	O
the	O
earliest	O
stages	O
of	O
atherosclerosis	O
may	O
be	O
mediated	O
by	O
an	O
autoimmune	O
reaction	O
against	O
heat	B-protein
shock	I-protein
protein	I-protein
60	I-protein
(	O
Hsp60	B-protein
)	O
.	O

The	O
interactions	O
of	O
Hsp60-specific	B-cell_line
T	I-cell_line
cells	I-cell_line
with	O
arterial	O
endothelial	B-cell_type
cells	I-cell_type
(	O
EC	B-cell_type
)	O
require	O
expression	O
of	O
both	O
Hsp60	B-protein
and	O
certain	O
adhesion	B-protein
molecules	I-protein
shown	O
to	O
be	O
induced	O
simultaneously	O
in	O
EC	B-cell_type
by	O
mechanical	O
and	O
other	O
types	O
of	O
stress	O
.	O

Recently	O
,	O
it	O
was	O
shown	O
that	O
suppression	O
of	O
T	O
cell-mediated	O
immune	O
responses	O
by	O
cyclosporin	O
A	O
(	O
CyA	O
)	O
enhanced	O
atherosclerotic	O
lesion	O
formation	O
in	O
mice	O
.	O

In	O
contrast	O
,	O
aspirin	O
was	O
found	O
to	O
lower	O
the	O
risk	O
of	O
myocardial	O
infarction	O
in	O
men	O
.	O

These	O
conflicting	O
observations	O
may	O
be	O
due	O
to	O
different	O
effects	O
of	O
anti-inflammatory	O
agents	O
on	O
adhesion	O
molecule	O
and	O
Hsp	O
expression	O
in	O
EC	B-cell_type
,	O
respectively	O
.	O

MATERIAL	O
AND	O
METHODS	O
:	O
In	O
the	O
present	O
study	O
,	O
we	O
analyzed	O
the	O
effects	O
of	O
CyA	O
,	O
aspirin	O
,	O
and	O
indomethacin	O
on	O
T	O
cell	O
proliferation	O
using	O
a	O
proliferation	O
assay	O
.	O

To	O
explore	O
the	O
expression	O
of	O
adhesion	B-protein
molecules	I-protein
,	O
monocyte	B-protein
chemoattractant	I-protein
protein-1	I-protein
(	O
MCP-1	B-protein
)	O
,	O
and	O
Hsp60	B-protein
in	O
human	B-cell_type
umbilical	I-cell_type
vein	I-cell_type
endothelial	I-cell_type
cells	I-cell_type
(	O
HUVECs	B-cell_type
)	O
,	O
Northern	O
blot	O
analyses	O
were	O
used	O
.	O

To	O
examine	O
the	O
activation	O
status	O
of	O
the	O
transcription	B-protein
factors	I-protein
nuclear	B-protein
factor	I-protein
kappaB	I-protein
(	O
NF-kappaB	B-protein
)	O
and	O
heat	B-protein
shock	I-protein
factor-1	I-protein
(	O
HSF-1	B-protein
)	O
,	O
electrophoretic	O
mobility	O
shift	O
assays	O
were	O
performed	O
.	O

RESULTS	O
:	O
With	O
the	O
exception	O
of	O
indomethacin	O
,	O
the	O
used	O
immunosuppressive	O
and	O
anti-inflammatory	O
agents	O
significantly	O
inhibited	O
T	O
cell	O
proliferation	O
in	O
response	O
to	O
influenza	B-protein
virus	I-protein
antigen	I-protein
in	O
a	O
dose-dependent	O
manner	O
.	O

Interestingly	O
,	O
CyA	O
and	O
indomethacin	O
did	O
not	O
suppress	O
tumor	B-protein
necrosis	I-protein
factor-alpha	I-protein
(	O
TNF-alpha	B-protein
)	O
-induced	O
adhesion	O
molecule	O
expression	O
on	O
HUVECs	B-cell_type
,	O
whereas	O
aspirin	O
had	O
an	O
inhibitory	O
effect	O
.	O

These	O
observations	O
correlated	O
with	O
the	O
modulation	O
of	O
NF-kappaB	B-protein
activity	O
in	O
EC	B-cell_type
.	O

All	O
agents	O
tested	O
induced	O
expression	O
of	O
Hsp60	B-protein
6	O
hr	O
after	O
application	O
.	O

In	O
addition	O
,	O
aspirin	O
and	O
indomethacin	O
,	O
but	O
not	O
CyA	O
,	O
induced	O
Hsp70	B-protein
expression	O
in	O
HUVECs	B-cell_type
that	O
correlated	O
with	O
induction	O
of	O
HSF-1	B-protein
activity	O
.	O

CONCLUSION	O
:	O
Our	O
results	O
show	O
that	O
the	O
tested	O
agents	O
(	O
except	O
indomethacin	O
)	O
are	O
inhibitors	O
of	O
the	O
T	O
cell-mediated	O
immune	O
response	O
,	O
as	O
expected	O
,	O
that	O
aspirin	O
is	O
an	O
effective	O
suppressor	O
of	O
adhesion	B-protein
molecule	I-protein
expression	O
,	O
and	O
that	O
all	O
three	O
agents	O
can	O
induce	O
Hsp60	B-protein
in	O
HUVECs	B-cell_type
.	O

These	O
data	O
provide	O
the	O
molecular	O
basis	O
for	O
the	O
notion	O
that	O
(	O
1	O
)	O
part	O
of	O
the	O
anti-atherogenic	O
effect	O
of	O
aspirin	O
may	O
be	O
due	O
to	O
the	O
prevention	O
of	O
the	O
adhesion	O
of	O
sensitized	B-cell_type
T	I-cell_type
cells	I-cell_type
to	O
stressed	O
EC	B-cell_type
;	O
(	O
2	O
)	O
that	O
part	O
of	O
the	O
atherosclerosis-promoting	O
effect	O
of	O
CyA	O
may	O
be	O
due	O
to	O
its	O
potential	O
as	O
an	O
inducer	O
of	O
Hsp60	B-protein
expression	O
and	O
its	O
inability	O
to	O
down-regulate	O
adhesion	B-protein
molecule	I-protein
expression	O
on	O
EC	B-cell_type
;	O
and	O
(	O
3	O
)	O
that	O
down-regulation	O
of	O
MCP-1	B-protein
expression	O
by	O
aspirin	O
may	O
result	O
in	O
decreased	O
recruitment	O
of	O
monocytes	B-cell_type
into	O
the	O
arterial	O
intima	O
beneath	O
stressed	O
EC	B-cell_type
.	O

In	O
vivo	O
modulation	O
of	O
glucocorticoid	B-RNA
receptor	I-RNA
mRNA	I-RNA
by	O
inhaled	O
fluticasone	O
propionate	O
in	O
bronchial	O
mucosa	O
and	O
blood	B-cell_type
lymphocytes	I-cell_type
in	O
subjects	O
with	O
mild	O
asthma	O
.	O

BACKGROUND	O
:	O
In	O
vivo	O
regulation	O
of	O
the	O
glucocorticoid	B-protein
receptor	I-protein
(	O
GR	B-protein
)	O
by	O
glucocorticoids	O
provides	O
a	O
means	O
of	O
modulating	O
sensitivity	O
of	O
targeted	O
cells	O
.	O

OBJECTIVE	O
:	O
We	O
sought	O
to	O
determine	O
the	O
in	O
vivo	O
modulation	O
of	O
GR	B-RNA
mRNA	I-RNA
expression	O
by	O
fluticasone	O
propionate	O
(	O
FP	O
)	O
in	O
subjects	O
with	O
mild	O
asthma	O
.	O

METHODS	O
:	O
Ten	O
atopic	O
asthmatic	O
subjects	O
were	O
treated	O
with	O
FP	O
250	O
microg	O
twice	O
daily	O
for	O
4	O
weeks	O
.	O

Before	O
and	O
after	O
treatment	O
,	O
the	O
patients	O
underwent	O
fiberoptic	O
bronchoscopy	O
with	O
endobronchial	O
biopsy	O
and	O
sampling	O
of	O
venous	O
blood	O
for	O
measurements	O
of	O
GR	B-RNA
mRNA	I-RNA
levels	O
.	O

A	O
solution	O
hybridization	O
assay	O
was	O
used	O
for	O
quantitative	O
analysis	O
of	O
GR	B-RNA
mRNA	I-RNA
.	O

In	O
addition	O
,	O
a	O
24-hour	O
urinary	O
cortisol	O
excretion	O
and	O
an	O
adrenocorticotropic	O
hormone	O
test	O
before	O
and	O
after	O
treatment	O
with	O
FP	O
were	O
performed	O
.	O

RESULTS	O
:	O
A	O
high	O
interindividual	O
variation	O
in	O
GR	B-RNA
mRNA	I-RNA
expression	O
was	O
seen	O
.	O

However	O
,	O
we	O
detected	O
a	O
significant	O
reduction	O
of	O
the	O
GR	B-RNA
mRNA	I-RNA
levels	O
in	O
the	O
endobronchial	O
biopsy	O
specimens	O
after	O
FP	O
treatment	O
(	O
36.6	O
+/-	O
23.1	O
and	O
25.0	O
+/-	O
10.9	O
amol	O
GR	B-RNA
mRNA	I-RNA
/microg	O
RNA	O
,	O
respectively	O
;	O
P	O
<	O
.01	O
)	O
.	O

In	O
the	O
peripheral	O
blood	B-cell_type
lymphocytes	I-cell_type
an	O
even	O
more	O
striking	O
downregulation	O
of	O
the	O
GR	O
by	O
its	O
cognate	O
ligand	O
was	O
documented	O
(	O
30.3	O
+/-	O
26.5	O
and	O
8.8	O
+/-	O
5	O
amol	O
GR	B-RNA
mRNA	I-RNA
/microg	O
RNA	O
,	O
respectively	O
;	O
P	O
<	O
.001	O
)	O
,	O
possibly	O
reflecting	O
differences	O
in	O
glucocorticoid	O
sensitivity	O
between	O
tissues	O
.	O

A	O
small	O
but	O
significant	O
reduction	O
of	O
the	O
24-hour	O
urinary	O
cortisol	O
excretion	O
was	O
observed	O
(	O
233	O
+/-	O
109	O
and	O
157	O
+/-	O
66	O
nmol/L	O
,	O
respectively	O
;	O
P	O
<	O
.01	O
)	O
,	O
whereas	O
the	O
feedback	O
regulation	O
of	O
glucocorticoid	O
synthesis	O
by	O
means	O
of	O
the	O
hypothalamic-pituitary-adrenal	O
axis	O
as	O
assessed	O
by	O
the	O
adrenocorticotropic	O
hormone	O
test	O
remained	O
normal	O
after	O
treatment	O
with	O
FP	O
.	O

CONCLUSION	O
:	O
The	O
results	O
in	O
this	O
study	O
confirm	O
the	O
potency	O
of	O
the	O
inhaled	O
corticosteroid	O
FP	O
and	O
provide	O
evidence	O
for	O
a	O
considerable	O
tissue-specific	O
interindividual	O
variation	O
in	O
the	O
expression	O
of	O
the	O
GR	B-protein
.	O

[	O
Corticoids	O
and	O
allergy	O
]	O

Inflammation	O
is	O
constantly	O
observed	O
in	O
allergic	O
reactions	O
.	O

Corticosteroids	O
are	O
most	O
effective	O
in	O
preventing	O
the	O
late	O
phase	O
of	O
allergic	O
reaction	O
.	O

The	O
action	O
of	O
glucocorticosteroids	O
is	O
mediated	O
through	O
glucocorticoid	B-protein
receptors	I-protein
present	O
in	O
the	O
cellular	O
cytoplasm	O
.	O

When	O
activated	O
,	O
glucocorticoid	B-protein
receptors	I-protein
form	O
a	O
dimer	B-protein
and	O
bind	O
to	O
DNA	O
after	O
migration	O
into	O
the	O
nucleus	O
.	O

Interaction	O
to	O
DNA	O
induces	O
changes	O
in	O
the	O
transcription	O
rate	O
,	O
leading	O
to	O
either	O
gene	O
induction	O
or	O
gene	O
repression	O
.	O

Glucocorticoid	O
receptors	O
are	O
also	O
able	O
to	O
interact	O
with	O
transcriptional	O
factors	O
such	O
as	O
AP-1	B-protein
(	O
activator	B-protein
protein-1	I-protein
)	O
of	O
NF-kappa	B-protein
B	I-protein
(	O
nuclear	B-protein
factor-kappa	I-protein
B	I-protein
)	O
.	O

Through	O
these	O
actions	O
glucocorticosteroids	O
are	O
susceptible	O
to	O
modify	O
functions	O
of	O
cells	O
involved	O
in	O
the	O
allergic	O
inflammatory	O
response	O
.	O

They	O
are	O
in	O
particular	O
able	O
to	O
inhibit	O
most	O
of	O
the	O
pro-inflammatory	O
functions	O
of	O
the	O
eosinophils	B-cell_type
.	O

Jeg-3	O
human	O
choriocarcinoma-induced	O
immunosuppression	O
:	O
downregulation	O
of	O
interleukin-2	B-protein
,	O
interleukin-2	B-protein
receptor	I-protein
alpha-chain	I-protein
,	O
and	O
its	O
Jak/Stat	B-protein
signaling	O
pathway	O
.	O

PROBLEM	O
:	O
The	O
mechanisms	O
of	O
the	O
immunosuppressive	O
and	O
immunosuppression-inducing	O
capacities	O
of	O
Jeg-3	B-cell_line
human	I-cell_line
choriocarcinoma	I-cell_line
cell	I-cell_line
line	I-cell_line
supernatants	O
(	O
HCSs	O
)	O
are	O
not	O
yet	O
completely	O
understood	O
.	O

The	O
influence	O
on	O
interleukin	B-protein
(	I-protein
IL	I-protein
)	I-protein
-2	I-protein
,	O
IL-4	B-protein
and	O
interferon	B-protein
(	I-protein
IFN	I-protein
)	I-protein
-gamma	I-protein
production	O
;	O
IL-2	B-protein
receptor	I-protein
(	I-protein
IL-2R	I-protein
)	I-protein
alpha	I-protein
-	O
,	O
beta	B-protein
-	O
,	O
and	O
gamma-chain	B-protein
;	O
and	O
the	O
signaling	B-protein
pathway	I-protein
molecules	I-protein
Janus	B-protein
kinase	I-protein
(	B-protein
Jak	I-protein
)	I-protein
1	I-protein
,	O
Jak3	B-protein
,	O
signal	O
transducers	O
and	O
activators	B-protein
of	I-protein
transcription	I-protein
(	B-protein
Stat	I-protein
)	I-protein
1	I-protein
,	O
Stat3	B-protein
,	O
and	O
Stat5	B-protein
should	O
be	O
investigated	O
.	O

METHOD	O
OF	O
STUDY	O
:	O
For	O
assessment	O
of	O
IL	O
production	O
,	O
whole	O
peripheral	O
venous	O
blood	O
from	O
healthy	O
donors	O
was	O
stimulated	O
with	O
phorbol-myristate-acetate	O
and	O
ionomycine	O
.	O

Secretion	O
of	O
ILs	B-protein
was	O
blocked	O
with	O
monensine	O
.	O

Intracellular	O
ILs	B-protein
were	O
analyzed	O
by	O
flow	O
cytometry	O
.	O

For	O
IL-2R	B-protein
and	O
signaling	O
pathway	O
molecule	O
analysis	O
,	O
peripheral	O
blood	B-cell_type
lymphocytes	I-cell_type
were	O
stimulated	O
with	O
phytohemagglutinin	B-protein
(	O
PHA	B-protein
)	O
.	O

IL-2R	O
chains	O
were	O
measured	O
by	O
flow	O
cytometry	O
,	O
and	O
Jaks/Stats	B-protein
by	O
sodium	O
dodecyl	O
sulfate	O
polyacrylamide	O
gel	O
electrophoresis	O
(	O
SDS-PAGE	O
)	O
and	O
Western	O
blot	O
.	O

RESULTS	O
:	O
Phorbol-myristate-acetate	O
and	O
ionomycine	O
strongly	O
increase	O
the	O
percent-age	O
of	O
IL-2+	B-cell_line
cells	I-cell_line
;	O
an	O
additional	O
50	O
%	O
HCSs	O
significantly	O
suppresses	O
the	O
percentage	O
to	O
,	O
or	O
below	O
the	O
level	O
of	O
unstimulated	B-cell_type
cells	I-cell_type
.	O

IFN-gamma	O
production	O
is	O
strongly	O
decreased	O
by	O
HCSs	O
in	O
some	O
cases	O
,	O
but	O
not	O
in	O
others	O
.	O

PHA	B-protein
stimulates	O
IL-2R	O
alpha-	O
,	O
beta-	O
,	O
and	O
gamma-chain	O
expression	O
and	O
their	O
signaling	B-protein
pathway	I-protein
molecules	I-protein
Jak1	B-protein
,	O
Jak3	B-protein
,	O
Stat1	O
,	O
Stat3	B-protein
,	O
and	O
Stat5	B-protein
.	O

50	O
%	O
HCS	O
downregulates	O
the	O
alpha-chain	B-protein
and	O
slightly	O
upregulates	O
the	O
beta-chain	B-protein
.	O

Jak1	O
,	O
Jak3	O
,	O
Stat1	O
,	O
Stat3	O
,	O
and	O
Stat5	O
expression	O
is	O
suppressed	O
approximately	O
to	O
,	O
or	O
below	O
the	O
level	O
of	O
unstimulated	B-cell_type
cells	I-cell_type
.	O

CONCLUSIONS	O
:	O
HCS	O
forcefully	O
blocks	O
the	O
production	O
of	O
IL-2	B-protein
;	O
the	O
IL-2R	B-protein
alpha-chain	I-protein
;	O
and	O
Jak1	O
,	O
Jak3	O
,	O
Stat1	O
,	O
Stat3	O
,	O
and	O
Stat5	O
expression	O
.	O

The	O
observed	O
phenomena	O
might	O
be	O
caused	O
by	O
downregulation	O
of	O
an	O
IL-2R	B-DNA
regulation	I-DNA
gene	I-DNA
,	O
and	O
might	O
play	O
a	O
key	O
role	O
in	O
the	O
expansion	O
of	O
choriocarcinoma	O
,	O
and	O
possibly	O
in	O
the	O
survival	O
of	O
the	O
fetal	O
allograft	O
.	O

Apoptosis-resistant	B-cell_line
T	I-cell_line
cells	I-cell_line
have	O
a	O
deficiency	O
in	O
NF-kappaB	B-protein
-mediated	O
induction	O
of	O
Fas	B-protein
ligand	I-protein
transcription	O
.	O

Apoptosis	O
induced	O
through	O
the	O
TCR	B-protein
in	O
CD4+	B-cell_type
T	I-cell_type
cells	I-cell_type
is	O
mostly	O
mediated	O
by	O
the	O
inducible	O
expression	O
of	O
Fas	B-protein
ligand	I-protein
(	O
FasL	B-protein
)	O
as	O
a	O
primary	O
event	O
leading	O
to	O
the	O
commitment	O
to	O
death	O
.	O

To	O
gain	O
a	O
better	O
understanding	O
of	O
the	O
transcriptional	O
events	O
that	O
regulate	O
this	O
expression	O
,	O
we	O
took	O
advantage	O
of	O
our	O
previously	O
described	O
mutant	B-cell_line
Jurkat	I-cell_line
cells	I-cell_line
.	O

These	O
cells	O
are	O
deficient	O
in	O
FasL	B-protein
expression	O
and	O
apoptosis	O
induced	O
upon	O
TCR	B-protein
triggering	O
,	O
although	O
their	O
cytokine	O
(	O
IL-2	B-protein
and	O
IFN-gamma	B-protein
)	O
production	O
is	O
normal	O
.	O

Here	O
we	O
show	O
that	O
both	O
a	O
FasL-	B-DNA
and	I-DNA
a	I-DNA
consensus	I-DNA
NF-kappaB-	I-DNA
reporter	I-DNA
construct	I-DNA
are	O
inefficiently	O
induced	O
in	O
these	O
cells	O
compared	O
to	O
wild-type	B-cell_type
cells	I-cell_type
.	O

In	O
addition	O
,	O
we	O
demonstrate	O
that	O
the	O
inducible	O
transcriptional	O
activity	O
of	O
the	O
FasL	B-DNA
reporter	I-DNA
is	O
abolished	O
by	O
specific	O
inhibitors	O
of	O
NF-kappaB	B-protein
activation	O
.	O

Thus	O
,	O
we	O
could	O
trace	O
the	O
deficit	O
of	O
the	O
mutant	B-cell_type
cells	I-cell_type
to	O
an	O
inefficient	O
NF-kappaB	B-protein
activation	O
,	O
evidencing	O
a	O
relevant	O
role	O
for	O
NF-kappaB	B-protein
in	O
the	O
regulation	O
of	O
FasL	B-protein
expression	O
in	O
activated	B-cell_type
T	I-cell_type
cells	I-cell_type
.	O

Furthermore	O
,	O
our	O
results	O
suggest	O
that	O
the	O
induction	O
of	O
FasL	B-protein
versus	O
cytokine	B-DNA
gene	I-DNA
expression	O
is	O
differentially	O
sensitive	O
to	O
NF-kappaB	B-protein
deprivation	O
.	O

Decreased	O
proteasome	B-protein
-mediated	O
degradation	O
in	O
T	B-cell_type
cells	I-cell_type
from	O
the	O
elderly	O
:	O
A	O
role	O
in	O
immune	O
senescence	O
.	O

Induction	O
of	O
NFkappaB	B-protein
is	O
a	O
highly	O
regulated	O
process	O
requiring	O
phosphorylation	O
,	O
ubiquitination	O
,	O
and	O
proteasome	B-protein
-mediated	O
degradation	O
of	O
the	O
cytosolic	B-protein
inhibitor	I-protein
IkappaBalpha	B-protein
.	O

Analyses	O
of	O
the	O
regulation	O
of	O
IkappaBalpha	B-protein
in	O
TNF-alpha-treated	B-cell_type
T	I-cell_type
lymphocytes	I-cell_type
from	O
young	O
and	O
elderly	O
donors	O
revealed	O
severely	O
compromised	O
degradation	O
of	O
IkappaBalpha	B-protein
in	O
T	B-cell_type
cells	I-cell_type
from	O
the	O
elderly	O
.	O

Examination	O
of	O
activation-induced	O
phosphorylation	O
and	O
ubiquitination	O
of	O
IkappaBalpha	B-protein
did	O
not	O
demonstrate	O
any	O
significant	O
age-related	O
alterations	O
.	O

However	O
,	O
examination	O
of	O
proteasome	B-protein
activity	O
in	O
these	O
T	B-cell_type
cells	I-cell_type
using	O
fluorogenic	O
peptide	O
assays	O
revealed	O
a	O
significant	O
age-related	O
decline	O
in	O
chymotryptic	O
activity	O
.	O

These	O
results	O
suggest	O
that	O
a	O
decline	O
in	O
proteasome	B-protein
activity	O
results	O
in	O
a	O
failure	O
to	O
fully	O
degrade	O
IkappaBalpha	B-protein
in	O
the	O
elderly	O
.	O

This	O
failure	O
to	O
degrade	O
IkappaBalpha	B-protein
may	O
underlie	O
both	O
the	O
observed	O
decrease	O
in	O
NFkappaB	B-protein
induction	O
and	O
the	O
IL-2	B-protein
receptor	O
expression	O
in	O
TNF-treated	B-cell_line
T	I-cell_line
cells	I-cell_line
during	O
aging	O
.	O

Thus	O
,	O
decreased	O
proteasome	B-protein
-mediated	O
degradation	O
may	O
be	O
central	O
to	O
immune	O
dysfunction	O
that	O
accompanies	O
aging	O
.	O

Copyright	O
1999	O
Academic	O
Press	O
.	O

Inhibition	O
of	O
IL-4	B-protein
-inducible	O
gene	O
expression	O
in	O
human	B-cell_type
monocytes	I-cell_type
by	O
type	B-protein
I	I-protein
and	I-protein
type	I-protein
II	I-protein
interferons	I-protein
.	O

The	O
Th2-type	B-protein
cytokines	I-protein
,	O
interleukin-4	B-protein
(	O
IL-4	B-protein
)	O
and	O
interleukin-13	B-protein
(	O
IL-13	B-protein
)	O
,	O
induce	O
expression	O
of	O
a	O
distinct	O
subset	O
of	O
genes	O
in	O
human	B-cell_type
monocytes	I-cell_type
,	O
including	O
FcepsilonRIIb	B-protein
(	O
CD23	B-protein
)	O
,	O
15-lipoxygenase	B-protein
,	O
IL-1	B-protein
receptor	I-protein
antagonist	I-protein
(	O
IL-1ra	B-protein
)	O
,	O
and	O
type	B-protein
I	I-protein
and	I-protein
type	I-protein
II	I-protein
IL-1	I-protein
receptors	I-protein
(	O
IL-1R	B-protein
)	O
.	O

Type	B-protein
I	I-protein
interferons	I-protein
(	O
IFN-alpha	B-protein
and	O
IFN-beta	B-protein
)	O
and	O
type	B-protein
II	I-protein
interferon	I-protein
(	O
IFN-gamma	B-protein
)	O
inhibit	O
induction	O
of	O
these	O
genes	O
by	O
IL-4	B-protein
and	O
IL-13	B-protein
.	O

However	O
,	O
the	O
mechanism	O
by	O
which	O
IFNs	B-protein
mediate	O
this	O
inhibition	O
has	O
not	O
been	O
defined	O
.	O

In	O
this	O
overview	O
,	O
we	O
discuss	O
the	O
role	O
of	O
the	O
transcription	B-protein
factor	I-protein
,	O
STAT6	B-protein
(	O
signal	B-protein
transducer	I-protein
and	I-protein
activator	I-protein
of	I-protein
transcription-6	I-protein
)	O
in	O
mediating	O
IL-4-	O
and	O
IL-13-induced	O
gene	O
expression	O
in	O
monocytes	B-cell_type
.	O

We	O
also	O
discuss	O
our	O
recent	O
findings	O
that	O
type	B-protein
I	I-protein
and	I-protein
type	I-protein
II	I-protein
IFNs	I-protein
suppress	O
IL-4	B-protein
/	O
IL-13	B-protein
-inducible	O
gene	O
expression	O
by	O
inhibiting	O
tyrosine	O
phosphorylation	O
and	O
nuclear	O
translocation	O
of	O
STAT6	B-protein
.	O

The	O
ability	O
of	O
type	B-protein
I	I-protein
and	I-protein
type	I-protein
II	I-protein
IFNs	I-protein
to	O
inhibit	O
IL-4	B-protein
/	O
IL-13	B-protein
-induced	O
STAT6	B-protein
activity	O
is	O
dose-	O
and	O
time-dependent	O
,	O
and	O
is	O
not	O
unique	O
to	O
monocytes	B-cell_type
because	O
IFNs	B-protein
induce	O
the	O
same	O
effects	O
in	O
fibroblasts	B-cell_type
.	O

Inhibition	O
of	O
STAT6	B-protein
activity	O
is	O
not	O
evident	O
unless	O
cells	O
are	O
preincubated	O
with	O
IFN	B-protein
for	O
at	O
least	O
1	O
h	O
before	O
IL-4	B-protein
stimulation	O
.	O

Furthermore	O
,	O
inhibition	O
can	O
be	O
blocked	O
by	O
actinomycin	O
D	O
,	O
indicating	O
a	O
requirement	O
for	O
de	O
novo	O
transcription	O
.	O

We	O
propose	O
a	O
model	O
in	O
which	O
stimulation	O
of	O
monocytes	B-cell_type
by	O
IFN	B-protein
activates	O
de	O
novo	O
synthesis	O
of	O
an	O
inhibitory	B-protein
factor	I-protein
,	O
possibly	O
one	O
or	O
more	O
members	O
of	O
the	O
SOCS/	B-protein
SSI/CIS	I-protein
gene	I-protein
family	I-protein
,	O
capable	O
of	O
suppressing	O
activation	O
of	O
STAT6	B-protein
by	O
IL-4	B-protein
and	O
IL-13	B-protein
.	O

Because	O
STAT6	B-protein
activation	O
plays	O
an	O
essential	O
role	O
in	O
IL-4	B-protein
/	O
IL-13	B-protein
-induced	O
gene	O
expression	O
,	O
the	O
ability	O
of	O
IFN-beta	B-protein
and	O
IFN-gamma	B-protein
to	O
inhibit	O
STAT6	B-protein
activity	O
provides	O
an	O
explanation	O
for	O
how	O
IFNs	B-protein
can	O
suppress	O
IL-4	B-protein
/	O
IL-13	B-protein
-inducible	O
gene	O
expression	O
.	O

HLA	B-protein
class	I-protein
I	I-protein
-mediated	O
induction	O
of	O
cell	O
proliferation	O
involves	O
cyclin	B-DNA
E	I-DNA
-mediated	O
inactivation	O
of	O
Rb	O
function	O
and	O
induction	O
of	O
E2F	B-protein
activity	O
.	O

Chronic	O
rejection	O
of	O
transplanted	O
organs	O
is	O
manifested	O
as	O
atherosclerosis	O
of	O
the	O
blood	O
vessels	O
of	O
the	O
allograft	O
.	O

HLA	B-protein
class	I-protein
I	I-protein
Ags	I-protein
have	O
been	O
implicated	O
to	O
play	O
a	O
major	O
role	O
in	O
this	O
process	O
,	O
since	O
signaling	O
via	O
HLA	B-protein
class	I-protein
I	I-protein
molecules	I-protein
can	O
induce	O
the	O
proliferation	O
of	O
aortic	B-cell_type
endothelial	I-cell_type
as	O
well	O
as	O
smooth	B-cell_type
muscle	I-cell_type
cells	I-cell_type
.	O

In	O
this	O
study	O
,	O
we	O
show	O
that	O
HLA	B-protein
class	I-protein
I	I-protein
-mediated	O
induction	O
of	O
cell	O
proliferation	O
correlates	O
with	O
inactivation	O
of	O
the	O
Rb	B-protein
protein	I-protein
in	O
the	O
T	B-cell_line
cell	I-cell_line
line	I-cell_line
Jurkat	I-cell_line
as	O
well	O
as	O
human	B-cell_type
aortic	I-cell_type
endothelial	I-cell_type
cells	I-cell_type
.	O

HLA	B-protein
class	I-protein
I	I-protein
-mediated	O
inactivation	O
of	O
Rb	B-protein
can	O
be	O
inhibited	O
specifically	O
by	O
neutralizing	B-protein
Abs	I-protein
to	O
basic	B-protein
fibroblast	I-protein
growth	I-protein
factor	I-protein
(	O
bFGF	B-protein
)	O
,	O
suggesting	O
a	O
role	O
for	O
FGF	B-protein
receptors	I-protein
in	O
the	O
signaling	O
process	O
.	O

Signaling	O
through	O
HLA	B-protein
class	I-protein
I	I-protein
molecules	I-protein
induced	O
cyclin	B-DNA
E	I-DNA
-associated	O
kinase	O
activity	O
within	O
4	O
h	O
in	O
quiescent	B-cell_type
endothelial	I-cell_type
cells	I-cell_type
,	O
and	O
appeared	O
to	O
mediate	O
the	O
inactivation	O
of	O
Rb	B-protein
.	O

A	O
cdk2	O
inhibitor	O
,	O
Olomoucine	O
,	O
as	O
well	O
as	O
a	O
dominant-negative	B-DNA
cdk2	I-DNA
construct	I-DNA
prevented	O
HLA	B-protein
class	I-protein
I	I-protein
-mediated	O
inactivation	O
of	O
Rb	B-protein
;	O
in	O
contrast	O
,	O
dominant-negative	B-DNA
cdk4	I-DNA
and	I-DNA
cdk6	I-DNA
constructs	I-DNA
had	O
no	O
effect	O
.	O

Furthermore	O
,	O
there	O
was	O
no	O
increase	O
in	O
cyclin	B-protein
D-associated	I-protein
kinase	I-protein
activity	O
upon	O
HLA	B-protein
class	I-protein
I	I-protein
ligation	O
,	O
suggesting	O
that	O
cyclin	B-protein
E-dependent	I-protein
kinase	I-protein
activity	O
mediates	O
Rb	B-protein
inactivation	O
,	O
leading	O
to	O
E2F	B-protein
activation	O
and	O
cell	O
proliferation	O
.	O

Immunosuppressant	O
PG490	O
(	O
triptolide	O
)	O
inhibits	O
T-cell	B-protein
interleukin-2	I-protein
expression	O
at	O
the	O
level	O
of	O
purine-box/nuclear	B-protein
factor	I-protein
of	O
activated	B-cell_type
T-cells	I-cell_type
and	O
NF-kappaB	B-protein
transcriptional	O
activation	O
.	O

PG490	O
(	O
triptolide	O
)	O
is	O
a	O
diterpene	O
triepoxide	O
with	O
potent	O
immunosuppressive	O
and	O
antiinflammatory	O
properties	O
.	O

PG490	O
inhibits	O
interleukin	B-protein
(	I-protein
IL	I-protein
)	I-protein
-2	I-protein
expression	O
by	O
normal	B-cell_type
human	I-cell_type
peripheral	I-cell_type
blood	I-cell_type
lymphocytes	I-cell_type
stimulated	O
with	O
phorbol	O
12-myristate	O
13-acetate	O
(	O
PMA	O
)	O
and	O
antibody	O
to	O
CD3	B-protein
(	O
IC50	O
of	O
10	O
ng/ml	O
)	O
,	O
and	O
with	O
PMA	O
and	O
ionomycin	O
(	O
Iono	O
,	O
IC50	O
of	O
40	O
ng/ml	O
)	O
.	O

In	O
Jurkat	B-cell_line
T-cells	I-cell_line
,	O
PG490	O
inhibits	O
PMA/Iono-stimulated	O
IL-2	B-protein
transcription	O
.	O

PG490	O
inhibits	O
the	O
induction	O
of	O
DNA	O
binding	O
activity	O
at	O
the	O
purine-box/antigen	B-DNA
receptor	I-DNA
response	I-DNA
element	I-DNA
(	I-DNA
ARRE	I-DNA
)	I-DNA
/nuclear	I-DNA
factor	I-DNA
of	I-DNA
activated	I-DNA
T-cells	I-DNA
(	I-DNA
NF-AT	I-DNA
)	I-DNA
target	I-DNA
sequence	I-DNA
but	O
not	O
at	O
the	O
NF-kappaB	B-DNA
site	I-DNA
.	O

PG490	O
can	O
completely	O
inhibit	O
transcriptional	O
activation	O
at	O
the	O
purine-box/ARRE/NF-AT	B-DNA
and	I-DNA
NF-kappaB	I-DNA
target	I-DNA
DNA	I-DNA
sequences	I-DNA
triggered	O
by	O
all	O
stimuli	O
examined	O
(	O
PMA	O
,	O
PMA/Iono	O
,	O
tumor	B-protein
necrosis	I-protein
factor-alpha	I-protein
)	O
.	O

PG490	O
also	O
inhibits	O
PMA-stimulated	O
activation	O
of	O
a	O
chimeric	B-protein
transcription	I-protein
factor	I-protein
in	O
which	O
the	O
C-terminal	B-protein
TA1	I-protein
transactivation	I-protein
domain	I-protein
of	O
NF-kappaB	B-protein
p65	I-protein
is	O
fused	O
to	O
the	O
DNA	B-protein
binding	I-protein
domain	I-protein
of	O
GAL4	B-protein
.	O

In	O
16HBE	B-cell_type
human	I-cell_type
bronchial	I-cell_type
epithelial	I-cell_type
cells	I-cell_type
,	O
IL-8	B-protein
expression	O
is	O
regulated	O
predominantly	O
by	O
NF-kappaB	B-protein
,	O
and	O
PG490	O
but	O
not	O
cyclosporin	O
A	O
can	O
completely	O
inhibit	O
expression	O
of	O
IL-8	B-protein
.	O

The	O
mechanism	O
of	O
PG490	O
inhibition	O
of	O
cytokine	B-DNA
gene	I-DNA
expression	O
differs	O
from	O
cyclosporin	O
A	O
and	O
involves	O
nuclear	O
inhibition	O
of	O
transcriptional	O
activation	O
of	O
NF-kappaB	B-protein
and	O
the	O
purine-box	B-DNA
regulator	I-DNA
operating	O
at	O
the	O
ARRE/NF-AT	B-DNA
site	I-DNA
at	O
a	O
step	O
after	O
specific	O
DNA	O
binding	O
.	O

Unexpected	O
and	O
coordinated	O
expression	O
of	O
Spi-1	B-protein
,	O
Fli-1	B-protein
,	O
and	O
megakaryocytic	B-DNA
genes	I-DNA
in	O
four	O
Epo-dependent	B-cell_line
cell	I-cell_line
lines	I-cell_line
established	O
from	O
transgenic	O
mice	O
displaying	O
erythroid-specific	O
expression	O
of	O
a	O
thermosensitive	B-protein
SV40	I-protein
T	I-protein
antigen	I-protein
.	O

Most	O
erythroleukemic	B-cell_line
cell	I-cell_line
lines	I-cell_line
established	O
in	O
vitro	O
coexpress	O
erythrocytic	B-protein
and	I-protein
megakaryocytic	I-protein
markers	I-protein
that	O
often	O
are	O
associated	O
with	O
expression	O
of	O
Spi-1	B-protein
and/or	O
Fli-1	B-protein
transcription	I-protein
factors	I-protein
known	O
as	O
transactivators	B-protein
of	I-protein
megakaryocyte-specific	I-protein
promoters	I-protein
.	O

In	O
the	O
present	O
study	O
,	O
we	O
examined	O
the	O
possibility	O
of	O
establishing	O
new	B-cell_line
cell	I-cell_line
lines	I-cell_line
keeping	O
strictly	O
erythroid-specific	O
properties	O
in	O
vitro	O
through	O
the	O
targeted	O
and	O
conditional	O
immortalization	O
of	O
erythrocytic	B-cell_type
progenitors	I-cell_type
.	O

For	O
that	O
purpose	O
,	O
we	O
established	O
several	O
lines	O
of	O
transgenic	O
mice	O
displaying	O
erythroid-specific	O
expression	O
of	O
a	O
thermosensitive	B-protein
SV40	I-protein
T	I-protein
antigen	I-protein
.	O

As	O
expected	O
,	O
these	O
transgenic	O
mice	O
developed	O
splenomegaly	O
due	O
to	O
the	O
massive	O
amplification	O
of	O
Ter	B-cell_line
119	I-cell_line
positive	I-cell_line
erythroid	I-cell_line
nucleated	I-cell_line
cells	I-cell_line
expressing	O
T	B-protein
antigen	I-protein
.	O

Despite	O
this	O
drastic	O
effect	O
in	O
vivo	O
,	O
the	O
in	O
vitro	O
immortalization	O
of	O
erythropoietin-dependent	B-cell_type
erythroid	I-cell_type
progenitors	I-cell_type
unexpectedly	O
occurred	O
at	O
low	O
frequency	O
,	O
and	O
all	O
four	O
cell	B-cell_line
lines	I-cell_line
established	O
expressed	O
both	O
erythrocytic	B-protein
(	I-protein
globins	I-protein
)	I-protein
and	I-protein
megakaryocytic	I-protein
markers	I-protein
(	O
glycoprotein	B-protein
IIb	I-protein
,	O
platelet	B-protein
factor	I-protein
4	I-protein
)	O
as	O
well	O
as	O
Spi-1	B-protein
and	O
Fli-1	B-protein
transcripts	I-protein
at	O
permissive	O
temperature	O
.	O

Switching	O
the	O
cells	O
to	O
the	O
nonpermissive	O
temperature	O
led	O
to	O
a	O
marked	O
increase	O
in	O
globin	B-DNA
gene	I-DNA
expression	O
and	O
concomitant	O
decrease	O
in	O
expression	O
of	O
Spi-1	B-protein
,	O
Fli-1	B-protein
,	O
and	O
megakaryocytic	B-DNA
genes	I-DNA
in	O
an	O
erythropoietin	B-protein
-dependent	O
manner	O
.	O

Interestingly	O
,	O
enhanced	O
expression	O
of	O
Spi-1	B-DNA
and	I-DNA
Fli-1	I-DNA
genes	I-DNA
already	O
was	O
detected	O
in	O
the	O
Ter	B-cell_line
119	I-cell_line
positive	I-cell_line
cell	I-cell_line
population	I-cell_line
of	O
transgenic	O
mice	O
spleen	O
in	O
vivo	O
.	O

However	O
,	O
like	O
normal	B-cell_line
Ter	I-cell_line
119	I-cell_line
erythroid	I-cell_line
cells	I-cell_line
,	O
these	O
Ter	B-cell_line
119	I-cell_line
positive	I-cell_line
cells	I-cell_line
from	O
transgenic	O
mice	O
still	O
expressed	O
high	O
levels	O
of	O
beta-globin	B-protein
and	O
very	O
low	O
or	O
undetectable	O
glycoprotein	B-protein
IIb	I-protein
and	O
platelet	B-protein
factor	I-protein
4	I-protein
megakaryocytic	I-protein
transcripts	I-protein
.	O

Taken	O
together	O
,	O
these	O
data	O
indicate	O
that	O
the	O
unexpected	O
expression	O
of	O
megakaryocytic	B-DNA
genes	I-DNA
is	O
a	O
specific	O
property	O
of	O
immortalized	B-cell_line
cells	I-cell_line
that	O
can	O
not	O
be	O
explained	O
only	O
by	O
enhanced	O
expression	O
of	O
Spi-1	B-DNA
and/or	I-DNA
Fli-1	I-DNA
genes	I-DNA
.	O

Fludarabine-induced	O
immunosuppression	O
is	O
associated	O
with	O
inhibition	O
of	O
STAT1	B-protein
signaling	O
.	O

Fludarabine	O
is	O
a	O
nucleoside	O
analog	O
used	O
in	O
the	O
treatment	O
of	O
hematologic	O
malignancies	O
that	O
can	O
induce	O
severe	O
and	O
prolonged	O
immunosuppression	O
.	O

Although	O
it	O
can	O
be	O
incorporated	O
into	O
the	O
DNA	O
of	O
dividing	O
cells	O
,	O
fludarabine	O
is	O
also	O
a	O
potent	O
inhibitor	O
of	O
cells	O
with	O
a	O
low	O
growth	O
fraction	O
,	O
thus	O
it	O
must	O
have	O
other	O
mechanisms	O
of	O
action	O
.	O

STAT1	B-protein
,	O
which	O
is	O
activated	O
in	O
response	O
to	O
many	O
lymphocyte-activating	B-protein
cytokines	I-protein
including	O
the	O
interferons	B-protein
,	O
is	O
essential	O
for	O
cell-mediated	O
immunity	O
,	O
as	O
the	O
absence	O
of	O
this	O
protein	O
is	O
associated	O
with	O
prominent	O
defects	O
in	O
the	O
ability	O
to	O
control	O
viral	O
infections	O
.	O

Here	O
we	O
show	O
that	O
fludarabine	O
,	O
but	O
not	O
the	O
immunosuppressant	O
cyclosporine	O
A	O
,	O
inhibits	O
the	O
cytokine	B-protein
-induced	O
activation	O
of	O
STAT1	B-protein
and	O
STAT1	B-protein
-dependent	O
gene	O
transcription	O
in	O
normal	B-cell_type
resting	I-cell_type
or	I-cell_type
activated	I-cell_type
lymphocytes	I-cell_type
.	O

Fludarabine	O
caused	O
a	O
specific	O
depletion	O
of	O
STAT1	B-protein
protein	I-protein
(	O
and	O
mRNA	O
)	O
but	O
not	O
of	O
other	O
STATs	B-protein
.	O

This	O
loss	O
of	O
STAT1	B-protein
was	O
also	O
seen	O
in	O
cells	O
from	O
patients	O
treated	O
with	O
fludarabine	O
in	O
vivo	O
.	O

Brief	O
exposure	O
to	O
fludarabine	O
led	O
to	O
a	O
sustained	O
loss	O
of	O
STAT1	B-protein
,	O
analogous	O
to	O
the	O
prolonged	O
period	O
of	O
immunosuppression	O
induced	O
by	O
exposure	O
to	O
the	O
drug	O
in	O
vivo	O
.	O

Thus	O
,	O
STAT1	B-protein
may	O
be	O
a	O
useful	O
target	O
in	O
the	O
development	O
of	O
new	O
immunosuppressive	O
and	O
antineoplastic	O
agents	O
.	O

Studies	O
into	O
the	O
effect	O
of	O
tyrosine	B-protein
phosphatase	I-protein
inhibitor	O
phenylarsine	O
oxide	O
on	O
NFkappaB	B-protein
activation	O
in	O
T	B-cell_type
lymphocytes	I-cell_type
during	O
aging	O
:	O
evidence	O
for	O
altered	O
IkappaB-alpha	B-protein
phosphorylation	O
and	O
degradation	O
.	O

Nuclear	B-protein
Factor	I-protein
kappa	I-protein
B	I-protein
(	O
NFkappaB	B-protein
)	O
is	O
a	O
critical	O
regulator	O
of	O
several	O
genes	O
involved	O
in	O
immune	O
and	O
inflammatory	O
responses	O
.	O

Treatment	O
of	O
T	B-cell_type
cells	I-cell_type
with	O
a	O
variety	O
of	O
stimuli	O
,	O
including	O
TNF-alpha	B-protein
,	O
leads	O
to	O
the	O
translocation	O
of	O
the	O
active	O
p65-50	B-protein
heterodimer	I-protein
to	O
the	O
nucleus	O
,	O
albeit	O
at	O
a	O
lower	O
level	O
in	O
T	B-cell_type
cells	I-cell_type
from	O
the	O
elderly	O
.	O

We	O
demonstrate	O
here	O
that	O
pretreatment	O
with	O
PAO	O
results	O
in	O
the	O
inhibition	O
of	O
NFkappaB	B-protein
induction	O
in	O
TNF-alpha	B-protein
treated	O
T	B-cell_type
cells	I-cell_type
,	O
suggesting	O
a	O
role	O
for	O
PAO-sensitive	B-protein
phosphatase	I-protein
in	O
the	O
activation	O
of	O
the	O
NFkappaB	B-protein
via	O
this	O
pathway	O
in	O
human	B-cell_type
T	I-cell_type
cells	I-cell_type
.	O

Furthermore	O
,	O
it	O
demonstrates	O
that	O
aging	O
does	O
not	O
influence	O
the	O
sensitivity	O
of	O
this	O
phosphatase	B-protein
.	O

Treatment	O
with	O
DMP	O
prior	O
to	O
treatment	O
with	O
PAO	O
and	O
TNF	B-protein
abolishes	O
the	O
inhibition	O
induced	O
by	O
PAO	O
,	O
in	O
T	B-cell_type
cells	I-cell_type
from	O
both	O
young	O
and	O
old	O
donors	O
,	O
alike	O
.	O

Finally	O
,	O
we	O
demonstrate	O
that	O
a	O
failure	O
to	O
degrade	O
IkappaB-alpha	B-protein
in	O
cytosols	O
of	O
TNF-treated	B-cell_type
T	I-cell_type
cells	I-cell_type
pretreated	O
with	O
PAO	O
is	O
due	O
to	O
its	O
interference	O
with	O
the	O
phosphorylation	O
of	O
IkappaB-alpha	B-protein
and	O
not	O
due	O
to	O
its	O
inhibitory	O
effect	O
on	O
proteasomal	O
degradation	O
.	O

These	O
data	O
collectively	O
suggest	O
that	O
PAO	O
interferes	O
with	O
the	O
phosphorylation	O
and	O
the	O
regulated	O
degradation	O
of	O
IkappaB-alpha	B-protein
,	O
induced	O
by	O
TNF	B-protein
,	O
without	O
affecting	O
the	O
chymotryptic	O
activity	O
of	O
the	O
proteasome	B-protein
,	O
independent	O
of	O
age	O
.	O

Spi-C	B-protein
,	O
a	O
novel	O
Ets	B-protein
protein	I-protein
that	O
is	O
temporally	O
regulated	O
during	O
B	O
lymphocyte	O
development	O
.	O

A	O
novel	O
Ets	B-protein
protein	I-protein
was	O
isolated	O
by	O
yeast	O
one-hybrid	O
screening	O
of	O
a	O
cDNA	B-DNA
library	I-DNA
made	O
from	O
lipopolysaccharide-stimulated	B-cell_line
mouse	I-cell_line
splenic	I-cell_line
B	I-cell_line
cells	I-cell_line
,	O
using	O
the	O
SP6	B-DNA
kappa	I-DNA
promoter	I-DNA
kappaY	I-DNA
element	I-DNA
as	O
a	O
bait	O
.	O

The	O
novel	O
Ets	B-protein
protein	I-protein
was	O
most	O
closely	O
related	O
to	O
PU.1	B-protein
and	O
Spi-B	B-protein
within	O
the	O
DNA	B-DNA
binding	I-DNA
Ets	I-DNA
domain	I-DNA
and	O
was	O
therefore	O
named	O
Spi-C	B-protein
.	O

However	O
,	O
Spi-C	B-protein
may	O
represent	O
a	O
novel	O
subgroup	O
within	O
the	O
Ets	B-protein
protein	I-protein
family	I-protein
,	O
as	O
it	O
differed	O
significantly	O
from	O
Spi-B	B-protein
and	O
PU.1	B-protein
within	O
helix	B-protein
1	I-protein
of	O
the	O
Ets	B-protein
domain	I-protein
.	O

Spi-C	B-protein
was	O
encoded	O
by	O
a	O
single-copy	B-DNA
gene	I-DNA
that	O
was	O
mapped	O
to	O
chromosome	B-DNA
10	I-DNA
,	O
region	B-DNA
C	I-DNA
.	O

Spi-C	B-protein
interacted	O
with	O
DNA	O
similarly	O
to	O
PU.1	B-protein
as	O
judged	O
by	O
methylation	O
interference	O
,	O
band-shift	O
and	O
site	O
selection	O
analysis	O
,	O
and	O
activated	O
transcription	O
of	O
a	O
kappaY	B-DNA
element	I-DNA
reporter	I-DNA
gene	I-DNA
upon	O
co-transfection	O
of	O
HeLa	B-cell_line
cells	I-cell_line
.	O

Spi-C	B-RNA
RNA	I-RNA
was	O
expressed	O
in	O
mature	B-cell_type
B	I-cell_type
lymphocytes	I-cell_type
and	O
at	O
lower	O
levels	O
in	O
macrophages	B-cell_type
.	O

Furthermore	O
,	O
pre-B	B-cell_line
cell	I-cell_line
and	I-cell_line
plasma	I-cell_line
cell	I-cell_line
lines	I-cell_line
were	O
Spi-C	B-protein
-negative	O
,	O
suggesting	O
that	O
Spi-C	B-protein
might	O
be	O
a	O
regulatory	B-protein
molecule	I-protein
during	O
a	O
specific	O
phase	O
of	O
B	O
lymphoid	O
development	O
.	O

Glucocorticoid-induced	O
cell	O
death	O
requires	O
autoinduction	O
of	O
glucocorticoid	B-protein
receptor	I-protein
expression	O
in	O
human	B-cell_type
leukemic	I-cell_type
T	I-cell_type
cells	I-cell_type
.	O

In	O
contrast	O
to	O
the	O
negative	O
autoregulation	O
of	O
glucocorticoid	B-protein
receptor	I-protein
(	O
GR	B-protein
)	O
expression	O
seen	O
in	O
most	O
cells	O
and	O
tissues	O
,	O
GR	B-protein
expression	O
is	O
positively	O
autoregulated	O
in	O
human	B-cell_type
leukemic	I-cell_type
T	I-cell_type
cells	I-cell_type
and	O
in	O
other	O
cells	O
sensitive	O
to	O
glucocorticoid-induced	O
cell	O
death	O
.	O

To	O
determine	O
whether	O
positive	O
autoregulation	O
is	O
a	O
necessary	O
component	O
of	O
glucocorticoid-induced	O
cell	O
death	O
,	O
a	O
wild-type	B-DNA
GR	I-DNA
gene	I-DNA
under	O
the	O
control	O
of	O
a	O
tetracycline-regulated	B-DNA
promoter	I-DNA
was	O
stably	O
transfected	O
into	O
glucocorticoid-resistant	B-cell_line
cells	I-cell_line
lacking	O
endogenous	O
functional	O
receptor	O
.	O

Transfectants	B-cell_line
grown	O
in	O
the	O
presence	O
of	O
tetracycline	O
contained	O
about	O
15	O
,	O
000	O
receptors/cell	O
,	O
a	O
value	O
approximately	O
equal	O
to	O
basal	O
level	O
GR	B-protein
expression	O
in	O
glucocorticoid-sensitive	B-cell_line
6TG1.1	I-cell_line
cells	I-cell_line
before	O
steroid	O
treatment	O
.	O

Under	O
these	O
conditions	O
,	O
dexamethasone	O
had	O
a	O
minimal	O
effect	O
on	O
cell	O
growth	O
,	O
elicited	O
little	O
internucleosomal	O
DNA	O
fragmentation	O
,	O
and	O
induced	O
no	O
cell	O
cycle	O
perturbation	O
.	O

In	O
the	O
absence	O
of	O
tetracycline	O
,	O
GR	B-RNA
mRNA	I-RNA
and	O
protein	O
expression	O
increased	O
2-3-fold	O
,	O
and	O
cells	O
expressed	O
48	O
,	O
000	O
receptors	O
,	O
a	O
level	O
nearly	O
equivalent	O
to	O
that	O
present	O
in	O
6TG1.1	B-cell_line
cells	I-cell_line
after	O
18	O
h	O
of	O
autoinduction	O
.	O

Under	O
these	O
conditions	O
,	O
dexamethasone	O
markedly	O
inhibited	O
cell	O
growth	O
,	O
caused	O
G1	O
arrest	O
,	O
and	O
induced	O
significant	O
internucleosomal	O
DNA	O
fragmentation	O
.	O

These	O
studies	O
therefore	O
suggest	O
that	O
basal	O
level	O
GR	B-protein
expression	O
is	O
inadequate	O
to	O
mediate	O
glucocorticoid-induced	O
apoptosis	O
in	O
glucocorticoid-sensitive	B-cell_line
T	I-cell_line
cells	I-cell_line
and	O
that	O
positive	O
autoregulation	O
is	O
a	O
necessary	O
component	O
of	O
this	O
process	O
.	O

Constitutive	O
activation	O
of	O
NF-kappaB	B-protein
in	O
primary	B-cell_type
adult	I-cell_type
T-cell	I-cell_type
leukemia	I-cell_type
cells	I-cell_type
.	O

Human	O
T-cell	O
leukemia	O
virus	O
type	O
I	O
(	O
HTLV-I	O
)	O
is	O
an	O
etiologic	O
agent	O
of	O
adult	O
T-cell	O
leukemia	O
(	O
ATL	O
)	O
.	O

The	O
viral	B-protein
protein	I-protein
Tax	B-protein
induces	O
the	O
activation	O
and	O
nuclear	O
translocalization	O
of	O
transcription	B-protein
factor	I-protein
NF-kappaB	B-protein
,	O
which	O
is	O
proposed	O
to	O
play	O
a	O
crucial	O
role	O
in	O
the	O
transformation	O
of	O
T	B-cell_type
cells	I-cell_type
by	O
HTLV-I	O
.	O

However	O
,	O
the	O
HTLV-I	B-DNA
genes	I-DNA
including	O
Tax	B-protein
are	O
not	O
expressed	O
significantly	O
in	O
primary	B-cell_type
leukemic	I-cell_type
cells	I-cell_type
from	O
ATL	O
patients	O
.	O

In	O
this	O
study	O
,	O
we	O
examined	O
the	O
basis	O
for	O
NF-kappaB	B-protein
activation	O
in	O
freshly	B-cell_type
isolated	I-cell_type
leukemic	I-cell_type
cells	I-cell_type
from	O
ATL	O
patients	O
.	O

We	O
found	O
that	O
leukemic	B-cell_type
cells	I-cell_type
from	O
ATL	O
patients	O
,	O
like	O
HTLV-I-infected	B-cell_line
T-cell	I-cell_line
lines	I-cell_line
,	O
display	O
constitutive	O
NF-kappaB	B-protein
DNA	O
binding	O
activity	O
and	O
increased	O
degradation	O
of	O
IkappaBalpha	B-protein
(	O
an	O
inhibitor	O
of	O
NF-kappaB	B-protein
)	O
.	O

Whereas	O
the	O
NF-kappaB	B-protein
binding	O
activity	O
in	O
Tax-expressing	B-cell_line
T-cell	I-cell_line
lines	I-cell_line
consisted	O
mostly	O
of	O
p50/c-Rel	B-protein
,	O
fresh	O
ATL	O
samples	O
contained	O
p50/p50	B-protein
and	I-protein
p50/p65	I-protein
heterodimers	I-protein
.	O

One	O
T-cell	B-cell_line
line	I-cell_line
derived	O
from	O
ATL	O
leukemic	B-cell_type
cells	I-cell_type
,	O
TL-Om1	O
,	O
displayed	O
constitutive	O
NF-kappaB	B-protein
activity	O
,	O
as	O
well	O
as	O
enhanced	O
degradation	O
of	O
IkappaBalpha	B-protein
,	O
despite	O
the	O
lack	O
of	O
detectable	O
Tax	B-protein
expression	O
.	O

Interestingly	O
,	O
the	O
NF-kappaB	B-protein
in	O
TL-Om1	O
consists	O
of	O
p50/p50	B-protein
and	O
p50/p65	B-protein
like	O
that	O
in	O
fresh	O
primary	B-cell_type
leukemic	I-cell_type
cells	I-cell_type
.	O

Our	O
results	O
suggest	O
that	O
activation	O
of	O
NF-kappaB	B-protein
occurs	O
through	O
a	O
Tax	B-protein
-independent	O
mechanism	O
in	O
leukemic	B-cell_type
cells	I-cell_type
of	O
ATL	O
patients	O
,	O
possibly	O
due	O
to	O
differential	O
NF-kappaB	B-protein
subunit	O
activation	O
.	O

Interferon-alpha	B-protein
induction	O
of	O
STATs1	B-protein
,	I-protein
-3	I-protein
DNA	O
binding	O
and	O
growth	O
arrest	O
is	O
independent	O
of	O
Lck	B-protein
and	O
active	O
mitogen-activated	B-protein
kinase	I-protein
in	O
T	B-cell_type
cells	I-cell_type
.	O

Type	O
I	O
interferons	B-protein
(	O
IFNs	B-protein
)	O
are	O
a	O
family	O
of	O
cytokines	B-protein
that	O
have	O
antiviral	O
and	O
antiproliferative	O
effects	O
.	O

Data	O
regarding	O
the	O
processes	O
by	O
which	O
these	O
cytokines	B-protein
transduce	O
signals	O
from	O
the	O
cell	O
membrane	O
to	O
the	O
nucleus	O
are	O
becoming	O
increasingly	O
complex	O
.	O

The	O
most	O
characterized	O
pathway	O
is	O
via	O
JAK	B-protein
-STAT	B-protein
signaling	O
.	O

Previous	O
studies	O
established	O
a	O
potential	O
role	O
for	O
the	O
Src-family	B-protein
kinase	I-protein
Lck	B-protein
in	O
JAK	B-protein
-STAT	B-protein
signaling	O
.	O

Therefore	O
,	O
this	O
study	O
was	O
designed	O
to	O
analyze	O
the	O
role	O
of	O
Lck	B-protein
in	O
IFN-alpha	B-protein
signaling	O
by	O
using	O
the	O
Jurkat	O
,	O
JCam	O
(	O
an	O
Lck-defective	B-cell_line
cell	I-cell_line
line	I-cell_line
derived	O
from	O
Jurkat	B-cell_line
)	O
,	O
and	O
JCam/Lck	B-cell_line
(	O
JCam	B-cell_line
cells	I-cell_line
with	O
Lck	B-protein
restored	O
)	O
.	O

The	O
results	O
show	O
that	O
IFN-alpha	B-protein
can	O
induce	O
MAPK	B-protein
activity	O
,	O
but	O
only	O
in	O
cells	O
containing	O
Lck	B-protein
.	O

Furthermore	O
,	O
STATs1	B-protein
and	I-protein
-3	I-protein
are	O
effectively	O
phosphorylated	O
and	O
activated	O
to	O
bind	O
DNA	O
in	O
the	O
absence	O
of	O
Lck	B-protein
expression	O
in	O
IFN-alpha-treated	B-cell_line
cells	I-cell_line
.	O

Finally	O
,	O
the	O
results	O
demonstrate	O
that	O
IFN-alpha	B-protein
exerts	O
an	O
antiproliferative	O
effect	O
in	O
all	O
three	O
cell	O
lines	O
.	O

These	O
data	O
indicate	O
that	O
Lck	B-protein
and	O
active	O
MAPK	B-protein
do	O
not	O
affect	O
IFN-alpha	B-protein
-induced	O
growth	O
arrest	O
or	O
induction	O
of	O
STAT1s1	O
and	O
-3	O
DNA	O
binding	O
ability	O
.	O

Copyright	O
1999	O
Academic	O
Press	O
.	O

Selective	O
activation	O
and	O
functional	O
significance	O
of	O
p38alpha	B-protein
mitogen-activated	I-protein
protein	I-protein
kinase	I-protein
in	O
lipopolysaccharide-stimulated	B-cell_line
neutrophils	I-cell_line
.	O

Activation	O
of	O
leukocytes	B-cell_type
by	O
proinflammatory	O
stimuli	O
selectively	O
initiates	O
intracellular	O
signal	O
transduction	O
via	O
sequential	O
phosphorylation	O
of	O
kinases	B-protein
.	O

Lipopolysaccharide	O
(	O
LPS	O
)	O
stimulation	O
of	O
human	B-cell_type
neutrophils	I-cell_type
is	O
known	O
to	O
result	O
in	O
activation	O
of	O
p38	B-protein
mitogen-activated	I-protein
protein	I-protein
kinase	I-protein
(	O
MAPk	B-protein
)	O
;	O
however	O
,	O
the	O
upstream	B-protein
activator	I-protein
(	O
s	O
)	O
of	O
p38	B-protein
MAPk	I-protein
is	O
unknown	O
,	O
and	O
consequences	O
of	O
p38	B-protein
MAPk	I-protein
activation	O
remain	O
largely	O
undefined	O
.	O

We	O
investigated	O
the	O
MAPk	B-protein
kinase	I-protein
(	O
MKK	B-protein
)	O
that	O
activates	O
p38	B-protein
MAPk	I-protein
in	O
response	O
to	O
LPS	O
,	O
the	O
p38	B-protein
MAPk	I-protein
isoforms	I-protein
that	O
are	O
activated	O
as	O
part	O
of	O
this	O
pathway	O
,	O
and	O
the	O
functional	O
responses	O
affected	O
by	O
p38	B-protein
MAPk	I-protein
activation	O
.	O

Although	O
MKK3	B-protein
,	O
MKK4	B-protein
,	O
and	O
MKK6	B-protein
all	O
activated	O
p38	B-protein
MAPk	I-protein
in	O
experimental	O
models	O
,	O
only	O
MKK3	B-protein
was	O
found	O
to	O
activate	O
recombinant	O
p38	B-protein
MAPk	I-protein
in	O
LPS-treated	O
neutrophils	O
.	O

Of	O
p38	B-protein
MAPk	I-protein
isoforms	I-protein
studied	O
,	O
only	O
p38alpha	B-protein
and	O
p38delta	B-protein
were	O
detected	O
in	O
neutrophils	B-cell_type
.	O

LPS	O
stimulation	O
selectively	O
activated	O
p38alpha	B-protein
.	O

Specific	O
inhibitors	O
of	O
p38alpha	B-protein
MAPk	I-protein
blocked	O
LPS-induced	O
adhesion	O
,	O
nuclear	O
factor-kappa	O
B	O
(	O
NF-kappaB	B-protein
)	O
activation	O
,	O
and	O
synthesis	O
of	O
tumor	B-protein
necrosis	I-protein
factor-alpha	I-protein
(	O
TNF-alpha	B-protein
)	O
.	O

Inhibition	O
of	O
p38alpha	B-protein
MAPk	I-protein
resulted	O
in	O
a	O
transient	O
decrease	O
in	O
TNF-alpha	B-RNA
mRNA	I-RNA
accumulation	O
but	O
persistent	O
loss	O
of	O
TNF-alpha	B-protein
synthesis	O
.	O

These	O
findings	O
support	O
a	O
pathway	O
by	O
which	O
LPS	O
stimulation	O
of	O
neutrophils	B-cell_type
results	O
in	O
activation	O
of	O
MKK3	B-protein
,	O
which	O
in	O
turn	O
activates	O
p38alpha	B-protein
MAPk	I-protein
,	O
ultimately	O
regulating	O
adhesion	O
,	O
NF-kappaB	B-protein
activation	O
,	O
enhanced	O
gene	O
expression	O
of	O
TNF-alpha	B-protein
,	O
and	O
regulation	O
of	O
TNF-alpha	B-protein
synthesis	O
.	O

The	O
evolutionarily	B-DNA
conserved	I-DNA
sequence	I-DNA
upstream	O
of	O
the	O
human	B-protein
Ig	I-protein
heavy	I-protein
chain	I-protein
S	I-protein
gamma	I-protein
3	I-protein
region	I-protein
is	O
an	O
inducible	B-DNA
promoter	I-DNA
:	O
synergistic	O
activation	O
by	O
CD40	B-protein
ligand	I-protein
and	O
IL-4	B-protein
via	O
cooperative	O
NF-kappa	B-DNA
B	I-DNA
and	I-DNA
STAT-6	I-DNA
binding	I-DNA
sites	I-DNA
.	O

Germline	O
C	O
gamma	O
gene	O
transcription	O
is	O
a	O
crucial	O
event	O
in	O
the	O
process	O
that	O
leads	O
to	O
switch	O
DNA	O
recombination	O
to	O
IgG	B-protein
,	O
but	O
its	O
regulation	O
in	O
the	O
human	O
is	O
poorly	O
understood	O
.	O

We	O
took	O
advantage	O
of	O
our	O
monoclonal	O
model	O
of	O
germinal	B-cell_type
center	I-cell_type
B	I-cell_type
cell	I-cell_type
differentiation	O
,	O
IgM+	B-cell_line
IgD+	I-cell_line
CL-01	I-cell_line
cells	I-cell_line
,	O
to	O
define	O
the	O
role	O
of	O
the	O
I	B-protein
gamma	I-protein
3	I-protein
evolutionarily	B-DNA
conserved	I-DNA
sequence	I-DNA
(	O
ECS	B-DNA
)	O
in	O
the	O
germline	B-DNA
transcriptional	O
activation	O
of	O
the	O
human	B-DNA
C	I-DNA
gamma	I-DNA
3	I-DNA
gene	I-DNA
.	O

The	O
I	B-protein
gamma	I-protein
3	I-protein
ECS	B-DNA
lies	O
upstream	O
of	O
the	O
major	B-DNA
I	I-DNA
gamma	I-DNA
3	I-DNA
transcription	I-DNA
initiation	I-DNA
site	I-DNA
and	O
displays	O
more	O
than	O
90	O
%	O
identity	O
with	O
the	O
corresponding	O
human	B-DNA
I	I-DNA
gamma	I-DNA
1	I-DNA
,	O
I	B-DNA
gamma	I-DNA
2	I-DNA
,	O
and	O
I	B-DNA
gamma	I-DNA
4	I-DNA
regions	O
.	O

Reporter	B-DNA
luciferase	I-DNA
gene	I-DNA
vectors	I-DNA
containing	O
the	O
human	B-DNA
gamma	I-DNA
3	I-DNA
ECS	I-DNA
were	O
used	O
to	O
transfect	O
CL-01	B-cell_line
cells	I-cell_line
,	O
which	O
have	O
been	O
shown	O
to	O
undergo	O
Smu	O
--	O
>	O
S	O
gamma	O
3	O
DNA	O
recombination	O
,	O
upon	O
engagement	O
of	O
CD40	B-protein
by	O
CD40	B-protein
ligand	I-protein
(	O
CD40L	B-protein
)	O
and	O
exposure	O
to	O
IL-4	B-protein
.	O

In	O
these	O
transfected	O
CL-01	B-cell_line
cells	I-cell_line
,	O
CD40	O
:	O
CD40L	B-protein
engagement	O
and	O
exposure	O
to	O
IL-4	B-protein
synergistically	O
induced	O
gamma	O
3	O
ECS-dependent	O
luciferase	B-DNA
reporter	I-DNA
gene	I-DNA
activation	O
.	O

Targeted	O
mutational	O
analysis	O
demonstrated	O
that	O
a	O
tandem	O
NF-kappa	B-DNA
B/Rel	I-DNA
binding	I-DNA
motif	I-DNA
is	O
critical	O
for	O
the	O
gamma	B-DNA
3	I-DNA
ECS	I-DNA
responsiveness	O
to	O
both	O
CD40L	B-protein
and	O
IL-4	B-protein
,	O
while	O
a	O
STAT-6-binding	B-DNA
site	I-DNA
is	O
additionally	O
required	O
for	O
IL-4	B-protein
inducibility	O
.	O

Electrophoretic	O
mobility	O
shift	O
assays	O
showed	O
that	O
p50/p65/c-Rel	B-protein
and	O
STAT-6	B-protein
are	O
effectively	O
induced	O
by	O
CD40L	B-protein
and	O
IL-4	B-protein
,	O
respectively	O
,	O
and	O
bind	O
to	O
specific	O
DNA	B-DNA
motifs	I-DNA
within	O
the	O
ECS	B-DNA
.	O

These	O
partially	O
overlapping	O
CD40L	B-DNA
and	I-DNA
IL-4	I-DNA
responsive	I-DNA
elements	I-DNA
are	O
functionally	O
cooperative	O
as	O
the	O
disruption	O
of	O
one	O
of	O
them	O
prevents	O
synergistic	O
promoter	O
activation	O
.	O

Thus	O
,	O
the	O
gamma	B-DNA
3	I-DNA
ECS	I-DNA
is	O
an	O
inducible	O
promoter	O
containing	O
cis	B-DNA
elements	I-DNA
that	O
critically	O
mediate	O
CD40L	B-protein
and	O
IL-4	B-protein
-triggered	O
transcriptional	O
activation	O
of	O
the	O
human	B-DNA
C	I-DNA
gamma	I-DNA
3	I-DNA
gene	I-DNA
.	O

CIITA	B-protein
-induced	O
occupation	O
of	O
MHC	B-DNA
class	I-DNA
II	I-DNA
promoters	I-DNA
is	O
independent	O
of	O
the	O
cooperative	O
stabilization	O
of	O
the	O
promoter-bound	B-protein
multi-protein	I-protein
complexes	I-protein
.	O

Precise	O
regulation	O
of	O
MHC	B-cell_type
class	I-cell_type
II	I-cell_type
expression	O
plays	O
a	O
crucial	O
role	O
in	O
the	O
control	O
of	O
the	O
immune	O
response	O
.	O

The	O
transactivator	B-protein
CIITA	B-protein
behaves	O
as	O
a	O
master	O
controller	O
of	O
constitutive	O
and	O
inducible	O
MHC	B-DNA
class	I-DNA
II	I-DNA
gene	I-DNA
activation	O
,	O
but	O
its	O
exact	O
mechanism	O
of	O
action	O
is	O
not	O
known	O
.	O

Activation	O
of	O
MHC	B-DNA
class	I-DNA
II	I-DNA
promoters	I-DNA
requires	O
binding	O
of	O
at	O
least	O
three	O
distinct	O
multi-protein	B-protein
complexes	I-protein
(	O
RFX	B-protein
,	O
X2BP	B-protein
and	O
NF-Y	B-protein
)	O
.	O

It	O
is	O
known	O
that	O
the	O
stability	O
of	O
this	O
binding	O
results	O
from	O
cooperative	O
interactions	O
between	O
these	O
proteins	O
.	O

We	O
show	O
here	O
that	O
expression	O
of	O
CIITA	B-protein
in	O
MHC	B-cell_line
class	I-cell_line
II	I-cell_line
-cells	I-cell_line
triggers	O
occupation	O
of	O
the	O
promoters	O
by	O
these	O
complexes	O
.	O

This	O
observation	O
raised	O
the	O
possibility	O
that	O
the	O
effect	O
of	O
CIITA	B-protein
on	O
promoter	O
occupation	O
is	O
mediated	O
by	O
an	O
effect	O
on	O
the	O
cooperative	O
stabilization	O
of	O
the	O
DNA-bound	B-protein
multi-protein	I-protein
complexes	I-protein
.	O

We	O
show	O
,	O
however	O
,	O
that	O
the	O
presence	O
of	O
CIITA	B-protein
does	O
not	O
affect	O
the	O
stability	O
of	O
the	O
higher-order	O
protein	O
complex	O
formed	O
on	O
DNA	O
by	O
RFX	B-protein
,	O
X2BP	B-protein
and	O
NF-Y	B-protein
.	O

This	O
suggests	O
other	O
mechanisms	O
for	O
CIITA	B-protein
-induced	O
promoter	O
occupancy	O
,	O
such	O
as	O
an	O
effect	O
on	O
chromatin	B-DNA
structure	O
leading	O
to	O
increased	O
accessibility	O
of	O
MHC	B-DNA
class	I-DNA
II	I-DNA
promoters	I-DNA
.	O

This	O
ability	O
of	O
CIITA	B-protein
to	O
facilitate	O
promoter	O
occupation	O
is	O
undissociable	O
from	O
its	O
transactivation	O
potential	O
.	O

Finally	O
,	O
we	O
conclude	O
that	O
this	O
effect	O
of	O
CIITA	B-protein
is	O
cell-type	O
specific	O
,	O
since	O
expression	O
of	O
CIITA	B-protein
is	O
not	O
required	O
for	O
normal	O
occupation	O
of	O
MHC	B-DNA
class	I-DNA
II	I-DNA
promoters	I-DNA
in	O
B	B-cell_type
lymphocytes	I-cell_type
.	O

GrpL	B-protein
,	O
a	O
Grb2	B-protein
-related	O
adaptor	B-protein
protein	I-protein
,	O
interacts	O
with	O
SLP-76	B-protein
to	O
regulate	O
nuclear	B-protein
factor	I-protein
of	I-protein
activated	I-protein
T	I-protein
cell	I-protein
activation	O
.	O

Propagation	O
of	O
signals	O
from	O
the	O
T	B-protein
cell	I-protein
antigen	I-protein
receptor	I-protein
(	O
TCR	B-protein
)	O
involves	O
a	O
number	O
of	O
adaptor	O
molecules	O
.	O

SH2	B-protein
domain-containing	I-protein
protein	I-protein
76	I-protein
(	O
SLP-76	B-protein
)	O
interacts	O
with	O
the	O
guanine	B-protein
nucleotide	I-protein
exchange	I-protein
factor	I-protein
Vav	B-protein
to	O
activate	O
the	O
nuclear	B-protein
factor	I-protein
of	I-protein
activated	I-protein
cells	I-protein
(	O
NF-AT	B-protein
)	O
,	O
and	O
its	O
expression	O
is	O
required	O
for	O
normal	O
T	B-cell_type
cell	I-cell_type
development	O
.	O

We	O
report	O
the	O
cloning	O
and	O
characterization	O
of	O
a	O
novel	O
Grb2-like	B-protein
adaptor	I-protein
molecule	I-protein
designated	O
as	O
Grb2-related	B-protein
protein	I-protein
of	I-protein
the	I-protein
lymphoid	I-protein
system	I-protein
(	O
GrpL	B-protein
)	O
.	O

Expression	O
of	O
GrpL	B-protein
is	O
restricted	O
to	O
hematopoietic	O
tissues	O
,	O
and	O
it	O
is	O
distinguished	O
from	O
Grb2	B-protein
by	O
having	O
a	O
proline-rich	B-protein
region	I-protein
.	O

GrpL	B-protein
can	O
be	O
coimmunoprecipitated	O
with	O
SLP-76	B-protein
but	O
not	O
with	O
Sos1	B-protein
or	O
Sos2	B-protein
from	O
Jurkat	B-cell_line
cell	I-cell_line
lysates	O
.	O

In	O
contrast	O
,	O
Grb2	B-protein
can	O
be	O
coimmunoprecipitated	O
with	O
Sos1	B-protein
and	O
Sos2	B-protein
but	O
not	O
with	O
SLP-76	B-protein
.	O

Moreover	O
,	O
tyrosine-phosphorylated	B-protein
LAT/pp36/38	I-protein
in	O
detergent	O
lysates	O
prepared	O
from	O
anti-CD3	B-cell_type
stimulated	I-cell_type
T	I-cell_type
cells	I-cell_type
associated	O
with	O
Grb2	B-protein
but	O
not	O
GrpL	B-protein
.	O

These	O
data	O
reveal	O
the	O
presence	O
of	O
distinct	O
complexes	O
involving	O
GrpL	B-protein
and	O
Grb2	B-protein
in	O
T	B-cell_type
cells	I-cell_type
.	O

A	O
functional	O
role	O
of	O
the	O
GrpL-SLP-76	B-protein
complex	I-protein
is	O
suggested	O
by	O
the	O
ability	O
of	O
GrpL	B-protein
to	O
act	O
alone	O
or	O
in	O
concert	O
with	O
SLP-76	B-protein
to	O
augment	O
NF-AT	B-protein
activation	O
in	O
Jurkat	B-cell_line
T	B-cell_type
cells	I-cell_type
.	O

Differential	O
induction	O
of	O
interferon	B-protein
(	I-protein
IFN	I-protein
)	I-protein
-inducible	I-protein
protein	I-protein
10	I-protein
following	O
differentiation	O
of	O
a	O
monocyte	B-cell_type
,	O
macrophage	B-cell_type
cell	I-cell_type
lineage	O
is	O
related	O
to	O
the	O
changes	O
of	O
nuclear	B-protein
proteins	I-protein
bound	O
to	O
IFN	B-DNA
stimulus	I-DNA
response	I-DNA
element	I-DNA
and	O
kappaB	B-DNA
sites	I-DNA
.	O

We	O
examined	O
chemokine	B-protein
gene	O
expression	O
following	O
the	O
differentiation	O
of	O
a	O
monocyte	B-cell_type
,	O
macrophage	B-cell_line
cell	I-cell_line
lineage	I-cell_line
.	O

The	O
human	B-cell_line
monoblastic	I-cell_line
cell	I-cell_line
line	I-cell_line
,	O
U937	B-cell_line
was	O
differentiated	O
to	O
macrophages	B-cell_type
by	O
the	O
treatment	O
with	O
either	O
phorbol	O
12-myristate	O
13-acetate	O
(	O
PMA	O
)	O
,	O
retinoic	O
acid	O
(	O
RA	O
)	O
,	O
or	O
vitamin	O
D3	O
(	O
VitD3	O
)	O
.	O

The	O
gene	O
expression	O
of	O
interferon	B-protein
(	I-protein
IFN	I-protein
)	I-protein
-inducible	I-protein
protein	I-protein
10	I-protein
(	O
IP-10	B-protein
)	O
(	O
a	O
CXC	B-protein
chemokine	I-protein
)	O
was	O
markedly	O
augmented	O
by	O
the	O
IFNgamma	B-protein
treatment	O
in	O
PMA	O
-or	O
RA-differentiated	O
U937	B-cell_line
cells	I-cell_line
,	O
but	O
only	O
marginally	O
in	O
undifferentiated	O
or	O
VitD3-treated	B-cell_line
cells	I-cell_line
.	O

In	O
contrast	O
,	O
another	O
inducible	O
gene	O
expression	O
of	O
monocyte	B-protein
chemotactic	I-protein
protein-1	I-protein
(	O
a	O
CC	B-protein
chemokine	I-protein
)	O
and	O
the	O
activation	O
of	O
the	O
transcriptional	B-protein
factor	I-protein
(	O
FcRFgamma	B-protein
)	O
bound	O
to	O
the	O
gamma	B-DNA
response	I-DNA
region	I-DNA
were	O
similarly	O
or	O
less	O
abundantly	O
induced	O
by	O
IFNgamma	B-protein
treatment	O
in	O
PMA	O
-or	O
RA-differentiated	O
U937	B-cell_line
cells	I-cell_line
,	O
indicating	O
that	O
increased	O
IP-10	B-RNA
mRNA	I-RNA
induction	O
was	O
not	O
due	O
to	O
the	O
augmented	O
ability	O
of	O
the	O
cells	O
to	O
respond	O
to	O
the	O
presence	O
of	O
IFNgamma	B-protein
.	O

Increased	O
expression	O
of	O
IFNgamma	B-protein
-induced	O
IP-10	B-RNA
mRNA	I-RNA
following	O
the	O
differentiation	O
of	O
U937	B-cell_line
cells	I-cell_line
was	O
mediated	O
largely	O
by	O
augmented	O
transcriptional	O
activity	O
of	O
the	O
gene	O
and	O
was	O
related	O
to	O
differentiation-dependent	O
changes	O
of	O
the	O
proteins	O
bound	O
to	O
IFN	B-DNA
stimulus	I-DNA
response	I-DNA
element	I-DNA
(	I-DNA
ISRE	I-DNA
)	I-DNA
and	O
kB	B-DNA
sites	I-DNA
,	O
suggesting	O
that	O
these	O
nuclear	B-protein
proteins	I-protein
may	O
determine	O
the	O
IP-10	B-RNA
mRNA	I-RNA
inducibility	O
by	O
IFNgamma	B-protein
.	O

Role	O
of	O
cellular	B-protein
tumor	I-protein
necrosis	I-protein
factor	I-protein
receptor-associated	I-protein
factors	I-protein
in	O
NF-kappaB	B-protein
activation	O
and	O
lymphocyte	B-cell_type
transformation	O
by	O
herpesvirus	O
Saimiri	O
STP	B-protein
.	O

The	O
STP	B-protein
oncoproteins	I-protein
of	O
the	O
herpesvirus	O
saimiri	O
(	O
HVS	O
)	O
subgroup	O
A	O
strain	O
11	O
and	O
subgroup	O
C	O
strain	O
488	O
are	O
now	O
found	O
to	O
be	O
stably	O
associated	O
with	O
tumor	B-protein
necrosis	I-protein
factor	I-protein
receptor-associated	I-protein
factor	I-protein
(	I-protein
TRAF	I-protein
)	I-protein
1	I-protein
,	I-protein
2	I-protein
,	I-protein
or	I-protein
3	I-protein
.	O

Mutational	O
analyses	O
identified	O
residues	O
of	O
PXQXT/S	B-protein
in	O
STP-A11	B-protein
as	O
critical	O
for	O
TRAF	B-protein
association	O
.	O

In	O
addition	O
,	O
a	O
somewhat	O
divergent	O
region	O
of	O
STP-C488	B-protein
is	O
critical	O
for	O
TRAF	B-protein
association	O
.	O

Mutational	O
analysis	O
also	O
revealed	O
that	O
STP-C488	B-protein
induced	O
NF-kappaB	B-protein
activation	O
that	O
was	O
correlated	O
with	O
its	O
ability	O
to	O
associate	O
with	O
TRAFs	B-protein
.	O

The	O
HVS	O
STP-C488	B-protein
P10	O
--	O
>	O
R	O
mutant	O
was	O
deficient	O
in	O
human	O
T-lymphocyte	O
transformation	O
to	O
interleukin-2-independent	O
growth	O
but	O
showed	O
wild-type	O
phenotype	O
for	O
marmoset	O
T-lymphocyte	O
transformation	O
in	O
vitro	O
and	O
in	O
vivo	O
.	O

The	O
STP-C488	B-protein
P10	I-protein
--	I-protein
>	I-protein
R	I-protein
mutant	I-protein
was	O
also	O
defective	O
in	O
Rat-1	O
fibroblast	O
transformation	O
,	O
and	O
fibroblast	O
cell	O
transformation	O
was	O
blocked	O
by	O
a	O
TRAF2	B-protein
dominant-negative	O
mutant	O
.	O

These	O
data	O
implicate	O
TRAFs	B-protein
in	O
STP-C488	B-protein
-mediated	O
transformation	O
of	O
human	B-cell_type
lymphocytes	I-cell_type
and	O
rodent	O
fibroblasts	B-cell_type
.	O

Other	O
factors	O
are	O
implicated	O
in	O
immortalization	O
of	O
common	B-cell_type
marmoset	I-cell_type
T	I-cell_type
lymphocytes	I-cell_type
and	O
may	O
also	O
be	O
critical	O
in	O
the	O
transformation	O
of	O
human	B-cell_type
lymphocytes	I-cell_type
and	O
rodent	B-cell_type
fibroblasts	I-cell_type
.	O

Cleavage	O
of	O
transcription	B-protein
factor	I-protein
SP1	B-protein
by	O
caspases	B-protein
during	O
anti-IgM-induced	O
B-cell	B-cell_type
apoptosis	O
.	O

Apoptosis	O
is	O
instrumental	O
in	O
the	O
processes	O
generating	O
the	O
diversity	O
of	O
the	O
B-cell	O
repertoire	O
.	O

Autoreactive	B-cell_type
B-cells	I-cell_type
are	O
eliminated	O
by	O
anti-IgM	B-protein
crosslinking	O
after	O
encountering	O
self-antigens	B-protein
,	O
but	O
precise	O
mechanisms	O
leading	O
to	O
B-cell	B-cell_type
apoptosis	O
are	O
still	O
not	O
well	O
understood	O
.	O

We	O
report	O
here	O
the	O
cleavage	O
of	O
the	O
transcription	B-protein
factor	I-protein
SP1	B-protein
in	O
the	O
human	B-cell_line
Burkitt	I-cell_line
lymphoma	I-cell_line
cell	I-cell_line
line	I-cell_line
BL60	I-cell_line
during	O
anti-IgM	B-protein
-induced	O
apoptosis	O
.	O

Western	O
blot	O
analysis	O
revealed	O
two	O
cleavage	O
products	O
of	O
approximately	O
68	B-protein
kDa	I-protein
and	O
45	B-protein
kDa	I-protein
after	O
induction	O
of	O
apoptosis	O
.	O

Cleavage	O
could	O
be	O
completely	O
inhibited	O
by	O
zDEVD-fmk	O
,	O
an	O
inhibitor	O
specific	O
for	O
caspase	B-protein
3-like	I-protein
proteases	I-protein
.	O

In-vitro	O
cleavage	O
of	O
recombinant	B-protein
SP1	I-protein
by	O
recombinant	B-protein
caspase	I-protein
3	I-protein
(	O
CPP32	B-protein
)	O
or	O
caspase	B-protein
7	I-protein
(	O
Mch	B-protein
3	I-protein
)	O
results	O
in	O
similar	O
cleavage	O
products	O
as	O
those	O
observed	O
in	O
vivo	O
.	O

Recombinant	B-protein
caspase	I-protein
6	I-protein
(	O
Mch	B-protein
2	I-protein
)	O
primarily	O
generates	O
a	O
68-kDa	O
cleavage	O
product	O
,	O
as	O
observed	O
after	O
calcium	O
ionophore	O
(	O
CaI	O
)	O
induced	O
B-cell	B-cell_type
apoptosis	O
.	O

In	O
contrast	O
,	O
caspase	O
1	O
(	O
ICE	O
)	O
did	O
not	O
cleave	O
SP1	B-protein
in	O
vitro	O
.	O

The	O
time	O
course	O
of	O
SP1	B-protein
cleavage	O
during	O
anti-IgM-induced	O
apoptosis	O
is	O
paralleled	O
by	O
an	O
increase	O
of	O
caspase	O
activity	O
measured	O
by	O
DEVD-p-nitroanilide	O
(	O
DEVD-pNA	O
)	O
cleavage	O
.	O

DNA	O
band-shift	O
assays	O
revealed	O
a	O
decrease	O
in	O
the	O
intensity	O
of	O
the	O
full	O
length	O
SP1	B-protein
/DNA	O
complex	O
and	O
an	O
increase	O
in	O
the	O
intensity	O
of	O
a	O
smaller	O
complex	O
due	O
to	O
the	O
binding	O
of	O
one	O
SP1	B-protein
cleavage	O
product	O
.	O

By	O
Edman	O
sequencing	O
we	O
could	O
identify	O
a	O
caspase	O
3	O
cleavage	O
site	O
after	O
Asp584	O
(	O
D584AQPQAGR	O
)	O
,	O
generating	O
a	O
22-kDa	O
C-terminal	O
SP1	B-protein
protein	O
fragment	O
which	O
still	O
contains	O
the	O
DNA	O
binding	O
site	O
.	O

Our	O
results	O
show	O
the	O
cleavage	O
of	O
the	O
human	O
transcription	B-protein
factor	I-protein
SP1	B-protein
in	O
vivo	O
and	O
in	O
vitro	O
,	O
underlining	O
the	O
central	O
role	O
of	O
caspase	B-protein
3-like	I-protein
proteases	I-protein
during	O
the	O
process	O
of	O
anti-IgM-induced	O
apoptosis	O
.	O

Stimulation	O
of	O
CD40	B-protein
on	O
immunogenic	O
human	O
malignant	O
melanomas	O
augments	O
their	O
cytotoxic	B-cell_type
T	I-cell_type
lymphocyte	I-cell_type
-mediated	O
lysis	O
and	O
induces	O
apoptosis	O
.	O

Here	O
,	O
we	O
report	O
the	O
functional	O
expression	O
of	O
CD40	B-protein
on	O
human	O
malignant	O
melanomas	O
(	O
MMs	O
)	O
.	O

Comparison	O
of	O
tumor	O
specimen	O
from	O
MM	O
precursor	O
lesions	O
,	O
primary	O
tumors	O
,	O
and	O
metastases	O
revealed	O
that	O
CD40	B-protein
surface	O
expression	O
is	O
down-regulated	O
during	O
tumor	O
progression	O
.	O

CD40	B-protein
expression	O
was	O
confirmed	O
in	O
7	O
human	B-cell_line
MM	I-cell_line
cell	I-cell_line
lines	I-cell_line
established	O
from	O
immunogenic	O
primary	O
tumors	O
or	O
metastases	O
,	O
whereas	O
11	O
cell	B-cell_line
lines	I-cell_line
established	O
from	O
advanced	O
stages	O
were	O
CD40	B-protein
negative	O
.	O

CD40	B-protein
expression	O
could	O
be	O
enhanced	O
in	O
CD40	B-protein
-positive	O
MM	O
by	O
stimulation	O
with	O
IFN-gamma	B-protein
and	O
tumor	B-protein
necrosis	I-protein
factor-alpha	I-protein
but	O
not	O
by	O
interleukin	B-protein
(	I-protein
IL	I-protein
)	I-protein
-1beta	I-protein
or	O
CD40	B-protein
triggering	O
.	O

CD40	B-protein
ligation	O
on	O
MM	O
by	O
CD40L-transfected	B-cell_line
murine	I-cell_line
L-cells	I-cell_line
or	O
by	O
a	O
soluble	O
CD40L	B-protein
fusion	I-protein
protein	I-protein
up-regulated	O
their	O
expression	O
of	O
intercellular	B-protein
adhesion	I-protein
molecule-1	I-protein
and	O
MHC	B-protein
class	I-protein
I	I-protein
and	I-protein
class	I-protein
II	I-protein
molecules	I-protein
and	O
their	O
secretion	O
of	O
IL-6	B-protein
,	O
IL-8	B-protein
,	O
tumor	B-protein
necrosis	I-protein
factor-a	I-protein
,	O
and	O
granulocyte	B-protein
macrophage	I-protein
colony-stimulating	I-protein
factor	I-protein
and	O
also	O
induced	O
a	O
rapid	O
activation	O
of	O
the	O
transcription	B-protein
factor	I-protein
nuclear	B-protein
factor	I-protein
kappaB	I-protein
.	O

Furthermore	O
,	O
CD40	B-protein
ligation	O
of	O
a	O
HLA-A2+	B-cell_line
,	I-cell_line
MelanA/MART1+	I-cell_line
MM	I-cell_line
cell	I-cell_line
line	I-cell_line
enhanced	O
its	O
susceptibility	O
to	O
specific	O
lysis	O
by	O
a	O
HLA-A2-restricted	B-cell_line
,	I-cell_line
MelanA/MART-1-specific	I-cell_line
CTL	I-cell_line
clone	I-cell_line
.	O

Finally	O
,	O
CD40	B-protein
ligation	O
induced	O
growth	O
inhibition	O
and	O
apoptosis	O
in	O
MM	O
.	O

These	O
results	O
indicate	O
that	O
CD40	B-protein
-CD40L	B-protein
interactions	O
may	O
play	O
an	O
important	O
role	O
in	O
augmenting	O
antitumor	O
immunity	O
and	O
inducing	O
apoptosis	O
in	O
some	O
CD40	B-protein
-positive	O
immunogenic	O
human	O
MMs	O
.	O

Human	O
immunodeficiency	O
virus-associated	O
Hodgkin	O
's	O
disease	O
derives	O
from	O
post-germinal	B-cell_type
center	I-cell_type
B	I-cell_type
cells	I-cell_type
.	O

Human	O
immunodeficiency	O
virus-associated	O
Hodgkin	O
's	O
disease	O
(	O
HIV-HD	O
)	O
displays	O
several	O
peculiarities	O
when	O
compared	O
with	O
HD	O
of	O
the	O
general	O
population	O
.	O

These	O
include	O
overrepresentation	O
of	O
clinically	O
aggressive	O
histologic	O
types	O
and	O
frequent	O
infection	O
of	O
Reed-Sternberg	B-cell_line
(	I-cell_line
RS	I-cell_line
)	I-cell_line
cells	I-cell_line
by	O
Epstein-Barr	O
virus	O
(	O
EBV	O
)	O
.	O

Recently	O
,	O
we	O
have	O
reported	O
that	O
the	O
histogenesis	O
of	O
HD	O
of	O
the	O
general	O
population	O
may	O
be	O
assessed	O
by	O
monitoring	O
the	O
expression	O
pattern	O
of	O
BCL-6	B-protein
,	O
a	O
transcription	B-protein
factor	I-protein
expressed	O
in	O
germinal	B-cell_line
center	I-cell_line
(	I-cell_line
GC	I-cell_line
)	I-cell_line
B	I-cell_line
cells	I-cell_line
,	O
and	O
of	O
CD138/syndecan-1	B-protein
(	O
syn-1	B-protein
)	O
,	O
a	O
proteoglycan	O
associated	O
with	O
post-GC	O
,	O
terminal	O
B-cell	B-cell_type
differentiation	O
.	O

In	O
this	O
study	O
,	O
we	O
have	O
applied	O
these	O
two	O
markers	O
to	O
the	O
study	O
of	O
HIV-HD	O
histogenesis	O
and	O
correlated	O
their	O
expression	O
status	O
to	O
the	O
virologic	O
features	O
of	O
this	O
disease	O
.	O

We	O
have	O
found	O
that	O
RS	B-cell_line
cells	I-cell_line
of	O
all	O
histologic	O
categories	O
of	O
HIV-HD	O
consistently	O
display	O
the	O
BCL-6	B-protein
(	O
-	O
)	O
/syn-1	O
(	O
+	O
)	O
phenotype	O
and	O
thus	O
reflect	O
post-GC	B-cell_line
B	I-cell_line
cells	I-cell_line
.	O

Although	O
BCL-6	B-protein
(	O
-	O
)	O
/syn-1	O
(	O
+	O
)	O
RS	B-cell_line
cells	I-cell_line
of	O
HIV-HD	O
express	O
CD40	B-protein
,	O
they	O
are	O
not	O
surrounded	O
by	O
CD40	B-cell_type
ligand-positive	I-cell_type
(	I-cell_type
CD40L+	I-cell_type
)	I-cell_type
reactive	I-cell_type
T	I-cell_type
lymphocytes	I-cell_type
,	O
which	O
,	O
in	O
HD	O
of	O
the	O
general	O
population	O
,	O
are	O
thought	O
to	O
regulate	O
the	O
disease	O
phenotype	O
through	O
CD40	B-protein
/CD40L	B-protein
interactions	O
.	O

Conversely	O
,	O
RS	B-cell_line
cells	I-cell_line
of	O
virtually	O
all	O
HIV-HD	O
express	O
the	O
EBV-encoded	B-protein
latent	I-protein
membrane	I-protein
protein	I-protein
1	I-protein
(	O
LMP1	B-protein
)	O
,	O
which	O
,	O
being	O
functionally	O
homologous	O
to	O
CD40	B-protein
,	O
may	O
contribute	O
,	O
at	O
least	O
in	O
part	O
,	O
to	O
the	O
modulation	O
of	O
the	O
HIV-HD	O
phenotype	O
.	O

MDS1/EVI1	B-DNA
enhances	O
TGF-beta1	B-protein
signaling	O
and	O
strengthens	O
its	O
growth-inhibitory	O
effect	O
but	O
the	O
leukemia-associated	B-protein
fusion	I-protein
protein	I-protein
AML1/MDS1/EVI1	B-protein
,	O
product	O
of	O
the	O
t	O
(	O
3	O
;	O
21	O
)	O
,	O
abrogates	O
growth-inhibition	O
in	O
response	O
to	O
TGF-beta1	B-protein
.	O

MDS1/EVI1	B-DNA
,	O
located	O
on	O
chromosome	B-DNA
3	I-DNA
band	I-DNA
q26	I-DNA
,	O
encodes	O
a	O
zinc-finger	B-protein
DNA-binding	I-protein
transcription	I-protein
activator	I-protein
not	O
detected	O
in	O
normal	B-cell_type
hematopoietic	I-cell_type
cells	I-cell_type
but	O
expressed	O
in	O
several	O
normal	O
tissues	O
.	O

MDS1/EVI1	B-DNA
is	O
inappropriately	O
activated	O
in	O
myeloid	B-cell_type
leukemias	I-cell_type
following	O
chromosomal	O
rearrangements	O
involving	O
band	B-protein
3q26	I-protein
.	O

The	O
rearrangements	O
lead	O
either	O
to	O
gene	O
truncation	O
,	O
and	O
to	O
expression	O
of	O
the	O
transcription	B-protein
repressor	I-protein
EVI1	I-protein
,	O
as	O
seen	O
in	O
the	O
t	B-DNA
(	I-DNA
3	I-DNA
;	I-DNA
3	I-DNA
)	I-DNA
(	I-DNA
q21	I-DNA
;	I-DNA
q26	I-DNA
)	I-DNA
and	O
inv	B-DNA
(	I-DNA
3	I-DNA
)	I-DNA
(	I-DNA
q21q26	I-DNA
)	I-DNA
,	O
or	O
to	O
gene	O
fusion	O
,	O
as	O
seen	O
in	O
the	O
t	B-DNA
(	I-DNA
3	I-DNA
;	I-DNA
21	I-DNA
)	I-DNA
(	I-DNA
q26	I-DNA
;	I-DNA
q22	I-DNA
)	I-DNA
which	O
results	O
in	O
the	O
fusion	O
protein	O
AML1/MDS1/EVI1	B-protein
.	O

This	O
fusion	O
protein	O
contains	O
the	O
DNA-binding	B-protein
domain	I-protein
of	O
the	O
transcription	B-protein
factor	I-protein
AML1	B-protein
fused	O
in-frame	O
to	O
the	O
entire	O
MDS1/EVI1	B-DNA
with	O
the	O
exclusion	O
of	O
its	O
first	O
12	O
amino	O
acids	O
.	O

In	O
this	O
report	O
,	O
we	O
have	O
analyzed	O
the	O
response	O
of	O
the	O
hematopoietic	B-cell_line
precursor	I-cell_line
cell	I-cell_line
line	I-cell_line
32Dcl3	I-cell_line
,	O
expressing	O
either	O
the	O
normal	B-protein
protein	I-protein
MDS1/EVI1	I-protein
or	O
the	O
fusion	B-protein
protein	I-protein
AML1/MDS1/EVI1	I-protein
,	O
to	O
factors	O
that	O
control	O
cell	O
differentiation	O
or	O
cell	O
replication	O
.	O

The	O
32Dcl3	B-cell_line
cells	I-cell_line
are	O
IL-3	B-protein
-dependent	O
for	O
growth	O
and	O
they	O
differentiate	O
into	O
granulocytes	O
when	O
exposed	O
to	O
G-CSF	B-protein
.	O

They	O
are	O
growth-inhibited	O
by	O
TGF-beta1	B-protein
.	O

We	O
show	O
that	O
whereas	O
the	O
expression	O
of	O
MDS1/EVI1	B-DNA
has	O
no	O
effect	O
on	O
granulocytic	O
differentiation	O
induced	O
by	O
G-CSF	B-protein
,	O
expression	O
of	O
AML1/MDS1/EVI1	B-protein
blocks	O
differentiation	O
resulting	O
in	O
cell	O
death	O
.	O

This	O
effect	O
is	O
similar	O
to	O
that	O
previously	O
described	O
by	O
others	O
for	O
32Dcl3	B-cell_line
cells	I-cell_line
that	O
express	O
transgenic	B-protein
Evil	I-protein
.	O

Furthermore	O
,	O
we	O
show	O
that	O
whereas	O
the	O
expression	O
of	O
the	O
fusion	O
protein	O
AML1/MDS1/EVI1	B-protein
completely	O
abrogates	O
the	O
growth-inhibitory	O
effect	O
of	O
TGF-beta1	B-protein
and	O
allows	O
32Dcl3	B-cell_line
cells	I-cell_line
to	O
proliferate	O
,	O
expression	O
of	O
the	O
normal	O
protein	O
MDS1/EVI1	B-DNA
has	O
the	O
opposite	O
effect	O
,	O
and	O
it	O
strengthens	O
the	O
response	O
of	O
cells	O
to	O
the	O
growth-inhibitory	O
effect	O
of	O
TGF-beta1	B-protein
.	O

By	O
using	O
the	O
yeast	O
two-hybrid	O
system	O
,	O
we	O
also	O
show	O
that	O
EVI1	B-protein
(	O
contained	O
in	O
its	O
entirety	O
in	O
MDS1/EVI1	B-DNA
and	O
AML1/MDS1/EVI1	B-protein
)	O
physically	O
interacts	O
with	O
SMAD3	B-protein
,	O
which	O
is	O
an	O
intracellular	O
mediator	O
of	O
TGF-beta1	B-protein
signaling	O
.	O

Finally	O
,	O
we	O
have	O
correlated	O
the	O
response	O
of	O
the	O
cells	O
to	O
G-CSF	B-protein
or	O
TGF-beta1	B-protein
with	O
the	O
ability	O
of	O
the	O
normal	O
and	O
fusion	B-protein
proteins	I-protein
to	O
activate	O
or	O
repress	O
promoters	O
which	O
they	O
can	O
directly	O
regulate	O
by	O
binding	O
to	O
the	O
promoter	B-DNA
site	I-DNA
.	O

We	O
propose	O
that	O
mutations	O
of	O
MDS1/EVI1	B-DNA
either	O
by	O
gene	O
truncation	O
resulting	O
in	O
the	O
transcription	B-protein
repressor	I-protein
EVI1	I-protein
or	O
by	O
gene	O
fusion	O
to	O
AML1	B-protein
lead	O
to	O
an	O
altered	O
cellular	O
response	O
to	O
growth	O
and	O
differentiation	B-protein
factors	I-protein
that	O
could	O
result	O
in	O
leukemic	O
transformation	O
.	O

The	O
different	O
response	O
of	O
myeloid	O
cells	O
ectopically	O
expressing	O
the	O
normal	O
or	O
the	O
fusion	B-protein
protein	I-protein
to	O
G-CSF	B-protein
and	O
TGF-beta1	B-protein
could	O
depend	O
on	O
the	O
different	O
transactivation	O
properties	O
of	O
these	O
proteins	O
resulting	O
in	O
divergent	O
expression	O
of	O
downstream	B-DNA
genes	I-DNA
regulated	O
by	O
the	O
two	O
proteins	O
.	O

Abnormalities	O
of	O
cyclic	O
adenosine	O
monophosphate	O
signaling	O
in	O
platelets	B-cell_type
from	O
untreated	O
patients	O
with	O
bipolar	O
disorder	O
.	O

BACKGROUND	O
:	O
Abnormalities	O
in	O
the	O
cyclic	O
adenosine	O
monophosphate	O
(	O
cAMP	O
)	O
-dependent	O
phosphorylation	O
system	O
have	O
been	O
recently	O
reported	O
in	O
patients	O
with	O
bipolar	O
disorder	O
.	O

We	O
evaluated	O
the	O
immunoreactivity	O
of	O
the	O
regulatory	B-protein
and	I-protein
catalytic	I-protein
subunits	I-protein
of	O
cAMP-dependent	B-protein
protein	I-protein
kinase	I-protein
(	O
protein	B-protein
kinase	I-protein
A	I-protein
)	O
and	O
1	O
of	O
its	O
substrates	O
,	O
Rap1	B-protein
,	O
in	O
platelets	B-cell_type
from	O
untreated	O
euthymic	O
,	O
manic	O
,	O
and	O
depressed	O
patients	O
with	O
bipolar	O
disorder	O
and	O
healthy	O
subjects	O
.	O

METHODS	O
:	O
Platelets	B-cell_type
were	O
collected	O
from	O
112	O
drug-free	O
patients	O
with	O
bipolar	O
disorder	O
(	O
52	O
euthymic	O
,	O
29	O
depressed	O
,	O
and	O
31	O
manic	O
)	O
and	O
62	O
healthy	O
subjects	O
.	O

The	O
levels	O
of	O
cAMP-dependent	B-protein
protein	I-protein
kinase	I-protein
and	O
Rap1	B-protein
were	O
assessed	O
by	O
Western	O
blot	O
analysis	O
,	O
immunostaining	O
,	O
and	O
computer-assisted	O
imaging	O
.	O

RESULTS	O
:	O
The	O
immunolabeling	O
of	O
the	O
catalytic	B-protein
subunit	I-protein
of	O
cAMP-dependent	B-protein
protein	I-protein
kinase	I-protein
was	O
significantly	O
different	O
among	O
groups	O
(	O
P	O
<	O
.001	O
)	O
,	O
with	O
higher	O
values	O
in	O
untreated	O
depressed	O
and	O
manic	O
patients	O
with	O
bipolar	O
disorder	O
compared	O
with	O
untreated	O
euthymic	O
patients	O
with	O
bipolar	O
disorder	O
and	O
healthy	O
subjects	O
.	O

No	O
significant	O
differences	O
were	O
found	O
in	O
the	O
immunolabeling	O
of	O
the	O
regulatory	B-protein
subunits	I-protein
(	O
type	O
I	O
and	O
type	O
II	O
)	O
of	O
cAMP-dependent	B-protein
protein	I-protein
kinase	I-protein
.	O

The	O
immunolabeling	O
of	O
Rap1	B-protein
was	O
significantly	O
higher	O
(	O
P	O
<	O
.001	O
)	O
in	O
untreated	O
euthymic	O
,	O
depressed	O
,	O
and	O
manic	O
patients	O
than	O
in	O
healthy	O
persons	O
.	O

CONCLUSIONS	O
:	O
Levels	O
of	O
Rap1	B-protein
and	O
the	O
catalytic	B-protein
subunit	I-protein
of	O
cAMP-dependent	B-protein
protein	I-protein
kinase	I-protein
are	O
altered	O
in	O
the	O
platelets	B-cell_type
of	O
bipolar	O
patients	O
.	O

These	O
findings	O
may	O
provide	O
clues	O
toward	O
understanding	O
the	O
involvement	O
of	O
cAMP	O
signaling	O
in	O
the	O
pathogenesis	O
of	O
bipolar	O
disorder	O
.	O

Molecular	O
regulation	O
of	O
cytokine	B-DNA
gene	I-DNA
expression	O
during	O
the	O
immune	O
response	O
.	O

Cytokine	B-protein
expression	O
by	O
immune	O
system	O
cells	O
plays	O
an	O
important	O
role	O
in	O
the	O
regulation	O
of	O
the	O
immune	O
response	O
.	O

On	O
first	O
encounter	O
with	O
antigen	O
,	O
naive	B-cell_type
CD4+	I-cell_type
T	I-cell_type
helper	I-cell_type
(	I-cell_type
Th	I-cell_type
)	I-cell_type
cells	I-cell_type
differentiate	O
into	O
cytokine-producing	B-cell_line
effector	I-cell_line
cells	I-cell_line
.	O

Two	O
types	O
of	O
effector	O
cells	O
characterized	O
by	O
their	O
distinct	O
expression	O
of	O
cytokine	B-protein
profiles	O
have	O
been	O
described	O
.	O

Th1	O
cells	O
produce	O
IL-2	B-protein
and	O
IFN-gamma	B-protein
,	O
whereas	O
Th2	B-cell_line
cells	I-cell_line
produce	O
IL-4	B-protein
,	O
IL-5	B-protein
,	O
IL-6	B-protein
,	O
IL-10	B-protein
,	O
and	O
IL-13	B-protein
.	O

In	O
many	O
pathological	O
situations	O
,	O
the	O
balance	O
between	O
Th1	O
and	O
Th2	O
immune	O
responses	O
determines	O
the	O
outcome	O
of	O
diverse	O
immunologically	O
mediated	O
clinical	O
syndromes	O
including	O
infectious	O
,	O
autoimmune	O
,	O
and	O
allergic	O
diseases	O
.	O

However	O
,	O
the	O
molecular	O
basis	O
for	O
the	O
tissue-specific	O
expression	O
of	O
Th1/Th2-like	B-protein
cytokines	I-protein
has	O
remained	O
elusive	O
.	O

In	O
this	O
review	O
we	O
evaluate	O
the	O
possible	O
in	O
vivo	O
role	O
of	O
different	O
transcription	O
factors	O
and	O
transcriptional	O
mechanisms	O
in	O
T	O
cell	O
differentiation	O
and	O
the	O
immune	O
response	O
.	O

Tcf-1	B-protein
-mediated	O
transcription	O
in	O
T	B-cell_type
lymphocytes	I-cell_type
:	O
differential	O
role	O
for	O
glycogen	B-protein
synthase	I-protein
kinase-3	I-protein
in	O
fibroblasts	B-cell_type
and	O
T	B-cell_type
cells	I-cell_type
.	O

Beta-catenin	O
is	O
the	O
vertebrate	O
homolog	O
of	O
the	O
Drosophila	B-DNA
segment	I-DNA
polarity	I-DNA
gene	I-DNA
Armadillo	B-DNA
and	O
plays	O
roles	O
in	O
both	O
cell-cell	O
adhesion	O
and	O
transduction	O
of	O
the	O
Wnt	O
signaling	O
cascade	O
.	O

Recently	O
,	O
members	O
of	O
the	O
Lef/Tcf	B-protein
transcription	I-protein
factor	I-protein
family	I-protein
have	O
been	O
identified	O
as	O
protein	O
partners	O
of	O
beta-catenin	B-protein
,	O
explaining	O
how	O
beta-catenin	B-protein
alters	O
gene	O
expression	O
.	O

Here	O
we	O
report	O
that	O
in	O
T	B-cell_type
cells	I-cell_type
,	O
Tcf-1	B-protein
also	O
becomes	O
transcriptionally	O
active	O
through	O
interaction	O
with	O
beta-catenin	B-protein
,	O
suggesting	O
that	O
the	O
Wnt	O
signal	O
transduction	O
pathway	O
is	O
operational	O
in	O
T	B-cell_type
lymphocytes	I-cell_type
as	O
well	O
.	O

However	O
,	O
although	O
Wnt	O
signals	O
are	O
known	O
to	O
inhibit	O
the	O
activity	O
of	O
the	O
negative	B-protein
regulatory	I-protein
protein	I-protein
kinase	I-protein
glycogen	B-protein
synthase	I-protein
kinase-3beta	I-protein
(	O
GSK-3beta	B-protein
)	O
,	O
resulting	O
in	O
increased	O
levels	O
of	O
beta-catenin	B-protein
,	O
we	O
find	O
no	O
evidence	O
for	O
involvement	O
of	O
GSK-3beta	B-protein
in	O
Tcf-mediated	O
transcription	O
in	O
T	B-cell_type
cells	I-cell_type
.	O

That	O
is	O
,	O
a	O
dominant	B-protein
negative	I-protein
GSK-3beta	I-protein
does	O
not	O
specifically	O
activate	O
Tcf	O
transcription	O
and	O
stimuli	O
(	O
lithium	O
or	O
phytohemagglutinin	B-protein
)	O
that	O
inhibit	O
GSK-3beta	B-protein
activity	O
also	O
do	O
not	O
activate	O
Tcf	B-DNA
reporter	I-DNA
genes	I-DNA
.	O

Thus	O
,	O
inhibition	O
of	O
GSK-3beta	B-protein
is	O
insufficient	O
to	O
activate	O
Tcf-dependent	O
transcription	O
in	O
T	B-cell_type
lymphocytes	I-cell_type
.	O

In	O
contrast	O
,	O
in	O
C57MG	B-cell_line
fibroblast	I-cell_line
cells	I-cell_line
,	O
lithium	O
inactivates	O
GSK-3beta	B-protein
and	O
induces	O
Tcf-controlled	O
transcription	O
.	O

This	O
is	O
the	O
first	O
demonstration	O
that	O
lithium	O
can	O
alter	O
gene	O
expression	O
of	O
Tcf-responsive	B-DNA
genes	I-DNA
,	O
and	O
points	O
to	O
a	O
difference	O
in	O
regulation	O
of	O
Wnt	O
signaling	O
between	O
fibroblasts	B-cell_type
and	O
lymphocytes	B-cell_type
.	O

SHP2-interacting	B-protein
transmembrane	I-protein
adaptor	I-protein
protein	I-protein
(	O
SIT	B-protein
)	O
,	O
a	O
novel	O
disulfide-linked	B-protein
dimer	I-protein
regulating	O
human	O
T	O
cell	O
activation	O
.	O

T	B-cell_type
lymphocytes	I-cell_type
express	O
several	O
low	B-protein
molecular	I-protein
weight	I-protein
transmembrane	I-protein
adaptor	I-protein
proteins	I-protein
that	O
recruit	O
src	B-protein
homology	I-protein
(	I-protein
SH	I-protein
)	I-protein
2	I-protein
domain-containing	I-protein
intracellular	I-protein
molecules	I-protein
to	O
the	O
cell	O
membrane	O
via	O
tyrosine-based	O
signaling	O
motifs	O
.	O

We	O
describe	O
here	O
a	O
novel	O
molecule	O
of	O
this	O
group	O
termed	O
SIT	B-protein
(	O
SHP2	B-protein
interacting	I-protein
transmembrane	I-protein
adaptor	I-protein
protein	I-protein
)	O
.	O

SIT	B-protein
is	O
a	O
disulfide-linked	B-protein
homodimeric	I-protein
glycoprotein	I-protein
that	O
is	O
expressed	O
in	O
lymphocytes	B-cell_type
.	O

After	O
tyrosine	O
phosphorylation	O
by	O
src	B-protein
and	O
possibly	O
syk	B-protein
protein	B-protein
tyrosine	I-protein
kinases	I-protein
SIT	B-protein
recruits	O
the	O
SH2	B-protein
domain-containing	I-protein
tyrosine	I-protein
phosphatase	I-protein
SHP2	B-protein
via	O
an	O
immunoreceptor	O
tyrosine-based	O
inhibition	O
motif	O
.	O

Overexpression	O
of	O
SIT	B-protein
in	O
Jurkat	B-cell_line
cells	I-cell_line
downmodulates	O
T	O
cell	O
receptor-	O
and	O
phytohemagglutinin-mediated	O
activation	O
of	O
the	O
nuclear	B-protein
factor	I-protein
of	I-protein
activated	I-protein
T	I-protein
cells	I-protein
(	O
NF-AT	B-protein
)	O
by	O
interfering	O
with	O
signaling	O
processes	O
that	O
are	O
probably	O
located	O
upstream	O
of	O
activation	O
of	O
phospholipase	B-protein
C	I-protein
.	O

However	O
,	O
binding	O
of	O
SHP2	B-protein
to	O
SIT	B-protein
is	O
not	O
required	O
for	O
inhibition	O
of	O
NF-AT	B-protein
induction	O
,	O
suggesting	O
that	O
SIT	B-protein
not	O
only	O
regulates	O
NF-AT	B-protein
activity	O
but	O
also	O
controls	O
NF-AT	B-protein
unrelated	O
pathways	O
of	O
T	O
cell	O
activation	O
involving	O
SHP2	B-protein
.	O

Extracellular-regulated	B-protein
kinase	I-protein
1/2	I-protein
,	O
Jun	B-protein
N-terminal	I-protein
kinase	I-protein
,	O
and	O
c-Jun	B-protein
are	O
involved	O
in	O
NF-kappa	B-protein
B	I-protein
-dependent	O
IL-6	B-protein
expression	O
in	O
human	O
monocytes	O
.	O

In	O
the	O
present	O
study	O
we	O
investigated	O
the	O
possible	O
involvement	O
of	O
the	O
mitogen-activated	B-protein
protein	I-protein
kinase	I-protein
family	I-protein
members	O
extracellular-regulated	B-protein
kinase	I-protein
1/2	I-protein
(	O
ERK1/2	B-protein
)	O
and	O
c-	O
Jun	B-protein
N-terminal	I-protein
kinase	I-protein
(	O
JNK	B-protein
)	O
in	O
mediating	O
IL-6	B-protein
gene	O
expression	O
in	O
human	B-cell_type
monocytes	I-cell_type
,	O
in	O
particular	O
their	O
role	O
in	O
enhancing	O
NF-kappa	B-protein
B	I-protein
activity	O
.	O

Freshly	O
isolated	O
monocytes	O
treated	O
with	O
the	O
protein	O
phosphatase	O
inhibitor	O
okadaic	O
acid	O
secreted	O
high	O
levels	O
of	O
IL-6	B-protein
protein	I-protein
,	O
which	O
coincided	O
with	O
enhanced	O
binding	O
activity	O
of	O
NF-kappa	B-protein
B	I-protein
as	O
well	O
as	O
with	O
phosphorylation	O
and	O
activation	O
of	O
the	O
ERK1/2	B-protein
and	I-protein
JNK	I-protein
proteins	I-protein
.	O

The	O
ERK	O
pathway-specific	O
inhibitor	O
PD98059	O
inhibited	O
IL-6	B-protein
secretion	O
from	O
monocytes	B-cell_type
.	O

Transient	O
overexpression	O
of	O
inactive	O
mutants	O
of	O
either	O
Raf-1	B-protein
or	O
JNK1	B-protein
showed	O
that	O
both	O
pathways	O
were	O
involved	O
in	O
kappa	O
B-dependent	O
IL-6	B-protein
promoter	O
activity	O
.	O

By	O
using	O
PD98059	O
,	O
we	O
demonstrated	O
that	O
the	O
Raf1/MEK1/	O
ERK1/2	B-protein
pathway	O
did	O
not	O
affect	O
the	O
DNA	O
binding	O
of	O
NF-kappa	B-protein
B	I-protein
but	O
,	O
rather	O
,	O
acted	O
at	O
the	O
level	O
of	O
transcriptional	O
activity	O
of	O
NF-kappa	B-protein
B	I-protein
.	O

Interestingly	O
,	O
it	O
was	O
shown	O
that	O
NF-kappa	B-protein
B	I-protein
-mediated	O
gene	O
transcription	O
,	O
both	O
in	O
the	O
context	O
of	O
the	O
IL-6	B-DNA
promoter	I-DNA
as	O
well	O
as	O
on	O
its	O
own	O
,	O
was	O
dependent	O
on	O
both	O
serine	O
kinase	O
activity	O
and	O
interaction	O
with	O
c-Jun	B-protein
protein	I-protein
.	O

We	O
conclude	O
that	O
okadaic	O
acid-induced	O
IL-6	B-protein
gene	O
expression	O
is	O
at	O
least	O
partly	O
mediated	O
through	O
the	O
ERK1/2	B-protein
and	O
JNK	B-protein
pathway-dependent	O
activation	O
of	O
NF-kappa	B-protein
B	I-protein
transcriptional	O
capacity	O
.	O

Our	O
results	O
suggest	O
that	O
the	O
JNK	B-protein
pathway	O
may	O
regulate	O
NF-kappa	B-protein
B	I-protein
-mediated	O
gene	O
transcription	O
through	O
its	O
phosphorylation	O
and	O
activation	O
of	O
c-Jun	B-protein
.	O

The	O
Epstein-Barr	B-protein
virus	I-protein
nuclear	I-protein
antigen	I-protein
2	I-protein
(	O
EBNA2	B-protein
)	O
,	O
a	O
protein	O
required	O
for	O
B	B-cell_type
lymphocyte	I-cell_type
immortalization	O
,	O
induces	O
the	O
synthesis	O
of	O
type	B-protein
I	I-protein
interferon	I-protein
in	O
Burkitt	B-cell_line
's	I-cell_line
lymphoma	I-cell_line
cell	I-cell_line
lines	I-cell_line
.	O

Epstein-Barr	B-protein
virus	I-protein
nuclear	I-protein
antigen	I-protein
2	I-protein
(	O
EBNA2	B-protein
)	O
,	O
a	O
protein	O
involved	O
in	O
cell	O
transformation	O
,	O
interferes	O
with	O
the	O
cellular	O
response	O
to	O
type	B-protein
I	I-protein
interferons	I-protein
(	O
IFN-alpha/beta	B-protein
)	O
.	O

We	O
investigated	O
the	O
function	O
of	O
conditionally	O
expressed	O
EBNA2	B-protein
in	O
the	O
context	O
of	O
the	O
IFN	B-protein
response	O
in	O
Burkitt	B-cell_line
's	I-cell_line
lymphoma	I-cell_line
cell	I-cell_line
lines	I-cell_line
.	O

Expression	O
of	O
EBNA2	B-protein
led	O
to	O
the	O
transcriptional	O
activation	O
of	O
both	O
endogenous	O
or	O
transfected	O
IFN-stimulated	B-DNA
genes	I-DNA
(	O
ISGs	B-DNA
)	O
,	O
genes	O
which	O
contain	O
within	O
their	O
promoters	B-DNA
either	O
the	O
interferon-stimulated	B-DNA
response	I-DNA
element	I-DNA
(	O
ISRE	B-DNA
)	O
or	O
the	O
gamma	B-DNA
interferon	I-DNA
activation	I-DNA
site	I-DNA
(	O
GAS	B-DNA
)	O
.	O

In	O
search	O
of	O
a	O
molecular	O
mechanism	O
for	O
the	O
transcriptional	O
induction	O
of	O
ISGs	B-DNA
,	O
we	O
observed	O
an	O
EBNA2	B-protein
-dependent	O
synthesis	O
of	O
IFN-beta	O
mRNA	O
at	O
low	O
levels	O
and	O
the	O
secretion	O
of	O
low	O
amounts	O
of	O
IFN	O
.	O

A	O
transfected	O
IFN-beta	O
promoter	O
responded	O
to	O
EBNA2	B-protein
activation	O
,	O
and	O
a	O
sequence	O
closely	O
resembling	O
a	O
RBP-Jkappa	B-DNA
binding	I-DNA
site	I-DNA
was	O
pinpointed	O
as	O
a	O
potential	O
target	O
of	O
EBNA2	B-protein
activity	O
.	O

EBNA2	B-protein
-dependent	O
transcriptional	O
induction	O
of	O
the	O
IFN-beta	B-DNA
promoter	I-DNA
occurred	O
in	O
EBV-negative	B-cell_line
Burkitt	I-cell_line
's	I-cell_line
lymphoma	I-cell_line
cells	I-cell_line
,	O
indicating	O
that	O
other	O
EBV	B-DNA
genes	I-DNA
were	O
not	O
required	O
for	O
the	O
induction	O
of	O
IFN-beta	B-protein
synthesis	O
.	O

PGG-glucan	O
,	O
a	O
soluble	O
beta-	O
(	O
1	O
,	O
3	O
)	O
-glucan	O
,	O
enhances	O
the	O
oxidative	O
burst	O
response	O
,	O
microbicidal	O
activity	O
,	O
and	O
activates	O
an	O
NF-kappa	B-protein
B-like	I-protein
factor	I-protein
in	O
human	B-cell_type
PMN	I-cell_type
:	O
evidence	O
for	O
a	O
glycosphingolipid	B-protein
beta-	I-protein
(	I-protein
1	I-protein
,	I-protein
3	I-protein
)	I-protein
-glucan	I-protein
receptor	I-protein
.	O

PGG-Glucan	O
,	O
a	O
soluble	O
beta-	O
(	O
1	O
,	O
6	O
)	O
-branched	O
beta-	O
(	O
1	O
,	O
3	O
)	O
-linked	O
glucose	O
homopolymer	O
derived	O
from	O
the	O
cell	O
wall	O
of	O
the	O
yeast	O
Saccharomyces	O
cerevisiae	O
,	O
is	O
an	O
immunomodulator	O
which	O
enhances	O
leukocyte	O
anti-infective	O
activity	O
and	O
enhances	O
myeloid	O
and	O
megakaryocyte	O
progenitor	O
proliferation	O
.	O

Incubation	O
of	O
human	O
whole	O
blood	O
with	O
PGG-Glucan	O
significantly	O
enhanced	O
the	O
oxidative	O
burst	O
response	O
of	O
subsequently	B-cell_type
isolated	I-cell_type
blood	I-cell_type
leukocytes	I-cell_type
to	O
both	O
soluble	O
and	O
particulate	O
activators	O
in	O
a	O
dose-dependent	O
manner	O
,	O
and	O
increased	O
leukocyte	O
microbicidal	O
activity	O
.	O

No	O
evidence	O
for	O
inflammatory	O
cytokine	B-protein
production	O
was	O
obtained	O
under	O
these	O
conditions	O
.	O

Electrophoretic	O
mobility	O
shift	O
assays	O
demonstrated	O
that	O
PGG-Glucan	O
induced	O
the	O
activation	O
of	O
an	O
NF-kappaB-like	B-protein
nuclear	I-protein
transcription	I-protein
factor	I-protein
in	O
purified	B-cell_type
human	I-cell_type
neutrophils	I-cell_type
.	O

The	O
binding	O
of	O
3H-PGG-Glucan	O
to	O
human	O
leukocyte	O
membranes	O
was	O
specific	O
,	O
concentration-dependent	O
,	O
saturable	O
,	O
and	O
high	O
affinity	O
(	O
Kd	O
approximately	O
6	O
nM	O
)	O
.	O

A	O
monoclonal	B-protein
antibody	I-protein
specific	O
to	O
the	O
glycosphingolipid	O
lactosylceramide	O
was	O
able	O
to	O
inhibit	O
activation	O
of	O
the	O
NF-kappaB-like	B-protein
factor	I-protein
by	O
PGG-Glucan	O
,	O
and	O
ligand	O
binding	O
data	O
,	O
including	O
polysaccharide	O
specificity	O
,	O
suggested	O
that	O
the	O
PGG-Glucan	O
binding	O
moiety	O
was	O
lactosylceramide	O
.	O

These	O
results	O
indicate	O
that	O
PGG-Glucan	O
enhances	O
neutrophil	O
anti-microbial	O
functions	O
and	O
that	O
interaction	O
between	O
this	O
beta-glucan	O
and	O
human	B-cell_type
neutrophils	I-cell_type
is	O
mediated	O
by	O
the	O
glycosphingolipid	O
lactosylceramide	O
present	O
at	O
the	O
cell	O
surface	O
.	O

Glucocorticoids	O
promote	O
nonphlogistic	O
phagocytosis	O
of	O
apoptotic	B-cell_type
leukocytes	I-cell_type
.	O

Phagocyte	O
recognition	O
,	O
uptake	O
,	O
and	O
nonphlogistic	O
degradation	O
of	O
neutrophils	B-cell_type
and	O
other	O
leukocytes	B-cell_type
undergoing	O
apoptosis	O
promote	O
the	O
resolution	O
of	O
inflammation	O
.	O

This	O
study	O
assessed	O
the	O
effects	O
of	O
anti-inflammatory	O
glucocorticoids	O
on	O
this	O
leukocyte	O
clearance	O
mechanism	O
.	O

Pretreatment	O
of	O
``	O
semimature	O
''	O
5-day	O
human	B-cell_type
monocyte-derived	I-cell_type
macrophages	I-cell_type
(	O
M	O
phi	O
)	O
for	O
24	O
h	O
with	O
methylprednisolone	O
,	O
dexamethasone	O
,	O
and	O
hydrocortisone	O
,	O
but	O
not	O
the	O
nonglucocorticoid	O
steroids	O
aldosterone	O
,	O
estradiol	O
,	O
and	O
progesterone	O
,	O
potentiated	O
phagocytosis	O
of	O
apoptotic	B-cell_type
neutrophils	I-cell_type
.	O

These	O
effects	O
were	O
specific	O
in	O
that	O
the	O
potentiated	O
phagocytosis	O
of	O
apoptotic	B-cell_type
neutrophils	I-cell_type
was	O
completely	O
blocked	O
by	O
the	O
glucocorticoid	B-protein
receptor	I-protein
antagonist	O
RU38486	O
,	O
and	O
glucocorticoids	O
did	O
not	O
promote	O
5-day	O
M	O
phi	O
ingestion	O
of	O
opsonized	B-cell_type
erythrocytes	I-cell_type
.	O

Similar	O
glucocorticoid-mediated	O
potentiation	O
was	O
observed	O
with	O
5-day	O
M	O
phi	O
uptake	O
of	O
alternative	O
apoptotic	O
``	O
targets	O
''	O
(	O
eosinophils	B-cell_type
and	O
Jurkat	B-cell_line
T	I-cell_line
cells	I-cell_line
)	O
and	O
in	O
uptake	O
of	O
apoptotic	B-cell_type
neutrophils	I-cell_type
by	O
alternative	O
phagocytes	B-cell_type
(	O
human	B-cell_type
glomerular	I-cell_type
mesangial	I-cell_type
cells	I-cell_type
and	O
murine	B-cell_line
M	I-cell_line
phi	I-cell_line
elicited	O
into	O
the	O
peritoneum	O
or	O
derived	O
from	O
bone	O
marrow	O
)	O
.	O

Importantly	O
,	O
methylprednisolone-mediated	O
enhancement	O
of	O
the	O
uptake	O
of	O
apoptotic	B-cell_type
neutrophils	I-cell_type
did	O
not	O
trigger	O
the	O
release	O
of	O
the	O
chemokines	B-protein
IL-8	B-protein
and	O
monocyte	B-protein
chemoattractant	I-protein
protein-1	I-protein
.	O

Furthermore	O
,	O
longer-term	O
potentiation	O
by	O
methylprednisolone	O
was	O
observed	O
in	O
maturing	B-cell_line
human	I-cell_line
monocyte-derived	I-cell_line
M	I-cell_line
phi	I-cell_line
,	O
with	O
greater	O
increases	O
in	O
5-day	O
M	B-cell_line
phi	I-cell_line
uptake	O
of	O
apoptotic	B-cell_type
cells	I-cell_type
being	O
observed	O
the	O
earlier	O
glucocorticoids	O
were	O
added	O
during	O
monocyte	O
maturation	O
into	O
M	B-cell_line
phi	I-cell_line
.	O

We	O
conclude	O
that	O
potentiation	O
of	O
nonphlogistic	O
clearance	O
of	O
apoptotic	B-cell_type
leukocytes	I-cell_type
by	O
phagocytes	B-cell_type
is	O
a	O
hitherto	O
unrecognized	O
property	O
of	O
glucocorticoids	O
that	O
has	O
potential	O
implications	O
for	O
therapies	O
aimed	O
at	O
promoting	O
the	O
resolution	O
of	O
inflammatory	O
diseases	O
.	O

1	O
,	O
25-Dihydroxyvitamin	O
D3	O
induces	O
differentiation	O
of	O
a	O
retinoic	B-cell_line
acid-resistant	I-cell_line
acute	I-cell_line
promyelocytic	I-cell_line
leukemia	I-cell_line
cell	I-cell_line
line	I-cell_line
(	O
UF-1	B-cell_line
)	O
associated	O
with	O
expression	O
of	O
p21	B-protein
(	I-protein
WAF1/CIP1	I-protein
)	I-protein
and	O
p27	B-protein
(	I-protein
KIP1	I-protein
)	I-protein
.	O

Retinoic	O
acid	O
(	O
RA	O
)	O
resistance	O
is	O
a	O
serious	O
problem	O
for	O
patients	O
with	O
acute	O
promyelocytic	O
leukemia	O
(	O
APL	O
)	O
who	O
are	O
receiving	O
all-trans	O
RA	O
.	O

However	O
,	O
the	O
mechanisms	O
and	O
strategies	O
to	O
overcome	O
RA	O
resistance	O
by	O
APL	B-cell_type
cells	I-cell_type
are	O
still	O
unclear	O
.	O

The	O
biologic	O
effects	O
of	O
RA	O
are	O
mediated	O
by	O
two	O
distinct	O
families	O
of	O
transcriptional	B-protein
factors	I-protein
:	O
RA	B-protein
receptors	I-protein
(	O
RARs	B-protein
)	O
and	O
retinoid	B-protein
X	I-protein
receptors	I-protein
(	O
RXRs	B-protein
)	O
.	O

RXRs	B-protein
heterodimerize	O
with	O
1	B-protein
,	I-protein
25-dihydroxyvitamin	I-protein
D3	I-protein
[	I-protein
1	I-protein
,	I-protein
25	I-protein
(	I-protein
OH	I-protein
)	I-protein
2D3	I-protein
]	I-protein
receptor	I-protein
(	O
VDR	B-protein
)	O
,	O
enabling	O
their	O
efficient	O
transcriptional	O
activation	O
.	O

The	O
cyclin-dependent	B-protein
kinase	I-protein
(	I-protein
cdk	I-protein
)	I-protein
inhibitor	I-protein
p21	B-protein
(	I-protein
WAF1/CIP1	I-protein
)	I-protein
has	O
a	O
vitamin	B-DNA
D3-responsive	I-DNA
element	I-DNA
(	O
VDRE	B-DNA
)	O
in	O
its	O
promoter	B-DNA
,	O
and	O
1	O
,	O
25	O
(	O
OH	O
)	O
2D3	O
enhances	O
the	O
expression	O
of	O
p21	B-protein
(	I-protein
WAF1/CIP1	I-protein
)	I-protein
and	O
induces	O
differentiation	O
of	O
selected	O
myeloid	B-cell_line
leukemic	I-cell_line
cell	I-cell_line
lines	I-cell_line
.	O

We	O
have	O
recently	O
established	O
a	O
novel	O
APL	B-cell_line
cell	I-cell_line
line	I-cell_line
(	O
UF-1	B-cell_line
)	O
with	O
features	O
of	O
RA	O
resistance	O
.	O

1	O
,	O
25	O
(	O
OH	O
)	O
2D3	O
can	O
induce	O
growth	O
inhibition	O
and	O
G1	O
arrest	O
of	O
UF-1	B-cell_line
cells	I-cell_line
,	O
resulting	O
in	O
differentiation	O
of	O
these	O
cells	O
toward	O
granulocytes	B-cell_type
.	O

This	O
1	O
,	O
25	O
(	O
OH	O
)	O
2D3-induced	O
G1	O
arrest	O
is	O
enhanced	O
by	O
all-trans	O
RA	O
.	O

Also	O
,	O
1	O
,	O
25	O
(	O
OH	O
)	O
2D3	O
(	O
10	O
(	O
-10	O
)	O
to	O
10	O
(	O
-7	O
)	O
mol/L	O
)	O
in	O
combination	O
with	O
RA	O
markedly	O
inhibits	O
cellular	O
proliferation	O
in	O
a	O
dose-	O
and	O
time-dependent	O
manner	O
.	O

Associated	O
with	O
these	O
findings	O
,	O
the	O
levels	O
of	O
p21	B-protein
(	I-protein
WAF1/CIP1	I-protein
)	I-protein
and	O
p27	B-RNA
(	I-RNA
KIP1	I-RNA
)	I-RNA
mRNA	I-RNA
and	O
protein	O
increased	O
in	O
these	O
cells	O
.	O

Northern	O
blot	O
analysis	O
showed	O
that	O
p21	B-RNA
(	I-RNA
WAF1/CIP1	I-RNA
)	I-RNA
and	I-RNA
p27	I-RNA
(	I-RNA
KIP1	I-RNA
)	I-RNA
mRNA	I-RNA
and	O
protein	O
increased	O
in	O
these	O
cells	O
.	O

Northern	O
blot	O
analysis	O
showed	O
that	O
p21	B-protein
(	I-protein
WAF1/CIP1	I-protein
)	I-protein
and	O
p27	B-protein
(	I-protein
KIP1	I-protein
)	I-protein
transcripts	O
were	O
induced	O
after	O
6	O
hours	O
'	O
exposure	O
to	O
1	O
,	O
25	O
(	O
OH	O
)	O
2D3	O
and	O
then	O
decreased	O
to	O
basal	O
levels	O
over	O
48	O
hours	O
.	O

Western	O
blot	O
experiments	O
showed	O
that	O
p21	B-protein
(	I-protein
WAF1/CIP1	I-protein
)	I-protein
protein	O
levels	O
increased	O
and	O
became	O
detectable	O
after	O
12	O
hours	O
of	O
1	O
,	O
25	O
(	O
OH	O
)	O
2D3	O
treatment	O
and	O
induction	O
of	O
p27	B-protein
(	I-protein
KIP1	I-protein
)	I-protein
protein	O
was	O
much	O
more	O
gradual	O
and	O
sustained	O
in	O
UF-1	B-cell_line
cells	I-cell_line
.	O

Interestingly	O
,	O
the	O
combination	O
of	O
1	O
,	O
25	O
(	O
OH	O
)	O
2D3	O
and	O
RA	O
markedly	O
enhanced	O
the	O
levels	O
of	O
p27	B-protein
(	I-protein
KIP1	I-protein
)	I-protein
transcript	O
and	O
protein	O
as	O
compared	O
with	O
levels	O
induced	O
by	O
1	O
,	O
25	O
(	O
OH	O
)	O
2D3	O
alone	O
.	O

In	O
addition	O
,	O
exogenous	O
p27	B-protein
(	I-protein
KIP1	I-protein
)	I-protein
expression	O
can	O
enhance	O
the	O
level	O
of	O
CD11b	B-protein
antigen	I-protein
in	O
myeloid	B-cell_type
leukemic	I-cell_type
cells	I-cell_type
.	O

In	O
contrast	O
,	O
RA	O
alone	O
can	O
induce	O
G1	O
arrest	O
of	O
UF-1	B-cell_line
cells	I-cell_line
;	O
however	O
,	O
it	O
did	O
not	O
result	O
in	O
an	O
increase	O
of	O
p21	B-protein
(	I-protein
WAF1/CIP1	I-protein
)	I-protein
and	O
p27	B-protein
(	I-protein
KIP1	I-protein
)	I-protein
transcript	O
and	O
protein	O
expression	O
in	O
RA-resistant	O
cells	O
.	O

Taken	O
together	O
,	O
we	O
conclude	O
that	O
1	O
,	O
25	O
(	O
OH	O
)	O
2D3	O
induces	O
increased	O
expression	O
of	O
cdk	B-protein
inhibitors	I-protein
,	O
which	O
mediates	O
a	O
G1	O
arrest	O
,	O
and	O
this	O
may	O
be	O
associated	O
with	O
differentiation	O
of	O
RA-resistant	O
UF-1	B-cell_line
cells	I-cell_line
toward	O
mature	O
granulocytes	B-cell_type
.	O

Molecular	O
mechanisms	O
of	O
neutrophil-endothelial	O
cell	O
adhesion	O
induced	O
by	O
redox	O
imbalance	O
.	O

Previous	O
studies	O
have	O
implicated	O
a	O
role	O
for	O
intracellular	O
thiols	O
in	O
the	O
activation	O
of	O
nuclear	B-protein
factor-kappaB	I-protein
and	O
transcriptional	O
regulation	O
of	O
endothelial	B-protein
cell	I-protein
adhesion	I-protein
molecules	I-protein
.	O

This	O
study	O
was	O
designed	O
to	O
determine	O
whether	O
changes	O
in	O
endothelial	O
cell	O
glutathione	O
(	O
GSH	O
)	O
or	O
oxidized	O
glutathione	O
(	O
GSSG	O
)	O
can	O
alter	O
neutrophil	O
adhesivity	O
and	O
to	O
define	O
the	O
molecular	O
mechanism	O
that	O
underlies	O
this	O
GSSG/GSH-induced	O
adhesion	O
response	O
.	O

Treatment	O
of	O
human	B-cell_line
umbilical	I-cell_line
vein	I-cell_line
endothelial	I-cell_line
cell	I-cell_line
(	I-cell_line
HUVEC	I-cell_line
)	I-cell_line
monolayers	I-cell_line
for	O
6	O
hours	O
with	O
0.2	O
mmol/L	O
diamide	O
and	O
1	O
mmol/L	O
buthionine	O
sulfoximine	O
(	O
BSO	O
)	O
decreased	O
GSH	O
levels	O
and	O
increased	O
the	O
ratio	O
of	O
GSSG	O
to	O
GSH	O
without	O
cell	O
toxicity	O
.	O

These	O
redox	O
changes	O
are	O
similar	O
to	O
those	O
observed	O
with	O
anoxia/reoxygenation	O
.	O

Diamide	O
plus	O
BSO-induced	O
thiol/disulfide	O
imbalance	O
was	O
associated	O
with	O
a	O
biphasic	O
increase	O
in	O
neutrophil	B-cell_type
adhesion	O
to	O
HUVECs	B-cell_line
with	O
peak	O
responses	O
observed	O
at	O
15	O
minutes	O
(	O
phase	O
1	O
)	O
and	O
240	O
minutes	O
(	O
phase	O
2	O
)	O
.	O

N-Acetylcysteine	O
treatment	O
attenuated	O
neutrophil	B-cell_type
adhesion	O
in	O
both	O
phases	O
,	O
which	O
indicated	O
a	O
role	O
for	O
GSH	O
in	O
the	O
adhesion	O
responses	O
.	O

Interestingly	O
,	O
phase	O
1	O
adhesion	O
was	O
inversely	O
correlated	O
with	O
GSH	O
levels	O
but	O
not	O
with	O
the	O
GSSG/GSH	O
ratio	O
,	O
whereas	O
phase	O
2	O
neutrophil	B-cell_type
adhesion	O
was	O
positively	O
correlated	O
with	O
GSSG/GSH	O
ratio	O
but	O
not	O
with	O
GSH	O
levels	O
.	O

Intercellular	B-protein
adhesion	I-protein
molecule-1	I-protein
and	O
P-selectin-specific	B-protein
monoclonal	I-protein
antibodies	I-protein
attenuated	O
the	O
increased	O
neutrophil	B-cell_type
adhesion	O
during	O
both	O
phases	O
,	O
whereas	O
an	O
anti-E-selectin	B-protein
monoclonal	I-protein
antibody	I-protein
also	O
attenuated	O
the	O
phase	O
2	O
response	O
.	O

Pretreatment	O
with	O
actinomycin	O
D	O
and	O
cycloheximide	O
or	O
with	O
competing	O
ds-oligonucleotides	O
that	O
contained	O
nuclear	B-protein
factor-kappaB	I-protein
or	O
activator	B-protein
protein-1	I-protein
cognate	O
DNA	O
sequences	O
significantly	O
attenuated	O
the	O
phase	O
2	O
response	O
,	O
which	O
implicated	O
a	O
role	O
for	O
de	O
novo	O
protein	O
synthesis	O
.	O

Surface	O
expression	O
of	O
intercellular	B-protein
adhesion	I-protein
molecule-1	I-protein
,	O
P-selectin	B-protein
,	O
and	O
E-selectin	B-protein
on	O
HUVECs	B-cell_line
correlated	O
with	O
the	O
phase	O
1	O
and	O
2	O
neutrophil	B-cell_type
adhesion	O
responses	O
.	O

This	O
study	O
demonstrates	O
that	O
changes	O
in	O
endothelial	O
cell	O
GSSG/GSH	O
cause	O
transcription-independent	O
and	O
transcription-dependent	O
surface	O
expression	O
of	O
different	O
endothelial	B-protein
cell	I-protein
adhesion	I-protein
molecules	I-protein
,	O
which	O
leads	O
to	O
a	O
2-phase	O
neutrophil	B-cell_type
-endothelial	O
adhesion	O
response	O
.	O

Glucocorticoid	O
hormone	O
suppression	O
of	O
human	O
neutrophil	B-cell_type
-mediated	O
tumor	O
cell	O
cytostasis	O
.	O

In	O
the	O
present	O
study	O
,	O
we	O
have	O
investigated	O
the	O
effect	O
of	O
glucocorticoid	O
hormones	O
on	O
neutrophil	B-cell_type
-mediated	O
tumor	O
cell	O
cytostasis	O
and	O
found	O
that	O
hydrocortisone	O
and	O
a	O
synthetic	O
hormone	O
,	O
dexamethasone	O
(	O
Dex	O
)	O
,	O
inhibited	O
cytostasis	O
in	O
the	O
presence	O
or	O
absence	O
of	O
tumor	B-protein
necrosis	I-protein
factor-alpha	I-protein
.	O

The	O
effect	O
of	O
Dex	O
was	O
completely	O
reversed	O
by	O
a	O
glucocorticoid	B-protein
receptor	I-protein
antagonist	O
,	O
RU38486	O
.	O

To	O
clarify	O
the	O
underlying	O
mechanisms	O
,	O
we	O
examined	O
effects	O
of	O
Dex	O
on	O
the	O
binding	O
avidity	O
of	O
beta2	B-protein
integrin	I-protein
on	O
the	O
neutrophil	B-cell_type
surface	O
and	O
how	O
these	O
might	O
in	O
turn	O
affect	O
neutrophil	B-cell_type
-to-tumor	O
cell	O
binding	O
.	O

Dex	O
was	O
found	O
to	O
inhibit	O
these	O
neutrophil	B-cell_type
properties	O
,	O
and	O
RU38486	O
completely	O
suppressed	O
both	O
forms	O
of	O
Dex	O
inhibition	O
.	O

Taken	O
together	O
,	O
our	O
findings	O
suggest	O
that	O
glucocorticoid	O
hormone	O
inhibition	O
of	O
neutrophil	B-cell_type
-mediated	O
tumor	O
cell	O
cytostasis	O
is	O
at	O
least	O
partially	O
due	O
to	O
a	O
lowering	O
of	O
the	O
ligand	O
binding	O
avidity	O
of	O
beta2	B-protein
integrin	I-protein
on	O
the	O
neutrophil	B-cell_type
surface	O
.	O

Constitutive	O
activation	O
of	O
an	O
epithelial	O
signal	O
transducer	O
and	O
activator	O
of	O
transcription	O
(	O
STAT	B-protein
)	O
pathway	O
in	O
asthma	O
.	O

Cytokine	B-protein
effects	O
on	O
immunity	O
and	O
inflammation	O
often	O
depend	O
on	O
the	O
transcription	B-protein
factors	I-protein
termed	O
signal	B-protein
transducers	I-protein
and	I-protein
activators	I-protein
of	I-protein
transcription	I-protein
(	O
STATs	B-protein
)	O
,	O
so	O
STAT	B-protein
signaling	O
pathways	O
are	O
candidates	O
for	O
influencing	O
inflammatory	O
disease	O
.	O

We	O
reasoned	O
that	O
selective	O
IFN	B-protein
responsiveness	O
of	O
the	O
first	O
STAT	B-protein
family	I-protein
member	I-protein
(	O
Stat1	B-protein
)	O
and	O
Stat1-dependent	B-DNA
immune-response	I-DNA
genes	I-DNA
such	O
as	O
intercellular	B-protein
adhesion	I-protein
molecule-1	I-protein
(	O
ICAM-1	B-protein
)	O
,	O
IFN	B-protein
regulatory	I-protein
factor-1	I-protein
(	O
IRF-1	B-protein
)	O
,	O
and	O
Stat1	B-protein
itself	O
in	O
airway	B-cell_type
epithelial	I-cell_type
cells	I-cell_type
provides	O
a	O
basis	O
for	O
detecting	O
cytokine	B-protein
signaling	O
abnormalities	O
in	O
inflammatory	O
airway	O
disease	O
.	O

On	O
the	O
basis	O
of	O
nuclear	O
localization	O
and	O
phosphorylation	O
,	O
we	O
found	O
that	O
epithelial	B-protein
Stat1	I-protein
(	O
but	O
not	O
other	O
control	O
transcription	B-protein
factors	I-protein
)	O
was	O
invariably	O
activated	O
in	O
asthmatic	O
compared	O
with	O
normal	O
control	O
or	O
chronic	O
bronchitis	O
subjects	O
.	O

Furthermore	O
,	O
epithelial	O
levels	O
of	O
activated	O
Stat1	B-protein
correlated	O
with	O
levels	O
of	O
expression	O
for	O
epithelial	B-protein
ICAM-1	I-protein
,	O
IRF-1	B-protein
,	O
and	O
Stat1	B-protein
,	O
and	O
in	O
turn	O
,	O
ICAM-1	B-protein
levels	O
correlated	O
with	O
T-cell	O
accumulation	O
in	O
tissue	O
.	O

However	O
,	O
only	O
low	O
levels	O
of	O
IFN-gamma	B-protein
or	O
IFN-gamma-producing	B-cell_type
cells	I-cell_type
were	O
detected	O
in	O
airway	O
tissue	O
in	O
all	O
subjects	O
.	O

The	O
results	O
therefore	O
provide	O
initial	O
evidence	O
linking	O
abnormal	O
behavior	O
of	O
STAT	B-protein
pathways	O
for	O
cytokine	B-protein
signaling	O
to	O
the	O
development	O
of	O
an	O
inflammatory	O
disease	O
.	O

In	O
that	O
context	O
,	O
the	O
results	O
also	O
change	O
the	O
current	O
scheme	O
for	O
asthma	O
pathogenesis	O
to	O
one	O
that	O
must	O
include	O
a	O
localized	O
gain	O
in	O
transcriptional	O
signal	O
ordinarily	O
used	O
for	O
a	O
T	B-protein
helper	I-protein
1-type	I-protein
cytokine	I-protein
(	O
IFN-gamma	B-protein
)	O
in	O
combination	O
with	O
allergy-driven	O
overproduction	O
of	O
T	B-protein
helper	I-protein
2-type	I-protein
cytokines	I-protein
.	O

Leukocyte	B-cell_type
populations	I-cell_type
,	O
hormone	B-protein
receptors	I-protein
and	O
apoptosis	O
in	O
eutopic	O
and	O
ectopic	O
first	O
trimester	O
human	O
pregnancies	O
.	O

The	O
implantation	O
of	O
trophoblast	B-cell_type
cells	I-cell_type
at	O
extrauterine	O
sites	O
still	O
results	O
in	O
decidualization	O
.	O

The	O
objective	O
of	O
the	O
present	O
study	O
was	O
to	O
compare	O
decidualization	O
at	O
eutopic	O
and	O
ectopic	O
implantation	O
sites	O
.	O

Tissues	O
from	O
women	O
undergoing	O
elective	O
termination	O
of	O
uterine	O
pregnancy	O
and	O
from	O
women	O
with	O
ectopic	O
pregnancy	O
were	O
used	O
to	O
detect	O
the	O
presence	O
of	O
cells	O
important	O
for	O
the	O
maintenance	O
of	O
pregnancy	O
,	O
such	O
as	O
BCL-2+	B-cell_type
,	I-cell_type
CD56+	I-cell_type
,	I-cell_type
CD3+	I-cell_type
,	I-cell_type
CD8+	I-cell_type
and	I-cell_type
CD68+	I-cell_type
cells	I-cell_type
,	O
and	O
the	O
presence	O
of	O
oestrogen	B-protein
(	I-protein
ER	I-protein
)	I-protein
and	I-protein
progesterone	I-protein
receptors	I-protein
(	O
PR	B-protein
)	O
by	O
immunohistochemistry	O
.	O

In-situ	O
detection	O
of	O
fragmented	O
DNA	O
was	O
performed	O
to	O
identify	O
apoptotic	B-cell_type
cells	I-cell_type
.	O

The	O
percentage	O
of	O
CD3+	B-cell_type
cells	I-cell_type
among	O
all	O
immunocompetent	B-cell_type
cells	I-cell_type
in	O
the	O
tubal	O
epithelium	O
was	O
46.6	O
%	O
(	O
39.9	O
%	O
of	O
CD3+	B-cell_type
were	O
also	O
CD8+	B-cell_type
)	O
;	O
the	O
other	O
53.4	O
%	O
were	O
CD68+	B-cell_type
cells	I-cell_type
.	O

CD56+	B-cell_type
cells	I-cell_type
were	O
undetectable	O
in	O
ectopic	O
decidua	O
at	O
the	O
feto-maternal	O
interface	O
in	O
ectopic	O
tissue	O
.	O

In	O
uterine	O
decidua	O
,	O
we	O
found	O
29.9	O
%	O
CD3+	B-cell_type
cells	I-cell_type
(	O
2.2	O
%	O
of	O
CD3+	O
were	O
CD8+	O
)	O
,	O
51.6	O
%	O
CD56+	B-cell_type
cells	I-cell_type
and	O
18.5	O
%	O
CD68+	B-cell_type
cells	I-cell_type
.	O

The	O
ratio	O
of	O
BCL2+	B-cell_type
to	O
CD3+	B-cell_type
cells	I-cell_type
in	O
ectopic	O
pregnancy	O
was	O
0.41	O
.	O

In	O
uterine	O
pregnancy	O
,	O
the	O
ratio	O
of	O
BCL-2	B-protein
to	O
CD3	O
was	O
0.44	O
and	O
0.39	O
for	O
CD56	O
.	O

Tissues	O
from	O
both	O
ectopic	O
and	O
uterine	O
pregnancies	O
were	O
positive	O
for	O
PR	B-protein
.	O

Fewer	O
apoptotic	B-cell_type
cell	I-cell_type
bodies	I-cell_type
were	O
present	O
in	O
ectopic	O
pregnancy	O
.	O

The	O
use	O
of	O
tissue	O
obtained	O
from	O
ectopic	O
pregnancy	O
may	O
become	O
an	O
excellent	O
model	O
to	O
identify	O
the	O
mechanism	O
of	O
trophoblast	O
invasion	O
in	O
eutopic	O
pregnancies	O
.	O

Angiotensin	B-protein
II	I-protein
activates	O
the	O
proinflammatory	B-protein
transcription	I-protein
factor	I-protein
nuclear	B-protein
factor-kappaB	I-protein
in	O
human	B-cell_type
monocytes	I-cell_type
.	O

The	O
renin	B-protein
-angiotensin	O
system	O
may	O
contribute	O
to	O
the	O
pathogenesis	O
of	O
atherosclerosis	O
.	O

A	O
common	O
feature	O
of	O
all	O
stages	O
of	O
atherosclerosis	O
is	O
inflammation	O
of	O
the	O
vessel	O
wall	O
.	O

The	O
transcription	O
factor	O
nuclear	B-protein
factor-kappaB	I-protein
(	O
NF-kappaB	B-protein
)	O
participates	O
in	O
most	O
signaling	O
pathways	O
involved	O
in	O
inflammation	O
.	O

This	O
study	O
therefore	O
examined	O
the	O
effect	O
of	O
angiotensin	B-protein
(	I-protein
ANG	I-protein
)	I-protein
II	I-protein
on	O
NF-kappaB	B-protein
activation	O
in	O
monocytic	B-cell_type
cells	I-cell_type
,	O
a	O
major	O
cellular	O
component	O
of	O
human	O
atheroma	O
,	O
by	O
electrophoretic	O
mobility	O
shift	O
assay	O
.	O

ANG	B-protein
II	I-protein
,	O
like	O
TNFalpha	B-protein
,	O
caused	O
rapid	O
activation	O
of	O
NF-kappaB	B-protein
in	O
human	B-cell_type
mononuclear	I-cell_type
cells	I-cell_type
isolated	O
from	O
peripheral	O
blood	O
by	O
Ficoll	O
density	O
gradient	O
.	O

This	O
ANG	B-protein
II	I-protein
effect	O
was	O
blocked	O
by	O
the	O
angiotensin	O
AT1	O
receptor	O
antagonist	O
losartan	O
.	O

Specificity	O
of	O
ANG	B-protein
II	I-protein
-induced	O
NF-kappaB	B-protein
activation	O
was	O
ascertained	O
by	O
supershift	O
and	O
competition	O
experiments	O
.	O

Moreover	O
,	O
ANG	B-protein
II	I-protein
stimulated	O
NF-kappaB	B-protein
activation	O
in	O
human	B-cell_type
monocytes	I-cell_type
,	O
but	O
not	O
in	O
lymphocytes	B-cell_type
from	O
the	O
same	O
preparation	O
.	O

Together	O
,	O
the	O
data	O
demonstrate	O
the	O
ability	O
of	O
the	O
vasoactive	O
peptide	O
ANG	B-protein
II	I-protein
to	O
activate	O
inflammatory	O
pathways	O
in	O
human	B-cell_type
monocytes	I-cell_type
.	O

Copyright	O
1999	O
Academic	O
Press	O
.	O

Signal	O
transduction	O
pathways	O
activated	O
in	O
endothelial	B-cell_type
cells	I-cell_type
following	O
infection	O
with	O
Chlamydia	O
pneumoniae	O
.	O

Chlamydia	O
pneumoniae	O
is	O
an	O
important	O
respiratory	O
pathogen	O
.	O

Recently	O
,	O
its	O
presence	O
has	O
been	O
demonstrated	O
in	O
atherosclerotic	O
lesions	O
.	O

In	O
this	O
study	O
,	O
we	O
characterized	O
C.	O
pneumoniae-mediated	O
activation	O
of	O
endothelial	B-cell_type
cells	I-cell_type
and	O
demonstrated	O
an	O
enhanced	O
expression	O
of	O
endothelial	B-protein
adhesion	I-protein
molecules	I-protein
followed	O
by	O
subsequent	O
rolling	O
,	O
adhesion	O
,	O
and	O
transmigration	O
of	O
leukocytes	B-cell_type
(	O
monocytes	B-cell_type
,	O
granulocytes	B-cell_type
)	O
.	O

These	O
effects	O
were	O
blocked	O
by	O
mAbs	B-protein
against	O
endothelial	B-protein
and/or	I-protein
leukocyte	I-protein
adhesion	I-protein
molecules	I-protein
(	O
beta1	B-protein
and	I-protein
beta2	I-protein
integrins	I-protein
)	O
.	O

Additionally	O
,	O
activation	O
of	O
different	O
signal	O
transduction	O
pathways	O
in	O
C.	B-cell_type
pneumoniae-infected	I-cell_type
endothelial	I-cell_type
cells	I-cell_type
was	O
shown	O
:	O
protein	O
tyrosine	O
phosphorylation	O
,	O
up-regulation	O
of	O
phosphorylated	O
p42/p44	B-protein
mitogen-activated	I-protein
protein	I-protein
kinase	I-protein
,	O
and	O
NF-kappaB	B-protein
activation/translocation	O
occurred	O
within	O
10-15	O
min	O
.	O

Increased	O
mRNA	B-RNA
and	O
surface	O
expression	O
of	O
E-selectin	B-protein
,	O
ICAM-1	B-protein
,	O
and	O
VCAM-1	B-protein
were	O
noted	O
within	O
hours	O
.	O

Thus	O
,	O
C.	O
pneumoniae	O
triggers	O
a	O
cascade	O
of	O
events	O
that	O
could	O
lead	O
to	O
endothelial	O
activation	O
,	O
inflammation	O
,	O
and	O
thrombosis	O
,	O
which	O
in	O
turn	O
may	O
result	O
in	O
or	O
may	O
promote	O
atherosclerosis	O
.	O

Transient	O
pseudo-hypoaldosteronism	O
following	O
resection	O
of	O
the	O
ileum	O
:	O
normal	O
level	O
of	O
lymphocytic	B-protein
aldosterone	I-protein
receptors	I-protein
outside	O
the	O
acute	O
phase	O
.	O

Pseudo-hypoaldosteronism	O
(	O
PHA	O
)	O
is	O
due	O
to	O
mineralocorticoid	O
resistance	O
and	O
manifests	O
as	O
hyponatremia	O
and	O
hyperkalemia	O
with	O
increased	O
plasma	O
aldosterone	O
levels	O
.	O

It	O
may	O
be	O
familial	O
or	O
secondary	O
to	O
abnormal	O
renal	O
sodium	O
handling	O
.	O

We	O
report	O
the	O
case	O
of	O
a	O
54-year-old	O
woman	O
with	O
multifocal	O
cancer	O
of	O
the	O
colon	O
,	O
who	O
developed	O
PHA	O
after	O
subtotal	O
colectomy	O
,	O
ileal	O
resection	O
and	O
jejunostomy	O
.	O

She	O
was	O
treated	O
with	O
6	O
g	O
of	O
salt	O
daily	O
to	O
prevent	O
dehydration	O
,	O
which	O
she	O
stopped	O
herself	O
because	O
of	O
reduced	O
fecal	O
losses	O
.	O

One	O
month	O
later	O
she	O
was	O
admitted	O
with	O
signs	O
of	O
acute	O
adrenal	O
failure	O
,	O
i.e.	O
fatigue	O
,	O
severe	O
nausea	O
,	O
blood	O
pressure	O
of	O
80/60	O
mmHg	O
,	O
extracellular	O
dehydration	O
,	O
hyponatremia	O
(	O
118	O
mmol/l	O
)	O
;	O
hyperkalemia	O
(	O
7.6	O
mmol/l	O
)	O
,	O
increased	O
blood	O
urea	O
nitrogen	O
(	O
BUN	O
)	O
(	O
200	O
mg/dl	O
)	O
and	O
creatininemia	O
(	O
2.5	O
mg/dl	O
)	O
,	O
and	O
decreased	O
plasma	O
bicarbonates	O
level	O
(	O
HCO3-	O
:	O
16	O
mmol/l	O
;	O
N	O
:	O
27-30	O
)	O
.	O

However	O
,	O
the	O
plasma	O
cortisol	O
was	O
high	O
(	O
66	O
microg/100	O
ml	O
at	O
10	O
:	O
00	O
h	O
;	O
N	O
:	O
8-15	O
)	O
and	O
the	O
ACTH	O
was	O
normal	O
(	O
13	O
pg/ml	O
,	O
N	O
:	O
10-60	O
)	O
;	O
there	O
was	O
a	O
marked	O
increase	O
in	O
plasma	O
renin	O
activity	O
(	O
>	O
37	O
ng/ml/h	O
;	O
N	O
supine	O
<	O
3	O
)	O
,	O
active	O
renin	O
(	O
869	O
pg/ml	O
;	O
N	O
supine	O
:	O
1.120	O
)	O
,	O
aldosterone	O
(	O
>	O
2000	O
pg/ml	O
;	O
N	O
supine	O
<	O
150	O
)	O
and	O
plasma	O
AVP	O
(	O
20	O
pmol/l	O
;	O
N	O
:	O
0.5-2.5	O
)	O
.	O

The	O
plasma	O
ANH	O
level	O
was	O
38	O
pmol/l	O
(	O
N	O
supine	O
:	O
5-25	O
)	O
.	O

A	O
urinary	O
steroidogram	O
resulted	O
in	O
highly	O
elevated	O
tetrahydrocortisol	O
(	O
THF	O
:	O
13.3	O
mg/24h	O
;	O
N	O
:	O
1.4+/-0.8	O
)	O
with	O
no	O
increase	O
in	O
tetrahydrocortisone	O
(	O
THE	O
:	O
3.16	O
mg/24h	O
;	O
N	O
:	O
2.7+/-2.0	O
)	O
excretion	O
,	O
and	O
with	O
low	O
THE/THF	O
(	O
0.24	O
;	O
N	O
:	O
1.87+/-0.36	O
)	O
and	O
alpha	O
THF/THF	O
(	O
0.35	O
;	O
N	O
:	O
0.92+/-0.42	O
)	O
ratios	O
.	O

The	O
number	O
of	O
mineralocorticoid	B-protein
receptors	I-protein
in	O
mononuclear	B-cell_type
leukocytes	I-cell_type
was	O
in	O
the	O
lower	O
normal	O
range	O
for	O
age	O
,	O
while	O
the	O
number	O
of	O
glucocorticoid	B-protein
receptors	I-protein
was	O
reduced	O
.	O

Small-bowel	O
resection	O
in	O
ileostomized	O
patients	O
causes	O
excessive	O
fecal	O
sodium	O
losses	O
and	O
results	O
in	O
chronic	O
sodium	O
depletion	O
with	O
contraction	O
of	O
the	O
plasma	O
volume	O
and	O
severe	O
secondary	O
hyperaldosteronism	O
.	O

Nevertheless	O
,	O
this	O
hyperaldosteronism	O
may	O
be	O
associated	O
with	O
hyponatremia	O
and	O
hyperkalemia	O
suggesting	O
PHA	O
related	O
to	O
the	O
major	O
importance	O
of	O
the	O
colon	O
for	O
the	O
absorption	O
of	O
sodium	O
.	O

In	O
conclusion	O
,	O
this	O
case	O
report	O
emphasizes	O
1	O
)	O
the	O
possibility	O
of	O
a	O
syndrome	O
of	O
acquired	O
PHA	O
with	O
severe	O
hyperkalemia	O
after	O
resection	O
of	O
the	O
ileum	O
and	O
colon	O
responding	O
to	O
oral	O
salt	O
supplementation	O
;	O
2	O
)	O
the	O
major	O
increase	O
in	O
AVP	O
and	O
the	O
small	O
increase	O
in	O
ANH	O
;	O
3	O
)	O
the	O
strong	O
increase	O
in	O
urinary	O
THF	O
with	O
low	O
THE/THF	O
and	O
alpha	O
THF/THF	O
ratios	O
;	O
4	O
)	O
the	O
normal	O
number	O
of	O
lymphocytic	B-protein
mineralocorticoid	I-protein
receptors	I-protein
outside	O
the	O
acute	O
episode	O
.	O

Modulation	O
of	O
the	O
immune	O
response	O
by	O
progesterone-induced	B-protein
lymphocyte	I-protein
factors	I-protein
.	O

Rat	O
spleen	O
and	O
peripheral	B-cell_type
blood	I-cell_type
lymphocytes	I-cell_type
express	O
progesterone	B-protein
receptors	I-protein
whose	O
concentration	O
is	O
increased	O
greatly	O
during	O
the	O
early	O
phase	O
of	O
pregnancy	O
.	O

After	O
stimulation	O
of	O
progesterone	O
the	O
expression	O
of	O
receptors	O
was	O
augmented	O
2-3	O
times	O
.	O

When	O
cells	O
were	O
cultured	O
in	O
the	O
presence	O
of	O
progesterone	O
they	O
released	O
a	O
soluble	B-protein
factor	I-protein
that	O
inhibited	O
cellular	O
immunoreactions	O
(	O
MLR	O
,	O
CRC	O
)	O
and	O
cellular	O
proliferation	O
as	O
measured	O
by	O
thymidine	O
incorporation	O
by	O
spleen-cell	B-cell_line
culture	I-cell_line
.	O

This	O
factor	O
also	O
inhibited	O
the	O
synthesis	O
of	O
anti-DNP	B-protein
antibodies	I-protein
by	O
a	O
mouse	B-cell_line
hybridoma	I-cell_line
and	O
diminished	O
the	O
proportion	O
of	O
cells	O
in	O
phase	O
S	O
.	O

However	O
,	O
the	O
percentage	O
of	O
asymmetric	B-protein
molecules	I-protein
produced	O
by	O
the	O
hybridoma	B-cell_line
remained	O
unaltered	O
.	O

These	O
results	O
support	O
the	O
hypothesis	O
that	O
soluble	B-protein
factors	I-protein
released	O
by	O
rat	B-cell_type
lymphocytes	I-cell_type
modulate	O
the	O
immune	O
response	O
of	O
the	O
mother	O
and	O
participate	O
in	O
the	O
mechanism	O
that	O
protects	O
the	O
fetus	O
against	O
antipaternal	B-protein
antibodies	I-protein
.	O

Differential	O
regulation	O
of	O
4E-BP1	B-protein
and	O
4E-BP2	B-protein
,	O
two	O
repressors	O
of	O
translation	O
initiation	O
,	O
during	O
human	B-cell_type
myeloid	I-cell_type
cell	I-cell_type
differentiation	O
.	O

Human	O
myeloid	O
differentiation	O
is	O
accompanied	O
by	O
a	O
decrease	O
in	O
cell	O
proliferation	O
.	O

Because	O
the	O
translation	O
rate	O
is	O
an	O
important	O
determinant	O
of	O
cell	O
proliferation	O
,	O
we	O
have	O
investigated	O
translation	O
initiation	O
during	O
human	B-cell_type
myeloid	I-cell_type
cell	I-cell_type
differentiation	O
using	O
the	O
HL-60	B-cell_line
promyelocytic	I-cell_line
leukemia	I-cell_line
cell	I-cell_line
line	I-cell_line
and	O
the	O
U-937	B-cell_line
monoblastic	I-cell_line
cell	I-cell_line
line	I-cell_line
.	O

A	O
decrease	O
in	O
the	O
translation	O
rate	O
is	O
observed	O
when	O
the	O
cells	O
are	O
induced	O
to	O
differentiate	O
along	O
the	O
monocytic/macrophage	O
pathway	O
or	O
along	O
the	O
granulocytic	O
pathway	O
.	O

The	O
inhibition	O
in	O
protein	O
synthesis	O
correlates	O
with	O
specific	O
regulation	O
of	O
two	O
repressors	O
of	O
translation	O
initiation	O
,	O
4E-BP1	B-protein
and	O
4E-BP2	B-protein
.	O

Induction	O
of	O
HL-60	B-cell_line
and	O
U-937	B-cell_line
cell	O
differentiation	O
into	O
monocytes/macrophages	B-cell_type
by	O
IFN-gamma	B-protein
or	O
PMA	O
results	O
in	O
a	O
dephosphorylation	O
and	O
consequent	O
activation	O
of	O
4E-BP1	B-protein
.	O

Dephosphorylation	O
of	O
4E-BP1	B-protein
was	O
also	O
observed	O
when	O
U-937	B-cell_line
cells	I-cell_line
were	O
induced	O
to	O
differentiate	O
into	O
monocytes/macrophages	B-cell_type
following	O
treatment	O
with	O
retinoic	O
acid	O
or	O
DMSO	O
.	O

In	O
contrast	O
,	O
treatment	O
of	O
HL-60	B-cell_line
cells	I-cell_line
with	O
retinoic	O
acid	O
or	O
DMSO	O
,	O
which	O
results	O
in	O
a	O
granulocytic	O
differentiation	O
of	O
these	O
cells	O
,	O
decreases	O
4E-BP1	B-protein
amount	O
without	O
affecting	O
its	O
phosphorylation	O
and	O
strongly	O
increases	O
4E-BP2	B-protein
amount	O
.	O

Taken	O
together	O
,	O
these	O
data	O
provide	O
evidence	O
for	O
differential	O
regulation	O
of	O
the	O
translational	O
machinery	O
during	O
human	O
myeloid	O
differentiation	O
,	O
specific	O
to	O
the	O
monocytic/macrophage	O
pathway	O
or	O
to	O
the	O
granulocytic	O
pathway	O
.	O

Nonimmunoglobulin	O
gene	O
hypermutation	O
in	O
germinal	B-cell_type
center	I-cell_type
B	I-cell_type
cells	I-cell_type
.	O

Somatic	O
hypermutation	O
is	O
the	O
most	O
critical	O
mechanism	O
underlying	O
the	O
diversification	O
of	O
Ig	B-DNA
genes	I-DNA
.	O

Although	O
mutation	O
occurs	O
specifically	O
in	O
B	B-cell_type
cells	I-cell_type
during	O
the	O
germinal	O
center	O
reaction	O
,	O
it	O
remains	O
a	O
matter	O
of	O
debate	O
whether	O
the	O
mutation	O
machinery	O
also	O
targets	O
non-Ig	B-DNA
genes	I-DNA
.	O

We	O
have	O
studied	O
mutations	O
in	O
the	O
5	B-DNA
'	I-DNA
noncoding	I-DNA
region	I-DNA
of	O
the	O
Bcl6	B-DNA
gene	I-DNA
in	O
different	O
subtypes	O
of	O
lymphomas	O
.	O

We	O
found	O
frequent	O
hypermutation	O
in	O
follicular	O
lymphoma	O
(	O
25	O
of	O
59	O
=	O
42	O
%	O
)	O
(	O
germinal	O
center	O
cell	O
origin	O
)	O
and	O
mucosa-associated	O
lymphoid	O
tissue	O
(	O
MALT	O
)	O
lymphoma	O
(	O
19	O
of	O
45	O
=	O
42	O
%	O
)	O
(	O
postgerminal	O
center	O
)	O
,	O
but	O
only	O
occasionally	O
in	O
mantle	O
cell	O
lymphoma	O
(	O
1	O
of	O
21	O
=	O
4.8	O
%	O
)	O
(	O
pregerminal	O
center	O
)	O
.	O

Most	O
mutations	O
were	O
outside	O
the	O
motifs	O
potentially	O
important	O
for	O
transcription	O
,	O
suggesting	O
they	O
were	O
not	O
important	O
in	O
lymphomagenesis	O
but	O
may	O
,	O
like	O
Ig	O
mutation	O
,	O
represent	O
an	O
inherent	O
feature	O
of	O
the	O
lymphoma	B-cell_type
precursor	I-cell_type
cells	I-cell_type
.	O

Therefore	O
,	O
we	O
investigated	O
their	O
normal	O
cell	O
counterparts	O
microdissected	O
from	O
a	O
reactive	O
tonsil	O
.	O

Bcl6	O
mutation	O
was	O
found	O
in	O
13	O
of	O
24	O
(	O
54	O
%	O
)	O
clones	O
from	O
the	O
germinal	O
centre	O
but	O
only	O
in	O
1	O
of	O
24	O
(	O
4	O
%	O
)	O
clones	O
from	O
the	O
naive	B-cell_type
B	I-cell_type
cells	I-cell_type
of	O
the	O
mantle	O
zone	O
.	O

The	O
frequency	O
,	O
distribution	O
,	O
and	O
nature	O
of	O
these	O
mutations	O
were	O
similar	O
to	O
those	O
resulting	O
from	O
the	O
Ig	O
hypermutation	O
process	O
.	O

The	O
results	O
show	O
unequivocal	O
evidence	O
of	O
non-	O
Ig	B-DNA
gene	I-DNA
hypermutation	O
in	O
germinal	B-cell_type
center	I-cell_type
B	I-cell_type
cells	I-cell_type
and	O
provide	O
fresh	O
insights	O
into	O
the	O
process	O
of	O
hypermutation	O
and	O
lymphomagenesis	O
.	O

Impaired	O
binding	O
of	O
a	O
DQ2	B-protein
and	O
DQ8	B-protein
-binding	O
HSV	O
VP16	O
peptide	O
to	O
a	O
DQA1*0501/DQB1*0302	B-protein
trans	I-protein
class	I-protein
II	I-protein
heterodimer	I-protein
.	O

DQalpha	B-protein
and	I-protein
DQbeta	I-protein
trans	I-protein
heterodimeric	I-protein
HLA-DQ	I-protein
molecules	I-protein
form	O
in	O
individuals	O
heterozygous	O
for	O
the	O
DQ2	B-protein
and	O
DQ8	B-protein
specificities	O
.	O

Unique	O
functions	O
and	O
disease	O
associations	O
have	O
been	O
postulated	O
for	O
such	O
trans-dimers	B-protein
,	O
which	O
may	O
be	O
different	O
from	O
cis-encoded	B-protein
DQ	I-protein
molecules	I-protein
encoded	O
by	O
the	O
corresponding	O
haplotypes	O
.	O

We	O
analyzed	O
the	O
ability	O
of	O
the	O
trans-dimer	O
encoded	O
by	O
HLA-DQA1*0501/DQB1*0302	B-protein
to	O
bind	O
a	O
peptide	O
antigen	O
which	O
interacts	O
with	O
DQ	B-protein
molecules	I-protein
encoded	O
by	O
both	O
parental	O
haplotypes	O
.	O

Markedly	O
impaired	O
binding	O
was	O
observed	O
,	O
consistent	O
with	O
both	O
the	O
use	O
of	O
different	O
anchor	O
residues	O
and	O
with	O
changes	O
in	O
levels	O
of	O
DQ	O
cis-	O
dimer	B-protein
availability	O
for	O
peptide	O
binding	O
interactions	O
.	O

Detection	O
of	O
intracellular	B-protein
phosphorylated	I-protein
STAT-1	I-protein
by	O
flow	O
cytometry	O
.	O

We	O
have	O
applied	O
flow	O
cytometry	O
to	O
the	O
investigation	O
of	O
interferon-gamma	B-protein
activation	O
of	O
human	B-cell_type
monocytes	I-cell_type
.	O

This	O
approach	O
uses	O
monoclonal	B-protein
antibodies	I-protein
that	O
distinguish	O
between	O
the	O
native	O
and	O
phosphorylated	O
forms	O
of	O
STAT-1	B-protein
.	O

It	O
enables	O
rapid	O
and	O
quantitative	O
assessment	O
of	O
STAT-1	B-protein
phosphorylation	O
on	O
a	O
discrete	O
cell	O
basis	O
and	O
is	O
both	O
more	O
sensitive	O
and	O
less	O
time	O
consuming	O
than	O
immunoblotting	O
.	O

Furthermore	O
,	O
it	O
allows	O
for	O
discrimination	O
between	O
a	O
mixture	O
of	O
cells	O
that	O
differ	O
in	O
their	O
response	O
to	O
interferon-gamma	B-protein
.	O

This	O
approach	O
should	O
allow	O
for	O
the	O
evaluation	O
of	O
different	O
intracellular	O
signaling	O
pathways	O
using	O
a	O
combination	O
of	O
monoclonal	O
reagents	O
that	O
are	O
specific	O
for	O
native	O
and	O
activation	B-protein
modified	I-protein
proteins	I-protein
.	O

Application	O
of	O
this	O
form	O
of	O
testing	O
should	O
prove	O
valuable	O
in	O
screening	O
for	O
signaling	O
defects	O
in	O
selected	O
patients	O
with	O
recurrent	O
infections	O
.	O

In	O
addition	O
,	O
this	O
technique	O
should	O
permit	O
dissection	O
of	O
a	O
full	O
range	O
of	O
cellular	O
signaling	O
pathways	O
at	O
the	O
protein	O
level	O
.	O

Activation	O
of	O
nuclear	B-protein
factor-kappaB	I-protein
by	O
lipopolysaccharide	O
in	O
mononuclear	B-cell_type
leukocytes	I-cell_type
is	O
prevented	O
by	O
inhibitors	O
of	O
cytosolic	B-protein
phospholipase	I-protein
A2	I-protein
.	O

In	O
monocytes	B-cell_type
,	O
lipopolysaccharide	O
induces	O
synthesis	O
and	O
activity	O
of	O
the	O
85-kDa	O
cytosolic	B-protein
phospholipase	I-protein
A2	I-protein
.	O

This	O
enzyme	O
releases	O
arachidonic	O
acid	O
and	O
lyso-phospholipids	O
from	O
membranes	O
which	O
are	O
metabolized	O
to	O
eicosanoids	O
and	O
platelet-activating-factor	O
.	O

These	O
lipid	O
mediators	O
increase	O
activity	O
of	O
transcription	B-protein
factors	I-protein
and	O
expression	O
of	O
cytokine	B-DNA
genes	I-DNA
indicating	O
a	O
function	O
for	O
cytosolic	B-protein
phospholipase	I-protein
A2	I-protein
in	O
signal	O
transduction	O
and	O
inflammation	O
.	O

We	O
have	O
shown	O
previously	O
that	O
trifluoromethylketone	O
inhibitors	O
of	O
cytosolic	B-protein
phospholipase	I-protein
A2	I-protein
suppressed	O
interleukin-1beta	O
protein	O
and	O
steady-state	O
mRNA	O
levels	O
in	O
human	O
lipopolysaccharide-stimulated	B-cell_type
peripheral	I-cell_type
blood	I-cell_type
mononuclear	I-cell_type
leukocytes	I-cell_type
.	O

In	O
this	O
study	O
,	O
the	O
subcellular	O
mechanisms	O
were	O
analyzed	O
by	O
which	O
trifluoromethylketones	O
interfere	O
with	O
gene	O
expression	O
.	O

We	O
found	O
that	O
they	O
reduced	O
the	O
initial	O
interleukin-1beta	B-RNA
mRNA	I-RNA
transcription	O
rate	O
through	O
prevention	O
of	O
degradation	O
of	O
inhibitor-kappaB	B-protein
alpha	I-protein
.	O

Consequently	O
,	O
cytosolic	O
activation	O
,	O
nuclear	O
translocation	O
and	O
DNA-binding	O
of	O
nuclear	B-protein
factor-kappaB	I-protein
were	O
decreased	O
.	O

Trifluoromethylketones	O
ameliorate	O
chronic	O
inflammation	O
in	O
vivo	O
.	O

Thus	O
,	O
this	O
therapeutic	O
potency	O
may	O
reside	O
in	O
retention	O
of	O
inactive	O
nuclear	B-protein
factor-kappaB	I-protein
in	O
the	O
cytosol	B-cell_type
thereby	O
abrogating	O
interleukin-1beta	B-protein
gene	O
transcription	O
.	O

Cellular	O
disposition	O
of	O
sulphamethoxazole	O
and	O
its	O
metabolites	O
:	O
implications	O
for	O
hypersensitivity	O
.	O

1.	O
Bioactivation	O
of	O
sulphamethoxazole	O
(	O
SMX	O
)	O
to	O
chemically-reactive	O
metabolites	O
and	O
subsequent	O
protein	O
conjugation	O
is	O
thought	O
to	O
be	O
involved	O
in	O
SMX	O
hypersensitivity	O
.	O

We	O
have	O
therefore	O
examined	O
the	O
cellular	O
metabolism	O
,	O
disposition	O
and	O
conjugation	O
of	O
SMX	O
and	O
its	O
metabolites	O
in	O
vitro	O
.	O

2.	O
Flow	O
cytometry	O
revealed	O
binding	O
of	O
N-hydroxy	O
(	O
SMX-NHOH	O
)	O
and	O
nitroso	O
(	O
SMX-NO	O
)	O
metabolites	O
of	O
SMX	O
,	O
but	O
not	O
of	O
SMX	O
itself	O
,	O
to	O
the	O
surface	O
of	O
viable	O
white	B-cell_type
blood	I-cell_type
cells	I-cell_type
.	O

Cellular	O
haptenation	O
by	O
SMX-NO	O
was	O
reduced	O
by	O
exogenous	O
glutathione	O
(	O
GSH	O
)	O
.	O

3.	O
SMX-NHOH	O
and	O
SMX-NO	O
were	O
rapidly	O
reduced	O
back	O
to	O
the	O
parent	O
compound	O
by	O
cysteine	O
(	O
CYS	O
)	O
,	O
GSH	O
,	O
human	B-cell_type
peripheral	I-cell_type
blood	I-cell_type
cells	I-cell_type
and	O
plasma	O
,	O
suggesting	O
that	O
this	O
is	O
an	O
important	O
and	O
ubiquitous	B-protein
bioinactivation	O
mechanism	O
.	O

4.	O
Fluorescence	O
HPLC	O
showed	O
that	O
SMX-NHOH	O
and	O
SMX-NO	O
depleted	O
CYS	O
and	O
GSH	O
in	O
buffer	O
,	O
and	O
to	O
a	O
lesser	O
extent	O
,	O
in	O
cells	O
and	O
plasma	O
.	O

5.	O
Neutrophil	O
apoptosis	O
and	O
inhibition	O
of	O
neutrophil	O
function	O
were	O
induced	O
at	O
lower	O
concentrations	O
of	O
SMX-NHOH	O
and	O
SMX-NO	O
than	O
those	O
inducing	O
loss	O
of	O
membrane	O
viability	O
,	O
with	O
SMX	O
having	O
no	O
effect	O
.	O

Lymphocytes	B-cell_type
were	O
significantly	O
(	O
P	O
<	O
0.05	O
)	O
more	O
sensitive	O
to	O
the	O
direct	O
cytotoxic	O
effects	O
of	O
SMX-NO	O
than	O
neutrophils	B-cell_type
.	O

6.	O
Partitioning	O
of	O
SMX-NHOH	O
into	O
red	B-cell_type
blood	I-cell_type
cells	I-cell_type
was	O
significantly	O
(	O
P	O
<	O
0.05	O
)	O
lower	O
than	O
with	O
the	O
hydroxylamine	O
of	O
dapsone	O
.	O

7.	O
Our	O
results	O
suggest	O
that	O
the	O
balance	O
between	O
oxidation	O
of	O
SMX	O
to	O
its	O
toxic	O
metabolites	O
and	O
their	O
reduction	O
is	O
an	O
important	O
protective	O
cellular	O
mechanism	O
.	O

If	O
an	O
imbalance	O
exists	O
,	O
haptenation	O
of	O
the	O
toxic	O
metabolites	O
to	O
bodily	O
proteins	O
including	O
the	O
surface	O
of	O
viable	O
cells	O
can	O
occur	O
,	O
and	O
may	O
result	O
in	O
drug	O
hypersensitivity	O
.	O

Bcl-6	B-protein
expression	O
in	O
reactive	O
follicular	O
hyperplasia	O
,	O
follicular	O
lymphoma	O
,	O
and	O
angioimmunoblastic	O
T-cell	O
lymphoma	O
with	O
hyperplastic	O
germinal	O
centers	O
:	O
heterogeneity	O
of	O
intrafollicular	B-cell_type
T-cells	I-cell_type
and	O
their	O
altered	O
distribution	O
in	O
the	O
pathogenesis	O
of	O
angioimmunoblastic	O
T-cell	O
lymphoma	O
.	O

BACKGROUND	O
:	O
The	O
Bcl-6	B-protein
gene	I-protein
product	I-protein
,	O
a	O
nuclear	B-protein
phosphoprotein	I-protein
,	O
is	O
expressed	O
independently	O
of	O
Bcl-6	B-protein
gene	O
rearrangement	O
.	O

In	O
lymph	O
nodes	O
,	O
expression	O
of	O
Bcl-6	B-protein
protein	O
is	O
restricted	O
to	O
germinal	B-cell_type
center	I-cell_type
(	I-cell_type
GC	I-cell_type
)	I-cell_type
B-cells	I-cell_type
and	O
10	O
%	O
to	O
15	O
%	O
of	O
CD3/CD4+	B-cell_type
intrafollicular	I-cell_type
T	I-cell_type
cells	I-cell_type
.	O

Interfollicular	O
cells	O
are	O
negative	O
for	O
Bcl-6	B-protein
protein	I-protein
,	O
except	O
for	O
rare	O
CD3+/CD4+	B-cell_type
T	I-cell_type
cells	I-cell_type
.	O

Recently	O
,	O
we	O
reported	O
cases	O
of	O
angioimmunoblastic	O
T-cell	O
lymphoma	O
(	O
AITL	O
)	O
with	O
hyperplastic	O
GCs	O
(	O
AITL/GC	O
)	O
,	O
and	O
observed	O
that	O
borders	O
of	O
enlarged	O
GCs	O
were	O
ill	O
defined	O
,	O
with	O
features	O
suggestive	O
of	O
an	O
outward	O
migration	O
of	O
GC	B-cell_type
cells	I-cell_type
to	O
surrounding	O
interfollicular	O
zones	O
.	O

This	O
prompted	O
a	O
study	O
of	O
follicular	O
borders	O
with	O
Bcl-6	B-protein
staining	O
in	O
reactive	O
follicular	O
hyperplasias	O
and	O
follicular	O
lymphomas	O
to	O
compare	O
with	O
AITL/GC	O
.	O

MATERIALS	O
AND	O
METHODS	O
:	O
Formalin-fixed	O
paraffin	O
sections	O
were	O
used	O
for	O
immunostaining	O
of	O
Bcl-6	B-protein
.	O

Six	O
cases	O
of	O
AITL/GC	O
,	O
12	O
nonspecific	O
reactive	O
follicular	O
hyperplasia	O
(	O
FH	O
)	O
,	O
7	O
HIV	O
adenopathy	O
,	O
10	O
follicular	O
lymphoma	O
(	O
FL	O
)	O
,	O
and	O
8	O
typical	O
AITL	O
(	O
ie	O
,	O
AITL	O
without	O
GC	O
)	O
were	O
studied	O
.	O

Double	O
staining	O
for	O
Bcl-6/CD20	B-protein
,	O
Bcl-6/CD3	B-protein
,	O
and	O
Bcl-6/CD57	B-protein
was	O
performed	O
in	O
selected	O
cases	O
.	O

RESULTS	O
:	O
In	O
FH	O
and	O
HIV	O
adenopathy	O
,	O
staining	O
for	O
Bcl-6	B-protein
revealed	O
densely	O
populated	O
GCs	O
with	O
well-defined	O
and	O
regular	O
GC	O
borders	O
,	O
whereas	O
Bcl-6+	B-cell_type
cells	I-cell_type
were	O
rare	O
in	O
the	O
interfollicular	O
areas	O
.	O

An	O
occasional	O
GC	O
with	O
an	O
ill-defined	O
border	O
was	O
invariably	O
surrounded	O
by	O
a	O
broad	O
mantle	O
zone	O
;	O
those	O
with	O
indistinct	O
mantle	O
zones	O
had	O
well-defined	O
,	O
regular	O
borders	O
.	O

In	O
FL	O
,	O
follicles	O
were	O
densely	O
populated	O
,	O
and	O
their	O
borders	O
were	O
irregular	O
,	O
with	O
some	O
Bcl-6+	B-cell_type
cells	I-cell_type
in	O
the	O
interfollicular	O
zones	O
.	O

In	O
AITL/GC	O
,	O
GCs	O
were	O
less	O
dense	O
,	O
GC	O
borders	O
were	O
ill	O
defined	O
and	O
irregular	O
,	O
and	O
the	O
number	O
of	O
interfollicular	B-cell_type
Bcl-6+	I-cell_type
cells	I-cell_type
was	O
markedly	O
increased	O
.	O

Double	O
staining	O
revealed	O
that	O
these	O
interfollicular	B-cell_type
Bcl-6+	I-cell_type
cells	I-cell_type
in	O
AITL/GC	O
were	O
Bcl6+/CD3+/CD20-/CD57-	B-cell_type
T	I-cell_type
cells	I-cell_type
.	O

Moreover	O
,	O
CD3+	B-cell_type
intrafollicular	I-cell_type
T	I-cell_type
cells	I-cell_type
were	O
depleted	O
in	O
AITL/GC	O
,	O
whereas	O
they	O
were	O
abundant	O
in	O
FH	O
.	O

Intrafollicular	O
CD57+	B-cell_type
cells	I-cell_type
did	O
not	O
stain	O
for	O
Bcl-6	B-protein
,	O
and	O
were	O
also	O
depleted	O
in	O
AITL/GC	O
.	O

In	O
typical	O
AITL	O
,	O
some	O
neoplastic	O
cells	O
were	O
positive	O
for	O
Bcl-6	B-protein
,	O
showing	O
variable	O
degrees	O
of	O
staining	O
.	O

CONCLUSIONS	O
:	O
(	O
1	O
)	O
GCs	O
of	O
AITL/GC	O
differed	O
from	O
those	O
of	O
other	O
reactive	O
follicular	O
hyperplasias	O
and	O
follicular	O
lymphomas	O
,	O
and	O
staining	O
for	O
Bcl-6	B-protein
was	O
useful	O
to	O
discern	O
them	O
.	O

(	O
2	O
)	O
Intrafollicular	B-cell_type
CD3+	I-cell_type
T	I-cell_type
cells	I-cell_type
,	O
many	O
of	O
which	O
were	O
also	O
positive	O
for	O
Bcl-6	B-protein
,	O
were	O
markedly	O
depleted	O
in	O
AITL/GC	O
,	O
with	O
increased	O
interfollicular	O
Bcl-6+/CD3+	B-cell_type
cells	I-cell_type
,	O
suggesting	O
an	O
outward	O
migration	O
of	O
intrafollicular	B-cell_type
T	I-cell_type
cells	I-cell_type
in	O
this	O
condition	O
.	O

(	O
3	O
)	O
Interfollicular	B-cell_type
Bcl-6+/CD3+	I-cell_type
cells	I-cell_type
in	O
AITL/GC	O
were	O
too	O
numerous	O
to	O
be	O
accounted	O
for	O
by	O
migration	O
alone	O
,	O
suggesting	O
local	O
proliferation	O
.	O

(	O
4	O
)	O
Intrafollicular	B-cell_type
CD57+	I-cell_type
cells	I-cell_type
were	O
negative	O
for	O
Bcl-6	B-protein
,	O
indicating	O
heterogeneity	O
of	O
the	O
intrafollicular	B-cell_type
T-cell	I-cell_type
population	I-cell_type
.	O

(	O
5	O
)	O
Some	O
neoplastic	O
cells	O
in	O
AITL	O
stained	O
for	O
Bcl-6	B-protein
,	O
suggesting	O
up-regulation	O
of	O
Bcl-6	B-protein
expression	O
in	O
this	O
tumor	O
.	O

Human	O
cytomegalovirus	O
binding	O
to	O
human	B-cell_type
monocytes	I-cell_type
induces	O
immunoregulatory	O
gene	O
expression	O
.	O

To	O
continue	O
our	O
investigation	O
of	O
the	O
cellular	O
events	O
that	O
occur	O
following	O
human	O
CMV	O
(	O
HCMV	O
)	O
infection	O
,	O
we	O
focused	O
on	O
the	O
regulation	O
of	O
cellular	O
activation	O
following	O
viral	O
binding	O
to	O
human	B-cell_type
monocytes	I-cell_type
.	O

First	O
,	O
we	O
showed	O
that	O
viral	O
binding	O
induced	O
a	O
number	O
of	O
immunoregulatory	B-cell_type
genes	I-cell_type
(	O
IL-1beta	B-protein
,	O
A20	B-protein
,	O
NF-kappaB-p105/p50	B-protein
,	O
and	O
IkappaBalpha	B-protein
)	O
in	O
unactivated	O
monocytes	B-cell_type
and	O
that	O
neutralizing	B-protein
Abs	I-protein
to	O
the	O
major	O
HCMV	B-protein
glycoproteins	I-protein
,	O
gB	B-protein
(	O
UL55	B-protein
)	O
and	O
gH	B-protein
(	O
UL75	B-protein
)	O
,	O
inhibited	O
the	O
induction	O
of	O
these	O
genes	O
.	O

Next	O
,	O
we	O
demonstrated	O
that	O
these	O
viral	O
ligands	O
directly	O
up-regulated	O
monocyte	O
gene	O
expression	O
upon	O
their	O
binding	O
to	O
their	O
appropriate	O
cellular	O
receptors	O
.	O

We	O
then	O
investigated	O
if	O
HCMV	O
binding	O
also	O
resulted	O
in	O
the	O
translation	O
and	O
secretion	O
of	O
cytokines	B-protein
.	O

Our	O
results	O
showed	O
that	O
HCMV	O
binding	O
to	O
monocytes	B-cell_type
resulted	O
in	O
the	O
production	O
and	O
release	O
of	O
IL-1beta	B-protein
protein	I-protein
.	O

Because	O
these	O
induced	O
gene	O
products	O
have	O
NF-kappaB	B-DNA
sites	I-DNA
in	O
their	O
promoter	B-DNA
regions	I-DNA
,	O
we	O
next	O
examined	O
whether	O
there	O
was	O
an	O
up-regulation	O
of	O
nuclear	O
NF-kappaB	B-protein
levels	O
.	O

These	O
experiments	O
showed	O
that	O
,	O
in	O
fact	O
,	O
NF-kappaB	B-protein
was	O
translocated	O
to	O
the	O
nucleus	O
following	O
viral	O
binding	O
or	O
purified	O
viral	O
ligand	O
binding	O
.	O

Changes	O
in	O
IkappaBalpha	B-protein
levels	O
correlated	O
with	O
the	O
changes	O
in	O
NF-kappaB	B-protein
translocation	O
.	O

Lastly	O
,	O
we	O
demonstrated	O
that	O
p38	B-protein
kinase	O
activity	O
played	O
a	O
central	O
role	O
in	O
IL-1beta	B-protein
production	O
and	O
that	O
it	O
was	O
rapidly	O
up-regulated	O
following	O
infection	O
.	O

These	O
results	O
support	O
our	O
hypothesis	O
that	O
HCMV	O
initiates	O
a	O
signal	O
transduction	O
pathway	O
that	O
leads	O
to	O
monocyte	O
activation	O
and	O
pinpoints	O
a	O
potential	O
mechanism	O
whereby	O
HCMV	O
infection	O
of	O
monocytes	B-cell_type
can	O
result	O
in	O
profound	O
pathogenesis	O
,	O
especially	O
in	O
chronic	O
inflammatory-type	O
conditions	O
.	O

Regulation	O
of	O
the	O
megakaryocytic	B-DNA
glycoprotein	I-DNA
IX	I-DNA
promoter	I-DNA
by	O
the	O
oncogenic	B-protein
Ets	I-protein
transcription	I-protein
factor	I-protein
Fli-1	B-protein
.	O

Glycoprotein	B-protein
(	I-protein
GP	I-protein
)	I-protein
IX	I-protein
is	O
a	O
subunit	O
of	O
the	O
von	B-protein
Willebrand	I-protein
receptor	I-protein
,	O
GPIb-V-IX	B-protein
,	O
which	O
mediates	O
adhesion	O
of	O
platelets	B-cell_type
to	O
the	O
subendothelium	O
of	O
damaged	O
blood	O
vessels	O
.	O

Previous	O
characterization	O
of	O
the	O
GPIX	B-DNA
promoter	I-DNA
identified	O
a	O
functional	O
Ets	O
site	O
that	O
,	O
when	O
disrupted	O
,	O
reduced	O
promoter	O
activity	O
.	O

However	O
,	O
the	O
Ets	B-protein
protein	I-protein
(	O
s	O
)	O
that	O
regulated	O
GPIX	B-DNA
promoter	I-DNA
expression	O
was	O
unknown	O
.	O

In	O
this	O
study	O
,	O
transient	O
cotransfection	O
of	O
several	O
GPIX	B-DNA
promoter/reporter	I-DNA
constructs	I-DNA
into	O
293T	B-cell_line
kidney	I-cell_line
fibroblasts	I-cell_line
with	O
a	O
Fli-1	B-DNA
expression	I-DNA
vector	I-DNA
shows	O
that	O
the	O
oncogenic	O
protein	O
Fli-1	B-protein
can	O
transactivate	O
the	O
GPIX	B-DNA
promoter	I-DNA
when	O
an	O
intact	O
GPIX	B-DNA
Ets	I-DNA
site	I-DNA
is	O
present	O
.	O

In	O
addition	O
,	O
Fli-1	B-protein
binding	O
of	O
the	O
GPIX	B-DNA
Ets	I-DNA
site	I-DNA
was	O
identified	O
in	O
antibody	O
supershift	O
experiments	O
in	O
nuclear	O
extracts	O
derived	O
from	O
hematopoietic	B-cell_type
human	I-cell_type
erythroleukemia	I-cell_type
cells	I-cell_type
.	O

Comparative	O
studies	O
showed	O
that	O
Fli-1	B-protein
was	O
also	O
able	O
to	O
transactivate	O
the	O
GPIbalpha	B-DNA
and	O
,	O
to	O
a	O
lesser	O
extent	O
,	O
the	O
GPIIb	B-DNA
promoter	I-DNA
.	O

Immunoblot	O
analysis	O
identified	O
Fli-1	B-protein
protein	I-protein
in	O
lysates	O
derived	O
from	O
platelets	B-cell_type
.	O

In	O
addition	O
,	O
expression	O
of	O
Fli-1	B-protein
was	O
identified	O
immunohistochemically	O
in	O
megakaryocytes	B-cell_type
derived	O
from	O
CD34	B-cell_type
(	I-cell_type
+	I-cell_type
)	I-cell_type
cells	I-cell_type
treated	O
with	O
the	O
megakaryocyte	B-protein
differentiation	I-protein
and	I-protein
proliferation	I-protein
factor	I-protein
,	O
thrombopoietin	B-protein
.	O

These	O
results	O
suggest	O
that	O
Fli-1	B-protein
is	O
likely	O
to	O
regulate	O
lineage-specific	B-DNA
genes	I-DNA
during	O
megakaryocytopoiesis	O
.	O

Expression	O
of	O
IkappaBalpha	B-protein
in	O
the	O
nucleus	O
of	O
human	B-cell_type
peripheral	I-cell_type
blood	I-cell_type
T	I-cell_type
lymphocytes	I-cell_type
.	O

According	O
to	O
current	O
models	O
the	O
inhibitory	O
capacity	O
of	O
I	B-protein
(	I-protein
kappa	I-protein
)	I-protein
B	I-protein
(	I-protein
alpha	I-protein
)	I-protein
would	O
be	O
mediated	O
through	O
the	O
retention	O
of	O
Rel/NF-kappaB	B-protein
proteins	I-protein
in	O
the	O
cytosol	B-cell_type
.	O

However	O
,	O
I	B-protein
(	I-protein
kappa	I-protein
)	I-protein
B	I-protein
(	I-protein
alpha	I-protein
)	I-protein
has	O
also	O
been	O
detected	O
in	O
the	O
nucleus	O
of	O
cell	O
lines	O
and	O
when	O
overexpressed	O
by	O
transient	O
transfection	O
.	O

To	O
gain	O
better	O
insight	O
into	O
the	O
potential	O
role	O
of	O
nuclear	B-protein
I	I-protein
(	I-protein
kappa	I-protein
)	I-protein
B	I-protein
(	I-protein
alpha	I-protein
)	I-protein
in	O
a	O
physiological	O
context	O
we	O
have	O
analysed	O
its	O
presence	O
in	O
the	O
nucleus	O
of	O
human	B-cell_type
peripheral	I-cell_type
blood	I-cell_type
T	I-cell_type
lymphocytes	I-cell_type
(	O
PBL	B-cell_type
)	O
.	O

We	O
demonstrate	O
the	O
nuclear	O
localization	O
of	O
I	B-protein
(	I-protein
kappa	I-protein
)	I-protein
B	I-protein
(	I-protein
alpha	I-protein
)	I-protein
in	O
PBL	B-cell_type
by	O
different	O
techniques	O
:	O
Western	O
blot	O
,	O
indirect	O
immunofluorescence	O
and	O
electron	O
microscopy	O
.	O

Low	O
levels	O
of	O
nuclear	O
I	B-protein
(	I-protein
kappa	I-protein
)	I-protein
B	I-protein
(	I-protein
alpha	I-protein
)	I-protein
were	O
detected	O
in	O
resting	O
cells	O
whereas	O
a	O
superinduction	O
was	O
obtained	O
after	O
PMA	O
activation	O
.	O

The	O
nuclear	O
pool	O
of	O
I	B-protein
(	I-protein
kappa	I-protein
)	I-protein
B	I-protein
(	I-protein
alpha	I-protein
)	I-protein
showed	O
a	O
higher	O
stability	O
than	O
cytosolic	O
I	B-protein
(	I-protein
kappa	I-protein
)	I-protein
B	I-protein
(	I-protein
alpha	I-protein
)	I-protein
and	O
was	O
partially	O
independent	O
of	O
the	O
resynthesis	O
of	O
the	O
protein	O
.	O

Unexpectedly	O
,	O
the	O
presence	O
of	O
nuclear	B-protein
I	I-protein
(	I-protein
kappa	I-protein
)	I-protein
B	I-protein
(	I-protein
alpha	I-protein
)	I-protein
did	O
not	O
inhibit	O
NF-kappaB	B-protein
binding	O
to	O
DNA	O
and	O
this	O
phenomenon	O
was	O
not	O
due	O
to	O
the	O
presence	O
of	O
IkappaBbeta	B-protein
at	O
the	O
nuclear	O
level	O
.	O

Immunoprecipitation	O
experiments	O
failed	O
to	O
demonstrate	O
an	O
association	O
between	O
nuclear	O
I	B-protein
(	I-protein
kappa	I-protein
)	I-protein
B	I-protein
(	I-protein
alpha	I-protein
)	I-protein
and	O
NF-kappaB	B-protein
proteins	O
.	O

Our	O
results	O
demonstrate	O
that	O
in	O
resting	O
and	O
PMA-activated	B-cell_type
human	I-cell_type
PBL	I-cell_type
,	O
I	B-protein
(	I-protein
kappa	I-protein
)	I-protein
B	I-protein
(	I-protein
alpha	I-protein
)	I-protein
is	O
present	O
in	O
the	O
nucleus	O
in	O
an	O
apparently	O
inactive	O
form	O
unable	O
to	O
disrupt	O
NF-kappaB	B-protein
binding	O
from	O
DNA	O
.	O

Impaired	O
fetal	B-cell_type
thymocyte	I-cell_type
development	O
after	O
efficient	O
adenovirus-mediated	O
inhibition	O
of	O
NF-kappa	B-protein
B	I-protein
activation	O
.	O

We	O
introduce	O
a	O
new	O
experimental	O
system	O
combining	O
adenovirus-mediated	O
gene	O
transfer	O
and	O
fetal	O
thymic	O
organ	O
culture	O
(	O
FTOC	O
)	O
.	O

This	O
system	O
allowed	O
us	O
to	O
efficiently	O
express	O
in	O
developing	O
thymocytes	O
a	O
mutant	O
form	O
of	O
the	O
NF-kappa	B-protein
B	I-protein
inhibitor	O
I	B-protein
kappa	I-protein
B	I-protein
alpha	I-protein
(	O
mut-I	B-protein
kappa	I-protein
B	I-protein
)	O
and	O
to	O
study	O
the	O
maturation	O
defects	O
occurring	O
when	O
NF-kappa	B-protein
B	I-protein
activation	O
is	O
inhibited	O
during	O
fetal	O
development	O
.	O

Fetal	B-cell_type
thymocytes	I-cell_type
infected	O
with	O
adenovirus	O
containing	O
mut-I	B-protein
kappa	I-protein
B	I-protein
were	O
found	O
to	O
develop	O
normally	O
until	O
the	O
CD44	B-protein
-CD25+	O
,	O
CD4	B-protein
-	O
CD8	B-protein
-	O
double-negative	O
stage	O
,	O
while	O
production	O
of	O
more	O
mature	O
double-positive	O
and	O
single-positive	O
populations	O
was	O
strongly	O
decreased	O
.	O

Proliferation	O
,	O
as	O
measured	O
by	O
the	O
percentage	O
of	O
cells	O
in	O
cycle	O
appeared	O
normal	O
,	O
as	O
did	O
rearrangement	O
and	O
expression	O
of	O
the	O
TCR	B-protein
beta-chain	I-protein
.	O

However	O
,	O
apoptosis	O
was	O
much	O
higher	O
in	O
FTOC	O
infected	O
with	O
adenovirus	O
containing	O
mut-I	B-protein
kappa	I-protein
B	I-protein
than	O
in	O
FTOC	O
infected	O
with	O
a	O
control	O
virus	O
.	O

Taken	O
together	O
,	O
these	O
results	O
suggest	O
that	O
NF-kappa	B-protein
B	I-protein
plays	O
a	O
crucial	O
role	O
in	O
ensuring	O
the	O
differentiation	O
and	O
survival	O
of	O
thymocytes	B-cell_type
in	O
the	O
early	O
stages	O
of	O
their	O
development	O
.	O

The	O
relationship	O
between	O
Ca2+-ATPase	B-protein
and	O
freely	O
exchangeable	O
Ca2+	O
in	O
the	O
dense	O
tubules	O
:	O
a	O
study	O
in	O
platelets	B-cell_type
from	O
women	O
.	O

The	O
main	O
aims	O
of	O
this	O
work	O
were	O
to	O
examine	O
in	O
women	O
:	O
the	O
relationship	O
between	O
the	O
freely	O
exchangeable	O
Ca2+	O
(	O
FECa2+	O
)	O
in	O
the	O
dense	O
tubules	O
and	O
the	O
activity	O
of	O
the	O
sarco	B-protein
(	I-protein
endo	I-protein
)	I-protein
plasmic	I-protein
reticulum	I-protein
(	I-protein
SER	I-protein
)	I-protein
Ca2+-ATPase	I-protein
(	I-protein
SERCA	I-protein
)	I-protein
in	O
platelets	B-cell_type
,	O
and	O
the	O
relationship	O
of	O
these	O
parameters	O
with	O
blood	O
pressure	O
and	O
serum	B-protein
lipoproteins	I-protein
.	O

Platelets	O
from	O
14	O
white	O
and	O
13	O
black	O
women	O
in	O
good	O
health	O
were	O
studied	O
.	O

The	O
FECa2+	O
was	O
measured	O
as	O
the	O
ionomycin-evoked	O
Ca2+	O
release	O
(	O
in	O
the	O
presence	O
of	O
thapsigargin	O
)	O
in	O
Ca2+-free	O
medium	O
.	O

SERCA	B-protein
activity	O
was	O
measured	O
as	O
the	O
thapsigargin	O
sensitive	O
,	O
Ca2+	O
dependent	O
and	O
ouabain	O
resistant	O
,	O
ATP	O
hydrolyses	O
in	O
platelet	O
membranes	O
.	O

Relative	O
expressions	O
of	O
SERCA	B-protein
2	O
and	O
3	O
isoforms	O
and	O
Ras-related	B-protein
protein	I-protein
(	I-protein
Rap	I-protein
)	I-protein
1	I-protein
in	O
platelet	O
membranes	O
were	O
determined	O
by	O
Western	O
immunoblots	O
.	O

Highly	O
significant	O
correlations	O
were	O
observed	O
for	O
FECa2+	O
in	O
the	O
dense	O
tubules	O
with	O
:	O
1	O
)	O
the	O
maximal	O
reaction	O
velocity	O
(	O
Vmax	O
)	O
of	O
the	O
SERCA	B-protein
(	O
r	O
=	O
0.592	O
,	O
P	O
=	O
.0014	O
)	O
,	O
and	O
2	O
)	O
Rapl	B-protein
(	O
r	O
=	O
0.551	O
,	O
P	O
=	O
.0035	O
)	O
.	O

In	O
addition	O
,	O
negative	O
correlations	O
were	O
observed	O
between	O
FECa2+	O
in	O
the	O
dense	O
tubules	O
and	O
age	O
.	O

No	O
correlations	O
were	O
observed	O
for	O
these	O
variables	O
with	O
blood	O
pressure	O
or	O
serum	B-protein
lipoproteins	I-protein
.	O

We	O
conclude	O
the	O
FECa2+	O
and	O
the	O
Vmax	O
of	O
the	O
SERCA	B-protein
are	O
reliable	O
indicators	O
of	O
Ca2+	O
load	O
in	O
platelets	B-cell_type
from	O
women	O
.	O

However	O
,	O
in	O
women	O
,	O
unlike	O
previous	O
observations	O
in	O
men	O
,	O
these	O
platelet	O
parameters	O
are	O
not	O
correlated	O
with	O
blood	O
pressure	O
and	O
serum	B-protein
lipoproteins	I-protein
.	O

Cobalt	O
chloride-induced	O
signaling	O
in	O
endothelium	O
leading	O
to	O
the	O
augmented	O
adherence	O
of	O
sickle	B-cell_type
red	I-cell_type
blood	I-cell_type
cells	I-cell_type
and	O
transendothelial	O
migration	O
of	O
monocyte-like	B-cell_line
HL-60	I-cell_line
cells	I-cell_line
is	O
blocked	O
by	O
PAF-receptor	O
antagonist	O
.	O

In	O
response	O
to	O
hypoxia	O
,	O
sickle	B-cell_type
red	I-cell_type
blood	I-cell_type
cells	I-cell_type
(	O
SS	B-cell_type
RBC	I-cell_type
)	O
and	O
leukocytes	B-cell_type
exhibit	O
increased	O
adherence	O
to	O
the	O
vascular	O
endothelium	O
,	O
while	O
diapedesis	O
of	O
leukocytes	B-cell_type
through	O
the	O
blood	O
vessel	O
increases	O
.	O

However	O
,	O
the	O
cellular	O
signaling	O
pathway	O
(	O
s	O
)	O
caused	O
by	O
hypoxia	O
is	O
poorly	O
understood	O
.	O

We	O
utilized	O
CoCl2	O
as	O
a	O
mimetic	O
molecule	O
for	O
hypoxia	O
to	O
study	O
cellular	O
signaling	O
pathways	O
.	O

We	O
found	O
that	O
in	O
human	B-cell_type
umbilical	I-cell_type
vein	I-cell_type
endothelial	I-cell_type
cells	I-cell_type
(	O
HUVEC	B-cell_type
)	O
,	O
CoCl2	O
at	O
2	O
mM	O
concentration	O
induced	O
the	O
surface	O
expression	O
of	O
a	O
subset	O
of	O
CAMs	B-protein
(	O
VCAM-1	B-protein
)	O
and	O
activation	O
of	O
transcription	B-protein
factor	I-protein
NF-kappaB	B-protein
in	O
the	O
nuclear	O
extracts	O
of	O
HUVEC	B-cell_type
.	O

Furthermore	O
,	O
CoCl2	O
also	O
caused	O
time-dependent	O
tyrosine	O
phosphorylation	O
of	O
mitogen-activated	B-protein
protein	I-protein
(	I-protein
MAP	I-protein
)	I-protein
kinase	I-protein
isoform	O
ERK2	B-protein
without	O
significantly	O
affecting	O
ERK1	B-protein
,	O
indicating	O
ERK2	B-protein
is	O
the	O
preferred	O
substrate	O
for	O
upstream	B-protein
kinase	I-protein
of	O
the	O
MAPK	B-protein
pathway	O
.	O

Inhibitors	O
of	O
MAP	B-protein
kinase	I-protein
(	O
PD98059	O
)	O
or	O
platelet-activating	O
factor	O
(	O
PAF	O
)	O
-	O
receptor	O
antagonist	O
(	O
CV3988	O
)	O
inhibited	O
the	O
CoCl2-induced	O
NF-kappaB	B-protein
activation	O
and	O
VCAM-1	B-protein
expression	O
.	O

Augmented	O
expression	O
of	O
VCAM-1	B-protein
led	O
to	O
increased	O
SS	B-cell_type
RBC	I-cell_type
adhesion	O
,	O
inhibitable	O
by	O
a	O
VCAM-1	B-protein
antibody	I-protein
.	O

Additionally	O
,	O
CoCl2	O
caused	O
a	O
two-	O
to	O
threefold	O
increase	O
in	O
the	O
rate	O
of	O
transendothelial	O
migration	O
of	O
monocyte-like	B-cell_line
HL-60	I-cell_line
cells	I-cell_line
and	O
a	O
twentyfold	O
increase	O
in	O
phosphorylation	O
of	O
platelet	B-protein
endothelial	I-protein
cell	I-protein
adhesion	I-protein
molecules	I-protein
(	O
PECAM-1	B-protein
)	O
.	O

The	O
transendothelial	O
migration	O
of	O
monocytes	B-cell_type
was	O
inhibited	O
by	O
an	O
antibody	O
to	O
PECAM-1	B-protein
.	O

Both	O
phosphorylation	O
of	O
PECAM-1	B-protein
and	O
transendothelial	O
migration	O
of	O
monocytes	B-cell_type
in	O
response	O
to	O
CoCl2	O
were	O
inhibited	O
by	O
protein	O
kinase	O
inhibitor	O
(	O
GF109203X	O
)	O
and	O
augmented	O
by	O
protein	O
phosphatase	O
inhibitor	O
(	O
Calyculin	O
A	O
)	O
.	O

Our	O
data	O
suggests	O
that	O
CoCl2-induced	O
cellular	O
signals	O
directing	O
increased	O
expression	O
of	O
VCAM-1	B-protein
in	O
HUVEC	B-cell_type
involve	O
downstream	O
activation	O
of	O
MAP	B-protein
kinase	I-protein
and	O
NF-kappaB	B-protein
,	O
while	O
the	O
phosphorylation	O
of	O
PECAM-1	B-protein
occurs	O
as	O
a	O
result	O
of	O
activation	O
of	O
PKC	B-protein
.	O

We	O
conclude	O
that	O
PAF-receptor	O
antagonist	O
inhibits	O
the	O
CoCl2	O
-or	O
hypoxia-induced	O
increase	O
in	O
the	O
adhesion	O
of	O
SS	B-cell_type
RBC	I-cell_type
,	O
PECAM-1	B-protein
phosphorylation	O
,	O
and	O
the	O
concomitant	O
transendothelial	O
migration	O
of	O
monocytes	B-cell_type
.	O

Bacterial	O
lipopolysaccharide	O
activates	O
nuclear	B-protein
factor-kappaB	I-protein
through	O
interleukin-1	B-protein
signaling	I-protein
mediators	I-protein
in	O
cultured	B-cell_line
human	I-cell_line
dermal	I-cell_line
endothelial	I-cell_line
cells	I-cell_line
and	O
mononuclear	B-cell_type
phagocytes	I-cell_type
.	O

Bacterial	O
lipopolysaccharide	O
(	O
LPS	O
)	O
-mediated	O
immune	O
responses	O
,	O
including	O
activation	O
of	O
monocytes	B-cell_type
,	O
macrophages	B-cell_type
,	O
and	O
endothelial	B-cell_type
cells	I-cell_type
,	O
play	O
an	O
important	O
role	O
in	O
the	O
pathogenesis	O
of	O
Gram-negative	O
bacteria-induced	O
sepsis	O
syndrome	O
.	O

Activation	O
of	O
NF-kappaB	B-protein
is	O
thought	O
to	O
be	O
required	O
for	O
cytokine	O
release	O
from	O
LPS-responsive	B-cell_type
cells	I-cell_type
,	O
a	O
critical	O
step	O
for	O
endotoxic	O
effects	O
.	O

Here	O
we	O
investigated	O
the	O
role	O
and	O
involvement	O
of	O
interleukin-1	B-protein
(	O
IL-1	B-protein
)	O
and	O
tumor	B-protein
necrosis	I-protein
factor	I-protein
(	O
TNF-alpha	B-protein
)	O
signal	B-protein
transducer	I-protein
molecules	I-protein
in	O
LPS	O
signaling	O
in	O
human	B-cell_type
dermal	I-cell_type
microvessel	I-cell_type
endothelial	I-cell_type
cells	I-cell_type
(	O
HDMEC	B-cell_type
)	O
and	O
THP-1	B-cell_line
monocytic	I-cell_line
cells	I-cell_line
.	O

LPS	O
stimulation	O
of	O
HDMEC	B-cell_type
and	O
THP-1	B-cell_line
cells	I-cell_line
initiated	O
an	O
IL-1	B-protein
receptor	I-protein
-like	O
NF-kappaB	B-protein
signaling	O
cascade	O
.	O

In	O
transient	O
cotransfection	O
experiments	O
,	O
dominant	O
negative	O
mutants	O
of	O
the	O
IL-1	B-protein
signaling	O
pathway	O
,	O
including	O
MyD88	B-protein
,	O
IRAK	B-protein
,	O
IRAK2	B-protein
,	O
and	O
TRAF6	B-protein
inhibited	O
both	O
IL-1	B-protein
-and	O
LPS-induced	O
NF-kappaB	B-protein
-luciferase	B-protein
activity	O
.	O

LPS-induced	O
NF-kappaB	B-protein
activation	O
was	O
not	O
inhibited	O
by	O
a	O
dominant	O
negative	O
mutant	O
of	O
TRAF2	B-protein
that	O
is	O
involved	O
in	O
TNF	B-protein
signaling	O
.	O

LPS-induced	O
activation	O
of	O
NF-kappaB-responsive	B-DNA
reporter	I-DNA
gene	I-DNA
was	O
not	O
inhibited	O
by	O
IL-1	B-protein
receptor	O
antagonist	O
.	O

TLR2	B-protein
and	O
TLR4	B-protein
were	O
expressed	O
on	O
the	O
cell	O
surface	O
of	O
HDMEC	B-cell_type
and	O
THP-1	B-cell_line
cells	I-cell_line
.	O

These	O
findings	O
suggest	O
that	O
a	O
signal	B-protein
transduction	I-protein
molecule	I-protein
in	O
the	O
LPS	O
receptor	O
complex	O
may	O
belong	O
to	O
the	O
IL-1	B-protein
receptor/toll-like	O
receptor	O
(	O
TLR	O
)	O
super	O
family	O
,	O
and	O
the	O
LPS	O
signaling	O
cascade	O
uses	O
an	O
analogous	O
molecular	O
framework	O
for	O
signaling	O
as	O
IL-1	B-protein
in	O
mononuclear	B-cell_type
phagocytes	I-cell_type
and	O
endothelial	B-cell_type
cells	I-cell_type
.	O

Signal	O
transduction	O
through	O
interferon-gamma	B-protein
receptor	I-protein
on	O
human	B-cell_type
eosinophils	I-cell_type
.	O

BACKGROUND	O
:	O
We	O
reported	O
on	O
the	O
constitutive	O
interferon-gamma	B-protein
receptor	I-protein
(	O
IFN-gammaR	B-protein
)	O
expression	O
on	O
eosinophils	B-cell_type
.	O

But	O
signal	O
transduction	O
through	O
IFN-gammaR	B-protein
on	O
eosinophils	B-cell_type
remains	O
to	O
be	O
elucidated	O
.	O

In	O
this	O
study	O
,	O
we	O
examined	O
the	O
involvement	O
of	O
the	O
Jak/Stat	B-protein
pathway	O
in	O
the	O
signaling	O
of	O
eosinophils	B-cell_type
after	O
IFN-gammaR	B-protein
conjugation	O
by	O
the	O
ligand	O
binding	O
.	O

METHODS	O
:	O
Purified	B-cell_type
peripheral	I-cell_type
eosinophils	I-cell_type
were	O
stimulated	O
with	O
IFN-gamma	B-protein
at	O
37	O
degrees	O
C	O
for	O
1-60	O
min	O
.	O

Tyrosine	O
phosphorylation	O
of	O
IFN-gammaR	B-protein
,	O
Jak1	B-protein
,	O
Jak2	B-protein
,	O
and	O
Stat1alpha	B-protein
was	O
examined	O
by	O
immunoblotting	O
.	O

Gel-shift	O
assay	O
was	O
also	O
examined	O
to	O
show	O
the	O
formation	O
of	O
Stat1alpha-DNA	B-protein
complexes	I-protein
.	O

RESULTS	O
:	O
We	O
show	O
that	O
binding	O
of	O
IFN-gamma	B-protein
to	O
human	B-cell_type
eosinophils	I-cell_type
initiated	O
a	O
series	O
of	O
events	O
that	O
resulted	O
in	O
the	O
rapid	O
tyrosine	O
phosphorylation	O
of	O
not	O
only	O
the	O
IFN-gammaRalpha	B-protein
chain	I-protein
but	O
also	O
Jak1	B-protein
,	O
Jak2	B-protein
,	O
and	O
Stat1alpha	B-protein
.	O

In	O
addition	O
,	O
IFN-gamma	B-protein
enhanced	O
the	O
DNA-binding	O
activity	O
of	O
Stat1alpha	B-protein
.	O

CONCLUSION	O
:	O
These	O
data	O
indicate	O
that	O
IFN-gamma	B-protein
affects	O
eosinophils	B-cell_type
through	O
its	O
specific	O
receptor	O
and	O
utilizes	O
the	O
Jak/Stat	B-protein
pathway	O
as	O
its	O
mode	O
of	O
signaling	O
.	O

Expression	O
of	O
E2A-HLF	B-protein
chimeric	I-protein
protein	I-protein
induced	O
T-cell	O
apoptosis	O
,	O
B-cell	O
maturation	O
arrest	O
,	O
and	O
development	O
of	O
acute	O
lymphoblastic	O
leukemia	O
.	O

The	O
E2A-HLF	B-DNA
fusion	I-DNA
gene	I-DNA
,	O
generated	O
by	O
t	B-DNA
(	I-DNA
17	I-DNA
;	I-DNA
19	I-DNA
)	I-DNA
(	I-DNA
q22	I-DNA
;	I-DNA
p13	I-DNA
)	I-DNA
in	O
acute	O
lymphoblastic	O
leukemia	O
(	O
ALL	O
)	O
,	O
encodes	O
a	O
chimeric	B-protein
transcription	I-protein
factor	I-protein
in	O
which	O
the	O
trans-activating	B-protein
domains	I-protein
of	O
E2A	B-protein
are	O
fused	O
to	O
the	O
DNA-	B-protein
binding	I-protein
and	I-protein
dimerization	I-protein
domains	I-protein
of	O
hepatic	B-protein
leukemic	I-protein
factor	I-protein
(	O
HLF	B-protein
)	O
.	O

To	O
investigate	O
its	O
biological	O
role	O
,	O
we	O
generated	O
transgenic	O
mice	O
expressing	O
E2A-HLF	B-protein
using	O
Ig	B-DNA
enhancer	I-DNA
and	I-DNA
promoter	I-DNA
,	O
which	O
direct	O
transgene	O
expression	O
in	O
cells	O
committed	O
to	O
the	O
lymphoid	O
lineage	O
.	O

The	O
transgenic	O
mice	O
exhibited	O
abnormal	O
development	O
in	O
the	O
thymus	O
and	O
spleen	O
and	O
were	O
susceptible	O
to	O
infection	O
.	O

The	O
thymus	O
contained	O
small	O
numbers	O
of	O
thymocytes	B-cell_type
,	O
and	O
TUNEL	O
staining	O
showed	O
that	O
higher	O
population	O
of	O
thymocytes	B-cell_type
were	O
undergoing	O
apoptosis	O
.	O

The	O
spleen	O
exhibited	O
a	O
marked	O
reduction	O
in	O
splenic	B-cell_type
lymphocytes	I-cell_type
and	O
the	O
flow	O
cytometric	O
analyses	O
and	O
the	O
in	O
vitro	O
colony	O
formation	O
assays	O
showed	O
that	O
the	O
B-cell	O
maturation	O
was	O
blocked	O
at	O
a	O
very	O
early	O
developmental	O
stage	O
.	O

These	O
findings	O
indicated	O
that	O
the	O
expression	O
of	O
E2A-HLF	B-protein
induced	O
T-cell	O
apoptosis	O
and	O
B-cell	O
maturation	O
arrest	O
in	O
vivo	O
and	O
that	O
the	O
susceptibility	O
of	O
the	O
transgenic	O
mice	O
to	O
infection	O
was	O
due	O
to	O
immunodeficiency	O
.	O

Moreover	O
,	O
several	O
transgenic	O
mice	O
developed	O
acute	O
leukemia	O
,	O
classified	O
as	O
T-ALL	O
based	O
on	O
the	O
surface	O
marker	O
analysis	O
and	O
DNA	O
rearrangements	O
,	O
suggesting	O
that	O
an	O
additional	O
event	O
is	O
required	O
for	O
malignant	O
transformation	O
of	O
lymphoid	B-cell_type
cells	I-cell_type
expressing	O
E2A-HLF	B-protein
.	O

Our	O
findings	O
provide	O
insight	O
into	O
the	O
biological	O
function	O
of	O
E2A-HLF	B-protein
in	O
lymphoid	O
development	O
and	O
also	O
its	O
role	O
in	O
leukemogenesis	O
.	O

Retinoid	B-protein
X	I-protein
receptor	I-protein
(	O
RXR	B-protein
)	O
agonist-induced	O
activation	O
of	O
dominant-negative	O
RXR	B-protein
-retinoic	O
acid	O
receptor	O
alpha403	O
heterodimers	O
is	O
developmentally	O
regulated	O
during	O
myeloid	O
differentiation	O
.	O

The	O
multiple	O
biologic	O
activities	O
of	O
retinoic	O
acid	O
(	O
RA	O
)	O
are	O
mediated	O
through	O
RAR	B-protein
and	O
retinoid	B-protein
X	I-protein
receptor	I-protein
(	I-protein
RXR	I-protein
)	I-protein
nuclear	I-protein
receptors	I-protein
that	O
interact	O
with	O
specific	O
DNA	B-DNA
target	I-DNA
sequences	I-DNA
as	O
heterodimers	B-protein
(	O
RXR-RAR	B-protein
)	O
or	O
homodimers	B-protein
(	O
RXR-RXR	B-protein
)	O
.	O

RA	O
receptor	O
activation	O
appears	O
critical	O
to	O
regulating	O
important	O
aspects	O
of	O
hematopoiesis	O
,	O
since	O
transducing	O
a	O
COOH-terminally	B-protein
truncated	I-protein
RARalpha	I-protein
exhibiting	O
dominant-negative	O
activity	O
(	O
RARalpha403	B-protein
)	O
into	O
normal	O
mouse	O
bone	O
marrow	O
generates	O
hematopoietic	B-cell_line
growth	I-cell_line
factor-dependent	I-cell_line
cell	I-cell_line
lines	I-cell_line
frozen	O
at	O
the	O
multipotent	O
progenitor	O
(	O
EML	O
)	O
or	O
committed	O
promyelocyte	O
(	O
MPRO	O
)	O
stages	O
.	O

Nevertheless	O
,	O
relatively	O
high	O
,	O
pharmacological	O
concentrations	O
of	O
RA	O
(	O
1	O
to	O
10	O
&	O
mgr	O
;	O
M	O
)	O
overcome	O
these	O
differentiation	O
blocks	O
and	O
induce	O
terminal	O
granulocytic	O
differentiation	O
of	O
the	O
MPRO	B-cell_type
promyelocytes	I-cell_type
while	O
potentiating	O
interleukin-3	B-protein
(	O
IL-3	B-protein
)	O
-induced	O
commitment	O
of	O
EML	B-cell_type
cells	I-cell_type
to	O
the	O
granulocyte/monocyte	O
lineage	O
.	O

In	O
the	O
present	O
study	O
,	O
we	O
utilized	O
RXR	B-protein
-and	O
RAR	B-protein
-specific	O
agonists	O
and	O
antagonists	O
to	O
determine	O
how	O
RA	O
overcomes	O
the	O
dominant-negative	O
activity	O
of	O
the	O
truncated	B-protein
RARalpha	I-protein
in	O
these	O
different	O
myeloid	O
developmental	O
stages	O
.	O

Unexpectedly	O
,	O
we	O
observed	O
that	O
an	O
RXR	B-protein
-specific	O
,	O
rather	O
than	O
an	O
RAR	B-protein
-specific	O
,	O
agonist	O
induces	O
terminal	O
granulocytic	O
differentiation	O
of	O
MPRO	B-cell_type
promyelocytes	I-cell_type
,	O
and	O
this	O
differentiation	O
is	O
associated	O
with	O
activation	O
of	O
DNA	B-DNA
response	I-DNA
elements	I-DNA
corresponding	O
to	O
RAR-RXR	B-protein
heterodimers	I-protein
rather	O
than	O
RXR-RXR	B-protein
homodimers	I-protein
.	O

This	O
RXR	B-protein
agonist	O
activity	O
is	O
blocked	O
by	O
RAR	B-protein
-specific	O
antagonists	O
,	O
suggesting	O
extensive	O
cross-talk	O
between	O
the	O
partners	O
of	O
the	O
RXR	B-protein
-RARalpha403	I-protein
heterodimer	I-protein
.	O

In	O
contrast	O
,	O
in	O
the	O
more	O
immature	O
,	O
multipotent	O
EML	B-cell_type
cells	I-cell_type
we	O
observed	O
that	O
this	O
RXR	B-protein
-specific	O
agonist	O
is	O
inactive	O
either	O
in	O
potentiating	O
IL-3	B-protein
-mediated	O
commitment	O
of	O
EML	B-cell_type
cells	I-cell_type
to	O
the	O
granulocyte	B-cell_type
lineage	I-cell_type
or	O
in	O
transactivating	O
RAR-RXR	B-DNA
response	I-DNA
elements	I-DNA
.	O

RA	O
-triggered	O
GALdbd-	O
RARalpha	B-protein
hybrid	O
activity	O
in	O
these	O
cells	O
indicates	O
that	O
the	O
multipotent	O
EML	B-cell_type
cells	I-cell_type
harbor	O
substantial	O
nuclear	O
hormone	O
receptor	O
coactivator	B-protein
activity	O
.	O

However	O
,	O
the	O
histone	B-protein
deacetylase	I-protein
(	I-protein
HDAC	I-protein
)	I-protein
inhibitor	I-protein
trichostatin	O
A	O
readily	O
activates	O
an	O
RXR-RAR	B-DNA
reporter	I-DNA
construct	I-DNA
in	O
the	O
multipotent	O
EML	B-cell_type
cells	I-cell_type
but	O
not	O
in	O
the	O
committed	O
MPRO	B-cell_type
promyelocytes	I-cell_type
,	O
indicating	O
that	O
differences	O
in	O
HDAC-containing	B-protein
repressor	I-protein
complexes	I-protein
in	O
these	O
two	O
closely	O
related	O
but	O
distinct	O
hematopoietic	B-cell_type
lineages	I-cell_type
might	O
account	O
for	O
the	O
differential	O
activation	O
of	O
the	O
RXR-RARalpha403	B-protein
heterodimers	I-protein
that	O
we	O
observed	O
at	O
these	O
different	O
stages	O
of	O
myeloid	O
development	O
.	O

The	O
functional	O
synergy	O
between	O
IL-12	B-protein
and	O
IL-2	B-protein
involves	O
p38	B-protein
mitogen-activated	I-protein
protein	I-protein
kinase	I-protein
and	O
is	O
associated	O
with	O
the	O
augmentation	O
of	O
STAT	O
serine	O
phosphorylation	O
.	O

IL-12	B-protein
and	O
IL-2	B-protein
can	O
stimulate	O
mitogen-	B-cell_type
or	I-cell_type
CD3-activated	I-cell_type
T	I-cell_type
cells	I-cell_type
to	O
proliferate	O
,	O
produce	O
IFN-gamma	B-protein
,	O
and	O
kill	O
tumor	B-cell_type
cells	I-cell_type
.	O

The	O
magnitude	O
of	O
these	O
functional	O
responses	O
is	O
greatly	O
augmented	O
when	O
T	B-cell_type
cells	I-cell_type
are	O
activated	O
by	O
the	O
combination	O
of	O
IL-12	B-protein
and	O
IL-2	B-protein
.	O

Although	O
peripheral	O
blood	O
T	B-cell_type
cells	I-cell_type
are	O
largely	O
unresponsive	O
to	O
these	O
cytokines	B-protein
without	O
prior	O
activation	O
,	O
a	O
small	O
subset	O
of	O
CD8+	B-cell_type
T	I-cell_type
cells	I-cell_type
(	O
CD8+CD18bright	B-cell_type
)	O
is	O
strongly	O
activated	O
by	O
the	O
combination	O
of	O
IL-12	B-protein
and	O
IL-2	B-protein
.	O

In	O
this	O
report	O
we	O
show	O
that	O
the	O
functional	O
synergy	O
between	O
IL-12	B-protein
and	O
IL-2	B-protein
in	O
CD8+CD18bright	B-cell_type
T	I-cell_type
cells	I-cell_type
correlates	O
with	O
the	O
activation	O
of	O
the	O
stress	B-protein
kinases	I-protein
,	O
p38	B-protein
mitogen-activated	I-protein
protein	I-protein
(	I-protein
MAP	I-protein
)	I-protein
kinase	I-protein
and	O
stress-activated	B-protein
protein	I-protein
kinase	I-protein
(	I-protein
SAPK	I-protein
)	I-protein
/Jun	I-protein
N-terminal	I-protein
kinase	I-protein
,	O
but	O
not	O
with	O
the	O
activation	O
of	O
the	O
extracellular	B-protein
signal-regulated	I-protein
kinases	I-protein
.	O

The	O
functional	O
synergy	O
between	O
IL-2	B-protein
and	O
IL-12	B-protein
is	O
also	O
associated	O
with	O
a	O
prominent	O
increase	O
in	O
STAT1	B-protein
and	O
STAT3	B-protein
serine	O
phosphorylation	O
over	O
that	O
observed	O
with	O
IL-12	B-protein
or	O
IL-2	B-protein
alone	O
.	O

By	O
contrast	O
,	O
STAT	B-protein
tyrosine	O
phosphorylation	O
is	O
not	O
augmented	O
over	O
that	O
seen	O
with	O
either	O
cytokine	O
alone	O
.	O

A	O
specific	O
inhibitor	O
of	O
p38	O
MAP	O
kinase	O
completely	O
inhibits	O
the	O
serine	O
phosphorylation	O
of	O
STAT1	B-protein
and	O
STAT3	B-protein
induced	O
by	O
IL-12	B-protein
and	O
IL-2	B-protein
and	O
abrogates	O
the	O
functional	O
synergy	O
between	O
IL-12	B-protein
and	O
IL-2	B-protein
without	O
affecting	O
STAT	O
tyrosine	O
phosphorylation	O
.	O

This	O
suggests	O
that	O
p38	O
MAP	O
kinase	O
may	O
play	O
an	O
important	O
role	O
in	O
regulating	O
STAT	O
serine	O
phosphorylation	O
in	O
response	O
to	O
the	O
combination	O
of	O
IL-12	B-protein
and	O
IL-2	B-protein
.	O

Furthermore	O
,	O
these	O
findings	O
indicate	O
that	O
the	O
optimal	O
activation	O
of	O
T	B-cell_type
cells	I-cell_type
by	O
IL-12	B-protein
and	O
IL-2	B-protein
may	O
depend	O
on	O
an	O
interaction	O
between	O
the	O
p38	B-protein
MAP	I-protein
kinase	I-protein
and	O
Janus	B-protein
kinase/STAT	I-protein
signaling	O
pathways	O
.	O

Activation	O
of	O
NF-kappaB	B-protein
in	O
Mycobacterium	O
tuberculosis	O
-induced	O
interleukin-2	B-protein
receptor	I-protein
expression	O
in	O
mononuclear	B-cell_type
phagocytes	I-cell_type
.	O

Soluble	O
interleukin-2	B-protein
receptor-alpha	I-protein
(	O
IL-2Ralpha	B-protein
)	O
has	O
been	O
reported	O
to	O
be	O
increased	O
in	O
the	O
sera	O
of	O
patients	O
with	O
advanced	O
tuberculosis	O
,	O
and	O
levels	O
decline	O
after	O
therapy	O
in	O
accordance	O
with	O
improvement	O
of	O
radiologic	O
findings	O
.	O

We	O
investigated	O
expression	O
of	O
the	O
IL-2Ralpha	B-protein
in	O
bronchoalveolar	B-cell_type
lavage	I-cell_type
(	I-cell_type
BAL	I-cell_type
)	I-cell_type
cells	I-cell_type
in	O
active	O
pulmonary	O
tuberculosis	O
,	O
and	O
evaluated	O
the	O
mechanism	O
Mycobacterium	O
tuberculosis	O
induces	O
in	O
the	O
IL-2Ralpha	B-protein
using	O
the	O
THP-1	B-cell_line
mononuclear	I-cell_line
phagocyte	I-cell_line
cell	I-cell_line
line	I-cell_line
.	O

We	O
found	O
IL-2Ralpha	B-protein
expression	O
to	O
be	O
increased	O
in	O
BAL	O
cells	O
from	O
involved	O
sites	O
of	O
active	O
pulmonary	O
tuberculosis	O
.	O

Expression	O
of	O
the	O
alpha-chain	B-protein
of	O
IL-2Ralpha	B-protein
on	O
peripheral	B-cell_type
blood	I-cell_type
monocytes	I-cell_type
(	O
PBM	B-cell_type
)	O
was	O
induced	O
by	O
M.	O
tuberculosis	O
by	O
flow	O
cytometry	O
evaluation	O
.	O

Northern	O
analysis	O
demonstrated	O
increased	O
IL-2Ralpha	B-protein
gene	O
expression	O
after	O
stimulation	O
with	O
M.	O
tuberculosis	O
which	O
was	O
further	O
induced	O
by	O
interferon-gamma	B-protein
(	O
IFN-gamma	B-protein
)	O
.	O

The	O
IL-2Ralpha	B-DNA
promoter	I-DNA
containing	O
the	O
nuclear	B-DNA
factor	I-DNA
kappa	I-DNA
B	I-DNA
(	I-DNA
NF-kappaB	I-DNA
)	I-DNA
site	I-DNA
was	O
transcriptionally	O
induced	O
by	O
M.	O
tuberculosis	O
and	O
this	O
NF-kappaB	B-protein
site	O
could	O
confer	O
inducibility	O
to	O
a	O
heterologous	B-DNA
herpes	I-DNA
thymidine	I-DNA
kinase	I-DNA
(	I-DNA
TK	I-DNA
)	I-DNA
promoter	I-DNA
by	O
M.	O
tuberculosis	O
.	O

Electrophoretic	O
mobility	O
shift	O
assays	O
(	O
EMSAs	O
)	O
revealed	O
specific	O
binding	O
of	O
nuclear	O
protein	O
to	O
the	O
NF-kappaB	B-DNA
site	I-DNA
upon	O
induction	O
with	O
M.	O
tuberculosis	O
.	O

Using	O
antibodies	O
against	O
the	O
p50	B-protein
and	O
p65	B-protein
subunits	I-protein
of	O
NF-kappaB	B-protein
in	O
EMSAs	O
,	O
the	O
involvement	O
of	O
both	O
p50	B-protein
and	O
p65	B-protein
proteins	I-protein
was	O
further	O
demonstrated	O
.	O

Functional	O
expression	O
of	O
the	O
IL-2Ralpha	B-protein
on	O
mononuclear	B-cell_type
phagocytes	I-cell_type
in	O
M.	O
tuberculosis	O
infection	O
may	O
play	O
an	O
important	O
immunomodulatory	O
role	O
in	O
the	O
host	O
response	O
.	O

Vitamin	B-protein
D	I-protein
receptor	I-protein
3'-untranslated	B-DNA
region	I-DNA
polymorphisms	O
:	O
lack	O
of	O
effect	O
on	O
mRNA	O
stability	O
.	O

Allelic	O
variation	O
at	O
the	O
3'-end	O
of	O
the	O
vitamin	B-DNA
D	I-DNA
receptor	I-DNA
(	I-DNA
VDR	I-DNA
)	I-DNA
gene	I-DNA
has	O
been	O
associated	O
with	O
a	O
3-5-fold	O
increased	O
risk	O
of	O
developing	O
prostate	O
cancer	O
and	O
with	O
differences	O
in	O
bone	O
mineralization	O
.	O

This	O
genetic	O
diversity	O
does	O
not	O
alter	O
the	O
VDR	B-protein
protein	I-protein
structurally	O
,	O
but	O
instead	O
may	O
be	O
a	O
marker	O
(	O
s	O
)	O
of	O
other	O
,	O
nearby	O
polymorphisms	O
that	O
influence	O
message	O
stability	O
or	O
translation	O
.	O

The	O
work	O
reported	O
here	O
was	O
instigated	O
to	O
identify	O
additional	O
VDR	B-protein
3'-UTR	B-DNA
polymorphisms	O
that	O
may	O
have	O
functional	O
significance	O
and	O
to	O
then	O
test	O
whether	O
these	O
genetic	O
variants	O
alter	O
message	O
stability	O
.	O

Initially	O
,	O
four	O
novel	O
,	O
frequently	O
occurring	O
sequence	B-DNA
variants	I-DNA
were	O
identified	O
that	O
associated	O
with	O
two	O
common	O
haplotypes	O
that	O
were	O
described	O
previously	O
.	O

These	O
common	O
sequence	O
variants	O
were	O
not	O
found	O
within	O
three	O
message-destabilizing	B-DNA
elements	I-DNA
that	O
we	O
mapped	O
within	O
the	O
3'-UTR	B-DNA
of	O
the	O
vitamin	B-RNA
D	I-RNA
receptor	I-RNA
mRNA	I-RNA
.	O

Furthermore	O
,	O
the	O
two	O
VDR	B-DNA
3'-UTR	I-DNA
haplotypes	O
conferred	O
an	O
identical	O
half-life	O
on	O
a	O
heterologous	B-DNA
beta-globin	I-DNA
reporter	I-DNA
gene	I-DNA
,	O
in	O
an	O
in	O
vitro	O
assay	O
.	O

We	O
therefore	O
conclude	O
that	O
common	O
polymorphisms	O
within	O
the	O
VDR	B-DNA
3'-UTR	I-DNA
do	O
not	O
influence	O
message	O
stability	O
.	O

IL-2	B-protein
-mediated	O
cell	O
cycle	O
progression	O
and	O
inhibition	O
of	O
apoptosis	O
does	O
not	O
require	O
NF-kappa	B-protein
B	I-protein
or	O
activating	O
protein-1	O
activation	O
in	O
primary	O
human	O
T	O
cells	O
.	O

The	O
IL-2	B-protein
growth	O
hormone	O
is	O
the	O
major	O
growth	O
factor	O
of	O
activated	O
T	B-cell_type
lymphocytes	I-cell_type
during	O
a	O
developing	O
immune	O
response	O
.	O

IL-2	B-protein
is	O
required	O
not	O
only	O
for	O
cell	O
cycle	O
progression	O
but	O
also	O
to	O
protect	O
Ag-activated	B-cell_type
T	I-cell_type
cells	I-cell_type
from	O
programmed	O
cell	O
death	O
.	O

In	O
several	O
cell	O
types	O
,	O
activation	O
of	O
NF-kappa	B-protein
B	I-protein
and/or	O
activating	B-protein
protein-1	I-protein
(	O
AP-1	B-protein
)	O
has	O
been	O
demonstrated	O
to	O
be	O
extremely	O
important	O
in	O
blocking	O
apoptosis	O
.	O

To	O
determine	O
whether	O
either	O
or	O
both	O
of	O
these	O
transcription	B-protein
factors	I-protein
are	O
involved	O
in	O
cell	O
survival	O
or	O
cell	O
cycle	O
progression	O
in	O
response	O
to	O
IL-2	B-protein
,	O
primary	B-cell_type
human	I-cell_type
T	I-cell_type
cells	I-cell_type
responsive	O
to	O
the	O
growth	O
factor	O
were	O
analyzed	O
for	O
NF-kappa	O
B	O
and	O
AP-1	O
activation	O
.	O

The	O
current	O
study	O
clearly	O
demonstrates	O
that	O
IL-2	B-protein
does	O
not	O
induce	O
I	B-protein
kappa	I-protein
B	I-protein
alpha	O
degradation	O
or	O
NF-kappa	B-protein
B	I-protein
activation	O
in	O
primary	B-cell_type
human	I-cell_type
T	I-cell_type
cells	I-cell_type
that	O
respond	O
to	O
IL-2	B-protein
by	O
entering	O
the	O
cell	O
cycle	O
and	O
avoiding	O
apoptosis	O
.	O

Similarly	O
,	O
IL-2	B-protein
neither	O
activates	O
JNK	B-protein
nor	O
increases	O
AP-1	B-protein
binding	O
activity	O
to	O
a	O
consensus	O
o-tetradecanoylphorbol	B-DNA
13-acetate	I-DNA
(	I-DNA
TPA	I-DNA
)	I-DNA
response	I-DNA
element	I-DNA
.	O

On	O
the	O
other	O
hand	O
,	O
the	O
growth	B-protein
factor	I-protein
does	O
induce	O
the	O
activation	O
of	O
STAT3	B-protein
and	O
STAT5	B-protein
in	O
these	O
cells	O
,	O
as	O
has	O
been	O
previously	O
demonstrated	O
.	O

These	O
data	O
show	O
that	O
neither	O
NF-kappa	B-protein
B	I-protein
nor	O
AP-1	B-protein
activation	O
is	O
required	O
for	O
IL-2	B-protein
-mediated	O
survival	O
or	O
cell	O
cycle	O
progression	O
in	O
activated	O
primary	B-cell_type
human	I-cell_type
T	I-cell_type
cells	I-cell_type
.	O

Estrone	O
potentiates	O
myeloid	O
cell	O
differentiation	O
:	O
a	O
role	O
for	O
17	B-protein
beta-hydroxysteroid	I-protein
dehydrogenase	I-protein
in	O
modulating	O
hemopoiesis	O
.	O

Hormones	O
such	O
as	O
1	O
alpha	O
,	O
25-dihydroxy	O
vitamin	O
D3	O
(	O
D3	O
)	O
,	O
all-trans	O
retinoic	O
acid	O
,	O
and	O
9-cis	O
retinoic	O
acid	O
stimulate	O
differentiation	O
of	O
myeloid	B-cell_type
progenitor	I-cell_type
cells	I-cell_type
via	O
their	O
interaction	O
with	O
specific	O
hormone	B-protein
receptors	I-protein
.	O

However	O
,	O
the	O
sensitivity	O
of	O
cells	O
to	O
these	O
agents	O
is	O
not	O
merely	O
governed	O
by	O
the	O
expression	O
of	O
their	O
receptors	O
and	O
the	O
availability	O
of	O
ligand	O
to	O
bind	O
them	O
.	O

Recent	O
studies	O
from	O
our	O
group	O
suggested	O
that	O
the	O
actions	O
of	O
D3	O
and	O
retinoids	O
on	O
myelopoiesis	O
also	O
are	O
influenced	O
by	O
endogenous	O
mechanisms	O
involving	O
other	O
steroid	O
hormones	O
.	O

In	O
this	O
study	O
we	O
examined	O
the	O
influence	O
of	O
local	O
estrogen	O
metabolism	O
on	O
the	O
differentiation	O
of	O
HL60	B-cell_line
cells	I-cell_line
and	O
normal	O
primitive	O
myeloid	B-cell_type
progenitor	I-cell_type
cells	I-cell_type
.	O

Quantitative	O
thin-layer	O
chromatography	O
(	O
TLC	O
)	O
analyses	O
showed	O
that	O
HL60	B-cell_line
and	O
normal	B-cell_type
cells	I-cell_type
are	O
able	O
to	O
generate	O
estrone	O
(	O
E1	O
)	O
from	O
estradiol	O
(	O
E2	O
)	O
.	O

Neither	O
cell	O
population	O
generated	O
significant	O
amounts	O
of	O
E2	O
from	O
E1	O
.	O

Reverse	O
transcriptase	O
polymerase	O
chain	O
reaction	O
and	O
Northern	O
analyses	O
confirmed	O
that	O
normal	O
and	O
leukemic	O
myeloid	B-cell_type
progenitor	I-cell_type
cells	I-cell_type
expressed	O
mRNA	B-RNA
for	O
the	O
type	O
I	O
and	O
IV	O
isoforms	O
of	O
17	B-protein
beta-hydroxysteroid	I-protein
dehydrogenase	I-protein
.	O

Conversion	O
of	O
E2	O
to	O
E1	O
was	O
upregulated	O
within	O
24	O
hours	O
when	O
HL60	B-cell_line
cells	I-cell_line
were	O
treated	O
with	O
either	O
all-trans	O
retinoic	O
acid	O
or	O
D3	O
at	O
doses	O
that	O
induce	O
their	O
differentiation	O
toward	O
neutrophils	B-cell_type
or	O
monocytes	B-cell_type
,	O
respectively	O
.	O

Similarly	O
,	O
D3-induced	O
monocyte	O
differentiation	O
of	O
normal	O
myeloid	B-cell_type
progenitor	I-cell_type
cells	I-cell_type
was	O
associated	O
with	O
increased	O
capacity	O
to	O
generate	O
E1	O
from	O
E2	O
.	O

When	O
HL60	B-cell_line
cells	I-cell_line
or	O
normal	O
myeloid	B-cell_type
progenitor	I-cell_type
cells	I-cell_type
were	O
exposed	O
to	O
exogenous	O
E1	O
they	O
became	O
more	O
sensitive	O
to	O
the	O
differentiation-inducing	O
effects	O
of	O
D3	O
.	O

Data	O
presented	O
provide	O
further	O
evidence	O
for	O
the	O
local	O
modulation	O
of	O
myelopoiesis	O
by	O
intracrine	O
mechanisms	O
.	O

In	O
particular	O
,	O
our	O
findings	O
suggest	O
that	O
local	O
metabolism	O
of	O
steroids	O
by	O
normal	O
as	O
well	O
as	O
leukemic	B-cell_type
myeloid	I-cell_type
cells	I-cell_type
influences	O
their	O
responsiveness	O
to	O
D3	O
and	O
retinoids	O
.	O

Phosphorylation	O
of	O
TRAF2	B-protein
inhibits	O
binding	O
to	O
the	O
CD40	B-protein
cytoplasmic	I-protein
domain	I-protein
.	O

TRAF2	B-protein
is	O
a	O
signal	B-protein
transducing	I-protein
adaptor	I-protein
molecule	I-protein
which	O
binds	O
to	O
the	O
CD40	B-protein
cytoplasmic	I-protein
domain	I-protein
.	O

We	O
have	O
found	O
that	O
it	O
is	O
phosphorylated	O
,	O
predominantly	O
on	O
serine	O
residues	O
,	O
when	O
transiently	O
overexpressed	O
in	O
293	B-cell_line
cells	I-cell_line
.	O

The	O
phosphorylation	O
appears	O
to	O
be	O
related	O
to	O
the	O
signaling	O
events	O
that	O
are	O
activated	O
by	O
TRAF2	B-protein
under	O
these	O
circumstances	O
,	O
since	O
two	O
nonfunctional	O
mutants	O
were	O
found	O
to	O
be	O
phosphorylated	O
significantly	O
less	O
than	O
the	O
wild-type	B-protein
protein	I-protein
.	O

Furthermore	O
,	O
the	O
phosphorylation	O
status	O
of	O
TRAF2	B-protein
had	O
significant	O
effects	O
on	O
the	O
ability	O
of	O
the	O
protein	O
to	O
bind	O
to	O
CD40	B-protein
,	O
as	O
evidenced	O
by	O
our	O
observations	O
that	O
the	O
CD40	B-protein
cytoplasmic	I-protein
domain	I-protein
interacted	O
preferentially	O
with	O
underphosphorylated	O
TRAF2	B-protein
and	O
that	O
phosphatase	B-protein
treatment	O
significantly	O
enhanced	O
the	O
binding	O
of	O
TRAF2	B-protein
to	O
CD40	B-protein
.	O

We	O
conclude	O
from	O
these	O
studies	O
that	O
the	O
phosphorylation	O
of	O
TRAF2	B-protein
is	O
likely	O
to	O
play	O
an	O
important	O
role	O
in	O
regulating	O
signaling	O
by	O
virtue	O
of	O
its	O
ability	O
to	O
influence	O
the	O
CD40	B-protein
-TRAF2	B-protein
interaction	O
.	O

Copyright	O
1999	O
Academic	O
Press	O
.	O

A	O
direct	O
interaction	O
between	O
the	O
adaptor	B-protein
protein	I-protein
Cbl-b	B-protein
and	O
the	O
kinase	B-protein
zap-70	B-protein
induces	O
a	O
positive	O
signal	O
in	O
T	B-cell_type
cells	I-cell_type
.	O

Engagement	O
of	O
the	O
T-cell	B-protein
receptor	I-protein
(	I-protein
TCR	I-protein
)	I-protein
-CD3	I-protein
complex	I-protein
induces	O
a	O
rapid	O
increase	O
in	O
the	O
activities	O
of	O
Src-family	B-protein
and	O
Syk/Zap-70-family	B-protein
kinases	I-protein
[	O
1	O
]	O
[	O
2	O
]	O
.	O

These	O
activated	B-protein
kinases	I-protein
then	O
induce	O
the	O
tyrosine	O
phosphorylation	O
of	O
multiple	B-protein
intracellular	I-protein
proteins	I-protein
,	O
eventually	O
leading	O
to	O
T-cell	O
activation	O
.	O

One	O
of	O
the	O
prominent	O
substrates	O
for	O
these	O
kinases	B-protein
is	O
the	O
adaptor	B-protein
protein	I-protein
Cbl	O
[	O
3	O
]	O
and	O
recent	O
studies	O
suggest	O
that	O
Cbl	B-protein
negatively	O
regulates	O
upstream	B-protein
kinases	I-protein
such	O
as	O
Syk	B-protein
and	O
Zap-70	B-protein
[	O
4	O
]	O
[	O
5	O
]	O
.	O

Cbl-b	B-protein
,	O
a	O
homologue	O
of	O
Cbl	B-protein
,	O
is	O
widely	O
expressed	O
in	O
many	O
tissues	O
and	O
cells	O
including	O
hematopoietic	B-cell_type
cells	I-cell_type
[	O
6	O
]	O
[	O
7	O
]	O
.	O

Cbl-b	B-protein
undergoes	O
rapid	O
tyrosine	O
phosphorylation	O
upon	O
stimulation	O
of	O
the	O
TCR	B-protein
and	O
cytokine	O
receptors	O
[	O
8	O
]	O
[	O
9	O
]	O
.	O

The	O
role	O
of	O
Cbl-b	B-protein
is	O
unclear	O
,	O
however	O
.	O

Here	O
,	O
we	O
show	O
that	O
overexpression	O
of	O
Cbl-b	B-protein
in	O
T	B-cell_type
cells	I-cell_type
induced	O
the	O
constitutive	O
activation	O
of	O
the	O
transcription	B-protein
factor	I-protein
nuclear	I-protein
factor	I-protein
of	I-protein
activated	I-protein
T	I-protein
cells	I-protein
(	O
NFAT	B-protein
)	O
.	O

A	O
loss-of-function	O
mutation	O
in	O
Cbl-b	B-protein
disrupted	O
the	O
interaction	O
between	O
Cbl-b	B-protein
and	O
Zap-70	B-protein
and	O
nearly	O
completely	O
abrogated	O
the	O
Cbl-b	B-protein
-mediated	O
activation	O
of	O
NFAT	B-protein
.	O

Unlike	O
the	O
proposed	O
role	O
of	O
Cbl	B-protein
as	O
a	O
negative	O
regulator	O
,	O
our	O
results	O
suggest	O
that	O
the	O
Cbl	B-protein
homologue	O
Cbl-b	B-protein
has	O
a	O
positive	O
role	O
in	O
T-cell	O
signaling	O
,	O
most	O
likely	O
via	O
a	O
direct	O
interaction	O
with	O
the	O
upstream	B-protein
kinase	I-protein
Zap-70	B-protein
.	O

Grf40	B-protein
,	O
A	O
novel	O
Grb2	B-protein
family	I-protein
member	I-protein
,	O
is	O
involved	O
in	O
T	O
cell	O
signaling	O
through	O
interaction	O
with	O
SLP-76	B-protein
and	O
LAT	B-protein
.	O

We	O
molecularly	O
cloned	O
a	O
new	O
Grb2	B-protein
family	I-protein
member	I-protein
,	O
named	O
Grf40	B-protein
,	O
containing	O
the	O
common	O
SH3-SH2-SH3	B-protein
motif	I-protein
.	O

Expression	O
of	O
Grf40	B-protein
is	O
predominant	O
in	O
hematopoietic	B-cell_type
cells	I-cell_type
,	O
particularly	O
T	B-cell_type
cells	I-cell_type
.	O

Grf40	B-protein
binds	O
to	O
the	O
SH2	B-protein
domain-containing	I-protein
leukocyte	I-protein
protein	I-protein
of	O
76	O
kD	O
(	O
SLP-76	B-protein
)	O
via	O
its	O
SH3	O
domain	O
more	O
tightly	O
than	O
Grb2	B-protein
.	O

Incidentally	O
,	O
Grf40	B-protein
binds	O
to	O
linker	B-protein
for	I-protein
activation	I-protein
of	I-protein
T	I-protein
cells	I-protein
(	O
LAT	B-protein
)	O
possibly	O
via	O
its	O
SH2	B-protein
domain	I-protein
.	O

Overexpression	O
of	O
wild-type	B-protein
Grf40	I-protein
in	O
Jurkat	B-cell_line
cells	I-cell_line
induced	O
a	O
significant	O
increase	O
of	O
SLP-76-dependent	B-DNA
interleukin	I-DNA
(	I-DNA
IL	I-DNA
)	I-DNA
-2	I-DNA
promoter	I-DNA
and	O
nuclear	B-protein
factor	I-protein
of	I-protein
activated	I-protein
T	I-protein
cell	I-protein
(	O
NF-AT	B-protein
)	O
activation	O
upon	O
T	B-protein
cell	I-protein
receptor	I-protein
(	O
TCR	B-protein
)	O
stimulation	O
,	O
whereas	O
the	O
COOH-terminal	B-protein
SH3-deleted	I-protein
Grf40	I-protein
mutant	I-protein
lacked	O
any	O
recognizable	O
increase	O
in	O
IL-2	B-DNA
promoter	I-DNA
activity	O
.	O

Furthermore	O
,	O
the	O
SH2-deleted	B-protein
Grf40	I-protein
mutant	I-protein
led	O
to	O
a	O
marked	O
inhibition	O
of	O
these	O
regulatory	O
activities	O
,	O
the	O
effect	O
of	O
which	O
is	O
apparently	O
stronger	O
than	O
that	O
of	O
the	O
SH2-deleted	B-protein
Grb2	I-protein
mutant	I-protein
.	O

Our	O
data	O
suggest	O
that	O
Grf40	B-protein
is	O
an	O
adaptor	B-protein
molecule	I-protein
involved	O
in	O
TCR	B-protein
-mediated	O
signaling	O
through	O
a	O
more	O
efficient	O
interaction	O
than	O
Grb2	B-protein
with	O
SLP-76	B-protein
and	O
LAT	B-protein
.	O

Modulation	O
of	O
the	O
immune	O
response	O
and	O
tumor	O
growth	O
by	O
activated	O
Ras	B-protein
.	O

As	O
a	O
result	O
of	O
its	O
transforming	O
abilities	O
,	O
activated	B-protein
Ras	I-protein
is	O
expressed	O
in	O
a	O
great	O
number	O
of	O
cancers	O
.	O

The	O
ras	O
mutation	O
frequency	O
varies	O
between	O
95	O
%	O
in	O
pancreatic	O
cancer	O
and	O
5	O
%	O
in	O
breast	O
cancer	O
.	O

In	O
leukemia	O
,	O
the	O
highest	O
frequency	O
(	O
30	O
%	O
)	O
is	O
found	O
in	O
acute	O
myeloid	O
leukemia	O
.	O

The	O
presence	O
of	O
ras	O
mutations	O
has	O
been	O
correlated	O
with	O
a	O
poor	O
prognosis	O
and	O
negative	O
clinical	O
outcome	O
.	O

This	O
suggests	O
that	O
mutated	B-protein
Ras	I-protein
activates	O
mechanisms	O
,	O
which	O
favor	O
tumor	O
growth	O
,	O
enhance	O
the	O
metastatic	O
capacity	O
of	O
tumors	O
or	O
modulate	O
tumor-specific	O
immune	O
responses	O
.	O

Several	O
new	O
functions	O
of	O
Ras	B-protein
,	O
such	O
as	O
downregulation	O
of	O
major	B-protein
histocompatibility	I-protein
complex	I-protein
molecules	I-protein
,	O
upregulation	O
of	O
certain	O
cytokines	B-protein
,	O
growth	B-protein
factors	I-protein
and	O
degradative	B-protein
enzymes	I-protein
have	O
been	O
uncovered	O
in	O
the	O
last	O
decade	O
.	O

Additionally	O
,	O
mutated	B-protein
Ras	I-protein
can	O
also	O
serve	O
as	O
a	O
primary	O
target	O
for	O
the	O
development	O
of	O
immunotherapy	O
or	O
drug	O
therapy	O
.	O

This	O
review	O
will	O
discuss	O
the	O
mechanisms	O
by	O
which	O
Ras	B-protein
expressing	O
tumors	O
are	O
able	O
to	O
evade	O
destruction	O
by	O
the	O
immune	O
system	O
and	O
enhance	O
their	O
growth	O
and	O
metastatic	O
potential	O
.	O

It	O
will	O
further	O
elaborate	O
on	O
the	O
attempts	O
to	O
develop	O
successful	O
immunotherapy	O
and	O
drug	O
therapy	O
targeting	O
Ras	B-protein
expressing	O
tumors	O
.	O

Modulation	O
of	O
E2F	B-protein
complexes	I-protein
during	O
G0	O
to	O
S	O
phase	O
transition	O
in	O
human	B-cell_type
primary	I-cell_type
B-lymphocytes	I-cell_type
.	O

The	O
pocket	B-protein
protein-E2F	I-protein
complexes	I-protein
are	O
convergence	O
points	O
for	O
cell	O
cycle	O
signaling	O
.	O

In	O
the	O
present	O
report	O
,	O
we	O
identified	O
and	O
monitored	O
the	O
pocket	B-protein
protein-E2F	I-protein
complexes	I-protein
in	O
human	B-cell_type
primary	I-cell_type
B-lymphocytes	I-cell_type
after	O
activation	O
by	O
phorbol	O
12-myristate	O
13-acetate	O
.	O

Consistent	O
with	O
previous	O
data	O
from	O
human	B-cell_type
and	I-cell_type
mouse	I-cell_type
fibroblasts	I-cell_type
and	O
T-lymphocytes	B-cell_type
,	O
E2F4	B-protein
and	O
DP1	B-protein
form	O
the	O
predominant	O
E2F	B-protein
heterodimers	I-protein
both	O
in	O
G0	O
and	O
G1	O
phases	O
of	O
the	O
human	O
B-lymphocyte	O
cell	O
cycle	O
,	O
whereas	O
E2F1	B-protein
and	I-protein
-3	I-protein
are	O
first	O
detected	O
in	O
late	O
G1	O
,	O
and	O
their	O
expression	O
levels	O
increase	O
towards	O
S	O
phase	O
.	O

Intriguingly	O
,	O
the	O
major	B-protein
E2F	I-protein
complex	I-protein
that	O
we	O
detected	O
in	O
quiescent	B-cell_type
human	I-cell_type
B-lymphocytes	I-cell_type
is	O
consisted	O
of	O
pRB	B-protein
,	O
E2F4	B-protein
,	O
and	O
DP1	B-protein
.	O

Though	O
the	O
levels	O
of	O
DP1	B-protein
and	I-protein
-2	I-protein
increase	O
when	O
cells	O
progress	O
from	O
G0	O
to	O
S	O
,	O
the	O
proportion	O
of	O
DP1	B-protein
to	O
DP2	B-protein
remains	O
relatively	O
constant	O
during	O
the	O
cell	O
cycle	O
.	O

We	O
also	O
observed	O
an	O
increase	O
in	O
electrophoretic	O
mobility	O
of	O
the	O
predominant	O
E2F	B-protein
components	I-protein
,	O
DP1	B-protein
and	O
E2F4	B-protein
,	O
as	O
B-lymphocytes	B-cell_type
progressed	O
from	O
G0	O
into	O
early	O
G1	O
.	O

This	O
increase	O
in	O
mobility	O
was	O
attributable	O
to	O
dephosphorylation	O
,	O
as	O
lambda	O
phosphatase	O
treatment	O
could	O
convert	O
the	O
slower	B-protein
migrating	I-protein
forms	I-protein
into	O
the	O
corresponding	B-protein
faster	I-protein
mobility	I-protein
forms	I-protein
.	O

We	O
further	O
demonstrated	O
that	O
this	O
change	O
in	O
phosphorylation	O
status	O
correlates	O
with	O
a	O
decrease	O
in	O
DNA	O
binding	O
activity	O
.	O

This	O
modulation	O
of	O
DNA	O
binding	O
activity	O
mediated	O
through	O
the	O
dephosphorylation	O
of	O
DP1	B-protein
and	O
E2F4	B-protein
could	O
help	O
to	O
explain	O
the	O
lack	O
of	O
in	O
vivo	O
DNA	O
footprinting	O
in	O
late	O
G1	O
and	O
S	O
phases	O
of	O
gene	B-DNA
promoters	I-DNA
negatively	O
regulated	O
through	O
E2F	B-DNA
sites	I-DNA
and	O
suggests	O
a	O
novel	O
mechanism	O
for	O
controlling	O
E2F	B-protein
transcriptional	O
activity	O
during	O
the	O
transition	O
from	O
quiescence	O
to	O
proliferation	O
.	O

Engagement	O
of	O
natural	O
cytotoxicity	O
programs	O
regulates	O
AP-1	B-protein
expression	O
in	O
the	O
NKL	B-cell_line
human	I-cell_line
NK	I-cell_line
cell	I-cell_line
line	I-cell_line
.	O

NK	O
cell	O
cytotoxicity	O
is	O
a	O
fast	O
and	O
efficient	O
mechanism	O
of	O
target	O
cell	O
lysis	O
.	O

Using	O
transcription	O
analysis	O
,	O
such	O
as	O
multiplex	O
messenger	O
assays	O
,	O
we	O
show	O
here	O
that	O
natural	O
cytotoxicity	O
exerted	O
by	O
the	O
human	B-cell_line
NKL	I-cell_line
cell	I-cell_line
line	I-cell_line
correlates	O
with	O
mRNA	O
accumulation	O
of	O
very	B-protein
early	I-protein
activator	I-protein
protein	I-protein
(	I-protein
AP	I-protein
)	I-protein
-1	I-protein
transcription	B-DNA
factor	I-DNA
genes	I-DNA
such	O
as	O
JunB	B-DNA
,	O
FosB	B-DNA
and	O
c-Fos	B-DNA
.	O

In	O
addition	O
,	O
DNA-binding	O
activities	O
of	O
Jun-Fos	B-protein
heterodimers	I-protein
were	O
observed	O
by	O
electrophoretic	O
mobility	O
shift	O
assays	O
during	O
the	O
course	O
of	O
natural	O
cytotoxicity	O
.	O

Interaction	O
between	O
immunoglobulin-like	B-protein
transcript-2/leukocyte	I-protein
Ig-like	I-protein
receptor	I-protein
1	I-protein
on	O
NKL	B-cell_type
cells	I-cell_type
and	O
HLA-B27	B-protein
on	O
target	B-cell_type
cells	I-cell_type
leads	O
to	O
an	O
impairment	O
of	O
NKL	O
natural	O
cytotoxicity	O
,	O
which	O
correlates	O
with	O
an	O
absence	O
of	O
JunB	O
,	O
FosB	O
,	O
and	O
c-Fos	O
transcription	O
,	O
as	O
well	O
as	O
an	O
absence	O
of	O
their	O
DNA-binding	O
activity	O
.	O

Our	O
studies	O
thus	O
indicate	O
that	O
,	O
despite	O
the	O
rapidity	O
of	O
NK	O
cell-mediated	O
lysis	O
,	O
AP-1	B-protein
transcription	I-protein
factor	I-protein
is	O
activated	O
during	O
the	O
early	O
stage	O
of	O
NK	O
cell	O
cytolytic	O
programs	O
and	O
that	O
engagement	O
of	O
NK	B-protein
cell	I-protein
inhibitory	I-protein
receptors	I-protein
for	O
MHC	B-protein
class	I-protein
I	I-protein
molecules	I-protein
impairs	O
the	O
very	O
early	O
activation	O
of	O
AP-1	B-protein
.	O

Evidence	O
for	O
a	O
polyclonal	O
etiology	O
of	O
palmar	O
fibromatosis	O
.	O

X	B-DNA
chromosome	I-DNA
inactivation	O
patterns	O
at	O
the	O
androgen	O
receptor	O
locus	O
were	O
evaluated	O
to	O
determine	O
clonality	O
in	O
microdissected	O
lesional	O
tissue	O
and	O
in	O
leukocytes	B-cell_type
from	O
2	O
women	O
with	O
Dupuytren	O
's	O
disease	O
.	O

The	O
tissue	O
from	O
both	O
patients	O
generated	O
a	O
polyclonal	O
pattern	O
of	O
X	B-DNA
chromosome	I-DNA
inactivation	O
of	O
the	O
human	B-DNA
androgen	I-DNA
receptor	I-DNA
gene	I-DNA
.	O

This	O
finding	O
supports	O
a	O
polyclonal	O
reactive	O
process	O
as	O
the	O
underlying	O
etiology	O
for	O
palmar	O
fibromatosis	O
.	O

Inhibition	O
of	O
cyclooxygenase-2	B-protein
expression	O
by	O
4-trifluoromethyl	O
derivatives	O
of	O
salicylate	O
,	O
triflusal	O
,	O
and	O
its	O
deacetylated	O
metabolite	O
,	O
2-hydroxy-4-trifluoromethylbenzoic	O
acid	O
.	O

The	O
therapeutic	O
potential	O
of	O
drugs	O
that	O
block	O
the	O
induction	O
of	O
cyclooxygenase-2	B-protein
has	O
been	O
emphasized	O
.	O

When	O
two	O
4-trifluoromethyl	O
salicylate	O
derivatives	O
[	O
2-acetoxy-4-trifluoromethyl-benzoic	O
acid	O
(	O
triflusal	O
)	O
and	O
its	O
deacetylated	O
metabolite	O
2-hydroxy-4-trifluoromethylbenzoic	O
acid	O
(	O
HTB	O
)	O
]	O
were	O
compared	O
with	O
aspirin	O
and	O
sodium	O
salicylate	O
as	O
cyclooxygenase-2	B-protein
(	O
COX-2	O
)	O
inhibitors	O
,	O
we	O
observed	O
that	O
in	O
bacterial	O
lipopolysaccharide-activated	O
human	O
blood	O
,	O
triflusal	O
,	O
aspirin	O
,	O
and	O
HTB	O
,	O
but	O
not	O
sodium	O
salicylate	O
,	O
inhibited	O
COX-2-mediated	O
prostaglandin	O
E2	O
(	O
PGE2	O
)	O
production	O
(	O
IC50	O
=	O
0.16	O
,	O
0.18	O
,	O
0.39	O
,	O
and	O
>	O
10	O
mM	O
,	O
respectively	O
)	O
.	O

However	O
,	O
only	O
triflusal	O
and	O
aspirin	O
inhibited	O
purified	B-protein
COX-2	I-protein
enzyme	I-protein
.	O

To	O
test	O
this	O
apparent	O
discrepancy	O
,	O
we	O
realized	O
that	O
HTB	O
and	O
triflusal	O
(	O
but	O
neither	O
aspirin	O
nor	O
salicylate	O
)	O
produced	O
a	O
concentration-dependent	O
inhibition	O
of	O
COX-2	B-protein
protein	O
expression	O
in	O
peripheral	B-cell_type
human	I-cell_type
mononuclear	I-cell_type
cells	I-cell_type
.	O

This	O
observation	O
was	O
further	O
confirmed	O
in	O
a	O
rat	O
air	O
pouch	O
model	O
in	O
vivo	O
,	O
in	O
which	O
both	O
aspirin	O
and	O
triflusal	O
inhibited	O
PGE2	O
production	O
(	O
ID50	O
=	O
18.9	O
and	O
11.4	O
mg/kg	O
p.o.	O
,	O
respectively	O
)	O
but	O
only	O
triflusal-treated	O
animals	O
showed	O
a	O
decrease	O
in	O
COX-2	B-protein
expression	O
.	O

This	O
different	O
behavior	O
may	O
be	O
,	O
at	O
least	O
in	O
part	O
,	O
due	O
to	O
the	O
ability	O
of	O
HTB	O
and	O
triflusal	O
to	O
block	O
the	O
activation	O
of	O
the	O
transcription	O
factor	O
nuclear	B-protein
factor-kappaB	I-protein
to	O
a	O
higher	O
extent	O
than	O
aspirin	O
and	O
sodium	O
salicylate	O
.	O

Thus	O
,	O
in	O
addition	O
to	O
inhibiting	O
the	O
COX-2	O
activity	O
at	O
therapeutic	O
concentrations	O
,	O
triflusal	O
is	O
able	O
to	O
block	O
through	O
its	O
metabolite	O
HTB	O
the	O
expression	O
of	O
new	O
enzyme	O
,	O
and	O
hence	O
the	O
resumption	O
of	O
PGE2	O
synthesis	O
.	O

Triflusal	O
and	O
HTB	O
may	O
exert	O
beneficial	O
effects	O
in	O
processes	O
in	O
which	O
de	O
novo	O
COX-2	B-protein
expression	O
is	O
involved	O
and	O
,	O
in	O
a	O
broader	O
sense	O
,	O
in	O
pathological	O
situations	O
in	O
which	O
genes	O
under	O
nuclear	B-protein
factor-kappaB	I-protein
control	O
are	O
up-regulated	O
.	O

Evidence	O
for	O
distinct	O
intracellular	O
signaling	O
pathways	O
in	O
CD34+	B-cell_type
progenitor	I-cell_type
to	O
dendritic	O
cell	O
differentiation	O
from	O
a	O
human	O
cell	O
line	O
model	O
.	O

Intracellular	O
signals	O
that	O
mediate	O
differentiation	O
of	O
pluripotent	B-cell_type
hemopoietic	I-cell_type
progenitors	I-cell_type
to	O
dendritic	B-cell_type
cells	I-cell_type
(	O
DC	B-cell_type
)	O
are	O
largely	O
undefined	O
.	O

We	O
have	O
previously	O
shown	O
that	O
protein	B-protein
kinase	I-protein
C	I-protein
(	O
PKC	B-protein
)	O
activation	O
(	O
with	O
phorbol	O
ester	O
(	O
PMA	O
)	O
alone	O
)	O
specifically	O
induces	O
differentiation	O
of	O
primary	B-cell_line
human	I-cell_line
CD34+	I-cell_line
hemopoietic	I-cell_line
progenitor	I-cell_line
cells	I-cell_line
(	O
HPC	B-cell_line
)	O
to	O
mature	B-cell_type
DC	I-cell_type
.	O

We	O
now	O
find	O
that	O
cytokine-driven	O
(	O
granulocyte-macrophage	O
CSF	O
and	O
TNF-alpha	O
)	O
CD34+	O
HPC	B-cell_line
--	O
>	O
DC	O
differentiation	O
is	O
preferentially	O
blocked	O
by	O
inhibitors	O
of	O
PKC	B-protein
activation	O
.	O

To	O
further	O
identify	O
intracellular	O
signals	O
and	O
downstream	O
events	O
important	O
in	O
CD34+	B-cell_line
HPC	I-cell_line
--	O
>	O
DC	B-cell_type
differentiation	O
we	O
have	O
characterized	O
a	O
human	O
leukemic	O
cell	O
line	O
model	O
of	O
this	O
process	O
.	O

The	O
CD34+	B-cell_line
myelomonocytic	I-cell_line
cell	I-cell_line
line	I-cell_line
KG1	B-cell_line
differentiates	O
into	O
dendritic-like	O
cells	O
in	O
response	O
to	O
granulocyte-macrophage	B-protein
CSF	I-protein
plus	O
TNF-alpha	B-protein
,	O
or	O
PMA	O
(	O
with	O
or	O
without	O
the	O
calcium	O
ionophore	O
ionomycin	O
,	O
or	O
TNF-alpha	B-protein
)	O
,	O
with	O
different	O
stimuli	O
mediating	O
different	O
aspects	O
of	O
the	O
process	O
.	O

Phenotypic	O
DC	B-cell_type
characteristics	O
of	O
KG1	B-cell_line
dendritic-like	I-cell_line
cells	I-cell_line
include	O
morphology	O
(	O
loosely	B-cell_type
adherent	I-cell_type
cells	I-cell_type
with	O
long	O
neurite	O
processes	O
)	O
,	O
MHC	B-protein
I+/	O
MHC	B-protein
IIbright/CD83+/CD86+/	O
CD14	B-protein
-	O
surface	O
Ag	O
expression	O
,	O
and	O
RelB	B-protein
and	O
DC	B-cell_type
-CK1	O
gene	O
expression	O
.	O

Functional	O
DC	B-cell_type
characteristics	O
include	O
fluid	O
phase	O
macromolecule	O
uptake	O
(	O
FITC-dextran	O
)	O
and	O
activation	O
of	O
resting	B-cell_type
T	I-cell_type
cells	I-cell_type
.	O

Comparison	O
of	O
KG1	B-cell_line
to	O
the	O
PMA-unresponsive	B-cell_line
subline	I-cell_line
KG1a	I-cell_line
reveals	O
differences	O
in	O
expression	O
of	O
TNF	B-protein
receptors	I-protein
1	I-protein
and	I-protein
2	I-protein
;	O
PKC	B-protein
isoforms	I-protein
alpha	I-protein
,	I-protein
beta	I-protein
I	I-protein
,	I-protein
beta	I-protein
II	I-protein
,	I-protein
and	I-protein
mu	I-protein
;	O
and	O
RelB	B-protein
,	O
suggesting	O
that	O
these	O
components/pathways	O
are	O
important	O
for	O
DC	B-cell_type
differentiation	O
.	O

Together	O
,	O
these	O
findings	O
demonstrate	O
that	O
cytokine	O
or	O
phorbol	O
ester	O
stimulation	O
of	O
KG1	B-cell_line
is	O
a	O
model	O
of	O
human	B-cell_line
CD34+	I-cell_line
HPC	I-cell_line
to	O
DC	B-cell_type
differentiation	O
and	O
suggest	O
that	O
specific	O
intracellular	O
signaling	O
pathways	O
mediate	O
specific	O
events	O
in	O
DC	B-cell_type
lineage	O
commitment	O
.	O

Involvement	O
of	O
adenylate	B-protein
cyclase	I-protein
and	O
p70	B-protein
(	I-protein
S6	I-protein
)	I-protein
-kinase	I-protein
activation	O
in	O
IL-10	B-protein
up-regulation	O
in	O
human	B-cell_type
monocytes	I-cell_type
by	O
gp41	B-protein
envelope	I-protein
protein	I-protein
of	O
human	O
immunodeficiency	O
virus	O
type	O
1	O
.	O

Our	O
previous	O
results	O
show	O
that	O
recombinant	B-protein
gp41	I-protein
(	O
aa565-647	B-protein
)	O
,	O
the	O
extracellular	B-protein
domain	I-protein
of	O
HIV-1	B-protein
transmembrane	I-protein
glycoprotein	I-protein
,	O
stimulates	O
interleukin-10	B-protein
(	O
IL-10	B-protein
)	O
production	O
in	O
human	B-cell_type
monocytes	I-cell_type
.	O

The	O
signal	O
cascade	O
transducing	O
this	O
effect	O
is	O
not	O
yet	O
clear	O
.	O

In	O
this	O
study	O
,	O
we	O
examined	O
whether	O
gp41	B-protein
-induced	O
IL-10	B-protein
up-regulation	O
is	O
mediated	O
by	O
the	O
previously	O
described	O
synergistic	O
activation	O
of	O
cAMP	O
and	O
NF-kappaB	B-protein
pathways	O
.	O

gp41	B-protein
induced	O
cAMP	O
accumulation	O
in	O
monocytes	B-cell_type
in	O
a	O
time-	O
and	O
concentration-dependent	O
manner	O
and	O
the	O
adenylate	B-protein
cyclase	I-protein
inhibitor	O
SQ	O
22536	O
suppressed	O
gp41	B-protein
-induced	O
IL-10	B-protein
production	O
in	O
monocytes	B-cell_type
.	O

In	O
contrast	O
,	O
gp41	B-protein
failed	O
to	O
stimulate	O
NF-kappaB	B-protein
binding	O
activity	O
in	O
as	O
much	O
as	O
no	O
NF-kappaB	B-protein
bound	O
to	O
the	O
main	B-DNA
NF-kappaB-binding	I-DNA
site	I-DNA
2	O
of	O
the	O
IL-10	B-DNA
promoter	I-DNA
after	O
addition	O
of	O
gp41	B-protein
.	O

We	O
also	O
examined	O
the	O
involvement	O
of	O
other	O
signal	O
transduction	O
pathways	O
.	O

Specific	O
inhibitors	O
of	O
p70	B-protein
(	I-protein
S6	I-protein
)	I-protein
-kinase	I-protein
(	O
rapamycin	O
)	O
,	O
and	O
Gi	B-protein
protein	I-protein
(	O
pertussis	B-protein
toxin	I-protein
)	O
,	O
prevented	O
induction	O
of	O
IL-10	B-protein
production	O
by	O
gp41	B-protein
in	O
monocytes	B-cell_type
,	O
while	O
inhibitors	O
of	O
the	O
phosphatidylinositol	B-protein
3-kinase	I-protein
(	O
PI	B-protein
3-kinase	I-protein
)	O
(	O
wortmannin	O
)	O
and	O
mitogen-activated	O
protein	O
kinase	O
(	O
MAPK	B-protein
)	O
pathway	O
(	O
PD	O
98059	O
)	O
did	O
not	O
.	O

Thus	O
HIV-1	O
gp41	B-protein
-induced	O
IL-10	B-protein
up-regulation	O
in	O
monocytes	B-cell_type
may	O
not	O
involve	O
NF-kappaB	B-protein
,	O
MAPK	B-protein
,	O
or	O
PI	B-protein
3-kinase	I-protein
activation	O
,	O
but	O
rather	O
may	O
operate	O
through	O
activation	O
of	O
adenylate	B-protein
cyclase	I-protein
and	O
pertussis-toxin-sensitive	B-protein
Gi/Go	I-protein
protein	I-protein
to	O
effect	O
p70	B-protein
(	I-protein
S6	I-protein
)	I-protein
-kinase	I-protein
activation	O
.	O

Analysis	O
of	O
the	O
modulation	O
of	O
transcriptional	O
activity	O
in	O
myelopoiesis	O
and	O
leukemogenesis	O
.	O

Acute	O
myeloid	O
leukemia	O
(	O
AML	O
)	O
is	O
still	O
associated	O
with	O
a	O
mortality	O
of	O
60	O
to	O
80	O
%	O
.	O

AML	O
is	O
characterized	O
by	O
a	O
block	O
in	O
myeloid	O
differentiation	O
.	O

The	O
transcription	B-protein
factors	I-protein
PU.1	B-protein
and	O
C/EBPalpha	B-protein
are	O
responsible	O
for	O
normal	O
myeloid	O
differentiation	O
from	O
stem	B-cell_type
cells	I-cell_type
to	O
monocytes	B-cell_type
or	O
granulocytes	O
.	O

In	O
particular	O
,	O
PU.1	B-protein
induces	O
expression	O
of	O
the	O
macrophage	B-protein
colony-stimulating	I-protein
factor	I-protein
(	I-protein
M-CSF	I-protein
)	I-protein
receptor	I-protein
and	O
the	O
development	O
of	O
monocytes	B-cell_type
,	O
whereas	O
C/EBPalpha	B-protein
increases	O
the	O
expression	O
of	O
the	O
granulocyte	B-protein
colony-stimulating	I-protein
factor	I-protein
(	I-protein
G-CSF	I-protein
)	I-protein
receptor	I-protein
and	O
leads	O
to	O
mature	O
granulocytes	B-cell_type
.	O

In	O
AML	O
,	O
chromosomal	O
aberrations	O
result	O
in	O
oncoproteins	B-protein
such	O
as	O
AML1/ETO	B-protein
,	O
PML/RARalpha	B-protein
,	O
or	O
activated	B-protein
Ras	I-protein
,	O
which	O
can	O
deregulate	O
genes	O
important	O
for	O
normal	O
myelopoiesis	O
.	O

Thus	O
,	O
AML1/ETO	B-protein
can	O
bind	O
to	O
the	O
transcription	B-protein
factor	I-protein
C/EBPalpha	B-protein
,	O
inhibit	O
C/EBPalpha	B-protein
-dependent	O
transcription	O
,	O
and	O
block	O
granulocytic	O
differentiation	O
.	O

However	O
,	O
AML1/ETO	B-protein
can	O
also	O
synergize	O
with	O
the	O
transcription	B-protein
factor	I-protein
AML1	B-protein
to	O
enhance	O
the	O
activity	O
of	O
the	O
M-CSF	B-DNA
receptor	I-DNA
promoter	I-DNA
.	O

On	O
the	O
other	O
hand	O
,	O
the	O
PML/RARalpha	B-protein
fusion	I-protein
protein	I-protein
causes	O
transcriptional	O
repression	O
by	O
recruiting	O
the	O
nuclear	B-protein
corepressor	I-protein
(	I-protein
N-CoR	I-protein
)	I-protein
histone	I-protein
deacetylase	I-protein
complex	I-protein
to	O
the	O
DNA	O
,	O
which	O
results	O
in	O
decreased	O
histone	B-protein
acetylation	O
and	O
a	O
repressive	O
chromatin	B-DNA
organization	O
.	O

Here	O
we	O
describe	O
methods	O
to	O
investigate	O
whether	O
and	O
how	O
signaling	O
agonists	O
induce	O
myeloid	O
differentiation	O
and	O
how	O
oncoproteins	B-protein
might	O
cause	O
AML	O
by	O
modulating	O
the	O
activity	O
of	O
transcription	B-protein
factors	I-protein
that	O
are	O
pivotal	O
for	O
normal	O
myeloid	O
development	O
.	O

Copyright	O
1999	O
Academic	O
Press	O
.	O

NF-ATc	B-protein
isoforms	I-protein
are	O
differentially	O
expressed	O
and	O
regulated	O
in	O
murine	B-cell_type
T	I-cell_type
and	I-cell_type
mast	I-cell_type
cells	I-cell_type
.	O

NF	B-protein
of	I-protein
activated	I-protein
T	I-protein
cells	I-protein
(	O
NF-AT	B-protein
)	O
denotes	O
a	O
family	O
of	O
transcription	B-protein
factors	I-protein
that	O
regulate	O
the	O
activation-dependent	O
expression	O
of	O
many	O
immunologically	B-protein
important	I-protein
proteins	I-protein
.	O

At	O
least	O
four	O
distinct	O
genes	O
encode	O
the	O
various	O
family	O
members	O
,	O
and	O
several	O
isoforms	O
of	O
these	O
have	O
been	O
identified	O
as	O
well	O
.	O

The	O
overlapping	O
expression	O
patterns	O
and	O
similar	O
in	O
vitro	O
binding	O
and	O
trans-activation	O
activities	O
on	O
various	O
promoter	B-DNA
elements	I-DNA
of	O
NF-AT-regulated	B-DNA
genes	I-DNA
suggest	O
some	O
redundancy	O
in	O
the	O
function	O
of	O
these	O
proteins	O
.	O

However	O
,	O
the	O
phenotypic	O
analysis	O
of	O
NF-AT	B-protein
-deficient	O
mice	O
supports	O
the	O
idea	O
that	O
there	O
are	O
tissue-	O
and	O
gene-	O
specific	O
functions	O
as	O
well	O
.	O

In	O
this	O
study	O
we	O
have	O
characterized	O
the	O
expression	O
of	O
NF-AT	B-DNA
cDNAs	I-DNA
in	O
murine	O
mast	B-cell_type
cells	I-cell_type
.	O

The	O
majority	O
of	O
clones	O
identified	O
correspond	O
to	O
two	O
NF-ATc	B-protein
isoforms	I-protein
that	O
differ	O
only	O
in	O
their	O
amino-terminal	B-protein
sequence	I-protein
.	O

Despite	O
minimal	O
discrepancies	O
in	O
the	O
coding	B-DNA
region	I-DNA
,	O
there	O
are	O
striking	O
tissue-	O
and	O
cell	O
type-specific	O
differences	O
in	O
isoform	O
expression	O
patterns	O
.	O

Detection	O
of	O
NF-ATc.alpha	B-RNA
mRNA	I-RNA
is	O
strictly	O
dependent	O
on	O
cell	O
activation	O
signals	O
in	O
both	O
T	B-cell_line
and	I-cell_line
mast	I-cell_line
cell	I-cell_line
lines	I-cell_line
.	O

In	O
contrast	O
,	O
the	O
beta	B-protein
isoform	I-protein
is	O
expressed	O
at	O
very	O
low	O
constitutive	O
levels	O
in	O
both	O
cell	O
types	O
but	O
is	O
only	O
up-regulated	O
in	O
response	O
to	O
mast	O
cell	O
activation	O
signals	O
delivered	O
through	O
the	O
FcepsilonRI	B-protein
or	O
via	O
calcium	O
ionophores	O
.	O

These	O
results	O
demonstrate	O
another	O
level	O
of	O
regulation	O
within	O
the	O
NF-AT	B-protein
family	I-protein
that	O
can	O
contribute	O
to	O
cell	O
type-specific	O
gene	O
expression	O
.	O

Crossreactive	O
recognition	O
of	O
viral	O
,	O
self	O
,	O
and	O
bacterial	O
peptide	O
ligands	O
by	O
human	B-cell_type
class	I-cell_type
I-restricted	I-cell_type
cytotoxic	I-cell_type
T	I-cell_type
lymphocyte	I-cell_type
clonotypes	I-cell_type
:	I-cell_type
implications	O
for	O
molecular	O
mimicry	O
in	O
autoimmune	O
disease	O
.	O

The	O
immunodominant	O
,	O
CD8	B-cell_type
(	I-cell_type
+	I-cell_type
)	I-cell_type
cytotoxic	I-cell_type
T	I-cell_type
lymphocyte	I-cell_type
(	O
CTL	O
)	O
response	O
to	O
the	O
HLA-B8-restricted	O
peptide	O
,	O
RAKFKQLL	O
,	O
located	O
in	O
the	O
Epstein-Barr	B-protein
virus	I-protein
immediate-early	I-protein
antigen	I-protein
,	O
BZLF1	B-protein
,	O
is	O
characterized	O
by	O
a	O
diverse	O
T	B-protein
cell	I-protein
receptor	I-protein
(	I-protein
TCR	I-protein
)	I-protein
repertoire	I-protein
.	O

Here	O
,	O
we	O
show	O
that	O
this	O
diversity	O
can	O
be	O
partitioned	O
on	O
the	O
basis	O
of	O
crossreactive	O
cytotoxicity	O
patterns	O
involving	O
the	O
recognition	O
of	O
a	O
self	O
peptide-RSKFRQIV-located	O
in	O
a	O
serine/threonine	B-protein
kinase	I-protein
and	O
a	O
bacterial	O
peptide-RRKYKQII-located	O
in	O
Staphylococcus	B-protein
aureus	I-protein
replication	I-protein
initiation	I-protein
protein	I-protein
.	O

Thus	O
CTL	B-cell_line
clones	I-cell_line
that	O
recognized	O
the	O
viral	O
,	O
self	O
,	O
and	O
bacterial	O
peptides	O
expressed	O
a	O
highly	O
restricted	O
alphabeta	O
TCR	B-protein
phenotype	O
.	O

The	O
CTL	B-cell_line
clones	I-cell_line
that	O
recognized	O
viral	O
and	O
self	O
peptides	O
were	O
more	O
oligoclonal	O
,	O
whereas	O
clones	O
that	O
strictly	O
recognized	O
the	O
viral	O
peptide	O
displayed	O
a	O
diverse	O
TCR	B-protein
profile	O
.	O

Interestingly	O
,	O
the	O
self	O
and	O
bacterial	O
peptides	O
equally	O
were	O
substantially	O
less	O
effective	O
than	O
the	O
cognate	O
viral	O
peptide	O
in	O
sensitizing	O
target	O
cell	O
lysis	O
,	O
and	O
also	O
resulted	O
only	O
in	O
a	O
weak	O
reactivation	O
of	O
memory	B-cell_type
CTLs	I-cell_type
in	O
limiting	O
dilution	O
assays	O
,	O
whereas	O
the	O
cognate	O
peptide	O
was	O
highly	O
immunogenic	O
.	O

The	O
described	O
crossreactions	O
show	O
that	O
human	O
antiviral	O
,	O
CD8	O
(	O
+	O
)	O
CTL	O
responses	O
can	O
be	O
shaped	O
by	O
peptide	O
ligands	O
derived	O
from	O
autoantigens	O
and	O
environmental	O
bacterial	O
antigens	O
,	O
thereby	O
providing	O
a	O
firm	O
structural	O
basis	O
for	O
molecular	O
mimicry	O
involving	O
class	O
I-restricted	B-cell_line
CTLs	I-cell_line
in	O
the	O
pathogenesis	O
of	O
autoimmune	O
disease	O
.	O

RFLAT-1	B-protein
:	O
a	O
new	O
zinc	B-protein
finger	I-protein
transcription	I-protein
factor	I-protein
that	O
activates	O
RANTES	B-DNA
gene	I-DNA
expression	O
in	O
T	B-cell_type
lymphocytes	I-cell_type
.	O

RANTES	B-protein
(	O
Regulated	B-protein
upon	I-protein
Activation	I-protein
,	I-protein
Normal	I-protein
T	I-protein
cell	I-protein
Expressed	I-protein
and	I-protein
Secreted	I-protein
)	O
is	O
a	O
chemoattractant	B-protein
cytokine	I-protein
(	O
chemokine	B-protein
)	O
important	O
in	O
the	O
generation	O
of	O
inflammatory	O
infiltrate	O
and	O
human	O
immunodeficiency	O
virus	O
entry	O
into	O
immune	B-cell_type
cells	I-cell_type
.	O

RANTES	B-protein
is	O
expressed	O
late	O
(	O
3-5	O
days	O
)	O
after	O
activation	O
in	O
T	B-cell_type
lymphocytes	I-cell_type
.	O

Using	O
expression	O
cloning	O
,	O
we	O
identified	O
the	O
first	O
``	O
late	O
''	O
T	B-protein
lymphocyte	I-protein
associated	I-protein
transcription	I-protein
factor	I-protein
and	O
named	O
it	O
``	O
RANTES	B-protein
Factor	I-protein
of	I-protein
Late	I-protein
Activated	I-protein
T	I-protein
Lymphocytes-1	I-protein
``	O
(	O
RFLAT-1	B-protein
)	O
.	O

RFLAT-1	B-protein
is	O
a	O
novel	O
,	O
phosphorylated	O
,	O
zinc	B-protein
finger	I-protein
transcription	I-protein
factor	I-protein
that	O
is	O
expressed	O
in	O
T	B-cell_type
cells	I-cell_type
3	O
days	O
after	O
activation	O
,	O
coincident	O
with	O
RANTES	B-protein
expression	O
.	O

While	O
Rel	B-protein
proteins	I-protein
play	O
the	O
dominant	O
role	O
in	O
RANTES	B-DNA
gene	I-DNA
expression	O
in	O
fibroblasts	O
,	O
RFLAT-1	B-protein
is	O
a	O
strong	O
transactivator	O
for	O
RANTES	B-protein
in	O
T	B-cell_type
cells	I-cell_type
.	O

Fas	B-protein
ligand	I-protein
induction	O
in	O
human	B-cell_type
NK	I-cell_type
cells	I-cell_type
is	O
regulated	O
by	O
redox	O
through	O
a	O
calcineurin-nuclear	B-protein
factors	I-protein
of	O
activated	O
T	O
cell-dependent	O
pathway	O
.	O

Fas	B-protein
ligand	I-protein
(	O
FasL	B-protein
)	O
on	O
cytotoxic	O
lymphocytes	O
is	O
important	O
for	O
mediating	O
apoptosis	O
of	O
activated	O
lymphocytes	O
and	O
other	O
target	O
cells	O
.	O

We	O
have	O
reported	O
that	O
NK	O
cell	O
functions	O
,	O
such	O
as	O
proliferation	O
,	O
cell	O
death	O
,	O
and	O
killing	O
activity	O
,	O
are	O
subject	O
to	O
regulation	O
by	O
cellular	O
redox	O
status	O
.	O

Here	O
,	O
we	O
report	O
that	O
expression	O
of	O
FasL	B-protein
protein	I-protein
and	O
mRNA	B-RNA
in	O
activated	B-cell_type
NK	I-cell_type
cells	I-cell_type
is	O
also	O
regulated	O
by	O
redox	O
.	O

Ligation	O
of	O
CD16	B-protein
on	O
IL-2-preactivated	B-cell_type
NK	I-cell_type
cells	I-cell_type
resulted	O
in	O
reduction	O
of	O
intracellular	O
peroxide	O
level	O
as	O
well	O
as	O
induction	O
of	O
FasL	B-protein
expression	O
.	O

This	O
CD16	B-protein
-induced	O
FasL	B-protein
expression	O
was	O
suppressed	O
by	O
oxidative	O
stress	O
,	O
including	O
thiol	O
deprivation	O
or	O
treatment	O
with	O
hydrogen	O
peroxide	O
(	O
H2O2	O
)	O
.	O

Addition	O
of	O
thiol-reducing	O
compounds	O
,	O
such	O
as	O
L-cystine	O
,	O
2-ME	O
,	O
or	O
N-acetyl	O
cysteine	O
,	O
restored	O
FasL	B-protein
expression	O
.	O

These	O
data	O
suggest	O
that	O
CD16	B-protein
stimulation	O
requires	O
cellular	O
reducing	O
status	O
for	O
FasL	B-protein
induction	O
in	O
NK	B-cell_type
cells	I-cell_type
.	O

Because	O
FasL	O
gene	O
activation	O
following	O
CD16	B-protein
cross-linking	O
is	O
regulated	O
by	O
the	O
NF	B-protein
of	I-protein
activated	I-protein
T	I-protein
cells	I-protein
(	O
NFAT	B-protein
)	O
,	O
we	O
examined	O
the	O
effect	O
of	O
oxidative	O
stresses	O
on	O
NFAT	B-protein
activation	O
.	O

Electrophoretic	O
mobility	O
shift	O
assays	O
revealed	O
that	O
both	O
thiol	O
insufficiency	O
and	O
H2O2	O
treatment	O
suppressed	O
DNA-binding	O
activity	O
of	O
NFAT	B-protein
and	O
that	O
addition	O
of	O
thiol-reducing	O
compounds	O
reversed	O
or	O
even	O
enhanced	O
it	O
.	O

Furthermore	O
,	O
these	O
oxidative	O
stresses	O
inhibited	O
activity	O
of	O
calcineurin	O
,	O
a	O
serine/	O
threonine	B-protein
phosphatase	I-protein
that	O
regulates	O
NFAT	B-protein
activation	O
.	O

These	O
results	O
suggest	O
that	O
suppression	O
of	O
calcineurin	B-protein
and	O
NFAT	B-protein
activation	O
is	O
a	O
mechanism	O
by	O
which	O
oxidative	O
stress	O
inhibits	O
FasL	B-protein
induction	O
in	O
activated	B-cell_type
NK	I-cell_type
cells	I-cell_type
and	O
further	O
support	O
the	O
hypothesis	O
that	O
thiol-reducing	O
compounds	O
might	O
be	O
required	O
for	O
maintenance	O
of	O
optimal	O
NK	O
functions	O
under	O
physiologic	O
oxidative	O
conditions	O
.	O

Heterogeneity	O
of	O
clonal	O
development	O
in	O
chronic	B-DNA
myeloproliferative	I-DNA
disorders	I-DNA
.	O

Recent	O
reports	O
have	O
suggested	O
a	O
previously	O
unexpected	O
variability	O
in	O
the	O
expression	O
of	O
the	O
dominant	B-cell_line
neoplastic	I-cell_line
clone	I-cell_line
in	O
myeloproliferative	O
disorders	O
(	O
MPD	O
)	O
.	O

We	O
evaluated	O
49	O
female	O
patients	O
with	O
MPD	O
and	O
informative	O
at	O
the	O
X-linked	B-DNA
androgen	I-DNA
receptor	I-DNA
(	I-DNA
AR	I-DNA
)	I-DNA
locus	I-DNA
to	O
establish	O
the	O
X	B-DNA
chromosome	I-DNA
inactivation	O
pattern	O
of	O
hemopoietic	B-cell_type
cells	I-cell_type
.	O

Whereas	O
in	O
chronic	O
myelogenous	O
leukemia	O
(	O
CML	O
)	O
the	O
granulocytes	B-cell_type
(	O
PMN	B-cell_type
)	O
were	O
uniformly	O
of	O
monoclonal	O
origin	O
,	O
a	O
striking	O
heterogeneity	O
of	O
clonal	O
development	O
was	O
found	O
in	O
PMN	B-cell_type
from	O
patients	O
with	O
other	O
MPD	O
,	O
with	O
up	O
to	O
50	O
%	O
of	O
them	O
expressing	O
a	O
polyclonal	O
pattern	O
of	O
X	O
inactivation	O
.	O

CD80	B-protein
and	O
CD86	B-protein
are	O
not	O
equivalent	O
in	O
their	O
ability	O
to	O
induce	O
the	O
tyrosine	O
phosphorylation	O
of	O
CD28	B-protein
.	O

Ligation	O
of	O
either	O
CD80	B-protein
(	O
B7-1	B-protein
)	O
or	O
CD86	B-protein
(	O
B7-2	B-protein
)	O
,	O
two	O
principal	O
ligands	O
for	O
CD28	B-protein
,	O
is	O
thought	O
to	O
skew	O
the	O
immune	O
response	O
toward	O
Th1	O
or	O
Th2	O
differentiation	O
.	O

We	O
have	O
examined	O
early	O
signal	O
transduction	O
pathways	O
recruited	O
following	O
T	O
cell	O
stimulation	O
with	O
either	O
CD80	B-protein
or	O
CD86	B-protein
.	O

Purified	B-cell_line
human	I-cell_line
peripheral	I-cell_line
T	I-cell_line
cells	I-cell_line
or	O
Jurkat	B-cell_line
T	I-cell_line
cells	I-cell_line
were	O
stimulated	O
with	O
Chinese	O
hamster	O
ovary	O
(	O
CHO	O
)	O
cells	O
expressing	O
either	O
human	B-protein
CD80	I-protein
(	O
CHO-CD80	B-protein
)	O
or	O
human	B-protein
CD86	I-protein
(	O
CHO-CD86	B-protein
)	O
or	O
with	O
anti-CD28	B-protein
monoclonal	I-protein
antibody	I-protein
(	O
mAb	O
)	O
.	O

In	O
the	O
presence	O
of	O
phorbol	O
12-myristate	O
13-acetate	O
,	O
both	O
CHO-CD80	B-protein
and	O
CHO-CD86	B-protein
,	O
like	O
anti-CD28	B-protein
mAb	I-protein
,	O
were	O
capable	O
of	O
stimulating	O
cytokine	B-protein
production	O
from	O
both	O
human	B-cell_type
peripheral	I-cell_type
T	I-cell_type
cells	I-cell_type
and	O
Jurkat	B-cell_line
T	I-cell_line
cells	I-cell_line
.	O

Both	O
CHO-CD80	B-protein
and	O
CHO-CD86	B-protein
,	O
in	O
the	O
presence	O
of	O
anti-CD3	B-protein
mAb	I-protein
,	O
costimulated	O
NFAT	B-protein
-dependent	O
transcriptional	O
activation	O
.	O

Several	O
intracellular	O
signaling	B-protein
proteins	I-protein
,	O
such	O
as	O
CBL	B-protein
and	O
VAV	B-protein
,	O
were	O
phosphorylated	O
on	O
tyrosine	O
in	O
response	O
to	O
CD80	B-protein
,	O
CD86	B-protein
,	O
and	O
anti-CD28	B-protein
mAb	I-protein
.	O

Surprisingly	O
,	O
although	O
stimulation	O
of	O
Jurkat	B-cell_line
T	I-cell_line
cells	I-cell_line
with	O
either	O
CHO-CD80	B-protein
or	O
anti-CD28	B-protein
mAb	I-protein
resulted	O
in	O
robust	O
tyrosine	O
phosphorylation	O
of	O
CD28	B-protein
itself	O
,	O
ligation	O
with	O
CHO-CD86	B-protein
was	O
unable	O
to	O
induce	O
detectable	O
CD28	B-protein
tyrosyl	O
phosphorylation	O
over	O
a	O
range	O
of	O
stimulation	O
conditions	O
.	O

In	O
addition	O
,	O
the	O
association	O
of	O
phosphoinositide	B-protein
3-kinase	I-protein
with	O
CD28	B-protein
and	O
enhanced	O
tyrosine	O
phosphorylation	O
of	O
phospholipase	O
Cgamma	O
were	O
seen	O
after	O
anti-CD28	O
mAb	O
and	O
CHO-CD80	O
stimulation	O
but	O
to	O
a	O
much	O
lesser	O
extent	O
after	O
CHO-CD86	B-protein
stimulation	O
.	O

Thus	O
,	O
ligation	O
of	O
CD28	B-protein
with	O
either	O
CD80	B-protein
or	O
CD86	B-protein
leads	O
to	O
shared	O
early	O
signal	O
transduction	O
events	O
such	O
as	O
the	O
tyrosine	O
phosphorylation	O
of	O
CBL	B-protein
and	O
VAV	B-protein
,	O
to	O
NFAT	B-protein
-mediated	O
transcriptional	O
activation	O
,	O
and	O
to	O
the	O
costimulation	O
of	O
interleukin-2	B-protein
and	O
granulocyte-macrophage	B-protein
colony-stimulating	I-protein
factor	I-protein
production	O
.	O

However	O
,	O
CD80	B-protein
and	O
CD86	B-protein
also	O
induce	O
distinct	O
signal	O
transduction	O
pathways	O
including	O
the	O
tyrosine	O
phosphorylation	O
of	O
CD28	B-protein
and	O
phospholipase	B-protein
Cgamma1	I-protein
and	O
the	O
SH2	B-protein
-dependent	O
association	O
of	O
phosphoinositide	B-protein
3-kinase	I-protein
with	O
CD28	B-protein
.	O

These	O
quantitative	O
,	O
if	O
not	O
qualitative	O
,	O
differences	O
between	O
signaling	O
initiated	O
by	O
these	O
two	O
ligands	O
for	O
CD28	B-protein
may	O
contribute	O
to	O
functional	O
differences	O
(	O
e.g.	O
Th1	O
or	O
Th2	O
differentiation	O
)	O
in	O
T	O
cell	O
responses	O
.	O

Binding	O
of	O
HMG-I	B-protein
(	I-protein
Y	I-protein
)	I-protein
elicits	O
structural	O
changes	O
in	O
a	O
silencer	O
of	O
the	O
human	B-DNA
beta-globin	I-DNA
gene	I-DNA
.	O

Proteins	O
involved	O
in	O
repression	O
of	O
the	O
human	B-DNA
beta-globin	I-DNA
gene	I-DNA
may	O
be	O
useful	O
in	O
the	O
treatment	O
of	O
sickle	O
cell	O
anemia	O
,	O
in	O
conjunction	O
with	O
therapy	O
to	O
reactivate	O
fetal	B-DNA
globin	I-DNA
genes	I-DNA
.	O

If	O
there	O
is	O
a	O
reciprocal	O
elevation	O
of	O
gamma-globin	B-protein
expression	O
upon	O
repression	O
,	O
this	O
approach	O
could	O
be	O
useful	O
in	O
additional	O
hemoglobinopathies	O
.	O

We	O
previously	O
showed	O
that	O
repression	O
of	O
the	O
beta-globin	O
gene	O
appears	O
to	O
be	O
mediated	O
through	O
two	O
DNA	B-DNA
sequences	I-DNA
,	O
silencers	B-DNA
I	I-DNA
and	I-DNA
II	I-DNA
,	O
and	O
identified	O
a	O
protein	O
termed	O
BP1	B-protein
which	O
binds	O
to	O
both	O
silencer	O
sequences	O
.	O

In	O
this	O
study	O
,	O
we	O
cloned	O
two	O
cDNAs	B-DNA
encoding	O
proteins	O
which	O
bind	O
to	O
an	O
oligonucleotide	O
in	O
silencer	B-DNA
I	I-DNA
containing	O
a	O
BP1	B-protein
binding	O
site	O
.	O

These	O
cDNAs	B-DNA
correspond	O
to	O
HMG-I	B-protein
and	O
HMG-Y	B-protein
,	O
isoforms	O
regarded	O
as	O
architectural	B-protein
proteins	I-protein
.	O

We	O
demonstrate	O
that	O
binding	O
of	O
HMG-I	B-protein
(	I-protein
Y	I-protein
)	I-protein
to	O
this	O
oligonucleotide	O
causes	O
bending/flexure	O
of	O
the	O
DNA	O
.	O

HMG-I	B-protein
(	I-protein
Y	I-protein
)	I-protein
also	O
binds	O
to	O
a	O
second	O
oligonucleotide	O
containing	O
a	O
BP1	B-DNA
binding	I-DNA
site	I-DNA
located	O
in	O
a	O
negative	B-DNA
control	I-DNA
region	I-DNA
upstream	O
of	O
the	O
delta-globin	B-DNA
gene	I-DNA
,	O
suggesting	O
a	O
role	O
for	O
HMG-I	B-protein
(	I-protein
Y	I-protein
)	I-protein
in	O
repression	O
of	O
adult	O
globin	O
genes	O
.	O

Expression	O
studies	O
revealed	O
that	O
HMG-I	B-protein
(	I-protein
Y	I-protein
)	I-protein
is	O
ubiquitously	O
expressed	O
in	O
human	O
tissues	O
that	O
do	O
not	O
express	O
beta-globin	B-protein
,	O
being	O
present	O
in	O
48	O
of	O
50	O
tissues	O
and	O
six	O
hematopoietic	B-cell_line
cell	I-cell_line
lines	I-cell_line
examined	O
.	O

Furthermore	O
,	O
HMG-I	B-protein
(	I-protein
Y	I-protein
)	I-protein
expression	O
is	O
down-regulated	O
during	O
differentiation	O
of	O
primary	B-cell_type
erythroid	I-cell_type
cells	I-cell_type
.	O

We	O
present	O
a	O
model	O
in	O
which	O
HMG-I	B-protein
(	I-protein
Y	I-protein
)	I-protein
alters	O
DNA	O
conformation	O
to	O
allow	O
binding	O
of	O
repressor	B-protein
proteins	I-protein
,	O
and	O
in	O
which	O
the	O
relative	O
amount	O
of	O
HMG-I	O
(	O
Y	O
)	O
helps	O
to	O
determine	O
the	O
repressive	O
state	O
of	O
the	O
beta-globin	B-DNA
gene	I-DNA
.	O

Interactions	O
between	O
the	O
class	B-protein
II	I-protein
transactivator	I-protein
and	O
CREB	B-protein
binding	I-protein
protein	I-protein
increase	O
transcription	O
of	O
major	B-DNA
histocompatibility	I-DNA
complex	I-DNA
class	I-DNA
II	I-DNA
genes	I-DNA
.	O

Class	B-DNA
II	I-DNA
major	I-DNA
histocompatibility	I-DNA
(	I-DNA
class	I-DNA
II	I-DNA
)	I-DNA
genes	I-DNA
are	O
regulated	O
in	O
a	O
B-cell-specific	O
and	O
gamma	O
interferon-inducible	O
fashion	O
.	O

The	O
master	O
switch	O
for	O
the	O
expression	O
of	O
these	O
genes	O
is	O
the	O
class	B-protein
II	I-protein
transactivator	I-protein
(	O
CIITA	B-protein
)	O
.	O

In	O
this	O
report	O
,	O
we	O
demonstrate	O
that	O
one	O
of	O
the	O
functions	O
of	O
CIITA	B-protein
is	O
to	O
recruit	O
the	O
CREB	B-protein
binding	I-protein
protein	I-protein
(	O
CBP	B-protein
)	O
to	O
class	B-DNA
II	I-DNA
promoters	I-DNA
.	O

Not	O
only	O
functional	O
but	O
also	O
specific	O
binding	O
interactions	O
between	O
CIITA	B-protein
and	O
CBP	B-protein
were	O
demonstrated	O
.	O

Moreover	O
,	O
a	O
dominant	O
negative	O
form	O
of	O
CBP	B-protein
decreased	O
the	O
activity	O
of	O
class	B-DNA
II	I-DNA
promoters	I-DNA
and	O
levels	O
of	O
class	B-protein
II	I-protein
determinants	I-protein
on	O
the	O
surface	O
of	O
cells	O
.	O

Finally	O
,	O
the	O
inhibition	O
of	O
class	B-DNA
II	I-DNA
gene	I-DNA
expression	O
by	O
the	O
glucocorticoid	O
hormone	O
could	O
be	O
attributed	O
to	O
the	O
squelching	O
of	O
CBP	B-protein
by	O
the	O
glucocorticoid	B-protein
receptor	I-protein
.	O

We	O
conclude	O
that	O
CBP	B-protein
,	O
a	O
histone	B-protein
acetyltransferase	I-protein
,	O
plays	O
an	O
important	O
role	O
in	O
the	O
transcription	O
of	O
class	B-DNA
II	I-DNA
genes	I-DNA
.	O

Role	O
of	O
cyclic	B-protein
AMP	I-protein
response	I-protein
element-binding	I-protein
protein	I-protein
in	O
cyclic	O
AMP	O
inhibition	O
of	O
NF-kappaB	B-protein
-mediated	O
transcription	O
.	O

The	O
NF-kappaB	B-protein
family	O
of	O
transcription	O
factors	O
regulates	O
the	O
inducible	O
expression	O
of	O
a	O
variety	O
of	O
genes	O
.	O

Recently	O
,	O
we	O
showed	O
that	O
elevation	O
of	O
intracellular	O
cyclic	O
AMP	O
inhibits	O
NF-kappaB	B-protein
-mediated	O
transcription	O
in	O
human	B-cell_type
monocytes	I-cell_type
and	O
endothelial	B-cell_type
cells	I-cell_type
without	O
preventing	O
nuclear	O
translocation	O
of	O
NF-kappaB	B-protein
complexes	I-protein
.	O

The	O
present	O
study	O
examined	O
the	O
molecular	O
mechanism	O
of	O
this	O
inhibition	O
.	O

We	O
hypothesized	O
that	O
activation	O
of	O
the	O
protein	B-protein
kinase	I-protein
A	I-protein
signaling	O
pathway	O
may	O
inhibit	O
NF-kappaB	B-protein
-mediated	O
transcription	O
by	O
phosphorylating	O
proteins	O
,	O
such	O
as	O
cAMP	B-protein
response	I-protein
element-binding	I-protein
protein	I-protein
(	O
CREB	B-protein
)	O
,	O
which	O
compete	O
for	O
limiting	O
amounts	O
of	O
the	O
coactivator	O
CBP	B-protein
.	O

Here	O
,	O
we	O
show	O
that	O
the	O
amino-terminal	B-protein
region	I-protein
(	O
amino	B-protein
acids	I-protein
1-450	I-protein
)	O
of	O
CBP	B-protein
specifically	O
interacts	O
with	O
the	O
carboxyl-terminal	B-protein
region	I-protein
(	O
amino	B-protein
acids	I-protein
286-551	I-protein
)	O
of	O
NF-kappaB	B-protein
p65	B-protein
(	O
RelA	B-protein
)	O
both	O
in	O
vitro	O
and	O
in	O
vivo	O
.	O

Functional	O
studies	O
using	O
human	O
endothelial	B-cell_type
cells	I-cell_type
demonstrated	O
that	O
overexpression	O
of	O
CBP	B-protein
rescued	O
cAMP	O
inhibition	O
of	O
NF-kappaB	B-protein
-mediated	O
transcription	O
and	O
transcription	O
mediated	O
by	O
a	O
chimeric	B-protein
protein	I-protein
,	O
GAL4-p65	B-protein
(	I-protein
286-551	I-protein
)	I-protein
,	O
which	O
contained	O
the	O
GAL4	B-protein
DNA	I-protein
binding	I-protein
domain	I-protein
fused	O
to	O
the	O
carboxyl-terminal	B-protein
region	I-protein
of	O
p65	B-protein
(	O
amino	B-protein
acids	I-protein
286-551	I-protein
)	O
.	O

In	O
contrast	O
,	O
overexpression	O
of	O
CREB	B-protein
inhibited	O
GAL4	B-protein
-p65	O
(	O
286-551	O
)	O
-mediated	O
transcription	O
.	O

These	O
results	O
suggest	O
that	O
activation	O
of	O
the	O
protein	B-protein
kinase	I-protein
A	I-protein
pathway	O
inhibits	O
NF-kappaB	B-protein
transcription	O
by	O
phosphorylating	O
CREB	B-protein
,	O
which	O
competes	O
with	O
p65	B-protein
for	O
limiting	O
amounts	O
of	O
CBP	B-protein
.	O

Glucocorticoid	B-protein
receptors	I-protein
in	O
cord	B-cell_type
blood	I-cell_type
lymphocytes	I-cell_type
of	O
healthy	O
neonates	O
and	O
of	O
preterms	O
suffering	O
from	O
respiratory	O
distress	O
syndrome	O
.	O

We	O
measured	O
the	O
number	O
of	O
glucocorticoid	B-protein
receptors	I-protein
(	O
GR	B-protein
)	O
in	O
cord	B-cell_type
blood	I-cell_type
lymphocytes	I-cell_type
and	O
the	O
binding	O
affinity	O
(	O
Kd	O
)	O
in	O
15	O
term	O
and	O
in	O
20	O
preterm	O
babies	O
.	O

Thirteen	O
preterms	O
of	O
the	O
latter	O
group	O
received	O
prenatal	O
steroid	O
treatment	O
.	O

Seven	O
preterms	O
developed	O
neonatal	O
respiratory	O
distress	O
syndrome	O
(	O
NRDS	O
)	O
.	O

The	O
number	O
of	O
GR	B-protein
and	O
the	O
Kd	O
were	O
similar	O
in	O
the	O
term	O
and	O
preterm	O
(	O
with	O
and	O
without	O
NRDS	O
)	O
babies	O
.	O

The	O
maximum	O
(	O
3H	O
)	O
-thymidine	O
incorporation	O
into	O
DNA	O
of	O
cord	B-cell_type
blood	I-cell_type
lymphocytes	I-cell_type
from	O
all	O
preterms	O
,	O
with	O
or	O
without	O
NRDS	O
was	O
suppressed	O
when	O
compared	O
to	O
that	O
from	O
term	O
babies	O
or	O
adults	O
.	O

This	O
could	O
partly	O
be	O
explained	O
by	O
the	O
antenatal	O
steroid	O
treatment	O
.	O

Sensitivity	O
(	O
ID50	O
)	O
of	O
the	O
lymphocytes	B-cell_type
for	O
the	O
inhibitory	O
effect	O
of	O
dexamethasone	O
was	O
the	O
same	O
in	O
all	O
groups	O
.	O

In	O
this	O
study	O
on	O
the	O
number	O
and	O
function	O
of	O
GR	B-protein
in	O
lymphocytes	B-cell_type
,	O
we	O
were	O
unable	O
to	O
find	O
a	O
relation	O
between	O
the	O
functionality	O
of	O
the	O
GR	B-protein
and	O
the	O
development	O
of	O
NRDS	O
.	O

Inefficient	O
termination	O
of	O
antigen	O
responses	O
in	O
NF-ATp	B-protein
-deficient	O
mice	O
.	O

In	O
order	O
to	O
elucidate	O
the	O
role	O
of	O
NF-ATp	B-protein
,	O
one	O
of	O
the	O
most	O
prominent	O
members	O
of	O
family	O
of	O
NF-AT	B-protein
transcription	I-protein
factors	I-protein
in	O
peripheral	B-cell_type
T	I-cell_type
lymphocytes	I-cell_type
,	O
in	O
T	O
cell	O
activation	O
and	O
differentiation	O
we	O
created	O
NF-ATp	B-protein
-deficient	O
mice	O
by	O
gene	O
targeting	O
.	O

Such	O
NF-ATp	B-protein
-/-	O
mice	O
are	O
born	O
and	O
appear	O
to	O
develop	O
a	O
normal	O
immune	O
system	O
.	O

Apart	O
from	O
clear-cut	O
defects	O
in	O
the	O
synthesis	O
of	O
mRNAs	B-RNA
for	O
Th2-type	B-protein
lymphokines	I-protein
,	O
such	O
as	O
IL-4	B-protein
,	O
IL-5	B-protein
,	O
IL-10	B-protein
and	O
IL-13	B-protein
,	O
in	O
primary	O
and	O
secondary	O
stimulations	O
of	O
spleen	B-cell_type
cells	I-cell_type
in	O
vitro	O
,	O
of	O
a	O
distinct	O
impaired	O
deletion	O
of	O
V	B-cell_line
beta	I-cell_line
11+/CD4+	I-cell_line
T	I-cell_line
lymphocytes	I-cell_line
from	O
these	O
mice	O
was	O
detected	O
after	O
superantigen	O
injection	O
.	O

Moreover	O
,	O
NF-ATp	B-protein
-/-	O
mice	O
older	O
than	O
6	O
weeks	O
show	O
an	O
2-5	O
fold	O
increase	O
in	O
number	O
of	O
lymphocytes	B-cell_type
.	O

This	O
is	O
correlated	O
with	O
an	O
increased	O
expression	O
of	O
activation	B-protein
markers	I-protein
CD44	B-protein
and	O
CD69	B-protein
and	O
decreased	O
expression	O
of	O
CD62	B-protein
.	O

AML	B-protein
and	I-protein
Ets	I-protein
proteins	I-protein
regulate	O
the	O
I	B-DNA
alpha1	I-DNA
germ-line	I-DNA
promoter	I-DNA
.	O

The	O
immunoglobulin	B-protein
heavy	I-protein
chain	I-protein
(	O
IgH	B-protein
)	O
class	O
switch	O
recombination	O
of	O
B	B-cell_type
lymphocytes	I-cell_type
preferentially	O
targets	O
unrearranged	O
IgH	B-DNA
genes	I-DNA
that	O
have	O
already	O
been	O
rendered	O
transcriptionally	O
active	O
.	O

Transcription	O
of	O
the	O
germ-line	B-DNA
IgH	I-DNA
genes	I-DNA
is	O
controlled	O
by	O
intervening	B-DNA
(	I-DNA
I	I-DNA
)	I-DNA
regions	I-DNA
upstream	O
of	O
their	O
switch	O
regions	O
.	O

The	O
I	O
alpha1	O
promoter	O
activates	O
transcription	O
of	O
the	O
human	B-DNA
germ-line	I-DNA
C	I-DNA
alpha1	I-DNA
gene	I-DNA
for	O
IgA1	B-protein
and	O
mediates	O
the	O
transforming	B-protein
growth	I-protein
factor	I-protein
(	I-protein
TGF	I-protein
)	I-protein
-beta1	I-protein
responsiveness	O
of	O
this	O
locus	O
.	O

Here	O
we	O
show	O
that	O
the	O
I	O
alpha1	O
promoter	O
contains	O
several	O
binding	O
sites	O
for	O
the	O
AML/PEBP2/CBF	B-protein
family	I-protein
of	I-protein
transcription	I-protein
factors	I-protein
and	O
that	O
AML	B-protein
and	I-protein
Ets	I-protein
proteins	I-protein
are	O
major	O
regulators	O
of	O
the	O
basal	O
and	O
TGF-beta-inducible	O
promoter	O
activity	O
.	O

Our	O
data	O
constitute	O
a	O
starting	O
point	O
for	O
studies	O
to	O
elucidate	O
the	O
molecular	O
mechanism	O
by	O
which	O
TGF-beta	B-protein
regulates	O
IgA	B-protein
production	O
.	O

Daidzein	O
and	O
genistein	O
glucuronides	O
in	O
vitro	O
are	O
weakly	O
estrogenic	O
and	O
activate	O
human	B-cell_type
natural	I-cell_type
killer	I-cell_type
cells	I-cell_type
at	O
nutritionally	O
relevant	O
concentrations	O
.	O

Daidzein	O
and	O
genistein	O
glucuronides	O
(	O
DG	O
and	O
GG	O
)	O
,	O
major	O
isoflavone	O
metabolites	O
,	O
may	O
be	O
partly	O
responsible	O
for	O
biological	O
effects	O
of	O
isoflavones	O
,	O
such	O
as	O
estrogen	O
receptor	O
binding	O
and	O
natural	B-cell_type
killer	I-cell_type
cell	I-cell_type
(	O
NK	O
)	O
activation	O
or	O
inhibition	O
.	O

DG	O
and	O
GG	O
were	O
synthesized	O
using	O
3-methylcholanthrene-induced	O
rat	O
liver	O
microsomes	O
.	O

The	O
Km	O
and	O
Vmax	O
for	O
daidzein	O
and	O
genistein	O
were	O
9.0	O
and	O
7.7	O
micromol/L	O
,	O
and	O
0.7	O
and	O
1.6	O
micromol/	O
(	O
mg	O
protein.	O
min	O
)	O
,	O
respectively	O
.	O

The	O
absence	O
of	O
ultraviolet	O
absorbance	O
maxima	O
shifts	O
in	O
the	O
presence	O
of	O
sodium	O
acetate	O
confirmed	O
that	O
the	O
synthesized	O
products	O
were	O
7-O-glucuronides	O
.	O

DG	O
and	O
GG	O
were	O
further	O
purified	O
by	O
a	O
Sephadex	O
LH-20	O
column	O
.	O

DG	O
and	O
GG	O
competed	O
with	O
the	O
binding	O
of	O
17beta-	O
(	O
3H	O
)	O
estradiol	O
to	O
estrogen	B-protein
receptors	I-protein
of	O
B6D2F1	O
mouse	O
uterine	O
cytosol	O
.	O

The	O
concentrations	O
required	O
for	O
50	O
%	O
displacement	O
of	O
17beta-	O
(	O
3H	O
)	O
estradiol	O
(	O
CB50	O
)	O
were	O
:	O
17beta-estradiol	O
,	O
1.34	O
nmol/L	O
;	O
diethylstilbestrol	O
,	O
1.46	O
nmol/L	O
;	O
daidzein	O
,	O
1.6	O
micromol/L	O
;	O
DG	O
,	O
14.7	O
micromol/L	O
;	O
genistein	O
,	O
0.154	O
micromol/L	O
;	O
GG	O
,	O
7.27	O
micromol/L	O
.	O

In	O
human	B-cell_type
peripheral	I-cell_type
blood	I-cell_type
NK	I-cell_type
cells	I-cell_type
,	O
genistein	O
at	O
<	O
0.5	O
micromol/L	O
and	O
DG	O
and	O
GG	O
at	O
0.1-10	O
micromol/L	O
enhanced	O
NK	O
cell-mediated	O
K562	B-cell_line
cancer	I-cell_line
cell	I-cell_line
killing	O
significantly	O
(	O
P	O
<	O
0.05	O
)	O
.	O

At	O
>	O
0.5	O
micromol/L	O
,	O
genistein	O
inhibited	O
NK	O
cytotoxicity	O
significantly	O
(	O
P	O
<	O
0.05	O
)	O
.	O

The	O
glucuronides	O
only	O
inhibited	O
NK	O
cytotoxicity	O
at	O
50	O
micromol/L	O
.	O

Isoflavones	O
,	O
and	O
especially	O
the	O
isoflavone	O
glucuronides	O
,	O
enhanced	O
activation	O
of	O
NK	B-cell_type
cells	I-cell_type
by	O
interleukin-2	B-protein
(	O
IL-2	B-protein
)	O
,	O
additively	O
.	O

At	O
physiological	O
concentrations	O
,	O
DG	O
and	O
GG	O
were	O
weakly	O
estrogenic	O
,	O
and	O
they	O
activated	O
human	B-cell_type
NK	I-cell_type
cells	I-cell_type
in	O
nutritionally	O
relevant	O
concentrations	O
in	O
vitro	O
,	O
probably	O
at	O
a	O
site	O
different	O
from	O
IL-2	B-protein
action	O
.	O

Cross-linking	O
of	O
CD44	B-protein
on	O
rheumatoid	B-cell_type
synovial	I-cell_type
cells	I-cell_type
up-regulates	O
VCAM-1	B-protein
.	O

CD44	O
is	O
a	O
ubiquitous	O
molecule	O
also	O
known	O
as	O
hyaluronic	O
acid	O
or	O
homing	O
receptor	O
.	O

However	O
,	O
the	O
cellular	O
functions	O
and	O
its	O
role	O
in	O
inflammation	O
,	O
for	O
example	O
,	O
rheumatoid	O
synovitis	O
,	O
are	O
currently	O
unknown	O
.	O

In	O
this	O
study	O
,	O
we	O
propose	O
a	O
novel	O
function	O
for	O
CD44	O
.	O

Using	O
synovial	O
cells	O
from	O
rheumatoid	O
arthritis	O
(	O
RA	O
)	O
patients	O
,	O
we	O
demonstrated	O
that	O
CD44	O
cross-linking	O
and	O
binding	O
to	O
hyaluronan	O
augmented	O
VCAM-1	B-protein
expression	O
and	O
subsequently	O
VCAM-1	B-protein
-mediated	O
cell	O
adhesion	O
.	O

Briefly	O
,	O
we	O
found	O
that	O
1	O
)	O
rheumatoid	B-cell_type
synovial	I-cell_type
cells	I-cell_type
highly	O
expressed	O
CD44	B-protein
;	O
2	O
)	O
cross-linking	O
of	O
CD44	B-protein
markedly	O
but	O
transiently	O
augmented	O
VCAM-1	B-protein
expression	O
and	O
its	O
mRNA	O
transcription	O
much	O
more	O
than	O
did	O
IL-1beta	B-protein
and	O
TNF-alpha	O
;	O
3	O
)	O
hyaluronan	O
,	O
especially	O
when	O
fragmented	O
,	O
also	O
up-regulated	O
VCAM-1	B-protein
;	O
4	O
)	O
CD44	B-protein
activated	O
the	O
transcription	O
factor	O
AP-1	O
;	O
and	O
5	O
)	O
the	O
integrin	B-protein
-dependent	O
adhesive	O
function	O
of	O
RA	B-cell_type
synovial	I-cell_type
cells	I-cell_type
to	O
T	B-cell_type
cells	I-cell_type
was	O
also	O
amplified	O
by	O
CD44	B-protein
cross-linking	O
.	O

These	O
results	O
indicate	O
that	O
the	O
adhesion	O
of	O
RA	B-cell_type
synovial	I-cell_type
cells	I-cell_type
to	O
matrices	O
such	O
as	O
hyaluronic	O
acid	O
through	O
CD44	B-protein
could	O
up-regulate	O
VCAM-1	B-protein
expression	O
and	O
VCAM-1	B-protein
-mediated	O
adhesion	O
to	O
T	B-cell_type
cells	I-cell_type
,	O
which	O
might	O
in	O
turn	O
cause	O
activation	O
of	O
T	B-cell_type
cells	I-cell_type
and	O
synovial	B-cell_type
cells	I-cell_type
in	O
RA	O
synovitis	O
.	O

We	O
therefore	O
propose	O
that	O
such	O
cross-talking	O
among	O
distinct	O
adhesion	O
molecules	O
may	O
be	O
involved	O
in	O
the	O
pathogenesis	O
of	O
inflammation	O
,	O
including	O
RA	O
synovitis	O
.	O

NF-kappaB	B-protein
activation	O
is	O
a	O
critical	O
regulator	O
of	O
human	O
granulocyte	O
apoptosis	O
in	O
vitro	O
.	O

During	O
beneficial	O
inflammation	O
,	O
potentially	O
tissue-damaging	B-cell_type
granulocytes	I-cell_type
undergo	O
apoptosis	O
before	O
being	O
cleared	O
by	O
phagocytes	O
in	O
a	O
non-phlogistic	O
manner	O
.	O

Here	O
we	O
show	O
that	O
the	O
rate	O
of	O
constitutive	O
apoptosis	O
in	O
human	B-cell_type
neutrophils	I-cell_type
and	O
eosinophils	B-cell_type
is	O
greatly	O
accelerated	O
in	O
both	O
a	O
rapid	O
and	O
concentration-dependent	O
manner	O
by	O
the	O
fungal	O
metabolite	O
gliotoxin	O
,	O
but	O
not	O
by	O
its	O
inactive	O
analog	O
methylthiogliotoxin	O
.	O

This	O
induction	O
of	O
apoptosis	O
was	O
abolished	O
by	O
the	O
caspase	O
inhibitor	O
zVAD-fmk	O
,	O
correlated	O
with	O
the	O
inhibition	O
of	O
nuclear	B-protein
factor-kappa	I-protein
B	I-protein
(	O
NF-kappaB	B-protein
)	O
,	O
and	O
was	O
mimicked	O
by	O
a	O
cell	O
permeable	O
inhibitory	O
peptide	O
of	O
NF-kappaB	B-protein
,	O
SN-50	O
;	O
other	O
NF-kappaB	B-protein
inhibitors	O
,	O
curcumin	O
and	O
pyrrolidine	O
dithiocarbamate	O
;	O
and	O
the	O
proteasome	O
inhibitor	O
,	O
MG-132	O
.	O

Gliotoxin	O
also	O
augmented	O
dramatically	O
the	O
early	O
(	O
2-6	O
h	O
)	O
pro-apoptotic	O
effects	O
of	O
tumor	B-protein
necrosis	I-protein
factor-alpha	I-protein
(	O
TNF-alpha	B-protein
)	O
in	O
neutrophils	B-cell_type
and	O
unmasked	O
the	O
ability	O
of	O
TNF-alpha	B-protein
to	O
induce	O
eosinophil	B-cell_type
apoptosis	O
.	O

In	O
neutrophils	B-cell_type
,	O
TNF-alpha	B-protein
caused	O
a	O
gliotoxin-inhibitable	O
activation	O
of	O
an	O
inducible	O
form	O
of	O
NF-kappaB	B-protein
,	O
a	O
response	O
that	O
may	O
underlie	O
the	O
ability	O
of	O
TNF-alpha	B-protein
to	O
delay	O
apoptosis	O
at	O
later	O
times	O
(	O
12-24	O
h	O
)	O
and	O
limit	O
its	O
early	O
killing	O
effect	O
.	O

Furthermore	O
,	O
cycloheximide	O
displayed	O
a	O
similar	O
capacity	O
to	O
enhance	O
TNF-alpha	B-protein
induced	O
neutrophil	O
apoptosis	O
even	O
at	O
time	O
points	O
when	O
cycloheximide	O
alone	O
had	O
no	O
pro-apoptotic	O
effect	O
,	O
suggesting	O
that	O
NF-kappaB	B-protein
may	O
regulate	O
the	O
production	O
of	O
protein	O
(	O
s	O
)	O
which	O
protect	O
neutrophils	B-cell_type
from	O
the	O
cytotoxic	O
effects	O
of	O
TNF-alpha	B-protein
.	O

These	O
data	O
shed	O
light	O
on	O
the	O
biochemical	O
and	O
molecular	O
mechanisms	O
regulating	O
human	O
granulocyte	O
apoptosis	O
and	O
,	O
in	O
particular	O
,	O
indicate	O
that	O
the	O
transcription	B-protein
factor	I-protein
NF-kappaB	B-protein
plays	O
a	O
crucial	O
role	O
in	O
regulating	O
the	O
physiological	O
cell	O
death	O
pathway	O
in	O
granulocytes	B-cell_type
.	O

Role	O
of	O
Egr-2	B-protein
in	O
up-regulation	O
of	O
Fas	B-protein
ligand	I-protein
in	O
normal	O
T	B-cell_type
cells	I-cell_type
and	O
aberrant	B-cell_type
double-negative	I-cell_type
lpr	I-cell_type
and	I-cell_type
gld	I-cell_type
T	I-cell_type
cells	I-cell_type
.	O

We	O
previously	O
identified	O
a	O
Fas	B-DNA
ligand	I-DNA
regulatory	I-DNA
element	I-DNA
(	O
FLRE	B-DNA
)	O
in	O
the	O
Fas	B-DNA
ligand	I-DNA
(	I-DNA
fasL	I-DNA
)	I-DNA
promoter	I-DNA
that	O
binds	O
Egr	B-protein
family	I-protein
proteins	I-protein
and	O
demonstrated	O
that	O
Egr-3	B-protein
(	O
PILOT	B-protein
)	O
but	O
not	O
Egr-1	B-protein
(	O
NGFI-A	B-protein
,	O
Krox-24	B-protein
,	O
Tis-8	B-protein
,	O
and	O
Zif-268	B-protein
)	O
induces	O
transcription	O
of	O
fasL	B-protein
.	O

The	O
aberrant	B-cell_type
CD4	I-cell_type
(	I-cell_type
-	I-cell_type
)	I-cell_type
CD8	I-cell_type
(	I-cell_type
-	I-cell_type
)	I-cell_type
T	I-cell_type
cells	I-cell_type
from	O
lpr/lpr	O
and	O
gld/gld	O
mice	O
,	O
which	O
have	O
mutations	O
in	O
the	O
genes	O
encoding	O
Fas	B-protein
and	O
FasL	B-protein
,	O
respectively	O
,	O
have	O
an	O
activated	O
phenotype	O
and	O
constitutively	O
express	O
high	O
levels	O
of	O
fasL	B-RNA
mRNA	I-RNA
,	O
prompting	O
us	O
to	O
ask	O
what	O
role	O
if	O
any	O
the	O
FLRE	B-DNA
and	O
Egr	B-protein
family	I-protein
proteins	I-protein
have	O
in	O
this	O
aberrant	O
expression	O
of	O
fasL	B-protein
.	O

Unstimulated	O
MRL-lpr/lpr	B-cell_line
and	I-cell_line
C3H-gld/gld	I-cell_line
CD4	I-cell_line
(	I-cell_line
-	I-cell_line
)	I-cell_line
CD8	I-cell_line
(	I-cell_line
-	I-cell_line
)	I-cell_line
T	I-cell_line
cells	I-cell_line
constitutively	O
contained	O
high	O
levels	O
of	O
two	O
proteins	O
that	O
bound	O
to	O
the	O
FLRE	B-DNA
.	O

Supershift	O
analysis	O
revealed	O
these	O
proteins	O
to	O
be	O
Egr-1	B-protein
and	O
Egr-2	B-protein
(	O
Krox-20	O
)	O
;	O
Egr-3	B-protein
was	O
not	O
detected	O
.	O

Activation	O
of	O
normal	B-cell_type
lymph	I-cell_type
node	I-cell_type
cells	I-cell_type
resulted	O
in	O
increased	O
expression	O
of	O
Egr-1	B-protein
,	I-protein
-2	I-protein
,	I-protein
and	I-protein
-3	I-protein
.	O

As	O
with	O
egr-3	B-DNA
,	O
expression	O
of	O
egr-2	B-DNA
was	O
blocked	O
by	O
cyclosporin	O
A	O
.	O

Although	O
overexpressed	O
Egr-1	B-protein
was	O
ineffective	O
,	O
overexpressed	O
Egr-2	B-protein
was	O
as	O
potent	O
as	O
Egr-3	B-protein
in	O
inducing	O
fasL	B-DNA
promoter-dependent	I-DNA
reporter	I-DNA
constructs	I-DNA
in	O
T	O
cell	O
hybridomas	O
and	O
HeLa	O
cells	O
,	O
and	O
both	O
up-regulated	O
endogenous	O
fasL	B-RNA
mRNA	I-RNA
in	O
HeLa	B-cell_line
cells	I-cell_line
.	O

FasL-dependent	B-DNA
reporter	I-DNA
constructs	I-DNA
in	O
MRL-lpr/lpr	B-cell_line
and	I-cell_line
C3H-gld/gld	I-cell_line
CD4	I-cell_line
(	I-cell_line
-	I-cell_line
)	I-cell_line
CD8	I-cell_line
(	I-cell_line
-	I-cell_line
)	I-cell_line
T	I-cell_line
cells	I-cell_line
were	O
constitutively	O
active	O
,	O
and	O
this	O
activity	O
was	O
largely	O
prevented	O
by	O
mutation	O
of	O
the	O
critical	O
Egr	B-DNA
family	I-DNA
binding	I-DNA
element	I-DNA
.	O

Thus	O
,	O
Egr-2	B-protein
,	O
in	O
addition	O
to	O
Egr-3	B-protein
,	O
regulates	O
FasL	B-protein
expression	O
in	O
activated	O
normal	O
T	B-cell_type
cells	I-cell_type
,	O
and	O
Egr-2	B-protein
is	O
likely	O
to	O
play	O
a	O
direct	O
role	O
in	O
aberrant	O
fasL	B-protein
up-regulation	O
in	O
lpr/lpr	B-cell_line
and	I-cell_line
gld/gld	I-cell_line
CD4	I-cell_line
(	I-cell_line
-	I-cell_line
)	I-cell_line
CD8	I-cell_line
(	I-cell_line
-	I-cell_line
)	I-cell_line
T	I-cell_line
cells	I-cell_line
.	O

The	O
activity	O
of	O
the	O
CCAAT-box	B-protein
binding	I-protein
factor	I-protein
NF-Y	I-protein
is	O
modulated	O
through	O
the	O
regulated	O
expression	O
of	O
its	O
A	B-protein
subunit	I-protein
during	O
monocyte	O
to	O
macrophage	O
differentiation	O
:	O
regulation	O
of	O
tissue-specific	B-DNA
genes	I-DNA
through	O
a	O
ubiquitous	O
transcription	B-protein
factor	I-protein
.	O

In	O
this	O
study	O
,	O
we	O
analyzed	O
the	O
regulation	O
of	O
NF-Y	B-protein
expression	O
during	O
human	O
monocyte	O
to	O
macrophage	O
maturation	O
.	O

NF-Y	B-protein
is	O
a	O
ubiquitous	O
and	O
evolutionarily	O
conserved	O
transcription	B-protein
factor	I-protein
that	O
binds	O
specifically	O
to	O
the	O
CCAAT	B-DNA
motif	I-DNA
present	O
in	O
the	O
5	B-DNA
'	I-DNA
promoter	I-DNA
region	I-DNA
of	O
a	O
wide	O
variety	O
of	O
genes	O
.	O

We	O
show	O
here	O
that	O
in	O
circulating	B-cell_type
monocytes	I-cell_type
,	O
NF-Y	B-protein
binding	O
activity	O
is	O
not	O
detected	O
on	O
the	O
CCAAT	B-DNA
motif	I-DNA
present	O
in	O
the	O
promoters	B-DNA
of	I-DNA
genes	I-DNA
such	O
as	O
major	B-DNA
histocompatibility	I-DNA
complex	I-DNA
(	I-DNA
MHC	I-DNA
)	I-DNA
class	I-DNA
II	I-DNA
,	O
gp91-phox	B-DNA
,	O
mig	B-DNA
,	O
and	O
fibronectin	O
,	O
whereas	O
during	O
macrophage	O
differentiation	O
,	O
a	O
progressive	O
increase	O
in	O
NF-Y	B-protein
binding	O
activity	O
is	O
observed	O
on	O
these	O
promoters	O
.	O

Analysis	O
of	O
NF-Y	B-protein
subunit	O
expression	O
indicates	O
that	O
the	O
absence	O
of	O
NF-Y	B-protein
activity	O
in	O
circulating	B-cell_type
monocytes	I-cell_type
is	O
caused	O
by	O
a	O
lack	O
of	O
the	O
A	B-protein
subunit	I-protein
.	O

Furthermore	O
,	O
addition	O
of	O
the	O
recombinant	O
NF-Y	B-protein
A	B-protein
subunit	I-protein
restores	O
NF-Y	B-protein
binding	O
.	O

We	O
show	O
that	O
the	O
lack	O
of	O
NF-YA	B-protein
protein	I-protein
is	O
due	O
to	O
posttranscriptional	O
regulation	O
and	O
not	O
to	O
a	O
specific	O
proteolytic	O
activity	O
.	O

In	O
fact	O
,	O
NF-YA	B-RNA
mRNA	I-RNA
is	O
present	O
at	O
the	O
same	O
level	O
at	O
all	O
days	O
of	O
monocyte	O
cultivation	O
,	O
whereas	O
the	O
protein	O
is	O
absent	O
in	O
freshly	B-cell_type
isolated	I-cell_type
monocytes	I-cell_type
but	O
is	O
progressively	O
synthesized	O
during	O
the	O
maturation	O
process	O
.	O

We	O
thus	O
conclude	O
that	O
the	O
NF-Y	B-protein
A	B-protein
subunit	I-protein
plays	O
a	O
relevant	O
role	O
in	O
activating	O
transcription	O
of	O
genes	O
highly	O
expressed	O
in	O
mature	B-cell_type
monocytes	I-cell_type
.	O

In	O
line	O
with	O
this	O
conclusion	O
,	O
we	O
show	O
that	O
the	O
cut/CDP	B-protein
protein	I-protein
,	O
a	O
transcriptional	O
repressor	O
that	O
inhibits	O
gpc91-phox	B-DNA
gene	I-DNA
expression	O
by	O
preventing	O
NF-Y	B-protein
binding	O
to	O
the	O
CAAT	B-DNA
box	I-DNA
,	O
is	O
absent	O
in	O
monocytes	B-cell_type
.	O

Interdomain	B-protein
B	I-protein
in	O
ZAP-70	B-protein
regulates	O
but	O
is	O
not	O
required	O
for	O
ZAP-70	B-protein
signaling	O
function	O
in	O
lymphocytes	B-cell_type
.	O

The	O
protein	O
tyrosine	O
kinase	O
ZAP-70	B-protein
plays	O
an	O
important	O
role	O
in	O
T-cell	O
activation	O
and	O
development	O
.	O

After	O
T-cell	B-protein
receptor	I-protein
stimulation	O
,	O
ZAP-70	B-protein
associates	O
with	O
the	O
receptor	O
and	O
is	O
phosphorylated	O
on	O
many	O
tyrosines	O
,	O
including	O
Y292	O
,	O
Y315	O
,	O
and	O
Y319	O
within	O
interdomain	O
B	O
.	O

Previously	O
,	O
we	O
demonstrated	O
that	O
Y292	O
negatively	O
regulates	O
ZAP-70	B-protein
function	O
and	O
that	O
Y315	O
positively	O
regulates	O
ZAP-70	B-protein
function	O
by	O
interacting	O
with	O
Vav	B-protein
.	O

Recent	O
studies	O
have	O
suggested	O
that	O
Y319	O
also	O
positively	O
regulate	O
ZAP-70	B-protein
function	O
.	O

Paradoxically	O
,	O
removal	O
of	O
interdomain	B-protein
B	I-protein
(	O
to	O
create	O
the	O
construct	O
designated	O
Delta	B-protein
)	O
,	O
containing	O
the	O
Y292	O
,	O
Y315	O
,	O
and	O
Y319	O
sites	O
,	O
did	O
not	O
eliminate	O
the	O
ability	O
of	O
ZAP-70	B-protein
to	O
induce	O
multiple	B-DNA
gene	I-DNA
reporters	I-DNA
in	O
Syk-deficient	B-cell_line
DT-40	I-cell_line
B	I-cell_line
cells	I-cell_line
and	O
ZAP-70/Syk-deficient	B-cell_line
Jurkat	I-cell_line
cells	I-cell_line
.	O

Here	O
we	O
show	O
that	O
Delta	B-protein
still	O
utilizes	O
the	O
same	O
pathways	O
as	O
wild-type	O
ZAP-70	B-protein
to	O
mediate	O
NF-AT	B-protein
induction	O
.	O

This	O
is	O
manifested	O
by	O
the	O
ability	O
of	O
Delta	B-protein
to	O
restore	O
induction	O
of	O
calcium	O
fluxes	O
and	O
mitogen-activated	B-protein
protein	I-protein
kinase	I-protein
activation	O
and	O
by	O
the	O
ability	O
of	O
dominant	O
negative	O
Ras	B-protein
and	O
FK506	B-protein
to	O
block	O
the	O
induction	O
of	O
NF-AT	B-protein
activity	O
mediated	O
by	O
Delta	B-protein
.	O

Biochemically	O
we	O
show	O
that	O
the	O
stimulated	O
tyrosine	O
phosphorylation	O
of	O
Vav	B-protein
,	O
Shc	B-protein
,	O
and	O
ZAP-70	B-protein
itself	O
is	O
diminished	O
,	O
whereas	O
that	O
of	O
Slp-76	B-protein
is	O
increased	O
in	O
cells	O
reconstituted	O
with	O
Delta	B-protein
.	O

Deletion	O
of	O
interdomain	B-protein
B	I-protein
did	O
not	O
affect	O
the	O
ability	O
of	O
ZAP-70	B-protein
to	O
bind	O
to	O
the	O
receptor	O
.	O

The	O
in	O
vitro	O
kinase	O
activity	O
of	O
ZAP-70	B-protein
lacking	O
interdomain	B-protein
B	I-protein
was	O
markedly	O
reduced	O
,	O
but	O
the	O
kinase	O
activity	O
was	O
still	O
required	O
for	O
the	O
protein	O
's	O
in	O
vivo	O
activity	O
.	O

Based	O
on	O
these	O
data	O
,	O
we	O
concluded	O
that	O
interdomain	B-protein
B	I-protein
regulates	O
but	O
is	O
not	O
required	O
for	O
ZAP-70	B-protein
signaling	O
function	O
leading	O
to	O
cellular	O
responses	O
.	O

Differential	O
induction	O
of	O
DNA-binding	B-protein
activities	I-protein
following	O
CD19	B-protein
cross-linking	O
in	O
human	B-cell_type
B	I-cell_type
lineage	I-cell_type
cells	I-cell_type
.	O

The	O
B	B-protein
cell-specific	I-protein
cell	I-protein
surface	I-protein
molecule	I-protein
CD19	B-protein
is	O
expressed	O
at	O
all	O
stages	O
of	O
B	O
cell	O
development	O
,	O
including	O
normal	O
plasma	O
cells	O
,	O
and	O
mediates	O
signal	O
transduction	O
via	O
interaction	O
with	O
cytoplasmic	B-protein
effector	I-protein
proteins	I-protein
.	O

Cross-linking	O
CD19	B-protein
on	O
early	O
human	B-cell_type
B	I-cell_type
lineage	I-cell_type
cells	I-cell_type
induces	O
the	O
formation	O
of	O
a	O
CD19/Vav/phosphatidylinositol-3	B-protein
kinase	I-protein
complex	I-protein
,	O
tyrosine	O
phosphorylation	O
of	O
CD19	B-protein
and	O
Vav	B-protein
,	O
and	O
activation	O
of	O
the	O
Ras	B-protein
pathway	O
.	O

To	O
further	O
explore	O
the	O
ramifications	O
of	O
CD19	B-protein
signaling	O
,	O
the	O
current	O
study	O
examined	O
whether	O
phosphorylation	O
of	O
Elk-1	B-protein
,	O
activation	O
of	O
activator	B-protein
protein-1	I-protein
(	O
AP-1	B-protein
)	O
,	O
or	O
activation	O
of	O
nuclear	O
factor-kappaB	O
(	O
NF-kappaB	B-protein
)	O
transcription	B-protein
factors	I-protein
occurred	O
following	O
CD19	B-protein
cross-linking	O
.	O

The	O
cells	O
used	O
were	O
the	O
BLIN-1	B-cell_line
pre-B	I-cell_line
cell	I-cell_line
line	I-cell_line
expressing	O
low	O
levels	O
of	O
cell	B-protein
surface	I-protein
mu	I-protein
heavy	I-protein
chain	I-protein
associated	O
with	O
surrogate	B-protein
light	I-protein
chain	I-protein
and	O
the	O
1E8	O
immature	O
B	O
cell	O
line	O
expressing	O
cell	B-protein
surface	I-protein
mu/kappa	I-protein
.	O

Lysates	O
from	O
CD19	B-protein
cross-linked	O
1E8	B-cell_line
cells	I-cell_line
induced	O
robust	O
phosphorylation	O
of	O
an	O
Elk-1	B-protein
fusion	I-protein
protein	I-protein
in	O
vitro	O
,	O
whereas	O
no	O
phosphorylation	O
of	O
Elk-1	B-protein
fusion	I-protein
protein	I-protein
occurred	O
using	O
lysates	O
from	O
CD19	B-cell_line
cross-linked	I-cell_line
BLIN-1	I-cell_line
cells	I-cell_line
.	O

An	O
electrophoretic	O
mobility	O
shift	O
assay	O
employing	O
AP-1	B-protein
and	O
NF-kappaB	B-protein
consensus	O
oligonucleotides	O
was	O
used	O
to	O
demonstrate	O
that	O
AP-1	B-protein
-binding	O
activity	O
increased	O
,	O
while	O
constitutive	O
NF-kappaB	B-protein
-binding	O
activity	O
was	O
not	O
enhanced	O
,	O
following	O
2	O
h	O
of	O
CD19	B-protein
cross-linking	O
in	O
1E8	B-cell_line
cells	I-cell_line
.	O
Supershift	O
experiments	O
revealed	O
that	O
JunD	B-protein
and	O
c-Fos	B-protein
proteins	I-protein
mediated	O
anti-	O
CD19	B-protein
induced	O
AP-1	B-protein
-binding	O
activity	O
in	O
1E8	B-cell_line
cells	I-cell_line
.	O

In	O
contrast	O
,	O
CD19	B-protein
cross-linking	O
in	O
BLIN-1	B-cell_line
cells	I-cell_line
resulted	O
in	O
the	O
induction	O
of	O
NF-kappaB	B-protein
,	O
but	O
had	O
no	O
apparent	O
effect	O
on	O
AP-1	B-protein
-binding	O
activity	O
.	O

These	O
data	O
suggest	O
that	O
CD19	B-protein
-mediated	O
signal	O
transduction	O
activates	O
different	O
transcription	B-protein
factors	I-protein
at	O
juxtaposed	O
stages	O
of	O
B	O
cell	O
development	O
that	O
may	O
culminate	O
in	O
the	O
activation	O
or	O
suppression	O
of	O
distinct	O
sets	O
of	O
genes	B-DNA
.	O

Oxidants	O
,	O
transcription	B-protein
factors	I-protein
,	O
and	O
intestinal	O
inflammation	O
.	O

It	O
is	O
now	O
well	O
appreciated	O
that	O
chronic	O
gut	O
inflammation	O
is	O
characterized	O
by	O
enhanced	O
production	O
of	O
reactive	O
metabolites	O
of	O
oxygen	O
and	O
nitrogen	O
.	O

Some	O
of	O
these	O
oxidants	O
are	O
known	O
to	O
modulate	O
the	O
expression	O
of	O
a	O
variety	O
of	O
genes	O
that	O
are	O
involved	O
in	O
the	O
immune	O
and	O
inflammatory	O
responses	O
.	O

For	O
example	O
,	O
certain	O
oxidants	O
are	O
known	O
to	O
activate	O
the	O
nuclear	B-protein
transcription	I-protein
factor	I-protein
kappa	I-protein
B	I-protein
,	O
which	O
regulates	O
the	O
expression	O
of	O
a	O
variety	O
of	O
different	O
adhesion	B-protein
molecules	I-protein
,	O
cytokines	B-protein
,	O
and	O
enzymes	B-protein
.	O

Oxidants	O
are	O
also	O
known	O
to	O
activate	O
another	O
transcription	B-protein
factor	I-protein
,	O
activator	B-protein
protein-1	I-protein
.	O

This	O
transcription	B-protein
factor	I-protein
is	O
composed	O
of	O
products	O
from	O
the	O
fos	B-protein
and	I-protein
jun	I-protein
proto-oncogene	I-protein
family	I-protein
and	O
is	O
believed	O
to	O
be	O
important	O
in	O
regulating	O
cell	O
growth	O
and	O
proliferation	O
.	O

Finally	O
,	O
oxidants	O
are	O
believed	O
to	O
promote	O
intestinal	B-cell_type
epithelial	I-cell_type
cell	I-cell_type
apoptosis	O
,	O
and	O
the	O
B-cell	B-protein
lymphoma/leukemia-2	I-protein
gene	I-protein
product	I-protein
is	O
believed	O
to	O
inhibit	O
this	O
phenomenon	O
in	O
an	O
antioxidant-dependent	O
manner	O
.	O

Taken	O
together	O
,	O
these	O
observations	O
suggest	O
that	O
nontoxic	O
concentrations	O
of	O
reactive	O
metabolites	O
of	O
oxygen	O
and	O
nitrogen	O
play	O
an	O
important	O
role	O
in	O
regulating	O
the	O
expression	O
of	O
genes	O
involved	O
in	O
the	O
inflammatory	O
response	O
and	O
in	O
modulating	O
apoptosis	O
.	O

Identification	O
of	O
target	B-DNA
genes	I-DNA
of	O
the	O
lymphoid-specific	B-protein
transcription	I-protein
factor	I-protein
Oct2	I-protein
.	O

The	O
Oct2	B-protein
transcription	B-protein
factor	I-protein
is	O
expressed	O
predominantly	O
in	O
B	B-cell_type
lymphocytes	I-cell_type
and	O
plays	O
an	O
essential	O
role	O
during	O
the	O
terminal	O
phase	O
of	O
B	O
cell	O
differentiation	O
.	O

The	O
regulatory	B-DNA
regions	I-DNA
of	O
several	O
genes	O
specifically	O
expressed	O
in	O
B	B-cell_type
cells	I-cell_type
contain	O
functional	B-DNA
binding	I-DNA
sites	I-DNA
for	O
Oct2	B-protein
.	O

Nevertheless	O
,	O
none	O
of	O
the	O
genes	O
originally	O
thought	O
to	O
be	O
regulated	O
by	O
Oct2	B-protein
were	O
affected	O
in	O
their	O
expression	O
in	O
Oct2-deficient	B-cell_line
B	I-cell_line
cells	I-cell_line
.	O

In	O
an	O
attempt	O
to	O
find	O
such	O
elusive	O
Oct2	B-protein
target	B-DNA
genes	I-DNA
and	O
to	O
understand	O
the	O
molecular	O
function	O
of	O
Oct2	B-protein
in	O
B	O
cell	O
development	O
,	O
we	O
isolated	O
cDNAs	B-DNA
for	O
Oct2	B-protein
target	B-DNA
genes	I-DNA
.	O

So	O
far	O
,	O
we	O
have	O
identified	O
five	O
potential	O
targets	O
for	O
Oct2	B-protein
:	O
the	O
membrane	B-protein
glycoprotein	I-protein
CD36	B-protein
,	O
the	O
cysteine-rich	B-protein
secreted	I-protein
protein	I-protein
3	I-protein
(	O
CRISP-3	B-protein
)	O
,	O
a	O
mouse	O
homolog	O
of	O
the	O
human	B-protein
monocyte/neutrophil	I-protein
elastase	I-protein
inhibitor	I-protein
(	O
mEI	B-protein
)	O
and	O
two	O
unknown	O
cDNA	B-DNA
sequences	I-DNA
Nov1	B-DNA
and	O
Nov2	B-DNA
.	O

These	O
target	B-DNA
genes	I-DNA
show	O
quite	O
distinct	O
expression	O
patterns	O
demonstrating	O
that	O
transcription	B-protein
factors	I-protein
in	O
addition	O
to	O
Oct2	B-protein
are	O
involved	O
in	O
their	O
regulation	O
.	O

Whereas	O
CD36	B-protein
and	O
mEI	B-protein
were	O
expressed	O
in	O
all	O
hematopoetic	B-cell_line
cell	I-cell_line
lines	I-cell_line
containing	O
Oct2	B-protein
,	O
.	O

CRISP-3	B-protein
is	O
pre-B	O
cell-specific	O
,	O
Nov1	B-DNA
is	O
plasma	O
B	O
cell-specific	O
and	O
Nov2	B-DNA
is	O
B	O
cell-specifically	O
expressed	O
.	O

RFX-B	B-DNA
is	O
the	O
gene	O
responsible	O
for	O
the	O
most	O
common	O
cause	O
of	O
the	O
bare	O
lymphocyte	O
syndrome	O
,	O
an	O
MHC	B-protein
class	I-protein
II	I-protein
immunodeficiency	O
[	O
published	O
erratum	O
appears	O
in	O
Immunity	O
1999	O
Mar	O
;	O
10	O
(	O
3	O
)	O
:	O
399	O
]	O

The	O
bare	O
lymphocyte	O
syndrome	O
(	O
BLS	O
)	O
is	O
characterized	O
by	O
the	O
absence	O
of	O
MHC	B-protein
class	I-protein
II	I-protein
transcription	O
and	O
humoral-	O
and	O
cellular-mediated	O
immune	O
responses	O
to	O
foreign	O
antigens	O
.	O

Three	O
of	O
the	O
four	O
BLS	O
genetic	O
complementation	O
groups	O
have	O
defects	O
in	O
the	O
activity	O
of	O
the	O
MHC	B-protein
class	I-protein
II	I-protein
transcription	I-protein
factor	I-protein
RFX	B-protein
.	O

We	O
have	O
purified	O
the	O
RFX	B-protein
complex	I-protein
and	O
sequenced	O
its	O
three	O
subunits	O
.	O

The	O
sequence	O
of	O
the	O
smallest	O
subunit	O
describes	O
a	O
novel	O
gene	O
,	O
termed	O
RFX-B	B-DNA
.	O

RFX-B	B-DNA
complements	O
the	O
predominant	O
BLS	B-protein
complementation	I-protein
group	I-protein
(	O
group	B-protein
B	I-protein
)	O
and	O
was	O
found	O
to	O
be	O
mutant	O
in	O
cell	B-cell_line
lines	I-cell_line
from	O
this	O
BLS	O
group	O
.	O

The	O
protein	O
has	O
no	O
known	O
DNA-binding	B-protein
domain	I-protein
but	O
does	O
contain	O
three	O
ankyrin	O
repeats	O
that	O
are	O
likely	O
to	O
be	O
important	O
in	O
protein-protein	O
interactions	O
.	O

Binding	O
of	O
c-Rel	B-protein
to	O
STAT5	B-DNA
target	I-DNA
sequences	I-DNA
in	O
HTLV-I-transformed	B-cell_type
T	I-cell_type
cells	I-cell_type
.	O

The	O
type	O
I	O
human	O
T-cell	O
leukemia	O
virus	O
(	O
HTLV-I	O
)	O
induces	O
abnormal	O
growth	O
and	O
subsequent	O
transformation	O
of	O
T	B-cell_type
cells	I-cell_type
,	O
which	O
is	O
associated	O
with	O
the	O
development	O
of	O
an	O
acute	O
T-cell	O
malignancy	O
termed	O
adult	O
T-cell	O
leukemia	O
.	O

A	O
characteristic	O
of	O
HTLV-I-transformed	B-cell_type
T	I-cell_type
cells	I-cell_type
is	O
the	O
constitutive	O
nuclear	O
expression	O
of	O
NF-kappaB/Rel	B-protein
family	I-protein
of	O
transcription	O
factors	O
,	O
which	O
appears	O
to	O
be	O
essential	O
for	O
the	O
growth	O
of	O
these	O
transformed	B-cell_type
cells	I-cell_type
.	O

Although	O
NF-kappaB/Rel	B-protein
factors	I-protein
are	O
known	O
to	O
induce	O
the	O
expression	O
of	O
T-cell	B-protein
growth	I-protein
factor	I-protein
interleukin	I-protein
(	I-protein
IL	I-protein
)	I-protein
-2	I-protein
,	O
it	O
is	O
unclear	O
how	O
they	O
participate	O
in	O
the	O
IL-2	B-protein
-independent	O
growth	O
of	O
HTLV-I-transformed	B-cell_line
cells	I-cell_line
.	O

In	O
this	O
study	O
,	O
we	O
show	O
that	O
certain	O
NF-kappaB/Rel	B-protein
members	I-protein
,	O
predominantly	O
c-Rel	B-protein
,	O
interact	O
with	O
enhancer	O
sequences	O
for	O
STAT5	B-protein
,	O
a	O
key	O
transcription	O
factor	O
mediating	O
IL-2	B-protein
-induced	O
T-cell	O
proliferation	O
.	O

Reporter	O
gene	O
assays	O
reveal	O
that	O
the	O
binding	O
of	O
c-Rel	B-protein
to	O
the	O
STAT5	B-protein
site	O
present	O
in	O
the	O
Fc	B-DNA
gammaR1	I-DNA
gene	I-DNA
leads	O
to	O
potent	O
transactivation	O
of	O
this	O
enhancer	O
.	O

Binding	O
of	O
c-Rel	B-protein
to	O
the	O
Fc	B-DNA
gammaR1	I-DNA
STAT	I-DNA
site	I-DNA
also	O
occurs	O
in	O
human	O
peripheral	B-cell_type
blood	I-cell_type
T	I-cell_type
cells	I-cell_type
immortalized	O
with	O
HTLV-I	O
in	O
vitro	O
and	O
is	O
correlated	O
with	O
enhanced	O
levels	O
of	O
proliferation	O
of	O
these	O
cells	O
.	O

These	O
results	O
raise	O
the	O
possibility	O
that	O
NF-kappaB/Rel	B-protein
may	O
participate	O
in	O
the	O
growth	O
control	O
of	O
HTLV-I-transformed	B-cell_line
T	I-cell_line
cells	I-cell_line
by	O
regulating	O
genes	O
driven	O
by	O
both	O
kappaB	B-DNA
and	O
certain	O
STAT	B-DNA
enhancers	I-DNA
.	O

Activation-dependent	O
transcriptional	O
regulation	O
of	O
the	O
human	B-DNA
Fas	I-DNA
promoter	I-DNA
requires	O
NF-kappaB	B-protein
p50-p65	I-protein
recruitment	O
.	O

Fas	B-protein
(	O
CD95	B-protein
)	O
and	O
Fas	B-protein
ligand	I-protein
(	O
CD95L	B-protein
)	O
are	O
an	O
interacting	O
receptor-ligand	O
pair	O
required	O
for	O
immune	O
homeostasis	O
.	O

Lymphocyte	O
activation	O
results	O
in	O
the	O
upregulation	O
of	O
Fas	B-protein
expression	O
and	O
the	O
acquisition	O
of	O
sensitivity	O
to	O
FasL	B-protein
-mediated	O
apoptosis	O
.	O

Although	O
Fas	O
upregulation	O
is	O
central	O
to	O
the	O
preservation	O
of	O
immunologic	O
tolerance	O
,	O
little	O
is	O
known	O
about	O
the	O
molecular	O
machinery	O
underlying	O
this	O
process	O
.	O

To	O
investigate	O
the	O
events	O
involved	O
in	O
activation-induced	O
Fas	B-protein
upregulation	O
,	O
we	O
have	O
examined	O
mRNA	O
accumulation	O
,	O
fas	O
promoter	O
activity	O
,	O
and	O
protein	O
expression	O
in	O
the	O
Jurkat	B-cell_line
T-cell	I-cell_line
line	I-cell_line
treated	O
with	O
phorbol	O
myristate	O
acetate	O
and	O
ionomycin	O
(	O
P/I	O
)	O
,	O
pharmacological	O
mimics	O
of	O
T-cell	B-protein
receptor	I-protein
activation	O
.	O

Although	O
resting	B-cell_line
Jurkat	I-cell_line
cells	I-cell_line
express	O
Fas	B-protein
,	O
Fas	B-RNA
mRNA	I-RNA
was	O
induced	O
approximately	O
10-fold	O
in	O
2	O
h	O
upon	O
P/I	O
stimulation	O
.	O

Using	O
sequential	B-DNA
deletion	I-DNA
mutants	I-DNA
of	O
the	O
human	B-DNA
fas	I-DNA
promoter	I-DNA
in	O
transient	O
transfection	O
assays	O
,	O
we	O
identified	O
a	O
47-bp	B-DNA
sequence	I-DNA
(	O
positions	B-DNA
-306	I-DNA
to	I-DNA
-260	I-DNA
relative	O
to	O
the	O
ATG	O
)	O
required	O
for	O
activation-driven	O
fas	O
upregulation	O
.	O

Sequence	O
analysis	O
revealed	O
the	O
presence	O
of	O
a	O
previously	O
unrecognized	B-DNA
composite	I-DNA
binding	I-DNA
site	I-DNA
for	O
both	O
the	O
Sp1	B-protein
and	O
NF-kappaB	B-protein
transcription	B-protein
factors	I-protein
at	O
positions	B-DNA
-295	I-DNA
to	I-DNA
-286	I-DNA
.	O

Electrophoretic	O
mobility	O
shift	O
assay	O
(	O
EMSA	O
)	O
and	O
supershift	O
analyses	O
of	O
this	O
region	O
documented	O
constitutive	O
binding	O
of	O
Sp1	B-protein
in	O
unactivated	O
nuclear	O
extracts	O
and	O
inducible	O
binding	O
of	O
p50-p65	B-protein
NF-kappaB	I-protein
heterodimers	I-protein
after	O
P/I	O
activation	O
.	O

Sp1	B-protein
and	O
NF-kappaB	B-protein
transcription	O
factor	O
binding	O
was	O
shown	O
to	O
be	O
mutually	O
exclusive	O
by	O
EMSA	O
displacement	O
studies	O
with	O
purified	O
recombinant	O
Sp1	B-protein
and	O
recombinant	O
p50	B-protein
.	O

The	O
functional	O
contribution	O
of	O
the	O
kappaB-Sp1	B-DNA
composite	I-DNA
site	I-DNA
in	O
P/I-inducible	B-DNA
fas	I-DNA
promoter	I-DNA
activation	O
was	O
verified	O
by	O
using	O
kappaB-	O
Sp1	B-protein
concatamers	O
(	O
-295	B-DNA
to	I-DNA
-286	I-DNA
)	O
in	O
a	O
thymidine	B-DNA
kinase	I-DNA
promoter-driven	I-DNA
reporter	I-DNA
construct	I-DNA
and	O
native	B-DNA
promoter	I-DNA
constructs	I-DNA
in	O
Jurkat	B-cell_line
cells	I-cell_line
overexpressing	O
IkappaB-alpha	B-protein
.	O

Site-directed	O
mutagenesis	O
of	O
the	O
critical	O
guanine	O
nucleotides	O
in	O
the	O
kappaB-Sp1	B-DNA
element	I-DNA
documented	O
the	O
essential	O
role	O
of	O
this	O
site	O
in	O
activation-dependent	O
fas	O
promoter	O
induction	O
.	O

Evidence	O
for	O
repression	O
of	O
IL-2	B-DNA
gene	I-DNA
activation	O
in	O
anergic	B-cell_type
T	I-cell_type
cells	I-cell_type
.	O

The	O
induction	O
of	O
clonal	O
anergy	O
in	O
a	O
T	O
cell	O
inhibits	O
IL-2	B-protein
secretion	O
because	O
of	O
the	O
development	O
of	O
a	O
proximal	O
signal	O
transduction	O
defect	O
.	O

Fusion	O
of	O
anergic	B-cell_type
murine	I-cell_type
T	I-cell_type
cells	I-cell_type
to	O
human	B-cell_type
Jurkat	I-cell_type
T	I-cell_type
leukemia	I-cell_type
cells	I-cell_type
and	O
formation	O
of	O
heterokaryons	B-cell_line
failed	O
to	O
result	O
in	O
a	O
complementation	O
of	O
this	O
signaling	O
defect	O
and	O
restoration	O
of	O
murine	B-RNA
IL-2	I-RNA
mRNA	I-RNA
inducibility	O
.	O

Instead	O
,	O
signal	O
transduction	O
to	O
the	O
human	O
IL-2	B-DNA
gene	I-DNA
became	O
disrupted	O
.	O

Heterokaryons	B-cell_line
formed	O
by	O
the	O
fusion	O
of	O
anergic	B-cell_type
murine	I-cell_type
T	I-cell_type
cells	I-cell_type
to	O
normal	B-cell_type
murine	I-cell_type
T	I-cell_type
cells	I-cell_type
also	O
failed	O
to	O
accumulate	O
intracellular	B-protein
IL-2	I-protein
protein	I-protein
in	O
response	O
to	O
stimulation	O
either	O
with	O
the	O
combination	O
of	O
CD3	B-protein
and	O
CD28	B-protein
mAbs	I-protein
or	O
with	O
ionomycin	O
plus	O
a	O
protein	B-protein
kinase	I-protein
C	I-protein
-activating	O
phorbol	O
ester	O
.	O

The	O
results	O
argue	O
against	O
a	O
loss-of-function	O
signaling	O
defect	O
as	O
the	O
sole	O
basis	O
for	O
clonal	O
anergy	O
induction	O
and	O
document	O
the	O
presence	O
of	O
a	O
dominant-acting	B-protein
repressor	I-protein
molecule	I-protein
that	O
inhibits	O
signal	O
transduction	O
to	O
the	O
IL-2	B-DNA
gene	I-DNA
within	O
viable	O
anergic	B-cell_type
T	I-cell_type
cells	I-cell_type
.	O

Comparison	O
of	O
HTLV-I	O
basal	O
transcription	O
and	O
expression	O
of	O
CREB/ATF-1/CREM	B-protein
family	I-protein
members	I-protein
in	O
peripheral	B-cell_type
blood	I-cell_type
mononuclear	I-cell_type
cells	I-cell_type
and	O
Jurkat	B-cell_line
T	I-cell_line
cells	I-cell_line
.	O

HTLV-I	O
is	O
the	O
etiologic	O
agent	O
of	O
adult	O
T-cell	O
leukemia/lymphoma	O
and	O
is	O
associated	O
with	O
tropical	O
spastic	O
paraparesis/HTLV-I-associated	O
myelopathy	O
.	O

Following	O
integration	O
into	O
the	O
host	O
cell	O
genome	O
,	O
HTLV-I	O
replication	O
is	O
regulated	O
by	O
both	O
host	O
and	O
viral	O
mechanisms	O
that	O
control	O
transcription	O
.	O

Low	O
levels	O
of	O
viral	O
transcription	O
(	O
basal	O
transcription	O
)	O
occur	O
before	O
expression	O
of	O
the	O
virally	B-protein
encoded	I-protein
Tax	I-protein
protein	I-protein
(	O
Tax	B-protein
-mediated	O
transcription	O
)	O
.	O

Members	O
of	O
the	O
cyclic	B-protein
adenosine	I-protein
monophosphate	I-protein
(	I-protein
cAMP	I-protein
)	I-protein
response	I-protein
element	I-protein
binding	I-protein
(	I-protein
CREB	I-protein
)	I-protein
/activating	I-protein
transcription	I-protein
factor	I-protein
1	I-protein
(	I-protein
ATF-1	I-protein
)	I-protein
family	I-protein
of	O
transcription	B-protein
factors	I-protein
bind	O
three	O
21-bp	B-DNA
repeats	I-DNA
(	O
Tax-responsive	B-DNA
element-1	I-DNA
,	O
or	O
TRE-1	B-DNA
)	O
within	O
the	O
viral	B-DNA
promoter	I-DNA
and	O
are	O
important	O
for	O
basal	O
and	O
Tax-mediated	O
transcription	O
.	O

Using	O
mitogen	O
stimulated	O
and	O
quiescent	O
peripheral	B-cell_type
blood	I-cell_type
mononuclear	I-cell_type
cells	I-cell_type
(	O
PBMC	B-cell_type
)	O
and	O
Jurkat	B-cell_line
cells	I-cell_line
,	O
we	O
compared	O
differences	O
in	O
basal	O
transcription	O
and	O
amounts	O
and	O
binding	O
of	O
transcription	B-protein
factors	I-protein
with	O
TRE-1	B-DNA
.	O

We	O
demonstrate	O
that	O
amounts	O
of	O
transcriptionally	O
active	O
phosphorylated	B-protein
CREB	I-protein
protein	I-protein
(	O
P-CREB	B-protein
)	O
differ	O
between	O
activated	O
PBMC	B-cell_type
and	O
Jurkat	B-cell_line
cells	I-cell_line
.	O

Following	O
stimulation	O
,	O
P-CREB	B-protein
levels	O
remain	O
elevated	O
in	O
PBMC	B-cell_type
for	O
up	O
to	O
24	O
hours	O
whereas	O
CREB	O
is	O
dephosphorylated	O
in	O
Jurkat	B-cell_line
cells	I-cell_line
within	O
4	O
hours	O
following	O
stimulation	O
.	O

The	O
differences	O
in	O
P-CREB	B-protein
levels	O
between	O
PBMC	B-cell_type
and	O
Jurkat	B-cell_line
cells	I-cell_line
were	O
directly	O
correlated	O
with	O
basal	O
transcription	O
of	O
HTLV-I	O
in	O
the	O
two	O
cell	O
types	O
.	O

Using	O
electrophoretic	O
mobility	O
shift	O
assays	O
,	O
we	O
determined	O
that	O
the	O
pattern	O
of	O
band	O
migration	O
differed	O
between	O
the	O
two	O
cell	O
types	O
.	O

These	O
data	O
demonstrate	O
that	O
PBMC	B-cell_type
differentially	O
regulate	O
basal	O
HTLV-I	O
transcription	O
compared	O
with	O
Jurkat	B-cell_line
T	I-cell_line
cells	I-cell_line
,	O
and	O
this	O
differential	O
regulation	O
is	O
due	O
,	O
in	O
part	O
to	O
differential	O
phosphorylation	O
and	O
binding	O
of	O
CREB/ATF-1	B-protein
to	O
TRE-1	B-DNA
in	O
the	O
HTLV-I	O
promoter	O
.	O

We	O
demonstrate	O
the	O
utility	O
of	O
using	O
primary	O
lymphocyte	O
models	O
to	O
study	O
HTLV-I	O
transcription	O
in	O
the	O
context	O
of	O
cell	O
signaling	O
and	O
suggest	O
that	O
activated	O
PBMC	B-cell_type
maintain	O
elevated	O
levels	O
of	O
P-CREB	B-protein
,	O
which	O
promote	O
basal	O
HTLV-I	O
transcription	O
and	O
enhance	O
viral	O
persistence	O
in	O
vivo	O
.	O

Anoxia/reoxygenation-induced	O
tolerance	O
with	O
respect	O
to	O
polymorphonuclear	O
leukocyte	O
adhesion	O
to	O
cultured	B-cell_line
endothelial	I-cell_line
cells	I-cell_line
.	O

A	O
nuclear	B-protein
factor-kappaB	I-protein
-mediated	O
phenomenon	O
.	O

Exposing	O
human	B-cell_line
umbilical	I-cell_line
vein	I-cell_line
endothelial	I-cell_line
cells	I-cell_line
(	O
HUVECs	B-cell_line
)	O
to	O
anoxia/reoxygenation	O
(	O
A/R	O
)	O
results	O
in	O
an	O
increase	O
in	O
polymorphonuclear	O
leukocyte	O
(	O
PMN	B-cell_type
)	O
adhesion	O
to	O
HUVECs	B-cell_line
.	O

This	O
A/R-induced	O
hyperadhesion	O
is	O
completely	O
prevented	O
by	O
a	O
previous	O
(	O
24	O
hours	O
earlier	O
)	O
exposure	O
of	O
HUVECs	B-cell_line
to	O
A/R	O
.	O

This	O
phenomenon	O
has	O
been	O
termed	O
``	O
A/R	O
tolerance.	O
''	O

Exposing	O
HUVECs	B-cell_line
to	O
A/R	O
induces	O
an	O
increase	O
in	O
nuclear	B-protein
factor	I-protein
kappaB	I-protein
(	O
NF-kappaB	B-protein
)	O
in	O
HUVEC	O
nuclei	O
within	O
4	O
hours	O
.	O

Interfering	O
with	O
either	O
NF-kappaB	B-protein
activation	O
(	O
proteasome	B-protein
inhibitor	O
)	O
or	O
translocation	O
(	O
double-stranded	O
oligonucleotides	O
containing	O
NF-kappaB	B-DNA
binding	I-DNA
sequence	I-DNA
)	O
prevents	O
the	O
development	O
of	O
A/R	O
tolerance	O
(	O
ie	O
,	O
the	O
increase	O
in	O
A/R-induced	O
PMN	O
adhesion	O
to	O
HUVECs	B-cell_line
is	O
the	O
same	O
after	O
the	O
first	O
and	O
second	O
A/R	O
challenges	O
)	O
.	O

NO	O
production	O
by	O
HUVECs	B-cell_line
is	O
increased	O
after	O
the	O
second	O
A/R	O
challenge	O
,	O
but	O
not	O
after	O
the	O
first	O
A/R	O
challenge	O
.	O

Inhibition	O
of	O
NO	B-protein
synthase	I-protein
(	O
NOS	B-protein
)	O
during	O
the	O
second	O
A/R	O
challenge	O
prevents	O
the	O
development	O
of	O
A/R	O
tolerance	O
with	O
respect	O
to	O
PMN	O
adhesion	O
.	O

However	O
,	O
while	O
HUVECs	B-cell_line
contained	O
endothelial	O
NOS	B-protein
protein	I-protein
,	O
no	O
inducible	O
NOS	B-protein
was	O
detected	O
in	O
either	O
tolerant	O
or	O
nontolerant	B-cell_type
cells	I-cell_type
.	O

Further	O
studies	O
indicated	O
that	O
inhibition	O
of	O
GTP-cyclohydrolase	B-protein
I	I-protein
(	O
an	O
enzyme	O
involved	O
in	O
de	O
novo	O
synthesis	O
of	O
an	O
important	O
cofactor	O
for	O
NOS	B-protein
activity	O
,	O
tetrahydrobiopterin	O
)	O
prevented	O
the	O
generation	O
of	O
NO	O
in	O
A/R-tolerant	B-cell_line
cells	I-cell_line
.	O

Extracellular	O
generation	O
of	O
NO	O
(	O
NO	O
donor	O
)	O
did	O
not	O
effect	O
the	O
hyperadhesion	O
response	O
induced	O
by	O
the	O
initial	O
A/R	O
challenge	O
.	O

A/R	O
also	O
induced	O
an	O
oxidant	O
stress	O
in	O
naive	O
HUVECs	B-cell_line
,	O
but	O
not	O
in	O
A/R-tolerant	B-cell_line
HUVECs	I-cell_line
.	O

Inhibition	O
of	O
NOS	B-protein
during	O
the	O
second	O
A/R	O
insult	O
results	O
in	O
the	O
generation	O
of	O
an	O
oxidant	O
stress	O
similar	O
to	O
that	O
observed	O
after	O
the	O
first	O
A/R	O
challenge	O
.	O

Taken	O
together	O
,	O
the	O
findings	O
of	O
the	O
present	O
study	O
are	O
consistent	O
with	O
a	O
role	O
for	O
NF-kappaB	B-protein
in	O
the	O
development	O
of	O
A/R	O
tolerance	O
(	O
with	O
respect	O
to	O
PMN	B-cell_type
adhesion	O
)	O
,	O
perhaps	O
by	O
transcriptional	O
regulation	O
of	O
GTP-cyclohydrolase	B-protein
.	O

The	O
increased	O
NO	O
production	O
during	O
the	O
second	O
A/R	O
insult	O
reduces	O
PMN	O
adhesion	O
most	O
likely	O
by	O
reducing	O
the	O
intracellular	O
oxidant	O
stress	O
induced	O
by	O
A/R	O
.	O

Mildly	O
oxidized	O
low-density	B-protein
lipoproteins	I-protein
decrease	O
early	O
production	O
of	O
interleukin	B-protein
2	I-protein
and	O
nuclear	B-protein
factor	I-protein
kappaB	I-protein
binding	O
to	O
DNA	O
in	O
activated	B-cell_type
T-lymphocytes	I-cell_type
.	O

Activated	O
T-lymphocytes	O
are	O
found	O
early	O
in	O
atherosclerosis	O
lesions	O
,	O
but	O
little	O
is	O
known	O
about	O
their	O
role	O
.	O

Oxidized	O
low-density	B-protein
lipoproteins	I-protein
(	O
oxLDLs	B-protein
)	O
are	O
considered	O
to	O
be	O
involved	O
in	O
the	O
pathogenesis	O
of	O
the	O
lesions	O
,	O
and	O
we	O
have	O
previously	O
demonstrated	O
that	O
oxLDLs	B-protein
inhibit	O
not	O
only	O
interleukin	B-protein
(	I-protein
IL	I-protein
)	I-protein
-2-receptor	I-protein
expression	O
on	O
the	O
surface	O
of	O
in	O
vitro-activated	O
T-lymphocytes	O
but	O
also	O
their	O
proliferation	O
.	O

We	O
have	O
now	O
investigated	O
the	O
effect	O
of	O
oxLDLs	B-protein
on	O
blast	O
differentiation	O
,	O
on	O
IL-2	B-protein
synthesis	O
and	O
on	O
the	O
activation	O
of	O
the	O
nuclear	B-protein
factor	I-protein
kappaB	I-protein
(	O
NF-kappaB	B-protein
)	O
system	O
in	O
activated	O
lymphocytes	O
.	O

Mildly	O
oxLDLs	B-protein
(	O
50	O
and	O
100	O
microgram/ml	O
)	O
decreased	O
the	O
number	O
of	O
lymphoblasts	B-cell_type
and	O
the	O
level	O
of	O
IL-2	O
concentration	O
in	O
the	O
culture	O
supernatants	O
after	O
activation	O
of	O
lymphocytes	B-cell_type
by	O
phytohaemagglutinin	B-protein
and	O
PMA+ionomycin	O
.	O

The	O
inhibition	O
of	O
IL-2	B-protein
production	O
was	O
observed	O
in	O
the	O
CD3	B-protein
(	O
+	O
)	O
T-lymphocyte	O
cytoplasm	O
as	O
early	O
as	O
4	O
h	O
after	O
activation	O
by	O
PMA+ionomycin	O
.	O

The	O
study	O
of	O
NF-kappaB	B-protein
showed	O
that	O
oxLDLs	B-protein
led	O
to	O
a	O
decrease	O
of	O
activation-induced	B-protein
p65/p50	I-protein
NF-kappaB	B-protein
heterodimer	O
binding	O
to	O
DNA	O
,	O
whereas	O
the	O
presence	O
of	O
the	O
constitutive	O
nuclear	O
form	O
of	O
p50	B-protein
dimer	I-protein
was	O
unchanged	O
.	O

This	O
was	O
correlated	O
with	O
an	O
unchanged	O
level	O
of	O
the	O
active	O
form	O
of	O
the	O
cytosolic	B-protein
inhibitor	I-protein
protein	I-protein
IkappaB-alpha	B-protein
.	O

Taken	O
together	O
,	O
these	O
observations	O
suggest	O
that	O
the	O
immunosuppressive	O
effect	O
of	O
oxLDLs	B-protein
might	O
operate	O
via	O
a	O
dysregulation	O
of	O
the	O
T-lymphocyte	B-cell_type
activation	O
mechanisms	O
.	O

The	O
B29	B-DNA
(	I-DNA
immunoglobulin	I-DNA
beta-chain	I-DNA
)	I-DNA
gene	I-DNA
is	O
a	O
genetic	O
target	O
for	O
early	B-protein
B-cell	I-protein
factor	I-protein
.	O

Early	B-protein
B-cell	I-protein
factor	I-protein
(	O
EBF	B-protein
)	O
is	O
a	O
transcription	B-protein
factor	I-protein
suggested	O
as	O
essential	O
for	O
early	O
B-lymphocyte	B-cell_type
development	O
by	O
findings	O
in	O
mice	O
where	O
the	O
coding	O
gene	O
has	O
been	O
inactivated	O
by	O
homologous	O
disruption	O
.	O

This	O
makes	O
the	O
identification	O
of	O
genetic	O
targets	O
for	O
this	O
transcription	B-protein
factor	I-protein
pertinent	O
for	O
the	O
understanding	O
of	O
early	O
B-cell	O
development	O
.	O

The	O
lack	O
of	O
B29	B-RNA
transcripts	I-RNA
,	O
coding	O
for	O
the	O
beta	B-protein
subunit	I-protein
of	O
the	O
B-cell	O
receptor	O
complex	O
,	O
in	O
pro-B	B-cell_type
cells	I-cell_type
from	O
EBF	B-protein
-deficient	O
mice	O
suggested	O
that	O
B29	O
might	O
be	O
a	O
genetic	O
target	O
for	O
EBF	B-protein
.	O

We	O
here	O
present	O
data	O
suggesting	O
that	O
EBF	B-protein
interacts	O
with	O
three	O
independent	O
sites	O
within	O
the	O
mouse	B-DNA
B29	I-DNA
promoter	I-DNA
.	O

Furthermore	O
,	O
ectopic	O
expression	O
of	O
EBF	B-protein
in	O
HeLa	B-cell_line
cells	I-cell_line
activated	O
a	O
B29	B-DNA
promoter-controlled	I-DNA
reporter	I-DNA
construct	I-DNA
13-fold	O
and	O
induced	O
a	O
low	O
level	O
of	O
expression	O
from	O
the	O
endogenous	B-DNA
B29	I-DNA
gene	I-DNA
.	O

Finally	O
,	O
mutations	O
in	O
the	O
EBF	B-protein
binding	O
sites	O
diminished	O
B29	B-DNA
promoter	I-DNA
activity	O
in	O
pre-B	B-cell_type
cells	I-cell_type
while	O
the	O
same	O
mutations	O
did	O
not	O
have	O
as	O
striking	O
an	O
effect	O
on	O
the	O
promoter	O
function	O
in	O
B-cell	B-cell_line
lines	I-cell_line
of	O
later	O
differentiation	O
stages	O
.	O

These	O
data	O
suggest	O
that	O
the	O
B29	B-DNA
gene	I-DNA
is	O
a	O
genetic	O
target	O
for	O
EBF	B-protein
in	O
early	O
B-cell	O
development	O
.	O

Delta-opioid	O
receptors	O
expressed	O
by	O
Jurkat	B-cell_line
T	I-cell_line
cells	I-cell_line
enhance	O
IL-2	B-protein
secretion	O
by	O
increasing	O
AP-1	B-protein
complexes	I-protein
and	O
activity	O
of	O
the	O
NF-AT/AP-1-binding	B-DNA
promoter	I-DNA
element	I-DNA
.	O

Recent	O
molecular	O
evidence	O
points	O
to	O
transient	O
and/or	O
stage-specific	O
expression	O
of	O
delta-	B-protein
and	I-protein
kappa-opioid	I-protein
receptors	I-protein
by	O
thymic	B-cell_type
and	I-cell_type
peripheral	I-cell_type
T	I-cell_type
lymphocytes	I-cell_type
.	O

Since	O
medical	O
treatments	O
or	O
stress	O
commonly	O
increase	O
opioid	O
levels	O
,	O
it	O
is	O
important	O
to	O
understand	O
the	O
mechanisms	O
by	O
which	O
opioids	O
affect	O
T	O
lymphocyte	O
functions	O
.	O

We	O
therefore	O
created	O
and	O
studied	O
a	O
T	B-cell_line
cell	I-cell_line
line	I-cell_line
expressing	O
the	O
cloned	B-protein
delta-opioid	I-protein
receptor	I-protein
(	O
DOR1	B-protein
)	O
.	O

DOR1	B-protein
ligation	O
by	O
a	O
specific	O
DOR1	B-protein
agonist	O
,	O
deltorphin	O
,	O
augmented	O
IL-2	B-protein
secretion	O
by	O
synergizing	O
with	O
signals	O
from	O
TCR-CD3	B-protein
and	O
CD28	B-protein
.	O

Reporter	O
gene	O
constructs	O
were	O
used	O
to	O
map	O
this	O
effect	O
of	O
deltorphin	O
to	O
the	O
AP-1-	B-DNA
and	I-DNA
NF-AT/AP-1-binding	I-DNA
sites	I-DNA
of	O
the	O
IL-2	B-DNA
promoter	I-DNA
.	O

Although	O
DOR1	B-protein
signaling	O
increased	O
[	O
Ca2+	O
]	O
i	O
,	O
deltorphin	O
enhanced	O
transcriptional	O
activity	O
of	O
the	O
NF-AT/AP-1-binding	B-DNA
site	I-DNA
via	O
a	O
mechanism	O
independent	O
of	O
calcineurin	B-protein
and	O
distinct	O
from	O
the	O
effects	O
of	O
elevated	O
[	O
Ca2+	O
]	O
i	O
.	O

Deltorphin	O
also	O
increased	O
accumulation	O
of	O
AP-1	B-protein
transcription	I-protein
factor	I-protein
complexes	I-protein
,	O
suggesting	O
that	O
DOR1	B-protein
augments	O
IL-2	B-protein
secretion	O
by	O
increasing	O
the	O
AP-1	B-protein
component	I-protein
of	O
the	O
NF-AT/AP-1	B-protein
transcription	I-protein
factor	I-protein
.	O

These	O
results	O
advance	O
the	O
molecular	O
understanding	O
of	O
opioid	O
effects	O
on	O
lymphocytes	B-cell_type
,	O
and	O
in	O
addition	O
,	O
demonstrate	O
regulation	O
of	O
IL-2	B-protein
synthesis	O
and	O
secretion	O
by	O
the	O
novel	O
mechanism	O
of	O
receptor-mediated	O
AP-1	B-protein
induction	O
.	O

Induction	O
of	O
interleukin-12	B-protein
p40	B-RNA
transcript	I-RNA
by	O
CD40	B-protein
ligation	O
via	O
activation	O
of	O
nuclear	B-protein
factor-kappaB	I-protein
.	O

Interleukin-12	B-protein
is	O
produced	O
in	O
response	O
to	O
infection	O
with	O
bacteria	O
or	O
parasites	O
or	O
to	O
bacterial	O
constituents	O
such	O
as	O
LPS	O
in	O
monocytes/macrophages	B-cell_type
and	O
dendritic	B-cell_type
cells	I-cell_type
,	O
and	O
also	O
generated	O
by	O
the	O
interaction	O
between	O
activated	B-cell_type
T	I-cell_type
cells	I-cell_type
and	O
antigen-presenting	B-cell_type
cells	I-cell_type
via	O
CD40-CD40	B-protein
ligand	I-protein
(	O
CD40L	B-protein
)	O
.	O

So	O
far	O
,	O
transcriptional	O
analyses	O
of	O
p40	B-protein
have	O
been	O
carried	O
out	O
only	O
using	O
bacterial	O
constituents	O
such	O
as	O
LPS	O
as	O
stimuli	O
.	O

In	O
the	O
present	O
study	O
,	O
we	O
have	O
characterized	O
the	O
transcriptional	O
induction	O
of	O
p40	B-protein
by	O
CD40	B-protein
ligation	O
in	O
a	O
human	B-cell_line
B	I-cell_line
lymphoblastoid	I-cell_line
cell	I-cell_line
line	I-cell_line
,	O
Daudi	B-cell_line
,	O
and	O
a	O
human	B-cell_line
acute	I-cell_line
monocytic	I-cell_line
leukemia	I-cell_line
cell	I-cell_line
line	I-cell_line
,	O
THP-1	B-cell_line
.	O

These	O
cells	O
,	O
stimulated	O
by	O
an	O
agonistic	O
monoclonal	O
antibody	O
against	O
CD40	B-protein
or	O
by	O
transfection	O
with	O
a	O
CD40L	B-DNA
expression	I-DNA
vector	I-DNA
,	O
secreted	O
p40	B-protein
and	O
showed	O
enhanced	O
p40	B-RNA
mRNA	I-RNA
expression	O
.	O

Sequence	O
analysis	O
of	O
the	O
p40	B-DNA
promoter	I-DNA
region	I-DNA
identified	O
two	O
potential	B-DNA
nuclear	I-DNA
factor	I-DNA
(	I-DNA
NF	I-DNA
)	I-DNA
-kappaB	I-DNA
binding	I-DNA
sites	I-DNA
conserved	O
between	O
mouse	O
and	O
human	O
.	O

Electrophoretic	O
mobility	O
shift	O
assay	O
revealed	O
that	O
the	O
potential	O
NF-kappaB	B-DNA
binding	I-DNA
sequence	I-DNA
which	O
is	O
located	O
around	O
120	B-DNA
bp	I-DNA
upstream	I-DNA
of	O
the	O
transcription	B-DNA
initiation	I-DNA
site	I-DNA
in	O
murine	B-DNA
and	I-DNA
human	I-DNA
p40	I-DNA
genes	I-DNA
formed	O
an	O
NF-kappaB	B-protein
complex	I-protein
with	O
nuclear	O
extract	O
from	O
Daudi	B-cell_line
cells	I-cell_line
stimulated	O
by	O
CD40	B-protein
ligation	O
.	O

Moreover	O
,	O
transfection	O
of	O
Daudi	B-cell_line
cells	I-cell_line
with	O
the	O
polymerized	O
NF-kappaB	B-DNA
binding	I-DNA
sequence	I-DNA
ligated	O
to	O
a	O
thymidine	B-DNA
kinase/chloramphenicol	I-DNA
acetyltransferase	I-DNA
(	I-DNA
CAT	I-DNA
)	I-DNA
reporter	I-DNA
plasmid	I-DNA
greatly	O
induced	O
CAT	B-protein
activity	O
,	O
but	O
transfection	O
with	O
the	O
polymerized	B-DNA
mutated	I-DNA
NF-kappaB	I-DNA
binding	I-DNA
sequence	I-DNA
did	O
not	O
.	O

These	O
results	O
suggest	O
that	O
the	O
NF-kappaB	B-DNA
binding	I-DNA
site	I-DNA
located	O
around	O
120	O
bp	O
upstream	O
of	O
the	O
transcription	B-DNA
initiation	I-DNA
site	I-DNA
in	O
murine	B-DNA
and	I-DNA
human	I-DNA
p40	I-DNA
promoter	I-DNA
regions	I-DNA
could	O
be	O
important	O
for	O
the	O
p40	B-protein
induction	O
by	O
CD40	B-protein
ligation	O
via	O
activation	O
of	O
NF-kappaB	B-protein
.	O

High	O
frequency	O
of	O
germ-line	O
BRCA2	B-DNA
mutations	O
among	O
Hungarian	O
male	O
breast	O
cancer	O
patients	O
without	O
family	O
history	O
.	O

To	O
determine	O
the	O
contribution	O
of	O
BRCA1	B-DNA
and	O
BRCA2	B-DNA
mutations	O
to	O
the	O
pathogenesis	O
of	O
male	O
breast	O
cancer	O
in	O
Hungary	O
,	O
the	O
country	O
with	O
the	O
highest	O
male	O
breast	O
cancer	O
mortality	O
rates	O
in	O
continental	O
Europe	O
,	O
a	O
series	O
of	O
18	O
male	O
breast	O
cancer	O
patients	O
and	O
three	O
patients	O
with	O
gynecomastia	O
was	O
analyzed	O
for	O
germ-line	O
mutations	O
in	O
both	O
BRCA1	B-DNA
and	O
BRCA2	B-DNA
.	O

Although	O
no	O
germ-line	O
BRCA1	B-DNA
mutation	O
was	O
observed	O
,	O
6	O
of	O
the	O
18	O
male	O
breast	O
cancer	O
cases	O
(	O
33	O
%	O
)	O
carried	O
truncating	O
mutations	O
in	O
the	O
BRCA2	B-DNA
gene	O
.	O

Unexpectedly	O
,	O
none	O
of	O
them	O
reported	O
a	O
family	O
history	O
for	O
breast/ovarian	O
cancer	O
.	O

Four	O
of	O
six	O
truncating	O
mutations	O
were	O
novel	O
,	O
and	O
two	O
mutations	O
were	O
recurrent	O
.	O

Four	O
patients	O
(	O
22	O
%	O
)	O
had	O
a	O
family	O
history	O
of	O
breast/ovarian	O
cancer	O
in	O
at	O
least	O
one	O
first-	O
or	O
second-degree	O
relative	O
;	O
however	O
,	O
no	O
BRCA2	B-DNA
mutation	O
was	O
identified	O
among	O
them	O
.	O

No	O
mutation	O
was	O
identified	O
in	O
either	O
of	O
the	O
genes	O
in	O
the	O
gynecomastias	O
.	O

These	O
results	O
provide	O
evidence	O
for	O
a	O
strong	O
genetic	O
component	O
of	O
male	O
breast	O
cancer	O
in	O
Hungary	O
.	O

T-cell	O
expression	O
of	O
the	O
human	B-DNA
GATA-3	I-DNA
gene	I-DNA
is	O
regulated	O
by	O
a	O
non-lineage-specific	B-DNA
silencer	I-DNA
.	O

The	O
GATA-3	B-protein
transcription	I-protein
factor	I-protein
is	O
required	O
for	O
development	O
of	O
the	O
T-cell	B-cell_line
lineage	I-cell_line
and	O
Th2	B-DNA
cytokine	I-DNA
gene	I-DNA
expression	O
in	O
CD4	B-cell_type
T-cells	I-cell_type
.	O

We	O
have	O
mapped	O
the	O
DNase-I-hypersensitive	B-DNA
(	I-DNA
HS	I-DNA
)	I-DNA
regions	I-DNA
of	O
the	O
human	B-DNA
GATA-3	I-DNA
gene	I-DNA
in	O
T-cells	B-cell_type
and	O
non-T-cells	B-cell_type
and	O
studied	O
their	O
transcriptional	O
activities	O
.	O

HS	B-DNA
I-III	I-DNA
,	O
located	O
5	O
'	O
from	O
the	O
transcriptional	B-DNA
initiation	I-DNA
site	I-DNA
,	O
were	O
found	O
in	O
hematopoietic	B-cell_type
and	I-cell_type
non-hematopoietic	I-cell_type
cells	I-cell_type
,	O
whereas	O
HS	B-DNA
IV-VII	I-DNA
,	O
located	O
3	O
'	O
from	O
the	O
transcriptional	B-DNA
start	I-DNA
site	I-DNA
,	O
were	O
exclusively	O
observed	O
in	O
T-cells	B-cell_type
.	O

Among	O
these	O
hypersensitive	B-DNA
sites	I-DNA
,	O
two	O
transcriptional	B-DNA
control	I-DNA
elements	I-DNA
were	O
found	O
,	O
one	O
in	O
the	O
first	B-DNA
intron	I-DNA
of	O
the	O
GATA-3	B-DNA
gene	I-DNA
and	O
the	O
other	O
between	B-DNA
8.3	I-DNA
and	I-DNA
5.9	I-DNA
kilobases	I-DNA
5	O
'	O
from	O
the	O
GATA-3	B-DNA
transcriptional	I-DNA
initiation	I-DNA
site	I-DNA
.	O

The	O
first	B-DNA
intron	I-DNA
acted	O
as	O
a	O
strong	O
transcriptional	O
activator	O
in	O
a	O
position-dependent	O
manner	O
and	O
with	O
no	O
cell-type	O
specificity	O
.	O

The	O
upstream	B-DNA
regulatory	I-DNA
element	I-DNA
could	O
confer	O
T-cell	O
specificity	O
to	O
the	O
GATA-3	B-DNA
promoter	I-DNA
activity	O
,	O
and	O
analysis	O
of	O
this	O
region	O
revealed	O
a	O
707-base	B-DNA
pair	I-DNA
silencer	I-DNA
that	O
drastically	O
inhibited	O
GATA-3	B-DNA
promoter	I-DNA
activity	O
in	O
non-T-cells	B-cell_type
.	O

Two	O
CAGGTG	O
E-boxes	O
,	O
located	O
at	O
the	O
5'-	B-DNA
and	I-DNA
3'-ends	I-DNA
of	O
the	O
silencer	O
,	O
were	O
necessary	O
for	O
this	O
silencer	O
activity	O
.	O

The	O
3'-CAGGTG	B-DNA
E-box	I-DNA
could	O
bind	O
USF	B-protein
proteins	I-protein
,	O
the	O
ubiquitous	B-protein
repressor	I-protein
ZEB	B-protein
,	O
or	O
the	O
basic	B-protein
helix-loop-helix	I-protein
proteins	I-protein
E2A	B-protein
and	O
HEB	B-protein
,	O
and	O
we	O
showed	O
that	O
a	O
competition	O
between	O
ZEB	B-protein
and	O
E2A/HEB	B-protein
proteins	I-protein
is	O
involved	O
in	O
the	O
silencer	O
activity	O
.	O

Reactive	O
oxygen	O
intermediate-dependent	O
NF-kappaB	B-protein
activation	O
by	O
interleukin-1beta	B-protein
requires	O
5-lipoxygenase	B-protein
or	O
NADPH	O
oxidase	O
activity	O
.	O

We	O
previously	O
reported	O
that	O
the	O
role	O
of	O
reactive	O
oxygen	O
intermediates	O
(	O
ROIs	O
)	O
in	O
NF-kappaB	B-protein
activation	O
by	O
proinflammatory	B-protein
cytokines	I-protein
was	O
cell	O
specific	O
.	O

However	O
,	O
the	O
sources	O
for	O
ROIs	O
in	O
various	O
cell	O
types	O
are	O
yet	O
to	O
be	O
determined	O
and	O
might	O
include	O
5-lipoxygenase	B-protein
(	O
5-LOX	B-protein
)	O
and	O
NADPH	O
oxidase	O
.	O

5-LOX	B-protein
and	O
5-LOX	B-protein
activating	I-protein
protein	I-protein
(	O
FLAP	B-protein
)	O
are	O
coexpressed	O
in	O
lymphoid	B-cell_type
cells	I-cell_type
but	O
not	O
in	O
monocytic	B-cell_type
or	I-cell_type
epithelial	I-cell_type
cells	I-cell_type
.	O

Stimulation	O
of	O
lymphoid	B-cell_type
cells	I-cell_type
with	O
interleukin-1beta	B-protein
(	O
IL-1beta	B-protein
)	O
led	O
to	O
ROI	O
production	O
and	O
NF-kappaB	B-protein
activation	O
,	O
which	O
could	O
both	O
be	O
blocked	O
by	O
antioxidants	O
or	O
FLAP	B-protein
inhibitors	O
,	O
confirming	O
that	O
5-LOX	B-protein
was	O
the	O
source	O
of	O
ROIs	O
and	O
was	O
required	O
for	O
NF-kappaB	B-protein
activation	O
in	O
these	O
cells	O
.	O

IL-1beta	B-protein
stimulation	O
of	O
epithelial	B-cell_type
cells	I-cell_type
did	O
not	O
generate	O
any	O
ROIs	O
and	O
NF-kappaB	B-protein
induction	O
was	O
not	O
influenced	O
by	O
5-LOX	B-protein
inhibitors	O
.	O

However	O
,	O
reintroduction	O
of	O
a	O
functional	O
5-LOX	B-protein
system	O
in	O
these	O
cells	O
allowed	O
ROI	O
production	O
and	O
5-LOX	B-protein
-dependent	O
NF-kappaB	B-protein
activation	O
.	O

In	O
monocytic	B-cell_type
cells	I-cell_type
,	O
IL-1beta	B-protein
treatment	O
led	O
to	O
a	O
production	O
of	O
ROIs	O
which	O
is	O
independent	O
of	O
the	O
5-LOX	B-protein
enzyme	I-protein
but	O
requires	O
the	O
NADPH	O
oxidase	O
activity	O
.	O

This	O
pathway	O
involves	O
the	O
Rac1	B-protein
and	O
Cdc42	B-protein
GTPases	B-protein
,	O
two	O
enzymes	O
which	O
are	O
not	O
required	O
for	O
NF-kappaB	B-protein
activation	O
by	O
IL-1beta	B-protein
in	O
epithelial	B-cell_type
cells	I-cell_type
.	O

In	O
conclusion	O
,	O
three	O
different	O
cell-specific	O
pathways	O
lead	O
to	O
NF-kappaB	B-protein
activation	O
by	O
IL-1beta	B-protein
:	O
a	O
pathway	O
dependent	O
on	O
ROI	O
production	O
by	O
5-LOX	B-protein
in	O
lymphoid	B-cell_type
cells	I-cell_type
,	O
an	O
ROI-	O
and	O
5-LOX	B-protein
-independent	O
pathway	O
in	O
epithelial	B-cell_type
cells	I-cell_type
,	O
and	O
a	O
pathway	O
requiring	O
ROI	O
production	O
by	O
NADPH	B-protein
oxidase	I-protein
in	O
monocytic	B-cell_type
cells	I-cell_type
.	O

Cutting	O
edge	O
:	O
dominant	O
effect	O
of	O
Ile50Val	B-protein
variant	I-protein
of	O
the	O
human	B-protein
IL-4	I-protein
receptor	I-protein
alpha-chain	I-protein
in	O
IgE	B-protein
synthesis	O
.	O

Two	O
variants	O
of	O
the	O
IL-4R	B-DNA
alpha-chain	I-DNA
(	I-DNA
IL-4Ralpha	I-DNA
)	I-DNA
gene	I-DNA
have	O
been	O
recently	O
identified	O
in	O
association	O
with	O
different	O
atopic	O
disorders	O
.	O

To	O
clarify	O
the	O
etiological	O
relationship	O
between	O
the	O
two	O
variants	O
,	O
we	O
analyzed	O
responsiveness	O
to	O
IL-4	B-protein
of	O
transfectants	O
with	O
four	O
kinds	O
of	O
IL-4Ralpha	B-protein
carrying	O
either	O
Val	O
or	O
Ile	O
at	O
50	B-protein
and	O
either	O
Gln	O
or	O
Arg	O
at	O
551	B-protein
.	O

The	O
substitution	O
of	O
Ile	O
for	O
Val	O
augmented	O
STAT6	B-protein
activation	O
,	O
proliferation	O
,	O
and	O
transcription	O
activity	O
of	O
the	O
Iepsilon	B-DNA
promoter	I-DNA
by	O
IL-4	B-protein
,	O
whereas	O
that	O
of	O
Arg	O
for	O
Gln	O
did	O
not	O
change	O
these	O
IL-4	B-protein
signals	O
.	O

Arg551	O
was	O
not	O
associated	O
with	O
atopic	O
asthma	O
in	O
the	O
Japanese	O
population	O
.	O

CD23	B-protein
expression	O
and	O
IgE	B-protein
synthesis	O
by	O
IL-4	B-protein
were	O
augmented	O
in	O
Ile50-bearing	B-cell_line
PBMC	I-cell_line
,	O
compared	O
with	O
those	O
bearing	O
Val50	O
.	O

Taken	O
together	O
,	O
substitution	O
of	O
Arg551	O
does	O
not	O
enhance	O
the	O
IL-4	B-protein
signal	O
for	O
generation	O
of	O
germline	O
epsilon	O
transcript	O
,	O
whereas	O
the	O
substitution	O
of	O
Ile50	O
contributes	O
to	O
enhancement	O
of	O
IgE	B-protein
synthesis	O
.	O

A	O
novel	O
growth-factor-dependent	B-cell_line
myeloid	I-cell_line
cell	I-cell_line
line	I-cell_line
derived	O
from	O
mouse	B-cell_type
bone	I-cell_type
marrow	I-cell_type
cells	I-cell_type
contains	O
progenitors	O
endowed	O
with	O
high	O
proliferative	O
potential	O
.	O

Constitutive	O
expression	O
of	O
human	B-protein
colony-stimulating	I-protein
factor-1	I-protein
receptor	I-protein
(	O
CSF-1R	B-protein
)	O
confers	O
long-lasting	O
CSF-1	B-protein
-dependent	O
proliferation	O
to	O
mouse	B-cell_line
myeloid	I-cell_line
cell	I-cell_line
lines	I-cell_line
.	O

We	O
developed	O
mice	O
transgenic	O
for	O
human	O
CSF-1R	B-protein
because	O
mouse	O
CSF-1	B-protein
can	O
not	O
activate	O
human	O
CSF-1R	B-protein
.	O

Then	O
bone	B-cell_type
marrow	I-cell_type
cells	I-cell_type
from	O
transgenic	O
mice	O
were	O
plated	O
onto	O
MS-5	O
stromal	O
cells	O
expressing	O
the	O
membrane	B-protein
form	I-protein
of	O
human	B-protein
CSF-1	I-protein
(	O
2M-1	B-cell_line
cells	I-cell_line
)	O
in	O
order	O
to	O
combine	O
the	O
hematopoietic	O
supporting	O
properties	O
of	O
stromal	B-cell_type
cells	I-cell_type
and	O
the	O
proliferative	O
effects	O
of	O
CSF-1	B-protein
.	O

Thus	O
,	O
we	O
were	O
able	O
to	O
derive	O
a	O
hematopoietic	B-cell_line
cell	I-cell_line
line	I-cell_line
,	O
called	O
47.10	B-cell_line
,	O
that	O
grew	O
indefinitely	O
under	O
these	O
conditions	O
,	O
whereas	O
no	O
cell	O
line	O
could	O
be	O
developed	O
from	O
nontransgenic	O
mice	O
.	O

Proliferation	O
of	O
47.10	B-cell_line
cells	I-cell_line
is	O
severely	O
affected	O
by	O
neutralizing	O
anti-CSF-1R	B-protein
monoclonal	I-protein
antibodies	I-protein
.	O

Morphologic	O
and	O
cytofluorometry	O
analysis	O
established	O
that	O
most	O
47.10	B-cell_line
cells	I-cell_line
are	O
immature	B-cell_type
myelomonocytic	I-cell_type
cells	I-cell_type
.	O

Consistent	O
with	O
this	O
phenotype	O
,	O
the	O
myeloid	B-protein
transcription	I-protein
factor	I-protein
PU.1	I-protein
,	O
but	O
not	O
the	O
erythroid	B-protein
transcription	I-protein
factor	I-protein
GATA-1	I-protein
,	O
is	O
expressed	O
in	O
47.10	B-cell_line
cells	I-cell_line
.	O

A	O
few	O
47.10	B-cell_line
cells	I-cell_line
(	O
3-5	O
%	O
)	O
do	O
not	O
express	O
lineage	O
specific	O
markers	O
;	O
they	O
differentiate	O
spontaneously	O
to	O
lineage-positive	B-cell_line
cells	I-cell_line
after	O
replating	O
on	O
2M-1	B-cell_line
cells	I-cell_line
.	O

In	O
agar	O
cultures	O
,	O
47.10	B-cell_line
cells	I-cell_line
form	O
7-	O
and	O
14-day	O
colonies	O
in	O
response	O
to	O
a	O
cocktail	O
of	O
granulocyte/macrophage	B-protein
colony-stimulating	I-protein
factor	I-protein
(	O
2.5	O
ng/mL	O
)	O
,	O
interleukin-3	B-protein
(	O
1	O
ng/mL	O
)	O
,	O
and	O
mouse	O
CSF-1	B-protein
(	O
10	O
ng/mL	O
)	O
.	O

Under	O
these	O
conditions	O
,	O
about	O
0.5	O
%	O
of	O
47.10	B-cell_line
cells	I-cell_line
formed	O
large	O
14-day	O
colonies	O
(	O
>	O
1	O
mm	O
)	O
composed	O
of	O
mature	B-cell_type
monocytes	I-cell_type
and	O
granulocytes	B-cell_type
,	O
reflecting	O
the	O
presence	O
of	O
progenitors	O
endowed	O
with	O
high	O
proliferative	O
potential	O
(	O
HPP-47.10	B-cell_line
cells	I-cell_line
)	O
.	O

In	O
conclusion	O
,	O
we	O
have	O
characterized	O
a	O
novel	O
continuous	B-cell_line
myeloid	I-cell_line
cell	I-cell_line
line	I-cell_line
presenting	O
a	O
hierarchical	O
structure	O
similar	O
to	O
that	O
of	O
the	O
bone	B-cell_line
marrow	I-cell_line
progenitor	I-cell_line
cell	I-cell_line
compartment	I-cell_line
.	O

Regulation	O
of	O
IL-4	B-protein
expression	O
by	O
the	O
transcription	B-protein
factor	I-protein
JunB	B-protein
during	O
T	O
helper	O
cell	O
differentiation	O
.	O

The	O
molecular	O
basis	O
for	O
restricted	O
cytokine	B-protein
expression	O
by	O
T	B-cell_type
helper	I-cell_type
1	I-cell_type
(	I-cell_type
Th1	I-cell_type
)	I-cell_type
and	I-cell_type
T	I-cell_type
helper	I-cell_type
2	I-cell_type
(	I-cell_type
Th2	I-cell_type
)	I-cell_type
cells	I-cell_type
is	O
unclear	O
.	O

Previous	O
studies	O
found	O
that	O
P1	B-DNA
,	O
an	O
element	O
of	O
the	O
interleukin	B-DNA
4	I-DNA
(	I-DNA
IL-4	I-DNA
)	I-DNA
promoter	I-DNA
that	O
binds	O
AP-1	O
,	O
is	O
important	O
for	O
Th2-restricted	O
IL-4	B-protein
expression	O
.	O

Here	O
we	O
show	O
that	O
JunB	B-protein
,	O
but	O
not	O
the	O
other	O
Jun	B-protein
family	I-protein
members	I-protein
,	O
was	O
selectively	O
induced	O
in	O
Th2	B-cell_type
cells	I-cell_type
and	O
not	O
in	O
Th1	B-cell_type
cells	I-cell_type
during	O
differentiation	O
.	O

JunB	B-protein
has	O
previously	O
been	O
considered	O
to	O
be	O
a	O
negative	O
regulator	O
of	O
transcription	O
.	O

However	O
,	O
we	O
show	O
that	O
JunB	B-protein
binds	O
directly	O
to	O
the	O
P1	B-DNA
site	I-DNA
and	O
synergizes	O
with	O
c-Maf	B-protein
to	O
activate	O
an	O
IL-4	B-DNA
luciferase	I-DNA
reporter	I-DNA
gene	I-DNA
.	O

JunB	B-protein
-control	O
of	O
IL-4	B-protein
expression	O
is	O
mediated	O
by	O
the	O
phosphorylation	O
of	O
JunB	B-protein
at	O
Thr102	O
and-	O
104	O
by	O
JNK	B-protein
MAP	I-protein
kinase	I-protein
.	O

The	O
synergy	O
between	O
c-Maf	B-protein
and	O
JunB	B-protein
can	O
be	O
attributed	O
to	O
cooperative	O
DNA	O
binding	O
,	O
which	O
is	O
facilitated	O
by	O
JunB	B-protein
phosphorylation	O
.	O

In	O
transgenic	O
mice	O
,	O
elevated	O
JunB	B-protein
levels	O
caused	O
increased	O
expression	O
of	O
several	O
Th2	B-protein
cytokines	I-protein
in	O
developing	O
Th1	B-cell_type
cells	I-cell_type
.	O

JunB	B-protein
also	O
upregulated	O
IL-4	B-protein
expression	O
in	O
response	O
to	O
immunization	O
.	O

Thus	O
,	O
the	O
early	O
increase	O
of	O
JunB	B-protein
protein	O
in	O
Th2	B-cell_type
cells	I-cell_type
can	O
provide	O
the	O
specificity	O
for	O
c-Maf	B-protein
in	O
IL-4	B-protein
expression	O
during	O
T	O
cell	O
development	O
and	O
directs	O
thereby	O
Th2	O
differentiation	O
.	O

Human	B-protein
T-cell	I-protein
leukemia	I-protein
virus	I-protein
type	I-protein
1	I-protein
tax	I-protein
protein	I-protein
abrogates	O
interleukin-2	B-protein
dependence	O
in	O
a	O
mouse	B-cell_line
T-cell	I-cell_line
line	I-cell_line
.	O

Human	O
T-cell	O
leukemia	O
virus	O
type	O
1	O
(	O
HTLV-1	O
)	O
is	O
the	O
etiologic	O
agent	O
of	O
adult	O
T-cell	O
leukemia	O
.	O

Tax	B-protein
,	O
the	O
viral	B-protein
protein	I-protein
,	O
is	O
thought	O
to	O
be	O
crucial	O
in	O
the	O
development	O
of	O
the	O
disease	O
,	O
since	O
it	O
transforms	O
healthy	B-cell_type
T	I-cell_type
cells	I-cell_type
in	O
vitro	O
and	O
induces	O
tumors	O
in	O
transgenic	O
animals	O
.	O

We	O
examined	O
the	O
effect	O
of	O
Tax	B-protein
activity	O
on	O
the	O
growth	O
of	O
the	O
interleukin-2	B-cell_line
(	I-cell_line
IL-2	I-cell_line
)	I-cell_line
-dependent	I-cell_line
T-cell	I-cell_line
line	I-cell_line
CTLL-2	B-cell_line
.	O

Stable	O
expression	O
of	O
Tax	B-protein
in	O
CTLL-2	B-cell_line
transformed	O
cell	O
growth	O
from	O
being	O
IL-2	B-protein
dependent	O
to	O
IL-2	B-protein
independent	O
.	O

Tax	B-protein
stimulated	O
transcription	O
through	O
NF-kappaB	B-protein
and	O
the	O
cyclic	B-DNA
AMP-responsive	I-DNA
element-like	I-DNA
sequence	I-DNA
in	O
the	O
HTLV-1	O
promoter	O
.	O

The	O
finding	O
of	O
Tax	B-protein
mutants	O
segregating	O
these	O
two	O
pathways	O
suggested	O
that	O
the	O
NF-kappaB	B-protein
pathway	O
was	O
essential	O
for	O
IL-2	B-protein
-independent	O
growth	O
of	O
CTLL-2	B-cell_type
cells	I-cell_type
while	O
the	O
CRE	B-DNA
pathway	O
was	O
unnecessary	O
.	O

However	O
,	O
both	O
pathways	O
were	O
necessary	O
for	O
another	O
transformation-related	O
activity	O
(	O
colony	O
formation	O
in	O
soft	O
agar	O
)	O
of	O
CTLL-2/Tax	B-protein
.	O

Our	O
results	O
show	O
that	O
Tax	B-protein
has	O
at	O
least	O
two	O
distinct	O
activities	O
on	O
T	B-cell_type
cells	I-cell_type
,	O
and	O
suggest	O
that	O
Tax	B-protein
plays	O
a	O
crucial	O
role	O
in	O
IL-2	B-protein
-independent	O
T-cell	O
transformation	O
induced	O
by	O
HTLV-1	O
,	O
in	O
addition	O
to	O
its	O
well-known	O
IL-2	B-protein
-dependent	O
cell	O
transformation	O
.	O

Accessing	O
Epstein-Barr	O
virus-specific	O
T-cell	O
memory	O
with	O
peptide-loaded	B-cell_line
dendritic	I-cell_line
cells	I-cell_line
.	O

The	O
conventional	O
means	O
of	O
studying	O
Epstein-Barr	O
virus	O
(	O
EBV	O
)	O
-induced	O
cytotoxic	B-cell_type
T-lymphocyte	I-cell_type
(	O
CTL	O
)	O
memory	O
,	O
by	O
in	O
vitro	O
stimulation	O
with	O
the	O
latently	O
infected	O
autologous	O
lymphoblastoid	B-cell_line
cell	I-cell_line
line	I-cell_line
(	O
LCL	B-cell_line
)	O
,	O
has	O
important	O
limitations	O
.	O

First	O
,	O
it	O
gives	O
no	O
information	O
on	O
memory	O
to	O
lytic	B-protein
cycle	I-protein
antigens	I-protein
;	O
second	O
,	O
it	O
preferentially	O
amplifies	O
the	O
dominant	O
components	O
of	O
latent	O
antigen-specific	O
memory	O
at	O
the	O
expense	O
of	O
key	O
subdominant	O
reactivities	O
.	O

Here	O
we	O
describe	O
an	O
alternative	O
approach	O
,	O
based	O
on	O
in	O
vitro	O
stimulation	O
with	O
epitope	B-cell_line
peptide-loaded	I-cell_line
dendritic	I-cell_line
cells	I-cell_line
(	O
DCs	B-cell_line
)	O
,	O
which	O
allows	O
one	O
to	O
probe	O
the	O
CTL	O
repertoire	O
for	O
any	O
individual	O
reactivity	O
of	O
choice	O
;	O
this	O
method	O
proved	O
significantly	O
more	O
efficient	O
than	O
stimulation	O
with	O
peptide	O
alone	O
.	O

Using	O
this	O
approach	O
we	O
first	O
show	O
that	O
reactivities	O
to	O
the	O
immunodominant	O
and	O
subdominant	O
lytic	B-protein
cycle	I-protein
epitopes	I-protein
identified	O
by	O
T	B-cell_type
cells	I-cell_type
during	O
primary	O
EBV	O
infection	O
are	O
regularly	O
detectable	O
in	O
the	O
CTL	O
memory	O
of	O
virus	O
carriers	O
;	O
this	O
implies	O
that	O
in	O
such	O
carriers	O
chronic	O
virus	O
replication	O
remains	O
under	O
direct	O
T-cell	O
control	O
.	O

We	O
further	O
show	O
that	O
subdominant	O
latent	O
cycle	O
reactivities	O
to	O
epitopes	O
in	O
the	O
latent	B-protein
membrane	I-protein
protein	I-protein
LMP2	I-protein
,	O
though	O
rarely	O
undetectable	O
in	O
LCL	B-cell_line
-stimulated	O
populations	O
,	O
can	O
be	O
reactivated	O
by	O
DC	O
stimulation	O
and	O
selectively	O
expanded	O
as	O
polyclonal	O
CTL	B-cell_line
lines	I-cell_line
;	O
the	O
adoptive	O
transfer	O
of	O
such	O
preparations	O
may	O
be	O
of	O
value	O
in	O
targeting	O
certain	O
EBV-positive	O
malignancies	O
.	O

Regulation	O
of	O
the	O
human	B-DNA
interleukin-2	I-DNA
gene	I-DNA
by	O
the	O
alpha	B-protein
and	I-protein
beta	I-protein
isoforms	I-protein
of	O
the	O
glucocorticoid	B-protein
receptor	I-protein
.	O

The	O
immunosuppressive	O
effects	O
of	O
glucocorticoids	O
are	O
largely	O
due	O
to	O
transcriptional	O
inhibition	O
of	O
immunologically	B-DNA
relevant	I-DNA
genes	I-DNA
,	O
such	O
as	O
the	O
interleukin-2	B-DNA
(	I-DNA
IL-2	I-DNA
)	I-DNA
gene	I-DNA
.	O

These	O
effects	O
are	O
mediated	O
by	O
the	O
intracellular	O
glucocorticoid	B-protein
receptor	I-protein
(	O
GR	B-protein
)	O
.	O

In	O
humans	O
,	O
alternative	O
splicing	O
of	O
the	O
GR	B-RNA
precursor	I-RNA
mRNA	I-RNA
gives	O
rise	O
to	O
two	O
receptor	O
isoforms	O
,	O
termed	O
GRalpha	B-protein
and	O
GRbeta	B-protein
.	O

We	O
previously	O
demonstrated	O
that	O
GRbeta	B-protein
could	O
antagonize	O
GRalpha	B-protein
-mediated	O
transactivation	O
of	O
a	O
glucocorticoid-responsive	B-DNA
element	I-DNA
(	I-DNA
GRE	I-DNA
)	I-DNA
-driven	I-DNA
reporter	I-DNA
gene	I-DNA
in	O
COS-7	B-cell_line
cells	I-cell_line
.	O

The	O
present	O
study	O
was	O
designed	O
to	O
analyze	O
the	O
roles	O
of	O
the	O
two	O
GR	B-protein
isoforms	I-protein
on	O
glucocorticoid-mediated	O
transrepression	O
of	O
the	O
IL-2	B-DNA
gene	I-DNA
.	O

Using	O
a	O
recently	O
developed	O
transfection	O
technique	O
,	O
we	O
demonstrate	O
that	O
in	O
primary	B-cell_type
human	I-cell_type
lymphocytes	I-cell_type
,	O
stimulation	O
of	O
a	O
548	B-DNA
bp	I-DNA
IL-2	I-DNA
promoter-luciferase	I-DNA
reporter	I-DNA
construct	I-DNA
by	O
phorbol	O
ester	O
and	O
calcium	O
ionophore	O
is	O
reversed	O
by	O
dexamethasone	O
to	O
a	O
similar	O
extent	O
as	O
in	O
Jurkat	O
T	O
lymphoma	O
cells	O
transfected	O
with	O
a	O
GRalpha	B-protein
expression	O
vector	O
.	O

Transfection	O
of	O
a	O
GRbeta	B-protein
expression	O
vector	O
alone	O
did	O
not	O
result	O
in	O
IL-2	B-DNA
promoter	I-DNA
repression	O
in	O
response	O
to	O
glucocorticoids	O
.	O

Furthermore	O
,	O
GRbeta	B-protein
did	O
not	O
antagonize	O
the	O
repressive	O
effects	O
of	O
GRalpha	B-protein
on	O
IL-2	B-DNA
promoter	I-DNA
activity	O
.	O

Surprisingly	O
,	O
overexpression	O
of	O
GRbeta	B-protein
in	O
Jurkat	B-cell_line
cells	I-cell_line
did	O
not	O
cause	O
significant	O
inhibition	O
of	O
GRalpha	B-protein
-induced	O
transactivation	O
of	O
a	O
GRE-dependent	B-DNA
luciferase	I-DNA
reporter	I-DNA
gene	I-DNA
either	O
.	O

We	O
conclude	O
that	O
the	O
transrepressive	O
effect	O
of	O
glucocorticoids	O
on	O
IL-2	B-DNA
gene	I-DNA
transcription	O
is	O
exclusively	O
mediated	O
by	O
GRalpha	B-protein
.	O

GRbeta	B-protein
can	O
neither	O
antagonize	O
GRalpha	B-protein
-mediated	O
transactivation	O
nor	O
transrepression	O
in	O
Jurkat	B-cell_line
cells	I-cell_line
,	O
indicating	O
a	O
cell	O
type-specific	O
pattern	O
of	O
GRbeta	B-protein
-mediated	O
antiglucocorticoid	O
activity	O
.	O

Extinction	O
of	O
immunoglobulin	B-DNA
gene	I-DNA
expression	O
in	O
B	B-cell_type
cells	I-cell_type
upon	O
fusion	O
with	O
HeLa	B-cell_line
cells	I-cell_line
is	O
preceded	O
by	O
rapid	O
nuclear	O
depletion	O
of	O
essential	B-protein
transcription	I-protein
factors	I-protein
and	O
is	O
accompanied	O
by	O
widespread	O
inactivation	O
of	O
genes	O
expressed	O
in	O
a	O
B	O
cell-specific	O
manner	O
.	O

When	O
immunoglobulin	B-cell_type
(	I-cell_type
Ig	I-cell_type
)	I-cell_type
expressing	I-cell_type
B	I-cell_type
cells	I-cell_type
are	O
fused	O
with	O
non-B	B-cell_type
cells	I-cell_type
,	O
Ig	O
expression	O
is	O
rapidly	O
suppressed	O
at	O
the	O
level	O
of	O
transcription	O
,	O
a	O
phenomenon	O
termed	O
extinction	O
.	O

Here	O
we	O
demonstrate	O
that	O
fusion	O
of	O
HeLa	B-cell_line
cells	I-cell_line
with	O
either	O
diploid	B-cell_type
or	I-cell_type
tetraploid	I-cell_type
B	I-cell_type
cells	I-cell_type
(	O
Daudi	B-cell_line
)	O
results	O
in	O
widespread	O
extinction	O
of	O
several	O
other	O
B	B-DNA
cell-encoded	I-DNA
genes	I-DNA
that	O
are	O
expressed	O
in	O
a	O
B	O
cell-specific	O
manner	O
.	O

In	O
contrast	O
,	O
expression	O
of	O
B	B-DNA
cell-expressed	I-DNA
genes	I-DNA
that	O
are	O
not	O
dependent	O
on	O
cell-specific	O
controls	O
is	O
unaffected	O
.	O

We	O
show	O
that	O
the	O
molecular	O
mechanism	O
(	O
s	O
)	O
underlying	O
Ig	B-DNA
gene	I-DNA
extinction	O
can	O
be	O
explained	O
,	O
at	O
least	O
in	O
part	O
,	O
by	O
a	O
lack	O
of	O
transcription	B-protein
factors	I-protein
that	O
are	O
essential	O
for	O
Ig	B-DNA
gene	I-DNA
transcription	O
.	O

These	O
transcription	B-protein
factors	I-protein
are	O
either	O
not	O
produced	O
due	O
to	O
block	O
of	O
transcription	O
of	O
their	O
respective	O
genes	O
(	O
Oct-2	B-DNA
,	O
OBF-1	B-DNA
,	O
PU.1	B-protein
)	O
,	O
or	O
are	O
rendered	O
inactive	O
posttranslationally	O
(	O
NF-kappa	B-protein
B	I-protein
,	O
E47	B-DNA
)	O
.	O

By	O
isolating	O
Daudi	B-cell_line
x	I-cell_line
HeLa	I-cell_line
heterokaryons	I-cell_line
a	O
few	O
hours	O
after	O
fusion	O
,	O
we	O
have	O
studied	O
the	O
initial	O
fate	O
of	O
two	O
B	B-protein
cell-specific	I-protein
transcription	I-protein
factors	I-protein
involved	O
in	O
Ig	B-DNA
gene	I-DNA
transcription	O
,	O
Oct-2	B-DNA
and	O
NF-kappa	B-protein
B	I-protein
.	O

This	O
report	O
provides	O
the	O
first	O
demonstration	O
that	O
upon	O
fusion	O
with	O
HeLa	B-cell_line
cells	I-cell_line
,	O
the	O
nuclear	O
contents	O
of	O
B	B-protein
cell-expressed	I-protein
transcription	I-protein
factors	I-protein
are	O
depleted	O
within	O
a	O
few	O
hours	O
with	O
kinetics	O
that	O
are	O
as	O
fast	O
or	O
faster	O
than	O
that	O
of	O
Ig	B-DNA
gene	I-DNA
extinction	O
.	O

Thus	O
,	O
the	O
extinguishing	O
mechanism	O
is	O
effective	O
very	O
early	O
after	O
fusion	O
.	O

We	O
suggest	O
that	O
extinction	O
of	O
Ig	B-DNA
genes	I-DNA
is	O
part	O
of	O
a	O
global	O
mechanism	O
that	O
suppresses	O
the	O
differentiation	O
program	O
foreign	O
to	O
the	O
HeLa	B-cell_line
phenotype	I-cell_line
.	O

Evidence	O
for	O
suppressed	O
activity	O
of	O
the	O
transcription	B-protein
factor	I-protein
NFAT1	B-protein
at	O
its	O
proximal	B-DNA
binding	I-DNA
element	I-DNA
P0	B-DNA
in	O
the	O
IL-4	B-DNA
promoter	I-DNA
associated	O
with	O
enhanced	O
IL-4	B-DNA
gene	I-DNA
transcription	O
in	O
T	B-cell_type
cells	I-cell_type
of	O
atopic	O
patients	O
.	O

Allergen-specific	O
T	B-cell_type
cells	I-cell_type
in	O
atopic	O
patients	O
are	O
polarized	O
IL-4-producing	B-cell_line
Th2	I-cell_line
cells	I-cell_line
,	O
promoting	O
IgE	B-protein
synthesis	O
by	O
B	B-cell_type
cells	I-cell_type
.	O

The	O
molecular	O
basis	O
for	O
increased	O
IL-4	B-DNA
gene	I-DNA
expression	O
in	O
atopy	O
is	O
not	O
fully	O
understood	O
.	O

IL-4	B-DNA
gene	I-DNA
regulation	O
in	O
general	O
involves	O
the	O
nuclear	B-protein
factor	I-protein
of	I-protein
activated	I-protein
T	I-protein
cells	I-protein
(	I-protein
NFAT	I-protein
)	I-protein
family	I-protein
of	O
transcription	B-protein
factors	I-protein
,	O
of	O
which	O
NFAT1	B-protein
and	O
NFAT2	B-protein
are	O
most	O
prominent	O
in	O
peripheral	B-cell_type
T	I-cell_type
cells	I-cell_type
.	O

Recently	O
,	O
a	O
unique	O
inhibitory	O
role	O
of	O
NFAT1	B-protein
in	O
IL-4	B-DNA
gene	I-DNA
control	O
was	O
shown	O
in	O
the	O
mouse	O
.	O

In	O
a	O
series	O
of	O
electrophoretic	O
mobility	O
shift	O
assays	O
with	O
protein	O
extracts	O
of	O
highly	B-cell_line
polarized	I-cell_line
Th2	I-cell_line
clones	I-cell_line
from	O
atopics	O
and	O
Th1	B-cell_line
clones	I-cell_line
from	O
controls	O
we	O
compared	O
DNA-binding	O
activities	O
at	O
the	O
two	O
NFAT-binding	B-DNA
elements	I-DNA
P0	B-DNA
and	O
P1	B-DNA
of	O
the	O
crucial	O
proximal	O
human	O
IL-4	B-DNA
promoter	I-DNA
.	O

At	O
the	O
most	O
proximal	O
P0	B-DNA
site	O
,	O
NFAT-containing	O
complexes	O
devoid	O
of	O
NFAT2	B-protein
were	O
readily	O
inducible	O
in	O
the	O
Th1	B-cell_line
clones	I-cell_line
,	O
but	O
hardly	O
or	O
not	O
in	O
the	O
Th2	B-cell_line
clones	I-cell_line
.	O

In	O
contrast	O
,	O
both	O
in	O
Th1	B-cell_line
and	I-cell_line
Th2	I-cell_line
clones	I-cell_line
NFAT-containing	O
complexes	O
were	O
strongly	O
inducible	O
at	O
the	O
P1	B-DNA
site	I-DNA
,	O
consisting	O
of	O
NFAT2	B-protein
and	O
a	O
P0	B-DNA
-compatible	O
NFAT	B-protein
activity	O
,	O
without	O
apparent	O
differences	O
between	O
Th1	B-cell_line
and	I-cell_line
Th2	I-cell_line
clones	I-cell_line
.	O

Like	O
in	O
Th2	B-cell_line
clones	I-cell_line
,	O
suppressed	O
NFAT-	O
P0	B-DNA
complex	O
formation	O
was	O
observed	O
also	O
at	O
the	O
polyclonal	O
level	O
in	O
peripheral	B-cell_type
blood	I-cell_type
mononuclear	I-cell_type
cells	I-cell_type
(	O
PBMC	B-cell_type
)	O
of	O
three	O
of	O
five	O
severe	O
atopic	O
dermatitis	O
patients	O
with	O
strongly	O
elevated	O
serum	O
IgE	B-protein
levels	O
,	O
but	O
not	O
in	O
control	O
PBMC	B-cell_type
.	O

These	O
findings	O
suggest	O
that	O
high-level	O
IL-4	B-protein
production	O
in	O
atopic	B-cell_type
Th2	I-cell_type
cells	I-cell_type
is	O
associated	O
with	O
selective	O
reduction	O
of	O
suppressive	O
NFAT1	B-protein
activity	O
at	O
the	O
IL-4	B-DNA
P0	I-DNA
element	I-DNA
and	O
that	O
some	O
patients	O
with	O
this	O
multifactorial	O
disease	O
may	O
have	O
a	O
putative	O
systemic	O
disorder	O
at	O
this	O
level	O
.	O

Differential	O
expression	O
and	O
phosphorylation	O
of	O
CTCF	B-protein
,	O
a	O
c-myc	O
transcriptional	O
regulator	O
,	O
during	O
differentiation	O
of	O
human	O
myeloid	O
cells	O
.	O

CTCF	B-protein
is	O
a	O
transcriptional	O
repressor	O
of	O
the	O
c-myc	O
gene	O
.	O

Although	O
CTCF	B-protein
has	O
been	O
characterized	O
in	O
some	O
detail	O
,	O
there	O
is	O
very	O
little	O
information	O
about	O
the	O
regulation	O
of	O
CTCF	B-protein
activity	O
.	O

Therefore	O
we	O
investigated	O
CTCF	B-protein
expression	O
and	O
phosphorylation	O
during	O
induced	O
differentiation	O
of	O
human	B-cell_type
myeloid	I-cell_type
leukemia	I-cell_type
cells	I-cell_type
.	O

We	O
found	O
that	O
:	O
(	O
i	O
)	O
both	O
CTCF	B-RNA
mRNA	I-RNA
and	O
protein	O
are	O
down-regulated	O
during	O
terminal	O
differentiation	O
in	O
most	O
cell	O
lines	O
tested	O
;	O
(	O
ii	O
)	O
CTCF	B-protein
down-regulation	O
is	O
retarded	O
and	O
less	O
pronounced	O
than	O
that	O
of	O
c-myc	B-DNA
;	O
(	O
iii	O
)	O
CTCF	B-protein
protein	I-protein
is	O
differentially	O
phosphorylated	O
and	O
the	O
phosphorylation	O
profiles	O
depend	O
on	O
the	O
differentiation	O
pathway	O
.	O

We	O
concluded	O
that	O
CTCF	B-protein
expression	O
and	O
activity	O
is	O
controlled	O
at	O
transcriptional	O
and	O
post-transcriptional	O
levels	O
.	O

Glucocorticoid	O
resistance	O
in	O
the	O
squirrel	O
monkey	O
is	O
associated	O
with	O
overexpression	O
of	O
the	O
immunophilin	B-protein
FKBP51	I-protein
.	O

Squirrel	O
monkeys	O
are	O
neotropical	O
primates	O
that	O
have	O
high	O
circulating	O
cortisol	O
to	O
compensate	O
for	O
expression	O
of	O
glucocorticoid	B-protein
receptors	I-protein
(	O
GRs	B-protein
)	O
with	O
reduced	O
affinity	O
.	O

The	O
low	O
binding	O
affinity	O
of	O
squirrel	O
monkey	O
GR	B-protein
does	O
not	O
result	O
from	O
substitutions	O
in	O
the	O
receptor	O
,	O
because	O
squirrel	B-protein
monkey	I-protein
GR	I-protein
expressed	O
in	O
vitro	O
exhibits	O
high	O
affinity	O
.	O

Rather	O
,	O
squirrel	O
monkeys	O
express	O
a	O
soluble	O
factor	O
that	O
,	O
in	O
mixing	O
studies	O
of	O
cytosol	O
from	O
squirrel	B-cell_type
monkey	I-cell_type
lymphocytes	I-cell_type
(	O
SML	B-cell_type
)	O
and	O
mouse	O
L929	O
cells	O
,	O
reduced	O
GR	O
binding	O
affinity	O
by	O
11-fold	O
.	O

In	O
an	O
effort	O
to	O
identify	O
this	O
factor	O
,	O
the	O
cellular	O
levels	O
of	O
components	O
of	O
the	O
GR	B-protein
heterocomplex	I-protein
in	O
SML	B-cell_type
and	O
human	B-cell_type
lymphocytes	I-cell_type
(	O
HL	B-cell_type
)	O
were	O
compared	O
.	O

The	O
immunophilin	B-protein
FKBP51	I-protein
was	O
13-fold	O
higher	O
in	O
SML	B-cell_type
than	O
in	O
HL	O
cytosol	O
;	O
FKBP52	B-protein
in	O
SML	B-cell_type
was	O
42	O
%	O
of	O
that	O
in	O
HL	O
cytosol	O
.	O

A	O
role	O
for	O
changes	O
in	O
immunophilins	B-protein
,	O
causing	O
glucocorticoid	O
resistance	O
in	O
neotropical	O
primates	O
,	O
is	O
supported	O
by	O
the	O
following	O
:	O
the	O
changes	O
in	O
FKBP51	B-protein
and	O
FKBP52	B-protein
were	O
observed	O
in	O
cells	O
from	O
other	O
neotropical	O
primates	O
with	O
glucocorticoid	O
resistance	O
;	O
the	O
elevated	O
level	O
of	O
FKBP51	B-protein
was	O
reflected	O
in	O
an	O
abundance	O
of	O
FKBP51	B-protein
in	O
heat	B-protein
shock	I-protein
protein	I-protein
90	I-protein
complexes	I-protein
in	O
SML	B-cell_type
;	O
when	O
cytosols	O
of	O
SML	B-cell_type
and	O
L929	B-cell_line
cells	I-cell_line
were	O
mixed	O
,	O
the	O
decrease	O
in	O
GR	O
binding	O
was	O
associated	O
with	O
incorporation	O
of	O
FKBP51	B-protein
into	O
GR	B-protein
heterocomplexes	I-protein
;	O
the	O
effect	O
of	O
SML	B-cell_type
cytosol	O
on	O
GR	O
binding	O
was	O
reproduced	O
with	O
cytosol	O
from	O
COS	B-cell_line
cells	I-cell_line
expressing	O
squirrel	O
monkey	O
FKBP51	B-protein
;	O
and	O
both	O
the	O
effect	O
of	O
SML	B-cell_type
cytosol	O
on	O
GR	O
binding	O
and	O
the	O
incorporation	O
of	O
FKBP51	B-protein
into	O
GR	B-protein
heterocomplexes	I-protein
were	O
blocked	O
by	O
FK506	O
.	O

Regulation	O
of	O
GR	O
binding	O
by	O
FKBP51	B-protein
represents	O
a	O
previously	O
unrecognized	O
mechanism	O
for	O
regulating	O
glucocorticoid	O
sensitivity	O
.	O

High-level	O
replication	O
of	O
human	O
immunodeficiency	O
virus	O
in	O
thymocytes	B-cell_type
requires	O
NF-kappaB	B-protein
activation	O
through	O
interaction	O
with	O
thymic	B-cell_type
epithelial	I-cell_type
cells	I-cell_type
.	O

We	O
have	O
previously	O
demonstrated	O
that	O
interaction	O
of	O
infected	O
thymocytes	B-cell_type
with	O
autologous	O
thymic	B-cell_type
epithelial	I-cell_type
cells	I-cell_type
(	O
TEC	B-cell_type
)	O
is	O
a	O
prerequisite	O
for	O
a	O
high	O
level	O
of	O
human	O
immunodeficiency	O
virus	O
type	O
1	O
(	O
HIV-1	O
)	O
replication	O
in	O
thymocytes	B-cell_type
(	O
M.Rothe	O
,	O
L.Chene	O
,	O
M.Nugeyre	O
,	O
F.Barre-Sinoussi	O
,	O
and	O
N.Israel	O
,	O
J.Virol.72	O
:	O
5852-5861	O
,	O
1998	O
)	O
.	O

We	O
report	O
here	O
that	O
this	O
activation	O
of	O
HIV	O
replication	O
takes	O
place	O
at	O
the	O
transcriptional	O
level	O
through	O
activation	O
of	O
the	O
Rel/NF-kappaB	B-protein
transcription	B-protein
factors	I-protein
.	O

We	O
first	O
demonstrate	O
that	O
an	O
HIV-1	O
provirus	O
(	O
SF-2	O
strain	O
)	O
very	O
effectively	O
replicates	O
in	O
thymocytes	B-cell_type
cocultured	O
with	O
TEC	B-cell_type
whereas	O
this	O
provirus	O
,	O
with	O
kappaB	B-DNA
sites	I-DNA
deleted	O
,	O
fails	O
to	O
replicate	O
.	O

We	O
provide	O
evidence	O
that	O
several	O
NF-kappaB	B-protein
complexes	I-protein
are	O
constitutively	O
found	O
in	O
the	O
nuclei	O
of	O
thymocytes	B-cell_type
either	O
freshly	O
isolated	O
from	O
the	O
thymus	O
or	O
maintained	O
in	O
coculture	O
with	O
autologous	O
or	O
heterologous	O
TEC	B-cell_type
.	O

The	O
prevalent	O
complex	O
is	O
the	O
heterodimer	B-protein
p50-p65	I-protein
.	O

NF-kappaB	B-protein
activity	O
is	O
tightly	O
correlated	O
with	O
the	O
transcriptional	O
activity	O
of	O
a	O
long	B-DNA
terminal	I-DNA
repeat	I-DNA
(	O
LTR	B-DNA
)	O
of	O
HIV-1	O
transfected	O
in	O
thymocytes	B-cell_type
.	O

The	O
cotransfection	O
of	O
this	O
LTR	B-DNA
with	O
a	O
mutated	O
IkappaBalpha	B-protein
molecule	I-protein
formally	O
demonstrates	O
that	O
LTR	B-DNA
transactivation	O
is	O
regulated	O
by	O
members	O
of	O
the	O
Rel/NF-kappaB	B-protein
family	I-protein
in	O
thymocytes	B-cell_type
.	O

We	O
also	O
showed	O
that	O
tumor	B-protein
necrosis	I-protein
factor	I-protein
(	O
TNF	B-protein
)	O
and	O
to	O
a	O
lesser	O
extent	O
interleukin-1	B-protein
(	O
IL-1	B-protein
)	O
,	O
secreted	O
within	O
the	O
coculture	O
,	O
induce	O
NF-kappaB	B-protein
activity	O
and	O
a	O
correlative	O
LTR	B-DNA
transactivation	O
.	O

However	O
IL-7	B-protein
,	O
a	O
crucial	O
factor	O
for	O
thymopoiesis	O
that	O
is	O
secreted	O
mainly	O
by	O
TEC	B-cell_type
,	O
is	O
a	O
necessary	O
cofactor	O
for	O
NF-kappaB	B-protein
activation	O
elicited	O
by	O
TNF	B-protein
or	O
IL-1	B-protein
.	O

Together	O
,	O
these	O
data	O
indicate	O
that	O
NF-kappaB	B-protein
activation	O
,	O
required	O
for	O
a	O
high	O
level	O
of	O
HIV	O
replication	O
in	O
thymocytes	B-cell_type
,	O
is	O
regulated	O
in	O
a	O
specific	O
manner	O
in	O
the	O
thymic	O
microenvironment	O
which	O
provides	O
the	O
necessary	O
cytokines	O
:	O
TNF	B-protein
,	O
IL-1	B-protein
,	O
and	O
IL-7	B-protein
.	O

Imbalanced	O
expression	O
of	O
the	O
glucocorticoid	B-protein
receptor	I-protein
isoforms	I-protein
in	O
cultured	B-cell_type
lymphocytes	I-cell_type
from	O
a	O
patient	O
with	O
systemic	O
glucocorticoid	O
resistance	O
and	O
chronic	O
lymphocytic	O
leukemia	O
.	O

The	O
human	B-protein
glucocorticoid	I-protein
receptor	I-protein
(	O
GR	B-protein
)	O
is	O
expressed	O
as	O
two	O
alternatively	O
spliced	O
isoforms	O
,	O
GRalpha	B-protein
and	O
GRbeta	B-protein
.	O

Whereas	O
GRalpha	B-protein
is	O
a	O
hormone-activated	O
transcription	B-protein
factor	I-protein
,	O
GRbeta	B-protein
does	O
not	O
bind	O
glucocorticoids	O
(	O
GCs	O
)	O
,	O
is	O
transcriptionally	O
inactive	O
,	O
and	O
is	O
a	O
potential	O
inhibitor	O
of	O
activated	O
GRalpha	B-protein
.	O

Differential	O
expression	O
of	O
GR	B-protein
isoforms	I-protein
may	O
play	O
a	O
role	O
in	O
generalized	O
or	O
tissue-specific	O
GC	O
resistance	O
.	O

GCs	O
induce	O
apoptosis	O
in	O
neoplastic	B-cell_type
lymphoid	I-cell_type
cells	I-cell_type
;	O
and	O
,	O
defective	O
apoptosis	O
is	O
implicated	O
in	O
the	O
genesis	O
of	O
chronic	O
lymphocytic	O
leukemia	O
(	O
CLL	O
)	O
.	O

We	O
studied	O
a	O
patient	O
with	O
generalized	O
GC	O
resistance	O
and	O
CLL	O
.	O

GR	O
number	O
in	O
the	O
patient	O
's	O
transformed	B-cell_line
lymphocytes	I-cell_line
was	O
approximately	O
one	O
half	O
that	O
of	O
control	O
cells	O
with	O
a	O
approximately	O
10-fold	O
reduction	O
in	O
binding	O
affinity	O
for	O
dexamethasone	O
.	O

In	O
vitro	O
apoptosis	O
induction	O
in	O
CLL	B-cell_line
cells	I-cell_line
was	O
delayed	O
in	O
response	O
to	O
GCs	O
,	O
but	O
not	O
to	O
other	O
apoptosis	O
inducers	O
.	O

Sequencing	O
of	O
the	O
GR	B-DNA
cDNA	I-DNA
and	O
gene	O
including	O
the	O
2.3-kb	O
coding	O
region	O
,	O
the	O
intron/exon	O
junctions	O
,	O
the	O
known	O
5'-regulatory	B-DNA
region	I-DNA
,	O
and	O
approximately	O
300	O
bp	O
of	O
the	O
3'-region	B-DNA
revealed	O
no	O
alterations	O
.	O

Western	O
blot	O
with	O
an	O
N-terminal	O
antibody	O
showed	O
normal	O
levels	O
of	O
immunoreactive	B-protein
GR	I-protein
,	O
but	O
quantitative	O
analysis	O
with	O
isoform-specific	O
C-terminal	B-protein
antibodies	I-protein
revealed	O
a	O
markedly	O
reduced	O
GRalpha	B-protein
expression	O
,	O
and	O
high	O
GRbeta	B-protein
expression	O
.	O

These	O
findings	O
indicate	O
that	O
imbalanced	O
expression	O
of	O
the	O
GR	B-protein
isoforms	I-protein
may	O
be	O
a	O
mechanism	O
of	O
GC	O
resistance	O
,	O
and	O
may	O
have	O
implications	O
for	O
tumorigenesis	O
by	O
enhancing	O
cell	O
survival	O
.	O

Copyright	O
1999	O
Academic	O
Press	O
.	O

Intranuclear	O
targeted	O
delivery	O
of	O
functional	O
NF-kappaB	B-protein
by	O
70	B-protein
kDa	I-protein
heat	I-protein
shock	I-protein
protein	I-protein
.	O

The	O
70	B-protein
kDa	I-protein
heat	I-protein
shock	I-protein
protein	I-protein
(	O
Hsp70	B-protein
)	O
is	O
a	O
highly	O
conserved	O
,	O
ubiquitous	B-protein
protein	I-protein
involved	O
in	O
chaperoning	B-protein
proteins	I-protein
to	O
various	O
cellular	O
organelles	O
.	O

Here	O
we	O
show	O
that	O
when	O
added	O
exogenously	O
to	O
cells	O
,	O
Hsp70	B-protein
is	O
readily	O
imported	O
into	O
both	O
cytoplasmic	O
and	O
nuclear	O
compartments	O
in	O
a	O
cell-type-specific	O
fashion	O
.	O

We	O
exploited	O
this	O
ability	O
of	O
Hsp70	B-protein
to	O
deliver	O
NF-kappaB	B-protein
,	O
a	O
key	O
transcriptional	O
regulator	O
of	O
inflammatory	O
responses	O
.	O

We	O
demonstrate	O
that	O
a	O
fusion	O
protein	O
composed	O
of	O
a	O
C-terminal	O
Hsp70	B-protein
peptide	O
and	O
the	O
p50	B-protein
subunit	I-protein
of	O
NF-kappaB	B-protein
was	O
directed	O
into	O
the	O
nucleus	O
of	O
cells	O
,	O
could	O
bind	O
DNA	O
specifically	O
,	O
and	O
activated	O
Igkappa	B-protein
expression	O
and	O
TNFalpha	B-protein
production	O
.	O

We	O
therefore	O
propose	O
that	O
Hsp70	B-protein
can	O
be	O
used	O
as	O
a	O
vehicle	O
for	O
intracytoplasmic	O
and	O
intranuclear	O
delivery	O
of	O
proteins	O
or	O
DNA	O
to	O
modulate	O
gene	O
expression	O
and	O
thereby	O
control	O
immune	O
responses	O
.	O

Characterization	O
of	O
the	O
human	B-DNA
elk-1	I-DNA
promoter	I-DNA
.	O

Potential	O
role	O
of	O
a	O
downstream	B-DNA
intronic	I-DNA
sequence	I-DNA
for	O
elk-1	B-DNA
gene	I-DNA
expression	O
in	O
monocytes	B-cell_type
.	O

To	O
characterize	O
the	O
human	B-DNA
elk-1	I-DNA
promoter	I-DNA
,	O
we	O
mapped	O
the	O
transcriptional	B-DNA
start	I-DNA
site	I-DNA
and	O
isolated	O
elk-1-specific	B-cell_line
genomic	I-cell_line
phage	I-cell_line
clones	I-cell_line
that	O
contained	O
extensive	O
upstream	B-DNA
and	I-DNA
downstream	I-DNA
sequences	I-DNA
.	O

A	O
TATA-like	B-DNA
motif	I-DNA
was	O
identified	O
immediately	O
upstream	O
of	O
the	O
transcriptional	B-DNA
start	I-DNA
site	I-DNA
.	O

Functional	O
analyses	O
of	O
DNA	B-DNA
fragments	I-DNA
containing	O
the	O
TATA	B-DNA
element	I-DNA
and	O
the	O
identification	O
of	O
a	O
DNase	B-DNA
I-hypersensitive	I-DNA
chromatin	I-DNA
site	I-DNA
(	O
HS	B-DNA
1	I-DNA
)	O
in	O
close	O
proximity	O
to	O
the	O
TATA	B-DNA
box	I-DNA
suggest	O
that	O
the	O
identified	O
TATA	B-DNA
motif	I-DNA
is	O
important	O
for	O
elk-1	B-DNA
transcription	O
in	O
vivo	O
.	O

Sequences	O
upstream	O
and	O
downstream	O
from	O
the	O
TATA	B-DNA
box	I-DNA
were	O
found	O
to	O
contribute	O
to	O
elk-1	B-DNA
promoter	O
activity	O
.	O

A	O
second	O
hypersensitive	O
site	O
(	O
HS	O
2	O
)	O
was	O
identified	O
within	O
the	O
first	O
intron	O
in	O
pre-monocytic	O
cells	O
,	O
which	O
express	O
Elk-1	O
only	O
when	O
differentiating	O
to	O
monocytes	B-cell_type
.	O

In	O
a	O
variety	O
of	O
other	O
cell	O
types	O
,	O
which	O
display	O
a	O
constitutive	O
Elk-1	B-protein
expression	O
,	O
HS	O
2	O
did	O
not	O
exist	O
,	O
suggesting	O
that	O
inducibility	O
of	O
elk-1	B-DNA
expression	O
is	O
associated	O
with	O
the	O
presence	O
of	O
HS	O
2	O
.	O

Egr-1	O
and	O
the	O
serum	O
response	O
factor	O
were	O
found	O
to	O
interact	O
specifically	O
with	O
the	O
intronic	B-DNA
sequence	I-DNA
at	O
+265	O
and	O
+448	O
,	O
respectively	O
.	O

Because	O
Egr-1	B-RNA
mRNA	I-RNA
and	O
protein	O
levels	O
were	O
observed	O
to	O
increase	O
significantly	O
before	O
induction	O
of	O
elk-1	B-DNA
expression	O
,	O
we	O
propose	O
that	O
Egr-1	B-protein
is	O
important	O
for	O
the	O
regulation	O
of	O
elk-1	B-DNA
transcription	O
in	O
differentiating	O
monocytes	B-cell_type
.	O

Immunohistochemical	O
study	O
of	O
c-fos-positive	B-protein
lymphocytes	I-protein
infiltrated	O
into	O
human	O
squamous	O
cell	O
carcinomas	O
of	O
the	O
head	O
and	O
neck	O
during	O
radiation	O
therapy	O
and	O
its	O
clinical	O
significance	O
.	O

C-fos	B-DNA
has	O
been	O
reported	O
to	O
be	O
one	O
of	O
the	O
immediate	B-DNA
early	I-DNA
genes	I-DNA
in	O
signal	O
transduction	O
systems	O
after	O
many	O
kinds	O
of	O
stresses	O
,	O
including	O
ionizing	O
radiation	O
.	O

Changes	O
in	O
c-fos	B-DNA
expression	O
induced	O
by	O
radiation	O
therapy	O
in	O
tumor	O
tissues	O
have	O
not	O
yet	O
been	O
reported	O
.	O

In	O
this	O
study	O
,	O
we	O
have	O
attempted	O
to	O
determine	O
whether	O
c-fos	B-DNA
expression	O
is	O
induced	O
by	O
radiotherapy	O
in	O
human	O
squamous	O
cell	O
carcinomas	O
of	O
the	O
head	O
and	O
neck	O
and	O
to	O
establish	O
a	O
possible	O
correlation	O
between	O
c-fos	B-DNA
expression	O
and	O
the	O
therapeutic	O
effects	O
of	O
radiation	O
therapy	O
.	O

Twenty-seven	O
patients	O
with	O
tumors	O
of	O
the	O
oral	O
cavity	O
,	O
oropharynx	O
,	O
and	O
maxillary	O
sinus	O
were	O
examined	O
,	O
all	O
of	O
which	O
were	O
confirmed	O
as	O
squamous	O
cell	O
carcinomas	O
.	O

After	O
obtaining	O
the	O
patients	O
'	O
informed	O
consent	O
,	O
biopsies	O
were	O
performed	O
before	O
treatment	O
and	O
at	O
doses	O
of	O
4	O
,	O
10	O
,	O
and	O
20	O
Gy	O
of	O
radiotherapy	O
,	O
and	O
the	O
specimens	O
were	O
preserved	O
in	O
liquid	O
nitrogen	O
for	O
further	O
examination	O
.	O

Serial	O
sectioning	O
of	O
6	O
micrometer	O
was	O
performed	O
using	O
a	O
cryostat	O
,	O
and	O
samples	O
were	O
immunohistochemically	O
stained	O
using	O
the	O
streptoavidin	B-protein
-biotin	B-protein
peroxidase	I-protein
method	O
and	O
a	O
monoclonal	O
antibody	O
against	O
c-fos	O
.	O

Three	O
of	O
the	O
27	O
patients	O
with	O
squamous	O
cell	O
carcinoma	O
showed	O
slight	O
expression	O
of	O
c-fos	O
in	O
their	O
tumor	O
cells	O
before	O
and/or	O
at	O
4	O
or	O
10	O
Gy	O
of	O
radiotherapy	O
.	O

The	O
tumors	O
showed	O
high	O
radiosensitivity	O
.	O

Concerning	O
tumor-infiltrating	B-cell_type
lymphocytes	I-cell_type
,	O
the	O
rate	O
of	O
moderate	O
or	O
remarkable	O
grades	O
of	O
c-fos-positive	B-protein
lymphocytes	I-protein
before	O
radiotherapy	O
and	O
at	O
radiation	O
doses	O
of	O
4	O
,	O
10	O
,	O
and	O
20	O
Gy	O
was	O
8.0	O
,	O
29.2	O
,	O
4.8	O
,	O
and	O
0	O
%	O
,	O
respectively	O
.	O

The	O
relationship	O
between	O
the	O
immunohistochemical	O
findings	O
and	O
the	O
antitumor	O
effect	O
at	O
a	O
radiation	O
dose	O
of	O
20	O
Gy	O
was	O
examined	O
on	O
the	O
corresponding	O
H	O
&	O
E-stained	O
sections	O
.	O

In	O
patients	O
whose	O
infiltration	O
of	O
c-fos-positive	B-protein
lymphocytes	I-protein
into	O
tumor	O
tissues	O
were	O
moderate	O
or	O
remarkable	O
at	O
4	O
Gy	O
of	O
radiotherapy	O
,	O
the	O
tumors	O
responded	O
significantly	O
well	O
to	O
radiation	O
therapy	O
(	O
P	O
<	O
0.025	O
,	O
chi2	O
test	O
)	O
,	O
and	O
the	O
patients	O
took	O
a	O
significantly	O
favorable	O
clinical	O
course	O
(	O
P	O
<	O
0.05	O
,	O
chi2	O
test	O
)	O
.	O

In	O
a	O
sample	O
from	O
one	O
of	O
the	O
patients	O
,	O
c-fos-positive	B-protein
lymphocytes	I-protein
were	O
identified	O
as	O
CD4	O
positive	O
and	O
CD8	O
negative	O
.	O

Therefore	O
,	O
the	O
high	O
radiosensitivity	O
of	O
squamous	O
cell	O
carcinomas	O
in	O
our	O
samples	O
could	O
be	O
explained	O
by	O
an	O
overexpression	O
of	O
c-fos	B-protein
in	O
the	O
tumor-infiltrating	B-cell_type
lymphocytes	I-cell_type
induced	O
by	O
small	O
doses	O
of	O
radiation	O
therapy	O
,	O
and	O
these	O
activated	B-cell_type
lymphocytes	I-cell_type
exerted	O
a	O
cytotoxic	O
effect	O
against	O
the	O
cancer	B-cell_type
cells	I-cell_type
.	O

Paternal	O
expression	O
of	O
WT1	B-protein
in	O
human	B-cell_type
fibroblasts	I-cell_type
and	O
lymphocytes	B-cell_type
.	O

The	O
Wilms	B-DNA
'	I-DNA
tumor	I-DNA
suppressor	I-DNA
gene	I-DNA
(	O
WT1	B-protein
)	O
was	O
previously	O
identified	O
as	O
being	O
imprinted	O
,	O
with	O
frequent	O
maternal	O
expression	O
in	O
human	O
placentae	O
and	O
fetal	O
brains	O
.	O

We	O
examined	O
the	O
allele-specific	O
expression	O
of	O
WT1	B-protein
in	O
cultured	O
human	B-cell_type
fibroblasts	I-cell_type
from	O
15	O
individuals	O
.	O

Seven	O
of	O
15	O
fibroblast	B-cell_line
lines	I-cell_line
were	O
heterozygous	O
for	O
polymorphic	B-DNA
alleles	I-DNA
,	O
and	O
the	O
expression	O
patterns	O
were	O
variable	O
,	O
i.e.	O
,	O
equal	O
,	O
unequal	O
or	O
monoallelic	O
paternal	O
expression	O
in	O
three	O
,	O
two	O
and	O
two	O
cases	O
,	O
respectively	O
.	O

Exclusive	O
paternal	O
expression	O
of	O
WT1	B-protein
was	O
also	O
shown	O
in	O
non-cultured	B-cell_type
peripheral	I-cell_type
lymphocytes	I-cell_type
from	O
the	O
latter	O
two	O
individuals	O
.	O

The	O
allele-specific	O
expression	O
profiles	O
of	O
other	O
imprinted	B-DNA
genes	I-DNA
,	O
IGF2	B-DNA
and	O
H19	B-DNA
,	O
on	O
human	B-DNA
chromosome	I-DNA
11	I-DNA
were	O
constant	O
and	O
consistent	O
with	O
those	O
in	O
other	O
tissues	O
.	O

Our	O
unexpected	O
observations	O
of	O
paternal	O
or	O
biallelic	O
expression	O
of	O
WT1	B-protein
in	O
fibroblasts	B-cell_type
and	O
lymphocytes	B-cell_type
,	O
together	O
with	O
the	O
previous	O
findings	O
of	O
maternal	O
or	O
biallelic	O
expression	O
in	O
placentae	O
and	O
brains	O
,	O
suggest	O
that	O
the	O
allele-specific	O
regulatory	O
system	O
of	O
WT1	B-protein
is	O
unique	O
and	O
may	O
be	O
controlled	O
by	O
a	O
putative	O
tissue-	O
and	O
individual-specific	O
modifier	O
.	O

T	O
cell	O
reactivity	O
to	O
Sjogren	O
's	O
syndrome	O
related	O
antigen	O
La	B-protein
(	I-protein
SSB	I-protein
)	I-protein
.	O

OBJECTIVE	O
.	O

Many	O
patients	O
with	O
primary	O
Sjogren	O
's	O
syndrome	O
(	O
SS	O
)	O
make	O
high	O
titer	O
IgG	B-protein
autoantibodies	I-protein
to	O
the	O
La	B-protein
(	I-protein
SSB	I-protein
)	I-protein
antigen	O
,	O
suggesting	O
antigen	O
specific	O
T	O
cell-B	O
cell	O
interactions	O
.	O

T	O
cell	O
responses	O
to	O
some	O
nuclear	O
antigens	O
,	O
particularly	O
U1RNP	B-protein
,	O
have	O
been	O
detected	O
in	O
patients	O
with	O
systemic	O
lupus	O
erythematosus	O
(	O
SLE	O
)	O
and	O
in	O
healthy	O
subjects	O
.	O

We	O
investigated	O
T	O
cell	O
reactivity	O
to	O
the	O
autoantigen	B-protein
SSB	I-protein
in	O
patients	O
with	O
SS	O
and	O
healthy	O
controls	O
.	O

METHODS	O
.	O

Using	O
the	O
[	O
3H	O
]	O
thymidine	O
proliferation	O
assay	O
,	O
we	O
determined	O
reactivity	O
to	O
purified	B-protein
recombinant	I-protein
SSB	I-protein
(	O
rSSB	B-protein
)	O
in	O
20	O
patients	O
with	O
SS	O
and	O
19	O
controls	O
.	O

Specificity	O
was	O
determined	O
using	O
tetanus	O
toxoid	O
,	O
endotoxin	O
,	O
and	O
3	O
other	O
autoantigens	B-protein
(	O
PBC.M2	B-protein
,	O
Sc170	B-protein
,	O
and	O
GAD	B-protein
)	O
.	O

Precursor	O
frequency	O
was	O
calculated	O
by	O
limiting	O
dilution	O
analysis	O
.	O

HLA	O
Class	O
II	O
dependency	O
was	O
investigated	O
using	O
anti-Class	B-protein
II	I-protein
monoclonal	I-protein
antibodies	I-protein
.	O

HLA-DR	O
typing	O
was	O
by	O
polymerase	O
chain	O
reaction	O
and	O
sequence	O
specific	O
oligonucleotide	O
typing	O
.	O

RESULTS	O
.	O

Six	O
of	O
20	O
patients	O
with	O
SS	O
and	O
10/19	O
controls	O
proliferated	O
to	O
La	O
(	O
rSSB	B-protein
)	O
.	O

Precursor	O
frequency	O
of	O
anti-SSB	B-cell_line
T	I-cell_line
cells	I-cell_line
was	O
1	O
:	O
77	O
,	O
040	O
and	O
1	O
:	O
115	O
,	O
000	O
in	O
2	O
healthy	O
subjects	O
and	O
1	O
:	O
230	O
,	O
250	O
and	O
1	O
:	O
103	O
,	O
034	O
in	O
two	O
patients	O
with	O
SS	O
.	O

Anti-	O
HLA-DR	B-protein
abrogated	O
proliferation	O
to	O
SSB	B-protein
and	O
tetanus	O
toxoid	O
.	O

Thirteen	O
of	O
15	O
patients	O
with	O
SS	O
and	O
4/17	O
controls	O
were	O
HLA-DR3	B-protein
positive	O
,	O
with	O
no	O
apparent	O
association	O
of	O
HLA-DR3	B-protein
with	O
SSB	B-protein
reactivity	O
in	O
controls	O
.	O

CONCLUSION	O
.	O

Anti-La	B-cell_line
(	I-cell_line
SSB	I-cell_line
)	I-cell_line
specific	I-cell_line
T	I-cell_line
cells	I-cell_line
occur	O
in	O
a	O
significant	O
proportion	O
of	O
controls	O
and	O
in	O
some	O
patients	O
with	O
SS	O
.	O

The	O
function	O
of	O
SSB	B-cell_line
T	I-cell_line
cells	I-cell_line
in	O
controls	O
remains	O
to	O
be	O
defined	O
.	O

They	O
may	O
represent	O
immunoregulatory	B-cell_type
cells	I-cell_type
,	O
and	O
further	O
analysis	O
of	O
these	O
cells	O
,	O
and	O
a	O
comparison	O
to	O
those	O
found	O
in	O
patients	O
with	O
SS	O
,	O
may	O
elucidate	O
normal	O
immunoregulation	O
and	O
the	O
derangements	O
that	O
lead	O
to	O
Sjogren	O
's	O
syndrome	O
.	O

Anti-rheumatic	O
compound	O
aurothioglucose	O
inhibits	O
tumor	B-protein
necrosis	I-protein
factor-alpha	I-protein
-induced	O
HIV-1	O
replication	O
in	O
latently	O
infected	O
OM10.1	B-cell_line
and	I-cell_line
Ach2	I-cell_line
cells	I-cell_line
.	O

NF-kappaB	B-protein
is	O
a	O
potent	O
cellular	O
activator	O
of	O
HIV-1	O
gene	O
expression	O
.	O

Down-regulation	O
of	O
NF-kappaB	B-protein
activation	O
is	O
known	O
to	O
inhibit	O
HIV	O
replication	O
from	O
the	O
latently	B-cell_type
infected	I-cell_type
cells	I-cell_type
.	O

Gold	O
compounds	O
have	O
been	O
effectively	O
used	O
for	O
many	O
decades	O
in	O
the	O
treatment	O
of	O
rheumatoid	O
arthritis	O
.	O

We	O
previously	O
reported	O
that	O
gold	O
compounds	O
,	O
especially	O
aurothioglucose	O
(	O
AuTG	O
)	O
containing	O
monovalent	O
gold	O
ion	O
,	O
inhibited	O
the	O
DNA-binding	O
of	O
NF-kappaB	B-protein
in	O
vitro	O
.	O

In	O
this	O
report	O
we	O
have	O
examined	O
the	O
efficacy	O
of	O
the	O
gold	O
compound	O
AuTG	O
as	O
an	O
inhibitor	O
of	O
HIV	O
replication	O
in	O
latently	O
infected	O
OM10.1	B-cell_line
and	I-cell_line
Ach2	I-cell_line
cells	I-cell_line
.	O

Tumor	B-protein
necrosis	I-protein
factor	I-protein
(	I-protein
TNF	I-protein
)	I-protein
-alpha	I-protein
-induced	O
HIV-1	O
replication	O
in	O
OM10.1	B-cell_line
or	O
Ach2	B-cell_line
cells	I-cell_line
was	O
significantly	O
inhibited	O
by	O
non-cytotoxic	O
doses	O
of	O
AuTG	O
(	O
>	O
10	O
microM	O
in	O
OM10.1	O
cells	O
and	O
>	O
25	O
F.M	O
in	O
Ach2	B-cell_line
cells	I-cell_line
)	O
,	O
while	O
25	O
microM	O
of	O
the	O
counter-anion	B-protein
thioglucose	I-protein
(	O
TG	B-protein
)	O
or	O
gold	O
compound	O
containing	O
divalent	O
gold	O
ion	O
,	O
HAuCl3	O
,	O
had	O
no	O
effect	O
.	O

The	O
effect	O
of	O
AuTG	O
on	O
NF-kappaB	B-protein
-dependent	O
gene	O
expression	O
was	O
confirmed	O
by	O
a	O
transient	O
CAT	B-protein
assay	O
.	O

Specific	O
staining	O
as	O
well	O
as	O
electron	O
microscopic	O
examinations	O
revealed	O
the	O
accumulation	O
of	O
metal	O
gold	O
in	O
the	O
cells	O
,	O
supporting	O
our	O
previous	O
hypothesis	O
that	O
gold	O
ions	O
could	O
block	O
NF-kappaB	B-protein
-DNA	O
binding	O
by	O
a	O
redox	O
mechanism	O
.	O

These	O
observations	O
indicate	O
that	O
the	O
monovalent	O
gold	O
compound	O
AuTG	O
is	O
a	O
potentially	O
useful	O
drug	O
for	O
the	O
treatment	O
of	O
patients	O
infected	O
with	O
HIV	O
.	O

Clonality	O
of	O
isolated	B-cell_type
eosinophils	I-cell_type
in	O
the	O
hypereosinophilic	O
syndrome	O
.	O

The	O
idiopathic	O
hypereosinophilic	O
syndrome	O
(	O
IHES	O
)	O
is	O
a	O
rare	O
disorder	O
characterized	O
by	O
unexplained	O
,	O
persistent	O
eosinophilia	O
associated	O
with	O
multiple	O
organ	O
dysfunction	O
due	O
to	O
eosinophilic	O
tissue	O
infiltration	O
.	O

In	O
the	O
absence	O
of	O
karyotypic	O
abnormalities	O
,	O
there	O
is	O
no	O
specific	O
test	O
to	O
detect	O
clonal	O
eosinophilia	O
in	O
IHES	O
.	O

Analysis	O
of	O
X-chromosome	B-DNA
inactivation	O
patterns	O
can	O
be	O
used	O
to	O
determine	O
whether	O
proliferative	O
disorders	O
are	O
clonal	O
in	O
origin	O
.	O

Methylation	O
of	O
HpaII	B-DNA
and	I-DNA
Hha	I-DNA
I	I-DNA
sites	I-DNA
near	O
the	O
polymorphic	B-DNA
trinucleotide	I-DNA
repeat	I-DNA
of	O
the	O
human	B-DNA
androgen	I-DNA
receptor	I-DNA
gene	I-DNA
(	O
HUMARA	B-DNA
)	O
has	O
been	O
shown	O
to	O
correlate	O
with	O
X-inactivation	O
.	O

In	O
this	O
study	O
,	O
we	O
have	O
used	O
the	O
polymerase	O
chain	O
reaction	O
(	O
PCR	O
)	O
with	O
nested	O
primers	O
to	O
analyze	O
X-inactivation	O
patterns	O
of	O
the	O
HUMARA	B-DNA
loci	I-DNA
in	O
purified	B-cell_type
eosinophils	I-cell_type
from	O
female	O
patients	O
with	O
eosinophilia	O
.	O

Peripheral	B-cell_type
blood	I-cell_type
eosinophils	I-cell_type
were	O
isolated	O
by	O
their	O
autofluoresence	O
using	O
flow	O
cytometric	O
sorting	O
.	O

Eosinophils	B-cell_type
purified	O
from	O
a	O
female	O
patient	O
presenting	O
with	O
IHES	O
were	O
found	O
to	O
show	O
a	O
clonal	O
pattern	O
of	O
X-inactivation	O
.	O

Eosinophil-depleted	B-cell_type
leukocytes	I-cell_type
from	O
this	O
patient	O
were	O
polyclonal	O
by	O
HUMARA	B-DNA
analysis	O
,	O
thus	O
excluding	O
skewedness	O
of	O
random	O
X-inactivation	O
.	O

After	O
corticosteroid	O
suppression	O
of	O
her	O
blood	O
eosinophilia	O
,	O
a	O
clonal	O
population	O
of	O
eosinophils	B-cell_type
could	O
no	O
longer	O
be	O
detected	O
in	O
purified	B-cell_type
eosinophils	I-cell_type
.	O

In	O
contrast	O
,	O
eosinophils	B-cell_type
purified	O
from	O
a	O
patient	O
with	O
Churg-Strauss	O
syndrome	O
and	O
from	O
six	O
patients	O
with	O
reactive	O
eosinophilias	O
attributed	O
to	O
allergy	O
,	O
parasitic	O
infection	O
,	O
or	O
drug	O
reaction	O
showed	O
a	O
polyclonal	O
pattern	O
of	O
X-inactivation	O
by	O
HUMARA	B-DNA
analysis	O
.	O

The	O
finding	O
of	O
clonal	O
eosinophilia	O
in	O
a	O
patient	O
presenting	O
with	O
IHES	O
indicates	O
that	O
such	O
patients	O
may	O
have	O
,	O
in	O
reality	O
,	O
a	O
low-grade	O
clonal	O
disorder	O
that	O
can	O
be	O
distinguished	O
from	O
reactive	O
eosinophilias	O
by	O
HUMARA	B-DNA
analysis	O
.	O

Further	O
,	O
the	O
method	O
described	O
can	O
be	O
used	O
to	O
monitor	O
disease	O
progression	O
.	O

GA-binding	B-protein
protein	I-protein
factors	I-protein
,	O
in	O
concert	O
with	O
the	O
coactivator	B-protein
CREB	I-protein
binding	I-protein
protein/p300	I-protein
,	O
control	O
the	O
induction	O
of	O
the	O
interleukin	B-DNA
16	I-DNA
promoter	I-DNA
in	O
T	B-cell_type
lymphocytes	I-cell_type
.	O

Interleukin	B-protein
16	I-protein
(	O
IL-16	B-protein
)	O
is	O
a	O
chemotactic	B-protein
cytokine	I-protein
that	O
binds	O
to	O
the	O
CD4	B-protein
receptor	I-protein
and	O
affects	O
the	O
activation	O
of	O
T	B-cell_type
cells	I-cell_type
and	O
replication	O
of	O
HIV	O
.	O

It	O
is	O
expressed	O
as	O
a	O
large	O
67-kDa	B-protein
precursor	I-protein
protein	I-protein
(	O
pro-IL-16	B-protein
)	O
in	O
lymphocytes	B-cell_type
,	O
macrophages	B-cell_type
,	O
and	O
mast	B-cell_type
cells	I-cell_type
,	O
as	O
well	O
as	O
in	O
airway	B-cell_type
epithelial	I-cell_type
cells	I-cell_type
from	O
asthmatics	O
after	O
challenge	O
with	O
allergen	O
.	O

This	O
pro-IL-16	B-protein
is	O
subsequently	O
processed	O
to	O
the	O
mature	O
cytokine	O
of	O
13	B-protein
kDa	I-protein
.	O

To	O
study	O
the	O
expression	O
of	O
IL-16	B-protein
at	O
the	O
transcriptional	O
level	O
,	O
we	O
cloned	O
the	O
human	B-DNA
chromosomal	I-DNA
IL-16	I-DNA
gene	I-DNA
and	O
analyzed	O
its	O
promoter	O
.	O

The	O
human	B-DNA
IL-16	I-DNA
gene	I-DNA
consists	O
of	O
seven	O
exons	B-DNA
and	O
six	O
introns	B-DNA
.	O

The	O
5	B-DNA
'	I-DNA
sequences	I-DNA
up	O
to	O
nucleotide	O
-120	O
of	O
the	O
human	O
and	O
murine	O
IL-16	B-protein
genes	O
share	O
>	O
84	O
%	O
sequence	O
homology	O
and	O
harbor	B-DNA
promoter	I-DNA
elements	I-DNA
for	O
constitutive	O
and	O
inducible	O
transcription	O
in	O
T	B-cell_type
cells	I-cell_type
.	O

Although	O
both	O
promoters	O
lack	O
any	O
TATA	B-DNA
box	I-DNA
,	O
they	O
contain	O
two	O
CAAT	B-DNA
box-like	I-DNA
motifs	I-DNA
and	O
three	O
binding	B-DNA
sites	I-DNA
of	O
GA-binding	B-protein
protein	I-protein
(	I-protein
GABP	I-protein
)	I-protein
transcription	I-protein
factors	I-protein
.	O

Two	O
of	O
these	O
motifs	O
are	O
part	O
of	O
a	O
highly	O
conserved	O
and	O
inducible	O
dyad	B-DNA
symmetry	I-DNA
element	I-DNA
shown	O
previously	O
to	O
control	O
a	O
remote	O
IL-2	B-DNA
enhancer	I-DNA
and	O
the	O
CD18	B-DNA
promoter	I-DNA
.	O

In	O
concert	O
with	O
the	O
coactivator	B-protein
CREB	I-protein
binding	I-protein
protein/p300	I-protein
,	O
which	O
interacts	O
with	O
GABPalpha	B-protein
,	O
the	O
binding	O
of	O
GABPalpha	B-protein
and	O
-beta	B-protein
to	O
the	O
dyad	B-DNA
symmetry	I-DNA
element	I-DNA
controls	O
the	O
induction	O
of	O
IL-16	B-DNA
promoter	I-DNA
in	O
T	B-cell_type
cells	I-cell_type
.	O

Supplementing	O
the	O
data	O
on	O
the	O
processing	O
of	O
pro-IL-16	B-protein
,	O
our	O
results	O
indicate	O
the	O
complexity	O
of	O
IL-16	B-protein
expression	O
,	O
which	O
is	O
tightly	O
controlled	O
at	O
the	O
transcriptional	O
and	O
posttranslational	O
levels	O
in	O
T	B-cell_type
lymphocytes	I-cell_type
.	O

Tuberculosis	O
and	O
chronic	O
hepatitis	O
B	O
virus	O
infection	O
in	O
Africans	O
and	O
variation	O
in	O
the	O
vitamin	B-DNA
D	I-DNA
receptor	I-DNA
gene	I-DNA
.	O

The	O
active	O
metabolite	O
of	O
vitamin	O
D	O
,	O
1	O
,	O
25	O
dihydroxyvitamin	O
D3	O
,	O
is	O
an	O
important	O
immunoregulatory	O
hormone	O
[	O
1	O
]	O
.	O

Its	O
effects	O
are	O
exerted	O
by	O
interaction	O
with	O
the	O
vitamin	B-protein
D	I-protein
receptor	I-protein
,	O
which	O
is	O
present	O
on	O
human	B-cell_type
monocytes	I-cell_type
and	O
activated	B-cell_type
T	I-cell_type
and	I-cell_type
B	I-cell_type
lymphocytes	I-cell_type
.	O

Variation	O
in	O
the	O
vitamin	B-DNA
D	I-DNA
receptor	I-DNA
gene	I-DNA
was	O
typed	O
in	O
2015	O
subjects	O
from	O
large	O
case-control	O
studies	O
of	O
three	O
major	O
infectious	O
diseases	O
:	O
tuberculosis	O
,	O
malaria	O
,	O
and	O
hepatitis	O
B	O
virus	O
.	O

Homozygotes	O
for	O
a	O
polymorphism	O
at	O
codon	B-DNA
352	I-DNA
(	O
genotype	O
tt	O
)	O
were	O
significantly	O
underrepresented	O
among	O
those	O
with	O
tuberculosis	O
(	O
chi2=6.22	O
,	O
1	O
df	O
,	O
P=.01	O
)	O
and	O
persistent	O
hepatitis	O
B	O
infection	O
(	O
chi2=6.25	O
,	O
1	O
df	O
,	O
P=.01	O
)	O
but	O
not	O
in	O
subjects	O
with	O
clinical	O
malaria	O
compared	O
with	O
the	O
other	O
genotypes	O
.	O

Therefore	O
,	O
this	O
genetic	O
variant	O
,	O
which	O
predisposes	O
to	O
low	O
bone	O
mineral	O
density	O
in	O
many	O
populations	O
,	O
may	O
confer	O
resistance	O
to	O
certain	O
infectious	O
diseases	O
.	O

Inhibition	O
of	O
NF-kappa	B-protein
B	I-protein
activation	O
in	O
vitro	O
and	O
in	O
vivo	O
:	O
role	O
of	O
26S	B-protein
proteasome	I-protein
.	O

It	O
is	O
becoming	O
increasingly	O
apparent	O
that	O
NF-kappa	B-protein
B	I-protein
plays	O
a	O
critical	O
role	O
in	O
regulating	O
the	O
inflammatory	O
response	O
.	O

Data	O
obtained	O
from	O
studies	O
in	O
our	O
laboratories	O
demonstrate	O
that	O
the	O
proteasome	O
plays	O
an	O
important	O
role	O
in	O
the	O
inflammatory	O
cascade	O
by	O
regulating	O
the	O
activation	O
of	O
NF-kappa	B-protein
B	I-protein
.	O

Indeed	O
,	O
the	O
availability	O
of	O
selective	O
and	O
orally	O
active	O
proteasome	O
inhibitors	O
should	O
prove	O
useful	O
in	O
delineating	O
the	O
roles	O
of	O
the	O
proteasome	O
and	O
NF-kappa	B-protein
B	I-protein
in	O
other	O
pathophysiological	O
conditions	O
such	O
as	O
cancer	O
and	O
heart	O
disease	O
.	O

Tissue	O
factor	O
expression	O
of	O
human	B-cell_type
monocytes	I-cell_type
is	O
suppressed	O
by	O
lysophosphatidylcholine	O
.	O

The	O
expression	O
of	O
tissue	B-protein
factor	I-protein
(	O
TF	B-protein
)	O
,	O
the	O
principal	O
initiator	O
of	O
coagulation	O
,	O
is	O
increased	O
during	O
inflammation	O
and	O
atherosclerosis	O
.	O

Both	O
conditions	O
are	O
promoted	O
by	O
lysophosphatidylcholine	O
(	O
lysoPC	O
)	O
.	O

We	O
observed	O
in	O
the	O
present	O
study	O
that	O
lysoPC	O
(	O
1	O
to	O
10	O
micromol/L	O
)	O
dose-dependently	O
reduced	O
TF	B-protein
activity	O
in	O
human	B-cell_type
monocytes	I-cell_type
,	O
as	O
elicited	O
by	O
lipopolysaccharide	O
(	O
LPS	O
)	O
.	O

Lysophosphatidylethanolamine	O
(	O
lysoPE	O
)	O
and	O
other	O
lysophospholipids	O
did	O
not	O
affect	O
LPS-induced	O
TF	O
activity	O
of	O
human	B-cell_type
monocytes	I-cell_type
.	O

TF	O
antigen	O
expression	O
as	O
elicited	O
by	O
LPS	O
was	O
also	O
lowered	O
by	O
lysoPC	O
.	O

Phospholipid	O
analyses	O
indicated	O
a	O
selective	O
increase	O
in	O
the	O
lysoPC	O
content	O
of	O
the	O
monocytes	B-cell_type
after	O
preincubation	O
with	O
the	O
lysophospholipid	O
.	O

LysoPC	O
inhibited	O
the	O
TF	O
activity	O
of	O
Mono	B-cell_line
Mac-6	I-cell_line
cells	I-cell_line
to	O
a	O
similar	O
extent	O
as	O
in	O
the	O
monocytes	B-cell_type
.	O

LPS	O
binding	O
to	O
plasma	O
membrane	O
receptors	O
and	O
internalization	O
of	O
LPS	O
into	O
monocytes	B-cell_type
were	O
not	O
affected	O
by	O
lysoPC	O
.	O

In	O
contrast	O
,	O
LPS-mediated	O
nuclear	O
binding	O
of	O
nuclear	B-protein
factor-kappaB/Rel	I-protein
to	O
a	O
TF-specific	B-DNA
kappaB	I-DNA
site	I-DNA
was	O
inhibited	O
by	O
lysoPC	O
.	O

Induction	O
of	O
TF	B-RNA
mRNA	I-RNA
expression	O
by	O
LPS	O
tended	O
to	O
be	O
partially	O
reduced	O
by	O
the	O
lysophospholipid	O
.	O

Preincubation	O
with	O
lysoPC	O
increased	O
monocytic	O
cAMP	O
levels	O
.	O

Inhibition	O
of	O
adenylyl	B-protein
cyclase	I-protein
by	O
pretreatment	O
with	O
2'-deoxy-3'-adenosine	B-protein
monophosphate	I-protein
partially	O
reversed	O
the	O
inhibition	O
of	O
TF	O
activity	O
promoted	O
by	O
lysoPC	O
.	O

In	O
conclusion	O
,	O
lysoPC	O
markedly	O
decreases	O
LPS-mediated	O
TF	O
expression	O
of	O
human	B-cell_type
monocytes	I-cell_type
,	O
the	O
effect	O
probably	O
being	O
mediated	O
by	O
both	O
transcriptional	O
and	O
posttranscriptional	O
mechanisms	O
.	O

LysoPC	O
may	O
thus	O
attenuate	O
activation	O
of	O
coagulation	O
during	O
inflammation	O
and	O
atherosclerosis	O
.	O

Regulation	O
of	O
fas-ligand	O
expression	O
during	O
activation-induced	O
cell	O
death	O
in	O
T	B-cell_type
lymphocytes	I-cell_type
via	O
nuclear	B-protein
factor	I-protein
kappaB	I-protein
.	O

T	O
cell	O
receptor	O
engagement	O
activates	O
transcription	B-protein
factors	I-protein
important	O
for	O
cytokine	B-DNA
gene	I-DNA
regulation	O
.	O

Additionally	O
,	O
this	O
signaling	O
pathway	O
also	O
leads	O
to	O
activation-induced	O
apoptosis	O
in	O
T	B-cell_type
lymphocytes	I-cell_type
that	O
is	O
dependent	O
on	O
FasL	O
transcription	O
and	O
expression	O
.	O

Here	O
we	O
demonstrate	O
that	O
nuclear	B-protein
factor	I-protein
kappaB	I-protein
(	O
NF-kappaB	B-protein
)	O
,	O
which	O
is	O
involved	O
in	O
the	O
transcriptional	O
regulation	O
of	O
many	O
cytokine	B-DNA
genes	I-DNA
expressed	O
in	O
activated	B-cell_type
lymphocytes	I-cell_type
,	O
also	O
plays	O
a	O
role	O
in	O
T	O
cell	O
activation-induced	O
FasL	B-protein
expression	O
.	O

Inhibition	O
of	O
NF-kappaB	B-protein
activity	O
in	O
a	O
T	B-cell_line
cell	I-cell_line
hybridoma	I-cell_line
leads	O
to	O
decreased	O
FasL	B-protein
expression	O
and	O
apoptosis	O
upon	O
T	B-protein
cell	I-protein
receptor	I-protein
stimulation	O
.	O

We	O
identified	O
the	O
NF-kappaB	B-DNA
site	I-DNA
in	O
the	O
FasL	B-DNA
promoter	I-DNA
that	O
contributes	O
to	O
such	O
regulation	O
.	O

Co-expression	O
of	O
p65	B-protein
(	I-protein
Rel	I-protein
A	I-protein
)	I-protein
with	O
the	O
FasL	B-DNA
promoter	I-DNA
enhanced	O
its	O
activity	O
,	O
and	O
co-expression	O
of	O
IkappaB	B-protein
dramatically	O
inhibited	O
the	O
inducible	B-DNA
promoter	I-DNA
activity	O
.	O

In	O
contrast	O
,	O
the	O
transcription	B-protein
factor	I-protein
AP-1	I-protein
is	O
not	O
required	O
for	O
activation-induced	O
FasL	B-protein
promoter	O
activity	O
.	O

These	O
results	O
define	O
a	O
role	O
for	O
NF-kappaB	B-protein
in	O
mediating	O
FasL	B-protein
expression	O
during	O
T	O
cell	O
activation	O
.	O

Promoter	B-DNA
sequence	I-DNA
,	O
exon	O
:	O
intron	O
structure	O
,	O
and	O
synteny	O
of	O
genetic	O
location	O
show	O
that	O
a	O
chicken	B-protein
cytokine	I-protein
with	O
T-cell	O
proliferative	O
activity	O
is	O
IL2	B-protein
and	O
not	O
IL15	B-protein
.	O

The	O
gene	O
encoding	O
a	O
chicken	B-protein
cytokine	I-protein
with	O
T-cell	O
proliferative	O
activity	O
was	O
cloned	O
,	O
sequenced	O
,	O
and	O
mapped	O
.	O

The	O
results	O
show	O
that	O
this	O
cytokine	B-protein
is	O
chicken	O
IL2	B-protein
and	O
not	O
IL15	B-protein
.	O

The	O
exon	O
:	O
intron	O
structure	O
of	O
chicken	B-protein
IL2	I-protein
corresponds	O
almost	O
exactly	O
to	O
those	O
of	O
mammalian	O
IL2s	B-protein
with	O
the	O
exceptions	O
of	O
exon	B-DNA
2	I-DNA
and	O
introns	B-DNA
2	O
and	O
3	O
which	O
are	O
shorter	O
.	O

Chicken	O
IL2	B-protein
contains	O
five	O
repeats	O
of	O
the	O
``	O
instability	O
''	O
motif	O
ATTTA	O
in	O
the	O
3'untranslated	B-DNA
region	I-DNA
in	O
exon	B-DNA
4	I-DNA
.	O

It	O
is	O
a	O
single-copy	B-DNA
gene	I-DNA
,	O
with	O
neither	O
structural	O
(	O
amino	O
acid	O
)	O
nor	O
promoter	O
sequence	O
polymorphisms	O
identified	O
.	O

Analysis	O
of	O
the	O
predicted	O
amino	O
acid	O
sequence	O
suggests	O
that	O
overall	O
protein	B-protein
structure	I-protein
is	O
conserved	O
,	O
but	O
the	O
receptor	O
binding	O
sites	O
are	O
not	O
.	O

A	O
number	O
of	O
potential	B-DNA
regulatory	I-DNA
sequences	I-DNA
similar	O
to	O
those	O
found	O
in	O
mammals	O
have	O
been	O
identified	O
in	O
the	O
promoter	B-DNA
.	O

These	O
include	O
(	O
5'-3	O
'	O
)	O
a	O
composite	O
NF-AT/	B-DNA
``	I-DNA
AP-1	I-DNA
''	I-DNA
element	I-DNA
,	O
a	O
CD28	B-DNA
response	I-DNA
element	I-DNA
,	O
an	O
AP-1	B-DNA
element	I-DNA
,	O
an	O
NF-AT	B-DNA
element	I-DNA
,	O
and	O
the	O
AP-1	B-DNA
part	I-DNA
of	I-DNA
an	I-DNA
AP-1/octamer	I-DNA
composite	I-DNA
element	I-DNA
.	O

The	O
mammalian	B-protein
NF-kappaB	I-protein
and	O
octamer	B-DNA
binding	I-DNA
sites	I-DNA
seem	O
to	O
be	O
absent	O
,	O
although	O
there	O
are	O
alternative	O
potential	O
NF-kappaB	B-protein
and	O
octamer-binding	B-DNA
elements	I-DNA
in	O
the	O
chicken	B-DNA
IL2	I-DNA
promoter	I-DNA
,	O
in	O
close	O
proximity	O
to	O
their	O
mammalian	B-DNA
homologues	I-DNA
.	O

Sequence	O
comparisons	O
also	O
predict	O
other	O
potential	O
transcription	O
factor	O
binding	O
sites	O
as	O
yet	O
undescribed	O
in	O
mammalian	B-DNA
IL2	I-DNA
promoters	I-DNA
.	O

A	O
Taq	B-DNA
I	I-DNA
polymorphism	I-DNA
was	O
identified	O
which	O
enabled	O
chicken	O
IL2	B-protein
to	O
be	O
mapped	O
to	O
chromosome	B-DNA
4	I-DNA
,	O
linked	O
to	O
ANX5	B-DNA
,	O
with	O
synteny	O
with	O
mouse	B-DNA
chromosome	I-DNA
3	I-DNA
and	O
human	B-DNA
chromosome	I-DNA
4	I-DNA
.	O

This	O
is	O
the	O
first	O
non-mammalian	B-DNA
cytokine	I-DNA
gene	I-DNA
to	O
be	O
mapped	O
.	O

Endothelial	O
production	O
of	O
MCP-1	B-protein
:	O
modulation	O
by	O
heparin	O
and	O
consequences	O
for	O
mononuclear	O
cell	O
activation	O
.	O

Heparin	O
is	O
a	O
polyanionic	O
glycosaminoglycan	O
(	O
GAG	O
)	O
that	O
can	O
bind	O
with	O
high	O
affinity	O
to	O
a	O
range	O
of	O
cytokines	B-protein
including	O
interferon-gamma	B-protein
(	O
IFN-gamma	B-protein
)	O
and	O
members	O
of	O
the	O
chemokine	B-protein
superfamily	I-protein
.	O

This	O
GAG	O
also	O
possesses	O
immunomodulatory	O
activity	O
in	O
vivo	O
and	O
can	O
antagonize	O
the	O
capacity	O
of	O
IFN-gamma	B-protein
to	O
induce	O
class	B-protein
II	I-protein
MHC	I-protein
antigen	I-protein
expression	O
,	O
and	O
to	O
up-regulate	O
intercellular	B-protein
adhesion	I-protein
molecule-1	I-protein
,	O
by	O
cultured	B-cell_line
endothelial	I-cell_line
cells	I-cell_line
.	O

Previous	O
studies	O
have	O
shown	O
that	O
binding	O
to	O
cell-surface	O
heparan	O
sulphate	O
is	O
essential	O
for	O
optimal	O
activity	O
of	O
IFN-gamma	B-protein
and	O
that	O
free	O
heparin	O
competitively	O
inhibits	O
this	O
sequestration	O
process	O
.	O

The	O
present	O
study	O
was	O
performed	O
to	O
increase	O
our	O
understanding	O
of	O
the	O
immunosuppressive	O
activity	O
of	O
heparin	O
by	O
investigation	O
of	O
potential	O
antagonism	O
of	O
the	O
production	O
and	O
function	O
of	O
monocyte	B-protein
chemotactic	I-protein
peptide-1	I-protein
(	O
MCP-1	B-protein
)	O
,	O
a	O
chemokine	B-protein
important	O
for	O
mononuclear	O
leucocyte	O
recruitment	O
across	O
vascular	O
endothelium	O
.	O

It	O
was	O
found	O
that	O
mixture	O
of	O
heparin	O
with	O
IFN-gamma	B-protein
inhibited	O
up-regulation	O
of	O
the	O
signal	O
transducer	O
and	O
activator	O
of	O
transcription	O
protein	O
,	O
STAT-1	B-protein
produced	O
normally	O
by	O
treatment	O
of	O
endothelial	B-cell_type
cells	I-cell_type
with	O
IFN-gamma	B-protein
.	O

An	O
inhibition	O
of	O
MCP-1	B-protein
production	O
was	O
observed	O
that	O
was	O
specifically	O
caused	O
by	O
mixture	O
of	O
IFN-gamma	B-protein
with	O
heparin-like	O
,	O
and	O
therefore	O
cytokine-binding	O
,	O
GAGs	O
.	O

It	O
was	O
also	O
shown	O
that	O
mixture	O
of	O
heparin-like	O
GAGs	O
with	O
MCP-1	B-protein
inhibited	O
the	O
rapid	O
tyrosine	O
phosphorylation	O
of	O
phosphatidylinositol	B-protein
3-kinase	I-protein
which	O
is	O
normally	O
produced	O
by	O
treatment	O
of	O
mononuclear	B-cell_type
leucocytes	I-cell_type
with	O
this	O
chemokine	B-protein
.	O

Blockade	O
of	O
this	O
intracellular	O
signalling	O
event	O
was	O
associated	O
with	O
a	O
reduction	O
in	O
the	O
normal	O
transendothelial	O
migration	O
response	O
towards	O
MCP-1	B-protein
.	O

Results	O
from	O
this	O
study	O
indicate	O
that	O
soluble	O
,	O
heparin-like	O
GAGs	O
can	O
block	O
IFN-gamma	B-protein
-dependent	O
up-regulation	O
of	O
MCP-1	B-protein
production	O
by	O
cultured	B-cell_line
endothelial	I-cell_line
cells	I-cell_line
,	O
and	O
can	O
also	O
antagonize	O
the	O
leucocyte-activating	O
and	O
migration-promoting	O
properties	O
of	O
pre-existing	O
MCP-1	B-protein
.	O

These	O
activities	O
may	O
contribute	O
to	O
the	O
immunomodulatory	O
properties	O
of	O
heparin	O
.	O

[	O
Molecular-biologic	O
aspects	O
of	O
interaction	O
between	O
nervous	O
and	O
immune	O
systems	O
]	O

The	O
problem	O
of	O
the	O
neuro-immuno	O
interactions	O
on	O
the	O
level	O
of	O
the	O
protein	B-protein
trans-factors	I-protein
,	O
stimulating	O
interleukin-2	B-DNA
(	I-DNA
IL-2	I-DNA
)	I-DNA
gene	I-DNA
expression	O
was	O
discussed	O
.	O

The	O
physico-chemical	O
and	O
functional	O
parameters	O
of	O
the	O
low	B-protein
molecular	I-protein
nuclear	I-protein
proteins	I-protein
(	O
SP	B-protein
and	O
BP-	B-protein
14	I-protein
,	I-protein
18	I-protein
,	I-protein
19	I-protein
kDs	I-protein
)	O
isolated	O
from	O
splenic	B-cell_type
and	I-cell_type
brain	I-cell_type
cells	I-cell_type
of	O
immunized	O
rats	O
were	O
studied	O
.	O

The	O
binding	O
of	O
these	O
proteins	O
to	O
the	O
regulatory	O
region	O
of	O
IL-2	B-DNA
gene	I-DNA
in	O
vitro	O
and	O
stimulation	O
of	O
the	O
IL-2mRNA	B-RNA
synthesis	O
in	O
splenic	B-cell_line
T-lymphocytes	I-cell_line
culture	I-cell_line
in	O
normal	O
conditions	O
were	O
shown	O
.	O

The	O
protective	O
effect	O
of	O
SP	B-protein
and	O
BP	B-protein
on	O
the	O
IL-2mRNA	B-RNA
synthesis	O
in	O
stressful	O
conditions	O
and	O
by	O
the	O
T-cells	B-cell_type
treatment	O
with	O
the	O
CsA	O
was	O
demonstrated	O
.	O

Interferon-alpha	B-protein
activates	O
multiple	O
STAT	B-protein
proteins	I-protein
and	O
upregulates	O
proliferation-associated	O
IL-2Ralpha	B-protein
,	O
c-myc	B-DNA
,	I-DNA
and	I-DNA
pim-1	I-DNA
genes	I-DNA
in	O
human	B-cell_type
T	I-cell_type
cells	I-cell_type
.	O

Interferon-alpha	B-protein
(	O
IFN-alpha	B-protein
)	O
is	O
a	O
pleiotropic	B-protein
cytokine	I-protein
that	O
has	O
antiviral	O
,	O
antiproliferative	O
,	O
and	O
immunoregulatory	B-protein
functions	O
.	O

There	O
is	O
increasing	O
evidence	O
that	O
IFN-alpha	B-protein
has	O
an	O
important	O
role	O
in	O
T-cell	O
biology	O
.	O

We	O
have	O
analyzed	O
the	O
expression	O
of	O
IL-2Ralpha	B-protein
,	O
c-myc	B-DNA
,	O
and	O
pim-1	B-DNA
genes	I-DNA
in	O
anti-CD3-activated	B-cell_type
human	I-cell_type
T	I-cell_type
lymphocytes	I-cell_type
.	O

The	O
induction	O
of	O
these	O
genes	O
is	O
associated	O
with	O
interleukin-2	B-protein
(	O
IL-2	B-protein
)	O
-induced	O
T-cell	O
proliferation	O
.	O

Treatment	O
of	O
T	B-cell_type
lymphocytes	I-cell_type
with	O
IFN-alpha	B-protein
,	O
IL-2	B-protein
,	O
IL-12	B-protein
,	O
and	O
IL-15	B-protein
upregulated	O
IL-2Ralpha	B-protein
,	O
c-myc	B-DNA
,	O
and	O
pim-1	B-DNA
gene	I-DNA
expression	O
.	O

IFN-alpha	B-protein
also	O
sensitized	B-cell_line
T	I-cell_line
cells	I-cell_line
to	O
IL-2	B-protein
-induced	O
proliferation	O
,	O
further	O
suggesting	O
that	O
IFN-alpha	B-protein
may	O
be	O
involved	O
in	O
the	O
regulation	O
of	O
T-cell	O
mitogenesis	O
.	O

When	O
we	O
analyzed	O
the	O
nature	O
of	O
STAT	B-protein
proteins	I-protein
capable	O
of	O
binding	O
to	O
IL-2Ralpha	B-protein
,	O
pim-1	B-DNA
,	I-DNA
and	I-DNA
IRF-1	I-DNA
GAS	I-DNA
elements	I-DNA
after	O
cytokine	B-protein
stimulation	O
,	O
we	O
observed	O
IFN-alpha	B-protein
-induced	O
binding	O
of	O
STAT1	B-protein
,	O
STAT3	B-protein
,	O
and	O
STAT4	B-protein
,	O
but	O
not	O
STAT5	B-protein
to	O
all	O
of	O
these	O
elements	O
.	O

Yet	O
,	O
IFN-alpha	B-protein
was	O
able	O
to	O
activate	O
binding	O
of	O
STAT5	B-protein
to	O
the	O
high-affinity	O
IFP53	O
GAS	O
site	O
.	O

IFN-alpha	B-protein
enhanced	O
tyrosine	O
phosphorylation	O
of	O
STAT1	O
,	O
STAT3	B-protein
,	O
STAT4	B-protein
,	O
STAT5a	B-protein
,	O
and	O
STAT5b	B-protein
.	O

IL-12	B-protein
induced	O
STAT4	B-protein
and	O
IL-2	B-protein
and	O
IL-15	B-protein
induced	O
STAT5	B-protein
binding	O
to	O
the	O
GAS	B-DNA
elements	I-DNA
.	O

Taken	O
together	O
,	O
our	O
results	O
suggest	O
that	O
IFN-alpha	B-protein
,	O
IL-2	B-protein
,	O
IL-12	B-protein
,	O
and	O
IL-15	B-protein
have	O
overlapping	O
activities	O
on	O
human	B-cell_type
T	I-cell_type
cells	I-cell_type
.	O

These	O
findings	O
thus	O
emphasize	O
the	O
importance	O
of	O
IFN-alpha	B-protein
as	O
a	O
T-cell	B-protein
regulatory	I-protein
cytokine	I-protein
.	O

The	O
Megakaryocyte/Platelet-specific	B-DNA
enhancer	I-DNA
of	O
the	O
alpha2beta1	B-DNA
integrin	I-DNA
gene	I-DNA
:	O
two	O
tandem	O
AP1	B-DNA
sites	I-DNA
and	O
the	O
mitogen-activated	B-protein
protein	I-protein
kinase	I-protein
signaling	O
cascade	O
.	O

The	O
alpha2beta1	B-protein
integrin	I-protein
,	O
a	O
collagen	O
receptor	O
on	O
platelets	B-cell_type
and	O
megakaryocytes	B-cell_type
,	O
is	O
required	O
for	O
normal	O
platelet	O
function	O
.	O

Transcriptional	O
regulation	O
of	O
the	O
alpha2	B-DNA
integrin	I-DNA
gene	I-DNA
in	O
cells	O
undergoing	O
megakaryocytic	O
differentiation	O
requires	O
a	O
core	B-DNA
promoter	I-DNA
between	O
bp	O
-30	O
and	O
-92	O
,	O
a	O
silencer	B-DNA
between	O
bp	O
-92	O
and	O
-351	O
,	O
and	O
megakaryocytic	B-DNA
enhancers	I-DNA
in	O
the	O
distal	B-DNA
5	I-DNA
'	I-DNA
flank	I-DNA
.	O

We	O
have	O
now	O
identified	O
a	O
229-bp	B-DNA
region	I-DNA
of	O
the	O
distal	B-DNA
5	I-DNA
'	I-DNA
flank	I-DNA
of	O
the	O
alpha2	B-DNA
integrin	I-DNA
gene	I-DNA
required	O
for	O
high-level	B-cell_type
enhancer	I-cell_type
activity	I-cell_type
in	I-cell_type
cells	I-cell_type
with	O
megakaryocytic	O
features	O
.	O

Two	O
tandem	O
AP1	B-DNA
binding	I-DNA
sites	I-DNA
with	O
dyad	O
symmetry	O
are	O
required	O
for	O
enhancer	O
activity	O
and	O
for	O
DNA-protein	B-protein
complex	I-protein
formation	O
with	O
members	O
of	O
the	O
c-fos/c-jun	B-protein
family	I-protein
.	O

The	O
requirement	O
for	O
AP1	B-protein
activation	O
suggested	O
a	O
role	O
for	O
the	O
mitogen-activated	B-protein
protein	I-protein
kinase	I-protein
(	O
MAPK	B-protein
)	O
signaling	O
pathway	O
in	O
regulating	O
alpha2	B-DNA
integrin	I-DNA
gene	I-DNA
expression	O
.	O

Inhibition	O
of	O
the	O
MAP	B-protein
kinase	I-protein
cascade	O
with	O
PD98059	O
,	O
a	O
specific	O
inhibitor	O
of	O
MAPK	B-protein
kinase	I-protein
1	I-protein
,	O
prevented	O
the	O
expression	O
of	O
the	O
alpha2	B-protein
integrin	I-protein
subunit	I-protein
in	O
cells	O
induced	O
to	O
become	O
megakaryocytic	O
.	O

We	O
provide	O
a	O
model	O
of	O
megakaryocytic	O
differentiation	O
in	O
which	O
expression	O
of	O
the	O
alpha2	B-DNA
integrin	I-DNA
gene	I-DNA
requires	O
signaling	O
via	O
the	O
MAP	B-protein
kinase	I-protein
pathway	O
to	O
activate	O
two	O
tandem	O
AP1	B-DNA
binding	I-DNA
sites	I-DNA
in	O
the	O
alpha2	B-DNA
integrin	I-DNA
enhancer	I-DNA
.	O

Functional	O
association	O
of	O
Nmi	B-protein
with	O
Stat5	B-protein
and	O
Stat1	B-protein
in	O
IL-2	B-protein
-and	O
IFNgamma	B-protein
-mediated	O
signaling	O
.	O

Using	O
the	O
coiled-coil	O
region	O
of	O
Stat5b	B-protein
as	O
the	O
bait	O
in	O
a	O
yeast	O
two-hybrid	O
screen	O
,	O
we	O
identified	O
the	O
association	O
of	O
Nmi	B-protein
,	O
a	O
protein	O
of	O
unknown	O
function	O
previously	O
reported	O
as	O
an	O
N-Myc	B-protein
interactor	O
.	O

We	O
further	O
show	O
that	O
Nmi	B-protein
interacts	O
with	O
all	O
STATs	B-protein
except	O
Stat2	B-protein
.	O

We	O
evaluated	O
two	O
cytokine	O
systems	O
,	O
IL-2	B-protein
and	O
IFNgamma	B-protein
,	O
and	O
demonstrate	O
that	O
Nmi	B-protein
augments	O
STAT	B-protein
-mediated	O
transcription	O
in	O
response	O
to	O
these	O
cytokines	B-protein
.	O

Interestingly	O
,	O
Nmi	B-protein
lacks	O
an	O
intrinsic	O
transcriptional	B-protein
activation	I-protein
domain	I-protein
;	O
instead	O
,	O
Nmi	B-protein
enhances	O
the	O
association	O
of	O
CBP/p300	B-protein
coactivator	I-protein
proteins	I-protein
with	O
Stat1	B-protein
and	O
Stat5	B-protein
,	O
and	O
together	O
with	O
CBP/p300	B-protein
can	O
augment	O
IL-2-	O
and	O
IFNgamma-dependent	O
transcription	O
.	O

Therefore	O
,	O
our	O
data	O
not	O
only	O
reveal	O
that	O
Nmi	B-protein
can	O
potentiate	O
STAT	B-protein
-dependent	O
transcription	O
,	O
but	O
also	O
suggest	O
that	O
it	O
can	O
augment	O
coactivator	O
protein	O
recruitment	O
to	O
at	O
least	O
some	O
members	O
of	O
a	O
group	O
of	O
sequence-specific	B-protein
transcription	I-protein
factors	I-protein
.	O

Lactobacilli	O
and	O
vaginal	O
host	O
defense	O
:	O
activation	O
of	O
the	O
human	B-DNA
immunodeficiency	I-DNA
virus	I-DNA
type	I-DNA
1	I-DNA
long	I-DNA
terminal	I-DNA
repeat	I-DNA
,	O
cytokine	B-protein
production	O
,	O
and	O
NF-kappaB	B-protein
.	O

Lactobacilli	O
,	O
a	O
component	O
of	O
the	O
normal	O
vaginal	O
flora	O
,	O
can	O
activate	O
the	O
human	B-DNA
immunodeficiency	I-DNA
virus	I-DNA
(	I-DNA
HIV	I-DNA
)	I-DNA
-1	I-DNA
long	I-DNA
terminal	I-DNA
repeat	I-DNA
(	O
LTR	B-DNA
)	O
in	O
the	O
Jurkat	B-cell_line
T	I-cell_line
lymphocyte	I-cell_line
and	O
THP-1	B-cell_line
macrophage	I-cell_line
cell	I-cell_line
lines	I-cell_line
.	O

Activation	O
of	O
the	O
LTR	B-DNA
in	O
Jurkat	B-cell_line
cells	I-cell_line
was	O
strongly	O
enhanced	O
by	O
vanadate	O
and	O
inhibited	O
by	O
catalase	B-protein
,	O
implicating	O
H2O2	O
.	O

In	O
contrast	O
,	O
activation	O
in	O
THP-1	B-protein
cells	I-protein
occurred	O
in	O
the	O
absence	O
of	O
vanadate	O
and	O
was	O
unaffected	O
by	O
catalase	B-protein
.	O

The	O
active	O
material	O
partitioned	O
into	O
the	O
phenol	O
layer	O
on	O
hot	O
aqueous	O
phenol	O
extraction	O
.	O

Lactobacilli	O
also	O
increased	O
tumor	B-protein
necrosis	I-protein
factor	I-protein
-alphaand	O
interleukin	B-protein
-1betaproduction	O
and	O
activated	O
NF-kappaB	B-protein
in	O
THP-1	B-protein
cells	I-protein
and	O
increased	O
tumor	B-protein
necrosis	I-protein
factor	I-protein
-alphaproduction	O
by	O
human	B-cell_type
monocytes	I-cell_type
.	O

Human	O
vaginal	O
fluid	O
specimens	O
had	O
comparable	O
properties	O
,	O
which	O
correlated	O
with	O
their	O
bacterial	O
content	O
.	O

These	O
findings	O
suggest	O
the	O
presence	O
in	O
vaginal	O
fluid	O
of	O
agent	O
(	O
s	O
)	O
derived	O
from	O
indigenous	O
bacteria	O
that	O
can	O
activate	O
the	O
HIV-1	B-DNA
LTR	I-DNA
,	O
cytokine	B-protein
production	O
,	O
and	O
NF-kappaB	B-protein
in	O
cells	O
of	O
macrophage	B-cell_type
lineage	I-cell_type
,	O
with	O
possible	O
influence	O
on	O
vaginal	O
physiology	O
and	O
host	O
defense	O
.	O

T	O
cell	O
priming	O
enhances	O
IL-4	B-DNA
gene	I-DNA
expression	O
by	O
increasing	O
nuclear	B-protein
factor	I-protein
of	I-protein
activated	I-protein
T	I-protein
cells	I-protein
.	O

The	O
repetitive	O
activation	O
of	O
T	B-cell_type
cells	I-cell_type
(	O
priming	O
)	O
enhances	O
the	O
expression	O
of	O
many	O
cytokines	B-protein
,	O
such	O
as	O
IL-4	O
,	O
but	O
not	O
others	O
,	O
such	O
as	O
IL-2	B-protein
.	O

Molecular	O
mechanisms	O
underlying	O
selective	O
expression	O
of	O
cytokines	B-protein
by	O
T	B-cell_type
cells	I-cell_type
remain	O
poorly	O
understood	O
.	O

Here	O
we	O
show	O
that	O
priming	O
of	O
CD4	B-cell_type
T	I-cell_type
cells	I-cell_type
selectively	O
enhances	O
IL-4	B-protein
expression	O
relative	O
to	O
IL-2	B-protein
expression	O
by	O
a	O
transcriptional	O
mechanism	O
involving	O
nuclear	B-protein
factor	I-protein
of	I-protein
activated	I-protein
T	I-protein
cells	I-protein
(	I-protein
NFAT	I-protein
)	I-protein
proteins	I-protein
.	O

As	O
detected	O
by	O
in	O
vivo	O
footprinting	O
,	O
priming	O
markedly	O
increases	O
the	O
activation-dependent	O
engagement	O
of	O
the	O
P0	B-DNA
and	O
P1	B-DNA
NFAT-binding	B-DNA
elements	I-DNA
of	O
the	O
IL-4	B-DNA
promoter	I-DNA
.	O

Moreover	O
,	O
each	O
proximal	B-DNA
P	I-DNA
element	I-DNA
is	O
essential	O
for	O
optimal	O
IL-4	B-DNA
promoter	I-DNA
activity	O
.	O

Activated	O
primed	O
CD4	B-cell_type
T	I-cell_type
cells	I-cell_type
contain	O
more	O
NFAT1	B-protein
and	O
support	O
greater	O
NFAT	B-protein
-directed	O
transcription	O
than	O
unprimed	O
CD4	B-cell_type
T	I-cell_type
cells	I-cell_type
,	O
while	O
activator	B-protein
protein	I-protein
1	I-protein
binding	O
and	O
activator	B-protein
protein	I-protein
1	I-protein
-mediated	O
transcription	O
by	O
both	O
cell	O
types	O
is	O
similar	O
.	O

Increased	O
expression	O
of	O
wild-type	O
NFAT1	B-protein
substantially	O
increases	O
IL-4	B-DNA
promoter	I-DNA
activity	O
in	O
unprimed	O
CD4	B-cell_type
T	I-cell_type
cells	I-cell_type
,	O
suggesting	O
NFAT1	B-protein
may	O
be	O
limiting	O
for	O
IL-4	B-protein
gene	O
expression	O
in	O
this	O
cell	O
type	O
.	O

Furthermore	O
,	O
a	O
truncated	O
form	O
of	O
NFAT1	B-protein
acts	O
as	O
a	O
dominant-negative	O
,	O
reducing	O
IL-4	B-DNA
promoter	I-DNA
activity	O
in	O
primed	O
CD4	B-cell_type
T	I-cell_type
cells	I-cell_type
and	O
confirming	O
the	O
importance	O
of	O
endogenous	B-protein
NFAT	I-protein
to	O
increased	O
IL-4	B-protein
gene	O
expression	O
by	O
effector	O
T	O
cells	O
.	O

NFAT1	B-protein
appears	O
to	O
be	O
the	O
major	O
NFAT	B-protein
family	I-protein
member	I-protein
responsible	O
for	O
the	O
initial	O
increased	O
expression	O
of	O
IL-4	B-protein
by	O
primed	O
CD4	B-cell_type
T	I-cell_type
cells	I-cell_type
.	O

Differential	O
monocyte	O
adhesion	O
and	O
adhesion	B-protein
molecule	I-protein
expression	O
in	O
venous	O
and	O
arterial	O
endothelial	O
cells	O
.	O

We	O
compared	O
U-937	B-cell_line
cell	I-cell_line
adhesion	O
and	O
adhesion	B-protein
molecule	I-protein
expression	O
in	O
human	B-cell_type
umbilical	I-cell_type
venous	I-cell_type
(	O
HUVECs	B-cell_type
)	O
and	O
arterial	B-cell_type
(	I-cell_type
HUAECs	I-cell_type
)	I-cell_type
endothelial	I-cell_type
cells	I-cell_type
exposed	O
to	O
tumor	B-protein
necrosis	I-protein
factor	I-protein
(	O
TNF	B-protein
)	O
,	O
interleukin-1	B-protein
,	O
and	O
lipopolysaccharide	O
(	O
LPS	O
)	O
.	O

TNF	B-protein
and	O
LPS	O
stimulated	O
vascular	B-protein
cell	I-protein
adhesion	I-protein
molecule	I-protein
(	O
VCAM	B-protein
)	O
-1	O
surface	O
expression	O
and	O
adhesion	O
of	O
U-937	B-cell_line
monocyte-like	I-cell_line
cells	I-cell_line
to	O
HUVECs	B-cell_type
but	O
not	O
to	O
HUAECs	B-cell_type
.	O

Antibody	O
studies	O
demonstrated	O
that	O
in	O
HUVECs	B-cell_type
at	O
least	O
75	O
%	O
of	O
the	O
adhesion	O
response	O
is	O
VCAM-1	B-protein
mediated	O
.	O

Interleukin-1	B-protein
stimulated	O
U-937	B-cell_line
cell	I-cell_line
adhesion	O
to	O
and	O
VCAM-1	B-protein
surface	O
expression	O
in	O
both	O
HUVECs	B-cell_type
and	O
HUAECs	B-cell_type
.	O

Pyrrolidinedithiocarbamate	O
and	O
the	O
proteasome	O
inhibitor	O
MG-132	O
blocked	O
TNF	B-protein
-and	O
LPS-stimulated	O
U-937	B-cell_line
cell	I-cell_line
adhesion	O
to	O
HUVECs	B-cell_type
.	O

These	O
agents	O
also	O
significantly	O
decreased	O
TNF	B-protein
-and	O
LPS-stimulated	O
increases	O
in	O
HUVEC	B-protein
surface	I-protein
VCAM-1	I-protein
.	O

TNF	B-protein
increased	O
VCAM-1	B-protein
protein	O
and	O
mRNA	B-RNA
in	O
HUVECs	B-cell_type
that	O
was	O
blocked	O
by	O
pyrrolidinedithiocarbamate	O
.	O

However	O
,	O
neither	O
TNF	B-protein
or	O
LPS	O
stimulated	O
VCAM-1	B-protein
expression	O
in	O
HUAECs	B-cell_type
.	O

TNF	B-protein
stimulated	O
expression	O
of	O
both	O
intercellular	B-protein
adhesion	I-protein
molecule-1	I-protein
and	O
E-selectin	B-protein
in	O
HUVECs	B-cell_type
,	O
but	O
in	O
HUAECs	B-cell_type
,	O
only	O
intercellular	B-protein
adhesion	I-protein
molecule-1	I-protein
was	O
increased	O
.	O

Electrophoretic	O
mobility	O
shift	O
assays	O
demonstrated	O
no	O
difference	O
in	O
the	O
pattern	O
of	O
TNF	B-protein
-stimulated	O
nuclear	B-protein
factor-kappaB	I-protein
activation	O
between	O
HUVECs	B-cell_type
and	O
HUAECs	B-cell_type
.	O

These	O
studies	O
demonstrate	O
a	O
novel	O
and	O
striking	O
insensitivity	O
of	O
arterial	O
endothelium	O
to	O
the	O
effects	O
of	O
TNF	B-protein
and	O
LPS	O
and	O
indicate	O
a	O
dissociation	O
between	O
the	O
ability	O
of	O
HUAECs	B-cell_type
to	O
upregulate	O
nuclear	B-protein
factor-kappaB	I-protein
and	O
VCAM-1	B-protein
.	O

Functional	O
testosterone	B-protein
receptors	I-protein
in	O
plasma	O
membranes	O
of	O
T	B-cell_type
cells	I-cell_type
.	O

T	B-cell_type
cells	I-cell_type
are	O
considered	O
to	O
be	O
unresponsive	O
to	O
testosterone	O
due	O
to	O
the	O
absence	O
of	O
androgen	B-protein
receptors	I-protein
(	O
AR	B-protein
)	O
.	O

Here	O
,	O
we	O
demonstrate	O
the	O
testosterone	O
responsiveness	O
of	O
murine	B-cell_type
splenic	I-cell_type
T	I-cell_type
cells	I-cell_type
in	O
vitro	O
as	O
well	O
as	O
the	O
presence	O
of	O
unconventional	B-protein
cell	I-protein
surface	I-protein
receptors	I-protein
for	O
testosterone	O
and	O
classical	B-protein
intracellular	I-protein
AR	I-protein
.	O

Binding	O
sites	O
for	O
testosterone	O
on	O
the	O
surface	O
of	O
both	O
CD4	B-cell_type
(	I-cell_type
+	I-cell_type
)	I-cell_type
and	I-cell_type
CD8	I-cell_type
(	I-cell_type
+	I-cell_type
)	I-cell_type
subsets	I-cell_type
of	O
T	B-cell_type
cells	I-cell_type
are	O
directly	O
revealed	O
with	O
the	O
impeded	O
ligand	O
testosterone-BSA-FITC	O
by	O
confocal	O
laser	O
scanning	O
microscopy	O
(	O
CLSM	O
)	O
and	O
flow	O
cytometry	O
,	O
respectively	O
.	O

Binding	O
of	O
the	O
plasma	O
membrane	O
impermeable	O
testosterone-BSA	B-protein
conjugate	I-protein
induces	O
a	O
rapid	O
rise	O
(	O
<	O
5	O
s	O
)	O
in	O
[	O
Ca2+	O
]	O
i	O
of	O
Fura-2-loaded	B-cell_type
T	I-cell_type
cells	I-cell_type
.	O

This	O
rise	O
reflects	O
influx	O
of	O
extracellular	O
Ca2+	O
through	O
non-voltage-gated	O
and	O
Ni2+-blockable	B-protein
Ca2+	I-protein
channels	I-protein
of	O
the	O
plasma	O
membrane	O
.	O

The	O
testosterone-BSA-induced	O
Ca2+	O
import	O
is	O
not	O
affected	O
by	O
cyproterone	O
,	O
a	O
blocker	O
of	O
the	O
AR	B-protein
.	O

In	O
addition	O
,	O
AR	B-protein
are	O
not	O
detectable	O
on	O
the	O
surface	O
of	O
intact	B-cell_type
T	I-cell_type
cells	I-cell_type
when	O
using	O
anti-AR	B-protein
antibodies	I-protein
directed	O
against	O
the	O
amino	B-protein
and	I-protein
carboxy	I-protein
terminus	I-protein
of	O
the	O
AR	B-protein
,	O
although	O
T	B-cell_type
cells	I-cell_type
contain	O
AR	B-protein
,	O
as	O
revealed	O
by	O
reverse	O
transcription-polymerase	O
chain	O
reactions	O
and	O
Western	O
blotting	O
.	O

AR	B-protein
can	O
be	O
visualized	O
with	O
the	O
anti-AR	B-protein
antibodies	I-protein
in	O
the	O
cytoplasm	O
of	O
permeabilized	B-cell_type
T	I-cell_type
cells	I-cell_type
by	O
using	O
CLSM	O
,	O
though	O
AR	B-protein
are	O
not	O
detectable	O
in	O
cytosol	O
fractions	O
when	O
using	O
the	O
charcoal	O
binding	O
assay	O
with	O
3H-R1881	O
as	O
ligand	O
.	O

Cytoplasmic	B-protein
AR	I-protein
do	O
not	O
translocate	O
to	O
the	O
nucleus	O
of	O
T	B-cell_type
cells	I-cell_type
in	O
the	O
presence	O
of	O
testosterone	O
,	O
in	O
contrast	O
to	O
cytoplasmic	B-protein
AR	I-protein
in	O
human	B-cell_line
cancer	I-cell_line
LNCaP	I-cell_line
cells	I-cell_line
.	O

These	O
findings	O
suggest	O
that	O
the	O
classical	B-protein
AR	I-protein
present	O
in	O
splenic	B-cell_type
T	I-cell_type
cells	I-cell_type
are	O
not	O
active	O
in	O
the	O
genomic	O
pathway	O
.	O

By	O
contrast	O
,	O
the	O
cell	B-protein
surface	I-protein
receptors	I-protein
for	O
testosterone	O
are	O
in	O
a	O
functionally	O
active	O
state	O
,	O
enabling	O
T	B-cell_type
cells	I-cell_type
a	O
nongenomic	O
response	O
to	O
testosterone	O
.	O

Limited	O
proteolysis	O
for	O
assaying	O
ligand	O
binding	O
affinities	O
of	O
nuclear	B-protein
receptors	I-protein
.	O

The	O
binding	O
of	O
natural	O
or	O
synthetic	O
ligands	O
to	O
nuclear	B-protein
receptors	I-protein
is	O
the	O
triggering	O
event	O
leading	O
to	O
gene	O
transcription	O
activation	O
or	O
repression	O
.	O

Ligand	O
binding	O
to	O
the	O
ligand	B-protein
binding	I-protein
domain	I-protein
of	O
these	O
receptors	B-protein
induces	O
conformational	O
changes	O
that	O
are	O
evidenced	O
by	O
an	O
increased	O
resistance	O
of	O
this	O
domain	O
to	O
proteases	B-protein
.	O

In	B-protein
vitro	I-protein
labeled	I-protein
receptors	I-protein
were	O
incubated	O
with	O
various	O
synthetic	O
or	O
natural	O
agonists	O
or	O
antagonists	O
and	O
submitted	O
to	O
trypsin	B-protein
digestion	O
.	O

Proteolysis	O
products	O
were	O
separated	O
by	O
SDS-PAGE	O
and	O
quantified	O
.	O

The	O
amount	O
of	O
trypsin	B-protein
-resistant	O
fragments	O
was	O
proportional	O
to	O
receptor	O
occupancy	O
by	O
the	O
ligand	O
,	O
and	O
allowed	O
the	O
determination	O
of	O
dissociation	O
constants	O
(	O
kDa	O
)	O
.	O

Using	O
the	O
wild-type	B-protein
or	I-protein
mutated	I-protein
human	I-protein
retinoic	I-protein
acid	I-protein
receptor	I-protein
alpha	I-protein
as	O
a	O
model	O
,	O
kDa	O
values	O
determined	O
by	O
classical	O
competition	O
binding	O
assays	O
using	O
tritiated	O
ligands	O
are	O
in	O
agreement	O
with	O
those	O
measured	O
by	O
the	O
proteolytic	O
assay	O
.	O

This	O
method	O
was	O
successfully	O
extended	O
to	O
human	B-protein
retinoic	I-protein
X	I-protein
receptor	I-protein
alpha	I-protein
,	O
glucocorticoid	B-protein
receptor	I-protein
,	O
and	O
progesterone	B-protein
receptor	I-protein
,	O
thus	O
providing	O
a	O
basis	O
for	O
a	O
new	O
,	O
faster	O
assay	O
to	O
determine	O
simultaneously	O
the	O
affinity	O
and	O
conformation	O
of	O
receptors	O
when	O
bound	O
to	O
a	O
given	O
ligand	O
.	O

Genes	O
that	O
regulate	O
interleukin-4	B-protein
expression	O
in	O
T	B-cell_type
cells	I-cell_type
.	O

Interleukin-4	B-protein
is	O
an	O
immunomodulatory	B-protein
cytokine	I-protein
which	O
plays	O
a	O
central	O
role	O
in	O
the	O
regulation	O
of	O
allergic	O
and	O
atopic	O
immune	O
responses	O
.	O

Significant	O
progress	O
has	O
been	O
made	O
in	O
gaining	O
a	O
detailed	O
understanding	O
of	O
the	O
transcriptional	O
regulation	O
of	O
the	O
interleukin-4	B-DNA
gene	I-DNA
.	O

The	O
recent	O
identification	O
and	O
characterization	O
of	O
several	O
key	O
transcription	B-protein
factors	I-protein
has	O
helped	O
to	O
elucidate	O
the	O
molecular	O
mechanisms	O
of	O
T	B-DNA
helper	I-DNA
cell	I-DNA
cytokine	I-DNA
gene	I-DNA
expression	O
.	O

B	B-cell_type
lymphocytes	I-cell_type
from	O
patients	O
with	O
chronic	O
lymphocytic	O
leukemia	O
contain	O
signal	B-protein
transducer	I-protein
and	I-protein
activator	I-protein
of	I-protein
transcription	I-protein
(	I-protein
STAT	I-protein
)	I-protein
1	I-protein
and	O
STAT3	B-protein
constitutively	O
phosphorylated	O
on	O
serine	O
residues	O
.	O

To	O
explore	O
the	O
pathogenesis	O
of	O
chronic	O
lymphocytic	O
leukemia	O
(	O
CLL	O
)	O
,	O
we	O
examined	O
whether	O
phosphorylation	O
of	O
one	O
or	O
more	O
signal	B-protein
transducer	I-protein
and	I-protein
activator	I-protein
of	I-protein
transcription	I-protein
(	I-protein
STAT	I-protein
)	I-protein
factors	I-protein
was	O
abnormal	O
in	O
cells	O
from	O
CLL	O
patients	O
.	O

No	O
constitutive	O
tyrosine	O
phosphorylation	O
was	O
detected	O
on	O
any	O
STAT	B-protein
in	O
CLL	B-cell_line
cells	I-cell_line
.	O

To	O
assess	O
the	O
phosphorylation	O
of	O
serine	O
residues	O
of	O
STAT1	B-protein
and	O
STAT3	B-protein
in	O
CLL	B-cell_line
cells	I-cell_line
,	O
we	O
raised	O
antibodies	O
that	O
specifically	O
recognize	O
the	O
form	O
of	O
STAT1	B-protein
phosphorylated	O
on	O
ser-727	O
and	O
the	O
form	O
of	O
STAT3	B-protein
phosphorylated	O
on	O
ser-727	O
.	O

We	O
found	O
that	O
in	O
100	O
%	O
of	O
patients	O
with	O
CLL	O
(	O
n	O
=	O
32	O
)	O
,	O
STAT1	B-protein
and	O
STAT3	B-protein
were	O
constitutively	O
phosphorylated	O
on	O
serine	O
.	O

This	O
was	O
in	O
contrast	O
to	O
normal	O
peripheral	O
blood	O
B	B-cell_type
lymphocytes	I-cell_type
or	O
CD5+	B-cell_type
)	I-cell_type
B	I-cell_type
cells	I-cell_type
isolated	O
from	O
tonsils	O
,	O
in	O
which	O
this	O
phosphorylation	O
was	O
absent	O
.	O

Serine	O
phosphorylation	O
of	O
STAT1	B-protein
and	O
STAT3	B-protein
was	O
seen	O
occasionally	O
in	O
other	O
leukemias	O
,	O
but	O
it	O
was	O
a	O
universal	O
finding	O
only	O
in	O
CLL	O
.	O

The	O
serine	O
phosphorylation	O
of	O
these	O
STATs	B-protein
was	O
a	O
continuous	O
process	O
,	O
as	O
incubation	O
of	O
CLL	B-cell_line
cells	I-cell_line
with	O
the	O
kinase	B-protein
inhibitor	I-protein
H7	I-protein
led	O
to	O
the	O
dephosphorylation	O
of	O
these	O
serine	O
residues	O
.	O

The	O
STAT	O
serine	O
kinase	O
in	O
CLL	O
cells	O
has	O
not	O
been	O
identified	O
,	O
and	O
appears	O
to	O
be	O
neither	O
mitogen-activated	B-protein
protein	I-protein
kinase	I-protein
nor	O
pp70	B-protein
(	I-protein
s6k	I-protein
)	I-protein
.	O

In	O
summary	O
,	O
the	O
constitutive	O
serine	O
phosphorylation	O
of	O
STAT1	B-protein
and	O
STAT3	B-protein
is	O
present	O
in	O
all	O
CLL	O
samples	O
tested	O
to	O
date	O
,	O
although	O
the	O
physiologic	O
significance	O
of	O
this	O
modification	O
remains	O
to	O
be	O
determined	O
.	O

Activation	O
of	O
human	O
immunodeficiency	O
virus	O
type	O
1	O
expression	O
by	O
Gardnerella	O
vaginalis	O
.	O

Bacterial	O
vaginosis	O
(	O
BV	O
)	O
is	O
associated	O
with	O
an	O
increased	O
rate	O
of	O
sexual	O
transmission	O
of	O
human	O
immunodeficiency	O
virus	O
(	O
HIV	O
)	O
type	O
1	O
,	O
and	O
Gardnerella	O
vaginalis	O
is	O
frequently	O
isolated	O
from	O
the	O
genital	O
tracts	O
of	O
women	O
with	O
BV	O
.	O

G.	O
vaginalis	O
lysates	O
were	O
found	O
to	O
significantly	O
stimulate	O
HIV	O
expression	O
in	O
monocytoid	B-cell_type
cells	I-cell_type
.	O

Stimulation	O
was	O
significantly	O
higher	O
when	O
lysates	O
were	O
heated	O
at	O
100	O
degrees	O
C	O
for	O
5	O
min	O
but	O
was	O
reduced	O
by	O
treatment	O
with	O
lysozyme	B-protein
or	O
protease	B-protein
.	O

G.	O
vaginalis	O
lysates	O
also	O
activated	O
HIV	O
expression	O
in	O
certain	O
T	B-cell_line
cell	I-cell_line
lines	I-cell_line
.	O

G.	O
vaginalis	O
lysates	O
activated	O
HIV	O
long-terminal	O
repeat	O
transcription	O
in	O
HIV-infected	B-cell_type
cells	I-cell_type
and	O
increased	O
NF-kappaB	B-protein
binding	O
activity	O
,	O
indicating	O
an	O
effect	O
by	O
G.	O
vaginalis	O
on	O
HIV	O
transcription	O
.	O

The	O
activation	O
of	O
HIV	O
production	O
by	O
G.	O
vaginalis	O
suggests	O
that	O
genital	O
tract	O
infection	O
with	O
G.	O
vaginalis	O
increases	O
the	O
risk	O
of	O
HIV	O
transmission	O
by	O
increasing	O
HIV	O
expression	O
in	O
the	O
genital	O
tract	O
.	O

This	O
may	O
explain	O
,	O
at	O
least	O
in	O
part	O
,	O
the	O
increased	O
rate	O
of	O
HIV	O
transmission	O
in	O
women	O
with	O
BV	O
.	O

Interleukin-10	B-protein
inhibits	O
expression	O
of	O
both	O
interferon	B-DNA
alpha-	I-DNA
and	I-DNA
interferon	I-DNA
gamma-	I-DNA
induced	I-DNA
genes	I-DNA
by	O
suppressing	O
tyrosine	O
phosphorylation	O
of	O
STAT1	B-protein
.	O

Interleukin-10	B-protein
(	O
IL-10	B-protein
)	O
helps	O
maintain	O
polarized	B-cell_type
T-helper	I-cell_type
cells	I-cell_type
in	O
a	O
T-helper	B-cell_type
lymphocyte	I-cell_type
2	I-cell_type
(	I-cell_type
Th2	I-cell_type
)	I-cell_type
phenotype	I-cell_type
.	O

Part	O
of	O
this	O
process	O
involves	O
the	O
prevention	O
of	O
the	O
development	O
of	O
Th1	B-cell_type
cells	I-cell_type
,	O
which	O
are	O
a	O
primary	O
source	O
of	O
interferon	B-protein
gamma	I-protein
(	O
IFNgamma	B-protein
)	O
,	O
a	O
potent	O
activator	O
of	O
monocytes	B-cell_type
and	O
an	O
inhibitor	O
of	O
Th2	O
proliferation	O
.	O

Because	O
monocytes	B-cell_type
and	O
macrophages	O
are	O
important	O
mediators	O
of	O
Th1-type	O
responses	O
,	O
such	O
as	O
delayed-type	O
hypersensitivity	O
,	O
we	O
sought	O
to	O
determine	O
if	O
IL-10	B-protein
could	O
directly	O
mediate	O
inhibition	O
of	O
IFNgamma-	O
and	O
IFNalpha-induced	O
gene	O
expression	O
in	O
these	O
cells	O
.	O

Highly	O
purified	O
monocytes	B-cell_type
were	O
incubated	O
with	O
IL-10	B-protein
for	O
60	O
to	O
90	O
minutes	O
before	O
the	O
addition	O
of	O
IFNgamma	B-protein
or	O
IFNalpha	B-protein
.	O

IL-10	B-protein
preincubation	O
resulted	O
in	O
the	O
inhibition	O
of	O
gene	O
expression	O
for	O
several	O
IFN-induced	B-DNA
genes	I-DNA
,	O
such	O
as	O
IP-10	B-protein
,	O
ISG54	B-protein
,	O
and	O
intercellular	B-protein
adhesion	I-protein
molecule-1	I-protein
.	O

The	O
reduction	O
in	O
gene	O
expression	O
resulted	O
from	O
the	O
ability	O
of	O
IL-10	B-protein
to	O
suppress	O
IFN	B-protein
-induced	O
assembly	O
of	O
signal	B-protein
transducer	I-protein
and	I-protein
activator	I-protein
of	I-protein
transcription	I-protein
(	I-protein
STAT	I-protein
)	I-protein
factors	I-protein
to	O
specific	B-DNA
promoter	I-DNA
motifs	I-DNA
on	O
IFNalpha-	B-DNA
and	I-DNA
IFNgamma-inducible	I-DNA
genes	I-DNA
.	O

This	O
was	O
accomplished	O
by	O
preventing	O
the	O
IFN-induced	O
tyrosine	O
phosphorylation	O
of	O
STAT1	B-protein
,	O
a	O
component	O
of	O
both	O
IFNalpha-	B-protein
and	I-protein
IFNgamma-induced	I-protein
DNA	I-protein
binding	I-protein
complexes	I-protein
.	O

Therefore	O
,	O
IL-10	B-protein
can	O
directly	O
inhibit	O
STAT-dependent	B-DNA
early	I-DNA
response	I-DNA
gene	I-DNA
expression	O
induced	O
by	O
both	O
IFNalpha	B-protein
and	O
IFNgamma	B-protein
in	O
monocytes	B-cell_type
by	O
suppressing	O
the	O
tyrosine	O
phosphorylation	O
of	O
STAT1	B-protein
.	O

This	O
may	O
occur	O
through	O
the	O
ability	O
of	O
IL-10	B-protein
to	O
induce	O
expression	O
of	O
the	O
gene	O
,	O
suppressor	O
of	O
cytokine	B-protein
signaling	I-protein
3	I-protein
(	O
SOCS3	B-protein
)	O
.	O

Clonality	O
analysis	O
of	O
refractory	O
anemia	O
with	O
ring	B-cell_type
sideroblasts	I-cell_type
:	O
simultaneous	O
study	O
of	O
clonality	O
and	O
cytochemistry	O
of	O
bone	B-cell_type
marrow	I-cell_type
progenitors	I-cell_type
.	O

X	O
chromosome	O
inactivation	O
and	O
polymorphism	O
of	O
the	O
human	B-DNA
androgen	I-DNA
receptor	I-DNA
(	I-DNA
HUMARA	I-DNA
)	I-DNA
gene	I-DNA
has	O
been	O
applied	O
for	O
analyzing	O
the	O
clonality	O
of	O
blood	B-cell_type
cells	I-cell_type
.	O

In	O
the	O
present	O
study	O
,	O
the	O
clonal	O
relationship	O
was	O
investigated	O
between	O
peripheral	B-cell_type
blood	I-cell_type
polymorphonuclear	I-cell_type
cells	I-cell_type
(	O
PMNCs	B-cell_type
)	O
and	O
marrow	B-cell_type
progenitor	I-cell_type
cells	I-cell_type
and	O
the	O
origin	O
of	O
ringed	B-cell_type
sideroblasts	I-cell_type
in	O
patients	O
with	O
refractory	O
anemia	O
with	O
ring	B-cell_type
sideroblasts	I-cell_type
(	O
RARS	B-cell_type
)	O
by	O
polymerase	O
chain	O
reaction	O
(	O
PCR	O
)	O
of	O
HUMARA	B-DNA
gene	I-DNA
.	O

The	O
X-inactivation	O
patterns	O
of	O
circulating	O
PMNCs	B-cell_type
and	O
T	B-cell_type
lymphocytes	I-cell_type
as	O
well	O
as	O
individual	O
granulocyte	B-cell_line
colonies	I-cell_line
grown	O
in	O
vitro	O
from	O
bone	O
marrow	O
cells	O
were	O
analyzed	O
.	O

The	O
development	O
of	O
ringed	B-cell_type
sideroblasts	I-cell_type
in	O
erythroid	B-cell_line
colonies	I-cell_line
by	O
iron	O
staining	O
and	O
their	O
X-inactivation	O
pattern	O
were	O
also	O
examined	O
.	O

All	O
three	O
RARS	B-cell_type
patients	O
showed	O
monoclonal	O
PMNCs	B-cell_type
.	O

In	O
granulocyte	B-cell_line
colonies	I-cell_line
,	O
however	O
,	O
two	O
different	O
X-inactivation	O
patterns	O
were	O
observed	O
in	O
all	O
patients	O
,	O
indicating	O
that	O
non-clonal	B-cell_type
progenitor	I-cell_type
cells	I-cell_type
remained	O
in	O
the	O
bone	O
marrow	O
.	O

All	O
erythroid	B-cell_line
colonies	I-cell_line
consisted	O
of	O
ringed	B-cell_type
sideroblasts	I-cell_type
exclusively	O
showed	O
one	O
pattern	O
dominant	O
in	O
those	O
of	O
PMNCs	B-cell_type
.	O

Our	O
findings	O
suggest	O
that	O
non-clonal	B-cell_type
progenitor	I-cell_type
cells	I-cell_type
persist	O
in	O
some	O
RARS	B-cell_type
cases	O
,	O
that	O
erythroid	B-cell_type
progenitors	I-cell_type
show	O
mosaicism	O
,	O
and	O
that	O
ringed	B-cell_type
sideroblasts	I-cell_type
may	O
be	O
derived	O
from	O
an	O
abnormal	O
clone	O
involved	O
in	O
the	O
pathogenesis	O
of	O
this	O
disease	O
.	O

Granulosa	O
cell	O
tumor	O
of	O
the	O
ovary	O
.	O

Immunohistochemical	O
evidence	O
of	O
low	O
proliferative	O
activity	O
and	O
virtual	O
absence	O
of	O
mutation	O
of	O
the	O
p53	B-DNA
tumor-suppressor	I-DNA
gene	I-DNA
.	O

BACKGROUND	O
AND	O
METHODS	O
:	O
Because	O
the	O
use	O
of	O
immunohistochemistry	O
in	O
the	O
diagnosis	O
of	O
granulosa	O
cell	O
tumor	O
(	O
GCT	O
)	O
has	O
not	O
been	O
fully	O
explored	O
,	O
routinely	O
processed	O
(	O
formalin-fixed	O
,	O
paraffin-embedded	O
)	O
tissue	O
from	O
11	O
GCT	O
,	O
adult	O
type	O
,	O
was	O
investigated	O
immunohistochemically	O
(	O
ABC	O
method	O
)	O
with	O
a	O
broad	O
spectrum	O
of	O
antibodies	O
against	O
various	O
markers	O
,	O
including	O
p53	B-protein
and	O
Ki-67	B-protein
.	O

All	O
of	O
the	O
tumors	O
exhibited	O
typical	O
morphology	O
,	O
were	O
limited	O
to	O
the	O
ovary	O
(	O
stage	O
I	O
)	O
,	O
and	O
7	O
cases	O
followed	O
a	O
benign	O
clinical	O
course	O
.	O

RESULTS	O
:	O
All	O
the	O
tumors	O
exhibited	O
strong	O
expression	O
of	O
vimentin	B-protein
,	O
but	O
most	O
other	O
antigens	O
(	O
including	O
smooth	B-protein
muscle	I-protein
actin	I-protein
)	O
were	O
expressed	O
infrequently	O
by	O
a	O
minority	O
of	O
tumor	B-cell_type
cells	I-cell_type
or	O
not	O
at	O
all	O
.	O

Tumor	O
cells	O
in	O
9	O
GCT	O
expressed	O
inhibin	O
A	O
.	O

All	O
the	O
tumors	O
exhibited	O
very	O
low	O
proliferative	O
activity	O
,	O
fewer	O
than	O
10	O
%	O
of	O
the	O
tumor	O
cell	O
nuclei	O
being	O
stained	O
by	O
the	O
antibody	B-protein
MIB-1	I-protein
(	O
Ki-67	B-protein
antigen	I-protein
)	O
.	O

The	O
antibody	B-protein
D07	I-protein
revealed	O
marked	O
overexpression	O
of	O
p53	B-protein
protein	I-protein
in	O
only	O
one	O
tumor	O
.	O

Clinical	O
outcome	O
was	O
not	O
found	O
to	O
be	O
related	O
to	O
immunophenotypic	O
differences	O
.	O

CONCLUSIONS	O
:	O
The	O
diagnosis	O
of	O
GCT	O
should	O
be	O
based	O
primarily	O
on	O
the	O
typical	O
morphology	O
revealed	O
by	O
conventional	O
stains	O
,	O
but	O
additional	O
immunohistochemical	O
staining	O
with	O
a	O
small	O
panel	O
of	O
selected	O
antibodies	O
(	O
for	O
example	O
,	O
against	O
keratin	B-protein
,	O
vimentin	B-protein
,	O
and	O
inhibin	B-protein
A	I-protein
)	O
may	O
be	O
helpful	O
in	O
a	O
few	O
cases	O
.	O

The	O
very	O
low	O
proliferative	O
activity	O
and	O
the	O
lack	O
of	O
overexpression	O
of	O
p53	B-protein
protein	I-protein
are	O
consistent	O
with	O
the	O
benign	O
clinical	O
behavior	O
of	O
the	O
majority	O
of	O
GCT	O
.	O

Protective	O
effects	O
of	O
notch-1	B-protein
on	O
TCR	B-protein
-induced	O
apoptosis	O
.	O

The	O
Notch	B-protein
receptor	I-protein
protein	I-protein
was	O
originally	O
identified	O
in	O
Drosophila	O
and	O
is	O
known	O
to	O
mediate	O
cell	O
to	O
cell	O
communication	O
and	O
influence	O
cell	O
fate	O
decisions	O
.	O

Members	O
of	O
this	O
family	O
have	O
been	O
isolated	O
from	O
invertebrates	O
as	O
well	O
as	O
vertebrates	O
.	O

We	O
isolated	O
mouse	B-protein
Notch-1	I-protein
in	O
a	O
yeast	O
two-hybrid	O
screen	O
with	O
Nur77	B-protein
,	O
which	O
is	O
a	O
protein	O
that	O
has	O
been	O
shown	O
previously	O
to	O
be	O
required	O
for	O
apoptosis	O
in	O
T	B-cell_line
cell	I-cell_line
lines	I-cell_line
.	O

The	O
data	O
presented	O
below	O
indicate	O
that	O
Notch-1	B-protein
expression	O
provides	O
significant	O
protection	O
to	O
T	B-cell_line
cell	I-cell_line
lines	I-cell_line
from	O
TCR	B-protein
-mediated	O
apoptosis	O
.	O

These	O
data	O
demonstrate	O
a	O
new	O
antiapoptotic	O
role	O
for	O
Notch-1	B-protein
,	O
providing	O
evidence	O
that	O
,	O
in	O
addition	O
to	O
regulating	O
cell	O
fate	O
decisions	O
,	O
Notch-1	B-protein
can	O
play	O
a	O
critical	O
role	O
in	O
controlling	O
levels	O
of	O
cell	O
death	O
in	O
T	B-cell_type
cells	I-cell_type
.	O

Comparison	O
of	O
primary	O
sensitization	O
of	O
naive	B-cell_type
human	I-cell_type
T	I-cell_type
cells	I-cell_type
to	O
varicella-zoster	O
virus	O
peptides	O
by	O
dendritic	B-cell_type
cells	I-cell_type
in	O
vitro	O
with	O
responses	O
elicited	O
in	O
vivo	O
by	O
varicella	O
vaccination	O
.	O

Dendritic	B-cell_type
cells	I-cell_type
(	O
DC	B-cell_type
)	O
are	O
potent	O
APC	B-cell_type
during	O
primary	O
and	O
secondary	O
immune	O
responses	O
.	O

The	O
first	O
objective	O
of	O
this	O
study	O
was	O
to	O
determine	O
whether	O
human	B-cell_type
DC	I-cell_type
mediate	O
in	O
vitro	O
sensitization	O
of	O
naive	B-cell_type
CD4+	I-cell_type
T	I-cell_type
cells	I-cell_type
to	O
epitopes	B-protein
of	O
the	O
immediate	B-protein
early	I-protein
62	I-protein
(	I-protein
IE62	I-protein
)	I-protein
protein	I-protein
of	O
varicella	O
zoster	O
virus	O
(	O
VZV	O
)	O
.	O

The	O
induction	O
of	O
CD4+	B-protein
T	O
cell	O
proliferative	O
responses	O
to	O
eight	O
synthetic	O
peptides	O
representing	O
amino	O
acid	O
sequences	O
of	O
the	O
VZV	B-protein
IE62	I-protein
protein	I-protein
was	O
assessed	O
using	O
T	B-cell_type
cells	I-cell_type
and	O
DC	B-cell_type
from	O
VZV-susceptible	O
donors	O
.	O

The	O
second	O
objective	O
was	O
to	O
compare	O
in	O
vitro	O
responses	O
of	O
naive	B-cell_type
T	I-cell_type
cells	I-cell_type
with	O
responses	O
to	O
VZV	O
peptides	O
induced	O
in	O
vivo	O
after	O
immunization	O
with	O
varicella	O
vaccine	O
.	O

T	O
cell	O
proliferation	O
was	O
induced	O
by	O
three	O
peptides	O
,	O
P1	O
,	O
P4	O
,	O
and	O
P7	O
,	O
in	O
71-100	O
%	O
of	O
the	O
donors	O
tested	O
before	O
and	O
after	O
vaccination	O
using	O
DC	B-cell_type
as	O
APC	B-cell_type
.	O

Monocytes	B-cell_type
were	O
effective	O
APC	B-cell_type
for	O
VZV	O
peptides	O
only	O
after	O
immunization	O
.	O

Two	O
peptides	O
,	O
P2	O
and	O
P8	O
,	O
induced	O
naive	O
T	O
cell	O
proliferation	O
less	O
effectively	O
and	O
were	O
also	O
less	O
immunogenic	O
for	O
T	B-cell_type
cells	I-cell_type
from	O
vaccinated	O
or	O
naturally	O
immune	O
donors	O
.	O

T	O
cell	O
recognition	O
of	O
specific	O
peptides	O
was	O
concordant	O
between	O
naive	O
,	O
DC	B-cell_type
-mediated	O
responses	O
,	O
and	O
postvaccine	O
responses	O
using	O
monocytes	B-cell_type
as	O
APC	B-cell_type
in	O
69	O
%	O
of	O
comparisons	O
(	O
p	O
=	O
0.05	O
;	O
chi2	O
)	O
;	O
the	O
predictive	O
value	O
of	O
a	O
positive	O
response	O
to	O
an	O
IE62	O
peptide	O
before	O
immunization	O
for	O
T	O
cell	O
sensitization	O
in	O
vivo	O
was	O
82	O
%	O
.	O

These	O
observations	O
indicate	O
that	O
primary	O
T	O
cell	O
responses	O
detected	O
in	O
vitro	O
using	O
DC	B-cell_type
as	O
APC	B-cell_type
may	O
be	O
useful	O
to	O
characterize	O
the	O
potential	O
immunogenicity	O
of	O
viral	O
protein	O
epitopes	O
in	O
vivo	O
.	O

Mechanism	O
of	O
interleukin-10	B-protein
inhibition	O
of	O
T-helper	O
cell	O
activation	O
by	O
superantigen	B-protein
at	O
the	O
level	O
of	O
the	O
cell	O
cycle	O
.	O

We	O
have	O
analyzed	O
the	O
effects	O
of	O
interleukin-10	B-protein
(	O
IL-10	B-protein
)	O
on	O
the	O
entry	O
of	O
quiescent	O
CD4	B-cell_type
(	I-cell_type
+	I-cell_type
)	I-cell_type
T	I-cell_type
cells	I-cell_type
into	O
the	O
cell	O
cycle	O
upon	O
stimulation	O
with	O
the	O
superantigen	B-protein
staphylococcal	B-protein
enterotoxin	I-protein
B	I-protein
(	O
SEB	B-protein
)	O
.	O

IL-10	B-protein
arrested	O
cells	O
at	O
G0/G1	O
.	O

IL-10	B-protein
treatment	O
prevented	O
the	O
downregulation	O
of	O
p27	B-protein
(	I-protein
Kip1	I-protein
)	O
,	O
an	O
inhibitory	B-protein
protein	I-protein
that	O
controls	O
progression	O
out	O
of	O
the	O
G0	O
phase	O
of	O
the	O
cell	O
cycle	O
.	O

IL-10	B-protein
also	O
prevented	O
the	O
upregulation	O
of	O
the	O
G1	B-protein
cyclins	I-protein
D2	B-protein
and	O
D3	B-protein
,	O
proteins	O
necessary	O
for	O
entry	O
and	O
progression	O
through	O
the	O
G1	O
phase	O
of	O
the	O
cell	O
cycle	O
.	O

Associated	O
with	O
the	O
inhibition	O
of	O
the	O
cell	O
cycle	O
,	O
IL-10	B-protein
suppressed	O
SEB	B-protein
induction	O
of	O
interleukin-2	B-protein
(	O
IL-2	B-protein
)	O
.	O

Addition	O
of	O
exogenous	O
IL-2	B-protein
to	O
IL-10-treated	B-cell_line
cells	I-cell_line
significantly	O
reversed	O
the	O
antiproliferative	O
effects	O
of	O
IL-10	B-protein
.	O

Moreover	O
,	O
IL-10	B-protein
effects	O
on	O
the	O
early	B-protein
G1	I-protein
proteins	I-protein
p27	B-protein
(	I-protein
Kip1	I-protein
)	I-protein
and	O
cyclin	B-protein
D2	I-protein
were	O
similarly	O
reversed	O
by	O
exogenous	O
IL-2	B-protein
.	O

Although	O
this	O
reversal	O
by	O
IL-2	B-protein
was	O
pronounced	O
,	O
it	O
was	O
not	O
complete	O
,	O
suggesting	O
that	O
IL-10	B-protein
may	O
have	O
some	O
effects	O
not	O
directly	O
related	O
to	O
the	O
suppression	O
of	O
IL-2	B-protein
production	O
.	O

Cell	O
separation	O
experiments	O
suggest	O
that	O
IL-10	B-protein
can	O
effect	O
purified	O
CD4	B-cell_type
(	I-cell_type
+	I-cell_type
)	I-cell_type
T	I-cell_type
cells	I-cell_type
directly	O
,	O
providing	O
functional	O
evidence	O
for	O
the	O
presence	O
of	O
IL-10	B-protein
receptors	O
on	O
CD4	B-cell_type
(	I-cell_type
+	I-cell_type
)	I-cell_type
T	I-cell_type
cells	I-cell_type
.	O

IL-10	B-protein
also	O
inhibited	O
expression	O
of	O
IL-2	B-protein
transcriptional	I-protein
regulators	I-protein
c-fos	B-protein
and	O
c-jun	B-protein
,	O
which	O
also	O
inhibit	O
other	O
cell	O
functions	O
.	O

Our	O
studies	O
show	O
that	O
the	O
mechanism	O
of	O
IL-10	B-protein
regulation	O
of	O
quiescent	O
CD4	O
(	O
+	O
)	O
T-cell	O
activation	O
is	O
mainly	O
by	O
blocking	O
induction	O
of	O
IL-2	B-protein
that	O
is	O
critical	O
to	O
downregulation	O
of	O
p27	B-protein
(	I-protein
Kip1	I-protein
)	I-protein
and	O
upregulation	O
of	O
D	B-protein
cyclins	I-protein
in	O
T-cell	O
activation	O
and	O
entry	O
into	O
the	O
cell	O
cycle	O
.	O

IFN-gamma	B-protein
and	O
IL-10	B-protein
inhibit	O
induction	O
of	O
IL-1	O
receptor	O
type	O
I	O
and	O
type	O
II	O
gene	O
expression	O
by	O
IL-4	B-protein
and	O
IL-13	B-protein
in	O
human	O
monocytes	B-cell_type
.	O

The	O
Th2-type	B-protein
cytokines	I-protein
IL-4	B-protein
and	O
IL-13	B-protein
induce	O
expression	O
of	O
a	O
distinct	O
subset	O
of	O
genes	O
in	O
human	B-cell_type
monocytes	I-cell_type
.	O

These	O
include	O
Fc	B-protein
epsilonRII	I-protein
(	O
CD23	B-protein
)	O
,	O
15-lipoxygenase	B-protein
,	O
IL-1	B-protein
receptor	I-protein
antagonist	I-protein
(	O
IL-1ra	B-protein
)	O
,	O
and	O
type	B-protein
I	I-protein
and	I-protein
type	I-protein
II	I-protein
IL-1	I-protein
receptors	I-protein
(	O
IL-1R	B-protein
)	O
.	O

IFN-gamma	B-protein
has	O
been	O
shown	O
to	O
inhibit	O
induction	O
of	O
CD23	B-protein
and	O
15-lipoxygenase	B-protein
in	O
monocytes	B-cell_type
;	O
however	O
,	O
the	O
effects	O
of	O
IFN-gamma	B-protein
on	O
type	O
I	O
and	O
type	O
II	O
IL-1R	O
gene	O
expression	O
have	O
not	O
been	O
defined	O
.	O

We	O
examined	O
the	O
effects	O
of	O
IFN-gamma	B-protein
on	O
both	O
basal	O
and	O
IL-4	B-protein
/	O
IL-13	B-protein
-induced	O
IL-1R	B-DNA
gene	I-DNA
expression	O
in	O
primary	B-cell_type
monocytes	I-cell_type
.	O

IL-4	B-protein
and	O
IL-13	B-protein
induced	O
dose-	O
and	O
time-dependent	O
increases	O
in	O
IL-1RI	O
and	O
IL-1RII	O
mRNA	O
levels	O
.	O

IFN-gamma	B-protein
decreased	O
basal	O
expression	O
as	O
well	O
as	O
the	O
induction	O
of	O
these	O
genes	O
by	O
IL-4	B-protein
and	O
IL-13	B-protein
.	O

Inhibition	O
of	O
IL-1RI	B-protein
and	O
IL-1RII	O
mRNA	O
levels	O
by	O
IFN-gamma	B-protein
was	O
transcriptionally	O
mediated	O
,	O
and	O
correlated	O
directly	O
with	O
decreased	O
production	O
of	O
soluble	O
IL-1RII	B-protein
.	O

Furthermore	O
,	O
the	O
ability	O
to	O
suppress	O
IL-1RI	O
and	O
IL-1RII	B-protein
mRNA	O
levels	O
was	O
not	O
unique	O
to	O
IFN-gamma	B-protein
because	O
IL-10	B-protein
also	O
inhibited	O
expression	O
of	O
these	O
genes	O
in	O
IL-4/IL-13-stimulated	B-cell_line
monocytes	I-cell_line
.	O

Inhibition	O
of	O
IL-1R	B-DNA
gene	I-DNA
expression	O
by	O
IFN-gamma	B-protein
and	O
IL-10	B-protein
was	O
not	O
due	O
to	O
down-regulation	O
of	O
surface	B-protein
IL-4R	I-protein
because	O
pretreatment	O
with	O
these	O
cytokines	O
did	O
not	O
decrease	O
the	O
number	O
of	O
IL-4	B-protein
binding	O
sites	O
per	O
cell	O
.	O

However	O
,	O
suppression	O
of	O
IL-1R	B-DNA
gene	I-DNA
expression	O
by	O
IFN-gamma	B-protein
and	O
IL-10	B-protein
was	O
associated	O
with	O
decreased	O
tyrosine	O
phosphorylation	O
and	O
nuclear	O
translocation	O
of	O
the	O
IL-4/IL-13-inducible	B-protein
transcription	I-protein
factor	I-protein
,	O
Stat6	B-protein
,	O
suggesting	O
a	O
potential	O
mechanism	O
by	O
which	O
IFN-gamma	B-protein
and	O
IL-10	B-protein
may	O
mediate	O
their	O
suppressive	O
effects	O
.	O

These	O
findings	O
demonstrate	O
that	O
certain	O
cytokines	O
,	O
including	O
IFN-gamma	B-protein
and	O
IL-10	B-protein
,	O
antagonize	O
the	O
ability	O
of	O
IL-4	B-protein
and	O
IL-13	B-protein
to	O
induce	O
increased	O
expression	O
of	O
the	O
IL-1RI	O
and	O
IL-1RII	B-DNA
genes	I-DNA
in	O
monocytes	B-cell_type
.	O

Cytokine	B-protein
rescue	O
from	O
glucocorticoid	O
induced	O
apoptosis	O
in	O
T	B-cell_type
cells	I-cell_type
is	O
mediated	O
through	O
inhibition	O
of	O
IkappaBalpha	B-protein
.	O

We	O
previously	O
reported	O
that	O
dexamethasone	O
(	O
DEX	O
)	O
,	O
a	O
synthetic	O
glucocorticoid	O
,	O
causes	O
apoptosis	O
in	O
mature	B-cell_line
Th	I-cell_line
cell	I-cell_line
lines	I-cell_line
,	O
and	O
that	O
this	O
induction	O
of	O
cell	O
death	O
is	O
prevented	O
by	O
specific	O
cytokines	B-protein
,	O
namely	O
,	O
by	O
IL-2	B-protein
in	O
Th1	B-cell_type
cells	I-cell_type
and	O
by	O
IL-4	B-protein
in	O
Th2	B-cell_type
cells	I-cell_type
.	O

We	O
now	O
show	O
that	O
this	O
differential	O
rescue	O
by	O
specific	O
cytokines	B-protein
in	O
Th	B-cell_type
cells	I-cell_type
correlates	O
with	O
the	O
level	O
of	O
IkappaBalpha	B-protein
that	O
is	O
regulated	O
by	O
DEX	O
and	O
cytokines	B-protein
.	O

In	O
both	O
cell	O
types	O
the	O
cellular	O
levels	O
of	O
IkappaBalpha	B-RNA
mRNA	I-RNA
and	O
protein	O
were	O
evaluated	O
by	O
DEX	O
treatment	O
.	O

Interestingly	O
,	O
the	O
DEX-mediated	O
IkappaBalpha	B-protein
induction	O
was	O
completely	O
inhibited	O
by	O
IL-2	B-protein
,	O
but	O
not	O
IL-4	B-protein
,	O
in	O
Th1	B-cell_type
cells	I-cell_type
,	O
while	O
the	O
reverse	O
profile	O
was	O
seen	O
in	O
Th2	B-cell_type
cells	I-cell_type
.	O

In	O
both	O
cell	O
types	O
,	O
the	O
cytokine	B-protein
that	O
inhibits	O
the	O
induction	O
of	O
IkappaBalpha	B-protein
by	O
DEX	O
,	O
also	O
rescues	O
these	O
cells	O
from	O
DEX-induced	O
apoptosis	O
,	O
although	O
the	O
rescue	O
cytokine	O
is	O
different	O
in	O
Th1	B-cell_type
and	I-cell_type
Th2	I-cell_type
cells	I-cell_type
.	O

Our	O
results	O
imply	O
that	O
T	B-cell_type
cells	I-cell_type
need	O
to	O
maintain	O
a	O
certain	O
level	O
of	O
NF-kappaB	B-protein
transcriptional	O
activity	O
in	O
order	O
to	O
survive	O
;	O
up-	O
or	O
down-regulation	O
of	O
nuclear	B-protein
NF	I-protein
kappaB	I-protein
through	O
modulation	O
of	O
IkappaBalpha	B-protein
expression	O
by	O
cytokines	B-protein
or	O
DEX	O
may	O
lead	O
to	O
cell	O
survival	O
or	O
cell	O
death	O
,	O
respectively	O
.	O

Expression	O
of	O
transcription	B-DNA
factor	I-DNA
genes	I-DNA
after	O
influenza	O
A	O
virus	O
infection	O
.	O

Infection	O
of	O
human	O
monocytes	B-cell_type
with	O
influenza	O
A	O
virus	O
induces	O
a	O
broad	O
range	O
of	O
proinflammatory	B-protein
cytokines	I-protein
and	O
mononuclear	O
cell	O
attracting	O
chemokines	B-protein
before	O
the	O
infected	B-cell_type
cells	I-cell_type
undergo	O
apoptosis	O
.	O

The	O
underlying	O
mechanisms	O
by	O
which	O
the	O
corresponding	O
genes	O
are	O
transcriptionally	O
initiated	O
after	O
virus	O
infection	O
are	O
still	O
poorly	O
understood	O
.	O

Activation	O
of	O
NF-kappa	B-protein
B	I-protein
seems	O
to	O
play	O
an	O
important	O
role	O
in	O
the	O
regulation	O
of	O
many	O
proinflammatory	B-DNA
cytokine	I-DNA
genes	I-DNA
,	O
but	O
can	O
not	O
be	O
the	O
only	O
mechanism	O
,	O
since	O
several	O
cytokine	B-DNA
genes	I-DNA
lack	O
respective	O
binding	B-DNA
sites	I-DNA
in	O
their	O
promoter	B-DNA
regions	I-DNA
.	O

Therefore	O
,	O
we	O
additionally	O
investigated	O
other	O
transcription	B-protein
factors	I-protein
of	O
possible	O
importance	O
such	O
as	O
CREB	B-protein
,	O
CTF	B-protein
,	O
OTF-1	B-protein
,	O
and	O
OTF-2	B-protein
.	O

To	O
explore	O
long-term	O
regulatory	O
mechanisms	O
,	O
we	O
investigated	O
the	O
induction	O
of	O
transcription	B-protein
factors	I-protein
on	O
the	O
gene	O
expression	O
level	O
which	O
may	O
be	O
important	O
to	O
substitute	O
for	O
metabolized	B-protein
transcription	I-protein
factor	I-protein
proteins	I-protein
after	O
their	O
activation	O
.	O

We	O
identified	O
a	O
cell-type-specific	O
differential	O
response	O
:	O
CREB	B-DNA
,	I-DNA
CTF	I-DNA
,	I-DNA
OTF-1	I-DNA
,	I-DNA
OFT-2	I-DNA
,	I-DNA
and	I-DNA
NF-kappa	I-DNA
B	I-DNA
genes	I-DNA
were	O
strongly	O
induced	O
1	O
to	O
4	O
hours	O
after	O
influenza	O
A	O
virus	O
infection	O
in	O
the	O
monocytic	B-cell_line
cell	I-cell_line
line	I-cell_line
Mono	B-cell_line
Mac	I-cell_line
6	I-cell_line
,	O
while	O
in	O
freshly	O
prepared	O
human	O
monocytes	B-cell_type
no	O
significant	O
changes	O
were	O
detected	O
.	O

In	O
infected	O
monocytes	B-cell_type
,	O
which	O
die	O
by	O
apoptosis	O
,	O
the	O
expression	O
of	O
CREB	B-protein
,	O
CTF	B-protein
,	O
and	O
OTF-2	B-protein
was	O
rather	O
suppressed	O
8	O
hours	O
after	O
infection	O
.	O

In	O
conclusion	O
,	O
the	O
long-term	O
regulation	O
of	O
transcription	B-protein
factor	I-protein
gene	O
expression	O
in	O
non-proliferating	B-cell_type
cells	I-cell_type
seems	O
to	O
be	O
of	O
minor	O
importance	O
after	O
influenza	O
infection	O
since	O
in	O
apoptosisprone	B-cell_type
cells	I-cell_type
an	O
immediate	O
availability	O
of	O
transcription	B-protein
factor	I-protein
proteins	I-protein
is	O
required	O
.	O

Peripheral	B-cell_type
blood	I-cell_type
mononuclear	I-cell_type
cells	I-cell_type
isolated	O
from	O
patients	O
with	O
diabetic	O
nephropathy	O
show	O
increased	O
activation	O
of	O
the	O
oxidative-stress	B-protein
sensitive	I-protein
transcription	I-protein
factor	I-protein
NF-kappaB	B-protein
.	O

Increased	O
oxidative	O
stress	O
and	O
subsequent	O
activation	O
of	O
the	O
transcription	O
factor	O
NF-kappaB	B-protein
has	O
been	O
linked	O
to	O
the	O
development	O
of	O
late	O
diabetic	O
complications	O
.	O

To	O
determine	O
whether	O
oxidative	O
stress	O
dependent	O
NF-kappaB	B-protein
activation	O
is	O
evident	O
in	O
patients	O
with	O
diabetic	O
nephropathy	O
we	O
used	O
an	O
Electrophoretic	O
Mobility	O
Shift	O
Assay	O
based	O
semiquantitative	O
detection	O
system	O
which	O
enabled	O
us	O
to	O
determine	O
NF-kappaB	B-protein
activation	O
in	O
ex	O
vivo	O
isolated	B-cell_type
peripheral	I-cell_type
blood	I-cell_type
mononuclear	I-cell_type
cells	I-cell_type
.	O

We	O
examined	O
33	O
patients	O
with	O
diabetes	O
mellitus	O
(	O
Type	O
I	O
and	O
Type	O
II	O
)	O
.	O

Patients	O
with	O
diabetic	O
nephropathy	O
showed	O
higher	O
NF-kappaB	B-protein
binding	O
activity	O
in	O
Electrophoretic	O
Mobility	O
Shift	O
Assays	O
and	O
stronger	O
immunohistological	O
staining	O
for	O
activated	O
NF-kappaBp65	B-protein
than	O
patients	O
without	O
renal	O
complications	O
.	O

NF-kappaB	B-protein
binding	O
activity	O
correlated	O
with	O
the	O
degree	O
of	O
albuminuria	O
(	O
r	O
=	O
0.316	O
)	O
and	O
with	O
thrombomodulin	B-protein
plasma	O
concentrations	O
(	O
r	O
=	O
0.33	O
)	O
,	O
indicative	O
for	O
albuminuria	O
associated	O
endothelial	O
dysfunction	O
.	O

In	O
a	O
3	O
day	O
intervention	O
study	O
in	O
which	O
600	O
mg	O
of	O
the	O
antioxidant	O
thioctic	O
acid	O
(	O
alpha-lipoic	O
acid	O
)	O
per	O
day	O
were	O
given	O
to	O
nine	O
patients	O
with	O
diabetic	O
nephropathy	O
oxidative	O
stress	O
in	O
plasma	O
samples	O
was	O
decreased	O
by	O
48	O
%	O
and	O
NF-kappaB	B-protein
binding	O
activity	O
in	O
ex	O
vivo	O
isolated	B-cell_type
peripheral	I-cell_type
blood	I-cell_type
mononuclear	I-cell_type
cells	I-cell_type
by	O
38	O
%	O
.	O

In	O
conclusion	O
,	O
activation	O
of	O
the	O
transcription	B-protein
factor	I-protein
NF-kappaB	B-protein
in	O
ex	O
vivo	O
isolated	B-cell_type
peripheral	I-cell_type
blood	I-cell_type
mononuclear	I-cell_type
cells	I-cell_type
of	O
patients	O
with	O
diabetes	O
mellitus	O
correlates	O
with	O
the	O
degree	O
of	O
diabetic	O
nephropathy	O
.	O

NF-kappaB	B-protein
activation	O
is	O
at	O
least	O
in	O
part	O
dependent	O
on	O
oxidative	O
stress	O
since	O
thioctic	O
acid	O
(	O
alpha-lipoic	O
acid	O
)	O
reduced	O
NF-kappaB	B-protein
binding	O
activity	O
.	O

Osteoclast	B-protein
markers	I-protein
accumulate	O
on	O
cells	O
developing	O
from	O
human	B-cell_type
peripheral	I-cell_type
blood	I-cell_type
mononuclear	I-cell_type
precursors	I-cell_type
.	O

Recent	O
studies	O
show	O
that	O
human	B-cell_type
osteoclasts	I-cell_type
develop	O
in	O
vitro	O
from	O
hematopoietic	B-cell_type
cells	I-cell_type
;	O
however	O
,	O
special	O
cultures	O
conditions	O
and/or	O
cytokine	O
mobilized	O
peripheral	O
blood	O
are	O
apparently	O
required	O
.	O

Here	O
,	O
we	O
report	O
that	O
cells	O
expressing	O
osteoclast	B-protein
markers	I-protein
differentiate	O
from	O
precursors	O
present	O
in	O
nonmobilized	B-cell_type
peripheral	I-cell_type
blood	I-cell_type
mononuclear	I-cell_type
cells	I-cell_type
(	O
PBMC	B-cell_type
)	O
,	O
without	O
the	O
addition	O
of	O
stromal	B-cell_type
cells	I-cell_type
,	O
growth	B-protein
factors	I-protein
,	O
cytokines	O
or	O
steroids	O
;	O
and	O
characterize	O
their	O
phenotype	O
.	O

Three	O
days	O
after	O
establishing	O
high-density	O
PBMC	B-cell_type
cultures	O
(	O
1.5	O
x	O
10	O
(	O
6	O
)	O
cells/cm2	O
)	O
,	O
in	O
serum-containing	O
medium	O
,	O
small	O
adherent	B-cell_line
colonies	I-cell_line
of	O
tartrate	B-cell_line
resistant	I-cell_line
acid	I-cell_line
phosphatase	I-cell_line
positive	I-cell_line
(	I-cell_line
TRAP+	I-cell_line
)	I-cell_line
cells	I-cell_line
emerge	O
,	O
amidst	O
massive	O
monocyte	O
cell	O
death	O
.	O

These	O
adherent	B-cell_type
cells	I-cell_type
have	O
an	O
eccentrically	O
placed	O
,	O
round	O
nucleus	O
,	O
and	O
express	O
low	O
levels	O
of	O
TRAP	B-protein
and	O
sodium	B-protein
fluoride-resistant-	I-protein
alpha-naphthyl-acetate-esterase	I-protein
(	O
NaF-R-NSE	B-protein
)	O
.	O

Over	O
the	O
next	O
week	O
,	O
this	O
cell	O
population	O
accumulates	O
phenotypic	O
markers	O
of	O
osteoclasts	B-cell_type
(	O
vitronectin	B-protein
receptor	I-protein
[	O
VR	B-protein
]	O
,	O
calcitonin	B-protein
receptor	I-protein
,	O
TRAP	B-protein
,	O
cathepsin	B-protein
K	I-protein
protein	I-protein
,	O
and	O
mRNA	B-RNA
)	O
with	O
increased	O
nuclearity	O
,	O
covering	O
the	O
entire	O
surface	O
by	O
15	O
days	O
.	O

When	O
cultured	O
on	O
bone	O
,	O
VR+	B-cell_line
,	I-cell_line
TRAP+	I-cell_line
cells	I-cell_line
of	O
low	O
multinuclearity	O
appear	O
and	O
cover	O
up	O
to	O
50	O
%	O
of	O
the	O
surface	O
.	O

Resorption	O
lacunae	O
can	O
be	O
observed	O
by	O
day	O
22	O
.	O

Although	O
these	O
pits	O
are	O
not	O
nearly	O
as	O
numerous	O
as	O
the	O
cells	O
of	O
preosteoclast	B-cell_type
phenotype	I-cell_type
,	O
they	O
do	O
represent	O
the	O
activity	O
of	O
a	O
subset	O
of	O
osteoclast-like	B-cell_type
cells	I-cell_type
that	O
has	O
achieved	O
osteoclastic	O
maturity	O
under	O
these	O
culture	O
conditions	O
.	O

Transcripts	O
for	O
osteoprotegerin	B-protein
ligand	I-protein
(	O
OPGL	B-protein
)	O
,	O
an	O
osteoclast	B-protein
differentiation	I-protein
factor	I-protein
(	O
also	O
known	O
as	O
RANKL	B-protein
and	O
TRANCE	B-protein
)	O
are	O
expressed	O
,	O
likely	O
by	O
adherent	B-cell_type
cells	I-cell_type
.	O

Thus	O
,	O
an	O
adherent	O
population	O
of	O
cells	O
,	O
with	O
preosteoclast/	O
osteoclast	B-cell_type
phenotypic	O
properties	O
,	O
arises	O
selectively	O
under	O
simple	O
culture	O
conditions	O
from	O
normal	O
PBMC	B-cell_type
.	O

Further	O
characterization	O
of	O
these	O
cells	O
should	O
identify	O
factors	O
involved	O
in	O
the	O
growth	O
,	O
terminal	O
differentiation	O
and	O
activation	O
of	O
osteoclasts	B-cell_type
.	O

Oleic	O
acid	O
inhibits	O
endothelial	O
activation	O
:	O
A	O
direct	O
vascular	O
antiatherogenic	O
mechanism	O
of	O
a	O
nutritional	O
component	O
in	O
the	O
mediterranean	O
diet	O
.	O

Because	O
oleic	O
acid	O
is	O
implicated	O
in	O
the	O
antiatherogenic	O
effects	O
attributed	O
to	O
the	O
Mediterranean	O
diet	O
,	O
we	O
investigated	O
whether	O
this	O
fatty	O
acid	O
can	O
modulate	O
endothelial	O
activation	O
,	O
ie	O
,	O
the	O
concerted	O
expression	O
of	O
gene	B-protein
products	I-protein
involved	O
in	O
leukocyte	O
recruitment	O
and	O
early	O
atherogenesis	O
.	O

We	O
incubated	O
sodium	O
oleate	O
with	O
human	B-cell_type
umbilical	I-cell_type
vein	I-cell_type
endothelial	I-cell_type
cells	I-cell_type
for	O
0	O
to	O
72	O
hours	O
,	O
followed	O
by	O
coincubation	O
of	O
oleate	O
with	O
human	B-protein
recombinant	I-protein
tumor	I-protein
necrosis	I-protein
factor	I-protein
,	O
interleukin	B-protein
(	I-protein
IL	I-protein
)	I-protein
-1alpha	I-protein
,	O
IL-1beta	B-protein
,	O
IL-4	B-protein
,	O
Escherichia	O
coli	O
lipopolysaccharide	O
(	O
LPS	O
)	O
,	O
or	O
phorbol	O
12-myristate	O
13-acetate	O
for	O
a	O
further	O
6	O
to	O
24	O
hours	O
.	O

The	O
endothelial	O
expression	O
of	O
vascular	B-protein
cell	I-protein
adhesion	I-protein
molecule-1	I-protein
(	O
VCAM-1	B-protein
)	O
,	O
E-selectin	B-protein
,	O
and	O
intercellular	B-protein
adhesion	I-protein
molecule-1	I-protein
was	O
monitored	O
by	O
cell	O
surface	O
enzyme	O
immunoassays	O
or	O
flow	O
cytometry	O
,	O
and	O
steady-state	O
levels	O
of	O
VCAM-1	B-RNA
mRNA	I-RNA
were	O
assessed	O
by	O
Northern	O
blot	O
analysis	O
.	O

At	O
10	O
to	O
100	O
micromol/L	O
for	O
>	O
24	O
hours	O
,	O
oleate	O
inhibited	O
the	O
expression	O
of	O
all	O
adhesion	B-protein
molecules	I-protein
tested	O
.	O

After	O
a	O
72-hour	O
incubation	O
with	O
oleate	O
and	O
a	O
further	O
16-hour	O
incubation	O
with	O
oleate	O
plus	O
1	O
microg/mL	O
LPS	O
,	O
VCAM-1	B-protein
expression	O
was	O
reduced	O
by	O
>	O
40	O
%	O
compared	O
with	O
control	O
.	O

Adhesion	O
of	O
monocytoid	B-cell_line
U937	I-cell_line
cells	I-cell_line
to	O
LPS-treated	O
endothelial	O
cells	O
was	O
reduced	O
concomitantly	O
.	O

Oleate	O
also	O
produced	O
a	O
quantitatively	O
similar	O
reduction	O
of	O
VCAM-1	B-RNA
mRNA	I-RNA
levels	O
on	O
Northern	O
blot	O
analysis	O
and	O
inhibited	O
nuclear	B-protein
factor-kappaB	I-protein
activation	O
on	O
electrophoretic	O
mobility	O
shift	O
assays	O
.	O

Incubation	O
of	O
endothelial	B-cell_type
cells	I-cell_type
with	O
oleate	O
for	O
72	O
hours	O
decreased	O
the	O
relative	O
proportions	O
of	O
saturated	O
(	O
palmitic	O
and	O
stearic	O
)	O
acids	O
in	O
total	O
cell	O
lipids	O
and	O
increased	O
the	O
proportions	O
of	O
oleate	O
in	O
total	O
cell	O
lipids	O
without	O
significantly	O
changing	O
the	O
relative	O
proportions	O
of	O
polyunsaturated	O
fatty	O
acids	O
.	O

Although	O
less	O
potent	O
than	O
polyunsaturated	O
fatty	O
acids	O
in	O
inhibiting	O
endothelial	O
activation	O
,	O
oleic	O
acid	O
may	O
contribute	O
to	O
the	O
prevention	O
of	O
atherogenesis	O
through	O
selective	O
displacement	O
of	O
saturated	O
fatty	O
acids	O
in	O
cell	O
membrane	O
phospholipids	O
and	O
a	O
consequent	O
modulation	O
of	O
gene	O
expression	O
for	O
molecules	O
involved	O
in	O
monocyte	O
recruitment	O
.	O

Both	O
Stat3	B-protein
-activation	O
and	O
Stat3	B-protein
-independent	O
BCL2	B-protein
downregulation	O
are	O
important	O
for	O
interleukin-6	B-protein
-induced	O
apoptosis	O
of	O
1A9-M	B-cell_line
cells	I-cell_line
.	O

A	O
unique	O
subclone	O
of	O
a	O
bone	B-cell_line
marrow-derived	I-cell_line
stromal	I-cell_line
cell	I-cell_line
line	I-cell_line
,	O
BMS2.4	B-cell_line
,	O
produces	O
soluble	B-protein
factors	I-protein
that	O
inhibit	O
proliferation	O
of	O
several	O
types	O
of	O
hematopoietic	B-cell_line
cell	I-cell_line
lines	I-cell_line
.	O

An	O
understanding	O
of	O
these	O
molecules	O
may	O
be	O
informative	O
about	O
negative	O
regulatory	O
circuits	O
that	O
can	O
potentially	O
limit	O
blood	O
cell	O
formation	O
.	O

We	O
used	O
expression	O
cloning	O
to	O
identify	O
interleukin-6	B-protein
(	O
IL-6	B-protein
)	O
as	O
one	O
factor	O
that	O
suppressed	O
growth	O
of	O
a	O
pre-B-cell	B-cell_line
variant	I-cell_line
line	I-cell_line
,	O
1A9-M	B-cell_line
.	O

Moreover	O
,	O
IL-6	B-protein
induced	O
macrophage-differentiation	O
and	O
apoptosis	O
of	O
1A9-M	B-cell_line
cells	I-cell_line
.	O

During	O
this	O
process	O
,	O
IL-6	B-protein
downregulated	O
expression	O
of	O
BCL2	B-protein
in	O
1A9-M	B-cell_line
cells	I-cell_line
and	O
stimulated	O
BCL-XL	O
expression	O
,	O
but	O
had	O
no	O
effect	O
on	O
p53	O
,	O
Bax	O
,	O
or	O
Bak	O
gene	O
expression	O
.	O

Mechanisms	O
for	O
transduction	O
of	O
IL-6	B-protein
-induced	O
signals	O
were	O
then	O
evaluated	O
in	O
IL-6-stimulated	B-cell_line
1A9-M	I-cell_line
cells	I-cell_line
.	O

Whereas	O
the	O
signal	B-protein
transducer	I-protein
and	I-protein
activator	I-protein
of	I-protein
transcription	I-protein
3	I-protein
(	O
Stat3	B-protein
)	O
was	O
phosphorylated	O
and	O
activated	O
,	O
there	O
was	O
no	O
effect	O
on	O
either	O
Stat1	B-protein
or	O
Stat5	B-protein
.	O

The	O
importance	O
of	O
BCL2	B-protein
and	O
Stat3	B-protein
on	O
IL-6	B-protein
-induced	O
macrophage-differentiation	O
and	O
apoptosis	O
was	O
studied	O
with	O
1A9-M	B-cell_line
cells	I-cell_line
expressing	O
human	B-protein
BCL2	I-protein
or	O
a	O
dominant-negative	O
form	O
of	O
Stat3	B-protein
,	O
respectively	O
.	O

IL-6	B-protein
-induced	O
apoptosis	O
,	O
but	O
not	O
macrophage-differentiation	O
,	O
was	O
blocked	O
by	O
continuously	O
expressed	O
BCL2	B-protein
.	O

A	O
dominant-negative	B-protein
form	I-protein
of	I-protein
Stat3	I-protein
inhibited	O
both	O
macrophage-differentiation	O
and	O
apoptosis	O
induced	O
by	O
IL-6	B-protein
.	O

However	O
,	O
diminished	O
Stat3	B-protein
activity	O
did	O
not	O
prevent	O
IL-6	B-protein
-induced	O
downregulation	O
of	O
the	O
BCL2	B-DNA
gene	I-DNA
.	O

Therefore	O
,	O
activation	O
of	O
Stat3	B-protein
is	O
essential	O
for	O
IL-6	B-protein
-induced	O
macrophage-differentiation	O
and	O
programmed	O
cell	O
death	O
in	O
this	O
model	O
.	O

Whereas	O
overexpression	O
of	O
BCL2	B-protein
abrogates	O
the	O
apoptotic	O
response	O
,	O
Stat3	B-protein
-independent	O
signals	O
appear	O
to	O
downregulate	O
expression	O
of	O
the	O
BCL2	B-DNA
gene	I-DNA
.	O

Involvement	O
of	O
mitogen-activated	B-protein
protein	I-protein
kinase	I-protein
pathways	O
in	O
interleukin-8	B-protein
production	O
by	O
human	B-cell_type
monocytes	I-cell_type
and	O
polymorphonuclear	B-cell_type
cells	I-cell_type
stimulated	O
with	O
lipopolysaccharide	O
or	O
Mycoplasma	B-protein
fermentans	I-protein
membrane	I-protein
lipoproteins	I-protein
.	O

Interleukin-8	B-protein
(	O
IL-8	B-protein
)	O
is	O
a	O
chemokine	B-protein
that	O
belongs	O
to	O
the	O
alpha-chemokine	B-protein
or	O
CXC	B-protein
subfamily	I-protein
and	O
is	O
produced	O
by	O
a	O
wide	O
variety	O
of	O
human	O
cells	O
,	O
including	O
monocytes	B-cell_type
and	O
polymorphonuclear	B-cell_type
cells	I-cell_type
(	O
PMN	B-cell_type
)	O
.	O

IL-8	B-protein
is	O
secreted	O
in	O
response	O
to	O
inflammatory	O
stimuli	O
,	O
notably	O
bacterial	O
products	O
such	O
as	O
lipopolysaccharide	O
(	O
LPS	O
)	O
,	O
but	O
little	O
is	O
known	O
about	O
the	O
mechanisms	O
by	O
which	O
these	O
agents	O
mediate	O
IL-8	B-protein
induction	O
.	O

In	O
this	O
report	O
,	O
we	O
show	O
that	O
Mycoplasma	B-protein
fermentans	I-protein
lipid-associated	I-protein
membrane	I-protein
proteins	I-protein
(	O
LAMPf	B-protein
)	O
induce	O
the	O
production	O
of	O
high	O
levels	O
of	O
IL-8	B-protein
by	O
THP-1	B-cell_line
(	I-cell_line
human	I-cell_line
monocyte	I-cell_line
)	I-cell_line
cells	I-cell_line
and	O
PMN	B-cell_type
at	O
the	O
same	O
extent	O
as	O
LPS	O
.	O

It	O
was	O
previously	O
demonstrated	O
that	O
stimulation	O
of	O
monocytic	O
cells	O
with	O
either	O
LPS	O
or	O
LAMPf	B-protein
led	O
to	O
a	O
series	O
of	O
common	O
downstream	O
signaling	O
events	O
,	O
including	O
the	O
activation	O
of	O
protein	B-protein
tyrosine	I-protein
kinase	I-protein
and	O
of	O
mitogen-activated	B-protein
protein	I-protein
kinase	I-protein
cascades	O
.	O

By	O
using	O
PD-98059	O
and	O
SB203580	O
,	O
two	O
potent	O
and	O
selective	O
inhibitors	O
of	O
MEK1	B-protein
(	O
a	O
kinase	B-protein
upstream	O
of	O
ERK1/2	B-protein
)	O
and	O
p38	B-protein
,	O
respectively	O
,	O
we	O
have	O
demonstrated	O
that	O
both	O
ERK1/2	O
and	O
p38	O
cascades	O
play	O
a	O
key	O
role	O
in	O
the	O
production	O
of	O
IL-8	B-protein
by	O
monocytes	B-cell_type
and	O
PMN	B-cell_type
stimulated	O
with	O
bacterial	O
fractions	O
.	O

Regulation	O
of	O
IL-6	B-protein
synthesis	O
in	O
human	B-cell_type
peripheral	I-cell_type
blood	I-cell_type
mononuclear	I-cell_type
cells	I-cell_type
by	O
C3a	B-protein
and	O
C3a	B-protein
(	I-protein
desArg	I-protein
)	I-protein
.	O

The	O
anaphylatoxin	B-protein
C3a	B-protein
has	O
been	O
reported	O
to	O
have	O
immunomodulatory	O
effects	O
on	O
a	O
number	O
of	O
different	O
cell	O
types	O
.	O

In	O
this	O
study	O
we	O
investigated	O
the	O
effects	O
of	O
C3a	B-protein
and	O
C3a	B-protein
(	I-protein
desArg	I-protein
)	I-protein
on	O
gene	O
expression	O
and	O
protein	O
secretion	O
of	O
IL-6	B-protein
in	O
human	O
PBMCs	B-cell_type
,	O
either	O
alone	O
or	O
in	O
combination	O
with	O
LPS	O
or	O
IL-1beta	B-protein
.	O

C3a	B-protein
or	O
C3a	B-protein
(	I-protein
desArg	I-protein
)	I-protein
alone	O
exhibited	O
no	O
effect	O
on	O
the	O
expression	O
or	O
secretion	O
of	O
IL-6	B-protein
.	O

However	O
,	O
when	O
PBMC	B-cell_type
were	O
stimulated	O
with	O
LPS	O
or	O
IL-1beta	B-protein
,	O
both	O
C3a	B-protein
and	O
C3a	B-protein
(	I-protein
desArg	I-protein
)	I-protein
were	O
found	O
to	O
enhance	O
IL-6	B-protein
release	O
by	O
PBMC	B-cell_type
in	O
a	O
dose-dependent	O
manner	O
.	O

Since	O
C3a	B-protein
has	O
been	O
shown	O
to	O
induce	O
PGE2	O
production	O
by	O
monocytes	B-cell_type
,	O
and	O
PGE2	O
has	O
been	O
shown	O
to	O
influence	O
cytokine	O
production	O
,	O
we	O
investigated	O
the	O
potential	O
role	O
of	O
PGE2	O
in	O
C3a	B-protein
-mediated	O
enhancement	O
of	O
LPS-	O
and	O
IL-1beta-induced	O
IL-6	O
production	O
.	O

Indomethacin	O
blocked	O
PGE2	O
release	O
,	O
but	O
had	O
no	O
influence	O
on	O
the	O
observed	O
effects	O
of	O
C3a	B-protein
,	O
suggesting	O
that	O
the	O
effects	O
of	O
C3a	B-protein
on	O
IL-6	B-protein
production	O
are	O
independent	O
of	O
PGE2	O
formation	O
by	O
monocytes	B-cell_type
.	O

Northern	O
blot	O
analysis	O
showed	O
that	O
C3a	B-protein
as	O
well	O
as	O
C3a	B-protein
(	I-protein
desArg	I-protein
)	I-protein
enhanced	O
LPS	O
-induced	B-RNA
mRNA	I-RNA
levels	O
for	O
IL-6	B-protein
.	O

Pretreatment	O
of	O
PBMCs	B-cell_type
with	O
pertussis	B-protein
toxin	I-protein
blocked	O
the	O
functions	O
of	O
C3a	B-protein
and	O
C3a	B-protein
(	I-protein
desArg	I-protein
)	I-protein
,	O
indicating	O
that	O
the	O
actions	O
of	O
these	O
two	O
molecules	O
are	O
mediated	O
by	O
a	O
G	B-protein
protein	I-protein
-coupled	O
pathway	O
.	O

Furthermore	O
,	O
we	O
investigated	O
the	O
effects	O
of	O
C3a	B-protein
and	O
C3a	B-protein
(	I-protein
desArg	I-protein
)	I-protein
on	O
induction	O
of	O
NF-kappaB	B-protein
and	O
activating	B-protein
protein-1	I-protein
binding	O
.	O

Both	O
molecules	O
enhanced	O
LPS-induced	O
NF-kappaB	B-protein
and	O
activating	B-protein
protein-1	I-protein
binding	O
activity	O
.	O

These	O
results	O
demonstrate	O
the	O
capacity	O
of	O
intact	O
C3a	B-protein
and	O
its	O
circulating	O
des-Arg	B-protein
form	I-protein
to	O
exert	O
immunmodulatory	O
effects	O
in	O
vitro	O
.	O

Phenylarsine	O
oxide	O
inhibits	O
ex	O
vivo	O
HIV-1	O
expression	O
.	O

Phenylarsine	O
oxide	O
(	O
PAO	O
)	O
,	O
which	O
is	O
described	O
as	O
an	O
inhibitor	O
of	O
tyrosine	B-protein
phosphatase	I-protein
activity	O
,	O
inhibits	O
H2O2	O
release	O
from	O
human	B-cell_type
peripheral	I-cell_type
blood	I-cell_type
mononuclear	I-cell_type
cells	I-cell_type
(	O
PBMCs	B-cell_type
)	O
as	O
measured	O
by	O
electrochemistry	O
.	O

Since	O
human	O
immunodeficiency	O
virus	O
type	O
1	O
(	O
HIV-1	O
)	O
replication	O
is	O
known	O
to	O
be	O
favored	O
under	O
oxidative	O
stress	O
conditions	O
,	O
ex	O
vivo	O
experiments	O
using	O
uninfected	O
PBMCs	B-cell_type
,	O
primary	B-cell_type
monocytes	I-cell_type
or	O
a	O
latently	O
infected	O
promonocytic	B-cell_line
U1	I-cell_line
cell	I-cell_line
line	I-cell_line
show	O
that	O
HIV-1	O
replication	O
and	O
reactivation	O
,	O
monitored	O
by	O
p24	B-protein
antigen	I-protein
measurement	O
,	O
are	O
inhibited	O
by	O
PAO	O
in	O
a	O
time-	O
and	O
concentration-dependent	O
manner	O
.	O

These	O
observations	O
can	O
be	O
linked	O
with	O
the	O
inhibition	O
of	O
NF-kappa	B-protein
B	I-protein
activation	O
when	O
uninfected	O
monocytes	O
are	O
induced	O
by	O
either	O
tumor	B-protein
necrosis	I-protein
factor	I-protein
alpha	I-protein
(	O
TNF-alpha	B-protein
)	O
phorbol	O
12-myristate	O
13-acetate	O
(	O
PMA	O
)	O
or	O
lipopolysaccharide	O
(	O
LPS	O
)	O
.	O

Pharmacological	O
control	O
of	O
antigen	O
responsiveness	O
in	O
genetically	B-cell_line
modified	I-cell_line
T	I-cell_line
lymphocytes	I-cell_line
.	O

A	O
chimeric	B-DNA
TCR	I-DNA
gene	I-DNA
,	O
comprising	O
an	O
anti-hapten	B-protein
single-chain	I-protein
Ab	I-protein
variable	I-protein
fragment	I-protein
fused	O
to	O
the	O
transmembrane	B-protein
and	I-protein
cytoplasmic	I-protein
regions	I-protein
of	O
the	O
human	B-protein
TCR	I-protein
zeta-chain	I-protein
,	O
was	O
used	O
to	O
determine	O
whether	O
the	O
tetracycline-regulatable	O
system	O
could	O
be	O
used	O
to	O
regulate	O
gene	O
expression	O
in	O
T	B-cell_type
cells	I-cell_type
.	O

Jurkat	B-cell_line
T	I-cell_line
cells	I-cell_line
were	O
stably	O
transfected	O
with	O
a	O
single	O
vector	O
encoding	O
the	O
tetracycline	B-protein
trans-activator	I-protein
protein	I-protein
,	O
controlled	O
by	O
a	O
constitutive	B-DNA
promoter	I-DNA
,	O
and	O
the	O
chimeric	B-protein
TCR	I-protein
,	O
under	O
the	O
control	O
of	O
a	O
trans-activator	B-DNA
protein-responsive	I-DNA
promoter	I-DNA
.	O

In	O
the	O
absence	O
of	O
tetracyclines	O
,	O
the	O
transfected	O
T	B-cell_type
cells	I-cell_type
were	O
shown	O
to	O
express	O
the	O
chimeric	B-protein
receptor	I-protein
on	O
the	O
cell	O
surface	O
and	O
could	O
be	O
activated	O
by	O
its	O
cognate	B-protein
Ag	I-protein
,	O
leading	O
to	O
the	O
secretion	O
of	O
IL-2	B-protein
.	O

When	O
the	O
cells	O
were	O
exposed	O
to	O
increasing	O
concentrations	O
of	O
tetracyclines	O
,	O
surface	O
expression	O
of	O
the	O
chimeric	B-protein
receptor	I-protein
was	O
suppressed	O
in	O
a	O
dose-dependent	O
manner	O
,	O
and	O
this	O
suppression	O
was	O
sufficient	O
to	O
result	O
in	O
complete	O
loss	O
of	O
responsiveness	O
to	O
the	O
targeted	B-protein
Ag	I-protein
.	O

Prolonged	O
suppression	O
of	O
trans-gene	O
expression	O
for	O
up	O
to	O
7	O
days	O
was	O
observed	O
after	O
doxycycline	O
was	O
removed	O
from	O
the	O
cultures	O
,	O
but	O
eventual	O
recovery	O
of	O
surface	O
expression	O
was	O
complete	O
,	O
and	O
the	O
absolute	O
time	O
to	O
recovery	O
was	O
directly	O
proportional	O
to	O
the	O
initial	O
concentration	O
of	O
the	O
drug	O
.	O

Pharmacologic	O
control	O
of	O
trans-gene	O
expression	O
in	O
gene-modified	B-cell_line
T	I-cell_line
cells	I-cell_line
will	O
not	O
only	O
facilitate	O
new	O
approaches	O
to	O
the	O
study	O
of	O
different	O
aspects	O
of	O
T	O
cell	O
biology	O
,	O
but	O
will	O
also	O
provide	O
the	O
basis	O
for	O
new	O
gene	O
therapy	O
strategies	O
.	O

Glucocorticoid	B-protein
receptors	I-protein
,	O
fibromyalgia	O
and	O
low	O
back	O
pain	O
.	O

Recently	O
,	O
fibromyalgia	O
(	O
FMS	O
)	O
was	O
shown	O
to	O
be	O
a	O
disorder	O
associated	O
with	O
an	O
altered	O
functioning	O
of	O
the	O
stress	O
response	O
system	O
.	O

FMS	O
patients	O
display	O
a	O
hyperreactive	O
pituitary	O
adrenocorticotropic	O
hormone	O
(	O
ACTH	O
)	O
release	O
in	O
response	O
to	O
corticotropin-releasing	O
hormone	O
(	O
CRH	O
)	O
and	O
to	O
insulin-induced	O
hypoglycemia	O
.	O

We	O
suggested	O
that	O
negative	O
feedback	O
of	O
cortisol	O
could	O
be	O
deranged	O
.	O

Therefore	O
we	O
investigated	O
the	O
properties	O
and	O
function	O
of	O
the	O
glucocorticoid	B-protein
receptors	I-protein
(	O
GR	B-protein
)	O
in	O
FMS	O
patients	O
and	O
compared	O
the	O
results	O
with	O
those	O
of	O
healthy	O
persons	O
and	O
patients	O
with	O
chronic	O
low	O
back	O
pain	O
(	O
LBP	O
a	O
localized	O
pain	O
condition	O
)	O
.	O

Forty	O
primary	O
FMS	O
patients	O
(	O
F	O
:	O
M	O
=	O
36	O
:	O
4	O
)	O
,	O
28	O
LBP	O
patients	O
(	O
25	O
:	O
3	O
)	O
and	O
14	O
(	O
12	O
:	O
2	O
)	O
healthy	O
,	O
sedentary	O
control	O
persons	O
were	O
recruited	O
for	O
the	O
study	O
.	O

Urinary	O
free	O
cortisol	O
excretion	O
in	O
FMS	O
and	O
LBP	O
patients	O
was	O
lower	O
compared	O
to	O
controls	O
.	O

Only	O
FMS	O
patients	O
displayed	O
lower	O
CBG	O
and	O
basal	O
serum	O
cortisol	O
concentrations	O
when	O
compared	O
to	O
controls	O
.	O

However	O
,	O
plasma	O
free	O
cortisol	O
concentrations	O
were	O
similar	O
in	O
the	O
three	O
groups	O
.	O

There	O
was	O
no	O
difference	O
in	O
the	O
number	O
of	O
GR	B-protein
per	O
cell	O
among	O
the	O
three	O
groups	O
(	O
FMS	O
:	O
6498	O
+/-	O
252	O
,	O
LBP	O
:	O
6625	O
+/-	O
284	O
,	O
controls	O
:	O
6576	O
+/-	O
304	O
)	O
,	O
but	O
the	O
dissociation	O
constant	O
(	O
Kd	O
)	O
of	O
the	O
FMS	O
(	O
14.5	O
+/-	O
0.9	O
nmol/l	O
)	O
and	O
LBP	O
(	O
14.7	O
+/-	O
1.3	O
nmol/l	O
)	O
subjects	O
was	O
significantly	O
higher	O
than	O
that	O
of	O
the	O
controls	O
(	O
10.9	O
+/-	O
0.8	O
nmol/l	O
)	O
(	O
p	O
<	O
.05	O
)	O
.	O

The	O
maximal	O
stimulation	O
of	O
the	O
lymphocytes	B-cell_type
,	O
as	O
measured	O
by	O
the	O
maximal	O
thymidine	O
incorporation	O
(	O
in	O
the	O
absence	O
of	O
cortisol	O
)	O
in	O
the	O
FMS	O
group	O
was	O
approximately	O
1.5	O
times	O
higher	O
(	O
p	O
<	O
.05	O
)	O
than	O
in	O
the	O
control	O
or	O
LBP	O
group	O
.	O

The	O
ED50	O
(	O
the	O
cortisol	O
concentration	O
giving	O
50	O
%	O
inhibition	O
of	O
the	O
thymidine	O
incorporation	O
)	O
,	O
however	O
,	O
was	O
identical	O
in	O
all	O
three	O
groups	O
.	O

We	O
conclude	O
that	O
FMS	O
patients	O
have	O
a	O
mild	O
hypocortisolemia	O
,	O
increased	O
cortisol	O
feedback	O
resistance	O
in	O
combination	O
probably	O
with	O
a	O
reduced	O
CRH	O
synthesis	O
or	O
release	O
in	O
the	O
hypothalamus	O
.	O

The	O
role	O
of	O
the	O
GR	B-protein
and	O
mineralocorticoid	B-protein
receptor	I-protein
(	O
MR	B-protein
)	O
in	O
the	O
CRH	O
regulation	O
in	O
the	O
FMS	O
patients	O
remains	O
to	O
be	O
solved	O
.	O

Temporal	O
control	O
of	O
IgH	B-DNA
gene	I-DNA
expression	O
in	O
developing	B-cell_type
B	I-cell_type
cells	I-cell_type
by	O
the	O
3	B-DNA
'	I-DNA
locus	I-DNA
control	I-DNA
region	I-DNA
.	O

The	O
suggested	O
roles	O
of	O
the	O
downstream	B-DNA
3	I-DNA
'	I-DNA
regions	I-DNA
acting	O
as	O
a	O
Locus	B-DNA
Control	I-DNA
Region	I-DNA
(	O
LCR	B-DNA
)	O
,	O
have	O
allowed	O
comparisons	O
to	O
be	O
made	O
between	O
the	O
regulation	O
of	O
the	O
IgH	B-DNA
locus	I-DNA
with	O
other	O
model	O
systems	O
whose	O
gene	O
expression	O
is	O
governed	O
by	O
LCR	B-DNA
activity	O
.	O

Here	O
we	O
summarize	O
the	O
importance	O
of	O
the	O
IgH	B-DNA
3'LCR	I-DNA
and	O
its	O
putative	O
functional	O
role	O
in	O
IgH	B-DNA
gene	I-DNA
expression	O
and	O
compare	O
it	O
with	O
the	O
5'LCR	B-DNA
regulatory	I-DNA
region	I-DNA
of	O
the	O
human	B-DNA
beta-globin	I-DNA
locus	I-DNA
.	O

HLA	O
binding	O
characteristics	O
and	O
generation	O
of	O
cytotoxic	B-cell_type
lymphocytes	I-cell_type
against	O
peptides	O
derived	O
from	O
oncogenic	B-protein
proteins	I-protein
.	O

AIMS	O
AND	O
BACKGROUND	O
:	O
Structurally	O
altered	O
proteins	O
(	O
derived	O
from	O
chromosomal	O
translocations	O
or	O
gene	O
mutations	O
)	O
can	O
be	O
considered	O
tumor	O
specific	O
antigens	O
and	O
represent	O
an	O
attractive	O
target	O
for	O
a	O
T-cell	O
mediated	O
response	O
.	O

T	O
lymphocytes	O
recognize	O
antigens	O
in	O
the	O
form	O
of	O
peptides	O
bound	O
to	O
HLA-molecules	B-protein
.	O

MATERIALS	O
AND	O
METHODS	O
:	O
Peptides	O
derived	O
from	O
oncogenic	B-protein
proteins	I-protein
were	O
screened	O
for	O
the	O
presence	O
of	O
HLA	B-protein
binding	I-protein
motifs	I-protein
;	O
actual	O
binding	O
were	O
evaluated	O
by	O
HLA	O
stabilization	O
experiments	O
using	O
transfectants	O
and	O
specific	O
anti-HLA	B-protein
antibodies	I-protein
.	O

Specific	O
lymphocytes	B-cell_type
were	O
induced	O
by	O
in	O
vitro	O
peptide	O
sensitization	O
and	O
screened	O
by	O
thymidine	O
uptake	O
or	O
cellular	O
cytotoxic	O
assays	O
.	O

RESULTS	O
:	O
We	O
identified	O
peptides	O
derived	O
from	O
EWS/FLI-1	B-protein
fusion	I-protein
protein	I-protein
and	O
from	O
mutated	B-protein
K-RAS	I-protein
protein	I-protein
(	O
encompassing	O
respectively	O
the	O
fusion	B-protein
point	I-protein
and	O
the	O
mutation	O
at	O
position	B-protein
12	I-protein
)	O
that	O
showed	O
binding	B-protein
motif	I-protein
for	O
HLA-Cw*0702	B-protein
and	O
HLA-A3	B-protein
respectively	O
.	O

The	O
actual	O
binding	O
of	O
these	O
peptides	O
was	O
analysed	O
in	O
a	O
stabilization	O
assay	O
.	O

We	O
detected	O
binding	O
for	O
the	O
EWS/FLI-1	O
peptide	O
and	O
for	O
5	O
RAS	O
peptides	O
(	O
1	O
wild	O
type	O
and	O
4	O
mutated	O
)	O
.	O

The	O
effect	O
of	O
temperature	O
,	O
beta	B-protein
2-microglobulin	I-protein
(	O
beta	B-protein
2-m	I-protein
)	O
and	O
fetal	O
calf	O
serum	O
(	O
FCS	O
)	O
on	O
the	O
binding	O
and	O
the	O
stability	O
of	O
the	O
HLA/peptide	B-protein
complex	I-protein
was	O
studied	O
.	O

A	O
low	O
temperature	O
(	O
26	O
degrees	O
C	O
)	O
increased	O
the	O
binding	O
both	O
in	O
HLA-A3	B-protein
and	O
HLA-Cw*0702	B-protein
,	O
while	O
FCS	O
reduced	O
it	O
.	O

beta	B-protein
2-m	I-protein
increased	O
the	O
binding	O
to	O
the	O
HLA-A3	B-protein
molecule	I-protein
but	O
did	O
not	O
influence	O
the	O
binding	O
to	O
the	O
HLA-Cw*0702	B-protein
.	O

The	O
stability	O
of	O
already	O
formed	O
complexed	O
was	O
somewhat	O
different	O
in	O
the	O
HLA-A3	B-protein
and	O
HLA-Cw*0702	B-protein
system	O
:	O
both	O
were	O
more	O
stable	O
at	O
26	O
degrees	O
C	O
than	O
at	O
37	O
degrees	O
C	O
but	O
while	O
the	O
beta	B-protein
2-m	I-protein
and	O
FCS	O
did	O
not	O
influence	O
the	O
stability	O
of	O
the	O
HLA-A3/peptide	B-protein
complex	I-protein
,	O
they	O
seemed	O
to	O
cause	O
opposite	O
effects	O
in	O
the	O
HLA-Cw*0702	B-protein
system	O
(	O
beta	B-protein
2-m	I-protein
stabilized	O
and	O
FCS	O
destabilized	O
the	O
complex	O
)	O
.	O

Finally	O
,	O
we	O
were	O
able	O
to	O
generate	O
a	O
specific	O
CD8+	B-cell_line
CTL	I-cell_line
line	I-cell_line
against	O
a	O
K-RAS	O
mutated	O
peptide	O
.	O

CONCLUSIONS	O
:	O
Although	O
binding	B-protein
motifs	I-protein
and	O
actual	O
HLA	O
binding	O
can	O
be	O
detected	O
in	O
several	O
cases	O
,	O
the	O
generation	O
of	O
a	O
cellular	O
response	O
is	O
infrequent	O
,	O
confirming	O
that	O
HLA	O
binding	O
is	O
necessary	O
but	O
not	O
sufficient	O
to	O
obtain	O
an	O
in	O
vitro	O
response	O
.	O

Further	O
optimization	O
of	O
culture	O
conditions	O
,	O
type	O
of	O
Antigen	B-cell_type
Presenting	I-cell_type
Cells	I-cell_type
(	O
APC	B-cell_type
)	O
,	O
peptides	O
,	O
use	O
of	O
stabilizers	O
like	O
beta	B-protein
2-m	I-protein
are	O
still	O
needed	O
.	O

OCA-B	B-protein
is	O
a	O
functional	O
analog	O
of	O
VP16	B-protein
but	O
targets	O
a	O
separate	O
surface	O
of	O
the	O
Oct-1	B-protein
POU	I-protein
domain	I-protein
[	O
published	O
erratum	O
appears	O
in	O
Mol	O
Cell	O
Biol	O
1998	O
Apr	O
;	O
18	O
(	O
4	O
)	O
:	O
2430	O
]	O

OCA-B	B-protein
is	O
a	O
B-cell-specific	B-protein
coregulator	I-protein
of	O
the	O
broadly	O
expressed	O
POU	B-protein
domain	I-protein
transcription	I-protein
factor	I-protein
Oct-1	B-protein
.	O

OCA-B	B-protein
associates	O
with	O
the	O
Oct-1	B-protein
POU	I-protein
domain	I-protein
,	O
a	O
bipartite	O
DNA-binding	O
structure	O
containing	O
a	O
POU-specific	B-protein
(	I-protein
POU	I-protein
[	I-protein
S	I-protein
]	I-protein
)	I-protein
domain	I-protein
joined	O
by	O
a	O
flexible	O
linker	O
to	O
a	O
POU	B-protein
homeodomain	I-protein
(	O
POU	B-protein
[	I-protein
H	I-protein
]	I-protein
)	O
.	O

Here	O
,	O
we	O
show	O
that	O
OCA-B	B-protein
alters	O
the	O
activity	O
of	O
Oct-1	B-protein
in	O
two	O
ways	O
.	O

It	O
provides	O
a	O
transcriptional	O
activation	O
domain	O
which	O
,	O
unlike	O
Oct-1	B-protein
,	O
activates	O
an	O
mRNA-type	B-DNA
promoter	I-DNA
effectively	O
,	O
and	O
it	O
stabilizes	O
Oct-1	B-protein
on	O
the	O
Oct-1-responsive	B-DNA
octamer	I-DNA
sequence	I-DNA
ATGCAAAT	O
.	O

These	O
properties	O
of	O
OCA-B	B-protein
parallel	O
those	O
displayed	O
by	O
the	O
herpes	B-protein
simplex	I-protein
virus	I-protein
Oct-1	I-protein
coregulator	I-protein
VP16	B-protein
.	O

OCA-B	B-protein
,	O
however	O
,	O
interacts	O
with	O
a	O
different	O
surface	O
of	O
the	O
DNA-bound	O
Oct-1	B-protein
POU	I-protein
domain	I-protein
,	O
interacting	O
with	O
both	O
the	O
POU	B-protein
(	I-protein
S	I-protein
)	I-protein
and	I-protein
POU	I-protein
(	I-protein
H	I-protein
)	I-protein
domains	I-protein
and	O
the	O
center	O
of	O
the	O
ATGCAAAT	B-DNA
octamer	I-DNA
sequence	I-DNA
.	O

The	O
OCA-B	O
and	O
VP16	B-protein
interactions	O
with	O
the	O
Oct-1	B-protein
POU	I-protein
domain	I-protein
are	O
sufficiently	O
different	O
to	O
permit	O
OCA-B	B-protein
and	O
VP16	B-protein
to	O
bind	O
the	O
Oct-1	B-protein
POU	I-protein
domain	I-protein
simultaneously	O
.	O

These	O
results	O
emphasize	O
the	O
structural	O
versatility	O
of	O
the	O
Oct-1	B-protein
POU	I-protein
domain	I-protein
in	O
its	O
interaction	O
with	O
coregulators	O
.	O

Phosphatidylinositol	B-protein
3-kinase	I-protein
couples	O
the	O
interleukin-2	B-protein
receptor	I-protein
to	O
the	O
cell	B-protein
cycle	I-protein
regulator	I-protein
E2F	B-protein
.	O

Cell	O
cycle	O
progression	O
initiated	O
by	O
interleukin-2	B-protein
(	O
IL-2	B-protein
)	O
in	O
T	B-cell_type
cells	I-cell_type
is	O
critical	O
for	O
lymphoproliferation	O
and	O
an	O
immune	O
response	O
.	O

Phosphatidyl	B-protein
inositol	I-protein
3-kinase	I-protein
(	O
PI3K	B-protein
)	O
is	O
activated	O
by	O
IL-2	B-protein
.	O

However	O
,	O
nuclear	O
targets	O
for	O
PI3K	B-protein
are	O
not	O
known	O
.	O

Here	O
we	O
identify	O
the	O
cell	B-protein
cycle	I-protein
regulator	I-protein
E2F	B-protein
as	O
an	O
IL-2	B-protein
target	O
in	O
T	O
lymphocytes	B-cell_type
and	O
PI3K	B-protein
as	O
the	O
critical	O
signaling	O
pathway	O
.	O

We	O
eliminate	O
both	O
Stat5	B-protein
and	O
Raf	B-protein
/MEK	B-protein
pathways	O
from	O
E2F	B-protein
regulation	O
.	O

Protein	B-protein
kinase	I-protein
B	I-protein
(	O
PKB	B-protein
)	O
is	O
activated	O
by	O
IL-2	B-protein
via	O
PI3K	B-protein
.	O

The	O
expression	O
of	O
an	O
active	O
PKB	B-protein
is	O
sufficient	O
to	O
induce	O
E2F	B-protein
activity	O
.	O

Inhibition	O
of	O
PI3K	B-protein
inhibits	O
phosphorylation	O
of	O
Rb	B-protein
,	O
induction	O
of	O
cyclin	B-protein
D3	I-protein
,	O
and	O
degradation	O
of	O
p27kip1	B-protein
.	O

These	O
results	O
establish	O
a	O
crucial	O
PI3K	B-protein
/	O
PKB	B-protein
-mediated	O
link	O
between	O
the	O
IL-2	B-protein
teceptor	I-protein
and	O
the	O
cell	O
cycle	O
machinery	O
.	O

The	O
Epstein-Barr	B-protein
virus	I-protein
oncogene	I-protein
product	I-protein
latent	B-protein
membrane	I-protein
protein	I-protein
1	I-protein
engages	O
the	O
tumor	O
necrosis	O
factor	O
receptor-associated	O
death	O
domain	O
protein	O
to	O
mediate	O
B	O
lymphocyte	O
growth	O
transformation	O
and	O
activate	O
NF-kappaB	O
.	O

The	O
Epstein-Barr	O
virus	O
latent	B-protein
membrane	I-protein
protein	I-protein
1	I-protein
(	O
LMP1	B-protein
)	O
is	O
essential	O
for	O
the	O
transformation	O
of	O
B	B-cell_type
lymphocytes	I-cell_type
into	O
lymphoblastoid	B-cell_line
cell	I-cell_line
lines	I-cell_line
.	O

Previous	O
data	O
are	O
consistent	O
with	O
a	O
model	O
that	O
LMP1	B-protein
is	O
a	O
constitutively	B-protein
activated	I-protein
receptor	I-protein
that	O
transduces	O
signals	O
for	O
transformation	O
through	O
its	O
carboxyl-terminal	B-protein
cytoplasmic	I-protein
tail	I-protein
.	O

One	O
transformation	B-protein
effector	I-protein
site	I-protein
(	O
TES1	B-protein
)	O
,	O
located	O
within	O
the	O
membrane	B-protein
proximal	I-protein
45	I-protein
residues	I-protein
of	O
the	O
cytoplasmic	O
tail	O
,	O
constitutively	O
engages	O
tumor	B-protein
necrosis	I-protein
factor	I-protein
receptor-associated	I-protein
factors	I-protein
.	O

Signals	O
from	O
TES1	B-protein
are	O
sufficient	O
to	O
drive	O
initial	O
proliferation	O
of	O
infected	O
resting	O
B	O
lymphocytes	B-cell_type
,	O
but	O
most	O
lymphoblastoid	B-cell_type
cells	I-cell_type
infected	O
with	O
a	O
virus	O
that	O
does	O
not	O
express	O
the	O
155	B-protein
residues	I-protein
beyond	O
TES1	B-protein
fail	O
to	O
grow	O
as	O
long-term	B-cell_line
cell	I-cell_line
lines	I-cell_line
.	O

We	O
now	O
find	O
that	O
mutating	O
two	O
tyrosines	O
to	O
an	O
isoleucine	O
at	O
the	O
carboxyl	B-protein
end	I-protein
of	O
the	O
cytoplasmic	B-protein
tail	I-protein
cripples	O
the	O
ability	O
of	O
EBV	O
to	O
cause	O
lymphoblastoid	O
cell	O
outgrowth	O
,	O
thereby	O
marking	O
a	O
second	O
transformation	B-protein
effector	I-protein
site	I-protein
,	O
TES2	B-protein
.	O

A	O
yeast	O
two-hybrid	O
screen	O
identified	O
TES2	B-protein
interacting	I-protein
proteins	I-protein
,	O
including	O
the	O
tumor	B-protein
necrosis	I-protein
factor	I-protein
receptor-associated	I-protein
death	I-protein
domain	I-protein
protein	I-protein
(	O
TRADD	B-protein
)	O
.	O

TRADD	B-protein
was	O
the	O
only	O
protein	O
that	O
interacted	O
with	O
wild-type	B-protein
TES2	I-protein
and	O
not	O
with	O
isoleucine-mutated	B-protein
TES2	I-protein
.	O

TRADD	B-protein
associated	O
with	O
wild-type	B-protein
LMP1	I-protein
but	O
not	O
with	O
isoleucine-mutated	O
LMP1	B-protein
in	O
mammalian	O
cells	O
,	O
and	O
TRADD	B-protein
constitutively	O
associated	O
with	O
LMP1	B-protein
in	O
EBV-transformed	B-cell_line
cells	I-cell_line
.	O

In	O
transfection	O
assays	O
,	O
TRADD	B-protein
and	O
TES2	B-protein
synergistically	O
mediated	O
high-level	O
NF-kappaB	B-protein
activation	O
.	O

These	O
results	O
indicate	O
that	O
LMP1	B-protein
appropriates	O
TRADD	B-protein
to	O
enable	O
efficient	O
long-term	O
lymphoblastoid	O
cell	O
outgrowth	O
.	O

High-level	O
NF-kappaB	B-protein
activation	O
also	O
appears	O
to	O
be	O
a	O
critical	O
component	O
of	O
long-term	O
outgrowth	O
.	O

Inhibition	O
of	O
T	B-cell_type
cell	I-cell_type
and	O
promotion	O
of	O
natural	O
killer	O
cell	O
development	O
by	O
the	O
dominant	B-protein
negative	I-protein
helix	I-protein
loop	I-protein
helix	I-protein
factor	I-protein
Id3	B-protein
.	O

Bipotential	B-cell_type
T/natural	I-cell_type
killer	I-cell_type
(	I-cell_type
NK	I-cell_type
)	I-cell_type
progenitor	I-cell_type
cells	I-cell_type
are	O
present	O
in	O
the	O
human	O
thymus	O
.	O

Despite	O
their	O
bipotential	O
capacity	O
,	O
these	O
progenitors	O
develop	O
predominantly	O
to	O
T	B-cell_type
cells	I-cell_type
in	O
the	O
thymus	O
.	O

The	O
mechanisms	O
controlling	O
this	O
developmental	O
choice	O
are	O
unknown	O
.	O

Here	O
we	O
present	O
evidence	O
that	O
a	O
member	O
(	O
s	O
)	O
of	O
the	O
family	O
of	O
basic	B-protein
helix	I-protein
loop	I-protein
helix	I-protein
(	I-protein
bHLH	I-protein
)	I-protein
transcription	I-protein
factors	I-protein
determines	O
lineage	O
specification	O
of	O
NK/T	B-cell_type
cell	I-cell_type
progenitors	I-cell_type
.	O

The	O
natural	O
dominant	B-protein
negative	I-protein
HLH	I-protein
factor	I-protein
Id3	B-protein
,	O
which	O
blocks	O
transcriptional	O
activity	O
of	O
a	O
number	O
of	O
known	O
bHLH	B-protein
factors	I-protein
,	O
was	O
expressed	O
in	O
CD34+	B-cell_type
progenitor	I-cell_type
cells	I-cell_type
by	O
retrovirus-mediated	O
gene	O
transfer	O
.	O

Constitutive	O
expression	O
of	O
Id3	B-protein
completely	O
blocks	O
development	O
of	O
CD34+	B-cell_type
cells	I-cell_type
into	O
T	B-cell_type
cells	I-cell_type
in	O
a	O
fetal	O
thymic	O
organ	O
culture	O
(	O
FTOC	O
)	O
.	O

In	O
contrast	O
,	O
development	O
into	O
NK	B-cell_type
cells	I-cell_type
in	O
an	O
FTOC	O
is	O
enhanced	O
.	O

Thus	O
,	O
the	O
activity	O
of	O
a	O
bHLH	B-protein
transcription	I-protein
factor	I-protein
is	O
necessary	O
for	O
T	O
lineage	O
differentiation	O
of	O
bipotential	B-cell_type
precursors	I-cell_type
,	O
in	O
the	O
absence	O
of	O
which	O
a	O
default	O
pathway	O
leading	O
to	O
NK	O
cell	O
development	O
is	O
chosen	O
.	O

Our	O
results	O
identify	O
a	O
molecular	O
switch	O
for	O
lineage	O
specification	O
in	O
early	B-cell_type
lymphoid	I-cell_type
precursors	I-cell_type
of	O
humans	O
.	O

Late	O
gene	O
expression	O
from	O
the	O
Epstein-Barr	O
virus	O
BcLF1	B-DNA
and	I-DNA
BFRF3	I-DNA
promoters	I-DNA
does	O
not	O
require	O
DNA	O
replication	O
in	O
cis	O
.	O

Late	O
gene	O
expression	O
follows	O
and	O
is	O
dependent	O
upon	O
lytic	O
replication	O
of	O
the	O
viral	B-DNA
genome	I-DNA
.	O

Although	O
experimental	O
evidence	O
is	O
lacking	O
,	O
lytic	O
viral	O
DNA	O
replication	O
is	O
believed	O
to	O
remove	O
modifications	O
or	O
binding	B-protein
factors	I-protein
from	O
the	O
genome	O
which	O
serve	O
to	O
repress	O
late	O
gene	O
expression	O
during	O
latency	O
or	O
the	O
early	O
lytic	O
cycle	O
.	O

We	O
have	O
developed	O
a	O
reporter	O
assay	O
to	O
begin	O
characterizing	O
the	O
mechanisms	O
that	O
regulate	O
late	O
gene	O
expression	O
in	O
Epstein-Barr	O
virus	O
(	O
EBV	O
)	O
.	O

In	O
this	O
model	O
system	O
,	O
the	O
activities	O
of	O
late	B-DNA
promoter-reporter	I-DNA
fusions	I-DNA
are	O
measured	O
following	O
transient	O
transfection	O
into	O
tissue	B-cell_line
culture	I-cell_line
cells	I-cell_line
expressing	O
EBV	O
during	O
different	O
stages	O
of	O
the	O
lytic	O
cycle	O
.	O

This	O
system	O
faithfully	O
recapitulates	O
late	O
expression	O
patterns	O
from	O
the	O
endogenous	O
virus	O
,	O
implicating	O
specific	O
cis-active	B-DNA
sequences	I-DNA
in	O
the	O
control	O
of	O
late	O
gene	O
expression	O
.	O

In	O
addition	O
,	O
these	O
promoters	O
respond	O
only	O
indirectly	O
to	O
the	O
viral	B-DNA
immediate-early	I-DNA
transactivator	I-DNA
,	O
ZEBRA	B-DNA
.	O

This	O
indirect	O
response	O
is	O
mediated	O
by	O
other	O
viral	O
or	O
virally	O
induced	O
activities	O
downstream	O
of	O
ZEBRA	B-DNA
in	O
the	O
lytic	O
cascade	O
.	O

In	O
this	O
system	O
,	O
late	O
gene	O
expression	O
is	O
sensitive	O
to	O
inhibitors	O
of	O
the	O
viral	B-protein
DNA	I-protein
polymerase	I-protein
such	O
as	O
phosphonoacetic	O
acid	O
,	O
although	O
the	O
reporters	O
lack	O
a	O
eukaryotic	O
origin	O
of	O
replication	O
and	O
are	O
not	O
replicated	O
under	O
the	O
assay	O
conditions	O
.	O

Thus	O
,	O
replication	O
of	O
the	O
transcriptional	B-DNA
template	I-DNA
is	O
not	O
a	O
prerequisite	O
for	O
expression	O
with	O
late	O
kinetics	O
,	O
a	O
finding	O
inconsistent	O
with	O
the	O
current	O
models	O
which	O
posit	O
a	O
cis-active	O
relationship	O
between	O
lytic	O
EBV	O
DNA	O
replication	O
and	O
late	O
gene	O
expression	O
.	O

Rather	O
,	O
analysis	O
of	O
this	O
system	O
has	O
revealed	O
a	O
trans	O
relationship	O
between	O
late	O
gene	O
expression	O
and	O
viral	O
DNA	O
replication	O
and	O
highlights	O
the	O
indirect	O
and	O
complex	O
link	O
between	O
these	O
two	O
events	O
.	O

Modulation	O
of	O
mRNA	O
expression	O
of	O
a	O
novel	B-DNA
human	I-DNA
myeloid-selective	I-DNA
CCAAT/enhancer	I-DNA
binding	I-DNA
protein	I-DNA
gene	I-DNA
(	O
C/EBP	B-DNA
epsilon	I-DNA
)	O
.	O

Human	O
C/EBP	B-DNA
epsilon	I-DNA
is	O
a	O
newly	O
cloned	O
gene	O
coding	O
for	O
a	O
CCAAT/enhancer	B-protein
binding	I-protein
protein	I-protein
that	O
may	O
be	O
involved	O
in	O
the	O
regulation	O
of	O
myeloid	O
differentiation	O
.	O

Our	O
studies	O
showed	O
that	O
levels	O
of	O
C/EBP	B-RNA
epsilon	I-RNA
mRNA	I-RNA
were	O
markedly	O
increased	O
in	O
NB4	B-cell_line
cells	I-cell_line
(	O
promyelocytic	B-cell_line
leukemia	I-cell_line
line	I-cell_line
)	O
,	O
because	O
they	O
were	O
induced	O
by	O
9-cis	O
retinoic	O
acid	O
(	O
9-cis	O
RA	O
)	O
to	O
differentiate	O
towards	O
granulocytes	B-cell_type
.	O

Accumulation	O
of	O
C/EBP	B-RNA
epsilon	I-RNA
mRNA	I-RNA
occurred	O
as	O
early	O
as	O
1	O
hour	O
after	O
exposure	O
of	O
NB4	B-cell_line
cells	I-cell_line
to	O
9-cis	O
RA	O
(	O
5	O
x	O
10	O
(	O
-7	O
)	O
mol/L	O
)	O
;	O
and	O
at	O
48	O
hours	O
,	O
levels	O
were	O
increased	O
by	O
5.1-fold	O
.	O

Dose-response	O
studies	O
showed	O
that	O
10	O
(	O
-7	O
)	O
to	O
10	O
(	O
-6	O
)	O
mol/L	O
9-cis	O
RA	O
(	O
12	O
hours	O
)	O
resulted	O
in	O
peak	O
levels	O
of	O
C/EBP	B-RNA
epsilon	I-RNA
mRNA	I-RNA
;	O
but	O
even	O
10	O
(	O
-10	O
)	O
mol/L	O
9-cis	O
RA	O
increased	O
levels	O
of	O
these	O
transcripts	O
.	O

NB4	B-cell_line
cells	I-cell_line
pulse-exposed	O
(	O
30	O
minutes	O
)	O
to	O
all-trans	O
retinoic	O
acid	O
(	O
ATRA	O
)	O
,	O
washed	O
,	O
and	O
cultured	O
(	O
3	O
days	O
)	O
with	O
either	O
dimethylsulfoxide	O
(	O
DMSO	O
)	O
or	O
hexamethylene	O
bisacetamide	O
(	O
HMBA	O
)	O
had	O
a	O
prominent	O
increase	O
in	O
levels	O
of	O
C/EBP	B-RNA
epsilon	I-RNA
mRNA	I-RNA
and	O
an	O
increase	O
in	O
granulocytic	O
differentiation	O
,	O
but	O
exposure	O
to	O
either	O
DMSO	O
or	O
HMBA	O
alone	O
had	O
no	O
effect	O
on	O
base	O
levels	O
of	O
C/EBP	O
epsilon	O
and	O
did	O
not	O
induce	O
differentiation	O
.	O

Macrophage-differentiation	O
of	O
NB4	B-cell_line
reduced	O
levels	O
of	O
C/EBP	B-RNA
epsilon	I-RNA
mRNA	I-RNA
.	O

Nuclear	O
run-off	O
assays	O
and	O
half-life	O
studies	O
showed	O
that	O
accumulation	O
of	O
C/EBP	B-RNA
epsilon	I-RNA
mRNA	I-RNA
by	O
9-cis	O
RA	O
was	O
due	O
to	O
enhanced	O
transcription	O
.	O

Furthermore	O
,	O
this	O
C/EBP	B-RNA
epsilon	I-RNA
mRNA	I-RNA
accumulation	O
did	O
not	O
require	O
synthesis	O
of	O
new	O
protein	B-protein
factors	I-protein
because	O
9-cis	O
RA	O
induced	O
C/EBP	B-RNA
epsilon	I-RNA
mRNA	I-RNA
accumulation	O
in	O
the	O
absence	O
of	O
new	O
protein	O
synthesis	O
.	O

ATRA	O
also	O
induced	O
expression	O
of	O
C/EBP	B-protein
epsilon	I-protein
protein	I-protein
in	O
NB4	B-cell_line
cells	I-cell_line
,	O
as	O
shown	O
by	O
Western	O
blotting	O
.	O

In	O
contrast	O
to	O
the	O
increase	O
of	O
C/EBP	O
epsilon	O
in	O
9-cis	O
RA-mediated	O
granulocytic	O
differentiation	O
,	O
the	O
DMSO-induced	O
differentiation	O
of	O
HL-60	B-cell_line
cells	I-cell_line
down	O
the	O
granulocytic	O
pathway	O
was	O
associated	O
with	O
an	O
initial	O
reduction	O
of	O
C/EBP	B-RNA
epsilon	I-RNA
mRNA	I-RNA
levels	O
.	O

In	O
summary	O
,	O
we	O
have	O
discovered	O
that	O
expression	O
of	O
C/EBP	B-RNA
epsilon	I-RNA
mRNA	I-RNA
is	O
markedly	O
enhanced	O
as	O
the	O
NB4	B-cell_line
promyelocytes	I-cell_line
are	O
induced	O
by	O
retinoids	O
to	O
differentiate	O
towards	O
granulocytes	B-cell_type
.	O

This	O
induction	O
of	O
C/EBP	B-RNA
epsilon	I-RNA
mRNA	I-RNA
expression	O
is	O
transcriptionally	O
mediated	O
and	O
occurs	O
in	O
the	O
absence	O
of	O
synthesis	O
of	O
additional	O
protein	B-protein
factors	I-protein
.	O

We	O
suspect	O
that	O
the	O
C/EBP	B-DNA
epsilon	I-DNA
promoter/enhancer	I-DNA
contains	O
a	O
retinoic	B-DNA
acid-response	I-DNA
element	I-DNA
that	O
is	O
directly	O
stimulated	O
by	O
retinoids	O
.	O

Dual	O
effects	O
of	O
LPS	B-protein
antibodies	I-protein
on	O
cellular	O
uptake	O
of	O
LPS	O
and	O
LPS-induced	O
proinflammatory	O
functions	O
.	O

Human	B-cell_type
phagocytes	I-cell_type
recognize	O
bacterial	O
LPS	O
(	O
endotoxin	O
)	O
through	O
membrane	B-protein
CD14	I-protein
(	O
mCD14	B-protein
)	O
,	O
a	O
proinflammatory	B-protein
LPS	I-protein
receptor	I-protein
.	O

This	O
study	O
tested	O
the	O
hypothesis	O
that	O
anti-LPS	B-protein
Abs	I-protein
neutralize	O
endotoxin	O
by	O
blocking	O
cellular	O
uptake	O
through	O
mCD14	B-protein
.	O

Ab-associated	O
changes	O
in	O
the	O
uptake	O
and	O
cellular	O
distribution	O
of	O
FITC-LPS	O
were	O
assessed	O
by	O
flow	O
cytometry	O
and	O
laser	O
scanning	O
confocal	O
microscopy	O
in	O
human	B-cell_line
CD14-transfected	I-cell_line
Chinese	I-cell_line
hamster	I-cell_line
ovary	I-cell_line
fibroblasts	I-cell_line
(	O
CHO-CD14	B-cell_line
cells	I-cell_line
)	O
and	O
human	B-cell_type
peripheral	I-cell_type
blood	I-cell_type
monocytes	I-cell_type
.	O

LPS	O
core-	B-protein
and	I-protein
O-side	I-protein
chain-specific	I-protein
mAbs	I-protein
inhibited	O
mCD14	B-protein
-mediated	O
LPS	O
uptake	O
by	O
both	O
cell	O
types	O
in	O
the	O
presence	O
of	O
serum	O
.	O

O-side	B-protein
chain-specific	I-protein
mAb	I-protein
concurrently	O
enhanced	O
complement-dependent	O
LPS	O
uptake	O
by	O
monocytes	O
through	O
complement	B-protein
receptor-1	I-protein
(	O
CR1	B-protein
)	O
and	O
uptake	O
by	O
CHO-CD14	B-cell_line
cells	I-cell_line
involving	O
another	O
heat-labile	B-protein
serum	I-protein
factor	I-protein
(	O
s	O
)	O
and	O
cell-associated	B-protein
recognition	I-protein
molecule	I-protein
(	O
s	O
)	O
.	O

Core-specific	B-protein
mAb	I-protein
inhibited	O
mCD14	B-protein
-mediated	O
uptake	O
of	O
homologous	O
and	O
heterologous	O
LPS	O
,	O
while	O
producing	O
less	O
concurrent	O
enhancement	O
of	O
non-	O
mCD14	B-protein
-mediated	O
LPS	O
uptake	O
.	O

The	O
modulation	O
by	O
anti-LPS	B-protein
mAbs	I-protein
of	O
mCD14	B-protein
-mediated	O
LPS	O
uptake	O
was	O
associated	O
with	O
inhibition	O
of	O
LPS-induced	B-protein
nuclear	I-protein
factor-kappaB	I-protein
(	O
NF-kappaB	B-protein
)	O
translocation	O
and	O
TNF-alpha	B-protein
secretion	O
in	O
CHO-CD14	B-cell_line
cells	I-cell_line
and	O
monocytes	O
,	O
respectively	O
,	O
while	O
mAb	O
enhancement	O
of	O
non-	O
mCD14	B-protein
-mediated	O
LPS	O
uptake	O
stimulated	O
these	O
activities	O
.	O

LPS-specific	B-protein
Abs	I-protein
thus	O
mediate	O
anti-inflammatory	O
and	O
proinflammatory	O
functions	O
,	O
respectively	O
,	O
by	O
preventing	O
target	O
cell	O
uptake	O
of	O
LPS	O
through	O
mCD14	B-protein
and	O
augmenting	O
uptake	O
through	O
CR1	B-protein
or	O
other	O
cell	B-protein
receptors	I-protein
.	O

Four	O
P-like	B-DNA
elements	I-DNA
are	O
required	O
for	O
optimal	O
transcription	O
of	O
the	O
mouse	B-DNA
IL-4	I-DNA
gene	I-DNA
:	O
involvement	O
of	O
a	O
distinct	O
set	O
of	O
nuclear	B-protein
factor	I-protein
of	I-protein
activated	I-protein
T	I-protein
cells	I-protein
and	O
activator	B-protein
protein-1	I-protein
family	I-protein
proteins	I-protein
.	O

We	O
previously	O
identified	O
the	O
P	B-DNA
sequence	I-DNA
as	O
a	O
critical	O
regulatory	B-DNA
element	I-DNA
of	O
the	O
human	B-DNA
IL-4	I-DNA
promoter	I-DNA
.	O

In	O
the	O
mouse	B-DNA
IL-4	I-DNA
promoter	I-DNA
,	O
there	O
are	O
five	O
elements	O
homologous	O
to	O
the	O
human	O
P	B-DNA
sequence	I-DNA
designated	O
conserved	B-DNA
lymphokine	I-DNA
element	I-DNA
0	I-DNA
(	O
CLE0	B-DNA
)	O
,	O
P	B-DNA
,	O
P2	B-DNA
,	O
P3	B-DNA
and	O
P4	B-DNA
.	O

To	O
characterize	O
the	O
role	O
of	O
these	O
P-like	B-DNA
elements	I-DNA
and	O
their	O
binding	B-protein
factors	I-protein
in	O
the	O
native	B-DNA
promoter	I-DNA
,	O
we	O
did	O
transient	O
transfection	O
and	O
electrophoretic	O
mobility	O
shift	O
assays	O
(	O
EMSA	O
)	O
.	O

Transfection	O
of	O
EL-4	B-cell_line
cells	I-cell_line
with	O
the	O
IL-4	B-DNA
promoter-reporter	I-DNA
constructs	I-DNA
carrying	O
mutated	B-DNA
P-like	I-DNA
elements	I-DNA
showed	O
that	O
four	O
P-like	B-DNA
elements	I-DNA
,	O
CLE0	B-DNA
,	O
P	B-DNA
,	O
P2	B-DNA
and	O
P4	B-DNA
,	O
but	O
not	O
P3	B-DNA
,	O
were	O
required	O
for	O
optimal	O
activation	O
of	O
the	O
IL-4	B-DNA
promoter	I-DNA
.	O

EMSA	O
showed	O
that	O
both	O
constitutive	O
and	O
inducible	O
complexes	O
bound	O
to	O
CLE0	B-DNA
,	O
P	B-DNA
,	O
P2	B-DNA
and	O
P4	B-DNA
,	O
whereas	O
only	O
a	O
constitutive	O
complex	O
bound	O
to	O
P3	B-DNA
.	O

In	O
competition	O
and	O
antibody	O
supershift	O
assays	O
in	O
EMSA	O
,	O
complexes	O
formed	O
with	O
P	B-DNA
or	O
P2	B-DNA
proved	O
to	O
contain	O
nuclear	B-protein
factor	I-protein
of	I-protein
activated	I-protein
T	I-protein
cells	I-protein
(	I-protein
NFAT	I-protein
)	I-protein
family	I-protein
proteins	I-protein
as	O
major	O
components	O
.	O

Activator	B-protein
protein	I-protein
(	I-protein
AP	I-protein
)	I-protein
-1	I-protein
family	I-protein
proteins	I-protein
interacted	O
with	O
CLE0	B-DNA
,	O
P	O
,	O
P2	B-DNA
and	O
P4	B-DNA
.	O

NFAT/AP-1	B-protein
complex	I-protein
formed	O
only	O
with	O
P	B-DNA
and	O
P2	B-DNA
.	O

Cross-competition	O
assays	O
among	O
the	O
P-like	B-DNA
elements	I-DNA
revealed	O
element-specific	B-protein
and	I-protein
common	I-protein
complexes	I-protein
.	O

Six	O
tandem	O
repeats	O
of	O
the	O
P	B-DNA
element	I-DNA
linked	O
to	O
the	O
SV40	B-DNA
promoter	I-DNA
responded	O
to	O
phorbol	O
12-myristate	O
13-acetate	O
,	O
while	O
that	O
of	O
other	O
elements	O
did	O
not.	O
It	O
would	O
thus	O
appear	O
that	O
components	O
of	O
each	O
P-like	B-protein
element-binding	I-protein
complexes	I-protein
are	O
not	O
identical	O
and	O
may	O
coordinately	O
contribute	O
to	O
transcriptional	O
activity	O
.	O

Constitutive	O
expression	O
c-fos	B-RNA
,	I-RNA
c-jun	I-RNA
,	I-RNA
and	I-RNA
NF	I-RNA
kappa	I-RNA
B	I-RNA
mRNA	I-RNA
is	O
in	O
nucleated	B-cell_type
fetal	I-cell_type
blood	I-cell_type
cells	I-cell_type
and	O
up-regulation	O
of	O
c-fos	B-protein
and	O
c-jun	B-protein
with	O
anti-CD3	B-protein
stimulation	O
.	O

Fetal	B-cell_type
and	I-cell_type
neonatal	I-cell_type
lymphocytes	I-cell_type
are	O
relatively	O
resistant	O
to	O
activation	O
and	O
cytokine	B-protein
production	O
when	O
stimulated	O
either	O
via	O
their	O
T-cell	B-protein
antigen	I-protein
receptors	I-protein
or	O
lectins	B-protein
.	O

The	O
molecular	O
mechanism	O
(	O
s	O
)	O
responsible	O
for	O
this	O
phenomenon	O
have	O
not	O
been	O
clearly	O
elucidated	O
.	O

We	O
have	O
hypothesized	O
that	O
such	O
defects	O
in	O
fetal/neonatal	O
T-cell	O
activation	O
may	O
be	O
due	O
to	O
lack	O
of	O
expression	O
of	O
the	O
transcriptional	B-protein
regulatory	I-protein
elements	I-protein
required	O
for	O
T-cell	O
activation	O
.	O

We	O
used	O
reverse	B-protein
transcriptase	I-protein
-polymerase	O
chain	O
reaction	O
to	O
examine	O
both	O
fetal	O
and	O
term	O
neonatal	O
cord	O
bloods	O
for	O
mRNA	O
expression	O
of	O
three	O
transcription	B-protein
factors	I-protein
implicated	O
in	O
T-cell	O
activation	O
:	O
c-jun	B-protein
,	O
c-fos	B-protein
,	O
and	O
NF	B-protein
kappa	I-protein
B	I-protein
(	O
p50	B-protein
subunit	I-protein
)	O
.	O

We	O
demonstrate	O
that	O
mRNAs	B-RNA
for	O
all	O
three	O
of	O
these	O
regulatory	O
factors	O
are	O
expressed	O
in	O
fetal	B-cell_type
blood	I-cell_type
cells	I-cell_type
by	O
the	O
27th	O
week	O
of	O
gestation	O
and	O
in	O
term	O
cord	O
bloods	O
.	O

Activation	O
of	O
term	B-cell_type
infant	I-cell_type
cord	I-cell_type
blood	I-cell_type
mononuclear	I-cell_type
cells	I-cell_type
with	O
anti-CD3	B-protein
monoclonal	I-protein
antibodies	I-protein
resulted	O
in	O
up-regulation	O
of	O
both	O
c-jun	B-protein
and	O
c-fos	O
mRNAs	B-RNA
within	O
15	O
min	O
of	O
stimulation	O
.	O

However	O
,	O
secretion	O
of	O
IL-2	B-protein
by	O
anti-CD3-stimulated	B-cell_line
cord	I-cell_line
blood	I-cell_line
mononuclear	I-cell_line
cells	I-cell_line
was	O
still	O
blunted	O
compared	O
with	O
control	B-cell_type
cells	I-cell_type
from	O
adults	O
.	O

We	O
conclude	O
that	O
fetal	B-cell_type
nucleated	I-cell_type
blood	I-cell_type
cells	I-cell_type
constitutively	O
express	O
important	O
genes	O
for	O
cytokine	B-protein
regulation	O
and	O
are	O
able	O
to	O
increase	O
intracellular	O
accumulation	O
of	O
the	O
mRNAs	B-RNA
for	O
these	O
factors	O
in	O
response	O
to	O
anti-CD3	B-protein
stimulation	O
.	O

Thus	O
,	O
qualitative	O
differences	O
in	O
the	O
capacity	O
to	O
regulate	O
these	O
factors	O
could	O
not	O
be	O
shown	O
in	O
fetal	B-cell_type
blood	I-cell_type
cells	I-cell_type
.	O

Quantitative	O
experiments	O
comparing	O
binding	O
of	O
these	O
transcription	B-protein
factors	I-protein
to	O
the	O
IL-2	B-DNA
promoter	I-DNA
are	O
currently	O
under	O
investigation	O
.	O

Nuclear	O
accumulation	O
of	O
NFAT4	B-protein
opposed	O
by	O
the	O
JNK	B-protein
signal	O
transduction	O
pathway	O
.	O

The	O
nuclear	B-protein
factor	I-protein
of	I-protein
activated	I-protein
T	I-protein
cells	I-protein
(	I-protein
NFAT	I-protein
)	I-protein
group	I-protein
of	O
transcription	B-protein
factors	I-protein
is	O
retained	O
in	O
the	O
cytoplasm	O
of	O
quiescent	B-cell_type
cells	I-cell_type
.	O

NFAT	B-protein
activation	O
is	O
mediated	O
in	O
part	O
by	O
induced	O
nuclear	O
import	O
.	O

This	O
process	O
requires	O
calcium-dependent	O
dephosphorylation	O
of	O
NFAT	B-protein
caused	O
by	O
the	O
phosphatase	B-protein
calcineurin	B-protein
.	O

The	O
c-Jun	B-protein
amino-terminal	I-protein
kinase	I-protein
(	O
JNK	B-protein
)	O
phosphorylates	O
NFAT4	B-protein
on	O
two	O
sites	O
.	O

Mutational	O
removal	O
of	O
the	O
JNK	B-protein
phosphorylation	I-protein
sites	I-protein
caused	O
constitutive	O
nuclear	O
localization	O
of	O
NFAT4	B-protein
.	O

In	O
contrast	O
,	O
JNK	B-protein
activation	O
in	O
calcineurin-stimulated	B-cell_line
cells	I-cell_line
caused	O
nuclear	O
exclusion	O
of	O
NFAT4	B-protein
.	O

These	O
findings	O
show	O
that	O
the	O
nuclear	O
accumulation	O
of	O
NFAT4	B-protein
promoted	O
by	O
calcineurin	B-protein
is	O
opposed	O
by	O
the	O
JNK	B-protein
signal	O
transduction	O
pathway	O
.	O

Thiol	O
modulation	O
inhibits	O
the	O
interleukin	B-protein
(	I-protein
IL	I-protein
)	I-protein
-1	I-protein
-mediated	O
activation	O
of	O
an	O
IL-1	B-protein
receptor-associated	I-protein
protein	I-protein
kinase	I-protein
and	O
NF-kappa	B-protein
B	I-protein
.	O

The	O
interleukin-1	B-protein
receptor	I-protein
type	I-protein
I	I-protein
(	O
IL-1RI	B-protein
)	O
is	O
associated	O
with	O
other	O
proteins	O
thus	O
forming	O
a	O
complex	B-protein
system	I-protein
by	O
which	O
IL-1	B-protein
exerts	O
its	O
various	O
signals	O
.	O

The	O
initiating	O
event	O
is	O
still	O
uncertain	O
,	O
but	O
activation	O
of	O
a	O
recently	O
described	O
receptor-associated	B-protein
protein	I-protein
kinase	I-protein
is	O
one	O
of	O
the	O
earliest	O
events	O
detectable	O
(	O
Martin	O
et	O
al.	O
,	O
Eur.J.Immunol.1994.24	O
:	O
1566	O
)	O
.	O

IL-1	B-protein
signaling	O
is	O
commonly	O
accompanied	O
by	O
oxidative	O
processes	O
and	O
is	O
thought	O
to	O
be	O
subject	O
to	O
redox	O
regulation	O
.	O

We	O
therefore	O
investigated	O
whether	O
the	O
activation	O
of	O
the	O
IL-1RI-associated	B-protein
protein	I-protein
kinase	I-protein
could	O
be	O
a	O
target	O
for	O
redox	O
regulation	O
and	O
whether	O
an	O
altered	O
activity	O
of	O
the	O
kinase	O
could	O
influence	O
IL-1	B-protein
-mediated	O
NF-kappa	B-protein
B	I-protein
activation	O
.	O

A	O
murine	B-cell_line
T	I-cell_line
cell	I-cell_line
line	I-cell_line
,	O
EL4	B-cell_line
,	O
was	O
stimulated	O
with	O
IL-1	B-protein
with	O
and	O
without	O
pretreatment	O
with	O
different	O
compounds	O
known	O
to	O
influence	O
the	O
cellular	O
redox	O
status	O
.	O

Thiol	O
modifying	O
agents	O
like	O
diamide	O
,	O
menadione	O
,	O
pyrrolidine	O
dithiocarbamate	O
(	O
PDTC	O
)	O
,	O
diethyl	O
dithiocarbamate	O
or	O
phenylarsine	O
oxide	O
inhibited	O
the	O
IL-1	B-protein
-induced	O
activation	O
of	O
the	O
IL-1RI-associated	B-protein
protein	I-protein
kinase	I-protein
.	O

N-Acetylcysteine	O
,	O
alpha	O
,	O
alpha'-dipyridyl	O
,	O
aminotriazole	O
or	O
nitrofurantoin	O
did	O
not	O
show	O
any	O
effect	O
.	O

The	O
inhibition	O
by	O
PDTC	O
was	O
reversible	O
unless	O
glutathione	O
synthesis	O
was	O
blocked	O
by	O
buthionine	O
sulfoximine	O
.	O

The	O
described	O
conditions	O
which	O
inhibited	O
or	O
prevented	O
the	O
activation	O
of	O
the	O
IL-1RI-associated	B-protein
kinase	I-protein
similarly	O
impaired	O
the	O
activation	O
of	O
NF-kappa	B-protein
B	I-protein
in	O
EL4	B-cell_line
cells	I-cell_line
.	O

From	O
these	O
observations	O
we	O
conclude	O
that	O
free	O
thiols	O
in	O
the	O
IL-1RI	B-protein
complex	I-protein
are	O
essential	O
for	O
the	O
activation	O
of	O
the	O
IL-1RI-associated	B-protein
protein	I-protein
kinase	I-protein
and	O
that	O
this	O
process	O
is	O
mandatory	O
for	O
IL-1	B-protein
signaling	O
leading	O
to	O
NF-kappa	B-protein
B	I-protein
activation	O
.	O

Switching	O
gears	O
during	O
T-cell	O
maturation	O
:	O
RANTES	B-protein
and	O
late	O
transcription	O
.	O

Although	O
much	O
is	O
understood	O
about	O
the	O
induction	O
of	O
genes	B-DNA
expressed	O
early	O
(	O
within	O
24	O
h	O
)	O
after	O
T-cell	O
activation	O
,	O
little	O
is	O
known	O
about	O
the	O
regulation	O
of	O
expression	O
of	O
genes	B-DNA
expressed	O
'late	O
'	O
(	O
three	O
or	O
more	O
days	O
)	O
post-stimulation	O
.	O

A	O
better	O
understanding	O
of	O
transcriptional	O
regulation	O
at	O
this	O
important	O
stage	O
of	O
T-cell	O
maturation	O
may	O
yield	O
new	O
insights	O
into	O
T-cell	O
development	O
and	O
new	O
immunotherapeutic	O
targets	O
.	O

Involvement	O
of	O
different	O
transduction	O
pathways	O
in	O
NF-kappa	B-protein
B	I-protein
activation	O
by	O
several	O
inducers	B-DNA
.	O

Double-stimulation	O
was	O
used	O
to	O
demonstrate	O
that	O
,	O
in	O
a	O
T	B-cell_line
lymphocytic	I-cell_line
cell	I-cell_line
line	I-cell_line
(	O
CEM	B-cell_line
)	O
,	O
phorbol	O
myristate	O
acetate	O
(	O
PMA	O
)	O
rapidly	O
induced	O
NF-kappa	B-protein
B	I-protein
through	O
a	O
signaling	O
pathway	O
which	O
did	O
not	O
involve	O
reactive	O
oxygen	O
species	O
(	O
ROS	O
)	O
and	O
was	O
different	O
from	O
the	O
activation	O
triggered	O
by	O
either	O
H2O2	O
or	O
tumor	B-protein
necrosis	I-protein
factor-alpha	I-protein
(	O
TNF-alpha	B-protein
)	O
.	O

Since	O
these	O
latter	O
compounds	O
were	O
known	O
to	O
activate	O
NF-kappa	B-protein
B	I-protein
translocation	O
in	O
a	O
redox-sensitive	O
way	O
,	O
we	O
have	O
demonstrated	O
that	O
NF-kappa	B-protein
B	I-protein
activation	O
by	O
PMA	O
was	O
resistant	O
to	O
antioxidant	O
N-acetyl-L-cysteine	O
(	O
NAC	O
)	O
and	O
sensitive	O
to	O
kinase	O
inhibitors	O
staurosporine	O
and	O
H7	O
while	O
activation	O
by	O
H2O2	O
or	O
TNF-alpha	B-protein
were	O
not	O
.	O

Blockade	O
of	O
T-cell	O
activation	O
by	O
dithiocarbamates	O
involves	O
novel	O
mechanisms	O
of	O
inhibition	O
of	O
nuclear	B-protein
factor	I-protein
of	I-protein
activated	I-protein
T	I-protein
cells	I-protein
.	O

Dithiocarbamates	O
(	O
DTCs	O
)	O
have	O
recently	O
been	O
reported	O
as	O
powerful	O
inhibitors	O
of	O
NF-kappaB	B-protein
activation	O
in	O
a	O
number	O
of	O
cell	O
types	O
.	O

Given	O
the	O
role	O
of	O
this	O
transcription	O
factor	O
in	O
the	O
regulation	O
of	O
gene	O
expression	O
in	O
the	O
inflammatory	O
response	O
,	O
NF-kappaB	B-protein
inhibitors	O
have	O
been	O
suggested	O
as	O
potential	O
therapeutic	O
drugs	O
for	O
inflammatory	O
diseases	O
.	O

We	O
show	O
here	O
that	O
DTCs	O
inhibited	O
both	O
interleukin	B-protein
2	I-protein
(	O
IL-2	B-protein
)	O
synthesis	O
and	O
membrane	O
expression	O
of	O
antigens	B-protein
which	O
are	O
induced	O
during	O
T-cell	O
activation	O
.	O

This	O
inhibition	O
,	O
which	O
occurred	O
with	O
a	O
parallel	O
activation	O
of	O
c-Jun	B-protein
transactivating	O
functions	O
and	O
expression	O
,	O
was	O
reflected	O
by	O
transfection	O
experiments	O
at	O
the	O
IL-2	B-DNA
promoter	I-DNA
level	O
,	O
and	O
involved	O
not	O
only	O
the	O
inhibition	O
of	O
NF-kappaB	B-protein
-driven	O
reporter	O
activation	O
but	O
also	O
that	O
of	O
nuclear	B-protein
factor	I-protein
of	I-protein
activated	I-protein
T	I-protein
cells	I-protein
(	O
NFAT	B-protein
)	O
.	O

Accordingly	O
,	O
electrophoretic	O
mobility	O
shift	O
assays	O
(	O
EMSAs	O
)	O
indicated	O
that	O
pyrrolidine	O
DTC	O
(	O
PDTC	O
)	O
prevented	O
NF-kappaB	B-protein
,	O
and	O
NFAT	B-protein
DNA-binding	O
activity	O
in	O
T	B-cell_type
cells	I-cell_type
stimulated	O
with	O
either	O
phorbol	O
myristate	O
acetate	O
plus	O
ionophore	O
or	O
antibodies	O
against	O
the	O
CD3-T-cell	B-protein
receptor	I-protein
complex	I-protein
and	O
simultaneously	O
activated	O
the	O
binding	O
of	O
AP-1	B-protein
.	O

Furthermore	O
,	O
PDTC	O
differentially	O
targeted	O
both	O
NFATp	B-protein
and	I-protein
NFATc	I-protein
family	I-protein
members	I-protein
,	O
inhibiting	O
the	O
transactivation	O
functions	O
of	O
NFATp	B-protein
and	O
mRNA	O
induction	O
of	O
NFATc	B-protein
.	O

Strikingly	O
,	O
Western	O
blotting	O
and	O
immunocytochemical	O
experiments	O
indicated	O
that	O
PDTC	O
promoted	O
a	O
transient	O
and	O
rapid	O
shuttling	O
of	O
NFATp	B-protein
and	O
NFATc	B-protein
,	O
leading	O
to	O
their	O
accelerated	O
export	O
from	O
the	O
nucleus	O
of	O
activated	B-cell_type
T	I-cell_type
cells	I-cell_type
.	O

We	O
propose	O
that	O
the	O
activation	O
of	O
an	O
NFAT	O
kinase	O
by	O
PDTC	O
could	O
be	O
responsible	O
for	O
the	O
rapid	O
shuttling	O
of	O
the	O
NFAT	B-protein
,	O
therefore	O
transiently	O
converting	O
the	O
sustained	O
transactivation	O
of	O
this	O
transcription	B-protein
factor	I-protein
that	O
occurs	O
during	O
lymphocyte	O
activation	O
,	O
and	O
show	O
that	O
c-Jun	B-protein
NH2-terminal	I-protein
kinase	I-protein
(	O
JNK	B-protein
)	O
can	O
act	O
by	O
directly	O
phosphorylating	O
NFATp	B-protein
.	O

In	O
addition	O
,	O
the	O
combined	O
inhibitory	O
effects	O
on	O
NFAT	B-protein
and	O
NF-KB	B-protein
support	O
a	O
potential	O
use	O
of	O
DTCs	O
as	O
immunosuppressants	O
.	O

Activation	O
of	O
a	O
novel	B-DNA
gene	I-DNA
in	O
3q21	B-DNA
and	O
identification	O
of	O
intergenic	O
fusion	O
transcripts	O
with	O
ecotropic	B-DNA
viral	I-DNA
insertion	I-DNA
site	I-DNA
I	I-DNA
in	O
leukemia	O
.	O

We	O
have	O
identified	O
a	O
novel	B-DNA
gene	I-DNA
,	O
GR6	B-DNA
,	O
located	O
within	O
the	O
leukemia	O
breakpoint	O
region	O
of	O
3q21	B-DNA
,	O
that	O
is	O
normally	O
expressed	O
in	O
early	O
fetal	O
development	O
but	O
not	O
in	O
adult	O
peripheral	O
blood	O
.	O

GR6	B-DNA
is	O
activated	O
in	O
the	O
UCSD-AML1	B-cell_line
cell	I-cell_line
line	I-cell_line
and	O
in	O
a	O
leukemic	B-cell_line
sample	I-cell_line
,	O
both	O
of	O
which	O
carry	O
a	O
t	B-DNA
(	I-DNA
3	I-DNA
;	I-DNA
3	I-DNA
)	I-DNA
(	I-DNA
q21	I-DNA
;	I-DNA
q26	I-DNA
)	I-DNA
.	O

In	O
UCSD-AML1	B-cell_line
,	O
we	O
have	O
also	O
identified	O
fusion	B-RNA
transcripts	I-RNA
between	O
the	O
ecotropic	B-DNA
viral	I-DNA
insertion	I-DNA
site	I-DNA
I	I-DNA
(	I-DNA
EVI1	I-DNA
)	I-DNA
gene	I-DNA
in	O
3q26	B-DNA
and	O
GR6	B-DNA
and	O
between	O
EVI1	B-DNA
and	O
Ribophorin	B-DNA
I	I-DNA
that	O
maps	O
30	O
kb	O
telomeric	O
to	O
GR6	B-DNA
in	O
3q21	B-DNA
.	O

All	O
fusions	O
splice	O
the	O
5	B-DNA
'	I-DNA
ends	I-DNA
of	O
the	O
3q21	B-DNA
genes	I-DNA
into	O
exon	B-DNA
2	I-DNA
of	O
the	O
EVI1	B-DNA
gene	O
,	O
an	O
event	O
that	O
is	O
similar	O
to	O
the	O
normal	O
intergenic	O
splicing	O
of	O
MDS1-EVI1	B-DNA
and	O
to	O
those	O
previously	O
documented	O
in	O
leukemias	O
with	O
t	B-DNA
(	I-DNA
3	I-DNA
;	I-DNA
21	I-DNA
)	I-DNA
and	O
t	B-DNA
(	I-DNA
3	I-DNA
;	I-DNA
12	I-DNA
)	I-DNA
,	O
in	O
which	O
acute	O
myelogenous	B-DNA
leukemia	I-DNA
1-EVI1	I-DNA
fusions	I-DNA
and	O
ETV6-EVI1	B-DNA
fusions	I-DNA
,	O
respectively	O
,	O
occur	O
.	O

The	O
Ribophorin	B-DNA
I-EVI1	I-DNA
fusion	I-DNA
in	O
particular	O
may	O
be	O
a	O
common	O
occurrence	O
in	O
t	B-DNA
(	I-DNA
3	I-DNA
;	I-DNA
3	I-DNA
)	I-DNA
.	O

The	O
A-myb	B-protein
transcription	I-protein
factor	I-protein
in	O
neoplastic	B-cell_type
and	I-cell_type
normal	I-cell_type
B	I-cell_type
cells	I-cell_type
.	O

The	O
myb	B-protein
family	I-protein
of	O
transcription	B-protein
factors	I-protein
has	O
been	O
strongly	O
implicated	O
in	O
the	O
regulation	O
of	O
cell	O
growth	O
and	O
differentiation	O
in	O
the	O
haematopoietic	O
system	O
.	O

The	O
v-myb	B-DNA
oncogene	I-DNA
,	O
carried	O
by	O
avian	O
defective	O
retroviruses	O
,	O
causes	O
leukaemias	O
in	O
the	O
chicken	O
and	O
transforms	O
haematopoietic	B-cell_type
cells	I-cell_type
in	O
vitro	O
.	O

Its	O
normal	O
cellular	O
equivalent	O
c-myb	B-DNA
,	O
has	O
been	O
shown	O
to	O
promote	O
the	O
proliferation	O
and	O
block	O
the	O
differentiation	O
of	O
haematopoietic	B-cell_type
cells	I-cell_type
in	O
several	O
experimental	O
models	O
and	O
is	O
required	O
for	O
fetal	O
haematopoiesis	O
.	O

Two	O
other	O
members	O
of	O
the	O
family	O
have	O
been	O
cloned	O
more	O
recently	O
,	O
A-myb	B-protein
and	O
B-myb	B-protein
,	O
which	O
show	O
sequence	O
homology	O
with	O
c-myb	B-DNA
in	O
several	O
domains	O
,	O
of	O
which	O
the	O
DNA	B-protein
binding	I-protein
domain	I-protein
as	O
well	O
as	O
other	O
regulatory	B-protein
domains	I-protein
.	O

Both	O
have	O
been	O
shown	O
to	O
be	O
transcription	B-protein
factors	I-protein
.	O

B-myb	B-protein
is	O
also	O
involved	O
in	O
the	O
control	O
of	O
proliferation	O
and	O
differentiation	O
,	O
but	O
,	O
unlike	O
c-myb	B-DNA
,	O
it	O
is	O
expressed	O
in	O
many	O
cell	O
types	O
.	O

The	O
third	O
member	O
of	O
the	O
family	B-protein
,	O
A-myb	B-protein
,	O
shows	O
the	O
most	O
restricted	O
pattern	O
of	O
expression	O
,	O
suggesting	O
a	O
very	O
specific	O
role	O
for	O
this	O
transcription	B-protein
factor	I-protein
.	O

A-myb	B-protein
is	O
expressed	O
in	O
a	O
subpopulation	O
of	O
normal	B-cell_type
B	I-cell_type
lymphocytes	I-cell_type
activated	O
in	O
vivo	O
and	O
localised	O
in	O
the	O
germinal	O
center	O
of	O
peripheral	O
lymphoid	O
organs	O
and	O
is	O
not	O
detected	O
at	O
significant	O
levels	O
in	O
all	O
other	O
mature	O
or	O
immature	B-cell_type
haematopoietic	I-cell_type
populations	I-cell_type
studied	O
,	O
including	O
bone	B-cell_type
marrow	I-cell_type
cells	I-cell_type
,	O
T	B-cell_type
lymphocytes	I-cell_type
,	O
granulocytes	B-cell_type
,	O
monocytes	B-cell_type
,	O
either	O
at	O
rest	O
or	O
after	O
in	O
vitro	O
activation	O
.	O

These	O
studies	O
indicate	O
that	O
A-myb	B-protein
plays	O
a	O
role	O
during	O
a	O
narrow	O
window	O
of	O
normal	B-cell_type
B	I-cell_type
cell	I-cell_type
differentiation	O
.	O

A-myb	B-protein
expression	O
has	O
also	O
been	O
studied	O
in	O
a	O
wide	O
range	O
of	O
neoplastic	B-cell_type
B	I-cell_type
cells	I-cell_type
,	O
representing	O
the	O
whole	O
spectrum	O
of	O
B	O
cell	O
differentiation	O
.	O

A-myb	B-protein
is	O
strongly	O
expressed	O
in	O
Burkitt	O
's	O
lymphomas	O
(	O
BL	O
)	O
and	O
slg+	O
B-acute	O
lymphoblastic	O
leukaemias	O
(	O
B-ALL	O
)	O
and	O
not	O
in	O
all	O
other	O
leukaemias/lymphomas	O
tested	O
,	O
with	O
the	O
exception	O
of	O
a	O
subset	O
of	O
CLL	O
(	O
about	O
25	O
%	O
of	O
cases	O
)	O
.	O

It	O
is	O
intriguing	O
that	O
the	O
A-myb	B-DNA
genome	I-DNA
has	O
been	O
localised	O
relatively	O
close	O
to	O
the	O
c-myc	B-DNA
gene	I-DNA
on	O
chromosome	B-DNA
8	I-DNA
,	O
suggesting	O
that	O
the	O
c-myc	O
translocation	O
in	O
BL	O
and	O
B-ALL	O
may	O
affect	O
A-myb	B-protein
transcription	O
.	O

Studies	O
are	O
in	O
progress	O
to	O
investigate	O
the	O
functional	O
relationship	O
between	O
A-myb	B-protein
and	O
c-myc	B-DNA
,	O
particularly	O
in	O
the	O
context	O
of	O
BL	B-cell_type
cells	I-cell_type
and	O
to	O
determine	O
whether	O
A-myb	B-protein
is	O
deregulated	O
in	O
these	O
cells	O
.	O

Expression	O
of	O
bcl-6	B-protein
protein	I-protein
in	O
normal	O
skin	O
and	O
epidermal	O
neoplasms	O
.	O

Bcl-6	B-protein
protein	I-protein
is	O
a	O
recently	O
identified	O
novel	O
transcription	B-protein
factor	I-protein
whose	O
deregulated	O
expression	O
is	O
associated	O
with	O
diffuse	O
large	O
B	O
cell	O
lymphomas	O
.	O

It	O
was	O
recently	O
shown	O
by	O
us	O
that	O
the	O
protein	O
is	O
located	O
in	O
germinal	B-cell_type
center	I-cell_type
B	I-cell_type
cells	I-cell_type
and	O
their	O
neoplastic	B-cell_type
counterparts	I-cell_type
.	O

In	O
the	O
present	O
study	O
,	O
the	O
expression	O
of	O
bcl-6	B-protein
protein	I-protein
on	O
normal	O
epidermis	O
,	O
benign	O
,	O
and	O
malignant	O
tumors	O
originating	O
from	O
epidermal	B-cell_type
cells	I-cell_type
,	O
and	O
squamous	B-cell_line
cell	I-cell_line
carcinoma	I-cell_line
(	I-cell_line
SCC	I-cell_line
)	I-cell_line
cell	I-cell_line
lines	I-cell_line
are	O
investigated	O
.	O

With	O
the	O
use	O
of	O
immunohistochemistry	O
,	O
bcl-6	B-protein
protein	I-protein
was	O
shown	O
to	O
stain	O
intensely	O
on	O
normal	B-cell_line
prickle	I-cell_line
cells	I-cell_line
,	O
but	O
none	O
to	O
only	O
slightly	O
on	O
epidermal	B-cell_type
basal	I-cell_type
cells	I-cell_type
.	O

Papillomas	O
and	O
keratoacanthomas	O
copied	O
their	O
normal	O
counterparts	O
in	O
the	O
mode	O
of	O
expression	O
.	O

Various	O
levels	O
of	O
expression	O
were	O
found	O
on	O
seborrheic	O
keratoses	O
,	O
while	O
the	O
expression	O
level	O
on	O
basal	O
cell	O
epitheliomas	O
was	O
low	O
.	O

Peculiarly	O
,	O
eccrine	O
poromas	O
and	O
undifferentiated	O
spindle-shaped	O
basal	O
cell	O
epitheliomas	O
were	O
totally	O
unstained	O
.	O

Squamous	O
cell	O
carcinomas	O
showed	O
a	O
variety	O
of	O
expression	O
levels	O
,	O
while	O
two	O
undifferentiated	O
spindle-shaped	O
carcinomas	O
and	O
one	O
undifferentiated	O
SCC	B-cell_line
cell	I-cell_line
line	I-cell_line
remained	O
unstained	O
.	O

These	O
results	O
suggest	O
that	O
the	O
expression	O
of	O
bcl-6	B-protein
protein	I-protein
may	O
be	O
associated	O
with	O
morphological	O
differentiation	O
in	O
normal	O
and	O
neoplastic	B-cell_type
epidermal	I-cell_type
cells	I-cell_type
.	O

Sp3	B-protein
mediates	O
transcriptional	O
activation	O
of	O
the	O
leukocyte	B-DNA
integrin	I-DNA
genes	I-DNA
CD11C	B-DNA
and	O
CD11B	B-DNA
and	O
cooperates	O
with	O
c-Jun	O
to	O
activate	O
CD11C	B-DNA
.	O

The	O
leukocyte	B-DNA
integrin	I-DNA
genes	I-DNA
CD11c	B-DNA
and	O
CD11b	B-DNA
are	O
expressed	O
predominately	O
in	O
myelomonocytic	O
cells	O
.	O

In	O
previous	O
experiments	O
,	O
the	O
-70	B-DNA
to	I-DNA
-65	I-DNA
and	I-DNA
-121	I-DNA
to	I-DNA
-103	I-DNA
regions	I-DNA
of	O
the	O
CD11c	B-DNA
promoter	I-DNA
and	O
the	O
-66	B-DNA
to	I-DNA
-59	I-DNA
region	I-DNA
of	O
the	O
CD11b	B-DNA
promoter	I-DNA
were	O
shown	O
to	O
be	O
essential	O
for	O
Sp1-	B-protein
mediated	O
activation	O
of	O
these	O
genes	O
.	O

In	O
vivo	O
genomic	O
footprinting	O
had	O
also	O
revealed	O
cell-specific	O
binding	O
of	O
protein	O
,	O
presumably	O
Sp1	B-protein
,	O
to	O
these	O
regions	O
.	O

In	O
this	O
study	O
,	O
electrophoretic	O
mobility	O
shift	O
analysis	O
showed	O
that	O
the	O
Sp1-related	B-protein
factor	I-protein
,	O
Sp3	B-protein
,	O
also	O
binds	O
at	O
or	O
near	O
these	O
same	O
regions	O
.	O

Cotransfection	O
of	O
Sp3	B-protein
along	O
with	O
CD11c	B-DNA
promoter-luciferase	I-DNA
constructs	I-DNA
into	O
Sp-deficient	B-cell_line
Drosophila	I-cell_line
Schneider	I-cell_line
2	I-cell_line
cells	I-cell_line
showed	O
that	O
Sp3	B-protein
could	O
activate	O
the	O
CD11c	B-DNA
promoter	I-DNA
.	O

Deletion	O
of	O
both	O
the	O
-70	B-DNA
to	I-DNA
-65	I-DNA
and	I-DNA
-121	I-DNA
to	I-DNA
-103	I-DNA
regions	I-DNA
of	O
the	O
CD11c	B-DNA
promoter	I-DNA
resulted	O
in	O
the	O
loss	O
of	O
activation	O
by	O
Sp3	B-protein
.	O

Both	O
sites	O
showed	O
activation	O
by	O
Sp3	B-protein
;	O
however	O
,	O
the	O
-70	B-DNA
to	I-DNA
-65	I-DNA
region	I-DNA
was	O
more	O
responsive	O
to	O
Sp3	B-protein
than	O
to	O
Sp1	B-protein
.	O

Similar	O
transfection	O
analysis	O
of	O
the	O
-66	B-DNA
to	I-DNA
-59	I-DNA
region	I-DNA
of	O
the	O
CD11b	B-DNA
promoter	I-DNA
showed	O
Sp3	B-protein
-dependent	O
expression	O
.	O

Further	O
,	O
cotransfection	O
analysis	O
in	O
Drosophila	B-cell_line
cells	I-cell_line
showed	O
that	O
Sp3	B-protein
,	O
as	O
was	O
previously	O
shown	O
for	O
Sp1	B-protein
,	O
also	O
synergizes	O
with	O
c-Jun	B-protein
to	O
activate	O
CD11c	B-DNA
.	O

Antisense	O
experiments	O
that	O
knocked	O
out	O
endogenous	O
Sp3	B-protein
expression	O
in	O
the	O
myelomocytic	B-cell_line
cell	I-cell_line
line	I-cell_line
,	O
HL60	B-cell_line
,	O
revealed	O
that	O
Sp3	B-protein
participates	O
in	O
activation	O
of	O
the	O
CD11c	B-DNA
and	I-DNA
CD11b	I-DNA
promoters	I-DNA
in	O
vivo	O
.	O

The	O
winged-helix	B-protein
transcription	I-protein
factor	I-protein
Trident	B-protein
is	O
expressed	O
in	O
actively	O
dividing	B-cell_type
lymphocytes	I-cell_type
.	O

We	O
recently	O
identified	O
the	O
winged-helix	B-protein
transcription	I-protein
factor	I-protein
Trident	B-protein
and	O
described	O
its	O
expression	O
pattern	O
in	O
synchronized	B-cell_type
fibroblasts	I-cell_type
.	O

We	O
have	O
now	O
studied	O
Trident	B-protein
expression	O
in	O
cell	B-cell_line
lines	I-cell_line
,	O
differentiating	B-cell_type
thymocytes	I-cell_type
and	O
in	O
lymphocytes	O
derived	O
from	O
peripheral	O
blood	O
.	O

During	O
T	O
cell	O
differentiation	O
,	O
expression	O
peaked	O
in	O
the	O
actively	B-cell_type
dividing	I-cell_type
immature	I-cell_type
single	I-cell_type
positive	I-cell_type
cells	I-cell_type
.	O

In	O
peripheral	O
blood	O
lymphocytes	O
,	O
expression	O
of	O
Trident	B-RNA
mRNA	I-RNA
was	O
absent	O
,	O
but	O
could	O
be	O
induced	O
upon	O
stimulation	O
with	O
mitogens	O
in	O
vitro	O
.	O

These	O
observations	O
imply	O
a	O
function	O
for	O
Trident	B-protein
in	O
dividing	B-cell_type
lymphocytes	I-cell_type
.	O

Estrogen	B-protein
receptor	I-protein
diminishes	O
DNA-binding	O
activities	O
of	O
chicken	B-protein
GATA-1	I-protein
and	O
CACCC-binding	B-protein
proteins	I-protein
.	O

The	O
estrogen	B-protein
receptor	I-protein
(	O
ER	B-protein
)	O
repressed	O
erythroid	O
differentiation	O
and	O
erythroid-specific	B-DNA
gene	I-DNA
expression	O
.	O

In	O
this	O
study	O
,	O
we	O
investigated	O
the	O
effect	O
of	O
ER	B-protein
alpha	I-protein
(	O
referred	O
to	O
throughout	O
as	O
ER	B-protein
)	O
on	O
DNA-binding	O
activities	O
of	O
transcription	B-protein
factors	I-protein
involved	O
in	O
regulating	O
the	O
expression	O
of	O
erythroid-specific	B-DNA
genes	I-DNA
,	O
and	O
,	O
in	O
particular	O
,	O
the	O
histone	B-DNA
H5	I-DNA
gene	I-DNA
.	O

Using	O
electrophoretic	O
mobility	O
shift	O
assays	O
,	O
we	O
found	O
that	O
in	O
the	O
presence	O
of	O
rabbit	O
reticulocyte	O
lysate	O
,	O
human	B-protein
ER	I-protein
reduced	O
the	O
binding	O
activities	O
of	O
chicken	B-protein
immature	I-protein
erythrocyte	I-protein
nuclear	I-protein
extracted	I-protein
proteins	I-protein
to	O
GATA	B-DNA
and	I-DNA
CACCC	I-DNA
sites	I-DNA
in	O
the	O
H5	B-DNA
promoter	I-DNA
and	I-DNA
enhancer	I-DNA
.	O

In	O
contrast	O
,	O
the	O
binding	O
activities	O
of	O
NF1	B-protein
and	O
Sp1	B-protein
were	O
not	O
affected	O
by	O
ER	B-protein
.	O

Binding	O
of	O
ER	B-protein
to	O
an	O
estrogen	B-DNA
response	I-DNA
element	I-DNA
was	O
enhanced	O
by	O
addition	O
of	O
rabbit	O
reticulocyte	O
lysate	O
.	O

This	O
lysate	O
was	O
also	O
necessary	O
for	O
ER	B-protein
to	O
diminish	O
the	O
DNA-binding	O
activity	O
of	O
GATA-1	B-protein
.	O

These	O
results	O
suggest	O
that	O
additional	O
factor	O
(	O
s	O
)	O
are	O
necessary	O
for	O
full	O
ER	B-protein
function	O
.	O

Both	O
GATA-1	B-protein
and	O
CACCC-binding	B-protein
proteins	I-protein
are	O
critical	O
for	O
the	O
developmentally	O
regulated	O
expression	O
of	O
erythroid-specific	B-DNA
genes	I-DNA
.	O

We	O
hypothesize	O
that	O
interference	O
in	O
DNA-binding	O
activities	O
of	O
GATA-1	B-protein
and	O
CACCC-binding	B-protein
proteins	I-protein
is	O
the	O
mechanism	O
by	O
which	O
the	O
ER	B-protein
inhibits	O
regulation	O
of	O
these	O
genes	O
.	O

Regulation	O
of	O
Id3	B-protein
cell	O
cycle	O
function	O
by	O
Cdk-2-dependent	O
phosphorylation	O
.	O

The	O
functions	O
of	O
basic	B-protein
helix-loop-helix	I-protein
(	I-protein
bHLH	I-protein
)	I-protein
transcription	I-protein
factors	I-protein
in	O
activating	O
differentiation-linked	O
gene	O
expression	O
and	O
in	O
inducing	O
G1	O
cell	O
cycle	O
arrest	O
are	O
negatively	O
regulated	O
by	O
members	O
of	O
the	O
Id	B-protein
family	I-protein
of	I-protein
HLH	I-protein
proteins	I-protein
.	O

These	O
bHLH	B-protein
antagonists	I-protein
are	O
induced	O
during	O
a	O
mitogenic	O
signalling	O
response	O
,	O
and	O
they	O
function	O
by	O
sequestering	O
their	O
bHLH	B-protein
targets	I-protein
in	O
inactive	B-protein
heterodimers	I-protein
that	O
are	O
unable	O
to	O
bind	O
to	O
specific	O
gene	B-DNA
regulatory	I-DNA
(	I-DNA
E	I-DNA
box	I-DNA
)	I-DNA
sequences	I-DNA
.	O

Recently	O
,	O
cyclin	O
E-Cdk2-	O
and	O
cyclin	O
A-Cdk2-dependent	O
phosphorylation	O
of	O
a	O
single	O
conserved	O
serine	O
residue	O
(	O
Ser5	O
)	O
in	O
Id2	B-protein
has	O
been	O
shown	O
to	O
occur	O
during	O
late	O
G1-to-S	O
phase	O
transition	O
of	O
the	O
cell	O
cycle	O
,	O
and	O
this	O
neutralizes	O
the	O
function	O
of	O
Id2	B-protein
in	O
abrogating	O
E-box-dependent	B-protein
bHLH	I-protein
homo	O
-or	O
heterodimer	O
complex	O
formation	O
in	O
vitro	O
(	O
E.Hara	O
,	O
M.Hall	O
,	O
and	O
G.Peters	O
,	O
EMBO	O
J.16	O
:	O
332-342	O
,	O
1997	O
)	O
.	O

We	O
now	O
show	O
that	O
an	O
analogous	O
cell-cycle-regulated	O
phosphorylation	O
of	O
Id3	B-protein
alters	O
the	O
specificity	O
of	O
Id3	B-protein
for	O
abrogating	O
both	O
E-box-dependent	B-protein
bHLH	I-protein
homo-	O
or	O
heterodimer	O
complex	O
formation	O
in	O
vitro	O
and	O
E-box-dependent	O
reporter	B-DNA
gene	I-DNA
function	O
in	O
vivo	O
.	O

Furthermore	O
,	O
compared	O
with	O
wild-type	B-protein
Id3	I-protein
,	O
an	O
Id3	B-protein
Asp5	I-protein
mutant	I-protein
(	O
mimicking	O
phosphorylation	O
)	O
is	O
unable	O
to	O
promote	O
cell	O
cycle	O
S	O
phase	O
entry	O
in	O
transfected	B-cell_line
fibroblasts	I-cell_line
,	O
whereas	O
an	O
Id3	B-protein
Ala5	I-protein
mutant	I-protein
(	O
ablating	O
phosphorylation	O
)	O
displays	O
an	O
activity	O
significantly	O
greater	O
than	O
that	O
of	O
wild-type	B-protein
Id3	I-protein
protein	I-protein
.	O

Cdk2-dependent	O
phosphorylation	O
therefore	O
provides	O
a	O
switch	O
during	O
late	O
G1-to-S	O
phase	O
that	O
both	O
nullifies	O
an	O
early	O
G1	O
cell	O
cycle	O
regulatory	O
function	O
of	O
Id3	B-protein
and	O
modulates	O
its	O
target	O
bHLH	B-protein
specificity	O
.	O

These	O
data	O
also	O
demonstrate	O
that	O
the	O
ability	O
of	O
Id3	B-protein
to	O
promote	O
cell	O
cycle	O
S	O
phase	O
entry	O
is	O
not	O
simply	O
a	O
function	O
of	O
its	O
ability	O
to	O
modulate	O
bHLH	B-protein
heterodimer-dependent	O
gene	O
expression	O
and	O
establish	O
a	O
biologically	O
important	O
mechanism	O
through	O
which	O
Cdk2	O
and	O
Id-bHLH	O
functions	O
are	O
integrated	O
in	O
the	O
coordination	O
of	O
cell	O
proliferation	O
and	O
differentiation	O
.	O

Molecular	O
cloning	O
and	O
functional	O
characterization	O
of	O
murine	B-protein
cDNA	I-protein
encoding	I-protein
transcription	I-protein
factor	I-protein
NFATc	B-protein
.	O

Transcription	B-protein
factors	I-protein
of	O
the	O
NFAT	B-protein
(	I-protein
nuclear	I-protein
factor	I-protein
of	I-protein
activated	I-protein
T	I-protein
cells	I-protein
)	I-protein
family	I-protein
play	O
important	O
roles	O
in	O
immune	O
and	O
inflammatory	O
responses	O
by	O
regulating	O
the	O
expression	O
of	O
genes	O
encoding	O
cytokines	B-protein
and	O
immunoregulatory	B-protein
proteins	I-protein
.	O

Here	O
we	O
describe	O
cloning	O
and	O
characterization	O
of	O
full-length	O
cDNA	B-protein
encoding	I-protein
murine	I-protein
(	I-protein
m	I-protein
)	I-protein
NFATc	I-protein
which	O
predicts	O
that	O
the	O
protein	O
has	O
all	O
the	O
conserved	B-protein
structural	I-protein
motifs	I-protein
of	O
NFAT	B-protein
family	I-protein
members	I-protein
,	O
including	O
the	O
rel	O
homology	O
domain	O
,	O
the	O
NFAT	B-protein
homology	I-protein
domain	I-protein
and	O
the	O
nuclear	O
translocation	O
signals	O
.	O

mNFATc	B-protein
complexed	O
with	O
AP-1	B-protein
bound	O
specifically	O
to	O
the	O
murine	B-protein
IL-2	I-protein
NFAT	I-protein
recognition	I-protein
sequence	I-protein
and	O
activated	O
transcription	O
from	O
the	O
co-transfected	B-DNA
IL-2	I-DNA
promoter	I-DNA
in	O
COS-7	B-cell_line
cells	I-cell_line
.	O

Northern	O
blot	O
analysis	O
showed	O
that	O
the	O
cDNA	B-DNA
probe	I-DNA
hybridized	O
with	O
a	O
4.5	O
kb	O
transcript	O
which	O
is	O
highly	O
inducible	O
in	O
murine	B-cell_type
T	I-cell_type
cells	I-cell_type
.	O

By	O
Northern	O
and	O
in	O
situ	O
hybridization	O
,	O
mNFATc	B-RNA
transcript	I-RNA
was	O
detected	O
from	O
the	O
early	O
stage	O
of	O
development	O
.	O

In	O
the	O
mouse	O
embryo	O
,	O
mNFATc	B-RNA
transcript	I-RNA
was	O
strongly	O
expressed	O
in	O
thymus	O
,	O
lung	O
and	O
submandibular	O
gland	O
and	O
weakly	O
in	O
skeletal	O
muscle	O
and	O
heart	O
suggesting	O
that	O
mNFATc	B-protein
may	O
have	O
a	O
role	O
both	O
in	O
embryogenesis	O
and	O
in	O
mature	B-cell_type
T	I-cell_type
cells	I-cell_type
.	O

TNFalpha	B-protein
cooperates	O
with	O
the	O
protein	B-protein
kinase	I-protein
A	I-protein
pathway	O
to	O
synergistically	O
increase	O
HIV-1	B-DNA
LTR	I-DNA
transcription	O
via	O
downstream	O
TRE-like	B-DNA
cAMP	I-DNA
response	I-DNA
elements	I-DNA
.	O

Activating	B-protein
protein-1	I-protein
(	O
AP-1	B-protein
)	O
binding	O
TPA	B-DNA
responsive	I-DNA
elements	I-DNA
(	O
TRE	B-DNA
)	O
are	O
located	O
downstream	O
of	O
the	O
transcription	B-DNA
initiation	I-DNA
site	I-DNA
in	O
the	O
U5	B-DNA
region	I-DNA
of	O
the	O
HIV-1	B-DNA
long	I-DNA
terminal	I-DNA
repeat	I-DNA
(	O
LTR	B-DNA
)	O
.	O

These	O
downstream	B-DNA
sequence	I-DNA
elements	I-DNA
,	O
termed	O
DSE	B-DNA
,	O
can	O
bind	O
both	O
AP-1	B-protein
and	O
CREB/ATF	B-protein
transcription	B-protein
factors	I-protein
.	O

Recently	O
,	O
we	O
demonstrated	O
that	O
the	O
DSE	B-DNA
are	O
also	O
cAMP-responsive	B-DNA
elements	I-DNA
(	O
CRE	B-DNA
)	O
,	O
since	O
they	O
mediated	O
activation	O
signals	O
elicited	O
by	O
cholera	B-protein
toxin	I-protein
(	O
Ctx	B-protein
)	O
,	O
a	O
potent	O
activator	O
of	O
the	O
cAMP-dependent	O
protein	B-protein
kinase	I-protein
A	I-protein
(	O
PKA	B-protein
)	O
signal	O
transduction	O
pathway	O
.	O

In	O
the	O
present	O
study	O
,	O
we	O
demonstrate	O
that	O
the	O
HIV-1	B-DNA
DSE	I-DNA
can	O
mediate	O
the	O
transcriptional	O
synergy	O
elicited	O
by	O
the	O
combination	O
of	O
Ctx	B-protein
and	O
TNFalpha	B-protein
.	O

Ctx	B-protein
combined	O
with	O
TNFalpha	B-protein
or	O
IL-1beta	B-protein
to	O
produce	O
a	O
synergistic	O
increase	O
in	O
p24	B-protein
antigen	I-protein
production	O
in	O
U1	B-cell_line
promonocytic	I-cell_line
cells	I-cell_line
.	O

Transfection	O
studies	O
of	O
LTR	B-DNA
reporter	I-DNA
constructs	I-DNA
indicated	O
that	O
mutation	O
of	O
the	O
DSE	B-DNA
sites	I-DNA
abrogated	O
the	O
LTR	B-DNA
-mediated	O
synergy	O
induced	O
by	O
Ctx	B-protein
and	O
TNFalpha	B-protein
,	O
whereas	O
the	O
synergy	O
induced	O
by	O
Ctx	B-protein
and	O
IL-1beta	B-protein
was	O
unaffected	O
,	O
suggesting	O
TNFalpha	B-protein
and	O
IL-1beta	B-protein
cooperate	O
differently	O
with	O
the	O
cAMP	O
/PKA	B-protein
activation	O
pathway	O
to	O
induce	O
HIV-1	O
expression	O
in	O
U1	B-cell_line
cells	I-cell_line
.	O

Because	O
the	O
DSE	B-DNA
are	O
also	O
TRE	B-DNA
sites	O
,	O
we	O
assessed	O
the	O
effect	O
of	O
the	O
agonist	O
combinations	O
on	O
AP-1	B-protein
-dependent	O
transcription	O
.	O

TNFalpha	B-protein
as	O
well	O
as	O
IL-1beta	B-protein
cooperated	O
with	O
Ctx	B-protein
to	O
produce	O
a	O
synergistic	O
activation	O
of	O
AP-1	B-protein
-mediated	O
transcription	O
.	O

These	O
data	O
indicate	O
that	O
the	O
TRE-like	B-DNA
cAMP-responsive	I-DNA
DSE	I-DNA
sites	I-DNA
within	O
the	O
5'-untranslated	B-DNA
leader	I-DNA
can	O
mediate	O
the	O
transcriptional	O
cooperativity	O
between	O
TNFalpha	B-protein
and	O
the	O
cAMP	O
/PKA	B-protein
pathway	O
.	O

Since	O
the	O
DSE	B-DNA
and	O
TRE	B-DNA
sites	O
can	O
not	O
bind	O
CREB/ATF	B-protein
homodimers	I-protein
,	O
we	O
propose	O
a	O
mechanism	O
in	O
which	O
the	O
HIV-1	O
DSE	B-DNA
bind	O
heterodimers	B-protein
composed	O
of	O
both	O
AP-1	B-protein
and	I-protein
CREB/ATF	I-protein
proteins	I-protein
.	O

Copyright	O
1997	O
Academic	O
Press	O
.	O

Association	O
of	O
glucocorticoid	O
insensitivity	O
with	O
increased	O
expression	O
of	O
glucocorticoid	B-protein
receptor	I-protein
beta	I-protein
.	O

In	O
many	O
chronic	O
inflammatory	O
disorders	O
,	O
glucocorticoid	O
(	O
GC	O
)	O
insensitivity	O
is	O
a	O
challenging	O
clinical	O
problem	O
associated	O
with	O
life-threatening	O
disease	O
progression	O
.	O

The	O
molecular	O
basis	O
of	O
GC	O
insensitivity	O
,	O
however	O
,	O
is	O
unknown	O
.	O

Alternative	O
splicing	O
of	O
the	O
GC	B-RNA
receptor	I-RNA
(	I-RNA
R	I-RNA
)	I-RNA
pre-messenger	I-RNA
RNA	I-RNA
generates	O
a	O
second	O
GCR	B-protein
,	O
termed	O
GCR-beta	B-protein
,	O
which	O
does	O
not	O
bind	O
GCs	O
but	O
antagonizes	O
the	O
transactivating	O
activity	O
of	O
the	O
classic	O
GCR	B-protein
,	O
termed	O
GCR-alpha	B-protein
.	O

In	O
the	O
current	O
study	O
,	O
we	O
demonstrate	O
that	O
GC-insensitive	O
asthma	O
is	O
associated	O
with	O
a	O
significantly	O
higher	O
number	O
of	O
GCR-beta-immunoreactive	B-cell_type
cells	I-cell_type
in	O
peripheral	O
blood	O
than	O
GC-sensitive	O
asthmatics	O
or	O
normal	O
controls	O
.	O

Furthermore	O
,	O
we	O
show	O
that	O
patients	O
with	O
GC-insensitive	O
asthma	O
have	O
cytokine-induced	O
abnormalities	O
in	O
the	O
DNA	O
binding	O
capability	O
of	O
the	O
GCR	B-protein
.	O

These	O
abnormalities	O
can	O
be	O
reproduced	O
by	O
transfection	O
of	O
cell	B-cell_line
lines	I-cell_line
with	O
the	O
GCR-beta	B-protein
gene	O
resulting	O
in	O
significant	O
reduction	O
of	O
their	O
GCR-alpha	B-protein
DNA	O
binding	O
capacity	O
.	O

We	O
conclude	O
that	O
increased	O
expression	O
of	O
GCR-beta	B-protein
is	O
cytokine	B-protein
inducible	O
and	O
may	O
account	O
for	O
GC	O
insensitivity	O
in	O
this	O
common	O
inflammatory	O
condition	O
.	O

Epstein-Barr	O
virus	O
EBNA3C	B-protein
represses	O
Cp	B-DNA
,	O
the	O
major	O
promoter	O
for	O
EBNA	B-protein
expression	O
,	O
but	O
has	O
no	O
effect	O
on	O
the	O
promoter	O
of	O
the	O
cell	B-DNA
gene	I-DNA
CD21	I-DNA
.	O

EBNA3C	B-protein
is	O
a	O
potent	O
repressor	O
of	O
transcription	O
when	O
bound	O
to	O
DNA	O
as	O
a	O
fusion	O
with	O
the	O
DNA	B-protein
binding	I-protein
domain	I-protein
(	O
DBD	B-protein
)	O
of	O
GALA	O
.	O

A	O
survey	O
of	O
promoters	O
has	O
revealed	O
that	O
the	O
wild-type	B-protein
,	I-protein
unfused	I-protein
EBNA3C	I-protein
can	O
specifically	O
repress	O
expression	O
from	O
reporter	B-DNA
plasmids	I-DNA
containing	O
the	O
Epstein-Barr	O
virus	O
Cp	B-DNA
latency-associated	I-DNA
promoter	I-DNA
.	O

Repression	O
of	O
Cp	B-DNA
activity	O
required	O
amino	B-protein
acids	I-protein
207	I-protein
to	I-protein
368	I-protein
,	O
which	O
encompasses	O
a	O
region	O
resembling	O
a	O
basic	B-protein
DBD	I-protein
adjacent	O
to	O
a	O
leucine	B-protein
zipper	I-protein
DNA	I-protein
binding	I-protein
motif	I-protein
and	O
a	O
site	O
which	O
binds	O
to	O
the	O
cellular	B-protein
factor	I-protein
CBF1/RBP-Jkappa	I-protein
.	O

However	O
,	O
amino	O
acids	O
207	O
to	O
368	O
are	O
dispensable	O
when	O
the	O
protein	O
is	O
bound	O
to	O
DNA	O
as	O
a	O
fusion	O
with	O
the	O
GAL4	O
DBD	B-protein
,	O
thus	O
implicating	O
this	O
region	O
in	O
DNA	O
binding	O
.	O

Mutation	O
of	O
the	O
CBF1/RBP-Jkappa	B-protein
binding	I-protein
site	I-protein
in	O
EBNA3C	B-protein
abrogated	O
repression	O
,	O
strongly	O
suggesting	O
that	O
CBF1/RBP-Jkappa	B-protein
is	O
necessary	O
for	O
targeting	O
the	O
viral	O
protein	O
to	O
Cp	B-DNA
.	O

Consistent	O
with	O
this	O
result	O
,	O
mutation	O
of	O
the	O
EBNA2	B-DNA
response	I-DNA
element	I-DNA
(	O
a	O
CBF1/RBP-Jkappa	B-DNA
binding	I-DNA
site	I-DNA
)	O
in	O
Cp	B-DNA
also	O
prevented	O
significant	O
repression	O
.	O

In	O
addition	O
,	O
amino	B-protein
acids	I-protein
346	I-protein
to	I-protein
543	I-protein
,	O
which	O
were	O
previously	O
defined	O
as	O
important	O
for	O
the	O
repressor	O
activity	O
of	O
the	O
GAL4-EBNA3C	B-protein
fusion	I-protein
proteins	I-protein
,	O
also	O
appear	O
to	O
be	O
necessary	O
for	O
the	O
repression	O
of	O
Cp	B-DNA
.	O

Since	O
repression	O
by	O
these	O
fusions	O
was	O
not	O
observed	O
in	O
all	O
cell	O
types	O
,	O
it	O
seems	O
likely	O
that	O
EBNA3C	B-protein
either	O
depends	O
on	O
a	O
corepressor	B-protein
which	O
may	O
interact	O
with	O
amino	B-protein
acids	I-protein
346	I-protein
to	I-protein
543	I-protein
or	O
is	O
modified	O
in	O
a	O
cell-specific	O
manner	O
in	O
order	O
to	O
repress	O
.	O

These	O
data	O
are	O
consistent	O
with	O
EBNA3C	B-protein
contributing	O
to	O
the	O
regulation	O
of	O
EBNA	B-protein
expression	O
in	O
latently	B-cell_type
infected	I-cell_type
B	I-cell_type
cells	I-cell_type
through	O
CBF1/RBP-Jkappa	B-protein
and	O
another	O
factor	O
,	O
but	O
this	O
need	O
not	O
directly	O
involve	O
EBNA2	B-protein
.	O

Finally	O
,	O
although	O
it	O
has	O
been	O
reported	O
that	O
EBNA3C	B-protein
can	O
upregulate	O
CD21	B-protein
in	O
some	O
B	B-cell_type
cells	I-cell_type
,	O
we	O
were	O
unable	O
to	O
demonstrate	O
any	O
effect	O
of	O
EBNA3C	B-protein
on	O
reporter	B-DNA
plasmids	I-DNA
which	O
contain	O
the	O
CD21	B-DNA
promoter	I-DNA
.	O

Relationship	O
between	O
glucocorticoid	B-protein
receptor	I-protein
and	O
response	O
to	O
glucocorticoid	O
therapy	O
in	O
ulcerative	O
colitis	O
.	O

PURPOSE	O
:	O
To	O
clarify	O
the	O
relationship	O
between	O
the	O
glucocorticoid	B-protein
receptor	I-protein
and	O
the	O
effectiveness	O
of	O
glucocorticoid	O
therapy	O
in	O
patients	O
with	O
ulcerative	O
colitis	O
,	O
we	O
investigated	O
the	O
number	O
and	O
apparent	O
dissociation	O
constant	O
of	O
glucocorticoid	B-protein
receptor	I-protein
in	O
peripheral	B-cell_type
blood	I-cell_type
mononuclear	I-cell_type
leukocytes	I-cell_type
of	O
patients	O
with	O
ulcerative	O
colitis	O
.	O

MATERIALS	O
AND	O
METHODS	O
:	O
Eleven	O
patients	O
with	O
ulcerative	O
colitis	O
(	O
5	O
who	O
responded	O
to	O
intravenous	O
glucocorticoids	O
and	O
6	O
who	O
did	O
not	O
)	O
and	O
ten	O
control	O
subjects	O
were	O
studied	O
.	O

The	O
number	O
and	O
apparent	O
dissociation	O
constant	O
of	O
glucocorticoid	B-protein
receptor	I-protein
were	O
measured	O
using	O
a	O
whole-cell	O
binding	O
assay	O
.	O

Results	O
were	O
expressed	O
as	O
a	O
median	O
(	O
interquartile	O
range	O
)	O
.	O

RESULTS	O
:	O
The	O
number	O
of	O
glucocorticoid	B-protein
receptors	I-protein
from	O
the	O
six	O
nonresponders	O
,	O
five	O
responders	O
,	O
and	O
ten	O
healthy	O
controls	O
were	O
4922	O
(	O
range	O
,	O
4484-5643	O
)	O
,	O
3413	O
(	O
range	O
,	O
3183-4450	O
)	O
,	O
and	O
3610	O
(	O
range	O
,	O
2594-3979	O
)	O
binding	O
sites/cell	O
,	O
respectively	O
.	O

The	O
apparent	O
dissociation	O
constant	O
of	O
the	O
glucocorticoid	B-protein
receptors	I-protein
from	O
the	O
nonresponders	O
,	O
responders	O
,	O
and	O
healthy	O
controls	O
were	O
7.03	O
(	O
range	O
,	O
5.66-10	O
)	O
,	O
4.27	O
(	O
range	O
,	O
4-5.13	O
)	O
,	O
and	O
6.18	O
(	O
range	O
,	O
5.86-6.74	O
)	O
nM	O
,	O
respectively	O
.	O

Nonresponders	O
had	O
a	O
significant	O
increase	O
both	O
in	O
the	O
number	O
of	O
binding	B-protein
sites	I-protein
and	O
in	O
the	O
apparent	O
dissociation	O
constant	O
compared	O
with	O
responders	O
(	O
P	O
=	O
0.045	O
;	O
P	O
=	O
0.029	O
)	O
.	O

CONCLUSIONS	O
:	O
The	O
increased	O
number	O
and	O
apparent	O
dissociation	O
constant	O
of	O
glucocorticoid	B-protein
receptor	I-protein
are	O
closely	O
associated	O
with	O
the	O
effectiveness	O
of	O
glucocorticoid	O
therapy	O
.	O

The	O
measurement	O
of	O
the	O
number	O
and	O
apparent	O
dissociation	O
constant	O
of	O
glucocorticoid	B-protein
receptor	I-protein
may	O
be	O
useful	O
in	O
predicting	O
response	O
to	O
glucocorticoids	O
.	O

Cooperation	O
of	O
binding	B-protein
sites	I-protein
for	O
STAT6	B-protein
and	O
NF	B-protein
kappa	I-protein
B/rel	I-protein
in	O
the	O
IL-4	B-protein
-induced	O
up-regulation	O
of	O
the	O
human	B-DNA
IgE	I-DNA
germline	I-DNA
promoter	I-DNA
.	O

Ig	B-protein
heavy	I-protein
chain	I-protein
class	O
switching	O
is	O
directed	O
by	O
cytokines	B-protein
inducing	O
transcription	O
from	O
unrearranged	O
CH	B-DNA
genes	I-DNA
.	O

Subsequently	O
,	O
such	O
primed	B-cell_type
cells	I-cell_type
can	O
undergo	O
switch	O
recombination	O
to	O
express	O
the	O
selected	O
new	O
isotype	O
.	O

In	O
the	O
case	O
of	O
IgE	B-protein
class	O
switching	O
,	O
IL-4	B-protein
activates	O
the	O
IgE	B-DNA
germline	I-DNA
promoter	I-DNA
by	O
inducing	O
the	O
interaction	O
of	O
the	O
transcription	B-protein
factor	I-protein
STAT6	B-protein
(	O
IL-4STAT	B-protein
)	O
with	O
a	O
responsive	B-DNA
DNA	I-DNA
element	I-DNA
in	O
the	O
proximal	B-DNA
region	I-DNA
of	O
the	O
promoter	B-DNA
.	O

This	O
study	O
describes	O
the	O
characterization	O
of	O
two	O
additional	O
cis-acting	B-DNA
elements	I-DNA
that	O
interact	O
with	O
members	O
of	O
the	O
NF	B-protein
kappa	I-protein
B/rel	I-protein
transcription	I-protein
factor	I-protein
family	I-protein
in	O
an	O
IL-4	B-protein
-independent	O
fashion	O
.	O

Electrophoretic	O
mobility	O
shift	O
assays	O
show	O
that	O
the	O
nucleoprotein	B-protein
complex	I-protein
formed	O
on	O
the	O
upstream	B-DNA
site	I-DNA
(	O
NF	B-protein
kappa	I-protein
B1	I-protein
)	O
contains	O
the	O
classical	B-protein
p50/p65	I-protein
heterodimer	I-protein
.	O

The	O
complex	O
on	O
the	O
proximal	B-DNA
site	I-DNA
(	O
NF	B-protein
kappa	I-protein
B2	I-protein
)	O
appears	O
to	O
be	O
composed	O
of	O
p50	B-protein
and	O
relB	B-protein
.	O

IgE	B-DNA
germline	I-DNA
promoter	I-DNA
reporter	I-DNA
gene	I-DNA
constructs	I-DNA
carrying	O
point	O
mutations	O
in	O
the	O
NF	B-protein
kappa	I-protein
B2	I-protein
site	O
were	O
largely	O
unresponsive	O
to	O
IL-4	B-protein
stimulation	O
in	O
transient	O
transfection	O
experiments	O
,	O
while	O
plasmids	O
with	O
similar	O
mutations	O
in	O
the	O
NF	B-protein
kappa	I-protein
B1	I-protein
site	O
responded	O
to	O
cytokine	B-protein
stimulation	O
better	O
than	O
the	O
wild-type	B-DNA
promoter	I-DNA
.	O

The	O
NF	B-protein
kappa	I-protein
B2	I-protein
effect	O
was	O
dependent	O
on	O
the	O
presence	O
of	O
the	O
STAT6	B-DNA
binding	I-DNA
site	I-DNA
,	O
demonstrating	O
that	O
the	O
NF	B-protein
kappa	I-protein
B2	I-protein
motif	I-protein
is	O
necessary	O
but	O
not	O
sufficient	O
for	O
mediating	O
cytokine	B-protein
up-regulation	O
.	O

In	O
addition	O
,	O
the	O
combination	O
of	O
a	O
NF	B-DNA
kappa	I-DNA
B/rel	I-DNA
binding	I-DNA
site	I-DNA
and	O
the	O
STAT6	B-DNA
response	I-DNA
element	I-DNA
conferred	O
IL-4	B-protein
inducibility	O
to	O
a	O
heterologous	B-DNA
minimal	I-DNA
promoter	I-DNA
,	O
while	O
the	O
individual	O
sites	O
had	O
no	O
effect	O
.	O

The	O
available	O
data	O
suggest	O
that	O
the	O
NF	B-protein
kappa	I-protein
B2	I-protein
nucleoprotein	I-protein
complex	I-protein
may	O
cooperate	O
with	O
DNA-bound	B-protein
STAT6	I-protein
to	O
achieve	O
IL-4	B-protein
-dependent	O
activation	O
of	O
the	O
human	B-DNA
IgE	I-DNA
germline	I-DNA
gene	I-DNA
.	O

Alcohol-induced	O
regulation	O
of	O
nuclear	B-protein
regulatory	I-protein
factor-kappa	I-protein
beta	I-protein
in	O
human	B-cell_type
monocytes	I-cell_type
.	O

Acute	O
ethanol	O
exposure	O
has	O
the	O
capacity	O
to	O
modulate	O
immune	O
functions	O
,	O
particularly	O
,	O
to	O
down	O
regulate	O
monocyte	O
production	O
of	O
inflammatory	B-protein
cytokines	I-protein
.	O

However	O
,	O
the	O
intracellular	O
mechanisms	O
for	O
these	O
effects	O
of	O
ethanol	O
are	O
yet	O
to	O
be	O
understood	O
.	O

Considering	O
that	O
nuclear	B-protein
regulatory	I-protein
factor-kappa	I-protein
beta	I-protein
(	B-protein
NF-kappa	I-protein
B	I-protein
)	I-protein
/Rel	I-protein
is	O
a	O
common	O
regulatory	B-protein
element	I-protein
of	O
the	O
promoter	B-DNA
region	I-DNA
of	O
the	O
inflammatory	B-DNA
cytokine	I-DNA
genes	I-DNA
,	O
herein	O
,	O
we	O
tested	O
the	O
hypothesis	O
that	O
acute	O
ethanol	O
affects	O
NF-kappa	B-protein
B	I-protein
activation	O
in	O
human	B-cell_type
monocytes	I-cell_type
.	O

Adherence-isolated	B-cell_line
monocytes	I-cell_line
showed	O
constitutive	O
DNA	O
binding	O
activity	O
of	O
NF-kappa	B-protein
B	I-protein
.	O

A	O
clinically	O
relevant	O
dose	O
(	O
25	O
mM	O
)	O
of	O
acute	O
ethanol	O
treatment	O
in	O
vitro	O
increased	O
NF-kappa	B-protein
B	I-protein
binding	O
activity	O
in	O
monocytes	B-cell_type
with	O
a	O
preferential	O
induction	O
of	O
the	O
inhibitory	O
,	O
p50/p50	B-protein
,	O
NF-kappa	B-protein
B/Rel	I-protein
homodimer	I-protein
,	O
and	O
resulted	O
in	O
no	O
induction	O
of	O
the	O
p65/p50	B-protein
heterodimer	I-protein
.	O

In	O
contrast	O
,	O
lipopolysaccharide	O
stimulation	O
primarily	O
induced	O
the	O
p65/p50	B-protein
heterodimer	I-protein
that	O
has	O
been	O
shown	O
to	O
result	O
in	O
gene	O
activation	O
.	O

Thus	O
,	O
such	O
unique	O
activation	O
of	O
the	O
inhibitory	B-protein
p50/p50	I-protein
homodimer	I-protein
by	O
acute	O
ethanol	O
treatment	O
may	O
result	O
in	O
inhibition	O
rather	O
than	O
activation	O
of	O
NF-kappa	B-DNA
B-regulated	I-DNA
inflammatory	I-DNA
cytokine	I-DNA
genes	I-DNA
.	O

Consequently	O
,	O
these	O
results	O
suggest	O
that	O
physiologically	O
relevant	O
concentrations	O
of	O
ethanol	O
may	O
affect	O
production	O
of	O
inflammatory	B-protein
cytokines	I-protein
,	O
such	O
as	O
tumor	B-protein
necrosis	I-protein
factor-alpha	I-protein
,	O
interleukin-1	B-protein
beta	I-protein
,	O
and	O
interleukin-6	B-protein
by	O
disrupting	O
NF-kappa	B-protein
B	I-protein
signaling	O
in	O
monocytes	B-cell_type
.	O

LPS	O
tolerance	O
in	O
monocytes/macrophages	B-cell_type
:	O
three	O
3	O
'	O
cytosins	O
are	O
required	O
in	O
the	O
DNA	B-DNA
binding	I-DNA
motif	I-DNA
for	O
detection	O
of	O
upregulated	O
NF-kappa	B-protein
B	I-protein
p50	I-protein
homodimers	I-protein
.	O

When	O
monocytes	B-cell_type
are	O
stimulated	O
with	O
LPS	O
(	O
lipopolysaccharide	O
)	O
repeatedly	O
then	O
the	O
initially	O
high	O
expression	O
of	O
the	O
TNF	B-DNA
(	I-DNA
tumor	I-DNA
necrosis	I-DNA
factor	I-DNA
)	I-DNA
gene	I-DNA
is	O
only	O
very	O
low	O
,	O
i.e.	O
the	O
cells	O
are	O
tolerant	O
to	O
LPS	O
.	O

Tolerant	O
cells	O
still	O
express	O
the	O
CD14	B-protein
receptor	I-protein
and	O
they	O
can	O
still	O
be	O
activated	O
to	O
mobilize	O
NF-kappa	B-protein
B	I-protein
into	O
nucleus	O
.	O

Analysis	O
of	O
the	O
binding	O
proteins	O
employing	O
the	O
-605	O
motif	O
of	O
the	O
human	B-DNA
TNF	I-DNA
promoter	I-DNA
(	O
GGGGCTGTCCC	O
)	O
revealed	O
that	O
in	O
tolerant	O
cells	O
of	O
the	O
human	B-cell_line
monocytic	I-cell_line
cell	I-cell_line
line	I-cell_line
Mono	B-cell_line
Mac	I-cell_line
6	I-cell_line
there	O
is	O
a	O
predominance	O
of	O
p50p50	B-protein
of	O
NF-kappa	B-protein
B	I-protein
.	O

We	O
now	O
show	O
that	O
a	O
mutant	B-DNA
motif	I-DNA
that	O
exchanges	O
the	O
terminal	O
3	O
'	O
C	O
for	O
a	O
G	O
fails	O
to	O
bind	O
the	O
p50	B-protein
homodimer	I-protein
that	O
is	O
upregulated	O
in	O
LPS	O
toler	O
ant	O
human	B-cell_line
Mono	I-cell_line
Mac	I-cell_line
6	I-cell_line
cells	I-cell_line
.	O

The	O
same	O
is	O
true	O
for	O
nuclear	O
extracts	O
taken	O
from	O
the	O
murine	B-cell_line
P388D1	I-cell_line
macrophage	I-cell_line
cell	I-cell_line
line	I-cell_line
when	O
tested	O
with	O
the	O
-516	B-DNA
motif	I-DNA
of	O
the	O
murine	B-DNA
TNF	I-DNA
promoter	I-DNA
(	O
GGGGGCTTTCCC	O
)	O
.	O

Here	O
the	O
wild	B-DNA
type	I-DNA
motif	I-DNA
gives	O
efficient	O
binding	O
of	O
p50p50	B-protein
that	O
again	O
is	O
upregulated	O
in	O
tolerant	B-cell_type
cells	I-cell_type
whereas	O
a	O
mutant	O
with	O
a	O
3	O
'	O
G	O
shows	O
hardly	O
any	O
binding	O
of	O
p50p50	B-protein
.	O

Conversely	O
,	O
the	O
murine	B-DNA
kappa	I-DNA
light	I-DNA
chain	I-DNA
enhancer	I-DNA
motif	I-DNA
(	O
GGGGACTTTCCG	O
)	O
does	O
not	O
efficiently	O
bind	O
the	O
nuclear	O
p50p50	B-protein
from	O
tolerant	B-cell_line
murine	I-cell_line
P388	I-cell_line
macrophages	I-cell_line
.	O

Binding	O
is	O
,	O
however	O
,	O
readily	O
detected	O
when	O
the	O
3	O
'	O
G	O
is	O
replaced	O
by	O
a	O
C	O
.	O

These	O
data	O
show	O
that	O
the	O
detection	O
of	O
upregulated	O
p50	B-protein
homodimers	I-protein
in	O
LPS	O
tolerant	B-cell_type
cells	I-cell_type
is	O
dependent	O
on	O
subtle	O
differences	O
in	O
the	O
sequence	O
of	O
the	O
DNA	B-DNA
binding	I-DNA
motif	I-DNA
.	O

Cyclosporin	O
A	O
inhibits	O
early	O
mRNA	O
expression	O
of	O
G0/G1	B-DNA
switch	I-DNA
gene	I-DNA
2	I-DNA
(	O
G0S2	B-DNA
)	O
in	O
cultured	B-cell_line
human	I-cell_line
blood	I-cell_line
mononuclear	I-cell_line
cells	I-cell_line
.	O

Cyclosporin	O
A	O
(	O
CsA	O
)	O
may	O
achieve	O
its	O
immunosuppressive	O
effects	O
by	O
inhibiting	O
the	O
calcium-	B-protein
and	I-protein
calmodulin-dependent	I-protein
phosphatase	I-protein
calcineurin	B-protein
which	O
is	O
required	O
for	O
activation	O
of	O
target	B-DNA
genes	I-DNA
by	O
members	O
of	O
the	O
NFAT	B-protein
(	I-protein
nuclear	I-protein
factor	I-protein
of	I-protein
activated	I-protein
T	I-protein
cells	I-protein
)	I-protein
transcription	I-protein
factor	I-protein
family	I-protein
.	O

Among	O
these	O
target	B-DNA
genes	I-DNA
is	O
the	O
gene	O
encoding	O
interleukin-2	B-protein
(	O
IL2	B-protein
)	O
,	O
a	O
cytokine	B-protein
facilitating	O
progression	O
through	O
the	O
G1	O
phase	O
of	O
the	O
cell	O
cycle	O
.	O

However	O
,	O
IL2	B-protein
does	O
not	O
reverse	O
CsA	O
inhibition	O
,	O
suggesting	O
that	O
at	O
least	O
one	O
other	O
NFAT-sensitive	B-DNA
gene	I-DNA
may	O
be	O
involved	O
.	O

The	O
human	B-DNA
G0/G1	I-DNA
switch	I-DNA
gene	I-DNA
,	O
G0S2	B-DNA
,	O
has	O
potential	O
NFAT-binding	B-DNA
sites	I-DNA
in	O
the	O
5	B-DNA
'	I-DNA
flank	I-DNA
and	O
encodes	O
a	O
small	B-protein
basic	I-protein
potential	I-protein
phosphoprotein	I-protein
of	O
unknown	O
function	O
.	O

Using	O
a	O
sensitive	O
,	O
reverse	O
transcription-polymerase	O
chain	O
reaction	O
(	O
RT-PCR	O
)	O
assay	O
,	O
G0S2	B-DNA
mRNA	O
levels	O
were	O
assayed	O
in	O
cultured	B-cell_line
blood	I-cell_line
mononuclear	I-cell_line
cells	I-cell_line
.	O

Freshly	O
isolated	O
cells	O
contain	O
high	O
levels	O
of	O
G0S2	B-RNA
mRNA	I-RNA
which	O
rapidly	O
decline	O
.	O

This	O
``	O
spontaneous	O
stimulation	O
''	O
is	O
also	O
noted	O
with	O
some	O
other	O
G0S	B-DNA
genes	I-DNA
and	O
has	O
been	O
attributed	O
to	O
some	O
aspect	O
of	O
the	O
isolation	O
procedure	O
.	O

In	O
cells	O
that	O
have	O
been	O
preincubated	O
to	O
lower	O
mRNA	O
levels	O
,	O
there	O
is	O
a	O
transient	O
increase	O
in	O
G0S2	B-RNA
mRNA	I-RNA
,	O
peaking	O
between	O
1-2	O
h	O
,	O
in	O
response	O
to	O
Concanavalin-A	O
(	O
ConA	O
)	O
,	O
or	O
to	O
the	O
combination	O
of	O
phorbol	O
ester	O
(	O
TPA	O
)	O
,	O
and	O
the	O
calcium	O
ionophore	O
,	O
ionomycin	O
.	O

Both	O
these	O
responses	O
are	O
inhibited	O
by	O
CsA	O
.	O

Our	O
results	O
suggest	O
that	O
G0S2	B-DNA
expression	O
is	O
required	O
to	O
commit	O
cells	O
to	O
enter	O
the	O
G1	O
phase	O
of	O
the	O
cell	O
cycle	O
,	O
and	O
that	O
,	O
while	O
not	O
excluding	O
other	O
possible	O
targets	O
,	O
early	O
inhibition	O
of	O
G0S2	B-DNA
expression	O
by	O
CsA	O
may	O
be	O
important	O
in	O
achieving	O
immunosuppression	O
.	O

G0S2	B-DNA
may	O
be	O
of	O
value	O
as	O
a	O
reporter	O
gene	O
for	O
analyzing	O
the	O
mechanism	O
of	O
action	O
of	O
CsA	O
and	O
its	O
influence	O
on	O
the	O
positive	O
and	O
negative	O
selection	O
of	O
lymphocytes	B-cell_type
in	O
response	O
to	O
self	O
and	O
not-self	O
antigens	O
.	O

c-Rel	B-protein
and	I-protein
p65	I-protein
subunits	I-protein
bind	O
to	O
an	O
upstream	B-DNA
NF-kappaB	I-DNA
site	I-DNA
in	O
human	B-DNA
granulocyte	I-DNA
macrophage-colony	I-DNA
stimulating	I-DNA
factor	I-DNA
promoter	I-DNA
involved	O
in	O
phorbol	O
ester	O
response	O
in	O
5637	B-cell_line
cells	I-cell_line
.	O

To	O
further	O
clarify	O
the	O
complex	O
transcriptional	O
regulation	O
of	O
the	O
human	B-DNA
GM-CSF	I-DNA
gene	I-DNA
,	O
which	O
was	O
extensively	O
investigated	O
in	O
activated	B-cell_type
T	I-cell_type
cells	I-cell_type
,	O
we	O
have	O
studied	O
the	O
role	O
of	O
an	O
upstream	O
NF-kappaB	B-DNA
like	I-DNA
site	I-DNA
in	O
the	O
5637	B-cell_line
non-lymphoid	I-cell_line
cell	I-cell_line
line	I-cell_line
,	O
which	O
derives	O
from	O
a	O
bladder	O
carcinoma	O
and	O
constitutively	O
produces	O
GM-CSF	B-protein
.	O

This	O
sequence	O
,	O
named	O
the	O
A	O
element	O
,	O
has	O
an	O
active	O
role	O
on	O
GM-CSF	B-protein
transcription	O
and	O
is	O
responsive	O
to	O
the	O
tumor	B-DNA
promoter	I-DNA
PMA	I-DNA
in	O
transient	O
transfection	O
experiments	O
.	O

We	O
describe	O
here	O
a	O
heterodimeric	B-protein
binding	I-protein
complex	I-protein
of	O
NF-kappaB	B-protein
subunits	I-protein
(	O
c-Rel	B-protein
and	O
p65	B-protein
)	O
which	O
is	O
identical	O
to	O
the	O
one	O
obtained	O
using	O
the	O
HIV-LTR-kappaB	B-DNA
site	I-DNA
as	O
recognition	O
sequence	O
and	O
different	O
from	O
the	O
one	O
(	O
c-Rel	B-protein
and	O
p50	B-protein
)	O
observed	O
with	O
nuclear	O
extracts	O
from	O
Mo	B-cell_line
T-lymphoid	I-cell_line
HTLV-II	I-cell_line
infected	I-cell_line
cells	I-cell_line
.	O

Repression	O
of	O
human	O
immunodeficiency	O
virus	O
type	O
1	O
through	O
the	O
novel	O
cooperation	O
of	O
human	B-protein
factors	I-protein
YY1	B-protein
and	O
LSF	B-protein
[	O
published	O
erratum	O
appears	O
in	O
J	O
Virol	O
1998	O
Feb	O
;	O
72	O
(	O
2	O
)	O
:	O
1709	O
]	O

A	O
subpopulation	O
of	O
stably	B-cell_type
infected	I-cell_type
CD4+	I-cell_type
cells	I-cell_type
capable	O
of	O
producing	O
virus	O
upon	O
stimulation	O
has	O
been	O
identified	O
in	O
human	O
immunodeficiency	O
virus	O
(	O
HIV	O
)	O
-positive	O
individuals	O
(	O
T.-W.Chun	O
,	O
D.Finzi	O
,	O
J.Margolick	O
,	O
K.Chadwick	O
,	O
D.Schwartz	O
,	O
and	O
R.F.Siliciano	O
,	O
Nat.Med.1	O
:	O
1284-1290	O
,	O
1995	O
)	O
.	O

Few	O
host	O
factors	O
that	O
directly	O
limit	O
HIV-1	O
transcription	O
and	O
could	O
support	O
this	O
state	O
of	O
nonproductive	O
HIV-1	O
infection	O
have	O
been	O
described	O
.	O

YY1	B-protein
,	O
a	O
widely	O
distributed	O
human	B-protein
transcription	I-protein
factor	I-protein
,	O
is	O
known	O
to	O
inhibit	O
HIV-1	B-DNA
long	I-DNA
terminal	I-DNA
repeat	I-DNA
(	O
LTR	B-DNA
)	O
transcription	O
and	O
virus	O
production	O
.	O

LSF	B-protein
(	O
also	O
known	O
as	O
LBP-1	B-protein
,	O
UBP	B-protein
,	O
and	O
CP-2	B-protein
)	O
has	O
been	O
shown	O
to	O
repress	O
LTR	O
transcription	O
in	O
vitro	O
,	O
but	O
transient	O
expression	O
of	O
LSF	B-protein
has	O
no	O
effect	O
on	O
LTR	B-DNA
activity	O
in	O
vivo	O
.	O

We	O
report	O
that	O
both	O
YY1	B-protein
and	O
LSF	B-protein
participate	O
in	O
the	O
formation	O
of	O
a	O
complex	O
that	O
recognizes	O
the	O
initiation	O
region	O
of	O
the	O
HIV-1	B-DNA
LTR	I-DNA
.	O

Further	O
,	O
we	O
have	O
found	O
that	O
these	O
factors	O
cooperate	O
in	O
the	O
repression	O
of	O
LTR	B-DNA
expression	O
and	O
viral	O
replication	O
.	O

This	O
cooperative	O
function	O
may	O
account	O
for	O
the	O
divergent	O
effects	O
of	O
LSF	B-protein
previously	O
observed	O
in	O
vitro	O
and	O
in	O
vivo	O
.	O

Thus	O
,	O
the	O
cooperation	O
of	O
two	O
general	O
cellular	O
transcription	O
factors	O
may	O
allow	O
for	O
the	O
selective	O
downregulation	O
of	O
HIV	O
transcription	O
.	O

Through	O
this	O
mechanism	O
of	O
gene	O
regulation	O
,	O
YY1	B-protein
and	O
LSF	B-protein
could	O
contribute	O
to	O
the	O
establishment	O
and	O
maintenance	O
of	O
a	O
population	O
of	O
cells	O
stably	O
but	O
nonproductively	O
infected	O
with	O
HIV-1	O
.	O

Analysis	O
of	O
interactions	O
between	O
huGATA-3	B-protein
transcription	O
factor	O
and	O
three	O
GATA	B-DNA
regulatory	I-DNA
elements	I-DNA
of	O
HIV-1	B-DNA
long	I-DNA
terminal	I-DNA
repeat	I-DNA
,	O
by	O
surface	O
plasmon	O
resonance	O
.	O

Relative	O
affinities	O
of	O
transcriptional	B-DNA
regulatory	I-DNA
elements	I-DNA
for	O
their	O
respective	O
factor	O
have	O
been	O
essentially	O
studied	O
by	O
bandshift	O
analysis	O
.	O

Here	O
we	O
report	O
a	O
real-time	O
study	O
of	O
factor/DNA	O
interactions	O
using	O
a	O
surface	O
plasmon	O
resonance	O
approach	O
and	O
further	O
characterization	O
of	O
recovered	B-protein
proteins	I-protein
involved	O
in	O
this	O
interaction	O
.	O

For	O
this	O
purpose	O
,	O
human	B-protein
GATA-3	I-protein
,	O
either	O
recombinant	O
or	O
in	O
nuclear	O
extracts	O
,	O
and	O
three	O
natural	B-DNA
GATA	I-DNA
elements	I-DNA
of	O
the	O
HIV-1	B-DNA
long	I-DNA
terminal	I-DNA
repeat	I-DNA
(	O
sites	B-DNA
1	I-DNA
,	I-DNA
2	I-DNA
,	I-DNA
and	I-DNA
3	I-DNA
)	O
were	O
chosen	O
,	O
in	O
which	O
only	O
site	B-DNA
2	I-DNA
is	O
a	O
noncanonical	O
GATA	B-DNA
site	I-DNA
.	O

Direct	O
analysis	O
of	O
sensorgrams	O
,	O
with	O
recombinant	B-protein
huGATA-3	I-protein
,	O
allowed	O
the	O
comparison	O
of	O
association	O
and	O
dissociation	O
profiles	O
of	O
the	O
three	O
DNA	B-DNA
regions	I-DNA
and	O
their	O
ranking	O
according	O
to	O
their	O
relative	O
affinities	O
.	O

This	O
result	O
,	O
confirmed	O
by	O
competitions	O
with	O
each	O
GATA	B-DNA
site	I-DNA
,	O
demonstrated	O
the	O
higher	O
relative	O
affinity	O
(	O
at	O
least	O
sevenfold	O
)	O
of	O
site	O
3	O
.	O

Interactions	O
between	O
the	O
canonical	O
and	O
unique	O
GATA	B-DNA
site	I-DNA
3	I-DNA
and	O
nuclear	O
extracts	O
were	O
also	O
studied	O
in	O
real	O
time	O
and	O
provided	O
information	O
on	O
its	O
association	O
and	O
dissociation	O
rates	O
for	O
native	O
huGATA-3	B-protein
.	O

Finally	O
,	O
recovered	O
protein	O
was	O
identified	O
as	O
genuine	O
huGATA-3	B-protein
by	O
SDS-PAGE	O
,	O
Western	O
blotting	O
,	O
and	O
bandshift	O
assays	O
.	O

Copyright	O
1997	O
Academic	O
Press	O
.	O

Stable	O
transfection	O
of	O
U937	B-cell_line
cells	I-cell_line
with	O
sense	O
or	O
antisense	B-DNA
RXR-alpha	I-DNA
cDNA	I-DNA
suggests	O
a	O
role	O
for	O
RXR-alpha	B-protein
in	O
the	O
control	O
of	O
monoblastic	O
differentiation	O
induced	O
by	O
retinoic	O
acid	O
and	O
vitamin	O
D	O
.	O

Although	O
retinoic	O
acid	O
(	O
RA	O
)	O
has	O
been	O
known	O
for	O
many	O
years	O
to	O
be	O
a	O
modulating	O
agent	O
that	O
plays	O
a	O
role	O
in	O
generating	O
both	O
granulocytes	B-cell_type
and	O
monocytes	B-cell_type
,	O
the	O
molecular	O
mechanism	O
underlying	O
this	O
role	O
has	O
not	O
been	O
defined	O
in	O
the	O
monoblast	B-cell_type
lineage	I-cell_type
.	O

In	O
particular	O
,	O
the	O
part	O
played	O
by	O
the	O
retinoid	B-protein
X	I-protein
receptors	I-protein
(	O
RXRs	B-protein
)	O
,	O
which	O
are	O
members	O
of	O
the	O
steroid/thyroid	B-protein
hormone	I-protein
nuclear	I-protein
receptor	I-protein
family	I-protein
,	O
has	O
not	O
been	O
explored	O
.	O

In	O
this	O
study	O
,	O
therefore	O
,	O
the	O
human	B-cell_line
monoblastic	I-cell_line
leukemia	I-cell_line
cell	I-cell_line
line	I-cell_line
U937	I-cell_line
has	O
been	O
used	O
as	O
a	O
model	O
system	O
to	O
investigate	O
the	O
role	O
of	O
one	O
of	O
the	O
RXRs	B-protein
,	O
RXR-alpha	B-protein
,	O
in	O
monoblast	O
differentiation	O
.	O

RXR-alpha	B-RNA
mRNA	I-RNA
was	O
present	O
in	O
untreated	O
U937	B-cell_line
cells	I-cell_line
,	O
and	O
levels	O
increased	O
after	O
induction	O
of	O
differentiation	O
with	O
phorbol	O
ester	O
.	O

The	O
same	O
was	O
found	O
for	O
RXR-beta	B-RNA
mRNA	I-RNA
.	O

Using	O
plasmids	O
containing	O
sense	O
or	O
antisense	B-DNA
RXR-alpha	I-DNA
sequences	I-DNA
under	O
the	O
control	O
of	O
an	O
inducible	O
promoter	O
,	O
we	O
generated	O
stably	O
transfected	O
cell	O
lines	O
which	O
expressed	O
either	O
increased	O
or	O
decreased	O
levels	O
of	O
RXR-alpha	B-protein
,	O
respectively	O
.	O

The	O
sense	B-cell_line
cell	I-cell_line
lines	I-cell_line
(	O
U	B-cell_line
alpha	I-cell_line
S	I-cell_line
and	O
its	O
clonal	O
derivative	O
alpha	O
G2S	B-cell_line
)	O
showed	O
increased	O
sensitivity	O
to	O
RA	O
,	O
while	O
the	O
antisense	B-cell_line
cell	I-cell_line
lines	I-cell_line
(	O
U	B-cell_line
alpha	I-cell_line
A	I-cell_line
and	O
its	O
clonal	O
derivative	O
alpha	O
B5A	B-cell_line
)	O
showed	O
decreased	O
sensitivity	O
to	O
RA	O
,	O
as	O
demonstrated	O
by	O
growth	O
inhibition	O
and	O
by	O
regulation	O
of	O
an	O
RA-responsive	B-DNA
reporter	I-DNA
gene	I-DNA
.	O

Both	O
U	B-cell_line
alpha	I-cell_line
A	I-cell_line
and	O
alpha	O
B5A	B-cell_line
also	O
failed	O
to	O
respond	O
to	O
another	O
modulating	O
agent	O
,	O
1	O
alpha	O
,	O
25-dihydroxycholecalciferol	O
(	O
DHCC	O
)	O
,	O
but	O
only	O
U	B-cell_line
alpha	I-cell_line
S	I-cell_line
and	O
not	O
alpha	B-protein
G2S	I-protein
showed	O
an	O
enhanced	O
response	O
to	O
DHCC	O
.	O

The	O
combination	O
of	O
RA	O
and	O
DHCC	O
together	O
inhibited	O
growth	O
of	O
both	O
sense	O
and	O
antisense	B-cell_line
cell	I-cell_line
lines	I-cell_line
.	O

In	O
addition	O
,	O
alpha	B-protein
G2S	I-protein
exhibited	O
increased	O
expression	O
of	O
CD11b	B-protein
and	O
CD54	B-protein
,	O
while	O
alpha	B-cell_line
B5A	I-cell_line
cells	I-cell_line
showed	O
increased	O
expression	O
of	O
CD102	B-protein
,	O
suggesting	O
that	O
RXR-alpha	B-protein
has	O
a	O
role	O
in	O
regulating	O
expression	O
of	O
cell	B-protein
adhesion	I-protein
molecules	I-protein
in	O
U937	B-cell_line
cells	I-cell_line
.	O

These	O
results	O
demonstrate	O
that	O
RXR-alpha	B-protein
has	O
a	O
role	O
in	O
mediating	O
growth	O
inhibition	O
and	O
cell	O
adhesion	O
during	O
myelomonocytic	O
differentiation	O
,	O
and	O
suggest	O
that	O
different	O
species	O
of	O
heterodimers	B-protein
involving	O
RXR-alpha	B-protein
may	O
control	O
the	O
acquisition	O
of	O
different	O
features	O
of	O
mature	O
monocyte/macrophage	O
function	O
.	O

Transcriptional	O
activation	O
of	O
the	O
vascular	B-DNA
cell	I-DNA
adhesion	I-DNA
molecule-1	I-DNA
gene	I-DNA
in	O
T	B-cell_type
lymphocytes	I-cell_type
expressing	O
human	B-protein
T-cell	I-protein
leukemia	I-protein
virus	I-protein
type	I-protein
1	I-protein
Tax	I-protein
protein	I-protein
.	O

Recruitment	O
and	O
extravasation	O
of	O
T	B-cell_type
cells	I-cell_type
through	O
the	O
blood-brain	O
barrier	O
are	O
favored	O
by	O
adhesion	B-protein
molecule	I-protein
-mediated	O
interactions	O
of	O
circulating	B-cell_type
T	I-cell_type
cells	I-cell_type
with	O
endothelial	B-cell_type
cells	I-cell_type
.	O

Since	O
a	O
common	O
pathological	O
finding	O
in	O
human	O
T-cell	O
leukemia	O
virus	O
type	O
1	O
(	O
HTLV-1	O
)	O
-associated	O
diseases	O
is	O
the	O
infiltration	O
of	O
HTLV-1-infected	B-cell_type
T	I-cell_type
lymphocytes	I-cell_type
into	O
various	O
organs	O
,	O
we	O
have	O
looked	O
for	O
the	O
profile	O
of	O
adhesion	B-protein
molecules	I-protein
expressed	O
by	O
HTLV-1-transformed	B-cell_type
T	I-cell_type
cells	I-cell_type
.	O

Flow	O
cytometry	O
analysis	O
indicated	O
that	O
these	O
cells	O
were	O
expressing	O
high	O
levels	O
of	O
vascular	B-protein
cell	I-protein
adhesion	I-protein
molecule	I-protein
1	I-protein
(	O
VCAM-1	B-protein
[	O
CD106	B-protein
]	O
)	O
,	O
a	O
110-kDa	O
member	O
of	O
the	O
immunoglobulin	B-protein
gene	I-protein
superfamily	I-protein
,	O
first	O
identified	O
on	O
endothelial	B-cell_type
cells	I-cell_type
stimulated	O
with	O
inflammatory	B-protein
cytokines	I-protein
.	O

This	O
adhesion	O
molecule	O
was	O
also	O
expressed	O
by	O
T	B-cell_type
cells	I-cell_type
obtained	O
from	O
one	O
patient	O
with	O
HTLV-1-associated	O
myelopathy/tropical	O
spastic	O
paraparesis	O
but	O
not	O
by	O
activated	B-cell_type
T	I-cell_type
cells	I-cell_type
isolated	O
from	O
one	O
normal	O
blood	O
donor	O
.	O

The	O
role	O
of	O
the	O
viral	B-protein
trans-activator	I-protein
Tax	I-protein
protein	I-protein
in	O
the	O
induction	O
of	O
VCAM-1	B-protein
was	O
first	O
indicated	O
by	O
the	O
detection	O
of	O
this	O
adhesion	B-protein
molecule	I-protein
on	O
Jurkat	B-cell_line
T-cell	I-cell_line
clones	I-cell_line
stably	O
expressing	O
the	O
tax	O
gene	O
.	O

The	O
effect	O
of	O
Tax	B-protein
on	O
VCAM-1	B-protein
gene	O
transcription	O
was	O
next	O
confirmed	O
in	O
JPX-9	B-cell_line
cells	I-cell_line
,	O
a	O
subclone	O
of	O
Jurkat	B-cell_line
cells	I-cell_line
,	O
carrying	O
the	O
tax	B-DNA
sequences	I-DNA
under	O
the	O
control	O
of	O
an	O
inducible	B-DNA
promoter	I-DNA
.	O

Furthermore	O
,	O
deletion	O
and	O
mutation	O
analyses	O
of	O
the	O
VCAM-1	B-DNA
promoter	I-DNA
performed	O
with	O
chloramphenicol	B-DNA
acetyltransferase	I-DNA
constructs	I-DNA
revealed	O
that	O
Tax	B-protein
was	O
trans	O
activating	O
the	O
VCAM-1	B-DNA
promoter	I-DNA
via	O
two	O
NF-kappaB	B-DNA
sites	I-DNA
present	O
at	O
bp	O
-72	O
and	O
-57	O
in	O
the	O
VCAM-1	B-DNA
gene	I-DNA
promoter	I-DNA
,	O
with	O
both	O
of	O
them	O
being	O
required	O
for	O
the	O
Tax	B-protein
-induced	O
expression	O
of	O
this	O
adhesion	B-protein
molecule	I-protein
.	O

Finally	O
,	O
gel	O
mobility	O
shift	O
assays	O
demonstrated	O
the	O
nuclear	O
translocation	O
of	O
proteins	O
specifically	O
bound	O
to	O
these	O
two	O
NF-kappaB	B-DNA
motifs	I-DNA
,	O
confirming	O
that	O
VCAM-1	B-protein
was	O
induced	O
on	O
Tax-expressing	B-cell_line
cells	I-cell_line
in	O
a	O
kappaB	B-protein
-dependent	O
manner	O
.	O

Collectively	O
,	O
these	O
results	O
therefore	O
suggest	O
that	O
the	O
exclusive	O
Tax	B-protein
-induced	O
expression	O
of	O
VCAM-1	B-protein
on	O
T	B-cell_type
cells	I-cell_type
may	O
represent	O
a	O
pivotal	O
event	O
in	O
the	O
progression	O
of	O
HTLV-1-associated	O
diseases	O
.	O

HIV-1	B-protein
Vpr	I-protein
suppresses	O
immune	O
activation	O
and	O
apoptosis	O
through	O
regulation	O
of	O
nuclear	B-protein
factor	I-protein
kappa	I-protein
B	I-protein
[	O
see	O
comments	O
]	O

The	O
HIV-1	B-protein
accessory	I-protein
gene	I-protein
product	I-protein
Vpr	B-protein
can	O
influence	O
viral	O
pathogenesis	O
by	O
affecting	O
viral	O
replication	O
as	O
well	O
as	O
host	O
cell	O
transcription	O
and	O
proliferation	O
.	O

We	O
have	O
investigated	O
the	O
effects	O
of	O
Vpr	B-protein
on	O
host	O
cell	O
activation	O
and	O
confirm	O
that	O
it	O
influences	O
cellular	O
proliferation	O
.	O

However	O
,	O
we	O
have	O
also	O
found	O
that	O
Vpr	B-protein
modulates	O
T-cell	O
receptor	O
(	O
TCR	B-protein
)	O
-triggered	O
apoptosis	O
in	O
a	O
manner	O
similar	O
to	O
that	O
of	O
glucocorticoids	O
.	O

In	O
the	O
absence	O
of	O
TCR	B-protein
-mediated	O
activation	O
,	O
Vpr	B-protein
induces	O
apoptosis	O
whereas	O
in	O
its	O
presence	O
,	O
Vpr	B-protein
interrupts	O
the	O
expected	O
induction	O
of	O
apoptosis	O
.	O

This	O
regulation	O
of	O
apoptosis	O
is	O
linked	O
to	O
Vpr	B-protein
suppression	O
of	O
NF-kappa	B-protein
B	I-protein
activity	O
via	O
the	O
induction	O
of	O
I	B-protein
kappa	I-protein
B	I-protein
,	O
an	O
inhibitor	O
of	O
NF-kappa	B-protein
B	I-protein
.	O

Further	O
,	O
Vpr	B-protein
suppresses	O
expression	O
of	O
IL-2	B-protein
,	O
IL-10	B-protein
,	O
IL-12	B-protein
,	O
TNF	B-protein
alpha	I-protein
and	O
IL-4	B-protein
,	O
all	O
of	O
which	O
are	O
NF-kappa	B-protein
B	I-protein
-dependent	O
.	O

The	O
effects	O
of	O
Vpr	B-protein
could	O
be	O
reversed	O
by	O
RU486	O
.	O

Our	O
finding	O
that	O
Vpr	B-protein
can	O
regulate	O
NF-kappa	B-protein
B	I-protein
supports	O
the	O
hypothesis	O
that	O
some	O
aspects	O
of	O
viral	O
pathogenesis	O
are	O
the	O
consequence	O
of	O
cell	O
dysregulation	O
by	O
Vpr	B-protein
.	O

Tissue	O
transglutaminase-dependent	O
posttranslational	O
modification	O
of	O
the	O
retinoblastoma	B-protein
gene	I-protein
product	I-protein
in	O
promonocytic	B-cell_line
cells	I-cell_line
undergoing	O
apoptosis	O
.	O

The	O
retinoblastoma	B-protein
gene	I-protein
product	I-protein
(	O
pRB	B-protein
)	O
plays	O
an	O
important	O
role	O
in	O
controlling	O
both	O
cell	O
release	O
from	O
the	O
G1	O
phase	O
and	O
apoptosis	O
.	O

We	O
show	O
here	O
that	O
in	O
the	O
early	O
phases	O
of	O
apoptosis	O
,	O
pRB	B-protein
is	O
posttranslationally	O
modified	O
by	O
a	O
tissue	O
transglutaminase	O
(	O
tTG	B-protein
)	O
-catalyzed	O
reaction	O
.	O

In	O
fact	O
,	O
by	O
employing	O
a	O
novel	O
haptenized	O
lysis	O
synthetic	O
substrate	O
which	O
allows	O
the	O
isolation	O
of	O
glutaminyl-tTG	O
substrates	O
in	O
vivo	O
,	O
we	O
identified	O
pRB	B-protein
as	O
a	O
potential	O
tTG	O
substrate	O
in	O
U937	B-cell_line
cells	I-cell_line
undergoing	O
apoptosis	O
.	O

In	O
keeping	O
with	O
this	O
finding	O
,	O
we	O
showed	O
that	O
apoptosis	O
of	O
U937	B-cell_line
cells	I-cell_line
is	O
characterized	O
by	O
the	O
rapid	O
disappearance	O
of	O
the	O
105	O
,	O
000-	O
to	O
110	O
,	O
000-molecular-weight	O
pRB	B-protein
forms	O
concomitantly	O
with	O
the	O
appearance	O
of	O
a	O
smear	O
of	O
immunoreactive	O
products	O
with	O
a	O
molecular	O
weight	O
of	O
greater	O
than	O
250	O
,	O
000	O
.	O

The	O
shift	O
in	O
pRB	B-protein
molecular	O
weight	O
was	O
reproduced	O
by	O
adding	O
exogenous	O
purified	O
tTG	O
to	O
extracts	O
obtained	O
from	O
viable	O
U937	B-cell_line
cells	I-cell_line
and	O
was	O
prevented	O
by	O
dansylcadaverine	O
,	O
a	O
potent	O
enzyme	O
inhibitor	O
.	O

The	O
effect	O
of	O
the	O
pRB	B-protein
posttranslational	O
modification	O
during	O
apoptosis	O
was	O
investigated	O
by	O
determining	O
the	O
E2F-1	B-protein
levels	O
and	O
by	O
isolating	O
and	O
characterizing	O
pRB-null	B-cell_line
clones	I-cell_line
from	O
U937	B-cell_line
cells	I-cell_line
.	O

Notably	O
,	O
the	O
lack	O
of	O
pRB	B-protein
in	O
these	O
U937-derived	B-cell_line
clones	I-cell_line
renders	O
these	O
p53-null	B-cell_line
cells	I-cell_line
highly	O
resistant	O
to	O
apoptosis	O
induced	O
by	O
serum	O
withdrawal	O
,	O
calphostin	O
C	O
,	O
and	O
ceramide	O
.	O

Taken	O
together	O
,	O
these	O
data	O
suggest	O
that	O
tTG	B-protein
,	O
acting	O
on	O
the	O
pRB	B-protein
protein	I-protein
,	O
might	O
play	O
an	O
important	O
role	O
in	O
the	O
cell	O
progression	O
through	O
the	O
death	O
program	O
.	O

STAT3	B-protein
is	O
a	O
serine	B-protein
kinase	I-protein
target	I-protein
in	O
T	B-cell_type
lymphocytes	I-cell_type
.	O

Interleukin	B-protein
2	I-protein
and	O
T	B-protein
cell	I-protein
antigen	I-protein
receptor	I-protein
signals	O
converge	O
upon	O
serine	O
727	O
.	O

Interleukin	B-protein
2	I-protein
(	O
IL-2	B-protein
)	O
induces	O
tyrosine	O
phosphorylation	O
of	O
STATs	B-protein
3	I-protein
and	I-protein
5	I-protein
(	O
signal	O
transducer	O
and	O
activator	O
of	O
transcription	O
)	O
.	O

We	O
now	O
show	O
that	O
IL-2	B-protein
regulation	O
of	O
STAT3	B-protein
proteins	I-protein
in	O
T	B-cell_type
cells	I-cell_type
is	O
a	O
complex	O
response	O
involving	O
activation	O
of	O
two	O
forms	O
of	O
STAT3	B-protein
:	O
90-kDa	O
STAT3alpha	B-protein
and	O
an	O
83-kDa	B-protein
carboxyl-terminal	I-protein
truncated	I-protein
STAT3beta	I-protein
.	O

The	O
phosphorylation	O
of	O
STAT	B-protein
proteins	I-protein
on	O
serine	O
residues	O
is	O
also	O
required	O
for	O
competent	O
STAT	B-protein
transcription	O
.	O

A	O
critical	O
serine	B-protein
phosphorylation	I-protein
site	I-protein
in	O
STAT3alpha	B-protein
is	O
at	O
position	O
727	O
.	O

In	O
this	O
study	O
we	O
have	O
produced	O
an	O
antisera	O
specific	O
for	O
STAT3alpha	B-protein
proteins	I-protein
phosphorylated	O
on	O
serine	O
727	O
and	O
used	O
this	O
to	O
monitor	O
the	O
phosphorylation	O
of	O
this	O
residue	O
during	O
T	O
lymphocyte	O
activation	O
.	O

Our	O
results	O
show	O
that	O
phosphorylation	O
of	O
STAT3alpha	B-protein
on	O
serine	O
727	O
is	O
not	O
constitutive	O
in	O
quiescent	B-cell_type
T	I-cell_type
cells	I-cell_type
but	O
can	O
be	O
induced	O
by	O
the	O
cytokine	B-protein
IL-2	I-protein
.	O

Interestingly	O
,	O
triggering	O
of	O
the	O
T	B-protein
cell	I-protein
antigen	I-protein
receptor	I-protein
complex	I-protein
or	O
activation	O
of	O
protein	B-protein
kinase	I-protein
C	I-protein
with	O
phorbol	O
esters	O
also	O
induces	O
phosphorylation	O
of	O
serine	O
727	O
but	O
without	O
simultaneously	O
inducing	O
STAT3	B-protein
tyrosine	O
phosphorylation	O
or	O
DNA	O
binding	O
.	O

Hence	O
,	O
the	O
present	O
results	O
show	O
that	O
STAT3	B-protein
serine	O
phosphorylation	O
can	O
be	O
regulated	O
independently	O
of	O
the	O
tyrosine	O
phosphorylation	O
of	O
this	O
molecule	O
.	O

IL-2	B-protein
and	O
T	B-protein
cell	I-protein
antigen	I-protein
receptor	I-protein
complex	I-protein
induction	O
of	O
STAT3alpha	B-protein
serine	O
727	O
phosphorylation	O
is	O
dependent	O
on	O
the	O
activity	O
of	O
the	O
MEK	B-protein
/ERK	B-protein
pathway	O
.	O

Previous	O
studies	O
have	O
identified	O
H-7-sensitive	O
kinase	O
pathways	O
that	O
regulate	O
STAT3	B-protein
DNA	O
binding	O
.	O

We	O
show	O
that	O
H-7-sensitive	O
pathways	O
regulate	O
STAT3	B-protein
DNA	O
binding	O
in	O
T	B-cell_type
cells	I-cell_type
.	O

Nevertheless	O
,	O
we	O
show	O
that	O
H-7-sensitive	B-protein
kinases	I-protein
do	O
not	O
regulate	O
STAT3	B-protein
tyrosine	O
phosphorylation	O
or	O
phosphorylation	O
of	O
serine	O
727	O
.	O

These	O
results	O
thus	O
show	O
that	O
STAT3	B-protein
proteins	I-protein
are	O
targets	O
for	O
multiple	O
kinase	O
pathways	O
in	O
T	B-cell_type
cells	I-cell_type
and	O
can	O
integrate	O
signals	O
from	O
both	O
cytokine	B-protein
receptors	I-protein
and	O
antigen	B-protein
receptors	I-protein
.	O

NF-kappa	B-protein
B/Rel	I-protein
family	I-protein
members	I-protein
regulating	O
the	O
ICAM-1	B-DNA
promoter	I-DNA
in	O
monocytic	B-cell_line
THP-1	I-cell_line
cells	I-cell_line
.	O

A	O
kappa	B-DNA
B-site	I-DNA
was	O
identified	O
in	O
the	O
promoter	O
of	O
the	O
intercellular	B-DNA
adhesion	I-DNA
molecule-1	I-DNA
(	I-DNA
ICAM-1	I-DNA
)	I-DNA
gene	I-DNA
,	O
which	O
is	O
involved	O
in	O
regulation	O
of	O
ICAM-1	B-protein
expression	O
by	O
tumor	B-protein
necrosis	I-protein
factor	I-protein
alpha	I-protein
(	O
TNF-alpha	B-protein
)	O
and	O
glucocorticoids	O
.	O

We	O
now	O
report	O
on	O
the	O
transcription	B-protein
factors	I-protein
which	O
bind	O
and	O
transactivate	O
this	O
enhancer	B-DNA
sequence	I-DNA
.	O

In	O
vitro	O
,	O
the	O
ICAM-1	B-DNA
kappa	I-DNA
B	I-DNA
site	I-DNA
appeared	O
to	O
bind	O
RelA	B-protein
and	O
c-Rel	B-protein
homodimers	I-protein
as	O
well	O
as	O
heterodimers	O
with	O
NF-kappa	B-protein
B1	I-protein
,	O
but	O
weakly	O
NF-kappa	B-protein
B1	I-protein
homodimers	I-protein
.	O

In	O
addition	O
,	O
both	O
RelA	B-protein
and	O
c-Rel	B-protein
,	O
but	O
not	O
NF-kappa	B-protein
B1	I-protein
,	O
were	O
shown	O
to	O
transactivate	O
an	O
ICAM-1	B-DNA
kappa	I-DNA
B-reporter	I-DNA
construct	I-DNA
.	O

In	O
monocytic	B-cell_line
THP-1	I-cell_line
cells	I-cell_line
TNF-alpha	B-protein
induced	O
two	O
nuclear	B-protein
complexes	I-protein
which	O
in	O
vitro	O
bound	O
to	O
the	O
ICAM-1	B-DNA
kappa	I-DNA
B	I-DNA
site	I-DNA
.	O

Using	O
antibodies	O
in	O
an	O
electrophoretic	O
mobility	O
supershift	O
assay	O
,	O
one	O
of	O
these	O
complexes	O
was	O
shown	O
to	O
contain	O
NF-kappa	B-protein
B1	I-protein
and	O
RelA	B-protein
,	O
and	O
to	O
bind	O
with	O
higher	O
affinity	O
to	O
the	O
consensus	B-DNA
kappa	I-DNA
B	I-DNA
site	I-DNA
in	O
the	O
HIV	B-DNA
long	I-DNA
terminal	I-DNA
repeat	I-DNA
.	O

The	O
second	O
complex	O
contained	O
RelA	B-protein
,	O
and	O
exhibited	O
higher	O
affinity	O
towards	O
the	O
ICAM-1	B-DNA
kappa	I-DNA
B	I-DNA
than	O
to	O
the	O
HIV	B-DNA
kappa	I-DNA
B	I-DNA
site	I-DNA
.	O

The	O
glucocorticoid	B-protein
receptor	I-protein
was	O
shown	O
to	O
repress	O
activity	O
of	O
both	O
the	O
RelA	B-protein
homodimer	I-protein
and	O
the	O
NF-kappa	B-protein
B1/RelA	I-protein
heterodimer	I-protein
.	O

We	O
argue	O
that	O
in	O
vivo	O
RelA	B-protein
homodimers	I-protein
are	O
likely	O
to	O
play	O
a	O
dominant	O
role	O
in	O
TNF-alpha	B-protein
-induced	O
ICAM-1	B-protein
transcription	O
in	O
monocytic	B-cell_type
cells	I-cell_type
.	O

Competent	O
transcription	O
initiation	O
by	O
RNA	B-protein
polymerase	I-protein
II	I-protein
in	O
cell-free	B-cell_type
extracts	I-cell_type
from	O
xeroderma	O
pigmentosum	O
groups	O
B	O
and	O
D	O
in	O
an	O
optimized	O
RNA	O
transcription	O
assay	O
.	O

The	O
human	O
autosomal	O
recessive	O
disease	O
,	O
xeroderma	O
pigmentosum	O
(	O
XP	O
)	O
,	O
can	O
result	O
from	O
mutations	O
in	O
any	O
one	O
of	O
seven	O
genes	O
,	O
designated	O
XPA	B-DNA
through	O
XPG	B-DNA
.	O

Of	O
these	O
,	O
the	O
XPB	B-DNA
and	I-DNA
XPD	I-DNA
genes	I-DNA
encode	O
proteins	O
that	O
are	O
subunits	O
of	O
a	O
general	B-protein
transcription	I-protein
factor	I-protein
,	O
TFIIH	B-protein
,	O
involved	O
in	O
both	O
nucleotide	O
excision	O
repair	O
(	O
NER	O
)	O
and	O
initiation	O
of	O
mRNA	O
transcription	O
by	O
RNA	B-protein
polymerase	I-protein
II	I-protein
.	O

In	O
humans	O
,	O
mutation	O
of	O
the	O
XPB	B-DNA
or	I-DNA
XPD	I-DNA
gene	I-DNA
impairs	O
NER	O
,	O
resulting	O
in	O
hyper-sensitivity	O
to	O
sunlight	O
and	O
greatly	O
increased	O
skin	O
tumor	O
formation	O
.	O

However	O
,	O
no	O
transcription	O
deficiency	O
has	O
been	O
demonstrated	O
in	O
either	O
XP-B	O
or	O
XP-D	O
.	O

We	O
have	O
employed	O
an	O
optimized	O
cell-free	O
RNA	O
transcription	O
assay	O
to	O
analyze	O
transcription	O
activity	O
of	O
XP-B	O
and	O
XP-D	O
.	O

Although	O
the	O
growth	O
rate	O
was	O
normal	O
,	O
the	O
XP-B	B-cell_line
and	I-cell_line
XP-D	I-cell_line
cells	I-cell_line
contained	O
reduced	O
amounts	O
of	O
TFIIH	B-protein
.	O

Extracts	O
prepared	O
from	O
XP-B	B-cell_line
and	I-cell_line
XP-D	I-cell_line
lymphoblastoid	I-cell_line
cells	I-cell_line
exhibited	O
similar	O
transcription	O
activity	O
from	O
the	O
adenovirus	B-DNA
major	I-DNA
late	I-DNA
promoter	I-DNA
when	O
compared	O
to	O
that	O
in	O
extracts	O
from	O
normal	O
cells	O
.	O

Thus	O
,	O
we	O
conclude	O
that	O
the	O
XP-B	B-cell_line
and	I-cell_line
XP-D	I-cell_line
lymphoblastoid	I-cell_line
cells	I-cell_line
do	O
not	O
have	O
impaired	O
RNA	O
transcription	O
activity	O
.	O

We	O
consider	O
the	O
possible	O
consequences	O
of	O
the	O
reduced	O
cellular	O
content	O
of	O
TFIIH	B-protein
for	O
the	O
clinical	O
symptoms	O
in	O
XP-B	O
or	O
XP-D	O
patients	O
,	O
and	O
discuss	O
a	O
'conditional	O
phenotype	O
'	O
that	O
may	O
involve	O
an	O
impairment	O
of	O
cellular	O
function	O
only	O
under	O
certain	O
growth	O
conditions	O
.	O

A	O
novel	O
form	O
of	O
the	O
myeloid-specific	B-protein
zinc	I-protein
finger	I-protein
protein	I-protein
(	O
MZF-2	B-protein
)	O
.	O

BACKGROUND	O
:	O
Myeloid	O
cell	O
development	O
is	O
controlled	O
by	O
tissue-specific	O
transcription	B-protein
factors	I-protein
.	O

Human	B-protein
myeloid	I-protein
zinc	I-protein
finger	I-protein
protein	I-protein
(	O
MZF-1	B-protein
)	O
is	O
a	O
putative	O
transcription	O
factor	O
containing	O
13	B-protein
zinc	I-protein
fingers	I-protein
,	O
and	O
has	O
been	O
suggested	O
that	O
it	O
regulates	O
the	O
development	O
of	O
neutrophilic	B-cell_type
granulocytes	I-cell_type
.	O

RESULTS	O
:	O
Here	O
,	O
we	O
have	O
isolated	O
the	O
murine	B-DNA
and	I-DNA
human	I-DNA
cDNAs	I-DNA
which	O
encode	O
a	O
novel	O
form	O
of	O
MZF	B-protein
protein	I-protein
(	O
MZF-2	B-protein
)	O
.	O

Murine	B-protein
and	I-protein
human	I-protein
MZF-2	I-protein
proteins	I-protein
consisted	O
of	O
814	O
and	O
775	O
amino	O
acids	O
,	O
respectively	O
,	O
and	O
have	O
identity	O
of	O
75.3	O
%	O
between	O
them	O
.	O

The	O
C-terminal	B-protein
half	I-protein
of	O
human	B-protein
MZF-2	I-protein
,	O
carrying	O
the	O
zinc	B-protein
finger	I-protein
domains	I-protein
,	O
was	O
completely	O
identical	O
with	O
that	O
of	O
human	B-protein
MZF-1	I-protein
,	O
whereas	O
the	O
N-terminal	B-protein
half	I-protein
of	O
MZF-2	B-protein
was	O
different	O
from	O
the	O
corresponding	O
region	O
of	O
human	O
MZF-1	B-protein
,	O
and	O
was	O
coded	O
by	O
distinct	O
exons	B-DNA
.	O

MZF-2	B-RNA
mRNA	I-RNA
was	O
expressed	O
in	O
myeloid	O
cells	O
,	O
particularly	O
in	O
the	O
cells	O
committed	O
to	O
the	O
neutrophilic	B-cell_type
lineage	I-cell_type
,	O
and	O
down-regulated	O
by	O
G-CSF	B-protein
.	O

CONCLUSIONS	O
:	O
MZF-1	B-RNA
and	I-RNA
MZF-2	I-RNA
mRNAs	I-RNA
seem	O
to	O
be	O
produced	O
by	O
the	O
alternative	O
use	O
of	O
two	O
different	O
transcription	B-DNA
initiation	I-DNA
sites	I-DNA
.	O

The	O
distinct	O
N-terminal	B-protein
half	I-protein
of	O
MZF-2	B-protein
carries	O
two	O
characteristic	O
domains	O
,	O
a	O
leucine-rich	B-protein
domain	I-protein
called	O
LeR	B-protein
and	O
an	O
acidic	B-protein
domain	I-protein
,	O
which	O
suggests	O
a	O
unique	O
function	O
of	O
MZF-2	B-protein
in	O
neutrophil	O
development	O
.	O

Impaired	O
cortisol	O
binding	O
to	O
glucocorticoid	B-protein
receptors	I-protein
in	O
hypertensive	O
patients	O
.	O

We	O
compared	O
glucocorticoid	O
receptor	O
binding	O
characteristics	O
and	O
glucocorticoid	O
responsiveness	O
of	O
human	B-cell_type
mononuclear	I-cell_type
leukocytes	I-cell_type
(	O
HML	B-cell_type
)	O
from	O
hypertensive	O
patients	O
and	O
matched	O
normotensive	O
volunteers	O
.	O

We	O
also	O
considered	O
associations	O
of	O
these	O
variables	O
with	O
plasma	O
renin	B-protein
activity	O
,	O
aldosterone	O
,	O
cortisol	O
,	O
corticotropin	O
,	O
and	O
electrolyte	O
concentrations	O
.	O

We	O
calculated	O
binding	O
affinity	O
(	O
Kd	O
;	O
nmol/L	O
)	O
and	O
capacity	O
(	O
Bmax	O
;	O
sites/cell	O
)	O
for	O
dexamethasone	O
and	O
cortisol	O
from	O
homologous	O
and	O
heterologous	O
competition	O
curves	O
for	O
specific	O
[	O
3H	O
]	O
dexamethasone	O
binding	O
sites	O
on	O
HML	B-cell_type
isolated	O
from	O
the	O
blood	O
of	O
normotensive	O
volunteers	O
and	O
subjects	O
with	O
essential	O
hypertension	O
.	O

Glucocorticoid	O
responsiveness	O
of	O
HML	B-cell_type
was	O
evaluated	O
as	O
IC50	O
values	O
(	O
nmol/L	O
)	O
for	O
dexamethasone	O
and	O
cortisol	O
for	O
the	O
inhibition	O
of	O
lysozyme	B-protein
release	O
.	O

We	O
measured	O
plasma	O
hormones	O
by	O
radioimmunoassay	O
.	O

Kd	O
values	O
(	O
mean+/-SE	O
)	O
for	O
cortisol	O
in	O
HML	B-cell_type
of	O
hypertensive	O
patients	O
were	O
higher	O
than	O
in	O
control	O
subjects	O
(	O
24.6+/-2.4	O
versus	O
17.5+/-1.7	O
nmol/L	O
,	O
P	O
<	O
.04	O
)	O
.	O

Binding	O
capacity	O
(	O
4978+/-391	O
versus	O
4131+/-321	O
sites/cell	O
)	O
,	O
Kd	O
values	O
for	O
dexamethasone	O
(	O
6.7+/-0.5	O
versus	O
5.7+/-0.3	O
nmol/L	O
)	O
,	O
and	O
IC50	O
values	O
for	O
dexamethasone	O
(	O
3.4+/-0.3	O
versus	O
3.1+/-0.2	O
nmol/L	O
)	O
and	O
cortisol	O
(	O
12.2+/-1.6	O
versus	O
9.5+/-0.3	O
nmol/L	O
)	O
were	O
not	O
significantly	O
different	O
.	O

Patients	O
with	O
renin	B-protein
values	O
less	O
than	O
0.13	O
ng	O
angiotensin	O
I/L	O
per	O
second	O
were	O
markedly	O
less	O
sensitive	O
to	O
cortisol	O
than	O
those	O
with	O
higher	O
values	O
.	O

Both	O
Kd	O
(	O
30.3+/-2.5	O
versus	O
19.2+/-2.4	O
nmol/L	O
)	O
and	O
IC50	O
values	O
(	O
15.5+/-1.8	O
versus	O
8.9+/-1.2	O
nmol/L	O
)	O
for	O
cortisol	O
were	O
significantly	O
higher	O
in	O
patients	O
with	O
lower	O
renin	B-protein
values	O
(	O
P	O
<	O
.03	O
)	O
.	O

Other	O
variables	O
,	O
including	O
plasma	O
hormone	O
and	O
electrolyte	O
values	O
and	O
binding	O
characteristics	O
for	O
dexamethasone	O
,	O
were	O
not	O
different	O
.	O

These	O
data	O
suggest	O
that	O
cortisol	O
binding	O
to	O
glucocorticoid	B-protein
receptor	I-protein
is	O
slightly	O
impaired	O
in	O
patients	O
with	O
essential	O
hypertension	O
.	O

In	O
vivo	O
,	O
this	O
could	O
lead	O
to	O
inappropriate	O
binding	O
of	O
cortisol	O
to	O
mineralocorticoid	O
receptors	O
.	O

Hence	O
,	O
decreased	O
sensitivity	O
to	O
cortisol	O
is	O
associated	O
with	O
renin	B-protein
suppression	O
.	O

This	O
hypothesis	O
is	O
supported	O
by	O
evidence	O
of	O
hypertension	O
and	O
low	O
renin	B-protein
activity	O
,	O
which	O
others	O
have	O
described	O
in	O
patients	O
with	O
primary	O
glucocorticoid	O
resistance	O
due	O
to	O
mutations	O
of	O
the	O
glucocorticoid	B-protein
receptor	I-protein
.	O

PU.1/Pip	B-protein
and	O
basic	B-protein
helix	I-protein
loop	I-protein
helix	I-protein
zipper	I-protein
transcription	I-protein
factors	I-protein
interact	O
with	O
binding	B-DNA
sites	I-DNA
in	O
the	O
CD20	B-DNA
promoter	I-DNA
to	O
help	O
confer	O
lineage-	O
and	O
stage-specific	O
expression	O
of	O
CD20	B-protein
in	O
B	B-cell_type
lymphocytes	I-cell_type
.	O

CD20	B-protein
is	O
a	O
B-lineage-specific	B-DNA
gene	I-DNA
expressed	O
at	O
the	O
pre-B-cell	O
stage	O
of	O
B-cell	O
development	O
that	O
disappears	O
on	O
differentiation	O
to	O
plasma	B-cell_type
cells	I-cell_type
.	O

As	O
such	O
,	O
it	O
serves	O
as	O
an	O
excellent	O
paradigm	O
for	O
the	O
study	O
of	O
lineage	O
and	O
developmental	O
stage-specific	O
gene	O
expression	O
.	O

Using	O
in	O
vivo	O
footprinting	O
we	O
identified	O
two	O
sites	O
in	O
the	O
promoter	O
at	O
-45	B-DNA
and	I-DNA
-160	I-DNA
that	O
were	O
occupied	O
only	O
in	O
CD20	B-protein
+	O
B	O
cells	O
.	O

The	O
-45	B-DNA
site	I-DNA
is	O
an	O
E	B-DNA
box	I-DNA
that	O
binds	O
basic	B-protein
helix-loop-helix-zipper	I-protein
proteins	I-protein
whereas	O
the	O
-160	B-DNA
site	I-DNA
is	O
a	O
composite	B-DNA
PU.1	I-DNA
and	I-DNA
Pip	I-DNA
binding	I-DNA
site	I-DNA
.	O

Transfection	O
studies	O
with	O
reporter	B-DNA
constructs	I-DNA
and	O
various	O
expression	O
vectors	O
verified	O
the	O
importance	O
of	O
these	O
sites	O
.	O

The	O
composite	B-DNA
PU.1	I-DNA
and	I-DNA
Pip	I-DNA
site	I-DNA
likely	O
accounts	O
for	O
both	O
lineage	O
and	O
stage-specific	O
expression	O
of	O
CD20	B-protein
whereas	O
the	O
CD20	B-protein
E	I-protein
box	I-protein
binding	I-protein
proteins	I-protein
enhance	O
overall	O
promoter	O
activity	O
and	O
may	O
link	O
the	O
promoter	O
to	O
a	O
distant	B-DNA
enhancer	I-DNA
.	O

Glucocorticoids	O
and	O
the	O
immune	O
function	O
in	O
the	O
human	O
immunodeficiency	O
virus	O
infection	O
:	O
a	O
study	O
in	O
hypercortisolemic	O
and	O
cortisol-resistant	O
patients	O
.	O

Immunological	O
studies	O
in	O
human	O
immunodeficiency	O
virus	O
(	O
HIV	O
)	O
-positive	O
patients	O
suggest	O
that	O
the	O
disease	O
progression	O
is	O
accompanied	O
by	O
a	O
defective	O
production	O
of	O
type	O
1	B-protein
cytokines	I-protein
(	O
interleukin-2	B-protein
(	O
IL-2	B-protein
)	O
and	O
IL-12	B-protein
]	O
,	O
an	O
increased	O
production	O
of	O
type	B-protein
2	I-protein
cytokines	I-protein
(	O
IL-4	B-protein
,	O
IL-6	B-protein
,	O
and	O
IL-10	B-protein
)	O
,	O
and	O
an	O
increased	O
production	O
of	O
IgE	B-protein
.	O

HIV	O
infection	O
is	O
also	O
associated	O
with	O
activation	O
of	O
the	O
hypothalamo-pituitary-adrenal	O
axis	O
function	O
and	O
increased	O
plasma	O
and	O
urinary	O
cortisol	O
concentrations	O
.	O

As	O
cortisol	O
is	O
involved	O
in	O
the	O
physiological	O
regulation	O
of	O
cytokines	B-protein
,	O
a	O
study	O
was	O
conducted	O
to	O
examine	O
cytokine	B-protein
patterns	O
in	O
two	O
groups	O
of	O
hypercortisolemic	O
patients	O
,	O
one	O
with	O
normal	O
sensitivity	O
to	O
glucocorticoids	O
and	O
the	O
other	O
with	O
glucocorticoid	O
resistance	O
.	O

Ten	O
HIV-infected	O
patients	O
with	O
normal	O
receptor	O
affinity	O
to	O
glucocorticoids	O
(	O
AIDS-C	O
)	O
,	O
10	O
HIV-infected	O
patients	O
with	O
low	O
receptor	O
affinity	O
to	O
glucocorticoids	O
(	O
AIDS-GR	O
)	O
,	O
and	O
20	O
healthy	O
subjects	O
were	O
studied	O
.	O

Receptor	O
characteristics	O
of	O
peripheral	B-cell_type
blood	I-cell_type
mononuclear	I-cell_type
cells	I-cell_type
were	O
evaluated	O
by	O
[	O
3H	O
]	O
dexamethasone	O
binding	O
.	O

Serum	O
cortisol	O
and	O
urinary	O
free	O
cortisol	O
were	O
measured	O
by	O
RIA	O
.	O

Serum	O
ACTH	O
and	O
IgE	B-protein
were	O
measured	O
by	O
immunoradiometric	O
assay	O
,	O
and	O
IL-2	B-protein
,	O
IL-4	B-protein
,	O
and	O
IL-10	B-protein
cytokines	B-protein
and	O
interferon-gamma	B-protein
were	O
measured	O
by	O
enzyme-linked	O
immunosorbent	O
assay	O
.	O

AIDS-C	O
patients	O
showed	O
low	O
IL-2	B-protein
and	O
high	O
IL-4	B-protein
,	O
IL-10	B-protein
,	O
and	O
IgE	B-protein
concentratios	O
;	O
conversely	O
,	O
AIDS-GR	O
patients	O
showed	O
high	O
IL-2	B-protein
and	O
low	O
IL-4	B-protein
and	O
IgE	B-protein
concentrations	O
.	O

Thus	O
,	O
in	O
HIV	O
infection	O
,	O
elevated	O
cortisol	O
levels	O
suppress	O
cell-mediated	O
immunity	O
and	O
stimulate	O
humoral	O
immunity	O
,	O
whereas	O
this	O
response	O
is	O
not	O
detected	O
in	O
cortisol-resistant	O
patients	O
.	O

These	O
findings	O
indicate	O
that	O
cortisol	O
and	O
its	O
receptors	O
are	O
critically	O
involved	O
in	O
the	O
regulation	O
of	O
immune	O
function	O
in	O
HIV	O
infection	O
.	O

Monocytic	O
differentiation	O
of	O
HL-60	B-cell_line
promyelocytic	I-cell_line
leukemia	I-cell_line
cells	I-cell_line
correlates	O
with	O
the	O
induction	O
of	O
Bcl-xL	B-protein
.	O

Treatment	O
of	O
human	B-cell_line
promyelocytic	I-cell_line
leukemia	I-cell_line
HL-60	I-cell_line
cells	I-cell_line
with	O
phorbol	O
esters	O
ultimately	O
induces	O
the	O
differentiation	O
of	O
these	O
cells	O
along	O
the	O
monocyte/macrophage	B-cell_type
lineage	I-cell_type
,	O
whereas	O
treatment	O
with	O
retinoic	O
acid	O
or	O
DMSO	O
induces	O
granulocytic/neutrophillic	O
differentiation	O
.	O

In	O
this	O
study	O
,	O
we	O
demonstrate	O
the	O
disparate	O
fates	O
of	O
HL-60	B-cell_line
cells	I-cell_line
treated	O
with	O
the	O
phorbol	O
ester	O
12	O
,	O
13-phorbol	O
dibutyric	O
acid	O
(	O
PDBu	O
)	O
or	O
DMSO	O
.	O

After	O
DMSO	O
treatment	O
,	O
HL-60	B-cell_line
cells	I-cell_line
eventually	O
died	O
via	O
apoptosis	O
,	O
whereas	O
the	O
viability	O
of	O
PDBu-treated	B-cell_line
cells	I-cell_line
was	O
not	O
affected	O
during	O
the	O
same	O
interval	O
.	O

The	O
levels	O
of	O
the	O
apoptosis	O
effector	O
proteins	O
Bak	B-protein
and	O
Bad	B-protein
were	O
enhanced	O
,	O
whereas	O
there	O
was	O
a	O
slight	O
down-regulation	O
of	O
the	O
apoptosis	B-protein
suppressor	I-protein
protein	I-protein
Bcl-2	B-protein
after	O
treatment	O
of	O
the	O
cells	O
with	O
PDBu	O
and	O
DMSO	O
.	O

Treatment	O
with	O
DMSO	O
resulted	O
in	O
the	O
elevation	O
of	O
the	O
apoptosis	B-protein
effector	I-protein
Bax	B-protein
,	O
whereas	O
treatment	O
with	O
PDBu	O
did	O
not	O
significantly	O
alter	O
the	O
levels	O
of	O
this	O
protein	O
.	O

However	O
,	O
treatment	O
of	O
HL-60	B-cell_line
cells	I-cell_line
with	O
PDBu	O
induced	O
the	O
rapid	O
expression	O
of	O
the	O
apoptosis	B-protein
suppressor	I-protein
protein	I-protein
Bcl-xL	B-protein
,	O
whereas	O
the	O
expression	O
of	O
this	O
protein	O
remained	O
unaltered	O
in	O
DMSO-treated	O
cells	O
.	O

The	O
generality	O
of	O
this	O
finding	O
was	O
confirmed	O
by	O
the	O
induction	O
of	O
Bcl-xL	B-protein
in	O
human	B-cell_line
myeloid	I-cell_line
U-937	I-cell_line
cells	I-cell_line
,	O
human	B-cell_type
peripheral	I-cell_type
blood	I-cell_type
monocytes	I-cell_type
exposed	O
to	O
phorbol	O
ester	O
,	O
and	O
mouse	B-cell_line
thioglycollate-activated	I-cell_line
and	I-cell_line
resident	I-cell_line
peritoneal	I-cell_line
macrophages	I-cell_line
.	O

PDBu-treated	B-cell_line
HL-60	I-cell_line
cells	I-cell_line
remained	O
viable	O
for	O
7	O
days	O
and	O
thereafter	O
began	O
to	O
die	O
via	O
apoptosis	O
,	O
with	O
a	O
concomitant	O
down-regulation	O
of	O
Bcl-xL	B-protein
.	O

In	O
conclusion	O
,	O
we	O
propose	O
that	O
Bcl-xL	B-protein
expression	O
is	O
associated	O
with	O
differentiation	O
and	O
survival	O
of	O
hematopoietic	B-cell_type
cells	I-cell_type
along	O
the	O
monocyte/macrophage	B-cell_type
lineage	I-cell_type
.	O

Monochloramine	O
inhibits	O
phorbol	O
ester-inducible	O
neutrophil	O
respiratory	O
burst	O
activation	O
and	O
T	O
cell	O
interleukin-2	B-protein
receptor	O
expression	O
by	O
inhibiting	O
inducible	O
protein	B-protein
kinase	I-protein
C	I-protein
activity	O
.	O

Monochloramine	O
derivatives	O
are	O
long	O
lived	O
physiological	O
oxidants	O
produced	O
by	O
neutrophils	B-cell_type
during	O
the	O
respiratory	O
burst	O
.	O

The	O
effects	O
of	O
chemically	O
prepared	O
monochloramine	O
(	O
NH2Cl	O
)	O
on	O
protein	B-protein
kinase	I-protein
C	I-protein
(	O
PKC	B-protein
)	O
and	O
PKC	B-protein
-mediated	O
cellular	O
responses	O
were	O
studied	O
in	O
elicited	B-cell_type
rat	I-cell_type
peritoneal	I-cell_type
neutrophils	I-cell_type
and	O
human	B-cell_line
Jurkat	I-cell_line
T	I-cell_line
cells	I-cell_line
.	O

Neutrophils	O
pretreated	O
with	O
NH2Cl	O
(	O
30-50	O
microM	O
)	O
showed	O
a	O
marked	O
decrease	O
in	O
the	O
respiratory	O
burst	O
activity	O
induced	O
by	O
phorbol	O
12-myristate	O
13-acetate	O
(	O
PMA	O
)	O
,	O
which	O
is	O
a	O
potent	O
PKC	B-protein
activator	O
.	O

These	O
cells	O
,	O
however	O
,	O
were	O
viable	O
and	O
showed	O
a	O
complete	O
respiratory	O
burst	O
upon	O
arachidonic	O
acid	O
stimulation	O
,	O
which	O
induces	O
the	O
respiratory	O
burst	O
by	O
a	O
PKC	B-protein
-independent	O
mechanism	O
.	O

The	O
NH2Cl-treated	B-cell_line
neutrophils	I-cell_line
showed	O
a	O
decrease	O
in	O
both	O
PKC	B-protein
activity	O
and	O
PMA-induced	O
phosphorylation	O
of	O
a	O
47-kDa	B-protein
protein	I-protein
,	O
which	O
corresponds	O
to	O
the	O
cytosolic	B-protein
factor	I-protein
of	O
NADPH	B-protein
oxidase	I-protein
,	O
p47	B-protein
(	I-protein
phox	I-protein
)	I-protein
.	O

Jurkat	B-cell_line
T	I-cell_line
cells	I-cell_line
pretreated	O
with	O
NH2Cl	O
(	O
20-70	O
microM	O
)	O
showed	O
a	O
decrease	O
in	O
the	O
expression	O
of	O
the	O
interleukin-2	B-protein
receptor	B-protein
alpha	I-protein
chain	I-protein
following	O
PMA	O
stimulation	O
.	O

This	O
was	O
also	O
accompanied	O
by	O
a	O
decrease	O
in	O
both	O
PKC	B-protein
activity	O
and	O
nuclear	O
transcription	O
factor-	O
kappaB	B-protein
activation	O
,	O
also	O
without	O
loss	O
of	O
cell	O
viability	O
.	O

These	O
results	O
show	O
that	O
NH2Cl	O
inhibits	O
PKC	B-protein
-mediated	O
cellular	O
responses	O
through	O
inhibition	O
of	O
the	O
inducible	O
PKC	B-protein
activity	O
.	O

Evidence	O
that	O
calcineurin	O
is	O
rate-limiting	O
for	O
primary	O
human	O
lymphocyte	O
activation	O
.	O

Cyclosporine	O
(	O
CsA	O
)	O
is	O
both	O
a	O
clinical	O
immunosuppressive	O
drug	O
and	O
a	O
probe	O
to	O
dissect	O
intracellular	O
signaling	O
pathways	O
.	O

In	O
vitro	O
,	O
CsA	O
inhibits	O
lymphocyte	B-DNA
gene	I-DNA
activation	O
by	O
inhibiting	O
the	O
phosphatase	B-protein
activity	O
of	O
calcineurin	B-protein
(	O
CN	B-protein
)	O
.	O

In	O
clinical	O
use	O
,	O
CsA	O
treatment	O
inhibits	O
50-75	O
%	O
of	O
CN	B-protein
activity	O
in	O
circulating	B-cell_type
leukocytes	I-cell_type
.	O

We	O
modeled	O
this	O
degree	O
of	O
CN	B-protein
inhibition	O
in	O
primary	B-cell_type
human	I-cell_type
leukocytes	I-cell_type
in	O
vitro	O
in	O
order	O
to	O
study	O
the	O
effect	O
of	O
partial	O
CN	B-protein
inhibition	O
on	O
the	O
downstream	O
signaling	O
events	O
that	O
lead	O
to	O
gene	O
activation	O
.	O

In	O
CsA-treated	B-cell_line
leukocytes	I-cell_line
stimulated	O
by	O
calcium	O
ionophore	O
,	O
the	O
degree	O
of	O
reduction	O
in	O
CN	B-protein
activity	O
was	O
accompanied	O
by	O
a	O
similar	O
degree	O
of	O
inhibition	O
of	O
each	O
event	O
tested	O
:	O
dephosphorylation	O
of	O
nuclear	B-protein
factor	I-protein
of	I-protein
activated	I-protein
T	I-protein
cell	I-protein
proteins	I-protein
,	O
nuclear	O
DNA	O
binding	O
,	O
activation	O
of	O
a	O
transfected	B-DNA
reporter	I-DNA
gene	I-DNA
construct	I-DNA
,	O
IFN-gamma	O
and	O
IL-2	O
mRNA	O
accumulation	O
,	O
and	O
IFN-gamma	B-protein
production	O
.	O

Furthermore	O
,	O
the	O
degree	O
of	O
CN	B-protein
inhibition	O
was	O
reflected	O
by	O
a	O
similar	O
degree	O
of	O
reduction	O
in	O
lymphocyte	O
proliferation	O
and	O
IFN-gamma	B-protein
production	O
in	O
the	O
allogeneic	B-cell_line
mixed	I-cell_line
lymphocyte	I-cell_line
cultures	I-cell_line
.	O

These	O
data	O
support	O
the	O
conclusion	O
that	O
CN	B-protein
activity	O
is	O
rate-limiting	O
for	O
the	O
activation	O
of	O
primary	B-cell_type
human	I-cell_type
T	I-cell_type
lymphocytes	I-cell_type
.	O

Thus	O
,	O
the	O
reduction	O
of	O
CN	B-protein
activity	O
observed	O
in	O
CsA-treated	O
patients	O
is	O
accompanied	O
by	O
a	O
similar	O
degree	O
of	O
reduction	O
in	O
lymphocyte	B-DNA
gene	I-DNA
activation	O
,	O
and	O
accounts	O
for	O
the	O
immunosuppression	O
observed	O
.	O

Selection	O
of	O
down-regulated	B-DNA
sequences	I-DNA
along	O
the	O
monocytic	O
differentiation	O
of	O
leukemic	B-cell_line
HL60	I-cell_line
cells	I-cell_line
.	O

In	O
order	O
to	O
dissect	O
the	O
molecular	O
mechanisms	O
of	O
monocytic	O
differentiation	O
we	O
have	O
developed	O
a	O
subtractive	O
hybridisation	O
method	O
based	O
on	O
a	O
simplified	O
'representational	O
difference	O
analysis'	O
.	O

We	O
have	O
selected	O
16	B-DNA
sequences	I-DNA
and	O
confirmed	O
their	O
down-regulation	O
along	O
the	O
TPA-induced	O
monocytic	O
differentiation	O
of	O
HL60	B-cell_line
cells	I-cell_line
.	O

Among	O
these	O
sequences	O
we	O
have	O
identified	O
the	O
alpha-tubulin	B-protein
,	O
the	O
TaxREB	B-protein
protein	I-protein
and	O
two	O
ribosomal	B-DNA
protein	I-DNA
sequences	I-DNA
which	O
had	O
not	O
been	O
previously	O
described	O
as	O
differentially	O
expressed	O
.	O

These	O
results	O
add	O
to	O
our	O
knowledge	O
about	O
the	O
molecules	O
implicated	O
along	O
the	O
monocytic	O
differentiation	O
and	O
growth	O
arrest	O
of	O
leukemic	B-cell_type
cells	I-cell_type
and	O
provide	O
a	O
first	O
step	O
in	O
the	O
study	O
of	O
their	O
respective	O
roles	O
.	O

Control	O
of	O
NF-kappa	B-protein
B	I-protein
activity	O
by	O
the	O
I	B-protein
kappa	I-protein
B	I-protein
beta	I-protein
inhibitor	I-protein
.	O

The	O
transcription	B-protein
factor	I-protein
NF-kappa	B-protein
B	I-protein
is	O
maintained	O
in	O
an	O
inactive	O
cytoplasmic	O
state	O
by	O
I	B-protein
kappa	I-protein
B	I-protein
inhibitors	I-protein
.	O

In	O
mammalian	B-cell_type
cells	I-cell_type
,	O
I	B-protein
kappa	I-protein
B	I-protein
alpha	I-protein
and	O
I	B-protein
kappa	I-protein
B	I-protein
beta	I-protein
proteins	I-protein
have	O
been	O
purified	O
and	O
shown	O
to	O
be	O
the	O
inhibitors	O
of	O
NF-kappa	B-protein
B	I-protein
through	O
their	O
association	O
with	O
the	O
p65	B-protein
or	I-protein
c-Rel	I-protein
subunits	I-protein
.	O

In	O
addition	O
,	O
we	O
have	O
isolated	O
a	O
third	O
NF-kappa	B-protein
B	I-protein
inhibitor	I-protein
,	O
I	B-protein
kappa	I-protein
B	I-protein
epsilon	I-protein
(	O
1	O
)	O
.	O

Upon	O
treatment	O
with	O
a	O
large	O
variety	O
of	O
inducers	O
,	O
I	B-protein
kappa	I-protein
B	I-protein
alpha	I-protein
,	O
I	B-protein
kappa	I-protein
B	I-protein
beta	I-protein
are	O
proteolytically	O
degraded	O
,	O
resulting	O
in	O
NF-kappa	B-protein
B	I-protein
translocation	O
into	O
the	O
nucleus	O
.	O

Here	O
we	O
show	O
that	O
in	O
E29.1	B-cell_line
T	I-cell_line
cell	I-cell_line
hybridoma	I-cell_line
I	B-protein
kappa	I-protein
B	I-protein
alpha	I-protein
and	O
I	B-protein
kappa	I-protein
B	I-protein
beta	I-protein
are	O
equally	O
associated	O
with	O
p65	B-protein
and	O
that	O
I	B-protein
kappa	I-protein
B	I-protein
beta	I-protein
is	O
degraded	O
in	O
response	O
to	O
TNF	B-protein
alpha	I-protein
in	O
contrast	O
to	O
what	O
has	O
been	O
originally	O
published	O
.	O

Our	O
data	O
also	O
suggest	O
that	O
,	O
unlike	O
I	B-protein
kappa	I-protein
B	I-protein
alpha	I-protein
,	O
I	B-protein
kappa	I-protein
B	I-protein
beta	I-protein
is	O
constitutively	O
phosphorylated	O
and	O
resynthesized	O
as	O
a	O
hypophosphorylated	B-protein
form	I-protein
.	O

The	O
absence	O
of	O
slow	O
migrating	O
forms	O
of	O
I	B-protein
kappa	I-protein
B	I-protein
beta	I-protein
following	O
stimulation	O
suggests	O
that	O
the	O
phosphorylation	O
does	O
not	O
necessarily	O
constitute	O
the	O
signal-induced	O
event	O
which	O
targets	O
the	O
molecule	O
for	O
proteolysis	O
.	O

Agonistic	O
activity	O
of	O
a	O
CD40-specific	B-protein
single-chain	I-protein
Fv	I-protein
constructed	O
from	O
the	O
variable	B-protein
regions	I-protein
of	O
mAb	B-protein
G28-5	I-protein
.	O

A	O
single-chain	B-protein
Fv	I-protein
(	O
sFv	B-protein
)	O
was	O
expressed	O
from	O
the	O
variable	B-protein
regions	I-protein
of	O
the	O
CD40-specific	O
mAb	B-protein
G28-5	I-protein
.	O

The	O
molecule	O
bound	O
CD40	B-protein
with	O
a	O
high	O
affinity	O
(	O
2.2	O
nM	O
)	O
and	O
was	O
a	O
monomer	O
in	O
solution	O
.	O

Surprisingly	O
,	O
G28-5	B-protein
sFv	I-protein
was	O
a	O
potent	O
CD40	B-protein
agonist	I-protein
that	O
rapidly	O
crosslinked	O
CD40	B-protein
on	O
the	O
cell	O
surface	O
but	O
did	O
not	O
crosslink	O
CD40-Ig	B-protein
in	O
solution	O
.	O

G28-5	B-protein
sFv	I-protein
was	O
a	O
more	O
potent	O
agonist	O
than	O
G28-5	B-protein
IgG	I-protein
and	O
was	O
able	O
to	O
stimulate	O
CD40	B-protein
responses	O
by	O
B	B-cell_type
cells	I-cell_type
and	O
monocytes	O
.	O

G28-5	B-protein
IgG	I-protein
partially	O
blocked	O
,	O
whereas	O
G28-5	B-protein
sFv	I-protein
augmented	O
CD40	B-protein
responses	O
during	O
stimulation	O
with	O
natural	B-protein
ligand	I-protein
(	O
gp39-CD8	B-protein
fusion	I-protein
protein	I-protein
)	O
.	O

These	O
results	O
indicate	O
that	O
the	O
functional	O
activity	O
of	O
ligands	O
built	O
from	O
the	O
binding	B-protein
site	I-protein
of	O
G28-5	B-protein
is	O
highly	O
dependent	O
upon	O
the	O
size	O
and	O
physical	O
properties	O
of	O
the	O
molecule	O
both	O
in	O
solution	O
and	O
on	O
the	O
cell	O
surfaces	O
.	O

C/EBP	B-protein
activates	O
the	O
human	B-DNA
corticotropin-releasing	I-DNA
hormone	I-DNA
gene	I-DNA
promoter	I-DNA
.	O

The	O
purpose	O
of	O
these	O
studies	O
was	O
to	O
identify	O
whether	O
transcription	O
factors	O
,	O
associated	O
with	O
cytokine	O
signalling	O
,	O
affected	O
promoter	O
activity	O
of	O
the	O
corticotropin	B-DNA
releasing	I-DNA
hormone	I-DNA
(	I-DNA
CRH	I-DNA
)	I-DNA
gene	I-DNA
.	O

Fragments	O
of	O
a	O
3.6	O
kb	O
sequence	O
of	O
the	O
human	B-DNA
CRH	I-DNA
gene	I-DNA
promoter	I-DNA
were	O
amplified	O
by	O
PCR	O
and	O
ligated	O
upstream	O
of	O
a	O
CAT	B-DNA
reporter	I-DNA
.	O

These	O
constructs	O
were	O
transfected	O
into	O
a	O
variety	O
of	O
cell	O
lines	O
,	O
either	O
alone	O
or	O
together	O
,	O
with	O
transcription	B-protein
factor	I-protein
expression	O
vectors	O
.	O

Basal	O
activity	O
of	O
a	O
3070	B-DNA
bp	I-DNA
CRH	I-DNA
promoter	I-DNA
fragment	I-DNA
was	O
only	O
seen	O
in	O
neuronal	O
and	O
lymphoblastoid	B-cell_line
cell	I-cell_line
lines	I-cell_line
.	O

Promoter	O
activity	O
was	O
increased	O
by	O
the	O
transcription	B-protein
factors	I-protein
C/EBPbeta	B-protein
(	O
NF-IL6	B-protein
)	O
and	O
more	O
strongly	O
,	O
by	O
C/EBPdelta	B-protein
(	O
NF-IL6beta	B-protein
)	O
.	O

Increased	O
CRH	B-protein
promoter	O
activity	O
following	O
phorbol	O
ester	O
treatment	O
was	O
inhibited	O
by	O
a	O
dominant	O
negative	O
NF-IL6	B-protein
mutant	I-protein
,	O
showing	O
that	O
the	O
effects	O
of	O
phorbol	O
ester	O
were	O
principally	O
mediated	O
by	O
C/EBP	B-protein
.	O

Moreover	O
,	O
the	O
inverse	O
changes	O
in	O
the	O
expression	O
of	O
CRH	B-protein
in	O
the	O
hypothalamus	O
and	O
spleens	O
of	O
arthritic	O
rats	O
were	O
paralleled	O
by	O
similar	O
inverse	O
changes	O
in	O
NF-IL6beta	B-protein
expression	O
in	O
these	O
organs	O
.	O

These	O
data	O
show	O
that	O
some	O
transcription	B-protein
factors	I-protein
associated	O
with	O
cytokine	B-protein
signalling	O
can	O
also	O
activate	O
the	O
CRH	B-DNA
promoter	I-DNA
.	O

Aberrant	O
splicing	O
of	O
the	O
TSG101	B-DNA
and	I-DNA
FHIT	I-DNA
genes	I-DNA
occurs	O
frequently	O
in	O
multiple	O
malignancies	O
and	O
in	O
normal	O
tissues	O
and	O
mimics	O
alterations	O
previously	O
described	O
in	O
tumours	O
.	O

Intragenic	O
deletions	O
of	O
TSG101	B-DNA
,	O
the	O
human	O
homolog	O
of	O
a	O
mouse	B-DNA
gene	I-DNA
(	O
tsg101	B-DNA
)	O
that	O
acts	O
to	O
suppress	O
malignant	O
cell	O
growth	O
,	O
were	O
reported	O
in	O
human	B-cell_type
breast	I-cell_type
tumours	I-cell_type
.	O

We	O
screened	O
TSG101	B-DNA
for	O
somatic	O
mutations	O
in	O
DNA	O
and	O
RNA	O
samples	O
isolated	O
from	O
a	O
variety	O
of	O
common	O
human	O
malignancies	O
,	O
EBV-immortalised	B-cell_type
B-cells	I-cell_type
,	O
and	O
normal	O
lung	O
parenchyma	O
.	O

Intragenic	O
TSG101	B-DNA
deletions	O
in	O
RNA	B-RNA
transcripts	I-RNA
were	O
frequently	O
found	O
in	O
all	O
types	O
of	O
samples	O
.	O

Analysis	O
of	O
DNA	O
failed	O
to	O
show	O
genomic	O
rearrangements	O
corresponding	O
to	O
transcripts	O
containing	O
deletions	O
in	O
the	O
same	O
samples	O
.	O

The	O
breakpoints	O
of	O
most	O
transcript	O
deletions	O
coincide	O
with	O
genuine	O
or	O
cryptic	O
splice	B-DNA
site	I-DNA
sequences	I-DNA
,	O
suggesting	O
that	O
they	O
result	O
from	O
alternative	O
or	O
aberrant	O
splicing	O
.	O

A	O
similar	O
spectrum	O
of	O
transcript	O
deletions	O
has	O
previously	O
been	O
described	O
in	O
the	O
putative	B-DNA
tumour	I-DNA
suppressor	I-DNA
gene	I-DNA
FHIT	B-DNA
.	O

We	O
analysed	O
FHIT	B-DNA
in	O
the	O
same	O
series	O
of	O
RNA	B-RNA
samples	I-RNA
and	O
detected	O
truncated	O
FHIT	B-RNA
transcripts	I-RNA
frequently	O
in	O
both	O
tumour	O
and	O
normal	O
tissues	O
.	O

In	O
addition	O
,	O
transcripts	O
from	O
TSG101	B-DNA
,	O
FHIT	B-DNA
and	O
seven	O
other	O
genes	O
were	O
analysed	O
in	O
RNA	O
isolated	O
from	O
normal	B-cell_type
peripheral	I-cell_type
blood	I-cell_type
lymphocytes	I-cell_type
.	O

Large	O
TSG101	B-DNA
and	O
FHIT	B-DNA
intragenic	O
transcript	O
deletions	O
were	O
detected	O
and	O
these	O
appeared	O
to	O
be	O
the	O
predominant	O
transcript	O
in	O
'aged	B-cell_type
'	I-cell_type
lymphocytes	I-cell_type
.	O

Similar	O
alterations	O
were	O
not	O
detected	O
in	O
transcripts	O
of	O
the	O
other	O
genes	O
which	O
were	O
analysed	O
.	O

Our	O
findings	O
demonstrate	O
that	O
truncated	B-RNA
TSG101	I-RNA
and	I-RNA
FHIT	I-RNA
transcripts	I-RNA
are	O
commonly	O
detected	O
in	O
both	O
normal	O
and	O
malignant	O
tissues	O
and	O
that	O
a	O
significant	O
fraction	O
of	O
these	O
are	O
likely	O
to	O
be	O
the	O
result	O
of	O
aberrant	O
splicing	O
.	O

While	O
we	O
can	O
not	O
exclude	O
that	O
alterations	O
in	O
TSG101	B-DNA
and	O
FHIT	B-DNA
occur	O
during	O
cancer	O
development	O
,	O
our	O
data	O
indicate	O
that	O
in	O
this	O
context	O
the	O
commonly	O
observed	O
transcript	O
abnormalities	O
are	O
misleading	O
.	O

Inhibition	O
of	O
proliferation	O
and	O
apoptosis	O
of	O
human	B-cell_type
and	I-cell_type
rat	I-cell_type
T	I-cell_type
lymphocytes	I-cell_type
by	O
curcumin	O
,	O
a	O
curry	O
pigment	O
.	O

Curcumin	O
(	O
diferuoylmethane	O
)	O
,	O
the	O
yellow	O
pigment	O
in	O
the	O
rhizome	O
of	O
tumeric	O
(	O
Curcuma	O
longa	O
)	O
,	O
an	O
ingredient	O
of	O
curry	O
spice	O
,	O
is	O
known	O
to	O
exhibit	O
a	O
variety	O
of	O
pharmacological	O
effects	O
including	O
antitumor	O
,	O
antiinflammatory	O
,	O
and	O
antiinfectious	O
activities	O
.	O

Although	O
its	O
precise	O
mode	O
of	O
action	O
remains	O
elusive	O
,	O
curcumin	O
has	O
been	O
shown	O
to	O
suppress	O
the	O
activity	O
of	O
the	O
AP-1	B-protein
transcription	B-protein
factor	I-protein
in	O
cells	O
stimulated	O
to	O
proliferate	O
.	O

In	O
this	O
study	O
,	O
we	O
observed	O
that	O
curcumin	O
(	O
50	O
microM	O
)	O
inhibited	O
proliferation	O
of	O
rat	B-cell_type
thymocytes	I-cell_type
stimulated	O
with	O
concanavalin	O
A	O
(	O
Con	O
A	O
)	O
as	O
well	O
as	O
that	O
of	O
human	B-cell_type
Jurkat	I-cell_type
lymphoblastoid	I-cell_type
cells	I-cell_type
in	O
the	O
logarithmic	O
growth	O
phase	O
.	O

The	O
pigment	O
also	O
inhibited	O
apoptosis	O
in	O
dexamethasone-treated	B-cell_line
rat	I-cell_line
thymocytes	I-cell_line
and	O
in	O
UV-irradiated	B-cell_line
Jurkat	I-cell_line
cells	I-cell_line
as	O
judged	O
by	O
DNA	O
ladder	O
formation	O
,	O
cellular	O
morphological	O
changes	O
,	O
and	O
flow	O
cytometry	O
analysis	O
.	O

The	O
inhibition	O
of	O
apoptosis	O
by	O
curcumin	O
in	O
rat	B-cell_type
thymocytes	I-cell_type
was	O
accompanied	O
by	O
partial	O
suppression	O
of	O
AP-1	B-protein
activity	O
.	O

Complete	O
suppression	O
of	O
AP-1	B-protein
activity	O
was	O
observed	O
in	O
Con	B-cell_line
A-treated	I-cell_line
,	I-cell_line
proliferating	I-cell_line
thymocytes	I-cell_line
.	O

The	O
capacity	O
of	O
curcumin	O
to	O
inhibit	O
both	O
cell	O
growth	O
and	O
death	O
strongly	O
implies	O
that	O
these	O
two	O
biological	O
processes	O
share	O
a	O
common	O
pathway	O
at	O
some	O
point	O
and	O
that	O
curcumin	O
affects	O
a	O
common	O
step	O
,	O
presumably	O
involving	O
a	O
modulation	O
of	O
the	O
AP-1	B-protein
transcription	B-protein
factor	I-protein
.	O

Interleukin-7	B-protein
upregulates	O
the	O
interleukin-2-gene	B-DNA
expression	O
in	O
activated	B-cell_type
human	I-cell_type
T	I-cell_type
lymphocytes	I-cell_type
at	O
the	O
transcriptional	O
level	O
by	O
enhancing	O
the	O
DNA	O
binding	O
activities	O
of	O
both	O
nuclear	O
factor	O
of	O
activated	B-cell_type
T	I-cell_type
cells	I-cell_type
and	O
activator	B-protein
protein-1	I-protein
.	O

In	O
the	O
present	O
report	O
,	O
we	O
studied	O
the	O
role	O
of	O
the	O
stromal-derived	B-protein
cytokine	I-protein
interleukin-7	I-protein
(	O
IL-7	B-protein
)	O
in	O
the	O
IL-2-gene	B-DNA
regulation	O
in	O
activated	B-cell_type
T	I-cell_type
lymphocytes	I-cell_type
.	O

Production	O
of	O
IL-2	B-protein
requires	O
the	O
formation	O
of	O
transcription	B-protein
factors	I-protein
involved	O
in	O
the	O
IL-2-gene	B-DNA
regulation	O
.	O

T-cell	B-protein
receptor	I-protein
(	B-protein
TCR	I-protein
)	I-protein
/CD3	I-protein
engagement	O
results	O
in	O
the	O
activation	O
of	O
nuclear	O
factor	O
of	O
activated	B-cell_type
T	I-cell_type
cells	I-cell_type
(	O
NFAT	B-protein
)	O
,	O
activator	B-protein
protein-1	I-protein
(	O
AP-1	B-protein
)	O
,	O
and	O
nuclear	B-protein
factor	I-protein
kappaB	I-protein
(	O
NFkappaB	B-protein
)	O
,	O
whereas	O
the	O
CD28	B-protein
responsive	I-protein
complex	I-protein
(	O
CD28RC	B-protein
)	O
is	O
activated	O
in	O
response	O
to	O
the	O
CD28	B-protein
signal	O
.	O

Costimulation	O
of	O
phytohemagglutinin/anti-CD28	B-cell_line
activated	I-cell_line
T	I-cell_line
lymphocytes	I-cell_line
with	O
IL-7	B-protein
induces	O
a	O
fivefold	O
enhanced	O
IL-2	B-protein
-mRNA	O
accumulation	O
and	O
a	O
2.5-fold	O
enhanced	O
protein	O
secretion	O
.	O

The	O
IL-2-gene	B-DNA
transcription	O
rate	O
is	O
increased	O
3.4-fold	O
,	O
indicating	O
that	O
the	O
effect	O
of	O
IL-7	B-protein
is	O
in	O
part	O
mediated	O
at	O
the	O
transcriptional	O
level	O
.	O

The	O
molecular	O
mechanisms	O
underlying	O
the	O
IL-7	B-protein
effect	O
involve	O
the	O
upregulation	O
of	O
the	O
DNA	O
binding	O
activity	O
of	O
NFAT	B-protein
(	O
60	O
%	O
)	O
and	O
AP-1	B-protein
(	O
120	O
%	O
)	O
,	O
without	O
affecting	O
the	O
activities	O
of	O
NFkappaB	B-protein
and	O
CD28RC	B-protein
,	O
which	O
was	O
confirmed	O
by	O
transfection	O
assays	O
.	O

We	O
also	O
show	O
that	O
the	O
IL-7	B-protein
-induced	O
enhancement	O
of	O
the	O
AP-1	B-protein
-DNA	O
binding	O
activity	O
is	O
not	O
cyclosporin	O
A-sensitive	O
.	O

Since	O
AP-1	B-protein
is	O
part	O
of	O
the	O
NFAT	B-protein
complex	I-protein
,	O
we	O
conclude	O
that	O
the	O
IL-7	B-protein
-signaling	O
pathway	O
is	O
involved	O
in	O
the	O
activation	O
of	O
the	O
fos	B-protein
and	I-protein
jun	I-protein
proteins	I-protein
of	O
which	O
AP-1	B-protein
consists	O
.	O

The	O
spatial	O
distribution	O
of	O
human	B-DNA
immunoglobulin	I-DNA
genes	I-DNA
within	O
the	O
nucleus	O
:	O
evidence	O
for	O
gene	O
topography	O
independent	O
of	O
cell	O
type	O
and	O
transcriptional	O
activity	O
.	O

The	O
three-dimensional	O
positioning	O
of	O
immunoglobulin	B-DNA
(	I-DNA
Ig	I-DNA
)	I-DNA
genes	I-DNA
within	O
the	O
nucleus	O
of	O
human	B-cell_type
cells	I-cell_type
was	O
investigated	O
using	O
in	O
situ	O
hybridization	O
and	O
confocal	O
microscopy	O
.	O

The	O
visualization	O
of	O
heavy	B-DNA
and	I-DNA
light	I-DNA
chain	I-DNA
genes	I-DNA
in	O
B-lymphoid	B-cell_type
cells	I-cell_type
showed	O
that	O
the	O
three	O
Ig	B-DNA
genes	I-DNA
are	O
differentially	O
and	O
nonrandomly	O
distributed	O
in	O
different	O
nuclear	O
subvolumes	O
:	O
the	O
kappa	B-DNA
genes	I-DNA
were	O
found	O
to	O
be	O
preferentially	O
confined	O
to	O
an	O
outer	O
nuclear	O
volume	O
,	O
whereas	O
the	O
gamma	B-DNA
and	I-DNA
lambda	I-DNA
genes	I-DNA
consistently	O
occupied	O
more	O
central	O
positions	O
within	O
the	O
nucleus	O
,	O
the	O
lambda	B-DNA
genes	I-DNA
being	O
more	O
interior	O
when	O
compared	O
with	O
the	O
gamma	B-DNA
genes	I-DNA
.	O

The	O
data	O
further	O
show	O
that	O
these	O
overall	O
topographical	O
distributions	O
are	O
independent	O
of	O
gene	O
transcriptional	O
activity	O
and	O
are	O
conserved	O
in	O
different	B-cell_type
cell	I-cell_type
types	I-cell_type
.	O

Although	O
subtle	O
gene	O
movements	O
within	O
those	O
defined	O
topographical	O
regions	O
can	O
not	O
be	O
excluded	O
by	O
this	O
study	O
,	O
the	O
results	O
indicate	O
that	O
tissue	O
specificity	O
of	O
gene	O
expression	O
is	O
not	O
accompanied	O
by	O
drastic	O
changes	O
in	O
gene	O
nuclear	O
topography	O
,	O
rather	O
suggesting	O
that	O
gene	O
organization	O
within	O
the	O
nucleus	O
may	O
be	O
primarily	O
dependent	O
on	O
structural	O
constraints	O
imposed	O
on	O
the	O
respective	O
chromosomes	B-DNA
.	O

Dominant	O
cytotoxic	B-cell_type
T	I-cell_type
lymphocyte	I-cell_type
response	O
to	O
the	O
immediate-early	B-protein
trans-activator	I-protein
protein	I-protein
,	O
BZLF1	B-protein
,	O
in	O
persistent	O
type	O
A	O
or	O
B	O
Epstein-Barr	O
virus	O
infection	O
.	O

Five	O
healthy	O
human	O
leukocyte	O
antigen-B8	O
(	O
HLA-B8	O
)	O
-positive	O
virus	O
carriers	O
were	O
studied	O
to	O
investigate	O
the	O
CD8+	B-cell_type
cytotoxic	I-cell_type
T	I-cell_type
lymphocyte	I-cell_type
(	O
CTL	O
)	O
response	O
to	O
an	O
HLA-B8-restricted	O
peptide	O
,	O
RAKFKQLLQ	O
,	O
located	O
in	O
the	O
Epstein-Barr	B-protein
virus	I-protein
(	I-protein
EBV	I-protein
)	I-protein
immediate-early	I-protein
trans-activator	I-protein
protein	I-protein
,	O
BZLF1	B-protein
.	O

Of	O
the	O
5	O
virus	O
carriers	O
,	O
4	O
were	O
infected	O
with	O
type	O
A	O
and	O
1	O
with	O
type	O
B	O
EBV	O
.	O

Using	O
limiting-dilution	O
analysis	O
of	O
peripheral	B-cell_type
blood	I-cell_type
mononuclear	I-cell_type
cells	I-cell_type
,	O
a	O
high	O
RAKFKQLLQ-specific	O
CTL	O
precursor	O
frequency	O
was	O
demonstrated	O
after	O
specific	O
peptide	O
or	O
autologous	O
lymphoblastoid	O
cell	O
line	O
stimulation	O
in	O
both	O
type	O
A	O
and	O
type	O
B	O
EBV	O
carriers	O
.	O

The	O
RAKFKQLLQ-specific	O
CTL	O
precursor	O
frequencies	O
in	O
all	O
5	O
persons	O
were	O
at	O
least	O
as	O
dominant	O
as	O
those	O
observed	O
with	O
two	O
other	O
EBV-associated	B-protein
,	I-protein
HLA-B8-restricted	I-protein
latent	I-protein
epitopes	I-protein
,	O
FLRGRAYGL	O
and	O
QAKWRLQTL	O
.	O

These	O
findings	O
show	O
that	O
healthy	O
virus	O
carriers	O
maintain	O
a	O
high	O
frequency	O
of	O
BZLF1-specific	B-cell_type
memory	I-cell_type
T	I-cell_type
cells	I-cell_type
,	O
potentially	O
to	O
control	O
virus	O
spread	O
from	O
lytically	B-cell_type
infected	I-cell_type
cells	I-cell_type
.	O

The	O
DNA	B-protein
binding	I-protein
domain	I-protein
of	O
the	O
A-MYB	B-protein
transcription	B-protein
factor	I-protein
is	O
responsible	O
for	O
its	O
B	O
cell-specific	O
activity	O
and	O
binds	O
to	O
a	O
B	B-protein
cell	I-protein
110-kDa	I-protein
nuclear	I-protein
protein	I-protein
.	O

Expression	O
studies	O
as	O
well	O
as	O
the	O
use	O
of	O
transgenic	O
animals	O
have	O
demonstrated	O
that	O
the	O
A-MYB	B-protein
transcription	B-protein
factor	I-protein
plays	O
central	O
and	O
specific	O
role	O
in	O
the	O
regulation	O
of	O
mature	B-cell_type
B	I-cell_type
cell	I-cell_type
proliferation	O
and/or	O
differentiation	O
.	O

Furthermore	O
,	O
it	O
is	O
highly	O
expressed	O
in	O
Burkitt	B-cell_line
's	I-cell_line
lymphoma	I-cell_line
cells	I-cell_line
and	O
may	O
participate	O
in	O
the	O
pathogenesis	O
of	O
this	O
disease	O
.	O

We	O
have	O
therefore	O
investigated	O
the	O
transcriptional	O
activity	O
of	O
A-MYB	B-protein
and	O
its	O
regulation	O
in	O
several	O
human	B-cell_line
lymphoid	I-cell_line
cell	I-cell_line
lines	I-cell_line
using	O
co-transfection	O
assays	O
and	O
show	O
that	O
A-MYB	B-protein
is	O
transcriptionally	O
active	O
in	O
all	O
the	O
B	B-cell_line
cell	I-cell_line
lines	I-cell_line
studied	O
,	O
but	O
not	O
in	O
T	B-cell_type
cells	I-cell_type
.	O

In	O
particular	O
the	O
best	O
responder	B-cell_line
cell	I-cell_line
line	I-cell_line
was	O
the	O
Burkitt	B-cell_line
's	I-cell_line
cell	I-cell_line
line	I-cell_line
Namalwa	I-cell_line
.	O

The	O
activity	O
of	O
A-MYB	B-protein
in	O
B	B-cell_type
and	I-cell_type
not	I-cell_type
T	I-cell_type
cells	I-cell_type
was	O
observed	O
when	O
either	O
an	O
artificial	O
construct	O
or	O
the	O
c-MYC	B-DNA
promoter	I-DNA
was	O
used	O
as	O
a	O
reporter	O
.	O

Furthermore	O
,	O
the	O
functional	B-protein
domains	I-protein
responsible	O
for	O
DNA	O
binding	O
,	O
transactivation	O
,	O
and	O
negative	O
regulation	O
,	O
previously	O
characterized	O
in	O
a	O
fibroblast	O
context	O
,	O
were	O
found	O
to	O
have	O
similar	O
activity	O
in	O
B	B-cell_type
cells	I-cell_type
.	O

The	O
region	O
of	O
A-MYB	B-protein
responsible	O
for	O
the	O
B	O
cell	O
specific	O
activity	O
was	O
defined	O
to	O
be	O
the	O
N-terminal	B-protein
218	I-protein
amino	I-protein
acids	I-protein
containing	O
the	O
DNA	B-protein
binding	I-protein
domain	I-protein
.	O

Finally	O
,	O
a	O
110-kDa	B-protein
protein	I-protein
has	O
been	O
identified	O
in	O
the	O
nuclei	O
of	O
all	O
the	O
B	B-cell_line
,	I-cell_line
but	I-cell_line
not	I-cell_line
T	I-cell_line
,	I-cell_line
cell	I-cell_line
lines	I-cell_line
that	O
specifically	O
binds	O
to	O
this	O
A-MYB	B-protein
N-terminal	I-protein
domain	I-protein
.	O

We	O
hypothesize	O
that	O
this	O
110-kDa	B-protein
protein	I-protein
may	O
be	O
a	O
functionally	O
important	O
B	B-protein
cell-specific	I-protein
co-activator	I-protein
of	O
A-MYB	B-protein
.	O

Transcription	O
factor	O
Egr-1	B-protein
activity	O
down-regulates	O
Fas	O
and	O
CD23	O
expression	O
in	O
B	B-cell_type
cells	I-cell_type
.	O

Activation	O
of	O
mature	O
B	B-cell_type
cells	I-cell_type
via	O
Ag	B-protein
receptor	I-protein
cross-linking	O
induces	O
transient	O
expression	O
of	O
the	O
transcription	B-protein
factor	I-protein
Egr-1	B-protein
.	O

Although	O
the	O
activating	O
signals	O
leading	O
to	O
Egr-1	B-protein
induction	O
have	O
been	O
studied	O
extensively	O
,	O
little	O
is	O
known	O
about	O
the	O
genes	O
that	O
are	O
placed	O
further	O
downstream	O
within	O
this	O
activation	O
cascade	O
and	O
that	O
are	O
transcriptionally	O
regulated	O
by	O
Egr-1	B-protein
.	O

To	O
identify	O
such	O
target	B-DNA
genes	I-DNA
,	O
we	O
established	O
Egr-1-overexpressing	B-cell_line
transfectants	I-cell_line
from	O
the	O
murine	B-cell_line
B	I-cell_line
cell	I-cell_line
line	I-cell_line
K46	I-cell_line
and	O
from	O
human	B-cell_line
Ramos	I-cell_line
B	I-cell_line
cells	I-cell_line
.	O

All	O
clones	O
derived	O
from	O
K46	B-cell_line
B	I-cell_line
cells	I-cell_line
showed	O
increased	O
expression	O
of	O
CD44	B-protein
.	O

Most	O
interestingly	O
,	O
expression	O
of	O
CD95	B-protein
(	O
Fas/Apo-1	B-protein
)	O
and	O
of	O
CD23	B-protein
was	O
down-regulated	O
in	O
all	O
K46	B-cell_line
transfectants	I-cell_line
.	O

As	O
a	O
consequence	O
,	O
they	O
became	O
resistant	O
to	O
apoptosis	O
induced	O
by	O
anti-CD95	B-protein
Ab	I-protein
treatment	O
.	O

Similarly	O
,	O
the	O
Egr-1-expressing	B-cell_line
Ramos	I-cell_line
cells	I-cell_line
showed	O
reduced	O
levels	O
of	O
CD95	B-protein
expression	O
.	O

Thus	O
,	O
Egr-1	B-protein
seems	O
to	O
control	O
the	O
expression	O
of	O
downstream	B-DNA
target	I-DNA
genes	I-DNA
not	O
only	O
as	O
a	O
transcriptional	O
activator	O
,	O
but	O
also	O
as	O
a	O
repressor	B-protein
molecule	I-protein
.	O

In	O
B	B-cell_type
cells	I-cell_type
,	O
Egr-1	B-protein
therefore	O
plays	O
a	O
critical	O
role	O
in	O
integrating	O
the	O
short-lived	O
signal	O
delivered	O
by	O
triggering	O
of	O
the	O
Ag	B-protein
receptor	I-protein
into	O
phenotypic	O
changes	O
,	O
including	O
repression	O
of	O
CD95	B-protein
and	O
CD23	B-protein
transcription	O
.	O

Regulation	O
of	O
NF-kappa	B-protein
B	I-protein
activity	O
by	O
I	O
kappa	O
B	O
alpha	O
and	O
I	O
kappa	O
B	O
beta	O
stability	O
.	O

Transcription	B-protein
factor	I-protein
NF-kappa	B-protein
B	I-protein
must	O
be	O
released	O
from	O
cytoplasmic	B-protein
inhibitory	I-protein
molecules	I-protein
(	O
I	B-protein
kappa	I-protein
Bs	I-protein
)	O
in	O
order	O
to	O
move	O
to	O
the	O
nucleus	O
and	O
to	O
activate	O
its	O
target	B-DNA
genes	I-DNA
.	O

Little	O
is	O
known	O
about	O
the	O
mechanisms	O
regulating	O
the	O
maintenance	O
of	O
constitutive	B-protein
nuclear	I-protein
NF-kappa	I-protein
B	I-protein
in	O
some	O
cell-types	O
and	O
of	O
sustained	O
nuclear	O
NF-kappa	B-protein
B	I-protein
activity	O
after	O
stimulation	O
.	O

Increased	O
turnover	O
has	O
been	O
implicated	O
in	O
the	O
regulation	O
of	O
constitutive	O
NF-kappa	B-protein
B	I-protein
activity	O
in	O
mature	B-cell_type
B	I-cell_type
cells	I-cell_type
.	O

We	O
therefore	O
compared	O
the	O
turnover	O
of	O
I	B-protein
kappa	I-protein
B	I-protein
alpha	I-protein
and	O
I	B-protein
kappa	I-protein
B	I-protein
beta	I-protein
in	O
mature	B-cell_type
B	I-cell_type
cells	I-cell_type
and	O
HeLa	B-cell_line
cells	I-cell_line
.	O

Both	O
proteins	O
display	O
a	O
high	O
turnover	O
in	O
B	B-cell_type
cells	I-cell_type
although	O
I	B-protein
kappa	I-protein
B	I-protein
beta	I-protein
is	O
considerably	O
more	O
stable	O
than	O
I	B-protein
kappa	I-protein
B	I-protein
alpha	I-protein
.	O

The	O
half-life	O
of	O
both	O
inhibitors	O
is	O
increased	O
in	O
HeLa	B-cell_line
cells	I-cell_line
.	O

In	O
contrast	O
,	O
all	O
other	O
NF-kappa	B-protein
B	I-protein
/I	O
kappa	O
B	O
molecules	O
tested	O
are	O
relatively	O
stable	O
in	O
both	O
cell-types	O
.	O

The	O
elevated	O
turnover	O
of	O
endogenous	O
I	B-protein
kappa	I-protein
B	I-protein
alpha	I-protein
in	O
Namalwa	B-cell_type
cells	I-cell_type
is	O
inhibited	O
by	O
a	O
proteasome	O
inhibitor	O
and	O
thus	O
seems	O
to	O
be	O
driven	O
by	O
the	O
same	O
degradation	O
machinery	O
as	O
the	O
slower	O
turnover	O
in	O
non-B	B-cell_type
cells	I-cell_type
.	O

Furthermore	O
,	O
we	O
investigated	O
the	O
processes	O
involved	O
in	O
persistent	O
activation	O
of	O
NF-kappa	B-protein
B	I-protein
.	O

TNF-alpha	O
signaling	O
leads	O
to	O
a	O
rapid	O
depletion	O
of	O
cellular	O
I	B-protein
kappa	I-protein
B	I-protein
beta	I-protein
pools	O
.	O

I	B-protein
kappa	I-protein
B	I-protein
alpha	I-protein
is	O
efficiently	O
resynthesized	O
whereas	O
I	B-protein
kappa	I-protein
B	I-protein
beta	I-protein
levels	O
stay	O
low	O
for	O
a	O
prolonged	O
time	O
.	O

NF-kappa	B-protein
B	I-protein
binding	O
activity	O
can	O
be	O
detected	O
for	O
several	O
hours	O
after	O
stimulation	O
.	O

We	O
found	O
that	O
removal	O
of	O
the	O
TNF-alpha	B-protein
containing	O
medium	O
causes	O
a	O
rapid	O
decrease	O
in	O
nuclear	B-protein
NF-kappa	I-protein
B	I-protein
.	O

A	O
phosphoform	O
of	O
newly	O
synthesized	O
I	B-protein
kappa	I-protein
B	I-protein
alpha	I-protein
is	O
visible	O
when	O
degradation	O
by	O
the	O
proteasome	B-protein
is	O
inhibited	O
and	O
new	O
I	B-protein
kappa	I-protein
B	I-protein
alpha	I-protein
displays	O
the	O
same	O
properties	O
regarding	O
phosphorylation	O
and	O
degradation	O
in	O
response	O
to	O
a	O
second	O
inducer	O
.	O

There	O
is	O
no	O
significant	O
difference	O
in	O
the	O
turnover	O
of	O
pre-	O
and	O
post-inductive	O
I	B-protein
kappa	I-protein
B	I-protein
alpha	I-protein
.	O

These	O
observations	O
suggest	O
that	O
resynthesis	O
of	O
I	B-protein
kappa	I-protein
B	I-protein
alpha	I-protein
and	O
removal	O
of	O
the	O
stimulus	O
are	O
obligatory	O
steps	O
for	O
the	O
inactivation	O
of	O
nuclear	B-protein
NF	I-protein
kappa	I-protein
B	I-protein
.	O

Selection	O
of	O
a	O
diverse	O
TCR	B-protein
repertoire	I-protein
in	O
response	O
to	O
an	O
Epstein-Barr	B-protein
virus-encoded	I-protein
transactivator	I-protein
protein	I-protein
BZLF1	B-protein
by	O
CD8+	B-cell_type
cytotoxic	I-cell_type
T	I-cell_type
lymphocytes	I-cell_type
during	O
primary	O
and	O
persistent	O
infection	O
.	O

We	O
investigated	O
the	O
CD8+	B-protein
cytotoxic	I-protein
T	I-protein
lymphocyte	I-protein
(	I-protein
CTL	I-protein
)	I-protein
repertoire	I-protein
to	O
an	O
HLA	O
B8-restricted	O
peptide	O
,	O
RAKFKQLLQ	O
,	O
located	O
in	O
the	O
Epstein-Barr	B-protein
virus	I-protein
(	I-protein
EBV	I-protein
)	I-protein
immediate-early	I-protein
protein	I-protein
,	O
BZLF1	B-protein
.	O

Repertoire	O
selection	O
was	O
monitored	O
by	O
determining	O
the	O
TCR	B-protein
beta	I-protein
chain	I-protein
sequences	I-protein
of	O
RAKFKQLLQ-specific	B-cell_line
CTL	I-cell_line
established	O
from	O
primary	O
infected	O
and	O
healthy	O
virus	O
carriers	O
.	O

PCR	O
analysis	O
of	O
spontaneous	B-cell_line
EBV-transformed	I-cell_line
lymphoblastoid	I-cell_line
cell	I-cell_line
lines	I-cell_line
(	O
LCL	B-cell_line
)	O
from	O
three	O
individuals	O
with	O
primary	O
infection	O
showed	O
that	O
two	O
were	O
infected	O
with	O
type	O
A	O
and	O
one	O
with	O
type	O
B	O
EBV	O
.	O

Polyclonal	B-cell_line
and	I-cell_line
clonal	I-cell_line
CTL	I-cell_line
that	O
were	O
generated	O
by	O
stimulating	O
peripheral	B-cell_type
blood	I-cell_type
mononuclear	I-cell_type
cells	I-cell_type
with	O
an	O
HLA	B-cell_line
B8+	I-cell_line
homozygous	I-cell_line
LCL	I-cell_line
lysed	I-cell_line
T	I-cell_line
cell	I-cell_line
blasts	I-cell_line
pulsed	O
with	O
the	O
peptide	O
,	O
RAKFKQLLQ	O
;	O
lysis	O
of	O
certain	O
HLA	O
B8+	O
LCL	O
targets	O
was	O
associated	O
with	O
the	O
abundance	O
of	O
BZLF1	B-RNA
transcripts	I-RNA
.	O

TCR	B-DNA
beta	I-DNA
analysis	O
showed	O
that	O
while	O
there	O
was	O
loop	O
length	O
restriction	O
in	O
the	O
putative	O
peptide	O
contact	O
site	O
of	O
all	O
responding	O
beta	B-protein
chains	I-protein
,	O
diverse	O
and	O
unique	B-cell_line
(	I-cell_line
non-recurrent	I-cell_line
)	I-cell_line
TCR	I-cell_line
beta	I-cell_line
clonotypes	I-cell_line
were	O
selected	O
in	O
individuals	O
during	O
primary	O
infection	O
and	O
continued	O
to	O
emerge	O
after	O
long-term	O
virus	O
exposure	O
.	O

TCR	B-protein
-contact	O
site	O
heterogeneity	O
was	O
excluded	O
as	O
the	O
selective	O
force	O
in	O
diversity	O
generation	O
since	O
the	O
epitope-encoded	O
sequences	O
were	O
found	O
to	O
be	O
identical	O
within	O
endogenous	O
virus	O
isolates	O
.	O

In	O
this	O
first	O
study	O
of	O
TCR	B-protein
repertoire	I-protein
selection	O
for	O
an	O
EBV	B-protein
lytic	I-protein
antigen	I-protein
,	O
a	O
BZLF1	B-protein
-reactive	O
component	O
of	O
diverse	O
clonotypes	O
was	O
identified	O
in	O
primary	O
type	O
A	O
or	O
type	O
B	O
EBV	O
infection	O
which	O
was	O
sustained	O
in	O
the	O
EBV-specific	O
memory	O
response	O
throughout	O
life-long	O
infection	O
.	O

This	O
diversity	O
selection	O
is	O
likely	O
to	O
play	O
a	O
critical	O
role	O
in	O
maintaining	O
a	O
balanced	O
viral	O
load	O
throughout	O
EBV	O
persistence	O
.	O

Molecular	O
mechanisms	O
of	O
anoxia/reoxygenation-induced	O
neutrophil	O
adherence	O
to	O
cultured	B-cell_line
endothelial	I-cell_line
cells	I-cell_line
.	O

The	O
objectives	O
of	O
this	O
study	O
were	O
to	O
(	O
1	O
)	O
determine	O
the	O
time	O
course	O
of	O
neutrophil	O
adhesion	O
to	O
monolayers	O
of	O
human	B-cell_line
umbilical	I-cell_line
vein	I-cell_line
endothelial	I-cell_line
cells	I-cell_line
(	O
HUVECs	B-cell_line
)	O
that	O
were	O
exposed	O
to	O
60	O
minutes	O
of	O
anoxia	O
followed	O
by	O
30	O
to	O
600	O
minutes	O
of	O
reoxygenation	O
and	O
(	O
2	O
)	O
define	O
the	O
mechanisms	O
responsible	O
for	O
both	O
the	O
early	O
(	O
minutes	O
)	O
and	O
late	O
(	O
hours	O
)	O
hyperadhesivity	O
of	O
postanoxic	B-cell_line
HUVECs	I-cell_line
to	O
human	B-cell_type
neutrophils	I-cell_type
.	O

The	O
results	O
clearly	O
demonstrate	O
that	O
anoxia/reoxygenation	O
(	O
A/R	O
)	O
leads	O
to	O
a	O
biphasic	O
increase	O
in	O
neutrophil	O
adhesion	O
to	O
HUVECs	B-cell_line
,	O
with	O
peak	O
responses	O
occurring	O
at	O
30	O
minutes	O
(	O
phase	O
1	O
)	O
and	O
240	O
minutes	O
(	O
phase	O
2	O
)	O
after	O
reoxygenation	O
.	O

Oxypurinol	O
and	O
catalase	B-protein
inhibited	O
phase-1	O
adhesion	O
,	O
suggesting	O
a	O
role	O
for	O
xanthine	B-protein
oxidase	I-protein
and	O
H2O2	O
.	O

In	O
comparison	O
,	O
platelet	B-protein
activating	I-protein
factor	I-protein
(	O
PAF	B-protein
)	O
contributed	O
to	O
both	O
phases	O
of	O
neutrophil	O
adhesion	O
.	O

Anti-intercellular	B-protein
adhesion	I-protein
molecule-1	I-protein
(	O
ICAM-1	B-protein
)	O
and	O
anti-P-selectin	B-protein
antibodies	I-protein
(	O
monoclonal	B-protein
antibodies	I-protein
[	O
mAbs	B-protein
]	O
)	O
attenuated	O
phase-1	O
neutrophil	O
adhesion	O
,	O
consistent	O
with	O
roles	O
for	O
constitutively	O
expressed	O
ICAM-1	B-protein
and	O
enhanced	O
surface	O
expression	O
of	O
preformed	O
P-selectin	B-protein
.	O

Phase-2	O
neutrophil	O
adhesion	O
was	O
attenuated	O
by	O
an	O
anti-E-selectin	B-protein
mAb	I-protein
,	O
indicating	O
a	O
dominant	O
role	O
of	O
this	O
adhesion	O
molecule	O
in	O
the	O
late	O
phase	O
response	O
.	O

Pretreatment	O
with	O
actinomycin	O
D	O
and	O
cycloheximide	O
or	O
with	O
competing	O
ds-oligonucleotides	O
containing	O
the	O
nuclear	B-protein
factor-kappa	I-protein
B	I-protein
or	O
activator	B-protein
protein-1	I-protein
cognate	B-DNA
DNA	I-DNA
sequences	I-DNA
significantly	O
attenuated	O
phase-2	O
response	O
,	O
suggesting	O
a	O
role	O
for	O
de	O
novo	O
macromolecule	O
synthesis	O
.	O

Surface	O
expression	O
of	O
ICAM-1	B-protein
,	O
P-selectin	B-protein
,	O
and	O
E-selectin	B-protein
on	O
HUVECs	B-cell_line
correlated	O
with	O
the	O
phase-1	O
and	O
-2	O
neutrophil	O
adhesion	O
responses	O
.	O

Collectively	O
,	O
these	O
findings	O
indicate	O
that	O
A/R	O
elicits	O
a	O
two-phase	O
neutrophil-endothelial	O
cell	O
adhesion	O
response	O
that	O
involves	O
transcription-independent	O
and	O
transcription-dependent	O
surface	O
expression	O
of	O
different	O
endothelial	B-protein
cell	I-protein
adhesion	I-protein
molecules	I-protein
.	O

Characterization	O
of	O
CD40	B-protein
signaling	O
determinants	O
regulating	O
nuclear	B-protein
factor-kappa	I-protein
B	I-protein
activation	O
in	O
B	B-cell_type
lymphocytes	I-cell_type
.	O

CD40	B-protein
signaling	O
to	O
B	B-cell_type
cells	I-cell_type
is	O
important	O
for	O
generating	O
an	O
effective	O
humoral	O
immune	O
response	O
.	O

CD40	B-protein
ligation	O
leads	O
to	O
B	O
cell	O
activation	O
events	O
such	O
as	O
proliferation	O
,	O
Ig	O
secretion	O
,	O
isotype	O
switching	O
,	O
and	O
up-regulation	O
of	O
cell	B-protein
surface	I-protein
molecules	I-protein
,	O
as	O
well	O
as	O
the	O
generation	O
of	O
memory	B-cell_type
B	I-cell_type
cells	I-cell_type
.	O

Many	O
of	O
these	O
events	O
are	O
dependent	O
upon	O
the	O
ability	O
of	O
CD40	B-protein
to	O
activate	O
the	O
transcription	O
factor	O
NF-kappa	B-protein
B	I-protein
(	O
NF-kappa	B-protein
B	I-protein
)	O
.	O

To	O
define	O
the	O
CD40	B-protein
signaling	O
components	O
upstream	O
of	O
NF-kappa	B-protein
B	I-protein
activation	O
and	O
the	O
functional	O
consequences	O
downstream	O
of	O
NF-kappa	B-protein
B	I-protein
activation	O
,	O
we	O
examined	O
mouse	B-cell_line
B	I-cell_line
cell	I-cell_line
transfectants	I-cell_line
expressing	O
wild-type	B-protein
or	I-protein
mutant	I-protein
human	I-protein
CD40	I-protein
.	O

Analysis	O
of	O
CD40	B-protein
cytoplasmic	I-protein
domain	I-protein
truncation	O
and	O
point	O
mutants	O
defined	O
a	O
10-amino	B-protein
acid	I-protein
CD40	I-protein
cytoplasmic	I-protein
signaling	I-protein
determinant	I-protein
required	O
for	O
NF-kappa	B-protein
B	I-protein
activation	O
.	O

A	O
threonine	O
residue	O
at	O
position	B-protein
234	I-protein
,	O
previously	O
shown	O
to	O
be	O
important	O
for	O
CD40	B-protein
association	O
with	O
TNF	B-protein
receptor-associated	I-protein
factor	I-protein
2	I-protein
(	O
TRAF2	B-protein
)	O
,	O
TRAF3	B-protein
,	O
and	O
TRAF5	B-protein
,	O
was	O
not	O
required	O
for	O
NF-kappa	B-protein
B	I-protein
activation	O
.	O

This	O
suggests	O
that	O
in	O
B	B-cell_type
cells	I-cell_type
,	O
CD40	B-protein
-induced	O
NF-kappa	B-protein
B	I-protein
activation	O
can	O
occur	O
independently	O
of	O
TRAF2	B-protein
and	O
TRAF5	B-protein
association	O
.	O

NF-kappa	B-protein
B	I-protein
activation	O
was	O
independent	O
of	O
the	O
transmembrane	B-protein
domain	I-protein
of	O
CD40	B-protein
,	O
suggesting	O
that	O
it	O
is	O
independent	O
of	O
p23	B-protein
,	O
a	O
molecule	O
that	O
associates	O
with	O
CD40	B-protein
in	O
a	O
region	O
other	O
than	O
the	O
cytoplasmic	B-protein
domain	I-protein
.	O

Proteasome-dependent	O
inhibitory	O
kappa	O
B	O
alpha	O
(	O
I	B-protein
kappa	I-protein
B	I-protein
alpha	I-protein
)	O
and	O
I	B-protein
kappa	I-protein
B	I-protein
beta	I-protein
degradation	O
occurred	O
downstream	O
of	O
CD40	B-protein
ligation	O
and	O
preceded	O
CD40	B-protein
-mediated	O
NF-kappa	B-protein
B	I-protein
nuclear	O
translocation	O
.	O

CD40-	O
or	O
pervanadate-mediated	O
I	O
kappa	O
B	O
tyrosine	O
phosphorylation	O
was	O
not	O
detected	O
.	O

NF-kappa	B-protein
B	I-protein
activation	O
correlated	O
with	O
the	O
ability	O
of	O
CD40	B-protein
to	O
induce	O
Ab	O
secretion	O
and	O
the	O
up-regulation	O
of	O
ICAM-1	B-protein
and	O
LFA-1	B-protein
.	O

However	O
,	O
NF-kappa	B-protein
B	I-protein
activation	O
was	O
insufficient	O
for	O
CD40	B-protein
-mediated	O
up-regulation	O
of	O
B7-1	B-protein
,	O
Fas	B-protein
,	O
and	O
CD23	B-protein
.	O

CD30	B-protein
-dependent	O
degradation	O
of	O
TRAF2	B-protein
:	O
implications	O
for	O
negative	O
regulation	O
of	O
TRAF	B-protein
signaling	O
and	O
the	O
control	O
of	O
cell	O
survival	O
.	O

CD30	B-protein
is	O
a	O
cell-surface	B-protein
receptor	I-protein
that	O
can	O
augment	O
lymphocyte	O
activation	O
and	O
survival	O
through	O
its	O
ability	O
to	O
induce	O
the	O
transcription	B-protein
factor	I-protein
NF-kappaB	B-protein
.	O

CD30	B-protein
,	O
however	O
,	O
has	O
also	O
been	O
implicated	O
in	O
the	O
induction	O
of	O
apoptotic	O
cell	O
death	O
of	O
lymphocytes	B-cell_type
.	O

Here	O
we	O
show	O
that	O
one	O
of	O
the	O
effects	O
of	O
CD30	B-protein
signal	O
transduction	O
is	O
to	O
render	O
cells	O
sensitive	O
to	O
apoptosis	O
induced	O
by	O
the	O
type	B-protein
1	I-protein
tumor	I-protein
necrosis	I-protein
factor	I-protein
receptor	I-protein
(	O
TNFR1	B-protein
)	O
.	O

This	O
sensitization	O
is	O
dependent	O
on	O
the	O
TRAF-binding	B-protein
sites	I-protein
within	O
the	O
CD30	B-protein
cytoplasmic	B-protein
domain	I-protein
.	O

One	O
of	O
the	O
proteins	O
that	O
binds	O
to	O
these	O
sites	O
is	O
TRAF2	B-protein
,	O
a	O
signal	B-protein
transduction	I-protein
molecule	I-protein
that	O
is	O
also	O
utilized	O
by	O
TNFR1	B-protein
to	O
mediate	O
the	O
activation	O
of	O
several	O
downstream	O
kinases	B-protein
and	O
transcription	B-protein
factors	I-protein
.	O

During	O
CD30	B-protein
signal	O
transduction	O
,	O
we	O
found	O
that	O
binding	O
of	O
TRAF2	B-protein
to	O
the	O
cytoplasmic	B-protein
domain	I-protein
of	O
CD30	B-protein
results	O
in	O
the	O
rapid	O
depletion	O
of	O
TRAF2	B-protein
and	O
the	O
associated	O
protein	O
TRAF1	B-protein
by	O
proteolysis	O
.	O

These	O
data	O
suggest	O
a	O
model	O
in	O
which	O
CD30	B-protein
limits	O
its	O
own	O
ability	O
to	O
transduce	O
cell	O
survival	O
signals	O
through	O
signal-coupled	O
depletion	O
of	O
TRAF2	B-protein
.	O

Depletion	O
of	O
intracellular	O
TRAF2	B-protein
and	O
its	O
coassociated	B-protein
proteins	I-protein
also	O
increased	O
the	O
sensitivity	O
of	O
the	O
cell	O
to	O
undergoing	O
apoptosis	O
during	O
activation	O
of	O
death-inducing	B-protein
receptors	I-protein
such	O
as	O
TNFR1	B-protein
.	O

Consistent	O
with	O
this	O
hypothesis	O
,	O
expression	O
of	O
a	O
dominant-negative	B-protein
form	I-protein
of	O
TRAF2	B-protein
was	O
found	O
to	O
potentiate	O
TNFR1	B-protein
-mediated	O
death	O
.	O

These	O
studies	O
provide	O
a	O
potential	O
mechanism	O
through	O
which	O
CD30	B-protein
,	O
as	O
well	O
as	O
other	O
TRAF-binding	B-protein
members	I-protein
of	O
the	O
TNFR	B-protein
superfamily	I-protein
,	O
can	O
negatively	O
regulate	O
cell	O
survival	O
.	O

Analysis	O
of	O
myeloid-associated	B-DNA
genes	I-DNA
in	O
human	B-cell_type
hematopoietic	I-cell_type
progenitor	I-cell_type
cells	I-cell_type
.	O

The	O
distribution	O
of	O
myeloid	B-protein
lineage-associated	I-protein
cytokine	I-protein
receptors	I-protein
and	O
lysosomal	B-protein
proteins	I-protein
was	O
analyzed	O
in	O
human	B-cell_line
CD34+	I-cell_line
cord	I-cell_line
blood	I-cell_line
cell	I-cell_line
(	I-cell_line
CB	I-cell_line
)	I-cell_line
subsets	I-cell_line
at	O
different	O
stages	O
of	O
myeloid	O
commitment	O
by	O
reverse-transcriptase	O
polymerase	O
chain	O
reaction	O
(	O
RT-PCR	O
)	O
.	O

The	O
highly	O
specific	O
granulomonocyte-associated	B-protein
lysosomal	I-protein
proteins	I-protein
myeloperoxidase	B-protein
(	O
MPO	B-protein
)	O
and	O
lysozyme	B-protein
(	O
LZ	B-protein
)	O
,	O
as	O
well	O
as	O
the	O
transcription	B-protein
factor	I-protein
PU.1	B-protein
,	O
were	O
already	O
detectable	O
in	O
the	O
most	O
immature	O
CD34+Thy-1+	B-cell_line
subset	I-cell_line
.	O

Messenger	B-RNA
RNA	I-RNA
(	O
mRNA	B-RNA
)	O
levels	O
for	O
the	O
granulocyte-colony	B-protein
stimulating	I-protein
factor	I-protein
(	I-protein
G-CSF	I-protein
)	I-protein
receptor	I-protein
,	O
granulocyte-macrophage	B-protein
(	I-protein
GM	I-protein
)	I-protein
-CSF	I-protein
receptor	I-protein
alpha	I-protein
subunit	I-protein
and	O
tumor	B-protein
necrosis	I-protein
factor	I-protein
(	I-protein
TNF	I-protein
)	I-protein
receptors	I-protein
I	I-protein
(	I-protein
p55	I-protein
)	I-protein
and	I-protein
II	I-protein
(	I-protein
p75	I-protein
)	I-protein
were	O
also	O
detected	O
in	O
this	O
subset	O
in	O
addition	O
to	O
c-kit	B-protein
and	O
flt-3	B-protein
,	O
receptors	O
known	O
to	O
be	O
expressed	O
on	O
progenitor	B-cell_type
cells	I-cell_type
.	O

By	O
contrast	O
,	O
the	O
monocyte-macrophage	B-protein
colony	I-protein
stimulating	I-protein
factor	I-protein
(	I-protein
M-CSF	I-protein
)	I-protein
receptor	I-protein
was	O
largely	O
absent	O
at	O
this	O
stage	O
and	O
in	O
the	O
CD34+Thy-1-CD45RA-	B-cell_line
subsets	I-cell_line
.	O

The	O
M-CSF	B-protein
receptor	I-protein
was	O
first	O
detectable	O
in	O
the	O
myeloid-committed	B-cell_line
CD34+Thy-l-CD45RA+	I-cell_line
subset	I-cell_line
.	O

All	O
other	O
molecules	O
studied	O
were	O
found	O
to	O
be	O
expressed	O
at	O
this	O
stage	O
of	O
differentiation	O
.	O

Different	O
cocktails	O
of	O
the	O
identified	O
ligands	O
were	O
added	O
to	O
sorted	B-cell_line
CD34+Thy-1+	I-cell_line
single	I-cell_line
cells	I-cell_line
.	O

Low	O
proliferative	O
capacity	O
was	O
observed	O
after	O
1	O
week	O
in	O
culture	O
in	O
the	O
presence	O
of	O
stem	B-protein
cell	I-protein
factor	I-protein
(	O
SCF	B-protein
)	O
+	O
Flt-3	B-protein
ligand	I-protein
(	O
FL	B-protein
)	O
+	O
G-CSF	B-protein
.	O

Addition	O
of	O
GM-CSF	B-protein
to	O
this	O
basic	O
cocktail	O
consistently	O
increased	O
the	O
clonogenic	O
capacity	O
of	O
single	B-cell_line
CD34+Thy-1+	I-cell_line
cells	I-cell_line
,	O
and	O
this	O
effect	O
was	O
further	O
enhanced	O
(	O
up	O
to	O
72.3	O
+/-	O
4.3	O
%	O
on	O
day	O
7	O
)	O
by	O
the	O
inclusion	O
of	O
TNF-alpha	B-protein
.	O

In	O
conclusion	O
,	O
the	O
presence	O
of	O
myeloid-associated	B-RNA
growth	I-RNA
factor	I-RNA
receptor	I-RNA
transcripts	I-RNA
in	O
CD34+	B-cell_line
CB	I-cell_line
subsets	I-cell_line
does	O
not	O
discriminate	O
the	O
various	O
stages	O
of	O
differentiation	O
,	O
with	O
the	O
exception	O
of	O
the	O
M-CSF	B-protein
receptor	I-protein
.	O

In	O
addition	O
,	O
we	O
show	O
that	O
TNF-alpha	B-protein
is	O
a	O
potent	O
costimulatory	O
factor	O
of	O
the	O
very	O
immature	B-cell_line
CD34+Thy-1+	I-cell_line
CB	I-cell_line
subset	I-cell_line
.	O

Induction	O
of	O
endothelial	B-protein
cell	I-protein
surface	I-protein
adhesion	I-protein
molecules	I-protein
by	O
tumor	B-protein
necrosis	I-protein
factor	I-protein
is	O
blocked	O
by	O
protein	O
tyrosine	O
phosphatase	O
inhibitors	O
:	O
role	O
of	O
the	O
nuclear	B-protein
transcription	I-protein
factor	I-protein
NF-kappa	I-protein
B	I-protein
.	O

Recent	O
studies	O
from	O
our	O
laboratory	O
have	O
indicated	O
that	O
protein	B-protein
tyrosine	I-protein
phosphatase	I-protein
(	O
PTPase	B-protein
)	O
inhibitors	O
can	O
down-modulate	O
the	O
tumor	B-protein
necrosis	I-protein
factor	I-protein
(	O
TNF	B-protein
)	O
-mediated	O
activation	O
of	O
the	O
nuclear	B-protein
transcription	I-protein
factor	I-protein
NF-kappa	I-protein
B	I-protein
in	O
ML-1a	B-cell_line
,	O
a	O
monocytic	B-cell_line
cell	I-cell_line
line	I-cell_line
(	O
Singh	O
and	O
Aggarwal	O
,	O
J.	O
Biol.	O
Chem.	O
1995	O
:	O
270	O
:	O
10631	O
)	O
.	O

Since	O
TNF	B-protein
is	O
one	O
of	O
the	O
major	O
inducers	O
of	O
various	O
adhesion	B-protein
molecules	I-protein
in	O
human	O
endothelial	O
cells	O
and	O
their	O
expression	O
is	O
known	O
to	O
require	O
the	O
activation	O
of	O
NF-kappa	B-protein
B	I-protein
,	O
we	O
examined	O
the	O
effect	O
of	O
PTPase	B-protein
inhibitors	O
on	O
the	O
TNF	B-protein
-mediated	O
induction	O
of	O
intracellular	B-protein
adhesion	I-protein
molecule	I-protein
(	I-protein
ICAM	I-protein
)	I-protein
-1	I-protein
,	O
vascular	B-protein
cell	I-protein
adhesion	I-protein
molecule	I-protein
(	I-protein
VCAM	I-protein
)	I-protein
-1	I-protein
and	O
endothelial	B-protein
leukocyte	I-protein
adhesion	I-protein
molecule	I-protein
(	I-protein
ELAM	I-protein
)	I-protein
-1	I-protein
.	O

Like	O
ML-1a	B-cell_line
,	O
human	B-cell_line
dermal	I-cell_line
microvessel	I-cell_line
endothelial	I-cell_line
cells	I-cell_line
(	O
MVEC	B-cell_line
)	O
treated	O
with	O
TNF	B-protein
rapidly	O
activated	O
(	O
within	O
30	O
min	O
)	O
NF-kappa	B-protein
B	I-protein
;	O
this	O
effect	O
was	O
completely	O
abolished	O
by	O
co-treatment	O
with	O
phenylarsine	O
oxide	O
(	O
PAO	O
)	O
,	O
a	O
specific	O
inhibitor	O
of	O
PTPase	B-protein
.	O

The	O
induction	O
of	O
ICAM-1	B-protein
,	O
VCAM-1	B-protein
,	O
and	O
ELAM-1	B-protein
by	O
TNF	B-protein
in	O
MVEC	B-cell_line
occurred	O
within	O
6	O
h	O
and	O
was	O
also	O
completely	O
down-regulated	O
by	O
PAO	O
in	O
a	O
dose-dependent	O
manner	O
.	O

PAO	O
was	O
found	O
to	O
be	O
effective	O
even	O
when	O
added	O
3	O
h	O
after	O
TNF	B-protein
,	O
suggesting	O
a	O
rapid	O
mode	O
of	O
action	O
of	O
this	O
inhibitor	O
.	O

Besides	O
PAO	O
,	O
other	O
inhibitors	O
of	O
PTPase	B-protein
,	O
including	O
pervanadate	O
and	O
diamide	O
,	O
also	O
blocked	O
TNF	B-protein
-dependent	O
NF-kappa	B-protein
B	I-protein
activation	O
and	O
induction	O
of	O
all	O
the	O
three	O
adhesion	B-protein
proteins	I-protein
.	O

Consistent	O
with	O
these	O
results	O
,	O
the	O
attachment	O
of	O
monocytes	O
to	O
MVEC	B-cell_line
was	O
also	O
blocked	O
by	O
the	O
PTPase	B-protein
inhibitors	O
.	O

Thus	O
,	O
overall	O
,	O
our	O
results	O
demonstrate	O
that	O
a	O
PTPase	B-protein
is	O
involved	O
either	O
directly	O
or	O
indirectly	O
in	O
the	O
pathway	O
leading	O
to	O
the	O
induction	O
of	O
endothelial	B-protein
cell	I-protein
adhesion	I-protein
molecules	I-protein
by	O
TNF	B-protein
.	O

Because	O
of	O
their	O
role	O
in	O
cell	O
adhesion	O
,	O
PTPase	B-protein
may	O
provide	O
a	O
novel	O
target	O
of	O
drug	O
development	O
for	O
treatment	O
of	O
inflammation	O
,	O
atherogenesis	O
,	O
and	O
tumor	O
metastasis	O
.	O

Regulation	O
of	O
nuclear	B-protein
factor-kappa	I-protein
B	I-protein
and	O
its	O
inhibitor	O
I	B-protein
kappa	I-protein
B-alpha/MAD-3	I-protein
in	O
monocytes	B-cell_type
by	O
Mycobacterium	O
tuberculosis	O
and	O
during	O
human	O
tuberculosis	O
.	O

Blood	B-cell_type
monocytes	I-cell_type
from	O
patients	O
with	O
active	O
tuberculosis	O
are	O
activated	O
in	O
vivo	O
,	O
as	O
evidenced	O
by	O
an	O
increase	O
in	O
the	O
stimulated	O
release	O
of	O
proinflammatory	B-protein
cytokines	I-protein
,	O
such	O
as	O
TNF-alpha	B-protein
,	O
and	O
the	O
spontaneous	O
expression	O
of	O
IL-2R	B-protein
.	O

Further	O
,	O
monocytes	B-cell_type
from	O
patients	O
demonstrate	O
an	O
augmented	O
susceptibility	O
to	O
a	O
productive	O
infection	O
with	O
HIV-1	O
in	O
vitro	O
.	O

Mycobacterium	O
tuberculosis	O
and	O
its	O
components	O
are	O
strong	O
signals	O
to	O
activate	O
monocytes	B-cell_type
to	O
production	O
of	O
cytokines	B-protein
.	O

In	O
this	O
study	O
we	O
examined	O
the	O
basis	O
of	O
activation	O
of	O
monocytes	B-cell_type
during	O
active	O
tuberculosis	O
and	O
by	O
M.	O
tuberculosis	O
.	O

We	O
found	O
a	O
constitutive	O
degradation	O
of	O
I	B-protein
kappa	I-protein
B-alpha	I-protein
,	O
the	O
major	O
cytoplasmic	B-protein
inhibitor	I-protein
of	O
nuclear	B-protein
factor	I-protein
kappa	I-protein
B	I-protein
(	O
NF-kappa	B-protein
B	I-protein
)	O
,	O
in	O
freshly	O
isolated	O
PBMC	B-cell_type
and	O
monocytes	B-cell_type
from	O
patients	O
with	O
tuberculosis	O
.	O

In	O
contrast	O
,	O
I	B-protein
kappa	I-protein
B-alpha	I-protein
levels	O
in	O
PBMC	B-cell_type
and	O
monocytes	B-cell_type
from	O
healthy	O
subjects	O
or	O
from	O
patients	O
with	O
nontuberculous	O
pulmonary	O
conditions	O
were	O
intact	O
.	O

Further	O
,	O
by	O
electrophoretic	O
mobility	O
shift	O
assay	O
,	O
NF-kappa	B-protein
B	I-protein
was	O
activated	O
in	O
monocytes	B-cell_type
from	O
tuberculous	O
patients	O
.	O

The	O
expression	O
of	O
I	B-protein
kappa	I-protein
B-alpha	I-protein
gene	O
,	O
which	O
is	O
responsive	O
to	O
activation	O
by	O
NF-kappa	B-protein
B	I-protein
,	O
was	O
up-regulated	O
in	O
PBMC	B-cell_type
and	O
monocytes	B-cell_type
from	O
patients	O
,	O
but	O
not	O
in	O
mononuclear	B-cell_type
cells	I-cell_type
from	O
healthy	O
subjects	O
or	O
those	O
with	O
nontuberculous	O
lung	O
diseases	O
.	O

By	O
contrast	O
,	O
the	O
expression	O
of	O
other	O
adherence-associated	B-DNA
early	I-DNA
genes	I-DNA
,	O
such	O
as	O
IL-8	B-protein
and	O
IL-1	B-protein
beta	I-protein
,	O
was	O
not	O
up-regulated	O
in	O
PBMC	B-cell_type
of	O
tuberculous	O
patients	O
.	O

Further	O
,	O
M.	O
tuberculosis	O
and	O
its	O
tuberculin	B-protein
,	O
purified	B-protein
protein	I-protein
derivative	I-protein
,	O
induced	O
the	O
degradation	O
of	O
I	B-protein
kappa	I-protein
B-alpha	I-protein
and	O
the	O
expression	O
of	O
I	B-RNA
kappa	I-RNA
B-alpha	I-RNA
mRNA	I-RNA
,	O
and	O
purified	O
protein	O
derivative	O
induced	O
the	O
activation	O
of	O
NF-kappa	B-protein
B	I-protein
in	O
monocytes	B-cell_type
.	O

Cooperation	O
of	O
Spi-1/PU.1	B-protein
with	O
an	O
activated	B-protein
erythropoietin	I-protein
receptor	I-protein
inhibits	O
apoptosis	O
and	O
Epo	B-protein
-dependent	O
differentiation	O
in	O
primary	B-cell_type
erythroblasts	I-cell_type
and	O
induces	O
their	O
Kit	O
ligand-dependent	O
proliferation	O
.	O

Spi-1/PU.1	B-protein
is	O
a	O
myeloid-	B-protein
and	I-protein
B-cell	I-protein
specific	I-protein
transcription	I-protein
factor	I-protein
which	O
is	O
also	O
involved	O
in	O
Friend	O
virus-induced	O
murine	O
erythroleukemia	O
.	O

The	O
pre-leukemic	O
phase	O
of	O
Friend	O
erythroleukemia	O
results	O
from	O
activation	O
of	O
the	O
erythropoietin	B-protein
receptor	I-protein
(	O
EpoR	B-protein
)	O
by	O
the	O
spleen	B-protein
focus	I-protein
forming	I-protein
virus	I-protein
(	I-protein
SFFV	I-protein
)	I-protein
envelope	I-protein
glycoprotein	I-protein
,	O
followed	O
by	O
the	O
emergence	O
of	O
leukemic	O
clones	O
characterized	O
by	O
overexpression	O
of	O
Spi-1	B-protein
and	O
mutation	O
of	O
the	O
p53	B-DNA
tumor	I-DNA
suppressor	I-DNA
gene	I-DNA
.	O

We	O
developed	O
a	O
heterologous	O
system	O
to	O
analyze	O
the	O
contribution	O
of	O
these	O
alterations	O
to	O
the	O
induction	O
of	O
primary	O
erythroblast	O
transformation	O
.	O

Avian	B-cell_type
erythroblasts	I-cell_type
expressing	O
the	O
activated	B-protein
mouse	I-protein
EpoR	I-protein
(	I-protein
R129C	I-protein
)	I-protein
differentiated	O
into	O
erythrocytes	B-cell_type
in	O
response	O
to	O
hEpo	B-protein
.	O

Expression	O
of	O
Spi-1	B-protein
in	O
these	O
cells	O
inhibited	O
this	O
ability	O
to	O
differentiate	O
and	O
rescued	O
the	O
cells	O
from	O
the	O
apoptotic	O
cell	O
death	O
program	O
normally	O
induced	O
upon	O
hEpo	B-protein
withdrawal	O
.	O

Although	O
devoid	O
of	O
any	O
effect	O
by	O
itself	O
,	O
a	O
mutant	B-protein
p53	I-protein
cooperated	O
with	O
Spi-1	B-protein
and	O
EpoR	B-protein
(	I-protein
R129C	I-protein
)	I-protein
to	O
reinforce	O
both	O
phenotypes	O
.	O

Analysis	O
of	O
erythroblasts	O
co-expressing	O
Spi-1	B-protein
and	O
the	O
wild-type	B-protein
mouse	I-protein
EpoR	I-protein
showed	O
that	O
differentiation	O
arrest	O
and	O
inhibition	O
of	O
apoptosis	O
depended	O
on	O
specific	O
cooperation	O
between	O
Spi-1	B-protein
and	O
EpoR	B-protein
(	I-protein
R129C	I-protein
)	I-protein
.	O

This	O
cooperation	O
was	O
also	O
required	O
to	O
induce	O
the	O
sustained	O
proliferation	O
of	O
differentiation-blocked	B-cell_line
erythroblasts	I-cell_line
in	O
response	O
to	O
ligand	O
activation	O
of	O
the	O
endogenous	B-protein
tyrosine	I-protein
kinase	I-protein
receptor	I-protein
c-Kit	B-protein
.	O

These	O
results	O
show	O
that	O
Spi-1/	O
PU.1	B-protein
requires	O
signals	O
emanating	O
from	O
specific	O
cytokine	O
and	O
growth	O
factor	O
receptors	O
to	O
affect	O
the	O
survival	O
,	O
proliferation	O
and	O
differentiation	O
control	O
of	O
primary	B-cell_type
erythroblasts	I-cell_type
.	O

They	O
also	O
suggest	O
that	O
the	O
function	O
of	O
Spi-1/PU.1	B-protein
in	O
the	O
late	O
phase	O
of	O
Friend	O
leukemia	O
requires	O
specific	O
signaling	O
from	O
the	O
gp55-modified	B-protein
EpoR	I-protein
generated	O
during	O
the	O
early	O
phase	O
of	O
the	O
disease	O
.	O

The	O
role	O
of	O
Rel/NF-kappa	B-protein
B	I-protein
proteins	I-protein
in	O
viral	O
oncogenesis	O
and	O
the	O
regulation	O
of	O
viral	O
transcription	O
.	O

Rel/NF-kappa	B-protein
B	I-protein
is	O
a	O
ubiquitous	B-protein
transcription	I-protein
factor	I-protein
that	O
consists	O
of	O
multiple	B-protein
polypeptide	I-protein
subunits	I-protein
,	O
and	O
is	O
subject	O
to	O
complex	O
regulatory	O
mechanisms	O
that	O
involve	O
protein-protein	O
interactions	O
,	O
phosphorylation	O
,	O
ubiquitination	O
,	O
proteolytic	O
degradation	O
,	O
and	O
nucleocytoplasmic	O
translocation	O
.	O

The	O
sophisticated	O
control	O
of	O
Rel/NF-kappa	B-protein
B	I-protein
activity	O
is	O
not	O
surprising	O
since	O
this	O
transcription	B-protein
factor	I-protein
is	O
involved	O
in	O
a	O
wide	O
array	O
of	O
cellular	O
responses	O
to	O
extracellular	O
cues	O
,	O
associated	O
with	O
growth	O
,	O
development	O
,	O
apoptosis	O
,	O
and	O
pathogen	O
invasion	O
.	O

Thus	O
,	O
it	O
is	O
not	O
unexpected	O
that	O
this	O
versatile	O
cellular	O
homeostatic	O
switch	O
would	O
be	O
affected	O
by	O
a	O
variety	O
of	O
viral	O
pathogens	O
,	O
which	O
have	O
evolved	O
mechanisms	O
to	O
utilize	O
various	O
aspects	O
of	O
Rel/NF-kappa	B-protein
B	I-protein
activity	O
to	O
facilitate	O
their	O
replication	O
,	O
cell	O
survival	O
and	O
possibly	O
evasion	O
of	O
immune	O
responses	O
.	O

This	O
review	O
will	O
cover	O
the	O
molecular	O
mechanisms	O
that	O
are	O
utilized	O
by	O
mammalian	O
oncogenic	O
viruses	O
to	O
affect	O
the	O
activity	O
of	O
Rel/NF-kappa	B-protein
B	I-protein
transcription	B-protein
factors	I-protein
and	O
the	O
role	O
of	O
Rel/NF-kappa	B-protein
B	I-protein
in	O
the	O
regulation	O
of	O
viral	O
gene	O
expression	O
and	O
replication	O
.	O

Cellular	O
and	O
molecular	O
mechanisms	O
of	O
IL-5	B-protein
synthesis	O
in	O
atopic	O
diseases	O
:	O
a	O
study	O
with	O
allergen-specific	B-cell_line
human	I-cell_line
helper	I-cell_line
T	I-cell_line
cells	I-cell_line
.	O

BACKGROUND	O
:	O
Cytokines	B-protein
produced	O
by	O
helper	B-cell_type
T	I-cell_type
cells	I-cell_type
are	O
intimately	O
involved	O
in	O
chronic	O
allergic	O
diseases	O
associated	O
with	O
eosinophilic	O
inflammation	O
.	O

OBJECTIVE	O
:	O
We	O
investigated	O
the	O
production	O
of	O
IL-5	B-protein
,	O
a	O
potent	O
growth	O
factor	O
and	O
chemotactic	O
factor	O
for	O
eosinophils	B-cell_type
,	O
by	O
CD4+	B-cell_type
T	I-cell_type
lymphocytes	I-cell_type
in	O
patients	O
with	O
asthma	O
.	O

METHODS	O
:	O
Allergen-specific	B-cell_line
T	I-cell_line
cell	I-cell_line
clones	I-cell_line
and	O
T	B-cell_line
cell	I-cell_line
hybridomas	I-cell_line
were	O
established	O
from	O
the	O
peripheral	B-cell_type
blood	I-cell_type
lymphocytes	I-cell_type
of	O
patients	O
with	O
asthma	O
,	O
and	O
the	O
responses	O
to	O
various	O
stimuli	O
were	O
determined	O
.	O

RESULTS	O
:	O
After	O
nonspecific	O
stimulation	O
,	O
IL-5	B-protein
production	O
by	O
CD4+	B-cell_type
T	I-cell_type
cells	I-cell_type
from	O
both	O
atopic	O
and	O
nonatopic	O
subjects	O
with	O
asthma	O
was	O
significantly	O
enhanced	O
compared	O
with	O
that	O
by	O
cells	O
from	O
healthy	O
controls	O
.	O

Peripheral	B-cell_type
blood	I-cell_type
mononuclear	I-cell_type
cells	I-cell_type
from	O
atopic	O
asthma	O
patients	O
both	O
proliferated	O
and	O
produced	O
IL-5	B-protein
after	O
incubation	O
with	O
mite	O
allergen	O
,	O
suggesting	O
that	O
mite-specific	B-cell_type
helper	I-cell_type
T	I-cell_type
cells	I-cell_type
were	O
involved	O
in	O
the	O
eosinophilic	O
inflammation	O
of	O
atopic	O
asthma	O
.	O

A	O
human	O
IL-5	B-DNA
promoter/enhancer	I-DNA
luciferase	I-DNA
gene	I-DNA
construct	I-DNA
transfected	O
into	O
IL-5-producing	B-cell_line
T	I-cell_line
cell	I-cell_line
clones	I-cell_line
was	O
clearly	O
transcribed	O
after	O
stimulation	O
,	O
indicating	O
that	O
the	O
515	O
base	O
pair	O
IL-5	B-DNA
gene	I-DNA
segment	I-DNA
upstream	O
of	O
the	O
coding	O
region	O
was	O
sufficient	O
to	O
respond	O
to	O
activating	O
signals	O
in	O
human	O
helper	B-cell_type
T	I-cell_type
cells	I-cell_type
.	O

The	O
same	O
gene	O
segment	O
was	O
not	O
transcribed	O
in	O
IL-5-nonproducing	B-cell_line
T	I-cell_line
cell	I-cell_line
clones	I-cell_line
,	O
suggesting	O
that	O
human	O
T	O
cell	O
IL-5	B-protein
synthesis	O
is	O
regulated	O
at	O
the	O
transcriptional	O
level	O
.	O

Experiments	O
with	O
T	B-cell_line
cell	I-cell_line
hybridomas	I-cell_line
confirmed	O
these	O
findings	O
and	O
suggested	O
that	O
a	O
unique	B-protein
transcription	I-protein
factor	I-protein
may	O
be	O
essential	O
for	O
human	O
IL-5	B-protein
gene	O
transcription	O
.	O

CONCLUSION	O
:	O
Enhanced	O
IL-5	B-protein
production	O
by	O
helper	B-cell_type
T	I-cell_type
cells	I-cell_type
seems	O
to	O
cause	O
the	O
eosinophilic	O
inflammation	O
of	O
both	O
atopic	O
and	O
nonatopic	O
asthma	O
.	O

Elucidation	O
of	O
IL-5	B-protein
-specific	O
regulatory	O
mechanisms	O
may	O
facilitate	O
the	O
development	O
of	O
novel	O
treatments	O
for	O
allergic	O
diseases	O
associated	O
with	O
eosinophilic	O
inflammation	O
.	O

Cyclosporin	O
A	O
inhibits	O
monocyte	O
tissue	B-protein
factor	I-protein
activation	O
in	O
cardiac	O
transplant	O
recipients	O
.	O

BACKGROUND	O
:	O
Fibrin	O
deposition	O
and	O
thrombosis	O
have	O
been	O
implicated	O
in	O
both	O
allograft	O
rejection	O
and	O
vasculopathy	O
after	O
cardiac	O
transplantation	O
.	O

Because	O
monocytes	B-cell_type
play	O
a	O
pivotal	O
role	O
in	O
the	O
pathophysiology	O
of	O
intravascular	O
coagulation	O
activation	O
through	O
their	O
ability	O
to	O
synthesize	O
tissue	B-protein
factor	I-protein
(	O
TF	B-protein
)	O
,	O
we	O
asked	O
(	O
1	O
)	O
whether	O
monocyte	O
TF	B-protein
activation	O
occurs	O
in	O
cardiac	O
transplant	O
recipients	O
and	O
(	O
2	O
)	O
whether	O
monocyte	O
TF	B-protein
expression	O
is	O
affected	O
by	O
treatment	O
with	O
cyclosporin	O
A	O
(	O
CsA	O
)	O
.	O

METHODS	O
AND	O
RESULTS	O
:	O
We	O
measured	O
levels	O
of	O
TF	B-protein
activity	O
in	O
peripheral	B-cell_type
blood	I-cell_type
mononuclear	I-cell_type
cells	I-cell_type
and	O
highly	B-cell_type
purified	I-cell_type
monocytes/macrophages	I-cell_type
from	O
10	O
consecutive	O
cardiac	O
transplant	O
recipients	O
and	O
10	O
healthy	O
control	O
subjects	O
.	O

TF	B-protein
activity	O
generated	O
by	O
both	O
unstimulated	B-cell_line
and	O
endotoxin-stimulated	B-cell_line
cells	I-cell_line
was	O
significantly	O
higher	O
in	O
transplant	O
recipients	O
than	O
in	O
control	O
subjects	O
(	O
P	O
<	O
.05	O
)	O
.	O

Increased	O
monocyte	O
TF	B-protein
expression	O
in	O
transplant	O
recipients	O
was	O
shown	O
to	O
be	O
adversely	O
affected	O
by	O
treatment	O
with	O
CsA	O
:	O
TF	B-protein
induction	O
was	O
markedly	O
reduced	O
by	O
CsA	O
serum	O
concentrations	O
reaching	O
peak	O
CsA	O
drug	O
levels	O
.	O

Inhibition	O
of	O
TF	B-protein
induction	O
in	O
the	O
presence	O
of	O
high	O
CsA	O
blood	O
concentrations	O
was	O
also	O
observed	O
when	O
stimulation	O
of	O
cells	O
was	O
performed	O
with	O
interferon-gamma	B-protein
or	O
interleukin-1beta	B-protein
.	O

As	O
shown	O
by	O
reverse	O
transcription-polymerase	O
chain	O
reaction	O
and	O
electrophoretic	O
mobility	O
shift	O
assay	O
,	O
respectively	O
,	O
treatment	O
with	O
CsA	O
leads	O
to	O
decreased	O
TF	B-RNA
mRNA	I-RNA
expression	O
and	O
reduced	O
activation	O
of	O
the	O
NF-kappaB	B-protein
transcription	I-protein
factor	I-protein
,	O
which	O
is	O
known	O
to	O
contribute	O
to	O
the	O
induction	O
of	O
the	O
TF	B-DNA
promotor	I-DNA
in	O
human	B-cell_type
monocytes	I-cell_type
.	O

CONCLUSIONS	O
:	O
This	O
study	O
demonstrates	O
that	O
TF	B-protein
activation	O
,	O
occurring	O
in	O
mononuclear	B-cell_type
cells	I-cell_type
of	O
cardiac	O
transplant	O
recipients	O
,	O
is	O
inhibited	O
by	O
treatment	O
with	O
CsA	O
.	O

Inhibition	O
of	O
monocyte	O
TF	B-protein
induction	O
by	O
CsA	O
may	O
contribute	O
to	O
its	O
successful	O
use	O
in	O
cardiac	O
transplant	O
medicine	O
and	O
might	O
be	O
useful	O
in	O
managing	O
further	O
settings	O
of	O
vascular	O
pathology	O
also	O
known	O
to	O
involve	O
TF	B-protein
expression	O
and	O
NF-kappaB	B-protein
activation	O
.	O

IL-2	B-protein
and	O
IL-7	B-protein
induce	O
heterodimerization	O
of	O
STAT5	B-protein
isoforms	I-protein
in	O
human	B-cell_type
peripheral	I-cell_type
blood	I-cell_type
T	I-cell_type
lymphoblasts	I-cell_type
.	O

Despite	O
differences	O
in	O
T	O
cell	O
responses	O
induced	O
by	O
interleukin	B-protein
(	I-protein
IL	I-protein
)	I-protein
-2	I-protein
and	O
IL-7	B-protein
,	O
both	O
cytokines	B-protein
modulate	O
T	O
cell	O
functions	O
by	O
activation	O
of	O
signal	B-protein
transducers	I-protein
and	I-protein
activators	I-protein
of	I-protein
transcription	I-protein
(	I-protein
STAT	I-protein
)	I-protein
proteins	I-protein
.	O

We	O
examined	O
the	O
contribution	O
of	O
the	O
two	O
isoforms	O
of	O
STAT5	B-protein
,	O
STAT5A	B-protein
and	O
STAT5B	B-protein
,	O
to	O
IL-2-	O
and	O
IL-7-induced	O
activation	O
of	O
human	B-cell_type
peripheral	I-cell_type
blood	I-cell_type
T	I-cell_type
lymphoblasts	I-cell_type
.	O

Both	O
cytokines	B-protein
induced	O
assembly	O
of	O
STAT5A	B-protein
and	O
STAT5B	B-protein
containing	O
complexes	O
capable	O
of	O
binding	O
to	O
the	O
interferon-gamma	B-DNA
activation	I-DNA
sequence	I-DNA
(	O
GAS	B-DNA
)	O
,	O
and	O
these	O
complexes	O
rapidly	O
translocated	O
(	O
within	O
1	O
min	O
)	O
into	O
the	O
nucleus	O
of	O
IL-2-	B-cell_line
or	I-cell_line
IL-7-treated	I-cell_line
cells	I-cell_line
.	O

The	O
kinetics	O
of	O
this	O
translocation	O
were	O
delayed	O
in	O
IL-7-treated	B-cell_line
as	O
compared	O
to	O
IL-2-treated	B-cell_line
cells	I-cell_line
.	O

IL-2	B-protein
and	O
IL-7	B-protein
were	O
equivalent	O
in	O
their	O
ability	O
to	O
induce	O
tyrosine	O
phosphorylation	O
of	O
STAT5A	B-protein
and	O
STAT5B	B-protein
and	O
to	O
facilitate	O
binding	O
of	O
these	O
STATs	B-protein
to	O
an	O
immobilized	B-DNA
GAS	I-DNA
element	I-DNA
.	O

Both	O
IL-2	B-protein
and	O
IL-7	B-protein
induced	O
substantial	O
amounts	O
of	O
STAT5A	B-protein
/STAT5B	B-protein
heterodimerization	O
.	O

Moreover	O
,	O
we	O
observed	O
constitutive	O
association	O
of	O
STAT3	B-protein
with	O
each	O
STAT5	B-protein
isomer	I-protein
.	O

These	O
data	O
suggest	O
that	O
IL-2	B-protein
and	O
IL-7	B-protein
induce	O
assembly	O
of	O
STAT	B-protein
heterodimers	I-protein
in	O
a	O
similar	O
manner	O
and	O
that	O
subsequent	O
cellular	O
responses	O
may	O
be	O
driven	O
by	O
induction	O
of	O
similar	O
sets	O
of	O
genes	B-DNA
.	O

Transcription	B-protein
factor	I-protein
NF-kappaB	B-protein
regulates	O
inducible	O
Oct-2	B-DNA
gene	I-DNA
expression	O
in	O
precursor	B-cell_type
B	I-cell_type
lymphocytes	I-cell_type
.	O

The	O
POU	B-protein
transcription	I-protein
factors	I-protein
Oct-1	B-protein
and	O
Oct-2	B-protein
regulate	O
the	O
activity	O
of	O
octamer-dependent	B-DNA
promoters	I-DNA
,	O
including	O
those	O
that	O
direct	O
transcription	O
from	O
rearranged	O
immunoglobulin	B-protein
genes	I-protein
.	O

Unlike	O
Oct-1	B-protein
,	O
which	O
is	O
constitutively	O
expressed	O
in	O
many	O
cell	O
types	O
,	O
Oct-2	B-protein
expression	O
is	O
restricted	O
primarily	O
to	O
B	B-cell_type
lymphocytes	I-cell_type
and	O
can	O
be	O
induced	O
in	O
precursor	B-cell_type
B	I-cell_type
cells	I-cell_type
by	O
stimulation	O
with	O
bacterial	O
lipopolysaccharide	O
(	O
LPS	O
)	O
.	O

However	O
,	O
the	O
precise	O
factors	O
that	O
mediate	O
this	O
induction	O
mechanism	O
remain	O
unknown	O
.	O

In	O
the	O
present	O
study	O
,	O
we	O
monitored	O
Oct-2	B-protein
expression	O
in	O
cells	O
arrested	O
for	O
the	O
activation	O
of	O
NF-kappaB	B-protein
,	O
an	O
LPS-responsive	B-protein
member	I-protein
of	O
the	O
Rel	B-protein
transcription	I-protein
factor	I-protein
family	I-protein
.	O

Despite	O
stimulation	O
with	O
LPS	O
,	O
disruption	O
of	O
the	O
NF-kappaB	B-protein
signaling	O
pathway	O
in	O
precursor	B-cell_type
B	I-cell_type
cells	I-cell_type
led	O
to	O
the	O
loss	O
of	O
inducible	O
Oct-2	B-protein
DNA	O
binding	O
activity	O
in	O
vitro	O
and	O
the	O
suppression	O
of	O
Oct-2	B-protein
-directed	O
transcription	O
in	O
vivo	O
.	O

This	O
biochemical	O
defect	O
correlated	O
with	O
a	O
specific	O
block	O
to	O
Oct-2	B-DNA
gene	I-DNA
expression	O
at	O
the	O
level	O
of	O
transcription	O
,	O
whereas	O
the	O
expression	O
of	O
Oct-1	B-protein
was	O
unaffected	O
.	O

The	O
finding	O
that	O
Oct-2	B-protein
is	O
under	O
NF-kappaB	B-protein
control	O
highlights	O
an	O
important	O
cross-talk	O
mechanism	O
involving	O
two	O
distinct	O
transcription	B-protein
factor	I-protein
families	I-protein
that	O
regulate	O
B	B-cell_type
lymphocyte	I-cell_type
function	O
.	O

Suppression	O
of	O
MHC	B-protein
class	I-protein
II	I-protein
expression	O
by	O
human	B-DNA
class	I-DNA
II	I-DNA
trans-activator	I-DNA
constructs	I-DNA
lacking	O
the	O
N-terminal	B-protein
domain	I-protein
.	O

The	O
class	B-protein
II	I-protein
trans-activator	I-protein
(	O
CIITA	B-protein
)	O
is	O
a	O
bi-	B-protein
or	I-protein
multi-functional	I-protein
domain	I-protein
protein	I-protein
which	O
plays	O
a	O
critical	O
role	O
in	O
the	O
expression	O
of	O
MHC	B-DNA
class	I-DNA
II	I-DNA
genes	I-DNA
.	O

We	O
report	O
that	O
removal	O
of	O
the	O
N-terminal	B-protein
151	I-protein
amino	I-protein
acids	I-protein
,	O
encompassing	O
all	O
of	O
the	O
acidic	B-protein
domain	I-protein
but	O
leaving	O
intact	O
the	O
proline/serine/threonine-rich	B-protein
domain	I-protein
,	O
results	O
in	O
a	O
mutant	O
protein	O
with	O
potent	O
suppressive	O
properties	O
for	O
MHC	B-protein
class	I-protein
II	I-protein
expression	O
.	O

HeLa	B-cell_line
cells	I-cell_line
stably	O
or	O
transiently	O
transfected	O
with	O
mutant	B-DNA
CIITA	I-DNA
constructs	I-DNA
showed	O
up	O
to	O
99	O
%	O
suppression	O
of	O
MHC	B-protein
class	I-protein
II	I-protein
antigen	O
induction	O
by	O
IFN-gamma	B-protein
and	O
marked	O
suppression	O
of	O
HLA-DRA	B-RNA
mRNA	I-RNA
expression	O
.	O

Transient	O
transfection	O
of	O
a	O
B	O
lymphoma	O
line	O
resulted	O
in	O
up	O
to	O
89	O
%	O
reduction	O
of	O
constitutive	O
MHC	B-protein
class	I-protein
II	I-protein
expression	O
within	O
5	O
days	O
and	O
suppression	O
of	O
HLA-DRA	B-RNA
mRNA	I-RNA
synthesis	O
.	O

Helenalin	O
,	O
an	O
anti-inflammatory	O
sesquiterpene	O
lactone	O
from	O
Arnica	O
,	O
selectively	O
inhibits	O
transcription	B-protein
factor	I-protein
NF-kappaB	B-protein
[	O
see	O
comments	O
]	O

Alcoholic	O
extracts	O
prepared	O
form	O
Arnicae	O
flos	O
,	O
the	O
collective	O
name	O
for	O
flowerheads	O
from	O
Arnica	O
montana	O
and	O
A.	O
chamissonis	O
ssp.	O
foliosa	O
,	O
are	O
used	O
therapeutically	O
as	O
anti-inflammatory	O
remedies	O
.	O

The	O
active	O
ingredients	O
mediating	O
the	O
pharmacological	O
effect	O
are	O
mainly	O
sesquiterpene	O
lactones	O
,	O
such	O
as	O
helenalin	O
,	O
11alpha	O
,	O
13-dihydrohelenalin	O
,	O
chamissonolid	O
and	O
their	O
ester	O
derivatives	O
.	O

While	O
these	O
compounds	O
affect	O
various	O
cellular	O
processes	O
,	O
current	O
data	O
do	O
not	O
fully	O
explain	O
how	O
sesquiterpene	O
lactones	O
exert	O
their	O
anti-inflammatory	O
effect	O
.	O

We	O
show	O
here	O
that	O
helenalin	O
,	O
and	O
,	O
to	O
a	O
much	O
lesser	O
degree	O
,	O
11alpha	O
,	O
13-dihydrohelenalin	O
and	O
chamissonolid	O
,	O
inhibit	O
activation	O
of	O
transcription	B-protein
factor	I-protein
NF-kappaB	B-protein
.	O

This	O
difference	O
in	O
efficacy	O
,	O
which	O
correlates	O
with	O
the	O
compounds	O
'	O
anti-inflammatory	O
potency	O
in	O
vivo	O
,	O
may	O
be	O
explained	O
by	O
differences	O
in	O
structure	O
and	O
conformation	O
.	O

NF-kappaB	B-protein
,	O
which	O
resides	O
in	O
an	O
inactive	O
,	O
cytoplasmic	B-protein
complex	I-protein
in	O
unstimulated	B-cell_line
cells	I-cell_line
,	O
is	O
activated	O
by	O
phosphorylation	O
and	O
degradation	O
of	O
its	O
inhibitory	B-protein
subunit	I-protein
,	O
IkappaB	B-protein
.	O

Helenalin	O
inhibits	O
NF-kappaB	B-protein
activation	O
in	O
response	O
to	O
four	O
different	O
stimuli	O
in	O
T-cells	B-cell_type
,	O
B-cells	B-cell_type
and	O
epithelial	B-cell_type
cells	I-cell_type
and	O
abrogates	O
kappaB	B-protein
-driven	O
gene	O
expression	O
.	O

This	O
inhibition	O
is	O
selective	O
,	O
as	O
the	O
activity	O
of	O
four	O
other	O
transcription	B-protein
factors	I-protein
,	O
Oct-1	B-protein
,	O
TBP	B-protein
,	O
Sp1	B-protein
and	O
STAT	B-protein
5	I-protein
was	O
not	O
affected	O
.	O

We	O
show	O
that	O
inhibition	O
is	O
not	O
due	O
to	O
a	O
direct	O
modification	O
of	O
the	O
active	O
NF-kappaB	B-protein
heterodimer	I-protein
.	O

Rather	O
,	O
helenalin	O
modifies	O
the	O
NF-kappaB/IkappaB	B-protein
complex	I-protein
,	O
preventing	O
the	O
release	O
of	O
IkappaB	B-protein
.	O

These	O
data	O
suggest	O
a	O
molecular	O
mechanism	O
for	O
the	O
anti-inflammatory	O
effect	O
of	O
sesquiterpene	O
lactones	O
,	O
which	O
differs	O
from	O
that	O
of	O
other	O
nonsteroidal	O
anti-inflammatory	O
drugs	O
(	O
NSAIDs	O
)	O
,	O
indomethacin	O
and	O
acetyl	O
salicylic	O
acid	O
.	O

The	O
tax	B-protein
protein	I-protein
of	O
human	O
T-cell	O
leukemia	O
virus	O
type	O
1	O
mediates	O
the	O
transactivation	O
of	O
the	O
c-sis/platelet-derived	B-DNA
growth	I-DNA
factor-B	I-DNA
promoter	I-DNA
through	O
interactions	O
with	O
the	O
zinc	B-protein
finger	I-protein
transcription	I-protein
factors	I-protein
Sp1	B-protein
and	O
NGFI-A/Egr-1	B-protein
.	O

Transcriptional	O
up-regulation	O
of	O
the	O
c-sis/platelet-derived	B-DNA
growth	I-DNA
factor-B	I-DNA
(	I-DNA
PDGF-B	I-DNA
)	I-DNA
proto-oncogene	I-DNA
by	O
the	O
Tax	B-protein
protein	I-protein
of	O
human	O
T-cell	O
leukemia	O
virus	O
type	O
1	O
has	O
been	O
implicated	O
as	O
one	O
possible	O
mechanism	O
of	O
cellular	O
transformation	O
by	O
human	O
T-cell	O
leukemia	O
virus	O
type	O
1	O
.	O

In	O
previous	O
work	O
,	O
we	O
identified	O
an	O
essential	O
site	O
in	O
the	O
c-sis/PDGF-B	B-DNA
promoter	I-DNA
,	O
Tax-responsive	B-DNA
element	I-DNA
1	I-DNA
(	O
TRE1	B-DNA
)	O
,	O
necessary	O
for	O
transactivation	O
by	O
Tax	B-protein
.	O

We	O
also	O
identified	O
Sp1	B-protein
,	O
Sp3	O
,	O
and	O
NGFI-A/Egr-1	B-protein
as	O
the	O
primary	B-protein
nuclear	I-protein
transcription	I-protein
factors	I-protein
binding	O
to	O
TRE1	B-DNA
which	O
mediate	O
Tax	B-protein
responsiveness	O
.	O

In	O
the	O
present	O
work	O
,	O
we	O
have	O
investigated	O
the	O
mechanism	O
(	O
s	O
)	O
whereby	O
Tax	B-protein
transactivates	O
the	O
c-sis/PDGF-B	B-DNA
proto-oncogene	I-DNA
.	O

In	O
vitro	O
transcription	O
assays	O
showed	O
that	O
Tax	B-protein
was	O
able	O
to	O
significantly	O
increase	O
the	O
transcriptional	O
activity	O
of	O
a	O
template	O
containing	O
the	O
-257	B-DNA
to	I-DNA
+74	I-DNA
region	I-DNA
of	O
the	O
c-sis/PDGF-B	B-DNA
promoter	I-DNA
.	O

Electrophoretic	O
mobility	O
shift	O
assay	O
analysis	O
showed	O
that	O
Tax	B-protein
increased	O
the	O
DNA	O
binding	O
activity	O
of	O
both	O
Sp1	B-protein
and	O
NGFI-A/Egr-1	B-protein
using	O
a	O
TRE1	B-DNA
probe	I-DNA
.	O

Analysis	O
of	O
Tax	B-protein
mutants	I-protein
showed	O
that	O
two	O
mutants	O
,	O
IEXC29S	B-protein
and	O
IEXL320G	B-protein
,	O
were	O
unable	O
to	O
significantly	O
transactivate	O
the	O
c-sis/PDGF-B	B-DNA
promoter	I-DNA
.	O

Finally	O
,	O
co-immunoprecipitation	O
analysis	O
revealed	O
that	O
Tax	B-protein
is	O
able	O
to	O
stably	O
bind	O
to	O
both	O
Sp1	B-protein
and	O
NGFI-A/Egr-1	B-protein
.	O

Interestingly	O
,	O
co-immunoprecipitation	O
analysis	O
also	O
revealed	O
that	O
Tax	B-protein
mutant	O
IEXC29S	B-protein
is	O
unable	O
to	O
interact	O
with	O
NGFI-A/Egr-1	B-protein
,	O
whereas	O
Tax	B-protein
mutant	O
IEXL320G	B-protein
is	O
able	O
to	O
interact	O
with	O
NGFI-A/Egr-1	B-protein
.	O

Nuclear	O
localization	O
of	O
RelB	B-protein
is	O
associated	O
with	O
effective	O
antigen-presenting	O
cell	O
function	O
.	O

Dendritic	B-cell_type
cells	I-cell_type
(	O
DC	B-cell_type
)	O
are	O
potent	O
APCs	B-cell_type
that	O
enter	O
resting	O
tissues	O
as	O
precursors	O
and	O
,	O
after	O
Ag	O
exposure	O
,	O
differentiate	O
and	O
migrate	O
to	O
draining	O
lymph	O
nodes	O
.	O

The	O
phenotype	O
of	O
RelB	B-protein
knockout	O
mice	O
implicates	O
this	O
member	O
of	O
the	O
NF	B-protein
kappa	I-protein
B/Rel	I-protein
family	I-protein
in	O
DC	B-cell_type
differentiation	O
.	O

To	O
further	O
elucidate	O
the	O
role	O
of	O
RelB	B-protein
in	O
DC	B-cell_type
differentiation	O
,	O
mRNA	B-RNA
,	O
intracellular	O
protein	O
expression	O
,	O
and	O
DNA	O
binding	O
activity	O
of	O
RelB	B-protein
were	O
examined	O
in	O
immature	O
and	O
differentiated	O
human	B-cell_type
DC	I-cell_type
,	O
as	O
well	O
as	O
other	O
PB	B-cell_type
mononuclear	I-cell_type
cell	I-cell_type
populations	I-cell_type
.	O

RelB	B-protein
protein	O
and	O
mRNA	B-RNA
were	O
detected	O
constitutively	O
in	O
lymphocytes	B-cell_type
and	O
in	O
activated	B-cell_type
monocytes	I-cell_type
,	O
differentiated	B-cell_type
DC	I-cell_type
,	O
and	O
monocyte-derived	B-cell_line
DC	I-cell_line
.	O

Immunohistochemical	O
staining	O
demonstrated	O
RelB	B-protein
within	O
the	O
differentiated	B-cell_type
lymph	I-cell_type
node	I-cell_type
interdigitating	I-cell_type
DC	I-cell_type
and	O
follicular	B-cell_type
DC	I-cell_type
,	O
but	O
not	O
undifferentiated	B-cell_type
DC	I-cell_type
in	O
normal	O
skin	O
.	O

Active	O
nuclear	O
RelB	B-protein
was	O
detected	O
by	O
supershift	O
assay	O
only	O
in	O
differentiated	O
DC	B-cell_type
derived	O
from	O
either	O
PB	B-cell_type
precursors	I-cell_type
or	O
monocytes	B-cell_type
and	O
in	O
activated	B-cell_type
B	I-cell_type
cells	I-cell_type
.	O

These	O
RelB+	B-cell_type
APC	I-cell_type
were	O
potent	O
stimulators	O
of	O
the	O
MLR	B-protein
.	O

The	O
data	O
indicate	O
that	O
RelB	B-protein
expression	O
is	O
regulated	O
both	O
transcriptionally	O
and	O
post-translationally	O
in	O
myeloid	B-cell_type
cells	I-cell_type
.	O

Within	O
the	O
nucleus	O
,	O
RelB	B-protein
may	O
specifically	O
transactivate	O
genes	O
that	O
are	O
critical	O
for	O
APC	B-cell_type
function	O
.	O

NF-AT	B-protein
activation	O
induced	O
by	O
a	O
CAML	B-protein
-interacting	O
member	O
of	O
the	O
tumor	B-protein
necrosis	I-protein
factor	I-protein
receptor	I-protein
superfamily	I-protein
.	O

Activation	O
of	O
the	O
nuclear	B-protein
factor	I-protein
of	I-protein
activated	I-protein
T	I-protein
cells	I-protein
transcription	B-protein
factor	I-protein
(	O
NF-AT	B-protein
)	O
is	O
a	O
key	O
event	O
underlying	O
lymphocyte	O
action	O
.	O

The	O
CAML	B-protein
(	I-protein
calcium-modulator	I-protein
and	I-protein
cyclophilin	I-protein
ligand	I-protein
)	I-protein
protein	I-protein
is	O
a	O
coinducer	O
of	O
NF-AT	B-protein
activation	O
when	O
overexpressed	O
in	O
Jurkat	B-cell_line
T	I-cell_line
cells	I-cell_line
.	O

A	O
member	O
of	O
the	O
tumor	B-protein
necrosis	I-protein
factor	I-protein
receptor	I-protein
superfamily	I-protein
was	O
isolated	O
by	O
virtue	O
of	O
its	O
affinity	O
for	O
CAML	B-protein
.	O

Cross-linking	O
of	O
this	O
lymphocyte-specific	B-protein
protein	I-protein
,	O
designated	O
TACI	B-protein
(	O
transmembrane	B-protein
activator	I-protein
and	I-protein
CAML-interactor	I-protein
)	O
,	O
on	O
the	O
surface	O
of	O
transfected	B-cell_line
Jurkat	I-cell_line
cells	I-cell_line
with	O
TACI-specific	B-protein
antibodies	I-protein
led	O
to	O
activation	O
of	O
the	O
transcription	B-protein
factors	I-protein
NF-AT	B-protein
,	O
AP-1	B-protein
,	O
and	O
NFkappaB	B-protein
.	O

TACI	B-protein
-induced	O
activation	O
of	O
NF-AT	B-protein
was	O
specifically	O
blocked	O
by	O
a	O
dominant-negative	B-protein
CAML	I-protein
mutant	I-protein
,	O
thus	O
implicating	O
CAML	B-protein
as	O
a	O
signaling	O
intermediate	O
.	O

Rel/NF-kappa	B-protein
B	I-protein
transcription	B-protein
factors	I-protein
and	O
the	O
control	O
of	O
apoptosis	O
.	O

The	O
process	O
of	O
apoptosis	O
is	O
used	O
to	O
eliminate	O
unwanted	B-cell_type
cells	I-cell_type
from	O
a	O
wide	O
variety	O
of	O
organisms	O
.	O

Various	O
extracellular	O
signals	O
,	O
often	O
converging	O
in	O
common	O
intracellular	O
pathways	O
,	O
can	O
induce	O
apoptosis	O
in	O
a	O
cell-type-specific	O
fashion	O
.	O

Recent	O
work	O
from	O
several	O
laboratories	O
has	O
demonstrated	O
that	O
Rel/NF-kappa	B-protein
B	I-protein
transcription	B-protein
factors	I-protein
regulate	O
apoptosis	O
in	O
many	O
cell	O
types	O
.	O

In	O
most	O
cells	O
,	O
Rel/NF-kappa	B-protein
B	I-protein
transcription	B-protein
factors	I-protein
appear	O
to	O
mediate	O
survival	O
signals	O
that	O
protect	O
cells	O
from	O
apoptosis	O
;	O
however	O
,	O
under	O
some	O
circumstances	O
,	O
activation	O
of	O
these	O
factors	O
may	O
also	O
promote	O
apoptosis	O
.	O

A	O
thiol	O
antioxidant	O
regulates	O
IgE	B-protein
isotype	I-protein
switching	O
by	O
inhibiting	O
activation	O
of	O
nuclear	B-protein
factor-kappaB	I-protein
.	O

The	O
binding	B-DNA
site	I-DNA
for	O
nuclear	B-protein
factor-kappaB	I-protein
(	O
NF-kappaB	B-protein
)	O
is	O
present	O
at	O
the	O
promoter	B-DNA
region	I-DNA
of	O
the	O
germline	B-DNA
Cepsilon	I-DNA
gene	I-DNA
,	O
but	O
there	O
is	O
little	O
information	O
on	O
whether	O
this	O
factor	O
is	O
involved	O
in	O
regulating	O
IgE	B-protein
synthesis	O
by	O
human	B-cell_type
B	I-cell_type
cells	I-cell_type
.	O

Accordingly	O
,	O
we	O
studied	O
the	O
role	O
of	O
NF-kappaB	B-protein
in	O
germline	B-DNA
Cepsilon	O
transcription	O
by	O
using	O
two	O
human	B-cell_line
Burkitt	I-cell_line
's	I-cell_line
lymphoma	I-cell_line
B	I-cell_line
cell	I-cell_line
lines	I-cell_line
,	O
DND39	B-cell_line
and	O
DG75	B-cell_line
.	O

In	O
both	O
cell	B-cell_line
lines	I-cell_line
,	O
n-acetyl-L-cysteine	O
(	O
NAC	O
)	O
,	O
a	O
potent	O
thiol	O
antioxidant	O
,	O
inhibited	O
the	O
triggering	O
of	O
the	O
nuclear	O
expression	O
of	O
NF-kappaB	B-protein
by	O
IL-4	B-protein
and	O
by	O
anti-CD40	B-protein
monoclonal	I-protein
antibody	I-protein
.	O

Although	O
IL-4	B-protein
activated	O
signal	B-protein
transducers	I-protein
and	I-protein
activators	I-protein
of	I-protein
transcription	I-protein
(	I-protein
STAT	I-protein
)	I-protein
6	I-protein
in	O
addition	O
to	O
NF-kappaB	B-protein
,	O
NAC	O
treatment	O
or	O
the	O
transfection	O
of	O
decoy	O
oligodeoxynucleotides	O
for	O
NF-kappaB	B-protein
or	O
STAT6	B-protein
only	O
partly	O
blocked	O
IL-4	B-protein
-induced	O
germline	B-DNA
Cepsilon	O
transcription	O
.	O

However	O
,	O
these	O
two	O
decoy	O
oligodeoxynucleotides	O
together	O
almost	O
completely	O
abrogated	O
IL-4	B-protein
-induced	O
germline	B-DNA
Cepsilon	O
transcription	O
.	O

Of	O
note	O
,	O
CD40	B-protein
-mediated	O
enhancement	O
of	O
IL-4	B-protein
-driven	O
germline	B-DNA
Cepsilon	O
transcription	O
was	O
markedly	O
decreased	O
by	O
NAC	O
or	O
by	O
a	O
decoy	O
oligodeoxynucleotide	O
for	O
NF-kappaB	B-protein
.	O

The	O
effect	O
of	O
NAC	O
was	O
also	O
examined	O
on	O
deletional	O
switch	O
recombination	O
underlying	O
the	O
isotype	O
switch	O
to	O
IgE	B-protein
.	O

NAC	O
inhibited	O
the	O
generation	O
of	O
Smu/Sepsilon	B-protein
switch	I-protein
fragments	I-protein
in	O
normal	O
human	B-cell_type
B	I-cell_type
cells	I-cell_type
costimulated	O
with	O
IL-4	B-protein
and	O
anti-CD40	B-protein
monoclonal	I-protein
antibody	I-protein
.	O

It	O
also	O
abolished	O
IL-4	B-protein
-induced	O
upregulation	O
of	O
CD40	B-protein
but	O
promoted	O
upregulation	O
of	O
CD23	O
.	O

These	O
results	O
suggest	O
that	O
coordination	O
of	O
NF-kappaB	B-protein
and	O
STAT6	B-protein
may	O
be	O
required	O
for	O
induction	O
of	O
germline	B-DNA
Cepsilon	O
transcription	O
by	O
IL-4	B-protein
,	O
and	O
that	O
CD40	B-protein
-mediated	O
NF-kappaB	B-protein
activation	O
may	O
be	O
important	O
in	O
regulating	O
both	O
enhancement	O
of	O
germline	B-DNA
Cepsilon	O
transcription	O
and	O
class	O
switching	O
to	O
IgE	B-protein
.	O

Pathogenesis	O
.	O

There	O
are	O
many	O
hypotheses	O
concerning	O
the	O
pathogenesis	O
of	O
endometriosis	O
,	O
though	O
no	O
single	O
theory	O
can	O
explain	O
all	O
cases	O
.	O

It	O
is	O
likely	O
that	O
several	O
mechanisms	O
are	O
involved	O
.	O

Early	O
studies	O
concentrated	O
on	O
the	O
histogenesis	O
of	O
the	O
endometriotic	O
lesion	O
.	O

Recent	O
evidence	O
has	O
implicated	O
components	O
of	O
the	O
immune	O
system	O
in	O
the	O
pathogenesis	O
of	O
endometriosis	O
.	O

This	O
review	O
considers	O
the	O
evidence	O
for	O
different	O
theories	O
of	O
the	O
histogenesis	O
of	O
endometriosis	O
and	O
discusses	O
possible	O
immune	O
factors	O
that	O
may	O
be	O
involved	O
in	O
the	O
pathophysiology	O
of	O
the	O
disease	O
.	O

ATF1	B-protein
and	O
CREB	B-protein
trans-activate	O
a	O
cell	B-DNA
cycle	I-DNA
regulated	I-DNA
histone	I-DNA
H4	I-DNA
gene	I-DNA
at	O
a	O
distal	B-DNA
nuclear	I-DNA
matrix	I-DNA
associated	I-DNA
promoter	I-DNA
element	I-DNA
.	O

Proteins	O
of	O
the	O
ATF/	O
CREB	B-protein
class	O
of	O
transcription	B-protein
factors	I-protein
stimulate	O
gene	O
expression	O
of	O
several	O
cell	B-DNA
growth-related	I-DNA
genes	I-DNA
through	O
protein	B-DNA
kinase	I-DNA
A-related	I-DNA
cAMP	I-DNA
response	I-DNA
elements	I-DNA
.	O

The	O
promoter	O
activity	O
of	O
cell	B-DNA
cycle	I-DNA
regulated	I-DNA
histone	I-DNA
H4	I-DNA
genes	I-DNA
is	O
regulated	O
by	O
at	O
least	O
four	O
principal	B-DNA
cis-acting	I-DNA
elements	I-DNA
which	O
mediate	O
G1/S	O
phase	O
control	O
and/or	O
enhancement	O
of	O
transcription	O
during	O
the	O
cell	O
cycle	O
.	O

Using	O
protein-DNA	O
interaction	O
assays	O
we	O
show	O
that	O
the	O
H4	B-DNA
promoter	I-DNA
contains	O
two	O
ATF/	O
CREB	B-protein
recognition	O
motifs	O
which	O
interact	O
with	O
CREB	B-protein
,	O
ATF1	B-protein
,	O
and	O
ATF2	B-protein
but	O
not	O
with	O
ATF4/CREB2	B-protein
.	O

One	O
ATF/CRE	B-DNA
motif	I-DNA
is	O
located	O
in	O
the	O
distal	B-DNA
promoter	I-DNA
at	O
the	O
nuclear	B-DNA
matrix-associated	I-DNA
Site	I-DNA
IV	I-DNA
,	O
and	O
the	O
second	O
motif	O
is	O
present	O
in	O
the	O
proximal	B-DNA
promoter	I-DNA
at	O
Site	B-DNA
I	I-DNA
.	O

Both	O
ATF/CRE	B-DNA
motifs	I-DNA
overlap	O
binding	B-DNA
sequences	I-DNA
for	O
the	O
multifunctional	B-protein
YY1	I-protein
transcription	I-protein
factor	I-protein
,	O
which	O
has	O
previously	O
been	O
shown	O
to	O
be	O
nuclear	O
matrix	O
associated	O
.	O

Subnuclear	O
fractionation	O
reveals	O
that	O
there	O
are	O
two	O
ATF1	B-protein
isoforms	I-protein
which	O
appear	O
to	O
differ	O
with	O
respect	O
to	O
DNA	O
binding	O
activity	O
and	O
partition	O
selectively	O
between	O
nuclear	O
matrix	O
and	O
nonmatrix	O
compartments	O
,	O
consistent	O
with	O
the	O
role	O
of	O
the	O
nuclear	O
matrix	O
in	O
regulating	O
gene	O
expression	O
.	O

Site-directed	O
mutational	O
studies	O
demonstrate	O
that	O
Site	B-DNA
I	I-DNA
and	O
Site	B-DNA
IV	I-DNA
together	O
support	O
ATF1-	O
and	O
CREB-induced	O
trans-activation	O
of	O
the	O
H4	B-DNA
promoter	I-DNA
.	O

Thus	O
,	O
our	O
data	O
establish	O
that	O
ATF/CREB	B-protein
factors	I-protein
functionally	O
modulate	O
histone	B-DNA
H4	I-DNA
gene	I-DNA
transcription	O
at	O
distal	B-DNA
and	I-DNA
proximal	I-DNA
promoter	I-DNA
elements	I-DNA
.	O

Is	O
celiac	O
disease	O
due	O
to	O
molecular	O
mimicry	O
between	O
gliadin	O
peptide	O
-HLA	B-protein
class	I-protein
II	I-protein
molecule	I-protein
-T	O
cell	O
interactions	O
and	O
those	O
of	O
some	O
unidentified	B-protein
superantigen	I-protein
?	O

This	O
paper	O
presents	O
a	O
new	O
hypothesis	O
for	O
the	O
etiology	O
and	O
pathogenesis	O
of	O
celiac	O
disease	O
(	O
CD	O
)	O
.	O

It	O
is	O
our	O
contention	O
that	O
CD	O
is	O
triggered	O
by	O
the	O
binding	O
of	O
one	O
or	O
more	O
gliadin	O
peptides	O
to	O
CD-associated	B-protein
HLA	I-protein
class	I-protein
II	I-protein
molecules	I-protein
.	O

Furthermore	O
,	O
we	O
propose	O
that	O
these	O
putative	O
CD	O
peptides	O
bind	O
to	O
oligosaccharide	O
residues	O
on	O
HLA	B-protein
class	I-protein
II	I-protein
molecules	I-protein
distal	O
to	O
the	O
peptide-binding	B-protein
groove	I-protein
invoking	O
recognition	O
and	O
binding	O
by	O
specialized	O
subsets	O
of	O
gamma	B-cell_type
delta	I-cell_type
T	I-cell_type
cell	I-cell_type
receptor-bearing	I-cell_type
lymphocytes	I-cell_type
.	O

The	O
binding	O
of	O
these	O
gamma	B-cell_type
delta	I-cell_type
T	I-cell_type
cells	I-cell_type
serves	O
as	O
a	O
signal	O
for	O
abrogation	O
of	O
oral	O
tolerance	O
to	O
ingested	B-protein
proteins	I-protein
setting	O
in	O
motion	O
a	O
series	O
of	O
immune	O
responses	O
directed	O
against	O
the	O
small	O
intestinal	O
epithelium	O
of	O
CD	O
patients	O
.	O

CD	O
patients	O
are	O
victimized	O
by	O
this	O
self-distructed	O
immune	O
response	O
because	O
of	O
inheritance	O
of	O
certain	O
combinations	O
of	O
HLA-DQ	O
and	O
DR	O
haplotypes	O
.	O

Dimers	O
encoded	O
by	O
HLA-DR	B-protein
haplotypes	O
may	O
be	O
the	O
primary	B-DNA
restriction	I-DNA
elements	I-DNA
for	O
lectin-like	O
,	O
gliadin	O
peptides	O
while	O
the	O
degree	O
of	O
immune	O
suppression	O
(	O
or	O
lack	O
thereof	O
)	O
to	O
ingested	O
gliadins	O
is	O
governed	O
by	O
inherited	O
HLA-DQ	B-DNA
haplotypes	O
.	O

Finally	O
,	O
we	O
speculate	O
that	O
molecular	O
mimicry	O
between	O
one	O
or	O
more	O
gliadin	O
peptides	O
and	O
some	O
,	O
as	O
yet	O
unidentified	O
,	O
bacterial	B-protein
or	I-protein
viral	I-protein
superantigen	I-protein
plays	O
a	O
role	O
in	O
disease	O
pathogenesis	O
.	O

Epstein-Barr	O
virus	O
latent	B-protein
membrane	I-protein
protein-1	I-protein
triggers	O
AP-1	B-protein
activity	O
via	O
the	O
c-Jun	B-protein
N-terminal	O
kinase	O
cascade	O
.	O

The	O
Epstein-Barr	O
virus	O
latent	B-protein
membrane	I-protein
protein-1	I-protein
(	O
LMP-1	B-protein
)	O
is	O
an	O
integral	B-protein
membrane	I-protein
protein	I-protein
which	O
transforms	O
fibroblasts	B-cell_type
and	O
is	O
essential	O
for	O
EBV-mediated	O
B-cell	O
immortalization	O
.	O

LMP-1	B-protein
has	O
been	O
shown	O
to	O
trigger	O
cellular	O
NF-kappa	B-protein
B	I-protein
activity	O
which	O
,	O
however	O
,	O
can	O
not	O
fully	O
explain	O
the	O
oncogenic	O
potential	O
of	O
LMP-1	B-protein
.	O

Here	O
we	O
show	O
that	O
LMP-1	B-protein
induces	O
the	O
activity	O
of	O
the	O
AP-1	B-protein
transcription	I-protein
factor	I-protein
,	O
a	O
dimer	O
of	O
Jun/Jun	B-protein
or	I-protein
Jun/Fos	I-protein
proteins	I-protein
.	O

LMP-1	B-protein
effects	O
on	O
AP-1	B-protein
are	O
mediated	O
through	O
activation	O
of	O
the	O
c-Jun	B-protein
N-terminal	O
kinase	O
(	O
JNK	B-protein
)	O
cascade	O
,	O
but	O
not	O
the	O
extracellular	B-protein
signal-regulated	I-protein
kinase	I-protein
(	O
Erk	B-protein
)	O
pathway	O
.	O

Consequently	O
,	O
LMP-1	B-protein
triggers	O
the	O
activity	O
of	O
the	O
c-Jun	B-protein
N-terminal	I-protein
transactivation	I-protein
domain	I-protein
which	O
is	O
known	O
to	O
be	O
activated	O
upon	O
JNK	B-protein
-mediated	O
phosphorylation	O
.	O

Deletion	O
analysis	O
indicates	O
that	O
the	O
55	O
C-terminal	B-protein
amino	I-protein
acids	I-protein
of	O
the	O
LMP-1	B-protein
molecule	I-protein
,	O
but	O
not	O
its	O
TRAF	B-protein
interaction	I-protein
domain	I-protein
,	O
are	O
essential	O
for	O
AP-1	B-protein
activation	O
.	O

JNK	B-protein
-mediated	O
transcriptional	O
activation	O
of	O
AP-1	B-protein
is	O
the	O
direct	O
output	O
of	O
LMP	B-protein
-1-triggered	O
signaling	O
,	O
as	O
shown	O
by	O
an	O
inducible	O
LMP-1	B-protein
mutant	I-protein
.	O

Using	O
a	O
tetracycline-regulated	B-DNA
LMP-1	I-DNA
allele	I-DNA
,	O
we	O
demonstrate	O
that	O
JNK	B-protein
is	O
also	O
an	O
effector	O
of	O
non-cytotoxic	O
LMP-1	B-protein
signaling	O
in	O
B	B-cell_type
cells	I-cell_type
,	O
the	O
physiological	O
target	O
cells	O
of	O
EBV	O
.	O

In	O
summary	O
,	O
our	O
data	O
reveal	O
a	O
novel	O
effector	O
of	O
LMP-1	B-protein
,	O
the	O
SEK/	O
JNK	B-protein
/	O
c-Jun	B-protein
/	O
AP-1	B-protein
pathway	O
,	O
which	O
contributes	O
to	O
our	O
understanding	O
of	O
the	O
immortalizing	O
and	O
transforming	O
potential	O
of	O
LMP-1	B-protein
.	O

Abnormal	O
apoptosis	O
and	O
cell	O
cycle	O
progression	O
in	O
humans	O
exposed	O
to	O
methyl	O
tertiary-butyl	O
ether	O
and	O
benzene	O
contaminating	O
water	O
.	O

1.	O
In	O
this	O
study	O
we	O
hypothesized	O
that	O
in	O
individuals	O
with	O
certain	O
genetic	O
makeup	O
,	O
MTBE	O
,	O
benzene	O
or	O
their	O
metabolites	O
act	O
as	O
adducts	O
and	O
may	O
induce	O
programmed	O
cell	O
death	O
.	O

2.	O
Our	O
study	O
involved	O
a	O
group	O
of	O
60	O
male	O
and	O
female	O
subjects	O
who	O
were	O
exposed	O
to	O
MTBE	O
and	O
benzene-contaminated	O
water	O
concentrations	O
up	O
to	O
76	O
PPB	O
for	O
MTBE	O
and	O
14	O
PPB	O
for	O
benzene	O
,	O
for	O
a	O
period	O
of	O
5	O
to	O
8	O
years	O
.	O

For	O
comparison	O
,	O
we	O
recruited	O
a	O
control	O
group	O
consisting	O
of	O
32	O
healthy	O
males	O
and	O
females	O
with	O
similar	O
age	O
distribution	O
and	O
without	O
a	O
history	O
of	O
exposure	O
to	O
MTBE	O
or	O
benzene	O
.	O

3	O
.	O
Peripheral	B-cell_type
blood	I-cell_type
lymphocytes	I-cell_type
(	O
PBL	B-cell_type
)	O
of	O
both	O
groups	O
were	O
tested	O
for	O
the	O
percentage	O
of	O
apoptotic	B-cell_type
cells	I-cell_type
and	O
cell	O
cycle	O
progression	O
using	O
flow	O
cytometry	O
.	O

4.	O
When	O
apoptotic	B-cell_type
lymphocytes	I-cell_type
from	O
exposed	O
individuals	O
were	O
compared	O
to	O
apoptotic	B-cell_type
lymphocytes	I-cell_type
from	O
the	O
control	O
group	O
,	O
statistically-significant	O
differences	O
between	O
each	O
mean	O
group	O
were	O
detected	O
(	O
26.4	O
+/-	O
1.8	O
and	O
12.1	O
+/-	O
1.3	O
,	O
respectively	O
)	O
,	O
indicating	O
an	O
increased	O
rate	O
of	O
apoptosis	O
in	O
80.5	O
%	O
of	O
exposed	O
individuals	O
(	O
P	O
<	O
0.0001	O
,	O
Mann-Whitney	O
U-Test	O
)	O
.	O

MTBE	O
and	O
benzene-induced	O
apoptosis	O
is	O
attributed	O
to	O
a	O
discrete	O
block	O
within	O
the	O
cell	O
cycle	O
progression	O
.	O

Because	O
cell	O
cycle	O
analysis	O
showed	O
that	O
in	O
PBL	B-cell_type
from	O
chemically-exposed	O
individuals	O
,	O
between	O
20-50	O
%	O
of	O
cells	O
were	O
accumulated	O
at	O
the	O
S-G2/M	O
boundaries	O
.	O

5.	O
One	O
of	O
the	O
signaling	B-protein
molecules	I-protein
which	O
mediates	O
programmed	O
cell	O
death	O
is	O
nuclear	B-protein
factor	I-protein
Kappa-B	I-protein
(	O
NF-kappa	B-protein
B	I-protein
)	O
.	O

NF-kappa	B-protein
B	I-protein
was	O
examined	O
as	O
one	O
of	O
the	O
many	O
molecular	O
mechanisms	O
for	O
mediating	O
cell	O
death	O
by	O
MTBE	O
and	O
benzene	O
.	O

Indeed	O
,	O
addition	O
of	O
inhibitors	O
of	O
NF-kappa	B-protein
B	I-protein
activation	O
pyrrolidine	O
dithiocarbamate	O
(	O
PDTC	O
)	O
,	O
to	O
the	O
lymphocytes	B-cell_type
of	O
the	O
chemically-exposed	O
group	O
was	O
capable	O
of	O
inhibiting	O
programmed	O
cell	O
death	O
by	O
40	O
%	O
.	O

This	O
reversal	O
of	O
apoptosis	O
almost	O
to	O
the	O
control	O
level	O
by	O
inhibitor	O
of	O
NF-kappa	B-protein
B	I-protein
activation	O
may	O
indicate	O
involvement	O
of	O
this	O
signaling	B-protein
molecule	I-protein
in	O
MTBE	O
and	O
benzene	O
induction	O
of	O
programmed	O
cell	O
death	O
.	O

Purification	O
and	O
characterization	O
of	O
the	O
human	B-protein
SR	I-protein
31747A-binding	I-protein
protein	I-protein
.	O

A	O
nuclear	B-protein
membrane	I-protein
protein	I-protein
related	O
to	O
yeast	B-protein
sterol	I-protein
isomerase	I-protein
.	O

SR	O
31747A	O
,	O
defined	O
as	O
a	O
sigma	O
ligand	O
,	O
is	O
a	O
novel	O
immunosuppressive	O
agent	O
that	O
blocks	O
proliferation	O
of	O
human	B-cell_type
and	I-cell_type
mouse	I-cell_type
lymphocytes	I-cell_type
.	O

Using	O
a	O
radiolabeled	O
chemical	O
probe	O
,	O
we	O
here	O
purified	O
a	O
target	O
of	O
SR	O
31747A	O
and	O
called	O
it	O
SR	B-protein
31747A-binding	I-protein
protein	I-protein
(	O
SR-BP	B-protein
)	O
.	O

Purified	B-protein
SR-BP	I-protein
retained	O
its	O
binding	O
properties	O
and	O
migrated	O
on	O
SDS-polyacrylamide	O
gel	O
as	O
a	O
Mr	B-protein
28	I-protein
,	I-protein
000	I-protein
protein	I-protein
.	O

Cloning	O
of	O
the	O
cDNA	B-DNA
encoding	O
human	B-protein
SR-BP	I-protein
shows	O
an	O
open	B-DNA
reading	I-DNA
frame	I-DNA
for	O
a	O
223-amino	B-protein
acid	I-protein
protein	I-protein
,	O
which	O
is	O
homologous	O
to	O
the	O
recently	O
cloned	O
sigma	B-protein
1	I-protein
receptor	I-protein
.	O

Interestingly	O
,	O
the	O
deduced	O
amino	O
acid	O
sequence	O
was	O
found	O
to	O
be	O
related	O
to	O
fungal	B-protein
C8-C7	I-protein
sterol	I-protein
isomerase	I-protein
,	O
encoded	O
by	O
the	O
ERG2	B-DNA
gene	I-DNA
.	O

The	O
ERG2	B-protein
gene	I-protein
product	I-protein
has	O
been	O
identified	O
recently	O
as	O
the	O
molecular	O
target	O
of	O
SR	O
31747A	O
that	O
mediates	O
antiproliferative	O
effects	O
of	O
the	O
drug	O
in	O
yeast	O
.	O

Northern	O
blot	O
analysis	O
of	O
SR-BP	B-protein
gene	O
expression	O
revealed	O
a	O
single	O
transcript	O
of	O
2	B-RNA
kilobases	I-RNA
which	O
was	O
widely	O
expressed	O
among	O
organs	O
,	O
with	O
the	O
highest	O
abundance	O
in	O
liver	O
and	O
the	O
lowest	O
abundance	O
in	O
brain	O
.	O

Subcellular	O
localization	O
analysis	O
in	O
various	O
cells	O
,	O
using	O
a	O
specific	B-protein
monoclonal	I-protein
antibody	I-protein
raised	O
against	O
SR-BP	B-protein
,	O
demonstrated	O
that	O
this	O
protein	O
was	O
associated	O
with	O
the	O
nuclear	O
envelope	O
.	O

When	O
studying	O
the	O
binding	O
of	O
SR	O
31747A	O
on	O
membranes	O
from	O
yeast	O
expressing	O
SR-BP	B-protein
,	O
we	O
found	O
a	O
pharmacological	O
profile	O
of	O
sigma	B-protein
1	I-protein
receptors	I-protein
;	O
binding	O
was	O
displaced	O
by	O
(	O
+	O
)	O
-pentazocine	O
,	O
haloperidol	O
,	O
and	O
(	O
+	O
)	O
-SKF	O
10	O
,	O
047	O
,	O
with	O
(	O
+	O
)	O
-SKF	O
10	O
,	O
047	O
being	O
a	O
more	O
potent	O
competitor	O
than	O
(	O
-	O
)	O
-SKF	O
10	O
,	O
047	O
.	O

Scatchard	O
plot	O
analysis	O
revealed	O
Kd	O
values	O
of	O
7.1	O
nM	O
and	O
0.15	O
nM	O
for	O
(	O
+	O
)	O
-pentazocine	O
and	O
SR	O
31747A	O
,	O
respectively	O
,	O
indicating	O
an	O
affinity	O
of	O
SR-BP	B-protein
50-fold	O
higher	O
for	O
SR	O
31747A	O
than	O
for	O
pentazocine	O
.	O

Additionally	O
,	O
we	O
showed	O
that	O
pentazocine	O
,	O
a	O
competitive	O
inhibitor	O
of	O
SR	O
31747A	O
binding	O
,	O
also	O
prevents	O
the	O
immunosuppressive	O
effect	O
of	O
SR	O
31747A	O
.	O

Taken	O
together	O
,	O
these	O
findings	O
strongly	O
suggest	O
that	O
SR-BP	B-protein
represents	O
the	O
molecular	O
target	O
for	O
SR	O
31747A	O
in	O
mammalian	O
tissues	O
,	O
which	O
could	O
be	O
critical	O
for	O
T	O
cell	O
proliferation	O
.	O

Phospholipase	B-protein
C	I-protein
gamma	I-protein
1	I-protein
overexpression	O
and	O
activation	O
induced	O
by	O
interferon	B-protein
beta	I-protein
in	O
human	B-cell_type
T	I-cell_type
lymphocytes	I-cell_type
:	O
an	O
ISGF3	B-protein
-independent	O
response	O
.	O

Interferons	B-protein
exert	O
their	O
antiviral	O
,	O
antiproliferative	O
and	O
immunoregulatory	B-protein
activities	O
by	O
stimulating	O
the	O
expression	O
of	O
several	O
genes	O
.	O

Such	O
genes	O
disclose	O
a	O
common	O
element	O
within	O
their	O
promoters	B-DNA
,	O
defined	O
Interferon	B-DNA
Stimulated	I-DNA
Response	I-DNA
Element	I-DNA
(	O
ISRE	B-DNA
)	O
,	O
which	O
binds	O
a	O
nuclear	B-protein
factor	I-protein
(	O
s	O
)	O
translocated	O
from	O
the	O
cytoplasm	O
to	O
the	O
nucleus	O
(	O
ISGF3	B-protein
)	O
after	O
the	O
binding	O
of	O
interferon	B-protein
(	O
IFN	B-protein
)	O
to	O
the	O
specific	O
receptor	O
.	O

Here	O
we	O
report	O
the	O
induction	O
of	O
the	O
synthesis	O
and	O
of	O
the	O
hydrolytic	O
activity	O
of	O
phospholipase	B-protein
C	I-protein
gamma	I-protein
1	I-protein
(	O
PLC	B-protein
gamma	I-protein
1	I-protein
)	O
in	O
human	B-cell_type
T	I-cell_type
lymphocytes	I-cell_type
by	O
IFN-beta	B-protein
.	O

The	O
increased	O
level	O
of	O
PLC	B-protein
gamma	I-protein
1	I-protein
becomes	O
evident	O
after	O
90	O
min	O
of	O
IFN-beta	B-protein
treatment	O
and	O
is	O
still	O
detectable	O
after	O
24	O
h	O
.	O

Neither	O
the	O
PLC	B-protein
gamma	I-protein
1	I-protein
overexpression	O
induced	O
by	O
IFN	B-protein
nor	O
the	O
increased	O
hydrolytic	O
activity	O
of	O
the	O
enzyme	B-protein
appear	O
to	O
be	O
affected	O
by	O
pretreatment	O
of	O
the	O
cells	O
with	O
the	O
protein	O
tyrosine	B-protein
kinase	I-protein
inhibitor	O
genistein	O
,	O
which	O
is	O
known	O
to	O
prevent	O
the	O
association	O
of	O
ISGF3	B-protein
components	O
.	O

These	O
results	O
suggest	O
that	O
in	O
human	B-cell_type
T	I-cell_type
lymphocytes	I-cell_type
IFN-beta	B-protein
can	O
activate	O
other	O
transcription	B-protein
factor	I-protein
(	O
s	O
)	O
distinct	O
from	O
ISGF3	B-protein
to	O
regulate	O
PLC	B-protein
gamma	I-protein
1	I-protein
expression	O
.	O

In	O
addition	O
,	O
the	O
ability	O
of	O
this	O
enzyme	B-protein
to	O
hydrolyse	O
PIP2	O
,	O
also	O
in	O
the	O
presence	O
of	O
genistein	O
,	O
implies	O
the	O
possibility	O
that	O
this	O
enzyme	O
can	O
exert	O
its	O
hydrolytic	O
activity	O
independently	O
of	O
protein	B-protein
tyrosine	I-protein
kinase	I-protein
activation	O
.	O

Negative	O
regulation	O
by	O
HLA-DO	B-protein
of	O
MHC	B-protein
class	I-protein
II	I-protein
-restricted	O
antigen	O
processing	O
.	O

HLA-DM	B-protein
is	O
a	O
major	B-protein
histocompatibility	I-protein
complex	I-protein
(	I-protein
MHC	I-protein
)	I-protein
class	I-protein
II-like	I-protein
molecule	I-protein
that	O
facilitates	O
antigen	O
processing	O
by	O
catalyzing	O
the	O
exchange	O
of	O
invariant	O
chain-derived	O
peptides	O
(	O
CLIP	O
)	O
from	O
class	B-protein
II	I-protein
molecules	I-protein
for	O
antigenic	O
peptides	O
.	O

HLA-DO	B-protein
is	O
a	O
second	O
class	B-protein
II-like	I-protein
molecule	I-protein
that	O
physically	O
associates	O
with	O
HLA-DM	B-protein
in	O
B	B-cell_type
cells	I-cell_type
.	O

HLA-DO	B-protein
was	O
shown	O
to	O
block	O
HLA-DM	B-protein
function	O
.	O

Purified	O
HLA-DM-DO	B-protein
complexes	I-protein
could	O
not	O
promote	O
peptide	O
exchange	O
in	O
vitro	O
.	O

Expression	O
of	O
HLA-DO	B-protein
in	O
a	O
class	B-cell_line
II+	I-cell_line
and	I-cell_line
DM+	I-cell_line
,	I-cell_line
DO-	I-cell_line
human	I-cell_line
T	I-cell_line
cell	I-cell_line
line	I-cell_line
caused	O
the	O
accumulation	O
of	O
class	B-protein
II-CLIP	I-protein
complexes	I-protein
,	O
indicating	O
that	O
HLA-DO	B-protein
blocked	O
DM	O
function	O
in	O
vivo	O
and	O
suggesting	O
that	O
HLA-DO	B-protein
is	O
an	O
important	O
modulator	O
of	O
class	O
II-restricted	O
antigen	O
processing	O
.	O

Vitamin	B-protein
D	I-protein
receptor	I-protein
:	O
no	O
evidence	O
for	O
allele-specific	O
mRNA	O
stability	O
in	O
cells	O
which	O
are	O
heterozygous	O
for	O
the	O
Taq	B-protein
I	I-protein
restriction	I-protein
enzyme	I-protein
polymorphism	O
.	O

Allelic	O
variations	O
of	O
the	O
vitamin	B-DNA
D	I-DNA
receptor	I-DNA
(	I-DNA
VDR	I-DNA
)	I-DNA
gene	I-DNA
have	O
been	O
associated	O
with	O
the	O
risk	O
of	O
developing	O
prostate	O
cancer	O
in	O
men	O
and	O
osteoporosis	O
in	O
postmenopausal	O
women	O
.	O

Three	O
RFLPs	B-DNA
(	O
TaqI	B-DNA
,	O
ApaI	B-DNA
,	O
BsmI	B-DNA
)	O
define	O
two	O
common	O
haplotypes	O
:	O
BAt	O
and	O
baT	O
.	O

None	O
of	O
these	O
polymorphisms	B-DNA
change	O
the	O
translated	B-protein
protein	I-protein
.	O

Since	O
sequence	B-DNA
variations	I-DNA
in	O
the	O
3	B-DNA
'	I-DNA
UTR	I-DNA
of	O
VDR	B-protein
have	O
been	O
linked	O
to	O
the	O
different	O
haplotypes	O
,	O
investigators	O
have	O
proposed	O
that	O
the	O
stability	O
of	O
VDR	B-RNA
mRNA	I-RNA
is	O
influenced	O
by	O
allelic	O
variations	O
.	O

Indirect	O
evidence	O
suggested	O
that	O
allele	B-DNA
T	I-DNA
is	O
less	O
stable	O
than	O
allele	B-DNA
t	I-DNA
.	O

In	O
this	O
study	O
,	O
we	O
used	O
a	O
RT-PCR	O
based	O
approach	O
to	O
compare	O
the	O
stability	O
of	O
the	O
big	B-DNA
T	I-DNA
and	I-DNA
small	I-DNA
t	I-DNA
allele	I-DNA
in	O
normal	B-cell_type
heterozygous	I-cell_type
lymphocytes	I-cell_type
and	O
the	O
heterozygous	B-cell_line
cell	I-cell_line
lines	I-cell_line
NB4	B-cell_line
(	O
myeloid	O
leukemia	O
)	O
and	O
PC-3	B-cell_line
and	O
DU	B-cell_line
145	I-cell_line
(	O
prostate	O
cancers	O
)	O
.	O

In	O
all	O
three	O
cases	O
,	O
we	O
did	O
not	O
find	O
a	O
significant	O
difference	O
in	O
stability	O
.	O

Interestingly	O
,	O
we	O
consistently	O
observed	O
30	O
%	O
less	O
RT-PCR	B-DNA
product	I-DNA
derived	O
from	O
the	O
small	B-RNA
t	I-RNA
allele	I-RNA
mRNA	I-RNA
in	O
steady	O
state	O
,	O
a	O
finding	O
which	O
also	O
speaks	O
against	O
a	O
higher	O
stability	O
of	O
the	O
small	B-RNA
t	I-RNA
allele	I-RNA
mRNA	I-RNA
.	O

These	O
results	O
indicate	O
a	O
variation	O
in	O
transcriptional	O
regulation	O
rather	O
than	O
mRNA	O
stability	O
between	O
the	O
alleles	B-DNA
.	O

We	O
hypothesize	O
that	O
an	O
unknown	O
gene	O
or	O
genes	O
in	O
linkage	O
with	O
the	O
polymorphisms	B-DNA
is	O
(	O
are	O
)	O
responsible	O
for	O
the	O
relationship	O
between	O
risk	O
of	O
prostate	O
cancer	O
and	O
VDR	B-protein
polymorphisms	B-DNA
.	O

Replication	O
of	O
human	O
immunodeficiency	O
virus-1	O
in	O
primary	B-cell_type
human	I-cell_type
T	I-cell_type
cells	I-cell_type
is	O
dependent	O
on	O
the	O
autocrine	O
secretion	O
of	O
tumor	B-protein
necrosis	I-protein
factor	I-protein
through	O
the	O
control	O
of	O
nuclear	B-protein
factor-kappa	I-protein
B	I-protein
activation	O
.	O

Tumor	B-protein
necrosis	I-protein
factor	I-protein
(	I-protein
TNF	I-protein
)	I-protein
-alpha	I-protein
controls	O
T-cell	O
activation	O
and	O
is	O
a	O
major	O
inducer	O
of	O
human	O
immunodeficiency	O
virus	O
(	O
HIV	O
)	O
-1	O
replication	O
in	O
chronically	B-cell_type
infected	I-cell_type
cells	I-cell_type
.	O

Therefore	O
,	O
we	O
have	O
investigated	O
its	O
role	O
in	O
primary	O
cultures	O
of	O
HIV-infected	B-cell_type
human	I-cell_type
T	I-cell_type
lymphocytes	I-cell_type
by	O
using	O
neutralizing	O
anti-TNF-alpha	B-protein
antibodies	I-protein
or	O
TNF-alpha	B-protein
.	O

Primary	O
resting	O
T	O
lymphocytes	O
produced	O
TNF-alpha	B-protein
and	O
supported	O
HIV	O
replication	O
after	O
T-cell	O
receptor	O
activation	O
.	O

Addition	O
of	O
neutralizing	O
anti-TNF-alpha	B-protein
antibodies	I-protein
drastically	O
reduced	O
p24	B-protein
antigen	I-protein
release	O
and	O
prevented	O
CD4+	B-protein
cell	O
depletion	O
associated	O
with	O
infection	O
.	O

Anti-TNF-alpha	B-protein
also	O
prevented	O
nuclear	B-protein
factor-kappa	I-protein
B	I-protein
(	O
NF-kappa	B-protein
B	I-protein
)	O
activation	O
,	O
and	O
a	O
good	O
correlation	O
between	O
this	O
inhibition	O
and	O
inhibition	O
of	O
HIV	O
replication	O
was	O
observed	O
.	O

Moreover	O
,	O
supplementing	O
the	O
cultures	O
with	O
high	O
doses	O
of	O
IL-2	O
reverted	O
anti-	O
TNF-alpha	B-protein
inhibition	O
of	O
cell	O
proliferation	O
but	O
did	O
not	O
affect	O
the	O
inhibition	O
of	O
HIV	O
p24	B-protein
antigen	I-protein
release	O
or	O
NF-kappa	B-protein
B	I-protein
activation	O
in	O
the	O
same	O
cultures	O
.	O

Moreover	O
,	O
anti-TNF-alpha	B-protein
inhibited	O
HIV-1	B-DNA
long	I-DNA
terminal	I-DNA
repeat	I-DNA
(	O
LTR	B-DNA
)	O
-driven	O
transcription	O
of	O
a	O
reporter	B-DNA
gene	I-DNA
in	O
primary	B-cell_type
T	I-cell_type
cells	I-cell_type
in	O
response	O
to	O
activation	O
,	O
either	O
in	O
the	O
presence	O
or	O
the	O
absence	O
of	O
HIV-1	B-protein
Tat	I-protein
.	O

Our	O
results	O
support	O
an	O
important	O
role	O
for	O
autocrine	O
TNF-alpha	B-protein
secretion	O
in	O
controlling	O
HIV	O
replication	O
in	O
primary	B-cell_type
T	I-cell_type
cells	I-cell_type
because	O
of	O
its	O
ability	O
to	O
maintain	O
NF-kappa	B-protein
B	I-protein
elevated	O
in	O
the	O
nucleus	O
of	O
T	B-cell_type
cells	I-cell_type
.	O

Hypoxia	O
enhances	O
induction	O
of	O
endothelial	B-protein
ICAM-1	I-protein
:	O
role	O
for	O
metabolic	O
acidosis	O
and	O
proteasomes	B-protein
.	O

Intercellular	B-protein
adhesion	I-protein
molecule	I-protein
1	I-protein
(	O
ICAM-1	B-protein
)	O
is	O
an	O
important	O
molecule	O
in	O
promotion	O
of	O
polymorphonuclear	O
neutrophil	O
transendothelial	O
migration	O
during	O
inflammation	O
.	O

Coincident	O
with	O
many	O
inflammatory	O
diseases	O
is	O
tissue	O
hypoxia	O
.	O

Thus	O
we	O
hypothesized	O
that	O
combinations	O
of	O
hypoxia	O
and	O
inflammatory	O
stimuli	O
may	O
differentially	O
regulate	O
expression	O
of	O
endothelial	B-protein
ICAM-1	I-protein
.	O

Human	B-cell_type
endothelial	I-cell_type
cells	I-cell_type
were	O
exposed	O
to	O
hypoxia	O
in	O
the	O
presence	O
or	O
absence	O
of	O
added	O
lipopolysaccharide	O
(	O
LPS	O
)	O
and	O
examined	O
for	O
expression	O
of	O
functional	O
ICAM-1	B-protein
.	O

Although	O
hypoxia	O
alone	O
did	O
not	O
induce	O
ICAM-1	B-protein
,	O
the	O
combination	O
of	O
LPS	O
and	O
hypoxia	O
enhanced	O
(	O
3	O
+/-	O
0.4-fold	O
over	O
normoxia	O
)	O
ICAM-1	B-protein
expression	O
.	O

Combinations	O
of	O
hypoxia	O
and	O
LPS	O
significantly	O
increased	O
lymphocyte	O
binding	O
,	O
and	O
such	O
increases	O
were	O
inhibited	O
by	O
addition	O
of	O
anti-ICAM-1	B-protein
antibodies	I-protein
or	O
antisense	O
oligonucleotides	O
.	O

Hypoxic	O
endothelia	O
showed	O
a	O
>	O
10-fold	O
increase	O
in	O
sensitivity	O
to	O
inhibitors	O
of	O
proteasome	B-protein
activation	O
,	O
and	O
combinations	O
of	O
hypoxia	O
and	O
LPS	O
enhanced	O
proteasome	B-protein
-dependent	O
cytoplasmic-to-nuclear	O
localization	O
of	O
the	O
nuclear	B-protein
transcription	I-protein
factor-kappa	I-protein
B	I-protein
p65	I-protein
(	I-protein
Rel	I-protein
A	I-protein
)	I-protein
subunit	I-protein
.	O

Such	O
proteasome	B-protein
activation	O
correlated	O
with	O
hypoxia-evoked	O
decreases	O
in	O
both	O
extracellular	O
and	O
intracellular	O
pH	O
.	O

We	O
conclude	O
from	O
these	O
studies	O
that	O
endothelial	O
hypoxia	O
provides	O
a	O
novel	O
,	O
proteasome	B-protein
-dependent	O
stimulus	O
for	O
ICAM-1	B-protein
induction	O
.	O

Differanisole	O
A	O
,	O
a	O
novel	O
antitumor	O
antibiotic	O
,	O
enhances	O
growth	O
inhibition	O
and	O
differentiation	O
of	O
human	B-cell_type
myeloid	I-cell_type
leukemia	I-cell_type
cells	I-cell_type
induced	O
by	O
9-cis	O
retinoic	O
acid	O
.	O

Differanisole	O
A	O
,	O
3	O
,	O
5-dichloro-2-hydroxy-4-methoxy-6-n-propylbenzoic	O
acid	O
,	O
inhibited	O
growth	O
of	O
human	B-cell_type
myeloid	I-cell_type
leukemia	I-cell_type
cells	I-cell_type
.	O

The	O
compound	O
induced	O
G1	O
arrest	O
and	O
granulocytic	O
differentiation	O
of	O
HL-60	B-cell_line
cells	I-cell_line
,	O
although	O
the	O
differentiation-inducing	O
effect	O
was	O
modest	O
.	O

Differanisole	O
A	O
and	O
9-cis	O
retinoic	O
acid	O
(	O
9cisRA	O
)	O
synergistically	O
inhibited	O
the	O
growth	O
and	O
induced	O
functional	O
and	O
morphologic	O
differentiation	O
of	O
HL-60	B-cell_line
and	I-cell_line
NB4	I-cell_line
cells	I-cell_line
,	O
whereas	O
the	O
combined	O
treatment	O
with	O
differanisole	O
A	O
and	O
all-trans	O
retinoic	O
acid	O
or	O
1alpha	O
,	O
25-dihydroxyvitamin	O
D3	O
was	O
less	O
effective	O
.	O

Similar	O
results	O
were	O
obtained	O
in	O
primary	O
culture	O
of	O
leukemia	B-cell_type
cells	I-cell_type
from	O
a	O
patient	O
with	O
acute	O
promyelocytic	O
leukemia	O
.	O

The	O
synergistic	O
effect	O
on	O
growth	O
inhibition	O
and	O
induction	O
of	O
differentiation	O
required	O
simultaneous	O
treatment	O
with	O
differanisole	O
A	O
and	O
9cisRA	O
.	O

Differanisole	O
A	O
and	O
an	O
RXR-specific	O
ligand	O
(	O
Ro47-5944	O
)	O
cooperatively	O
inhibited	O
the	O
cell	O
growth	O
,	O
while	O
the	O
combined	O
effect	O
of	O
differanisole	O
A	O
and	O
an	O
RAR-specific	O
ligand	O
Am80	O
was	O
just	O
additive	O
.	O

Differanisole	O
A	O
in	O
combination	O
with	O
9cisRA	O
may	O
have	O
implications	O
for	O
therapy	O
of	O
acute	O
promyelocytic	O
leukemia	O
patients	O
.	O

The	O
activation	O
of	O
the	O
JAK2	B-protein
/STAT5	B-protein
pathway	O
is	O
commonly	O
involved	O
in	O
signaling	O
through	O
the	O
human	B-protein
IL-5	I-protein
receptor	I-protein
.	O

The	O
JAK	B-protein
(	I-protein
Janus	I-protein
kinase	I-protein
)	I-protein
family	I-protein
of	O
protein	B-protein
tyrosine	I-protein
kinases	I-protein
and	O
the	O
STATs	B-protein
(	O
signal	B-protein
transducers	I-protein
and	I-protein
activators	I-protein
of	I-protein
transcription	I-protein
)	O
have	O
been	O
shown	O
to	O
be	O
activated	O
in	O
response	O
to	O
a	O
number	O
of	O
cytokines	B-protein
and	O
growth	B-protein
factors	I-protein
.	O

In	O
this	O
study	O
,	O
we	O
evaluated	O
the	O
activation	O
of	O
JAK	B-protein
/STAT	B-protein
pathway	O
upon	O
human	B-protein
interleukin-5	I-protein
(	O
hIL-5	B-protein
)	O
stimulation	O
of	O
two	O
different	O
hIL-5-responsive	B-cell_line
cell	I-cell_line
lines	I-cell_line
,	O
hIL-5	B-cell_line
receptor	I-cell_line
alpha-subunit	I-cell_line
(	I-cell_line
hIL-5R	I-cell_line
alpha	I-cell_line
)	I-cell_line
cDNA-transfected	I-cell_line
TF-1	I-cell_line
(	O
TF-h5R	B-cell_line
alpha	I-cell_line
)	O
and	O
butyric-acid-treated	B-cell_line
YY-1	I-cell_line
(	O
YY-Bu	B-cell_line
)	O
,	O
and	O
peripheral	B-cell_line
eosinophils	I-cell_line
.	O

Immunoprecipitation	O
and	O
electrophoretic	O
mobility	O
shift	O
analysis	O
revealed	O
that	O
tyrosine	O
phosphorylation	O
of	O
JAK2	B-protein
and	O
activation	O
of	O
STAT5	B-protein
were	O
induced	O
upon	O
stimulation	O
with	O
hIL-5	B-protein
in	O
all	O
three	O
cell	O
types	O
,	O
while	O
STAT1	B-protein
activation	O
was	O
only	O
observed	O
in	O
eosinophils	B-cell_type
.	O

These	O
results	O
indicate	O
that	O
JAK2	B-protein
/STAT5	B-protein
activation	O
is	O
a	O
common	O
JAK	B-protein
/STAT	B-protein
pathway	O
for	O
hIL-5	B-protein
-mediated	O
signal	O
in	O
these	O
cells	O
.	O

Dysregulation	O
of	O
monocytic	B-protein
nuclear	I-protein
factor-kappa	I-protein
B	I-protein
by	O
oxidized	O
low-density	B-protein
lipoprotein	I-protein
.	O

Nuclear	B-protein
factor-kappa	I-protein
B	I-protein
(	I-protein
NF-kappa	I-protein
B	I-protein
)	I-protein
/Rel	I-protein
transcription	I-protein
factors	I-protein
may	O
be	O
involved	O
in	O
atherosclerosis	O
,	O
as	O
is	O
suggested	O
by	O
the	O
presence	O
of	O
activated	O
NF-kappa	B-protein
B	I-protein
in	O
human	O
atherosclerotic	O
lesions	O
.	O

The	O
aim	O
of	O
the	O
present	O
study	O
was	O
to	O
investigate	O
the	O
effects	O
of	O
oxidized	B-protein
LDL	I-protein
(	O
oxLDL	B-protein
)	O
on	O
the	O
NF-kappa	B-protein
B	I-protein
system	O
in	O
human	O
THP-1	B-cell_line
monocytic	I-cell_line
cells	I-cell_line
as	O
well	O
as	O
adherent	B-cell_type
monocytes	I-cell_type
.	O

Our	O
results	O
demonstrate	O
that	O
short-term	O
incubation	O
of	O
these	O
cells	O
with	O
oxLDL	B-protein
activated	I-protein
p50/p65	I-protein
containing	O
NF-kappa	B-protein
B	I-protein
dimers	I-protein
and	O
induced	O
the	O
expression	O
of	O
the	O
target	B-DNA
gene	I-DNA
IL-8	I-DNA
.	O

This	O
activation	O
of	O
NF-kappa	B-protein
B	I-protein
was	O
inhibited	O
by	O
the	O
antioxidant	O
and	O
H2O2	O
scavenger	O
pyrrolidine	O
dithiocarbamate	O
and	O
the	O
proteasome	B-protein
inhibitor	O
PSI	O
.	O

The	O
oxLDL	B-protein
-induced	O
NF-kappa	B-protein
B	I-protein
activation	O
was	O
accompanied	O
by	O
an	O
initial	O
depletion	O
of	O
I	B-protein
kappa	I-protein
B-alpha	I-protein
followed	O
by	O
a	O
slight	O
transient	O
increase	O
in	O
the	O
level	O
of	O
this	O
inhibitor	O
protein	O
.	O

In	O
contrast	O
,	O
long-term	O
treatment	O
with	O
oxLDL	B-protein
prevented	O
the	O
lipopolysaccharide-induced	O
depletion	O
of	O
I	B-protein
kappa	I-protein
B-alpha	I-protein
,	O
accompanied	O
by	O
an	O
inhibition	O
of	O
both	O
NF-kappa	B-protein
B	I-protein
activation	O
and	O
the	O
expression	O
of	O
tumor	B-DNA
necrosis	I-DNA
factor-alpha	I-DNA
and	I-DNA
interleukin-1	I-DNA
beta	I-DNA
genes	I-DNA
.	O

These	O
observations	O
provide	O
additional	O
evidence	O
that	O
oxLDL	B-protein
is	O
a	O
potent	O
modulator	O
of	O
gene	O
expression	O
and	O
suggest	O
that	O
(	O
dys	O
)	O
regulation	O
of	O
NF-kappa	B-protein
B/Rel	I-protein
is	O
likely	O
to	O
play	O
an	O
important	O
role	O
in	O
atherogenesis	O
.	O

Suppression	O
of	O
nuclear	B-protein
factor	I-protein
kappa	I-protein
B	I-protein
and	O
CD18	B-protein
-mediated	O
leukocyte	O
adhesion	O
to	O
the	O
corneal	O
endothelium	O
by	O
dexamethasone	O
.	O

PURPOSE	O
:	O
To	O
demonstrate	O
that	O
leukocyte	O
adhesion	O
to	O
cultured	B-cell_line
corneal	I-cell_line
endothelial	I-cell_line
cells	I-cell_line
is	O
mediated	O
by	O
the	O
CD18	B-protein
antigen	I-protein
,	O
and	O
to	O
determine	O
whether	O
dexamethasone	O
directly	O
suppresses	O
adhesion	O
by	O
inhibiting	O
activation	O
of	O
nuclear	B-protein
factor	I-protein
kappa	I-protein
B	I-protein
(	O
NFkappaB	B-protein
)	O
.	O

METHODS	O
:	O
Cultured	O
bovine	O
corneal	O
endothelium	O
was	O
stimulated	O
for	O
6	O
hours	O
by	O
40	O
micron/ml	O
tumor	B-protein
necrosis	I-protein
factor	I-protein
alpha	I-protein
(	O
TNFalpha	B-protein
)	O
.	O

Dexamethasone	O
was	O
added	O
1	O
hour	O
before	O
TNFalpha	B-protein
stimulation	O
in	O
the	O
dexamethasone	O
group	O
.	O

After	O
stimulation	O
,	O
neutrophils	O
separated	O
from	O
a	O
healthy	O
human	O
volunteer	O
were	O
added	O
with	O
or	O
without	O
anti-CD18	B-protein
antibody	I-protein
.	O

The	O
culture	O
plate	O
was	O
settled	O
for	O
15	O
minutes	O
at	O
37	O
degrees	O
C	O
,	O
and	O
then	O
neutrophils	B-cell_type
were	O
activated	O
by	O
N-formyl-methionyl-leucyl-phenylalanine	O
for	O
5	O
minutes	O
.	O

Nonadherent	O
neutrophils	B-cell_type
were	O
removed	O
by	O
sealing	O
and	O
inverting	O
the	O
culture	O
well	O
.	O

The	O
intracellular	O
localization	O
of	O
NFkappaB	B-protein
after	O
TNFalpha	B-protein
simulation	O
was	O
determined	O
by	O
confocal	O
immunocytochemistry	O
using	O
an	O
anti-p65	B-protein
antibody	I-protein
.	O

RESULTS	O
:	O
Neutrophil	O
adhesion	O
to	O
cultured	B-cell_line
corneal	I-cell_line
endothelial	I-cell_line
cells	I-cell_line
increased	O
significantly	O
on	O
exposure	O
to	O
TNFalpha	B-protein
(	O
451.4+/-45.4	O
cells/mm2	O
,	O
n	O
=	O
16	O
)	O
compared	O
to	O
control	O
(	O
156.7+/-27.3	O
cells/mm2	O
,	O
n	O
=	O
16	O
,	O
P	O
<	O
0.01	O
)	O
.	O

This	O
increased	O
adhesion	O
was	O
suppressed	O
by	O
the	O
addition	O
of	O
anti-CD18	B-protein
antibody	I-protein
(	O
157.6+/-25.1	O
cells/mm2	O
,	O
n	O
=	O
8	O
,	O
P	O
<	O
0.01	O
)	O
and	O
by	O
pretreatment	O
with	O
10	O
(	O
-7	O
)	O
M	O
dexamethasone	O
(	O
207.9+/-31.5	O
cells/mm2	O
,	O
n	O
=	O
10	O
,	O
P	O
<	O
0.01	O
)	O
.	O

Immunocytochemistry	O
60	O
minutes	O
after	O
stimulation	O
revealed	O
that	O
NFkappaB	B-protein
was	O
located	O
in	O
the	O
cytoplasm	O
in	O
unstimulated	B-cell_type
cells	I-cell_type
;	O
however	O
,	O
the	O
addition	O
of	O
TNFalpha	B-protein
caused	O
NFkappaB	B-protein
to	O
translocate	O
into	O
the	O
nucleus	O
.	O

Pretreatment	O
with	O
dexamethasone	O
tapered	O
NFkappaB	B-protein
translocation	O
into	O
the	O
nucleus	O
.	O

CONCLUSIONS	O
:	O
Leukocyte	O
adhesion	O
to	O
the	O
corneal	O
endothelium	O
was	O
shown	O
to	O
be	O
mediated	O
by	O
CD18	B-protein
expressed	O
on	O
activated	B-cell_type
leukocytes	I-cell_type
.	O

Pretreatment	O
of	O
the	O
endothelium	O
with	O
dexamethasone	O
inhibited	O
leukocyte	O
adhesion	O
;	O
this	O
may	O
be	O
due	O
in	O
part	O
to	O
the	O
suppression	O
of	O
NFkappaB	B-protein
entry	O
into	O
the	O
nucleus	O
.	O

Molecular	O
characterization	O
and	O
pattern	O
of	O
tissue	O
expression	O
of	O
the	O
gene	O
for	O
neutrophil	B-protein
gelatinase-associated	I-protein
lipocalin	I-protein
from	O
humans	O
.	O

Neutrophil	B-protein
gelatinase-associated	I-protein
lipocalin	I-protein
(	O
NGAL	B-protein
)	O
is	O
a	O
25-kDa	B-protein
lipocalin	I-protein
first	O
identified	O
as	O
a	O
protein	O
stored	O
in	O
specific	O
granules	O
of	O
the	O
human	B-cell_type
neutrophil	I-cell_type
.	O

The	O
protein	O
is	O
believed	O
to	O
bind	O
small	O
lipophilic	O
substances	O
such	O
as	O
bacterial	O
derived	O
formylpeptides	O
and	O
lipopolysaccharides	O
(	O
LPS	O
)	O
and	O
might	O
function	O
as	O
a	O
modulator	O
of	O
inflammation	O
.	O

To	O
characterize	O
the	O
regulation	O
of	O
NGAL	B-protein
further	O
,	O
we	O
have	O
cloned	O
and	O
sequenced	O
a	O
5869-bp	B-DNA
region	I-DNA
of	O
the	O
NGAL	B-DNA
gene	I-DNA
including	O
1695	O
bp	O
of	O
the	O
5	B-DNA
'	I-DNA
nontranscribed	I-DNA
region	I-DNA
and	O
a	O
3696-bp	B-DNA
coding	I-DNA
region	I-DNA
encompassing	O
seven	B-DNA
exons	I-DNA
and	I-DNA
six	I-DNA
introns	I-DNA
.	O

The	O
transcriptional	B-DNA
start	I-DNA
sites	I-DNA
were	O
identified	O
by	O
an	O
RNase	B-protein
protection	O
assay	O
.	O

The	O
NGAL	B-protein
gene	O
is	O
highly	O
homologous	O
to	O
the	O
mouse	B-DNA
gene	I-DNA
24p3	I-DNA
.	O

NGAL	B-protein
was	O
expressed	O
in	O
bone	O
marrow	O
and	O
in	O
tissues	O
that	O
are	O
prone	O
to	O
exposure	O
to	O
microorganisms	O
.	O

Potential	O
cis-acting	B-DNA
elements	I-DNA
were	O
identified	O
in	O
the	O
promoter	B-DNA
region	I-DNA
of	O
the	O
NGAL	B-DNA
gene	I-DNA
by	O
computer	O
analysis	O
and	O
include	O
binding	B-DNA
sites	I-DNA
for	O
CTF/CBP	B-protein
,	O
the	O
hematopoietic	B-protein
transcription	I-protein
factors	I-protein
GATA-1	B-protein
and	O
PU.1	B-protein
,	O
and	O
the	O
LPS-inducible	B-protein
factor	I-protein
NF-kappa	I-protein
B	I-protein
.	O

Human	B-cell_type
neutrophils	I-cell_type
express	O
GH-N	B-RNA
gene	I-RNA
transcripts	I-RNA
and	O
the	O
pituitary	B-protein
transcription	I-protein
factor	I-protein
Pit-1b	B-protein
.	O

Since	O
GH	B-protein
stimulates	O
the	O
development	O
and	O
function	O
of	O
granulocytes	B-cell_type
,	O
we	O
investigated	O
the	O
expression	O
of	O
GH	B-protein
in	O
granulocyte	B-cell_type
subsets	I-cell_type
.	O

By	O
immunocytochemistry	O
,	O
25	O
+/-	O
7	O
%	O
of	O
the	O
human	B-cell_type
neutrophils	I-cell_type
were	O
shown	O
to	O
express	O
immunoreactive	B-protein
GH	I-protein
,	O
whereas	O
eosinophils	B-cell_type
were	O
negative	O
.	O

Reversed	O
transcription	O
(	O
RT	O
)	O
-PCR	O
analysis	O
demonstrated	O
GH	B-RNA
mRNA	I-RNA
in	O
neutrophils	B-cell_type
.	O

Restriction	O
analysis	O
revealed	O
that	O
neutrophils	B-cell_type
express	O
the	O
GH-N	B-DNA
gene	I-DNA
but	O
not	O
the	O
GH-V	B-DNA
gene	I-DNA
.	O

Furthermore	O
,	O
we	O
demonstrated	O
by	O
western	O
blot	O
analysis	O
that	O
neutrophils	B-cell_type
express	O
an	O
alternatively	O
spliced	O
variant	O
of	O
the	O
pituitary	B-protein
transcription	I-protein
factor	I-protein
Pit-1	B-protein
,	O
designated	O
Pit-1b	B-protein
.	O

The	O
ability	O
of	O
BHRF1	B-protein
to	O
inhibit	O
apoptosis	O
is	O
dependent	O
on	O
stimulus	O
and	O
cell	O
type	O
.	O

The	O
development	O
of	O
resistance	O
to	O
host	O
defense	O
mechanisms	O
such	O
as	O
tumor	O
necrosis	O
factor	O
(	O
TNF	O
)	O
-	O
and	O
Fas-mediated	O
apoptosis	O
of	O
transformed	B-cell_type
or	O
virus-infected	B-cell_type
cells	I-cell_type
may	O
be	O
a	O
critical	O
component	O
in	O
the	O
development	O
of	O
disease	O
.	O

To	O
find	O
genes	O
that	O
protect	O
cells	O
from	O
apoptosis	O
,	O
we	O
used	O
an	O
expression	O
cloning	O
strategy	O
and	O
identified	O
BHRF1	B-protein
,	O
an	O
Epstein-Barr	B-protein
virus	I-protein
(	I-protein
EBV	I-protein
)	I-protein
early-lytic-cycle	I-protein
protein	I-protein
with	O
distant	O
homology	O
to	O
Bcl-2	B-protein
,	O
as	O
an	O
anti-apoptosis	B-protein
protein	I-protein
.	O

Expression	O
of	O
BHRF1	B-protein
in	O
MCF-Fas	B-cell_line
cells	I-cell_line
conferred	O
nearly	O
complete	O
resistance	O
against	O
both	O
anti-Fas	B-protein
antibody	I-protein
and	O
TNF-mediated	O
apoptosis	O
.	O

In	O
addition	O
,	O
BHRF1	B-protein
protected	O
these	O
cells	O
from	O
monocyte-mediated	O
killing	O
but	O
failed	O
to	O
protect	O
them	O
from	O
killing	O
mediated	O
by	O
lymphokine-activated	B-cell_type
killer	I-cell_type
cells	I-cell_type
.	O

The	O
ability	O
of	O
BHRF1	B-protein
to	O
protect	O
MCF-Fas	B-cell_line
cells	I-cell_line
from	O
apoptosis	O
induced	O
by	O
various	O
stimuli	O
was	O
identical	O
to	O
that	O
of	O
Bcl-2	B-protein
and	O
Bcl-xL	B-protein
.	O

Moreover	O
,	O
the	O
mechanism	O
of	O
action	O
of	O
BHRF1	B-protein
resembled	O
that	O
of	O
Bcl-2	B-protein
and	O
Bcl-xL	B-protein
as	O
it	O
inhibited	O
TNF-	O
and	O
anti-Fas-induced	O
activation	O
of	O
two	O
enzymes	O
participating	O
in	O
the	O
apoptosis	O
pathway	O
,	O
cytosolic	B-protein
phospholipase	I-protein
A2	I-protein
and	O
caspase-3/CPP32	B-protein
,	O
but	O
did	O
not	O
interfere	O
with	O
the	O
activation	O
of	O
NF-kappaB-like	B-protein
transcription	I-protein
factors	I-protein
.	O

A	O
putative	O
function	O
of	O
BHRF1	B-protein
in	O
EBV-infected	B-cell_type
epithelial	I-cell_type
cells	I-cell_type
may	O
be	O
to	O
protect	O
virus-infected	O
cells	O
from	O
TNF-	O
and/or	O
anti-Fas-	O
induced	O
cell	O
death	O
in	O
order	O
to	O
maximize	O
virus	O
production	O
.	O

Surprisingly	O
,	O
expression	O
of	O
neither	O
BHRF1	B-protein
nor	O
Bcl-2	B-protein
in	O
a	O
B-cell	B-cell_line
line	I-cell_line
,	O
BJAB	B-cell_line
,	O
protected	O
the	O
cells	O
from	O
anti-Fas-mediated	O
apoptosis	O
even	O
though	O
they	O
increased	O
the	O
survival	O
of	O
serum-starved	B-cell_type
cells	I-cell_type
.	O

Thus	O
,	O
the	O
protective	O
role	O
of	O
BHRF1	B-protein
against	O
apoptosis	O
resembles	O
that	O
of	O
Bcl-2	B-protein
in	O
being	O
cell	O
type	O
specific	O
and	O
dependent	O
on	O
the	O
apoptotic	O
stimulus	O
.	O

Genomic	O
organization	O
,	O
sequence	O
,	O
and	O
transcriptional	O
regulation	O
of	O
the	O
human	B-DNA
eotaxin	I-DNA
gene	I-DNA
.	O

Eotaxin	B-protein
is	O
an	O
eosinophil	B-protein
specific	I-protein
beta-chemokine	I-protein
assumed	O
to	O
be	O
involved	O
in	O
eosinophilic	O
inflammatory	O
diseases	O
such	O
as	O
atopic	O
dermatitis	O
,	O
allergic	O
rhinitis	O
,	O
asthma	O
and	O
parasitic	O
infections	O
.	O

Its	O
expression	O
is	O
stimulus-	O
and	O
cell-specific	O
.	O

We	O
here	O
describe	O
the	O
genomic	O
organisation	O
(	O
3	O
exons	B-DNA
of	O
132	O
,	O
112	O
and	O
542	O
bp	O
and	O
2	O
introns	B-DNA
of	O
1211	O
and	O
378	O
bp	O
)	O
and	O
sequence	O
including	O
3	O
kb	O
of	O
DNA	O
from	O
the	O
immediate	O
5	B-DNA
'	I-DNA
upstream	I-DNA
region	I-DNA
of	O
the	O
human	B-DNA
eotaxin	I-DNA
gene	I-DNA
.	O

Among	O
the	O
regulatory	B-DNA
promoter	I-DNA
elements	I-DNA
potentially	O
regulating	O
eotaxin	B-DNA
gene	I-DNA
expression	O
and/or	O
mediating	O
the	O
effects	O
of	O
anti-inflammatory	O
drugs	O
we	O
identified	O
consensus	B-DNA
sequences	I-DNA
known	O
to	O
interact	O
with	O
nuclear	B-protein
factors	I-protein
like	O
NF-IL6	B-protein
,	O
AP-1	B-protein
,	O
a	O
NF-kappa-B	B-DNA
like	I-DNA
consensus	I-DNA
sequence	I-DNA
and	O
gamma-interferon-	B-DNA
as	I-DNA
well	I-DNA
as	I-DNA
glucocorticoid	I-DNA
response	I-DNA
elements	I-DNA
.	O

Differential	O
interaction	O
of	O
nuclear	B-protein
factors	I-protein
with	O
the	O
leukocyte-specific	B-DNA
pp52	I-DNA
promoter	I-DNA
in	O
B	B-cell_type
and	I-cell_type
T	I-cell_type
cells	I-cell_type
.	O

The	O
leukocyte-specific	O
,	O
cytoskeleton-binding	O
pp52	O
(	O
LSP-1	O
,	O
WP-34	O
)	O
protein	O
is	O
widely	O
expressed	O
in	O
multiple	O
leukocyte	O
lineages	O
,	O
including	O
B	B-cell_type
and	I-cell_type
T	I-cell_type
lymphocytes	I-cell_type
,	O
granulocytes	B-cell_type
,	O
and	O
macrophages	B-cell_type
.	O

We	O
previously	O
detected	O
a	O
tissue-specific	B-DNA
promoter	I-DNA
preceding	O
the	O
exon	O
encoding	O
the	O
N	B-protein
terminus	I-protein
of	O
the	O
pp52	B-protein
leukocyte	I-protein
protein	I-protein
.	O

Here	O
we	O
describe	O
the	O
functional	O
characterization	O
of	O
this	O
promoter	O
and	O
identification	O
of	O
the	O
factors	O
in	O
B	B-cell_type
and	I-cell_type
T	I-cell_type
cells	I-cell_type
that	O
regulate	O
its	O
activity	O
.	O

The	O
pp52	B-DNA
promoter	I-DNA
contains	O
an	O
initiator	O
specifying	O
the	O
unique	O
5	B-DNA
'	I-DNA
terminus	I-DNA
of	O
pp52	B-RNA
mRNA	I-RNA
,	O
tandem	O
pairs	O
of	O
Ets	B-DNA
and	I-DNA
SP1	I-DNA
motifs	I-DNA
,	O
and	O
a	O
lone	B-DNA
C/EBP	I-DNA
motif	I-DNA
.	O

All	O
these	O
motifs	O
are	O
essential	O
and	O
collectively	O
control	O
transcriptional	O
activity	O
.	O

DNA	O
binding	O
studies	O
and	O
Ab	O
supershift	O
assays	O
revealed	O
that	O
different	O
combinations	O
of	O
factors	O
interact	O
with	O
these	O
motifs	O
in	O
B	B-cell_type
cells	I-cell_type
vs	O
T	B-cell_type
cells	I-cell_type
.	O

The	O
Ets	B-DNA
motifs	I-DNA
are	O
preferentially	O
bound	O
by	O
PU-1	B-protein
in	O
B	O
cell	O
extracts	O
from	O
all	O
stages	O
of	O
development	O
,	O
whereas	O
a	O
different	O
Ets	B-protein
family	I-protein
member	I-protein
reacts	O
with	O
these	O
motifs	O
in	O
T	O
cell	O
extracts	O
.	O

The	O
C/EBP	B-DNA
motif	I-DNA
is	O
bound	O
by	O
Ig/EBP-1	B-protein
in	O
pre-B	O
cell	O
and	O
T	O
cell	O
extracts	O
,	O
but	O
is	O
replaced	O
by	O
nuclear	B-protein
factor-IL-6beta	I-protein
or	O
a	O
nuclear	B-protein
factor-IL-6beta-Ig/EBP-1	I-protein
heterodimer	I-protein
in	O
plasmacytoma	O
cell	O
extracts	O
.	O

Despite	O
its	O
reported	O
role	O
as	O
a	O
negative	O
regulator	O
of	O
transcription	O
,	O
Ig/EBP-1	B-protein
appears	O
to	O
exert	O
a	O
stimulatory	O
effect	O
on	O
this	O
promoter	B-DNA
.	O

These	O
findings	O
reveal	O
the	O
features	O
controlling	O
the	O
pp52	B-DNA
promoter	I-DNA
in	O
B	B-cell_type
and	I-cell_type
T	I-cell_type
cells	I-cell_type
and	O
provide	O
the	O
foundation	O
for	O
determining	O
the	O
regulation	O
of	O
this	O
promoter	B-DNA
in	O
other	O
leukocyte	B-cell_type
lineages	I-cell_type
.	O

Regulation	O
of	O
B-cell	O
commitment	O
to	O
plasma	B-cell_type
cells	I-cell_type
or	O
to	O
memory	B-cell_type
B	I-cell_type
cells	I-cell_type
.	O

During	O
humoral	O
immune	O
responses	O
,	O
B-lymphocyte	O
activation	O
is	O
followed	O
by	O
differentiation	O
along	O
either	O
the	O
plasma	O
cell	O
pathway	O
or	O
the	O
memory	O
B-cell	O
pathway	O
.	O

Recent	O
studies	O
suggest	O
that	O
CD40-CD40	B-protein
ligand	I-protein
,	O
OX-OX40	B-protein
ligand	I-protein
,	O
a	O
group	O
of	O
cytokines	B-protein
and	O
intracellular	O
transcriptional	O
factors	O
may	O
all	O
contribute	O
to	O
B-lymphocyte	O
differentiation	O
control	O
.	O

Transcription	B-protein
factor	I-protein
binding	O
sites	O
downstream	O
of	O
the	O
human	B-DNA
immunodeficiency	I-DNA
virus	I-DNA
type	I-DNA
1	I-DNA
transcription	I-DNA
start	I-DNA
site	I-DNA
are	O
important	O
for	O
virus	O
infectivity	O
.	O

When	O
transcriptionally	O
active	O
,	O
the	O
human	O
immunodeficiency	O
virus	O
(	O
HIV	O
)	O
promoter	B-DNA
contains	O
a	O
nucleosome-free	O
region	O
encompassing	O
both	O
the	O
promoter/enhancer	B-DNA
region	I-DNA
and	O
a	O
large	O
region	O
(	O
255	B-DNA
nucleotides	I-DNA
[	O
nt	O
]	O
)	O
downstream	O
of	O
the	O
transcription	B-DNA
start	I-DNA
site	I-DNA
.	O

We	O
have	O
previously	O
identified	O
new	O
binding	O
sites	O
for	O
transcription	B-protein
factors	I-protein
downstream	O
of	O
the	O
transcription	B-DNA
start	I-DNA
site	I-DNA
(	O
nt	B-DNA
465	I-DNA
to	I-DNA
720	I-DNA
)	O
:	O
three	O
AP-1	B-DNA
sites	I-DNA
(	O
I	O
,	O
II	O
,	O
and	O
III	O
)	O
,	O
an	O
AP3-like	B-DNA
motif	I-DNA
(	O
AP3-L	B-DNA
)	O
,	O
a	O
downstream	B-DNA
binding	I-DNA
factor	I-DNA
(	I-DNA
DBF	I-DNA
)	I-DNA
site	I-DNA
,	O
and	O
juxtaposed	B-DNA
Sp1	I-DNA
sites	I-DNA
.	O

Here	O
,	O
we	O
show	O
that	O
the	O
DBF	B-DNA
site	I-DNA
is	O
an	O
interferon-responsive	B-DNA
factor	I-DNA
(	I-DNA
IRF	I-DNA
)	I-DNA
binding	I-DNA
site	I-DNA
and	O
that	O
the	O
AP3-L	B-DNA
motif	I-DNA
binds	O
the	O
T-cell-specific	B-protein
factor	I-protein
NF-AT	B-protein
.	O

Mutations	O
that	O
abolish	O
the	O
binding	O
of	O
each	O
factor	O
to	O
its	O
cognate	O
site	O
are	O
introduced	O
in	O
an	O
infectious	O
HIV-1	O
molecular	O
clone	O
to	O
study	O
their	O
effect	O
on	O
HIV-1	O
transcription	O
and	O
replication	O
.	O

Individual	O
mutation	O
of	O
the	O
DBF	O
or	O
AP3-L	B-DNA
site	O
as	O
well	O
as	O
the	O
double	O
mutation	B-DNA
AP-1	I-DNA
(	I-DNA
III	I-DNA
)	I-DNA
/AP3-L	I-DNA
did	O
not	O
affect	O
HIV-1	O
replication	O
compared	O
to	O
that	O
of	O
the	O
wild-type	O
virus	O
.	O

In	O
contrast	O
,	O
proviruses	O
carrying	O
mutations	O
in	O
the	O
Sp1	B-DNA
sites	I-DNA
were	O
totally	O
defective	O
in	O
terms	O
of	O
replication	O
.	O

Virus	O
production	O
occurred	O
with	O
slightly	O
delayed	O
kinetics	O
for	O
viruses	O
containing	O
combined	O
mutations	O
in	O
the	O
AP-1	B-DNA
(	I-DNA
III	I-DNA
)	I-DNA
,	O
AP3-L	B-DNA
,	O
and	O
DBF	B-DNA
sites	I-DNA
and	O
in	O
the	O
AP3-L	B-DNA
and	O
DBF-sites	B-DNA
,	O
whereas	O
viruses	O
mutated	O
in	O
the	O
AP-1	B-DNA
(	I-DNA
I	I-DNA
,	I-DNA
II	I-DNA
,	I-DNA
III	I-DNA
)	I-DNA
and	O
AP3-L	B-DNA
sites	I-DNA
and	O
in	O
the	O
AP-1	O
(	O
I	O
,	O
II	O
,	O
III	O
)	O
,	O
AP3-L	B-DNA
,	O
and	O
DBF	B-DNA
sites	I-DNA
exhibited	O
a	O
severely	O
defective	O
replicative	O
phenotype	O
.	O

No	O
RNA-packaging	O
defect	O
could	O
be	O
measured	O
for	O
any	O
of	O
the	O
mutant	O
viruses	O
as	O
determined	O
by	O
quantification	O
of	O
their	O
HIV	B-RNA
genomic	I-RNA
RNA	I-RNA
.	O

Measurement	O
of	O
the	O
transcriptional	O
activity	O
of	O
the	O
HIV-1	B-DNA
promoter	I-DNA
after	O
transient	O
transfection	O
of	O
the	O
HIV-1	B-DNA
provirus	I-DNA
DNA	I-DNA
or	O
of	O
long	B-DNA
terminal	I-DNA
repeat-luciferase	I-DNA
constructs	I-DNA
showed	O
a	O
positive	O
correlation	O
between	O
the	O
transcriptional	O
and	O
the	O
replication	O
defects	O
for	O
most	O
mutants	O
.	O

Glucocorticoid	B-protein
receptor	I-protein
regulates	O
expression	O
of	O
L-selectin	B-protein
and	O
CD11/CD18	B-protein
on	O
human	B-cell_type
neutrophils	I-cell_type
[	O
see	O
comments	O
]	O

BACKGROUND	O
:	O
Recent	O
studies	O
have	O
raised	O
the	O
hypothesis	O
that	O
glucocorticoids	O
could	O
diminish	O
the	O
ability	O
of	O
endothelial	B-cell_type
cells	I-cell_type
to	O
direct	O
leukocyte	O
traffic	O
into	O
inflamed	O
tissues	O
by	O
inhibiting	O
expression	O
of	O
the	O
adhesion	B-protein
molecules	I-protein
endothelial-leukocyte	B-protein
adhesion	I-protein
molecule-1	I-protein
and	O
intercellular	B-protein
adhesion	I-protein
molecule-1	I-protein
.	O

The	O
aim	O
of	O
the	O
present	O
study	O
was	O
to	O
investigate	O
whether	O
glucocorticoids	O
also	O
regulate	O
the	O
expression	O
of	O
L-selectin	B-protein
and	O
CD11/CD18	B-protein
integrins	B-protein
on	O
human	B-cell_type
neutrophil	I-cell_type
granulocytes	I-cell_type
.	O

METHODS	O
AND	O
RESULTS	O
:	O
Incubation	O
of	O
human	O
whole	O
blood	O
with	O
platelet-activating	B-protein
factor	I-protein
(	O
PAF	B-protein
,	O
1	O
mumol/L	O
)	O
evoked	O
downregulation	O
of	O
L-selectin	B-protein
and	O
upregulation	O
of	O
CD11/CD18	B-protein
adhesion	B-protein
receptors	I-protein
on	O
neutrophils	O
as	O
measured	O
by	O
flow	O
cytometry	O
.	O

While	O
dexamethasone	O
(	O
0.1	O
nmol/L	O
to	O
100	O
mumol/L	O
)	O
did	O
not	O
affect	O
expression	O
of	O
adhesion	B-protein
molecules	I-protein
on	O
resting	B-cell_type
neutrophils	I-cell_type
,	O
it	O
attenuated	O
the	O
PAF	B-protein
-induced	O
changes	O
in	O
L-selectin	B-protein
and	O
CD18	B-protein
expression	O
in	O
a	O
time-	O
and	O
concentration-dependent	O
fashion	O
with	O
IC50	O
values	O
of	O
31	O
and	O
13	O
nmol/L	O
,	O
respectively	O
.	O

These	O
effects	O
of	O
dexamethasone	O
were	O
completely	O
aborted	O
by	O
RU-486	O
(	O
10	O
mumol/L	O
)	O
,	O
which	O
blocks	O
transcriptional	O
activation	O
of	O
the	O
glucocorticoid	B-protein
receptor	I-protein
,	O
and	O
by	O
the	O
protein	O
synthesis	O
inhibitor	O
cycloheximide	O
(	O
35.5	O
mumol/L	O
)	O
.	O

Dexamethasone	O
,	O
up	O
to	O
a	O
concentration	O
of	O
1	O
mumol/L	O
,	O
neither	O
affected	O
significantly	O
the	O
release	O
of	O
granule	B-protein
enzymes	I-protein
nor	O
interfered	O
with	O
PAF	B-protein
binding	O
to	O
its	O
membrane	B-protein
receptors	I-protein
.	O

CONCLUSIONS	O
:	O
Our	O
results	O
show	O
that	O
glucocorticoids	O
at	O
clinically	O
relevant	O
concentrations	O
exert	O
specific	O
actions	O
on	O
expression	O
of	O
adhesion	B-protein
molecules	I-protein
on	O
activated	B-cell_type
neutrophils	I-cell_type
,	O
which	O
are	O
mediated	O
through	O
ligation	O
of	O
glucocorticoid	B-protein
receptors	I-protein
and	O
induction	O
of	O
protein	O
synthesis	O
,	O
and	O
suggest	O
a	O
novel	O
mechanism	O
by	O
which	O
anti-inflammatory	O
corticosteroids	O
may	O
inhibit	O
leukocyte	O
accumulation	O
.	O

The	O
immediate-early	O
gene	O
product	O
Egr-1	B-protein
regulates	O
the	O
human	B-DNA
interleukin-2	I-DNA
receptor	I-DNA
beta-chain	I-DNA
promoter	I-DNA
through	O
noncanonical	B-DNA
Egr	I-DNA
and	I-DNA
Sp1	I-DNA
binding	I-DNA
sites	I-DNA
.	O

The	O
interleukin-2	B-protein
IL-2	I-protein
receptor	I-protein
beta-chain	I-protein
(	O
IL-2Rbeta	B-protein
)	O
is	O
an	O
essential	O
component	O
of	O
the	O
receptors	O
for	O
IL-2	B-protein
and	O
IL-15	B-protein
.	O

Although	O
IL-2Rbeta	B-protein
is	O
constitutively	O
expressed	O
by	O
lymphocytes	O
,	O
its	O
expression	O
can	O
be	O
further	O
induced	O
by	O
a	O
number	O
of	O
stimuli	O
,	O
including	O
phorbol	O
12-myristate	O
13-acetate	O
(	O
PMA	O
)	O
.	O

We	O
have	O
now	O
characterized	O
factors	O
that	O
bind	O
to	O
an	O
enhancer	O
region	O
located	O
between	O
nucleotides	B-DNA
-170	I-DNA
and	I-DNA
-139	I-DNA
of	O
the	O
human	O
IL-2Rbeta	B-DNA
promoter	I-DNA
.	O

Both	O
Sp1	B-protein
and	O
Sp3	B-protein
bound	O
to	O
the	O
5	B-DNA
'	I-DNA
portion	I-DNA
of	O
this	O
region	O
,	O
whereas	O
a	O
PMA-inducible	B-protein
factor	I-protein
(	O
PIF	B-protein
)	O
mainly	O
bound	O
to	O
its	O
3	B-DNA
'	I-DNA
portion	I-DNA
and	O
bound	O
to	O
the	O
Sp	B-DNA
binding	I-DNA
motifs	I-DNA
as	O
well	O
.	O

In	O
Jurkat	B-cell_line
T	I-cell_line
cells	I-cell_line
,	O
induction	O
of	O
PIF	B-protein
DNA	O
binding	O
activity	O
was	O
rapidly	O
induced	O
,	O
required	O
de	O
novo	O
protein	O
synthesis	O
,	O
and	O
was	O
sustained	O
at	O
a	O
high	O
level	O
for	O
at	O
least	O
23	O
h	O
.	O

Interestingly	O
,	O
PIF	B-protein
was	O
constitutively	O
activated	O
in	O
human	B-cell_line
T-cell	I-cell_line
leukemia	I-cell_line
virus	I-cell_line
type	I-cell_line
1-transformed	I-cell_line
MT-2	I-cell_line
cells	I-cell_line
.	O

In	O
this	O
paper	O
,	O
we	O
demonstrate	O
that	O
PIF	B-protein
is	O
Egr-1	B-protein
based	O
on	O
its	O
recognition	O
by	O
anti-	O
Egr-1	B-protein
antisera	O
in	O
gel	O
mobility	O
shift	O
assays	O
,	O
even	O
though	O
the	O
IL-2Rbeta	B-DNA
DNA	I-DNA
binding	I-DNA
motif	I-DNA
differed	O
substantially	O
from	O
the	O
canonical	O
Egr-1	B-DNA
binding	I-DNA
site	I-DNA
.	O

In	O
addition	O
,	O
Egr-1	B-protein
bound	O
to	O
the	O
Sp	B-DNA
binding	I-DNA
site	I-DNA
.	O

In	O
Jurkat	B-cell_line
cells	I-cell_line
,	O
both	O
sites	O
were	O
required	O
for	O
maximal	O
IL-2Rbeta	B-protein
promoter	O
activity	O
,	O
and	O
in	O
HeLaS3	O
cells	O
,	O
transfection	O
of	O
Egr-1	B-protein
could	O
drive	O
activity	O
of	O
a	O
reporter	O
construct	O
containing	O
both	O
sites	O
.	O

Moreover	O
,	O
Sp1	B-protein
and	O
Egr-1	B-protein
could	O
form	O
a	O
complex	O
with	O
kinetics	O
that	O
correlated	O
with	O
the	O
production	O
of	O
Egr-1	B-protein
in	O
Jurkat	B-cell_line
cells	I-cell_line
upon	O
PMA	O
stimulation	O
.	O

Thus	O
,	O
Sp1	B-protein
and	O
Egr-1	B-protein
physically	O
and	O
functionally	O
cooperate	O
to	O
mediate	O
maximal	O
IL-2Rbeta	B-DNA
promoter	I-DNA
activity	O
.	O

Overexpression	O
of	O
HSF2-beta	B-protein
inhibits	O
hemin	B-protein
-induced	O
heat	O
shock	O
gene	O
expression	O
and	O
erythroid	O
differentiation	O
in	O
K562	B-cell_line
cells	I-cell_line
.	O

Acquisition	O
of	O
heat	O
shock	O
factor	O
2	O
(	O
HSF2	O
)	O
DNA	O
binding	O
activity	O
is	O
accompanied	O
by	O
induced	O
transcription	O
of	O
heat	B-DNA
shock	I-DNA
genes	I-DNA
in	O
hemin-treated	O
K562	B-cell_line
cells	I-cell_line
undergoing	O
erythroid	O
differentiation	O
.	O

Previous	O
studies	O
revealed	O
that	O
HSF2	B-protein
consists	O
of	O
two	O
alternatively	O
spliced	O
isoforms	O
,	O
HSF2-alpha	B-protein
and	O
HSF2-beta	B-protein
,	O
whose	O
relative	O
abundance	O
is	O
developmentally	O
regulated	O
and	O
varies	O
between	O
different	O
tissues	O
.	O

To	O
investigate	O
whether	O
the	O
molar	O
ratio	O
of	O
HSF2-alpha	B-protein
and	O
HSF2-beta	B-protein
isoforms	O
is	O
crucial	O
for	O
the	O
activation	O
of	O
HSF2	B-protein
and	O
whether	O
the	O
HSF2	B-protein
isoforms	O
play	O
functionally	O
distinct	O
roles	O
during	O
the	O
hemin-mediated	O
erythroid	O
differentiation	O
,	O
we	O
generated	O
cell	O
clones	O
expressing	O
different	O
levels	O
of	O
HSF2-alpha	B-protein
and	O
HSF2-beta	B-protein
.	O

We	O
show	O
that	O
in	O
parental	O
K562	B-cell_line
cells	I-cell_line
,	O
the	O
HSF2-alpha	B-protein
isoform	I-protein
is	O
predominantly	O
expressed	O
and	O
HSF2	B-protein
can	O
be	O
activated	O
upon	O
hemin	O
treatment	O
.	O

In	O
contrast	O
,	O
when	O
HSF2-beta	B-protein
is	O
expressed	O
at	O
levels	O
exceeding	O
those	O
of	O
endogenous	B-protein
HSF2-alpha	I-protein
,	O
the	O
hemin-induced	O
DNA	O
binding	O
activity	O
and	O
transcription	O
of	O
heat	B-DNA
shock	I-DNA
genes	I-DNA
are	O
repressed	O
,	O
whereas	O
overexpression	O
of	O
HSF2-alpha	B-protein
results	O
in	O
an	O
enhanced	O
hemin	B-protein
response	O
.	O

Furthermore	O
,	O
the	O
hemin	B-protein
-induced	O
accumulation	O
of	O
globin	B-protein
,	O
known	O
as	O
a	O
marker	O
of	O
erythroid	O
differentiation	O
,	O
is	O
decreased	O
in	O
cells	O
overexpressing	O
HSF2-beta	B-protein
.	O

We	O
suggest	O
that	O
HSF2-beta	B-protein
acts	O
as	O
a	O
negative	O
regulator	O
of	O
HSF2	B-protein
activity	O
during	O
hemin-mediated	O
erythroid	O
differentiation	O
of	O
K562	B-cell_line
cells	I-cell_line
.	O

Sequential	O
development	O
of	O
structural	O
and	O
functional	O
alterations	O
in	O
T	B-cell_type
cells	I-cell_type
from	O
tumor-bearing	O
mice	O
.	O

The	O
TCR	B-protein
alpha	I-protein
beta	I-protein
or	I-protein
-gamma	I-protein
delta	I-protein
chains	I-protein
bind	O
the	O
peptide	O
ligand	O
,	O
whereas	O
the	O
associated	O
CD3	B-protein
delta	I-protein
epsilon	I-protein
gamma	I-protein
and	O
TCR	B-protein
zeta	I-protein
subunits	I-protein
couple	O
the	O
TCR	B-protein
to	O
intracellular	O
signal	O
transduction	O
components	O
.	O

Recently	O
,	O
several	O
groups	O
have	O
described	O
marked	O
alterations	O
in	O
signal	O
transduction	O
elements	O
in	O
T	B-cell_type
cells	I-cell_type
from	O
cancer	O
patients	O
or	O
in	O
mice	O
bearing	O
tumor	O
for	O
a	O
few	O
weeks	O
(	O
>	O
26	O
days	O
)	O
.	O

The	O
sequence	O
in	O
which	O
these	O
alterations	O
develop	O
is	O
unknown	O
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
explore	O
the	O
kinetics	O
of	O
the	O
development	O
of	O
alterations	O
in	O
signal	O
transduction	O
molecules	O
(	O
TCR	B-protein
zeta	I-protein
chain	I-protein
,	O
NF	B-protein
kappaB	I-protein
family	I-protein
proteins	I-protein
,	O
and	O
tyrosine	B-protein
kinase	I-protein
p56	I-protein
(	I-protein
lck	I-protein
)	I-protein
)	O
in	O
mice	O
bearing	O
MC38	O
colon	O
adenocarcinoma	O
.	O

The	O
results	O
demonstrate	O
that	O
alterations	O
in	O
NF	B-protein
kappaB	I-protein
family	I-protein
proteins	I-protein
,	O
specifically	O
the	O
failure	O
of	O
p65	B-protein
translocation	O
to	O
the	O
nucleus	O
,	O
occur	O
earlier	O
and	O
more	O
frequently	O
than	O
the	O
decrease	O
in	O
zeta-chain	B-protein
.	O

These	O
defects	O
are	O
paralleled	O
by	O
an	O
impaired	O
ability	O
to	O
produce	O
Th1	B-protein
cytokines	I-protein
(	O
IL-2	B-protein
and	O
IFN-gamma	B-protein
)	O
.	O

These	O
initial	O
changes	O
are	O
followed	O
by	O
the	O
eventual	O
loss	O
of	O
TCR	B-protein
zeta	I-protein
chain	I-protein
and	O
p56	B-protein
(	I-protein
lck	I-protein
)	I-protein
and	O
a	O
marked	O
decrease	O
in	O
cytotoxic	O
function	O
.	O

An	O
increased	O
rate	O
of	O
lysosomal	O
degradation	O
is	O
one	O
of	O
the	O
mechanisms	O
responsible	O
for	O
the	O
loss	O
of	O
zeta-chain	B-protein
.	O

HLA-DMA	O
and	O
HLA-DMB	O
gene	O
expression	O
functions	O
through	O
the	O
conserved	O
S-X-Y	B-DNA
region	I-DNA
.	O

The	O
MHC	B-protein
class	I-protein
II	I-protein
homologous	I-protein
proteins	I-protein
HLA-DMA	B-protein
and	O
HLA-DMB	B-protein
function	O
in	O
the	O
loading	O
of	O
peptides	O
onto	O
class	B-protein
II	I-protein
molecules	I-protein
.	O

Like	O
the	O
class	B-DNA
II	I-DNA
genes	I-DNA
,	O
the	O
HLA-DM	B-DNA
genes	I-DNA
contain	O
upstream	O
regulatory	O
sequences	O
similar	O
to	O
the	O
S-X-Y	B-DNA
regulatory	I-DNA
region	I-DNA
as	O
well	O
as	O
additional	O
putative	O
regulatory	O
sites	O
.	O

To	O
determine	O
whether	O
the	O
DM	B-DNA
genes	I-DNA
are	O
regulated	O
in	O
a	O
similar	O
manner	O
as	O
class	B-DNA
II	I-DNA
genes	I-DNA
,	O
a	O
series	O
of	O
in	O
vivo	O
and	O
in	O
vitro	O
analyses	O
was	O
performed	O
.	O

Deletion	O
analysis	O
showed	O
that	O
expression	O
from	O
the	O
DM	B-DNA
promoters	I-DNA
is	O
dependent	O
on	O
the	O
conserved	O
S-X-Y	B-DNA
region	I-DNA
.	O

The	O
class	B-protein
II-specific	I-protein
transcription	I-protein
factors	I-protein
RFX	B-protein
and	O
CIITA	B-protein
are	O
also	O
required	O
for	O
expression	O
,	O
as	O
cell	O
lines	O
deficient	O
in	O
these	O
factors	O
failed	O
to	O
allow	O
transcription	O
from	O
the	O
DM	B-DNA
promoters	I-DNA
.	O

In	O
addition	O
,	O
in	O
vivo	O
footprint	O
analysis	O
showed	O
the	O
putative	O
X	B-DNA
and	I-DNA
Y	I-DNA
boxes	I-DNA
to	O
be	O
occupied	O
by	O
transcription	B-protein
factors	I-protein
in	O
wild-type	B-cell_type
B	I-cell_type
cells	I-cell_type
,	O
but	O
not	O
in	O
RFX-deficient	B-cell_line
B	I-cell_line
cells	I-cell_line
.	O

In	O
astrocytes	B-cell_type
,	O
IFN-gamma	B-protein
treatment	O
induced	O
increased	O
occupancy	O
of	O
these	O
sites	O
.	O

None	O
of	O
the	O
other	O
putative	O
regulatory	O
sites	O
was	O
occupied	O
in	O
vivo	O
,	O
indicating	O
that	O
they	O
may	O
not	O
be	O
functional	O
.	O

Finally	O
,	O
gel	O
shift	O
analysis	O
showed	O
synergistic	O
complex	O
formation	O
between	O
proteins	O
that	O
bind	O
to	O
the	O
putative	O
X	B-DNA
boxes	I-DNA
of	O
the	O
DM	O
genes	O
,	O
as	O
is	O
found	O
for	O
the	O
DRA	B-DNA
gene	I-DNA
.	O

Therefore	O
,	O
the	O
DM	B-DNA
genes	I-DNA
share	O
a	O
common	O
mechanism	O
of	O
regulation	O
with	O
the	O
class	B-DNA
II	I-DNA
genes	I-DNA
.	O

Effect	O
of	O
adenovirus	O
2	O
on	O
cellular	O
gene	O
activation	O
in	O
blood-derived	B-cell_type
monocytes	I-cell_type
and	O
macrophages	B-cell_type
.	O

We	O
have	O
investigated	O
the	O
effect	O
of	O
adenovirus	O
2	O
(	O
Ad2	O
)	O
infection	O
on	O
human	B-cell_type
monocytes	I-cell_type
and	O
monocyte-derived	B-cell_type
macrophages	I-cell_type
with	O
regard	O
to	O
expression	O
of	O
TNF-alpha	B-protein
and	O
IL-1	B-protein
beta	I-protein
.	O

In	O
monocytes	O
,	O
the	O
virus	O
was	O
bound	O
to	O
the	O
surface	O
without	O
being	O
internalized	O
.	O

On	O
the	O
other	O
hand	O
,	O
Ad2	O
was	O
internalized	O
by	O
macrophages	B-cell_type
.	O

No	O
virus	O
replication	O
and	O
no	O
transcription	O
of	O
the	O
Ad2	B-DNA
early	I-DNA
genes	I-DNA
was	O
observed	O
in	O
either	O
of	O
the	O
cells	O
.	O

Ad2	O
infection	O
induced	O
transient	O
increase	O
in	O
the	O
mRNA	B-RNA
levels	O
for	O
TNF-alpha	B-protein
and	O
IL-1	B-protein
beta	I-protein
in	O
both	O
monocytes	B-cell_type
and	O
in	O
macrophages	B-cell_type
,	O
although	O
the	O
kinetics	O
of	O
the	O
transcription	O
was	O
slightly	O
different	O
.	O

The	O
production	O
of	O
both	O
cytokines	B-protein
,	O
measured	O
by	O
ELISA	O
tests	O
,	O
was	O
enhanced	O
in	O
monocytes	B-cell_type
.	O

In	O
macrophages	B-cell_type
,	O
a	O
slight	O
enhancement	O
of	O
TNF-alpha	B-protein
production	O
was	O
seen	O
,	O
whereas	O
IL-1	B-protein
beta	I-protein
was	O
not	O
detected	O
.	O

The	O
data	O
indicate	O
that	O
cellular	B-DNA
genes	I-DNA
might	O
be	O
activated	O
by	O
Ad2	O
virus	O
infection	O
in	O
nonpermissive	O
cells	O
where	O
no	O
viral	B-protein
gene	I-protein
products	I-protein
could	O
be	O
detected	O
.	O

Structure	O
and	O
function	O
analysis	O
of	O
the	O
human	B-DNA
myeloid	I-DNA
cell	I-DNA
nuclear	I-DNA
differentiation	I-DNA
antigen	I-DNA
promoter	I-DNA
:	O
evidence	O
for	O
the	O
role	O
of	O
Sp1	B-protein
and	O
not	O
of	O
c-Myb	B-protein
or	O
PU.1	B-protein
in	O
myelomonocytic	O
lineage-specific	O
expression	O
.	O

The	O
human	B-protein
myeloid	I-protein
nuclear	I-protein
differentiation	I-protein
antigen	I-protein
(	O
MNDA	B-protein
)	O
is	O
expressed	O
specifically	O
in	O
maturing	B-cell_type
cells	I-cell_type
of	O
the	O
myelomonocytic	O
lineage	O
and	O
in	O
monocytes	B-cell_type
and	O
granulocytes	B-cell_type
.	O

Epitope	O
enhancement	O
was	O
used	O
to	O
confirm	O
the	O
strict	O
lineage-	O
and	O
stage-specific	O
expression	O
of	O
MNDA	B-protein
in	O
bone	O
marrow	O
as	O
well	O
as	O
in	O
other	O
paraffin-embedded	O
fixed	O
tissues	O
.	O

A	O
1-kb	B-DNA
region	I-DNA
of	O
the	O
gene	O
that	O
includes	O
5	B-DNA
'	I-DNA
flanking	I-DNA
sequence	I-DNA
was	O
reported	O
earlier	O
to	O
contain	O
functional	O
promoter	O
activity	O
and	O
was	O
specifically	O
demethylated	O
in	O
expressing	B-cell_type
cells	I-cell_type
in	O
contrast	O
to	O
null	B-cell_type
cells	I-cell_type
.	O

Further	O
analysis	O
has	O
revealed	O
that	O
this	O
1-kb	B-DNA
fragment	I-DNA
promotes	O
higher	O
reporter	O
gene	O
activity	O
in	O
MNDA	B-protein
-expressing	B-cell_type
cells	I-cell_type
than	O
non-expressing	B-cell_type
cells	I-cell_type
,	O
indicating	O
cell-specific	O
differences	O
in	O
transactivation	O
.	O

This	O
sequence	O
contains	O
consensus	B-DNA
elements	I-DNA
consistent	O
with	O
myeloid-specific	O
gene	O
expression	O
,	O
including	O
a	O
PU.1	B-DNA
consensus	I-DNA
site	I-DNA
near	O
the	O
major	O
transcription	B-DNA
start	I-DNA
site	I-DNA
and	O
a	O
cluster	O
of	O
c-Myb	B-DNA
sites	I-DNA
located	O
several	O
hundred	O
bases	O
upstream	O
of	O
this	O
region	O
.	O

However	O
,	O
analysis	O
of	O
deletion	B-DNA
mutants	I-DNA
localized	O
nearly	O
all	O
of	O
the	O
promoter	O
activity	O
to	O
a	O
short	O
region	O
(	O
-73	B-DNA
to	I-DNA
-16	I-DNA
)	O
that	O
did	O
not	O
include	O
the	O
cluster	O
of	O
c-Myb	B-DNA
sites	I-DNA
.	O

A	O
4-bp	O
mutation	O
of	O
the	O
core	B-DNA
Sp1	I-DNA
consensus	I-DNA
element	I-DNA
(	O
GC	B-DNA
box	I-DNA
)	O
(	O
-20	O
)	O
reduced	O
overall	O
promoter	O
activity	O
of	O
the	O
1-kb	B-DNA
fragment	I-DNA
.	O

Mutation	O
of	O
the	O
PU.1	B-DNA
site	I-DNA
did	O
not	O
significantly	O
affect	O
promoter	O
activity	O
.	O

Only	O
a	O
small	O
region	O
(	O
-35	O
to	O
+22	O
)	O
including	O
the	O
Sp1	B-DNA
element	I-DNA
and	O
transcription	B-DNA
start	I-DNA
site	I-DNA
,	O
but	O
not	O
the	O
PU.1	B-DNA
site	I-DNA
was	O
footprinted	O
.	O

The	O
4-bp	O
mutation	O
of	O
the	O
core	O
Sp1	B-DNA
consensus	I-DNA
element	I-DNA
abolished	O
footprinting	O
at	O
the	O
site	O
and	O
an	O
antibody	O
super-shift	O
reaction	O
showed	O
that	O
Sp1	B-protein
is	O
one	O
of	O
the	O
factors	O
binding	O
the	O
consensus	B-DNA
site	I-DNA
.	O

The	O
Sp1	B-DNA
site	I-DNA
also	O
co-localizes	O
with	O
a	O
DNase	B-DNA
I	I-DNA
hypersensitive	I-DNA
site	I-DNA
.	O

The	O
results	O
indicate	O
that	O
DNA	O
methylation	O
,	O
chromatin	B-DNA
structure	O
,	O
and	O
transactivation	O
at	O
an	O
Sp1	B-DNA
site	I-DNA
contribute	O
to	O
the	O
highly	O
restricted	O
expression	O
of	O
this	O
myelomonocytic	B-DNA
lineage	I-DNA
specific	I-DNA
gene	I-DNA
.	O

Critical	O
cytoplasmic	B-protein
domains	I-protein
of	O
human	B-protein
interleukin-9	I-protein
receptor	I-protein
alpha	I-protein
chain	I-protein
in	O
interleukin	B-protein
-9-mediated	O
cell	O
proliferation	O
and	O
signal	O
transduction	O
.	O

Interleukin-9	B-protein
receptor	I-protein
(	I-protein
IL-9R	I-protein
)	I-protein
complex	I-protein
consists	O
of	O
a	O
ligand-specific	B-protein
alpha	I-protein
chain	I-protein
and	O
IL-2R	B-protein
gamma	I-protein
chain	I-protein
.	O

In	O
this	O
study	O
,	O
two	O
regions	O
in	O
the	O
cytoplasmic	B-protein
domain	I-protein
of	O
human	B-protein
IL-9Ralpha	I-protein
were	O
found	O
to	O
be	O
important	O
for	O
IL-9	B-protein
-mediated	O
cell	O
growth	O
.	O

A	O
membrane-proximal	B-protein
region	I-protein
that	O
contains	O
the	O
BOX1	B-protein
consensus	I-protein
sequence	I-protein
is	O
required	O
for	O
IL-9	B-protein
-induced	O
cell	O
proliferation	O
and	O
tyrosine	O
phosphorylation	O
of	O
Janus	B-protein
kinases	I-protein
(	O
JAKs	B-protein
)	O
.	O

Deletion	O
of	O
this	O
region	O
or	O
internal	O
deletion	O
of	O
the	O
BOX1	B-protein
motif	I-protein
abrogated	O
IL-9	B-protein
-induced	O
cell	O
proliferation	O
and	O
signal	O
transduction	O
.	O

However	O
,	O
substitution	O
of	O
the	O
Pro-X-Pro	B-protein
in	O
the	O
BOX1	B-protein
motif	I-protein
with	O
Ala-X-Ala	B-protein
failed	O
to	O
abolish	O
IL-9	B-protein
-induced	O
cell	O
proliferation	O
but	O
decreased	O
IL-9	B-protein
-mediated	O
tyrosine	O
phosphorylation	O
of	O
JAK	B-protein
kinases	I-protein
,	O
insulin	B-protein
receptor	I-protein
substrate-2	I-protein
,	O
and	O
signal	B-protein
transducer	I-protein
and	I-protein
activator	I-protein
of	I-protein
transcription	I-protein
3	I-protein
(	O
STAT3	B-protein
)	O
and	O
expression	O
of	O
c-myc	B-DNA
and	O
junB	B-DNA
.	O

Another	O
important	O
region	O
is	O
downstream	O
of	O
the	O
BOX1	B-protein
motif	I-protein
and	O
contains	O
a	O
STAT3	B-DNA
binding	I-DNA
motif	I-DNA
YLPQ	B-DNA
.	O

Deletion	O
of	O
this	O
region	O
significantly	O
impaired	O
IL-9	B-protein
-induced	O
cell	O
growth	O
,	O
activation	O
of	O
JAK	B-protein
kinases	I-protein
,	O
insulin	B-protein
receptor	I-protein
substrate-2	I-protein
,	O
and	O
STAT3	B-protein
and	O
expression	O
of	O
early	B-DNA
response	I-DNA
genes	I-DNA
.	O

A	O
point	O
mutation	O
changing	O
YLPQ	B-DNA
into	O
YLPA	B-DNA
greatly	O
reduced	O
IL-9	B-protein
-induced	O
activation	O
of	O
STAT3	B-protein
and	O
expression	O
of	O
c-myc	B-DNA
but	O
did	O
not	O
affect	O
cell	O
proliferation	O
.	O

These	O
results	O
suggest	O
that	O
cooperation	O
or	O
cross-talk	O
of	O
signaling	O
molecules	O
associated	O
with	O
different	O
domains	O
of	O
IL-9Ralpha	B-protein
other	O
than	O
STAT3	B-protein
is	O
essential	O
for	O
IL-9	B-protein
-mediated	O
cell	O
growth	O
.	O

Bcl-2	B-protein
protein	I-protein
inhibits	O
bufalin-induced	O
apoptosis	O
through	O
inhibition	O
of	O
mitogen-activated	B-protein
protein	I-protein
kinase	I-protein
activation	O
in	O
human	B-cell_line
leukemia	I-cell_line
U937	I-cell_line
cells	I-cell_line
.	O

In	O
a	O
previous	O
study	O
,	O
we	O
demonstrated	O
that	O
bufalin	O
,	O
which	O
is	O
an	O
active	O
principle	O
of	O
Chinese	O
medicine	O
,	O
chan'su	O
,	O
caused	O
apoptosis	O
in	O
human	B-cell_line
leukemia	I-cell_line
U937	I-cell_line
cells	I-cell_line
by	O
anomalous	O
activation	O
of	O
mitogen-activated	B-protein
protein	I-protein
kinase	I-protein
(	O
MAPK	B-protein
)	O
via	O
the	O
signaling	O
pathway	O
of	O
Ras	B-protein
,	O
Raf-1	B-protein
,	O
and	O
MAPK	B-protein
kinase-1	I-protein
.	O

Here	O
,	O
we	O
report	O
the	O
effect	O
of	O
overexpression	O
of	O
bcl-2	B-protein
in	O
U937	B-cell_line
cells	I-cell_line
on	O
the	O
signaling	O
pathway	O
of	O
apoptosis	O
that	O
is	O
induced	O
by	O
bufalin	O
.	O

The	O
results	O
indicated	O
that	O
the	O
apoptosis	O
induced	O
by	O
bufalin	O
in	O
U937	B-cell_line
cells	I-cell_line
was	O
significantly	O
inhibited	O
by	O
overexpression	O
of	O
the	O
Bcl-2	B-protein
protein	I-protein
.	O

No	O
significant	O
difference	O
was	O
detected	O
in	O
the	O
activation	O
of	O
MAPK	B-protein
kinase-1	I-protein
that	O
is	O
induced	O
by	O
bufalin	O
in	O
wild-type	O
or	O
Bcl-2-overexpressed	B-cell_type
U937	I-cell_type
cells	I-cell_type
;	O
however	O
,	O
the	O
activation	O
of	O
MAPK	B-protein
by	O
bufalin	O
was	O
significantly	O
attenuated	O
in	O
the	O
cells	O
overexpressing	O
Bcl-2	B-protein
.	O

Bufalin	O
treatment	O
activated	B-protein
activator	I-protein
protein-1	I-protein
transcriptional	O
activity	O
;	O
however	O
,	O
this	O
activation	O
was	O
decreased	O
to	O
40	O
%	O
in	O
bcl-2	B-protein
-overexpressed	O
U937	B-cell_line
cells	I-cell_line
.	O

These	O
results	O
indicate	O
that	O
Bcl-2	B-protein
acts	O
downstream	O
of	O
MAPK	B-protein
kinase-1	I-protein
but	O
upstream	O
of	O
MAPK	B-protein
and	O
suggest	O
that	O
,	O
in	O
the	O
signaling	O
pathway	O
of	O
the	O
apoptotic	O
process	O
induced	O
by	O
bufalin	O
,	O
the	O
transcriptional	O
activity	O
of	O
activator	B-protein
protein-1	I-protein
may	O
be	O
down-regulated	O
through	O
the	O
inhibition	O
of	O
MAPK	B-protein
activity	O
by	O
Bcl-2	B-protein
.	O

Pancreatic	O
islet	O
expression	O
studies	O
and	O
polymorphic	O
DNA	O
markers	O
in	O
the	O
genes	O
encoding	O
hepatocyte	B-protein
nuclear	I-protein
factor-3alpha	I-protein
,	I-protein
-3beta	I-protein
,	I-protein
-3gamma	I-protein
,	I-protein
-4gamma	I-protein
,	I-protein
and	I-protein
-6	I-protein
.	O

The	O
genes	O
encoding	O
the	O
functionally	O
related	O
hepatocyte	B-protein
nuclear	I-protein
factors	I-protein
HNF-1alpha	B-protein
and	O
HNF-4alpha	B-protein
play	O
a	O
critical	O
role	O
in	O
normal	O
pancreatic	O
beta-cell	O
function	O
.	O

Mutations	O
in	O
these	O
liver-enriched	B-protein
transcription	I-protein
factors	I-protein
result	O
in	O
two	O
forms	O
of	O
early-onset	O
type	O
2	O
diabetes	O
(	O
maturity-onset	O
diabetes	O
of	O
the	O
young	O
[	O
MODY	O
]	O
)	O
,	O
MODY3	O
and	O
MODY1	O
,	O
which	O
are	O
characterized	O
by	O
impaired	O
glucose-stimulated	O
insulin	O
secretion	O
,	O
early	O
disease	O
onset	O
,	O
and	O
autosomal	O
dominant	O
inheritance	O
.	O

The	O
transcriptional	O
hierarchy	O
of	O
HNFs	O
suggests	O
that	O
other	O
proteins	O
of	O
the	O
regulatory	O
cascade	O
might	O
be	O
responsible	O
for	O
other	O
forms	O
of	O
MODY	O
and/or	O
late-onset	O
type	O
2	O
diabetes	O
.	O

In	O
this	O
study	O
,	O
we	O
show	O
that	O
HNF-3alpha	B-protein
,	I-protein
-3beta	I-protein
,	I-protein
-3gamma	I-protein
,	I-protein
-4gamma	I-protein
,	I-protein
and	I-protein
-6	I-protein
are	O
expressed	O
in	O
pancreatic	B-cell_type
beta-cells	I-cell_type
.	O

We	O
report	O
the	O
identification	O
and	O
characterization	O
of	O
simple	B-DNA
tandem	I-DNA
repeat	I-DNA
DNA	I-DNA
polymorphisms	I-DNA
in	O
the	O
genes	O
encoding	O
HNF-3alpha	B-protein
,	O
-3beta	B-protein
,	O
-3gamma	B-protein
,	O
-4gamma	B-protein
,	O
and	O
-6	B-protein
and	O
the	O
mapping	O
of	O
HNF-6	B-protein
to	O
chromosome	B-DNA
bands	I-DNA
15q21.1-21.2	B-DNA
by	O
fluorescence	O
in	O
situ	O
hybridization	O
.	O

These	O
markers	O
will	O
be	O
useful	O
to	O
study	O
the	O
role	O
of	O
genetic	O
variation	O
in	O
these	O
genes	O
in	O
the	O
pathogenesis	O
of	O
type	O
2	O
diabetes	O
.	O

Induction	O
of	O
nuclear	B-protein
factor	I-protein
kappa	I-protein
B/Rel	I-protein
nuclear	O
activity	O
in	O
human	B-cell_type
peripheral	I-cell_type
blood	I-cell_type
T	I-cell_type
lymphocytes	I-cell_type
by	O
anti-HLA	B-protein
class	I-protein
I	I-protein
monoclonal	I-protein
antibodies	I-protein
.	O

Monoclonal	O
antibodies	O
against	O
either	O
monomorphic	O
or	O
polymorphic	O
determinants	O
of	O
class	B-protein
I	I-protein
antigen	I-protein
induced	O
in	O
PBMC	B-cell_type
and	O
highly	O
purified	B-cell_type
T	I-cell_type
lymphocytes	I-cell_type
the	O
nuclear	O
activity	O
of	O
NF-kappa	B-protein
B/Rel	I-protein
complexes	I-protein
.	O

These	O
included	O
both	O
p50/p50	B-protein
and	O
p50/p65	B-protein
dimers	I-protein
,	O
recognized	O
by	O
specific	B-protein
antibodies	I-protein
in	O
EMSA	O
.	O

The	O
induced	O
complexes	B-protein
were	O
detectable	O
in	O
extracts	O
of	O
cells	O
incubated	O
with	O
anti-class	B-protein
I	I-protein
monoclonal	I-protein
antibody	I-protein
(	O
mAb	B-protein
)	O
for	O
1.5	O
h	O
;	O
the	O
induction	O
was	O
maximal	O
at	O
5	O
h	O
,	O
persistent	O
at	O
16	O
h	O
and	O
no	O
longer	O
observed	O
at	O
40	O
h	O
.	O

The	O
mAb	B-protein
failed	O
to	O
induce	O
NF-kappa	B-protein
B/Rel	I-protein
nuclear	O
activity	O
in	O
cells	O
incubated	O
in	O
the	O
presence	O
of	O
3	O
,	O
4-dichloroisocoumarin	O
,	O
an	O
inhibitor	O
of	O
I	B-protein
kappa	I-protein
B-alpha	I-protein
degradation	O
.	O

Together	O
,	O
these	O
results	O
suggest	O
that	O
class	O
I	O
triggering	O
can	O
induce	O
the	O
activity	O
of	O
NF-kappa	B-protein
B/Rel	I-protein
nuclear	O
activity	O
in	O
peripheral	B-cell_type
blood	I-cell_type
T	I-cell_type
lymphocytes	I-cell_type
,	O
thereby	O
modulating	O
the	O
expression	O
of	O
genes	O
regulated	O
by	O
these	O
transcription	B-protein
factors	I-protein
.	O

Anti-Ehrlichia	B-protein
chaffeensis	I-protein
antibody	I-protein
complexed	O
with	O
E.	O
chaffeensis	O
induces	O
potent	O
proinflammatory	B-RNA
cytokine	I-RNA
mRNA	I-RNA
expression	O
in	O
human	B-cell_type
monocytes	I-cell_type
through	O
sustained	O
reduction	O
of	O
IkappaB-alpha	B-protein
and	O
activation	O
of	O
NF-kappaB	B-protein
.	O

Ehrlichia	O
chaffeensis	O
is	O
an	O
obligatory	O
intracellular	O
bacterium	O
that	O
infects	O
monocytes	B-cell_type
and	O
macrophages	B-cell_type
and	O
is	O
the	O
etiologic	O
agent	O
of	O
human	O
ehrlichiosis	O
in	O
the	O
United	O
States	O
.	O

Our	O
previous	O
studies	O
showed	O
that	O
the	O
exposure	O
of	O
human	B-cell_type
monocytes	I-cell_type
to	O
E.	O
chaffeensis	O
induces	O
the	O
expression	O
of	O
interleukin-1beta	B-protein
(	O
IL-1beta	B-protein
)	O
,	O
IL-8	B-protein
,	O
and	O
IL-10	B-DNA
genes	I-DNA
in	O
vitro	O
but	O
not	O
the	O
expression	O
of	O
tumor	B-RNA
necrosis	I-RNA
factor	I-RNA
alpha	I-RNA
(	I-RNA
TNF-alpha	I-RNA
)	I-RNA
and	I-RNA
IL-6	I-RNA
mRNAs	I-RNA
.	O

In	O
this	O
study	O
,	O
the	O
effect	O
of	O
anti-E.	B-protein
chaffeensis	I-protein
antibody	I-protein
complexed	O
with	O
E.	O
chaffeensis	O
on	O
the	O
expression	O
of	O
major	B-protein
proinflammatory	I-protein
cytokines	I-protein
in	O
human	B-cell_type
monocytes	I-cell_type
was	O
examined	O
.	O

Human	B-cell_line
monocytic	I-cell_line
cell	I-cell_line
line	I-cell_line
THP-1	I-cell_line
was	O
treated	O
with	O
E.	O
chaffeensis	O
which	O
had	O
been	O
preincubated	O
with	O
human	O
anti-E.	O
chaffeensis	O
serum	O
for	O
2	O
h	O
,	O
and	O
the	O
levels	O
of	O
cytokine	B-RNA
mRNAs	I-RNA
were	O
evaluated	O
by	O
competitive	O
reverse	O
transcription-PCR	O
.	O

Anti-E.	B-protein
chaffeensis	I-protein
antibody	I-protein
complexed	O
with	O
E.	O
chaffeensis	O
significantly	O
enhanced	O
mRNA	O
expression	O
of	O
IL-1beta	B-protein
in	O
THP-1	B-cell_line
cells	I-cell_line
.	O

The	O
expression	O
of	O
TNF-alpha	B-RNA
and	I-RNA
IL-6	I-RNA
mRNAs	I-RNA
was	O
also	O
induced	O
.	O

The	O
levels	O
of	O
secreted	O
IL-1beta	B-protein
,	O
TNF-alpha	B-protein
,	O
and	O
IL-6	B-protein
during	O
24	O
h	O
of	O
stimulation	O
were	O
comparable	O
to	O
those	O
induced	O
by	O
Escherichia	O
coli	O
lipopolysaccharide	O
at	O
1	O
microg/ml	O
.	O

Fab	O
fragment	O
of	O
anti-E.	B-protein
chaffeensis	I-protein
immunoglobulin	I-protein
G	I-protein
complexed	O
with	O
E.	O
chaffeensis	O
did	O
not	O
induce	O
any	O
of	O
these	O
three	O
cytokines	O
,	O
indicating	O
that	O
ehrlichial	O
binding	O
is	O
required	O
for	O
IL-1beta	B-RNA
mRNA	I-RNA
expression	O
and	O
that	O
binding	O
of	O
the	O
immune	B-protein
complex	I-protein
to	O
the	O
Fc	B-protein
gamma	I-protein
receptor	I-protein
is	O
required	O
for	O
TNF-alpha	B-protein
and	O
IL-6	B-RNA
mRNA	I-RNA
expression	O
and	O
enhanced	O
IL-1beta	B-RNA
mRNA	I-RNA
expression	O
.	O

Furthermore	O
,	O
prolonged	O
degradation	O
of	O
IkappaB-alpha	B-protein
and	O
activation	O
of	O
NF-kappaB	B-protein
were	O
demonstrated	O
in	O
THP-1	B-cell_line
cells	I-cell_line
exposed	O
to	O
anti-E.	O
chaffeensis	O
serum	O
and	O
E.	O
chaffeensis	O
.	O

This	O
result	O
implies	O
that	O
development	O
of	O
anti-E.	B-protein
chaffeensis	I-protein
antibody	I-protein
in	O
patients	O
can	O
result	O
in	O
the	O
production	O
of	O
major	B-protein
proinflammatory	I-protein
cytokines	I-protein
,	O
which	O
may	O
play	O
an	O
important	O
role	O
in	O
the	O
pathophysiology	O
of	O
ehrlichiosis	O
and	O
immune	O
responses	O
to	O
it	O
.	O

The	O
class	B-protein
II	I-protein
trans-activator	I-protein
CIITA	I-protein
interacts	O
with	O
the	O
TBP-associated	B-protein
factor	I-protein
TAFII32	I-protein
.	O

The	O
class	B-protein
II	I-protein
trans-	I-protein
activator	I-protein
(	O
CIITA	B-protein
)	O
is	O
the	O
main	O
transcriptional	O
co-activator	O
for	O
the	O
expression	O
of	O
MHC	B-protein
class	I-protein
II	I-protein
proteins	I-protein
.	O

Its	O
N-terminal	B-protein
125	I-protein
amino	I-protein
acids	I-protein
function	O
as	O
an	O
independent	B-protein
transcriptional	I-protein
activation	I-protein
domain	I-protein
.	O

Analyses	O
of	O
the	O
primary	B-protein
amino	I-protein
acid	I-protein
sequence	I-protein
of	O
the	O
activation	B-protein
domain	I-protein
predict	O
the	O
presence	O
of	O
three	O
alpha-helices	B-protein
,	O
each	O
with	O
a	O
high	O
proportion	O
of	O
acidic	O
residues	O
.	O

Using	O
site-directed	O
mutagenesis	O
,	O
we	O
found	O
that	O
two	O
of	O
these	O
predicted	O
alpha-helices	B-protein
are	O
required	O
for	O
full	O
transcriptional	O
activation	O
by	O
CIITA	B-protein
.	O

Moreover	O
,	O
a	O
CIITA	B-protein
protein	I-protein
in	O
which	O
both	O
functional	O
alpha-helices	B-protein
have	O
been	O
deleted	O
displays	O
a	O
dominant	O
negative	O
phenotype	O
.	O

This	O
activation	B-protein
domain	I-protein
of	O
CIITA	B-protein
interacts	O
with	O
the	O
32	B-protein
kDa	I-protein
subunit	I-protein
of	O
the	O
general	B-protein
transcription	I-protein
complex	I-protein
TFIID	B-protein
,	O
TAFII32	B-protein
.	O

Decreased	O
transcriptional	O
activation	O
by	O
N-terminal	B-protein
deletions	I-protein
of	O
CIITA	B-protein
is	O
correlated	O
directly	O
with	O
their	O
reduced	O
binding	O
to	O
TAFII32	B-protein
.	O

We	O
conclude	O
that	O
interactions	O
between	O
TAFII32	B-protein
and	O
CIITA	B-protein
are	O
responsible	O
for	O
activation	O
of	O
class	B-DNA
II	I-DNA
genes	I-DNA
.	O

Characterization	O
of	O
interleukin-10	B-protein
receptor	I-protein
expression	O
on	O
B-cell	B-cell_line
chronic	I-cell_line
lymphocytic	I-cell_line
leukemia	I-cell_line
cells	I-cell_line
.	O

B-cell	B-cell_line
chronic	I-cell_line
lymphocytic	I-cell_line
leukemia	I-cell_line
(	I-cell_line
B-CLL	I-cell_line
)	I-cell_line
cells	I-cell_line
accumulate	O
in	O
vivo	O
in	O
the	O
G0/G1	O
phase	O
of	O
the	O
cell	O
cycle	O
,	O
suggesting	O
that	O
their	O
malignant	O
expansion	O
is	O
due	O
,	O
at	O
least	O
in	O
part	O
,	O
to	O
a	O
delay	O
in	O
cell	O
death	O
.	O

However	O
,	O
the	O
cellular	O
or	O
molecular	B-protein
factors	I-protein
responsible	O
for	O
a	O
delay	O
in	O
B-CLL	O
cell	O
death	O
are	O
unknown	O
.	O

B-CLL	O
cells	O
do	O
express	O
receptors	O
for	O
interferon-alpha	B-protein
(	O
IFN-alpha	B-protein
)	O
and	O
IFN-gamma	B-protein
,	O
and	O
activation	O
of	O
both	O
has	O
been	O
shown	O
to	O
promote	O
B-CLL	O
survival	O
in	O
vitro	O
by	O
preventing	O
apoptosis	O
.	O

The	O
interleukin-10	B-protein
(	I-protein
IL-10	I-protein
)	I-protein
receptor	I-protein
is	O
another	O
member	O
of	O
the	O
IFN	B-protein
receptor	I-protein
family	I-protein
,	O
but	O
its	O
ligand	O
,	O
IL-10	B-protein
,	O
has	O
been	O
reported	O
to	O
induce	O
apoptosis	O
in	O
B-CLL	B-cell_line
cells	I-cell_line
.	O

In	O
the	O
current	O
study	O
,	O
we	O
undertook	O
a	O
biochemical	O
analysis	O
of	O
IL-10	B-protein
receptor	I-protein
expression	O
on	O
freshly	O
isolated	O
B-CLL	B-cell_line
cells	I-cell_line
and	O
characterized	O
the	O
functional	O
responsiveness	O
of	O
IL-10	B-protein
binding	O
to	O
its	O
constitutively	B-protein
expressed	I-protein
receptor	I-protein
.	O

We	O
show	O
that	O
B-CLL	B-cell_line
cells	I-cell_line
bind	O
IL-10	B-protein
with	O
significant	O
specificity	O
and	O
express	O
between	O
47	O
and	O
127	O
IL-10	B-protein
receptor	I-protein
sites	O
per	O
cell	O
,	O
with	O
a	O
dissociation	O
constant	O
in	O
the	O
range	O
of	O
168	O
to	O
426	O
x	O
10	O
(	O
-12	O
)	O
mol/L	O
.	O

Ligand	O
binding	O
and	O
activation	O
of	O
the	O
IL-10	B-protein
receptor	I-protein
expressed	O
on	O
B-CLL	B-cell_line
cells	I-cell_line
results	O
in	O
the	O
phosphorylation	O
of	O
signal	B-protein
transducer	I-protein
and	I-protein
activator	I-protein
of	I-protein
transcription	I-protein
1	I-protein
(	O
STAT1	B-protein
)	O
and	O
STAT3	B-protein
proteins	O
.	O

This	O
pattern	O
of	O
STAT	B-protein
protein	I-protein
phosphorylation	O
is	O
identical	O
to	O
IL-10	B-protein
receptor	I-protein
activation	O
on	O
normal	B-cell_type
cells	I-cell_type
and	O
similar	O
to	O
IFN-alpha	B-protein
(	O
STAT1	B-protein
and	O
STAT3	B-protein
)	O
and	O
IFN-gamma	B-protein
(	O
STAT1	B-protein
)	O
receptor	O
activation	O
in	O
CLL	B-cell_line
.	O

Further	O
,	O
in	O
consecutive	O
samples	O
of	O
fresh	O
blood	O
obtained	O
from	O
patients	O
with	O
B-CLL	B-cell_line
cells	I-cell_line
,	O
the	O
addition	O
of	O
IL-10	B-protein
inhibited	O
B-CLL	B-cell_line
proliferation	O
,	O
enhanced	O
B-CLL	B-cell_line
differentiation	O
,	O
but	O
did	O
not	O
induce	O
apoptosis	O
.	O

Indeed	O
,	O
IL-10	B-protein
,	O
like	O
IFN-gamma	B-protein
,	O
was	O
able	O
to	O
significantly	O
reduce	O
the	O
amount	O
of	O
B-CLL	O
cell	O
death	O
caused	O
by	O
hydrocortisone-induced	O
apoptosis	O
.	O

We	O
conclude	O
that	O
cytokines	B-protein
,	O
which	O
signal	O
through	O
the	O
interferon	B-protein
family	I-protein
of	O
receptors	O
,	O
have	O
comparable	O
functional	O
effects	O
on	O
B-CLL	B-cell_line
cells	I-cell_line
.	O

Involvement	O
of	O
the	O
N-terminal	B-protein
region	I-protein
of	O
the	O
human	B-protein
mineralocorticoid	I-protein
receptor	I-protein
hormone-binding	I-protein
domain	I-protein
in	O
agonist	O
and	O
antagonist	O
binding	O
as	O
revealed	O
by	O
a	O
new	B-protein
monoclonal	I-protein
antibody	I-protein
.	O

To	O
gain	O
a	O
better	O
understanding	O
of	O
the	O
mechanism	O
of	O
binding	O
to	O
the	O
human	B-protein
mineralocorticoid	I-protein
receptor	I-protein
(	O
hMR	B-protein
)	O
,	O
we	O
developed	O
a	O
new	O
monoclonal	B-protein
antibody	I-protein
(	O
mAb	B-protein
)	O
raised	O
against	O
the	O
hormone-binding	B-protein
domain	I-protein
(	O
HBD	B-protein
)	O
.	O

For	O
this	O
purpose	O
,	O
mice	O
were	O
immunized	O
with	O
a	O
fusion	B-protein
protein	I-protein
including	O
the	O
sequence	O
Thr729-Lys984	B-protein
of	O
hMR	B-protein
.	O

After	O
ELISA	O
screening	O
,	O
mAb	B-protein
18C7	I-protein
was	O
selected	O
for	O
its	O
specificity	O
towards	O
the	O
HBD	B-protein
.	O

This	O
antibody	O
recognized	O
both	O
the	O
denatured	O
and	O
native	B-protein
MR	I-protein
forms	I-protein
,	O
as	O
well	O
as	O
the	O
hetero-oligomeric	B-protein
MR	I-protein
form	I-protein
and	O
the	O
transformed	B-protein
MR	I-protein
state	I-protein
.	O

By	O
using	O
several	O
HBD	B-protein
subfragments	I-protein
,	O
the	O
mAb	B-protein
18C7	I-protein
epitope	I-protein
was	O
located	O
in	O
the	O
N-terminal	B-protein
region	I-protein
of	O
the	O
HBD	B-protein
from	O
Thr729	B-protein
to	I-protein
Leu765	I-protein
.	O

We	O
then	O
studied	O
the	O
effect	O
of	O
the	O
antibody	O
on	O
aldosterone	O
and	O
progesterone	O
binding	O
to	O
the	O
hMR	B-protein
.	O

When	O
18C7	B-protein
was	O
incubated	O
with	O
liganded	B-protein
MR	I-protein
,	O
it	O
was	O
able	O
to	O
partly	O
displace	O
(	O
20	O
%	O
)	O
the	O
hormone	O
from	O
its	O
binding	O
site	O
.	O

When	O
18C7	B-protein
was	O
incubated	O
with	O
MR	B-protein
before	O
aldosterone	O
or	O
progesterone	O
,	O
the	O
antibody	O
inhibited	O
75-80	O
%	O
of	O
the	O
binding	O
.	O

The	O
effect	O
of	O
18C7	B-protein
on	O
the	O
binding	O
was	O
similar	O
with	O
both	O
hormones	O
.	O

A	O
sucrose	O
gradient	O
analysis	O
indicated	O
the	O
simultaneous	O
presence	O
of	O
two	O
kinds	O
of	O
receptor	O
complexes	O
:	O
the	O
steroid-MR	B-protein
complex	I-protein
and	O
the	O
antibody-MR	B-protein
complex	I-protein
.	O

After	O
its	O
associated	O
proteins	O
,	O
especially	O
the	O
heat-shock	B-protein
protein	I-protein
hsp90	I-protein
,	O
had	O
been	O
cross-linked	O
with	O
the	O
hMR	B-protein
by	O
dimethylpimelimidate	O
,	O
18C7	B-protein
was	O
still	O
able	O
to	O
react	O
with	O
the	O
receptor	O
.	O

Our	O
results	O
indicated	O
that	O
the	O
epitope	B-protein
recognized	O
by	O
18C7	B-protein
was	O
directly	O
implicated	O
in	O
hormone	O
binding	O
.	O

The	O
lack	O
of	O
steroid	O
binding	O
of	O
HBD	B-protein
mutants	O
with	O
the	O
Thr729-Leu765	B-protein
sequence	I-protein
deleted	O
[	O
Jalaguier	O
,	O
Mesnier	O
,	O
Leger	O
and	O
Auzou	O
(	O
1996	O
)	O
J.Steroid	O
Biochem.Mol.Biol.57	O
,	O
43-50	O
]	O
supports	O
this	O
hypothesis	O
.	O

Because	O
of	O
the	O
similar	O
behaviours	O
of	O
aldosterone	O
and	O
progesterone	O
,	O
we	O
conclude	O
that	O
the	O
N-terminal	B-protein
Thr729-Leu765	I-protein
region	I-protein
of	O
the	O
HBD	B-protein
is	O
similarly	O
involved	O
in	O
the	O
binding	O
of	O
both	O
hormones	O
.	O

Molecular	O
cloning	O
of	O
SLAP-130	B-protein
,	O
an	O
SLP-76-associated	B-protein
substrate	I-protein
of	O
the	O
T	B-protein
cell	I-protein
antigen	I-protein
receptor-stimulated	I-protein
protein	I-protein
tyrosine	I-protein
kinases	I-protein
.	O

Previous	O
work	O
has	O
demonstrated	O
that	O
SLP-76	B-protein
,	O
a	O
Grb2-associated	B-protein
tyrosine-phosphorylated	I-protein
protein	I-protein
,	O
augments	O
Interleukin-2	B-DNA
promoter	I-DNA
activity	O
when	O
overexpressed	O
in	O
the	O
Jurkat	B-cell_line
T	I-cell_line
cell	I-cell_line
line	I-cell_line
.	O

This	O
activity	O
requires	O
regions	O
of	O
SLP-76	B-protein
that	O
mediate	O
protein-protein	O
interactions	O
with	O
other	O
molecules	O
in	O
T	B-cell_type
cells	I-cell_type
,	O
suggesting	O
that	O
SLP-76	B-protein
-associated	O
proteins	O
also	O
function	O
to	O
regulate	O
signal	O
transduction	O
.	O

Here	O
we	O
describe	O
the	O
molecular	O
cloning	O
of	O
SLAP-130	B-protein
,	O
a	O
SLP-76-associated	B-protein
phosphoprotein	I-protein
of	O
130	O
kDa	O
.	O

We	O
demonstrate	O
that	O
SLAP-130	B-protein
is	O
hematopoietic	O
cell-specific	O
and	O
associates	O
with	O
the	O
SH2	B-protein
domain	I-protein
of	O
SLP-76	B-protein
.	O

Additionally	O
,	O
we	O
show	O
that	O
SLAP-130	B-protein
is	O
a	O
substrate	O
of	O
the	O
T	B-protein
cell	I-protein
antigen	I-protein
receptor-induced	I-protein
protein	I-protein
tyrosine	B-protein
kinases	I-protein
.	O

Interestingly	O
,	O
we	O
find	O
that	O
in	O
contrast	O
to	O
SLP-76	B-protein
,	O
overexpression	O
of	O
SLAP-130	B-protein
diminishes	O
T	B-protein
cell	I-protein
antigen	I-protein
receptor	I-protein
-induced	O
activation	O
of	O
the	O
interleukin-2	B-DNA
promoter	I-DNA
in	O
Jurkat	B-cell_line
T	I-cell_line
cells	I-cell_line
and	O
interferes	O
with	O
the	O
augmentation	O
of	O
interleukin-2	B-DNA
promoter	I-DNA
activity	O
seen	O
when	O
SLP-76	B-protein
is	O
overexpressed	O
in	O
these	O
cells	O
.	O

These	O
data	O
suggest	O
that	O
SLP-76	B-protein
recruits	O
a	O
negative	O
regulator	O
,	O
SLAP-130	B-protein
,	O
as	O
well	O
as	O
positive	O
regulators	O
of	O
signal	O
transduction	O
in	O
T	B-cell_type
cells	I-cell_type
.	O

Molecular	O
actions	O
of	O
prolactin	O
in	O
the	O
immune	O
system	O
.	O

The	O
immunoregulatory	B-protein
properties	O
of	O
prolactin	O
,	O
a	O
pituitary	O
peptide	O
hormone	O
,	O
have	O
received	O
renewed	O
attention	O
.	O

The	O
prolactin	B-protein
receptor	I-protein
,	O
a	O
member	O
of	O
the	O
hematopoietin/cytokine	B-protein
receptor	I-protein
superfamily	I-protein
,	O
is	O
ubiquitously	O
expressed	O
by	O
cells	O
in	O
the	O
immune	O
system	O
.	O

Certain	O
subpopulations	O
of	O
lymphocytes	B-cell_type
synthesize	O
and	O
secrete	O
biologically	O
active	O
prolactin	O
,	O
which	O
suggests	O
that	O
prolactin	O
can	O
act	O
as	O
an	O
autocrine	O
and/or	O
paracrine	O
factor	O
to	O
modulate	O
the	O
activities	O
of	O
cells	O
of	O
the	O
immune	O
system	O
.	O

This	O
review	O
focuses	O
on	O
the	O
molecular	O
actions	O
of	O
prolactin	O
in	O
the	O
immune	O
system	O
.	O

Emphasis	O
is	O
given	O
to	O
recent	O
information	O
about	O
the	O
molecular	O
mechanisms	O
of	O
prolactin	O
receptor	O
signal	O
transduction	O
,	O
and	O
the	O
signaling	B-protein
molecules	I-protein
and	O
prolactin-inducible	B-DNA
target	I-DNA
genes	I-DNA
that	O
participate	O
in	O
these	O
responses	O
.	O

In	O
particular	O
,	O
the	O
prolactin-inducible	B-DNA
interferon	I-DNA
regulatory	I-DNA
factor-1	I-DNA
gene	I-DNA
and	O
its	O
roles	O
in	O
mediating	O
diverse	O
immune	O
responses	O
.	O

Transcriptional	O
regulation	O
during	O
myelopoiesis	O
.	O

The	O
coordinated	O
production	O
of	O
all	O
blood	B-cell_type
cells	I-cell_type
from	O
a	O
common	B-cell_type
stem	I-cell_type
cell	I-cell_type
is	O
a	O
highly	O
regulated	O
process	O
involving	O
successive	O
stages	O
of	O
commitment	O
and	O
differentiation	O
.	O

From	O
analyses	O
of	O
mice	O
deficient	O
in	O
transcription	B-DNA
factor	I-DNA
genes	I-DNA
and	O
from	O
the	O
characterizations	O
of	O
chromosome	B-DNA
breakpoints	I-DNA
in	O
human	O
leukemias	O
,	O
it	O
has	O
become	O
evident	O
that	O
transcription	B-protein
factors	I-protein
are	O
important	O
regulators	O
of	O
hematopoiesis	O
.	O

During	O
myelopoiesis	O
,	O
which	O
includes	O
the	O
development	O
of	O
granulocytic	B-cell_type
and	I-cell_type
monocytic	I-cell_type
lineages	I-cell_type
,	O
transcription	B-protein
factors	I-protein
from	O
several	O
families	O
are	O
active	O
,	O
including	O
AML1/CBF	B-DNA
beta	I-DNA
,	O
C/EBP	B-DNA
,	O
Ets	B-DNA
,	O
c-Myb	B-DNA
,	O
HOX	B-DNA
,	O
and	O
MZF-1	B-DNA
.	O

Few	O
of	O
these	O
factors	O
are	O
expressed	O
exclusively	O
in	O
myeloid	B-cell_type
cells	I-cell_type
;	O
instead	O
it	O
appears	O
that	O
they	O
cooperatively	O
regulate	O
transcription	O
of	O
myeloid-specific	B-DNA
genes	I-DNA
.	O

Here	O
we	O
discuss	O
recent	O
advances	O
in	O
transcriptional	O
regulation	O
during	O
myelopoiesis	O
.	O

Activation	O
of	O
transcription	O
factor	O
NF-kappa	B-protein
B	I-protein
by	O
phagocytic	O
stimuli	O
in	O
human	O
neutrophils	O
.	O

Phagocytosis	O
represents	O
an	O
important	O
physiological	O
trigger	O
for	O
the	O
inducible	O
expression	O
of	O
several	O
genes	O
in	O
human	B-cell_type
neutrophils	I-cell_type
.	O

Here	O
,	O
we	O
report	O
that	O
a	O
DNA-binding	O
activity	O
primarily	O
consisting	O
of	O
the	O
classical	O
NF-kappa	B-protein
B	I-protein
heterodimer	I-protein
,	O
p50/RelA	B-protein
,	O
is	O
induced	O
in	O
phagocytosing	B-cell_type
neutrophils	I-cell_type
.	O

Under	O
these	O
conditions	O
,	O
NF-kappa	B-protein
B	I-protein
activation	O
was	O
found	O
to	O
be	O
a	O
rapid	O
and	O
transient	O
response	O
,	O
reaching	O
a	O
maximum	O
by	O
10-15	O
min	O
,	O
and	O
returning	O
to	O
near-basal	O
levels	O
by	O
30	O
min	O
.	O

In	O
neutrophils	O
undergoing	O
the	O
phagocytosis	O
of	O
opsonized	O
yeasts	O
,	O
the	O
onset	O
of	O
NF-kappa	B-protein
B	I-protein
activation	O
was	O
paralleled	O
by	O
a	O
decline	O
in	O
immunoreactive	O
I	B-protein
kappa	I-protein
B-alpha	I-protein
protein	O
levels	O
,	O
and	O
the	O
cellular	O
I	B-protein
kappa	I-protein
B	I-protein
-alpha	O
pool	O
was	O
replenished	O
by	O
30	O
min	O
,	O
in	O
agreement	O
with	O
our	O
gel	O
shift	O
data	O
.	O

We	O
conclude	O
that	O
NF-kappa	B-protein
B	I-protein
activation	O
could	O
constitute	O
one	O
of	O
the	O
mechanisms	O
whereby	O
the	O
expression	O
of	O
kappa	B-DNA
B-responsive	I-DNA
genes	I-DNA
is	O
enhanced	O
in	O
phagocytosing	B-cell_type
neutrophils	I-cell_type
.	O

To	O
our	O
knowledge	O
,	O
this	O
represents	O
the	O
first	O
demonstration	O
that	O
phagocytic	O
stimuli	O
can	O
induce	O
NF-kappa	B-protein
B	I-protein
activation	O
in	O
human	B-cell_type
neutrophils	I-cell_type
.	O

Induction	O
of	O
human	O
immunodeficiency	O
virus	O
type	O
1	O
expression	O
in	O
monocytic	B-cell_type
cells	I-cell_type
by	O
Cryptococcus	O
neoformans	O
and	O
Candida	O
albicans	O
.	O

Because	O
candidiasis	O
and	O
cryptococcosis	O
are	O
common	O
in	O
human	O
immunodeficiency	O
virus	O
(	O
HIV	O
)	O
-infected	O
persons	O
,	O
the	O
effect	O
of	O
Cryptococcus	O
neoformans	O
and	O
Candida	O
albicans	O
on	O
HIV	O
expression	O
in	O
monocytic	B-cell_type
cells	I-cell_type
was	O
examined	O
.	O

Stimulation	O
of	O
the	O
latently	O
HIV-infected	B-cell_line
myelomonocytic	I-cell_line
cell	I-cell_line
line	I-cell_line
OM-10.1	O
with	O
C.	O
neoformans	O
and	O
C.	O
albicans	O
in	O
the	O
presence	O
of	O
pooled	O
human	O
serum	O
caused	O
a	O
ratio-dependent	O
increase	O
in	O
HIV	O
production	O
.	O

Induction	O
of	O
HIV	O
by	O
C.	O
neoformans	O
was	O
enhanced	O
by	O
anti-capsular	B-protein
antibody	I-protein
,	O
while	O
induction	O
by	O
both	O
organisms	O
was	O
inhibited	O
by	O
anti-TNF-alpha	B-protein
antibody	I-protein
.	O

In	O
THP-1	O
cells	O
transfected	O
with	O
HIV	B-DNA
plasmid	I-DNA
constructs	I-DNA
,	O
both	O
organisms	O
induced	O
transcription	O
from	O
the	O
HIV	B-DNA
long	I-DNA
terminal	I-DNA
repeat	I-DNA
that	O
was	O
dependent	O
on	O
intact	O
NF-kappaB	B-DNA
binding	I-DNA
sequences	I-DNA
.	O

Thus	O
,	O
C.	O
neoformans	O
and	O
C.	O
albicans	O
enhance	O
HIV	O
expression	O
in	O
monocytic	B-cell_type
cells	I-cell_type
through	O
a	O
TNF-alpha-	O
and	O
NF-kappaB-dependent	O
mechanism	O
.	O

In	O
HIV-infected	O
patients	O
,	O
such	O
enhancement	O
may	O
further	O
impair	O
host	O
immunity	O
and	O
could	O
accelerate	O
the	O
course	O
of	O
HIV	O
disease	O
.	O

Nuclear	O
levels	O
of	O
NF-kappaB	B-protein
correlate	O
with	O
syncytium-forming	O
capacity	O
of	O
8e51	B-cell_line
cells	I-cell_line
,	O
expressing	O
a	O
defective	O
HIV	O
virus	O
.	O

The	O
double	B-DNA
NF-kappaB	I-DNA
site	I-DNA
identified	O
in	O
the	O
LTR	B-DNA
of	O
the	O
human	O
immunodeficiency	O
virus-1	O
(	O
HIV-1	O
)	O
has	O
been	O
demonstrated	O
to	O
be	O
necessary	O
for	O
efficient	O
viral	O
transcription	O
.	O

In	O
this	O
report	O
we	O
present	O
the	O
characterisation	O
of	O
NF-kappaB	B-protein
subunits	I-protein
engaged	O
in	O
complexes	O
binding	O
to	O
the	O
HIV-1	B-DNA
NF-kappaB	I-DNA
site	I-DNA
in	O
human	B-cell_line
8e51	I-cell_line
T-cells	I-cell_line
,	O
that	O
harbour	O
a	O
defective	O
HIV-1	O
.	O

At	O
least	O
four	O
different	O
specific	O
NF-kappaB	B-protein
complexes	I-protein
are	O
present	O
in	O
the	O
nucleus	O
of	O
these	O
cells	O
.	O

With	O
the	O
use	O
of	O
specific	B-protein
antibodies	I-protein
we	O
have	O
determined	O
the	O
composition	O
of	O
each	O
complex	O
using	O
electrophoretic	O
mobility	O
shift	O
assays	O
.	O

The	O
results	O
show	O
the	O
presence	O
of	O
several	O
NF-kappaB	B-protein
family	I-protein
members	I-protein
,	I-protein
with	O
the	O
transactivating	O
RelA	B-protein
being	O
engaged	O
in	O
multiple	O
complexes	O
.	O

The	O
importance	O
of	O
NF-kappaB	B-protein
complexes	I-protein
in	O
viral	O
functions	O
has	O
been	O
established	O
comparing	O
the	O
level	O
of	O
NF-kappaB	O
DNA-binding	O
complexes	O
with	O
syncytia-forming	O
activity	O
of	O
8e51	B-cell_line
cells	I-cell_line
.	O

In	O
fact	O
,	O
8e51	B-cell_line
cells	I-cell_line
that	O
had	O
almost	O
lost	O
their	O
syncytia-forming	O
capacity	O
were	O
found	O
to	O
contain	O
at	O
least	O
10	O
times	O
less	O
active	O
NF-kappaB	B-protein
DNA-binding	I-protein
complex	I-protein
than	O
the	O
actively	B-cell_type
fusing	I-cell_type
cells	I-cell_type
.	O

The	O
correlation	O
is	O
specific	O
as	O
the	O
level	O
of	O
at	O
least	O
three	O
other	O
transcription	B-protein
factors	I-protein
did	O
not	O
change	O
.	O

c-Myb	B-DNA
and	O
Ets	B-protein
proteins	I-protein
synergize	O
to	O
overcome	O
transcriptional	O
repression	O
by	O
ZEB	B-protein
.	O

The	O
Zfh	B-protein
family	I-protein
of	O
zinc	B-protein
finger/homeodomain	I-protein
proteins	I-protein
was	O
first	O
identified	O
in	O
Drosophila	O
where	O
it	O
is	O
required	O
for	O
differentiation	O
of	O
tissues	O
such	O
as	O
the	O
central	O
nervous	O
system	O
and	O
muscle	O
.	O

ZEB	B-protein
,	O
a	O
vertebrate	O
homolog	O
of	O
Zfh-1	B-protein
,	O
binds	O
a	O
subset	O
of	O
E	B-DNA
boxes	I-DNA
and	O
blocks	O
myogenesis	O
through	O
transcriptional	O
repression	O
of	O
muscle	B-DNA
genes	I-DNA
.	O

We	O
present	O
evidence	O
here	O
that	O
ZEB	B-protein
also	O
has	O
an	O
important	O
role	O
in	O
controlling	O
hematopoietic	B-DNA
gene	I-DNA
transcription	O
.	O

Two	O
families	O
of	O
transcription	B-protein
factors	I-protein
that	O
are	O
required	O
for	O
normal	O
hematopoiesis	O
are	O
c-Myb	B-protein
and	O
Ets	B-protein
.	O

These	O
factors	O
act	O
synergistically	O
to	O
activate	O
transcription	O
,	O
and	O
this	O
synergy	O
is	O
required	O
for	O
transcription	O
of	O
at	O
least	O
several	O
important	O
hematopoietic	B-DNA
genes	I-DNA
.	O

ZEB	B-protein
blocks	O
the	O
activity	O
of	O
c-Myb	B-protein
and	O
Ets	B-protein
individually	O
,	O
but	O
together	O
the	O
factors	O
synergize	O
to	O
resist	O
this	O
repression	O
.	O

Such	O
repression	O
imposes	O
a	O
requirement	O
for	O
both	O
c-Myb	B-protein
and	O
Ets	B-protein
for	O
transcriptional	O
activity	O
,	O
providing	O
one	O
explanation	O
for	O
why	O
synergy	O
between	O
these	O
factors	O
is	O
important	O
.	O

The	O
balance	O
between	O
repression	O
by	O
ZEB	B-protein
and	O
transcriptional	O
activation	O
by	O
c-Myb	B-protein
/Ets	B-protein
provides	O
a	O
flexible	O
regulatory	O
mechanism	O
for	O
controlling	O
gene	O
expression	O
in	O
hematopoietic	B-cell_type
cells	I-cell_type
.	O

We	O
demonstrate	O
that	O
one	O
target	O
of	O
this	O
positive/negative	O
regulation	O
in	O
vivo	O
is	O
the	O
alpha4	B-protein
integrin	I-protein
,	O
which	O
play	O
a	O
key	O
role	O
in	O
normal	O
hematopoiesis	O
and	O
function	O
of	O
mature	B-cell_type
leukocytes	I-cell_type
.	O

Comparison	O
of	O
the	O
transactivation	B-protein
domains	I-protein
of	O
Stat5	B-protein
and	O
Stat6	B-protein
in	O
lymphoid	B-cell_type
cells	I-cell_type
and	O
mammary	B-cell_type
epithelial	I-cell_type
cells	I-cell_type
.	O

Stat	B-protein
(	O
signal	B-protein
transducers	I-protein
and	I-protein
activators	I-protein
of	I-protein
transcription	I-protein
)	O
and	O
Jak	B-protein
(	O
Janus	B-protein
kinases	I-protein
)	O
proteins	O
are	O
central	O
components	O
in	O
the	O
signal	O
transduction	O
events	O
in	O
hematopoietic	B-cell_type
and	I-cell_type
epithelial	I-cell_type
cells	I-cell_type
.	O

They	O
are	O
rapidly	O
activated	O
by	O
various	O
cytokines	B-protein
,	O
hormones	O
,	O
and	O
growth	O
factors	O
.	O

Upon	O
ligand	O
binding	O
and	O
cytokine	B-protein
receptor	I-protein
dimerization	O
,	O
Stat	B-protein
proteins	I-protein
are	O
phosphorylated	O
on	O
tyrosine	O
residues	O
by	O
Jak	B-protein
kinases	I-protein
.	O

Activated	O
Stat	B-protein
proteins	I-protein
form	O
homo-	O
or	O
heterodimers	O
,	O
translocate	O
to	O
the	O
nucleus	O
,	O
and	O
induce	O
transcription	O
from	O
responsive	O
genes	O
.	O

Stat5	B-protein
and	O
Stat6	B-protein
are	O
transcription	B-protein
factors	I-protein
active	O
in	O
mammary	B-cell_type
epithelial	I-cell_type
cells	I-cell_type
and	O
immune	O
cells	O
.	O

Prolactin	O
activates	O
Stat5	B-protein
,	O
and	O
interleukin-4	B-protein
(	O
IL-4	B-protein
)	O
activates	O
Stat6	B-protein
.	O

Both	O
cytokines	B-protein
are	O
able	O
to	O
stimulate	O
cell	O
proliferation	O
,	O
differentiation	O
,	O
and	O
survival	O
.	O

We	O
investigated	O
the	O
transactivation	O
potential	O
of	O
Stat6	B-protein
and	O
found	O
that	O
it	O
is	O
not	O
restricted	O
to	O
lymphocytes	O
.	O

IL-4	B-protein
-dependent	O
activation	O
of	O
Stat6	B-protein
was	O
also	O
observed	O
in	O
HC11	B-cell_line
mammary	I-cell_line
epithelial	I-cell_line
cells	I-cell_line
.	O

In	O
these	O
cells	O
,	O
Stat6	B-protein
activation	O
led	O
to	O
the	O
induction	O
of	O
the	O
beta-casein	B-DNA
gene	I-DNA
promoter	I-DNA
.	O

The	O
induction	O
of	O
this	O
promoter	O
was	O
confirmed	O
in	O
COS7	B-cell_line
cells	I-cell_line
.	O

The	O
glucocorticoid	B-protein
receptor	I-protein
was	O
able	O
to	O
further	O
enhance	O
IL-4	B-protein
-induced	O
gene	O
transcription	O
through	O
the	O
action	O
of	O
Stat6	B-protein
.	O

Deletion	O
analysis	O
of	O
the	O
carboxyl-terminal	B-protein
region	I-protein
of	O
Stat6	B-protein
and	O
recombination	O
of	O
this	O
region	O
with	O
a	O
heterologous	B-protein
DNA	I-protein
binding	I-protein
domain	I-protein
allowed	O
the	O
delimitation	O
and	O
characterization	O
of	O
the	O
transactivation	O
domain	O
of	O
Stat6	B-protein
.	O

The	O
potencies	O
of	O
the	O
transactivation	B-protein
domains	I-protein
of	O
Stat5	B-protein
,	O
Stat6	B-protein
,	O
and	O
viral	B-protein
protein	I-protein
VP16	I-protein
were	O
compared	O
.	O

Stat6	B-protein
had	O
a	O
transactivation	O
domain	O
which	O
was	O
about	O
10-fold	O
stronger	O
than	O
that	O
of	O
Stat5	B-protein
.	O

In	O
pre-B	B-cell_type
cells	I-cell_type
(	O
Ba/F3	O
)	O
,	O
the	O
transactivation	O
domain	O
of	O
Stat6	B-protein
was	O
IL-4	B-protein
regulated	O
,	O
independently	O
from	O
its	O
DNA	O
binding	O
function	O
.	O

ETS1	B-protein
,	O
NFkappaB	B-protein
and	O
AP1	B-protein
synergistically	O
transactivate	O
the	O
human	B-DNA
GM-CSF	I-DNA
promoter	I-DNA
.	O

Activation	O
of	O
helper	B-cell_type
T	I-cell_type
cells	I-cell_type
results	O
in	O
coordinate	O
expression	O
of	O
a	O
number	O
of	O
cytokines	B-protein
involved	O
in	O
differentiation	O
,	O
proliferation	O
and	O
activation	O
of	O
the	O
haematopoietic	O
system	O
.	O

Granulocyte-macrophage	B-protein
colony	I-protein
stimulating	I-protein
factor	I-protein
(	O
GM-CSF	B-protein
)	O
is	O
one	O
such	O
cytokine	B-protein
,	O
whose	O
increased	O
expression	O
results	O
mostly	O
from	O
increases	O
in	O
transcription	O
.	O

Cis-acting	B-DNA
elements	I-DNA
with	O
NFkappaB	B-DNA
,	I-DNA
AP1	I-DNA
and	I-DNA
ETS-like	I-DNA
binding	I-DNA
motifs	I-DNA
have	O
been	O
identified	O
in	O
the	O
promoter	O
region	O
of	O
the	O
GM-CSF	B-DNA
gene	I-DNA
,	O
and	O
are	O
important	O
or	O
essential	O
for	O
transcriptional	O
activity	O
following	O
T	O
cell	O
activation	O
.	O

ETS1	B-protein
is	O
a	O
transcription	B-protein
factor	I-protein
of	O
the	O
ETS	B-protein
family	I-protein
that	O
is	O
expressed	O
in	O
T	B-cell_type
cells	I-cell_type
.	O

We	O
have	O
previously	O
shown	O
that	O
ETS1	B-protein
can	O
transactivate	O
GM-CSF	B-protein
in	O
Jurkat	B-cell_line
T	I-cell_line
cells	I-cell_line
,	O
but	O
only	O
after	O
the	O
cells	O
have	O
been	O
stimulated	O
by	O
treatment	O
with	O
PMA	O
and	O
ionomycin	O
,	O
agents	O
that	O
mimic	O
T	O
cell	O
activation	O
.	O

Thus	O
we	O
proposed	O
that	O
ETS1	B-protein
,	O
which	O
is	O
expressed	O
constitutively	O
in	O
Jurkat	B-cell_line
cells	I-cell_line
,	O
may	O
act	O
in	O
concert	O
with	O
PMA/ionomycin	B-protein
inducible	I-protein
factors	I-protein
.	O

Here	O
we	O
show	O
that	O
ETS1	B-protein
can	O
transactivate	O
a	O
GM-CSF	B-DNA
reporter	I-DNA
construct	I-DNA
in	O
unstimulated	O
Jurkat	B-cell_line
cells	I-cell_line
,	O
providing	O
that	O
either	O
NFkappaB	B-protein
or	O
AP1	B-protein
transcription	B-protein
factors	I-protein
are	O
supplied	O
by	O
co-transfection	O
.	O

We	O
confirm	O
that	O
binding	O
of	O
endogenous	O
NFkappaB	B-protein
and	O
AP1	B-protein
is	O
induced	O
following	O
PMA/ionomycin	O
treatment	O
of	O
T	B-cell_type
cells	I-cell_type
.	O

Transactivation	O
by	O
ETS1	B-protein
,	O
NFkappaB	B-protein
and	O
AP1	B-protein
is	O
synergistic	O
,	O
and	O
mutation	O
of	O
the	O
individual	O
binding	O
sites	O
reveals	O
that	O
the	O
transcriptional	O
activities	O
of	O
these	O
factors	O
are	O
interdependent	O
.	O

Our	O
results	O
suggest	O
that	O
constitutive	O
ETS1	B-protein
,	O
and	O
inducible	O
NFkappaB	B-protein
and	O
AP1	B-protein
,	O
cooperate	O
as	O
part	O
of	O
a	O
higher	O
order	O
transcriptional	B-protein
complex	I-protein
in	O
activated	O
T	B-cell_type
cells	I-cell_type
.	O

Abnormal	O
T	B-cell_type
lymphocyte	I-cell_type
development	O
induced	O
by	O
targeted	O
overexpression	O
of	O
IkappaB	B-protein
alpha	I-protein
.	O

A	O
role	O
in	O
thymic	O
maturation	O
for	O
factors	O
of	O
the	O
NF-kappaB	B-protein
family	I-protein
has	O
long	O
been	O
suspected	O
,	O
but	O
not	O
yet	O
proven	O
.	O

Transgenic	O
mice	O
with	O
a	O
lymphocyte-specific	O
defect	O
in	O
NF-kappaB	B-protein
activation	O
were	O
produced	O
by	O
targeted	O
expression	O
of	O
human	O
IkappaB	B-protein
alpha	I-protein
.	O

The	O
thymic	O
cellularity	O
of	O
these	O
mice	O
was	O
significantly	O
decreased	O
.	O

The	O
proportion	O
of	O
mature	O
,	O
TCRhigh	B-cell_type
thymocytes	I-cell_type
of	O
the	O
alphabeta	B-cell_type
lineage	I-cell_type
was	O
reduced	O
,	O
and	O
the	O
remaining	O
TCRhigh	B-cell_type
population	I-cell_type
contained	O
an	O
unusually	O
high	O
proportion	O
of	O
double-positive	B-cell_line
cells	I-cell_line
.	O

This	O
defect	O
in	O
maturation	O
resulted	O
in	O
a	O
transgene	O
dose-dependent	O
reduction	O
in	O
peripheral	B-cell_type
T	I-cell_type
lymphocytes	I-cell_type
,	O
with	O
the	O
CD8	B-cell_type
lineage	I-cell_type
being	O
more	O
severely	O
affected	O
.	O

These	O
data	O
provide	O
direct	O
evidence	O
for	O
the	O
involvement	O
of	O
NF-kappaB/Rel	B-protein
family	I-protein
proteins	I-protein
in	O
late	O
stages	O
of	O
T	B-cell_type
lymphocyte	I-cell_type
development	O
,	O
coincident	O
with	O
positive	O
and	O
negative	O
selection	O
.	O

CD40	B-protein
is	O
a	O
functional	O
activation	B-protein
antigen	I-protein
and	O
B7-independent	B-protein
T	I-protein
cell	I-protein
costimulatory	I-protein
molecule	I-protein
on	O
normal	O
human	B-cell_type
lung	I-cell_type
fibroblasts	I-cell_type
.	O

CD40	B-protein
is	O
an	O
important	O
signaling	O
and	O
activation	O
Ag	O
found	O
on	O
certain	O
bone	B-cell_type
marrow-derived	I-cell_type
cells	I-cell_type
.	O

Recently	O
,	O
CD40	B-protein
also	O
has	O
been	O
shown	O
to	O
be	O
expressed	O
by	O
mesenchymal	B-cell_type
cells	I-cell_type
,	O
including	O
human	B-cell_type
fibroblasts	I-cell_type
.	O

Little	O
is	O
known	O
about	O
the	O
role	O
of	O
CD40	B-protein
in	O
fibroblasts	B-cell_type
.	O

The	O
current	O
study	O
investigates	O
the	O
hypothesis	O
that	O
CD40	B-protein
expressed	O
on	O
lung	B-cell_type
fibroblasts	I-cell_type
is	O
an	O
activation	O
structure	O
and	O
mechanism	O
for	O
interaction	O
with	O
hemopoietic	B-cell_type
cells	I-cell_type
.	O

Communication	O
between	O
resident	O
tissue	O
fibroblasts	B-cell_type
and	O
T	B-cell_type
cells	I-cell_type
is	O
necessary	O
for	O
normal	O
wound	O
healing	O
,	O
and	O
can	O
be	O
pathologic	O
,	O
resulting	O
in	O
tissue	O
fibrosis	O
.	O

Signaling	O
through	O
CD40	B-protein
with	O
soluble	O
CD40	B-protein
ligand	O
stimulated	O
fibroblast	O
activation	O
,	O
as	O
evidenced	O
by	O
mobilization	O
of	O
nuclear	O
factor-kappaB	O
and	O
by	O
induction	O
of	O
the	O
proinflammatory	O
and	O
chemoattractant	O
cytokines	B-protein
IL-6	B-protein
and	O
IL-8	B-protein
.	O

IFN-gamma-primed	B-cell_line
lung	I-cell_line
fibroblasts	I-cell_line
costimulate	O
T	O
lymphocyte	O
proliferation	O
utilizing	O
CD40	B-protein
,	O
but	O
not	O
the	O
well-studied	O
costimulatory	B-protein
molecules	I-protein
B7-1	B-protein
and	O
B7-2	B-protein
.	O

Data	O
reported	O
herein	O
support	O
the	O
hypothesis	O
that	O
cognate	O
interactions	O
between	O
tissue	B-cell_type
fibroblasts	I-cell_type
and	O
infiltrating	O
T	O
lymphocytes	O
,	O
via	O
the	O
CD40	B-protein
/CD40L	B-protein
pathway	O
,	O
augment	O
inflammation	O
and	O
may	O
promote	O
fibrogenesis	O
by	O
activating	O
both	O
cell	O
types	O
.	O

Biphasic	O
control	O
of	O
NF-kappa	B-protein
B	I-protein
activation	O
induced	O
by	O
the	O
triggering	O
of	O
HLA-DR	B-protein
antigens	I-protein
expressed	O
on	O
B	B-cell_type
cells	I-cell_type
.	O

The	O
regulation	O
of	O
NF-kappa	B-protein
B	I-protein
activation	O
following	O
the	O
triggering	O
of	O
HLA-DR	B-protein
antigens	I-protein
by	O
mAb	B-protein
L243	I-protein
has	O
been	O
studied	O
at	O
various	O
times	O
in	O
Raji	B-cell_line
cells	I-cell_line
.	O

Electrophoretic	O
mobility	O
shift	O
assays	O
demonstrated	O
a	O
strong	O
increase	O
of	O
NF-kappa	B-protein
B	I-protein
DNA	O
binding	O
after	O
triggering	O
of	O
HLA-DR	B-protein
antigens	I-protein
.	O

Using	O
TNF-alpha-activity	B-protein
neutralizing	I-protein
antibodies	I-protein
,	O
the	O
authors	O
demonstrated	O
that	O
the	O
upregulation	O
of	O
NF-kappa	B-protein
B	I-protein
was	O
found	O
to	O
depend	O
,	O
at	O
later	O
time	O
point	O
,	O
on	O
an	O
autocrine	O
effect	O
of	O
TNF-alpha	B-protein
secreted	O
following	O
triggering	O
of	O
HLA-DR	B-protein
antigens	I-protein
.	O

In	O
contrast	O
,	O
it	O
was	O
found	O
to	O
be	O
TNF-alpha	B-protein
independent	O
in	O
the	O
early	O
time	O
point	O
.	O

Moreover	O
,	O
the	O
upregulation	O
of	O
NF-kappa	B-protein
B	I-protein
binding	O
activity	O
is	O
regulated	O
by	O
the	O
triggering	O
of	O
selected	O
epitopes	B-protein
of	O
HLA-DR	B-protein
antigens	I-protein
.	O

In	O
fact	O
,	O
mAb	B-protein
L243	I-protein
but	O
not	O
the	O
staphylococcal	B-protein
superantigens	I-protein
,	O
staphylococcal	B-protein
exotoxin	I-protein
toxic	I-protein
shock	I-protein
syndrome	I-protein
toxin-I	I-protein
or	O
staphylococcal	B-protein
enterotoxin	I-protein
B	I-protein
,	O
regulate	O
the	O
NF-kappa	B-protein
B	I-protein
binding	O
activity	O
.	O

Regulation	O
of	O
inosine-5'-monophosphate	B-protein
dehydrogenase	I-protein
type	I-protein
II	I-protein
gene	O
expression	O
in	O
human	B-cell_type
T	I-cell_type
cells	I-cell_type
.	O

Role	O
for	O
a	O
novel	O
5	B-DNA
'	I-DNA
palindromic	I-DNA
octamer	I-DNA
sequence	I-DNA
.	O

Expression	O
of	O
the	O
gene	O
encoding	O
human	B-protein
inosine-	I-protein
5'-monophosphate	I-protein
dehydrogenase	I-protein
(	I-protein
IMPDH	I-protein
)	I-protein
type	I-protein
II	I-protein
,	O
an	O
enzyme	B-protein
catalyzing	O
the	O
rate-limiting	O
step	O
in	O
the	O
generation	O
of	O
guanine	O
nucleotides	O
,	O
is	O
increased	O
more	O
than	O
10-fold	O
in	O
activated	B-cell_type
peripheral	I-cell_type
blood	I-cell_type
T	I-cell_type
lymphocytes	I-cell_type
and	O
is	O
required	O
for	O
T	O
cell	O
activation	O
.	O

We	O
have	O
examined	O
the	O
5'-regulatory	B-DNA
sequences	I-DNA
that	O
are	O
important	O
for	O
the	O
transcriptional	O
regulation	O
of	O
this	O
gene	O
in	O
T	B-cell_type
cells	I-cell_type
.	O

DNase	B-protein
I	I-protein
mapping	O
of	O
genomic	B-DNA
DNA	I-DNA
identified	O
a	O
hypersensitive	B-DNA
element	I-DNA
near	O
the	O
transcription	B-DNA
initiation	I-DNA
site	I-DNA
.	O

Fine	O
mapping	O
by	O
in	O
vivo	O
footprinting	O
demonstrated	O
five	O
transcription	O
factor	O
binding	O
sites	O
that	O
are	O
occupied	O
in	O
both	O
resting	O
and	O
activated	B-cell_type
peripheral	I-cell_type
blood	I-cell_type
T	I-cell_type
lymphocytes	I-cell_type
;	O
these	O
are	O
tandem	B-DNA
CRE	I-DNA
motifs	I-DNA
,	O
a	O
Sp1	B-DNA
site	I-DNA
,	O
an	O
overlapping	O
Egr-1/Sp1	B-DNA
site	I-DNA
,	O
and	O
a	O
novel	O
palindromic	B-DNA
octamer	I-DNA
sequence	I-DNA
(	O
POS	B-DNA
)	O
.	O

The	O
tandem	O
CRE	B-DNA
and	I-DNA
POS	I-DNA
sites	I-DNA
are	O
of	O
major	O
functional	O
importance	O
as	O
judged	O
by	O
mutational	O
and	O
electrophoretic	O
mobility	O
shift	O
analyses	O
.	O

These	O
data	O
provide	O
evidence	O
that	O
expression	O
of	O
the	O
human	B-DNA
IMPDH	I-DNA
type	I-DNA
II	I-DNA
gene	I-DNA
is	O
predominantly	O
regulated	O
by	O
the	O
nuclear	B-protein
factors	I-protein
ATF-2	B-protein
and	O
an	O
as	O
yet	O
unidentified	O
POS-binding	B-protein
protein	I-protein
.	O

Additional	O
major	O
protein-DNA	O
interactions	O
do	O
not	O
occur	O
within	O
the	O
promoter	O
region	O
after	O
T	O
lymphocyte	O
activation	O
,	O
indicating	O
a	O
requirement	O
for	O
additional	O
protein-protein	O
interactions	O
and/or	O
post-translational	O
modifications	O
of	O
pre-bound	B-protein
transcription	I-protein
factors	I-protein
to	O
account	O
for	O
the	O
observed	O
increase	O
in	O
IMPDH	O
type	O
II	O
gene	O
expression	O
.	O

Distinct	O
mechanisms	O
for	O
N-acetylcysteine	O
inhibition	O
of	O
cytokine-induced	B-protein
E-selectin	I-protein
and	O
VCAM-1	B-protein
expression	O
.	O

We	O
have	O
examined	O
the	O
effects	O
of	O
N-acetyl-L-cysteine	O
(	O
NAC	O
)	O
,	O
a	O
well-characterized	O
,	O
thiol-containing	O
antioxidant	O
,	O
on	O
agonist-induced	O
monocytic	O
cell	O
adhesion	O
to	O
endothelial	B-cell_type
cells	I-cell_type
(	O
EC	B-cell_type
)	O
.	O

NAC	O
inhibited	O
interleukin-1	B-protein
(	O
IL-1	B-protein
beta	I-protein
)	O
-induced	O
,	O
but	O
not	O
basal	O
,	O
adhesion	O
with	O
50	O
%	O
inhibition	O
at	O
approximately	O
20	O
mM	O
.	O

Monocytic	O
cell	O
adhesion	O
to	O
EC	B-cell_type
in	O
response	O
to	O
tumor	B-protein
necrosis	I-protein
factor-alpha	I-protein
(	O
TNF-alpha	B-protein
)	O
,	O
lipopolysaccharide	O
(	O
LPS	O
)	O
,	O
alpha-thrombin	B-protein
,	O
or	O
phorbol	O
12-myristate	O
13-acetate	O
(	O
PMA	O
)	O
was	O
similarly	O
inhibited	O
by	O
NAC	O
.	O

Unlike	O
published	O
studies	O
with	O
pyrrolidinedithiocarbamate	O
,	O
which	O
specifically	O
inhibited	O
vascular	B-protein
cell	I-protein
adhesion	I-protein
molecule	I-protein
1	I-protein
(	O
VCAM-1	B-protein
)	O
,	O
NAC	O
inhibited	O
IL-1	B-RNA
beta-induced	I-RNA
mRNA	I-RNA
and	O
cell	O
surface	O
expression	O
of	O
both	O
E-selectin	B-protein
and	O
VCAM-1	B-protein
.	O

NAC	O
had	O
no	O
effect	O
on	O
the	O
half-life	O
of	O
E-selectin	B-RNA
or	I-RNA
VCAM-1	I-RNA
mRNA	I-RNA
.	O

Although	O
NAC	O
reduced	O
nuclear	B-protein
factor-kappa	I-protein
B	I-protein
(	O
NF-kappa	B-protein
B	I-protein
)	O
activation	O
in	O
EC	B-cell_type
as	O
measured	O
by	O
gel-shift	O
assays	O
using	O
an	O
oligonucleotide	B-DNA
probe	I-DNA
corresponding	O
to	O
the	O
consensus	O
NF-kappa	B-DNA
B	I-DNA
binding	I-DNA
sites	I-DNA
of	O
the	O
VCAM-1	B-DNA
gene	I-DNA
(	O
VCAM-NF-kappa	B-protein
B	I-protein
)	O
,	O
the	O
antioxidant	O
had	O
no	O
appreciable	O
effect	O
when	O
an	O
oligomer	O
corresponding	O
to	O
the	O
consensus	B-DNA
NF-kappa	I-DNA
B	I-DNA
binding	I-DNA
site	I-DNA
of	O
the	O
E-selectin	B-DNA
gene	I-DNA
(	O
E-selectin	B-protein
-NF-kappa	B-protein
B	I-protein
)	O
was	O
used	O
.	O

Because	O
NF-kappa	B-protein
B	I-protein
has	O
been	O
reported	O
to	O
be	O
redox	O
sensitive	O
,	O
we	O
studied	O
the	O
effects	O
of	O
NAC	O
on	O
the	O
EC	B-cell_type
redox	O
environment	O
.	O

NAC	O
caused	O
an	O
expected	O
dramatic	O
increase	O
in	O
the	O
reduced	O
glutathione	O
(	O
GSH	O
)	O
levels	O
in	O
EC	B-cell_type
.	O

In	O
vitro	O
studies	O
demonstrated	O
that	O
whereas	O
the	O
binding	O
affinity	O
of	O
NF-kappa	B-protein
B	I-protein
to	O
the	O
VCAM-NF-kappa	B-DNA
B	I-DNA
oligomer	I-DNA
peaked	O
at	O
a	O
GSH-to-oxidized	O
glutathione	O
(	O
GSSG	O
)	O
ratio	O
of	O
approximately	O
200	O
and	O
decreased	O
at	O
higher	O
ratios	O
,	O
the	O
binding	O
to	O
the	O
E-selectin-NF-kappa	B-DNA
B	I-DNA
oligomer	I-DNA
appeared	O
relatively	O
unaffected	O
even	O
at	O
ratios	O
>	O
400	O
,	O
i.e.	O
,	O
those	O
achieved	O
in	O
EC	B-cell_type
treated	O
with	O
40	O
mM	O
NAC	O
.	O

These	O
results	O
suggest	O
that	O
NF-kappa	B-protein
B	I-protein
binding	O
to	O
its	O
consensus	O
sequences	O
in	O
the	O
VCAM-1	B-protein
and	O
E-selectin	B-DNA
gene	I-DNA
exhibits	O
marked	O
differences	O
in	O
redox	O
sensitivity	O
,	O
allowing	O
for	O
differential	O
gene	O
expression	O
regulated	O
by	O
the	O
same	O
transcription	O
factor	O
.	O

Our	O
data	O
also	O
demonstrate	O
that	O
NAC	O
increases	O
the	O
GSH-to-GSSG	O
ratio	O
within	O
the	O
EC	B-cell_type
suggesting	O
one	O
possible	O
mechanism	O
through	O
which	O
this	O
antioxidant	O
inhibits	O
agonist-induced	O
monocyte	O
adhesion	O
to	O
EC	B-cell_type
.	O

Opposite	O
effects	O
of	O
the	O
acute	B-protein
promyelocytic	I-protein
leukemia	I-protein
PML-retinoic	I-protein
acid	I-protein
receptor	I-protein
alpha	I-protein
(	O
RAR	B-protein
alpha	I-protein
)	O
and	O
PLZF-RAR	B-protein
alpha	I-protein
fusion	I-protein
proteins	I-protein
on	O
retinoic	O
acid	O
signalling	O
.	O

Fusion	O
proteins	O
involving	O
the	O
retinoic	O
acid	O
receptor	B-protein
alpha	I-protein
(	O
RAR	B-protein
alpha	I-protein
)	O
and	O
the	O
PML	B-protein
or	O
PLZF	B-protein
nuclear	I-protein
protein	I-protein
are	O
the	O
genetic	O
markers	O
of	O
acute	O
promyelocytic	O
leukemias	O
(	O
APLs	O
)	O
.	O

APLs	O
with	O
the	O
PML-RAR	B-protein
alpha	I-protein
or	O
the	O
PLZF-RAR	B-protein
alpha	I-protein
fusion	I-protein
protein	I-protein
are	O
phenotypically	O
indistinguishable	O
except	O
that	O
they	O
differ	O
in	O
their	O
sensitivity	O
to	O
retinoic	O
acid	O
(	O
RA	O
)	O
-induced	O
differentiation	O
:	O
PML-RAR	B-protein
alpha	I-protein
blasts	O
are	O
sensitive	O
to	O
RA	O
and	O
patients	O
enter	O
disease	O
remission	O
after	O
RA	O
treatment	O
,	O
while	O
patients	O
with	O
PLZF-RAR	B-protein
alpha	I-protein
do	O
not	O
.	O

We	O
here	O
report	O
that	O
(	O
i	O
)	O
like	O
PML-RAR	B-protein
alpha	I-protein
expression	O
,	O
PLZF-RAR	B-protein
alpha	I-protein
expression	O
blocks	O
terminal	O
differentiation	O
of	O
hematopoietic	O
precursor	O
cell	O
lines	O
(	O
U937	B-cell_line
and	O
HL-60	B-cell_line
)	O
in	O
response	O
to	O
different	O
stimuli	O
(	O
vitamin	O
D3	O
,	O
transforming	O
growth	O
factor	O
beta1	O
,	O
and	O
dimethyl	O
sulfoxide	O
)	O
;	O
(	O
ii	O
)	O
PML-RAR	B-protein
alpha	I-protein
,	O
but	O
not	O
PLZF-RAR	B-protein
alpha	I-protein
,	O
increases	O
RA	O
sensitivity	O
of	O
hematopoietic	B-cell_type
precursor	I-cell_type
cells	I-cell_type
and	O
restores	O
RA	O
sensitivity	O
of	O
RA-resistant	B-cell_type
hematopoietic	I-cell_type
cells	I-cell_type
;	O
(	O
iii	O
)	O
PML-RAR	B-protein
alpha	I-protein
and	O
PLZF-RAR	B-protein
alpha	I-protein
have	O
similar	O
RA	O
binding	O
affinities	O
;	O
and	O
(	O
iv	O
)	O
PML-RAR	B-protein
alpha	I-protein
enhances	O
the	O
RA	O
response	O
of	O
RA	B-DNA
target	I-DNA
genes	I-DNA
(	O
those	O
for	O
RAR	B-protein
beta	I-protein
,	O
RAR	B-protein
gamma	I-protein
,	O
and	O
transglutaminase	B-protein
type	I-protein
II	I-protein
[	O
TGase	B-protein
]	O
)	O
in	O
vivo	O
,	O
while	O
PLZF-RAR	B-protein
alpha	I-protein
expression	O
has	O
either	O
no	O
effect	O
(	O
RAR	B-protein
beta	I-protein
)	O
or	O
an	O
inhibitory	O
activity	O
(	O
RAR	B-protein
gamma	I-protein
and	O
type	B-protein
II	I-protein
TGase	I-protein
)	O
.	O

These	O
data	O
demonstrate	O
that	O
PML-RAR	B-protein
alpha	I-protein
and	O
PLZF-RAR	B-protein
alpha	I-protein
have	O
similar	O
(	O
inhibitory	O
)	O
effects	O
on	O
RA-independent	O
differentiation	O
and	O
opposite	O
(	O
stimulatory	O
or	O
inhibitory	O
)	O
effects	O
on	O
RA-dependent	O
differentiation	O
and	O
that	O
they	O
behave	O
in	O
vivo	O
as	O
RA-dependent	B-DNA
enhancers	I-DNA
or	O
inhibitors	O
of	O
RA-responsive	B-DNA
genes	I-DNA
,	O
respectively	O
.	O

Their	O
different	O
activities	O
on	O
the	O
RA	O
signalling	O
pathway	O
might	O
underlie	O
the	O
different	O
responses	O
of	O
PML-RAR	B-protein
alpha	I-protein
and	O
PLZF-RAR	B-protein
alpha	I-protein
APLs	O
to	O
RA	O
treatment	O
.	O

The	O
PLZF-RAR	B-protein
alpha	I-protein
fusion	I-protein
protein	I-protein
contains	O
an	O
approximately	O
120-amino-acid	B-protein
N-terminal	I-protein
motif	I-protein
(	O
called	O
the	O
POZ	B-protein
domain	I-protein
)	O
,	O
which	O
is	O
also	O
found	O
in	O
a	O
variety	O
of	O
zinc	O
finger	O
proteins	O
and	O
a	O
group	O
of	O
poxvirus	B-protein
proteins	I-protein
and	O
which	O
mediates	O
protein-protein	O
interactions	O
.	O

Deletion	O
of	O
the	O
PLZF	B-protein
POZ	I-protein
domain	I-protein
partially	O
abrogated	O
the	O
inhibitory	O
effect	O
of	O
PLZF-RAR	B-protein
alpha	I-protein
on	O
RA-induced	O
differentiation	O
and	O
on	O
RA-mediated	O
type	B-protein
II	I-protein
TGase	I-protein
up-regulation	O
,	O
suggesting	O
that	O
POZ-mediated	O
protein	O
interactions	O
might	O
be	O
responsible	O
for	O
the	O
inhibitory	O
transcriptional	O
activities	O
of	O
PLZF-RAR	B-protein
alpha	I-protein
.	O

A	O
human	O
homologue	O
of	O
the	O
Drosophila	B-protein
Toll	I-protein
protein	I-protein
signals	O
activation	O
of	O
adaptive	O
immunity	O
[	O
see	O
comments	O
]	O

Induction	O
of	O
the	O
adaptive	O
immune	O
response	O
depends	O
on	O
the	O
expression	O
of	O
co-stimulatory	B-protein
molecules	I-protein
and	O
cytokines	B-protein
by	O
antigen-presenting	B-cell_type
cells	I-cell_type
.	O

The	O
mechanisms	O
that	O
control	O
the	O
initial	O
induction	O
of	O
these	O
signals	O
upon	O
infection	O
are	O
poorly	O
understood	O
.	O

It	O
has	O
been	O
proposed	O
that	O
their	O
expression	O
is	O
controlled	O
by	O
the	O
non-clonal	O
,	O
or	O
innate	O
,	O
component	O
of	O
immunity	O
that	O
preceded	O
in	O
evolution	O
the	O
development	O
of	O
an	O
adaptive	O
immune	O
system	O
in	O
vertebrates	O
.	O

We	O
report	O
here	O
the	O
cloning	O
and	O
characterization	O
of	O
a	O
human	B-protein
homologue	I-protein
of	O
the	O
Drosophila	B-protein
toll	I-protein
protein	I-protein
(	O
Toll	B-protein
)	O
which	O
has	O
been	O
shown	O
to	O
induce	O
the	O
innate	O
immune	O
response	O
in	O
adult	O
Drosophila	O
.	O

Like	O
Drosophila	O
Toll	B-protein
,	O
human	B-protein
Toll	I-protein
is	O
a	O
type	O
I	O
transmembrane	O
protein	O
with	O
an	O
extracellular	O
domain	O
consisting	O
of	O
a	O
leucine-rich	B-protein
repeat	I-protein
(	I-protein
LRR	I-protein
)	I-protein
domain	I-protein
,	O
and	O
a	O
cytoplasmic	O
domain	O
homologous	O
to	O
the	O
cytoplasmic	B-protein
domain	I-protein
of	O
the	O
human	B-protein
interleukin	I-protein
(	I-protein
IL	I-protein
)	I-protein
-1	I-protein
receptor	I-protein
.	O

Both	O
Drosophila	O
Toll	B-protein
and	O
the	O
IL-1	O
receptor	O
are	O
known	O
to	O
signal	O
through	O
the	O
NF-kappaB	B-protein
pathway	O
.	O

We	O
show	O
that	O
a	O
constitutively	O
active	O
mutant	O
of	O
human	B-protein
Toll	I-protein
transfected	O
into	O
human	O
cell	O
lines	O
can	O
induce	O
the	O
activation	O
of	O
NF-kappaB	B-protein
and	O
the	O
expression	O
of	O
NF-kappaB-controlled	B-DNA
genes	I-DNA
for	O
the	O
inflammatory	B-protein
cytokines	I-protein
IL-1	B-protein
,	O
IL-6	B-protein
and	O
IL-8	B-protein
,	O
as	O
well	O
as	O
the	O
expression	O
of	O
the	O
co-stimulatory	B-protein
molecule	I-protein
B7.1	B-protein
,	O
which	O
is	O
required	O
for	O
the	O
activation	O
of	O
naive	B-cell_type
T	I-cell_type
cells	I-cell_type
.	O

Role	O
of	O
ascorbate	O
in	O
the	O
activation	O
of	O
NF-kappaB	B-protein
by	O
tumour	B-protein
necrosis	I-protein
factor-alpha	I-protein
in	O
T-cells	B-cell_type
.	O

The	O
first	O
product	O
of	O
ascorbate	O
oxidation	O
,	O
the	O
ascorbate	O
free	O
radical	O
(	O
AFR	O
)	O
,	O
acts	O
in	O
biological	O
systems	O
mainly	O
as	O
an	O
oxidant	O
,	O
and	O
through	O
its	O
role	O
in	O
the	O
plasma	O
membrane	O
redox	O
system	O
exerts	O
different	O
effects	O
on	O
the	O
cell	O
.	O

We	O
have	O
investigated	O
the	O
role	O
of	O
ascorbate	O
,	O
AFR	O
and	O
dehydroascorbate	O
(	O
DHA	O
)	O
in	O
the	O
activation	O
of	O
the	O
NF-kappaB	B-protein
transcription	I-protein
factor	I-protein
in	O
Jurkat	B-cell_line
T-cells	I-cell_line
stimulated	O
by	O
tumour	B-protein
necrosis	I-protein
factor-alpha	I-protein
(	O
TNF-alpha	B-protein
)	O
.	O

Here	O
we	O
show	O
,	O
by	O
electrophoretic	O
mobility	O
shift	O
assays	O
,	O
that	O
ascorbate	O
increases	O
the	O
binding	O
of	O
NF-kappaB	B-protein
to	O
DNA	O
in	O
TNF-alpha-stimulated	B-cell_line
Jurkat	I-cell_line
cells	I-cell_line
.	O

The	O
ability	O
of	O
ascorbate	O
to	O
enhance	O
cytoplasmic	O
inhibitory	O
IkBalpha	B-protein
protein	I-protein
degradation	O
correlates	O
completely	O
with	O
its	O
capacity	O
to	O
induce	O
NF-kappaB	B-protein
binding	O
to	O
DNA	O
and	O
to	O
potentiate	O
NF-kappaB	B-protein
-mediated	O
transactivation	O
of	O
the	O
HIV-1	B-DNA
long	I-DNA
terminal	I-DNA
repeat	I-DNA
promoter	I-DNA
in	O
TNF-alpha-stimulated	B-cell_line
Jurkat	I-cell_line
cells	I-cell_line
but	O
not	O
in	O
cells	O
stimulated	O
with	O
PMA	O
plus	O
ionomycin	O
.	O

AFR	O
behaves	O
like	O
ascorbate	O
,	O
while	O
DHA	O
and	O
ascorbate	O
phosphate	O
do	O
not	O
affect	O
TNF-alpha	B-protein
-mediated	O
NF-kappaB	B-protein
activation	O
.	O

These	O
results	O
provide	O
new	O
evidence	O
for	O
a	O
possible	O
relationship	O
between	O
the	O
activation	O
of	O
the	O
electron-transport	O
system	O
at	O
the	O
plasma	O
membrane	O
by	O
ascorbate	O
or	O
its	O
free	O
radical	O
and	O
redox-dependent	O
gene	O
transcription	O
in	O
T-cells	B-cell_type
.	O

Human	O
cytomegalovirus	O
induces	O
interleukin-8	B-protein
production	O
by	O
a	O
human	B-cell_line
monocytic	I-cell_line
cell	I-cell_line
line	I-cell_line
,	O
THP-1	B-cell_line
,	O
through	O
acting	O
concurrently	O
on	O
AP-1-	B-DNA
and	I-DNA
NF-kappaB-binding	I-DNA
sites	I-DNA
of	O
the	O
interleukin-8	B-DNA
gene	I-DNA
.	O

Cytomegalovirus	O
(	O
CMV	O
)	O
infection	O
induced	O
interleukin-8	B-protein
(	O
IL-8	B-protein
)	O
gene	O
transcription	O
in	O
a	O
human	B-cell_line
monocytic	I-cell_line
cell	I-cell_line
line	I-cell_line
,	O
THP-1	B-cell_line
cells	I-cell_line
,	O
leading	O
to	O
IL-8	B-protein
secretion	O
.	O

The	O
functional	O
analysis	O
of	O
the	O
IL-8	B-DNA
gene	I-DNA
revealed	O
that	O
both	O
AP-1-	B-DNA
and	I-DNA
NF-kappaB	I-DNA
factor-binding	I-DNA
elements	I-DNA
were	O
involved	O
in	O
conferring	O
the	O
responsiveness	O
to	O
CMV	O
.	O

Moreover	O
,	O
electrophoretic	O
mobility	O
shift	O
assays	O
demonstrated	O
that	O
CMV	O
induced	O
the	O
formation	O
of	O
NF-kappaB	B-protein
and	O
AP-1	B-protein
complexes	I-protein
.	O

These	O
results	O
suggest	O
that	O
CMV	O
activates	O
these	O
transcriptional	B-protein
factors	I-protein
,	O
resulting	O
in	O
IL-8	B-protein
gene	O
expression	O
.	O

Construction	O
and	O
biological	O
characterization	O
of	O
an	O
interleukin-12	B-protein
fusion	I-protein
protein	I-protein
(	O
Flexi-12	B-protein
)	O
:	O
delivery	O
to	O
acute	B-cell_type
myeloid	I-cell_type
leukemic	I-cell_type
blasts	I-cell_type
using	O
adeno-associated	O
virus	O
.	O

Interleukin-12	B-protein
(	O
IL-12	B-protein
)	O
is	O
a	O
cytokine	B-protein
that	O
exhibits	O
pleiotropic	O
effects	O
on	O
lymphocytes	B-cell_type
and	O
natural	B-cell_type
killer	I-cell_type
cells	I-cell_type
and	O
has	O
been	O
shown	O
to	O
have	O
promise	O
for	O
the	O
immunotherapy	O
of	O
cancer	O
.	O

The	O
combination	O
of	O
the	O
immune	B-protein
costimulatory	I-protein
molecule	I-protein
B7.1	B-protein
and	O
IL-12	B-protein
has	O
been	O
shown	O
to	O
be	O
synergistic	O
for	O
T	O
cell	O
activation	O
.	O

By	O
transfecting	O
tumor	O
cells	O
with	O
both	O
IL-12	B-DNA
and	I-DNA
B7.1	I-DNA
cDNAs	I-DNA
,	O
it	O
may	O
be	O
possible	O
to	O
use	O
these	O
modified	O
targets	O
as	O
vaccines	O
.	O

A	O
major	O
obstacle	O
in	O
designing	O
a	O
vector	O
to	O
deliver	O
these	O
genes	O
results	O
from	O
the	O
structure	O
of	O
IL-12	B-protein
.	O

Functional	O
IL-12	B-protein
is	O
a	O
heterodimer	B-protein
composed	O
of	O
two	O
distinct	O
subunits	O
that	O
are	O
encoded	O
by	O
separate	O
genes	O
on	O
different	O
chromosomes	O
.	O

Production	O
of	O
functional	B-protein
IL-12	I-protein
requires	O
the	O
coordinated	O
expression	O
of	O
both	O
genes	O
.	O

This	O
presents	O
several	O
problems	O
in	O
vectors	O
,	O
particularly	O
those	O
in	O
which	O
additional	O
genes	O
,	O
either	O
a	O
co-stimulatory	B-DNA
gene	I-DNA
or	O
a	O
selectable	O
marker	O
,	O
are	O
inserted	O
.	O

Therefore	O
,	O
we	O
have	O
constructed	O
a	O
single	O
cDNA	B-DNA
that	O
encodes	O
a	O
single-chain	B-protein
protein	I-protein
,	O
called	O
Flexi-12	B-protein
,	O
which	O
retains	O
all	O
of	O
the	O
biological	O
characteristics	O
of	O
recombinant	O
IL-12	B-protein
(	O
rIL-12	B-protein
)	O
.	O

The	O
monomeric	O
polypeptide	O
Flexi-12	B-protein
is	O
able	O
to	O
induce	O
the	O
proliferation	O
of	O
phytohemagglutinin	B-cell_line
(	I-cell_line
PHA	I-cell_line
)	I-cell_line
blasts	I-cell_line
,	O
induce	O
PHA	B-cell_line
blasts	I-cell_line
to	O
secrete	O
interferon-gamma	B-protein
(	O
IFN-gamma	B-protein
)	O
and	O
additionally	O
,	O
by	O
preincubation	O
,	O
enhance	O
the	O
killing	O
of	O
K562	O
targets	O
by	O
PBLs	B-cell_type
.	O

These	O
phenomena	O
are	O
in	O
a	O
dose-dependent	O
manner	O
comparable	O
to	O
that	O
seen	O
with	O
rIL-12	B-protein
.	O

We	O
have	O
also	O
shown	O
that	O
tyrosine	O
phosphorylation	O
of	O
the	O
STAT	B-protein
4	I-protein
transcription	I-protein
factor	I-protein
,	O
which	O
has	O
been	O
shown	O
to	O
be	O
unique	O
to	O
the	O
IL-12	B-protein
signaling	O
pathway	O
,	O
occurs	O
with	O
Flexi-12	B-protein
at	O
levels	O
similar	O
to	O
those	O
seen	O
with	O
rIL-12	B-protein
.	O

We	O
have	O
packaged	O
Flexi-12	B-protein
into	O
a	O
recombinant	O
adeno-associated	O
virus	O
(	O
AAV	O
)	O
and	O
used	O
this	O
vector	O
to	O
infect	O
acute	B-cell_type
myeloid	I-cell_type
leukemic	I-cell_type
(	I-cell_type
AML	I-cell_type
)	I-cell_type
blasts	I-cell_type
.	O

Infected	O
AML	B-cell_type
blasts	I-cell_type
produced	O
between	O
2	O
and	O
6	O
ng	O
of	O
IL-12/10	O
(	O
6	O
)	O
cells	O
per	O
ml	O
per	O
48	O
hr	O
.	O

These	O
studies	O
also	O
confirm	O
that	O
AAV	O
is	O
an	O
efficient	O
delivery	O
vehicle	O
for	O
cytokines	B-protein
to	O
leukemic	O
cells	O
.	O

Direct	O
analysis	O
of	O
these	O
modified	O
cells	O
acting	O
as	O
tumor	O
vaccines	O
is	O
underway	O
.	O

Plasma	O
sialyltransferase	B-protein
levels	O
in	O
psychiatric	O
disorders	O
as	O
a	O
possible	O
indicator	O
of	O
HPA	O
axis	O
function	O
.	O

A	O
dysfunction	O
in	O
the	O
regulation	O
of	O
the	O
hypothalamic-pituitary-adrenal	O
(	O
HPA	O
)	O
axis	O
,	O
possibly	O
attributed	O
to	O
a	O
change	O
in	O
glucocorticoid	B-protein
receptor	I-protein
(	O
GR	B-protein
)	O
functionality	O
,	O
has	O
been	O
implicated	O
in	O
depression	O
.	O

We	O
have	O
measured	O
both	O
lymphocyte	B-protein
GR	I-protein
receptor	O
binding	O
parameters	O
and	O
plasma	O
sialyltransferase	B-protein
activity	O
,	O
as	O
a	O
biochemical	O
marker	O
of	O
GR	B-protein
function	O
,	O
in	O
two	O
groups	O
of	O
patients	O
suffering	O
from	O
depression	O
or	O
schizophrenia	O
and	O
in	O
a	O
group	O
of	O
age-	O
and	O
sex-matched	O
controls	O
.	O

While	O
there	O
was	O
a	O
significant	O
increase	O
in	O
plasma	O
cortisol	O
levels	O
in	O
the	O
depressed	O
group	O
,	O
there	O
were	O
no	O
changes	O
in	O
the	O
lymphocyte	O
GR	B-protein
binding	O
parameters	O
(	O
K	O
(	O
m	O
)	O
and	O
Bmax	O
)	O
.	O

There	O
was	O
,	O
however	O
,	O
a	O
significant	O
decrease	O
in	O
the	O
plasma	B-protein
sialyltransferase	I-protein
:	I-protein
cortisol	O
ratio	O
in	O
the	O
depressed	O
group	O
suggesting	O
an	O
inability	O
of	O
the	O
raised	O
cortisol	O
levels	O
to	O
induce	O
enzyme	O
expression	O
and	O
this	O
ratio	O
may	O
provide	O
a	O
useful	O
biochemical	O
marker	O
of	O
cortisol	O
receptor	O
function	O
.	O

Although	O
there	O
was	O
an	O
increase	O
in	O
the	O
plasma	O
activity	O
of	O
the	O
alpha	B-protein
2	I-protein
,	I-protein
6	I-protein
sialyltransferase	I-protein
isozyme	I-protein
in	O
the	O
schizophrenic	O
group	O
,	O
no	O
other	O
changes	O
were	O
determined	O
.	O

Therefore	O
,	O
while	O
the	O
total	O
plasma	B-protein
sialyltransferase	I-protein
:	O
cortisol	O
ratio	O
reflects	O
HPA	O
axis	O
function	O
,	O
alterations	O
in	O
specific	O
isozyme	O
activity	O
may	O
also	O
be	O
associated	O
with	O
other	O
CNS	O
disease	O
states	O
.	O

Regulation	O
of	O
CD95	B-protein
(	I-protein
Fas	I-protein
)	I-protein
ligand	I-protein
expression	O
by	O
TCR	B-protein
-mediated	O
signaling	O
events	O
.	O

Stimulation	O
of	O
mature	B-cell_type
peripheral	I-cell_type
T	I-cell_type
cells	I-cell_type
by	O
TCR	B-protein
engagement	O
results	O
in	O
activation	O
of	O
signals	O
that	O
drive	O
induction	O
of	O
cytokine	B-protein
gene	O
expression	O
and	O
clonal	O
expansion	O
.	O

However	O
,	O
under	O
some	O
conditions	O
,	O
engagement	O
of	O
the	O
TCR	B-protein
leads	O
instead	O
to	O
apoptosis	O
.	O

Recent	O
studies	O
demonstrate	O
that	O
TCR	B-protein
-stimulated	O
apoptosis	O
requires	O
expression	O
of	O
CD95	B-protein
ligand	I-protein
on	O
activated	B-cell_type
T	I-cell_type
cells	I-cell_type
followed	O
by	O
an	O
interaction	O
between	O
CD95	B-protein
ligand	I-protein
and	O
the	O
CD95	B-protein
receptor	I-protein
also	O
expressed	O
on	O
this	O
population	O
.	O

The	O
experiments	O
reported	O
in	O
this	O
study	O
were	O
designed	O
to	O
address	O
the	O
signaling	O
events	O
triggered	O
by	O
TCR	B-protein
engagement	O
that	O
are	O
important	O
for	O
regulating	O
CD95	B-protein
ligand	I-protein
gene	O
expression	O
.	O

To	O
approach	O
this	O
,	O
we	O
generated	O
a	O
luciferase	B-DNA
reporter	I-DNA
construct	I-DNA
containing	O
elements	O
of	O
the	O
CD95	B-protein
ligand	I-protein
promoter	O
.	O

Using	O
a	O
previously	O
described	O
mutant	O
of	O
the	O
Jurkat	B-cell_line
T	I-cell_line
cell	I-cell_line
line	I-cell_line
,	O
we	O
show	O
that	O
proximal	O
signaling	O
events	O
dependent	O
on	O
the	O
presence	O
of	O
the	O
CD45	B-protein
tyrosine	I-protein
phosphatase	I-protein
are	O
required	O
for	O
TCR	B-protein
-stimulated	O
CD95	B-protein
ligand	I-protein
expression	O
.	O

Transient	O
transfection	O
studies	O
demonstrate	O
further	O
that	O
TCR	B-protein
-stimulated	O
activation	O
of	O
the	O
Ras	B-protein
signaling	O
pathway	O
is	O
required	O
for	O
optimal	O
activation	O
of	O
CD95	B-protein
ligand	I-protein
.	O

Next	O
,	O
in	O
an	O
effort	O
to	O
determine	O
critical	O
transcription	B-protein
factors	I-protein
that	O
regulate	O
CD95	B-protein
ligand	I-protein
expression	O
,	O
we	O
demonstrate	O
a	O
cyclosporin	B-DNA
A-sensitive	I-DNA
nuclear	I-DNA
factor-AT	I-DNA
response	I-DNA
element	I-DNA
in	O
the	O
promoter	B-DNA
region	I-DNA
of	O
this	O
gene	O
that	O
is	O
critical	O
for	O
optimal	O
CD95	B-protein
ligand	I-protein
reporter	O
activity	O
in	O
stimulated	B-cell_type
T	I-cell_type
cells	I-cell_type
.	O

Together	O
,	O
these	O
studies	O
begin	O
a	O
dissection	O
of	O
the	O
biochemical	O
events	O
that	O
lead	O
to	O
expression	O
of	O
CD95	B-protein
ligand	I-protein
,	O
a	O
required	O
step	O
for	O
TCR	B-protein
-induced	O
apoptosis	O
.	O

Reactive	O
oxygen	O
species	O
and	O
antioxidants	O
in	O
inflammatory	O
diseases	O
.	O

This	O
paper	O
aims	O
to	O
review	O
the	O
role	O
of	O
free	O
radical-induced	O
tissue	O
damage	O
and	O
antioxidant	O
defence	O
mechanisms	O
in	O
inflammatory	O
diseases	O
that	O
involve	O
pathogenic	O
processes	O
similar	O
to	O
the	O
periodontal	O
diseases	O
.	O

There	O
is	O
a	O
clearly	O
defined	O
and	O
substantial	O
role	O
for	O
free	O
radicals	O
or	O
reactive	O
oxygen	O
species	O
(	O
ROS	O
)	O
in	O
periodontitis	O
,	O
but	O
little	O
research	O
has	O
been	O
performed	O
in	O
this	O
area	O
.	O

This	O
paper	O
reviews	O
the	O
considerable	O
data	O
available	O
relating	O
ROS	O
activity	O
and	O
antioxidant	O
defence	O
to	O
inflammatory	O
diseases	O
and	O
attempts	O
to	O
draw	O
parallels	O
with	O
periodontitis	O
,	O
in	O
an	O
effort	O
to	O
stimulate	O
more	O
periodontal	O
research	O
in	O
this	O
important	O
area	O
.	O

The	O
recent	O
discovery	O
of	O
the	O
transcription	B-protein
factor	I-protein
nuclear	I-protein
factor	I-protein
kappa	I-protein
B	I-protein
(	O
NF-kappa	B-protein
B	I-protein
)	O
is	O
reviewed	O
and	O
several	O
potential	O
pathways	O
for	O
cytokine	B-protein
-induced	O
periodontal	O
tissue	O
damage	O
,	O
mediated	O
by	O
NF-kappa	B-protein
B1	I-protein
are	O
discussed	O
.	O

Emphasis	O
is	O
placed	O
on	O
cytokines	B-protein
that	O
have	O
been	O
studied	O
in	O
periodontitis	O
,	O
principally	O
TNF-alpha	B-protein
,	O
IL-1	B-protein
,	O
IL-6	B-protein
,	O
IL-8	B-protein
and	O
beta-interferon	B-protein
.	O

The	O
link	O
between	O
cellular	O
production	O
of	O
such	O
important	O
mediators	O
of	O
inflammation	O
and	O
the	O
antioxidant	O
(	O
AO	O
)	O
thiols	O
,	O
cysteine	O
and	O
reduced	O
glutathione	O
(	O
GSH	O
)	O
,	O
is	O
discussed	O
and	O
it	O
is	O
hypothesised	O
that	O
NF-kappa	B-protein
B	I-protein
antagonists	O
may	O
offer	O
important	O
therapeutic	O
benefits	O
.	O

Mutations	O
in	O
the	O
TSC2	B-DNA
gene	I-DNA
:	O
analysis	O
of	O
the	O
complete	O
coding	O
sequence	O
using	O
the	O
protein	O
truncation	O
test	O
(	O
PTT	O
)	O
.	O

Mutations	O
in	O
the	O
TSC2	B-DNA
gene	I-DNA
on	O
chromosome	B-DNA
16p13.3	I-DNA
are	O
responsible	O
for	O
approximately	O
50	O
%	O
of	O
familial	O
tuberous	O
sclerosis	O
(	O
TSC	O
)	O
.	O

The	O
gene	O
has	O
41	B-DNA
small	I-DNA
exons	I-DNA
spanning	O
45	B-DNA
kb	I-DNA
of	O
genomic	B-DNA
DNA	I-DNA
and	O
encoding	O
a	O
5.5	B-RNA
kb	I-RNA
mRNA	I-RNA
.	O

Large	O
germline	O
deletions	O
of	O
TSC2	B-DNA
occur	O
in	O
<	O
5	O
%	O
of	O
cases	O
,	O
and	O
a	O
number	O
of	O
small	O
intragenic	O
mutations	O
have	O
been	O
described	O
.	O

We	O
analysed	O
mRNA	O
from	O
18	O
unrelated	O
cases	O
of	O
TSC	O
for	O
TSC2	B-DNA
mutations	I-DNA
using	O
the	O
protein	O
truncation	O
test	O
(	O
PTT	O
)	O
.	O

Three	O
cases	O
were	O
predicted	O
to	O
be	O
TSC2	B-DNA
mutations	I-DNA
on	O
the	O
basis	O
of	O
linkage	O
analysis	O
or	O
because	O
a	O
hamartoma	O
from	O
the	O
patient	O
showed	O
loss	O
of	O
heterozygosity	O
for	O
16p13.3	B-DNA
markers	I-DNA
.	O

Three	O
overlapping	O
PCR	B-DNA
products	I-DNA
,	O
covering	O
the	O
complete	O
coding	O
sequence	O
of	O
mRNA	B-RNA
,	O
were	O
generated	O
from	O
lymphoblastoid	B-cell_line
cell	I-cell_line
lines	I-cell_line
,	O
translated	O
into	O
35S-methionine	B-protein
labelled	I-protein
protein	I-protein
,	O
and	O
analysed	O
by	O
SDS-PAGE	O
.	O

PCR	B-DNA
products	I-DNA
showing	O
PTT	O
shifts	O
were	O
directly	O
sequenced	O
,	O
and	O
mutations	O
confirmed	O
by	O
restriction	O
enzyme	O
digestion	O
where	O
possible	O
.	O

Six	O
PTT	O
shifts	O
were	O
identified	O
.	O

Five	O
of	O
these	O
were	O
caused	O
by	O
mutations	O
predicted	O
to	O
produce	O
a	O
truncated	B-protein
protein	I-protein
:	O
(	O
i	O
)	O
a	O
sporadic	O
case	O
showed	O
a	O
32	B-DNA
bp	I-DNA
deletion	I-DNA
in	O
exon	B-RNA
11	I-RNA
,	O
and	O
a	O
mutant	B-RNA
mRNA	I-RNA
without	O
exon	B-RNA
11	I-RNA
was	O
produced	O
;	O
the	O
normal	O
exon	O
10	O
was	O
also	O
spliced	O
out	O
;	O
(	O
ii	O
)	O
a	O
sporadic	O
case	O
had	O
a	O
1	B-DNA
bp	I-DNA
deletion	I-DNA
in	O
exon	B-RNA
12	I-RNA
(	O
1634delT	B-RNA
)	O
;	O
(	O
iii	O
)	O
a	O
TSC2-linked	B-RNA
mother	I-RNA
and	I-RNA
daughter	I-RNA
pair	I-RNA
had	O
a	O
G	O
--	O
>	O
T	O
transversion	O
in	O
exon	B-RNA
23	I-RNA
(	O
G2715T	B-RNA
)	O
introducing	O
a	O
cryptic	O
splice	O
site	O
causing	O
a	O
29	O
bp	O
truncation	O
of	O
mRNA	O
from	O
exon	B-RNA
23	I-RNA
;	O
(	O
iv	O
)	O
a	O
sporadic	O
case	O
showed	O
a	O
2	B-DNA
bp	I-DNA
deletion	I-DNA
in	O
exon	B-RNA
36	I-RNA
;	O
(	O
v	O
)	O
a	O
sporadic	O
case	O
showed	O
a	O
1	B-DNA
bp	I-DNA
insertion	I-DNA
disrupting	O
the	O
donor	O
splice	O
site	O
of	O
exon	B-RNA
37	I-RNA
(	O
5007+2insA	B-RNA
)	O
,	O
resulting	O
in	O
the	O
use	O
of	O
an	O
upstream	B-RNA
exonic	I-RNA
cryptic	I-RNA
splice	I-RNA
site	I-RNA
to	O
cause	O
a	O
29	B-RNA
bp	I-RNA
truncation	I-RNA
of	O
mRNA	B-RNA
from	O
exon	B-RNA
37	I-RNA
.	O

In	O
one	O
case	O
,	O
the	O
PTT	O
shift	O
was	O
explained	O
by	O
in-frame	O
splicing	O
out	O
of	O
exon	B-RNA
10	I-RNA
,	O
in	O
the	O
presence	O
of	O
a	O
normal	B-DNA
exon	I-DNA
10	I-DNA
genomic	I-DNA
sequence	I-DNA
.	O

Alternative	O
splicing	O
of	O
exon	B-RNA
10	I-RNA
of	O
the	O
TSC2	B-DNA
gene	I-DNA
may	O
be	O
a	O
normal	O
variant	O
.	O

Three	O
3rd	O
base	O
substitution	O
polymorphisms	O
were	O
also	O
detected	O
during	O
direct	O
sequencing	O
of	O
PCR	B-DNA
products	I-DNA
.	O

Confirmed	O
mutations	O
were	O
identified	O
in	O
28	O
%	O
of	O
the	O
families	O
studied	O
and	O
on	O
the	O
assumption	O
that	O
half	O
of	O
the	O
sporadic	O
cases	O
should	O
have	O
TSC2	B-DNA
mutations	I-DNA
,	O
a	O
crude	O
estimate	O
of	O
the	O
detection	O
rate	O
would	O
be	O
60	O
%	O
.	O

This	O
compares	O
favourably	O
with	O
other	O
screening	O
methods	O
used	O
for	O
TSC2	B-DNA
,	O
notably	O
SSCP	O
,	O
and	O
since	O
PTT	O
involves	O
much	O
less	O
work	O
it	O
may	O
be	O
the	O
method	O
of	O
choice	O
.	O

alpha-Tocopheryl	O
succinate	O
inhibits	O
monocytic	O
cell	O
adhesion	O
to	O
endothelial	B-cell_type
cells	I-cell_type
by	O
suppressing	O
NF-kappa	B-protein
B	I-protein
mobilization	O
.	O

The	O
adherence	O
of	O
monocytes	B-cell_type
to	O
activated	O
endothelium	O
is	O
an	O
early	O
event	O
in	O
atherogenesis	O
.	O

Because	O
antioxidants	O
have	O
been	O
considered	O
to	O
be	O
of	O
antiatherosclerotic	O
potential	O
,	O
we	O
investigated	O
the	O
effects	O
of	O
alpha-tocopherol	O
(	O
TCP	O
)	O
and	O
its	O
acetate	O
and	O
succinate	O
esters	O
on	O
monocyte	O
adhesion	O
to	O
cytokine-stimulated	B-cell_line
human	I-cell_line
umbilical	I-cell_line
vein	I-cell_line
endothelial	I-cell_line
cells	I-cell_line
(	O
HUVEC	B-cell_line
)	O
.	O

Endothelial	B-cell_type
cells	I-cell_type
were	O
treated	O
with	O
TCP	O
,	O
alpha-tocopherol	O
acetate	O
(	O
TCP	O
acetate	O
)	O
,	O
or	O
alpha-tocopheryl	O
succinate	O
(	O
TCP	O
succinate	O
)	O
before	O
stimulation	O
with	O
tumor	B-protein
necrosis	I-protein
factor-alpha	I-protein
(	O
TNF-alpha	B-protein
;	O
10	O
U/ml	O
,	O
6	O
h	O
)	O
or	O
interleukin-1	B-protein
beta	I-protein
(	O
IL-1	B-protein
beta	I-protein
;	O
10	O
U/ml	O
,	O
6	O
h	O
)	O
.	O

Cytokine-stimulated	O
cell	O
surface	O
expression	O
of	O
vascular	B-protein
cell	I-protein
adhesion	I-protein
molecule-1	I-protein
(	O
VCAM-1	B-protein
,	O
CD106	B-protein
)	O
and	O
E-selectin	B-protein
(	O
ELAM-1	B-protein
,	O
CD62E	B-protein
)	O
,	O
but	O
not	O
of	O
intercellular	B-protein
adhesion	I-protein
molecule-1	I-protein
(	O
ICAM-1	B-protein
,	O
CD54	B-protein
)	O
,	O
was	O
time-	O
and	O
dose-dependently	O
inhibited	O
by	O
TCP	O
succinate	O
but	O
not	O
by	O
TCP	O
or	O
TCP	O
acetate	O
.	O

TCP	O
succinate	O
(	O
200	O
microM	O
,	O
24	O
h	O
)	O
reduced	O
TNF-induced	B-protein
VCAM-1	I-protein
and	O
E-selectin	B-protein
expression	O
from	O
a	O
specific	O
mean	O
fluorescence	O
intensity	O
of	O
151	O
+/-	O
28	O
to	O
12	O
+/-	O
4	O
channels	O
and	O
from	O
225	O
+/-	O
38	O
to	O
79	O
+/-	O
21	O
channels	O
,	O
respectively	O
.	O

Succinate	O
alone	O
had	O
no	O
effect	O
.	O

Decreased	O
adhesion	B-protein
molecule	I-protein
expression	O
was	O
associated	O
with	O
a	O
reduction	O
of	O
monocytic	O
cell	O
adhesion	O
.	O

TCP	O
succinate	O
(	O
20	O
microM	O
,	O
72	O
h	O
)	O
,	O
but	O
not	O
TCP	O
(	O
200	O
microM	O
,	O
72	O
h	O
)	O
,	O
reduced	O
U-937	B-cell_line
cell	I-cell_line
adhesion	O
to	O
TNF-alpha-stimulated	B-cell_line
(	I-cell_line
10	I-cell_line
U/ml	I-cell_line
,	I-cell_line
6	I-cell_line
h	I-cell_line
)	I-cell_line
HUVEC	I-cell_line
by	O
30	O
%	O
(	O
P	O
<	O
0.025	O
)	O
and	O
to	O
IL-1	B-cell_line
beta-stimulated	I-cell_line
HUVEC	I-cell_line
by	O
56	O
%	O
(	O
P	O
<	O
0.010	O
)	O
.	O

Electrophoretic	O
mobility-shift	O
assays	O
of	O
HUVEC	B-cell_line
nuclear	B-protein
proteins	I-protein
revealed	O
a	O
decrease	O
in	O
TNF-alpha-stimulated	B-protein
nuclear	I-protein
factor-kappa	I-protein
B	I-protein
(	O
NF-kappa	B-protein
B	I-protein
)	O
activation	O
after	O
pretreatment	O
of	O
HUVEC	B-cell_line
with	O
TCP	O
succinate	O
but	O
not	O
with	O
TCP	O
,	O
TCP	O
acetate	O
,	O
or	O
succinate	O
alone	O
.	O

In	O
conclusion	O
,	O
we	O
demonstrate	O
that	O
the	O
vitamin	O
E	O
derivative	O
TCP	O
succinate	O
prevents	O
monocytic	O
cell	O
adhesion	O
to	O
cytokine-stimulated	O
endothelial	B-cell_type
cells	I-cell_type
by	O
inhibiting	O
the	O
activation	O
of	O
NF-kappa	B-protein
B	I-protein
,	O
further	O
emphasizing	O
the	O
antiatherosclerotic	O
potential	O
of	O
lipid	O
soluble	O
antioxidants	O
.	O

The	O
product	O
of	O
the	O
murine	B-DNA
homolog	I-DNA
of	O
the	O
Drosophila	B-DNA
extra	I-DNA
sex	I-DNA
combs	I-DNA
gene	I-DNA
displays	O
transcriptional	B-protein
repressor	I-protein
activity	O
.	O

The	O
heterogeneous	B-protein
nuclear	I-protein
ribonucleoprotein	I-protein
K	I-protein
protein	I-protein
represents	O
a	O
novel	O
class	O
of	O
proteins	O
that	O
may	O
act	O
as	O
docking	O
platforms	O
that	O
orchestrate	O
cross-talk	O
among	O
molecules	O
involved	O
in	O
signal	O
transduction	O
and	O
gene	O
expression	O
.	O

Using	O
a	O
fragment	O
of	O
K	B-protein
protein	I-protein
as	O
bait	O
in	O
the	O
yeast	O
two-hybrid	O
screen	O
,	O
we	O
isolated	O
a	O
cDNA	B-DNA
that	O
encodes	O
a	O
protein	O
whose	O
primary	O
structure	O
has	O
extensive	O
similarity	O
to	O
the	O
Drosophila	B-protein
melanogaster	I-protein
extra	I-protein
sex	I-protein
combs	I-protein
(	I-protein
esc	I-protein
)	I-protein
gene	I-protein
product	I-protein
,	O
Esc	B-protein
,	O
a	O
putative	O
silencer	O
of	O
homeotic	B-DNA
genes	I-DNA
.	O

The	O
cDNA	B-DNA
that	O
we	O
isolated	O
is	O
identical	O
to	O
the	O
cDNA	B-DNA
of	O
the	O
recently	O
positionally	O
cloned	O
mouse	B-DNA
embryonic	I-DNA
ectoderm	I-DNA
development	I-DNA
gene	I-DNA
,	O
eed	O
.	O

Like	O
Esc	B-protein
,	O
Eed	B-protein
contains	O
six	O
WD-40	B-protein
repeats	I-protein
in	O
the	O
C-terminal	B-protein
half	I-protein
of	O
the	O
protein	O
and	O
is	O
thought	O
to	O
repress	O
homeotic	O
gene	O
expression	O
during	O
mouse	O
embryogenesis	O
.	O

Eed	B-protein
binds	O
to	O
K	B-protein
protein	I-protein
through	O
a	O
domain	O
in	O
its	O
N	B-protein
terminus	I-protein
,	O
but	O
interestingly	O
,	O
this	O
domain	O
is	O
not	O
found	O
in	O
the	O
Drosophila	O
Esc	B-protein
.	O

Gal4-Eed	B-protein
fusion	I-protein
protein	I-protein
represses	O
transcription	O
of	O
a	O
reporter	O
gene	O
driven	O
by	O
a	O
promoter	O
that	O
contains	O
Gal4-binding	B-DNA
DNA	I-DNA
elements	I-DNA
.	O

Eed	B-protein
also	O
represses	O
transcription	O
when	O
recruited	O
to	O
a	O
target	O
promoter	O
by	O
Gal4-K	B-protein
protein	I-protein
.	O

Point	O
mutations	O
within	O
the	O
eed	O
gene	O
that	O
are	O
responsible	O
for	O
severe	O
embryonic	O
development	O
abnormalities	O
abolished	O
the	O
transcriptional	B-protein
repressor	I-protein
activity	O
of	O
Eed	B-protein
.	O

Results	O
of	O
this	O
study	O
suggest	O
that	O
Eed	B-protein
-restricted	O
homeotic	O
gene	O
expression	O
during	O
embryogenesis	O
reflects	O
the	O
action	O
of	O
Eed	B-protein
as	O
a	O
transcriptional	B-protein
repressor	I-protein
.	O

The	O
Eed	B-protein
-mediated	O
transcriptional	O
effects	O
are	O
likely	O
to	O
reflect	O
the	O
interaction	O
of	O
Eed	B-protein
with	O
multiple	O
molecular	O
partners	O
,	O
including	O
K	B-protein
protein	I-protein
.	O

Interferons	B-protein
up-regulate	O
STAT1	B-protein
,	O
STAT2	B-protein
,	O
and	O
IRF	B-protein
family	O
transcription	O
factor	O
gene	O
expression	O
in	O
human	B-cell_type
peripheral	I-cell_type
blood	I-cell_type
mononuclear	I-cell_type
cells	I-cell_type
and	O
macrophages	B-cell_type
.	O

IFN	B-protein
signaling	O
is	O
mediated	O
by	O
binding	O
of	O
IFNs	B-protein
to	O
their	O
receptors	O
and	O
subsequent	O
activation	O
of	O
Janus	O
tyrosine	O
kinase	O
(	O
JAK	B-protein
)	O
-	O
STAT	B-protein
signaling	O
pathway	O
.	O

Stimulation	O
of	O
cells	O
with	O
IFN-alpha	B-protein
leads	O
to	O
the	O
assembly	O
of	O
IFN-stimulated	B-protein
gene	I-protein
factor	I-protein
3	I-protein
transcription	I-protein
factor	I-protein
complex	I-protein
formed	O
by	O
STAT1	B-protein
,	O
STAT2	B-protein
,	O
and	O
p48	B-protein
protein	I-protein
.	O

IFN-gamma	B-protein
signaling	O
is	O
mediated	O
by	O
homodimeric	B-protein
STAT1	I-protein
protein	I-protein
.	O

Although	O
these	O
signaling	O
molecules	O
are	O
expressed	O
constitutively	O
,	O
there	O
is	O
also	O
evidence	O
of	O
transcriptional	O
regulation	O
by	O
IFNs	B-protein
.	O

We	O
have	O
characterized	O
the	O
expression	O
of	O
STAT	B-protein
and	I-protein
IFN	I-protein
regulatory	I-protein
factor	I-protein
(	I-protein
IRF	I-protein
)	I-protein
family	I-protein
transcription	I-protein
factors	I-protein
in	O
primary	B-cell_type
human	I-cell_type
blood	I-cell_type
mononuclear	I-cell_type
cells	I-cell_type
and	O
macrophages	B-cell_type
in	O
response	O
to	O
IFN-alpha	O
and	O
IFN-gamma	O
stimulation	O
.	O

We	O
show	O
that	O
IFN-alpha	B-protein
and	O
IFN-gamma	B-protein
rapidly	O
and	O
efficiently	O
enhanced	O
STAT1	B-protein
,	O
STAT2	B-protein
,	O
p48	B-protein
,	O
and	O
IRF-1	B-DNA
gene	I-DNA
expression	O
.	O

IFN-gamma	B-protein
induced	O
IRF-1	B-DNA
gene	I-DNA
expression	O
more	O
strongly	O
than	O
IFN-alpha	B-protein
.	O

Stimulation	O
experiments	O
in	O
the	O
presence	O
of	O
protein	O
synthesis	O
inhibitor	O
,	O
cycloheximide	O
,	O
suggested	O
that	O
these	O
genes	O
were	O
activated	O
directly	O
by	O
IFNs	B-protein
.	O

IRF-2	B-DNA
gene	I-DNA
was	O
apparently	O
only	O
weakly	O
responsive	O
to	O
IFNs	B-protein
in	O
these	O
cells	O
.	O

When	O
macrophages	B-cell_type
were	O
pretreated	O
with	O
low	O
doses	O
of	O
IFN-gamma	B-protein
and	O
then	O
stimulated	O
with	O
IFN-alpha	B-protein
,	O
clearly	O
enhanced	O
formation	O
of	O
specific	O
transcription	B-protein
factor	I-protein
complexes	O
was	O
detected	O
.	O

This	O
suggests	O
that	O
higher	O
intracellular	O
levels	O
of	O
STAT1	B-protein
,	O
STAT2	B-protein
,	O
and	O
p48	B-protein
protein	I-protein
may	O
result	O
in	O
enhanced	O
signal	O
transduction	O
for	O
cytokines	B-protein
utilizing	O
these	O
transcription	B-protein
factors	I-protein
.	O

The	O
role	O
of	O
nuclear	B-protein
factor-kappa	I-protein
B	I-protein
in	O
cytokine	B-DNA
gene	I-DNA
regulation	O
.	O

Transcription	B-protein
factors	I-protein
are	O
DNA-binding	B-protein
proteins	I-protein
that	O
regulate	O
gene	O
expression	O
.	O

Nuclear	B-protein
factor-kappa	I-protein
B	I-protein
(	O
NF-kappa	B-protein
B	I-protein
)	O
is	O
a	O
critical	O
transcription	B-protein
factor	I-protein
for	O
maximal	O
expression	O
of	O
many	O
cytokines	B-protein
that	O
are	O
involved	O
in	O
the	O
pathogenesis	O
of	O
inflammatory	O
diseases	O
,	O
such	O
as	O
adult	O
respiratory	O
distress	O
syndrome	O
(	O
ARDS	O
)	O
and	O
sepsis	O
syndrome	O
.	O

Activation	O
and	O
regulation	O
of	O
NF-kappa	B-protein
B	I-protein
are	O
tightly	O
controlled	O
by	O
a	O
group	O
of	O
inhibitory	B-protein
proteins	I-protein
(	O
I	B-protein
kappa	I-protein
B	I-protein
)	O
that	O
sequester	O
NF-kappa	B-protein
B	I-protein
in	O
the	O
cytoplasm	O
of	O
immune/inflammatory	B-cell_type
effector	I-cell_type
cells	I-cell_type
.	O

NF-kappa	B-protein
B	I-protein
activation	O
involves	O
signaled	O
phosphorylation	O
,	O
ubiquitination	O
,	O
and	O
proteolysis	O
of	O
I	B-protein
kappa	I-protein
B	I-protein
.	O

Liberated	O
NF-kappa	B-protein
B	I-protein
migrates	O
to	O
the	O
nucleus	O
,	O
where	O
it	O
binds	O
to	O
specific	B-DNA
promoter	I-DNA
sites	I-DNA
and	O
activates	O
gene	O
transcription	O
.	O

The	O
activation	O
of	O
NF-kappa	B-protein
B	I-protein
initiates	O
both	O
extracellular	O
and	O
intracellular	O
regulatory	O
events	O
that	O
result	O
in	O
autoregulation	O
of	O
the	O
inflammatory	O
cascade	O
through	O
modulation	O
of	O
NF-kappa	B-protein
B	I-protein
activation	O
.	O

Recently	O
,	O
activation	O
of	O
NF-kappa	B-protein
B	I-protein
has	O
been	O
linked	O
to	O
ARDS	O
and	O
has	O
been	O
shown	O
to	O
be	O
a	O
critical	O
proximal	O
step	O
in	O
the	O
initiation	O
of	O
neutrophilic	O
inflammation	O
in	O
animal	O
models	O
.	O

Activation	O
of	O
NF-kappa	B-protein
B	I-protein
can	O
be	O
inhibited	O
in	O
vivo	O
by	O
treatment	O
with	O
antioxidants	O
,	O
corticosteroids	O
,	O
and	O
the	O
induction	O
of	O
endotoxin	B-protein
tolerance	O
.	O

Identification	O
of	O
more	O
specific	O
and	O
efficacious	O
inhibitors	O
of	O
NF-kappa	B-protein
B	I-protein
activation	O
might	O
prove	O
beneficial	O
for	O
the	O
treatment	O
of	O
cytokine-mediated	O
inflammatory	O
diseases	O
.	O

Chimeric	B-protein
oncoprotein	I-protein
E2a-Pbx1	B-protein
induces	O
apoptosis	O
of	O
hematopoietic	B-cell_type
cells	I-cell_type
by	O
a	O
p53	B-protein
-independent	O
mechanism	O
that	O
is	O
suppressed	O
by	O
Bcl-2	B-protein
.	O

The	O
chimeric	B-protein
oncoprotein	I-protein
E2a-Pbx1	B-protein
results	O
from	O
fusion	O
of	O
the	O
E2A	B-DNA
and	I-DNA
PBX1	I-DNA
genes	I-DNA
following	O
t	B-DNA
(	I-DNA
1	I-DNA
;	I-DNA
19	I-DNA
)	I-DNA
chromosomal	I-DNA
translocations	I-DNA
in	O
B	O
cell	O
precursor	O
acute	O
leukemias	O
.	O

Experimentally	O
B	B-cell_type
cell	I-cell_type
progenitors	I-cell_type
do	O
not	O
tolerate	O
constitutive	O
expression	O
of	O
E2a-Pbx1	B-protein
which	O
contrasts	O
with	O
transformation	O
of	O
several	O
other	O
cell	O
types	O
following	O
its	O
stable	O
expression	O
both	O
in	O
vitro	O
and	O
in	O
vivo	O
.	O

To	O
further	O
investigate	O
the	O
effects	O
of	O
E2a-Pbx1	B-protein
on	O
the	O
B	B-cell_type
cell	I-cell_type
progenitors	I-cell_type
,	O
we	O
conditionally	O
expressed	O
E2a-Pbx1	B-protein
under	O
control	O
of	O
a	O
metal	O
response	O
element	O
in	O
hematopoietic	B-cell_line
precursor	I-cell_line
cell	I-cell_line
lines	I-cell_line
in	O
vitro	O
.	O

Inducible	O
expression	O
of	O
E2a-Pbx1	B-protein
resulted	O
in	O
cell	O
death	O
with	O
the	O
morphologic	O
and	O
molecular	O
features	O
of	O
apoptosis	O
.	O

A	O
structure-function	O
analysis	O
demonstrated	O
that	O
induction	O
of	O
apoptosis	O
was	O
not	O
a	O
dominant-negative	O
effect	O
of	O
the	O
E2a	B-protein
moiety	I-protein
but	O
,	O
rather	O
,	O
required	O
the	O
DNA-binding	B-protein
homeodomain	I-protein
of	O
Pbx1	B-protein
.	O

E2a-	O
Pbx1	B-protein
-induced	O
apoptosis	O
proceeded	O
through	O
a	O
BCL2	B-protein
-responsive	O
checkpoint	O
eventuating	O
in	O
PARP	B-protein
inactivation	O
but	O
did	O
require	O
p53	B-protein
.	O

Constitutive	O
expression	O
of	O
E2a-Pbx1	B-protein
did	O
not	O
induce	O
apoptosis	O
or	O
continued	O
cycling	O
of	O
Rat-1	B-cell_line
fibroblasts	I-cell_line
in	O
low	O
serum	O
conditions	O
.	O

These	O
studies	O
demonstrate	O
that	O
E2a-Pbx1	B-protein
initiates	O
programmed	O
cell	O
death	O
of	O
hematopoietic	B-cell_type
precursers	I-cell_type
by	O
a	O
mechanism	O
that	O
requires	O
its	O
chimeric	O
transcriptional	O
properties	O
,	O
but	O
,	O
unlike	O
other	O
nuclear	B-protein
oncoproteins	I-protein
,	O
is	O
independent	O
of	O
p53	B-protein
.	O

CCAAT/enhancer	B-protein
binding	I-protein
protein	I-protein
epsilon	I-protein
is	O
preferentially	O
up-regulated	O
during	O
granulocytic	O
differentiation	O
and	O
its	O
functional	O
versatility	O
is	O
determined	O
by	O
alternative	O
use	O
of	O
promoters	B-DNA
and	O
differential	O
splicing	O
.	O

CCAAT/enhancer	B-protein
binding	I-protein
protein	I-protein
(	I-protein
C/EBP	I-protein
)	I-protein
epsilon	I-protein
is	O
a	O
recently	O
cloned	O
member	O
of	O
the	O
C/EBP	B-protein
family	I-protein
of	O
transcription	B-protein
factors	I-protein
and	O
is	O
expressed	O
exclusively	O
in	O
cells	O
of	O
hematopoietic	O
origin	O
.	O

The	O
human	B-DNA
C/EBPepsilon	I-DNA
gene	I-DNA
is	O
transcribed	O
by	O
two	O
alternative	O
promoters	B-DNA
,	O
Palpha	B-DNA
and	O
Pbeta	B-DNA
.	O

A	O
combination	O
of	O
differential	O
splicing	O
and	O
alternative	O
use	O
of	O
promoters	B-DNA
generates	O
four	O
mRNA	B-RNA
isoforms	I-RNA
,	O
of	O
2.6	O
kb	O
and	O
1.3-1.5	O
kb	O
in	O
size	O
.	O

These	O
transcripts	O
can	O
encode	O
three	O
proteins	O
of	O
calculated	O
molecular	O
mass	O
32.2	B-RNA
kDa	I-RNA
,	O
27.8	B-RNA
kDa	I-RNA
,	O
and	O
14.3	B-RNA
kDa	I-RNA
.	O

Accordingly	O
,	O
Western	O
blots	O
with	O
antibodies	B-protein
specific	O
for	O
the	O
DNA-binding	O
domain	O
,	O
that	O
is	O
common	O
to	O
all	O
forms	O
,	O
identify	O
multiple	O
proteins	O
.	O

C/EBPepsilon	B-RNA
mRNA	I-RNA
was	O
greatly	O
induced	O
during	O
in	O
vitro	O
granulocytic	O
differentiation	O
of	O
human	B-cell_type
primary	I-cell_type
CD34	I-cell_type
(	I-cell_type
+	I-cell_type
)	I-cell_type
cells	I-cell_type
.	O

Retinoic	O
acid	O
treatment	O
of	O
HL60	B-cell_line
promyelocytic	I-cell_line
leukemia	I-cell_line
cells	I-cell_line
for	O
24	O
hr	O
induced	O
C/EBPepsilon	B-RNA
mRNA	I-RNA
levels	O
by	O
4-fold	O
,	O
while	O
prolonged	O
treatment	O
gradually	O
reduced	O
mRNA	O
expression	O
to	O
pretreatment	O
levels	O
.	O

Transient	O
transfection	O
experiments	O
with	O
expression	O
vectors	O
for	O
two	O
of	O
the	O
isoforms	O
demonstrated	O
that	O
the	O
32.2-kDa	B-protein
protein	I-protein
is	O
an	O
activator	O
of	O
transcription	O
of	O
granulocyte	B-DNA
colony-stimulating	I-DNA
factor	I-DNA
receptor	I-DNA
promoter	I-DNA
,	O
while	O
the	O
14.3-kDa	B-protein
protein	I-protein
is	O
not	O
.	O

Thus	O
,	O
C/EBPepsilon	B-protein
is	O
regulated	O
in	O
a	O
complex	O
fashion	O
and	O
may	O
play	O
a	O
role	O
in	O
the	O
regulation	O
of	O
genes	O
involved	O
in	O
myeloid	O
differentiation	O
.	O

Effects	O
of	O
TPA	B-protein
,	O
bryostatin	B-protein
1	I-protein
,	O
and	O
retinoic	O
acid	O
on	O
PO-B	B-protein
,	O
AP-1	B-protein
,	O
and	O
AP-2	B-protein
DNA	O
binding	O
during	O
HL-60	O
differentiation	O
.	O

PO-B	B-protein
was	O
originally	O
characterized	O
as	O
a	O
transcriptional	B-protein
regulatory	I-protein
factor	I-protein
of	O
the	O
pro-opiomelanocortin	B-DNA
(	I-DNA
POMC	I-DNA
)	I-DNA
gene	I-DNA
;	O
however	O
,	O
it	O
has	O
become	O
increasingly	O
clear	O
that	O
this	O
protein	O
may	O
be	O
active	O
in	O
tissues	O
outside	O
the	O
pituitary	O
,	O
since	O
it	O
is	O
present	O
in	O
diverse	O
cell	O
types	O
,	O
including	O
differentiated	O
HL-60	B-cell_type
promyelocytic	I-cell_type
leukemia	I-cell_type
cells	I-cell_type
.	O

We	O
previously	O
showed	O
that	O
PO-B	B-protein
DNA-binding	O
is	O
progressively	O
induced	O
during	O
differentiation	O
of	O
promyelomonocytic	B-cell_line
leukemic	I-cell_line
HL-60	I-cell_line
cells	I-cell_line
to	O
the	O
macrophage-like	B-cell_type
lineage	I-cell_type
(	O
with	O
phorbol	O
esters	O
)	O
.	O

We	O
now	O
report	O
that	O
PO-B	B-protein
DNA-binding	O
in	O
HL-60	B-cell_line
cells	I-cell_line
is	O
similarly	O
induced	O
during	O
differentiation	O
to	O
the	O
granulocytic	B-cell_type
lineage	I-cell_type
(	O
with	O
either	O
retinoic	O
acid	O
or	O
dimethylsulfoxide	O
)	O
.	O

Either	O
a	O
genetic	O
or	O
pharmacologic	O
blockade	O
of	O
HL-60	O
differentiation	O
prohibited	O
these	O
inductive	O
effects	O
.	O

These	O
studies	O
have	O
prompted	O
our	O
interest	O
in	O
the	O
dynamics	O
of	O
other	O
transcription	B-protein
factor	I-protein
changes	O
during	O
HL-60	O
differentiation	O
.	O

Of	O
these	O
,	O
we	O
observed	O
that	O
another	O
transcription	B-protein
factor	I-protein
(	O
AP-1	B-protein
)	O
is	O
also	O
robustly	O
induced	O
at	O
the	O
DNA-binding	O
level	O
during	O
macrophage-like	O
HL-60	O
differentiation	O
,	O
but	O
not	O
during	O
granulocytic	O
differentiation	O
.	O

Conversely	O
,	O
the	O
DNA-binding	O
of	O
the	O
transcription	B-protein
factor	I-protein
AP-2	B-protein
was	O
slightly	O
reduced	O
by	O
TPA	B-protein
-induced	O
HL-60	O
differentiation	O
but	O
unchanged	O
during	O
granulocyte	O
differentiation	O
.	O

From	O
these	O
data	O
,	O
we	O
conclude	O
that	O
the	O
induction	O
of	O
PO-B	B-protein
DNA	O
binding	O
is	O
a	O
general	O
marker	O
of	O
HL-60	O
myelomonocytic	O
differentiation	O
,	O
but	O
that	O
qualitative	O
aspects	O
of	O
the	O
induction	O
of	O
additional	O
distinct	O
transcription	B-protein
factors	I-protein
,	O
such	O
as	O
AP-1	B-protein
,	O
may	O
contribute	O
to	O
lineage-specific	O
determinants	O
of	O
cell	O
fate	O
.	O

A	O
novel	O
genetic	O
system	O
to	O
isolate	O
a	O
dominant	B-protein
negative	I-protein
effector	I-protein
on	O
DNA-binding	O
activity	O
of	O
Oct-2	B-protein
.	O

Recent	O
studies	O
have	O
revealed	O
that	O
interactions	O
between	O
transcription	B-protein
factors	I-protein
play	O
an	O
important	O
role	O
in	O
regulation	O
of	O
gene	O
expression	O
in	O
eukaryotic	B-cell_type
cells	I-cell_type
.	O

To	O
isolate	O
cDNA	O
clones	O
that	O
dominantly	O
inhibit	O
the	O
DNA-binding	O
activity	O
of	O
Oct-2	B-protein
,	O
chosen	O
as	O
a	O
representative	O
factor	O
,	O
we	O
have	O
developed	O
a	O
novel	O
screening	O
system	O
.	O

This	O
employs	O
an	O
Escherichia	O
coli	O
tester	O
strain	O
carrying	O
a	O
modified	B-DNA
lac	I-DNA
operon	I-DNA
as	O
a	O
reporter	B-DNA
gene	I-DNA
,	O
with	O
the	O
lac	O
operator	O
sequence	O
replaced	O
by	O
an	O
octamer	B-DNA
sequence	I-DNA
.	O

Oct-2	B-protein
expressed	O
in	O
this	O
tester	O
strain	O
represses	O
the	O
expression	O
of	O
the	O
reporter	O
gene	O
and	O
changes	O
the	O
phenotype	O
of	O
the	O
cell	O
from	O
Lac+to	O
Lac-	O
.	O

Introduction	O
of	O
a	O
cDNA	O
expression	O
library	O
prepared	O
from	O
a	O
human	B-cell_line
T-cell	I-cell_line
line	I-cell_line
into	O
the	O
Oct-2	B-protein
-harboring	O
tester	O
strain	O
allowed	O
selection	O
of	O
three	O
Lac+clones	O
out	O
of	O
1	O
x	O
10	O
(	O
5	O
)	O
transformants	O
.	O

One	O
of	O
them	O
,	O
hT86	O
,	O
encoding	O
a	O
putative	B-protein
zinc	I-protein
finger	I-protein
protein	I-protein
was	O
found	O
to	O
derepress	O
beta-galactosidase	B-protein
activity	O
in	O
the	O
Oct-2	B-protein
-harboring	O
tester	O
strain	O
at	O
the	O
transcriptional	O
level	O
.	O

In	O
gel	O
mobility	O
shift	O
assays	O
,	O
hT86	O
attenuated	O
the	O
intensity	O
of	O
the	O
retarded	O
band	O
composed	O
of	O
the	O
octamer	B-DNA
probe	I-DNA
and	O
Oct-2	B-protein
,	O
suggesting	O
a	O
dominant	O
negative	O
effect	O
on	O
the	O
DNA-binding	O
activity	O
of	O
Oct-2	B-protein
.	O

The	O
strategy	O
described	O
here	O
provides	O
a	O
new	O
approach	O
for	O
studying	O
protein-protein	O
interactions	O
that	O
govern	O
the	O
complex	O
regulation	O
of	O
gene	O
expression	O
.	O

Tap	B-protein
:	O
a	O
novel	O
cellular	B-protein
protein	I-protein
that	O
interacts	O
with	O
tip	O
of	O
herpesvirus	O
saimiri	O
and	O
induces	O
lymphocyte	B-cell_type
aggregation	O
.	O

Tip	O
of	O
herpesvirus	O
saimiri	O
associates	O
with	O
Lck	B-protein
and	O
down-regulates	O
Lck	B-protein
-mediated	O
activation	O
.	O

We	O
identified	O
a	O
novel	O
cellular	O
Tip-associated	B-protein
protein	I-protein
(	O
Tap	B-protein
)	O
by	O
a	O
yeast	O
two-hybrid	O
screen	O
.	O

Tap	B-protein
associated	O
with	O
Tip	B-protein
following	O
transient	O
expression	O
in	O
COS-1	B-cell_line
cells	I-cell_line
and	O
stable	O
expression	O
in	O
human	B-cell_line
Jurkat-T	I-cell_line
cells	I-cell_line
.	O

Expression	O
of	O
Tip	B-protein
and	O
Tap	B-protein
in	O
Jurkat-T	B-cell_line
cells	I-cell_line
induced	O
dramatic	O
cell	O
aggregation	O
.	O

Aggregation	O
was	O
likely	O
caused	O
by	O
the	O
up-regulated	O
surface	O
expression	O
of	O
adhesion	B-protein
molecules	I-protein
including	O
integrin	B-protein
alpha	I-protein
,	O
L-selectin	B-protein
,	O
ICAM-3	B-protein
,	O
and	O
H-CAM	B-protein
.	O

Furthermore	O
,	O
NF-kappaB	B-protein
transcriptional	I-protein
factor	I-protein
of	O
aggregated	O
cells	O
had	O
approximately	O
40-fold	O
higher	O
activity	O
than	O
that	O
of	O
parental	B-cell_type
cells	I-cell_type
.	O

Thus	O
,	O
Tap	B-protein
is	O
likely	O
to	O
be	O
an	O
important	O
cellular	O
mediator	O
of	O
Tip	B-protein
function	O
in	O
T	O
cell	O
transformation	O
by	O
herpesvirus	O
saimiri	O
.	O

Human	B-cell_type
monocyte	I-cell_type
binding	O
to	O
fibronectin	B-protein
enhances	O
IFN-gamma	B-protein
-induced	O
early	O
signaling	O
events	O
.	O

Leukocyte	B-protein
integrins	I-protein
are	O
fundamentally	O
important	O
in	O
modulating	O
adhesion	O
to	O
extracellular	O
matrix	O
components	O
and	O
to	O
other	O
cells	O
.	O

This	O
integrin-mediated	O
adhesion	O
controls	O
leukocyte	O
arrest	O
and	O
extravasation	O
during	O
the	O
onset	O
of	O
inflammatory	O
responses	O
.	O

Moreover	O
,	O
integrin	B-protein
-ligand	O
interactions	O
trigger	O
signaling	O
pathways	O
that	O
may	O
influence	O
leukocyte	O
phenotype	O
and	O
function	O
at	O
sites	O
of	O
inflammation	O
.	O

In	O
the	O
current	O
studies	O
,	O
we	O
evaluated	O
the	O
combinatorial	O
effects	O
of	O
monocyte	O
adhesion	O
and	O
IFN-gamma	B-protein
on	O
intracellular	O
signaling	O
pathways	O
.	O

IFN-gamma	B-protein
triggers	O
a	O
well-defined	O
signal	O
transduction	O
pathway	O
,	O
which	O
although	O
not	O
directly	O
stimulated	O
by	O
monocyte	O
adherence	O
to	O
fibronectin	B-protein
or	O
arginine-glycine-aspartate	B-protein
(	I-protein
RGD	I-protein
)	I-protein
-coated	I-protein
substrata	I-protein
,	O
was	O
enhanced	O
significantly	O
in	O
these	O
matrix-adherent	B-cell_type
cells	I-cell_type
.	O

Compared	O
with	O
monocytes	O
in	O
suspension	O
or	O
adherent	O
on	O
plastic	O
surfaces	O
,	O
monocytes	O
adherent	O
to	O
fibronectin	B-protein
or	O
RGD	O
exhibited	O
a	O
greater	O
than	O
threefold	O
increase	O
in	O
steady	O
state	O
levels	O
of	O
IFN-gamma-induced	B-RNA
mRNA	I-RNA
for	O
the	O
high	B-protein
affinity	I-protein
Fc	I-protein
gammaRI	I-protein
receptor	I-protein
.	O

By	O
electrophoretic	O
mobility	O
shift	O
assays	O
,	O
this	O
increase	O
in	O
mRNA	B-RNA
was	O
associated	O
with	O
a	O
5-	O
to	O
10-fold	O
increase	O
in	O
the	O
STAT1-containing	B-protein
DNA-binding	I-protein
complex	I-protein
that	O
binds	O
to	O
Fc	B-DNA
gammaRI	I-DNA
promoter	I-DNA
elements	I-DNA
.	O

Furthermore	O
,	O
the	O
tyrosine	O
phosphorylation	O
of	O
STAT1	B-protein
and	O
the	O
tyrosine	B-protein
kinases	I-protein
JAK1	B-protein
and	O
JAK2	B-protein
was	O
enhanced	O
significantly	O
in	O
RGD-adherent	B-cell_type
monocytes	I-cell_type
compared	O
with	O
control	B-cell_type
cells	I-cell_type
.	O

These	O
results	O
suggest	O
a	O
novel	O
mechanism	O
by	O
which	O
integrin	B-protein
-mediated	O
cell	O
adhesion	O
can	O
modulate	O
the	O
magnitude	O
of	O
cytokine	B-protein
-induced	O
signal	O
transduction	O
pathways	O
,	O
thereby	O
amplifying	O
cellular	O
events	O
leading	O
to	O
monocyte	O
activation	O
and	O
inflammation	O
.	O

Surfactant	B-protein
protein	I-protein
A	I-protein
activates	O
NF-kappa	B-protein
B	I-protein
in	O
the	O
THP-1	B-cell_line
monocytic	I-cell_line
cell	I-cell_line
line	I-cell_line
.	O

The	O
expression	O
of	O
many	O
genes	O
for	O
which	O
products	O
are	O
involved	O
in	O
inflammation	O
is	O
controlled	O
by	O
the	O
transcriptional	B-protein
regulator	I-protein
nuclear	I-protein
factor	I-protein
(	I-protein
NF	I-protein
)	I-protein
-kappa	I-protein
B	I-protein
.	O

Because	O
surfactant	B-protein
protein	I-protein
(	I-protein
SP	I-protein
)	I-protein
A	I-protein
is	O
involved	O
in	O
local	O
host	O
defense	O
in	O
the	O
lung	O
and	O
alters	O
immune	O
cell	O
function	O
by	O
modulating	O
the	O
expression	O
of	O
proinflammatory	B-protein
cytokines	I-protein
as	O
well	O
as	O
surface	B-protein
proteins	I-protein
involved	O
in	O
inflammation	O
,	O
we	O
hypothesized	O
that	O
SP-A	B-protein
exerts	O
its	O
action	O
,	O
at	O
least	O
in	O
part	O
,	O
via	O
activation	O
of	O
NF-kappa	B-protein
B	I-protein
.	O

We	O
used	O
gel	O
shift	O
assays	O
to	O
determine	O
whether	O
SP-A	B-protein
activated	O
NF-kappa	B-protein
B	I-protein
in	O
the	O
THP-1	B-cell_line
cell	I-cell_line
line	I-cell_line
,	O
a	O
human	B-cell_line
monocytic	I-cell_line
cell	I-cell_line
line	I-cell_line
.	O

Activation	O
of	O
NF-kappa	B-protein
B	I-protein
in	O
THP-1	B-cell_line
cells	I-cell_line
by	O
SP-A	B-protein
doses	O
as	O
low	O
as	O
1	O
microgram/ml	O
occurred	O
within	O
30	O
min	O
of	O
SP-A	B-protein
treatment	O
,	O
peaked	O
at	O
60	O
min	O
,	O
and	O
then	O
declined	O
.	O

This	O
activation	O
is	O
inhibited	O
by	O
known	O
inhibitors	O
of	O
NF-kappa	B-protein
B	I-protein
or	O
by	O
simultaneous	O
treatment	O
of	O
the	O
cells	O
with	O
surfactant	O
lipids	O
.	O

Moreover	O
,	O
the	O
NF-kappa	B-protein
B	I-protein
inhibitors	I-protein
blocked	O
SP-A	B-protein
-dependent	O
increases	O
in	O
tumor	B-RNA
necrosis	I-RNA
factor-alpha	I-RNA
mRNA	I-RNA
levels	O
.	O

These	O
observations	O
suggest	O
a	O
mechanism	O
by	O
which	O
SP-A	B-protein
plays	O
a	O
role	O
in	O
the	O
pathogenesis	O
of	O
some	O
lung	O
conditions	O
and	O
point	O
to	O
potential	O
therapeutic	O
measures	O
that	O
could	O
be	O
used	O
to	O
prevent	O
SP-A	B-protein
induced	O
inflammation	O
in	O
the	O
lung	O
.	O

GABP	B-protein
factors	I-protein
bind	O
to	O
a	O
distal	B-DNA
interleukin	I-DNA
2	I-DNA
(	I-DNA
IL-2	I-DNA
)	I-DNA
enhancer	I-DNA
and	O
contribute	O
to	O
c-Raf	B-protein
-mediated	O
increase	O
in	O
IL-2	B-protein
induction	O
.	O

Triggering	O
of	O
the	O
T-cell	B-protein
receptor-CD3	I-protein
complex	I-protein
activates	O
two	O
major	O
signal	O
cascades	O
in	O
T	B-cell_type
lymphocytes	I-cell_type
,	O
(	O
i	O
)	O
Ca2+-dependent	O
signal	O
cascades	O
and	O
(	O
ii	O
)	O
protein	B-protein
kinase	I-protein
cascades	O
.	O

Both	O
signal	O
cascades	O
contribute	O
to	O
the	O
induction	O
of	O
the	O
interleukin	B-DNA
2	I-DNA
(	I-DNA
IL-2	I-DNA
)	I-DNA
gene	I-DNA
during	O
T-cell	O
activation	O
.	O

Prominent	O
protein	B-protein
kinase	I-protein
cascades	O
are	O
those	O
that	O
activate	O
mitogen-activated	B-protein
protein	I-protein
(	I-protein
MAP	I-protein
)	I-protein
kinases	I-protein
.	O

We	O
show	O
here	O
that	O
c-Raf	B-protein
,	O
which	O
is	O
at	O
the	O
helm	O
of	O
the	O
classic	O
MAP-	O
Erk	B-protein
cascade	O
,	O
contributes	O
to	O
IL-2	B-protein
induction	O
through	O
a	O
distal	B-DNA
enhancer	I-DNA
element	I-DNA
spanning	O
the	O
nucleotides	O
from	O
positions	O
-502	O
to	O
-413	O
in	O
front	O
of	O
the	O
transcriptional	O
start	O
site	O
of	O
the	O
IL-2	B-DNA
gene	I-DNA
.	O

Induction	O
of	O
this	O
distal	B-DNA
IL-2	I-DNA
enhancer	I-DNA
differs	O
from	O
induction	O
of	O
the	O
proximal	B-DNA
IL-2	I-DNA
promoter-enhancer	I-DNA
,	O
since	O
it	O
is	O
induced	O
by	O
phorbol	O
esters	O
alone	O
and	O
independent	O
from	O
Ca2+	O
signals	O
.	O

In	O
DNA-protein	O
binding	O
studies	O
,	O
we	O
detected	O
the	O
binding	O
of	O
transcription	B-protein
factors	I-protein
GABP	B-protein
alpha	I-protein
and	I-protein
-beta	I-protein
to	O
a	O
dyad	B-DNA
symmetry	I-DNA
element	I-DNA
(	O
DSE	B-DNA
)	O
of	O
the	O
distal	B-DNA
enhancer	I-DNA
,	O
which	O
is	O
formed	O
by	O
palindromic	B-DNA
binding	I-DNA
sites	I-DNA
of	O
Ets-like	B-protein
factors	I-protein
.	O

Introduction	O
of	O
point	O
mutations	O
suppressing	O
GABP	O
binding	O
to	O
the	O
DSE	B-DNA
interfered	O
with	O
the	O
induction	O
of	O
the	O
distal	B-DNA
enhancer	I-DNA
and	O
the	O
entire	O
IL-2	B-DNA
promoter-enhancer	I-DNA
,	O
while	O
overexpression	O
of	O
both	O
GABP	B-protein
factors	I-protein
enhanced	O
the	O
IL-2	B-DNA
promoter-enhancer	I-DNA
induction	O
.	O

Overexpression	O
of	O
BXB	B-protein
,	O
a	O
constitutive	O
active	O
version	O
of	O
c-Raf	B-protein
,	O
and	O
of	O
further	O
members	O
of	O
the	O
Ras	B-protein
-	O
Raf	B-protein
-	O
Erk	B-protein
signal	O
cascade	O
exerted	O
an	O
increase	O
of	O
GABP	B-protein
-mediated	O
promoter-enhancer	O
induction	O
.	O

In	O
conjunction	O
with	O
previously	O
published	O
data	O
on	O
c-Raf	B-protein
-induced	O
phosphorylation	O
of	O
GABP	B-protein
factors	I-protein
(	O
E.Flory	O
,	O
A.	O
Hoffmeyer	O
,	O
U.Smola	O
,	O
U.R.Rapp	O
,	O
and	O
J.T.Bruder	O
,	O
J.Virol.70	O
:	O
2260-	O
2268	O
,	O
1996	O
)	O
,	O
these	O
results	O
indicate	O
a	O
contribution	O
of	O
GABP	B-protein
factors	I-protein
to	O
the	O
Raf	B-protein
-mediated	O
enhancement	O
of	O
IL-2	B-protein
induction	O
during	O
T-cell	O
activation	O
.	O

Lipopolysaccharide	O
induction	O
of	O
the	O
tumor	B-DNA
necrosis	I-DNA
factor-alpha	I-DNA
promoter	I-DNA
in	O
human	B-cell_type
monocytic	I-cell_type
cells	I-cell_type
.	O

Regulation	O
by	O
Egr-1	B-protein
,	O
c-Jun	B-protein
,	O
and	O
NF-kappaB	B-protein
transcription	B-protein
factors	I-protein
.	O

Biosynthesis	O
of	O
tumor	B-protein
necrosis	I-protein
factor-alpha	I-protein
(	O
TNF-alpha	B-protein
)	O
is	O
predominantly	O
by	O
cells	O
of	O
the	O
monocytic	B-cell_type
lineage	I-cell_type
.	O

This	O
study	O
examined	O
the	O
role	O
of	O
various	O
cis-acting	B-DNA
regulatory	I-DNA
elements	I-DNA
in	O
the	O
lipopolysaccharide	O
(	O
LPS	O
)	O
induction	O
of	O
the	O
human	B-DNA
TNF-alpha	I-DNA
promoter	I-DNA
in	O
cells	O
of	O
monocytic	B-cell_type
lineage	I-cell_type
.	O

Functional	O
analysis	O
of	O
monocytic	B-cell_line
THP-1	I-cell_line
cells	I-cell_line
transfected	O
with	O
plasmids	B-DNA
containing	O
various	O
lengths	O
of	O
TNF-alpha	B-DNA
promoter	I-DNA
localized	O
enhancer	B-DNA
elements	I-DNA
in	O
a	O
region	O
(	O
-182	B-DNA
to	I-DNA
-37	I-DNA
base	I-DNA
pairs	I-DNA
(	O
bp	O
)	O
)	O
that	O
were	O
required	O
for	O
optimal	O
transcription	O
of	O
the	O
TNF-alpha	B-DNA
gene	I-DNA
in	O
response	O
to	O
LPS	O
.	O

Two	O
regions	O
were	O
identified	O
:	O
region	B-DNA
I	I-DNA
(	O
-182	B-DNA
to	I-DNA
-162	I-DNA
bp	I-DNA
)	O
contained	O
an	O
overlapping	O
Sp1/Egr-1	B-DNA
site	I-DNA
,	O
and	O
region	B-DNA
II	I-DNA
(	O
-119	B-DNA
to	I-DNA
-88	I-DNA
)	O
contained	O
CRE	B-DNA
and	O
NF-kappaB	B-DNA
(	I-DNA
designated	I-DNA
kappaB3	I-DNA
)	I-DNA
sites	I-DNA
.	O

In	O
unstimulated	O
THP-1	B-cell_line
,	O
CRE-binding	B-protein
protein	I-protein
and	O
,	O
to	O
a	O
lesser	O
extent	O
,	O
c-Jun	B-protein
complexes	I-protein
were	O
found	O
to	O
bind	O
to	O
the	O
CRE	B-DNA
site	I-DNA
.	O

LPS	O
stimulation	O
increased	O
the	O
binding	O
of	O
c-Jun-containing	B-protein
complexes	I-protein
.	O

In	O
addition	O
,	O
LPS	O
stimulation	O
induced	O
the	O
binding	O
of	O
cognate	O
nuclear	B-protein
factors	I-protein
to	O
the	O
Egr-1	B-DNA
and	I-DNA
kappaB3	I-DNA
sites	I-DNA
,	O
which	O
were	O
identified	O
as	O
Egr-1	B-protein
and	O
p50/p65	B-protein
,	O
respectively	O
.	O

The	O
CRE	B-DNA
and	I-DNA
kappaB3	I-DNA
sites	I-DNA
in	O
region	B-DNA
II	I-DNA
together	O
conferred	O
strong	O
LPS	O
responsiveness	O
to	O
a	O
heterologous	B-DNA
promoter	I-DNA
,	O
whereas	O
individually	O
they	O
failed	O
to	O
provide	O
transcriptional	O
activation	O
.	O

Furthermore	O
,	O
increasing	O
the	O
spacing	O
between	O
the	O
CRE	B-DNA
and	I-DNA
the	I-DNA
kappaB3	I-DNA
sites	I-DNA
completely	O
abolished	O
LPS	O
induction	O
,	O
suggesting	O
a	O
cooperative	O
interaction	O
between	O
c-Jun	B-protein
complexes	I-protein
and	O
p50/p65	B-protein
.	O

These	O
studies	O
indicate	O
that	O
maximal	O
LPS	O
induction	O
of	O
the	O
TNF-alpha	B-DNA
promoter	I-DNA
is	O
mediated	O
by	O
concerted	O
participation	O
of	O
at	O
least	O
two	O
separate	O
cis-acting	B-DNA
regulatory	I-DNA
elements	I-DNA
.	O

Rescue	O
by	O
cytokines	B-protein
of	O
apoptotic	O
cell	O
death	O
induced	O
by	O
IL-2	B-protein
deprivation	O
of	O
human	B-cell_line
antigen-specific	I-cell_line
T	I-cell_line
cell	I-cell_line
clones	I-cell_line
.	O

The	O
control	O
of	O
cell	O
survival	O
and	O
cell	O
death	O
is	O
of	O
central	O
importance	O
in	O
tissues	O
with	O
high	O
cell	O
turnover	O
such	O
as	O
the	O
lymphoid	O
system	O
.	O

We	O
have	O
examined	O
the	O
effect	O
of	O
cytokines	B-protein
on	O
IL-2	B-protein
deprivation-induced	O
apoptosis	O
of	O
human	B-cell_line
antigen-specific	I-cell_line
T	I-cell_line
helper	I-cell_line
clones	I-cell_line
with	O
different	O
cytokine	B-protein
production	O
profiles	O
.	O

We	O
found	O
that	O
IL-2	B-protein
,	O
interferon-alpha	B-protein
(	O
IFN-alpha	B-protein
)	O
,	O
and	O
IFN-beta	B-protein
inhibited	O
IL-2	B-protein
deprivation	O
apoptosis	O
in	O
Th0	B-cell_line
,	I-cell_line
Th1	I-cell_line
,	I-cell_line
and	I-cell_line
Th2	I-cell_line
clones	I-cell_line
.	O

We	O
also	O
found	O
that	O
IL-2	B-protein
protects	O
T	B-cell_line
cell	I-cell_line
clones	I-cell_line
from	O
IL-2	B-protein
deprivation	O
apoptosis	O
accompanying	O
active	O
proliferation	O
and	O
enhanced	O
expression	O
of	O
P53	B-protein
,	O
Rb	B-protein
and	O
Bcl-xL	B-protein
proteins	I-protein
.	O

In	O
contrast	O
,	O
IFN-alpha/beta	B-protein
rescued	O
T	B-cell_line
cell	I-cell_line
clones	I-cell_line
from	O
apoptosis	O
without	O
active	O
proliferation	O
,	O
and	O
expression	O
of	O
apoptosis-associated	B-protein
proteins	I-protein
tested	O
so	O
far	O
was	O
unaffected	O
.	O

This	O
may	O
be	O
due	O
to	O
the	O
fact	O
that	O
T	B-cell_type
cells	I-cell_type
treated	O
with	O
IL-2	B-protein
contained	O
those	O
located	O
in	O
S	O
+	O
G2/M	O
phases	O
of	O
the	O
cell	O
cycle	O
,	O
whereas	O
the	O
vast	O
majority	O
of	O
T	B-cell_type
cells	I-cell_type
treated	O
with	O
IFN-alpha/beta	B-protein
were	O
located	O
in	O
G0/G1	O
phase	O
.	O

IFN-alpha/beta	B-protein
specifically	O
induced	O
tyrosine	O
phosphorylation	O
and	O
translocation	O
into	O
nucleus	O
of	O
signal	B-protein
transducers	I-protein
and	I-protein
activators	I-protein
of	I-protein
transcription	I-protein
(	I-protein
STAT	I-protein
)	I-protein
2	I-protein
protein	I-protein
in	O
the	O
T	B-cell_line
cell	I-cell_line
clones	I-cell_line
.	O

In	O
addition	O
,	O
over-expression	O
of	O
STAT2	B-protein
by	O
transfection	O
of	O
the	O
cDNA	O
prevented	O
apoptosis	O
of	O
the	O
T	B-cell_line
cell	I-cell_line
clones	I-cell_line
.	O

Our	O
present	O
study	O
shows	O
that	O
IFN-alpha	B-protein
and	I-protein
-beta	I-protein
mediate	O
anti-apoptotic	O
effect	O
through	O
other	O
pathways	O
than	O
that	O
of	O
IL-2	B-protein
in	O
growth	O
factor	O
deprivation	O
apoptosis	O
.	O

Interleukin-10	B-protein
inhibits	O
interferon-gamma-induced	O
intercellular	B-DNA
adhesion	I-DNA
molecule-1	I-DNA
gene	I-DNA
transcription	O
in	O
human	B-cell_type
monocytes	I-cell_type
.	O

Interleukin-10	B-protein
(	O
IL-10	B-protein
)	O
is	O
a	O
potent	O
monocyte	B-protein
regulatory	I-protein
cytokine	I-protein
that	O
inhibits	O
gene	O
expression	O
of	O
proinflammatory	B-protein
mediators	I-protein
.	O

In	O
this	O
study	O
,	O
we	O
investigated	O
the	O
mechanism	O
by	O
which	O
IL-10	B-protein
downregulates	O
expression	O
of	O
intercellular	B-protein
adhesion	I-protein
molecule-1	I-protein
(	O
ICAM-1	B-protein
)	O
on	O
the	O
cell	O
surface	O
of	O
normal	B-cell_type
human	I-cell_type
monocytes	I-cell_type
activated	O
with	O
interferon-gamma	B-protein
(	O
IFN-gamma	B-protein
)	O
.	O

IL-10	B-protein
inhibition	O
of	O
IFN-gamma	B-protein
-induced	O
ICAM-1	B-protein
expression	O
was	O
apparent	O
as	O
early	O
as	O
3	O
hours	O
and	O
was	O
blocked	O
by	O
an	O
anti-IL-10	B-protein
antibody	I-protein
but	O
not	O
by	O
an	O
isotype-matched	B-protein
control	I-protein
antibody	I-protein
.	O

Northern	O
blot	O
analysis	O
showed	O
that	O
IL-10	B-protein
reduced	O
the	O
accumulation	O
of	O
ICAM-1	B-RNA
mRNA	I-RNA
in	O
IFN-gamma-stimulated	B-cell_line
monocytes	I-cell_line
.	O

IL-10	B-protein
inhibition	O
of	O
ICAM-1	B-RNA
steady-state	I-RNA
mRNA	I-RNA
was	O
detected	O
at	O
3	O
hours	O
and	O
remained	O
at	O
24	O
hours	O
.	O

Nuclear	O
run-on	O
transcription	O
assays	O
showed	O
that	O
IL-10	B-protein
inhibited	O
the	O
rate	O
of	O
IFN-gamma	B-protein
-induced	O
transcription	O
of	O
the	O
ICAM-1	B-DNA
gene	I-DNA
,	O
and	O
mRNA	O
stability	O
studies	O
showed	O
that	O
IL-10	B-protein
did	O
not	O
alter	O
the	O
half-life	O
of	O
IFN-gamma-induced	B-RNA
ICAM-1	I-RNA
message	I-RNA
.	O

Thus	O
,	O
IL-10	B-protein
inhibits	O
IFN-gamma	B-protein
-induced	O
ICAM-1	B-protein
expression	O
in	O
monocytes	B-cell_type
primarily	O
at	O
the	O
level	O
of	O
gene	O
transcription	O
.	O

Activation	O
of	O
IFN-gamma-responsive	B-DNA
genes	I-DNA
requires	O
tyrosine	O
phosphorylation	O
of	O
the	O
transcriptional	O
factor	O
STAT-1alpha	B-protein
(	O
signal	B-protein
transducer	I-protein
and	I-protein
activator	I-protein
of	I-protein
transcription-1alpha	I-protein
)	O
.	O

However	O
,	O
IL-10	B-protein
did	O
not	O
affect	O
IFN-gamma	B-protein
-induced	O
tyrosine	O
phosphorylation	O
of	O
STAT-1alpha	B-protein
or	O
alter	O
STAT-1alpha	B-protein
binding	O
to	O
the	O
IFN-gamma	B-DNA
response	I-DNA
element	I-DNA
(	O
IRE	B-DNA
)	O
in	O
the	O
ICAM-1	B-DNA
promoter	I-DNA
.	O

Instead	O
,	O
IL-10	B-protein
prevented	O
IFN-gamma	B-protein
-induced	O
binding	O
activity	O
at	O
the	O
NF-kappaB	B-protein
site	O
of	O
the	O
tumor	B-DNA
necrosis	I-DNA
factor	I-DNA
alpha	I-DNA
(	I-DNA
TNF-alpha	I-DNA
)	I-DNA
-responsive	I-DNA
NF-kappaB/C-EBP	I-DNA
composite	I-DNA
element	I-DNA
in	O
the	O
ICAM-1	B-DNA
promoter	I-DNA
.	O

These	O
data	O
indicate	O
that	O
IL-10	B-protein
inhibits	O
IFN-gamma	B-protein
-induced	O
transcription	O
of	O
the	O
ICAM-1	B-DNA
gene	I-DNA
by	O
a	O
regulatory	O
mechanism	O
that	O
may	O
involve	O
NF-kappaB	B-protein
.	O

Specific	O
complex	O
formation	O
between	O
the	O
type	B-protein
II	I-protein
bare	I-protein
lymphocyte	I-protein
syndrome-associated	I-protein
transactivators	I-protein
CIITA	B-protein
and	O
RFX5	B-protein
.	O

Two	O
of	O
the	O
genes	O
defective	O
in	O
the	O
five	O
complementation	O
groups	O
identified	O
in	O
the	O
class	O
II-negative	O
bare	O
lymphocyte	O
syndrome	O
or	O
corresponding	O
laboratory	O
mutants	O
have	O
been	O
cloned	O
.	O

One	O
gene	O
encodes	O
a	O
protein	O
,	O
RFX5	B-protein
,	O
that	O
is	O
a	O
member	O
of	O
the	O
RFX	B-protein
family	I-protein
of	I-protein
DNA	I-protein
binding	I-protein
proteins	I-protein
.	O

The	O
other	O
,	O
CIITA	B-protein
,	O
encodes	O
a	O
large	O
protein	O
with	O
a	O
defined	O
acidic	B-protein
transcriptional	I-protein
activation	I-protein
domain	I-protein
;	O
this	O
protein	O
does	O
not	O
interact	O
with	O
DNA	O
.	O

Expression	B-DNA
plasmids	I-DNA
encoding	O
regions	O
of	O
RFX5	B-protein
fused	O
to	O
the	O
GAL4	B-protein
DNA	I-protein
binding	I-protein
domain	I-protein
activated	O
transcription	O
from	O
a	O
reporter	O
construct	O
containing	O
GAL4	B-DNA
sites	I-DNA
in	O
a	O
cotransfection	O
assay	O
in	O
the	O
Raji	B-cell_line
human	I-cell_line
B	I-cell_line
cell	I-cell_line
line	I-cell_line
.	O

However	O
,	O
these	O
plasmids	B-DNA
produced	O
transcriptional	O
activity	O
in	O
HeLa	B-cell_line
cells	I-cell_line
only	O
in	O
conjunction	O
with	O
interferon	B-protein
gamma	I-protein
stimulation	O
,	O
a	O
condition	O
in	O
which	O
expression	O
of	O
both	O
CIITA	B-protein
and	O
class	B-protein
II	I-protein
major	I-protein
histocompatibility	I-protein
complex	I-protein
surface	I-protein
proteins	I-protein
are	O
induced	O
.	O

Furthermore	O
,	O
these	O
plasmids	B-DNA
were	O
not	O
active	O
in	O
RJ2.2.5	B-cell_line
,	O
an	O
in	O
vitro	O
mutagenized	O
derivative	O
of	O
Raji	B-cell_line
in	O
which	O
both	O
copies	O
of	O
CIITA	B-protein
are	O
defective	O
.	O

Transcriptional	O
activation	O
by	O
the	O
RFX5	B-protein
fusion	I-protein
protein	I-protein
could	O
be	O
restored	O
in	O
RJ2.2.5	B-cell_line
by	O
cotransfection	O
with	O
a	O
CIITA	B-DNA
expression	I-DNA
plasmid	I-DNA
.	O

Finally	O
,	O
a	O
direct	O
interaction	O
between	O
RFX5	B-protein
and	O
CIITA	B-protein
was	O
detected	O
with	O
the	O
yeast	O
two-hybrid	O
and	O
far-Western	O
blot	O
assays	O
.	O

Thus	O
,	O
RFX5	B-protein
can	O
activate	O
transcription	O
only	O
in	O
cooperation	O
with	O
CIITA	B-protein
.	O

RFX5	B-protein
and	O
CIITA	B-protein
associate	O
to	O
form	O
a	O
complex	O
capable	O
of	O
activating	O
transcription	O
from	O
class	B-DNA
II	I-DNA
major	I-DNA
histocompatibility	I-DNA
complex	I-DNA
promoters	I-DNA
.	O

In	O
this	O
complex	O
,	O
promoter	O
specificity	O
is	O
determined	O
by	O
the	O
DNA	O
binding	O
domain	O
of	O
RFX5	B-protein
and	O
the	O
general	O
transcription	O
apparatus	O
is	O
recruited	O
by	O
the	O
acidic	B-protein
activation	I-protein
domain	I-protein
of	O
CIITA	B-protein
.	O

Involvement	O
of	O
phosphatidylinositol	B-protein
3-kinase	I-protein
in	O
NFAT	B-protein
activation	O
in	O
T	B-cell_type
cells	I-cell_type
.	O

Phosphatidylinositol	B-protein
3-kinase	I-protein
(	O
PI3-K	B-protein
)	O
has	O
been	O
implicated	O
in	O
the	O
regulation	O
of	O
cell	O
proliferation	O
in	O
many	O
cell	O
types	O
.	O

We	O
have	O
previously	O
shown	O
that	O
in	O
T	B-cell_type
cells	I-cell_type
the	O
PI3-K	B-protein
inhibitor	O
,	O
wortmannin	O
,	O
interferes	O
with	O
activation	O
of	O
the	O
mitogen-activated	B-protein
kinase	I-protein
,	O
Erk2	B-protein
,	O
after	O
T	B-protein
cell	I-protein
receptor	I-protein
(	O
TcR	B-protein
)	O
stimulation	O
.	O

To	O
further	O
explore	O
the	O
involvement	O
of	O
PI3-K	B-protein
in	O
T	O
cell	O
activation	O
,	O
we	O
created	O
a	O
set	O
of	O
potentially	O
dominant	B-DNA
negative	I-DNA
PI3-K	I-DNA
constructs	I-DNA
comprising	O
individual	O
or	O
tandem	B-DNA
domains	I-DNA
of	O
the	O
regulatory	B-protein
p85	I-protein
subunit	I-protein
and	O
tested	O
their	O
effect	O
on	O
downstream	O
signaling	O
events	O
like	O
Erk2	B-protein
activation	O
and	O
transcription	O
from	O
an	O
NFAT	B-DNA
(	I-DNA
nuclear	I-DNA
factor	I-DNA
of	I-DNA
activated	I-DNA
T	I-DNA
cells	I-DNA
)	I-DNA
element	I-DNA
taken	O
from	O
the	O
interleukin-2	B-DNA
promoter	I-DNA
.	O

Following	O
TcR	B-protein
stimulation	O
,	O
activation	O
of	O
Erk2	B-protein
was	O
only	O
inhibited	O
by	O
a	O
previously	O
described	O
truncated	B-protein
form	I-protein
of	I-protein
p85	I-protein
that	O
can	O
not	O
bind	O
the	O
catalytic	B-protein
subunit	I-protein
,	O
but	O
not	O
by	O
other	O
constructs	O
of	O
p85	B-protein
.	O

In	O
contrast	O
,	O
several	O
mutant	O
p85	B-protein
alleles	O
had	O
dramatic	O
effects	O
on	O
NFAT	B-protein
activation	O
.	O

Most	O
interestingly	O
,	O
the	O
N-terminal	B-protein
SH2	I-protein
domain	I-protein
had	O
an	O
inhibitory	O
effect	O
,	O
whereas	O
a	O
mutant	B-protein
p85	I-protein
containing	O
only	O
the	O
two	B-protein
SH2	I-protein
domains	I-protein
enhanced	O
basal	O
NFAT	B-protein
activity	O
in	O
a	O
Ras	B-protein
-dependent	O
manner	O
.	O

Ionomycin	O
induced	O
synergistic	O
activation	O
of	O
NFAT	B-protein
in	O
cells	O
expressing	O
p85	B-protein
mutants	I-protein
that	O
contained	O
the	O
C-terminal	B-protein
SH2	I-protein
domain	I-protein
.	O

Analysis	O
of	O
phosphotyrosine-containing	B-protein
proteins	I-protein
bound	O
to	O
truncated	O
p85	B-protein
constructs	I-protein
revealed	O
cooperative	O
binding	O
of	O
the	O
two	B-protein
SH2	I-protein
domains	I-protein
but	O
no	O
apparent	O
differences	O
between	O
the	O
N-	B-protein
and	I-protein
C-	I-protein
terminal	I-protein
SH2	I-protein
domains	I-protein
.	O

Wortmannin	O
did	O
not	O
interfere	O
with	O
NFAT	B-protein
activation	O
,	O
although	O
it	O
inhibited	O
PI3-K	B-protein
and	O
Erk2	B-protein
activation	O
in	O
the	O
same	O
experiment	O
.	O

These	O
results	O
suggest	O
that	O
PI3-K	B-protein
is	O
involved	O
in	O
NFAT	B-protein
activation	O
through	O
a	O
complex	O
adaptor	O
function	O
of	O
its	O
regulatory	B-protein
subunit	I-protein
and	O
that	O
its	O
lipid	B-protein
kinase	I-protein
activity	O
is	O
dispensable	O
for	O
this	O
effect	O
.	O

Acute	O
leukemia	O
with	O
promyelocytic	O
features	O
in	O
PML/RARalpha	O
transgenic	O
mice	O
.	O

Acute	O
promyelocytic	O
leukemia	O
(	O
APL	O
)	O
is	O
associated	O
with	O
reciprocal	O
chromosomal	O
translocations	O
involving	O
the	O
retinoic	B-DNA
acid	I-DNA
receptor	I-DNA
alpha	I-DNA
(	I-DNA
RARalpha	I-DNA
)	I-DNA
locus	I-DNA
on	O
chromosome	B-DNA
17	I-DNA
.	O

In	O
the	O
majority	O
of	O
cases	O
,	O
RARalpha	B-protein
translocates	O
and	O
fuses	O
with	O
the	O
promyelocytic	B-DNA
leukemia	I-DNA
(	I-DNA
PML	I-DNA
)	I-DNA
gene	I-DNA
located	O
on	O
chromosome	B-DNA
15	I-DNA
.	O

The	O
resulting	O
fusion	B-DNA
genes	I-DNA
encode	O
the	O
two	O
structurally	O
unique	O
PML/RARalpha	B-protein
and	O
RARalpha/PML	B-protein
fusion	I-protein
proteins	I-protein
as	O
well	O
as	O
aberrant	B-protein
PML	I-protein
gene	I-protein
products	I-protein
,	O
the	O
respective	O
pathogenetic	O
roles	O
of	O
which	O
have	O
not	O
been	O
elucidated	O
.	O

We	O
have	O
generated	O
transgenic	O
mice	O
in	O
which	O
the	O
PML/RARalpha	B-protein
fusion	I-protein
protein	I-protein
is	O
specifically	O
expressed	O
in	O
the	O
myeloid-promyelocytic	B-cell_type
lineage	I-cell_type
.	O

During	O
their	O
first	O
year	O
of	O
life	O
,	O
all	O
the	O
PML/	O
RARalpha	B-protein
transgenic	O
mice	O
have	O
an	O
abnormal	O
hematopoiesis	O
that	O
can	O
best	O
be	O
described	O
as	O
a	O
myeloproliferative	O
disorder	O
.	O

Between	O
12	O
and	O
14	O
months	O
of	O
age	O
,	O
10	O
%	O
of	O
them	O
develop	O
a	O
form	O
of	O
acute	O
leukemia	O
with	O
a	O
differentiation	O
block	O
at	O
the	O
promyelocytic	O
stage	O
that	O
closely	O
mimics	O
human	O
APL	O
even	O
in	O
its	O
response	O
to	O
retinoic	O
acid	O
.	O

Our	O
results	O
are	O
conclusive	O
in	O
vivo	O
evidence	O
that	O
PML/RARalpha	B-protein
plays	O
a	O
crucial	O
role	O
in	O
the	O
pathogenesis	O
of	O
APL	O
.	O

Constitutive	O
and	O
inducible	O
protein/DNA	O
interactions	O
of	O
the	O
interferon-gamma	B-DNA
promoter	I-DNA
in	O
vivo	O
in	O
[	O
corrected	O
]	O
CD45RA	B-cell_type
and	I-cell_type
CD45R0	I-cell_type
T	I-cell_type
helper	I-cell_type
subsets	I-cell_type
[	O
published	O
erratum	O
appears	O
in	O
Eur	O
J	O
Immunol	O
1997	O
Jul	O
;	O
27	O
(	O
7	O
)	O
:	O
1830	O
]	O

Interferon-gamma	O
(	O
IFN-gamma	B-protein
)	O
is	O
a	O
key	O
cytokine	O
of	O
T	B-cell_type
lymphocytes	I-cell_type
with	O
major	O
regulatory	O
functions	O
in	O
the	O
immune	O
system	O
.	O

To	O
determine	O
and	O
compare	O
protein/DNA	O
interactions	O
at	O
the	O
native	O
IFN-gamma	B-protein
locus	O
in	O
T	B-cell_type
cells	I-cell_type
,	O
we	O
analyzed	O
the	O
human	B-DNA
IFN-gamma	I-DNA
promoter	I-DNA
by	O
ligation-mediated	O
polymerase	O
chain	O
reaction	O
(	O
LM-PCR	O
)	O
techniques	O
.	O

Accordingly	O
,	O
Jurkat	B-cell_line
T	I-cell_line
cells	I-cell_line
and	O
primary	B-cell_type
CD45RA	I-cell_type
and	I-cell_type
CD45R0	I-cell_type
CD4+	I-cell_type
T	I-cell_type
cell	I-cell_type
subsets	I-cell_type
isolated	O
from	O
peripheral	O
blood	O
using	O
immunomagnetic	O
beads	O
were	O
cultured	O
and	O
analyzed	O
by	O
LM-PCR	O
.	O

Constitutive	O
and	O
inducible	O
protein/DNA	O
interactions	O
of	O
the	O
IFN-gamma	B-DNA
promoter	I-DNA
in	O
vivo	O
were	O
detected	O
in	O
all	O
T	B-cell_type
cells	I-cell_type
tested	O
.	O

Interestingly	O
,	O
an	O
inducible	O
footprint	O
between	O
-183	B-DNA
and	I-DNA
-196	I-DNA
was	O
consistently	O
observed	O
in	O
Jurkat	B-cell_line
T	I-cell_line
cells	I-cell_line
and	O
CD45RA	B-cell_type
and	I-cell_type
CD45R0	I-cell_type
T	I-cell_type
helper	I-cell_type
subsets	I-cell_type
upon	O
stimulation	O
with	O
phorbol	O
12-myristate	O
13-acetate+	O
phytohemagglutinin	B-protein
(	O
PMA+	O
PHA	B-protein
)	O
that	O
was	O
highly	O
sensitive	O
to	O
treatment	O
with	O
corticosteroids	O
.	O

This	O
novel	B-DNA
target	I-DNA
site	I-DNA
,	O
denoted	O
the	O
C-site	B-DNA
,	O
was	O
shown	O
by	O
several	O
criteria	O
,	O
including	O
cell	O
distribution	O
studies	O
,	O
stimulation	O
experiments	O
,	O
supershift	O
assays	O
,	O
and	O
cross-competition	O
electrophoretic	O
mobility	O
shift	O
assays	O
to	O
bind	O
the	O
transcription	B-protein
factor	I-protein
AP-1	I-protein
.	O

Mutation	O
of	O
the	O
C-site	B-DNA
that	O
prevented	O
AP-1	B-protein
binding	O
to	O
this	O
site	O
was	O
sufficient	O
strikingly	O
to	O
reduce	O
inducible	O
promoter	O
activity	O
in	O
primary	B-cell_type
CD45R0	I-cell_type
T	I-cell_type
cells	I-cell_type
.	O

In	O
summary	O
,	O
the	O
data	O
demonstrate	O
that	O
IFN-gamma	B-protein
gene	O
transcription	O
in	O
primary	B-cell_type
T	I-cell_type
cells	I-cell_type
is	O
regulated	O
in	O
vivo	O
at	O
the	O
level	O
of	O
constitutive	O
and	O
inducible	O
protein/DNA	O
interactions	O
.	O

We	O
propose	O
a	O
model	O
where	O
basal	O
transcription	O
is	O
maintained	O
by	O
binding	O
of	O
various	O
transcription	B-protein
factors	I-protein
to	O
the	O
IFN-gamma	B-DNA
promoter	I-DNA
,	O
whereas	O
PMA+	O
PHA	B-protein
-inducible	O
IFN-gamma	B-protein
transcription	O
in	O
CD45R0	B-cell_type
T	I-cell_type
cells	I-cell_type
is	O
associated	O
with	O
binding	O
of	O
AP-1	B-protein
to	O
the	O
C-site	B-DNA
.	O

Activation	O
domain	O
requirements	O
for	O
disruption	O
of	O
Epstein-Barr	O
virus	O
latency	O
by	O
ZEBRA	B-protein
.	O

Latent	O
infection	O
of	O
B	B-cell_type
lymphocytes	I-cell_type
by	O
Epstein-Barr	O
virus	O
(	O
EBV	O
)	O
can	O
be	O
disrupted	O
by	O
expression	O
of	O
the	O
EBV	B-protein
ZEBRA	I-protein
protein	I-protein
.	O

ZEBRA	B-protein
,	O
a	O
transcriptional	O
activator	O
,	O
initiates	O
the	O
EBV	O
lytic	O
cascade	O
by	O
activating	O
viral	O
gene	O
expression	O
.	O

ZEBRA	B-protein
is	O
also	O
indispensable	O
for	O
viral	O
replication	O
and	O
binds	O
directly	O
to	O
the	O
EBV	O
lytic	O
origin	O
of	O
replication	O
.	O

The	O
studies	O
described	O
herein	O
demonstrate	O
that	O
the	O
activation	O
domain	O
.	O

ZEBRA	B-protein
activation	O
can	O
be	O
replaced	O
by	O
a	O
heterologous	B-protein
acidic	I-protein
,	I-protein
proline-rich	I-protein
,	I-protein
or	I-protein
glutamine-rich	I-protein
activation	I-protein
domain	I-protein
.	O

ZEBRA	B-protein
activation	O
domain	O
swap	O
constructs	O
retain	O
ZEBRA	B-protein
's	O
native	O
abilities	O
to	O
activate	O
specific	O
EBV	B-DNA
promoters	I-DNA
,	O
to	O
disrupt	O
EBV	O
latency	O
,	O
and	O
to	O
stimulate	O
replication	O
at	O
the	O
EBV	B-DNA
lytic	I-DNA
origin	I-DNA
.	O

Additional	O
work	O
,	O
employing	O
sequential	O
and	O
internal	O
deletions	O
of	O
ZEBRA	B-protein
's	O
N-terminal	B-protein
activation	I-protein
domain	I-protein
,	O
indicates	O
that	O
its	O
separate	O
activities	O
are	O
not	O
attributable	O
to	O
specific	O
subdomains	B-protein
but	O
are	O
spread	O
throughout	O
its	O
N	B-protein
terminus	I-protein
and	O
therefore	O
can	O
not	O
be	O
inactivated	O
by	O
deleting	O
localized	O
regions	O
.	O

CholecystokininB	B-protein
receptor	I-protein
from	O
human	B-cell_line
Jurkat	I-cell_line
lymphoblastic	I-cell_line
T	I-cell_line
cells	I-cell_line
is	O
involved	O
in	O
activator	B-protein
protein-1	I-protein
-responsive	O
gene	O
activation	O
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
analyze	O
the	O
role	O
of	O
cholecystokinin	B-protein
(	I-protein
CCK	I-protein
(	I-protein
B	I-protein
)	I-protein
)	I-protein
receptor	I-protein
in	O
human	B-cell_line
lymphoblastic	I-cell_line
Jurkat	I-cell_line
T	I-cell_line
cells	I-cell_line
.	O

We	O
investigated	O
the	O
trophic	O
effect	O
resulting	O
from	O
activation	O
of	O
such	O
a	O
receptor	O
by	O
using	O
the	O
reporter	B-DNA
gene	I-DNA
strategy	O
.	O

For	O
this	O
purpose	O
,	O
we	O
transiently	O
transfected	O
Jurkat	B-cell_line
T	I-cell_line
cells	I-cell_line
with	O
the	O
reporter	B-DNA
plasmid	I-DNA
p	I-DNA
[	I-DNA
(	I-DNA
TRE	I-DNA
)	I-DNA
3-tk-Luc	I-DNA
]	I-DNA
and	O
found	O
that	O
CCK-8	O
was	O
able	O
to	O
dose-dependently	O
induce	O
luciferase	B-protein
expression	O
related	O
to	O
activator	B-protein
protein-1	I-protein
(	O
AP-1	B-protein
)	O
activation	O
with	O
a	O
maximal	O
response	O
identical	O
to	O
that	O
obtained	O
with	O
compounds	O
known	O
to	O
activate	O
AP-1	B-protein
complex	I-protein
(	O
quantitatively	O
,	O
the	O
same	O
level	O
of	O
induction	O
was	O
obtained	O
with	O
1	O
nM	O
12-O-tetradecanoylphorbol-13-acetate	O
,	O
100	O
microM	O
diacylglycerol	O
,	O
or	O
4	O
nM	O
epidermal	O
growth	O
factor	O
)	O
.	O

The	O
involvement	O
of	O
the	O
CCK	B-protein
(	I-protein
B	I-protein
)	I-protein
receptor	I-protein
in	O
such	O
a	O
stimulation	O
was	O
demonstrated	O
by	O
the	O
inhibiting	O
effect	O
of	O
the	O
selective	O
CCK	B-protein
(	I-protein
B	I-protein
)	I-protein
receptor	I-protein
antagonist	O
PD-135	O
,	O
158	O
.	O

This	O
effect	O
was	O
confirmed	O
in	O
COS-7	O
cells	O
transfected	O
with	O
the	O
cDNA	O
of	O
CCK	B-protein
(	I-protein
B	I-protein
)	I-protein
receptor	I-protein
cloned	O
from	O
Jurkat	B-cell_line
T	I-cell_line
cells	I-cell_line
.	O

To	O
better	O
understand	O
the	O
AP-1	B-protein
-dependent	O
luciferase	B-protein
expression	O
in	O
Jurkat	B-cell_line
T	I-cell_line
cells	I-cell_line
,	O
we	O
tested	O
two	O
specific	O
inhibitors	O
of	O
serine/threonine	B-protein
phosphatases-1	I-protein
and	I-protein
-2A	I-protein
:	O
okadaic	O
acid	O
and	O
calyculin	O
A	O
.	O

These	O
compounds	O
strongly	O
increased	O
the	O
phorbol-12-myristate-13-acetate	O
response	O
,	O
whereas	O
we	O
have	O
not	O
observed	O
a	O
contribution	O
of	O
phosphatase	O
inhibitors	O
on	O
a	O
CCK-8-induced	O
luciferase	B-protein
activity	O
.	O

To	O
confirm	O
that	O
CCK	B-protein
(	I-protein
B	I-protein
)	I-protein
receptors	I-protein
are	O
involved	O
in	O
AP-1	B-protein
response	O
,	O
we	O
investigated	O
the	O
CCK-8	O
effect	O
on	O
interleukin-2	B-protein
expression	O
,	O
a	O
natural	O
endogenous	B-DNA
gene	I-DNA
regulated	O
by	O
several	O
factors	O
,	O
including	O
AP-1	B-protein
.	O

In	O
Jurkat	B-cell_line
T	I-cell_line
cells	I-cell_line
activated	O
by	O
phorbol-12-myristate-13-acetate	O
and	O
phytohemagglutinin	B-protein
,	O
CCK-8	O
induced	O
IL-2	O
expression	O
.	O

This	O
induction	O
was	O
abolished	O
by	O
PD-135	O
,	O
158	O
.	O

Our	O
results	O
indicate	O
that	O
CCK-8	O
exerts	O
a	O
trophic	O
effect	O
in	O
Jurkat	B-cell_line
T	I-cell_line
cells	I-cell_line
through	O
stimulation	O
of	O
CCK	B-protein
(	I-protein
B	I-protein
)	I-protein
receptors	I-protein
by	O
modulation	O
of	O
expression	O
of	O
AP-1-regulated	B-DNA
genes	I-DNA
.	O

A	O
conserved	O
tissue-specific	O
structure	O
at	O
a	O
human	B-DNA
T-cell	I-DNA
receptor	I-DNA
beta-chain	I-DNA
core	I-DNA
promoter	I-DNA
.	O

The	O
T-cell	B-DNA
receptor	I-DNA
(	I-DNA
TCR	I-DNA
)	I-DNA
beta-chain	I-DNA
promoters	I-DNA
have	O
been	O
characterized	O
as	O
nonstructured	B-DNA
basal	I-DNA
promoters	I-DNA
that	O
carry	O
a	O
single	O
conserved	O
ubiquitous	B-DNA
cyclic	I-DNA
AMP-responsive	I-DNA
element	I-DNA
.	O

Our	O
investigation	O
of	O
the	O
human	B-DNA
TCR	I-DNA
beta	I-DNA
gene	I-DNA
uncovers	O
a	O
surprisingly	O
complex	O
and	O
tissue-specific	O
structure	O
at	O
the	O
TCR	B-DNA
Vbeta	I-DNA
8.1	I-DNA
promoter	I-DNA
.	O

The	O
core	O
of	O
the	O
promoter	B-DNA
(	O
positions	B-DNA
-42	I-DNA
to	I-DNA
+11	I-DNA
)	O
is	O
recognized	O
by	O
the	O
lymphoid	B-protein
cell-specific	I-protein
transcription	I-protein
factors	I-protein
Ets-1	B-protein
,	O
LEF1	B-protein
,	O
and	O
AML1	B-protein
as	O
well	O
as	O
by	O
CREB/ATF-1	B-protein
,	O
as	O
is	O
demonstrated	O
in	O
gel	O
shift	O
and	O
footprinting	O
experiments	O
.	O

With	O
the	O
exception	O
of	O
LEF1	B-protein
,	O
these	O
factors	O
activate	O
transcription	O
in	O
T	B-cell_type
cells	I-cell_type
.	O

Binding	B-DNA
sites	I-DNA
at	O
the	O
core	O
region	O
show	O
little	O
conservation	O
with	O
consensus	B-DNA
sites	I-DNA
.	O

Nonetheless	O
,	O
CREB	B-protein
,	O
Ets-1	B-protein
,	O
and	O
AML1	B-protein
bind	O
and	O
activate	O
cooperatively	O
and	O
very	O
efficiently	O
through	O
the	O
nonconsensus	B-DNA
binding	I-DNA
sites	I-DNA
at	O
the	O
core	B-DNA
promoter	I-DNA
region	I-DNA
.	O

Moderate	O
ubiquitous	O
activation	O
is	O
further	O
induced	O
by	O
CREB/ATF	B-protein
and	I-protein
Sp1	I-protein
factors	I-protein
through	O
proximal	B-DNA
upstream	I-DNA
elements	I-DNA
.	O

The	O
tissue-specific	B-DNA
core	I-DNA
promoter	I-DNA
structure	I-DNA
is	O
apparently	O
conserved	O
in	O
other	O
T-cell-specifically	B-DNA
expressed	I-DNA
genes	I-DNA
such	O
as	O
the	O
CD4	B-DNA
gene	I-DNA
.	O

Our	O
observations	O
suggest	O
that	O
both	O
the	O
enhancer	B-DNA
and	O
the	O
promoter	B-DNA
have	O
a	O
complex	O
tissue-specific	O
structure	O
whose	O
functional	O
interplay	O
potentiates	O
T-cell-specific	O
transcription	O
.	O

The	O
cytoplasmic	B-protein
domain	I-protein
of	O
granulocyte-macrophage	B-protein
colony-stimulating	I-protein
factor	I-protein
(	I-protein
GM-CSF	I-protein
)	I-protein
receptor	I-protein
alpha	I-protein
subunit	I-protein
is	O
essential	O
for	O
both	O
GM-CSF	B-protein
-mediated	O
growth	O
and	O
differentiation	O
.	O

Granulocyte-macrophage	B-protein
colony-stimulating	I-protein
factor	I-protein
(	O
GM-CSF	B-protein
)	O
regulates	O
differentiation	O
,	O
survival	O
,	O
and	O
proliferation	O
of	O
colony-forming	B-cell_line
unit-granulocyte-macrophage	I-cell_line
progenitor	I-cell_line
cells	I-cell_line
.	O

The	O
biologic	O
actions	O
of	O
GM-CSF	B-protein
are	O
mediated	O
by	O
binding	O
to	O
a	O
specific	O
receptor	O
consisting	O
of	O
two	O
chains	O
designated	O
as	O
alpha	B-protein
and	I-protein
beta	I-protein
subunits	I-protein
.	O

We	O
have	O
demonstrated	O
that	O
the	O
murine	B-cell_line
FDC-P1-derived	I-cell_line
cell	I-cell_line
line	I-cell_line
WT-19	B-cell_line
transfected	O
with	O
the	O
human	B-protein
GM-CSF	I-protein
receptor	I-protein
alpha	I-protein
and	I-protein
beta	I-protein
subunits	I-protein
(	O
GM-CSFRalpha	B-protein
and	I-protein
beta	I-protein
)	O
can	O
be	O
induced	O
to	O
differentiate	O
by	O
the	O
addition	O
of	O
human	B-protein
GM-CSF	I-protein
(	O
hGM-CSF	B-protein
)	O
.	O

By	O
expressing	O
a	O
series	O
of	O
GM-CSFRalpha	B-protein
mutants	I-protein
in	O
WT19	B-cell_line
cells	I-cell_line
,	O
we	O
have	O
determined	O
the	O
amino	B-protein
acid	I-protein
domains	I-protein
of	O
the	O
GM-CSFRalpha	B-protein
cytoplasmic	B-protein
domain	I-protein
that	O
regulate	O
cell	O
differentiation	O
,	O
proliferation	O
,	O
and	O
survival	O
.	O

We	O
found	O
that	O
the	O
membrane	B-protein
proximal	I-protein
proline-rich	I-protein
domain	I-protein
and	O
adjacent	B-protein
16	I-protein
residues	I-protein
are	O
essential	O
for	O
both	O
hGM-CSF	B-protein
-dependent	O
cell	O
proliferation	O
and	O
differentiation	O
.	O

In	O
contrast	O
,	O
the	O
C-terminal	B-protein
region	I-protein
of	O
the	O
GM-CSFRalpha	B-protein
cytoplasmic	I-protein
domain	I-protein
was	O
not	O
necessary	O
for	O
cell	O
differentiation	O
mediated	O
by	O
hGM-CSF	B-protein
,	O
but	O
the	O
removal	O
of	O
this	O
region	O
severely	O
impaired	O
the	O
ability	O
of	O
hGM-CSF	B-protein
to	O
support	O
cell	O
survival	O
.	O

While	O
the	O
activation	O
of	O
JAK2	B-protein
,	O
Shc	B-protein
,	O
Erk	B-protein
,	O
and	O
STAT5	B-protein
proteins	I-protein
correlated	O
with	O
hGM-CSF	B-protein
-mediated	O
cell	O
growth	O
,	O
cellular	O
differentiation	O
occurred	O
in	O
the	O
absence	O
of	O
activation	O
of	O
these	O
signal	O
transduction	O
pathways	O
.	O

gamma-Interferon	B-protein
-induced	O
resistance	O
to	O
1	O
,	O
25-	O
(	O
OH	O
)	O
2	O
D3	O
in	O
human	B-cell_type
monocytes	I-cell_type
and	O
macrophages	B-cell_type
:	O
a	O
mechanism	O
for	O
the	O
hypercalcemia	O
of	O
various	O
granulomatoses	O
.	O

The	O
hypercalcemia	O
of	O
various	O
granulomatoses	O
is	O
caused	O
by	O
endogenous	O
1	O
,	O
25-dihydroxyvitamin	O
D	O
[	O
1	O
,	O
25-	O
(	O
OH	O
)	O
2D3	O
]	O
overproduction	O
by	O
disease-activated	O
macrophages	B-cell_type
.	O

The	O
inability	O
of	O
1	O
,	O
25	O
(	O
OH	O
)	O
2D3	O
to	O
suppress	O
its	O
synthesis	O
in	O
macrophages	B-cell_type
contrasts	O
with	O
the	O
tight	O
control	O
of	O
its	O
production	O
in	O
macrophage	O
precursors	O
,	O
peripheral	B-cell_type
blood	I-cell_type
monocytes	I-cell_type
(	O
PBM	B-cell_type
)	O
.	O

We	O
examined	O
whether	O
1	O
,	O
25	O
(	O
OH	O
)	O
2D3	O
resistance	O
develops	O
as	O
PBM	B-cell_type
differentiate	O
to	O
macrophages	B-cell_type
or	O
with	O
macrophage	O
activation	O
.	O

Normal	O
human	B-cell_type
pulmonary	I-cell_type
alveolar	I-cell_type
macrophages	I-cell_type
(	O
PAM	B-cell_type
)	O
are	O
less	O
sensitive	O
to	O
1	O
,	O
25	O
(	O
OH	O
)	O
2D3	O
than	O
PBM	B-cell_type
,	O
despite	O
similar	O
vitamin	B-protein
D	I-protein
receptor	I-protein
content	O
;	O
however	O
,	O
both	O
PBM	B-cell_type
and	O
PAM	B-cell_type
respond	O
to	O
exogenous	O
1	O
,	O
25-	O
(	O
OH	O
)	O
2D3	O
by	O
inhibiting	O
1	O
,	O
25	O
(	O
OH	O
)	O
2D3	O
synthesis	O
and	O
inducing	O
1	O
,	O
25	O
(	O
OH	O
)	O
2D3	O
degradation	O
through	O
enhancement	O
of	O
24-hydroxylase	B-protein
mRNA	O
levels	O
and	O
activity	O
.	O

The	O
human	B-cell_line
monocytic	I-cell_line
cell	I-cell_line
line	I-cell_line
THP-1	B-cell_line
mimics	O
PAM	B-cell_type
in	O
1	O
,	O
25	O
(	O
OH	O
)	O
2D3	O
synthesis	O
and	O
sensitivity	O
to	O
exogenous	O
1	O
,	O
25	O
(	O
OH	O
)	O
2D3	O
.	O

We	O
utilized	O
THP-1	B-cell_line
cells	I-cell_line
to	O
examine	O
the	O
response	O
to	O
1	O
,	O
25	O
(	O
OH	O
)	O
2D3	O
with	O
macrophage	O
activation	O
.	O

Activation	O
of	O
THP-1	B-cell_line
cells	I-cell_line
with	O
gamma-interferon	B-protein
(	O
gamma-IFN	B-protein
)	O
enhances	O
1	O
,	O
25	O
(	O
OH	O
)	O
2D3	O
synthesis	O
30-fold	O
,	O
blocks	O
1	O
,	O
25-	O
(	O
OH	O
)	O
2D3	O
suppression	O
of	O
its	O
synthesis	O
,	O
and	O
reduces	O
by	O
42.2	O
%	O
1	O
,	O
25-	O
(	O
OH	O
)	O
2D3	O
induction	O
of	O
its	O
degradation	O
.	O

The	O
antagonistic	O
effects	O
of	O
gamma-IFN	B-protein
are	O
not	O
merely	O
restricted	O
to	O
enzymatic	O
activities	O
.	O

In	O
THP-1	B-cell_line
cells	I-cell_line
and	O
in	O
normal	O
PBM	B-cell_type
,	O
gamma-IFN	B-protein
inhibits	O
1	O
,	O
25-	O
(	O
OH	O
)	O
2D3	O
induction	O
of	O
24-hydroxylase	B-protein
mRNA	O
levels	O
without	O
reducing	O
mRNA	O
stability	O
,	O
suggesting	O
gamma-IFN	B-protein
inhibition	O
of	O
1	O
,	O
25	O
(	O
OH	O
)	O
2D3	O
transactivating	O
function	O
.	O

These	O
results	O
explain	O
1	O
,	O
25	O
(	O
OH	O
)	O
2D3	O
overproduction	O
in	O
granulomatoses	O
and	O
demonstrate	O
potent	O
inhibition	O
by	O
gamma-IFN	B-protein
of	O
1	O
,	O
25	O
(	O
OH	O
)	O
2D3	O
action	O
in	O
immune	B-cell_type
cells	I-cell_type
.	O

Molecular	O
cloning	O
and	O
characterization	O
of	O
a	O
cDNA	B-DNA
,	O
CHEMR1	B-DNA
,	O
encoding	O
a	O
chemokine	B-protein
receptor	I-protein
with	O
a	O
homology	O
to	O
the	O
human	B-protein
C-C	I-protein
chemokine	I-protein
receptor	I-protein
,	O
CCR-4	B-protein
.	O

Chemokines	B-protein
refer	O
to	O
a	O
rapidly	O
expanding	O
family	O
of	O
small	O
cytokines	B-protein
whose	O
primary	O
function	O
is	O
recruitment	O
of	O
leukocytes	O
to	O
inflammatory	O
sites	O
.	O

These	O
are	O
known	O
to	O
bind	O
to	O
seven-transmembrane-domain	B-protein
containing	I-protein
receptors	I-protein
.	O

A	O
cDNA	B-DNA
clone	I-DNA
,	O
CHEMR1	B-DNA
,	O
resembling	O
the	O
typical	O
G	B-protein
protein-coupled	I-protein
receptor	I-protein
,	O
was	O
isolated	O
from	O
a	O
mouse	B-DNA
cytotoxic	I-DNA
T-lymphocyte	I-DNA
(	I-DNA
CTL	I-DNA
)	I-DNA
library	I-DNA
.	O

Northern	O
blot	O
analysis	O
in	O
mouse	O
cell	O
lines	O
suggests	O
that	O
its	O
expression	O
is	O
found	O
in	O
a	O
variety	O
of	O
cells	O
,	O
including	O
T	B-cell_type
cells	I-cell_type
,	O
B	B-cell_type
cells	I-cell_type
,	O
and	O
macrophages	B-cell_type
.	O

The	O
CHEMR1	B-DNA
gene	I-DNA
Scya3r2	B-DNA
is	O
a	O
single-copy	B-DNA
gene	I-DNA
whose	O
open	O
reading	O
frame	O
may	O
be	O
in	O
a	O
single	O
exon	O
and	O
maps	O
to	O
the	O
distal	O
region	O
of	O
mouse	B-DNA
Chr	I-DNA
9	I-DNA
where	O
the	O
mouse	B-DNA
macrophage	I-DNA
inflammatory	I-DNA
protein-1alpha	I-DNA
(	I-DNA
MIP-1alpha	I-DNA
)	I-DNA
receptor	I-DNA
gene	I-DNA
Scya3r	B-DNA
and	O
two	O
related	O
C-C	B-DNA
chemokine	I-DNA
receptor-like	I-DNA
genes	I-DNA
reside	O
.	O

Amino	O
acid	O
sequence	O
comparison	O
shows	O
that	O
CHEMR1	B-DNA
is	O
84	O
%	O
identical	O
to	O
human	B-protein
CCR-4	I-protein
,	O
indicating	O
that	O
CHEMR1	B-DNA
is	O
likely	O
to	O
be	O
a	O
mouse	B-protein
CCR-4	I-protein
.	O

Binding	O
assays	O
using	O
125I-labeled	B-protein
C-C	I-protein
chemokines	I-protein
in	O
mammalian	B-cell_type
cells	I-cell_type
indicated	O
that	O
CHEMR1	B-DNA
did	O
not	O
bind	O
MIP-1alpha	O
,	O
RANTES	O
,	O
or	O
MIP-1beta	O
,	O
whereas	O
CCR-1	B-protein
binds	O
MIP-1alpha	B-protein
and	O
RANTES	B-protein
.	O

Our	O
result	O
is	O
different	O
from	O
the	O
reported	O
properties	O
of	O
human	B-protein
CCR-4	I-protein
.	O

This	O
suggests	O
that	O
CHEMR1	B-DNA
may	O
be	O
a	O
receptor	O
for	O
unidentified	O
C-C	B-protein
chemokine	I-protein
or	O
a	O
low-affinity	O
receptor	O
for	O
MIP-1alpha	B-protein
.	O

Transactivation	O
by	O
CIITA	B-protein
,	O
the	O
type	B-protein
II	I-protein
bare	I-protein
lymphocyte	I-protein
syndrome-associated	I-protein
factor	I-protein
,	O
requires	O
participation	O
of	O
multiple	O
regions	O
of	O
the	O
TATA	B-protein
box	I-protein
binding	I-protein
protein	I-protein
.	O

CIITA	B-protein
is	O
a	O
positive	O
regulator	O
of	O
class	B-DNA
II	I-DNA
major	I-DNA
histocompatibility	I-DNA
complex	I-DNA
gene	I-DNA
transcription	O
that	O
has	O
been	O
found	O
to	O
be	O
defective	O
in	O
one	O
of	O
the	O
five	O
complementation	O
groups	O
of	O
class	B-cell_line
II	I-cell_line
major	I-cell_line
histocompatibility	I-cell_line
complex-negative	I-cell_line
cell	I-cell_line
lines	I-cell_line
.	O

Its	O
N-terminal	B-protein
region	I-protein
is	O
capable	O
of	O
activating	O
transcription	O
from	O
a	O
reporter	O
gene	O
when	O
fused	O
to	O
a	O
DNA	B-protein
binding	I-protein
domain	I-protein
.	O

We	O
have	O
investigated	O
the	O
mechanism	O
of	O
transactivation	O
mediated	O
by	O
the	O
CIITA	B-protein
activation	I-protein
domain	I-protein
by	O
studying	O
its	O
role	O
in	O
the	O
process	O
of	O
transcription	O
initiation	O
and	O
elongation	O
.	O

Specifically	O
the	O
altered	O
specificity	O
TBP	O
(	O
TATA	B-protein
box	I-protein
binding	I-protein
protein	I-protein
)	O
assay	O
has	O
been	O
used	O
to	O
analyze	O
the	O
response	O
of	O
the	O
CIITA	B-protein
activation	I-protein
domain	I-protein
to	O
mutations	O
in	O
TBP	B-protein
known	O
to	O
disrupt	O
its	O
interaction	O
with	O
its	O
associated	B-protein
general	I-protein
factors	I-protein
.	O

Transactivation	O
by	O
CIITA	B-protein
was	O
extremely	O
sensitive	O
to	O
a	O
mutation	O
in	O
TBP	B-protein
that	O
in	O
yeast	O
is	O
known	O
to	O
abolish	O
VP16	B-protein
-mediated	O
transcription	O
but	O
leaves	O
basal	O
transcription	O
unaffected	O
.	O

A	O
TBP	O
mutant	O
defective	O
in	O
interaction	O
with	O
TBP-associated	B-protein
factor	I-protein
TAFII250	B-protein
also	O
failed	O
to	O
mediate	O
transactivation	O
through	O
the	O
CIITA	B-protein
activation	I-protein
domain	I-protein
.	O

Certain	O
interactions	O
between	O
TBP	B-protein
and	O
general	B-protein
factors	I-protein
that	O
are	O
specifically	O
required	O
for	O
acidic	B-protein
activation	I-protein
domains	I-protein
were	O
also	O
required	O
for	O
CIITA	B-protein
-mediated	O
transactivation	O
to	O
reach	O
its	O
full	O
potential	O
.	O

Finally	O
,	O
like	O
VP16	O
,	O
CIITA	B-protein
was	O
able	O
to	O
stimulate	O
elongation	O
of	O
transcription	O
.	O

Overall	O
the	O
mechanism	O
of	O
transactivation	O
by	O
the	O
human	B-protein
B-cell-specific	I-protein
CIITA	I-protein
is	O
very	O
similar	O
to	O
that	O
mediated	O
by	O
the	O
herpes	B-protein
virus	I-protein
transactivator	I-protein
VP16	B-protein
in	O
the	O
ways	O
that	O
have	O
been	O
tested	O
.	O

Relief	O
of	O
cyclin	B-protein
A	I-protein
gene	O
transcriptional	O
inhibition	O
during	O
activation	O
of	O
human	B-cell_type
primary	I-cell_type
T	I-cell_type
lymphocytes	I-cell_type
via	O
CD2	B-protein
and	O
CD28	B-protein
adhesion	B-protein
molecules	I-protein
.	O

Cyclin	B-protein
A	I-protein
transcription	O
is	O
cell	O
cycle	O
regulated	O
and	O
induced	O
by	O
cell	O
proliferative	O
signals	O
.	O

To	O
understand	O
the	O
mechanisms	O
underlined	O
in	O
this	O
regulation	O
in	O
normal	O
human	O
cells	O
,	O
we	O
have	O
analysed	O
in	O
vivo	O
protein-DNA	O
interactions	O
at	O
the	O
Cyclin	B-protein
A	I-protein
locus	O
in	O
primary	B-cell_type
T	I-cell_type
lymphocytes	I-cell_type
.	O

Stimulation	O
of	O
purified	O
T	O
lymphocytes	O
by	O
a	O
combination	O
of	O
monoclonal	B-protein
antibodies	I-protein
directed	O
at	O
CD2	B-protein
and	O
CD28	B-protein
adhesion	B-protein
molecules	I-protein
gives	O
rise	O
to	O
a	O
long	O
lasting	O
proliferation	O
in	O
the	O
absence	O
of	O
accessory	B-cell_type
cells	I-cell_type
.	O

Cyclin	B-protein
A	I-protein
was	O
observed	O
after	O
4	O
days	O
of	O
costimulation	O
with	O
anti	B-protein
CD2	I-protein
+	O
CD28	B-protein
whereas	O
stimulation	O
by	O
anti	B-protein
CD2	I-protein
or	O
anti	B-protein
CD28	I-protein
alone	O
was	O
not	O
effective	O
.	O

In	O
vivo	O
genomic	O
DMS	O
footprinting	O
revealed	O
upstream	O
of	O
the	O
major	O
transcription	B-DNA
initiation	I-DNA
sites	I-DNA
,	O
the	O
presence	O
of	O
at	O
least	O
three	O
protein	B-DNA
binding	I-DNA
sites	I-DNA
,	O
two	O
of	O
which	O
were	O
constitutively	O
occupied	O
.	O

They	O
bind	O
in	O
vitro	O
respectively	O
ATF-1	B-protein
and	O
NF-Y	B-protein
proteins	I-protein
.	O

The	O
third	O
site	O
was	O
occupied	O
in	O
quiescent	O
cells	O
or	O
in	O
cells	O
stimulated	O
by	O
anti	B-protein
CD2	I-protein
or	O
anti	B-protein
CD28	I-protein
alone	O
.	O

The	O
mitogenic	O
combination	O
of	O
anti	B-protein
CD2	I-protein
+	O
anti	B-protein
CD28	I-protein
released	O
the	O
footprint	O
as	O
cells	O
were	O
committed	O
to	O
proliferation	O
.	O

Consistent	O
with	O
theses	O
results	O
,	O
nuclear	O
extracts	O
prepared	O
from	O
quiescent	O
cells	O
formed	O
a	O
specific	O
complex	O
with	O
this	O
element	O
,	O
whereas	O
extracts	O
prepared	O
from	O
cells	O
treated	O
with	O
anti	B-protein
CD2	I-protein
+	O
anti	B-protein
CD28	I-protein
failed	O
to	O
do	O
so	O
after	O
cells	O
entered	O
a	O
proliferative	O
state	O
.	O

An	O
enhancer-blocking	B-DNA
element	I-DNA
between	O
alpha	B-DNA
and	I-DNA
delta	I-DNA
gene	I-DNA
segments	I-DNA
within	O
the	O
human	B-DNA
T	I-DNA
cell	I-DNA
receptor	I-DNA
alpha/delta	I-DNA
locus	I-DNA
.	O

T	B-protein
cell	I-protein
receptor	I-protein
(	I-protein
TCR	I-protein
)	I-protein
alpha	I-protein
and	O
delta	O
gene	O
segments	O
are	O
organized	O
within	O
a	O
single	O
genetic	O
locus	O
but	O
are	O
differentially	O
regulated	O
during	O
T	O
cell	O
development	O
.	O

An	O
enhancer-blocking	B-DNA
element	I-DNA
(	O
BEAD-1	B-DNA
,	O
for	O
blocking	O
element	B-DNA
alpha/delta	I-DNA
1	I-DNA
)	O
was	O
localized	O
to	O
a	O
2.0-kb	B-DNA
region	I-DNA
3	O
'	O
of	O
TCR	B-DNA
delta	I-DNA
gene	I-DNA
segments	I-DNA
and	O
5	O
'	O
of	O
TCR	B-DNA
alpha	I-DNA
joining	I-DNA
gene	I-DNA
segments	I-DNA
within	O
this	O
locus	O
.	O

BEAD-1	B-DNA
blocked	O
the	O
ability	O
of	O
the	O
TCR	B-DNA
delta	I-DNA
enhancer	I-DNA
(	O
Edelta	B-DNA
)	O
to	O
activate	O
a	O
promoter	O
when	O
located	O
between	O
the	O
two	O
in	O
a	O
chromatin-integrated	B-DNA
construct	I-DNA
.	O

We	O
propose	O
that	O
BEAD-1	B-DNA
functions	O
as	O
a	O
boundary	O
that	O
separates	O
the	O
TCR	B-DNA
alpha/delta	I-DNA
locus	I-DNA
into	O
distinct	O
regulatory	B-DNA
domains	I-DNA
controlled	O
by	O
Edelta	B-DNA
and	O
the	O
TCR	B-DNA
alpha	I-DNA
enhancer	I-DNA
,	O
and	O
that	O
it	O
prevents	O
Edelta	B-DNA
from	O
opening	O
the	O
chromatin	B-DNA
of	O
the	O
TCR	B-DNA
alpha	I-DNA
joining	O
gene	O
segments	O
for	O
VDJ	O
recombination	O
at	O
an	O
early	O
stage	O
of	O
T	O
cell	O
development	O
.	O

Uncoupling	O
of	O
cell	O
cycle	O
arrest	O
from	O
the	O
expression	O
of	O
monocytic	O
differentiation	O
markers	O
in	O
HL60	B-cell_line
cell	I-cell_line
variants	I-cell_line
.	O

Differentiation	O
generally	O
leads	O
to	O
cell	O
cycle	O
arrest	O
.	O

Human	B-cell_line
leukemia	I-cell_line
HL60	I-cell_line
cells	I-cell_line
respond	O
to	O
the	O
presence	O
of	O
1	O
,	O
25-dihydroxyvitamin	O
D3	O
(	O
1	O
,	O
25D3	O
)	O
by	O
expressing	O
a	O
number	O
of	O
markers	O
of	O
the	O
monocyte/macrophage	O
phenotype	O
and	O
become	O
arrested	O
predominantly	O
in	O
the	O
G1	O
phase	O
of	O
the	O
cell	O
cycle	O
.	O

We	O
have	O
recently	O
reported	O
a	O
series	O
(	O
A	O
)	O
of	O
1	O
,	O
25D3-resistant	O
variants	O
of	O
HL60	B-cell_line
cells	I-cell_line
which	O
proliferate	O
in	O
the	O
presence	O
of	O
1	O
,	O
25D3	O
and	O
do	O
not	O
express	O
differentiation	O
markers	O
(	O
Exp.	O
Cell	O
Res.	O
224	O
,	O
312	O
,	O
1996	O
)	O
.	O

We	O
now	O
describe	O
another	O
series	O
(	O
B	O
)	O
of	O
such	O
variants	O
,	O
which	O
differ	O
from	O
A	O
series	O
cells	O
grown	O
in	O
similar	O
concentrations	O
of	O
1	O
,	O
25D3	O
in	O
that	O
they	O
express	O
the	O
CD14	B-protein
antigen	I-protein
and	O
nonspecific	O
esterase	B-protein
,	O
characteristic	O
of	O
the	O
monocyte	O
,	O
while	O
continuing	O
to	O
proliferate	O
and	O
they	O
develop	O
hypotetraploid	O
DNA	O
(	O
4C	O
)	O
content	O
at	O
higher	O
concentrations	O
of	O
ambient	O
1	O
,	O
25D3	O
than	O
the	O
A	O
series	O
cells	O
.	O

Cells	O
in	O
the	O
B	O
series	O
with	O
4C	O
DNA	O
content	O
(	O
100B	O
and	O
200B	O
)	O
also	O
differed	O
from	O
the	O
A	B-cell_line
series	I-cell_line
4C	I-cell_line
cells	I-cell_line
by	O
the	O
absence	O
of	O
DNA	O
binding	O
by	O
the	O
full-length	O
Sp1	B-protein
transcription	B-protein
factor	I-protein
.	O

However	O
,	O
B	O
series	O
cells	O
resembled	O
the	O
A	O
series	O
cells	O
in	O
exhibiting	O
faster	O
growth	O
rates	O
than	O
the	O
parental	O
HL60	B-cell_line
cells	I-cell_line
and	O
showed	O
high	O
levels	O
of	O
vitamin	B-protein
D	I-protein
receptor	I-protein
and	O
retinoid	B-protein
receptor	I-protein
X	I-protein
proteins	I-protein
.	O

These	O
results	O
show	O
that	O
the	O
initial	O
steps	O
in	O
the	O
1	O
,	O
25D3	O
signaling	O
pathway	O
are	O
intact	O
in	O
B	O
series	O
resistant	O
cells	O
and	O
lead	O
to	O
the	O
appearance	O
of	O
early	O
markers	O
of	O
monocytic	O
differentiation	O
.	O

However	O
,	O
the	O
progression	O
to	O
subsequent	O
events	O
which	O
comprise	O
terminal	O
differentiation	O
and	O
cell	O
cycle	O
arrest	O
is	O
halted	O
during	O
the	O
adaptation	O
to	O
the	O
presence	O
of	O
1	O
,	O
25D3	O
in	O
these	O
cells	O
.	O

Thus	O
,	O
the	O
availability	O
of	O
these	O
variant	O
cells	O
should	O
provide	O
a	O
system	O
for	O
studying	O
the	O
link	O
between	O
differentiation	O
and	O
cell	O
cycle	O
arrest	O
.	O

Inhibition	O
of	O
human	O
immunodeficiency	O
virus	O
type	O
1	O
replication	O
in	O
vitro	O
by	O
a	O
novel	O
combination	O
of	O
anti-Tat	B-protein
single-chain	I-protein
intrabodies	I-protein
and	O
NF-kappa	O
B	O
antagonists	O
.	O

Human	B-protein
immunodeficiency	I-protein
virus	I-protein
type	I-protein
1	I-protein
(	I-protein
HIV-1	I-protein
)	I-protein
Tat	I-protein
,	O
an	O
early	O
regulatory	B-protein
protein	I-protein
that	O
is	O
critical	O
for	O
viral	O
gene	O
expression	O
and	O
replication	O
,	O
transactivates	O
the	O
HIV-1	B-DNA
long	I-DNA
terminal	I-DNA
repeat	I-DNA
(	O
LTR	B-DNA
)	O
via	O
its	O
binding	O
to	O
the	O
transactivation	B-DNA
response	I-DNA
element	I-DNA
(	O
TAR	B-DNA
)	O
and	O
,	O
along	O
with	O
other	O
cellular	O
factors	O
,	O
increases	O
viral	O
transcription	O
initiation	O
and	O
elongation	O
.	O

Tat	O
also	O
superactivates	O
the	O
HIV-1	B-DNA
promoter	I-DNA
through	O
a	O
TAR	B-DNA
-independent	O
mechanism	O
,	O
including	O
tumor	O
necrosis	O
factor	O
alpha-induced	O
and	O
protein	O
kinase	O
C	O
(	O
PKC	B-protein
)	O
-dependent	O
activation	O
of	O
NF-kappa	B-protein
B	I-protein
,	O
and	O
inhibitors	O
of	O
Tat	B-protein
and	O
NF-kappa	B-protein
B	I-protein
cooperatively	O
down-regulate	O
this	O
Tat	B-protein
-mediated	O
LTR	B-DNA
superactivation	O
.	O

In	O
this	O
study	O
,	O
a	O
combined	O
pharmacologic	O
and	O
genetic	O
strategy	O
using	O
two	O
PKC	B-protein
(	O
NF-kappa	B-protein
B	I-protein
)	O
inhibitors	O
,	O
pentoxifylline	O
(	O
PTX	O
)	O
and	O
Go-6976	O
,	O
and	O
a	O
stably	O
expressed	O
anti-Tat	B-protein
single-chain	I-protein
intracellular	I-protein
antibody	I-protein
(	O
sFv	B-protein
intrabody	I-protein
)	O
was	O
employed	O
to	O
obtain	O
cooperative	O
inhibition	O
of	O
both	O
HIV-1	O
LTR	B-DNA
-driven	O
gene	O
expression	O
and	O
HIV-1	O
replication	O
.	O

Treatment	O
of	O
cells	O
with	O
PTX	O
and	O
Go-6976	O
resulted	O
in	O
cooperative	O
inhibition	O
of	O
both	O
HIV-1	B-DNA
LTR	I-DNA
-driven	O
gene	O
expression	O
and	O
HIV-1	O
replication	O
.	O

In	O
addition	O
,	O
the	O
combined	O
use	O
of	O
anti-Tat	B-protein
sFv	I-protein
intrabodies	I-protein
and	O
the	O
two	O
NF-kappa	B-protein
B	I-protein
inhibitors	O
retained	O
the	O
virus	O
in	O
the	O
latent	O
state	O
for	O
as	O
long	O
as	O
45	O
days	O
.	O

The	O
combined	O
treatment	O
resulted	O
in	O
more	O
durable	O
inhibition	O
of	O
HIV-1	O
replication	O
than	O
was	O
seen	O
with	O
the	O
NF-kappa	B-protein
B	I-protein
inhibitors	O
alone	O
or	O
the	O
anti-	O
Tat	B-protein
sFv	I-protein
intrabodies	I-protein
alone	O
.	O

Together	O
,	O
these	O
results	O
suggest	O
that	O
in	O
future	O
clinical	O
gene	O
therapy	O
trials	O
,	O
a	O
combined	O
pharmacologic	O
and	O
genetic	O
strategy	O
like	O
the	O
one	O
reported	O
here	O
may	O
improve	O
the	O
survival	O
of	O
transduced	B-cell_line
cells	I-cell_line
and	O
prolong	O
clinical	O
benefit	O
.	O

Transcription	B-protein
factors	I-protein
in	O
immune-mediated	O
disease	O
.	O

A	O
large	O
amount	O
of	O
detailed	O
information	O
about	O
the	O
intracellular	B-protein
proteins	I-protein
regulating	O
NF-kappa	B-protein
B	I-protein
activation	O
and	O
the	O
cellular	O
response	O
to	O
NF-kappa	B-protein
B	I-protein
activation	O
has	O
emerged	O
recently	O
.	O

Several	O
small	O
molecules	O
,	O
an	O
antisense	B-DNA
oligonucleotide	I-DNA
,	O
and	O
gene	O
therapeutic	O
agents	O
that	O
inhibit	O
NF-kappa	B-protein
b	I-protein
activation	O
have	O
been	O
described	O
.	O

Despite	O
this	O
,	O
there	O
are	O
still	O
significant	O
gaps	O
in	O
our	O
understanding	O
of	O
this	O
process	O
and	O
its	O
consequences	O
.	O

In	O
contrast	O
,	O
the	O
characterization	O
of	O
transcription	B-protein
factors	I-protein
selectively	O
regulating	O
cytokine	O
production	O
by	O
CD4+	B-cell_type
T	I-cell_type
cell	I-cell_type
subsets	I-cell_type
is	O
at	O
a	O
very	O
early	O
stage	O
.	O

Three	O
interacting	B-protein
proteins	I-protein
have	O
recently	O
been	O
shown	O
to	O
contribute	O
to	O
subset-restricted	O
expression	O
of	O
the	O
IL-4	B-DNA
gene	I-DNA
.	O

There	O
are	O
other	O
elements	O
regulating	O
IL-4	B-DNA
gene	I-DNA
expression	O
,	O
however	O
,	O
and	O
the	O
relative	O
importance	O
of	O
these	O
recently	O
identified	O
proteins	O
has	O
yet	O
to	O
be	O
determined	O
.	O

Involvement	O
of	O
Rel	B-protein
,	I-protein
Fos	I-protein
,	I-protein
and	I-protein
Jun	I-protein
proteins	I-protein
in	O
binding	O
activity	O
to	O
the	O
IL-2	B-DNA
promoter	I-DNA
CD28	I-DNA
response	I-DNA
element/AP-1	I-DNA
sequence	I-DNA
in	O
human	B-cell_type
T	I-cell_type
cells	I-cell_type
.	O

CD28	B-protein
is	O
an	O
important	O
costimulatory	B-protein
molecule	I-protein
in	O
the	O
activation	O
of	O
human	B-cell_type
T	I-cell_type
cells	I-cell_type
.	O

Costimulation	O
of	O
T	B-cell_type
cells	I-cell_type
through	O
both	O
the	O
Ag	O
receptor	O
and	O
CD28	B-protein
leads	O
to	O
high	O
level	O
IL-2	B-protein
production	O
,	O
which	O
is	O
vital	O
to	O
the	O
development	O
of	O
an	O
immune	O
response	O
in	O
vivo	O
.	O

Previous	O
reports	O
have	O
suggested	O
the	O
CD28	B-protein
stimulation	O
contributes	O
to	O
the	O
activation	O
of	O
the	O
IL-2	B-DNA
promoter	I-DNA
by	O
up-regulating	O
the	O
activity	O
of	O
several	O
transcription	B-protein
factors	I-protein
,	O
including	O
AP-1	B-protein
and	O
nuclear	B-protein
factor-kappaB	I-protein
(	I-protein
NF-kappaB	I-protein
)	I-protein
/Rel	I-protein
family	I-protein
members	I-protein
as	O
well	O
as	O
an	O
uncharacterized	B-protein
transcription	I-protein
factor	I-protein
called	O
CD28	B-protein
response	O
complex	O
.	O

While	O
several	O
lines	O
of	O
investigation	O
have	O
suggested	O
that	O
NF-kappaB/Rel	B-protein
family	I-protein
members	I-protein
make	O
up	O
the	O
CD28	B-protein
response	O
complex	O
transcription	B-protein
factor	I-protein
,	O
other	O
work	O
has	O
not	O
supported	O
this	O
conclusion	O
.	O

Recent	O
studies	O
suggest	O
that	O
the	O
CD28	B-DNA
response	I-DNA
element	I-DNA
(	O
CD28RE	B-DNA
)	O
does	O
not	O
function	O
independently	O
but	O
works	O
instead	O
in	O
conjunction	O
with	O
the	O
adjacent	B-DNA
promoter	I-DNA
proximal	I-DNA
AP-1-binding	I-DNA
site	I-DNA
and	O
this	O
hypothesis	O
is	O
confirmed	O
here	O
.	O

Also	O
in	O
the	O
current	O
study	O
,	O
binding	O
activity	O
to	O
the	O
CD28RE/AP-1	B-DNA
sequence	I-DNA
of	O
the	O
IL-2	B-DNA
promoter	I-DNA
is	O
evaluated	O
.	O

Although	O
four	O
specific	O
complexes	O
can	O
be	O
detected	O
binding	O
to	O
this	O
sequence	O
,	O
only	O
one	O
of	O
these	O
complexes	O
is	O
specific	O
for	O
both	O
the	O
CD28RE	B-DNA
and	O
the	O
adjacent	B-DNA
AP-1	I-DNA
site	I-DNA
.	O

Of	O
the	O
NF-kappaB/Rel	B-protein
family	I-protein
members	I-protein
tested	O
,	O
this	O
CD28RE/AP-1-specific	B-protein
complex	I-protein
contains	O
predominantly	O
c-Rel	B-protein
,	O
despite	O
the	O
fact	O
that	O
both	O
p50	B-protein
and	O
RelA	B-protein
can	O
efficiently	O
bind	O
to	O
the	O
CD28RE	B-DNA
.	O

c-Fos	B-protein
and	O
c-Jun	B-protein
are	O
also	O
found	O
in	O
this	O
CD28RE/AP-1-specific	B-protein
complex	I-protein
.	O

These	O
data	O
indicate	O
that	O
functional	O
complexes	O
encompassing	O
both	O
the	O
CD28RE	B-DNA
and	O
the	O
AP-1-binding	B-DNA
sites	I-DNA
influence	O
IL-2	B-DNA
promoter	I-DNA
activity	O
in	O
CD28	B-protein
-costimulated	O
T	B-cell_type
cells	I-cell_type
.	O

Inducible	O
expression	O
and	O
phosphorylation	O
of	O
coactivator	B-protein
BOB.1/OBF.1	I-protein
in	O
T	B-cell_type
cells	I-cell_type
[	O
see	O
comments	O
]	O

BOB.1/OBF.1	B-protein
is	O
a	O
transcriptional	B-protein
coactivator	I-protein
that	O
is	O
constitutively	O
expressed	O
in	O
B	B-cell_type
cells	I-cell_type
and	O
interacts	O
with	O
the	O
Oct1	O
and	O
Oct2	O
transcription	B-protein
factors	I-protein
.	O

Upon	O
activation	O
of	O
Jurkat	B-cell_line
T	I-cell_line
cells	I-cell_line
and	O
primary	B-cell_type
murine	I-cell_type
thymocytes	I-cell_type
with	O
phorbol	O
esters	O
and	O
ionomycin	O
,	O
BOB.1/OBF.1	B-protein
expression	O
and	O
transactivation	O
function	O
were	O
induced	O
.	O

BOB.1/OBF.1	B-protein
was	O
phosphorylated	O
at	O
Ser184	O
both	O
in	O
vivo	O
and	O
in	O
vitro	O
,	O
and	O
this	O
modification	O
was	O
required	O
for	O
inducible	O
activation	O
.	O

Mutation	O
of	O
Ser184	O
also	O
diminished	O
transactivation	O
function	O
in	O
B	B-cell_type
cells	I-cell_type
,	O
suggesting	O
that	O
the	O
activating	O
phosphorylation	O
that	O
is	O
inducible	O
in	O
T	B-cell_type
cells	I-cell_type
is	O
constitutively	O
present	O
in	O
B	B-cell_type
cells	I-cell_type
.	O

Thus	O
,	O
BOB.1/OBF.1	B-protein
is	O
a	O
transcriptional	B-protein
coactivator	I-protein
that	O
is	O
critically	O
regulated	O
by	O
posttranslational	O
modifications	O
to	O
mediate	O
cell	O
type-specific	O
gene	O
expression	O
.	O

Increased	O
expression	O
of	O
Gs	B-protein
(	I-protein
alpha	I-protein
)	I-protein
enhances	O
activation	O
of	O
the	O
adenylyl	B-protein
cyclase	I-protein
signal	O
transduction	O
cascade	O
.	O

Expression	O
of	O
the	O
stimulatory	O
G	B-protein
protein	I-protein
,	O
G	B-protein
(	I-protein
S	I-protein
)	I-protein
alpha	I-protein
,	O
can	O
vary	O
over	O
a	O
3-fold	O
range	O
in	O
human	O
tissues	O
and	O
in	O
rodent	O
central	O
nervous	O
system	O
.	O

In	O
fact	O
,	O
the	O
offspring	O
of	O
alcoholics	O
have	O
higher	O
levels	O
of	O
G	B-protein
(	I-protein
S	I-protein
)	I-protein
alpha	I-protein
expression	O
in	O
certain	O
tissues	O
compared	O
with	O
the	O
offspring	O
of	O
nonalcoholics	O
.	O

The	O
aim	O
of	O
this	O
research	O
was	O
to	O
test	O
the	O
hypothesis	O
that	O
a	O
causal	O
relationship	O
exists	O
between	O
the	O
level	O
of	O
expression	O
of	O
G	B-protein
(	I-protein
S	I-protein
)	I-protein
alpha	I-protein
and	O
induction	O
of	O
the	O
adenylyl	B-protein
cyclase	I-protein
(	O
AC	O
)	O
cascade	O
.	O

The	O
methodology	O
employed	O
transient	O
transfection	O
of	O
HEK	B-cell_line
293	I-cell_line
cells	I-cell_line
with	O
a	O
cDNA	O
for	O
the	O
52-kDa	O
form	O
of	O
G	B-protein
(	I-protein
S	I-protein
)	I-protein
alpha	I-protein
under	O
regulation	O
by	O
inducible	B-DNA
metallothionein	I-DNA
promoters	I-DNA
.	O

Transfectants	O
were	O
exposed	O
to	O
varying	O
concentrations	O
(	O
0-125	O
microM	O
)	O
of	O
zinc	O
sulfate	O
that	O
produced	O
a	O
3-fold	O
range	O
of	O
membrane	O
G	B-protein
(	I-protein
S	I-protein
)	I-protein
alpha	I-protein
expression	O
.	O

The	O
range	O
of	O
G	B-protein
(	I-protein
S	I-protein
)	I-protein
alpha	I-protein
expression	O
produced	O
was	O
found	O
to	O
mimic	O
a	O
physiologically	O
relevant	O
spectrum	O
of	O
G	B-protein
(	I-protein
S	I-protein
)	I-protein
alpha	I-protein
expression	O
in	O
membranes	O
derived	O
from	O
human	O
tissues	O
and	O
rat	O
brain	O
.	O

It	O
was	O
observed	O
that	O
induction	O
of	O
G	B-protein
(	I-protein
S	I-protein
)	I-protein
alpha	I-protein
expression	O
increased	O
constitutive	O
as	O
well	O
as	O
stimulated	O
cAMP	O
accumulation	O
.	O

Moreover	O
,	O
induction	O
of	O
G	B-protein
(	I-protein
S	I-protein
)	I-protein
alpha	I-protein
expression	O
increased	O
events	O
distal	O
to	O
the	O
accumulation	O
of	O
cAMP	O
including	O
the	O
phosphorylation	O
of	O
the	O
transcription	O
factor	O
,	O
cAMP	B-protein
response	I-protein
element	I-protein
binding	I-protein
protein	I-protein
and	O
transcriptional	O
activation	O
of	O
cAMP-dependent	B-DNA
reporter	I-DNA
genes	I-DNA
.	O

In	O
summary	O
,	O
these	O
studies	O
show	O
that	O
the	O
amount	O
of	O
G	B-protein
(	I-protein
S	I-protein
)	I-protein
alpha	I-protein
expression	O
has	O
a	O
marked	O
impact	O
on	O
the	O
level	O
of	O
activity	O
of	O
the	O
AC	O
cascade	O
from	O
the	O
membrane	O
through	O
to	O
the	O
nucleus	O
.	O

It	O
is	O
hypothesized	O
that	O
individuals	O
who	O
differ	O
in	O
G	B-protein
(	I-protein
S	I-protein
)	I-protein
alpha	I-protein
expression	O
may	O
also	O
differ	O
in	O
the	O
expression	O
of	O
certain	O
cAMP-dependent	B-DNA
genes	I-DNA
.	O

Thrombin	B-protein
generation	O
by	O
apoptotic	B-cell_type
vascular	I-cell_type
smooth	I-cell_type
muscle	I-cell_type
cells	I-cell_type
.	O

Thrombin	B-protein
activation	O
requires	O
assembly	O
of	O
a	O
prothrombinase	B-protein
complex	I-protein
of	O
activated	O
coagulation	B-protein
factors	I-protein
on	O
an	O
anionic	O
phospholipid	O
surface	O
,	O
classically	O
provided	O
by	O
activated	B-cell_type
platelets	I-cell_type
.	O

We	O
have	O
previously	O
shown	O
that	O
anionic	O
phosphatidylserine	O
is	O
exposed	O
by	O
rat	B-cell_type
vascular	I-cell_type
smooth	I-cell_type
muscle	I-cell_type
cells	I-cell_type
(	O
VSMCs	B-cell_type
)	O
undergoing	O
apoptosis	O
after	O
serum	O
withdrawal	O
.	O

In	O
this	O
study	O
,	O
using	O
a	O
chromogenic	O
assay	O
,	O
we	O
have	O
shown	O
thrombin	B-protein
generation	O
by	O
apoptotic	B-cell_type
VSMCs	I-cell_type
expressing	O
c-myc	B-protein
(	O
VSMC-myc	B-cell_line
)	O
with	O
an	O
area	O
under	O
the	O
thrombin	B-protein
-generation	O
curve	O
(	O
AUC	O
)	O
of	O
305	O
+/-	O
17	O
nmol	O
x	O
min/L	O
and	O
a	O
peak	O
thrombin	B-protein
(	O
PT	O
)	O
of	O
154	O
+/-	O
9	O
nmol/L	O
.	O

The	O
thrombin	B-protein
-generating	O
potential	O
of	O
the	O
apoptotic	B-cell_line
VSMC-myc	I-cell_line
cells	I-cell_line
was	O
greater	O
than	O
that	O
of	O
unactivated	B-cell_type
platelets	I-cell_type
(	O
P	O
=	O
.003	O
for	O
AUC	O
;	O
P	O
=	O
.0002	O
for	O
PT	O
)	O
and	O
similar	O
to	O
calcium-ionophore	O
activated	B-cell_type
platelets	I-cell_type
(	O
AUC	O
of	O
332	O
+/-	O
15	O
nmol	O
x	O
min/L	O
,	O
P	O
=	O
.3	O
;	O
PT	O
of	O
172	O
+/-	O
8	O
nmol/L	O
,	O
P	O
=	O
.2	O
)	O
.	O

Thrombin	B-protein
activation	O
was	O
also	O
seen	O
with	O
apoptotic	B-cell_type
human	I-cell_type
VSMCs	I-cell_type
(	O
AUC	O
of	O
211	O
+/-	O
8	O
nmol	O
x	O
min/L	O
;	O
PT	O
of	O
103	O
+/-	O
4	O
nmol/L	O
)	O
and	O
was	O
inhibited	O
by	O
annexin	O
V	O
(	O
P	O
<	O
.0001	O
for	O
AUC	O
and	O
PT	O
)	O
.	O

VSMC-myc	B-cell_line
cells	I-cell_line
maintained	O
in	O
serum	O
generated	O
less	O
thrombin	B-protein
than	O
after	O
serum	O
withdrawal	O
(	O
P	O
=	O
.0002	O
for	O
AUC	O
and	O
PT	O
)	O
.	O

VSMCs	B-cell_type
derived	O
from	O
human	O
coronary	O
atherosclerotic	O
plaques	O
that	O
apoptose	O
even	O
in	O
serum	O
also	O
generated	O
thrombin	B-protein
(	O
AUC	O
of	O
260	O
+/-	O
2	O
nmol	O
x	O
min/L	O
;	O
PT	O
of	O
128	O
+/-	O
4	O
nmol/L	O
)	O
.	O

We	O
conclude	O
that	O
apoptotic	B-cell_type
VSMCs	I-cell_type
possess	O
a	O
significant	O
thrombin	B-protein
-generating	O
capacity	O
secondary	O
to	O
phosphatidylserine	O
exposure	O
.	O

Apoptotic	O
cells	O
within	O
atherosclerotic	O
plaques	O
may	O
allow	O
local	O
thrombin	B-protein
activation	O
,	O
thereby	O
contributing	O
to	O
disease	O
progression	O
.	O

An	O
isotype-specific	O
activator	O
of	O
major	B-DNA
histocompatibility	I-DNA
complex	I-DNA
(	I-DNA
MHC	I-DNA
)	I-DNA
class	I-DNA
II	I-DNA
genes	I-DNA
that	O
is	O
independent	O
of	O
class	B-protein
II	I-protein
transactivator	I-protein
.	O

Patients	O
with	O
one	O
type	O
of	O
major	B-protein
histocompatibility	I-protein
complex	I-protein
class	I-protein
II	I-protein
combined	O
immunodeficiency	O
have	O
mutations	O
in	O
a	O
gene	O
termed	O
class	B-protein
II	I-protein
transactivator	I-protein
(	O
CIITA	B-protein
)	O
,	O
which	O
coordinately	O
controls	O
the	O
transcription	O
of	O
the	O
three	O
major	O
human	B-DNA
class	I-DNA
II	I-DNA
genes	I-DNA
,	O
HLA-DR	B-DNA
,	I-DNA
-DQ	I-DNA
,	I-DNA
and	I-DNA
-DP	I-DNA
.	O

However	O
,	O
the	O
experimentally	O
derived	O
B-lymphoblastoid	B-cell_line
cell	I-cell_line
line	I-cell_line
,	O
clone	B-cell_line
13	I-cell_line
,	O
expresses	O
high	O
levels	O
of	O
HLADQ	B-protein
in	O
the	O
absence	O
of	O
HLA-DR	B-DNA
and	O
HLA-DP	B-DNA
,	O
despite	O
its	O
mapping	O
by	O
complementation	O
analysis	O
to	O
this	O
group	O
.	O

It	O
was	O
possible	O
that	O
one	O
of	O
the	O
clone	B-DNA
13	I-DNA
CIITA	I-DNA
alleles	I-DNA
bore	O
a	O
mutation	O
that	O
allowed	O
HLA-DQ	B-DNA
,	O
but	O
not	O
HLA-DR	O
or	O
-DP	O
transcription	O
.	O

Alternatively	O
,	O
another	O
factor	O
,	O
distinct	O
from	O
CIITA	B-protein
,	O
might	O
control	O
HLA-DQ	B-DNA
expression	O
.	O

We	O
report	O
here	O
that	O
ectopic	O
expression	O
of	O
CIITA	B-DNA
cDNAs	I-DNA
derived	O
by	O
reverse	O
transcriptase	O
polymerase	O
chain	O
reaction	O
from	O
clone	B-cell_line
13	I-cell_line
do	O
not	O
restore	O
expression	O
of	O
HLA-DQ	B-DNA
in	O
another	O
CIITA-deficient	B-cell_line
cell	I-cell_line
line	I-cell_line
,	O
RJ2.2.5	B-cell_line
.	O

In	O
addition	O
,	O
no	O
CIITA	B-protein
protein	O
is	O
detectable	O
in	O
clone	B-cell_line
13	I-cell_line
nuclear	O
extracts	O
.	O

In	O
contrast	O
,	O
somatic	O
cell	O
fusion	O
between	O
clone	B-cell_line
13	I-cell_line
and	O
RJ2.2.5	B-cell_line
restored	O
expression	O
of	O
the	O
HLA-DQ	B-DNA
haplotype	O
encoded	O
by	O
the	O
RJ2.2.5	B-DNA
DQB	I-DNA
gene	I-DNA
.	O

Taken	O
together	O
,	O
these	O
data	O
demonstrate	O
the	O
existence	O
of	O
an	O
HLA-DQ	B-protein
isotype-specific	I-protein
trans-acting	I-protein
factor	I-protein
,	O
which	O
functions	O
independently	O
of	O
CIITA	B-protein
.	O

Homodimerization	O
of	O
the	O
human	B-protein
interleukin	I-protein
4	I-protein
receptor	I-protein
alpha	I-protein
chain	I-protein
induces	O
Cepsilon	B-RNA
germline	I-RNA
transcripts	I-RNA
in	O
B	B-cell_type
cells	I-cell_type
in	O
the	O
absence	O
of	O
the	O
interleukin	B-protein
2	I-protein
receptor	I-protein
gamma	I-protein
chain	I-protein
.	O

The	O
cytokines	B-protein
interleukin	B-protein
(	I-protein
IL	I-protein
)	I-protein
-4	I-protein
and	O
IL-13	B-protein
play	O
a	O
critical	O
role	O
in	O
inducing	O
Cepsilon	B-RNA
germline	I-RNA
transcripts	I-RNA
and	O
IgE	B-protein
isotype	I-protein
switching	O
in	O
human	B-cell_type
B	I-cell_type
cells	I-cell_type
.	O

The	O
IL-4	B-protein
receptor	I-protein
(	O
IL-4R	B-protein
)	O
in	O
B	B-cell_type
cells	I-cell_type
is	O
composed	O
of	O
two	O
chains	O
,	O
the	O
IL-4-binding	B-protein
IL-4Ralpha	I-protein
chain	I-protein
,	O
which	O
is	O
shared	O
with	O
the	O
IL-13R	B-protein
,	O
and	O
the	O
IL-2Rgamma	B-protein
(	I-protein
gammac	I-protein
)	I-protein
chain	I-protein
,	O
which	O
is	O
shared	O
with	O
IL-7R	B-protein
,	O
IL-9R	B-protein
,	O
and	O
IL-15R	B-protein
.	O

IL-4	B-protein
induces	O
Cepsilon	B-RNA
germline	I-RNA
transcripts	I-RNA
and	O
IgE	B-protein
isotype	I-protein
switching	O
in	O
B	B-cell_type
cells	I-cell_type
from	O
patients	O
with	O
gammac	B-protein
chain	I-protein
deficiency	O
.	O

Induction	O
of	O
Cepsilon	B-RNA
germline	I-RNA
transcripts	I-RNA
by	O
IL-4	B-protein
in	O
B	B-cell_type
cells	I-cell_type
that	O
lack	O
the	O
gammac	B-protein
chain	I-protein
may	O
involve	O
signaling	O
via	O
the	O
IL-13R	B-protein
.	O

Alternatively	O
,	O
the	O
IL-4Ralpha	B-protein
chain	I-protein
may	O
transduce	O
intracellular	O
signals	O
that	O
lead	O
to	O
Cepsilon	B-DNA
gene	I-DNA
transcription	O
independently	O
of	O
its	O
association	O
with	O
other	O
chains	O
.	O

We	O
show	O
that	O
ligand-induced	O
homodimerization	O
of	O
chimeric	B-protein
surface	I-protein
receptors	I-protein
consisting	O
of	O
the	O
extracellular	B-protein
and	I-protein
transmembrane	I-protein
domains	I-protein
of	O
the	O
erythropoietin	B-protein
receptor	I-protein
and	O
of	O
the	O
intracellular	B-protein
domain	I-protein
of	O
IL-4Ralpha	B-protein
induces	O
Janus	B-protein
kinase	I-protein
1	I-protein
(	O
Jak1	B-protein
)	O
activation	O
,	O
STAT6	B-protein
activation	O
,	O
and	O
Cepsilon	B-RNA
germline	I-RNA
transcripts	I-RNA
in	O
human	B-cell_line
B	I-cell_line
cell	I-cell_line
line	I-cell_line
BJAB	I-cell_line
.	O

Disruption	O
of	O
the	O
Jak1-binding	B-protein
proline-rich	I-protein
Box1	I-protein
region	I-protein
of	O
IL-4Ralpha	B-protein
abolished	O
signaling	O
by	O
this	O
chimeric	B-protein
receptor	I-protein
.	O

Furthermore	O
,	O
B	B-cell_type
cells	I-cell_type
transfected	O
with	O
a	O
chimeric	B-protein
CD8alpha/IL-4Ralpha	I-protein
receptor	I-protein
,	O
which	O
is	O
expressed	O
on	O
the	O
cell	O
surface	O
as	O
a	O
homodimer	B-protein
,	O
constitutively	O
expressed	O
Cepsilon	B-RNA
germline	I-RNA
transcripts	I-RNA
.	O

These	O
results	O
suggest	O
that	O
homodimerization	O
of	O
the	O
IL-4Ralpha	B-protein
chain	I-protein
is	O
sufficient	O
to	O
transduce	O
Jak1	B-protein
-dependent	O
intracellular	O
signals	O
that	O
lead	O
to	O
IgE	B-protein
isotype	I-protein
switching	O
.	O

Transcriptional	O
activity	O
and	O
constitutive	O
nuclear	O
localization	O
of	O
the	O
ETS	B-protein
protein	I-protein
Elf-1	B-protein
.	O

Elf-1	B-protein
is	O
a	O
lymphoid-specific	B-protein
transcription	I-protein
factor	I-protein
that	O
belongs	O
to	O
the	O
ETS	B-protein
protein	I-protein
family	I-protein
.	O

It	O
can	O
bind	O
to	O
DNA	O
target	O
sequences	O
within	O
a	O
variety	O
of	O
cytokine	B-DNA
genes	I-DNA
.	O

We	O
demonstrate	O
that	O
Elf-1	B-protein
is	O
constitutively	O
localized	O
in	O
the	O
nucleus	O
which	O
is	O
dependent	O
on	O
the	O
presence	O
of	O
amino	B-protein
acids	I-protein
86-265	I-protein
.	O

Analysis	O
of	O
Gal4-Elf-1	B-protein
fusion	I-protein
proteins	I-protein
revealed	O
that	O
the	O
N-terminal	O
86	O
amino	O
acids	O
of	O
Elf-1	B-protein
contain	O
a	O
transcriptional	B-protein
activation	I-protein
domain	I-protein
,	O
the	O
activity	O
of	O
which	O
is	O
attenuated	O
by	O
an	O
internal	B-protein
repression	I-protein
domain	I-protein
.	O

Furthermore	O
,	O
Elf-1	B-protein
interacts	O
specifically	O
with	O
the	O
E74	B-DNA
target	I-DNA
sequence	I-DNA
and	O
can	O
stimulate	O
transcription	O
driven	O
by	O
the	O
E74	B-DNA
site	I-DNA
independent	O
of	O
mitogenic	O
signaling	O
.	O

Thus	O
,	O
Elf-1	B-protein
is	O
able	O
to	O
stimulate	O
gene	O
transcription	O
which	O
may	O
be	O
required	O
for	O
the	O
development	O
and	O
activity	O
of	O
lymphocytes	B-cell_type
.	O

Characterization	O
of	O
peripheral	B-cell_type
blood	I-cell_type
T-lymphocytes	I-cell_type
transduced	O
with	O
HTLV-I	B-protein
Tax	I-protein
mutants	I-protein
with	O
different	O
trans-activating	O
phenotypes	O
.	O

Tax1	B-protein
,	O
a	O
transcriptional	B-protein
trans-activator	I-protein
of	O
the	O
Human	O
T-cell	O
leukemia	O
virus	O
type	O
I	O
(	O
HTLV-I	O
)	O
,	O
induces	O
the	O
expression	O
of	O
many	O
cellular	O
genes	O
through	O
interaction	O
with	O
at	O
least	O
three	O
distinct	O
cellular	B-protein
transcription	I-protein
factors	I-protein
;	O
CREB/ATF	B-protein
,	O
NF-kappaB	B-protein
,	O
and	O
SRF	B-protein
.	O

This	O
Tax1	B-protein
-induced	O
activation	O
of	O
cellular	B-DNA
genes	I-DNA
is	O
considered	O
to	O
be	O
a	O
critical	O
event	O
in	O
T-cell	O
transformation	O
by	O
HTLV-I	O
.	O

To	O
elucidate	O
the	O
role	O
of	O
each	O
Tax1	B-protein
-inducible	O
transcriptional	O
pathway	O
in	O
T-cell	O
transformation	O
,	O
we	O
introduced	O
Tax1	B-protein
mutants	I-protein
with	O
different	O
trans-activating	O
phenotypes	O
into	O
peripheral	B-cell_type
blood	I-cell_type
lymphocytes	I-cell_type
(	O
PBL	B-cell_type
)	O
by	O
retroviral	O
vectors	O
.	O

Analysis	O
of	O
these	O
PBLs	B-cell_type
revealed	O
that	O
activation	O
of	O
the	O
NF-kappaB	B-protein
pathway	O
is	O
sufficient	O
to	O
promote	O
the	O
growth	O
response	O
to	O
IL-2	B-protein
.	O

However	O
,	O
for	O
the	O
clonal	O
expansion	O
of	O
CD4+	B-cell_type
T-cells	I-cell_type
,	O
which	O
is	O
a	O
characteristic	O
result	O
of	O
HTLV-I	O
infection	O
,	O
activation	O
of	O
the	O
CREB/ATF	O
and	O
SRF	O
pathways	O
is	O
also	O
required	O
.	O

Epstein-Barr	O
virus	O
binding	O
to	O
CD21	B-protein
activates	O
the	O
initial	O
viral	B-DNA
promoter	I-DNA
via	O
NF-kappaB	B-protein
induction	O
.	O

Epstein-Barr	O
virus	O
(	O
EBV	O
)	O
,	O
an	O
oncogenic	O
human	O
herpesvirus	O
,	O
binds	O
to	O
and	O
infects	O
normal	B-cell_type
human	I-cell_type
B	I-cell_type
lymphocytes	I-cell_type
via	O
CD21	B-protein
,	O
the	O
CR2	B-protein
complement	I-protein
receptor	I-protein
.	O

Studies	O
of	O
the	O
mechanisms	O
that	O
enable	O
EBV	O
to	O
infect	O
nonactivated	O
,	O
noncycling	B-cell_type
B	I-cell_type
cells	I-cell_type
provide	O
compelling	O
evidence	O
for	O
a	O
sequence	O
of	O
events	O
in	O
which	O
EBV	O
binding	O
to	O
CD21	B-protein
on	O
purified	O
resting	B-cell_type
human	I-cell_type
B	I-cell_type
cells	I-cell_type
rapidly	O
activates	O
the	O
NF-kappaB	B-protein
transcription	B-protein
factor	I-protein
,	O
which	O
,	O
in	O
turn	O
,	O
binds	O
to	O
and	O
mediates	O
transcriptional	O
activation	O
of	O
Wp	O
,	O
the	O
initial	O
viral	B-DNA
latent	I-DNA
gene	I-DNA
promoter	I-DNA
.	O

Thus	O
,	O
EBV	O
binding	O
to	O
its	O
cellular	O
receptor	O
on	O
resting	O
B	O
cells	O
triggers	O
an	O
NF-kappaB	B-protein
-dependent	O
intracellular	O
signaling	O
pathway	O
which	O
is	O
required	O
for	O
infection	O
.	O

Synthetic	O
glucocorticoids	O
that	O
dissociate	O
transactivation	O
and	O
AP-1	B-protein
transrepression	O
exhibit	O
antiinflammatory	O
activity	O
in	O
vivo	O
.	O

Some	O
of	O
the	O
most	O
potent	O
antiinflammatory	O
and	O
immunosuppressive	O
agents	O
are	O
synthetic	O
glucocorticoids	O
.	O

However	O
,	O
major	O
side	O
effects	O
severely	O
limit	O
their	O
therapeutic	O
use	O
.	O

The	O
development	O
of	O
improved	O
glucocorticoid-based	O
drugs	O
will	O
require	O
the	O
separation	O
of	O
beneficial	O
from	O
deleterious	O
effects	O
.	O

One	O
possibility	O
toward	O
this	O
goal	O
is	O
to	O
try	O
to	O
dissociate	O
two	O
main	O
activities	O
of	O
glucocorticoids	O
,	O
i.e.	O
transactivation	O
and	O
transrepression	O
.	O

Screening	O
of	O
a	O
library	O
of	O
compounds	O
using	O
transactivation	O
and	O
AP-1	B-protein
transrepression	O
models	O
in	O
transiently	O
transfected	O
cells	O
identified	O
dissociated	O
glucocorticoids	O
,	O
which	O
exert	O
strong	O
AP-1	B-protein
inhibition	O
but	O
little	O
or	O
no	O
transactivation	O
.	O

Importantly	O
,	O
despite	O
high	O
ligand	O
binding	O
affinity	O
,	O
the	O
prototypic	O
dissociated	O
compound	O
,	O
RU24858	O
,	O
acted	O
as	O
a	O
weak	O
agonist	O
and	O
did	O
not	O
efficiently	O
antagonize	O
dexamethasone-induced	O
transcription	O
in	O
transfected	B-cell_type
cells	I-cell_type
.	O

Similar	O
results	O
were	O
obtained	O
in	O
hepatic	B-cell_line
HTC	I-cell_line
cells	I-cell_line
for	O
the	O
transactivation	O
of	O
the	O
endogenous	B-DNA
tyrosine	I-DNA
amino	I-DNA
transferase	I-DNA
gene	I-DNA
(	O
TAT	B-DNA
)	O
,	O
which	O
encodes	O
one	O
of	O
the	O
enzymes	O
involved	O
in	O
the	O
glucocorticoid-dependent	O
stimulation	O
of	O
neoglucogenesis	O
.	O

To	O
investigate	O
whether	O
dissociated	O
glucocorticoids	O
retained	O
the	O
antiinflammatory	O
and	O
immunosuppressive	O
potential	O
of	O
classic	O
glucocorticoids	O
,	O
several	O
in	O
vitro	O
and	O
in	O
vivo	O
models	O
were	O
used	O
.	O

Indeed	O
,	O
secretion	O
of	O
the	O
proinflammatory	B-protein
lymphokine	I-protein
interleukin-1beta	I-protein
was	O
severely	O
inhibited	O
by	O
dissociated	O
glucocorticoids	O
in	O
human	B-cell_line
monocytic	I-cell_line
THP	I-cell_line
1	I-cell_line
cells	I-cell_line
.	O

Moreover	O
,	O
in	O
two	O
in	O
vivo	O
models	O
,	O
these	O
compounds	O
exerted	O
an	O
antiinflammatory	O
and	O
immunosuppressive	O
activity	O
as	O
potent	O
as	O
that	O
of	O
the	O
classic	O
glucocorticoid	O
prednisolone	O
.	O

These	O
results	O
may	O
lead	O
to	O
an	O
improvement	O
of	O
antiinflammatory	O
and	O
immunosuppressive	O
therapies	O
and	O
provide	O
a	O
novel	O
concept	O
for	O
drug	O
discovery	O
.	O

In	O
vivo	O
footprinting	O
and	O
mutational	O
analysis	O
of	O
the	O
proximal	B-DNA
CD19	I-DNA
promoter	I-DNA
reveal	O
important	O
roles	O
for	O
an	O
SP1/Egr-1	B-DNA
binding	I-DNA
site	I-DNA
and	O
a	O
novel	O
site	O
termed	O
the	O
PyG	B-DNA
box	I-DNA
.	O

CD19	B-protein
expression	O
begins	O
at	O
the	O
pro-B	O
cell	O
stage	O
of	O
B	O
cell	O
development	O
.	O

As	O
such	O
it	O
serves	O
as	O
a	O
good	O
prototype	O
for	O
B	B-DNA
cell-specific	I-DNA
genes	I-DNA
whose	O
expression	O
begins	O
shortly	O
after	O
lineage	O
commitment	O
.	O

To	O
understand	O
the	O
molecular	O
mechanisms	O
controlling	O
CD19	B-protein
gene	O
expression	O
,	O
we	O
isolated	O
and	O
functionally	O
characterized	O
the	O
CD19	B-DNA
promoter	I-DNA
using	O
in	O
vivo	O
footprinting	O
,	O
gel	O
shift	O
assays	O
,	O
and	O
transfection	O
studies	O
.	O

Reporter	O
constructs	O
spanning	O
portions	O
of	O
the	O
promoter	O
identified	O
a	O
region	B-DNA
between	I-DNA
-85	I-DNA
and	I-DNA
-200	I-DNA
that	O
produced	O
high	O
levels	O
of	O
reporter	O
gene	O
activity	O
in	O
lymphoid	B-cell_type
cells	I-cell_type
.	O

In	O
vivo	O
footprinting	O
identified	O
protected	O
regions	O
over	O
the	O
known	O
high	O
affinity	O
B	B-DNA
cell	I-DNA
lineage-specific	I-DNA
activator	I-DNA
protein	I-DNA
(	I-DNA
BSAP	I-DNA
)	I-DNA
site	I-DNA
,	O
the	O
low	B-DNA
affinity	I-DNA
BSAP	I-DNA
site	I-DNA
,	O
a	O
SP1/Egr-1	B-DNA
site	I-DNA
termed	O
the	O
CD19	B-DNA
GC	I-DNA
box	I-DNA
,	O
and	O
two	O
novel	O
sites	O
named	O
the	O
AT	B-DNA
box	I-DNA
and	O
PyG	B-DNA
box	I-DNA
.	O

Phorbol	O
ester	O
treatment	O
of	O
a	O
pre-B	B-cell_line
cell	I-cell_line
line	I-cell_line
up-regulated	O
CD19	B-protein
expression	O
,	O
induced	O
Egr-1	B-protein
,	O
and	O
enhanced	O
the	O
footprint	O
over	O
the	O
GC	O
box	O
.	O

Gel	O
shift	O
assays	O
demonstrated	O
SP1	O
and	O
Egr-1	B-protein
binding	O
to	O
the	O
CD19	B-DNA
GC	I-DNA
box	I-DNA
,	O
while	O
unknown	O
nuclear	O
proteins	O
bound	O
the	O
PyG	B-DNA
and	I-DNA
AT	I-DNA
boxes	I-DNA
.	O

Mutations	O
in	O
the	O
AT	B-DNA
box	I-DNA
or	O
in	O
the	O
BSAP	B-DNA
sites	I-DNA
did	O
not	O
affect	O
CD19	B-protein
reporter	B-DNA
construct	I-DNA
activity	O
,	O
while	O
a	O
mutation	O
of	O
the	O
GC	B-DNA
box	I-DNA
reduced	O
it	O
modestly	O
,	O
and	O
a	O
PyG	B-DNA
box	I-DNA
mutation	O
reduced	O
it	O
dramatically	O
.	O

BSAP	B-protein
failed	O
to	O
trans-activate	O
CD19	B-DNA
promoter	I-DNA
constructs	I-DNA
in	O
B	B-cell_type
cells	I-cell_type
or	O
non-B	B-cell_type
cells	I-cell_type
,	O
suggesting	O
that	O
cis	O
elements	O
such	O
as	O
the	O
PyG	B-DNA
and	I-DNA
GC	I-DNA
boxes	I-DNA
are	O
also	O
necessary	O
for	O
high	O
level	O
CD19	B-DNA
promoter	I-DNA
expression	O
.	O

EBF	B-protein
and	O
E47	B-protein
collaborate	O
to	O
induce	O
expression	O
of	O
the	O
endogenous	B-DNA
immunoglobulin	I-DNA
surrogate	I-DNA
light	I-DNA
chain	I-DNA
genes	I-DNA
.	O

Early	B-protein
B	I-protein
cell	I-protein
factor	I-protein
(	O
EBF	B-protein
)	O
and	O
E47	B-protein
participate	O
in	O
the	O
transcriptional	O
control	O
of	O
early	O
B	O
lymphocyte	O
differentiation	O
.	O

With	O
the	O
aim	O
of	O
identifying	O
genetic	O
targets	O
for	O
these	O
transcription	O
factors	O
,	O
we	O
stably	O
transfected	B-DNA
cDNAs	I-DNA
encoding	O
EBF	B-protein
or	O
a	O
covalent	O
homodimer	O
of	O
E47	B-protein
,	O
individually	O
or	O
together	O
,	O
into	O
immature	B-cell_line
hematopoietic	I-cell_line
Ba/F3	I-cell_line
cells	I-cell_line
,	O
which	O
lack	O
both	O
factors	O
.	O

In	O
combination	O
,	O
EBF	B-protein
and	O
E47	B-protein
induce	O
efficient	O
expression	O
of	O
the	O
endogenous	B-DNA
immunoglobulin	I-DNA
surrogate	I-DNA
light	I-DNA
chain	I-DNA
genes	I-DNA
,	O
lambda5	B-DNA
and	O
VpreB	B-DNA
,	O
whereas	O
other	O
pre-B	B-DNA
cell-specific	I-DNA
genes	I-DNA
remain	O
silent	O
.	O

Multiple	O
functionally	O
important	O
EBF	B-DNA
and	I-DNA
E47	I-DNA
binding	I-DNA
sites	I-DNA
were	O
identified	O
in	O
the	O
lambda5	B-DNA
promoter/enhancer	I-DNA
region	I-DNA
,	O
indicating	O
that	O
lambda5	B-DNA
is	O
a	O
direct	O
genetic	O
target	O
for	O
these	O
transcription	B-protein
factors	I-protein
.	O

Taken	O
together	O
,	O
these	O
data	O
suggest	O
that	O
EBF	B-protein
and	O
E47	B-protein
synergize	O
to	O
activate	O
expression	O
of	O
a	O
subset	O
of	O
genes	O
that	O
define	O
an	O
early	O
stage	O
of	O
the	O
B	B-cell_type
cell	I-cell_type
lineage	I-cell_type
.	O

Cytokines	B-protein
:	O
shared	O
receptors	B-protein
,	O
distinct	O
functions	O
.	O

That	O
the	O
signal	O
transduction	O
pathways	O
used	O
by	O
the	O
cytokines	B-protein
IL-2	B-protein
and	O
IL-15	B-protein
are	O
identical	O
would	O
suggest	O
that	O
these	O
cytokines	B-protein
have	O
redundant	O
roles	O
in	O
lymphoid	O
development	O
;	O
instead	O
,	O
IL-2	B-protein
is	O
the	O
guardian	O
of	O
thymus-derived	O
T-cell	O
homeostasis	O
,	O
while	O
interleukin-15	B-protein
promotes	O
extrathymic	O
development	O
of	O
T	B-cell_type
and	I-cell_type
NK	I-cell_type
cells	I-cell_type
.	O

The	O
IL-4	B-protein
receptor	I-protein
alpha-chain	I-protein
cytoplasmic	I-protein
domain	I-protein
is	O
sufficient	O
for	O
activation	O
of	O
JAK-1	B-protein
and	O
STAT6	B-protein
and	O
the	O
induction	O
of	O
IL-4	B-protein
-specific	O
gene	O
expression	O
.	O

The	O
common	B-protein
gamma-chain	I-protein
(	O
gamma	B-protein
(	I-protein
c	I-protein
)	I-protein
)	O
is	O
a	O
functional	O
component	O
of	O
the	O
IL-4R	B-protein
,	O
yet	O
cells	O
lacking	O
gamma	B-protein
(	I-protein
c	I-protein
)	I-protein
are	O
able	O
to	O
respond	O
to	O
IL-4	B-protein
.	O

This	O
has	O
led	O
to	O
the	O
suggestion	O
that	O
a	O
surrogate	B-protein
gamma'-chain	I-protein
,	O
which	O
can	O
interact	O
with	O
the	O
IL-4R	B-protein
alpha	I-protein
chain	I-protein
to	O
mediate	O
signaling	O
,	O
is	O
expressed	O
on	O
cells	O
lacking	O
gamma	B-protein
(	I-protein
c	I-protein
)	I-protein
.	O

An	O
alternative	O
possibility	O
is	O
that	O
in	O
the	O
absence	O
of	O
gamma	B-protein
(	I-protein
c	I-protein
)	I-protein
,	O
the	O
IL-4R	B-protein
alpha	I-protein
chain	I-protein
is	O
able	O
to	O
transduce	O
signals	O
by	O
homodimerization	O
.	O

To	O
test	O
this	O
latter	O
possibility	O
,	O
a	O
chimeric	B-protein
receptor	I-protein
containing	O
the	O
extracellular	B-protein
domain	I-protein
of	O
c-kit	B-protein
(	O
the	O
stem	B-protein
cell	I-protein
factor	I-protein
(	I-protein
SCF	I-protein
)	I-protein
receptor	I-protein
)	O
and	O
the	O
cytoplasmic	B-protein
and	I-protein
transmembrane	I-protein
domains	I-protein
of	O
the	O
IL-4R	B-protein
alpha	I-protein
chain	I-protein
was	O
generated	O
.	O

Treatment	O
of	O
cells	O
expressing	O
the	O
chimeric	B-protein
receptor	I-protein
kit/IL-4R	B-protein
alpha	I-protein
with	O
SCF	B-protein
induces	O
activation	O
of	O
the	O
IL-4R	B-protein
alpha-associated	I-protein
kinase	I-protein
JAK-1	B-protein
and	O
the	O
transcription	B-protein
factor	I-protein
STAT6	B-protein
.	O

However	O
,	O
tyrosine	O
phosphorylation	O
of	O
JAK-3	B-protein
,	O
which	O
associates	O
with	O
gamma	B-protein
(	I-protein
c	I-protein
)	I-protein
,	O
is	O
not	O
induced	O
by	O
SCF	B-protein
in	O
these	O
cells	O
.	O

SCF	B-protein
-mediated	O
ligation	O
of	O
kit/IL-4R	B-protein
alpha	I-protein
is	O
sufficient	O
to	O
elicit	O
IL-4	B-protein
-specific	O
gene	O
expression	O
,	O
including	O
up-regulation	O
of	O
CD23	B-protein
and	O
synthesis	O
of	O
germ-line	B-RNA
epsilon	I-RNA
transcripts	I-RNA
.	O

In	O
the	O
T	B-cell_line
cell	I-cell_line
line	I-cell_line
CTLL2	I-cell_line
,	O
ligation	O
of	O
kit/IL-4R	B-protein
alpha	I-protein
induces	O
cellular	O
proliferation	O
.	O

Finally	O
,	O
in	O
JAK-1-deficient	B-cell_line
HeLa	I-cell_line
cells	I-cell_line
,	O
STAT6	B-protein
activation	O
by	O
IL-4	B-protein
is	O
completely	O
abolished	O
.	O

Together	O
,	O
these	O
data	O
demonstrate	O
that	O
the	O
IL-4R	B-protein
alpha	I-protein
cytoplasmic	I-protein
domain	I-protein
is	O
sufficient	O
to	O
activate	O
JAK-1	B-protein
and	O
STAT6	B-protein
and	O
to	O
induce	O
expression	O
of	O
IL-4	B-DNA
target	I-DNA
genes	I-DNA
,	O
thus	O
identifying	O
a	O
mechanism	O
by	O
which	O
IL-4	B-protein
signaling	O
can	O
proceed	O
in	O
the	O
absence	O
of	O
JAK-3	B-protein
and	O
gamma	B-protein
(	I-protein
c	I-protein
)	I-protein
.	O

Histamine	O
modulates	O
the	O
expression	O
of	O
c-fos	B-DNA
through	O
cyclic	O
AMP	O
production	O
via	O
the	O
H2	B-protein
receptor	I-protein
in	O
the	O
human	B-cell_line
promonocytic	I-cell_line
cell	I-cell_line
line	I-cell_line
U937	I-cell_line
.	O

We	O
examined	O
the	O
effects	O
of	O
histamine	O
and	O
its	O
agonists	O
on	O
the	O
expression	O
of	O
the	O
c-fos	B-DNA
and	I-DNA
c-myc	I-DNA
proto-oncogenes	I-DNA
at	O
the	O
transcriptional	O
and	O
translational	O
levels	O
in	O
the	O
human	B-cell_line
promonocytic	I-cell_line
U937	I-cell_line
cell	I-cell_line
line	I-cell_line
.	O

Histamine	O
transiently	O
increased	O
cAMP	O
and	O
c-fos	B-DNA
expression	O
through	O
H2	B-protein
receptors	I-protein
.	O

Dibutyryl	O
cAMP	O
also	O
increased	O
c-fos	B-RNA
mRNA	I-RNA
and	O
protein	B-protein
,	O
and	O
levels	O
remained	O
elevated	O
even	O
after	O
12	O
hr	O
of	O
treatment	O
.	O

Dose-dependence	O
studies	O
using	O
histamine	O
and	O
dimaprit	O
showed	O
that	O
the	O
EC50	O
values	O
for	O
cAMP	O
production	O
and	O
c-fos	B-DNA
increase	O
were	O
similar	O
,	O
suggesting	O
that	O
cAMP	O
might	O
be	O
involved	O
in	O
c-fos	B-DNA
induction	O
via	O
H2	B-protein
receptors	I-protein
.	O

Furthermore	O
,	O
studies	O
carried	O
out	O
using	O
H7	B-protein
,	O
a	O
protein	B-protein
kinase	I-protein
A/protein	I-protein
kinase	I-protein
C	I-protein
inhibitor	I-protein
,	O
blocked	O
c-fos	B-DNA
induction	O
,	O
whereas	O
no	O
effect	O
was	O
observed	O
with	O
bisindolylmaleimide	O
,	O
a	O
specific	O
protein	B-protein
kinase	I-protein
C	I-protein
inhibitor	O
.	O

No	O
modification	O
of	O
c-myc	B-DNA
expression	O
could	O
be	O
detected	O
on	O
treatment	O
with	O
histamine	O
or	O
its	O
analogues	O
.	O

Nevertheless	O
,	O
dibutyryl	O
cAMP	O
induced	O
a	O
down-regulation	O
of	O
the	O
levels	O
of	O
this	O
proto-oncogene	B-DNA
.	O

In	O
addition	O
,	O
dibutyryl	O
cAMP	O
inhibited	O
cell	O
growth	O
in	O
a	O
dose-dependent	O
manner	O
,	O
whereas	O
histamine	O
failed	O
to	O
affect	O
proliferation	O
and	O
differentiation	O
of	O
U937	B-cell_line
cells	I-cell_line
.	O

Cells	O
pretreated	O
with	O
dimaprit	O
showed	O
a	O
decrease	O
in	O
the	O
cAMP	O
response	O
to	O
subsequent	O
addition	O
of	O
H2	O
agonists	O
,	O
whereas	O
the	O
cAMP	O
response	O
to	O
prostaglandin	O
E2	O
remained	O
unaltered	O
.	O

This	O
homologous	O
mechanism	O
of	O
H2	B-protein
receptor	I-protein
desensitization	O
was	O
time	O
dependent	O
.	O

These	O
results	O
indicate	O
that	O
histamine	O
activates	O
several	O
mechanisms	O
involved	O
in	O
the	O
induction	O
of	O
differentiation	O
,	O
such	O
as	O
cAMP	O
and	O
c-fos	B-DNA
production	O
,	O
but	O
fails	O
to	O
promote	O
differentiation	O
of	O
U937	B-cell_line
cells	I-cell_line
,	O
apparently	O
due	O
to	O
the	O
rapid	O
desensitization	O
of	O
H2	B-protein
receptors	I-protein
.	O

Induction	O
of	O
cytokine	B-protein
expression	O
in	O
leukocytes	B-cell_type
by	O
binding	O
of	O
thrombin-stimulated	B-cell_type
platelets	I-cell_type
.	O

BACKGROUND	O
:	O
Activated	B-cell_type
platelets	I-cell_type
tether	O
and	O
activate	O
myeloid	B-cell_type
leukocytes	I-cell_type
.	O

To	O
investigate	O
the	O
potential	O
relevance	O
of	O
this	O
mechanism	O
in	O
acute	O
myocardial	O
infarction	O
(	O
AMI	O
)	O
,	O
we	O
examined	O
cytokine	B-protein
induction	O
by	O
leukocyte-platelet	O
adhesion	O
and	O
the	O
occurrence	O
of	O
leukocyte-platelet	O
conjugates	O
in	O
patients	O
with	O
AMI	O
.	O

METHODS	O
AND	O
RESULTS	O
:	O
We	O
obtained	O
peripheral	O
venous	O
blood	O
samples	O
in	O
20	O
patients	O
with	O
AMI	O
before	O
and	O
daily	O
for	O
5	O
days	O
after	O
direct	O
percutaneous	O
transluminal	O
coronary	O
angioplasty	O
(	O
PTCA	O
)	O
and	O
in	O
20	O
patients	O
undergoing	O
elective	O
PTCA	O
.	O

Throughout	O
the	O
study	O
period	O
,	O
CD41	O
immunofluorescence	O
of	O
leukocytes	B-cell_type
(	O
flow	O
cytometry	O
)	O
revealed	O
increased	O
leukocyte-platelet	O
adhesion	O
in	O
patients	O
with	O
AMI	O
compared	O
with	O
control	O
patients	O
(	O
mean	O
+/-	O
SE	O
of	O
fluorescence	O
[	O
channels	O
]	O
before	O
PTCA	O
:	O
77	O
+/-	O
16	O
versus	O
35	O
+/-	O
9	O
;	O
P	O
=	O
.003	O
)	O
.	O

In	O
vitro	O
,	O
thrombin-stimulated	B-cell_type
fixed	I-cell_type
platelets	I-cell_type
bound	O
to	O
neutrophils	B-cell_type
and	O
monocytes	B-cell_type
.	O

Within	O
2	O
hours	O
,	O
this	O
resulted	O
in	O
increased	O
mRNA	O
for	O
interleukin	B-protein
(	I-protein
IL	I-protein
)	I-protein
,	I-protein
1	I-protein
beta	I-protein
,	O
IL-8	B-protein
,	O
and	O
monocyte	B-protein
chemoattractant	I-protein
protein	I-protein
(	I-protein
MCP	I-protein
)	I-protein
-1	I-protein
in	O
unfractionated	O
leukocytes	B-cell_type
.	O

After	O
4	O
hours	O
,	O
IL-1	B-protein
beta	I-protein
and	O
IL-8	B-protein
concentration	O
of	O
the	O
cell-free	O
supernatant	O
had	O
increased	O
by	O
268	O
+/-	O
36	O
%	O
and	O
210	O
+/-	O
7	O
%	O
,	O
respectively	O
,	O
and	O
cellular	O
MCP-1	B-protein
content	O
had	O
increased	O
by	O
170	O
+/-	O
8	O
%	O
.	O

Addition	O
of	O
activated	B-cell_type
platelets	I-cell_type
to	O
adherent	O
monocytes	B-cell_type
had	O
a	O
similar	O
effect	O
and	O
was	O
associated	O
with	O
nuclear	B-protein
factor-kappa	I-protein
B	I-protein
activation	O
.	O

Inhibition	O
of	O
binding	O
by	O
anti-P	B-protein
selectin	I-protein
antibodies	I-protein
reduced	O
the	O
effect	O
of	O
activated	B-cell_type
platelets	I-cell_type
on	O
cytokine	B-protein
production	O
.	O

CONCLUSIONS	O
:	O
In	O
patients	O
with	O
AMI	O
,	O
leukocyte-platelet	O
adhesion	O
is	O
increased	O
.	O

Binding	O
of	O
activated	B-cell_type
platelets	I-cell_type
induces	O
IL-1	B-protein
beta	I-protein
,	O
IL-8	B-protein
,	O
and	O
MCP-1	B-protein
in	O
leukocytes	B-cell_type
.	O

Our	O
findings	O
suggest	O
that	O
leukocyte-platelet	O
adhesion	O
contributes	O
to	O
the	O
regulation	O
of	O
inflammatory	O
responses	O
in	O
AMI	O
.	O

Immediate	O
early	O
and	O
early	B-protein
lytic	I-protein
cycle	I-protein
proteins	I-protein
are	O
frequent	O
targets	O
of	O
the	O
Epstein-Barr	O
virus-induced	O
cytotoxic	O
T	O
cell	O
response	O
.	O

Epstein-Barr	O
virus	O
(	O
EBV	O
)	O
,	O
a	O
human	O
gamma-herpesvirus	O
,	O
can	O
establish	O
both	O
nonproductive	O
(	O
latent	O
)	O
and	O
productive	O
(	O
lytic	O
)	O
infections	O
.	O

Although	O
the	O
CD8+	O
cytotoxic	O
T	O
lymphocyte	O
(	O
CTL	O
)	O
response	O
to	O
latently	B-cell_type
infected	I-cell_type
cells	I-cell_type
is	O
well	O
characterized	O
,	O
very	O
little	O
is	O
known	O
about	O
T	O
cell	O
controls	O
over	O
lytic	O
infection	O
;	O
this	O
imbalance	O
in	O
our	O
understanding	O
belies	O
the	O
importance	O
of	O
virus-replicative	O
lesions	O
in	O
several	O
aspects	O
of	O
EBV	O
disease	O
pathogenesis	O
.	O

The	O
present	O
work	O
shows	O
that	O
the	O
primary	O
CD8+	O
CTL	O
response	O
to	O
EBV	O
in	O
infectious	O
mononucleosis	O
patients	O
contains	O
multiple	O
lytic	O
antigen-specific	O
reactivities	O
at	O
levels	O
at	O
least	O
as	O
high	O
as	O
those	O
seen	O
against	O
latent	B-protein
antigens	I-protein
;	O
similar	O
reactivities	O
are	O
also	O
detectable	O
in	O
CTL	O
memory	O
.	O

Clonal	O
analysis	O
revealed	O
individual	O
responses	O
to	O
the	O
two	O
immediate	B-protein
early	I-protein
proteins	I-protein
BZLF1	B-protein
and	O
BRLF1	B-protein
,	O
and	O
to	O
three	O
(	O
BMLF1	B-protein
,	O
BMRF1	B-protein
,	O
and	O
BALF2	B-protein
)	O
of	O
the	O
six	O
early	B-protein
proteins	I-protein
tested	O
.	O

In	O
several	O
cases	O
,	O
the	O
peptide	O
epitope	O
and	O
HLA-restricting	O
determinant	O
recognized	O
by	O
these	O
CTLs	B-cell_type
has	O
been	O
defined	O
,	O
one	O
unusual	O
feature	O
being	O
the	O
number	O
of	O
responses	O
restricted	O
through	O
HLA-C	B-DNA
alleles	I-DNA
.	O

The	O
work	O
strongly	O
suggests	O
that	O
EBV-replicative	O
lesions	O
are	O
subject	O
to	O
direct	O
CTL	O
control	O
in	O
vivo	O
and	O
that	O
immediate	B-protein
early	I-protein
and	I-protein
early	I-protein
proteins	I-protein
are	O
frequently	O
the	O
immunodominant	O
targets	O
.	O

This	O
contrasts	O
with	O
findings	O
in	O
alpha-	O
and	O
beta-	O
herpesvirus	O
systems	O
(	O
herpes	O
simplex	O
,	O
cytomegalovirus	O
)	O
where	O
viral	O
interference	O
with	O
the	O
antigen-processing	O
pathway	O
during	O
lytic	O
infection	O
renders	O
immediate	B-protein
early	I-protein
and	I-protein
early	I-protein
proteins	I-protein
much	O
less	O
immunogenic	O
.	O

The	O
unique	O
capacity	O
of	O
gamma-herpesvirus	O
to	O
amplify	O
the	O
viral	O
load	O
in	O
vivo	O
through	O
a	O
latent	O
growth-transforming	O
infection	O
may	O
have	O
rendered	O
these	O
agents	O
less	O
dependent	O
upon	O
viral	O
replication	O
as	O
a	O
means	O
of	O
successfully	O
colonizing	O
their	O
hosts	O
.	O

Triggering	O
of	O
HLA-DR	B-protein
antigens	I-protein
differentially	O
modulates	O
tumor	B-protein
necrosis	I-protein
factor	I-protein
alpha	I-protein
release	O
by	O
B	B-cell_type
cells	I-cell_type
at	O
distinct	O
stage	O
of	O
maturation	O
.	O

Triggering	O
of	O
HLA	B-protein
class	I-protein
II	I-protein
antigens	I-protein
by	O
the	O
anti-HLA-DR	B-protein
monoclonal	I-protein
antibody	I-protein
(	I-protein
mAb	I-protein
)	I-protein
L243	I-protein
significantly	O
(	O
P	O
<	O
0.05	O
)	O
and	O
differentially	O
enhanced	O
the	O
release	O
of	O
tumor	B-protein
necrosis	I-protein
factor	I-protein
alpha	I-protein
(	O
TNF-alpha	B-protein
)	O
by	O
the	O
non-Hodgkin	B-cell_type
's	I-cell_type
lymphoma	I-cell_type
cells	I-cell_type
Ri-I	B-cell_line
,	O
Ci-I	B-cell_line
,	O
and	O
Sc-I	B-cell_line
,	O
which	O
are	O
at	O
a	O
distinct	O
stage	O
of	O
B-cell	O
differentiation	O
,	O
and	O
by	O
the	O
more	O
mature	O
Burkitt	B-cell_line
lymphoma	I-cell_line
cell	I-cell_line
Raji	I-cell_line
;	O
in	O
contrast	O
,	O
it	O
did	O
not	O
induce	O
TNF-alpha	B-protein
release	O
by	O
the	O
pre-B	B-cell_type
leukemia	I-cell_type
cells	I-cell_type
Nalm-6	B-cell_line
and	O
BV173	B-cell_line
.	O

TNF-alpha	B-protein
release	O
peaked	O
at	O
24	O
h	O
and	O
decreased	O
thereafter	O
,	O
and	O
it	O
was	O
dose	O
dependent	O
and	O
preceded	O
by	O
an	O
increase	O
of	O
TNF-alpha	B-RNA
mRNA	I-RNA
detectable	O
after	O
3	O
h	O
of	O
stimulation	O
with	O
mAb	B-protein
L243	I-protein
.	O

Secreted	O
TNF-alpha	B-protein
mediated	O
the	O
enhancement	O
of	O
nuclear	B-protein
factor	I-protein
kappa	I-protein
B	I-protein
(	O
NF-kappa	B-protein
B	I-protein
)	O
and	O
activator	O
protein-1	O
(	O
AP-1	B-protein
)	O
binding	O
activity	O
;	O
in	O
fact	O
,	O
the	O
triggering	O
of	O
HLA-DR	B-protein
antigens	I-protein
in	O
the	O
presence	O
of	O
antihuman	B-protein
TNF-alpha-neutralizing	I-protein
antibodies	I-protein
did	O
not	O
upregulate	O
NF-kappa	B-protein
B	I-protein
and	O
AP-1	B-protein
.	O

In	O
contrast	O
,	O
released	O
TNF-alpha	B-protein
was	O
not	O
responsible	O
for	O
the	O
homotypic	O
aggregation	O
of	O
Ri-I	B-cell_line
,	O
Ci-I	B-cell_line
,	O
Sc-I	B-cell_line
,	O
and	O
Raji	B-cell_line
cells	I-cell_line
induced	O
by	O
mAb	B-protein
L243	I-protein
,	O
and	O
it	O
did	O
not	O
affect	O
the	O
proliferation	O
of	O
B	B-cell_type
cells	I-cell_type
investigated	O
.	O

Altogether	O
,	O
our	O
data	O
demonstrate	O
that	O
:	O
(	O
a	O
)	O
the	O
ability	O
of	O
B	B-cell_type
cells	I-cell_type
to	O
release	O
TNF-alpha	B-protein
after	O
triggering	O
of	O
HLA-DR	B-protein
antigens	I-protein
depends	O
on	O
their	O
stage	O
of	O
differentiation	O
;	O
(	O
b	O
)	O
levels	O
of	O
released	O
TNF-alpha	B-protein
seem	O
to	O
correlate	O
with	O
the	O
stage	O
of	O
B-cell	O
maturation	O
but	O
do	O
not	O
correlate	O
with	O
the	O
amounts	O
of	O
cell	B-protein
surface	I-protein
HLA-DR	I-protein
antigens	I-protein
;	O
(	O
c	O
)	O
secreted	O
TNF-alpha	B-protein
regulates	O
the	O
levels	O
of	O
expression	O
of	O
NF-kappa	B-protein
B	I-protein
and	O
AP-1	B-protein
by	O
an	O
autocrine	O
loop	O
;	O
and	O
(	O
d	O
)	O
intracellular	O
signals	O
mediating	O
TNF-alpha	B-protein
release	O
by	O
B	B-cell_type
cells	I-cell_type
are	O
distinct	O
from	O
those	O
regulating	O
homotypic	O
aggregation	O
and	O
proliferation	O
.	O

Transcription	B-protein
factor	I-protein
GATA-3	I-protein
is	O
differentially	O
expressed	O
in	O
murine	B-cell_line
Th1	I-cell_line
and	I-cell_line
Th2	I-cell_line
cells	I-cell_line
and	O
controls	O
Th2-specific	O
expression	O
of	O
the	O
interleukin-5	B-DNA
gene	I-DNA
.	O

Interleukin-5	B-protein
(	O
IL-5	B-protein
)	O
,	O
which	O
is	O
produced	O
by	O
CD4	B-cell_type
(	I-cell_type
+	I-cell_type
)	I-cell_type
T	I-cell_type
helper	I-cell_type
2	I-cell_type
(	I-cell_type
Th2	I-cell_type
)	I-cell_type
cells	I-cell_type
,	O
but	O
not	O
by	O
Th1	B-cell_type
cells	I-cell_type
,	O
plays	O
a	O
key	O
role	O
in	O
the	O
development	O
of	O
eosinophilia	O
in	O
asthma	O
.	O

Despite	O
increasing	O
evidence	O
that	O
the	O
outcome	O
of	O
many	O
diseases	O
is	O
determined	O
by	O
the	O
ratio	O
of	O
the	O
two	O
subsets	O
of	O
CD4	B-cell_type
(	I-cell_type
+	I-cell_type
)	I-cell_type
T	I-cell_type
helper	I-cell_type
cells	I-cell_type
,	O
Th1	B-cell_type
and	O
Th2	B-cell_type
,	O
the	O
molecular	O
basis	O
for	O
Th1-	O
and	O
Th2-	O
specific	O
gene	O
expression	O
remains	O
to	O
be	O
elucidated	O
.	O

We	O
previously	O
established	O
a	O
critical	O
role	O
for	O
the	O
transcription	B-protein
factor	I-protein
GATA-3	B-protein
in	O
IL-5	B-DNA
promoter	I-DNA
activation	O
in	O
EL-4	B-cell_line
cells	I-cell_line
,	O
which	O
express	O
both	O
Th1-	B-protein
and	I-protein
Th2-type	I-protein
cytokines	I-protein
.	O

Our	O
studies	O
reported	O
here	O
demonstrate	O
that	O
GATA-3	B-protein
is	O
critical	O
for	O
expression	O
of	O
the	O
IL-5	B-protein
gene	O
in	O
bona	B-cell_type
fide	I-cell_type
Th2	I-cell_type
cells	I-cell_type
.	O

Whereas	O
mutations	O
in	O
the	O
GATA-3	B-protein
site	O
abolished	O
antigen-	O
or	O
cAMP-	O
stimulated	O
IL-5	O
promoter	O
activation	O
in	O
Th2	O
cells	O
,	O
ectopic	O
expression	O
of	O
GATA-3	B-protein
in	O
Th1	B-cell_type
cells	I-cell_type
or	O
in	O
a	O
non-lymphoid	B-cell_line
,	I-cell_line
non-IL-5-producing	I-cell_line
cell	I-cell_line
line	I-cell_line
activated	O
the	O
IL-5	B-DNA
promoter	I-DNA
.	O

During	O
the	O
differentiation	O
of	O
naive	B-cell_type
CD4	I-cell_type
(	I-cell_type
+	I-cell_type
)	I-cell_type
T	I-cell_type
cells	I-cell_type
isolated	O
from	O
T	O
cell	O
receptor	O
transgenic	O
mice	O
,	O
GATA-3	B-protein
gene	O
expression	O
was	O
up-regulated	O
in	O
developing	O
Th2	B-cell_type
cells	I-cell_type
,	O
but	O
was	O
down-regulated	O
in	O
Th1	B-cell_type
cells	I-cell_type
,	O
and	O
antigen-	B-cell_type
or	I-cell_type
cAMP-activated	I-cell_type
Th2	I-cell_type
cells	I-cell_type
(	O
but	O
not	O
Th1	B-cell_type
cells	I-cell_type
)	O
expressed	O
the	O
GATA-3	B-protein
protein	I-protein
.	O

Thus	O
,	O
GATA-3	B-protein
may	O
play	O
an	O
important	O
role	O
in	O
the	O
balance	O
between	O
Th1	B-cell_type
and	O
Th2	B-cell_type
subsets	I-cell_type
in	O
immune	O
responses	O
.	O

Inhibition	O
of	O
GATA-3	B-protein
activity	O
has	O
therapeutic	O
potential	O
in	O
the	O
treatment	O
of	O
asthma	O
and	O
other	O
hypereosinophilic	O
diseases	O
.	O

A	O
shortened	O
life	O
span	O
of	O
EKLF-/-	B-cell_type
adult	I-cell_type
erythrocytes	I-cell_type
,	O
due	O
to	O
a	O
deficiency	O
of	O
beta-globin	B-protein
chains	I-protein
,	O
is	O
ameliorated	O
by	O
human	B-protein
gamma-globin	I-protein
chains	I-protein
.	O

Using	O
homologous	O
recombination	O
,	O
both	O
EKLF	B-DNA
alleles	I-DNA
in	O
murine	B-cell_line
embryonic	I-cell_line
stem	I-cell_line
(	I-cell_line
ES	I-cell_line
)	I-cell_line
cells	I-cell_line
were	O
inactivated	O
.	O

These	O
EKLF-/-	B-cell_line
ES	I-cell_line
cells	I-cell_line
were	O
capable	O
of	O
undergoing	O
in	O
vitro	O
differentiation	O
to	O
form	O
definitive	O
erythroid	O
colonies	O
that	O
were	O
similar	O
in	O
size	O
and	O
number	O
to	O
those	O
formed	O
by	O
wild-type	B-cell_type
ES	I-cell_type
cells	I-cell_type
.	O

However	O
,	O
the	O
EKLF-/-	B-cell_line
colonies	I-cell_line
were	O
poorly	O
hemoglobinized	O
and	O
enucleated	B-cell_type
erythrocytes	I-cell_type
in	O
these	O
colonies	O
contained	O
numerous	O
Heinz	O
bodies	O
.	O

Reverse	O
transcriptase-polymerase	O
chain	O
reaction	O
(	O
RT-PCR	O
)	O
analyses	O
revealed	O
that	O
adult	O
and	O
embryonic	B-DNA
globin	I-DNA
genes	I-DNA
were	O
appropriately	O
regulated	O
,	O
with	O
the	O
exception	O
of	O
beta	B-protein
h1-globin	I-protein
,	O
which	O
continued	O
to	O
be	O
expressed	O
at	O
a	O
very	O
low	O
level	O
.	O

The	O
ratio	O
of	O
adult	B-RNA
beta-globin/alpha-globin	I-RNA
mRNA	I-RNA
in	O
the	O
mutant	B-cell_line
ES	I-cell_line
cells	I-cell_line
was	O
1/15	O
of	O
that	O
in	O
wild-type	B-cell_type
ES	I-cell_type
cells	I-cell_type
.	O

When	O
the	O
EKLF-/-	B-cell_line
cells	I-cell_line
were	O
injected	O
into	O
blastocysts	O
,	O
they	O
did	O
not	O
contribute	O
at	O
a	O
detectable	O
level	O
to	O
the	O
mature	O
erythrocyte	O
compartment	O
of	O
the	O
chimeric	O
animals	O
,	O
based	O
on	O
analysis	O
of	O
glucose	B-protein
phosphate	I-protein
isomerase-1	I-protein
(	I-protein
GPI-1	I-protein
)	I-protein
isozymes	I-protein
and	O
hemoglobins	O
that	O
distinguish	O
ES	B-cell_type
cell-derived	I-cell_type
erythrocytes	I-cell_type
from	O
host	O
blastocyst-derived	B-cell_type
erythrocytes	I-cell_type
.	O

In	O
contrast	O
,	O
semiquantitative	O
RT-PCR	O
analysis	O
of	O
RNA	O
from	O
reticulocytes	B-cell_type
of	O
the	O
same	O
chimeric	O
animals	O
suggested	O
that	O
the	O
ES	B-cell_type
cell-derived	I-cell_type
reticulocytes	I-cell_type
were	O
present	O
at	O
a	O
level	O
of	O
6	O
%	O
to	O
8	O
%	O
.	O

This	O
indicated	O
that	O
the	O
EKLF-/-	B-cell_line
erythrocytes	I-cell_line
in	O
adult	O
animals	O
must	O
be	O
short-lived	O
,	O
apparently	O
due	O
to	O
the	O
imbalance	O
of	O
beta-	B-protein
versus	I-protein
alpha-globin	I-protein
chains	I-protein
,	O
leading	O
to	O
the	O
precipitation	O
of	O
excess	O
alpha-globin	B-protein
chains	I-protein
to	O
form	O
Heinz	O
bodies	O
.	O

Consistent	O
with	O
this	O
hypothesis	O
,	O
the	O
short	O
life	O
span	O
was	O
ameliorated	O
by	O
introduction	O
into	O
the	O
EKLF-/-	B-cell_line
ES	I-cell_line
cells	I-cell_line
of	O
a	O
human	B-DNA
LCR/gamma-globin	I-DNA
gene	I-DNA
,	O
as	O
evidenced	O
by	O
the	O
presence	O
of	O
ES	B-cell_type
cell-derived	I-cell_type
reticulocytes	I-cell_type
as	O
well	O
as	O
mature	B-cell_type
erythrocytes	I-cell_type
in	O
the	O
blood	O
of	O
the	O
chimeric	O
animals	O
.	O

RP1	B-DNA
,	O
a	O
new	O
member	O
of	O
the	O
adenomatous	B-DNA
polyposis	I-DNA
coli-binding	I-DNA
EB1-like	I-DNA
gene	I-DNA
family	I-DNA
,	O
is	O
differentially	O
expressed	O
in	O
activated	B-cell_type
T	I-cell_type
cells	I-cell_type
.	O

Cross-linking	O
of	O
the	O
CD3	B-protein
and	I-protein
CD28	I-protein
molecules	I-protein
on	O
T	B-cell_type
lymphocytes	I-cell_type
represents	O
one	O
of	O
the	O
most	O
effective	O
signals	O
for	O
T	B-cell_type
lymphocyte	I-cell_type
activation	O
and	O
triggering	O
of	O
their	O
cytotoxic	O
effector	O
function	O
.	O

To	O
identify	O
genes	O
that	O
are	O
expressed	O
in	O
T	B-cell_type
cells	I-cell_type
after	O
stimulation	O
,	O
mRNA	O
from	O
T	B-cell_type
lymphocytes	I-cell_type
that	O
had	O
been	O
activated	O
by	O
the	O
simultaneous	O
stimulation	O
of	O
the	O
CD3	B-protein
and	O
CD28	B-protein
trigger	O
molecules	O
was	O
transcribed	O
for	O
a	O
differential	O
mRNA	O
display	O
analysis	O
into	O
cDNA	O
and	O
was	O
compared	O
with	O
cDNA	O
from	O
CD28	B-protein
-or	O
CD3	B-protein
-activated	O
or	O
resting	O
lymphocytes	B-cell_type
.	O

Differential	O
expression	O
was	O
confirmed	O
subsequently	O
by	O
Northern	O
blot	O
analysis	O
.	O

One	O
of	O
the	O
cDNA	B-DNA
fragments	I-DNA
expressed	O
specifically	O
in	O
CD3	B-protein
-and	O
CD28	B-protein
-activated	B-cell_type
T	I-cell_type
cells	I-cell_type
was	O
designated	O
RP1	B-DNA
.	O

The	O
predictive	B-DNA
protein-coding	I-DNA
region	I-DNA
of	O
RP1	B-DNA
had	O
a	O
significant	O
homology	O
to	O
members	O
of	O
the	O
recently	O
found	O
adenomatous	B-DNA
polyposis	I-DNA
coli	I-DNA
(	I-DNA
APC	I-DNA
)	I-DNA
protein-binding	I-DNA
EB1	I-DNA
gene	I-DNA
family	I-DNA
,	O
which	O
codes	O
for	O
yet	O
unknown	O
protein	O
(	O
s	O
)	O
.	O

Bacterially	O
expressed	O
RP1	B-protein
protein	I-protein
revealed	O
specific	O
binding	O
to	O
wild-type	B-protein
but	O
not	O
to	O
mutated	B-protein
APC	I-protein
protein	I-protein
.	O

The	O
rapid	O
up-regulation	O
of	O
RP1	B-RNA
mRNA	I-RNA
in	O
properly	O
activated	B-cell_type
T	I-cell_type
cells	I-cell_type
suggests	O
that	O
this	O
gene	O
might	O
belong	O
to	O
the	O
immediate/early	B-DNA
gene	I-DNA
family	I-DNA
,	O
which	O
controls	O
the	O
signal	O
transduction	O
cascade	O
downstream	O
of	O
the	O
TCR	B-protein
.	O

As	O
the	O
expression	O
level	O
of	O
the	O
RP1	B-DNA
gene	I-DNA
in	O
activated	B-cell_type
T	I-cell_type
cells	I-cell_type
and	O
a	O
spectrum	O
of	O
tumor-derived	B-cell_line
cell	I-cell_line
lines	I-cell_line
correlates	O
with	O
the	O
proliferative	O
status	O
of	O
the	O
cells	O
,	O
members	O
of	O
the	O
EB1-like	B-DNA
gene	I-DNA
family	I-DNA
may	O
not	O
only	O
be	O
involved	O
in	O
the	O
tumorigenesis	O
of	O
colorectal	O
cancers	O
but	O
may	O
also	O
play	O
a	O
role	O
in	O
the	O
proliferative	O
control	O
of	O
normal	B-cell_type
cells	I-cell_type
.	O

Cyclosporin	O
A	O
interferes	O
with	O
the	O
inducible	O
degradation	O
of	O
NF-kappa	B-protein
B	I-protein
inhibitors	O
,	O
but	O
not	O
with	O
the	O
processing	O
of	O
p105/	O
NF-kappa	B-protein
B1	I-protein
in	O
T	B-cell_type
cells	I-cell_type
.	O

The	O
transcription	B-protein
factor	I-protein
NF-kappa	B-protein
B	I-protein
controls	O
the	O
induction	O
of	O
numerous	O
cytokine	B-DNA
promoters	I-DNA
during	O
the	O
activation	O
of	O
T	B-cell_type
lymphocytes	I-cell_type
.	O

Inhibition	O
of	O
T	O
cell	O
activation	O
by	O
the	O
immunosuppressants	O
cyclosporin	O
A	O
(	O
CsA	O
)	O
and	O
FK506	O
exerts	O
a	O
suppressive	O
effect	O
on	O
the	O
induction	O
of	O
these	O
NF-kappa	B-DNA
B-controlled	I-DNA
cytokine	I-DNA
promoters	I-DNA
.	O

We	O
show	O
for	O
human	B-cell_line
Jurkat	I-cell_line
T	I-cell_line
leukemia	I-cell_line
cells	I-cell_line
,	O
as	O
well	O
as	O
human	B-cell_type
and	I-cell_type
mouse	I-cell_type
primary	I-cell_type
T	I-cell_type
lymphocytes	I-cell_type
,	O
that	O
this	O
inhibitory	O
effect	O
is	O
accompanied	O
by	O
an	O
impaired	O
nuclear	O
translocation	O
of	O
the	O
Rel	B-protein
proteins	I-protein
c-Rel	B-protein
,	O
RelA/p65	B-protein
and	O
NF-kappa	B-protein
B1/p50	I-protein
,	O
whereas	O
the	O
nuclear	O
appearance	O
of	O
RelB	B-protein
remains	O
unaffected	O
.	O

CsA	O
does	O
not	O
interfere	O
with	O
the	O
synthesis	O
of	O
Rel	B-protein
proteins	I-protein
,	O
but	O
prevents	O
the	O
inducible	O
degradation	O
of	O
cytosolic	B-protein
NF-kappa	I-protein
B	I-protein
inhibitors	I-protein
I	B-protein
kappa	I-protein
B	I-protein
alpha	I-protein
and	O
I	B-protein
kappa	I-protein
B	I-protein
beta	I-protein
upon	O
T	O
cell	O
activation	O
.	O

CsA	O
neither	O
inhibits	O
the	O
processing	O
of	O
the	O
NF-kappa	B-protein
B1	I-protein
precursor	I-protein
p105	B-protein
to	O
p50	B-protein
,	O
nor	O
does	O
it	O
``	O
stabilize	O
''	O
the	O
C-terminal	O
portion	O
of	O
p105	B-protein
,	O
I	B-protein
kappa	I-protein
B	I-protein
gamma	I-protein
,	O
which	O
is	O
degraded	O
during	O
p105	B-protein
processing	O
to	O
mature	B-protein
p50	I-protein
.	O

These	O
results	O
indicate	O
that	O
CsA	O
interferes	O
with	O
a	O
specific	O
event	O
in	O
the	O
signal-induced	O
degradation	O
of	O
I	B-protein
kappa	I-protein
B	I-protein
alpha	I-protein
and	O
I	B-protein
kappa	I-protein
B	I-protein
beta	I-protein
,	O
but	O
does	O
not	O
affect	O
the	O
processing	O
of	O
NF-kappa	B-protein
B1/p105	I-protein
to	O
p50	B-protein
.	O

Activation	O
of	O
nuclear	B-protein
factor-kappa	I-protein
B	I-protein
by	O
beta-amyloid	O
peptides	O
and	O
interferon-gamma	B-protein
in	O
murine	O
microglia	O
.	O

An	O
increasing	O
body	O
of	O
evidence	O
suggests	O
that	O
amyloid-beta	O
(	O
A	O
beta	O
)	O
peptides	O
and	O
microglia	B-cell_type
are	O
crucially	O
involved	O
in	O
the	O
pathogenesis	O
of	O
Alzheimer	O
's	O
disease	O
.	O

In	O
an	O
effort	O
to	O
further	O
elucidate	O
the	O
biological	O
effects	O
of	O
A	O
beta	O
towards	O
microglia	B-cell_type
,	O
we	O
investigated	O
the	O
ability	O
of	O
A	O
beta	O
peptides	O
to	O
activate	O
nuclear	B-protein
factor	I-protein
(	I-protein
NF	I-protein
)	I-protein
-kappa	I-protein
B	I-protein
in	O
the	O
N9	B-cell_line
murine	I-cell_line
microglial	I-cell_line
cell	I-cell_line
line	I-cell_line
.	O

Co-stimulation	O
of	O
microglia	B-cell_type
with	O
suboptimal	O
concentrations	O
of	O
A	O
beta	O
(	O
25-35	O
)	O
and	O
100	O
U/ml	O
IFN	B-protein
gamma	I-protein
resulted	O
in	O
the	O
detection	O
of	O
a	O
specific	O
NF-kappa	B-protein
B	I-protein
DNA-binding	O
activity	O
in	O
nuclear	O
extracts	O
,	O
as	O
determined	O
in	O
gel	O
mobility	O
shift	O
assays	O
.	O

This	O
response	O
required	O
at	O
least	O
120	O
min	O
to	O
be	O
evident	O
and	O
supershift	O
experiments	O
revealed	O
that	O
the	O
NF-kappa	B-protein
B	I-protein
complex	I-protein
contains	O
both	O
RelA	B-protein
and	O
p50	B-protein
.	O

Accordingly	O
,	O
immunoblot	O
experiments	O
showed	O
that	O
amongst	O
NF-kappa	B-protein
B	I-protein
/Rel	B-protein
proteins	I-protein
,	O
RelA	B-protein
and	O
p50	B-protein
are	O
mobilized	O
to	O
the	O
nucleus	O
following	O
microglial	O
cell	O
stimulation	O
with	O
A	O
beta	O
(	O
25-35	O
)	O
plus	O
IFN	B-protein
gamma	I-protein
.	O

Higher	O
concentrations	O
of	O
A	O
beta	O
(	O
25-35	O
)	O
were	O
effective	O
by	O
themselves	O
in	O
inducing	O
NF-kappa	B-protein
B	I-protein
activation	O
,	O
both	O
in	O
the	O
N9	B-cell_line
microglial	I-cell_line
cell	I-cell_line
line	I-cell_line
and	O
in	O
rat	B-cell_line
primary	I-cell_line
microglia	I-cell_line
,	O
as	O
well	O
as	O
in	O
human	B-cell_type
monocytes	I-cell_type
.	O

For	O
purposes	O
of	O
comparison	O
,	O
microglia	B-cell_type
were	O
also	O
stimulated	O
with	O
bacterial	O
LPS	O
,	O
a	O
known	O
NF-kappa	B-protein
B	I-protein
inducer	O
.	O

As	O
expected	O
,	O
LPS	O
strongly	O
induced	O
the	O
formation	O
of	O
two	O
NF-kappa	B-protein
B	I-protein
DNA-binding	O
activities	O
,	O
one	O
of	O
which	O
was	O
identified	O
as	O
RelA/p50	B-protein
.	O

The	O
LPS	O
response	O
was	O
also	O
more	O
rapid	O
,	O
as	O
it	O
was	O
already	O
evident	O
by	O
40	O
min	O
and	O
remained	O
sustained	O
for	O
up	O
to	O
3	O
h	O
.	O

Collectively	O
,	O
these	O
findings	O
indicate	O
that	O
NF-kappa	B-protein
B	I-protein
activation	O
might	O
constitute	O
one	O
of	O
the	O
mechanisms	O
underlying	O
the	O
inducible	O
expression	O
of	O
kappa	B-DNA
B-dependent	I-DNA
genes	I-DNA
in	O
microglia	B-cell_type
stimulated	O
by	O
A	O
beta	O
peptides	O
and	O
IFN	B-protein
gamma	I-protein
,	O
or	O
by	O
LPS	O
.	O

Glucocorticoid-mediated	O
repression	O
of	O
cytokine	B-DNA
gene	I-DNA
transcription	O
in	O
human	O
arteritis-SCID	B-protein
chimeras	I-protein
.	O

Giant	O
cell	O
arteritis	O
(	O
GCA	O
)	O
is	O
a	O
vasculitic	O
syndrome	O
that	O
preferentially	O
affects	O
medium	O
and	O
large-sized	O
arteries	O
.	O

Glucocorticoid	O
therapy	O
resolves	O
clinical	O
symptoms	O
within	O
hours	O
to	O
days	O
,	O
but	O
therapy	O
has	O
to	O
be	O
continued	O
over	O
several	O
years	O
to	O
prevent	O
disease	O
relapses	O
.	O

It	O
is	O
not	O
known	O
whether	O
and	O
how	O
glucocorticoids	O
affect	O
the	O
function	O
of	O
the	O
inflammatory	O
infiltrate	O
or	O
why	O
the	O
disease	O
persists	O
subclinically	O
despite	O
chronic	O
treatment	O
.	O

GCA	O
is	O
self-sustained	O
in	O
temporal	O
arteries	O
engrafted	O
into	O
SCID	O
mice	O
,	O
providing	O
a	O
model	O
in	O
which	O
the	O
mechanisms	O
of	O
action	O
and	O
limitations	O
of	O
glucocorticoid	O
therapy	O
can	O
be	O
examined	O
in	O
vivo	O
.	O

Administration	O
of	O
dexamethasone	O
to	O
temporal	B-cell_line
artery-SCID	I-cell_line
chimeras	I-cell_line
for	O
1	O
wk	O
induced	O
a	O
partial	O
suppression	O
of	O
T	O
cell	O
and	O
macrophage	O
function	O
as	O
indicated	O
by	O
the	O
reduced	O
tissue	O
concentrations	O
of	O
IL-2	B-RNA
,	I-RNA
IL-1beta	I-RNA
,	I-RNA
and	I-RNA
IL-6	I-RNA
mRNA	I-RNA
,	O
and	O
by	O
the	O
diminished	O
expression	O
of	O
inducible	O
NO	B-protein
synthase	I-protein
.	O

In	O
contrast	O
,	O
synthesis	O
of	O
IFN-gamma	B-RNA
mRNA	I-RNA
was	O
only	O
slightly	O
decreased	O
,	O
and	O
expression	O
of	O
TGF-beta1	B-protein
was	O
unaffected	O
.	O

These	O
findings	O
correlated	O
with	O
activation	O
of	O
the	O
IkappaBalpha	B-DNA
gene	I-DNA
and	O
blockade	O
of	O
the	O
nuclear	O
translocation	O
of	O
NFkappaB	B-protein
in	O
the	O
xenotransplanted	O
tissue	O
.	O

Dose-response	O
experiments	O
suggested	O
that	O
steroid	O
doses	O
currently	O
used	O
in	O
clinical	O
medicine	O
are	O
suboptimal	O
in	O
repressing	O
NFkappaB	B-protein
-mediated	O
cytokine	B-protein
production	O
in	O
the	O
inflammatory	O
lesions	O
.	O

Chronic	O
steroid	O
therapy	O
was	O
able	O
to	O
deplete	O
the	O
T	B-protein
cell	I-protein
products	I-protein
IL-2	B-protein
and	O
IFN-gamma	B-protein
,	O
whereas	O
the	O
activation	O
of	O
tissue-infiltrating	B-cell_type
macrophages	I-cell_type
was	O
only	O
partially	O
affected	O
.	O

IL-1beta	B-protein
transcription	O
was	O
abrogated	O
;	O
in	O
contrast	O
,	O
TGF-beta1	B-RNA
mRNA	I-RNA
synthesis	O
was	O
steroid	O
resistant	O
.	O

The	O
persistence	O
of	O
TGF-beta1-transcribing	B-cell_type
macrophages	I-cell_type
,	O
despite	O
paralysis	O
of	O
T	O
cell	O
function	O
,	O
may	O
provide	O
an	O
explanation	O
for	O
the	O
chronicity	O
of	O
the	O
disease	O
,	O
and	O
may	O
identify	O
a	O
novel	O
therapeutic	O
target	O
in	O
this	O
inflammatory	O
vasculopathy	O
.	O

Defective	O
survival	O
and	O
activation	O
of	O
thymocytes	B-cell_type
in	O
transgenic	O
mice	O
expressing	O
a	O
catalytically	B-protein
inactive	I-protein
form	I-protein
of	O
Ca2+/calmodulin-dependent	B-protein
protein	I-protein
kinase	I-protein
IV	I-protein
.	O

We	O
have	O
generated	O
transgenic	O
mice	O
that	O
express	O
a	O
catalytically	B-protein
inactive	I-protein
form	I-protein
of	O
Ca2+/calmodulin-dependent	B-protein
protein	I-protein
kinase	I-protein
IV	I-protein
(	O
CaMKIV	B-protein
)	O
specifically	O
in	O
thymic	B-cell_type
T	I-cell_type
cells	I-cell_type
.	O

The	O
presence	O
of	O
this	O
protein	O
results	O
in	O
a	O
markedly	O
reduced	O
thymic	O
cellularity	O
,	O
although	O
the	O
distribution	O
of	O
the	O
remaining	O
cells	O
is	O
normal	O
based	O
on	O
evaluation	O
of	O
the	O
CD4	B-protein
and	O
CD8	B-protein
cell	B-protein
surface	I-protein
antigens	I-protein
that	O
are	O
used	O
to	O
gauge	O
T	O
cell	O
development	O
.	O

Isolated	O
thymic	B-cell_type
T	I-cell_type
cells	I-cell_type
from	O
the	O
transgenic	O
mice	O
also	O
show	O
a	O
dramatically	O
decreased	O
survival	O
rate	O
when	O
evaluated	O
in	O
culture	O
under	O
conditions	O
that	O
do	O
not	O
favor	O
activation	O
.	O

When	O
challenged	O
with	O
an	O
activating	O
stimulus	O
such	O
as	O
alpha-CD3	B-protein
or	O
a	O
combination	O
of	O
phorbol	O
ester	O
plus	O
ionophore	O
,	O
the	O
cells	O
are	O
severely	O
compromised	O
in	O
their	O
ability	O
to	O
produce	O
the	O
cytokine	B-protein
interleukin-2	B-protein
(	O
IL-2	B-protein
)	O
.	O

Reduction	O
of	O
IL-2	B-protein
production	O
is	O
secondary	O
to	O
the	O
inability	O
to	O
phosphorylate	O
the	O
cAMP	B-protein
response	I-protein
element	I-protein
binding	I-protein
protein	I-protein
,	O
CREB	B-protein
,	O
and	O
induce	O
expression	O
of	O
the	O
immediate	B-DNA
early	I-DNA
genes	I-DNA
such	O
as	O
Fos	B-DNA
B	I-DNA
that	O
are	O
required	O
to	O
transactivate	O
the	O
IL-2	B-DNA
promoter	I-DNA
.	O

Because	O
transgene	O
expression	O
was	O
regulated	O
by	O
the	O
proximal	B-DNA
promoter	I-DNA
of	O
the	O
murine	B-DNA
lck	I-DNA
gene	I-DNA
and	O
this	O
promoter	O
is	O
inactivated	O
in	O
T	B-cell_type
cells	I-cell_type
that	O
exit	O
the	O
thymus	O
,	O
the	O
mutant	B-protein
hCaMKIV	I-protein
is	O
not	O
present	O
in	O
peripheral	B-cell_type
T	I-cell_type
cells	I-cell_type
.	O

Consequently	O
,	O
T	B-cell_type
lymphocytes	I-cell_type
present	O
in	O
the	O
spleen	O
can	O
be	O
activated	O
normally	O
in	O
response	O
to	O
either	O
stimulus	O
mentioned	O
above	O
,	O
demonstrating	O
that	O
the	O
effects	O
of	O
the	O
inactive	B-protein
CaMKIV	I-protein
on	O
activation	O
are	O
reversible	O
.	O

Our	O
results	O
suggest	O
that	O
CaMKIV	B-protein
may	O
represent	O
a	O
physiologically	O
relevant	O
CREB	B-protein
kinase	I-protein
in	O
T	B-cell_type
cells	I-cell_type
and	O
that	O
the	O
enzyme	O
is	O
also	O
required	O
to	O
ensure	O
normal	O
expansion	O
of	O
T	B-cell_type
cells	I-cell_type
in	O
the	O
thymus	O
.	O

Whereas	O
the	O
pathway	O
responsible	O
for	O
this	O
latter	O
role	O
is	O
yet	O
to	O
be	O
elucidated	O
,	O
it	O
is	O
unlikely	O
to	O
include	O
CREB	B-protein
phosphorylation	O
.	O

A	O
new	O
mouse	B-DNA
gene	I-DNA
,	O
SRG3	B-DNA
,	O
related	O
to	O
the	O
SWI3	B-DNA
of	O
Saccharomyces	O
cerevisiae	O
,	O
is	O
required	O
for	O
apoptosis	O
induced	O
by	O
glucocorticoids	O
in	O
a	O
thymoma	B-cell_line
cell	I-cell_line
line	I-cell_line
.	O

We	O
isolated	O
a	O
new	O
mouse	B-DNA
gene	I-DNA
that	O
is	O
highly	O
expressed	O
in	O
thymocytes	B-cell_type
,	O
testis	O
,	O
and	O
brain	O
.	O

This	O
gene	O
,	O
SRG3	B-DNA
,	O
showed	O
a	O
significant	O
sequence	O
homology	O
to	O
SWI3	B-DNA
,	O
a	O
yeast	B-DNA
transcriptional	I-DNA
activator	I-DNA
,	O
and	O
its	O
human	B-DNA
homolog	I-DNA
BAF155	I-DNA
.	O

SRG3	B-DNA
encodes	O
1	O
,	O
100	O
amino	O
acids	O
and	O
has	O
33-47	O
%	O
identity	O
with	O
SWI3	B-protein
protein	I-protein
over	O
three	O
regions	O
.	O

The	O
SRG3	B-protein
protein	I-protein
contains	O
an	O
acidic	B-protein
NH2	I-protein
terminus	I-protein
,	O
a	O
myb-like	B-protein
DNA	I-protein
binding	I-protein
domain	I-protein
,	O
a	O
leucine-zipper	B-protein
motif	I-protein
,	O
and	O
a	O
proline-	B-protein
and	I-protein
glutamine-rich	I-protein
region	I-protein
at	O
its	O
COOH	B-protein
terminus	I-protein
.	O

Rabbit	O
antiserum	O
raised	O
against	O
a	O
COOH-terminal	O
polypeptide	O
of	O
the	O
SRG3	B-DNA
recognized	O
a	O
protein	O
with	O
an	O
apparent	O
molecular	O
mass	O
of	O
155	O
kD	O
.	O

The	O
serum	O
also	O
detected	O
a	O
170-kD	B-protein
protein	I-protein
that	O
seems	O
to	O
be	O
a	O
mouse	O
homologue	O
of	O
human	B-protein
BAF170	I-protein
.	O

Immunoprecipitation	O
of	O
cell	O
extract	O
with	O
the	O
antiserum	O
against	O
the	O
mouse	B-protein
SRG3	I-protein
also	O
brought	O
down	O
a	O
195-kD	B-protein
protein	I-protein
that	O
could	O
be	O
recognized	O
by	O
an	O
antiserum	O
raised	O
against	O
human	B-protein
SWI2	I-protein
protein	I-protein
.	O

The	O
results	O
suggest	O
that	O
the	O
SRG3	B-protein
protein	I-protein
associates	O
with	O
a	O
mouse	B-protein
SWI2	I-protein
.	O

The	O
SRG3	B-protein
protein	I-protein
is	O
expressed	O
about	O
three	O
times	O
higher	O
in	O
thymocytes	B-cell_type
than	O
in	O
peripheral	B-cell_type
lymphocytes	I-cell_type
.	O

The	O
expression	O
of	O
anti-sense	B-protein
RNA	I-protein
to	O
SRG3	B-RNA
mRNA	I-RNA
in	O
a	O
thymoma	B-cell_line
cell	I-cell_line
line	I-cell_line
,	O
S49.1	B-cell_line
,	O
reduced	O
the	O
expression	O
level	O
of	O
the	O
SRG3	B-protein
protein	I-protein
,	O
and	O
decreased	O
the	O
apoptotic	O
cell	O
death	O
induced	O
by	O
glucocorticoids	O
.	O

These	O
results	O
suggest	O
that	O
the	O
SRG3	B-protein
protein	I-protein
is	O
involved	O
in	O
the	O
glucocorticoid-induced	O
apoptosis	O
in	O
the	O
thymoma	B-cell_line
cell	I-cell_line
line	I-cell_line
.	O

This	O
implicates	O
that	O
the	O
SRG3	B-DNA
may	O
play	O
an	O
important	O
regulatory	O
role	O
during	O
T	O
cell	O
development	O
in	O
thymus	O
.	O

Transcriptional	O
induction	O
of	O
collagenase-1	B-protein
in	O
differentiated	B-cell_line
monocyte-like	I-cell_line
(	I-cell_line
U937	I-cell_line
)	I-cell_line
cells	I-cell_line
is	O
regulated	O
by	O
AP-1	B-protein
and	O
an	O
upstream	B-DNA
C/EBP-beta	I-DNA
site	I-DNA
.	O

In	O
this	O
report	O
,	O
we	O
demonstrate	O
that	O
the	O
AP-1	B-protein
site	O
and	O
a	O
distal	B-DNA
promoter	I-DNA
element	I-DNA
regulate	O
transcriptional	O
induction	O
of	O
collagenase-1	B-protein
during	O
monocytic	O
differentiation	O
.	O

Chloramphenicol	B-DNA
acetyltransferase	I-DNA
expression	I-DNA
constructs	I-DNA
containing	O
regions	O
of	O
the	O
human	B-DNA
collagenase-1	I-DNA
promoter	I-DNA
were	O
stably	O
or	O
transiently	O
transfected	O
into	O
U937	B-cell_line
cells	I-cell_line
,	O
and	O
reporter	O
activity	O
was	O
assessed	O
at	O
various	O
times	O
after	O
the	O
onset	O
of	O
phorbol	O
12-myristate	O
13-acetate	O
(	O
PMA	O
)	O
-mediated	O
differentiation	O
.	O

Rapid	O
and	O
strong	O
induction	O
of	O
promoter	O
activity	O
was	O
lost	O
in	O
constructs	O
with	O
a	O
mutant	B-DNA
AP-1	I-DNA
element	I-DNA
;	O
however	O
,	O
at	O
16-96	O
h	O
post-PMA	O
,	O
the	O
mutant	B-DNA
collagenase-1	I-DNA
promoter	I-DNA
displayed	O
AP-1	B-protein
independent	O
PMA-mediated	O
transactivation	O
.	O

The	O
AP-1	B-DNA
mutant	I-DNA
constructs	I-DNA
also	O
showed	O
delayed	O
transcriptional	O
activation	O
in	O
PMA-treated	B-cell_line
fibroblasts	I-cell_line
.	O

Western	O
and	O
supershift	O
analyses	O
indicated	O
that	O
functional	B-protein
Jun	I-protein
and	I-protein
Fos	I-protein
proteins	I-protein
were	O
present	O
in	O
nuclear	O
extracts	O
of	O
PMA-differentiated	B-cell_line
U937	I-cell_line
cells	I-cell_line
.	O

Promoter	O
deletion	O
constructs	O
demonstrated	O
the	O
potential	O
role	O
of	O
distal	B-DNA
promoter	I-DNA
sequences	I-DNA
in	O
regulating	O
collagenase-1	B-protein
transcription	O
.	O

In	O
particular	O
,	O
Western	O
,	O
supershift	O
,	O
and	O
promoter	O
deletion	O
analyses	O
suggested	O
a	O
role	O
for	O
CCAAT/enhancer-binding	B-DNA
protein-beta	I-DNA
(	I-DNA
C/EBP-beta	I-DNA
)	I-DNA
binding	I-DNA
site	I-DNA
between	O
-2010	B-DNA
and	I-DNA
-1954	I-DNA
in	O
regulating	O
transcription	O
of	O
collagenase-1	B-protein
in	O
monocytic	B-cell_type
cells	I-cell_type
.	O

Our	O
findings	O
suggest	O
that	O
distinct	O
regulatory	B-DNA
elements	I-DNA
,	O
acting	O
somewhat	O
independently	O
of	O
each	O
other	O
,	O
control	O
expression	O
of	O
collagenase-1	B-protein
.	O

In	O
addition	O
,	O
our	O
data	O
suggests	O
that	O
the	O
rapid	O
PMA-mediated	O
induction	O
of	O
collagenase-1	B-protein
transcription	O
is	O
controlled	O
by	O
a	O
mechanism	O
distinct	O
from	O
that	O
regulating	O
the	O
sustained	O
expression	O
of	O
this	O
proteinase	B-protein
in	O
activated	B-cell_type
macrophages	I-cell_type
.	O

Quantification	O
of	O
vitamin	B-RNA
D	I-RNA
receptor	I-RNA
mRNA	I-RNA
by	O
competitive	O
polymerase	O
chain	O
reaction	O
in	O
PBMC	B-cell_type
:	O
lack	O
of	O
correspondence	O
with	O
common	B-DNA
allelic	I-DNA
variants	I-DNA
.	O

It	O
has	O
been	O
recently	O
claimed	O
that	O
polymorphism	O
for	O
the	O
vitamin	B-protein
D	I-protein
receptor	I-protein
(	O
VDR	B-protein
)	O
influences	O
several	O
aspects	O
of	O
calcium	O
and	O
bone	O
metabolism	O
.	O

To	O
evaluate	O
the	O
physiologic	O
plausibility	O
of	O
these	O
claims	O
,	O
we	O
compared	O
the	O
abundance	O
of	O
the	O
VDR	B-RNA
mRNA	I-RNA
in	O
peripheral	B-cell_type
blood	I-cell_type
mononuclear	I-cell_type
cells	I-cell_type
(	O
PBMCs	B-cell_type
)	O
between	O
different	O
VDR	B-protein
genotypes	I-protein
using	O
a	O
quantitative	O
reverse	O
transcribed	O
polymerase	O
chain	O
reaction-based	O
method	O
.	O

The	O
method	O
is	O
based	O
on	O
the	O
coamplification	O
of	O
VDR	B-DNA
cDNA	I-DNA
and	O
an	O
internal	O
standard	O
consisting	O
of	O
known	O
concentrations	O
of	O
a	O
human	B-DNA
VDR	I-DNA
CDNA	I-DNA
mutated	O
at	O
a	O
BglII	B-DNA
restriction	I-DNA
site	I-DNA
;	O
the	O
interassay	O
coefficient	O
of	O
variation	O
is	O
11	O
%	O
.	O

To	O
validate	O
the	O
method	O
,	O
we	O
made	O
use	O
of	O
earlier	O
receptor	O
binding	O
studies	O
indicating	O
that	O
normal	B-cell_type
human	I-cell_type
monocytes	I-cell_type
and	O
activated	O
,	O
but	O
not	O
resting	O
,	O
lymphocytes	B-cell_type
expressed	O
the	O
VDR	B-protein
.	O

The	O
concentration	O
of	O
the	O
VDR	B-RNA
mRNA	I-RNA
was	O
10	O
(	O
-8	O
)	O
to	O
10	O
(	O
-7	O
)	O
g/g	O
of	O
total	O
RNA	O
in	O
cell-sorted	B-cell_type
monocytes	I-cell_type
and	O
in	O
in	B-cell_type
vitro	I-cell_type
activated	I-cell_type
lymphocytes	I-cell_type
,	O
but	O
only	O
10	O
(	O
-12	O
)	O
g/g	O
of	O
total	O
mRNA	O
in	O
resting	O
lymphocytes	B-cell_type
,	O
establishing	O
that	O
the	O
VDR	B-RNA
mRNA	I-RNA
determined	O
by	O
our	O
method	O
in	O
PBMCs	B-cell_type
is	O
due	O
to	O
constitutive	O
expression	O
in	O
monocytes	B-cell_type
.	O

Following	O
an	O
initial	O
genotype	O
screening	O
of	O
85	O
normal	O
volunteers	O
by	O
polymerase	O
chain	O
reaction	O
or	O
restriction	B-DNA
fragment	I-DNA
length	I-DNA
polymorphism	I-DNA
analysis	O
,	O
14	O
individuals	O
with	O
the	O
Bb	O
genotype	O
,	O
12	O
with	O
the	O
bb	O
genotype	O
,	O
and	O
12	O
with	O
the	O
BB	O
genotype	O
were	O
selected	O
.	O

The	O
concentration	O
of	O
the	O
VDR	B-RNA
mRNA	I-RNA
,	O
corrected	O
for	O
the	O
number	O
of	O
monocytes	B-cell_type
,	O
was	O
similar	O
among	O
the	O
three	O
genotype	O
groups	O
,	O
as	O
were	O
the	O
other	O
variables	O
examined	O
:	O
serum	B-protein
calcitriol	I-protein
,	O
serum	B-protein
osteocalcin	I-protein
,	O
and	O
vertebral	O
and	O
hip	O
bone	O
density	O
.	O

We	O
conclude	O
that	O
VDR	B-protein
polymorphism	O
does	O
not	O
affect	O
the	O
abundance	O
of	O
the	O
VDR	B-RNA
mRNA	I-RNA
.	O

Oncogenic	O
forms	O
of	O
NOTCH1	B-protein
lacking	O
either	O
the	O
primary	B-DNA
binding	I-DNA
site	I-DNA
for	O
RBP-Jkappa	B-protein
or	O
nuclear	B-protein
localization	I-protein
sequences	I-protein
retain	O
the	O
ability	O
to	O
associate	O
with	O
RBP-Jkappa	B-protein
and	O
activate	O
transcription	O
.	O

Truncated	O
forms	O
of	O
the	O
NOTCH1	B-protein
transmembrane	I-protein
receptor	I-protein
engineered	O
to	O
resemble	O
mutant	O
forms	O
of	O
NOTCH1	B-protein
found	O
in	O
certain	O
cases	O
of	O
human	O
T	O
cell	O
leukemia/lymphoma	O
(	O
T-ALL	O
)	O
efficiently	O
induce	O
T-ALL	O
when	O
expressed	O
in	O
the	O
bone	O
marrow	O
of	O
mice	O
.	O

Unlike	O
full-sized	O
NOTCH1	B-protein
,	O
two	O
such	O
truncated	O
forms	O
of	O
the	O
protein	O
either	O
lacking	O
a	O
major	O
portion	O
of	O
the	O
extracellular	B-protein
domain	I-protein
(	O
DeltaE	B-protein
)	O
or	O
consisting	O
only	O
of	O
the	O
intracellular	B-protein
domain	I-protein
(	O
ICN	B-protein
)	O
were	O
found	O
to	O
activate	O
transcription	O
in	O
cultured	O
cells	O
,	O
presumably	O
through	O
RBP-Jkappa	B-protein
response	O
elements	O
within	O
DNA	O
.	O

Both	O
truncated	O
forms	O
also	O
bound	O
to	O
the	O
transcription	B-protein
factor	I-protein
RBP-Jkappa	I-protein
in	O
extracts	O
prepared	O
from	O
human	B-cell_line
and	I-cell_line
murine	I-cell_line
T-ALL	I-cell_line
cell	I-cell_line
lines	I-cell_line
.	O

Transcriptional	O
activation	O
required	O
the	O
presence	O
of	O
a	O
weak	O
RBP-Jkappa-binding	B-protein
site	I-protein
within	O
the	O
NOTCH1	B-protein
ankyrin	I-protein
repeat	I-protein
region	I-protein
of	O
the	O
intracellular	B-protein
domain	I-protein
.	O

Unexpectedly	O
,	O
a	O
second	O
,	O
stronger	O
RBP-Jkappa-binding	B-protein
site	I-protein
,	O
which	O
lies	O
within	O
the	O
intracellular	B-protein
domain	I-protein
close	O
to	O
the	O
transmembrane	O
region	O
and	O
significantly	O
augments	O
association	O
with	O
RBP-Jkappa	B-protein
,	O
was	O
not	O
needed	O
for	O
oncogenesis	O
or	O
for	O
transcriptional	O
activation	O
.	O

While	O
ICN	B-protein
appeared	O
primarily	O
in	O
the	O
nucleus	O
,	O
DeltaE	B-protein
localized	O
to	O
cytoplasmic	O
and	O
nuclear	O
membranes	O
,	O
suggesting	O
that	O
intranuclear	O
localization	O
is	O
not	O
essential	O
for	O
oncogenesis	O
or	O
transcriptional	O
activation	O
.	O

In	O
support	O
of	O
this	O
interpretation	O
,	O
mutation	O
of	O
putative	O
nuclear	B-protein
localization	I-protein
sequences	I-protein
decreased	O
nuclear	O
localization	O
and	O
increased	O
transcriptional	O
activation	O
by	O
membrane-bound	B-protein
DeltaE	I-protein
.	O

Transcriptional	O
activation	O
by	O
this	O
mutant	O
form	O
of	O
membrane-bound	B-protein
DeltaE	I-protein
was	O
approximately	O
equivalent	O
to	O
that	O
produced	O
by	O
intranuclear	B-protein
ICN	I-protein
.	O

These	O
data	O
are	O
most	O
consistent	O
with	O
NOTCH1	B-protein
oncogenesis	O
and	O
transcriptional	O
activation	O
being	O
independent	O
of	O
association	O
with	O
RBP-Jkappa	B-protein
at	O
promoter	B-DNA
sites	I-DNA
.	O

Sp	B-protein
family	I-protein
members	I-protein
preferentially	O
interact	O
with	O
the	O
promoter	B-DNA
proximal	I-DNA
repeat	I-DNA
within	O
the	O
HTLV-I	B-DNA
enhancer	I-DNA
.	O

Human	O
T	O
cell	O
lymphotropic	O
virus	O
type	O
I	O
(	O
HTLV-I	O
)	O
encodes	O
the	O
transactivator	B-protein
protein	I-protein
,	O
Tax	B-protein
,	O
which	O
facilitates	O
viral	O
transcription	O
from	O
three	O
21	B-DNA
bp	I-DNA
repeated	I-DNA
elements	I-DNA
within	O
the	O
U3	B-DNA
region	I-DNA
of	O
the	O
long	B-DNA
terminal	I-DNA
repeat	I-DNA
(	O
LTR	B-DNA
)	O
.	O

Examination	O
of	O
the	O
basal	B-protein
factors	I-protein
interacting	O
with	O
the	O
21	B-DNA
bp	I-DNA
repeat	I-DNA
elements	I-DNA
through	O
electrophoretic	O
mobility	O
shift	O
(	O
EMS	O
)	O
analyses	O
has	O
demonstrated	O
the	O
formation	O
of	O
DNA-protein	B-protein
complexes	I-protein
common	O
to	O
each	O
of	O
the	O
21	B-DNA
bp	I-DNA
repeats	I-DNA
(	O
C1-C3	B-DNA
)	O
as	O
well	O
as	O
three	O
DNA-protein	B-protein
complexes	I-protein
specific	O
to	O
the	O
promoter	B-DNA
proximal	I-DNA
(	I-DNA
pp	I-DNA
)	I-DNA
repeat	I-DNA
(	O
U1	B-DNA
(	O
U1A/U1B	B-DNA
)	O
and	O
U2	B-DNA
;	O
1-4	O
)	O
.	O

These	O
studies	O
have	O
indicated	O
that	O
the	O
individual	O
repeats	O
are	O
not	O
identical	O
with	O
respect	O
to	O
the	O
cellular	B-protein
factors	I-protein
with	O
which	O
they	O
interact	O
.	O

EMS	O
analyses	O
utilizing	O
a	O
series	O
of	O
mutated	B-DNA
pp	I-DNA
repeat	I-DNA
elements	I-DNA
demonstrate	O
that	O
the	O
nucleotide	O
sequence	O
requirements	O
for	O
U1	B-DNA
(	O
U1A/U1B	B-DNA
)	O
and	O
U2	B-DNA
formation	O
are	O
separable	O
from	O
those	O
required	O
for	O
C1-C3	B-DNA
formation	O
.	O

Competition	O
EMS	O
analyses	O
utilizing	O
Sp1	O
and	O
CREB	O
binding	O
site	O
oligonucleotides	O
demonstrate	O
that	O
Sp	B-protein
family	I-protein
members	I-protein
are	O
critical	O
components	O
of	O
U1	B-DNA
(	O
U1A/U1B	B-DNA
)	O
and	O
U2	B-DNA
and	O
that	O
ATF/CREB	B-protein
family	I-protein
members	I-protein
are	O
critical	O
components	O
of	O
C1-C3	B-DNA
.	O

EMS	O
supershift	O
analyses	O
have	O
demonstrated	O
that	O
Sp1	B-protein
is	O
involved	O
in	O
U1A	O
formation	O
while	O
Sp3	B-protein
is	O
involved	O
in	O
U1B	O
and	O
U2	O
formation	O
.	O

EMS	O
analyses	O
performed	O
with	O
nuclear	O
extracts	O
from	O
Tax-expressing	B-cell_line
Jurkat	I-cell_line
cells	I-cell_line
and	O
HTLV-I-transformed	B-cell_type
peripheral	I-cell_type
blood	I-cell_type
mononuclear	I-cell_type
cells	I-cell_type
demonstrate	O
that	O
Tax	B-protein
prevents	O
the	O
formation	O
of	O
U1	B-DNA
(	O
U1A/U1B	B-DNA
)	O
and	O
U2	B-DNA
DNA-protein	B-protein
complexes	I-protein
.	O

Therefore	O
,	O
Tax	B-protein
appears	O
to	O
inhibit	O
the	O
interaction	O
of	O
Sp	B-protein
family	I-protein
members	I-protein
with	O
the	O
pp	B-DNA
repeat	I-DNA
.	O

Based	O
on	O
these	O
observations	O
,	O
it	O
is	O
possible	O
that	O
the	O
interaction	O
of	O
Sp	B-protein
and	O
ATF/CREB	B-protein
family	I-protein
members	I-protein
with	O
the	O
pp	B-DNA
repeat	I-DNA
during	O
basal	O
and	O
Tax	B-protein
-mediated	O
transcription	O
may	O
play	O
a	O
critical	O
role	O
in	O
viral	O
gene	O
expression	O
during	O
the	O
initial	O
stages	O
of	O
virus	O
infection	O
or	O
during	O
activation	O
of	O
a	O
latent	O
infection	O
.	O

Lineage-	O
and	O
stage-specific	O
expression	O
of	O
runt	B-protein
box	I-protein
polypeptides	I-protein
in	O
primitive	O
and	O
definitive	O
hematopoiesis	O
.	O

Translocations	O
involving	O
the	O
human	B-DNA
CBFA2	I-DNA
locus	I-DNA
have	O
been	O
associated	O
with	O
leukemia	O
.	O

This	O
gene	O
,	O
originally	O
named	O
AML1	B-DNA
,	O
is	O
a	O
human	O
homologue	O
of	O
the	O
Drosophila	B-DNA
gene	I-DNA
runt	I-DNA
that	O
controls	O
early	O
events	O
in	O
fly	O
embryogenesis	O
.	O

To	O
clarify	O
the	O
role	O
of	O
mammalian	B-protein
runt	I-protein
products	I-protein
in	O
normal	O
and	O
leukemic	O
hematopoiesis	O
,	O
we	O
have	O
studied	O
their	O
pattern	O
of	O
expression	O
in	O
mouse	O
hematopoietic	O
tissues	O
in	O
the	O
adult	O
and	O
during	O
ontogeny	O
using	O
an	O
anti-runt	O
box	O
antiserum	O
.	O

In	O
the	O
adult	O
bone	O
marrow	O
,	O
we	O
found	O
expression	O
of	O
runt	O
polypeptides	O
in	O
differentiating	B-cell_type
myeloid	I-cell_type
cells	I-cell_type
and	O
in	O
B	B-cell_type
lymphocytes	I-cell_type
.	O

Within	O
the	O
erythroid	B-cell_type
lineage	I-cell_type
,	O
runt	O
expression	O
is	O
biphasic	O
,	O
clearly	O
present	O
in	O
the	O
erythroblasts	B-cell_type
of	O
early	O
blood	O
islands	O
and	O
of	O
the	O
fetal	O
liver	O
,	O
but	O
absent	O
in	O
the	O
adult	O
.	O

Biochemical	O
analysis	O
by	O
Western	O
blotting	O
of	O
fetal	B-cell_type
and	I-cell_type
adult	I-cell_type
hematopoietic	I-cell_type
populations	I-cell_type
shows	O
several	O
runt	B-protein
isoforms	I-protein
.	O

At	O
least	O
one	O
of	O
them	O
appears	O
to	O
be	O
myeloid	O
specific	O
.	O

Signal	B-protein
transducer	I-protein
and	I-protein
activator	I-protein
of	I-protein
transcription-3	I-protein
(	O
STAT3	B-protein
)	O
is	O
constitutively	O
activated	O
in	O
normal	O
,	O
self-renewing	B-cell_type
B-1	I-cell_type
cells	I-cell_type
but	O
only	O
inducibly	O
expressed	O
in	O
conventional	O
B	B-cell_type
lymphocytes	I-cell_type
[	O
see	O
comments	O
]	O

Cytokine	B-protein
and	O
growth	B-protein
factor	I-protein
receptor	I-protein
engagement	O
leads	O
to	O
the	O
rapid	O
phosphorylation	O
and	O
activation	O
of	O
latent	O
,	O
cytosolic	B-protein
signal	I-protein
transducers	I-protein
and	I-protein
activators	I-protein
of	I-protein
transcription	I-protein
(	I-protein
STAT	I-protein
)	I-protein
proteins	I-protein
,	O
which	O
then	O
translocate	O
to	O
the	O
nucleus	O
where	O
they	O
regulate	O
transcriptional	O
events	O
from	O
specific	B-DNA
promoter	I-DNA
sequences	I-DNA
.	O

STAT3	B-protein
expression	O
in	O
particular	O
has	O
been	O
associated	O
with	O
Abl	B-protein
,	O
Src	B-protein
,	O
and	O
HTLV-1	O
transformation	O
of	O
normal	B-cell_type
cells	I-cell_type
.	O

B-1	B-cell_type
lymphocytes	I-cell_type
are	O
self-renewing	O
,	O
CD5+	B-cell_type
B	I-cell_type
cells	I-cell_type
that	O
display	O
a	O
propensity	O
for	O
malignant	O
transformation	O
and	O
are	O
the	O
normal	O
counterpart	O
to	O
human	O
chronic	O
lymphocytic	O
leukemias	O
.	O

Further	O
,	O
B-1	B-cell_type
cells	I-cell_type
are	O
characterized	O
by	O
aberrant	O
intracellular	O
signaling	O
,	O
including	O
hyperresponsiveness	O
to	O
phorbol	O
ester	O
PKC	O
agonists	O
.	O

Here	O
we	O
demonstrate	O
that	O
B-1	B-cell_type
lymphocytes	I-cell_type
constitutively	O
express	O
nuclear	B-protein
activated	I-protein
STAT3	I-protein
,	O
which	O
is	O
not	O
expressed	O
by	O
unmanipulated	B-cell_type
conventional	I-cell_type
(	I-cell_type
B-2	I-cell_type
)	I-cell_type
lymphocytes	I-cell_type
.	O

In	O
contrast	O
,	O
STAT3	B-protein
activation	O
is	O
induced	O
in	O
B-2	B-cell_type
cells	I-cell_type
after	O
antigen	O
receptor	O
engagement	O
in	O
a	O
delayed	O
fashion	O
(	O
after	O
3	O
h	O
)	O
.	O

Induction	O
of	O
STAT3	B-protein
is	O
inhibited	O
by	O
both	O
the	O
serine/threonine	O
protein	O
kinase	O
inhibitor	O
H-7	O
and	O
the	O
immunosuppressive	O
drug	O
rapamycin	O
and	O
requires	O
de	O
novo	O
protein	O
synthesis	O
,	O
demonstrating	O
novel	O
coupling	O
between	O
sIg	B-protein
and	O
STAT	B-protein
proteins	I-protein
that	O
differs	O
from	O
the	O
classical	O
paradigm	O
for	O
STAT	B-protein
induction	O
by	O
cytokine	B-protein
receptors	I-protein
.	O

The	O
inability	O
of	O
prolonged	O
stimulation	O
of	O
conventional	O
B-2	B-cell_type
cells	I-cell_type
with	O
anti-Ig	B-protein
,	O
a	O
treatment	O
sufficient	O
to	O
induce	O
CD5	B-protein
expression	O
,	O
to	O
result	O
in	O
sustained	O
STAT3	B-protein
activation	O
suggests	O
that	O
STAT3	B-protein
is	O
a	O
specific	O
nuclear	O
marker	O
for	O
B-1	B-cell_type
cells	I-cell_type
.	O

Thus	O
,	O
STAT3	B-protein
may	O
play	O
a	O
role	O
in	O
B	O
cell	O
antigen-specific	O
signaling	O
responses	O
,	O
and	O
its	O
constitutive	O
activation	O
is	O
associated	O
with	O
a	O
normal	O
cell	O
population	O
exhibiting	O
intrinsic	O
proliferative	O
behavior	O
.	O

Significance	O
of	O
quantitative	O
analysis	O
of	O
AML1/ETO	B-RNA
transcripts	I-RNA
in	O
peripheral	B-cell_type
blood	I-cell_type
stem	I-cell_type
cells	I-cell_type
from	O
t	O
(	O
8	O
;	O
21	O
)	O
acute	O
myelogenous	O
leukemia	O
.	O

Autologous	O
peripheral	B-cell_type
blood	I-cell_type
stem	I-cell_type
cell	I-cell_type
transplantation	O
(	O
PBSCT	O
)	O
is	O
replacing	O
autologous	O
bone	O
marrow	O
transplantation	O
(	O
BMT	O
)	O
in	O
the	O
treatment	O
of	O
leukemia	O
.	O

One	O
of	O
the	O
potential	O
advantages	O
of	O
autologous	O
PBSCT	O
is	O
the	O
possibility	O
that	O
peripheral	B-cell_type
blood	I-cell_type
stem	I-cell_type
cells	I-cell_type
(	O
PBSC	B-cell_type
)	O
are	O
less	O
likely	O
to	O
be	O
contaminated	O
by	O
leukemic	B-cell_type
cells	I-cell_type
than	O
bone	O
marrow	O
grafts	O
.	O

However	O
,	O
the	O
major	O
problem	O
still	O
remains	O
the	O
high	O
incidence	O
of	O
leukemic	O
relapse	O
following	O
autologous	O
PBSCT	O
,	O
which	O
may	O
be	O
caused	O
by	O
the	O
reinfusion	O
of	O
PBSC	B-cell_type
contaminated	O
by	O
leukemic	B-cell_type
cells	I-cell_type
.	O

Recently	O
,	O
we	O
have	O
developed	O
a	O
quantitative	O
assay	O
using	O
competitive	O
reverse	B-protein
transcriptase	I-protein
polymerase	I-protein
chain	O
reaction	O
that	O
estimates	O
the	O
number	O
of	O
AML1/ETO	B-RNA
transcripts	I-RNA
in	O
t	O
(	O
8	O
;	O
21	O
)	O
acute	O
myelogenous	O
leukemia	O
(	O
AML	O
)	O
,	O
in	O
order	O
to	O
determine	O
the	O
degree	O
of	O
leukemic	O
cell	O
contamination	O
in	O
PBSC	B-cell_type
harvests	O
,	O
and	O
to	O
monitor	O
minimal	O
residual	O
disease	O
(	O
MRD	O
)	O
quantitatively	O
in	O
patients	O
with	O
t	O
(	O
8	O
;	O
21	O
)	O
AML	O
.	O

Our	O
data	O
indicate	O
that	O
although	O
PBSC	B-cell_type
harvests	O
collected	O
after	O
consolidation	O
chemotherapy	O
are	O
contaminated	O
by	O
leukemic	B-cell_type
cells	I-cell_type
,	O
the	O
degree	O
of	O
leukemic	O
cell	O
contamination	O
decreases	O
with	O
repeated	O
cycles	O
of	O
chemotherapy	O
.	O

Furthermore	O
,	O
the	O
MRD	O
in	O
PBSC	B-cell_type
harvests	O
is	O
less	O
than	O
in	O
the	O
corresponding	O
bone	O
marrow	O
obtained	O
on	O
the	O
day	O
of	O
the	O
PBSC	B-cell_type
collection	O
.	O

There	O
appears	O
to	O
be	O
no	O
relationship	O
between	O
the	O
number	O
of	O
AML1/ETO	B-RNA
transcripts	I-RNA
found	O
in	O
the	O
infused	O
PBSC	B-cell_type
harvests	O
and	O
the	O
incidence	O
of	O
leukemic	O
relapse	O
following	O
autologous	O
PBSCT	O
in	O
our	O
study	O
.	O

However	O
,	O
a	O
substantial	O
decrease	O
of	O
AML1/ETO	B-RNA
transcripts	I-RNA
was	O
seen	O
following	O
autologous	O
PBSCT	O
.	O

Thus	O
,	O
the	O
quantitative	O
analysis	O
of	O
AML1/ETO	B-RNA
transcripts	I-RNA
may	O
be	O
clinically	O
useful	O
in	O
patients	O
with	O
t	O
(	O
8	O
;	O
21	O
)	O
AML	O
.	O

Upregulation	O
of	O
c-Fos	B-protein
in	O
activated	B-cell_type
T	I-cell_type
lymphoid	I-cell_type
and	I-cell_type
monocytic	I-cell_type
cells	I-cell_type
by	O
human	B-protein
immunodeficiency	I-protein
virus-1	I-protein
Tat	I-protein
protein	I-protein
.	O

The	O
regulatory	B-protein
Tat	I-protein
protein	I-protein
of	O
the	O
human	O
immunodeficiency	O
virus	O
type-1	O
(	O
HIV-1	O
)	O
is	O
essential	O
for	O
viral	O
replication	O
and	O
also	O
shows	O
pleiotropic	O
activities	O
on	O
various	O
cell	O
functions	O
.	O

To	O
get	O
further	O
insights	O
into	O
the	O
molecular	O
mechanisms	O
underlying	O
the	O
biological	O
activity	O
of	O
Tat	B-protein
,	O
we	O
investigated	O
the	O
effect	O
of	O
endogenous	O
and	O
exogenous	O
Tat	B-protein
protein	I-protein
on	O
c-fos	O
gene	O
expression	O
in	O
T	B-cell_line
lymphoblastoid	I-cell_line
(	I-cell_line
Jurkat	I-cell_line
)	I-cell_line
and	I-cell_line
monocytic	I-cell_line
(	I-cell_line
U937	I-cell_line
)	I-cell_line
cell	I-cell_line
lines	I-cell_line
,	O
as	O
well	O
as	O
in	O
primary	B-cell_type
peripheral	I-cell_type
blood	I-cell_type
mononuclear	I-cell_type
cells	I-cell_type
(	O
PBMC	B-cell_type
)	O
.	O

Transient	O
cotransfection	O
of	O
tat	B-DNA
cDNA	I-DNA
in	O
sense	O
orientation	O
(	O
tat/S	B-DNA
)	O
,	O
together	O
with	O
a	O
plasmid	B-DNA
containing	O
the	O
c-fos	B-DNA
promoter	I-DNA
(	O
FC3	B-DNA
,	O
from-	O
711	B-DNA
to	I-DNA
+42	I-DNA
)	O
in	O
front	O
of	O
the	O
bacterial	B-DNA
chloramphenicol	I-DNA
acetyltransferase	I-DNA
(	I-DNA
CAT	I-DNA
)	I-DNA
gene	I-DNA
significantly	O
enhanced	O
CAT	B-protein
activity	O
in	O
Jurkat	B-cell_line
cells	I-cell_line
activated	O
by	O
the	O
addition	O
of	O
15	O
%	O
fetal	O
calf	O
serum	O
(	O
FCS	O
)	O
or	O
5	O
micrograms/mL	O
phytohemagglutinin	B-protein
plus	O
10	O
(	O
-7	O
)	O
mol/L	O
phorbol	O
myristate	O
acetate	O
(	O
PMA	O
)	O
and	O
U937	B-cell_line
cells	I-cell_line
activated	O
by	O
15	O
%	O
FCS	O
or	O
10	O
(	O
-7	O
)	O
mol/L	O
PMA	O
.	O

This	O
effect	O
was	O
specifically	O
due	O
to	O
Tat	B-protein
,	O
since	O
Jurkat	B-cell_line
and	O
U937	B-cell_line
cells	I-cell_line
cotransfected	O
either	O
with	O
tat	B-DNA
cDNA	I-DNA
in	O
antisense	O
orientation	O
(	O
tat/AS	B-DNA
)	O
,	O
tat	B-DNA
carrying	O
a	O
mutation	O
in	O
the	O
aminoacid	B-protein
cys22-gly22	I-protein
(	O
tat	B-DNA
22/S	I-DNA
)	O
or	O
with	O
the	O
backbone	B-DNA
vector	I-DNA
alone	I-DNA
(	O
pRPneo-SL3	B-DNA
)	O
did	O
not	O
show	O
any	O
significant	O
difference	O
in	O
c-fos	B-DNA
promoter	I-DNA
activity	O
as	O
compared	O
to	O
cells	O
transfected	O
with	O
FC3	B-DNA
plasmid	I-DNA
alone	O
.	O

By	O
using	O
deletion	O
mutants	O
of	O
the	O
c-fos	B-DNA
promoter	I-DNA
,	O
we	O
found	O
that	O
the	O
minimal	B-DNA
DNA	I-DNA
sequence	I-DNA
required	O
for	O
Tat	B-protein
activity	O
was	O
located	O
between	O
nucleotides	B-DNA
-404/-220	I-DNA
and	O
that	O
the	O
serum	B-DNA
responsive	I-DNA
element	I-DNA
(	O
SRE	B-DNA
,	O
-317/-288	B-DNA
)	O
,	O
present	O
within	O
this	O
region	O
,	O
was	O
still	O
responsive	O
to	O
Tat	B-protein
.	O

A	O
single	B-DNA
point	I-DNA
mutation	I-DNA
in	O
the	O
SRE	B-DNA
completely	O
abrogated	O
the	O
responsiveness	O
to	O
tat/S	B-DNA
.	O

Exogenous	O
recombinant	B-protein
Tat	I-protein
protein	I-protein
was	O
also	O
able	O
to	O
upregulate	O
c-fos	B-DNA
promoter	I-DNA
activity	O
in	O
serum-activated	O
Jurkat	O
and	O
U937	B-cell_line
cells	I-cell_line
,	O
as	O
well	O
as	O
endogenous	O
c-fos	B-RNA
mRNA	I-RNA
expression	O
and	O
c-Fos	B-protein
protein	O
synthesis	O
in	O
both	O
serum-activated	B-cell_line
cell	I-cell_line
lines	I-cell_line
and	O
primary	B-cell_type
PBMC	I-cell_type
.	O

c-Fos	B-protein
protein	O
was	O
shown	O
essential	O
for	O
an	O
optimal	O
transactivation	O
of	O
the	O
HIV-1	O
long	B-DNA
terminal	I-DNA
repeat	I-DNA
(	O
LTR	B-DNA
)	O
by	O
Tat	B-protein
:	O
incubation	O
of	O
Jurkat	B-cell_line
cells	I-cell_line
with	O
antisense	O
,	O
but	O
not	O
sense	O
,	O
c-fos	O
oligonucleotides	O
significantly	O
reduced	O
either	O
the	O
Tat	B-protein
-enhanced	O
expression	O
of	O
an	O
LTR-CAT	B-DNA
reporter	I-DNA
construct	I-DNA
or	O
the	O
levels	O
of	O
gag	B-protein
p24	I-protein
in	O
the	O
culture	O
supernatants	O
of	O
Jurkat	B-cell_line
cells	I-cell_line
and	O
PBMC	B-cell_type
acutely	O
infected	O
with	O
HIV-1	O
.	O

Our	O
data	O
suggest	O
that	O
the	O
c-fos	B-DNA
upregulation	O
mediated	O
by	O
Tat	B-protein
might	O
play	O
a	O
significant	O
role	O
in	O
the	O
control	O
of	O
viral	O
gene	O
transactivation	O
.	O

Cytokine	B-protein
signal	I-protein
networks	I-protein
and	O
a	O
new	O
era	O
in	O
biomedical	O
research	O
.	O

Elucidation	O
of	O
the	O
biochemical	O
nature	O
of	O
the	O
signal	O
transduction	O
pathway	O
that	O
regulate	O
transcription	O
and	O
replication	O
is	O
the	O
focus	O
of	O
attention	O
in	O
molecular	O
biology	O
.	O

This	O
research	O
may	O
make	O
feasible	O
manipulation	O
of	O
growth	O
and	O
differentiation	O
of	O
mammalian	B-cell_type
cells	I-cell_type
,	O
which	O
in	O
turn	O
would	O
have	O
profound	O
implication	O
in	O
biomedical	O
research	O
on	O
cell	O
and	O
gene	O
therapy	O
,	O
and	O
development	O
of	O
pharmaceutical	O
products	O
.	O

Cytokines	B-protein
control	O
growth	O
,	O
differentiation	O
,	O
death	O
,	O
and	O
function	O
of	O
cells	O
of	O
lymphocytic	B-cell_type
,	I-cell_type
hemopoietic	I-cell_type
systems	I-cell_type
,	O
and	O
together	O
with	O
nerve	B-cell_type
cells	I-cell_type
provide	O
a	O
pertinent	O
model	O
to	O
study	O
intercellular	O
communications	O
and	O
intercellular	O
signal	O
networks	O
.	O

This	O
review	O
outlines	O
general	O
features	O
of	O
signal	O
transduction	O
and	O
several	O
aspects	O
of	O
cytokine	B-protein
networks	I-protein
are	O
discussed	O
with	O
emphasis	O
on	O
:	O
transcriptional	O
regulation	O
of	O
Th1	O
and	O
Th2-specific	O
cytokine	B-DNA
genes	I-DNA
in	O
T	B-cell_type
cells	I-cell_type
,	O
the	O
roles	O
of	O
cytokines	B-protein
and	O
their	O
receptors	O
in	O
growth	O
and	O
differentiation	O
of	O
hemopoietic	B-cell_type
cells	I-cell_type
,	O
and	O
the	O
manipulation	O
of	O
cytokine	B-protein
networks	I-protein
.	O

Regulation	O
of	O
the	O
tissue	B-DNA
factor	I-DNA
gene	I-DNA
in	O
human	B-cell_type
monocytic	I-cell_type
cells	I-cell_type
.	O

Role	O
of	O
AP-1	B-protein
,	O
NF-kappa	B-protein
B/Rel	I-protein
,	O
and	O
Sp1	B-protein
proteins	O
in	O
uninduced	O
and	O
lipopolysaccharide-induced	O
expression	O
.	O

Tissue	B-protein
factor	I-protein
(	O
TF	O
)	O
expression	O
by	O
peripheral	B-cell_type
blood	I-cell_type
monocytes	I-cell_type
during	O
sepsis	O
initiates	O
intravascular	O
thrombosis	O
.	O

Bacterial	O
lipopolysaccharide	O
(	O
LPS	O
)	O
rapidly	O
induces	O
TF	B-DNA
gene	I-DNA
transcription	O
in	O
monocytes	B-cell_type
.	O

The	O
human	B-DNA
TF	I-DNA
promoter	I-DNA
contains	O
binding	O
sites	O
for	O
the	O
transcription	O
factors	O
AP-1	B-protein
,	O
c-Rel/p65	B-protein
,	O
Egr-1	B-protein
,	O
and	O
Sp1	B-protein
.	O

NF-kappa	B-protein
B/Rel	I-protein
proteins	I-protein
have	O
been	O
shown	O
to	O
physically	O
interact	O
with	O
both	O
AP-1	B-protein
and	I-protein
Sp1	I-protein
proteins	I-protein
.	O

In	O
this	O
study	O
,	O
we	O
investigated	O
the	O
role	O
of	O
these	O
transcription	B-protein
factors	I-protein
in	O
uninduced	O
and	O
LPS-induced	O
TF	B-DNA
gene	I-DNA
expression	O
in	O
human	B-cell_type
monocytic	I-cell_type
THP-1	I-cell_type
cells	I-cell_type
.	O

Deletional	O
analysis	O
indicated	O
that	O
five	O
Sp1	B-DNA
sites	I-DNA
mediated	O
basal	O
expression	O
in	O
uninduced	B-cell_type
cells	I-cell_type
.	O

The	O
two	O
AP-1	B-DNA
sites	I-DNA
bound	O
c-Fos/c-Jun	B-protein
heterodimers	I-protein
in	O
both	O
unstimulated	B-cell_type
and	I-cell_type
LPS-stimulated	I-cell_type
cells	I-cell_type
.	O

Maximal	O
LPS	O
induction	O
of	O
the	O
TF	B-DNA
promoter	I-DNA
required	O
the	O
two	O
AP-1	B-protein
sites	O
and	O
the	O
kappa	B-DNA
B	I-DNA
site	I-DNA
within	O
the	O
LPS	B-DNA
response	I-DNA
element	I-DNA
.	O

Disruption	O
of	O
the	O
conserved	O
spacing	O
between	O
the	O
proximal	B-DNA
AP-1	I-DNA
site	I-DNA
and	O
the	O
kappa	B-DNA
B	I-DNA
site	I-DNA
abolished	O
LPS	O
induction	O
.	O

Replacement	O
of	O
the	O
two	O
AP-1	B-DNA
sites	I-DNA
with	O
intrinsically	O
bent	O
DNA	O
partially	O
restored	O
LPS	O
induction	O
,	O
suggesting	O
an	O
additional	O
structural	O
role	O
for	O
the	O
AP-1	B-DNA
sites	I-DNA
.	O

Synergistic	O
transactivation	O
of	O
the	O
LPS	B-DNA
response	I-DNA
element	I-DNA
in	O
Drosophila	B-cell_line
Schneider	I-cell_line
cells	I-cell_line
by	O
coexpression	O
of	O
c-Fos	B-protein
,	O
c-Jun	B-protein
,	O
c-Rel	B-protein
,	O
and	O
p65	B-protein
or	O
c-Jun	B-protein
and	O
p65	B-protein
required	O
the	O
transactivation	B-protein
domains	I-protein
of	O
c-Jun	B-protein
and	O
p65	B-protein
.	O

These	O
data	O
indicated	O
that	O
c-Fos	B-protein
/c-Jun	B-protein
,	O
c-Rel	B-protein
/p65	B-protein
,	O
and	O
Sp1	B-protein
regulate	O
TF	B-DNA
gene	I-DNA
expression	O
in	O
human	B-cell_type
monocytic	I-cell_type
cells	I-cell_type
.	O

Inhibitory	O
effect	O
of	O
growth	O
hormone	O
on	O
TNF-alpha	B-protein
secretion	O
and	O
nuclear	B-protein
factor-kappaB	I-protein
translocation	O
in	O
lipopolysaccharide-stimulated	B-cell_type
human	I-cell_type
monocytes	I-cell_type
.	O

Several	O
studies	O
have	O
pointed	O
to	O
a	O
link	O
between	O
immune	O
and	O
endocrine	O
systems	O
,	O
including	O
a	O
regulatory	O
function	O
of	O
GH	O
on	O
monocyte	O
activation	O
.	O

The	O
present	O
study	O
demonstrates	O
that	O
human	O
THP-1	B-cell_line
promonocytic	I-cell_line
cells	I-cell_line
,	O
engineered	O
by	O
gene	O
transfer	O
to	O
constitutively	O
produce	O
human	O
growth	O
hormone	O
(	O
hGH	O
)	O
,	O
secreted	O
depressed	O
amounts	O
of	O
TNF-alpha	B-protein
in	O
response	O
to	O
challenge	O
by	O
LPS	O
.	O

The	O
effect	O
of	O
GH	O
appears	O
to	O
occur	O
in	O
an	O
autocrine	O
fashion	O
,	O
since	O
the	O
inhibitory	O
effect	O
on	O
TNF-alpha	B-protein
secretion	O
by	O
constitutive	O
GH	O
production	O
could	O
be	O
abolished	O
in	O
the	O
presence	O
of	O
anti-hGH	B-protein
mAb	I-protein
.	O

The	O
GH-induced	O
inhibitory	O
effect	O
was	O
also	O
observed	O
using	O
normal	B-cell_type
human	I-cell_type
monocytes	I-cell_type
and	O
monocyte-derived	B-cell_type
macrophages	I-cell_type
.	O

Inhibition	O
of	O
TNF-alpha	B-protein
production	O
by	O
THP-1-hGH-transfected	B-cell_line
cells	I-cell_line
cultured	O
in	O
the	O
presence	O
of	O
LPS	O
is	O
dependent	O
on	O
a	O
selective	O
pathway	O
,	O
since	O
no	O
inhibition	O
of	O
TNF-alpha	B-protein
production	O
was	O
observed	O
when	O
cells	O
were	O
cultured	O
in	O
the	O
presence	O
of	O
PMA	O
.	O

Inhibition	O
of	O
TNF-alpha	B-protein
secretion	O
by	O
LPS-stimulated	B-cell_line
THP-1-hGH	I-cell_line
cells	I-cell_line
was	O
associated	O
with	O
a	O
decrease	O
in	O
nuclear	O
translocation	O
of	O
nuclear	B-protein
factor-kappaB	I-protein
.	O

The	O
capacity	O
of	O
GH	O
to	O
inhibit	O
LPS-induced	O
TNF-alpha	B-protein
production	O
by	O
monocytes	B-cell_type
without	O
altering	O
other	O
pathways	O
leading	O
to	O
TNF-alpha	B-protein
production	O
may	O
be	O
of	O
potential	O
relevance	O
in	O
septic	O
shock	O
,	O
since	O
GH	O
is	O
available	O
for	O
clinical	O
use	O
.	O

Nuclear	B-protein
factor-kappaB	I-protein
activation	O
in	O
human	B-cell_type
monocytes	I-cell_type
stimulated	O
with	O
lipopolysaccharide	O
is	O
inhibited	O
by	O
fibroblast	O
conditioned	O
medium	O
and	O
exogenous	O
PGE2	O
.	O

The	O
nuclear	B-protein
factor	I-protein
kappaB	I-protein
(	O
NF-kappaB	B-protein
)	O
is	O
thought	O
to	O
be	O
crucially	O
involved	O
in	O
the	O
gene	O
activation	O
of	O
several	O
cytokines	B-protein
,	O
including	O
tumor	B-protein
necrosis	I-protein
factor	I-protein
alpha	I-protein
(	O
TNF	B-protein
)	O
.	O

Previously	O
,	O
we	O
showed	O
that	O
fibroblast	O
conditioned	O
medium	O
(	O
FCM	O
)	O
is	O
able	O
to	O
inhibit	O
both	O
TNF	B-RNA
mRNA	I-RNA
accumulation	O
and	O
protein	O
release	O
in	O
peripheral	B-cell_line
blood-derived	I-cell_line
human	I-cell_line
monocytes	I-cell_line
(	O
PBM	B-cell_line
)	O
stimulated	O
with	O
lipopolysaccharide	O
(	O
LPS	O
)	O
.	O

In	O
this	O
study	O
we	O
have	O
investigated	O
the	O
effect	O
of	O
FCM	O
on	O
the	O
LPS-induced	O
DNA-binding	O
activity	O
of	O
NF-kappaB	B-protein
,	O
by	O
means	O
of	O
electrophoretic	O
shift	O
assay	O
(	O
EMSA	O
)	O
.	O

We	O
provide	O
evidence	O
that	O
FCM	O
strongly	O
inhibits	O
the	O
LPS-induced	O
NF-kappaB	B-protein
activation	O
in	O
PBM	B-cell_line
.	O

Furthermore	O
,	O
we	O
show	O
that	O
exogenous	O
PGE2	O
mimics	O
the	O
NF-kappaB	B-protein
inhibitory	O
effect	O
of	O
FCM	O
.	O

On	O
the	O
other	O
hand	O
,	O
FCM	O
produced	O
in	O
the	O
presence	O
of	O
indomethacin	O
does	O
not	O
inhibit	O
NF-kappaB	B-protein
activation	O
by	O
LPS	O
.	O

Our	O
results	O
lend	O
further	O
support	O
to	O
the	O
hypothesis	O
that	O
inflammatory	O
and	O
immune	O
responses	O
of	O
monocytes/macrophages	B-cell_type
may	O
be	O
modulated	O
at	O
the	O
molecular	O
level	O
by	O
signals	O
originating	O
from	O
tissue	B-cell_type
structural	I-cell_type
cells	I-cell_type
such	O
as	O
fibroblasts	B-cell_type
.	O

Human	B-protein
neutrophil	I-protein
elastase	I-protein
proteolytically	O
activates	O
the	O
platelet	B-protein
integrin	I-protein
alphaIIbbeta3	B-protein
through	O
cleavage	O
of	O
the	O
carboxyl	B-protein
terminus	I-protein
of	O
the	O
alphaIIb	B-protein
subunit	I-protein
heavy	I-protein
chain	I-protein
.	O

Involvement	O
in	O
the	O
potentiation	O
of	O
platelet	O
aggregation	O
.	O

Neutrophil	B-protein
elastase	I-protein
(	O
NE	B-protein
)	O
and	O
cathepsin	B-protein
G	I-protein
are	O
two	O
serine	B-protein
proteinases	I-protein
released	O
concomitantly	O
by	O
stimulated	O
polymorphonuclear	B-cell_type
neutrophils	I-cell_type
.	O

We	O
previously	O
demonstrated	O
that	O
while	O
NE	B-protein
by	O
itself	O
does	O
not	O
activate	O
human	B-cell_type
platelets	I-cell_type
,	O
it	O
strongly	O
enhances	O
the	O
weak	O
aggregation	O
induced	O
by	O
a	O
threshold	O
concentration	O
of	O
cathepsin	B-protein
G	I-protein
(	O
threshold	O
of	O
cathepsin	B-protein
G	I-protein
)	O
(	O
Renesto	O
,	O
P.	O
,	O
and	O
Chignard	O
,	O
M.	O
(	O
1993	O
)	O
Blood	O
82	O
,	O
139-144	O
)	O
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
delineate	O
the	O
molecular	O
mechanisms	O
involved	O
in	O
this	O
potentiation	O
process	O
.	O

Two	O
main	O
pieces	O
of	O
data	O
prompted	O
us	O
to	O
focus	O
on	O
the	O
activation	O
of	O
the	O
platelet	B-protein
fibrinogen	I-protein
receptor	I-protein
,	O
the	O
alphaIIbbeta3	B-protein
integrin	I-protein
.	O

First	O
,	O
previous	O
studies	O
have	O
shown	O
this	O
integrin	B-protein
to	O
be	O
particularly	O
prone	O
to	O
proteolytic	O
regulation	O
of	O
its	O
function	O
.	O

Second	O
,	O
we	O
found	O
that	O
the	O
potentiating	O
activity	O
of	O
NE	B-protein
on	O
the	O
threshold	O
of	O
cathepsin	B-protein
G	I-protein
-induced	O
platelet	O
aggregation	O
was	O
strictly	O
dependent	O
on	O
the	O
presence	O
of	O
exogenous	B-protein
fibrinogen	I-protein
.	O

Using	O
flow	O
cytometry	O
analysis	O
,	O
NE	B-protein
was	O
shown	O
to	O
trigger	O
a	O
time-dependent	O
binding	O
of	O
PAC-1	B-protein
and	O
AP-5	B-protein
,	O
two	O
monoclonal	B-protein
antibodies	I-protein
specific	O
for	O
the	O
activated	O
and	O
ligand-occupied	O
conformers	O
of	O
alphaIIbbeta3	B-protein
.	O

Furthermore	O
,	O
the	O
potentiated	O
aggregation	O
was	O
shown	O
to	O
result	O
from	O
an	O
increased	O
capacity	O
of	O
platelets	O
to	O
bind	O
fibrinogen	O
.	O

Indeed	O
,	O
the	O
combination	O
of	O
NE	B-protein
and	O
threshold	O
of	O
cathepsin	B-protein
G	I-protein
increased	O
the	O
binding	O
of	O
PAC-1	B-protein
approximately	O
5.5-fold	O
over	O
basal	O
values	O
measured	O
on	O
nontreated	B-cell_type
platelets	I-cell_type
,	O
whereas	O
this	O
binding	O
raised	O
only	O
by	O
approximately	O
3-fold	O
in	O
threshold	O
of	O
cathepsin	B-cell_type
G-stimulated	I-cell_type
platelets	I-cell_type
(	O
p	O
<	O
0.05	O
)	O
.	O

By	O
contrast	O
,	O
phosphatidic	O
acid	O
accumulation	O
,	O
pleckstrin	O
phosphorylation	O
,	O
and	O
calcium	O
mobilization	O
produced	O
by	O
the	O
combination	O
of	O
NE	B-protein
and	O
threshold	O
of	O
cathepsin	B-protein
G	I-protein
were	O
not	O
significantly	O
different	O
from	O
those	O
measured	O
with	O
threshold	O
of	O
cathepsin	B-protein
G	I-protein
alone	O
(	O
p	O
>	O
0.05	O
)	O
,	O
indicating	O
that	O
the	O
phospholipase	B-protein
C	I-protein
/protein	B-protein
kinase	I-protein
C	I-protein
pathway	O
is	O
not	O
involved	O
in	O
the	O
potentiation	O
of	O
aggregation	O
.	O

The	O
foregoing	O
data	O
,	O
as	O
well	O
as	O
the	O
requirement	O
of	O
catalytically	O
active	O
NE	B-protein
to	O
trigger	O
alphaIIbbeta3	B-protein
activation	O
and	O
potentiate	O
threshold	O
of	O
cathepsin	B-protein
G	I-protein
-initiated	O
platelet	O
aggregation	O
,	O
led	O
us	O
to	O
examine	O
whether	O
the	O
structure	O
of	O
this	O
integrin	B-protein
was	O
affected	O
by	O
NE	B-protein
.	O

Immunoblot	O
and	O
flow	O
cytometry	O
analysis	O
revealed	O
a	O
limited	O
proteolysis	O
of	O
the	O
carboxyl	B-protein
terminus	I-protein
of	O
the	O
alphaIIb	B-protein
subunit	I-protein
heavy	I-protein
chain	I-protein
(	O
alphaIIbH	B-protein
)	O
,	O
as	O
judged	O
by	O
the	O
disappearance	O
of	O
the	O
epitope	O
for	O
the	O
monoclonal	B-protein
antibody	I-protein
PMI-1	I-protein
.	O

Mass	O
spectrometry	O
studies	O
performed	O
on	O
a	O
synthetic	O
peptide	O
mapping	O
over	O
the	O
cleavage	B-protein
domain	I-protein
of	O
alphaIIbH	B-protein
predicted	O
the	O
site	O
of	O
proteolysis	O
as	O
located	O
between	O
Val837	O
and	O
Asp838	O
.	O

Treatment	O
by	O
NE	B-protein
of	O
ATP-depleted	B-cell_type
platelets	I-cell_type
or	O
Chinese	B-cell_line
hamster	I-cell_line
ovary	I-cell_line
cells	I-cell_line
expressing	O
human	B-protein
recombinant	I-protein
alphaIIbbeta3	I-protein
clearly	O
established	O
that	O
activation	O
of	O
the	O
integrin	B-protein
was	O
independent	O
of	O
signal	O
transduction	O
events	O
and	O
was	O
concomitant	O
with	O
the	O
proteolysis	O
of	O
alphaIIbH	B-protein
.	O

AP-1	B-protein
derived	O
from	O
mature	B-cell_type
monocytes	I-cell_type
and	O
astrocytes	B-cell_type
preferentially	O
interacts	O
with	O
the	O
HTLV-I	B-DNA
promoter	I-DNA
central	O
21	B-DNA
bp	I-DNA
repeat	I-DNA
.	O

Characterization	O
of	O
the	O
cellular	O
transcription	B-protein
factors	I-protein
interacting	O
with	O
the	O
human	B-DNA
T	I-DNA
cell	I-DNA
lymphotropic	I-DNA
virus	I-DNA
type	I-DNA
I	I-DNA
(	I-DNA
HTLV-I	I-DNA
)	I-DNA
long	I-DNA
terminal	I-DNA
repeat	I-DNA
(	O
LTR	B-DNA
)	O
is	O
essential	O
to	O
dissecting	O
the	O
mechanisms	O
involved	O
in	O
viral	O
transcription	O
that	O
may	O
be	O
pertinent	O
to	O
the	O
oncogenic	O
and	O
neuropathogenic	O
processes	O
associated	O
with	O
HTLV-I	O
infection	O
in	O
both	O
the	O
immune	O
and	O
nervous	O
systems	O
.	O

Electrophoretic	O
mobility	O
shift	O
(	O
EMS	O
)	O
analyses	O
utilizing	O
oligonucleotides	O
homologous	O
to	O
each	O
of	O
the	O
21	B-DNA
bp	I-DNA
repeat	I-DNA
elements	I-DNA
reacted	O
with	O
nuclear	O
extracts	O
derived	O
from	O
cell	B-cell_line
lines	I-cell_line
of	O
lymphocytic	B-cell_type
,	I-cell_type
monocytic	I-cell_type
,	I-cell_type
neuronal	I-cell_type
,	I-cell_type
and	I-cell_type
glial	I-cell_type
cell	I-cell_type
origin	I-cell_type
have	O
demonstrated	O
differential	O
binding	O
of	O
cellular	B-protein
factors	I-protein
to	O
the	O
three	O
21	B-DNA
bp	I-DNA
repeats	I-DNA
(	O
1-4	O
)	O
.	O

ATF/CREB	B-protein
and	O
Sp	B-protein
family	I-protein
members	I-protein
interacted	O
with	O
the	O
21	B-DNA
bp	I-DNA
repeats	I-DNA
to	O
form	O
DNA-protein	B-protein
complexes	I-protein
common	O
to	O
all	O
cell	O
types	O
examined	O
.	O

However	O
,	O
a	O
unique	O
DNA-protein	B-protein
complex	I-protein
was	O
detected	O
when	O
the	O
promoter	O
central	O
21	B-DNA
bp	I-DNA
repeat	I-DNA
was	O
reacted	O
with	O
nuclear	O
extracts	O
derived	O
from	O
either	O
the	O
U-373	B-cell_line
MG	I-cell_line
glioblastoma	I-cell_line
cell	I-cell_line
line	I-cell_line
or	O
the	O
THP-1	B-cell_line
mature	I-cell_line
monocytic	I-cell_line
cell	I-cell_line
line	I-cell_line
.	O

Based	O
on	O
nucleotide	O
sequence	O
requirements	O
and	O
immunoreactivity	O
,	O
we	O
demonstrate	O
that	O
this	O
DNA-protein	B-protein
complex	I-protein
is	O
comprised	O
of	O
the	O
AP-1	B-protein
components	O
,	O
Fos	B-protein
and	O
Jun	B-protein
.	O

HIV	O
does	O
not	O
replicate	O
in	O
naive	B-cell_type
CD4	I-cell_type
T	I-cell_type
cells	I-cell_type
stimulated	O
with	O
CD3/CD28	B-protein
.	O

In	O
this	O
report	O
,	O
we	O
demonstrate	O
that	O
the	O
T	O
cell	O
tropic	O
strain	O
of	O
HIV	O
,	O
LAI	O
,	O
does	O
not	O
replicate	O
in	O
naive	B-cell_type
CD4	I-cell_type
T	I-cell_type
cells	I-cell_type
stimulated	O
by	O
cross-linking	O
CD3	B-protein
and	O
CD28	B-protein
.	O

In	O
contrast	O
,	O
LAI	O
replicates	O
well	O
in	O
memory	B-cell_type
CD4	I-cell_type
T	I-cell_type
cells	I-cell_type
stimulated	O
in	O
the	O
same	O
way	O
.	O

Unlike	O
this	O
physiologically	O
relevant	O
stimulation	O
,	O
PHA	B-protein
stimulates	O
productive	O
LAI	O
replication	O
in	O
both	O
naive	B-cell_type
and	I-cell_type
memory	I-cell_type
T	I-cell_type
cells	I-cell_type
.	O

These	O
studies	O
were	O
conducted	O
with	O
highly	O
purified	O
(	O
FACS-isolated	O
)	O
subsets	O
of	O
CD4	B-cell_type
T	I-cell_type
cells	I-cell_type
identified	O
by	O
expression	O
of	O
both	O
CD45RA	B-protein
and	O
CD62L	B-protein
.	O

Remixing	O
of	O
purified	B-cell_type
T	I-cell_type
cells	I-cell_type
showed	O
that	O
naive	B-cell_type
T	I-cell_type
cells	I-cell_type
do	O
not	O
suppress	O
LAI	O
replication	O
in	O
memory	B-cell_type
T	I-cell_type
cells	I-cell_type
and	O
that	O
memory	B-cell_type
T	I-cell_type
cells	I-cell_type
do	O
not	O
restore	O
LAI	O
expression	O
in	O
naive	B-cell_type
T	I-cell_type
cells	I-cell_type
.	O

The	O
suppression	O
of	O
productive	O
LAI	O
replication	O
in	O
naive	B-cell_type
T	I-cell_type
cells	I-cell_type
is	O
not	O
due	O
to	O
differential	O
expression	O
of	O
viral	B-protein
coreceptors	I-protein
,	O
nor	O
is	O
it	O
due	O
to	O
inhibition	O
of	O
activation	O
of	O
the	O
important	O
HIV	O
transcription	B-protein
factors	I-protein
,	O
nuclear	B-protein
factor-kappaB	I-protein
and	O
activator	B-protein
protein-1	I-protein
.	O

The	O
inherent	O
resistance	O
of	O
naive	B-cell_type
T	I-cell_type
cells	I-cell_type
to	O
productive	O
HIV	O
infection	O
,	O
coupled	O
with	O
their	O
proliferative	O
advantage	O
as	O
demonstrated	O
here	O
,	O
provides	O
a	O
sound	O
basis	O
for	O
proposed	O
clinical	O
therapies	O
using	O
ex	O
vivo	O
expansion	O
and	O
reinfusion	O
of	O
CD4	B-cell_type
T	I-cell_type
cells	I-cell_type
from	O
HIV-infected	O
adults	O
.	O

A	O
PMLRARalpha	B-DNA
transgene	I-DNA
initiates	O
murine	O
acute	O
promyelocytic	O
leukemia	O
.	O

The	O
malignant	B-cell_type
cells	I-cell_type
of	O
acute	O
promyelocytic	O
leukemia	O
(	O
APL	O
)	O
contain	O
a	O
reciprocal	O
chromosomal	O
translocation	O
that	O
fuses	O
the	O
promyelocytic	B-DNA
leukemia	I-DNA
gene	I-DNA
(	O
PML	O
)	O
with	O
the	O
retinoic	B-DNA
acid	I-DNA
receptor	I-DNA
alpha	I-DNA
gene	I-DNA
(	O
RAR	B-protein
alpha	I-protein
)	O
.	O

To	O
test	O
the	O
hypothesis	O
that	O
the	O
chimera	B-protein
PMLRAR	I-protein
alpha	I-protein
plays	O
a	O
role	O
in	O
leukemogenesis	O
,	O
we	O
expressed	O
a	O
PMLRAR	B-DNA
alpha	I-DNA
cDNA	I-DNA
in	O
myeloid	B-cell_type
cells	I-cell_type
of	O
transgenic	O
mice	O
.	O

PMLRAR	O
alpha	O
transgenic	O
mice	O
exhibited	O
impaired	O
neutrophil	O
maturation	O
early	O
in	O
life	O
,	O
which	O
progressed	O
at	O
a	O
low	O
frequency	O
over	O
the	O
course	O
of	O
several	O
months	O
to	O
overt	O
APL	O
.	O

Both	O
the	O
preleukemic	O
state	O
and	O
the	O
leukemia	O
could	O
be	O
transplanted	O
to	O
nontransgenic	O
mice	O
,	O
and	O
the	O
transplanted	O
preleukemia	O
could	O
progress	O
to	O
APL	O
.	O

The	O
APL	O
recapitulated	O
features	O
of	O
the	O
human	O
disease	O
,	O
including	O
a	O
response	O
to	O
retinoic	O
acid	O
.	O

Retinoic	O
acid	O
caused	O
the	O
leukemic	B-cell_type
cells	I-cell_type
to	O
differentiate	O
in	O
vitro	O
and	O
in	O
vivo	O
,	O
eliciting	O
remissions	O
of	O
both	O
the	O
preleukemic	O
state	O
and	O
APL	O
in	O
mice	O
.	O

Our	O
results	O
demonstrate	O
that	O
PMLRAR	B-protein
alpha	I-protein
impairs	O
neutrophil	O
differentiation	O
and	O
initiates	O
the	O
development	O
of	O
APL	O
.	O

The	O
transgenic	O
mice	O
described	O
here	O
provide	O
an	O
apparently	O
accurate	O
model	O
for	O
human	O
APL	O
that	O
includes	O
clear	O
evidence	O
of	O
tumor	O
progression	O
.	O

The	O
model	O
should	O
be	O
useful	O
for	O
exploring	O
the	O
molecular	O
pathogenesis	O
of	O
APL	O
and	O
the	O
mechanisms	O
of	O
the	O
therapeutic	O
response	O
to	O
retinoic	O
acid	O
,	O
as	O
well	O
as	O
for	O
preclinical	O
studies	O
of	O
therapeutic	O
regimens	O
.	O

DNA	O
methylation	O
changes	O
in	O
hematologic	O
malignancies	O
:	O
biologic	O
and	O
clinical	O
implications	O
.	O

DNA	O
methylation	O
changes	O
are	O
among	O
the	O
most	O
common	O
detectable	O
abnormalities	O
in	O
human	O
neoplasia	O
.	O

Hypermethylation	O
within	O
the	O
promoters	B-DNA
of	O
selected	O
genes	O
appears	O
to	O
be	O
especially	O
common	O
in	O
all	O
types	O
of	O
human	B-cell_type
hematopoietic	I-cell_type
neoplasms	I-cell_type
,	O
and	O
is	O
usually	O
associated	O
with	O
inactivation	O
of	O
the	O
involved	O
gene	O
(	O
s	O
)	O
.	O

Such	O
hypermethylation-associated	O
silencing	O
of	O
gene	O
expression	O
has	O
been	O
shown	O
for	O
several	O
genes	O
regulating	O
the	O
growth	O
and	O
differentiation	O
of	O
hematopoietic	B-cell_type
cells	I-cell_type
,	O
including	O
the	O
estrogen	B-DNA
receptor	I-DNA
(	I-DNA
ER	I-DNA
)	I-DNA
gene	I-DNA
,	O
P15	O
,	O
P16	O
and	O
others	O
.	O

Hypermethylation	O
within	O
the	O
promoters	B-DNA
of	O
some	O
genes	O
appear	O
to	O
be	O
an	O
early	O
event	O
in	O
the	O
pathogenesis	O
of	O
neoplasia	O
(	O
ER	B-DNA
,	O
P15	B-DNA
)	O
,	O
while	O
other	O
genes	O
seem	O
to	O
become	O
methylated	O
during	O
the	O
progression	O
of	O
leukemias	O
(	O
HIC1	O
,	O
c-abl	O
)	O
.	O

The	O
high	O
prevalence	O
of	O
promoter	O
methylation	O
suggests	O
that	O
this	O
molecular	O
abnormality	O
can	O
be	O
used	O
to	O
monitor	O
disease	O
activity	O
during	O
therapy	O
.	O

In	O
addition	O
,	O
new	O
technology	O
allows	O
the	O
sensitive	O
identification	O
of	O
gene	O
hypermethylation	O
in	O
a	O
background	O
of	O
normal	B-cell_type
cells	I-cell_type
,	O
suggesting	O
possible	O
new	O
strategies	O
for	O
the	O
detection	O
of	O
minimal	O
residual	O
disease	O
.	O

Finally	O
,	O
reactivation	O
of	O
tumor-suppressor	O
gene	O
expression	O
through	O
pharmacologic	O
inhibition	O
of	O
DNA	B-protein
methyltransferase	I-protein
and	O
resultant	O
DNA	O
demethylation	O
appears	O
to	O
be	O
a	O
promising	O
new	O
avenue	O
of	O
therapy	O
in	O
acute	O
leukemia	O
.	O

Redox	O
regulation	O
of	O
the	O
mitogen-activated	B-protein
protein	I-protein
kinase	I-protein
pathway	O
during	O
lymphocyte	O
activation	O
.	O

We	O
have	O
previously	O
demonstrated	O
an	O
obligatory	O
requirement	O
for	O
intracellular	O
reactive	O
oxygen	O
species	O
generation	O
during	O
T	O
lymphocyte	O
activation	O
,	O
and	O
have	O
proposed	O
that	O
intracellular	O
reactive	O
oxygen	O
species	O
may	O
act	O
as	O
signalling	O
agents	O
in	O
the	O
regulation	O
of	O
certain	O
cellular	O
processes	O
,	O
for	O
example	O
,	O
during	O
cell	O
cycle	O
entry	O
.	O

To	O
test	O
this	O
hypothesis	O
,	O
we	O
have	O
been	O
interested	O
to	O
determine	O
which	O
,	O
if	O
any	O
,	O
cell	O
cycle	O
entry	O
events	O
are	O
affected	O
by	O
oxidative	O
signalling	O
.	O

In	O
earlier	O
studies	O
,	O
we	O
have	O
identified	O
the	O
transcription	B-protein
factors	I-protein
NF-kappa	B-protein
B	I-protein
and	O
AP-1	B-protein
as	O
molecular	O
targets	O
for	O
oxidative	O
signalling	O
processes	O
during	O
cell	O
cycle	O
entry	O
,	O
and	O
have	O
shown	O
that	O
oxidative	O
signalling	O
is	O
involved	O
in	O
the	O
regulation	O
of	O
early	O
changes	O
in	O
gene	O
expression	O
during	O
the	O
G0	O
to	O
G1	O
phase	O
transition	O
.	O

To	O
extend	O
these	O
initial	O
observations	O
,	O
we	O
have	O
examined	O
the	O
effect	O
of	O
antioxidant	O
treatment	O
on	O
the	O
activity	O
of	O
the	O
mitogen-activated	B-protein
protein	I-protein
kinases	I-protein
erk1	B-protein
and	O
erk2	B-protein
,	O
as	O
members	O
of	O
a	O
signal	O
transduction	O
pathway	O
known	O
to	O
directly	O
regulate	O
transcription	O
factor	O
function	O
.	O

Using	O
as	O
a	O
probe	O
cysteamine	O
,	O
an	O
aminothiol	O
compound	O
with	O
both	O
antioxidant	O
and	O
antiproliferative	O
activity	O
,	O
we	O
have	O
identified	O
erk2	B-protein
,	O
a	O
key	O
element	O
of	O
the	O
MAP	O
kinase	O
pathway	O
,	O
as	O
being	O
responsive	O
to	O
oxidative	O
signalling	O
during	O
lymphocyte	O
activation	O
.	O

These	O
observations	O
provide	O
further	O
evidence	O
to	O
suggest	O
a	O
role	O
for	O
intracellular	O
oxidant	O
generation	O
as	O
a	O
regulatory	O
mechanism	O
during	O
cell	O
cycle	O
entry	O
,	O
and	O
establish	O
a	O
link	O
between	O
oxidative	O
signalling	O
and	O
other	O
aspects	O
of	O
the	O
intracellular	O
signalling	O
network	O
that	O
is	O
activated	O
in	O
response	O
to	O
mitogenic	O
stimulation	O
.	O

Physical	O
and	O
functional	O
interaction	O
between	O
the	O
human	B-protein
T-cell	I-protein
lymphotropic	I-protein
virus	I-protein
type	I-protein
1	I-protein
Tax1	I-protein
protein	I-protein
and	O
the	O
CCAAT	B-protein
binding	I-protein
protein	I-protein
NF-Y	B-protein
.	O

Tax1	B-protein
,	O
a	O
potent	O
activator	O
of	O
human	O
T-cell	O
lymphotropic	O
virus	O
type	O
1	O
(	O
HTLV-1	O
)	O
transcription	O
,	O
has	O
been	O
shown	O
to	O
modulate	O
expression	O
of	O
many	O
cellular	B-DNA
genes	I-DNA
.	O

Tax1	B-protein
does	O
not	O
bind	O
DNA	O
directly	O
but	O
regulates	O
transcription	O
through	O
protein-protein	O
interactions	O
with	O
sequence-specific	B-protein
transcription	I-protein
factors	I-protein
.	O

Using	O
the	O
yeast	O
two-hybrid	O
system	O
to	O
screen	O
for	O
proteins	O
which	O
interact	O
with	O
Tax1	B-protein
,	O
we	O
isolated	O
the	O
B	B-protein
subunit	I-protein
of	O
the	O
CCAAT	B-protein
binding	I-protein
protein	I-protein
NF-Y	B-protein
from	O
a	O
HeLa	B-DNA
cDNA	I-DNA
library	I-DNA
.	O

The	O
interaction	O
of	O
Tax1	B-protein
with	O
NF-YB	B-protein
was	O
specific	O
in	O
that	O
NF-YB	B-protein
did	O
not	O
interact	O
with	O
a	O
variety	O
of	O
other	O
transcription	B-protein
factors	I-protein
,	O
including	O
human	B-protein
immunodeficiency	I-protein
virus	I-protein
Tat	I-protein
,	O
human	B-protein
papillomavirus	I-protein
E6	I-protein
,	O
and	O
Bicoid	B-protein
,	O
or	O
with	O
the	O
M7	B-protein
(	I-protein
amino	I-protein
acids	I-protein
29CP-AS	I-protein
)	I-protein
Tax1	I-protein
mutant	I-protein
.	O

However	O
,	O
NF-YB	B-protein
did	O
interact	O
with	O
the	O
C-terminal	B-protein
Tax1	I-protein
mutants	I-protein
M22	B-protein
(	O
130TL-AS	B-protein
)	O
and	O
M47	B-protein
(	O
319LL-RS	B-protein
)	O
.	O

We	O
also	O
show	O
that	O
in	O
vitro-translated	O
NF-YB	B-protein
specifically	O
bound	O
to	O
a	O
glutathione	B-protein
S-transferase-Tax1	I-protein
fusion	I-protein
protein	I-protein
.	O

Further	O
,	O
Tax1	B-protein
coimmunoprecipitated	O
with	O
NF-Y	B-protein
from	O
nuclear	O
extracts	O
of	O
HTLV-1-transformed	B-cell_type
cells	I-cell_type
,	O
providing	O
evidence	O
for	O
in	O
vivo	O
interaction	O
of	O
Tax1	B-protein
and	O
NF-YB	B-protein
.	O

We	O
further	O
demonstrate	O
that	O
Tax1	B-protein
specifically	O
activated	O
the	O
NF-Y-responsive	B-DNA
DQbeta	I-DNA
promoter	I-DNA
,	O
as	O
well	O
as	O
a	O
minimal	B-DNA
promoter	I-DNA
which	O
contains	O
only	O
the	O
Y-box	B-DNA
element	I-DNA
.	O

In	O
addition	O
,	O
mutation	O
of	O
the	O
Y-box	B-DNA
element	I-DNA
alone	O
abrogated	O
Tax1	B-protein
-mediated	O
activation	O
.	O

Taken	O
together	O
,	O
these	O
data	O
indicate	O
that	O
Tax1	B-protein
interacts	O
with	O
NF-Y	B-protein
through	O
the	O
B	B-protein
subunit	I-protein
and	O
that	O
this	O
interaction	O
results	O
in	O
activation	O
of	O
the	O
major	B-DNA
histocompatibility	I-DNA
complex	I-DNA
class	I-DNA
II	I-DNA
promoter	I-DNA
.	O

Through	O
activation	O
of	O
this	O
and	O
other	O
NF-Y	B-protein
driven	O
promoters	B-DNA
,	O
the	O
Tax1	B-protein
-NF-Y	B-protein
interaction	O
may	O
play	O
a	O
critical	O
role	O
in	O
causing	O
cellular	O
transformation	O
and	O
HTLV-1	O
pathogenesis	O
.	O

High	O
levels	O
of	O
the	O
DNA-binding	O
activity	O
of	O
E2F	B-protein
in	O
adult	O
T-cell	O
leukemia	O
and	O
human	B-cell_type
T-cell	I-cell_type
leukemia	I-cell_type
virus	I-cell_type
type	I-cell_type
I-infected	I-cell_type
cells	I-cell_type
:	O
possible	O
enhancement	O
of	O
DNA-binding	O
of	O
E2F	B-protein
by	O
the	O
human	B-protein
T-cell	I-protein
leukemia	I-protein
virus	I-protein
I	I-protein
transactivating	I-protein
protein	I-protein
,	O
Tax	B-protein
.	O

Transcription	B-protein
factor	I-protein
E2F	B-protein
binds	O
to	O
cellular	B-DNA
promoters	I-DNA
of	O
certain	O
growth-	B-DNA
and	I-DNA
cell	I-DNA
cycle-controlling	I-DNA
genes	I-DNA
and	O
forms	O
distinct	O
heteromeric	B-protein
complexes	I-protein
with	O
other	O
nuclear	B-protein
proteins	I-protein
.	O

It	O
has	O
therefore	O
been	O
proposed	O
that	O
E2F	B-protein
is	O
involved	O
in	O
cellular	O
proliferation	O
control	O
.	O

Human	O
T-cell	O
leukemia	O
virus	O
type	O
I	O
(	O
HTLV-I	O
)	O
is	O
an	O
etiological	O
agent	O
of	O
adult	O
T-cell	O
leukemia	O
(	O
ATL	O
)	O
.	O

We	O
show	O
here	O
by	O
mobility-shift	O
assay	O
that	O
E2F-containing	B-protein
DNA-binding	I-protein
complexes	I-protein
were	O
detected	O
in	O
HTLV-I-infected	B-cell_line
T-cell	I-cell_line
lines	I-cell_line
and	O
leukemic	B-cell_type
cells	I-cell_type
obtained	O
from	O
ATL	O
patients	O
but	O
not	O
in	O
an	O
uninfected	B-cell_line
T-cell	I-cell_line
line	I-cell_line
,	O
Jurkat	B-cell_line
,	O
and	O
normal	B-cell_type
peripheral	I-cell_type
blood	I-cell_type
mononuclear	I-cell_type
cells	I-cell_type
.	O

The	O
Tax	B-protein
protein	I-protein
,	O
encoded	O
by	O
HTLV-I	O
,	O
is	O
a	O
potent	O
transcription	O
activator	O
of	O
viral	O
and	O
several	O
cellular	B-DNA
genes	I-DNA
.	O

We	O
demonstrate	O
that	O
expression	O
of	O
Tax	B-protein
can	O
induce	O
the	O
E2F-containing	B-protein
DNA-binding	I-protein
complexes	I-protein
in	O
Jurkat	B-cell_line
T	I-cell_line
cells	I-cell_line
.	O

Thus	O
,	O
Tax	B-protein
,	O
through	O
enhancement	O
of	O
the	O
DNA-binding	O
activity	O
of	O
E2F	B-protein
,	O
may	O
be	O
capable	O
of	O
regulating	O
cellular	O
gene	O
expression	O
implicated	O
in	O
the	O
proliferation	O
and	O
transformation	O
of	O
T	B-cell_type
cells	I-cell_type
in	O
ATL	O
.	O

This	O
activity	O
may	O
be	O
relevant	O
to	O
the	O
mechanisms	O
whereby	O
HTLV-I	O
which	O
does	O
not	O
contain	O
oncogenes	B-DNA
induces	O
neoplasia	O
.	O

Dissociation	O
of	O
the	O
Jak	B-protein
kinase	I-protein
pathway	O
from	O
G-CSF	B-protein
receptor	I-protein
signaling	O
in	O
neutrophils	O
.	O

Activation	O
of	O
the	O
granulocyte	B-protein
colony-stimulating	I-protein
factor	I-protein
receptor	I-protein
(	O
G-CSFR	B-protein
)	O
induces	O
rapid	O
tyrosine	O
phosphorylation	O
of	O
multiple	O
intracellular	B-protein
substrates	I-protein
in	O
proliferating	B-cell_type
cells	I-cell_type
and	O
nonproliferating	B-cell_type
,	I-cell_type
terminally	I-cell_type
differentiated	I-cell_type
neutrophils	I-cell_type
.	O

The	O
kinases	O
that	O
couple	O
ligand	O
binding	O
to	O
tyrosine	O
phosphorylation	O
of	O
cellular	B-protein
substrates	I-protein
by	O
the	O
G-CSFR	O
with	O
activation	O
of	O
specific	O
functional	O
programs	O
are	O
largely	O
unknown	O
.	O

In	O
this	O
study	O
,	O
we	O
examined	O
early	O
signaling	O
events	O
in	O
proliferating	B-cell_type
and	O
terminally	B-cell_type
differentiated	I-cell_type
cells	I-cell_type
following	O
G-CSF	B-protein
stimulation	O
to	O
determine	O
whether	O
identical	O
signaling	O
cascades	O
are	O
activated	O
.	O

In	O
murine	B-cell_line
Ba/F3	I-cell_line
cells	I-cell_line
transfected	O
with	O
the	O
human	B-protein
G-CSFR	I-protein
and	O
NFS-60	B-cell_line
cells	I-cell_line
constitutively	O
expressing	O
the	O
murine	B-protein
G-CSFR	I-protein
,	O
G-CSF	B-protein
induced	O
tyrosine	O
phosphorylation	O
and	O
activation	O
of	O
Jak1	B-protein
,	O
Jak2	B-protein
,	O
and	O
Tyk2	B-protein
.	O

Tyrosine	O
phosphorylation	O
of	O
Stat3	B-protein
and	O
,	O
to	O
a	O
lesser	O
extent	O
,	O
Stat1	B-protein
was	O
also	O
detected	O
following	O
G-CSF	B-protein
stimulation	O
.	O

Using	O
a	O
mitogenically	B-protein
incompetent	I-protein
human	I-protein
G-CSFR	I-protein
mutant	I-protein
in	O
which	O
Pro639	O
and	O
Pro641	O
were	O
substituted	O
by	O
alanine	O
,	O
the	O
box	B-protein
1	I-protein
PDP	I-protein
motif	I-protein
was	O
found	O
to	O
be	O
required	O
for	O
activation	O
of	O
Jak	B-protein
kinases	I-protein
,	O
tyrosine	O
phosphorylation	O
of	O
the	O
G-CSFR	B-protein
,	O
and	O
recruitment	O
of	O
Stat	B-protein
proteins	I-protein
.	O

Notably	O
,	O
no	O
activation	O
of	O
Jak1	B-protein
,	O
Jak2	B-protein
,	O
Tyk2	B-protein
,	O
Stat1	B-protein
,	O
or	O
Stat3	B-protein
was	O
observed	O
in	O
neutrophils	B-cell_type
following	O
G-CSF	B-protein
stimulation	O
.	O

In	O
addition	O
,	O
there	O
was	O
no	O
detectable	O
activation	O
in	O
neutrophils	B-cell_type
of	O
the	O
recently	O
cloned	O
Jak3	B-protein
kinase	I-protein
,	O
which	O
has	O
been	O
reported	O
to	O
be	O
expressed	O
at	O
high	O
levels	O
as	O
myeloid	B-cell_type
cells	I-cell_type
undergo	O
terminal	O
neutrophilic	O
maturation	O
.	O

These	O
results	O
indicate	O
a	O
lack	O
of	O
involvement	O
of	O
Jak	B-protein
kinases	I-protein
in	O
signaling	O
by	O
the	O
G-CSFR	B-protein
in	O
neutrophils	B-cell_type
,	O
and	O
suggest	O
utilization	O
of	O
alternative	O
signal	O
transduction	O
pathways	O
distinct	O
from	O
those	O
in	O
proliferating	B-cell_type
cells	I-cell_type
.	O

Activation	O
of	O
the	O
Jak	B-protein
-Stat	B-protein
pathway	O
correlates	O
with	O
proliferative	O
signaling	O
by	O
the	O
G-CSFR	B-protein
and	O
requires	O
the	O
membrane-proximal	B-protein
box	I-protein
1	I-protein
PXP	I-protein
motif	I-protein
,	O
which	O
is	O
conserved	O
in	O
members	O
of	O
the	O
cytokine	B-protein
receptor	I-protein
superfamily	I-protein
.	O

Impaired	O
induction	O
of	O
c-fos/c-jun	B-DNA
genes	I-DNA
and	O
of	O
transcriptional	B-protein
regulatory	I-protein
proteins	I-protein
binding	O
distinct	O
c-fos/c-jun	B-DNA
promoter	I-DNA
elements	I-DNA
in	O
activated	B-cell_type
human	I-cell_type
T	I-cell_type
cells	I-cell_type
during	O
aging	O
.	O

The	O
activation	O
of	O
transcriptional	B-protein
factor	I-protein
c-Fos/c-Jun	O
AP-1	B-protein
is	O
essential	O
for	O
normal	O
T	B-cell_type
cell	I-cell_type
responsiveness	O
and	O
is	O
often	O
impaired	O
in	O
T	B-cell_type
cells	I-cell_type
during	O
aging	O
.	O

In	O
the	O
present	O
study	O
,	O
we	O
investigated	O
whether	O
aberrancies	O
in	O
the	O
regulation	O
of	O
c-fos/c-jun	B-DNA
at	O
the	O
mRNA	O
or	O
protein	O
level	O
might	O
underlie	O
the	O
age-associated	O
impairments	O
of	O
AP-1	B-protein
in	O
human	B-cell_type
T	I-cell_type
cells	I-cell_type
.	O

Whereas	O
T	B-cell_type
cells	I-cell_type
from	O
young	O
subjects	O
stimulated	O
with	O
cross-linked	B-protein
anti-CD3epsilon	I-protein
mAb	I-protein
OKT3	B-protein
plus	O
PMA	O
or	O
with	O
the	O
lectin	B-protein
PHA	B-protein
plus	O
PMA	O
demonstrated	O
considerable	O
increases	O
in	O
c-Fos	B-protein
protein	O
expression	O
,	O
the	O
expression	O
of	O
c-Fos	B-protein
but	O
not	O
c-Jun	B-protein
was	O
markedly	O
reduced	O
in	O
stimulated	O
T	B-cell_type
cells	I-cell_type
from	O
certain	O
elderly	O
subjects	O
.	O

In	O
addition	O
,	O
RNase	B-protein
protection	O
assays	O
revealed	O
that	O
anti-CD3/	O
PMA-stimulated	B-cell_type
T	I-cell_type
cells	I-cell_type
from	O
a	O
substantial	O
proportion	O
of	O
elderly	O
subjects	O
exhibited	O
decreased	O
levels	O
of	O
c-fos	B-RNA
and/or	I-RNA
c-jun	I-RNA
mRNA	I-RNA
compared	O
to	O
T	B-cell_type
cells	I-cell_type
from	O
young	O
subjects	O
.	O

Using	O
electrophoretic	O
mobility	O
shift	O
assays	O
,	O
the	O
levels	O
of	O
nuclear	B-protein
regulatory	I-protein
proteins	I-protein
recognizing	O
the	O
AP-1	B-DNA
consensus	I-DNA
TRE	I-DNA
motif	I-DNA
,	O
the	O
proximal	B-DNA
c-jun	I-DNA
TRE-like	I-DNA
promoter	I-DNA
element	I-DNA
,	O
and	O
the	O
c-fos	B-DNA
serum	I-DNA
response	I-DNA
element	I-DNA
(	O
SRE	B-DNA
)	O
were	O
determined	O
in	O
resting	B-cell_type
and	I-cell_type
stimulated	I-cell_type
T	I-cell_type
cells	I-cell_type
.	O

Although	O
the	O
stimulation	O
of	O
T	B-cell_type
cells	I-cell_type
from	O
young	O
subjects	O
resulted	O
in	O
coordinated	O
increases	O
of	O
nuclear	B-protein
protein	I-protein
complexes	I-protein
binding	O
the	O
AP-1	B-DNA
TRE	I-DNA
,	O
c-jun	B-DNA
TRE	I-DNA
,	O
and	O
c-fos	B-DNA
SRE	I-DNA
DNA	I-DNA
sequence	I-DNA
motifs	I-DNA
,	O
age-related	O
reductions	O
in	O
the	O
activation	O
of	O
AP-1	B-protein
were	O
accompanied	O
by	O
decreased	O
levels	O
of	O
c-jun	B-protein
TRE	I-protein
and	I-protein
c-fos	I-protein
SRE	I-protein
binding	I-protein
complexes	I-protein
.	O

Furthermore	O
,	O
the	O
nuclear	B-protein
protein	I-protein
complexes	I-protein
binding	O
the	O
SRE	B-DNA
motif	I-DNA
induced	O
in	O
activated	B-cell_type
T	I-cell_type
cells	I-cell_type
of	O
young	O
and	O
elderly	O
subjects	O
contained	O
serum	B-protein
response	I-protein
factor	I-protein
and	O
Elk-1	B-protein
pointing	O
toward	O
age-related	O
defects	O
in	O
the	O
activation	O
of	O
transcriptional	B-protein
regulatory	I-protein
proteins	I-protein
distinct	O
from	O
c-jun/AP-1	B-protein
.	O

These	O
results	O
suggest	O
that	O
underlying	O
aberrancies	O
in	O
the	O
induction	O
of	O
c-fos/c-jun	B-DNA
as	O
well	O
as	O
their	O
nuclear	B-protein
regulatory	I-protein
proteins	I-protein
may	O
contribute	O
to	O
the	O
age-related	O
impairments	O
of	O
AP-1	B-protein
activation	O
in	O
human	B-cell_type
T	I-cell_type
cells	I-cell_type
.	O

Retinoic	O
acid-induced	O
modulation	O
of	O
IL-2	B-RNA
mRNA	I-RNA
production	O
and	O
IL-2	B-protein
receptor	O
expression	O
on	O
T	B-cell_type
cells	I-cell_type
.	O

BACKGROUND	O
:	O
Retinoic	O
acid	O
(	O
RA	O
)	O
has	O
important	O
immune-modulating	O
effects	O
on	O
both	O
T	O
and	O
B	O
cell	O
function	O
.	O

Our	O
laboratory	O
has	O
shown	O
that	O
RA	O
can	O
enhance	O
in	O
vitro	O
polyclonal	O
B	O
cell	O
immunoglobulin	B-protein
(	O
Ig	O
)	O
response	O
.	O

Investigating	O
cytokines	B-protein
known	O
to	O
affect	O
B	O
cell	O
differentiation	O
,	O
we	O
have	O
recently	O
shown	O
that	O
IL-6	B-protein
production	O
is	O
augmented	O
by	O
RA	O
.	O

In	O
the	O
present	O
study	O
we	O
have	O
examined	O
the	O
immune	O
modulating	O
effects	O
of	O
RA	O
on	O
IL-2	B-RNA
mRNA	I-RNA
,	O
another	O
important	O
cytokine	B-protein
for	O
B	O
cell	O
immunoglobulin	B-protein
production	O
,	O
the	O
expression	O
of	O
IL-2	B-protein
receptors	I-protein
on	O
T	B-cell_type
cells	I-cell_type
,	O
and	O
the	O
RA	B-protein
nuclear	I-protein
receptors	I-protein
.	O

METHODS	O
:	O
Purified	O
T	B-cell_type
cells	I-cell_type
were	O
obtained	O
from	O
adenoidal	O
tissues	O
,	O
and	O
incubated	O
with	O
RA	O
(	O
10	O
(	O
-7	O
)	O
M	O
)	O
or	O
DMSO	O
solvent/media	O
control	O
for	O
0	O
,	O
6-8	O
,	O
and	O
24	O
h	O
.	O

Total	O
mRNA	B-RNA
was	O
extracted	O
from	O
T	B-cell_type
cells	I-cell_type
,	O
and	O
using	O
RT-PCR	O
,	O
changes	O
in	O
the	O
production	O
of	O
IL-2	B-protein
and	O
RA	B-protein
receptors	I-protein
(	O
RAR	B-protein
)	O
-	O
alpha	B-RNA
,	O
beta	B-RNA
,	O
gamma	B-RNA
mRNA	I-RNA
were	O
determined	O
.	O

The	O
effects	O
of	O
RA	O
on	O
IL-2-alpha	O
receptor	O
expression	O
was	O
determined	O
by	O
flow	O
cytometry	O
on	O
T	B-cell_type
cells	I-cell_type
.	O

CONCLUSION	O
:	O
These	O
studies	O
suggest	O
that	O
RA	O
can	O
augment	O
IL-2	B-RNA
mRNA	I-RNA
production	O
by	O
T	B-cell_type
cells	I-cell_type
with	O
a	O
possible	O
paracrine	O
effect	O
on	O
IL-2R-alpha	B-protein
expression	O
.	O

These	O
changes	O
appear	O
to	O
be	O
mediated	O
by	O
RAR-alpha	B-protein
.	O

Thus	O
,	O
IL-2	B-protein
may	O
be	O
another	O
important	O
cytokine	B-protein
modulated	O
by	O
RA	O
in	O
the	O
immune	O
response	O
.	O

Involvement	O
of	O
an	O
SAF-like	B-protein
transcription	I-protein
factor	I-protein
in	O
the	O
activation	O
of	O
serum	B-DNA
amyloid	I-DNA
A	I-DNA
gene	I-DNA
in	O
monocyte/macrophage	B-cell_type
cells	I-cell_type
by	O
lipopolysaccharide	O
.	O

Serum	B-protein
amyloid	I-protein
A	I-protein
(	O
SAA	B-protein
)	O
has	O
been	O
linked	O
to	O
atherosclerosis	O
because	O
of	O
its	O
ability	O
to	O
remodel	O
high-density	O
lipoprotein	O
by	O
the	O
depletion	O
of	O
apolipoprotein	O
A1	O
,	O
its	O
ability	O
to	O
bind	O
cholesterol	O
,	O
and	O
its	O
presence	O
in	O
the	O
atherosclerotic	O
plaques	O
of	O
coronary	O
and	O
carotid	O
arteries	O
.	O

In	O
the	O
present	O
study	O
,	O
we	O
investigated	O
the	O
induction	O
mechanism	O
of	O
SAA	B-DNA
gene	I-DNA
in	O
THP-1	B-cell_line
monocyte/macrophage	I-cell_line
cells	I-cell_line
which	O
play	O
a	O
critical	O
role	O
in	O
the	O
development	O
of	O
atherosclerotic	O
fatty	O
streak	O
and	O
plaque	O
formation	O
.	O

We	O
and	O
others	O
have	O
shown	O
that	O
SAA	B-protein
gene	O
is	O
induced	O
in	O
monocyte/macrophage	B-cell_type
cells	I-cell_type
by	O
lipopolysaccharide	O
(	O
LPS	O
)	O
.	O

By	O
promoter	O
function	O
analysis	O
,	O
we	O
show	O
that	O
the	O
SAA	B-DNA
promoter	I-DNA
sequence	I-DNA
between	O
-280	O
and	O
-226	O
can	O
confer	O
LPS	O
responsiveness	O
.	O

Gel	O
electrophoretic	O
mobility	O
shift	O
assay	O
detected	O
an	O
induced	O
DNA-binding	O
activity	O
in	O
these	O
cells	O
in	O
response	O
to	O
LPS	O
.	O

Characterization	O
of	O
the	O
DNA-binding	B-protein
protein	I-protein
by	O
UV	O
cross-linking	O
,	O
Southwestern	O
blot	O
,	O
and	O
antibody	O
ablation/supershift	O
assays	O
revealed	O
that	O
it	O
is	O
similar	O
to	O
a	O
recently	O
reported	O
nuclear	B-protein
factor	I-protein
designated	O
SAF	B-protein
.	O

These	O
results	O
demonstrated	O
that	O
LPS-mediated	O
SAA	B-protein
gene	O
induction	O
in	O
monocyte/macrophage	B-cell_type
cells	I-cell_type
is	O
primarily	O
due	O
to	O
the	O
induction	O
of	O
SAF	B-protein
activity	O
.	O

Cytomegalovirus	B-DNA
immediate	I-DNA
early	I-DNA
genes	I-DNA
upregulate	O
interleukin-6	B-protein
gene	O
expression	O
.	O

BACKGROUND	O
:	O
The	O
immediate	B-DNA
early	I-DNA
genes	I-DNA
(	O
IE	B-DNA
)	O
of	O
human	O
cytomegalovirus	O
(	O
CMV	O
)	O
can	O
be	O
expressed	O
in	O
monocytic	B-cell_type
cells	I-cell_type
and	O
are	O
known	O
to	O
regulate	O
viral	B-DNA
and	I-DNA
cellular	I-DNA
genes	I-DNA
.	O

Interleukin-6	B-protein
(	O
IL-6	B-protein
)	O
plays	O
a	O
central	O
role	O
in	O
numerous	O
inflammatory	O
and	O
immune	O
processes	O
.	O

Interleukin-6	B-protein
levels	O
are	O
increased	O
in	O
lung	O
transplant	O
patients	O
clinically	O
diagnosed	O
with	O
CMV	O
pneumonitis	O
.	O

The	O
regulation	O
of	O
IL-6	B-protein
is	O
dependent	O
on	O
various	O
stimuli	O
that	O
include	O
lipopolysaccharide	O
(	O
LPS	O
)	O
,	O
viruses	O
,	O
and	O
other	O
cytokines	B-protein
.	O

These	O
studies	O
examined	O
the	O
ability	O
of	O
CMV	O
IE	O
gene	O
products	O
to	O
modulate	O
IL-6	B-protein
production	O
.	O

METHODS	O
:	O
THP-1	B-cell_line
cells	I-cell_line
,	O
a	O
monocytic	B-cell_line
cell	I-cell_line
line	I-cell_line
,	O
were	O
transfected	O
with	O
the	O
CMV	B-DNA
IE	I-DNA
genes	I-DNA
.	O

Interleukin-6	B-protein
protein	O
and	O
IL-6	B-RNA
mRNA	I-RNA
were	O
measured	O
in	O
control	O
and	O
CMV	B-cell_type
immediate	I-cell_type
early	I-cell_type
transfected	I-cell_type
cells	I-cell_type
.	O

Cotransfection	O
of	O
CMV	B-DNA
IE	I-DNA
genes	I-DNA
and	O
IL-6	B-DNA
chloramphenicol	I-DNA
acetyl	I-DNA
transferase	I-DNA
(	I-DNA
CAT	I-DNA
)	I-DNA
or	I-DNA
IL-6	I-DNA
luciferase	I-DNA
constructs	I-DNA
were	O
used	O
to	O
study	O
IL-6	B-protein
promoter	O
activity	O
.	O

RESULTS	O
:	O
Interleukin-6	B-protein
protein	I-protein
and	O
mRNA	O
production	O
were	O
significantly	O
increased	O
in	O
cells	O
transfected	O
with	O
the	O
CMV	B-DNA
IE	I-DNA
genes	I-DNA
and	O
stimulated	O
with	O
LPS	O
compared	O
to	O
LPS-stimulated	B-cell_line
control	I-cell_line
cells	I-cell_line
.	O

Cytomegalovirus	B-protein
IE	I-protein
gene	I-protein
products	I-protein
significantly	O
enhanced	O
LPS	O
stimulation	O
of	O
IL-6	B-DNA
promoter	I-DNA
activity	O
in	O
both	O
IL-6	B-protein
CAT	O
and	O
IL-6	O
luciferase	O
assays	O
.	O

A	O
deletion	O
construct	O
that	O
contains	O
a	O
NF-kappa	B-DNA
B	I-DNA
site	I-DNA
but	O
is	O
missing	O
the	O
multiple	O
response	O
region	O
demonstrated	O
a	O
continued	O
increase	O
in	O
IL-6	B-protein
luciferase	B-protein
activity	O
in	O
LPS-stimulated	B-cell_line
CMV	I-cell_line
transfected	I-cell_line
cells	I-cell_line
.	O

CONCLUSION	O
:	O
Cytomegalovirus	B-protein
immediate	I-protein
early	I-protein
gene	I-protein
products	I-protein
significantly	O
enhanced	O
expression	O
of	O
IL-6	B-protein
in	O
LPS-stimulated	O
cells	O
.	O

The	O
increase	O
in	O
IL-6	B-protein
luciferase	B-protein
activity	O
occurs	O
in	O
the	O
absence	O
of	O
the	O
multiple	O
response	O
region	O
,	O
the	O
area	O
of	O
the	O
IL-6	B-DNA
promoter	I-DNA
responsive	O
to	O
IL-1	B-protein
,	O
TNF	B-protein
alpha	I-protein
,	O
cyclic	O
amp	O
,	O
and	O
phorbol	O
12-myristate	O
13-acetate	O
.	O

The	O
ability	O
of	O
CMV	B-protein
IE	I-protein
gene	I-protein
products	I-protein
to	O
enhance	O
IL-6	B-protein
production	O
may	O
play	O
an	O
important	O
role	O
in	O
immune	O
inflammatory	O
states	O
associated	O
with	O
CMV	O
infection	O
.	O

Induction	O
of	O
relA	B-protein
(	I-protein
p65	I-protein
)	I-protein
and	O
I	B-protein
kappa	I-protein
B	I-protein
alpha	I-protein
subunit	I-protein
expression	O
during	O
differentiation	O
of	O
human	B-cell_type
peripheral	I-cell_type
blood	I-cell_type
monocytes	I-cell_type
to	O
macrophages	B-cell_type
.	O

We	O
evaluated	O
the	O
expression	O
and	O
DNA	O
binding	O
activity	O
of	O
nuclear	B-protein
factor	I-protein
(	I-protein
NF	I-protein
)	I-protein
-kappa	I-protein
B	I-protein
subunits	I-protein
in	O
human	B-cell_type
peripheral	I-cell_type
blood	I-cell_type
monocytes	I-cell_type
and	O
in	O
monocyte-derived	B-cell_type
macrophages	I-cell_type
(	O
MDMs	B-cell_type
)	O
.	O

Constitutive	O
DNA	O
binding	O
activity	O
consisting	O
of	O
p50	B-protein
homodimers	I-protein
was	O
detected	O
in	O
nuclear	O
extracts	O
from	O
both	O
cell	O
types	O
.	O

An	O
additional	O
complex	O
composed	O
of	O
p50/RelA	B-protein
(	I-protein
p65	I-protein
)	I-protein
heterodimers	I-protein
appeared	O
only	O
in	O
nuclear	O
extracts	O
from	O
7-day	O
MDMs	B-cell_type
.	O

Immunoblot	O
analysis	O
showed	O
that	O
the	O
p50	O
subunit	O
was	O
constitutively	O
expressed	O
in	O
monocytes	B-cell_type
and	O
MDMs	B-cell_type
.	O

In	O
contrast	O
,	O
the	O
RelA	B-protein
(	I-protein
p65	I-protein
)	I-protein
subunit	I-protein
was	O
barely	O
detectable	O
in	O
monocytes	B-cell_type
,	O
but	O
its	O
level	O
increased	O
markedly	O
in	O
MDMs	B-cell_type
.	O

Analysis	O
of	O
RelA	B-RNA
(	I-RNA
p65	I-RNA
)	I-RNA
mRNA	I-RNA
revealed	O
that	O
the	O
stability	O
of	O
RelA	B-RNA
(	I-RNA
p65	I-RNA
)	I-RNA
mRNA	I-RNA
was	O
significantly	O
higher	O
in	O
MDMs	B-cell_type
,	O
compared	O
with	O
monocytes	B-cell_type
.	O

In	O
MDMs	B-cell_type
,	O
an	O
upregulation	O
of	O
I	B-protein
kappa	I-protein
B	I-protein
alpha	I-protein
synthesis	O
as	O
well	O
as	O
the	O
appearance	O
of	O
a	O
novel	O
M	O
(	O
r	O
)	O
40	O
,	O
000	O
form	O
of	O
I	B-protein
kappa	I-protein
B	I-protein
alpha	I-protein
were	O
also	O
observed	O
.	O

These	O
results	O
suggest	O
that	O
macrophage	O
differentiation	O
results	O
in	O
the	O
expression	O
of	O
active	O
p50/RelA	B-protein
(	I-protein
p65	I-protein
)	I-protein
heterodimers	I-protein
with	O
the	O
capacity	O
to	O
activate	O
target	O
gene	O
expression	O
.	O

The	O
parallel	O
induction	O
of	O
I	B-protein
kappa	I-protein
B	I-protein
alpha	I-protein
synthesis	O
may	O
allow	O
for	O
the	O
continuous	O
presence	O
of	O
a	O
cytoplasmic	O
reservoir	O
of	O
p50/RelA	B-protein
(	I-protein
p65	I-protein
)	I-protein
complexes	I-protein
that	O
are	O
readily	O
available	O
for	O
inducer-mediated	O
stimulation	O
.	O

Nuclear	B-protein
Rel-A	I-protein
and	I-protein
c-Rel	I-protein
protein	I-protein
complexes	I-protein
are	O
differentially	O
distributed	O
within	O
human	B-cell_type
thymocytes	I-cell_type
.	O

Nuclear	B-protein
factor-kappa	I-protein
B	I-protein
(	I-protein
NF-kappa	I-protein
B	I-protein
)	I-protein
/Rel	I-protein
proteins	I-protein
are	O
inducible	O
transcriptional	B-protein
regulators	I-protein
of	O
numerous	O
cellular	B-DNA
genes	I-DNA
.	O

They	O
are	O
particularly	O
abundant	O
in	O
lymphoid	O
tissues	O
and	O
are	O
thought	O
to	O
be	O
critical	O
for	O
the	O
transcription	O
of	O
genes	O
involved	O
in	O
immune	O
and	O
inflammatory	O
responses	O
.	O

We	O
have	O
reported	O
previously	O
that	O
a	O
nuclear	O
NF-kappa	B-protein
B	I-protein
activity	O
was	O
present	O
in	O
freshly	O
extracted	O
human	B-cell_type
thymocytes	I-cell_type
in	O
the	O
absence	O
of	O
in	O
vitro	O
treatment	O
of	O
these	O
cells	O
.	O

In	O
the	O
present	O
report	O
,	O
we	O
identified	O
NF-kappa	B-protein
B	I-protein
proteins	I-protein
extracted	O
from	O
human	O
thymocyte	O
nuclei	O
as	O
being	O
p50/p65	B-protein
and	I-protein
p50/c-Rel	I-protein
complexes	I-protein
.	O

Immunochemical	O
and	O
immunofluorescent	O
staining	O
of	O
thymus	O
sections	O
using	O
specific	B-protein
Abs	I-protein
allowed	O
visualization	O
of	O
nuclear	B-protein
NF-kappa	I-protein
B	I-protein
proteins	I-protein
in	O
both	O
thymocytes	B-cell_type
and	O
nonthymocyte	B-cell_type
cells	I-cell_type
.	O

This	O
detection	O
suggested	O
a	O
preferential	O
activation	O
of	O
p50/c-Rel	B-protein
in	O
medullary	B-cell_type
thymocytes	I-cell_type
,	O
whereas	O
p50/p65	B-protein
was	O
present	O
in	O
both	O
cortical	O
and	O
medullary	O
regions	O
of	O
human	O
thymus	O
lobules	O
.	O

However	O
,	O
the	O
intensity	O
of	O
p65	B-protein
labeling	O
was	O
much	O
higher	O
in	O
several	O
thymocytes	B-cell_type
from	O
the	O
medulla	O
.	O

p65	O
,	O
p50	O
,	O
and	O
c-Rel	O
activities	O
were	O
found	O
in	O
both	O
CD4-	B-cell_type
and	I-cell_type
CD8-positive	I-cell_type
thymocytes	I-cell_type
.	O

These	O
observations	O
suggest	O
that	O
p65	B-protein
and	I-protein
c-Rel	I-protein
complexes	I-protein
play	O
distinct	O
roles	O
in	O
gene	O
expression	O
and	O
that	O
both	O
forms	O
of	O
NF-kappa	B-protein
B	I-protein
play	O
critical	O
roles	O
during	O
late	O
stages	O
of	O
the	O
intrathymic	O
maturation	O
of	O
T	B-cell_type
cells	I-cell_type
.	O

ALY	B-protein
,	O
a	O
context-dependent	B-protein
coactivator	I-protein
of	O
LEF-1	B-protein
and	O
AML-1	B-protein
,	O
is	O
required	O
for	O
TCRalpha	B-DNA
enhancer	I-DNA
function	O
.	O

LEF-1	B-protein
is	O
a	O
transcription	O
factor	O
that	O
participates	O
in	O
the	O
regulation	O
of	O
the	O
T-cell	B-DNA
receptor	I-DNA
alpha	I-DNA
(	I-DNA
TCR	I-DNA
alpha	I-DNA
)	I-DNA
enhancer	I-DNA
by	O
facilitating	O
the	O
assembly	O
of	O
multiple	B-protein
proteins	I-protein
into	O
a	O
higher	O
order	O
nucleoprotein	B-protein
complex	I-protein
.	O

The	O
function	O
of	O
LEF-1	B-protein
is	O
dependent	O
,	O
in	O
part	O
,	O
on	O
the	O
HMG	B-protein
domain	I-protein
that	O
induces	O
a	O
sharp	O
bend	O
in	O
the	O
DNA	O
helix	O
,	O
and	O
on	O
an	O
activation	B-protein
domain	I-protein
that	O
stimulates	O
transcription	O
only	O
in	O
a	O
specific	O
context	O
of	O
other	O
enhancer-binding	B-protein
proteins	I-protein
.	O

With	O
the	O
aim	O
of	O
gaining	O
insight	O
into	O
the	O
function	O
of	O
context-dependent	B-protein
activation	I-protein
domains	I-protein
,	O
we	O
cloned	O
ALY	B-protein
,	O
a	O
novel	O
LEF-1-interacting	B-protein
protein	I-protein
.	O

ALY	B-protein
is	O
a	O
ubiquitously	O
expressed	O
,	O
nuclear	O
protein	O
that	O
specifically	O
associates	O
with	O
the	O
activation	B-protein
domains	I-protein
of	O
LEF-1	B-protein
and	O
AML-1	B-protein
(	O
CBF	B-protein
alpha2	I-protein
,	O
PEBP2	B-protein
alpha	I-protein
(	O
B	O
)	O
,	O
which	O
is	O
another	O
protein	O
component	O
of	O
the	O
TCR	B-protein
alpha	I-protein
enhancer	I-protein
complex	I-protein
.	O

In	O
addition	O
,	O
ALY	B-protein
can	O
increase	O
DNA	O
binding	O
by	O
both	O
LEF-1	B-protein
and	O
AML	B-protein
proteins	I-protein
.	O

Overexpression	O
of	O
ALY	B-protein
stimulates	O
the	O
activity	O
of	O
the	O
TCR	B-protein
alpha	I-protein
enhancer	I-protein
complex	I-protein
reconstituted	O
in	O
transfected	B-cell_line
nonlymphoid	I-cell_line
HeLa	I-cell_line
cells	I-cell_line
,	O
whereas	O
down-regulation	O
of	O
ALY	B-protein
by	O
anti-sense	O
oligonucleotides	O
virtually	O
eliminates	O
TCR	B-DNA
alpha	I-DNA
enhancer	I-DNA
activity	O
in	O
T	B-cell_type
cells	I-cell_type
.	O

Similar	O
to	O
LEF-1	B-protein
,	O
ALY	B-protein
can	O
stimulate	O
transcription	O
in	O
the	O
context	O
of	O
the	O
TCR	B-DNA
alpha	I-DNA
enhancer	I-DNA
but	O
apparently	O
not	O
when	O
tethered	O
to	O
DNA	O
through	O
an	O
heterologous	B-protein
DNA-binding	I-protein
domain	I-protein
.	O

We	O
propose	O
that	O
ALY	B-protein
mediates	O
context-dependent	O
transcriptional	O
activation	O
by	O
facilitating	O
the	O
functional	O
collaboration	O
of	O
multiple	B-protein
proteins	I-protein
in	O
the	O
TCR	B-protein
alpha	I-protein
enhancer	I-protein
complex	I-protein
.	O

AML1a	B-protein
but	O
not	O
AML1b	B-protein
inhibits	O
erythroid	O
differentiation	O
induced	O
by	O
sodium	O
butyrate	O
and	O
enhances	O
the	O
megakaryocytic	O
differentiation	O
of	O
K562	B-cell_type
leukemia	I-cell_type
cells	I-cell_type
.	O

AML1	B-protein
may	O
play	O
a	O
role	O
in	O
growth	O
and	O
differentiation	O
of	O
cells	O
along	O
erythroid	B-cell_type
and/or	I-cell_type
megakaryocytic	I-cell_type
lineages	I-cell_type
,	O
because	O
a	O
significant	O
level	O
of	O
the	O
AML1	B-protein
gene	O
is	O
expressed	O
in	O
these	O
cells	O
.	O

We	O
overexpressed	O
AML1a	B-protein
(	O
without	O
the	O
transcription-activating	B-protein
domain	I-protein
)	O
and	O
AML1b	B-protein
(	O
with	O
the	O
domain	O
)	O
proteins	O
in	O
K562	B-cell_type
leukemia	I-cell_type
cells	I-cell_type
,	O
which	O
can	O
be	O
induced	O
to	O
differentiate	O
into	O
hemoglobin-producing	B-cell_type
cells	I-cell_type
and	O
megakaryocytes	B-cell_type
.	O

The	O
AML1a-transfected	B-cell_line
K562	I-cell_line
cells	I-cell_line
had	O
a	O
reduced	O
capacity	O
to	O
differentiate	O
in	O
the	O
presence	O
of	O
sodium	O
n-butyrate	O
but	O
not	O
in	O
the	O
presence	O
of	O
other	O
inducers	O
,	O
such	O
as	O
hemin	O
,	O
1-beta-D-arabinofuranosylcytosine	O
,	O
and	O
herbimycin	O
A	O
.	O

The	O
AML1	B-protein
antisense	O
oligodeoxynucleotide	O
but	O
not	O
the	O
sense	O
oligomer	O
recovered	O
its	O
differentiation-inducing	O
capacity	O
in	O
the	O
presence	O
of	O
butyrate	O
.	O

On	O
the	O
other	O
hand	O
,	O
AML1b	B-protein
conferred	O
a	O
similar	O
differentiation-inducing	O
capacity	O
upon	O
K562	B-cell_line
cells	I-cell_line
transfected	O
with	O
vector	O
alone	O
.	O

AML1a	B-protein
expression	O
was	O
associated	O
with	O
enhanced	O
sensitivity	O
to	O
megakaryocytic	O
differentiation	O
induced	O
by	O
phorbol	O
ester	O
.	O

These	O
results	O
provide	O
evidence	O
that	O
AML1	B-protein
proteins	O
play	O
a	O
role	O
in	O
erythroid	O
and	O
megakaryocytic	O
differentiation	O
.	O

Identification	O
of	O
sequence	O
alterations	O
in	O
the	O
upstream	B-DNA
regulatory	I-DNA
region	I-DNA
of	O
the	O
estrogen	B-DNA
receptor	I-DNA
gene	I-DNA
in	O
an	O
ER-negative	B-cell_line
breast	I-cell_line
cancer	I-cell_line
cell	I-cell_line
line	I-cell_line
.	O

Given	O
the	O
important	O
role	O
of	O
the	O
estrogen	B-protein
receptor	I-protein
(	O
ER	B-protein
)	O
in	O
the	O
development	O
and	O
physiology	O
of	O
the	O
breast	O
,	O
it	O
is	O
essential	O
to	O
delineate	O
the	O
mechanisms	O
responsible	O
for	O
its	O
failed	O
expression	O
in	O
some	O
breast	O
tumors	O
.	O

We	O
have	O
cloned	O
and	O
sequenced	O
a	O
portion	O
of	O
the	O
ER	B-protein
upstream	B-DNA
regulatory	I-DNA
region	I-DNA
from	O
the	O
ER-positive	B-cell_line
MCF-7	I-cell_line
and	O
the	O
ER-negative	B-cell_line
MDA-MB-231	I-cell_line
breast	I-cell_line
cancer	I-cell_line
cell	I-cell_line
lines	I-cell_line
to	O
determine	O
if	O
sequence	O
alterations	O
in	O
this	O
region	O
account	O
for	O
the	O
ER	B-protein
-negative	O
phenotype	O
of	O
some	O
tumors	O
.	O

From	O
this	O
,	O
we	O
identified	O
a	O
number	O
of	O
variations	O
between	O
the	O
sequences	O
,	O
two	O
of	O
which	O
were	O
determined	O
to	O
be	O
associated	O
with	O
a	O
50	O
%	O
decrease	O
in	O
CAT	B-protein
activity	O
.	O

Suppression	O
by	O
azelastine	O
hydrochloride	O
of	O
NF-kappa	B-protein
B	I-protein
activation	O
involved	O
in	O
generation	O
of	O
cytokines	B-protein
and	O
nitric	O
oxide	O
.	O

The	O
influence	O
of	O
the	O
anti-allergy	O
agent	O
azelastine	O
hydrochloride	O
(	O
Azeptin	O
)	O
on	O
NF-kappa	B-protein
B	I-protein
activation	O
associated	O
with	O
the	O
generation	O
of	O
cytokines	B-protein
and	O
nitric	O
oxide	O
(	O
NO	O
)	O
was	O
investigated	O
in	O
various	O
kinds	O
of	O
human	B-cell_type
and	I-cell_type
mouse	I-cell_type
cells	I-cell_type
.	O

Azeptin	O
dose-dependently	O
suppressed	O
both	O
DNA	O
and	O
protein	O
synthesis	O
in	O
human	B-cell_type
gingival	I-cell_type
fibroblasts	I-cell_type
(	O
HF	B-cell_type
)	O
and	O
also	O
suppressed	O
blastogenesis	O
of	O
human	B-cell_type
peripheral	I-cell_type
blood	I-cell_type
lymphocytes	I-cell_type
(	O
PBL	B-cell_type
)	O
.	O
Generation	O
of	O
tumor	B-protein
necrosis	I-protein
factor-alpha	I-protein
,	O
interleukin	B-protein
1-beta	I-protein
,	O
granulocyte-macrophage	B-protein
colony-stimulating	I-protein
factor	I-protein
and	O
interleukin-6	B-protein
from	O
10	O
(	O
-5	O
)	O
M	O
Azeptin-treated	O
PBL	B-cell_type
and	O
human	B-cell_type
monocytes	I-cell_type
(	O
HM	B-cell_type
)	O
was	O
decreased	O
to	O
approximately	O
1/3	O
to	O
2/3	O
of	O
the	O
control	O
levels	O
.	O

In	O
parallel	O
with	O
the	O
decreased	O
cytokine	B-protein
generation	O
,	O
each	O
cytokine	B-RNA
mRNA	I-RNA
was	O
less	O
expressed	O
in	O
the	O
presence	O
of	O
10	O
(	O
-5	O
)	O
M	O
Azeptin	O
.	O

In	O
addition	O
,	O
both	O
inducible	O
nitric	B-protein
oxide	I-protein
synthase	I-protein
-mRNA	O
level	O
and	O
NO	O
generation	O
in	O
mouse	B-cell_type
peritoneal	I-cell_type
macrophages	I-cell_type
were	O
suppressed	O
by	O
10	O
(	O
-5	O
)	O
M	O
Azeptin	O
.	O

Being	O
compatible	O
with	O
those	O
results	O
,	O
Azeptin	O
(	O
10	O
(	O
-5	O
)	O
M	O
)	O
suppressed	O
activation	O
of	O
NF-kappa	B-protein
B	I-protein
in	O
PBL	B-cell_type
,	O
HM	O
and	O
HF	B-cell_type
.	O

These	O
results	O
appear	O
to	O
indicate	O
that	O
suppression	O
of	O
cytokine	B-protein
and	O
NO	O
generation	O
by	O
Azeptin	O
results	O
at	O
least	O
partially	O
from	O
the	O
inhibition	O
of	O
NF-kappa	B-protein
B	I-protein
activation	O
.	O

Differential	O
interaction	O
of	O
nuclear	O
factors	O
with	O
the	O
PRE-I	B-DNA
enhancer	I-DNA
element	I-DNA
of	O
the	O
human	B-DNA
IL-4	I-DNA
promoter	I-DNA
in	O
different	O
T	B-cell_type
cell	I-cell_type
subsets	I-cell_type
.	O

The	O
immunomodulatory	O
cytokine	B-protein
IL-4	B-protein
affects	O
cells	O
of	O
most	O
hemopoietic	B-cell_type
lineages	I-cell_type
.	O

IL-4	B-protein
is	O
secreted	O
by	O
activated	O
Th2	B-cell_type
but	O
not	O
Th1	B-cell_type
cells	I-cell_type
and	O
plays	O
a	O
major	O
role	O
in	O
the	O
immune	O
response	O
by	O
modulating	O
the	O
differentiation	O
of	O
naive	B-cell_type
Th	I-cell_type
cells	I-cell_type
toward	O
the	O
Th2	B-cell_type
phenotype	I-cell_type
.	O

We	O
have	O
previously	O
identified	O
an	O
enhancer	B-DNA
element	I-DNA
,	O
PRE-I	B-DNA
,	O
that	O
is	O
essential	O
for	O
the	O
function	O
of	O
the	O
human	B-DNA
IL-4	I-DNA
promoter	I-DNA
.	O

To	O
investigate	O
the	O
mechanisms	O
responsible	O
for	O
tissue-specific	O
expression	O
of	O
the	O
IL-4	B-protein
gene	O
,	O
we	O
analyzed	O
nuclear	B-protein
factors	I-protein
binding	O
to	O
the	O
PRE-I	B-DNA
site	I-DNA
and	O
compared	O
the	O
binding	O
activities	O
of	O
these	O
factors	O
to	O
the	O
IL-4	B-protein
promoter	O
of	O
Th1	B-cell_type
and	I-cell_type
Th2	I-cell_type
cells	I-cell_type
.	O

We	O
show	O
that	O
PRE-I	B-DNA
interacts	O
with	O
PMA	O
-and	O
PMA/ionomycin-inducible	O
,	O
cyclosporin	O
A-sensitive	O
nuclear	B-protein
factors	I-protein
.	O

Using	O
anti-C/EBPbeta	B-protein
(	O
NF-IL6	B-protein
)	O
,	O
anti-C/EBPdelta	B-protein
(	O
NF-IL6beta	B-protein
)	O
,	O
anti-NF-ATc	B-protein
,	O
anti-NF-ATp	B-protein
,	O
anti-Fos	B-protein
,	O
and	O
anti-Jun	B-protein
Abs	I-protein
we	O
demonstrate	O
that	O
the	O
previously	O
identified	O
PRE-I	B-protein
binding	I-protein
factor	I-protein
POS-1	B-protein
is	O
composed	O
of	O
different	O
transcription	B-protein
factors	I-protein
in	O
different	O
Th	O
cell	O
subsets	O
.	O

In	O
the	O
IL-4-producing	B-cell_line
Th0-like	I-cell_line
human	I-cell_line
Jurkat	I-cell_line
and	O
mouse	B-cell_line
EL-4	I-cell_line
cells	I-cell_line
,	O
POS-1	B-protein
(	O
designated	O
POS-1a	B-protein
)	O
contains	O
NF-IL6beta	B-protein
and	O
Jun	B-protein
.	O

In	O
the	O
mouse	B-cell_line
Th2	I-cell_line
D10	I-cell_line
cells	I-cell_line
and	O
in	O
the	O
human	B-cell_line
Th2	I-cell_line
clones	I-cell_line
,	O
POS-1	B-protein
(	O
designated	O
POS-1b	B-protein
)	O
contains	O
NF-IL6beta	B-protein
,	O
Jun	B-protein
,	O
and	O
NF-ATc/p	B-protein
.	O

In	O
contrast	O
,	O
POS-1	B-protein
was	O
not	O
found	O
in	O
nuclear	O
extracts	O
of	O
human	B-cell_line
Th1	I-cell_line
clones	I-cell_line
.	O

These	O
findings	O
suggest	O
that	O
PRE-I	B-DNA
may	O
play	O
a	O
role	O
in	O
the	O
differential	O
regulation	O
of	O
IL-4	B-DNA
gene	I-DNA
expression	O
levels	O
.	O

Regulation	O
of	O
human	O
epsilon	O
germline	B-DNA
transcription	O
:	O
role	O
of	O
B-cell-specific	B-protein
activator	I-protein
protein	I-protein
.	O

Germline	B-protein
transcripts	I-protein
initiate	O
from	O
promoters	B-DNA
upstream	O
of	O
the	O
immunoglobulin	B-DNA
switch	I-DNA
region	I-DNA
,	O
and	O
are	O
necessary	O
to	O
target	O
the	O
appropriate	O
switch	O
region	O
for	O
recombination	O
and	O
switching	O
.	O

Different	O
cytokines	B-protein
activate	O
transcription	O
at	O
the	O
appropriate	O
germline	B-DNA
promoter	I-DNA
.	O

Because	O
binding	B-DNA
sites	I-DNA
for	O
B-cell-specific	B-protein
activator	I-protein
protein	I-protein
(	O
BSAP	B-protein
)	O
are	O
located	O
upstream	O
of	O
several	O
switch	O
regions	O
in	O
the	O
immunoglobulin	B-DNA
heavy	I-DNA
chain	I-DNA
gene	I-DNA
cluster	I-DNA
,	O
BSAP	B-protein
might	O
play	O
a	O
role	O
in	O
the	O
regulation	O
of	O
germline	B-DNA
transcription	O
and	O
isotype	O
switching	O
.	O

We	O
investigated	O
whether	O
BSAP	B-protein
plays	O
a	O
role	O
in	O
the	O
transcriptional	O
regulation	O
of	O
the	O
epsilon	O
germline	B-DNA
promoter	I-DNA
in	O
human	B-cell_type
B	I-cell_type
cells	I-cell_type
.	O

Our	O
results	O
showed	O
that	O
BSAP	B-protein
plays	O
a	O
role	O
in	O
both	O
IL-4	B-protein
-dependent	O
induction	O
and	O
CD40	B-protein
-mediated	O
upregulation	O
of	O
human	O
epsilon	O
germline	B-DNA
transcription	O
.	O

BSAP	B-protein
is	O
unique	O
among	O
the	O
transcription	B-protein
factors	I-protein
that	O
regulate	O
epsilon	O
germline	B-DNA
expression	O
,	O
because	O
it	O
is	O
B	O
cell	O
specific	O
,	O
and	O
is	O
at	O
the	O
merging	O
point	O
of	O
two	O
signalling	O
pathways	O
that	O
are	O
critical	O
for	O
IgE	B-protein
switching	O
.	O

Experimental	O
expression	O
in	O
mice	O
and	O
spontaneous	O
expression	O
in	O
human	O
SLE	O
of	O
polyomavirus	B-protein
T-antigen	I-protein
.	O

A	O
molecular	O
basis	O
for	O
induction	O
of	O
antibodies	B-protein
to	O
DNA	O
and	O
eukaryotic	B-protein
transcription	I-protein
factors	I-protein
.	O

We	O
have	O
previously	O
demonstrated	O
that	O
experimental	O
expression	O
of	O
the	O
polyomavirus	B-protein
transcription	I-protein
factor	I-protein
T-antigen	I-protein
has	O
the	O
potential	O
to	O
induce	O
anti-DNA	B-protein
antibodies	I-protein
in	O
mice	O
.	O

Two	O
sets	O
of	O
independent	O
evidences	O
are	O
presented	O
here	O
that	O
demonstrate	O
a	O
biological	O
relevance	O
for	O
this	O
model	O
.	O

First	O
,	O
we	O
describe	O
results	O
demonstrating	O
that	O
mice	O
inoculated	O
with	O
T-antigen-expressing	B-DNA
plasmids	I-DNA
produced	O
antibodies	B-protein
,	O
not	O
only	O
to	O
T-antigen	B-protein
and	O
DNA	O
,	O
but	O
also	O
to	O
the	O
DNA-binding	B-protein
eukaryotic	I-protein
transcription	I-protein
factors	I-protein
TATA-binding	B-protein
protein	I-protein
(	O
TBP	B-protein
)	O
,	O
and	O
to	O
the	O
cAMP-response-element-binding	B-protein
protein	I-protein
(	O
CREB	B-protein
)	O
.	O

Secondly	O
,	O
we	O
investigated	O
whether	O
polyomavirus	O
reactivation	O
occurs	O
in	O
SLE	O
patients	O
,	O
and	O
whether	O
antibodies	B-protein
to	O
T-antigen	B-protein
,	O
DNA	O
,	O
and	O
to	O
TBP	B-protein
and	O
CREB	B-protein
are	O
linked	O
to	O
such	O
events	O
.	O

Both	O
within	O
and	O
among	O
these	O
SLE	O
patients	O
,	O
frequent	O
polyomavirus	O
reactivations	O
were	O
observed	O
that	O
could	O
not	O
be	O
explained	O
by	O
certain	O
rearrangements	O
of	O
the	O
noncoding	O
control	O
regions	O
,	O
nor	O
by	O
corticosteroid	O
treatment	O
.	O

Linked	O
to	O
these	O
events	O
,	O
antibodies	B-protein
to	O
T-antigen	B-protein
,	O
DNA	O
,	O
TBP	B-protein
,	O
and	O
CREB	B-protein
were	O
detected	O
,	O
identical	O
to	O
what	O
we	O
observed	O
in	O
mice	O
.	O

Antibodies	O
recognizing	O
double-stranded	O
DNA	O
were	O
confined	O
to	O
patients	O
with	O
frequent	O
polyomavirus	O
reactivations	O
.	O

The	O
results	O
described	O
here	O
indicate	O
that	O
cognate	O
interaction	O
of	O
B	O
cells	O
recognizing	O
DNA	O
or	O
DNA-associated	B-protein
proteins	I-protein
and	O
T	B-cell_type
cells	I-cell_type
recognizing	O
T	B-protein
antigen	I-protein
had	O
taken	O
place	O
as	O
a	O
consequence	O
of	O
complex	O
formation	O
between	O
T	B-protein
ag	I-protein
and	O
DNA	O
in	O
vivo	O
in	O
the	O
context	O
of	O
polyomavirus	O
reactivations	O
.	O

Jak3	B-protein
is	O
associated	O
with	O
CD40	B-protein
and	O
is	O
critical	O
for	O
CD40	B-protein
induction	O
of	O
gene	O
expression	O
in	O
B	B-cell_type
cells	I-cell_type
.	O

CD40	B-protein
is	O
a	O
receptor	O
that	O
is	O
critical	O
for	O
the	O
survival	O
,	O
growth	O
,	O
differentiation	O
,	O
and	O
isotype	O
switching	O
of	O
B	B-cell_type
lymphocytes	I-cell_type
.	O

Although	O
CD40	B-protein
lacks	O
intrinsic	O
tyrosine	O
kinase	O
activity	O
,	O
its	O
ligation	O
induces	O
protein	O
tyrosine	O
phosphorylation	O
,	O
which	O
is	O
necessary	O
for	O
several	O
CD40	B-protein
-mediated	O
events	O
.	O

We	O
show	O
that	O
engagement	O
of	O
CD40	B-protein
induces	O
tyrosine	O
phosphorylation	O
and	O
activation	O
of	O
Jak3	B-protein
as	O
well	O
as	O
of	O
STAT3	B-protein
.	O

Jak3	B-protein
is	O
constitutively	O
associated	O
with	O
CD40	B-protein
,	O
and	O
this	O
interaction	O
requires	O
a	O
proline-rich	B-protein
sequence	I-protein
in	O
the	O
membrane-proximal	B-protein
region	I-protein
of	O
CD40	B-protein
.	O

Deletion	O
of	O
this	O
sequence	O
abolishes	O
the	O
capacity	O
of	O
CD40	B-protein
to	O
induce	O
expression	O
of	O
CD23	B-protein
,	O
ICAM-1	B-protein
,	O
and	O
lymphotoxin-alpha	B-DNA
genes	I-DNA
in	O
B	B-cell_type
cells	I-cell_type
.	O

These	O
results	O
indicate	O
that	O
signaling	O
through	O
Jak3	B-protein
is	O
activated	O
by	O
CD40	B-protein
and	O
plays	O
an	O
important	O
role	O
in	O
CD40	B-protein
-mediated	O
functions	O
.	O

Transcription	B-protein
factors	I-protein
required	O
for	O
lymphoid	O
lineage	O
commitment	O
.	O

Intimate	O
interactions	O
between	O
multipotential	O
hemopoietic	B-cell_type
stem	I-cell_type
cells	I-cell_type
and	O
their	O
microenvironment	O
work	O
towards	O
redefining	O
the	O
identity	O
and	O
the	O
differentiative	O
fate	O
of	O
these	O
primitive	B-cell_type
cells	I-cell_type
.	O

Molecular	O
cues	O
delivered	O
by	O
the	O
microenvironment	O
frequently	O
act	O
in	O
an	O
instructive	O
fashion	O
by	O
initiating	O
intracellular	O
signaling	O
pathways	O
that	O
ultimately	O
target	O
a	O
select	O
group	O
of	O
transcription	B-protein
factors	I-protein
.	O

These	O
transcriptional	O
regulators	O
in	O
turn	O
trigger	O
a	O
cascade	O
of	O
genetic	O
changes	O
that	O
ultimately	O
determine	O
the	O
course	O
of	O
the	O
cells	O
during	O
differentiation	O
.	O

Gene	O
inactivation	O
studies	O
on	O
the	O
PU.1	B-DNA
,	I-DNA
Ikaros	I-DNA
and	I-DNA
GATA-3	I-DNA
genes	I-DNA
have	O
revealed	O
that	O
their	O
encoded	O
factors	O
are	O
essential	O
for	O
the	O
earliest	O
commitment	O
step	O
into	O
the	O
B	B-cell_type
and	I-cell_type
T	I-cell_type
lymphoid	I-cell_type
lineages	I-cell_type
.	O

Interleukin-4	B-protein
signaling	O
in	O
B	B-cell_type
lymphocytes	I-cell_type
from	O
patients	O
with	O
X-linked	O
severe	O
combined	O
immunodeficiency	O
.	O

Interleukin-4	B-protein
(	O
IL-4	B-protein
)	O
is	O
an	O
important	O
cytokine	O
for	O
B	O
and	O
T	O
lymphocyte	O
function	O
and	O
mediates	O
its	O
effects	O
via	O
a	O
receptor	O
that	O
contains	O
gammac	B-protein
.	O

B	B-cell_type
cells	I-cell_type
derived	O
from	O
patients	O
with	O
X-linked	O
severe	O
combined	O
immunodeficiency	O
(	O
X-SCID	O
)	O
are	O
deficient	O
in	O
gammac	O
and	O
provide	O
a	O
useful	O
model	O
in	O
which	O
to	O
dissect	O
the	O
role	O
of	O
this	O
subunit	O
in	O
IL-4	B-protein
-mediated	O
signaling	O
.	O

We	O
found	O
that	O
although	O
IL-4	B-protein
stimulation	O
of	O
X-SCID	B-cell_type
B	I-cell_type
cells	I-cell_type
did	O
not	O
result	O
in	O
Janus	B-protein
tyrosine	I-protein
kinase-3	I-protein
(	O
JAK3	B-protein
)	O
phosphorylation	O
,	O
other	O
IL-4	B-protein
substrates	I-protein
including	O
JAK1	B-protein
and	O
IRS-1	B-protein
were	O
phosphorylated	O
.	O

Additionally	O
,	O
we	O
detected	O
signal	B-protein
transducers	I-protein
and	I-protein
activators	I-protein
of	I-protein
transcription	I-protein
6	I-protein
(	O
STAT6	B-protein
)	O
tyrosine	O
phosphorylation	O
and	O
DNA	O
binding	O
activity	O
in	O
X-SCID	B-cell_type
B	I-cell_type
cells	I-cell_type
with	O
a	O
wide	O
range	O
of	O
gammac	B-protein
mutations	O
.	O

However	O
,	O
reconstitution	O
of	O
these	O
X-SCID	B-cell_type
B	I-cell_type
cells	I-cell_type
with	O
gammac	B-protein
enhanced	O
IL-4	B-protein
-mediated	O
responses	O
including	O
STAT6	B-protein
phosphorylation	O
and	O
DNA	O
binding	O
activity	O
and	O
resulted	O
in	O
increased	O
CD23	B-protein
expression	O
.	O

Thus	O
,	O
gammac	B-protein
is	O
not	O
necessary	O
to	O
trigger	O
IL-4	B-protein
-mediated	O
responses	O
in	O
B	B-cell_type
cells	I-cell_type
,	O
but	O
its	O
presence	O
is	O
important	O
for	O
optimal	O
IL-4	B-protein
-signaling	O
.	O

These	O
results	O
suggest	O
that	O
two	O
distinct	O
IL-4	B-protein
signaling	O
pathways	O
exist	O
.	O

Cell-to-cell	O
contact	O
activates	O
the	O
long	B-DNA
terminal	I-DNA
repeat	I-DNA
of	O
human	O
immunodeficiency	O
virus	O
1	O
through	O
its	O
kappaB	B-DNA
motif	I-DNA
.	O

Cell-to-cell	O
contact	O
between	O
peripheral	B-cell_type
blood	I-cell_type
lymphocytes	I-cell_type
and	O
transfected	B-cell_line
human	I-cell_line
colonic	I-cell_line
carcinoma	I-cell_line
cell	I-cell_line
line	I-cell_line
HT29	I-cell_line
activates	O
transcription	O
of	O
the	O
long	B-DNA
terminal	I-DNA
repeats	I-DNA
(	O
LTR	B-DNA
)	O
of	O
human	O
immunodeficiency	O
virus	O
.	O

HIV-1	B-DNA
LTR	I-DNA
transcription	O
is	O
controlled	O
by	O
a	O
complex	O
array	O
of	O
virus-encoded	B-protein
and	I-protein
cellular	I-protein
proteins	I-protein
.	O

Using	O
various	O
constructs	O
expressing	O
a	O
lacZ	B-DNA
reporter	I-DNA
gene	I-DNA
under	O
the	O
control	O
of	O
the	O
intact	O
or	O
three	O
deleted	O
forms	O
of	O
HIV-1	B-DNA
LTR	I-DNA
,	O
we	O
obtained	O
evidence	O
that	O
the	O
kappaB	B-DNA
regulatory	I-DNA
elements	I-DNA
located	O
in	O
the	O
U3	B-DNA
region	I-DNA
are	O
involved	O
in	O
cell-to-cell	O
activation	O
of	O
HIV-1	B-DNA
LTR	I-DNA
.	O

Cell-to-cell	O
contact	O
activates	O
in	O
vitro	O
binding	O
of	O
the	O
nuclear	B-protein
factor	I-protein
kappaB	I-protein
(	I-protein
NF-kappaB	I-protein
)	I-protein
p50/p65	I-protein
heterodimer	I-protein
to	O
an	O
HIV-1	O
kappaB	O
oligonucleotide	O
.	O

Cell-to-cell	O
contact	O
activation	O
of	O
NF-kappaB	B-protein
was	O
only	O
partially	O
inhibited	O
by	O
100	O
microM	O
pyrrolidine	O
dithiocarbamate	O
and	O
was	O
not	O
correlated	O
with	O
a	O
significant	O
decrease	O
of	O
cellular	B-protein
inhibitor	I-protein
kappaB	I-protein
alpha	I-protein
.	O

NF-kappaB	B-protein
nuclear	O
activation	O
was	O
not	O
detectable	O
before	O
1	O
h	O
after	O
cell	O
contact	O
and	O
was	O
dependent	O
on	O
protein	O
synthesis	O
.	O

Identification	O
of	O
nucleotide	B-DNA
sequences	I-DNA
that	O
regulate	O
transcription	O
of	O
the	O
MCF13	O
murine	O
leukemia	O
virus	O
long	B-DNA
terminal	I-DNA
repeat	I-DNA
in	O
activated	O
T	B-cell_type
cells	I-cell_type
.	O

The	O
region	O
downstream	O
of	O
the	O
enhancer	B-DNA
(	O
DEN	B-DNA
)	O
of	O
the	O
long	B-DNA
terminal	I-DNA
repeat	I-DNA
of	O
the	O
mink	O
cell	O
focus-forming	O
murine	O
leukemia	O
virus	O
is	O
important	O
for	O
viral	O
pathogenicity	O
.	O

Another	O
important	O
activity	O
of	O
DEN	B-DNA
is	O
its	O
control	O
of	O
transcription	O
in	O
activated	B-cell_type
T	I-cell_type
cells	I-cell_type
,	O
and	O
we	O
have	O
determined	O
that	O
an	O
NF-kappaB	B-protein
site	O
is	O
critical	O
for	O
this	O
activity	O
.	O

Possible	O
role	O
of	O
nuclear	B-protein
factor-kappa	I-protein
B	I-protein
activity	O
in	O
germline	B-DNA
C	O
epsilon	O
transcription	O
in	O
a	O
human	B-cell_line
Burkitt	I-cell_line
lymphoma	I-cell_line
B	I-cell_line
cell	I-cell_line
line	I-cell_line
.	O

Nuclear	B-protein
factor-kappa	I-protein
B	I-protein
(	O
NF-kappa	B-protein
B	I-protein
)	O
plays	O
a	O
broad	O
role	O
in	O
gene	O
regulation	O
,	O
but	O
it	O
is	O
not	O
evident	O
whether	O
NF-kappa	B-protein
B	I-protein
acts	O
as	O
a	O
messenger	O
system	O
for	O
germline	B-DNA
C	O
epsilon	O
transcription	O
.	O

We	O
report	O
here	O
that	O
the	O
signaling	O
cascade	O
triggered	O
by	O
interleukin-4	B-protein
(	O
IL-4	B-protein
)	O
or	O
anti-CD40	B-protein
monoclonal	I-protein
antibody	I-protein
(	O
mAb	B-protein
)	O
participates	O
in	O
NF-kappa	B-protein
B	I-protein
activation	O
responsible	O
for	O
germline	B-DNA
C	O
epsilon	O
transcription	O
in	O
a	O
human	B-cell_line
Burkitt	I-cell_line
lymphoma	I-cell_line
B	I-cell_line
cell	I-cell_line
line	I-cell_line
,	O
DND39	B-cell_line
.	O

Both	O
IL-4	B-protein
and	O
anti-	O
CD40	B-protein
mAb	I-protein
induced	O
activation	O
of	O
phosphatidylinositol	B-protein
3-kinase	I-protein
(	O
PI3-kinase	B-protein
)	O
,	O
translocation	O
of	O
a	O
zeta	O
isoform	O
of	O
protein	B-protein
kinase	I-protein
C	I-protein
,	O
and	O
nuclear	O
expression	O
of	O
NF-kappa	B-protein
B	I-protein
.	O

All	O
such	O
events	O
were	O
abrogated	O
by	O
treatment	O
with	O
LY294002	O
,	O
a	O
specific	O
inhibitor	O
of	O
PI3-kinase	B-protein
.	O

In	O
addition	O
,	O
N-acetyl-L-cysteine	O
(	O
NAC	O
)	O
,	O
a	O
potent	O
antioxidant	O
,	O
decreased	O
NF-kappa	B-protein
B	I-protein
activation	O
caused	O
by	O
IL-4	B-protein
,	O
anti-CD40	B-protein
mAb	I-protein
,	O
or	O
their	O
combination	O
.	O

NAC	O
was	O
also	O
effective	O
in	O
diminishing	O
germline	B-DNA
C	O
epsilon	O
transcription	O
,	O
and	O
its	O
potency	O
was	O
higher	O
in	O
cultures	O
costimulated	O
with	O
IL-4	B-protein
and	O
anti-CD40	B-protein
mAb	I-protein
than	O
in	O
those	O
stimulated	O
with	O
IL-4	B-protein
alone	O
.	O

These	O
results	O
indicate	O
that	O
IL-4	B-protein
and	O
ligation	O
of	O
CD40	B-protein
induce	O
NF-kappa	B-protein
B	I-protein
expression	O
via	O
at	O
least	O
a	O
mechanism	O
dependent	O
on	O
the	O
PI3-kinase	B-protein
pathway	O
and	O
suggest	O
that	O
NF-kappa	B-protein
B	I-protein
sensitive	O
to	O
NAC	O
may	O
play	O
a	O
role	O
in	O
regulating	O
germline	B-DNA
C	O
epsilon	O
transcription	O
.	O

Differentiation	O
of	O
U-937	B-cell_line
promonocytic	I-cell_line
cells	I-cell_line
by	O
etoposide	O
and	O
ICRF-193	O
,	O
two	O
antitumour	O
DNA	B-protein
topoisomerase	I-protein
II	I-protein
inhibitors	O
with	O
different	O
mechanisms	O
of	O
action	O
.	O

We	O
have	O
compared	O
the	O
action	O
on	O
U-937	B-cell_line
human	I-cell_line
promonocytic	I-cell_line
leukemia	I-cell_line
cells	I-cell_line
of	O
two	O
DNA	B-protein
topoisomerase	I-protein
II	I-protein
inhibitors	O
,	O
namely	O
the	O
epipodophyllotoxin	O
etoposide	O
and	O
the	O
bisdioxopiperazine	O
ICRF-193	O
.	O

One	O
hour	O
pulse-treatment	O
with	O
3	O
microM	O
etoposide	O
caused	O
topoisomerase	B-protein
associated	O
,	O
primary	O
DNA	O
breakage	O
,	O
which	O
was	O
rapidly	O
followed	O
by	O
apoptosis	O
.	O

By	O
contrast	O
,	O
these	O
effects	O
were	O
not	O
observed	O
upon	O
pulse-treatment	O
with	O
6	O
microM	O
ICRF-193	O
.	O

However	O
,	O
continuous	O
treatments	O
with	O
subcytotoxic	O
concentrations	O
of	O
etoposide	O
(	O
0.15	O
microM	O
)	O
and	O
ICRF-193	O
(	O
0.3	O
microM	O
)	O
produced	O
several	O
similar	O
effects	O
,	O
namely	O
decreased	O
cell	O
proliferation	O
,	O
accumulation	O
of	O
cells	O
at	O
G2	O
,	O
increase	O
in	O
cell	O
mass	O
,	O
and	O
induction	O
of	O
differentiation	O
.	O

Under	O
these	O
conditions	O
,	O
etoposide	O
produced	O
a	O
biphasic	O
activation	O
of	O
protein	B-protein
kinase	I-protein
C	I-protein
,	O
which	O
consisted	O
in	O
an	O
early	O
transient	O
activation	O
(	O
from	O
hours	O
1	O
to	O
6	O
)	O
of	O
the	O
membrane-bound	B-protein
enzyme	I-protein
followed	O
by	O
a	O
later	O
activation	O
(	O
hour	O
48	O
)	O
of	O
the	O
total	O
,	O
membrane-bound	B-protein
and	I-protein
cytosolic	I-protein
enzyme	I-protein
.	O

By	O
contrast	O
,	O
ICRF-193	O
only	O
provoked	O
a	O
late	O
activation	O
(	O
from	O
hours	O
72	O
to	O
96	O
)	O
of	O
the	O
total	O
enzyme	O
.	O

When	O
used	O
at	O
differentiation-inducing	O
concentrations	O
,	O
both	O
topoisomerase	B-protein
inhibitors	O
caused	O
a	O
great	O
stimulation	O
of	O
AP-1	B-protein
binding	O
activity	O
,	O
with	O
maximum	O
value	O
at	O
hour	O
12	O
in	O
etoposide-treated	O
cells	O
and	O
at	O
hour	O
48	O
in	O
ICRF-193-treated	B-cell_type
cells	I-cell_type
.	O

By	O
contrast	O
,	O
the	O
binding	O
activity	O
of	O
the	O
NF-kappa	B-protein
(	I-protein
B	I-protein
)	I-protein
and	O
EGR-1	B-protein
transcription	B-protein
factors	I-protein
was	O
little	O
affected	O
.	O

It	O
is	O
concluded	O
that	O
topoisomerase	O
II	O
inhibitors	O
may	O
induce	O
the	O
differentiation	O
of	O
promonocytic	O
cells	O
,	O
independently	O
of	O
their	O
capacity	O
to	O
cause	O
DNA	O
strand	O
breaks	O
.	O

However	O
,	O
there	O
are	O
other	O
effects	O
,	O
such	O
as	O
the	O
early	O
activation	O
of	O
protein	B-protein
kinase	I-protein
C	I-protein
,	O
which	O
are	O
probably	O
derived	O
from	O
the	O
production	O
of	O
primary	O
DNA	O
breakage	O
by	O
some	O
anti-	O
topoisomerase	B-protein
drugs	O
.	O

GATA-1	B-protein
DNA	O
binding	O
activity	O
is	O
down-regulated	O
in	O
late	O
S	O
phase	O
in	O
erythroid	B-cell_type
cells	I-cell_type
.	O

We	O
have	O
set	O
out	O
to	O
test	O
a	O
model	O
for	O
tissue-specific	O
gene	O
expression	O
that	O
relies	O
on	O
the	O
early	O
replication	O
of	O
expressed	O
genes	O
to	O
sequester	O
limiting	O
activating	O
transcription	B-protein
factors	I-protein
.	O

Using	O
an	O
erythroid	B-cell_line
cell	I-cell_line
line	I-cell_line
,	O
we	O
have	O
tested	O
the	O
changes	O
in	O
the	O
DNA	O
binding	O
activity	O
of	O
the	O
lineage-restricted	B-protein
transcription	I-protein
factor	I-protein
GATA-1	B-protein
through	O
the	O
cell	O
cycle	O
.	O

We	O
find	O
that	O
GATA-1	B-protein
activity	O
is	O
low	O
in	O
G1	O
,	O
peaks	O
in	O
mid-S	O
phase	O
,	O
and	O
then	O
decreases	O
in	O
G2/M	O
.	O

In	O
contrast	O
,	O
the	O
binding	O
activities	O
of	O
two	O
ubiquitous	O
transcription	B-protein
factors	I-protein
,	O
Oct1	B-protein
and	O
Sp1	B-protein
,	O
remain	O
high	O
in	O
G2/M	O
.	O

GATA-1	B-protein
protein	O
and	O
mRNA	B-RNA
vary	O
in	O
a	O
similar	O
manner	O
through	O
the	O
cell	O
cycle	O
,	O
suggesting	O
that	O
the	O
expression	O
of	O
the	O
gene	O
or	O
the	O
stability	O
of	O
its	O
message	O
is	O
regulated	O
.	O

Although	O
a	O
number	O
of	O
transcription	B-protein
factors	I-protein
involved	O
in	O
the	O
control	O
of	O
the	O
cell	O
cycle	O
or	O
DNA	O
replication	O
have	O
been	O
shown	O
to	O
peak	O
in	O
S	O
phase	O
,	O
this	O
is	O
the	O
first	O
example	O
of	O
a	O
lineage-restricted	B-protein
transcription	I-protein
factor	I-protein
displaying	O
S	O
phase-specific	O
DNA	O
binding	O
activity	O
.	O

One	O
interpretation	O
of	O
these	O
data	O
leads	O
to	O
a	O
model	O
in	O
which	O
the	O
peak	O
in	O
GATA-1	B-protein
DNA	O
binding	O
amplifies	O
the	O
effect	O
of	O
early	O
replication	O
on	O
the	O
activation	O
of	O
erythroid-specific	B-DNA
genes	I-DNA
at	O
the	O
same	O
time	O
as	O
preventing	O
activation	O
of	O
non-erythroid	B-DNA
genes	I-DNA
containing	O
GATA-responsive	B-DNA
elements	I-DNA
.	O

These	O
results	O
may	O
also	O
relate	O
to	O
recent	O
data	O
implicating	O
GATA-1	B-protein
function	O
in	O
apoptosis	O
and	O
cell	O
cycle	O
progression	O

Activation	O
of	O
the	O
NF-kappaB	B-protein
pathway	O
by	O
inflammatory	O
stimuli	O
in	O
human	B-cell_type
neutrophils	I-cell_type
.	O

Activated	B-cell_type
neutrophils	I-cell_type
have	O
the	O
ability	O
to	O
upregulate	O
the	O
expression	O
of	O
many	O
genes	O
,	O
in	O
particular	O
those	O
encoding	O
cytokines	B-protein
and	O
chemokines	B-protein
,	O
and	O
to	O
subsequently	O
release	O
the	O
corresponding	O
proteins	O
.	O

Although	O
little	O
is	O
known	O
to	O
date	O
concerning	O
the	O
regulation	O
of	O
gene	O
transcription	O
in	O
neutrophils	B-cell_type
,	O
it	O
is	O
noteworthy	O
that	O
many	O
of	O
these	O
genes	O
depend	O
on	O
the	O
activation	O
of	O
transcription	B-protein
factors	I-protein
,	O
such	O
as	O
NF-kappaB	B-protein
,	O
for	O
inducible	O
expression	O
.	O

We	O
therefore	O
investigated	O
whether	O
NF-kappaB/Rel	B-protein
proteins	I-protein
are	O
expressed	O
in	O
human	B-cell_type
neutrophils	I-cell_type
,	O
as	O
well	O
as	O
their	O
fate	O
on	O
cell	O
activation	O
.	O

We	O
now	O
report	O
that	O
dimers	O
consisting	O
of	O
p50	B-protein
NFkappaB1	I-protein
,	O
p65	B-protein
RelA	I-protein
,	O
and/or	O
c-Rel	B-protein
are	O
present	O
in	O
neutrophils	B-cell_type
and	O
that	O
the	O
greater	O
part	O
of	O
these	O
protein	B-protein
complexes	I-protein
is	O
physically	O
associated	O
with	O
cytoplasmic	B-protein
IkappaB-alpha	I-protein
in	O
resting	O
cells	O
.	O

Following	O
neutrophil	O
stimulation	O
with	O
proinflammatory	O
agonists	O
(	O
such	O
as	O
lipopolysaccharide	O
[	O
LPS	O
]	O
,	O
tumor	B-protein
necrosis	I-protein
factor-alpha	I-protein
[	O
TNF-alpha	B-protein
]	O
,	O
and	O
fMet-Leu-Phe	O
)	O
that	O
induce	O
the	O
production	O
of	O
cytokines	B-protein
and	O
chemokines	B-protein
in	O
these	O
cells	O
,	O
NF-kappaB/Rel	B-protein
proteins	I-protein
translocated	O
to	O
nuclear	O
fractions	O
,	O
resulting	O
in	O
a	O
transient	O
induction	O
of	O
NF-kappaB	B-protein
DNA	O
binding	O
activity	O
,	O
as	O
determined	O
in	O
gel	O
mobility	O
shift	O
assays	O
.	O

The	O
onset	O
of	O
both	O
processes	O
was	O
found	O
to	O
be	O
closely	O
paralleled	O
by	O
,	O
and	O
dependent	O
on	O
,	O
IkappaB-alpha	B-protein
degradation	O
.	O

Proinflammatory	B-cell_type
neutrophil	I-cell_type
stimuli	O
also	O
promoted	O
the	O
accumulation	O
of	O
IkappaB-alpha	B-RNA
mRNA	I-RNA
transcripts	I-RNA
,	O
resulting	O
in	O
the	O
reexpression	O
of	O
the	O
IkappaB-alpha	B-protein
protein	I-protein
.	O

To	O
our	O
knowledge	O
,	O
this	O
constitutes	O
the	O
first	O
indication	O
that	O
NF-kappaB	B-protein
activation	O
may	O
underlie	O
the	O
action	O
of	O
proinflammatory	O
stimuli	O
towards	O
human	O
neutrophil	O
gene	O
expression	O
and	O
,	O
as	O
such	O
,	O
adds	O
a	O
new	O
facet	O
to	O
our	O
understanding	O
of	O
neutrophil	B-cell_type
biology	I-cell_type
.	O

Two	O
distinct	O
pathways	O
of	O
interleukin-5	B-protein
synthesis	O
in	O
allergen-specific	B-cell_line
human	I-cell_line
T-cell	I-cell_line
clones	I-cell_line
are	O
suppressed	O
by	O
glucocorticoids	O
.	O

Glucocorticoids	O
(	O
GC	O
)	O
have	O
long	O
been	O
used	O
as	O
the	O
most	O
effective	O
agents	O
for	O
the	O
treatment	O
of	O
allergic	O
diseases	O
accompanied	O
by	O
eosinophilia	O
such	O
as	O
chronic	O
asthma	O
and	O
atopic	O
dermatitis	O
.	O

The	O
development	O
of	O
chronic	O
eosinophilic	O
inflammation	O
is	O
dependent	O
on	O
interleukin-5	B-protein
(	O
IL-5	B-protein
)	O
,	O
a	O
selective	B-protein
eosinophil-activating	I-protein
factor	I-protein
,	O
produced	O
by	O
helper	B-cell_type
T	I-cell_type
cells	I-cell_type
.	O

To	O
delineate	O
the	O
regulatory	O
mechanisms	O
of	O
human	O
IL-5	B-protein
synthesis	O
,	O
we	O
established	O
allergen-specific	B-cell_line
CD4+	I-cell_line
T-cell	I-cell_line
clones	I-cell_line
from	O
asthmatic	O
patients	O
.	O

GC	O
efficiently	O
suppressed	O
IL-5	B-protein
synthesis	O
of	O
T-cell	O
clones	O
activated	O
via	O
either	O
T-cell	B-protein
receptor	I-protein
(	O
TCR	B-protein
)	O
or	O
IL-2	B-protein
receptor	I-protein
(	O
IL-2R	B-protein
)	O
.	O

Induction	O
of	O
IL-5	B-RNA
mRNA	I-RNA
upon	O
TCR	B-protein
and	O
IL-2R	B-protein
stimulation	O
was	O
totally	O
inhibited	O
by	O
dexamethasone	O
.	O

Human	O
IL-5	B-protein
promoter/enhancer-luciferase	O
gene	O
construct	O
transfected	O
to	O
T-cell	B-cell_line
clones	I-cell_line
was	O
transcribed	O
on	O
either	O
TCR	B-protein
or	O
IL-2R	B-protein
stimulation	O
and	O
was	O
clearly	O
downregulated	O
by	O
dexamethasone	O
,	O
indicating	O
that	O
the	O
approximately	O
500-bp	B-DNA
human	I-DNA
IL-5	I-DNA
gene	I-DNA
segment	I-DNA
located	O
5	B-DNA
'	I-DNA
upstream	I-DNA
of	O
the	O
coding	O
region	O
contains	O
activation-inducible	B-DNA
enhancer	I-DNA
elements	I-DNA
responsible	O
for	O
the	O
regulation	O
by	O
GC	O
.	O

Electrophoretic	O
mobility	O
shift	O
assay	O
analysis	O
suggested	O
that	O
AP-1	B-protein
and	O
NF-kappaB	B-protein
are	O
among	O
the	O
possible	O
targets	O
of	O
GC	O
actions	O
on	O
TCR-stimulated	B-cell_type
T	I-cell_type
cells	I-cell_type
.	O

NF-AT	B-protein
and	O
NF-kappaB	B-protein
were	O
not	O
significantly	O
induced	O
by	O
IL-2	B-protein
stimulation	O
.	O

Our	O
results	O
showing	O
that	O
GC	O
suppressed	O
IL-5	B-protein
production	O
by	O
human	B-cell_type
CD4+	I-cell_type
T	I-cell_type
cells	I-cell_type
activated	O
by	O
two	O
distinct	O
stimuli	O
,	O
TCR	B-protein
and	O
IL-2R	B-protein
stimulation	O
,	O
underscore	O
the	O
efficacy	O
of	O
GC	O
in	O
the	O
treatment	O
of	O
allergic	O
diseases	O
via	O
suppression	O
of	O
T-cell	O
IL-5	B-protein
synthesis	O
.	O

Itk	B-protein
,	O
a	O
T	B-protein
cell-specific	I-protein
tyrosine	I-protein
kinase	I-protein
,	O
is	O
required	O
for	O
CD2-mediated	B-DNA
interleukin-2	I-DNA
promoter	I-DNA
activation	O
in	O
the	O
human	B-cell_line
T	I-cell_line
cell	I-cell_line
line	I-cell_line
Jurkat	I-cell_line
.	O

We	O
investigated	O
the	O
functional	O
role	O
of	O
Itk	B-protein
,	O
a	O
member	O
of	O
the	O
cytoplasmic	B-protein
tyrosine	I-protein
kinase	I-protein
Tec	I-protein
family	I-protein
,	O
in	O
T	O
cell	O
activation	O
.	O

Stimulation	O
of	O
either	O
CD2	B-protein
or	O
T	O
cell	O
receptor	O
(	O
TCR	B-protein
)	O
/CD3	O
on	O
Tcells	O
by	O
monoclonal	O
antibody-mediated	O
cross-linking	O
induced	O
tyrosine	O
phosphorylation	O
of	O
Itk	B-protein
,	O
which	O
was	O
maximal	O
as	O
early	O
as	O
1	O
min	O
after	O
stimulation	O
.	O

The	O
tyrosine	O
kinase	O
activity	O
in	O
the	O
anti-	O
Itk	B-protein
immunoprecipitate	O
was	O
significantly	O
activated	O
upon	O
these	O
stimulations	O
.	O

Interleukin-2	O
(	O
IL-2	B-protein
)	O
promoter	O
activity	O
stimulated	O
by	O
cross-linking	O
of	O
CD2	B-protein
,	O
TCR	B-protein
/CD3	O
,	O
and	O
CD28	B-protein
with	O
antibodies	B-protein
was	O
significantly	O
reduced	O
by	O
transient	O
expression	O
of	O
an	O
Itk	B-protein
mutant	I-protein
lacking	O
the	O
kinase	O
activity	O
.	O

The	O
reduction	O
paralleled	O
a	O
decrease	O
in	O
tyrosine	O
phosphorylation	O
of	O
endogenous	B-protein
wild-type	I-protein
Itk	I-protein
.	O

Stimulation	O
of	O
CD2	B-protein
or	O
TCR/CD3	B-protein
induced	O
activation	O
of	O
the	O
nuclear	B-protein
factor	I-protein
of	I-protein
activated	I-protein
T	I-protein
cells	I-protein
(	O
NFAT	B-protein
)	O
,	O
the	O
binding	B-DNA
site	I-DNA
of	O
which	O
is	O
included	O
in	O
the	O
IL-2	B-DNA
gene	I-DNA
promoter	I-DNA
.	O

The	O
activation	O
of	O
NFAT	B-protein
was	O
also	O
impaired	O
by	O
expression	O
of	O
the	O
Itk	B-protein
mutant	I-protein
.	O

These	O
results	O
demonstrate	O
that	O
Itk	B-protein
plays	O
a	O
role	O
in	O
IL-2	B-protein
production	O
,	O
indicating	O
a	O
critical	O
involvement	O
of	O
Itk	B-protein
in	O
the	O
initial	O
stage	O
of	O
T	O
cell	O
activation	O
by	O
mediating	O
signals	O
from	O
the	O
TCR/CD3	B-protein
complex	I-protein
,	O
CD2	B-protein
,	O
and	O
CD28	B-protein
.	O

Expression	O
of	O
LAZ3/BCL6	B-protein
in	O
follicular	O
center	O
(	O
FC	O
)	O
B	O
cells	O
of	O
reactive	O
lymph	O
nodes	O
and	O
FC-derived	O
non-Hodgkin	O
lymphomas	O
.	O

Chromosomal	O
translocation	O
resulting	O
in	O
abnormal	O
expression	O
of	O
the	O
LAZ3/BCL6	B-DNA
gene	I-DNA
in	O
B	B-cell_type
cells	I-cell_type
has	O
been	O
implicated	O
in	O
the	O
tumorigenesis	O
of	O
non-Hodgkin	O
lymphoma	O
(	O
NHL	O
)	O
.	O

Therefore	O
we	O
studied	O
the	O
expression	O
pattern	O
of	O
LAZ3/BCL6	B-protein
by	O
in	O
situ	O
hybridization	O
with	O
synthetic	O
oligonucleotide	O
probes	O
in	O
frozen	O
tissue	O
sections	O
from	O
five	O
reactive	O
lymph	O
nodes	O
and	O
38	O
B	O
cell	O
and	O
non-B	O
NHL	O
.	O

In	O
addition	O
,	O
we	O
investigated	O
the	O
expression	O
of	O
LAZ3/BCL6	B-protein
by	O
Northern	O
blot	O
analysis	O
on	O
multiple	O
human	O
tissues	O
.	O

The	O
LAZ3/BCL6	B-RNA
transcript	I-RNA
was	O
found	O
in	O
a	O
variety	O
of	O
tissues	O
,	O
including	O
skeletal	O
muscle	O
,	O
peripheral	B-cell_type
blood	I-cell_type
leukocytes	I-cell_type
,	O
and	O
weakly	O
in	O
normal	O
lymph	O
nodes	O
.	O

In	O
the	O
tumor	O
samples	O
,	O
expression	O
of	O
LAZ3/BCL6	B-protein
was	O
observed	O
in	O
68	O
%	O
of	O
all	O
B	O
cell	O
NHL	O
and	O
none	O
of	O
the	O
non-B	O
lymphomas	O
.	O

All	O
cases	O
of	O
follicular	O
,	O
mixed	O
small	O
and	O
large	O
cell	O
lymphomas	O
showed	O
LAZ3/BCL6	B-protein
expression	O
confined	O
to	O
the	O
neoplastic	O
follicles	O
.	O

A	O
follicular	O
expression	O
pattern	O
was	O
also	O
found	O
in	O
all	O
non-malignant	O
reactive	O
lymph	O
nodes	O
.	O

Hence	O
,	O
the	O
expression	O
of	O
LAZ3/BCL6	B-protein
does	O
not	O
correlate	O
to	O
malignancy	O
,	O
but	O
reflects	O
the	O
origin	O
of	O
B	B-cell_type
cells	I-cell_type
from	O
the	O
germinal	O
centers	O
.	O

Jak1	B-protein
expression	O
is	O
required	O
for	O
mediating	O
interleukin-4-induced	O
tyrosine	O
phosphorylation	O
of	O
insulin	O
receptor	O
substrate	O
and	O
Stat6	B-protein
signaling	B-protein
molecules	I-protein
.	O

The	O
Jak1	B-protein
,	I-protein
Jak2	I-protein
,	I-protein
Jak3	I-protein
,	I-protein
and	I-protein
Fes	I-protein
tyrosine	I-protein
kinases	I-protein
have	O
been	O
demonstrated	O
to	O
undergo	O
tyrosine	O
phosphorylation	O
in	O
response	O
to	O
interleukin	B-protein
(	I-protein
IL	I-protein
)	I-protein
-4	I-protein
stimulation	O
in	O
different	O
cell	O
systems	O
.	O

However	O
,	O
it	O
is	O
not	O
clear	O
which	O
,	O
if	O
any	O
,	O
of	O
these	O
kinases	O
are	O
responsible	O
for	O
initiating	O
IL-4-induced	O
tyrosine	O
phosphorylation	O
of	O
intracellular	B-protein
substrates	I-protein
in	O
vivo	O
.	O

In	O
the	O
present	O
study	O
,	O
we	O
have	O
utilized	O
a	O
mutant	B-cell_line
Jak1-deficient	I-cell_line
HeLa	I-cell_line
cell	I-cell_line
line	I-cell_line
,	O
E1C3	B-cell_line
,	O
and	O
its	O
parental	B-cell_line
Jak1-expressing	I-cell_line
counterpart	I-cell_line
,	O
1D4	B-cell_line
,	O
to	O
analyze	O
the	O
role	O
of	O
Jak1	B-protein
in	O
mediating	O
IL-4-induced	O
tyrosine	O
phosphorylation	O
events	O
.	O

IL-4	O
treatment	O
rapidly	O
induced	O
tyrosine	O
phosphorylation	O
of	O
insulin	B-protein
receptor	I-protein
substrate	I-protein
(	I-protein
IRS	I-protein
)	I-protein
-1	I-protein
and	O
IRS-2	B-protein
in	O
1D4	B-cell_line
but	O
not	O
in	O
E1C3	B-cell_line
cells	I-cell_line
.	O

IL-4	B-protein
-mediated	O
tyrosine	O
phosphorylation	O
of	O
Stat6	B-protein
was	O
pronounced	O
in	O
1D4	B-cell_line
cells	I-cell_line
,	O
while	O
no	O
IL-4	B-protein
-induced	O
Stat6	B-protein
phosphorylation	O
was	O
detected	O
in	O
E1C3	B-cell_line
cells	I-cell_line
.	O

IL-4	B-protein
also	O
induced	O
Stat6	B-protein
DNA	O
binding	O
activity	O
from	O
lysates	O
of	O
1D4	B-cell_line
but	O
not	O
E1C3	B-cell_line
cells	I-cell_line
utilizing	O
a	O
radiolabeled	B-DNA
immunoglobulin	I-DNA
heavy	I-DNA
chain	I-DNA
germline	I-DNA
epsilon	I-DNA
promotor	I-DNA
sequence	I-DNA
(	O
Iepsilon	B-DNA
)	O
in	O
an	O
electrophoretic	O
mobility	O
shift	O
assay	O
.	O

Reconstitution	O
of	O
Jak1	B-protein
expression	O
in	O
E1C3	B-cell_line
cells	I-cell_line
restored	O
the	O
ability	O
of	O
IL-4	B-protein
to	O
induce	O
IRS	B-DNA
and	O
Stat6	B-protein
tyrosine	O
phosphorylation	O
.	O

These	O
results	O
provide	O
evidence	O
that	O
Jak1	B-protein
expression	O
is	O
required	O
for	O
mediating	O
tyrosine	O
phosphorylation	O
and	O
activation	O
of	O
crucial	O
molecules	O
involved	O
in	O
IL-4	B-protein
signal	O
transduction	O
.	O

Oxidant-regulation	O
of	O
gene	O
expression	O
in	O
the	O
chronically	O
inflamed	O
intestine	O
.	O

It	O
is	O
becoming	O
increasingly	O
apparent	O
that	O
the	O
chronic	O
gut	O
inflammation	O
observed	O
in	O
the	O
idiopathic	O
inflammatory	O
bowel	O
diseases	O
(	O
e.g.	O
ulcerative	O
colitis	O
,	O
Crohn	O
's	O
disease	O
)	O
is	O
associated	O
with	O
enhanced	O
production	O
of	O
leukocyte-derived	O
oxidants	O
.	O

Oxidants	O
such	O
as	O
hydrogen	O
peroxide	O
are	O
known	O
to	O
activate	O
certain	O
transcription	B-protein
factors	I-protein
such	O
as	O
nuclear	B-protein
transcription	I-protein
factor	I-protein
kappa	I-protein
beta	I-protein
.	O

Nuclear	B-protein
transcription	I-protein
factor	I-protein
kB	I-protein
(	O
NF-kappa	B-protein
B	I-protein
)	O
is	O
a	O
ubiquitous	B-protein
transcription	I-protein
factor	I-protein
and	O
pleiotropic	B-protein
regulator	I-protein
of	O
numerous	O
genes	O
involved	O
in	O
the	O
immune	O
and	O
inflammatory	O
responses	O
.	O

This	O
transcription	B-protein
factor	I-protein
is	O
activated	O
via	O
the	O
selective	O
phosphorylation	O
,	O
ubiquination	O
and	O
degradation	O
of	O
its	O
inhibitor	B-protein
protein	I-protein
I-kB	I-protein
thereby	O
allowing	O
translocation	O
of	O
NF-kappa	B-protein
B	I-protein
into	O
the	O
nucleus	O
where	O
it	O
upregulates	O
the	O
transcription	O
of	O
a	O
variety	O
of	O
adhesion	B-protein
molecules	I-protein
(	O
e.g	O
.	O
ICAM-1	B-protein
,	O
VCAM-1	B-protein
)	O
,	O
cytokines	B-protein
(	O
TNF	B-protein
,	O
IL-1	B-protein
,	O
IL-6	B-protein
)	O
and	O
enzymes	B-protein
(	O
iNOS	B-protein
)	O
.	O

The	O
proteolytic	O
degradation	O
of	O
the	O
post-translationally	O
modified	O
I-kappa	B-protein
B	I-protein
is	O
known	O
to	O
be	O
mediated	O
by	O
the	O
26S	B-protein
proteasome	I-protein
complex	I-protein
.	O

Based	O
upon	O
work	O
from	O
our	O
laboratory	O
,	O
we	O
propose	O
that	O
inhibition	O
of	O
NF-kappa	B-protein
B	I-protein
activation	O
produces	O
significant	O
anti	O
inflammatory	O
activity	O
which	O
may	O
be	O
mediated	O
by	O
the	O
inhibition	O
of	O
transcription	O
of	O
certain	O
pro-inflammatory	B-protein
mediators	I-protein
and	O
adhesion	B-protein
molecules	I-protein
.	O

Generation	O
of	O
cytotoxic	B-cell_type
T	I-cell_type
lymphocytes	I-cell_type
against	O
immunorecessive	B-protein
epitopes	I-protein
after	O
multiple	O
immunizations	O
with	O
adenovirus	O
vectors	O
is	O
dependent	O
on	O
haplotype	O
.	O

Currently	O
,	O
adenovirus	O
(	O
Ad	O
)	O
is	O
being	O
considered	O
as	O
a	O
vector	O
for	O
the	O
treatment	O
of	O
cystic	O
fibrosis	O
as	O
well	O
as	O
other	O
diseases	O
.	O

However	O
,	O
the	O
cytotoxic	B-cell_type
T	I-cell_type
lymphocyte	I-cell_type
(	O
CTL	B-cell_type
)	O
response	O
to	O
Ad	O
could	O
limit	O
the	O
effectiveness	O
of	O
such	O
approaches	O
.	O

Since	O
the	O
CTL	B-cell_type
response	O
to	O
virus	O
infection	O
is	O
often	O
focused	O
on	O
one	O
or	O
a	O
few	O
immunodominant	B-protein
epitopes	I-protein
,	O
one	O
approach	O
to	O
circumvent	O
this	O
response	O
is	O
to	O
create	O
vectors	O
that	O
lack	O
these	O
immunodominant	B-protein
epitopes	I-protein
.	O

The	O
effectiveness	O
of	O
this	O
approach	O
was	O
tested	O
by	O
immunizing	O
mice	O
with	O
human	O
group	O
C	O
adenoviruses	O
.	O

Three	O
mouse	O
strains	O
(	O
C57BL/10SnJ	O
[	O
H-2b	O
]	O
,	O
C3HeB/FeJ	O
[	O
H-2k	O
]	O
,	O
and	O
BALB/cByJ	O
[	O
H-2d	O
]	O
)	O
were	O
immunized	O
with	O
wild-type	O
Ad	O
or	O
Ad	O
vectors	O
lacking	O
the	O
immunodominant	B-protein
antigen	I-protein
(	O
s	O
)	O
,	O
and	O
the	O
CTL	B-cell_type
responses	O
were	O
measured	O
.	O

In	O
C57BL/10	O
(	O
B10	O
)	O
mice	O
,	O
a	O
single	O
inoculation	O
intraperitoneally	O
(	O
i.p.	O
)	O
led	O
to	O
the	O
recognition	O
of	O
an	O
immunodominant	B-protein
antigen	I-protein
in	O
E1A	B-DNA
.	O

When	O
B10	O
mice	O
were	O
inoculated	O
multiple	O
times	O
either	O
i.p	O
.	O

or	O
intranasally	O
with	O
wild-type	O
Ad	O
or	O
an	O
Ad	O
vector	O
lacking	O
most	O
of	O
the	O
E1	B-DNA
region	I-DNA
,	O
subdominant	O
epitopes	O
outside	O
this	O
region	O
were	O
recognized	O
.	O

In	O
contrast	O
,	O
C3H	O
mice	O
inoculated	O
with	O
wild-type	O
Ad	O
recognized	O
an	O
epitope	O
mapping	O
within	O
E1B	B-DNA
.	O
When	O
inoculated	O
twice	O
with	O
Ad	O
vectors	O
lacking	O
both	O
E1A	B-DNA
and	O
E1B	B-DNA
,	O
no	O
immunorecessive	B-protein
epitopes	I-protein
were	O
recognized	O
.	O

The	O
immune	O
response	O
to	O
Ad	O
in	O
BALB/c	O
mice	O
was	O
more	O
complex	O
.	O

CTLs	B-cell_type
from	O
BALB/c	O
mice	O
inoculated	O
i.p.	O
with	O
wild-type	O
Ad	O
recognized	O
E1B	B-DNA
in	O
the	O
context	O
of	O
the	O
major	B-DNA
histocompatibility	I-DNA
complex	I-DNA
(	I-DNA
MHC	I-DNA
)	I-DNA
class	I-DNA
I	I-DNA
Dd	I-DNA
allele	I-DNA
and	O
a	O
region	O
outside	O
E1	B-DNA
associated	O
with	O
the	O
Kd	B-DNA
allele	I-DNA
.	O

When	O
BALB/c	O
mice	O
were	O
inoculated	O
with	O
E1	B-DNA
-deleted	O
Ad	O
vectors	O
,	O
only	O
the	O
immunodominant	B-protein
Kd-restricted	I-protein
epitope	I-protein
was	O
recognized	O
,	O
and	O
Dd-restricted	O
CTLs	B-cell_type
did	O
not	O
develop	O
.	O

This	O
report	O
indicates	O
that	O
the	O
emergence	O
of	O
CTLs	B-cell_type
against	O
immunorecessive	B-protein
epitopes	I-protein
following	O
multiple	O
administrations	O
of	O
Ad	O
vectors	O
lacking	O
immunodominant	O
antigens	O
is	O
dependent	O
on	O
haplotype	O
and	O
could	O
present	O
an	O
obstacle	O
to	O
gene	O
therapy	O
in	O
an	O
MHC	B-protein
-diverse	O
human	O
population	O
.	O

Characterization	O
of	O
the	O
human	B-DNA
platelet/endothelial	I-DNA
cell	I-DNA
adhesion	I-DNA
molecule-1	I-DNA
promoter	I-DNA
:	O
identification	O
of	O
a	O
GATA-2	B-DNA
binding	I-DNA
element	I-DNA
required	O
for	O
optimal	O
transcriptional	O
activity	O
.	O

Platelet/endothelial	B-protein
cell	I-protein
adhesion	I-protein
molecule-1	I-protein
(	O
PECAM-1	B-protein
)	O
is	O
a	O
130-kD	B-protein
member	I-protein
of	O
the	O
Ig	B-DNA
gene	I-DNA
superfamily	I-DNA
that	O
is	O
expressed	O
on	O
platelets	B-cell_type
,	O
endothelial	B-cell_type
cells	I-cell_type
,	O
and	O
certain	O
leukocyte	B-cell_type
subsets	I-cell_type
.	O

To	O
examine	O
the	O
factors	O
controlling	O
vascular-specific	O
expression	O
of	O
PECAM-1	B-protein
,	O
we	O
cloned	O
the	O
5'-flanking	B-DNA
region	I-DNA
of	O
the	O
PECAM-1	B-DNA
gene	I-DNA
and	O
analyzed	O
its	O
transcriptional	O
activity	O
.	O

5'-Rapid	O
amplification	O
of	O
cDNA	B-DNA
ends	I-DNA
(	O
5'-RACE	B-DNA
)	O
analysis	O
showed	O
that	O
transcription	O
initiation	O
occurred	O
at	O
several	O
closely	O
spaced	O
nearby	O
sites	O
originating	O
approximately	O
204	B-DNA
bp	I-DNA
upstream	I-DNA
from	O
the	O
translation	B-DNA
start	I-DNA
site	I-DNA
.	O

Analysis	O
of	O
the	O
sequence	O
immediately	O
upstream	O
from	O
the	O
transcription	B-DNA
initiation	I-DNA
site	I-DNA
(	O
TIS	B-DNA
)	O
showed	O
no	O
canonical	O
TATA	B-DNA
or	O
CAAT	B-DNA
elements	I-DNA
,	O
however	O
an	O
initiator	O
element	O
commonly	O
found	O
in	O
TATA-less	B-DNA
promoters	I-DNA
encompassed	O
the	O
TIS	B-DNA
.	O

5'-serially	B-DNA
truncated	I-DNA
PECAM-1	I-DNA
promoter	I-DNA
segments	I-DNA
cloned	O
in	O
front	O
of	O
a	O
luciferase	B-DNA
reporter	I-DNA
drove	O
transcription	O
in	O
both	O
a	O
lineage-	O
and	O
orientation-specific	O
manner	O
.	O

Putative	O
cis-acting	B-DNA
control	I-DNA
elements	I-DNA
present	O
within	O
a	O
300-bp	B-DNA
core	I-DNA
promoter	I-DNA
included	O
two	O
ets	B-DNA
sites	I-DNA
,	O
an	O
Sp1	B-DNA
site	I-DNA
,	O
tandem	O
E-box	B-DNA
domains	I-DNA
,	O
two	O
GATA-associated	B-DNA
sites	I-DNA
(	O
CACCC	O
)	O
,	O
an	O
AP-2	B-DNA
binding	I-DNA
site	I-DNA
,	O
and	O
a	O
GATA	B-DNA
element	I-DNA
at	O
-24	B-DNA
.	O

Mutational	O
analysis	O
showed	O
that	O
optimal	O
transcriptional	O
activity	O
required	O
the	O
GATA	B-DNA
sequence	I-DNA
at	O
position	O
-24	B-DNA
,	O
and	O
gel-shift	O
assays	O
further	O
showed	O
that	O
the	O
GATA-2	B-protein
transcription	I-protein
factor	I-protein
,	O
but	O
not	O
GATA-1	B-protein
,	O
bound	O
to	O
this	O
region	O
of	O
the	O
PECAM-1	B-DNA
promoter	I-DNA
.	O

Understanding	O
the	O
cis-	B-protein
and	I-protein
transacting	I-protein
factors	I-protein
that	O
regulate	O
the	O
tissue-specific	O
expression	O
of	O
PECAM-1	B-protein
should	O
increase	O
our	O
understanding	O
of	O
the	O
mechanisms	O
by	O
which	O
vascular-specific	O
gene	O
expression	O
is	O
achieved	O
.	O

A	O
negative	O
regulatory	O
region	O
containing	O
a	O
glucocorticosteroid	B-DNA
response	I-DNA
element	I-DNA
(	O
nGRE	B-DNA
)	O
in	O
the	O
human	B-DNA
interleukin-1beta	I-DNA
gene	I-DNA
.	O

Interleukin-1	B-protein
beta	I-protein
(	O
IL-1beta	B-protein
)	O
is	O
one	O
of	O
the	O
most	O
important	O
inflammatory	B-protein
mediators	I-protein
in	O
human	O
inflammatory	O
and	O
immunological	O
diseases	O
.	O

The	O
regulation	O
of	O
human	B-protein
IL-1beta	I-protein
gene	O
expression	O
has	O
been	O
studied	O
for	O
several	O
years	O
,	O
and	O
a	O
few	O
regulatory	B-DNA
elements	I-DNA
have	O
been	O
discovered	O
in	O
the	O
promoter	B-DNA
region	I-DNA
.	O

However	O
,	O
little	O
is	O
known	O
about	O
negative	O
regulation	O
of	O
IL-1beta	B-protein
expression	O
at	O
the	O
transcriptional	O
level	O
,	O
which	O
may	O
play	O
an	O
important	O
role	O
in	O
anti-inflammatory	O
and	O
immunosuppressive	O
effects	O
.	O

We	O
have	O
identified	O
a	O
negative	B-DNA
regulatory	I-DNA
element	I-DNA
located	O
in	O
the	O
region	O
between	O
-685	B-DNA
and	I-DNA
-395	I-DNA
.	O

Within	O
this	O
region	O
,	O
a	O
19-bp	B-DNA
nuclear	I-DNA
factor	I-DNA
binding	I-DNA
site	I-DNA
(	O
-570	B-DNA
to	I-DNA
-552	I-DNA
)	O
was	O
characterized	O
by	O
DNase	B-protein
I	I-protein
footprinting	O
and	O
electromobility	O
shift	O
assay	O
.	O

A	O
consensus	B-DNA
sequence	I-DNA
for	O
a	O
negative	B-DNA
glucocorticoid	I-DNA
response	I-DNA
element	I-DNA
(	O
nGRE	B-DNA
)	O
and	O
a	O
transcription	B-DNA
activator	I-DNA
protein-2	I-DNA
binding	I-DNA
site	I-DNA
were	O
noted	O
within	O
this	O
footprint	O
.	O

Functional	O
studies	O
showed	O
a	O
2.5-fold	O
increase	O
in	O
promoter	O
activity	O
when	O
this	O
19-bp	B-DNA
binding	I-DNA
site	I-DNA
was	O
deleted	O
in	O
the	O
reporter	B-DNA
constructs	I-DNA
IL-1beta	B-protein
/CAT	B-protein
and	O
IL-1beta	B-protein
/SV40	B-DNA
promoter	I-DNA
/CAT	B-protein
.	O

Dexamethasone	O
(	O
10	O
(	O
-8	O
)	O
M	O
)	O
repressed	O
chloramphenicol	B-protein
acetyltransferase	I-protein
(	O
CAT	B-protein
)	O
production	O
by	O
75	O
%	O
in	O
the	O
wild-type	B-DNA
fragment	I-DNA
but	O
not	O
in	O
a	O
deletion	B-DNA
mutant	I-DNA
lacking	O
the	O
19-bp	B-DNA
site	I-DNA
.	O

A	O
protein	O
of	O
about	O
150	B-protein
kD	I-protein
that	O
bound	O
to	O
this	O
negative	B-DNA
regulatory	I-DNA
sequence	I-DNA
was	O
identified	O
by	O
UV	O
cross-linking	O
.	O

This	O
is	O
the	O
first	O
description	O
of	O
a	O
negative	B-DNA
regulatory	I-DNA
region	I-DNA
responsive	O
to	O
glucocorticoids	O
in	O
a	O
cytokine	B-DNA
gene	I-DNA
.	O

Interaction	O
of	O
transcription	B-protein
factors	I-protein
RFX1	B-protein
and	O
MIBP1	B-protein
with	O
the	O
gamma	B-DNA
motif	I-DNA
of	O
the	O
negative	B-DNA
regulatory	I-DNA
element	I-DNA
of	O
the	O
hepatitis	B-DNA
B	I-DNA
virus	I-DNA
core	I-DNA
promoter	I-DNA
.	O

The	O
negative	B-DNA
regulatory	I-DNA
element	I-DNA
(	O
NRE	B-DNA
)	O
of	O
the	O
hepatitis	B-DNA
B	I-DNA
virus	I-DNA
(	I-DNA
HBV	I-DNA
)	I-DNA
core	I-DNA
promoter	I-DNA
contains	O
three	O
subregions	O
which	O
act	O
synergistically	O
to	O
suppress	O
core	O
promoter	O
activity	O
.	O

One	O
of	O
these	O
subregions	O
,	O
NRE	B-DNA
gamma	I-DNA
,	O
is	O
active	O
in	O
both	O
HeLa	B-cell_line
cervical	I-cell_line
carcinoma	I-cell_line
cells	I-cell_line
and	O
Huh7	B-cell_line
hepatoma	I-cell_line
cells	I-cell_line
and	O
was	O
found	O
to	O
be	O
bound	O
by	O
a	O
protein	O
factor	O
present	O
in	O
both	O
cell	O
types	O
.	O

Here	O
we	O
show	O
that	O
the	O
transcription	B-protein
factor	I-protein
RFX1	B-protein
can	O
bind	O
to	O
NRE	B-DNA
gamma	I-DNA
and	O
transactivate	O
the	O
core	B-DNA
promoter	I-DNA
through	O
this	O
site	O
.	O

Mutations	O
which	O
abrogated	O
the	O
gene-suppressive	O
activity	O
of	O
NRE	B-DNA
gamma	I-DNA
prevented	O
RFX1	B-protein
from	O
binding	O
to	O
NRE	B-DNA
gamma	I-DNA
.	O

In	O
addition	O
,	O
RFX1	B-protein
can	O
bind	O
simultaneously	O
,	O
most	O
likely	O
as	O
a	O
heterodimer	B-protein
,	O
with	O
the	O
transcription	B-protein
factor	I-protein
MIBP1	B-protein
to	O
NRE	B-DNA
gamma	I-DNA
.	O

In	O
the	O
absence	O
of	O
a	O
cloned	O
MIBP1	B-DNA
gene	I-DNA
for	O
further	O
studies	O
,	O
we	O
hypothesize	O
that	O
RFX1	B-protein
acts	O
with	O
MIBP1	B-protein
to	O
negatively	O
regulate	O
the	O
core	O
promoter	O
activity	O
through	O
the	O
NRE	B-DNA
gamma	I-DNA
site	I-DNA
.	O

The	O
ability	O
of	O
RFX1	B-protein
to	O
transactivate	O
the	O
core	B-DNA
promoter	I-DNA
raises	O
the	O
possibility	O
that	O
RFX1	B-protein
may	O
play	O
a	O
dual	O
role	O
in	O
regulating	O
HBV	O
gene	O
expression	O

Use	O
of	O
arsenic	O
trioxide	O
(	O
As2O3	O
)	O
in	O
the	O
treatment	O
of	O
acute	O
promyelocytic	O
leukemia	O
(	O
APL	O
)	O
:	O
II	O
.	O

Clinical	O
efficacy	O
and	O
pharmacokinetics	O
in	O
relapsed	O
patients	O
.	O

The	O
therapeutic	O
effect	O
of	O
arsenic	O
trioxide	O
(	O
As2O3	O
)	O
in	O
the	O
treatment	O
of	O
acute	O
promyelocytic	O
leukemia	O
(	O
APL	O
)	O
was	O
evaluated	O
among	O
15	O
APL	O
patients	O
at	O
relapse	O
after	O
all-trans	O
retinoic	O
acid	O
(	O
ATRA	O
)	O
induced	O
and	O
chemotherapy	O
maintained	O
complete	O
remission	O
(	O
CR	O
)	O
.	O

As2O3	O
was	O
administered	O
intravenously	O
at	O
the	O
dose	O
of	O
10	O
mg/d	O
.	O

Clinical	O
CR	O
was	O
achieved	O
in	O
nine	O
of	O
10	O
(	O
90	O
%	O
)	O
patients	O
treated	O
with	O
As2O3	O
alone	O
and	O
in	O
the	O
remaining	O
five	O
patients	O
treated	O
by	O
the	O
combination	O
of	O
As2O3	O
and	O
low-dose	O
chemotherapeutic	O
drugs	O
or	O
ATRA	O
.	O

During	O
the	O
treatment	O
with	O
As2O3	O
,	O
there	O
was	O
no	O
bone	O
marrow	O
depression	O
and	O
only	O
limited	O
side	O
effects	O
were	O
encountered	O
.	O

Pharmacokinetic	O
studies	O
,	O
which	O
were	O
performed	O
in	O
eight	O
patients	O
,	O
showed	O
that	O
after	O
a	O
peak	O
level	O
of	O
5.54	O
micromol/L	O
to	O
7.30	O
micromol/L	O
,	O
plasma	O
arsenic	O
was	O
rapidly	O
eliminated	O
,	O
and	O
the	O
continuous	O
administration	O
of	O
As2O3	O
did	O
not	O
alter	O
its	O
pharmacokinetic	O
behaviors	O
.	O

In	O
addition	O
,	O
increased	O
amounts	O
of	O
arsenic	O
appeared	O
in	O
the	O
urine	O
,	O
with	O
a	O
daily	O
excretion	O
accounting	O
for	O
approximately	O
1	O
%	O
to	O
8	O
%	O
of	O
the	O
total	O
daily	O
dose	O
administered	O
.	O

Arsenic	O
contents	O
in	O
hair	O
and	O
nail	O
were	O
increased	O
,	O
and	O
the	O
peak	O
content	O
of	O
arsenic	O
could	O
reach	O
2.5	O
to	O
2.7	O
microg/g	O
tissue	O
at	O
CR	O
.	O

On	O
the	O
other	O
hand	O
,	O
a	O
decline	O
of	O
the	O
arsenic	O
content	O
in	O
hair	O
and	O
nail	O
was	O
observed	O
after	O
withdrawal	O
of	O
the	O
drug	O
.	O

We	O
conclude	O
that	O
As2O3	O
treatment	O
is	O
an	O
effective	O
and	O
relatively	O
safe	O
drug	O
in	O
APL	O
patients	O
refractory	O
to	O
ATRA	O
and	O
conventional	O
chemotherapy	O
.	O

Nucleolin	B-protein
is	O
one	O
component	O
of	O
the	O
B	B-protein
cell-specific	I-protein
transcription	I-protein
factor	I-protein
and	O
switch	B-protein
region	I-protein
binding	I-protein
protein	I-protein
,	O
LR1	B-protein
.	O

LR1	B-protein
is	O
a	O
B	O
cell-specific	O
,	O
sequence-specific	O
DNA	O
binding	O
activity	O
that	O
regulates	O
transcription	O
in	O
activated	B-cell_type
B	I-cell_type
cells	I-cell_type
.	O

LR1	B-protein
also	O
binds	O
Ig	B-protein
heavy	I-protein
chain	I-protein
switch	O
region	O
sequences	O
and	O
may	O
function	O
in	O
class	O
switch	O
recombination	O
.	O

LR1	B-protein
contains	O
two	O
polypeptides	O
,	O
of	O
106	O
kDa	O
and	O
45	O
kDa	O
,	O
and	O
here	O
we	O
report	O
that	O
the	O
106-kDa	B-protein
component	I-protein
of	O
LR1	B-protein
is	O
nucleolin	B-protein
.	O

This	O
identification	O
,	O
initially	O
made	O
by	O
microsequence	O
analysis	O
,	O
was	O
verified	O
by	O
showing	O
that	O
(	O
i	O
)	O
LR1	B-protein
-DNA	O
binding	O
activity	O
increased	O
in	O
B	B-cell_type
cells	I-cell_type
transfected	O
with	O
a	O
nucleolin	B-DNA
cDNA	I-DNA
expression	I-DNA
construct	I-DNA
;	O
(	O
ii	O
)	O
LR1	B-protein
-DNA	O
binding	O
activity	O
was	O
recognized	O
by	O
antibodies	O
raised	O
against	O
recombinant	B-protein
human	I-protein
nucleolin	I-protein
;	O
and	O
(	O
iii	O
)	O
in	O
B	B-cell_type
cells	I-cell_type
transfected	O
with	O
epitope-tagged	B-DNA
nucleolin	I-DNA
expression	I-DNA
constructs	I-DNA
,	O
the	O
LR1-DNA	B-protein
complex	I-protein
was	O
recognized	O
by	O
the	O
anti-tag	B-protein
antibody	I-protein
.	O

Nucleolin	B-protein
is	O
an	O
abundant	B-protein
nucleolar	I-protein
protein	I-protein
which	O
is	O
believed	O
to	O
play	O
a	O
role	O
in	O
rDNA	B-DNA
transcription	O
or	O
organization	O
,	O
or	O
rRNA	B-RNA
processing	O
.	O

Homology	O
between	O
nucleolin	B-protein
and	O
histone	B-protein
H1	I-protein
suggests	O
that	O
nucleolin	B-protein
may	O
alter	O
DNA	O
organization	O
in	O
response	O
to	O
cell	O
cycle	O
controls	O
,	O
and	O
the	O
nucleolin	B-protein
component	O
of	O
LR1	B-protein
may	O
therefore	O
function	O
to	O
organize	O
switch	B-DNA
regions	I-DNA
before	O
,	O
during	O
,	O
or	O
after	O
switch	O
recombination	O
.	O

The	O
demonstration	O
that	O
nucleolin	B-protein
is	O
a	O
component	O
of	O
a	O
B	B-protein
cell-specific	I-protein
complex	I-protein
that	O
binds	O
switch	O
region	O
sequences	O
suggests	O
that	O
the	O
G-rich	B-DNA
switch	I-DNA
regions	I-DNA
may	O
have	O
evolved	O
from	O
rDNA	B-DNA
.	O

Glucocorticoid-resistance	O
in	O
peripheral-blood	B-cell_type
lymphocytes	I-cell_type
does	O
not	O
correlate	O
with	O
number	O
of	O
affinity	O
of	O
glucocorticoid-receptors	B-protein
in	O
chronic	O
renal	O
failure	O
patients	O
.	O

Glucocorticoid	O
(	O
GC	O
)	O
resistance	O
in	O
patients	O
with	O
chronic	O
renal	O
failure	O
(	O
CRF	O
)	O
seriously	O
impairs	O
successive	O
GC	O
therapy	O
after	O
renal	O
transplantation	O
.	O

We	O
examined	O
the	O
relationship	O
between	O
GC-receptor	O
(	O
GC-R	O
)	O
parameters	O
in	O
peripheral-blood	B-cell_type
mononuclear	I-cell_type
cells	I-cell_type
(	O
PBMC	B-cell_type
)	O
and	O
PBMC	B-cell_type
resistance	O
to	O
GC	O
in	O
21	O
CRF	O
patients	O
and	O
18	O
healthy	O
subjects	O
.	O

Each	O
subject	O
group	O
was	O
divided	O
into	O
two	O
subgroups	O
according	O
to	O
PBMC	B-cell_type
sensitivity	O
to	O
prednisolone	O
in	O
a	O
mitogen	O
assay	O
procedure	O
;	O
i.e.	O
,	O
sensitive	O
(	O
IC50	O
<	O
381	O
ng/mL	O
)	O
and	O
resistant	O
(	O
IC50	O
>	O
381	O
ng/mL	O
)	O
groups	O
.	O

In	O
healthy	O
subjects	O
,	O
the	O
mean	O
GC-R	B-protein
Bmax	O
and	O
Kd	O
in	O
quiescent	O
PBMC	B-cell_type
of	O
the	O
GC-sensitive	O
group	O
were	O
2.89	O
+/-	O
1.23	O
fmol/10	O
(	O
6	O
)	O
cells	O
and	O
4.00	O
+/-	O
2.24	O
nM	O
,	O
respectively	O
.	O

The	O
Bmax	O
in	O
these	O
subjects	O
significantly	O
increased	O
to	O
6.61	O
+/-	O
2.02	O
(	O
257.7	O
+/-	O
107.8	O
%	O
)	O
after	O
24	O
h	O
stimulation	O
with	O
concanavalin	O
A	O
(	O
p	O
<	O
0.01	O
)	O
,	O
while	O
the	O
Kd	O
change	O
was	O
not	O
significant	O
.	O

The	O
GC-R	B-protein
Bmax	O
and	O
Kd	O
in	O
quiescent	O
PBMC	B-cell_type
of	O
the	O
GC-resistant	O
group	O
were	O
5.33	O
+/-	O
1.37	O
fmol/10	O
(	O
6	O
)	O
cells	O
and	O
3.20	O
+/-	O
1.39	O
nM	O
,	O
respectively	O
.	O

Both	O
of	O
these	O
parameters	O
,	O
however	O
,	O
did	O
not	O
change	O
significantly	O
after	O
mitogen	B-protein
stimulation	O
.	O

There	O
was	O
a	O
significant	O
negative	O
correlation	O
between	O
IC50S	O
of	O
prednisolone	O
and	O
increase-ratios	O
(	O
post/pre	O
ratio	O
)	O
of	O
Bmax	O
after	O
mitogen	B-protein
stimulation	O
(	O
p	O
<	O
0.05	O
)	O
.	O

In	O
CRF	O
patients	O
,	O
Bmax	O
and	O
Kd	O
in	O
quiescent	O
PBMC	B-cell_type
of	O
the	O
GC-sensitive	O
group	O
were	O
6.04	O
+/-	O
2.35	O
fmol/10	O
(	O
6	O
)	O
cells	O
and	O
3.49	O
+/-	O
1.72	O
nM	O
,	O
respectively	O
,	O
while	O
those	O
in	O
PBMC	B-cell_type
of	O
the	O
GC-resistant	O
group	O
were	O
5.13	O
+/-	O
2.31	O
fmol/10	O
(	O
6	O
)	O
cells	O
and	O
4.04	O
+/-	O
1.62	O
nM	O
,	O
respectively	O
.	O

The	O
Bmax	O
and	O
Kd	O
were	O
not	O
significantly	O
changed	O
after	O
mitogen	B-protein
stimulation	O
in	O
both	O
subgroups	O
of	O
CRF	O
.	O

Moreover	O
,	O
in	O
contrast	O
to	O
healthy	O
subjects	O
,	O
there	O
was	O
no	O
correlation	O
between	O
IC50	O
and	O
GC-R	B-protein
parameters	O
in	O
CRF	O
.	O

We	O
concluded	O
that	O
,	O
in	O
healthy	O
subjects	O
,	O
decreased	O
PBMC	B-cell_type
capacity	O
to	O
amplify	O
GC-R	B-protein
numbers	O
in	O
response	O
to	O
mitogen	B-protein
is	O
correlated	O
with	O
GC	O
resistance	O
,	O
whereas	O
in	O
CRF	O
patients	O
the	O
resistant	O
mechanism	O
is	O
not	O
correlated	O
with	O
GC-R	B-protein
parameters	O
.	O

An	O
unknown	O
event	O
might	O
be	O
involved	O
in	O
GC-resistance	O
of	O
CRF	O
.	O

Alteration	O
of	O
a	O
single	O
serine	O
in	O
the	O
basic	B-protein
domain	I-protein
of	O
the	O
Epstein-Barr	B-protein
virus	I-protein
ZEBRA	I-protein
protein	I-protein
separates	O
its	O
functions	O
of	O
transcriptional	O
activation	O
and	O
disruption	O
of	O
latency	O
.	O

The	O
ZEBRA	B-protein
protein	I-protein
from	O
Epstein-Barr	O
virus	O
(	O
EBV	O
)	O
activates	O
a	O
switch	O
from	O
the	O
latent	O
to	O
the	O
lytic	O
expression	O
program	O
of	O
the	O
virus	O
.	O

ZEBRA	B-protein
,	O
a	O
member	O
of	O
the	O
bZIP	B-protein
family	I-protein
of	O
DNA-binding	B-protein
proteins	I-protein
,	O
is	O
a	O
transcriptional	O
activator	O
capable	O
of	O
inducing	O
expression	O
from	O
viral	B-DNA
lytic	I-DNA
cycle	I-DNA
promoters	I-DNA
.	O

It	O
had	O
previously	O
been	O
thought	O
that	O
ZEBRA	B-protein
's	O
capacity	O
to	O
disrupt	O
EBV	O
latency	O
resided	O
primarily	O
in	O
its	O
ability	O
to	O
activate	O
transcription	O
of	O
genes	O
that	O
encode	O
products	O
required	O
for	O
lytic	O
replication	O
.	O

We	O
generated	O
a	O
point	O
mutant	O
of	O
ZEBRA	B-protein
,	O
Z	B-protein
(	I-protein
S186A	I-protein
)	I-protein
,	O
that	O
was	O
not	O
impaired	O
in	O
its	O
ability	O
to	O
activate	O
transcription	O
;	O
however	O
,	O
this	O
mutation	O
abolished	O
its	O
ability	O
to	O
initiate	O
the	O
viral	O
lytic	O
cascade	O
.	O

The	O
mutant	O
,	O
containing	O
a	O
serine-to-alanine	O
substitution	O
in	O
the	O
DNA-binding	B-protein
domain	I-protein
of	O
the	O
protein	O
,	O
bound	O
to	O
several	O
known	O
ZEBRA-binding	B-DNA
sites	I-DNA
and	O
activated	O
transcription	O
from	O
reporters	O
bearing	O
known	O
ZEBRA-responsive	B-DNA
promoters	I-DNA
but	O
did	O
not	O
disrupt	O
latency	O
in	O
EBV-infected	B-cell_line
cell	I-cell_line
lines	I-cell_line
.	O

Therefore	O
,	O
initiation	O
of	O
the	O
EBV	O
lytic	O
cycle	O
by	O
the	O
ZEBRA	B-protein
protein	I-protein
requires	O
a	O
function	O
in	O
addition	O
to	O
transcriptional	O
activation	O
;	O
a	O
change	O
of	O
serine	O
186	O
to	O
alanine	O
in	O
the	O
DNA-binding	B-protein
domain	I-protein
of	O
ZEBRA	B-protein
abolished	O
this	O
additional	O
function	O
and	O
uncovered	O
a	O
new	O
role	O
for	O
the	O
ZEBRA	B-protein
protein	I-protein
in	O
disruption	O
of	O
EBV	O
latency	O
.	O

The	O
additional	O
function	O
that	O
is	O
required	O
for	O
initiation	O
of	O
the	O
lytic	O
viral	O
life	O
cycle	O
is	O
likely	O
to	O
require	O
phosphorylation	O
of	O
serine	O
186	O
of	O
the	O
ZEBRA	B-protein
protein	I-protein
,	O
which	O
may	O
influence	O
either	O
DNA	O
recognition	O
or	O
transcriptional	O
activation	O
of	O
lytic	B-DNA
viral	I-DNA
promoters	I-DNA
in	O
a	O
chromatinized	B-DNA
viral	I-DNA
episome	I-DNA
.	O

Immune	O
hyperactivation	O
of	O
HIV-1-infected	B-cell_type
T	I-cell_type
cells	I-cell_type
mediated	O
by	O
Tat	B-protein
and	O
the	O
CD28	B-protein
pathway	O
.	O

Human	O
immunodeficiency	O
virus-type	O
1	O
(	O
HIV-1	O
)	O
infection	O
is	O
characterized	O
by	O
a	O
chronic	O
state	O
of	O
immune	O
hyperactivation	O
in	O
patients	O
.	O

Infection	O
of	O
human	B-cell_type
peripheral	I-cell_type
blood	I-cell_type
lymphocytes	I-cell_type
with	O
HIV-1	O
in	O
vitro	O
resulted	O
in	O
increased	O
interleukin-2	O
(	O
IL-2	O
)	O
secretion	O
in	O
response	O
to	O
T	O
cell	O
activation	O
via	O
the	O
CD3	B-protein
and	I-protein
CD28	I-protein
receptors	I-protein
.	O

Expression	O
of	O
the	O
HIV-1	B-protein
transactivator	I-protein
Tat	B-protein
recapitulated	O
this	O
phenotype	O
and	O
was	O
associated	O
with	O
increased	O
IL-2	B-protein
secretion	O
in	O
response	O
to	O
costimulation	O
with	O
CD3	B-protein
plus	O
CD28	B-protein
.	O

IL-2	B-protein
superinduction	O
by	O
Tat	B-protein
occurred	O
at	O
the	O
transcriptional	O
level	O
,	O
was	O
mediated	O
by	O
the	O
CD28-responsive	B-DNA
element	I-DNA
in	O
the	O
IL-2	B-DNA
promoter	I-DNA
,	O
and	O
was	O
exclusively	O
dependent	O
on	O
the	O
29	B-protein
amino	I-protein
acids	I-protein
encoded	O
by	O
the	O
second	B-DNA
exon	I-DNA
of	I-DNA
Tat	I-DNA
.	O

Response	O
to	O
intranasal	O
fluticasone	O
propionate	O
in	O
perennial	O
allergic	O
rhinitis	O
not	O
associated	O
with	O
glucocorticoid	B-protein
receptor	I-protein
characteristics	O
.	O

BACKGROUND	O
:	O
The	O
reduction	O
of	O
symptoms	O
due	O
to	O
treatment	O
with	O
corticosteroids	O
varies	O
among	O
patients	O
with	O
perennial	O
rhinitis	O
.	O

Most	O
patients	O
will	O
respond	O
but	O
a	O
few	O
patients	O
respond	O
less	O
to	O
these	O
drugs	O
.	O

OBJECTIVE	O
:	O
To	O
investigate	O
the	O
association	O
in	O
reduction	O
of	O
symptoms	O
due	O
to	O
glucocorticoids	O
and	O
glucocorticoid	B-protein
receptor	I-protein
characteristics	O
in	O
patients	O
with	O
perennial	O
allergic	O
rhinitis	O
,	O
in	O
vitro	O
glucocorticoid	B-protein
receptor	I-protein
binding	O
studies	O
were	O
performed	O
with	O
peripheral	B-cell_type
blood	I-cell_type
mononuclear	I-cell_type
cells	I-cell_type
using	O
dexamethasone	O
and	O
in	O
vitro	O
production	O
of	O
mediators	B-protein
were	O
measured	O
.	O

METHODS	O
:	O
During	O
a	O
double-blind	O
placebo-controlled	O
crossover	O
study	O
,	O
200	O
micrograms	O
fluticasone	O
propionate	O
aqueous	O
nasal	O
spray	O
(	O
in	O
the	O
active	O
treatment	O
period	O
)	O
and	O
placebo	O
(	O
in	O
the	O
placebo	O
treatment	O
period	O
)	O
were	O
administered	O
twice	O
daily	O
for	O
2	O
weeks	O
to	O
22	O
patients	O
allergic	O
to	O
house	O
dust	O
mite	O
.	O

At	O
the	O
end	O
of	O
both	O
treatment	O
periods	O
symptoms	O
were	O
scored	O
after	O
allergen	O
provocation	O
(	O
100	O
,	O
1000	O
,	O
10000	O
BU/mL	O
)	O
and	O
during	O
the	O
9.5	O
hours	O
after	O
this	O
challenge	O
.	O

Receptor	O
binding	O
studies	O
with	O
dexamethasone	O
were	O
performed	O
with	O
peripheral	B-cell_type
blood	I-cell_type
mononuclear	I-cell_type
cells	I-cell_type
.	O

Leukotriene	O
B4	O
produced	O
by	O
monocytes	B-cell_type
in	O
vitro	O
and	O
soluble	O
interleukin-2	B-protein
receptor	I-protein
released	O
by	O
lymphocytes	B-cell_type
in	O
vitro	O
and	O
cortisol	O
levels	O
in	O
plasma	O
were	O
determined	O
.	O

RESULTS	O
:	O
No	O
significant	O
partial	O
correlations	O
of	O
the	O
number	O
of	O
the	O
peripheral	B-protein
blood	I-protein
mononuclear	I-protein
cell	I-protein
glucocorticoid	I-protein
receptors	I-protein
(	O
6821	O
+/-	O
5669	O
binding	O
sites	O
per	O
cell	O
)	O
and	O
the	O
affinity	O
(	O
Kd	O
:	O
16.5	O
+/-	O
13.51	O
nmol/L	O
)	O
for	O
the	O
glucocorticoid	B-protein
receptors	I-protein
with	O
the	O
symptom	O
score	O
(	O
placebo	O
:	O
4.3	O
+/-	O
2.45	O
pts	O
;	O
fluticasone	O
:	O
2.4	O
+/-	O
1.55	O
pts	O
)	O
after	O
active	O
treatment	O
were	O
found	O
.	O

Also	O
no	O
significant	O
partial	O
correlations	O
of	O
the	O
levels	O
of	O
leukotriene	O
B4	O
(	O
45.6	O
+/-	O
105.3	O
ng/10	O
(	O
6	O
)	O
cells	O
)	O
produced	O
by	O
monocytes	B-cell_type
in	O
vitro	O
,	O
soluble	O
interleukin-2	B-protein
receptor	I-protein
(	O
734	O
+/-	O
237	O
ng/10	O
(	O
6	O
)	O
cells	O
)	O
released	O
by	O
lymphocytes	B-cell_type
in	O
vitro	O
and	O
cortisol	O
levels	O
(	O
571	O
+/-	O
236	O
ng/mL	O
)	O
in	O
plasma	O
with	O
the	O
symptom	O
score	O
after	O
active	O
treatment	O
were	O
found	O
.	O

CONCLUSIONS	O
:	O
The	O
reduction	O
of	O
symptoms	O
due	O
to	O
topical	O
fluticasone	O
propionate	O
in	O
patients	O
with	O
rhinitis	O
and	O
allergy	O
to	O
house	O
dust	O
mite	O
is	O
not	O
correlated	O
with	O
the	O
characteristics	O
of	O
the	O
glucocorticoid	B-protein
receptor	I-protein
.	O

Constitutive	O
expression	O
of	O
p50	B-protein
homodimer	I-protein
in	O
freshly	B-cell_type
isolated	I-cell_type
human	I-cell_type
monocytes	I-cell_type
decreases	O
with	O
in	O
vitro	O
and	O
in	O
vivo	O
differentiation	O
:	O
a	O
possible	O
mechanism	O
influencing	O
human	O
immunodeficiency	O
virus	O
replication	O
in	O
monocytes	B-cell_type
and	O
mature	O
macrophages	O
.	O

Human	O
immunodeficiency	O
virus	O
type	O
1	O
(	O
HIV-1	O
)	O
replicates	O
more	O
efficiently	O
in	O
vitro	O
in	O
differentiated	B-cell_type
macrophages	I-cell_type
than	O
in	O
freshly	B-cell_type
isolated	I-cell_type
monocytes	I-cell_type
.	O

We	O
investigated	O
whether	O
this	O
may	O
be	O
partly	O
explained	O
by	O
changes	O
in	O
expression	O
of	O
NF-kappaB	B-protein
with	O
monocyte	O
differentiation	O
.	O

We	O
demonstrated	O
that	O
constitutive	O
expression	O
of	O
NF-kappaB	B-protein
in	O
primary	B-cell_type
human	I-cell_type
monocytes	I-cell_type
changed	O
significantly	O
with	O
differentiation	O
in	O
vitro	O
to	O
monocyte-derived	B-cell_type
macrophages	I-cell_type
(	O
MDMs	B-cell_type
)	O
and	O
differentiation	O
in	O
vivo	O
to	O
alveolar	B-cell_type
macrophages	I-cell_type
(	O
AMs	B-cell_type
)	O
.	O

Freshly	O
isolated	O
monocytes	O
constitutively	O
expressed	O
high	O
levels	O
of	O
transcriptionally	B-protein
inactive	I-protein
p50	I-protein
homodimer	I-protein
which	O
decreased	O
with	O
time	O
in	O
culture	O
in	O
favor	O
of	O
the	O
transcriptionally	O
active	O
p50/p65	B-protein
and	I-protein
p50/RelB	I-protein
heterodimers	I-protein
.	O

As	O
in	O
MDMs	B-cell_type
,	O
AMs	B-cell_type
constitutively	O
expressed	O
p50/p65	B-protein
and	O
p50/RelB	B-protein
although	O
at	O
lower	O
levels	O
.	O

HIV	O
infection	O
of	O
fresh	O
monocytes	B-cell_type
failed	O
to	O
induce	O
p50/p65	B-protein
as	O
seen	O
in	O
MDMs	B-cell_type
.	O

The	O
replacement	O
of	O
p50	B-protein
homodimers	I-protein
with	O
transcriptionally	O
active	O
heterodimers	O
following	O
time	O
in	O
culture	O
may	O
partially	O
explain	O
the	O
progressive	O
increase	O
in	O
susceptibility	O
of	O
monocytes	B-cell_type
to	O
HIV	O
infection	O
during	O
in	O
vitro	O
culture	O
.	O

The	O
change	O
in	O
NF-kappaB	B-protein
components	I-protein
with	O
monocyte	O
differentiation	O
in	O
vivo	O
may	O
also	O
explain	O
the	O
different	O
transcriptional	O
activities	O
of	O
these	O
cell	O
populations	O
in	O
HIV-infected	O
individuals	O
.	O

NF-kappa	B-protein
B	I-protein
-independent	O
suppression	O
of	O
HIV	O
expression	O
by	O
ascorbic	O
acid	O
.	O

Ascorbic	O
acid	O
(	O
ascorbate	O
or	O
vitamin	O
C	O
)	O
has	O
been	O
shown	O
to	O
suppress	O
the	O
induction	O
of	O
HIV	O
in	O
latently	B-cell_type
infected	I-cell_type
T	I-cell_type
lymphocytic	I-cell_type
cells	I-cell_type
following	O
stimulation	O
with	O
a	O
tumor	O
promoter	O
(	O
PMA	O
)	O
and	O
inflammatory	B-protein
cytokine	I-protein
(	O
TNF-alpha	B-protein
)	O
.	O

To	O
assess	O
whether	O
this	O
inhibition	O
was	O
mediated	O
via	O
modulation	O
of	O
the	O
cellular	B-protein
transcription	I-protein
factor	I-protein
,	O
NF-kappa	B-protein
B	I-protein
,	O
we	O
carried	O
out	O
gel	O
shift	O
analysis	O
on	O
nuclear	O
extracts	O
prepared	O
under	O
different	O
conditions	O
of	O
cell	O
stimulation	O
in	O
the	O
presence	O
or	O
absence	O
of	O
ascorbate	O
,	O
N-acetylcysteine	O
(	O
NAC	O
)	O
,	O
or	O
zidovudine	O
(	O
AZT	O
)	O
.	O

Pretreatment	O
of	O
ACH-2	B-cell_line
T	I-cell_line
cells	I-cell_line
by	O
NAC	O
followed	O
by	O
stimulation	O
with	O
PMA	O
,	O
TNF-alpha	B-protein
,	O
or	O
hydrogen	O
peroxide	O
(	O
H2O2	O
)	O
resulted	O
in	O
strong	O
suppression	O
of	O
NF-kappa	B-protein
B	I-protein
activation	O
.	O

In	O
contrast	O
,	O
neither	O
ascorbate	O
nor	O
AZT	O
affected	O
NF-kappa	B-protein
B	I-protein
activity	O
under	O
all	O
three	O
induction	O
conditions	O
in	O
the	O
ACH-2	B-cell_line
cell	I-cell_line
line	I-cell_line
.	O

Ascorbate	O
and	O
AZT	O
also	O
had	O
no	O
effect	O
on	O
NF-kappa	B-protein
B	I-protein
activation	O
following	O
TNF-alpha-	O
or	O
PMA-induced	O
stimulation	O
of	O
U1	O
promonocytic	O
cells	O
.	O

These	O
results	O
suggest	O
that	O
the	O
molecular	O
mechanism	O
of	O
HIV	O
inhibition	O
by	O
ascorbate	O
is	O
not	O
mediated	O
via	O
NF-kappa	B-protein
B	I-protein
inhibition	O
,	O
unlike	O
that	O
seen	O
with	O
other	O
antioxidants	O
.	O

A	O
T	B-DNA
cell-specific	I-DNA
enhancer	I-DNA
in	O
the	O
interleukin-3	B-DNA
locus	I-DNA
is	O
activated	O
cooperatively	O
by	O
Oct	B-DNA
and	I-DNA
NFAT	I-DNA
elements	I-DNA
within	O
a	O
DNase	B-DNA
I-hypersensitive	I-DNA
site	I-DNA
.	O

Interleukin-3	B-protein
(	O
IL-3	B-protein
)	O
is	O
a	O
cytokine	B-protein
that	O
is	O
expressed	O
primarily	O
in	O
activated	B-cell_type
T	I-cell_type
cells	I-cell_type
.	O

Here	O
we	O
identified	O
an	O
inducible	O
T	B-DNA
cell-specific	I-DNA
enhancer	I-DNA
14	O
kb	O
upstream	O
of	O
the	O
IL-3	B-DNA
gene	I-DNA
that	O
responded	O
to	O
activation	O
of	O
T	B-protein
cell	I-protein
receptor	I-protein
signaling	O
pathways	O
.	O

The	O
IL-3	B-protein
enhancer	O
spanned	O
an	O
inducible	O
cyclosporin	B-DNA
A-sensitive	I-DNA
DNase	I-DNA
I-hypersensitive	I-DNA
site	I-DNA
found	O
only	O
in	O
T	B-cell_type
cells	I-cell_type
.	O

Four	O
NFAT-like	B-DNA
elements	I-DNA
exist	O
within	O
the	O
enhancer	O
.	O

The	O
two	O
most	O
active	O
NFAT-like	B-DNA
elements	I-DNA
were	O
located	O
at	O
the	O
center	O
of	O
the	O
DNase	B-DNA
I-hypersensitive	I-DNA
site	I-DNA
.	O

One	O
of	O
these	O
NFAT-like	B-DNA
elements	I-DNA
encompassed	O
overlapping	O
Oct-	B-DNA
and	I-DNA
NFATp/c-binding	I-DNA
sites	I-DNA
,	O
which	O
functioned	O
in	O
a	O
highly	O
synergistic	O
manner	O
.	O

We	O
suggest	O
that	O
the	O
T	O
cell-specific	O
expression	O
of	O
the	O
IL-3	B-DNA
gene	I-DNA
is	O
partly	O
controlled	O
through	O
the	O
enhancer	O
by	O
cooperation	O
between	O
Oct	B-protein
and	I-protein
NFAT	I-protein
family	I-protein
proteins	I-protein
.	O

Adenovirus	B-protein
E1B	I-protein
19K	I-protein
protein	I-protein
is	O
required	O
for	O
efficient	O
DNA	O
replication	O
in	O
U937	B-cell_line
cells	I-cell_line
.	O

The	O
adenovirus	B-DNA
E1B	I-DNA
19K	I-DNA
gene	I-DNA
plays	O
an	O
essential	O
role	O
in	O
transformation	O
of	O
primary	B-cell_type
rodent	I-cell_type
cells	I-cell_type
in	O
cooperation	O
with	O
E1A	B-protein
and	O
in	O
the	O
inhibition	O
of	O
apoptosis	O
during	O
lytic	O
infection	O
.	O

It	O
has	O
been	O
shown	O
that	O
this	O
E1B	B-protein
19K	I-protein
protein	I-protein
is	O
not	O
necessary	O
for	O
viral	O
DNA	O
replication	O
in	O
human	B-cell_line
cell	I-cell_line
lines	I-cell_line
,	O
such	O
as	O
HeLa	B-cell_line
and	O
KB	B-cell_line
.	O

We	O
reported	O
here	O
that	O
the	O
E1B	B-protein
19K	I-protein
mutant	O
viruses	O
were	O
unable	O
to	O
replicate	O
efficiently	O
in	O
a	O
monocyte	B-cell_line
cell	I-cell_line
line	I-cell_line
,	O
U937	B-cell_line
.	O

Viral	O
DNA	O
synthesis	O
and	O
late	O
gene	O
expression	O
were	O
found	O
to	O
be	O
defective	O
in	O
U937	B-cell_line
cells	I-cell_line
infected	O
with	O
E1B	B-protein
19K	I-protein
mutants	O
compared	O
with	O
wild-type	O
virus	O
.	O

Early	O
viral	O
RNA	O
splicing	O
patterns	O
also	O
differ	O
between	O
wild-type	B-cell_line
and	I-cell_line
dl337-infected	I-cell_line
cells	I-cell_line
.	O

Furthermore	O
,	O
the	O
defect	O
in	O
viral	O
replication	O
could	O
be	O
complemented	O
by	O
dl312	O
virus	O
defective	O
in	O
E1A	B-protein
expression	O
4	O
days	O
after	O
infection	O
with	O
E1B	O
mutants	O
,	O
suggesting	O
persistence	O
of	O
the	O
E1B	B-DNA
mutant	I-DNA
genome	I-DNA
in	O
the	O
infected	O
cells	O
despite	O
defective	O
onset	O
of	O
the	O
late	O
phase	O
of	O
replication	O
.	O

These	O
results	O
imply	O
that	O
E1B	B-protein
19K	I-protein
is	O
required	O
for	O
efficient	O
viral	O
DNA	O
replication	O
in	O
U937	B-cell_line
cells	I-cell_line
.	O

Inefficient	O
DNA	O
replication	O
is	O
also	O
found	O
in	O
another	O
monocyte	B-cell_line
cell	I-cell_line
line	I-cell_line
,	O
THP-1	B-cell_line

Activation	O
of	O
Ras	O
and	O
mitogen-activated	B-protein
protein	I-protein
kinase	I-protein
pathway	O
by	O
terminal	B-protein
complement	I-protein
complexes	I-protein
is	O
G	B-protein
protein	I-protein
dependent	O
.	O

Assembly	O
of	O
terminal	B-protein
complement	I-protein
complexes	I-protein
(	O
TCC	B-protein
)	O
C5b-7	B-protein
,	O
C5b-8	B-protein
,	O
and	O
C5b-9	B-protein
on	O
target	O
cells	O
during	O
acute	O
and	O
chronic	O
inflammation	O
induces	O
hydrolysis	O
of	O
plasma	O
membrane	O
phospholipids	O
and	O
heterotrimeric	O
G	B-protein
protein	I-protein
activation	O
.	O

TCC	B-protein
also	O
stimulate	O
a	O
variety	O
of	O
cellular	O
activities	O
,	O
which	O
include	O
cytokine	B-protein
synthesis	O
,	O
proto-oncogene	B-DNA
activation	O
,	O
and	O
mitotic	O
signaling	O
.	O

Now	O
we	O
report	O
that	O
sublytic	O
TCC	B-protein
induced	O
Ras	B-protein
,	O
Raf-1	B-protein
,	O
and	O
extracellular	B-protein
signal-regulated	I-protein
kinase	I-protein
(	I-protein
ERK	I-protein
)	I-protein
1	I-protein
activation	O
in	O
JY25	O
B	O
cell	O
line	O
.	O

When	O
cells	O
were	O
exposed	O
to	O
C5b-9	B-protein
,	O
GTP-bound	B-protein
Ras	I-protein
in	O
anti-C5b-9	B-protein
immunoprecipitates	I-protein
was	O
increased	O
3.2-fold	O
at	O
2	O
min	O
,	O
while	O
GTP-bound	B-protein
Ras	I-protein
in	O
anti-Ras	B-protein
immunoprecipitates	I-protein
was	O
increased	O
2-fold	O
at	O
10	O
min	O
.	O

Both	O
C5b-9	B-protein
and	O
C5b-7	B-protein
,	O
but	O
not	O
C5b6	B-protein
,	O
increased	O
Raf-1	B-protein
kinase	O
activity	O
maximum	O
3.3-fold	O
at	O
2	O
min	O
and	O
2.8-fold	O
at	O
5	O
min	O
,	O
respectively	O
.	O

ERK1	B-protein
activity	O
was	O
2-fold	O
increased	O
by	O
C5b-9	B-protein
at	O
2	O
min	O
and	O
by	O
C5b-7	B-protein
at	O
10	O
min	O
,	O
over	O
the	O
C5b6	B-protein
level	O
.	O

The	O
role	O
of	O
mitogen-activated	B-protein
protein	I-protein
kinase	I-protein
(	O
MAPK	B-protein
)	O
pathway	O
on	O
TCC	B-protein
-inducible	O
mitotic	O
signaling	O
was	O
evaluated	O
by	O
assessing	O
DNA	O
synthesis	O
and	O
activator	B-protein
protein	I-protein
1	I-protein
(	O
AP-1	B-protein
)	O
DNA-binding	O
activity	O
.	O

The	O
MAPK/ERK-specific	O
inhibitor	O
PD	O
098	O
,	O
059	O
abolished	O
the	O
C5b-9	B-protein
-induced	O
DNA	O
synthesis	O
.	O

Involvement	O
of	O
G	B-protein
protein	I-protein
in	O
the	O
activation	O
of	O
MAPK	B-protein
pathway	O
by	O
TCC	B-protein
was	O
indicated	O
by	O
inhibition	O
of	O
Raf-1	B-protein
and	O
ERK1	B-protein
kinase	O
activity	O
,	O
as	O
well	O
as	O
the	O
DNA	O
synthesis	O
by	O
pretreatment	O
of	O
cells	O
with	O
pertussis	B-protein
toxin	I-protein
.	O

Overexpression	O
of	O
beta-adrenergic	O
receptor	O
kinase	O
1	O
carboxyl-terminal	O
peptide	O
in	O
JY25	B-cell_line
cells	I-cell_line
also	O
inhibited	O
Raf-1	B-protein
and	O
ERK1	B-protein
activity	O
,	O
indicating	O
a	O
direct	O
involvement	O
of	O
G	O
betagamma	O
subunits	O
in	O
the	O
signal	O
transduction	O
generated	O
through	O
activation	O
of	O
MAPK	B-protein
pathway	O
by	O
TCC	B-protein
assembly	O
in	O
the	O
plasma	O
membrane	O
.	O

Spontaneous	O
occurrence	O
of	O
early	O
region	O
1A	O
reiteration	O
mutants	O
of	O
type	O
5	O
adenovirus	O
in	O
persistently	B-cell_type
infected	I-cell_type
human	I-cell_type
T-lymphocytes	I-cell_type
.	O

Mutants	O
of	O
type	O
5	O
adenovirus	O
(	O
Ad5	O
)	O
with	O
reiterated	B-DNA
DNA	I-DNA
sequences	I-DNA
in	O
the	O
E1a	B-DNA
region	I-DNA
appeared	O
in	O
a	O
human	B-cell_line
T-lymphocyte	I-cell_line
cell	I-cell_line
line	I-cell_line
,	O
Molt-4	B-cell_line
,	O
persistently	O
infected	O
with	O
H5sub304	O
,	O
a	O
deletion/substitution	O
mutant	O
that	O
has	O
a	O
wild-type	O
phenotype	O
in	O
viral	O
replication	O
.	O

Endonuclease	B-protein
analyses	O
and	O
DNA	O
sequencing	O
revealed	O
DNA	O
reiteration	O
in	O
each	O
mutant	O
.	O

In	O
the	O
four	O
representative	O
mutants	O
investigated	O
,	O
the	O
DNA	B-DNA
reiterations	I-DNA
all	O
started	O
within	O
a	O
six-base-pair	B-DNA
consensus	I-DNA
sequence	I-DNA
,	O
G	O
(	O
or	O
C	O
)	O
CTGTG	O
,	O
located	O
in	O
the	O
second	O
exon	B-DNA
of	O
the	O
E1a	B-DNA
region	I-DNA
(	O
at	O
nt	O
1333	O
,	O
1367	O
,	O
or	O
1419	O
)	O
.	O

There	O
was	O
not	O
any	O
DNA	O
homology	O
between	O
the	O
breakpoints	O
in	O
the	O
second	O
exon	B-DNA
and	O
the	O
inserting	B-DNA
sequences	I-DNA
(	O
starting	O
at	O
nt	O
532	O
,	O
710	O
,	O
or	O
792	O
)	O
.	O

Northern	O
analyses	O
suggested	O
that	O
the	O
reiterated	B-DNA
splicing	I-DNA
sites	I-DNA
of	O
the	O
representative	O
mutants	O
were	O
all	O
used	O
in	O
RNA	O
splicing	O
,	O
and	O
the	O
closest	O
donor	O
and	O
recipient	O
joints	O
were	O
used	O
most	O
frequently	O
.	O

These	O
observations	O
imply	O
that	O
during	O
persistent	O
infection	O
Ad5	O
underwent	O
spontaneous	O
mutations	O
by	O
sequence-specific	O
breakage	O
and	O
nonhomologous	O
end-end	O
joining	O
recombination	O
events	O
.	O

These	O
E1a	O
reiteration	O
mutants	O
could	O
be	O
propagated	O
in	O
HeLa	B-cell_line
,	O
A549	B-cell_line
,	O
and	O
KB	B-cell_line
cells	I-cell_line
;	O
they	O
were	O
genetically	O
stable	O
;	O
and	O
they	O
killed	O
CREF	B-cell_line
cells	I-cell_line
at	O
a	O
strikingly	O
high	O
frequency	O
.	O

Preliminary	O
observations	O
tend	O
to	O
correlate	O
this	O
CREF	O
cell	O
killing	O
with	O
the	O
accumulation	O
of	O
the	O
early	B-protein
viral	I-protein
proteins	I-protein
and/or	O
viral	B-DNA
DNA	I-DNA
in	O
the	O
infected	B-cell_type
cells	I-cell_type
.	O

This	O
degree	O
of	O
cell	O
damage	O
was	O
not	O
observed	O
in	O
Ad5wt	O
or	O
H5sub304	O
infection	O
of	O
CREF	B-cell_line
cells	I-cell_line
.	O

The	O
observed	O
E1a	B-DNA
reiterations	I-DNA
provide	O
a	O
model	O
to	O
gain	O
insight	O
into	O
understanding	O
the	O
evolutionary	O
events	O
of	O
some	O
,	O
if	O
not	O
all	O
,	O
adenovirus	O
types	O
during	O
many	O
years	O
of	O
symbiotic	O
,	O
persistent	O
relationship	O
in	O
human	O
tonsils	O
and	O
adenoids	O
and	O
possibly	O
other	O
lymphoid	O
organs	O
.	O

Preferential	O
presentation	O
of	O
herpes	B-protein
simplex	I-protein
virus	I-protein
T-cell	I-protein
antigen	I-protein
by	O
HLA	B-protein
DQA1*0501/DQB1*0201	I-protein
in	O
comparison	O
to	O
HLA	B-protein
DQA1*0201/DQB1*0201	I-protein
.	O

The	O
HLA	B-DNA
DQA1	I-DNA
locus	I-DNA
is	O
polymorphic	O
.	O

Haplotypes	O
containing	O
HLA	B-DNA
DQA1*0501	I-DNA
,	O
but	O
not	O
HLA	B-DNA
DQA1*0201	I-DNA
,	O
together	O
with	O
HLA	B-DNA
DQB1*0201	I-DNA
are	O
associated	O
with	O
Grave	O
's	O
disease	O
and	O
celiac	O
sprue	O
.	O

In	O
this	O
report	O
,	O
we	O
demonstrate	O
a	O
functional	O
correlate	O
of	O
DQA1	O
polymorphism	O
.	O

T	B-cell_type
cells	I-cell_type
infiltrating	O
a	O
herpes	O
simplex	O
virus	O
(	O
HSV	O
)	O
lesion	O
from	O
a	O
HLA	O
DQ	O
2	O
,	O
7	O
individual	O
yielded	O
a	O
virus-specific	B-cell_line
CD4+	I-cell_line
clone	I-cell_line
restricted	O
by	O
DQ2	B-protein
.	O

Presentation	O
of	O
viral	O
peptide	O
and	O
protein	O
segregated	O
with	O
DQA1	B-DNA
allele	I-DNA
,	O
because	O
cell	O
lines	O
bearing	O
DQA1*0501/DQB1*0201	B-protein
heterodimers	I-protein
presented	O
antigen	O
in	O
proliferation	O
and	O
cytotoxicity	O
assays	O
much	O
more	O
efficiently	O
than	O
cell	B-cell_line
lines	I-cell_line
bearing	O
DQA1*0201/DQB1*0201	B-protein
.	O

Binding	O
of	O
viral	O
peptide	O
to	O
cell	O
lines	O
bearing	O
DQA1*0201	B-protein
,	O
in	O
comparison	O
to	O
DQA1*0501	B-protein
,	O
was	O
only	O
moderately	O
reduced	O
and	O
may	O
not	O
explain	O
this	O
effect	O
.	O

Truncation	O
and	O
substitution	O
analyses	O
of	O
peptide	O
binding	O
and	O
T-cell	O
activation	O
were	O
performed	O
to	O
determine	O
which	O
viral	O
peptide	O
residues	O
contacting	O
TCR	B-protein
might	O
therefore	O
be	O
presented	O
in	O
an	O
altered	O
conformation	O
by	O
DQA1*0201/DQB1*0201	B-protein
.	O

Residues	O
432	O
,	O
435	O
,	O
437	O
,	O
438	O
,	O
and	O
440	O
(	O
position	B-DNA
P1	I-DNA
,	I-DNA
P4	I-DNA
,	I-DNA
P6	I-DNA
,	I-DNA
P7	I-DNA
,	I-DNA
and	I-DNA
P9	I-DNA
)	O
contributed	O
to	O
DQ2	B-protein
binding	O
,	O
whereas	O
residues	O
431	O
,	O
433	O
,	O
434	O
,	O
and	O
436	O
(	O
positions	B-DNA
P	I-DNA
1	I-DNA
,	I-DNA
P2	I-DNA
,	I-DNA
P3	I-DNA
,	I-DNA
and	I-DNA
P5	I-DNA
)	O
contributed	O
to	O
TCR	B-protein
contact	O
.	O

Differential	O
presentation	O
of	O
peptide	O
by	O
HLA	B-protein
DQ2	I-protein
heterodimers	I-protein
varying	O
at	O
the	O
DQA1	B-DNA
locus	I-DNA
may	O
have	O
relevance	O
to	O
host	O
defense	O
and	O
the	O
pathogenesis	O
of	O
HLA	O
DQ2	B-protein
-associated	O
autoimmune	O
diseases	O
.	O

Inhibitor	O
(	O
IK	O
)	O
of	O
IFN-gamma	B-protein
induced	O
HLA	B-protein
class	I-protein
II	I-protein
antigens	I-protein
expression	O
also	O
inhibits	O
HLA	B-protein
class	I-protein
II	I-protein
constitutive	O
expression	O
in	O
the	O
human	B-cell_line
Raji	I-cell_line
B	I-cell_line
cell	I-cell_line
line	I-cell_line
.	O

The	O
expression	O
of	O
major	B-protein
histocompatibility	I-protein
complex	I-protein
(	I-protein
MHC	I-protein
)	I-protein
class	I-protein
II	I-protein
antigens	I-protein
is	O
constitutive	O
in	O
professional	B-cell_type
antigen	I-cell_type
presenting	I-cell_type
cells	I-cell_type
(	O
APCs	B-cell_type
)	O
but	O
can	O
also	O
be	O
induced	O
by	O
interferon-gamma	B-protein
(	O
IFN-gamma	B-protein
)	O
on	O
the	O
majority	O
of	O
the	O
non	O
professional	B-cell_type
APCs	I-cell_type
(	O
e.g	O
.	O
fibroblasts	B-cell_type
)	O
.	O

We	O
have	O
recently	O
characterised	O
a	O
new	O
factor	O
called	O
IK	B-protein
which	O
is	O
an	O
efficient	O
inhibitor	O
of	O
IFN-gamma	B-protein
induction	O
of	O
MHC	B-protein
class	I-protein
II	I-protein
antigens	I-protein
expression	O
.	O

Here	O
,	O
we	O
demonstrate	O
a	O
novel	O
role	O
for	O
IK	B-protein
in	O
MHC	B-protein
class	I-protein
II	I-protein
expression	O
since	O
over-expression	O
of	O
this	O
protein	O
by	O
stable	O
transfection	O
into	O
human	O
B	O
cells	O
led	O
to	O
a	O
total	O
disappearance	O
of	O
constitutive	O
MHC	B-RNA
class	I-RNA
II	I-RNA
mRNA	I-RNA
expression	O
.	O

The	O
class	B-DNA
II	I-DNA
transactivator	I-DNA
(	O
CIITA	B-DNA
)	O
is	O
necessary	O
for	O
both	O
constitutive	O
and	O
IFN-gamma	B-protein
induced	O
MHC	B-protein
class	I-protein
II	I-protein
expressions	O
.	O

Examination	O
of	O
CIITA	B-RNA
mRNA	I-RNA
in	O
IK	B-protein
stably	O
transfected	O
clones	O
revealed	O
a	O
marked	O
reduction	O
of	O
CIITA	B-RNA
mRNA	I-RNA
transcription	O
.	O

Taken	O
together	O
these	O
results	O
demonstrate	O
that	O
the	O
IK	B-protein
protein	I-protein
plays	O
a	O
key	O
role	O
in	O
the	O
constitutive	O
expression	O
of	O
MHC	B-protein
class	I-protein
II	I-protein
antigens	I-protein
and	O
that	O
inhibition	O
induced	O
by	O
IK	B-protein
is	O
upstream	O
of	O
CIITA	B-DNA
in	O
this	O
regulatory	O
pathway	O
.	O

Selective	O
expression	O
of	O
an	O
interleukin-12	B-protein
receptor	I-protein
component	I-protein
by	O
human	B-cell_type
T	I-cell_type
helper	I-cell_type
1	I-cell_type
cells	I-cell_type
.	O

Interleukin-12	B-protein
(	O
IL-12	B-protein
)	O
,	O
a	O
heterodimeric	B-protein
cytokine	I-protein
produced	O
by	O
activated	O
monocytes	O
and	O
dendritic	O
cells	O
,	O
plays	O
a	O
crucial	O
role	O
in	O
regulating	O
interferon	B-protein
(	I-protein
IFN	I-protein
)	I-protein
-gamma	I-protein
production	O
and	O
in	O
the	O
generation	O
of	O
IFN-gamma-producing	B-cell_type
T	I-cell_type
helper	I-cell_type
1	I-cell_type
(	I-cell_type
Th1	I-cell_type
)	I-cell_type
cells	I-cell_type
.	O

Here	O
we	O
show	O
that	O
the	O
IL-12	B-protein
receptor	I-protein
(	I-protein
IL-12R	I-protein
)	I-protein
beta	I-protein
2	I-protein
subunit	I-protein
,	O
a	O
recently	O
cloned	O
binding	B-protein
and	I-protein
signal	I-protein
transducing	I-protein
component	I-protein
of	O
the	O
IL-12R	B-protein
,	O
is	O
expressed	O
on	O
human	B-cell_line
Th1	I-cell_line
but	I-cell_line
not	I-cell_line
Th2	I-cell_line
clones	I-cell_line
and	O
is	O
induced	O
during	O
differentiation	O
of	O
human	B-cell_type
naive	I-cell_type
cells	I-cell_type
along	O
the	O
Th1	O
but	O
not	O
the	O
Th2	O
pathway	O
.	O

IL-12	B-protein
and	O
type	B-protein
I	I-protein
but	I-protein
not	I-protein
type	I-protein
II	I-protein
interferons	I-protein
induce	O
expression	O
of	O
the	O
IL-12R	B-protein
beta	I-protein
2	I-protein
chain	I-protein
during	O
in	O
vitro	O
T	O
cell	O
differentiation	O
after	O
antigen	O
receptor	O
triggering	O
.	O

The	O
selective	O
expression	O
and	O
regulation	O
of	O
the	O
IL-12R	B-protein
beta	I-protein
2	I-protein
subunit	I-protein
may	O
help	O
to	O
understand	O
the	O
basis	O
of	O
Th1/Th2	O
differentiation	O
and	O
may	O
provide	O
therapeutic	O
options	O
for	O
altering	O
the	O
Th1/Th2	O
balance	O
in	O
several	O
immuno-pathological	O
conditions	O
such	O
as	O
autoimmune	O
diseases	O
and	O
allergies	O
.	O

The	O
T	B-protein
cell	I-protein
activation	I-protein
factor	I-protein
NF-ATc	B-protein
positively	O
regulates	O
HIV-1	O
replication	O
and	O
gene	O
expression	O
in	O
T	B-cell_type
cells	I-cell_type
.	O

Clinical	O
deterioration	O
in	O
human	O
immunodeficiency	O
virus	O
type	O
1	O
(	O
HIV-1	O
)	O
infection	O
is	O
associated	O
with	O
increased	O
levels	O
of	O
viral	O
replication	O
and	O
burden	O
in	O
the	O
peripheral	O
blood	O
and	O
lymphoid	O
organs	O
.	O

T	O
cell	O
activation	O
and	O
ensuing	O
cellular	O
gene	O
activation	O
can	O
be	O
critical	O
for	O
HIV-1	O
replication	O
.	O

The	O
hypothesis	O
that	O
the	O
nuclear	B-protein
factor	I-protein
of	I-protein
activated	I-protein
T	I-protein
cells	I-protein
(	O
NF-AT	B-protein
)	O
may	O
influence	O
HIV-1	O
replication	O
is	O
therefore	O
compelling	O
given	O
the	O
tight	O
correlation	O
of	O
HIV-1	O
transcriptional	O
induction	O
to	O
T	O
cell	O
activation	O
.	O

We	O
report	O
that	O
certain	O
NF-AT	B-protein
(	I-protein
Rel	I-protein
)	I-protein
family	I-protein
members	I-protein
productively	O
bind	O
the	O
kappaB	B-DNA
regulatory	I-DNA
elements	I-DNA
,	O
synergize	O
with	O
NF-kappaB	B-protein
and	O
Tat	B-protein
in	O
transcriptional	O
activation	O
of	O
HIV-1	O
,	O
and	O
enhance	O
HIV-1	O
replication	O
in	O
T	B-cell_type
cells	I-cell_type
.	O

These	O
results	O
link	O
regulatory	B-protein
factors	I-protein
critical	O
to	O
T	O
cell	O
commitment	O
directly	O
to	O
HIV-1	O
replication	O
.	O

Transcription	O
mediated	O
by	O
NFAT	B-protein
is	O
highly	O
inducible	O
in	O
effector	O
CD4+	B-cell_type
T	I-cell_type
helper	I-cell_type
2	I-cell_type
(	I-cell_type
Th2	I-cell_type
)	I-cell_type
cells	I-cell_type
but	O
not	O
in	O
Th1	B-cell_type
cells	I-cell_type
.	O

Transcriptional	B-protein
factors	I-protein
of	O
the	O
NFAT	B-protein
family	I-protein
play	O
an	O
important	O
role	O
in	O
regulating	O
the	O
expression	O
of	O
several	O
cytokine	B-DNA
genes	I-DNA
during	O
the	O
immune	O
response	O
,	O
such	O
as	O
the	O
genes	O
for	O
interleukin	B-protein
2	I-protein
(	O
IL-2	B-protein
)	O
and	O
IL-4	B-protein
,	O
among	O
others	O
.	O

Upon	O
antigen	O
stimulation	O
,	O
precursor	O
CD4+	B-cell_type
T	I-cell_type
helper	I-cell_type
(	I-cell_type
pTh	I-cell_type
)	I-cell_type
cells	I-cell_type
proliferate	O
and	O
differentiate	O
into	O
two	O
populations	O
of	O
effector	B-cell_type
cells	I-cell_type
(	O
eTh1	B-cell_type
and	O
eTh2	B-cell_type
)	O
,	O
each	O
one	O
expressing	O
a	O
specific	O
pattern	O
of	O
cytokines	B-protein
that	O
distinguishes	O
them	O
from	O
their	O
precursors	O
.	O

eTh2	B-cell_type
cells	I-cell_type
are	O
the	O
major	O
source	O
of	O
IL-4	B-protein
,	O
while	O
gamma	B-protein
interferon	I-protein
is	O
produced	O
by	O
eTh1	B-cell_type
cells	I-cell_type
.	O

Here	O
we	O
have	O
used	O
reporter	O
transgenic	O
mice	O
to	O
show	O
that	O
DNA	O
binding	O
and	O
transcriptional	O
activities	O
of	O
NFAT	B-protein
are	O
transiently	O
induced	O
during	O
the	O
differentiation	O
of	O
pTh	B-cell_type
cells	I-cell_type
into	O
either	O
eTh1	B-cell_type
or	O
eTh2	B-cell_type
cells	I-cell_type
to	O
mediate	O
the	O
expression	O
of	O
IL-2	B-protein
as	O
a	O
common	O
growth	O
factor	O
in	O
both	O
pathways	O
.	O

However	O
,	O
although	O
NFAT	B-protein
DNA	O
binding	O
is	O
similarly	O
induced	O
in	O
both	O
eTh1	B-cell_type
and	O
eTh2	B-cell_type
cells	I-cell_type
upon	O
antigen	O
stimulation	O
,	O
only	O
the	O
NFAT	B-protein
complexes	I-protein
present	O
in	O
eTh2	B-cell_type
cells	I-cell_type
are	O
able	O
to	O
mediate	O
high-level	O
transcription	O
,	O
and	O
relatively	O
little	O
NFAT	B-protein
transcriptional	O
activity	O
was	O
induced	O
in	O
eTh1	B-cell_type
cells	I-cell_type
.	O

In	O
contrast	O
to	O
activated	O
pTh	B-cell_type
cells	I-cell_type
,	O
neither	O
eTh1	B-cell_type
nor	O
eTh2	B-cell_type
cells	I-cell_type
produced	O
significant	O
IL-2	B-protein
upon	O
stimulation	O
,	O
but	O
the	O
high	O
levels	O
of	O
NFAT	B-protein
transcriptional	O
activities	O
directly	O
correlate	O
with	O
the	O
IL-4	B-protein
production	O
induced	O
in	O
response	O
to	O
antigen	O
stimulation	O
in	O
eTh2	B-cell_type
cells	I-cell_type
.	O

These	O
data	O
suggest	O
that	O
activated	O
NFAT	B-protein
is	O
involved	O
in	O
the	O
effector	O
function	O
of	O
eTh2	B-cell_type
cells	I-cell_type
and	O
that	O
the	O
failure	O
of	O
eTh1	B-cell_type
cells	I-cell_type
to	O
produce	O
IL-4	B-protein
in	O
response	O
to	O
an	O
antigen	O
is	O
due	O
,	O
at	O
least	O
partially	O
,	O
to	O
a	O
failure	O
to	O
induce	O
high-level	O
transcription	O
of	O
the	O
IL-4	B-DNA
gene	I-DNA
by	O
NFAT	B-protein
.	O

Regulation	O
of	O
NFAT	B-protein
could	O
be	O
therefore	O
a	O
critical	O
element	O
in	O
the	O
polarization	O
to	O
eTh1	B-cell_type
or	O
eTh2	B-cell_type
.	O

Activation	O
of	O
the	O
transcription	B-protein
factor	I-protein
NF-kappaB	B-protein
in	O
lipopolysaccharide-stimulated	B-cell_line
U937	I-cell_line
cells	I-cell_line
.	O

During	O
the	O
course	O
of	O
serious	O
bacterial	O
infections	O
,	O
lipopolysaccharide	O
(	O
LPS	O
)	O
interacts	O
with	O
monocyte/macrophage	B-protein
receptors	I-protein
,	O
resulting	O
in	O
the	O
generation	O
of	O
inflammatory	B-protein
cytokines	I-protein
.	O

Transcription	B-protein
factor	I-protein
NF-kappaB	B-protein
is	O
crucial	O
in	O
activating	O
the	O
transcription	O
of	O
genes	O
encoding	O
proinflammatory	B-protein
cytokines	I-protein
.	O

In	O
this	O
paper	O
,	O
we	O
demonstrate	O
that	O
the	O
activation	O
of	O
NF-kappaB	B-protein
by	O
LPS	O
in	O
a	O
promonocytic	B-cell_line
cell	I-cell_line
line	I-cell_line
(	O
U937	B-cell_line
)	O
followed	O
a	O
rather	O
slow	O
kinetics	O
,	O
depending	O
on	O
the	O
rate	O
of	O
IkappaB-alpha	B-protein
inhibitor	O
hydrolysis	O
.	O

No	O
degradation	O
of	O
p105	B-protein
and	I-protein
p100	I-protein
inhibitors	I-protein
was	O
observed	O
under	O
these	O
conditions	O
.	O

The	O
transduction	O
pathway	O
leading	O
to	O
NF-kappaB	B-protein
activation	O
in	O
U937	B-cell_line
cells	I-cell_line
involved	O
the	O
intracellular	O
generation	O
of	O
reactive	O
oxygen	O
species	O
(	O
ROS	O
)	O
,	O
as	O
demonstrated	O
by	O
the	O
concomitant	O
inhibitory	O
effects	O
of	O
antioxidants	O
on	O
NF-kappaB	B-protein
activation	O
and	O
the	O
emission	O
of	O
a	O
fluorescent	O
probe	O
reacting	O
intracellularly	O
with	O
hydrogen	O
peroxide	O
.	O

This	O
ROS	O
pathway	O
was	O
also	O
characterized	O
by	O
the	O
use	O
of	O
other	O
inhibitors	O
.	O

This	O
finding	O
indicates	O
that	O
phospholipase	B-protein
A2	I-protein
and	O
5-lipoxygenase	B-protein
are	O
also	O
involved	O
.	O

However	O
,	O
the	O
NF-kappaB	B-protein
activation	O
pathway	O
involving	O
the	O
acidic	B-protein
sphingomyelinase	I-protein
of	O
the	O
endolysosomial	O
membrane	O
did	O
not	O
seem	O
to	O
participate	O
in	O
the	O
LPS-induced	O
NF-kappaB	B-protein
activation	O
in	O
U937	B-cell_line
cells	I-cell_line
.	O

c-Rel	B-protein
is	O
a	O
target	O
of	O
pentoxifylline-mediated	O
inhibition	O
of	O
T	O
lymphocyte	O
activation	O
.	O

The	O
possible	O
clinical	O
use	O
of	O
the	O
methyl	O
xanthine	O
derivative	O
,	O
pentoxifylline	O
(	O
PF	O
)	O
,	O
for	O
the	O
treatment	O
of	O
T	O
cell-dependent	O
diseases	O
is	O
being	O
noted	O
with	O
increasing	O
interest	O
.	O

In	O
this	O
paper	O
,	O
we	O
studied	O
the	O
molecular	O
consequences	O
of	O
PF	O
treatment	O
during	O
lymphocyte	O
activation	O
.	O

We	O
found	O
that	O
in	O
T	B-cell_type
cells	I-cell_type
,	O
anti-CD3-induced	O
c-Rel	B-protein
expression	O
was	O
blocked	O
by	O
PF	O
,	O
whereas	O
the	O
induction	O
of	O
other	O
NF-kappaB	B-protein
family	I-protein
members	I-protein
was	O
not	O
significantly	O
affected	O
.	O

However	O
,	O
induction	O
of	O
NF-AT	B-protein
,	O
which	O
has	O
the	O
same	O
signaling	O
requirements	O
as	O
c-Rel	B-protein
induction	O
,	O
was	O
not	O
inhibited	O
by	O
PF	O
.	O

Among	O
genes	O
that	O
respond	O
to	O
these	O
transcription	B-protein
factors	I-protein
,	O
IL-2	B-RNA
mRNA	I-RNA
induction	O
was	O
suppressed	O
by	O
PF	O
,	O
whereas	O
IL-2R	B-RNA
(	I-RNA
alpha	I-RNA
)	I-RNA
chain	I-RNA
mRNA	I-RNA
induction	O
was	O
not	O
affected	O
.	O

These	O
observations	O
implicated	O
c-Rel	B-protein
as	O
an	O
IL-2	B-protein
promoter	I-protein
factor	I-protein
,	O
for	O
which	O
experimental	O
support	O
was	O
obtained	O
from	O
transient	O
transfection	O
experiments	O
.	O

In	O
contrast	O
with	O
the	O
observation	O
in	O
T	B-cell_type
cells	I-cell_type
,	O
c-Rel	B-protein
induction	O
was	O
not	O
blocked	O
by	O
PF	O
in	O
B	B-cell_type
cells	I-cell_type
.	O

The	O
greater	O
selectivity	O
of	O
PF	O
,	O
compared	O
with	O
FK506	O
,	O
at	O
both	O
the	O
molecular	O
and	O
cellular	O
levels	O
may	O
prove	O
advantageous	O
in	O
manipulating	O
T	O
cell	O
responses	O
in	O
vivo	O
.	O

V3	B-protein
loop	I-protein
of	O
human	O
immunodeficiency	O
virus	O
type	O
1	O
suppresses	O
interleukin	B-protein
2	I-protein
-induced	O
T	O
cell	O
growth	O
[	O
published	O
erratum	O
appears	O
in	O
AIDS	O
Res	O
Hum	O
Retroviruses	O
1997	O
May	O
1	O
;	O
13	O
(	O
7	O
)	O
:	O
633	O
]	O

We	O
tested	O
the	O
effect	O
of	O
three	O
linear	O
or	O
two	O
loop	O
peptides	O
derived	O
from	O
the	O
V3	B-protein
region	I-protein
of	O
the	O
HTLV-III	O
BH10	O
clone	O
or	O
the	O
SF2	O
strain	O
of	O
human	O
immunodeficiency	O
virus	O
type	O
1	O
on	O
IL-2	B-protein
-driven	O
T	O
cell	O
proliferation	O
.	O

V3-BH10	B-protein
,	O
which	O
consists	O
of	O
42	B-protein
amino	I-protein
acids	I-protein
and	O
has	O
a	O
loop	B-protein
structure	I-protein
,	O
suppressed	O
IL-2	B-protein
-driven	O
proliferation	O
of	O
all	O
IL-2-dependent	B-cell_line
cells	I-cell_line
[	O
Kit225	B-cell_line
,	O
ED-40515	B-cell_line
(	I-cell_line
+	I-cell_line
)	I-cell_line
,	O
KT-3	B-cell_line
,	O
7-day	B-cell_line
PHA-blasts	I-cell_line
,	O
and	O
fresh	B-cell_type
peripheral	I-cell_type
blood	I-cell_type
mononuclear	I-cell_type
cells	I-cell_type
]	O
tested	O
,	O
whereas	O
it	O
did	O
not	O
suppress	O
the	O
cell	O
growth	O
of	O
IL-2-independent	B-cell_line
cell	I-cell_line
lines	I-cell_line
(	O
Hut102	B-cell_line
,	O
Molt-4	B-cell_line
,	O
and	O
Jurkat	B-cell_line
)	O
.	O

This	O
suppressive	O
effect	O
was	O
also	O
seen	O
in	O
IL-2	B-protein
-driven	O
cell	O
growth	O
of	O
CD8-positive	B-cell_type
lymphocytes	I-cell_type
purified	O
from	O
7-day	B-cell_type
PHA-blasts	I-cell_type
,	O
indicating	O
that	O
CD4	B-protein
molecules	I-protein
were	O
not	O
required	O
for	O
the	O
suppression	O
.	O

The	O
treatment	O
with	O
anti-V3	B-protein
loop	I-protein
monoclonal	I-protein
antibody	I-protein
(	O
902	B-protein
antibody	I-protein
)	O
completely	O
abolished	O
the	O
suppressive	O
effect	O
of	O
V3-BH10	B-protein
.	O

In	O
addition	O
,	O
V3-BH10	B-protein
generated	O
the	O
arrest	O
of	O
Kit225	B-cell_line
cells	I-cell_line
and	O
also	O
purified	B-cell_line
CD8-positive	I-cell_line
lymphocytes	I-cell_line
in	O
G1	O
phase	O
in	O
the	O
presence	O
of	O
IL-2	B-protein
.	O

Neither	O
chromatin	B-DNA
condensation	O
nor	O
DNA	O
fragmentation	O
was	O
detected	O
in	O
Kit225	B-cell_line
cells	I-cell_line
cultured	O
with	O
V3-BH10	B-protein
and	O
IL-2	B-protein
.	O

V3-BH10	B-protein
neither	O
blocked	O
radiolabeled	O
IL-2	B-protein
binding	O
to	O
IL-2	B-protein
receptors	I-protein
nor	O
affected	O
tyrosyl	O
phosphorylation	O
of	O
several	O
cellular	B-protein
proteins	I-protein
(	O
p120	B-protein
,	O
p98	B-protein
,	O
p96	B-protein
,	O
p54	B-protein
,	O
and	O
p38	B-protein
)	O
,	O
which	O
is	O
immediately	O
induced	O
by	O
IL-2	B-protein
stimulation	O
.	O

However	O
,	O
V3-BH10	B-protein
enhanced	O
IL-2	B-protein
-induced	B-RNA
mRNA	I-RNA
expression	O
of	O
c-fos	B-DNA
but	O
not	O
c-myc	B-DNA
or	O
junB	B-DNA
.	O

Thus	O
,	O
the	O
binding	O
of	O
V3	B-protein
loop	I-protein
of	O
gp120	B-protein
to	O
the	O
cell	O
surface	O
molecule	O
(	O
s	O
)	O
appears	O
to	O
affect	O
intracellular	O
IL-2	B-protein
signaling	O
,	O
which	O
leads	O
to	O
the	O
suppression	O
of	O
IL-2	B-protein
-induced	O
T	O
cell	O
growth	O

A	O
negative	O
role	O
for	O
phosphoinositide	B-protein
3-kinase	I-protein
in	O
T-cell	B-protein
antigen	I-protein
receptor	I-protein
function	O
.	O

BACKGROUND	O
:	O
A	O
delicate	O
balance	O
between	O
positive	O
and	O
negative	O
regulatory	O
mechanisms	O
during	O
T-cell	O
activation	O
determines	O
the	O
specificity	O
and	O
magnitude	O
of	O
an	O
immune	O
response	O
.	O

Phosphoinositide	B-protein
3-kinase	I-protein
(	O
PI	B-protein
3-kinase	I-protein
)	O
is	O
activated	O
by	O
a	O
diverse	O
set	O
of	O
receptors	O
that	O
determine	O
T-cell	O
function	O
,	O
including	O
the	O
T-cell	B-protein
antigen	I-protein
receptor	I-protein
(	O
TCR	B-protein
)	O
,	O
the	O
costimulatory	B-protein
receptor	I-protein
CD28	I-protein
,	O
and	O
negative	B-protein
regulators	I-protein
of	O
T-cell	O
activation	O
such	O
as	O
CTLA-4	B-protein
.	O

PI	B-protein
3-kinase	I-protein
is	O
also	O
regulated	O
by	O
the	O
haematopoietic	O
cytokines	O
that	O
determine	O
T-cell	O
differentiation	O
and	O
lymphocyte	B-cell_type
proliferation	O
.	O

PI	B-protein
3-kinase	I-protein
can	O
thus	O
dynamically	O
influence	O
the	O
outcome	O
of	O
the	O
immune	O
reactions	O
at	O
various	O
stages	O
.	O

In	O
this	O
study	O
,	O
we	O
investigated	O
the	O
importance	O
of	O
PI	B-protein
3-kinase	I-protein
in	O
TCR	B-protein
-directed	O
T-cell	O
activation	O
using	O
activated	O
or	O
inhibitory	O
versions	O
of	O
PI	B-protein
3-kinase	I-protein
.	O

RESULTS	O
:	O
Certain	O
aspects	O
of	O
TCR	B-protein
responses	O
such	O
as	O
the	O
induction	O
of	O
transcriptional	O
activity	O
of	O
AP1	B-protein
and	O
serum	B-protein
response	I-protein
factor	I-protein
were	O
not	O
affected	O
by	O
expression	O
of	O
the	O
mutant	O
forms	O
of	O
PI	B-protein
3-kinase	I-protein
.	O

We	O
found	O
,	O
however	O
,	O
that	O
PI	B-protein
3-kinase	I-protein
profoundly	O
influenced	O
the	O
transactivation	O
capacity	O
of	O
'	O
nuclear	B-protein
factor	I-protein
of	I-protein
activated	I-protein
T	I-protein
cells	I-protein
'	O
(	O
NF-AT	B-protein
)	O
elicited	O
by	O
the	O
TCR	B-protein
:	O
expression	O
of	O
an	O
activated	O
form	O
of	O
PI	B-protein
3-kinase	I-protein
inhibited	O
TCR	B-protein
-mediated	O
NF-AT	B-protein
responses	O
,	O
whereas	O
expression	O
of	O
a	O
dominant	O
negative	O
mutant	O
of	O
PI	B-protein
3-kinase	I-protein
potently	O
enhanced	O
TCR	B-protein
-controlled	O
NF-AT	B-protein
induction	O
.	O

These	O
effects	O
of	O
PI	B-protein
3-kinase	I-protein
were	O
not	O
mediated	O
by	O
previously	O
identified	O
PI	B-protein
3-kinase	I-protein
effectors	I-protein
,	O
such	O
as	O
protein	B-protein
kinase	I-protein
B	I-protein
,	O
a	O
positive	B-protein
regulator	I-protein
of	O
PI	B-protein
3-kinase	I-protein
,	O
or	O
the	O
GTPase	B-protein
Rac	I-protein
,	O
and	O
are	O
therefore	O
likely	O
to	O
involve	O
a	O
novel	O
,	O
as	O
yet	O
unknown	O
,	O
effector	B-protein
molecule	I-protein
.	O

CONCLUSIONS	O
:	O
Our	O
results	O
establish	O
that	O
PI	B-protein
3-kinase	I-protein
can	O
both	O
positively	O
and	O
negatively	O
regulate	O
T-cell	O
function	O
,	O
and	O
uncover	O
a	O
previously	O
unrecognized	O
function	O
for	O
PI	B-protein
3-kinase	I-protein
in	O
T	B-cell_type
cells	I-cell_type
as	O
a	O
selective	O
negative	O
regulator	O
of	O
TCR	B-protein
-signalling	O
events	O
and	O
therefore	O
as	O
a	O
determinant	O
of	O
T-cell	O
homeostasis	O
.	O

The	O
Pax-5	B-DNA
gene	I-DNA
is	O
alternatively	O
spliced	O
during	O
B-cell	O
development	O
.	O

The	O
transcription	B-protein
factor	I-protein
Pax-5	I-protein
is	O
expressed	O
during	O
the	O
early	O
stages	O
of	O
B-cell	O
differentiation	O
and	O
influences	O
the	O
expression	O
of	O
several	O
B-cell-specific	B-DNA
genes	I-DNA
.	O

In	O
addition	O
to	O
the	O
existing	O
isoform	O
(	O
Pax-5	B-protein
,	O
which	O
we	O
have	O
named	O
Pax-5a	B-protein
)	O
,	O
we	O
have	O
isolated	O
three	O
new	O
isoforms	O
,	O
Pax-5b	B-protein
,	O
Pax-5d	B-protein
,	O
and	O
Pax-5e	B-protein
,	O
from	O
murine	O
spleen	O
and	O
B-lymphoid	B-cell_line
cell	I-cell_line
lines	I-cell_line
using	O
library	O
screenings	O
and	O
polymerase	O
chain	O
reaction	O
amplification	O
.	O

Isoforms	O
Pax-5b	B-protein
and	O
Pax-5e	B-protein
have	O
spliced	O
out	O
their	O
second	O
exon	O
,	O
resulting	O
in	O
proteins	O
with	O
only	O
a	O
partial	O
DNA-binding	B-protein
domain	I-protein
.	O

Isoforms	O
Pax-5d	O
and	O
Pax-5e	B-protein
have	O
deleted	O
the	O
3'-region	B-protein
,	O
which	O
encodes	O
the	O
transactivating	O
domain	O
,	O
and	O
replaced	O
it	O
with	O
a	O
novel	O
sequence	O
.	O

The	O
existence	O
of	O
alternative	O
Pax-5	B-RNA
transcripts	I-RNA
was	O
confirmed	O
using	O
RNase	B-protein
protection	O
assays	O
.	O

Furthermore	O
,	O
Pax-5a	B-protein
and	O
Pax-5b	B-protein
proteins	I-protein
were	O
detected	O
using	O
Western	O
blot	O
analysis	O
.	O

Pax-5a	B-protein
was	O
detectable	O
in	O
pro-	B-cell_line
,	I-cell_line
pre-	I-cell_line
,	I-cell_line
and	I-cell_line
mature	I-cell_line
B-cell	I-cell_line
lines	I-cell_line
,	O
but	O
not	O
in	O
two	O
plasmacytomas	O
;	O
Pax-5b	B-protein
was	O
shown	O
to	O
be	O
present	O
at	O
low	O
levels	O
in	O
mature	B-cell_line
B-cell	I-cell_line
lines	I-cell_line
and	O
,	O
unexpectedly	O
,	O
in	O
one	O
plasma	O
cell	O
line	O
,	O
but	O
not	O
in	O
pro-B-cell	B-cell_line
or	I-cell_line
T-cell	I-cell_line
lines	I-cell_line
.	O

Mobility	O
shift	O
assays	O
showed	O
that	O
in	O
vitro	O
translated	O
Pax-5a	B-protein
and	O
Pax-5d	B-protein
,	O
but	O
not	O
Pax-5b	B-protein
or	O
Pax-5e	B-protein
,	O
could	O
interact	O
with	O
a	O
B-cell-specific	B-DNA
activator	I-DNA
protein-binding	I-DNA
site	I-DNA
on	O
the	O
blk	B-DNA
promoter	I-DNA
.	O

Using	O
this	O
assay	O
,	O
we	O
also	O
showed	O
that	O
Pax-5d	B-protein
was	O
present	O
in	O
nuclear	O
extracts	O
of	O
some	O
(	O
but	O
not	O
all	O
)	O
B-lymphoid	B-cell_line
lines	I-cell_line
and	O
interacts	O
with	O
the	O
B-cell-specific	B-DNA
activator	I-DNA
protein-binding	I-DNA
site	I-DNA
.	O

The	O
pattern	O
of	O
differential	O
expression	O
of	O
alternatively	B-protein
spliced	I-protein
Pax-5	I-protein
isoforms	I-protein
suggests	O
that	O
they	O
may	O
be	O
important	O
regulators	B-protein
of	I-protein
transcription	I-protein
during	O
B-cell	O
maturation	O
.	O

Reconstitution	O
of	O
T	O
cell	O
antigen	O
receptor-induced	O
Erk2	B-protein
kinase	I-protein
activation	O
in	O
Lck-negative	B-cell_line
JCaM1	I-cell_line
cells	I-cell_line
by	O
Syk	B-protein
.	O

The	O
two	O
related	O
protein-tyrosine	B-protein
kinases	I-protein
Syk	B-protein
and	O
Zap	B-protein
are	O
rapidly	O
phosphorylated	O
on	O
tyrosine	O
residues	O
and	O
enzymatically	O
activated	O
upon	O
crosslinking	O
of	O
the	O
T	B-protein
cell	I-protein
antigen	I-protein
receptor	I-protein
.	O

We	O
have	O
previously	O
reported	O
that	O
the	O
activation	O
of	O
Syk	B-protein
is	O
less	O
dependent	O
on	O
the	O
Src	B-protein
family	I-protein
kinase	I-protein
Lck	B-protein
than	O
the	O
activation	O
of	O
Zap	B-protein
.	O

Here	O
we	O
report	O
that	O
overexpression	O
of	O
Syk	B-protein
in	O
the	O
Lck-negative	B-cell_line
JCaM1	I-cell_line
cells	I-cell_line
enabled	O
the	O
T	B-protein
cell	I-protein
antigen	I-protein
receptor/CD3	I-protein
complex	I-protein
to	O
induce	O
a	O
normal	O
activation	O
of	O
the	O
mitogen-activated	B-protein
protein	I-protein
kinase	I-protein
(	O
MAPK	B-protein
)	O
pathway	O
and	O
expression	O
of	O
a	O
nuclear	B-protein
factor	I-protein
of	I-protein
activated	I-protein
T	I-protein
cells	I-protein
reporter	O
construct	O
.	O

In	O
contrast	O
,	O
Zap	B-protein
and	O
other	O
protein-tyrosine	B-protein
kinases	I-protein
were	O
unable	O
to	O
reconstitute	O
these	O
signaling	O
pathways	O
when	O
expressed	O
at	O
the	O
same	O
levels	O
.	O

In	O
parallel	O
,	O
Syk	B-protein
was	O
phosphorylated	O
on	O
tyrosine	O
,	O
while	O
Zap	B-protein
was	O
not	O
.	O

The	O
Syk	B-protein
-mediated	O
T	B-protein
cell	I-protein
antigen	I-protein
receptor	I-protein
-induced	O
MAPK	B-protein
activation	O
was	O
detectable	O
within	O
1	O
min	O
of	O
receptor	O
stimulation	O
and	O
peaked	O
at	O
3-5	O
min	O
.	O

The	O
capacity	O
of	O
Syk	B-protein
to	O
reconstitute	O
the	O
MAPK	B-protein
response	O
required	O
the	O
catalytic	O
activity	O
of	O
Syk	B-protein
,	O
an	O
intact	O
autophosphorylation	B-protein
site	I-protein
(	O
Y518	O
and	O
Y519	O
)	O
,	O
both	O
Src	B-protein
homology	I-protein
2	I-protein
domains	I-protein
and	O
it	O
was	O
blocked	O
by	O
the	O
inhibitory	B-protein
N17-mutated	I-protein
dominant-negative	I-protein
Ras	I-protein
construct	I-protein
.	O

A	O
Y341	O
--	O
>	O
F	B-protein
mutant	I-protein
of	O
Syk	B-protein
,	O
which	O
is	O
deficient	O
in	O
its	O
interaction	O
with	O
phospholipase	B-protein
Cy1	I-protein
and	O
Vav	B-protein
,	O
was	O
less	O
efficient	O
than	O
wild-type	B-protein
Syk	I-protein
.	O

Our	O
results	O
suggest	O
that	O
Syk	B-protein
,	O
in	O
contrast	O
to	O
Zap	B-protein
,	O
can	O
transduce	O
signals	O
from	O
the	O
T	B-protein
cell	I-protein
antigen	I-protein
receptor	I-protein
independently	O
of	O
Lck	B-protein
.	O

Activation	O
of	O
the	O
transcription	B-protein
factor	I-protein
MEF2C	B-protein
by	O
the	O
MAP	B-protein
kinase	I-protein
p38	I-protein
in	O
inflammation	O
.	O

For	O
cells	O
of	O
the	O
innate	O
immune	O
system	O
to	O
mount	O
a	O
host	O
defence	O
response	O
to	O
infection	O
,	O
they	O
must	O
recognize	O
products	O
of	O
microbial	O
pathogens	O
such	O
as	O
lipopolysaccharide	O
(	O
LPS	O
)	O
,	O
the	O
endotoxin	O
secreted	O
by	O
Gram-negative	O
bacteria	O
.	O

These	O
cellular	O
responses	O
require	O
intracellular	O
signalling	O
pathways	O
,	O
such	O
as	O
the	O
four	O
MAP	B-protein
kinase	I-protein
(	O
MAPK	B-protein
)	O
pathways	O
.	O

In	O
mammalian	O
cells	O
the	O
MAPK	B-protein
p38	I-protein
is	O
thought	O
to	O
play	O
an	O
important	O
role	O
in	O
the	O
regulation	O
of	O
cellular	O
responses	O
during	O
infection	O
through	O
its	O
effects	O
on	O
the	O
expression	O
of	O
proinflammatory	B-protein
molecules	I-protein
.	O

One	O
means	O
of	O
understanding	O
the	O
role	O
of	O
p38	B-protein
in	O
these	O
responses	O
is	O
to	O
identify	O
proteins	O
with	O
functions	O
regulated	O
by	O
p38	B-protein
-catalysed	O
phosphorylation	O
.	O

Here	O
we	O
demonstrate	O
a	O
link	O
between	O
the	O
p38	B-protein
pathway	O
and	O
a	O
member	O
of	O
the	O
myocyte-enhancer	B-protein
factor	I-protein
2	I-protein
(	I-protein
MEF2	I-protein
)	I-protein
group	I-protein
of	O
transcription	B-protein
factors	I-protein
.	O

We	O
found	O
that	O
in	O
monocytic	B-cell_type
cells	I-cell_type
,	O
LPS	O
increases	O
the	O
transactivation	O
activity	O
of	O
MEF2C	B-protein
through	O
p38	B-protein
-catalysed	O
phosphorylation	O
.	O

One	O
consequence	O
of	O
MEF2C	B-protein
activation	O
is	O
increased	O
c-jun	B-DNA
gene	I-DNA
transcription	O
.	O

Our	O
results	O
show	O
that	O
p38	B-protein
may	O
influence	O
host	O
defence	O
and	O
inflammation	O
by	O
maintaining	O
the	O
balance	O
of	O
c-Jun	B-protein
protein	I-protein
consumed	O
during	O
infection	O
.	O

Cellular	O
redox	O
status	O
influences	O
both	O
cytotoxic	O
and	O
NF-kappa	O
B	O
activation	O
in	O
natural	B-cell_type
killer	I-cell_type
cells	I-cell_type
.	O

The	O
role	O
of	O
cellular	O
redox	O
status	O
in	O
both	O
cytotoxic	O
activity	O
and	O
NF-kappa	B-protein
B	I-protein
activation	O
in	O
natural	B-cell_type
killer	I-cell_type
(	I-cell_type
NK	I-cell_type
)	I-cell_type
cells	I-cell_type
was	O
investigated	O
.	O

The	O
results	O
indicate	O
that	O
stimulation	O
of	O
NK	B-cell_type
cells	I-cell_type
,	O
either	O
freshly	O
isolated	O
from	O
peripheral	B-cell_type
blood	I-cell_type
lymphocytes	I-cell_type
(	O
PBL	B-cell_type
)	O
or	O
long-term	B-cell_line
cultured	I-cell_line
NK	I-cell_line
clones	I-cell_line
,	O
with	O
specific	O
cell	O
targets	O
results	O
in	O
an	O
increased	O
binding	O
activity	O
of	O
NF-kappa	B-protein
B	I-protein
and	O
AP-1	B-protein
transcription	B-protein
factors	I-protein
measured	O
by	O
gel	O
retardation	O
.	O

Pretreatment	O
of	O
NK	B-cell_type
cells	I-cell_type
with	O
the	O
antioxidant	O
pyrrolidine	O
dithiocarbarmate	O
(	O
PDTC	O
)	O
leads	O
to	O
the	O
inhibition	O
of	O
NF-kappa	B-protein
B	I-protein
activation	O
but	O
the	O
AP-1	B-protein
binding	O
to	O
DNA	O
was	O
superinduced	O
.	O

The	O
inhibition	O
of	O
NF-kappa	B-protein
B	I-protein
by	O
PDTC	O
paralleled	O
with	O
an	O
inhibition	O
of	O
spontaneous	O
cytotoxicity	O
mediated	O
by	O
NK	B-cell_type
cells	I-cell_type
.	O

Moreover	O
,	O
the	O
inhibitors	O
of	O
serine	B-protein
proteases	I-protein
,	O
N-alpha-tosyl-L-lysine	O
chloromethyl	O
ketone	O
and	O
N-alpha-tosyl-L-phenylalanine	O
chloromethyl	O
ketone	O
,	O
also	O
blocked	O
the	O
cytolytic	O
activity	O
of	O
NK	B-cell_type
cells	I-cell_type
against	O
the	O
sensitive	O
target	O
K562	B-cell_line
.	O

In	O
contrast	O
,	O
NK	O
activity	O
was	O
not	O
affected	O
by	O
pretreatment	O
of	O
the	O
effector	O
cells	O
with	O
the	O
proteasome	B-protein
inhibitor	O
N-acetyl-leu-leu-norleucinal	O
which	O
selectively	O
inhibits	O
NF-kappa	B-protein
B	I-protein
activation	O
.	O

Altogether	O
,	O
these	O
results	O
support	O
the	O
hypothesis	O
that	O
the	O
activation	O
of	O
NK	B-cell_type
cells	I-cell_type
involved	O
transcriptional	O
and	O
post-transcriptional	O
events	O
,	O
and	O
that	O
reactive	O
intermediates	O
may	O
play	O
an	O
important	O
role	O
in	O
the	O
molecular	O
processes	O
related	O
with	O
the	O
generation	O
of	O
a	O
cytotoxic	O
response	O
by	O
NK	B-cell_type
cells	I-cell_type
.	O

The	O
predominant	O
E2F	B-protein
complex	I-protein
in	O
human	B-cell_type
primary	I-cell_type
haemopoietic	I-cell_type
cells	I-cell_type
and	O
in	O
AML	B-cell_type
blasts	I-cell_type
contains	O
E2F-4	B-protein
,	O
DP-1	B-protein
and	O
p130	B-protein
.	O

The	O
E2F	B-protein
family	I-protein
of	O
transcription	B-protein
factors	I-protein
are	O
thought	O
to	O
play	O
an	O
important	O
role	O
in	O
the	O
control	O
of	O
cell	O
cycle	O
progression	O
.	O

There	O
is	O
now	O
also	O
increasing	O
evidence	O
that	O
some	O
family	O
members	O
may	O
act	O
as	O
oncogenes	B-DNA
or	O
tumour	B-DNA
suppressor	I-DNA
genes	I-DNA
.	O

The	O
characterization	O
of	O
these	O
proteins	O
in	O
human	B-cell_type
primary	I-cell_type
haemopoietic	I-cell_type
cells	I-cell_type
and	O
acute	B-cell_type
myeloid	I-cell_type
leukaemia	I-cell_type
(	I-cell_type
AML	I-cell_type
)	I-cell_type
blasts	I-cell_type
may	O
thus	O
give	O
an	O
insight	O
to	O
the	O
molecular	O
mechanisms	O
governing	O
proliferation	O
and	O
leukaemogenesis	O
in	O
these	O
cells	O
.	O

Therefore	O
we	O
analysed	O
the	O
expression	O
of	O
E2F	B-protein
-DNA	O
binding	O
activity	O
and	O
the	O
constituent	O
proteins	O
found	O
in	O
the	O
complexes	O
in	O
human	B-cell_type
primary	I-cell_type
haemopoietic	I-cell_type
cells	I-cell_type
of	O
various	O
lineages	O
.	O

We	O
also	O
studied	O
blasts	O
from	O
18	O
patients	O
with	O
acute	O
myeloid	O
leukaemia	O
(	O
AML	O
)	O
.	O

On	O
electromobility	O
shift	O
assays	O
(	O
EMSA	O
)	O
a	O
single	O
E2F-DNA	B-protein
binding	I-protein
complex	I-protein
was	O
detected	O
in	O
T	B-cell_type
cells	I-cell_type
,	O
B	B-cell_type
cells	I-cell_type
and	O
monocytes	B-cell_type
which	O
was	O
shown	O
to	O
contain	O
E2F-4	B-protein
,	O
DP-1	B-protein
and	O
p130	B-protein
,	O
indicating	O
that	O
all	O
quiescent	B-cell_type
haemopoietic	I-cell_type
cells	I-cell_type
have	O
the	O
same	O
complex	O
.	O

Examination	O
of	O
18	O
AML	O
samples	O
by	O
EMSA	O
revealed	O
the	O
presence	O
of	O
E2F	B-protein
binding	O
and	O
no	O
gross	O
abnormalities	O
were	O
detected	O
.	O

An	O
E2F-4/p130	B-protein
complex	I-protein
was	O
detected	O
in	O
representative	O
samples	O
of	O
all	O
FAB	B-protein
types	O
analysed	O
.	O

Thus	O
abnormalities	O
of	O
E2F	B-protein
function	O
are	O
unlikely	O
to	O
play	O
a	O
primary	O
pathogenic	O
role	O
in	O
AML	O
.	O

Characterization	O
of	O
a	O
mutant	B-cell_line
cell	I-cell_line
line	I-cell_line
that	O
does	O
not	O
activate	O
NF-kappaB	B-protein
in	O
response	O
to	O
multiple	O
stimuli	O
.	O

Numerous	O
genes	O
required	O
during	O
the	O
immune	O
or	O
inflammation	O
response	O
as	O
well	O
as	O
the	O
adhesion	O
process	O
are	O
regulated	O
by	O
nuclear	B-protein
factor	I-protein
kappaB	I-protein
(	O
NF-kappaB	B-protein
)	O
.	O

Associated	O
with	O
its	O
inhibitor	O
,	O
I	B-protein
kappaB	I-protein
,	O
NF-kappaB	B-protein
resides	O
as	O
an	O
inactive	O
form	O
in	O
the	O
cytoplasm	O
.	O

Upon	O
stimulation	O
by	O
various	O
agents	O
,	O
I	B-protein
kappaB	I-protein
is	O
proteolyzed	O
and	O
NF-kappaB	B-protein
translocates	O
to	O
the	O
nucleus	O
,	O
where	O
it	O
activates	O
its	O
target	O
genes	O
.	O

The	O
transduction	O
pathways	O
that	O
lead	O
to	O
I	B-protein
kappaB	I-protein
inactivation	O
remain	O
poorly	O
understood	O
.	O

In	O
this	O
study	O
,	O
we	O
have	O
characterized	O
a	O
cellular	O
mutant	O
,	O
the	O
70/Z3-derived	B-cell_line
1.3E2	I-cell_line
murine	I-cell_line
pre-B	I-cell_line
cell	I-cell_line
line	I-cell_line
,	O
that	O
does	O
not	O
activate	O
NF-kappaB	B-protein
in	O
response	O
to	O
several	O
stimuli	O
.	O

We	O
demonstrate	O
that	O
upon	O
stimulation	O
by	O
lipopolysaccharide	O
,	O
Taxol	O
,	O
phorbol	O
myristate	O
acetate	O
,	O
interleukin-1	B-protein
,	O
or	O
double-stranded	B-RNA
RNA	I-RNA
,	O
I	B-protein
kappaB	I-protein
alpha	I-protein
is	O
not	O
degraded	O
,	O
as	O
a	O
result	O
of	O
an	O
absence	O
of	O
induced	O
phosphorylation	O
on	O
serines	O
32	O
and	O
36	O
.	O

Neither	O
a	O
mutation	O
in	O
I	B-protein
kappaB	I-protein
alpha	I-protein
nor	O
a	O
mutation	O
in	O
p50	B-protein
or	O
relA	B-protein
,	O
the	O
two	O
major	O
subunits	O
of	O
NF-kappaB	B-protein
in	O
this	O
cell	O
line	O
,	O
accounts	O
for	O
this	O
phosphorylation	O
defect	O
.	O

As	O
well	O
as	O
culminating	O
in	O
the	O
inducible	O
phosphorylation	O
of	O
I	B-protein
kappaB	I-protein
alpha	O
on	O
serines	O
32	O
and	O
36	O
,	O
all	O
the	O
stimuli	O
that	O
are	O
inactive	O
on	O
1.3E2	B-cell_line
cells	I-cell_line
exhibit	O
a	O
sensitivity	O
to	O
the	O
antioxidant	O
pyrrolidine	O
dithiocarbamate	O
(	O
PDTC	O
)	O
.	O

In	O
contrast	O
,	O
stimuli	O
such	O
as	O
hyperosmotic	O
shock	O
or	O
phosphatase	O
inhibitors	O
,	O
which	O
use	O
PDTC-insensitive	O
pathways	O
,	O
induce	O
I	B-protein
kappaB	I-protein
alpha	O
degradation	O
in	O
1.3E2	B-cell_line
.	O

Analysis	O
of	O
the	O
redox	O
status	O
of	O
1.3E2	B-cell_line
does	O
not	O
reveal	O
any	O
difference	O
from	O
wild-type	B-cell_line
70Z/3	I-cell_line
.	O

We	O
also	O
report	O
that	O
the	O
human	B-protein
T-cell	I-protein
leukemia	I-protein
virus	I-protein
type	I-protein
1	I-protein
(	I-protein
HTLV-1	I-protein
)	I-protein
-derived	I-protein
Tax	I-protein
trans-activator	I-protein
induces	O
NF-kappaB	B-protein
activity	O
in	O
1.3E2	B-cell_line
,	O
suggesting	O
that	O
this	O
viral	O
protein	O
does	O
not	O
operate	O
via	O
the	O
defective	O
pathway	O
.	O

Finally	O
,	O
we	O
show	O
that	O
two	O
other	O
I	B-protein
kappaB	I-protein
molecules	I-protein
,	O
I	B-protein
kappaB	I-protein
beta	I-protein
and	O
the	O
recently	O
identified	O
I	B-protein
kappaB	I-protein
epsilon	I-protein
,	O
are	O
not	O
degraded	O
in	O
the	O
1.3E2	B-cell_line
cell	O
line	O
following	O
stimulation	O
.	O

Our	O
results	O
demonstrate	O
that	O
1.3E2	B-cell_line
is	O
a	O
cellular	B-protein
transduction	I-protein
mutant	I-protein
exhibiting	O
a	O
defect	O
in	O
a	O
step	O
that	O
is	O
required	O
by	O
several	O
different	O
stimuli	O
to	O
activate	O
NF-kappaB	B-protein
.	O

In	O
addition	O
,	O
this	O
analysis	O
suggests	O
a	O
common	O
step	O
in	O
the	O
signaling	O
pathways	O
that	O
trigger	O
I	B-protein
kappaB	I-protein
alpha	I-protein
,	O
I	B-protein
kappaB	I-protein
beta	I-protein
,	O
and	O
I	B-protein
kappaB	I-protein
epsilon	I-protein
degradation	O
.	O

Involvement	O
of	O
Egr-1	B-protein
/RelA	B-protein
synergy	O
in	O
distinguishing	O
T	O
cell	O
activation	O
from	O
tumor	B-protein
necrosis	I-protein
factor-alpha	I-protein
-induced	O
NF-kappa	B-protein
B1	I-protein
transcription	O
.	O

NF-kappa	B-protein
B	I-protein
is	O
an	O
important	O
transcription	B-protein
factor	I-protein
required	O
for	O
T	O
cell	O
proliferation	O
and	O
other	O
immunological	O
functions	O
.	O

The	O
NF-kappa	B-DNA
B1	I-DNA
gene	I-DNA
encodes	O
a	O
105-kD	B-protein
protein	I-protein
that	O
is	O
the	O
precursor	O
of	O
the	O
p50	B-protein
component	I-protein
of	O
NF-kappa	B-protein
B	I-protein
.	O

